id	sid	tid	token	lemma	pos
cord-005478-5iu38pr6	1	1	key	key	JJ
cord-005478-5iu38pr6	1	2	:	:	:
cord-005478-5iu38pr6	1	3	cord-005478	cord-005478	NNP
cord-005478-5iu38pr6	1	4	-	-	HYPH
cord-005478-5iu38pr6	1	5	5iu38pr6	5iu38pr6	CD
cord-005478-5iu38pr6	1	6	authors	author	NNS
cord-005478-5iu38pr6	1	7	:	:	:
cord-005478-5iu38pr6	2	1	nan	nan	NNP
cord-005478-5iu38pr6	2	2	title	title	NN
cord-005478-5iu38pr6	2	3	:	:	:
cord-005478-5iu38pr6	2	4	The	the	DT
cord-005478-5iu38pr6	2	5	45th	45th	JJ
cord-005478-5iu38pr6	2	6	Annual	Annual	NNP
cord-005478-5iu38pr6	2	7	Meeting	Meeting	NNP
cord-005478-5iu38pr6	2	8	of	of	IN
cord-005478-5iu38pr6	2	9	the	the	DT
cord-005478-5iu38pr6	2	10	European	European	NNP
cord-005478-5iu38pr6	2	11	Society	Society	NNP
cord-005478-5iu38pr6	2	12	for	for	IN
cord-005478-5iu38pr6	2	13	Blood	blood	NN
cord-005478-5iu38pr6	2	14	and	and	CC
cord-005478-5iu38pr6	2	15	Marrow	marrow	NN
cord-005478-5iu38pr6	2	16	Transplantation	transplantation	NN
cord-005478-5iu38pr6	2	17	:	:	:
cord-005478-5iu38pr6	2	18	Physicians	physician	NNS
cord-005478-5iu38pr6	2	19	–	–	:
cord-005478-5iu38pr6	2	20	Oral	oral	JJ
cord-005478-5iu38pr6	2	21	Session	Session	NNP
cord-005478-5iu38pr6	2	22	date	date	NN
cord-005478-5iu38pr6	2	23	:	:	:
cord-005478-5iu38pr6	2	24	2019	2019	CD
cord-005478-5iu38pr6	2	25	-	-	HYPH
cord-005478-5iu38pr6	2	26	07	07	CD
cord-005478-5iu38pr6	2	27	-	-	HYPH
cord-005478-5iu38pr6	2	28	03	03	CD
cord-005478-5iu38pr6	2	29	journal	journal	NN
cord-005478-5iu38pr6	2	30	:	:	:
cord-005478-5iu38pr6	3	1	Bone	Bone	NNP
cord-005478-5iu38pr6	3	2	Marrow	marrow	NN
cord-005478-5iu38pr6	3	3	Transplant	transplant	NN
cord-005478-5iu38pr6	3	4	DOI	doi	NN
cord-005478-5iu38pr6	3	5	:	:	:
cord-005478-5iu38pr6	3	6	10.1038	10.1038	CD
cord-005478-5iu38pr6	3	7	/	/	SYM
cord-005478-5iu38pr6	3	8	s41409	s41409	JJ
cord-005478-5iu38pr6	3	9	-	-	HYPH
cord-005478-5iu38pr6	3	10	019	019	CD
cord-005478-5iu38pr6	3	11	-	-	HYPH
cord-005478-5iu38pr6	3	12	0562	0562	CD
cord-005478-5iu38pr6	3	13	-	-	SYM
cord-005478-5iu38pr6	3	14	9	9	CD
cord-005478-5iu38pr6	3	15	sha	sha	NN
cord-005478-5iu38pr6	3	16	:	:	:
cord-005478-5iu38pr6	3	17	467b54359e9725df79f8baf527b0b12600fb0b30	467b54359e9725df79f8baf527b0b12600fb0b30	CD
cord-005478-5iu38pr6	3	18	doc_id	doc_id	CD
cord-005478-5iu38pr6	3	19	:	:	:
cord-005478-5iu38pr6	3	20	5478	5478	CD
cord-005478-5iu38pr6	3	21	cord_uid	cord_uid	NNS
cord-005478-5iu38pr6	3	22	:	:	:
cord-005478-5iu38pr6	4	1	5iu38pr6	5iu38pr6	NNP
cord-005478-5iu38pr6	4	2	nan	nan	NNP
cord-005478-5iu38pr6	4	3	Methods	method	NNS
cord-005478-5iu38pr6	4	4	:	:	:
cord-005478-5iu38pr6	4	5	Study	study	NN
cord-005478-5iu38pr6	4	6	aim	aim	NN
cord-005478-5iu38pr6	4	7	was	be	VBD
cord-005478-5iu38pr6	4	8	to	to	TO
cord-005478-5iu38pr6	4	9	evaluate	evaluate	VB
cord-005478-5iu38pr6	4	10	the	the	DT
cord-005478-5iu38pr6	4	11	schedule	schedule	NN
cord-005478-5iu38pr6	4	12	of	of	IN
cord-005478-5iu38pr6	4	13	IST	IST	NNP
cord-005478-5iu38pr6	4	14	given	give	VBN
cord-005478-5iu38pr6	4	15	in	in	IN
cord-005478-5iu38pr6	4	16	combination	combination	NN
cord-005478-5iu38pr6	4	17	with	with	IN
cord-005478-5iu38pr6	4	18	PT	PT	NNP
cord-005478-5iu38pr6	4	19	-	-	HYPH
cord-005478-5iu38pr6	4	20	Cy	Cy	NNP
cord-005478-5iu38pr6	4	21	as	as	IN
cord-005478-5iu38pr6	4	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	4	23	-	-	HYPH
cord-005478-5iu38pr6	4	24	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	4	25	post	post	NN
cord-005478-5iu38pr6	4	26	-	-	JJ
cord-005478-5iu38pr6	4	27	haplo	haplo	JJ
cord-005478-5iu38pr6	4	28	for	for	IN
cord-005478-5iu38pr6	4	29	acute	acute	JJ
cord-005478-5iu38pr6	4	30	leukemia	leukemia	NN
cord-005478-5iu38pr6	4	31	(	(	-LRB-
cord-005478-5iu38pr6	4	32	AL	AL	NNP
cord-005478-5iu38pr6	4	33	)	)	-RRB-
cord-005478-5iu38pr6	4	34	and	and	CC
cord-005478-5iu38pr6	4	35	reported	report	VBD
cord-005478-5iu38pr6	4	36	to	to	IN
cord-005478-5iu38pr6	4	37	the	the	DT
cord-005478-5iu38pr6	4	38	ALWP	ALWP	NNP
cord-005478-5iu38pr6	4	39	/	/	SYM
cord-005478-5iu38pr6	4	40	EBMT	EBMT	NNP
cord-005478-5iu38pr6	4	41	registry	registry	NN
cord-005478-5iu38pr6	4	42	.	.	.
cord-005478-5iu38pr6	5	1	Patients	patient	NNS
cord-005478-5iu38pr6	5	2	were	be	VBD
cord-005478-5iu38pr6	5	3	divided	divide	VBN
cord-005478-5iu38pr6	5	4	into	into	IN
cord-005478-5iu38pr6	5	5	3	3	CD
cord-005478-5iu38pr6	5	6	groups	group	NNS
cord-005478-5iu38pr6	5	7	:	:	:
cord-005478-5iu38pr6	5	8	received	receive	VBD
cord-005478-5iu38pr6	5	9	cyclosporine	cyclosporine	NNP
cord-005478-5iu38pr6	5	10	A	a	DT
cord-005478-5iu38pr6	5	11	-	-	HYPH
cord-005478-5iu38pr6	5	12	mycofenolate	mycofenolate	NN
cord-005478-5iu38pr6	5	13	-	-	HYPH
cord-005478-5iu38pr6	5	14	mofetil(CSA-+MMF	mofetil(csa-+mmf	JJ
cord-005478-5iu38pr6	5	15	)	)	-RRB-
cord-005478-5iu38pr6	5	16	initiated	initiate	VBN
cord-005478-5iu38pr6	5	17	at	at	IN
cord-005478-5iu38pr6	5	18	day+1	day+1	NNP
cord-005478-5iu38pr6	5	19	(	(	-LRB-
cord-005478-5iu38pr6	5	20	group-1	group-1	NN
cord-005478-5iu38pr6	5	21	,	,	,
cord-005478-5iu38pr6	5	22	n=124	n=124	CD
cord-005478-5iu38pr6	5	23	)	)	-RRB-
cord-005478-5iu38pr6	5	24	or	or	CC
cord-005478-5iu38pr6	5	25	CSA	CSA	NNP
cord-005478-5iu38pr6	5	26	+	+	CC
cord-005478-5iu38pr6	5	27	MMF	mmf	NN
cord-005478-5iu38pr6	6	1	both	both	DT
cord-005478-5iu38pr6	6	2	started	start	VBD
cord-005478-5iu38pr6	6	3	at	at	IN
cord-005478-5iu38pr6	6	4	day+5	day+5	NNP
cord-005478-5iu38pr6	6	5	(	(	-LRB-
cord-005478-5iu38pr6	6	6	group-2	group-2	NNP
cord-005478-5iu38pr6	6	7	,	,	,
cord-005478-5iu38pr6	6	8	n=170	n=170	NNP
cord-005478-5iu38pr6	6	9	)	)	-RRB-
cord-005478-5iu38pr6	6	10	and	and	CC
cord-005478-5iu38pr6	6	11	tacrolimus	tacrolimus	NN
cord-005478-5iu38pr6	6	12	+	+	CC
cord-005478-5iu38pr6	6	13	MMF	mmf	NN
cord-005478-5iu38pr6	6	14	from	from	IN
cord-005478-5iu38pr6	6	15	day+5	day+5	NNP
cord-005478-5iu38pr6	6	16	(	(	-LRB-
cord-005478-5iu38pr6	6	17	group-3	group-3	NNP
cord-005478-5iu38pr6	6	18	,	,	,
cord-005478-5iu38pr6	6	19	n=215	n=215	ADD
cord-005478-5iu38pr6	6	20	)	)	-RRB-
cord-005478-5iu38pr6	6	21	.	.	.
cord-005478-5iu38pr6	7	1	Transplants	transplant	NNS
cord-005478-5iu38pr6	7	2	were	be	VBD
cord-005478-5iu38pr6	7	3	performed	perform	VBN
cord-005478-5iu38pr6	7	4	from	from	IN
cord-005478-5iu38pr6	7	5	2006	2006	CD
cord-005478-5iu38pr6	7	6	-	-	SYM
cord-005478-5iu38pr6	7	7	2017	2017	CD
cord-005478-5iu38pr6	7	8	and	and	CC
cord-005478-5iu38pr6	7	9	median	median	NN
cord-005478-5iu38pr6	7	10	follow	follow	NN
cord-005478-5iu38pr6	7	11	up	up	RP
cord-005478-5iu38pr6	7	12	is	be	VBZ
cord-005478-5iu38pr6	7	13	21	21	CD
cord-005478-5iu38pr6	7	14	months	month	NNS
cord-005478-5iu38pr6	8	1	(	(	-LRB-
cord-005478-5iu38pr6	8	2	range	range	NNP
cord-005478-5iu38pr6	8	3	11	11	CD
cord-005478-5iu38pr6	8	4	-	-	SYM
cord-005478-5iu38pr6	8	5	36	36	CD
cord-005478-5iu38pr6	8	6	)	)	-RRB-
cord-005478-5iu38pr6	8	7	.	.	.
cord-005478-5iu38pr6	9	1	PT	PT	NNP
cord-005478-5iu38pr6	9	2	-	-	HYPH
cord-005478-5iu38pr6	9	3	CY	CY	NNP
cord-005478-5iu38pr6	9	4	was	be	VBD
cord-005478-5iu38pr6	9	5	given	give	VBN
cord-005478-5iu38pr6	9	6	on	on	IN
cord-005478-5iu38pr6	9	7	Day+3	Day+3	NNP
cord-005478-5iu38pr6	9	8	and	and	CC
cord-005478-5iu38pr6	9	9	Day+5	Day+5	NNP
cord-005478-5iu38pr6	9	10	in	in	IN
cord-005478-5iu38pr6	9	11	group-1	group-1	NNP
cord-005478-5iu38pr6	9	12	and	and	CC
cord-005478-5iu38pr6	9	13	on	on	IN
cord-005478-5iu38pr6	9	14	day+3	day+3	ADD
cord-005478-5iu38pr6	9	15	and	and	CC
cord-005478-5iu38pr6	9	16	day+4	day+4	JJ
cord-005478-5iu38pr6	9	17	in	in	IN
cord-005478-5iu38pr6	9	18	group-2	group-2	NNP
cord-005478-5iu38pr6	9	19	and	and	CC
cord-005478-5iu38pr6	9	20	3	3	CD
cord-005478-5iu38pr6	9	21	.	.	.
cord-005478-5iu38pr6	10	1	Results	result	NNS
cord-005478-5iu38pr6	10	2	:	:	:
cord-005478-5iu38pr6	11	1	Acute	acute	JJ
cord-005478-5iu38pr6	11	2	myeloid	myeloid	NN
cord-005478-5iu38pr6	11	3	leukemia	leukemia	NN
cord-005478-5iu38pr6	11	4	(	(	-LRB-
cord-005478-5iu38pr6	11	5	AML	AML	NNP
cord-005478-5iu38pr6	11	6	)	)	-RRB-
cord-005478-5iu38pr6	11	7	was	be	VBD
cord-005478-5iu38pr6	11	8	the	the	DT
cord-005478-5iu38pr6	11	9	most	most	RBS
cord-005478-5iu38pr6	11	10	common	common	JJ
cord-005478-5iu38pr6	11	11	indication	indication	NN
cord-005478-5iu38pr6	11	12	for	for	IN
cord-005478-5iu38pr6	11	13	haplo	haplo	NNP
cord-005478-5iu38pr6	11	14	(	(	-LRB-
cord-005478-5iu38pr6	11	15	76	76	CD
cord-005478-5iu38pr6	11	16	%	%	NN
cord-005478-5iu38pr6	11	17	)	)	-RRB-
cord-005478-5iu38pr6	11	18	and	and	CC
cord-005478-5iu38pr6	11	19	approximately	approximately	RB
cord-005478-5iu38pr6	11	20	45	45	CD
cord-005478-5iu38pr6	11	21	%	%	NN
cord-005478-5iu38pr6	11	22	of	of	IN
cord-005478-5iu38pr6	11	23	patients	patient	NNS
cord-005478-5iu38pr6	11	24	were	be	VBD
cord-005478-5iu38pr6	11	25	transplanted	transplant	VBN
cord-005478-5iu38pr6	11	26	in	in	IN
cord-005478-5iu38pr6	11	27	CR1	CR1	NNP
cord-005478-5iu38pr6	11	28	.	.	.
cord-005478-5iu38pr6	12	1	There	there	EX
cord-005478-5iu38pr6	12	2	were	be	VBD
cord-005478-5iu38pr6	12	3	some	some	DT
cord-005478-5iu38pr6	12	4	differences	difference	NNS
cord-005478-5iu38pr6	12	5	among	among	IN
cord-005478-5iu38pr6	12	6	groups	group	NNS
cord-005478-5iu38pr6	12	7	:	:	:
cord-005478-5iu38pr6	12	8	patients	patient	NNS
cord-005478-5iu38pr6	12	9	in	in	IN
cord-005478-5iu38pr6	12	10	group-1	group-1	NNP
cord-005478-5iu38pr6	12	11	were	be	VBD
cord-005478-5iu38pr6	12	12	younger	young	JJR
cord-005478-5iu38pr6	12	13	(	(	-LRB-
cord-005478-5iu38pr6	12	14	median	median	JJ
cord-005478-5iu38pr6	12	15	age	age	NN
cord-005478-5iu38pr6	12	16	46	46	CD
cord-005478-5iu38pr6	12	17	years	year	NNS
cord-005478-5iu38pr6	12	18	,	,	,
cord-005478-5iu38pr6	12	19	p	p	NN
cord-005478-5iu38pr6	12	20	<	<	XX
cord-005478-5iu38pr6	12	21	0.02	0.02	CD
cord-005478-5iu38pr6	12	22	)	)	-RRB-
cord-005478-5iu38pr6	12	23	were	be	VBD
cord-005478-5iu38pr6	12	24	transplanted	transplant	VBN
cord-005478-5iu38pr6	12	25	in	in	IN
cord-005478-5iu38pr6	12	26	more	more	JJR
cord-005478-5iu38pr6	12	27	recent	recent	JJ
cord-005478-5iu38pr6	12	28	year	year	NN
cord-005478-5iu38pr6	12	29	(	(	-LRB-
cord-005478-5iu38pr6	12	30	2015	2015	CD
cord-005478-5iu38pr6	12	31	,	,	,
cord-005478-5iu38pr6	12	32	p	p	NN
cord-005478-5iu38pr6	12	33	<	<	XX
cord-005478-5iu38pr6	12	34	0.001	0.001	CD
cord-005478-5iu38pr6	12	35	)	)	-RRB-
cord-005478-5iu38pr6	12	36	,	,	,
cord-005478-5iu38pr6	12	37	received	receive	VBD
cord-005478-5iu38pr6	12	38	more	more	RBR
cord-005478-5iu38pr6	12	39	frequently	frequently	RB
cord-005478-5iu38pr6	12	40	a	a	DT
cord-005478-5iu38pr6	12	41	regimen	regimen	NN
cord-005478-5iu38pr6	12	42	based	base	VBN
cord-005478-5iu38pr6	12	43	on	on	IN
cord-005478-5iu38pr6	12	44	TBF	TBF	NNP
cord-005478-5iu38pr6	12	45	(	(	-LRB-
cord-005478-5iu38pr6	12	46	thiotepa	thiotepa	JJ
cord-005478-5iu38pr6	12	47	,	,	,
cord-005478-5iu38pr6	12	48	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	12	49	and	and	CC
cord-005478-5iu38pr6	12	50	busulfan	busulfan	NN
cord-005478-5iu38pr6	12	51	)	)	-RRB-
cord-005478-5iu38pr6	13	1	(	(	-LRB-
cord-005478-5iu38pr6	13	2	83	83	CD
cord-005478-5iu38pr6	13	3	%	%	NN
cord-005478-5iu38pr6	13	4	,	,	,
cord-005478-5iu38pr6	13	5	p	p	NN
cord-005478-5iu38pr6	13	6	<	<	XX
cord-005478-5iu38pr6	13	7	0.001	0.001	CD
cord-005478-5iu38pr6	13	8	)	)	-RRB-
cord-005478-5iu38pr6	13	9	and	and	CC
cord-005478-5iu38pr6	13	10	bone	bone	NN
cord-005478-5iu38pr6	13	11	marrow	marrow	NN
cord-005478-5iu38pr6	13	12	(	(	-LRB-
cord-005478-5iu38pr6	13	13	BM	BM	NNP
cord-005478-5iu38pr6	13	14	)	)	-RRB-
cord-005478-5iu38pr6	13	15	as	as	IN
cord-005478-5iu38pr6	13	16	source	source	NN
cord-005478-5iu38pr6	13	17	of	of	IN
cord-005478-5iu38pr6	13	18	stem	stem	NN
cord-005478-5iu38pr6	13	19	cells	cell	NNS
cord-005478-5iu38pr6	13	20	(	(	-LRB-
cord-005478-5iu38pr6	13	21	77	77	CD
cord-005478-5iu38pr6	13	22	%	%	NN
cord-005478-5iu38pr6	13	23	,	,	,
cord-005478-5iu38pr6	13	24	p	p	NN
cord-005478-5iu38pr6	13	25	<	<	XX
cord-005478-5iu38pr6	13	26	0.001	0.001	CD
cord-005478-5iu38pr6	13	27	)	)	-RRB-
cord-005478-5iu38pr6	13	28	,	,	,
cord-005478-5iu38pr6	13	29	with	with	IN
cord-005478-5iu38pr6	13	30	no	no	DT
cord-005478-5iu38pr6	13	31	ATG	ATG	NNP
cord-005478-5iu38pr6	13	32	(	(	-LRB-
cord-005478-5iu38pr6	13	33	100	100	CD
cord-005478-5iu38pr6	13	34	%	%	NN
cord-005478-5iu38pr6	13	35	,	,	,
cord-005478-5iu38pr6	13	36	p	p	NN
cord-005478-5iu38pr6	13	37	<	<	XX
cord-005478-5iu38pr6	13	38	0.001	0.001	CD
cord-005478-5iu38pr6	13	39	)	)	-RRB-
cord-005478-5iu38pr6	13	40	.	.	.
cord-005478-5iu38pr6	14	1	Probability	probability	NN
cord-005478-5iu38pr6	14	2	of	of	IN
cord-005478-5iu38pr6	14	3	OS	OS	NNP
cord-005478-5iu38pr6	14	4	at	at	IN
cord-005478-5iu38pr6	14	5	2	2	CD
cord-005478-5iu38pr6	14	6	years	year	NNS
cord-005478-5iu38pr6	14	7	was	be	VBD
cord-005478-5iu38pr6	14	8	59	59	CD
cord-005478-5iu38pr6	14	9	%	%	NN
cord-005478-5iu38pr6	14	10	,	,	,
cord-005478-5iu38pr6	14	11	48	48	CD
cord-005478-5iu38pr6	14	12	%	%	NN
cord-005478-5iu38pr6	14	13	and	and	CC
cord-005478-5iu38pr6	14	14	44	44	CD
cord-005478-5iu38pr6	14	15	%	%	NN
cord-005478-5iu38pr6	14	16	,	,	,
cord-005478-5iu38pr6	14	17	for	for	IN
cord-005478-5iu38pr6	14	18	the	the	DT
cord-005478-5iu38pr6	14	19	3	3	CD
cord-005478-5iu38pr6	14	20	groups	group	NNS
cord-005478-5iu38pr6	14	21	,	,	,
cord-005478-5iu38pr6	14	22	respectively	respectively	RB
cord-005478-5iu38pr6	14	23	,	,	,
cord-005478-5iu38pr6	14	24	p=0.15	p=0.15	NNP
cord-005478-5iu38pr6	14	25	.	.	.
cord-005478-5iu38pr6	15	1	Probability	probability	NN
cord-005478-5iu38pr6	15	2	of	of	IN
cord-005478-5iu38pr6	15	3	LFS	lfs	NN
cord-005478-5iu38pr6	15	4	and	and	CC
cord-005478-5iu38pr6	15	5	GRFS	GRFS	NNP
cord-005478-5iu38pr6	15	6	at	at	IN
cord-005478-5iu38pr6	15	7	2	2	CD
cord-005478-5iu38pr6	15	8	years	year	NNS
cord-005478-5iu38pr6	15	9	were	be	VBD
cord-005478-5iu38pr6	15	10	52	52	CD
cord-005478-5iu38pr6	15	11	%	%	NN
cord-005478-5iu38pr6	15	12	and	and	CC
cord-005478-5iu38pr6	15	13	46	46	CD
cord-005478-5iu38pr6	15	14	%	%	NN
cord-005478-5iu38pr6	15	15	,	,	,
cord-005478-5iu38pr6	15	16	43	43	CD
cord-005478-5iu38pr6	15	17	%	%	NN
cord-005478-5iu38pr6	15	18	and	and	CC
cord-005478-5iu38pr6	15	19	36	36	CD
cord-005478-5iu38pr6	15	20	%	%	NN
cord-005478-5iu38pr6	15	21	,	,	,
cord-005478-5iu38pr6	15	22	39	39	CD
cord-005478-5iu38pr6	15	23	%	%	NN
cord-005478-5iu38pr6	15	24	and	and	CC
cord-005478-5iu38pr6	15	25	33	33	CD
cord-005478-5iu38pr6	15	26	%	%	NN
cord-005478-5iu38pr6	15	27	,	,	,
cord-005478-5iu38pr6	15	28	for	for	IN
cord-005478-5iu38pr6	15	29	the	the	DT
cord-005478-5iu38pr6	15	30	3	3	CD
cord-005478-5iu38pr6	15	31	groups	group	NNS
cord-005478-5iu38pr6	15	32	,	,	,
cord-005478-5iu38pr6	15	33	respectively	respectively	RB
cord-005478-5iu38pr6	15	34	,	,	,
cord-005478-5iu38pr6	15	35	(	(	-LRB-
cord-005478-5iu38pr6	15	36	LFS	LFS	NNP
cord-005478-5iu38pr6	15	37	p=0.05	p=0.05	NNP
cord-005478-5iu38pr6	15	38	,	,	,
cord-005478-5iu38pr6	15	39	GRFS	GRFS	NNP
cord-005478-5iu38pr6	15	40	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	15	41	.	.	.
cord-005478-5iu38pr6	16	1	Overall	overall	RB
cord-005478-5iu38pr6	16	2	the	the	DT
cord-005478-5iu38pr6	16	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	16	4	incidence	incidence	NN
cord-005478-5iu38pr6	16	5	(	(	-LRB-
cord-005478-5iu38pr6	16	6	CI	CI	NNP
cord-005478-5iu38pr6	16	7	)	)	-RRB-
cord-005478-5iu38pr6	16	8	of	of	IN
cord-005478-5iu38pr6	16	9	grade	grade	NN
cord-005478-5iu38pr6	16	10	II	II	NNP
cord-005478-5iu38pr6	16	11	-	-	HYPH
cord-005478-5iu38pr6	16	12	IV	IV	NNP
cord-005478-5iu38pr6	16	13	acute	acute	JJ
cord-005478-5iu38pr6	16	14	GVHD	GVHD	NNP
cord-005478-5iu38pr6	16	15	was	be	VBD
cord-005478-5iu38pr6	16	16	18	18	CD
cord-005478-5iu38pr6	16	17	%	%	NN
cord-005478-5iu38pr6	16	18	,	,	,
cord-005478-5iu38pr6	16	19	39	39	CD
cord-005478-5iu38pr6	16	20	%	%	NN
cord-005478-5iu38pr6	16	21	and	and	CC
cord-005478-5iu38pr6	16	22	25	25	CD
cord-005478-5iu38pr6	16	23	%	%	NN
cord-005478-5iu38pr6	16	24	,	,	,
cord-005478-5iu38pr6	16	25	for	for	IN
cord-005478-5iu38pr6	16	26	the	the	DT
cord-005478-5iu38pr6	16	27	3	3	CD
cord-005478-5iu38pr6	16	28	groups	group	NNS
cord-005478-5iu38pr6	16	29	,	,	,
cord-005478-5iu38pr6	16	30	respectively	respectively	RB
cord-005478-5iu38pr6	16	31	,	,	,
cord-005478-5iu38pr6	16	32	p	p	NN
cord-005478-5iu38pr6	16	33	<	<	XX
cord-005478-5iu38pr6	16	34	0.001	0.001	CD
cord-005478-5iu38pr6	16	35	,	,	,
cord-005478-5iu38pr6	16	36	and	and	CC
cord-005478-5iu38pr6	16	37	the	the	DT
cord-005478-5iu38pr6	16	38	CI	CI	NNP
cord-005478-5iu38pr6	16	39	of	of	IN
cord-005478-5iu38pr6	16	40	chronic	chronic	JJ
cord-005478-5iu38pr6	16	41	GVHD	GVHD	NNP
cord-005478-5iu38pr6	16	42	was	be	VBD
cord-005478-5iu38pr6	16	43	23	23	CD
cord-005478-5iu38pr6	16	44	%	%	NN
cord-005478-5iu38pr6	16	45	,	,	,
cord-005478-5iu38pr6	16	46	21	21	CD
cord-005478-5iu38pr6	16	47	%	%	NN
cord-005478-5iu38pr6	16	48	and	and	CC
cord-005478-5iu38pr6	16	49	25	25	CD
cord-005478-5iu38pr6	16	50	%	%	NN
cord-005478-5iu38pr6	16	51	;	;	,
cord-005478-5iu38pr6	16	52	p=0.28	p=0.28	NNP
cord-005478-5iu38pr6	16	53	.	.	.
cord-005478-5iu38pr6	17	1	The	the	DT
cord-005478-5iu38pr6	17	2	CI	CI	NNP
cord-005478-5iu38pr6	17	3	of	of	IN
cord-005478-5iu38pr6	17	4	relapse	relapse	NN
cord-005478-5iu38pr6	17	5	at	at	IN
cord-005478-5iu38pr6	17	6	2	2	CD
cord-005478-5iu38pr6	17	7	years	year	NNS
cord-005478-5iu38pr6	17	8	was	be	VBD
cord-005478-5iu38pr6	17	9	26	26	CD
cord-005478-5iu38pr6	17	10	%	%	NN
cord-005478-5iu38pr6	17	11	,	,	,
cord-005478-5iu38pr6	17	12	37	37	CD
cord-005478-5iu38pr6	17	13	%	%	NN
cord-005478-5iu38pr6	17	14	and	and	CC
cord-005478-5iu38pr6	17	15	35	35	CD
cord-005478-5iu38pr6	17	16	%	%	NN
cord-005478-5iu38pr6	17	17	(	(	-LRB-
cord-005478-5iu38pr6	17	18	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	17	19	)	)	-RRB-
cord-005478-5iu38pr6	17	20	and	and	CC
cord-005478-5iu38pr6	17	21	Background	background	NN
cord-005478-5iu38pr6	17	22	:	:	:
cord-005478-5iu38pr6	18	1	Patients	patient	NNS
cord-005478-5iu38pr6	18	2	with	with	IN
cord-005478-5iu38pr6	18	3	acute	acute	JJ
cord-005478-5iu38pr6	18	4	myeloid	myeloid	NN
cord-005478-5iu38pr6	18	5	leukaemia	leukaemia	NN
cord-005478-5iu38pr6	18	6	(	(	-LRB-
cord-005478-5iu38pr6	18	7	AML	AML	NNP
cord-005478-5iu38pr6	18	8	)	)	-RRB-
cord-005478-5iu38pr6	18	9	often	often	RB
cord-005478-5iu38pr6	18	10	achieve	achieve	VBP
cord-005478-5iu38pr6	18	11	remission	remission	NN
cord-005478-5iu38pr6	18	12	but	but	CC
cord-005478-5iu38pr6	18	13	subsequently	subsequently	RB
cord-005478-5iu38pr6	18	14	die	die	VBP
cord-005478-5iu38pr6	18	15	of	of	IN
cord-005478-5iu38pr6	18	16	relapse	relapse	NN
cord-005478-5iu38pr6	18	17	driven	drive	VBN
cord-005478-5iu38pr6	18	18	by	by	IN
cord-005478-5iu38pr6	18	19	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	18	20	resistant	resistant	JJ
cord-005478-5iu38pr6	18	21	leukemic	leukemic	JJ
cord-005478-5iu38pr6	18	22	stem	stem	NN
cord-005478-5iu38pr6	18	23	cells	cell	NNS
cord-005478-5iu38pr6	18	24	(	(	-LRB-
cord-005478-5iu38pr6	18	25	LSCs	lsc	NNS
cord-005478-5iu38pr6	18	26	)	)	-RRB-
cord-005478-5iu38pr6	18	27	.	.	.
cord-005478-5iu38pr6	19	1	Here	here	RB
cord-005478-5iu38pr6	19	2	we	-PRON-	PRP
cord-005478-5iu38pr6	19	3	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	19	4	that	that	IN
cord-005478-5iu38pr6	19	5	LSCs	lsc	NNS
cord-005478-5iu38pr6	19	6	must	must	MD
cord-005478-5iu38pr6	19	7	also	also	RB
cord-005478-5iu38pr6	19	8	escape	escape	VB
cord-005478-5iu38pr6	19	9	immunosurveillance	immunosurveillance	NN
cord-005478-5iu38pr6	19	10	to	to	TO
cord-005478-5iu38pr6	19	11	initiate	initiate	VB
cord-005478-5iu38pr6	19	12	and	and	CC
cord-005478-5iu38pr6	19	13	maintain	maintain	VB
cord-005478-5iu38pr6	19	14	cancer	cancer	NN
cord-005478-5iu38pr6	19	15	and	and	CC
cord-005478-5iu38pr6	19	16	investigate	investigate	VB
cord-005478-5iu38pr6	19	17	the	the	DT
cord-005478-5iu38pr6	19	18	interplay	interplay	NN
cord-005478-5iu38pr6	19	19	with	with	IN
cord-005478-5iu38pr6	19	20	NKG2D	nkg2d	CD
cord-005478-5iu38pr6	19	21	,	,	,
cord-005478-5iu38pr6	19	22	a	a	DT
cord-005478-5iu38pr6	19	23	danger	danger	NN
cord-005478-5iu38pr6	19	24	detector	detector	NN
cord-005478-5iu38pr6	19	25	expressed	express	VBN
cord-005478-5iu38pr6	19	26	by	by	IN
cord-005478-5iu38pr6	19	27	cytotoxic	cytotoxic	JJ
cord-005478-5iu38pr6	19	28	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	19	29	such	such	JJ
cord-005478-5iu38pr6	19	30	as	as	IN
cord-005478-5iu38pr6	19	31	natural	natural	JJ
cord-005478-5iu38pr6	19	32	killer	killer	NN
cord-005478-5iu38pr6	19	33	(	(	-LRB-
cord-005478-5iu38pr6	19	34	NK	NK	NNP
cord-005478-5iu38pr6	19	35	)	)	-RRB-
cord-005478-5iu38pr6	19	36	cells	cell	NNS
cord-005478-5iu38pr6	19	37	that	that	WDT
cord-005478-5iu38pr6	19	38	recognizes	recognize	VBZ
cord-005478-5iu38pr6	19	39	stress	stress	NN
cord-005478-5iu38pr6	19	40	-	-	HYPH
cord-005478-5iu38pr6	19	41	induced	induce	VBN
cord-005478-5iu38pr6	19	42	ligands	ligand	NNS
cord-005478-5iu38pr6	19	43	(	(	-LRB-
cord-005478-5iu38pr6	19	44	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	19	45	)	)	-RRB-
cord-005478-5iu38pr6	19	46	of	of	IN
cord-005478-5iu38pr6	19	47	the	the	DT
cord-005478-5iu38pr6	19	48	MIC	MIC	NNP
cord-005478-5iu38pr6	19	49	and	and	CC
cord-005478-5iu38pr6	19	50	ULBP	ULBP	NNP
cord-005478-5iu38pr6	19	51	protein	protein	NN
cord-005478-5iu38pr6	19	52	families	family	NNS
cord-005478-5iu38pr6	19	53	on	on	IN
cord-005478-5iu38pr6	19	54	AML	AML	NNP
cord-005478-5iu38pr6	19	55	cells	cell	NNS
cord-005478-5iu38pr6	19	56	.	.	.
cord-005478-5iu38pr6	20	1	Methods	method	NNS
cord-005478-5iu38pr6	20	2	:	:	:
cord-005478-5iu38pr6	20	3	175	175	CD
cord-005478-5iu38pr6	20	4	de	de	NNP
cord-005478-5iu38pr6	20	5	novo	novo	NNP
cord-005478-5iu38pr6	20	6	AML	AML	NNP
cord-005478-5iu38pr6	20	7	were	be	VBD
cord-005478-5iu38pr6	20	8	stained	stain	VBN
cord-005478-5iu38pr6	20	9	with	with	IN
cord-005478-5iu38pr6	20	10	antibodies	antibody	NNS
cord-005478-5iu38pr6	20	11	against	against	IN
cord-005478-5iu38pr6	20	12	MICA	MICA	NNP
cord-005478-5iu38pr6	20	13	,	,	,
cord-005478-5iu38pr6	20	14	MICB	MICB	NNP
cord-005478-5iu38pr6	20	15	and	and	CC
cord-005478-5iu38pr6	20	16	ULB2/5/6	ULB2/5/6	NNP
cord-005478-5iu38pr6	20	17	or	or	CC
cord-005478-5iu38pr6	20	18	an	an	DT
cord-005478-5iu38pr6	20	19	NKG2D	NKG2D	NNP
cord-005478-5iu38pr6	20	20	-	-	HYPH
cord-005478-5iu38pr6	20	21	Fc	Fc	NNP
cord-005478-5iu38pr6	20	22	chimeric	chimeric	JJ
cord-005478-5iu38pr6	20	23	protein	protein	NN
cord-005478-5iu38pr6	20	24	recognizing	recognize	VBG
cord-005478-5iu38pr6	20	25	pan	pan	JJ
cord-005478-5iu38pr6	20	26	-	-	HYPH
cord-005478-5iu38pr6	20	27	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	20	28	.	.	.
cord-005478-5iu38pr6	21	1	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	21	2	pos	pos	NNP
cord-005478-5iu38pr6	21	3	and	and	CC
cord-005478-5iu38pr6	21	4	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	21	5	neg	neg	JJ
cord-005478-5iu38pr6	21	6	AML	AML	NNP
cord-005478-5iu38pr6	21	7	cells	cell	NNS
cord-005478-5iu38pr6	21	8	sorted	sort	VBN
cord-005478-5iu38pr6	21	9	from	from	IN
cord-005478-5iu38pr6	21	10	the	the	DT
cord-005478-5iu38pr6	21	11	same	same	JJ
cord-005478-5iu38pr6	21	12	patient	patient	NN
cord-005478-5iu38pr6	21	13	were	be	VBD
cord-005478-5iu38pr6	21	14	analysed	analyse	VBN
cord-005478-5iu38pr6	21	15	in	in	IN
cord-005478-5iu38pr6	21	16	colony	colony	NN
cord-005478-5iu38pr6	21	17	forming	form	VBG
cord-005478-5iu38pr6	21	18	assays	assay	NNS
cord-005478-5iu38pr6	21	19	,	,	,
cord-005478-5iu38pr6	21	20	leukemogenesis	leukemogenesis	NN
cord-005478-5iu38pr6	21	21	assays	assay	NNS
cord-005478-5iu38pr6	21	22	in	in	IN
cord-005478-5iu38pr6	21	23	NSG	NSG	NNP
cord-005478-5iu38pr6	21	24	mice	mouse	NNS
cord-005478-5iu38pr6	21	25	,	,	,
cord-005478-5iu38pr6	21	26	by	by	IN
cord-005478-5iu38pr6	21	27	RNAseq	RNAseq	NNP
cord-005478-5iu38pr6	21	28	,	,	,
cord-005478-5iu38pr6	21	29	gene	gene	NN
cord-005478-5iu38pr6	21	30	expression	expression	NN
cord-005478-5iu38pr6	21	31	arrays	array	NNS
cord-005478-5iu38pr6	21	32	,	,	,
cord-005478-5iu38pr6	21	33	qRT	qRT	NNP
cord-005478-5iu38pr6	21	34	-	-	HYPH
cord-005478-5iu38pr6	21	35	PCR	PCR	NNP
cord-005478-5iu38pr6	21	36	and	and	CC
cord-005478-5iu38pr6	21	37	targeted	target	VBD
cord-005478-5iu38pr6	21	38	next	next	JJ
cord-005478-5iu38pr6	21	39	generation	generation	NN
cord-005478-5iu38pr6	21	40	sequencing	sequencing	NN
cord-005478-5iu38pr6	21	41	.	.	.
cord-005478-5iu38pr6	22	1	AML	AML	NNP
cord-005478-5iu38pr6	22	2	cells	cell	NNS
cord-005478-5iu38pr6	22	3	co	co	VBP
cord-005478-5iu38pr6	22	4	-	-	JJ
cord-005478-5iu38pr6	22	5	cultured	cultured	JJ
cord-005478-5iu38pr6	22	6	or	or	CC
cord-005478-5iu38pr6	22	7	not	not	RB
cord-005478-5iu38pr6	22	8	with	with	IN
cord-005478-5iu38pr6	22	9	NK	NK	NNP
cord-005478-5iu38pr6	22	10	cells	cell	NNS
cord-005478-5iu38pr6	22	11	(	(	-LRB-
cord-005478-5iu38pr6	22	12	control	control	NN
cord-005478-5iu38pr6	22	13	or	or	CC
cord-005478-5iu38pr6	22	14	anti	anti	JJ
cord-005478-5iu38pr6	22	15	-	-	JJ
cord-005478-5iu38pr6	22	16	NKG2D	nkg2d	JJ
cord-005478-5iu38pr6	22	17	pre	pre	JJ
cord-005478-5iu38pr6	22	18	-	-	VBN
cord-005478-5iu38pr6	22	19	treated	treated	JJ
cord-005478-5iu38pr6	22	20	)	)	-RRB-
cord-005478-5iu38pr6	22	21	were	be	VBD
cord-005478-5iu38pr6	22	22	co	co	JJ
cord-005478-5iu38pr6	22	23	-	-	JJ
cord-005478-5iu38pr6	22	24	stained	stain	VBN
cord-005478-5iu38pr6	22	25	for	for	IN
cord-005478-5iu38pr6	22	26	additional	additional	JJ
cord-005478-5iu38pr6	22	27	stem	stem	NN
cord-005478-5iu38pr6	22	28	/	/	SYM
cord-005478-5iu38pr6	22	29	immunological	immunological	JJ
cord-005478-5iu38pr6	22	30	markers	marker	NNS
cord-005478-5iu38pr6	22	31	.	.	.
cord-005478-5iu38pr6	23	1	PARP1	PARP1	NNP
cord-005478-5iu38pr6	23	2	expression	expression	NN
cord-005478-5iu38pr6	23	3	was	be	VBD
cord-005478-5iu38pr6	23	4	analysed	analyse	VBN
cord-005478-5iu38pr6	23	5	by	by	IN
cord-005478-5iu38pr6	23	6	qRT	qRT	NNP
cord-005478-5iu38pr6	23	7	-	-	HYPH
cord-005478-5iu38pr6	23	8	PCR	PCR	NNP
cord-005478-5iu38pr6	23	9	and	and	CC
cord-005478-5iu38pr6	23	10	immunoblot	immunoblot	NNP
cord-005478-5iu38pr6	23	11	,	,	,
cord-005478-5iu38pr6	23	12	and	and	CC
cord-005478-5iu38pr6	23	13	binding	bind	VBG
cord-005478-5iu38pr6	23	14	to	to	IN
cord-005478-5iu38pr6	23	15	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	23	16	promoters	promoter	NNS
cord-005478-5iu38pr6	23	17	by	by	IN
cord-005478-5iu38pr6	23	18	chromatin	chromatin	NN
cord-005478-5iu38pr6	23	19	immunoprecipitation	immunoprecipitation	NN
cord-005478-5iu38pr6	23	20	.	.	.
cord-005478-5iu38pr6	24	1	PARP1	PARP1	NNP
cord-005478-5iu38pr6	24	2	inhibition	inhibition	NN
cord-005478-5iu38pr6	24	3	(	(	-LRB-
cord-005478-5iu38pr6	24	4	PARPi	PARPi	NNP
cord-005478-5iu38pr6	24	5	)	)	-RRB-
cord-005478-5iu38pr6	24	6	in	in	IN
cord-005478-5iu38pr6	24	7	AML	AML	NNP
cord-005478-5iu38pr6	24	8	cells	cell	NNS
cord-005478-5iu38pr6	24	9	was	be	VBD
cord-005478-5iu38pr6	24	10	performed	perform	VBN
cord-005478-5iu38pr6	24	11	in	in	IN
cord-005478-5iu38pr6	24	12	vitro	vitro	FW
cord-005478-5iu38pr6	24	13	or	or	CC
cord-005478-5iu38pr6	24	14	in	in	IN
cord-005478-5iu38pr6	24	15	vivo	vivo	NN
cord-005478-5iu38pr6	24	16	using	use	VBG
cord-005478-5iu38pr6	24	17	siRNAs	siRNAs	NNP
cord-005478-5iu38pr6	24	18	or	or	CC
cord-005478-5iu38pr6	24	19	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	24	20	(	(	-LRB-
cord-005478-5iu38pr6	24	21	AG-14361	AG-14361	NNP
cord-005478-5iu38pr6	24	22	,	,	,
cord-005478-5iu38pr6	24	23	veliparib	veliparib	NNP
cord-005478-5iu38pr6	24	24	)	)	-RRB-
cord-005478-5iu38pr6	24	25	.	.	.
cord-005478-5iu38pr6	25	1	Results	result	NNS
cord-005478-5iu38pr6	25	2	:	:	:
cord-005478-5iu38pr6	26	1	Heterogeneous	heterogeneous	JJ
cord-005478-5iu38pr6	26	2	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	26	3	expression	expression	NN
cord-005478-5iu38pr6	26	4	was	be	VBD
cord-005478-5iu38pr6	26	5	detected	detect	VBN
cord-005478-5iu38pr6	26	6	among	among	IN
cord-005478-5iu38pr6	26	7	leukemic	leukemic	JJ
cord-005478-5iu38pr6	26	8	cells	cell	NNS
cord-005478-5iu38pr6	26	9	of	of	IN
cord-005478-5iu38pr6	26	10	the	the	DT
cord-005478-5iu38pr6	26	11	same	same	JJ
cord-005478-5iu38pr6	26	12	patient	patient	NN
cord-005478-5iu38pr6	26	13	(	(	-LRB-
cord-005478-5iu38pr6	26	14	Fig	Fig	NNP
cord-005478-5iu38pr6	26	15	.	.	.
cord-005478-5iu38pr6	26	16	 	 	_SP
cord-005478-5iu38pr6	26	17	1a	1a	CD
cord-005478-5iu38pr6	26	18	)	)	-RRB-
cord-005478-5iu38pr6	26	19	.	.	.
cord-005478-5iu38pr6	27	1	Interestingly	interestingly	RB
cord-005478-5iu38pr6	27	2	,	,	,
cord-005478-5iu38pr6	27	3	when	when	WRB
cord-005478-5iu38pr6	27	4	compared	compare	VBN
cord-005478-5iu38pr6	27	5	to	to	IN
cord-005478-5iu38pr6	27	6	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	27	7	pos	pos	NN
cord-005478-5iu38pr6	27	8	subpopulations	subpopulation	NNS
cord-005478-5iu38pr6	27	9	,	,	,
cord-005478-5iu38pr6	27	10	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	27	11	neg	neg	JJ
cord-005478-5iu38pr6	27	12	AML	AML	NNP
cord-005478-5iu38pr6	27	13	cells	cell	NNS
cord-005478-5iu38pr6	27	14	isolated	isolate	VBN
cord-005478-5iu38pr6	27	15	from	from	IN
cord-005478-5iu38pr6	27	16	the	the	DT
cord-005478-5iu38pr6	27	17	same	same	JJ
cord-005478-5iu38pr6	27	18	patient	patient	NN
cord-005478-5iu38pr6	27	19	showed	show	VBD
cord-005478-5iu38pr6	27	20	immature	immature	JJ
cord-005478-5iu38pr6	27	21	morphology	morphology	NN
cord-005478-5iu38pr6	27	22	,	,	,
cord-005478-5iu38pr6	27	23	enhanced	enhance	VBN
cord-005478-5iu38pr6	27	24	in	in	IN
cord-005478-5iu38pr6	27	25	vitro	vitro	FW
cord-005478-5iu38pr6	27	26	clonogenicity	clonogenicity	NN
cord-005478-5iu38pr6	27	27	(	(	-LRB-
cord-005478-5iu38pr6	27	28	39±47	39±47	JJ
cord-005478-5iu38pr6	27	29	colonies	colony	NNS
cord-005478-5iu38pr6	27	30	vs.	vs.	IN
cord-005478-5iu38pr6	27	31	1±4	1±4	CD
cord-005478-5iu38pr6	27	32	,	,	,
cord-005478-5iu38pr6	27	33	p	p	NN
cord-005478-5iu38pr6	27	34	<	<	XX
cord-005478-5iu38pr6	27	35	0.001	0.001	CD
cord-005478-5iu38pr6	27	36	,	,	,
cord-005478-5iu38pr6	27	37	n=32	n=32	NNP
cord-005478-5iu38pr6	27	38	AML	AML	NNP
cord-005478-5iu38pr6	27	39	patients	patient	NNS
cord-005478-5iu38pr6	27	40	)	)	-RRB-
cord-005478-5iu38pr6	27	41	and	and	CC
cord-005478-5iu38pr6	27	42	selective	selective	JJ
cord-005478-5iu38pr6	27	43	abilities	ability	NNS
cord-005478-5iu38pr6	27	44	to	to	TO
cord-005478-5iu38pr6	27	45	initiate	initiate	VB
cord-005478-5iu38pr6	27	46	leukemia	leukemia	NN
cord-005478-5iu38pr6	27	47	(	(	-LRB-
cord-005478-5iu38pr6	28	1	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	28	2	neg	neg	JJ
cord-005478-5iu38pr6	28	3	,	,	,
cord-005478-5iu38pr6	28	4	64/70	64/70	CD
cord-005478-5iu38pr6	28	5	,	,	,
cord-005478-5iu38pr6	28	6	91	91	CD
cord-005478-5iu38pr6	28	7	%	%	NN
cord-005478-5iu38pr6	28	8	;	;	:
cord-005478-5iu38pr6	28	9	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	28	10	pos	pos	NN
cord-005478-5iu38pr6	28	11	,	,	,
cord-005478-5iu38pr6	28	12	0/78	0/78	CD
cord-005478-5iu38pr6	28	13	,	,	,
cord-005478-5iu38pr6	28	14	0	0	CD
cord-005478-5iu38pr6	28	15	%	%	NN
cord-005478-5iu38pr6	28	16	;	;	:
cord-005478-5iu38pr6	28	17	p	p	NN
cord-005478-5iu38pr6	28	18	<	<	XX
cord-005478-5iu38pr6	28	19	0.00001	0.00001	CD
cord-005478-5iu38pr6	28	20	,	,	,
cord-005478-5iu38pr6	28	21	Fig	Fig	NNP
cord-005478-5iu38pr6	28	22	.	.	.
cord-005478-5iu38pr6	29	1	1b	1b	LS
cord-005478-5iu38pr6	29	2	,	,	,
cord-005478-5iu38pr6	29	3	n=19	n=19	JJ
cord-005478-5iu38pr6	29	4	AML	AML	NNP
cord-005478-5iu38pr6	29	5	patients	patient	NNS
cord-005478-5iu38pr6	29	6	)	)	-RRB-
cord-005478-5iu38pr6	29	7	and	and	CC
cord-005478-5iu38pr6	29	8	survive	survive	VBP
cord-005478-5iu38pr6	29	9	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	29	10	in	in	IN
cord-005478-5iu38pr6	29	11	NSG	NSG	NNP
cord-005478-5iu38pr6	29	12	mice	mouse	NNS
cord-005478-5iu38pr6	29	13	devoid	devoid	JJ
cord-005478-5iu38pr6	29	14	of	of	IN
cord-005478-5iu38pr6	29	15	functional	functional	JJ
cord-005478-5iu38pr6	29	16	NK	NK	NNP
cord-005478-5iu38pr6	29	17	cells	cell	NNS
cord-005478-5iu38pr6	29	18	.	.	.
cord-005478-5iu38pr6	30	1	In	in	IN
cord-005478-5iu38pr6	30	2	mice	mouse	NNS
cord-005478-5iu38pr6	30	3	,	,	,
cord-005478-5iu38pr6	30	4	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	30	5	neg	neg	JJ
cord-005478-5iu38pr6	30	6	AML	AML	NNP
cord-005478-5iu38pr6	30	7	cells	cell	NNS
cord-005478-5iu38pr6	30	8	generated	generate	VBD
cord-005478-5iu38pr6	30	9	both	both	DT
cord-005478-5iu38pr6	30	10	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	30	11	pos	pos	NN
cord-005478-5iu38pr6	30	12	and	and	CC
cord-005478-5iu38pr6	30	13	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	30	14	neg	neg	JJ
cord-005478-5iu38pr6	30	15	progeny	progeny	NN
cord-005478-5iu38pr6	30	16	of	of	IN
cord-005478-5iu38pr6	30	17	which	which	WDT
cord-005478-5iu38pr6	30	18	again	again	RB
cord-005478-5iu38pr6	30	19	only	only	RB
cord-005478-5iu38pr6	30	20	latter	latter	RB
cord-005478-5iu38pr6	30	21	was	be	VBD
cord-005478-5iu38pr6	30	22	able	able	JJ
cord-005478-5iu38pr6	30	23	to	to	TO
cord-005478-5iu38pr6	30	24	induce	induce	VB
cord-005478-5iu38pr6	30	25	leukemia	leukemia	NN
cord-005478-5iu38pr6	30	26	in	in	IN
cord-005478-5iu38pr6	30	27	re	re	NN
cord-005478-5iu38pr6	30	28	-	-	NN
cord-005478-5iu38pr6	30	29	transplant	transplant	NN
cord-005478-5iu38pr6	30	30	assays	assay	NNS
cord-005478-5iu38pr6	30	31	.	.	.
cord-005478-5iu38pr6	31	1	Similar	similar	JJ
cord-005478-5iu38pr6	31	2	leukemia	leukemia	NN
cord-005478-5iu38pr6	31	3	-	-	HYPH
cord-005478-5iu38pr6	31	4	specific	specific	JJ
cord-005478-5iu38pr6	31	5	mutations	mutation	NNS
cord-005478-5iu38pr6	31	6	were	be	VBD
cord-005478-5iu38pr6	31	7	detected	detect	VBN
cord-005478-5iu38pr6	31	8	in	in	IN
cord-005478-5iu38pr6	31	9	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	31	10	neg	neg	NN
cord-005478-5iu38pr6	31	11	compared	compare	VBN
cord-005478-5iu38pr6	31	12	to	to	IN
cord-005478-5iu38pr6	31	13	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	31	14	pos	pos	NNP
cord-005478-5iu38pr6	31	15	AML	AML	NNP
cord-005478-5iu38pr6	31	16	cells	cell	NNS
cord-005478-5iu38pr6	31	17	from	from	IN
cord-005478-5iu38pr6	31	18	the	the	DT
cord-005478-5iu38pr6	31	19	same	same	JJ
cord-005478-5iu38pr6	31	20	AML	AML	NNP
cord-005478-5iu38pr6	31	21	but	but	CC
cord-005478-5iu38pr6	31	22	published	publish	VBD
cord-005478-5iu38pr6	31	23	LSC	LSC	NNP
cord-005478-5iu38pr6	31	24	(	(	-LRB-
cord-005478-5iu38pr6	31	25	Fig	Fig	NNP
cord-005478-5iu38pr6	31	26	.	.	.
cord-005478-5iu38pr6	31	27	1c	1c	NNP
cord-005478-5iu38pr6	31	28	)	)	-RRB-
cord-005478-5iu38pr6	31	29	,	,	,
cord-005478-5iu38pr6	31	30	HSC	HSC	NNP
cord-005478-5iu38pr6	31	31	and	and	CC
cord-005478-5iu38pr6	31	32	17genes	17genes	CD
cord-005478-5iu38pr6	31	33	stemness	stemness	JJ
cord-005478-5iu38pr6	31	34	score	score	NN
cord-005478-5iu38pr6	31	35	signatures	signature	NNS
cord-005478-5iu38pr6	31	36	were	be	VBD
cord-005478-5iu38pr6	31	37	specifically	specifically	RB
cord-005478-5iu38pr6	31	38	enriched	enrich	VBN
cord-005478-5iu38pr6	31	39	in	in	IN
cord-005478-5iu38pr6	31	40	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	31	41	neg	neg	JJ
cord-005478-5iu38pr6	31	42	subfractions	subfraction	NNS
cord-005478-5iu38pr6	31	43	.	.	.
cord-005478-5iu38pr6	32	1	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	32	2	neg	neg	NN
cord-005478-5iu38pr6	32	3	cells	cell	NNS
cord-005478-5iu38pr6	32	4	enriched	enrich	VBN
cord-005478-5iu38pr6	32	5	for	for	IN
cord-005478-5iu38pr6	32	6	LSCs	lsc	NNS
cord-005478-5iu38pr6	32	7	defined	define	VBN
cord-005478-5iu38pr6	32	8	by	by	IN
cord-005478-5iu38pr6	32	9	alternative	alternative	JJ
cord-005478-5iu38pr6	32	10	markers	marker	NNS
cord-005478-5iu38pr6	32	11	(	(	-LRB-
cord-005478-5iu38pr6	32	12	CD34	CD34	NNP
cord-005478-5iu38pr6	32	13	+	+	CC
cord-005478-5iu38pr6	32	14	,	,	,
cord-005478-5iu38pr6	32	15	CD38	CD38	NNP
cord-005478-5iu38pr6	32	16	-	-	HYPH
cord-005478-5iu38pr6	32	17	,	,	,
cord-005478-5iu38pr6	32	18	GPR56	GPR56	NNP
cord-005478-5iu38pr6	32	19	+	+	NN
cord-005478-5iu38pr6	32	20	)	)	-RRB-
cord-005478-5iu38pr6	33	1	but	but	CC
cord-005478-5iu38pr6	33	2	could	could	MD
cord-005478-5iu38pr6	33	3	identify	identify	VB
cord-005478-5iu38pr6	33	4	cells	cell	NNS
cord-005478-5iu38pr6	33	5	with	with	IN
cord-005478-5iu38pr6	33	6	functional	functional	JJ
cord-005478-5iu38pr6	33	7	and	and	CC
cord-005478-5iu38pr6	33	8	molecular	molecular	JJ
cord-005478-5iu38pr6	33	9	LSC	LSC	NNP
cord-005478-5iu38pr6	33	10	activity	activity	NN
cord-005478-5iu38pr6	33	11	also	also	RB
cord-005478-5iu38pr6	33	12	in	in	IN
cord-005478-5iu38pr6	33	13	CD34	CD34	NNP
cord-005478-5iu38pr6	33	14	non	non	RB
cord-005478-5iu38pr6	33	15	-	-	JJ
cord-005478-5iu38pr6	33	16	expressing	express	VBG
cord-005478-5iu38pr6	33	17	AML	AML	NNP
cord-005478-5iu38pr6	33	18	(	(	-LRB-
cord-005478-5iu38pr6	33	19	n=11	n=11	NNP
cord-005478-5iu38pr6	33	20	analyzed	analyze	VBD
cord-005478-5iu38pr6	33	21	patients	patient	NNS
cord-005478-5iu38pr6	33	22	)	)	-RRB-
cord-005478-5iu38pr6	33	23	.	.	.
cord-005478-5iu38pr6	34	1	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	34	2	expression	expression	NN
cord-005478-5iu38pr6	34	3	was	be	VBD
cord-005478-5iu38pr6	34	4	repressed	repress	VBN
cord-005478-5iu38pr6	34	5	by	by	IN
cord-005478-5iu38pr6	34	6	PARP1	PARP1	NNP
cord-005478-5iu38pr6	34	7	recruitment	recruitment	NN
cord-005478-5iu38pr6	34	8	at	at	IN
cord-005478-5iu38pr6	34	9	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	34	10	promoters	promoter	NNS
cord-005478-5iu38pr6	34	11	.	.	.
cord-005478-5iu38pr6	35	1	PARP1	PARP1	NNP
cord-005478-5iu38pr6	35	2	inhibition	inhibition	NN
cord-005478-5iu38pr6	35	3	(	(	-LRB-
cord-005478-5iu38pr6	35	4	PARPi	PARPi	NNP
cord-005478-5iu38pr6	35	5	)	)	-RRB-
cord-005478-5iu38pr6	35	6	induced	induce	VBD
cord-005478-5iu38pr6	35	7	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	35	8	surface	surface	NN
cord-005478-5iu38pr6	35	9	expression	expression	NN
cord-005478-5iu38pr6	35	10	in	in	IN
cord-005478-5iu38pr6	35	11	LSCs	lsc	NNS
cord-005478-5iu38pr6	35	12	and	and	CC
cord-005478-5iu38pr6	35	13	co	co	NN
cord-005478-5iu38pr6	35	14	-	-	NN
cord-005478-5iu38pr6	35	15	treatment	treatment	NN
cord-005478-5iu38pr6	35	16	with	with	IN
cord-005478-5iu38pr6	35	17	PARPi	PARPi	NNS
cord-005478-5iu38pr6	35	18	and	and	CC
cord-005478-5iu38pr6	35	19	NK	NK	NNP
cord-005478-5iu38pr6	35	20	cells	cell	NNS
cord-005478-5iu38pr6	35	21	(	(	-LRB-
cord-005478-5iu38pr6	35	22	but	but	CC
cord-005478-5iu38pr6	35	23	not	not	RB
cord-005478-5iu38pr6	35	24	with	with	IN
cord-005478-5iu38pr6	35	25	either	either	RB
cord-005478-5iu38pr6	35	26	alone	alone	RB
cord-005478-5iu38pr6	35	27	)	)	-RRB-
cord-005478-5iu38pr6	35	28	suppressed	suppress	VBD
cord-005478-5iu38pr6	35	29	leukemogenesis	leukemogenesis	NN
cord-005478-5iu38pr6	35	30	in	in	IN
cord-005478-5iu38pr6	35	31	patient	patient	NN
cord-005478-5iu38pr6	35	32	derived	derive	VBN
cord-005478-5iu38pr6	35	33	xenograft	xenograft	NN
cord-005478-5iu38pr6	35	34	(	(	-LRB-
cord-005478-5iu38pr6	35	35	PDX	PDX	NNP
cord-005478-5iu38pr6	35	36	)	)	-RRB-
cord-005478-5iu38pr6	35	37	models	model	NNS
cord-005478-5iu38pr6	35	38	(	(	-LRB-
cord-005478-5iu38pr6	35	39	Fig	Fig	NNP
cord-005478-5iu38pr6	35	40	.	.	.
cord-005478-5iu38pr6	35	41	2c	2c	NNP
cord-005478-5iu38pr6	35	42	)	)	-RRB-
cord-005478-5iu38pr6	36	1	cotransplanted	cotransplante	VBN
cord-005478-5iu38pr6	36	2	with	with	IN
cord-005478-5iu38pr6	36	3	NK	NK	NNP
cord-005478-5iu38pr6	36	4	cells	cell	NNS
cord-005478-5iu38pr6	36	5	.	.	.
cord-005478-5iu38pr6	37	1	Low	low	JJ
cord-005478-5iu38pr6	37	2	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	37	3	surface	surface	NN
cord-005478-5iu38pr6	37	4	or	or	CC
cord-005478-5iu38pr6	37	5	high	high	JJ
cord-005478-5iu38pr6	38	1	PARP1	PARP1	NNP
cord-005478-5iu38pr6	39	1	mRNA	mRNA	NNP
cord-005478-5iu38pr6	39	2	expression	expression	NN
cord-005478-5iu38pr6	39	3	associated	associate	VBN
cord-005478-5iu38pr6	39	4	with	with	IN
cord-005478-5iu38pr6	39	5	poor	poor	JJ
cord-005478-5iu38pr6	39	6	outcome	outcome	NN
cord-005478-5iu38pr6	39	7	in	in	IN
cord-005478-5iu38pr6	39	8	AML	AML	NNP
cord-005478-5iu38pr6	39	9	patients	patient	NNS
cord-005478-5iu38pr6	39	10	.	.	.
cord-005478-5iu38pr6	40	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	40	2	,	,	,
cord-005478-5iu38pr6	40	3	NKG2DL	nkg2dl	JJ
cord-005478-5iu38pr6	40	4	neg	neg	JJ
cord-005478-5iu38pr6	40	5	and	and	CC
cord-005478-5iu38pr6	40	6	CD34	CD34	NNP
cord-005478-5iu38pr6	40	7	+	+	CC
cord-005478-5iu38pr6	40	8	LSCs	lsc	NNS
cord-005478-5iu38pr6	40	9	showed	show	VBD
cord-005478-5iu38pr6	40	10	reduced	reduced	JJ
cord-005478-5iu38pr6	40	11	expression	expression	NN
cord-005478-5iu38pr6	40	12	of	of	IN
cord-005478-5iu38pr6	40	13	other	other	JJ
cord-005478-5iu38pr6	40	14	immune	immune	JJ
cord-005478-5iu38pr6	40	15	stimulatory	stimulatory	JJ
cord-005478-5iu38pr6	40	16	molecules	molecule	NNS
cord-005478-5iu38pr6	40	17	(	(	-LRB-
cord-005478-5iu38pr6	40	18	e.g.	e.g.	RB
cord-005478-5iu38pr6	40	19	CD112	CD112	NNP
cord-005478-5iu38pr6	40	20	,	,	,
cord-005478-5iu38pr6	40	21	CD155	CD155	NNP
cord-005478-5iu38pr6	40	22	,	,	,
cord-005478-5iu38pr6	40	23	CD80	CD80	NNP
cord-005478-5iu38pr6	40	24	,	,	,
cord-005478-5iu38pr6	40	25	CD86	CD86	NNP
cord-005478-5iu38pr6	40	26	)	)	-RRB-
cord-005478-5iu38pr6	40	27	and	and	CC
cord-005478-5iu38pr6	40	28	different	different	JJ
cord-005478-5iu38pr6	40	29	expression	expression	NN
cord-005478-5iu38pr6	40	30	of	of	IN
cord-005478-5iu38pr6	40	31	immune	immune	JJ
cord-005478-5iu38pr6	40	32	or	or	CC
cord-005478-5iu38pr6	40	33	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	40	34	response	response	NN
cord-005478-5iu38pr6	40	35	gene	gene	NN
cord-005478-5iu38pr6	40	36	signatures	signature	NNS
cord-005478-5iu38pr6	40	37	(	(	-LRB-
cord-005478-5iu38pr6	40	38	GSEA	GSEA	NNP
cord-005478-5iu38pr6	40	39	)	)	-RRB-
cord-005478-5iu38pr6	40	40	.	.	.
cord-005478-5iu38pr6	41	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	41	2	:	:	:
cord-005478-5iu38pr6	42	1	These	these	DT
cord-005478-5iu38pr6	42	2	data	datum	NNS
cord-005478-5iu38pr6	42	3	indicate	indicate	VBP
cord-005478-5iu38pr6	42	4	that	that	IN
cord-005478-5iu38pr6	42	5	LSCs	lsc	NNS
cord-005478-5iu38pr6	42	6	escape	escape	VB
cord-005478-5iu38pr6	42	7	NK	NK	NNP
cord-005478-5iu38pr6	42	8	cell	cell	NN
cord-005478-5iu38pr6	42	9	recognition	recognition	NN
cord-005478-5iu38pr6	42	10	by	by	IN
cord-005478-5iu38pr6	42	11	selectively	selectively	RB
cord-005478-5iu38pr6	42	12	suppressing	suppress	VBG
cord-005478-5iu38pr6	42	13	the	the	DT
cord-005478-5iu38pr6	42	14	surface	surface	NN
cord-005478-5iu38pr6	42	15	expression	expression	NN
cord-005478-5iu38pr6	42	16	of	of	IN
cord-005478-5iu38pr6	42	17	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	42	18	and	and	CC
cord-005478-5iu38pr6	42	19	other	other	JJ
cord-005478-5iu38pr6	42	20	immunostimulatory	immunostimulatory	NN
cord-005478-5iu38pr6	42	21	molecules	molecule	NNS
cord-005478-5iu38pr6	42	22	.	.	.
cord-005478-5iu38pr6	43	1	Absence	absence	NN
cord-005478-5iu38pr6	43	2	of	of	IN
cord-005478-5iu38pr6	43	3	NKG2DL	NKG2DL	NNP
cord-005478-5iu38pr6	43	4	can	can	MD
cord-005478-5iu38pr6	43	5	identify	identify	VB
cord-005478-5iu38pr6	43	6	LSCs	lsc	NNS
cord-005478-5iu38pr6	43	7	across	across	IN
cord-005478-5iu38pr6	43	8	genetic	genetic	JJ
cord-005478-5iu38pr6	43	9	AML	AML	NNP
cord-005478-5iu38pr6	43	10	subtypes	subtype	NNS
cord-005478-5iu38pr6	43	11	(	(	-LRB-
cord-005478-5iu38pr6	43	12	including	include	VBG
cord-005478-5iu38pr6	43	13	CD34	CD34	NNP
cord-005478-5iu38pr6	43	14	negative	negative	JJ
cord-005478-5iu38pr6	43	15	AMLs	aml	NNS
cord-005478-5iu38pr6	43	16	)	)	-RRB-
cord-005478-5iu38pr6	43	17	.	.	.
cord-005478-5iu38pr6	44	1	This	this	DT
cord-005478-5iu38pr6	44	2	LSC	LSC	NNP
cord-005478-5iu38pr6	44	3	specific	specific	JJ
cord-005478-5iu38pr6	44	4	mechanism	mechanism	NN
cord-005478-5iu38pr6	44	5	of	of	IN
cord-005478-5iu38pr6	44	6	immune	immune	JJ
cord-005478-5iu38pr6	44	7	evasion	evasion	NN
cord-005478-5iu38pr6	44	8	could	could	MD
cord-005478-5iu38pr6	44	9	be	be	VB
cord-005478-5iu38pr6	44	10	overcome	overcome	VBN
cord-005478-5iu38pr6	44	11	by	by	IN
cord-005478-5iu38pr6	44	12	treatment	treatment	NN
cord-005478-5iu38pr6	44	13	with	with	IN
cord-005478-5iu38pr6	44	14	PARP1	PARP1	NNP
cord-005478-5iu38pr6	44	15	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	44	16	,	,	,
cord-005478-5iu38pr6	44	17	which	which	WDT
cord-005478-5iu38pr6	44	18	in	in	IN
cord-005478-5iu38pr6	44	19	conjunction	conjunction	NN
cord-005478-5iu38pr6	44	20	with	with	IN
cord-005478-5iu38pr6	44	21	functional	functional	JJ
cord-005478-5iu38pr6	44	22	NK	NK	NNP
cord-005478-5iu38pr6	44	23	cells	cell	NNS
cord-005478-5iu38pr6	44	24	holds	hold	VBZ
cord-005478-5iu38pr6	44	25	promise	promise	NN
cord-005478-5iu38pr6	44	26	to	to	TO
cord-005478-5iu38pr6	44	27	eradicate	eradicate	VB
cord-005478-5iu38pr6	44	28	LSCs	lsc	NNS
cord-005478-5iu38pr6	44	29	and	and	CC
cord-005478-5iu38pr6	44	30	promote	promote	VB
cord-005478-5iu38pr6	44	31	immune	immune	NN
cord-005478-5iu38pr6	44	32	-	-	HYPH
cord-005478-5iu38pr6	44	33	mediated	mediate	VBN
cord-005478-5iu38pr6	44	34	cure	cure	NN
cord-005478-5iu38pr6	44	35	of	of	IN
cord-005478-5iu38pr6	44	36	AML	AML	NNP
cord-005478-5iu38pr6	44	37	.	.	.
cord-005478-5iu38pr6	45	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	45	2	:	:	:
cord-005478-5iu38pr6	45	3	C.L.	c.l.	NN
cord-005478-5iu38pr6	45	4	:	:	:
cord-005478-5iu38pr6	46	1	Sanofi	Sanofi	NNP
cord-005478-5iu38pr6	46	2	,	,	,
cord-005478-5iu38pr6	46	3	Novartis	Novartis	NNP
cord-005478-5iu38pr6	46	4	,	,	,
cord-005478-5iu38pr6	46	5	Otsuka	Otsuka	NNP
cord-005478-5iu38pr6	46	6	(	(	-LRB-
cord-005478-5iu38pr6	46	7	consultancy	consultancy	NN
cord-005478-5iu38pr6	46	8	)	)	-RRB-
cord-005478-5iu38pr6	46	9	;	;	:
cord-005478-5iu38pr6	46	10	Roche	Roche	NNP
cord-005478-5iu38pr6	46	11	(	(	-LRB-
cord-005478-5iu38pr6	46	12	research	research	NN
cord-005478-5iu38pr6	46	13	funding	funding	NN
cord-005478-5iu38pr6	46	14	)	)	-RRB-
cord-005478-5iu38pr6	47	1	Background	background	NN
cord-005478-5iu38pr6	47	2	:	:	:
cord-005478-5iu38pr6	48	1	In	in	IN
cord-005478-5iu38pr6	48	2	contrast	contrast	NN
cord-005478-5iu38pr6	48	3	to	to	IN
cord-005478-5iu38pr6	48	4	imatinib	imatinib	NN
cord-005478-5iu38pr6	48	5	,	,	,
cord-005478-5iu38pr6	48	6	data	datum	NNS
cord-005478-5iu38pr6	48	7	on	on	IN
cord-005478-5iu38pr6	48	8	the	the	DT
cord-005478-5iu38pr6	48	9	use	use	NN
cord-005478-5iu38pr6	48	10	of	of	IN
cord-005478-5iu38pr6	48	11	2	2	CD
cord-005478-5iu38pr6	48	12	nd	nd	NNP
cord-005478-5iu38pr6	48	13	and	and	CC
cord-005478-5iu38pr6	48	14	3	3	CD
cord-005478-5iu38pr6	48	15	rd	rd	NNP
cord-005478-5iu38pr6	48	16	generation	generation	NN
cord-005478-5iu38pr6	48	17	tyrosin	tyrosin	NNP
cord-005478-5iu38pr6	48	18	kinase	kinase	NNP
cord-005478-5iu38pr6	48	19	inhibitors	inhibitors	NNP
cord-005478-5iu38pr6	48	20	(	(	-LRB-
cord-005478-5iu38pr6	48	21	TKI	TKI	NNP
cord-005478-5iu38pr6	48	22	)	)	-RRB-
cord-005478-5iu38pr6	48	23	in	in	IN
cord-005478-5iu38pr6	48	24	the	the	DT
cord-005478-5iu38pr6	48	25	treatment	treatment	NN
cord-005478-5iu38pr6	48	26	of	of	IN
cord-005478-5iu38pr6	48	27	minimal	minimal	JJ
cord-005478-5iu38pr6	48	28	residual	residual	JJ
cord-005478-5iu38pr6	48	29	disease	disease	NN
cord-005478-5iu38pr6	48	30	(	(	-LRB-
cord-005478-5iu38pr6	48	31	MRD	MRD	NNP
cord-005478-5iu38pr6	48	32	)	)	-RRB-
cord-005478-5iu38pr6	48	33	,	,	,
cord-005478-5iu38pr6	48	34	molecular	molecular	JJ
cord-005478-5iu38pr6	48	35	and	and	CC
cord-005478-5iu38pr6	48	36	hematological	hematological	JJ
cord-005478-5iu38pr6	48	37	relapse	relapse	NN
cord-005478-5iu38pr6	48	38	(	(	-LRB-
cord-005478-5iu38pr6	48	39	MR	MR	NNP
cord-005478-5iu38pr6	48	40	/	/	SYM
cord-005478-5iu38pr6	48	41	HR	HR	NNP
cord-005478-5iu38pr6	48	42	)	)	-RRB-
cord-005478-5iu38pr6	48	43	after	after	IN
cord-005478-5iu38pr6	48	44	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	48	45	stem	stem	NN
cord-005478-5iu38pr6	48	46	cell	cell	NN
cord-005478-5iu38pr6	48	47	transplantation	transplantation	NN
cord-005478-5iu38pr6	48	48	(	(	-LRB-
cord-005478-5iu38pr6	48	49	SCT	SCT	NNP
cord-005478-5iu38pr6	48	50	)	)	-RRB-
cord-005478-5iu38pr6	48	51	in	in	IN
cord-005478-5iu38pr6	48	52	Philadelphia	Philadelphia	NNP
cord-005478-5iu38pr6	48	53	chromosome	chromosome	NN
cord-005478-5iu38pr6	48	54	positive	positive	JJ
cord-005478-5iu38pr6	48	55	(	(	-LRB-
cord-005478-5iu38pr6	48	56	Ph+	ph+	JJ
cord-005478-5iu38pr6	48	57	)	)	-RRB-
cord-005478-5iu38pr6	48	58	acute	acute	JJ
cord-005478-5iu38pr6	48	59	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	48	60	leukemia	leukemia	NN
cord-005478-5iu38pr6	48	61	(	(	-LRB-
cord-005478-5iu38pr6	48	62	ALL	all	DT
cord-005478-5iu38pr6	48	63	)	)	-RRB-
cord-005478-5iu38pr6	48	64	are	be	VBP
cord-005478-5iu38pr6	48	65	scarce	scarce	JJ
cord-005478-5iu38pr6	48	66	.	.	.
cord-005478-5iu38pr6	49	1	Methods	method	NNS
cord-005478-5iu38pr6	49	2	:	:	:
cord-005478-5iu38pr6	50	1	We	-PRON-	PRP
cord-005478-5iu38pr6	50	2	performed	perform	VBD
cord-005478-5iu38pr6	50	3	a	a	DT
cord-005478-5iu38pr6	50	4	retrospective	retrospective	NN
cord-005478-5iu38pr6	50	5	,	,	,
cord-005478-5iu38pr6	50	6	EBMT	EBMT	NNP
cord-005478-5iu38pr6	50	7	registry	registry	NN
cord-005478-5iu38pr6	50	8	based	base	VBN
cord-005478-5iu38pr6	50	9	analysis	analysis	NN
cord-005478-5iu38pr6	50	10	,	,	,
cord-005478-5iu38pr6	50	11	including	include	VBG
cord-005478-5iu38pr6	50	12	patients	patient	NNS
cord-005478-5iu38pr6	50	13	with	with	IN
cord-005478-5iu38pr6	50	14	documented	document	VBN
cord-005478-5iu38pr6	50	15	use	use	NN
cord-005478-5iu38pr6	50	16	of	of	IN
cord-005478-5iu38pr6	50	17	2	2	CD
cord-005478-5iu38pr6	50	18	nd	nd	NNP
cord-005478-5iu38pr6	50	19	or	or	CC
cord-005478-5iu38pr6	50	20	3	3	CD
cord-005478-5iu38pr6	50	21	rd	rd	NNP
cord-005478-5iu38pr6	50	22	generation	generation	NN
cord-005478-5iu38pr6	50	23	TKI	TKI	NNP
cord-005478-5iu38pr6	50	24	given	give	VBN
cord-005478-5iu38pr6	50	25	for	for	IN
cord-005478-5iu38pr6	50	26	persisting	persist	VBG
cord-005478-5iu38pr6	50	27	MRD	MRD	NNP
cord-005478-5iu38pr6	50	28	,	,	,
cord-005478-5iu38pr6	50	29	MR	MR	NNP
cord-005478-5iu38pr6	50	30	or	or	CC
cord-005478-5iu38pr6	50	31	HR	HR	NNP
cord-005478-5iu38pr6	50	32	after	after	IN
cord-005478-5iu38pr6	50	33	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	50	34	in	in	IN
cord-005478-5iu38pr6	50	35	2006	2006	CD
cord-005478-5iu38pr6	50	36	-2016	-2016	NNP
cord-005478-5iu38pr6	50	37	Choice	Choice	NNP
cord-005478-5iu38pr6	50	38	of	of	IN
cord-005478-5iu38pr6	50	39	TKI	TKI	NNP
cord-005478-5iu38pr6	50	40	,	,	,
cord-005478-5iu38pr6	50	41	efficacy	efficacy	NN
cord-005478-5iu38pr6	50	42	,	,	,
cord-005478-5iu38pr6	50	43	and	and	CC
cord-005478-5iu38pr6	50	44	toxicity	toxicity	NN
cord-005478-5iu38pr6	50	45	of	of	IN
cord-005478-5iu38pr6	50	46	TKI	TKI	NNP
cord-005478-5iu38pr6	50	47	and	and	CC
cord-005478-5iu38pr6	50	48	patient	patient	JJ
cord-005478-5iu38pr6	50	49	outcome	outcome	NN
cord-005478-5iu38pr6	50	50	were	be	VBD
cord-005478-5iu38pr6	50	51	analysed	analyse	VBN
cord-005478-5iu38pr6	50	52	.	.	.
cord-005478-5iu38pr6	51	1	Results	result	NNS
cord-005478-5iu38pr6	51	2	:	:	:
cord-005478-5iu38pr6	51	3	140	140	CD
cord-005478-5iu38pr6	51	4	patients	patient	NNS
cord-005478-5iu38pr6	51	5	(	(	-LRB-
cord-005478-5iu38pr6	51	6	female	female	JJ
cord-005478-5iu38pr6	51	7	58	58	CD
cord-005478-5iu38pr6	51	8	,	,	,
cord-005478-5iu38pr6	51	9	male	male	JJ
cord-005478-5iu38pr6	51	10	82	82	CD
cord-005478-5iu38pr6	51	11	)	)	-RRB-
cord-005478-5iu38pr6	51	12	were	be	VBD
cord-005478-5iu38pr6	51	13	identified	identify	VBN
cord-005478-5iu38pr6	51	14	,	,	,
cord-005478-5iu38pr6	51	15	out	out	IN
cord-005478-5iu38pr6	51	16	of	of	IN
cord-005478-5iu38pr6	51	17	which	which	WDT
cord-005478-5iu38pr6	51	18	136	136	CD
cord-005478-5iu38pr6	51	19	had	have	VBD
cord-005478-5iu38pr6	51	20	also	also	RB
cord-005478-5iu38pr6	51	21	received	receive	VBN
cord-005478-5iu38pr6	51	22	a	a	DT
cord-005478-5iu38pr6	51	23	TKI	TKI	NNP
cord-005478-5iu38pr6	51	24	(	(	-LRB-
cord-005478-5iu38pr6	51	25	78	78	CD
cord-005478-5iu38pr6	51	26	%	%	NN
cord-005478-5iu38pr6	51	27	imatinib	imatinib	RB
cord-005478-5iu38pr6	51	28	)	)	-RRB-
cord-005478-5iu38pr6	51	29	before	before	IN
cord-005478-5iu38pr6	51	30	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	51	31	.	.	.
cord-005478-5iu38pr6	52	1	Median	median	JJ
cord-005478-5iu38pr6	52	2	age	age	NN
cord-005478-5iu38pr6	52	3	at	at	IN
cord-005478-5iu38pr6	52	4	transplant	transplant	NN
cord-005478-5iu38pr6	52	5	was	be	VBD
cord-005478-5iu38pr6	52	6	48	48	CD
cord-005478-5iu38pr6	52	7	years	year	NNS
cord-005478-5iu38pr6	52	8	(	(	-LRB-
cord-005478-5iu38pr6	52	9	18	18	CD
cord-005478-5iu38pr6	52	10	-	-	SYM
cord-005478-5iu38pr6	52	11	66	66	CD
cord-005478-5iu38pr6	52	12	)	)	-RRB-
cord-005478-5iu38pr6	52	13	,	,	,
cord-005478-5iu38pr6	52	14	81	81	CD
cord-005478-5iu38pr6	52	15	%	%	NN
cord-005478-5iu38pr6	52	16	were	be	VBD
cord-005478-5iu38pr6	52	17	transplanted	transplant	VBN
cord-005478-5iu38pr6	52	18	in	in	IN
cord-005478-5iu38pr6	52	19	first	first	JJ
cord-005478-5iu38pr6	52	20	complete	complete	JJ
cord-005478-5iu38pr6	52	21	remission	remission	NN
cord-005478-5iu38pr6	52	22	(	(	-LRB-
cord-005478-5iu38pr6	52	23	CR1	CR1	NNP
cord-005478-5iu38pr6	52	24	)	)	-RRB-
cord-005478-5iu38pr6	52	25	,	,	,
cord-005478-5iu38pr6	52	26	51	51	CD
cord-005478-5iu38pr6	52	27	%	%	NN
cord-005478-5iu38pr6	52	28	of	of	IN
cord-005478-5iu38pr6	52	29	the	the	DT
cord-005478-5iu38pr6	52	30	patients	patient	NNS
cord-005478-5iu38pr6	52	31	were	be	VBD
cord-005478-5iu38pr6	52	32	in	in	IN
cord-005478-5iu38pr6	52	33	molecular	molecular	JJ
cord-005478-5iu38pr6	52	34	CR	cr	NN
cord-005478-5iu38pr6	52	35	.	.	.
cord-005478-5iu38pr6	53	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	53	2	was	be	VBD
cord-005478-5iu38pr6	53	3	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	53	4	in	in	IN
cord-005478-5iu38pr6	53	5	71	71	CD
cord-005478-5iu38pr6	53	6	%	%	NN
cord-005478-5iu38pr6	53	7	and	and	CC
cord-005478-5iu38pr6	53	8	reduced	reduce	VBN
cord-005478-5iu38pr6	53	9	in	in	IN
cord-005478-5iu38pr6	53	10	29	29	CD
cord-005478-5iu38pr6	53	11	%	%	NN
cord-005478-5iu38pr6	53	12	,	,	,
cord-005478-5iu38pr6	53	13	donors	donor	NNS
cord-005478-5iu38pr6	53	14	were	be	VBD
cord-005478-5iu38pr6	53	15	matched	match	VBN
cord-005478-5iu38pr6	53	16	siblings	sibling	NNS
cord-005478-5iu38pr6	53	17	(	(	-LRB-
cord-005478-5iu38pr6	53	18	48	48	CD
cord-005478-5iu38pr6	53	19	%	%	NN
cord-005478-5iu38pr6	53	20	)	)	-RRB-
cord-005478-5iu38pr6	53	21	,	,	,
cord-005478-5iu38pr6	53	22	unrelated	unrelated	JJ
cord-005478-5iu38pr6	53	23	(	(	-LRB-
cord-005478-5iu38pr6	53	24	41	41	CD
cord-005478-5iu38pr6	53	25	%	%	NN
cord-005478-5iu38pr6	53	26	)	)	-RRB-
cord-005478-5iu38pr6	53	27	,	,	,
cord-005478-5iu38pr6	53	28	haploidentical	haploidentical	NNP
cord-005478-5iu38pr6	53	29	(	(	-LRB-
cord-005478-5iu38pr6	53	30	6	6	CD
cord-005478-5iu38pr6	53	31	%	%	NN
cord-005478-5iu38pr6	53	32	)	)	-RRB-
cord-005478-5iu38pr6	53	33	and	and	CC
cord-005478-5iu38pr6	53	34	cord	cord	NN
cord-005478-5iu38pr6	53	35	blood	blood	NN
cord-005478-5iu38pr6	53	36	(	(	-LRB-
cord-005478-5iu38pr6	53	37	5	5	CD
cord-005478-5iu38pr6	53	38	%	%	NN
cord-005478-5iu38pr6	53	39	)	)	-RRB-
cord-005478-5iu38pr6	53	40	.	.	.
cord-005478-5iu38pr6	54	1	After	after	IN
cord-005478-5iu38pr6	54	2	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	54	3	,	,	,
cord-005478-5iu38pr6	54	4	111	111	CD
cord-005478-5iu38pr6	54	5	patients	patient	NNS
cord-005478-5iu38pr6	54	6	developed	develop	VBD
cord-005478-5iu38pr6	54	7	HR	hr	NN
cord-005478-5iu38pr6	54	8	,	,	,
cord-005478-5iu38pr6	54	9	23	23	CD
cord-005478-5iu38pr6	54	10	MR	MR	NNP
cord-005478-5iu38pr6	54	11	and	and	CC
cord-005478-5iu38pr6	54	12	6	6	CD
cord-005478-5iu38pr6	54	13	had	have	VBD
cord-005478-5iu38pr6	54	14	persisting	persist	VBG
cord-005478-5iu38pr6	54	15	MRD	MRD	NNP
cord-005478-5iu38pr6	54	16	.	.	.
cord-005478-5iu38pr6	55	1	For	for	IN
cord-005478-5iu38pr6	55	2	treatment	treatment	NN
cord-005478-5iu38pr6	55	3	,	,	,
cord-005478-5iu38pr6	55	4	patients	patient	NNS
cord-005478-5iu38pr6	55	5	received	receive	VBD
cord-005478-5iu38pr6	55	6	dasatinib	dasatinib	NN
cord-005478-5iu38pr6	55	7	(	(	-LRB-
cord-005478-5iu38pr6	55	8	n=104	n=104	NNP
cord-005478-5iu38pr6	55	9	)	)	-RRB-
cord-005478-5iu38pr6	55	10	,	,	,
cord-005478-5iu38pr6	55	11	nilotinib	nilotinib	NNP
cord-005478-5iu38pr6	55	12	(	(	-LRB-
cord-005478-5iu38pr6	55	13	n=18	n=18	NN
cord-005478-5iu38pr6	55	14	)	)	-RRB-
cord-005478-5iu38pr6	55	15	and	and	CC
cord-005478-5iu38pr6	55	16	ponatinib	ponatinib	NNP
cord-005478-5iu38pr6	55	17	(	(	-LRB-
cord-005478-5iu38pr6	55	18	n=18	n=18	NN
cord-005478-5iu38pr6	55	19	)	)	-RRB-
cord-005478-5iu38pr6	55	20	.	.	.
cord-005478-5iu38pr6	56	1	Median	median	JJ
cord-005478-5iu38pr6	56	2	interval	interval	NN
cord-005478-5iu38pr6	56	3	between	between	IN
cord-005478-5iu38pr6	56	4	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	56	5	of	of	IN
cord-005478-5iu38pr6	56	6	persisting	persist	VBG
cord-005478-5iu38pr6	56	7	MRD	MRD	NNP
cord-005478-5iu38pr6	56	8	or	or	CC
cord-005478-5iu38pr6	56	9	MR	MR	NNP
cord-005478-5iu38pr6	56	10	/	/	SYM
cord-005478-5iu38pr6	56	11	HR	HR	NNP
cord-005478-5iu38pr6	56	12	and	and	CC
cord-005478-5iu38pr6	56	13	first	first	JJ
cord-005478-5iu38pr6	56	14	application	application	NN
cord-005478-5iu38pr6	56	15	of	of	IN
cord-005478-5iu38pr6	56	16	a	a	DT
cord-005478-5iu38pr6	56	17	TKI	TKI	NNP
cord-005478-5iu38pr6	56	18	was	be	VBD
cord-005478-5iu38pr6	56	19	10	10	CD
cord-005478-5iu38pr6	56	20	days	day	NNS
cord-005478-5iu38pr6	56	21	,	,	,
cord-005478-5iu38pr6	56	22	median	median	JJ
cord-005478-5iu38pr6	56	23	duration	duration	NN
cord-005478-5iu38pr6	56	24	of	of	IN
cord-005478-5iu38pr6	56	25	TKI	TKI	NNP
cord-005478-5iu38pr6	56	26	treatment	treatment	NN
cord-005478-5iu38pr6	56	27	was	be	VBD
cord-005478-5iu38pr6	56	28	154	154	CD
cord-005478-5iu38pr6	56	29	days	day	NNS
cord-005478-5iu38pr6	56	30	(	(	-LRB-
cord-005478-5iu38pr6	56	31	range	range	NNP
cord-005478-5iu38pr6	56	32	4	4	CD
cord-005478-5iu38pr6	56	33	-2193	-2193	NN
cord-005478-5iu38pr6	56	34	)	)	-RRB-
cord-005478-5iu38pr6	56	35	.	.	.
cord-005478-5iu38pr6	57	1	Fifty	fifty	CD
cord-005478-5iu38pr6	57	2	-	-	HYPH
cord-005478-5iu38pr6	57	3	eight	eight	CD
cord-005478-5iu38pr6	57	4	patients	patient	NNS
cord-005478-5iu38pr6	57	5	were	be	VBD
cord-005478-5iu38pr6	57	6	treated	treat	VBN
cord-005478-5iu38pr6	57	7	with	with	IN
cord-005478-5iu38pr6	57	8	TKI	TKI	NNP
cord-005478-5iu38pr6	57	9	only	only	RB
cord-005478-5iu38pr6	57	10	(	(	-LRB-
cord-005478-5iu38pr6	57	11	dasatinib	dasatinib	NNP
cord-005478-5iu38pr6	57	12	,	,	,
cord-005478-5iu38pr6	57	13	n=50	n=50	NNP
cord-005478-5iu38pr6	57	14	,	,	,
cord-005478-5iu38pr6	57	15	nilotinib	nilotinib	NNP
cord-005478-5iu38pr6	57	16	,	,	,
cord-005478-5iu38pr6	57	17	n=3	n=3	NN
cord-005478-5iu38pr6	57	18	,	,	,
cord-005478-5iu38pr6	57	19	ponatinib	ponatinib	NNP
cord-005478-5iu38pr6	57	20	,	,	,
cord-005478-5iu38pr6	57	21	n=5	n=5	JJ
cord-005478-5iu38pr6	57	22	)	)	-RRB-
cord-005478-5iu38pr6	57	23	,	,	,
cord-005478-5iu38pr6	57	24	while	while	IN
cord-005478-5iu38pr6	57	25	82	82	CD
cord-005478-5iu38pr6	57	26	received	receive	VBD
cord-005478-5iu38pr6	57	27	additional	additional	JJ
cord-005478-5iu38pr6	57	28	treatment	treatment	NN
cord-005478-5iu38pr6	57	29	such	such	JJ
cord-005478-5iu38pr6	57	30	as	as	IN
cord-005478-5iu38pr6	57	31	DLI	DLI	NNP
cord-005478-5iu38pr6	57	32	,	,	,
cord-005478-5iu38pr6	57	33	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	57	34	,	,	,
cord-005478-5iu38pr6	57	35	or	or	CC
cord-005478-5iu38pr6	57	36	second	second	JJ
cord-005478-5iu38pr6	57	37	alloSCT	allosct	NN
cord-005478-5iu38pr6	57	38	.	.	.
cord-005478-5iu38pr6	58	1	Main	main	JJ
cord-005478-5iu38pr6	58	2	toxicities	toxicity	NNS
cord-005478-5iu38pr6	58	3	of	of	IN
cord-005478-5iu38pr6	58	4	dasatinib	dasatinib	NN
cord-005478-5iu38pr6	58	5	were	be	VBD
cord-005478-5iu38pr6	58	6	effusion	effusion	NN
cord-005478-5iu38pr6	58	7	,	,	,
cord-005478-5iu38pr6	58	8	edema	edema	NN
cord-005478-5iu38pr6	58	9	,	,	,
cord-005478-5iu38pr6	58	10	or	or	CC
cord-005478-5iu38pr6	58	11	other	other	JJ
cord-005478-5iu38pr6	58	12	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	58	13	complaints	complaint	NNS
cord-005478-5iu38pr6	58	14	(	(	-LRB-
cord-005478-5iu38pr6	58	15	10	10	CD
cord-005478-5iu38pr6	58	16	-15	-15	CD
cord-005478-5iu38pr6	58	17	%	%	NN
cord-005478-5iu38pr6	58	18	of	of	IN
cord-005478-5iu38pr6	58	19	patients	patient	NNS
cord-005478-5iu38pr6	58	20	)	)	-RRB-
cord-005478-5iu38pr6	58	21	and	and	CC
cord-005478-5iu38pr6	58	22	infections	infection	NNS
cord-005478-5iu38pr6	58	23	(	(	-LRB-
cord-005478-5iu38pr6	58	24	13	13	CD
cord-005478-5iu38pr6	58	25	%	%	NN
cord-005478-5iu38pr6	58	26	)	)	-RRB-
cord-005478-5iu38pr6	58	27	.	.	.
cord-005478-5iu38pr6	59	1	No	no	DT
cord-005478-5iu38pr6	59	2	particular	particular	JJ
cord-005478-5iu38pr6	59	3	side	side	NN
cord-005478-5iu38pr6	59	4	effects	effect	NNS
cord-005478-5iu38pr6	59	5	were	be	VBD
cord-005478-5iu38pr6	59	6	reported	report	VBN
cord-005478-5iu38pr6	59	7	for	for	IN
cord-005478-5iu38pr6	59	8	nilotinib	nilotinib	NNP
cord-005478-5iu38pr6	59	9	and	and	CC
cord-005478-5iu38pr6	59	10	ponatinib	ponatinib	NNP
cord-005478-5iu38pr6	59	11	(	(	-LRB-
cord-005478-5iu38pr6	59	12	no	no	DT
cord-005478-5iu38pr6	59	13	vascular	vascular	JJ
cord-005478-5iu38pr6	59	14	events	event	NNS
cord-005478-5iu38pr6	59	15	)	)	-RRB-
cord-005478-5iu38pr6	59	16	.	.	.
cord-005478-5iu38pr6	60	1	Dose	dose	JJ
cord-005478-5iu38pr6	60	2	reduction	reduction	NN
cord-005478-5iu38pr6	60	3	of	of	IN
cord-005478-5iu38pr6	60	4	TKI	TKI	NNP
cord-005478-5iu38pr6	60	5	was	be	VBD
cord-005478-5iu38pr6	60	6	required	require	VBN
cord-005478-5iu38pr6	60	7	in	in	IN
cord-005478-5iu38pr6	60	8	32	32	CD
cord-005478-5iu38pr6	60	9	%	%	NN
cord-005478-5iu38pr6	60	10	.	.	.
cord-005478-5iu38pr6	61	1	Response	response	NN
cord-005478-5iu38pr6	61	2	rates	rate	NNS
cord-005478-5iu38pr6	61	3	were	be	VBD
cord-005478-5iu38pr6	61	4	71	71	CD
cord-005478-5iu38pr6	61	5	%	%	NN
cord-005478-5iu38pr6	61	6	(	(	-LRB-
cord-005478-5iu38pr6	61	7	entire	entire	JJ
cord-005478-5iu38pr6	61	8	cohort	cohort	NN
cord-005478-5iu38pr6	61	9	)	)	-RRB-
cord-005478-5iu38pr6	61	10	and	and	CC
cord-005478-5iu38pr6	61	11	72	72	CD
cord-005478-5iu38pr6	61	12	%	%	NN
cord-005478-5iu38pr6	61	13	(	(	-LRB-
cord-005478-5iu38pr6	61	14	patients	patient	NNS
cord-005478-5iu38pr6	61	15	receiving	receive	VBG
cord-005478-5iu38pr6	61	16	TKI	TKI	NNP
cord-005478-5iu38pr6	61	17	only	only	RB
cord-005478-5iu38pr6	61	18	)	)	-RRB-
cord-005478-5iu38pr6	61	19	.	.	.
cord-005478-5iu38pr6	62	1	For	for	IN
cord-005478-5iu38pr6	62	2	the	the	DT
cord-005478-5iu38pr6	62	3	entire	entire	JJ
cord-005478-5iu38pr6	62	4	cohort	cohort	NN
cord-005478-5iu38pr6	62	5	,	,	,
cord-005478-5iu38pr6	62	6	2-and	2-and	CD
cord-005478-5iu38pr6	62	7	5-year	5-year	CD
cord-005478-5iu38pr6	62	8	overall	overall	JJ
cord-005478-5iu38pr6	62	9	survival	survival	NN
cord-005478-5iu38pr6	62	10	(	(	-LRB-
cord-005478-5iu38pr6	62	11	OS	OS	NNP
cord-005478-5iu38pr6	62	12	)	)	-RRB-
cord-005478-5iu38pr6	62	13	from	from	IN
cord-005478-5iu38pr6	62	14	first	first	JJ
cord-005478-5iu38pr6	62	15	application	application	NN
cord-005478-5iu38pr6	62	16	of	of	IN
cord-005478-5iu38pr6	62	17	TKI	TKI	NNP
cord-005478-5iu38pr6	62	18	was	be	VBD
cord-005478-5iu38pr6	62	19	49	49	CD
cord-005478-5iu38pr6	62	20	%	%	NN
cord-005478-5iu38pr6	62	21	and	and	CC
cord-005478-5iu38pr6	62	22	33	33	CD
cord-005478-5iu38pr6	62	23	%	%	NN
cord-005478-5iu38pr6	62	24	.	.	.
cord-005478-5iu38pr6	63	1	Two	two	CD
cord-005478-5iu38pr6	63	2	-	-	HYPH
cord-005478-5iu38pr6	63	3	year	year	NN
cord-005478-5iu38pr6	63	4	OS	OS	NNP
cord-005478-5iu38pr6	63	5	was	be	VBD
cord-005478-5iu38pr6	63	6	comparable	comparable	JJ
cord-005478-5iu38pr6	63	7	in	in	IN
cord-005478-5iu38pr6	63	8	patients	patient	NNS
cord-005478-5iu38pr6	63	9	treated	treat	VBN
cord-005478-5iu38pr6	63	10	for	for	IN
cord-005478-5iu38pr6	63	11	persisting	persist	VBG
cord-005478-5iu38pr6	63	12	MRD	MRD	NNP
cord-005478-5iu38pr6	63	13	/	/	SYM
cord-005478-5iu38pr6	63	14	MR	MR	NNP
cord-005478-5iu38pr6	63	15	and	and	CC
cord-005478-5iu38pr6	63	16	for	for	IN
cord-005478-5iu38pr6	63	17	HR	HR	NNP
cord-005478-5iu38pr6	63	18	(	(	-LRB-
cord-005478-5iu38pr6	63	19	48	48	CD
cord-005478-5iu38pr6	63	20	%	%	NN
cord-005478-5iu38pr6	63	21	and	and	CC
cord-005478-5iu38pr6	63	22	50	50	CD
cord-005478-5iu38pr6	63	23	%	%	NN
cord-005478-5iu38pr6	63	24	)	)	-RRB-
cord-005478-5iu38pr6	63	25	.	.	.
cord-005478-5iu38pr6	64	1	Among	among	IN
cord-005478-5iu38pr6	64	2	patients	patient	NNS
cord-005478-5iu38pr6	64	3	treated	treat	VBN
cord-005478-5iu38pr6	64	4	with	with	IN
cord-005478-5iu38pr6	64	5	TKI	TKI	NNP
cord-005478-5iu38pr6	64	6	only	only	RB
cord-005478-5iu38pr6	64	7	,	,	,
cord-005478-5iu38pr6	64	8	2/5-year	2/5-year	CD
cord-005478-5iu38pr6	64	9	OS	os	NN
cord-005478-5iu38pr6	64	10	was	be	VBD
cord-005478-5iu38pr6	64	11	38%/33	38%/33	CD
cord-005478-5iu38pr6	64	12	%	%	NN
cord-005478-5iu38pr6	64	13	.	.	.
cord-005478-5iu38pr6	65	1	Rate	rate	NN
cord-005478-5iu38pr6	65	2	of	of	IN
cord-005478-5iu38pr6	65	3	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	65	4	was	be	VBD
cord-005478-5iu38pr6	65	5	11	11	CD
cord-005478-5iu38pr6	65	6	%	%	NN
cord-005478-5iu38pr6	65	7	for	for	IN
cord-005478-5iu38pr6	65	8	the	the	DT
cord-005478-5iu38pr6	65	9	whole	whole	JJ
cord-005478-5iu38pr6	65	10	population	population	NN
cord-005478-5iu38pr6	65	11	and	and	CC
cord-005478-5iu38pr6	65	12	14	14	CD
cord-005478-5iu38pr6	65	13	%	%	NN
cord-005478-5iu38pr6	65	14	for	for	IN
cord-005478-5iu38pr6	65	15	the	the	DT
cord-005478-5iu38pr6	65	16	TKI	TKI	NNP
cord-005478-5iu38pr6	65	17	alone	alone	RB
cord-005478-5iu38pr6	65	18	cohort	cohort	NN
cord-005478-5iu38pr6	65	19	.	.	.
cord-005478-5iu38pr6	66	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	66	2	:	:	:
cord-005478-5iu38pr6	67	1	The	the	DT
cord-005478-5iu38pr6	67	2	use	use	NN
cord-005478-5iu38pr6	67	3	of	of	IN
cord-005478-5iu38pr6	67	4	2	2	CD
cord-005478-5iu38pr6	67	5	nd	nd	NNP
cord-005478-5iu38pr6	67	6	and	and	CC
cord-005478-5iu38pr6	67	7	3	3	CD
cord-005478-5iu38pr6	67	8	rd	rd	NNP
cord-005478-5iu38pr6	67	9	generation	generation	NN
cord-005478-5iu38pr6	67	10	TKI	TKI	NNP
cord-005478-5iu38pr6	67	11	,	,	,
cord-005478-5iu38pr6	67	12	given	give	VBN
cord-005478-5iu38pr6	67	13	alone	alone	JJ
cord-005478-5iu38pr6	67	14	or	or	CC
cord-005478-5iu38pr6	67	15	in	in	IN
cord-005478-5iu38pr6	67	16	combination	combination	NN
cord-005478-5iu38pr6	67	17	with	with	IN
cord-005478-5iu38pr6	67	18	other	other	JJ
cord-005478-5iu38pr6	67	19	therapies	therapy	NNS
cord-005478-5iu38pr6	67	20	for	for	IN
cord-005478-5iu38pr6	67	21	treating	treat	VBG
cord-005478-5iu38pr6	67	22	persisting	persist	VBG
cord-005478-5iu38pr6	67	23	MRD	MRD	NNP
cord-005478-5iu38pr6	67	24	,	,	,
cord-005478-5iu38pr6	67	25	MR	MR	NNP
cord-005478-5iu38pr6	67	26	or	or	CC
cord-005478-5iu38pr6	67	27	HR	HR	NNP
cord-005478-5iu38pr6	67	28	after	after	IN
cord-005478-5iu38pr6	67	29	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	67	30	in	in	IN
cord-005478-5iu38pr6	67	31	Ph+	Ph+	NNP
cord-005478-5iu38pr6	68	1	ALL	all	DT
cord-005478-5iu38pr6	68	2	was	be	VBD
cord-005478-5iu38pr6	68	3	not	not	RB
cord-005478-5iu38pr6	68	4	associated	associate	VBN
cord-005478-5iu38pr6	68	5	with	with	IN
cord-005478-5iu38pr6	68	6	increased	increase	VBN
cord-005478-5iu38pr6	68	7	toxicities	toxicity	NNS
cord-005478-5iu38pr6	68	8	.	.	.
cord-005478-5iu38pr6	69	1	Dasatinib	Dasatinib	NNP
cord-005478-5iu38pr6	69	2	was	be	VBD
cord-005478-5iu38pr6	69	3	the	the	DT
cord-005478-5iu38pr6	69	4	most	most	RBS
cord-005478-5iu38pr6	69	5	frequently	frequently	RB
cord-005478-5iu38pr6	69	6	used	use	VBN
cord-005478-5iu38pr6	69	7	drug	drug	NN
cord-005478-5iu38pr6	69	8	.	.	.
cord-005478-5iu38pr6	70	1	Outcome	outcome	NN
cord-005478-5iu38pr6	70	2	compared	compare	VBN
cord-005478-5iu38pr6	70	3	favorably	favorably	RB
cord-005478-5iu38pr6	70	4	with	with	IN
cord-005478-5iu38pr6	70	5	published	publish	VBN
cord-005478-5iu38pr6	70	6	results	result	NNS
cord-005478-5iu38pr6	70	7	on	on	IN
cord-005478-5iu38pr6	70	8	relapse	relapse	NN
cord-005478-5iu38pr6	70	9	after	after	IN
cord-005478-5iu38pr6	70	10	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	70	11	in	in	IN
cord-005478-5iu38pr6	70	12	Ph	Ph	NNP
cord-005478-5iu38pr6	70	13	negative	negative	JJ
cord-005478-5iu38pr6	70	14	ALL	all	DT
cord-005478-5iu38pr6	70	15	,	,	,
cord-005478-5iu38pr6	70	16	suggesting	suggest	VBG
cord-005478-5iu38pr6	70	17	that	that	IN
cord-005478-5iu38pr6	70	18	treatment	treatment	NN
cord-005478-5iu38pr6	70	19	with	with	IN
cord-005478-5iu38pr6	70	20	TKI	TKI	NNP
cord-005478-5iu38pr6	70	21	could	could	MD
cord-005478-5iu38pr6	70	22	improve	improve	VB
cord-005478-5iu38pr6	70	23	survival	survival	NN
cord-005478-5iu38pr6	70	24	after	after	IN
cord-005478-5iu38pr6	70	25	post	post	JJ
cord-005478-5iu38pr6	70	26	-	-	JJ
cord-005478-5iu38pr6	70	27	transplant	transplant	JJ
cord-005478-5iu38pr6	70	28	relapse	relapse	NN
cord-005478-5iu38pr6	70	29	,	,	,
cord-005478-5iu38pr6	70	30	even	even	RB
cord-005478-5iu38pr6	70	31	when	when	WRB
cord-005478-5iu38pr6	70	32	given	give	VBN
cord-005478-5iu38pr6	70	33	as	as	IN
cord-005478-5iu38pr6	70	34	single	single	JJ
cord-005478-5iu38pr6	70	35	therapy	therapy	NN
cord-005478-5iu38pr6	70	36	.	.	.
cord-005478-5iu38pr6	71	1	Type	type	NN
cord-005478-5iu38pr6	71	2	of	of	IN
cord-005478-5iu38pr6	71	3	relapse	relapse	NN
cord-005478-5iu38pr6	71	4	did	do	VBD
cord-005478-5iu38pr6	71	5	not	not	RB
cord-005478-5iu38pr6	71	6	influence	influence	VB
cord-005478-5iu38pr6	71	7	response	response	NN
cord-005478-5iu38pr6	71	8	rates	rate	NNS
cord-005478-5iu38pr6	71	9	and	and	CC
cord-005478-5iu38pr6	71	10	outcome	outcome	NN
cord-005478-5iu38pr6	71	11	.	.	.
cord-005478-5iu38pr6	72	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	72	2	:	:	:
cord-005478-5iu38pr6	72	3	Nothing	nothing	NN
cord-005478-5iu38pr6	72	4	to	to	TO
cord-005478-5iu38pr6	72	5	declare	declare	VB
cord-005478-5iu38pr6	72	6	Multi	multi	JJ
cord-005478-5iu38pr6	72	7	-	-	JJ
cord-005478-5iu38pr6	72	8	state	state	JJ
cord-005478-5iu38pr6	72	9	modelling	modelling	NN
cord-005478-5iu38pr6	72	10	of	of	IN
cord-005478-5iu38pr6	72	11	the	the	DT
cord-005478-5iu38pr6	72	12	interplay	interplay	NN
cord-005478-5iu38pr6	72	13	between	between	IN
cord-005478-5iu38pr6	72	14	remission	remission	NN
cord-005478-5iu38pr6	72	15	-	-	HYPH
cord-005478-5iu38pr6	72	16	induction	induction	NN
cord-005478-5iu38pr6	72	17	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	72	18	and	and	CC
cord-005478-5iu38pr6	72	19	consolidation	consolidation	NN
cord-005478-5iu38pr6	72	20	with	with	IN
cord-005478-5iu38pr6	72	21	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	72	22	in	in	IN
cord-005478-5iu38pr6	72	23	newly	newly	RB
cord-005478-5iu38pr6	72	24	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	72	25	AML	AML	NNP
cord-005478-5iu38pr6	72	26	patients	patient	NNS
cord-005478-5iu38pr6	72	27	reduced	reduce	VBN
cord-005478-5iu38pr6	72	28	rate	rate	NN
cord-005478-5iu38pr6	72	29	of	of	IN
cord-005478-5iu38pr6	72	30	relapse	relapse	NN
cord-005478-5iu38pr6	72	31	in	in	IN
cord-005478-5iu38pr6	72	32	the	the	DT
cord-005478-5iu38pr6	72	33	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	72	34	arm	arm	NN
cord-005478-5iu38pr6	72	35	,	,	,
cord-005478-5iu38pr6	72	36	discovering	discover	VBG
cord-005478-5iu38pr6	72	37	a	a	DT
cord-005478-5iu38pr6	72	38	significant	significant	JJ
cord-005478-5iu38pr6	72	39	difference	difference	NN
cord-005478-5iu38pr6	72	40	between	between	IN
cord-005478-5iu38pr6	72	41	the	the	DT
cord-005478-5iu38pr6	72	42	treatment	treatment	NN
cord-005478-5iu38pr6	72	43	arms	arm	NNS
cord-005478-5iu38pr6	72	44	in	in	IN
cord-005478-5iu38pr6	72	45	the	the	DT
cord-005478-5iu38pr6	72	46	hazard	hazard	NN
cord-005478-5iu38pr6	72	47	of	of	IN
cord-005478-5iu38pr6	72	48	relapse	relapse	NN
cord-005478-5iu38pr6	72	49	only	only	RB
cord-005478-5iu38pr6	72	50	after	after	IN
cord-005478-5iu38pr6	72	51	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	72	52	(	(	-LRB-
cord-005478-5iu38pr6	72	53	HR	HR	NNP
cord-005478-5iu38pr6	72	54	0.65	0.65	CD
cord-005478-5iu38pr6	72	55	,	,	,
cord-005478-5iu38pr6	72	56	95	95	CD
cord-005478-5iu38pr6	72	57	%	%	NN
cord-005478-5iu38pr6	72	58	CI	CI	NNP
cord-005478-5iu38pr6	72	59	0.46	0.46	CD
cord-005478-5iu38pr6	72	60	-	-	HYPH
cord-005478-5iu38pr6	72	61	0.94	0.94	CD
cord-005478-5iu38pr6	72	62	,	,	,
cord-005478-5iu38pr6	72	63	p	p	NN
cord-005478-5iu38pr6	72	64	-	-	HYPH
cord-005478-5iu38pr6	72	65	value	value	NN
cord-005478-5iu38pr6	72	66	=	=	SYM
cord-005478-5iu38pr6	72	67	0.02	0.02	CD
cord-005478-5iu38pr6	72	68	)	)	-RRB-
cord-005478-5iu38pr6	72	69	,	,	,
cord-005478-5iu38pr6	72	70	and	and	CC
cord-005478-5iu38pr6	72	71	not	not	RB
cord-005478-5iu38pr6	72	72	before	before	IN
cord-005478-5iu38pr6	72	73	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	72	74	(	(	-LRB-
cord-005478-5iu38pr6	72	75	HR	HR	NNP
cord-005478-5iu38pr6	72	76	0.81	0.81	CD
cord-005478-5iu38pr6	72	77	,	,	,
cord-005478-5iu38pr6	72	78	.	.	.
cord-005478-5iu38pr6	73	1	In	in	IN
cord-005478-5iu38pr6	73	2	addition	addition	NN
cord-005478-5iu38pr6	73	3	,	,	,
cord-005478-5iu38pr6	73	4	we	-PRON-	PRP
cord-005478-5iu38pr6	73	5	found	find	VBD
cord-005478-5iu38pr6	73	6	increased	increase	VBN
cord-005478-5iu38pr6	73	7	NRM	NRM	NNP
cord-005478-5iu38pr6	73	8	in	in	IN
cord-005478-5iu38pr6	73	9	the	the	DT
cord-005478-5iu38pr6	73	10	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	73	11	arm	arm	NN
cord-005478-5iu38pr6	73	12	before	before	IN
cord-005478-5iu38pr6	73	13	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	73	14	(	(	-LRB-
cord-005478-5iu38pr6	73	15	HR	HR	NNP
cord-005478-5iu38pr6	73	16	1.95	1.95	CD
cord-005478-5iu38pr6	73	17	,	,	,
cord-005478-5iu38pr6	73	18	95	95	CD
cord-005478-5iu38pr6	73	19	%	%	NN
cord-005478-5iu38pr6	73	20	CI	CI	NNP
cord-005478-5iu38pr6	73	21	1.15	1.15	CD
cord-005478-5iu38pr6	73	22	-	-	HYPH
cord-005478-5iu38pr6	73	23	3.31	3.31	CD
cord-005478-5iu38pr6	73	24	,	,	,
cord-005478-5iu38pr6	73	25	p	p	NN
cord-005478-5iu38pr6	73	26	-	-	HYPH
cord-005478-5iu38pr6	73	27	value	value	NN
cord-005478-5iu38pr6	73	28	=	=	SYM
cord-005478-5iu38pr6	73	29	0.01	0.01	CD
cord-005478-5iu38pr6	73	30	)	)	-RRB-
cord-005478-5iu38pr6	73	31	,	,	,
cord-005478-5iu38pr6	73	32	and	and	CC
cord-005478-5iu38pr6	73	33	not	not	RB
cord-005478-5iu38pr6	73	34	after	after	IN
cord-005478-5iu38pr6	73	35	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	73	36	(	(	-LRB-
cord-005478-5iu38pr6	73	37	HR	HR	NNP
cord-005478-5iu38pr6	73	38	0.80	0.80	CD
cord-005478-5iu38pr6	73	39	,	,	,
cord-005478-5iu38pr6	73	40	95	95	CD
cord-005478-5iu38pr6	73	41	%	%	NN
cord-005478-5iu38pr6	73	42	CI	CI	NNP
cord-005478-5iu38pr6	73	43	0.50	0.50	CD
cord-005478-5iu38pr6	73	44	-	-	HYPH
cord-005478-5iu38pr6	73	45	1.28	1.28	CD
cord-005478-5iu38pr6	73	46	,	,	,
cord-005478-5iu38pr6	73	47	p	p	NN
cord-005478-5iu38pr6	73	48	-	-	HYPH
cord-005478-5iu38pr6	73	49	value	value	NN
cord-005478-5iu38pr6	73	50	=	=	SYM
cord-005478-5iu38pr6	73	51	0.34	0.34	CD
cord-005478-5iu38pr6	73	52	)	)	-RRB-
cord-005478-5iu38pr6	73	53	.	.	.
cord-005478-5iu38pr6	74	1	These	these	DT
cord-005478-5iu38pr6	74	2	effects	effect	NNS
cord-005478-5iu38pr6	74	3	are	be	VBP
cord-005478-5iu38pr6	74	4	statistically	statistically	RB
cord-005478-5iu38pr6	74	5	significantly	significantly	RB
cord-005478-5iu38pr6	74	6	different	different	JJ
cord-005478-5iu38pr6	74	7	(	(	-LRB-
cord-005478-5iu38pr6	74	8	interaction	interaction	NN
cord-005478-5iu38pr6	74	9	test	test	NN
cord-005478-5iu38pr6	74	10	HR	hr	NN
cord-005478-5iu38pr6	74	11	0.41	0.41	CD
cord-005478-5iu38pr6	74	12	,	,	,
cord-005478-5iu38pr6	74	13	95	95	CD
cord-005478-5iu38pr6	74	14	%	%	NN
cord-005478-5iu38pr6	74	15	CI	CI	NNP
cord-005478-5iu38pr6	74	16	0.20	0.20	CD
cord-005478-5iu38pr6	74	17	-	-	HYPH
cord-005478-5iu38pr6	74	18	0.83	0.83	CD
cord-005478-5iu38pr6	74	19	,	,	,
cord-005478-5iu38pr6	74	20	p	p	NN
cord-005478-5iu38pr6	74	21	-	-	HYPH
cord-005478-5iu38pr6	74	22	value	value	NN
cord-005478-5iu38pr6	74	23	=	=	SYM
cord-005478-5iu38pr6	74	24	0.01	0.01	CD
cord-005478-5iu38pr6	74	25	)	)	-RRB-
cord-005478-5iu38pr6	74	26	.	.	.
cord-005478-5iu38pr6	75	1	At	at	IN
cord-005478-5iu38pr6	75	2	two	two	CD
cord-005478-5iu38pr6	75	3	years	year	NNS
cord-005478-5iu38pr6	75	4	after	after	IN
cord-005478-5iu38pr6	75	5	registration	registration	NN
cord-005478-5iu38pr6	75	6	,	,	,
cord-005478-5iu38pr6	75	7	20.4	20.4	CD
cord-005478-5iu38pr6	75	8	%	%	NN
cord-005478-5iu38pr6	75	9	(	(	-LRB-
cord-005478-5iu38pr6	75	10	95	95	CD
cord-005478-5iu38pr6	75	11	%	%	NN
cord-005478-5iu38pr6	75	12	CI	CI	NNP
cord-005478-5iu38pr6	75	13	16.6	16.6	CD
cord-005478-5iu38pr6	75	14	-	-	HYPH
cord-005478-5iu38pr6	75	15	24.1	24.1	CD
cord-005478-5iu38pr6	75	16	)	)	-RRB-
cord-005478-5iu38pr6	75	17	of	of	IN
cord-005478-5iu38pr6	75	18	the	the	DT
cord-005478-5iu38pr6	75	19	patients	patient	NNS
cord-005478-5iu38pr6	75	20	in	in	IN
cord-005478-5iu38pr6	75	21	the	the	DT
cord-005478-5iu38pr6	75	22	control	control	NN
cord-005478-5iu38pr6	75	23	arm	arm	NN
cord-005478-5iu38pr6	75	24	,	,	,
cord-005478-5iu38pr6	75	25	and	and	CC
cord-005478-5iu38pr6	75	26	19.9	19.9	CD
cord-005478-5iu38pr6	75	27	%	%	NN
cord-005478-5iu38pr6	75	28	(	(	-LRB-
cord-005478-5iu38pr6	75	29	16	16	CD
cord-005478-5iu38pr6	75	30	.	.	NN
cord-005478-5iu38pr6	75	31	1	1	CD
cord-005478-5iu38pr6	75	32	-	-	SYM
cord-005478-5iu38pr6	75	33	23.6	23.6	CD
cord-005478-5iu38pr6	75	34	)	)	-RRB-
cord-005478-5iu38pr6	75	35	in	in	IN
cord-005478-5iu38pr6	75	36	the	the	DT
cord-005478-5iu38pr6	75	37	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	75	38	arm	arm	NN
cord-005478-5iu38pr6	75	39	were	be	VBD
cord-005478-5iu38pr6	75	40	alive	alive	JJ
cord-005478-5iu38pr6	75	41	relapse	relapse	NN
cord-005478-5iu38pr6	75	42	-	-	HYPH
cord-005478-5iu38pr6	75	43	free	free	JJ
cord-005478-5iu38pr6	75	44	in	in	IN
cord-005478-5iu38pr6	75	45	CR	CR	NNP
cord-005478-5iu38pr6	75	46	without	without	IN
cord-005478-5iu38pr6	75	47	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	75	48	,	,	,
cord-005478-5iu38pr6	75	49	while	while	IN
cord-005478-5iu38pr6	75	50	20.9	20.9	CD
cord-005478-5iu38pr6	75	51	%	%	NN
cord-005478-5iu38pr6	75	52	(	(	-LRB-
cord-005478-5iu38pr6	75	53	16.7	16.7	CD
cord-005478-5iu38pr6	75	54	-	-	SYM
cord-005478-5iu38pr6	75	55	25.1	25.1	CD
cord-005478-5iu38pr6	75	56	)	)	-RRB-
cord-005478-5iu38pr6	75	57	and	and	CC
cord-005478-5iu38pr6	75	58	26	26	CD
cord-005478-5iu38pr6	75	59	.	.	.
cord-005478-5iu38pr6	75	60	8	8	CD
cord-005478-5iu38pr6	75	61	%	%	NN
cord-005478-5iu38pr6	75	62	(	(	-LRB-
cord-005478-5iu38pr6	75	63	22.3	22.3	CD
cord-005478-5iu38pr6	75	64	-	-	HYPH
cord-005478-5iu38pr6	75	65	31.4	31.4	CD
cord-005478-5iu38pr6	75	66	)	)	-RRB-
cord-005478-5iu38pr6	75	67	were	be	VBD
cord-005478-5iu38pr6	75	68	alive	alive	JJ
cord-005478-5iu38pr6	75	69	relapse	relapse	NN
cord-005478-5iu38pr6	75	70	-	-	HYPH
cord-005478-5iu38pr6	75	71	free	free	JJ
cord-005478-5iu38pr6	75	72	after	after	IN
cord-005478-5iu38pr6	75	73	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	75	74	.	.	.
cord-005478-5iu38pr6	76	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	76	2	:	:	:
cord-005478-5iu38pr6	77	1	Presented	present	VBN
cord-005478-5iu38pr6	77	2	results	result	NNS
cord-005478-5iu38pr6	77	3	suggest	suggest	VBP
cord-005478-5iu38pr6	77	4	that	that	IN
cord-005478-5iu38pr6	77	5	the	the	DT
cord-005478-5iu38pr6	77	6	rate	rate	NN
cord-005478-5iu38pr6	77	7	of	of	IN
cord-005478-5iu38pr6	77	8	relapse	relapse	NN
cord-005478-5iu38pr6	77	9	after	after	IN
cord-005478-5iu38pr6	77	10	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	77	11	is	be	VBZ
cord-005478-5iu38pr6	77	12	lower	low	JJR
cord-005478-5iu38pr6	77	13	among	among	IN
cord-005478-5iu38pr6	77	14	patients	patient	NNS
cord-005478-5iu38pr6	77	15	whose	whose	WP$
cord-005478-5iu38pr6	77	16	induction	induction	NN
cord-005478-5iu38pr6	77	17	therapy	therapy	NN
cord-005478-5iu38pr6	77	18	includes	include	VBZ
cord-005478-5iu38pr6	77	19	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	77	20	.	.	.
cord-005478-5iu38pr6	78	1	These	these	DT
cord-005478-5iu38pr6	78	2	results	result	NNS
cord-005478-5iu38pr6	78	3	could	could	MD
cord-005478-5iu38pr6	78	4	possibly	possibly	RB
cord-005478-5iu38pr6	78	5	be	be	VB
cord-005478-5iu38pr6	78	6	explained	explain	VBN
cord-005478-5iu38pr6	78	7	by	by	IN
cord-005478-5iu38pr6	78	8	higher	high	JJR
cord-005478-5iu38pr6	78	9	rate	rate	NN
cord-005478-5iu38pr6	78	10	of	of	IN
cord-005478-5iu38pr6	78	11	MRD	MRD	NNP
cord-005478-5iu38pr6	78	12	negativity	negativity	NN
cord-005478-5iu38pr6	78	13	achieved	achieve	VBN
cord-005478-5iu38pr6	78	14	in	in	IN
cord-005478-5iu38pr6	78	15	the	the	DT
cord-005478-5iu38pr6	78	16	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	78	17	arm	arm	NN
cord-005478-5iu38pr6	78	18	before	before	IN
cord-005478-5iu38pr6	78	19	proceeding	proceed	VBG
cord-005478-5iu38pr6	78	20	to	to	IN
cord-005478-5iu38pr6	78	21	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	78	22	.	.	.
cord-005478-5iu38pr6	79	1	We	-PRON-	PRP
cord-005478-5iu38pr6	79	2	also	also	RB
cord-005478-5iu38pr6	79	3	observed	observe	VBD
cord-005478-5iu38pr6	79	4	a	a	DT
cord-005478-5iu38pr6	79	5	higher	high	JJR
cord-005478-5iu38pr6	79	6	NRM	NRM	NNP
cord-005478-5iu38pr6	79	7	rate	rate	NN
cord-005478-5iu38pr6	79	8	in	in	IN
cord-005478-5iu38pr6	79	9	CR	CR	NNP
cord-005478-5iu38pr6	79	10	before	before	IN
cord-005478-5iu38pr6	79	11	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	79	12	in	in	IN
cord-005478-5iu38pr6	79	13	the	the	DT
cord-005478-5iu38pr6	79	14	clofarabine	clofarabine	NNP
cord-005478-5iu38pr6	79	15	arm	arm	NN
cord-005478-5iu38pr6	79	16	,	,	,
cord-005478-5iu38pr6	79	17	indicating	indicate	VBG
cord-005478-5iu38pr6	79	18	that	that	IN
cord-005478-5iu38pr6	79	19	the	the	DT
cord-005478-5iu38pr6	79	20	favorable	favorable	JJ
cord-005478-5iu38pr6	79	21	effect	effect	NN
cord-005478-5iu38pr6	79	22	of	of	IN
cord-005478-5iu38pr6	79	23	clofarabine	clofarabine	NN
cord-005478-5iu38pr6	79	24	on	on	IN
cord-005478-5iu38pr6	79	25	relapse	relapse	NN
cord-005478-5iu38pr6	79	26	may	may	MD
cord-005478-5iu38pr6	79	27	be	be	VB
cord-005478-5iu38pr6	79	28	compromised	compromise	VBN
cord-005478-5iu38pr6	79	29	by	by	IN
cord-005478-5iu38pr6	79	30	toxicity	toxicity	NN
cord-005478-5iu38pr6	79	31	.	.	.
cord-005478-5iu38pr6	80	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	80	2	Trial	Trial	NNP
cord-005478-5iu38pr6	80	3	Registry	Registry	NNP
cord-005478-5iu38pr6	80	4	:	:	:
cord-005478-5iu38pr6	80	5	HOVON	HOVON	NNP
cord-005478-5iu38pr6	80	6	102	102	CD
cord-005478-5iu38pr6	80	7	study	study	NN
cord-005478-5iu38pr6	80	8	is	be	VBZ
cord-005478-5iu38pr6	80	9	registered	register	VBN
cord-005478-5iu38pr6	80	10	at	at	IN
cord-005478-5iu38pr6	80	11	Netherlands	Netherlands	NNP
cord-005478-5iu38pr6	80	12	Trial	Trial	NNP
cord-005478-5iu38pr6	80	13	Registry	Registry	NNP
cord-005478-5iu38pr6	80	14	#	#	NN
cord-005478-5iu38pr6	80	15	NTR2187	NTR2187	NNP
cord-005478-5iu38pr6	80	16	Disclosure	disclosure	NN
cord-005478-5iu38pr6	80	17	:	:	:
cord-005478-5iu38pr6	80	18	Nothing	nothing	NN
cord-005478-5iu38pr6	80	19	to	to	TO
cord-005478-5iu38pr6	80	20	declare	declare	VB
cord-005478-5iu38pr6	80	21	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	80	22	transplant	transplant	NN
cord-005478-5iu38pr6	80	23	with	with	IN
cord-005478-5iu38pr6	80	24	post	post	JJ
cord-005478-5iu38pr6	80	25	-	-	JJ
cord-005478-5iu38pr6	80	26	transplant	transplant	JJ
cord-005478-5iu38pr6	80	27	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	80	28	for	for	IN
cord-005478-5iu38pr6	80	29	T	t	NN
cord-005478-5iu38pr6	80	30	-	-	HYPH
cord-005478-5iu38pr6	80	31	cell	cell	NN
cord-005478-5iu38pr6	80	32	acute	acute	JJ
cord-005478-5iu38pr6	80	33	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	80	34	leukemia	leukemia	NN
cord-005478-5iu38pr6	80	35	:	:	:
cord-005478-5iu38pr6	80	36	Outcome	outcome	NN
cord-005478-5iu38pr6	80	37	strongly	strongly	RB
cord-005478-5iu38pr6	80	38	correlates	correlate	VBZ
cord-005478-5iu38pr6	80	39	with	with	IN
cord-005478-5iu38pr6	80	40	disease	disease	NN
cord-005478-5iu38pr6	80	41	status	status	NN
cord-005478-5iu38pr6	80	42	;	;	:
cord-005478-5iu38pr6	80	43	a	a	DT
cord-005478-5iu38pr6	80	44	report	report	NN
cord-005478-5iu38pr6	80	45	from	from	IN
cord-005478-5iu38pr6	80	46	the	the	DT
cord-005478-5iu38pr6	80	47	EBMT	EBMT	NNP
cord-005478-5iu38pr6	80	48	acute	acute	JJ
cord-005478-5iu38pr6	80	49	leukemia	leukemia	NN
cord-005478-5iu38pr6	80	50	working	work	VBG
cord-005478-5iu38pr6	80	51	party	party	NN
cord-005478-5iu38pr6	80	52	Background	Background	NNP
cord-005478-5iu38pr6	80	53	:	:	:
cord-005478-5iu38pr6	80	54	Partial	partial	JJ
cord-005478-5iu38pr6	80	55	tandem	tandem	NN
cord-005478-5iu38pr6	80	56	duplication	duplication	NN
cord-005478-5iu38pr6	80	57	of	of	IN
cord-005478-5iu38pr6	80	58	MLL	MLL	NNP
cord-005478-5iu38pr6	80	59	(	(	-LRB-
cord-005478-5iu38pr6	80	60	MLL	MLL	NNP
cord-005478-5iu38pr6	80	61	-	-	HYPH
cord-005478-5iu38pr6	80	62	PTD	PTD	NNP
cord-005478-5iu38pr6	80	63	)	)	-RRB-
cord-005478-5iu38pr6	80	64	is	be	VBZ
cord-005478-5iu38pr6	80	65	an	an	DT
cord-005478-5iu38pr6	80	66	infrequent	infrequent	JJ
cord-005478-5iu38pr6	80	67	mutation	mutation	NN
cord-005478-5iu38pr6	80	68	in	in	IN
cord-005478-5iu38pr6	80	69	AML	AML	NNP
cord-005478-5iu38pr6	80	70	which	which	WDT
cord-005478-5iu38pr6	80	71	produces	produce	VBZ
cord-005478-5iu38pr6	80	72	a	a	DT
cord-005478-5iu38pr6	80	73	number	number	NN
cord-005478-5iu38pr6	80	74	gain	gain	NN
cord-005478-5iu38pr6	80	75	of	of	IN
cord-005478-5iu38pr6	80	76	5	5	CD
cord-005478-5iu38pr6	80	77	'	'	POS
cord-005478-5iu38pr6	80	78	acetyltransferase	acetyltransferase	NN
cord-005478-5iu38pr6	80	79	domains	domain	NNS
cord-005478-5iu38pr6	80	80	of	of	IN
cord-005478-5iu38pr6	80	81	KMT2A	KMT2A	NNP
cord-005478-5iu38pr6	80	82	protein	protein	NN
cord-005478-5iu38pr6	80	83	as	as	IN
cord-005478-5iu38pr6	80	84	a	a	DT
cord-005478-5iu38pr6	80	85	result	result	NN
cord-005478-5iu38pr6	80	86	of	of	IN
cord-005478-5iu38pr6	80	87	a	a	DT
cord-005478-5iu38pr6	80	88	repeated	repeat	VBN
cord-005478-5iu38pr6	80	89	exon	exon	NN
cord-005478-5iu38pr6	80	90	3	3	CD
cord-005478-5iu38pr6	80	91	-	-	SYM
cord-005478-5iu38pr6	80	92	9/10	9/10	CD
cord-005478-5iu38pr6	80	93	gene	gene	NN
cord-005478-5iu38pr6	80	94	sequence	sequence	NN
cord-005478-5iu38pr6	80	95	.	.	.
cord-005478-5iu38pr6	81	1	MLL	MLL	NNP
cord-005478-5iu38pr6	81	2	-	-	HYPH
cord-005478-5iu38pr6	81	3	PTD	PTD	NNP
cord-005478-5iu38pr6	81	4	leads	lead	VBZ
cord-005478-5iu38pr6	81	5	to	to	IN
cord-005478-5iu38pr6	81	6	a	a	DT
cord-005478-5iu38pr6	81	7	disturbed	disturbed	JJ
cord-005478-5iu38pr6	81	8	histone	histone	NN
cord-005478-5iu38pr6	81	9	acetylation	acetylation	NN
cord-005478-5iu38pr6	81	10	and	and	CC
cord-005478-5iu38pr6	81	11	upregulation	upregulation	NN
cord-005478-5iu38pr6	81	12	of	of	IN
cord-005478-5iu38pr6	81	13	determined	determine	VBN
cord-005478-5iu38pr6	81	14	HOX	HOX	NNP
cord-005478-5iu38pr6	81	15	genes	gene	NNS
cord-005478-5iu38pr6	81	16	.	.	.
cord-005478-5iu38pr6	82	1	MLL	MLL	NNP
cord-005478-5iu38pr6	82	2	-	-	HYPH
cord-005478-5iu38pr6	82	3	PTD	PTD	NNP
cord-005478-5iu38pr6	82	4	AML	AML	NNP
cord-005478-5iu38pr6	82	5	defines	define	VBZ
cord-005478-5iu38pr6	82	6	a	a	DT
cord-005478-5iu38pr6	82	7	specific	specific	JJ
cord-005478-5iu38pr6	82	8	AML	AML	NNP
cord-005478-5iu38pr6	82	9	entity	entity	NN
cord-005478-5iu38pr6	82	10	,	,	,
cord-005478-5iu38pr6	82	11	distinguishable	distinguishable	JJ
cord-005478-5iu38pr6	82	12	from	from	IN
cord-005478-5iu38pr6	82	13	cases	case	NNS
cord-005478-5iu38pr6	82	14	of	of	IN
cord-005478-5iu38pr6	82	15	AML	AML	NNP
cord-005478-5iu38pr6	82	16	with	with	IN
cord-005478-5iu38pr6	82	17	MLL	MLL	NNP
cord-005478-5iu38pr6	82	18	rearrangement	rearrangement	NN
cord-005478-5iu38pr6	82	19	,	,	,
cord-005478-5iu38pr6	82	20	with	with	IN
cord-005478-5iu38pr6	82	21	a	a	DT
cord-005478-5iu38pr6	82	22	characteristic	characteristic	JJ
cord-005478-5iu38pr6	82	23	pattern	pattern	NN
cord-005478-5iu38pr6	82	24	of	of	IN
cord-005478-5iu38pr6	82	25	co	co	NNS
cord-005478-5iu38pr6	82	26	-	-	NNS
cord-005478-5iu38pr6	82	27	mutations	mutation	NNS
cord-005478-5iu38pr6	82	28	,	,	,
cord-005478-5iu38pr6	82	29	including	include	VBG
cord-005478-5iu38pr6	82	30	a	a	DT
cord-005478-5iu38pr6	82	31	high	high	JJ
cord-005478-5iu38pr6	82	32	association	association	NN
cord-005478-5iu38pr6	82	33	with	with	IN
cord-005478-5iu38pr6	82	34	FLT3-ITD	FLT3-ITD	NNP
cord-005478-5iu38pr6	83	1	(	(	-LRB-
cord-005478-5iu38pr6	83	2	Q	Q	NNP
cord-005478-5iu38pr6	83	3	-	-	HYPH
cord-005478-5iu38pr6	83	4	Y	Y	NNP
cord-005478-5iu38pr6	83	5	Sun	Sun	NNP
cord-005478-5iu38pr6	83	6	et	et	FW
cord-005478-5iu38pr6	83	7	al	al	NNP
cord-005478-5iu38pr6	83	8	.	.	NNP
cord-005478-5iu38pr6	83	9	,	,	,
cord-005478-5iu38pr6	83	10	Leukemia	Leukemia	NNP
cord-005478-5iu38pr6	83	11	2017	2017	CD
cord-005478-5iu38pr6	83	12	)	)	-RRB-
cord-005478-5iu38pr6	83	13	.	.	.
cord-005478-5iu38pr6	84	1	Prognosis	prognosis	NN
cord-005478-5iu38pr6	84	2	of	of	IN
cord-005478-5iu38pr6	84	3	MLL	MLL	NNP
cord-005478-5iu38pr6	84	4	-	-	HYPH
cord-005478-5iu38pr6	84	5	PTD	PTD	NNP
cord-005478-5iu38pr6	84	6	-	-	HYPH
cord-005478-5iu38pr6	84	7	AML	AML	NNP
cord-005478-5iu38pr6	84	8	is	be	VBZ
cord-005478-5iu38pr6	84	9	remarkably	remarkably	RB
cord-005478-5iu38pr6	84	10	poor	poor	JJ
cord-005478-5iu38pr6	84	11	,	,	,
cord-005478-5iu38pr6	84	12	with	with	IN
cord-005478-5iu38pr6	84	13	initial	initial	JJ
cord-005478-5iu38pr6	84	14	chemoresistance	chemoresistance	NN
cord-005478-5iu38pr6	84	15	and	and	CC
cord-005478-5iu38pr6	84	16	high	high	JJ
cord-005478-5iu38pr6	84	17	relapse	relapse	NN
cord-005478-5iu38pr6	84	18	rate	rate	NN
cord-005478-5iu38pr6	84	19	;	;	:
cord-005478-5iu38pr6	84	20	as	as	IN
cord-005478-5iu38pr6	84	21	a	a	DT
cord-005478-5iu38pr6	84	22	consequence	consequence	NN
cord-005478-5iu38pr6	84	23	,	,	,
cord-005478-5iu38pr6	84	24	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	84	25	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	84	26	cell	cell	NN
cord-005478-5iu38pr6	84	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	84	28	(	(	-LRB-
cord-005478-5iu38pr6	84	29	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	84	30	)	)	-RRB-
cord-005478-5iu38pr6	85	1	in	in	IN
cord-005478-5iu38pr6	85	2	early	early	JJ
cord-005478-5iu38pr6	85	3	phase	phase	NN
cord-005478-5iu38pr6	85	4	is	be	VBZ
cord-005478-5iu38pr6	85	5	recommended	recommend	VBN
cord-005478-5iu38pr6	85	6	to	to	TO
cord-005478-5iu38pr6	85	7	overcome	overcome	VB
cord-005478-5iu38pr6	85	8	its	-PRON-	PRP$
cord-005478-5iu38pr6	85	9	high	high	JJ
cord-005478-5iu38pr6	85	10	-	-	HYPH
cord-005478-5iu38pr6	85	11	risk	risk	NN
cord-005478-5iu38pr6	85	12	prognostic	prognostic	JJ
cord-005478-5iu38pr6	85	13	impact	impact	NN
cord-005478-5iu38pr6	85	14	(	(	-LRB-
cord-005478-5iu38pr6	85	15	JP	JP	NNP
cord-005478-5iu38pr6	85	16	Patel	Patel	NNP
cord-005478-5iu38pr6	85	17	et	et	NNP
cord-005478-5iu38pr6	85	18	al	al	NNP
cord-005478-5iu38pr6	85	19	.	.	NNP
cord-005478-5iu38pr6	85	20	,	,	,
cord-005478-5iu38pr6	85	21	NEJM	NEJM	NNP
cord-005478-5iu38pr6	85	22	2012	2012	CD
cord-005478-5iu38pr6	85	23	;	;	:
cord-005478-5iu38pr6	85	24	V	V	NNP
cord-005478-5iu38pr6	85	25	Grossmann	Grossmann	NNP
cord-005478-5iu38pr6	85	26	et	et	NNP
cord-005478-5iu38pr6	85	27	al	al	NNP
cord-005478-5iu38pr6	85	28	,	,	,
cord-005478-5iu38pr6	85	29	Blood	blood	NN
cord-005478-5iu38pr6	85	30	2012	2012	CD
cord-005478-5iu38pr6	85	31	)	)	-RRB-
cord-005478-5iu38pr6	85	32	.	.	.
cord-005478-5iu38pr6	86	1	Nonetheless	nonetheless	RB
cord-005478-5iu38pr6	86	2	,	,	,
cord-005478-5iu38pr6	86	3	studies	study	NNS
cord-005478-5iu38pr6	86	4	focusing	focus	VBG
cord-005478-5iu38pr6	86	5	on	on	IN
cord-005478-5iu38pr6	86	6	transplant	transplant	NN
cord-005478-5iu38pr6	86	7	outcome	outcome	NN
cord-005478-5iu38pr6	86	8	have	have	VBP
cord-005478-5iu38pr6	86	9	not	not	RB
cord-005478-5iu38pr6	86	10	been	be	VBN
cord-005478-5iu38pr6	86	11	previously	previously	RB
cord-005478-5iu38pr6	86	12	addressed	address	VBN
cord-005478-5iu38pr6	86	13	.	.	.
cord-005478-5iu38pr6	87	1	Methods	method	NNS
cord-005478-5iu38pr6	87	2	:	:	:
cord-005478-5iu38pr6	87	3	For	for	IN
cord-005478-5iu38pr6	87	4	this	this	DT
cord-005478-5iu38pr6	87	5	purpose	purpose	NN
cord-005478-5iu38pr6	87	6	,	,	,
cord-005478-5iu38pr6	87	7	we	-PRON-	PRP
cord-005478-5iu38pr6	87	8	analysed	analyse	VBD
cord-005478-5iu38pr6	87	9	the	the	DT
cord-005478-5iu38pr6	87	10	outcome	outcome	NN
cord-005478-5iu38pr6	87	11	of	of	IN
cord-005478-5iu38pr6	87	12	MLL	MLL	NNP
cord-005478-5iu38pr6	87	13	-	-	HYPH
cord-005478-5iu38pr6	87	14	PTD	PTD	NNP
cord-005478-5iu38pr6	87	15	AML	AML	NNP
cord-005478-5iu38pr6	87	16	adult	adult	NN
cord-005478-5iu38pr6	87	17	patients	patient	NNS
cord-005478-5iu38pr6	87	18	reported	report	VBN
cord-005478-5iu38pr6	87	19	to	to	IN
cord-005478-5iu38pr6	87	20	EBMT	EBMT	NNP
cord-005478-5iu38pr6	87	21	who	who	WP
cord-005478-5iu38pr6	87	22	had	have	VBD
cord-005478-5iu38pr6	87	23	received	receive	VBN
cord-005478-5iu38pr6	87	24	an	an	DT
cord-005478-5iu38pr6	87	25	alloHCT	allohct	NN
cord-005478-5iu38pr6	87	26	from	from	IN
cord-005478-5iu38pr6	87	27	matched	match	VBN
cord-005478-5iu38pr6	87	28	related	related	JJ
cord-005478-5iu38pr6	87	29	or	or	CC
cord-005478-5iu38pr6	87	30	unrelated	unrelated	JJ
cord-005478-5iu38pr6	87	31	donors	donor	NNS
cord-005478-5iu38pr6	87	32	in	in	IN
cord-005478-5iu38pr6	87	33	CR1	CR1	NNP
cord-005478-5iu38pr6	87	34	during	during	IN
cord-005478-5iu38pr6	87	35	the	the	DT
cord-005478-5iu38pr6	87	36	period	period	NN
cord-005478-5iu38pr6	87	37	2000	2000	CD
cord-005478-5iu38pr6	87	38	-	-	SYM
cord-005478-5iu38pr6	87	39	2016	2016	CD
cord-005478-5iu38pr6	87	40	.	.	.
cord-005478-5iu38pr6	88	1	Molecular	molecular	JJ
cord-005478-5iu38pr6	88	2	screening	screening	NN
cord-005478-5iu38pr6	88	3	of	of	IN
cord-005478-5iu38pr6	88	4	MLL	MLL	NNP
cord-005478-5iu38pr6	88	5	-	-	HYPH
cord-005478-5iu38pr6	88	6	PTD	PTD	NNP
cord-005478-5iu38pr6	88	7	was	be	VBD
cord-005478-5iu38pr6	88	8	performed	perform	VBN
cord-005478-5iu38pr6	88	9	locally	locally	RB
cord-005478-5iu38pr6	88	10	,	,	,
cord-005478-5iu38pr6	88	11	but	but	CC
cord-005478-5iu38pr6	88	12	the	the	DT
cord-005478-5iu38pr6	88	13	presence	presence	NN
cord-005478-5iu38pr6	88	14	of	of	IN
cord-005478-5iu38pr6	88	15	this	this	DT
cord-005478-5iu38pr6	88	16	mutation	mutation	NN
cord-005478-5iu38pr6	88	17	was	be	VBD
cord-005478-5iu38pr6	88	18	verified	verify	VBN
cord-005478-5iu38pr6	88	19	specifically	specifically	RB
cord-005478-5iu38pr6	88	20	by	by	IN
cord-005478-5iu38pr6	88	21	a	a	DT
cord-005478-5iu38pr6	88	22	focused	focused	JJ
cord-005478-5iu38pr6	88	23	questionnaire	questionnaire	NN
cord-005478-5iu38pr6	88	24	among	among	IN
cord-005478-5iu38pr6	88	25	participating	participate	VBG
cord-005478-5iu38pr6	88	26	centres	centre	NNS
cord-005478-5iu38pr6	88	27	.	.	.
cord-005478-5iu38pr6	89	1	Results	result	NNS
cord-005478-5iu38pr6	89	2	:	:	:
cord-005478-5iu38pr6	90	1	Overall	overall	RB
cord-005478-5iu38pr6	90	2	,	,	,
cord-005478-5iu38pr6	90	3	we	-PRON-	PRP
cord-005478-5iu38pr6	90	4	identified	identify	VBD
cord-005478-5iu38pr6	90	5	58	58	CD
cord-005478-5iu38pr6	90	6	patients	patient	NNS
cord-005478-5iu38pr6	90	7	fulfilling	fulfil	VBG
cord-005478-5iu38pr6	90	8	inclusion	inclusion	NN
cord-005478-5iu38pr6	90	9	criteria	criterion	NNS
cord-005478-5iu38pr6	90	10	(	(	-LRB-
cord-005478-5iu38pr6	90	11	median	median	JJ
cord-005478-5iu38pr6	90	12	age	age	NN
cord-005478-5iu38pr6	90	13	,	,	,
cord-005478-5iu38pr6	90	14	52.8	52.8	CD
cord-005478-5iu38pr6	90	15	years	year	NNS
cord-005478-5iu38pr6	90	16	;	;	:
cord-005478-5iu38pr6	90	17	29/58	29/58	CD
cord-005478-5iu38pr6	90	18	female	female	JJ
cord-005478-5iu38pr6	90	19	patients	patient	NNS
cord-005478-5iu38pr6	90	20	)	)	-RRB-
cord-005478-5iu38pr6	90	21	.	.	.
cord-005478-5iu38pr6	91	1	Most	Most	JJS
cord-005478-5iu38pr6	91	2	patients	patient	NNS
cord-005478-5iu38pr6	91	3	harboured	harbour	VBD
cord-005478-5iu38pr6	91	4	an	an	DT
cord-005478-5iu38pr6	91	5	intermediate	intermediate	JJ
cord-005478-5iu38pr6	91	6	risk	risk	NN
cord-005478-5iu38pr6	91	7	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	91	8	(	(	-LRB-
cord-005478-5iu38pr6	91	9	50/56	50/56	CD
cord-005478-5iu38pr6	91	10	;	;	:
cord-005478-5iu38pr6	91	11	89	89	CD
cord-005478-5iu38pr6	91	12	%	%	NN
cord-005478-5iu38pr6	91	13	of	of	IN
cord-005478-5iu38pr6	91	14	available	available	JJ
cord-005478-5iu38pr6	91	15	)	)	-RRB-
cord-005478-5iu38pr6	91	16	and	and	CC
cord-005478-5iu38pr6	91	17	14	14	CD
cord-005478-5iu38pr6	91	18	(	(	-LRB-
cord-005478-5iu38pr6	91	19	14/54	14/54	CD
cord-005478-5iu38pr6	91	20	,	,	,
cord-005478-5iu38pr6	91	21	26	26	CD
cord-005478-5iu38pr6	91	22	%	%	NN
cord-005478-5iu38pr6	91	23	of	of	IN
cord-005478-5iu38pr6	91	24	available	available	JJ
cord-005478-5iu38pr6	91	25	)	)	-RRB-
cord-005478-5iu38pr6	91	26	patients	patient	NNS
cord-005478-5iu38pr6	91	27	presented	present	VBN
cord-005478-5iu38pr6	91	28	with	with	IN
cord-005478-5iu38pr6	91	29	concomitant	concomitant	JJ
cord-005478-5iu38pr6	91	30	FLT3-ITD	FLT3-ITD	NNP
cord-005478-5iu38pr6	91	31	.	.	.
cord-005478-5iu38pr6	92	1	Donor	donor	NN
cord-005478-5iu38pr6	92	2	was	be	VBD
cord-005478-5iu38pr6	92	3	a	a	DT
cord-005478-5iu38pr6	92	4	matched	match	VBN
cord-005478-5iu38pr6	92	5	sibling	sibling	NN
cord-005478-5iu38pr6	92	6	in	in	IN
cord-005478-5iu38pr6	92	7	27	27	CD
cord-005478-5iu38pr6	92	8	transplants	transplant	NNS
cord-005478-5iu38pr6	92	9	(	(	-LRB-
cord-005478-5iu38pr6	92	10	47	47	CD
cord-005478-5iu38pr6	92	11	%	%	NN
cord-005478-5iu38pr6	92	12	)	)	-RRB-
cord-005478-5iu38pr6	92	13	and	and	CC
cord-005478-5iu38pr6	92	14	an	an	DT
cord-005478-5iu38pr6	92	15	unrelated	unrelated	JJ
cord-005478-5iu38pr6	92	16	donor	donor	NN
cord-005478-5iu38pr6	92	17	in	in	IN
cord-005478-5iu38pr6	92	18	the	the	DT
cord-005478-5iu38pr6	92	19	remaining	remain	VBG
cord-005478-5iu38pr6	92	20	cases	case	NNS
cord-005478-5iu38pr6	92	21	.	.	.
cord-005478-5iu38pr6	93	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	93	2	was	be	VBD
cord-005478-5iu38pr6	93	3	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	93	4	(	(	-LRB-
cord-005478-5iu38pr6	93	5	MAC	MAC	NNP
cord-005478-5iu38pr6	93	6	)	)	-RRB-
cord-005478-5iu38pr6	93	7	in	in	IN
cord-005478-5iu38pr6	93	8	35	35	CD
cord-005478-5iu38pr6	93	9	procedures	procedure	NNS
cord-005478-5iu38pr6	93	10	(	(	-LRB-
cord-005478-5iu38pr6	93	11	61	61	CD
cord-005478-5iu38pr6	93	12	%	%	NN
cord-005478-5iu38pr6	93	13	)	)	-RRB-
cord-005478-5iu38pr6	93	14	and	and	CC
cord-005478-5iu38pr6	93	15	reduced	reduce	VBN
cord-005478-5iu38pr6	93	16	intensity	intensity	NN
cord-005478-5iu38pr6	93	17	in	in	IN
cord-005478-5iu38pr6	93	18	22	22	CD
cord-005478-5iu38pr6	93	19	(	(	-LRB-
cord-005478-5iu38pr6	93	20	40	40	CD
cord-005478-5iu38pr6	93	21	%	%	NN
cord-005478-5iu38pr6	93	22	)	)	-RRB-
cord-005478-5iu38pr6	93	23	.	.	.
cord-005478-5iu38pr6	94	1	In	in	IN
cord-005478-5iu38pr6	94	2	vivo	vivo	NNP
cord-005478-5iu38pr6	94	3	T	t	NN
cord-005478-5iu38pr6	94	4	-	-	HYPH
cord-005478-5iu38pr6	94	5	cell	cell	NN
cord-005478-5iu38pr6	94	6	depletion	depletion	NN
cord-005478-5iu38pr6	94	7	was	be	VBD
cord-005478-5iu38pr6	94	8	used	use	VBN
cord-005478-5iu38pr6	94	9	in	in	IN
cord-005478-5iu38pr6	94	10	36	36	CD
cord-005478-5iu38pr6	94	11	(	(	-LRB-
cord-005478-5iu38pr6	94	12	64	64	CD
cord-005478-5iu38pr6	94	13	%	%	NN
cord-005478-5iu38pr6	94	14	)	)	-RRB-
cord-005478-5iu38pr6	94	15	of	of	IN
cord-005478-5iu38pr6	94	16	transplants	transplant	NNS
cord-005478-5iu38pr6	94	17	.	.	.
cord-005478-5iu38pr6	95	1	At	at	IN
cord-005478-5iu38pr6	95	2	two	two	CD
cord-005478-5iu38pr6	95	3	years	year	NNS
cord-005478-5iu38pr6	95	4	,	,	,
cord-005478-5iu38pr6	95	5	cumulative	cumulative	JJ
cord-005478-5iu38pr6	95	6	incidence	incidence	NN
cord-005478-5iu38pr6	95	7	of	of	IN
cord-005478-5iu38pr6	95	8	relapse	relapse	NN
cord-005478-5iu38pr6	95	9	(	(	-LRB-
cord-005478-5iu38pr6	95	10	CIR	CIR	NNP
cord-005478-5iu38pr6	95	11	)	)	-RRB-
cord-005478-5iu38pr6	95	12	was	be	VBD
cord-005478-5iu38pr6	95	13	33	33	CD
cord-005478-5iu38pr6	95	14	%	%	NN
cord-005478-5iu38pr6	95	15	(	(	-LRB-
cord-005478-5iu38pr6	95	16	95	95	CD
cord-005478-5iu38pr6	95	17	%	%	NN
cord-005478-5iu38pr6	95	18	CI	ci	NN
cord-005478-5iu38pr6	95	19	:	:	:
cord-005478-5iu38pr6	95	20	21	21	CD
cord-005478-5iu38pr6	95	21	-	-	SYM
cord-005478-5iu38pr6	95	22	45	45	CD
cord-005478-5iu38pr6	95	23	)	)	-RRB-
cord-005478-5iu38pr6	95	24	,	,	,
cord-005478-5iu38pr6	95	25	and	and	CC
cord-005478-5iu38pr6	95	26	non	non	JJ
cord-005478-5iu38pr6	95	27	-	-	JJ
cord-005478-5iu38pr6	95	28	relapse	relapse	JJ
cord-005478-5iu38pr6	95	29	mortality	mortality	NN
cord-005478-5iu38pr6	95	30	(	(	-LRB-
cord-005478-5iu38pr6	95	31	NRM	NRM	NNP
cord-005478-5iu38pr6	95	32	)	)	-RRB-
cord-005478-5iu38pr6	95	33	16	16	CD
cord-005478-5iu38pr6	95	34	%	%	NN
cord-005478-5iu38pr6	95	35	(	(	-LRB-
cord-005478-5iu38pr6	95	36	8)	8)	NNP
cord-005478-5iu38pr6	95	37	(	(	-LRB-
cord-005478-5iu38pr6	95	38	9	9	CD
cord-005478-5iu38pr6	95	39	)	)	-RRB-
cord-005478-5iu38pr6	95	40	(	(	-LRB-
cord-005478-5iu38pr6	95	41	10	10	CD
cord-005478-5iu38pr6	95	42	)	)	-RRB-
cord-005478-5iu38pr6	95	43	(	(	-LRB-
cord-005478-5iu38pr6	95	44	11	11	CD
cord-005478-5iu38pr6	95	45	)	)	-RRB-
cord-005478-5iu38pr6	96	1	(	(	-LRB-
cord-005478-5iu38pr6	96	2	12	12	CD
cord-005478-5iu38pr6	96	3	)	)	-RRB-
cord-005478-5iu38pr6	96	4	(	(	-LRB-
cord-005478-5iu38pr6	96	5	13	13	CD
cord-005478-5iu38pr6	96	6	)	)	-RRB-
cord-005478-5iu38pr6	97	1	(	(	-LRB-
cord-005478-5iu38pr6	97	2	14	14	CD
cord-005478-5iu38pr6	97	3	)	)	-RRB-
cord-005478-5iu38pr6	98	1	(	(	-LRB-
cord-005478-5iu38pr6	98	2	15	15	CD
cord-005478-5iu38pr6	98	3	)	)	-RRB-
cord-005478-5iu38pr6	98	4	(	(	-LRB-
cord-005478-5iu38pr6	98	5	16	16	CD
cord-005478-5iu38pr6	98	6	)	)	-RRB-
cord-005478-5iu38pr6	98	7	(	(	-LRB-
cord-005478-5iu38pr6	98	8	17	17	CD
cord-005478-5iu38pr6	98	9	)	)	-RRB-
cord-005478-5iu38pr6	98	10	(	(	-LRB-
cord-005478-5iu38pr6	98	11	18	18	CD
cord-005478-5iu38pr6	98	12	)	)	-RRB-
cord-005478-5iu38pr6	98	13	(	(	-LRB-
cord-005478-5iu38pr6	98	14	19	19	CD
cord-005478-5iu38pr6	98	15	)	)	-RRB-
cord-005478-5iu38pr6	98	16	(	(	-LRB-
cord-005478-5iu38pr6	98	17	20	20	CD
cord-005478-5iu38pr6	98	18	)	)	-RRB-
cord-005478-5iu38pr6	98	19	(	(	-LRB-
cord-005478-5iu38pr6	98	20	21	21	CD
cord-005478-5iu38pr6	98	21	)	)	-RRB-
cord-005478-5iu38pr6	98	22	(	(	-LRB-
cord-005478-5iu38pr6	98	23	22	22	CD
cord-005478-5iu38pr6	98	24	)	)	-RRB-
cord-005478-5iu38pr6	98	25	(	(	-LRB-
cord-005478-5iu38pr6	98	26	23	23	CD
cord-005478-5iu38pr6	98	27	)	)	-RRB-
cord-005478-5iu38pr6	98	28	(	(	-LRB-
cord-005478-5iu38pr6	98	29	24	24	CD
cord-005478-5iu38pr6	98	30	)	)	-RRB-
cord-005478-5iu38pr6	98	31	(	(	-LRB-
cord-005478-5iu38pr6	98	32	25	25	CD
cord-005478-5iu38pr6	98	33	)	)	-RRB-
cord-005478-5iu38pr6	98	34	(	(	-LRB-
cord-005478-5iu38pr6	98	35	26	26	CD
cord-005478-5iu38pr6	98	36	)	)	-RRB-
cord-005478-5iu38pr6	98	37	;	;	:
cord-005478-5iu38pr6	99	1	100-day	100-day	JJ
cord-005478-5iu38pr6	99	2	acute	acute	JJ
cord-005478-5iu38pr6	99	3	GvHD	gvhd	NN
cord-005478-5iu38pr6	99	4	of	of	IN
cord-005478-5iu38pr6	99	5	grade	grade	NN
cord-005478-5iu38pr6	99	6	III	III	NNP
cord-005478-5iu38pr6	99	7	-	-	HYPH
cord-005478-5iu38pr6	99	8	IV	IV	NNP
cord-005478-5iu38pr6	99	9	was	be	VBD
cord-005478-5iu38pr6	99	10	7	7	CD
cord-005478-5iu38pr6	99	11	%	%	NN
cord-005478-5iu38pr6	99	12	(	(	-LRB-
cord-005478-5iu38pr6	99	13	2	2	CD
cord-005478-5iu38pr6	99	14	-	-	SYM
cord-005478-5iu38pr6	99	15	16	16	CD
cord-005478-5iu38pr6	99	16	)	)	-RRB-
cord-005478-5iu38pr6	99	17	and	and	CC
cord-005478-5iu38pr6	100	1	2-yr	2-yr	JJ
cord-005478-5iu38pr6	100	2	chronic	chronic	JJ
cord-005478-5iu38pr6	100	3	GvHD	GvHD	NNP
cord-005478-5iu38pr6	100	4	was	be	VBD
cord-005478-5iu38pr6	100	5	38	38	CD
cord-005478-5iu38pr6	100	6	%	%	NN
cord-005478-5iu38pr6	100	7	(	(	-LRB-
cord-005478-5iu38pr6	100	8	extensive	extensive	JJ
cord-005478-5iu38pr6	100	9	,	,	,
cord-005478-5iu38pr6	100	10	13	13	CD
cord-005478-5iu38pr6	100	11	%	%	NN
cord-005478-5iu38pr6	100	12	,	,	,
cord-005478-5iu38pr6	100	13	6	6	CD
cord-005478-5iu38pr6	100	14	-	-	SYM
cord-005478-5iu38pr6	100	15	23	23	CD
cord-005478-5iu38pr6	100	16	)	)	-RRB-
cord-005478-5iu38pr6	100	17	.	.	.
cord-005478-5iu38pr6	101	1	Two	two	CD
cord-005478-5iu38pr6	101	2	-	-	HYPH
cord-005478-5iu38pr6	101	3	year	year	NN
cord-005478-5iu38pr6	101	4	overall	overall	JJ
cord-005478-5iu38pr6	101	5	survival	survival	NN
cord-005478-5iu38pr6	101	6	(	(	-LRB-
cord-005478-5iu38pr6	101	7	OS	OS	NNP
cord-005478-5iu38pr6	101	8	)	)	-RRB-
cord-005478-5iu38pr6	101	9	was	be	VBD
cord-005478-5iu38pr6	101	10	56	56	CD
cord-005478-5iu38pr6	101	11	%	%	NN
cord-005478-5iu38pr6	101	12	(	(	-LRB-
cord-005478-5iu38pr6	101	13	45	45	CD
cord-005478-5iu38pr6	101	14	-	-	SYM
cord-005478-5iu38pr6	101	15	71	71	CD
cord-005478-5iu38pr6	101	16	)	)	-RRB-
cord-005478-5iu38pr6	101	17	,	,	,
cord-005478-5iu38pr6	101	18	with	with	IN
cord-005478-5iu38pr6	101	19	leukemia	leukemia	NN
cord-005478-5iu38pr6	101	20	-	-	HYPH
cord-005478-5iu38pr6	101	21	free	free	JJ
cord-005478-5iu38pr6	101	22	survival	survival	NN
cord-005478-5iu38pr6	101	23	(	(	-LRB-
cord-005478-5iu38pr6	101	24	LFS	LFS	NNP
cord-005478-5iu38pr6	101	25	)	)	-RRB-
cord-005478-5iu38pr6	101	26	and	and	CC
cord-005478-5iu38pr6	101	27	graft	graft	NN
cord-005478-5iu38pr6	101	28	-	-	HYPH
cord-005478-5iu38pr6	101	29	and	and	CC
cord-005478-5iu38pr6	101	30	relapse	relapse	NN
cord-005478-5iu38pr6	101	31	-	-	HYPH
cord-005478-5iu38pr6	101	32	free	free	JJ
cord-005478-5iu38pr6	101	33	survival	survival	NN
cord-005478-5iu38pr6	101	34	(	(	-LRB-
cord-005478-5iu38pr6	101	35	GRFS	GRFS	NNP
cord-005478-5iu38pr6	101	36	)	)	-RRB-
cord-005478-5iu38pr6	101	37	of	of	IN
cord-005478-5iu38pr6	101	38	51	51	CD
cord-005478-5iu38pr6	101	39	%	%	NN
cord-005478-5iu38pr6	101	40	(	(	-LRB-
cord-005478-5iu38pr6	101	41	40	40	CD
cord-005478-5iu38pr6	101	42	-	-	SYM
cord-005478-5iu38pr6	101	43	65	65	CD
cord-005478-5iu38pr6	101	44	)	)	-RRB-
cord-005478-5iu38pr6	101	45	and	and	CC
cord-005478-5iu38pr6	101	46	39	39	CD
cord-005478-5iu38pr6	101	47	%	%	NN
cord-005478-5iu38pr6	101	48	(	(	-LRB-
cord-005478-5iu38pr6	101	49	27	27	CD
cord-005478-5iu38pr6	101	50	-	-	SYM
cord-005478-5iu38pr6	101	51	58	58	CD
cord-005478-5iu38pr6	101	52	)	)	-RRB-
cord-005478-5iu38pr6	101	53	,	,	,
cord-005478-5iu38pr6	101	54	respectively	respectively	RB
cord-005478-5iu38pr6	101	55	(	(	-LRB-
cord-005478-5iu38pr6	101	56	Figure	figure	NN
cord-005478-5iu38pr6	101	57	)	)	-RRB-
cord-005478-5iu38pr6	101	58	.	.	.
cord-005478-5iu38pr6	102	1	Multivariate	multivariate	JJ
cord-005478-5iu38pr6	102	2	analysis	analysis	NN
cord-005478-5iu38pr6	102	3	did	do	VBD
cord-005478-5iu38pr6	102	4	not	not	RB
cord-005478-5iu38pr6	102	5	identify	identify	VB
cord-005478-5iu38pr6	102	6	any	any	DT
cord-005478-5iu38pr6	102	7	prognostic	prognostic	JJ
cord-005478-5iu38pr6	102	8	factor	factor	NN
cord-005478-5iu38pr6	102	9	for	for	IN
cord-005478-5iu38pr6	102	10	LFS	lfs	NN
cord-005478-5iu38pr6	102	11	;	;	:
cord-005478-5iu38pr6	102	12	notably	notably	RB
cord-005478-5iu38pr6	102	13	,	,	,
cord-005478-5iu38pr6	102	14	presence	presence	NN
cord-005478-5iu38pr6	102	15	of	of	IN
cord-005478-5iu38pr6	102	16	FLT3-ITD	FLT3-ITD	NNP
cord-005478-5iu38pr6	102	17	,	,	,
cord-005478-5iu38pr6	102	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	102	19	regimen	regimen	NN
cord-005478-5iu38pr6	102	20	intensity	intensity	NN
cord-005478-5iu38pr6	102	21	or	or	CC
cord-005478-5iu38pr6	102	22	donor	donor	NN
cord-005478-5iu38pr6	102	23	type	type	NN
cord-005478-5iu38pr6	102	24	did	do	VBD
cord-005478-5iu38pr6	102	25	not	not	RB
cord-005478-5iu38pr6	102	26	influence	influence	VB
cord-005478-5iu38pr6	102	27	outcome	outcome	NN
cord-005478-5iu38pr6	102	28	.	.	.
cord-005478-5iu38pr6	103	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	103	2	:	:	:
cord-005478-5iu38pr6	104	1	These	these	DT
cord-005478-5iu38pr6	104	2	results	result	NNS
cord-005478-5iu38pr6	104	3	support	support	VBP
cord-005478-5iu38pr6	104	4	the	the	DT
cord-005478-5iu38pr6	104	5	potential	potential	JJ
cord-005478-5iu38pr6	104	6	clinical	clinical	JJ
cord-005478-5iu38pr6	104	7	benefit	benefit	NN
cord-005478-5iu38pr6	104	8	of	of	IN
cord-005478-5iu38pr6	104	9	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	104	10	performed	perform	VBN
cord-005478-5iu38pr6	104	11	in	in	IN
cord-005478-5iu38pr6	104	12	CR1	CR1	NNP
cord-005478-5iu38pr6	104	13	in	in	IN
cord-005478-5iu38pr6	104	14	patients	patient	NNS
cord-005478-5iu38pr6	104	15	with	with	IN
cord-005478-5iu38pr6	104	16	MLL	MLL	NNP
cord-005478-5iu38pr6	104	17	-	-	HYPH
cord-005478-5iu38pr6	104	18	PTD	PTD	NNP
cord-005478-5iu38pr6	104	19	AML	AML	NNP
cord-005478-5iu38pr6	104	20	,	,	,
cord-005478-5iu38pr6	104	21	with	with	IN
cord-005478-5iu38pr6	104	22	a	a	DT
cord-005478-5iu38pr6	104	23	decreased	decrease	VBN
cord-005478-5iu38pr6	104	24	relapse	relapse	NN
cord-005478-5iu38pr6	104	25	risk	risk	NN
cord-005478-5iu38pr6	104	26	compared	compare	VBN
cord-005478-5iu38pr6	104	27	to	to	IN
cord-005478-5iu38pr6	104	28	previously	previously	RB
cord-005478-5iu38pr6	104	29	reported	report	VBN
cord-005478-5iu38pr6	104	30	series	series	NN
cord-005478-5iu38pr6	104	31	,	,	,
cord-005478-5iu38pr6	104	32	suggesting	suggest	VBG
cord-005478-5iu38pr6	104	33	the	the	DT
cord-005478-5iu38pr6	104	34	existence	existence	NN
cord-005478-5iu38pr6	104	35	of	of	IN
cord-005478-5iu38pr6	104	36	a	a	DT
cord-005478-5iu38pr6	104	37	tangible	tangible	JJ
cord-005478-5iu38pr6	104	38	graft	graft	NN
cord-005478-5iu38pr6	104	39	-	-	HYPH
cord-005478-5iu38pr6	104	40	versus	versus	IN
cord-005478-5iu38pr6	104	41	-	-	HYPH
cord-005478-5iu38pr6	104	42	leukemia	leukemia	NN
cord-005478-5iu38pr6	104	43	effect	effect	NN
cord-005478-5iu38pr6	104	44	(	(	-LRB-
cord-005478-5iu38pr6	104	45	GvL	gvl	NN
cord-005478-5iu38pr6	104	46	)	)	-RRB-
cord-005478-5iu38pr6	104	47	in	in	IN
cord-005478-5iu38pr6	104	48	this	this	DT
cord-005478-5iu38pr6	104	49	setting	setting	NN
cord-005478-5iu38pr6	104	50	.	.	.
cord-005478-5iu38pr6	105	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	105	2	:	:	:
cord-005478-5iu38pr6	105	3	Nothing	nothing	NN
cord-005478-5iu38pr6	105	4	to	to	TO
cord-005478-5iu38pr6	105	5	declare	declare	VB
cord-005478-5iu38pr6	105	6	O017	O017	NNP
cord-005478-5iu38pr6	105	7	Safety	safety	NN
cord-005478-5iu38pr6	105	8	and	and	CC
cord-005478-5iu38pr6	105	9	efficacy	efficacy	NN
cord-005478-5iu38pr6	105	10	of	of	IN
cord-005478-5iu38pr6	105	11	reduced	reduce	VBN
cord-005478-5iu38pr6	105	12	intensity	intensity	NN
cord-005478-5iu38pr6	105	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	105	14	regimen	regimen	NN
cord-005478-5iu38pr6	105	15	combined	combine	VBN
cord-005478-5iu38pr6	105	16	with	with	IN
cord-005478-5iu38pr6	105	17	anti	anti	JJ
cord-005478-5iu38pr6	105	18	-	-	JJ
cord-005478-5iu38pr6	105	19	thymocyte	thymocyte	JJ
cord-005478-5iu38pr6	105	20	globulin	globulin	NN
cord-005478-5iu38pr6	105	21	and	and	CC
cord-005478-5iu38pr6	105	22	post	post	JJ
cord-005478-5iu38pr6	105	23	-	-	NN
cord-005478-5iu38pr6	105	24	transplantation	transplantation	JJ
cord-005478-5iu38pr6	105	25	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	105	26	as	as	IN
cord-005478-5iu38pr6	105	27	graft	graft	NN
cord-005478-5iu38pr6	105	28	versus	versus	IN
cord-005478-5iu38pr6	105	29	host	host	NN
cord-005478-5iu38pr6	105	30	disease	disease	NN
cord-005478-5iu38pr6	105	31	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	105	32	for	for	IN
cord-005478-5iu38pr6	105	33	acute	acute	JJ
cord-005478-5iu38pr6	105	34	myeloid	myeloid	NN
cord-005478-5iu38pr6	105	35	leukemia	leukemia	NN
cord-005478-5iu38pr6	105	36	Background	background	NN
cord-005478-5iu38pr6	105	37	:	:	:
cord-005478-5iu38pr6	105	38	We	-PRON-	PRP
cord-005478-5iu38pr6	105	39	aimed	aim	VBD
cord-005478-5iu38pr6	105	40	to	to	TO
cord-005478-5iu38pr6	105	41	evaluate	evaluate	VB
cord-005478-5iu38pr6	105	42	the	the	DT
cord-005478-5iu38pr6	105	43	safety	safety	NN
cord-005478-5iu38pr6	105	44	and	and	CC
cord-005478-5iu38pr6	105	45	efficacy	efficacy	NN
cord-005478-5iu38pr6	105	46	of	of	IN
cord-005478-5iu38pr6	105	47	the	the	DT
cord-005478-5iu38pr6	105	48	use	use	NN
cord-005478-5iu38pr6	105	49	of	of	IN
cord-005478-5iu38pr6	105	50	reduced	reduced	JJ
cord-005478-5iu38pr6	105	51	intensity	intensity	NN
cord-005478-5iu38pr6	105	52	conditioning	conditioning	NN
cord-005478-5iu38pr6	105	53	regimen	regimen	NN
cord-005478-5iu38pr6	105	54	(	(	-LRB-
cord-005478-5iu38pr6	105	55	RIC	RIC	NNP
cord-005478-5iu38pr6	105	56	)	)	-RRB-
cord-005478-5iu38pr6	105	57	combined	combine	VBN
cord-005478-5iu38pr6	105	58	with	with	IN
cord-005478-5iu38pr6	105	59	anti	anti	JJ
cord-005478-5iu38pr6	105	60	-	-	JJ
cord-005478-5iu38pr6	105	61	thymocyte	thymocyte	JJ
cord-005478-5iu38pr6	105	62	globulin	globulin	NN
cord-005478-5iu38pr6	105	63	(	(	-LRB-
cord-005478-5iu38pr6	105	64	ATG	ATG	NNP
cord-005478-5iu38pr6	105	65	)	)	-RRB-
cord-005478-5iu38pr6	105	66	and	and	CC
cord-005478-5iu38pr6	105	67	posttransplant	posttransplant	NNP
cord-005478-5iu38pr6	105	68	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	105	69	(	(	-LRB-
cord-005478-5iu38pr6	105	70	PTCy	PTCy	NNP
cord-005478-5iu38pr6	105	71	)	)	-RRB-
cord-005478-5iu38pr6	105	72	for	for	IN
cord-005478-5iu38pr6	105	73	graft	graft	NN
cord-005478-5iu38pr6	105	74	versus	versus	IN
cord-005478-5iu38pr6	105	75	host	host	NN
cord-005478-5iu38pr6	105	76	disease	disease	NN
cord-005478-5iu38pr6	105	77	(	(	-LRB-
cord-005478-5iu38pr6	105	78	GVHD	GVHD	NNP
cord-005478-5iu38pr6	105	79	)	)	-RRB-
cord-005478-5iu38pr6	105	80	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	105	81	in	in	IN
cord-005478-5iu38pr6	105	82	patients	patient	NNS
cord-005478-5iu38pr6	105	83	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	105	84	with	with	IN
cord-005478-5iu38pr6	105	85	acute	acute	JJ
cord-005478-5iu38pr6	105	86	myeloid	myeloid	NN
cord-005478-5iu38pr6	105	87	leukemia	leukemia	NN
cord-005478-5iu38pr6	105	88	(	(	-LRB-
cord-005478-5iu38pr6	105	89	AML	AML	NNP
cord-005478-5iu38pr6	105	90	)	)	-RRB-
cord-005478-5iu38pr6	105	91	.	.	.
cord-005478-5iu38pr6	106	1	Methods	method	NNS
cord-005478-5iu38pr6	106	2	:	:	:
cord-005478-5iu38pr6	107	1	One	one	CD
cord-005478-5iu38pr6	107	2	hundred	hundred	CD
cord-005478-5iu38pr6	107	3	four	four	CD
cord-005478-5iu38pr6	107	4	adult	adult	NN
cord-005478-5iu38pr6	107	5	patients	patient	NNS
cord-005478-5iu38pr6	107	6	were	be	VBD
cord-005478-5iu38pr6	107	7	included	include	VBN
cord-005478-5iu38pr6	107	8	.	.	.
cord-005478-5iu38pr6	108	1	All	all	DT
cord-005478-5iu38pr6	108	2	patients	patient	NNS
cord-005478-5iu38pr6	108	3	received	receive	VBD
cord-005478-5iu38pr6	108	4	the	the	DT
cord-005478-5iu38pr6	108	5	same	same	JJ
cord-005478-5iu38pr6	108	6	RIC	RIC	NNP
cord-005478-5iu38pr6	108	7	regimen	regimen	NN
cord-005478-5iu38pr6	108	8	including	include	VBG
cord-005478-5iu38pr6	108	9	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	108	10	(	(	-LRB-
cord-005478-5iu38pr6	108	11	30mg	30mg	NNP
cord-005478-5iu38pr6	108	12	/	/	SYM
cord-005478-5iu38pr6	108	13	m2	m2	NNP
cord-005478-5iu38pr6	108	14	/	/	SYM
cord-005478-5iu38pr6	108	15	day	day	NN
cord-005478-5iu38pr6	108	16	day	day	NN
cord-005478-5iu38pr6	108	17	-5	-5	JJ
cord-005478-5iu38pr6	108	18	to	to	IN
cord-005478-5iu38pr6	108	19	-2	-2	NNP
cord-005478-5iu38pr6	108	20	)	)	-RRB-
cord-005478-5iu38pr6	108	21	,	,	,
cord-005478-5iu38pr6	108	22	busulfan	busulfan	NNP
cord-005478-5iu38pr6	108	23	(	(	-LRB-
cord-005478-5iu38pr6	108	24	3.2kg/	3.2kg/	CD
cord-005478-5iu38pr6	108	25	m2	m2	NNP
cord-005478-5iu38pr6	108	26	/	/	SYM
cord-005478-5iu38pr6	108	27	day	day	NN
cord-005478-5iu38pr6	108	28	day	day	NN
cord-005478-5iu38pr6	108	29	-3	-3	NNP
cord-005478-5iu38pr6	108	30	and	and	CC
cord-005478-5iu38pr6	108	31	-2	-2	NNP
cord-005478-5iu38pr6	108	32	)	)	-RRB-
cord-005478-5iu38pr6	108	33	,	,	,
cord-005478-5iu38pr6	108	34	and	and	CC
cord-005478-5iu38pr6	108	35	total	total	JJ
cord-005478-5iu38pr6	108	36	body	body	NN
cord-005478-5iu38pr6	108	37	irradiation	irradiation	NN
cord-005478-5iu38pr6	108	38	(	(	-LRB-
cord-005478-5iu38pr6	108	39	200	200	CD
cord-005478-5iu38pr6	108	40	cGy	cGy	NNS
cord-005478-5iu38pr6	108	41	)	)	-RRB-
cord-005478-5iu38pr6	108	42	(	(	-LRB-
cord-005478-5iu38pr6	108	43	day	day	NN
cord-005478-5iu38pr6	108	44	-1	-1	CD
cord-005478-5iu38pr6	108	45	)	)	-RRB-
cord-005478-5iu38pr6	109	1	combined	combine	VBN
cord-005478-5iu38pr6	109	2	with	with	IN
cord-005478-5iu38pr6	109	3	rabbit	rabbit	NN
cord-005478-5iu38pr6	109	4	-	-	HYPH
cord-005478-5iu38pr6	109	5	ATG	ATG	NNP
cord-005478-5iu38pr6	109	6	(	(	-LRB-
cord-005478-5iu38pr6	109	7	4.5	4.5	CD
cord-005478-5iu38pr6	109	8	mg	mg	NNP
cord-005478-5iu38pr6	109	9	/	/	SYM
cord-005478-5iu38pr6	109	10	kg	kg	NNP
cord-005478-5iu38pr6	109	11	:	:	:
cord-005478-5iu38pr6	109	12	day	day	NN
cord-005478-5iu38pr6	109	13	-3	-3	NNP
cord-005478-5iu38pr6	109	14	to	to	IN
cord-005478-5iu38pr6	109	15	-1	-1	NN
cord-005478-5iu38pr6	109	16	)	)	-RRB-
cord-005478-5iu38pr6	109	17	,	,	,
cord-005478-5iu38pr6	109	18	PTCy	PTCy	NNPS
cord-005478-5iu38pr6	109	19	(	(	-LRB-
cord-005478-5iu38pr6	109	20	50mg	50mg	NNP
cord-005478-5iu38pr6	109	21	/	/	SYM
cord-005478-5iu38pr6	109	22	kg	kg	NN
cord-005478-5iu38pr6	109	23	/	/	SYM
cord-005478-5iu38pr6	109	24	day	day	NN
cord-005478-5iu38pr6	109	25	:	:	:
cord-005478-5iu38pr6	109	26	day	day	NN
cord-005478-5iu38pr6	109	27	+3,+4	+3,+4	NNP
cord-005478-5iu38pr6	109	28	)	)	-RRB-
cord-005478-5iu38pr6	109	29	,	,	,
cord-005478-5iu38pr6	109	30	and	and	CC
cord-005478-5iu38pr6	109	31	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	109	32	.	.	.
cord-005478-5iu38pr6	110	1	Unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	110	2	peripheral	peripheral	JJ
cord-005478-5iu38pr6	110	3	blood	blood	NN
cord-005478-5iu38pr6	110	4	stem	stem	NN
cord-005478-5iu38pr6	110	5	cells	cell	NNS
cord-005478-5iu38pr6	110	6	were	be	VBD
cord-005478-5iu38pr6	110	7	infused	infuse	VBN
cord-005478-5iu38pr6	110	8	.	.	.
cord-005478-5iu38pr6	111	1	Last	last	JJ
cord-005478-5iu38pr6	111	2	follow	follow	NN
cord-005478-5iu38pr6	111	3	-	-	HYPH
cord-005478-5iu38pr6	111	4	up	up	NN
cord-005478-5iu38pr6	111	5	was	be	VBD
cord-005478-5iu38pr6	111	6	November	November	NNP
cord-005478-5iu38pr6	111	7	2018	2018	CD
cord-005478-5iu38pr6	111	8	.	.	.
cord-005478-5iu38pr6	112	1	Median	median	JJ
cord-005478-5iu38pr6	112	2	follow	follow	NN
cord-005478-5iu38pr6	112	3	-	-	HYPH
cord-005478-5iu38pr6	112	4	up	up	NN
cord-005478-5iu38pr6	112	5	was	be	VBD
cord-005478-5iu38pr6	112	6	19	19	CD
cord-005478-5iu38pr6	112	7	months	month	NNS
cord-005478-5iu38pr6	113	1	(	(	-LRB-
cord-005478-5iu38pr6	113	2	range	range	NNP
cord-005478-5iu38pr6	113	3	5	5	CD
cord-005478-5iu38pr6	113	4	-	-	SYM
cord-005478-5iu38pr6	113	5	35	35	CD
cord-005478-5iu38pr6	113	6	)	)	-RRB-
cord-005478-5iu38pr6	113	7	.	.	.
cord-005478-5iu38pr6	114	1	Results	result	NNS
cord-005478-5iu38pr6	114	2	:	:	:
cord-005478-5iu38pr6	115	1	Findings	finding	NNS
cord-005478-5iu38pr6	115	2	are	be	VBP
cord-005478-5iu38pr6	115	3	summarized	summarize	VBN
cord-005478-5iu38pr6	115	4	in	in	IN
cord-005478-5iu38pr6	115	5	Figure	Figure	NNP
cord-005478-5iu38pr6	115	6	1	1	CD
cord-005478-5iu38pr6	115	7	.	.	.
cord-005478-5iu38pr6	116	1	One	one	CD
cord-005478-5iu38pr6	116	2	year	year	NN
cord-005478-5iu38pr6	116	3	overall	overall	JJ
cord-005478-5iu38pr6	116	4	survival	survival	NN
cord-005478-5iu38pr6	116	5	(	(	-LRB-
cord-005478-5iu38pr6	116	6	OS	os	NN
cord-005478-5iu38pr6	116	7	)	)	-RRB-
cord-005478-5iu38pr6	116	8	progression	progression	NN
cord-005478-5iu38pr6	116	9	-	-	HYPH
cord-005478-5iu38pr6	116	10	free	free	JJ
cord-005478-5iu38pr6	116	11	survival	survival	NN
cord-005478-5iu38pr6	116	12	(	(	-LRB-
cord-005478-5iu38pr6	116	13	PFS	PFS	NNP
cord-005478-5iu38pr6	116	14	)	)	-RRB-
cord-005478-5iu38pr6	116	15	and	and	CC
cord-005478-5iu38pr6	116	16	non	non	JJ
cord-005478-5iu38pr6	116	17	-	-	JJ
cord-005478-5iu38pr6	116	18	relapse	relapse	JJ
cord-005478-5iu38pr6	116	19	mortality	mortality	NN
cord-005478-5iu38pr6	116	20	(	(	-LRB-
cord-005478-5iu38pr6	116	21	NRM	NRM	NNP
cord-005478-5iu38pr6	116	22	)	)	-RRB-
cord-005478-5iu38pr6	116	23	was	be	VBD
cord-005478-5iu38pr6	116	24	67.7	67.7	CD
cord-005478-5iu38pr6	116	25	%	%	NN
cord-005478-5iu38pr6	116	26	(	(	-LRB-
cord-005478-5iu38pr6	116	27	95	95	CD
cord-005478-5iu38pr6	116	28	%	%	NN
cord-005478-5iu38pr6	116	29	CI	CI	NNP
cord-005478-5iu38pr6	116	30	58.6	58.6	CD
cord-005478-5iu38pr6	116	31	-	-	HYPH
cord-005478-5iu38pr6	116	32	76.8	76.8	CD
cord-005478-5iu38pr6	116	33	)	)	-RRB-
cord-005478-5iu38pr6	116	34	,	,	,
cord-005478-5iu38pr6	116	35	60.8	60.8	CD
cord-005478-5iu38pr6	116	36	%	%	NN
cord-005478-5iu38pr6	116	37	(	(	-LRB-
cord-005478-5iu38pr6	116	38	95	95	CD
cord-005478-5iu38pr6	116	39	%	%	NN
cord-005478-5iu38pr6	116	40	CI	CI	NNP
cord-005478-5iu38pr6	116	41	51	51	CD
cord-005478-5iu38pr6	116	42	.	.	.
cord-005478-5iu38pr6	117	1	1	1	LS
cord-005478-5iu38pr6	117	2	-	-	SYM
cord-005478-5iu38pr6	117	3	70.5	70.5	CD
cord-005478-5iu38pr6	117	4	)	)	-RRB-
cord-005478-5iu38pr6	117	5	and	and	CC
cord-005478-5iu38pr6	117	6	16.4	16.4	CD
cord-005478-5iu38pr6	117	7	%	%	NN
cord-005478-5iu38pr6	117	8	(	(	-LRB-
cord-005478-5iu38pr6	117	9	95	95	CD
cord-005478-5iu38pr6	117	10	%	%	NN
cord-005478-5iu38pr6	117	11	CI	CI	NNP
cord-005478-5iu38pr6	117	12	6	6	CD
cord-005478-5iu38pr6	117	13	.	.	.
cord-005478-5iu38pr6	117	14	9	9	CD
cord-005478-5iu38pr6	117	15	-	-	SYM
cord-005478-5iu38pr6	117	16	25.8	25.8	CD
cord-005478-5iu38pr6	117	17	)	)	-RRB-
cord-005478-5iu38pr6	117	18	respectively	respectively	RB
cord-005478-5iu38pr6	117	19	.	.	.
cord-005478-5iu38pr6	118	1	Main	main	JJ
cord-005478-5iu38pr6	118	2	causes	cause	NNS
cord-005478-5iu38pr6	118	3	of	of	IN
cord-005478-5iu38pr6	118	4	death	death	NN
cord-005478-5iu38pr6	118	5	were	be	VBD
cord-005478-5iu38pr6	118	6	relapse	relapse	NN
cord-005478-5iu38pr6	118	7	(	(	-LRB-
cord-005478-5iu38pr6	118	8	18	18	CD
cord-005478-5iu38pr6	118	9	%	%	NN
cord-005478-5iu38pr6	118	10	)	)	-RRB-
cord-005478-5iu38pr6	118	11	and	and	CC
cord-005478-5iu38pr6	118	12	infection	infection	NN
cord-005478-5iu38pr6	118	13	(	(	-LRB-
cord-005478-5iu38pr6	118	14	13	13	CD
cord-005478-5iu38pr6	118	15	%	%	NN
cord-005478-5iu38pr6	118	16	)	)	-RRB-
cord-005478-5iu38pr6	118	17	.	.	.
cord-005478-5iu38pr6	119	1	Three	three	CD
cord-005478-5iu38pr6	119	2	patients	patient	NNS
cord-005478-5iu38pr6	119	3	had	have	VBD
cord-005478-5iu38pr6	119	4	residual	residual	JJ
cord-005478-5iu38pr6	119	5	disease	disease	NN
cord-005478-5iu38pr6	119	6	prior	prior	JJ
cord-005478-5iu38pr6	119	7	-	-	HYPH
cord-005478-5iu38pr6	119	8	transplant	transplant	NN
cord-005478-5iu38pr6	119	9	and	and	CC
cord-005478-5iu38pr6	119	10	they	-PRON-	PRP
cord-005478-5iu38pr6	119	11	had	have	VBD
cord-005478-5iu38pr6	119	12	a	a	DT
cord-005478-5iu38pr6	119	13	significant	significant	JJ
cord-005478-5iu38pr6	119	14	worst	bad	JJS
cord-005478-5iu38pr6	119	15	OS	os	NN
cord-005478-5iu38pr6	119	16	(	(	-LRB-
cord-005478-5iu38pr6	119	17	p=0.000	p=0.000	NNP
cord-005478-5iu38pr6	119	18	)	)	-RRB-
cord-005478-5iu38pr6	119	19	and	and	CC
cord-005478-5iu38pr6	119	20	RFS	RFS	NNP
cord-005478-5iu38pr6	119	21	(	(	-LRB-
cord-005478-5iu38pr6	119	22	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	119	23	)	)	-RRB-
cord-005478-5iu38pr6	119	24	.	.	.
cord-005478-5iu38pr6	120	1	Patients	patient	NNS
cord-005478-5iu38pr6	120	2	who	who	WP
cord-005478-5iu38pr6	120	3	had	have	VBD
cord-005478-5iu38pr6	120	4	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	120	5	performance	performance	NN
cord-005478-5iu38pr6	120	6	status	status	NN
cord-005478-5iu38pr6	120	7	(	(	-LRB-
cord-005478-5iu38pr6	120	8	KPS	KPS	NNP
cord-005478-5iu38pr6	120	9	)	)	-RRB-
cord-005478-5iu38pr6	120	10	≤80	≤80	.
cord-005478-5iu38pr6	121	1	%	%	NN
cord-005478-5iu38pr6	121	2	had	have	VBD
cord-005478-5iu38pr6	121	3	a	a	DT
cord-005478-5iu38pr6	121	4	significantly	significantly	RB
cord-005478-5iu38pr6	121	5	worse	bad	JJR
cord-005478-5iu38pr6	121	6	OS	OS	NNP
cord-005478-5iu38pr6	121	7	(	(	-LRB-
cord-005478-5iu38pr6	121	8	p=0.004	p=0.004	NNP
cord-005478-5iu38pr6	121	9	)	)	-RRB-
cord-005478-5iu38pr6	121	10	and	and	CC
cord-005478-5iu38pr6	121	11	PFS	PFS	NNP
cord-005478-5iu38pr6	121	12	(	(	-LRB-
cord-005478-5iu38pr6	121	13	p=0.014	p=0.014	NNS
cord-005478-5iu38pr6	121	14	)	)	-RRB-
cord-005478-5iu38pr6	121	15	.	.	.
cord-005478-5iu38pr6	122	1	The	the	DT
cord-005478-5iu38pr6	122	2	achievement	achievement	NN
cord-005478-5iu38pr6	122	3	of	of	IN
cord-005478-5iu38pr6	122	4	≥95	≥95	NNP
cord-005478-5iu38pr6	122	5	%	%	NN
cord-005478-5iu38pr6	122	6	chimerism	chimerism	NN
cord-005478-5iu38pr6	122	7	of	of	IN
cord-005478-5iu38pr6	122	8	Background	background	NN
cord-005478-5iu38pr6	122	9	:	:	:
cord-005478-5iu38pr6	122	10	Indications	indication	NNS
cord-005478-5iu38pr6	122	11	for	for	IN
cord-005478-5iu38pr6	122	12	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	122	13	stem	stem	NN
cord-005478-5iu38pr6	122	14	cell	cell	NN
cord-005478-5iu38pr6	122	15	transplantation	transplantation	NN
cord-005478-5iu38pr6	122	16	(	(	-LRB-
cord-005478-5iu38pr6	122	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	122	18	)	)	-RRB-
cord-005478-5iu38pr6	122	19	for	for	IN
cord-005478-5iu38pr6	122	20	adults	adult	NNS
cord-005478-5iu38pr6	122	21	with	with	IN
cord-005478-5iu38pr6	122	22	ALL	all	DT
cord-005478-5iu38pr6	122	23	evolve	evolve	VB
cord-005478-5iu38pr6	122	24	over	over	IN
cord-005478-5iu38pr6	122	25	time	time	NN
cord-005478-5iu38pr6	122	26	and	and	CC
cord-005478-5iu38pr6	122	27	vary	vary	VBP
cord-005478-5iu38pr6	122	28	among	among	IN
cord-005478-5iu38pr6	122	29	countries	country	NNS
cord-005478-5iu38pr6	122	30	.	.	.
cord-005478-5iu38pr6	123	1	Methods	method	NNS
cord-005478-5iu38pr6	123	2	:	:	:
cord-005478-5iu38pr6	124	1	The	the	DT
cord-005478-5iu38pr6	124	2	goal	goal	NN
cord-005478-5iu38pr6	124	3	of	of	IN
cord-005478-5iu38pr6	124	4	this	this	DT
cord-005478-5iu38pr6	124	5	study	study	NN
cord-005478-5iu38pr6	124	6	was	be	VBD
cord-005478-5iu38pr6	124	7	to	to	TO
cord-005478-5iu38pr6	124	8	assess	assess	VB
cord-005478-5iu38pr6	124	9	general	general	JJ
cord-005478-5iu38pr6	124	10	trends	trend	NNS
cord-005478-5iu38pr6	124	11	in	in	IN
cord-005478-5iu38pr6	124	12	the	the	DT
cord-005478-5iu38pr6	124	13	number	number	NN
cord-005478-5iu38pr6	124	14	of	of	IN
cord-005478-5iu38pr6	124	15	various	various	JJ
cord-005478-5iu38pr6	124	16	types	type	NNS
cord-005478-5iu38pr6	124	17	of	of	IN
cord-005478-5iu38pr6	124	18	HSCTs	hsct	NNS
cord-005478-5iu38pr6	124	19	performed	perform	VBN
cord-005478-5iu38pr6	124	20	between	between	IN
cord-005478-5iu38pr6	124	21	years	year	NNS
cord-005478-5iu38pr6	124	22	2001	2001	CD
cord-005478-5iu38pr6	124	23	and	and	CC
cord-005478-5iu38pr6	124	24	2015	2015	CD
cord-005478-5iu38pr6	124	25	in	in	IN
cord-005478-5iu38pr6	124	26	Europe	Europe	NNP
cord-005478-5iu38pr6	124	27	.	.	.
cord-005478-5iu38pr6	125	1	Data	datum	NNS
cord-005478-5iu38pr6	125	2	reported	report	VBD
cord-005478-5iu38pr6	125	3	to	to	IN
cord-005478-5iu38pr6	125	4	the	the	DT
cord-005478-5iu38pr6	125	5	EBMT	EBMT	NNP
cord-005478-5iu38pr6	125	6	registry	registry	NN
cord-005478-5iu38pr6	125	7	were	be	VBD
cord-005478-5iu38pr6	125	8	used	use	VBN
cord-005478-5iu38pr6	125	9	for	for	IN
cord-005478-5iu38pr6	125	10	this	this	DT
cord-005478-5iu38pr6	125	11	analysis	analysis	NN
cord-005478-5iu38pr6	125	12	.	.	.
cord-005478-5iu38pr6	126	1	In	in	IN
cord-005478-5iu38pr6	126	2	addition	addition	NN
cord-005478-5iu38pr6	126	3	,	,	,
cord-005478-5iu38pr6	126	4	we	-PRON-	PRP
cord-005478-5iu38pr6	126	5	evaluated	evaluate	VBD
cord-005478-5iu38pr6	126	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	126	7	rates	rate	NNS
cord-005478-5iu38pr6	126	8	with	with	IN
cord-005478-5iu38pr6	126	9	respect	respect	NN
cord-005478-5iu38pr6	126	10	to	to	IN
cord-005478-5iu38pr6	126	11	the	the	DT
cord-005478-5iu38pr6	126	12	incidence	incidence	NN
cord-005478-5iu38pr6	126	13	of	of	IN
cord-005478-5iu38pr6	126	14	ALL	all	DT
cord-005478-5iu38pr6	126	15	in	in	IN
cord-005478-5iu38pr6	126	16	selected	select	VBN
cord-005478-5iu38pr6	126	17	European	european	JJ
cord-005478-5iu38pr6	126	18	countries	country	NNS
cord-005478-5iu38pr6	126	19	.	.	.
cord-005478-5iu38pr6	127	1	Results	result	NNS
cord-005478-5iu38pr6	127	2	:	:	:
cord-005478-5iu38pr6	128	1	Altogether	altogether	RB
cord-005478-5iu38pr6	128	2	,	,	,
cord-005478-5iu38pr6	128	3	15346	15346	CD
cord-005478-5iu38pr6	128	4	first	first	JJ
cord-005478-5iu38pr6	128	5	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	128	6	(	(	-LRB-
cord-005478-5iu38pr6	128	7	n=13460	n=13460	CD
cord-005478-5iu38pr6	128	8	)	)	-RRB-
cord-005478-5iu38pr6	128	9	or	or	CC
cord-005478-5iu38pr6	128	10	autologous	autologous	JJ
cord-005478-5iu38pr6	128	11	(	(	-LRB-
cord-005478-5iu38pr6	128	12	n=1886	n=1886	CD
cord-005478-5iu38pr6	128	13	)	)	-RRB-
cord-005478-5iu38pr6	128	14	HSCTs	hsct	NNS
cord-005478-5iu38pr6	128	15	were	be	VBD
cord-005478-5iu38pr6	128	16	performed	perform	VBN
cord-005478-5iu38pr6	128	17	in	in	IN
cord-005478-5iu38pr6	128	18	the	the	DT
cord-005478-5iu38pr6	128	19	period	period	NN
cord-005478-5iu38pr6	128	20	2001	2001	CD
cord-005478-5iu38pr6	128	21	-2015	-2015	NNS
cord-005478-5iu38pr6	128	22	.	.	.
cord-005478-5iu38pr6	129	1	Comparing	compare	VBG
cord-005478-5iu38pr6	129	2	years	year	NNS
cord-005478-5iu38pr6	129	3	2013	2013	CD
cord-005478-5iu38pr6	129	4	-2015	-2015	NNS
cord-005478-5iu38pr6	129	5	and	and	CC
cord-005478-5iu38pr6	129	6	2001	2001	CD
cord-005478-5iu38pr6	130	1	-2003	-2003	NNP
cord-005478-5iu38pr6	130	2	,	,	,
cord-005478-5iu38pr6	130	3	the	the	DT
cord-005478-5iu38pr6	130	4	number	number	NN
cord-005478-5iu38pr6	130	5	of	of	IN
cord-005478-5iu38pr6	130	6	alloHSCTs	alloHSCTs	NNP
cord-005478-5iu38pr6	130	7	performed	perform	VBN
cord-005478-5iu38pr6	130	8	in	in	IN
cord-005478-5iu38pr6	130	9	first	first	JJ
cord-005478-5iu38pr6	130	10	CR	CR	NNP
cord-005478-5iu38pr6	130	11	increased	increase	VBD
cord-005478-5iu38pr6	130	12	by	by	IN
cord-005478-5iu38pr6	130	13	136	136	CD
cord-005478-5iu38pr6	130	14	%	%	NN
cord-005478-5iu38pr6	130	15	,	,	,
cord-005478-5iu38pr6	130	16	most	most	RBS
cord-005478-5iu38pr6	130	17	prominently	prominently	RB
cord-005478-5iu38pr6	130	18	for	for	IN
cord-005478-5iu38pr6	130	19	transplantations	transplantation	NNS
cord-005478-5iu38pr6	130	20	from	from	IN
cord-005478-5iu38pr6	130	21	unrelated	unrelated	JJ
cord-005478-5iu38pr6	130	22	(	(	-LRB-
cord-005478-5iu38pr6	130	23	272	272	CD
cord-005478-5iu38pr6	130	24	%	%	NN
cord-005478-5iu38pr6	130	25	)	)	-RRB-
cord-005478-5iu38pr6	130	26	and	and	CC
cord-005478-5iu38pr6	130	27	mismatched	mismatch	VBN
cord-005478-5iu38pr6	130	28	related	related	JJ
cord-005478-5iu38pr6	130	29	donors	donor	NNS
cord-005478-5iu38pr6	130	30	(	(	-LRB-
cord-005478-5iu38pr6	130	31	339	339	CD
cord-005478-5iu38pr6	130	32	%	%	NN
cord-005478-5iu38pr6	130	33	)	)	-RRB-
cord-005478-5iu38pr6	130	34	.	.	.
cord-005478-5iu38pr6	131	1	The	the	DT
cord-005478-5iu38pr6	131	2	number	number	NN
cord-005478-5iu38pr6	131	3	of	of	IN
cord-005478-5iu38pr6	131	4	HSCTs	hsct	NNS
cord-005478-5iu38pr6	131	5	from	from	IN
cord-005478-5iu38pr6	131	6	matched	match	VBN
cord-005478-5iu38pr6	131	7	sibling	sibling	NN
cord-005478-5iu38pr6	131	8	donors	donor	NNS
cord-005478-5iu38pr6	131	9	increased	increase	VBD
cord-005478-5iu38pr6	131	10	by	by	IN
cord-005478-5iu38pr6	131	11	42	42	CD
cord-005478-5iu38pr6	131	12	%	%	NN
cord-005478-5iu38pr6	131	13	,	,	,
cord-005478-5iu38pr6	131	14	while	while	IN
cord-005478-5iu38pr6	131	15	the	the	DT
cord-005478-5iu38pr6	131	16	number	number	NN
cord-005478-5iu38pr6	131	17	of	of	IN
cord-005478-5iu38pr6	131	18	autoHSCTs	autohscts	DT
cord-005478-5iu38pr6	131	19	decreased	decrease	VBD
cord-005478-5iu38pr6	131	20	by	by	IN
cord-005478-5iu38pr6	131	21	70	70	CD
cord-005478-5iu38pr6	131	22	%	%	NN
cord-005478-5iu38pr6	131	23	.	.	.
cord-005478-5iu38pr6	132	1	The	the	DT
cord-005478-5iu38pr6	132	2	increase	increase	NN
cord-005478-5iu38pr6	132	3	of	of	IN
cord-005478-5iu38pr6	132	4	the	the	DT
cord-005478-5iu38pr6	132	5	use	use	NN
cord-005478-5iu38pr6	132	6	of	of	IN
cord-005478-5iu38pr6	132	7	alloHSCT	alloHSCT	NNP
cord-005478-5iu38pr6	132	8	,	,	,
cord-005478-5iu38pr6	132	9	irrespective	irrespective	RB
cord-005478-5iu38pr6	132	10	of	of	IN
cord-005478-5iu38pr6	132	11	the	the	DT
cord-005478-5iu38pr6	132	12	disease	disease	NN
cord-005478-5iu38pr6	132	13	stage	stage	NN
cord-005478-5iu38pr6	132	14	,	,	,
cord-005478-5iu38pr6	132	15	was	be	VBD
cord-005478-5iu38pr6	132	16	stronger	strong	JJR
cord-005478-5iu38pr6	132	17	for	for	IN
cord-005478-5iu38pr6	132	18	Ph	Ph	NNP
cord-005478-5iu38pr6	132	19	-	-	HYPH
cord-005478-5iu38pr6	132	20	pos	pos	NNP
cord-005478-5iu38pr6	132	21	(	(	-LRB-
cord-005478-5iu38pr6	132	22	166	166	CD
cord-005478-5iu38pr6	132	23	%	%	NN
cord-005478-5iu38pr6	132	24	)	)	-RRB-
cord-005478-5iu38pr6	132	25	than	than	IN
cord-005478-5iu38pr6	132	26	Ph	Ph	NNP
cord-005478-5iu38pr6	132	27	-	-	NN
cord-005478-5iu38pr6	132	28	neg	neg	NNP
cord-005478-5iu38pr6	132	29	ALL	all	DT
cord-005478-5iu38pr6	132	30	(	(	-LRB-
cord-005478-5iu38pr6	132	31	38	38	CD
cord-005478-5iu38pr6	132	32	%	%	NN
cord-005478-5iu38pr6	132	33	)	)	-RRB-
cord-005478-5iu38pr6	132	34	.	.	.
cord-005478-5iu38pr6	133	1	Among	among	IN
cord-005478-5iu38pr6	133	2	patients	patient	NNS
cord-005478-5iu38pr6	133	3	aged	age	VBN
cord-005478-5iu38pr6	133	4	>	>	SYM
cord-005478-5iu38pr6	133	5	55	55	CD
cord-005478-5iu38pr6	133	6	years	year	NNS
cord-005478-5iu38pr6	133	7	,	,	,
cord-005478-5iu38pr6	133	8	the	the	DT
cord-005478-5iu38pr6	133	9	number	number	NN
cord-005478-5iu38pr6	133	10	of	of	IN
cord-005478-5iu38pr6	133	11	alloHSCT	alloHSCT	NNP
cord-005478-5iu38pr6	133	12	increased	increase	VBN
cord-005478-5iu38pr6	133	13	by	by	IN
cord-005478-5iu38pr6	133	14	559	559	CD
cord-005478-5iu38pr6	133	15	%	%	NN
cord-005478-5iu38pr6	133	16	while	while	IN
cord-005478-5iu38pr6	133	17	among	among	IN
cord-005478-5iu38pr6	133	18	younger	young	JJR
cord-005478-5iu38pr6	133	19	adults	adult	NNS
cord-005478-5iu38pr6	133	20	(	(	-LRB-
cord-005478-5iu38pr6	133	21	18	18	CD
cord-005478-5iu38pr6	133	22	-	-	SYM
cord-005478-5iu38pr6	133	23	55	55	CD
cord-005478-5iu38pr6	133	24	years	year	NNS
cord-005478-5iu38pr6	133	25	)	)	-RRB-
cord-005478-5iu38pr6	133	26	,	,	,
cord-005478-5iu38pr6	133	27	by	by	IN
cord-005478-5iu38pr6	133	28	59	59	CD
cord-005478-5iu38pr6	133	29	%	%	NN
cord-005478-5iu38pr6	133	30	.	.	.
cord-005478-5iu38pr6	134	1	Between	between	IN
cord-005478-5iu38pr6	134	2	2001	2001	CD
cord-005478-5iu38pr6	134	3	and	and	CC
cord-005478-5iu38pr6	134	4	2003	2003	CD
cord-005478-5iu38pr6	134	5	,	,	,
cord-005478-5iu38pr6	134	6	peripheral	peripheral	JJ
cord-005478-5iu38pr6	134	7	blood	blood	NN
cord-005478-5iu38pr6	134	8	was	be	VBD
cord-005478-5iu38pr6	134	9	used	use	VBN
cord-005478-5iu38pr6	134	10	as	as	IN
cord-005478-5iu38pr6	134	11	source	source	NN
cord-005478-5iu38pr6	134	12	of	of	IN
cord-005478-5iu38pr6	134	13	stem	stem	NN
cord-005478-5iu38pr6	134	14	cells	cell	NNS
cord-005478-5iu38pr6	134	15	in	in	IN
cord-005478-5iu38pr6	134	16	61	61	CD
cord-005478-5iu38pr6	134	17	%	%	NN
cord-005478-5iu38pr6	134	18	cases	case	NNS
cord-005478-5iu38pr6	134	19	of	of	IN
cord-005478-5iu38pr6	134	20	alloHSCT	alloHSCT	NNP
cord-005478-5iu38pr6	134	21	,	,	,
cord-005478-5iu38pr6	134	22	compared	compare	VBN
cord-005478-5iu38pr6	134	23	to	to	IN
cord-005478-5iu38pr6	134	24	84	84	CD
cord-005478-5iu38pr6	134	25	%	%	NN
cord-005478-5iu38pr6	134	26	between	between	IN
cord-005478-5iu38pr6	134	27	2013	2013	CD
cord-005478-5iu38pr6	134	28	-	-	SYM
cord-005478-5iu38pr6	134	29	2015	2015	CD
cord-005478-5iu38pr6	134	30	.	.	.
cord-005478-5iu38pr6	135	1	The	the	DT
cord-005478-5iu38pr6	135	2	use	use	NN
cord-005478-5iu38pr6	135	3	of	of	IN
cord-005478-5iu38pr6	135	4	bone	bone	NN
cord-005478-5iu38pr6	135	5	marrow	marrow	NN
cord-005478-5iu38pr6	135	6	decreased	decrease	VBD
cord-005478-5iu38pr6	135	7	from	from	IN
cord-005478-5iu38pr6	135	8	38	38	CD
cord-005478-5iu38pr6	135	9	%	%	NN
cord-005478-5iu38pr6	135	10	to	to	IN
cord-005478-5iu38pr6	135	11	16	16	CD
cord-005478-5iu38pr6	135	12	%	%	NN
cord-005478-5iu38pr6	135	13	,	,	,
cord-005478-5iu38pr6	135	14	respectively	respectively	RB
cord-005478-5iu38pr6	135	15	.	.	.
cord-005478-5iu38pr6	136	1	The	the	DT
cord-005478-5iu38pr6	136	2	proportion	proportion	NN
cord-005478-5iu38pr6	136	3	of	of	IN
cord-005478-5iu38pr6	136	4	alloHSCT	allohsct	NN
cord-005478-5iu38pr6	136	5	with	with	IN
cord-005478-5iu38pr6	136	6	reduced	reduce	VBN
cord-005478-5iu38pr6	136	7	-	-	HYPH
cord-005478-5iu38pr6	136	8	intensity	intensity	NN
cord-005478-5iu38pr6	136	9	conditioning	conditioning	NN
cord-005478-5iu38pr6	136	10	(	(	-LRB-
cord-005478-5iu38pr6	136	11	RIC	RIC	NNP
cord-005478-5iu38pr6	136	12	)	)	-RRB-
cord-005478-5iu38pr6	136	13	increased	increase	VBD
cord-005478-5iu38pr6	136	14	from	from	IN
cord-005478-5iu38pr6	136	15	6	6	CD
cord-005478-5iu38pr6	136	16	%	%	NN
cord-005478-5iu38pr6	136	17	to	to	TO
cord-005478-5iu38pr6	136	18	27	27	CD
cord-005478-5iu38pr6	136	19	%	%	NN
cord-005478-5iu38pr6	136	20	.	.	.
cord-005478-5iu38pr6	137	1	Among	among	IN
cord-005478-5iu38pr6	137	2	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	137	3	transplantations	transplantation	NNS
cord-005478-5iu38pr6	137	4	,	,	,
cord-005478-5iu38pr6	137	5	regimens	regimen	NNS
cord-005478-5iu38pr6	137	6	based	base	VBN
cord-005478-5iu38pr6	137	7	on	on	IN
cord-005478-5iu38pr6	137	8	total	total	JJ
cord-005478-5iu38pr6	137	9	body	body	NN
cord-005478-5iu38pr6	137	10	irradiation	irradiation	NN
cord-005478-5iu38pr6	137	11	were	be	VBD
cord-005478-5iu38pr6	137	12	the	the	DT
cord-005478-5iu38pr6	137	13	preferable	preferable	JJ
cord-005478-5iu38pr6	137	14	option	option	NN
cord-005478-5iu38pr6	137	15	(	(	-LRB-
cord-005478-5iu38pr6	137	16	app	app	NN
cord-005478-5iu38pr6	137	17	.	.	.
cord-005478-5iu38pr6	138	1	80	80	CD
cord-005478-5iu38pr6	138	2	%	%	NN
cord-005478-5iu38pr6	138	3	over	over	IN
cord-005478-5iu38pr6	138	4	the	the	DT
cord-005478-5iu38pr6	138	5	whole	whole	JJ
cord-005478-5iu38pr6	138	6	study	study	NN
cord-005478-5iu38pr6	138	7	period	period	NN
cord-005478-5iu38pr6	138	8	)	)	-RRB-
cord-005478-5iu38pr6	138	9	.	.	.
cord-005478-5iu38pr6	139	1	In	in	IN
cord-005478-5iu38pr6	139	2	contrast	contrast	NN
cord-005478-5iu38pr6	139	3	,	,	,
cord-005478-5iu38pr6	139	4	among	among	IN
cord-005478-5iu38pr6	139	5	RIC	RIC	NNP
cord-005478-5iu38pr6	139	6	regimens	regimen	NNS
cord-005478-5iu38pr6	139	7	,	,	,
cord-005478-5iu38pr6	139	8	the	the	DT
cord-005478-5iu38pr6	139	9	use	use	NN
cord-005478-5iu38pr6	139	10	of	of	IN
cord-005478-5iu38pr6	139	11	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	139	12	predominated	predominate	VBN
cord-005478-5iu38pr6	139	13	(	(	-LRB-
cord-005478-5iu38pr6	139	14	84	84	CD
cord-005478-5iu38pr6	139	15	%	%	NN
cord-005478-5iu38pr6	139	16	between	between	IN
cord-005478-5iu38pr6	139	17	2013	2013	CD
cord-005478-5iu38pr6	139	18	-	-	SYM
cord-005478-5iu38pr6	139	19	2015	2015	CD
cord-005478-5iu38pr6	139	20	)	)	-RRB-
cord-005478-5iu38pr6	139	21	.	.	.
cord-005478-5iu38pr6	140	1	In	in	IN
cord-005478-5iu38pr6	140	2	most	most	JJS
cord-005478-5iu38pr6	140	3	of	of	IN
cord-005478-5iu38pr6	140	4	analyzed	analyze	VBN
cord-005478-5iu38pr6	140	5	individual	individual	JJ
cord-005478-5iu38pr6	140	6	countries	country	NNS
cord-005478-5iu38pr6	140	7	,	,	,
cord-005478-5iu38pr6	140	8	the	the	DT
cord-005478-5iu38pr6	140	9	estimated	estimate	VBN
cord-005478-5iu38pr6	140	10	rates	rate	NNS
cord-005478-5iu38pr6	140	11	of	of	IN
cord-005478-5iu38pr6	140	12	alloHSCT	alloHSCT	NNP
cord-005478-5iu38pr6	140	13	(	(	-LRB-
cord-005478-5iu38pr6	140	14	no	no	UH
cord-005478-5iu38pr6	140	15	.	.	.
cord-005478-5iu38pr6	140	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	140	17	per	per	IN
cord-005478-5iu38pr6	140	18	100	100	CD
cord-005478-5iu38pr6	140	19	newly	newly	RB
cord-005478-5iu38pr6	140	20	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	140	21	ALL	all	DT
cord-005478-5iu38pr6	140	22	)	)	-RRB-
cord-005478-5iu38pr6	140	23	for	for	IN
cord-005478-5iu38pr6	140	24	patients	patient	NNS
cord-005478-5iu38pr6	140	25	in	in	IN
cord-005478-5iu38pr6	140	26	CR1	CR1	NNP
cord-005478-5iu38pr6	140	27	increased	increase	VBD
cord-005478-5iu38pr6	140	28	over	over	IN
cord-005478-5iu38pr6	140	29	time	time	NN
cord-005478-5iu38pr6	140	30	.	.	.
cord-005478-5iu38pr6	141	1	However	however	RB
cord-005478-5iu38pr6	141	2	,	,	,
cord-005478-5iu38pr6	141	3	the	the	DT
cord-005478-5iu38pr6	141	4	values	value	NNS
cord-005478-5iu38pr6	141	5	for	for	IN
cord-005478-5iu38pr6	141	6	a	a	DT
cord-005478-5iu38pr6	141	7	period	period	NN
cord-005478-5iu38pr6	141	8	2013	2013	CD
cord-005478-5iu38pr6	141	9	-	-	SYM
cord-005478-5iu38pr6	141	10	2015	2015	CD
cord-005478-5iu38pr6	141	11	varied	vary	VBN
cord-005478-5iu38pr6	141	12	strongly	strongly	RB
cord-005478-5iu38pr6	141	13	,	,	,
cord-005478-5iu38pr6	141	14	being	be	VBG
cord-005478-5iu38pr6	141	15	highest	high	JJS
cord-005478-5iu38pr6	141	16	in	in	IN
cord-005478-5iu38pr6	141	17	Finland	Finland	NNP
cord-005478-5iu38pr6	141	18	(	(	-LRB-
cord-005478-5iu38pr6	141	19	57.9	57.9	CD
cord-005478-5iu38pr6	141	20	)	)	-RRB-
cord-005478-5iu38pr6	141	21	,	,	,
cord-005478-5iu38pr6	141	22	followed	follow	VBN
cord-005478-5iu38pr6	141	23	by	by	IN
cord-005478-5iu38pr6	141	24	the	the	DT
cord-005478-5iu38pr6	141	25	Netherlands	Netherlands	NNP
cord-005478-5iu38pr6	141	26	(	(	-LRB-
cord-005478-5iu38pr6	141	27	35.4	35.4	CD
cord-005478-5iu38pr6	141	28	)	)	-RRB-
cord-005478-5iu38pr6	141	29	and	and	CC
cord-005478-5iu38pr6	141	30	Sweden	Sweden	NNP
cord-005478-5iu38pr6	141	31	(	(	-LRB-
cord-005478-5iu38pr6	141	32	35.4	35.4	CD
cord-005478-5iu38pr6	141	33	)	)	-RRB-
cord-005478-5iu38pr6	141	34	while	while	IN
cord-005478-5iu38pr6	141	35	lowest	low	JJS
cord-005478-5iu38pr6	141	36	in	in	IN
cord-005478-5iu38pr6	141	37	Russia	Russia	NNP
cord-005478-5iu38pr6	141	38	(	(	-LRB-
cord-005478-5iu38pr6	141	39	2.6	2.6	CD
cord-005478-5iu38pr6	141	40	)	)	-RRB-
cord-005478-5iu38pr6	141	41	.	.	.
cord-005478-5iu38pr6	142	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	142	2	:	:	:
cord-005478-5iu38pr6	143	1	Results	result	NNS
cord-005478-5iu38pr6	143	2	of	of	IN
cord-005478-5iu38pr6	143	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	143	4	analysis	analysis	NN
cord-005478-5iu38pr6	143	5	indicate	indicate	VBP
cord-005478-5iu38pr6	143	6	continued	continue	VBN
cord-005478-5iu38pr6	143	7	trend	trend	NN
cord-005478-5iu38pr6	143	8	to	to	IN
cord-005478-5iu38pr6	143	9	increased	increase	VBN
cord-005478-5iu38pr6	143	10	use	use	NN
cord-005478-5iu38pr6	143	11	of	of	IN
cord-005478-5iu38pr6	143	12	alloHSCT	allohsct	NN
cord-005478-5iu38pr6	143	13	for	for	IN
cord-005478-5iu38pr6	143	14	adults	adult	NNS
cord-005478-5iu38pr6	143	15	with	with	IN
cord-005478-5iu38pr6	143	16	ALL	all	DT
cord-005478-5iu38pr6	143	17	,	,	,
cord-005478-5iu38pr6	143	18	which	which	WDT
cord-005478-5iu38pr6	143	19	may	may	MD
cord-005478-5iu38pr6	143	20	be	be	VB
cord-005478-5iu38pr6	143	21	attributed	attribute	VBN
cord-005478-5iu38pr6	143	22	to	to	IN
cord-005478-5iu38pr6	143	23	increasing	increase	VBG
cord-005478-5iu38pr6	143	24	availability	availability	NN
cord-005478-5iu38pr6	143	25	of	of	IN
cord-005478-5iu38pr6	143	26	unrelated	unrelated	JJ
cord-005478-5iu38pr6	143	27	donors	donor	NNS
cord-005478-5iu38pr6	143	28	.	.	.
cord-005478-5iu38pr6	144	1	However	however	RB
cord-005478-5iu38pr6	144	2	,	,	,
cord-005478-5iu38pr6	144	3	it	-PRON-	PRP
cord-005478-5iu38pr6	144	4	may	may	MD
cord-005478-5iu38pr6	144	5	also	also	RB
cord-005478-5iu38pr6	144	6	be	be	VB
cord-005478-5iu38pr6	144	7	speculated	speculate	VBN
cord-005478-5iu38pr6	144	8	that	that	IN
cord-005478-5iu38pr6	144	9	the	the	DT
cord-005478-5iu38pr6	144	10	introduction	introduction	NN
cord-005478-5iu38pr6	144	11	of	of	IN
cord-005478-5iu38pr6	144	12	tyrosine	tyrosine	NN
cord-005478-5iu38pr6	144	13	kinase	kinase	NN
cord-005478-5iu38pr6	144	14	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	144	15	allowed	allow	VBD
cord-005478-5iu38pr6	144	16	higher	high	JJR
cord-005478-5iu38pr6	144	17	proportion	proportion	NN
cord-005478-5iu38pr6	144	18	of	of	IN
cord-005478-5iu38pr6	144	19	patients	patient	NNS
cord-005478-5iu38pr6	144	20	with	with	IN
cord-005478-5iu38pr6	144	21	Ph	Ph	NNP
cord-005478-5iu38pr6	144	22	-	-	HYPH
cord-005478-5iu38pr6	144	23	pos	pos	NNP
cord-005478-5iu38pr6	144	24	ALL	all	DT
cord-005478-5iu38pr6	144	25	proceeding	proceed	VBG
cord-005478-5iu38pr6	144	26	to	to	IN
cord-005478-5iu38pr6	144	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	144	28	.	.	.
cord-005478-5iu38pr6	145	1	Finally	finally	RB
cord-005478-5iu38pr6	145	2	,	,	,
cord-005478-5iu38pr6	145	3	the	the	DT
cord-005478-5iu38pr6	145	4	implementation	implementation	NN
cord-005478-5iu38pr6	145	5	of	of	IN
cord-005478-5iu38pr6	145	6	RIC	RIC	NNP
cord-005478-5iu38pr6	145	7	regimens	regimen	NNS
cord-005478-5iu38pr6	145	8	contributed	contribute	VBD
cord-005478-5iu38pr6	145	9	to	to	IN
cord-005478-5iu38pr6	145	10	wider	wide	JJR
cord-005478-5iu38pr6	145	11	use	use	NN
cord-005478-5iu38pr6	145	12	of	of	IN
cord-005478-5iu38pr6	145	13	alloHSCT	allohsct	NN
cord-005478-5iu38pr6	145	14	among	among	IN
cord-005478-5iu38pr6	145	15	older	old	JJR
cord-005478-5iu38pr6	145	16	adults	adult	NNS
cord-005478-5iu38pr6	145	17	.	.	.
cord-005478-5iu38pr6	146	1	Limitations	limitation	NNS
cord-005478-5iu38pr6	146	2	of	of	IN
cord-005478-5iu38pr6	146	3	the	the	DT
cord-005478-5iu38pr6	146	4	analysis	analysis	NN
cord-005478-5iu38pr6	146	5	include	include	VBP
cord-005478-5iu38pr6	146	6	any	any	DT
cord-005478-5iu38pr6	146	7	assumptions	assumption	NNS
cord-005478-5iu38pr6	146	8	made	make	VBD
cord-005478-5iu38pr6	146	9	regarding	regard	VBG
cord-005478-5iu38pr6	146	10	ALL	all	DT
cord-005478-5iu38pr6	146	11	incidence	incidence	NN
cord-005478-5iu38pr6	146	12	for	for	IN
cord-005478-5iu38pr6	146	13	the	the	DT
cord-005478-5iu38pr6	146	14	specified	specify	VBN
cord-005478-5iu38pr6	146	15	time	time	NN
cord-005478-5iu38pr6	146	16	period	period	NN
cord-005478-5iu38pr6	146	17	and	and	CC
cord-005478-5iu38pr6	146	18	possible	possible	JJ
cord-005478-5iu38pr6	146	19	variation	variation	NN
cord-005478-5iu38pr6	146	20	in	in	IN
cord-005478-5iu38pr6	146	21	reporting	report	VBG
cord-005478-5iu38pr6	146	22	to	to	IN
cord-005478-5iu38pr6	146	23	the	the	DT
cord-005478-5iu38pr6	146	24	EBMT	EBMT	NNP
cord-005478-5iu38pr6	146	25	registry	registry	NN
cord-005478-5iu38pr6	146	26	from	from	IN
cord-005478-5iu38pr6	146	27	different	different	JJ
cord-005478-5iu38pr6	146	28	countries	country	NNS
cord-005478-5iu38pr6	146	29	over	over	IN
cord-005478-5iu38pr6	146	30	time	time	NN
cord-005478-5iu38pr6	146	31	.	.	.
cord-005478-5iu38pr6	147	1	Year	year	NN
cord-005478-5iu38pr6	147	2	Type	type	NN
cord-005478-5iu38pr6	147	3	of	of	IN
cord-005478-5iu38pr6	147	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	5	2001	2001	CD
cord-005478-5iu38pr6	147	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	7	-2003	-2003	HYPH
cord-005478-5iu38pr6	147	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	9	2004	2004	CD
cord-005478-5iu38pr6	147	10	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	11	-2006	-2006	:
cord-005478-5iu38pr6	147	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	13	2007	2007	CD
cord-005478-5iu38pr6	147	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	15	-2009	-2009	WDT
cord-005478-5iu38pr6	147	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	17	2010	2010	CD
cord-005478-5iu38pr6	147	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	19	-2012	-2012	HYPH
cord-005478-5iu38pr6	147	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	21	2014	2014	CD
cord-005478-5iu38pr6	147	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	147	23	-2015	-2015	.
cord-005478-5iu38pr6	148	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	148	2	:	:	:
cord-005478-5iu38pr6	148	3	SG	SG	NNP
cord-005478-5iu38pr6	148	4	has	have	VBZ
cord-005478-5iu38pr6	148	5	received	receive	VBN
cord-005478-5iu38pr6	148	6	honoraria	honoraria	NN
cord-005478-5iu38pr6	148	7	for	for	IN
cord-005478-5iu38pr6	148	8	Amgen	Amgen	NNP
cord-005478-5iu38pr6	148	9	.	.	.
cord-005478-5iu38pr6	149	1	AS	AS	NNP
cord-005478-5iu38pr6	149	2	and	and	CC
cord-005478-5iu38pr6	149	3	SW	SW	NNP
cord-005478-5iu38pr6	149	4	are	be	VBP
cord-005478-5iu38pr6	149	5	employees	employee	NNS
cord-005478-5iu38pr6	149	6	of	of	IN
cord-005478-5iu38pr6	149	7	Amgen	Amgen	NNP
cord-005478-5iu38pr6	149	8	and	and	CC
cord-005478-5iu38pr6	149	9	own	own	JJ
cord-005478-5iu38pr6	149	10	shares	share	NNS
cord-005478-5iu38pr6	149	11	in	in	IN
cord-005478-5iu38pr6	149	12	Amgen	Amgen	NNP
cord-005478-5iu38pr6	149	13	.	.	.
cord-005478-5iu38pr6	150	1	MM	MM	NNP
cord-005478-5iu38pr6	150	2	has	have	VBZ
cord-005478-5iu38pr6	150	3	received	receive	VBN
cord-005478-5iu38pr6	150	4	honoraria	honoraria	NN
cord-005478-5iu38pr6	150	5	for	for	IN
cord-005478-5iu38pr6	150	6	speaking	speak	VBG
cord-005478-5iu38pr6	150	7	for	for	IN
cord-005478-5iu38pr6	150	8	Amgen	Amgen	NNP
cord-005478-5iu38pr6	150	9	and	and	CC
cord-005478-5iu38pr6	150	10	Pfizer	Pfizer	NNP
cord-005478-5iu38pr6	150	11	.	.	.
cord-005478-5iu38pr6	151	1	Outcome	outcome	NN
cord-005478-5iu38pr6	151	2	of	of	IN
cord-005478-5iu38pr6	151	3	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	151	4	-	-	HYPH
cord-005478-5iu38pr6	151	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	151	6	in	in	IN
cord-005478-5iu38pr6	151	7	adult	adult	NN
cord-005478-5iu38pr6	151	8	patients	patient	NNS
cord-005478-5iu38pr6	151	9	with	with	IN
cord-005478-5iu38pr6	151	10	PHpositive	PHpositive	NNPS
cord-005478-5iu38pr6	151	11	-	-	:
cord-005478-5iu38pr6	151	12	all	all	DT
cord-005478-5iu38pr6	151	13	in	in	IN
cord-005478-5iu38pr6	151	14	the	the	DT
cord-005478-5iu38pr6	151	15	era	era	NN
cord-005478-5iu38pr6	151	16	of	of	IN
cord-005478-5iu38pr6	151	17	TKI	TKI	NNP
cord-005478-5iu38pr6	151	18	:	:	:
cord-005478-5iu38pr6	152	1	A	a	DT
cord-005478-5iu38pr6	152	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	152	3	analysis	analysis	NN
cord-005478-5iu38pr6	152	4	of	of	IN
cord-005478-5iu38pr6	152	5	Università	Università	NNP
cord-005478-5iu38pr6	152	6	degli	degli	NN
cord-005478-5iu38pr6	152	7	Studi	Studi	NNP
cord-005478-5iu38pr6	152	8	e	e	NN
cord-005478-5iu38pr6	152	9	Ospedale	Ospedale	NNP
cord-005478-5iu38pr6	152	10	Maggiore	Maggiore	NNP
cord-005478-5iu38pr6	152	11	Policlinico	Policlinico	NNP
cord-005478-5iu38pr6	152	12	di	di	FW
cord-005478-5iu38pr6	152	13	Milano	Milano	NNP
cord-005478-5iu38pr6	152	14	,	,	,
cord-005478-5iu38pr6	152	15	Milano	Milano	NNP
cord-005478-5iu38pr6	152	16	,	,	,
cord-005478-5iu38pr6	152	17	Italy	Italy	NNP
cord-005478-5iu38pr6	152	18	,	,	,
cord-005478-5iu38pr6	152	19	33	33	CD
cord-005478-5iu38pr6	152	20	Genova	Genova	NNP
cord-005478-5iu38pr6	152	21	,	,	,
cord-005478-5iu38pr6	152	22	Italy	Italy	NNP
cord-005478-5iu38pr6	152	23	,	,	,
cord-005478-5iu38pr6	152	24	34	34	CD
cord-005478-5iu38pr6	152	25	Azienda	Azienda	NNP
cord-005478-5iu38pr6	152	26	Socio	Socio	NNP
cord-005478-5iu38pr6	152	27	Sanitaria	Sanitaria	NNP
cord-005478-5iu38pr6	152	28	Territoriale	Territoriale	NNP
cord-005478-5iu38pr6	152	29	Papa	Papa	NNP
cord-005478-5iu38pr6	152	30	Giovanni	Giovanni	NNP
cord-005478-5iu38pr6	152	31	XXIII	XXIII	NNP
cord-005478-5iu38pr6	152	32	,	,	,
cord-005478-5iu38pr6	152	33	Bergamo	Bergamo	NNP
cord-005478-5iu38pr6	152	34	,	,	,
cord-005478-5iu38pr6	153	1	Italy	Italy	NNP
cord-005478-5iu38pr6	153	2	Background	Background	NNP
cord-005478-5iu38pr6	153	3	:	:	:
cord-005478-5iu38pr6	153	4	We	-PRON-	PRP
cord-005478-5iu38pr6	153	5	conducted	conduct	VBD
cord-005478-5iu38pr6	153	6	a	a	DT
cord-005478-5iu38pr6	153	7	retrospective	retrospective	NN
cord-005478-5iu38pr6	153	8	,	,	,
cord-005478-5iu38pr6	153	9	nationwide	nationwide	JJ
cord-005478-5iu38pr6	153	10	analysis	analysis	NN
cord-005478-5iu38pr6	153	11	to	to	TO
cord-005478-5iu38pr6	153	12	describe	describe	VB
cord-005478-5iu38pr6	153	13	the	the	DT
cord-005478-5iu38pr6	153	14	clinical	clinical	JJ
cord-005478-5iu38pr6	153	15	outcome	outcome	NN
cord-005478-5iu38pr6	153	16	of	of	IN
cord-005478-5iu38pr6	153	17	adult	adult	NN
cord-005478-5iu38pr6	153	18	patients	patient	NNS
cord-005478-5iu38pr6	153	19	with	with	IN
cord-005478-5iu38pr6	153	20	Philadelphia	Philadelphia	NNP
cord-005478-5iu38pr6	153	21	chromosome	chromosome	NN
cord-005478-5iu38pr6	153	22	-	-	HYPH
cord-005478-5iu38pr6	153	23	positive	positive	JJ
cord-005478-5iu38pr6	153	24	acute	acute	JJ
cord-005478-5iu38pr6	153	25	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	153	26	leukemia	leukemia	NN
cord-005478-5iu38pr6	153	27	(	(	-LRB-
cord-005478-5iu38pr6	153	28	Ph+ALL	Ph+ALL	NNP
cord-005478-5iu38pr6	153	29	)	)	-RRB-
cord-005478-5iu38pr6	153	30	undergoing	undergo	VBG
cord-005478-5iu38pr6	153	31	allogeneic	allogeneic	VBG
cord-005478-5iu38pr6	153	32	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	153	33	stem	stem	NN
cord-005478-5iu38pr6	153	34	cell	cell	NN
cord-005478-5iu38pr6	153	35	transplantation	transplantation	NN
cord-005478-5iu38pr6	153	36	(	(	-LRB-
cord-005478-5iu38pr6	153	37	HSCT	HSCT	NNP
cord-005478-5iu38pr6	153	38	)	)	-RRB-
cord-005478-5iu38pr6	153	39	after	after	IN
cord-005478-5iu38pr6	153	40	being	be	VBG
cord-005478-5iu38pr6	153	41	treated	treat	VBN
cord-005478-5iu38pr6	153	42	with	with	IN
cord-005478-5iu38pr6	153	43	a	a	DT
cord-005478-5iu38pr6	153	44	TKI	TKI	NNP
cord-005478-5iu38pr6	153	45	based	base	VBN
cord-005478-5iu38pr6	153	46	therapy	therapy	NN
cord-005478-5iu38pr6	153	47	.	.	.
cord-005478-5iu38pr6	154	1	Methods	method	NNS
cord-005478-5iu38pr6	154	2	:	:	:
cord-005478-5iu38pr6	154	3	A	a	DT
cord-005478-5iu38pr6	154	4	total	total	NN
cord-005478-5iu38pr6	154	5	of	of	IN
cord-005478-5iu38pr6	154	6	441	441	CD
cord-005478-5iu38pr6	154	7	patients	patient	NNS
cord-005478-5iu38pr6	154	8	were	be	VBD
cord-005478-5iu38pr6	154	9	included	include	VBN
cord-005478-5iu38pr6	154	10	in	in	IN
cord-005478-5iu38pr6	154	11	the	the	DT
cord-005478-5iu38pr6	154	12	study	study	NN
cord-005478-5iu38pr6	154	13	.	.	.
cord-005478-5iu38pr6	155	1	The	the	DT
cord-005478-5iu38pr6	155	2	median	median	JJ
cord-005478-5iu38pr6	155	3	age	age	NN
cord-005478-5iu38pr6	155	4	at	at	IN
cord-005478-5iu38pr6	155	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	155	6	was	be	VBD
cord-005478-5iu38pr6	155	7	44	44	CD
cord-005478-5iu38pr6	156	1	(	(	-LRB-
cord-005478-5iu38pr6	156	2	range	range	NN
cord-005478-5iu38pr6	156	3	:	:	:
cord-005478-5iu38pr6	156	4	18	18	CD
cord-005478-5iu38pr6	156	5	-	-	SYM
cord-005478-5iu38pr6	156	6	70	70	CD
cord-005478-5iu38pr6	156	7	)	)	-RRB-
cord-005478-5iu38pr6	156	8	.	.	.
cord-005478-5iu38pr6	157	1	All	all	DT
cord-005478-5iu38pr6	157	2	441	441	CD
cord-005478-5iu38pr6	157	3	patients	patient	NNS
cord-005478-5iu38pr6	157	4	(	(	-LRB-
cord-005478-5iu38pr6	157	5	100	100	CD
cord-005478-5iu38pr6	157	6	%	%	NN
cord-005478-5iu38pr6	157	7	)	)	-RRB-
cord-005478-5iu38pr6	157	8	received	receive	VBD
cord-005478-5iu38pr6	157	9	TKI	TKI	NNP
cord-005478-5iu38pr6	157	10	before	before	IN
cord-005478-5iu38pr6	157	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	157	12	(	(	-LRB-
cord-005478-5iu38pr6	157	13	performed	perform	VBN
cord-005478-5iu38pr6	157	14	between	between	IN
cord-005478-5iu38pr6	157	15	2005	2005	CD
cord-005478-5iu38pr6	157	16	-	-	SYM
cord-005478-5iu38pr6	157	17	2016	2016	CD
cord-005478-5iu38pr6	157	18	)	)	-RRB-
cord-005478-5iu38pr6	157	19	.	.	.
cord-005478-5iu38pr6	158	1	Of	of	IN
cord-005478-5iu38pr6	158	2	these	these	DT
cord-005478-5iu38pr6	158	3	patients	patient	NNS
cord-005478-5iu38pr6	158	4	,	,	,
cord-005478-5iu38pr6	158	5	404	404	CD
cord-005478-5iu38pr6	158	6	(	(	-LRB-
cord-005478-5iu38pr6	158	7	92	92	CD
cord-005478-5iu38pr6	158	8	%	%	NN
cord-005478-5iu38pr6	158	9	)	)	-RRB-
cord-005478-5iu38pr6	158	10	were	be	VBD
cord-005478-5iu38pr6	158	11	in	in	IN
cord-005478-5iu38pr6	158	12	cytologic	cytologic	JJ
cord-005478-5iu38pr6	158	13	complete	complete	JJ
cord-005478-5iu38pr6	158	14	remission	remission	NN
cord-005478-5iu38pr6	158	15	(	(	-LRB-
cord-005478-5iu38pr6	158	16	CR	CR	NNP
cord-005478-5iu38pr6	158	17	)	)	-RRB-
cord-005478-5iu38pr6	158	18	while	while	IN
cord-005478-5iu38pr6	158	19	37	37	CD
cord-005478-5iu38pr6	158	20	(	(	-LRB-
cord-005478-5iu38pr6	158	21	8	8	CD
cord-005478-5iu38pr6	158	22	%	%	NN
cord-005478-5iu38pr6	158	23	)	)	-RRB-
cord-005478-5iu38pr6	158	24	had	have	VBD
cord-005478-5iu38pr6	158	25	an	an	DT
cord-005478-5iu38pr6	158	26	active	active	JJ
cord-005478-5iu38pr6	158	27	disease	disease	NN
cord-005478-5iu38pr6	158	28	at	at	IN
cord-005478-5iu38pr6	158	29	the	the	DT
cord-005478-5iu38pr6	158	30	time	time	NN
cord-005478-5iu38pr6	158	31	of	of	IN
cord-005478-5iu38pr6	158	32	HSCT	HSCT	NNP
cord-005478-5iu38pr6	158	33	.	.	.
cord-005478-5iu38pr6	159	1	Molecularly	Molecularly	NNP
cord-005478-5iu38pr6	159	2	Measurable	Measurable	NNP
cord-005478-5iu38pr6	159	3	Residual	Residual	NNP
cord-005478-5iu38pr6	159	4	Disease	Disease	NNP
cord-005478-5iu38pr6	159	5	(	(	-LRB-
cord-005478-5iu38pr6	159	6	MRD	MRD	NNP
cord-005478-5iu38pr6	159	7	)	)	-RRB-
cord-005478-5iu38pr6	159	8	was	be	VBD
cord-005478-5iu38pr6	159	9	negative	negative	JJ
cord-005478-5iu38pr6	159	10	in	in	IN
cord-005478-5iu38pr6	159	11	147	147	CD
cord-005478-5iu38pr6	159	12	patients	patient	NNS
cord-005478-5iu38pr6	159	13	(	(	-LRB-
cord-005478-5iu38pr6	159	14	36	36	CD
cord-005478-5iu38pr6	159	15	%	%	NN
cord-005478-5iu38pr6	159	16	)	)	-RRB-
cord-005478-5iu38pr6	159	17	at	at	IN
cord-005478-5iu38pr6	159	18	the	the	DT
cord-005478-5iu38pr6	159	19	time	time	NN
cord-005478-5iu38pr6	159	20	of	of	IN
cord-005478-5iu38pr6	159	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	159	22	.	.	.
cord-005478-5iu38pr6	160	1	The	the	DT
cord-005478-5iu38pr6	160	2	donor	donor	NN
cord-005478-5iu38pr6	160	3	was	be	VBD
cord-005478-5iu38pr6	160	4	unrelated	unrelated	JJ
cord-005478-5iu38pr6	160	5	in	in	IN
cord-005478-5iu38pr6	160	6	46	46	CD
cord-005478-5iu38pr6	160	7	%	%	NN
cord-005478-5iu38pr6	160	8	of	of	IN
cord-005478-5iu38pr6	160	9	cases	case	NNS
cord-005478-5iu38pr6	160	10	.	.	.
cord-005478-5iu38pr6	161	1	The	the	DT
cord-005478-5iu38pr6	161	2	prevalent	prevalent	JJ
cord-005478-5iu38pr6	161	3	source	source	NN
cord-005478-5iu38pr6	161	4	of	of	IN
cord-005478-5iu38pr6	161	5	stem	stem	NN
cord-005478-5iu38pr6	161	6	cells	cell	NNS
cord-005478-5iu38pr6	161	7	was	be	VBD
cord-005478-5iu38pr6	161	8	peripheral	peripheral	JJ
cord-005478-5iu38pr6	161	9	blood	blood	NN
cord-005478-5iu38pr6	161	10	(	(	-LRB-
cord-005478-5iu38pr6	161	11	70	70	CD
cord-005478-5iu38pr6	161	12	%	%	NN
cord-005478-5iu38pr6	161	13	)	)	-RRB-
cord-005478-5iu38pr6	161	14	.	.	.
cord-005478-5iu38pr6	162	1	The	the	DT
cord-005478-5iu38pr6	162	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	162	3	regimen	regimen	NN
cord-005478-5iu38pr6	162	4	was	be	VBD
cord-005478-5iu38pr6	162	5	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	162	6	in	in	IN
cord-005478-5iu38pr6	162	7	82	82	CD
cord-005478-5iu38pr6	162	8	%	%	NN
cord-005478-5iu38pr6	162	9	of	of	IN
cord-005478-5iu38pr6	162	10	cases	case	NNS
cord-005478-5iu38pr6	162	11	(	(	-LRB-
cord-005478-5iu38pr6	162	12	TBI	TBI	NNP
cord-005478-5iu38pr6	162	13	-	-	HYPH
cord-005478-5iu38pr6	162	14	based	base	VBN
cord-005478-5iu38pr6	162	15	in	in	IN
cord-005478-5iu38pr6	162	16	50	50	CD
cord-005478-5iu38pr6	162	17	%	%	NN
cord-005478-5iu38pr6	162	18	)	)	-RRB-
cord-005478-5iu38pr6	162	19	and	and	CC
cord-005478-5iu38pr6	162	20	included	include	VBD
cord-005478-5iu38pr6	162	21	ATG	ATG	NNP
cord-005478-5iu38pr6	162	22	in	in	IN
cord-005478-5iu38pr6	162	23	51	51	CD
cord-005478-5iu38pr6	162	24	%	%	NN
cord-005478-5iu38pr6	162	25	of	of	IN
cord-005478-5iu38pr6	162	26	cases	case	NNS
cord-005478-5iu38pr6	162	27	.	.	.
cord-005478-5iu38pr6	163	1	Results	result	NNS
cord-005478-5iu38pr6	163	2	:	:	:
cord-005478-5iu38pr6	164	1	With	with	IN
cord-005478-5iu38pr6	164	2	a	a	DT
cord-005478-5iu38pr6	164	3	median	median	JJ
cord-005478-5iu38pr6	164	4	follow	follow	NN
cord-005478-5iu38pr6	164	5	-	-	HYPH
cord-005478-5iu38pr6	164	6	up	up	NN
cord-005478-5iu38pr6	164	7	after	after	IN
cord-005478-5iu38pr6	164	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	164	9	of	of	IN
cord-005478-5iu38pr6	164	10	39.4	39.4	CD
cord-005478-5iu38pr6	164	11	months	month	NNS
cord-005478-5iu38pr6	164	12	(	(	-LRB-
cord-005478-5iu38pr6	164	13	range	range	NN
cord-005478-5iu38pr6	164	14	:	:	:
cord-005478-5iu38pr6	164	15	,	,	,
cord-005478-5iu38pr6	164	16	the	the	DT
cord-005478-5iu38pr6	164	17	probability	probability	NN
cord-005478-5iu38pr6	164	18	of	of	IN
cord-005478-5iu38pr6	164	19	Overall	Overall	NNP
cord-005478-5iu38pr6	164	20	Survival	Survival	NNP
cord-005478-5iu38pr6	164	21	(	(	-LRB-
cord-005478-5iu38pr6	164	22	OS	OS	NNP
cord-005478-5iu38pr6	164	23	)	)	-RRB-
cord-005478-5iu38pr6	164	24	at	at	IN
cord-005478-5iu38pr6	164	25	1	1	CD
cord-005478-5iu38pr6	164	26	,	,	,
cord-005478-5iu38pr6	164	27	2	2	CD
cord-005478-5iu38pr6	164	28	and	and	CC
cord-005478-5iu38pr6	164	29	5	5	CD
cord-005478-5iu38pr6	164	30	years	year	NNS
cord-005478-5iu38pr6	164	31	was	be	VBD
cord-005478-5iu38pr6	164	32	69.6	69.6	CD
cord-005478-5iu38pr6	164	33	%	%	NN
cord-005478-5iu38pr6	164	34	,	,	,
cord-005478-5iu38pr6	164	35	61.1	61.1	CD
cord-005478-5iu38pr6	164	36	%	%	NN
cord-005478-5iu38pr6	164	37	,	,	,
cord-005478-5iu38pr6	164	38	and	and	CC
cord-005478-5iu38pr6	164	39	50.3	50.3	CD
cord-005478-5iu38pr6	164	40	%	%	NN
cord-005478-5iu38pr6	164	41	,	,	,
cord-005478-5iu38pr6	164	42	respectively	respectively	RB
cord-005478-5iu38pr6	164	43	,	,	,
cord-005478-5iu38pr6	164	44	with	with	IN
cord-005478-5iu38pr6	164	45	a	a	DT
cord-005478-5iu38pr6	164	46	median	median	JJ
cord-005478-5iu38pr6	164	47	OS	os	NN
cord-005478-5iu38pr6	164	48	of	of	IN
cord-005478-5iu38pr6	164	49	62	62	CD
cord-005478-5iu38pr6	164	50	months	month	NNS
cord-005478-5iu38pr6	164	51	.	.	.
cord-005478-5iu38pr6	165	1	Progression	Progression	NNP
cord-005478-5iu38pr6	165	2	Free	Free	NNP
cord-005478-5iu38pr6	165	3	Survival	Survival	NNP
cord-005478-5iu38pr6	165	4	(	(	-LRB-
cord-005478-5iu38pr6	165	5	PFS	PFS	NNP
cord-005478-5iu38pr6	165	6	)	)	-RRB-
cord-005478-5iu38pr6	165	7	at	at	IN
cord-005478-5iu38pr6	165	8	1	1	CD
cord-005478-5iu38pr6	165	9	,	,	,
cord-005478-5iu38pr6	165	10	2	2	CD
cord-005478-5iu38pr6	165	11	and	and	CC
cord-005478-5iu38pr6	165	12	5	5	CD
cord-005478-5iu38pr6	165	13	years	year	NNS
cord-005478-5iu38pr6	165	14	was	be	VBD
cord-005478-5iu38pr6	165	15	60.2	60.2	CD
cord-005478-5iu38pr6	165	16	%	%	NN
cord-005478-5iu38pr6	165	17	,	,	,
cord-005478-5iu38pr6	165	18	52.1	52.1	CD
cord-005478-5iu38pr6	165	19	%	%	NN
cord-005478-5iu38pr6	165	20	and	and	CC
cord-005478-5iu38pr6	165	21	43.7	43.7	CD
cord-005478-5iu38pr6	165	22	%	%	NN
cord-005478-5iu38pr6	165	23	,	,	,
cord-005478-5iu38pr6	165	24	respectively	respectively	RB
cord-005478-5iu38pr6	165	25	.	.	.
cord-005478-5iu38pr6	166	1	OS	OS	NNP
cord-005478-5iu38pr6	166	2	and	and	CC
cord-005478-5iu38pr6	166	3	PFS	PFS	NNP
cord-005478-5iu38pr6	166	4	were	be	VBD
cord-005478-5iu38pr6	166	5	significantly	significantly	RB
cord-005478-5iu38pr6	166	6	better	well	JJR
cord-005478-5iu38pr6	166	7	in	in	IN
cord-005478-5iu38pr6	166	8	patients	patient	NNS
cord-005478-5iu38pr6	166	9	with	with	IN
cord-005478-5iu38pr6	166	10	CR	CR	NNP
cord-005478-5iu38pr6	166	11	and	and	CC
cord-005478-5iu38pr6	166	12	MRD	MRD	NNP
cord-005478-5iu38pr6	166	13	-	-	HYPH
cord-005478-5iu38pr6	166	14	negativity	negativity	NN
cord-005478-5iu38pr6	166	15	at	at	IN
cord-005478-5iu38pr6	166	16	the	the	DT
cord-005478-5iu38pr6	166	17	time	time	NN
cord-005478-5iu38pr6	166	18	of	of	IN
cord-005478-5iu38pr6	166	19	transplant	transplant	NN
cord-005478-5iu38pr6	166	20	compared	compare	VBN
cord-005478-5iu38pr6	166	21	to	to	IN
cord-005478-5iu38pr6	166	22	patients	patient	NNS
cord-005478-5iu38pr6	166	23	with	with	IN
cord-005478-5iu38pr6	166	24	CR	CR	NNP
cord-005478-5iu38pr6	166	25	but	but	CC
cord-005478-5iu38pr6	166	26	MRD	MRD	NNP
cord-005478-5iu38pr6	166	27	-	-	HYPH
cord-005478-5iu38pr6	166	28	positive	positive	JJ
cord-005478-5iu38pr6	166	29	(	(	-LRB-
cord-005478-5iu38pr6	166	30	50	50	CD
cord-005478-5iu38pr6	166	31	%	%	NN
cord-005478-5iu38pr6	166	32	OS	os	NN
cord-005478-5iu38pr6	166	33	not	not	RB
cord-005478-5iu38pr6	166	34	reached	reach	VBN
cord-005478-5iu38pr6	166	35	vs.	vs.	CC
cord-005478-5iu38pr6	166	36	36	36	CD
cord-005478-5iu38pr6	166	37	months	month	NNS
cord-005478-5iu38pr6	166	38	,	,	,
cord-005478-5iu38pr6	166	39	P=0,015	p=0,015	JJ
cord-005478-5iu38pr6	166	40	;	;	:
cord-005478-5iu38pr6	166	41	50	50	CD
cord-005478-5iu38pr6	166	42	%	%	NN
cord-005478-5iu38pr6	166	43	PFS	PFS	NNP
cord-005478-5iu38pr6	166	44	not	not	RB
cord-005478-5iu38pr6	166	45	reached	reach	VBN
cord-005478-5iu38pr6	166	46	vs	vs	IN
cord-005478-5iu38pr6	166	47	26	26	CD
cord-005478-5iu38pr6	166	48	months	month	NNS
cord-005478-5iu38pr6	166	49	,	,	,
cord-005478-5iu38pr6	166	50	P=0.003	P=0.003	NNP
cord-005478-5iu38pr6	166	51	)	)	-RRB-
cord-005478-5iu38pr6	166	52	.	.	.
cord-005478-5iu38pr6	167	1	The	the	DT
cord-005478-5iu38pr6	167	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	167	3	incidence	incidence	NN
cord-005478-5iu38pr6	167	4	of	of	IN
cord-005478-5iu38pr6	167	5	relapse	relapse	NN
cord-005478-5iu38pr6	167	6	(	(	-LRB-
cord-005478-5iu38pr6	167	7	CIR	CIR	NNP
cord-005478-5iu38pr6	167	8	)	)	-RRB-
cord-005478-5iu38pr6	167	9	at	at	IN
cord-005478-5iu38pr6	167	10	5	5	CD
cord-005478-5iu38pr6	167	11	years	year	NNS
cord-005478-5iu38pr6	167	12	was	be	VBD
cord-005478-5iu38pr6	167	13	significantly	significantly	RB
cord-005478-5iu38pr6	167	14	lower	low	JJR
cord-005478-5iu38pr6	167	15	in	in	IN
cord-005478-5iu38pr6	167	16	patients	patient	NNS
cord-005478-5iu38pr6	167	17	with	with	IN
cord-005478-5iu38pr6	167	18	CR	CR	NNP
cord-005478-5iu38pr6	167	19	and	and	CC
cord-005478-5iu38pr6	167	20	.4	.4	CD
cord-005478-5iu38pr6	167	21	%	%	NN
cord-005478-5iu38pr6	167	22	,	,	,
cord-005478-5iu38pr6	167	23	P=0.001	P=0.001	NNP
cord-005478-5iu38pr6	167	24	)	)	-RRB-
cord-005478-5iu38pr6	167	25	.	.	.
cord-005478-5iu38pr6	168	1	The	the	DT
cord-005478-5iu38pr6	168	2	non	non	JJ
cord-005478-5iu38pr6	168	3	relapse	relapse	NN
cord-005478-5iu38pr6	168	4	mortality	mortality	NN
cord-005478-5iu38pr6	168	5	(	(	-LRB-
cord-005478-5iu38pr6	168	6	NRM	NRM	NNP
cord-005478-5iu38pr6	168	7	)	)	-RRB-
cord-005478-5iu38pr6	168	8	after	after	IN
cord-005478-5iu38pr6	168	9	1	1	CD
cord-005478-5iu38pr6	168	10	,	,	,
cord-005478-5iu38pr6	168	11	2	2	CD
cord-005478-5iu38pr6	168	12	,	,	,
cord-005478-5iu38pr6	168	13	and	and	CC
cord-005478-5iu38pr6	168	14	5	5	CD
cord-005478-5iu38pr6	168	15	years	year	NNS
cord-005478-5iu38pr6	168	16	was	be	VBD
cord-005478-5iu38pr6	168	17	19.1	19.1	CD
cord-005478-5iu38pr6	168	18	%	%	NN
cord-005478-5iu38pr6	168	19	(	(	-LRB-
cord-005478-5iu38pr6	168	20	95%CI	95%ci	CD
cord-005478-5iu38pr6	168	21	:	:	:
cord-005478-5iu38pr6	168	22	15.5	15.5	CD
cord-005478-5iu38pr6	168	23	-	-	HYPH
cord-005478-5iu38pr6	168	24	22.9	22.9	CD
cord-005478-5iu38pr6	168	25	)	)	-RRB-
cord-005478-5iu38pr6	168	26	,	,	,
cord-005478-5iu38pr6	168	27	20.7	20.7	CD
cord-005478-5iu38pr6	168	28	%	%	NN
cord-005478-5iu38pr6	168	29	(	(	-LRB-
cord-005478-5iu38pr6	168	30	95%CI	95%ci	CD
cord-005478-5iu38pr6	168	31	:	:	:
cord-005478-5iu38pr6	168	32	17	17	CD
cord-005478-5iu38pr6	168	33	-	-	SYM
cord-005478-5iu38pr6	168	34	24.7	24.7	CD
cord-005478-5iu38pr6	168	35	)	)	-RRB-
cord-005478-5iu38pr6	168	36	,	,	,
cord-005478-5iu38pr6	168	37	and	and	CC
cord-005478-5iu38pr6	168	38	24.1	24.1	CD
cord-005478-5iu38pr6	168	39	%	%	NN
cord-005478-5iu38pr6	168	40	(	(	-LRB-
cord-005478-5iu38pr6	168	41	95%CI	95%ci	CD
cord-005478-5iu38pr6	168	42	:	:	:
cord-005478-5iu38pr6	168	43	20	20	CD
cord-005478-5iu38pr6	168	44	-	-	SYM
cord-005478-5iu38pr6	168	45	28.5	28.5	CD
cord-005478-5iu38pr6	168	46	)	)	-RRB-
cord-005478-5iu38pr6	168	47	,	,	,
cord-005478-5iu38pr6	168	48	respectively	respectively	RB
cord-005478-5iu38pr6	168	49	.	.	.
cord-005478-5iu38pr6	169	1	The	the	DT
cord-005478-5iu38pr6	169	2	subgroup	subgroup	NN
cord-005478-5iu38pr6	169	3	of	of	IN
cord-005478-5iu38pr6	169	4	patients	patient	NNS
cord-005478-5iu38pr6	169	5	with	with	IN
cord-005478-5iu38pr6	169	6	MRDnegative	MRDnegative	NNP
cord-005478-5iu38pr6	169	7	both	both	DT
cord-005478-5iu38pr6	169	8	at	at	IN
cord-005478-5iu38pr6	169	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	169	10	and	and	CC
cord-005478-5iu38pr6	169	11	at	at	IN
cord-005478-5iu38pr6	169	12	3rd	3rd	JJ
cord-005478-5iu38pr6	169	13	month	month	NN
cord-005478-5iu38pr6	169	14	after	after	IN
cord-005478-5iu38pr6	169	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	169	16	had	have	VBD
cord-005478-5iu38pr6	169	17	a	a	DT
cord-005478-5iu38pr6	169	18	better	well	JJR
cord-005478-5iu38pr6	169	19	outcome	outcome	NN
cord-005478-5iu38pr6	169	20	(	(	-LRB-
cord-005478-5iu38pr6	169	21	5	5	CD
cord-005478-5iu38pr6	169	22	year	year	NN
cord-005478-5iu38pr6	169	23	OS	OS	NNP
cord-005478-5iu38pr6	169	24	70	70	CD
cord-005478-5iu38pr6	169	25	%	%	NN
cord-005478-5iu38pr6	169	26	)	)	-RRB-
cord-005478-5iu38pr6	169	27	.	.	.
cord-005478-5iu38pr6	170	1	Conversely	conversely	RB
cord-005478-5iu38pr6	170	2	,	,	,
cord-005478-5iu38pr6	170	3	the	the	DT
cord-005478-5iu38pr6	170	4	37	37	CD
cord-005478-5iu38pr6	170	5	patients	patient	NNS
cord-005478-5iu38pr6	170	6	who	who	WP
cord-005478-5iu38pr6	170	7	underwent	undergo	VBD
cord-005478-5iu38pr6	170	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	170	9	with	with	IN
cord-005478-5iu38pr6	170	10	active	active	JJ
cord-005478-5iu38pr6	170	11	Ph+ALL	Ph+ALL	NNP
cord-005478-5iu38pr6	170	12	had	have	VBD
cord-005478-5iu38pr6	170	13	a	a	DT
cord-005478-5iu38pr6	170	14	median	median	JJ
cord-005478-5iu38pr6	170	15	OS	OS	NNP
cord-005478-5iu38pr6	170	16	and	and	CC
cord-005478-5iu38pr6	170	17	PFS	PFS	NNP
cord-005478-5iu38pr6	170	18	of	of	IN
cord-005478-5iu38pr6	170	19	7	7	CD
cord-005478-5iu38pr6	170	20	and	and	CC
cord-005478-5iu38pr6	170	21	5	5	CD
cord-005478-5iu38pr6	170	22	months	month	NNS
cord-005478-5iu38pr6	170	23	,	,	,
cord-005478-5iu38pr6	170	24	respectively	respectively	RB
cord-005478-5iu38pr6	170	25	.	.	.
cord-005478-5iu38pr6	171	1	Background	background	NN
cord-005478-5iu38pr6	171	2	:	:	:
cord-005478-5iu38pr6	172	1	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	172	2	(	(	-LRB-
cord-005478-5iu38pr6	172	3	Haplo	Haplo	NNP
cord-005478-5iu38pr6	172	4	)	)	-RRB-
cord-005478-5iu38pr6	172	5	donors	donor	NNS
cord-005478-5iu38pr6	172	6	have	have	VBP
cord-005478-5iu38pr6	172	7	expanded	expand	VBN
cord-005478-5iu38pr6	172	8	patient	patient	JJ
cord-005478-5iu38pr6	172	9	transplant	transplant	NN
cord-005478-5iu38pr6	172	10	access	access	NN
cord-005478-5iu38pr6	172	11	.	.	.
cord-005478-5iu38pr6	173	1	However	however	RB
cord-005478-5iu38pr6	173	2	,	,	,
cord-005478-5iu38pr6	173	3	outcome	outcome	NN
cord-005478-5iu38pr6	173	4	of	of	IN
cord-005478-5iu38pr6	173	5	patients	patient	NNS
cord-005478-5iu38pr6	173	6	with	with	IN
cord-005478-5iu38pr6	173	7	acute	acute	JJ
cord-005478-5iu38pr6	173	8	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	173	9	leukemia	leukemia	NN
cord-005478-5iu38pr6	173	10	(	(	-LRB-
cord-005478-5iu38pr6	173	11	ALL	all	DT
cord-005478-5iu38pr6	173	12	)	)	-RRB-
cord-005478-5iu38pr6	173	13	undergoing	undergo	VBG
cord-005478-5iu38pr6	173	14	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	173	15	stem	stem	NN
cord-005478-5iu38pr6	173	16	cell	cell	NN
cord-005478-5iu38pr6	173	17	transplant	transplant	NN
cord-005478-5iu38pr6	173	18	(	(	-LRB-
cord-005478-5iu38pr6	173	19	ASCT	ASCT	NNP
cord-005478-5iu38pr6	173	20	)	)	-RRB-
cord-005478-5iu38pr6	173	21	with	with	IN
cord-005478-5iu38pr6	173	22	Haplo	Haplo	NNP
cord-005478-5iu38pr6	173	23	donors	donor	NNS
cord-005478-5iu38pr6	173	24	in	in	IN
cord-005478-5iu38pr6	173	25	Argentina	Argentina	NNP
cord-005478-5iu38pr6	173	26	has	have	VBZ
cord-005478-5iu38pr6	173	27	not	not	RB
cord-005478-5iu38pr6	173	28	been	be	VBN
cord-005478-5iu38pr6	173	29	reported	report	VBN
cord-005478-5iu38pr6	173	30	.	.	.
cord-005478-5iu38pr6	174	1	We	-PRON-	PRP
cord-005478-5iu38pr6	174	2	aimed	aim	VBD
cord-005478-5iu38pr6	174	3	to	to	TO
cord-005478-5iu38pr6	174	4	analyze	analyze	VB
cord-005478-5iu38pr6	174	5	the	the	DT
cord-005478-5iu38pr6	174	6	outcome	outcome	NN
cord-005478-5iu38pr6	174	7	of	of	IN
cord-005478-5iu38pr6	174	8	ASCT	ASCT	NNP
cord-005478-5iu38pr6	174	9	in	in	IN
cord-005478-5iu38pr6	174	10	patients	patient	NNS
cord-005478-5iu38pr6	174	11	with	with	IN
cord-005478-5iu38pr6	174	12	ALL	all	DT
cord-005478-5iu38pr6	174	13	,	,	,
cord-005478-5iu38pr6	174	14	particularly	particularly	RB
cord-005478-5iu38pr6	174	15	results	result	VBZ
cord-005478-5iu38pr6	174	16	with	with	IN
cord-005478-5iu38pr6	174	17	Haplo	Haplo	NNP
cord-005478-5iu38pr6	174	18	donors	donor	NNS
cord-005478-5iu38pr6	174	19	.	.	.
cord-005478-5iu38pr6	175	1	Methods	method	NNS
cord-005478-5iu38pr6	175	2	:	:	:
cord-005478-5iu38pr6	175	3	We	-PRON-	PRP
cord-005478-5iu38pr6	175	4	collected	collect	VBD
cord-005478-5iu38pr6	175	5	data	datum	NNS
cord-005478-5iu38pr6	175	6	from	from	IN
cord-005478-5iu38pr6	175	7	patients	patient	NNS
cord-005478-5iu38pr6	175	8	with	with	IN
cord-005478-5iu38pr6	175	9	an	an	DT
cord-005478-5iu38pr6	175	10	ALL	all	DT
cord-005478-5iu38pr6	175	11	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	175	12	who	who	WP
cord-005478-5iu38pr6	175	13	underwent	undergo	VBD
cord-005478-5iu38pr6	175	14	ASCT	ASCT	NNP
cord-005478-5iu38pr6	175	15	in	in	IN
cord-005478-5iu38pr6	175	16	first	first	JJ
cord-005478-5iu38pr6	175	17	complete	complete	JJ
cord-005478-5iu38pr6	175	18	remission	remission	NN
cord-005478-5iu38pr6	175	19	(	(	-LRB-
cord-005478-5iu38pr6	175	20	CR1	CR1	NNP
cord-005478-5iu38pr6	175	21	)	)	-RRB-
cord-005478-5iu38pr6	175	22	and	and	CC
cord-005478-5iu38pr6	175	23	subsequent	subsequent	JJ
cord-005478-5iu38pr6	175	24	remissions	remission	NNS
cord-005478-5iu38pr6	175	25	(	(	-LRB-
cord-005478-5iu38pr6	175	26	CR2	CR2	NNP
cord-005478-5iu38pr6	175	27	+	+	CC
cord-005478-5iu38pr6	175	28	)	)	-RRB-
cord-005478-5iu38pr6	175	29	in	in	IN
cord-005478-5iu38pr6	175	30	15	15	CD
cord-005478-5iu38pr6	175	31	centers	center	NNS
cord-005478-5iu38pr6	175	32	in	in	IN
cord-005478-5iu38pr6	175	33	Argentina	Argentina	NNP
cord-005478-5iu38pr6	175	34	,	,	,
cord-005478-5iu38pr6	175	35	affiliated	affiliate	VBN
cord-005478-5iu38pr6	175	36	to	to	IN
cord-005478-5iu38pr6	175	37	GATMO	GATMO	NNP
cord-005478-5iu38pr6	175	38	,	,	,
cord-005478-5iu38pr6	175	39	between	between	IN
cord-005478-5iu38pr6	175	40	2008	2008	CD
cord-005478-5iu38pr6	175	41	and	and	CC
cord-005478-5iu38pr6	175	42	Patients	patient	NNS
cord-005478-5iu38pr6	175	43	that	that	WDT
cord-005478-5iu38pr6	175	44	underwent	undergo	VBD
cord-005478-5iu38pr6	175	45	ASCT	ASCT	NNP
cord-005478-5iu38pr6	175	46	with	with	IN
cord-005478-5iu38pr6	175	47	matched	match	VBN
cord-005478-5iu38pr6	175	48	donors	donor	NNS
cord-005478-5iu38pr6	175	49	(	(	-LRB-
cord-005478-5iu38pr6	175	50	sibling	sibling	NN
cord-005478-5iu38pr6	175	51	and	and	CC
cord-005478-5iu38pr6	175	52	unrelated	unrelated	JJ
cord-005478-5iu38pr6	175	53	)	)	-RRB-
cord-005478-5iu38pr6	175	54	and	and	CC
cord-005478-5iu38pr6	175	55	Haplo	Haplo	NNP
cord-005478-5iu38pr6	175	56	donors	donor	NNS
cord-005478-5iu38pr6	175	57	(	(	-LRB-
cord-005478-5iu38pr6	175	58	with	with	IN
cord-005478-5iu38pr6	175	59	post	post	JJ
cord-005478-5iu38pr6	175	60	-	-	JJ
cord-005478-5iu38pr6	175	61	transplant	transplant	NN
cord-005478-5iu38pr6	175	62	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	175	63	)	)	-RRB-
cord-005478-5iu38pr6	175	64	were	be	VBD
cord-005478-5iu38pr6	175	65	included	include	VBN
cord-005478-5iu38pr6	175	66	.	.	.
cord-005478-5iu38pr6	176	1	Both	both	DT
cord-005478-5iu38pr6	176	2	donor	donor	NN
cord-005478-5iu38pr6	176	3	categories	category	NNS
cord-005478-5iu38pr6	176	4	were	be	VBD
cord-005478-5iu38pr6	176	5	compared	compare	VBN
cord-005478-5iu38pr6	176	6	in	in	IN
cord-005478-5iu38pr6	176	7	terms	term	NNS
cord-005478-5iu38pr6	176	8	of	of	IN
cord-005478-5iu38pr6	176	9	overall	overall	JJ
cord-005478-5iu38pr6	176	10	survival	survival	NN
cord-005478-5iu38pr6	176	11	(	(	-LRB-
cord-005478-5iu38pr6	176	12	OS	OS	NNP
cord-005478-5iu38pr6	176	13	)	)	-RRB-
cord-005478-5iu38pr6	176	14	,	,	,
cord-005478-5iu38pr6	176	15	nonrelapsed	nonrelapsed	JJ
cord-005478-5iu38pr6	176	16	mortality	mortality	NN
cord-005478-5iu38pr6	176	17	(	(	-LRB-
cord-005478-5iu38pr6	176	18	NRM	NRM	NNP
cord-005478-5iu38pr6	176	19	)	)	-RRB-
cord-005478-5iu38pr6	176	20	and	and	CC
cord-005478-5iu38pr6	176	21	cumulative	cumulative	JJ
cord-005478-5iu38pr6	176	22	incidence	incidence	NN
cord-005478-5iu38pr6	176	23	of	of	IN
cord-005478-5iu38pr6	176	24	relapse	relapse	NN
cord-005478-5iu38pr6	176	25	(	(	-LRB-
cord-005478-5iu38pr6	176	26	CIR	CIR	NNP
cord-005478-5iu38pr6	176	27	)	)	-RRB-
cord-005478-5iu38pr6	176	28	.	.	.
cord-005478-5iu38pr6	177	1	Graft	graft	NN
cord-005478-5iu38pr6	177	2	versus	versus	IN
cord-005478-5iu38pr6	177	3	host	host	NN
cord-005478-5iu38pr6	177	4	disease	disease	NN
cord-005478-5iu38pr6	177	5	(	(	-LRB-
cord-005478-5iu38pr6	177	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	177	7	)	)	-RRB-
cord-005478-5iu38pr6	177	8	was	be	VBD
cord-005478-5iu38pr6	177	9	also	also	RB
cord-005478-5iu38pr6	177	10	evaluated	evaluate	VBN
cord-005478-5iu38pr6	177	11	.	.	.
cord-005478-5iu38pr6	178	1	Multivariate	multivariate	JJ
cord-005478-5iu38pr6	178	2	analysis	analysis	NN
cord-005478-5iu38pr6	178	3	was	be	VBD
cord-005478-5iu38pr6	178	4	performed	perform	VBN
cord-005478-5iu38pr6	178	5	by	by	IN
cord-005478-5iu38pr6	178	6	Cox	Cox	NNP
cord-005478-5iu38pr6	178	7	regression	regression	NN
cord-005478-5iu38pr6	178	8	for	for	IN
cord-005478-5iu38pr6	178	9	OS	OS	NNP
cord-005478-5iu38pr6	178	10	and	and	CC
cord-005478-5iu38pr6	178	11	Fine	fine	JJ
cord-005478-5iu38pr6	178	12	-	-	HYPH
cord-005478-5iu38pr6	178	13	Gray	Gray	NNP
cord-005478-5iu38pr6	178	14	for	for	IN
cord-005478-5iu38pr6	178	15	CI	CI	NNP
cord-005478-5iu38pr6	178	16	of	of	IN
cord-005478-5iu38pr6	178	17	competing	compete	VBG
cord-005478-5iu38pr6	178	18	events	event	NNS
cord-005478-5iu38pr6	178	19	.	.	.
cord-005478-5iu38pr6	179	1	A	a	DT
cord-005478-5iu38pr6	179	2	further	further	JJ
cord-005478-5iu38pr6	179	3	propensity	propensity	NN
cord-005478-5iu38pr6	179	4	score	score	NN
cord-005478-5iu38pr6	179	5	(	(	-LRB-
cord-005478-5iu38pr6	179	6	PS	PS	NNP
cord-005478-5iu38pr6	179	7	)	)	-RRB-
cord-005478-5iu38pr6	179	8	adjustment	adjustment	NN
cord-005478-5iu38pr6	179	9	was	be	VBD
cord-005478-5iu38pr6	179	10	performed	perform	VBN
cord-005478-5iu38pr6	179	11	by	by	IN
cord-005478-5iu38pr6	179	12	donor	donor	NN
cord-005478-5iu38pr6	179	13	group	group	NN
cord-005478-5iu38pr6	179	14	.	.	.
cord-005478-5iu38pr6	180	1	Results	result	NNS
cord-005478-5iu38pr6	180	2	:	:	:
cord-005478-5iu38pr6	181	1	In	in	IN
cord-005478-5iu38pr6	181	2	a	a	DT
cord-005478-5iu38pr6	181	3	10-year	10-year	CD
cord-005478-5iu38pr6	181	4	period	period	NN
cord-005478-5iu38pr6	181	5	,	,	,
cord-005478-5iu38pr6	181	6	236	236	CD
cord-005478-5iu38pr6	181	7	patients	patient	NNS
cord-005478-5iu38pr6	181	8	were	be	VBD
cord-005478-5iu38pr6	181	9	included	include	VBN
cord-005478-5iu38pr6	181	10	(	(	-LRB-
cord-005478-5iu38pr6	181	11	mean	mean	VB
cord-005478-5iu38pr6	181	12	age	age	NN
cord-005478-5iu38pr6	181	13	31y	31y	NNS
cord-005478-5iu38pr6	181	14	;	;	:
cord-005478-5iu38pr6	181	15	range	range	VBP
cord-005478-5iu38pr6	181	16	16	16	CD
cord-005478-5iu38pr6	181	17	-	-	SYM
cord-005478-5iu38pr6	181	18	64	64	CD
cord-005478-5iu38pr6	181	19	;	;	:
cord-005478-5iu38pr6	181	20	male	male	JJ
cord-005478-5iu38pr6	181	21	63.1	63.1	CD
cord-005478-5iu38pr6	181	22	%	%	NN
cord-005478-5iu38pr6	181	23	)	)	-RRB-
cord-005478-5iu38pr6	181	24	;	;	:
cord-005478-5iu38pr6	181	25	188	188	CD
cord-005478-5iu38pr6	181	26	(	(	-LRB-
cord-005478-5iu38pr6	181	27	80	80	CD
cord-005478-5iu38pr6	181	28	%	%	NN
cord-005478-5iu38pr6	181	29	)	)	-RRB-
cord-005478-5iu38pr6	181	30	during	during	IN
cord-005478-5iu38pr6	181	31	last	last	JJ
cord-005478-5iu38pr6	181	32	5	5	CD
cord-005478-5iu38pr6	181	33	years	year	NNS
cord-005478-5iu38pr6	181	34	.	.	.
cord-005478-5iu38pr6	182	1	ALL	all	DT
cord-005478-5iu38pr6	182	2	phenotype	phenotype	NN
cord-005478-5iu38pr6	182	3	was	be	VBD
cord-005478-5iu38pr6	182	4	B	b	NN
cord-005478-5iu38pr6	182	5	(	(	-LRB-
cord-005478-5iu38pr6	182	6	79	79	CD
cord-005478-5iu38pr6	182	7	%	%	NN
cord-005478-5iu38pr6	182	8	)	)	-RRB-
cord-005478-5iu38pr6	182	9	and	and	CC
cord-005478-5iu38pr6	182	10	T	T	NNP
cord-005478-5iu38pr6	182	11	(	(	-LRB-
cord-005478-5iu38pr6	182	12	21	21	CD
cord-005478-5iu38pr6	182	13	%	%	NN
cord-005478-5iu38pr6	182	14	)	)	-RRB-
cord-005478-5iu38pr6	182	15	.	.	.
cord-005478-5iu38pr6	183	1	At	at	IN
cord-005478-5iu38pr6	183	2	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	183	3	,	,	,
cord-005478-5iu38pr6	183	4	47/236	47/236	CD
cord-005478-5iu38pr6	183	5	(	(	-LRB-
cord-005478-5iu38pr6	183	6	20	20	CD
cord-005478-5iu38pr6	183	7	%	%	NN
cord-005478-5iu38pr6	183	8	)	)	-RRB-
cord-005478-5iu38pr6	183	9	had	have	VBD
cord-005478-5iu38pr6	183	10	CNS	CNS	NNP
cord-005478-5iu38pr6	183	11	involvement	involvement	NN
cord-005478-5iu38pr6	183	12	and	and	CC
cord-005478-5iu38pr6	183	13	75/236	75/236	CD
cord-005478-5iu38pr6	183	14	(	(	-LRB-
cord-005478-5iu38pr6	183	15	32	32	CD
cord-005478-5iu38pr6	183	16	%	%	NN
cord-005478-5iu38pr6	183	17	)	)	-RRB-
cord-005478-5iu38pr6	183	18	were	be	VBD
cord-005478-5iu38pr6	183	19	Philadelphia	Philadelphia	NNP
cord-005478-5iu38pr6	183	20	chromosome	chromosome	NN
cord-005478-5iu38pr6	183	21	positive	positive	JJ
cord-005478-5iu38pr6	183	22	.	.	.
cord-005478-5iu38pr6	184	1	ASCT	ASCT	NNP
cord-005478-5iu38pr6	184	2	was	be	VBD
cord-005478-5iu38pr6	184	3	performed	perform	VBN
cord-005478-5iu38pr6	184	4	in	in	IN
cord-005478-5iu38pr6	184	5	CR1	CR1	NNP
cord-005478-5iu38pr6	184	6	(	(	-LRB-
cord-005478-5iu38pr6	184	7	n=126	n=126	ADD
cord-005478-5iu38pr6	184	8	;	;	:
cord-005478-5iu38pr6	184	9	53	53	CD
cord-005478-5iu38pr6	184	10	%	%	NN
cord-005478-5iu38pr6	184	11	)	)	-RRB-
cord-005478-5iu38pr6	184	12	and	and	CC
cord-005478-5iu38pr6	184	13	in	in	IN
cord-005478-5iu38pr6	184	14	CR2	CR2	NNP
cord-005478-5iu38pr6	184	15	+	+	CC
cord-005478-5iu38pr6	185	1	(	(	-LRB-
cord-005478-5iu38pr6	185	2	n=110	n=110	VB
cord-005478-5iu38pr6	185	3	;	;	:
cord-005478-5iu38pr6	185	4	47	47	CD
cord-005478-5iu38pr6	185	5	%	%	NN
cord-005478-5iu38pr6	185	6	)	)	-RRB-
cord-005478-5iu38pr6	185	7	after	after	IN
cord-005478-5iu38pr6	185	8	a	a	DT
cord-005478-5iu38pr6	185	9	median	median	JJ
cord-005478-5iu38pr6	185	10	time	time	NN
cord-005478-5iu38pr6	185	11	from	from	IN
cord-005478-5iu38pr6	185	12	ALL	all	DT
cord-005478-5iu38pr6	185	13	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	185	14	to	to	IN
cord-005478-5iu38pr6	185	15	ASCT	ASCT	NNP
cord-005478-5iu38pr6	185	16	of	of	IN
cord-005478-5iu38pr6	185	17	9	9	CD
cord-005478-5iu38pr6	185	18	and	and	CC
cord-005478-5iu38pr6	185	19	26	26	CD
cord-005478-5iu38pr6	185	20	months	month	NNS
cord-005478-5iu38pr6	185	21	,	,	,
cord-005478-5iu38pr6	185	22	respectively	respectively	RB
cord-005478-5iu38pr6	185	23	.	.	.
cord-005478-5iu38pr6	186	1	Comorbidity	comorbidity	NN
cord-005478-5iu38pr6	186	2	index	index	NN
cord-005478-5iu38pr6	186	3	(	(	-LRB-
cord-005478-5iu38pr6	186	4	HCT	HCT	NNP
cord-005478-5iu38pr6	186	5	-	-	HYPH
cord-005478-5iu38pr6	186	6	CI	CI	NNP
cord-005478-5iu38pr6	186	7	)	)	-RRB-
cord-005478-5iu38pr6	186	8	was	be	VBD
cord-005478-5iu38pr6	186	9	0	0	CD
cord-005478-5iu38pr6	186	10	-	-	SYM
cord-005478-5iu38pr6	186	11	1	1	CD
cord-005478-5iu38pr6	186	12	in	in	IN
cord-005478-5iu38pr6	186	13	199/236	199/236	CD
cord-005478-5iu38pr6	186	14	(	(	-LRB-
cord-005478-5iu38pr6	186	15	90	90	CD
cord-005478-5iu38pr6	186	16	%	%	NN
cord-005478-5iu38pr6	186	17	)	)	-RRB-
cord-005478-5iu38pr6	186	18	.	.	.
cord-005478-5iu38pr6	187	1	Donors	donor	NNS
cord-005478-5iu38pr6	187	2	were	be	VBD
cord-005478-5iu38pr6	187	3	matched	match	VBN
cord-005478-5iu38pr6	187	4	(	(	-LRB-
cord-005478-5iu38pr6	187	5	n=175	n=175	NNP
cord-005478-5iu38pr6	187	6	;	;	:
cord-005478-5iu38pr6	187	7	74	74	CD
cord-005478-5iu38pr6	187	8	%	%	NN
cord-005478-5iu38pr6	187	9	;	;	:
cord-005478-5iu38pr6	187	10	146	146	CD
cord-005478-5iu38pr6	187	11	related	relate	VBN
cord-005478-5iu38pr6	187	12	and	and	CC
cord-005478-5iu38pr6	187	13	29	29	CD
cord-005478-5iu38pr6	187	14	unrelated	unrelated	JJ
cord-005478-5iu38pr6	187	15	)	)	-RRB-
cord-005478-5iu38pr6	187	16	and	and	CC
cord-005478-5iu38pr6	187	17	Haplo	Haplo	NNP
cord-005478-5iu38pr6	187	18	(	(	-LRB-
cord-005478-5iu38pr6	187	19	n=61	n=61	NNP
cord-005478-5iu38pr6	187	20	;	;	:
cord-005478-5iu38pr6	187	21	26	26	CD
cord-005478-5iu38pr6	187	22	%	%	NN
cord-005478-5iu38pr6	187	23	)	)	-RRB-
cord-005478-5iu38pr6	187	24	.	.	.
cord-005478-5iu38pr6	188	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	188	2	regimen	regimen	NN
cord-005478-5iu38pr6	188	3	was	be	VBD
cord-005478-5iu38pr6	188	4	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	188	5	in	in	IN
cord-005478-5iu38pr6	188	6	215/236	215/236	CD
cord-005478-5iu38pr6	188	7	(	(	-LRB-
cord-005478-5iu38pr6	188	8	91	91	CD
cord-005478-5iu38pr6	188	9	%	%	NN
cord-005478-5iu38pr6	188	10	;	;	:
cord-005478-5iu38pr6	188	11	170	170	CD
cord-005478-5iu38pr6	188	12	patients	patient	NNS
cord-005478-5iu38pr6	188	13	with	with	IN
cord-005478-5iu38pr6	188	14	total	total	JJ
cord-005478-5iu38pr6	188	15	body	body	NN
cord-005478-5iu38pr6	188	16	irradiation	irradiation	NN
cord-005478-5iu38pr6	188	17	)	)	-RRB-
cord-005478-5iu38pr6	188	18	,	,	,
cord-005478-5iu38pr6	188	19	and	and	CC
cord-005478-5iu38pr6	188	20	this	this	DT
cord-005478-5iu38pr6	188	21	conditioning	conditioning	NN
cord-005478-5iu38pr6	188	22	was	be	VBD
cord-005478-5iu38pr6	188	23	more	more	RBR
cord-005478-5iu38pr6	188	24	frequent	frequent	JJ
cord-005478-5iu38pr6	188	25	in	in	IN
cord-005478-5iu38pr6	188	26	matched	match	VBN
cord-005478-5iu38pr6	188	27	(	(	-LRB-
cord-005478-5iu38pr6	188	28	95	95	CD
cord-005478-5iu38pr6	188	29	%	%	NN
cord-005478-5iu38pr6	188	30	)	)	-RRB-
cord-005478-5iu38pr6	188	31	than	than	IN
cord-005478-5iu38pr6	188	32	Haplo	Haplo	NNP
cord-005478-5iu38pr6	188	33	(	(	-LRB-
cord-005478-5iu38pr6	188	34	79	79	CD
cord-005478-5iu38pr6	188	35	%	%	NN
cord-005478-5iu38pr6	188	36	)	)	-RRB-
cord-005478-5iu38pr6	188	37	(	(	-LRB-
cord-005478-5iu38pr6	188	38	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	188	39	)	)	-RRB-
cord-005478-5iu38pr6	188	40	donors	donor	NNS
cord-005478-5iu38pr6	188	41	.	.	.
cord-005478-5iu38pr6	189	1	Two	two	CD
cord-005478-5iu38pr6	189	2	-	-	HYPH
cord-005478-5iu38pr6	189	3	years	year	NNS
cord-005478-5iu38pr6	189	4	OS	OS	NNP
cord-005478-5iu38pr6	189	5	was	be	VBD
cord-005478-5iu38pr6	189	6	54	54	CD
cord-005478-5iu38pr6	189	7	%	%	NN
cord-005478-5iu38pr6	189	8	(	(	-LRB-
cord-005478-5iu38pr6	189	9	95%CI	95%ci	CD
cord-005478-5iu38pr6	189	10	46	46	CD
cord-005478-5iu38pr6	189	11	-	-	SYM
cord-005478-5iu38pr6	189	12	60	60	CD
cord-005478-5iu38pr6	189	13	)	)	-RRB-
cord-005478-5iu38pr6	189	14	for	for	IN
cord-005478-5iu38pr6	189	15	the	the	DT
cord-005478-5iu38pr6	189	16	entire	entire	JJ
cord-005478-5iu38pr6	189	17	population	population	NN
cord-005478-5iu38pr6	189	18	;	;	:
cord-005478-5iu38pr6	189	19	55	55	CD
cord-005478-5iu38pr6	189	20	%	%	NN
cord-005478-5iu38pr6	189	21	(	(	-LRB-
cord-005478-5iu38pr6	189	22	95CI	95ci	CD
cord-005478-5iu38pr6	189	23	47	47	CD
cord-005478-5iu38pr6	189	24	-	-	SYM
cord-005478-5iu38pr6	189	25	63	63	CD
cord-005478-5iu38pr6	189	26	)	)	-RRB-
cord-005478-5iu38pr6	189	27	for	for	IN
cord-005478-5iu38pr6	189	28	matched	match	VBN
cord-005478-5iu38pr6	189	29	donors	donor	NNS
cord-005478-5iu38pr6	189	30	and	and	CC
cord-005478-5iu38pr6	189	31	49	49	CD
cord-005478-5iu38pr6	189	32	%	%	NN
cord-005478-5iu38pr6	189	33	(	(	-LRB-
cord-005478-5iu38pr6	189	34	95	95	CD
cord-005478-5iu38pr6	189	35	%	%	NN
cord-005478-5iu38pr6	189	36	CI	CI	NNP
cord-005478-5iu38pr6	189	37	34	34	CD
cord-005478-5iu38pr6	189	38	-	-	SYM
cord-005478-5iu38pr6	189	39	62	62	CD
cord-005478-5iu38pr6	189	40	)	)	-RRB-
cord-005478-5iu38pr6	189	41	for	for	IN
cord-005478-5iu38pr6	189	42	Haplo	Haplo	NNP
cord-005478-5iu38pr6	189	43	donors	donor	NNS
cord-005478-5iu38pr6	189	44	(	(	-LRB-
cord-005478-5iu38pr6	189	45	p=0.350	p=0.350	NNP
cord-005478-5iu38pr6	189	46	)	)	-RRB-
cord-005478-5iu38pr6	189	47	.	.	.
cord-005478-5iu38pr6	190	1	In	in	IN
cord-005478-5iu38pr6	190	2	the	the	DT
cord-005478-5iu38pr6	190	3	multivariate	multivariate	JJ
cord-005478-5iu38pr6	190	4	analysis	analysis	NN
cord-005478-5iu38pr6	190	5	,	,	,
cord-005478-5iu38pr6	190	6	pretransplant	pretransplant	NN
cord-005478-5iu38pr6	190	7	status	status	NN
cord-005478-5iu38pr6	190	8	(	(	-LRB-
cord-005478-5iu38pr6	190	9	CR1	CR1	NNP
cord-005478-5iu38pr6	190	10	vs	vs	IN
cord-005478-5iu38pr6	190	11	CR2	CR2	NNP
cord-005478-5iu38pr6	190	12	+	+	CC
cord-005478-5iu38pr6	190	13	;	;	:
cord-005478-5iu38pr6	190	14	HR	HR	NNP
cord-005478-5iu38pr6	190	15	2.06	2.06	CD
cord-005478-5iu38pr6	190	16	,	,	,
cord-005478-5iu38pr6	190	17	p	p	NN
cord-005478-5iu38pr6	190	18	<	<	XX
cord-005478-5iu38pr6	190	19	0.001	0.001	CD
cord-005478-5iu38pr6	190	20	)	)	-RRB-
cord-005478-5iu38pr6	190	21	,	,	,
cord-005478-5iu38pr6	190	22	CNS	CNS	NNP
cord-005478-5iu38pr6	190	23	status	status	NN
cord-005478-5iu38pr6	190	24	at	at	IN
cord-005478-5iu38pr6	190	25	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	190	26	(	(	-LRB-
cord-005478-5iu38pr6	190	27	yes	yes	UH
cord-005478-5iu38pr6	190	28	vs	vs	IN
cord-005478-5iu38pr6	190	29	no	no	UH
cord-005478-5iu38pr6	190	30	;	;	:
cord-005478-5iu38pr6	190	31	HR	hr	NN
cord-005478-5iu38pr6	190	32	1.70	1.70	CD
cord-005478-5iu38pr6	190	33	;	;	:
cord-005478-5iu38pr6	190	34	p=0.019	p=0.019	NNP
cord-005478-5iu38pr6	190	35	)	)	-RRB-
cord-005478-5iu38pr6	190	36	and	and	CC
cord-005478-5iu38pr6	190	37	unrelated	unrelated	JJ
cord-005478-5iu38pr6	190	38	donors	donor	NNS
cord-005478-5iu38pr6	190	39	(	(	-LRB-
cord-005478-5iu38pr6	190	40	yes	yes	UH
cord-005478-5iu38pr6	190	41	vs	vs	IN
cord-005478-5iu38pr6	190	42	no	no	UH
cord-005478-5iu38pr6	190	43	;	;	:
cord-005478-5iu38pr6	190	44	HR	hr	NN
cord-005478-5iu38pr6	190	45	1.77	1.77	CD
cord-005478-5iu38pr6	190	46	;	;	:
cord-005478-5iu38pr6	190	47	p=0.036	p=0.036	NNS
cord-005478-5iu38pr6	190	48	)	)	-RRB-
cord-005478-5iu38pr6	191	1	were	be	VBD
cord-005478-5iu38pr6	191	2	independently	independently	RB
cord-005478-5iu38pr6	191	3	associated	associate	VBN
cord-005478-5iu38pr6	191	4	with	with	IN
cord-005478-5iu38pr6	191	5	OS	os	NN
cord-005478-5iu38pr6	191	6	;	;	:
cord-005478-5iu38pr6	191	7	donor	donor	NN
cord-005478-5iu38pr6	191	8	category	category	NN
cord-005478-5iu38pr6	191	9	had	have	VBD
cord-005478-5iu38pr6	191	10	not	not	RB
cord-005478-5iu38pr6	191	11	impact	impact	NN
cord-005478-5iu38pr6	191	12	in	in	IN
cord-005478-5iu38pr6	191	13	the	the	DT
cord-005478-5iu38pr6	191	14	OS	os	NN
cord-005478-5iu38pr6	191	15	.	.	.
cord-005478-5iu38pr6	192	1	By	by	IN
cord-005478-5iu38pr6	192	2	adjusting	adjust	VBG
cord-005478-5iu38pr6	192	3	the	the	DT
cord-005478-5iu38pr6	192	4	PS	PS	NNP
cord-005478-5iu38pr6	192	5	term	term	NN
cord-005478-5iu38pr6	192	6	(	(	-LRB-
cord-005478-5iu38pr6	192	7	ROC	ROC	NNP
cord-005478-5iu38pr6	192	8	area	area	NN
cord-005478-5iu38pr6	192	9	0.787	0.787	CD
cord-005478-5iu38pr6	192	10	)	)	-RRB-
cord-005478-5iu38pr6	192	11	,	,	,
cord-005478-5iu38pr6	192	12	no	no	DT
cord-005478-5iu38pr6	192	13	difference	difference	NN
cord-005478-5iu38pr6	192	14	was	be	VBD
cord-005478-5iu38pr6	192	15	found	find	VBN
cord-005478-5iu38pr6	192	16	by	by	IN
cord-005478-5iu38pr6	192	17	donor	donor	NN
cord-005478-5iu38pr6	192	18	category	category	NN
cord-005478-5iu38pr6	192	19	.	.	.
cord-005478-5iu38pr6	193	1	Twoyears	Twoyears	NNP
cord-005478-5iu38pr6	193	2	NRM	NRM	NNP
cord-005478-5iu38pr6	193	3	was	be	VBD
cord-005478-5iu38pr6	193	4	24	24	CD
cord-005478-5iu38pr6	193	5	%	%	NN
cord-005478-5iu38pr6	193	6	(	(	-LRB-
cord-005478-5iu38pr6	193	7	95%CI	95%ci	CD
cord-005478-5iu38pr6	193	8	18	18	CD
cord-005478-5iu38pr6	193	9	-	-	SYM
cord-005478-5iu38pr6	193	10	31	31	CD
cord-005478-5iu38pr6	193	11	)	)	-RRB-
cord-005478-5iu38pr6	193	12	for	for	IN
cord-005478-5iu38pr6	193	13	matched	match	VBN
cord-005478-5iu38pr6	193	14	and	and	CC
cord-005478-5iu38pr6	193	15	22	22	CD
cord-005478-5iu38pr6	193	16	%	%	NN
cord-005478-5iu38pr6	193	17	(	(	-LRB-
cord-005478-5iu38pr6	193	18	95%CI	95%ci	CD
cord-005478-5iu38pr6	193	19	12	12	CD
cord-005478-5iu38pr6	193	20	-	-	SYM
cord-005478-5iu38pr6	193	21	33	33	CD
cord-005478-5iu38pr6	193	22	)	)	-RRB-
cord-005478-5iu38pr6	193	23	for	for	IN
cord-005478-5iu38pr6	193	24	Haplo	Haplo	NNP
cord-005478-5iu38pr6	193	25	(	(	-LRB-
cord-005478-5iu38pr6	193	26	p=0.999	p=0.999	NNP
cord-005478-5iu38pr6	193	27	)	)	-RRB-
cord-005478-5iu38pr6	193	28	donors	donor	NNS
cord-005478-5iu38pr6	193	29	;	;	:
cord-005478-5iu38pr6	193	30	older	old	JJR
cord-005478-5iu38pr6	193	31	donors	donor	NNS
cord-005478-5iu38pr6	193	32	(	(	-LRB-
cord-005478-5iu38pr6	193	33	p=0.049	p=0.049	NNP
cord-005478-5iu38pr6	193	34	)	)	-RRB-
cord-005478-5iu38pr6	193	35	and	and	CC
cord-005478-5iu38pr6	193	36	unrelated	unrelated	JJ
cord-005478-5iu38pr6	193	37	donors	donor	NNS
cord-005478-5iu38pr6	193	38	(	(	-LRB-
cord-005478-5iu38pr6	193	39	p=0.001	p=0.001	NNS
cord-005478-5iu38pr6	193	40	)	)	-RRB-
cord-005478-5iu38pr6	193	41	were	be	VBD
cord-005478-5iu38pr6	193	42	associated	associate	VBN
cord-005478-5iu38pr6	193	43	with	with	IN
cord-005478-5iu38pr6	193	44	higher	high	JJR
cord-005478-5iu38pr6	193	45	NRM	NRM	NNP
cord-005478-5iu38pr6	193	46	.	.	.
cord-005478-5iu38pr6	194	1	Two	two	CD
cord-005478-5iu38pr6	194	2	-	-	HYPH
cord-005478-5iu38pr6	194	3	years	year	NNS
cord-005478-5iu38pr6	194	4	CIR	CIR	NNP
cord-005478-5iu38pr6	194	5	was	be	VBD
cord-005478-5iu38pr6	194	6	25	25	CD
cord-005478-5iu38pr6	194	7	%	%	NN
cord-005478-5iu38pr6	194	8	(	(	-LRB-
cord-005478-5iu38pr6	194	9	95%CI	95%ci	CD
cord-005478-5iu38pr6	194	10	19	19	CD
cord-005478-5iu38pr6	194	11	-	-	SYM
cord-005478-5iu38pr6	194	12	33	33	CD
cord-005478-5iu38pr6	194	13	)	)	-RRB-
cord-005478-5iu38pr6	194	14	for	for	IN
cord-005478-5iu38pr6	194	15	matched	match	VBN
cord-005478-5iu38pr6	194	16	and	and	CC
cord-005478-5iu38pr6	194	17	38	38	CD
cord-005478-5iu38pr6	194	18	%	%	NN
cord-005478-5iu38pr6	194	19	(	(	-LRB-
cord-005478-5iu38pr6	194	20	95%CI	95%ci	CD
cord-005478-5iu38pr6	194	21	24	24	CD
cord-005478-5iu38pr6	194	22	-	-	SYM
cord-005478-5iu38pr6	194	23	51	51	CD
cord-005478-5iu38pr6	194	24	)	)	-RRB-
cord-005478-5iu38pr6	194	25	for	for	IN
cord-005478-5iu38pr6	194	26	Haplo	Haplo	NNP
cord-005478-5iu38pr6	194	27	(	(	-LRB-
cord-005478-5iu38pr6	194	28	p=0.137	p=0.137	NNP
cord-005478-5iu38pr6	194	29	)	)	-RRB-
cord-005478-5iu38pr6	194	30	donors	donor	NNS
cord-005478-5iu38pr6	194	31	;	;	:
cord-005478-5iu38pr6	194	32	only	only	RB
cord-005478-5iu38pr6	194	33	male	male	JJ
cord-005478-5iu38pr6	194	34	donors	donor	NNS
cord-005478-5iu38pr6	194	35	were	be	VBD
cord-005478-5iu38pr6	194	36	associated	associate	VBN
cord-005478-5iu38pr6	194	37	with	with	IN
cord-005478-5iu38pr6	194	38	higher	high	JJR
cord-005478-5iu38pr6	194	39	CIR	CIR	NNP
cord-005478-5iu38pr6	194	40	(	(	-LRB-
cord-005478-5iu38pr6	194	41	p=0.031	p=0.031	NNP
cord-005478-5iu38pr6	194	42	)	)	-RRB-
cord-005478-5iu38pr6	194	43	.	.	.
cord-005478-5iu38pr6	195	1	CI	CI	NNP
cord-005478-5iu38pr6	195	2	of	of	IN
cord-005478-5iu38pr6	195	3	grade	grade	NN
cord-005478-5iu38pr6	195	4	3	3	CD
cord-005478-5iu38pr6	195	5	-	-	SYM
cord-005478-5iu38pr6	195	6	4	4	CD
cord-005478-5iu38pr6	195	7	acute	acute	JJ
cord-005478-5iu38pr6	195	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	195	9	was	be	VBD
cord-005478-5iu38pr6	195	10	20	20	CD
cord-005478-5iu38pr6	195	11	%	%	NN
cord-005478-5iu38pr6	195	12	vs	vs	IN
cord-005478-5iu38pr6	195	13	17	17	CD
cord-005478-5iu38pr6	195	14	%	%	NN
cord-005478-5iu38pr6	195	15	(	(	-LRB-
cord-005478-5iu38pr6	195	16	p=0.784	p=0.784	NNP
cord-005478-5iu38pr6	195	17	)	)	-RRB-
cord-005478-5iu38pr6	195	18	and	and	CC
cord-005478-5iu38pr6	195	19	chronic	chronic	JJ
cord-005478-5iu38pr6	195	20	GVHD	GVHD	NNP
cord-005478-5iu38pr6	195	21	was	be	VBD
cord-005478-5iu38pr6	195	22	35	35	CD
cord-005478-5iu38pr6	195	23	%	%	NN
cord-005478-5iu38pr6	195	24	vs	vs	IN
cord-005478-5iu38pr6	195	25	27	27	CD
cord-005478-5iu38pr6	195	26	%	%	NN
cord-005478-5iu38pr6	195	27	(	(	-LRB-
cord-005478-5iu38pr6	196	1	p=0.057	p=0.057	NNP
cord-005478-5iu38pr6	196	2	)	)	-RRB-
cord-005478-5iu38pr6	196	3	for	for	IN
cord-005478-5iu38pr6	196	4	matched	match	VBN
cord-005478-5iu38pr6	196	5	and	and	CC
cord-005478-5iu38pr6	196	6	Haplo	Haplo	NNP
cord-005478-5iu38pr6	196	7	donors	donor	NNS
cord-005478-5iu38pr6	196	8	respectively	respectively	RB
cord-005478-5iu38pr6	196	9	.	.	.
cord-005478-5iu38pr6	197	1	In	in	IN
cord-005478-5iu38pr6	197	2	both	both	DT
cord-005478-5iu38pr6	197	3	groups	group	NNS
cord-005478-5iu38pr6	197	4	,	,	,
cord-005478-5iu38pr6	197	5	matched	match	VBN
cord-005478-5iu38pr6	197	6	and	and	CC
cord-005478-5iu38pr6	197	7	Haplo	Haplo	NNP
cord-005478-5iu38pr6	197	8	donors	donor	NNS
cord-005478-5iu38pr6	197	9	,	,	,
cord-005478-5iu38pr6	197	10	the	the	DT
cord-005478-5iu38pr6	197	11	half	half	NN
cord-005478-5iu38pr6	197	12	of	of	IN
cord-005478-5iu38pr6	197	13	deaths	death	NNS
cord-005478-5iu38pr6	197	14	were	be	VBD
cord-005478-5iu38pr6	197	15	due	due	JJ
cord-005478-5iu38pr6	197	16	to	to	IN
cord-005478-5iu38pr6	197	17	relapse	relapse	NN
cord-005478-5iu38pr6	197	18	.	.	.
cord-005478-5iu38pr6	198	1	Background	background	NN
cord-005478-5iu38pr6	198	2	:	:	:
cord-005478-5iu38pr6	199	1	Relapse	relapse	NN
cord-005478-5iu38pr6	199	2	is	be	VBZ
cord-005478-5iu38pr6	199	3	the	the	DT
cord-005478-5iu38pr6	199	4	most	most	RBS
cord-005478-5iu38pr6	199	5	important	important	JJ
cord-005478-5iu38pr6	199	6	cause	cause	NN
cord-005478-5iu38pr6	199	7	for	for	IN
cord-005478-5iu38pr6	199	8	treatment	treatment	NN
cord-005478-5iu38pr6	199	9	failure	failure	NN
cord-005478-5iu38pr6	199	10	in	in	IN
cord-005478-5iu38pr6	199	11	pediatric	pediatric	JJ
cord-005478-5iu38pr6	199	12	B	b	NN
cord-005478-5iu38pr6	199	13	-	-	HYPH
cord-005478-5iu38pr6	199	14	precursor	precursor	NN
cord-005478-5iu38pr6	199	15	acute	acute	JJ
cord-005478-5iu38pr6	199	16	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	199	17	leukemia	leukemia	NN
cord-005478-5iu38pr6	199	18	(	(	-LRB-
cord-005478-5iu38pr6	199	19	BCP	BCP	NNP
cord-005478-5iu38pr6	199	20	-	-	HYPH
cord-005478-5iu38pr6	199	21	ALL	ALL	NNP
cord-005478-5iu38pr6	199	22	)	)	-RRB-
cord-005478-5iu38pr6	199	23	occurring	occur	VBG
cord-005478-5iu38pr6	199	24	in	in	IN
cord-005478-5iu38pr6	199	25	10	10	CD
cord-005478-5iu38pr6	199	26	-	-	SYM
cord-005478-5iu38pr6	199	27	20	20	CD
cord-005478-5iu38pr6	199	28	%	%	NN
cord-005478-5iu38pr6	199	29	of	of	IN
cord-005478-5iu38pr6	199	30	patients	patient	NNS
cord-005478-5iu38pr6	199	31	.	.	.
cord-005478-5iu38pr6	200	1	Mechanisms	mechanism	NNS
cord-005478-5iu38pr6	200	2	of	of	IN
cord-005478-5iu38pr6	200	3	ineffective	ineffective	JJ
cord-005478-5iu38pr6	200	4	graft	graft	NN
cord-005478-5iu38pr6	200	5	-	-	HYPH
cord-005478-5iu38pr6	200	6	versus	versus	IN
cord-005478-5iu38pr6	200	7	-	-	HYPH
cord-005478-5iu38pr6	200	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	200	9	(	(	-LRB-
cord-005478-5iu38pr6	200	10	GvL	gvl	NN
cord-005478-5iu38pr6	200	11	)	)	-RRB-
cord-005478-5iu38pr6	200	12	effects	effect	NNS
cord-005478-5iu38pr6	200	13	or	or	CC
cord-005478-5iu38pr6	200	14	T	t	NN
cord-005478-5iu38pr6	200	15	-	-	HYPH
cord-005478-5iu38pr6	200	16	cell	cell	NN
cord-005478-5iu38pr6	200	17	responses	response	NNS
cord-005478-5iu38pr6	200	18	against	against	IN
cord-005478-5iu38pr6	200	19	ALL	all	DT
cord-005478-5iu38pr6	200	20	remain	remain	VBP
cord-005478-5iu38pr6	200	21	to	to	TO
cord-005478-5iu38pr6	200	22	be	be	VB
cord-005478-5iu38pr6	200	23	investigated	investigate	VBN
cord-005478-5iu38pr6	200	24	.	.	.
cord-005478-5iu38pr6	201	1	Methods	method	NNS
cord-005478-5iu38pr6	201	2	:	:	:
cord-005478-5iu38pr6	201	3	We	-PRON-	PRP
cord-005478-5iu38pr6	201	4	analyzed	analyze	VBD
cord-005478-5iu38pr6	201	5	parameters	parameter	NNS
cord-005478-5iu38pr6	201	6	of	of	IN
cord-005478-5iu38pr6	201	7	immunosurveillance	immunosurveillance	NN
cord-005478-5iu38pr6	201	8	in	in	IN
cord-005478-5iu38pr6	201	9	bone	bone	NN
cord-005478-5iu38pr6	201	10	marrow	marrow	NN
cord-005478-5iu38pr6	201	11	(	(	-LRB-
cord-005478-5iu38pr6	201	12	BM	BM	NNP
cord-005478-5iu38pr6	201	13	)	)	-RRB-
cord-005478-5iu38pr6	201	14	samples	sample	NNS
cord-005478-5iu38pr6	201	15	of	of	IN
cord-005478-5iu38pr6	201	16	100	100	CD
cord-005478-5iu38pr6	201	17	pediatric	pediatric	JJ
cord-005478-5iu38pr6	201	18	patients	patient	NNS
cord-005478-5iu38pr6	201	19	to	to	TO
cord-005478-5iu38pr6	201	20	identify	identify	VB
cord-005478-5iu38pr6	201	21	potential	potential	JJ
cord-005478-5iu38pr6	201	22	mechanisms	mechanism	NNS
cord-005478-5iu38pr6	201	23	of	of	IN
cord-005478-5iu38pr6	201	24	T	t	NN
cord-005478-5iu38pr6	201	25	-	-	HYPH
cord-005478-5iu38pr6	201	26	cell	cell	NN
cord-005478-5iu38pr6	201	27	suppression	suppression	NN
cord-005478-5iu38pr6	201	28	.	.	.
cord-005478-5iu38pr6	202	1	Expression	expression	NN
cord-005478-5iu38pr6	202	2	of	of	IN
cord-005478-5iu38pr6	202	3	co	co	JJ
cord-005478-5iu38pr6	202	4	-	-	JJ
cord-005478-5iu38pr6	202	5	stimulatory/	stimulatory/	JJ
cord-005478-5iu38pr6	202	6	co	co	JJ
cord-005478-5iu38pr6	202	7	-	-	JJ
cord-005478-5iu38pr6	202	8	inhibitory	inhibitory	JJ
cord-005478-5iu38pr6	202	9	molecules	molecule	NNS
cord-005478-5iu38pr6	202	10	was	be	VBD
cord-005478-5iu38pr6	202	11	analyzed	analyze	VBN
cord-005478-5iu38pr6	202	12	to	to	TO
cord-005478-5iu38pr6	202	13	identify	identify	VB
cord-005478-5iu38pr6	202	14	implications	implication	NNS
cord-005478-5iu38pr6	202	15	for	for	IN
cord-005478-5iu38pr6	202	16	GvL.	gvl.	NN
cord-005478-5iu38pr6	202	17	Expression	expression	NN
cord-005478-5iu38pr6	202	18	was	be	VBD
cord-005478-5iu38pr6	202	19	correlated	correlate	VBN
cord-005478-5iu38pr6	202	20	with	with	IN
cord-005478-5iu38pr6	202	21	clinical	clinical	JJ
cord-005478-5iu38pr6	202	22	outcome	outcome	NN
cord-005478-5iu38pr6	202	23	(	(	-LRB-
cord-005478-5iu38pr6	202	24	8	8	CD
cord-005478-5iu38pr6	202	25	years	year	NNS
cord-005478-5iu38pr6	202	26	mean	mean	VBP
cord-005478-5iu38pr6	202	27	followup	followup	JJ
cord-005478-5iu38pr6	202	28	)	)	-RRB-
cord-005478-5iu38pr6	202	29	.	.	.
cord-005478-5iu38pr6	203	1	T	t	NN
cord-005478-5iu38pr6	203	2	-	-	HYPH
cord-005478-5iu38pr6	203	3	cell	cell	NN
cord-005478-5iu38pr6	203	4	immunoglobulin	immunoglobulin	NN
cord-005478-5iu38pr6	203	5	and	and	CC
cord-005478-5iu38pr6	203	6	mucin	mucin	NN
cord-005478-5iu38pr6	203	7	-	-	HYPH
cord-005478-5iu38pr6	203	8	domain	domain	NN
cord-005478-5iu38pr6	203	9	containing-3	containing-3	NN
cord-005478-5iu38pr6	204	1	(	(	-LRB-
cord-005478-5iu38pr6	204	2	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	204	3	)	)	-RRB-
cord-005478-5iu38pr6	204	4	overexpression	overexpression	NN
cord-005478-5iu38pr6	204	5	and	and	CC
cord-005478-5iu38pr6	204	6	CRISPR	CRISPR	NNP
cord-005478-5iu38pr6	204	7	/	/	SYM
cord-005478-5iu38pr6	204	8	Cas9-mediated	cas9-mediate	VBN
cord-005478-5iu38pr6	204	9	knockout	knockout	NN
cord-005478-5iu38pr6	205	1	(	(	-LRB-
cord-005478-5iu38pr6	205	2	KO	KO	NNP
cord-005478-5iu38pr6	205	3	)	)	-RRB-
cord-005478-5iu38pr6	205	4	in	in	IN
cord-005478-5iu38pr6	205	5	primary	primary	JJ
cord-005478-5iu38pr6	205	6	T	t	NN
cord-005478-5iu38pr6	205	7	cells	cell	NNS
cord-005478-5iu38pr6	205	8	were	be	VBD
cord-005478-5iu38pr6	205	9	performed	perform	VBN
cord-005478-5iu38pr6	205	10	to	to	TO
cord-005478-5iu38pr6	205	11	analyze	analyze	VB
cord-005478-5iu38pr6	205	12	its	-PRON-	PRP$
cord-005478-5iu38pr6	205	13	role	role	NN
cord-005478-5iu38pr6	205	14	for	for	IN
cord-005478-5iu38pr6	205	15	anti	anti	JJ
cord-005478-5iu38pr6	205	16	-	-	JJ
cord-005478-5iu38pr6	205	17	leukemic	leukemic	JJ
cord-005478-5iu38pr6	205	18	T	t	NN
cord-005478-5iu38pr6	205	19	-	-	HYPH
cord-005478-5iu38pr6	205	20	cell	cell	NN
cord-005478-5iu38pr6	205	21	functionality	functionality	NN
cord-005478-5iu38pr6	205	22	.	.	.
cord-005478-5iu38pr6	206	1	To	to	TO
cord-005478-5iu38pr6	206	2	induce	induce	VB
cord-005478-5iu38pr6	206	3	an	an	DT
cord-005478-5iu38pr6	206	4	interaction	interaction	NN
cord-005478-5iu38pr6	206	5	of	of	IN
cord-005478-5iu38pr6	206	6	T	t	NN
cord-005478-5iu38pr6	206	7	cells	cell	NNS
cord-005478-5iu38pr6	206	8	with	with	IN
cord-005478-5iu38pr6	206	9	leukemic	leukemic	JJ
cord-005478-5iu38pr6	206	10	blasts	blast	NNS
cord-005478-5iu38pr6	206	11	,	,	,
cord-005478-5iu38pr6	206	12	anti	anti	JJ
cord-005478-5iu38pr6	206	13	-	-	JJ
cord-005478-5iu38pr6	206	14	CD19/-CD3	cd19/-cd3	JJ
cord-005478-5iu38pr6	206	15	bispecific	bispecific	NN
cord-005478-5iu38pr6	206	16	T	t	NN
cord-005478-5iu38pr6	206	17	-	-	HYPH
cord-005478-5iu38pr6	206	18	cell	cell	NN
cord-005478-5iu38pr6	206	19	engager	engager	NN
cord-005478-5iu38pr6	206	20	(	(	-LRB-
cord-005478-5iu38pr6	206	21	BiTE	BiTE	NNP
cord-005478-5iu38pr6	206	22	)	)	-RRB-
cord-005478-5iu38pr6	206	23	was	be	VBD
cord-005478-5iu38pr6	206	24	added	add	VBN
cord-005478-5iu38pr6	206	25	and	and	CC
cord-005478-5iu38pr6	206	26	T	t	NN
cord-005478-5iu38pr6	206	27	-	-	HYPH
cord-005478-5iu38pr6	206	28	cell	cell	NN
cord-005478-5iu38pr6	206	29	activation/	activation/	NNS
cord-005478-5iu38pr6	206	30	proliferation	proliferation	NN
cord-005478-5iu38pr6	206	31	were	be	VBD
cord-005478-5iu38pr6	206	32	analyzed	analyze	VBN
cord-005478-5iu38pr6	206	33	.	.	.
cord-005478-5iu38pr6	207	1	Fold	fold	VB
cord-005478-5iu38pr6	207	2	change	change	NN
cord-005478-5iu38pr6	207	3	(	(	-LRB-
cord-005478-5iu38pr6	207	4	FC	FC	NNP
cord-005478-5iu38pr6	207	5	)	)	-RRB-
cord-005478-5iu38pr6	207	6	was	be	VBD
cord-005478-5iu38pr6	207	7	created	create	VBN
cord-005478-5iu38pr6	207	8	by	by	IN
cord-005478-5iu38pr6	207	9	comparing	compare	VBG
cord-005478-5iu38pr6	207	10	levels	level	NNS
cord-005478-5iu38pr6	207	11	of	of	IN
cord-005478-5iu38pr6	207	12	T	t	NN
cord-005478-5iu38pr6	207	13	-	-	HYPH
cord-005478-5iu38pr6	207	14	cell	cell	NN
cord-005478-5iu38pr6	207	15	activation/	activation/	NNS
cord-005478-5iu38pr6	207	16	proliferation	proliferation	NN
cord-005478-5iu38pr6	207	17	before	before	IN
cord-005478-5iu38pr6	207	18	vs.	vs.	NN
cord-005478-5iu38pr6	207	19	after	after	IN
cord-005478-5iu38pr6	207	20	co	co	NN
cord-005478-5iu38pr6	207	21	-	-	NN
cord-005478-5iu38pr6	207	22	culture	culture	NN
cord-005478-5iu38pr6	207	23	.	.	.
cord-005478-5iu38pr6	208	1	Transcriptome	Transcriptome	NNP
cord-005478-5iu38pr6	208	2	analysis	analysis	NN
cord-005478-5iu38pr6	208	3	of	of	IN
cord-005478-5iu38pr6	208	4	primary	primary	JJ
cord-005478-5iu38pr6	208	5	BM	BM	NNP
cord-005478-5iu38pr6	208	6	samples	sample	NNS
cord-005478-5iu38pr6	208	7	identified	identify	VBD
cord-005478-5iu38pr6	208	8	expression	expression	NN
cord-005478-5iu38pr6	208	9	levels	level	NNS
cord-005478-5iu38pr6	208	10	of	of	IN
cord-005478-5iu38pr6	208	11	known	know	VBN
cord-005478-5iu38pr6	208	12	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	208	13	inducers	inducer	NNS
cord-005478-5iu38pr6	208	14	.	.	.
cord-005478-5iu38pr6	209	1	Results	result	NNS
cord-005478-5iu38pr6	209	2	:	:	:
cord-005478-5iu38pr6	210	1	Flow	flow	VB
cord-005478-5iu38pr6	210	2	cytometric	cytometric	NN
cord-005478-5iu38pr6	210	3	analyses	analysis	NNS
cord-005478-5iu38pr6	210	4	of	of	IN
cord-005478-5iu38pr6	210	5	100	100	CD
cord-005478-5iu38pr6	210	6	BCP	BCP	NNP
cord-005478-5iu38pr6	210	7	-	-	HYPH
cord-005478-5iu38pr6	210	8	ALL	all	DT
cord-005478-5iu38pr6	210	9	samples	sample	NNS
cord-005478-5iu38pr6	210	10	showed	show	VBD
cord-005478-5iu38pr6	210	11	increased	increase	VBN
cord-005478-5iu38pr6	210	12	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	210	13	expression	expression	NN
cord-005478-5iu38pr6	210	14	on	on	IN
cord-005478-5iu38pr6	210	15	CD4	CD4	NNP
cord-005478-5iu38pr6	210	16	+	+	CC
cord-005478-5iu38pr6	210	17	BM	BM	NNP
cord-005478-5iu38pr6	210	18	T	T	NNP
cord-005478-5iu38pr6	210	19	cells	cell	NNS
cord-005478-5iu38pr6	210	20	at	at	IN
cord-005478-5iu38pr6	210	21	initial	initial	JJ
cord-005478-5iu38pr6	210	22	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	210	23	in	in	IN
cord-005478-5iu38pr6	210	24	patients	patient	NNS
cord-005478-5iu38pr6	210	25	with	with	IN
cord-005478-5iu38pr6	210	26	relapse	relapse	NN
cord-005478-5iu38pr6	210	27	in	in	IN
cord-005478-5iu38pr6	210	28	the	the	DT
cord-005478-5iu38pr6	210	29	course	course	NN
cord-005478-5iu38pr6	210	30	of	of	IN
cord-005478-5iu38pr6	210	31	disease	disease	NN
cord-005478-5iu38pr6	210	32	.	.	.
cord-005478-5iu38pr6	211	1	Multivariate	multivariate	JJ
cord-005478-5iu38pr6	211	2	analysis	analysis	NN
cord-005478-5iu38pr6	211	3	confirmed	confirm	VBD
cord-005478-5iu38pr6	211	4	7-fold	7-fold	CD
cord-005478-5iu38pr6	211	5	increased	increase	VBN
cord-005478-5iu38pr6	211	6	relapse	relapse	NN
cord-005478-5iu38pr6	211	7	risk	risk	NN
cord-005478-5iu38pr6	211	8	in	in	IN
cord-005478-5iu38pr6	211	9	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	211	10	high	high	RB
cord-005478-5iu38pr6	212	1	(	(	-LRB-
cord-005478-5iu38pr6	212	2	n=37	n=37	NNP
cord-005478-5iu38pr6	212	3	)	)	-RRB-
cord-005478-5iu38pr6	213	1	vs.	vs.	FW
cord-005478-5iu38pr6	213	2	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	213	3	low	low	JJ
cord-005478-5iu38pr6	213	4	expressing	express	VBG
cord-005478-5iu38pr6	214	1	(	(	-LRB-
cord-005478-5iu38pr6	214	2	n=37	n=37	JJ
cord-005478-5iu38pr6	214	3	)	)	-RRB-
cord-005478-5iu38pr6	214	4	patients	patient	NNS
cord-005478-5iu38pr6	214	5	.	.	.
cord-005478-5iu38pr6	215	1	PD-1	pd-1	DT
cord-005478-5iu38pr6	215	2	expression	expression	NN
cord-005478-5iu38pr6	215	3	on	on	IN
cord-005478-5iu38pr6	215	4	BM	BM	NNP
cord-005478-5iu38pr6	215	5	T	T	NNP
cord-005478-5iu38pr6	215	6	cells	cell	NNS
cord-005478-5iu38pr6	215	7	alone	alone	RB
cord-005478-5iu38pr6	215	8	had	have	VBD
cord-005478-5iu38pr6	215	9	no	no	DT
cord-005478-5iu38pr6	215	10	impact	impact	NN
cord-005478-5iu38pr6	215	11	on	on	IN
cord-005478-5iu38pr6	215	12	relapse	relapse	NN
cord-005478-5iu38pr6	215	13	-	-	HYPH
cord-005478-5iu38pr6	215	14	free	free	JJ
cord-005478-5iu38pr6	215	15	survival	survival	NN
cord-005478-5iu38pr6	215	16	(	(	-LRB-
cord-005478-5iu38pr6	215	17	RFS	RFS	NNP
cord-005478-5iu38pr6	215	18	)	)	-RRB-
cord-005478-5iu38pr6	215	19	,	,	,
cord-005478-5iu38pr6	215	20	whereas	whereas	IN
cord-005478-5iu38pr6	215	21	patients	patient	NNS
cord-005478-5iu38pr6	215	22	with	with	IN
cord-005478-5iu38pr6	215	23	high	high	JJ
cord-005478-5iu38pr6	215	24	percentage	percentage	NN
cord-005478-5iu38pr6	215	25	of	of	IN
cord-005478-5iu38pr6	215	26	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	215	27	/	/	SYM
cord-005478-5iu38pr6	215	28	PD-1	PD-1	NNP
cord-005478-5iu38pr6	215	29	double	double	JJ
cord-005478-5iu38pr6	215	30	positive	positive	JJ
cord-005478-5iu38pr6	215	31	CD4	CD4	NNP
cord-005478-5iu38pr6	215	32	+	+	CC
cord-005478-5iu38pr6	215	33	BM	BM	NNP
cord-005478-5iu38pr6	215	34	T	T	NNP
cord-005478-5iu38pr6	215	35	cells	cell	NNS
cord-005478-5iu38pr6	215	36	showed	show	VBD
cord-005478-5iu38pr6	215	37	significantly	significantly	RB
cord-005478-5iu38pr6	215	38	decreased	decrease	VBD
cord-005478-5iu38pr6	215	39	RFS	RFS	NNP
cord-005478-5iu38pr6	215	40	(	(	-LRB-
cord-005478-5iu38pr6	215	41	87.8	87.8	CD
cord-005478-5iu38pr6	215	42	%	%	NN
cord-005478-5iu38pr6	215	43	vs	vs	IN
cord-005478-5iu38pr6	215	44	41.7	41.7	CD
cord-005478-5iu38pr6	215	45	%	%	NN
cord-005478-5iu38pr6	215	46	)	)	-RRB-
cord-005478-5iu38pr6	215	47	.	.	.
cord-005478-5iu38pr6	216	1	Co	co	NN
cord-005478-5iu38pr6	216	2	-	-	NN
cord-005478-5iu38pr6	216	3	culture	culture	NN
cord-005478-5iu38pr6	216	4	experiments	experiment	NNS
cord-005478-5iu38pr6	216	5	revealed	reveal	VBD
cord-005478-5iu38pr6	216	6	that	that	IN
cord-005478-5iu38pr6	216	7	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	216	8	is	be	VBZ
cord-005478-5iu38pr6	216	9	induced	induce	VBN
cord-005478-5iu38pr6	216	10	in	in	IN
cord-005478-5iu38pr6	216	11	primary	primary	JJ
cord-005478-5iu38pr6	216	12	T	t	NN
cord-005478-5iu38pr6	216	13	cells	cell	NNS
cord-005478-5iu38pr6	216	14	by	by	IN
cord-005478-5iu38pr6	216	15	contact	contact	NN
cord-005478-5iu38pr6	216	16	with	with	IN
cord-005478-5iu38pr6	216	17	leukemic	leukemic	JJ
cord-005478-5iu38pr6	216	18	cells	cell	NNS
cord-005478-5iu38pr6	216	19	(	(	-LRB-
cord-005478-5iu38pr6	216	20	mean	mean	VB
cord-005478-5iu38pr6	216	21	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	216	22	expression	expression	NN
cord-005478-5iu38pr6	216	23	51.1	51.1	CD
cord-005478-5iu38pr6	216	24	%	%	NN
cord-005478-5iu38pr6	216	25	vs.	vs.	IN
cord-005478-5iu38pr6	216	26	29	29	CD
cord-005478-5iu38pr6	216	27	.7	.7	CD
cord-005478-5iu38pr6	216	28	%	%	NN
cord-005478-5iu38pr6	216	29	on	on	IN
cord-005478-5iu38pr6	216	30	T	T	NNP
cord-005478-5iu38pr6	216	31	cells	cell	NNS
cord-005478-5iu38pr6	216	32	with	with	IN
cord-005478-5iu38pr6	216	33	vs.	vs.	NN
cord-005478-5iu38pr6	216	34	without	without	IN
cord-005478-5iu38pr6	216	35	addition	addition	NN
cord-005478-5iu38pr6	216	36	of	of	IN
cord-005478-5iu38pr6	216	37	leukemic	leukemic	JJ
cord-005478-5iu38pr6	216	38	cells	cell	NNS
cord-005478-5iu38pr6	216	39	,	,	,
cord-005478-5iu38pr6	216	40	n=3	n=3	NN
cord-005478-5iu38pr6	216	41	)	)	-RRB-
cord-005478-5iu38pr6	216	42	.	.	.
cord-005478-5iu38pr6	217	1	Transcriptome	Transcriptome	NNP
cord-005478-5iu38pr6	217	2	analysis	analysis	NN
cord-005478-5iu38pr6	217	3	was	be	VBD
cord-005478-5iu38pr6	217	4	performed	perform	VBN
cord-005478-5iu38pr6	217	5	to	to	TO
cord-005478-5iu38pr6	217	6	identify	identify	VB
cord-005478-5iu38pr6	217	7	expression	expression	NN
cord-005478-5iu38pr6	217	8	levels	level	NNS
cord-005478-5iu38pr6	217	9	of	of	IN
cord-005478-5iu38pr6	217	10	known	know	VBN
cord-005478-5iu38pr6	217	11	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	217	12	ligands/	ligands/	NN
cord-005478-5iu38pr6	217	13	inducers	inducer	NNS
cord-005478-5iu38pr6	217	14	in	in	IN
cord-005478-5iu38pr6	217	15	BM	BM	NNP
cord-005478-5iu38pr6	217	16	samples	sample	NNS
cord-005478-5iu38pr6	217	17	with	with	IN
cord-005478-5iu38pr6	217	18	high	high	JJ
cord-005478-5iu38pr6	217	19	vs.	vs.	IN
cord-005478-5iu38pr6	217	20	low	low	JJ
cord-005478-5iu38pr6	217	21	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	217	22	expression	expression	NN
cord-005478-5iu38pr6	217	23	.	.	.
cord-005478-5iu38pr6	218	1	No	no	DT
cord-005478-5iu38pr6	218	2	significant	significant	JJ
cord-005478-5iu38pr6	218	3	differences	difference	NNS
cord-005478-5iu38pr6	218	4	in	in	IN
cord-005478-5iu38pr6	218	5	expression	expression	NN
cord-005478-5iu38pr6	218	6	levels	level	NNS
cord-005478-5iu38pr6	218	7	of	of	IN
cord-005478-5iu38pr6	218	8	High	high	JJ
cord-005478-5iu38pr6	218	9	-	-	HYPH
cord-005478-5iu38pr6	218	10	Mobility	Mobility	NNP
cord-005478-5iu38pr6	218	11	-	-	HYPH
cord-005478-5iu38pr6	218	12	Group	Group	NNP
cord-005478-5iu38pr6	218	13	-	-	HYPH
cord-005478-5iu38pr6	218	14	Protein	Protein	NNP
cord-005478-5iu38pr6	218	15	B1	B1	NNP
cord-005478-5iu38pr6	218	16	(	(	-LRB-
cord-005478-5iu38pr6	218	17	HMGB1	HMGB1	NNP
cord-005478-5iu38pr6	218	18	)	)	-RRB-
cord-005478-5iu38pr6	218	19	,	,	,
cord-005478-5iu38pr6	218	20	Carcinoembryonic	Carcinoembryonic	NNP
cord-005478-5iu38pr6	218	21	antigen	antigen	NN
cord-005478-5iu38pr6	218	22	-	-	HYPH
cord-005478-5iu38pr6	218	23	related	relate	VBN
cord-005478-5iu38pr6	218	24	cell	cell	NN
cord-005478-5iu38pr6	218	25	adhesion	adhesion	NN
cord-005478-5iu38pr6	218	26	molecule	molecule	NN
cord-005478-5iu38pr6	218	27	1	1	CD
cord-005478-5iu38pr6	219	1	(	(	-LRB-
cord-005478-5iu38pr6	219	2	CEA	CEA	NNP
cord-005478-5iu38pr6	219	3	-	-	HYPH
cord-005478-5iu38pr6	219	4	CAM1	CAM1	NNP
cord-005478-5iu38pr6	219	5	)	)	-RRB-
cord-005478-5iu38pr6	219	6	or	or	CC
cord-005478-5iu38pr6	219	7	Galectin	Galectin	NNP
cord-005478-5iu38pr6	219	8	9	9	CD
cord-005478-5iu38pr6	219	9	were	be	VBD
cord-005478-5iu38pr6	219	10	observed	observe	VBN
cord-005478-5iu38pr6	219	11	.	.	.
cord-005478-5iu38pr6	220	1	Known	know	VBN
cord-005478-5iu38pr6	220	2	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	220	3	inducers	inducer	NNS
cord-005478-5iu38pr6	220	4	IL-12	IL-12	NNP
cord-005478-5iu38pr6	220	5	,	,	,
cord-005478-5iu38pr6	220	6	IL-15	IL-15	NNP
cord-005478-5iu38pr6	220	7	,	,	,
cord-005478-5iu38pr6	220	8	IL-27	IL-27	NNP
cord-005478-5iu38pr6	220	9	,	,	,
cord-005478-5iu38pr6	220	10	IL-7	IL-7	NNP
cord-005478-5iu38pr6	220	11	or	or	CC
cord-005478-5iu38pr6	220	12	Transforming	transform	VBG
cord-005478-5iu38pr6	220	13	growth	growth	NN
cord-005478-5iu38pr6	220	14	factor	factor	NN
cord-005478-5iu38pr6	221	1	beta	beta	NN
cord-005478-5iu38pr6	221	2	1	1	CD
cord-005478-5iu38pr6	221	3	(	(	-LRB-
cord-005478-5iu38pr6	221	4	TGF	TGF	NNP
cord-005478-5iu38pr6	221	5	-	-	HYPH
cord-005478-5iu38pr6	221	6	β1	β1	NNP
cord-005478-5iu38pr6	221	7	)	)	-RRB-
cord-005478-5iu38pr6	221	8	were	be	VBD
cord-005478-5iu38pr6	221	9	not	not	RB
cord-005478-5iu38pr6	221	10	differentially	differentially	RB
cord-005478-5iu38pr6	221	11	expressed	express	VBN
cord-005478-5iu38pr6	221	12	indicating	indicate	VBG
cord-005478-5iu38pr6	221	13	that	that	IN
cord-005478-5iu38pr6	221	14	another	another	DT
cord-005478-5iu38pr6	221	15	mechanism	mechanism	NN
cord-005478-5iu38pr6	221	16	must	must	MD
cord-005478-5iu38pr6	221	17	be	be	VB
cord-005478-5iu38pr6	221	18	responsible	responsible	JJ
cord-005478-5iu38pr6	221	19	for	for	IN
cord-005478-5iu38pr6	221	20	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	221	21	overexpression	overexpression	NN
cord-005478-5iu38pr6	221	22	.	.	.
cord-005478-5iu38pr6	222	1	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	222	2	overexpression	overexpression	NN
cord-005478-5iu38pr6	222	3	and	and	CC
cord-005478-5iu38pr6	222	4	CRISPR/	CRISPR/	NNP
cord-005478-5iu38pr6	222	5	Cas9-mediated	cas9-mediate	VBD
cord-005478-5iu38pr6	222	6	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	222	7	KO	KO	NNP
cord-005478-5iu38pr6	222	8	were	be	VBD
cord-005478-5iu38pr6	222	9	performed	perform	VBN
cord-005478-5iu38pr6	222	10	to	to	TO
cord-005478-5iu38pr6	222	11	analyze	analyze	VB
cord-005478-5iu38pr6	222	12	functional	functional	JJ
cord-005478-5iu38pr6	222	13	relevance	relevance	NN
cord-005478-5iu38pr6	222	14	of	of	IN
cord-005478-5iu38pr6	222	15	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	222	16	expression	expression	NN
cord-005478-5iu38pr6	222	17	in	in	IN
cord-005478-5iu38pr6	222	18	an	an	DT
cord-005478-5iu38pr6	222	19	in	in	FW
cord-005478-5iu38pr6	222	20	vitro	vitro	FW
cord-005478-5iu38pr6	222	21	leukemia	leukemia	NN
cord-005478-5iu38pr6	222	22	model	model	NN
cord-005478-5iu38pr6	222	23	.	.	.
cord-005478-5iu38pr6	223	1	T	T	NNP
cord-005478-5iu38pr6	223	2	cells	cell	NNS
cord-005478-5iu38pr6	223	3	of	of	IN
cord-005478-5iu38pr6	223	4	healthy	healthy	JJ
cord-005478-5iu38pr6	223	5	donors	donor	NNS
cord-005478-5iu38pr6	223	6	were	be	VBD
cord-005478-5iu38pr6	223	7	co	co	JJ
cord-005478-5iu38pr6	223	8	-	-	JJ
cord-005478-5iu38pr6	223	9	cultured	cultured	JJ
cord-005478-5iu38pr6	223	10	with	with	IN
cord-005478-5iu38pr6	223	11	leukemic	leukemic	JJ
cord-005478-5iu38pr6	223	12	cells	cell	NNS
cord-005478-5iu38pr6	223	13	and	and	CC
cord-005478-5iu38pr6	223	14	anti	anti	JJ
cord-005478-5iu38pr6	223	15	-	-	JJ
cord-005478-5iu38pr6	223	16	CD19/-CD3	cd19/-cd3	JJ
cord-005478-5iu38pr6	223	17	BiTE	bite	NN
cord-005478-5iu38pr6	223	18	to	to	TO
cord-005478-5iu38pr6	223	19	induce	induce	VB
cord-005478-5iu38pr6	223	20	anti	anti	JJ
cord-005478-5iu38pr6	223	21	-	-	JJ
cord-005478-5iu38pr6	223	22	leukemic	leukemic	JJ
cord-005478-5iu38pr6	223	23	T	t	NN
cord-005478-5iu38pr6	223	24	-	-	HYPH
cord-005478-5iu38pr6	223	25	cell	cell	NN
cord-005478-5iu38pr6	223	26	response	response	NN
cord-005478-5iu38pr6	223	27	.	.	.
cord-005478-5iu38pr6	224	1	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	224	2	KO	KO	NNP
cord-005478-5iu38pr6	224	3	T	T	NNP
cord-005478-5iu38pr6	224	4	cells	cell	NNS
cord-005478-5iu38pr6	224	5	showed	show	VBD
cord-005478-5iu38pr6	224	6	significantly	significantly	RB
cord-005478-5iu38pr6	224	7	increased	increase	VBN
cord-005478-5iu38pr6	224	8	activation	activation	NN
cord-005478-5iu38pr6	224	9	compared	compare	VBN
cord-005478-5iu38pr6	224	10	to	to	IN
cord-005478-5iu38pr6	224	11	wildtype	wildtype	NN
cord-005478-5iu38pr6	224	12	T	t	NN
cord-005478-5iu38pr6	224	13	cells	cell	NNS
cord-005478-5iu38pr6	224	14	(	(	-LRB-
cord-005478-5iu38pr6	224	15	FC	FC	NNP
cord-005478-5iu38pr6	224	16	of	of	IN
cord-005478-5iu38pr6	224	17	CD69	CD69	NNP
cord-005478-5iu38pr6	224	18	expression	expression	NN
cord-005478-5iu38pr6	224	19	5.0	5.0	CD
cord-005478-5iu38pr6	224	20	vs.	vs.	IN
cord-005478-5iu38pr6	224	21	3.2	3.2	CD
cord-005478-5iu38pr6	224	22	,	,	,
cord-005478-5iu38pr6	224	23	n=3	n=3	NN
cord-005478-5iu38pr6	224	24	)	)	-RRB-
cord-005478-5iu38pr6	224	25	.	.	.
cord-005478-5iu38pr6	225	1	In	in	IN
cord-005478-5iu38pr6	225	2	contrast	contrast	NN
cord-005478-5iu38pr6	225	3	,	,	,
cord-005478-5iu38pr6	225	4	proliferation	proliferation	NN
cord-005478-5iu38pr6	225	5	of	of	IN
cord-005478-5iu38pr6	225	6	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	225	7	overexpressing	overexpresse	VBG
cord-005478-5iu38pr6	225	8	T	t	NN
cord-005478-5iu38pr6	225	9	cells	cell	NNS
cord-005478-5iu38pr6	225	10	was	be	VBD
cord-005478-5iu38pr6	225	11	significantly	significantly	RB
cord-005478-5iu38pr6	225	12	impaired	impair	VBN
cord-005478-5iu38pr6	225	13	(	(	-LRB-
cord-005478-5iu38pr6	225	14	FC	FC	NNP
cord-005478-5iu38pr6	225	15	1.6	1.6	CD
cord-005478-5iu38pr6	225	16	vs.	vs.	IN
cord-005478-5iu38pr6	225	17	2.3	2.3	CD
cord-005478-5iu38pr6	225	18	,	,	,
cord-005478-5iu38pr6	225	19	n=3	n=3	NN
cord-005478-5iu38pr6	225	20	)	)	-RRB-
cord-005478-5iu38pr6	225	21	,	,	,
cord-005478-5iu38pr6	225	22	whereas	whereas	IN
cord-005478-5iu38pr6	225	23	TIM-3	TIM-3	NNP
cord-005478-5iu38pr6	225	24	KO	KO	NNP
cord-005478-5iu38pr6	225	25	T	T	NNP
cord-005478-5iu38pr6	225	26	cells	cell	NNS
cord-005478-5iu38pr6	225	27	showed	show	VBD
cord-005478-5iu38pr6	225	28	higher	high	JJR
cord-005478-5iu38pr6	225	29	proliferation	proliferation	NN
cord-005478-5iu38pr6	225	30	levels	level	NNS
cord-005478-5iu38pr6	225	31	compared	compare	VBN
cord-005478-5iu38pr6	225	32	to	to	IN
cord-005478-5iu38pr6	225	33	controls	control	NNS
cord-005478-5iu38pr6	225	34	(	(	-LRB-
cord-005478-5iu38pr6	225	35	FC	FC	NNP
cord-005478-5iu38pr6	225	36	6.5	6.5	CD
cord-005478-5iu38pr6	225	37	vs.	vs.	IN
cord-005478-5iu38pr6	225	38	2.4	2.4	CD
cord-005478-5iu38pr6	225	39	,	,	,
cord-005478-5iu38pr6	225	40	n=3	n=3	NN
cord-005478-5iu38pr6	225	41	)	)	-RRB-
cord-005478-5iu38pr6	225	42	.	.	.
cord-005478-5iu38pr6	226	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	226	2	:	:	:
cord-005478-5iu38pr6	227	1	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	227	2	expression	expression	NN
cord-005478-5iu38pr6	227	3	on	on	IN
cord-005478-5iu38pr6	227	4	CD4	CD4	NNP
cord-005478-5iu38pr6	227	5	+	+	CC
cord-005478-5iu38pr6	227	6	BM	BM	NNP
cord-005478-5iu38pr6	227	7	T	T	NNP
cord-005478-5iu38pr6	227	8	cells	cell	NNS
cord-005478-5iu38pr6	227	9	is	be	VBZ
cord-005478-5iu38pr6	227	10	a	a	DT
cord-005478-5iu38pr6	227	11	strong	strong	JJ
cord-005478-5iu38pr6	227	12	predictor	predictor	NN
cord-005478-5iu38pr6	227	13	for	for	IN
cord-005478-5iu38pr6	227	14	pediatric	pediatric	JJ
cord-005478-5iu38pr6	227	15	BCP	BCP	NNP
cord-005478-5iu38pr6	227	16	-	-	:
cord-005478-5iu38pr6	227	17	ALL	all	DT
cord-005478-5iu38pr6	227	18	relapse	relapse	NN
cord-005478-5iu38pr6	227	19	and	and	CC
cord-005478-5iu38pr6	227	20	is	be	VBZ
cord-005478-5iu38pr6	227	21	induced	induce	VBN
cord-005478-5iu38pr6	227	22	by	by	IN
cord-005478-5iu38pr6	227	23	T	t	NN
cord-005478-5iu38pr6	227	24	-	-	HYPH
cord-005478-5iu38pr6	227	25	cell	cell	NN
cord-005478-5iu38pr6	227	26	interaction	interaction	NN
cord-005478-5iu38pr6	227	27	with	with	IN
cord-005478-5iu38pr6	227	28	leukemic	leukemic	JJ
cord-005478-5iu38pr6	227	29	cells	cell	NNS
cord-005478-5iu38pr6	227	30	.	.	.
cord-005478-5iu38pr6	228	1	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	228	2	expression	expression	NN
cord-005478-5iu38pr6	228	3	decreases	decrease	VBZ
cord-005478-5iu38pr6	228	4	anti	anti	JJ
cord-005478-5iu38pr6	228	5	-	-	JJ
cord-005478-5iu38pr6	228	6	leukemic	leukemic	JJ
cord-005478-5iu38pr6	228	7	T	t	NN
cord-005478-5iu38pr6	228	8	-	-	HYPH
cord-005478-5iu38pr6	228	9	cell	cell	NN
cord-005478-5iu38pr6	228	10	activation	activation	NN
cord-005478-5iu38pr6	228	11	and	and	CC
cord-005478-5iu38pr6	228	12	proliferation	proliferation	NN
cord-005478-5iu38pr6	228	13	and	and	CC
cord-005478-5iu38pr6	228	14	thus	thus	RB
cord-005478-5iu38pr6	228	15	constitutes	constitute	VBZ
cord-005478-5iu38pr6	228	16	a	a	DT
cord-005478-5iu38pr6	228	17	new	new	JJ
cord-005478-5iu38pr6	228	18	mechanism	mechanism	NN
cord-005478-5iu38pr6	228	19	of	of	IN
cord-005478-5iu38pr6	228	20	immune	immune	JJ
cord-005478-5iu38pr6	228	21	escape	escape	NN
cord-005478-5iu38pr6	228	22	and	and	CC
cord-005478-5iu38pr6	228	23	potentially	potentially	RB
cord-005478-5iu38pr6	228	24	insufficient	insufficient	JJ
cord-005478-5iu38pr6	228	25	GvL	gvl	NN
cord-005478-5iu38pr6	228	26	effects	effect	NNS
cord-005478-5iu38pr6	228	27	in	in	IN
cord-005478-5iu38pr6	228	28	pediatric	pediatric	JJ
cord-005478-5iu38pr6	228	29	BCP	BCP	NNP
cord-005478-5iu38pr6	228	30	-	-	HYPH
cord-005478-5iu38pr6	228	31	ALL	ALL	NNP
cord-005478-5iu38pr6	228	32	.	.	.
cord-005478-5iu38pr6	229	1	Targeting	target	VBG
cord-005478-5iu38pr6	229	2	the	the	DT
cord-005478-5iu38pr6	229	3	TIM-3	tim-3	JJ
cord-005478-5iu38pr6	229	4	axis	axis	NN
cord-005478-5iu38pr6	229	5	can	can	MD
cord-005478-5iu38pr6	229	6	be	be	VB
cord-005478-5iu38pr6	229	7	of	of	IN
cord-005478-5iu38pr6	229	8	interest	interest	NN
cord-005478-5iu38pr6	229	9	to	to	TO
cord-005478-5iu38pr6	229	10	improve	improve	VB
cord-005478-5iu38pr6	229	11	future	future	JJ
cord-005478-5iu38pr6	229	12	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	229	13	of	of	IN
cord-005478-5iu38pr6	229	14	advanced	advanced	JJ
cord-005478-5iu38pr6	229	15	BCP	BCP	NNP
cord-005478-5iu38pr6	229	16	-	-	HYPH
cord-005478-5iu38pr6	229	17	ALL	ALL	NNP
cord-005478-5iu38pr6	229	18	.	.	.
cord-005478-5iu38pr6	230	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	230	2	:	:	:
cord-005478-5iu38pr6	230	3	Nothing	nothing	NN
cord-005478-5iu38pr6	230	4	to	to	TO
cord-005478-5iu38pr6	230	5	declare	declare	VB
cord-005478-5iu38pr6	230	6	.	.	.
cord-005478-5iu38pr6	231	1	Abstract	Abstract	NNP
cord-005478-5iu38pr6	231	2	already	already	RB
cord-005478-5iu38pr6	231	3	published	publish	VBN
cord-005478-5iu38pr6	231	4	.	.	.
cord-005478-5iu38pr6	232	1	Multiparameter	Multiparameter	NNP
cord-005478-5iu38pr6	232	2	flow	flow	NN
cord-005478-5iu38pr6	232	3	cytometric	cytometric	FW
cord-005478-5iu38pr6	232	4	minimal	minimal	JJ
cord-005478-5iu38pr6	232	5	residual	residual	JJ
cord-005478-5iu38pr6	232	6	disease	disease	NN
cord-005478-5iu38pr6	232	7	before	before	IN
cord-005478-5iu38pr6	232	8	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	232	9	allogeneic	allogeneic	NNP
cord-005478-5iu38pr6	232	10	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	232	11	cell	cell	NN
cord-005478-5iu38pr6	232	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	232	13	in	in	IN
cord-005478-5iu38pr6	232	14	acute	acute	JJ
cord-005478-5iu38pr6	232	15	myeloid	myeloid	NN
cord-005478-5iu38pr6	232	16	leukemia	leukemia	NN
cord-005478-5iu38pr6	232	17	influences	influence	NNS
cord-005478-5iu38pr6	232	18	patients	patient	VBZ
cord-005478-5iu38pr6	232	19	survival	survival	NN
cord-005478-5iu38pr6	232	20	in	in	IN
cord-005478-5iu38pr6	233	1	first	first	JJ
cord-005478-5iu38pr6	233	2	and	and	CC
cord-005478-5iu38pr6	233	3	second	second	JJ
cord-005478-5iu38pr6	233	4	complete	complete	JJ
cord-005478-5iu38pr6	233	5	remission	remission	NN
cord-005478-5iu38pr6	233	6	Background	background	NN
cord-005478-5iu38pr6	233	7	:	:	:
cord-005478-5iu38pr6	234	1	The	the	DT
cord-005478-5iu38pr6	234	2	growing	grow	VBG
cord-005478-5iu38pr6	234	3	evidence	evidence	NN
cord-005478-5iu38pr6	234	4	from	from	IN
cord-005478-5iu38pr6	234	5	the	the	DT
cord-005478-5iu38pr6	234	6	literature	literature	NN
cord-005478-5iu38pr6	234	7	strongly	strongly	RB
cord-005478-5iu38pr6	234	8	suggest	suggest	VBP
cord-005478-5iu38pr6	234	9	that	that	IN
cord-005478-5iu38pr6	234	10	multiparameter	multiparameter	NNP
cord-005478-5iu38pr6	234	11	flow	flow	VB
cord-005478-5iu38pr6	234	12	cytometric	cytometric	NNP
cord-005478-5iu38pr6	234	13	(	(	-LRB-
cord-005478-5iu38pr6	234	14	MFC	MFC	NNP
cord-005478-5iu38pr6	234	15	)	)	-RRB-
cord-005478-5iu38pr6	234	16	minimal	minimal	JJ
cord-005478-5iu38pr6	234	17	residual	residual	JJ
cord-005478-5iu38pr6	234	18	disease	disease	NN
cord-005478-5iu38pr6	234	19	(	(	-LRB-
cord-005478-5iu38pr6	234	20	MRD	MRD	NNP
cord-005478-5iu38pr6	234	21	)	)	-RRB-
cord-005478-5iu38pr6	234	22	assessment	assessment	NN
cord-005478-5iu38pr6	234	23	in	in	IN
cord-005478-5iu38pr6	234	24	AML	AML	NNP
cord-005478-5iu38pr6	234	25	can	can	MD
cord-005478-5iu38pr6	234	26	be	be	VB
cord-005478-5iu38pr6	234	27	used	use	VBN
cord-005478-5iu38pr6	234	28	to	to	TO
cord-005478-5iu38pr6	234	29	risk	risk	NN
cord-005478-5iu38pr6	234	30	-	-	HYPH
cord-005478-5iu38pr6	234	31	stratify	stratify	VB
cord-005478-5iu38pr6	234	32	patients	patient	NNS
cord-005478-5iu38pr6	234	33	at	at	IN
cord-005478-5iu38pr6	234	34	the	the	DT
cord-005478-5iu38pr6	234	35	time	time	NN
cord-005478-5iu38pr6	234	36	of	of	IN
cord-005478-5iu38pr6	234	37	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	234	38	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	234	39	stem	stem	NN
cord-005478-5iu38pr6	234	40	cell	cell	NN
cord-005478-5iu38pr6	234	41	transplantation	transplantation	NN
cord-005478-5iu38pr6	234	42	(	(	-LRB-
cord-005478-5iu38pr6	234	43	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	234	44	)	)	-RRB-
cord-005478-5iu38pr6	234	45	.	.	.
cord-005478-5iu38pr6	235	1	We	-PRON-	PRP
cord-005478-5iu38pr6	235	2	sought	seek	VBD
cord-005478-5iu38pr6	235	3	to	to	TO
cord-005478-5iu38pr6	235	4	determine	determine	VB
cord-005478-5iu38pr6	235	5	the	the	DT
cord-005478-5iu38pr6	235	6	significance	significance	NN
cord-005478-5iu38pr6	235	7	of	of	IN
cord-005478-5iu38pr6	235	8	MFC	MFC	NNP
cord-005478-5iu38pr6	235	9	-	-	HYPH
cord-005478-5iu38pr6	235	10	MRD	MRD	NNP
cord-005478-5iu38pr6	235	11	status	status	NN
cord-005478-5iu38pr6	235	12	in	in	IN
cord-005478-5iu38pr6	235	13	patients	patient	NNS
cord-005478-5iu38pr6	235	14	with	with	IN
cord-005478-5iu38pr6	235	15	AML	AML	NNP
cord-005478-5iu38pr6	235	16	in	in	IN
cord-005478-5iu38pr6	235	17	first	first	JJ
cord-005478-5iu38pr6	235	18	or	or	CC
cord-005478-5iu38pr6	235	19	second	second	JJ
cord-005478-5iu38pr6	235	20	complete	complete	JJ
cord-005478-5iu38pr6	235	21	remission	remission	NN
cord-005478-5iu38pr6	235	22	(	(	-LRB-
cord-005478-5iu38pr6	235	23	CR	CR	NNP
cord-005478-5iu38pr6	235	24	)	)	-RRB-
cord-005478-5iu38pr6	235	25	treated	treat	VBN
cord-005478-5iu38pr6	235	26	with	with	IN
cord-005478-5iu38pr6	235	27	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	235	28	conditioning	conditioning	NN
cord-005478-5iu38pr6	235	29	(	(	-LRB-
cord-005478-5iu38pr6	235	30	MAC	MAC	NNP
cord-005478-5iu38pr6	235	31	)	)	-RRB-
cord-005478-5iu38pr6	235	32	alloHCT	allohct	XX
cord-005478-5iu38pr6	235	33	at	at	IN
cord-005478-5iu38pr6	235	34	six	six	CD
cord-005478-5iu38pr6	235	35	centers	center	NNS
cord-005478-5iu38pr6	235	36	of	of	IN
cord-005478-5iu38pr6	235	37	the	the	DT
cord-005478-5iu38pr6	235	38	Polish	Polish	NNP
cord-005478-5iu38pr6	235	39	Adult	Adult	NNP
cord-005478-5iu38pr6	235	40	Leukemia	Leukemia	NNP
cord-005478-5iu38pr6	235	41	Group	Group	NNP
cord-005478-5iu38pr6	235	42	(	(	-LRB-
cord-005478-5iu38pr6	235	43	PALG	PALG	NNP
cord-005478-5iu38pr6	235	44	)	)	-RRB-
cord-005478-5iu38pr6	235	45	.	.	.
cord-005478-5iu38pr6	236	1	Methods	method	NNS
cord-005478-5iu38pr6	236	2	:	:	:
cord-005478-5iu38pr6	236	3	MRD	MRD	NNP
cord-005478-5iu38pr6	236	4	was	be	VBD
cord-005478-5iu38pr6	236	5	assessed	assess	VBN
cord-005478-5iu38pr6	236	6	by	by	IN
cord-005478-5iu38pr6	236	7	6-color	6-color	CD
cord-005478-5iu38pr6	236	8	(	(	-LRB-
cord-005478-5iu38pr6	236	9	8-color	8-color	CD
cord-005478-5iu38pr6	236	10	since	since	IN
cord-005478-5iu38pr6	236	11	2017	2017	CD
cord-005478-5iu38pr6	236	12	)	)	-RRB-
cord-005478-5iu38pr6	237	1	MFC	MFC	NNP
cord-005478-5iu38pr6	237	2	performed	perform	VBD
cord-005478-5iu38pr6	237	3	on	on	IN
cord-005478-5iu38pr6	237	4	bone	bone	NN
cord-005478-5iu38pr6	237	5	marrow	marrow	NN
cord-005478-5iu38pr6	237	6	aspirates	aspirate	NNS
cord-005478-5iu38pr6	237	7	obtained	obtain	VBN
cord-005478-5iu38pr6	237	8	as	as	IN
cord-005478-5iu38pr6	237	9	routine	routine	JJ
cord-005478-5iu38pr6	237	10	assessment	assessment	NN
cord-005478-5iu38pr6	237	11	before	before	IN
cord-005478-5iu38pr6	237	12	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	237	13	.	.	.
cord-005478-5iu38pr6	238	1	All	all	DT
cord-005478-5iu38pr6	238	2	consecutive	consecutive	JJ
cord-005478-5iu38pr6	238	3	patients	patient	NNS
cord-005478-5iu38pr6	238	4	undergoing	undergo	VBG
cord-005478-5iu38pr6	238	5	MAC	MAC	NNP
cord-005478-5iu38pr6	238	6	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	238	7	were	be	VBD
cord-005478-5iu38pr6	238	8	included	include	VBN
cord-005478-5iu38pr6	238	9	in	in	IN
cord-005478-5iu38pr6	238	10	the	the	DT
cord-005478-5iu38pr6	238	11	analysis	analysis	NN
cord-005478-5iu38pr6	238	12	if	if	IN
cord-005478-5iu38pr6	238	13	they	-PRON-	PRP
cord-005478-5iu38pr6	238	14	underwent	undergo	VBD
cord-005478-5iu38pr6	238	15	pre	pre	JJ
cord-005478-5iu38pr6	238	16	-	-	JJ
cord-005478-5iu38pr6	238	17	HCT	hct	JJ
cord-005478-5iu38pr6	238	18	MFC	MFC	NNP
cord-005478-5iu38pr6	238	19	-	-	HYPH
cord-005478-5iu38pr6	238	20	MRD	MRD	NNP
cord-005478-5iu38pr6	238	21	analysis	analysis	NN
cord-005478-5iu38pr6	238	22	from	from	IN
cord-005478-5iu38pr6	238	23	May	May	NNP
cord-005478-5iu38pr6	238	24	2013	2013	CD
cord-005478-5iu38pr6	238	25	until	until	IN
cord-005478-5iu38pr6	238	26	January	January	NNP
cord-005478-5iu38pr6	238	27	2018	2018	CD
cord-005478-5iu38pr6	238	28	.	.	.
cord-005478-5iu38pr6	239	1	The	the	DT
cord-005478-5iu38pr6	239	2	abnormal	abnormal	JJ
cord-005478-5iu38pr6	239	3	population	population	NN
cord-005478-5iu38pr6	239	4	was	be	VBD
cord-005478-5iu38pr6	239	5	quantified	quantify	VBN
cord-005478-5iu38pr6	239	6	as	as	IN
cord-005478-5iu38pr6	239	7	a	a	DT
cord-005478-5iu38pr6	239	8	percentage	percentage	NN
cord-005478-5iu38pr6	239	9	of	of	IN
cord-005478-5iu38pr6	239	10	the	the	DT
cord-005478-5iu38pr6	239	11	total	total	NN
cord-005478-5iu38pr6	240	1	CD45	CD45	NNP
cord-005478-5iu38pr6	240	2	+	+	CC
cord-005478-5iu38pr6	240	3	white	white	JJ
cord-005478-5iu38pr6	240	4	cell	cell	NN
cord-005478-5iu38pr6	240	5	events	event	NNS
cord-005478-5iu38pr6	240	6	.	.	.
cord-005478-5iu38pr6	241	1	Residual	residual	JJ
cord-005478-5iu38pr6	241	2	disease	disease	NN
cord-005478-5iu38pr6	241	3	at	at	IN
cord-005478-5iu38pr6	241	4	a	a	DT
cord-005478-5iu38pr6	241	5	≥	≥	CD
cord-005478-5iu38pr6	241	6	0.1	0.1	CD
cord-005478-5iu38pr6	241	7	%	%	NN
cord-005478-5iu38pr6	241	8	level	level	NN
cord-005478-5iu38pr6	241	9	was	be	VBD
cord-005478-5iu38pr6	241	10	considered	consider	VBN
cord-005478-5iu38pr6	241	11	MRD	MRD	NNP
cord-005478-5iu38pr6	241	12	-	-	HYPH
cord-005478-5iu38pr6	241	13	positive	positive	JJ
cord-005478-5iu38pr6	241	14	(	(	-LRB-
cord-005478-5iu38pr6	241	15	MRD+	MRD+	NNP
cord-005478-5iu38pr6	241	16	)	)	-RRB-
cord-005478-5iu38pr6	241	17	.	.	.
cord-005478-5iu38pr6	242	1	Results	result	NNS
cord-005478-5iu38pr6	242	2	:	:	:
cord-005478-5iu38pr6	243	1	We	-PRON-	PRP
cord-005478-5iu38pr6	243	2	identified	identify	VBD
cord-005478-5iu38pr6	243	3	83	83	CD
cord-005478-5iu38pr6	243	4	adult	adult	NN
cord-005478-5iu38pr6	243	5	patients	patient	NNS
cord-005478-5iu38pr6	243	6	(	(	-LRB-
cord-005478-5iu38pr6	243	7	median	median	JJ
cord-005478-5iu38pr6	243	8	age	age	NN
cord-005478-5iu38pr6	243	9	41	41	CD
cord-005478-5iu38pr6	243	10	years	year	NNS
cord-005478-5iu38pr6	243	11	,	,	,
cord-005478-5iu38pr6	243	12	range	range	VBP
cord-005478-5iu38pr6	243	13	19	19	CD
cord-005478-5iu38pr6	243	14	-	-	SYM
cord-005478-5iu38pr6	243	15	64	64	CD
cord-005478-5iu38pr6	243	16	)	)	-RRB-
cord-005478-5iu38pr6	243	17	with	with	IN
cord-005478-5iu38pr6	243	18	AML	AML	NNP
cord-005478-5iu38pr6	243	19	undergoing	undergo	VBG
cord-005478-5iu38pr6	243	20	alloHCT	alloHCT	VBD
cord-005478-5iu38pr6	243	21	from	from	IN
cord-005478-5iu38pr6	243	22	either	either	DT
cord-005478-5iu38pr6	243	23	HLA	HLA	NNP
cord-005478-5iu38pr6	243	24	-	-	HYPH
cord-005478-5iu38pr6	243	25	identical	identical	JJ
cord-005478-5iu38pr6	243	26	sibling	sibling	NN
cord-005478-5iu38pr6	243	27	(	(	-LRB-
cord-005478-5iu38pr6	243	28	n=30	n=30	NNP
cord-005478-5iu38pr6	243	29	)	)	-RRB-
cord-005478-5iu38pr6	243	30	or	or	CC
cord-005478-5iu38pr6	243	31	unrelated	unrelated	JJ
cord-005478-5iu38pr6	243	32	donor	donor	NN
cord-005478-5iu38pr6	243	33	(	(	-LRB-
cord-005478-5iu38pr6	243	34	n=53	n=53	NNP
cord-005478-5iu38pr6	243	35	)	)	-RRB-
cord-005478-5iu38pr6	243	36	,	,	,
cord-005478-5iu38pr6	243	37	in	in	IN
cord-005478-5iu38pr6	243	38	CR1	CR1	NNP
cord-005478-5iu38pr6	243	39	(	(	-LRB-
cord-005478-5iu38pr6	243	40	n=72	n=72	NNP
cord-005478-5iu38pr6	243	41	)	)	-RRB-
cord-005478-5iu38pr6	243	42	or	or	CC
cord-005478-5iu38pr6	243	43	CR2	CR2	NNP
cord-005478-5iu38pr6	243	44	(	(	-LRB-
cord-005478-5iu38pr6	243	45	n=11	n=11	NNP
cord-005478-5iu38pr6	243	46	)	)	-RRB-
cord-005478-5iu38pr6	243	47	,	,	,
cord-005478-5iu38pr6	243	48	who	who	WP
cord-005478-5iu38pr6	243	49	were	be	VBD
cord-005478-5iu38pr6	243	50	conditioned	condition	VBN
cord-005478-5iu38pr6	243	51	with	with	IN
cord-005478-5iu38pr6	243	52	i.v	i.v	NNP
cord-005478-5iu38pr6	243	53	.	.	NNP
cord-005478-5iu38pr6	243	54	busulfan	busulfan	NNP
cord-005478-5iu38pr6	243	55	given	give	VBN
cord-005478-5iu38pr6	243	56	in	in	IN
cord-005478-5iu38pr6	243	57	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	243	58	dose	dose	NN
cord-005478-5iu38pr6	243	59	(	(	-LRB-
cord-005478-5iu38pr6	243	60	9,6	9,6	CD
cord-005478-5iu38pr6	243	61	-	-	HYPH
cord-005478-5iu38pr6	243	62	12,8	12,8	CD
cord-005478-5iu38pr6	243	63	mg	mg	NNP
cord-005478-5iu38pr6	243	64	/	/	SYM
cord-005478-5iu38pr6	243	65	kg	kg	NNP
cord-005478-5iu38pr6	243	66	)	)	-RRB-
cord-005478-5iu38pr6	243	67	in	in	IN
cord-005478-5iu38pr6	243	68	combination	combination	NN
cord-005478-5iu38pr6	243	69	with	with	IN
cord-005478-5iu38pr6	243	70	Flu	Flu	NNP
cord-005478-5iu38pr6	243	71	(	(	-LRB-
cord-005478-5iu38pr6	243	72	n=46	n=46	JJ
cord-005478-5iu38pr6	243	73	)	)	-RRB-
cord-005478-5iu38pr6	243	74	or	or	CC
cord-005478-5iu38pr6	243	75	Cy	Cy	NNP
cord-005478-5iu38pr6	243	76	(	(	-LRB-
cord-005478-5iu38pr6	243	77	n=37	n=37	JJ
cord-005478-5iu38pr6	243	78	)	)	-RRB-
cord-005478-5iu38pr6	243	79	.	.	.
cord-005478-5iu38pr6	244	1	GvHD	GvHD	NNP
cord-005478-5iu38pr6	244	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	244	3	consisted	consist	VBD
cord-005478-5iu38pr6	244	4	of	of	IN
cord-005478-5iu38pr6	244	5	calcineurin	calcineurin	JJ
cord-005478-5iu38pr6	244	6	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	244	7	combined	combine	VBN
cord-005478-5iu38pr6	244	8	with	with	IN
cord-005478-5iu38pr6	244	9	MTX	MTX	NNP
cord-005478-5iu38pr6	244	10	plus	plus	CC
cord-005478-5iu38pr6	244	11	ATG	ATG	NNP
cord-005478-5iu38pr6	244	12	in	in	IN
cord-005478-5iu38pr6	244	13	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	244	14	from	from	IN
cord-005478-5iu38pr6	244	15	unrelated	unrelated	JJ
cord-005478-5iu38pr6	244	16	donors	donor	NNS
cord-005478-5iu38pr6	244	17	.	.	.
cord-005478-5iu38pr6	245	1	Positive	positive	JJ
cord-005478-5iu38pr6	245	2	MRD	MRD	NNP
cord-005478-5iu38pr6	245	3	status	status	NN
cord-005478-5iu38pr6	245	4	before	before	IN
cord-005478-5iu38pr6	245	5	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	245	6	was	be	VBD
cord-005478-5iu38pr6	245	7	detected	detect	VBN
cord-005478-5iu38pr6	245	8	in	in	IN
cord-005478-5iu38pr6	245	9	30/72	30/72	CD
cord-005478-5iu38pr6	245	10	(	(	-LRB-
cord-005478-5iu38pr6	245	11	42	42	CD
cord-005478-5iu38pr6	245	12	%	%	NN
cord-005478-5iu38pr6	245	13	)	)	-RRB-
cord-005478-5iu38pr6	245	14	pts	pt	NNS
cord-005478-5iu38pr6	245	15	in	in	IN
cord-005478-5iu38pr6	245	16	CR1	CR1	NNP
cord-005478-5iu38pr6	245	17	and	and	CC
cord-005478-5iu38pr6	245	18	6/11	6/11	CD
cord-005478-5iu38pr6	245	19	(	(	-LRB-
cord-005478-5iu38pr6	245	20	55	55	CD
cord-005478-5iu38pr6	245	21	%	%	NN
cord-005478-5iu38pr6	245	22	)	)	-RRB-
cord-005478-5iu38pr6	245	23	pts	pt	NNS
cord-005478-5iu38pr6	245	24	in	in	IN
cord-005478-5iu38pr6	245	25	CR2	CR2	NNP
cord-005478-5iu38pr6	245	26	.	.	.
cord-005478-5iu38pr6	246	1	The	the	DT
cord-005478-5iu38pr6	246	2	MRD(-	MRD(-	NNP
cord-005478-5iu38pr6	246	3	)	)	-RRB-
cord-005478-5iu38pr6	246	4	and	and	CC
cord-005478-5iu38pr6	246	5	MRD(+	mrd(+	CD
cord-005478-5iu38pr6	246	6	)	)	-RRB-
cord-005478-5iu38pr6	246	7	groups	group	NNS
cord-005478-5iu38pr6	246	8	did	do	VBD
cord-005478-5iu38pr6	246	9	not	not	RB
cord-005478-5iu38pr6	246	10	differ	differ	VB
cord-005478-5iu38pr6	246	11	in	in	IN
cord-005478-5iu38pr6	246	12	terms	term	NNS
cord-005478-5iu38pr6	246	13	of	of	IN
cord-005478-5iu38pr6	246	14	gender	gender	NN
cord-005478-5iu38pr6	246	15	,	,	,
cord-005478-5iu38pr6	246	16	age	age	NN
cord-005478-5iu38pr6	246	17	,	,	,
cord-005478-5iu38pr6	246	18	ELN	ELN	NNP
cord-005478-5iu38pr6	246	19	cytogenetic	cytogenetic	NN
cord-005478-5iu38pr6	246	20	and	and	CC
cord-005478-5iu38pr6	246	21	molecular	molecular	JJ
cord-005478-5iu38pr6	246	22	genetic	genetic	JJ
cord-005478-5iu38pr6	246	23	risk	risk	NN
cord-005478-5iu38pr6	246	24	,	,	,
cord-005478-5iu38pr6	246	25	first	first	JJ
cord-005478-5iu38pr6	246	26	and	and	CC
cord-005478-5iu38pr6	246	27	second	second	JJ
cord-005478-5iu38pr6	246	28	CR	cr	NN
cord-005478-5iu38pr6	246	29	,	,	,
cord-005478-5iu38pr6	246	30	conditioning	conditioning	NN
cord-005478-5iu38pr6	246	31	regimen	regimen	NN
cord-005478-5iu38pr6	246	32	,	,	,
cord-005478-5iu38pr6	246	33	HSC	HSC	NNP
cord-005478-5iu38pr6	246	34	source	source	NN
cord-005478-5iu38pr6	246	35	,	,	,
cord-005478-5iu38pr6	246	36	and	and	CC
cord-005478-5iu38pr6	246	37	type	type	NN
cord-005478-5iu38pr6	246	38	of	of	IN
cord-005478-5iu38pr6	246	39	donor	donor	NN
cord-005478-5iu38pr6	246	40	.	.	.
cord-005478-5iu38pr6	247	1	The	the	DT
cord-005478-5iu38pr6	247	2	3-year	3-year	CD
cord-005478-5iu38pr6	247	3	overall	overall	JJ
cord-005478-5iu38pr6	247	4	survival	survival	NN
cord-005478-5iu38pr6	247	5	(	(	-LRB-
cord-005478-5iu38pr6	247	6	OS	OS	NNP
cord-005478-5iu38pr6	247	7	)	)	-RRB-
cord-005478-5iu38pr6	247	8	for	for	IN
cord-005478-5iu38pr6	247	9	MRD(-	mrd(-	CD
cord-005478-5iu38pr6	247	10	)	)	-RRB-
cord-005478-5iu38pr6	247	11	and	and	CC
cord-005478-5iu38pr6	247	12	MRD(+	mrd(+	CD
cord-005478-5iu38pr6	247	13	)	)	-RRB-
cord-005478-5iu38pr6	247	14	patients	patient	NNS
cord-005478-5iu38pr6	247	15	were	be	VBD
cord-005478-5iu38pr6	247	16	77	77	CD
cord-005478-5iu38pr6	247	17	%	%	NN
cord-005478-5iu38pr6	247	18	and	and	CC
cord-005478-5iu38pr6	247	19	49	49	CD
cord-005478-5iu38pr6	247	20	%	%	NN
cord-005478-5iu38pr6	247	21	(	(	-LRB-
cord-005478-5iu38pr6	247	22	log	log	NN
cord-005478-5iu38pr6	247	23	-	-	HYPH
cord-005478-5iu38pr6	247	24	rank	rank	NN
cord-005478-5iu38pr6	247	25	p=	p=	NNP
cord-005478-5iu38pr6	247	26	0.023	0.023	CD
cord-005478-5iu38pr6	247	27	)	)	-RRB-
cord-005478-5iu38pr6	247	28	.	.	.
cord-005478-5iu38pr6	248	1	The	the	DT
cord-005478-5iu38pr6	248	2	respective	respective	JJ
cord-005478-5iu38pr6	248	3	3-year	3-year	CD
cord-005478-5iu38pr6	248	4	leukemia	leukemia	NN
cord-005478-5iu38pr6	248	5	-	-	HYPH
cord-005478-5iu38pr6	248	6	free	free	JJ
cord-005478-5iu38pr6	248	7	survival	survival	NN
cord-005478-5iu38pr6	248	8	(	(	-LRB-
cord-005478-5iu38pr6	248	9	LFS	LFS	NNP
cord-005478-5iu38pr6	248	10	)	)	-RRB-
cord-005478-5iu38pr6	248	11	were	be	VBD
cord-005478-5iu38pr6	248	12	61	61	CD
cord-005478-5iu38pr6	248	13	%	%	NN
cord-005478-5iu38pr6	248	14	and	and	CC
cord-005478-5iu38pr6	248	15	37	37	CD
cord-005478-5iu38pr6	248	16	%	%	NN
cord-005478-5iu38pr6	248	17	(	(	-LRB-
cord-005478-5iu38pr6	248	18	log	log	NN
cord-005478-5iu38pr6	248	19	-	-	HYPH
cord-005478-5iu38pr6	248	20	rank	rank	NN
cord-005478-5iu38pr6	248	21	p=0.012	p=0.012	NNP
cord-005478-5iu38pr6	248	22	)	)	-RRB-
cord-005478-5iu38pr6	248	23	.	.	.
cord-005478-5iu38pr6	249	1	In	in	IN
cord-005478-5iu38pr6	249	2	univariate	univariate	JJ
cord-005478-5iu38pr6	249	3	and	and	CC
cord-005478-5iu38pr6	249	4	multivariate	multivariate	JJ
cord-005478-5iu38pr6	249	5	Cox	Cox	NNP
cord-005478-5iu38pr6	249	6	proportional	proportional	JJ
cord-005478-5iu38pr6	249	7	hazard	hazard	NN
cord-005478-5iu38pr6	249	8	model	model	NN
cord-005478-5iu38pr6	249	9	the	the	DT
cord-005478-5iu38pr6	249	10	only	only	JJ
cord-005478-5iu38pr6	249	11	significant	significant	JJ
cord-005478-5iu38pr6	249	12	adverse	adverse	JJ
cord-005478-5iu38pr6	249	13	prognostic	prognostic	JJ
cord-005478-5iu38pr6	249	14	factors	factor	NNS
cord-005478-5iu38pr6	249	15	for	for	IN
cord-005478-5iu38pr6	249	16	LFS	lfs	NN
cord-005478-5iu38pr6	249	17	were	be	VBD
cord-005478-5iu38pr6	249	18	MRD(+	MRD(+	NNS
cord-005478-5iu38pr6	249	19	)	)	-RRB-
cord-005478-5iu38pr6	250	1	(	(	-LRB-
cord-005478-5iu38pr6	250	2	HR	HR	NNP
cord-005478-5iu38pr6	250	3	2.45	2.45	CD
cord-005478-5iu38pr6	250	4	,	,	,
cord-005478-5iu38pr6	250	5	p=0	p=0	NNP
cord-005478-5iu38pr6	250	6	.025	.025	CD
cord-005478-5iu38pr6	250	7	)	)	-RRB-
cord-005478-5iu38pr6	250	8	and	and	CC
cord-005478-5iu38pr6	250	9	high	high	JJ
cord-005478-5iu38pr6	250	10	ELN	ELN	NNP
cord-005478-5iu38pr6	250	11	genetic	genetic	JJ
cord-005478-5iu38pr6	250	12	risk	risk	NN
cord-005478-5iu38pr6	250	13	(	(	-LRB-
cord-005478-5iu38pr6	250	14	HR	HR	NNP
cord-005478-5iu38pr6	250	15	3.70	3.70	CD
cord-005478-5iu38pr6	250	16	,	,	,
cord-005478-5iu38pr6	250	17	p=0.0009	p=0.0009	NNP
cord-005478-5iu38pr6	250	18	)	)	-RRB-
cord-005478-5iu38pr6	250	19	.	.	.
cord-005478-5iu38pr6	251	1	The	the	DT
cord-005478-5iu38pr6	251	2	same	same	JJ
cord-005478-5iu38pr6	251	3	factors	factor	NNS
cord-005478-5iu38pr6	251	4	significantly	significantly	RB
cord-005478-5iu38pr6	251	5	influenced	influence	VBD
cord-005478-5iu38pr6	251	6	OS	OS	NNP
cord-005478-5iu38pr6	251	7	[	[	-LRB-
cord-005478-5iu38pr6	251	8	HR	hr	NN
cord-005478-5iu38pr6	251	9	2.48	2.48	CD
cord-005478-5iu38pr6	251	10	,	,	,
cord-005478-5iu38pr6	251	11	p=0.036	p=0.036	JJ
cord-005478-5iu38pr6	251	12	and	and	CC
cord-005478-5iu38pr6	251	13	HR	HR	NNP
cord-005478-5iu38pr6	251	14	3.47	3.47	CD
cord-005478-5iu38pr6	251	15	,	,	,
cord-005478-5iu38pr6	251	16	p=0	p=0	JJ
cord-005478-5iu38pr6	251	17	.004	.004	CD
cord-005478-5iu38pr6	251	18	for	for	IN
cord-005478-5iu38pr6	251	19	MRD(+	mrd(+	CD
cord-005478-5iu38pr6	251	20	)	)	-RRB-
cord-005478-5iu38pr6	251	21	and	and	CC
cord-005478-5iu38pr6	251	22	high	high	JJ
cord-005478-5iu38pr6	251	23	ELN	ELN	NNP
cord-005478-5iu38pr6	251	24	risk	risk	NN
cord-005478-5iu38pr6	251	25	,	,	,
cord-005478-5iu38pr6	251	26	respectively	respectively	RB
cord-005478-5iu38pr6	251	27	]	]	-RRB-
cord-005478-5iu38pr6	251	28	.	.	.
cord-005478-5iu38pr6	252	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	252	2	:	:	:
cord-005478-5iu38pr6	253	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	253	2	findings	finding	NNS
cord-005478-5iu38pr6	253	3	confirm	confirm	VBP
cord-005478-5iu38pr6	253	4	that	that	IN
cord-005478-5iu38pr6	253	5	pre	pre	JJ
cord-005478-5iu38pr6	253	6	-	-	JJ
cord-005478-5iu38pr6	253	7	transplant	transplant	JJ
cord-005478-5iu38pr6	253	8	residual	residual	JJ
cord-005478-5iu38pr6	253	9	disease	disease	NN
cord-005478-5iu38pr6	253	10	at	at	IN
cord-005478-5iu38pr6	253	11	a	a	DT
cord-005478-5iu38pr6	253	12	≥	≥	CD
cord-005478-5iu38pr6	253	13	0.1	0.1	CD
cord-005478-5iu38pr6	253	14	%	%	NN
cord-005478-5iu38pr6	253	15	level	level	NN
cord-005478-5iu38pr6	253	16	assessed	assess	VBN
cord-005478-5iu38pr6	253	17	by	by	IN
cord-005478-5iu38pr6	253	18	MFC	MFC	NNP
cord-005478-5iu38pr6	253	19	is	be	VBZ
cord-005478-5iu38pr6	253	20	independent	independent	JJ
cord-005478-5iu38pr6	253	21	risk	risk	NN
cord-005478-5iu38pr6	253	22	factor	factor	NN
cord-005478-5iu38pr6	253	23	for	for	IN
cord-005478-5iu38pr6	253	24	both	both	CC
cord-005478-5iu38pr6	253	25	LFS	LFS	NNP
cord-005478-5iu38pr6	253	26	and	and	CC
cord-005478-5iu38pr6	253	27	OS	OS	NNP
cord-005478-5iu38pr6	253	28	in	in	IN
cord-005478-5iu38pr6	253	29	patients	patient	NNS
cord-005478-5iu38pr6	253	30	undergoing	undergo	VBG
cord-005478-5iu38pr6	253	31	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	253	32	.	.	.
cord-005478-5iu38pr6	254	1	In	in	IN
cord-005478-5iu38pr6	254	2	addition	addition	NN
cord-005478-5iu38pr6	254	3	,	,	,
cord-005478-5iu38pr6	254	4	the	the	DT
cord-005478-5iu38pr6	254	5	results	result	NNS
cord-005478-5iu38pr6	254	6	of	of	IN
cord-005478-5iu38pr6	254	7	our	-PRON-	PRP$
cord-005478-5iu38pr6	254	8	study	study	NN
cord-005478-5iu38pr6	254	9	show	show	NN
cord-005478-5iu38pr6	254	10	that	that	IN
cord-005478-5iu38pr6	254	11	MAC	MAC	NNP
cord-005478-5iu38pr6	254	12	alloHSCT	allohsct	NN
cord-005478-5iu38pr6	254	13	outcomes	outcome	NNS
cord-005478-5iu38pr6	254	14	in	in	IN
cord-005478-5iu38pr6	254	15	patients	patient	NNS
cord-005478-5iu38pr6	254	16	with	with	IN
cord-005478-5iu38pr6	254	17	AML	AML	NNP
cord-005478-5iu38pr6	254	18	in	in	IN
cord-005478-5iu38pr6	254	19	first	first	JJ
cord-005478-5iu38pr6	254	20	and	and	CC
cord-005478-5iu38pr6	254	21	second	second	JJ
cord-005478-5iu38pr6	254	22	CR	CR	NNP
cord-005478-5iu38pr6	254	23	are	be	VBP
cord-005478-5iu38pr6	254	24	significantly	significantly	RB
cord-005478-5iu38pr6	254	25	influenced	influence	VBN
cord-005478-5iu38pr6	254	26	by	by	IN
cord-005478-5iu38pr6	254	27	both	both	DT
cord-005478-5iu38pr6	254	28	MFC	MFC	NNP
cord-005478-5iu38pr6	254	29	-	-	HYPH
cord-005478-5iu38pr6	254	30	MRD	MRD	NNP
cord-005478-5iu38pr6	254	31	status	status	NN
cord-005478-5iu38pr6	254	32	and	and	CC
cord-005478-5iu38pr6	254	33	ELN	ELN	NNP
cord-005478-5iu38pr6	254	34	cytogenetic	cytogenetic	NN
cord-005478-5iu38pr6	254	35	and	and	CC
cord-005478-5iu38pr6	254	36	molecular	molecular	JJ
cord-005478-5iu38pr6	254	37	genetic	genetic	JJ
cord-005478-5iu38pr6	254	38	risk	risk	NN
cord-005478-5iu38pr6	254	39	.	.	.
cord-005478-5iu38pr6	255	1	[	[	-LRB-
cord-005478-5iu38pr6	255	2	[	[	-LRB-
cord-005478-5iu38pr6	255	3	O023	O023	NNP
cord-005478-5iu38pr6	255	4	Image	image	NN
cord-005478-5iu38pr6	255	5	]	]	-RRB-
cord-005478-5iu38pr6	255	6	1	1	CD
cord-005478-5iu38pr6	255	7	.	.	.
cord-005478-5iu38pr6	256	1	Leukemia	leukemia	NN
cord-005478-5iu38pr6	256	2	-	-	HYPH
cord-005478-5iu38pr6	256	3	free	free	JJ
cord-005478-5iu38pr6	256	4	survival	survival	NN
cord-005478-5iu38pr6	256	5	according	accord	VBG
cord-005478-5iu38pr6	256	6	to	to	IN
cord-005478-5iu38pr6	256	7	pre	pre	JJ
cord-005478-5iu38pr6	256	8	-	-	JJ
cord-005478-5iu38pr6	256	9	transplant	transplant	JJ
cord-005478-5iu38pr6	256	10	minimal	minimal	JJ
cord-005478-5iu38pr6	256	11	residual	residual	JJ
cord-005478-5iu38pr6	256	12	disease	disease	NN
cord-005478-5iu38pr6	256	13	level	level	NN
cord-005478-5iu38pr6	256	14	]	]	-RRB-
cord-005478-5iu38pr6	257	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	257	2	:	:	:
cord-005478-5iu38pr6	258	1	Nothing	nothing	NN
cord-005478-5iu38pr6	258	2	to	to	TO
cord-005478-5iu38pr6	258	3	declare	declare	VB
cord-005478-5iu38pr6	258	4	O024	O024	NNP
cord-005478-5iu38pr6	258	5	Second	second	JJ
cord-005478-5iu38pr6	258	6	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	258	7	stem	stem	NN
cord-005478-5iu38pr6	258	8	cell	cell	NN
cord-005478-5iu38pr6	258	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	258	10	in	in	IN
cord-005478-5iu38pr6	258	11	acute	acute	JJ
cord-005478-5iu38pr6	258	12	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	258	13	leukemia	leukemia	NN
cord-005478-5iu38pr6	258	14	patients	patient	NNS
cord-005478-5iu38pr6	258	15	in	in	IN
cord-005478-5iu38pr6	258	16	second	second	JJ
cord-005478-5iu38pr6	258	17	complete	complete	JJ
cord-005478-5iu38pr6	258	18	remission	remission	NN
cord-005478-5iu38pr6	258	19	or	or	CC
cord-005478-5iu38pr6	258	20	relapse	relapse	NN
cord-005478-5iu38pr6	258	21	:	:	:
cord-005478-5iu38pr6	259	1	A	a	DT
cord-005478-5iu38pr6	259	2	study	study	NN
cord-005478-5iu38pr6	259	3	on	on	IN
cord-005478-5iu38pr6	259	4	behalf	behalf	NN
cord-005478-5iu38pr6	259	5	of	of	IN
cord-005478-5iu38pr6	259	6	the	the	DT
cord-005478-5iu38pr6	259	7	ALWP	ALWP	NNP
cord-005478-5iu38pr6	259	8	/	/	SYM
cord-005478-5iu38pr6	259	9	EBMT	EBMT	NNP
cord-005478-5iu38pr6	259	10	Background	Background	NNP
cord-005478-5iu38pr6	259	11	:	:	:
cord-005478-5iu38pr6	260	1	Second	second	JJ
cord-005478-5iu38pr6	260	2	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	260	3	transplantation	transplantation	NN
cord-005478-5iu38pr6	260	4	(	(	-LRB-
cord-005478-5iu38pr6	260	5	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	260	6	)	)	-RRB-
cord-005478-5iu38pr6	260	7	is	be	VBZ
cord-005478-5iu38pr6	260	8	a	a	DT
cord-005478-5iu38pr6	260	9	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	260	10	option	option	NN
cord-005478-5iu38pr6	260	11	for	for	IN
cord-005478-5iu38pr6	260	12	patients	patient	NNS
cord-005478-5iu38pr6	260	13	(	(	-LRB-
cord-005478-5iu38pr6	260	14	pts	pts	NN
cord-005478-5iu38pr6	260	15	)	)	-RRB-
cord-005478-5iu38pr6	260	16	relapsing	relapse	VBG
cord-005478-5iu38pr6	260	17	(	(	-LRB-
cord-005478-5iu38pr6	260	18	Rel	Rel	NNP
cord-005478-5iu38pr6	260	19	)	)	-RRB-
cord-005478-5iu38pr6	260	20	after	after	IN
cord-005478-5iu38pr6	260	21	first	first	JJ
cord-005478-5iu38pr6	260	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	260	23	(	(	-LRB-
cord-005478-5iu38pr6	260	24	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	260	25	)	)	-RRB-
cord-005478-5iu38pr6	261	1	however	however	RB
cord-005478-5iu38pr6	261	2	most	most	JJS
cord-005478-5iu38pr6	261	3	of	of	IN
cord-005478-5iu38pr6	261	4	the	the	DT
cord-005478-5iu38pr6	261	5	available	available	JJ
cord-005478-5iu38pr6	261	6	data	data	NN
cord-005478-5iu38pr6	261	7	is	be	VBZ
cord-005478-5iu38pr6	261	8	in	in	IN
cord-005478-5iu38pr6	261	9	acute	acute	JJ
cord-005478-5iu38pr6	261	10	myelogenous	myelogenous	NN
cord-005478-5iu38pr6	261	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	261	12	(	(	-LRB-
cord-005478-5iu38pr6	261	13	AML	AML	NNP
cord-005478-5iu38pr6	261	14	)	)	-RRB-
cord-005478-5iu38pr6	261	15	and	and	CC
cord-005478-5iu38pr6	261	16	there	there	EX
cord-005478-5iu38pr6	261	17	is	be	VBZ
cord-005478-5iu38pr6	261	18	very	very	RB
cord-005478-5iu38pr6	261	19	limited	limited	JJ
cord-005478-5iu38pr6	261	20	data	datum	NNS
cord-005478-5iu38pr6	261	21	on	on	IN
cord-005478-5iu38pr6	261	22	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	262	1	in	in	IN
cord-005478-5iu38pr6	262	2	patients	patient	NNS
cord-005478-5iu38pr6	262	3	(	(	-LRB-
cord-005478-5iu38pr6	262	4	pts	pt	NNS
cord-005478-5iu38pr6	262	5	)	)	-RRB-
cord-005478-5iu38pr6	262	6	with	with	IN
cord-005478-5iu38pr6	262	7	ALL	all	DT
cord-005478-5iu38pr6	262	8	.	.	.
cord-005478-5iu38pr6	263	1	Therefore	therefore	RB
cord-005478-5iu38pr6	263	2	,	,	,
cord-005478-5iu38pr6	263	3	the	the	DT
cord-005478-5iu38pr6	263	4	ALWP	ALWP	NNP
cord-005478-5iu38pr6	263	5	of	of	IN
cord-005478-5iu38pr6	263	6	the	the	DT
cord-005478-5iu38pr6	263	7	EBMT	EBMT	NNP
cord-005478-5iu38pr6	263	8	performed	perform	VBD
cord-005478-5iu38pr6	263	9	a	a	DT
cord-005478-5iu38pr6	263	10	large	large	JJ
cord-005478-5iu38pr6	263	11	registry	registry	NN
cord-005478-5iu38pr6	263	12	analysis	analysis	NN
cord-005478-5iu38pr6	263	13	to	to	TO
cord-005478-5iu38pr6	263	14	study	study	VB
cord-005478-5iu38pr6	263	15	the	the	DT
cord-005478-5iu38pr6	263	16	outcome	outcome	NN
cord-005478-5iu38pr6	263	17	of	of	IN
cord-005478-5iu38pr6	263	18	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	263	19	in	in	IN
cord-005478-5iu38pr6	263	20	pts	pt	NNS
cord-005478-5iu38pr6	263	21	with	with	IN
cord-005478-5iu38pr6	263	22	ALL	all	DT
cord-005478-5iu38pr6	263	23	.	.	.
cord-005478-5iu38pr6	264	1	Methods	method	NNS
cord-005478-5iu38pr6	264	2	:	:	:
cord-005478-5iu38pr6	264	3	We	-PRON-	PRP
cord-005478-5iu38pr6	264	4	studied	study	VBD
cord-005478-5iu38pr6	264	5	245	245	CD
cord-005478-5iu38pr6	264	6	pts	pt	NNS
cord-005478-5iu38pr6	264	7	receiving	receive	VBG
cord-005478-5iu38pr6	264	8	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	264	9	as	as	IN
cord-005478-5iu38pr6	264	10	a	a	DT
cord-005478-5iu38pr6	264	11	salvage	salvage	NN
cord-005478-5iu38pr6	264	12	treatment	treatment	NN
cord-005478-5iu38pr6	264	13	between	between	IN
cord-005478-5iu38pr6	264	14	the	the	DT
cord-005478-5iu38pr6	264	15	years	year	NNS
cord-005478-5iu38pr6	264	16	(	(	-LRB-
cord-005478-5iu38pr6	264	17	y	y	NN
cord-005478-5iu38pr6	264	18	)	)	-RRB-
cord-005478-5iu38pr6	264	19	2000	2000	CD
cord-005478-5iu38pr6	264	20	-	-	SYM
cord-005478-5iu38pr6	264	21	2017	2017	CD
cord-005478-5iu38pr6	264	22	for	for	IN
cord-005478-5iu38pr6	264	23	Rel	Rel	NNP
cord-005478-5iu38pr6	264	24	following	follow	VBG
cord-005478-5iu38pr6	265	1	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	265	2	in	in	IN
cord-005478-5iu38pr6	265	3	CR1	CR1	NNP
cord-005478-5iu38pr6	265	4	.	.	.
cord-005478-5iu38pr6	266	1	Median	median	JJ
cord-005478-5iu38pr6	266	2	follow	follow	NN
cord-005478-5iu38pr6	266	3	-	-	HYPH
cord-005478-5iu38pr6	266	4	up	up	NN
cord-005478-5iu38pr6	266	5	of	of	IN
cord-005478-5iu38pr6	266	6	surviving	survive	VBG
cord-005478-5iu38pr6	266	7	pts	pts	NN
cord-005478-5iu38pr6	266	8	was	be	VBD
cord-005478-5iu38pr6	266	9	58	58	CD
cord-005478-5iu38pr6	266	10	months	month	NNS
cord-005478-5iu38pr6	267	1	(	(	-LRB-
cord-005478-5iu38pr6	267	2	IQR	iqr	NN
cord-005478-5iu38pr6	267	3	:	:	:
cord-005478-5iu38pr6	267	4	24	24	CD
cord-005478-5iu38pr6	267	5	-	-	SYM
cord-005478-5iu38pr6	267	6	98	98	CD
cord-005478-5iu38pr6	267	7	)	)	-RRB-
cord-005478-5iu38pr6	267	8	.	.	.
cord-005478-5iu38pr6	268	1	Results	result	NNS
cord-005478-5iu38pr6	268	2	:	:	:
cord-005478-5iu38pr6	269	1	142	142	CD
cord-005478-5iu38pr6	269	2	pts	pt	NNS
cord-005478-5iu38pr6	269	3	(	(	-LRB-
cord-005478-5iu38pr6	269	4	58	58	CD
cord-005478-5iu38pr6	269	5	%	%	NN
cord-005478-5iu38pr6	269	6	)	)	-RRB-
cord-005478-5iu38pr6	269	7	were	be	VBD
cord-005478-5iu38pr6	269	8	males	male	NNS
cord-005478-5iu38pr6	269	9	and	and	CC
cord-005478-5iu38pr6	269	10	median	median	JJ
cord-005478-5iu38pr6	269	11	age	age	NN
cord-005478-5iu38pr6	269	12	at	at	IN
cord-005478-5iu38pr6	269	13	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	269	14	was	be	VBD
cord-005478-5iu38pr6	269	15	34.6	34.6	CD
cord-005478-5iu38pr6	269	16	years	year	NNS
cord-005478-5iu38pr6	270	1	(	(	-LRB-
cord-005478-5iu38pr6	270	2	range	range	NN
cord-005478-5iu38pr6	270	3	:	:	:
cord-005478-5iu38pr6	270	4	18	18	CD
cord-005478-5iu38pr6	270	5	-	-	SYM
cord-005478-5iu38pr6	270	6	74	74	CD
cord-005478-5iu38pr6	270	7	)	)	-RRB-
cord-005478-5iu38pr6	270	8	.	.	.
cord-005478-5iu38pr6	271	1	Median	median	JJ
cord-005478-5iu38pr6	271	2	time	time	NN
cord-005478-5iu38pr6	271	3	from	from	IN
cord-005478-5iu38pr6	271	4	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	271	5	to	to	IN
cord-005478-5iu38pr6	271	6	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	271	7	was	be	VBD
cord-005478-5iu38pr6	271	8	463	463	CD
cord-005478-5iu38pr6	271	9	(	(	-LRB-
cord-005478-5iu38pr6	271	10	63	63	CD
cord-005478-5iu38pr6	271	11	-	-	SYM
cord-005478-5iu38pr6	271	12	5482	5482	CD
cord-005478-5iu38pr6	271	13	)	)	-RRB-
cord-005478-5iu38pr6	271	14	days	day	NNS
cord-005478-5iu38pr6	271	15	(	(	-LRB-
cord-005478-5iu38pr6	271	16	d	d	NN
cord-005478-5iu38pr6	271	17	)	)	-RRB-
cord-005478-5iu38pr6	271	18	and	and	CC
cord-005478-5iu38pr6	271	19	from	from	IN
cord-005478-5iu38pr6	271	20	Rel	Rel	NNP
cord-005478-5iu38pr6	271	21	to	to	IN
cord-005478-5iu38pr6	271	22	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	272	1	it	-PRON-	PRP
cord-005478-5iu38pr6	272	2	was	be	VBD
cord-005478-5iu38pr6	272	3	114	114	CD
cord-005478-5iu38pr6	272	4	(	(	-LRB-
cord-005478-5iu38pr6	272	5	15	15	CD
cord-005478-5iu38pr6	272	6	-	-	SYM
cord-005478-5iu38pr6	272	7	348	348	CD
cord-005478-5iu38pr6	272	8	)	)	-RRB-
cord-005478-5iu38pr6	273	1	d.	d.	NNP
cord-005478-5iu38pr6	274	1	At	at	IN
cord-005478-5iu38pr6	274	2	the	the	DT
cord-005478-5iu38pr6	274	3	time	time	NN
cord-005478-5iu38pr6	274	4	of	of	IN
cord-005478-5iu38pr6	274	5	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	274	6	157(64	157(64	CD
cord-005478-5iu38pr6	274	7	%	%	NN
cord-005478-5iu38pr6	274	8	)	)	-RRB-
cord-005478-5iu38pr6	274	9	pts	pt	NNS
cord-005478-5iu38pr6	274	10	were	be	VBD
cord-005478-5iu38pr6	274	11	in	in	IN
cord-005478-5iu38pr6	274	12	CR2	CR2	NNP
cord-005478-5iu38pr6	274	13	while	while	IN
cord-005478-5iu38pr6	274	14	88	88	CD
cord-005478-5iu38pr6	274	15	(	(	-LRB-
cord-005478-5iu38pr6	274	16	36	36	CD
cord-005478-5iu38pr6	274	17	%	%	NN
cord-005478-5iu38pr6	274	18	)	)	-RRB-
cord-005478-5iu38pr6	274	19	had	have	VBD
cord-005478-5iu38pr6	274	20	advanced	advance	VBN
cord-005478-5iu38pr6	274	21	disease.101	disease.101	NNP
cord-005478-5iu38pr6	275	1	(	(	-LRB-
cord-005478-5iu38pr6	275	2	41	41	CD
cord-005478-5iu38pr6	275	3	%	%	NN
cord-005478-5iu38pr6	275	4	)	)	-RRB-
cord-005478-5iu38pr6	275	5	pts	pt	NNS
cord-005478-5iu38pr6	275	6	received	receive	VBD
cord-005478-5iu38pr6	275	7	sibling	sibling	NN
cord-005478-5iu38pr6	275	8	donor	donor	NN
cord-005478-5iu38pr6	275	9	(	(	-LRB-
cord-005478-5iu38pr6	275	10	MSD	MSD	NNP
cord-005478-5iu38pr6	275	11	)	)	-RRB-
cord-005478-5iu38pr6	275	12	and	and	CC
cord-005478-5iu38pr6	275	13	144	144	CD
cord-005478-5iu38pr6	275	14	(	(	-LRB-
cord-005478-5iu38pr6	275	15	59	59	CD
cord-005478-5iu38pr6	275	16	%	%	NN
cord-005478-5iu38pr6	275	17	)	)	-RRB-
cord-005478-5iu38pr6	275	18	unrelated	unrelated	JJ
cord-005478-5iu38pr6	275	19	donor	donor	NN
cord-005478-5iu38pr6	275	20	(	(	-LRB-
cord-005478-5iu38pr6	275	21	UD	UD	NNP
cord-005478-5iu38pr6	275	22	)	)	-RRB-
cord-005478-5iu38pr6	275	23	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	276	1	(	(	-LRB-
cord-005478-5iu38pr6	276	2	10/10	10/10	CD
cord-005478-5iu38pr6	276	3	-	-	SYM
cord-005478-5iu38pr6	276	4	63	63	CD
cord-005478-5iu38pr6	276	5	;	;	:
cord-005478-5iu38pr6	276	6	9/10	9/10	CD
cord-005478-5iu38pr6	276	7	-	-	SYM
cord-005478-5iu38pr6	276	8	10	10	CD
cord-005478-5iu38pr6	276	9	,	,	,
cord-005478-5iu38pr6	276	10	missing	miss	VBG
cord-005478-5iu38pr6	276	11	HLA-71	HLA-71	NNP
cord-005478-5iu38pr6	276	12	)	)	-RRB-
cord-005478-5iu38pr6	276	13	.	.	.
cord-005478-5iu38pr6	277	1	In	in	IN
cord-005478-5iu38pr6	277	2	34	34	CD
cord-005478-5iu38pr6	277	3	%	%	NN
cord-005478-5iu38pr6	277	4	of	of	IN
cord-005478-5iu38pr6	277	5	pts	pt	NNS
cord-005478-5iu38pr6	277	6	with	with	IN
cord-005478-5iu38pr6	277	7	available	available	JJ
cord-005478-5iu38pr6	277	8	data	datum	NNS
cord-005478-5iu38pr6	277	9	the	the	DT
cord-005478-5iu38pr6	277	10	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	277	11	was	be	VBD
cord-005478-5iu38pr6	277	12	performed	perform	VBN
cord-005478-5iu38pr6	277	13	from	from	IN
cord-005478-5iu38pr6	277	14	the	the	DT
cord-005478-5iu38pr6	277	15	same	same	JJ
cord-005478-5iu38pr6	277	16	donor	donor	NN
cord-005478-5iu38pr6	277	17	.	.	.
cord-005478-5iu38pr6	278	1	The	the	DT
cord-005478-5iu38pr6	278	2	majority	majority	NN
cord-005478-5iu38pr6	278	3	of	of	IN
cord-005478-5iu38pr6	278	4	pts	pt	NNS
cord-005478-5iu38pr6	278	5	with	with	IN
cord-005478-5iu38pr6	278	6	available	available	JJ
cord-005478-5iu38pr6	278	7	MRD	MRD	NNP
cord-005478-5iu38pr6	278	8	data	datum	NNS
cord-005478-5iu38pr6	278	9	transplanted	transplant	VBN
cord-005478-5iu38pr6	278	10	in	in	IN
cord-005478-5iu38pr6	278	11	CR2	CR2	NNP
cord-005478-5iu38pr6	278	12	(	(	-LRB-
cord-005478-5iu38pr6	278	13	64/84	64/84	CD
cord-005478-5iu38pr6	278	14	pts	pts	NN
cord-005478-5iu38pr6	278	15	)	)	-RRB-
cord-005478-5iu38pr6	278	16	were	be	VBD
cord-005478-5iu38pr6	278	17	MRD	MRD	NNP
cord-005478-5iu38pr6	278	18	negative	negative	JJ
cord-005478-5iu38pr6	278	19	pre	pre	NNP
cord-005478-5iu38pr6	278	20	-	-	JJ
cord-005478-5iu38pr6	278	21	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	278	22	.	.	.
cord-005478-5iu38pr6	279	1	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	279	2	performance	performance	NN
cord-005478-5iu38pr6	279	3	status	status	NN
cord-005478-5iu38pr6	279	4	was	be	VBD
cord-005478-5iu38pr6	279	5	>	>	XX
cord-005478-5iu38pr6	279	6	90	90	CD
cord-005478-5iu38pr6	279	7	in	in	IN
cord-005478-5iu38pr6	279	8	60	60	CD
cord-005478-5iu38pr6	279	9	%	%	NN
cord-005478-5iu38pr6	279	10	of	of	IN
cord-005478-5iu38pr6	279	11	pts	pt	NNS
cord-005478-5iu38pr6	279	12	.	.	.
cord-005478-5iu38pr6	280	1	93	93	CD
cord-005478-5iu38pr6	280	2	%	%	NN
cord-005478-5iu38pr6	280	3	were	be	VBD
cord-005478-5iu38pr6	280	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	280	5	with	with	IN
cord-005478-5iu38pr6	280	6	PB	PB	NNP
cord-005478-5iu38pr6	280	7	graft	graft	NN
cord-005478-5iu38pr6	280	8	.	.	.
cord-005478-5iu38pr6	281	1	204	204	CD
cord-005478-5iu38pr6	281	2	(	(	-LRB-
cord-005478-5iu38pr6	281	3	83	83	CD
cord-005478-5iu38pr6	281	4	%	%	NN
cord-005478-5iu38pr6	281	5	)	)	-RRB-
cord-005478-5iu38pr6	281	6	pts	pt	NNS
cord-005478-5iu38pr6	281	7	received	receive	VBD
cord-005478-5iu38pr6	281	8	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	281	9	based	base	VBN
cord-005478-5iu38pr6	281	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	281	11	(	(	-LRB-
cord-005478-5iu38pr6	281	12	reduced	reduce	VBN
cord-005478-5iu38pr6	281	13	intensity	intensity	NN
cord-005478-5iu38pr6	281	14	63	63	CD
cord-005478-5iu38pr6	281	15	%	%	NN
cord-005478-5iu38pr6	281	16	,	,	,
cord-005478-5iu38pr6	281	17	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	281	18	37	37	CD
cord-005478-5iu38pr6	281	19	%	%	NN
cord-005478-5iu38pr6	281	20	)	)	-RRB-
cord-005478-5iu38pr6	281	21	while	while	IN
cord-005478-5iu38pr6	281	22	it	-PRON-	PRP
cord-005478-5iu38pr6	281	23	was	be	VBD
cord-005478-5iu38pr6	281	24	TBI	TBI	NNP
cord-005478-5iu38pr6	281	25	based	base	VBN
cord-005478-5iu38pr6	281	26	in	in	IN
cord-005478-5iu38pr6	281	27	41(17	41(17	CD
cord-005478-5iu38pr6	281	28	%	%	NN
cord-005478-5iu38pr6	281	29	)	)	-RRB-
cord-005478-5iu38pr6	281	30	pts	pts	NN
cord-005478-5iu38pr6	281	31	.	.	.
cord-005478-5iu38pr6	282	1	109	109	CD
cord-005478-5iu38pr6	282	2	(	(	-LRB-
cord-005478-5iu38pr6	282	3	52	52	CD
cord-005478-5iu38pr6	282	4	%	%	NN
cord-005478-5iu38pr6	282	5	)	)	-RRB-
cord-005478-5iu38pr6	282	6	pts	pt	NNS
cord-005478-5iu38pr6	282	7	received	receive	VBN
cord-005478-5iu38pr6	282	8	in	in	IN
cord-005478-5iu38pr6	282	9	vivo	vivo	NNP
cord-005478-5iu38pr6	282	10	T	t	NN
cord-005478-5iu38pr6	282	11	-	-	HYPH
cord-005478-5iu38pr6	282	12	cell	cell	NN
cord-005478-5iu38pr6	282	13	depleted	deplete	VBN
cord-005478-5iu38pr6	282	14	(	(	-LRB-
cord-005478-5iu38pr6	282	15	TCD	TCD	NNP
cord-005478-5iu38pr6	282	16	)	)	-RRB-
cord-005478-5iu38pr6	282	17	grafts	graft	NNS
cord-005478-5iu38pr6	282	18	.	.	.
cord-005478-5iu38pr6	283	1	94	94	CD
cord-005478-5iu38pr6	283	2	%	%	NN
cord-005478-5iu38pr6	283	3	of	of	IN
cord-005478-5iu38pr6	283	4	the	the	DT
cord-005478-5iu38pr6	283	5	pts	pts	NN
cord-005478-5iu38pr6	283	6	engrafted	engraft	VBN
cord-005478-5iu38pr6	283	7	.	.	.
cord-005478-5iu38pr6	284	1	Acute	acute	JJ
cord-005478-5iu38pr6	284	2	graft	graft	NN
cord-005478-5iu38pr6	284	3	-	-	HYPH
cord-005478-5iu38pr6	284	4	versus	versus	IN
cord-005478-5iu38pr6	284	5	-	-	HYPH
cord-005478-5iu38pr6	284	6	host	host	NN
cord-005478-5iu38pr6	284	7	disease	disease	NN
cord-005478-5iu38pr6	284	8	(	(	-LRB-
cord-005478-5iu38pr6	284	9	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	284	10	)	)	-RRB-
cord-005478-5iu38pr6	285	1	≥	≥	NNP
cord-005478-5iu38pr6	285	2	II	II	NNP
cord-005478-5iu38pr6	285	3	and	and	CC
cord-005478-5iu38pr6	285	4	≥	≥	NNP
cord-005478-5iu38pr6	285	5	III	III	NNP
cord-005478-5iu38pr6	285	6	-	-	HYPH
cord-005478-5iu38pr6	285	7	IV	IV	NNP
cord-005478-5iu38pr6	285	8	occurred	occur	VBD
cord-005478-5iu38pr6	285	9	in	in	IN
cord-005478-5iu38pr6	285	10	33	33	CD
cord-005478-5iu38pr6	285	11	%	%	NN
cord-005478-5iu38pr6	285	12	and	and	CC
cord-005478-5iu38pr6	285	13	17	17	CD
cord-005478-5iu38pr6	285	14	%	%	NN
cord-005478-5iu38pr6	285	15	of	of	IN
cord-005478-5iu38pr6	285	16	the	the	DT
cord-005478-5iu38pr6	285	17	pts	pts	NN
cord-005478-5iu38pr6	285	18	.	.	.
cord-005478-5iu38pr6	286	1	Incidence	incidence	NN
cord-005478-5iu38pr6	286	2	of	of	IN
cord-005478-5iu38pr6	286	3	2y	2y	CD
cord-005478-5iu38pr6	286	4	total	total	JJ
cord-005478-5iu38pr6	286	5	and	and	CC
cord-005478-5iu38pr6	286	6	extensive	extensive	JJ
cord-005478-5iu38pr6	286	7	chronic	chronic	JJ
cord-005478-5iu38pr6	286	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	286	9	was	be	VBD
cord-005478-5iu38pr6	286	10	38	38	CD
cord-005478-5iu38pr6	286	11	%	%	NN
cord-005478-5iu38pr6	286	12	and	and	CC
cord-005478-5iu38pr6	286	13	19	19	CD
cord-005478-5iu38pr6	286	14	%	%	NN
cord-005478-5iu38pr6	286	15	,	,	,
cord-005478-5iu38pr6	286	16	respectively	respectively	RB
cord-005478-5iu38pr6	286	17	.	.	.
cord-005478-5iu38pr6	287	1	Main	main	JJ
cord-005478-5iu38pr6	287	2	causes	cause	NNS
cord-005478-5iu38pr6	287	3	of	of	IN
cord-005478-5iu38pr6	287	4	death	death	NN
cord-005478-5iu38pr6	287	5	were	be	VBD
cord-005478-5iu38pr6	287	6	leukemia	leukemia	NN
cord-005478-5iu38pr6	287	7	recurrence	recurrence	NN
cord-005478-5iu38pr6	287	8	in	in	IN
cord-005478-5iu38pr6	287	9	54	54	CD
cord-005478-5iu38pr6	287	10	%	%	NN
cord-005478-5iu38pr6	287	11	,	,	,
cord-005478-5iu38pr6	287	12	GVHD	GVHD	NNP
cord-005478-5iu38pr6	287	13	in	in	IN
cord-005478-5iu38pr6	287	14	18	18	CD
cord-005478-5iu38pr6	287	15	%	%	NN
cord-005478-5iu38pr6	287	16	and	and	CC
cord-005478-5iu38pr6	287	17	infections	infection	NNS
cord-005478-5iu38pr6	287	18	in	in	IN
cord-005478-5iu38pr6	287	19	19	19	CD
cord-005478-5iu38pr6	287	20	%	%	NN
cord-005478-5iu38pr6	287	21	.	.	.
cord-005478-5iu38pr6	288	1	At	at	IN
cord-005478-5iu38pr6	288	2	2	2	CD
cord-005478-5iu38pr6	288	3	and	and	CC
cord-005478-5iu38pr6	288	4	5	5	CD
cord-005478-5iu38pr6	288	5	y	y	NNP
cord-005478-5iu38pr6	288	6	,	,	,
cord-005478-5iu38pr6	288	7	the	the	DT
cord-005478-5iu38pr6	288	8	cumulative	cumulative	JJ
cord-005478-5iu38pr6	288	9	incidence	incidence	NN
cord-005478-5iu38pr6	288	10	of	of	IN
cord-005478-5iu38pr6	288	11	NRM	NRM	NNP
cord-005478-5iu38pr6	288	12	,	,	,
cord-005478-5iu38pr6	288	13	RI	RI	NNP
cord-005478-5iu38pr6	288	14	,	,	,
cord-005478-5iu38pr6	288	15	LFS	LFS	NNP
cord-005478-5iu38pr6	288	16	,	,	,
cord-005478-5iu38pr6	288	17	OS	OS	NNP
cord-005478-5iu38pr6	288	18	and	and	CC
cord-005478-5iu38pr6	288	19	GRFS	GRFS	NNP
cord-005478-5iu38pr6	288	20	were	be	VBD
cord-005478-5iu38pr6	288	21	24	24	CD
cord-005478-5iu38pr6	288	22	%	%	NN
cord-005478-5iu38pr6	288	23	&	&	CC
cord-005478-5iu38pr6	288	24	26	26	CD
cord-005478-5iu38pr6	288	25	%	%	NN
cord-005478-5iu38pr6	288	26	:	:	:
cord-005478-5iu38pr6	288	27	56	56	CD
cord-005478-5iu38pr6	288	28	%	%	NN
cord-005478-5iu38pr6	288	29	&	&	CC
cord-005478-5iu38pr6	288	30	62	62	CD
cord-005478-5iu38pr6	288	31	%	%	NN
cord-005478-5iu38pr6	288	32	,	,	,
cord-005478-5iu38pr6	288	33	20	20	CD
cord-005478-5iu38pr6	288	34	%	%	NN
cord-005478-5iu38pr6	288	35	&	&	CC
cord-005478-5iu38pr6	288	36	12	12	CD
cord-005478-5iu38pr6	288	37	%	%	NN
cord-005478-5iu38pr6	288	38	,	,	,
cord-005478-5iu38pr6	288	39	30	30	CD
cord-005478-5iu38pr6	288	40	%	%	NN
cord-005478-5iu38pr6	288	41	&	&	CC
cord-005478-5iu38pr6	288	42	14	14	CD
cord-005478-5iu38pr6	288	43	%	%	NN
cord-005478-5iu38pr6	288	44	and	and	CC
cord-005478-5iu38pr6	288	45	12	12	CD
cord-005478-5iu38pr6	288	46	%	%	NN
cord-005478-5iu38pr6	288	47	&	&	CC
cord-005478-5iu38pr6	288	48	7	7	CD
cord-005478-5iu38pr6	288	49	%	%	NN
cord-005478-5iu38pr6	288	50	,	,	,
cord-005478-5iu38pr6	288	51	respectively	respectively	RB
cord-005478-5iu38pr6	288	52	.	.	.
cord-005478-5iu38pr6	289	1	In	in	IN
cord-005478-5iu38pr6	289	2	MVA	MVA	NNP
cord-005478-5iu38pr6	289	3	no	no	DT
cord-005478-5iu38pr6	289	4	factor	factor	NN
cord-005478-5iu38pr6	289	5	predict	predict	VB
cord-005478-5iu38pr6	289	6	NRM	NRM	NNP
cord-005478-5iu38pr6	289	7	.	.	.
cord-005478-5iu38pr6	290	1	In	in	IN
cord-005478-5iu38pr6	290	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	290	3	analysis	analysis	NN
cord-005478-5iu38pr6	290	4	,	,	,
cord-005478-5iu38pr6	290	5	RI	RI	NNP
cord-005478-5iu38pr6	290	6	was	be	VBD
cord-005478-5iu38pr6	290	7	independently	independently	RB
cord-005478-5iu38pr6	290	8	associated	associate	VBN
cord-005478-5iu38pr6	290	9	with	with	IN
cord-005478-5iu38pr6	290	10	time	time	NN
cord-005478-5iu38pr6	290	11	from	from	IN
cord-005478-5iu38pr6	290	12	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	290	13	to	to	IN
cord-005478-5iu38pr6	290	14	Rel	Rel	NNP
cord-005478-5iu38pr6	290	15	,	,	,
cord-005478-5iu38pr6	290	16	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	290	17	≥II	≥II	NNP
cord-005478-5iu38pr6	290	18	after	after	IN
cord-005478-5iu38pr6	290	19	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	290	20	and	and	CC
cord-005478-5iu38pr6	290	21	in	in	IN
cord-005478-5iu38pr6	290	22	vivo	vivo	NNP
cord-005478-5iu38pr6	290	23	TCD	TCD	NNP
cord-005478-5iu38pr6	290	24	and	and	CC
cord-005478-5iu38pr6	290	25	LFS	LFS	NNP
cord-005478-5iu38pr6	290	26	the	the	DT
cord-005478-5iu38pr6	290	27	prognostic	prognostic	JJ
cord-005478-5iu38pr6	290	28	factors	factor	NNS
cord-005478-5iu38pr6	290	29	were	be	VBD
cord-005478-5iu38pr6	290	30	time	time	NN
cord-005478-5iu38pr6	290	31	from	from	IN
cord-005478-5iu38pr6	290	32	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	290	33	to	to	IN
cord-005478-5iu38pr6	290	34	Rel	Rel	NNP
cord-005478-5iu38pr6	290	35	and	and	CC
cord-005478-5iu38pr6	290	36	KPS≥90	KPS≥90	NNPS
cord-005478-5iu38pr6	290	37	at	at	IN
cord-005478-5iu38pr6	290	38	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	290	39	.	.	.
cord-005478-5iu38pr6	291	1	Factors	factor	NNS
cord-005478-5iu38pr6	291	2	associated	associate	VBN
cord-005478-5iu38pr6	291	3	with	with	IN
cord-005478-5iu38pr6	291	4	OS	OS	NNP
cord-005478-5iu38pr6	291	5	were	be	VBD
cord-005478-5iu38pr6	291	6	age	age	NN
cord-005478-5iu38pr6	291	7	(	(	-LRB-
cord-005478-5iu38pr6	291	8	per	per	IN
cord-005478-5iu38pr6	291	9	10	10	CD
cord-005478-5iu38pr6	291	10	years	year	NNS
cord-005478-5iu38pr6	291	11	)	)	-RRB-
cord-005478-5iu38pr6	291	12	,	,	,
cord-005478-5iu38pr6	291	13	time	time	NN
cord-005478-5iu38pr6	291	14	from	from	IN
cord-005478-5iu38pr6	291	15	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	291	16	to	to	IN
cord-005478-5iu38pr6	291	17	Rel	Rel	NNP
cord-005478-5iu38pr6	291	18	,	,	,
cord-005478-5iu38pr6	291	19	RIC	RIC	NNP
cord-005478-5iu38pr6	291	20	at	at	IN
cord-005478-5iu38pr6	291	21	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	291	22	,	,	,
cord-005478-5iu38pr6	291	23	KPS>90	kps>90	JJ
cord-005478-5iu38pr6	291	24	at	at	IN
cord-005478-5iu38pr6	291	25	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	291	26	and	and	CC
cord-005478-5iu38pr6	291	27	UD	UD	NNP
cord-005478-5iu38pr6	291	28	vs	vs	IN
cord-005478-5iu38pr6	291	29	MSD	MSD	NNP
cord-005478-5iu38pr6	291	30	.	.	.
cord-005478-5iu38pr6	292	1	Longer	long	JJR
cord-005478-5iu38pr6	292	2	time	time	NN
cord-005478-5iu38pr6	292	3	internal	internal	JJ
cord-005478-5iu38pr6	292	4	from	from	IN
cord-005478-5iu38pr6	292	5	Rel	Rel	NNP
cord-005478-5iu38pr6	292	6	to	to	IN
cord-005478-5iu38pr6	292	7	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	293	1	and	and	CC
cord-005478-5iu38pr6	293	2	in	in	IN
cord-005478-5iu38pr6	293	3	vivo	vivo	NNP
cord-005478-5iu38pr6	293	4	TCD	TCD	NNP
cord-005478-5iu38pr6	293	5	was	be	VBD
cord-005478-5iu38pr6	293	6	associated	associate	VBN
cord-005478-5iu38pr6	293	7	with	with	IN
cord-005478-5iu38pr6	293	8	inferior	inferior	JJ
cord-005478-5iu38pr6	293	9	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	293	10	.	.	.
cord-005478-5iu38pr6	294	1	Lastly	lastly	RB
cord-005478-5iu38pr6	294	2	for	for	IN
cord-005478-5iu38pr6	294	3	GRFS	GRFS	NNP
cord-005478-5iu38pr6	294	4	the	the	DT
cord-005478-5iu38pr6	294	5	prognostic	prognostic	JJ
cord-005478-5iu38pr6	294	6	factors	factor	NNS
cord-005478-5iu38pr6	294	7	were	be	VBD
cord-005478-5iu38pr6	294	8	time	time	NN
cord-005478-5iu38pr6	294	9	from	from	IN
cord-005478-5iu38pr6	294	10	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	294	11	to	to	IN
cord-005478-5iu38pr6	294	12	Rel	Rel	NNP
cord-005478-5iu38pr6	294	13	,	,	,
cord-005478-5iu38pr6	294	14	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	294	15	≥II	≥II	NNP
cord-005478-5iu38pr6	294	16	after	after	IN
cord-005478-5iu38pr6	294	17	HSCT1	HSCT1	NNP
cord-005478-5iu38pr6	294	18	,	,	,
cord-005478-5iu38pr6	294	19	RIC	RIC	NNP
cord-005478-5iu38pr6	294	20	at	at	IN
cord-005478-5iu38pr6	294	21	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	295	1	and	and	CC
cord-005478-5iu38pr6	295	2	KPS≥90	KPS≥90	NNS
cord-005478-5iu38pr6	295	3	at	at	IN
cord-005478-5iu38pr6	295	4	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	295	5	.	.	.
cord-005478-5iu38pr6	296	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	296	2	:	:	:
cord-005478-5iu38pr6	297	1	Results	result	NNS
cord-005478-5iu38pr6	297	2	of	of	IN
cord-005478-5iu38pr6	297	3	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	297	4	in	in	IN
cord-005478-5iu38pr6	297	5	ALL	all	DT
cord-005478-5iu38pr6	297	6	pts	pts	NN
cord-005478-5iu38pr6	297	7	with	with	IN
cord-005478-5iu38pr6	297	8	Rel	Rel	NNP
cord-005478-5iu38pr6	297	9	or	or	CC
cord-005478-5iu38pr6	297	10	CR2	CR2	NNP
cord-005478-5iu38pr6	297	11	are	be	VBP
cord-005478-5iu38pr6	297	12	poor	poor	JJ
cord-005478-5iu38pr6	297	13	with	with	IN
cord-005478-5iu38pr6	297	14	only	only	RB
cord-005478-5iu38pr6	297	15	14	14	CD
cord-005478-5iu38pr6	297	16	%	%	NN
cord-005478-5iu38pr6	297	17	OS	os	NN
cord-005478-5iu38pr6	297	18	and	and	CC
cord-005478-5iu38pr6	297	19	7	7	CD
cord-005478-5iu38pr6	297	20	%	%	NN
cord-005478-5iu38pr6	297	21	GRFS	grfs	NN
cord-005478-5iu38pr6	297	22	at	at	IN
cord-005478-5iu38pr6	297	23	5	5	CD
cord-005478-5iu38pr6	297	24	y	y	NN
cord-005478-5iu38pr6	297	25	with	with	IN
cord-005478-5iu38pr6	297	26	very	very	RB
cord-005478-5iu38pr6	297	27	high	high	JJ
cord-005478-5iu38pr6	297	28	RI	ri	NN
cord-005478-5iu38pr6	297	29	of	of	IN
cord-005478-5iu38pr6	297	30	62%.The	62%.the	CD
cord-005478-5iu38pr6	297	31	prognostic	prognostic	JJ
cord-005478-5iu38pr6	297	32	factors	factor	NNS
cord-005478-5iu38pr6	297	33	are	be	VBP
cord-005478-5iu38pr6	297	34	similar	similar	JJ
cord-005478-5iu38pr6	297	35	to	to	IN
cord-005478-5iu38pr6	297	36	those	those	DT
cord-005478-5iu38pr6	297	37	previously	previously	RB
cord-005478-5iu38pr6	297	38	reported	report	VBN
cord-005478-5iu38pr6	297	39	for	for	IN
cord-005478-5iu38pr6	297	40	HSCT2	HSCT2	NNP
cord-005478-5iu38pr6	297	41	in	in	IN
cord-005478-5iu38pr6	297	42	AML	AML	NNP
cord-005478-5iu38pr6	297	43	.	.	.
cord-005478-5iu38pr6	298	1	The	the	DT
cord-005478-5iu38pr6	298	2	future	future	JJ
cord-005478-5iu38pr6	298	3	goals	goal	NNS
cord-005478-5iu38pr6	298	4	are	be	VBP
cord-005478-5iu38pr6	298	5	to	to	TO
cord-005478-5iu38pr6	298	6	prevent	prevent	VB
cord-005478-5iu38pr6	298	7	and	and	CC
cord-005478-5iu38pr6	298	8	treat	treat	VB
cord-005478-5iu38pr6	298	9	relapsed	relapse	VBN
cord-005478-5iu38pr6	298	10	ALL	all	DT
cord-005478-5iu38pr6	298	11	by	by	IN
cord-005478-5iu38pr6	298	12	MRD	MRD	NNP
cord-005478-5iu38pr6	298	13	driven	drive	VBD
cord-005478-5iu38pr6	298	14	novel	novel	JJ
cord-005478-5iu38pr6	298	15	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	298	16	antibodies	antibody	NNS
cord-005478-5iu38pr6	298	17	and	and	CC
cord-005478-5iu38pr6	298	18	CAR	car	NN
cord-005478-5iu38pr6	298	19	-	-	HYPH
cord-005478-5iu38pr6	298	20	T	t	NN
cord-005478-5iu38pr6	298	21	cell	cell	NN
cord-005478-5iu38pr6	298	22	therapy	therapy	NN
cord-005478-5iu38pr6	298	23	.	.	.
cord-005478-5iu38pr6	299	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	299	2	:	:	:
cord-005478-5iu38pr6	299	3	Nothing	nothing	NN
cord-005478-5iu38pr6	299	4	to	to	TO
cord-005478-5iu38pr6	299	5	declare	declare	VB
cord-005478-5iu38pr6	299	6	.	.	.
cord-005478-5iu38pr6	300	1	Aplastic	aplastic	JJ
cord-005478-5iu38pr6	300	2	anaemia	anaemia	NN
cord-005478-5iu38pr6	300	3	Outcomes	outcome	NNS
cord-005478-5iu38pr6	300	4	of	of	IN
cord-005478-5iu38pr6	300	5	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	300	6	stem	stem	NN
cord-005478-5iu38pr6	300	7	cell	cell	NN
cord-005478-5iu38pr6	300	8	transplantation	transplantation	NN
cord-005478-5iu38pr6	300	9	(	(	-LRB-
cord-005478-5iu38pr6	300	10	hsct	hsct	NNP
cord-005478-5iu38pr6	300	11	)	)	-RRB-
cord-005478-5iu38pr6	300	12	for	for	IN
cord-005478-5iu38pr6	300	13	older	old	JJR
cord-005478-5iu38pr6	300	14	patients	patient	NNS
cord-005478-5iu38pr6	300	15	(	(	-LRB-
cord-005478-5iu38pr6	300	16	>	>	NFP
cord-005478-5iu38pr6	300	17	50	50	CD
cord-005478-5iu38pr6	300	18	years	year	NNS
cord-005478-5iu38pr6	300	19	)	)	-RRB-
cord-005478-5iu38pr6	300	20	with	with	IN
cord-005478-5iu38pr6	300	21	severe	severe	JJ
cord-005478-5iu38pr6	300	22	aplastic	aplastic	JJ
cord-005478-5iu38pr6	300	23	anaemia	anaemia	NN
cord-005478-5iu38pr6	300	24	using	use	VBG
cord-005478-5iu38pr6	300	25	alemtuzumab	alemtuzumab	VBN
cord-005478-5iu38pr6	300	26	-	-	HYPH
cord-005478-5iu38pr6	300	27	based	base	VBN
cord-005478-5iu38pr6	300	28	(	(	-LRB-
cord-005478-5iu38pr6	300	29	'	'	``
cord-005478-5iu38pr6	300	30	FCC	FCC	NNP
cord-005478-5iu38pr6	300	31	'	'	''
cord-005478-5iu38pr6	300	32	)	)	-RRB-
cord-005478-5iu38pr6	300	33	regimen	regimen	NN
cord-005478-5iu38pr6	300	34	:	:	:
cord-005478-5iu38pr6	300	35	King	King	NNP
cord-005478-5iu38pr6	300	36	's	's	POS
cord-005478-5iu38pr6	300	37	college	college	NN
cord-005478-5iu38pr6	300	38	hospital	hospital	NN
cord-005478-5iu38pr6	300	39	experience	experience	NN
cord-005478-5iu38pr6	300	40	Background	background	NN
cord-005478-5iu38pr6	300	41	:	:	:
cord-005478-5iu38pr6	301	1	Treatment	treatment	NN
cord-005478-5iu38pr6	301	2	of	of	IN
cord-005478-5iu38pr6	301	3	older	old	JJR
cord-005478-5iu38pr6	301	4	patients	patient	NNS
cord-005478-5iu38pr6	301	5	with	with	IN
cord-005478-5iu38pr6	301	6	severe	severe	JJ
cord-005478-5iu38pr6	301	7	aplastic	aplastic	JJ
cord-005478-5iu38pr6	301	8	anaemia	anaemia	NN
cord-005478-5iu38pr6	301	9	(	(	-LRB-
cord-005478-5iu38pr6	301	10	SAA	SAA	NNP
cord-005478-5iu38pr6	301	11	)	)	-RRB-
cord-005478-5iu38pr6	301	12	is	be	VBZ
cord-005478-5iu38pr6	301	13	problematic	problematic	JJ
cord-005478-5iu38pr6	301	14	with	with	IN
cord-005478-5iu38pr6	301	15	poor	poor	JJ
cord-005478-5iu38pr6	301	16	long	long	JJ
cord-005478-5iu38pr6	301	17	-	-	HYPH
cord-005478-5iu38pr6	301	18	term	term	NN
cord-005478-5iu38pr6	301	19	survival	survival	NN
cord-005478-5iu38pr6	301	20	after	after	IN
cord-005478-5iu38pr6	301	21	treatment	treatment	NN
cord-005478-5iu38pr6	301	22	with	with	IN
cord-005478-5iu38pr6	301	23	antithymocyte	antithymocyte	NNP
cord-005478-5iu38pr6	301	24	globulin	globulin	NNP
cord-005478-5iu38pr6	301	25	(	(	-LRB-
cord-005478-5iu38pr6	301	26	ATG	ATG	NNP
cord-005478-5iu38pr6	301	27	)	)	-RRB-
cord-005478-5iu38pr6	301	28	and/or	and/or	CC
cord-005478-5iu38pr6	301	29	ciclosporin	ciclosporin	NNP
cord-005478-5iu38pr6	301	30	(	(	-LRB-
cord-005478-5iu38pr6	301	31	CSA	CSA	NNP
cord-005478-5iu38pr6	301	32	)	)	-RRB-
cord-005478-5iu38pr6	301	33	.	.	.
cord-005478-5iu38pr6	302	1	Use	use	NN
cord-005478-5iu38pr6	302	2	of	of	IN
cord-005478-5iu38pr6	302	3	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	302	4	,	,	,
cord-005478-5iu38pr6	302	5	low	low	JJ
cord-005478-5iu38pr6	302	6	dose	dose	NN
cord-005478-5iu38pr6	302	7	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	302	8	(	(	-LRB-
cord-005478-5iu38pr6	302	9	CY	CY	NNP
cord-005478-5iu38pr6	302	10	)	)	-RRB-
cord-005478-5iu38pr6	302	11	and	and	CC
cord-005478-5iu38pr6	302	12	ATG	ATG	NNP
cord-005478-5iu38pr6	302	13	(	(	-LRB-
cord-005478-5iu38pr6	302	14	'	'	``
cord-005478-5iu38pr6	302	15	FCATG	FCATG	NNP
cord-005478-5iu38pr6	302	16	'	'	''
cord-005478-5iu38pr6	302	17	)	)	-RRB-
cord-005478-5iu38pr6	303	1	conditioning	conditioning	NN
cord-005478-5iu38pr6	303	2	suggests	suggest	VBZ
cord-005478-5iu38pr6	303	3	better	well	JJR
cord-005478-5iu38pr6	303	4	outcomes	outcome	NNS
cord-005478-5iu38pr6	303	5	among	among	IN
cord-005478-5iu38pr6	303	6	older	old	JJR
cord-005478-5iu38pr6	303	7	patients	patient	NNS
cord-005478-5iu38pr6	303	8	transplanted	transplant	VBN
cord-005478-5iu38pr6	303	9	from	from	IN
cord-005478-5iu38pr6	303	10	matched	match	VBN
cord-005478-5iu38pr6	303	11	sibling	sibling	NN
cord-005478-5iu38pr6	303	12	donors	donor	NNS
cord-005478-5iu38pr6	303	13	compared	compare	VBN
cord-005478-5iu38pr6	303	14	to	to	IN
cord-005478-5iu38pr6	303	15	high	high	JJ
cord-005478-5iu38pr6	303	16	dose	dose	NN
cord-005478-5iu38pr6	303	17	CY/	CY/	NNS
cord-005478-5iu38pr6	303	18	ATG	ATG	NNP
cord-005478-5iu38pr6	303	19	conditioning	conditioning	NN
cord-005478-5iu38pr6	303	20	,	,	,
cord-005478-5iu38pr6	303	21	but	but	CC
cord-005478-5iu38pr6	303	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	303	23	remains	remain	VBZ
cord-005478-5iu38pr6	303	24	a	a	DT
cord-005478-5iu38pr6	303	25	serious	serious	JJ
cord-005478-5iu38pr6	303	26	concern	concern	NN
cord-005478-5iu38pr6	303	27	.	.	.
cord-005478-5iu38pr6	304	1	We	-PRON-	PRP
cord-005478-5iu38pr6	304	2	have	have	VBP
cord-005478-5iu38pr6	304	3	transplanted	transplant	VBN
cord-005478-5iu38pr6	304	4	SAA	SAA	NNP
cord-005478-5iu38pr6	304	5	patients	patient	NNS
cord-005478-5iu38pr6	304	6	aged	age	VBN
cord-005478-5iu38pr6	304	7	>	>	XX
cord-005478-5iu38pr6	304	8	50	50	CD
cord-005478-5iu38pr6	304	9	years	year	NNS
cord-005478-5iu38pr6	304	10	,	,	,
cord-005478-5iu38pr6	304	11	predominantly	predominantly	RB
cord-005478-5iu38pr6	304	12	from	from	IN
cord-005478-5iu38pr6	304	13	unrelated	unrelated	JJ
cord-005478-5iu38pr6	304	14	donors	donor	NNS
cord-005478-5iu38pr6	304	15	,	,	,
cord-005478-5iu38pr6	304	16	using	use	VBG
cord-005478-5iu38pr6	304	17	alemtuzumabbased	alemtuzumabbase	VBN
cord-005478-5iu38pr6	304	18	(	(	-LRB-
cord-005478-5iu38pr6	304	19	'	'	``
cord-005478-5iu38pr6	304	20	FCC	FCC	NNP
cord-005478-5iu38pr6	304	21	'	'	''
cord-005478-5iu38pr6	304	22	)	)	-RRB-
cord-005478-5iu38pr6	304	23	regimen	regimen	NN
cord-005478-5iu38pr6	304	24	.	.	.
cord-005478-5iu38pr6	305	1	Methods	method	NNS
cord-005478-5iu38pr6	305	2	:	:	:
cord-005478-5iu38pr6	305	3	From	from	IN
cord-005478-5iu38pr6	305	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	305	5	FCC	FCC	NNP
cord-005478-5iu38pr6	305	6	SAA	SAA	NNP
cord-005478-5iu38pr6	305	7	database	database	NN
cord-005478-5iu38pr6	305	8	of	of	IN
cord-005478-5iu38pr6	305	9	65	65	CD
cord-005478-5iu38pr6	305	10	patients	patient	NNS
cord-005478-5iu38pr6	305	11	,	,	,
cord-005478-5iu38pr6	305	12	27	27	CD
cord-005478-5iu38pr6	305	13	aged	age	VBN
cord-005478-5iu38pr6	305	14	>	>	XX
cord-005478-5iu38pr6	305	15	50	50	CD
cord-005478-5iu38pr6	305	16	years	year	NNS
cord-005478-5iu38pr6	305	17	were	be	VBD
cord-005478-5iu38pr6	305	18	transplanted	transplant	VBN
cord-005478-5iu38pr6	305	19	between	between	IN
cord-005478-5iu38pr6	305	20	2007	2007	CD
cord-005478-5iu38pr6	305	21	-	-	SYM
cord-005478-5iu38pr6	305	22	18	18	CD
cord-005478-5iu38pr6	305	23	.	.	.
cord-005478-5iu38pr6	306	1	Median	median	JJ
cord-005478-5iu38pr6	306	2	age	age	NN
cord-005478-5iu38pr6	306	3	was	be	VBD
cord-005478-5iu38pr6	306	4	61	61	CD
cord-005478-5iu38pr6	306	5	years	year	NNS
cord-005478-5iu38pr6	307	1	(	(	-LRB-
cord-005478-5iu38pr6	307	2	range	range	NNP
cord-005478-5iu38pr6	307	3	51	51	CD
cord-005478-5iu38pr6	307	4	-	-	SYM
cord-005478-5iu38pr6	307	5	71	71	CD
cord-005478-5iu38pr6	307	6	)	)	-RRB-
cord-005478-5iu38pr6	307	7	;	;	:
cord-005478-5iu38pr6	307	8	12	12	CD
cord-005478-5iu38pr6	307	9	aged	age	VBN
cord-005478-5iu38pr6	307	10	50	50	CD
cord-005478-5iu38pr6	307	11	-	-	SYM
cord-005478-5iu38pr6	307	12	59	59	CD
cord-005478-5iu38pr6	307	13	and	and	CC
cord-005478-5iu38pr6	307	14	15	15	CD
cord-005478-5iu38pr6	307	15	aged	aged	JJ
cord-005478-5iu38pr6	307	16	≥	≥	CD
cord-005478-5iu38pr6	307	17	60	60	CD
cord-005478-5iu38pr6	307	18	years	year	NNS
cord-005478-5iu38pr6	307	19	.	.	.
cord-005478-5iu38pr6	308	1	Donor	donor	NN
cord-005478-5iu38pr6	308	2	was	be	VBD
cord-005478-5iu38pr6	308	3	matched	match	VBN
cord-005478-5iu38pr6	308	4	sibling	sibling	NN
cord-005478-5iu38pr6	308	5	(	(	-LRB-
cord-005478-5iu38pr6	308	6	MSD	MSD	NNP
cord-005478-5iu38pr6	308	7	)	)	-RRB-
cord-005478-5iu38pr6	308	8	in	in	IN
cord-005478-5iu38pr6	308	9	6	6	CD
cord-005478-5iu38pr6	308	10	(	(	-LRB-
cord-005478-5iu38pr6	308	11	22	22	CD
cord-005478-5iu38pr6	308	12	%	%	NN
cord-005478-5iu38pr6	308	13	)	)	-RRB-
cord-005478-5iu38pr6	308	14	,	,	,
cord-005478-5iu38pr6	308	15	10/10	10/10	CD
cord-005478-5iu38pr6	308	16	matched	match	VBN
cord-005478-5iu38pr6	308	17	unrelated	unrelated	JJ
cord-005478-5iu38pr6	308	18	(	(	-LRB-
cord-005478-5iu38pr6	308	19	MUD	mud	NN
cord-005478-5iu38pr6	308	20	)	)	-RRB-
cord-005478-5iu38pr6	308	21	in	in	IN
cord-005478-5iu38pr6	308	22	18	18	CD
cord-005478-5iu38pr6	308	23	(	(	-LRB-
cord-005478-5iu38pr6	308	24	66	66	CD
cord-005478-5iu38pr6	308	25	%	%	NN
cord-005478-5iu38pr6	308	26	)	)	-RRB-
cord-005478-5iu38pr6	308	27	,	,	.
cord-005478-5iu38pr6	309	1	9/	9/	CD
cord-005478-5iu38pr6	309	2	10	10	CD
cord-005478-5iu38pr6	309	3	unrelated	unrelated	JJ
cord-005478-5iu38pr6	309	4	(	(	-LRB-
cord-005478-5iu38pr6	309	5	MMUD	MMUD	NNP
cord-005478-5iu38pr6	309	6	)	)	-RRB-
cord-005478-5iu38pr6	309	7	in	in	IN
cord-005478-5iu38pr6	309	8	3	3	CD
cord-005478-5iu38pr6	309	9	(	(	-LRB-
cord-005478-5iu38pr6	309	10	12	12	CD
cord-005478-5iu38pr6	309	11	%	%	NN
cord-005478-5iu38pr6	309	12	)	)	-RRB-
cord-005478-5iu38pr6	309	13	.	.	.
cord-005478-5iu38pr6	310	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	310	2	was	be	VBD
cord-005478-5iu38pr6	310	3	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	311	1	30mg	30mg	NNP
cord-005478-5iu38pr6	311	2	/	/	SYM
cord-005478-5iu38pr6	311	3	m	m	NNP
cord-005478-5iu38pr6	311	4	2	2	CD
cord-005478-5iu38pr6	311	5	x	x	SYM
cord-005478-5iu38pr6	311	6	4	4	CD
cord-005478-5iu38pr6	311	7	,	,	,
cord-005478-5iu38pr6	311	8	CY	CY	NNP
cord-005478-5iu38pr6	311	9	300	300	CD
cord-005478-5iu38pr6	311	10	mg	mg	NN
cord-005478-5iu38pr6	312	1	/m	/m	NNP
cord-005478-5iu38pr6	312	2	2	2	CD
cord-005478-5iu38pr6	312	3	x	x	SYM
cord-005478-5iu38pr6	312	4	4	4	CD
cord-005478-5iu38pr6	312	5	,	,	,
cord-005478-5iu38pr6	312	6	Alemtuzumab	Alemtuzumab	NNP
cord-005478-5iu38pr6	312	7	0.2mg	0.2mg	CD
cord-005478-5iu38pr6	312	8	/	/	SYM
cord-005478-5iu38pr6	312	9	kg	kg	NNS
cord-005478-5iu38pr6	312	10	daily	daily	RB
cord-005478-5iu38pr6	312	11	from	from	IN
cord-005478-5iu38pr6	312	12	day	day	NN
cord-005478-5iu38pr6	312	13	-7	-7	ADD
cord-005478-5iu38pr6	312	14	to	to	IN
cord-005478-5iu38pr6	312	15	-3	-3	NNP
cord-005478-5iu38pr6	312	16	.	.	.
cord-005478-5iu38pr6	313	1	Post	post	JJ
cord-005478-5iu38pr6	313	2	graft	graft	NN
cord-005478-5iu38pr6	313	3	immune	immune	JJ
cord-005478-5iu38pr6	313	4	suppression	suppression	NN
cord-005478-5iu38pr6	313	5	was	be	VBD
cord-005478-5iu38pr6	313	6	CSA	CSA	NNP
cord-005478-5iu38pr6	313	7	alone	alone	RB
cord-005478-5iu38pr6	313	8	.	.	.
cord-005478-5iu38pr6	314	1	2Gy	2Gy	NNP
cord-005478-5iu38pr6	315	1	TBI	TBI	NNP
cord-005478-5iu38pr6	315	2	was	be	VBD
cord-005478-5iu38pr6	315	3	added	add	VBN
cord-005478-5iu38pr6	315	4	to	to	IN
cord-005478-5iu38pr6	315	5	FCC	FCC	NNP
cord-005478-5iu38pr6	315	6	for	for	IN
cord-005478-5iu38pr6	315	7	MMUD	MMUD	NNP
cord-005478-5iu38pr6	315	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	315	9	.	.	.
cord-005478-5iu38pr6	316	1	All	all	DT
cord-005478-5iu38pr6	316	2	patients	patient	NNS
cord-005478-5iu38pr6	316	3	received	receive	VBD
cord-005478-5iu38pr6	316	4	peripheral	peripheral	JJ
cord-005478-5iu38pr6	316	5	blood	blood	NN
cord-005478-5iu38pr6	316	6	(	(	-LRB-
cord-005478-5iu38pr6	316	7	PBSC	PBSC	NNP
cord-005478-5iu38pr6	316	8	)	)	-RRB-
cord-005478-5iu38pr6	316	9	as	as	IN
cord-005478-5iu38pr6	316	10	stem	stem	NN
cord-005478-5iu38pr6	316	11	cell	cell	NN
cord-005478-5iu38pr6	316	12	source	source	NN
cord-005478-5iu38pr6	316	13	.	.	.
cord-005478-5iu38pr6	317	1	10/27	10/27	CD
cord-005478-5iu38pr6	317	2	(	(	-LRB-
cord-005478-5iu38pr6	317	3	36	36	CD
cord-005478-5iu38pr6	317	4	%	%	NN
cord-005478-5iu38pr6	317	5	)	)	-RRB-
cord-005478-5iu38pr6	317	6	patients	patient	NNS
cord-005478-5iu38pr6	317	7	were	be	VBD
cord-005478-5iu38pr6	317	8	HLA	HLA	NNP
cord-005478-5iu38pr6	317	9	alloimmunised	alloimmunise	VBN
cord-005478-5iu38pr6	317	10	.	.	.
cord-005478-5iu38pr6	318	1	PB	PB	NNP
cord-005478-5iu38pr6	318	2	telomere	telomere	NN
cord-005478-5iu38pr6	318	3	length	length	NN
cord-005478-5iu38pr6	318	4	(	(	-LRB-
cord-005478-5iu38pr6	318	5	TL	TL	NNP
cord-005478-5iu38pr6	318	6	)	)	-RRB-
cord-005478-5iu38pr6	318	7	by	by	IN
cord-005478-5iu38pr6	318	8	multiplex	multiplex	JJ
cord-005478-5iu38pr6	318	9	qPCR	qpcr	NN
cord-005478-5iu38pr6	318	10	measured	measure	VBN
cord-005478-5iu38pr6	318	11	in	in	IN
cord-005478-5iu38pr6	318	12	17	17	CD
cord-005478-5iu38pr6	318	13	patients	patient	NNS
cord-005478-5iu38pr6	318	14	,	,	,
cord-005478-5iu38pr6	318	15	was	be	VBD
cord-005478-5iu38pr6	318	16	<	<	NNP
cord-005478-5iu38pr6	318	17	1	1	CD
cord-005478-5iu38pr6	318	18	st	st	NNP
cord-005478-5iu38pr6	318	19	centile	centile	NN
cord-005478-5iu38pr6	318	20	in	in	IN
cord-005478-5iu38pr6	318	21	3	3	CD
cord-005478-5iu38pr6	318	22	(	(	-LRB-
cord-005478-5iu38pr6	318	23	17	17	CD
cord-005478-5iu38pr6	318	24	%	%	NN
cord-005478-5iu38pr6	318	25	)	)	-RRB-
cord-005478-5iu38pr6	318	26	,	,	,
cord-005478-5iu38pr6	318	27	<	<	XX
cord-005478-5iu38pr6	318	28	10	10	CD
cord-005478-5iu38pr6	318	29	th	th	XX
cord-005478-5iu38pr6	318	30	centile	centile	NN
cord-005478-5iu38pr6	318	31	in	in	IN
cord-005478-5iu38pr6	318	32	2	2	CD
cord-005478-5iu38pr6	318	33	(	(	-LRB-
cord-005478-5iu38pr6	318	34	11	11	CD
cord-005478-5iu38pr6	318	35	%	%	NN
cord-005478-5iu38pr6	318	36	)	)	-RRB-
cord-005478-5iu38pr6	318	37	and	and	CC
cord-005478-5iu38pr6	318	38	normal	normal	JJ
cord-005478-5iu38pr6	318	39	in	in	IN
cord-005478-5iu38pr6	318	40	12	12	CD
cord-005478-5iu38pr6	318	41	(	(	-LRB-
cord-005478-5iu38pr6	318	42	70	70	CD
cord-005478-5iu38pr6	318	43	%	%	NN
cord-005478-5iu38pr6	318	44	)	)	-RRB-
cord-005478-5iu38pr6	318	45	patients	patient	NNS
cord-005478-5iu38pr6	318	46	.	.	.
cord-005478-5iu38pr6	319	1	First	first	JJ
cord-005478-5iu38pr6	319	2	line	line	NN
cord-005478-5iu38pr6	319	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	319	4	was	be	VBD
cord-005478-5iu38pr6	319	5	performed	perform	VBN
cord-005478-5iu38pr6	319	6	in	in	IN
cord-005478-5iu38pr6	319	7	2/6	2/6	CD
cord-005478-5iu38pr6	319	8	(	(	-LRB-
cord-005478-5iu38pr6	319	9	38	38	CD
cord-005478-5iu38pr6	319	10	%	%	NN
cord-005478-5iu38pr6	319	11	)	)	-RRB-
cord-005478-5iu38pr6	319	12	MSD	MSD	NNP
cord-005478-5iu38pr6	319	13	and	and	CC
cord-005478-5iu38pr6	319	14	3/21	3/21	CD
cord-005478-5iu38pr6	319	15	(	(	-LRB-
cord-005478-5iu38pr6	319	16	12	12	CD
cord-005478-5iu38pr6	319	17	%	%	NN
cord-005478-5iu38pr6	319	18	)	)	-RRB-
cord-005478-5iu38pr6	319	19	among	among	IN
cord-005478-5iu38pr6	319	20	unrelated	unrelated	JJ
cord-005478-5iu38pr6	319	21	donors	donor	NNS
cord-005478-5iu38pr6	319	22	.	.	.
cord-005478-5iu38pr6	320	1	HCT	HCT	NNP
cord-005478-5iu38pr6	320	2	comorbidity	comorbidity	NN
cord-005478-5iu38pr6	320	3	index	index	NN
cord-005478-5iu38pr6	320	4	(	(	-LRB-
cord-005478-5iu38pr6	320	5	HTC	HTC	NNP
cord-005478-5iu38pr6	320	6	-	-	HYPH
cord-005478-5iu38pr6	320	7	CI	CI	NNP
cord-005478-5iu38pr6	320	8	)	)	-RRB-
cord-005478-5iu38pr6	320	9	score	score	NN
cord-005478-5iu38pr6	320	10	was	be	VBD
cord-005478-5iu38pr6	320	11	0	0	CD
cord-005478-5iu38pr6	320	12	-	-	SYM
cord-005478-5iu38pr6	320	13	1	1	CD
cord-005478-5iu38pr6	320	14	in	in	IN
cord-005478-5iu38pr6	320	15	10	10	CD
cord-005478-5iu38pr6	320	16	(	(	-LRB-
cord-005478-5iu38pr6	320	17	37	37	CD
cord-005478-5iu38pr6	320	18	%	%	NN
cord-005478-5iu38pr6	320	19	)	)	-RRB-
cord-005478-5iu38pr6	320	20	;	;	:
cord-005478-5iu38pr6	320	21	2	2	CD
cord-005478-5iu38pr6	320	22	in	in	IN
cord-005478-5iu38pr6	320	23	7	7	CD
cord-005478-5iu38pr6	320	24	(	(	-LRB-
cord-005478-5iu38pr6	320	25	25	25	CD
cord-005478-5iu38pr6	320	26	%	%	NN
cord-005478-5iu38pr6	320	27	)	)	-RRB-
cord-005478-5iu38pr6	320	28	and	and	CC
cord-005478-5iu38pr6	320	29	>	>	XX
cord-005478-5iu38pr6	320	30	2	2	CD
cord-005478-5iu38pr6	320	31	in	in	IN
cord-005478-5iu38pr6	320	32	10	10	CD
cord-005478-5iu38pr6	320	33	(	(	-LRB-
cord-005478-5iu38pr6	320	34	37	37	CD
cord-005478-5iu38pr6	320	35	%	%	NN
cord-005478-5iu38pr6	320	36	)	)	-RRB-
cord-005478-5iu38pr6	320	37	.	.	.
cord-005478-5iu38pr6	321	1	Results	result	NNS
cord-005478-5iu38pr6	321	2	:	:	:
cord-005478-5iu38pr6	322	1	Three	three	CD
cord-005478-5iu38pr6	322	2	patients	patient	NNS
cord-005478-5iu38pr6	322	3	had	have	VBD
cord-005478-5iu38pr6	322	4	invasive	invasive	JJ
cord-005478-5iu38pr6	322	5	fungal	fungal	JJ
cord-005478-5iu38pr6	322	6	infection	infection	NN
cord-005478-5iu38pr6	322	7	at	at	IN
cord-005478-5iu38pr6	322	8	time	time	NN
cord-005478-5iu38pr6	322	9	of	of	IN
cord-005478-5iu38pr6	322	10	HCT	HCT	NNP
cord-005478-5iu38pr6	322	11	and	and	CC
cord-005478-5iu38pr6	322	12	died	die	VBD
cord-005478-5iu38pr6	322	13	day	day	NN
cord-005478-5iu38pr6	322	14	+14	+14	CD
cord-005478-5iu38pr6	322	15	to	to	IN
cord-005478-5iu38pr6	322	16	21	21	CD
cord-005478-5iu38pr6	322	17	,	,	,
cord-005478-5iu38pr6	322	18	and	and	CC
cord-005478-5iu38pr6	322	19	one	one	CD
cord-005478-5iu38pr6	322	20	patient	patient	NN
cord-005478-5iu38pr6	322	21	died	die	VBD
cord-005478-5iu38pr6	322	22	at	at	IN
cord-005478-5iu38pr6	322	23	11	11	CD
cord-005478-5iu38pr6	322	24	months	month	NNS
cord-005478-5iu38pr6	322	25	from	from	IN
cord-005478-5iu38pr6	322	26	multiorgan	multiorgan	NN
cord-005478-5iu38pr6	322	27	failure	failure	NN
cord-005478-5iu38pr6	322	28	with	with	IN
cord-005478-5iu38pr6	322	29	recurrent	recurrent	JJ
cord-005478-5iu38pr6	322	30	parainfluenza	parainfluenza	NNP
cord-005478-5iu38pr6	322	31	virus	virus	NN
cord-005478-5iu38pr6	322	32	and	and	CC
cord-005478-5iu38pr6	322	33	CMV	CMV	NNP
cord-005478-5iu38pr6	322	34	.	.	.
cord-005478-5iu38pr6	323	1	Median	median	JJ
cord-005478-5iu38pr6	323	2	CD3	cd3	NN
cord-005478-5iu38pr6	323	3	chimerism	chimerism	NN
cord-005478-5iu38pr6	323	4	was	be	VBD
cord-005478-5iu38pr6	323	5	71	71	CD
cord-005478-5iu38pr6	323	6	%	%	NN
cord-005478-5iu38pr6	323	7	(	(	-LRB-
cord-005478-5iu38pr6	323	8	1	1	CD
cord-005478-5iu38pr6	323	9	-	-	SYM
cord-005478-5iu38pr6	323	10	100	100	CD
cord-005478-5iu38pr6	323	11	)	)	-RRB-
cord-005478-5iu38pr6	323	12	,	,	,
cord-005478-5iu38pr6	323	13	77	77	CD
cord-005478-5iu38pr6	323	14	%	%	NN
cord-005478-5iu38pr6	323	15	(	(	-LRB-
cord-005478-5iu38pr6	323	16	23	23	CD
cord-005478-5iu38pr6	323	17	-	-	SYM
cord-005478-5iu38pr6	323	18	100	100	CD
cord-005478-5iu38pr6	323	19	)	)	-RRB-
cord-005478-5iu38pr6	323	20	and	and	CC
cord-005478-5iu38pr6	323	21	60	60	CD
cord-005478-5iu38pr6	323	22	%	%	NN
cord-005478-5iu38pr6	323	23	(	(	-LRB-
cord-005478-5iu38pr6	323	24	22	22	CD
cord-005478-5iu38pr6	323	25	-	-	SYM
cord-005478-5iu38pr6	323	26	98	98	CD
cord-005478-5iu38pr6	323	27	)	)	-RRB-
cord-005478-5iu38pr6	323	28	at	at	IN
cord-005478-5iu38pr6	323	29	day	day	NN
cord-005478-5iu38pr6	323	30	+100	+100	NNS
cord-005478-5iu38pr6	323	31	,	,	,
cord-005478-5iu38pr6	323	32	Iyr	Iyr	NNP
cord-005478-5iu38pr6	323	33	and	and	CC
cord-005478-5iu38pr6	323	34	3yr	3yr	JJ
cord-005478-5iu38pr6	323	35	post	post	NN
cord-005478-5iu38pr6	323	36	HSCT	HSCT	NNP
cord-005478-5iu38pr6	323	37	.	.	.
cord-005478-5iu38pr6	324	1	One	one	CD
cord-005478-5iu38pr6	324	2	late	late	JJ
cord-005478-5iu38pr6	324	3	graft	graft	NN
cord-005478-5iu38pr6	324	4	failure	failure	NN
cord-005478-5iu38pr6	324	5	at	at	IN
cord-005478-5iu38pr6	324	6	6	6	CD
cord-005478-5iu38pr6	324	7	months	month	NNS
cord-005478-5iu38pr6	324	8	was	be	VBD
cord-005478-5iu38pr6	324	9	associated	associate	VBN
cord-005478-5iu38pr6	324	10	with	with	IN
cord-005478-5iu38pr6	324	11	low	low	JJ
cord-005478-5iu38pr6	324	12	CSA	CSA	NNP
cord-005478-5iu38pr6	324	13	blood	blood	NN
cord-005478-5iu38pr6	324	14	levels	level	NNS
cord-005478-5iu38pr6	324	15	,	,	,
cord-005478-5iu38pr6	324	16	and	and	CC
cord-005478-5iu38pr6	324	17	was	be	VBD
cord-005478-5iu38pr6	324	18	followed	follow	VBN
cord-005478-5iu38pr6	324	19	by	by	IN
cord-005478-5iu38pr6	324	20	successful	successful	JJ
cord-005478-5iu38pr6	324	21	2	2	CD
cord-005478-5iu38pr6	324	22	nd	nd	NNP
cord-005478-5iu38pr6	324	23	transplanted	transplant	VBN
cord-005478-5iu38pr6	324	24	with	with	IN
cord-005478-5iu38pr6	324	25	no	no	DT
cord-005478-5iu38pr6	324	26	GVHD	GVHD	NNP
cord-005478-5iu38pr6	324	27	.	.	.
cord-005478-5iu38pr6	325	1	5-year	5-year	CD
cord-005478-5iu38pr6	325	2	OS	OS	NNP
cord-005478-5iu38pr6	325	3	was	be	VBD
cord-005478-5iu38pr6	325	4	86	86	CD
cord-005478-5iu38pr6	325	5	%	%	NN
cord-005478-5iu38pr6	325	6	,	,	,
cord-005478-5iu38pr6	325	7	compared	compare	VBN
cord-005478-5iu38pr6	325	8	to	to	IN
cord-005478-5iu38pr6	325	9	96	96	CD
cord-005478-5iu38pr6	325	10	%	%	NN
cord-005478-5iu38pr6	325	11	among	among	IN
cord-005478-5iu38pr6	325	12	27	27	CD
cord-005478-5iu38pr6	325	13	patients	patient	NNS
cord-005478-5iu38pr6	325	14	aged	age	VBN
cord-005478-5iu38pr6	325	15	<	<	XX
cord-005478-5iu38pr6	325	16	50years	50years	XX
cord-005478-5iu38pr6	325	17	(	(	-LRB-
cord-005478-5iu38pr6	325	18	p=0.14	p=0.14	NNP
cord-005478-5iu38pr6	325	19	)	)	-RRB-
cord-005478-5iu38pr6	325	20	.	.	.
cord-005478-5iu38pr6	326	1	OS	OS	NNP
cord-005478-5iu38pr6	326	2	was	be	VBD
cord-005478-5iu38pr6	326	3	89	89	CD
cord-005478-5iu38pr6	326	4	%	%	NN
cord-005478-5iu38pr6	326	5	and	and	CC
cord-005478-5iu38pr6	326	6	82	82	CD
cord-005478-5iu38pr6	326	7	%	%	NN
cord-005478-5iu38pr6	326	8	for	for	IN
cord-005478-5iu38pr6	326	9	patients	patient	NNS
cord-005478-5iu38pr6	326	10	aged	age	VBN
cord-005478-5iu38pr6	327	1	50	50	CD
cord-005478-5iu38pr6	327	2	-	-	SYM
cord-005478-5iu38pr6	327	3	59	59	CD
cord-005478-5iu38pr6	327	4	and	and	CC
cord-005478-5iu38pr6	327	5	≥	≥	CD
cord-005478-5iu38pr6	327	6	60	60	CD
cord-005478-5iu38pr6	327	7	year	year	NN
cord-005478-5iu38pr6	327	8	,	,	,
cord-005478-5iu38pr6	327	9	respectively	respectively	RB
cord-005478-5iu38pr6	327	10	,	,	,
cord-005478-5iu38pr6	327	11	p=0.8	p=0.8	NNP
cord-005478-5iu38pr6	327	12	.	.	.
cord-005478-5iu38pr6	328	1	OS	OS	NNP
cord-005478-5iu38pr6	328	2	for	for	IN
cord-005478-5iu38pr6	328	3	MSD	MSD	NNP
cord-005478-5iu38pr6	328	4	,	,	,
cord-005478-5iu38pr6	328	5	MUD	mud	NN
cord-005478-5iu38pr6	328	6	and	and	CC
cord-005478-5iu38pr6	328	7	9/10	9/10	CD
cord-005478-5iu38pr6	328	8	MMUD	MMUD	NNP
cord-005478-5iu38pr6	328	9	was	be	VBD
cord-005478-5iu38pr6	328	10	100	100	CD
cord-005478-5iu38pr6	328	11	%	%	NN
cord-005478-5iu38pr6	328	12	,	,	,
cord-005478-5iu38pr6	328	13	80	80	CD
cord-005478-5iu38pr6	328	14	%	%	NN
cord-005478-5iu38pr6	328	15	and	and	CC
cord-005478-5iu38pr6	328	16	100	100	CD
cord-005478-5iu38pr6	328	17	%	%	NN
cord-005478-5iu38pr6	328	18	,	,	,
cord-005478-5iu38pr6	328	19	respectively	respectively	RB
cord-005478-5iu38pr6	328	20	.	.	.
cord-005478-5iu38pr6	329	1	HTC	HTC	NNP
cord-005478-5iu38pr6	329	2	-	-	HYPH
cord-005478-5iu38pr6	329	3	IC	ic	NN
cord-005478-5iu38pr6	329	4	score	score	NN
cord-005478-5iu38pr6	329	5	of	of	IN
cord-005478-5iu38pr6	329	6	>	>	XX
cord-005478-5iu38pr6	329	7	2	2	CD
cord-005478-5iu38pr6	329	8	was	be	VBD
cord-005478-5iu38pr6	329	9	associated	associate	VBN
cord-005478-5iu38pr6	329	10	with	with	IN
cord-005478-5iu38pr6	329	11	worse	bad	JJR
cord-005478-5iu38pr6	329	12	OS	os	NN
cord-005478-5iu38pr6	329	13	of	of	IN
cord-005478-5iu38pr6	329	14	72	72	CD
cord-005478-5iu38pr6	329	15	%	%	NN
cord-005478-5iu38pr6	329	16	compared	compare	VBN
cord-005478-5iu38pr6	329	17	to	to	IN
cord-005478-5iu38pr6	329	18	94	94	CD
cord-005478-5iu38pr6	329	19	%	%	NN
cord-005478-5iu38pr6	329	20	with	with	IN
cord-005478-5iu38pr6	329	21	score	score	NN
cord-005478-5iu38pr6	329	22	<	<	XX
cord-005478-5iu38pr6	329	23	2	2	CD
cord-005478-5iu38pr6	329	24	,	,	,
cord-005478-5iu38pr6	330	1	p=0.13	p=0.13	JJ
cord-005478-5iu38pr6	330	2	.	.	.
cord-005478-5iu38pr6	330	3	Outcomes	outcome	NNS
cord-005478-5iu38pr6	330	4	were	be	VBD
cord-005478-5iu38pr6	330	5	comparable	comparable	JJ
cord-005478-5iu38pr6	330	6	irrespective	irrespective	RB
cord-005478-5iu38pr6	330	7	of	of	IN
cord-005478-5iu38pr6	330	8	telomere	telomere	NN
cord-005478-5iu38pr6	330	9	length	length	NN
cord-005478-5iu38pr6	330	10	(	(	-LRB-
cord-005478-5iu38pr6	330	11	84	84	CD
cord-005478-5iu38pr6	330	12	%	%	NN
cord-005478-5iu38pr6	330	13	vs	vs	IN
cord-005478-5iu38pr6	330	14	80	80	CD
cord-005478-5iu38pr6	330	15	%	%	NN
cord-005478-5iu38pr6	330	16	for	for	IN
cord-005478-5iu38pr6	330	17	normal	normal	JJ
cord-005478-5iu38pr6	330	18	vs	vs	IN
cord-005478-5iu38pr6	330	19	short	short	JJ
cord-005478-5iu38pr6	330	20	telomere	telomere	NN
cord-005478-5iu38pr6	330	21	,	,	,
cord-005478-5iu38pr6	330	22	p=0.76	p=0.76	NNP
cord-005478-5iu38pr6	330	23	)	)	-RRB-
cord-005478-5iu38pr6	330	24	.	.	.
cord-005478-5iu38pr6	331	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	331	2	rates	rate	NNS
cord-005478-5iu38pr6	331	3	of	of	IN
cord-005478-5iu38pr6	331	4	acute	acute	JJ
cord-005478-5iu38pr6	331	5	and	and	CC
cord-005478-5iu38pr6	331	6	chronic	chronic	JJ
cord-005478-5iu38pr6	331	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	331	8	were	be	VBD
cord-005478-5iu38pr6	331	9	5	5	CD
cord-005478-5iu38pr6	331	10	%	%	NN
cord-005478-5iu38pr6	331	11	and	and	CC
cord-005478-5iu38pr6	331	12	12	12	CD
cord-005478-5iu38pr6	331	13	%	%	NN
cord-005478-5iu38pr6	331	14	,	,	,
cord-005478-5iu38pr6	331	15	respectively	respectively	RB
cord-005478-5iu38pr6	331	16	.	.	.
cord-005478-5iu38pr6	332	1	All	all	DT
cord-005478-5iu38pr6	332	2	cases	case	NNS
cord-005478-5iu38pr6	332	3	of	of	IN
cord-005478-5iu38pr6	332	4	acute	acute	JJ
cord-005478-5iu38pr6	332	5	GVHD	GVHD	NNP
cord-005478-5iu38pr6	332	6	were	be	VBD
cord-005478-5iu38pr6	332	7	confined	confine	VBN
cord-005478-5iu38pr6	332	8	to	to	IN
cord-005478-5iu38pr6	332	9	skin	skin	NN
cord-005478-5iu38pr6	332	10	and	and	CC
cord-005478-5iu38pr6	332	11	grade	grade	NN
cord-005478-5iu38pr6	332	12	I	I	NNP
cord-005478-5iu38pr6	332	13	/	/	SYM
cord-005478-5iu38pr6	332	14	II	II	NNP
cord-005478-5iu38pr6	332	15	only	only	RB
cord-005478-5iu38pr6	332	16	,	,	,
cord-005478-5iu38pr6	332	17	and	and	CC
cord-005478-5iu38pr6	332	18	no	no	DT
cord-005478-5iu38pr6	332	19	cases	case	NNS
cord-005478-5iu38pr6	332	20	of	of	IN
cord-005478-5iu38pr6	332	21	severe	severe	JJ
cord-005478-5iu38pr6	332	22	chronic	chronic	JJ
cord-005478-5iu38pr6	332	23	GVHD	GVHD	NNP
cord-005478-5iu38pr6	332	24	.	.	.
cord-005478-5iu38pr6	333	1	17	17	CD
cord-005478-5iu38pr6	333	2	(	(	-LRB-
cord-005478-5iu38pr6	333	3	62	62	CD
cord-005478-5iu38pr6	333	4	%	%	NN
cord-005478-5iu38pr6	333	5	)	)	-RRB-
cord-005478-5iu38pr6	333	6	patients	patient	NNS
cord-005478-5iu38pr6	333	7	needed	need	VBD
cord-005478-5iu38pr6	333	8	dose	dose	JJ
cord-005478-5iu38pr6	333	9	reduction	reduction	NN
cord-005478-5iu38pr6	333	10	of	of	IN
cord-005478-5iu38pr6	333	11	CSA	CSA	NNP
cord-005478-5iu38pr6	333	12	with	with	IN
cord-005478-5iu38pr6	333	13	addition	addition	NN
cord-005478-5iu38pr6	333	14	of	of	IN
cord-005478-5iu38pr6	333	15	mycophenolate	mycophenolate	NN
cord-005478-5iu38pr6	333	16	due	due	IN
cord-005478-5iu38pr6	333	17	to	to	IN
cord-005478-5iu38pr6	333	18	renal	renal	JJ
cord-005478-5iu38pr6	333	19	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	333	20	.	.	.
cord-005478-5iu38pr6	334	1	Rates	rate	NNS
cord-005478-5iu38pr6	334	2	of	of	IN
cord-005478-5iu38pr6	334	3	CMV	CMV	NNP
cord-005478-5iu38pr6	334	4	and	and	CC
cord-005478-5iu38pr6	334	5	EBV	EBV	NNP
cord-005478-5iu38pr6	334	6	reactivation	reactivation	NN
cord-005478-5iu38pr6	334	7	were	be	VBD
cord-005478-5iu38pr6	334	8	25	25	CD
cord-005478-5iu38pr6	334	9	%	%	NN
cord-005478-5iu38pr6	334	10	and	and	CC
cord-005478-5iu38pr6	334	11	27	27	CD
cord-005478-5iu38pr6	334	12	%	%	NN
cord-005478-5iu38pr6	334	13	respectively	respectively	RB
cord-005478-5iu38pr6	334	14	,	,	,
cord-005478-5iu38pr6	334	15	with	with	IN
cord-005478-5iu38pr6	334	16	no	no	DT
cord-005478-5iu38pr6	334	17	CMV	CMV	NNP
cord-005478-5iu38pr6	334	18	or	or	CC
cord-005478-5iu38pr6	334	19	EBV	EBV	NNP
cord-005478-5iu38pr6	334	20	disease	disease	NN
cord-005478-5iu38pr6	334	21	.	.	.
cord-005478-5iu38pr6	335	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	335	2	:	:	:
cord-005478-5iu38pr6	336	1	FCC	FCC	NNP
cord-005478-5iu38pr6	336	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	336	3	regimen	regimen	NN
cord-005478-5iu38pr6	336	4	enabled	enable	VBD
cord-005478-5iu38pr6	336	5	high	high	JJ
cord-005478-5iu38pr6	336	6	survival	survival	NN
cord-005478-5iu38pr6	336	7	and	and	CC
cord-005478-5iu38pr6	336	8	low	low	JJ
cord-005478-5iu38pr6	336	9	risk	risk	NN
cord-005478-5iu38pr6	336	10	of	of	IN
cord-005478-5iu38pr6	336	11	GVHD	GVHD	NNP
cord-005478-5iu38pr6	336	12	among	among	IN
cord-005478-5iu38pr6	336	13	older	old	JJR
cord-005478-5iu38pr6	336	14	patients	patient	NNS
cord-005478-5iu38pr6	336	15	with	with	IN
cord-005478-5iu38pr6	336	16	HCT	HCT	NNP
cord-005478-5iu38pr6	336	17	-	-	HYPH
cord-005478-5iu38pr6	336	18	CI	ci	NN
cord-005478-5iu38pr6	336	19	score	score	NN
cord-005478-5iu38pr6	336	20	<	<	XX
cord-005478-5iu38pr6	336	21	2	2	CD
cord-005478-5iu38pr6	337	1	and	and	CC
cord-005478-5iu38pr6	337	2	who	who	WP
cord-005478-5iu38pr6	337	3	did	do	VBD
cord-005478-5iu38pr6	337	4	not	not	RB
cord-005478-5iu38pr6	337	5	have	have	VB
cord-005478-5iu38pr6	337	6	established	establish	VBN
cord-005478-5iu38pr6	337	7	invasive	invasive	JJ
cord-005478-5iu38pr6	337	8	fungal	fungal	JJ
cord-005478-5iu38pr6	337	9	disease	disease	NN
cord-005478-5iu38pr6	337	10	at	at	IN
cord-005478-5iu38pr6	337	11	time	time	NN
cord-005478-5iu38pr6	337	12	of	of	IN
cord-005478-5iu38pr6	337	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	337	14	.	.	.
cord-005478-5iu38pr6	338	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	338	2	Trial	Trial	NNP
cord-005478-5iu38pr6	338	3	Registry	Registry	NNP
cord-005478-5iu38pr6	338	4	:	:	:
cord-005478-5iu38pr6	338	5	Not	not	RB
cord-005478-5iu38pr6	338	6	applicable	applicable	JJ
cord-005478-5iu38pr6	338	7	Disclosure	disclosure	NN
cord-005478-5iu38pr6	338	8	:	:	:
cord-005478-5iu38pr6	338	9	No	no	DT
cord-005478-5iu38pr6	338	10	conflicts	conflict	NNS
cord-005478-5iu38pr6	338	11	of	of	IN
cord-005478-5iu38pr6	338	12	interest	interest	NN
cord-005478-5iu38pr6	338	13	to	to	TO
cord-005478-5iu38pr6	338	14	declare	declare	VB
cord-005478-5iu38pr6	338	15	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	338	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	338	17	with	with	IN
cord-005478-5iu38pr6	338	18	post	post	JJ
cord-005478-5iu38pr6	338	19	-	-	JJ
cord-005478-5iu38pr6	338	20	transplant	transplant	NN
cord-005478-5iu38pr6	338	21	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	339	1	(	(	-LRB-
cord-005478-5iu38pr6	339	2	Haplo	Haplo	NNP
cord-005478-5iu38pr6	339	3	-	-	HYPH
cord-005478-5iu38pr6	339	4	PTCy	PTCy	NNP
cord-005478-5iu38pr6	339	5	)	)	-RRB-
cord-005478-5iu38pr6	339	6	for	for	IN
cord-005478-5iu38pr6	339	7	71	71	CD
cord-005478-5iu38pr6	339	8	patients	patient	NNS
cord-005478-5iu38pr6	339	9	with	with	IN
cord-005478-5iu38pr6	339	10	acquired	acquire	VBN
cord-005478-5iu38pr6	339	11	or	or	CC
cord-005478-5iu38pr6	339	12	inherited	inherit	VBN
cord-005478-5iu38pr6	339	13	bone	bone	NN
cord-005478-5iu38pr6	339	14	marrow	marrow	NN
cord-005478-5iu38pr6	339	15	failure	failure	NN
cord-005478-5iu38pr6	339	16	syndromes	syndrome	NNS
cord-005478-5iu38pr6	339	17	(	(	-LRB-
cord-005478-5iu38pr6	339	18	BMF	BMF	NNP
cord-005478-5iu38pr6	339	19	)	)	-RRB-
cord-005478-5iu38pr6	339	20	:	:	:
cord-005478-5iu38pr6	340	1	The	the	DT
cord-005478-5iu38pr6	340	2	experience	experience	NN
cord-005478-5iu38pr6	340	3	from	from	IN
cord-005478-5iu38pr6	340	4	Curitiba	Curitiba	NNP
cord-005478-5iu38pr6	340	5	,	,	,
cord-005478-5iu38pr6	340	6	Brazil	Brazil	NNP
cord-005478-5iu38pr6	340	7	Background	Background	NNP
cord-005478-5iu38pr6	340	8	:	:	:
cord-005478-5iu38pr6	340	9	Availability	availability	NN
cord-005478-5iu38pr6	340	10	of	of	IN
cord-005478-5iu38pr6	340	11	unrelated	unrelated	JJ
cord-005478-5iu38pr6	340	12	donors	donor	NNS
cord-005478-5iu38pr6	340	13	as	as	RB
cord-005478-5iu38pr6	340	14	well	well	RB
cord-005478-5iu38pr6	340	15	as	as	IN
cord-005478-5iu38pr6	340	16	time	time	NN
cord-005478-5iu38pr6	340	17	to	to	TO
cord-005478-5iu38pr6	340	18	find	find	VB
cord-005478-5iu38pr6	340	19	a	a	DT
cord-005478-5iu38pr6	340	20	donor	donor	NN
cord-005478-5iu38pr6	340	21	and	and	CC
cord-005478-5iu38pr6	340	22	the	the	DT
cord-005478-5iu38pr6	340	23	costs	cost	NNS
cord-005478-5iu38pr6	340	24	related	relate	VBN
cord-005478-5iu38pr6	340	25	to	to	IN
cord-005478-5iu38pr6	340	26	graft	graft	NN
cord-005478-5iu38pr6	340	27	acquisition	acquisition	NN
cord-005478-5iu38pr6	340	28	are	be	VBP
cord-005478-5iu38pr6	340	29	important	important	JJ
cord-005478-5iu38pr6	340	30	limitations	limitation	NNS
cord-005478-5iu38pr6	340	31	in	in	IN
cord-005478-5iu38pr6	340	32	countries	country	NNS
cord-005478-5iu38pr6	340	33	with	with	IN
cord-005478-5iu38pr6	340	34	ethnical	ethnical	JJ
cord-005478-5iu38pr6	340	35	minorities	minority	NNS
cord-005478-5iu38pr6	340	36	and	and	CC
cord-005478-5iu38pr6	340	37	fewer	few	JJR
cord-005478-5iu38pr6	340	38	resources	resource	NNS
cord-005478-5iu38pr6	340	39	.	.	.
cord-005478-5iu38pr6	341	1	Methods	method	NNS
cord-005478-5iu38pr6	341	2	:	:	:
cord-005478-5iu38pr6	341	3	We	-PRON-	PRP
cord-005478-5iu38pr6	341	4	describe	describe	VBP
cord-005478-5iu38pr6	341	5	the	the	DT
cord-005478-5iu38pr6	341	6	experience	experience	NN
cord-005478-5iu38pr6	341	7	of	of	IN
cord-005478-5iu38pr6	341	8	78	78	CD
cord-005478-5iu38pr6	341	9	transplants	transplant	NNS
cord-005478-5iu38pr6	341	10	in	in	IN
cord-005478-5iu38pr6	341	11	71	71	CD
cord-005478-5iu38pr6	341	12	patients(pts	patients(pt	NNS
cord-005478-5iu38pr6	341	13	)	)	-RRB-
cord-005478-5iu38pr6	341	14	with	with	IN
cord-005478-5iu38pr6	341	15	acquired	acquire	VBN
cord-005478-5iu38pr6	341	16	or	or	CC
cord-005478-5iu38pr6	341	17	inherited	inherit	VBN
cord-005478-5iu38pr6	341	18	BMF	BMF	NNP
cord-005478-5iu38pr6	341	19	submitted	submit	VBD
cord-005478-5iu38pr6	341	20	to	to	IN
cord-005478-5iu38pr6	341	21	an	an	DT
cord-005478-5iu38pr6	341	22	Haplo	Haplo	NNP
cord-005478-5iu38pr6	341	23	-	-	HYPH
cord-005478-5iu38pr6	341	24	PTCy	ptcy	NN
cord-005478-5iu38pr6	341	25	transplantation	transplantation	NN
cord-005478-5iu38pr6	341	26	between	between	IN
cord-005478-5iu38pr6	341	27	04.2008	04.2008	CD
cord-005478-5iu38pr6	341	28	and	and	CC
cord-005478-5iu38pr6	341	29	08.2018	08.2018	CD
cord-005478-5iu38pr6	341	30	.	.	.
cord-005478-5iu38pr6	342	1	The	the	DT
cord-005478-5iu38pr6	342	2	median	median	JJ
cord-005478-5iu38pr6	342	3	age	age	NN
cord-005478-5iu38pr6	342	4	was	be	VBD
cord-005478-5iu38pr6	342	5	9ys	9ys	JJ
cord-005478-5iu38pr6	342	6	,	,	,
cord-005478-5iu38pr6	342	7	70	70	CD
cord-005478-5iu38pr6	342	8	%	%	NN
cord-005478-5iu38pr6	342	9	were	be	VBD
cord-005478-5iu38pr6	342	10	male	male	JJ
cord-005478-5iu38pr6	342	11	and	and	CC
cord-005478-5iu38pr6	342	12	94	94	CD
cord-005478-5iu38pr6	342	13	%	%	NN
cord-005478-5iu38pr6	342	14	were	be	VBD
cord-005478-5iu38pr6	342	15	CMV	CMV	NNP
cord-005478-5iu38pr6	342	16	positive	positive	JJ
cord-005478-5iu38pr6	342	17	.	.	.
cord-005478-5iu38pr6	343	1	Haplo	Haplo	NNP
cord-005478-5iu38pr6	343	2	-	-	HYPH
cord-005478-5iu38pr6	343	3	PTCy	PTCy	NNP
cord-005478-5iu38pr6	343	4	was	be	VBD
cord-005478-5iu38pr6	343	5	the	the	DT
cord-005478-5iu38pr6	343	6	1	1	CD
cord-005478-5iu38pr6	343	7	st	st	NNP
cord-005478-5iu38pr6	343	8	transplant	transplant	NN
cord-005478-5iu38pr6	343	9	for	for	IN
cord-005478-5iu38pr6	343	10	62	62	CD
cord-005478-5iu38pr6	343	11	pts	pt	NNS
cord-005478-5iu38pr6	343	12	,	,	,
cord-005478-5iu38pr6	343	13	second	second	JJ
cord-005478-5iu38pr6	343	14	or	or	CC
cord-005478-5iu38pr6	343	15	third	third	JJ
cord-005478-5iu38pr6	343	16	for	for	IN
cord-005478-5iu38pr6	343	17	9pts	9pts	CD
cord-005478-5iu38pr6	343	18	.	.	.
cord-005478-5iu38pr6	344	1	Diagnosis	diagnosis	NN
cord-005478-5iu38pr6	344	2	:	:	:
cord-005478-5iu38pr6	345	1	Fanconi	Fanconi	NNP
cord-005478-5iu38pr6	345	2	Anemia	Anemia	NNP
cord-005478-5iu38pr6	345	3	(	(	-LRB-
cord-005478-5iu38pr6	345	4	FA	FA	NNP
cord-005478-5iu38pr6	345	5	,	,	,
cord-005478-5iu38pr6	345	6	N=48	N=48	NNP
cord-005478-5iu38pr6	345	7	)	)	-RRB-
cord-005478-5iu38pr6	345	8	,	,	,
cord-005478-5iu38pr6	345	9	acquired	acquire	VBD
cord-005478-5iu38pr6	345	10	severe	severe	JJ
cord-005478-5iu38pr6	345	11	aplastic	aplastic	JJ
cord-005478-5iu38pr6	345	12	anemia	anemia	NN
cord-005478-5iu38pr6	345	13	(	(	-LRB-
cord-005478-5iu38pr6	345	14	aSAA	aSAA	NNP
cord-005478-5iu38pr6	345	15	,	,	,
cord-005478-5iu38pr6	345	16	N=10	N=10	NNP
cord-005478-5iu38pr6	345	17	)	)	-RRB-
cord-005478-5iu38pr6	345	18	,	,	,
cord-005478-5iu38pr6	345	19	Telomere	telomere	NN
cord-005478-5iu38pr6	345	20	diseases	disease	NNS
cord-005478-5iu38pr6	345	21	(	(	-LRB-
cord-005478-5iu38pr6	345	22	N=6	N=6	NNP
cord-005478-5iu38pr6	345	23	)	)	-RRB-
cord-005478-5iu38pr6	345	24	;	;	:
cord-005478-5iu38pr6	345	25	other	other	JJ
cord-005478-5iu38pr6	345	26	inherited	inherit	VBN
cord-005478-5iu38pr6	345	27	BMF	BMF	NNP
cord-005478-5iu38pr6	345	28	(	(	-LRB-
cord-005478-5iu38pr6	345	29	N=7	N=7	NNP
cord-005478-5iu38pr6	345	30	)	)	-RRB-
cord-005478-5iu38pr6	345	31	.	.	.
cord-005478-5iu38pr6	346	1	All	all	DT
cord-005478-5iu38pr6	346	2	pts	pt	NNS
cord-005478-5iu38pr6	346	3	had	have	VBD
cord-005478-5iu38pr6	346	4	failed	fail	VBN
cord-005478-5iu38pr6	346	5	prior	prior	JJ
cord-005478-5iu38pr6	346	6	therapies	therapy	NNS
cord-005478-5iu38pr6	346	7	and	and	CC
cord-005478-5iu38pr6	346	8	96	96	CD
cord-005478-5iu38pr6	346	9	%	%	NN
cord-005478-5iu38pr6	346	10	had	have	VBD
cord-005478-5iu38pr6	346	11	previous	previous	JJ
cord-005478-5iu38pr6	346	12	blood	blood	NN
cord-005478-5iu38pr6	346	13	transfusions	transfusion	NNS
cord-005478-5iu38pr6	346	14	.	.	.
cord-005478-5iu38pr6	347	1	The	the	DT
cord-005478-5iu38pr6	347	2	majority	majority	NN
cord-005478-5iu38pr6	347	3	received	receive	VBD
cord-005478-5iu38pr6	347	4	a	a	DT
cord-005478-5iu38pr6	347	5	RIC	RIC	NNP
cord-005478-5iu38pr6	347	6	regimen	regimen	NN
cord-005478-5iu38pr6	347	7	with	with	IN
cord-005478-5iu38pr6	347	8	low	low	JJ
cord-005478-5iu38pr6	347	9	dose	dose	NN
cord-005478-5iu38pr6	347	10	TBI	TBI	NNP
cord-005478-5iu38pr6	347	11	(	(	-LRB-
cord-005478-5iu38pr6	347	12	N=69	N=69	NNP
cord-005478-5iu38pr6	347	13	,	,	,
cord-005478-5iu38pr6	347	14	97	97	CD
cord-005478-5iu38pr6	347	15	%	%	NN
cord-005478-5iu38pr6	347	16	)	)	-RRB-
cord-005478-5iu38pr6	347	17	.	.	.
cord-005478-5iu38pr6	348	1	Donors	donor	NNS
cord-005478-5iu38pr6	348	2	were	be	VBD
cord-005478-5iu38pr6	348	3	father(N=28	father(N=28	VBG
cord-005478-5iu38pr6	348	4	)	)	-RRB-
cord-005478-5iu38pr6	348	5	,	,	,
cord-005478-5iu38pr6	348	6	mother(N=31	mother(N=31	JJS
cord-005478-5iu38pr6	348	7	)	)	-RRB-
cord-005478-5iu38pr6	348	8	,	,	,
cord-005478-5iu38pr6	348	9	other	other	JJ
cord-005478-5iu38pr6	348	10	relatives(N=12	relatives(n=12	CD
cord-005478-5iu38pr6	348	11	)	)	-RRB-
cord-005478-5iu38pr6	348	12	.	.	.
cord-005478-5iu38pr6	349	1	Bone	bone	NN
cord-005478-5iu38pr6	349	2	marrow	marrow	NN
cord-005478-5iu38pr6	349	3	was	be	VBD
cord-005478-5iu38pr6	349	4	the	the	DT
cord-005478-5iu38pr6	349	5	stem	stem	NN
cord-005478-5iu38pr6	349	6	cell	cell	NN
cord-005478-5iu38pr6	349	7	source	source	NN
cord-005478-5iu38pr6	349	8	in	in	IN
cord-005478-5iu38pr6	349	9	70pts	70pts	CD
cord-005478-5iu38pr6	349	10	.	.	.
cord-005478-5iu38pr6	350	1	All	all	DT
cord-005478-5iu38pr6	350	2	pts	pts	NN
cord-005478-5iu38pr6	350	3	received	receive	VBD
cord-005478-5iu38pr6	350	4	GVHD	GVHD	NNP
cord-005478-5iu38pr6	350	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	350	6	that	that	WDT
cord-005478-5iu38pr6	350	7	included	include	VBD
cord-005478-5iu38pr6	350	8	PTCy	PTCy	NNS
cord-005478-5iu38pr6	350	9	followed	follow	VBN
cord-005478-5iu38pr6	350	10	by	by	IN
cord-005478-5iu38pr6	350	11	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	350	12	and	and	CC
cord-005478-5iu38pr6	350	13	Mycophenolate	Mycophenolate	NNP
cord-005478-5iu38pr6	350	14	mofetil	mofetil	NNP
cord-005478-5iu38pr6	350	15	.	.	.
cord-005478-5iu38pr6	351	1	FA	FA	NNP
cord-005478-5iu38pr6	351	2	pts	pts	NNP
cord-005478-5iu38pr6	351	3	received	receive	VBD
cord-005478-5iu38pr6	351	4	a	a	DT
cord-005478-5iu38pr6	351	5	modified	modified	JJ
cord-005478-5iu38pr6	351	6	preparatory	preparatory	JJ
cord-005478-5iu38pr6	351	7	regimen	regimen	NN
cord-005478-5iu38pr6	351	8	and	and	CC
cord-005478-5iu38pr6	351	9	PTCy	PTCy	NNS
cord-005478-5iu38pr6	351	10	at	at	IN
cord-005478-5iu38pr6	351	11	a	a	DT
cord-005478-5iu38pr6	351	12	total	total	JJ
cord-005478-5iu38pr6	351	13	dose	dose	NN
cord-005478-5iu38pr6	351	14	of	of	IN
cord-005478-5iu38pr6	351	15	50mg	50mg	NN
cord-005478-5iu38pr6	351	16	/	/	SYM
cord-005478-5iu38pr6	351	17	kg	kg	NNP
cord-005478-5iu38pr6	351	18	(	(	-LRB-
cord-005478-5iu38pr6	351	19	n=32	n=32	NNP
cord-005478-5iu38pr6	351	20	)	)	-RRB-
cord-005478-5iu38pr6	351	21	or	or	CC
cord-005478-5iu38pr6	351	22	60mg	60mg	NN
cord-005478-5iu38pr6	351	23	/	/	SYM
cord-005478-5iu38pr6	351	24	kg	kg	NNP
cord-005478-5iu38pr6	351	25	(	(	-LRB-
cord-005478-5iu38pr6	351	26	n=16	n=16	NNP
cord-005478-5iu38pr6	351	27	)	)	-RRB-
cord-005478-5iu38pr6	351	28	while	while	IN
cord-005478-5iu38pr6	351	29	other	other	JJ
cord-005478-5iu38pr6	351	30	BMF	BMF	NNP
cord-005478-5iu38pr6	351	31	received	receive	VBD
cord-005478-5iu38pr6	351	32	100mg	100mg	NNP
cord-005478-5iu38pr6	351	33	/	/	SYM
cord-005478-5iu38pr6	351	34	kg	kg	NN
cord-005478-5iu38pr6	351	35	Results	result	NNS
cord-005478-5iu38pr6	351	36	:	:	:
cord-005478-5iu38pr6	351	37	FA	fa	NN
cord-005478-5iu38pr6	351	38	pts	pts	NN
cord-005478-5iu38pr6	351	39	:	:	:
cord-005478-5iu38pr6	351	40	14	14	CD
cord-005478-5iu38pr6	351	41	pts	pt	NNS
cord-005478-5iu38pr6	351	42	did	do	VBD
cord-005478-5iu38pr6	351	43	not	not	RB
cord-005478-5iu38pr6	351	44	receive	receive	VB
cord-005478-5iu38pr6	351	45	ATG	ATG	NNP
cord-005478-5iu38pr6	351	46	in	in	IN
cord-005478-5iu38pr6	351	47	the	the	DT
cord-005478-5iu38pr6	351	48	preparatory	preparatory	JJ
cord-005478-5iu38pr6	351	49	regimen	regimen	NN
cord-005478-5iu38pr6	351	50	and	and	CC
cord-005478-5iu38pr6	351	51	all	all	DT
cord-005478-5iu38pr6	351	52	engrafted	engraft	VBN
cord-005478-5iu38pr6	351	53	,	,	,
cord-005478-5iu38pr6	351	54	despite	despite	IN
cord-005478-5iu38pr6	351	55	the	the	DT
cord-005478-5iu38pr6	351	56	presence	presence	NN
cord-005478-5iu38pr6	351	57	of	of	IN
cord-005478-5iu38pr6	351	58	donor	donor	NN
cord-005478-5iu38pr6	351	59	specific	specific	JJ
cord-005478-5iu38pr6	351	60	antibodies(DSA	antibodies(dsa	NN
cord-005478-5iu38pr6	351	61	)	)	-RRB-
cord-005478-5iu38pr6	351	62	in	in	IN
cord-005478-5iu38pr6	351	63	2	2	CD
cord-005478-5iu38pr6	351	64	pts	pts	NN
cord-005478-5iu38pr6	351	65	.	.	.
cord-005478-5iu38pr6	352	1	Three	three	CD
cord-005478-5iu38pr6	352	2	pts	pt	NNS
cord-005478-5iu38pr6	352	3	had	have	VBD
cord-005478-5iu38pr6	352	4	AML	AML	NNP
cord-005478-5iu38pr6	352	5	and	and	CC
cord-005478-5iu38pr6	352	6	2	2	CD
cord-005478-5iu38pr6	352	7	are	be	VBP
cord-005478-5iu38pr6	352	8	in	in	IN
cord-005478-5iu38pr6	352	9	remission	remission	NN
cord-005478-5iu38pr6	352	10	3	3	CD
cord-005478-5iu38pr6	352	11	and	and	CC
cord-005478-5iu38pr6	352	12	6ys	6ys	NN
cord-005478-5iu38pr6	352	13	after	after	IN
cord-005478-5iu38pr6	352	14	transplant	transplant	NN
cord-005478-5iu38pr6	352	15	.	.	.
cord-005478-5iu38pr6	353	1	7pts	7pts	NNP
cord-005478-5iu38pr6	353	2	died	die	VBD
cord-005478-5iu38pr6	353	3	due	due	JJ
cord-005478-5iu38pr6	353	4	to	to	IN
cord-005478-5iu38pr6	353	5	GVHD	GVHD	NNP
cord-005478-5iu38pr6	353	6	(	(	-LRB-
cord-005478-5iu38pr6	353	7	N=5	N=5	NNP
cord-005478-5iu38pr6	353	8	)	)	-RRB-
cord-005478-5iu38pr6	353	9	;	;	:
cord-005478-5iu38pr6	353	10	toxoplasmosis	toxoplasmosis	NN
cord-005478-5iu38pr6	353	11	/	/	SYM
cord-005478-5iu38pr6	353	12	CMV	CMV	NNP
cord-005478-5iu38pr6	353	13	pneumonia	pneumonia	NN
cord-005478-5iu38pr6	353	14	(	(	-LRB-
cord-005478-5iu38pr6	353	15	N=1	N=1	NNP
cord-005478-5iu38pr6	353	16	)	)	-RRB-
cord-005478-5iu38pr6	353	17	or	or	CC
cord-005478-5iu38pr6	353	18	relapse	relapse	NN
cord-005478-5iu38pr6	353	19	(	(	-LRB-
cord-005478-5iu38pr6	353	20	N=1	N=1	NNP
cord-005478-5iu38pr6	353	21	)	)	-RRB-
cord-005478-5iu38pr6	353	22	.	.	.
cord-005478-5iu38pr6	354	1	7/14	7/14	CD
cord-005478-5iu38pr6	354	2	pts	pt	NNS
cord-005478-5iu38pr6	354	3	are	be	VBP
cord-005478-5iu38pr6	354	4	alive	alive	JJ
cord-005478-5iu38pr6	354	5	with	with	IN
cord-005478-5iu38pr6	354	6	a	a	DT
cord-005478-5iu38pr6	354	7	median	median	JJ
cord-005478-5iu38pr6	354	8	follow	follow	NN
cord-005478-5iu38pr6	354	9	-	-	HYPH
cord-005478-5iu38pr6	354	10	up(FU	up(fu	NN
cord-005478-5iu38pr6	354	11	)	)	-RRB-
cord-005478-5iu38pr6	354	12	of	of	IN
cord-005478-5iu38pr6	354	13	6.7ys	6.7ys	CD
cord-005478-5iu38pr6	354	14	.	.	.
cord-005478-5iu38pr6	355	1	In	in	IN
cord-005478-5iu38pr6	355	2	the	the	DT
cord-005478-5iu38pr6	355	3	subgroup	subgroup	NN
cord-005478-5iu38pr6	355	4	of	of	IN
cord-005478-5iu38pr6	355	5	FA	FA	NNP
cord-005478-5iu38pr6	355	6	pts	pts	NN
cord-005478-5iu38pr6	355	7	receiving	receive	VBG
cord-005478-5iu38pr6	355	8	r	r	NN
cord-005478-5iu38pr6	355	9	-	-	HYPH
cord-005478-5iu38pr6	355	10	ATG(N=34	ATG(N=34	NNP
cord-005478-5iu38pr6	355	11	)	)	-RRB-
cord-005478-5iu38pr6	355	12	,	,	,
cord-005478-5iu38pr6	355	13	3pts	3pt	NNS
cord-005478-5iu38pr6	355	14	presented	present	VBD
cord-005478-5iu38pr6	355	15	primary	primary	JJ
cord-005478-5iu38pr6	355	16	or	or	CC
cord-005478-5iu38pr6	355	17	secondary	secondary	JJ
cord-005478-5iu38pr6	355	18	graft	graft	NN
cord-005478-5iu38pr6	355	19	failure(GF	failure(gf	NN
cord-005478-5iu38pr6	355	20	)	)	-RRB-
cord-005478-5iu38pr6	356	1	,	,	,
cord-005478-5iu38pr6	356	2	none	none	NN
cord-005478-5iu38pr6	356	3	had	have	VBD
cord-005478-5iu38pr6	356	4	DSA	DSA	NNP
cord-005478-5iu38pr6	356	5	and	and	CC
cord-005478-5iu38pr6	356	6	all	all	DT
cord-005478-5iu38pr6	356	7	died	die	VBD
cord-005478-5iu38pr6	356	8	despite	despite	IN
cord-005478-5iu38pr6	356	9	a	a	DT
cord-005478-5iu38pr6	356	10	2	2	CD
cord-005478-5iu38pr6	356	11	nd	nd	NNP
cord-005478-5iu38pr6	356	12	Haplo	Haplo	NNP
cord-005478-5iu38pr6	356	13	-	-	HYPH
cord-005478-5iu38pr6	356	14	PTCy	PTCy	NNP
cord-005478-5iu38pr6	356	15	with	with	IN
cord-005478-5iu38pr6	356	16	different	different	JJ
cord-005478-5iu38pr6	356	17	donors	donor	NNS
cord-005478-5iu38pr6	356	18	.	.	.
cord-005478-5iu38pr6	357	1	6pts	6pts	CD
cord-005478-5iu38pr6	357	2	had	have	VBD
cord-005478-5iu38pr6	357	3	advanced	advance	VBN
cord-005478-5iu38pr6	357	4	disease	disease	NN
cord-005478-5iu38pr6	357	5	and	and	CC
cord-005478-5iu38pr6	357	6	4	4	CD
cord-005478-5iu38pr6	357	7	are	be	VBP
cord-005478-5iu38pr6	357	8	in	in	IN
cord-005478-5iu38pr6	357	9	remission	remission	NN
cord-005478-5iu38pr6	357	10	at	at	IN
cord-005478-5iu38pr6	357	11	the	the	DT
cord-005478-5iu38pr6	357	12	last	last	JJ
cord-005478-5iu38pr6	357	13	FU	fu	NN
cord-005478-5iu38pr6	357	14	.	.	.
cord-005478-5iu38pr6	358	1	26/34pts	26/34pts	CD
cord-005478-5iu38pr6	358	2	are	be	VBP
cord-005478-5iu38pr6	358	3	alive	alive	JJ
cord-005478-5iu38pr6	358	4	at	at	IN
cord-005478-5iu38pr6	358	5	a	a	DT
cord-005478-5iu38pr6	358	6	median	median	NN
cord-005478-5iu38pr6	358	7	of	of	IN
cord-005478-5iu38pr6	358	8	4	4	CD
cord-005478-5iu38pr6	358	9	ys	ys	NN
cord-005478-5iu38pr6	358	10	after	after	IN
cord-005478-5iu38pr6	358	11	transplant	transplant	NN
cord-005478-5iu38pr6	358	12	.	.	.
cord-005478-5iu38pr6	359	1	Eight	eight	CD
cord-005478-5iu38pr6	359	2	pts	pt	NNS
cord-005478-5iu38pr6	359	3	died	die	VBD
cord-005478-5iu38pr6	359	4	due	due	IN
cord-005478-5iu38pr6	359	5	to	to	IN
cord-005478-5iu38pr6	359	6	GvHD	GvHD	NNP
cord-005478-5iu38pr6	359	7	(	(	-LRB-
cord-005478-5iu38pr6	359	8	N=4	N=4	NNP
cord-005478-5iu38pr6	359	9	)	)	-RRB-
cord-005478-5iu38pr6	359	10	;	;	:
cord-005478-5iu38pr6	359	11	RSV	RSV	NNP
cord-005478-5iu38pr6	359	12	pneumonitis	pneumonitis	NN
cord-005478-5iu38pr6	359	13	(	(	-LRB-
cord-005478-5iu38pr6	359	14	N=1	N=1	NNP
cord-005478-5iu38pr6	359	15	)	)	-RRB-
cord-005478-5iu38pr6	359	16	and	and	CC
cord-005478-5iu38pr6	359	17	GF	GF	NNP
cord-005478-5iu38pr6	359	18	(	(	-LRB-
cord-005478-5iu38pr6	359	19	N=3	N=3	NNP
cord-005478-5iu38pr6	359	20	)	)	-RRB-
cord-005478-5iu38pr6	359	21	.	.	.
cord-005478-5iu38pr6	360	1	All	all	DT
cord-005478-5iu38pr6	360	2	10	10	CD
cord-005478-5iu38pr6	360	3	pts	pt	NNS
cord-005478-5iu38pr6	360	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	360	5	with	with	IN
cord-005478-5iu38pr6	360	6	aSAA	aSAA	NNP
cord-005478-5iu38pr6	360	7	are	be	VBP
cord-005478-5iu38pr6	360	8	alive	alive	JJ
cord-005478-5iu38pr6	360	9	and	and	CC
cord-005478-5iu38pr6	360	10	fully	fully	RB
cord-005478-5iu38pr6	360	11	engrafted	engraft	VBN
cord-005478-5iu38pr6	360	12	at	at	IN
cord-005478-5iu38pr6	360	13	a	a	DT
cord-005478-5iu38pr6	360	14	median	median	NN
cord-005478-5iu38pr6	360	15	of	of	IN
cord-005478-5iu38pr6	360	16	5.6ys	5.6ys	CD
cord-005478-5iu38pr6	360	17	after	after	IN
cord-005478-5iu38pr6	360	18	transplant	transplant	NN
cord-005478-5iu38pr6	360	19	and	and	CC
cord-005478-5iu38pr6	360	20	none	none	NN
cord-005478-5iu38pr6	360	21	developed	develop	VBD
cord-005478-5iu38pr6	360	22	GvHD	GvHD	NNP
cord-005478-5iu38pr6	360	23	,	,	,
cord-005478-5iu38pr6	360	24	Nine	nine	CD
cord-005478-5iu38pr6	360	25	out	out	IN
cord-005478-5iu38pr6	360	26	of	of	IN
cord-005478-5iu38pr6	360	27	13pts	13pt	NNS
cord-005478-5iu38pr6	360	28	transplanted	transplant	VBN
cord-005478-5iu38pr6	360	29	for	for	IN
cord-005478-5iu38pr6	360	30	other	other	JJ
cord-005478-5iu38pr6	360	31	inherited	inherit	VBN
cord-005478-5iu38pr6	360	32	BMF	BMF	NNP
cord-005478-5iu38pr6	360	33	are	be	VBP
cord-005478-5iu38pr6	360	34	alive	alive	JJ
cord-005478-5iu38pr6	360	35	at	at	IN
cord-005478-5iu38pr6	360	36	a	a	DT
cord-005478-5iu38pr6	360	37	median	median	NN
cord-005478-5iu38pr6	360	38	of	of	IN
cord-005478-5iu38pr6	360	39	3ys	3ys	NN
cord-005478-5iu38pr6	360	40	after	after	IN
cord-005478-5iu38pr6	360	41	transplant	transplant	NN
cord-005478-5iu38pr6	360	42	.	.	.
cord-005478-5iu38pr6	361	1	GF	GF	NNP
cord-005478-5iu38pr6	361	2	occurred	occur	VBD
cord-005478-5iu38pr6	361	3	in	in	IN
cord-005478-5iu38pr6	361	4	4pts	4pts	CD
cord-005478-5iu38pr6	361	5	,	,	,
cord-005478-5iu38pr6	361	6	all	all	DT
cord-005478-5iu38pr6	361	7	received	receive	VBD
cord-005478-5iu38pr6	361	8	a	a	DT
cord-005478-5iu38pr6	361	9	2	2	CD
cord-005478-5iu38pr6	361	10	nd	nd	NNP
cord-005478-5iu38pr6	361	11	Haplo	Haplo	NNP
cord-005478-5iu38pr6	361	12	-	-	HYPH
cord-005478-5iu38pr6	361	13	PTCy	PTCy	NNPS
cord-005478-5iu38pr6	361	14	from	from	IN
cord-005478-5iu38pr6	361	15	different	different	JJ
cord-005478-5iu38pr6	361	16	donors	donor	NNS
cord-005478-5iu38pr6	361	17	and	and	CC
cord-005478-5iu38pr6	361	18	2	2	CD
cord-005478-5iu38pr6	361	19	are	be	VBP
cord-005478-5iu38pr6	361	20	alive	alive	JJ
cord-005478-5iu38pr6	361	21	and	and	CC
cord-005478-5iu38pr6	361	22	engrafted	engraft	VBN
cord-005478-5iu38pr6	361	23	.	.	.
cord-005478-5iu38pr6	362	1	4pts	4pts	NNPS
cord-005478-5iu38pr6	362	2	died	die	VBD
cord-005478-5iu38pr6	362	3	due	due	IN
cord-005478-5iu38pr6	362	4	to	to	IN
cord-005478-5iu38pr6	362	5	GvHD	GvHD	NNP
cord-005478-5iu38pr6	362	6	(	(	-LRB-
cord-005478-5iu38pr6	362	7	N=1	N=1	NNP
cord-005478-5iu38pr6	362	8	)	)	-RRB-
cord-005478-5iu38pr6	362	9	,	,	,
cord-005478-5iu38pr6	362	10	GF	GF	NNP
cord-005478-5iu38pr6	362	11	(	(	-LRB-
cord-005478-5iu38pr6	362	12	N=2	N=2	NNP
cord-005478-5iu38pr6	362	13	)	)	-RRB-
cord-005478-5iu38pr6	362	14	and	and	CC
cord-005478-5iu38pr6	362	15	TMA	TMA	NNP
cord-005478-5iu38pr6	362	16	(	(	-LRB-
cord-005478-5iu38pr6	362	17	N=1	N=1	NNP
cord-005478-5iu38pr6	362	18	)	)	-RRB-
cord-005478-5iu38pr6	362	19	.	.	.
cord-005478-5iu38pr6	363	1	Altogether	altogether	RB
cord-005478-5iu38pr6	363	2	CMV	CMV	NNP
cord-005478-5iu38pr6	363	3	reactivation	reactivation	NN
cord-005478-5iu38pr6	363	4	occurred	occur	VBD
cord-005478-5iu38pr6	363	5	in	in	IN
cord-005478-5iu38pr6	363	6	51pts	51pts	NN
cord-005478-5iu38pr6	363	7	(	(	-LRB-
cord-005478-5iu38pr6	363	8	72	72	CD
cord-005478-5iu38pr6	363	9	%	%	NN
cord-005478-5iu38pr6	363	10	)	)	-RRB-
cord-005478-5iu38pr6	363	11	,	,	,
cord-005478-5iu38pr6	363	12	at	at	IN
cord-005478-5iu38pr6	363	13	a	a	DT
cord-005478-5iu38pr6	363	14	median	median	NN
cord-005478-5iu38pr6	363	15	of	of	IN
cord-005478-5iu38pr6	363	16	31	31	CD
cord-005478-5iu38pr6	363	17	days	day	NNS
cord-005478-5iu38pr6	363	18	(	(	-LRB-
cord-005478-5iu38pr6	363	19	range:15	range:15	NNP
cord-005478-5iu38pr6	363	20	-	-	HYPH
cord-005478-5iu38pr6	363	21	90	90	CD
cord-005478-5iu38pr6	363	22	)	)	-RRB-
cord-005478-5iu38pr6	363	23	and	and	CC
cord-005478-5iu38pr6	363	24	hemorrhagic	hemorrhagic	JJ
cord-005478-5iu38pr6	363	25	cystitis	cystitis	NN
cord-005478-5iu38pr6	363	26	in	in	IN
cord-005478-5iu38pr6	363	27	31pts	31pts	NNP
cord-005478-5iu38pr6	363	28	(	(	-LRB-
cord-005478-5iu38pr6	363	29	44	44	CD
cord-005478-5iu38pr6	363	30	%	%	NN
cord-005478-5iu38pr6	363	31	)	)	-RRB-
cord-005478-5iu38pr6	363	32	at	at	IN
cord-005478-5iu38pr6	363	33	a	a	DT
cord-005478-5iu38pr6	363	34	median	median	NN
cord-005478-5iu38pr6	363	35	of	of	IN
cord-005478-5iu38pr6	363	36	44	44	CD
cord-005478-5iu38pr6	363	37	days	day	NNS
cord-005478-5iu38pr6	363	38	(	(	-LRB-
cord-005478-5iu38pr6	363	39	range:8	range:8	NNP
cord-005478-5iu38pr6	363	40	-	-	HYPH
cord-005478-5iu38pr6	363	41	65	65	CD
cord-005478-5iu38pr6	363	42	)	)	-RRB-
cord-005478-5iu38pr6	363	43	.	.	.
cord-005478-5iu38pr6	364	1	after	after	IN
cord-005478-5iu38pr6	364	2	transplant	transplant	NN
cord-005478-5iu38pr6	364	3	.	.	.
cord-005478-5iu38pr6	365	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	365	2	:	:	:
cord-005478-5iu38pr6	366	1	Haplo	Haplo	NNP
cord-005478-5iu38pr6	366	2	-	-	HYPH
cord-005478-5iu38pr6	366	3	PTCy	PTCy	NNPS
cord-005478-5iu38pr6	366	4	for	for	IN
cord-005478-5iu38pr6	366	5	pts	pt	NNS
cord-005478-5iu38pr6	366	6	with	with	IN
cord-005478-5iu38pr6	366	7	acquired	acquire	VBN
cord-005478-5iu38pr6	366	8	or	or	CC
cord-005478-5iu38pr6	366	9	inherited	inherit	VBN
cord-005478-5iu38pr6	366	10	BMF	BMF	NNP
cord-005478-5iu38pr6	366	11	should	should	MD
cord-005478-5iu38pr6	366	12	be	be	VB
cord-005478-5iu38pr6	366	13	offered	offer	VBN
cord-005478-5iu38pr6	366	14	for	for	IN
cord-005478-5iu38pr6	366	15	those	those	DT
cord-005478-5iu38pr6	366	16	who	who	WP
cord-005478-5iu38pr6	366	17	need	need	VBP
cord-005478-5iu38pr6	366	18	an	an	DT
cord-005478-5iu38pr6	366	19	immediate	immediate	JJ
cord-005478-5iu38pr6	366	20	transplant	transplant	NN
cord-005478-5iu38pr6	366	21	but	but	CC
cord-005478-5iu38pr6	366	22	lack	lack	VBP
cord-005478-5iu38pr6	366	23	a	a	DT
cord-005478-5iu38pr6	366	24	matched	match	VBN
cord-005478-5iu38pr6	366	25	donor	donor	NN
cord-005478-5iu38pr6	366	26	.	.	.
cord-005478-5iu38pr6	367	1	70	70	CD
cord-005478-5iu38pr6	367	2	%	%	NN
cord-005478-5iu38pr6	367	3	of	of	IN
cord-005478-5iu38pr6	367	4	pts	pt	NNS
cord-005478-5iu38pr6	367	5	are	be	VBP
cord-005478-5iu38pr6	367	6	alive	alive	JJ
cord-005478-5iu38pr6	367	7	at	at	IN
cord-005478-5iu38pr6	367	8	a	a	DT
cord-005478-5iu38pr6	367	9	median	median	JJ
cord-005478-5iu38pr6	367	10	FU	fu	NN
cord-005478-5iu38pr6	367	11	of	of	IN
cord-005478-5iu38pr6	367	12	3ys	3ys	NN
cord-005478-5iu38pr6	367	13	but	but	CC
cord-005478-5iu38pr6	367	14	GvHD	GvHD	NNP
cord-005478-5iu38pr6	367	15	is	be	VBZ
cord-005478-5iu38pr6	367	16	a	a	DT
cord-005478-5iu38pr6	367	17	major	major	JJ
cord-005478-5iu38pr6	367	18	complication	complication	NN
cord-005478-5iu38pr6	367	19	for	for	IN
cord-005478-5iu38pr6	367	20	pts	pt	NNS
cord-005478-5iu38pr6	367	21	with	with	IN
cord-005478-5iu38pr6	367	22	inherited	inherit	VBN
cord-005478-5iu38pr6	367	23	BMF	BMF	NNP
cord-005478-5iu38pr6	367	24	,	,	,
cord-005478-5iu38pr6	367	25	especially	especially	RB
cord-005478-5iu38pr6	367	26	FA	FA	NNP
cord-005478-5iu38pr6	367	27	.	.	.
cord-005478-5iu38pr6	368	1	New	new	JJ
cord-005478-5iu38pr6	368	2	approaches	approach	NNS
cord-005478-5iu38pr6	368	3	to	to	IN
cord-005478-5iu38pr6	368	4	GVHD	GVHD	NNP
cord-005478-5iu38pr6	368	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	368	6	and	and	CC
cord-005478-5iu38pr6	368	7	treatment	treatment	NN
cord-005478-5iu38pr6	368	8	are	be	VBP
cord-005478-5iu38pr6	368	9	needed	need	VBN
cord-005478-5iu38pr6	368	10	in	in	IN
cord-005478-5iu38pr6	368	11	order	order	NN
cord-005478-5iu38pr6	368	12	to	to	TO
cord-005478-5iu38pr6	368	13	improve	improve	VB
cord-005478-5iu38pr6	368	14	quality	quality	NN
cord-005478-5iu38pr6	368	15	of	of	IN
cord-005478-5iu38pr6	368	16	survival	survival	NN
cord-005478-5iu38pr6	368	17	for	for	IN
cord-005478-5iu38pr6	368	18	these	these	DT
cord-005478-5iu38pr6	368	19	pts	pt	NNS
cord-005478-5iu38pr6	368	20	.	.	.
cord-005478-5iu38pr6	369	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	369	2	:	:	:
cord-005478-5iu38pr6	369	3	Nothing	nothing	NN
cord-005478-5iu38pr6	369	4	to	to	TO
cord-005478-5iu38pr6	369	5	declare	declare	VB
cord-005478-5iu38pr6	369	6	Relationship	relationship	NN
cord-005478-5iu38pr6	369	7	between	between	IN
cord-005478-5iu38pr6	369	8	plasma	plasma	NN
cord-005478-5iu38pr6	369	9	rabbit	rabbit	NN
cord-005478-5iu38pr6	369	10	anti	anti	JJ
cord-005478-5iu38pr6	369	11	-	-	JJ
cord-005478-5iu38pr6	369	12	thymocyte	thymocyte	JJ
cord-005478-5iu38pr6	369	13	globulin	globulin	NN
cord-005478-5iu38pr6	369	14	level	level	NN
cord-005478-5iu38pr6	369	15	and	and	CC
cord-005478-5iu38pr6	369	16	response	response	NN
cord-005478-5iu38pr6	369	17	to	to	IN
cord-005478-5iu38pr6	369	18	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	369	19	therapy	therapy	NN
cord-005478-5iu38pr6	369	20	in	in	IN
cord-005478-5iu38pr6	369	21	patients	patient	NNS
cord-005478-5iu38pr6	369	22	with	with	IN
cord-005478-5iu38pr6	369	23	severe	severe	JJ
cord-005478-5iu38pr6	369	24	aplastic	aplastic	JJ
cord-005478-5iu38pr6	369	25	anemia	anemia	NN
cord-005478-5iu38pr6	369	26	:	:	:
cord-005478-5iu38pr6	369	27	Results	result	NNS
cord-005478-5iu38pr6	369	28	of	of	IN
cord-005478-5iu38pr6	369	29	a	a	DT
cord-005478-5iu38pr6	369	30	multicenter	multicenter	JJ
cord-005478-5iu38pr6	369	31	,	,	,
cord-005478-5iu38pr6	369	32	prospective	prospective	JJ
cord-005478-5iu38pr6	369	33	,	,	,
cord-005478-5iu38pr6	369	34	randomized	randomized	JJ
cord-005478-5iu38pr6	369	35	study	study	NN
cord-005478-5iu38pr6	369	36	Background	background	NN
cord-005478-5iu38pr6	369	37	:	:	:
cord-005478-5iu38pr6	369	38	Patients	patient	NNS
cord-005478-5iu38pr6	369	39	with	with	IN
cord-005478-5iu38pr6	369	40	acquired	acquire	VBN
cord-005478-5iu38pr6	369	41	aplastic	aplastic	JJ
cord-005478-5iu38pr6	369	42	anemia	anemia	NN
cord-005478-5iu38pr6	369	43	(	(	-LRB-
cord-005478-5iu38pr6	369	44	AA	AA	NNP
cord-005478-5iu38pr6	369	45	)	)	-RRB-
cord-005478-5iu38pr6	369	46	who	who	WP
cord-005478-5iu38pr6	369	47	do	do	VBP
cord-005478-5iu38pr6	369	48	not	not	RB
cord-005478-5iu38pr6	369	49	have	have	VB
cord-005478-5iu38pr6	369	50	HLA	HLA	NNP
cord-005478-5iu38pr6	369	51	-	-	HYPH
cord-005478-5iu38pr6	369	52	matched	match	VBN
cord-005478-5iu38pr6	369	53	donors	donor	NNS
cord-005478-5iu38pr6	369	54	receive	receive	VBP
cord-005478-5iu38pr6	369	55	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	369	56	therapy	therapy	NN
cord-005478-5iu38pr6	369	57	(	(	-LRB-
cord-005478-5iu38pr6	369	58	IST	IST	NNP
cord-005478-5iu38pr6	369	59	)	)	-RRB-
cord-005478-5iu38pr6	369	60	with	with	IN
cord-005478-5iu38pr6	369	61	anti	anti	JJ
cord-005478-5iu38pr6	369	62	-	-	JJ
cord-005478-5iu38pr6	369	63	thymocyte	thymocyte	JJ
cord-005478-5iu38pr6	369	64	globulin	globulin	NN
cord-005478-5iu38pr6	369	65	(	(	-LRB-
cord-005478-5iu38pr6	369	66	ATG	ATG	NNP
cord-005478-5iu38pr6	369	67	)	)	-RRB-
cord-005478-5iu38pr6	369	68	.	.	.
cord-005478-5iu38pr6	370	1	Previous	previous	JJ
cord-005478-5iu38pr6	370	2	studies	study	NNS
cord-005478-5iu38pr6	370	3	have	have	VBP
cord-005478-5iu38pr6	370	4	suggested	suggest	VBN
cord-005478-5iu38pr6	370	5	several	several	JJ
cord-005478-5iu38pr6	370	6	variables	variable	NNS
cord-005478-5iu38pr6	370	7	that	that	WDT
cord-005478-5iu38pr6	370	8	predict	predict	VBP
cord-005478-5iu38pr6	370	9	response	response	NN
cord-005478-5iu38pr6	370	10	to	to	IN
cord-005478-5iu38pr6	370	11	IST	IST	NNP
cord-005478-5iu38pr6	370	12	.	.	.
cord-005478-5iu38pr6	371	1	However	however	RB
cord-005478-5iu38pr6	371	2	,	,	,
cord-005478-5iu38pr6	371	3	no	no	DT
cord-005478-5iu38pr6	371	4	studies	study	NNS
cord-005478-5iu38pr6	371	5	have	have	VBP
cord-005478-5iu38pr6	371	6	investigated	investigate	VBN
cord-005478-5iu38pr6	371	7	the	the	DT
cord-005478-5iu38pr6	371	8	plasma	plasma	NN
cord-005478-5iu38pr6	371	9	ATG	ATG	NNP
cord-005478-5iu38pr6	371	10	level	level	NN
cord-005478-5iu38pr6	371	11	as	as	IN
cord-005478-5iu38pr6	371	12	a	a	DT
cord-005478-5iu38pr6	371	13	variable	variable	NN
cord-005478-5iu38pr6	371	14	.	.	.
cord-005478-5iu38pr6	372	1	In	in	IN
cord-005478-5iu38pr6	372	2	this	this	DT
cord-005478-5iu38pr6	372	3	study	study	NN
cord-005478-5iu38pr6	372	4	,	,	,
cord-005478-5iu38pr6	372	5	we	-PRON-	PRP
cord-005478-5iu38pr6	372	6	assessed	assess	VBD
cord-005478-5iu38pr6	372	7	the	the	DT
cord-005478-5iu38pr6	372	8	relationship	relationship	NN
cord-005478-5iu38pr6	372	9	between	between	IN
cord-005478-5iu38pr6	372	10	plasma	plasma	NN
cord-005478-5iu38pr6	372	11	rabbit	rabbit	NN
cord-005478-5iu38pr6	372	12	ATG	ATG	NNP
cord-005478-5iu38pr6	372	13	(	(	-LRB-
cord-005478-5iu38pr6	372	14	r	r	NN
cord-005478-5iu38pr6	372	15	-	-	HYPH
cord-005478-5iu38pr6	372	16	ATG	ATG	NNP
cord-005478-5iu38pr6	372	17	)	)	-RRB-
cord-005478-5iu38pr6	372	18	level	level	NN
cord-005478-5iu38pr6	372	19	and	and	CC
cord-005478-5iu38pr6	372	20	response	response	NN
cord-005478-5iu38pr6	372	21	to	to	IN
cord-005478-5iu38pr6	372	22	IST	IST	NNP
cord-005478-5iu38pr6	372	23	in	in	IN
cord-005478-5iu38pr6	372	24	patients	patient	NNS
cord-005478-5iu38pr6	372	25	with	with	IN
cord-005478-5iu38pr6	372	26	severe	severe	JJ
cord-005478-5iu38pr6	372	27	AA	aa	NN
cord-005478-5iu38pr6	372	28	.	.	.
cord-005478-5iu38pr6	373	1	Methods	method	NNS
cord-005478-5iu38pr6	373	2	:	:	:
cord-005478-5iu38pr6	374	1	Patients	patient	NNS
cord-005478-5iu38pr6	374	2	with	with	IN
cord-005478-5iu38pr6	374	3	severe	severe	JJ
cord-005478-5iu38pr6	374	4	AA	AA	NNP
cord-005478-5iu38pr6	374	5	who	who	WP
cord-005478-5iu38pr6	374	6	required	require	VBD
cord-005478-5iu38pr6	374	7	initial	initial	JJ
cord-005478-5iu38pr6	374	8	IST	IST	NNP
cord-005478-5iu38pr6	374	9	were	be	VBD
cord-005478-5iu38pr6	374	10	enrolled	enrol	VBN
cord-005478-5iu38pr6	374	11	from	from	IN
cord-005478-5iu38pr6	374	12	May	May	NNP
cord-005478-5iu38pr6	374	13	2012	2012	CD
cord-005478-5iu38pr6	374	14	to	to	IN
cord-005478-5iu38pr6	374	15	October	October	NNP
cord-005478-5iu38pr6	374	16	2017	2017	CD
cord-005478-5iu38pr6	374	17	.	.	.
cord-005478-5iu38pr6	375	1	The	the	DT
cord-005478-5iu38pr6	375	2	IST	IST	NNP
cord-005478-5iu38pr6	375	3	regimen	regimen	NN
cord-005478-5iu38pr6	375	4	included	include	VBD
cord-005478-5iu38pr6	375	5	r	r	NNP
cord-005478-5iu38pr6	375	6	-	-	HYPH
cord-005478-5iu38pr6	375	7	ATG	ATG	NNP
cord-005478-5iu38pr6	375	8	(	(	-LRB-
cord-005478-5iu38pr6	375	9	thymoglobulin	thymoglobulin	NNP
cord-005478-5iu38pr6	375	10	®	®	ADD
cord-005478-5iu38pr6	375	11	,	,	,
cord-005478-5iu38pr6	375	12	Sanofi	Sanofi	NNP
cord-005478-5iu38pr6	375	13	,	,	,
cord-005478-5iu38pr6	375	14	Cambridge	Cambridge	NNP
cord-005478-5iu38pr6	375	15	,	,	,
cord-005478-5iu38pr6	375	16	2.5	2.5	CD
cord-005478-5iu38pr6	375	17	or	or	CC
cord-005478-5iu38pr6	375	18	3.5	3.5	CD
cord-005478-5iu38pr6	375	19	mg	mg	NNP
cord-005478-5iu38pr6	375	20	/	/	SYM
cord-005478-5iu38pr6	375	21	kg	kg	NNP
cord-005478-5iu38pr6	375	22	/	/	SYM
cord-005478-5iu38pr6	375	23	day	day	NN
cord-005478-5iu38pr6	375	24	for	for	IN
cord-005478-5iu38pr6	375	25	5	5	CD
cord-005478-5iu38pr6	375	26	days	day	NNS
cord-005478-5iu38pr6	375	27	)	)	-RRB-
cord-005478-5iu38pr6	375	28	and	and	CC
cord-005478-5iu38pr6	375	29	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	375	30	A	a	NN
cord-005478-5iu38pr6	375	31	(	(	-LRB-
cord-005478-5iu38pr6	375	32	6	6	CD
cord-005478-5iu38pr6	375	33	mg	mg	NNP
cord-005478-5iu38pr6	375	34	/	/	SYM
cord-005478-5iu38pr6	375	35	kg	kg	NNP
cord-005478-5iu38pr6	375	36	/	/	SYM
cord-005478-5iu38pr6	375	37	day	day	NN
cord-005478-5iu38pr6	375	38	for	for	IN
cord-005478-5iu38pr6	375	39	minimum	minimum	JJ
cord-005478-5iu38pr6	375	40	6	6	CD
cord-005478-5iu38pr6	375	41	months	month	NNS
cord-005478-5iu38pr6	375	42	)	)	-RRB-
cord-005478-5iu38pr6	375	43	.	.	.
cord-005478-5iu38pr6	376	1	Plasma	plasma	NN
cord-005478-5iu38pr6	376	2	r	r	NN
cord-005478-5iu38pr6	376	3	-	-	HYPH
cord-005478-5iu38pr6	376	4	ATG	ATG	NNP
cord-005478-5iu38pr6	376	5	level	level	NN
cord-005478-5iu38pr6	376	6	was	be	VBD
cord-005478-5iu38pr6	376	7	measured	measure	VBN
cord-005478-5iu38pr6	376	8	using	use	VBG
cord-005478-5iu38pr6	376	9	a	a	DT
cord-005478-5iu38pr6	376	10	rabbit	rabbit	NN
cord-005478-5iu38pr6	376	11	IgG	igg	NN
cord-005478-5iu38pr6	376	12	ELISA	ELISA	NNP
cord-005478-5iu38pr6	376	13	kit	kit	NN
cord-005478-5iu38pr6	376	14	on	on	IN
cord-005478-5iu38pr6	376	15	days	day	NNS
cord-005478-5iu38pr6	376	16	14	14	CD
cord-005478-5iu38pr6	376	17	and	and	CC
cord-005478-5iu38pr6	376	18	28	28	CD
cord-005478-5iu38pr6	376	19	.	.	.
cord-005478-5iu38pr6	377	1	Response	response	NN
cord-005478-5iu38pr6	377	2	rate	rate	NN
cord-005478-5iu38pr6	377	3	was	be	VBD
cord-005478-5iu38pr6	377	4	defined	define	VBN
cord-005478-5iu38pr6	377	5	as	as	IN
cord-005478-5iu38pr6	377	6	complete	complete	JJ
cord-005478-5iu38pr6	377	7	and	and	CC
cord-005478-5iu38pr6	377	8	partial	partial	JJ
cord-005478-5iu38pr6	377	9	responses	response	NNS
cord-005478-5iu38pr6	377	10	at	at	IN
cord-005478-5iu38pr6	377	11	6	6	CD
cord-005478-5iu38pr6	377	12	months	month	NNS
cord-005478-5iu38pr6	377	13	.	.	.
cord-005478-5iu38pr6	378	1	Receiver	receiver	NN
cord-005478-5iu38pr6	378	2	operator	operator	NN
cord-005478-5iu38pr6	378	3	characteristic	characteristic	JJ
cord-005478-5iu38pr6	378	4	curves	curve	NNS
cord-005478-5iu38pr6	378	5	were	be	VBD
cord-005478-5iu38pr6	378	6	generated	generate	VBN
cord-005478-5iu38pr6	378	7	to	to	TO
cord-005478-5iu38pr6	378	8	discriminate	discriminate	VB
cord-005478-5iu38pr6	378	9	between	between	IN
cord-005478-5iu38pr6	378	10	response	response	NN
cord-005478-5iu38pr6	378	11	and	and	CC
cord-005478-5iu38pr6	378	12	no	no	DT
cord-005478-5iu38pr6	378	13	response	response	NN
cord-005478-5iu38pr6	378	14	to	to	IN
cord-005478-5iu38pr6	378	15	IST	IST	NNP
cord-005478-5iu38pr6	378	16	.	.	.
cord-005478-5iu38pr6	379	1	Results	result	NNS
cord-005478-5iu38pr6	379	2	:	:	:
cord-005478-5iu38pr6	380	1	A	a	DT
cord-005478-5iu38pr6	380	2	total	total	NN
cord-005478-5iu38pr6	380	3	of	of	IN
cord-005478-5iu38pr6	380	4	81	81	CD
cord-005478-5iu38pr6	380	5	patients	patient	NNS
cord-005478-5iu38pr6	380	6	(	(	-LRB-
cord-005478-5iu38pr6	380	7	aged	aged	JJ
cord-005478-5iu38pr6	380	8	1.7	1.7	CD
cord-005478-5iu38pr6	380	9	-	-	HYPH
cord-005478-5iu38pr6	380	10	67.9	67.9	CD
cord-005478-5iu38pr6	380	11	years	year	NNS
cord-005478-5iu38pr6	380	12	)	)	-RRB-
cord-005478-5iu38pr6	380	13	were	be	VBD
cord-005478-5iu38pr6	380	14	randomized	randomize	VBN
cord-005478-5iu38pr6	380	15	;	;	:
cord-005478-5iu38pr6	380	16	43	43	CD
cord-005478-5iu38pr6	380	17	and	and	CC
cord-005478-5iu38pr6	380	18	38	38	CD
cord-005478-5iu38pr6	380	19	patients	patient	NNS
cord-005478-5iu38pr6	380	20	received	receive	VBD
cord-005478-5iu38pr6	380	21	2.5	2.5	CD
cord-005478-5iu38pr6	380	22	and	and	CC
cord-005478-5iu38pr6	380	23	3.5	3.5	CD
cord-005478-5iu38pr6	380	24	mg	mg	NNP
cord-005478-5iu38pr6	380	25	/	/	SYM
cord-005478-5iu38pr6	380	26	kg	kg	NNS
cord-005478-5iu38pr6	380	27	of	of	IN
cord-005478-5iu38pr6	380	28	r	r	NNP
cord-005478-5iu38pr6	380	29	-	-	HYPH
cord-005478-5iu38pr6	380	30	ATG	ATG	NNP
cord-005478-5iu38pr6	380	31	,	,	,
cord-005478-5iu38pr6	380	32	respectively	respectively	RB
cord-005478-5iu38pr6	380	33	.	.	.
cord-005478-5iu38pr6	381	1	In	in	IN
cord-005478-5iu38pr6	381	2	the	the	DT
cord-005478-5iu38pr6	381	3	2.5	2.5	CD
cord-005478-5iu38pr6	381	4	mg	mg	NNP
cord-005478-5iu38pr6	381	5	group	group	NN
cord-005478-5iu38pr6	381	6	,	,	,
cord-005478-5iu38pr6	381	7	the	the	DT
cord-005478-5iu38pr6	381	8	response	response	NN
cord-005478-5iu38pr6	381	9	rate	rate	NN
cord-005478-5iu38pr6	381	10	was	be	VBD
cord-005478-5iu38pr6	381	11	63	63	CD
cord-005478-5iu38pr6	381	12	%	%	NN
cord-005478-5iu38pr6	381	13	,	,	,
cord-005478-5iu38pr6	381	14	which	which	WDT
cord-005478-5iu38pr6	381	15	was	be	VBD
cord-005478-5iu38pr6	381	16	comparable	comparable	JJ
cord-005478-5iu38pr6	381	17	with	with	IN
cord-005478-5iu38pr6	381	18	that	that	DT
cord-005478-5iu38pr6	381	19	in	in	IN
cord-005478-5iu38pr6	381	20	the	the	DT
cord-005478-5iu38pr6	381	21	3.5	3.5	CD
cord-005478-5iu38pr6	381	22	mg	mg	NNP
cord-005478-5iu38pr6	381	23	group	group	NN
cord-005478-5iu38pr6	381	24	(	(	-LRB-
cord-005478-5iu38pr6	381	25	58	58	CD
cord-005478-5iu38pr6	381	26	%	%	NN
cord-005478-5iu38pr6	381	27	)	)	-RRB-
cord-005478-5iu38pr6	382	1	(	(	-LRB-
cord-005478-5iu38pr6	382	2	P	p	NN
cord-005478-5iu38pr6	382	3	=	=	SYM
cord-005478-5iu38pr6	382	4	0.820	0.820	CD
cord-005478-5iu38pr6	382	5	)	)	-RRB-
cord-005478-5iu38pr6	382	6	.	.	.
cord-005478-5iu38pr6	383	1	Plasma	plasma	NN
cord-005478-5iu38pr6	383	2	r	r	NN
cord-005478-5iu38pr6	383	3	-	-	HYPH
cord-005478-5iu38pr6	383	4	ATG	ATG	NNP
cord-005478-5iu38pr6	383	5	level	level	NN
cord-005478-5iu38pr6	383	6	greatly	greatly	RB
cord-005478-5iu38pr6	383	7	varied	varied	JJ
cord-005478-5iu38pr6	383	8	in	in	IN
cord-005478-5iu38pr6	383	9	both	both	DT
cord-005478-5iu38pr6	383	10	groups	group	NNS
cord-005478-5iu38pr6	383	11	.	.	.
cord-005478-5iu38pr6	384	1	Median	median	JJ
cord-005478-5iu38pr6	384	2	r	r	NN
cord-005478-5iu38pr6	384	3	-	-	HYPH
cord-005478-5iu38pr6	384	4	ATG	ATG	NNP
cord-005478-5iu38pr6	384	5	level	level	NN
cord-005478-5iu38pr6	384	6	on	on	IN
cord-005478-5iu38pr6	384	7	days	day	NNS
cord-005478-5iu38pr6	384	8	14	14	CD
cord-005478-5iu38pr6	384	9	and	and	CC
cord-005478-5iu38pr6	384	10	28	28	CD
cord-005478-5iu38pr6	384	11	after	after	IN
cord-005478-5iu38pr6	384	12	IST	IST	NNP
cord-005478-5iu38pr6	384	13	was	be	VBD
cord-005478-5iu38pr6	384	14	15.2	15.2	CD
cord-005478-5iu38pr6	384	15	(	(	-LRB-
cord-005478-5iu38pr6	384	16	0.0	0.0	CD
cord-005478-5iu38pr6	384	17	-	-	SYM
cord-005478-5iu38pr6	384	18	97.7	97.7	CD
cord-005478-5iu38pr6	384	19	)	)	-RRB-
cord-005478-5iu38pr6	384	20	and	and	CC
cord-005478-5iu38pr6	384	21	1.8	1.8	CD
cord-005478-5iu38pr6	384	22	(	(	-LRB-
cord-005478-5iu38pr6	384	23	0.0	0.0	CD
cord-005478-5iu38pr6	384	24	-	-	SYM
cord-005478-5iu38pr6	384	25	74.9	74.9	CD
cord-005478-5iu38pr6	384	26	μg	μg	NNP
cord-005478-5iu38pr6	384	27	/	/	SYM
cord-005478-5iu38pr6	384	28	mL	mL	NNP
cord-005478-5iu38pr6	384	29	)	)	-RRB-
cord-005478-5iu38pr6	384	30	,	,	,
cord-005478-5iu38pr6	384	31	respectively	respectively	RB
cord-005478-5iu38pr6	384	32	,	,	,
cord-005478-5iu38pr6	384	33	which	which	WDT
cord-005478-5iu38pr6	384	34	was	be	VBD
cord-005478-5iu38pr6	384	35	not	not	RB
cord-005478-5iu38pr6	384	36	significantly	significantly	RB
cord-005478-5iu38pr6	384	37	different	different	JJ
cord-005478-5iu38pr6	384	38	between	between	IN
cord-005478-5iu38pr6	384	39	two	two	CD
cord-005478-5iu38pr6	384	40	dosages	dosage	NNS
cord-005478-5iu38pr6	384	41	of	of	IN
cord-005478-5iu38pr6	384	42	ATG	ATG	NNP
cord-005478-5iu38pr6	384	43	groups	group	NNS
cord-005478-5iu38pr6	384	44	(	(	-LRB-
cord-005478-5iu38pr6	384	45	day	day	NN
cord-005478-5iu38pr6	384	46	14	14	CD
cord-005478-5iu38pr6	384	47	,	,	,
cord-005478-5iu38pr6	384	48	P	p	NN
cord-005478-5iu38pr6	384	49	=	=	SYM
cord-005478-5iu38pr6	384	50	0.498	0.498	CD
cord-005478-5iu38pr6	384	51	;	;	:
cord-005478-5iu38pr6	384	52	day	day	NN
cord-005478-5iu38pr6	384	53	28	28	CD
cord-005478-5iu38pr6	384	54	,	,	,
cord-005478-5iu38pr6	384	55	P	p	NN
cord-005478-5iu38pr6	384	56	=	=	SYM
cord-005478-5iu38pr6	384	57	0.404	0.404	CD
cord-005478-5iu38pr6	384	58	)	)	-RRB-
cord-005478-5iu38pr6	384	59	.	.	.
cord-005478-5iu38pr6	385	1	According	accord	VBG
cord-005478-5iu38pr6	385	2	to	to	IN
cord-005478-5iu38pr6	385	3	the	the	DT
cord-005478-5iu38pr6	385	4	r	r	NNP
cord-005478-5iu38pr6	385	5	-	-	HYPH
cord-005478-5iu38pr6	385	6	ATG	ATG	NNP
cord-005478-5iu38pr6	385	7	level	level	NN
cord-005478-5iu38pr6	385	8	,	,	,
cord-005478-5iu38pr6	385	9	response	response	NN
cord-005478-5iu38pr6	385	10	rates	rate	NNS
cord-005478-5iu38pr6	385	11	were	be	VBD
cord-005478-5iu38pr6	385	12	significantly	significantly	RB
cord-005478-5iu38pr6	385	13	higher	high	JJR
cord-005478-5iu38pr6	385	14	in	in	IN
cord-005478-5iu38pr6	385	15	the	the	DT
cord-005478-5iu38pr6	385	16	group	group	NN
cord-005478-5iu38pr6	385	17	with	with	IN
cord-005478-5iu38pr6	385	18	higher	high	JJR
cord-005478-5iu38pr6	385	19	r	r	NNP
cord-005478-5iu38pr6	385	20	-	-	HYPH
cord-005478-5iu38pr6	385	21	ATG	ATG	NNP
cord-005478-5iu38pr6	385	22	level	level	NN
cord-005478-5iu38pr6	385	23	than	than	IN
cord-005478-5iu38pr6	385	24	in	in	IN
cord-005478-5iu38pr6	385	25	that	that	DT
cord-005478-5iu38pr6	385	26	with	with	IN
cord-005478-5iu38pr6	385	27	lower	low	JJR
cord-005478-5iu38pr6	385	28	ATG	ATG	NNP
cord-005478-5iu38pr6	385	29	level	level	NN
cord-005478-5iu38pr6	385	30	(	(	-LRB-
cord-005478-5iu38pr6	385	31	day	day	NN
cord-005478-5iu38pr6	385	32	14	14	CD
cord-005478-5iu38pr6	385	33	,	,	,
cord-005478-5iu38pr6	385	34	88	88	CD
cord-005478-5iu38pr6	385	35	%	%	NN
cord-005478-5iu38pr6	385	36	vs.	vs.	IN
cord-005478-5iu38pr6	385	37	52	52	CD
cord-005478-5iu38pr6	385	38	%	%	NN
cord-005478-5iu38pr6	385	39	,	,	,
cord-005478-5iu38pr6	385	40	respectively	respectively	RB
cord-005478-5iu38pr6	385	41	;	;	:
cord-005478-5iu38pr6	385	42	P	p	NN
cord-005478-5iu38pr6	385	43	=	=	SYM
cord-005478-5iu38pr6	385	44	0.006	0.006	CD
cord-005478-5iu38pr6	385	45	and	and	CC
cord-005478-5iu38pr6	385	46	day	day	NN
cord-005478-5iu38pr6	385	47	28	28	CD
cord-005478-5iu38pr6	385	48	,	,	,
cord-005478-5iu38pr6	385	49	79	79	CD
cord-005478-5iu38pr6	385	50	%	%	NN
cord-005478-5iu38pr6	385	51	vs.	vs.	IN
cord-005478-5iu38pr6	385	52	46	46	CD
cord-005478-5iu38pr6	385	53	%	%	NN
cord-005478-5iu38pr6	385	54	;	;	:
cord-005478-5iu38pr6	385	55	P	p	NN
cord-005478-5iu38pr6	385	56	=	=	SYM
cord-005478-5iu38pr6	385	57	0.005	0.005	CD
cord-005478-5iu38pr6	385	58	)	)	-RRB-
cord-005478-5iu38pr6	386	1	(	(	-LRB-
cord-005478-5iu38pr6	386	2	Figure	figure	NN
cord-005478-5iu38pr6	386	3	)	)	-RRB-
cord-005478-5iu38pr6	386	4	.	.	.
cord-005478-5iu38pr6	387	1	Cut	cut	VB
cord-005478-5iu38pr6	387	2	-	-	HYPH
cord-005478-5iu38pr6	387	3	off	off	RP
cord-005478-5iu38pr6	387	4	levels	level	NNS
cord-005478-5iu38pr6	387	5	at	at	IN
cord-005478-5iu38pr6	387	6	days	day	NNS
cord-005478-5iu38pr6	387	7	14	14	CD
cord-005478-5iu38pr6	387	8	and	and	CC
cord-005478-5iu38pr6	387	9	28	28	CD
cord-005478-5iu38pr6	387	10	were	be	VBD
cord-005478-5iu38pr6	387	11	21.6	21.6	CD
cord-005478-5iu38pr6	387	12	and	and	CC
cord-005478-5iu38pr6	387	13	4.8	4.8	CD
cord-005478-5iu38pr6	387	14	μg	μg	NNS
cord-005478-5iu38pr6	387	15	/	/	SYM
cord-005478-5iu38pr6	387	16	mL	ml	NN
cord-005478-5iu38pr6	387	17	,	,	,
cord-005478-5iu38pr6	387	18	respectively	respectively	RB
cord-005478-5iu38pr6	387	19	.	.	.
cord-005478-5iu38pr6	388	1	The	the	DT
cord-005478-5iu38pr6	388	2	vast	vast	JJ
cord-005478-5iu38pr6	388	3	majority	majority	NN
cord-005478-5iu38pr6	388	4	(	(	-LRB-
cord-005478-5iu38pr6	388	5	90	90	CD
cord-005478-5iu38pr6	388	6	%	%	NN
cord-005478-5iu38pr6	388	7	)	)	-RRB-
cord-005478-5iu38pr6	388	8	of	of	IN
cord-005478-5iu38pr6	388	9	patients	patient	NNS
cord-005478-5iu38pr6	388	10	with	with	IN
cord-005478-5iu38pr6	388	11	levels	level	NNS
cord-005478-5iu38pr6	388	12	higher	high	JJR
cord-005478-5iu38pr6	388	13	than	than	IN
cord-005478-5iu38pr6	388	14	cut	cut	VB
cord-005478-5iu38pr6	388	15	-	-	HYPH
cord-005478-5iu38pr6	388	16	off	off	RP
cord-005478-5iu38pr6	388	17	levels	level	NNS
cord-005478-5iu38pr6	388	18	on	on	IN
cord-005478-5iu38pr6	388	19	day	day	NN
cord-005478-5iu38pr6	388	20	14	14	CD
cord-005478-5iu38pr6	388	21	responded	respond	VBD
cord-005478-5iu38pr6	388	22	to	to	IN
cord-005478-5iu38pr6	388	23	IST	IST	NNP
cord-005478-5iu38pr6	388	24	.	.	.
cord-005478-5iu38pr6	389	1	In	in	IN
cord-005478-5iu38pr6	389	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	389	3	analysis	analysis	NN
cord-005478-5iu38pr6	389	4	,	,	,
cord-005478-5iu38pr6	389	5	higher	high	JJR
cord-005478-5iu38pr6	389	6	ATG	ATG	NNP
cord-005478-5iu38pr6	389	7	levels	level	NNS
cord-005478-5iu38pr6	389	8	at	at	IN
cord-005478-5iu38pr6	389	9	day	day	NN
cord-005478-5iu38pr6	389	10	28	28	CD
cord-005478-5iu38pr6	389	11	were	be	VBD
cord-005478-5iu38pr6	389	12	independent	independent	JJ
cord-005478-5iu38pr6	389	13	favorable	favorable	JJ
cord-005478-5iu38pr6	389	14	predictors	predictor	NNS
cord-005478-5iu38pr6	389	15	of	of	IN
cord-005478-5iu38pr6	389	16	response	response	NN
cord-005478-5iu38pr6	389	17	to	to	IN
cord-005478-5iu38pr6	389	18	IST	IST	NNP
cord-005478-5iu38pr6	389	19	at	at	IN
cord-005478-5iu38pr6	389	20	6	6	CD
cord-005478-5iu38pr6	389	21	months	month	NNS
cord-005478-5iu38pr6	389	22	(	(	-LRB-
cord-005478-5iu38pr6	389	23	OR	or	CC
cord-005478-5iu38pr6	389	24	=	=	SYM
cord-005478-5iu38pr6	389	25	0.29	0.29	CD
cord-005478-5iu38pr6	389	26	;	;	:
cord-005478-5iu38pr6	389	27	95	95	CD
cord-005478-5iu38pr6	389	28	%	%	NN
cord-005478-5iu38pr6	389	29	CI	ci	NN
cord-005478-5iu38pr6	389	30	:	:	:
cord-005478-5iu38pr6	389	31	0.09	0.09	CD
cord-005478-5iu38pr6	389	32	-	-	HYPH
cord-005478-5iu38pr6	389	33	0.93	0.93	CD
cord-005478-5iu38pr6	389	34	;	;	:
cord-005478-5iu38pr6	389	35	P	p	NN
cord-005478-5iu38pr6	389	36	=	=	SYM
cord-005478-5iu38pr6	389	37	0.037	0.037	CD
cord-005478-5iu38pr6	389	38	)	)	-RRB-
cord-005478-5iu38pr6	389	39	.	.	.
cord-005478-5iu38pr6	390	1	There	there	EX
cord-005478-5iu38pr6	390	2	were	be	VBD
cord-005478-5iu38pr6	390	3	no	no	DT
cord-005478-5iu38pr6	390	4	significant	significant	JJ
cord-005478-5iu38pr6	390	5	differences	difference	NNS
cord-005478-5iu38pr6	390	6	in	in	IN
cord-005478-5iu38pr6	390	7	the	the	DT
cord-005478-5iu38pr6	390	8	kinetics	kinetic	NNS
cord-005478-5iu38pr6	390	9	of	of	IN
cord-005478-5iu38pr6	390	10	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	390	11	subsets	subset	NNS
cord-005478-5iu38pr6	390	12	among	among	IN
cord-005478-5iu38pr6	390	13	patients	patient	NNS
cord-005478-5iu38pr6	390	14	treated	treat	VBN
cord-005478-5iu38pr6	390	15	with	with	IN
cord-005478-5iu38pr6	390	16	different	different	JJ
cord-005478-5iu38pr6	390	17	dosages	dosage	NNS
cord-005478-5iu38pr6	390	18	of	of	IN
cord-005478-5iu38pr6	390	19	ATG	ATG	NNP
cord-005478-5iu38pr6	390	20	.	.	.
cord-005478-5iu38pr6	391	1	However	however	RB
cord-005478-5iu38pr6	391	2	,	,	,
cord-005478-5iu38pr6	391	3	higher	high	JJR
cord-005478-5iu38pr6	391	4	ATG	ATG	NNP
cord-005478-5iu38pr6	391	5	level	level	NN
cord-005478-5iu38pr6	391	6	was	be	VBD
cord-005478-5iu38pr6	391	7	associated	associate	VBN
cord-005478-5iu38pr6	391	8	with	with	IN
cord-005478-5iu38pr6	391	9	lower	low	JJR
cord-005478-5iu38pr6	391	10	CD4	CD4	NNP
cord-005478-5iu38pr6	391	11	+	+	CC
cord-005478-5iu38pr6	391	12	T	T	NNP
cord-005478-5iu38pr6	391	13	and	and	CC
cord-005478-5iu38pr6	391	14	regulatory	regulatory	JJ
cord-005478-5iu38pr6	391	15	T	t	NN
cord-005478-5iu38pr6	391	16	cell	cell	NN
cord-005478-5iu38pr6	391	17	numbers	number	NNS
cord-005478-5iu38pr6	391	18	for	for	IN
cord-005478-5iu38pr6	391	19	the	the	DT
cord-005478-5iu38pr6	391	20	entire	entire	JJ
cord-005478-5iu38pr6	391	21	6-month	6-month	CD
cord-005478-5iu38pr6	391	22	period	period	NN
cord-005478-5iu38pr6	391	23	.	.	.
cord-005478-5iu38pr6	392	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	392	2	:	:	:
cord-005478-5iu38pr6	393	1	The	the	DT
cord-005478-5iu38pr6	393	2	present	present	JJ
cord-005478-5iu38pr6	393	3	data	datum	NNS
cord-005478-5iu38pr6	393	4	indicate	indicate	VBP
cord-005478-5iu38pr6	393	5	interindividual	interindividual	JJ
cord-005478-5iu38pr6	393	6	variability	variability	NN
cord-005478-5iu38pr6	393	7	in	in	IN
cord-005478-5iu38pr6	393	8	plasma	plasma	NN
cord-005478-5iu38pr6	393	9	r	r	NN
cord-005478-5iu38pr6	393	10	-	-	HYPH
cord-005478-5iu38pr6	393	11	ATG	ATG	NNP
cord-005478-5iu38pr6	393	12	level	level	NN
cord-005478-5iu38pr6	393	13	.	.	.
cord-005478-5iu38pr6	394	1	Higher	high	JJR
cord-005478-5iu38pr6	394	2	ATG	ATG	NNP
cord-005478-5iu38pr6	394	3	level	level	NN
cord-005478-5iu38pr6	394	4	resulted	result	VBD
cord-005478-5iu38pr6	394	5	in	in	IN
cord-005478-5iu38pr6	394	6	improved	improved	JJ
cord-005478-5iu38pr6	394	7	response	response	NN
cord-005478-5iu38pr6	394	8	to	to	IN
cord-005478-5iu38pr6	394	9	IST	IST	NNP
cord-005478-5iu38pr6	394	10	and	and	CC
cord-005478-5iu38pr6	394	11	correlated	correlate	VBN
cord-005478-5iu38pr6	394	12	with	with	IN
cord-005478-5iu38pr6	394	13	prolonged	prolong	VBN
cord-005478-5iu38pr6	394	14	immune	immune	JJ
cord-005478-5iu38pr6	394	15	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	394	16	.	.	.
cord-005478-5iu38pr6	395	1	Individualized	individualized	JJ
cord-005478-5iu38pr6	395	2	dosing	dosing	NN
cord-005478-5iu38pr6	395	3	of	of	IN
cord-005478-5iu38pr6	395	4	ATG	ATG	NNP
cord-005478-5iu38pr6	395	5	via	via	IN
cord-005478-5iu38pr6	395	6	a	a	DT
cord-005478-5iu38pr6	395	7	pharmacokinetic	pharmacokinetic	JJ
cord-005478-5iu38pr6	395	8	model	model	NN
cord-005478-5iu38pr6	395	9	may	may	MD
cord-005478-5iu38pr6	395	10	improve	improve	VB
cord-005478-5iu38pr6	395	11	the	the	DT
cord-005478-5iu38pr6	395	12	response	response	NN
cord-005478-5iu38pr6	395	13	rate	rate	NN
cord-005478-5iu38pr6	395	14	to	to	IN
cord-005478-5iu38pr6	395	15	IST	IST	NNP
cord-005478-5iu38pr6	395	16	and	and	CC
cord-005478-5iu38pr6	395	17	reduce	reduce	VB
cord-005478-5iu38pr6	395	18	the	the	DT
cord-005478-5iu38pr6	395	19	number	number	NN
cord-005478-5iu38pr6	395	20	of	of	IN
cord-005478-5iu38pr6	395	21	patients	patient	NNS
cord-005478-5iu38pr6	395	22	who	who	WP
cord-005478-5iu38pr6	395	23	require	require	VBP
cord-005478-5iu38pr6	395	24	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	395	25	stem	stem	NN
cord-005478-5iu38pr6	395	26	cell	cell	NN
cord-005478-5iu38pr6	395	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	395	28	following	follow	VBG
cord-005478-5iu38pr6	395	29	IST	IST	NNP
cord-005478-5iu38pr6	395	30	.	.	.
cord-005478-5iu38pr6	396	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	396	2	Background	background	NN
cord-005478-5iu38pr6	396	3	:	:	:
cord-005478-5iu38pr6	397	1	Radiation	radiation	NN
cord-005478-5iu38pr6	397	2	and	and	CC
cord-005478-5iu38pr6	397	3	DNA	dna	NN
cord-005478-5iu38pr6	397	4	alkylating	alkylating	JJ
cord-005478-5iu38pr6	397	5	agents	agent	NNS
cord-005478-5iu38pr6	397	6	used	use	VBN
cord-005478-5iu38pr6	397	7	in	in	IN
cord-005478-5iu38pr6	397	8	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	397	9	cell	cell	NN
cord-005478-5iu38pr6	397	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	397	11	(	(	-LRB-
cord-005478-5iu38pr6	397	12	HCT	HCT	NNP
cord-005478-5iu38pr6	397	13	)	)	-RRB-
cord-005478-5iu38pr6	397	14	can	can	MD
cord-005478-5iu38pr6	397	15	cause	cause	VB
cord-005478-5iu38pr6	397	16	organ	organ	NN
cord-005478-5iu38pr6	397	17	damage	damage	NN
cord-005478-5iu38pr6	397	18	,	,	,
cord-005478-5iu38pr6	397	19	malignancy	malignancy	NN
cord-005478-5iu38pr6	397	20	and	and	CC
cord-005478-5iu38pr6	397	21	death	death	NN
cord-005478-5iu38pr6	397	22	.	.	.
cord-005478-5iu38pr6	398	1	These	these	DT
cord-005478-5iu38pr6	398	2	risks	risk	NNS
cord-005478-5iu38pr6	398	3	are	be	VBP
cord-005478-5iu38pr6	398	4	heightened	heighten	VBN
cord-005478-5iu38pr6	398	5	in	in	IN
cord-005478-5iu38pr6	398	6	patients	patient	NNS
cord-005478-5iu38pr6	398	7	with	with	IN
cord-005478-5iu38pr6	398	8	genetic	genetic	JJ
cord-005478-5iu38pr6	398	9	bone	bone	NN
cord-005478-5iu38pr6	398	10	marrow	marrow	NN
cord-005478-5iu38pr6	398	11	failure	failure	NN
cord-005478-5iu38pr6	398	12	(	(	-LRB-
cord-005478-5iu38pr6	398	13	BMF	BMF	NNP
cord-005478-5iu38pr6	398	14	)	)	-RRB-
cord-005478-5iu38pr6	398	15	syndromes	syndrome	NNS
cord-005478-5iu38pr6	398	16	driven	drive	VBN
cord-005478-5iu38pr6	398	17	by	by	IN
cord-005478-5iu38pr6	398	18	defects	defect	NNS
cord-005478-5iu38pr6	398	19	in	in	IN
cord-005478-5iu38pr6	398	20	cellular	cellular	JJ
cord-005478-5iu38pr6	398	21	proliferation	proliferation	NN
cord-005478-5iu38pr6	398	22	or	or	CC
cord-005478-5iu38pr6	398	23	DNA	dna	NN
cord-005478-5iu38pr6	398	24	repair	repair	NN
cord-005478-5iu38pr6	398	25	,	,	,
cord-005478-5iu38pr6	398	26	including	include	VBG
cord-005478-5iu38pr6	398	27	dyskeratosis	dyskeratosis	NN
cord-005478-5iu38pr6	398	28	congenita	congenita	NNP
cord-005478-5iu38pr6	398	29	(	(	-LRB-
cord-005478-5iu38pr6	398	30	DC	DC	NNP
cord-005478-5iu38pr6	398	31	)	)	-RRB-
cord-005478-5iu38pr6	398	32	,	,	,
cord-005478-5iu38pr6	398	33	which	which	WDT
cord-005478-5iu38pr6	398	34	arises	arise	VBZ
cord-005478-5iu38pr6	398	35	from	from	IN
cord-005478-5iu38pr6	398	36	impaired	impaired	JJ
cord-005478-5iu38pr6	398	37	telomere	telomere	NN
cord-005478-5iu38pr6	398	38	maintenance	maintenance	NN
cord-005478-5iu38pr6	398	39	.	.	.
cord-005478-5iu38pr6	399	1	We	-PRON-	PRP
cord-005478-5iu38pr6	399	2	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	399	3	that	that	IN
cord-005478-5iu38pr6	399	4	proliferative	proliferative	JJ
cord-005478-5iu38pr6	399	5	defects	defect	NNS
cord-005478-5iu38pr6	399	6	in	in	IN
cord-005478-5iu38pr6	399	7	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	399	8	cells	cell	NNS
cord-005478-5iu38pr6	399	9	of	of	IN
cord-005478-5iu38pr6	399	10	patients	patient	NNS
cord-005478-5iu38pr6	399	11	with	with	IN
cord-005478-5iu38pr6	399	12	BMF	BMF	NNP
cord-005478-5iu38pr6	399	13	and	and	CC
cord-005478-5iu38pr6	399	14	very	very	RB
cord-005478-5iu38pr6	399	15	short	short	JJ
cord-005478-5iu38pr6	399	16	telomeres	telomere	NNS
cord-005478-5iu38pr6	399	17	might	may	MD
cord-005478-5iu38pr6	399	18	permit	permit	VB
cord-005478-5iu38pr6	399	19	myeloid	myeloid	NN
cord-005478-5iu38pr6	399	20	engraftment	engraftment	NN
cord-005478-5iu38pr6	399	21	following	follow	VBG
cord-005478-5iu38pr6	399	22	HCT	HCT	NNP
cord-005478-5iu38pr6	399	23	without	without	IN
cord-005478-5iu38pr6	399	24	the	the	DT
cord-005478-5iu38pr6	399	25	need	need	NN
cord-005478-5iu38pr6	399	26	for	for	IN
cord-005478-5iu38pr6	399	27	radiation	radiation	NN
cord-005478-5iu38pr6	399	28	or	or	CC
cord-005478-5iu38pr6	399	29	DNA	dna	NN
cord-005478-5iu38pr6	399	30	alkylating	alkylating	NN
cord-005478-5iu38pr6	399	31	agents	agent	NNS
cord-005478-5iu38pr6	399	32	.	.	.
cord-005478-5iu38pr6	400	1	We	-PRON-	PRP
cord-005478-5iu38pr6	400	2	conducted	conduct	VBD
cord-005478-5iu38pr6	400	3	a	a	DT
cord-005478-5iu38pr6	400	4	multi	multi	JJ
cord-005478-5iu38pr6	400	5	-	-	JJ
cord-005478-5iu38pr6	400	6	center	center	JJ
cord-005478-5iu38pr6	400	7	prospective	prospective	JJ
cord-005478-5iu38pr6	400	8	trial	trial	NN
cord-005478-5iu38pr6	400	9	(	(	-LRB-
cord-005478-5iu38pr6	400	10	NCT01659606	NCT01659606	NNP
cord-005478-5iu38pr6	400	11	)	)	-RRB-
cord-005478-5iu38pr6	400	12	evaluating	evaluate	VBG
cord-005478-5iu38pr6	400	13	engraftment	engraftment	NN
cord-005478-5iu38pr6	400	14	after	after	IN
cord-005478-5iu38pr6	400	15	HCT	HCT	NNP
cord-005478-5iu38pr6	400	16	without	without	IN
cord-005478-5iu38pr6	400	17	these	these	DT
cord-005478-5iu38pr6	400	18	agents	agent	NNS
cord-005478-5iu38pr6	400	19	.	.	.
cord-005478-5iu38pr6	401	1	Methods	method	NNS
cord-005478-5iu38pr6	401	2	:	:	:
cord-005478-5iu38pr6	401	3	We	-PRON-	PRP
cord-005478-5iu38pr6	401	4	enrolled	enrol	VBD
cord-005478-5iu38pr6	401	5	BMF	BMF	NNP
cord-005478-5iu38pr6	401	6	patients	patient	NNS
cord-005478-5iu38pr6	401	7	with	with	IN
cord-005478-5iu38pr6	401	8	genetic	genetic	JJ
cord-005478-5iu38pr6	401	9	validation	validation	NN
cord-005478-5iu38pr6	401	10	of	of	IN
cord-005478-5iu38pr6	401	11	DC	DC	NNP
cord-005478-5iu38pr6	401	12	or	or	CC
cord-005478-5iu38pr6	401	13	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	401	14	telomere	telomere	NN
cord-005478-5iu38pr6	401	15	length	length	NN
cord-005478-5iu38pr6	401	16	<	<	XX
cord-005478-5iu38pr6	401	17	1	1	CD
cord-005478-5iu38pr6	401	18	st	st	NNP
cord-005478-5iu38pr6	401	19	percentile	percentile	NN
cord-005478-5iu38pr6	401	20	by	by	IN
cord-005478-5iu38pr6	401	21	flow	flow	NN
cord-005478-5iu38pr6	401	22	-	-	HYPH
cord-005478-5iu38pr6	401	23	FISH	fish	NN
cord-005478-5iu38pr6	401	24	.	.	.
cord-005478-5iu38pr6	402	1	We	-PRON-	PRP
cord-005478-5iu38pr6	402	2	performed	perform	VBD
cord-005478-5iu38pr6	402	3	HCT	hct	NN
cord-005478-5iu38pr6	402	4	using	use	VBG
cord-005478-5iu38pr6	402	5	bone	bone	NN
cord-005478-5iu38pr6	402	6	marrow	marrow	NN
cord-005478-5iu38pr6	402	7	allografts	allograft	NNS
cord-005478-5iu38pr6	402	8	from	from	IN
cord-005478-5iu38pr6	402	9	related	related	JJ
cord-005478-5iu38pr6	402	10	or	or	CC
cord-005478-5iu38pr6	402	11	unrelated	unrelated	JJ
cord-005478-5iu38pr6	402	12	donors	donor	NNS
cord-005478-5iu38pr6	402	13	matched	match	VBN
cord-005478-5iu38pr6	402	14	at	at	IN
cord-005478-5iu38pr6	402	15	7	7	CD
cord-005478-5iu38pr6	402	16	or	or	CC
cord-005478-5iu38pr6	402	17	8	8	CD
cord-005478-5iu38pr6	402	18	of	of	IN
cord-005478-5iu38pr6	402	19	8	8	CD
cord-005478-5iu38pr6	402	20	HLA	HLA	NNP
cord-005478-5iu38pr6	402	21	alleles	allele	NNS
cord-005478-5iu38pr6	402	22	after	after	IN
cord-005478-5iu38pr6	402	23	a	a	DT
cord-005478-5iu38pr6	402	24	preparative	preparative	JJ
cord-005478-5iu38pr6	402	25	regimen	regimen	NN
cord-005478-5iu38pr6	402	26	consisting	consist	VBG
cord-005478-5iu38pr6	402	27	of	of	IN
cord-005478-5iu38pr6	402	28	only	only	JJ
cord-005478-5iu38pr6	402	29	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	402	30	and	and	CC
cord-005478-5iu38pr6	402	31	alemtuzumab	alemtuzumab	NNS
cord-005478-5iu38pr6	402	32	.	.	.
cord-005478-5iu38pr6	403	1	Graft	graft	NN
cord-005478-5iu38pr6	403	2	versus	versus	IN
cord-005478-5iu38pr6	403	3	host	host	NN
cord-005478-5iu38pr6	403	4	disease	disease	NN
cord-005478-5iu38pr6	403	5	(	(	-LRB-
cord-005478-5iu38pr6	403	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	403	7	)	)	-RRB-
cord-005478-5iu38pr6	403	8	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	403	9	consisted	consist	VBD
cord-005478-5iu38pr6	403	10	of	of	IN
cord-005478-5iu38pr6	403	11	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	403	12	A	A	NNP
cord-005478-5iu38pr6	403	13	and	and	CC
cord-005478-5iu38pr6	403	14	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	403	15	mofetil	mofetil	NNP
cord-005478-5iu38pr6	403	16	.	.	.
cord-005478-5iu38pr6	404	1	The	the	DT
cord-005478-5iu38pr6	404	2	primary	primary	JJ
cord-005478-5iu38pr6	404	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	404	4	of	of	IN
cord-005478-5iu38pr6	404	5	the	the	DT
cord-005478-5iu38pr6	404	6	trial	trial	NN
cord-005478-5iu38pr6	404	7	was	be	VBD
cord-005478-5iu38pr6	404	8	donor	donor	NN
cord-005478-5iu38pr6	404	9	myeloid	myeloid	NN
cord-005478-5iu38pr6	404	10	engraftment	engraftment	NN
cord-005478-5iu38pr6	404	11	,	,	,
cord-005478-5iu38pr6	404	12	defined	define	VBN
cord-005478-5iu38pr6	404	13	as	as	IN
cord-005478-5iu38pr6	404	14	an	an	DT
cord-005478-5iu38pr6	404	15	absolute	absolute	JJ
cord-005478-5iu38pr6	404	16	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	404	17	count	count	NN
cord-005478-5iu38pr6	404	18	≥500	≥500	''
cord-005478-5iu38pr6	404	19	cells/	cells/	CD
cord-005478-5iu38pr6	405	1	μL	μL	NFP
cord-005478-5iu38pr6	405	2	by	by	IN
cord-005478-5iu38pr6	405	3	day	day	NN
cord-005478-5iu38pr6	406	1	+42	+42	NN
cord-005478-5iu38pr6	406	2	and	and	CC
cord-005478-5iu38pr6	406	3	donor	donor	NN
cord-005478-5iu38pr6	406	4	myeloid	myeloid	NN
cord-005478-5iu38pr6	406	5	chimerism	chimerism	NN
cord-005478-5iu38pr6	406	6	>	>	XX
cord-005478-5iu38pr6	406	7	50	50	CD
cord-005478-5iu38pr6	406	8	%	%	NN
cord-005478-5iu38pr6	406	9	by	by	IN
cord-005478-5iu38pr6	406	10	day	day	NN
cord-005478-5iu38pr6	406	11	+100	+100	NNS
cord-005478-5iu38pr6	406	12	.	.	.
cord-005478-5iu38pr6	407	1	[	[	-LRB-
cord-005478-5iu38pr6	407	2	[	[	-LRB-
cord-005478-5iu38pr6	407	3	O029	o029	CC
cord-005478-5iu38pr6	407	4	Image	image	NN
cord-005478-5iu38pr6	407	5	]	]	-RRB-
cord-005478-5iu38pr6	407	6	1	1	CD
cord-005478-5iu38pr6	407	7	.	.	.
cord-005478-5iu38pr6	408	1	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	408	2	and	and	CC
cord-005478-5iu38pr6	408	3	Survival	Survival	NNP
cord-005478-5iu38pr6	408	4	after	after	IN
cord-005478-5iu38pr6	408	5	Radiation	Radiation	NNP
cord-005478-5iu38pr6	408	6	-	-	:
cord-005478-5iu38pr6	408	7	and	and	CC
cord-005478-5iu38pr6	408	8	Alkylator	Alkylator	NNP
cord-005478-5iu38pr6	408	9	-	-	HYPH
cord-005478-5iu38pr6	408	10	Free	Free	NNP
cord-005478-5iu38pr6	408	11	HCT	hct	NN
cord-005478-5iu38pr6	408	12	for	for	IN
cord-005478-5iu38pr6	408	13	BMF	BMF	NNP
cord-005478-5iu38pr6	408	14	with	with	IN
cord-005478-5iu38pr6	408	15	Very	very	RB
cord-005478-5iu38pr6	408	16	Short	short	JJ
cord-005478-5iu38pr6	408	17	Telomeres	Telomeres	NNPS
cord-005478-5iu38pr6	408	18	]	]	-RRB-
cord-005478-5iu38pr6	409	1	Results	result	NNS
cord-005478-5iu38pr6	409	2	:	:	:
cord-005478-5iu38pr6	410	1	Twenty	twenty	CD
cord-005478-5iu38pr6	410	2	patients	patient	NNS
cord-005478-5iu38pr6	410	3	(	(	-LRB-
cord-005478-5iu38pr6	410	4	age	age	NN
cord-005478-5iu38pr6	410	5	1.7	1.7	CD
cord-005478-5iu38pr6	410	6	-	-	SYM
cord-005478-5iu38pr6	410	7	31.5	31.5	CD
cord-005478-5iu38pr6	410	8	years	year	NNS
cord-005478-5iu38pr6	410	9	old	old	JJ
cord-005478-5iu38pr6	410	10	at	at	IN
cord-005478-5iu38pr6	410	11	HCT	HCT	NNP
cord-005478-5iu38pr6	410	12	)	)	-RRB-
cord-005478-5iu38pr6	410	13	received	receive	VBD
cord-005478-5iu38pr6	410	14	treatment	treatment	NN
cord-005478-5iu38pr6	410	15	between	between	IN
cord-005478-5iu38pr6	410	16	August	August	NNP
cord-005478-5iu38pr6	410	17	2012	2012	CD
cord-005478-5iu38pr6	410	18	-October	-October	:
cord-005478-5iu38pr6	410	19	2018	2018	CD
cord-005478-5iu38pr6	410	20	at	at	IN
cord-005478-5iu38pr6	410	21	7	7	CD
cord-005478-5iu38pr6	410	22	institutions	institution	NNS
cord-005478-5iu38pr6	410	23	.	.	.
cord-005478-5iu38pr6	411	1	Eighteen	eighteen	CD
cord-005478-5iu38pr6	411	2	of	of	IN
cord-005478-5iu38pr6	411	3	the	the	DT
cord-005478-5iu38pr6	411	4	20	20	CD
cord-005478-5iu38pr6	411	5	patients	patient	NNS
cord-005478-5iu38pr6	411	6	received	receive	VBD
cord-005478-5iu38pr6	411	7	unrelated	unrelated	JJ
cord-005478-5iu38pr6	411	8	donor	donor	NN
cord-005478-5iu38pr6	411	9	grafts	graft	NNS
cord-005478-5iu38pr6	411	10	(	(	-LRB-
cord-005478-5iu38pr6	411	11	15	15	CD
cord-005478-5iu38pr6	411	12	matched	match	VBN
cord-005478-5iu38pr6	411	13	,	,	,
cord-005478-5iu38pr6	411	14	3	3	CD
cord-005478-5iu38pr6	411	15	single	single	JJ
cord-005478-5iu38pr6	411	16	-	-	HYPH
cord-005478-5iu38pr6	411	17	allele	allele	NN
cord-005478-5iu38pr6	411	18	mismatched	mismatch	VBN
cord-005478-5iu38pr6	411	19	)	)	-RRB-
cord-005478-5iu38pr6	411	20	.	.	.
cord-005478-5iu38pr6	412	1	Primary	primary	JJ
cord-005478-5iu38pr6	412	2	myeloid	myeloid	NN
cord-005478-5iu38pr6	412	3	engraftment	engraftment	NN
cord-005478-5iu38pr6	412	4	was	be	VBD
cord-005478-5iu38pr6	412	5	achieved	achieve	VBN
cord-005478-5iu38pr6	412	6	in	in	IN
cord-005478-5iu38pr6	412	7	19	19	CD
cord-005478-5iu38pr6	412	8	of	of	IN
cord-005478-5iu38pr6	412	9	20	20	CD
cord-005478-5iu38pr6	412	10	patients	patient	NNS
cord-005478-5iu38pr6	412	11	(	(	-LRB-
cord-005478-5iu38pr6	412	12	95	95	CD
cord-005478-5iu38pr6	412	13	%	%	NN
cord-005478-5iu38pr6	412	14	)	)	-RRB-
cord-005478-5iu38pr6	412	15	at	at	IN
cord-005478-5iu38pr6	412	16	a	a	DT
cord-005478-5iu38pr6	412	17	median	median	JJ
cord-005478-5iu38pr6	412	18	22	22	CD
cord-005478-5iu38pr6	412	19	days	day	NNS
cord-005478-5iu38pr6	412	20	post	post	NN
cord-005478-5iu38pr6	412	21	-	-	JJ
cord-005478-5iu38pr6	412	22	HCT	hct	JJ
cord-005478-5iu38pr6	412	23	(	(	-LRB-
cord-005478-5iu38pr6	412	24	range	range	NN
cord-005478-5iu38pr6	412	25	1	1	CD
cord-005478-5iu38pr6	412	26	-	-	SYM
cord-005478-5iu38pr6	412	27	35	35	CD
cord-005478-5iu38pr6	412	28	days	day	NNS
cord-005478-5iu38pr6	412	29	)	)	-RRB-
cord-005478-5iu38pr6	412	30	.	.	.
cord-005478-5iu38pr6	413	1	The	the	DT
cord-005478-5iu38pr6	413	2	single	single	JJ
cord-005478-5iu38pr6	413	3	patient	patient	NN
cord-005478-5iu38pr6	413	4	with	with	IN
cord-005478-5iu38pr6	413	5	primary	primary	JJ
cord-005478-5iu38pr6	413	6	graft	graft	NN
cord-005478-5iu38pr6	413	7	failure	failure	NN
cord-005478-5iu38pr6	413	8	had	have	VBD
cord-005478-5iu38pr6	413	9	DC	DC	NNP
cord-005478-5iu38pr6	413	10	-	-	HYPH
cord-005478-5iu38pr6	413	11	related	relate	VBN
cord-005478-5iu38pr6	413	12	liver	liver	NN
cord-005478-5iu38pr6	413	13	disease	disease	NN
cord-005478-5iu38pr6	413	14	and	and	CC
cord-005478-5iu38pr6	413	15	hypersplenism	hypersplenism	NN
cord-005478-5iu38pr6	413	16	;	;	:
cord-005478-5iu38pr6	413	17	in	in	IN
cord-005478-5iu38pr6	413	18	this	this	DT
cord-005478-5iu38pr6	413	19	case	case	NN
cord-005478-5iu38pr6	413	20	,	,	,
cord-005478-5iu38pr6	413	21	splenectomy	splenectomy	NN
cord-005478-5iu38pr6	413	22	at	at	IN
cord-005478-5iu38pr6	413	23	day	day	NN
cord-005478-5iu38pr6	413	24	+47	+47	NNP
cord-005478-5iu38pr6	413	25	promptly	promptly	RB
cord-005478-5iu38pr6	413	26	revealed	reveal	VBD
cord-005478-5iu38pr6	413	27	donor	donor	NN
cord-005478-5iu38pr6	413	28	myeloid	myeloid	NN
cord-005478-5iu38pr6	413	29	engraftment	engraftment	NN
cord-005478-5iu38pr6	413	30	.	.	.
cord-005478-5iu38pr6	414	1	Of	of	IN
cord-005478-5iu38pr6	414	2	the	the	DT
cord-005478-5iu38pr6	414	3	other	other	JJ
cord-005478-5iu38pr6	414	4	19	19	CD
cord-005478-5iu38pr6	414	5	patients	patient	NNS
cord-005478-5iu38pr6	414	6	,	,	,
cord-005478-5iu38pr6	414	7	16	16	CD
cord-005478-5iu38pr6	414	8	had	have	VBD
cord-005478-5iu38pr6	414	9	sustained	sustain	VBN
cord-005478-5iu38pr6	414	10	myeloid	myeloid	JJ
cord-005478-5iu38pr6	414	11	engraftment	engraftment	NN
cord-005478-5iu38pr6	414	12	,	,	,
cord-005478-5iu38pr6	414	13	with	with	IN
cord-005478-5iu38pr6	414	14	a	a	DT
cord-005478-5iu38pr6	414	15	median	median	JJ
cord-005478-5iu38pr6	414	16	post	post	JJ
cord-005478-5iu38pr6	414	17	-	-	JJ
cord-005478-5iu38pr6	414	18	HCT	hct	JJ
cord-005478-5iu38pr6	414	19	follow	follow	NN
cord-005478-5iu38pr6	414	20	-	-	HYPH
cord-005478-5iu38pr6	414	21	up	up	NN
cord-005478-5iu38pr6	414	22	of	of	IN
cord-005478-5iu38pr6	414	23	21	21	CD
cord-005478-5iu38pr6	414	24	months	month	NNS
cord-005478-5iu38pr6	414	25	(	(	-LRB-
cord-005478-5iu38pr6	414	26	range	range	VBP
cord-005478-5iu38pr6	414	27	1	1	CD
cord-005478-5iu38pr6	414	28	-	-	SYM
cord-005478-5iu38pr6	414	29	74	74	CD
cord-005478-5iu38pr6	414	30	months	month	NNS
cord-005478-5iu38pr6	414	31	)	)	-RRB-
cord-005478-5iu38pr6	414	32	.	.	.
cord-005478-5iu38pr6	415	1	Three	three	CD
cord-005478-5iu38pr6	415	2	patients	patient	NNS
cord-005478-5iu38pr6	415	3	had	have	VBD
cord-005478-5iu38pr6	415	4	secondary	secondary	JJ
cord-005478-5iu38pr6	415	5	graft	graft	NN
cord-005478-5iu38pr6	415	6	failure	failure	NN
cord-005478-5iu38pr6	415	7	.	.	.
cord-005478-5iu38pr6	416	1	Two	two	CD
cord-005478-5iu38pr6	416	2	of	of	IN
cord-005478-5iu38pr6	416	3	these	these	DT
cord-005478-5iu38pr6	416	4	had	have	VBD
cord-005478-5iu38pr6	416	5	early	early	JJ
cord-005478-5iu38pr6	416	6	graft	graft	NN
cord-005478-5iu38pr6	416	7	rejection	rejection	NN
cord-005478-5iu38pr6	416	8	and	and	CC
cord-005478-5iu38pr6	416	9	underwent	undergo	VBD
cord-005478-5iu38pr6	416	10	successful	successful	JJ
cord-005478-5iu38pr6	416	11	repeat	repeat	NN
cord-005478-5iu38pr6	416	12	HCT	hct	NN
cord-005478-5iu38pr6	416	13	using	use	VBG
cord-005478-5iu38pr6	416	14	higher	high	JJR
cord-005478-5iu38pr6	416	15	intensity	intensity	NN
cord-005478-5iu38pr6	416	16	regimens	regimen	NNS
cord-005478-5iu38pr6	416	17	.	.	.
cord-005478-5iu38pr6	417	1	The	the	DT
cord-005478-5iu38pr6	417	2	third	third	JJ
cord-005478-5iu38pr6	417	3	patient	patient	NN
cord-005478-5iu38pr6	417	4	maintained	maintain	VBD
cord-005478-5iu38pr6	417	5	high	high	JJ
cord-005478-5iu38pr6	417	6	donor	donor	NN
cord-005478-5iu38pr6	417	7	chimerism	chimerism	NN
cord-005478-5iu38pr6	417	8	after	after	IN
cord-005478-5iu38pr6	417	9	primary	primary	JJ
cord-005478-5iu38pr6	417	10	engraftment	engraftment	NN
cord-005478-5iu38pr6	417	11	but	but	CC
cord-005478-5iu38pr6	417	12	developed	develop	VBD
cord-005478-5iu38pr6	417	13	severe	severe	JJ
cord-005478-5iu38pr6	417	14	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	417	15	in	in	IN
cord-005478-5iu38pr6	417	16	the	the	DT
cord-005478-5iu38pr6	417	17	setting	setting	NN
cord-005478-5iu38pr6	417	18	of	of	IN
cord-005478-5iu38pr6	417	19	multiple	multiple	JJ
cord-005478-5iu38pr6	417	20	viral	viral	JJ
cord-005478-5iu38pr6	417	21	reactivations	reactivation	NNS
cord-005478-5iu38pr6	417	22	,	,	,
cord-005478-5iu38pr6	417	23	and	and	CC
cord-005478-5iu38pr6	417	24	died	die	VBD
cord-005478-5iu38pr6	417	25	of	of	IN
cord-005478-5iu38pr6	417	26	a	a	DT
cord-005478-5iu38pr6	417	27	fungal	fungal	JJ
cord-005478-5iu38pr6	417	28	infection	infection	NN
cord-005478-5iu38pr6	417	29	90	90	CD
cord-005478-5iu38pr6	417	30	days	day	NNS
cord-005478-5iu38pr6	417	31	post	post	NN
cord-005478-5iu38pr6	417	32	-	-	NN
cord-005478-5iu38pr6	417	33	HCT	hct	NN
cord-005478-5iu38pr6	417	34	.	.	.
cord-005478-5iu38pr6	418	1	There	there	EX
cord-005478-5iu38pr6	418	2	was	be	VBD
cord-005478-5iu38pr6	418	3	one	one	CD
cord-005478-5iu38pr6	418	4	other	other	JJ
cord-005478-5iu38pr6	418	5	death	death	NN
cord-005478-5iu38pr6	418	6	,	,	,
cord-005478-5iu38pr6	418	7	due	due	IN
cord-005478-5iu38pr6	418	8	to	to	IN
cord-005478-5iu38pr6	418	9	DC	DC	NNP
cord-005478-5iu38pr6	418	10	-	-	HYPH
cord-005478-5iu38pr6	418	11	related	relate	VBN
cord-005478-5iu38pr6	418	12	gastrointestinal	gastrointestinal	JJ
cord-005478-5iu38pr6	418	13	complications	complication	NNS
cord-005478-5iu38pr6	418	14	19	19	CD
cord-005478-5iu38pr6	418	15	months	month	NNS
cord-005478-5iu38pr6	418	16	post	post	NN
cord-005478-5iu38pr6	418	17	-	-	NN
cord-005478-5iu38pr6	418	18	HCT	hct	NN
cord-005478-5iu38pr6	418	19	.	.	.
cord-005478-5iu38pr6	419	1	None	none	NN
cord-005478-5iu38pr6	419	2	of	of	IN
cord-005478-5iu38pr6	419	3	the	the	DT
cord-005478-5iu38pr6	419	4	16	16	CD
cord-005478-5iu38pr6	419	5	patients	patient	NNS
cord-005478-5iu38pr6	419	6	who	who	WP
cord-005478-5iu38pr6	419	7	engrafted	engraft	VBD
cord-005478-5iu38pr6	419	8	durably	durably	RB
cord-005478-5iu38pr6	419	9	under	under	IN
cord-005478-5iu38pr6	419	10	the	the	DT
cord-005478-5iu38pr6	419	11	protocol	protocol	NN
cord-005478-5iu38pr6	419	12	regimen	regimen	NN
cord-005478-5iu38pr6	419	13	had	have	VBD
cord-005478-5iu38pr6	419	14	acute	acute	JJ
cord-005478-5iu38pr6	419	15	GVHD	GVHD	NNP
cord-005478-5iu38pr6	419	16	.	.	.
cord-005478-5iu38pr6	420	1	Four	four	CD
cord-005478-5iu38pr6	420	2	had	have	VBD
cord-005478-5iu38pr6	420	3	chronic	chronic	JJ
cord-005478-5iu38pr6	420	4	GVHD	GVHD	NNP
cord-005478-5iu38pr6	420	5	(	(	-LRB-
cord-005478-5iu38pr6	420	6	3	3	CD
cord-005478-5iu38pr6	420	7	limited	limited	JJ
cord-005478-5iu38pr6	420	8	,	,	,
cord-005478-5iu38pr6	421	1	1	1	CD
cord-005478-5iu38pr6	421	2	extensive	extensive	JJ
cord-005478-5iu38pr6	421	3	)	)	-RRB-
cord-005478-5iu38pr6	421	4	,	,	,
cord-005478-5iu38pr6	421	5	treated	treat	VBN
cord-005478-5iu38pr6	421	6	successfully	successfully	RB
cord-005478-5iu38pr6	421	7	with	with	IN
cord-005478-5iu38pr6	421	8	limited	limited	JJ
cord-005478-5iu38pr6	421	9	courses	course	NNS
cord-005478-5iu38pr6	421	10	of	of	IN
cord-005478-5iu38pr6	421	11	topical	topical	JJ
cord-005478-5iu38pr6	421	12	or	or	CC
cord-005478-5iu38pr6	421	13	oral	oral	JJ
cord-005478-5iu38pr6	421	14	steroids	steroid	NNS
cord-005478-5iu38pr6	421	15	.	.	.
cord-005478-5iu38pr6	422	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	422	2	:	:	:
cord-005478-5iu38pr6	423	1	We	-PRON-	PRP
cord-005478-5iu38pr6	423	2	conclude	conclude	VBP
cord-005478-5iu38pr6	423	3	that	that	IN
cord-005478-5iu38pr6	423	4	this	this	DT
cord-005478-5iu38pr6	423	5	radiation	radiation	NN
cord-005478-5iu38pr6	423	6	-	-	HYPH
cord-005478-5iu38pr6	423	7	and	and	CC
cord-005478-5iu38pr6	423	8	alkylator	alkylator	NN
cord-005478-5iu38pr6	423	9	-	-	HYPH
cord-005478-5iu38pr6	423	10	free	free	JJ
cord-005478-5iu38pr6	423	11	HCT	hct	NN
cord-005478-5iu38pr6	423	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	423	13	regimen	regimen	NN
cord-005478-5iu38pr6	423	14	is	be	VBZ
cord-005478-5iu38pr6	423	15	an	an	DT
cord-005478-5iu38pr6	423	16	effective	effective	JJ
cord-005478-5iu38pr6	423	17	strategy	strategy	NN
cord-005478-5iu38pr6	423	18	for	for	IN
cord-005478-5iu38pr6	423	19	BMF	BMF	NNP
cord-005478-5iu38pr6	423	20	in	in	IN
cord-005478-5iu38pr6	423	21	patients	patient	NNS
cord-005478-5iu38pr6	423	22	with	with	IN
cord-005478-5iu38pr6	423	23	DC	DC	NNP
cord-005478-5iu38pr6	423	24	or	or	CC
cord-005478-5iu38pr6	423	25	very	very	RB
cord-005478-5iu38pr6	423	26	short	short	JJ
cord-005478-5iu38pr6	423	27	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	423	28	telomeres	telomere	NNS
cord-005478-5iu38pr6	423	29	.	.	.
cord-005478-5iu38pr6	424	1	Eliminating	eliminate	VBG
cord-005478-5iu38pr6	424	2	DNA	dna	NN
cord-005478-5iu38pr6	424	3	damaging	damaging	JJ
cord-005478-5iu38pr6	424	4	agents	agent	NNS
cord-005478-5iu38pr6	424	5	may	may	MD
cord-005478-5iu38pr6	424	6	reduce	reduce	VB
cord-005478-5iu38pr6	424	7	HCT	hct	NN
cord-005478-5iu38pr6	424	8	complications	complication	NNS
cord-005478-5iu38pr6	424	9	including	include	VBG
cord-005478-5iu38pr6	424	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	424	11	and	and	CC
cord-005478-5iu38pr6	424	12	enable	enable	VB
cord-005478-5iu38pr6	424	13	transplant	transplant	NN
cord-005478-5iu38pr6	424	14	in	in	IN
cord-005478-5iu38pr6	424	15	patients	patient	NNS
cord-005478-5iu38pr6	424	16	with	with	IN
cord-005478-5iu38pr6	424	17	high	high	JJ
cord-005478-5iu38pr6	424	18	-	-	HYPH
cord-005478-5iu38pr6	424	19	risk	risk	NN
cord-005478-5iu38pr6	424	20	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	424	21	.	.	.
cord-005478-5iu38pr6	425	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	425	2	Background	background	NN
cord-005478-5iu38pr6	425	3	:	:	:
cord-005478-5iu38pr6	426	1	The	the	DT
cord-005478-5iu38pr6	426	2	standard	standard	JJ
cord-005478-5iu38pr6	426	3	treatment	treatment	NN
cord-005478-5iu38pr6	426	4	of	of	IN
cord-005478-5iu38pr6	426	5	acquired	acquire	VBN
cord-005478-5iu38pr6	426	6	aplastic	aplastic	JJ
cord-005478-5iu38pr6	426	7	anemia	anemia	NN
cord-005478-5iu38pr6	426	8	(	(	-LRB-
cord-005478-5iu38pr6	426	9	AA	AA	NNP
cord-005478-5iu38pr6	426	10	)	)	-RRB-
cord-005478-5iu38pr6	426	11	is	be	VBZ
cord-005478-5iu38pr6	426	12	either	either	CC
cord-005478-5iu38pr6	426	13	intensive	intensive	JJ
cord-005478-5iu38pr6	426	14	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	426	15	therapy	therapy	NN
cord-005478-5iu38pr6	426	16	(	(	-LRB-
cord-005478-5iu38pr6	426	17	IST	IST	NNP
cord-005478-5iu38pr6	426	18	)	)	-RRB-
cord-005478-5iu38pr6	426	19	or	or	CC
cord-005478-5iu38pr6	426	20	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	426	21	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	426	22	cell	cell	NN
cord-005478-5iu38pr6	426	23	transplantation	transplantation	NN
cord-005478-5iu38pr6	426	24	(	(	-LRB-
cord-005478-5iu38pr6	426	25	HCT	HCT	NNP
cord-005478-5iu38pr6	426	26	)	)	-RRB-
cord-005478-5iu38pr6	426	27	.	.	.
cord-005478-5iu38pr6	427	1	As	as	IN
cord-005478-5iu38pr6	427	2	supportive	supportive	JJ
cord-005478-5iu38pr6	427	3	measures	measure	NNS
cord-005478-5iu38pr6	427	4	,	,	,
cord-005478-5iu38pr6	427	5	red	red	JJ
cord-005478-5iu38pr6	427	6	blood	blood	NN
cord-005478-5iu38pr6	427	7	cells	cell	NNS
cord-005478-5iu38pr6	427	8	and	and	CC
cord-005478-5iu38pr6	427	9	platelet	platelet	NN
cord-005478-5iu38pr6	427	10	transfusions	transfusion	NNS
cord-005478-5iu38pr6	427	11	are	be	VBP
cord-005478-5iu38pr6	427	12	the	the	DT
cord-005478-5iu38pr6	427	13	mainstay	mainstay	NN
cord-005478-5iu38pr6	427	14	of	of	IN
cord-005478-5iu38pr6	427	15	therapy	therapy	NN
cord-005478-5iu38pr6	427	16	and	and	CC
cord-005478-5iu38pr6	427	17	patients	patient	NNS
cord-005478-5iu38pr6	427	18	are	be	VBP
cord-005478-5iu38pr6	427	19	often	often	RB
cord-005478-5iu38pr6	427	20	multitransfused	multitransfuse	VBN
cord-005478-5iu38pr6	427	21	,	,	,
cord-005478-5iu38pr6	427	22	which	which	WDT
cord-005478-5iu38pr6	427	23	in	in	IN
cord-005478-5iu38pr6	427	24	turn	turn	NN
cord-005478-5iu38pr6	427	25	can	can	MD
cord-005478-5iu38pr6	427	26	lead	lead	VB
cord-005478-5iu38pr6	427	27	to	to	IN
cord-005478-5iu38pr6	427	28	anti	anti	JJ
cord-005478-5iu38pr6	427	29	-	-	JJ
cord-005478-5iu38pr6	427	30	human	human	JJ
cord-005478-5iu38pr6	427	31	leukocyte	leukocyte	NN
cord-005478-5iu38pr6	427	32	(	(	-LRB-
cord-005478-5iu38pr6	427	33	HLA	HLA	NNP
cord-005478-5iu38pr6	427	34	)	)	-RRB-
cord-005478-5iu38pr6	427	35	alloimmunization	alloimmunization	NN
cord-005478-5iu38pr6	427	36	.	.	.
cord-005478-5iu38pr6	428	1	In	in	IN
cord-005478-5iu38pr6	428	2	acquired	acquire	VBN
cord-005478-5iu38pr6	428	3	AA	AA	NNP
cord-005478-5iu38pr6	428	4	the	the	DT
cord-005478-5iu38pr6	428	5	rate	rate	NN
cord-005478-5iu38pr6	428	6	of	of	IN
cord-005478-5iu38pr6	428	7	HLA	HLA	NNP
cord-005478-5iu38pr6	428	8	-	-	HYPH
cord-005478-5iu38pr6	428	9	alloimmunization	alloimmunization	NNP
cord-005478-5iu38pr6	428	10	has	have	VBZ
cord-005478-5iu38pr6	428	11	previously	previously	RB
cord-005478-5iu38pr6	428	12	shown	show	VBN
cord-005478-5iu38pr6	428	13	a	a	DT
cord-005478-5iu38pr6	428	14	higher	high	JJR
cord-005478-5iu38pr6	428	15	frequency	frequency	NN
cord-005478-5iu38pr6	428	16	in	in	IN
cord-005478-5iu38pr6	428	17	patients	patient	NNS
cord-005478-5iu38pr6	428	18	with	with	IN
cord-005478-5iu38pr6	428	19	AA	AA	NNP
cord-005478-5iu38pr6	428	20	compared	compare	VBN
cord-005478-5iu38pr6	428	21	to	to	IN
cord-005478-5iu38pr6	428	22	hematological	hematological	JJ
cord-005478-5iu38pr6	428	23	malignancies	malignancy	NNS
cord-005478-5iu38pr6	428	24	.	.	.
cord-005478-5iu38pr6	429	1	However	however	RB
cord-005478-5iu38pr6	429	2	,	,	,
cord-005478-5iu38pr6	429	3	these	these	DT
cord-005478-5iu38pr6	429	4	results	result	NNS
cord-005478-5iu38pr6	429	5	date	date	VBP
cord-005478-5iu38pr6	429	6	back	back	RB
cord-005478-5iu38pr6	429	7	before	before	IN
cord-005478-5iu38pr6	429	8	the	the	DT
cord-005478-5iu38pr6	429	9	general	general	JJ
cord-005478-5iu38pr6	429	10	introduction	introduction	NN
cord-005478-5iu38pr6	429	11	of	of	IN
cord-005478-5iu38pr6	429	12	leukoreduction	leukoreduction	NN
cord-005478-5iu38pr6	429	13	of	of	IN
cord-005478-5iu38pr6	429	14	blood	blood	NN
cord-005478-5iu38pr6	429	15	products	product	NNS
cord-005478-5iu38pr6	429	16	and	and	CC
cord-005478-5iu38pr6	429	17	photochemical	photochemical	JJ
cord-005478-5iu38pr6	429	18	pathogen	pathogen	NN
cord-005478-5iu38pr6	429	19	reduction	reduction	NN
cord-005478-5iu38pr6	429	20	of	of	IN
cord-005478-5iu38pr6	429	21	platelet	platelet	NN
cord-005478-5iu38pr6	429	22	components	component	NNS
cord-005478-5iu38pr6	429	23	,	,	,
cord-005478-5iu38pr6	429	24	and	and	CC
cord-005478-5iu38pr6	429	25	are	be	VBP
cord-005478-5iu38pr6	429	26	based	base	VBN
cord-005478-5iu38pr6	429	27	on	on	IN
cord-005478-5iu38pr6	429	28	cell	cell	NN
cord-005478-5iu38pr6	429	29	-	-	HYPH
cord-005478-5iu38pr6	429	30	based	base	VBN
cord-005478-5iu38pr6	429	31	assays	assay	NNS
cord-005478-5iu38pr6	429	32	.	.	.
cord-005478-5iu38pr6	430	1	In	in	IN
cord-005478-5iu38pr6	430	2	recent	recent	JJ
cord-005478-5iu38pr6	430	3	years	year	NNS
cord-005478-5iu38pr6	430	4	,	,	,
cord-005478-5iu38pr6	430	5	leukoreduction	leukoreduction	NN
cord-005478-5iu38pr6	430	6	and	and	CC
cord-005478-5iu38pr6	430	7	pathogen	pathogen	NN
cord-005478-5iu38pr6	430	8	reduction	reduction	NN
cord-005478-5iu38pr6	430	9	of	of	IN
cord-005478-5iu38pr6	430	10	blood	blood	NN
cord-005478-5iu38pr6	430	11	products	product	NNS
cord-005478-5iu38pr6	430	12	became	become	VBD
cord-005478-5iu38pr6	430	13	standard	standard	JJ
cord-005478-5iu38pr6	430	14	in	in	IN
cord-005478-5iu38pr6	430	15	Switzerland	Switzerland	NNP
cord-005478-5iu38pr6	430	16	and	and	CC
cord-005478-5iu38pr6	430	17	the	the	DT
cord-005478-5iu38pr6	430	18	solid	solid	JJ
cord-005478-5iu38pr6	430	19	-	-	HYPH
cord-005478-5iu38pr6	430	20	phase	phase	NN
cord-005478-5iu38pr6	430	21	assay	assay	NN
cord-005478-5iu38pr6	430	22	(	(	-LRB-
cord-005478-5iu38pr6	430	23	Luminex	Luminex	NNP
cord-005478-5iu38pr6	430	24	®	®	NNP
cord-005478-5iu38pr6	430	25	technology	technology	NN
cord-005478-5iu38pr6	430	26	)	)	-RRB-
cord-005478-5iu38pr6	430	27	is	be	VBZ
cord-005478-5iu38pr6	430	28	now	now	RB
cord-005478-5iu38pr6	430	29	widely	widely	RB
cord-005478-5iu38pr6	430	30	available	available	JJ
cord-005478-5iu38pr6	430	31	to	to	TO
cord-005478-5iu38pr6	430	32	test	test	VB
cord-005478-5iu38pr6	430	33	for	for	IN
cord-005478-5iu38pr6	430	34	HLA	HLA	NNP
cord-005478-5iu38pr6	430	35	-	-	HYPH
cord-005478-5iu38pr6	430	36	antibodies	antibody	NNS
cord-005478-5iu38pr6	430	37	,	,	,
cord-005478-5iu38pr6	430	38	allowing	allow	VBG
cord-005478-5iu38pr6	430	39	a	a	DT
cord-005478-5iu38pr6	430	40	more	more	RBR
cord-005478-5iu38pr6	430	41	extensive	extensive	JJ
cord-005478-5iu38pr6	430	42	and	and	CC
cord-005478-5iu38pr6	430	43	detailed	detailed	JJ
cord-005478-5iu38pr6	430	44	characterization	characterization	NN
cord-005478-5iu38pr6	430	45	of	of	IN
cord-005478-5iu38pr6	430	46	HLA	HLA	NNP
cord-005478-5iu38pr6	430	47	-	-	HYPH
cord-005478-5iu38pr6	430	48	antibodies	antibody	NNS
cord-005478-5iu38pr6	430	49	.	.	.
cord-005478-5iu38pr6	431	1	With	with	IN
cord-005478-5iu38pr6	431	2	these	these	DT
cord-005478-5iu38pr6	431	3	techniques	technique	NNS
cord-005478-5iu38pr6	431	4	,	,	,
cord-005478-5iu38pr6	431	5	less	less	JJR
cord-005478-5iu38pr6	431	6	is	be	VBZ
cord-005478-5iu38pr6	431	7	known	know	VBN
cord-005478-5iu38pr6	431	8	on	on	IN
cord-005478-5iu38pr6	431	9	the	the	DT
cord-005478-5iu38pr6	431	10	exact	exact	JJ
cord-005478-5iu38pr6	431	11	incidence	incidence	NN
cord-005478-5iu38pr6	431	12	of	of	IN
cord-005478-5iu38pr6	431	13	HLA	HLA	NNP
cord-005478-5iu38pr6	431	14	-	-	HYPH
cord-005478-5iu38pr6	431	15	antibodies	antibody	NNS
cord-005478-5iu38pr6	431	16	and	and	CC
cord-005478-5iu38pr6	431	17	their	-PRON-	PRP$
cord-005478-5iu38pr6	431	18	magnitude	magnitude	NN
cord-005478-5iu38pr6	431	19	,	,	,
cord-005478-5iu38pr6	431	20	associated	associated	JJ
cord-005478-5iu38pr6	431	21	cofactors	cofactor	NNS
cord-005478-5iu38pr6	431	22	and	and	CC
cord-005478-5iu38pr6	431	23	its	-PRON-	PRP$
cord-005478-5iu38pr6	431	24	impact	impact	NN
cord-005478-5iu38pr6	431	25	on	on	IN
cord-005478-5iu38pr6	431	26	treatment	treatment	NN
cord-005478-5iu38pr6	431	27	outcomes	outcome	NNS
cord-005478-5iu38pr6	431	28	in	in	IN
cord-005478-5iu38pr6	431	29	acquired	acquire	VBN
cord-005478-5iu38pr6	431	30	AA	AA	NNP
cord-005478-5iu38pr6	431	31	.	.	.
cord-005478-5iu38pr6	432	1	Methods	method	NNS
cord-005478-5iu38pr6	432	2	:	:	:
cord-005478-5iu38pr6	432	3	We	-PRON-	PRP
cord-005478-5iu38pr6	432	4	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	432	5	investigated	investigate	VBD
cord-005478-5iu38pr6	432	6	54	54	CD
cord-005478-5iu38pr6	432	7	AA	AA	NNP
cord-005478-5iu38pr6	432	8	patients	patient	NNS
cord-005478-5iu38pr6	432	9	treated	treat	VBN
cord-005478-5iu38pr6	432	10	with	with	IN
cord-005478-5iu38pr6	432	11	IST	IST	NNP
cord-005478-5iu38pr6	432	12	(	(	-LRB-
cord-005478-5iu38pr6	432	13	n=44	n=44	NNP
cord-005478-5iu38pr6	432	14	)	)	-RRB-
cord-005478-5iu38pr6	432	15	and/or	and/or	CC
cord-005478-5iu38pr6	432	16	HCT	HCT	NNP
cord-005478-5iu38pr6	432	17	(	(	-LRB-
cord-005478-5iu38pr6	432	18	n=25	n=25	NN
cord-005478-5iu38pr6	432	19	)	)	-RRB-
cord-005478-5iu38pr6	432	20	at	at	IN
cord-005478-5iu38pr6	432	21	the	the	DT
cord-005478-5iu38pr6	432	22	University	University	NNP
cord-005478-5iu38pr6	432	23	Hospital	Hospital	NNP
cord-005478-5iu38pr6	432	24	of	of	IN
cord-005478-5iu38pr6	432	25	Basel	Basel	NNP
cord-005478-5iu38pr6	432	26	and	and	CC
cord-005478-5iu38pr6	432	27	the	the	DT
cord-005478-5iu38pr6	432	28	University	University	NNP
cord-005478-5iu38pr6	432	29	Children	Children	NNPS
cord-005478-5iu38pr6	432	30	's	's	POS
cord-005478-5iu38pr6	432	31	Hospital	Hospital	NNP
cord-005478-5iu38pr6	432	32	of	of	IN
cord-005478-5iu38pr6	432	33	Basel	Basel	NNP
cord-005478-5iu38pr6	432	34	(	(	-LRB-
cord-005478-5iu38pr6	432	35	Switzerland	Switzerland	NNP
cord-005478-5iu38pr6	432	36	)	)	-RRB-
cord-005478-5iu38pr6	432	37	regarding	regard	VBG
cord-005478-5iu38pr6	432	38	HLA	HLA	NNP
cord-005478-5iu38pr6	432	39	antibodies	antibody	NNS
cord-005478-5iu38pr6	432	40	since	since	IN
cord-005478-5iu38pr6	432	41	the	the	DT
cord-005478-5iu38pr6	432	42	introduction	introduction	NN
cord-005478-5iu38pr6	432	43	of	of	IN
cord-005478-5iu38pr6	432	44	testing	testing	NN
cord-005478-5iu38pr6	432	45	with	with	IN
cord-005478-5iu38pr6	432	46	the	the	DT
cord-005478-5iu38pr6	432	47	Luminex	Luminex	NNP
cord-005478-5iu38pr6	432	48	®	®	.
cord-005478-5iu38pr6	432	49	at	at	IN
cord-005478-5iu38pr6	432	50	our	-PRON-	PRP$
cord-005478-5iu38pr6	432	51	center	center	NN
cord-005478-5iu38pr6	432	52	in	in	IN
cord-005478-5iu38pr6	432	53	2008	2008	CD
cord-005478-5iu38pr6	432	54	.	.	.
cord-005478-5iu38pr6	433	1	At	at	RB
cord-005478-5iu38pr6	433	2	least	least	RBS
cord-005478-5iu38pr6	433	3	one	one	CD
cord-005478-5iu38pr6	433	4	HLA	HLA	NNP
cord-005478-5iu38pr6	433	5	antibody	antibody	NN
cord-005478-5iu38pr6	433	6	measurement	measurement	NN
cord-005478-5iu38pr6	433	7	before	before	IN
cord-005478-5iu38pr6	433	8	and/or	and/or	CC
cord-005478-5iu38pr6	433	9	after	after	IN
cord-005478-5iu38pr6	433	10	therapy	therapy	NN
cord-005478-5iu38pr6	433	11	was	be	VBD
cord-005478-5iu38pr6	433	12	available	available	JJ
cord-005478-5iu38pr6	433	13	per	per	IN
cord-005478-5iu38pr6	433	14	patient	patient	NN
cord-005478-5iu38pr6	433	15	.	.	.
cord-005478-5iu38pr6	434	1	All	all	DT
cord-005478-5iu38pr6	434	2	patients	patient	NNS
cord-005478-5iu38pr6	434	3	received	receive	VBD
cord-005478-5iu38pr6	434	4	leukoreduced	leukoreduced	JJ
cord-005478-5iu38pr6	434	5	blood	blood	NN
cord-005478-5iu38pr6	434	6	products	product	NNS
cord-005478-5iu38pr6	434	7	and	and	CC
cord-005478-5iu38pr6	434	8	as	as	IN
cord-005478-5iu38pr6	434	9	of	of	IN
cord-005478-5iu38pr6	434	10	2011	2011	CD
cord-005478-5iu38pr6	434	11	platelets	platelet	NNS
cord-005478-5iu38pr6	434	12	treated	treat	VBN
cord-005478-5iu38pr6	434	13	with	with	IN
cord-005478-5iu38pr6	434	14	INTERCEPT	INTERCEPT	NNP
cord-005478-5iu38pr6	434	15	®	®	.
cord-005478-5iu38pr6	434	16	(	(	-LRB-
cord-005478-5iu38pr6	434	17	UV+	UV+	NNP
cord-005478-5iu38pr6	434	18	amotosalen	amotosalen	NN
cord-005478-5iu38pr6	434	19	)	)	-RRB-
cord-005478-5iu38pr6	434	20	.	.	.
cord-005478-5iu38pr6	435	1	Results	result	NNS
cord-005478-5iu38pr6	435	2	:	:	:
cord-005478-5iu38pr6	436	1	Overall	overall	RB
cord-005478-5iu38pr6	436	2	,	,	,
cord-005478-5iu38pr6	436	3	HLA	HLA	NNP
cord-005478-5iu38pr6	436	4	-	-	HYPH
cord-005478-5iu38pr6	436	5	antibodies	antibody	NNS
cord-005478-5iu38pr6	436	6	were	be	VBD
cord-005478-5iu38pr6	436	7	detected	detect	VBN
cord-005478-5iu38pr6	436	8	in	in	IN
cord-005478-5iu38pr6	436	9	40	40	CD
cord-005478-5iu38pr6	436	10	(	(	-LRB-
cord-005478-5iu38pr6	436	11	74	74	CD
cord-005478-5iu38pr6	436	12	%	%	NN
cord-005478-5iu38pr6	436	13	)	)	-RRB-
cord-005478-5iu38pr6	436	14	patients	patient	NNS
cord-005478-5iu38pr6	436	15	with	with	IN
cord-005478-5iu38pr6	436	16	a	a	DT
cord-005478-5iu38pr6	436	17	higher	high	JJR
cord-005478-5iu38pr6	436	18	rate	rate	NN
cord-005478-5iu38pr6	436	19	of	of	IN
cord-005478-5iu38pr6	436	20	HLA	HLA	NNP
cord-005478-5iu38pr6	436	21	alloimmunziation	alloimmunziation	NN
cord-005478-5iu38pr6	436	22	by	by	IN
cord-005478-5iu38pr6	436	23	severity	severity	NN
cord-005478-5iu38pr6	436	24	of	of	IN
cord-005478-5iu38pr6	436	25	AA	AA	NNP
cord-005478-5iu38pr6	436	26	(	(	-LRB-
cord-005478-5iu38pr6	436	27	p	p	NN
cord-005478-5iu38pr6	436	28	<	<	XX
cord-005478-5iu38pr6	436	29	0.01	0.01	CD
cord-005478-5iu38pr6	436	30	)	)	-RRB-
cord-005478-5iu38pr6	436	31	.	.	.
cord-005478-5iu38pr6	437	1	The	the	DT
cord-005478-5iu38pr6	437	2	median	median	JJ
cord-005478-5iu38pr6	437	3	number	number	NN
cord-005478-5iu38pr6	437	4	of	of	IN
cord-005478-5iu38pr6	437	5	HLAantibodies	hlaantibodie	NNS
cord-005478-5iu38pr6	437	6	in	in	IN
cord-005478-5iu38pr6	437	7	each	each	DT
cord-005478-5iu38pr6	437	8	patient	patient	NN
cord-005478-5iu38pr6	437	9	before	before	IN
cord-005478-5iu38pr6	437	10	therapy	therapy	NN
cord-005478-5iu38pr6	437	11	(	(	-LRB-
cord-005478-5iu38pr6	437	12	i.e.	i.e.	FW
cord-005478-5iu38pr6	437	13	IST	IST	NNP
cord-005478-5iu38pr6	437	14	or	or	CC
cord-005478-5iu38pr6	437	15	HCT	HCT	NNP
cord-005478-5iu38pr6	437	16	)	)	-RRB-
cord-005478-5iu38pr6	437	17	was	be	VBD
cord-005478-5iu38pr6	437	18	3	3	CD
cord-005478-5iu38pr6	438	1	(	(	-LRB-
cord-005478-5iu38pr6	438	2	IQR	IQR	NNP
cord-005478-5iu38pr6	438	3	0	0	CD
cord-005478-5iu38pr6	438	4	-	-	SYM
cord-005478-5iu38pr6	438	5	25	25	CD
cord-005478-5iu38pr6	438	6	)	)	-RRB-
cord-005478-5iu38pr6	438	7	.	.	.
cord-005478-5iu38pr6	439	1	In	in	IN
cord-005478-5iu38pr6	439	2	patients	patient	NNS
cord-005478-5iu38pr6	439	3	undergoing	undergo	VBG
cord-005478-5iu38pr6	439	4	HCT	hct	NN
cord-005478-5iu38pr6	439	5	HLAantibodies	hlaantibodie	NNS
cord-005478-5iu38pr6	439	6	were	be	VBD
cord-005478-5iu38pr6	439	7	more	more	RBR
cord-005478-5iu38pr6	439	8	frequent	frequent	JJ
cord-005478-5iu38pr6	439	9	before	before	IN
cord-005478-5iu38pr6	439	10	treatment	treatment	NN
cord-005478-5iu38pr6	439	11	start	start	NN
cord-005478-5iu38pr6	439	12	as	as	IN
cord-005478-5iu38pr6	439	13	compared	compare	VBN
cord-005478-5iu38pr6	439	14	to	to	IN
cord-005478-5iu38pr6	439	15	patients	patient	NNS
cord-005478-5iu38pr6	439	16	with	with	IN
cord-005478-5iu38pr6	439	17	IST	IST	NNP
cord-005478-5iu38pr6	439	18	treatment	treatment	NN
cord-005478-5iu38pr6	439	19	(	(	-LRB-
cord-005478-5iu38pr6	439	20	median	median	NN
cord-005478-5iu38pr6	439	21	13	13	CD
cord-005478-5iu38pr6	439	22	(	(	-LRB-
cord-005478-5iu38pr6	439	23	IQR	IQR	NNP
cord-005478-5iu38pr6	439	24	0	0	CD
cord-005478-5iu38pr6	439	25	-	-	SYM
cord-005478-5iu38pr6	439	26	45	45	CD
cord-005478-5iu38pr6	439	27	)	)	-RRB-
cord-005478-5iu38pr6	439	28	versus	versus	IN
cord-005478-5iu38pr6	439	29	2.5	2.5	CD
cord-005478-5iu38pr6	439	30	(	(	-LRB-
cord-005478-5iu38pr6	439	31	IQR	IQR	NNP
cord-005478-5iu38pr6	439	32	0	0	CD
cord-005478-5iu38pr6	439	33	-	-	HYPH
cord-005478-5iu38pr6	439	34	16.5	16.5	CD
cord-005478-5iu38pr6	439	35	)	)	-RRB-
cord-005478-5iu38pr6	439	36	,	,	,
cord-005478-5iu38pr6	439	37	p	p	NN
cord-005478-5iu38pr6	439	38	<	<	XX
cord-005478-5iu38pr6	439	39	0.05	0.05	CD
cord-005478-5iu38pr6	439	40	)	)	-RRB-
cord-005478-5iu38pr6	439	41	.	.	.
cord-005478-5iu38pr6	440	1	Differences	difference	NNS
cord-005478-5iu38pr6	440	2	between	between	IN
cord-005478-5iu38pr6	440	3	treatments	treatment	NNS
cord-005478-5iu38pr6	440	4	remained	remain	VBD
cord-005478-5iu38pr6	440	5	after	after	IN
cord-005478-5iu38pr6	440	6	adjusting	adjust	VBG
cord-005478-5iu38pr6	440	7	for	for	IN
cord-005478-5iu38pr6	440	8	all	all	DT
cord-005478-5iu38pr6	440	9	covariates	covariate	NNS
cord-005478-5iu38pr6	440	10	(	(	-LRB-
cord-005478-5iu38pr6	440	11	p	p	NN
cord-005478-5iu38pr6	440	12	<	<	XX
cord-005478-5iu38pr6	440	13	0.01	0.01	CD
cord-005478-5iu38pr6	440	14	)	)	-RRB-
cord-005478-5iu38pr6	440	15	.	.	.
cord-005478-5iu38pr6	441	1	There	there	EX
cord-005478-5iu38pr6	441	2	was	be	VBD
cord-005478-5iu38pr6	441	3	no	no	DT
cord-005478-5iu38pr6	441	4	statistically	statistically	RB
cord-005478-5iu38pr6	441	5	significant	significant	JJ
cord-005478-5iu38pr6	441	6	difference	difference	NN
cord-005478-5iu38pr6	441	7	regarding	regard	VBG
cord-005478-5iu38pr6	442	1	the	the	DT
cord-005478-5iu38pr6	442	2	HLA	HLA	NNP
cord-005478-5iu38pr6	442	3	antibody	antibody	NN
cord-005478-5iu38pr6	442	4	mean	mean	VB
cord-005478-5iu38pr6	442	5	fluorescence	fluorescence	NN
cord-005478-5iu38pr6	442	6	intensity	intensity	NN
cord-005478-5iu38pr6	442	7	(	(	-LRB-
cord-005478-5iu38pr6	442	8	MFI	MFI	NNP
cord-005478-5iu38pr6	442	9	)	)	-RRB-
cord-005478-5iu38pr6	442	10	between	between	IN
cord-005478-5iu38pr6	442	11	the	the	DT
cord-005478-5iu38pr6	442	12	two	two	CD
cord-005478-5iu38pr6	442	13	treatment	treatment	NN
cord-005478-5iu38pr6	442	14	forms	form	NNS
cord-005478-5iu38pr6	442	15	(	(	-LRB-
cord-005478-5iu38pr6	442	16	overall	overall	JJ
cord-005478-5iu38pr6	442	17	mean	mean	JJ
cord-005478-5iu38pr6	442	18	MFI	MFI	NNP
cord-005478-5iu38pr6	442	19	of	of	IN
cord-005478-5iu38pr6	442	20	1580	1580	CD
cord-005478-5iu38pr6	443	1	+	+	CC
cord-005478-5iu38pr6	443	2	/-2075	/-2075	NN
cord-005478-5iu38pr6	443	3	)	)	-RRB-
cord-005478-5iu38pr6	443	4	.	.	.
cord-005478-5iu38pr6	444	1	The	the	DT
cord-005478-5iu38pr6	444	2	highest	high	JJS
cord-005478-5iu38pr6	444	3	mean	mean	JJ
cord-005478-5iu38pr6	444	4	HLAantibody	hlaantibody	NN
cord-005478-5iu38pr6	444	5	MFI	MFI	NNP
cord-005478-5iu38pr6	444	6	before	before	IN
cord-005478-5iu38pr6	444	7	therapy	therapy	NN
cord-005478-5iu38pr6	444	8	was	be	VBD
cord-005478-5iu38pr6	444	9	4747	4747	CD
cord-005478-5iu38pr6	444	10	(	(	-LRB-
cord-005478-5iu38pr6	444	11	+	+	CC
cord-005478-5iu38pr6	444	12	/-7221	/-7221	.
cord-005478-5iu38pr6	444	13	)	)	-RRB-
cord-005478-5iu38pr6	444	14	with	with	IN
cord-005478-5iu38pr6	444	15	a	a	DT
cord-005478-5iu38pr6	444	16	maximum	maximum	NN
cord-005478-5iu38pr6	444	17	of	of	IN
cord-005478-5iu38pr6	444	18	24020	24020	CD
cord-005478-5iu38pr6	444	19	.	.	.
cord-005478-5iu38pr6	445	1	Females	female	NNS
cord-005478-5iu38pr6	445	2	showed	show	VBD
cord-005478-5iu38pr6	445	3	a	a	DT
cord-005478-5iu38pr6	445	4	significantly	significantly	RB
cord-005478-5iu38pr6	445	5	higher	high	JJR
cord-005478-5iu38pr6	445	6	number	number	NN
cord-005478-5iu38pr6	445	7	of	of	IN
cord-005478-5iu38pr6	445	8	HLA	HLA	NNP
cord-005478-5iu38pr6	445	9	-	-	HYPH
cord-005478-5iu38pr6	445	10	antibodies	antibody	NNS
cord-005478-5iu38pr6	445	11	(	(	-LRB-
cord-005478-5iu38pr6	445	12	p	p	NN
cord-005478-5iu38pr6	445	13	<	<	XX
cord-005478-5iu38pr6	445	14	0.01	0.01	CD
cord-005478-5iu38pr6	445	15	)	)	-RRB-
cord-005478-5iu38pr6	445	16	and	and	CC
cord-005478-5iu38pr6	445	17	also	also	RB
cord-005478-5iu38pr6	445	18	higher	high	JJR
cord-005478-5iu38pr6	445	19	mean	mean	JJ
cord-005478-5iu38pr6	445	20	MFI	MFI	NNP
cord-005478-5iu38pr6	445	21	(	(	-LRB-
cord-005478-5iu38pr6	445	22	p	p	NN
cord-005478-5iu38pr6	445	23	<	<	XX
cord-005478-5iu38pr6	445	24	0.05	0.05	CD
cord-005478-5iu38pr6	445	25	)	)	-RRB-
cord-005478-5iu38pr6	445	26	.	.	.
cord-005478-5iu38pr6	446	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	446	2	,	,	,
cord-005478-5iu38pr6	446	3	the	the	DT
cord-005478-5iu38pr6	446	4	number	number	NN
cord-005478-5iu38pr6	446	5	of	of	IN
cord-005478-5iu38pr6	446	6	pregnancies	pregnancy	NNS
cord-005478-5iu38pr6	446	7	was	be	VBD
cord-005478-5iu38pr6	446	8	associated	associate	VBN
cord-005478-5iu38pr6	446	9	with	with	IN
cord-005478-5iu38pr6	446	10	higher	high	JJR
cord-005478-5iu38pr6	446	11	numbers	number	NNS
cord-005478-5iu38pr6	446	12	of	of	IN
cord-005478-5iu38pr6	446	13	HLA	HLA	NNP
cord-005478-5iu38pr6	446	14	-	-	HYPH
cord-005478-5iu38pr6	446	15	antibodies	antibody	NNS
cord-005478-5iu38pr6	446	16	(	(	-LRB-
cord-005478-5iu38pr6	446	17	p	p	NN
cord-005478-5iu38pr6	446	18	<	<	XX
cord-005478-5iu38pr6	446	19	0.01	0.01	CD
cord-005478-5iu38pr6	446	20	)	)	-RRB-
cord-005478-5iu38pr6	446	21	,	,	,
cord-005478-5iu38pr6	446	22	however	however	RB
cord-005478-5iu38pr6	446	23	the	the	DT
cord-005478-5iu38pr6	446	24	number	number	NN
cord-005478-5iu38pr6	446	25	of	of	IN
cord-005478-5iu38pr6	446	26	transfusions	transfusion	NNS
cord-005478-5iu38pr6	446	27	did	do	VBD
cord-005478-5iu38pr6	446	28	not	not	RB
cord-005478-5iu38pr6	446	29	have	have	VB
cord-005478-5iu38pr6	446	30	significant	significant	JJ
cord-005478-5iu38pr6	446	31	impact	impact	NN
cord-005478-5iu38pr6	446	32	on	on	IN
cord-005478-5iu38pr6	446	33	HLA	HLA	NNP
cord-005478-5iu38pr6	446	34	-	-	HYPH
cord-005478-5iu38pr6	446	35	antibody	antibody	NN
cord-005478-5iu38pr6	446	36	number	number	NN
cord-005478-5iu38pr6	446	37	and	and	CC
cord-005478-5iu38pr6	446	38	MFI	MFI	NNP
cord-005478-5iu38pr6	446	39	.	.	.
cord-005478-5iu38pr6	447	1	Regarding	regard	VBG
cord-005478-5iu38pr6	447	2	outcome	outcome	NN
cord-005478-5iu38pr6	447	3	,	,	,
cord-005478-5iu38pr6	447	4	there	there	EX
cord-005478-5iu38pr6	447	5	was	be	VBD
cord-005478-5iu38pr6	447	6	no	no	DT
cord-005478-5iu38pr6	447	7	significant	significant	JJ
cord-005478-5iu38pr6	447	8	association	association	NN
cord-005478-5iu38pr6	447	9	between	between	IN
cord-005478-5iu38pr6	447	10	the	the	DT
cord-005478-5iu38pr6	447	11	number	number	NN
cord-005478-5iu38pr6	447	12	of	of	IN
cord-005478-5iu38pr6	447	13	HLA	HLA	NNP
cord-005478-5iu38pr6	447	14	-	-	HYPH
cord-005478-5iu38pr6	447	15	antibodies	antibody	NNS
cord-005478-5iu38pr6	447	16	and	and	CC
cord-005478-5iu38pr6	447	17	engraftment	engraftment	NN
cord-005478-5iu38pr6	447	18	as	as	RB
cord-005478-5iu38pr6	447	19	well	well	RB
cord-005478-5iu38pr6	447	20	as	as	IN
cord-005478-5iu38pr6	447	21	bleeding	bleed	VBG
cord-005478-5iu38pr6	447	22	events	event	NNS
cord-005478-5iu38pr6	447	23	.	.	.
cord-005478-5iu38pr6	448	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	448	2	:	:	:
cord-005478-5iu38pr6	449	1	HLA	HLA	NNP
cord-005478-5iu38pr6	449	2	-	-	HYPH
cord-005478-5iu38pr6	449	3	alloimmunization	alloimmunization	NNP
cord-005478-5iu38pr6	449	4	is	be	VBZ
cord-005478-5iu38pr6	449	5	still	still	RB
cord-005478-5iu38pr6	449	6	frequent	frequent	JJ
cord-005478-5iu38pr6	449	7	in	in	IN
cord-005478-5iu38pr6	449	8	patients	patient	NNS
cord-005478-5iu38pr6	449	9	with	with	IN
cord-005478-5iu38pr6	449	10	acquired	acquire	VBN
cord-005478-5iu38pr6	449	11	AA	AA	NNP
cord-005478-5iu38pr6	449	12	but	but	CC
cord-005478-5iu38pr6	449	13	today	today	NN
cord-005478-5iu38pr6	449	14	number	number	NN
cord-005478-5iu38pr6	449	15	of	of	IN
cord-005478-5iu38pr6	449	16	pregnancies	pregnancy	NNS
cord-005478-5iu38pr6	449	17	and	and	CC
cord-005478-5iu38pr6	449	18	gender	gender	NN
cord-005478-5iu38pr6	449	19	seem	seem	VBP
cord-005478-5iu38pr6	449	20	to	to	TO
cord-005478-5iu38pr6	449	21	be	be	VB
cord-005478-5iu38pr6	449	22	more	more	RBR
cord-005478-5iu38pr6	449	23	important	important	JJ
cord-005478-5iu38pr6	449	24	for	for	IN
cord-005478-5iu38pr6	449	25	development	development	NN
cord-005478-5iu38pr6	449	26	of	of	IN
cord-005478-5iu38pr6	449	27	HLA	HLA	NNP
cord-005478-5iu38pr6	449	28	-	-	HYPH
cord-005478-5iu38pr6	449	29	alloimmunization	alloimmunization	NN
cord-005478-5iu38pr6	449	30	than	than	IN
cord-005478-5iu38pr6	449	31	number	number	NN
cord-005478-5iu38pr6	449	32	of	of	IN
cord-005478-5iu38pr6	449	33	transfusions	transfusion	NNS
cord-005478-5iu38pr6	449	34	.	.	.
cord-005478-5iu38pr6	450	1	Interestingly	interestingly	RB
cord-005478-5iu38pr6	450	2	,	,	,
cord-005478-5iu38pr6	450	3	patients	patient	NNS
cord-005478-5iu38pr6	450	4	treated	treat	VBN
cord-005478-5iu38pr6	450	5	by	by	IN
cord-005478-5iu38pr6	450	6	HCT	HCT	NNP
cord-005478-5iu38pr6	450	7	show	show	VBP
cord-005478-5iu38pr6	450	8	a	a	DT
cord-005478-5iu38pr6	450	9	higher	high	JJR
cord-005478-5iu38pr6	450	10	rate	rate	NN
cord-005478-5iu38pr6	450	11	of	of	IN
cord-005478-5iu38pr6	450	12	HLA	HLA	NNP
cord-005478-5iu38pr6	450	13	-	-	HYPH
cord-005478-5iu38pr6	450	14	alloimmunization	alloimmunization	NN
cord-005478-5iu38pr6	450	15	before	before	IN
cord-005478-5iu38pr6	450	16	treatment	treatment	NN
cord-005478-5iu38pr6	450	17	start	start	VBP
cord-005478-5iu38pr6	450	18	in	in	IN
cord-005478-5iu38pr6	450	19	comparison	comparison	NN
cord-005478-5iu38pr6	450	20	to	to	IN
cord-005478-5iu38pr6	450	21	IST	IST	NNP
cord-005478-5iu38pr6	450	22	,	,	,
cord-005478-5iu38pr6	450	23	thereby	thereby	RB
cord-005478-5iu38pr6	450	24	emphazing	emphaze	VBG
cord-005478-5iu38pr6	450	25	the	the	DT
cord-005478-5iu38pr6	450	26	importance	importance	NN
cord-005478-5iu38pr6	450	27	of	of	IN
cord-005478-5iu38pr6	450	28	blood	blood	NN
cord-005478-5iu38pr6	450	29	management	management	NN
cord-005478-5iu38pr6	450	30	and	and	CC
cord-005478-5iu38pr6	450	31	donor	donor	NN
cord-005478-5iu38pr6	450	32	selection	selection	NN
cord-005478-5iu38pr6	450	33	in	in	IN
cord-005478-5iu38pr6	450	34	HCT	HCT	NNP
cord-005478-5iu38pr6	450	35	in	in	IN
cord-005478-5iu38pr6	450	36	acquired	acquire	VBN
cord-005478-5iu38pr6	450	37	AA	AA	NNP
cord-005478-5iu38pr6	450	38	as	as	IN
cord-005478-5iu38pr6	450	39	HLA	HLA	NNP
cord-005478-5iu38pr6	450	40	-	-	HYPH
cord-005478-5iu38pr6	450	41	antibodies	antibody	NNS
cord-005478-5iu38pr6	450	42	can	can	MD
cord-005478-5iu38pr6	450	43	cause	cause	VB
cord-005478-5iu38pr6	450	44	platelet	platelet	NN
cord-005478-5iu38pr6	450	45	refractoriness	refractoriness	NN
cord-005478-5iu38pr6	450	46	and	and	CC
cord-005478-5iu38pr6	450	47	can	can	MD
cord-005478-5iu38pr6	450	48	represent	represent	VB
cord-005478-5iu38pr6	450	49	donor	donor	NN
cord-005478-5iu38pr6	450	50	-	-	HYPH
cord-005478-5iu38pr6	450	51	specific	specific	JJ
cord-005478-5iu38pr6	450	52	antibodies	antibody	NNS
cord-005478-5iu38pr6	450	53	in	in	IN
cord-005478-5iu38pr6	450	54	the	the	DT
cord-005478-5iu38pr6	450	55	setting	setting	NN
cord-005478-5iu38pr6	450	56	of	of	IN
cord-005478-5iu38pr6	450	57	mismatched	mismatched	JJ
cord-005478-5iu38pr6	450	58	HCT	hct	NN
cord-005478-5iu38pr6	450	59	(	(	-LRB-
cord-005478-5iu38pr6	450	60	e.g.	e.g.	IN
cord-005478-5iu38pr6	450	61	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	450	62	)	)	-RRB-
cord-005478-5iu38pr6	450	63	.	.	.
cord-005478-5iu38pr6	451	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	451	2	:	:	:
cord-005478-5iu38pr6	451	3	Nothing	nothing	NN
cord-005478-5iu38pr6	451	4	to	to	TO
cord-005478-5iu38pr6	451	5	declare	declare	VB
cord-005478-5iu38pr6	451	6	.	.	.
cord-005478-5iu38pr6	452	1	Health	health	NN
cord-005478-5iu38pr6	452	2	-	-	HYPH
cord-005478-5iu38pr6	452	3	related	relate	VBN
cord-005478-5iu38pr6	452	4	quality	quality	NN
cord-005478-5iu38pr6	452	5	of	of	IN
cord-005478-5iu38pr6	452	6	life	life	NN
cord-005478-5iu38pr6	452	7	in	in	IN
cord-005478-5iu38pr6	452	8	systemic	systemic	JJ
cord-005478-5iu38pr6	452	9	sclerosis	sclerosis	NN
cord-005478-5iu38pr6	452	10	before	before	IN
cord-005478-5iu38pr6	452	11	and	and	CC
cord-005478-5iu38pr6	452	12	after	after	IN
cord-005478-5iu38pr6	452	13	autologous	autologous	JJ
cord-005478-5iu38pr6	452	14	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	452	15	stem	stem	NN
cord-005478-5iu38pr6	452	16	cell	cell	NN
cord-005478-5iu38pr6	452	17	transplant	transplant	NN
cord-005478-5iu38pr6	453	1	-a	-a	:
cord-005478-5iu38pr6	453	2	systematic	systematic	JJ
cord-005478-5iu38pr6	453	3	review	review	NN
cord-005478-5iu38pr6	453	4	Background	background	NN
cord-005478-5iu38pr6	453	5	:	:	:
cord-005478-5iu38pr6	453	6	Autologous	autologous	JJ
cord-005478-5iu38pr6	453	7	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	453	8	stem	stem	NN
cord-005478-5iu38pr6	453	9	cell	cell	NN
cord-005478-5iu38pr6	453	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	453	11	(	(	-LRB-
cord-005478-5iu38pr6	453	12	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	453	13	)	)	-RRB-
cord-005478-5iu38pr6	453	14	for	for	IN
cord-005478-5iu38pr6	453	15	severe	severe	JJ
cord-005478-5iu38pr6	453	16	rapidly	rapidly	RB
cord-005478-5iu38pr6	453	17	progressive	progressive	JJ
cord-005478-5iu38pr6	453	18	Systemic	Systemic	NNP
cord-005478-5iu38pr6	453	19	Sclerosis	Sclerosis	NNP
cord-005478-5iu38pr6	453	20	(	(	-LRB-
cord-005478-5iu38pr6	453	21	SSc	SSc	NNS
cord-005478-5iu38pr6	453	22	)	)	-RRB-
cord-005478-5iu38pr6	453	23	allows	allow	VBZ
cord-005478-5iu38pr6	453	24	significant	significant	JJ
cord-005478-5iu38pr6	453	25	regression	regression	NN
cord-005478-5iu38pr6	453	26	in	in	IN
cord-005478-5iu38pr6	453	27	skin	skin	NN
cord-005478-5iu38pr6	453	28	and	and	CC
cord-005478-5iu38pr6	453	29	lung	lung	NN
cord-005478-5iu38pr6	453	30	fibrosis	fibrosis	NN
cord-005478-5iu38pr6	453	31	and	and	CC
cord-005478-5iu38pr6	453	32	improvements	improvement	NNS
cord-005478-5iu38pr6	453	33	in	in	IN
cord-005478-5iu38pr6	453	34	overall	overall	JJ
cord-005478-5iu38pr6	453	35	and	and	CC
cord-005478-5iu38pr6	453	36	event	event	NN
cord-005478-5iu38pr6	453	37	free	free	JJ
cord-005478-5iu38pr6	453	38	survival	survival	NN
cord-005478-5iu38pr6	453	39	up	up	IN
cord-005478-5iu38pr6	453	40	to	to	TO
cord-005478-5iu38pr6	453	41	7	7	CD
cord-005478-5iu38pr6	453	42	years	year	NNS
cord-005478-5iu38pr6	453	43	after	after	IN
cord-005478-5iu38pr6	453	44	transplant	transplant	NN
cord-005478-5iu38pr6	453	45	.	.	.
cord-005478-5iu38pr6	454	1	We	-PRON-	PRP
cord-005478-5iu38pr6	454	2	undertook	undertake	VBD
cord-005478-5iu38pr6	454	3	this	this	DT
cord-005478-5iu38pr6	454	4	study	study	NN
cord-005478-5iu38pr6	454	5	to	to	TO
cord-005478-5iu38pr6	454	6	synthesize	synthesize	VB
cord-005478-5iu38pr6	454	7	the	the	DT
cord-005478-5iu38pr6	454	8	evidence	evidence	NN
cord-005478-5iu38pr6	454	9	on	on	IN
cord-005478-5iu38pr6	454	10	changes	change	NNS
cord-005478-5iu38pr6	454	11	in	in	IN
cord-005478-5iu38pr6	454	12	healthrelated	healthrelated	JJ
cord-005478-5iu38pr6	454	13	quality	quality	NN
cord-005478-5iu38pr6	454	14	of	of	IN
cord-005478-5iu38pr6	454	15	life	life	NN
cord-005478-5iu38pr6	454	16	(	(	-LRB-
cord-005478-5iu38pr6	454	17	HRQoL	HRQoL	NNP
cord-005478-5iu38pr6	454	18	)	)	-RRB-
cord-005478-5iu38pr6	454	19	associated	associate	VBN
cord-005478-5iu38pr6	454	20	with	with	IN
cord-005478-5iu38pr6	454	21	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	454	22	for	for	IN
cord-005478-5iu38pr6	454	23	SSc	SSc	NNS
cord-005478-5iu38pr6	454	24	.	.	.
cord-005478-5iu38pr6	455	1	Methods	method	NNS
cord-005478-5iu38pr6	455	2	:	:	:
cord-005478-5iu38pr6	455	3	Autologous	autologous	JJ
cord-005478-5iu38pr6	455	4	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	455	5	stem	stem	NN
cord-005478-5iu38pr6	455	6	cell	cell	NN
cord-005478-5iu38pr6	455	7	transplantation	transplantation	NN
cord-005478-5iu38pr6	455	8	(	(	-LRB-
cord-005478-5iu38pr6	455	9	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	455	10	)	)	-RRB-
cord-005478-5iu38pr6	455	11	for	for	IN
cord-005478-5iu38pr6	455	12	severe	severe	JJ
cord-005478-5iu38pr6	455	13	rapidly	rapidly	RB
cord-005478-5iu38pr6	455	14	progressive	progressive	JJ
cord-005478-5iu38pr6	455	15	Systemic	Systemic	NNP
cord-005478-5iu38pr6	455	16	Sclerosis	Sclerosis	NNP
cord-005478-5iu38pr6	455	17	(	(	-LRB-
cord-005478-5iu38pr6	455	18	SSc	SSc	NNS
cord-005478-5iu38pr6	455	19	)	)	-RRB-
cord-005478-5iu38pr6	455	20	allows	allow	VBZ
cord-005478-5iu38pr6	455	21	significant	significant	JJ
cord-005478-5iu38pr6	455	22	regression	regression	NN
cord-005478-5iu38pr6	455	23	in	in	IN
cord-005478-5iu38pr6	455	24	skin	skin	NN
cord-005478-5iu38pr6	455	25	and	and	CC
cord-005478-5iu38pr6	455	26	lung	lung	NN
cord-005478-5iu38pr6	455	27	fibrosis	fibrosis	NN
cord-005478-5iu38pr6	455	28	and	and	CC
cord-005478-5iu38pr6	455	29	improvements	improvement	NNS
cord-005478-5iu38pr6	455	30	in	in	IN
cord-005478-5iu38pr6	455	31	overall	overall	JJ
cord-005478-5iu38pr6	455	32	and	and	CC
cord-005478-5iu38pr6	455	33	event	event	NN
cord-005478-5iu38pr6	455	34	free	free	JJ
cord-005478-5iu38pr6	455	35	survival	survival	NN
cord-005478-5iu38pr6	455	36	up	up	IN
cord-005478-5iu38pr6	455	37	to	to	TO
cord-005478-5iu38pr6	455	38	7	7	CD
cord-005478-5iu38pr6	455	39	years	year	NNS
cord-005478-5iu38pr6	455	40	after	after	IN
cord-005478-5iu38pr6	455	41	transplant	transplant	NN
cord-005478-5iu38pr6	455	42	.	.	.
cord-005478-5iu38pr6	456	1	We	-PRON-	PRP
cord-005478-5iu38pr6	456	2	undertook	undertake	VBD
cord-005478-5iu38pr6	456	3	this	this	DT
cord-005478-5iu38pr6	456	4	study	study	NN
cord-005478-5iu38pr6	456	5	to	to	TO
cord-005478-5iu38pr6	456	6	synthesize	synthesize	VB
cord-005478-5iu38pr6	456	7	the	the	DT
cord-005478-5iu38pr6	456	8	evidence	evidence	NN
cord-005478-5iu38pr6	456	9	on	on	IN
cord-005478-5iu38pr6	456	10	changes	change	NNS
cord-005478-5iu38pr6	456	11	in	in	IN
cord-005478-5iu38pr6	456	12	healthrelated	healthrelated	JJ
cord-005478-5iu38pr6	456	13	quality	quality	NN
cord-005478-5iu38pr6	456	14	of	of	IN
cord-005478-5iu38pr6	456	15	life	life	NN
cord-005478-5iu38pr6	456	16	(	(	-LRB-
cord-005478-5iu38pr6	456	17	HRQoL	HRQoL	NNP
cord-005478-5iu38pr6	456	18	)	)	-RRB-
cord-005478-5iu38pr6	456	19	associated	associate	VBN
cord-005478-5iu38pr6	456	20	with	with	IN
cord-005478-5iu38pr6	456	21	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	456	22	for	for	IN
cord-005478-5iu38pr6	456	23	SSc	SSc	NNS
cord-005478-5iu38pr6	456	24	.	.	.
cord-005478-5iu38pr6	457	1	Results	result	NNS
cord-005478-5iu38pr6	457	2	:	:	:
cord-005478-5iu38pr6	458	1	The	the	DT
cord-005478-5iu38pr6	458	2	search	search	NN
cord-005478-5iu38pr6	458	3	returned	return	VBD
cord-005478-5iu38pr6	458	4	656	656	CD
cord-005478-5iu38pr6	458	5	articles	article	NNS
cord-005478-5iu38pr6	458	6	.	.	.
cord-005478-5iu38pr6	459	1	Eight	eight	CD
cord-005478-5iu38pr6	459	2	were	be	VBD
cord-005478-5iu38pr6	459	3	selected	select	VBN
cord-005478-5iu38pr6	459	4	:	:	:
cord-005478-5iu38pr6	459	5	3	3	CD
cord-005478-5iu38pr6	459	6	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	459	7	phase	phase	NN
cord-005478-5iu38pr6	460	1	I	-PRON-	PRP
cord-005478-5iu38pr6	460	2	or	or	CC
cord-005478-5iu38pr6	460	3	II	ii	CD
cord-005478-5iu38pr6	460	4	trials	trial	NNS
cord-005478-5iu38pr6	460	5	,	,	,
cord-005478-5iu38pr6	460	6	2	2	CD
cord-005478-5iu38pr6	460	7	cohort	cohort	NN
cord-005478-5iu38pr6	460	8	studies	study	NNS
cord-005478-5iu38pr6	460	9	and	and	CC
cord-005478-5iu38pr6	460	10	3	3	CD
cord-005478-5iu38pr6	460	11	RCT	RCT	NNP
cord-005478-5iu38pr6	460	12	(	(	-LRB-
cord-005478-5iu38pr6	460	13	ASSIST	assist	VB
cord-005478-5iu38pr6	460	14	,	,	,
cord-005478-5iu38pr6	460	15	ASTIS	ASTIS	NNP
cord-005478-5iu38pr6	460	16	,	,	,
cord-005478-5iu38pr6	460	17	SCOT	SCOT	NNP
cord-005478-5iu38pr6	460	18	)	)	-RRB-
cord-005478-5iu38pr6	460	19	.	.	.
cord-005478-5iu38pr6	461	1	HRQoL	HRQoL	NNP
cord-005478-5iu38pr6	461	2	data	datum	NNS
cord-005478-5iu38pr6	461	3	from	from	IN
cord-005478-5iu38pr6	461	4	289	289	CD
cord-005478-5iu38pr6	461	5	SSc	SSc	NNS
cord-005478-5iu38pr6	461	6	patients	patient	NNS
cord-005478-5iu38pr6	461	7	treated	treat	VBN
cord-005478-5iu38pr6	461	8	with	with	IN
cord-005478-5iu38pr6	461	9	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	461	10	and	and	CC
cord-005478-5iu38pr6	461	11	125	125	CD
cord-005478-5iu38pr6	461	12	with	with	IN
cord-005478-5iu38pr6	461	13	intravenous	intravenous	JJ
cord-005478-5iu38pr6	461	14	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	461	15	(	(	-LRB-
cord-005478-5iu38pr6	461	16	CYC	CYC	NNP
cord-005478-5iu38pr6	461	17	)	)	-RRB-
cord-005478-5iu38pr6	461	18	as	as	IN
cord-005478-5iu38pr6	461	19	a	a	DT
cord-005478-5iu38pr6	461	20	comparator	comparator	NN
cord-005478-5iu38pr6	461	21	were	be	VBD
cord-005478-5iu38pr6	461	22	extracted	extract	VBN
cord-005478-5iu38pr6	461	23	.	.	.
cord-005478-5iu38pr6	462	1	HRQoL	HRQoL	NNP
cord-005478-5iu38pr6	462	2	was	be	VBD
cord-005478-5iu38pr6	462	3	assessed	assess	VBN
cord-005478-5iu38pr6	462	4	using	use	VBG
cord-005478-5iu38pr6	462	5	the	the	DT
cord-005478-5iu38pr6	462	6	Health	Health	NNP
cord-005478-5iu38pr6	462	7	Assessment	Assessment	NNP
cord-005478-5iu38pr6	462	8	Questionnaire	Questionnaire	NNP
cord-005478-5iu38pr6	462	9	-	-	HYPH
cord-005478-5iu38pr6	462	10	Disability	Disability	NNP
cord-005478-5iu38pr6	462	11	Index	Index	NNP
cord-005478-5iu38pr6	462	12	(	(	-LRB-
cord-005478-5iu38pr6	462	13	HAQ	HAQ	NNP
cord-005478-5iu38pr6	462	14	-	-	HYPH
cord-005478-5iu38pr6	462	15	DI	DI	NNP
cord-005478-5iu38pr6	462	16	)	)	-RRB-
cord-005478-5iu38pr6	462	17	(	(	-LRB-
cord-005478-5iu38pr6	462	18	n=275	n=275	CD
cord-005478-5iu38pr6	462	19	patients	patient	NNS
cord-005478-5iu38pr6	462	20	)	)	-RRB-
cord-005478-5iu38pr6	462	21	,	,	,
cord-005478-5iu38pr6	462	22	the	the	DT
cord-005478-5iu38pr6	462	23	Short	Short	NNP
cord-005478-5iu38pr6	462	24	-	-	HYPH
cord-005478-5iu38pr6	462	25	Form	Form	NNP
cord-005478-5iu38pr6	462	26	Health	Health	NNP
cord-005478-5iu38pr6	462	27	Survey	Survey	NNP
cord-005478-5iu38pr6	462	28	(	(	-LRB-
cord-005478-5iu38pr6	462	29	SF-36	SF-36	NNP
cord-005478-5iu38pr6	462	30	)	)	-RRB-
cord-005478-5iu38pr6	462	31	(	(	-LRB-
cord-005478-5iu38pr6	462	32	n=249	n=249	NNP
cord-005478-5iu38pr6	462	33	patients	patient	NNS
cord-005478-5iu38pr6	462	34	)	)	-RRB-
cord-005478-5iu38pr6	462	35	and	and	CC
cord-005478-5iu38pr6	462	36	the	the	DT
cord-005478-5iu38pr6	462	37	EuroQol	EuroQol	NNP
cord-005478-5iu38pr6	462	38	5	5	CD
cord-005478-5iu38pr6	462	39	Dimensions	Dimensions	NNPS
cord-005478-5iu38pr6	462	40	(	(	-LRB-
cord-005478-5iu38pr6	462	41	EQ-5D	EQ-5D	NNP
cord-005478-5iu38pr6	462	42	)	)	-RRB-
cord-005478-5iu38pr6	462	43	(	(	-LRB-
cord-005478-5iu38pr6	462	44	n=138	n=138	CD
cord-005478-5iu38pr6	462	45	patients	patient	NNS
cord-005478-5iu38pr6	462	46	)	)	-RRB-
cord-005478-5iu38pr6	462	47	.	.	.
cord-005478-5iu38pr6	463	1	HRQoL	HRQoL	NNP
cord-005478-5iu38pr6	463	2	was	be	VBD
cord-005478-5iu38pr6	463	3	analyzed	analyze	VBN
cord-005478-5iu38pr6	463	4	as	as	IN
cord-005478-5iu38pr6	463	5	a	a	DT
cord-005478-5iu38pr6	463	6	secondary	secondary	JJ
cord-005478-5iu38pr6	463	7	outcome	outcome	NN
cord-005478-5iu38pr6	463	8	in	in	IN
cord-005478-5iu38pr6	463	9	all	all	DT
cord-005478-5iu38pr6	463	10	studies	study	NNS
cord-005478-5iu38pr6	463	11	.	.	.
cord-005478-5iu38pr6	464	1	Quality	quality	NN
cord-005478-5iu38pr6	464	2	of	of	IN
cord-005478-5iu38pr6	464	3	the	the	DT
cord-005478-5iu38pr6	464	4	data	datum	NNS
cord-005478-5iu38pr6	464	5	was	be	VBD
cord-005478-5iu38pr6	464	6	assessed	assess	VBN
cord-005478-5iu38pr6	464	7	as	as	IN
cord-005478-5iu38pr6	464	8	high	high	JJ
cord-005478-5iu38pr6	464	9	.	.	.
cord-005478-5iu38pr6	465	1	HAQ	HAQ	NNP
cord-005478-5iu38pr6	465	2	-	-	HYPH
cord-005478-5iu38pr6	465	3	DI	DI	NNP
cord-005478-5iu38pr6	465	4	improved	improve	VBD
cord-005478-5iu38pr6	465	5	significantly	significantly	RB
cord-005478-5iu38pr6	465	6	more	more	RBR
cord-005478-5iu38pr6	465	7	with	with	IN
cord-005478-5iu38pr6	465	8	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	465	9	compared	compare	VBN
cord-005478-5iu38pr6	465	10	to	to	IN
cord-005478-5iu38pr6	465	11	CYC	CYC	NNP
cord-005478-5iu38pr6	465	12	(	(	-LRB-
cord-005478-5iu38pr6	465	13	-0.58	-0.58	CD
cord-005478-5iu38pr6	465	14	vs	vs	IN
cord-005478-5iu38pr6	465	15	-0.19	-0.19	CD
cord-005478-5iu38pr6	465	16	,	,	,
cord-005478-5iu38pr6	465	17	p=0.02	p=0.02	NN
cord-005478-5iu38pr6	465	18	at	at	IN
cord-005478-5iu38pr6	465	19	2	2	CD
cord-005478-5iu38pr6	465	20	years	year	NNS
cord-005478-5iu38pr6	465	21	in	in	IN
cord-005478-5iu38pr6	465	22	ASTIS	ASTIS	NNP
cord-005478-5iu38pr6	465	23	;	;	:
cord-005478-5iu38pr6	465	24	53	53	CD
cord-005478-5iu38pr6	465	25	%	%	NN
cord-005478-5iu38pr6	465	26	vs	vs	IN
cord-005478-5iu38pr6	465	27	16	16	CD
cord-005478-5iu38pr6	465	28	%	%	NN
cord-005478-5iu38pr6	465	29	improved	improve	VBN
cord-005478-5iu38pr6	465	30	at	at	IN
cord-005478-5iu38pr6	465	31	4.8	4.8	CD
cord-005478-5iu38pr6	465	32	years	year	NNS
cord-005478-5iu38pr6	465	33	in	in	IN
cord-005478-5iu38pr6	465	34	SCOT	SCOT	NNP
cord-005478-5iu38pr6	465	35	)	)	-RRB-
cord-005478-5iu38pr6	465	36	.	.	.
cord-005478-5iu38pr6	466	1	Scores	score	NNS
cord-005478-5iu38pr6	466	2	also	also	RB
cord-005478-5iu38pr6	466	3	improved	improve	VBD
cord-005478-5iu38pr6	466	4	pre	pre	JJ
cord-005478-5iu38pr6	466	5	-	-	JJ
cord-005478-5iu38pr6	466	6	post	post	JJ
cord-005478-5iu38pr6	466	7	AHSCT	ahsct	NN
cord-005478-5iu38pr6	466	8	in	in	IN
cord-005478-5iu38pr6	466	9	the	the	DT
cord-005478-5iu38pr6	466	10	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	466	11	studies	study	NNS
cord-005478-5iu38pr6	466	12	(	(	-LRB-
cord-005478-5iu38pr6	466	13	ranging	range	VBG
cord-005478-5iu38pr6	466	14	from	from	IN
cord-005478-5iu38pr6	466	15	-0.6	-0.6	CD
cord-005478-5iu38pr6	466	16	to	to	IN
cord-005478-5iu38pr6	466	17	-1.7	-1.7	CD
cord-005478-5iu38pr6	466	18	points	point	NNS
cord-005478-5iu38pr6	466	19	at	at	IN
cord-005478-5iu38pr6	466	20	one	one	CD
cord-005478-5iu38pr6	466	21	year	year	NN
cord-005478-5iu38pr6	466	22	(	(	-LRB-
cord-005478-5iu38pr6	466	23	all	all	DT
cord-005478-5iu38pr6	466	24	p	p	NN
cord-005478-5iu38pr6	466	25	<	<	XX
cord-005478-5iu38pr6	466	26	0.05	0.05	CD
cord-005478-5iu38pr6	466	27	)	)	-RRB-
cord-005478-5iu38pr6	466	28	,	,	,
cord-005478-5iu38pr6	466	29	and	and	CC
cord-005478-5iu38pr6	466	30	up	up	IN
cord-005478-5iu38pr6	466	31	to	to	IN
cord-005478-5iu38pr6	466	32	-1.5	-1.5	CD
cord-005478-5iu38pr6	466	33	points	point	NNS
cord-005478-5iu38pr6	466	34	at	at	IN
cord-005478-5iu38pr6	466	35	7.5	7.5	CD
cord-005478-5iu38pr6	466	36	years	year	NNS
cord-005478-5iu38pr6	466	37	(	(	-LRB-
cord-005478-5iu38pr6	466	38	p	p	NN
cord-005478-5iu38pr6	466	39	<	<	XX
cord-005478-5iu38pr6	466	40	0.001	0.001	CD
cord-005478-5iu38pr6	466	41	)	)	-RRB-
cord-005478-5iu38pr6	466	42	)	)	-RRB-
cord-005478-5iu38pr6	466	43	.	.	.
cord-005478-5iu38pr6	467	1	SF-36	SF-36	NNP
cord-005478-5iu38pr6	467	2	Physical	Physical	NNP
cord-005478-5iu38pr6	467	3	Component	Component	NNP
cord-005478-5iu38pr6	467	4	Summary	Summary	NNP
cord-005478-5iu38pr6	467	5	scores	score	NNS
cord-005478-5iu38pr6	467	6	were	be	VBD
cord-005478-5iu38pr6	467	7	significantly	significantly	RB
cord-005478-5iu38pr6	467	8	better	well	JJR
cord-005478-5iu38pr6	467	9	in	in	IN
cord-005478-5iu38pr6	467	10	subjects	subject	NNS
cord-005478-5iu38pr6	467	11	treated	treat	VBN
cord-005478-5iu38pr6	467	12	with	with	IN
cord-005478-5iu38pr6	467	13	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	467	14	compared	compare	VBN
cord-005478-5iu38pr6	467	15	to	to	IN
cord-005478-5iu38pr6	467	16	CYC	CYC	NNP
cord-005478-5iu38pr6	467	17	(	(	-LRB-
cord-005478-5iu38pr6	467	18	between	between	IN
cord-005478-5iu38pr6	467	19	group	group	NN
cord-005478-5iu38pr6	467	20	differences	difference	NNS
cord-005478-5iu38pr6	467	21	ranging	range	VBG
cord-005478-5iu38pr6	467	22	from	from	IN
cord-005478-5iu38pr6	467	23	26	26	CD
cord-005478-5iu38pr6	467	24	points	point	NNS
cord-005478-5iu38pr6	467	25	at	at	IN
cord-005478-5iu38pr6	467	26	one	one	CD
cord-005478-5iu38pr6	467	27	year	year	NN
cord-005478-5iu38pr6	467	28	in	in	IN
cord-005478-5iu38pr6	467	29	ASSIST	ASSIST	NNP
cord-005478-5iu38pr6	467	30	and	and	CC
cord-005478-5iu38pr6	467	31	6.1	6.1	CD
cord-005478-5iu38pr6	467	32	points	point	NNS
cord-005478-5iu38pr6	467	33	at	at	IN
cord-005478-5iu38pr6	467	34	2	2	CD
cord-005478-5iu38pr6	467	35	years	year	NNS
cord-005478-5iu38pr6	467	36	in	in	IN
cord-005478-5iu38pr6	467	37	ASTIS	ASTIS	NNP
cord-005478-5iu38pr6	467	38	(	(	-LRB-
cord-005478-5iu38pr6	467	39	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	467	40	)	)	-RRB-
cord-005478-5iu38pr6	467	41	;	;	:
cord-005478-5iu38pr6	467	42	56	56	CD
cord-005478-5iu38pr6	467	43	%	%	NN
cord-005478-5iu38pr6	467	44	vs	vs	IN
cord-005478-5iu38pr6	467	45	15	15	CD
cord-005478-5iu38pr6	467	46	%	%	NN
cord-005478-5iu38pr6	467	47	improved	improve	VBN
cord-005478-5iu38pr6	467	48	at	at	IN
cord-005478-5iu38pr6	467	49	4.8	4.8	CD
cord-005478-5iu38pr6	467	50	years	year	NNS
cord-005478-5iu38pr6	467	51	in	in	IN
cord-005478-5iu38pr6	467	52	SCOT	SCOT	NNP
cord-005478-5iu38pr6	467	53	(	(	-LRB-
cord-005478-5iu38pr6	467	54	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	467	55	)	)	-RRB-
cord-005478-5iu38pr6	467	56	)	)	-RRB-
cord-005478-5iu38pr6	467	57	.	.	.
cord-005478-5iu38pr6	468	1	Similar	similar	JJ
cord-005478-5iu38pr6	468	2	differences	difference	NNS
cord-005478-5iu38pr6	468	3	pre	pre	VBP
cord-005478-5iu38pr6	468	4	-	-	JJ
cord-005478-5iu38pr6	468	5	post	post	JJ
cord-005478-5iu38pr6	468	6	treatment	treatment	NN
cord-005478-5iu38pr6	468	7	scores	score	NNS
cord-005478-5iu38pr6	468	8	were	be	VBD
cord-005478-5iu38pr6	468	9	also	also	RB
cord-005478-5iu38pr6	468	10	reported	report	VBN
cord-005478-5iu38pr6	468	11	in	in	IN
cord-005478-5iu38pr6	468	12	an	an	DT
cord-005478-5iu38pr6	468	13	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	468	14	study	study	NN
cord-005478-5iu38pr6	468	15	(	(	-LRB-
cord-005478-5iu38pr6	468	16	increase	increase	NN
cord-005478-5iu38pr6	468	17	of	of	IN
cord-005478-5iu38pr6	468	18	20	20	CD
cord-005478-5iu38pr6	468	19	points	point	NNS
cord-005478-5iu38pr6	468	20	,	,	,
cord-005478-5iu38pr6	468	21	p	p	NN
cord-005478-5iu38pr6	468	22	<	<	XX
cord-005478-5iu38pr6	468	23	0.0001	0.0001	CD
cord-005478-5iu38pr6	468	24	)	)	-RRB-
cord-005478-5iu38pr6	468	25	.	.	.
cord-005478-5iu38pr6	469	1	In	in	IN
cord-005478-5iu38pr6	469	2	ASSIST	ASSIST	NNP
cord-005478-5iu38pr6	469	3	,	,	,
cord-005478-5iu38pr6	469	4	there	there	EX
cord-005478-5iu38pr6	469	5	was	be	VBD
cord-005478-5iu38pr6	469	6	a	a	DT
cord-005478-5iu38pr6	469	7	trend	trend	NN
cord-005478-5iu38pr6	469	8	for	for	IN
cord-005478-5iu38pr6	469	9	the	the	DT
cord-005478-5iu38pr6	469	10	SF-36	SF-36	NNP
cord-005478-5iu38pr6	469	11	Mental	Mental	NNP
cord-005478-5iu38pr6	469	12	Component	Component	NNP
cord-005478-5iu38pr6	469	13	Summary	Summary	NNP
cord-005478-5iu38pr6	469	14	score	score	NN
cord-005478-5iu38pr6	469	15	to	to	TO
cord-005478-5iu38pr6	469	16	improve	improve	VB
cord-005478-5iu38pr6	469	17	in	in	IN
cord-005478-5iu38pr6	469	18	the	the	DT
cord-005478-5iu38pr6	469	19	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	469	20	arm	arm	NN
cord-005478-5iu38pr6	469	21	(	(	-LRB-
cord-005478-5iu38pr6	469	22	46	46	CD
cord-005478-5iu38pr6	469	23	vs	vs	IN
cord-005478-5iu38pr6	469	24	58	58	CD
cord-005478-5iu38pr6	469	25	,	,	,
cord-005478-5iu38pr6	469	26	p=0.07	p=0.07	NNP
cord-005478-5iu38pr6	469	27	)	)	-RRB-
cord-005478-5iu38pr6	469	28	and	and	CC
cord-005478-5iu38pr6	469	29	worsen	worsen	VB
cord-005478-5iu38pr6	469	30	in	in	IN
cord-005478-5iu38pr6	469	31	the	the	DT
cord-005478-5iu38pr6	469	32	CYC	CYC	NNP
cord-005478-5iu38pr6	469	33	arm	arm	NN
cord-005478-5iu38pr6	469	34	(	(	-LRB-
cord-005478-5iu38pr6	469	35	56	56	CD
cord-005478-5iu38pr6	469	36	vs	vs	IN
cord-005478-5iu38pr6	469	37	42	42	CD
cord-005478-5iu38pr6	469	38	,	,	,
cord-005478-5iu38pr6	469	39	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	469	40	)	)	-RRB-
cord-005478-5iu38pr6	469	41	at	at	IN
cord-005478-5iu38pr6	469	42	one	one	CD
cord-005478-5iu38pr6	469	43	year	year	NN
cord-005478-5iu38pr6	469	44	.	.	.
cord-005478-5iu38pr6	470	1	There	there	EX
cord-005478-5iu38pr6	470	2	were	be	VBD
cord-005478-5iu38pr6	470	3	no	no	DT
cord-005478-5iu38pr6	470	4	significant	significant	JJ
cord-005478-5iu38pr6	470	5	differences	difference	NNS
cord-005478-5iu38pr6	470	6	between	between	IN
cord-005478-5iu38pr6	470	7	the	the	DT
cord-005478-5iu38pr6	470	8	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	470	9	and	and	CC
cord-005478-5iu38pr6	470	10	CYC	CYC	NNP
cord-005478-5iu38pr6	470	11	arms	arm	NNS
cord-005478-5iu38pr6	470	12	in	in	IN
cord-005478-5iu38pr6	470	13	ASTIS	ASTIS	NNP
cord-005478-5iu38pr6	470	14	and	and	CC
cord-005478-5iu38pr6	470	15	SCOT	SCOT	NNP
cord-005478-5iu38pr6	470	16	with	with	IN
cord-005478-5iu38pr6	470	17	2.0	2.0	CD
cord-005478-5iu38pr6	470	18	and	and	CC
cord-005478-5iu38pr6	470	19	4.8	4.8	CD
cord-005478-5iu38pr6	470	20	years	year	NNS
cord-005478-5iu38pr6	470	21	of	of	IN
cord-005478-5iu38pr6	470	22	follow	follow	NN
cord-005478-5iu38pr6	470	23	-	-	HYPH
cord-005478-5iu38pr6	470	24	up	up	NN
cord-005478-5iu38pr6	470	25	,	,	,
cord-005478-5iu38pr6	470	26	respectively	respectively	RB
cord-005478-5iu38pr6	470	27	.	.	.
cord-005478-5iu38pr6	471	1	Post	post	JJ
cord-005478-5iu38pr6	471	2	-	-	JJ
cord-005478-5iu38pr6	471	3	treatment	treatment	JJ
cord-005478-5iu38pr6	471	4	scores	score	NNS
cord-005478-5iu38pr6	471	5	improved	improve	VBD
cord-005478-5iu38pr6	471	6	significantly	significantly	RB
cord-005478-5iu38pr6	471	7	compared	compare	VBN
cord-005478-5iu38pr6	471	8	to	to	IN
cord-005478-5iu38pr6	471	9	pre	pre	JJ
cord-005478-5iu38pr6	471	10	-	-	JJ
cord-005478-5iu38pr6	471	11	treatment	treatment	NN
cord-005478-5iu38pr6	471	12	in	in	IN
cord-005478-5iu38pr6	471	13	an	an	DT
cord-005478-5iu38pr6	471	14	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	471	15	study	study	NN
cord-005478-5iu38pr6	471	16	(	(	-LRB-
cord-005478-5iu38pr6	471	17	from	from	IN
cord-005478-5iu38pr6	471	18	51	51	CD
cord-005478-5iu38pr6	471	19	to	to	TO
cord-005478-5iu38pr6	471	20	64	64	CD
cord-005478-5iu38pr6	471	21	points	point	NNS
cord-005478-5iu38pr6	471	22	,	,	,
cord-005478-5iu38pr6	471	23	p=0.005	p=0.005	NNP
cord-005478-5iu38pr6	471	24	)	)	-RRB-
cord-005478-5iu38pr6	471	25	.	.	.
cord-005478-5iu38pr6	472	1	ASTIS	ASTIS	NNP
cord-005478-5iu38pr6	472	2	showed	show	VBD
cord-005478-5iu38pr6	472	3	a	a	DT
cord-005478-5iu38pr6	472	4	significant	significant	JJ
cord-005478-5iu38pr6	472	5	difference	difference	NN
cord-005478-5iu38pr6	472	6	in	in	IN
cord-005478-5iu38pr6	472	7	the	the	DT
cord-005478-5iu38pr6	472	8	index	index	NN
cord-005478-5iu38pr6	472	9	-	-	HYPH
cord-005478-5iu38pr6	472	10	based	base	VBN
cord-005478-5iu38pr6	472	11	utility	utility	NN
cord-005478-5iu38pr6	472	12	score	score	NN
cord-005478-5iu38pr6	472	13	of	of	IN
cord-005478-5iu38pr6	472	14	the	the	DT
cord-005478-5iu38pr6	472	15	EQ-5D	EQ-5D	NNS
cord-005478-5iu38pr6	472	16	(	(	-LRB-
cord-005478-5iu38pr6	472	17	0.29	0.29	CD
cord-005478-5iu38pr6	472	18	,	,	,
cord-005478-5iu38pr6	472	19	p	p	NN
cord-005478-5iu38pr6	472	20	<	<	XX
cord-005478-5iu38pr6	472	21	0.001	0.001	CD
cord-005478-5iu38pr6	472	22	)	)	-RRB-
cord-005478-5iu38pr6	472	23	and	and	CC
cord-005478-5iu38pr6	472	24	a	a	DT
cord-005478-5iu38pr6	472	25	non	non	JJ
cord-005478-5iu38pr6	472	26	-	-	JJ
cord-005478-5iu38pr6	472	27	significant	significant	JJ
cord-005478-5iu38pr6	472	28	difference	difference	NN
cord-005478-5iu38pr6	472	29	in	in	IN
cord-005478-5iu38pr6	472	30	the	the	DT
cord-005478-5iu38pr6	472	31	general	general	JJ
cord-005478-5iu38pr6	472	32	health	health	NN
cord-005478-5iu38pr6	472	33	visual	visual	JJ
cord-005478-5iu38pr6	472	34	analogue	analogue	NN
cord-005478-5iu38pr6	472	35	scale	scale	NN
cord-005478-5iu38pr6	472	36	(	(	-LRB-
cord-005478-5iu38pr6	472	37	6.7	6.7	CD
cord-005478-5iu38pr6	472	38	,	,	,
cord-005478-5iu38pr6	472	39	p=0.36	p=0.36	NN
cord-005478-5iu38pr6	472	40	)	)	-RRB-
cord-005478-5iu38pr6	472	41	at	at	IN
cord-005478-5iu38pr6	472	42	two	two	CD
cord-005478-5iu38pr6	472	43	years	year	NNS
cord-005478-5iu38pr6	472	44	,	,	,
cord-005478-5iu38pr6	472	45	in	in	IN
cord-005478-5iu38pr6	472	46	favour	favour	NN
cord-005478-5iu38pr6	472	47	of	of	IN
cord-005478-5iu38pr6	472	48	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	472	49	compared	compare	VBN
cord-005478-5iu38pr6	472	50	to	to	IN
cord-005478-5iu38pr6	472	51	CYC	CYC	NNP
cord-005478-5iu38pr6	472	52	.	.	.
cord-005478-5iu38pr6	473	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	473	2	:	:	:
cord-005478-5iu38pr6	474	1	Although	although	IN
cord-005478-5iu38pr6	474	2	there	there	EX
cord-005478-5iu38pr6	474	3	is	be	VBZ
cord-005478-5iu38pr6	474	4	heterogeneity	heterogeneity	NN
cord-005478-5iu38pr6	474	5	in	in	IN
cord-005478-5iu38pr6	474	6	the	the	DT
cord-005478-5iu38pr6	474	7	reported	report	VBN
cord-005478-5iu38pr6	474	8	data	datum	NNS
cord-005478-5iu38pr6	474	9	,	,	,
cord-005478-5iu38pr6	474	10	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	474	11	in	in	IN
cord-005478-5iu38pr6	474	12	SSc	SSc	NNS
cord-005478-5iu38pr6	474	13	was	be	VBD
cord-005478-5iu38pr6	474	14	consistently	consistently	RB
cord-005478-5iu38pr6	474	15	associated	associate	VBN
cord-005478-5iu38pr6	474	16	with	with	IN
cord-005478-5iu38pr6	474	17	marked	marked	JJ
cord-005478-5iu38pr6	474	18	and	and	CC
cord-005478-5iu38pr6	474	19	sustained	sustained	JJ
cord-005478-5iu38pr6	474	20	improvement	improvement	NN
cord-005478-5iu38pr6	474	21	in	in	IN
cord-005478-5iu38pr6	474	22	HRQoL.	HRQoL.	NNP
cord-005478-5iu38pr6	475	1	This	this	DT
cord-005478-5iu38pr6	475	2	analysis	analysis	NN
cord-005478-5iu38pr6	475	3	provides	provide	VBZ
cord-005478-5iu38pr6	475	4	additional	additional	JJ
cord-005478-5iu38pr6	475	5	compelling	compelling	JJ
cord-005478-5iu38pr6	475	6	data	datum	NNS
cord-005478-5iu38pr6	475	7	for	for	IN
cord-005478-5iu38pr6	475	8	the	the	DT
cord-005478-5iu38pr6	475	9	role	role	NN
cord-005478-5iu38pr6	475	10	of	of	IN
cord-005478-5iu38pr6	475	11	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	475	12	in	in	IN
cord-005478-5iu38pr6	475	13	SSc	SSc	NNS
cord-005478-5iu38pr6	475	14	when	when	WRB
cord-005478-5iu38pr6	475	15	assessing	assess	VBG
cord-005478-5iu38pr6	475	16	patient	patient	NN
cord-005478-5iu38pr6	475	17	's	's	POS
cord-005478-5iu38pr6	475	18	point	point	NN
cord-005478-5iu38pr6	475	19	of	of	IN
cord-005478-5iu38pr6	475	20	view	view	NN
cord-005478-5iu38pr6	475	21	.	.	.
cord-005478-5iu38pr6	476	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	476	2	Trial	Trial	NNP
cord-005478-5iu38pr6	476	3	Registry	Registry	NNP
cord-005478-5iu38pr6	476	4	:	:	:
cord-005478-5iu38pr6	476	5	We	-PRON-	PRP
cord-005478-5iu38pr6	476	6	hypothesised	hypothesise	VBD
cord-005478-5iu38pr6	476	7	that	that	IN
cord-005478-5iu38pr6	476	8	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	476	9	induces	induce	VBZ
cord-005478-5iu38pr6	476	10	a	a	DT
cord-005478-5iu38pr6	476	11	rebooting	rebooting	NN
cord-005478-5iu38pr6	476	12	of	of	IN
cord-005478-5iu38pr6	476	13	thymic	thymic	JJ
cord-005478-5iu38pr6	476	14	function	function	NN
cord-005478-5iu38pr6	476	15	,	,	,
cord-005478-5iu38pr6	476	16	resulting	result	VBG
cord-005478-5iu38pr6	476	17	in	in	IN
cord-005478-5iu38pr6	476	18	the	the	DT
cord-005478-5iu38pr6	476	19	re	re	NN
cord-005478-5iu38pr6	476	20	-	-	NN
cord-005478-5iu38pr6	476	21	development	development	NN
cord-005478-5iu38pr6	476	22	of	of	IN
cord-005478-5iu38pr6	476	23	a	a	DT
cord-005478-5iu38pr6	476	24	functional	functional	JJ
cord-005478-5iu38pr6	476	25	,	,	,
cord-005478-5iu38pr6	476	26	tolerant	tolerant	JJ
cord-005478-5iu38pr6	476	27	immune	immune	JJ
cord-005478-5iu38pr6	476	28	system	system	NN
cord-005478-5iu38pr6	476	29	.	.	.
cord-005478-5iu38pr6	477	1	We	-PRON-	PRP
cord-005478-5iu38pr6	477	2	aimed	aim	VBD
cord-005478-5iu38pr6	477	3	to	to	TO
cord-005478-5iu38pr6	477	4	examine	examine	VB
cord-005478-5iu38pr6	477	5	cellsurface	cellsurface	NN
cord-005478-5iu38pr6	477	6	and	and	CC
cord-005478-5iu38pr6	477	7	DNA	dna	NN
cord-005478-5iu38pr6	477	8	markers	marker	NNS
cord-005478-5iu38pr6	477	9	of	of	IN
cord-005478-5iu38pr6	477	10	recent	recent	JJ
cord-005478-5iu38pr6	477	11	thymic	thymic	JJ
cord-005478-5iu38pr6	477	12	emigrants	emigrant	NNS
cord-005478-5iu38pr6	477	13	(	(	-LRB-
cord-005478-5iu38pr6	477	14	RTE	RTE	NNP
cord-005478-5iu38pr6	477	15	's	's	POS
cord-005478-5iu38pr6	477	16	)	)	-RRB-
cord-005478-5iu38pr6	477	17	longitudinally	longitudinally	RB
cord-005478-5iu38pr6	477	18	in	in	IN
cord-005478-5iu38pr6	477	19	a	a	DT
cord-005478-5iu38pr6	477	20	cohort	cohort	NN
cord-005478-5iu38pr6	477	21	of	of	IN
cord-005478-5iu38pr6	477	22	MS	MS	NNP
cord-005478-5iu38pr6	477	23	patients	patient	NNS
cord-005478-5iu38pr6	477	24	post	post	JJ
cord-005478-5iu38pr6	477	25	-	-	JJ
cord-005478-5iu38pr6	477	26	AHSCT	ahsct	NN
cord-005478-5iu38pr6	477	27	in	in	IN
cord-005478-5iu38pr6	477	28	order	order	NN
cord-005478-5iu38pr6	477	29	to	to	TO
cord-005478-5iu38pr6	477	30	identify	identify	VB
cord-005478-5iu38pr6	477	31	markers	marker	NNS
cord-005478-5iu38pr6	477	32	that	that	WDT
cord-005478-5iu38pr6	477	33	correlate	correlate	VBP
cord-005478-5iu38pr6	477	34	with	with	IN
cord-005478-5iu38pr6	477	35	a	a	DT
cord-005478-5iu38pr6	477	36	durable	durable	JJ
cord-005478-5iu38pr6	477	37	treatment	treatment	NN
cord-005478-5iu38pr6	477	38	response	response	NN
cord-005478-5iu38pr6	477	39	.	.	.
cord-005478-5iu38pr6	478	1	Methods	method	NNS
cord-005478-5iu38pr6	478	2	:	:	:
cord-005478-5iu38pr6	478	3	Peripheral	peripheral	JJ
cord-005478-5iu38pr6	478	4	blood	blood	NN
cord-005478-5iu38pr6	478	5	mononuclear	mononuclear	NN
cord-005478-5iu38pr6	478	6	cells	cell	NNS
cord-005478-5iu38pr6	478	7	(	(	-LRB-
cord-005478-5iu38pr6	478	8	PBMNCs	pbmnc	NNS
cord-005478-5iu38pr6	478	9	)	)	-RRB-
cord-005478-5iu38pr6	478	10	were	be	VBD
cord-005478-5iu38pr6	478	11	collected	collect	VBN
cord-005478-5iu38pr6	478	12	from	from	IN
cord-005478-5iu38pr6	478	13	patients	patient	NNS
cord-005478-5iu38pr6	478	14	enrolled	enrol	VBN
cord-005478-5iu38pr6	478	15	in	in	IN
cord-005478-5iu38pr6	478	16	the	the	DT
cord-005478-5iu38pr6	478	17	Phase	Phase	NNP
cord-005478-5iu38pr6	478	18	II	II	NNP
cord-005478-5iu38pr6	478	19	trial	trial	NN
cord-005478-5iu38pr6	478	20	at	at	IN
cord-005478-5iu38pr6	478	21	St	St	NNP
cord-005478-5iu38pr6	478	22	Vincent	Vincent	NNP
cord-005478-5iu38pr6	478	23	's	's	POS
cord-005478-5iu38pr6	478	24	Hospital	Hospital	NNP
cord-005478-5iu38pr6	478	25	Sydney	Sydney	NNP
cord-005478-5iu38pr6	478	26	for	for	IN
cord-005478-5iu38pr6	478	27	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	478	28	in	in	IN
cord-005478-5iu38pr6	478	29	MS	MS	NNP
cord-005478-5iu38pr6	478	30	(	(	-LRB-
cord-005478-5iu38pr6	478	31	Moore	Moore	NNP
cord-005478-5iu38pr6	478	32	et	et	NNP
cord-005478-5iu38pr6	478	33	al	al	NNP
cord-005478-5iu38pr6	478	34	,	,	,
cord-005478-5iu38pr6	478	35	JNNP	JNNP	NNP
cord-005478-5iu38pr6	478	36	in	in	IN
cord-005478-5iu38pr6	478	37	press	press	NN
cord-005478-5iu38pr6	478	38	)	)	-RRB-
cord-005478-5iu38pr6	478	39	.	.	.
cord-005478-5iu38pr6	479	1	A	a	DT
cord-005478-5iu38pr6	479	2	multicolour	multicolour	NN
cord-005478-5iu38pr6	479	3	flow	flow	NN
cord-005478-5iu38pr6	479	4	cytometry	cytometry	NN
cord-005478-5iu38pr6	479	5	panel	panel	NN
cord-005478-5iu38pr6	479	6	to	to	TO
cord-005478-5iu38pr6	479	7	optimally	optimally	RB
cord-005478-5iu38pr6	479	8	identify	identify	VB
cord-005478-5iu38pr6	479	9	RTE	RTE	NNP
cord-005478-5iu38pr6	479	10	's	's	POS
cord-005478-5iu38pr6	479	11	was	be	VBD
cord-005478-5iu38pr6	479	12	performed	perform	VBN
cord-005478-5iu38pr6	479	13	on	on	IN
cord-005478-5iu38pr6	479	14	10	10	CD
cord-005478-5iu38pr6	479	15	patient	patient	NN
cord-005478-5iu38pr6	479	16	samples	sample	NNS
cord-005478-5iu38pr6	479	17	at	at	IN
cord-005478-5iu38pr6	479	18	0	0	CD
cord-005478-5iu38pr6	479	19	,	,	,
cord-005478-5iu38pr6	479	20	6	6	CD
cord-005478-5iu38pr6	479	21	,	,	,
cord-005478-5iu38pr6	479	22	12	12	CD
cord-005478-5iu38pr6	479	23	,	,	,
cord-005478-5iu38pr6	479	24	24	24	CD
cord-005478-5iu38pr6	479	25	and	and	CC
cord-005478-5iu38pr6	479	26	36	36	CD
cord-005478-5iu38pr6	479	27	month	month	NN
cord-005478-5iu38pr6	479	28	timepoints	timepoint	NNS
cord-005478-5iu38pr6	479	29	,	,	,
cord-005478-5iu38pr6	479	30	allowing	allow	VBG
cord-005478-5iu38pr6	479	31	us	-PRON-	PRP
cord-005478-5iu38pr6	479	32	to	to	TO
cord-005478-5iu38pr6	479	33	track	track	VB
cord-005478-5iu38pr6	479	34	changes	change	NNS
cord-005478-5iu38pr6	479	35	in	in	IN
cord-005478-5iu38pr6	479	36	thymic	thymic	JJ
cord-005478-5iu38pr6	479	37	output	output	NN
cord-005478-5iu38pr6	479	38	longitudinally	longitudinally	RB
cord-005478-5iu38pr6	479	39	following	follow	VBG
cord-005478-5iu38pr6	479	40	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	479	41	.	.	.
cord-005478-5iu38pr6	480	1	DNA	dna	NN
cord-005478-5iu38pr6	480	2	markers	marker	NNS
cord-005478-5iu38pr6	480	3	of	of	IN
cord-005478-5iu38pr6	480	4	thymic	thymic	JJ
cord-005478-5iu38pr6	480	5	function	function	NN
cord-005478-5iu38pr6	481	1	-Sj	-Sj	NFP
cord-005478-5iu38pr6	481	2	:	:	:
cord-005478-5iu38pr6	482	1	b	b	LS
cord-005478-5iu38pr6	482	2	TREC	TREC	NNP
cord-005478-5iu38pr6	482	3	ratio	ratio	NN
cord-005478-5iu38pr6	482	4	was	be	VBD
cord-005478-5iu38pr6	482	5	performed	perform	VBN
cord-005478-5iu38pr6	482	6	in	in	IN
cord-005478-5iu38pr6	482	7	the	the	DT
cord-005478-5iu38pr6	482	8	same	same	JJ
cord-005478-5iu38pr6	482	9	cohort	cohort	NN
cord-005478-5iu38pr6	482	10	of	of	IN
cord-005478-5iu38pr6	482	11	patients	patient	NNS
cord-005478-5iu38pr6	482	12	,	,	,
cord-005478-5iu38pr6	482	13	on	on	IN
cord-005478-5iu38pr6	482	14	the	the	DT
cord-005478-5iu38pr6	482	15	same	same	JJ
cord-005478-5iu38pr6	482	16	bio	bio	JJ
cord-005478-5iu38pr6	482	17	-	-	HYPH
cord-005478-5iu38pr6	482	18	banked	bank	VBN
cord-005478-5iu38pr6	482	19	sample	sample	NN
cord-005478-5iu38pr6	482	20	to	to	TO
cord-005478-5iu38pr6	482	21	enhance	enhance	VB
cord-005478-5iu38pr6	482	22	the	the	DT
cord-005478-5iu38pr6	482	23	validity	validity	NN
cord-005478-5iu38pr6	482	24	of	of	IN
cord-005478-5iu38pr6	482	25	observed	observed	JJ
cord-005478-5iu38pr6	482	26	changes	change	NNS
cord-005478-5iu38pr6	482	27	.	.	.
cord-005478-5iu38pr6	483	1	Statistical	statistical	JJ
cord-005478-5iu38pr6	483	2	analysis	analysis	NN
cord-005478-5iu38pr6	483	3	was	be	VBD
cord-005478-5iu38pr6	483	4	performed	perform	VBN
cord-005478-5iu38pr6	483	5	with	with	IN
cord-005478-5iu38pr6	483	6	GraphPad	GraphPad	NNP
cord-005478-5iu38pr6	483	7	Prism	Prism	NNP
cord-005478-5iu38pr6	483	8	.	.	.
cord-005478-5iu38pr6	484	1	Results	result	NNS
cord-005478-5iu38pr6	484	2	:	:	:
cord-005478-5iu38pr6	485	1	A	a	DT
cord-005478-5iu38pr6	485	2	sustained	sustained	JJ
cord-005478-5iu38pr6	485	3	,	,	,
cord-005478-5iu38pr6	485	4	significant	significant	JJ
cord-005478-5iu38pr6	485	5	increase	increase	NN
cord-005478-5iu38pr6	485	6	in	in	IN
cord-005478-5iu38pr6	485	7	RTE	RTE	NNP
cord-005478-5iu38pr6	485	8	's	's	POS
cord-005478-5iu38pr6	485	9	and	and	CC
cord-005478-5iu38pr6	485	10	Sj	Sj	NNP
cord-005478-5iu38pr6	485	11	:	:	:
cord-005478-5iu38pr6	485	12	b	b	LS
cord-005478-5iu38pr6	485	13	TREC	TREC	NNP
cord-005478-5iu38pr6	485	14	was	be	VBD
cord-005478-5iu38pr6	485	15	detected	detect	VBN
cord-005478-5iu38pr6	485	16	between	between	IN
cord-005478-5iu38pr6	485	17	pre	pre	JJ
cord-005478-5iu38pr6	485	18	-	-	NN
cord-005478-5iu38pr6	485	19	transplant	transplant	JJ
cord-005478-5iu38pr6	485	20	and	and	CC
cord-005478-5iu38pr6	485	21	24	24	CD
cord-005478-5iu38pr6	485	22	month	month	NN
cord-005478-5iu38pr6	485	23	post	post	JJ
cord-005478-5iu38pr6	485	24	-	-	JJ
cord-005478-5iu38pr6	485	25	transplant	transplant	JJ
cord-005478-5iu38pr6	485	26	specimens	specimen	NNS
cord-005478-5iu38pr6	485	27	(	(	-LRB-
cord-005478-5iu38pr6	485	28	p	p	NN
cord-005478-5iu38pr6	485	29	=	=	SYM
cord-005478-5iu38pr6	485	30	0.024	0.024	CD
cord-005478-5iu38pr6	485	31	)	)	-RRB-
cord-005478-5iu38pr6	485	32	.	.	.
cord-005478-5iu38pr6	486	1	In	in	IN
cord-005478-5iu38pr6	486	2	patients	patient	NNS
cord-005478-5iu38pr6	486	3	where	where	WRB
cord-005478-5iu38pr6	486	4	similar	similar	JJ
cord-005478-5iu38pr6	486	5	analysis	analysis	NN
cord-005478-5iu38pr6	486	6	was	be	VBD
cord-005478-5iu38pr6	486	7	able	able	JJ
cord-005478-5iu38pr6	486	8	to	to	TO
cord-005478-5iu38pr6	486	9	be	be	VB
cord-005478-5iu38pr6	486	10	performed	perform	VBN
cord-005478-5iu38pr6	486	11	at	at	IN
cord-005478-5iu38pr6	486	12	36	36	CD
cord-005478-5iu38pr6	486	13	months	month	NNS
cord-005478-5iu38pr6	486	14	a	a	DT
cord-005478-5iu38pr6	486	15	trend	trend	NN
cord-005478-5iu38pr6	486	16	to	to	IN
cord-005478-5iu38pr6	486	17	increased	increase	VBN
cord-005478-5iu38pr6	486	18	markers	marker	NNS
cord-005478-5iu38pr6	486	19	of	of	IN
cord-005478-5iu38pr6	486	20	thymic	thymic	JJ
cord-005478-5iu38pr6	486	21	output	output	NN
cord-005478-5iu38pr6	486	22	was	be	VBD
cord-005478-5iu38pr6	486	23	observed	observe	VBN
cord-005478-5iu38pr6	486	24	.	.	.
cord-005478-5iu38pr6	487	1	A	a	DT
cord-005478-5iu38pr6	487	2	correlation	correlation	NN
cord-005478-5iu38pr6	487	3	between	between	IN
cord-005478-5iu38pr6	487	4	RTE	RTE	NNP
cord-005478-5iu38pr6	487	5	's	's	POS
cord-005478-5iu38pr6	487	6	and	and	CC
cord-005478-5iu38pr6	487	7	Sj	Sj	NNP
cord-005478-5iu38pr6	487	8	:	:	:
cord-005478-5iu38pr6	487	9	b	b	LS
cord-005478-5iu38pr6	487	10	TREC	TREC	NNP
cord-005478-5iu38pr6	487	11	was	be	VBD
cord-005478-5iu38pr6	487	12	observed	observe	VBN
cord-005478-5iu38pr6	487	13	(	(	-LRB-
cord-005478-5iu38pr6	487	14	r=0.70	r=0.70	NNP
cord-005478-5iu38pr6	487	15	,	,	,
cord-005478-5iu38pr6	487	16	p	p	NN
cord-005478-5iu38pr6	487	17	=	=	SYM
cord-005478-5iu38pr6	487	18	0.003	0.003	CD
cord-005478-5iu38pr6	487	19	)	)	-RRB-
cord-005478-5iu38pr6	487	20	.	.	.
cord-005478-5iu38pr6	488	1	Contrary	contrary	JJ
cord-005478-5iu38pr6	488	2	to	to	IN
cord-005478-5iu38pr6	488	3	other	other	JJ
cord-005478-5iu38pr6	488	4	publications	publication	NNS
cord-005478-5iu38pr6	488	5	in	in	IN
cord-005478-5iu38pr6	488	6	the	the	DT
cord-005478-5iu38pr6	488	7	field	field	NN
cord-005478-5iu38pr6	488	8	,	,	,
cord-005478-5iu38pr6	488	9	TREC	TREC	NNP
cord-005478-5iu38pr6	488	10	as	as	IN
cord-005478-5iu38pr6	488	11	a	a	DT
cord-005478-5iu38pr6	488	12	marker	marker	NN
cord-005478-5iu38pr6	488	13	of	of	IN
cord-005478-5iu38pr6	488	14	thymic	thymic	JJ
cord-005478-5iu38pr6	488	15	output	output	NN
cord-005478-5iu38pr6	488	16	did	do	VBD
cord-005478-5iu38pr6	488	17	not	not	RB
cord-005478-5iu38pr6	488	18	appear	appear	VB
cord-005478-5iu38pr6	488	19	to	to	TO
cord-005478-5iu38pr6	488	20	be	be	VB
cord-005478-5iu38pr6	488	21	lower	low	JJR
cord-005478-5iu38pr6	488	22	when	when	WRB
cord-005478-5iu38pr6	488	23	patients	patient	NNS
cord-005478-5iu38pr6	488	24	were	be	VBD
cord-005478-5iu38pr6	488	25	analysed	analyse	VBN
cord-005478-5iu38pr6	488	26	by	by	IN
cord-005478-5iu38pr6	488	27	age	age	NN
cord-005478-5iu38pr6	488	28	(	(	-LRB-
cord-005478-5iu38pr6	488	29	<	<	NNP
cord-005478-5iu38pr6	488	30	30	30	CD
cord-005478-5iu38pr6	488	31	yrs	yrs	NN
cord-005478-5iu38pr6	488	32	vs.	vs.	FW
cord-005478-5iu38pr6	488	33	>	>	XX
cord-005478-5iu38pr6	488	34	30	30	CD
cord-005478-5iu38pr6	488	35	yrs	yrs	NN
cord-005478-5iu38pr6	488	36	)	)	-RRB-
cord-005478-5iu38pr6	488	37	.	.	.
cord-005478-5iu38pr6	489	1	Greater	great	JJR
cord-005478-5iu38pr6	489	2	thymic	thymic	JJ
cord-005478-5iu38pr6	489	3	output	output	NN
cord-005478-5iu38pr6	489	4	as	as	IN
cord-005478-5iu38pr6	489	5	determined	determine	VBN
cord-005478-5iu38pr6	489	6	by	by	IN
cord-005478-5iu38pr6	489	7	Sj	Sj	NNP
cord-005478-5iu38pr6	489	8	:	:	:
cord-005478-5iu38pr6	489	9	b	b	LS
cord-005478-5iu38pr6	489	10	TREC	TREC	NNP
cord-005478-5iu38pr6	489	11	was	be	VBD
cord-005478-5iu38pr6	489	12	observed	observe	VBN
cord-005478-5iu38pr6	489	13	at	at	IN
cord-005478-5iu38pr6	489	14	all	all	DT
cord-005478-5iu38pr6	489	15	timepoints	timepoint	NNS
cord-005478-5iu38pr6	489	16	in	in	IN
cord-005478-5iu38pr6	489	17	patients	patient	NNS
cord-005478-5iu38pr6	489	18	who	who	WP
cord-005478-5iu38pr6	489	19	had	have	VBD
cord-005478-5iu38pr6	489	20	evidence	evidence	NN
cord-005478-5iu38pr6	489	21	of	of	IN
cord-005478-5iu38pr6	489	22	sustained	sustained	JJ
cord-005478-5iu38pr6	489	23	disease	disease	NN
cord-005478-5iu38pr6	489	24	remission	remission	NN
cord-005478-5iu38pr6	489	25	as	as	IN
cord-005478-5iu38pr6	489	26	opposed	oppose	VBN
cord-005478-5iu38pr6	489	27	to	to	IN
cord-005478-5iu38pr6	489	28	patients	patient	NNS
cord-005478-5iu38pr6	489	29	who	who	WP
cord-005478-5iu38pr6	489	30	experienced	experience	VBD
cord-005478-5iu38pr6	489	31	disease	disease	NN
cord-005478-5iu38pr6	489	32	relapse	relapse	NN
cord-005478-5iu38pr6	489	33	.	.	.
cord-005478-5iu38pr6	490	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	490	2	:	:	:
cord-005478-5iu38pr6	491	1	We	-PRON-	PRP
cord-005478-5iu38pr6	491	2	have	have	VBP
cord-005478-5iu38pr6	491	3	seen	see	VBN
cord-005478-5iu38pr6	491	4	evidence	evidence	NN
cord-005478-5iu38pr6	491	5	that	that	IN
cord-005478-5iu38pr6	491	6	sustained	sustain	VBD
cord-005478-5iu38pr6	491	7	thymic	thymic	JJ
cord-005478-5iu38pr6	491	8	reactivation	reactivation	NN
cord-005478-5iu38pr6	491	9	is	be	VBZ
cord-005478-5iu38pr6	491	10	a	a	DT
cord-005478-5iu38pr6	491	11	component	component	NN
cord-005478-5iu38pr6	491	12	of	of	IN
cord-005478-5iu38pr6	491	13	immune	immune	JJ
cord-005478-5iu38pr6	491	14	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	491	15	following	follow	VBG
cord-005478-5iu38pr6	491	16	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	491	17	for	for	IN
cord-005478-5iu38pr6	491	18	MS	MS	NNP
cord-005478-5iu38pr6	491	19	.	.	.
cord-005478-5iu38pr6	492	1	Previous	previous	JJ
cord-005478-5iu38pr6	492	2	studies	study	NNS
cord-005478-5iu38pr6	492	3	have	have	VBP
cord-005478-5iu38pr6	492	4	only	only	RB
cord-005478-5iu38pr6	492	5	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	492	6	thymic	thymic	JJ
cord-005478-5iu38pr6	492	7	activity	activity	NN
cord-005478-5iu38pr6	492	8	at	at	IN
cord-005478-5iu38pr6	492	9	12	12	CD
cord-005478-5iu38pr6	492	10	months	month	NNS
cord-005478-5iu38pr6	492	11	but	but	CC
cord-005478-5iu38pr6	492	12	this	this	DT
cord-005478-5iu38pr6	492	13	study	study	NN
cord-005478-5iu38pr6	492	14	confirms	confirm	VBZ
cord-005478-5iu38pr6	492	15	that	that	IN
cord-005478-5iu38pr6	492	16	thymic	thymic	JJ
cord-005478-5iu38pr6	492	17	activity	activity	NN
cord-005478-5iu38pr6	492	18	remains	remain	VBZ
cord-005478-5iu38pr6	492	19	prominent	prominent	JJ
cord-005478-5iu38pr6	492	20	at	at	IN
cord-005478-5iu38pr6	492	21	24	24	CD
cord-005478-5iu38pr6	492	22	and	and	CC
cord-005478-5iu38pr6	492	23	even	even	RB
cord-005478-5iu38pr6	492	24	36	36	CD
cord-005478-5iu38pr6	492	25	months	month	NNS
cord-005478-5iu38pr6	492	26	.	.	.
cord-005478-5iu38pr6	493	1	This	this	DT
cord-005478-5iu38pr6	493	2	thymic	thymic	JJ
cord-005478-5iu38pr6	493	3	regeneration	regeneration	NN
cord-005478-5iu38pr6	493	4	may	may	MD
cord-005478-5iu38pr6	493	5	contribute	contribute	VB
cord-005478-5iu38pr6	493	6	to	to	IN
cord-005478-5iu38pr6	493	7	a	a	DT
cord-005478-5iu38pr6	493	8	durable	durable	JJ
cord-005478-5iu38pr6	493	9	clinical	clinical	JJ
cord-005478-5iu38pr6	493	10	response	response	NN
cord-005478-5iu38pr6	493	11	in	in	IN
cord-005478-5iu38pr6	493	12	patients	patient	NNS
cord-005478-5iu38pr6	493	13	with	with	IN
cord-005478-5iu38pr6	493	14	MS	MS	NNP
cord-005478-5iu38pr6	493	15	post	post	NN
cord-005478-5iu38pr6	493	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	493	17	.	.	.
cord-005478-5iu38pr6	494	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	494	2	Background	background	NN
cord-005478-5iu38pr6	494	3	:	:	:
cord-005478-5iu38pr6	495	1	Allogeneic	Allogeneic	NNP
cord-005478-5iu38pr6	495	2	HSCT	HSCT	NNP
cord-005478-5iu38pr6	495	3	offers	offer	VBZ
cord-005478-5iu38pr6	495	4	the	the	DT
cord-005478-5iu38pr6	495	5	potential	potential	JJ
cord-005478-5iu38pr6	495	6	replacement	replacement	NN
cord-005478-5iu38pr6	495	7	of	of	IN
cord-005478-5iu38pr6	495	8	an	an	DT
cord-005478-5iu38pr6	495	9	aberrant	aberrant	JJ
cord-005478-5iu38pr6	495	10	immune	immune	JJ
cord-005478-5iu38pr6	495	11	system	system	NN
cord-005478-5iu38pr6	495	12	.	.	.
cord-005478-5iu38pr6	496	1	This	this	DT
cord-005478-5iu38pr6	496	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	496	3	study	study	NN
cord-005478-5iu38pr6	496	4	assessed	assess	VBD
cord-005478-5iu38pr6	496	5	long	long	JJ
cord-005478-5iu38pr6	496	6	-	-	HYPH
cord-005478-5iu38pr6	496	7	term	term	NN
cord-005478-5iu38pr6	496	8	outcomes	outcome	NNS
cord-005478-5iu38pr6	496	9	of	of	IN
cord-005478-5iu38pr6	496	10	this	this	DT
cord-005478-5iu38pr6	496	11	strategy	strategy	NN
cord-005478-5iu38pr6	496	12	in	in	IN
cord-005478-5iu38pr6	496	13	patients	patient	NNS
cord-005478-5iu38pr6	496	14	treated	treat	VBN
cord-005478-5iu38pr6	496	15	for	for	IN
cord-005478-5iu38pr6	496	16	severe	severe	JJ
cord-005478-5iu38pr6	496	17	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	496	18	diseases	disease	NNS
cord-005478-5iu38pr6	496	19	(	(	-LRB-
cord-005478-5iu38pr6	496	20	ADs	ad	NNS
cord-005478-5iu38pr6	496	21	)	)	-RRB-
cord-005478-5iu38pr6	496	22	,	,	,
cord-005478-5iu38pr6	496	23	reported	report	VBD
cord-005478-5iu38pr6	496	24	to	to	IN
cord-005478-5iu38pr6	496	25	the	the	DT
cord-005478-5iu38pr6	496	26	EBMT	EBMT	NNP
cord-005478-5iu38pr6	496	27	registry	registry	NN
cord-005478-5iu38pr6	496	28	.	.	.
cord-005478-5iu38pr6	497	1	Methods	method	NNS
cord-005478-5iu38pr6	497	2	:	:	:
cord-005478-5iu38pr6	497	3	Among	among	IN
cord-005478-5iu38pr6	497	4	the	the	DT
cord-005478-5iu38pr6	497	5	total	total	JJ
cord-005478-5iu38pr6	497	6	126	126	CD
cord-005478-5iu38pr6	497	7	patients	patient	NNS
cord-005478-5iu38pr6	497	8	who	who	WP
cord-005478-5iu38pr6	497	9	received	receive	VBD
cord-005478-5iu38pr6	497	10	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	497	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	497	12	between	between	IN
cord-005478-5iu38pr6	497	13	1997	1997	CD
cord-005478-5iu38pr6	497	14	-	-	SYM
cord-005478-5iu38pr6	497	15	2014	2014	CD
cord-005478-5iu38pr6	497	16	,	,	,
cord-005478-5iu38pr6	497	17	we	-PRON-	PRP
cord-005478-5iu38pr6	497	18	received	receive	VBD
cord-005478-5iu38pr6	497	19	detailed	detailed	JJ
cord-005478-5iu38pr6	497	20	questionnaires	questionnaire	NNS
cord-005478-5iu38pr6	497	21	on	on	IN
cord-005478-5iu38pr6	497	22	long	long	JJ
cord-005478-5iu38pr6	497	23	-	-	HYPH
cord-005478-5iu38pr6	497	24	term	term	NN
cord-005478-5iu38pr6	497	25	outcomes	outcome	NNS
cord-005478-5iu38pr6	497	26	from	from	IN
cord-005478-5iu38pr6	497	27	64	64	CD
cord-005478-5iu38pr6	497	28	patients	patient	NNS
cord-005478-5iu38pr6	497	29	.	.	.
cord-005478-5iu38pr6	498	1	The	the	DT
cord-005478-5iu38pr6	498	2	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	498	3	of	of	IN
cord-005478-5iu38pr6	498	4	AD	ad	NN
cord-005478-5iu38pr6	498	5	was	be	VBD
cord-005478-5iu38pr6	498	6	hematological	hematological	JJ
cord-005478-5iu38pr6	498	7	(	(	-LRB-
cord-005478-5iu38pr6	498	8	n=21	n=21	JJ
cord-005478-5iu38pr6	498	9	)	)	-RRB-
cord-005478-5iu38pr6	498	10	and	and	CC
cord-005478-5iu38pr6	498	11	nonhematological	nonhematological	NNP
cord-005478-5iu38pr6	498	12	(	(	-LRB-
cord-005478-5iu38pr6	498	13	n=43	n=43	NNP
cord-005478-5iu38pr6	498	14	)	)	-RRB-
cord-005478-5iu38pr6	498	15	,	,	,
cord-005478-5iu38pr6	498	16	among	among	IN
cord-005478-5iu38pr6	498	17	pediatric	pediatric	JJ
cord-005478-5iu38pr6	498	18	(	(	-LRB-
cord-005478-5iu38pr6	498	19	=	=	SYM
cord-005478-5iu38pr6	498	20	45	45	CD
cord-005478-5iu38pr6	498	21	)	)	-RRB-
cord-005478-5iu38pr6	498	22	and	and	CC
cord-005478-5iu38pr6	498	23	adult	adult	NN
cord-005478-5iu38pr6	498	24	(	(	-LRB-
cord-005478-5iu38pr6	498	25	=	=	SYM
cord-005478-5iu38pr6	498	26	19	19	CD
cord-005478-5iu38pr6	498	27	)	)	-RRB-
cord-005478-5iu38pr6	498	28	populations	population	NNS
cord-005478-5iu38pr6	498	29	.	.	.
cord-005478-5iu38pr6	499	1	The	the	DT
cord-005478-5iu38pr6	499	2	median	median	JJ
cord-005478-5iu38pr6	499	3	age	age	NN
cord-005478-5iu38pr6	499	4	of	of	IN
cord-005478-5iu38pr6	499	5	patients	patient	NNS
cord-005478-5iu38pr6	499	6	at	at	IN
cord-005478-5iu38pr6	499	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	499	8	was	be	VBD
cord-005478-5iu38pr6	499	9	11.14	11.14	CD
cord-005478-5iu38pr6	499	10	years	year	NNS
cord-005478-5iu38pr6	500	1	(	(	-LRB-
cord-005478-5iu38pr6	500	2	pediatric	pediatric	JJ
cord-005478-5iu38pr6	500	3	:	:	:
cord-005478-5iu38pr6	500	4	median	median	JJ
cord-005478-5iu38pr6	500	5	8.07	8.07	CD
cord-005478-5iu38pr6	500	6	years	year	NNS
cord-005478-5iu38pr6	500	7	,	,	,
cord-005478-5iu38pr6	500	8	range	range	VBP
cord-005478-5iu38pr6	500	9	1.22	1.22	CD
cord-005478-5iu38pr6	500	10	-	-	HYPH
cord-005478-5iu38pr6	500	11	17.77	17.77	CD
cord-005478-5iu38pr6	500	12	)	)	-RRB-
cord-005478-5iu38pr6	500	13	;	;	:
cord-005478-5iu38pr6	500	14	adult	adult	NN
cord-005478-5iu38pr6	500	15	:	:	:
cord-005478-5iu38pr6	500	16	median	median	JJ
cord-005478-5iu38pr6	500	17	31.30	31.30	CD
cord-005478-5iu38pr6	500	18	years	year	NNS
cord-005478-5iu38pr6	500	19	,	,	,
cord-005478-5iu38pr6	500	20	range	range	VBP
cord-005478-5iu38pr6	500	21	21.43	21.43	CD
cord-005478-5iu38pr6	500	22	-	-	HYPH
cord-005478-5iu38pr6	500	23	51.57	51.57	CD
cord-005478-5iu38pr6	500	24	)	)	-RRB-
cord-005478-5iu38pr6	500	25	.	.	.
cord-005478-5iu38pr6	501	1	All	all	DT
cord-005478-5iu38pr6	501	2	patients	patient	NNS
cord-005478-5iu38pr6	501	3	were	be	VBD
cord-005478-5iu38pr6	501	4	refractory	refractory	JJ
cord-005478-5iu38pr6	501	5	to	to	IN
cord-005478-5iu38pr6	501	6	previous	previous	JJ
cord-005478-5iu38pr6	501	7	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	501	8	therapies	therapy	NNS
cord-005478-5iu38pr6	501	9	(	(	-LRB-
cord-005478-5iu38pr6	501	10	median	median	NN
cord-005478-5iu38pr6	501	11	of	of	IN
cord-005478-5iu38pr6	501	12	4	4	CD
cord-005478-5iu38pr6	501	13	lines	line	NNS
cord-005478-5iu38pr6	501	14	of	of	IN
cord-005478-5iu38pr6	501	15	treatments	treatment	NNS
cord-005478-5iu38pr6	501	16	,	,	,
cord-005478-5iu38pr6	501	17	range	range	VBP
cord-005478-5iu38pr6	501	18	1	1	CD
cord-005478-5iu38pr6	501	19	-	-	SYM
cord-005478-5iu38pr6	501	20	13	13	CD
cord-005478-5iu38pr6	501	21	)	)	-RRB-
cord-005478-5iu38pr6	501	22	,	,	,
cord-005478-5iu38pr6	501	23	and	and	CC
cord-005478-5iu38pr6	501	24	eight	eight	CD
cord-005478-5iu38pr6	501	25	of	of	IN
cord-005478-5iu38pr6	501	26	them	-PRON-	PRP
cord-005478-5iu38pr6	501	27	received	receive	VBD
cord-005478-5iu38pr6	501	28	a	a	DT
cord-005478-5iu38pr6	501	29	previous	previous	JJ
cord-005478-5iu38pr6	501	30	autologous	autologous	JJ
cord-005478-5iu38pr6	501	31	transplant	transplant	NN
cord-005478-5iu38pr6	501	32	.	.	.
cord-005478-5iu38pr6	502	1	The	the	DT
cord-005478-5iu38pr6	502	2	graft	graft	NN
cord-005478-5iu38pr6	502	3	source	source	NN
cord-005478-5iu38pr6	502	4	was	be	VBD
cord-005478-5iu38pr6	502	5	PBSCs	pbsc	NNS
cord-005478-5iu38pr6	502	6	in	in	IN
cord-005478-5iu38pr6	502	7	38	38	CD
cord-005478-5iu38pr6	502	8	,	,	,
cord-005478-5iu38pr6	502	9	BM	BM	NNP
cord-005478-5iu38pr6	502	10	in	in	IN
cord-005478-5iu38pr6	502	11	24	24	CD
cord-005478-5iu38pr6	502	12	,	,	,
cord-005478-5iu38pr6	502	13	and	and	CC
cord-005478-5iu38pr6	502	14	cord	cord	NN
cord-005478-5iu38pr6	502	15	blood	blood	NN
cord-005478-5iu38pr6	502	16	in	in	IN
cord-005478-5iu38pr6	502	17	2	2	CD
cord-005478-5iu38pr6	502	18	patients	patient	NNS
cord-005478-5iu38pr6	502	19	.	.	.
cord-005478-5iu38pr6	503	1	Donors	donor	NNS
cord-005478-5iu38pr6	503	2	were	be	VBD
cord-005478-5iu38pr6	503	3	as	as	IN
cord-005478-5iu38pr6	503	4	follows	follow	VBZ
cord-005478-5iu38pr6	503	5	;	;	:
cord-005478-5iu38pr6	503	6	41	41	CD
cord-005478-5iu38pr6	503	7	%	%	NN
cord-005478-5iu38pr6	503	8	MRD	MRD	NNP
cord-005478-5iu38pr6	503	9	,	,	,
cord-005478-5iu38pr6	503	10	42	42	CD
cord-005478-5iu38pr6	503	11	%	%	NN
cord-005478-5iu38pr6	503	12	MUD	mud	NN
cord-005478-5iu38pr6	503	13	,	,	,
cord-005478-5iu38pr6	503	14	9	9	CD
cord-005478-5iu38pr6	503	15	%	%	NN
cord-005478-5iu38pr6	503	16	MMRD	MMRD	NNP
cord-005478-5iu38pr6	503	17	,	,	,
cord-005478-5iu38pr6	503	18	5	5	CD
cord-005478-5iu38pr6	503	19	%	%	NN
cord-005478-5iu38pr6	503	20	syngeneic	syngeneic	NNS
cord-005478-5iu38pr6	503	21	and	and	CC
cord-005478-5iu38pr6	503	22	3	3	CD
cord-005478-5iu38pr6	503	23	%	%	NN
cord-005478-5iu38pr6	503	24	cord	cord	NN
cord-005478-5iu38pr6	503	25	blood	blood	NN
cord-005478-5iu38pr6	503	26	.	.	.
cord-005478-5iu38pr6	504	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	504	2	was	be	VBD
cord-005478-5iu38pr6	504	3	MAC	MAC	NNP
cord-005478-5iu38pr6	504	4	in	in	IN
cord-005478-5iu38pr6	504	5	35	35	CD
cord-005478-5iu38pr6	504	6	and	and	CC
cord-005478-5iu38pr6	504	7	RIC	RIC	NNP
cord-005478-5iu38pr6	504	8	in	in	IN
cord-005478-5iu38pr6	504	9	29	29	CD
cord-005478-5iu38pr6	504	10	patients	patient	NNS
cord-005478-5iu38pr6	504	11	.	.	.
cord-005478-5iu38pr6	505	1	Serotherapy	Serotherapy	NNP
cord-005478-5iu38pr6	505	2	with	with	IN
cord-005478-5iu38pr6	505	3	ATG	ATG	NNP
cord-005478-5iu38pr6	505	4	was	be	VBD
cord-005478-5iu38pr6	505	5	given	give	VBN
cord-005478-5iu38pr6	505	6	in	in	IN
cord-005478-5iu38pr6	505	7	16	16	CD
cord-005478-5iu38pr6	505	8	patients	patient	NNS
cord-005478-5iu38pr6	505	9	,	,	,
cord-005478-5iu38pr6	505	10	while	while	IN
cord-005478-5iu38pr6	505	11	30	30	CD
cord-005478-5iu38pr6	505	12	patients	patient	NNS
cord-005478-5iu38pr6	505	13	received	receive	VBD
cord-005478-5iu38pr6	505	14	alemtuzumab	alemtuzumab	NNS
cord-005478-5iu38pr6	505	15	.	.	.
cord-005478-5iu38pr6	506	1	Post	post	JJ
cord-005478-5iu38pr6	506	2	-	-	JJ
cord-005478-5iu38pr6	506	3	transplant	transplant	JJ
cord-005478-5iu38pr6	506	4	GvHD	GvHD	NNP
cord-005478-5iu38pr6	506	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	506	6	was	be	VBD
cord-005478-5iu38pr6	506	7	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	506	8	-	-	HYPH
cord-005478-5iu38pr6	506	9	based	base	VBN
cord-005478-5iu38pr6	506	10	for	for	IN
cord-005478-5iu38pr6	506	11	the	the	DT
cord-005478-5iu38pr6	506	12	majority	majority	NN
cord-005478-5iu38pr6	506	13	of	of	IN
cord-005478-5iu38pr6	506	14	patients	patient	NNS
cord-005478-5iu38pr6	506	15	(	(	-LRB-
cord-005478-5iu38pr6	506	16	n=54	n=54	JJ
cord-005478-5iu38pr6	506	17	)	)	-RRB-
cord-005478-5iu38pr6	506	18	.	.	.
cord-005478-5iu38pr6	507	1	Results	result	NNS
cord-005478-5iu38pr6	507	2	:	:	:
cord-005478-5iu38pr6	508	1	Median	median	JJ
cord-005478-5iu38pr6	508	2	follow	follow	NN
cord-005478-5iu38pr6	508	3	-	-	HYPH
cord-005478-5iu38pr6	508	4	up	up	NN
cord-005478-5iu38pr6	508	5	was	be	VBD
cord-005478-5iu38pr6	508	6	67	67	CD
cord-005478-5iu38pr6	508	7	months	month	NNS
cord-005478-5iu38pr6	508	8	(	(	-LRB-
cord-005478-5iu38pr6	508	9	range	range	VBP
cord-005478-5iu38pr6	508	10	7.9	7.9	CD
cord-005478-5iu38pr6	508	11	-	-	SYM
cord-005478-5iu38pr6	508	12	189	189	CD
cord-005478-5iu38pr6	508	13	months	month	NNS
cord-005478-5iu38pr6	508	14	)	)	-RRB-
cord-005478-5iu38pr6	508	15	.	.	.
cord-005478-5iu38pr6	509	1	Toxicity	toxicity	NN
cord-005478-5iu38pr6	509	2	profile	profile	NN
cord-005478-5iu38pr6	509	3	was	be	VBD
cord-005478-5iu38pr6	509	4	similar	similar	JJ
cord-005478-5iu38pr6	509	5	to	to	IN
cord-005478-5iu38pr6	509	6	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	509	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	509	8	in	in	IN
cord-005478-5iu38pr6	509	9	other	other	JJ
cord-005478-5iu38pr6	509	10	contexts	context	NNS
cord-005478-5iu38pr6	509	11	.	.	.
cord-005478-5iu38pr6	510	1	The	the	DT
cord-005478-5iu38pr6	510	2	incidence	incidence	NN
cord-005478-5iu38pr6	510	3	of	of	IN
cord-005478-5iu38pr6	510	4	grades	grade	NNS
cord-005478-5iu38pr6	510	5	II	II	NNP
cord-005478-5iu38pr6	510	6	-	-	HYPH
cord-005478-5iu38pr6	510	7	IV	IV	NNP
cord-005478-5iu38pr6	510	8	acute	acute	JJ
cord-005478-5iu38pr6	510	9	GvHD	GvHD	NNP
cord-005478-5iu38pr6	510	10	was	be	VBD
cord-005478-5iu38pr6	510	11	16.4	16.4	CD
cord-005478-5iu38pr6	510	12	%	%	NN
cord-005478-5iu38pr6	510	13	(	(	-LRB-
cord-005478-5iu38pr6	510	14	95	95	CD
cord-005478-5iu38pr6	510	15	%	%	NN
cord-005478-5iu38pr6	510	16	CI	ci	NN
cord-005478-5iu38pr6	510	17	:	:	:
cord-005478-5iu38pr6	510	18	8.4	8.4	CD
cord-005478-5iu38pr6	510	19	-26.8	-26.8	CD
cord-005478-5iu38pr6	510	20	)	)	-RRB-
cord-005478-5iu38pr6	510	21	at	at	IN
cord-005478-5iu38pr6	510	22	100-days	100-days	CD
cord-005478-5iu38pr6	510	23	;	;	:
cord-005478-5iu38pr6	510	24	severe	severe	JJ
cord-005478-5iu38pr6	510	25	acute	acute	JJ
cord-005478-5iu38pr6	510	26	GvHD	GvHD	NNP
cord-005478-5iu38pr6	510	27	was	be	VBD
cord-005478-5iu38pr6	510	28	reported	report	VBN
cord-005478-5iu38pr6	510	29	in	in	IN
cord-005478-5iu38pr6	510	30	6.5	6.5	CD
cord-005478-5iu38pr6	510	31	%	%	NN
cord-005478-5iu38pr6	510	32	of	of	IN
cord-005478-5iu38pr6	510	33	them	-PRON-	PRP
cord-005478-5iu38pr6	510	34	.	.	.
cord-005478-5iu38pr6	511	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	511	2	incidence	incidence	NN
cord-005478-5iu38pr6	511	3	of	of	IN
cord-005478-5iu38pr6	511	4	chronic	chronic	JJ
cord-005478-5iu38pr6	511	5	GvHD	gvhd	NN
cord-005478-5iu38pr6	511	6	was	be	VBD
cord-005478-5iu38pr6	511	7	32.5	32.5	CD
cord-005478-5iu38pr6	511	8	%	%	NN
cord-005478-5iu38pr6	511	9	(	(	-LRB-
cord-005478-5iu38pr6	511	10	95	95	CD
cord-005478-5iu38pr6	511	11	%	%	NN
cord-005478-5iu38pr6	511	12	CI	ci	NN
cord-005478-5iu38pr6	511	13	:	:	:
cord-005478-5iu38pr6	511	14	20	20	CD
cord-005478-5iu38pr6	511	15	.	.	.
cord-005478-5iu38pr6	511	16	8	8	CD
cord-005478-5iu38pr6	511	17	-44.8	-44.8	CD
cord-005478-5iu38pr6	511	18	)	)	-RRB-
cord-005478-5iu38pr6	511	19	at	at	IN
cord-005478-5iu38pr6	511	20	5-year	5-year	CD
cord-005478-5iu38pr6	511	21	;	;	:
cord-005478-5iu38pr6	511	22	extensive	extensive	JJ
cord-005478-5iu38pr6	511	23	manifestations	manifestation	NNS
cord-005478-5iu38pr6	511	24	were	be	VBD
cord-005478-5iu38pr6	511	25	reported	report	VBN
cord-005478-5iu38pr6	511	26	for	for	IN
cord-005478-5iu38pr6	511	27	58	58	CD
cord-005478-5iu38pr6	511	28	%	%	NN
cord-005478-5iu38pr6	511	29	of	of	IN
cord-005478-5iu38pr6	511	30	chronic	chronic	JJ
cord-005478-5iu38pr6	511	31	GvHD	gvhd	NN
cord-005478-5iu38pr6	511	32	.	.	.
cord-005478-5iu38pr6	512	1	Overall	overall	JJ
cord-005478-5iu38pr6	512	2	graft	graft	NN
cord-005478-5iu38pr6	512	3	rejection	rejection	NN
cord-005478-5iu38pr6	512	4	rate	rate	NN
cord-005478-5iu38pr6	512	5	was	be	VBD
cord-005478-5iu38pr6	512	6	4.9	4.9	CD
cord-005478-5iu38pr6	512	7	%	%	NN
cord-005478-5iu38pr6	512	8	.	.	.
cord-005478-5iu38pr6	513	1	Seven	seven	CD
cord-005478-5iu38pr6	513	2	secondary	secondary	JJ
cord-005478-5iu38pr6	513	3	AD	ad	NN
cord-005478-5iu38pr6	513	4	and	and	CC
cord-005478-5iu38pr6	513	5	one	one	CD
cord-005478-5iu38pr6	513	6	case	case	NN
cord-005478-5iu38pr6	513	7	of	of	IN
cord-005478-5iu38pr6	513	8	new	new	JJ
cord-005478-5iu38pr6	513	9	malignancy	malignancy	NN
cord-005478-5iu38pr6	513	10	(	(	-LRB-
cord-005478-5iu38pr6	513	11	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	513	12	)	)	-RRB-
cord-005478-5iu38pr6	513	13	occurred	occur	VBD
cord-005478-5iu38pr6	513	14	.	.	.
cord-005478-5iu38pr6	514	1	Viral	viral	JJ
cord-005478-5iu38pr6	514	2	reactivations	reactivation	NNS
cord-005478-5iu38pr6	514	3	were	be	VBD
cord-005478-5iu38pr6	514	4	reported	report	VBN
cord-005478-5iu38pr6	514	5	in	in	IN
cord-005478-5iu38pr6	514	6	a	a	DT
cord-005478-5iu38pr6	514	7	total	total	NN
cord-005478-5iu38pr6	514	8	of	of	IN
cord-005478-5iu38pr6	514	9	33	33	CD
cord-005478-5iu38pr6	514	10	patients	patient	NNS
cord-005478-5iu38pr6	514	11	,	,	,
cord-005478-5iu38pr6	514	12	including	include	VBG
cord-005478-5iu38pr6	514	13	CMV	CMV	NNP
cord-005478-5iu38pr6	514	14	(	(	-LRB-
cord-005478-5iu38pr6	514	15	n=14	n=14	NNP
cord-005478-5iu38pr6	514	16	)	)	-RRB-
cord-005478-5iu38pr6	514	17	,	,	,
cord-005478-5iu38pr6	514	18	EBV	EBV	NNP
cord-005478-5iu38pr6	514	19	(	(	-LRB-
cord-005478-5iu38pr6	514	20	n=	n=	NNP
cord-005478-5iu38pr6	514	21	10	10	CD
cord-005478-5iu38pr6	514	22	)	)	-RRB-
cord-005478-5iu38pr6	514	23	,	,	,
cord-005478-5iu38pr6	514	24	Adenovirus	Adenovirus	NNP
cord-005478-5iu38pr6	514	25	(	(	-LRB-
cord-005478-5iu38pr6	514	26	n=5	n=5	NNP
cord-005478-5iu38pr6	514	27	)	)	-RRB-
cord-005478-5iu38pr6	514	28	,	,	,
cord-005478-5iu38pr6	514	29	BK	BK	NNP
cord-005478-5iu38pr6	514	30	virus	virus	NN
cord-005478-5iu38pr6	514	31	(	(	-LRB-
cord-005478-5iu38pr6	514	32	n=3	n=3	NN
cord-005478-5iu38pr6	514	33	)	)	-RRB-
cord-005478-5iu38pr6	514	34	,	,	,
cord-005478-5iu38pr6	514	35	HSV	HSV	NNP
cord-005478-5iu38pr6	514	36	(	(	-LRB-
cord-005478-5iu38pr6	514	37	n=2	n=2	NNS
cord-005478-5iu38pr6	514	38	)	)	-RRB-
cord-005478-5iu38pr6	514	39	,	,	,
cord-005478-5iu38pr6	514	40	HHV6	HHV6	NNP
cord-005478-5iu38pr6	514	41	(	(	-LRB-
cord-005478-5iu38pr6	514	42	n=3	n=3	NN
cord-005478-5iu38pr6	514	43	)	)	-RRB-
cord-005478-5iu38pr6	514	44	and	and	CC
cord-005478-5iu38pr6	514	45	VZV	VZV	NNP
cord-005478-5iu38pr6	514	46	(	(	-LRB-
cord-005478-5iu38pr6	514	47	n=2	n=2	NNS
cord-005478-5iu38pr6	514	48	)	)	-RRB-
cord-005478-5iu38pr6	514	49	.	.	.
cord-005478-5iu38pr6	515	1	Seven	seven	CD
cord-005478-5iu38pr6	515	2	cases	case	NNS
cord-005478-5iu38pr6	515	3	of	of	IN
cord-005478-5iu38pr6	515	4	invasive	invasive	JJ
cord-005478-5iu38pr6	515	5	fungal	fungal	JJ
cord-005478-5iu38pr6	515	6	infection	infection	NN
cord-005478-5iu38pr6	515	7	were	be	VBD
cord-005478-5iu38pr6	515	8	reported	report	VBN
cord-005478-5iu38pr6	515	9	(	(	-LRB-
cord-005478-5iu38pr6	515	10	one	one	CD
cord-005478-5iu38pr6	515	11	aspergillosis	aspergillosis	NN
cord-005478-5iu38pr6	515	12	and	and	CC
cord-005478-5iu38pr6	515	13	three	three	CD
cord-005478-5iu38pr6	515	14	candidiasis	candidiasi	NNS
cord-005478-5iu38pr6	515	15	)	)	-RRB-
cord-005478-5iu38pr6	515	16	.	.	.
cord-005478-5iu38pr6	516	1	Ten	ten	CD
cord-005478-5iu38pr6	516	2	bacterial	bacterial	JJ
cord-005478-5iu38pr6	516	3	infections	infection	NNS
cord-005478-5iu38pr6	516	4	(	(	-LRB-
cord-005478-5iu38pr6	516	5	only	only	RB
cord-005478-5iu38pr6	516	6	4	4	CD
cord-005478-5iu38pr6	516	7	patients	patient	NNS
cord-005478-5iu38pr6	516	8	developed	develop	VBD
cord-005478-5iu38pr6	516	9	infection	infection	NN
cord-005478-5iu38pr6	516	10	from	from	IN
cord-005478-5iu38pr6	516	11	Gram	gram	NN
cord-005478-5iu38pr6	516	12	-	-	HYPH
cord-005478-5iu38pr6	516	13	negative	negative	JJ
cord-005478-5iu38pr6	516	14	bacteria	bacteria	NNS
cord-005478-5iu38pr6	516	15	)	)	-RRB-
cord-005478-5iu38pr6	516	16	and	and	CC
cord-005478-5iu38pr6	516	17	four	four	CD
cord-005478-5iu38pr6	516	18	pneumonia	pneumonia	NN
cord-005478-5iu38pr6	516	19	were	be	VBD
cord-005478-5iu38pr6	516	20	observed	observe	VBN
cord-005478-5iu38pr6	516	21	.	.	.
cord-005478-5iu38pr6	517	1	At	at	IN
cord-005478-5iu38pr6	517	2	the	the	DT
cord-005478-5iu38pr6	517	3	last	last	JJ
cord-005478-5iu38pr6	517	4	follow	follow	NN
cord-005478-5iu38pr6	517	5	-	-	HYPH
cord-005478-5iu38pr6	517	6	up	up	NN
cord-005478-5iu38pr6	517	7	complete	complete	JJ
cord-005478-5iu38pr6	517	8	clinical	clinical	JJ
cord-005478-5iu38pr6	517	9	response	response	NN
cord-005478-5iu38pr6	517	10	was	be	VBD
cord-005478-5iu38pr6	517	11	obtained	obtain	VBN
cord-005478-5iu38pr6	517	12	in	in	IN
cord-005478-5iu38pr6	517	13	69.4	69.4	CD
cord-005478-5iu38pr6	517	14	%	%	NN
cord-005478-5iu38pr6	517	15	of	of	IN
cord-005478-5iu38pr6	517	16	patients	patient	NNS
cord-005478-5iu38pr6	517	17	,	,	,
cord-005478-5iu38pr6	517	18	while	while	IN
cord-005478-5iu38pr6	517	19	partial	partial	JJ
cord-005478-5iu38pr6	517	20	remission	remission	NN
cord-005478-5iu38pr6	517	21	was	be	VBD
cord-005478-5iu38pr6	517	22	reported	report	VBN
cord-005478-5iu38pr6	517	23	in	in	IN
cord-005478-5iu38pr6	517	24	6.5	6.5	CD
cord-005478-5iu38pr6	517	25	%	%	NN
cord-005478-5iu38pr6	517	26	.	.	.
cord-005478-5iu38pr6	518	1	Relapse	relapse	NN
cord-005478-5iu38pr6	518	2	incidence	incidence	NN
cord-005478-5iu38pr6	518	3	(	(	-LRB-
cord-005478-5iu38pr6	518	4	RI	RI	NNP
cord-005478-5iu38pr6	518	5	)	)	-RRB-
cord-005478-5iu38pr6	518	6	was	be	VBD
cord-005478-5iu38pr6	518	7	21.9	21.9	CD
cord-005478-5iu38pr6	518	8	%	%	NN
cord-005478-5iu38pr6	518	9	(	(	-LRB-
cord-005478-5iu38pr6	518	10	95	95	CD
cord-005478-5iu38pr6	518	11	%	%	NN
cord-005478-5iu38pr6	518	12	CI	ci	NN
cord-005478-5iu38pr6	518	13	:	:	:
cord-005478-5iu38pr6	518	14	11	11	CD
cord-005478-5iu38pr6	518	15	.	.	.
cord-005478-5iu38pr6	519	1	8	8	CD
cord-005478-5iu38pr6	519	2	-33.9	-33.9	CD
cord-005478-5iu38pr6	519	3	)	)	-RRB-
cord-005478-5iu38pr6	520	1	at	at	IN
cord-005478-5iu38pr6	520	2	the	the	DT
cord-005478-5iu38pr6	520	3	last	last	JJ
cord-005478-5iu38pr6	520	4	follow	follow	NN
cord-005478-5iu38pr6	520	5	-	-	HYPH
cord-005478-5iu38pr6	520	6	up	up	NN
cord-005478-5iu38pr6	520	7	.	.	.
cord-005478-5iu38pr6	521	1	Post	post	JJ
cord-005478-5iu38pr6	521	2	-	-	JJ
cord-005478-5iu38pr6	521	3	HSCT	hsct	JJ
cord-005478-5iu38pr6	521	4	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	521	5	disease	disease	NN
cord-005478-5iu38pr6	521	6	specific	specific	JJ
cord-005478-5iu38pr6	521	7	treatment	treatment	NN
cord-005478-5iu38pr6	521	8	was	be	VBD
cord-005478-5iu38pr6	521	9	required	require	VBN
cord-005478-5iu38pr6	521	10	for	for	IN
cord-005478-5iu38pr6	521	11	12	12	CD
cord-005478-5iu38pr6	521	12	patients	patient	NNS
cord-005478-5iu38pr6	521	13	.	.	.
cord-005478-5iu38pr6	522	1	In	in	IN
cord-005478-5iu38pr6	522	2	subgroup	subgroup	NN
cord-005478-5iu38pr6	522	3	analysis	analysis	NN
cord-005478-5iu38pr6	522	4	among	among	IN
cord-005478-5iu38pr6	522	5	different	different	JJ
cord-005478-5iu38pr6	522	6	diseases	disease	NNS
cord-005478-5iu38pr6	522	7	,	,	,
cord-005478-5iu38pr6	522	8	the	the	DT
cord-005478-5iu38pr6	522	9	OS	os	NN
cord-005478-5iu38pr6	522	10	rates	rate	NNS
cord-005478-5iu38pr6	522	11	were	be	VBD
cord-005478-5iu38pr6	522	12	similar	similar	JJ
cord-005478-5iu38pr6	522	13	between	between	IN
cord-005478-5iu38pr6	522	14	immune	immune	JJ
cord-005478-5iu38pr6	522	15	cytopenia	cytopenia	NNS
cord-005478-5iu38pr6	522	16	and	and	CC
cord-005478-5iu38pr6	522	17	other	other	JJ
cord-005478-5iu38pr6	522	18	ADs	ad	NNS
cord-005478-5iu38pr6	522	19	.	.	.
cord-005478-5iu38pr6	523	1	At	at	IN
cord-005478-5iu38pr6	523	2	5	5	CD
cord-005478-5iu38pr6	523	3	years	year	NNS
cord-005478-5iu38pr6	523	4	,	,	,
cord-005478-5iu38pr6	523	5	OS	OS	NNP
cord-005478-5iu38pr6	523	6	was	be	VBD
cord-005478-5iu38pr6	523	7	76	76	CD
cord-005478-5iu38pr6	523	8	%	%	NN
cord-005478-5iu38pr6	523	9	(	(	-LRB-
cord-005478-5iu38pr6	523	10	95	95	CD
cord-005478-5iu38pr6	523	11	%	%	NN
cord-005478-5iu38pr6	523	12	CI	ci	NN
cord-005478-5iu38pr6	523	13	:	:	:
cord-005478-5iu38pr6	523	14	64	64	CD
cord-005478-5iu38pr6	523	15	.	.	.
cord-005478-5iu38pr6	523	16	8	8	CD
cord-005478-5iu38pr6	523	17	-87.3	-87.3	CD
cord-005478-5iu38pr6	523	18	)	)	-RRB-
cord-005478-5iu38pr6	523	19	,	,	,
cord-005478-5iu38pr6	523	20	NRM	NRM	NNP
cord-005478-5iu38pr6	523	21	was	be	VBD
cord-005478-5iu38pr6	523	22	13.3	13.3	CD
cord-005478-5iu38pr6	523	23	%	%	NN
cord-005478-5iu38pr6	523	24	(	(	-LRB-
cord-005478-5iu38pr6	523	25	95	95	CD
cord-005478-5iu38pr6	523	26	%	%	NN
cord-005478-5iu38pr6	523	27	CI	ci	NN
cord-005478-5iu38pr6	523	28	:	:	:
cord-005478-5iu38pr6	523	29	6.1	6.1	CD
cord-005478-5iu38pr6	523	30	-23.2	-23.2	CD
cord-005478-5iu38pr6	523	31	)	)	-RRB-
cord-005478-5iu38pr6	523	32	and	and	CC
cord-005478-5iu38pr6	523	33	PFS	PFS	NNP
cord-005478-5iu38pr6	523	34	was	be	VBD
cord-005478-5iu38pr6	523	35	64.8	64.8	CD
cord-005478-5iu38pr6	523	36	%	%	NN
cord-005478-5iu38pr6	523	37	(	(	-LRB-
cord-005478-5iu38pr6	523	38	95	95	CD
cord-005478-5iu38pr6	523	39	%	%	NN
cord-005478-5iu38pr6	523	40	CI	ci	NN
cord-005478-5iu38pr6	523	41	:	:	:
cord-005478-5iu38pr6	523	42	52.1	52.1	CD
cord-005478-5iu38pr6	523	43	-77.6	-77.6	CD
cord-005478-5iu38pr6	523	44	)	)	-RRB-
cord-005478-5iu38pr6	523	45	,	,	,
cord-005478-5iu38pr6	523	46	with	with	IN
cord-005478-5iu38pr6	523	47	no	no	DT
cord-005478-5iu38pr6	523	48	differences	difference	NNS
cord-005478-5iu38pr6	523	49	between	between	IN
cord-005478-5iu38pr6	523	50	immune	immune	JJ
cord-005478-5iu38pr6	523	51	cytopenia	cytopenia	NNS
cord-005478-5iu38pr6	523	52	(	(	-LRB-
cord-005478-5iu38pr6	523	53	73.8	73.8	CD
cord-005478-5iu38pr6	523	54	%	%	NN
cord-005478-5iu38pr6	523	55	)	)	-RRB-
cord-005478-5iu38pr6	523	56	and	and	CC
cord-005478-5iu38pr6	523	57	other	other	JJ
cord-005478-5iu38pr6	523	58	ADs	ad	NNS
cord-005478-5iu38pr6	523	59	(	(	-LRB-
cord-005478-5iu38pr6	523	60	64.3	64.3	CD
cord-005478-5iu38pr6	523	61	%	%	NN
cord-005478-5iu38pr6	523	62	)	)	-RRB-
cord-005478-5iu38pr6	523	63	.	.	.
cord-005478-5iu38pr6	524	1	By	by	IN
cord-005478-5iu38pr6	524	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	524	3	analysis	analysis	NN
cord-005478-5iu38pr6	524	4	,	,	,
cord-005478-5iu38pr6	524	5	only	only	RB
cord-005478-5iu38pr6	524	6	one	one	CD
cord-005478-5iu38pr6	524	7	prognostic	prognostic	JJ
cord-005478-5iu38pr6	524	8	factor	factor	NN
cord-005478-5iu38pr6	524	9	remained	remain	VBD
cord-005478-5iu38pr6	524	10	significantly	significantly	RB
cord-005478-5iu38pr6	524	11	associated	associate	VBN
cord-005478-5iu38pr6	524	12	with	with	IN
cord-005478-5iu38pr6	524	13	long	long	JJ
cord-005478-5iu38pr6	524	14	-	-	HYPH
cord-005478-5iu38pr6	524	15	term	term	NN
cord-005478-5iu38pr6	524	16	outcomes	outcome	NNS
cord-005478-5iu38pr6	524	17	:	:	:
cord-005478-5iu38pr6	524	18	a	a	DT
cord-005478-5iu38pr6	524	19	more	more	RBR
cord-005478-5iu38pr6	524	20	recent	recent	JJ
cord-005478-5iu38pr6	524	21	year	year	NN
cord-005478-5iu38pr6	524	22	of	of	IN
cord-005478-5iu38pr6	524	23	transplant	transplant	NN
cord-005478-5iu38pr6	524	24	(	(	-LRB-
cord-005478-5iu38pr6	524	25	better	well	JJR
cord-005478-5iu38pr6	524	26	OS	OS	NNP
cord-005478-5iu38pr6	524	27	,	,	,
cord-005478-5iu38pr6	524	28	p=0.007	p=0.007	NN
cord-005478-5iu38pr6	524	29	;	;	:
cord-005478-5iu38pr6	524	30	lower	lower	VB
cord-005478-5iu38pr6	524	31	chronic	chronic	JJ
cord-005478-5iu38pr6	524	32	GvHD	gvhd	NN
cord-005478-5iu38pr6	524	33	,	,	,
cord-005478-5iu38pr6	524	34	p=0.047	p=0.047	NNS
cord-005478-5iu38pr6	524	35	)	)	-RRB-
cord-005478-5iu38pr6	524	36	.	.	.
cord-005478-5iu38pr6	525	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	525	2	:	:	:
cord-005478-5iu38pr6	526	1	This	this	DT
cord-005478-5iu38pr6	526	2	large	large	JJ
cord-005478-5iu38pr6	526	3	retrospective	retrospective	JJ
cord-005478-5iu38pr6	526	4	survey	survey	NN
cord-005478-5iu38pr6	526	5	of	of	IN
cord-005478-5iu38pr6	526	6	the	the	DT
cord-005478-5iu38pr6	526	7	EBMT	EBMT	NNP
cord-005478-5iu38pr6	526	8	registry	registry	NN
cord-005478-5iu38pr6	526	9	confirms	confirm	VBZ
cord-005478-5iu38pr6	526	10	the	the	DT
cord-005478-5iu38pr6	526	11	potential	potential	NN
cord-005478-5iu38pr6	526	12	of	of	IN
cord-005478-5iu38pr6	526	13	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	526	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	526	15	to	to	TO
cord-005478-5iu38pr6	526	16	produce	produce	VB
cord-005478-5iu38pr6	526	17	long	long	JJ
cord-005478-5iu38pr6	526	18	-	-	HYPH
cord-005478-5iu38pr6	526	19	term	term	NN
cord-005478-5iu38pr6	526	20	disease	disease	NN
cord-005478-5iu38pr6	526	21	remission	remission	NN
cord-005478-5iu38pr6	526	22	in	in	IN
cord-005478-5iu38pr6	526	23	a	a	DT
cord-005478-5iu38pr6	526	24	large	large	JJ
cord-005478-5iu38pr6	526	25	proportion	proportion	NN
cord-005478-5iu38pr6	526	26	of	of	IN
cord-005478-5iu38pr6	526	27	refractory	refractory	JJ
cord-005478-5iu38pr6	526	28	ADs	ad	NNS
cord-005478-5iu38pr6	526	29	,	,	,
cord-005478-5iu38pr6	526	30	with	with	IN
cord-005478-5iu38pr6	526	31	acceptable	acceptable	JJ
cord-005478-5iu38pr6	526	32	toxicities	toxicity	NNS
cord-005478-5iu38pr6	526	33	and	and	CC
cord-005478-5iu38pr6	526	34	NRM	NRM	NNP
cord-005478-5iu38pr6	526	35	.	.	.
cord-005478-5iu38pr6	527	1	Results	result	NNS
cord-005478-5iu38pr6	527	2	:	:	:
cord-005478-5iu38pr6	528	1	Twenty	twenty	CD
cord-005478-5iu38pr6	528	2	-	-	HYPH
cord-005478-5iu38pr6	528	3	seven	seven	CD
cord-005478-5iu38pr6	528	4	patients	patient	NNS
cord-005478-5iu38pr6	528	5	were	be	VBD
cord-005478-5iu38pr6	528	6	evaluated	evaluate	VBN
cord-005478-5iu38pr6	528	7	before	before	IN
cord-005478-5iu38pr6	528	8	and	and	CC
cord-005478-5iu38pr6	528	9	at	at	IN
cord-005478-5iu38pr6	528	10	6	6	CD
cord-005478-5iu38pr6	528	11	months	month	NNS
cord-005478-5iu38pr6	528	12	after	after	IN
cord-005478-5iu38pr6	528	13	transplant	transplant	NN
cord-005478-5iu38pr6	528	14	,	,	,
cord-005478-5iu38pr6	528	15	22	22	CD
cord-005478-5iu38pr6	528	16	of	of	IN
cord-005478-5iu38pr6	528	17	which	which	WDT
cord-005478-5iu38pr6	528	18	were	be	VBD
cord-005478-5iu38pr6	528	19	additionally	additionally	RB
cord-005478-5iu38pr6	528	20	evaluated	evaluate	VBN
cord-005478-5iu38pr6	528	21	at	at	IN
cord-005478-5iu38pr6	528	22	12	12	CD
cord-005478-5iu38pr6	528	23	months	month	NNS
cord-005478-5iu38pr6	528	24	.	.	.
cord-005478-5iu38pr6	529	1	At	at	IN
cord-005478-5iu38pr6	529	2	6	6	CD
cord-005478-5iu38pr6	529	3	and	and	CC
cord-005478-5iu38pr6	529	4	12	12	CD
cord-005478-5iu38pr6	529	5	months	month	NNS
cord-005478-5iu38pr6	529	6	after	after	IN
cord-005478-5iu38pr6	529	7	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	529	8	,	,	,
cord-005478-5iu38pr6	529	9	patients	patient	NNS
cord-005478-5iu38pr6	529	10	presented	present	VBD
cord-005478-5iu38pr6	529	11	significant	significant	JJ
cord-005478-5iu38pr6	529	12	improvement	improvement	NN
cord-005478-5iu38pr6	529	13	of	of	IN
cord-005478-5iu38pr6	530	1	mRSS	mRSS	NNP
cord-005478-5iu38pr6	530	2	(	(	-LRB-
cord-005478-5iu38pr6	530	3	p	p	NN
cord-005478-5iu38pr6	530	4	<	<	XX
cord-005478-5iu38pr6	530	5	0.01	0.01	CD
cord-005478-5iu38pr6	530	6	)	)	-RRB-
cord-005478-5iu38pr6	530	7	,	,	,
cord-005478-5iu38pr6	530	8	MIP	MIP	NNP
cord-005478-5iu38pr6	530	9	(	(	-LRB-
cord-005478-5iu38pr6	530	10	p	p	NN
cord-005478-5iu38pr6	530	11	<	<	XX
cord-005478-5iu38pr6	530	12	0.01	0.01	CD
cord-005478-5iu38pr6	530	13	)	)	-RRB-
cord-005478-5iu38pr6	530	14	,	,	,
cord-005478-5iu38pr6	530	15	MEP	MEP	NNP
cord-005478-5iu38pr6	530	16	(	(	-LRB-
cord-005478-5iu38pr6	530	17	p	p	NN
cord-005478-5iu38pr6	530	18	<	<	XX
cord-005478-5iu38pr6	530	19	0.01	0.01	CD
cord-005478-5iu38pr6	530	20	)	)	-RRB-
cord-005478-5iu38pr6	530	21	,	,	,
cord-005478-5iu38pr6	530	22	6MWT	6MWT	NNP
cord-005478-5iu38pr6	530	23	distance	distance	NN
cord-005478-5iu38pr6	530	24	(	(	-LRB-
cord-005478-5iu38pr6	530	25	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	530	26	)	)	-RRB-
cord-005478-5iu38pr6	530	27	,	,	,
cord-005478-5iu38pr6	530	28	and	and	CC
cord-005478-5iu38pr6	530	29	physical	physical	JJ
cord-005478-5iu38pr6	530	30	(	(	-LRB-
cord-005478-5iu38pr6	530	31	p	p	NN
cord-005478-5iu38pr6	530	32	<	<	XX
cord-005478-5iu38pr6	530	33	0.01	0.01	CD
cord-005478-5iu38pr6	530	34	)	)	-RRB-
cord-005478-5iu38pr6	530	35	and	and	CC
cord-005478-5iu38pr6	530	36	mental	mental	JJ
cord-005478-5iu38pr6	530	37	(	(	-LRB-
cord-005478-5iu38pr6	530	38	p=0.02	p=0.02	NN
cord-005478-5iu38pr6	530	39	)	)	-RRB-
cord-005478-5iu38pr6	530	40	components	component	NNS
cord-005478-5iu38pr6	530	41	of	of	IN
cord-005478-5iu38pr6	530	42	the	the	DT
cord-005478-5iu38pr6	530	43	SF-36	SF-36	NNP
cord-005478-5iu38pr6	530	44	,	,	,
cord-005478-5iu38pr6	530	45	when	when	WRB
cord-005478-5iu38pr6	530	46	compared	compare	VBN
cord-005478-5iu38pr6	530	47	to	to	IN
cord-005478-5iu38pr6	530	48	pretransplant	pretransplant	JJ
cord-005478-5iu38pr6	530	49	evaluations	evaluation	NNS
cord-005478-5iu38pr6	530	50	.	.	.
cord-005478-5iu38pr6	531	1	No	no	DT
cord-005478-5iu38pr6	531	2	changes	change	NNS
cord-005478-5iu38pr6	531	3	were	be	VBD
cord-005478-5iu38pr6	531	4	observed	observe	VBN
cord-005478-5iu38pr6	531	5	in	in	IN
cord-005478-5iu38pr6	531	6	FVC	FVC	NNP
cord-005478-5iu38pr6	531	7	after	after	IN
cord-005478-5iu38pr6	531	8	treatment	treatment	NN
cord-005478-5iu38pr6	531	9	.	.	.
cord-005478-5iu38pr6	532	1	Despite	despite	IN
cord-005478-5iu38pr6	532	2	a	a	DT
cord-005478-5iu38pr6	532	3	transient	transient	JJ
cord-005478-5iu38pr6	532	4	decline	decline	NN
cord-005478-5iu38pr6	532	5	in	in	IN
cord-005478-5iu38pr6	532	6	DLCO	DLCO	NNP
cord-005478-5iu38pr6	532	7	at	at	IN
cord-005478-5iu38pr6	532	8	6	6	CD
cord-005478-5iu38pr6	532	9	months	month	NNS
cord-005478-5iu38pr6	532	10	(	(	-LRB-
cord-005478-5iu38pr6	532	11	p	p	NN
cord-005478-5iu38pr6	532	12	<	<	XX
cord-005478-5iu38pr6	532	13	0.01	0.01	CD
cord-005478-5iu38pr6	532	14	)	)	-RRB-
cord-005478-5iu38pr6	532	15	after	after	IN
cord-005478-5iu38pr6	532	16	transplant	transplant	NN
cord-005478-5iu38pr6	532	17	,	,	,
cord-005478-5iu38pr6	532	18	DLCO	DLCO	NNP
cord-005478-5iu38pr6	532	19	levels	level	NNS
cord-005478-5iu38pr6	532	20	at	at	IN
cord-005478-5iu38pr6	532	21	12	12	CD
cord-005478-5iu38pr6	532	22	months	month	NNS
cord-005478-5iu38pr6	532	23	were	be	VBD
cord-005478-5iu38pr6	532	24	not	not	RB
cord-005478-5iu38pr6	532	25	different	different	JJ
cord-005478-5iu38pr6	532	26	from	from	IN
cord-005478-5iu38pr6	532	27	baseline	baseline	JJ
cord-005478-5iu38pr6	532	28	(	(	-LRB-
cord-005478-5iu38pr6	532	29	pre	pre	JJ
cord-005478-5iu38pr6	532	30	-	-	JJ
cord-005478-5iu38pr6	532	31	transplant	transplant	NN
cord-005478-5iu38pr6	532	32	)	)	-RRB-
cord-005478-5iu38pr6	532	33	.	.	.
cord-005478-5iu38pr6	533	1	Significant	significant	JJ
cord-005478-5iu38pr6	533	2	correlations	correlation	NNS
cord-005478-5iu38pr6	533	3	were	be	VBD
cord-005478-5iu38pr6	533	4	observed	observe	VBN
cord-005478-5iu38pr6	533	5	between	between	IN
cord-005478-5iu38pr6	533	6	the	the	DT
cord-005478-5iu38pr6	533	7	6MWT	6MWT	NNP
cord-005478-5iu38pr6	533	8	distance	distance	NN
cord-005478-5iu38pr6	533	9	and	and	CC
cord-005478-5iu38pr6	533	10	physical	physical	JJ
cord-005478-5iu38pr6	533	11	component	component	NN
cord-005478-5iu38pr6	533	12	score	score	NN
cord-005478-5iu38pr6	533	13	of	of	IN
cord-005478-5iu38pr6	533	14	quality	quality	NN
cord-005478-5iu38pr6	533	15	of	of	IN
cord-005478-5iu38pr6	533	16	life	life	NN
cord-005478-5iu38pr6	533	17	(	(	-LRB-
cord-005478-5iu38pr6	533	18	R=0.62	R=0.62	NNP
cord-005478-5iu38pr6	533	19	,	,	,
cord-005478-5iu38pr6	533	20	p	p	NN
cord-005478-5iu38pr6	533	21	<	<	XX
cord-005478-5iu38pr6	533	22	0.01	0.01	CD
cord-005478-5iu38pr6	533	23	)	)	-RRB-
cord-005478-5iu38pr6	533	24	.	.	.
cord-005478-5iu38pr6	534	1	No	no	DT
cord-005478-5iu38pr6	534	2	significant	significant	JJ
cord-005478-5iu38pr6	534	3	correlation	correlation	NN
cord-005478-5iu38pr6	534	4	was	be	VBD
cord-005478-5iu38pr6	534	5	observed	observe	VBN
cord-005478-5iu38pr6	534	6	between	between	IN
cord-005478-5iu38pr6	534	7	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	534	8	function	function	NN
cord-005478-5iu38pr6	534	9	and	and	CC
cord-005478-5iu38pr6	534	10	the	the	DT
cord-005478-5iu38pr6	534	11	other	other	JJ
cord-005478-5iu38pr6	534	12	evaluated	evaluate	VBN
cord-005478-5iu38pr6	534	13	variables	variable	NNS
cord-005478-5iu38pr6	534	14	(	(	-LRB-
cord-005478-5iu38pr6	534	15	mRSS	mrs	NNS
cord-005478-5iu38pr6	534	16	,	,	,
cord-005478-5iu38pr6	534	17	respiratory	respiratory	JJ
cord-005478-5iu38pr6	534	18	muscle	muscle	NN
cord-005478-5iu38pr6	534	19	strength	strength	NN
cord-005478-5iu38pr6	534	20	,	,	,
cord-005478-5iu38pr6	534	21	physical	physical	JJ
cord-005478-5iu38pr6	534	22	capacity	capacity	NN
cord-005478-5iu38pr6	534	23	and	and	CC
cord-005478-5iu38pr6	534	24	quality	quality	NN
cord-005478-5iu38pr6	534	25	of	of	IN
cord-005478-5iu38pr6	534	26	life	life	NN
cord-005478-5iu38pr6	534	27	)	)	-RRB-
cord-005478-5iu38pr6	534	28	.	.	.
cord-005478-5iu38pr6	535	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	535	2	:	:	:
cord-005478-5iu38pr6	536	1	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	536	2	significantly	significantly	RB
cord-005478-5iu38pr6	536	3	improves	improve	VBZ
cord-005478-5iu38pr6	536	4	the	the	DT
cord-005478-5iu38pr6	536	5	functional	functional	JJ
cord-005478-5iu38pr6	536	6	status	status	NN
cord-005478-5iu38pr6	536	7	of	of	IN
cord-005478-5iu38pr6	536	8	SSc	SSc	NNS
cord-005478-5iu38pr6	536	9	patients	patient	NNS
cord-005478-5iu38pr6	536	10	in	in	IN
cord-005478-5iu38pr6	536	11	the	the	DT
cord-005478-5iu38pr6	536	12	first	first	JJ
cord-005478-5iu38pr6	536	13	year	year	NN
cord-005478-5iu38pr6	536	14	of	of	IN
cord-005478-5iu38pr6	536	15	follow	follow	NN
cord-005478-5iu38pr6	536	16	-	-	HYPH
cord-005478-5iu38pr6	536	17	up	up	NN
cord-005478-5iu38pr6	536	18	.	.	.
cord-005478-5iu38pr6	537	1	Although	although	IN
cord-005478-5iu38pr6	537	2	the	the	DT
cord-005478-5iu38pr6	537	3	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	537	4	function	function	NN
cord-005478-5iu38pr6	537	5	remained	remain	VBD
cord-005478-5iu38pr6	537	6	stable	stable	JJ
cord-005478-5iu38pr6	537	7	after	after	IN
cord-005478-5iu38pr6	537	8	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	537	9	,	,	,
cord-005478-5iu38pr6	537	10	there	there	EX
cord-005478-5iu38pr6	537	11	was	be	VBD
cord-005478-5iu38pr6	537	12	significant	significant	JJ
cord-005478-5iu38pr6	537	13	increase	increase	NN
cord-005478-5iu38pr6	537	14	in	in	IN
cord-005478-5iu38pr6	537	15	the	the	DT
cord-005478-5iu38pr6	537	16	physical	physical	JJ
cord-005478-5iu38pr6	537	17	capacity	capacity	NN
cord-005478-5iu38pr6	537	18	and	and	CC
cord-005478-5iu38pr6	537	19	quality	quality	NN
cord-005478-5iu38pr6	537	20	of	of	IN
cord-005478-5iu38pr6	537	21	life	life	NN
cord-005478-5iu38pr6	537	22	of	of	IN
cord-005478-5iu38pr6	537	23	patients	patient	NNS
cord-005478-5iu38pr6	537	24	.	.	.
cord-005478-5iu38pr6	538	1	These	these	DT
cord-005478-5iu38pr6	538	2	results	result	NNS
cord-005478-5iu38pr6	538	3	can	can	MD
cord-005478-5iu38pr6	538	4	be	be	VB
cord-005478-5iu38pr6	538	5	interpreted	interpret	VBN
cord-005478-5iu38pr6	538	6	as	as	IN
cord-005478-5iu38pr6	538	7	positive	positive	JJ
cord-005478-5iu38pr6	538	8	outcomes	outcome	NNS
cord-005478-5iu38pr6	538	9	of	of	IN
cord-005478-5iu38pr6	538	10	AHSCT	AHSCT	NNP
cord-005478-5iu38pr6	538	11	for	for	IN
cord-005478-5iu38pr6	538	12	SSc	SSc	NNS
cord-005478-5iu38pr6	538	13	.	.	.
cord-005478-5iu38pr6	539	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	539	2	:	:	:
cord-005478-5iu38pr6	539	3	Nothing	nothing	NN
cord-005478-5iu38pr6	539	4	to	to	TO
cord-005478-5iu38pr6	539	5	declare	declare	VB
cord-005478-5iu38pr6	539	6	.	.	.
cord-005478-5iu38pr6	540	1	Model	model	NN
cord-005478-5iu38pr6	540	2	of	of	IN
cord-005478-5iu38pr6	540	3	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	540	4	and	and	CC
cord-005478-5iu38pr6	540	5	multicenter	multicenter	JJ
cord-005478-5iu38pr6	540	6	approach	approach	NN
cord-005478-5iu38pr6	540	7	for	for	IN
cord-005478-5iu38pr6	540	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	540	9	for	for	IN
cord-005478-5iu38pr6	540	10	children	child	NNS
cord-005478-5iu38pr6	540	11	with	with	IN
cord-005478-5iu38pr6	540	12	multiple	multiple	JJ
cord-005478-5iu38pr6	540	13	sclerosis	sclerosis	NN
cord-005478-5iu38pr6	540	14	:	:	:
cord-005478-5iu38pr6	540	15	Long-	Long-	NNP
cord-005478-5iu38pr6	540	16	 	 	_SP
cord-005478-5iu38pr6	541	1	Background	background	NN
cord-005478-5iu38pr6	541	2	:	:	:
cord-005478-5iu38pr6	542	1	HSCT	HSCT	NNP
cord-005478-5iu38pr6	542	2	for	for	IN
cord-005478-5iu38pr6	542	3	children	child	NNS
cord-005478-5iu38pr6	542	4	with	with	IN
cord-005478-5iu38pr6	542	5	multiple	multiple	JJ
cord-005478-5iu38pr6	542	6	sclerosis	sclerosis	NN
cord-005478-5iu38pr6	542	7	(	(	-LRB-
cord-005478-5iu38pr6	542	8	MS	MS	NNP
cord-005478-5iu38pr6	542	9	)	)	-RRB-
cord-005478-5iu38pr6	542	10	proved	prove	VBD
cord-005478-5iu38pr6	542	11	effectiveness	effectiveness	NN
cord-005478-5iu38pr6	542	12	and	and	CC
cord-005478-5iu38pr6	542	13	safety	safety	NN
cord-005478-5iu38pr6	542	14	.	.	.
cord-005478-5iu38pr6	543	1	It	-PRON-	PRP
cord-005478-5iu38pr6	543	2	is	be	VBZ
cord-005478-5iu38pr6	543	3	required	require	VBN
cord-005478-5iu38pr6	543	4	to	to	TO
cord-005478-5iu38pr6	543	5	improve	improve	VB
cord-005478-5iu38pr6	543	6	the	the	DT
cord-005478-5iu38pr6	543	7	results	result	NNS
cord-005478-5iu38pr6	543	8	by	by	IN
cord-005478-5iu38pr6	543	9	analysis	analysis	NN
cord-005478-5iu38pr6	543	10	of	of	IN
cord-005478-5iu38pr6	543	11	long	long	JJ
cord-005478-5iu38pr6	543	12	-	-	HYPH
cord-005478-5iu38pr6	543	13	term	term	NN
cord-005478-5iu38pr6	543	14	follow	follow	NN
cord-005478-5iu38pr6	543	15	-	-	HYPH
cord-005478-5iu38pr6	543	16	up	up	NN
cord-005478-5iu38pr6	543	17	and	and	CC
cord-005478-5iu38pr6	543	18	late	late	JJ
cord-005478-5iu38pr6	543	19	effects	effect	NNS
cord-005478-5iu38pr6	543	20	.	.	.
cord-005478-5iu38pr6	544	1	Several	several	JJ
cord-005478-5iu38pr6	544	2	challenges	challenge	NNS
cord-005478-5iu38pr6	544	3	identified	identify	VBN
cord-005478-5iu38pr6	544	4	in	in	IN
cord-005478-5iu38pr6	544	5	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	544	6	collaboration	collaboration	NN
cord-005478-5iu38pr6	544	7	for	for	IN
cord-005478-5iu38pr6	544	8	successful	successful	JJ
cord-005478-5iu38pr6	544	9	treatment	treatment	NN
cord-005478-5iu38pr6	544	10	as	as	RB
cord-005478-5iu38pr6	544	11	well	well	RB
cord-005478-5iu38pr6	544	12	as	as	IN
cord-005478-5iu38pr6	544	13	a	a	DT
cord-005478-5iu38pr6	544	14	problem	problem	NN
cord-005478-5iu38pr6	544	15	of	of	IN
cord-005478-5iu38pr6	544	16	switching	switch	VBG
cord-005478-5iu38pr6	544	17	these	these	DT
cord-005478-5iu38pr6	544	18	patients	patient	NNS
cord-005478-5iu38pr6	544	19	to	to	IN
cord-005478-5iu38pr6	544	20	the	the	DT
cord-005478-5iu38pr6	544	21	adult	adult	NN
cord-005478-5iu38pr6	544	22	healthcare	healthcare	NN
cord-005478-5iu38pr6	544	23	.	.	.
cord-005478-5iu38pr6	545	1	We	-PRON-	PRP
cord-005478-5iu38pr6	545	2	aimed	aim	VBD
cord-005478-5iu38pr6	545	3	to	to	TO
cord-005478-5iu38pr6	545	4	create	create	VB
cord-005478-5iu38pr6	545	5	a	a	DT
cord-005478-5iu38pr6	545	6	model	model	NN
cord-005478-5iu38pr6	545	7	of	of	IN
cord-005478-5iu38pr6	545	8	organization	organization	NN
cord-005478-5iu38pr6	545	9	of	of	IN
cord-005478-5iu38pr6	545	10	help	help	NN
cord-005478-5iu38pr6	545	11	for	for	IN
cord-005478-5iu38pr6	545	12	children	child	NNS
cord-005478-5iu38pr6	545	13	with	with	IN
cord-005478-5iu38pr6	545	14	severe	severe	JJ
cord-005478-5iu38pr6	545	15	refractory	refractory	JJ
cord-005478-5iu38pr6	545	16	multiple	multiple	JJ
cord-005478-5iu38pr6	545	17	sclerosis	sclerosis	NN
cord-005478-5iu38pr6	545	18	based	base	VBN
cord-005478-5iu38pr6	545	19	on	on	IN
cord-005478-5iu38pr6	545	20	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	545	21	and	and	CC
cord-005478-5iu38pr6	545	22	multicenter	multicenter	JJ
cord-005478-5iu38pr6	545	23	approach	approach	NN
cord-005478-5iu38pr6	545	24	.	.	.
cord-005478-5iu38pr6	546	1	Methods	method	NNS
cord-005478-5iu38pr6	546	2	:	:	:
cord-005478-5iu38pr6	546	3	Fifteen	fifteen	CD
cord-005478-5iu38pr6	546	4	children	child	NNS
cord-005478-5iu38pr6	546	5	with	with	IN
cord-005478-5iu38pr6	546	6	MS	MS	NNP
cord-005478-5iu38pr6	546	7	received	receive	VBD
cord-005478-5iu38pr6	546	8	autologous	autologous	JJ
cord-005478-5iu38pr6	546	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	546	10	(	(	-LRB-
cord-005478-5iu38pr6	546	11	aHSCT	aHSCT	NNP
cord-005478-5iu38pr6	546	12	)	)	-RRB-
cord-005478-5iu38pr6	546	13	from	from	IN
cord-005478-5iu38pr6	546	14	January	January	NNP
cord-005478-5iu38pr6	546	15	2010	2010	CD
cord-005478-5iu38pr6	546	16	to	to	IN
cord-005478-5iu38pr6	546	17	May	May	NNP
cord-005478-5iu38pr6	546	18	2018	2018	CD
cord-005478-5iu38pr6	546	19	.	.	.
cord-005478-5iu38pr6	547	1	Gender	gender	NN
cord-005478-5iu38pr6	547	2	:	:	:
cord-005478-5iu38pr6	547	3	females	female	NNS
cord-005478-5iu38pr6	547	4	-11	-11	VBN
cord-005478-5iu38pr6	547	5	,	,	,
cord-005478-5iu38pr6	547	6	males	male	NNS
cord-005478-5iu38pr6	547	7	-4	-4	NNP
cord-005478-5iu38pr6	547	8	.	.	.
cord-005478-5iu38pr6	548	1	Mean	mean	JJ
cord-005478-5iu38pr6	548	2	length	length	NN
cord-005478-5iu38pr6	548	3	of	of	IN
cord-005478-5iu38pr6	548	4	MS	MS	NNP
cord-005478-5iu38pr6	548	5	prior	prior	RB
cord-005478-5iu38pr6	549	1	aHSCT	aHSCT	NNP
cord-005478-5iu38pr6	549	2	was	be	VBD
cord-005478-5iu38pr6	549	3	22.7±8.4	22.7±8.4	CD
cord-005478-5iu38pr6	549	4	months	month	NNS
cord-005478-5iu38pr6	549	5	and	and	CC
cord-005478-5iu38pr6	549	6	mean	mean	VB
cord-005478-5iu38pr6	549	7	age	age	NN
cord-005478-5iu38pr6	549	8	of	of	IN
cord-005478-5iu38pr6	549	9	MS	MS	NNP
cord-005478-5iu38pr6	549	10	debut	debut	NN
cord-005478-5iu38pr6	549	11	was	be	VBD
cord-005478-5iu38pr6	549	12	12.7	12.7	CD
cord-005478-5iu38pr6	549	13	±2.1	±2.1	JJ
cord-005478-5iu38pr6	549	14	years	year	NNS
cord-005478-5iu38pr6	549	15	old	old	JJ
cord-005478-5iu38pr6	549	16	.	.	.
cord-005478-5iu38pr6	550	1	All	all	DT
cord-005478-5iu38pr6	550	2	patients	patient	NNS
cord-005478-5iu38pr6	550	3	had	have	VBD
cord-005478-5iu38pr6	550	4	severe	severe	JJ
cord-005478-5iu38pr6	550	5	refractory	refractory	JJ
cord-005478-5iu38pr6	550	6	MS	MS	NNP
cord-005478-5iu38pr6	550	7	treated	treat	VBN
cord-005478-5iu38pr6	550	8	with	with	IN
cord-005478-5iu38pr6	550	9	corticosteroids	corticosteroid	NNS
cord-005478-5iu38pr6	550	10	,	,	,
cord-005478-5iu38pr6	550	11	interferons	interferon	NNS
cord-005478-5iu38pr6	550	12	,	,	,
cord-005478-5iu38pr6	550	13	plasmapheresis	plasmapheresis	NN
cord-005478-5iu38pr6	550	14	and	and	CC
cord-005478-5iu38pr6	550	15	mitoxantron	mitoxantron	NNP
cord-005478-5iu38pr6	550	16	with	with	IN
cord-005478-5iu38pr6	550	17	negative	negative	JJ
cord-005478-5iu38pr6	550	18	results	result	NNS
cord-005478-5iu38pr6	550	19	.	.	.
cord-005478-5iu38pr6	551	1	These	these	DT
cord-005478-5iu38pr6	551	2	patients	patient	NNS
cord-005478-5iu38pr6	551	3	presented	present	VBD
cord-005478-5iu38pr6	551	4	signs	sign	NNS
cord-005478-5iu38pr6	551	5	of	of	IN
cord-005478-5iu38pr6	551	6	neuroinflammation	neuroinflammation	NN
cord-005478-5iu38pr6	551	7	.	.	.
cord-005478-5iu38pr6	552	1	Mean	mean	VB
cord-005478-5iu38pr6	552	2	baseline	baseline	JJ
cord-005478-5iu38pr6	552	3	EDSS	eds	NNS
cord-005478-5iu38pr6	552	4	before	before	IN
cord-005478-5iu38pr6	552	5	the	the	DT
cord-005478-5iu38pr6	552	6	start	start	NN
cord-005478-5iu38pr6	552	7	of	of	IN
cord-005478-5iu38pr6	552	8	mobilization	mobilization	NN
cord-005478-5iu38pr6	552	9	was	be	VBD
cord-005478-5iu38pr6	552	10	4.8±1.4	4.8±1.4	CD
cord-005478-5iu38pr6	552	11	.	.	.
cord-005478-5iu38pr6	553	1	Procedures	procedure	NNS
cord-005478-5iu38pr6	553	2	included	include	VBD
cord-005478-5iu38pr6	553	3	mobilization	mobilization	NN
cord-005478-5iu38pr6	553	4	with	with	IN
cord-005478-5iu38pr6	553	5	the	the	DT
cord-005478-5iu38pr6	553	6	help	help	NN
cord-005478-5iu38pr6	553	7	of	of	IN
cord-005478-5iu38pr6	553	8	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	553	9	and	and	CC
cord-005478-5iu38pr6	553	10	filgrastim	filgrastim	NN
cord-005478-5iu38pr6	553	11	and	and	CC
cord-005478-5iu38pr6	553	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	553	13	:	:	:
cord-005478-5iu38pr6	554	1	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	554	2	200	200	CD
cord-005478-5iu38pr6	554	3	mg	mg	NNP
cord-005478-5iu38pr6	554	4	/	/	SYM
cord-005478-5iu38pr6	554	5	kg	kg	NNP
cord-005478-5iu38pr6	554	6	and	and	CC
cord-005478-5iu38pr6	554	7	hATG	hATG	NNP
cord-005478-5iu38pr6	555	1	160	160	CD
cord-005478-5iu38pr6	555	2	mg	mg	NNP
cord-005478-5iu38pr6	555	3	/	/	SYM
cord-005478-5iu38pr6	555	4	kg	kg	NNP
cord-005478-5iu38pr6	555	5	.	.	.
cord-005478-5iu38pr6	556	1	All	all	DT
cord-005478-5iu38pr6	556	2	patients	patient	NNS
cord-005478-5iu38pr6	556	3	received	receive	VBD
cord-005478-5iu38pr6	556	4	at	at	IN
cord-005478-5iu38pr6	556	5	least	least	JJS
cord-005478-5iu38pr6	556	6	2	2	CD
cord-005478-5iu38pr6	556	7	x	x	SYM
cord-005478-5iu38pr6	556	8	10˄6	10˄6	CD
cord-005478-5iu38pr6	556	9	/	/	SYM
cord-005478-5iu38pr6	556	10	kg	kg	NN
cord-005478-5iu38pr6	556	11	CD34	CD34	NNP
cord-005478-5iu38pr6	556	12	+	+	CC
cord-005478-5iu38pr6	556	13	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	556	14	stem	stem	NN
cord-005478-5iu38pr6	556	15	cells	cell	NNS
cord-005478-5iu38pr6	556	16	(	(	-LRB-
cord-005478-5iu38pr6	556	17	mean	mean	VBP
cord-005478-5iu38pr6	556	18	4.3	4.3	CD
cord-005478-5iu38pr6	556	19	x	x	SYM
cord-005478-5iu38pr6	556	20	10˄6±2.6	10˄6±2.6	CD
cord-005478-5iu38pr6	556	21	x	x	SYM
cord-005478-5iu38pr6	556	22	10	10	CD
cord-005478-5iu38pr6	556	23	˄6	˄6	NN
cord-005478-5iu38pr6	556	24	)	)	-RRB-
cord-005478-5iu38pr6	556	25	.	.	.
cord-005478-5iu38pr6	557	1	We	-PRON-	PRP
cord-005478-5iu38pr6	557	2	analysed	analyse	VBD
cord-005478-5iu38pr6	557	3	the	the	DT
cord-005478-5iu38pr6	557	4	incidence	incidence	NN
cord-005478-5iu38pr6	557	5	and	and	CC
cord-005478-5iu38pr6	557	6	nature	nature	NN
cord-005478-5iu38pr6	557	7	of	of	IN
cord-005478-5iu38pr6	557	8	late	late	JJ
cord-005478-5iu38pr6	557	9	effects	effect	NNS
cord-005478-5iu38pr6	557	10	in	in	IN
cord-005478-5iu38pr6	557	11	patients	patient	NNS
cord-005478-5iu38pr6	557	12	with	with	IN
cord-005478-5iu38pr6	557	13	at	at	RB
cord-005478-5iu38pr6	557	14	least	least	RBS
cord-005478-5iu38pr6	557	15	one	one	CD
cord-005478-5iu38pr6	557	16	year	year	NN
cord-005478-5iu38pr6	557	17	of	of	IN
cord-005478-5iu38pr6	557	18	follow	follow	NN
cord-005478-5iu38pr6	557	19	-	-	HYPH
cord-005478-5iu38pr6	557	20	up	up	NN
cord-005478-5iu38pr6	557	21	(	(	-LRB-
cord-005478-5iu38pr6	557	22	based	base	VBN
cord-005478-5iu38pr6	557	23	on	on	IN
cord-005478-5iu38pr6	557	24	the	the	DT
cord-005478-5iu38pr6	557	25	standard	standard	JJ
cord-005478-5iu38pr6	557	26	protocol	protocol	NN
cord-005478-5iu38pr6	557	27	for	for	IN
cord-005478-5iu38pr6	557	28	late	late	JJ
cord-005478-5iu38pr6	557	29	effects	effect	NNS
cord-005478-5iu38pr6	557	30	)	)	-RRB-
cord-005478-5iu38pr6	557	31	.	.	.
cord-005478-5iu38pr6	558	1	Fertility	fertility	NN
cord-005478-5iu38pr6	558	2	preservation	preservation	NN
cord-005478-5iu38pr6	558	3	proposed	propose	VBN
cord-005478-5iu38pr6	558	4	for	for	IN
cord-005478-5iu38pr6	558	5	patients	patient	NNS
cord-005478-5iu38pr6	558	6	.	.	.
cord-005478-5iu38pr6	559	1	aHSCT	ahsct	RB
cord-005478-5iu38pr6	559	2	as	as	RB
cord-005478-5iu38pr6	559	3	well	well	RB
cord-005478-5iu38pr6	559	4	as	as	IN
cord-005478-5iu38pr6	559	5	pre	pre	JJ
cord-005478-5iu38pr6	559	6	-	-	NN
cord-005478-5iu38pr6	559	7	and	and	CC
cord-005478-5iu38pr6	559	8	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	559	9	care	care	NN
cord-005478-5iu38pr6	559	10	was	be	VBD
cord-005478-5iu38pr6	559	11	done	do	VBN
cord-005478-5iu38pr6	559	12	by	by	IN
cord-005478-5iu38pr6	559	13	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	559	14	team	team	NN
cord-005478-5iu38pr6	559	15	involved	involve	VBD
cord-005478-5iu38pr6	559	16	both	both	CC
cord-005478-5iu38pr6	559	17	transplant	transplant	NN
cord-005478-5iu38pr6	559	18	and	and	CC
cord-005478-5iu38pr6	559	19	neurological	neurological	JJ
cord-005478-5iu38pr6	559	20	team	team	NN
cord-005478-5iu38pr6	559	21	.	.	.
cord-005478-5iu38pr6	560	1	Technology	technology	NN
cord-005478-5iu38pr6	560	2	of	of	IN
cord-005478-5iu38pr6	560	3	transfer	transfer	NN
cord-005478-5iu38pr6	560	4	patients	patient	NNS
cord-005478-5iu38pr6	560	5	to	to	IN
cord-005478-5iu38pr6	560	6	adult	adult	NN
cord-005478-5iu38pr6	560	7	center	center	NN
cord-005478-5iu38pr6	560	8	for	for	IN
cord-005478-5iu38pr6	560	9	post	post	JJ
cord-005478-5iu38pr6	560	10	-	-	JJ
cord-005478-5iu38pr6	560	11	transplant	transplant	JJ
cord-005478-5iu38pr6	560	12	observation	observation	NN
cord-005478-5iu38pr6	560	13	was	be	VBD
cord-005478-5iu38pr6	560	14	identified	identify	VBN
cord-005478-5iu38pr6	560	15	.	.	.
cord-005478-5iu38pr6	561	1	Results	result	NNS
cord-005478-5iu38pr6	561	2	:	:	:
cord-005478-5iu38pr6	562	1	All	all	DT
cord-005478-5iu38pr6	562	2	patients	patient	NNS
cord-005478-5iu38pr6	562	3	survived	survive	VBD
cord-005478-5iu38pr6	562	4	.	.	.
cord-005478-5iu38pr6	563	1	Mean	mean	JJ
cord-005478-5iu38pr6	563	2	time	time	NN
cord-005478-5iu38pr6	563	3	to	to	IN
cord-005478-5iu38pr6	563	4	engraftment	engraftment	NN
cord-005478-5iu38pr6	563	5	was	be	VBD
cord-005478-5iu38pr6	563	6	11	11	CD
cord-005478-5iu38pr6	563	7	±1.6	±1.6	NNS
cord-005478-5iu38pr6	563	8	days	day	NNS
cord-005478-5iu38pr6	563	9	.	.	.
cord-005478-5iu38pr6	564	1	Eleven	eleven	CD
cord-005478-5iu38pr6	564	2	patients	patient	NNS
cord-005478-5iu38pr6	564	3	experienced	experience	VBD
cord-005478-5iu38pr6	564	4	culture	culture	NN
cord-005478-5iu38pr6	564	5	negative	negative	JJ
cord-005478-5iu38pr6	564	6	fever	fever	NN
cord-005478-5iu38pr6	564	7	,	,	,
cord-005478-5iu38pr6	564	8	one	one	CD
cord-005478-5iu38pr6	564	9	patient	patient	NN
cord-005478-5iu38pr6	564	10	-cystitis	-cystitis	RBR
cord-005478-5iu38pr6	564	11	,	,	,
cord-005478-5iu38pr6	564	12	and	and	CC
cord-005478-5iu38pr6	564	13	one	one	CD
cord-005478-5iu38pr6	564	14	patient	patient	NN
cord-005478-5iu38pr6	564	15	had	have	VBD
cord-005478-5iu38pr6	564	16	CMV	CMV	NNP
cord-005478-5iu38pr6	564	17	reactivation	reactivation	NN
cord-005478-5iu38pr6	564	18	within	within	IN
cord-005478-5iu38pr6	564	19	100	100	CD
cord-005478-5iu38pr6	564	20	days	day	NNS
cord-005478-5iu38pr6	564	21	of	of	IN
cord-005478-5iu38pr6	564	22	the	the	DT
cord-005478-5iu38pr6	564	23	transplant	transplant	NN
cord-005478-5iu38pr6	564	24	.	.	.
cord-005478-5iu38pr6	565	1	No	no	DT
cord-005478-5iu38pr6	565	2	patient	patient	NN
cord-005478-5iu38pr6	565	3	experienced	experience	VBD
cord-005478-5iu38pr6	565	4	an	an	DT
cord-005478-5iu38pr6	565	5	EDSS	EDSS	NNP
cord-005478-5iu38pr6	565	6	increase	increase	NN
cord-005478-5iu38pr6	565	7	post	post	JJ
cord-005478-5iu38pr6	565	8	-	-	JJ
cord-005478-5iu38pr6	565	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	565	10	above	above	IN
cord-005478-5iu38pr6	565	11	baseline	baseline	NN
cord-005478-5iu38pr6	565	12	,	,	,
cord-005478-5iu38pr6	565	13	and	and	CC
cord-005478-5iu38pr6	565	14	all	all	DT
cord-005478-5iu38pr6	565	15	patients	patient	NNS
cord-005478-5iu38pr6	565	16	improved	improve	VBD
cord-005478-5iu38pr6	565	17	.	.	.
cord-005478-5iu38pr6	566	1	Mean	mean	JJ
cord-005478-5iu38pr6	566	2	improvement	improvement	NN
cord-005478-5iu38pr6	566	3	of	of	IN
cord-005478-5iu38pr6	566	4	EDSS	EDSS	NNP
cord-005478-5iu38pr6	566	5	was	be	VBD
cord-005478-5iu38pr6	566	6	2.8±1.2	2.8±1.2	CD
cord-005478-5iu38pr6	566	7	during	during	IN
cord-005478-5iu38pr6	566	8	the	the	DT
cord-005478-5iu38pr6	566	9	first	first	JJ
cord-005478-5iu38pr6	566	10	60	60	CD
cord-005478-5iu38pr6	566	11	days	day	NNS
cord-005478-5iu38pr6	566	12	after	after	IN
cord-005478-5iu38pr6	566	13	aHSCT	ahsct	NN
cord-005478-5iu38pr6	567	1	(	(	-LRB-
cord-005478-5iu38pr6	567	2	fast	fast	JJ
cord-005478-5iu38pr6	567	3	recovery	recovery	NN
cord-005478-5iu38pr6	567	4	)	)	-RRB-
cord-005478-5iu38pr6	567	5	.	.	.
cord-005478-5iu38pr6	568	1	In	in	IN
cord-005478-5iu38pr6	568	2	-	-	HYPH
cord-005478-5iu38pr6	568	3	time	time	NN
cord-005478-5iu38pr6	568	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	568	5	patients	patient	NNS
cord-005478-5iu38pr6	568	6	improved	improve	VBD
cord-005478-5iu38pr6	568	7	better	well	RBR
cord-005478-5iu38pr6	568	8	.	.	.
cord-005478-5iu38pr6	569	1	Improvement	improvement	NN
cord-005478-5iu38pr6	569	2	confirmed	confirm	VBN
cord-005478-5iu38pr6	569	3	by	by	IN
cord-005478-5iu38pr6	569	4	immunological	immunological	JJ
cord-005478-5iu38pr6	569	5	data	datum	NNS
cord-005478-5iu38pr6	569	6	(	(	-LRB-
cord-005478-5iu38pr6	569	7	increasing	increase	VBG
cord-005478-5iu38pr6	569	8	of	of	IN
cord-005478-5iu38pr6	569	9	immune	immune	JJ
cord-005478-5iu38pr6	569	10	regulation	regulation	NN
cord-005478-5iu38pr6	569	11	index	index	NN
cord-005478-5iu38pr6	569	12	and	and	CC
cord-005478-5iu38pr6	569	13	T	T	NNP
cord-005478-5iu38pr6	569	14	-	-	HYPH
cord-005478-5iu38pr6	569	15	regs	reg	NNS
cord-005478-5iu38pr6	569	16	in	in	IN
cord-005478-5iu38pr6	569	17	comparison	comparison	NN
cord-005478-5iu38pr6	569	18	with	with	IN
cord-005478-5iu38pr6	569	19	the	the	DT
cord-005478-5iu38pr6	569	20	baseline	baseline	NN
cord-005478-5iu38pr6	569	21	)	)	-RRB-
cord-005478-5iu38pr6	569	22	.	.	.
cord-005478-5iu38pr6	570	1	Median	median	JJ
cord-005478-5iu38pr6	570	2	follow	follow	NN
cord-005478-5iu38pr6	570	3	-	-	HYPH
cord-005478-5iu38pr6	570	4	up	up	NN
cord-005478-5iu38pr6	570	5	period	period	NN
cord-005478-5iu38pr6	570	6	was	be	VBD
cord-005478-5iu38pr6	570	7	48	48	CD
cord-005478-5iu38pr6	570	8	months	month	NNS
cord-005478-5iu38pr6	570	9	(	(	-LRB-
cord-005478-5iu38pr6	570	10	8	8	CD
cord-005478-5iu38pr6	570	11	-	-	SYM
cord-005478-5iu38pr6	570	12	93	93	CD
cord-005478-5iu38pr6	570	13	months	month	NNS
cord-005478-5iu38pr6	570	14	)	)	-RRB-
cord-005478-5iu38pr6	570	15	.	.	.
cord-005478-5iu38pr6	571	1	Four	four	CD
cord-005478-5iu38pr6	571	2	patients	patient	NNS
cord-005478-5iu38pr6	571	3	(	(	-LRB-
cord-005478-5iu38pr6	571	4	26.7	26.7	CD
cord-005478-5iu38pr6	571	5	%	%	NN
cord-005478-5iu38pr6	571	6	)	)	-RRB-
cord-005478-5iu38pr6	571	7	experienced	experienced	JJ
cord-005478-5iu38pr6	571	8	exacerbations	exacerbation	NNS
cord-005478-5iu38pr6	571	9	(	(	-LRB-
cord-005478-5iu38pr6	571	10	both	both	DT
cord-005478-5iu38pr6	571	11	neurological	neurological	JJ
cord-005478-5iu38pr6	571	12	and	and	CC
cord-005478-5iu38pr6	571	13	MRI	MRI	NNP
cord-005478-5iu38pr6	571	14	)	)	-RRB-
cord-005478-5iu38pr6	571	15	in	in	IN
cord-005478-5iu38pr6	571	16	median	median	NN
cord-005478-5iu38pr6	571	17	of	of	IN
cord-005478-5iu38pr6	571	18	2	2	CD
cord-005478-5iu38pr6	571	19	years	year	NNS
cord-005478-5iu38pr6	571	20	(	(	-LRB-
cord-005478-5iu38pr6	571	21	1	1	CD
cord-005478-5iu38pr6	571	22	-	-	SYM
cord-005478-5iu38pr6	571	23	3	3	CD
cord-005478-5iu38pr6	571	24	years	year	NNS
cord-005478-5iu38pr6	571	25	)	)	-RRB-
cord-005478-5iu38pr6	571	26	after	after	IN
cord-005478-5iu38pr6	571	27	aHSCT	aHSCT	NNP
cord-005478-5iu38pr6	571	28	.	.	.
cord-005478-5iu38pr6	572	1	No	no	DT
cord-005478-5iu38pr6	572	2	onsets	onset	NNS
cord-005478-5iu38pr6	572	3	of	of	IN
cord-005478-5iu38pr6	572	4	secondary	secondary	JJ
cord-005478-5iu38pr6	572	5	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	572	6	disease	disease	NN
cord-005478-5iu38pr6	572	7	and	and	CC
cord-005478-5iu38pr6	572	8	malignancies	malignancy	NNS
cord-005478-5iu38pr6	572	9	was	be	VBD
cord-005478-5iu38pr6	572	10	seen	see	VBN
cord-005478-5iu38pr6	572	11	.	.	.
cord-005478-5iu38pr6	573	1	Cardiocascular	cardiocascular	JJ
cord-005478-5iu38pr6	573	2	late	late	JJ
cord-005478-5iu38pr6	573	3	effects	effect	NNS
cord-005478-5iu38pr6	573	4	were	be	VBD
cord-005478-5iu38pr6	573	5	seen	see	VBN
cord-005478-5iu38pr6	573	6	in	in	IN
cord-005478-5iu38pr6	573	7	6	6	CD
cord-005478-5iu38pr6	573	8	patients	patient	NNS
cord-005478-5iu38pr6	573	9	and	and	CC
cord-005478-5iu38pr6	573	10	endocrine	endocrine	NN
cord-005478-5iu38pr6	573	11	-in	-in	SYM
cord-005478-5iu38pr6	573	12	3	3	CD
cord-005478-5iu38pr6	573	13	patients	patient	NNS
cord-005478-5iu38pr6	573	14	(	(	-LRB-
cord-005478-5iu38pr6	573	15	all	all	DT
cord-005478-5iu38pr6	573	16	females	female	NNS
cord-005478-5iu38pr6	573	17	)	)	-RRB-
cord-005478-5iu38pr6	573	18	.	.	.
cord-005478-5iu38pr6	574	1	All	all	PDT
cord-005478-5iu38pr6	574	2	these	these	DT
cord-005478-5iu38pr6	574	3	late	late	JJ
cord-005478-5iu38pr6	574	4	effects	effect	NNS
cord-005478-5iu38pr6	574	5	were	be	VBD
cord-005478-5iu38pr6	574	6	successfully	successfully	RB
cord-005478-5iu38pr6	574	7	treated	treat	VBN
cord-005478-5iu38pr6	574	8	.	.	.
cord-005478-5iu38pr6	575	1	Patients	patient	NNS
cord-005478-5iu38pr6	575	2	after	after	IN
cord-005478-5iu38pr6	575	3	the	the	DT
cord-005478-5iu38pr6	575	4	age	age	NN
cord-005478-5iu38pr6	575	5	of	of	IN
cord-005478-5iu38pr6	575	6	18	18	CD
cord-005478-5iu38pr6	575	7	years	year	NNS
cord-005478-5iu38pr6	575	8	old	old	JJ
cord-005478-5iu38pr6	575	9	were	be	VBD
cord-005478-5iu38pr6	575	10	transferred	transfer	VBN
cord-005478-5iu38pr6	575	11	to	to	IN
cord-005478-5iu38pr6	575	12	partnering	partner	VBG
cord-005478-5iu38pr6	575	13	adult	adult	NN
cord-005478-5iu38pr6	575	14	center	center	NN
cord-005478-5iu38pr6	575	15	.	.	.
cord-005478-5iu38pr6	576	1	This	this	DT
cord-005478-5iu38pr6	576	2	center	center	NN
cord-005478-5iu38pr6	576	3	uses	use	VBZ
cord-005478-5iu38pr6	576	4	the	the	DT
cord-005478-5iu38pr6	576	5	same	same	JJ
cord-005478-5iu38pr6	576	6	protocol	protocol	NN
cord-005478-5iu38pr6	576	7	for	for	IN
cord-005478-5iu38pr6	576	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	576	9	(	(	-LRB-
cord-005478-5iu38pr6	576	10	in	in	IN
cord-005478-5iu38pr6	576	11	adults	adult	NNS
cord-005478-5iu38pr6	576	12	)	)	-RRB-
cord-005478-5iu38pr6	576	13	and	and	CC
cord-005478-5iu38pr6	576	14	posttransplant	posttransplant	NNP
cord-005478-5iu38pr6	576	15	observation	observation	NN
cord-005478-5iu38pr6	576	16	.	.	.
cord-005478-5iu38pr6	577	1	Detailed	detailed	JJ
cord-005478-5iu38pr6	577	2	scheme	scheme	NN
cord-005478-5iu38pr6	577	3	of	of	IN
cord-005478-5iu38pr6	577	4	transfer	transfer	NN
cord-005478-5iu38pr6	577	5	developed	develop	VBN
cord-005478-5iu38pr6	577	6	.	.	.
cord-005478-5iu38pr6	578	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	578	2	:	:	:
cord-005478-5iu38pr6	579	1	aHSCT	aHSCT	NNP
cord-005478-5iu38pr6	579	2	for	for	IN
cord-005478-5iu38pr6	579	3	pediatric	pediatric	JJ
cord-005478-5iu38pr6	579	4	patients	patient	NNS
cord-005478-5iu38pr6	579	5	with	with	IN
cord-005478-5iu38pr6	579	6	severe	severe	JJ
cord-005478-5iu38pr6	579	7	refractory	refractory	JJ
cord-005478-5iu38pr6	579	8	MS	MS	NNP
cord-005478-5iu38pr6	579	9	appears	appear	VBZ
cord-005478-5iu38pr6	579	10	to	to	TO
cord-005478-5iu38pr6	579	11	be	be	VB
cord-005478-5iu38pr6	579	12	safe	safe	JJ
cord-005478-5iu38pr6	579	13	and	and	CC
cord-005478-5iu38pr6	579	14	effective	effective	JJ
cord-005478-5iu38pr6	579	15	method	method	NN
cord-005478-5iu38pr6	579	16	and	and	CC
cord-005478-5iu38pr6	579	17	in	in	IN
cord-005478-5iu38pr6	579	18	-	-	HYPH
cord-005478-5iu38pr6	579	19	time	time	NN
cord-005478-5iu38pr6	579	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	579	21	can	can	MD
cord-005478-5iu38pr6	579	22	significantly	significantly	RB
cord-005478-5iu38pr6	579	23	improve	improve	VB
cord-005478-5iu38pr6	579	24	the	the	DT
cord-005478-5iu38pr6	579	25	outcomes	outcome	NNS
cord-005478-5iu38pr6	579	26	.	.	.
cord-005478-5iu38pr6	580	1	Most	Most	JJS
cord-005478-5iu38pr6	580	2	of	of	IN
cord-005478-5iu38pr6	580	3	the	the	DT
cord-005478-5iu38pr6	580	4	patients	patient	NNS
cord-005478-5iu38pr6	580	5	did	do	VBD
cord-005478-5iu38pr6	580	6	not	not	RB
cord-005478-5iu38pr6	580	7	experienced	experience	VBN
cord-005478-5iu38pr6	580	8	exacerbations	exacerbation	NNS
cord-005478-5iu38pr6	580	9	.	.	.
cord-005478-5iu38pr6	581	1	Late	late	JJ
cord-005478-5iu38pr6	581	2	effects	effect	NNS
cord-005478-5iu38pr6	581	3	found	find	VBN
cord-005478-5iu38pr6	581	4	in	in	IN
cord-005478-5iu38pr6	581	5	patients	patient	NNS
cord-005478-5iu38pr6	581	6	were	be	VBD
cord-005478-5iu38pr6	581	7	successfully	successfully	RB
cord-005478-5iu38pr6	581	8	treated	treat	VBN
cord-005478-5iu38pr6	581	9	.	.	.
cord-005478-5iu38pr6	582	1	We	-PRON-	PRP
cord-005478-5iu38pr6	582	2	provide	provide	VBP
cord-005478-5iu38pr6	582	3	a	a	DT
cord-005478-5iu38pr6	582	4	best	good	JJS
cord-005478-5iu38pr6	582	5	care	care	NN
cord-005478-5iu38pr6	582	6	for	for	IN
cord-005478-5iu38pr6	582	7	these	these	DT
cord-005478-5iu38pr6	582	8	patients	patient	NNS
cord-005478-5iu38pr6	582	9	in	in	IN
cord-005478-5iu38pr6	582	10	both	both	DT
cord-005478-5iu38pr6	582	11	childhood	childhood	NN
cord-005478-5iu38pr6	582	12	and	and	CC
cord-005478-5iu38pr6	582	13	adulthood	adulthood	NN
cord-005478-5iu38pr6	582	14	by	by	IN
cord-005478-5iu38pr6	582	15	transferring	transfer	VBG
cord-005478-5iu38pr6	582	16	them	-PRON-	PRP
cord-005478-5iu38pr6	582	17	to	to	IN
cord-005478-5iu38pr6	582	18	adult	adult	NN
cord-005478-5iu38pr6	582	19	center	center	NN
cord-005478-5iu38pr6	582	20	.	.	.
cord-005478-5iu38pr6	583	1	Thus	thus	RB
cord-005478-5iu38pr6	583	2	,	,	,
cord-005478-5iu38pr6	583	3	a	a	DT
cord-005478-5iu38pr6	583	4	unique	unique	JJ
cord-005478-5iu38pr6	583	5	multicenter	multicenter	JJ
cord-005478-5iu38pr6	583	6	and	and	CC
cord-005478-5iu38pr6	583	7	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	583	8	model	model	NN
cord-005478-5iu38pr6	583	9	of	of	IN
cord-005478-5iu38pr6	583	10	care	care	NN
cord-005478-5iu38pr6	583	11	for	for	IN
cord-005478-5iu38pr6	583	12	children	child	NNS
cord-005478-5iu38pr6	583	13	with	with	IN
cord-005478-5iu38pr6	583	14	severe	severe	JJ
cord-005478-5iu38pr6	583	15	refractory	refractory	JJ
cord-005478-5iu38pr6	583	16	MS	MS	NNP
cord-005478-5iu38pr6	583	17	was	be	VBD
cord-005478-5iu38pr6	583	18	found	find	VBN
cord-005478-5iu38pr6	583	19	.	.	.
cord-005478-5iu38pr6	584	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	584	2	Background	background	NN
cord-005478-5iu38pr6	584	3	:	:	:
cord-005478-5iu38pr6	585	1	Neuromyelitis	Neuromyelitis	NNP
cord-005478-5iu38pr6	585	2	optica	optica	NN
cord-005478-5iu38pr6	585	3	spectrum	spectrum	NN
cord-005478-5iu38pr6	585	4	disorder	disorder	NN
cord-005478-5iu38pr6	585	5	(	(	-LRB-
cord-005478-5iu38pr6	585	6	NMOSD	NMOSD	NNP
cord-005478-5iu38pr6	585	7	)	)	-RRB-
cord-005478-5iu38pr6	585	8	is	be	VBZ
cord-005478-5iu38pr6	585	9	an	an	DT
cord-005478-5iu38pr6	585	10	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	585	11	central	central	JJ
cord-005478-5iu38pr6	585	12	nervous	nervous	JJ
cord-005478-5iu38pr6	585	13	system	system	NN
cord-005478-5iu38pr6	585	14	disorder	disorder	NN
cord-005478-5iu38pr6	585	15	characterized	characterize	VBN
cord-005478-5iu38pr6	585	16	,	,	,
cord-005478-5iu38pr6	585	17	despite	despite	IN
cord-005478-5iu38pr6	585	18	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	585	19	treatments	treatment	NNS
cord-005478-5iu38pr6	585	20	,	,	,
cord-005478-5iu38pr6	585	21	by	by	IN
cord-005478-5iu38pr6	585	22	life	life	NN
cord-005478-5iu38pr6	585	23	-	-	HYPH
cord-005478-5iu38pr6	585	24	long	long	RB
cord-005478-5iu38pr6	585	25	,	,	,
cord-005478-5iu38pr6	585	26	severe	severe	JJ
cord-005478-5iu38pr6	585	27	,	,	,
cord-005478-5iu38pr6	585	28	and	and	CC
cord-005478-5iu38pr6	585	29	disabling	disable	VBG
cord-005478-5iu38pr6	585	30	attacks	attack	NNS
cord-005478-5iu38pr6	585	31	of	of	IN
cord-005478-5iu38pr6	585	32	optic	optic	JJ
cord-005478-5iu38pr6	585	33	neuritis	neuritis	NN
cord-005478-5iu38pr6	585	34	and	and	CC
cord-005478-5iu38pr6	585	35	myelitis	myelitis	NNP
cord-005478-5iu38pr6	585	36	.	.	.
cord-005478-5iu38pr6	586	1	The	the	DT
cord-005478-5iu38pr6	586	2	aim	aim	NN
cord-005478-5iu38pr6	586	3	is	be	VBZ
cord-005478-5iu38pr6	586	4	to	to	TO
cord-005478-5iu38pr6	586	5	determine	determine	VB
cord-005478-5iu38pr6	586	6	if	if	IN
cord-005478-5iu38pr6	586	7	autologous	autologous	JJ
cord-005478-5iu38pr6	586	8	nonmyeloablative	nonmyeloablative	JJ
cord-005478-5iu38pr6	586	9	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	586	10	stem	stem	NN
cord-005478-5iu38pr6	586	11	cell	cell	NN
cord-005478-5iu38pr6	586	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	586	13	could	could	MD
cord-005478-5iu38pr6	586	14	be	be	VB
cord-005478-5iu38pr6	586	15	an	an	DT
cord-005478-5iu38pr6	586	16	alternative	alternative	JJ
cord-005478-5iu38pr6	586	17	treatment	treatment	NN
cord-005478-5iu38pr6	586	18	option	option	NN
cord-005478-5iu38pr6	586	19	.	.	.
cord-005478-5iu38pr6	587	1	Methods	method	NNS
cord-005478-5iu38pr6	587	2	:	:	:
cord-005478-5iu38pr6	587	3	Following	follow	VBG
cord-005478-5iu38pr6	587	4	stem	stem	NN
cord-005478-5iu38pr6	587	5	cell	cell	NN
cord-005478-5iu38pr6	587	6	mobilization	mobilization	NN
cord-005478-5iu38pr6	587	7	with	with	IN
cord-005478-5iu38pr6	587	8	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	587	9	(	(	-LRB-
cord-005478-5iu38pr6	587	10	2	2	CD
cord-005478-5iu38pr6	587	11	g	g	NN
cord-005478-5iu38pr6	587	12	/	/	SYM
cord-005478-5iu38pr6	587	13	m	m	NN
cord-005478-5iu38pr6	587	14	2	2	CD
cord-005478-5iu38pr6	587	15	)	)	-RRB-
cord-005478-5iu38pr6	587	16	and	and	CC
cord-005478-5iu38pr6	587	17	filgrastim	filgrastim	NN
cord-005478-5iu38pr6	587	18	,	,	,
cord-005478-5iu38pr6	587	19	patients	patient	NNS
cord-005478-5iu38pr6	587	20	were	be	VBD
cord-005478-5iu38pr6	587	21	treated	treat	VBN
cord-005478-5iu38pr6	587	22	with	with	IN
cord-005478-5iu38pr6	587	23	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	587	24	(	(	-LRB-
cord-005478-5iu38pr6	587	25	200	200	CD
cord-005478-5iu38pr6	587	26	mg	mg	NNP
cord-005478-5iu38pr6	587	27	/	/	SYM
cord-005478-5iu38pr6	587	28	kg	kg	NNP
cord-005478-5iu38pr6	587	29	)	)	-RRB-
cord-005478-5iu38pr6	587	30	divided	divide	VBD
cord-005478-5iu38pr6	587	31	as	as	IN
cord-005478-5iu38pr6	587	32	50	50	CD
cord-005478-5iu38pr6	587	33	mg	mg	NNP
cord-005478-5iu38pr6	587	34	/	/	SYM
cord-005478-5iu38pr6	587	35	kg	kg	XX
cord-005478-5iu38pr6	587	36	intravenously	intravenously	RB
cord-005478-5iu38pr6	587	37	(	(	-LRB-
cord-005478-5iu38pr6	587	38	IV	IV	NNP
cord-005478-5iu38pr6	587	39	)	)	-RRB-
cord-005478-5iu38pr6	587	40	on	on	IN
cord-005478-5iu38pr6	587	41	day	day	NN
cord-005478-5iu38pr6	587	42	-5	-5	NNP
cord-005478-5iu38pr6	587	43	to	to	IN
cord-005478-5iu38pr6	587	44	day	day	NN
cord-005478-5iu38pr6	587	45	-2	-2	CD
cord-005478-5iu38pr6	587	46	,	,	,
cord-005478-5iu38pr6	587	47	rATG	ratg	JJ
cord-005478-5iu38pr6	588	1	(	(	-LRB-
cord-005478-5iu38pr6	588	2	thymoglobulin	thymoglobulin	NNP
cord-005478-5iu38pr6	588	3	)	)	-RRB-
cord-005478-5iu38pr6	588	4	given	give	VBN
cord-005478-5iu38pr6	588	5	IV	IV	NNP
cord-005478-5iu38pr6	588	6	at	at	IN
cord-005478-5iu38pr6	588	7	0.5	0.5	CD
cord-005478-5iu38pr6	588	8	mg	mg	NNP
cord-005478-5iu38pr6	588	9	/	/	SYM
cord-005478-5iu38pr6	588	10	kg	kg	NNS
cord-005478-5iu38pr6	588	11	on	on	IN
cord-005478-5iu38pr6	588	12	day	day	NN
cord-005478-5iu38pr6	588	13	-5	-5	NNP
cord-005478-5iu38pr6	588	14	,	,	,
cord-005478-5iu38pr6	588	15	1	1	CD
cord-005478-5iu38pr6	588	16	mg	mg	NNP
cord-005478-5iu38pr6	588	17	/	/	SYM
cord-005478-5iu38pr6	588	18	kg	kg	NNS
cord-005478-5iu38pr6	588	19	on	on	IN
cord-005478-5iu38pr6	588	20	day	day	NN
cord-005478-5iu38pr6	588	21	-4	-4	NNP
cord-005478-5iu38pr6	588	22	,	,	,
cord-005478-5iu38pr6	588	23	and	and	CC
cord-005478-5iu38pr6	588	24	1.5	1.5	CD
cord-005478-5iu38pr6	588	25	mg	mg	NNS
cord-005478-5iu38pr6	588	26	/	/	SYM
cord-005478-5iu38pr6	588	27	kg	kg	NNS
cord-005478-5iu38pr6	588	28	on	on	IN
cord-005478-5iu38pr6	588	29	days	day	NNS
cord-005478-5iu38pr6	589	1	-3	-3	NNP
cord-005478-5iu38pr6	589	2	,	,	,
cord-005478-5iu38pr6	590	1	-2	-2	LS
cord-005478-5iu38pr6	591	1	,	,	,
cord-005478-5iu38pr6	592	1	and	and	CC
cord-005478-5iu38pr6	592	2	-1	-1	LS
cord-005478-5iu38pr6	592	3	(	(	-LRB-
cord-005478-5iu38pr6	592	4	total	total	JJ
cord-005478-5iu38pr6	592	5	dose	dose	NN
cord-005478-5iu38pr6	592	6	6	6	CD
cord-005478-5iu38pr6	592	7	mg	mg	NNP
cord-005478-5iu38pr6	592	8	/	/	SYM
cord-005478-5iu38pr6	592	9	kg	kg	NNP
cord-005478-5iu38pr6	592	10	)	)	-RRB-
cord-005478-5iu38pr6	592	11	,	,	,
cord-005478-5iu38pr6	592	12	and	and	CC
cord-005478-5iu38pr6	592	13	rituximab	rituximab	VBD
cord-005478-5iu38pr6	592	14	500	500	CD
cord-005478-5iu38pr6	592	15	mg	mg	NNP
cord-005478-5iu38pr6	592	16	IV	IV	NNP
cord-005478-5iu38pr6	592	17	on	on	IN
cord-005478-5iu38pr6	592	18	days	day	NNS
cord-005478-5iu38pr6	592	19	-6	-6	JJ
cord-005478-5iu38pr6	592	20	and	and	CC
cord-005478-5iu38pr6	592	21	+1	+1	LS
cord-005478-5iu38pr6	592	22	.	.	.
cord-005478-5iu38pr6	593	1	Unselected	unselected	JJ
cord-005478-5iu38pr6	593	2	peripheral	peripheral	JJ
cord-005478-5iu38pr6	593	3	blood	blood	NN
cord-005478-5iu38pr6	593	4	stem	stem	NN
cord-005478-5iu38pr6	593	5	cells	cell	NNS
cord-005478-5iu38pr6	593	6	were	be	VBD
cord-005478-5iu38pr6	593	7	infused	infuse	VBN
cord-005478-5iu38pr6	593	8	on	on	IN
cord-005478-5iu38pr6	593	9	day	day	NN
cord-005478-5iu38pr6	593	10	0	0	CD
cord-005478-5iu38pr6	593	11	.	.	.
cord-005478-5iu38pr6	594	1	AQP4-IgG	AQP4-IgG	NNP
cord-005478-5iu38pr6	594	2	antibody	antibody	NN
cord-005478-5iu38pr6	594	3	status	status	NN
cord-005478-5iu38pr6	594	4	was	be	VBD
cord-005478-5iu38pr6	594	5	determined	determine	VBN
cord-005478-5iu38pr6	594	6	by	by	IN
cord-005478-5iu38pr6	594	7	CLIA	CLIA	NNP
cord-005478-5iu38pr6	594	8	validated	validate	VBD
cord-005478-5iu38pr6	594	9	ELISA	ELISA	NNP
cord-005478-5iu38pr6	594	10	or	or	CC
cord-005478-5iu38pr6	594	11	flow	flow	VB
cord-005478-5iu38pr6	594	12	cytometry	cytometry	NN
cord-005478-5iu38pr6	594	13	assays	assay	NNS
cord-005478-5iu38pr6	594	14	.	.	.
cord-005478-5iu38pr6	595	1	Cell	cell	NN
cord-005478-5iu38pr6	595	2	killing	kill	VBG
cord-005478-5iu38pr6	595	3	activity	activity	NN
cord-005478-5iu38pr6	595	4	was	be	VBD
cord-005478-5iu38pr6	595	5	measured	measure	VBN
cord-005478-5iu38pr6	595	6	using	use	VBG
cord-005478-5iu38pr6	595	7	a	a	DT
cord-005478-5iu38pr6	595	8	flow	flow	NN
cord-005478-5iu38pr6	595	9	cytometry	cytometry	NN
cord-005478-5iu38pr6	595	10	based	base	VBN
cord-005478-5iu38pr6	595	11	complement	complement	NN
cord-005478-5iu38pr6	595	12	assay	assay	NN
cord-005478-5iu38pr6	595	13	.	.	.
cord-005478-5iu38pr6	596	1	Results	result	NNS
cord-005478-5iu38pr6	596	2	:	:	:
cord-005478-5iu38pr6	597	1	Twelve	twelve	CD
cord-005478-5iu38pr6	597	2	(	(	-LRB-
cord-005478-5iu38pr6	598	1	eleven	eleven	CD
cord-005478-5iu38pr6	598	2	AQP4-IgG	aqp4-igg	NN
cord-005478-5iu38pr6	598	3	positive	positive	JJ
cord-005478-5iu38pr6	598	4	)	)	-RRB-
cord-005478-5iu38pr6	598	5	patients	patient	NNS
cord-005478-5iu38pr6	598	6	were	be	VBD
cord-005478-5iu38pr6	598	7	treated	treat	VBN
cord-005478-5iu38pr6	598	8	with	with	IN
cord-005478-5iu38pr6	598	9	a	a	DT
cord-005478-5iu38pr6	598	10	median	median	JJ
cord-005478-5iu38pr6	598	11	follow	follow	NN
cord-005478-5iu38pr6	598	12	-	-	HYPH
cord-005478-5iu38pr6	598	13	up	up	NN
cord-005478-5iu38pr6	598	14	of	of	IN
cord-005478-5iu38pr6	598	15	54	54	CD
cord-005478-5iu38pr6	598	16	months	month	NNS
cord-005478-5iu38pr6	598	17	.	.	.
cord-005478-5iu38pr6	599	1	Ten	ten	CD
cord-005478-5iu38pr6	599	2	patients	patient	NNS
cord-005478-5iu38pr6	599	3	are	be	VBP
cord-005478-5iu38pr6	599	4	more	more	JJR
cord-005478-5iu38pr6	599	5	than	than	IN
cord-005478-5iu38pr6	599	6	five	five	CD
cord-005478-5iu38pr6	599	7	years	year	NNS
cord-005478-5iu38pr6	599	8	post	post	NN
cord-005478-5iu38pr6	599	9	-	-	NN
cord-005478-5iu38pr6	599	10	transplant	transplant	NN
cord-005478-5iu38pr6	599	11	.	.	.
cord-005478-5iu38pr6	600	1	At	at	IN
cord-005478-5iu38pr6	600	2	five	five	CD
cord-005478-5iu38pr6	600	3	years	year	NNS
cord-005478-5iu38pr6	600	4	,	,	,
cord-005478-5iu38pr6	600	5	80	80	CD
cord-005478-5iu38pr6	600	6	%	%	NN
cord-005478-5iu38pr6	600	7	of	of	IN
cord-005478-5iu38pr6	600	8	patients	patient	NNS
cord-005478-5iu38pr6	600	9	were	be	VBD
cord-005478-5iu38pr6	600	10	relapse	relapse	NN
cord-005478-5iu38pr6	600	11	-	-	HYPH
cord-005478-5iu38pr6	600	12	free	free	JJ
cord-005478-5iu38pr6	600	13	off	off	RP
cord-005478-5iu38pr6	600	14	all	all	DT
cord-005478-5iu38pr6	600	15	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	600	16	(	(	-LRB-
cord-005478-5iu38pr6	600	17	p	p	NN
cord-005478-5iu38pr6	600	18	<	<	XX
cord-005478-5iu38pr6	600	19	0.001	0.001	CD
cord-005478-5iu38pr6	600	20	)	)	-RRB-
cord-005478-5iu38pr6	600	21	.	.	.
cord-005478-5iu38pr6	601	1	At	at	IN
cord-005478-5iu38pr6	601	2	one	one	CD
cord-005478-5iu38pr6	601	3	and	and	CC
cord-005478-5iu38pr6	601	4	five	five	CD
cord-005478-5iu38pr6	601	5	years	year	NNS
cord-005478-5iu38pr6	601	6	after	after	IN
cord-005478-5iu38pr6	601	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	601	8	,	,	,
cord-005478-5iu38pr6	601	9	EDSS	EDSS	NNP
cord-005478-5iu38pr6	601	10	improved	improve	VBD
cord-005478-5iu38pr6	601	11	from	from	IN
cord-005478-5iu38pr6	601	12	a	a	DT
cord-005478-5iu38pr6	601	13	baseline	baseline	JJ
cord-005478-5iu38pr6	601	14	mean	mean	NN
cord-005478-5iu38pr6	601	15	of	of	IN
cord-005478-5iu38pr6	601	16	4.3	4.3	CD
cord-005478-5iu38pr6	601	17	to	to	IN
cord-005478-5iu38pr6	601	18	2.8	2.8	CD
cord-005478-5iu38pr6	601	19	(	(	-LRB-
cord-005478-5iu38pr6	601	20	P<0.001	P<0.001	NNP
cord-005478-5iu38pr6	601	21	)	)	-RRB-
cord-005478-5iu38pr6	601	22	and	and	CC
cord-005478-5iu38pr6	601	23	3.25	3.25	CD
cord-005478-5iu38pr6	601	24	(	(	-LRB-
cord-005478-5iu38pr6	601	25	P<0.001	P<0.001	NNP
cord-005478-5iu38pr6	601	26	)	)	-RRB-
cord-005478-5iu38pr6	601	27	,	,	,
cord-005478-5iu38pr6	601	28	respectively	respectively	RB
cord-005478-5iu38pr6	601	29	.	.	.
cord-005478-5iu38pr6	602	1	NRS	NRS	NNP
cord-005478-5iu38pr6	602	2	improved	improve	VBD
cord-005478-5iu38pr6	602	3	after	after	IN
cord-005478-5iu38pr6	602	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	602	5	from	from	IN
cord-005478-5iu38pr6	602	6	a	a	DT
cord-005478-5iu38pr6	602	7	baseline	baseline	JJ
cord-005478-5iu38pr6	602	8	mean	mean	NN
cord-005478-5iu38pr6	602	9	of	of	IN
cord-005478-5iu38pr6	602	10	69.5	69.5	CD
cord-005478-5iu38pr6	602	11	to	to	IN
cord-005478-5iu38pr6	602	12	83.8	83.8	CD
cord-005478-5iu38pr6	602	13	at	at	IN
cord-005478-5iu38pr6	602	14	one	one	CD
cord-005478-5iu38pr6	602	15	year	year	NN
cord-005478-5iu38pr6	602	16	(	(	-LRB-
cord-005478-5iu38pr6	602	17	p<0.001	p<0.001	JJ
cord-005478-5iu38pr6	602	18	)	)	-RRB-
cord-005478-5iu38pr6	602	19	and	and	CC
cord-005478-5iu38pr6	602	20	85.9	85.9	CD
cord-005478-5iu38pr6	602	21	at	at	IN
cord-005478-5iu38pr6	602	22	five	five	CD
cord-005478-5iu38pr6	602	23	years	year	NNS
cord-005478-5iu38pr6	602	24	(	(	-LRB-
cord-005478-5iu38pr6	602	25	P<0.001	P<0.001	NNP
cord-005478-5iu38pr6	602	26	)	)	-RRB-
cord-005478-5iu38pr6	602	27	.	.	.
cord-005478-5iu38pr6	603	1	The	the	DT
cord-005478-5iu38pr6	603	2	SF-36	SF-36	NNP
cord-005478-5iu38pr6	603	3	quality	quality	NN
cord-005478-5iu38pr6	603	4	of	of	IN
cord-005478-5iu38pr6	603	5	life	life	NN
cord-005478-5iu38pr6	603	6	total	total	JJ
cord-005478-5iu38pr6	603	7	score	score	NN
cord-005478-5iu38pr6	603	8	improved	improve	VBN
cord-005478-5iu38pr6	603	9	from	from	IN
cord-005478-5iu38pr6	603	10	mean	mean	VB
cord-005478-5iu38pr6	603	11	34.2	34.2	CD
cord-005478-5iu38pr6	603	12	to	to	IN
cord-005478-5iu38pr6	603	13	55.1	55.1	CD
cord-005478-5iu38pr6	603	14	(	(	-LRB-
cord-005478-5iu38pr6	603	15	P=0.03	p=0.03	NN
cord-005478-5iu38pr6	603	16	)	)	-RRB-
cord-005478-5iu38pr6	603	17	and	and	CC
cord-005478-5iu38pr6	603	18	62.1	62.1	CD
cord-005478-5iu38pr6	603	19	(	(	-LRB-
cord-005478-5iu38pr6	603	20	P=0.001	P=0.001	NNP
cord-005478-5iu38pr6	603	21	)	)	-RRB-
cord-005478-5iu38pr6	603	22	.	.	.
cord-005478-5iu38pr6	604	1	AQP4-IgG	AQP4-IgG	NNP
cord-005478-5iu38pr6	604	2	serostatus	serostatus	NNP
cord-005478-5iu38pr6	604	3	converted	convert	VBD
cord-005478-5iu38pr6	604	4	to	to	IN
cord-005478-5iu38pr6	604	5	negative	negative	JJ
cord-005478-5iu38pr6	604	6	in	in	IN
cord-005478-5iu38pr6	604	7	nine	nine	CD
cord-005478-5iu38pr6	604	8	patients	patient	NNS
cord-005478-5iu38pr6	604	9	and	and	CC
cord-005478-5iu38pr6	604	10	complement	complement	VB
cord-005478-5iu38pr6	604	11	activating	activate	VBG
cord-005478-5iu38pr6	604	12	and	and	CC
cord-005478-5iu38pr6	604	13	cell	cell	NN
cord-005478-5iu38pr6	604	14	killing	kill	VBG
cord-005478-5iu38pr6	604	15	ability	ability	NN
cord-005478-5iu38pr6	604	16	of	of	IN
cord-005478-5iu38pr6	604	17	patient	patient	JJ
cord-005478-5iu38pr6	604	18	serum	serum	NN
cord-005478-5iu38pr6	604	19	was	be	VBD
cord-005478-5iu38pr6	604	20	switched	switch	VBN
cord-005478-5iu38pr6	604	21	off	off	RP
cord-005478-5iu38pr6	604	22	.	.	.
cord-005478-5iu38pr6	605	1	Two	two	CD
cord-005478-5iu38pr6	605	2	patients	patient	NNS
cord-005478-5iu38pr6	605	3	remained	remain	VBD
cord-005478-5iu38pr6	605	4	AQP4-IgG	aqp4-igg	RB
cord-005478-5iu38pr6	605	5	seropositive	seropositive	JJ
cord-005478-5iu38pr6	605	6	(	(	-LRB-
cord-005478-5iu38pr6	605	7	with	with	IN
cord-005478-5iu38pr6	605	8	persistent	persistent	JJ
cord-005478-5iu38pr6	605	9	cell	cell	NN
cord-005478-5iu38pr6	605	10	killing	kill	VBG
cord-005478-5iu38pr6	605	11	ability	ability	NN
cord-005478-5iu38pr6	605	12	)	)	-RRB-
cord-005478-5iu38pr6	605	13	and	and	CC
cord-005478-5iu38pr6	605	14	relapsed	relapse	VBD
cord-005478-5iu38pr6	605	15	within	within	IN
cord-005478-5iu38pr6	605	16	two	two	CD
cord-005478-5iu38pr6	605	17	years	year	NNS
cord-005478-5iu38pr6	605	18	of	of	IN
cord-005478-5iu38pr6	605	19	HSCT	HSCT	NNP
cord-005478-5iu38pr6	605	20	(	(	-LRB-
cord-005478-5iu38pr6	605	21	P	p	NN
cord-005478-5iu38pr6	605	22	<	<	XX
cord-005478-5iu38pr6	605	23	0.01	0.01	CD
cord-005478-5iu38pr6	605	24	)	)	-RRB-
cord-005478-5iu38pr6	605	25	.	.	.
cord-005478-5iu38pr6	606	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	606	2	:	:	:
cord-005478-5iu38pr6	607	1	Prolonged	prolonged	JJ
cord-005478-5iu38pr6	607	2	drug	drug	NN
cord-005478-5iu38pr6	607	3	-	-	HYPH
cord-005478-5iu38pr6	607	4	free	free	JJ
cord-005478-5iu38pr6	607	5	remission	remission	NN
cord-005478-5iu38pr6	607	6	with	with	IN
cord-005478-5iu38pr6	607	7	AQP4-IgG	aqp4-igg	DT
cord-005478-5iu38pr6	607	8	seroconversion	seroconversion	NN
cord-005478-5iu38pr6	607	9	to	to	IN
cord-005478-5iu38pr6	607	10	negative	negative	JJ
cord-005478-5iu38pr6	607	11	following	follow	VBG
cord-005478-5iu38pr6	607	12	nonmyeloablative	nonmyeloablative	JJ
cord-005478-5iu38pr6	607	13	autologous	autologous	JJ
cord-005478-5iu38pr6	607	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	607	15	warrants	warrant	NNS
cord-005478-5iu38pr6	607	16	further	further	JJ
cord-005478-5iu38pr6	607	17	investigation	investigation	NN
cord-005478-5iu38pr6	607	18	in	in	IN
cord-005478-5iu38pr6	607	19	larger	large	JJR
cord-005478-5iu38pr6	607	20	randomized	randomize	VBN
cord-005478-5iu38pr6	607	21	controlled	control	VBN
cord-005478-5iu38pr6	607	22	trial	trial	NN
cord-005478-5iu38pr6	607	23	.	.	.
cord-005478-5iu38pr6	608	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	608	2	Trial	Trial	NNP
cord-005478-5iu38pr6	608	3	Registry	Registry	NNP
cord-005478-5iu38pr6	608	4	:	:	:
cord-005478-5iu38pr6	608	5	Identifier	identifier	NN
cord-005478-5iu38pr6	608	6	:	:	:
cord-005478-5iu38pr6	608	7	NCT00787722	NCT00787722	NNP
cord-005478-5iu38pr6	609	1	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-005478-5iu38pr6	609	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	609	3	:	:	:
cord-005478-5iu38pr6	610	1	Nothing	nothing	NN
cord-005478-5iu38pr6	610	2	to	to	TO
cord-005478-5iu38pr6	610	3	declare	declare	VB
cord-005478-5iu38pr6	610	4	O038	O038	NNP
cord-005478-5iu38pr6	610	5	Abstract	Abstract	NNP
cord-005478-5iu38pr6	610	6	already	already	RB
cord-005478-5iu38pr6	610	7	published	publish	VBN
cord-005478-5iu38pr6	610	8	.	.	.
cord-005478-5iu38pr6	611	1	Autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	611	2	haemolytic	haemolytic	JJ
cord-005478-5iu38pr6	611	3	anaemia	anaemia	NN
cord-005478-5iu38pr6	611	4	after	after	IN
cord-005478-5iu38pr6	611	5	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	611	6	stem	stem	NN
cord-005478-5iu38pr6	611	7	cell	cell	NN
cord-005478-5iu38pr6	611	8	transplantation	transplantation	NN
cord-005478-5iu38pr6	611	9	in	in	IN
cord-005478-5iu38pr6	611	10	children	child	NNS
cord-005478-5iu38pr6	611	11	:	:	:
cord-005478-5iu38pr6	612	1	A	a	DT
cord-005478-5iu38pr6	612	2	french	french	JJ
cord-005478-5iu38pr6	612	3	multicenter	multicenter	JJ
cord-005478-5iu38pr6	612	4	study	study	NN
cord-005478-5iu38pr6	612	5	Background	Background	NNP
cord-005478-5iu38pr6	612	6	:	:	:
cord-005478-5iu38pr6	613	1	Autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	613	2	cytopenias	cytopenia	NNS
cord-005478-5iu38pr6	613	3	(	(	-LRB-
cord-005478-5iu38pr6	613	4	AIC	AIC	NNP
cord-005478-5iu38pr6	613	5	)	)	-RRB-
cord-005478-5iu38pr6	613	6	are	be	VBP
cord-005478-5iu38pr6	613	7	a	a	DT
cord-005478-5iu38pr6	613	8	rare	rare	JJ
cord-005478-5iu38pr6	613	9	but	but	CC
cord-005478-5iu38pr6	613	10	serious	serious	JJ
cord-005478-5iu38pr6	613	11	complication	complication	NN
cord-005478-5iu38pr6	613	12	of	of	IN
cord-005478-5iu38pr6	613	13	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	613	14	stem	stem	NN
cord-005478-5iu38pr6	613	15	cells	cell	NNS
cord-005478-5iu38pr6	613	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	613	17	(	(	-LRB-
cord-005478-5iu38pr6	613	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	613	19	)	)	-RRB-
cord-005478-5iu38pr6	613	20	.	.	.
cord-005478-5iu38pr6	614	1	The	the	DT
cord-005478-5iu38pr6	614	2	auto	auto	NN
cord-005478-5iu38pr6	614	3	immune	immune	JJ
cord-005478-5iu38pr6	614	4	haemolytic	haemolytic	JJ
cord-005478-5iu38pr6	614	5	anaemia	anaemia	NN
cord-005478-5iu38pr6	614	6	(	(	-LRB-
cord-005478-5iu38pr6	614	7	AIHA	AIHA	NNP
cord-005478-5iu38pr6	614	8	)	)	-RRB-
cord-005478-5iu38pr6	614	9	is	be	VBZ
cord-005478-5iu38pr6	614	10	the	the	DT
cord-005478-5iu38pr6	614	11	most	most	RBS
cord-005478-5iu38pr6	614	12	frequent	frequent	JJ
cord-005478-5iu38pr6	614	13	of	of	IN
cord-005478-5iu38pr6	614	14	these	these	DT
cord-005478-5iu38pr6	614	15	complications	complication	NNS
cord-005478-5iu38pr6	614	16	in	in	IN
cord-005478-5iu38pr6	614	17	paediatrics	paediatric	NNS
cord-005478-5iu38pr6	614	18	and	and	CC
cord-005478-5iu38pr6	614	19	is	be	VBZ
cord-005478-5iu38pr6	614	20	difficult	difficult	JJ
cord-005478-5iu38pr6	614	21	to	to	TO
cord-005478-5iu38pr6	614	22	treat	treat	VB
cord-005478-5iu38pr6	614	23	.	.	.
cord-005478-5iu38pr6	615	1	So	so	RB
cord-005478-5iu38pr6	615	2	far	far	RB
cord-005478-5iu38pr6	615	3	,	,	,
cord-005478-5iu38pr6	615	4	there	there	EX
cord-005478-5iu38pr6	615	5	has	have	VBZ
cord-005478-5iu38pr6	615	6	been	be	VBN
cord-005478-5iu38pr6	615	7	no	no	DT
cord-005478-5iu38pr6	615	8	nationwide	nationwide	JJ
cord-005478-5iu38pr6	615	9	post	post	NN
cord-005478-5iu38pr6	615	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	615	11	AIHA	AIHA	NNP
cord-005478-5iu38pr6	615	12	study	study	NN
cord-005478-5iu38pr6	615	13	.	.	.
cord-005478-5iu38pr6	616	1	Methods	method	NNS
cord-005478-5iu38pr6	616	2	:	:	:
cord-005478-5iu38pr6	617	1	This	this	DT
cord-005478-5iu38pr6	617	2	observational	observational	JJ
cord-005478-5iu38pr6	617	3	,	,	,
cord-005478-5iu38pr6	617	4	retrospective	retrospective	JJ
cord-005478-5iu38pr6	617	5	and	and	CC
cord-005478-5iu38pr6	617	6	multicentric	multicentric	JJ
cord-005478-5iu38pr6	617	7	study	study	NN
cord-005478-5iu38pr6	617	8	focused	focus	VBD
cord-005478-5iu38pr6	617	9	on	on	IN
cord-005478-5iu38pr6	617	10	French	french	JJ
cord-005478-5iu38pr6	617	11	paediatric	paediatric	JJ
cord-005478-5iu38pr6	617	12	cases	case	NNS
cord-005478-5iu38pr6	617	13	of	of	IN
cord-005478-5iu38pr6	617	14	AIHA	AIHA	NNP
cord-005478-5iu38pr6	617	15	after	after	IN
cord-005478-5iu38pr6	617	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	617	17	between	between	IN
cord-005478-5iu38pr6	617	18	January	January	NNP
cord-005478-5iu38pr6	617	19	2007	2007	CD
cord-005478-5iu38pr6	617	20	and	and	CC
cord-005478-5iu38pr6	617	21	January	January	NNP
cord-005478-5iu38pr6	617	22	2018	2018	CD
cord-005478-5iu38pr6	617	23	.	.	.
cord-005478-5iu38pr6	618	1	Data	datum	NNS
cord-005478-5iu38pr6	618	2	was	be	VBD
cord-005478-5iu38pr6	618	3	collected	collect	VBN
cord-005478-5iu38pr6	618	4	from	from	IN
cord-005478-5iu38pr6	618	5	national	national	JJ
cord-005478-5iu38pr6	618	6	reference	reference	NN
cord-005478-5iu38pr6	618	7	databases	database	NNS
cord-005478-5iu38pr6	618	8	and	and	CC
cord-005478-5iu38pr6	618	9	direct	direct	JJ
cord-005478-5iu38pr6	618	10	interview	interview	NN
cord-005478-5iu38pr6	618	11	of	of	IN
cord-005478-5iu38pr6	618	12	physicians	physician	NNS
cord-005478-5iu38pr6	618	13	.	.	.
cord-005478-5iu38pr6	619	1	The	the	DT
cord-005478-5iu38pr6	619	2	inclusion	inclusion	NN
cord-005478-5iu38pr6	619	3	criteria	criterion	NNS
cord-005478-5iu38pr6	619	4	were	be	VBD
cord-005478-5iu38pr6	619	5	patients	patient	NNS
cord-005478-5iu38pr6	619	6	between	between	IN
cord-005478-5iu38pr6	619	7	0	0	CD
cord-005478-5iu38pr6	619	8	to	to	TO
cord-005478-5iu38pr6	619	9	18	18	CD
cord-005478-5iu38pr6	619	10	years	year	NNS
cord-005478-5iu38pr6	619	11	old	old	JJ
cord-005478-5iu38pr6	619	12	who	who	WP
cord-005478-5iu38pr6	619	13	developed	develop	VBD
cord-005478-5iu38pr6	619	14	an	an	DT
cord-005478-5iu38pr6	619	15	AIHA	AIHA	NNP
cord-005478-5iu38pr6	619	16	or	or	CC
cord-005478-5iu38pr6	619	17	an	an	DT
cord-005478-5iu38pr6	619	18	Evans	Evans	NNP
cord-005478-5iu38pr6	619	19	syndrome	syndrome	NN
cord-005478-5iu38pr6	619	20	after	after	IN
cord-005478-5iu38pr6	619	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	619	22	.	.	.
cord-005478-5iu38pr6	620	1	Data	datum	NNS
cord-005478-5iu38pr6	620	2	concerning	concern	VBG
cord-005478-5iu38pr6	620	3	patient	patient	NN
cord-005478-5iu38pr6	620	4	,	,	,
cord-005478-5iu38pr6	620	5	primary	primary	JJ
cord-005478-5iu38pr6	620	6	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	620	7	,	,	,
cord-005478-5iu38pr6	620	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	620	9	procedure	procedure	NN
cord-005478-5iu38pr6	620	10	,	,	,
cord-005478-5iu38pr6	620	11	pre	pre	JJ
cord-005478-5iu38pr6	620	12	-	-	JJ
cord-005478-5iu38pr6	620	13	transplant	transplant	JJ
cord-005478-5iu38pr6	620	14	viral	viral	JJ
cord-005478-5iu38pr6	620	15	status	status	NN
cord-005478-5iu38pr6	620	16	,	,	,
cord-005478-5iu38pr6	620	17	blood	blood	NN
cord-005478-5iu38pr6	620	18	group	group	NN
cord-005478-5iu38pr6	620	19	compatibility	compatibility	NN
cord-005478-5iu38pr6	620	20	,	,	,
cord-005478-5iu38pr6	620	21	characteristics	characteristic	NNS
cord-005478-5iu38pr6	620	22	of	of	IN
cord-005478-5iu38pr6	620	23	cytopenia	cytopenia	NNP
cord-005478-5iu38pr6	620	24	,	,	,
cord-005478-5iu38pr6	620	25	delay	delay	VB
cord-005478-5iu38pr6	620	26	transplant	transplant	NN
cord-005478-5iu38pr6	620	27	-	-	HYPH
cord-005478-5iu38pr6	620	28	cytopenia	cytopenia	NNP
cord-005478-5iu38pr6	620	29	,	,	,
cord-005478-5iu38pr6	620	30	graft	graft	NN
cord-005478-5iu38pr6	620	31	vs	vs	IN
cord-005478-5iu38pr6	620	32	host	host	NN
cord-005478-5iu38pr6	620	33	reaction	reaction	NN
cord-005478-5iu38pr6	620	34	.	.	.
cord-005478-5iu38pr6	621	1	Laboratory	laboratory	NN
cord-005478-5iu38pr6	621	2	characteristics	characteristic	NNS
cord-005478-5iu38pr6	621	3	and	and	CC
cord-005478-5iu38pr6	621	4	therapies	therapy	NNS
cord-005478-5iu38pr6	621	5	were	be	VBD
cord-005478-5iu38pr6	621	6	analyzed	analyze	VBN
cord-005478-5iu38pr6	621	7	as	as	RB
cord-005478-5iu38pr6	621	8	well	well	RB
cord-005478-5iu38pr6	621	9	as	as	IN
cord-005478-5iu38pr6	621	10	the	the	DT
cord-005478-5iu38pr6	621	11	response	response	NN
cord-005478-5iu38pr6	621	12	to	to	IN
cord-005478-5iu38pr6	621	13	first	first	RB
cord-005478-5iu38pr6	621	14	,	,	,
cord-005478-5iu38pr6	621	15	second	second	JJ
cord-005478-5iu38pr6	621	16	or	or	CC
cord-005478-5iu38pr6	621	17	third	third	JJ
cord-005478-5iu38pr6	621	18	line	line	NN
cord-005478-5iu38pr6	621	19	treatments	treatment	NNS
cord-005478-5iu38pr6	621	20	.	.	.
cord-005478-5iu38pr6	622	1	Results	result	NNS
cord-005478-5iu38pr6	622	2	:	:	:
cord-005478-5iu38pr6	623	1	2856	2856	CD
cord-005478-5iu38pr6	623	2	paediatric	paediatric	JJ
cord-005478-5iu38pr6	623	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	623	4	were	be	VBD
cord-005478-5iu38pr6	623	5	performed	perform	VBN
cord-005478-5iu38pr6	623	6	in	in	IN
cord-005478-5iu38pr6	623	7	16	16	CD
cord-005478-5iu38pr6	623	8	French	french	JJ
cord-005478-5iu38pr6	623	9	paediatric	paediatric	JJ
cord-005478-5iu38pr6	623	10	centers	center	NNS
cord-005478-5iu38pr6	623	11	between	between	IN
cord-005478-5iu38pr6	623	12	2007	2007	CD
cord-005478-5iu38pr6	623	13	and	and	CC
cord-005478-5iu38pr6	623	14	2018	2018	CD
cord-005478-5iu38pr6	623	15	.	.	.
cord-005478-5iu38pr6	624	1	Among	among	IN
cord-005478-5iu38pr6	624	2	them	-PRON-	PRP
cord-005478-5iu38pr6	624	3	,	,	,
cord-005478-5iu38pr6	624	4	36	36	CD
cord-005478-5iu38pr6	624	5	children	child	NNS
cord-005478-5iu38pr6	624	6	developed	develop	VBD
cord-005478-5iu38pr6	624	7	an	an	DT
cord-005478-5iu38pr6	624	8	AIC	AIC	NNP
cord-005478-5iu38pr6	624	9	:	:	:
cord-005478-5iu38pr6	624	10	30	30	CD
cord-005478-5iu38pr6	624	11	AIHA	AIHA	NNP
cord-005478-5iu38pr6	624	12	,	,	,
cord-005478-5iu38pr6	624	13	1	1	CD
cord-005478-5iu38pr6	624	14	pancytopenia	pancytopenia	NNP
cord-005478-5iu38pr6	624	15	and	and	CC
cord-005478-5iu38pr6	624	16	5	5	CD
cord-005478-5iu38pr6	624	17	Evans	Evans	NNP
cord-005478-5iu38pr6	624	18	syndromes	syndrome	NNS
cord-005478-5iu38pr6	624	19	.	.	.
cord-005478-5iu38pr6	625	1	The	the	DT
cord-005478-5iu38pr6	625	2	median	median	JJ
cord-005478-5iu38pr6	625	3	age	age	NN
cord-005478-5iu38pr6	625	4	at	at	IN
cord-005478-5iu38pr6	625	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	625	6	was	be	VBD
cord-005478-5iu38pr6	625	7	4,9	4,9	CD
cord-005478-5iu38pr6	625	8	years	year	NNS
cord-005478-5iu38pr6	625	9	old	old	JJ
cord-005478-5iu38pr6	625	10	(	(	-LRB-
cord-005478-5iu38pr6	625	11	0	0	NFP
cord-005478-5iu38pr6	625	12	,	,	,
cord-005478-5iu38pr6	625	13	[	[	-LRB-
cord-005478-5iu38pr6	625	14	3	3	CD
cord-005478-5iu38pr6	625	15	]	]	-RRB-
cord-005478-5iu38pr6	625	16	[	[	-LRB-
cord-005478-5iu38pr6	625	17	4	4	CD
cord-005478-5iu38pr6	625	18	]	]	-RRB-
cord-005478-5iu38pr6	625	19	[	[	-LRB-
cord-005478-5iu38pr6	625	20	5	5	CD
cord-005478-5iu38pr6	625	21	]	]	-RRB-
cord-005478-5iu38pr6	625	22	[	[	-LRB-
cord-005478-5iu38pr6	625	23	6	6	CD
cord-005478-5iu38pr6	625	24	]	]	-RRB-
cord-005478-5iu38pr6	625	25	[	[	-LRB-
cord-005478-5iu38pr6	625	26	7	7	CD
cord-005478-5iu38pr6	625	27	]	]	-RRB-
cord-005478-5iu38pr6	625	28	[	[	-LRB-
cord-005478-5iu38pr6	625	29	8	8	CD
cord-005478-5iu38pr6	625	30	]	]	-RRB-
cord-005478-5iu38pr6	625	31	[	[	-LRB-
cord-005478-5iu38pr6	625	32	9	9	CD
cord-005478-5iu38pr6	625	33	]	]	-RRB-
cord-005478-5iu38pr6	625	34	[	[	-LRB-
cord-005478-5iu38pr6	625	35	10	10	CD
cord-005478-5iu38pr6	625	36	]	]	-RRB-
cord-005478-5iu38pr6	625	37	[	[	-LRB-
cord-005478-5iu38pr6	625	38	11	11	CD
cord-005478-5iu38pr6	625	39	]	]	-RRB-
cord-005478-5iu38pr6	625	40	[	[	-LRB-
cord-005478-5iu38pr6	625	41	12	12	CD
cord-005478-5iu38pr6	625	42	]	]	-RRB-
cord-005478-5iu38pr6	625	43	[	[	-LRB-
cord-005478-5iu38pr6	625	44	13	13	CD
cord-005478-5iu38pr6	625	45	]	]	-RRB-
cord-005478-5iu38pr6	625	46	[	[	-LRB-
cord-005478-5iu38pr6	625	47	14	14	CD
cord-005478-5iu38pr6	625	48	]	]	-RRB-
cord-005478-5iu38pr6	625	49	8)	8)	NN
cord-005478-5iu38pr6	625	50	.	.	.
cord-005478-5iu38pr6	626	1	Average	average	JJ
cord-005478-5iu38pr6	626	2	delay	delay	NN
cord-005478-5iu38pr6	626	3	between	between	IN
cord-005478-5iu38pr6	626	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	626	5	and	and	CC
cord-005478-5iu38pr6	626	6	AIC	AIC	NNP
cord-005478-5iu38pr6	626	7	was	be	VBD
cord-005478-5iu38pr6	626	8	192	192	CD
cord-005478-5iu38pr6	626	9	days	day	NNS
cord-005478-5iu38pr6	626	10	(	(	-LRB-
cord-005478-5iu38pr6	626	11	20	20	CD
cord-005478-5iu38pr6	626	12	-	-	SYM
cord-005478-5iu38pr6	626	13	600	600	CD
cord-005478-5iu38pr6	626	14	)	)	-RRB-
cord-005478-5iu38pr6	626	15	.	.	.
cord-005478-5iu38pr6	627	1	The	the	DT
cord-005478-5iu38pr6	627	2	median	median	JJ
cord-005478-5iu38pr6	627	3	follow	follow	NN
cord-005478-5iu38pr6	627	4	-	-	HYPH
cord-005478-5iu38pr6	627	5	up	up	NN
cord-005478-5iu38pr6	627	6	after	after	IN
cord-005478-5iu38pr6	627	7	transplant	transplant	NN
cord-005478-5iu38pr6	627	8	was	be	VBD
cord-005478-5iu38pr6	627	9	35,8	35,8	CD
cord-005478-5iu38pr6	627	10	months	month	NNS
cord-005478-5iu38pr6	627	11	(	(	-LRB-
cord-005478-5iu38pr6	627	12	5	5	CD
cord-005478-5iu38pr6	627	13	-	-	SYM
cord-005478-5iu38pr6	627	14	94	94	CD
cord-005478-5iu38pr6	627	15	)	)	-RRB-
cord-005478-5iu38pr6	627	16	.	.	.
cord-005478-5iu38pr6	628	1	23	23	CD
cord-005478-5iu38pr6	628	2	patients	patient	NNS
cord-005478-5iu38pr6	628	3	were	be	VBD
cord-005478-5iu38pr6	628	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	628	5	for	for	IN
cord-005478-5iu38pr6	628	6	non	non	JJ
cord-005478-5iu38pr6	628	7	-	-	JJ
cord-005478-5iu38pr6	628	8	malignant	malignant	JJ
cord-005478-5iu38pr6	628	9	disease	disease	NN
cord-005478-5iu38pr6	628	10	(	(	-LRB-
cord-005478-5iu38pr6	628	11	12	12	CD
cord-005478-5iu38pr6	628	12	benign	benign	JJ
cord-005478-5iu38pr6	628	13	hemopathies	hemopathie	NNS
cord-005478-5iu38pr6	628	14	,	,	,
cord-005478-5iu38pr6	628	15	11	11	CD
cord-005478-5iu38pr6	628	16	immunodeficiencies	immunodeficiency	NNS
cord-005478-5iu38pr6	628	17	)	)	-RRB-
cord-005478-5iu38pr6	628	18	and	and	CC
cord-005478-5iu38pr6	628	19	13	13	CD
cord-005478-5iu38pr6	628	20	for	for	IN
cord-005478-5iu38pr6	628	21	a	a	DT
cord-005478-5iu38pr6	628	22	malignant	malignant	JJ
cord-005478-5iu38pr6	628	23	one	one	CD
cord-005478-5iu38pr6	628	24	.	.	.
cord-005478-5iu38pr6	629	1	Stem	stem	JJ
cord-005478-5iu38pr6	629	2	cell	cell	NN
cord-005478-5iu38pr6	629	3	source	source	NN
cord-005478-5iu38pr6	629	4	was	be	VBD
cord-005478-5iu38pr6	629	5	bone	bone	NN
cord-005478-5iu38pr6	629	6	marrow	marrow	NN
cord-005478-5iu38pr6	629	7	for	for	IN
cord-005478-5iu38pr6	629	8	50	50	CD
cord-005478-5iu38pr6	629	9	%	%	NN
cord-005478-5iu38pr6	629	10	of	of	IN
cord-005478-5iu38pr6	629	11	patients	patient	NNS
cord-005478-5iu38pr6	629	12	,	,	,
cord-005478-5iu38pr6	629	13	peripheral	peripheral	JJ
cord-005478-5iu38pr6	629	14	blood	blood	NN
cord-005478-5iu38pr6	629	15	stem	stem	NN
cord-005478-5iu38pr6	629	16	cells	cell	NNS
cord-005478-5iu38pr6	629	17	for	for	IN
cord-005478-5iu38pr6	629	18	29	29	CD
cord-005478-5iu38pr6	629	19	%	%	NN
cord-005478-5iu38pr6	629	20	and	and	CC
cord-005478-5iu38pr6	629	21	cord	cord	NN
cord-005478-5iu38pr6	629	22	blood	blood	NN
cord-005478-5iu38pr6	629	23	for	for	IN
cord-005478-5iu38pr6	629	24	12	12	CD
cord-005478-5iu38pr6	629	25	%	%	NN
cord-005478-5iu38pr6	629	26	.	.	.
cord-005478-5iu38pr6	630	1	The	the	DT
cord-005478-5iu38pr6	630	2	donor	donor	NN
cord-005478-5iu38pr6	630	3	was	be	VBD
cord-005478-5iu38pr6	630	4	unrelated	unrelated	JJ
cord-005478-5iu38pr6	630	5	for	for	IN
cord-005478-5iu38pr6	630	6	65	65	CD
cord-005478-5iu38pr6	630	7	%	%	NN
cord-005478-5iu38pr6	630	8	of	of	IN
cord-005478-5iu38pr6	630	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	630	10	,	,	,
cord-005478-5iu38pr6	630	11	matched	match	VBD
cord-005478-5iu38pr6	630	12	related	relate	VBN
cord-005478-5iu38pr6	630	13	for	for	IN
cord-005478-5iu38pr6	630	14	15	15	CD
cord-005478-5iu38pr6	630	15	%	%	NN
cord-005478-5iu38pr6	630	16	and	and	CC
cord-005478-5iu38pr6	630	17	12	12	CD
cord-005478-5iu38pr6	630	18	%	%	NN
cord-005478-5iu38pr6	630	19	of	of	IN
cord-005478-5iu38pr6	630	20	procedures	procedure	NNS
cord-005478-5iu38pr6	630	21	were	be	VBD
cord-005478-5iu38pr6	630	22	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	630	23	.	.	.
cord-005478-5iu38pr6	631	1	76	76	CD
cord-005478-5iu38pr6	631	2	%	%	NN
cord-005478-5iu38pr6	631	3	of	of	IN
cord-005478-5iu38pr6	631	4	patients	patient	NNS
cord-005478-5iu38pr6	631	5	received	receive	VBD
cord-005478-5iu38pr6	631	6	ALS	als	NN
cord-005478-5iu38pr6	631	7	as	as	IN
cord-005478-5iu38pr6	631	8	part	part	NN
cord-005478-5iu38pr6	631	9	of	of	IN
cord-005478-5iu38pr6	631	10	their	-PRON-	PRP$
cord-005478-5iu38pr6	631	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	631	12	regimen	regimen	NN
cord-005478-5iu38pr6	631	13	,	,	,
cord-005478-5iu38pr6	631	14	it	-PRON-	PRP
cord-005478-5iu38pr6	631	15	was	be	VBD
cord-005478-5iu38pr6	631	16	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	631	17	in	in	IN
cord-005478-5iu38pr6	631	18	65	65	CD
cord-005478-5iu38pr6	631	19	%	%	NN
cord-005478-5iu38pr6	632	1	(	(	-LRB-
cord-005478-5iu38pr6	632	2	TBI	TBI	NNP
cord-005478-5iu38pr6	632	3	based	base	VBN
cord-005478-5iu38pr6	632	4	for	for	IN
cord-005478-5iu38pr6	632	5	6	6	CD
cord-005478-5iu38pr6	632	6	%	%	NN
cord-005478-5iu38pr6	632	7	)	)	-RRB-
cord-005478-5iu38pr6	632	8	and	and	CC
cord-005478-5iu38pr6	632	9	reduced	reduce	VBN
cord-005478-5iu38pr6	632	10	intensity	intensity	NN
cord-005478-5iu38pr6	632	11	in	in	IN
cord-005478-5iu38pr6	632	12	20	20	CD
cord-005478-5iu38pr6	632	13	%	%	NN
cord-005478-5iu38pr6	632	14	.	.	.
cord-005478-5iu38pr6	633	1	Direct	direct	JJ
cord-005478-5iu38pr6	633	2	anti	anti	JJ
cord-005478-5iu38pr6	633	3	-	-	JJ
cord-005478-5iu38pr6	633	4	globulin	globulin	JJ
cord-005478-5iu38pr6	633	5	test	test	NN
cord-005478-5iu38pr6	633	6	(	(	-LRB-
cord-005478-5iu38pr6	633	7	DAT	DAT	NNP
cord-005478-5iu38pr6	633	8	)	)	-RRB-
cord-005478-5iu38pr6	633	9	was	be	VBD
cord-005478-5iu38pr6	633	10	positive	positive	JJ
cord-005478-5iu38pr6	633	11	to	to	IN
cord-005478-5iu38pr6	633	12	IgG	IgG	NNP
cord-005478-5iu38pr6	633	13	+	+	CC
cord-005478-5iu38pr6	633	14	/-C3d	/-C3d	.
cord-005478-5iu38pr6	634	1	for	for	IN
cord-005478-5iu38pr6	634	2	52	52	CD
cord-005478-5iu38pr6	634	3	%	%	NN
cord-005478-5iu38pr6	634	4	of	of	IN
cord-005478-5iu38pr6	634	5	patients	patient	NNS
cord-005478-5iu38pr6	634	6	,	,	,
cord-005478-5iu38pr6	634	7	16	16	CD
cord-005478-5iu38pr6	634	8	patients	patient	NNS
cord-005478-5iu38pr6	634	9	had	have	VBD
cord-005478-5iu38pr6	634	10	a	a	DT
cord-005478-5iu38pr6	634	11	blood	blood	NN
cord-005478-5iu38pr6	634	12	group	group	NN
cord-005478-5iu38pr6	634	13	incompatibility	incompatibility	NN
cord-005478-5iu38pr6	634	14	(	(	-LRB-
cord-005478-5iu38pr6	634	15	8	8	CD
cord-005478-5iu38pr6	634	16	minor	minor	JJ
cord-005478-5iu38pr6	634	17	and	and	CC
cord-005478-5iu38pr6	634	18	8	8	CD
cord-005478-5iu38pr6	634	19	major	major	NN
cord-005478-5iu38pr6	634	20	)	)	-RRB-
cord-005478-5iu38pr6	634	21	.	.	.
cord-005478-5iu38pr6	635	1	64	64	CD
cord-005478-5iu38pr6	635	2	%	%	NN
cord-005478-5iu38pr6	635	3	of	of	IN
cord-005478-5iu38pr6	635	4	patients	patient	NNS
cord-005478-5iu38pr6	635	5	had	have	VBD
cord-005478-5iu38pr6	635	6	an	an	DT
cord-005478-5iu38pr6	635	7	acute	acute	JJ
cord-005478-5iu38pr6	635	8	GvH	gvh	NN
cord-005478-5iu38pr6	635	9	and	and	CC
cord-005478-5iu38pr6	635	10	chronic	chronic	JJ
cord-005478-5iu38pr6	635	11	GvH	gvh	NN
cord-005478-5iu38pr6	635	12	on	on	IN
cord-005478-5iu38pr6	635	13	time	time	NN
cord-005478-5iu38pr6	635	14	of	of	IN
cord-005478-5iu38pr6	635	15	AIHA	AIHA	NNP
cord-005478-5iu38pr6	635	16	was	be	VBD
cord-005478-5iu38pr6	635	17	find	find	VBN
cord-005478-5iu38pr6	635	18	in	in	IN
cord-005478-5iu38pr6	635	19	12	12	CD
cord-005478-5iu38pr6	635	20	%	%	NN
cord-005478-5iu38pr6	635	21	of	of	IN
cord-005478-5iu38pr6	635	22	patients	patient	NNS
cord-005478-5iu38pr6	635	23	.	.	.
cord-005478-5iu38pr6	636	1	For	for	IN
cord-005478-5iu38pr6	636	2	70	70	CD
cord-005478-5iu38pr6	636	3	%	%	NN
cord-005478-5iu38pr6	636	4	of	of	IN
cord-005478-5iu38pr6	636	5	patients	patient	NNS
cord-005478-5iu38pr6	636	6	the	the	DT
cord-005478-5iu38pr6	636	7	first	first	JJ
cord-005478-5iu38pr6	636	8	line	line	NN
cord-005478-5iu38pr6	636	9	treatment	treatment	NN
cord-005478-5iu38pr6	636	10	was	be	VBD
cord-005478-5iu38pr6	636	11	a	a	DT
cord-005478-5iu38pr6	636	12	combination	combination	NN
cord-005478-5iu38pr6	636	13	of	of	IN
cord-005478-5iu38pr6	636	14	steroids	steroid	NNS
cord-005478-5iu38pr6	636	15	(	(	-LRB-
cord-005478-5iu38pr6	636	16	2mg	2mg	NNP
cord-005478-5iu38pr6	636	17	/	/	SYM
cord-005478-5iu38pr6	636	18	kg	kg	NN
cord-005478-5iu38pr6	636	19	/	/	SYM
cord-005478-5iu38pr6	636	20	day	day	NN
cord-005478-5iu38pr6	636	21	)	)	-RRB-
cord-005478-5iu38pr6	636	22	,	,	,
cord-005478-5iu38pr6	636	23	intravenous	intravenous	JJ
cord-005478-5iu38pr6	636	24	immunoglobulin	immunoglobulin	NN
cord-005478-5iu38pr6	636	25	and	and	CC
cord-005478-5iu38pr6	636	26	rituximab	rituximab	NN
cord-005478-5iu38pr6	636	27	(	(	-LRB-
cord-005478-5iu38pr6	636	28	375mg	375mg	NNP
cord-005478-5iu38pr6	636	29	/	/	SYM
cord-005478-5iu38pr6	636	30	m	m	NN
cord-005478-5iu38pr6	636	31	2	2	CD
cord-005478-5iu38pr6	636	32	per	per	IN
cord-005478-5iu38pr6	636	33	week	week	NN
cord-005478-5iu38pr6	636	34	)	)	-RRB-
cord-005478-5iu38pr6	636	35	.	.	.
cord-005478-5iu38pr6	637	1	For	for	IN
cord-005478-5iu38pr6	637	2	41	41	CD
cord-005478-5iu38pr6	637	3	%	%	NN
cord-005478-5iu38pr6	637	4	of	of	IN
cord-005478-5iu38pr6	637	5	patients	patient	NNS
cord-005478-5iu38pr6	637	6	a	a	DT
cord-005478-5iu38pr6	637	7	second	second	JJ
cord-005478-5iu38pr6	637	8	or	or	CC
cord-005478-5iu38pr6	637	9	third	third	JJ
cord-005478-5iu38pr6	637	10	-	-	HYPH
cord-005478-5iu38pr6	637	11	line	line	NN
cord-005478-5iu38pr6	637	12	treatment	treatment	NN
cord-005478-5iu38pr6	637	13	was	be	VBD
cord-005478-5iu38pr6	637	14	required	require	VBN
cord-005478-5iu38pr6	637	15	(	(	-LRB-
cord-005478-5iu38pr6	637	16	Imurel	Imurel	NNP
cord-005478-5iu38pr6	637	17	,	,	,
cord-005478-5iu38pr6	637	18	Cellcept	Cellcept	NNP
cord-005478-5iu38pr6	637	19	,	,	,
cord-005478-5iu38pr6	637	20	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	637	21	,	,	,
cord-005478-5iu38pr6	637	22	Sirolimus	Sirolimus	NNP
cord-005478-5iu38pr6	637	23	,	,	,
cord-005478-5iu38pr6	637	24	Campath	Campath	NNP
cord-005478-5iu38pr6	637	25	,	,	,
cord-005478-5iu38pr6	637	26	Bortezomib	Bortezomib	NNP
cord-005478-5iu38pr6	637	27	)	)	-RRB-
cord-005478-5iu38pr6	637	28	.	.	.
cord-005478-5iu38pr6	638	1	8	8	CD
cord-005478-5iu38pr6	638	2	patients	patient	NNS
cord-005478-5iu38pr6	638	3	died	die	VBD
cord-005478-5iu38pr6	638	4	(	(	-LRB-
cord-005478-5iu38pr6	638	5	4	4	CD
cord-005478-5iu38pr6	638	6	relapse	relapse	NN
cord-005478-5iu38pr6	638	7	,	,	,
cord-005478-5iu38pr6	638	8	2	2	CD
cord-005478-5iu38pr6	638	9	infections	infection	NNS
cord-005478-5iu38pr6	638	10	and	and	CC
cord-005478-5iu38pr6	638	11	1	1	CD
cord-005478-5iu38pr6	638	12	severe	severe	JJ
cord-005478-5iu38pr6	638	13	anaemia	anaemia	NN
cord-005478-5iu38pr6	638	14	,	,	,
cord-005478-5iu38pr6	638	15	1	1	CD
cord-005478-5iu38pr6	638	16	multiple	multiple	JJ
cord-005478-5iu38pr6	638	17	organ	organ	NN
cord-005478-5iu38pr6	638	18	failure	failure	NN
cord-005478-5iu38pr6	638	19	)	)	-RRB-
cord-005478-5iu38pr6	638	20	.	.	.
cord-005478-5iu38pr6	639	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	639	2	:	:	:
cord-005478-5iu38pr6	640	1	This	this	DT
cord-005478-5iu38pr6	640	2	is	be	VBZ
cord-005478-5iu38pr6	640	3	the	the	DT
cord-005478-5iu38pr6	640	4	first	first	JJ
cord-005478-5iu38pr6	640	5	study	study	NN
cord-005478-5iu38pr6	640	6	describing	describe	VBG
cord-005478-5iu38pr6	640	7	precisely	precisely	RB
cord-005478-5iu38pr6	640	8	the	the	DT
cord-005478-5iu38pr6	640	9	AIHA	AIHA	NNP
cord-005478-5iu38pr6	640	10	post	post	NN
cord-005478-5iu38pr6	640	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	640	12	in	in	IN
cord-005478-5iu38pr6	640	13	pediatrics	pediatric	NNS
cord-005478-5iu38pr6	640	14	in	in	IN
cord-005478-5iu38pr6	640	15	France	France	NNP
cord-005478-5iu38pr6	640	16	along	along	IN
cord-005478-5iu38pr6	640	17	with	with	IN
cord-005478-5iu38pr6	640	18	the	the	DT
cord-005478-5iu38pr6	640	19	various	various	JJ
cord-005478-5iu38pr6	640	20	treatments	treatment	NNS
cord-005478-5iu38pr6	640	21	used	use	VBN
cord-005478-5iu38pr6	640	22	.	.	.
cord-005478-5iu38pr6	641	1	It	-PRON-	PRP
cord-005478-5iu38pr6	641	2	's	be	VBZ
cord-005478-5iu38pr6	641	3	a	a	DT
cord-005478-5iu38pr6	641	4	rare	rare	JJ
cord-005478-5iu38pr6	641	5	but	but	CC
cord-005478-5iu38pr6	641	6	severe	severe	JJ
cord-005478-5iu38pr6	641	7	complication	complication	NN
cord-005478-5iu38pr6	641	8	with	with	IN
cord-005478-5iu38pr6	641	9	multiple	multiple	JJ
cord-005478-5iu38pr6	641	10	risk	risk	NN
cord-005478-5iu38pr6	641	11	factors	factor	NNS
cord-005478-5iu38pr6	641	12	associated	associate	VBN
cord-005478-5iu38pr6	641	13	with	with	IN
cord-005478-5iu38pr6	641	14	a	a	DT
cord-005478-5iu38pr6	641	15	high	high	JJ
cord-005478-5iu38pr6	641	16	mortality	mortality	NN
cord-005478-5iu38pr6	641	17	rate	rate	NN
cord-005478-5iu38pr6	641	18	and	and	CC
cord-005478-5iu38pr6	641	19	no	no	DT
cord-005478-5iu38pr6	641	20	standardized	standardized	JJ
cord-005478-5iu38pr6	641	21	therapy	therapy	NN
cord-005478-5iu38pr6	641	22	at	at	IN
cord-005478-5iu38pr6	641	23	this	this	DT
cord-005478-5iu38pr6	641	24	time	time	NN
cord-005478-5iu38pr6	641	25	.	.	.
cord-005478-5iu38pr6	642	1	Further	further	JJ
cord-005478-5iu38pr6	642	2	studies	study	NNS
cord-005478-5iu38pr6	642	3	would	would	MD
cord-005478-5iu38pr6	642	4	allow	allow	VB
cord-005478-5iu38pr6	642	5	us	-PRON-	PRP
cord-005478-5iu38pr6	642	6	to	to	TO
cord-005478-5iu38pr6	642	7	understand	understand	VB
cord-005478-5iu38pr6	642	8	the	the	DT
cord-005478-5iu38pr6	642	9	disease	disease	NN
cord-005478-5iu38pr6	642	10	better	well	RBR
cord-005478-5iu38pr6	642	11	in	in	IN
cord-005478-5iu38pr6	642	12	order	order	NN
cord-005478-5iu38pr6	642	13	to	to	TO
cord-005478-5iu38pr6	642	14	prevent	prevent	VB
cord-005478-5iu38pr6	642	15	its	-PRON-	PRP$
cord-005478-5iu38pr6	642	16	occurrence	occurrence	NN
cord-005478-5iu38pr6	642	17	and	and	CC
cord-005478-5iu38pr6	642	18	treat	treat	VB
cord-005478-5iu38pr6	642	19	it	-PRON-	PRP
cord-005478-5iu38pr6	642	20	more	more	RBR
cord-005478-5iu38pr6	642	21	efficiently	efficiently	RB
cord-005478-5iu38pr6	642	22	.	.	.
cord-005478-5iu38pr6	643	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	643	2	:	:	:
cord-005478-5iu38pr6	643	3	Nothing	nothing	NN
cord-005478-5iu38pr6	643	4	to	to	TO
cord-005478-5iu38pr6	643	5	declare	declare	VB
cord-005478-5iu38pr6	643	6	Background	background	NN
cord-005478-5iu38pr6	643	7	:	:	:
cord-005478-5iu38pr6	644	1	The	the	DT
cord-005478-5iu38pr6	644	2	prognosis	prognosis	NN
cord-005478-5iu38pr6	644	3	of	of	IN
cord-005478-5iu38pr6	644	4	relapsed	relapse	VBN
cord-005478-5iu38pr6	644	5	/	/	SYM
cord-005478-5iu38pr6	644	6	refractory	refractory	JJ
cord-005478-5iu38pr6	644	7	acute	acute	JJ
cord-005478-5iu38pr6	644	8	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	644	9	leukemia	leukemia	NN
cord-005478-5iu38pr6	644	10	(	(	-LRB-
cord-005478-5iu38pr6	644	11	ALL	all	DT
cord-005478-5iu38pr6	644	12	)	)	-RRB-
cord-005478-5iu38pr6	644	13	,	,	,
cord-005478-5iu38pr6	644	14	non	non	JJ
cord-005478-5iu38pr6	644	15	Hodgkin	Hodgkin	NNP
cord-005478-5iu38pr6	644	16	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	644	17	(	(	-LRB-
cord-005478-5iu38pr6	644	18	NHL	NHL	NNP
cord-005478-5iu38pr6	644	19	)	)	-RRB-
cord-005478-5iu38pr6	644	20	or	or	CC
cord-005478-5iu38pr6	644	21	chronic	chronic	JJ
cord-005478-5iu38pr6	644	22	lymphocytic	lymphocytic	JJ
cord-005478-5iu38pr6	644	23	leukemia	leukemia	NN
cord-005478-5iu38pr6	644	24	(	(	-LRB-
cord-005478-5iu38pr6	644	25	CLL	CLL	NNP
cord-005478-5iu38pr6	644	26	)	)	-RRB-
cord-005478-5iu38pr6	644	27	is	be	VBZ
cord-005478-5iu38pr6	644	28	very	very	RB
cord-005478-5iu38pr6	644	29	poor	poor	JJ
cord-005478-5iu38pr6	644	30	,	,	,
cord-005478-5iu38pr6	644	31	particularly	particularly	RB
cord-005478-5iu38pr6	644	32	in	in	IN
cord-005478-5iu38pr6	644	33	patients	patient	NNS
cord-005478-5iu38pr6	644	34	relapsing	relapse	VBG
cord-005478-5iu38pr6	644	35	after	after	IN
cord-005478-5iu38pr6	644	36	autologous	autologous	JJ
cord-005478-5iu38pr6	644	37	(	(	-LRB-
cord-005478-5iu38pr6	644	38	autoHCT	autoHCT	NNP
cord-005478-5iu38pr6	644	39	)	)	-RRB-
cord-005478-5iu38pr6	644	40	or	or	CC
cord-005478-5iu38pr6	644	41	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	644	42	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	644	43	cell	cell	NN
cord-005478-5iu38pr6	644	44	transplantation	transplantation	NN
cord-005478-5iu38pr6	644	45	(	(	-LRB-
cord-005478-5iu38pr6	644	46	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	644	47	)	)	-RRB-
cord-005478-5iu38pr6	644	48	.	.	.
cord-005478-5iu38pr6	645	1	In	in	IN
cord-005478-5iu38pr6	645	2	the	the	DT
cord-005478-5iu38pr6	645	3	last	last	JJ
cord-005478-5iu38pr6	645	4	decade	decade	NN
cord-005478-5iu38pr6	645	5	,	,	,
cord-005478-5iu38pr6	645	6	several	several	JJ
cord-005478-5iu38pr6	645	7	chimeric	chimeric	JJ
cord-005478-5iu38pr6	645	8	antigen	antigen	NN
cord-005478-5iu38pr6	645	9	receptor	receptor	NN
cord-005478-5iu38pr6	645	10	anti	anti	NNP
cord-005478-5iu38pr6	645	11	-	-	JJ
cord-005478-5iu38pr6	645	12	CD19	cd19	JJ
cord-005478-5iu38pr6	645	13	(	(	-LRB-
cord-005478-5iu38pr6	645	14	CAR19	CAR19	NNP
cord-005478-5iu38pr6	645	15	)	)	-RRB-
cord-005478-5iu38pr6	645	16	constructs	construct	NNS
cord-005478-5iu38pr6	645	17	have	have	VBP
cord-005478-5iu38pr6	645	18	been	be	VBN
cord-005478-5iu38pr6	645	19	developed	develop	VBN
cord-005478-5iu38pr6	645	20	.	.	.
cord-005478-5iu38pr6	646	1	Two	two	CD
cord-005478-5iu38pr6	646	2	of	of	IN
cord-005478-5iu38pr6	646	3	them	-PRON-	PRP
cord-005478-5iu38pr6	646	4	(	(	-LRB-
cord-005478-5iu38pr6	646	5	tisa	tisa	NNP
cord-005478-5iu38pr6	646	6	-	-	HYPH
cord-005478-5iu38pr6	646	7	cel	cel	NNP
cord-005478-5iu38pr6	646	8	and	and	CC
cord-005478-5iu38pr6	646	9	axi	axi	NNP
cord-005478-5iu38pr6	646	10	-	-	HYPH
cord-005478-5iu38pr6	646	11	cel	cel	NNP
cord-005478-5iu38pr6	646	12	)	)	-RRB-
cord-005478-5iu38pr6	646	13	are	be	VBP
cord-005478-5iu38pr6	646	14	already	already	RB
cord-005478-5iu38pr6	646	15	approved	approve	VBN
cord-005478-5iu38pr6	646	16	by	by	IN
cord-005478-5iu38pr6	646	17	the	the	DT
cord-005478-5iu38pr6	646	18	FDA	FDA	NNP
cord-005478-5iu38pr6	646	19	and	and	CC
cord-005478-5iu38pr6	646	20	EMA	EMA	NNP
cord-005478-5iu38pr6	646	21	for	for	IN
cord-005478-5iu38pr6	646	22	ALL	all	DT
cord-005478-5iu38pr6	646	23	and	and	CC
cord-005478-5iu38pr6	646	24	NHL	NHL	NNP
cord-005478-5iu38pr6	646	25	.	.	.
cord-005478-5iu38pr6	647	1	However	however	RB
cord-005478-5iu38pr6	647	2	,	,	,
cord-005478-5iu38pr6	647	3	the	the	DT
cord-005478-5iu38pr6	647	4	availability	availability	NN
cord-005478-5iu38pr6	647	5	and	and	CC
cord-005478-5iu38pr6	647	6	affordability	affordability	NN
cord-005478-5iu38pr6	647	7	of	of	IN
cord-005478-5iu38pr6	647	8	these	these	DT
cord-005478-5iu38pr6	647	9	commercial	commercial	JJ
cord-005478-5iu38pr6	647	10	CARTs	cart	NNS
cord-005478-5iu38pr6	647	11	remains	remain	VBZ
cord-005478-5iu38pr6	647	12	a	a	DT
cord-005478-5iu38pr6	647	13	challenge	challenge	NN
cord-005478-5iu38pr6	647	14	in	in	IN
cord-005478-5iu38pr6	647	15	Europe	Europe	NNP
cord-005478-5iu38pr6	647	16	.	.	.
cord-005478-5iu38pr6	648	1	Methods	method	NNS
cord-005478-5iu38pr6	648	2	:	:	:
cord-005478-5iu38pr6	649	1	The	the	DT
cord-005478-5iu38pr6	649	2	first	first	JJ
cord-005478-5iu38pr6	649	3	academic	academic	JJ
cord-005478-5iu38pr6	649	4	pilot	pilot	NN
cord-005478-5iu38pr6	649	5	clinical	clinical	JJ
cord-005478-5iu38pr6	649	6	trial	trial	NN
cord-005478-5iu38pr6	649	7	(	(	-LRB-
cord-005478-5iu38pr6	649	8	clinicaltrials.gov	clinicaltrials.gov	NNP
cord-005478-5iu38pr6	649	9	NCT03144583	NCT03144583	NNP
cord-005478-5iu38pr6	649	10	)	)	-RRB-
cord-005478-5iu38pr6	649	11	using	use	VBG
cord-005478-5iu38pr6	649	12	our	-PRON-	PRP$
cord-005478-5iu38pr6	649	13	fully	fully	RB
cord-005478-5iu38pr6	649	14	academic	academic	JJ
cord-005478-5iu38pr6	649	15	(	(	-LRB-
cord-005478-5iu38pr6	649	16	A3B1	A3B1	NNP
cord-005478-5iu38pr6	649	17	:	:	:
cord-005478-5iu38pr6	649	18	CD8:4	CD8:4	NNP
cord-005478-5iu38pr6	649	19	-	-	HYPH
cord-005478-5iu38pr6	649	20	1BB	1BB	NNP
cord-005478-5iu38pr6	649	21	:	:	:
cord-005478-5iu38pr6	650	1	CD3Z	CD3Z	NNP
cord-005478-5iu38pr6	650	2	)	)	-RRB-
cord-005478-5iu38pr6	650	3	CAR19	CAR19	NNP
cord-005478-5iu38pr6	650	4	was	be	VBD
cord-005478-5iu38pr6	650	5	approved	approve	VBN
cord-005478-5iu38pr6	650	6	by	by	IN
cord-005478-5iu38pr6	650	7	the	the	DT
cord-005478-5iu38pr6	650	8	Spanish	Spanish	NNP
cord-005478-5iu38pr6	650	9	Agency	Agency	NNP
cord-005478-5iu38pr6	650	10	of	of	IN
cord-005478-5iu38pr6	650	11	Medicines	Medicines	NNPS
cord-005478-5iu38pr6	650	12	on	on	IN
cord-005478-5iu38pr6	650	13	May/2017	May/2017	NNPS
cord-005478-5iu38pr6	650	14	.	.	.
cord-005478-5iu38pr6	651	1	Eligibility	eligibility	NN
cord-005478-5iu38pr6	651	2	criteria	criterion	NNS
cord-005478-5iu38pr6	651	3	included	include	VBD
cord-005478-5iu38pr6	651	4	R	r	NN
cord-005478-5iu38pr6	651	5	/	/	SYM
cord-005478-5iu38pr6	651	6	R	r	NN
cord-005478-5iu38pr6	651	7	ALL	all	DT
cord-005478-5iu38pr6	651	8	(	(	-LRB-
cord-005478-5iu38pr6	651	9	adult	adult	NN
cord-005478-5iu38pr6	651	10	and	and	CC
cord-005478-5iu38pr6	651	11	pediatric	pediatric	JJ
cord-005478-5iu38pr6	651	12	)	)	-RRB-
cord-005478-5iu38pr6	651	13	,	,	,
cord-005478-5iu38pr6	651	14	NHL	NHL	NNP
cord-005478-5iu38pr6	651	15	and	and	CC
cord-005478-5iu38pr6	651	16	CLL	CLL	NNP
cord-005478-5iu38pr6	651	17	who	who	WP
cord-005478-5iu38pr6	651	18	had	have	VBD
cord-005478-5iu38pr6	651	19	failed	fail	VBN
cord-005478-5iu38pr6	651	20	standard	standard	JJ
cord-005478-5iu38pr6	651	21	available	available	JJ
cord-005478-5iu38pr6	651	22	therapy	therapy	NN
cord-005478-5iu38pr6	651	23	.	.	.
cord-005478-5iu38pr6	652	1	The	the	DT
cord-005478-5iu38pr6	652	2	primary	primary	JJ
cord-005478-5iu38pr6	652	3	objective	objective	NN
cord-005478-5iu38pr6	652	4	of	of	IN
cord-005478-5iu38pr6	652	5	the	the	DT
cord-005478-5iu38pr6	652	6	study	study	NN
cord-005478-5iu38pr6	652	7	was	be	VBD
cord-005478-5iu38pr6	652	8	safety	safety	NN
cord-005478-5iu38pr6	652	9	,	,	,
cord-005478-5iu38pr6	652	10	and	and	CC
cord-005478-5iu38pr6	652	11	secondary	secondary	JJ
cord-005478-5iu38pr6	652	12	objectives	objective	NNS
cord-005478-5iu38pr6	652	13	were	be	VBD
cord-005478-5iu38pr6	652	14	response	response	NN
cord-005478-5iu38pr6	652	15	rate	rate	NN
cord-005478-5iu38pr6	652	16	and	and	CC
cord-005478-5iu38pr6	652	17	its	-PRON-	PRP$
cord-005478-5iu38pr6	652	18	duration	duration	NN
cord-005478-5iu38pr6	652	19	(	(	-LRB-
cord-005478-5iu38pr6	652	20	progressionfree	progressionfree	NNP
cord-005478-5iu38pr6	652	21	survival	survival	NNP
cord-005478-5iu38pr6	652	22	)	)	-RRB-
cord-005478-5iu38pr6	652	23	.	.	.
cord-005478-5iu38pr6	653	1	Here	here	RB
cord-005478-5iu38pr6	653	2	we	-PRON-	PRP
cord-005478-5iu38pr6	653	3	report	report	VBP
cord-005478-5iu38pr6	653	4	an	an	DT
cord-005478-5iu38pr6	653	5	updated	update	VBN
cord-005478-5iu38pr6	653	6	analysis	analysis	NN
cord-005478-5iu38pr6	653	7	of	of	IN
cord-005478-5iu38pr6	653	8	this	this	DT
cord-005478-5iu38pr6	653	9	trial	trial	NN
cord-005478-5iu38pr6	653	10	.	.	.
cord-005478-5iu38pr6	654	1	Results	result	NNS
cord-005478-5iu38pr6	654	2	:	:	:
cord-005478-5iu38pr6	655	1	As	as	IN
cord-005478-5iu38pr6	655	2	of	of	IN
cord-005478-5iu38pr6	655	3	December/2018	december/2018	NN
cord-005478-5iu38pr6	655	4	we	-PRON-	PRP
cord-005478-5iu38pr6	655	5	have	have	VBP
cord-005478-5iu38pr6	655	6	included	include	VBN
cord-005478-5iu38pr6	655	7	35	35	CD
cord-005478-5iu38pr6	655	8	patients	patient	NNS
cord-005478-5iu38pr6	655	9	in	in	IN
cord-005478-5iu38pr6	655	10	the	the	DT
cord-005478-5iu38pr6	655	11	study	study	NN
cord-005478-5iu38pr6	655	12	.	.	.
cord-005478-5iu38pr6	656	1	Of	of	IN
cord-005478-5iu38pr6	656	2	these	these	DT
cord-005478-5iu38pr6	656	3	,	,	,
cord-005478-5iu38pr6	656	4	we	-PRON-	PRP
cord-005478-5iu38pr6	656	5	performed	perform	VBD
cord-005478-5iu38pr6	656	6	lymphoapheresis	lymphoapheresis	NN
cord-005478-5iu38pr6	656	7	to	to	IN
cord-005478-5iu38pr6	656	8	34	34	CD
cord-005478-5iu38pr6	656	9	and	and	CC
cord-005478-5iu38pr6	656	10	we	-PRON-	PRP
cord-005478-5iu38pr6	656	11	processed	process	VBD
cord-005478-5iu38pr6	656	12	the	the	DT
cord-005478-5iu38pr6	656	13	cells	cell	NNS
cord-005478-5iu38pr6	656	14	of	of	IN
cord-005478-5iu38pr6	656	15	33	33	CD
cord-005478-5iu38pr6	656	16	,	,	,
cord-005478-5iu38pr6	656	17	although	although	IN
cord-005478-5iu38pr6	656	18	for	for	IN
cord-005478-5iu38pr6	656	19	the	the	DT
cord-005478-5iu38pr6	656	20	moment	moment	NN
cord-005478-5iu38pr6	656	21	we	-PRON-	PRP
cord-005478-5iu38pr6	656	22	have	have	VBP
cord-005478-5iu38pr6	656	23	only	only	RB
cord-005478-5iu38pr6	656	24	infused	infuse	VBN
cord-005478-5iu38pr6	656	25	to	to	IN
cord-005478-5iu38pr6	656	26	25	25	CD
cord-005478-5iu38pr6	656	27	of	of	IN
cord-005478-5iu38pr6	656	28	them	-PRON-	PRP
cord-005478-5iu38pr6	656	29	.	.	.
cord-005478-5iu38pr6	657	1	The	the	DT
cord-005478-5iu38pr6	657	2	diagnoses	diagnosis	NNS
cord-005478-5iu38pr6	657	3	of	of	IN
cord-005478-5iu38pr6	657	4	these	these	DT
cord-005478-5iu38pr6	657	5	25	25	CD
cord-005478-5iu38pr6	657	6	patients	patient	NNS
cord-005478-5iu38pr6	657	7	were	be	VBD
cord-005478-5iu38pr6	657	8	ALL	all	DT
cord-005478-5iu38pr6	657	9	in	in	IN
cord-005478-5iu38pr6	657	10	20	20	CD
cord-005478-5iu38pr6	657	11	(	(	-LRB-
cord-005478-5iu38pr6	657	12	13	13	CD
cord-005478-5iu38pr6	657	13	adults	adult	NNS
cord-005478-5iu38pr6	657	14	)	)	-RRB-
cord-005478-5iu38pr6	657	15	,	,	,
cord-005478-5iu38pr6	657	16	NHL	NHL	NNP
cord-005478-5iu38pr6	657	17	in	in	IN
cord-005478-5iu38pr6	657	18	4	4	CD
cord-005478-5iu38pr6	657	19	and	and	CC
cord-005478-5iu38pr6	657	20	CLL	CLL	NNP
cord-005478-5iu38pr6	657	21	in	in	IN
cord-005478-5iu38pr6	657	22	1	1	CD
cord-005478-5iu38pr6	657	23	.	.	.
cord-005478-5iu38pr6	658	1	Median	median	JJ
cord-005478-5iu38pr6	658	2	age	age	NN
cord-005478-5iu38pr6	658	3	was	be	VBD
cord-005478-5iu38pr6	658	4	23	23	CD
cord-005478-5iu38pr6	658	5	years	year	NNS
cord-005478-5iu38pr6	658	6	and	and	CC
cord-005478-5iu38pr6	658	7	40	40	CD
cord-005478-5iu38pr6	658	8	%	%	NN
cord-005478-5iu38pr6	658	9	were	be	VBD
cord-005478-5iu38pr6	658	10	women	woman	NNS
cord-005478-5iu38pr6	658	11	.	.	.
cord-005478-5iu38pr6	659	1	Of	of	IN
cord-005478-5iu38pr6	659	2	the	the	DT
cord-005478-5iu38pr6	659	3	20	20	CD
cord-005478-5iu38pr6	659	4	patients	patient	NNS
cord-005478-5iu38pr6	659	5	with	with	IN
cord-005478-5iu38pr6	659	6	ALL	all	DT
cord-005478-5iu38pr6	659	7	,	,	,
cord-005478-5iu38pr6	659	8	17	17	CD
cord-005478-5iu38pr6	659	9	had	have	VBD
cord-005478-5iu38pr6	659	10	relapsed	relapse	VBN
cord-005478-5iu38pr6	659	11	after	after	IN
cord-005478-5iu38pr6	659	12	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	659	13	,	,	,
cord-005478-5iu38pr6	659	14	while	while	IN
cord-005478-5iu38pr6	659	15	3/4	3/4	CD
cord-005478-5iu38pr6	659	16	patients	patient	NNS
cord-005478-5iu38pr6	659	17	with	with	IN
cord-005478-5iu38pr6	659	18	NHL	NHL	NNP
cord-005478-5iu38pr6	659	19	had	have	VBD
cord-005478-5iu38pr6	659	20	relapsed	relapse	VBN
cord-005478-5iu38pr6	659	21	after	after	IN
cord-005478-5iu38pr6	659	22	autoHCT	autoHCT	NNP
cord-005478-5iu38pr6	659	23	.	.	.
cord-005478-5iu38pr6	660	1	After	after	IN
cord-005478-5iu38pr6	660	2	conditioning	condition	VBG
cord-005478-5iu38pr6	660	3	with	with	IN
cord-005478-5iu38pr6	660	4	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	660	5	(	(	-LRB-
cord-005478-5iu38pr6	660	6	90	90	CD
cord-005478-5iu38pr6	660	7	mg/	mg/	NN
cord-005478-5iu38pr6	660	8	m	m	NN
cord-005478-5iu38pr6	660	9	2	2	CD
cord-005478-5iu38pr6	660	10	)	)	-RRB-
cord-005478-5iu38pr6	660	11	and	and	CC
cord-005478-5iu38pr6	660	12	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	660	13	(	(	-LRB-
cord-005478-5iu38pr6	660	14	900	900	CD
cord-005478-5iu38pr6	660	15	mg	mg	NNP
cord-005478-5iu38pr6	660	16	/	/	SYM
cord-005478-5iu38pr6	660	17	m	m	NNP
cord-005478-5iu38pr6	660	18	2	2	CD
cord-005478-5iu38pr6	660	19	)	)	-RRB-
cord-005478-5iu38pr6	660	20	,	,	,
cord-005478-5iu38pr6	660	21	we	-PRON-	PRP
cord-005478-5iu38pr6	660	22	infused	infuse	VBD
cord-005478-5iu38pr6	660	23	0.4	0.4	CD
cord-005478-5iu38pr6	660	24	-	-	SYM
cord-005478-5iu38pr6	660	25	5	5	CD
cord-005478-5iu38pr6	660	26	x10	x10	CD
cord-005478-5iu38pr6	660	27	6	6	CD
cord-005478-5iu38pr6	660	28	ARI-0001	ari-0001	JJ
cord-005478-5iu38pr6	660	29	cells	cell	NNS
cord-005478-5iu38pr6	660	30	/kg	/kg	NFP
cord-005478-5iu38pr6	660	31	,	,	,
cord-005478-5iu38pr6	660	32	first	first	RB
cord-005478-5iu38pr6	660	33	as	as	IN
cord-005478-5iu38pr6	660	34	a	a	DT
cord-005478-5iu38pr6	660	35	single	single	JJ
cord-005478-5iu38pr6	660	36	infusion	infusion	NN
cord-005478-5iu38pr6	660	37	(	(	-LRB-
cord-005478-5iu38pr6	660	38	first	first	RB
cord-005478-5iu38pr6	660	39	19	19	CD
cord-005478-5iu38pr6	660	40	patients	patient	NNS
cord-005478-5iu38pr6	660	41	,	,	,
cord-005478-5iu38pr6	660	42	cohort	cohort	NN
cord-005478-5iu38pr6	660	43	1	1	CD
cord-005478-5iu38pr6	660	44	)	)	-RRB-
cord-005478-5iu38pr6	660	45	,	,	,
cord-005478-5iu38pr6	660	46	and	and	CC
cord-005478-5iu38pr6	660	47	then	then	RB
cord-005478-5iu38pr6	660	48	in	in	IN
cord-005478-5iu38pr6	660	49	2	2	CD
cord-005478-5iu38pr6	660	50	-	-	SYM
cord-005478-5iu38pr6	660	51	3	3	CD
cord-005478-5iu38pr6	660	52	fractions	fraction	NNS
cord-005478-5iu38pr6	660	53	(	(	-LRB-
cord-005478-5iu38pr6	660	54	last	last	JJ
cord-005478-5iu38pr6	660	55	6	6	CD
cord-005478-5iu38pr6	660	56	patients	patient	NNS
cord-005478-5iu38pr6	660	57	,	,	,
cord-005478-5iu38pr6	660	58	cohort	cohort	NN
cord-005478-5iu38pr6	660	59	2	2	CD
cord-005478-5iu38pr6	660	60	)	)	-RRB-
cord-005478-5iu38pr6	660	61	.	.	.
cord-005478-5iu38pr6	661	1	We	-PRON-	PRP
cord-005478-5iu38pr6	661	2	have	have	VBP
cord-005478-5iu38pr6	661	3	observed	observe	VBN
cord-005478-5iu38pr6	662	1	5	5	LS
cord-005478-5iu38pr6	662	2	(	(	-LRB-
cord-005478-5iu38pr6	662	3	20	20	CD
cord-005478-5iu38pr6	662	4	%	%	NN
cord-005478-5iu38pr6	662	5	)	)	-RRB-
cord-005478-5iu38pr6	662	6	cases	case	NNS
cord-005478-5iu38pr6	662	7	of	of	IN
cord-005478-5iu38pr6	662	8	severe	severe	JJ
cord-005478-5iu38pr6	662	9	cytokine	cytokine	NN
cord-005478-5iu38pr6	662	10	release	release	NN
cord-005478-5iu38pr6	662	11	syndrome	syndrome	NN
cord-005478-5iu38pr6	662	12	(	(	-LRB-
cord-005478-5iu38pr6	662	13	CRS	CRS	NNP
cord-005478-5iu38pr6	662	14	)	)	-RRB-
cord-005478-5iu38pr6	662	15	and	and	CC
cord-005478-5iu38pr6	662	16	the	the	DT
cord-005478-5iu38pr6	662	17	non	non	JJ
cord-005478-5iu38pr6	662	18	-	-	JJ
cord-005478-5iu38pr6	662	19	relapse	relapse	JJ
cord-005478-5iu38pr6	662	20	mortality	mortality	NN
cord-005478-5iu38pr6	662	21	(	(	-LRB-
cord-005478-5iu38pr6	662	22	NRM	NRM	NNP
cord-005478-5iu38pr6	662	23	)	)	-RRB-
cord-005478-5iu38pr6	662	24	was	be	VBD
cord-005478-5iu38pr6	662	25	12	12	CD
cord-005478-5iu38pr6	662	26	%	%	NN
cord-005478-5iu38pr6	662	27	(	(	-LRB-
cord-005478-5iu38pr6	662	28	3/25	3/25	CD
cord-005478-5iu38pr6	662	29	)	)	-RRB-
cord-005478-5iu38pr6	662	30	.	.	.
cord-005478-5iu38pr6	663	1	These	these	DT
cord-005478-5iu38pr6	663	2	deaths	death	NNS
cord-005478-5iu38pr6	663	3	were	be	VBD
cord-005478-5iu38pr6	663	4	due	due	JJ
cord-005478-5iu38pr6	663	5	to	to	IN
cord-005478-5iu38pr6	663	6	CRS	CRS	NNP
cord-005478-5iu38pr6	663	7	(	(	-LRB-
cord-005478-5iu38pr6	663	8	2	2	CD
cord-005478-5iu38pr6	663	9	)	)	-RRB-
cord-005478-5iu38pr6	663	10	and	and	CC
cord-005478-5iu38pr6	663	11	pseudomembranous	pseudomembranous	JJ
cord-005478-5iu38pr6	663	12	colitis	colitis	NN
cord-005478-5iu38pr6	663	13	(	(	-LRB-
cord-005478-5iu38pr6	663	14	1	1	CD
cord-005478-5iu38pr6	663	15	)	)	-RRB-
cord-005478-5iu38pr6	663	16	,	,	,
cord-005478-5iu38pr6	663	17	and	and	CC
cord-005478-5iu38pr6	663	18	all	all	DT
cord-005478-5iu38pr6	663	19	happened	happen	VBD
cord-005478-5iu38pr6	663	20	in	in	IN
cord-005478-5iu38pr6	663	21	cohort	cohort	NN
cord-005478-5iu38pr6	663	22	1	1	CD
cord-005478-5iu38pr6	663	23	.	.	.
cord-005478-5iu38pr6	664	1	We	-PRON-	PRP
cord-005478-5iu38pr6	664	2	had	have	VBD
cord-005478-5iu38pr6	664	3	no	no	DT
cord-005478-5iu38pr6	664	4	cases	case	NNS
cord-005478-5iu38pr6	664	5	of	of	IN
cord-005478-5iu38pr6	664	6	severe	severe	JJ
cord-005478-5iu38pr6	664	7	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	664	8	,	,	,
cord-005478-5iu38pr6	664	9	and	and	CC
cord-005478-5iu38pr6	664	10	grade	grade	NN
cord-005478-5iu38pr6	664	11	II	ii	CD
cord-005478-5iu38pr6	664	12	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	664	13	was	be	VBD
cord-005478-5iu38pr6	664	14	only	only	RB
cord-005478-5iu38pr6	664	15	seen	see	VBN
cord-005478-5iu38pr6	664	16	in	in	IN
cord-005478-5iu38pr6	664	17	2	2	CD
cord-005478-5iu38pr6	664	18	patients	patient	NNS
cord-005478-5iu38pr6	664	19	.	.	.
cord-005478-5iu38pr6	665	1	Of	of	IN
cord-005478-5iu38pr6	665	2	the	the	DT
cord-005478-5iu38pr6	665	3	14	14	CD
cord-005478-5iu38pr6	665	4	patients	patient	NNS
cord-005478-5iu38pr6	665	5	with	with	IN
cord-005478-5iu38pr6	665	6	active	active	JJ
cord-005478-5iu38pr6	665	7	ALL	all	DT
cord-005478-5iu38pr6	665	8	at	at	IN
cord-005478-5iu38pr6	665	9	inclusion	inclusion	NN
cord-005478-5iu38pr6	665	10	,	,	,
cord-005478-5iu38pr6	665	11	11	11	CD
cord-005478-5iu38pr6	665	12	had	have	VBD
cord-005478-5iu38pr6	665	13	enough	enough	JJ
cord-005478-5iu38pr6	665	14	follow	follow	NN
cord-005478-5iu38pr6	665	15	-	-	HYPH
cord-005478-5iu38pr6	665	16	up	up	NN
cord-005478-5iu38pr6	665	17	for	for	IN
cord-005478-5iu38pr6	665	18	efficacy	efficacy	NN
cord-005478-5iu38pr6	665	19	analysis	analysis	NN
cord-005478-5iu38pr6	665	20	,	,	,
cord-005478-5iu38pr6	665	21	and	and	CC
cord-005478-5iu38pr6	665	22	all	all	DT
cord-005478-5iu38pr6	665	23	of	of	IN
cord-005478-5iu38pr6	665	24	them	-PRON-	PRP
cord-005478-5iu38pr6	665	25	achieved	achieve	VBD
cord-005478-5iu38pr6	665	26	a	a	DT
cord-005478-5iu38pr6	665	27	CR	cr	NN
cord-005478-5iu38pr6	665	28	(	(	-LRB-
cord-005478-5iu38pr6	665	29	9	9	CD
cord-005478-5iu38pr6	665	30	of	of	IN
cord-005478-5iu38pr6	665	31	them	-PRON-	PRP
cord-005478-5iu38pr6	665	32	with	with	IN
cord-005478-5iu38pr6	665	33	negative	negative	JJ
cord-005478-5iu38pr6	665	34	MRD	MRD	NNP
cord-005478-5iu38pr6	665	35	)	)	-RRB-
cord-005478-5iu38pr6	665	36	.	.	.
cord-005478-5iu38pr6	666	1	With	with	IN
cord-005478-5iu38pr6	666	2	a	a	DT
cord-005478-5iu38pr6	666	3	median	median	JJ
cord-005478-5iu38pr6	666	4	follow	follow	NN
cord-005478-5iu38pr6	666	5	-	-	HYPH
cord-005478-5iu38pr6	666	6	up	up	NN
cord-005478-5iu38pr6	666	7	of	of	IN
cord-005478-5iu38pr6	666	8	8.7	8.7	CD
cord-005478-5iu38pr6	666	9	months	month	NNS
cord-005478-5iu38pr6	666	10	(	(	-LRB-
cord-005478-5iu38pr6	666	11	range	range	VBP
cord-005478-5iu38pr6	666	12	,	,	,
cord-005478-5iu38pr6	666	13	1.3	1.3	CD
cord-005478-5iu38pr6	666	14	-	-	SYM
cord-005478-5iu38pr6	666	15	14.8	14.8	CD
cord-005478-5iu38pr6	666	16	)	)	-RRB-
cord-005478-5iu38pr6	666	17	,	,	,
cord-005478-5iu38pr6	666	18	relapses	relapse	NNS
cord-005478-5iu38pr6	666	19	were	be	VBD
cord-005478-5iu38pr6	666	20	observed	observe	VBN
cord-005478-5iu38pr6	666	21	on	on	IN
cord-005478-5iu38pr6	666	22	days	day	NNS
cord-005478-5iu38pr6	666	23	+223	+223	NNP
cord-005478-5iu38pr6	666	24	(	(	-LRB-
cord-005478-5iu38pr6	666	25	CD19	CD19	NNP
cord-005478-5iu38pr6	666	26	+	+	CC
cord-005478-5iu38pr6	666	27	)	)	-RRB-
cord-005478-5iu38pr6	666	28	,	,	,
cord-005478-5iu38pr6	666	29	+105	+105	NNP
cord-005478-5iu38pr6	666	30	and	and	CC
cord-005478-5iu38pr6	666	31	+284	+284	NNP
cord-005478-5iu38pr6	666	32	(	(	-LRB-
cord-005478-5iu38pr6	666	33	CD19-	CD19-	NNP
cord-005478-5iu38pr6	666	34	)	)	-RRB-
cord-005478-5iu38pr6	666	35	,	,	,
cord-005478-5iu38pr6	666	36	leading	lead	VBG
cord-005478-5iu38pr6	666	37	to	to	IN
cord-005478-5iu38pr6	666	38	a	a	DT
cord-005478-5iu38pr6	666	39	progression	progression	NN
cord-005478-5iu38pr6	666	40	-	-	HYPH
cord-005478-5iu38pr6	666	41	free	free	JJ
cord-005478-5iu38pr6	666	42	survival	survival	NN
cord-005478-5iu38pr6	666	43	of	of	IN
cord-005478-5iu38pr6	666	44	53	53	CD
cord-005478-5iu38pr6	666	45	%	%	NN
cord-005478-5iu38pr6	666	46	at	at	IN
cord-005478-5iu38pr6	666	47	12	12	CD
cord-005478-5iu38pr6	666	48	months	month	NNS
cord-005478-5iu38pr6	666	49	.	.	.
cord-005478-5iu38pr6	667	1	In	in	IN
cord-005478-5iu38pr6	667	2	patients	patient	NNS
cord-005478-5iu38pr6	667	3	with	with	IN
cord-005478-5iu38pr6	667	4	NHL	NHL	NNP
cord-005478-5iu38pr6	667	5	/	/	SYM
cord-005478-5iu38pr6	667	6	CLL	CLL	NNP
cord-005478-5iu38pr6	668	1	we	-PRON-	PRP
cord-005478-5iu38pr6	668	2	have	have	VBP
cord-005478-5iu38pr6	668	3	documented	document	VBN
cord-005478-5iu38pr6	668	4	CR	cr	NN
cord-005478-5iu38pr6	668	5	in	in	IN
cord-005478-5iu38pr6	668	6	2	2	CD
cord-005478-5iu38pr6	668	7	,	,	,
cord-005478-5iu38pr6	668	8	one	one	CD
cord-005478-5iu38pr6	668	9	of	of	IN
cord-005478-5iu38pr6	668	10	them	-PRON-	PRP
cord-005478-5iu38pr6	668	11	(	(	-LRB-
cord-005478-5iu38pr6	668	12	NHL	NHL	NNP
cord-005478-5iu38pr6	668	13	)	)	-RRB-
cord-005478-5iu38pr6	668	14	relapsing	relapse	VBG
cord-005478-5iu38pr6	668	15	at	at	IN
cord-005478-5iu38pr6	668	16	day	day	NN
cord-005478-5iu38pr6	668	17	+259	+259	NNP
cord-005478-5iu38pr6	668	18	.	.	.
cord-005478-5iu38pr6	669	1	One	one	CD
cord-005478-5iu38pr6	669	2	NHL	NHL	NNP
cord-005478-5iu38pr6	669	3	patient	patient	NN
cord-005478-5iu38pr6	669	4	has	have	VBZ
cord-005478-5iu38pr6	669	5	not	not	RB
cord-005478-5iu38pr6	669	6	been	be	VBN
cord-005478-5iu38pr6	669	7	evaluated	evaluate	VBN
cord-005478-5iu38pr6	669	8	yet	yet	RB
cord-005478-5iu38pr6	669	9	and	and	CC
cord-005478-5iu38pr6	669	10	the	the	DT
cord-005478-5iu38pr6	669	11	other	other	JJ
cord-005478-5iu38pr6	669	12	2	2	CD
cord-005478-5iu38pr6	669	13	patients	patient	NNS
cord-005478-5iu38pr6	669	14	did	do	VBD
cord-005478-5iu38pr6	669	15	not	not	RB
cord-005478-5iu38pr6	669	16	respond	respond	VB
cord-005478-5iu38pr6	669	17	and	and	CC
cord-005478-5iu38pr6	669	18	have	have	VBP
cord-005478-5iu38pr6	669	19	died	die	VBN
cord-005478-5iu38pr6	669	20	due	due	IN
cord-005478-5iu38pr6	669	21	to	to	IN
cord-005478-5iu38pr6	669	22	their	-PRON-	PRP$
cord-005478-5iu38pr6	669	23	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	669	24	.	.	.
cord-005478-5iu38pr6	670	1	The	the	DT
cord-005478-5iu38pr6	670	2	CLL	CLL	NNP
cord-005478-5iu38pr6	670	3	patient	patient	NN
cord-005478-5iu38pr6	670	4	,	,	,
cord-005478-5iu38pr6	670	5	refractory	refractory	JJ
cord-005478-5iu38pr6	670	6	to	to	IN
cord-005478-5iu38pr6	670	7	5	5	CD
cord-005478-5iu38pr6	670	8	lines	line	NNS
cord-005478-5iu38pr6	670	9	of	of	IN
cord-005478-5iu38pr6	670	10	treatment	treatment	NN
cord-005478-5iu38pr6	670	11	,	,	,
cord-005478-5iu38pr6	670	12	achieved	achieve	VBD
cord-005478-5iu38pr6	670	13	a	a	DT
cord-005478-5iu38pr6	670	14	CR	cr	NN
cord-005478-5iu38pr6	670	15	,	,	,
cord-005478-5iu38pr6	670	16	which	which	WDT
cord-005478-5iu38pr6	670	17	is	be	VBZ
cord-005478-5iu38pr6	670	18	maintained	maintain	VBN
cord-005478-5iu38pr6	670	19	at	at	IN
cord-005478-5iu38pr6	670	20	day	day	NN
cord-005478-5iu38pr6	670	21	+377	+377	NNP
cord-005478-5iu38pr6	670	22	.	.	.
cord-005478-5iu38pr6	671	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	671	2	:	:	:
cord-005478-5iu38pr6	672	1	Treatment	treatment	NN
cord-005478-5iu38pr6	672	2	with	with	IN
cord-005478-5iu38pr6	672	3	ARI-0001	ari-0001	JJ
cord-005478-5iu38pr6	672	4	cells	cell	NNS
cord-005478-5iu38pr6	672	5	is	be	VBZ
cord-005478-5iu38pr6	672	6	effective	effective	JJ
cord-005478-5iu38pr6	672	7	with	with	IN
cord-005478-5iu38pr6	672	8	a	a	DT
cord-005478-5iu38pr6	672	9	response	response	NN
cord-005478-5iu38pr6	672	10	rate	rate	NN
cord-005478-5iu38pr6	672	11	of	of	IN
cord-005478-5iu38pr6	672	12	78.5	78.5	CD
cord-005478-5iu38pr6	672	13	%	%	NN
cord-005478-5iu38pr6	672	14	in	in	IN
cord-005478-5iu38pr6	672	15	ALL	all	DT
cord-005478-5iu38pr6	672	16	(	(	-LRB-
cord-005478-5iu38pr6	672	17	PFS	PFS	NNP
cord-005478-5iu38pr6	672	18	of	of	IN
cord-005478-5iu38pr6	672	19	53	53	CD
cord-005478-5iu38pr6	672	20	%	%	NN
cord-005478-5iu38pr6	672	21	at	at	IN
cord-005478-5iu38pr6	672	22	1y	1y	CD
cord-005478-5iu38pr6	672	23	)	)	-RRB-
cord-005478-5iu38pr6	672	24	and	and	CC
cord-005478-5iu38pr6	672	25	50	50	CD
cord-005478-5iu38pr6	672	26	%	%	NN
cord-005478-5iu38pr6	672	27	in	in	IN
cord-005478-5iu38pr6	672	28	NHL	NHL	NNP
cord-005478-5iu38pr6	672	29	/	/	SYM
cord-005478-5iu38pr6	672	30	CLL	CLL	NNP
cord-005478-5iu38pr6	672	31	.	.	.
cord-005478-5iu38pr6	673	1	We	-PRON-	PRP
cord-005478-5iu38pr6	673	2	also	also	RB
cord-005478-5iu38pr6	673	3	observed	observe	VBD
cord-005478-5iu38pr6	673	4	cases	case	NNS
cord-005478-5iu38pr6	673	5	of	of	IN
cord-005478-5iu38pr6	673	6	severe	severe	JJ
cord-005478-5iu38pr6	673	7	CRS	CRS	NNP
cord-005478-5iu38pr6	673	8	in	in	IN
cord-005478-5iu38pr6	673	9	20	20	CD
cord-005478-5iu38pr6	673	10	%	%	NN
cord-005478-5iu38pr6	673	11	and	and	CC
cord-005478-5iu38pr6	673	12	a	a	DT
cord-005478-5iu38pr6	673	13	NRM	NRM	NNP
cord-005478-5iu38pr6	673	14	of	of	IN
cord-005478-5iu38pr6	673	15	12	12	CD
cord-005478-5iu38pr6	673	16	%	%	NN
cord-005478-5iu38pr6	673	17	of	of	IN
cord-005478-5iu38pr6	673	18	patients	patient	NNS
cord-005478-5iu38pr6	673	19	,	,	,
cord-005478-5iu38pr6	673	20	though	though	IN
cord-005478-5iu38pr6	673	21	dose	dose	NN
cord-005478-5iu38pr6	673	22	fractioning	fractioning	NN
cord-005478-5iu38pr6	673	23	seems	seem	VBZ
cord-005478-5iu38pr6	673	24	to	to	TO
cord-005478-5iu38pr6	673	25	improve	improve	VB
cord-005478-5iu38pr6	673	26	safety	safety	NN
cord-005478-5iu38pr6	673	27	profile	profile	NN
cord-005478-5iu38pr6	673	28	.	.	.
cord-005478-5iu38pr6	674	1	Still	still	RB
cord-005478-5iu38pr6	674	2	,	,	,
cord-005478-5iu38pr6	674	3	longer	long	JJR
cord-005478-5iu38pr6	674	4	median	median	JJ
cord-005478-5iu38pr6	674	5	follow	follow	NN
cord-005478-5iu38pr6	674	6	-	-	HYPH
cord-005478-5iu38pr6	674	7	up	up	NN
cord-005478-5iu38pr6	674	8	and	and	CC
cord-005478-5iu38pr6	674	9	further	further	JJ
cord-005478-5iu38pr6	674	10	patient	patient	JJ
cord-005478-5iu38pr6	674	11	inclusions	inclusion	NNS
cord-005478-5iu38pr6	674	12	are	be	VBP
cord-005478-5iu38pr6	674	13	needed	need	VBN
cord-005478-5iu38pr6	674	14	.	.	.
cord-005478-5iu38pr6	675	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	675	2	Background	background	NN
cord-005478-5iu38pr6	675	3	:	:	:
cord-005478-5iu38pr6	676	1	BCMA	BCMA	NNP
cord-005478-5iu38pr6	676	2	CAR	CAR	NNP
cord-005478-5iu38pr6	676	3	-	-	HYPH
cord-005478-5iu38pr6	676	4	T	t	NN
cord-005478-5iu38pr6	676	5	cells	cell	NNS
cord-005478-5iu38pr6	676	6	have	have	VBP
cord-005478-5iu38pr6	676	7	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	676	8	substantial	substantial	JJ
cord-005478-5iu38pr6	676	9	preclinical	preclinical	JJ
cord-005478-5iu38pr6	676	10	and	and	CC
cord-005478-5iu38pr6	676	11	clinical	clinical	JJ
cord-005478-5iu38pr6	676	12	activity	activity	NN
cord-005478-5iu38pr6	676	13	for	for	IN
cord-005478-5iu38pr6	676	14	relapsed/	relapsed/	VBG
cord-005478-5iu38pr6	676	15	refractory	refractory	JJ
cord-005478-5iu38pr6	676	16	multiple	multiple	JJ
cord-005478-5iu38pr6	676	17	myeloma	myeloma	NN
cord-005478-5iu38pr6	676	18	(	(	-LRB-
cord-005478-5iu38pr6	676	19	RRMM	rrmm	NN
cord-005478-5iu38pr6	676	20	)	)	-RRB-
cord-005478-5iu38pr6	676	21	patients	patient	NNS
cord-005478-5iu38pr6	676	22	.	.	.
cord-005478-5iu38pr6	677	1	In	in	IN
cord-005478-5iu38pr6	677	2	different	different	JJ
cord-005478-5iu38pr6	677	3	clinical	clinical	JJ
cord-005478-5iu38pr6	677	4	trials	trial	NNS
cord-005478-5iu38pr6	677	5	,	,	,
cord-005478-5iu38pr6	677	6	the	the	DT
cord-005478-5iu38pr6	677	7	overall	overall	JJ
cord-005478-5iu38pr6	677	8	response	response	NN
cord-005478-5iu38pr6	677	9	rate	rate	NN
cord-005478-5iu38pr6	677	10	(	(	-LRB-
cord-005478-5iu38pr6	677	11	ORR	ORR	NNP
cord-005478-5iu38pr6	677	12	)	)	-RRB-
cord-005478-5iu38pr6	677	13	varied	vary	VBD
cord-005478-5iu38pr6	677	14	from	from	IN
cord-005478-5iu38pr6	677	15	50	50	CD
cord-005478-5iu38pr6	677	16	%	%	NN
cord-005478-5iu38pr6	677	17	to	to	TO
cord-005478-5iu38pr6	677	18	100	100	CD
cord-005478-5iu38pr6	677	19	%	%	NN
cord-005478-5iu38pr6	677	20	.	.	.
cord-005478-5iu38pr6	678	1	Complete	complete	JJ
cord-005478-5iu38pr6	678	2	remission	remission	NN
cord-005478-5iu38pr6	678	3	(	(	-LRB-
cord-005478-5iu38pr6	678	4	CR	cr	NN
cord-005478-5iu38pr6	678	5	)	)	-RRB-
cord-005478-5iu38pr6	678	6	rate	rate	NN
cord-005478-5iu38pr6	678	7	varied	vary	VBN
cord-005478-5iu38pr6	678	8	from	from	IN
cord-005478-5iu38pr6	678	9	7	7	CD
cord-005478-5iu38pr6	678	10	%	%	NN
cord-005478-5iu38pr6	678	11	to	to	TO
cord-005478-5iu38pr6	678	12	60	60	CD
cord-005478-5iu38pr6	678	13	%	%	NN
cord-005478-5iu38pr6	678	14	.	.	.
cord-005478-5iu38pr6	679	1	Previous	previous	JJ
cord-005478-5iu38pr6	679	2	studies	study	NNS
cord-005478-5iu38pr6	679	3	indicated	indicate	VBD
cord-005478-5iu38pr6	679	4	higher	high	JJR
cord-005478-5iu38pr6	679	5	CAR	car	NN
cord-005478-5iu38pr6	679	6	-	-	HYPH
cord-005478-5iu38pr6	679	7	T	t	NN
cord-005478-5iu38pr6	679	8	cell	cell	NN
cord-005478-5iu38pr6	679	9	expansion	expansion	NN
cord-005478-5iu38pr6	679	10	in	in	IN
cord-005478-5iu38pr6	679	11	vivo	vivo	NN
cord-005478-5iu38pr6	679	12	achieved	achieve	VBN
cord-005478-5iu38pr6	679	13	better	well	JJR
cord-005478-5iu38pr6	679	14	remission	remission	NN
cord-005478-5iu38pr6	679	15	.	.	.
cord-005478-5iu38pr6	680	1	Here	here	RB
cord-005478-5iu38pr6	680	2	we	-PRON-	PRP
cord-005478-5iu38pr6	680	3	developed	develop	VBD
cord-005478-5iu38pr6	680	4	a	a	DT
cord-005478-5iu38pr6	680	5	BCMA	BCMA	NNP
cord-005478-5iu38pr6	680	6	CAR	CAR	NNP
cord-005478-5iu38pr6	680	7	-	-	HYPH
cord-005478-5iu38pr6	680	8	T	t	NN
cord-005478-5iu38pr6	680	9	cell	cell	NN
cord-005478-5iu38pr6	680	10	product	product	NN
cord-005478-5iu38pr6	680	11	manufactured	manufacture	VBN
cord-005478-5iu38pr6	680	12	via	via	IN
cord-005478-5iu38pr6	680	13	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	680	14	vector	vector	NN
cord-005478-5iu38pr6	680	15	-	-	HYPH
cord-005478-5iu38pr6	680	16	mediated	mediate	VBN
cord-005478-5iu38pr6	680	17	transduction	transduction	NN
cord-005478-5iu38pr6	680	18	of	of	IN
cord-005478-5iu38pr6	680	19	activated	activate	VBN
cord-005478-5iu38pr6	680	20	T	T	NNP
cord-005478-5iu38pr6	680	21	cells	cell	NNS
cord-005478-5iu38pr6	680	22	to	to	TO
cord-005478-5iu38pr6	680	23	express	express	VB
cord-005478-5iu38pr6	680	24	a	a	DT
cord-005478-5iu38pr6	680	25	second	second	JJ
cord-005478-5iu38pr6	680	26	-	-	HYPH
cord-005478-5iu38pr6	680	27	generation	generation	NN
cord-005478-5iu38pr6	680	28	CAR	car	NN
cord-005478-5iu38pr6	680	29	with	with	IN
cord-005478-5iu38pr6	680	30	4	4	CD
cord-005478-5iu38pr6	680	31	-	-	HYPH
cord-005478-5iu38pr6	680	32	1BB	1BB	NNP
cord-005478-5iu38pr6	680	33	costimulatory	costimulatory	NN
cord-005478-5iu38pr6	680	34	domain	domain	NN
cord-005478-5iu38pr6	680	35	.	.	.
cord-005478-5iu38pr6	681	1	Methods	method	NNS
cord-005478-5iu38pr6	681	2	:	:	:
cord-005478-5iu38pr6	682	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	682	2	trial	trial	NN
cord-005478-5iu38pr6	682	3	(	(	-LRB-
cord-005478-5iu38pr6	682	4	ChiCTR1800017404	chictr1800017404	RB
cord-005478-5iu38pr6	682	5	)	)	-RRB-
cord-005478-5iu38pr6	682	6	was	be	VBD
cord-005478-5iu38pr6	682	7	initiated	initiate	VBN
cord-005478-5iu38pr6	682	8	to	to	TO
cord-005478-5iu38pr6	682	9	evaluate	evaluate	VB
cord-005478-5iu38pr6	682	10	the	the	DT
cord-005478-5iu38pr6	682	11	safety	safety	NN
cord-005478-5iu38pr6	682	12	and	and	CC
cord-005478-5iu38pr6	682	13	efficacy	efficacy	NN
cord-005478-5iu38pr6	682	14	of	of	IN
cord-005478-5iu38pr6	682	15	autologous	autologous	JJ
cord-005478-5iu38pr6	682	16	BCMA	BCMA	NNP
cord-005478-5iu38pr6	682	17	CAR	CAR	NNP
cord-005478-5iu38pr6	682	18	-	-	HYPH
cord-005478-5iu38pr6	682	19	T	t	NN
cord-005478-5iu38pr6	682	20	treatment	treatment	NN
cord-005478-5iu38pr6	682	21	for	for	IN
cord-005478-5iu38pr6	682	22	RRMM	RRMM	NNS
cord-005478-5iu38pr6	682	23	.	.	.
cord-005478-5iu38pr6	683	1	The	the	DT
cord-005478-5iu38pr6	683	2	enrolled	enrol	VBN
cord-005478-5iu38pr6	683	3	RRMM	rrmm	NN
cord-005478-5iu38pr6	683	4	patients	patient	NNS
cord-005478-5iu38pr6	683	5	either	either	CC
cord-005478-5iu38pr6	683	6	had	have	VBD
cord-005478-5iu38pr6	683	7	received	receive	VBN
cord-005478-5iu38pr6	683	8	at	at	IN
cord-005478-5iu38pr6	683	9	least	least	JJS
cord-005478-5iu38pr6	683	10	3	3	CD
cord-005478-5iu38pr6	683	11	prior	prior	JJ
cord-005478-5iu38pr6	683	12	treatment	treatment	NN
cord-005478-5iu38pr6	683	13	regimens	regimen	NNS
cord-005478-5iu38pr6	683	14	,	,	,
cord-005478-5iu38pr6	683	15	including	include	VBG
cord-005478-5iu38pr6	683	16	a	a	DT
cord-005478-5iu38pr6	683	17	proteasome	proteasome	VBN
cord-005478-5iu38pr6	683	18	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	683	19	,	,	,
cord-005478-5iu38pr6	683	20	an	an	DT
cord-005478-5iu38pr6	683	21	immunomodulatory	immunomodulatory	JJ
cord-005478-5iu38pr6	683	22	agent	agent	NN
cord-005478-5iu38pr6	683	23	,	,	,
cord-005478-5iu38pr6	683	24	anti	anti	JJ
cord-005478-5iu38pr6	683	25	-	-	JJ
cord-005478-5iu38pr6	683	26	CD38	cd38	JJ
cord-005478-5iu38pr6	683	27	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	683	28	antibody	antibody	NN
cord-005478-5iu38pr6	683	29	or	or	CC
cord-005478-5iu38pr6	683	30	were	be	VBD
cord-005478-5iu38pr6	683	31	double	double	JJ
cord-005478-5iu38pr6	683	32	or	or	CC
cord-005478-5iu38pr6	683	33	triple	triple	JJ
cord-005478-5iu38pr6	683	34	-	-	HYPH
cord-005478-5iu38pr6	683	35	refractory	refractory	JJ
cord-005478-5iu38pr6	683	36	,	,	,
cord-005478-5iu38pr6	683	37	and	and	CC
cord-005478-5iu38pr6	683	38	have	have	VBP
cord-005478-5iu38pr6	683	39	over	over	IN
cord-005478-5iu38pr6	683	40	30	30	CD
cord-005478-5iu38pr6	683	41	%	%	NN
cord-005478-5iu38pr6	683	42	BCMA	BCMA	NNP
cord-005478-5iu38pr6	683	43	expression	expression	NN
cord-005478-5iu38pr6	683	44	.	.	.
cord-005478-5iu38pr6	684	1	Patients	patient	NNS
cord-005478-5iu38pr6	684	2	were	be	VBD
cord-005478-5iu38pr6	684	3	subjected	subject	VBN
cord-005478-5iu38pr6	684	4	to	to	IN
cord-005478-5iu38pr6	684	5	a	a	DT
cord-005478-5iu38pr6	684	6	lymphodepleting	lymphodeplete	VBG
cord-005478-5iu38pr6	684	7	regimen	regimen	NN
cord-005478-5iu38pr6	684	8	with	with	IN
cord-005478-5iu38pr6	684	9	Flu	Flu	NNP
cord-005478-5iu38pr6	684	10	daily	daily	RB
cord-005478-5iu38pr6	684	11	for	for	IN
cord-005478-5iu38pr6	684	12	3	3	CD
cord-005478-5iu38pr6	684	13	days	day	NNS
cord-005478-5iu38pr6	684	14	(	(	-LRB-
cord-005478-5iu38pr6	684	15	30mg	30mg	NNP
cord-005478-5iu38pr6	684	16	/	/	SYM
cord-005478-5iu38pr6	684	17	m	m	NNP
cord-005478-5iu38pr6	684	18	2	2	CD
cord-005478-5iu38pr6	684	19	,	,	,
cord-005478-5iu38pr6	684	20	D4	d4	NN
cord-005478-5iu38pr6	684	21	to	to	IN
cord-005478-5iu38pr6	684	22	D2	D2	NNP
cord-005478-5iu38pr6	684	23	)	)	-RRB-
cord-005478-5iu38pr6	684	24	and	and	CC
cord-005478-5iu38pr6	684	25	Cy	Cy	NNP
cord-005478-5iu38pr6	684	26	(	(	-LRB-
cord-005478-5iu38pr6	684	27	500mg/	500mg/	CD
cord-005478-5iu38pr6	684	28	m	m	CD
cord-005478-5iu38pr6	684	29	2	2	CD
cord-005478-5iu38pr6	684	30	,	,	,
cord-005478-5iu38pr6	684	31	D-3	D-3	NNP
cord-005478-5iu38pr6	684	32	to	to	IN
cord-005478-5iu38pr6	684	33	D-2	D-2	NNP
cord-005478-5iu38pr6	684	34	)	)	-RRB-
cord-005478-5iu38pr6	684	35	prior	prior	RB
cord-005478-5iu38pr6	684	36	to	to	IN
cord-005478-5iu38pr6	684	37	the	the	DT
cord-005478-5iu38pr6	684	38	CAR	CAR	NNP
cord-005478-5iu38pr6	684	39	-	-	HYPH
cord-005478-5iu38pr6	684	40	T	t	NN
cord-005478-5iu38pr6	684	41	cell	cell	NN
cord-005478-5iu38pr6	684	42	infusion	infusion	NN
cord-005478-5iu38pr6	684	43	(	(	-LRB-
cord-005478-5iu38pr6	684	44	D0	D0	NNP
cord-005478-5iu38pr6	684	45	)	)	-RRB-
cord-005478-5iu38pr6	684	46	at	at	IN
cord-005478-5iu38pr6	684	47	a	a	DT
cord-005478-5iu38pr6	684	48	dose	dose	JJ
cord-005478-5iu38pr6	684	49	range	range	NN
cord-005478-5iu38pr6	684	50	of	of	IN
cord-005478-5iu38pr6	684	51	1	1	CD
cord-005478-5iu38pr6	684	52	-	-	SYM
cord-005478-5iu38pr6	684	53	5	5	CD
cord-005478-5iu38pr6	684	54	x10	x10	CD
cord-005478-5iu38pr6	684	55	6	6	CD
cord-005478-5iu38pr6	684	56	CAR+	CAR+	NNP
cord-005478-5iu38pr6	684	57	cells	cell	NNS
cord-005478-5iu38pr6	684	58	/	/	SYM
cord-005478-5iu38pr6	684	59	kg	kg	NNS
cord-005478-5iu38pr6	684	60	.	.	.
cord-005478-5iu38pr6	685	1	Results	result	NNS
cord-005478-5iu38pr6	685	2	:	:	:
cord-005478-5iu38pr6	686	1	As	as	IN
cord-005478-5iu38pr6	686	2	of	of	IN
cord-005478-5iu38pr6	686	3	the	the	DT
cord-005478-5iu38pr6	686	4	data	datum	NNS
cord-005478-5iu38pr6	686	5	cut	cut	VBN
cord-005478-5iu38pr6	686	6	-	-	HYPH
cord-005478-5iu38pr6	686	7	off	off	RP
cord-005478-5iu38pr6	686	8	date	date	NN
cord-005478-5iu38pr6	686	9	(	(	-LRB-
cord-005478-5iu38pr6	686	10	Nov	Nov	NNP
cord-005478-5iu38pr6	686	11	28th	28th	NN
cord-005478-5iu38pr6	686	12	,	,	,
cord-005478-5iu38pr6	686	13	2018	2018	CD
cord-005478-5iu38pr6	686	14	)	)	-RRB-
cord-005478-5iu38pr6	686	15	,	,	,
cord-005478-5iu38pr6	686	16	17	17	CD
cord-005478-5iu38pr6	686	17	patients	patient	NNS
cord-005478-5iu38pr6	686	18	,	,	,
cord-005478-5iu38pr6	686	19	median	median	JJ
cord-005478-5iu38pr6	686	20	age	age	NN
cord-005478-5iu38pr6	686	21	61.8	61.8	CD
cord-005478-5iu38pr6	686	22	(	(	-LRB-
cord-005478-5iu38pr6	686	23	49	49	CD
cord-005478-5iu38pr6	686	24	to	to	TO
cord-005478-5iu38pr6	686	25	75	75	CD
cord-005478-5iu38pr6	686	26	)	)	-RRB-
cord-005478-5iu38pr6	686	27	years	year	NNS
cord-005478-5iu38pr6	686	28	old	old	JJ
cord-005478-5iu38pr6	686	29	,	,	,
cord-005478-5iu38pr6	686	30	with	with	IN
cord-005478-5iu38pr6	686	31	a	a	DT
cord-005478-5iu38pr6	686	32	median	median	NN
cord-005478-5iu38pr6	686	33	of	of	IN
cord-005478-5iu38pr6	686	34	4.9	4.9	CD
cord-005478-5iu38pr6	686	35	(	(	-LRB-
cord-005478-5iu38pr6	686	36	0.4	0.4	CD
cord-005478-5iu38pr6	686	37	to	to	IN
cord-005478-5iu38pr6	686	38	10.8	10.8	CD
cord-005478-5iu38pr6	686	39	)	)	-RRB-
cord-005478-5iu38pr6	686	40	years	year	NNS
cord-005478-5iu38pr6	686	41	since	since	IN
cord-005478-5iu38pr6	686	42	MM	MM	NNP
cord-005478-5iu38pr6	686	43	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	686	44	,	,	,
cord-005478-5iu38pr6	686	45	were	be	VBD
cord-005478-5iu38pr6	686	46	infused	infuse	VBN
cord-005478-5iu38pr6	686	47	with	with	IN
cord-005478-5iu38pr6	686	48	BCMA	BCMA	NNP
cord-005478-5iu38pr6	686	49	CAR	CAR	NNP
cord-005478-5iu38pr6	686	50	-	-	HYPH
cord-005478-5iu38pr6	686	51	T	t	NN
cord-005478-5iu38pr6	686	52	cells	cell	NNS
cord-005478-5iu38pr6	686	53	.	.	.
cord-005478-5iu38pr6	687	1	Patients	patient	NNS
cord-005478-5iu38pr6	687	2	had	have	VBD
cord-005478-5iu38pr6	687	3	a	a	DT
cord-005478-5iu38pr6	687	4	median	median	NN
cord-005478-5iu38pr6	687	5	of	of	IN
cord-005478-5iu38pr6	687	6	14	14	CD
cord-005478-5iu38pr6	687	7	prior	prior	JJ
cord-005478-5iu38pr6	687	8	regimens	regimen	NNS
cord-005478-5iu38pr6	687	9	(	(	-LRB-
cord-005478-5iu38pr6	687	10	range	range	VBP
cord-005478-5iu38pr6	687	11	4	4	CD
cord-005478-5iu38pr6	687	12	to	to	IN
cord-005478-5iu38pr6	687	13	24	24	CD
cord-005478-5iu38pr6	687	14	)	)	-RRB-
cord-005478-5iu38pr6	687	15	(	(	-LRB-
cord-005478-5iu38pr6	687	16	Figure	figure	NN
cord-005478-5iu38pr6	687	17	1A	1a	NN
cord-005478-5iu38pr6	687	18	)	)	-RRB-
cord-005478-5iu38pr6	687	19	.	.	.
cord-005478-5iu38pr6	688	1	All	all	PDT
cord-005478-5iu38pr6	688	2	the	the	DT
cord-005478-5iu38pr6	688	3	17	17	CD
cord-005478-5iu38pr6	688	4	patients	patient	NNS
cord-005478-5iu38pr6	688	5	were	be	VBD
cord-005478-5iu38pr6	688	6	eligible	eligible	JJ
cord-005478-5iu38pr6	688	7	for	for	IN
cord-005478-5iu38pr6	688	8	initial	initial	JJ
cord-005478-5iu38pr6	688	9	evaluation	evaluation	NN
cord-005478-5iu38pr6	688	10	of	of	IN
cord-005478-5iu38pr6	688	11	early	early	JJ
cord-005478-5iu38pr6	688	12	clinical	clinical	JJ
cord-005478-5iu38pr6	688	13	response	response	NN
cord-005478-5iu38pr6	688	14	with	with	IN
cord-005478-5iu38pr6	688	15	a	a	DT
cord-005478-5iu38pr6	688	16	median	median	JJ
cord-005478-5iu38pr6	688	17	observation	observation	NN
cord-005478-5iu38pr6	688	18	period	period	NN
cord-005478-5iu38pr6	688	19	of	of	IN
cord-005478-5iu38pr6	688	20	12	12	CD
cord-005478-5iu38pr6	688	21	(	(	-LRB-
cord-005478-5iu38pr6	688	22	0.9	0.9	CD
cord-005478-5iu38pr6	688	23	to	to	TO
cord-005478-5iu38pr6	688	24	40	40	CD
cord-005478-5iu38pr6	688	25	)	)	-RRB-
cord-005478-5iu38pr6	688	26	weeks	week	NNS
cord-005478-5iu38pr6	688	27	.	.	.
cord-005478-5iu38pr6	689	1	ORR	ORR	NNP
cord-005478-5iu38pr6	689	2	was	be	VBD
cord-005478-5iu38pr6	689	3	100	100	CD
cord-005478-5iu38pr6	689	4	%	%	NN
cord-005478-5iu38pr6	689	5	.	.	.
cord-005478-5iu38pr6	690	1	All	all	PDT
cord-005478-5iu38pr6	690	2	the	the	DT
cord-005478-5iu38pr6	690	3	patients	patient	NNS
cord-005478-5iu38pr6	690	4	achieved	achieve	VBD
cord-005478-5iu38pr6	690	5	MRD	MRD	NNP
cord-005478-5iu38pr6	690	6	negative	negative	JJ
cord-005478-5iu38pr6	690	7	in	in	IN
cord-005478-5iu38pr6	690	8	bone	bone	NN
cord-005478-5iu38pr6	690	9	marrow	marrow	NN
cord-005478-5iu38pr6	690	10	by	by	IN
cord-005478-5iu38pr6	690	11	flow	flow	NN
cord-005478-5iu38pr6	690	12	cytometry	cytometry	NN
cord-005478-5iu38pr6	690	13	within	within	IN
cord-005478-5iu38pr6	690	14	1	1	CD
cord-005478-5iu38pr6	690	15	-	-	SYM
cord-005478-5iu38pr6	690	16	2	2	CD
cord-005478-5iu38pr6	690	17	weeks	week	NNS
cord-005478-5iu38pr6	690	18	after	after	IN
cord-005478-5iu38pr6	690	19	CAR	car	NN
cord-005478-5iu38pr6	690	20	-	-	HYPH
cord-005478-5iu38pr6	690	21	T	t	NN
cord-005478-5iu38pr6	690	22	infusion	infusion	NN
cord-005478-5iu38pr6	690	23	.	.	.
cord-005478-5iu38pr6	691	1	Partial	partial	JJ
cord-005478-5iu38pr6	691	2	response	response	NN
cord-005478-5iu38pr6	691	3	(	(	-LRB-
cord-005478-5iu38pr6	691	4	1	1	CD
cord-005478-5iu38pr6	691	5	PR	pr	NN
cord-005478-5iu38pr6	691	6	,	,	,
cord-005478-5iu38pr6	691	7	5.9	5.9	CD
cord-005478-5iu38pr6	691	8	%	%	NN
cord-005478-5iu38pr6	691	9	)	)	-RRB-
cord-005478-5iu38pr6	691	10	,	,	,
cord-005478-5iu38pr6	691	11	very	very	RB
cord-005478-5iu38pr6	691	12	good	good	JJ
cord-005478-5iu38pr6	691	13	PR	pr	NN
cord-005478-5iu38pr6	691	14	(	(	-LRB-
cord-005478-5iu38pr6	691	15	6	6	CD
cord-005478-5iu38pr6	691	16	VGPR	VGPR	NNS
cord-005478-5iu38pr6	691	17	,	,	,
cord-005478-5iu38pr6	691	18	35.3	35.3	CD
cord-005478-5iu38pr6	691	19	%	%	NN
cord-005478-5iu38pr6	691	20	)	)	-RRB-
cord-005478-5iu38pr6	691	21	,	,	,
cord-005478-5iu38pr6	691	22	and	and	CC
cord-005478-5iu38pr6	691	23	complete	complete	JJ
cord-005478-5iu38pr6	691	24	response	response	NN
cord-005478-5iu38pr6	691	25	(	(	-LRB-
cord-005478-5iu38pr6	691	26	10	10	CD
cord-005478-5iu38pr6	691	27	CR	cr	NN
cord-005478-5iu38pr6	691	28	,	,	,
cord-005478-5iu38pr6	691	29	58.9	58.9	CD
cord-005478-5iu38pr6	691	30	%	%	NN
cord-005478-5iu38pr6	691	31	)	)	-RRB-
cord-005478-5iu38pr6	691	32	within	within	IN
cord-005478-5iu38pr6	691	33	12	12	CD
cord-005478-5iu38pr6	691	34	weeks	week	NNS
cord-005478-5iu38pr6	691	35	post	post	NN
cord-005478-5iu38pr6	691	36	CAR	car	NN
cord-005478-5iu38pr6	691	37	-	-	HYPH
cord-005478-5iu38pr6	691	38	T	t	NN
cord-005478-5iu38pr6	691	39	infusion	infusion	NN
cord-005478-5iu38pr6	691	40	were	be	VBD
cord-005478-5iu38pr6	691	41	achieved	achieve	VBN
cord-005478-5iu38pr6	691	42	.	.	.
cord-005478-5iu38pr6	692	1	Durable	durable	JJ
cord-005478-5iu38pr6	692	2	responses	response	NNS
cord-005478-5iu38pr6	692	3	from	from	IN
cord-005478-5iu38pr6	692	4	4	4	CD
cord-005478-5iu38pr6	692	5	weeks	week	NNS
cord-005478-5iu38pr6	692	6	towards	towards	IN
cord-005478-5iu38pr6	692	7	the	the	DT
cord-005478-5iu38pr6	692	8	data	datum	NNS
cord-005478-5iu38pr6	692	9	cut	cut	VBN
cord-005478-5iu38pr6	692	10	-	-	HYPH
cord-005478-5iu38pr6	692	11	off	off	RP
cord-005478-5iu38pr6	692	12	date	date	NN
cord-005478-5iu38pr6	692	13	were	be	VBD
cord-005478-5iu38pr6	692	14	found	find	VBN
cord-005478-5iu38pr6	692	15	in	in	IN
cord-005478-5iu38pr6	692	16	15/17	15/17	CD
cord-005478-5iu38pr6	692	17	patients	patient	NNS
cord-005478-5iu38pr6	692	18	(	(	-LRB-
cord-005478-5iu38pr6	692	19	88.2	88.2	CD
cord-005478-5iu38pr6	692	20	%	%	NN
cord-005478-5iu38pr6	692	21	)	)	-RRB-
cord-005478-5iu38pr6	692	22	.	.	.
cord-005478-5iu38pr6	693	1	The	the	DT
cord-005478-5iu38pr6	693	2	disease	disease	NN
cord-005478-5iu38pr6	693	3	progressed	progress	VBD
cord-005478-5iu38pr6	693	4	in	in	IN
cord-005478-5iu38pr6	693	5	1	1	CD
cord-005478-5iu38pr6	693	6	patient	patient	NN
cord-005478-5iu38pr6	693	7	from	from	IN
cord-005478-5iu38pr6	693	8	PR	PR	NNP
cord-005478-5iu38pr6	693	9	by	by	IN
cord-005478-5iu38pr6	693	10	week	week	NN
cord-005478-5iu38pr6	693	11	5	5	CD
cord-005478-5iu38pr6	693	12	(	(	-LRB-
cord-005478-5iu38pr6	693	13	Figure	figure	NN
cord-005478-5iu38pr6	693	14	 	 	_SP
cord-005478-5iu38pr6	693	15	1B	1b	CD
cord-005478-5iu38pr6	693	16	)	)	-RRB-
cord-005478-5iu38pr6	693	17	.	.	.
cord-005478-5iu38pr6	694	1	One	one	CD
cord-005478-5iu38pr6	694	2	patient	patient	NN
cord-005478-5iu38pr6	694	3	died	die	VBD
cord-005478-5iu38pr6	694	4	of	of	IN
cord-005478-5iu38pr6	694	5	severe	severe	JJ
cord-005478-5iu38pr6	694	6	infection	infection	NN
cord-005478-5iu38pr6	694	7	by	by	IN
cord-005478-5iu38pr6	694	8	Day	day	NN
cord-005478-5iu38pr6	694	9	9	9	CD
cord-005478-5iu38pr6	694	10	.	.	.
cord-005478-5iu38pr6	695	1	All	all	DT
cord-005478-5iu38pr6	695	2	patients	patient	NNS
cord-005478-5iu38pr6	695	3	had	have	VBD
cord-005478-5iu38pr6	695	4	detectable	detectable	JJ
cord-005478-5iu38pr6	695	5	CAR	car	NN
cord-005478-5iu38pr6	695	6	-	-	HYPH
cord-005478-5iu38pr6	695	7	T	t	NN
cord-005478-5iu38pr6	695	8	expansion	expansion	NN
cord-005478-5iu38pr6	695	9	by	by	IN
cord-005478-5iu38pr6	695	10	flow	flow	NN
cord-005478-5iu38pr6	695	11	cytometry	cytometry	NN
cord-005478-5iu38pr6	695	12	from	from	IN
cord-005478-5iu38pr6	695	13	Day	day	NN
cord-005478-5iu38pr6	695	14	3	3	CD
cord-005478-5iu38pr6	695	15	post	post	NN
cord-005478-5iu38pr6	695	16	CAR	car	NN
cord-005478-5iu38pr6	695	17	-	-	HYPH
cord-005478-5iu38pr6	695	18	T	t	NN
cord-005478-5iu38pr6	695	19	cell	cell	NN
cord-005478-5iu38pr6	695	20	infusion	infusion	NN
cord-005478-5iu38pr6	695	21	.	.	.
cord-005478-5iu38pr6	696	1	Expansion	expansion	NN
cord-005478-5iu38pr6	696	2	peaks	peak	NNS
cord-005478-5iu38pr6	696	3	were	be	VBD
cord-005478-5iu38pr6	696	4	found	find	VBN
cord-005478-5iu38pr6	696	5	between	between	IN
cord-005478-5iu38pr6	696	6	Day	day	NN
cord-005478-5iu38pr6	696	7	6	6	CD
cord-005478-5iu38pr6	696	8	to	to	IN
cord-005478-5iu38pr6	696	9	Day	Day	NNP
cord-005478-5iu38pr6	696	10	17	17	CD
cord-005478-5iu38pr6	696	11	.	.	.
cord-005478-5iu38pr6	697	1	The	the	DT
cord-005478-5iu38pr6	697	2	peak	peak	NN
cord-005478-5iu38pr6	697	3	CAR	CAR	NNP
cord-005478-5iu38pr6	697	4	-	-	HYPH
cord-005478-5iu38pr6	697	5	T	t	NN
cord-005478-5iu38pr6	697	6	cell	cell	NN
cord-005478-5iu38pr6	697	7	expansion	expansion	NN
cord-005478-5iu38pr6	697	8	in	in	IN
cord-005478-5iu38pr6	697	9	CD3	CD3	NNP
cord-005478-5iu38pr6	697	10	+	+	CC
cord-005478-5iu38pr6	697	11	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	697	12	of	of	IN
cord-005478-5iu38pr6	697	13	peripheral	peripheral	JJ
cord-005478-5iu38pr6	697	14	blood	blood	NN
cord-005478-5iu38pr6	697	15	(	(	-LRB-
cord-005478-5iu38pr6	697	16	PB	PB	NNP
cord-005478-5iu38pr6	697	17	)	)	-RRB-
cord-005478-5iu38pr6	697	18	varied	vary	VBN
cord-005478-5iu38pr6	697	19	from	from	IN
cord-005478-5iu38pr6	697	20	35	35	CD
cord-005478-5iu38pr6	697	21	%	%	NN
cord-005478-5iu38pr6	697	22	to	to	TO
cord-005478-5iu38pr6	697	23	95	95	CD
cord-005478-5iu38pr6	697	24	%	%	NN
cord-005478-5iu38pr6	697	25	with	with	IN
cord-005478-5iu38pr6	697	26	a	a	DT
cord-005478-5iu38pr6	697	27	median	median	JJ
cord-005478-5iu38pr6	697	28	percentage	percentage	NN
cord-005478-5iu38pr6	697	29	of	of	IN
cord-005478-5iu38pr6	697	30	83.5	83.5	CD
cord-005478-5iu38pr6	697	31	%	%	NN
cord-005478-5iu38pr6	697	32	(	(	-LRB-
cord-005478-5iu38pr6	697	33	Figure	figure	NN
cord-005478-5iu38pr6	697	34	1C	1c	NN
cord-005478-5iu38pr6	697	35	)	)	-RRB-
cord-005478-5iu38pr6	697	36	.	.	.
cord-005478-5iu38pr6	698	1	The	the	DT
cord-005478-5iu38pr6	698	2	peak	peak	JJ
cord-005478-5iu38pr6	698	3	absolute	absolute	JJ
cord-005478-5iu38pr6	698	4	number	number	NN
cord-005478-5iu38pr6	698	5	of	of	IN
cord-005478-5iu38pr6	698	6	CAR	car	NN
cord-005478-5iu38pr6	698	7	-	-	HYPH
cord-005478-5iu38pr6	698	8	T	t	NN
cord-005478-5iu38pr6	698	9	cells	cell	NNS
cord-005478-5iu38pr6	698	10	in	in	IN
cord-005478-5iu38pr6	698	11	PB	PB	NNP
cord-005478-5iu38pr6	698	12	varied	varied	JJ
cord-005478-5iu38pr6	698	13	from	from	IN
cord-005478-5iu38pr6	698	14	530	530	CD
cord-005478-5iu38pr6	698	15	to	to	IN
cord-005478-5iu38pr6	698	16	23000	23000	CD
cord-005478-5iu38pr6	698	17	per	per	IN
cord-005478-5iu38pr6	698	18	μL	μl	NN
cord-005478-5iu38pr6	698	19	with	with	IN
cord-005478-5iu38pr6	698	20	a	a	DT
cord-005478-5iu38pr6	698	21	median	median	JJ
cord-005478-5iu38pr6	698	22	number	number	NN
cord-005478-5iu38pr6	698	23	of	of	IN
cord-005478-5iu38pr6	698	24	10300	10300	CD
cord-005478-5iu38pr6	698	25	per	per	IN
cord-005478-5iu38pr6	698	26	μL.	μL.	NNP
cord-005478-5iu38pr6	698	27	Cytokine	Cytokine	NNP
cord-005478-5iu38pr6	698	28	release	release	NN
cord-005478-5iu38pr6	698	29	syndrome	syndrome	NN
cord-005478-5iu38pr6	698	30	(	(	-LRB-
cord-005478-5iu38pr6	698	31	CRS	CRS	NNP
cord-005478-5iu38pr6	698	32	)	)	-RRB-
cord-005478-5iu38pr6	699	1	was	be	VBD
cord-005478-5iu38pr6	699	2	reported	report	VBN
cord-005478-5iu38pr6	699	3	in	in	IN
cord-005478-5iu38pr6	699	4	all	all	PDT
cord-005478-5iu38pr6	699	5	the	the	DT
cord-005478-5iu38pr6	699	6	17	17	CD
cord-005478-5iu38pr6	699	7	patients	patient	NNS
cord-005478-5iu38pr6	699	8	,	,	,
cord-005478-5iu38pr6	699	9	including	include	VBG
cord-005478-5iu38pr6	699	10	2	2	CD
cord-005478-5iu38pr6	699	11	with	with	IN
cord-005478-5iu38pr6	699	12	Grade	grade	NN
cord-005478-5iu38pr6	699	13	1	1	CD
cord-005478-5iu38pr6	699	14	,	,	,
cord-005478-5iu38pr6	699	15	4	4	CD
cord-005478-5iu38pr6	699	16	with	with	IN
cord-005478-5iu38pr6	699	17	Grade	grade	NN
cord-005478-5iu38pr6	699	18	2	2	CD
cord-005478-5iu38pr6	699	19	and	and	CC
cord-005478-5iu38pr6	699	20	11	11	CD
cord-005478-5iu38pr6	699	21	with	with	IN
cord-005478-5iu38pr6	699	22	Grade	Grade	NNP
cord-005478-5iu38pr6	699	23	3	3	CD
cord-005478-5iu38pr6	699	24	.	.	.
cord-005478-5iu38pr6	700	1	CAR	car	NN
cord-005478-5iu38pr6	700	2	-	-	HYPH
cord-005478-5iu38pr6	700	3	T	T	NNP
cord-005478-5iu38pr6	700	4	-related	-related	HYPH
cord-005478-5iu38pr6	700	5	AEs	AEs	NNP
cord-005478-5iu38pr6	700	6	were	be	VBD
cord-005478-5iu38pr6	700	7	9	9	CD
cord-005478-5iu38pr6	700	8	pancytopenia	pancytopenia	NNP
cord-005478-5iu38pr6	700	9	(	(	-LRB-
cord-005478-5iu38pr6	700	10	52.9	52.9	CD
cord-005478-5iu38pr6	700	11	%	%	NN
cord-005478-5iu38pr6	700	12	)	)	-RRB-
cord-005478-5iu38pr6	700	13	,	,	,
cord-005478-5iu38pr6	700	14	14	14	CD
cord-005478-5iu38pr6	700	15	fever	fever	NN
cord-005478-5iu38pr6	700	16	(	(	-LRB-
cord-005478-5iu38pr6	700	17	82.3	82.3	CD
cord-005478-5iu38pr6	700	18	%	%	NN
cord-005478-5iu38pr6	700	19	)	)	-RRB-
cord-005478-5iu38pr6	700	20	,	,	,
cord-005478-5iu38pr6	700	21	8	8	CD
cord-005478-5iu38pr6	700	22	nausea	nausea	NN
cord-005478-5iu38pr6	700	23	(	(	-LRB-
cord-005478-5iu38pr6	700	24	47.1	47.1	CD
cord-005478-5iu38pr6	700	25	%	%	NN
cord-005478-5iu38pr6	700	26	)	)	-RRB-
cord-005478-5iu38pr6	700	27	,	,	,
cord-005478-5iu38pr6	700	28	1	1	CD
cord-005478-5iu38pr6	700	29	heart	heart	NN
cord-005478-5iu38pr6	700	30	failure	failure	NN
cord-005478-5iu38pr6	700	31	(	(	-LRB-
cord-005478-5iu38pr6	700	32	5.8	5.8	CD
cord-005478-5iu38pr6	700	33	%	%	NN
cord-005478-5iu38pr6	700	34	)	)	-RRB-
cord-005478-5iu38pr6	700	35	.	.	.
cord-005478-5iu38pr6	701	1	No	no	DT
cord-005478-5iu38pr6	701	2	patient	patient	NN
cord-005478-5iu38pr6	701	3	died	die	VBD
cord-005478-5iu38pr6	701	4	of	of	IN
cord-005478-5iu38pr6	701	5	CRS	CRS	NNP
cord-005478-5iu38pr6	701	6	complication	complication	NN
cord-005478-5iu38pr6	701	7	.	.	.
cord-005478-5iu38pr6	702	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	702	2	:	:	:
cord-005478-5iu38pr6	703	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	703	2	data	datum	NNS
cord-005478-5iu38pr6	703	3	showed	show	VBD
cord-005478-5iu38pr6	703	4	BCMA	BCMA	NNP
cord-005478-5iu38pr6	703	5	CAR	CAR	NNP
cord-005478-5iu38pr6	703	6	-	-	HYPH
cord-005478-5iu38pr6	703	7	T	t	NN
cord-005478-5iu38pr6	703	8	treatment	treatment	NN
cord-005478-5iu38pr6	703	9	is	be	VBZ
cord-005478-5iu38pr6	703	10	safe	safe	JJ
cord-005478-5iu38pr6	703	11	with	with	IN
cord-005478-5iu38pr6	703	12	prominent	prominent	JJ
cord-005478-5iu38pr6	703	13	efficacy	efficacy	NN
cord-005478-5iu38pr6	703	14	.	.	.
cord-005478-5iu38pr6	704	1	We	-PRON-	PRP
cord-005478-5iu38pr6	704	2	also	also	RB
cord-005478-5iu38pr6	704	3	observed	observe	VBD
cord-005478-5iu38pr6	704	4	high	high	JJ
cord-005478-5iu38pr6	704	5	expansion	expansion	NN
cord-005478-5iu38pr6	704	6	level	level	NN
cord-005478-5iu38pr6	704	7	and	and	CC
cord-005478-5iu38pr6	704	8	long	long	JJ
cord-005478-5iu38pr6	704	9	term	term	NN
cord-005478-5iu38pr6	704	10	persistence	persistence	NN
cord-005478-5iu38pr6	704	11	of	of	IN
cord-005478-5iu38pr6	704	12	BCMA	BCMA	NNP
cord-005478-5iu38pr6	704	13	CAR	CAR	NNP
cord-005478-5iu38pr6	704	14	-	-	HYPH
cord-005478-5iu38pr6	704	15	T	t	NN
cord-005478-5iu38pr6	704	16	cells	cell	NNS
cord-005478-5iu38pr6	704	17	contribute	contribute	VBP
cord-005478-5iu38pr6	704	18	to	to	IN
cord-005478-5iu38pr6	704	19	potent	potent	JJ
cord-005478-5iu38pr6	704	20	anti	anti	JJ
cord-005478-5iu38pr6	704	21	-	-	JJ
cord-005478-5iu38pr6	704	22	myeloma	myeloma	JJ
cord-005478-5iu38pr6	704	23	activity	activity	NN
cord-005478-5iu38pr6	704	24	.	.	.
cord-005478-5iu38pr6	705	1	These	these	DT
cord-005478-5iu38pr6	705	2	initial	initial	JJ
cord-005478-5iu38pr6	705	3	data	datum	NNS
cord-005478-5iu38pr6	705	4	provide	provide	VBP
cord-005478-5iu38pr6	705	5	strong	strong	JJ
cord-005478-5iu38pr6	705	6	evidence	evidence	NN
cord-005478-5iu38pr6	705	7	to	to	TO
cord-005478-5iu38pr6	705	8	support	support	VB
cord-005478-5iu38pr6	705	9	the	the	DT
cord-005478-5iu38pr6	705	10	further	further	JJ
cord-005478-5iu38pr6	705	11	development	development	NN
cord-005478-5iu38pr6	705	12	of	of	IN
cord-005478-5iu38pr6	705	13	this	this	DT
cord-005478-5iu38pr6	705	14	anti	anti	JJ
cord-005478-5iu38pr6	705	15	-	-	JJ
cord-005478-5iu38pr6	705	16	myeloma	myeloma	JJ
cord-005478-5iu38pr6	705	17	cellular	cellular	JJ
cord-005478-5iu38pr6	705	18	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	705	19	.	.	.
cord-005478-5iu38pr6	706	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	706	2	Trial	Trial	NNP
cord-005478-5iu38pr6	706	3	Registry	Registry	NNP
cord-005478-5iu38pr6	706	4	:	:	:
cord-005478-5iu38pr6	706	5	ChiCTR1800017404	ChiCTR1800017404	.
cord-005478-5iu38pr6	707	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	707	2	:	:	:
cord-005478-5iu38pr6	707	3	Nothing	nothing	NN
cord-005478-5iu38pr6	707	4	to	to	TO
cord-005478-5iu38pr6	707	5	declare	declare	VB
cord-005478-5iu38pr6	707	6	Chimeric	chimeric	JJ
cord-005478-5iu38pr6	707	7	antigen	antigen	NN
cord-005478-5iu38pr6	707	8	receptor	receptor	NN
cord-005478-5iu38pr6	707	9	(	(	-LRB-
cord-005478-5iu38pr6	708	1	CAR)-mediated	car)-mediated	JJ
cord-005478-5iu38pr6	708	2	BCL11B	BCL11B	VBZ
cord-005478-5iu38pr6	708	3	suppression	suppression	NN
cord-005478-5iu38pr6	708	4	in	in	IN
cord-005478-5iu38pr6	708	5	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	708	6	progenitor	progenitor	NN
cord-005478-5iu38pr6	708	7	cells	cell	NNS
cord-005478-5iu38pr6	708	8	propagates	propagate	VBZ
cord-005478-5iu38pr6	708	9	natural	natural	JJ
cord-005478-5iu38pr6	708	10	killer	killer	NN
cord-005478-5iu38pr6	708	11	-	-	HYPH
cord-005478-5iu38pr6	708	12	like	like	JJ
cord-005478-5iu38pr6	708	13	cell	cell	NN
cord-005478-5iu38pr6	708	14	development	development	NN
cord-005478-5iu38pr6	708	15	Background	background	NN
cord-005478-5iu38pr6	708	16	:	:	:
cord-005478-5iu38pr6	709	1	The	the	DT
cord-005478-5iu38pr6	709	2	transcription	transcription	NN
cord-005478-5iu38pr6	709	3	factor	factor	NN
cord-005478-5iu38pr6	709	4	B	B	NNP
cord-005478-5iu38pr6	709	5	Cell	Cell	NNP
cord-005478-5iu38pr6	709	6	CLL	CLL	NNP
cord-005478-5iu38pr6	709	7	/	/	SYM
cord-005478-5iu38pr6	709	8	Lymphoma	Lymphoma	NNP
cord-005478-5iu38pr6	709	9	11B	11B	NNS
cord-005478-5iu38pr6	709	10	(	(	-LRB-
cord-005478-5iu38pr6	709	11	Bcl11b	Bcl11b	NNP
cord-005478-5iu38pr6	709	12	)	)	-RRB-
cord-005478-5iu38pr6	709	13	is	be	VBZ
cord-005478-5iu38pr6	709	14	indispensable	indispensable	JJ
cord-005478-5iu38pr6	709	15	for	for	IN
cord-005478-5iu38pr6	709	16	T	T	NNP
cord-005478-5iu38pr6	709	17	lineage	lineage	NN
cord-005478-5iu38pr6	709	18	development	development	NN
cord-005478-5iu38pr6	709	19	of	of	IN
cord-005478-5iu38pr6	709	20	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	709	21	progenitors	progenitor	NNS
cord-005478-5iu38pr6	709	22	.	.	.
cord-005478-5iu38pr6	710	1	Pre	pre	JJ
cord-005478-5iu38pr6	710	2	-	-	JJ
cord-005478-5iu38pr6	710	3	fabricated	fabricated	JJ
cord-005478-5iu38pr6	710	4	T	t	NN
cord-005478-5iu38pr6	710	5	cell	cell	NN
cord-005478-5iu38pr6	710	6	products	product	NNS
cord-005478-5iu38pr6	710	7	,	,	,
cord-005478-5iu38pr6	710	8	allowing	allow	VBG
cord-005478-5iu38pr6	710	9	for	for	IN
cord-005478-5iu38pr6	710	10	a	a	DT
cord-005478-5iu38pr6	710	11	wider	wide	JJR
cord-005478-5iu38pr6	710	12	choice	choice	NN
cord-005478-5iu38pr6	710	13	of	of	IN
cord-005478-5iu38pr6	710	14	effectively	effectively	RB
cord-005478-5iu38pr6	710	15	targetable	targetable	JJ
cord-005478-5iu38pr6	710	16	antigens	antigen	NNS
cord-005478-5iu38pr6	710	17	,	,	,
cord-005478-5iu38pr6	710	18	being	be	VBG
cord-005478-5iu38pr6	710	19	applicable	applicable	JJ
cord-005478-5iu38pr6	710	20	to	to	IN
cord-005478-5iu38pr6	710	21	a	a	DT
cord-005478-5iu38pr6	710	22	wider	wide	JJR
cord-005478-5iu38pr6	710	23	range	range	NN
cord-005478-5iu38pr6	710	24	of	of	IN
cord-005478-5iu38pr6	710	25	patients	patient	NNS
cord-005478-5iu38pr6	710	26	,	,	,
cord-005478-5iu38pr6	710	27	and	and	CC
cord-005478-5iu38pr6	710	28	minimizing	minimize	VBG
cord-005478-5iu38pr6	710	29	the	the	DT
cord-005478-5iu38pr6	710	30	risk	risk	NN
cord-005478-5iu38pr6	710	31	of	of	IN
cord-005478-5iu38pr6	710	32	long	long	JJ
cord-005478-5iu38pr6	710	33	-	-	HYPH
cord-005478-5iu38pr6	710	34	term	term	NN
cord-005478-5iu38pr6	710	35	sequalae	sequalae	NNS
cord-005478-5iu38pr6	710	36	from	from	IN
cord-005478-5iu38pr6	710	37	on	on	IN
cord-005478-5iu38pr6	710	38	target	target	NN
cord-005478-5iu38pr6	710	39	/	/	SYM
cord-005478-5iu38pr6	710	40	off	off	JJ
cord-005478-5iu38pr6	710	41	tumor	tumor	NN
cord-005478-5iu38pr6	710	42	effects	effect	NNS
cord-005478-5iu38pr6	710	43	would	would	MD
cord-005478-5iu38pr6	710	44	be	be	VB
cord-005478-5iu38pr6	710	45	highly	highly	RB
cord-005478-5iu38pr6	710	46	desirable	desirable	JJ
cord-005478-5iu38pr6	710	47	.	.	.
cord-005478-5iu38pr6	711	1	Here	here	RB
cord-005478-5iu38pr6	711	2	we	-PRON-	PRP
cord-005478-5iu38pr6	711	3	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	711	4	that	that	IN
cord-005478-5iu38pr6	711	5	antigen	antigen	NN
cord-005478-5iu38pr6	711	6	receptor	receptor	NN
cord-005478-5iu38pr6	711	7	engineering	engineering	NN
cord-005478-5iu38pr6	711	8	of	of	IN
cord-005478-5iu38pr6	711	9	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	711	10	stem	stem	NN
cord-005478-5iu38pr6	711	11	cells	cell	NNS
cord-005478-5iu38pr6	711	12	would	would	MD
cord-005478-5iu38pr6	711	13	fundamentally	fundamentally	RB
cord-005478-5iu38pr6	711	14	impact	impact	VB
cord-005478-5iu38pr6	711	15	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	711	16	progenitor	progenitor	NN
cord-005478-5iu38pr6	711	17	cell	cell	NN
cord-005478-5iu38pr6	711	18	fate	fate	NN
cord-005478-5iu38pr6	711	19	and	and	CC
cord-005478-5iu38pr6	711	20	as	as	IN
cord-005478-5iu38pr6	711	21	a	a	DT
cord-005478-5iu38pr6	711	22	consequence	consequence	NN
cord-005478-5iu38pr6	711	23	biological	biological	JJ
cord-005478-5iu38pr6	711	24	properties	property	NNS
cord-005478-5iu38pr6	711	25	thereby	thereby	RB
cord-005478-5iu38pr6	711	26	allowing	allow	VBG
cord-005478-5iu38pr6	711	27	to	to	TO
cord-005478-5iu38pr6	711	28	generate	generate	VB
cord-005478-5iu38pr6	711	29	an	an	DT
cord-005478-5iu38pr6	711	30	ubiquitously	ubiquitously	RB
cord-005478-5iu38pr6	711	31	available	available	JJ
cord-005478-5iu38pr6	711	32	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	711	33	cell	cell	NN
cord-005478-5iu38pr6	711	34	product	product	NN
cord-005478-5iu38pr6	711	35	for	for	IN
cord-005478-5iu38pr6	711	36	targeted	target	VBN
cord-005478-5iu38pr6	711	37	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	711	38	across	across	IN
cord-005478-5iu38pr6	711	39	MHC	MHC	NNP
cord-005478-5iu38pr6	711	40	barriers	barrier	NNS
cord-005478-5iu38pr6	711	41	.	.	.
cord-005478-5iu38pr6	712	1	Methods	method	NNS
cord-005478-5iu38pr6	712	2	:	:	:
cord-005478-5iu38pr6	713	1	Murine	murine	JJ
cord-005478-5iu38pr6	713	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	713	3	stem	stem	NN
cord-005478-5iu38pr6	713	4	cells	cell	NNS
cord-005478-5iu38pr6	713	5	were	be	VBD
cord-005478-5iu38pr6	713	6	transduced	transduce	VBN
cord-005478-5iu38pr6	713	7	with	with	IN
cord-005478-5iu38pr6	713	8	a	a	DT
cord-005478-5iu38pr6	713	9	broad	broad	JJ
cord-005478-5iu38pr6	713	10	panel	panel	NN
cord-005478-5iu38pr6	713	11	of	of	IN
cord-005478-5iu38pr6	713	12	1	1	CD
cord-005478-5iu38pr6	713	13	st	st	NNP
cord-005478-5iu38pr6	713	14	and	and	CC
cord-005478-5iu38pr6	713	15	2	2	CD
cord-005478-5iu38pr6	713	16	nd	nd	NNP
cord-005478-5iu38pr6	713	17	generation	generation	NN
cord-005478-5iu38pr6	713	18	murine	murine	JJ
cord-005478-5iu38pr6	713	19	CARs	car	NNS
cord-005478-5iu38pr6	713	20	containing	contain	VBG
cord-005478-5iu38pr6	713	21	different	different	JJ
cord-005478-5iu38pr6	713	22	costimulatory	costimulatory	NN
cord-005478-5iu38pr6	713	23	domains	domain	NNS
cord-005478-5iu38pr6	713	24	and	and	CC
cord-005478-5iu38pr6	713	25	numbers	number	NNS
cord-005478-5iu38pr6	713	26	of	of	IN
cord-005478-5iu38pr6	713	27	active	active	JJ
cord-005478-5iu38pr6	713	28	immune	immune	JJ
cord-005478-5iu38pr6	713	29	receptor	receptor	NN
cord-005478-5iu38pr6	713	30	-	-	HYPH
cord-005478-5iu38pr6	713	31	based	base	VBN
cord-005478-5iu38pr6	713	32	activation	activation	NN
cord-005478-5iu38pr6	713	33	motifs	motif	NNS
cord-005478-5iu38pr6	713	34	(	(	-LRB-
cord-005478-5iu38pr6	713	35	ITAMs	itam	NNS
cord-005478-5iu38pr6	713	36	)	)	-RRB-
cord-005478-5iu38pr6	713	37	against	against	IN
cord-005478-5iu38pr6	713	38	CD19	CD19	NNP
cord-005478-5iu38pr6	713	39	in	in	IN
cord-005478-5iu38pr6	713	40	a	a	DT
cord-005478-5iu38pr6	713	41	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	713	42	backbone	backbone	NN
cord-005478-5iu38pr6	713	43	and	and	CC
cord-005478-5iu38pr6	713	44	consecutively	consecutively	RB
cord-005478-5iu38pr6	713	45	differentiated	differentiate	VBN
cord-005478-5iu38pr6	713	46	into	into	IN
cord-005478-5iu38pr6	713	47	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	713	48	progenitors	progenitor	NNS
cord-005478-5iu38pr6	713	49	using	use	VBG
cord-005478-5iu38pr6	713	50	the	the	DT
cord-005478-5iu38pr6	713	51	OP9-DL1	OP9-DL1	NNP
cord-005478-5iu38pr6	713	52	feeder	feeder	NN
cord-005478-5iu38pr6	713	53	layer	layer	NN
cord-005478-5iu38pr6	713	54	system	system	NN
cord-005478-5iu38pr6	713	55	.	.	.
cord-005478-5iu38pr6	714	1	Resulting	result	VBG
cord-005478-5iu38pr6	714	2	products	product	NNS
cord-005478-5iu38pr6	714	3	were	be	VBD
cord-005478-5iu38pr6	714	4	comparatively	comparatively	RB
cord-005478-5iu38pr6	714	5	assessed	assess	VBN
cord-005478-5iu38pr6	714	6	in	in	IN
cord-005478-5iu38pr6	714	7	vitro	vitro	FW
cord-005478-5iu38pr6	714	8	and	and	CC
cord-005478-5iu38pr6	714	9	in	in	IN
cord-005478-5iu38pr6	714	10	vivo	vivo	FW
cord-005478-5iu38pr6	714	11	(	(	-LRB-
cord-005478-5iu38pr6	714	12	FACS	FACS	NNP
cord-005478-5iu38pr6	714	13	,	,	,
cord-005478-5iu38pr6	714	14	functional	functional	JJ
cord-005478-5iu38pr6	714	15	assays	assay	NNS
cord-005478-5iu38pr6	714	16	,	,	,
cord-005478-5iu38pr6	714	17	microarray	microarray	NNP
cord-005478-5iu38pr6	714	18	gene	gene	NN
cord-005478-5iu38pr6	714	19	transcript	transcript	NNP
cord-005478-5iu38pr6	714	20	analysis	analysis	NN
cord-005478-5iu38pr6	714	21	,	,	,
cord-005478-5iu38pr6	714	22	western	western	JJ
cord-005478-5iu38pr6	714	23	blotting	blotting	NN
cord-005478-5iu38pr6	714	24	,	,	,
cord-005478-5iu38pr6	714	25	timely	timely	RB
cord-005478-5iu38pr6	714	26	controlled	control	VBN
cord-005478-5iu38pr6	714	27	transgene	transgene	NN
cord-005478-5iu38pr6	714	28	expression	expression	NN
cord-005478-5iu38pr6	714	29	,	,	,
cord-005478-5iu38pr6	714	30	leukemia	leukemia	NN
cord-005478-5iu38pr6	714	31	challenge	challenge	NN
cord-005478-5iu38pr6	714	32	experiments	experiment	NNS
cord-005478-5iu38pr6	714	33	,	,	,
cord-005478-5iu38pr6	714	34	in	in	IN
cord-005478-5iu38pr6	714	35	vivo	vivo	NN
cord-005478-5iu38pr6	714	36	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	714	37	depletion	depletion	NN
cord-005478-5iu38pr6	714	38	experiments	experiment	NNS
cord-005478-5iu38pr6	714	39	)	)	-RRB-
cord-005478-5iu38pr6	714	40	upon	upon	IN
cord-005478-5iu38pr6	714	41	co	co	NN
cord-005478-5iu38pr6	714	42	-	-	NN
cord-005478-5iu38pr6	714	43	transplantation	transplantation	NN
cord-005478-5iu38pr6	714	44	into	into	IN
cord-005478-5iu38pr6	714	45	a	a	DT
cord-005478-5iu38pr6	714	46	MHC	MHC	NNP
cord-005478-5iu38pr6	714	47	-	-	HYPH
cord-005478-5iu38pr6	714	48	mismatched	mismatch	VBN
cord-005478-5iu38pr6	714	49	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	714	50	transplantation	transplantation	NN
cord-005478-5iu38pr6	714	51	model	model	NN
cord-005478-5iu38pr6	714	52	for	for	IN
cord-005478-5iu38pr6	714	53	relapsed	relapse	VBN
cord-005478-5iu38pr6	714	54	leukemia	leukemia	NN
cord-005478-5iu38pr6	714	55	.	.	.
cord-005478-5iu38pr6	715	1	Results	result	NNS
cord-005478-5iu38pr6	715	2	:	:	:
cord-005478-5iu38pr6	716	1	CAR	car	NN
cord-005478-5iu38pr6	716	2	expression	expression	NN
cord-005478-5iu38pr6	716	3	on	on	IN
cord-005478-5iu38pr6	716	4	early	early	JJ
cord-005478-5iu38pr6	716	5	ex	ex	NN
cord-005478-5iu38pr6	716	6	vivo	vivo	NN
cord-005478-5iu38pr6	716	7	generated	generate	VBN
cord-005478-5iu38pr6	716	8	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	716	9	progenitors	progenitor	NNS
cord-005478-5iu38pr6	716	10	suppresses	suppress	VBZ
cord-005478-5iu38pr6	716	11	Bcl11b	Bcl11b	NNS
cord-005478-5iu38pr6	716	12	(	(	-LRB-
cord-005478-5iu38pr6	716	13	Figure	figure	NN
cord-005478-5iu38pr6	716	14	1B	1b	CD
cord-005478-5iu38pr6	716	15	)	)	-RRB-
cord-005478-5iu38pr6	716	16	and	and	CC
cord-005478-5iu38pr6	716	17	leads	lead	VBZ
cord-005478-5iu38pr6	716	18	to	to	IN
cord-005478-5iu38pr6	716	19	decreased	decrease	VBD
cord-005478-5iu38pr6	716	20	T	T	NNP
cord-005478-5iu38pr6	716	21	cell	cell	NN
cord-005478-5iu38pr6	716	22	-	-	HYPH
cord-005478-5iu38pr6	716	23	associated	associate	VBN
cord-005478-5iu38pr6	716	24	gene	gene	NN
cord-005478-5iu38pr6	716	25	expression	expression	NN
cord-005478-5iu38pr6	716	26	.	.	.
cord-005478-5iu38pr6	717	1	Concomitantly	concomitantly	RB
cord-005478-5iu38pr6	717	2	,	,	,
cord-005478-5iu38pr6	717	3	suppressed	suppress	VBN
cord-005478-5iu38pr6	717	4	Bcl11b	Bcl11b	NNP
cord-005478-5iu38pr6	717	5	permits	permit	VBZ
cord-005478-5iu38pr6	717	6	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	717	7	progenitors	progenitor	NNS
cord-005478-5iu38pr6	717	8	to	to	TO
cord-005478-5iu38pr6	717	9	acquire	acquire	VB
cord-005478-5iu38pr6	717	10	NK	NK	NNP
cord-005478-5iu38pr6	717	11	cell	cell	NN
cord-005478-5iu38pr6	717	12	-	-	HYPH
cord-005478-5iu38pr6	717	13	like	like	JJ
cord-005478-5iu38pr6	717	14	properties	property	NNS
cord-005478-5iu38pr6	717	15	(	(	-LRB-
cord-005478-5iu38pr6	717	16	Figure	figure	NN
cord-005478-5iu38pr6	717	17	1A	1a	NN
cord-005478-5iu38pr6	717	18	)	)	-RRB-
cord-005478-5iu38pr6	717	19	and	and	CC
cord-005478-5iu38pr6	717	20	upon	upon	IN
cord-005478-5iu38pr6	717	21	adoptive	adoptive	JJ
cord-005478-5iu38pr6	717	22	transfer	transfer	NN
cord-005478-5iu38pr6	717	23	into	into	IN
cord-005478-5iu38pr6	717	24	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	717	25	stem	stem	NN
cord-005478-5iu38pr6	717	26	cell	cell	NN
cord-005478-5iu38pr6	717	27	transplant	transplant	NN
cord-005478-5iu38pr6	717	28	recipients	recipient	NNS
cord-005478-5iu38pr6	717	29	they	-PRON-	PRP
cord-005478-5iu38pr6	717	30	differentiate	differentiate	VBP
cord-005478-5iu38pr6	717	31	into	into	IN
cord-005478-5iu38pr6	717	32	CARinduced	carinduced	JJ
cord-005478-5iu38pr6	717	33	killer	killer	NN
cord-005478-5iu38pr6	717	34	cells	cell	NNS
cord-005478-5iu38pr6	717	35	(	(	-LRB-
cord-005478-5iu38pr6	717	36	CARiK	carik	NN
cord-005478-5iu38pr6	717	37	)	)	-RRB-
cord-005478-5iu38pr6	717	38	that	that	WDT
cord-005478-5iu38pr6	717	39	mediate	mediate	VBP
cord-005478-5iu38pr6	717	40	potent	potent	JJ
cord-005478-5iu38pr6	717	41	antigendirected	antigendirecte	VBN
cord-005478-5iu38pr6	717	42	antileukemic	antileukemic	JJ
cord-005478-5iu38pr6	717	43	activity	activity	NN
cord-005478-5iu38pr6	717	44	across	across	IN
cord-005478-5iu38pr6	717	45	MHC	MHC	NNP
cord-005478-5iu38pr6	717	46	barriers	barrier	NNS
cord-005478-5iu38pr6	717	47	(	(	-LRB-
cord-005478-5iu38pr6	717	48	Figure	figure	NN
cord-005478-5iu38pr6	717	49	 	 	_SP
cord-005478-5iu38pr6	717	50	1C	1c	NN
cord-005478-5iu38pr6	717	51	,	,	,
cord-005478-5iu38pr6	717	52	D	D	NNP
cord-005478-5iu38pr6	717	53	)	)	-RRB-
cord-005478-5iu38pr6	717	54	.	.	.
cord-005478-5iu38pr6	718	1	A	a	DT
cord-005478-5iu38pr6	718	2	CD28	CD28	NNP
cord-005478-5iu38pr6	718	3	,	,	,
cord-005478-5iu38pr6	718	4	but	but	CC
cord-005478-5iu38pr6	718	5	not	not	RB
cord-005478-5iu38pr6	718	6	4	4	CD
cord-005478-5iu38pr6	718	7	-	-	HYPH
cord-005478-5iu38pr6	718	8	1BB	1BB	NNP
cord-005478-5iu38pr6	718	9	,	,	,
cord-005478-5iu38pr6	718	10	costimulatory	costimulatory	NN
cord-005478-5iu38pr6	718	11	domain	domain	NN
cord-005478-5iu38pr6	718	12	and	and	CC
cord-005478-5iu38pr6	718	13	active	active	JJ
cord-005478-5iu38pr6	718	14	ITAMs	itam	NNS
cord-005478-5iu38pr6	718	15	are	be	VBP
cord-005478-5iu38pr6	718	16	critical	critical	JJ
cord-005478-5iu38pr6	718	17	for	for	IN
cord-005478-5iu38pr6	718	18	a	a	DT
cord-005478-5iu38pr6	718	19	functional	functional	JJ
cord-005478-5iu38pr6	718	20	CARiK	carik	NN
cord-005478-5iu38pr6	718	21	phenotype	phenotype	NN
cord-005478-5iu38pr6	718	22	.	.	.
cord-005478-5iu38pr6	719	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	719	2	:	:	:
cord-005478-5iu38pr6	720	1	These	these	DT
cord-005478-5iu38pr6	720	2	results	result	NNS
cord-005478-5iu38pr6	720	3	give	give	VBP
cord-005478-5iu38pr6	720	4	important	important	JJ
cord-005478-5iu38pr6	720	5	insights	insight	NNS
cord-005478-5iu38pr6	720	6	into	into	IN
cord-005478-5iu38pr6	720	7	differentiation	differentiation	NN
cord-005478-5iu38pr6	720	8	of	of	IN
cord-005478-5iu38pr6	720	9	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	720	10	progenitors	progenitor	NNS
cord-005478-5iu38pr6	720	11	driven	drive	VBN
cord-005478-5iu38pr6	720	12	by	by	IN
cord-005478-5iu38pr6	720	13	synthetic	synthetic	JJ
cord-005478-5iu38pr6	720	14	CAR	car	NN
cord-005478-5iu38pr6	720	15	transgene	transgene	NN
cord-005478-5iu38pr6	720	16	-	-	HYPH
cord-005478-5iu38pr6	720	17	expression	expression	NN
cord-005478-5iu38pr6	720	18	and	and	CC
cord-005478-5iu38pr6	720	19	inform	inform	VB
cord-005478-5iu38pr6	720	20	the	the	DT
cord-005478-5iu38pr6	720	21	potential	potential	JJ
cord-005478-5iu38pr6	720	22	use	use	NN
cord-005478-5iu38pr6	720	23	of	of	IN
cord-005478-5iu38pr6	720	24	ex	ex	FW
cord-005478-5iu38pr6	720	25	vivo	vivo	NN
cord-005478-5iu38pr6	720	26	generated	generate	VBN
cord-005478-5iu38pr6	720	27	CARiK	carik	NN
cord-005478-5iu38pr6	720	28	as	as	IN
cord-005478-5iu38pr6	720	29	an	an	DT
cord-005478-5iu38pr6	720	30	"	"	``
cord-005478-5iu38pr6	720	31	off	off	IN
cord-005478-5iu38pr6	720	32	-	-	HYPH
cord-005478-5iu38pr6	720	33	the	the	DT
cord-005478-5iu38pr6	720	34	-	-	HYPH
cord-005478-5iu38pr6	720	35	shelf	shelf	NN
cord-005478-5iu38pr6	720	36	"	"	''
cord-005478-5iu38pr6	720	37	product	product	NN
cord-005478-5iu38pr6	720	38	for	for	IN
cord-005478-5iu38pr6	720	39	targeted	target	VBN
cord-005478-5iu38pr6	720	40	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	720	41	.	.	.
cord-005478-5iu38pr6	721	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	721	2	:	:	:
cord-005478-5iu38pr6	722	1	M.v.d	M.v.d	NNP
cord-005478-5iu38pr6	722	2	.	.	.
cord-005478-5iu38pr6	722	3	B	b	NN
cord-005478-5iu38pr6	722	4	has	have	VBZ
cord-005478-5iu38pr6	722	5	IP	IP	NNP
cord-005478-5iu38pr6	722	6	Licensing	licensing	NN
cord-005478-5iu38pr6	722	7	with	with	IN
cord-005478-5iu38pr6	722	8	Seres	Seres	NNP
cord-005478-5iu38pr6	722	9	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	722	10	and	and	CC
cord-005478-5iu38pr6	722	11	Juno	Juno	NNP
cord-005478-5iu38pr6	722	12	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	722	13	.	.	.
cord-005478-5iu38pr6	723	1	M.v.d	M.v.d	NNP
cord-005478-5iu38pr6	723	2	.	.	.
cord-005478-5iu38pr6	724	1	B.	B.	NNP
cord-005478-5iu38pr6	724	2	has	have	VBZ
cord-005478-5iu38pr6	724	3	also	also	RB
cord-005478-5iu38pr6	724	4	received	receive	VBN
cord-005478-5iu38pr6	724	5	honorariums	honorarium	NNS
cord-005478-5iu38pr6	724	6	from	from	IN
cord-005478-5iu38pr6	724	7	Flagship	Flagship	NNP
cord-005478-5iu38pr6	724	8	Ventures	Ventures	NNPS
cord-005478-5iu38pr6	724	9	,	,	,
cord-005478-5iu38pr6	724	10	Novartis	Novartis	NNP
cord-005478-5iu38pr6	724	11	,	,	,
cord-005478-5iu38pr6	724	12	Evelo	Evelo	NNP
cord-005478-5iu38pr6	724	13	,	,	,
cord-005478-5iu38pr6	724	14	Seres	Seres	NNP
cord-005478-5iu38pr6	724	15	,	,	,
cord-005478-5iu38pr6	724	16	Jazz	Jazz	NNP
cord-005478-5iu38pr6	724	17	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	724	18	,	,	,
cord-005478-5iu38pr6	724	19	Therakos	Therakos	NNP
cord-005478-5iu38pr6	724	20	,	,	,
cord-005478-5iu38pr6	724	21	Amgen	Amgen	NNP
cord-005478-5iu38pr6	724	22	,	,	,
cord-005478-5iu38pr6	724	23	Merck	Merck	NNP
cord-005478-5iu38pr6	724	24	&	&	CC
cord-005478-5iu38pr6	724	25	Co	Co	NNP
cord-005478-5iu38pr6	724	26	,	,	,
cord-005478-5iu38pr6	724	27	Inc.	Inc.	NNP
cord-005478-5iu38pr6	724	28	,	,	,
cord-005478-5iu38pr6	724	29	Acute	Acute	NNP
cord-005478-5iu38pr6	724	30	Leukemia	Leukemia	NNP
cord-005478-5iu38pr6	724	31	Forum	Forum	NNP
cord-005478-5iu38pr6	724	32	(	(	-LRB-
cord-005478-5iu38pr6	724	33	ALF	ALF	NNP
cord-005478-5iu38pr6	724	34	)	)	-RRB-
cord-005478-5iu38pr6	724	35	,	,	,
cord-005478-5iu38pr6	724	36	and	and	CC
cord-005478-5iu38pr6	724	37	DKMS	DKMS	NNP
cord-005478-5iu38pr6	724	38	Medical	Medical	NNP
cord-005478-5iu38pr6	724	39	Council	Council	NNP
cord-005478-5iu38pr6	724	40	(	(	-LRB-
cord-005478-5iu38pr6	724	41	Board	Board	NNP
cord-005478-5iu38pr6	724	42	)	)	-RRB-
cord-005478-5iu38pr6	724	43	and	and	CC
cord-005478-5iu38pr6	724	44	research	research	NN
cord-005478-5iu38pr6	724	45	support	support	NN
cord-005478-5iu38pr6	724	46	and	and	CC
cord-005478-5iu38pr6	724	47	has	have	VBZ
cord-005478-5iu38pr6	724	48	stock	stock	NN
cord-005478-5iu38pr6	724	49	options	option	NNS
cord-005478-5iu38pr6	724	50	with	with	IN
cord-005478-5iu38pr6	724	51	Seres	Seres	NNP
cord-005478-5iu38pr6	724	52	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	724	53	.	.	.
cord-005478-5iu38pr6	725	1	A.G.	A.G.	NNP
cord-005478-5iu38pr6	725	2	has	have	VBZ
cord-005478-5iu38pr6	725	3	received	receive	VBN
cord-005478-5iu38pr6	725	4	research	research	NN
cord-005478-5iu38pr6	725	5	support	support	NN
cord-005478-5iu38pr6	725	6	from	from	IN
cord-005478-5iu38pr6	725	7	Aprea	Aprea	NNP
cord-005478-5iu38pr6	725	8	therapeutics	therapeutic	NNS
cord-005478-5iu38pr6	725	9	and	and	CC
cord-005478-5iu38pr6	725	10	Infinity	Infinity	NNP
cord-005478-5iu38pr6	725	11	therapeutics	therapeutic	NNS
cord-005478-5iu38pr6	725	12	.	.	.
cord-005478-5iu38pr6	726	1	All	all	DT
cord-005478-5iu38pr6	726	2	remaining	remain	VBG
cord-005478-5iu38pr6	726	3	authors	author	NNS
cord-005478-5iu38pr6	726	4	have	have	VBP
cord-005478-5iu38pr6	726	5	no	no	DT
cord-005478-5iu38pr6	726	6	conflict	conflict	NN
cord-005478-5iu38pr6	726	7	of	of	IN
cord-005478-5iu38pr6	726	8	interest	interest	NN
cord-005478-5iu38pr6	726	9	.	.	.
cord-005478-5iu38pr6	727	1	[	[	-LRB-
cord-005478-5iu38pr6	727	2	[	[	-LRB-
cord-005478-5iu38pr6	727	3	O043	o043	CD
cord-005478-5iu38pr6	727	4	Image	image	NN
cord-005478-5iu38pr6	727	5	]	]	-RRB-
cord-005478-5iu38pr6	727	6	1	1	CD
cord-005478-5iu38pr6	727	7	.	.	.
cord-005478-5iu38pr6	728	1	Figure	figure	NN
cord-005478-5iu38pr6	728	2	1	1	CD
cord-005478-5iu38pr6	728	3	:	:	:
cord-005478-5iu38pr6	728	4	CAR	car	NN
cord-005478-5iu38pr6	728	5	-	-	HYPH
cord-005478-5iu38pr6	728	6	induced	induce	VBN
cord-005478-5iu38pr6	728	7	killer	killer	NN
cord-005478-5iu38pr6	729	1	(	(	-LRB-
cord-005478-5iu38pr6	729	2	CARiK	carik	NN
cord-005478-5iu38pr6	729	3	)	)	-RRB-
cord-005478-5iu38pr6	729	4	cells	cell	NNS
cord-005478-5iu38pr6	729	5	provide	provide	VBP
cord-005478-5iu38pr6	729	6	strong	strong	JJ
cord-005478-5iu38pr6	729	7	anti	anti	JJ
cord-005478-5iu38pr6	729	8	-	-	JJ
cord-005478-5iu38pr6	729	9	leukemia	leukemia	JJ
cord-005478-5iu38pr6	729	10	effects	effect	NNS
cord-005478-5iu38pr6	729	11	in	in	IN
cord-005478-5iu38pr6	729	12	vivo	vivo	NN
cord-005478-5iu38pr6	729	13	.	.	.
cord-005478-5iu38pr6	729	14	]	]	-RRB-
cord-005478-5iu38pr6	730	1	(	(	-LRB-
cord-005478-5iu38pr6	730	2	A	a	NN
cord-005478-5iu38pr6	730	3	)	)	-RRB-
cord-005478-5iu38pr6	730	4	C57BL/6	c57bl/6	CD
cord-005478-5iu38pr6	731	1	(	(	-LRB-
cord-005478-5iu38pr6	731	2	B6	b6	NN
cord-005478-5iu38pr6	731	3	)	)	-RRB-
cord-005478-5iu38pr6	731	4	recipients	recipient	NNS
cord-005478-5iu38pr6	731	5	received	receive	VBD
cord-005478-5iu38pr6	731	6	3	3	CD
cord-005478-5iu38pr6	731	7	x	x	SYM
cord-005478-5iu38pr6	731	8	10	10	CD
cord-005478-5iu38pr6	731	9	6	6	CD
cord-005478-5iu38pr6	731	10	B6	b6	NN
cord-005478-5iu38pr6	731	11	TCD	TCD	NNP
cord-005478-5iu38pr6	731	12	-	-	HYPH
cord-005478-5iu38pr6	731	13	BM	BM	NNP
cord-005478-5iu38pr6	731	14	only	only	RB
cord-005478-5iu38pr6	731	15	or	or	CC
cord-005478-5iu38pr6	731	16	additionally	additionally	RB
cord-005478-5iu38pr6	731	17	with	with	IN
cord-005478-5iu38pr6	731	18	8	8	CD
cord-005478-5iu38pr6	731	19	x	x	SYM
cord-005478-5iu38pr6	731	20	10	10	CD
cord-005478-5iu38pr6	731	21	6	6	CD
cord-005478-5iu38pr6	731	22	syngeneic	syngeneic	NNS
cord-005478-5iu38pr6	731	23	im1928z1lymphoid	im1928z1lymphoid	JJ
cord-005478-5iu38pr6	731	24	progenitors	progenitor	NNS
cord-005478-5iu38pr6	731	25	.	.	.
cord-005478-5iu38pr6	732	1	Numbers	number	NNS
cord-005478-5iu38pr6	732	2	of	of	IN
cord-005478-5iu38pr6	732	3	NK1.1	nk1.1	NN
cord-005478-5iu38pr6	732	4	+	+	CC
cord-005478-5iu38pr6	732	5	CARiK	carik	NN
cord-005478-5iu38pr6	732	6	cells	cell	NNS
cord-005478-5iu38pr6	732	7	and	and	CC
cord-005478-5iu38pr6	732	8	frequencies	frequency	NNS
cord-005478-5iu38pr6	732	9	of	of	IN
cord-005478-5iu38pr6	732	10	CD3	CD3	NNP
cord-005478-5iu38pr6	732	11	+	+	CC
cord-005478-5iu38pr6	732	12	TCRβ	TCRβ	NNP
cord-005478-5iu38pr6	732	13	+	+	CC
cord-005478-5iu38pr6	732	14	progeny	progeny	NN
cord-005478-5iu38pr6	732	15	within	within	IN
cord-005478-5iu38pr6	732	16	the	the	DT
cord-005478-5iu38pr6	732	17	Tom+	Tom+	NNP
cord-005478-5iu38pr6	732	18	gate	gate	NN
cord-005478-5iu38pr6	732	19	in	in	IN
cord-005478-5iu38pr6	732	20	spleens	spleen	NNS
cord-005478-5iu38pr6	732	21	on	on	IN
cord-005478-5iu38pr6	732	22	day	day	NN
cord-005478-5iu38pr6	732	23	28	28	CD
cord-005478-5iu38pr6	733	1	(	(	-LRB-
cord-005478-5iu38pr6	733	2	im1928z1	im1928z1	UH
cord-005478-5iu38pr6	733	3	,	,	,
cord-005478-5iu38pr6	733	4	n=	n=	NNP
cord-005478-5iu38pr6	733	5	5	5	CD
cord-005478-5iu38pr6	733	6	;	;	,
cord-005478-5iu38pr6	733	7	iTom	itom	XX
cord-005478-5iu38pr6	733	8	,	,	,
cord-005478-5iu38pr6	733	9	n=	n=	NNP
cord-005478-5iu38pr6	733	10	4	4	CD
cord-005478-5iu38pr6	733	11	)	)	-RRB-
cord-005478-5iu38pr6	733	12	.	.	.
cord-005478-5iu38pr6	734	1	Statistics	statistic	NNS
cord-005478-5iu38pr6	734	2	was	be	VBD
cord-005478-5iu38pr6	734	3	performed	perform	VBN
cord-005478-5iu38pr6	734	4	by	by	IN
cord-005478-5iu38pr6	734	5	using	use	VBG
cord-005478-5iu38pr6	734	6	Students	student	NNS
cord-005478-5iu38pr6	734	7	t	t	XX
cord-005478-5iu38pr6	734	8	-	-	HYPH
cord-005478-5iu38pr6	734	9	test	test	NN
cord-005478-5iu38pr6	734	10	(	(	-LRB-
cord-005478-5iu38pr6	734	11	twotailed	twotailed	JJ
cord-005478-5iu38pr6	734	12	)	)	-RRB-
cord-005478-5iu38pr6	734	13	.	.	.
cord-005478-5iu38pr6	735	1	Data	datum	NNS
cord-005478-5iu38pr6	735	2	represent	represent	VBP
cord-005478-5iu38pr6	735	3	means	mean	VBZ
cord-005478-5iu38pr6	735	4	±	±	NNP
cord-005478-5iu38pr6	735	5	s.e.m	s.e.m	NN
cord-005478-5iu38pr6	735	6	.	.	.
cord-005478-5iu38pr6	736	1	(	(	-LRB-
cord-005478-5iu38pr6	736	2	B	b	NN
cord-005478-5iu38pr6	736	3	)	)	-RRB-
cord-005478-5iu38pr6	737	1	Western	western	JJ
cord-005478-5iu38pr6	737	2	blot	blot	NN
cord-005478-5iu38pr6	737	3	analysis	analysis	NN
cord-005478-5iu38pr6	737	4	for	for	IN
cord-005478-5iu38pr6	737	5	BCL11B	BCL11B	NNS
cord-005478-5iu38pr6	737	6	in	in	IN
cord-005478-5iu38pr6	737	7	lysates	lysate	NNS
cord-005478-5iu38pr6	737	8	from	from	IN
cord-005478-5iu38pr6	737	9	iTom	itom	JJ
cord-005478-5iu38pr6	737	10	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	737	11	progenitors	progenitor	NNS
cord-005478-5iu38pr6	737	12	,	,	,
cord-005478-5iu38pr6	737	13	im1928z1-lymphoid	im1928z1-lymphoid	SYM
cord-005478-5iu38pr6	737	14	progenitors	progenitor	NNS
cord-005478-5iu38pr6	737	15	or	or	CC
cord-005478-5iu38pr6	737	16	B6	B6	NNP
cord-005478-5iu38pr6	737	17	WT	WT	NNP
cord-005478-5iu38pr6	737	18	thymocytes	thymocyte	NNS
cord-005478-5iu38pr6	737	19	.	.	.
cord-005478-5iu38pr6	738	1	(	(	-LRB-
cord-005478-5iu38pr6	738	2	C	C	NNP
cord-005478-5iu38pr6	738	3	)	)	-RRB-
cord-005478-5iu38pr6	738	4	Recipients	recipient	NNS
cord-005478-5iu38pr6	738	5	co	co	VBP
cord-005478-5iu38pr6	738	6	-	-	VBN
cord-005478-5iu38pr6	738	7	transplanted	transplanted	JJ
cord-005478-5iu38pr6	739	1	with	with	IN
cord-005478-5iu38pr6	739	2	either	either	DT
cord-005478-5iu38pr6	739	3	syngeneic	syngeneic	NNS
cord-005478-5iu38pr6	739	4	(	(	-LRB-
cord-005478-5iu38pr6	739	5	syn	syn	NN
cord-005478-5iu38pr6	739	6	)	)	-RRB-
cord-005478-5iu38pr6	739	7	or	or	CC
cord-005478-5iu38pr6	739	8	MHC	MHC	NNP
cord-005478-5iu38pr6	740	1	class	class	NN
cord-005478-5iu38pr6	740	2	I	i	NN
cord-005478-5iu38pr6	740	3	and	and	CC
cord-005478-5iu38pr6	740	4	II	II	NNP
cord-005478-5iu38pr6	740	5	mismatched	mismatch	VBN
cord-005478-5iu38pr6	740	6	(	(	-LRB-
cord-005478-5iu38pr6	740	7	allo	allo	NN
cord-005478-5iu38pr6	740	8	)	)	-RRB-
cord-005478-5iu38pr6	740	9	im1928z1-expressing	im1928z1-expresse	VBG
cord-005478-5iu38pr6	740	10	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	740	11	progenitors	progenitor	NNS
cord-005478-5iu38pr6	740	12	(	(	-LRB-
cord-005478-5iu38pr6	740	13	n=	n=	NNP
cord-005478-5iu38pr6	740	14	10	10	CD
cord-005478-5iu38pr6	740	15	mice	mouse	NNS
cord-005478-5iu38pr6	740	16	,	,	,
cord-005478-5iu38pr6	740	17	respectively	respectively	RB
cord-005478-5iu38pr6	740	18	)	)	-RRB-
cord-005478-5iu38pr6	740	19	received	receive	VBD
cord-005478-5iu38pr6	740	20	1.2	1.2	CD
cord-005478-5iu38pr6	740	21	x	x	SYM
cord-005478-5iu38pr6	740	22	10	10	CD
cord-005478-5iu38pr6	740	23	6	6	CD
cord-005478-5iu38pr6	740	24	C1498-mCD19	C1498-mCD19	NNP
cord-005478-5iu38pr6	740	25	leukemic	leukemic	JJ
cord-005478-5iu38pr6	740	26	cells	cell	NNS
cord-005478-5iu38pr6	740	27	on	on	IN
cord-005478-5iu38pr6	740	28	day	day	NN
cord-005478-5iu38pr6	740	29	21	21	CD
cord-005478-5iu38pr6	740	30	after	after	IN
cord-005478-5iu38pr6	740	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	740	32	and	and	CC
cord-005478-5iu38pr6	740	33	monitored	monitor	VBN
cord-005478-5iu38pr6	740	34	for	for	IN
cord-005478-5iu38pr6	740	35	survival	survival	NN
cord-005478-5iu38pr6	740	36	.	.	.
cord-005478-5iu38pr6	741	1	(	(	-LRB-
cord-005478-5iu38pr6	741	2	D	D	NNP
cord-005478-5iu38pr6	741	3	)	)	-RRB-
cord-005478-5iu38pr6	741	4	CAR	car	NN
cord-005478-5iu38pr6	741	5	-	-	HYPH
cord-005478-5iu38pr6	741	6	lymphoid	lymphoid	NN
cord-005478-5iu38pr6	741	7	progenitor	progenitor	NN
cord-005478-5iu38pr6	741	8	-	-	HYPH
cord-005478-5iu38pr6	741	9	co	co	NN
cord-005478-5iu38pr6	741	10	-	-	JJ
cord-005478-5iu38pr6	741	11	transplanted	transplanted	JJ
cord-005478-5iu38pr6	741	12	mice	mouse	NNS
cord-005478-5iu38pr6	741	13	were	be	VBD
cord-005478-5iu38pr6	741	14	treated	treat	VBN
cord-005478-5iu38pr6	741	15	with	with	IN
cord-005478-5iu38pr6	741	16	weekly	weekly	JJ
cord-005478-5iu38pr6	741	17	i.p	i.p	NNP
cord-005478-5iu38pr6	741	18	.	.	.
cord-005478-5iu38pr6	741	19	injections	injection	NNS
cord-005478-5iu38pr6	741	20	of	of	IN
cord-005478-5iu38pr6	741	21	either	either	CC
cord-005478-5iu38pr6	741	22	an	an	DT
cord-005478-5iu38pr6	741	23	anti	anti	JJ
cord-005478-5iu38pr6	741	24	-	-	JJ
cord-005478-5iu38pr6	741	25	NK1.1	nk1.1	JJ
cord-005478-5iu38pr6	741	26	antibody	antibody	NN
cord-005478-5iu38pr6	741	27	(	(	-LRB-
cord-005478-5iu38pr6	741	28	clone	clone	NN
cord-005478-5iu38pr6	741	29	:	:	:
cord-005478-5iu38pr6	741	30	PK136	pk136	NN
cord-005478-5iu38pr6	741	31	;	;	:
cord-005478-5iu38pr6	741	32	200μg	200μg	NNP
cord-005478-5iu38pr6	741	33	/	/	SYM
cord-005478-5iu38pr6	741	34	dose	dose	NN
cord-005478-5iu38pr6	741	35	)	)	-RRB-
cord-005478-5iu38pr6	741	36	or	or	CC
cord-005478-5iu38pr6	742	1	with	with	IN
cord-005478-5iu38pr6	742	2	PBS	PBS	NNP
cord-005478-5iu38pr6	742	3	for	for	IN
cord-005478-5iu38pr6	742	4	control	control	NN
cord-005478-5iu38pr6	743	1	(	(	-LRB-
cord-005478-5iu38pr6	743	2	n=	n=	NNP
cord-005478-5iu38pr6	743	3	10	10	CD
cord-005478-5iu38pr6	743	4	per	per	IN
cord-005478-5iu38pr6	743	5	group	group	NN
cord-005478-5iu38pr6	743	6	)	)	-RRB-
cord-005478-5iu38pr6	743	7	.	.	.
cord-005478-5iu38pr6	744	1	All	all	DT
cord-005478-5iu38pr6	744	2	mice	mouse	NNS
cord-005478-5iu38pr6	744	3	received	receive	VBD
cord-005478-5iu38pr6	744	4	1.2	1.2	CD
cord-005478-5iu38pr6	744	5	x	x	SYM
cord-005478-5iu38pr6	744	6	10	10	CD
cord-005478-5iu38pr6	744	7	6	6	CD
cord-005478-5iu38pr6	744	8	C1498-mCD19	C1498-mCD19	NNP
cord-005478-5iu38pr6	744	9	cells	cell	NNS
cord-005478-5iu38pr6	744	10	on	on	IN
cord-005478-5iu38pr6	744	11	day	day	NN
cord-005478-5iu38pr6	744	12	21	21	CD
cord-005478-5iu38pr6	744	13	after	after	IN
cord-005478-5iu38pr6	744	14	transplantation	transplantation	NN
cord-005478-5iu38pr6	744	15	and	and	CC
cord-005478-5iu38pr6	744	16	were	be	VBD
cord-005478-5iu38pr6	744	17	monitored	monitor	VBN
cord-005478-5iu38pr6	744	18	for	for	IN
cord-005478-5iu38pr6	744	19	survival	survival	NN
cord-005478-5iu38pr6	744	20	.	.	.
cord-005478-5iu38pr6	745	1	Survival	survival	NN
cord-005478-5iu38pr6	745	2	curves	curve	NNS
cord-005478-5iu38pr6	745	3	were	be	VBD
cord-005478-5iu38pr6	745	4	compared	compare	VBN
cord-005478-5iu38pr6	745	5	using	use	VBG
cord-005478-5iu38pr6	745	6	Mantel	Mantel	NNP
cord-005478-5iu38pr6	745	7	-	-	HYPH
cord-005478-5iu38pr6	745	8	Cox	Cox	NNP
cord-005478-5iu38pr6	745	9	(	(	-LRB-
cord-005478-5iu38pr6	745	10	log	log	NN
cord-005478-5iu38pr6	745	11	-	-	HYPH
cord-005478-5iu38pr6	745	12	rank	rank	NN
cord-005478-5iu38pr6	745	13	)	)	-RRB-
cord-005478-5iu38pr6	745	14	test	test	NN
cord-005478-5iu38pr6	745	15	.	.	.
cord-005478-5iu38pr6	746	1	Significant	significant	JJ
cord-005478-5iu38pr6	746	2	differences	difference	NNS
cord-005478-5iu38pr6	746	3	are	be	VBP
cord-005478-5iu38pr6	746	4	indicated	indicate	VBN
cord-005478-5iu38pr6	746	5	by	by	IN
cord-005478-5iu38pr6	746	6	*	*	NFP
cord-005478-5iu38pr6	746	7	P	p	NN
cord-005478-5iu38pr6	746	8	<	<	XX
cord-005478-5iu38pr6	746	9	0.05	0.05	CD
cord-005478-5iu38pr6	746	10	,	,	.
cord-005478-5iu38pr6	747	1	*	*	NFP
cord-005478-5iu38pr6	747	2	*	*	NFP
cord-005478-5iu38pr6	747	3	*	*	NFP
cord-005478-5iu38pr6	747	4	P	p	NN
cord-005478-5iu38pr6	747	5	<	<	XX
cord-005478-5iu38pr6	747	6	0.001	0.001	CD
cord-005478-5iu38pr6	747	7	,	,	.
cord-005478-5iu38pr6	748	1	*	*	NFP
cord-005478-5iu38pr6	748	2	*	*	NFP
cord-005478-5iu38pr6	748	3	*	*	NFP
cord-005478-5iu38pr6	748	4	*	*	NFP
cord-005478-5iu38pr6	748	5	P	p	NN
cord-005478-5iu38pr6	748	6	<	<	XX
cord-005478-5iu38pr6	748	7	0.0001	0.0001	CD
cord-005478-5iu38pr6	748	8	.	.	.
cord-005478-5iu38pr6	749	1	Characterization	characterization	NN
cord-005478-5iu38pr6	749	2	of	of	IN
cord-005478-5iu38pr6	749	3	an	an	DT
cord-005478-5iu38pr6	749	4	HLA	HLA	NNP
cord-005478-5iu38pr6	749	5	-	-	HYPH
cord-005478-5iu38pr6	749	6	DPB1	dpb1	JJ
cord-005478-5iu38pr6	749	7	specific	specific	JJ
cord-005478-5iu38pr6	749	8	T	t	NN
cord-005478-5iu38pr6	749	9	-	-	HYPH
cord-005478-5iu38pr6	749	10	cell	cell	NN
cord-005478-5iu38pr6	749	11	receptor	receptor	NN
cord-005478-5iu38pr6	749	12	for	for	IN
cord-005478-5iu38pr6	749	13	adoptive	adoptive	JJ
cord-005478-5iu38pr6	749	14	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	749	15	Sebastian	Sebastian	NNP
cord-005478-5iu38pr6	749	16	Klobuch	Klobuch	NNP
cord-005478-5iu38pr6	749	17	1	1	CD
cord-005478-5iu38pr6	749	18	,	,	,
cord-005478-5iu38pr6	749	19	Elisabeth	Elisabeth	NNP
cord-005478-5iu38pr6	749	20	Neidlinger	Neidlinger	NNP
cord-005478-5iu38pr6	749	21	1	1	CD
cord-005478-5iu38pr6	749	22	,	,	,
cord-005478-5iu38pr6	749	23	Carina	Carina	NNP
cord-005478-5iu38pr6	749	24	Mirbeth	Mirbeth	NNP
cord-005478-5iu38pr6	749	25	1	1	CD
cord-005478-5iu38pr6	749	26	,	,	,
cord-005478-5iu38pr6	749	27	Wolfgang	Wolfgang	NNP
cord-005478-5iu38pr6	749	28	Herr	Herr	NNP
cord-005478-5iu38pr6	749	29	1,2	1,2	CD
cord-005478-5iu38pr6	749	30	,	,	,
cord-005478-5iu38pr6	749	31	Simone	Simone	NNP
cord-005478-5iu38pr6	749	32	Thomas	Thomas	NNP
cord-005478-5iu38pr6	749	33	1	1	CD
cord-005478-5iu38pr6	749	34	,	,	,
cord-005478-5iu38pr6	749	35	2	2	CD
cord-005478-5iu38pr6	749	36	Background	background	NN
cord-005478-5iu38pr6	749	37	:	:	:
cord-005478-5iu38pr6	750	1	HLA	HLA	NNP
cord-005478-5iu38pr6	750	2	-	-	HYPH
cord-005478-5iu38pr6	750	3	DPB1	dpb1	JJ
cord-005478-5iu38pr6	750	4	mismatches	mismatch	NNS
cord-005478-5iu38pr6	750	5	occur	occur	VBP
cord-005478-5iu38pr6	750	6	in	in	IN
cord-005478-5iu38pr6	750	7	up	up	IN
cord-005478-5iu38pr6	750	8	to	to	TO
cord-005478-5iu38pr6	750	9	80	80	CD
cord-005478-5iu38pr6	750	10	%	%	NN
cord-005478-5iu38pr6	750	11	of	of	IN
cord-005478-5iu38pr6	750	12	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	750	13	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	750	14	stem	stem	NN
cord-005478-5iu38pr6	750	15	cell	cell	NN
cord-005478-5iu38pr6	750	16	transplantations	transplantation	NNS
cord-005478-5iu38pr6	750	17	from	from	IN
cord-005478-5iu38pr6	750	18	HLA	HLA	NNP
cord-005478-5iu38pr6	750	19	10/10	10/10	CD
cord-005478-5iu38pr6	750	20	matched	match	VBN
cord-005478-5iu38pr6	750	21	donors	donor	NNS
cord-005478-5iu38pr6	750	22	and	and	CC
cord-005478-5iu38pr6	750	23	were	be	VBD
cord-005478-5iu38pr6	750	24	shown	show	VBN
cord-005478-5iu38pr6	750	25	to	to	TO
cord-005478-5iu38pr6	750	26	be	be	VB
cord-005478-5iu38pr6	750	27	associated	associate	VBN
cord-005478-5iu38pr6	750	28	with	with	IN
cord-005478-5iu38pr6	750	29	a	a	DT
cord-005478-5iu38pr6	750	30	decreased	decreased	JJ
cord-005478-5iu38pr6	750	31	risk	risk	NN
cord-005478-5iu38pr6	750	32	of	of	IN
cord-005478-5iu38pr6	750	33	leukemia	leukemia	NN
cord-005478-5iu38pr6	750	34	relapse	relapse	NN
cord-005478-5iu38pr6	750	35	.	.	.
cord-005478-5iu38pr6	751	1	Therefore	therefore	RB
cord-005478-5iu38pr6	751	2	,	,	,
cord-005478-5iu38pr6	751	3	targeting	target	VBG
cord-005478-5iu38pr6	751	4	HLA	HLA	NNP
cord-005478-5iu38pr6	751	5	-	-	HYPH
cord-005478-5iu38pr6	751	6	DPB1	DPB1	NNP
cord-005478-5iu38pr6	751	7	mismatched	mismatched	JJ
cord-005478-5iu38pr6	751	8	antigens	antigen	NNS
cord-005478-5iu38pr6	751	9	by	by	IN
cord-005478-5iu38pr6	751	10	donor	donor	NN
cord-005478-5iu38pr6	751	11	T	t	NN
cord-005478-5iu38pr6	751	12	cells	cell	NNS
cord-005478-5iu38pr6	751	13	seems	seem	VBZ
cord-005478-5iu38pr6	751	14	to	to	TO
cord-005478-5iu38pr6	751	15	be	be	VB
cord-005478-5iu38pr6	751	16	an	an	DT
cord-005478-5iu38pr6	751	17	attractive	attractive	JJ
cord-005478-5iu38pr6	751	18	strategy	strategy	NN
cord-005478-5iu38pr6	751	19	to	to	TO
cord-005478-5iu38pr6	751	20	enhance	enhance	VB
cord-005478-5iu38pr6	751	21	graft	graft	NN
cord-005478-5iu38pr6	751	22	-	-	HYPH
cord-005478-5iu38pr6	751	23	versusleukemia	versusleukemia	NN
cord-005478-5iu38pr6	751	24	effect	effect	NN
cord-005478-5iu38pr6	751	25	.	.	.
cord-005478-5iu38pr6	752	1	We	-PRON-	PRP
cord-005478-5iu38pr6	752	2	recently	recently	RB
cord-005478-5iu38pr6	752	3	established	establish	VBD
cord-005478-5iu38pr6	752	4	a	a	DT
cord-005478-5iu38pr6	752	5	reliable	reliable	JJ
cord-005478-5iu38pr6	752	6	method	method	NN
cord-005478-5iu38pr6	752	7	to	to	TO
cord-005478-5iu38pr6	752	8	generate	generate	VB
cord-005478-5iu38pr6	752	9	and	and	CC
cord-005478-5iu38pr6	752	10	isolate	isolate	VB
cord-005478-5iu38pr6	752	11	HLA	HLA	NNP
cord-005478-5iu38pr6	752	12	-	-	HYPH
cord-005478-5iu38pr6	752	13	DPB1	DPB1	NNP
cord-005478-5iu38pr6	752	14	mismatch	mismatch	NN
cord-005478-5iu38pr6	752	15	reactive	reactive	JJ
cord-005478-5iu38pr6	752	16	T	t	NN
cord-005478-5iu38pr6	752	17	cells	cell	NNS
cord-005478-5iu38pr6	752	18	receptors	receptor	NNS
cord-005478-5iu38pr6	752	19	(	(	-LRB-
cord-005478-5iu38pr6	752	20	TCR	TCR	NNP
cord-005478-5iu38pr6	752	21	)	)	-RRB-
cord-005478-5iu38pr6	752	22	.	.	.
cord-005478-5iu38pr6	753	1	TCR	TCR	NNP
cord-005478-5iu38pr6	753	2	-	-	HYPH
cord-005478-5iu38pr6	753	3	modified	modify	VBN
cord-005478-5iu38pr6	753	4	T	T	NNP
cord-005478-5iu38pr6	753	5	cells	cell	NNS
cord-005478-5iu38pr6	753	6	showed	show	VBD
cord-005478-5iu38pr6	753	7	leukemia	leukemia	NN
cord-005478-5iu38pr6	753	8	eradication	eradication	NN
cord-005478-5iu38pr6	753	9	of	of	IN
cord-005478-5iu38pr6	753	10	primary	primary	JJ
cord-005478-5iu38pr6	753	11	human	human	JJ
cord-005478-5iu38pr6	753	12	AML	AML	NNP
cord-005478-5iu38pr6	753	13	blasts	blast	NNS
cord-005478-5iu38pr6	753	14	in	in	IN
cord-005478-5iu38pr6	753	15	a	a	DT
cord-005478-5iu38pr6	753	16	xenogeneic	xenogeneic	JJ
cord-005478-5iu38pr6	753	17	NOD	NOD	NNP
cord-005478-5iu38pr6	753	18	/	/	SYM
cord-005478-5iu38pr6	753	19	SCID	SCID	NNP
cord-005478-5iu38pr6	753	20	/	/	SYM
cord-005478-5iu38pr6	753	21	IL2Rgc	IL2Rgc	NNP
cord-005478-5iu38pr6	753	22	-/-(NSG	-/-(NSG	NNP
cord-005478-5iu38pr6	753	23	)	)	-RRB-
cord-005478-5iu38pr6	753	24	mouse	mouse	NN
cord-005478-5iu38pr6	753	25	model	model	NN
cord-005478-5iu38pr6	753	26	.	.	.
cord-005478-5iu38pr6	754	1	However	however	RB
cord-005478-5iu38pr6	754	2	,	,	,
cord-005478-5iu38pr6	754	3	human	human	JJ
cord-005478-5iu38pr6	754	4	fibroblasts	fibroblast	NNS
cord-005478-5iu38pr6	754	5	used	use	VBN
cord-005478-5iu38pr6	754	6	as	as	IN
cord-005478-5iu38pr6	754	7	surrogate	surrogate	JJ
cord-005478-5iu38pr6	754	8	cells	cell	NNS
cord-005478-5iu38pr6	754	9	for	for	IN
cord-005478-5iu38pr6	754	10	graft	graft	NN
cord-005478-5iu38pr6	754	11	-	-	HYPH
cord-005478-5iu38pr6	754	12	versus	versus	IN
cord-005478-5iu38pr6	754	13	-	-	HYPH
cord-005478-5iu38pr6	754	14	host	host	NN
cord-005478-5iu38pr6	754	15	(	(	-LRB-
cord-005478-5iu38pr6	754	16	GvH	gvh	JJ
cord-005478-5iu38pr6	754	17	)	)	-RRB-
cord-005478-5iu38pr6	754	18	reactivity	reactivity	NN
cord-005478-5iu38pr6	754	19	were	be	VBD
cord-005478-5iu38pr6	754	20	also	also	RB
cord-005478-5iu38pr6	754	21	recognized	recognize	VBN
cord-005478-5iu38pr6	754	22	by	by	IN
cord-005478-5iu38pr6	754	23	HLA	HLA	NNP
cord-005478-5iu38pr6	754	24	-	-	HYPH
cord-005478-5iu38pr6	754	25	DPB1-specific	DPB1-specific	NNP
cord-005478-5iu38pr6	754	26	T	t	NN
cord-005478-5iu38pr6	754	27	cells	cell	NNS
cord-005478-5iu38pr6	754	28	upon	upon	IN
cord-005478-5iu38pr6	754	29	IFN	IFN	NNP
cord-005478-5iu38pr6	754	30	-	-	HYPH
cord-005478-5iu38pr6	754	31	γ	γ	NNP
cord-005478-5iu38pr6	754	32	pretreatment	pretreatment	NN
cord-005478-5iu38pr6	754	33	,	,	,
cord-005478-5iu38pr6	754	34	which	which	WDT
cord-005478-5iu38pr6	754	35	up	up	RB
cord-005478-5iu38pr6	754	36	-	-	HYPH
cord-005478-5iu38pr6	754	37	regulates	regulate	VBZ
cord-005478-5iu38pr6	754	38	HLA	HLA	NNP
cord-005478-5iu38pr6	754	39	-	-	HYPH
cord-005478-5iu38pr6	754	40	class	class	NN
cord-005478-5iu38pr6	754	41	II	ii	CD
cord-005478-5iu38pr6	754	42	expression	expression	NN
cord-005478-5iu38pr6	754	43	on	on	IN
cord-005478-5iu38pr6	754	44	these	these	DT
cord-005478-5iu38pr6	754	45	cells	cell	NNS
cord-005478-5iu38pr6	754	46	.	.	.
cord-005478-5iu38pr6	755	1	In	in	IN
cord-005478-5iu38pr6	755	2	this	this	DT
cord-005478-5iu38pr6	755	3	project	project	NN
cord-005478-5iu38pr6	755	4	,	,	,
cord-005478-5iu38pr6	755	5	we	-PRON-	PRP
cord-005478-5iu38pr6	755	6	aim	aim	VBP
cord-005478-5iu38pr6	755	7	at	at	IN
cord-005478-5iu38pr6	755	8	the	the	DT
cord-005478-5iu38pr6	755	9	isolation	isolation	NN
cord-005478-5iu38pr6	755	10	of	of	IN
cord-005478-5iu38pr6	755	11	TCRs	tcr	NNS
cord-005478-5iu38pr6	755	12	recognizing	recognize	VBG
cord-005478-5iu38pr6	755	13	mismatched	mismatch	VBN
cord-005478-5iu38pr6	755	14	HLA	HLA	NNP
cord-005478-5iu38pr6	755	15	-	-	HYPH
cord-005478-5iu38pr6	755	16	DPB1	DPB1	NNP
cord-005478-5iu38pr6	755	17	only	only	RB
cord-005478-5iu38pr6	755	18	on	on	IN
cord-005478-5iu38pr6	755	19	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	755	20	cells	cell	NNS
cord-005478-5iu38pr6	755	21	,	,	,
cord-005478-5iu38pr6	755	22	which	which	WDT
cord-005478-5iu38pr6	755	23	might	may	MD
cord-005478-5iu38pr6	755	24	lower	lower	VB
cord-005478-5iu38pr6	755	25	their	-PRON-	PRP$
cord-005478-5iu38pr6	755	26	risk	risk	NN
cord-005478-5iu38pr6	755	27	for	for	IN
cord-005478-5iu38pr6	755	28	GvHD	GvHD	NNP
cord-005478-5iu38pr6	755	29	.	.	.
cord-005478-5iu38pr6	756	1	Methods	method	NNS
cord-005478-5iu38pr6	756	2	:	:	:
cord-005478-5iu38pr6	757	1	Naive	naive	JJ
cord-005478-5iu38pr6	757	2	-	-	HYPH
cord-005478-5iu38pr6	757	3	enriched	enriched	JJ
cord-005478-5iu38pr6	757	4	CD4	CD4	NNP
cord-005478-5iu38pr6	757	5	T	T	NNP
cord-005478-5iu38pr6	757	6	cells	cell	NNS
cord-005478-5iu38pr6	757	7	were	be	VBD
cord-005478-5iu38pr6	757	8	stimulated	stimulate	VBN
cord-005478-5iu38pr6	757	9	with	with	IN
cord-005478-5iu38pr6	757	10	autologous	autologous	JJ
cord-005478-5iu38pr6	757	11	dendritic	dendritic	JJ
cord-005478-5iu38pr6	757	12	cells	cell	NNS
cord-005478-5iu38pr6	757	13	expressing	express	VBG
cord-005478-5iu38pr6	757	14	allo	allo	NNP
cord-005478-5iu38pr6	757	15	-	-	HYPH
cord-005478-5iu38pr6	757	16	HLA	HLA	NNP
cord-005478-5iu38pr6	757	17	-	-	HYPH
cord-005478-5iu38pr6	757	18	DPB1	DPB1	NNP
cord-005478-5iu38pr6	757	19	alleles	allele	NNS
cord-005478-5iu38pr6	757	20	upon	upon	IN
cord-005478-5iu38pr6	757	21	RNA	RNA	NNP
cord-005478-5iu38pr6	757	22	transfection	transfection	NN
cord-005478-5iu38pr6	757	23	.	.	.
cord-005478-5iu38pr6	758	1	To	to	TO
cord-005478-5iu38pr6	758	2	drive	drive	VB
cord-005478-5iu38pr6	758	3	the	the	DT
cord-005478-5iu38pr6	758	4	outgrowth	outgrowth	NN
cord-005478-5iu38pr6	758	5	of	of	IN
cord-005478-5iu38pr6	758	6	CD4	CD4	NNP
cord-005478-5iu38pr6	758	7	T	T	NNP
cord-005478-5iu38pr6	758	8	-	-	HYPH
cord-005478-5iu38pr6	758	9	cell	cell	NN
cord-005478-5iu38pr6	758	10	populations	population	NNS
cord-005478-5iu38pr6	758	11	expressing	express	VBG
cord-005478-5iu38pr6	758	12	'	'	``
cord-005478-5iu38pr6	758	13	CD4-independent	cd4-independent	NN
cord-005478-5iu38pr6	758	14	'	'	''
cord-005478-5iu38pr6	758	15	TCR	TCR	NNP
cord-005478-5iu38pr6	758	16	which	which	WDT
cord-005478-5iu38pr6	758	17	allow	allow	VBP
cord-005478-5iu38pr6	758	18	the	the	DT
cord-005478-5iu38pr6	758	19	redirection	redirection	NN
cord-005478-5iu38pr6	758	20	of	of	IN
cord-005478-5iu38pr6	758	21	both	both	CC
cord-005478-5iu38pr6	758	22	CD4	CD4	NNP
cord-005478-5iu38pr6	758	23	and	and	CC
cord-005478-5iu38pr6	758	24	CD8	CD8	NNP
cord-005478-5iu38pr6	758	25	T	T	NNP
cord-005478-5iu38pr6	758	26	cells	cell	NNS
cord-005478-5iu38pr6	758	27	,	,	,
cord-005478-5iu38pr6	758	28	we	-PRON-	PRP
cord-005478-5iu38pr6	758	29	blocked	block	VBD
cord-005478-5iu38pr6	758	30	the	the	DT
cord-005478-5iu38pr6	758	31	CD4	CD4	NNP
cord-005478-5iu38pr6	758	32	/	/	SYM
cord-005478-5iu38pr6	758	33	HLA	HLA	NNP
cord-005478-5iu38pr6	758	34	interactions	interaction	NNS
cord-005478-5iu38pr6	758	35	by	by	IN
cord-005478-5iu38pr6	758	36	the	the	DT
cord-005478-5iu38pr6	758	37	addition	addition	NN
cord-005478-5iu38pr6	758	38	of	of	IN
cord-005478-5iu38pr6	758	39	CD4	CD4	NNP
cord-005478-5iu38pr6	758	40	binding	bind	VBG
cord-005478-5iu38pr6	758	41	antibody	antibody	NN
cord-005478-5iu38pr6	758	42	.	.	.
cord-005478-5iu38pr6	759	1	Allo	Allo	NNP
cord-005478-5iu38pr6	759	2	-	-	HYPH
cord-005478-5iu38pr6	759	3	HLA	HLA	NNP
cord-005478-5iu38pr6	759	4	-	-	HYPH
cord-005478-5iu38pr6	759	5	DPB1	DPB1	NNP
cord-005478-5iu38pr6	759	6	reactive	reactive	JJ
cord-005478-5iu38pr6	759	7	cultures	culture	NNS
cord-005478-5iu38pr6	759	8	were	be	VBD
cord-005478-5iu38pr6	759	9	analyzed	analyze	VBN
cord-005478-5iu38pr6	759	10	for	for	IN
cord-005478-5iu38pr6	759	11	their	-PRON-	PRP$
cord-005478-5iu38pr6	759	12	recognition	recognition	NN
cord-005478-5iu38pr6	759	13	of	of	IN
cord-005478-5iu38pr6	759	14	primary	primary	JJ
cord-005478-5iu38pr6	759	15	AML	AML	NNP
cord-005478-5iu38pr6	759	16	blasts	blast	NNS
cord-005478-5iu38pr6	759	17	in	in	IN
cord-005478-5iu38pr6	759	18	IFN	IFN	NNP
cord-005478-5iu38pr6	759	19	-	-	HYPH
cord-005478-5iu38pr6	759	20	γ	γ	NNP
cord-005478-5iu38pr6	759	21	ELISpot	elispot	NN
cord-005478-5iu38pr6	759	22	as	as	RB
cord-005478-5iu38pr6	759	23	well	well	RB
cord-005478-5iu38pr6	759	24	as	as	IN
cord-005478-5iu38pr6	759	25	51	51	CD
cord-005478-5iu38pr6	759	26	Chromium	chromium	NN
cord-005478-5iu38pr6	759	27	-	-	HYPH
cord-005478-5iu38pr6	759	28	release	release	NN
cord-005478-5iu38pr6	759	29	assays	assay	NNS
cord-005478-5iu38pr6	759	30	.	.	.
cord-005478-5iu38pr6	760	1	Highly	highly	RB
cord-005478-5iu38pr6	760	2	reactive	reactive	JJ
cord-005478-5iu38pr6	760	3	CD4	CD4	NNP
cord-005478-5iu38pr6	760	4	T	T	NNP
cord-005478-5iu38pr6	760	5	cell	cell	NN
cord-005478-5iu38pr6	760	6	populations	population	NNS
cord-005478-5iu38pr6	760	7	were	be	VBD
cord-005478-5iu38pr6	760	8	further	further	RB
cord-005478-5iu38pr6	760	9	analyzed	analyze	VBN
cord-005478-5iu38pr6	760	10	for	for	IN
cord-005478-5iu38pr6	760	11	their	-PRON-	PRP$
cord-005478-5iu38pr6	760	12	IFN	IFN	NNP
cord-005478-5iu38pr6	760	13	-	-	HYPH
cord-005478-5iu38pr6	760	14	γ	γ	NN
cord-005478-5iu38pr6	760	15	secretion	secretion	NN
cord-005478-5iu38pr6	760	16	against	against	IN
cord-005478-5iu38pr6	760	17	nonhematopoietic	nonhematopoietic	JJ
cord-005478-5iu38pr6	760	18	cells	cell	NNS
cord-005478-5iu38pr6	760	19	.	.	.
cord-005478-5iu38pr6	761	1	TCRs	tcr	NNS
cord-005478-5iu38pr6	761	2	from	from	IN
cord-005478-5iu38pr6	761	3	most	most	RBS
cord-005478-5iu38pr6	761	4	promising	promising	JJ
cord-005478-5iu38pr6	761	5	CD4	CD4	NNP
cord-005478-5iu38pr6	761	6	T	T	NNP
cord-005478-5iu38pr6	761	7	cell	cell	NN
cord-005478-5iu38pr6	761	8	clones	clone	NNS
cord-005478-5iu38pr6	761	9	with	with	IN
cord-005478-5iu38pr6	761	10	an	an	DT
cord-005478-5iu38pr6	761	11	HLA	HLA	NNP
cord-005478-5iu38pr6	761	12	-	-	HYPH
cord-005478-5iu38pr6	761	13	DPB1	dpb1	JJ
cord-005478-5iu38pr6	761	14	specific	specific	JJ
cord-005478-5iu38pr6	761	15	recognition	recognition	NN
cord-005478-5iu38pr6	761	16	of	of	IN
cord-005478-5iu38pr6	761	17	hematopoietic	hematopoietic	NN
cord-005478-5iu38pr6	761	18	but	but	CC
cord-005478-5iu38pr6	761	19	not	not	RB
cord-005478-5iu38pr6	761	20	non	non	JJ
cord-005478-5iu38pr6	761	21	-	-	JJ
cord-005478-5iu38pr6	761	22	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	761	23	cells	cell	NNS
cord-005478-5iu38pr6	761	24	were	be	VBD
cord-005478-5iu38pr6	761	25	isolated	isolate	VBN
cord-005478-5iu38pr6	761	26	and	and	CC
cord-005478-5iu38pr6	761	27	further	further	RB
cord-005478-5iu38pr6	761	28	analyzed	analyze	VBN
cord-005478-5iu38pr6	761	29	.	.	.
cord-005478-5iu38pr6	762	1	Results	result	NNS
cord-005478-5iu38pr6	762	2	:	:	:
cord-005478-5iu38pr6	763	1	Two	two	CD
cord-005478-5iu38pr6	763	2	CD4-independent	cd4-independent	NN
cord-005478-5iu38pr6	763	3	T	t	NN
cord-005478-5iu38pr6	763	4	cell	cell	NN
cord-005478-5iu38pr6	763	5	clones	clone	NNS
cord-005478-5iu38pr6	763	6	with	with	IN
cord-005478-5iu38pr6	763	7	reactivity	reactivity	NN
cord-005478-5iu38pr6	763	8	to	to	IN
cord-005478-5iu38pr6	763	9	the	the	DT
cord-005478-5iu38pr6	763	10	HLA	HLA	NNP
cord-005478-5iu38pr6	763	11	-	-	HYPH
cord-005478-5iu38pr6	763	12	DPB1	DPB1	NNP
cord-005478-5iu38pr6	763	13	*	*	NFP
cord-005478-5iu38pr6	763	14	03:01	03:01	CD
cord-005478-5iu38pr6	763	15	mismatch	mismatch	NN
cord-005478-5iu38pr6	763	16	allele	allele	NN
cord-005478-5iu38pr6	763	17	specifically	specifically	RB
cord-005478-5iu38pr6	763	18	lysed	lyse	VBD
cord-005478-5iu38pr6	763	19	HLA	HLA	NNP
cord-005478-5iu38pr6	763	20	-	-	HYPH
cord-005478-5iu38pr6	763	21	DPB1	DPB1	NNP
cord-005478-5iu38pr6	764	1	*	*	NFP
cord-005478-5iu38pr6	764	2	03:01	03:01	CD
cord-005478-5iu38pr6	764	3	+	+	.
cord-005478-5iu38pr6	765	1	primary	primary	JJ
cord-005478-5iu38pr6	765	2	AML	AML	NNP
cord-005478-5iu38pr6	765	3	blasts	blast	NNS
cord-005478-5iu38pr6	765	4	.	.	.
cord-005478-5iu38pr6	766	1	Most	most	RBS
cord-005478-5iu38pr6	766	2	importantly	importantly	RB
cord-005478-5iu38pr6	766	3	,	,	,
cord-005478-5iu38pr6	766	4	one	one	CD
cord-005478-5iu38pr6	766	5	of	of	IN
cord-005478-5iu38pr6	766	6	these	these	DT
cord-005478-5iu38pr6	766	7	T	T	NNP
cord-005478-5iu38pr6	766	8	cell	cell	NN
cord-005478-5iu38pr6	766	9	clones	clone	NNS
cord-005478-5iu38pr6	766	10	did	do	VBD
cord-005478-5iu38pr6	766	11	not	not	RB
cord-005478-5iu38pr6	766	12	show	show	VB
cord-005478-5iu38pr6	766	13	IFN	IFN	NNP
cord-005478-5iu38pr6	766	14	-	-	HYPH
cord-005478-5iu38pr6	766	15	γ	γ	NN
cord-005478-5iu38pr6	766	16	secretion	secretion	NN
cord-005478-5iu38pr6	766	17	upon	upon	IN
cord-005478-5iu38pr6	766	18	co	co	NN
cord-005478-5iu38pr6	766	19	-	-	NN
cord-005478-5iu38pr6	766	20	culture	culture	NN
cord-005478-5iu38pr6	766	21	with	with	IN
cord-005478-5iu38pr6	766	22	IFN	IFN	NNP
cord-005478-5iu38pr6	766	23	-	-	HYPH
cord-005478-5iu38pr6	766	24	γ	γ	NNP
cord-005478-5iu38pr6	766	25	pretreated	pretreate	VBD
cord-005478-5iu38pr6	766	26	primary	primary	JJ
cord-005478-5iu38pr6	766	27	fibroblasts	fibroblast	NNS
cord-005478-5iu38pr6	766	28	.	.	.
cord-005478-5iu38pr6	767	1	Therefore	therefore	RB
cord-005478-5iu38pr6	767	2	,	,	,
cord-005478-5iu38pr6	767	3	we	-PRON-	PRP
cord-005478-5iu38pr6	767	4	isolated	isolate	VBD
cord-005478-5iu38pr6	767	5	this	this	DT
cord-005478-5iu38pr6	767	6	TCR	TCR	NNP
cord-005478-5iu38pr6	767	7	and	and	CC
cord-005478-5iu38pr6	767	8	transferred	transfer	VBD
cord-005478-5iu38pr6	767	9	it	-PRON-	PRP
cord-005478-5iu38pr6	767	10	into	into	IN
cord-005478-5iu38pr6	767	11	CD4	CD4	NNP
cord-005478-5iu38pr6	767	12	and	and	CC
cord-005478-5iu38pr6	767	13	CD8	CD8	NNP
cord-005478-5iu38pr6	767	14	T	T	NNP
cord-005478-5iu38pr6	767	15	cells	cell	NNS
cord-005478-5iu38pr6	767	16	from	from	IN
cord-005478-5iu38pr6	767	17	healthy	healthy	JJ
cord-005478-5iu38pr6	767	18	donors	donor	NNS
cord-005478-5iu38pr6	767	19	.	.	.
cord-005478-5iu38pr6	768	1	TCR	TCR	NNP
cord-005478-5iu38pr6	768	2	DP03	DP03	NNP
cord-005478-5iu38pr6	768	3	re	re	VBD
cord-005478-5iu38pr6	768	4	-	-	VBD
cord-005478-5iu38pr6	768	5	directed	direct	VBN
cord-005478-5iu38pr6	768	6	CD4	CD4	NNP
cord-005478-5iu38pr6	768	7	and	and	CC
cord-005478-5iu38pr6	768	8	CD8	CD8	NNP
cord-005478-5iu38pr6	768	9	T	T	NNP
cord-005478-5iu38pr6	768	10	cells	cell	NNS
cord-005478-5iu38pr6	768	11	specifically	specifically	RB
cord-005478-5iu38pr6	768	12	recognized	recognize	VBD
cord-005478-5iu38pr6	768	13	and	and	CC
cord-005478-5iu38pr6	768	14	lysed	lyse	VBN
cord-005478-5iu38pr6	768	15	primary	primary	JJ
cord-005478-5iu38pr6	768	16	AML	AML	NNP
cord-005478-5iu38pr6	768	17	blasts	blast	NNS
cord-005478-5iu38pr6	768	18	from	from	IN
cord-005478-5iu38pr6	768	19	several	several	JJ
cord-005478-5iu38pr6	768	20	HLA	HLA	NNP
cord-005478-5iu38pr6	768	21	-	-	HYPH
cord-005478-5iu38pr6	768	22	DPB1	DPB1	NNP
cord-005478-5iu38pr6	769	1	*	*	NFP
cord-005478-5iu38pr6	769	2	03:01	03:01	CD
cord-005478-5iu38pr6	769	3	+	+	SYM
cord-005478-5iu38pr6	769	4	patients	patient	NNS
cord-005478-5iu38pr6	769	5	in	in	IN
cord-005478-5iu38pr6	769	6	vitro	vitro	FW
cord-005478-5iu38pr6	769	7	.	.	.
cord-005478-5iu38pr6	770	1	Again	again	RB
cord-005478-5iu38pr6	770	2	,	,	,
cord-005478-5iu38pr6	770	3	cells	cell	NNS
cord-005478-5iu38pr6	770	4	of	of	IN
cord-005478-5iu38pr6	770	5	non	non	JJ
cord-005478-5iu38pr6	770	6	-	-	JJ
cord-005478-5iu38pr6	770	7	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	770	8	origin	origin	NN
cord-005478-5iu38pr6	770	9	(	(	-LRB-
cord-005478-5iu38pr6	770	10	fibroblasts	fibroblast	NNS
cord-005478-5iu38pr6	770	11	)	)	-RRB-
cord-005478-5iu38pr6	770	12	were	be	VBD
cord-005478-5iu38pr6	770	13	not	not	RB
cord-005478-5iu38pr6	770	14	recognized	recognize	VBN
cord-005478-5iu38pr6	770	15	even	even	RB
cord-005478-5iu38pr6	770	16	after	after	IN
cord-005478-5iu38pr6	770	17	IFN	IFN	NNP
cord-005478-5iu38pr6	770	18	-	-	HYPH
cord-005478-5iu38pr6	770	19	γ	γ	NNP
cord-005478-5iu38pr6	770	20	pretreatment	pretreatment	NN
cord-005478-5iu38pr6	770	21	and	and	CC
cord-005478-5iu38pr6	770	22	HLA	HLA	NNP
cord-005478-5iu38pr6	770	23	-	-	HYPH
cord-005478-5iu38pr6	770	24	DP	dp	NN
cord-005478-5iu38pr6	770	25	upregulation	upregulation	NN
cord-005478-5iu38pr6	770	26	.	.	.
cord-005478-5iu38pr6	771	1	To	to	TO
cord-005478-5iu38pr6	771	2	optimize	optimize	VB
cord-005478-5iu38pr6	771	3	TCR	TCR	NNP
cord-005478-5iu38pr6	771	4	expression	expression	NN
cord-005478-5iu38pr6	771	5	and	and	CC
cord-005478-5iu38pr6	771	6	activity	activity	NN
cord-005478-5iu38pr6	771	7	,	,	,
cord-005478-5iu38pr6	771	8	we	-PRON-	PRP
cord-005478-5iu38pr6	771	9	exchanged	exchange	VBD
cord-005478-5iu38pr6	771	10	the	the	DT
cord-005478-5iu38pr6	771	11	constant	constant	JJ
cord-005478-5iu38pr6	771	12	domains	domain	NNS
cord-005478-5iu38pr6	771	13	of	of	IN
cord-005478-5iu38pr6	771	14	the	the	DT
cord-005478-5iu38pr6	771	15	TCR	TCR	NNP
cord-005478-5iu38pr6	771	16	by	by	IN
cord-005478-5iu38pr6	771	17	their	-PRON-	PRP$
cord-005478-5iu38pr6	771	18	murine	murine	JJ
cord-005478-5iu38pr6	771	19	counterparts	counterpart	NNS
cord-005478-5iu38pr6	771	20	.	.	.
cord-005478-5iu38pr6	772	1	This	this	DT
cord-005478-5iu38pr6	772	2	modification	modification	NN
cord-005478-5iu38pr6	772	3	not	not	RB
cord-005478-5iu38pr6	772	4	only	only	RB
cord-005478-5iu38pr6	772	5	led	lead	VBN
cord-005478-5iu38pr6	772	6	to	to	IN
cord-005478-5iu38pr6	772	7	a	a	DT
cord-005478-5iu38pr6	772	8	higher	high	JJR
cord-005478-5iu38pr6	772	9	IFN	IFN	NNP
cord-005478-5iu38pr6	772	10	-	-	HYPH
cord-005478-5iu38pr6	772	11	γ	γ	NN
cord-005478-5iu38pr6	772	12	production	production	NN
cord-005478-5iu38pr6	772	13	and	and	CC
cord-005478-5iu38pr6	772	14	lysis	lysis	NN
cord-005478-5iu38pr6	772	15	of	of	IN
cord-005478-5iu38pr6	772	16	AML	AML	NNP
cord-005478-5iu38pr6	772	17	blasts	blast	NNS
cord-005478-5iu38pr6	772	18	,	,	,
cord-005478-5iu38pr6	772	19	but	but	CC
cord-005478-5iu38pr6	772	20	also	also	RB
cord-005478-5iu38pr6	772	21	induced	induce	VBD
cord-005478-5iu38pr6	772	22	recognition	recognition	NN
cord-005478-5iu38pr6	772	23	of	of	IN
cord-005478-5iu38pr6	772	24	IFN	IFN	NNP
cord-005478-5iu38pr6	772	25	-	-	HYPH
cord-005478-5iu38pr6	772	26	γ	γ	NNP
cord-005478-5iu38pr6	772	27	pretreated	pretreate	VBD
cord-005478-5iu38pr6	772	28	fibroblasts	fibroblast	NNS
cord-005478-5iu38pr6	772	29	.	.	.
cord-005478-5iu38pr6	773	1	However	however	RB
cord-005478-5iu38pr6	773	2	,	,	,
cord-005478-5iu38pr6	773	3	tumor	tumor	NN
cord-005478-5iu38pr6	773	4	cell	cell	NN
cord-005478-5iu38pr6	773	5	lines	line	NNS
cord-005478-5iu38pr6	773	6	overexpressing	overexpresse	VBG
cord-005478-5iu38pr6	773	7	HLA	HLA	NNP
cord-005478-5iu38pr6	773	8	-	-	HYPH
cord-005478-5iu38pr6	773	9	DPB1	DPB1	NNP
cord-005478-5iu38pr6	774	1	*	*	NFP
cord-005478-5iu38pr6	774	2	03:01	03:01	CD
cord-005478-5iu38pr6	774	3	were	be	VBD
cord-005478-5iu38pr6	774	4	also	also	RB
cord-005478-5iu38pr6	774	5	recognized	recognize	VBN
cord-005478-5iu38pr6	774	6	by	by	IN
cord-005478-5iu38pr6	774	7	CD4	CD4	NNP
cord-005478-5iu38pr6	774	8	T	T	NNP
cord-005478-5iu38pr6	774	9	cells	cell	NNS
cord-005478-5iu38pr6	774	10	engineered	engineer	VBN
cord-005478-5iu38pr6	774	11	with	with	IN
cord-005478-5iu38pr6	774	12	the	the	DT
cord-005478-5iu38pr6	774	13	wild	wild	JJ
cord-005478-5iu38pr6	774	14	-	-	HYPH
cord-005478-5iu38pr6	774	15	type	type	NN
cord-005478-5iu38pr6	774	16	or	or	CC
cord-005478-5iu38pr6	774	17	murinized	murinize	VBD
cord-005478-5iu38pr6	774	18	TCR	TCR	NNP
cord-005478-5iu38pr6	774	19	DP03	DP03	NNP
cord-005478-5iu38pr6	774	20	,	,	,
cord-005478-5iu38pr6	774	21	suggesting	suggest	VBG
cord-005478-5iu38pr6	774	22	that	that	IN
cord-005478-5iu38pr6	774	23	recognition	recognition	NN
cord-005478-5iu38pr6	774	24	of	of	IN
cord-005478-5iu38pr6	774	25	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	774	26	and	and	CC
cord-005478-5iu38pr6	774	27	non	non	JJ
cord-005478-5iu38pr6	774	28	-	-	JJ
cord-005478-5iu38pr6	774	29	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	774	30	cells	cell	NNS
cord-005478-5iu38pr6	774	31	is	be	VBZ
cord-005478-5iu38pr6	774	32	rather	rather	RB
cord-005478-5iu38pr6	774	33	triggered	trigger	VBN
cord-005478-5iu38pr6	774	34	by	by	IN
cord-005478-5iu38pr6	774	35	the	the	DT
cord-005478-5iu38pr6	774	36	avidity	avidity	NN
cord-005478-5iu38pr6	774	37	between	between	IN
cord-005478-5iu38pr6	774	38	the	the	DT
cord-005478-5iu38pr6	774	39	T	T	NNP
cord-005478-5iu38pr6	774	40	cell	cell	NN
cord-005478-5iu38pr6	774	41	and	and	CC
cord-005478-5iu38pr6	774	42	the	the	DT
cord-005478-5iu38pr6	774	43	target	target	NN
cord-005478-5iu38pr6	774	44	cell	cell	NN
cord-005478-5iu38pr6	774	45	than	than	IN
cord-005478-5iu38pr6	774	46	by	by	IN
cord-005478-5iu38pr6	774	47	the	the	DT
cord-005478-5iu38pr6	774	48	TCR	TCR	NNP
cord-005478-5iu38pr6	774	49	target	target	NN
cord-005478-5iu38pr6	774	50	epitope	epitope	NN
cord-005478-5iu38pr6	774	51	.	.	.
cord-005478-5iu38pr6	775	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	775	2	:	:	:
cord-005478-5iu38pr6	776	1	In	in	IN
cord-005478-5iu38pr6	776	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	776	3	,	,	,
cord-005478-5iu38pr6	776	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	776	5	data	datum	NNS
cord-005478-5iu38pr6	776	6	suggest	suggest	VBP
cord-005478-5iu38pr6	776	7	that	that	IN
cord-005478-5iu38pr6	776	8	allo	allo	NNP
cord-005478-5iu38pr6	776	9	-	-	HYPH
cord-005478-5iu38pr6	776	10	HLA	HLA	NNP
cord-005478-5iu38pr6	776	11	-	-	HYPH
cord-005478-5iu38pr6	776	12	DPB1	DPB1	NNP
cord-005478-5iu38pr6	776	13	specific	specific	JJ
cord-005478-5iu38pr6	776	14	TCRs	tcr	NNS
cord-005478-5iu38pr6	776	15	are	be	VBP
cord-005478-5iu38pr6	776	16	powerful	powerful	JJ
cord-005478-5iu38pr6	776	17	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	776	18	off	off	JJ
cord-005478-5iu38pr6	776	19	-	-	HYPH
cord-005478-5iu38pr6	776	20	theshelf	theshelf	NN
cord-005478-5iu38pr6	776	21	reagents	reagent	NNS
cord-005478-5iu38pr6	776	22	in	in	IN
cord-005478-5iu38pr6	776	23	allogeneic	allogeneic	FW
cord-005478-5iu38pr6	776	24	T	t	NN
cord-005478-5iu38pr6	776	25	-	-	HYPH
cord-005478-5iu38pr6	776	26	cell	cell	NN
cord-005478-5iu38pr6	776	27	therapy	therapy	NN
cord-005478-5iu38pr6	776	28	of	of	IN
cord-005478-5iu38pr6	776	29	leukemia	leukemia	NN
cord-005478-5iu38pr6	776	30	.	.	.
cord-005478-5iu38pr6	777	1	The	the	DT
cord-005478-5iu38pr6	777	2	isolation	isolation	NN
cord-005478-5iu38pr6	777	3	of	of	IN
cord-005478-5iu38pr6	777	4	allo	allo	NN
cord-005478-5iu38pr6	777	5	-	-	HYPH
cord-005478-5iu38pr6	777	6	HLA	HLA	NNP
cord-005478-5iu38pr6	777	7	-	-	HYPH
cord-005478-5iu38pr6	777	8	DPB1	DPB1	NNP
cord-005478-5iu38pr6	777	9	specific	specific	NN
cord-005478-5iu38pr6	777	10	TCR	TCR	NNP
cord-005478-5iu38pr6	777	11	without	without	IN
cord-005478-5iu38pr6	777	12	crossreactivity	crossreactivity	NN
cord-005478-5iu38pr6	777	13	to	to	IN
cord-005478-5iu38pr6	777	14	non	non	JJ
cord-005478-5iu38pr6	777	15	-	-	JJ
cord-005478-5iu38pr6	777	16	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	777	17	cells	cell	NNS
cord-005478-5iu38pr6	777	18	might	may	MD
cord-005478-5iu38pr6	777	19	be	be	VB
cord-005478-5iu38pr6	777	20	one	one	CD
cord-005478-5iu38pr6	777	21	strategy	strategy	NN
cord-005478-5iu38pr6	777	22	to	to	TO
cord-005478-5iu38pr6	777	23	avoid	avoid	VB
cord-005478-5iu38pr6	777	24	HLA	HLA	NNP
cord-005478-5iu38pr6	777	25	-	-	HYPH
cord-005478-5iu38pr6	777	26	DPB1	DPB1	NNP
cord-005478-5iu38pr6	777	27	specific	specific	JJ
cord-005478-5iu38pr6	777	28	GvH	gvh	JJ
cord-005478-5iu38pr6	777	29	reactivity	reactivity	NN
cord-005478-5iu38pr6	777	30	upon	upon	IN
cord-005478-5iu38pr6	777	31	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	777	32	situations	situation	NNS
cord-005478-5iu38pr6	777	33	(	(	-LRB-
cord-005478-5iu38pr6	777	34	e.g.	e.g.	IN
cord-005478-5iu38pr6	777	35	viral	viral	JJ
cord-005478-5iu38pr6	777	36	infections	infection	NNS
cord-005478-5iu38pr6	777	37	)	)	-RRB-
cord-005478-5iu38pr6	777	38	.	.	.
cord-005478-5iu38pr6	778	1	However	however	RB
cord-005478-5iu38pr6	778	2	,	,	,
cord-005478-5iu38pr6	778	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	778	4	data	datum	NNS
cord-005478-5iu38pr6	778	5	also	also	RB
cord-005478-5iu38pr6	778	6	indicate	indicate	VBP
cord-005478-5iu38pr6	778	7	that	that	IN
cord-005478-5iu38pr6	778	8	finding	finding	NN
cord-005478-5iu38pr6	778	9	of	of	IN
cord-005478-5iu38pr6	778	10	the	the	DT
cord-005478-5iu38pr6	778	11	most	most	RBS
cord-005478-5iu38pr6	778	12	suitable	suitable	JJ
cord-005478-5iu38pr6	778	13	TCR	TCR	NNP
cord-005478-5iu38pr6	778	14	candidate	candidate	NN
cord-005478-5iu38pr6	778	15	is	be	VBZ
cord-005478-5iu38pr6	778	16	challenging	challenging	JJ
cord-005478-5iu38pr6	778	17	.	.	.
cord-005478-5iu38pr6	779	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	779	2	:	:	:
cord-005478-5iu38pr6	779	3	Nothing	nothing	NN
cord-005478-5iu38pr6	779	4	to	to	TO
cord-005478-5iu38pr6	779	5	declare	declare	VB
cord-005478-5iu38pr6	779	6	.	.	.
cord-005478-5iu38pr6	780	1	Abstract	Abstract	NNP
cord-005478-5iu38pr6	780	2	already	already	RB
cord-005478-5iu38pr6	780	3	published	publish	VBN
cord-005478-5iu38pr6	780	4	.	.	.
cord-005478-5iu38pr6	781	1	Infusion	infusion	NN
cord-005478-5iu38pr6	781	2	of	of	IN
cord-005478-5iu38pr6	781	3	memory	memory	NN
cord-005478-5iu38pr6	781	4	T	T	NNP
cord-005478-5iu38pr6	781	5	cell	cell	NN
cord-005478-5iu38pr6	781	6	(	(	-LRB-
cord-005478-5iu38pr6	781	7	CD45RA	cd45ra	NN
cord-005478-5iu38pr6	781	8	-	-	HYPH
cord-005478-5iu38pr6	781	9	Depleted	Depleted	NNP
cord-005478-5iu38pr6	781	10	)	)	-RRB-
cord-005478-5iu38pr6	782	1	DLI	DLI	NNP
cord-005478-5iu38pr6	782	2	improves	improve	VBZ
cord-005478-5iu38pr6	782	3	CMV	CMV	NNP
cord-005478-5iu38pr6	782	4	-	-	HYPH
cord-005478-5iu38pr6	782	5	specific	specific	JJ
cord-005478-5iu38pr6	782	6	immune	immune	JJ
cord-005478-5iu38pr6	782	7	response	response	NN
cord-005478-5iu38pr6	782	8	early	early	RB
cord-005478-5iu38pr6	782	9	after	after	IN
cord-005478-5iu38pr6	782	10	ABT	abt	NN
cord-005478-5iu38pr6	782	11	cell	cell	NN
cord-005478-5iu38pr6	782	12	-	-	HYPH
cord-005478-5iu38pr6	782	13	depleted	deplete	VBN
cord-005478-5iu38pr6	782	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	782	15	:	:	:
cord-005478-5iu38pr6	783	1	First	first	JJ
cord-005478-5iu38pr6	783	2	results	result	NNS
cord-005478-5iu38pr6	783	3	of	of	IN
cord-005478-5iu38pr6	783	4	a	a	DT
cord-005478-5iu38pr6	783	5	prospective	prospective	JJ
cord-005478-5iu38pr6	783	6	randomized	randomized	JJ
cord-005478-5iu38pr6	783	7	trial	trial	NN
cord-005478-5iu38pr6	783	8	Background	background	NN
cord-005478-5iu38pr6	783	9	:	:	:
cord-005478-5iu38pr6	783	10	abT	abt	NN
cord-005478-5iu38pr6	783	11	cell	cell	NN
cord-005478-5iu38pr6	783	12	depletion	depletion	NN
cord-005478-5iu38pr6	783	13	effectively	effectively	RB
cord-005478-5iu38pr6	783	14	prevents	prevent	VBZ
cord-005478-5iu38pr6	783	15	severe	severe	JJ
cord-005478-5iu38pr6	783	16	GVHD	gvhd	NN
cord-005478-5iu38pr6	783	17	in	in	IN
cord-005478-5iu38pr6	783	18	mismatched	mismatched	JJ
cord-005478-5iu38pr6	783	19	HSCT	HSCT	NNP
cord-005478-5iu38pr6	783	20	,	,	,
cord-005478-5iu38pr6	783	21	but	but	CC
cord-005478-5iu38pr6	783	22	in	in	IN
cord-005478-5iu38pr6	783	23	a	a	DT
cord-005478-5iu38pr6	783	24	proportion	proportion	NN
cord-005478-5iu38pr6	783	25	of	of	IN
cord-005478-5iu38pr6	783	26	cases	case	NNS
cord-005478-5iu38pr6	783	27	delayed	delay	VBN
cord-005478-5iu38pr6	783	28	immune	immune	JJ
cord-005478-5iu38pr6	783	29	recovery	recovery	NN
cord-005478-5iu38pr6	783	30	leads	lead	VBZ
cord-005478-5iu38pr6	783	31	to	to	IN
cord-005478-5iu38pr6	783	32	increased	increase	VBN
cord-005478-5iu38pr6	783	33	infection	infection	NN
cord-005478-5iu38pr6	783	34	risk	risk	NN
cord-005478-5iu38pr6	783	35	and	and	CC
cord-005478-5iu38pr6	783	36	NRM	NRM	NNP
cord-005478-5iu38pr6	783	37	.	.	.
cord-005478-5iu38pr6	784	1	We	-PRON-	PRP
cord-005478-5iu38pr6	784	2	've	have	VB
cord-005478-5iu38pr6	784	3	shown	show	VBN
cord-005478-5iu38pr6	784	4	in	in	IN
cord-005478-5iu38pr6	784	5	a	a	DT
cord-005478-5iu38pr6	784	6	pilot	pilot	NN
cord-005478-5iu38pr6	784	7	study	study	NN
cord-005478-5iu38pr6	784	8	that	that	DT
cord-005478-5iu38pr6	784	9	infusion	infusion	NN
cord-005478-5iu38pr6	784	10	of	of	IN
cord-005478-5iu38pr6	784	11	low	low	JJ
cord-005478-5iu38pr6	784	12	-	-	HYPH
cord-005478-5iu38pr6	784	13	dose	dose	NN
cord-005478-5iu38pr6	784	14	memory	memory	NN
cord-005478-5iu38pr6	784	15	T	t	NN
cord-005478-5iu38pr6	784	16	cells	cell	NNS
cord-005478-5iu38pr6	784	17	(	(	-LRB-
cord-005478-5iu38pr6	784	18	CD45-RA	CD45-RA	NNP
cord-005478-5iu38pr6	784	19	depleted	deplete	VBN
cord-005478-5iu38pr6	784	20	)	)	-RRB-
cord-005478-5iu38pr6	784	21	is	be	VBZ
cord-005478-5iu38pr6	784	22	safe	safe	JJ
cord-005478-5iu38pr6	784	23	after	after	IN
cord-005478-5iu38pr6	784	24	engraftment	engraftment	NN
cord-005478-5iu38pr6	784	25	among	among	IN
cord-005478-5iu38pr6	784	26	recipients	recipient	NNS
cord-005478-5iu38pr6	784	27	of	of	IN
cord-005478-5iu38pr6	784	28	ab	ab	NNP
cord-005478-5iu38pr6	784	29	T	T	NNP
cord-005478-5iu38pr6	784	30	cell	cell	NN
cord-005478-5iu38pr6	784	31	-	-	HYPH
cord-005478-5iu38pr6	784	32	depleted	deplete	VBN
cord-005478-5iu38pr6	784	33	grafts	graft	NNS
cord-005478-5iu38pr6	784	34	(	(	-LRB-
cord-005478-5iu38pr6	784	35	PMID:29269793	pmid:29269793	NN
cord-005478-5iu38pr6	784	36	)	)	-RRB-
cord-005478-5iu38pr6	784	37	.	.	.
cord-005478-5iu38pr6	785	1	We	-PRON-	PRP
cord-005478-5iu38pr6	785	2	initiated	initiate	VBD
cord-005478-5iu38pr6	785	3	a	a	DT
cord-005478-5iu38pr6	785	4	prospective	prospective	JJ
cord-005478-5iu38pr6	785	5	trial	trial	NN
cord-005478-5iu38pr6	785	6	to	to	TO
cord-005478-5iu38pr6	785	7	directly	directly	RB
cord-005478-5iu38pr6	785	8	test	test	VB
cord-005478-5iu38pr6	785	9	the	the	DT
cord-005478-5iu38pr6	785	10	efficiency	efficiency	NN
cord-005478-5iu38pr6	785	11	of	of	IN
cord-005478-5iu38pr6	785	12	this	this	DT
cord-005478-5iu38pr6	785	13	approach	approach	NN
cord-005478-5iu38pr6	785	14	.	.	.
cord-005478-5iu38pr6	786	1	We	-PRON-	PRP
cord-005478-5iu38pr6	786	2	report	report	VBP
cord-005478-5iu38pr6	786	3	here	here	RB
cord-005478-5iu38pr6	786	4	an	an	DT
cord-005478-5iu38pr6	786	5	interim	interim	JJ
cord-005478-5iu38pr6	786	6	result	result	NN
cord-005478-5iu38pr6	786	7	of	of	IN
cord-005478-5iu38pr6	786	8	a	a	DT
cord-005478-5iu38pr6	786	9	prospective	prospective	NN
cord-005478-5iu38pr6	786	10	,	,	,
cord-005478-5iu38pr6	786	11	randomized	randomized	JJ
cord-005478-5iu38pr6	786	12	,	,	,
cord-005478-5iu38pr6	786	13	single	single	JJ
cord-005478-5iu38pr6	786	14	-	-	HYPH
cord-005478-5iu38pr6	786	15	centre	centre	NN
cord-005478-5iu38pr6	786	16	trial	trial	NN
cord-005478-5iu38pr6	786	17	(	(	-LRB-
cord-005478-5iu38pr6	786	18	NCT02942173	NCT02942173	NNP
cord-005478-5iu38pr6	786	19	)	)	-RRB-
cord-005478-5iu38pr6	786	20	.	.	.
cord-005478-5iu38pr6	787	1	Methods	method	NNS
cord-005478-5iu38pr6	787	2	:	:	:
cord-005478-5iu38pr6	788	1	A	a	DT
cord-005478-5iu38pr6	788	2	total	total	NN
cord-005478-5iu38pr6	788	3	of	of	IN
cord-005478-5iu38pr6	788	4	100	100	CD
cord-005478-5iu38pr6	788	5	paediatric	paediatric	JJ
cord-005478-5iu38pr6	788	6	patients	patient	NNS
cord-005478-5iu38pr6	788	7	with	with	IN
cord-005478-5iu38pr6	788	8	malignant	malignant	JJ
cord-005478-5iu38pr6	788	9	disorders	disorder	NNS
cord-005478-5iu38pr6	788	10	(	(	-LRB-
cord-005478-5iu38pr6	788	11	ALL	all	DT
cord-005478-5iu38pr6	788	12	,	,	,
cord-005478-5iu38pr6	788	13	n=56	n=56	NN
cord-005478-5iu38pr6	788	14	;	;	:
cord-005478-5iu38pr6	788	15	AML	AML	NNP
cord-005478-5iu38pr6	788	16	,	,	,
cord-005478-5iu38pr6	788	17	n=30	n=30	NN
cord-005478-5iu38pr6	788	18	;	;	:
cord-005478-5iu38pr6	788	19	NHL	NHL	NNP
cord-005478-5iu38pr6	788	20	,	,	,
cord-005478-5iu38pr6	788	21	n=8	n=8	NN
cord-005478-5iu38pr6	788	22	;	;	:
cord-005478-5iu38pr6	788	23	acute	acute	JJ
cord-005478-5iu38pr6	788	24	mixed	mixed	JJ
cord-005478-5iu38pr6	788	25	lineage	lineage	NN
cord-005478-5iu38pr6	788	26	leukemia	leukemia	NN
cord-005478-5iu38pr6	788	27	,	,	,
cord-005478-5iu38pr6	788	28	n=5	n=5	JJ
cord-005478-5iu38pr6	788	29	and	and	CC
cord-005478-5iu38pr6	788	30	MPD	MPD	NNP
cord-005478-5iu38pr6	788	31	,	,	,
cord-005478-5iu38pr6	788	32	n=1	n=1	CD
cord-005478-5iu38pr6	788	33	)	)	-RRB-
cord-005478-5iu38pr6	788	34	were	be	VBD
cord-005478-5iu38pr6	788	35	enrolled	enrol	VBN
cord-005478-5iu38pr6	788	36	between	between	IN
cord-005478-5iu38pr6	788	37	October	October	NNP
cord-005478-5iu38pr6	788	38	2016	2016	CD
cord-005478-5iu38pr6	788	39	and	and	CC
cord-005478-5iu38pr6	788	40	September	September	NNP
cord-005478-5iu38pr6	788	41	2018	2018	CD
cord-005478-5iu38pr6	788	42	.	.	.
cord-005478-5iu38pr6	789	1	Patients	patient	NNS
cord-005478-5iu38pr6	789	2	were	be	VBD
cord-005478-5iu38pr6	789	3	randomly	randomly	RB
cord-005478-5iu38pr6	789	4	assigned	assign	VBN
cord-005478-5iu38pr6	789	5	to	to	TO
cord-005478-5iu38pr6	789	6	receive	receive	VB
cord-005478-5iu38pr6	789	7	CD45RA	cd45ra	NN
cord-005478-5iu38pr6	789	8	-	-	HYPH
cord-005478-5iu38pr6	789	9	depleted	deplete	VBN
cord-005478-5iu38pr6	789	10	DLIs	dli	NNS
cord-005478-5iu38pr6	789	11	(	(	-LRB-
cord-005478-5iu38pr6	789	12	experimental	experimental	JJ
cord-005478-5iu38pr6	789	13	arm	arm	NN
cord-005478-5iu38pr6	789	14	)	)	-RRB-
cord-005478-5iu38pr6	789	15	,	,	,
cord-005478-5iu38pr6	789	16	n=54	n=54	NN
cord-005478-5iu38pr6	789	17	,	,	,
cord-005478-5iu38pr6	789	18	or	or	CC
cord-005478-5iu38pr6	789	19	not	not	RB
cord-005478-5iu38pr6	789	20	(	(	-LRB-
cord-005478-5iu38pr6	789	21	control	control	NN
cord-005478-5iu38pr6	789	22	arm	arm	NN
cord-005478-5iu38pr6	789	23	)	)	-RRB-
cord-005478-5iu38pr6	789	24	,	,	,
cord-005478-5iu38pr6	789	25	n=46	n=46	JJ
cord-005478-5iu38pr6	789	26	.	.	.
cord-005478-5iu38pr6	790	1	Median	median	JJ
cord-005478-5iu38pr6	790	2	age	age	NN
cord-005478-5iu38pr6	790	3	at	at	IN
cord-005478-5iu38pr6	790	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	790	5	was	be	VBD
cord-005478-5iu38pr6	790	6	8.9	8.9	CD
cord-005478-5iu38pr6	790	7	years	year	NNS
cord-005478-5iu38pr6	790	8	,	,	,
cord-005478-5iu38pr6	790	9	m	m	NN
cord-005478-5iu38pr6	790	10	:	:	:
cord-005478-5iu38pr6	790	11	f	f	NNP
cord-005478-5iu38pr6	790	12	ratio	ratio	NN
cord-005478-5iu38pr6	790	13	-42:58	-42:58	NNP
cord-005478-5iu38pr6	790	14	.	.	.
cord-005478-5iu38pr6	791	1	The	the	DT
cord-005478-5iu38pr6	791	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	791	3	consisted	consist	VBD
cord-005478-5iu38pr6	791	4	of	of	IN
cord-005478-5iu38pr6	791	5	either	either	DT
cord-005478-5iu38pr6	791	6	treosulfan	treosulfan	NNP
cord-005478-5iu38pr6	791	7	(	(	-LRB-
cord-005478-5iu38pr6	791	8	n=	n=	NNP
cord-005478-5iu38pr6	791	9	50	50	CD
cord-005478-5iu38pr6	791	10	)	)	-RRB-
cord-005478-5iu38pr6	791	11	or	or	CC
cord-005478-5iu38pr6	791	12	TBI	TBI	NNP
cord-005478-5iu38pr6	791	13	(	(	-LRB-
cord-005478-5iu38pr6	791	14	n=	n=	NNP
cord-005478-5iu38pr6	791	15	50	50	CD
cord-005478-5iu38pr6	791	16	)	)	-RRB-
cord-005478-5iu38pr6	791	17	in	in	IN
cord-005478-5iu38pr6	791	18	combination	combination	NN
cord-005478-5iu38pr6	791	19	with	with	IN
cord-005478-5iu38pr6	791	20	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	791	21	and	and	CC
cord-005478-5iu38pr6	791	22	thiotepa	thiotepa	NN
cord-005478-5iu38pr6	791	23	.	.	.
cord-005478-5iu38pr6	792	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	792	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	792	3	included	include	VBD
cord-005478-5iu38pr6	792	4	tocilizumab	tocilizumab	NNP
cord-005478-5iu38pr6	792	5	at	at	IN
cord-005478-5iu38pr6	792	6	8	8	CD
cord-005478-5iu38pr6	792	7	mg	mg	NN
cord-005478-5iu38pr6	792	8	/	/	SYM
cord-005478-5iu38pr6	792	9	kg	kg	NN
cord-005478-5iu38pr6	792	10	at	at	IN
cord-005478-5iu38pr6	792	11	day	day	NN
cord-005478-5iu38pr6	792	12	0	0	CD
cord-005478-5iu38pr6	792	13	,	,	,
cord-005478-5iu38pr6	792	14	abatacept	abatacept	NNP
cord-005478-5iu38pr6	792	15	at	at	IN
cord-005478-5iu38pr6	792	16	10	10	CD
cord-005478-5iu38pr6	792	17	mg	mg	NN
cord-005478-5iu38pr6	792	18	/	/	SYM
cord-005478-5iu38pr6	792	19	kg	kg	NN
cord-005478-5iu38pr6	792	20	at	at	IN
cord-005478-5iu38pr6	792	21	day	day	NN
cord-005478-5iu38pr6	792	22	0	0	CD
cord-005478-5iu38pr6	792	23	,	,	,
cord-005478-5iu38pr6	792	24	+7	+7	NN
cord-005478-5iu38pr6	792	25	,	,	,
cord-005478-5iu38pr6	792	26	+14	+14	CD
cord-005478-5iu38pr6	792	27	and	and	CC
cord-005478-5iu38pr6	792	28	+28	+28	NNS
cord-005478-5iu38pr6	792	29	,	,	,
cord-005478-5iu38pr6	792	30	and	and	CC
cord-005478-5iu38pr6	792	31	bortezomib	bortezomib	NNP
cord-005478-5iu38pr6	792	32	at	at	IN
cord-005478-5iu38pr6	792	33	1,3	1,3	CD
cord-005478-5iu38pr6	793	1	mg	mg	NNP
cord-005478-5iu38pr6	793	2	/	/	SYM
cord-005478-5iu38pr6	793	3	m	m	NNP
cord-005478-5iu38pr6	793	4	2	2	CD
cord-005478-5iu38pr6	793	5	at	at	IN
cord-005478-5iu38pr6	793	6	days	day	NNS
cord-005478-5iu38pr6	793	7	-5	-5	NNP
cord-005478-5iu38pr6	793	8	,	,	,
cord-005478-5iu38pr6	793	9	-2	-2	NNP
cord-005478-5iu38pr6	793	10	,	,	,
cord-005478-5iu38pr6	793	11	+2	+2	NNP
cord-005478-5iu38pr6	793	12	,	,	,
cord-005478-5iu38pr6	793	13	+5	+5	NN
cord-005478-5iu38pr6	793	14	.	.	.
cord-005478-5iu38pr6	794	1	Neither	neither	CC
cord-005478-5iu38pr6	794	2	antithymocyte	antithymocyte	NNP
cord-005478-5iu38pr6	794	3	globulin	globulin	NN
cord-005478-5iu38pr6	794	4	nor	nor	CC
cord-005478-5iu38pr6	794	5	calcineurin	calcineurin	NNP
cord-005478-5iu38pr6	794	6	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	794	7	were	be	VBD
cord-005478-5iu38pr6	794	8	used	use	VBN
cord-005478-5iu38pr6	794	9	.	.	.
cord-005478-5iu38pr6	795	1	Donors	donor	NNS
cord-005478-5iu38pr6	795	2	were	be	VBD
cord-005478-5iu38pr6	795	3	HLA	HLA	NNP
cord-005478-5iu38pr6	795	4	-	-	HYPH
cord-005478-5iu38pr6	795	5	haploidentical	haploidentical	NNP
cord-005478-5iu38pr6	795	6	(	(	-LRB-
cord-005478-5iu38pr6	795	7	n=94	n=94	NNP
cord-005478-5iu38pr6	795	8	)	)	-RRB-
cord-005478-5iu38pr6	795	9	or	or	CC
cord-005478-5iu38pr6	795	10	matched	match	VBN
cord-005478-5iu38pr6	795	11	(	(	-LRB-
cord-005478-5iu38pr6	795	12	n=6	n=6	JJ
cord-005478-5iu38pr6	795	13	)	)	-RRB-
cord-005478-5iu38pr6	795	14	.	.	.
cord-005478-5iu38pr6	796	1	All	all	DT
cord-005478-5iu38pr6	796	2	donors	donor	NNS
cord-005478-5iu38pr6	796	3	and	and	CC
cord-005478-5iu38pr6	796	4	76	76	CD
cord-005478-5iu38pr6	796	5	%	%	NN
cord-005478-5iu38pr6	796	6	of	of	IN
cord-005478-5iu38pr6	796	7	the	the	DT
cord-005478-5iu38pr6	796	8	recipients	recipient	NNS
cord-005478-5iu38pr6	796	9	were	be	VBD
cord-005478-5iu38pr6	796	10	CMV	CMV	NNP
cord-005478-5iu38pr6	796	11	seropositive	seropositive	JJ
cord-005478-5iu38pr6	796	12	.	.	.
cord-005478-5iu38pr6	797	1	PMBC	PMBC	NNP
cord-005478-5iu38pr6	797	2	grafts	graft	NNS
cord-005478-5iu38pr6	797	3	were	be	VBD
cord-005478-5iu38pr6	797	4	split	split	VBN
cord-005478-5iu38pr6	797	5	and	and	CC
cord-005478-5iu38pr6	798	1	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	798	2	/	/	SYM
cord-005478-5iu38pr6	798	3	CD19	CD19	NNP
cord-005478-5iu38pr6	798	4	depletion	depletion	NN
cord-005478-5iu38pr6	798	5	and	and	CC
cord-005478-5iu38pr6	798	6	CD45RA	cd45ra	NN
cord-005478-5iu38pr6	798	7	depletion	depletion	NN
cord-005478-5iu38pr6	798	8	were	be	VBD
cord-005478-5iu38pr6	798	9	performed	perform	VBN
cord-005478-5iu38pr6	798	10	with	with	IN
cord-005478-5iu38pr6	798	11	CliniMACS	CliniMACS	NNP
cord-005478-5iu38pr6	798	12	Prodigy	Prodigy	NNP
cord-005478-5iu38pr6	798	13	.	.	.
cord-005478-5iu38pr6	799	1	The	the	DT
cord-005478-5iu38pr6	799	2	median	median	JJ
cord-005478-5iu38pr6	799	3	dose	dose	NN
cord-005478-5iu38pr6	799	4	of	of	IN
cord-005478-5iu38pr6	799	5	CD34	CD34	NNP
cord-005478-5iu38pr6	799	6	+	+	CC
cord-005478-5iu38pr6	799	7	cells	cell	NNS
cord-005478-5iu38pr6	799	8	was	be	VBD
cord-005478-5iu38pr6	800	1	10x10	10x10	CD
cord-005478-5iu38pr6	800	2	6	6	CD
cord-005478-5iu38pr6	800	3	/kg	/kg	CD
cord-005478-5iu38pr6	800	4	,	,	,
cord-005478-5iu38pr6	800	5	αβT	αβt	NN
cord-005478-5iu38pr6	800	6	cells	cell	NNS
cord-005478-5iu38pr6	800	7	-28x10	-28x10	.
cord-005478-5iu38pr6	801	1	3	3	LS
cord-005478-5iu38pr6	802	1	/kg	/kg	NFP
cord-005478-5iu38pr6	802	2	.	.	.
cord-005478-5iu38pr6	803	1	In	in	IN
cord-005478-5iu38pr6	803	2	the	the	DT
cord-005478-5iu38pr6	803	3	experimental	experimental	JJ
cord-005478-5iu38pr6	803	4	arm	arm	NN
cord-005478-5iu38pr6	803	5	memory	memory	NN
cord-005478-5iu38pr6	803	6	DLIs	dli	NNS
cord-005478-5iu38pr6	803	7	were	be	VBD
cord-005478-5iu38pr6	803	8	infused	infuse	VBN
cord-005478-5iu38pr6	803	9	on	on	IN
cord-005478-5iu38pr6	803	10	day	day	NN
cord-005478-5iu38pr6	803	11	0	0	CD
cord-005478-5iu38pr6	803	12	at	at	IN
cord-005478-5iu38pr6	803	13	25x10	25x10	CD
cord-005478-5iu38pr6	803	14	3	3	CD
cord-005478-5iu38pr6	803	15	/kg	/kg	.
cord-005478-5iu38pr6	803	16	and	and	CC
cord-005478-5iu38pr6	803	17	on	on	IN
cord-005478-5iu38pr6	803	18	days	day	NNS
cord-005478-5iu38pr6	803	19	+30	+30	CD
cord-005478-5iu38pr6	803	20	,	,	,
cord-005478-5iu38pr6	803	21	+60	+60	NNP
cord-005478-5iu38pr6	803	22	,	,	,
cord-005478-5iu38pr6	803	23	+90	+90	CD
cord-005478-5iu38pr6	803	24	,	,	,
cord-005478-5iu38pr6	803	25	+120	+120	NNP
cord-005478-5iu38pr6	803	26	at	at	IN
cord-005478-5iu38pr6	803	27	50x10	50x10	CD
cord-005478-5iu38pr6	803	28	3	3	CD
cord-005478-5iu38pr6	804	1	/kg	/kg	NFP
cord-005478-5iu38pr6	804	2	.	.	.
cord-005478-5iu38pr6	805	1	In	in	IN
cord-005478-5iu38pr6	805	2	the	the	DT
cord-005478-5iu38pr6	805	3	control	control	NN
cord-005478-5iu38pr6	805	4	arm	arm	NN
cord-005478-5iu38pr6	805	5	8	8	CD
cord-005478-5iu38pr6	805	6	patients	patient	NNS
cord-005478-5iu38pr6	805	7	received	receive	VBD
cord-005478-5iu38pr6	805	8	DLI	DLI	NNP
cord-005478-5iu38pr6	805	9	after	after	IN
cord-005478-5iu38pr6	805	10	engraftment	engraftment	NN
cord-005478-5iu38pr6	805	11	to	to	TO
cord-005478-5iu38pr6	805	12	prevent	prevent	VB
cord-005478-5iu38pr6	805	13	relapse	relapse	NN
cord-005478-5iu38pr6	805	14	(	(	-LRB-
cord-005478-5iu38pr6	805	15	n=6	n=6	NNP
cord-005478-5iu38pr6	805	16	)	)	-RRB-
cord-005478-5iu38pr6	805	17	or	or	CC
cord-005478-5iu38pr6	805	18	treat	treat	VB
cord-005478-5iu38pr6	805	19	infections	infection	NNS
cord-005478-5iu38pr6	805	20	(	(	-LRB-
cord-005478-5iu38pr6	805	21	n=2	n=2	NNS
cord-005478-5iu38pr6	805	22	)	)	-RRB-
cord-005478-5iu38pr6	805	23	.	.	.
cord-005478-5iu38pr6	806	1	Primary	primary	JJ
cord-005478-5iu38pr6	806	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	806	3	were	be	VBD
cord-005478-5iu38pr6	806	4	the	the	DT
cord-005478-5iu38pr6	806	5	cumulative	cumulative	JJ
cord-005478-5iu38pr6	806	6	incidence	incidence	NN
cord-005478-5iu38pr6	806	7	(	(	-LRB-
cord-005478-5iu38pr6	806	8	CI	CI	NNP
cord-005478-5iu38pr6	806	9	)	)	-RRB-
cord-005478-5iu38pr6	806	10	of	of	IN
cord-005478-5iu38pr6	806	11	CMV	CMV	NNP
cord-005478-5iu38pr6	806	12	viremia	viremia	NN
cord-005478-5iu38pr6	806	13	(	(	-LRB-
cord-005478-5iu38pr6	806	14	>	>	VBZ
cord-005478-5iu38pr6	806	15	500	500	CD
cord-005478-5iu38pr6	806	16	copies	copy	NNS
cord-005478-5iu38pr6	806	17	/	/	SYM
cord-005478-5iu38pr6	806	18	ml	ml	NN
cord-005478-5iu38pr6	806	19	)	)	-RRB-
cord-005478-5iu38pr6	806	20	by	by	IN
cord-005478-5iu38pr6	806	21	day	day	NN
cord-005478-5iu38pr6	806	22	+100	+100	NNS
cord-005478-5iu38pr6	806	23	and	and	CC
cord-005478-5iu38pr6	806	24	the	the	DT
cord-005478-5iu38pr6	806	25	CI	CI	NNP
cord-005478-5iu38pr6	806	26	of	of	IN
cord-005478-5iu38pr6	806	27	acute	acute	JJ
cord-005478-5iu38pr6	806	28	GvHD	GvHD	NNP
cord-005478-5iu38pr6	806	29	grade	grade	NN
cord-005478-5iu38pr6	806	30	≥	≥	NNP
cord-005478-5iu38pr6	806	31	II	II	NNP
cord-005478-5iu38pr6	806	32	.	.	.
cord-005478-5iu38pr6	807	1	Results	result	NNS
cord-005478-5iu38pr6	807	2	:	:	:
cord-005478-5iu38pr6	808	1	Median	median	JJ
cord-005478-5iu38pr6	808	2	follow	follow	NN
cord-005478-5iu38pr6	808	3	-	-	HYPH
cord-005478-5iu38pr6	808	4	up	up	NN
cord-005478-5iu38pr6	808	5	for	for	IN
cord-005478-5iu38pr6	808	6	survivors	survivor	NNS
cord-005478-5iu38pr6	808	7	was	be	VBD
cord-005478-5iu38pr6	808	8	1	1	CD
cord-005478-5iu38pr6	808	9	year	year	NN
cord-005478-5iu38pr6	808	10	(	(	-LRB-
cord-005478-5iu38pr6	808	11	0,2	0,2	CD
cord-005478-5iu38pr6	808	12	-	-	SYM
cord-005478-5iu38pr6	808	13	2	2	CD
cord-005478-5iu38pr6	808	14	)	)	-RRB-
cord-005478-5iu38pr6	808	15	.	.	.
cord-005478-5iu38pr6	809	1	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	809	2	of	of	IN
cord-005478-5iu38pr6	809	3	WBC	WBC	NNP
cord-005478-5iu38pr6	809	4	and	and	CC
cord-005478-5iu38pr6	809	5	platelets	platelet	NNS
cord-005478-5iu38pr6	809	6	was	be	VBD
cord-005478-5iu38pr6	809	7	achieved	achieve	VBN
cord-005478-5iu38pr6	809	8	in	in	IN
cord-005478-5iu38pr6	809	9	99	99	CD
cord-005478-5iu38pr6	809	10	pts	pt	NNS
cord-005478-5iu38pr6	809	11	,	,	,
cord-005478-5iu38pr6	809	12	one	one	CD
cord-005478-5iu38pr6	809	13	patient	patient	NN
cord-005478-5iu38pr6	809	14	died	die	VBD
cord-005478-5iu38pr6	809	15	at	at	IN
cord-005478-5iu38pr6	809	16	day	day	NN
cord-005478-5iu38pr6	809	17	+8	+8	NFP
cord-005478-5iu38pr6	809	18	.	.	.
cord-005478-5iu38pr6	810	1	WBC	WBC	NNP
cord-005478-5iu38pr6	810	2	and	and	CC
cord-005478-5iu38pr6	810	3	platelets	platelet	NNS
cord-005478-5iu38pr6	810	4	engrafted	engraft	VBD
cord-005478-5iu38pr6	810	5	at	at	IN
cord-005478-5iu38pr6	810	6	a	a	DT
cord-005478-5iu38pr6	810	7	median	median	NN
cord-005478-5iu38pr6	810	8	of	of	IN
cord-005478-5iu38pr6	810	9	11	11	CD
cord-005478-5iu38pr6	810	10	days	day	NNS
cord-005478-5iu38pr6	810	11	and	and	CC
cord-005478-5iu38pr6	810	12	14	14	CD
cord-005478-5iu38pr6	810	13	days	day	NNS
cord-005478-5iu38pr6	810	14	,	,	,
cord-005478-5iu38pr6	810	15	respectively	respectively	RB
cord-005478-5iu38pr6	810	16	.	.	.
cord-005478-5iu38pr6	811	1	The	the	DT
cord-005478-5iu38pr6	811	2	incidence	incidence	NN
cord-005478-5iu38pr6	811	3	of	of	IN
cord-005478-5iu38pr6	811	4	CMV	CMV	NNP
cord-005478-5iu38pr6	811	5	viremia	viremia	NN
cord-005478-5iu38pr6	811	6	was	be	VBD
cord-005478-5iu38pr6	811	7	45	45	CD
cord-005478-5iu38pr6	811	8	%	%	NN
cord-005478-5iu38pr6	811	9	(	(	-LRB-
cord-005478-5iu38pr6	811	10	36	36	CD
cord-005478-5iu38pr6	811	11	-	-	SYM
cord-005478-5iu38pr6	811	12	56	56	CD
cord-005478-5iu38pr6	811	13	)	)	-RRB-
cord-005478-5iu38pr6	811	14	overall	overall	JJ
cord-005478-5iu38pr6	811	15	,	,	,
cord-005478-5iu38pr6	811	16	41	41	CD
cord-005478-5iu38pr6	811	17	%	%	NN
cord-005478-5iu38pr6	811	18	(	(	-LRB-
cord-005478-5iu38pr6	811	19	30	30	CD
cord-005478-5iu38pr6	811	20	-	-	SYM
cord-005478-5iu38pr6	811	21	56	56	CD
cord-005478-5iu38pr6	811	22	)	)	-RRB-
cord-005478-5iu38pr6	811	23	in	in	IN
cord-005478-5iu38pr6	811	24	the	the	DT
cord-005478-5iu38pr6	811	25	experimental	experimental	JJ
cord-005478-5iu38pr6	811	26	arm	arm	NN
cord-005478-5iu38pr6	811	27	vs.	vs.	CC
cord-005478-5iu38pr6	811	28	50	50	CD
cord-005478-5iu38pr6	811	29	%	%	NN
cord-005478-5iu38pr6	811	30	(	(	-LRB-
cord-005478-5iu38pr6	811	31	38	38	CD
cord-005478-5iu38pr6	811	32	-	-	SYM
cord-005478-5iu38pr6	811	33	67	67	CD
cord-005478-5iu38pr6	811	34	)	)	-RRB-
cord-005478-5iu38pr6	811	35	in	in	IN
cord-005478-5iu38pr6	811	36	the	the	DT
cord-005478-5iu38pr6	811	37	control	control	NN
cord-005478-5iu38pr6	811	38	arm	arm	NN
cord-005478-5iu38pr6	811	39	,	,	,
cord-005478-5iu38pr6	811	40	p	p	NN
cord-005478-5iu38pr6	811	41	=	=	SYM
cord-005478-5iu38pr6	811	42	ns	ns	XX
cord-005478-5iu38pr6	811	43	.	.	.
cord-005478-5iu38pr6	812	1	The	the	DT
cord-005478-5iu38pr6	812	2	CI	CI	NNP
cord-005478-5iu38pr6	812	3	of	of	IN
cord-005478-5iu38pr6	812	4	aGvHD	agvhd	NN
cord-005478-5iu38pr6	812	5	≥	≥	CD
cord-005478-5iu38pr6	812	6	grade	grade	NN
cord-005478-5iu38pr6	812	7	II	II	NNP
cord-005478-5iu38pr6	812	8	was	be	VBD
cord-005478-5iu38pr6	812	9	10	10	CD
cord-005478-5iu38pr6	812	10	%	%	NN
cord-005478-5iu38pr6	812	11	(	(	-LRB-
cord-005478-5iu38pr6	812	12	6	6	CD
cord-005478-5iu38pr6	812	13	-	-	SYM
cord-005478-5iu38pr6	812	14	18	18	CD
cord-005478-5iu38pr6	812	15	)	)	-RRB-
cord-005478-5iu38pr6	812	16	overall	overall	RB
cord-005478-5iu38pr6	812	17	,	,	,
cord-005478-5iu38pr6	812	18	10	10	CD
cord-005478-5iu38pr6	812	19	%	%	NN
cord-005478-5iu38pr6	812	20	(	(	-LRB-
cord-005478-5iu38pr6	812	21	4	4	CD
cord-005478-5iu38pr6	812	22	-	-	SYM
cord-005478-5iu38pr6	812	23	23	23	CD
cord-005478-5iu38pr6	812	24	)	)	-RRB-
cord-005478-5iu38pr6	812	25	in	in	IN
cord-005478-5iu38pr6	812	26	the	the	DT
cord-005478-5iu38pr6	812	27	experimental	experimental	JJ
cord-005478-5iu38pr6	812	28	arm	arm	NN
cord-005478-5iu38pr6	812	29	vs.	vs.	IN
cord-005478-5iu38pr6	812	30	9	9	CD
cord-005478-5iu38pr6	812	31	%	%	NN
cord-005478-5iu38pr6	812	32	(	(	-LRB-
cord-005478-5iu38pr6	812	33	4	4	CD
cord-005478-5iu38pr6	812	34	-	-	SYM
cord-005478-5iu38pr6	812	35	24	24	CD
cord-005478-5iu38pr6	812	36	)	)	-RRB-
cord-005478-5iu38pr6	812	37	in	in	IN
cord-005478-5iu38pr6	812	38	the	the	DT
cord-005478-5iu38pr6	812	39	control	control	NN
cord-005478-5iu38pr6	812	40	arm	arm	NN
cord-005478-5iu38pr6	812	41	,	,	,
cord-005478-5iu38pr6	812	42	p	p	NN
cord-005478-5iu38pr6	812	43	=	=	SYM
cord-005478-5iu38pr6	812	44	ns	ns	XX
cord-005478-5iu38pr6	812	45	.	.	.
cord-005478-5iu38pr6	813	1	Two	two	CD
cord-005478-5iu38pr6	813	2	patients	patient	NNS
cord-005478-5iu38pr6	813	3	died	die	VBD
cord-005478-5iu38pr6	813	4	,	,	,
cord-005478-5iu38pr6	813	5	one	one	CD
cord-005478-5iu38pr6	813	6	per	per	IN
cord-005478-5iu38pr6	813	7	treatment	treatment	NN
cord-005478-5iu38pr6	813	8	arm	arm	NN
cord-005478-5iu38pr6	813	9	,	,	,
cord-005478-5iu38pr6	813	10	resulting	result	VBG
cord-005478-5iu38pr6	813	11	in	in	IN
cord-005478-5iu38pr6	813	12	2	2	CD
cord-005478-5iu38pr6	813	13	%	%	NN
cord-005478-5iu38pr6	813	14	(	(	-LRB-
cord-005478-5iu38pr6	813	15	0	0	CD
cord-005478-5iu38pr6	813	16	-	-	SYM
cord-005478-5iu38pr6	813	17	14	14	CD
cord-005478-5iu38pr6	813	18	)	)	-RRB-
cord-005478-5iu38pr6	813	19	CI	CI	NNP
cord-005478-5iu38pr6	813	20	of	of	IN
cord-005478-5iu38pr6	813	21	TRM	TRM	NNP
cord-005478-5iu38pr6	813	22	at	at	IN
cord-005478-5iu38pr6	813	23	1	1	CD
cord-005478-5iu38pr6	813	24	year	year	NN
cord-005478-5iu38pr6	813	25	among	among	IN
cord-005478-5iu38pr6	813	26	the	the	DT
cord-005478-5iu38pr6	813	27	whole	whole	JJ
cord-005478-5iu38pr6	813	28	cohort	cohort	NN
cord-005478-5iu38pr6	813	29	.	.	.
cord-005478-5iu38pr6	814	1	Causes	cause	NNS
cord-005478-5iu38pr6	814	2	of	of	IN
cord-005478-5iu38pr6	814	3	death	death	NN
cord-005478-5iu38pr6	814	4	were	be	VBD
cord-005478-5iu38pr6	814	5	preengraftment	preengraftment	JJ
cord-005478-5iu38pr6	814	6	bloodstream	bloodstream	NN
cord-005478-5iu38pr6	814	7	infection	infection	NN
cord-005478-5iu38pr6	814	8	and	and	CC
cord-005478-5iu38pr6	814	9	disseminated	disseminate	VBN
cord-005478-5iu38pr6	814	10	adenovirus	adenovirus	NN
cord-005478-5iu38pr6	814	11	infection	infection	NN
cord-005478-5iu38pr6	814	12	.	.	.
cord-005478-5iu38pr6	815	1	Patients	patient	NNS
cord-005478-5iu38pr6	815	2	randomized	randomize	VBN
cord-005478-5iu38pr6	815	3	to	to	IN
cord-005478-5iu38pr6	815	4	experimental	experimental	JJ
cord-005478-5iu38pr6	815	5	arm	arm	NN
cord-005478-5iu38pr6	815	6	acquired	acquire	VBD
cord-005478-5iu38pr6	815	7	anti	anti	NNP
cord-005478-5iu38pr6	815	8	-	-	JJ
cord-005478-5iu38pr6	815	9	CMV	CMV	NNP
cord-005478-5iu38pr6	815	10	reactivity	reactivity	NN
cord-005478-5iu38pr6	815	11	significantly	significantly	RB
cord-005478-5iu38pr6	815	12	earlier	early	RBR
cord-005478-5iu38pr6	815	13	,	,	,
cord-005478-5iu38pr6	815	14	according	accord	VBG
cord-005478-5iu38pr6	815	15	to	to	IN
cord-005478-5iu38pr6	815	16	IFN	IFN	NNP
cord-005478-5iu38pr6	815	17	-	-	HYPH
cord-005478-5iu38pr6	815	18	g	g	NNP
cord-005478-5iu38pr6	815	19	ELISPOT	ELISPOT	NNP
cord-005478-5iu38pr6	815	20	assay	assay	NN
cord-005478-5iu38pr6	815	21	on	on	IN
cord-005478-5iu38pr6	815	22	day	day	NN
cord-005478-5iu38pr6	815	23	+30	+30	CD
cord-005478-5iu38pr6	815	24	after	after	IN
cord-005478-5iu38pr6	815	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	815	26	(	(	-LRB-
cord-005478-5iu38pr6	815	27	p=0,0001	p=0,0001	NNP
cord-005478-5iu38pr6	815	28	)	)	-RRB-
cord-005478-5iu38pr6	815	29	.	.	.
cord-005478-5iu38pr6	816	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	816	2	:	:	:
cord-005478-5iu38pr6	817	1	Co	co	NN
cord-005478-5iu38pr6	817	2	-	-	NN
cord-005478-5iu38pr6	817	3	infusion	infusion	NN
cord-005478-5iu38pr6	817	4	of	of	IN
cord-005478-5iu38pr6	817	5	donor	donor	NN
cord-005478-5iu38pr6	817	6	-	-	HYPH
cord-005478-5iu38pr6	817	7	derived	derive	VBN
cord-005478-5iu38pr6	817	8	memory	memory	NN
cord-005478-5iu38pr6	817	9	DLI	DLI	NNP
cord-005478-5iu38pr6	817	10	with	with	IN
cord-005478-5iu38pr6	817	11	the	the	DT
cord-005478-5iu38pr6	817	12	αβ	αβ	FW
cord-005478-5iu38pr6	817	13	T	T	NNP
cord-005478-5iu38pr6	817	14	cell	cell	NN
cord-005478-5iu38pr6	817	15	-	-	HYPH
cord-005478-5iu38pr6	817	16	depleted	deplete	VBN
cord-005478-5iu38pr6	817	17	graft	graft	NN
cord-005478-5iu38pr6	817	18	is	be	VBZ
cord-005478-5iu38pr6	817	19	safe	safe	JJ
cord-005478-5iu38pr6	817	20	and	and	CC
cord-005478-5iu38pr6	817	21	improves	improve	VBZ
cord-005478-5iu38pr6	817	22	recovery	recovery	NN
cord-005478-5iu38pr6	817	23	of	of	IN
cord-005478-5iu38pr6	817	24	virus	virus	NN
cord-005478-5iu38pr6	817	25	-	-	HYPH
cord-005478-5iu38pr6	817	26	specific	specific	JJ
cord-005478-5iu38pr6	817	27	immune	immune	JJ
cord-005478-5iu38pr6	817	28	responses	response	NNS
cord-005478-5iu38pr6	817	29	.	.	.
cord-005478-5iu38pr6	818	1	Replacement	replacement	NN
cord-005478-5iu38pr6	818	2	of	of	IN
cord-005478-5iu38pr6	818	3	ATG	ATG	NNP
cord-005478-5iu38pr6	818	4	with	with	IN
cord-005478-5iu38pr6	818	5	targeted	target	VBN
cord-005478-5iu38pr6	818	6	blockade	blockade	NN
cord-005478-5iu38pr6	818	7	of	of	IN
cord-005478-5iu38pr6	818	8	CD28	CD28	NNP
cord-005478-5iu38pr6	818	9	/	/	SYM
cord-005478-5iu38pr6	818	10	CD80	CD80	NNP
cord-005478-5iu38pr6	818	11	costimulation	costimulation	NN
cord-005478-5iu38pr6	818	12	and	and	CC
cord-005478-5iu38pr6	818	13	IL-6	IL-6	NNP
cord-005478-5iu38pr6	818	14	receptor	receptor	NN
cord-005478-5iu38pr6	818	15	does	do	VBZ
cord-005478-5iu38pr6	818	16	not	not	RB
cord-005478-5iu38pr6	818	17	compromise	compromise	VB
cord-005478-5iu38pr6	818	18	engraftment	engraftment	NN
cord-005478-5iu38pr6	818	19	and	and	CC
cord-005478-5iu38pr6	818	20	GVHD	GVHD	NNP
cord-005478-5iu38pr6	818	21	control	control	NN
cord-005478-5iu38pr6	818	22	,	,	,
cord-005478-5iu38pr6	818	23	and	and	CC
cord-005478-5iu38pr6	818	24	is	be	VBZ
cord-005478-5iu38pr6	818	25	associated	associate	VBN
cord-005478-5iu38pr6	818	26	with	with	IN
cord-005478-5iu38pr6	818	27	low	low	JJ
cord-005478-5iu38pr6	818	28	rate	rate	NN
cord-005478-5iu38pr6	818	29	of	of	IN
cord-005478-5iu38pr6	818	30	non	non	JJ
cord-005478-5iu38pr6	818	31	-	-	JJ
cord-005478-5iu38pr6	818	32	relapse	relapse	JJ
cord-005478-5iu38pr6	818	33	mortality	mortality	NN
cord-005478-5iu38pr6	818	34	.	.	.
cord-005478-5iu38pr6	819	1	[	[	-LRB-
cord-005478-5iu38pr6	819	2	[	[	-LRB-
cord-005478-5iu38pr6	819	3	O046	O046	NNP
cord-005478-5iu38pr6	819	4	Image	image	NN
cord-005478-5iu38pr6	819	5	]	]	-RRB-
cord-005478-5iu38pr6	819	6	1	1	CD
cord-005478-5iu38pr6	819	7	.	.	.
cord-005478-5iu38pr6	820	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	820	2	:	:	:
cord-005478-5iu38pr6	820	3	Nothing	nothing	NN
cord-005478-5iu38pr6	820	4	to	to	TO
cord-005478-5iu38pr6	820	5	declare	declare	VB
cord-005478-5iu38pr6	820	6	O047	o047	CD
cord-005478-5iu38pr6	820	7	conditioning	conditioning	NN
cord-005478-5iu38pr6	820	8	prior	prior	RB
cord-005478-5iu38pr6	820	9	to	to	IN
cord-005478-5iu38pr6	820	10	CD19-specific	cd19-specific	CD
cord-005478-5iu38pr6	820	11	CAR	car	NN
cord-005478-5iu38pr6	820	12	(	(	-LRB-
cord-005478-5iu38pr6	820	13	19	19	CD
cord-005478-5iu38pr6	820	14	-	-	HYPH
cord-005478-5iu38pr6	820	15	28Z	28z	CD
cord-005478-5iu38pr6	820	16	)	)	-RRB-
cord-005478-5iu38pr6	821	1	T	T	NNP
cord-005478-5iu38pr6	821	2	cells	cell	NNS
cord-005478-5iu38pr6	821	3	predicts	predict	VBZ
cord-005478-5iu38pr6	821	4	response	response	NN
cord-005478-5iu38pr6	821	5	and	and	CC
cord-005478-5iu38pr6	821	6	survival	survival	NN
cord-005478-5iu38pr6	821	7	in	in	IN
cord-005478-5iu38pr6	821	8	pediatric	pediatric	JJ
cord-005478-5iu38pr6	821	9	relapse	relapse	NN
cord-005478-5iu38pr6	821	10	/	/	SYM
cord-005478-5iu38pr6	821	11	refractory	refractory	NN
cord-005478-5iu38pr6	822	1	(	(	-LRB-
cord-005478-5iu38pr6	822	2	R	r	NN
cord-005478-5iu38pr6	822	3	/	/	SYM
cord-005478-5iu38pr6	822	4	R	r	NN
cord-005478-5iu38pr6	822	5	)	)	-RRB-
cord-005478-5iu38pr6	822	6	B	b	NN
cord-005478-5iu38pr6	822	7	-	-	:
cord-005478-5iu38pr6	822	8	ALL	all	DT
cord-005478-5iu38pr6	822	9	Background	background	NN
cord-005478-5iu38pr6	822	10	:	:	:
cord-005478-5iu38pr6	822	11	CD19-specific	CD19-specific	NNP
cord-005478-5iu38pr6	822	12	CAR	car	NN
cord-005478-5iu38pr6	822	13	T	t	NN
cord-005478-5iu38pr6	822	14	cells	cell	NNS
cord-005478-5iu38pr6	822	15	have	have	VBP
cord-005478-5iu38pr6	822	16	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	822	17	clinical	clinical	JJ
cord-005478-5iu38pr6	822	18	benefit	benefit	NN
cord-005478-5iu38pr6	822	19	in	in	IN
cord-005478-5iu38pr6	822	20	patients	patient	NNS
cord-005478-5iu38pr6	822	21	with	with	IN
cord-005478-5iu38pr6	822	22	R	r	NN
cord-005478-5iu38pr6	822	23	/	/	SYM
cord-005478-5iu38pr6	822	24	R	r	NN
cord-005478-5iu38pr6	822	25	B	b	NN
cord-005478-5iu38pr6	822	26	-	-	HYPH
cord-005478-5iu38pr6	822	27	cell	cell	NN
cord-005478-5iu38pr6	822	28	acute	acute	JJ
cord-005478-5iu38pr6	822	29	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	822	30	leukemia	leukemia	NN
cord-005478-5iu38pr6	822	31	(	(	-LRB-
cord-005478-5iu38pr6	822	32	B	b	NN
cord-005478-5iu38pr6	822	33	-	-	:
cord-005478-5iu38pr6	822	34	ALL	ALL	NNP
cord-005478-5iu38pr6	822	35	)	)	-RRB-
cord-005478-5iu38pr6	822	36	.	.	.
cord-005478-5iu38pr6	823	1	Several	several	JJ
cord-005478-5iu38pr6	823	2	factors	factor	NNS
cord-005478-5iu38pr6	823	3	have	have	VBP
cord-005478-5iu38pr6	823	4	been	be	VBN
cord-005478-5iu38pr6	823	5	associated	associate	VBN
cord-005478-5iu38pr6	823	6	with	with	IN
cord-005478-5iu38pr6	823	7	response	response	NN
cord-005478-5iu38pr6	823	8	including	include	VBG
cord-005478-5iu38pr6	823	9	conditioning	conditioning	NN
cord-005478-5iu38pr6	823	10	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	823	11	,	,	,
cord-005478-5iu38pr6	823	12	CD4/8	CD4/8	NNP
cord-005478-5iu38pr6	823	13	ratio	ratio	NN
cord-005478-5iu38pr6	823	14	,	,	,
cord-005478-5iu38pr6	823	15	and	and	CC
cord-005478-5iu38pr6	823	16	post	post	VB
cord-005478-5iu38pr6	823	17	infusion	infusion	NN
cord-005478-5iu38pr6	823	18	CAR	car	NN
cord-005478-5iu38pr6	823	19	T	T	NNP
cord-005478-5iu38pr6	823	20	cell	cell	NN
cord-005478-5iu38pr6	823	21	expansion	expansion	NN
cord-005478-5iu38pr6	823	22	.	.	.
cord-005478-5iu38pr6	824	1	Methods	method	NNS
cord-005478-5iu38pr6	824	2	:	:	:
cord-005478-5iu38pr6	824	3	We	-PRON-	PRP
cord-005478-5iu38pr6	824	4	studied	study	VBD
cord-005478-5iu38pr6	824	5	the	the	DT
cord-005478-5iu38pr6	824	6	feasibility	feasibility	NN
cord-005478-5iu38pr6	824	7	of	of	IN
cord-005478-5iu38pr6	824	8	a	a	DT
cord-005478-5iu38pr6	824	9	multi	multi	JJ
cord-005478-5iu38pr6	824	10	-	-	JJ
cord-005478-5iu38pr6	824	11	center	center	JJ
cord-005478-5iu38pr6	824	12	trial	trial	NN
cord-005478-5iu38pr6	824	13	of	of	IN
cord-005478-5iu38pr6	824	14	a	a	DT
cord-005478-5iu38pr6	824	15	MSK	MSK	NNP
cord-005478-5iu38pr6	824	16	-	-	HYPH
cord-005478-5iu38pr6	824	17	developed	develop	VBN
cord-005478-5iu38pr6	824	18	CD19-specific	cd19-specific	CD
cord-005478-5iu38pr6	824	19	CAR	car	NN
cord-005478-5iu38pr6	824	20	(	(	-LRB-
cord-005478-5iu38pr6	824	21	19	19	CD
cord-005478-5iu38pr6	824	22	-	-	SYM
cord-005478-5iu38pr6	824	23	28z	28z	ADD
cord-005478-5iu38pr6	824	24	)	)	-RRB-
cord-005478-5iu38pr6	824	25	for	for	IN
cord-005478-5iu38pr6	824	26	the	the	DT
cord-005478-5iu38pr6	824	27	treatment	treatment	NN
cord-005478-5iu38pr6	824	28	of	of	IN
cord-005478-5iu38pr6	824	29	R	r	NN
cord-005478-5iu38pr6	824	30	/	/	SYM
cord-005478-5iu38pr6	824	31	R	r	NN
cord-005478-5iu38pr6	824	32	B	b	NN
cord-005478-5iu38pr6	824	33	-	-	:
cord-005478-5iu38pr6	824	34	ALL	all	DT
cord-005478-5iu38pr6	824	35	,	,	,
cord-005478-5iu38pr6	824	36	the	the	DT
cord-005478-5iu38pr6	824	37	toxicity	toxicity	NN
cord-005478-5iu38pr6	824	38	following	follow	VBG
cord-005478-5iu38pr6	824	39	infusion	infusion	NN
cord-005478-5iu38pr6	824	40	,	,	,
cord-005478-5iu38pr6	824	41	and	and	CC
cord-005478-5iu38pr6	824	42	performed	perform	VBN
cord-005478-5iu38pr6	824	43	predictor	predictor	NN
cord-005478-5iu38pr6	824	44	analysis	analysis	NN
cord-005478-5iu38pr6	824	45	for	for	IN
cord-005478-5iu38pr6	824	46	optimal	optimal	JJ
cord-005478-5iu38pr6	824	47	response	response	NN
cord-005478-5iu38pr6	824	48	.	.	.
cord-005478-5iu38pr6	825	1	Pediatric	pediatric	JJ
cord-005478-5iu38pr6	825	2	and	and	CC
cord-005478-5iu38pr6	825	3	young	young	JJ
cord-005478-5iu38pr6	825	4	adult	adult	NN
cord-005478-5iu38pr6	825	5	patients	patient	NNS
cord-005478-5iu38pr6	825	6	with	with	IN
cord-005478-5iu38pr6	825	7	R	r	NN
cord-005478-5iu38pr6	825	8	/	/	SYM
cord-005478-5iu38pr6	825	9	R	r	NN
cord-005478-5iu38pr6	825	10	B	b	NN
cord-005478-5iu38pr6	825	11	-	-	:
cord-005478-5iu38pr6	825	12	ALL	all	DT
cord-005478-5iu38pr6	825	13	were	be	VBD
cord-005478-5iu38pr6	825	14	eligible	eligible	JJ
cord-005478-5iu38pr6	825	15	for	for	IN
cord-005478-5iu38pr6	825	16	infusion	infusion	NN
cord-005478-5iu38pr6	825	17	.	.	.
cord-005478-5iu38pr6	826	1	Patients	patient	NNS
cord-005478-5iu38pr6	826	2	received	receive	VBD
cord-005478-5iu38pr6	826	3	a	a	DT
cord-005478-5iu38pr6	826	4	cyclophosphamidebased	cyclophosphamidebased	JJ
cord-005478-5iu38pr6	826	5	(	(	-LRB-
cord-005478-5iu38pr6	826	6	Cy	Cy	NNP
cord-005478-5iu38pr6	826	7	)	)	-RRB-
cord-005478-5iu38pr6	826	8	conditioning	conditioning	NN
cord-005478-5iu38pr6	826	9	of	of	IN
cord-005478-5iu38pr6	826	10	high	high	JJ
cord-005478-5iu38pr6	826	11	dose	dose	NN
cord-005478-5iu38pr6	826	12	(	(	-LRB-
cord-005478-5iu38pr6	826	13	HD	HD	NNP
cord-005478-5iu38pr6	826	14	;	;	:
cord-005478-5iu38pr6	826	15	3g	3g	NNP
cord-005478-5iu38pr6	826	16	/	/	SYM
cord-005478-5iu38pr6	826	17	m2	m2	NNP
cord-005478-5iu38pr6	826	18	)	)	-RRB-
cord-005478-5iu38pr6	826	19	or	or	CC
cord-005478-5iu38pr6	826	20	low	low	JJ
cord-005478-5iu38pr6	826	21	dose	dose	NN
cord-005478-5iu38pr6	826	22	(	(	-LRB-
cord-005478-5iu38pr6	826	23	LD	LD	NNP
cord-005478-5iu38pr6	826	24	;	;	:
cord-005478-5iu38pr6	826	25	1.5g	1.5g	CD
cord-005478-5iu38pr6	826	26	/	/	SYM
cord-005478-5iu38pr6	826	27	m2	m2	NNP
cord-005478-5iu38pr6	826	28	)	)	-RRB-
cord-005478-5iu38pr6	826	29	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	826	30	.	.	.
cord-005478-5iu38pr6	827	1	Outcomes	outcome	NNS
cord-005478-5iu38pr6	827	2	of	of	IN
cord-005478-5iu38pr6	827	3	interest	interest	NN
cord-005478-5iu38pr6	827	4	were	be	VBD
cord-005478-5iu38pr6	827	5	complete	complete	JJ
cord-005478-5iu38pr6	827	6	response	response	NN
cord-005478-5iu38pr6	827	7	(	(	-LRB-
cord-005478-5iu38pr6	827	8	CR	CR	NNP
cord-005478-5iu38pr6	827	9	)	)	-RRB-
cord-005478-5iu38pr6	827	10	,	,	,
cord-005478-5iu38pr6	827	11	overall	overall	JJ
cord-005478-5iu38pr6	827	12	survival	survival	NN
cord-005478-5iu38pr6	827	13	(	(	-LRB-
cord-005478-5iu38pr6	827	14	OS	OS	NNP
cord-005478-5iu38pr6	827	15	)	)	-RRB-
cord-005478-5iu38pr6	827	16	.	.	.
cord-005478-5iu38pr6	828	1	Variables	variable	NNS
cord-005478-5iu38pr6	828	2	considered	consider	VBN
cord-005478-5iu38pr6	828	3	were	be	VBD
cord-005478-5iu38pr6	828	4	conditioning	condition	VBG
cord-005478-5iu38pr6	828	5	regimen	regimen	NN
cord-005478-5iu38pr6	828	6	(	(	-LRB-
cord-005478-5iu38pr6	828	7	HD	HD	NNP
cord-005478-5iu38pr6	828	8	-	-	HYPH
cord-005478-5iu38pr6	828	9	Cy	Cy	NNP
cord-005478-5iu38pr6	828	10	vs	vs	IN
cord-005478-5iu38pr6	828	11	LD	LD	NNP
cord-005478-5iu38pr6	828	12	-	-	HYPH
cord-005478-5iu38pr6	828	13	Cy	Cy	NNP
cord-005478-5iu38pr6	828	14	)	)	-RRB-
cord-005478-5iu38pr6	828	15	,	,	,
cord-005478-5iu38pr6	828	16	pre	pre	JJ
cord-005478-5iu38pr6	828	17	-	-	JJ
cord-005478-5iu38pr6	828	18	treatment	treatment	JJ
cord-005478-5iu38pr6	828	19	disease	disease	NN
cord-005478-5iu38pr6	828	20	burden	burden	NN
cord-005478-5iu38pr6	828	21	(	(	-LRB-
cord-005478-5iu38pr6	828	22	MRD	MRD	NNP
cord-005478-5iu38pr6	828	23	vs	vs	IN
cord-005478-5iu38pr6	828	24	morphologic	morphologic	JJ
cord-005478-5iu38pr6	828	25	)	)	-RRB-
cord-005478-5iu38pr6	828	26	,	,	,
cord-005478-5iu38pr6	828	27	complete	complete	JJ
cord-005478-5iu38pr6	828	28	remission	remission	NN
cord-005478-5iu38pr6	828	29	(	(	-LRB-
cord-005478-5iu38pr6	828	30	CR	cr	NN
cord-005478-5iu38pr6	828	31	)	)	-RRB-
cord-005478-5iu38pr6	828	32	status	status	NN
cord-005478-5iu38pr6	828	33	,	,	,
cord-005478-5iu38pr6	828	34	absolute	absolute	JJ
cord-005478-5iu38pr6	828	35	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	828	36	count	count	NN
cord-005478-5iu38pr6	828	37	(	(	-LRB-
cord-005478-5iu38pr6	828	38	ALC	ALC	NNP
cord-005478-5iu38pr6	828	39	)	)	-RRB-
cord-005478-5iu38pr6	828	40	change	change	NN
cord-005478-5iu38pr6	828	41	,	,	,
cord-005478-5iu38pr6	828	42	and	and	CC
cord-005478-5iu38pr6	828	43	in	in	IN
cord-005478-5iu38pr6	828	44	vivo	vivo	NNP
cord-005478-5iu38pr6	828	45	CAR	CAR	NNP
cord-005478-5iu38pr6	828	46	T	T	NNP
cord-005478-5iu38pr6	828	47	cell	cell	NN
cord-005478-5iu38pr6	828	48	expansion	expansion	NN
cord-005478-5iu38pr6	828	49	.	.	.
cord-005478-5iu38pr6	829	1	Results	result	NNS
cord-005478-5iu38pr6	829	2	:	:	:
cord-005478-5iu38pr6	829	3	25	25	CD
cord-005478-5iu38pr6	829	4	patients	patient	NNS
cord-005478-5iu38pr6	829	5	were	be	VBD
cord-005478-5iu38pr6	829	6	included	include	VBN
cord-005478-5iu38pr6	829	7	;	;	:
cord-005478-5iu38pr6	829	8	17	17	CD
cord-005478-5iu38pr6	829	9	patients	patient	NNS
cord-005478-5iu38pr6	829	10	received	receive	VBD
cord-005478-5iu38pr6	829	11	HD	HD	NNP
cord-005478-5iu38pr6	829	12	-	-	HYPH
cord-005478-5iu38pr6	829	13	Cy	Cy	NNP
cord-005478-5iu38pr6	829	14	and	and	CC
cord-005478-5iu38pr6	829	15	8	8	CD
cord-005478-5iu38pr6	829	16	received	receive	VBD
cord-005478-5iu38pr6	829	17	LD	LD	NNP
cord-005478-5iu38pr6	829	18	-	-	HYPH
cord-005478-5iu38pr6	829	19	Cy	Cy	NNP
cord-005478-5iu38pr6	829	20	prior	prior	RB
cord-005478-5iu38pr6	829	21	to	to	IN
cord-005478-5iu38pr6	829	22	CAR	car	NN
cord-005478-5iu38pr6	829	23	T	T	NNP
cord-005478-5iu38pr6	829	24	cell	cell	NN
cord-005478-5iu38pr6	829	25	infusion	infusion	NN
cord-005478-5iu38pr6	829	26	.	.	.
cord-005478-5iu38pr6	830	1	Among	among	IN
cord-005478-5iu38pr6	830	2	evaluable	evaluable	JJ
cord-005478-5iu38pr6	830	3	patients	patient	NNS
cord-005478-5iu38pr6	830	4	(	(	-LRB-
cord-005478-5iu38pr6	830	5	n=24	n=24	NNP
cord-005478-5iu38pr6	830	6	)	)	-RRB-
cord-005478-5iu38pr6	830	7	,	,	,
cord-005478-5iu38pr6	830	8	CR	CR	NNP
cord-005478-5iu38pr6	830	9	or	or	CC
cord-005478-5iu38pr6	830	10	CR	CR	NNP
cord-005478-5iu38pr6	830	11	with	with	IN
cord-005478-5iu38pr6	830	12	incomplete	incomplete	JJ
cord-005478-5iu38pr6	830	13	count	count	NN
cord-005478-5iu38pr6	830	14	recovery	recovery	NN
cord-005478-5iu38pr6	830	15	was	be	VBD
cord-005478-5iu38pr6	830	16	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	830	17	in	in	IN
cord-005478-5iu38pr6	830	18	94	94	CD
cord-005478-5iu38pr6	830	19	%	%	NN
cord-005478-5iu38pr6	830	20	and	and	CC
cord-005478-5iu38pr6	830	21	38	38	CD
cord-005478-5iu38pr6	830	22	%	%	NN
cord-005478-5iu38pr6	830	23	for	for	IN
cord-005478-5iu38pr6	830	24	HD	HD	NNP
cord-005478-5iu38pr6	830	25	-	-	HYPH
cord-005478-5iu38pr6	830	26	Cy	Cy	NNP
cord-005478-5iu38pr6	830	27	vs	vs	IN
cord-005478-5iu38pr6	830	28	LD	LD	NNP
cord-005478-5iu38pr6	830	29	-	-	HYPH
cord-005478-5iu38pr6	830	30	Cy	Cy	NNP
cord-005478-5iu38pr6	830	31	cohorts	cohort	NNS
cord-005478-5iu38pr6	830	32	respectively	respectively	RB
cord-005478-5iu38pr6	830	33	(	(	-LRB-
cord-005478-5iu38pr6	830	34	p=0·01	p=0·01	JJ
cord-005478-5iu38pr6	830	35	)	)	-RRB-
cord-005478-5iu38pr6	830	36	.	.	.
cord-005478-5iu38pr6	831	1	OS	OS	NNP
cord-005478-5iu38pr6	831	2	was	be	VBD
cord-005478-5iu38pr6	831	3	superior	superior	JJ
cord-005478-5iu38pr6	831	4	in	in	IN
cord-005478-5iu38pr6	831	5	the	the	DT
cord-005478-5iu38pr6	831	6	HD	HD	NNP
cord-005478-5iu38pr6	831	7	-	-	HYPH
cord-005478-5iu38pr6	831	8	Cy	Cy	NNP
cord-005478-5iu38pr6	831	9	cohort	cohort	NN
cord-005478-5iu38pr6	831	10	as	as	IN
cord-005478-5iu38pr6	831	11	compared	compare	VBN
cord-005478-5iu38pr6	831	12	to	to	IN
cord-005478-5iu38pr6	831	13	the	the	DT
cord-005478-5iu38pr6	831	14	LD	LD	NNP
cord-005478-5iu38pr6	831	15	-	-	HYPH
cord-005478-5iu38pr6	831	16	Cy	Cy	NNP
cord-005478-5iu38pr6	831	17	cohort	cohort	NN
cord-005478-5iu38pr6	831	18	(	(	-LRB-
cord-005478-5iu38pr6	831	19	median	median	JJ
cord-005478-5iu38pr6	831	20	OS	os	NN
cord-005478-5iu38pr6	831	21	=	=	NFP
cord-005478-5iu38pr6	831	22	not	not	RB
cord-005478-5iu38pr6	831	23	reached	reach	VBN
cord-005478-5iu38pr6	831	24	;	;	:
cord-005478-5iu38pr6	831	25	NR	NR	NNP
cord-005478-5iu38pr6	831	26	)	)	-RRB-
cord-005478-5iu38pr6	831	27	vs.	vs.	IN
cord-005478-5iu38pr6	831	28	4·7	4·7	CD
cord-005478-5iu38pr6	831	29	months	month	NNS
cord-005478-5iu38pr6	831	30	(	(	-LRB-
cord-005478-5iu38pr6	831	31	p=0·004	p=0·004	NN
cord-005478-5iu38pr6	831	32	;	;	:
cord-005478-5iu38pr6	831	33	Figure	figure	NN
cord-005478-5iu38pr6	831	34	1	1	CD
cord-005478-5iu38pr6	831	35	)	)	-RRB-
cord-005478-5iu38pr6	831	36	.	.	.
cord-005478-5iu38pr6	832	1	Lymphodepletion	Lymphodepletion	NNP
cord-005478-5iu38pr6	832	2	(	(	-LRB-
cord-005478-5iu38pr6	832	3	Delta	Delta	NNP
cord-005478-5iu38pr6	832	4	ALC	ALC	NNP
cord-005478-5iu38pr6	832	5	:	:	:
cord-005478-5iu38pr6	832	6	prior	prior	RB
cord-005478-5iu38pr6	832	7	to	to	IN
cord-005478-5iu38pr6	832	8	and	and	CC
cord-005478-5iu38pr6	832	9	following	follow	VBG
cord-005478-5iu38pr6	832	10	Cy	Cy	NNP
cord-005478-5iu38pr6	832	11	)	)	-RRB-
cord-005478-5iu38pr6	832	12	was	be	VBD
cord-005478-5iu38pr6	832	13	significantly	significantly	RB
cord-005478-5iu38pr6	832	14	higher	high	JJR
cord-005478-5iu38pr6	832	15	in	in	IN
cord-005478-5iu38pr6	832	16	the	the	DT
cord-005478-5iu38pr6	832	17	HD	HD	NNP
cord-005478-5iu38pr6	832	18	-	-	HYPH
cord-005478-5iu38pr6	832	19	Cy	Cy	NNP
cord-005478-5iu38pr6	832	20	cohort	cohort	NN
cord-005478-5iu38pr6	832	21	as	as	IN
cord-005478-5iu38pr6	832	22	compared	compare	VBN
cord-005478-5iu38pr6	832	23	to	to	IN
cord-005478-5iu38pr6	832	24	the	the	DT
cord-005478-5iu38pr6	832	25	LD	LD	NNP
cord-005478-5iu38pr6	832	26	-	-	HYPH
cord-005478-5iu38pr6	832	27	Cy	Cy	NNP
cord-005478-5iu38pr6	832	28	cohort	cohort	NN
cord-005478-5iu38pr6	832	29	(	(	-LRB-
cord-005478-5iu38pr6	832	30	p	p	XX
cord-005478-5iu38pr6	832	31	<	<	XX
cord-005478-5iu38pr6	832	32	0·001	0·001	CD
cord-005478-5iu38pr6	832	33	;	;	.
cord-005478-5iu38pr6	833	1	Figure	figure	NN
cord-005478-5iu38pr6	833	2	2	2	CD
cord-005478-5iu38pr6	833	3	)	)	-RRB-
cord-005478-5iu38pr6	833	4	.	.	.
cord-005478-5iu38pr6	834	1	The	the	DT
cord-005478-5iu38pr6	834	2	in	in	IN
cord-005478-5iu38pr6	834	3	vivo	vivo	NNP
cord-005478-5iu38pr6	834	4	CAR	car	NN
cord-005478-5iu38pr6	834	5	T	T	NNP
cord-005478-5iu38pr6	834	6	cell	cell	NN
cord-005478-5iu38pr6	834	7	expansion	expansion	NN
cord-005478-5iu38pr6	834	8	(	(	-LRB-
cord-005478-5iu38pr6	834	9	peak	peak	NNP
cord-005478-5iu38pr6	834	10	CAR	CAR	NNP
cord-005478-5iu38pr6	834	11	T	T	NNP
cord-005478-5iu38pr6	834	12	cell	cell	NN
cord-005478-5iu38pr6	834	13	vector	vector	NN
cord-005478-5iu38pr6	834	14	copy	copy	NN
cord-005478-5iu38pr6	834	15	number	number	NN
cord-005478-5iu38pr6	834	16	/	/	SYM
cord-005478-5iu38pr6	834	17	ml	ml	NN
cord-005478-5iu38pr6	834	18	)	)	-RRB-
cord-005478-5iu38pr6	834	19	in	in	IN
cord-005478-5iu38pr6	834	20	peripheral	peripheral	JJ
cord-005478-5iu38pr6	834	21	blood	blood	NN
cord-005478-5iu38pr6	834	22	was	be	VBD
cord-005478-5iu38pr6	834	23	higher	high	JJR
cord-005478-5iu38pr6	834	24	in	in	IN
cord-005478-5iu38pr6	834	25	the	the	DT
cord-005478-5iu38pr6	834	26	HD	HD	NNP
cord-005478-5iu38pr6	834	27	-	-	HYPH
cord-005478-5iu38pr6	834	28	Cy	Cy	NNP
cord-005478-5iu38pr6	834	29	cohort	cohort	NN
cord-005478-5iu38pr6	834	30	as	as	IN
cord-005478-5iu38pr6	834	31	compared	compare	VBN
cord-005478-5iu38pr6	834	32	to	to	IN
cord-005478-5iu38pr6	834	33	the	the	DT
cord-005478-5iu38pr6	834	34	LD	LD	NNP
cord-005478-5iu38pr6	834	35	-	-	HYPH
cord-005478-5iu38pr6	834	36	Cy	Cy	NNP
cord-005478-5iu38pr6	834	37	cohort	cohort	NN
cord-005478-5iu38pr6	834	38	(	(	-LRB-
cord-005478-5iu38pr6	834	39	p=0·01	p=0·01	JJ
cord-005478-5iu38pr6	834	40	;	;	.
cord-005478-5iu38pr6	835	1	Figure	figure	NN
cord-005478-5iu38pr6	835	2	2	2	CD
cord-005478-5iu38pr6	835	3	)	)	-RRB-
cord-005478-5iu38pr6	835	4	.	.	.
cord-005478-5iu38pr6	836	1	To	to	IN
cord-005478-5iu38pr6	836	2	less	less	JJR
cord-005478-5iu38pr6	836	3	extent	extent	NN
cord-005478-5iu38pr6	836	4	,	,	,
cord-005478-5iu38pr6	836	5	disease	disease	NN
cord-005478-5iu38pr6	836	6	burden	burden	NN
cord-005478-5iu38pr6	836	7	prior	prior	RB
cord-005478-5iu38pr6	836	8	to	to	IN
cord-005478-5iu38pr6	836	9	treatment	treatment	NN
cord-005478-5iu38pr6	836	10	with	with	IN
cord-005478-5iu38pr6	836	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	837	1	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	837	2	and	and	CC
cord-005478-5iu38pr6	837	3	CAR	CAR	NNP
cord-005478-5iu38pr6	837	4	T	t	NN
cord-005478-5iu38pr6	837	5	cells	cell	NNS
cord-005478-5iu38pr6	837	6	impacted	impact	VBD
cord-005478-5iu38pr6	837	7	response	response	NN
cord-005478-5iu38pr6	837	8	.	.	.
cord-005478-5iu38pr6	838	1	Disease	Disease	NNP
cord-005478-5iu38pr6	838	2	response	response	NN
cord-005478-5iu38pr6	838	3	was	be	VBD
cord-005478-5iu38pr6	838	4	93	93	CD
cord-005478-5iu38pr6	838	5	%	%	NN
cord-005478-5iu38pr6	838	6	(	(	-LRB-
cord-005478-5iu38pr6	838	7	13/14	13/14	CD
cord-005478-5iu38pr6	838	8	)	)	-RRB-
cord-005478-5iu38pr6	838	9	in	in	IN
cord-005478-5iu38pr6	838	10	low	low	JJ
cord-005478-5iu38pr6	838	11	disease	disease	NN
cord-005478-5iu38pr6	838	12	burden	burden	NN
cord-005478-5iu38pr6	838	13	group	group	NN
cord-005478-5iu38pr6	838	14	(	(	-LRB-
cord-005478-5iu38pr6	838	15	MRD	MRD	NNP
cord-005478-5iu38pr6	838	16	-	-	HYPH
cord-005478-5iu38pr6	838	17	cohort	cohort	NN
cord-005478-5iu38pr6	838	18	)	)	-RRB-
cord-005478-5iu38pr6	838	19	compared	compare	VBN
cord-005478-5iu38pr6	838	20	to	to	IN
cord-005478-5iu38pr6	838	21	50	50	CD
cord-005478-5iu38pr6	838	22	%	%	NN
cord-005478-5iu38pr6	838	23	(	(	-LRB-
cord-005478-5iu38pr6	838	24	5/10	5/10	CD
cord-005478-5iu38pr6	838	25	)	)	-RRB-
cord-005478-5iu38pr6	838	26	in	in	IN
cord-005478-5iu38pr6	838	27	the	the	DT
cord-005478-5iu38pr6	838	28	high	high	JJ
cord-005478-5iu38pr6	838	29	disease	disease	NN
cord-005478-5iu38pr6	838	30	burden	burden	NN
cord-005478-5iu38pr6	838	31	group	group	NN
cord-005478-5iu38pr6	838	32	(	(	-LRB-
cord-005478-5iu38pr6	838	33	morphologic	morphologic	JJ
cord-005478-5iu38pr6	838	34	cohort	cohort	NN
cord-005478-5iu38pr6	838	35	)	)	-RRB-
cord-005478-5iu38pr6	839	1	(	(	-LRB-
cord-005478-5iu38pr6	839	2	p=0·05	p=0·05	NNP
cord-005478-5iu38pr6	839	3	)	)	-RRB-
cord-005478-5iu38pr6	839	4	.	.	.
cord-005478-5iu38pr6	840	1	OS	OS	NNP
cord-005478-5iu38pr6	840	2	was	be	VBD
cord-005478-5iu38pr6	840	3	also	also	RB
cord-005478-5iu38pr6	840	4	superior	superior	JJ
cord-005478-5iu38pr6	840	5	in	in	IN
cord-005478-5iu38pr6	840	6	the	the	DT
cord-005478-5iu38pr6	840	7	low	low	JJ
cord-005478-5iu38pr6	840	8	disease	disease	NN
cord-005478-5iu38pr6	840	9	burden	burden	NNP
cord-005478-5iu38pr6	840	10	group	group	NN
cord-005478-5iu38pr6	840	11	(	(	-LRB-
cord-005478-5iu38pr6	840	12	median	median	JJ
cord-005478-5iu38pr6	840	13	OS	os	NN
cord-005478-5iu38pr6	840	14	=	=	SYM
cord-005478-5iu38pr6	840	15	NR	nr	NN
cord-005478-5iu38pr6	840	16	)	)	-RRB-
cord-005478-5iu38pr6	840	17	compared	compare	VBN
cord-005478-5iu38pr6	840	18	to	to	IN
cord-005478-5iu38pr6	840	19	high	high	JJ
cord-005478-5iu38pr6	840	20	disease	disease	NN
cord-005478-5iu38pr6	840	21	burden	burden	NN
cord-005478-5iu38pr6	840	22	group	group	NN
cord-005478-5iu38pr6	840	23	(	(	-LRB-
cord-005478-5iu38pr6	840	24	median	median	JJ
cord-005478-5iu38pr6	840	25	OS	os	NN
cord-005478-5iu38pr6	840	26	=	=	SYM
cord-005478-5iu38pr6	840	27	4.3	4.3	CD
cord-005478-5iu38pr6	840	28	months	month	NNS
cord-005478-5iu38pr6	840	29	;	;	:
cord-005478-5iu38pr6	840	30	p=0·01	p=0·01	JJ
cord-005478-5iu38pr6	840	31	)	)	-RRB-
cord-005478-5iu38pr6	840	32	.	.	.
cord-005478-5iu38pr6	841	1	Combined	combined	JJ
cord-005478-5iu38pr6	841	2	response	response	NN
cord-005478-5iu38pr6	841	3	for	for	IN
cord-005478-5iu38pr6	841	4	HD	HD	NNP
cord-005478-5iu38pr6	841	5	-	-	HYPH
cord-005478-5iu38pr6	841	6	Cy	Cy	NNP
cord-005478-5iu38pr6	841	7	/	/	SYM
cord-005478-5iu38pr6	841	8	MRD	MRD	NNP
cord-005478-5iu38pr6	841	9	was	be	VBD
cord-005478-5iu38pr6	841	10	100	100	CD
cord-005478-5iu38pr6	841	11	%	%	NN
cord-005478-5iu38pr6	841	12	(	(	-LRB-
cord-005478-5iu38pr6	841	13	12/12	12/12	CD
cord-005478-5iu38pr6	841	14	)	)	-RRB-
cord-005478-5iu38pr6	841	15	,	,	,
cord-005478-5iu38pr6	841	16	HD	HD	NNP
cord-005478-5iu38pr6	841	17	-	-	HYPH
cord-005478-5iu38pr6	841	18	Cy	Cy	NNP
cord-005478-5iu38pr6	841	19	/	/	SYM
cord-005478-5iu38pr6	841	20	Morphologic	Morphologic	NNP
cord-005478-5iu38pr6	841	21	75	75	CD
cord-005478-5iu38pr6	841	22	%	%	NN
cord-005478-5iu38pr6	841	23	(	(	-LRB-
cord-005478-5iu38pr6	841	24	3/4	3/4	CD
cord-005478-5iu38pr6	841	25	)	)	-RRB-
cord-005478-5iu38pr6	841	26	,	,	,
cord-005478-5iu38pr6	841	27	LD	LD	NNP
cord-005478-5iu38pr6	841	28	-	-	HYPH
cord-005478-5iu38pr6	841	29	Cy	Cy	NNP
cord-005478-5iu38pr6	841	30	/	/	SYM
cord-005478-5iu38pr6	841	31	MRD	MRD	NNP
cord-005478-5iu38pr6	842	1	50	50	CD
cord-005478-5iu38pr6	842	2	%	%	NN
cord-005478-5iu38pr6	842	3	(	(	-LRB-
cord-005478-5iu38pr6	842	4	1/2	1/2	CD
cord-005478-5iu38pr6	842	5	)	)	-RRB-
cord-005478-5iu38pr6	842	6	,	,	,
cord-005478-5iu38pr6	842	7	and	and	CC
cord-005478-5iu38pr6	842	8	LD	LD	NNP
cord-005478-5iu38pr6	842	9	-	-	HYPH
cord-005478-5iu38pr6	842	10	Cy	Cy	NNP
cord-005478-5iu38pr6	842	11	/	/	SYM
cord-005478-5iu38pr6	842	12	Morphologic	Morphologic	NNP
cord-005478-5iu38pr6	842	13	33	33	CD
cord-005478-5iu38pr6	842	14	%	%	NN
cord-005478-5iu38pr6	842	15	(	(	-LRB-
cord-005478-5iu38pr6	842	16	2/6	2/6	CD
cord-005478-5iu38pr6	842	17	)	)	-RRB-
cord-005478-5iu38pr6	842	18	.	.	.
cord-005478-5iu38pr6	843	1	Grade	grade	NN
cord-005478-5iu38pr6	843	2	III/	III/	NNP
cord-005478-5iu38pr6	843	3	IV	IV	NNP
cord-005478-5iu38pr6	843	4	toxicity	toxicity	NN
cord-005478-5iu38pr6	843	5	occurred	occur	VBD
cord-005478-5iu38pr6	843	6	in	in	IN
cord-005478-5iu38pr6	843	7	32	32	CD
cord-005478-5iu38pr6	843	8	%	%	NN
cord-005478-5iu38pr6	843	9	(	(	-LRB-
cord-005478-5iu38pr6	843	10	8/25	8/25	CD
cord-005478-5iu38pr6	843	11	)	)	-RRB-
cord-005478-5iu38pr6	843	12	of	of	IN
cord-005478-5iu38pr6	843	13	patients	patient	NNS
cord-005478-5iu38pr6	843	14	including	include	VBG
cord-005478-5iu38pr6	843	15	severe	severe	JJ
cord-005478-5iu38pr6	843	16	cytokine	cytokine	NN
cord-005478-5iu38pr6	843	17	release	release	NN
cord-005478-5iu38pr6	843	18	syndrome	syndrome	NN
cord-005478-5iu38pr6	843	19	(	(	-LRB-
cord-005478-5iu38pr6	843	20	sCRS	sCRS	NNP
cord-005478-5iu38pr6	843	21	)	)	-RRB-
cord-005478-5iu38pr6	843	22	in	in	IN
cord-005478-5iu38pr6	843	23	16	16	CD
cord-005478-5iu38pr6	843	24	%	%	NN
cord-005478-5iu38pr6	843	25	of	of	IN
cord-005478-5iu38pr6	843	26	patients	patient	NNS
cord-005478-5iu38pr6	843	27	and	and	CC
cord-005478-5iu38pr6	843	28	severe	severe	JJ
cord-005478-5iu38pr6	843	29	CAR	car	NN
cord-005478-5iu38pr6	843	30	-	-	HYPH
cord-005478-5iu38pr6	843	31	associated	associate	VBN
cord-005478-5iu38pr6	843	32	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	843	33	in	in	IN
cord-005478-5iu38pr6	843	34	28	28	CD
cord-005478-5iu38pr6	843	35	%	%	NN
cord-005478-5iu38pr6	843	36	of	of	IN
cord-005478-5iu38pr6	843	37	patients	patient	NNS
cord-005478-5iu38pr6	843	38	.	.	.
cord-005478-5iu38pr6	844	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	844	2	:	:	:
cord-005478-5iu38pr6	845	1	In	in	IN
cord-005478-5iu38pr6	845	2	this	this	DT
cord-005478-5iu38pr6	845	3	preliminary	preliminary	JJ
cord-005478-5iu38pr6	845	4	analysis	analysis	NN
cord-005478-5iu38pr6	845	5	we	-PRON-	PRP
cord-005478-5iu38pr6	845	6	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	845	7	that	that	IN
cord-005478-5iu38pr6	845	8	dose	dose	JJ
cord-005478-5iu38pr6	845	9	intensity	intensity	NN
cord-005478-5iu38pr6	845	10	of	of	IN
cord-005478-5iu38pr6	845	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	845	12	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	845	13	positively	positively	RB
cord-005478-5iu38pr6	845	14	correlated	correlate	VBD
cord-005478-5iu38pr6	845	15	with	with	IN
cord-005478-5iu38pr6	845	16	response	response	NN
cord-005478-5iu38pr6	845	17	and	and	CC
cord-005478-5iu38pr6	845	18	overall	overall	JJ
cord-005478-5iu38pr6	845	19	survival	survival	NN
cord-005478-5iu38pr6	845	20	for	for	IN
cord-005478-5iu38pr6	845	21	patients	patient	NNS
cord-005478-5iu38pr6	845	22	treated	treat	VBN
cord-005478-5iu38pr6	845	23	with	with	IN
cord-005478-5iu38pr6	845	24	CAR	CAR	NNP
cord-005478-5iu38pr6	845	25	T	T	NNP
cord-005478-5iu38pr6	845	26	cells	cell	NNS
cord-005478-5iu38pr6	845	27	and	and	CC
cord-005478-5iu38pr6	845	28	confirms	confirm	VBZ
cord-005478-5iu38pr6	845	29	,	,	,
cord-005478-5iu38pr6	845	30	to	to	IN
cord-005478-5iu38pr6	845	31	a	a	DT
cord-005478-5iu38pr6	845	32	lesser	less	JJR
cord-005478-5iu38pr6	845	33	extent	extent	NN
cord-005478-5iu38pr6	845	34	,	,	,
cord-005478-5iu38pr6	845	35	pre	pre	JJ
cord-005478-5iu38pr6	845	36	-	-	JJ
cord-005478-5iu38pr6	845	37	treatment	treatment	JJ
cord-005478-5iu38pr6	845	38	disease	disease	NN
cord-005478-5iu38pr6	845	39	burden	burden	NN
cord-005478-5iu38pr6	845	40	impacts	impact	NNS
cord-005478-5iu38pr6	845	41	both	both	CC
cord-005478-5iu38pr6	845	42	response	response	NN
cord-005478-5iu38pr6	845	43	and	and	CC
cord-005478-5iu38pr6	845	44	overall	overall	JJ
cord-005478-5iu38pr6	845	45	survival	survival	NN
cord-005478-5iu38pr6	845	46	.	.	.
cord-005478-5iu38pr6	846	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	846	2	Trial	Trial	NNP
cord-005478-5iu38pr6	846	3	Registry	Registry	NNP
cord-005478-5iu38pr6	846	4	:	:	:
cord-005478-5iu38pr6	846	5	NCT01860937	NCT01860937	NNP
cord-005478-5iu38pr6	846	6	Disclosure	disclosure	NN
cord-005478-5iu38pr6	846	7	:	:	:
cord-005478-5iu38pr6	847	1	The	the	DT
cord-005478-5iu38pr6	847	2	authors	author	NNS
cord-005478-5iu38pr6	847	3	acknowledge	acknowledge	VBP
cord-005478-5iu38pr6	847	4	William	William	NNP
cord-005478-5iu38pr6	847	5	Lawrence	Lawrence	NNP
cord-005478-5iu38pr6	847	6	and	and	CC
cord-005478-5iu38pr6	847	7	Blanche	Blanche	NNP
cord-005478-5iu38pr6	847	8	Hughes	Hughes	NNP
cord-005478-5iu38pr6	847	9	Foundation	Foundation	NNP
cord-005478-5iu38pr6	847	10	provided	provide	VBD
cord-005478-5iu38pr6	847	11	funding	funding	NN
cord-005478-5iu38pr6	847	12	for	for	IN
cord-005478-5iu38pr6	847	13	the	the	DT
cord-005478-5iu38pr6	847	14	conduct	conduct	NN
cord-005478-5iu38pr6	847	15	of	of	IN
cord-005478-5iu38pr6	847	16	this	this	DT
cord-005478-5iu38pr6	847	17	study	study	NN
cord-005478-5iu38pr6	847	18	with	with	IN
cord-005478-5iu38pr6	847	19	Juno	Juno	NNP
cord-005478-5iu38pr6	847	20	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	847	21	providing	provide	VBG
cord-005478-5iu38pr6	847	22	funding	funding	NN
cord-005478-5iu38pr6	847	23	for	for	IN
cord-005478-5iu38pr6	847	24	an	an	DT
cord-005478-5iu38pr6	847	25	extension	extension	NN
cord-005478-5iu38pr6	847	26	cohort	cohort	NN
cord-005478-5iu38pr6	847	27	of	of	IN
cord-005478-5iu38pr6	847	28	patients	patient	NNS
cord-005478-5iu38pr6	847	29	.	.	.
cord-005478-5iu38pr6	848	1	K.J.C.	K.J.C.	NNP
cord-005478-5iu38pr6	848	2	has	have	VBZ
cord-005478-5iu38pr6	848	3	received	receive	VBN
cord-005478-5iu38pr6	848	4	research	research	NN
cord-005478-5iu38pr6	848	5	support	support	NN
cord-005478-5iu38pr6	848	6	from	from	IN
cord-005478-5iu38pr6	848	7	Juno	Juno	NNP
cord-005478-5iu38pr6	848	8	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	848	9	;	;	:
cord-005478-5iu38pr6	848	10	has	have	VBZ
cord-005478-5iu38pr6	848	11	consulted	consult	VBN
cord-005478-5iu38pr6	848	12	,	,	,
cord-005478-5iu38pr6	848	13	participated	participate	VBN
cord-005478-5iu38pr6	848	14	in	in	IN
cord-005478-5iu38pr6	848	15	advisory	advisory	JJ
cord-005478-5iu38pr6	848	16	boards	board	NNS
cord-005478-5iu38pr6	848	17	,	,	,
cord-005478-5iu38pr6	848	18	or	or	CC
cord-005478-5iu38pr6	848	19	participated	participate	VBD
cord-005478-5iu38pr6	848	20	in	in	IN
cord-005478-5iu38pr6	848	21	educational	educational	JJ
cord-005478-5iu38pr6	848	22	seminars	seminar	NNS
cord-005478-5iu38pr6	848	23	for	for	IN
cord-005478-5iu38pr6	848	24	Juno	Juno	NNP
cord-005478-5iu38pr6	848	25	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	848	26	,	,	,
cord-005478-5iu38pr6	848	27	and	and	CC
cord-005478-5iu38pr6	848	28	Novartis	Novartis	NNP
cord-005478-5iu38pr6	848	29	.	.	.
cord-005478-5iu38pr6	849	1	R.	R.	NNP
cord-005478-5iu38pr6	849	2	J.B.	J.B.	NNP
cord-005478-5iu38pr6	850	1	M.S.	M.S.	NNP
cord-005478-5iu38pr6	850	2	I.R.	I.R.	NNP
cord-005478-5iu38pr6	850	3	are	be	VBP
cord-005478-5iu38pr6	850	4	co	co	NN
cord-005478-5iu38pr6	850	5	-	-	NN
cord-005478-5iu38pr6	850	6	founder	founder	NN
cord-005478-5iu38pr6	850	7	,	,	,
cord-005478-5iu38pr6	850	8	stock	stock	NN
cord-005478-5iu38pr6	850	9	holders	holder	NNS
cord-005478-5iu38pr6	850	10	,	,	,
cord-005478-5iu38pr6	850	11	and	and	CC
cord-005478-5iu38pr6	850	12	consultants	consultant	NNS
cord-005478-5iu38pr6	850	13	for	for	IN
cord-005478-5iu38pr6	850	14	Juno	Juno	NNP
cord-005478-5iu38pr6	850	15	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	850	16	.	.	.
cord-005478-5iu38pr6	851	1	C.S.S.	C.S.S.	NNP
cord-005478-5iu38pr6	851	2	has	have	VBZ
cord-005478-5iu38pr6	851	3	received	receive	VBN
cord-005478-5iu38pr6	851	4	research	research	NN
cord-005478-5iu38pr6	851	5	support	support	NN
cord-005478-5iu38pr6	851	6	from	from	IN
cord-005478-5iu38pr6	851	7	Juno	Juno	NNP
cord-005478-5iu38pr6	851	8	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	851	9	;	;	:
cord-005478-5iu38pr6	851	10	has	have	VBZ
cord-005478-5iu38pr6	851	11	consulted	consult	VBN
cord-005478-5iu38pr6	851	12	or	or	CC
cord-005478-5iu38pr6	851	13	participated	participate	VBN
cord-005478-5iu38pr6	851	14	in	in	IN
cord-005478-5iu38pr6	851	15	advisory	advisory	JJ
cord-005478-5iu38pr6	851	16	boards	board	NNS
cord-005478-5iu38pr6	851	17	for	for	IN
cord-005478-5iu38pr6	851	18	Juno	Juno	NNP
cord-005478-5iu38pr6	851	19	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	851	20	,	,	,
cord-005478-5iu38pr6	851	21	Kite	Kite	NNP
cord-005478-5iu38pr6	851	22	and	and	CC
cord-005478-5iu38pr6	851	23	Novartis	Novartis	NNP
cord-005478-5iu38pr6	851	24	.	.	.
cord-005478-5iu38pr6	852	1	Early	early	JJ
cord-005478-5iu38pr6	852	2	and	and	CC
cord-005478-5iu38pr6	852	3	late	late	JJ
cord-005478-5iu38pr6	852	4	hematologic	hematologic	JJ
cord-005478-5iu38pr6	852	5	toxicities	toxicity	NNS
cord-005478-5iu38pr6	852	6	in	in	IN
cord-005478-5iu38pr6	852	7	children	child	NNS
cord-005478-5iu38pr6	852	8	and	and	CC
cord-005478-5iu38pr6	852	9	adults	adult	NNS
cord-005478-5iu38pr6	852	10	treated	treat	VBN
cord-005478-5iu38pr6	852	11	with	with	IN
cord-005478-5iu38pr6	852	12	CD19-CAR	CD19-CAR	NNP
cord-005478-5iu38pr6	852	13	T	T	NNP
cord-005478-5iu38pr6	852	14	cells	cell	NNS
cord-005478-5iu38pr6	852	15	Elad	Elad	NNP
cord-005478-5iu38pr6	852	16	Jacoby	Jacoby	NNP
cord-005478-5iu38pr6	852	17	1,2	1,2	CD
cord-005478-5iu38pr6	852	18	,	,	,
cord-005478-5iu38pr6	852	19	Shalev	Shalev	NNP
cord-005478-5iu38pr6	852	20	Fried	Fried	NNP
cord-005478-5iu38pr6	852	21	1,2	1,2	CD
cord-005478-5iu38pr6	852	22	,	,	,
cord-005478-5iu38pr6	852	23	Abraham	Abraham	NNP
cord-005478-5iu38pr6	852	24	Avigdor	Avigdor	NNP
cord-005478-5iu38pr6	852	25	1,2	1,2	CD
cord-005478-5iu38pr6	852	26	,	,	,
cord-005478-5iu38pr6	852	27	Bella	Bella	NNP
cord-005478-5iu38pr6	852	28	Bielorai	Bielorai	NNP
cord-005478-5iu38pr6	852	29	1,2	1,2	CD
cord-005478-5iu38pr6	852	30	,	,	,
cord-005478-5iu38pr6	852	31	Amilia	Amilia	NNP
cord-005478-5iu38pr6	852	32	Meir	Meir	NNP
cord-005478-5iu38pr6	852	33	1	1	CD
cord-005478-5iu38pr6	852	34	,	,	,
cord-005478-5iu38pr6	852	35	Michal	Michal	NNP
cord-005478-5iu38pr6	852	36	Besser	Besser	NNP
cord-005478-5iu38pr6	852	37	1,2	1,2	NNP
cord-005478-5iu38pr6	852	38	,	,	,
cord-005478-5iu38pr6	852	39	Jacob	Jacob	NNP
cord-005478-5iu38pr6	852	40	Schachter	Schachter	NNP
cord-005478-5iu38pr6	852	41	1,2	1,2	CD
cord-005478-5iu38pr6	852	42	,	,	,
cord-005478-5iu38pr6	852	43	Avichai	Avichai	NNP
cord-005478-5iu38pr6	852	44	Shimoni	Shimoni	NNP
cord-005478-5iu38pr6	852	45	1,2	1,2	CD
cord-005478-5iu38pr6	852	46	,	,	,
cord-005478-5iu38pr6	852	47	Arnon	Arnon	NNP
cord-005478-5iu38pr6	852	48	Nagler	Nagler	NNP
cord-005478-5iu38pr6	852	49	,	,	,
cord-005478-5iu38pr6	852	50	1,2	1,2	CD
cord-005478-5iu38pr6	852	51	,	,	,
cord-005478-5iu38pr6	852	52	Amos	Amos	NNP
cord-005478-5iu38pr6	852	53	Toren	Toren	NNP
cord-005478-5iu38pr6	852	54	1	1	CD
cord-005478-5iu38pr6	852	55	,	,	,
cord-005478-5iu38pr6	852	56	2	2	CD
cord-005478-5iu38pr6	852	57	Background	background	NN
cord-005478-5iu38pr6	852	58	:	:	:
cord-005478-5iu38pr6	852	59	Autologous	autologous	JJ
cord-005478-5iu38pr6	852	60	T	t	NN
cord-005478-5iu38pr6	852	61	cells	cell	NNS
cord-005478-5iu38pr6	852	62	transduced	transduce	VBN
cord-005478-5iu38pr6	852	63	with	with	IN
cord-005478-5iu38pr6	852	64	CD19directed	cd19directed	JJ
cord-005478-5iu38pr6	852	65	chimeric	chimeric	JJ
cord-005478-5iu38pr6	852	66	antigen	antigen	NN
cord-005478-5iu38pr6	852	67	receptors	receptor	NNS
cord-005478-5iu38pr6	852	68	show	show	VBP
cord-005478-5iu38pr6	852	69	notable	notable	JJ
cord-005478-5iu38pr6	852	70	remission	remission	NN
cord-005478-5iu38pr6	852	71	rate	rate	NN
cord-005478-5iu38pr6	852	72	in	in	IN
cord-005478-5iu38pr6	852	73	advanced	advanced	JJ
cord-005478-5iu38pr6	852	74	patients	patient	NNS
cord-005478-5iu38pr6	852	75	,	,	,
cord-005478-5iu38pr6	852	76	leading	lead	VBG
cord-005478-5iu38pr6	852	77	to	to	IN
cord-005478-5iu38pr6	852	78	approval	approval	NN
cord-005478-5iu38pr6	852	79	by	by	IN
cord-005478-5iu38pr6	852	80	the	the	DT
cord-005478-5iu38pr6	852	81	FDA	FDA	NNP
cord-005478-5iu38pr6	852	82	and	and	CC
cord-005478-5iu38pr6	852	83	EMA	EMA	NNP
cord-005478-5iu38pr6	852	84	for	for	IN
cord-005478-5iu38pr6	852	85	treatment	treatment	NN
cord-005478-5iu38pr6	852	86	of	of	IN
cord-005478-5iu38pr6	852	87	relapsed	relapsed	JJ
cord-005478-5iu38pr6	852	88	and	and	CC
cord-005478-5iu38pr6	852	89	refractory	refractory	JJ
cord-005478-5iu38pr6	852	90	acute	acute	JJ
cord-005478-5iu38pr6	852	91	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	852	92	leukemia	leukemia	NN
cord-005478-5iu38pr6	852	93	(	(	-LRB-
cord-005478-5iu38pr6	852	94	ALL	all	DT
cord-005478-5iu38pr6	852	95	)	)	-RRB-
cord-005478-5iu38pr6	852	96	and	and	CC
cord-005478-5iu38pr6	852	97	non	non	JJ
cord-005478-5iu38pr6	852	98	-	-	JJ
cord-005478-5iu38pr6	852	99	Hodgkin	hodgkin	JJ
cord-005478-5iu38pr6	852	100	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	852	101	(	(	-LRB-
cord-005478-5iu38pr6	852	102	NHL	NHL	NNP
cord-005478-5iu38pr6	852	103	)	)	-RRB-
cord-005478-5iu38pr6	852	104	.	.	.
cord-005478-5iu38pr6	853	1	The	the	DT
cord-005478-5iu38pr6	853	2	most	most	RBS
cord-005478-5iu38pr6	853	3	common	common	JJ
cord-005478-5iu38pr6	853	4	adverse	adverse	JJ
cord-005478-5iu38pr6	853	5	events	event	NNS
cord-005478-5iu38pr6	853	6	reported	report	VBN
cord-005478-5iu38pr6	853	7	are	be	VBP
cord-005478-5iu38pr6	853	8	cytokine	cytokine	NN
cord-005478-5iu38pr6	853	9	-	-	HYPH
cord-005478-5iu38pr6	853	10	release	release	NN
cord-005478-5iu38pr6	853	11	syndrome	syndrome	NN
cord-005478-5iu38pr6	853	12	(	(	-LRB-
cord-005478-5iu38pr6	853	13	CRS	CRS	NNP
cord-005478-5iu38pr6	853	14	)	)	-RRB-
cord-005478-5iu38pr6	853	15	and	and	CC
cord-005478-5iu38pr6	853	16	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	853	17	.	.	.
cord-005478-5iu38pr6	854	1	Here	here	RB
cord-005478-5iu38pr6	854	2	we	-PRON-	PRP
cord-005478-5iu38pr6	854	3	study	study	VBP
cord-005478-5iu38pr6	854	4	and	and	CC
cord-005478-5iu38pr6	854	5	profile	profile	NN
cord-005478-5iu38pr6	854	6	of	of	IN
cord-005478-5iu38pr6	854	7	hematologic	hematologic	JJ
cord-005478-5iu38pr6	854	8	toxicity	toxicity	NN
cord-005478-5iu38pr6	854	9	of	of	IN
cord-005478-5iu38pr6	854	10	patients	patient	NNS
cord-005478-5iu38pr6	854	11	following	follow	VBG
cord-005478-5iu38pr6	854	12	locally	locally	RB
cord-005478-5iu38pr6	854	13	produced	produce	VBN
cord-005478-5iu38pr6	854	14	CAR	car	NN
cord-005478-5iu38pr6	854	15	T	t	NN
cord-005478-5iu38pr6	854	16	cells	cell	NNS
cord-005478-5iu38pr6	854	17	.	.	.
cord-005478-5iu38pr6	855	1	Methods	method	NNS
cord-005478-5iu38pr6	855	2	:	:	:
cord-005478-5iu38pr6	855	3	We	-PRON-	PRP
cord-005478-5iu38pr6	855	4	studied	study	VBD
cord-005478-5iu38pr6	855	5	the	the	DT
cord-005478-5iu38pr6	855	6	first	first	JJ
cord-005478-5iu38pr6	855	7	38	38	CD
cord-005478-5iu38pr6	855	8	patients	patient	NNS
cord-005478-5iu38pr6	855	9	treated	treat	VBN
cord-005478-5iu38pr6	855	10	on	on	IN
cord-005478-5iu38pr6	855	11	a	a	DT
cord-005478-5iu38pr6	855	12	phase	phase	NN
cord-005478-5iu38pr6	855	13	1b/2	1b/2	CD
cord-005478-5iu38pr6	855	14	clinical	clinical	JJ
cord-005478-5iu38pr6	855	15	trial	trial	NN
cord-005478-5iu38pr6	855	16	using	use	VBG
cord-005478-5iu38pr6	855	17	CD19	CD19	NNP
cord-005478-5iu38pr6	855	18	CAR	CAR	NNP
cord-005478-5iu38pr6	855	19	-	-	HYPH
cord-005478-5iu38pr6	855	20	T	t	NN
cord-005478-5iu38pr6	855	21	cells	cell	NNS
cord-005478-5iu38pr6	855	22	for	for	IN
cord-005478-5iu38pr6	855	23	B	b	NN
cord-005478-5iu38pr6	855	24	-	-	HYPH
cord-005478-5iu38pr6	855	25	cell	cell	NN
cord-005478-5iu38pr6	855	26	malignancies	malignancy	NNS
cord-005478-5iu38pr6	855	27	,	,	,
cord-005478-5iu38pr6	855	28	focusing	focus	VBG
cord-005478-5iu38pr6	855	29	on	on	IN
cord-005478-5iu38pr6	855	30	hematologic	hematologic	JJ
cord-005478-5iu38pr6	855	31	toxicities	toxicity	NNS
cord-005478-5iu38pr6	855	32	(	(	-LRB-
cord-005478-5iu38pr6	856	1	neutropenia	neutropenia	NNP
cord-005478-5iu38pr6	856	2	,	,	,
cord-005478-5iu38pr6	856	3	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	856	4	and	and	CC
cord-005478-5iu38pr6	856	5	anemia	anemia	NN
cord-005478-5iu38pr6	856	6	)	)	-RRB-
cord-005478-5iu38pr6	856	7	,	,	,
cord-005478-5iu38pr6	856	8	from	from	IN
cord-005478-5iu38pr6	856	9	the	the	DT
cord-005478-5iu38pr6	856	10	initial	initial	JJ
cord-005478-5iu38pr6	856	11	lymphodepleting	lymphodepleting	NN
cord-005478-5iu38pr6	856	12	regimen	regimen	NN
cord-005478-5iu38pr6	856	13	till	till	IN
cord-005478-5iu38pr6	856	14	progression	progression	NN
cord-005478-5iu38pr6	856	15	or	or	CC
cord-005478-5iu38pr6	856	16	an	an	DT
cord-005478-5iu38pr6	856	17	additional	additional	JJ
cord-005478-5iu38pr6	856	18	treatment	treatment	NN
cord-005478-5iu38pr6	856	19	was	be	VBD
cord-005478-5iu38pr6	856	20	administered	administer	VBN
cord-005478-5iu38pr6	856	21	.	.	.
cord-005478-5iu38pr6	857	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	857	2	levels	level	NNS
cord-005478-5iu38pr6	857	3	were	be	VBD
cord-005478-5iu38pr6	857	4	studied	study	VBN
cord-005478-5iu38pr6	857	5	using	use	VBG
cord-005478-5iu38pr6	857	6	Milliplex	Milliplex	NNP
cord-005478-5iu38pr6	857	7	Map	Map	NNP
cord-005478-5iu38pr6	857	8	,	,	,
cord-005478-5iu38pr6	857	9	human	human	JJ
cord-005478-5iu38pr6	857	10	cytokine	cytokine	NN
cord-005478-5iu38pr6	857	11	/	/	SYM
cord-005478-5iu38pr6	857	12	chemokine	chemokine	NN
cord-005478-5iu38pr6	857	13	panel	panel	NN
cord-005478-5iu38pr6	857	14	II	II	NNP
cord-005478-5iu38pr6	857	15	.	.	.
cord-005478-5iu38pr6	858	1	Results	result	NNS
cord-005478-5iu38pr6	858	2	:	:	:
cord-005478-5iu38pr6	859	1	Between	between	IN
cord-005478-5iu38pr6	859	2	July	July	NNP
cord-005478-5iu38pr6	859	3	2016	2016	CD
cord-005478-5iu38pr6	859	4	and	and	CC
cord-005478-5iu38pr6	859	5	March	March	NNP
cord-005478-5iu38pr6	859	6	2018	2018	CD
cord-005478-5iu38pr6	859	7	,	,	,
cord-005478-5iu38pr6	859	8	38	38	CD
cord-005478-5iu38pr6	859	9	patients	patient	NNS
cord-005478-5iu38pr6	859	10	were	be	VBD
cord-005478-5iu38pr6	859	11	enrolled	enrol	VBN
cord-005478-5iu38pr6	859	12	on	on	IN
cord-005478-5iu38pr6	859	13	the	the	DT
cord-005478-5iu38pr6	859	14	trial	trial	NN
cord-005478-5iu38pr6	859	15	,	,	,
cord-005478-5iu38pr6	859	16	and	and	CC
cord-005478-5iu38pr6	859	17	35	35	CD
cord-005478-5iu38pr6	859	18	patients	patient	NNS
cord-005478-5iu38pr6	859	19	who	who	WP
cord-005478-5iu38pr6	859	20	received	receive	VBD
cord-005478-5iu38pr6	859	21	CAR	car	NN
cord-005478-5iu38pr6	859	22	-	-	HYPH
cord-005478-5iu38pr6	859	23	T	t	NN
cord-005478-5iu38pr6	859	24	cells	cell	NNS
cord-005478-5iu38pr6	859	25	and	and	CC
cord-005478-5iu38pr6	859	26	survived	survive	VBD
cord-005478-5iu38pr6	859	27	more	more	JJR
cord-005478-5iu38pr6	859	28	than	than	IN
cord-005478-5iu38pr6	859	29	21	21	CD
cord-005478-5iu38pr6	859	30	days	day	NNS
cord-005478-5iu38pr6	859	31	were	be	VBD
cord-005478-5iu38pr6	859	32	included	include	VBN
cord-005478-5iu38pr6	859	33	in	in	IN
cord-005478-5iu38pr6	859	34	this	this	DT
cord-005478-5iu38pr6	859	35	analysis	analysis	NN
cord-005478-5iu38pr6	859	36	.	.	.
cord-005478-5iu38pr6	860	1	Neutropenia	neutropenia	NN
cord-005478-5iu38pr6	860	2	,	,	,
cord-005478-5iu38pr6	860	3	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	860	4	and	and	CC
cord-005478-5iu38pr6	860	5	anemia	anemia	NN
cord-005478-5iu38pr6	860	6	occurred	occur	VBD
cord-005478-5iu38pr6	860	7	frequently	frequently	RB
cord-005478-5iu38pr6	860	8	(	(	-LRB-
cord-005478-5iu38pr6	860	9	94	94	CD
cord-005478-5iu38pr6	860	10	%	%	NN
cord-005478-5iu38pr6	860	11	,	,	,
cord-005478-5iu38pr6	860	12	80	80	CD
cord-005478-5iu38pr6	860	13	%	%	NN
cord-005478-5iu38pr6	860	14	and	and	CC
cord-005478-5iu38pr6	860	15	51	51	CD
cord-005478-5iu38pr6	860	16	%	%	NN
cord-005478-5iu38pr6	860	17	,	,	,
cord-005478-5iu38pr6	860	18	respectively	respectively	RB
cord-005478-5iu38pr6	860	19	)	)	-RRB-
cord-005478-5iu38pr6	860	20	after	after	IN
cord-005478-5iu38pr6	860	21	CAR	car	NN
cord-005478-5iu38pr6	860	22	T	T	NNP
cord-005478-5iu38pr6	860	23	cell	cell	NN
cord-005478-5iu38pr6	860	24	infusion	infusion	NN
cord-005478-5iu38pr6	860	25	,	,	,
cord-005478-5iu38pr6	860	26	and	and	CC
cord-005478-5iu38pr6	860	27	were	be	VBD
cord-005478-5iu38pr6	860	28	associated	associate	VBN
cord-005478-5iu38pr6	860	29	with	with	IN
cord-005478-5iu38pr6	860	30	a	a	DT
cord-005478-5iu38pr6	860	31	prolonged	prolonged	JJ
cord-005478-5iu38pr6	860	32	or	or	CC
cord-005478-5iu38pr6	860	33	biphasic	biphasic	JJ
cord-005478-5iu38pr6	860	34	nature	nature	NN
cord-005478-5iu38pr6	860	35	:	:	:
cord-005478-5iu38pr6	861	1	In	in	IN
cord-005478-5iu38pr6	861	2	93	93	CD
cord-005478-5iu38pr6	861	3	%	%	NN
cord-005478-5iu38pr6	861	4	of	of	IN
cord-005478-5iu38pr6	861	5	patients	patient	NNS
cord-005478-5iu38pr6	861	6	hematologic	hematologic	JJ
cord-005478-5iu38pr6	861	7	toxicity	toxicity	NN
cord-005478-5iu38pr6	861	8	occurred	occur	VBD
cord-005478-5iu38pr6	861	9	or	or	CC
cord-005478-5iu38pr6	861	10	were	be	VBD
cord-005478-5iu38pr6	861	11	ongoing	ongoing	JJ
cord-005478-5iu38pr6	861	12	after	after	IN
cord-005478-5iu38pr6	861	13	21	21	CD
cord-005478-5iu38pr6	861	14	days	day	NNS
cord-005478-5iu38pr6	861	15	from	from	IN
cord-005478-5iu38pr6	861	16	cell	cell	NN
cord-005478-5iu38pr6	861	17	infusion	infusion	NN
cord-005478-5iu38pr6	861	18	,	,	,
cord-005478-5iu38pr6	861	19	and	and	CC
cord-005478-5iu38pr6	861	20	in	in	IN
cord-005478-5iu38pr6	861	21	52	52	CD
cord-005478-5iu38pr6	861	22	%	%	NN
cord-005478-5iu38pr6	861	23	(	(	-LRB-
cord-005478-5iu38pr6	861	24	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	861	25	)	)	-RRB-
cord-005478-5iu38pr6	861	26	and	and	CC
cord-005478-5iu38pr6	861	27	44	44	CD
cord-005478-5iu38pr6	861	28	%	%	NN
cord-005478-5iu38pr6	861	29	(	(	-LRB-
cord-005478-5iu38pr6	861	30	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	861	31	)	)	-RRB-
cord-005478-5iu38pr6	861	32	,	,	,
cord-005478-5iu38pr6	861	33	two	two	CD
cord-005478-5iu38pr6	861	34	trough	trough	NN
cord-005478-5iu38pr6	861	35	levels	level	NNS
cord-005478-5iu38pr6	861	36	were	be	VBD
cord-005478-5iu38pr6	861	37	noted	note	VBN
cord-005478-5iu38pr6	861	38	,	,	,
cord-005478-5iu38pr6	861	39	the	the	DT
cord-005478-5iu38pr6	861	40	second	second	JJ
cord-005478-5iu38pr6	861	41	trough	trough	NN
cord-005478-5iu38pr6	861	42	occurring	occur	VBG
cord-005478-5iu38pr6	861	43	after	after	IN
cord-005478-5iu38pr6	861	44	day	day	NN
cord-005478-5iu38pr6	861	45	+21	+21	CD
cord-005478-5iu38pr6	861	46	.	.	.
cord-005478-5iu38pr6	862	1	Later	later	JJ
cord-005478-5iu38pr6	862	2	events	event	NNS
cord-005478-5iu38pr6	862	3	of	of	IN
cord-005478-5iu38pr6	862	4	cytopenia	cytopenia	NNP
cord-005478-5iu38pr6	862	5	,	,	,
cord-005478-5iu38pr6	862	6	following	follow	VBG
cord-005478-5iu38pr6	862	7	more	more	JJR
cord-005478-5iu38pr6	862	8	than	than	IN
cord-005478-5iu38pr6	862	9	42	42	CD
cord-005478-5iu38pr6	862	10	days	day	NNS
cord-005478-5iu38pr6	862	11	from	from	IN
cord-005478-5iu38pr6	862	12	CAR	car	NN
cord-005478-5iu38pr6	862	13	infusion	infusion	NN
cord-005478-5iu38pr6	862	14	and	and	CC
cord-005478-5iu38pr6	862	15	in	in	IN
cord-005478-5iu38pr6	862	16	absence	absence	NN
cord-005478-5iu38pr6	862	17	of	of	IN
cord-005478-5iu38pr6	862	18	further	further	JJ
cord-005478-5iu38pr6	862	19	therapy	therapy	NN
cord-005478-5iu38pr6	862	20	,	,	,
cord-005478-5iu38pr6	862	21	occurred	occur	VBD
cord-005478-5iu38pr6	862	22	in	in	IN
cord-005478-5iu38pr6	862	23	62	62	CD
cord-005478-5iu38pr6	862	24	%	%	NN
cord-005478-5iu38pr6	862	25	(	(	-LRB-
cord-005478-5iu38pr6	862	26	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	862	27	)	)	-RRB-
cord-005478-5iu38pr6	862	28	,	,	,
cord-005478-5iu38pr6	862	29	44	44	CD
cord-005478-5iu38pr6	862	30	%	%	NN
cord-005478-5iu38pr6	862	31	(	(	-LRB-
cord-005478-5iu38pr6	862	32	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	862	33	)	)	-RRB-
cord-005478-5iu38pr6	862	34	and	and	CC
cord-005478-5iu38pr6	862	35	17	17	CD
cord-005478-5iu38pr6	862	36	%	%	NN
cord-005478-5iu38pr6	862	37	(	(	-LRB-
cord-005478-5iu38pr6	862	38	anemia	anemia	NN
cord-005478-5iu38pr6	862	39	requiring	require	VBG
cord-005478-5iu38pr6	862	40	PRBC	PRBC	NNP
cord-005478-5iu38pr6	862	41	transfusion	transfusion	NN
cord-005478-5iu38pr6	862	42	)	)	-RRB-
cord-005478-5iu38pr6	862	43	of	of	IN
cord-005478-5iu38pr6	862	44	patients	patient	NNS
cord-005478-5iu38pr6	862	45	.	.	.
cord-005478-5iu38pr6	863	1	We	-PRON-	PRP
cord-005478-5iu38pr6	863	2	identified	identify	VBD
cord-005478-5iu38pr6	863	3	a	a	DT
cord-005478-5iu38pr6	863	4	strong	strong	JJ
cord-005478-5iu38pr6	863	5	correlation	correlation	NN
cord-005478-5iu38pr6	863	6	between	between	IN
cord-005478-5iu38pr6	863	7	the	the	DT
cord-005478-5iu38pr6	863	8	late	late	JJ
cord-005478-5iu38pr6	863	9	hematologic	hematologic	JJ
cord-005478-5iu38pr6	863	10	toxicities	toxicity	NNS
cord-005478-5iu38pr6	863	11	(	(	-LRB-
cord-005478-5iu38pr6	863	12	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	863	13	and	and	CC
cord-005478-5iu38pr6	863	14	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	863	15	,	,	,
cord-005478-5iu38pr6	863	16	p=0.018	p=0.018	NNP
cord-005478-5iu38pr6	863	17	,	,	,
cord-005478-5iu38pr6	863	18	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	863	19	and	and	CC
cord-005478-5iu38pr6	863	20	anemia	anemia	NN
cord-005478-5iu38pr6	863	21	,	,	,
cord-005478-5iu38pr6	863	22	p	p	NN
cord-005478-5iu38pr6	863	23	<	<	XX
cord-005478-5iu38pr6	863	24	0.0001	0.0001	CD
cord-005478-5iu38pr6	863	25	,	,	,
cord-005478-5iu38pr6	863	26	anemia	anemia	NN
cord-005478-5iu38pr6	863	27	and	and	CC
cord-005478-5iu38pr6	863	28	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	863	29	p=0.05	p=0.05	JJ
cord-005478-5iu38pr6	863	30	)	)	-RRB-
cord-005478-5iu38pr6	863	31	.	.	.
cord-005478-5iu38pr6	864	1	On	on	IN
cord-005478-5iu38pr6	864	2	univariate	univariate	JJ
cord-005478-5iu38pr6	864	3	analysis	analysis	NN
cord-005478-5iu38pr6	864	4	,	,	,
cord-005478-5iu38pr6	864	5	factors	factor	NNS
cord-005478-5iu38pr6	864	6	affecting	affect	VBG
cord-005478-5iu38pr6	864	7	late	late	JJ
cord-005478-5iu38pr6	864	8	cytopenia	cytopenia	NNS
cord-005478-5iu38pr6	864	9	were	be	VBD
cord-005478-5iu38pr6	864	10	prior	prior	JJ
cord-005478-5iu38pr6	864	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	864	12	(	(	-LRB-
cord-005478-5iu38pr6	864	13	p=0.0015	p=0.0015	NNPS
cord-005478-5iu38pr6	864	14	,	,	,
cord-005478-5iu38pr6	864	15	0.0083	0.0083	CD
cord-005478-5iu38pr6	864	16	and	and	CC
cord-005478-5iu38pr6	864	17	0.02	0.02	CD
cord-005478-5iu38pr6	864	18	for	for	IN
cord-005478-5iu38pr6	864	19	anemia	anemia	NN
cord-005478-5iu38pr6	864	20	,	,	,
cord-005478-5iu38pr6	864	21	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	864	22	and	and	CC
cord-005478-5iu38pr6	864	23	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	864	24	respectively	respectively	RB
cord-005478-5iu38pr6	864	25	)	)	-RRB-
cord-005478-5iu38pr6	864	26	and	and	CC
cord-005478-5iu38pr6	864	27	higher	high	JJR
cord-005478-5iu38pr6	864	28	CRS	CRS	NNP
cord-005478-5iu38pr6	864	29	grade	grade	NN
cord-005478-5iu38pr6	864	30	p=0.003	p=0.003	NNP
cord-005478-5iu38pr6	864	31	,	,	,
cord-005478-5iu38pr6	864	32	0.018	0.018	CD
cord-005478-5iu38pr6	864	33	and	and	CC
cord-005478-5iu38pr6	864	34	0.04	0.04	CD
cord-005478-5iu38pr6	864	35	for	for	IN
cord-005478-5iu38pr6	864	36	late	late	JJ
cord-005478-5iu38pr6	864	37	anemia	anemia	NN
cord-005478-5iu38pr6	864	38	,	,	,
cord-005478-5iu38pr6	864	39	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	864	40	and	and	CC
cord-005478-5iu38pr6	864	41	anemia	anemia	NN
cord-005478-5iu38pr6	864	42	respectively	respectively	RB
cord-005478-5iu38pr6	864	43	)	)	-RRB-
cord-005478-5iu38pr6	864	44	.	.	.
cord-005478-5iu38pr6	865	1	Diagnosis	diagnosis	NN
cord-005478-5iu38pr6	865	2	(	(	-LRB-
cord-005478-5iu38pr6	865	3	ALL	all	DT
cord-005478-5iu38pr6	865	4	vs	vs	IN
cord-005478-5iu38pr6	865	5	NHL	NHL	NNP
cord-005478-5iu38pr6	865	6	)	)	-RRB-
cord-005478-5iu38pr6	865	7	or	or	CC
cord-005478-5iu38pr6	865	8	age	age	NN
cord-005478-5iu38pr6	865	9	were	be	VBD
cord-005478-5iu38pr6	865	10	not	not	RB
cord-005478-5iu38pr6	865	11	correlated	correlate	VBN
cord-005478-5iu38pr6	865	12	to	to	IN
cord-005478-5iu38pr6	865	13	the	the	DT
cord-005478-5iu38pr6	865	14	incidence	incidence	NN
cord-005478-5iu38pr6	865	15	of	of	IN
cord-005478-5iu38pr6	865	16	early	early	JJ
cord-005478-5iu38pr6	865	17	or	or	CC
cord-005478-5iu38pr6	865	18	late	late	JJ
cord-005478-5iu38pr6	865	19	post	post	JJ
cord-005478-5iu38pr6	865	20	-	-	JJ
cord-005478-5iu38pr6	865	21	CAR	car	NN
cord-005478-5iu38pr6	865	22	cytopenia	cytopenia	NNS
cord-005478-5iu38pr6	865	23	.	.	.
cord-005478-5iu38pr6	866	1	To	to	TO
cord-005478-5iu38pr6	866	2	further	further	JJ
cord-005478-5iu38pr6	866	3	study	study	VB
cord-005478-5iu38pr6	866	4	potential	potential	JJ
cord-005478-5iu38pr6	866	5	causes	cause	NNS
cord-005478-5iu38pr6	866	6	of	of	IN
cord-005478-5iu38pr6	866	7	late	late	JJ
cord-005478-5iu38pr6	866	8	events	event	NNS
cord-005478-5iu38pr6	866	9	in	in	IN
cord-005478-5iu38pr6	866	10	patients	patient	NNS
cord-005478-5iu38pr6	866	11	who	who	WP
cord-005478-5iu38pr6	866	12	were	be	VBD
cord-005478-5iu38pr6	866	13	in	in	IN
cord-005478-5iu38pr6	866	14	remission	remission	NN
cord-005478-5iu38pr6	866	15	,	,	,
cord-005478-5iu38pr6	866	16	and	and	CC
cord-005478-5iu38pr6	866	17	in	in	IN
cord-005478-5iu38pr6	866	18	absence	absence	NN
cord-005478-5iu38pr6	866	19	of	of	IN
cord-005478-5iu38pr6	866	20	signs	sign	NNS
cord-005478-5iu38pr6	866	21	of	of	IN
cord-005478-5iu38pr6	866	22	hemophagocytosis	hemophagocytosis	NN
cord-005478-5iu38pr6	866	23	,	,	,
cord-005478-5iu38pr6	866	24	patients	patient	NNS
cord-005478-5iu38pr6	866	25	'	'	POS
cord-005478-5iu38pr6	866	26	serum	serum	NN
cord-005478-5iu38pr6	866	27	was	be	VBD
cord-005478-5iu38pr6	866	28	analyzed	analyze	VBN
cord-005478-5iu38pr6	866	29	for	for	IN
cord-005478-5iu38pr6	866	30	chemokine	chemokine	NN
cord-005478-5iu38pr6	866	31	panel	panel	NN
cord-005478-5iu38pr6	866	32	at	at	IN
cord-005478-5iu38pr6	866	33	different	different	JJ
cord-005478-5iu38pr6	866	34	time	time	NN
cord-005478-5iu38pr6	866	35	points	point	NNS
cord-005478-5iu38pr6	866	36	.	.	.
cord-005478-5iu38pr6	867	1	As	as	IN
cord-005478-5iu38pr6	867	2	expected	expect	VBN
cord-005478-5iu38pr6	867	3	,	,	,
cord-005478-5iu38pr6	867	4	serum	serum	NN
cord-005478-5iu38pr6	867	5	thrombopoietin	thrombopoietin	XX
cord-005478-5iu38pr6	867	6	levels	level	NNS
cord-005478-5iu38pr6	867	7	were	be	VBD
cord-005478-5iu38pr6	867	8	correlated	correlate	VBN
cord-005478-5iu38pr6	867	9	with	with	IN
cord-005478-5iu38pr6	867	10	the	the	DT
cord-005478-5iu38pr6	867	11	platelet	platelet	NN
cord-005478-5iu38pr6	867	12	count	count	NN
cord-005478-5iu38pr6	867	13	.	.	.
cord-005478-5iu38pr6	868	1	We	-PRON-	PRP
cord-005478-5iu38pr6	868	2	observed	observe	VBD
cord-005478-5iu38pr6	868	3	that	that	IN
cord-005478-5iu38pr6	868	4	only	only	RB
cord-005478-5iu38pr6	868	5	in	in	IN
cord-005478-5iu38pr6	868	6	late	late	JJ
cord-005478-5iu38pr6	868	7	events	event	NNS
cord-005478-5iu38pr6	868	8	(	(	-LRB-
cord-005478-5iu38pr6	868	9	more	more	JJR
cord-005478-5iu38pr6	868	10	than	than	IN
cord-005478-5iu38pr6	868	11	21	21	CD
cord-005478-5iu38pr6	868	12	days	day	NNS
cord-005478-5iu38pr6	868	13	from	from	IN
cord-005478-5iu38pr6	868	14	infusion	infusion	NN
cord-005478-5iu38pr6	868	15	)	)	-RRB-
cord-005478-5iu38pr6	869	1	SDF-1	sdf-1	NN
cord-005478-5iu38pr6	869	2	serum	serum	NN
cord-005478-5iu38pr6	869	3	levels	level	NNS
cord-005478-5iu38pr6	869	4	correlated	correlate	VBN
cord-005478-5iu38pr6	869	5	to	to	IN
cord-005478-5iu38pr6	869	6	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	869	7	count	count	NN
cord-005478-5iu38pr6	870	1	(	(	-LRB-
cord-005478-5iu38pr6	870	2	R	r	NN
cord-005478-5iu38pr6	870	3	2	2	CD
cord-005478-5iu38pr6	870	4	=	=	SYM
cord-005478-5iu38pr6	870	5	0.3	0.3	CD
cord-005478-5iu38pr6	870	6	,	,	,
cord-005478-5iu38pr6	870	7	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	870	8	)	)	-RRB-
cord-005478-5iu38pr6	870	9	.	.	.
cord-005478-5iu38pr6	871	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	871	2	:	:	:
cord-005478-5iu38pr6	872	1	Cytopenia	Cytopenia	NNP
cord-005478-5iu38pr6	872	2	are	be	VBP
cord-005478-5iu38pr6	872	3	common	common	JJ
cord-005478-5iu38pr6	872	4	events	event	NNS
cord-005478-5iu38pr6	872	5	following	follow	VBG
cord-005478-5iu38pr6	872	6	CD19	CD19	NNP
cord-005478-5iu38pr6	872	7	CAR	CAR	NNP
cord-005478-5iu38pr6	872	8	T	t	NN
cord-005478-5iu38pr6	872	9	cell	cell	NN
cord-005478-5iu38pr6	872	10	therapy	therapy	NN
cord-005478-5iu38pr6	872	11	,	,	,
cord-005478-5iu38pr6	872	12	and	and	CC
cord-005478-5iu38pr6	872	13	may	may	MD
cord-005478-5iu38pr6	872	14	have	have	VB
cord-005478-5iu38pr6	872	15	a	a	DT
cord-005478-5iu38pr6	872	16	prolonged	prolonged	JJ
cord-005478-5iu38pr6	872	17	and	and	CC
cord-005478-5iu38pr6	872	18	even	even	RB
cord-005478-5iu38pr6	872	19	biphasic	biphasic	JJ
cord-005478-5iu38pr6	872	20	course	course	NN
cord-005478-5iu38pr6	872	21	.	.	.
cord-005478-5iu38pr6	873	1	Patients	patient	NNS
cord-005478-5iu38pr6	873	2	at	at	IN
cord-005478-5iu38pr6	873	3	risk	risk	NN
cord-005478-5iu38pr6	873	4	include	include	VBP
cord-005478-5iu38pr6	873	5	those	those	DT
cord-005478-5iu38pr6	873	6	following	follow	VBG
cord-005478-5iu38pr6	873	7	a	a	DT
cord-005478-5iu38pr6	873	8	recent	recent	JJ
cord-005478-5iu38pr6	873	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	873	10	or	or	CC
cord-005478-5iu38pr6	873	11	with	with	IN
cord-005478-5iu38pr6	873	12	high	high	JJ
cord-005478-5iu38pr6	873	13	grade	grade	NN
cord-005478-5iu38pr6	873	14	CRS	CRS	NNP
cord-005478-5iu38pr6	873	15	.	.	.
cord-005478-5iu38pr6	874	1	Late	late	JJ
cord-005478-5iu38pr6	874	2	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	874	3	events	event	NNS
cord-005478-5iu38pr6	874	4	which	which	WDT
cord-005478-5iu38pr6	874	5	occurred	occur	VBD
cord-005478-5iu38pr6	874	6	later	later	RB
cord-005478-5iu38pr6	874	7	than	than	IN
cord-005478-5iu38pr6	874	8	expected	expect	VBN
cord-005478-5iu38pr6	874	9	recovery	recovery	NN
cord-005478-5iu38pr6	874	10	from	from	IN
cord-005478-5iu38pr6	874	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	874	12	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	874	13	and	and	CC
cord-005478-5iu38pr6	874	14	following	follow	VBG
cord-005478-5iu38pr6	874	15	resolution	resolution	NN
cord-005478-5iu38pr6	874	16	of	of	IN
cord-005478-5iu38pr6	874	17	CRS	CRS	NNP
cord-005478-5iu38pr6	874	18	,	,	,
cord-005478-5iu38pr6	874	19	were	be	VBD
cord-005478-5iu38pr6	874	20	correlated	correlate	VBN
cord-005478-5iu38pr6	874	21	with	with	IN
cord-005478-5iu38pr6	874	22	serum	serum	NN
cord-005478-5iu38pr6	874	23	SDF1	SDF1	NNP
cord-005478-5iu38pr6	874	24	levels	level	NNS
cord-005478-5iu38pr6	874	25	,	,	,
cord-005478-5iu38pr6	874	26	similar	similar	JJ
cord-005478-5iu38pr6	874	27	to	to	IN
cord-005478-5iu38pr6	874	28	prior	prior	JJ
cord-005478-5iu38pr6	874	29	observations	observation	NNS
cord-005478-5iu38pr6	874	30	with	with	IN
cord-005478-5iu38pr6	874	31	late	late	JJ
cord-005478-5iu38pr6	874	32	onset	onset	NN
cord-005478-5iu38pr6	874	33	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	874	34	related	relate	VBN
cord-005478-5iu38pr6	874	35	to	to	IN
cord-005478-5iu38pr6	874	36	rituximab	rituximab	NN
cord-005478-5iu38pr6	875	1	(	(	-LRB-
cord-005478-5iu38pr6	875	2	Dunleavy	Dunleavy	NNP
cord-005478-5iu38pr6	875	3	,	,	,
cord-005478-5iu38pr6	875	4	Blood	blood	NN
cord-005478-5iu38pr6	875	5	2005	2005	CD
cord-005478-5iu38pr6	875	6	Background	Background	NNP
cord-005478-5iu38pr6	875	7	:	:	:
cord-005478-5iu38pr6	876	1	Acute	acute	JJ
cord-005478-5iu38pr6	876	2	myeloblastic	myeloblastic	JJ
cord-005478-5iu38pr6	876	3	leukemia	leukemia	NN
cord-005478-5iu38pr6	876	4	(	(	-LRB-
cord-005478-5iu38pr6	876	5	AML	AML	NNP
cord-005478-5iu38pr6	876	6	)	)	-RRB-
cord-005478-5iu38pr6	876	7	represents	represent	VBZ
cord-005478-5iu38pr6	876	8	40	40	CD
cord-005478-5iu38pr6	876	9	%	%	NN
cord-005478-5iu38pr6	876	10	of	of	IN
cord-005478-5iu38pr6	876	11	all	all	DT
cord-005478-5iu38pr6	876	12	leukemias	leukemia	NNS
cord-005478-5iu38pr6	876	13	of	of	IN
cord-005478-5iu38pr6	876	14	western	western	JJ
cord-005478-5iu38pr6	876	15	countries	country	NNS
cord-005478-5iu38pr6	876	16	,	,	,
cord-005478-5iu38pr6	876	17	being	be	VBG
cord-005478-5iu38pr6	876	18	the	the	DT
cord-005478-5iu38pr6	876	19	second	second	JJ
cord-005478-5iu38pr6	876	20	malignant	malignant	JJ
cord-005478-5iu38pr6	876	21	hemopathy	hemopathy	NNP
cord-005478-5iu38pr6	876	22	in	in	IN
cord-005478-5iu38pr6	876	23	pediatric	pediatric	JJ
cord-005478-5iu38pr6	876	24	population	population	NN
cord-005478-5iu38pr6	876	25	.	.	.
cord-005478-5iu38pr6	877	1	In	in	IN
cord-005478-5iu38pr6	877	2	the	the	DT
cord-005478-5iu38pr6	877	3	last	last	JJ
cord-005478-5iu38pr6	877	4	decades	decade	NNS
cord-005478-5iu38pr6	877	5	,	,	,
cord-005478-5iu38pr6	877	6	the	the	DT
cord-005478-5iu38pr6	877	7	survival	survival	NN
cord-005478-5iu38pr6	877	8	rate	rate	NN
cord-005478-5iu38pr6	877	9	has	have	VBZ
cord-005478-5iu38pr6	877	10	maintained	maintain	VBN
cord-005478-5iu38pr6	877	11	around	around	RB
cord-005478-5iu38pr6	877	12	60	60	CD
cord-005478-5iu38pr6	877	13	%	%	NN
cord-005478-5iu38pr6	877	14	,	,	,
cord-005478-5iu38pr6	877	15	being	be	VBG
cord-005478-5iu38pr6	877	16	relapse	relapse	VB
cord-005478-5iu38pr6	877	17	the	the	DT
cord-005478-5iu38pr6	877	18	main	main	JJ
cord-005478-5iu38pr6	877	19	problem	problem	NN
cord-005478-5iu38pr6	877	20	.	.	.
cord-005478-5iu38pr6	878	1	It	-PRON-	PRP
cord-005478-5iu38pr6	878	2	has	have	VBZ
cord-005478-5iu38pr6	878	3	been	be	VBN
cord-005478-5iu38pr6	878	4	highlighted	highlight	VBN
cord-005478-5iu38pr6	878	5	the	the	DT
cord-005478-5iu38pr6	878	6	role	role	NN
cord-005478-5iu38pr6	878	7	of	of	IN
cord-005478-5iu38pr6	878	8	immune	immune	JJ
cord-005478-5iu38pr6	878	9	system	system	NN
cord-005478-5iu38pr6	878	10	for	for	IN
cord-005478-5iu38pr6	878	11	the	the	DT
cord-005478-5iu38pr6	878	12	control	control	NN
cord-005478-5iu38pr6	878	13	of	of	IN
cord-005478-5iu38pr6	878	14	AML	AML	NNP
cord-005478-5iu38pr6	878	15	and	and	CC
cord-005478-5iu38pr6	878	16	new	new	JJ
cord-005478-5iu38pr6	878	17	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	878	18	strategies	strategy	NNS
cord-005478-5iu38pr6	878	19	have	have	VBP
cord-005478-5iu38pr6	878	20	been	be	VBN
cord-005478-5iu38pr6	878	21	developed	develop	VBN
cord-005478-5iu38pr6	878	22	.	.	.
cord-005478-5iu38pr6	879	1	In	in	IN
cord-005478-5iu38pr6	879	2	this	this	DT
cord-005478-5iu38pr6	879	3	setting	setting	NN
cord-005478-5iu38pr6	879	4	,	,	,
cord-005478-5iu38pr6	879	5	the	the	DT
cord-005478-5iu38pr6	879	6	use	use	NN
cord-005478-5iu38pr6	879	7	of	of	IN
cord-005478-5iu38pr6	879	8	alloreactive	alloreactive	NNP
cord-005478-5iu38pr6	879	9	Natural	Natural	NNP
cord-005478-5iu38pr6	879	10	Killer	Killer	NNP
cord-005478-5iu38pr6	879	11	(	(	-LRB-
cord-005478-5iu38pr6	879	12	NK	NK	NNP
cord-005478-5iu38pr6	879	13	)	)	-RRB-
cord-005478-5iu38pr6	879	14	cells	cell	NNS
cord-005478-5iu38pr6	879	15	could	could	MD
cord-005478-5iu38pr6	879	16	play	play	VB
cord-005478-5iu38pr6	879	17	a	a	DT
cord-005478-5iu38pr6	879	18	key	key	JJ
cord-005478-5iu38pr6	879	19	role	role	NN
cord-005478-5iu38pr6	879	20	not	not	RB
cord-005478-5iu38pr6	879	21	only	only	RB
cord-005478-5iu38pr6	879	22	in	in	IN
cord-005478-5iu38pr6	879	23	the	the	DT
cord-005478-5iu38pr6	879	24	context	context	NN
cord-005478-5iu38pr6	879	25	of	of	IN
cord-005478-5iu38pr6	879	26	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	879	27	stem	stem	NN
cord-005478-5iu38pr6	879	28	cell	cell	NN
cord-005478-5iu38pr6	879	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	879	30	(	(	-LRB-
cord-005478-5iu38pr6	879	31	HSCT	HSCT	NNP
cord-005478-5iu38pr6	879	32	)	)	-RRB-
cord-005478-5iu38pr6	879	33	but	but	CC
cord-005478-5iu38pr6	879	34	also	also	RB
cord-005478-5iu38pr6	879	35	as	as	IN
cord-005478-5iu38pr6	879	36	adoptive	adoptive	JJ
cord-005478-5iu38pr6	879	37	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	879	38	in	in	IN
cord-005478-5iu38pr6	879	39	patients	patient	NNS
cord-005478-5iu38pr6	879	40	with	with	IN
cord-005478-5iu38pr6	879	41	minimal	minimal	JJ
cord-005478-5iu38pr6	879	42	residual	residual	JJ
cord-005478-5iu38pr6	879	43	disease	disease	NN
cord-005478-5iu38pr6	879	44	.	.	.
cord-005478-5iu38pr6	880	1	In	in	IN
cord-005478-5iu38pr6	880	2	this	this	DT
cord-005478-5iu38pr6	880	3	project	project	NN
cord-005478-5iu38pr6	880	4	we	-PRON-	PRP
cord-005478-5iu38pr6	880	5	proposed	propose	VBD
cord-005478-5iu38pr6	880	6	including	include	VBG
cord-005478-5iu38pr6	880	7	the	the	DT
cord-005478-5iu38pr6	880	8	cellular	cellular	JJ
cord-005478-5iu38pr6	880	9	therapy	therapy	NN
cord-005478-5iu38pr6	880	10	with	with	IN
cord-005478-5iu38pr6	880	11	haploidentical	haploidentical	NNP
cord-005478-5iu38pr6	880	12	activated	activate	VBN
cord-005478-5iu38pr6	880	13	and	and	CC
cord-005478-5iu38pr6	880	14	expanded	expand	VBN
cord-005478-5iu38pr6	880	15	NK	NK	NNP
cord-005478-5iu38pr6	880	16	cells	cell	NNS
cord-005478-5iu38pr6	880	17	as	as	IN
cord-005478-5iu38pr6	880	18	adjuvant	adjuvant	NN
cord-005478-5iu38pr6	880	19	therapy	therapy	NN
cord-005478-5iu38pr6	880	20	in	in	IN
cord-005478-5iu38pr6	880	21	pediatric	pediatric	JJ
cord-005478-5iu38pr6	880	22	patients	patient	NNS
cord-005478-5iu38pr6	880	23	affected	affect	VBN
cord-005478-5iu38pr6	880	24	by	by	IN
cord-005478-5iu38pr6	880	25	AML	AML	NNP
cord-005478-5iu38pr6	880	26	in	in	IN
cord-005478-5iu38pr6	880	27	complete	complete	JJ
cord-005478-5iu38pr6	880	28	remission	remission	NN
cord-005478-5iu38pr6	880	29	and	and	CC
cord-005478-5iu38pr6	880	30	without	without	IN
cord-005478-5iu38pr6	880	31	indication	indication	NN
cord-005478-5iu38pr6	880	32	of	of	IN
cord-005478-5iu38pr6	880	33	HSCT	HSCT	NNP
cord-005478-5iu38pr6	880	34	.	.	.
cord-005478-5iu38pr6	881	1	Methods	method	NNS
cord-005478-5iu38pr6	882	1	:	:	:
cord-005478-5iu38pr6	882	2	It	-PRON-	PRP
cord-005478-5iu38pr6	882	3	is	be	VBZ
cord-005478-5iu38pr6	882	4	a	a	DT
cord-005478-5iu38pr6	882	5	multicentre	multicentre	NN
cord-005478-5iu38pr6	882	6	,	,	,
cord-005478-5iu38pr6	882	7	open	open	JJ
cord-005478-5iu38pr6	882	8	,	,	,
cord-005478-5iu38pr6	882	9	prospective	prospective	JJ
cord-005478-5iu38pr6	882	10	and	and	CC
cord-005478-5iu38pr6	882	11	no	no	DT
cord-005478-5iu38pr6	882	12	randomized	randomized	JJ
cord-005478-5iu38pr6	882	13	phase	phase	NN
cord-005478-5iu38pr6	882	14	II	ii	CD
cord-005478-5iu38pr6	882	15	clinical	clinical	JJ
cord-005478-5iu38pr6	882	16	trial	trial	NN
cord-005478-5iu38pr6	882	17	,	,	,
cord-005478-5iu38pr6	882	18	to	to	TO
cord-005478-5iu38pr6	882	19	evaluate	evaluate	VB
cord-005478-5iu38pr6	882	20	the	the	DT
cord-005478-5iu38pr6	882	21	efficacy	efficacy	NN
cord-005478-5iu38pr6	882	22	and	and	CC
cord-005478-5iu38pr6	882	23	safety	safety	NN
cord-005478-5iu38pr6	882	24	of	of	IN
cord-005478-5iu38pr6	882	25	allogenic	allogenic	JJ
cord-005478-5iu38pr6	882	26	NK	NK	NNP
cord-005478-5iu38pr6	882	27	cells	cell	NNS
cord-005478-5iu38pr6	882	28	infusion	infusion	NN
cord-005478-5iu38pr6	882	29	from	from	IN
cord-005478-5iu38pr6	882	30	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	882	31	donor	donor	NN
cord-005478-5iu38pr6	882	32	after	after	IN
cord-005478-5iu38pr6	882	33	a	a	DT
cord-005478-5iu38pr6	882	34	lympho	lympho	JJ
cord-005478-5iu38pr6	882	35	-	-	HYPH
cord-005478-5iu38pr6	882	36	ablative	ablative	JJ
cord-005478-5iu38pr6	882	37	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	882	38	in	in	IN
cord-005478-5iu38pr6	882	39	pediatric	pediatric	JJ
cord-005478-5iu38pr6	882	40	patients	patient	NNS
cord-005478-5iu38pr6	882	41	affected	affect	VBN
cord-005478-5iu38pr6	882	42	by	by	IN
cord-005478-5iu38pr6	882	43	low	low	JJ
cord-005478-5iu38pr6	882	44	and	and	CC
cord-005478-5iu38pr6	882	45	intermediate	intermediate	JJ
cord-005478-5iu38pr6	882	46	risk	risk	NN
cord-005478-5iu38pr6	882	47	AML	AML	NNP
cord-005478-5iu38pr6	882	48	in	in	IN
cord-005478-5iu38pr6	882	49	first	first	JJ
cord-005478-5iu38pr6	882	50	complete	complete	JJ
cord-005478-5iu38pr6	882	51	cytological	cytological	JJ
cord-005478-5iu38pr6	882	52	remission	remission	NN
cord-005478-5iu38pr6	882	53	.	.	.
cord-005478-5iu38pr6	883	1	Patients	patient	NNS
cord-005478-5iu38pr6	883	2	were	be	VBD
cord-005478-5iu38pr6	883	3	treated	treat	VBN
cord-005478-5iu38pr6	883	4	according	accord	VBG
cord-005478-5iu38pr6	883	5	to	to	IN
cord-005478-5iu38pr6	883	6	Spanish	spanish	JJ
cord-005478-5iu38pr6	883	7	protocol	protocol	NN
cord-005478-5iu38pr6	883	8	(	(	-LRB-
cord-005478-5iu38pr6	883	9	SEHOP	SEHOP	NNP
cord-005478-5iu38pr6	883	10	2002	2002	CD
cord-005478-5iu38pr6	883	11	)	)	-RRB-
cord-005478-5iu38pr6	883	12	including	include	VBG
cord-005478-5iu38pr6	883	13	2	2	CD
cord-005478-5iu38pr6	883	14	inductions	induction	NNS
cord-005478-5iu38pr6	883	15	plus	plus	CC
cord-005478-5iu38pr6	883	16	2	2	CD
cord-005478-5iu38pr6	883	17	consolidation	consolidation	NN
cord-005478-5iu38pr6	883	18	cycles	cycle	NNS
cord-005478-5iu38pr6	883	19	.	.	.
cord-005478-5iu38pr6	884	1	After	after	IN
cord-005478-5iu38pr6	884	2	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	884	3	patients	patient	NNS
cord-005478-5iu38pr6	884	4	received	receive	VBD
cord-005478-5iu38pr6	884	5	the	the	DT
cord-005478-5iu38pr6	884	6	infusion	infusion	NN
cord-005478-5iu38pr6	884	7	of	of	IN
cord-005478-5iu38pr6	884	8	activated	activate	VBN
cord-005478-5iu38pr6	884	9	and	and	CC
cord-005478-5iu38pr6	884	10	expanded	expand	VBN
cord-005478-5iu38pr6	884	11	NK	NK	NNP
cord-005478-5iu38pr6	884	12	cells	cell	NNS
cord-005478-5iu38pr6	884	13	(	(	-LRB-
cord-005478-5iu38pr6	884	14	NKAE	NKAE	NNP
cord-005478-5iu38pr6	884	15	)	)	-RRB-
cord-005478-5iu38pr6	884	16	after	after	IN
cord-005478-5iu38pr6	884	17	a	a	DT
cord-005478-5iu38pr6	884	18	lympho	lympho	JJ
cord-005478-5iu38pr6	884	19	-	-	HYPH
cord-005478-5iu38pr6	884	20	ablative	ablative	JJ
cord-005478-5iu38pr6	884	21	treatment	treatment	NN
cord-005478-5iu38pr6	884	22	based	base	VBN
cord-005478-5iu38pr6	884	23	on	on	IN
cord-005478-5iu38pr6	884	24	cyclophosphamide	cyclophosphamide	JJ
cord-005478-5iu38pr6	884	25	60mg	60mg	NNP
cord-005478-5iu38pr6	884	26	/	/	SYM
cord-005478-5iu38pr6	884	27	Kg	Kg	NNP
cord-005478-5iu38pr6	884	28	and	and	CC
cord-005478-5iu38pr6	884	29	fludarabine	fludarabine	NNP
cord-005478-5iu38pr6	884	30	125mg	125mg	NNP
cord-005478-5iu38pr6	884	31	/	/	SYM
cord-005478-5iu38pr6	884	32	Kg	Kg	NNP
cord-005478-5iu38pr6	884	33	.	.	.
cord-005478-5iu38pr6	885	1	NK	NK	NNP
cord-005478-5iu38pr6	885	2	cells	cell	NNS
cord-005478-5iu38pr6	885	3	were	be	VBD
cord-005478-5iu38pr6	885	4	obtained	obtain	VBN
cord-005478-5iu38pr6	885	5	from	from	IN
cord-005478-5iu38pr6	885	6	250	250	CD
cord-005478-5iu38pr6	885	7	ml	ml	NNS
cord-005478-5iu38pr6	885	8	of	of	IN
cord-005478-5iu38pr6	885	9	peripheral	peripheral	JJ
cord-005478-5iu38pr6	885	10	blood	blood	NN
cord-005478-5iu38pr6	885	11	from	from	IN
cord-005478-5iu38pr6	885	12	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	885	13	donors	donor	NNS
cord-005478-5iu38pr6	885	14	selected	select	VBN
cord-005478-5iu38pr6	885	15	based	base	VBN
cord-005478-5iu38pr6	885	16	on	on	IN
cord-005478-5iu38pr6	885	17	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	885	18	of	of	IN
cord-005478-5iu38pr6	885	19	KIR	KIR	NNP
cord-005478-5iu38pr6	885	20	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	885	21	and	and	CC
cord-005478-5iu38pr6	885	22	KIR	KIR	NNP
cord-005478-5iu38pr6	885	23	activators	activator	NNS
cord-005478-5iu38pr6	885	24	receptors	receptor	NNS
cord-005478-5iu38pr6	885	25	.	.	.
cord-005478-5iu38pr6	886	1	NK	NK	NNP
cord-005478-5iu38pr6	886	2	cells	cell	NNS
cord-005478-5iu38pr6	886	3	were	be	VBD
cord-005478-5iu38pr6	886	4	activated	activate	VBN
cord-005478-5iu38pr6	886	5	and	and	CC
cord-005478-5iu38pr6	886	6	expanded	expand	VBN
cord-005478-5iu38pr6	886	7	for	for	IN
cord-005478-5iu38pr6	886	8	3	3	CD
cord-005478-5iu38pr6	886	9	weeks	week	NNS
cord-005478-5iu38pr6	886	10	trough	trough	IN
cord-005478-5iu38pr6	886	11	co	co	NN
cord-005478-5iu38pr6	886	12	-	-	NN
cord-005478-5iu38pr6	886	13	culture	culture	NN
cord-005478-5iu38pr6	886	14	with	with	IN
cord-005478-5iu38pr6	886	15	the	the	DT
cord-005478-5iu38pr6	886	16	cellular	cellular	JJ
cord-005478-5iu38pr6	886	17	line	line	NN
cord-005478-5iu38pr6	886	18	K562-mbil15	k562-mbil15	NN
cord-005478-5iu38pr6	886	19	-	-	HYPH
cord-005478-5iu38pr6	886	20	41bbl	41bbl	CD
cord-005478-5iu38pr6	886	21	suitable	suitable	JJ
cord-005478-5iu38pr6	886	22	for	for	IN
cord-005478-5iu38pr6	886	23	clinical	clinical	JJ
cord-005478-5iu38pr6	886	24	use	use	NN
cord-005478-5iu38pr6	886	25	in	in	IN
cord-005478-5iu38pr6	886	26	humans	human	NNS
cord-005478-5iu38pr6	886	27	(	(	-LRB-
cord-005478-5iu38pr6	886	28	Good	Good	NNP
cord-005478-5iu38pr6	886	29	Manufacturing	Manufacturing	NNP
cord-005478-5iu38pr6	886	30	Practices	Practices	NNPS
cord-005478-5iu38pr6	886	31	,	,	,
cord-005478-5iu38pr6	886	32	GMP	GMP	NNP
cord-005478-5iu38pr6	886	33	)	)	-RRB-
cord-005478-5iu38pr6	886	34	.	.	.
cord-005478-5iu38pr6	887	1	Results	result	NNS
cord-005478-5iu38pr6	887	2	:	:	:
cord-005478-5iu38pr6	888	1	At	at	IN
cord-005478-5iu38pr6	888	2	this	this	DT
cord-005478-5iu38pr6	888	3	time	time	NN
cord-005478-5iu38pr6	888	4	14	14	CD
cord-005478-5iu38pr6	888	5	products	product	NNS
cord-005478-5iu38pr6	888	6	in	in	IN
cord-005478-5iu38pr6	888	7	7	7	CD
cord-005478-5iu38pr6	888	8	patients	patient	NNS
cord-005478-5iu38pr6	888	9	have	have	VBP
cord-005478-5iu38pr6	888	10	been	be	VBN
cord-005478-5iu38pr6	888	11	infused	infuse	VBN
cord-005478-5iu38pr6	888	12	,	,	,
cord-005478-5iu38pr6	888	13	with	with	IN
cord-005478-5iu38pr6	888	14	the	the	DT
cord-005478-5iu38pr6	888	15	following	follow	VBG
cord-005478-5iu38pr6	888	16	characteristics	characteristic	NNS
cord-005478-5iu38pr6	888	17	:	:	:
cord-005478-5iu38pr6	888	18	NK	NK	NNP
cord-005478-5iu38pr6	888	19	cells	cell	NNS
cord-005478-5iu38pr6	888	20	(	(	-LRB-
cord-005478-5iu38pr6	888	21	CD45	CD45	NNP
cord-005478-5iu38pr6	888	22	+	+	CC
cord-005478-5iu38pr6	888	23	CD56	CD56	NNP
cord-005478-5iu38pr6	888	24	+	+	SYM
cord-005478-5iu38pr6	888	25	CD3	cd3	NN
cord-005478-5iu38pr6	888	26	-	-	,
cord-005478-5iu38pr6	888	27	)	)	-RRB-
cord-005478-5iu38pr6	888	28	86.64	86.64	CD
cord-005478-5iu38pr6	888	29	±	±	CD
cord-005478-5iu38pr6	888	30	11.36	11.36	CD
cord-005478-5iu38pr6	888	31	%	%	NN
cord-005478-5iu38pr6	888	32	;	;	:
cord-005478-5iu38pr6	888	33	T	t	NN
cord-005478-5iu38pr6	888	34	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	888	35	(	(	-LRB-
cord-005478-5iu38pr6	888	36	CD45	CD45	NNP
cord-005478-5iu38pr6	888	37	+	+	CC
cord-005478-5iu38pr6	888	38	CD56	CD56	NNP
cord-005478-5iu38pr6	888	39	-CD3	-CD3	,
cord-005478-5iu38pr6	888	40	+	+	NN
cord-005478-5iu38pr6	888	41	)	)	-RRB-
cord-005478-5iu38pr6	889	1	2.94	2.94	CD
cord-005478-5iu38pr6	889	2	±	±	CD
cord-005478-5iu38pr6	889	3	3.55	3.55	CD
cord-005478-5iu38pr6	889	4	%	%	NN
cord-005478-5iu38pr6	889	5	.	.	.
cord-005478-5iu38pr6	890	1	One	one	CD
cord-005478-5iu38pr6	890	2	product	product	NN
cord-005478-5iu38pr6	890	3	was	be	VBD
cord-005478-5iu38pr6	890	4	rejected	reject	VBN
cord-005478-5iu38pr6	890	5	for	for	IN
cord-005478-5iu38pr6	890	6	quality	quality	NN
cord-005478-5iu38pr6	890	7	criteria	criterion	NNS
cord-005478-5iu38pr6	890	8	.	.	.
cord-005478-5iu38pr6	891	1	A	a	DT
cord-005478-5iu38pr6	891	2	mean	mean	NN
cord-005478-5iu38pr6	891	3	of	of	IN
cord-005478-5iu38pr6	891	4	51.14	51.14	CD
cord-005478-5iu38pr6	891	5	±	±	CD
cord-005478-5iu38pr6	891	6	53.99	53.99	CD
cord-005478-5iu38pr6	891	7	x	x	SYM
cord-005478-5iu38pr6	891	8	10	10	CD
cord-005478-5iu38pr6	891	9	6	6	CD
cord-005478-5iu38pr6	891	10	NK	NK	NNP
cord-005478-5iu38pr6	891	11	cells	cell	NNS
cord-005478-5iu38pr6	891	12	/	/	SYM
cord-005478-5iu38pr6	891	13	kg	kg	NNS
cord-005478-5iu38pr6	891	14	and	and	CC
cord-005478-5iu38pr6	891	15	0.69	0.69	CD
cord-005478-5iu38pr6	891	16	±	±	XX
cord-005478-5iu38pr6	892	1	0.35	0.35	CD
cord-005478-5iu38pr6	892	2	x	x	SYM
cord-005478-5iu38pr6	892	3	10	10	CD
cord-005478-5iu38pr6	892	4	6	6	CD
cord-005478-5iu38pr6	892	5	T	t	NN
cord-005478-5iu38pr6	892	6	cells	cell	NNS
cord-005478-5iu38pr6	892	7	/	/	SYM
cord-005478-5iu38pr6	892	8	kg	kg	NNS
cord-005478-5iu38pr6	892	9	were	be	VBD
cord-005478-5iu38pr6	892	10	infused	infuse	VBN
cord-005478-5iu38pr6	892	11	.	.	.
cord-005478-5iu38pr6	893	1	Median	median	JJ
cord-005478-5iu38pr6	893	2	age	age	NN
cord-005478-5iu38pr6	893	3	of	of	IN
cord-005478-5iu38pr6	893	4	the	the	DT
cord-005478-5iu38pr6	893	5	patients	patient	NNS
cord-005478-5iu38pr6	893	6	were	be	VBD
cord-005478-5iu38pr6	893	7	7	7	CD
cord-005478-5iu38pr6	893	8	years	year	NNS
cord-005478-5iu38pr6	893	9	(	(	-LRB-
cord-005478-5iu38pr6	893	10	1	1	CD
cord-005478-5iu38pr6	893	11	)	)	-RRB-
cord-005478-5iu38pr6	893	12	(	(	-LRB-
cord-005478-5iu38pr6	893	13	2	2	LS
cord-005478-5iu38pr6	893	14	)	)	-RRB-
cord-005478-5iu38pr6	893	15	(	(	-LRB-
cord-005478-5iu38pr6	893	16	3	3	LS
cord-005478-5iu38pr6	893	17	)	)	-RRB-
cord-005478-5iu38pr6	893	18	(	(	-LRB-
cord-005478-5iu38pr6	893	19	4	4	LS
cord-005478-5iu38pr6	893	20	)	)	-RRB-
cord-005478-5iu38pr6	893	21	(	(	-LRB-
cord-005478-5iu38pr6	893	22	5	5	LS
cord-005478-5iu38pr6	893	23	)	)	-RRB-
cord-005478-5iu38pr6	893	24	(	(	-LRB-
cord-005478-5iu38pr6	893	25	6	6	LS
cord-005478-5iu38pr6	893	26	)	)	-RRB-
cord-005478-5iu38pr6	893	27	(	(	-LRB-
cord-005478-5iu38pr6	893	28	7	7	LS
cord-005478-5iu38pr6	893	29	)	)	-RRB-
cord-005478-5iu38pr6	893	30	(	(	-LRB-
cord-005478-5iu38pr6	893	31	8)	8)	NNP
cord-005478-5iu38pr6	893	32	(	(	-LRB-
cord-005478-5iu38pr6	893	33	9	9	CD
cord-005478-5iu38pr6	893	34	)	)	-RRB-
cord-005478-5iu38pr6	893	35	(	(	-LRB-
cord-005478-5iu38pr6	893	36	10	10	CD
cord-005478-5iu38pr6	893	37	)	)	-RRB-
cord-005478-5iu38pr6	893	38	(	(	-LRB-
cord-005478-5iu38pr6	893	39	11	11	CD
cord-005478-5iu38pr6	893	40	)	)	-RRB-
cord-005478-5iu38pr6	893	41	(	(	-LRB-
cord-005478-5iu38pr6	893	42	12	12	CD
cord-005478-5iu38pr6	893	43	)	)	-RRB-
cord-005478-5iu38pr6	893	44	(	(	-LRB-
cord-005478-5iu38pr6	893	45	13	13	CD
cord-005478-5iu38pr6	893	46	)	)	-RRB-
cord-005478-5iu38pr6	893	47	(	(	-LRB-
cord-005478-5iu38pr6	893	48	14	14	CD
cord-005478-5iu38pr6	893	49	)	)	-RRB-
cord-005478-5iu38pr6	893	50	(	(	-LRB-
cord-005478-5iu38pr6	893	51	15	15	CD
cord-005478-5iu38pr6	893	52	)	)	-RRB-
cord-005478-5iu38pr6	893	53	(	(	-LRB-
cord-005478-5iu38pr6	893	54	16	16	CD
cord-005478-5iu38pr6	893	55	)	)	-RRB-
cord-005478-5iu38pr6	893	56	.	.	.
cord-005478-5iu38pr6	894	1	Treatment	treatment	NN
cord-005478-5iu38pr6	894	2	and	and	CC
cord-005478-5iu38pr6	894	3	infusions	infusion	NNS
cord-005478-5iu38pr6	894	4	were	be	VBD
cord-005478-5iu38pr6	894	5	well	well	RB
cord-005478-5iu38pr6	894	6	tolerated	tolerate	VBN
cord-005478-5iu38pr6	894	7	.	.	.
cord-005478-5iu38pr6	895	1	The	the	DT
cord-005478-5iu38pr6	895	2	main	main	JJ
cord-005478-5iu38pr6	895	3	adverse	adverse	JJ
cord-005478-5iu38pr6	895	4	event	event	NN
cord-005478-5iu38pr6	895	5	was	be	VBD
cord-005478-5iu38pr6	895	6	neutropenic	neutropenic	JJ
cord-005478-5iu38pr6	895	7	fever	fever	NN
cord-005478-5iu38pr6	895	8	in	in	IN
cord-005478-5iu38pr6	895	9	one	one	CD
cord-005478-5iu38pr6	895	10	patient	patient	NN
cord-005478-5iu38pr6	895	11	.	.	.
cord-005478-5iu38pr6	896	1	After	after	IN
cord-005478-5iu38pr6	896	2	a	a	DT
cord-005478-5iu38pr6	896	3	median	median	NN
cord-005478-5iu38pr6	896	4	follow	follow	NN
cord-005478-5iu38pr6	896	5	up	up	IN
cord-005478-5iu38pr6	896	6	of	of	IN
cord-005478-5iu38pr6	896	7	530	530	CD
cord-005478-5iu38pr6	896	8	days	day	NNS
cord-005478-5iu38pr6	896	9	(	(	-LRB-
cord-005478-5iu38pr6	896	10	371	371	CD
cord-005478-5iu38pr6	896	11	-	-	SYM
cord-005478-5iu38pr6	896	12	813	813	CD
cord-005478-5iu38pr6	896	13	)	)	-RRB-
cord-005478-5iu38pr6	896	14	all	all	PDT
cord-005478-5iu38pr6	896	15	the	the	DT
cord-005478-5iu38pr6	896	16	7	7	CD
cord-005478-5iu38pr6	896	17	patients	patient	NNS
cord-005478-5iu38pr6	896	18	are	be	VBP
cord-005478-5iu38pr6	896	19	alive	alive	JJ
cord-005478-5iu38pr6	896	20	.	.	.
cord-005478-5iu38pr6	897	1	Only	only	RB
cord-005478-5iu38pr6	897	2	one	one	CD
cord-005478-5iu38pr6	897	3	patient	patient	NN
cord-005478-5iu38pr6	897	4	showed	show	VBD
cord-005478-5iu38pr6	897	5	relapse	relapse	NN
cord-005478-5iu38pr6	897	6	at	at	IN
cord-005478-5iu38pr6	897	7	day	day	NN
cord-005478-5iu38pr6	897	8	+307	+307	NNP
cord-005478-5iu38pr6	897	9	after	after	IN
cord-005478-5iu38pr6	897	10	NK	NK	NNP
cord-005478-5iu38pr6	897	11	cells	cell	NNS
cord-005478-5iu38pr6	897	12	infusion	infusion	NN
cord-005478-5iu38pr6	897	13	and	and	CC
cord-005478-5iu38pr6	897	14	was	be	VBD
cord-005478-5iu38pr6	897	15	submitted	submit	VBN
cord-005478-5iu38pr6	897	16	to	to	IN
cord-005478-5iu38pr6	897	17	an	an	DT
cord-005478-5iu38pr6	897	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	897	19	from	from	IN
cord-005478-5iu38pr6	897	20	a	a	DT
cord-005478-5iu38pr6	897	21	matched	match	VBN
cord-005478-5iu38pr6	897	22	unrelated	unrelated	JJ
cord-005478-5iu38pr6	897	23	donor	donor	NN
cord-005478-5iu38pr6	897	24	.	.	.
cord-005478-5iu38pr6	898	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	898	2	:	:	:
cord-005478-5iu38pr6	899	1	The	the	DT
cord-005478-5iu38pr6	899	2	preliminary	preliminary	JJ
cord-005478-5iu38pr6	899	3	results	result	NNS
cord-005478-5iu38pr6	899	4	of	of	IN
cord-005478-5iu38pr6	899	5	this	this	DT
cord-005478-5iu38pr6	899	6	trial	trial	NN
cord-005478-5iu38pr6	899	7	suggest	suggest	VBP
cord-005478-5iu38pr6	899	8	that	that	IN
cord-005478-5iu38pr6	899	9	NK	NK	NNP
cord-005478-5iu38pr6	899	10	cells	cell	NNS
cord-005478-5iu38pr6	899	11	infusion	infusion	NN
cord-005478-5iu38pr6	899	12	as	as	IN
cord-005478-5iu38pr6	899	13	consolidative	consolidative	JJ
cord-005478-5iu38pr6	899	14	strategy	strategy	NN
cord-005478-5iu38pr6	899	15	in	in	IN
cord-005478-5iu38pr6	899	16	pediatric	pediatric	JJ
cord-005478-5iu38pr6	899	17	patients	patient	NNS
cord-005478-5iu38pr6	899	18	with	with	IN
cord-005478-5iu38pr6	899	19	AML	AML	NNP
cord-005478-5iu38pr6	899	20	,	,	,
cord-005478-5iu38pr6	899	21	is	be	VBZ
cord-005478-5iu38pr6	899	22	feasible	feasible	JJ
cord-005478-5iu38pr6	899	23	and	and	CC
cord-005478-5iu38pr6	899	24	secure	secure	JJ
cord-005478-5iu38pr6	899	25	.	.	.
cord-005478-5iu38pr6	900	1	The	the	DT
cord-005478-5iu38pr6	900	2	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	900	3	effect	effect	NN
cord-005478-5iu38pr6	900	4	should	should	MD
cord-005478-5iu38pr6	900	5	be	be	VB
cord-005478-5iu38pr6	900	6	confirmed	confirm	VBN
cord-005478-5iu38pr6	900	7	in	in	IN
cord-005478-5iu38pr6	900	8	a	a	DT
cord-005478-5iu38pr6	900	9	larger	large	JJR
cord-005478-5iu38pr6	900	10	cohort	cohort	NN
cord-005478-5iu38pr6	900	11	of	of	IN
cord-005478-5iu38pr6	900	12	patients	patient	NNS
cord-005478-5iu38pr6	900	13	.	.	.
cord-005478-5iu38pr6	901	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	901	2	Trial	Trial	NNP
cord-005478-5iu38pr6	901	3	Registry	Registry	NNP
cord-005478-5iu38pr6	901	4	:	:	:
cord-005478-5iu38pr6	901	5	Clinicaltrials.gov	Clinicaltrials.gov	NNP
cord-005478-5iu38pr6	901	6	(	(	-LRB-
cord-005478-5iu38pr6	901	7	NCT02763475	NCT02763475	NNP
cord-005478-5iu38pr6	901	8	)	)	-RRB-
cord-005478-5iu38pr6	901	9	and	and	CC
cord-005478-5iu38pr6	901	10	EudraCT	eudract	JJ
cord-005478-5iu38pr6	901	11	(	(	-LRB-
cord-005478-5iu38pr6	901	12	2015	2015	CD
cord-005478-5iu38pr6	901	13	-	-	HYPH
cord-005478-5iu38pr6	901	14	001901	001901	CD
cord-005478-5iu38pr6	901	15	-	-	SYM
cord-005478-5iu38pr6	901	16	15	15	CD
cord-005478-5iu38pr6	901	17	)	)	-RRB-
cord-005478-5iu38pr6	901	18	.	.	.
cord-005478-5iu38pr6	902	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	902	2	:	:	:
cord-005478-5iu38pr6	903	1	Authors	author	NNS
cord-005478-5iu38pr6	903	2	have	have	VBP
cord-005478-5iu38pr6	903	3	no	no	DT
cord-005478-5iu38pr6	903	4	conflict	conflict	NN
cord-005478-5iu38pr6	903	5	of	of	IN
cord-005478-5iu38pr6	903	6	interest	interest	NN
cord-005478-5iu38pr6	903	7	.	.	.
cord-005478-5iu38pr6	904	1	The	the	DT
cord-005478-5iu38pr6	904	2	trial	trial	NN
cord-005478-5iu38pr6	904	3	was	be	VBD
cord-005478-5iu38pr6	904	4	funded	fund	VBN
cord-005478-5iu38pr6	904	5	by	by	IN
cord-005478-5iu38pr6	904	6	"	"	``
cord-005478-5iu38pr6	904	7	Fundación	Fundación	NNP
cord-005478-5iu38pr6	904	8	Mutua	Mutua	NNP
cord-005478-5iu38pr6	904	9	Madrileña	Madrileña	NNP
cord-005478-5iu38pr6	904	10	"	"	``
cord-005478-5iu38pr6	904	11	Grant	Grant	NNP
cord-005478-5iu38pr6	904	12	O050	o050	CD
cord-005478-5iu38pr6	905	1	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	905	2	/	/	SYM
cord-005478-5iu38pr6	905	3	CD19	CD19	NNP
cord-005478-5iu38pr6	905	4	depleted	deplete	VBD
cord-005478-5iu38pr6	905	5	and	and	CC
cord-005478-5iu38pr6	905	6	IL-15	IL-15	NNP
cord-005478-5iu38pr6	905	7	stimulated	stimulate	VBD
cord-005478-5iu38pr6	905	8	donor	donor	NN
cord-005478-5iu38pr6	905	9	cell	cell	NN
cord-005478-5iu38pr6	905	10	infusions	infusion	NNS
cord-005478-5iu38pr6	905	11	can	can	MD
cord-005478-5iu38pr6	905	12	exert	exert	VB
cord-005478-5iu38pr6	905	13	anti	anti	JJ
cord-005478-5iu38pr6	905	14	-	-	JJ
cord-005478-5iu38pr6	905	15	tumor	tumor	JJ
cord-005478-5iu38pr6	905	16	effects	effect	NNS
cord-005478-5iu38pr6	905	17	after	after	IN
cord-005478-5iu38pr6	905	18	allosct	allosct	NNP
cord-005478-5iu38pr6	905	19	without	without	IN
cord-005478-5iu38pr6	905	20	inducing	induce	VBG
cord-005478-5iu38pr6	905	21	GVHD	GVHD	NNP
cord-005478-5iu38pr6	905	22	in	in	IN
cord-005478-5iu38pr6	905	23	vitro	vitro	FW
cord-005478-5iu38pr6	905	24	and	and	CC
cord-005478-5iu38pr6	905	25	in	in	IN
cord-005478-5iu38pr6	905	26	vivo	vivo	NNP
cord-005478-5iu38pr6	905	27	Background	background	NN
cord-005478-5iu38pr6	905	28	:	:	:
cord-005478-5iu38pr6	906	1	Natural	natural	JJ
cord-005478-5iu38pr6	906	2	killer	killer	NN
cord-005478-5iu38pr6	906	3	(	(	-LRB-
cord-005478-5iu38pr6	906	4	NK	NK	NNP
cord-005478-5iu38pr6	906	5	)	)	-RRB-
cord-005478-5iu38pr6	906	6	cells	cell	NNS
cord-005478-5iu38pr6	906	7	and	and	CC
cord-005478-5iu38pr6	906	8	γδ	γδ	NNP
cord-005478-5iu38pr6	906	9	T	T	NNP
cord-005478-5iu38pr6	906	10	-	-	HYPH
cord-005478-5iu38pr6	906	11	cells	cell	NNS
cord-005478-5iu38pr6	906	12	have	have	VBP
cord-005478-5iu38pr6	906	13	been	be	VBN
cord-005478-5iu38pr6	906	14	shown	show	VBN
cord-005478-5iu38pr6	906	15	to	to	TO
cord-005478-5iu38pr6	906	16	play	play	VB
cord-005478-5iu38pr6	906	17	a	a	DT
cord-005478-5iu38pr6	906	18	significant	significant	JJ
cord-005478-5iu38pr6	906	19	role	role	NN
cord-005478-5iu38pr6	906	20	in	in	IN
cord-005478-5iu38pr6	906	21	GvL	gvl	NN
cord-005478-5iu38pr6	906	22	effects	effect	NNS
cord-005478-5iu38pr6	906	23	after	after	IN
cord-005478-5iu38pr6	906	24	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	906	25	stem	stem	NN
cord-005478-5iu38pr6	906	26	cell	cell	NN
cord-005478-5iu38pr6	906	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	906	28	(	(	-LRB-
cord-005478-5iu38pr6	906	29	SCT	SCT	NNP
cord-005478-5iu38pr6	906	30	)	)	-RRB-
cord-005478-5iu38pr6	906	31	.	.	.
cord-005478-5iu38pr6	907	1	Both	both	DT
cord-005478-5iu38pr6	907	2	cell	cell	NN
cord-005478-5iu38pr6	907	3	types	type	NNS
cord-005478-5iu38pr6	907	4	are	be	VBP
cord-005478-5iu38pr6	907	5	not	not	RB
cord-005478-5iu38pr6	907	6	restricted	restrict	VBN
cord-005478-5iu38pr6	907	7	by	by	IN
cord-005478-5iu38pr6	907	8	MHC	MHC	NNP
cord-005478-5iu38pr6	907	9	molecules	molecule	NNS
cord-005478-5iu38pr6	907	10	which	which	WDT
cord-005478-5iu38pr6	907	11	makes	make	VBZ
cord-005478-5iu38pr6	907	12	them	-PRON-	PRP
cord-005478-5iu38pr6	907	13	unlikely	unlikely	JJ
cord-005478-5iu38pr6	907	14	to	to	TO
cord-005478-5iu38pr6	907	15	elicit	elicit	VB
cord-005478-5iu38pr6	907	16	graft	graft	NN
cord-005478-5iu38pr6	907	17	versus	versus	IN
cord-005478-5iu38pr6	907	18	host	host	NN
cord-005478-5iu38pr6	907	19	disease	disease	NN
cord-005478-5iu38pr6	907	20	(	(	-LRB-
cord-005478-5iu38pr6	907	21	GvHD	GvHD	NNP
cord-005478-5iu38pr6	907	22	)	)	-RRB-
cord-005478-5iu38pr6	907	23	even	even	RB
cord-005478-5iu38pr6	907	24	in	in	IN
cord-005478-5iu38pr6	907	25	mismatched	mismatched	JJ
cord-005478-5iu38pr6	907	26	SCT	SCT	NNP
cord-005478-5iu38pr6	907	27	and	and	CC
cord-005478-5iu38pr6	907	28	therefore	therefore	RB
cord-005478-5iu38pr6	907	29	are	be	VBP
cord-005478-5iu38pr6	907	30	suited	suit	VBN
cord-005478-5iu38pr6	907	31	also	also	RB
cord-005478-5iu38pr6	907	32	for	for	IN
cord-005478-5iu38pr6	907	33	cell	cell	NN
cord-005478-5iu38pr6	907	34	-	-	HYPH
cord-005478-5iu38pr6	907	35	based	base	VBN
cord-005478-5iu38pr6	907	36	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	907	37	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	907	38	.	.	.
cord-005478-5iu38pr6	908	1	Incubation	incubation	NN
cord-005478-5iu38pr6	908	2	with	with	IN
cord-005478-5iu38pr6	908	3	cytokines	cytokine	NNS
cord-005478-5iu38pr6	908	4	strongly	strongly	RB
cord-005478-5iu38pr6	908	5	enhances	enhance	VBZ
cord-005478-5iu38pr6	908	6	their	-PRON-	PRP$
cord-005478-5iu38pr6	908	7	spontaneous	spontaneous	JJ
cord-005478-5iu38pr6	908	8	and	and	CC
cord-005478-5iu38pr6	908	9	antibody	antibody	NN
cord-005478-5iu38pr6	908	10	dependent	dependent	JJ
cord-005478-5iu38pr6	908	11	cellular	cellular	JJ
cord-005478-5iu38pr6	908	12	cytotoxicity	cytotoxicity	NN
cord-005478-5iu38pr6	908	13	(	(	-LRB-
cord-005478-5iu38pr6	908	14	ADCC	ADCC	NNP
cord-005478-5iu38pr6	908	15	)	)	-RRB-
cord-005478-5iu38pr6	908	16	.	.	.
cord-005478-5iu38pr6	909	1	Methods	method	NNS
cord-005478-5iu38pr6	909	2	:	:	:
cord-005478-5iu38pr6	910	1	Thus	thus	RB
cord-005478-5iu38pr6	910	2	,	,	,
cord-005478-5iu38pr6	910	3	we	-PRON-	PRP
cord-005478-5iu38pr6	910	4	investigated	investigate	VBD
cord-005478-5iu38pr6	910	5	the	the	DT
cord-005478-5iu38pr6	910	6	efficacy	efficacy	NN
cord-005478-5iu38pr6	910	7	of	of	IN
cord-005478-5iu38pr6	910	8	a	a	DT
cord-005478-5iu38pr6	910	9	combination	combination	NN
cord-005478-5iu38pr6	910	10	of	of	IN
cord-005478-5iu38pr6	910	11	IL-15	IL-15	NNP
cord-005478-5iu38pr6	910	12	stimulated	stimulate	VBD
cord-005478-5iu38pr6	910	13	NK	NK	NNP
cord-005478-5iu38pr6	910	14	-	-	:
cord-005478-5iu38pr6	910	15	and	and	CC
cord-005478-5iu38pr6	910	16	γδ	γδ	NNP
cord-005478-5iu38pr6	910	17	T	T	NNP
cord-005478-5iu38pr6	910	18	-	-	HYPH
cord-005478-5iu38pr6	910	19	cells	cell	NNS
cord-005478-5iu38pr6	910	20	from	from	IN
cord-005478-5iu38pr6	910	21	mismatched	mismatched	JJ
cord-005478-5iu38pr6	910	22	donors	donor	NNS
cord-005478-5iu38pr6	910	23	in	in	IN
cord-005478-5iu38pr6	910	24	vitro	vitro	FW
cord-005478-5iu38pr6	910	25	and	and	CC
cord-005478-5iu38pr6	910	26	based	base	VBN
cord-005478-5iu38pr6	910	27	on	on	IN
cord-005478-5iu38pr6	910	28	urgent	urgent	JJ
cord-005478-5iu38pr6	910	29	medical	medical	JJ
cord-005478-5iu38pr6	910	30	need	need	NN
cord-005478-5iu38pr6	910	31	in	in	IN
cord-005478-5iu38pr6	910	32	ultra	ultra	JJ
cord-005478-5iu38pr6	910	33	high	high	JJ
cord-005478-5iu38pr6	910	34	risk	risk	NN
cord-005478-5iu38pr6	910	35	patients	patient	NNS
cord-005478-5iu38pr6	910	36	.	.	.
cord-005478-5iu38pr6	911	1	Results	result	NNS
cord-005478-5iu38pr6	911	2	:	:	:
cord-005478-5iu38pr6	912	1	In	in	IN
cord-005478-5iu38pr6	912	2	vitro	vitro	FW
cord-005478-5iu38pr6	912	3	data	datum	NNS
cord-005478-5iu38pr6	912	4	:	:	:
cord-005478-5iu38pr6	912	5	Spontaneous	spontaneous	JJ
cord-005478-5iu38pr6	912	6	cytotoxic	cytotoxic	JJ
cord-005478-5iu38pr6	912	7	activity	activity	NN
cord-005478-5iu38pr6	912	8	and	and	CC
cord-005478-5iu38pr6	912	9	ADCC	ADCC	NNP
cord-005478-5iu38pr6	912	10	with	with	IN
cord-005478-5iu38pr6	913	1	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	913	2	/	/	SYM
cord-005478-5iu38pr6	913	3	CD19	CD19	NNP
cord-005478-5iu38pr6	913	4	depleted	deplete	VBD
cord-005478-5iu38pr6	913	5	PBMCs	pbmc	NNS
cord-005478-5iu38pr6	913	6	from	from	IN
cord-005478-5iu38pr6	913	7	healthy	healthy	JJ
cord-005478-5iu38pr6	913	8	donors	donor	NNS
cord-005478-5iu38pr6	913	9	against	against	IN
cord-005478-5iu38pr6	913	10	LS	LS	NNP
cord-005478-5iu38pr6	913	11	(	(	-LRB-
cord-005478-5iu38pr6	913	12	neuroblastoma	neuroblastoma	NN
cord-005478-5iu38pr6	913	13	)	)	-RRB-
cord-005478-5iu38pr6	913	14	and	and	CC
cord-005478-5iu38pr6	913	15	Nalm-6	Nalm-6	NNP
cord-005478-5iu38pr6	913	16	(	(	-LRB-
cord-005478-5iu38pr6	913	17	leukemia	leukemia	NN
cord-005478-5iu38pr6	913	18	)	)	-RRB-
cord-005478-5iu38pr6	913	19	target	target	NN
cord-005478-5iu38pr6	913	20	cells	cell	NNS
cord-005478-5iu38pr6	913	21	after	after	IN
cord-005478-5iu38pr6	913	22	overnight	overnight	JJ
cord-005478-5iu38pr6	913	23	stimulation	stimulation	NN
cord-005478-5iu38pr6	913	24	with	with	IN
cord-005478-5iu38pr6	913	25	IL-15	IL-15	NNP
cord-005478-5iu38pr6	913	26	was	be	VBD
cord-005478-5iu38pr6	913	27	significantly	significantly	RB
cord-005478-5iu38pr6	913	28	increased	increase	VBN
cord-005478-5iu38pr6	913	29	compared	compare	VBN
cord-005478-5iu38pr6	913	30	to	to	IN
cord-005478-5iu38pr6	913	31	non	non	JJ
cord-005478-5iu38pr6	913	32	-	-	JJ
cord-005478-5iu38pr6	913	33	stimulated	stimulated	JJ
cord-005478-5iu38pr6	913	34	cells	cell	NNS
cord-005478-5iu38pr6	914	1	(	(	-LRB-
cord-005478-5iu38pr6	914	2	E	e	NN
cord-005478-5iu38pr6	914	3	:	:	:
cord-005478-5iu38pr6	914	4	T	t	NN
cord-005478-5iu38pr6	914	5	ratio	ratio	NN
cord-005478-5iu38pr6	914	6	20:1	20:1	CD
cord-005478-5iu38pr6	914	7	;	;	.
cord-005478-5iu38pr6	915	1	LS	LS	NNP
cord-005478-5iu38pr6	915	2	cells	cell	NNS
cord-005478-5iu38pr6	915	3	:	:	:
cord-005478-5iu38pr6	915	4	43	43	CD
cord-005478-5iu38pr6	915	5	%	%	NN
cord-005478-5iu38pr6	915	6	and	and	CC
cord-005478-5iu38pr6	915	7	61	61	CD
cord-005478-5iu38pr6	915	8	%	%	NN
cord-005478-5iu38pr6	915	9	vs	vs	IN
cord-005478-5iu38pr6	915	10	19	19	CD
cord-005478-5iu38pr6	915	11	%	%	NN
cord-005478-5iu38pr6	915	12	;	;	:
cord-005478-5iu38pr6	915	13	Nalm-6	Nalm-6	NNP
cord-005478-5iu38pr6	915	14	cells	cell	NNS
cord-005478-5iu38pr6	915	15	:	:	:
cord-005478-5iu38pr6	915	16	44	44	CD
cord-005478-5iu38pr6	915	17	%	%	NN
cord-005478-5iu38pr6	915	18	and	and	CC
cord-005478-5iu38pr6	915	19	68	68	CD
cord-005478-5iu38pr6	915	20	%	%	NN
cord-005478-5iu38pr6	915	21	vs	vs	IN
cord-005478-5iu38pr6	915	22	26	26	CD
cord-005478-5iu38pr6	915	23	%	%	NN
cord-005478-5iu38pr6	915	24	)	)	-RRB-
cord-005478-5iu38pr6	915	25	.	.	.
cord-005478-5iu38pr6	916	1	The	the	DT
cord-005478-5iu38pr6	916	2	results	result	NNS
cord-005478-5iu38pr6	916	3	for	for	IN
cord-005478-5iu38pr6	916	4	CD107a	CD107a	NNP
cord-005478-5iu38pr6	916	5	assays	assay	NNS
cord-005478-5iu38pr6	916	6	are	be	VBP
cord-005478-5iu38pr6	916	7	in	in	IN
cord-005478-5iu38pr6	916	8	line	line	NN
cord-005478-5iu38pr6	916	9	with	with	IN
cord-005478-5iu38pr6	916	10	the	the	DT
cord-005478-5iu38pr6	916	11	cytotoxicity	cytotoxicity	NN
cord-005478-5iu38pr6	916	12	approaches	approach	NNS
cord-005478-5iu38pr6	916	13	.	.	.
cord-005478-5iu38pr6	917	1	NK	NK	NNP
cord-005478-5iu38pr6	917	2	and	and	CC
cord-005478-5iu38pr6	917	3	γδ	γδ	NNP
cord-005478-5iu38pr6	917	4	T	T	NNP
cord-005478-5iu38pr6	917	5	-	-	HYPH
cord-005478-5iu38pr6	917	6	cells	cell	NNS
cord-005478-5iu38pr6	917	7	showed	show	VBD
cord-005478-5iu38pr6	917	8	a	a	DT
cord-005478-5iu38pr6	917	9	significantly	significantly	RB
cord-005478-5iu38pr6	917	10	stronger	strong	JJR
cord-005478-5iu38pr6	917	11	stimulation	stimulation	NN
cord-005478-5iu38pr6	917	12	after	after	IN
cord-005478-5iu38pr6	917	13	IL-15	IL-15	NNP
cord-005478-5iu38pr6	917	14	incubation	incubation	NN
cord-005478-5iu38pr6	917	15	+	+	CC
cord-005478-5iu38pr6	918	1	/-ADCC	/-ADCC	NNP
cord-005478-5iu38pr6	918	2	,	,	,
cord-005478-5iu38pr6	918	3	as	as	IN
cord-005478-5iu38pr6	918	4	measured	measure	VBN
cord-005478-5iu38pr6	918	5	by	by	IN
cord-005478-5iu38pr6	918	6	secreting	secrete	VBG
cord-005478-5iu38pr6	918	7	cytokines	cytokine	NNS
cord-005478-5iu38pr6	918	8	(	(	-LRB-
cord-005478-5iu38pr6	918	9	CD107a	CD107a	NNP
cord-005478-5iu38pr6	918	10	,	,	,
cord-005478-5iu38pr6	918	11	INFγ	INFγ	NNP
cord-005478-5iu38pr6	918	12	,	,	,
cord-005478-5iu38pr6	918	13	TNFα	TNFα	NNP
cord-005478-5iu38pr6	918	14	)	)	-RRB-
cord-005478-5iu38pr6	918	15	.	.	.
cord-005478-5iu38pr6	919	1	Moreover	moreover	RB
cord-005478-5iu38pr6	919	2	,	,	,
cord-005478-5iu38pr6	919	3	7	7	CD
cord-005478-5iu38pr6	919	4	patients	patient	NNS
cord-005478-5iu38pr6	919	5	at	at	IN
cord-005478-5iu38pr6	919	6	extremely	extremely	RB
cord-005478-5iu38pr6	919	7	high	high	JJ
cord-005478-5iu38pr6	919	8	risk	risk	NN
cord-005478-5iu38pr6	919	9	for	for	IN
cord-005478-5iu38pr6	919	10	relapse	relapse	NN
cord-005478-5iu38pr6	919	11	received	receive	VBD
cord-005478-5iu38pr6	919	12	NK-/	NK-/	NNP
cord-005478-5iu38pr6	919	13	γδ	γδ	IN
cord-005478-5iu38pr6	919	14	T	t	NN
cord-005478-5iu38pr6	919	15	-	-	HYPH
cord-005478-5iu38pr6	919	16	cell	cell	NN
cord-005478-5iu38pr6	919	17	infusions	infusion	NNS
cord-005478-5iu38pr6	919	18	after	after	IN
cord-005478-5iu38pr6	919	19	previous	previous	JJ
cord-005478-5iu38pr6	919	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	919	21	from	from	IN
cord-005478-5iu38pr6	919	22	haploidentical	haploidentical	NNP
cord-005478-5iu38pr6	919	23	(	(	-LRB-
cord-005478-5iu38pr6	919	24	n=5	n=5	NNP
cord-005478-5iu38pr6	919	25	)	)	-RRB-
cord-005478-5iu38pr6	919	26	or	or	CC
cord-005478-5iu38pr6	919	27	matched	match	VBN
cord-005478-5iu38pr6	919	28	donors	donor	NNS
cord-005478-5iu38pr6	919	29	(	(	-LRB-
cord-005478-5iu38pr6	919	30	n=	n=	NNP
cord-005478-5iu38pr6	919	31	2	2	CD
cord-005478-5iu38pr6	919	32	)	)	-RRB-
cord-005478-5iu38pr6	919	33	;	;	:
cord-005478-5iu38pr6	919	34	Diagnoses	diagnosis	NNS
cord-005478-5iu38pr6	919	35	:	:	:
cord-005478-5iu38pr6	919	36	T	T	NNP
cord-005478-5iu38pr6	919	37	-	-	HYPH
cord-005478-5iu38pr6	919	38	ALL	ALL	NNP
cord-005478-5iu38pr6	919	39	,	,	,
cord-005478-5iu38pr6	919	40	relapse	relapse	NN
cord-005478-5iu38pr6	919	41	after	after	IN
cord-005478-5iu38pr6	919	42	1	1	CD
cord-005478-5iu38pr6	919	43	st	st	NNP
cord-005478-5iu38pr6	919	44	SCT	SCT	NNP
cord-005478-5iu38pr6	919	45	n=1	n=1	NN
cord-005478-5iu38pr6	919	46	;	;	:
cord-005478-5iu38pr6	919	47	B	b	NN
cord-005478-5iu38pr6	919	48	-	-	HYPH
cord-005478-5iu38pr6	919	49	lineage	lineage	NN
cord-005478-5iu38pr6	919	50	-	-	,
cord-005478-5iu38pr6	919	51	ALL	all	DT
cord-005478-5iu38pr6	919	52	,	,	,
cord-005478-5iu38pr6	919	53	CR	CR	NNP
cord-005478-5iu38pr6	919	54	after	after	IN
cord-005478-5iu38pr6	919	55	2	2	CD
cord-005478-5iu38pr6	919	56	nd	nd	NNP
cord-005478-5iu38pr6	919	57	SCT	SCT	NNP
cord-005478-5iu38pr6	919	58	,	,	,
cord-005478-5iu38pr6	919	59	n=3	n=3	NN
cord-005478-5iu38pr6	919	60	;	;	:
cord-005478-5iu38pr6	919	61	AML	AML	NNP
cord-005478-5iu38pr6	919	62	,	,	,
cord-005478-5iu38pr6	919	63	relapse	relapse	NN
cord-005478-5iu38pr6	919	64	after	after	IN
cord-005478-5iu38pr6	919	65	1	1	CD
cord-005478-5iu38pr6	919	66	st	st	NNP
cord-005478-5iu38pr6	919	67	SCT	SCT	NNP
cord-005478-5iu38pr6	919	68	,	,	,
cord-005478-5iu38pr6	919	69	n=1	n=1	FW
cord-005478-5iu38pr6	919	70	;	;	,
cord-005478-5iu38pr6	919	71	relapsed	relapse	VBN
cord-005478-5iu38pr6	919	72	neuroblastoma	neuroblastoma	NN
cord-005478-5iu38pr6	919	73	,	,	,
cord-005478-5iu38pr6	919	74	PR	PR	NNP
cord-005478-5iu38pr6	919	75	after	after	IN
cord-005478-5iu38pr6	919	76	2	2	CD
cord-005478-5iu38pr6	919	77	nd	nd	NNP
cord-005478-5iu38pr6	919	78	SCT	SCT	NNP
cord-005478-5iu38pr6	919	79	,	,	,
cord-005478-5iu38pr6	919	80	n=1	n=1	FW
cord-005478-5iu38pr6	919	81	.	.	.
cord-005478-5iu38pr6	920	1	For	for	IN
cord-005478-5iu38pr6	920	2	that	that	DT
cord-005478-5iu38pr6	920	3	purpose	purpose	NN
cord-005478-5iu38pr6	920	4	magnetic	magnetic	JJ
cord-005478-5iu38pr6	920	5	microbeads	microbead	NNS
cord-005478-5iu38pr6	920	6	and	and	CC
cord-005478-5iu38pr6	920	7	the	the	DT
cord-005478-5iu38pr6	920	8	Clin	Clin	NNP
cord-005478-5iu38pr6	920	9	-	-	HYPH
cord-005478-5iu38pr6	920	10	iMACS	iMACS	NNP
cord-005478-5iu38pr6	920	11	®	®	NN
cord-005478-5iu38pr6	920	12	device	device	NN
cord-005478-5iu38pr6	920	13	were	be	VBD
cord-005478-5iu38pr6	920	14	used	use	VBN
cord-005478-5iu38pr6	920	15	for	for	IN
cord-005478-5iu38pr6	921	1	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	921	2	/	/	SYM
cord-005478-5iu38pr6	921	3	CD19	CD19	NNP
cord-005478-5iu38pr6	921	4	depletion	depletion	NN
cord-005478-5iu38pr6	921	5	of	of	IN
cord-005478-5iu38pr6	921	6	leukapheresis	leukapheresis	NN
cord-005478-5iu38pr6	921	7	products	product	NNS
cord-005478-5iu38pr6	921	8	from	from	IN
cord-005478-5iu38pr6	921	9	the	the	DT
cord-005478-5iu38pr6	921	10	original	original	JJ
cord-005478-5iu38pr6	921	11	donors	donor	NNS
cord-005478-5iu38pr6	921	12	.	.	.
cord-005478-5iu38pr6	922	1	Afterwards	afterwards	RB
cord-005478-5iu38pr6	922	2	,	,	,
cord-005478-5iu38pr6	922	3	remaining	remain	VBG
cord-005478-5iu38pr6	922	4	cells	cell	NNS
cord-005478-5iu38pr6	922	5	(	(	-LRB-
cord-005478-5iu38pr6	922	6	NK	NK	NNP
cord-005478-5iu38pr6	922	7	,	,	,
cord-005478-5iu38pr6	922	8	γδ	γδ	NNP
cord-005478-5iu38pr6	922	9	T	T	NNP
cord-005478-5iu38pr6	922	10	and	and	CC
cord-005478-5iu38pr6	922	11	myeloic	myeloic	NNP
cord-005478-5iu38pr6	922	12	cells	cell	NNS
cord-005478-5iu38pr6	922	13	)	)	-RRB-
cord-005478-5iu38pr6	922	14	were	be	VBD
cord-005478-5iu38pr6	922	15	stimulated	stimulate	VBN
cord-005478-5iu38pr6	922	16	with	with	IN
cord-005478-5iu38pr6	922	17	IL-15	IL-15	NNP
cord-005478-5iu38pr6	922	18	(	(	-LRB-
cord-005478-5iu38pr6	922	19	10	10	CD
cord-005478-5iu38pr6	922	20	ng	ng	NN
cord-005478-5iu38pr6	922	21	/	/	SYM
cord-005478-5iu38pr6	922	22	ml	ml	NN
cord-005478-5iu38pr6	922	23	)	)	-RRB-
cord-005478-5iu38pr6	922	24	overnight	overnight	RB
cord-005478-5iu38pr6	922	25	.	.	.
cord-005478-5iu38pr6	923	1	Efficacy	efficacy	NN
cord-005478-5iu38pr6	923	2	of	of	IN
cord-005478-5iu38pr6	923	3	the	the	DT
cord-005478-5iu38pr6	923	4	stimulation	stimulation	NN
cord-005478-5iu38pr6	923	5	procedure	procedure	NN
cord-005478-5iu38pr6	923	6	was	be	VBD
cord-005478-5iu38pr6	923	7	measured	measure	VBN
cord-005478-5iu38pr6	923	8	in	in	IN
cord-005478-5iu38pr6	923	9	3	3	CD
cord-005478-5iu38pr6	923	10	leukapheresis	leukapheresis	NN
cord-005478-5iu38pr6	923	11	products	product	NNS
cord-005478-5iu38pr6	923	12	:	:	:
cord-005478-5iu38pr6	923	13	after	after	IN
cord-005478-5iu38pr6	923	14	incubation	incubation	NN
cord-005478-5iu38pr6	923	15	with	with	IN
cord-005478-5iu38pr6	923	16	target	target	NN
cord-005478-5iu38pr6	923	17	cells	cell	NNS
cord-005478-5iu38pr6	923	18	(	(	-LRB-
cord-005478-5iu38pr6	923	19	LS	ls	NN
cord-005478-5iu38pr6	923	20	)	)	-RRB-
cord-005478-5iu38pr6	923	21	both	both	DT
cord-005478-5iu38pr6	923	22	,	,	,
cord-005478-5iu38pr6	923	23	NKcells	NKcells	NNP
cord-005478-5iu38pr6	923	24	as	as	RB
cord-005478-5iu38pr6	923	25	well	well	RB
cord-005478-5iu38pr6	923	26	as	as	IN
cord-005478-5iu38pr6	923	27	γδ	γδ	NNP
cord-005478-5iu38pr6	923	28	T	T	NNP
cord-005478-5iu38pr6	923	29	-	-	HYPH
cord-005478-5iu38pr6	923	30	cells	cell	NNS
cord-005478-5iu38pr6	923	31	showed	show	VBD
cord-005478-5iu38pr6	923	32	a	a	DT
cord-005478-5iu38pr6	923	33	significant	significant	JJ
cord-005478-5iu38pr6	923	34	increase	increase	NN
cord-005478-5iu38pr6	923	35	in	in	IN
cord-005478-5iu38pr6	923	36	CD107a	CD107a	NNP
cord-005478-5iu38pr6	923	37	secretion	secretion	NN
cord-005478-5iu38pr6	923	38	compared	compare	VBN
cord-005478-5iu38pr6	923	39	to	to	IN
cord-005478-5iu38pr6	923	40	non	non	JJ
cord-005478-5iu38pr6	923	41	-	-	JJ
cord-005478-5iu38pr6	923	42	stimulated	stimulate	VBN
cord-005478-5iu38pr6	923	43	effectors	effector	NNS
cord-005478-5iu38pr6	923	44	(	(	-LRB-
cord-005478-5iu38pr6	923	45	n=4	n=4	NNS
cord-005478-5iu38pr6	923	46	)	)	-RRB-
cord-005478-5iu38pr6	923	47	from	from	IN
cord-005478-5iu38pr6	923	48	healthy	healthy	JJ
cord-005478-5iu38pr6	923	49	donors	donor	NNS
cord-005478-5iu38pr6	923	50	(	(	-LRB-
cord-005478-5iu38pr6	923	51	NK	nk	NN
cord-005478-5iu38pr6	923	52	-	-	HYPH
cord-005478-5iu38pr6	923	53	cells	cell	NNS
cord-005478-5iu38pr6	923	54	:	:	:
cord-005478-5iu38pr6	923	55	75	75	CD
cord-005478-5iu38pr6	923	56	%	%	NN
cord-005478-5iu38pr6	923	57	vs	vs	IN
cord-005478-5iu38pr6	923	58	12	12	CD
cord-005478-5iu38pr6	923	59	%	%	NN
cord-005478-5iu38pr6	923	60	;	;	:
cord-005478-5iu38pr6	923	61	γδ	γδ	CC
cord-005478-5iu38pr6	923	62	Tcells	Tcells	NNP
cord-005478-5iu38pr6	923	63	:	:	:
cord-005478-5iu38pr6	923	64	44	44	CD
cord-005478-5iu38pr6	923	65	%	%	NN
cord-005478-5iu38pr6	923	66	vs	vs	IN
cord-005478-5iu38pr6	923	67	2	2	CD
cord-005478-5iu38pr6	923	68	%	%	NN
cord-005478-5iu38pr6	923	69	)	)	-RRB-
cord-005478-5iu38pr6	923	70	.	.	.
cord-005478-5iu38pr6	924	1	A	a	DT
cord-005478-5iu38pr6	924	2	median	median	JJ
cord-005478-5iu38pr6	924	3	number	number	NN
cord-005478-5iu38pr6	924	4	of	of	IN
cord-005478-5iu38pr6	924	5	12.4x10	12.4x10	CD
cord-005478-5iu38pr6	924	6	6	6	CD
cord-005478-5iu38pr6	924	7	NK	nk	NN
cord-005478-5iu38pr6	924	8	-	-	HYPH
cord-005478-5iu38pr6	924	9	cells	cell	NNS
cord-005478-5iu38pr6	924	10	and	and	CC
cord-005478-5iu38pr6	924	11	1.66x10	1.66x10	CD
cord-005478-5iu38pr6	924	12	6	6	CD
cord-005478-5iu38pr6	924	13	γδ	γδ	NN
cord-005478-5iu38pr6	924	14	T	t	NN
cord-005478-5iu38pr6	924	15	-	-	HYPH
cord-005478-5iu38pr6	924	16	cells	cell	NNS
cord-005478-5iu38pr6	924	17	and	and	CC
cord-005478-5iu38pr6	924	18	1.08x10	1.08x10	CD
cord-005478-5iu38pr6	924	19	3	3	CD
cord-005478-5iu38pr6	924	20	residual	residual	NN
cord-005478-5iu38pr6	924	21	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	924	22	cells/	cells/	CD
cord-005478-5iu38pr6	924	23	kg	kg	NNS
cord-005478-5iu38pr6	924	24	were	be	VBD
cord-005478-5iu38pr6	924	25	infused	infuse	VBN
cord-005478-5iu38pr6	924	26	.	.	.
cord-005478-5iu38pr6	925	1	Four	four	CD
cord-005478-5iu38pr6	925	2	patients	patient	NNS
cord-005478-5iu38pr6	925	3	had	have	VBD
cord-005478-5iu38pr6	925	4	received	receive	VBN
cord-005478-5iu38pr6	925	5	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	925	6	mAbs	mAbs	NNP
cord-005478-5iu38pr6	925	7	(	(	-LRB-
cord-005478-5iu38pr6	925	8	anti	anti	JJ
cord-005478-5iu38pr6	925	9	-	-	JJ
cord-005478-5iu38pr6	925	10	GD2	gd2	JJ
cord-005478-5iu38pr6	925	11	,	,	,
cord-005478-5iu38pr6	925	12	anti	anti	JJ
cord-005478-5iu38pr6	925	13	-	-	JJ
cord-005478-5iu38pr6	925	14	CD19	cd19	JJ
cord-005478-5iu38pr6	925	15	or	or	CC
cord-005478-5iu38pr6	925	16	anti	anti	JJ
cord-005478-5iu38pr6	925	17	-	-	JJ
cord-005478-5iu38pr6	925	18	CD38	CD38	NNP
cord-005478-5iu38pr6	925	19	)	)	-RRB-
cord-005478-5iu38pr6	925	20	within	within	IN
cord-005478-5iu38pr6	925	21	48	48	CD
cord-005478-5iu38pr6	925	22	hours	hour	NNS
cord-005478-5iu38pr6	925	23	after	after	IN
cord-005478-5iu38pr6	925	24	cell	cell	NN
cord-005478-5iu38pr6	925	25	infusion	infusion	NN
cord-005478-5iu38pr6	925	26	to	to	TO
cord-005478-5iu38pr6	925	27	induce	induce	VB
cord-005478-5iu38pr6	925	28	ADCC	ADCC	NNP
cord-005478-5iu38pr6	925	29	.	.	.
cord-005478-5iu38pr6	926	1	Side	side	JJ
cord-005478-5iu38pr6	926	2	effects	effect	NNS
cord-005478-5iu38pr6	926	3	were	be	VBD
cord-005478-5iu38pr6	926	4	treatable	treatable	JJ
cord-005478-5iu38pr6	926	5	cytokine	cytokine	NN
cord-005478-5iu38pr6	926	6	release	release	NN
cord-005478-5iu38pr6	926	7	syndrome	syndrome	NN
cord-005478-5iu38pr6	926	8	in	in	IN
cord-005478-5iu38pr6	926	9	3	3	CD
cord-005478-5iu38pr6	926	10	patients	patient	NNS
cord-005478-5iu38pr6	926	11	;	;	:
cord-005478-5iu38pr6	926	12	no	no	DT
cord-005478-5iu38pr6	926	13	GvHD	gvhd	NN
cord-005478-5iu38pr6	926	14	occurred	occur	VBD
cord-005478-5iu38pr6	926	15	.	.	.
cord-005478-5iu38pr6	927	1	Infused	infuse	VBN
cord-005478-5iu38pr6	927	2	cells	cell	NNS
cord-005478-5iu38pr6	927	3	could	could	MD
cord-005478-5iu38pr6	927	4	be	be	VB
cord-005478-5iu38pr6	927	5	tracked	track	VBN
cord-005478-5iu38pr6	927	6	by	by	IN
cord-005478-5iu38pr6	927	7	CD69	CD69	NNP
cord-005478-5iu38pr6	927	8	expression	expression	NN
cord-005478-5iu38pr6	927	9	for	for	IN
cord-005478-5iu38pr6	927	10	up	up	IN
cord-005478-5iu38pr6	927	11	to	to	TO
cord-005478-5iu38pr6	927	12	26	26	CD
cord-005478-5iu38pr6	927	13	days	day	NNS
cord-005478-5iu38pr6	927	14	in	in	IN
cord-005478-5iu38pr6	927	15	peripheral	peripheral	JJ
cord-005478-5iu38pr6	927	16	blood	blood	NN
cord-005478-5iu38pr6	927	17	.	.	.
cord-005478-5iu38pr6	928	1	Outcome	outcome	NN
cord-005478-5iu38pr6	928	2	:	:	:
cord-005478-5iu38pr6	928	3	2	2	CD
cord-005478-5iu38pr6	928	4	patients	patient	NNS
cord-005478-5iu38pr6	928	5	with	with	IN
cord-005478-5iu38pr6	928	6	T	T	NNP
cord-005478-5iu38pr6	928	7	-	-	HYPH
cord-005478-5iu38pr6	928	8	ALL	all	DT
cord-005478-5iu38pr6	928	9	and	and	CC
cord-005478-5iu38pr6	928	10	neuroblastoma	neuroblastoma	NN
cord-005478-5iu38pr6	928	11	responded	respond	VBD
cord-005478-5iu38pr6	928	12	and	and	CC
cord-005478-5iu38pr6	928	13	achieved	achieve	VBD
cord-005478-5iu38pr6	928	14	another	another	DT
cord-005478-5iu38pr6	928	15	CR	cr	NN
cord-005478-5iu38pr6	929	1	,	,	,
cord-005478-5iu38pr6	929	2	2	2	CD
cord-005478-5iu38pr6	929	3	patients	patient	NNS
cord-005478-5iu38pr6	929	4	maintained	maintain	VBD
cord-005478-5iu38pr6	929	5	their	-PRON-	PRP$
cord-005478-5iu38pr6	929	6	previous	previous	JJ
cord-005478-5iu38pr6	929	7	CR	cr	NN
cord-005478-5iu38pr6	929	8	for	for	IN
cord-005478-5iu38pr6	929	9	up	up	IN
cord-005478-5iu38pr6	929	10	to	to	IN
cord-005478-5iu38pr6	929	11	now	now	RB
cord-005478-5iu38pr6	929	12	55/222	55/222	CD
cord-005478-5iu38pr6	929	13	days	day	NNS
cord-005478-5iu38pr6	929	14	;	;	:
cord-005478-5iu38pr6	929	15	3	3	CD
cord-005478-5iu38pr6	929	16	patients	patient	NNS
cord-005478-5iu38pr6	929	17	progressed	progress	VBD
cord-005478-5iu38pr6	929	18	/	/	SYM
cord-005478-5iu38pr6	929	19	relapsed	relapse	VBD
cord-005478-5iu38pr6	929	20	after	after	IN
cord-005478-5iu38pr6	929	21	26/69/89	26/69/89	CD
cord-005478-5iu38pr6	929	22	days	day	NNS
cord-005478-5iu38pr6	929	23	.	.	.
cord-005478-5iu38pr6	930	1	Additional	additional	JJ
cord-005478-5iu38pr6	930	2	therapies	therapy	NNS
cord-005478-5iu38pr6	930	3	were	be	VBD
cord-005478-5iu38pr6	930	4	applied	apply	VBN
cord-005478-5iu38pr6	930	5	in	in	IN
cord-005478-5iu38pr6	930	6	4/7	4/7	CD
cord-005478-5iu38pr6	930	7	patients	patient	NNS
cord-005478-5iu38pr6	930	8	.	.	.
cord-005478-5iu38pr6	931	1	4	4	CD
cord-005478-5iu38pr6	931	2	patients	patient	NNS
cord-005478-5iu38pr6	931	3	are	be	VBP
cord-005478-5iu38pr6	931	4	alive	alive	JJ
cord-005478-5iu38pr6	931	5	(	(	-LRB-
cord-005478-5iu38pr6	931	6	median	median	JJ
cord-005478-5iu38pr6	931	7	follow	follow	VB
cord-005478-5iu38pr6	931	8	up	up	RB
cord-005478-5iu38pr6	931	9	:	:	:
cord-005478-5iu38pr6	931	10	248	248	CD
cord-005478-5iu38pr6	931	11	days	day	NNS
cord-005478-5iu38pr6	931	12	after	after	IN
cord-005478-5iu38pr6	931	13	infusion	infusion	NN
cord-005478-5iu38pr6	931	14	)	)	-RRB-
cord-005478-5iu38pr6	931	15	,	,	,
cord-005478-5iu38pr6	931	16	2/4	2/4	CD
cord-005478-5iu38pr6	931	17	are	be	VBP
cord-005478-5iu38pr6	931	18	disease	disease	NN
cord-005478-5iu38pr6	931	19	free	free	JJ
cord-005478-5iu38pr6	931	20	.	.	.
cord-005478-5iu38pr6	932	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	932	2	:	:	:
cord-005478-5iu38pr6	933	1	Infusion	infusion	NN
cord-005478-5iu38pr6	933	2	of	of	IN
cord-005478-5iu38pr6	933	3	a	a	DT
cord-005478-5iu38pr6	933	4	combination	combination	NN
cord-005478-5iu38pr6	933	5	of	of	IN
cord-005478-5iu38pr6	933	6	NK/	NK/	NNP
cord-005478-5iu38pr6	933	7	γδ	γδ	IN
cord-005478-5iu38pr6	933	8	Tcells	Tcells	NNP
cord-005478-5iu38pr6	933	9	can	can	MD
cord-005478-5iu38pr6	933	10	increase	increase	VB
cord-005478-5iu38pr6	933	11	anti	anti	JJ
cord-005478-5iu38pr6	933	12	-	-	JJ
cord-005478-5iu38pr6	933	13	tumor	tumor	JJ
cord-005478-5iu38pr6	933	14	effects	effect	NNS
cord-005478-5iu38pr6	933	15	and	and	CC
cord-005478-5iu38pr6	933	16	ADCC	ADCC	NNP
cord-005478-5iu38pr6	933	17	with	with	IN
cord-005478-5iu38pr6	933	18	appropriate	appropriate	JJ
cord-005478-5iu38pr6	933	19	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	933	20	mAbs	mabs	NN
cord-005478-5iu38pr6	933	21	without	without	IN
cord-005478-5iu38pr6	933	22	inducing	induce	VBG
cord-005478-5iu38pr6	933	23	GvHD	GvHD	NNP
cord-005478-5iu38pr6	933	24	even	even	RB
cord-005478-5iu38pr6	933	25	after	after	IN
cord-005478-5iu38pr6	933	26	mismatched	mismatch	VBN
cord-005478-5iu38pr6	933	27	SCT	SCT	NNP
cord-005478-5iu38pr6	933	28	.	.	.
cord-005478-5iu38pr6	934	1	Further	further	JJ
cord-005478-5iu38pr6	934	2	investigations	investigation	NNS
cord-005478-5iu38pr6	934	3	are	be	VBP
cord-005478-5iu38pr6	934	4	needed	need	VBN
cord-005478-5iu38pr6	934	5	to	to	TO
cord-005478-5iu38pr6	934	6	evaluate	evaluate	VB
cord-005478-5iu38pr6	934	7	the	the	DT
cord-005478-5iu38pr6	934	8	role	role	NN
cord-005478-5iu38pr6	934	9	of	of	IN
cord-005478-5iu38pr6	934	10	this	this	DT
cord-005478-5iu38pr6	934	11	cellular	cellular	JJ
cord-005478-5iu38pr6	934	12	therapy	therapy	NN
cord-005478-5iu38pr6	934	13	.	.	.
cord-005478-5iu38pr6	935	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	935	2	:	:	:
cord-005478-5iu38pr6	935	3	Nothing	nothing	NN
cord-005478-5iu38pr6	935	4	to	to	TO
cord-005478-5iu38pr6	935	5	declare	declare	VB
cord-005478-5iu38pr6	935	6	O051	O051	NNS
cord-005478-5iu38pr6	935	7	Abstract	Abstract	NNP
cord-005478-5iu38pr6	935	8	already	already	RB
cord-005478-5iu38pr6	935	9	published	publish	VBN
cord-005478-5iu38pr6	935	10	.	.	.
cord-005478-5iu38pr6	936	1	Identifying	identify	VBG
cord-005478-5iu38pr6	936	2	chimeric	chimeric	JJ
cord-005478-5iu38pr6	936	3	antigen	antigen	NN
cord-005478-5iu38pr6	936	4	receptor	receptor	NN
cord-005478-5iu38pr6	936	5	(	(	-LRB-
cord-005478-5iu38pr6	936	6	CAR	car	NN
cord-005478-5iu38pr6	936	7	)	)	-RRB-
cord-005478-5iu38pr6	936	8	centers	center	NNS
cord-005478-5iu38pr6	936	9	and	and	CC
cord-005478-5iu38pr6	936	10	CAR	car	NN
cord-005478-5iu38pr6	936	11	activity	activity	NN
cord-005478-5iu38pr6	936	12	in	in	IN
cord-005478-5iu38pr6	936	13	Europe	Europe	NNP
cord-005478-5iu38pr6	936	14	,	,	,
cord-005478-5iu38pr6	936	15	a	a	DT
cord-005478-5iu38pr6	936	16	survey	survey	NN
cord-005478-5iu38pr6	936	17	on	on	IN
cord-005478-5iu38pr6	936	18	behalf	behalf	NN
cord-005478-5iu38pr6	936	19	of	of	IN
cord-005478-5iu38pr6	936	20	the	the	DT
cord-005478-5iu38pr6	936	21	cellular	cellular	JJ
cord-005478-5iu38pr6	936	22	therapy	therapy	NNP
cord-005478-5iu38pr6	936	23	&	&	CC
cord-005478-5iu38pr6	936	24	immunobiology	immunobiology	NNP
cord-005478-5iu38pr6	936	25	working	working	NNP
cord-005478-5iu38pr6	936	26	-	-	HYPH
cord-005478-5iu38pr6	936	27	party	party	NN
cord-005478-5iu38pr6	936	28	(	(	-LRB-
cord-005478-5iu38pr6	936	29	CTIWP	CTIWP	NNP
cord-005478-5iu38pr6	936	30	)	)	-RRB-
cord-005478-5iu38pr6	936	31	of	of	IN
cord-005478-5iu38pr6	936	32	EBMT	EBMT	NNP
cord-005478-5iu38pr6	936	33	Background	Background	NNP
cord-005478-5iu38pr6	936	34	:	:	:
cord-005478-5iu38pr6	937	1	The	the	DT
cord-005478-5iu38pr6	937	2	use	use	NN
cord-005478-5iu38pr6	937	3	of	of	IN
cord-005478-5iu38pr6	937	4	chimeric	chimeric	JJ
cord-005478-5iu38pr6	937	5	antigen	antigen	NN
cord-005478-5iu38pr6	937	6	receptor	receptor	NN
cord-005478-5iu38pr6	937	7	(	(	-LRB-
cord-005478-5iu38pr6	937	8	CAR	car	NN
cord-005478-5iu38pr6	937	9	)	)	-RRB-
cord-005478-5iu38pr6	937	10	T	t	NN
cord-005478-5iu38pr6	937	11	cells	cell	NNS
cord-005478-5iu38pr6	937	12	has	have	VBZ
cord-005478-5iu38pr6	937	13	shown	show	VBN
cord-005478-5iu38pr6	937	14	outstanding	outstanding	JJ
cord-005478-5iu38pr6	937	15	efficacy	efficacy	NN
cord-005478-5iu38pr6	937	16	in	in	IN
cord-005478-5iu38pr6	937	17	patients	patient	NNS
cord-005478-5iu38pr6	937	18	with	with	IN
cord-005478-5iu38pr6	937	19	relapsed	relapse	VBN
cord-005478-5iu38pr6	937	20	/	/	SYM
cord-005478-5iu38pr6	937	21	refractory	refractory	JJ
cord-005478-5iu38pr6	937	22	B	b	NN
cord-005478-5iu38pr6	937	23	-	-	HYPH
cord-005478-5iu38pr6	937	24	cell	cell	NN
cord-005478-5iu38pr6	937	25	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	937	26	malignancies	malignancy	NNS
cord-005478-5iu38pr6	937	27	,	,	,
cord-005478-5iu38pr6	937	28	as	as	IN
cord-005478-5iu38pr6	937	29	reported	report	VBN
cord-005478-5iu38pr6	937	30	by	by	IN
cord-005478-5iu38pr6	937	31	many	many	JJ
cord-005478-5iu38pr6	937	32	groups	group	NNS
cord-005478-5iu38pr6	937	33	in	in	IN
cord-005478-5iu38pr6	937	34	United	United	NNP
cord-005478-5iu38pr6	937	35	States	States	NNP
cord-005478-5iu38pr6	937	36	(	(	-LRB-
cord-005478-5iu38pr6	937	37	US	US	NNP
cord-005478-5iu38pr6	937	38	)	)	-RRB-
cord-005478-5iu38pr6	937	39	and	and	CC
cord-005478-5iu38pr6	937	40	China	China	NNP
cord-005478-5iu38pr6	937	41	.	.	.
cord-005478-5iu38pr6	938	1	CAR	car	NN
cord-005478-5iu38pr6	938	2	-	-	HYPH
cord-005478-5iu38pr6	938	3	T	t	NN
cord-005478-5iu38pr6	938	4	cell	cell	NN
cord-005478-5iu38pr6	938	5	based	base	VBN
cord-005478-5iu38pr6	938	6	activity	activity	NN
cord-005478-5iu38pr6	938	7	in	in	IN
cord-005478-5iu38pr6	938	8	Europe	Europe	NNP
cord-005478-5iu38pr6	938	9	is	be	VBZ
cord-005478-5iu38pr6	938	10	still	still	RB
cord-005478-5iu38pr6	938	11	at	at	IN
cord-005478-5iu38pr6	938	12	early	early	JJ
cord-005478-5iu38pr6	938	13	stages	stage	NNS
cord-005478-5iu38pr6	938	14	.	.	.
cord-005478-5iu38pr6	939	1	Few	few	JJ
cord-005478-5iu38pr6	939	2	European	european	JJ
cord-005478-5iu38pr6	939	3	academic	academic	JJ
cord-005478-5iu38pr6	939	4	and	and	CC
cord-005478-5iu38pr6	939	5	pharma	pharma	NNS
cord-005478-5iu38pr6	939	6	-	-	HYPH
cord-005478-5iu38pr6	939	7	sponsored	sponsor	VBN
cord-005478-5iu38pr6	939	8	clinical	clinical	JJ
cord-005478-5iu38pr6	939	9	trials	trial	NNS
cord-005478-5iu38pr6	939	10	are	be	VBP
cord-005478-5iu38pr6	939	11	currently	currently	RB
cord-005478-5iu38pr6	939	12	opened	open	VBN
cord-005478-5iu38pr6	939	13	to	to	IN
cord-005478-5iu38pr6	939	14	inclusions	inclusion	NNS
cord-005478-5iu38pr6	939	15	,	,	,
cord-005478-5iu38pr6	939	16	and	and	CC
cord-005478-5iu38pr6	939	17	access	access	NN
cord-005478-5iu38pr6	939	18	to	to	IN
cord-005478-5iu38pr6	939	19	the	the	DT
cord-005478-5iu38pr6	939	20	two	two	CD
cord-005478-5iu38pr6	939	21	EMA	EMA	NNP
cord-005478-5iu38pr6	939	22	-	-	HYPH
cord-005478-5iu38pr6	939	23	approved	approve	VBN
cord-005478-5iu38pr6	939	24	autologous	autologous	JJ
cord-005478-5iu38pr6	939	25	CAR	car	NN
cord-005478-5iu38pr6	939	26	-	-	HYPH
cord-005478-5iu38pr6	939	27	T	T	NNP
cord-005478-5iu38pr6	939	28	products	product	NNS
cord-005478-5iu38pr6	939	29	remains	remain	VBZ
cord-005478-5iu38pr6	939	30	limited	limited	JJ
cord-005478-5iu38pr6	939	31	for	for	IN
cord-005478-5iu38pr6	939	32	the	the	DT
cord-005478-5iu38pr6	939	33	majority	majority	NN
cord-005478-5iu38pr6	939	34	of	of	IN
cord-005478-5iu38pr6	939	35	European	european	JJ
cord-005478-5iu38pr6	939	36	centers	center	NNS
cord-005478-5iu38pr6	939	37	,	,	,
cord-005478-5iu38pr6	939	38	since	since	IN
cord-005478-5iu38pr6	939	39	they	-PRON-	PRP
cord-005478-5iu38pr6	939	40	must	must	MD
cord-005478-5iu38pr6	939	41	undergo	undergo	VB
cord-005478-5iu38pr6	939	42	a	a	DT
cord-005478-5iu38pr6	939	43	tedious	tedious	JJ
cord-005478-5iu38pr6	939	44	and	and	CC
cord-005478-5iu38pr6	939	45	non	non	JJ
cord-005478-5iu38pr6	939	46	-	-	JJ
cord-005478-5iu38pr6	939	47	harmonized	harmonized	JJ
cord-005478-5iu38pr6	939	48	qualification	qualification	NN
cord-005478-5iu38pr6	939	49	process	process	NN
cord-005478-5iu38pr6	939	50	imposed	impose	VBN
cord-005478-5iu38pr6	939	51	by	by	IN
cord-005478-5iu38pr6	939	52	the	the	DT
cord-005478-5iu38pr6	939	53	manufacturer	manufacturer	NN
cord-005478-5iu38pr6	939	54	as	as	IN
cord-005478-5iu38pr6	939	55	part	part	NN
cord-005478-5iu38pr6	939	56	of	of	IN
cord-005478-5iu38pr6	939	57	the	the	DT
cord-005478-5iu38pr6	939	58	drug	drug	NN
cord-005478-5iu38pr6	939	59	label	label	NN
cord-005478-5iu38pr6	939	60	.	.	.
cord-005478-5iu38pr6	940	1	Improved	improve	VBN
cord-005478-5iu38pr6	940	2	awareness	awareness	NN
cord-005478-5iu38pr6	940	3	of	of	IN
cord-005478-5iu38pr6	940	4	CAR	car	NN
cord-005478-5iu38pr6	940	5	-	-	HYPH
cord-005478-5iu38pr6	940	6	T	T	NNP
cord-005478-5iu38pr6	940	7	centers	center	NNS
cord-005478-5iu38pr6	940	8	and	and	CC
cord-005478-5iu38pr6	940	9	ongoing	ongoing	JJ
cord-005478-5iu38pr6	940	10	CAR	car	NN
cord-005478-5iu38pr6	940	11	-	-	HYPH
cord-005478-5iu38pr6	940	12	T	T	NNP
cord-005478-5iu38pr6	940	13	activities	activity	NNS
cord-005478-5iu38pr6	940	14	in	in	IN
cord-005478-5iu38pr6	940	15	Europe	Europe	NNP
cord-005478-5iu38pr6	940	16	are	be	VBP
cord-005478-5iu38pr6	940	17	essential	essential	JJ
cord-005478-5iu38pr6	940	18	to	to	TO
cord-005478-5iu38pr6	940	19	promote	promote	VB
cord-005478-5iu38pr6	940	20	European	european	JJ
cord-005478-5iu38pr6	940	21	networking	networking	NN
cord-005478-5iu38pr6	940	22	activities	activity	NNS
cord-005478-5iu38pr6	940	23	,	,	,
cord-005478-5iu38pr6	940	24	improve	improve	VB
cord-005478-5iu38pr6	940	25	competitiveness	competitiveness	NN
cord-005478-5iu38pr6	940	26	of	of	IN
cord-005478-5iu38pr6	940	27	EU	EU	NNP
cord-005478-5iu38pr6	940	28	medical	medical	JJ
cord-005478-5iu38pr6	940	29	centers	center	NNS
cord-005478-5iu38pr6	940	30	,	,	,
cord-005478-5iu38pr6	940	31	and	and	CC
cord-005478-5iu38pr6	940	32	develop	develop	VB
cord-005478-5iu38pr6	940	33	clinical	clinical	JJ
cord-005478-5iu38pr6	940	34	trials	trial	NNS
cord-005478-5iu38pr6	940	35	,	,	,
cord-005478-5iu38pr6	940	36	education	education	NN
cord-005478-5iu38pr6	940	37	,	,	,
cord-005478-5iu38pr6	940	38	accreditation	accreditation	NN
cord-005478-5iu38pr6	940	39	,	,	,
cord-005478-5iu38pr6	940	40	and	and	CC
cord-005478-5iu38pr6	940	41	registration	registration	NN
cord-005478-5iu38pr6	940	42	/	/	SYM
cord-005478-5iu38pr6	940	43	long	long	JJ
cord-005478-5iu38pr6	940	44	-	-	HYPH
cord-005478-5iu38pr6	940	45	term	term	NN
cord-005478-5iu38pr6	940	46	follow	follow	NN
cord-005478-5iu38pr6	940	47	-	-	HYPH
cord-005478-5iu38pr6	940	48	up	up	NN
cord-005478-5iu38pr6	940	49	,	,	,
cord-005478-5iu38pr6	940	50	thus	thus	RB
cord-005478-5iu38pr6	940	51	fulfilling	fulfil	VBG
cord-005478-5iu38pr6	940	52	the	the	DT
cord-005478-5iu38pr6	940	53	needs	need	NNS
cord-005478-5iu38pr6	940	54	of	of	IN
cord-005478-5iu38pr6	940	55	stakeholders	stakeholder	NNS
cord-005478-5iu38pr6	940	56	.	.	.
cord-005478-5iu38pr6	941	1	Methods	method	NNS
cord-005478-5iu38pr6	941	2	:	:	:
cord-005478-5iu38pr6	942	1	A	a	DT
cord-005478-5iu38pr6	942	2	survey	survey	NN
cord-005478-5iu38pr6	942	3	questionnaire	questionnaire	NN
cord-005478-5iu38pr6	942	4	was	be	VBD
cord-005478-5iu38pr6	942	5	prepared	prepare	VBN
cord-005478-5iu38pr6	942	6	by	by	IN
cord-005478-5iu38pr6	942	7	the	the	DT
cord-005478-5iu38pr6	942	8	committee	committee	NN
cord-005478-5iu38pr6	942	9	members	member	NNS
cord-005478-5iu38pr6	942	10	of	of	IN
cord-005478-5iu38pr6	942	11	the	the	DT
cord-005478-5iu38pr6	942	12	EBMT	EBMT	NNP
cord-005478-5iu38pr6	942	13	Cellular	Cellular	NNP
cord-005478-5iu38pr6	942	14	-	-	HYPH
cord-005478-5iu38pr6	942	15	Therapy-&-Immunobiology	Therapy-&-Immunobiology	NNP
cord-005478-5iu38pr6	942	16	-	-	HYPH
cord-005478-5iu38pr6	942	17	Working	Working	NNP
cord-005478-5iu38pr6	942	18	-	-	HYPH
cord-005478-5iu38pr6	942	19	Party	Party	NNP
cord-005478-5iu38pr6	942	20	(	(	-LRB-
cord-005478-5iu38pr6	942	21	CTIWP	CTIWP	NNP
cord-005478-5iu38pr6	942	22	)	)	-RRB-
cord-005478-5iu38pr6	942	23	.	.	.
cord-005478-5iu38pr6	943	1	Questions	question	NNS
cord-005478-5iu38pr6	943	2	were	be	VBD
cord-005478-5iu38pr6	943	3	formulated	formulate	VBN
cord-005478-5iu38pr6	943	4	to	to	TO
cord-005478-5iu38pr6	943	5	identify	identify	VB
cord-005478-5iu38pr6	943	6	CAR	car	NN
cord-005478-5iu38pr6	943	7	-	-	HYPH
cord-005478-5iu38pr6	943	8	T	T	NNP
cord-005478-5iu38pr6	943	9	centers	center	NNS
cord-005478-5iu38pr6	943	10	and	and	CC
cord-005478-5iu38pr6	943	11	CAR	CAR	NNP
cord-005478-5iu38pr6	943	12	-	-	HYPH
cord-005478-5iu38pr6	943	13	T	t	NN
cord-005478-5iu38pr6	943	14	based	base	VBN
cord-005478-5iu38pr6	943	15	activity	activity	NN
cord-005478-5iu38pr6	943	16	in	in	IN
cord-005478-5iu38pr6	943	17	Europe	Europe	NNP
cord-005478-5iu38pr6	943	18	,	,	,
cord-005478-5iu38pr6	943	19	and	and	CC
cord-005478-5iu38pr6	943	20	to	to	TO
cord-005478-5iu38pr6	943	21	know	know	VB
cord-005478-5iu38pr6	943	22	the	the	DT
cord-005478-5iu38pr6	943	23	characteristics	characteristic	NNS
cord-005478-5iu38pr6	943	24	of	of	IN
cord-005478-5iu38pr6	943	25	centers	center	NNS
cord-005478-5iu38pr6	943	26	and	and	CC
cord-005478-5iu38pr6	943	27	the	the	DT
cord-005478-5iu38pr6	943	28	organization	organization	NN
cord-005478-5iu38pr6	943	29	for	for	IN
cord-005478-5iu38pr6	943	30	implementing	implement	VBG
cord-005478-5iu38pr6	943	31	a	a	DT
cord-005478-5iu38pr6	943	32	clinical	clinical	JJ
cord-005478-5iu38pr6	943	33	CAR	car	NN
cord-005478-5iu38pr6	943	34	-	-	HYPH
cord-005478-5iu38pr6	943	35	T	T	NNP
cord-005478-5iu38pr6	943	36	program	program	NN
cord-005478-5iu38pr6	943	37	.	.	.
cord-005478-5iu38pr6	944	1	Using	use	VBG
cord-005478-5iu38pr6	944	2	monkey	monkey	NN
cord-005478-5iu38pr6	944	3	survey	survey	NN
cord-005478-5iu38pr6	944	4	,	,	,
cord-005478-5iu38pr6	944	5	the	the	DT
cord-005478-5iu38pr6	944	6	survey	survey	NN
cord-005478-5iu38pr6	944	7	was	be	VBD
cord-005478-5iu38pr6	944	8	sent	send	VBN
cord-005478-5iu38pr6	944	9	to	to	IN
cord-005478-5iu38pr6	944	10	566	566	CD
cord-005478-5iu38pr6	944	11	EBMT	EBMT	NNP
cord-005478-5iu38pr6	944	12	-	-	HYPH
cord-005478-5iu38pr6	944	13	centers	center	NNS
cord-005478-5iu38pr6	944	14	.	.	.
cord-005478-5iu38pr6	945	1	Results	result	NNS
cord-005478-5iu38pr6	945	2	:	:	:
cord-005478-5iu38pr6	945	3	123	123	CD
cord-005478-5iu38pr6	945	4	centers	center	NNS
cord-005478-5iu38pr6	945	5	replied	reply	VBD
cord-005478-5iu38pr6	945	6	to	to	IN
cord-005478-5iu38pr6	945	7	the	the	DT
cord-005478-5iu38pr6	945	8	survey	survey	NN
cord-005478-5iu38pr6	945	9	.	.	.
cord-005478-5iu38pr6	946	1	340	340	CD
cord-005478-5iu38pr6	946	2	patients	patient	NNS
cord-005478-5iu38pr6	946	3	(	(	-LRB-
cord-005478-5iu38pr6	946	4	ALL	all	DT
cord-005478-5iu38pr6	946	5	45	45	CD
cord-005478-5iu38pr6	946	6	%	%	NN
cord-005478-5iu38pr6	946	7	,	,	,
cord-005478-5iu38pr6	946	8	NHL	NHL	NNP
cord-005478-5iu38pr6	946	9	32	32	CD
cord-005478-5iu38pr6	946	10	%	%	NN
cord-005478-5iu38pr6	946	11	,	,	,
cord-005478-5iu38pr6	946	12	MM	MM	NNP
cord-005478-5iu38pr6	946	13	10	10	CD
cord-005478-5iu38pr6	946	14	%	%	NN
cord-005478-5iu38pr6	946	15	,	,	,
cord-005478-5iu38pr6	946	16	CLL	CLL	NNP
cord-005478-5iu38pr6	946	17	5	5	CD
cord-005478-5iu38pr6	946	18	%	%	NN
cord-005478-5iu38pr6	946	19	,	,	,
cord-005478-5iu38pr6	946	20	AML	AML	NNP
cord-005478-5iu38pr6	946	21	1.6	1.6	CD
cord-005478-5iu38pr6	946	22	%	%	NN
cord-005478-5iu38pr6	946	23	,	,	,
cord-005478-5iu38pr6	946	24	Solid	solid	JJ
cord-005478-5iu38pr6	946	25	tumors	tumor	NNS
cord-005478-5iu38pr6	946	26	7	7	CD
cord-005478-5iu38pr6	946	27	%	%	NN
cord-005478-5iu38pr6	946	28	)	)	-RRB-
cord-005478-5iu38pr6	946	29	have	have	VBP
cord-005478-5iu38pr6	946	30	been	be	VBN
cord-005478-5iu38pr6	946	31	treated	treat	VBN
cord-005478-5iu38pr6	946	32	so	so	RB
cord-005478-5iu38pr6	946	33	far	far	RB
cord-005478-5iu38pr6	946	34	in	in	IN
cord-005478-5iu38pr6	946	35	31	31	CD
cord-005478-5iu38pr6	946	36	EBMT	EBMT	NNP
cord-005478-5iu38pr6	946	37	centers	center	NNS
cord-005478-5iu38pr6	946	38	from	from	IN
cord-005478-5iu38pr6	946	39	12	12	CD
cord-005478-5iu38pr6	946	40	countries	country	NNS
cord-005478-5iu38pr6	946	41	.	.	.
cord-005478-5iu38pr6	947	1	Most	Most	JJS
cord-005478-5iu38pr6	947	2	of	of	IN
cord-005478-5iu38pr6	947	3	these	these	DT
cord-005478-5iu38pr6	947	4	centers	center	NNS
cord-005478-5iu38pr6	947	5	are	be	VBP
cord-005478-5iu38pr6	947	6	JACIE	JACIE	NNP
cord-005478-5iu38pr6	947	7	-	-	HYPH
cord-005478-5iu38pr6	947	8	accredited	accredit	VBN
cord-005478-5iu38pr6	947	9	(	(	-LRB-
cord-005478-5iu38pr6	947	10	90	90	CD
cord-005478-5iu38pr6	947	11	%	%	NN
cord-005478-5iu38pr6	947	12	for	for	IN
cord-005478-5iu38pr6	947	13	clinical	clinical	JJ
cord-005478-5iu38pr6	947	14	activities	activity	NNS
cord-005478-5iu38pr6	947	15	;	;	:
cord-005478-5iu38pr6	947	16	93	93	CD
cord-005478-5iu38pr6	947	17	%	%	NN
cord-005478-5iu38pr6	947	18	for	for	IN
cord-005478-5iu38pr6	947	19	cell	cell	NN
cord-005478-5iu38pr6	947	20	collection	collection	NN
cord-005478-5iu38pr6	947	21	activities	activity	NNS
cord-005478-5iu38pr6	947	22	)	)	-RRB-
cord-005478-5iu38pr6	947	23	.	.	.
cord-005478-5iu38pr6	948	1	54	54	CD
cord-005478-5iu38pr6	948	2	additional	additional	JJ
cord-005478-5iu38pr6	948	3	centers	center	NNS
cord-005478-5iu38pr6	948	4	reported	report	VBD
cord-005478-5iu38pr6	948	5	plans	plan	NNS
cord-005478-5iu38pr6	948	6	to	to	TO
cord-005478-5iu38pr6	948	7	start	start	VB
cord-005478-5iu38pr6	948	8	CAR	car	NN
cord-005478-5iu38pr6	948	9	-	-	HYPH
cord-005478-5iu38pr6	948	10	T	T	NNP
cord-005478-5iu38pr6	948	11	cell	cell	NN
cord-005478-5iu38pr6	948	12	administration	administration	NN
cord-005478-5iu38pr6	948	13	within	within	IN
cord-005478-5iu38pr6	948	14	the	the	DT
cord-005478-5iu38pr6	948	15	following	following	JJ
cord-005478-5iu38pr6	948	16	6-months	6-months	CD
cord-005478-5iu38pr6	948	17	.	.	.
cord-005478-5iu38pr6	949	1	Most	Most	JJS
cord-005478-5iu38pr6	949	2	patients	patient	NNS
cord-005478-5iu38pr6	949	3	were	be	VBD
cord-005478-5iu38pr6	949	4	treated	treat	VBN
cord-005478-5iu38pr6	949	5	in	in	IN
cord-005478-5iu38pr6	949	6	the	the	DT
cord-005478-5iu38pr6	949	7	setting	setting	NN
cord-005478-5iu38pr6	949	8	of	of	IN
cord-005478-5iu38pr6	949	9	academic	academic	JJ
cord-005478-5iu38pr6	949	10	clinical	clinical	JJ
cord-005478-5iu38pr6	949	11	trials	trial	NNS
cord-005478-5iu38pr6	949	12	(	(	-LRB-
cord-005478-5iu38pr6	949	13	58.6%l	58.6%l	CD
cord-005478-5iu38pr6	949	14	)	)	-RRB-
cord-005478-5iu38pr6	949	15	or	or	CC
cord-005478-5iu38pr6	949	16	pharma	pharma	NNS
cord-005478-5iu38pr6	949	17	sponsored	sponsor	VBN
cord-005478-5iu38pr6	949	18	trials	trial	NNS
cord-005478-5iu38pr6	949	19	(	(	-LRB-
cord-005478-5iu38pr6	949	20	36%l	36%l	CD
cord-005478-5iu38pr6	949	21	)	)	-RRB-
cord-005478-5iu38pr6	949	22	.	.	.
cord-005478-5iu38pr6	950	1	Few	few	JJ
cord-005478-5iu38pr6	950	2	patients	patient	NNS
cord-005478-5iu38pr6	950	3	(	(	-LRB-
cord-005478-5iu38pr6	950	4	7	7	CD
cord-005478-5iu38pr6	950	5	%	%	NN
cord-005478-5iu38pr6	950	6	)	)	-RRB-
cord-005478-5iu38pr6	950	7	received	receive	VBD
cord-005478-5iu38pr6	950	8	marketed	market	VBN
cord-005478-5iu38pr6	950	9	CAR	CAR	NNP
cord-005478-5iu38pr6	950	10	-	-	HYPH
cord-005478-5iu38pr6	950	11	T	t	NN
cord-005478-5iu38pr6	950	12	cells	cell	NNS
cord-005478-5iu38pr6	950	13	.	.	.
cord-005478-5iu38pr6	951	1	PCR	PCR	NNP
cord-005478-5iu38pr6	951	2	(	(	-LRB-
cord-005478-5iu38pr6	951	3	36	36	CD
cord-005478-5iu38pr6	951	4	%	%	NN
cord-005478-5iu38pr6	951	5	)	)	-RRB-
cord-005478-5iu38pr6	951	6	and	and	CC
cord-005478-5iu38pr6	951	7	flow	flow	NN
cord-005478-5iu38pr6	951	8	-	-	HYPH
cord-005478-5iu38pr6	951	9	cytometry	cytometry	NN
cord-005478-5iu38pr6	951	10	(	(	-LRB-
cord-005478-5iu38pr6	951	11	60	60	CD
cord-005478-5iu38pr6	951	12	%	%	NN
cord-005478-5iu38pr6	951	13	)	)	-RRB-
cord-005478-5iu38pr6	951	14	were	be	VBD
cord-005478-5iu38pr6	951	15	used	use	VBN
cord-005478-5iu38pr6	951	16	to	to	IN
cord-005478-5iu38pr6	951	17	monitoring	monitor	VBG
cord-005478-5iu38pr6	951	18	the	the	DT
cord-005478-5iu38pr6	951	19	persistence	persistence	NN
cord-005478-5iu38pr6	951	20	of	of	IN
cord-005478-5iu38pr6	951	21	CAR	car	NN
cord-005478-5iu38pr6	951	22	-	-	HYPH
cord-005478-5iu38pr6	951	23	T	t	NN
cord-005478-5iu38pr6	951	24	cells	cell	NNS
cord-005478-5iu38pr6	951	25	after	after	IN
cord-005478-5iu38pr6	951	26	infusion	infusion	NN
cord-005478-5iu38pr6	951	27	.	.	.
cord-005478-5iu38pr6	952	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	952	2	levels	level	NNS
cord-005478-5iu38pr6	952	3	were	be	VBD
cord-005478-5iu38pr6	952	4	measured	measure	VBN
cord-005478-5iu38pr6	952	5	in	in	IN
cord-005478-5iu38pr6	952	6	78	78	CD
cord-005478-5iu38pr6	952	7	%	%	NN
cord-005478-5iu38pr6	952	8	of	of	IN
cord-005478-5iu38pr6	952	9	the	the	DT
cord-005478-5iu38pr6	952	10	cases	case	NNS
cord-005478-5iu38pr6	952	11	,	,	,
cord-005478-5iu38pr6	952	12	and	and	CC
cord-005478-5iu38pr6	952	13	NGS	NGS	NNP
cord-005478-5iu38pr6	952	14	was	be	VBD
cord-005478-5iu38pr6	952	15	performed	perform	VBN
cord-005478-5iu38pr6	952	16	in	in	IN
cord-005478-5iu38pr6	952	17	45	45	CD
cord-005478-5iu38pr6	952	18	%	%	NN
cord-005478-5iu38pr6	952	19	of	of	IN
cord-005478-5iu38pr6	952	20	the	the	DT
cord-005478-5iu38pr6	952	21	centers	center	NNS
cord-005478-5iu38pr6	952	22	.	.	.
cord-005478-5iu38pr6	953	1	Half	half	NN
cord-005478-5iu38pr6	953	2	of	of	IN
cord-005478-5iu38pr6	953	3	the	the	DT
cord-005478-5iu38pr6	953	4	centers	center	NNS
cord-005478-5iu38pr6	953	5	reported	report	VBN
cord-005478-5iu38pr6	953	6	to	to	TO
cord-005478-5iu38pr6	953	7	use	use	VB
cord-005478-5iu38pr6	953	8	"	"	``
cord-005478-5iu38pr6	953	9	point	point	NN
cord-005478-5iu38pr6	953	10	of	of	IN
cord-005478-5iu38pr6	953	11	care	care	NN
cord-005478-5iu38pr6	953	12	"	"	''
cord-005478-5iu38pr6	953	13	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	953	14	.	.	.
cord-005478-5iu38pr6	954	1	Patient	patient	JJ
cord-005478-5iu38pr6	954	2	management	management	NN
cord-005478-5iu38pr6	954	3	was	be	VBD
cord-005478-5iu38pr6	954	4	mainly	mainly	RB
cord-005478-5iu38pr6	954	5	carried	carry	VBN
cord-005478-5iu38pr6	954	6	out	out	RP
cord-005478-5iu38pr6	954	7	by	by	IN
cord-005478-5iu38pr6	954	8	bone	bone	NN
cord-005478-5iu38pr6	954	9	marrow	marrow	NN
cord-005478-5iu38pr6	954	10	transplant	transplant	NN
cord-005478-5iu38pr6	954	11	(	(	-LRB-
cord-005478-5iu38pr6	954	12	BMT	BMT	NNP
cord-005478-5iu38pr6	954	13	)	)	-RRB-
cord-005478-5iu38pr6	954	14	physicians	physician	NNS
cord-005478-5iu38pr6	954	15	(	(	-LRB-
cord-005478-5iu38pr6	954	16	85	85	CD
cord-005478-5iu38pr6	954	17	%	%	NN
cord-005478-5iu38pr6	954	18	)	)	-RRB-
cord-005478-5iu38pr6	954	19	.	.	.
cord-005478-5iu38pr6	955	1	However	however	RB
cord-005478-5iu38pr6	955	2	,	,	,
cord-005478-5iu38pr6	955	3	77	77	CD
cord-005478-5iu38pr6	955	4	%	%	NN
cord-005478-5iu38pr6	955	5	of	of	IN
cord-005478-5iu38pr6	955	6	the	the	DT
cord-005478-5iu38pr6	955	7	centers	center	NNS
cord-005478-5iu38pr6	955	8	reported	report	VBN
cord-005478-5iu38pr6	955	9	to	to	TO
cord-005478-5iu38pr6	955	10	have	have	VB
cord-005478-5iu38pr6	955	11	also	also	RB
cord-005478-5iu38pr6	955	12	implemented	implement	VBN
cord-005478-5iu38pr6	955	13	a	a	DT
cord-005478-5iu38pr6	955	14	"	"	``
cord-005478-5iu38pr6	955	15	CAR	CAR	NNP
cord-005478-5iu38pr6	955	16	-	-	HYPH
cord-005478-5iu38pr6	955	17	T	T	NNP
cord-005478-5iu38pr6	955	18	team	team	NN
cord-005478-5iu38pr6	955	19	"	"	''
cord-005478-5iu38pr6	955	20	,	,	,
cord-005478-5iu38pr6	955	21	as	as	IN
cord-005478-5iu38pr6	955	22	a	a	DT
cord-005478-5iu38pr6	955	23	multidisciplinary	multidisciplinary	JJ
cord-005478-5iu38pr6	955	24	team	team	NN
cord-005478-5iu38pr6	955	25	managed	manage	VBN
cord-005478-5iu38pr6	955	26	by	by	IN
cord-005478-5iu38pr6	955	27	a	a	DT
cord-005478-5iu38pr6	955	28	coordinator	coordinator	NN
cord-005478-5iu38pr6	955	29	,	,	,
cord-005478-5iu38pr6	955	30	with	with	IN
cord-005478-5iu38pr6	955	31	weekly	weekly	JJ
cord-005478-5iu38pr6	955	32	clinical	clinical	JJ
cord-005478-5iu38pr6	955	33	meetings	meeting	NNS
cord-005478-5iu38pr6	955	34	.	.	.
cord-005478-5iu38pr6	956	1	In	in	IN
cord-005478-5iu38pr6	956	2	more	more	JJR
cord-005478-5iu38pr6	956	3	than	than	IN
cord-005478-5iu38pr6	956	4	90	90	CD
cord-005478-5iu38pr6	956	5	%	%	NN
cord-005478-5iu38pr6	956	6	of	of	IN
cord-005478-5iu38pr6	956	7	the	the	DT
cord-005478-5iu38pr6	956	8	centers	center	NNS
cord-005478-5iu38pr6	956	9	,	,	,
cord-005478-5iu38pr6	956	10	there	there	EX
cord-005478-5iu38pr6	956	11	were	be	VBD
cord-005478-5iu38pr6	956	12	specific	specific	JJ
cord-005478-5iu38pr6	956	13	rules	rule	NNS
cord-005478-5iu38pr6	956	14	for	for	IN
cord-005478-5iu38pr6	956	15	transferring	transfer	VBG
cord-005478-5iu38pr6	956	16	patients	patient	NNS
cord-005478-5iu38pr6	956	17	to	to	IN
cord-005478-5iu38pr6	956	18	the	the	DT
cord-005478-5iu38pr6	956	19	intensive	intensive	JJ
cord-005478-5iu38pr6	956	20	-	-	HYPH
cord-005478-5iu38pr6	956	21	care	care	NN
cord-005478-5iu38pr6	956	22	-	-	HYPH
cord-005478-5iu38pr6	956	23	unit	unit	NN
cord-005478-5iu38pr6	956	24	.	.	.
cord-005478-5iu38pr6	957	1	In	in	IN
cord-005478-5iu38pr6	957	2	contrast	contrast	NN
cord-005478-5iu38pr6	957	3	,	,	,
cord-005478-5iu38pr6	957	4	only	only	RB
cord-005478-5iu38pr6	957	5	40	40	CD
cord-005478-5iu38pr6	957	6	%	%	NN
cord-005478-5iu38pr6	957	7	of	of	IN
cord-005478-5iu38pr6	957	8	the	the	DT
cord-005478-5iu38pr6	957	9	centers	center	NNS
cord-005478-5iu38pr6	957	10	had	have	VBD
cord-005478-5iu38pr6	957	11	a	a	DT
cord-005478-5iu38pr6	957	12	nurse	nurse	NN
cord-005478-5iu38pr6	957	13	coordinator	coordinator	NN
cord-005478-5iu38pr6	957	14	for	for	IN
cord-005478-5iu38pr6	957	15	management	management	NN
cord-005478-5iu38pr6	957	16	assistance	assistance	NN
cord-005478-5iu38pr6	957	17	of	of	IN
cord-005478-5iu38pr6	957	18	these	these	DT
cord-005478-5iu38pr6	957	19	patients	patient	NNS
cord-005478-5iu38pr6	957	20	.	.	.
cord-005478-5iu38pr6	958	1	77	77	CD
cord-005478-5iu38pr6	958	2	%	%	NN
cord-005478-5iu38pr6	958	3	of	of	IN
cord-005478-5iu38pr6	958	4	the	the	DT
cord-005478-5iu38pr6	958	5	centers	center	NNS
cord-005478-5iu38pr6	958	6	plan	plan	VBP
cord-005478-5iu38pr6	958	7	to	to	TO
cord-005478-5iu38pr6	958	8	expand	expand	VB
cord-005478-5iu38pr6	958	9	the	the	DT
cord-005478-5iu38pr6	958	10	capacity	capacity	NN
cord-005478-5iu38pr6	958	11	of	of	IN
cord-005478-5iu38pr6	958	12	their	-PRON-	PRP$
cord-005478-5iu38pr6	958	13	own	own	JJ
cord-005478-5iu38pr6	958	14	department	department	NN
cord-005478-5iu38pr6	958	15	for	for	IN
cord-005478-5iu38pr6	958	16	CAR	CAR	NNP
cord-005478-5iu38pr6	958	17	-	-	HYPH
cord-005478-5iu38pr6	958	18	T	T	NNP
cord-005478-5iu38pr6	958	19	program	program	NN
cord-005478-5iu38pr6	958	20	.	.	.
cord-005478-5iu38pr6	959	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	959	2	:	:	:
cord-005478-5iu38pr6	960	1	This	this	DT
cord-005478-5iu38pr6	960	2	survey	survey	NN
cord-005478-5iu38pr6	960	3	is	be	VBZ
cord-005478-5iu38pr6	960	4	the	the	DT
cord-005478-5iu38pr6	960	5	first	first	JJ
cord-005478-5iu38pr6	960	6	attempt	attempt	NN
cord-005478-5iu38pr6	960	7	to	to	TO
cord-005478-5iu38pr6	960	8	gather	gather	VB
cord-005478-5iu38pr6	960	9	information	information	NN
cord-005478-5iu38pr6	960	10	about	about	IN
cord-005478-5iu38pr6	960	11	CAR	car	NN
cord-005478-5iu38pr6	960	12	-	-	HYPH
cord-005478-5iu38pr6	960	13	T	t	NN
cord-005478-5iu38pr6	960	14	cell	cell	NN
cord-005478-5iu38pr6	960	15	activity	activity	NN
cord-005478-5iu38pr6	960	16	in	in	IN
cord-005478-5iu38pr6	960	17	Europe	Europe	NNP
cord-005478-5iu38pr6	960	18	.	.	.
cord-005478-5iu38pr6	961	1	This	this	DT
cord-005478-5iu38pr6	961	2	first	first	JJ
cord-005478-5iu38pr6	961	3	results	result	NNS
cord-005478-5iu38pr6	961	4	confirms	confirm	VBZ
cord-005478-5iu38pr6	961	5	active	active	JJ
cord-005478-5iu38pr6	961	6	and	and	CC
cord-005478-5iu38pr6	961	7	growing	grow	VBG
cord-005478-5iu38pr6	961	8	involvement	involvement	NN
cord-005478-5iu38pr6	961	9	and	and	CC
cord-005478-5iu38pr6	961	10	high	high	JJ
cord-005478-5iu38pr6	961	11	quality	quality	NN
cord-005478-5iu38pr6	961	12	standards	standard	NNS
cord-005478-5iu38pr6	961	13	of	of	IN
cord-005478-5iu38pr6	961	14	European	european	JJ
cord-005478-5iu38pr6	961	15	centers	center	NNS
cord-005478-5iu38pr6	961	16	having	have	VBG
cord-005478-5iu38pr6	961	17	CAR	car	NN
cord-005478-5iu38pr6	961	18	-	-	HYPH
cord-005478-5iu38pr6	961	19	T	t	NN
cord-005478-5iu38pr6	961	20	cell	cell	NN
cord-005478-5iu38pr6	961	21	program	program	NN
cord-005478-5iu38pr6	961	22	.	.	.
cord-005478-5iu38pr6	962	1	The	the	DT
cord-005478-5iu38pr6	962	2	expanding	expand	VBG
cord-005478-5iu38pr6	962	3	use	use	NN
cord-005478-5iu38pr6	962	4	of	of	IN
cord-005478-5iu38pr6	962	5	these	these	DT
cord-005478-5iu38pr6	962	6	complex	complex	JJ
cord-005478-5iu38pr6	962	7	ATMP	ATMP	NNS
cord-005478-5iu38pr6	962	8	approaches	approach	NNS
cord-005478-5iu38pr6	962	9	could	could	MD
cord-005478-5iu38pr6	962	10	be	be	VB
cord-005478-5iu38pr6	962	11	facilitated	facilitate	VBN
cord-005478-5iu38pr6	962	12	through	through	IN
cord-005478-5iu38pr6	962	13	harmonization	harmonization	NN
cord-005478-5iu38pr6	962	14	of	of	IN
cord-005478-5iu38pr6	962	15	the	the	DT
cord-005478-5iu38pr6	962	16	clinical	clinical	JJ
cord-005478-5iu38pr6	962	17	practice	practice	NN
cord-005478-5iu38pr6	962	18	,	,	,
cord-005478-5iu38pr6	962	19	shared	share	VBD
cord-005478-5iu38pr6	962	20	analysis	analysis	NN
cord-005478-5iu38pr6	962	21	of	of	IN
cord-005478-5iu38pr6	962	22	good	good	JJ
cord-005478-5iu38pr6	962	23	quality	quality	NN
cord-005478-5iu38pr6	962	24	data	datum	NNS
cord-005478-5iu38pr6	962	25	,	,	,
cord-005478-5iu38pr6	962	26	and	and	CC
cord-005478-5iu38pr6	962	27	by	by	IN
cord-005478-5iu38pr6	962	28	a	a	DT
cord-005478-5iu38pr6	962	29	centralized	centralized	JJ
cord-005478-5iu38pr6	962	30	European	european	JJ
cord-005478-5iu38pr6	962	31	clinical	clinical	JJ
cord-005478-5iu38pr6	962	32	trial	trial	NN
cord-005478-5iu38pr6	962	33	office	office	NN
cord-005478-5iu38pr6	962	34	.	.	.
cord-005478-5iu38pr6	963	1	The	the	DT
cord-005478-5iu38pr6	963	2	cellular	cellular	JJ
cord-005478-5iu38pr6	963	3	therapy	therapy	NN
cord-005478-5iu38pr6	963	4	CAR	car	NN
cord-005478-5iu38pr6	963	5	-	-	HYPH
cord-005478-5iu38pr6	963	6	T	t	NN
cord-005478-5iu38pr6	963	7	form	form	NN
cord-005478-5iu38pr6	963	8	is	be	VBZ
cord-005478-5iu38pr6	963	9	readily	readily	RB
cord-005478-5iu38pr6	963	10	available	available	JJ
cord-005478-5iu38pr6	963	11	to	to	TO
cord-005478-5iu38pr6	963	12	capture	capture	VB
cord-005478-5iu38pr6	963	13	in	in	IN
cord-005478-5iu38pr6	963	14	more	more	JJR
cord-005478-5iu38pr6	963	15	detail	detail	NN
cord-005478-5iu38pr6	963	16	safety	safety	NN
cord-005478-5iu38pr6	963	17	and	and	CC
cord-005478-5iu38pr6	963	18	efficacy	efficacy	NN
cord-005478-5iu38pr6	963	19	of	of	IN
cord-005478-5iu38pr6	963	20	this	this	DT
cord-005478-5iu38pr6	963	21	intervention	intervention	NN
cord-005478-5iu38pr6	963	22	and	and	CC
cord-005478-5iu38pr6	963	23	will	will	MD
cord-005478-5iu38pr6	963	24	allow	allow	VB
cord-005478-5iu38pr6	963	25	sharing	sharing	NN
cord-005478-5iu38pr6	963	26	in	in	IN
cord-005478-5iu38pr6	963	27	a	a	DT
cord-005478-5iu38pr6	963	28	transparent	transparent	JJ
cord-005478-5iu38pr6	963	29	process	process	NN
cord-005478-5iu38pr6	963	30	registry	registry	NN
cord-005478-5iu38pr6	963	31	data	datum	NNS
cord-005478-5iu38pr6	963	32	with	with	IN
cord-005478-5iu38pr6	963	33	stakeholders	stakeholder	NNS
cord-005478-5iu38pr6	963	34	.	.	.
cord-005478-5iu38pr6	964	1	Methods	method	NNS
cord-005478-5iu38pr6	964	2	:	:	:
cord-005478-5iu38pr6	964	3	This	this	DT
cord-005478-5iu38pr6	964	4	is	be	VBZ
cord-005478-5iu38pr6	964	5	an	an	DT
cord-005478-5iu38pr6	964	6	open	open	JJ
cord-005478-5iu38pr6	964	7	-	-	HYPH
cord-005478-5iu38pr6	964	8	label	label	NN
cord-005478-5iu38pr6	964	9	,	,	,
cord-005478-5iu38pr6	964	10	phase	phase	NN
cord-005478-5iu38pr6	964	11	1	1	CD
cord-005478-5iu38pr6	964	12	study	study	NN
cord-005478-5iu38pr6	964	13	(	(	-LRB-
cord-005478-5iu38pr6	964	14	ChiCTR1800017404	ChiCTR1800017404	NNP
cord-005478-5iu38pr6	964	15	)	)	-RRB-
cord-005478-5iu38pr6	964	16	.	.	.
cord-005478-5iu38pr6	965	1	Eligible	eligible	JJ
cord-005478-5iu38pr6	965	2	patients	patient	NNS
cord-005478-5iu38pr6	965	3	had	have	VBD
cord-005478-5iu38pr6	965	4	RRMM	RRMM	NNS
cord-005478-5iu38pr6	965	5	,	,	,
cord-005478-5iu38pr6	965	6	confirmed	confirm	VBD
cord-005478-5iu38pr6	965	7	as	as	IN
cord-005478-5iu38pr6	965	8	BCMA	BCMA	NNP
cord-005478-5iu38pr6	965	9	-	-	HYPH
cord-005478-5iu38pr6	965	10	positive	positive	JJ
cord-005478-5iu38pr6	965	11	by	by	IN
cord-005478-5iu38pr6	965	12	flow	flow	NN
cord-005478-5iu38pr6	965	13	cytometry	cytometry	NN
cord-005478-5iu38pr6	965	14	or	or	CC
cord-005478-5iu38pr6	965	15	pathological	pathological	JJ
cord-005478-5iu38pr6	965	16	examination	examination	NN
cord-005478-5iu38pr6	965	17	.	.	.
cord-005478-5iu38pr6	966	1	Autologous	autologous	JJ
cord-005478-5iu38pr6	966	2	T	t	NN
cord-005478-5iu38pr6	966	3	cells	cell	NNS
cord-005478-5iu38pr6	966	4	transduced	transduce	VBN
cord-005478-5iu38pr6	966	5	with	with	IN
cord-005478-5iu38pr6	966	6	a	a	DT
cord-005478-5iu38pr6	966	7	BCMAtargeted	bcmatargeted	JJ
cord-005478-5iu38pr6	966	8	chimeric	chimeric	JJ
cord-005478-5iu38pr6	966	9	antigen	antigen	NN
cord-005478-5iu38pr6	966	10	receptor	receptor	NN
cord-005478-5iu38pr6	966	11	(	(	-LRB-
cord-005478-5iu38pr6	966	12	CAR	car	NN
cord-005478-5iu38pr6	966	13	-	-	HYPH
cord-005478-5iu38pr6	966	14	BCMA	BCMA	NNP
cord-005478-5iu38pr6	966	15	T	t	NN
cord-005478-5iu38pr6	966	16	cells	cell	NNS
cord-005478-5iu38pr6	966	17	)	)	-RRB-
cord-005478-5iu38pr6	966	18	are	be	VBP
cord-005478-5iu38pr6	966	19	used(1×10	used(1×10	NNS
cord-005478-5iu38pr6	966	20	^	^	NFP
cord-005478-5iu38pr6	966	21	7	7	CD
cord-005478-5iu38pr6	966	22	/	/	SYM
cord-005478-5iu38pr6	966	23	kg	kg	NNP
cord-005478-5iu38pr6	966	24	CAR+T	CAR+T	NNP
cord-005478-5iu38pr6	966	25	cells	cell	NNS
cord-005478-5iu38pr6	966	26	)	)	-RRB-
cord-005478-5iu38pr6	966	27	,	,	,
cord-005478-5iu38pr6	966	28	following	follow	VBG
cord-005478-5iu38pr6	966	29	pre	pre	JJ
cord-005478-5iu38pr6	966	30	-	-	JJ
cord-005478-5iu38pr6	966	31	infusion	infusion	NN
cord-005478-5iu38pr6	966	32	treatment	treatment	NN
cord-005478-5iu38pr6	966	33	--	--	:
cord-005478-5iu38pr6	966	34	intravenous	intravenous	JJ
cord-005478-5iu38pr6	966	35	administration	administration	NN
cord-005478-5iu38pr6	966	36	and	and	CC
cord-005478-5iu38pr6	966	37	lymphodepletion	lymphodepletion	NNP
cord-005478-5iu38pr6	966	38	conditioning	conditioning	NN
cord-005478-5iu38pr6	966	39	(	(	-LRB-
cord-005478-5iu38pr6	966	40	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	966	41	and	and	CC
cord-005478-5iu38pr6	966	42	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	966	43	)	)	-RRB-
cord-005478-5iu38pr6	966	44	.	.	.
cord-005478-5iu38pr6	967	1	The	the	DT
cord-005478-5iu38pr6	967	2	primary	primary	JJ
cord-005478-5iu38pr6	967	3	outcome	outcome	NN
cord-005478-5iu38pr6	967	4	measure	measure	NN
cord-005478-5iu38pr6	967	5	is	be	VBZ
cord-005478-5iu38pr6	967	6	incidence	incidence	NN
cord-005478-5iu38pr6	967	7	of	of	IN
cord-005478-5iu38pr6	967	8	adverse	adverse	JJ
cord-005478-5iu38pr6	967	9	events	event	NNS
cord-005478-5iu38pr6	967	10	(	(	-LRB-
cord-005478-5iu38pr6	967	11	AEs	AEs	NNP
cord-005478-5iu38pr6	967	12	)	)	-RRB-
cord-005478-5iu38pr6	967	13	especially	especially	RB
cord-005478-5iu38pr6	967	14	clinical	clinical	JJ
cord-005478-5iu38pr6	967	15	events	event	NNS
cord-005478-5iu38pr6	967	16	,	,	,
cord-005478-5iu38pr6	967	17	including	include	VBG
cord-005478-5iu38pr6	967	18	CRS	CRS	NNP
cord-005478-5iu38pr6	967	19	,	,	,
cord-005478-5iu38pr6	967	20	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	967	21	and	and	CC
cord-005478-5iu38pr6	967	22	coagulopathy	coagulopathy	NN
cord-005478-5iu38pr6	967	23	,	,	,
cord-005478-5iu38pr6	967	24	et	et	FW
cord-005478-5iu38pr6	967	25	al	al	NNP
cord-005478-5iu38pr6	967	26	.	.	.
cord-005478-5iu38pr6	968	1	Additional	additional	JJ
cord-005478-5iu38pr6	968	2	outcome	outcome	NN
cord-005478-5iu38pr6	968	3	measures	measure	NNS
cord-005478-5iu38pr6	968	4	are	be	VBP
cord-005478-5iu38pr6	968	5	duration	duration	NN
cord-005478-5iu38pr6	968	6	and	and	CC
cord-005478-5iu38pr6	968	7	expansion	expansion	NN
cord-005478-5iu38pr6	968	8	of	of	IN
cord-005478-5iu38pr6	968	9	BCMA	BCMA	NNP
cord-005478-5iu38pr6	968	10	CAR	CAR	NNP
cord-005478-5iu38pr6	968	11	T	t	NN
cord-005478-5iu38pr6	968	12	cells	cell	NNS
cord-005478-5iu38pr6	968	13	.	.	.
cord-005478-5iu38pr6	969	1	Results	result	NNS
cord-005478-5iu38pr6	969	2	:	:	:
cord-005478-5iu38pr6	969	3	19	19	CD
cord-005478-5iu38pr6	969	4	patients	patient	NNS
cord-005478-5iu38pr6	969	5	(	(	-LRB-
cord-005478-5iu38pr6	969	6	median	median	JJ
cord-005478-5iu38pr6	969	7	age	age	NN
cord-005478-5iu38pr6	969	8	of	of	IN
cord-005478-5iu38pr6	969	9	61	61	CD
cord-005478-5iu38pr6	969	10	,	,	,
cord-005478-5iu38pr6	969	11	range	range	NN
cord-005478-5iu38pr6	969	12	41	41	CD
cord-005478-5iu38pr6	969	13	to	to	IN
cord-005478-5iu38pr6	969	14	71	71	CD
cord-005478-5iu38pr6	969	15	)	)	-RRB-
cord-005478-5iu38pr6	969	16	with	with	IN
cord-005478-5iu38pr6	969	17	RRMM	RRMM	NNS
cord-005478-5iu38pr6	969	18	have	have	VBP
cord-005478-5iu38pr6	969	19	received	receive	VBN
cord-005478-5iu38pr6	969	20	treatment	treatment	NN
cord-005478-5iu38pr6	969	21	.	.	.
cord-005478-5iu38pr6	970	1	The	the	DT
cord-005478-5iu38pr6	970	2	median	median	JJ
cord-005478-5iu38pr6	970	3	%	%	NN
cord-005478-5iu38pr6	970	4	PC	pc	NN
cord-005478-5iu38pr6	970	5	in	in	IN
cord-005478-5iu38pr6	970	6	BM	BM	NNP
cord-005478-5iu38pr6	970	7	at	at	IN
cord-005478-5iu38pr6	970	8	enrollment	enrollment	NN
cord-005478-5iu38pr6	970	9	was	be	VBD
cord-005478-5iu38pr6	970	10	30.23	30.23	CD
cord-005478-5iu38pr6	970	11	%	%	NN
cord-005478-5iu38pr6	970	12	(	(	-LRB-
cord-005478-5iu38pr6	970	13	range	range	NN
cord-005478-5iu38pr6	970	14	2	2	CD
cord-005478-5iu38pr6	970	15	%	%	NN
cord-005478-5iu38pr6	970	16	to	to	IN
cord-005478-5iu38pr6	970	17	72	72	CD
cord-005478-5iu38pr6	970	18	%	%	NN
cord-005478-5iu38pr6	970	19	)	)	-RRB-
cord-005478-5iu38pr6	970	20	.	.	.
cord-005478-5iu38pr6	971	1	4/19	4/19	CD
cord-005478-5iu38pr6	971	2	had	have	VBD
cord-005478-5iu38pr6	971	3	high	high	JJ
cord-005478-5iu38pr6	971	4	tumor	tumor	NN
cord-005478-5iu38pr6	971	5	burden	burden	NN
cord-005478-5iu38pr6	971	6	,	,	,
cord-005478-5iu38pr6	971	7	defined	define	VBN
cord-005478-5iu38pr6	971	8	as	as	IN
cord-005478-5iu38pr6	971	9	≥	≥	CD
cord-005478-5iu38pr6	971	10	50	50	CD
cord-005478-5iu38pr6	971	11	%	%	NN
cord-005478-5iu38pr6	971	12	bone	bone	NN
cord-005478-5iu38pr6	971	13	marrow	marrow	NN
cord-005478-5iu38pr6	971	14	plasma	plasma	NN
cord-005478-5iu38pr6	971	15	cells	cell	NNS
cord-005478-5iu38pr6	971	16	.	.	.
cord-005478-5iu38pr6	972	1	3/19	3/19	CD
cord-005478-5iu38pr6	972	2	had	have	VBD
cord-005478-5iu38pr6	972	3	prior	prior	JJ
cord-005478-5iu38pr6	972	4	autologous	autologous	JJ
cord-005478-5iu38pr6	972	5	stem	stem	NN
cord-005478-5iu38pr6	972	6	cell	cell	NN
cord-005478-5iu38pr6	972	7	transplant	transplant	NN
cord-005478-5iu38pr6	972	8	.	.	.
cord-005478-5iu38pr6	973	1	As	as	IN
cord-005478-5iu38pr6	973	2	of	of	IN
cord-005478-5iu38pr6	973	3	data	datum	NNS
cord-005478-5iu38pr6	973	4	cut	cut	VBN
cord-005478-5iu38pr6	973	5	-	-	HYPH
cord-005478-5iu38pr6	973	6	off	off	NN
cord-005478-5iu38pr6	973	7	(	(	-LRB-
cord-005478-5iu38pr6	973	8	Dec	Dec	NNP
cord-005478-5iu38pr6	973	9	1,2018	1,2018	CD
cord-005478-5iu38pr6	973	10	)	)	-RRB-
cord-005478-5iu38pr6	973	11	,	,	,
cord-005478-5iu38pr6	973	12	CRS	CRS	NNP
cord-005478-5iu38pr6	973	13	grade	grade	NN
cord-005478-5iu38pr6	973	14	1	1	CD
cord-005478-5iu38pr6	973	15	-	-	SYM
cord-005478-5iu38pr6	973	16	2	2	CD
cord-005478-5iu38pr6	973	17	occurred	occur	VBD
cord-005478-5iu38pr6	973	18	in	in	IN
cord-005478-5iu38pr6	973	19	8	8	CD
cord-005478-5iu38pr6	973	20	patients	patient	NNS
cord-005478-5iu38pr6	973	21	,	,	,
cord-005478-5iu38pr6	973	22	grade	grade	NN
cord-005478-5iu38pr6	973	23	3	3	CD
cord-005478-5iu38pr6	973	24	-	-	SYM
cord-005478-5iu38pr6	973	25	4	4	CD
cord-005478-5iu38pr6	973	26	occurred	occur	VBD
cord-005478-5iu38pr6	973	27	in	in	IN
cord-005478-5iu38pr6	973	28	11	11	CD
cord-005478-5iu38pr6	973	29	.	.	.
cord-005478-5iu38pr6	974	1	Surprisingly	surprisingly	RB
cord-005478-5iu38pr6	974	2	,	,	,
cord-005478-5iu38pr6	974	3	not	not	RB
cord-005478-5iu38pr6	974	4	a	a	DT
cord-005478-5iu38pr6	974	5	few	few	JJ
cord-005478-5iu38pr6	974	6	patients	patient	NNS
cord-005478-5iu38pr6	974	7	developed	develop	VBD
cord-005478-5iu38pr6	974	8	coagulation	coagulation	NN
cord-005478-5iu38pr6	974	9	disfunction	disfunction	NN
cord-005478-5iu38pr6	974	10	,	,	,
cord-005478-5iu38pr6	974	11	manifesting	manifest	VBG
cord-005478-5iu38pr6	974	12	elevated	elevate	VBN
cord-005478-5iu38pr6	974	13	D	d	NN
cord-005478-5iu38pr6	974	14	-	-	HYPH
cord-005478-5iu38pr6	974	15	dimer	dimer	NN
cord-005478-5iu38pr6	974	16	,	,	,
cord-005478-5iu38pr6	974	17	prolonged	prolonged	JJ
cord-005478-5iu38pr6	974	18	APTT	APTT	NNP
cord-005478-5iu38pr6	974	19	,	,	,
cord-005478-5iu38pr6	974	20	PT	PT	NNP
cord-005478-5iu38pr6	974	21	,	,	,
cord-005478-5iu38pr6	974	22	TT	TT	NNP
cord-005478-5iu38pr6	974	23	,	,	,
cord-005478-5iu38pr6	974	24	and	and	CC
cord-005478-5iu38pr6	974	25	decreased	decrease	VBD
cord-005478-5iu38pr6	974	26	fibrinogen	fibrinogen	NN
cord-005478-5iu38pr6	974	27	,	,	,
cord-005478-5iu38pr6	974	28	with	with	IN
cord-005478-5iu38pr6	974	29	0	0	CD
cord-005478-5iu38pr6	974	30	case	case	NN
cord-005478-5iu38pr6	974	31	of	of	IN
cord-005478-5iu38pr6	974	32	organ	organ	NN
cord-005478-5iu38pr6	974	33	bleeding	bleeding	NN
cord-005478-5iu38pr6	974	34	.	.	.
cord-005478-5iu38pr6	975	1	Laboratory	laboratory	NN
cord-005478-5iu38pr6	975	2	values	value	NNS
cord-005478-5iu38pr6	975	3	correlating	correlate	VBG
cord-005478-5iu38pr6	975	4	with	with	IN
cord-005478-5iu38pr6	975	5	CRS	CRS	NNP
cord-005478-5iu38pr6	975	6	reaching	reach	VBG
cord-005478-5iu38pr6	975	7	grade	grade	NN
cord-005478-5iu38pr6	975	8	3	3	CD
cord-005478-5iu38pr6	975	9	-	-	SYM
cord-005478-5iu38pr6	975	10	4	4	CD
cord-005478-5iu38pr6	976	1	(	(	-LRB-
cord-005478-5iu38pr6	976	2	N=11	N=11	NNP
cord-005478-5iu38pr6	976	3	)	)	-RRB-
cord-005478-5iu38pr6	977	1	compared	compare	VBN
cord-005478-5iu38pr6	977	2	to	to	IN
cord-005478-5iu38pr6	977	3	those	those	DT
cord-005478-5iu38pr6	977	4	with	with	IN
cord-005478-5iu38pr6	977	5	milder	mild	JJR
cord-005478-5iu38pr6	977	6	CRS	CRS	NNP
cord-005478-5iu38pr6	977	7	(	(	-LRB-
cord-005478-5iu38pr6	977	8	N=8	N=8	NNP
cord-005478-5iu38pr6	977	9	)	)	-RRB-
cord-005478-5iu38pr6	977	10	included	include	VBD
cord-005478-5iu38pr6	977	11	peak	peak	NN
cord-005478-5iu38pr6	977	12	ferritin	ferritin	NN
cord-005478-5iu38pr6	977	13	(	(	-LRB-
cord-005478-5iu38pr6	977	14	mean	mean	VB
cord-005478-5iu38pr6	977	15	:	:	:
cord-005478-5iu38pr6	977	16	31095.23	31095.23	CD
cord-005478-5iu38pr6	977	17	vs	vs	IN
cord-005478-5iu38pr6	977	18	1665.53	1665.53	CD
cord-005478-5iu38pr6	977	19	ug	ug	NNP
cord-005478-5iu38pr6	977	20	/	/	SYM
cord-005478-5iu38pr6	977	21	L	L	NNP
cord-005478-5iu38pr6	977	22	,	,	,
cord-005478-5iu38pr6	977	23	p	p	NN
cord-005478-5iu38pr6	977	24	<	<	XX
cord-005478-5iu38pr6	977	25	0.005	0.005	CD
cord-005478-5iu38pr6	977	26	)	)	-RRB-
cord-005478-5iu38pr6	977	27	,	,	,
cord-005478-5iu38pr6	977	28	peak	peak	NNP
cord-005478-5iu38pr6	977	29	IL-6	IL-6	NNP
cord-005478-5iu38pr6	977	30	(	(	-LRB-
cord-005478-5iu38pr6	977	31	mean	mean	VB
cord-005478-5iu38pr6	977	32	:	:	:
cord-005478-5iu38pr6	977	33	8001.07	8001.07	CD
cord-005478-5iu38pr6	977	34	vs	vs	IN
cord-005478-5iu38pr6	977	35	266.92	266.92	CD
cord-005478-5iu38pr6	977	36	pg	pg	NNP
cord-005478-5iu38pr6	977	37	/	/	SYM
cord-005478-5iu38pr6	977	38	mL	ml	NN
cord-005478-5iu38pr6	977	39	,	,	,
cord-005478-5iu38pr6	977	40	p	p	NN
cord-005478-5iu38pr6	977	41	<	<	XX
cord-005478-5iu38pr6	977	42	0.005	0.005	CD
cord-005478-5iu38pr6	977	43	)	)	-RRB-
cord-005478-5iu38pr6	977	44	,	,	,
cord-005478-5iu38pr6	977	45	peak	peak	NN
cord-005478-5iu38pr6	977	46	IL-10	IL-10	NNP
cord-005478-5iu38pr6	977	47	(	(	-LRB-
cord-005478-5iu38pr6	977	48	mean	mean	VB
cord-005478-5iu38pr6	977	49	:	:	:
cord-005478-5iu38pr6	977	50	324.89	324.89	CD
cord-005478-5iu38pr6	977	51	vs	vs	IN
cord-005478-5iu38pr6	977	52	43.81	43.81	CD
cord-005478-5iu38pr6	977	53	pg	pg	NN
cord-005478-5iu38pr6	977	54	/	/	SYM
cord-005478-5iu38pr6	977	55	mL	ml	NN
cord-005478-5iu38pr6	977	56	,	,	,
cord-005478-5iu38pr6	977	57	p	p	NN
cord-005478-5iu38pr6	977	58	<	<	XX
cord-005478-5iu38pr6	977	59	0.01	0.01	CD
cord-005478-5iu38pr6	977	60	)	)	-RRB-
cord-005478-5iu38pr6	977	61	,	,	,
cord-005478-5iu38pr6	977	62	and	and	CC
cord-005478-5iu38pr6	977	63	peak	peak	VB
cord-005478-5iu38pr6	977	64	IFN	IFN	NNP
cord-005478-5iu38pr6	977	65	-	-	HYPH
cord-005478-5iu38pr6	977	66	γ(mean	γ(mean	NNP
cord-005478-5iu38pr6	977	67	:	:	:
cord-005478-5iu38pr6	977	68	2936.46	2936.46	CD
cord-005478-5iu38pr6	977	69	vs	vs	IN
cord-005478-5iu38pr6	977	70	58.21	58.21	CD
cord-005478-5iu38pr6	977	71	pg	pg	NNP
cord-005478-5iu38pr6	977	72	/	/	SYM
cord-005478-5iu38pr6	977	73	mL	ml	NN
cord-005478-5iu38pr6	977	74	,	,	,
cord-005478-5iu38pr6	977	75	p	p	NN
cord-005478-5iu38pr6	977	76	<	<	XX
cord-005478-5iu38pr6	977	77	0.05	0.05	CD
cord-005478-5iu38pr6	977	78	)	)	-RRB-
cord-005478-5iu38pr6	977	79	.	.	.
cord-005478-5iu38pr6	978	1	No	no	DT
cord-005478-5iu38pr6	978	2	significant	significant	JJ
cord-005478-5iu38pr6	978	3	difference	difference	NN
cord-005478-5iu38pr6	978	4	was	be	VBD
cord-005478-5iu38pr6	978	5	seen	see	VBN
cord-005478-5iu38pr6	978	6	in	in	IN
cord-005478-5iu38pr6	978	7	peak	peak	NN
cord-005478-5iu38pr6	978	8	CRP	CRP	NNP
cord-005478-5iu38pr6	978	9	,	,	,
cord-005478-5iu38pr6	978	10	IL-2	IL-2	NNP
cord-005478-5iu38pr6	978	11	and	and	CC
cord-005478-5iu38pr6	978	12	TNF	TNF	NNP
cord-005478-5iu38pr6	978	13	-	-	HYPH
cord-005478-5iu38pr6	978	14	α	α	NNP
cord-005478-5iu38pr6	978	15	.	.	.
cord-005478-5iu38pr6	979	1	Patients	patient	NNS
cord-005478-5iu38pr6	979	2	with	with	IN
cord-005478-5iu38pr6	979	3	CRS	CRS	NNP
cord-005478-5iu38pr6	979	4	3	3	CD
cord-005478-5iu38pr6	979	5	-	-	SYM
cord-005478-5iu38pr6	979	6	4	4	CD
cord-005478-5iu38pr6	979	7	had	have	VBD
cord-005478-5iu38pr6	979	8	a	a	DT
cord-005478-5iu38pr6	979	9	higher	high	JJR
cord-005478-5iu38pr6	979	10	△	△	NNP
cord-005478-5iu38pr6	979	11	APTT	APTT	NNP
cord-005478-5iu38pr6	979	12	(	(	-LRB-
cord-005478-5iu38pr6	979	13	mean	mean	NNP
cord-005478-5iu38pr6	979	14	:	:	:
cord-005478-5iu38pr6	979	15	38.86	38.86	CD
cord-005478-5iu38pr6	979	16	vs	vs	IN
cord-005478-5iu38pr6	979	17	12.09	12.09	CD
cord-005478-5iu38pr6	979	18	s	s	NNP
cord-005478-5iu38pr6	979	19	,	,	,
cord-005478-5iu38pr6	979	20	p	p	NN
cord-005478-5iu38pr6	979	21	<	<	XX
cord-005478-5iu38pr6	979	22	0.01	0.01	CD
cord-005478-5iu38pr6	979	23	)	)	-RRB-
cord-005478-5iu38pr6	979	24	,	,	,
cord-005478-5iu38pr6	979	25	△	△	NNP
cord-005478-5iu38pr6	979	26	D	d	NN
cord-005478-5iu38pr6	979	27	-	-	HYPH
cord-005478-5iu38pr6	979	28	dimer	dimer	NNP
cord-005478-5iu38pr6	979	29	(	(	-LRB-
cord-005478-5iu38pr6	980	1	mean	mean	VB
cord-005478-5iu38pr6	980	2	:	:	:
cord-005478-5iu38pr6	980	3	44509.18	44509.18	CD
cord-005478-5iu38pr6	980	4	vs	vs	IN
cord-005478-5iu38pr6	980	5	13347.75	13347.75	CD
cord-005478-5iu38pr6	980	6	ug	ug	NNP
cord-005478-5iu38pr6	980	7	/	/	SYM
cord-005478-5iu38pr6	980	8	L	L	NNP
cord-005478-5iu38pr6	980	9	,	,	,
cord-005478-5iu38pr6	980	10	p	p	NN
cord-005478-5iu38pr6	980	11	<	<	XX
cord-005478-5iu38pr6	980	12	0.05	0.05	CD
cord-005478-5iu38pr6	980	13	)	)	-RRB-
cord-005478-5iu38pr6	980	14	and	and	CC
cord-005478-5iu38pr6	980	15	△	△	NNP
cord-005478-5iu38pr6	980	16	fibrinogen	fibrinogen	NN
cord-005478-5iu38pr6	980	17	(	(	-LRB-
cord-005478-5iu38pr6	980	18	mean	mean	VB
cord-005478-5iu38pr6	980	19	:	:	:
cord-005478-5iu38pr6	980	20	-1.68	-1.68	ADD
cord-005478-5iu38pr6	980	21	vs	vs	IN
cord-005478-5iu38pr6	980	22	-0.34	-0.34	CD
cord-005478-5iu38pr6	980	23	g	g	NNP
cord-005478-5iu38pr6	980	24	/	/	SYM
cord-005478-5iu38pr6	980	25	L	L	NNP
cord-005478-5iu38pr6	980	26	,	,	,
cord-005478-5iu38pr6	980	27	p	p	NN
cord-005478-5iu38pr6	980	28	<	<	XX
cord-005478-5iu38pr6	980	29	0.05	0.05	CD
cord-005478-5iu38pr6	980	30	)	)	-RRB-
cord-005478-5iu38pr6	980	31	compared	compare	VBN
cord-005478-5iu38pr6	980	32	to	to	IN
cord-005478-5iu38pr6	980	33	those	those	DT
cord-005478-5iu38pr6	980	34	with	with	IN
cord-005478-5iu38pr6	980	35	milder	mild	JJR
cord-005478-5iu38pr6	980	36	CRS	CRS	NNP
cord-005478-5iu38pr6	980	37	.	.	.
cord-005478-5iu38pr6	981	1	There	there	EX
cord-005478-5iu38pr6	981	2	was	be	VBD
cord-005478-5iu38pr6	981	3	no	no	DT
cord-005478-5iu38pr6	981	4	significant	significant	JJ
cord-005478-5iu38pr6	981	5	difference	difference	NN
cord-005478-5iu38pr6	981	6	in	in	IN
cord-005478-5iu38pr6	981	7	△	△	NNP
cord-005478-5iu38pr6	981	8	PT	PT	NNP
cord-005478-5iu38pr6	981	9	and	and	CC
cord-005478-5iu38pr6	981	10	△	△	NNP
cord-005478-5iu38pr6	981	11	TT.The	tt.the	JJ
cord-005478-5iu38pr6	981	12	changes	change	NNS
cord-005478-5iu38pr6	981	13	of	of	IN
cord-005478-5iu38pr6	981	14	D	d	NN
cord-005478-5iu38pr6	981	15	-	-	HYPH
cord-005478-5iu38pr6	981	16	dimer	dimer	NN
cord-005478-5iu38pr6	981	17	and	and	CC
cord-005478-5iu38pr6	981	18	APTT	APTT	NNP
cord-005478-5iu38pr6	981	19	were	be	VBD
cord-005478-5iu38pr6	981	20	in	in	IN
cord-005478-5iu38pr6	981	21	line	line	NN
cord-005478-5iu38pr6	981	22	with	with	IN
cord-005478-5iu38pr6	981	23	the	the	DT
cord-005478-5iu38pr6	981	24	indictors	indictor	NNS
cord-005478-5iu38pr6	981	25	of	of	IN
cord-005478-5iu38pr6	981	26	CRS	CRS	NNP
cord-005478-5iu38pr6	981	27	,	,	,
cord-005478-5iu38pr6	981	28	such	such	JJ
cord-005478-5iu38pr6	981	29	as	as	IN
cord-005478-5iu38pr6	981	30	CRP	CRP	NNP
cord-005478-5iu38pr6	981	31	,	,	,
cord-005478-5iu38pr6	981	32	IL-6	IL-6	NNP
cord-005478-5iu38pr6	981	33	and	and	CC
cord-005478-5iu38pr6	981	34	IL-10	IL-10	NNP
cord-005478-5iu38pr6	981	35	in	in	IN
cord-005478-5iu38pr6	981	36	some	some	DT
cord-005478-5iu38pr6	981	37	individual	individual	JJ
cord-005478-5iu38pr6	981	38	cases	case	NNS
cord-005478-5iu38pr6	981	39	.	.	.
cord-005478-5iu38pr6	982	1	The	the	DT
cord-005478-5iu38pr6	982	2	significant	significant	JJ
cord-005478-5iu38pr6	982	3	correlation	correlation	NN
cord-005478-5iu38pr6	982	4	between	between	IN
cord-005478-5iu38pr6	982	5	APTT	APTT	NNP
cord-005478-5iu38pr6	982	6	and	and	CC
cord-005478-5iu38pr6	982	7	CRP	CRP	NNP
cord-005478-5iu38pr6	982	8	(	(	-LRB-
cord-005478-5iu38pr6	982	9	p	p	NN
cord-005478-5iu38pr6	982	10	<	<	XX
cord-005478-5iu38pr6	982	11	0.05	0.05	CD
cord-005478-5iu38pr6	982	12	)	)	-RRB-
cord-005478-5iu38pr6	982	13	appeared	appear	VBD
cord-005478-5iu38pr6	982	14	on	on	IN
cord-005478-5iu38pr6	982	15	17	17	CD
cord-005478-5iu38pr6	982	16	patients	patient	NNS
cord-005478-5iu38pr6	982	17	(	(	-LRB-
cord-005478-5iu38pr6	982	18	89.5	89.5	CD
cord-005478-5iu38pr6	982	19	%	%	NN
cord-005478-5iu38pr6	982	20	)	)	-RRB-
cord-005478-5iu38pr6	982	21	,	,	,
cord-005478-5iu38pr6	982	22	while	while	IN
cord-005478-5iu38pr6	982	23	the	the	DT
cord-005478-5iu38pr6	982	24	significant	significant	JJ
cord-005478-5iu38pr6	982	25	correlation	correlation	NN
cord-005478-5iu38pr6	982	26	between	between	IN
cord-005478-5iu38pr6	982	27	IL-6	IL-6	NNP
cord-005478-5iu38pr6	982	28	and	and	CC
cord-005478-5iu38pr6	982	29	APTT	APTT	NNP
cord-005478-5iu38pr6	982	30	as	as	RB
cord-005478-5iu38pr6	982	31	well	well	RB
cord-005478-5iu38pr6	982	32	as	as	IN
cord-005478-5iu38pr6	982	33	between	between	IN
cord-005478-5iu38pr6	982	34	IL-6	IL-6	NNP
cord-005478-5iu38pr6	982	35	and	and	CC
cord-005478-5iu38pr6	982	36	D	d	NN
cord-005478-5iu38pr6	982	37	-	-	HYPH
cord-005478-5iu38pr6	982	38	dimer	dimer	NN
cord-005478-5iu38pr6	982	39	only	only	RB
cord-005478-5iu38pr6	982	40	appeared	appear	VBD
cord-005478-5iu38pr6	982	41	on	on	IN
cord-005478-5iu38pr6	982	42	7	7	CD
cord-005478-5iu38pr6	982	43	patients	patient	NNS
cord-005478-5iu38pr6	982	44	(	(	-LRB-
cord-005478-5iu38pr6	982	45	36.84	36.84	CD
cord-005478-5iu38pr6	982	46	%	%	NN
cord-005478-5iu38pr6	982	47	)	)	-RRB-
cord-005478-5iu38pr6	982	48	.	.	.
cord-005478-5iu38pr6	983	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	983	2	:	:	:
cord-005478-5iu38pr6	984	1	Early	early	JJ
cord-005478-5iu38pr6	984	2	safety	safety	NN
cord-005478-5iu38pr6	984	3	and	and	CC
cord-005478-5iu38pr6	984	4	efficacy	efficacy	NN
cord-005478-5iu38pr6	984	5	results	result	NNS
cord-005478-5iu38pr6	984	6	of	of	IN
cord-005478-5iu38pr6	984	7	BCMA	BCMA	NNP
cord-005478-5iu38pr6	984	8	CAR	CAR	NNP
cord-005478-5iu38pr6	984	9	T	t	NN
cord-005478-5iu38pr6	984	10	therapy	therapy	NN
cord-005478-5iu38pr6	984	11	in	in	IN
cord-005478-5iu38pr6	984	12	RRMM	RRMM	NNP
cord-005478-5iu38pr6	984	13	are	be	VBP
cord-005478-5iu38pr6	984	14	encouraging	encouraging	JJ
cord-005478-5iu38pr6	984	15	.	.	.
cord-005478-5iu38pr6	985	1	AEs	AEs	NNP
cord-005478-5iu38pr6	985	2	of	of	IN
cord-005478-5iu38pr6	985	3	coagulation	coagulation	NN
cord-005478-5iu38pr6	985	4	were	be	VBD
cord-005478-5iu38pr6	985	5	observed	observe	VBN
cord-005478-5iu38pr6	985	6	.	.	.
cord-005478-5iu38pr6	986	1	Changes	change	NNS
cord-005478-5iu38pr6	986	2	of	of	IN
cord-005478-5iu38pr6	986	3	APTT	APTT	NNP
cord-005478-5iu38pr6	986	4	,	,	,
cord-005478-5iu38pr6	986	5	D	d	NN
cord-005478-5iu38pr6	986	6	-	-	HYPH
cord-005478-5iu38pr6	986	7	dimer	dimer	NN
cord-005478-5iu38pr6	986	8	and	and	CC
cord-005478-5iu38pr6	986	9	fibrinogen	fibrinogen	NN
cord-005478-5iu38pr6	986	10	of	of	IN
cord-005478-5iu38pr6	986	11	patients	patient	NNS
cord-005478-5iu38pr6	986	12	with	with	IN
cord-005478-5iu38pr6	986	13	high	high	JJ
cord-005478-5iu38pr6	986	14	CRS	CRS	NNP
cord-005478-5iu38pr6	986	15	level	level	NN
cord-005478-5iu38pr6	986	16	were	be	VBD
cord-005478-5iu38pr6	986	17	more	more	RBR
cord-005478-5iu38pr6	986	18	significant	significant	JJ
cord-005478-5iu38pr6	986	19	than	than	IN
cord-005478-5iu38pr6	986	20	those	those	DT
cord-005478-5iu38pr6	986	21	with	with	IN
cord-005478-5iu38pr6	986	22	milder	mild	JJR
cord-005478-5iu38pr6	986	23	CRS	CRS	NNP
cord-005478-5iu38pr6	986	24	.	.	.
cord-005478-5iu38pr6	987	1	On	on	IN
cord-005478-5iu38pr6	987	2	the	the	DT
cord-005478-5iu38pr6	987	3	individual	individual	JJ
cord-005478-5iu38pr6	987	4	level	level	NN
cord-005478-5iu38pr6	987	5	,	,	,
cord-005478-5iu38pr6	987	6	APTT	APTT	NNP
cord-005478-5iu38pr6	987	7	correlated	correlate	VBD
cord-005478-5iu38pr6	987	8	with	with	IN
cord-005478-5iu38pr6	987	9	CRP	CRP	NNP
cord-005478-5iu38pr6	987	10	in	in	IN
cord-005478-5iu38pr6	987	11	the	the	DT
cord-005478-5iu38pr6	987	12	course	course	NN
cord-005478-5iu38pr6	987	13	of	of	IN
cord-005478-5iu38pr6	987	14	therapy	therapy	NN
cord-005478-5iu38pr6	987	15	.	.	.
cord-005478-5iu38pr6	988	1	Given	give	VBN
cord-005478-5iu38pr6	988	2	extensive	extensive	JJ
cord-005478-5iu38pr6	988	3	cross	cross	NN
cord-005478-5iu38pr6	988	4	-	-	NN
cord-005478-5iu38pr6	988	5	talk	talk	NN
cord-005478-5iu38pr6	988	6	between	between	IN
cord-005478-5iu38pr6	988	7	inflammation	inflammation	NN
cord-005478-5iu38pr6	988	8	and	and	CC
cord-005478-5iu38pr6	988	9	coagulation	coagulation	NN
cord-005478-5iu38pr6	988	10	,	,	,
cord-005478-5iu38pr6	988	11	coagulation	coagulation	NN
cord-005478-5iu38pr6	988	12	-	-	HYPH
cord-005478-5iu38pr6	988	13	related	relate	VBN
cord-005478-5iu38pr6	988	14	indictors	indictor	NNS
cord-005478-5iu38pr6	988	15	are	be	VBP
cord-005478-5iu38pr6	988	16	more	more	RBR
cord-005478-5iu38pr6	988	17	convenient	convenient	JJ
cord-005478-5iu38pr6	988	18	for	for	IN
cord-005478-5iu38pr6	988	19	monitoring	monitor	VBG
cord-005478-5iu38pr6	988	20	CRS	CRS	NNP
cord-005478-5iu38pr6	988	21	.	.	.
cord-005478-5iu38pr6	989	1	Also	also	RB
cord-005478-5iu38pr6	989	2	,	,	,
cord-005478-5iu38pr6	989	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	989	4	study	study	NN
cord-005478-5iu38pr6	989	5	suggests	suggest	VBZ
cord-005478-5iu38pr6	989	6	the	the	DT
cord-005478-5iu38pr6	989	7	importance	importance	NN
cord-005478-5iu38pr6	989	8	in	in	IN
cord-005478-5iu38pr6	989	9	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	989	10	and	and	CC
cord-005478-5iu38pr6	989	11	early	early	JJ
cord-005478-5iu38pr6	989	12	management	management	NN
cord-005478-5iu38pr6	989	13	for	for	IN
cord-005478-5iu38pr6	989	14	coagulopathy	coagulopathy	NN
cord-005478-5iu38pr6	989	15	to	to	TO
cord-005478-5iu38pr6	989	16	avoid	avoid	VB
cord-005478-5iu38pr6	989	17	CRS	CRS	NNP
cord-005478-5iu38pr6	989	18	-	-	HYPH
cord-005478-5iu38pr6	989	19	related	relate	VBN
cord-005478-5iu38pr6	989	20	mortality	mortality	NN
cord-005478-5iu38pr6	989	21	.	.	.
cord-005478-5iu38pr6	990	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	990	2	Trial	Trial	NNP
cord-005478-5iu38pr6	990	3	Registry	Registry	NNP
cord-005478-5iu38pr6	990	4	:	:	:
cord-005478-5iu38pr6	991	1	ChiCTR1800017404	ChiCTR1800017404	``
cord-005478-5iu38pr6	991	2	http://	http://	NNP
cord-005478-5iu38pr6	991	3	www.chictr.org.cn/abouten.aspx	www.chictr.org.cn/abouten.aspx	NNP
cord-005478-5iu38pr6	991	4	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	991	5	:	:	:
cord-005478-5iu38pr6	991	6	Nothing	nothing	NN
cord-005478-5iu38pr6	991	7	to	to	TO
cord-005478-5iu38pr6	991	8	declare	declare	VB
cord-005478-5iu38pr6	991	9	O054	o054	CD
cord-005478-5iu38pr6	991	10	Abstract	Abstract	NNP
cord-005478-5iu38pr6	991	11	already	already	RB
cord-005478-5iu38pr6	991	12	published	publish	VBN
cord-005478-5iu38pr6	991	13	.	.	.
cord-005478-5iu38pr6	992	1	Point	point	NN
cord-005478-5iu38pr6	992	2	-	-	HYPH
cord-005478-5iu38pr6	992	3	of	of	IN
cord-005478-5iu38pr6	992	4	-	-	HYPH
cord-005478-5iu38pr6	992	5	care	care	NN
cord-005478-5iu38pr6	992	6	production	production	NN
cord-005478-5iu38pr6	992	7	of	of	IN
cord-005478-5iu38pr6	992	8	CD19	CD19	NNP
cord-005478-5iu38pr6	992	9	CAR	CAR	NNP
cord-005478-5iu38pr6	992	10	-	-	HYPH
cord-005478-5iu38pr6	992	11	T	t	NN
cord-005478-5iu38pr6	992	12	cells	cell	NNS
cord-005478-5iu38pr6	992	13	in	in	IN
cord-005478-5iu38pr6	992	14	an	an	DT
cord-005478-5iu38pr6	992	15	automated	automated	JJ
cord-005478-5iu38pr6	992	16	closed	close	VBN
cord-005478-5iu38pr6	992	17	-	-	HYPH
cord-005478-5iu38pr6	992	18	system	system	NN
cord-005478-5iu38pr6	992	19	bioreactor	bioreactor	NN
cord-005478-5iu38pr6	992	20	:	:	:
cord-005478-5iu38pr6	992	21	Report	report	NN
cord-005478-5iu38pr6	992	22	of	of	IN
cord-005478-5iu38pr6	992	23	first	first	JJ
cord-005478-5iu38pr6	992	24	clinical	clinical	JJ
cord-005478-5iu38pr6	992	25	experience	experience	NN
cord-005478-5iu38pr6	992	26	Background	background	NN
cord-005478-5iu38pr6	993	1	:	:	:
cord-005478-5iu38pr6	993	2	CD19	CD19	NNP
cord-005478-5iu38pr6	993	3	CAR	CAR	NNP
cord-005478-5iu38pr6	993	4	-	-	HYPH
cord-005478-5iu38pr6	993	5	T	t	NN
cord-005478-5iu38pr6	993	6	cell	cell	NN
cord-005478-5iu38pr6	993	7	products	product	NNS
cord-005478-5iu38pr6	993	8	are	be	VBP
cord-005478-5iu38pr6	993	9	approved	approve	VBN
cord-005478-5iu38pr6	993	10	as	as	IN
cord-005478-5iu38pr6	993	11	therapy	therapy	NN
cord-005478-5iu38pr6	993	12	for	for	IN
cord-005478-5iu38pr6	993	13	advanced	advanced	JJ
cord-005478-5iu38pr6	993	14	B	b	NN
cord-005478-5iu38pr6	993	15	-	-	HYPH
cord-005478-5iu38pr6	993	16	cell	cell	NN
cord-005478-5iu38pr6	993	17	malignancies	malignancy	NNS
cord-005478-5iu38pr6	993	18	.	.	.
cord-005478-5iu38pr6	994	1	The	the	DT
cord-005478-5iu38pr6	994	2	predominant	predominant	JJ
cord-005478-5iu38pr6	994	3	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	994	4	model	model	NN
cord-005478-5iu38pr6	994	5	is	be	VBZ
cord-005478-5iu38pr6	994	6	a	a	DT
cord-005478-5iu38pr6	994	7	centralized	centralized	JJ
cord-005478-5iu38pr6	994	8	industrial	industrial	JJ
cord-005478-5iu38pr6	994	9	-	-	HYPH
cord-005478-5iu38pr6	994	10	type	type	NN
cord-005478-5iu38pr6	994	11	production	production	NN
cord-005478-5iu38pr6	994	12	process	process	NN
cord-005478-5iu38pr6	994	13	.	.	.
cord-005478-5iu38pr6	995	1	An	an	DT
cord-005478-5iu38pr6	995	2	alternative	alternative	JJ
cord-005478-5iu38pr6	995	3	approach	approach	NN
cord-005478-5iu38pr6	995	4	to	to	IN
cord-005478-5iu38pr6	995	5	CAR	car	NN
cord-005478-5iu38pr6	995	6	-	-	HYPH
cord-005478-5iu38pr6	995	7	T	t	NN
cord-005478-5iu38pr6	995	8	cell	cell	NN
cord-005478-5iu38pr6	995	9	production	production	NN
cord-005478-5iu38pr6	995	10	and	and	CC
cord-005478-5iu38pr6	995	11	delivery	delivery	NN
cord-005478-5iu38pr6	995	12	to	to	IN
cord-005478-5iu38pr6	995	13	the	the	DT
cord-005478-5iu38pr6	995	14	patient	patient	NN
cord-005478-5iu38pr6	995	15	is	be	VBZ
cord-005478-5iu38pr6	995	16	via	via	IN
cord-005478-5iu38pr6	995	17	a	a	DT
cord-005478-5iu38pr6	995	18	point	point	NN
cord-005478-5iu38pr6	995	19	-	-	HYPH
cord-005478-5iu38pr6	995	20	of	of	IN
cord-005478-5iu38pr6	995	21	care	care	NN
cord-005478-5iu38pr6	995	22	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	995	23	process	process	NN
cord-005478-5iu38pr6	995	24	.	.	.
cord-005478-5iu38pr6	996	1	Methods	method	NNS
cord-005478-5iu38pr6	996	2	:	:	:
cord-005478-5iu38pr6	996	3	Between	between	IN
cord-005478-5iu38pr6	996	4	February	February	NNP
cord-005478-5iu38pr6	996	5	2018	2018	CD
cord-005478-5iu38pr6	996	6	to	to	IN
cord-005478-5iu38pr6	996	7	November	November	NNP
cord-005478-5iu38pr6	996	8	2018	2018	CD
cord-005478-5iu38pr6	996	9	a	a	DT
cord-005478-5iu38pr6	996	10	total	total	NN
cord-005478-5iu38pr6	996	11	of	of	IN
cord-005478-5iu38pr6	996	12	15	15	CD
cord-005478-5iu38pr6	996	13	pts	pt	NNS
cord-005478-5iu38pr6	996	14	with	with	IN
cord-005478-5iu38pr6	996	15	relapsed	relapse	VBN
cord-005478-5iu38pr6	996	16	/	/	SYM
cord-005478-5iu38pr6	996	17	refractory	refractory	JJ
cord-005478-5iu38pr6	996	18	B	b	NN
cord-005478-5iu38pr6	996	19	-	-	HYPH
cord-005478-5iu38pr6	996	20	cell	cell	NN
cord-005478-5iu38pr6	996	21	malignancies	malignancy	NNS
cord-005478-5iu38pr6	996	22	(	(	-LRB-
cord-005478-5iu38pr6	996	23	4	4	CD
cord-005478-5iu38pr6	996	24	female	female	JJ
cord-005478-5iu38pr6	996	25	,	,	,
cord-005478-5iu38pr6	996	26	11	11	CD
cord-005478-5iu38pr6	996	27	male[GR1	male[gr1	CD
cord-005478-5iu38pr6	996	28	]	]	-RRB-
cord-005478-5iu38pr6	996	29	,	,	,
cord-005478-5iu38pr6	996	30	median	median	JJ
cord-005478-5iu38pr6	996	31	age	age	NN
cord-005478-5iu38pr6	996	32	12	12	CD
cord-005478-5iu38pr6	996	33	y	y	NN
cord-005478-5iu38pr6	996	34	)	)	-RRB-
cord-005478-5iu38pr6	996	35	were	be	VBD
cord-005478-5iu38pr6	996	36	screened	screen	VBN
cord-005478-5iu38pr6	996	37	,	,	,
cord-005478-5iu38pr6	996	38	10	10	CD
cord-005478-5iu38pr6	996	39	pts	pt	NNS
cord-005478-5iu38pr6	996	40	were	be	VBD
cord-005478-5iu38pr6	996	41	enrolled	enrol	VBN
cord-005478-5iu38pr6	996	42	for	for	IN
cord-005478-5iu38pr6	996	43	single	single	JJ
cord-005478-5iu38pr6	996	44	center	center	NN
cord-005478-5iu38pr6	996	45	,	,	,
cord-005478-5iu38pr6	996	46	phase	phase	NN
cord-005478-5iu38pr6	996	47	I	I	NNP
cord-005478-5iu38pr6	996	48	-	-	HYPH
cord-005478-5iu38pr6	996	49	II	II	NNP
cord-005478-5iu38pr6	996	50	trial	trial	NN
cord-005478-5iu38pr6	996	51	of	of	IN
cord-005478-5iu38pr6	996	52	safety	safety	NN
cord-005478-5iu38pr6	996	53	and	and	CC
cord-005478-5iu38pr6	996	54	clinical	clinical	JJ
cord-005478-5iu38pr6	996	55	efficacy	efficacy	NN
cord-005478-5iu38pr6	996	56	of	of	IN
cord-005478-5iu38pr6	996	57	automatically	automatically	RB
cord-005478-5iu38pr6	996	58	produced	produce	VBN
cord-005478-5iu38pr6	996	59	cell	cell	NN
cord-005478-5iu38pr6	996	60	therapy	therapy	NN
cord-005478-5iu38pr6	996	61	product	product	NN
cord-005478-5iu38pr6	996	62	,	,	,
cord-005478-5iu38pr6	996	63	5	5	CD
cord-005478-5iu38pr6	996	64	were	be	VBD
cord-005478-5iu38pr6	996	65	eligible	eligible	JJ
cord-005478-5iu38pr6	996	66	for	for	IN
cord-005478-5iu38pr6	996	67	compassionate	compassionate	JJ
cord-005478-5iu38pr6	996	68	use	use	NN
cord-005478-5iu38pr6	996	69	of	of	IN
cord-005478-5iu38pr6	996	70	therapy	therapy	NN
cord-005478-5iu38pr6	996	71	.	.	.
cord-005478-5iu38pr6	997	1	Seven	seven	CD
cord-005478-5iu38pr6	997	2	patients	patient	NNS
cord-005478-5iu38pr6	997	3	had	have	VBD
cord-005478-5iu38pr6	997	4	relapsed	relapse	VBN
cord-005478-5iu38pr6	997	5	B	b	NN
cord-005478-5iu38pr6	997	6	-	-	,
cord-005478-5iu38pr6	997	7	ALL	all	RB
cord-005478-5iu38pr6	997	8	after	after	IN
cord-005478-5iu38pr6	997	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	997	10	,	,	,
cord-005478-5iu38pr6	997	11	6	6	CD
cord-005478-5iu38pr6	997	12	pts	pt	NNS
cord-005478-5iu38pr6	997	13	had	have	VBD
cord-005478-5iu38pr6	997	14	refractory	refractory	JJ
cord-005478-5iu38pr6	997	15	relapse	relapse	NN
cord-005478-5iu38pr6	997	16	after	after	IN
cord-005478-5iu38pr6	997	17	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	997	18	,	,	,
cord-005478-5iu38pr6	997	19	1	1	CD
cord-005478-5iu38pr6	997	20	pt	pt	NN
cord-005478-5iu38pr6	997	21	had	have	VBD
cord-005478-5iu38pr6	997	22	refractory	refractory	JJ
cord-005478-5iu38pr6	997	23	induction	induction	NN
cord-005478-5iu38pr6	997	24	failure	failure	NN
cord-005478-5iu38pr6	997	25	,	,	,
cord-005478-5iu38pr6	997	26	1	1	CD
cord-005478-5iu38pr6	997	27	pt	pt	NN
cord-005478-5iu38pr6	997	28	had	have	VBD
cord-005478-5iu38pr6	997	29	refractory	refractory	JJ
cord-005478-5iu38pr6	997	30	primary	primary	JJ
cord-005478-5iu38pr6	997	31	mediastinal	mediastinal	JJ
cord-005478-5iu38pr6	997	32	Bcell	Bcell	NNP
cord-005478-5iu38pr6	997	33	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	997	34	(	(	-LRB-
cord-005478-5iu38pr6	997	35	PMBCL	PMBCL	NNP
cord-005478-5iu38pr6	997	36	)	)	-RRB-
cord-005478-5iu38pr6	997	37	.	.	.
cord-005478-5iu38pr6	998	1	Eight	eight	CD
cord-005478-5iu38pr6	998	2	patients	patient	NNS
cord-005478-5iu38pr6	998	3	received	receive	VBD
cord-005478-5iu38pr6	998	4	previous	previous	JJ
cord-005478-5iu38pr6	998	5	blinatumomab	blinatumomab	JJ
cord-005478-5iu38pr6	998	6	infusion	infusion	NN
cord-005478-5iu38pr6	998	7	.	.	.
cord-005478-5iu38pr6	999	1	Eight	eight	CD
cord-005478-5iu38pr6	999	2	patients	patient	NNS
cord-005478-5iu38pr6	999	3	had	have	VBD
cord-005478-5iu38pr6	999	4	high	high	JJ
cord-005478-5iu38pr6	999	5	disease	disease	NN
cord-005478-5iu38pr6	999	6	burden	burden	NN
cord-005478-5iu38pr6	999	7	>	>	XX
cord-005478-5iu38pr6	999	8	5	5	CD
cord-005478-5iu38pr6	999	9	%	%	NN
cord-005478-5iu38pr6	999	10	blast	blast	NN
cord-005478-5iu38pr6	999	11	cells	cell	NNS
cord-005478-5iu38pr6	999	12	in	in	IN
cord-005478-5iu38pr6	999	13	BM	BM	NNP
cord-005478-5iu38pr6	999	14	,	,	,
cord-005478-5iu38pr6	999	15	median	median	JJ
cord-005478-5iu38pr6	999	16	89	89	CD
cord-005478-5iu38pr6	999	17	%	%	NN
cord-005478-5iu38pr6	999	18	(	(	-LRB-
cord-005478-5iu38pr6	999	19	14	14	CD
cord-005478-5iu38pr6	999	20	-	-	SYM
cord-005478-5iu38pr6	999	21	100	100	CD
cord-005478-5iu38pr6	999	22	)	)	-RRB-
cord-005478-5iu38pr6	999	23	,	,	,
cord-005478-5iu38pr6	999	24	6	6	CD
cord-005478-5iu38pr6	999	25	pts	pt	NNS
cord-005478-5iu38pr6	999	26	had	have	VBD
cord-005478-5iu38pr6	999	27	minimal	minimal	JJ
cord-005478-5iu38pr6	999	28	residual	residual	JJ
cord-005478-5iu38pr6	999	29	disease	disease	NN
cord-005478-5iu38pr6	999	30	(	(	-LRB-
cord-005478-5iu38pr6	999	31	MRD	MRD	NNP
cord-005478-5iu38pr6	999	32	)	)	-RRB-
cord-005478-5iu38pr6	999	33	in	in	IN
cord-005478-5iu38pr6	999	34	BM	BM	NNP
cord-005478-5iu38pr6	999	35	.	.	.
cord-005478-5iu38pr6	1000	1	The	the	DT
cord-005478-5iu38pr6	1000	2	CliniMACS	CliniMACS	NNP
cord-005478-5iu38pr6	1000	3	Prodigy	Prodigy	NNP
cord-005478-5iu38pr6	1000	4	T	T	NNP
cord-005478-5iu38pr6	1000	5	cell	cell	NN
cord-005478-5iu38pr6	1000	6	transduction	transduction	NN
cord-005478-5iu38pr6	1000	7	(	(	-LRB-
cord-005478-5iu38pr6	1000	8	TCT	TCT	NNP
cord-005478-5iu38pr6	1000	9	)	)	-RRB-
cord-005478-5iu38pr6	1000	10	process	process	NN
cord-005478-5iu38pr6	1000	11	was	be	VBD
cord-005478-5iu38pr6	1000	12	used	use	VBN
cord-005478-5iu38pr6	1000	13	to	to	TO
cord-005478-5iu38pr6	1000	14	produce	produce	VB
cord-005478-5iu38pr6	1000	15	CD19	CD19	NNP
cord-005478-5iu38pr6	1000	16	CAR	CAR	NNP
cord-005478-5iu38pr6	1000	17	-	-	HYPH
cord-005478-5iu38pr6	1000	18	T	t	NN
cord-005478-5iu38pr6	1000	19	cells	cell	NNS
cord-005478-5iu38pr6	1000	20	from	from	IN
cord-005478-5iu38pr6	1000	21	fresh	fresh	JJ
cord-005478-5iu38pr6	1000	22	patientderived	patientderived	NNP
cord-005478-5iu38pr6	1000	23	leukapheresis	leukapheresis	NN
cord-005478-5iu38pr6	1000	24	product	product	NN
cord-005478-5iu38pr6	1000	25	.	.	.
cord-005478-5iu38pr6	1001	1	Automatic	automatic	JJ
cord-005478-5iu38pr6	1001	2	production	production	NN
cord-005478-5iu38pr6	1001	3	included	include	VBD
cord-005478-5iu38pr6	1001	4	CD4	CD4	NNP
cord-005478-5iu38pr6	1001	5	/	/	SYM
cord-005478-5iu38pr6	1001	6	CD8	CD8	NNP
cord-005478-5iu38pr6	1001	7	selection	selection	NN
cord-005478-5iu38pr6	1001	8	,	,	,
cord-005478-5iu38pr6	1001	9	stimulation	stimulation	NN
cord-005478-5iu38pr6	1001	10	with	with	IN
cord-005478-5iu38pr6	1001	11	MACS	MACS	NNP
cord-005478-5iu38pr6	1001	12	GMP	GMP	NNP
cord-005478-5iu38pr6	1001	13	T	t	NN
cord-005478-5iu38pr6	1001	14	Cell	cell	NN
cord-005478-5iu38pr6	1001	15	TransAct	TransAct	NNP
cord-005478-5iu38pr6	1001	16	,	,	,
cord-005478-5iu38pr6	1001	17	transduction	transduction	NN
cord-005478-5iu38pr6	1001	18	with	with	IN
cord-005478-5iu38pr6	1001	19	lentiviral	lentiviral	NNP
cord-005478-5iu38pr6	1001	20	(	(	-LRB-
cord-005478-5iu38pr6	1002	1	second	second	JJ
cord-005478-5iu38pr6	1002	2	generation	generation	NN
cord-005478-5iu38pr6	1002	3	CD19.4	CD19.4	NNP
cord-005478-5iu38pr6	1002	4	-	-	HYPH
cord-005478-5iu38pr6	1002	5	1BB	1BB	NNP
cord-005478-5iu38pr6	1002	6	zeta	zeta	NN
cord-005478-5iu38pr6	1002	7	)	)	-RRB-
cord-005478-5iu38pr6	1002	8	vector	vector	NN
cord-005478-5iu38pr6	1002	9	(	(	-LRB-
cord-005478-5iu38pr6	1002	10	Lentigen	Lentigen	NNP
cord-005478-5iu38pr6	1002	11	,	,	,
cord-005478-5iu38pr6	1002	12	Miltenyi	Miltenyi	NNP
cord-005478-5iu38pr6	1002	13	Biotec	Biotec	NNP
cord-005478-5iu38pr6	1002	14	company	company	NN
cord-005478-5iu38pr6	1002	15	)	)	-RRB-
cord-005478-5iu38pr6	1002	16	and	and	CC
cord-005478-5iu38pr6	1002	17	expansion	expansion	NN
cord-005478-5iu38pr6	1002	18	over	over	IN
cord-005478-5iu38pr6	1002	19	10	10	CD
cord-005478-5iu38pr6	1002	20	days	day	NNS
cord-005478-5iu38pr6	1002	21	in	in	IN
cord-005478-5iu38pr6	1002	22	the	the	DT
cord-005478-5iu38pr6	1002	23	presence	presence	NN
cord-005478-5iu38pr6	1002	24	of	of	IN
cord-005478-5iu38pr6	1002	25	TexMACS	TexMACS	NNP
cord-005478-5iu38pr6	1002	26	GMP	GMP	NNP
cord-005478-5iu38pr6	1002	27	Medium	Medium	NNP
cord-005478-5iu38pr6	1002	28	and	and	CC
cord-005478-5iu38pr6	1002	29	MACS	MACS	NNP
cord-005478-5iu38pr6	1002	30	GMP	GMP	NNP
cord-005478-5iu38pr6	1002	31	IL-7	IL-7	NNP
cord-005478-5iu38pr6	1002	32	/	/	SYM
cord-005478-5iu38pr6	1002	33	IL-15	IL-15	NNP
cord-005478-5iu38pr6	1002	34	combination	combination	NN
cord-005478-5iu38pr6	1002	35	.	.	.
cord-005478-5iu38pr6	1003	1	Final	final	JJ
cord-005478-5iu38pr6	1003	2	product	product	NN
cord-005478-5iu38pr6	1003	3	was	be	VBD
cord-005478-5iu38pr6	1003	4	administered	administer	VBN
cord-005478-5iu38pr6	1003	5	without	without	IN
cord-005478-5iu38pr6	1003	6	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	1003	7	after	after	IN
cord-005478-5iu38pr6	1003	8	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	1003	9	/	/	,
cord-005478-5iu38pr6	1003	10	cyclophosphamide	cyclophosphamide	RB
cord-005478-5iu38pr6	1003	11	preconditioning	preconditioning	NN
cord-005478-5iu38pr6	1003	12	.	.	.
cord-005478-5iu38pr6	1004	1	All	all	DT
cord-005478-5iu38pr6	1004	2	patients	patient	NNS
cord-005478-5iu38pr6	1004	3	received	receive	VBD
cord-005478-5iu38pr6	1004	4	prophylactic	prophylactic	JJ
cord-005478-5iu38pr6	1004	5	tocilizumab	tocilizumab	NNS
cord-005478-5iu38pr6	1004	6	at	at	IN
cord-005478-5iu38pr6	1004	7	8	8	CD
cord-005478-5iu38pr6	1004	8	mg	mg	NN
cord-005478-5iu38pr6	1004	9	/	/	SYM
cord-005478-5iu38pr6	1004	10	kg	kg	NNS
cord-005478-5iu38pr6	1004	11	.	.	.
cord-005478-5iu38pr6	1005	1	Results	result	NNS
cord-005478-5iu38pr6	1005	2	:	:	:
cord-005478-5iu38pr6	1006	1	All	all	DT
cord-005478-5iu38pr6	1006	2	production	production	NN
cord-005478-5iu38pr6	1006	3	cycles	cycle	NNS
cord-005478-5iu38pr6	1006	4	were	be	VBD
cord-005478-5iu38pr6	1006	5	successful	successful	JJ
cord-005478-5iu38pr6	1006	6	.	.	.
cord-005478-5iu38pr6	1007	1	Median	median	JJ
cord-005478-5iu38pr6	1007	2	transduction	transduction	NN
cord-005478-5iu38pr6	1007	3	efficiency	efficiency	NN
cord-005478-5iu38pr6	1007	4	was	be	VBD
cord-005478-5iu38pr6	1007	5	59	59	CD
cord-005478-5iu38pr6	1007	6	%	%	NN
cord-005478-5iu38pr6	1007	7	(	(	-LRB-
cord-005478-5iu38pr6	1007	8	32	32	CD
cord-005478-5iu38pr6	1007	9	-	-	SYM
cord-005478-5iu38pr6	1007	10	75	75	CD
cord-005478-5iu38pr6	1007	11	)	)	-RRB-
cord-005478-5iu38pr6	1007	12	.	.	.
cord-005478-5iu38pr6	1008	1	Median	median	JJ
cord-005478-5iu38pr6	1008	2	expansion	expansion	NN
cord-005478-5iu38pr6	1008	3	of	of	IN
cord-005478-5iu38pr6	1008	4	T	T	NNP
cord-005478-5iu38pr6	1008	5	cells	cell	NNS
cord-005478-5iu38pr6	1008	6	was	be	VBD
cord-005478-5iu38pr6	1008	7	36	36	CD
cord-005478-5iu38pr6	1008	8	fold	fold	JJ
cord-005478-5iu38pr6	1008	9	(	(	-LRB-
cord-005478-5iu38pr6	1008	10	18	18	CD
cord-005478-5iu38pr6	1008	11	-	-	SYM
cord-005478-5iu38pr6	1008	12	49	49	CD
cord-005478-5iu38pr6	1008	13	)	)	-RRB-
cord-005478-5iu38pr6	1008	14	.	.	.
cord-005478-5iu38pr6	1009	1	CD4	CD4	NNP
cord-005478-5iu38pr6	1009	2	/	/	SYM
cord-005478-5iu38pr6	1009	3	CD8	CD8	NNP
cord-005478-5iu38pr6	1009	4	ratio	ratio	NN
cord-005478-5iu38pr6	1009	5	in	in	IN
cord-005478-5iu38pr6	1009	6	the	the	DT
cord-005478-5iu38pr6	1009	7	final	final	JJ
cord-005478-5iu38pr6	1009	8	product	product	NN
cord-005478-5iu38pr6	1009	9	was	be	VBD
cord-005478-5iu38pr6	1009	10	0,6	0,6	CD
cord-005478-5iu38pr6	1009	11	.	.	.
cord-005478-5iu38pr6	1010	1	The	the	DT
cord-005478-5iu38pr6	1010	2	cell	cell	NN
cord-005478-5iu38pr6	1010	3	products	product	NNS
cord-005478-5iu38pr6	1010	4	were	be	VBD
cord-005478-5iu38pr6	1010	5	administered	administer	VBN
cord-005478-5iu38pr6	1010	6	at	at	IN
cord-005478-5iu38pr6	1010	7	1	1	CD
cord-005478-5iu38pr6	1010	8	*	*	SYM
cord-005478-5iu38pr6	1010	9	10	10	CD
cord-005478-5iu38pr6	1010	10	5	5	CD
cord-005478-5iu38pr6	1010	11	/kg	/kg	CD
cord-005478-5iu38pr6	1010	12	of	of	IN
cord-005478-5iu38pr6	1010	13	CAR	car	NN
cord-005478-5iu38pr6	1010	14	-	-	HYPH
cord-005478-5iu38pr6	1010	15	T	t	NN
cord-005478-5iu38pr6	1010	16	cells	cell	NNS
cord-005478-5iu38pr6	1010	17	in	in	IN
cord-005478-5iu38pr6	1010	18	5	5	CD
cord-005478-5iu38pr6	1010	19	pts	pt	NNS
cord-005478-5iu38pr6	1010	20	,	,	,
cord-005478-5iu38pr6	1010	21	5	5	CD
cord-005478-5iu38pr6	1010	22	*	*	SYM
cord-005478-5iu38pr6	1010	23	10	10	CD
cord-005478-5iu38pr6	1010	24	5	5	CD
cord-005478-5iu38pr6	1011	1	/kg	/kg	NFP
cord-005478-5iu38pr6	1011	2	in	in	IN
cord-005478-5iu38pr6	1011	3	5	5	CD
cord-005478-5iu38pr6	1011	4	pts	pt	NNS
cord-005478-5iu38pr6	1011	5	,	,	,
cord-005478-5iu38pr6	1011	6	1	1	CD
cord-005478-5iu38pr6	1011	7	*	*	SYM
cord-005478-5iu38pr6	1011	8	10	10	CD
cord-005478-5iu38pr6	1011	9	6	6	CD
cord-005478-5iu38pr6	1012	1	/kg	/kg	NFP
cord-005478-5iu38pr6	1012	2	in	in	IN
cord-005478-5iu38pr6	1012	3	5	5	CD
cord-005478-5iu38pr6	1012	4	pts	pt	NNS
cord-005478-5iu38pr6	1012	5	.	.	.
cord-005478-5iu38pr6	1013	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	1013	2	release	release	NN
cord-005478-5iu38pr6	1013	3	syndrome	syndrome	NN
cord-005478-5iu38pr6	1013	4	occurred	occur	VBD
cord-005478-5iu38pr6	1013	5	in	in	IN
cord-005478-5iu38pr6	1013	6	8	8	CD
cord-005478-5iu38pr6	1013	7	(	(	-LRB-
cord-005478-5iu38pr6	1013	8	53	53	CD
cord-005478-5iu38pr6	1013	9	%	%	NN
cord-005478-5iu38pr6	1013	10	)	)	-RRB-
cord-005478-5iu38pr6	1013	11	pts	pts	CC
cord-005478-5iu38pr6	1013	12	:	:	:
cord-005478-5iu38pr6	1013	13	grade	grade	NN
cord-005478-5iu38pr6	1013	14	I	-PRON-	PRP
cord-005478-5iu38pr6	1013	15	in	in	IN
cord-005478-5iu38pr6	1013	16	5	5	CD
cord-005478-5iu38pr6	1013	17	pts	pt	NNS
cord-005478-5iu38pr6	1013	18	,	,	,
cord-005478-5iu38pr6	1013	19	grade	grade	NN
cord-005478-5iu38pr6	1013	20	II	II	NNP
cord-005478-5iu38pr6	1013	21	in	in	IN
cord-005478-5iu38pr6	1013	22	2	2	CD
cord-005478-5iu38pr6	1013	23	pts	pt	NNS
cord-005478-5iu38pr6	1013	24	,	,	,
cord-005478-5iu38pr6	1013	25	grade	grade	NN
cord-005478-5iu38pr6	1013	26	IV	IV	NNP
cord-005478-5iu38pr6	1013	27	in	in	IN
cord-005478-5iu38pr6	1013	28	1	1	CD
cord-005478-5iu38pr6	1013	29	pts	pts	NN
cord-005478-5iu38pr6	1013	30	.	.	.
cord-005478-5iu38pr6	1014	1	CAR	car	NN
cord-005478-5iu38pr6	1014	2	-	-	HYPH
cord-005478-5iu38pr6	1014	3	T	t	NN
cord-005478-5iu38pr6	1014	4	cell	cell	NN
cord-005478-5iu38pr6	1014	5	related	relate	VBN
cord-005478-5iu38pr6	1014	6	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	1014	7	occurred	occur	VBD
cord-005478-5iu38pr6	1014	8	in	in	IN
cord-005478-5iu38pr6	1014	9	4	4	CD
cord-005478-5iu38pr6	1014	10	(	(	-LRB-
cord-005478-5iu38pr6	1014	11	26	26	CD
cord-005478-5iu38pr6	1014	12	%	%	NN
cord-005478-5iu38pr6	1014	13	)	)	-RRB-
cord-005478-5iu38pr6	1014	14	pts	pt	NNS
cord-005478-5iu38pr6	1014	15	,	,	,
cord-005478-5iu38pr6	1014	16	including	include	VBG
cord-005478-5iu38pr6	1014	17	one	one	CD
cord-005478-5iu38pr6	1014	18	fatal	fatal	JJ
cord-005478-5iu38pr6	1014	19	brain	brain	NN
cord-005478-5iu38pr6	1014	20	edema	edema	NN
cord-005478-5iu38pr6	1014	21	.	.	.
cord-005478-5iu38pr6	1015	1	Grade	grade	NN
cord-005478-5iu38pr6	1015	2	I	-PRON-	PRP
cord-005478-5iu38pr6	1015	3	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	1015	4	had	have	VBD
cord-005478-5iu38pr6	1015	5	2	2	CD
cord-005478-5iu38pr6	1015	6	pts	pts	NN
cord-005478-5iu38pr6	1015	7	,	,	,
cord-005478-5iu38pr6	1015	8	grade	grade	NN
cord-005478-5iu38pr6	1015	9	II	II	NNP
cord-005478-5iu38pr6	1015	10	-1	-1	NNP
cord-005478-5iu38pr6	1015	11	pt	pt	NN
cord-005478-5iu38pr6	1015	12	,	,	,
cord-005478-5iu38pr6	1015	13	grade	grade	NN
cord-005478-5iu38pr6	1015	14	V	V	NNP
cord-005478-5iu38pr6	1015	15	-1	-1	NN
cord-005478-5iu38pr6	1015	16	pt	pt	NN
cord-005478-5iu38pr6	1015	17	.	.	.
cord-005478-5iu38pr6	1016	1	Four	four	CD
cord-005478-5iu38pr6	1016	2	patients	patient	NNS
cord-005478-5iu38pr6	1016	3	were	be	VBD
cord-005478-5iu38pr6	1016	4	admitted	admit	VBN
cord-005478-5iu38pr6	1016	5	to	to	IN
cord-005478-5iu38pr6	1016	6	the	the	DT
cord-005478-5iu38pr6	1016	7	intensive	intensive	JJ
cord-005478-5iu38pr6	1016	8	care	care	NN
cord-005478-5iu38pr6	1016	9	unit	unit	NN
cord-005478-5iu38pr6	1016	10	(	(	-LRB-
cord-005478-5iu38pr6	1016	11	ICU	ICU	NNP
cord-005478-5iu38pr6	1016	12	)	)	-RRB-
cord-005478-5iu38pr6	1016	13	.	.	.
cord-005478-5iu38pr6	1017	1	Three	three	CD
cord-005478-5iu38pr6	1017	2	patients	patient	NNS
cord-005478-5iu38pr6	1017	3	died	die	VBD
cord-005478-5iu38pr6	1017	4	until	until	IN
cord-005478-5iu38pr6	1017	5	day	day	NN
cord-005478-5iu38pr6	1017	6	28	28	CD
cord-005478-5iu38pr6	1017	7	(	(	-LRB-
cord-005478-5iu38pr6	1017	8	2	2	CD
cord-005478-5iu38pr6	1017	9	due	due	JJ
cord-005478-5iu38pr6	1017	10	to	to	IN
cord-005478-5iu38pr6	1017	11	sepsis	sepsis	NN
cord-005478-5iu38pr6	1017	12	,	,	,
cord-005478-5iu38pr6	1017	13	1	1	CD
cord-005478-5iu38pr6	1017	14	due	due	JJ
cord-005478-5iu38pr6	1017	15	to	to	IN
cord-005478-5iu38pr6	1017	16	fatal	fatal	JJ
cord-005478-5iu38pr6	1017	17	brain	brain	NN
cord-005478-5iu38pr6	1017	18	edema	edema	NN
cord-005478-5iu38pr6	1017	19	and	and	CC
cord-005478-5iu38pr6	1017	20	sepsis	sepsis	NN
cord-005478-5iu38pr6	1017	21	,	,	,
cord-005478-5iu38pr6	1017	22	on	on	IN
cord-005478-5iu38pr6	1017	23	autopsy	autopsy	JJ
cord-005478-5iu38pr6	1017	24	in	in	IN
cord-005478-5iu38pr6	1017	25	the	the	DT
cord-005478-5iu38pr6	1017	26	brain	brain	NN
cord-005478-5iu38pr6	1017	27	vessels	vessel	NNS
cord-005478-5iu38pr6	1017	28	of	of	IN
cord-005478-5iu38pr6	1017	29	this	this	DT
cord-005478-5iu38pr6	1017	30	patient	patient	NN
cord-005478-5iu38pr6	1017	31	were	be	VBD
cord-005478-5iu38pr6	1017	32	found	find	VBN
cord-005478-5iu38pr6	1017	33	Klebsiella	Klebsiella	NNP
cord-005478-5iu38pr6	1017	34	pneumoniae	pneumoniae	NN
cord-005478-5iu38pr6	1017	35	emboli	emboli	VB
cord-005478-5iu38pr6	1017	36	)	)	-RRB-
cord-005478-5iu38pr6	1018	1	Twelve	twelve	CD
cord-005478-5iu38pr6	1018	2	patients	patient	NNS
cord-005478-5iu38pr6	1018	3	were	be	VBD
cord-005478-5iu38pr6	1018	4	evaluable	evaluable	JJ
cord-005478-5iu38pr6	1018	5	for	for	IN
cord-005478-5iu38pr6	1018	6	response	response	NN
cord-005478-5iu38pr6	1018	7	at	at	IN
cord-005478-5iu38pr6	1018	8	day	day	NN
cord-005478-5iu38pr6	1018	9	28	28	CD
cord-005478-5iu38pr6	1018	10	.	.	.
cord-005478-5iu38pr6	1019	1	Three	three	CD
cord-005478-5iu38pr6	1019	2	pts	pt	NNS
cord-005478-5iu38pr6	1019	3	had	have	VBD
cord-005478-5iu38pr6	1019	4	persistent	persistent	JJ
cord-005478-5iu38pr6	1019	5	leukemia	leukemia	NN
cord-005478-5iu38pr6	1019	6	,	,	,
cord-005478-5iu38pr6	1019	7	without	without	IN
cord-005478-5iu38pr6	1019	8	evidence	evidence	NN
cord-005478-5iu38pr6	1019	9	of	of	IN
cord-005478-5iu38pr6	1019	10	CAR	car	NN
cord-005478-5iu38pr6	1019	11	-	-	HYPH
cord-005478-5iu38pr6	1019	12	T	t	NN
cord-005478-5iu38pr6	1019	13	expansion	expansion	NN
cord-005478-5iu38pr6	1019	14	.	.	.
cord-005478-5iu38pr6	1020	1	MRD	MRD	NNP
cord-005478-5iu38pr6	1020	2	-	-	HYPH
cord-005478-5iu38pr6	1020	3	negative	negative	JJ
cord-005478-5iu38pr6	1020	4	responses	response	NNS
cord-005478-5iu38pr6	1020	5	were	be	VBD
cord-005478-5iu38pr6	1020	6	achieved	achieve	VBN
cord-005478-5iu38pr6	1020	7	in	in	IN
cord-005478-5iu38pr6	1020	8	8	8	CD
cord-005478-5iu38pr6	1020	9	cases	case	NNS
cord-005478-5iu38pr6	1020	10	among	among	IN
cord-005478-5iu38pr6	1020	11	11	11	CD
cord-005478-5iu38pr6	1020	12	evaluable	evaluable	JJ
cord-005478-5iu38pr6	1020	13	cases	case	NNS
cord-005478-5iu38pr6	1020	14	with	with	IN
cord-005478-5iu38pr6	1020	15	bone	bone	NN
cord-005478-5iu38pr6	1020	16	marrow	marrow	NN
cord-005478-5iu38pr6	1020	17	involvement	involvement	NN
cord-005478-5iu38pr6	1020	18	.	.	.
cord-005478-5iu38pr6	1021	1	Patient	patient	JJ
cord-005478-5iu38pr6	1021	2	with	with	IN
cord-005478-5iu38pr6	1021	3	PMBCL	PMBCL	NNP
cord-005478-5iu38pr6	1021	4	had	have	VBD
cord-005478-5iu38pr6	1021	5	a	a	DT
cord-005478-5iu38pr6	1021	6	decrease	decrease	NN
cord-005478-5iu38pr6	1021	7	in	in	IN
cord-005478-5iu38pr6	1021	8	metabolic	metabolic	JJ
cord-005478-5iu38pr6	1021	9	activity	activity	NN
cord-005478-5iu38pr6	1021	10	on	on	IN
cord-005478-5iu38pr6	1021	11	PET	PET	NNP
cord-005478-5iu38pr6	1021	12	/	/	SYM
cord-005478-5iu38pr6	1021	13	CT	CT	NNP
cord-005478-5iu38pr6	1021	14	scan	scan	NN
cord-005478-5iu38pr6	1021	15	.	.	.
cord-005478-5iu38pr6	1022	1	CD19(-	CD19(-	NNP
cord-005478-5iu38pr6	1022	2	)	)	-RRB-
cord-005478-5iu38pr6	1023	1	relapse	relapse	NN
cord-005478-5iu38pr6	1023	2	after	after	IN
cord-005478-5iu38pr6	1023	3	initial	initial	JJ
cord-005478-5iu38pr6	1023	4	response	response	NN
cord-005478-5iu38pr6	1023	5	was	be	VBD
cord-005478-5iu38pr6	1023	6	registered	register	VBN
cord-005478-5iu38pr6	1023	7	in	in	IN
cord-005478-5iu38pr6	1023	8	1	1	CD
cord-005478-5iu38pr6	1023	9	case	case	NN
cord-005478-5iu38pr6	1023	10	at	at	IN
cord-005478-5iu38pr6	1023	11	109	109	CD
cord-005478-5iu38pr6	1023	12	day	day	NN
cord-005478-5iu38pr6	1023	13	.	.	.
cord-005478-5iu38pr6	1024	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1024	2	:	:	:
cord-005478-5iu38pr6	1025	1	Production	production	NN
cord-005478-5iu38pr6	1025	2	of	of	IN
cord-005478-5iu38pr6	1025	3	CAR	CAR	NNP
cord-005478-5iu38pr6	1025	4	-	-	HYPH
cord-005478-5iu38pr6	1025	5	T	t	NN
cord-005478-5iu38pr6	1025	6	cells	cell	NNS
cord-005478-5iu38pr6	1025	7	with	with	IN
cord-005478-5iu38pr6	1025	8	the	the	DT
cord-005478-5iu38pr6	1025	9	CliniMACS	CliniMACS	NNP
cord-005478-5iu38pr6	1025	10	Prodigy	Prodigy	NNP
cord-005478-5iu38pr6	1025	11	TCT	TCT	NNP
cord-005478-5iu38pr6	1025	12	process	process	NN
cord-005478-5iu38pr6	1025	13	is	be	VBZ
cord-005478-5iu38pr6	1025	14	a	a	DT
cord-005478-5iu38pr6	1025	15	robust	robust	JJ
cord-005478-5iu38pr6	1025	16	option	option	NN
cord-005478-5iu38pr6	1025	17	that	that	WDT
cord-005478-5iu38pr6	1025	18	provides	provide	VBZ
cord-005478-5iu38pr6	1025	19	a	a	DT
cord-005478-5iu38pr6	1025	20	point	point	NN
cord-005478-5iu38pr6	1025	21	-	-	HYPH
cord-005478-5iu38pr6	1025	22	of	of	IN
cord-005478-5iu38pr6	1025	23	-	-	HYPH
cord-005478-5iu38pr6	1025	24	care	care	NN
cord-005478-5iu38pr6	1025	25	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	1025	26	approach	approach	NN
cord-005478-5iu38pr6	1025	27	to	to	TO
cord-005478-5iu38pr6	1025	28	enable	enable	VB
cord-005478-5iu38pr6	1025	29	rapid	rapid	JJ
cord-005478-5iu38pr6	1025	30	and	and	CC
cord-005478-5iu38pr6	1025	31	flexible	flexible	JJ
cord-005478-5iu38pr6	1025	32	delivery	delivery	NN
cord-005478-5iu38pr6	1025	33	of	of	IN
cord-005478-5iu38pr6	1025	34	CAR	car	NN
cord-005478-5iu38pr6	1025	35	-	-	HYPH
cord-005478-5iu38pr6	1025	36	T	t	NN
cord-005478-5iu38pr6	1025	37	cells	cell	NNS
cord-005478-5iu38pr6	1025	38	to	to	IN
cord-005478-5iu38pr6	1025	39	patients	patient	NNS
cord-005478-5iu38pr6	1025	40	in	in	IN
cord-005478-5iu38pr6	1025	41	need	need	NN
cord-005478-5iu38pr6	1025	42	.	.	.
cord-005478-5iu38pr6	1026	1	Robustness	robustness	NN
cord-005478-5iu38pr6	1026	2	and	and	CC
cord-005478-5iu38pr6	1026	3	consistency	consistency	NN
cord-005478-5iu38pr6	1026	4	of	of	IN
cord-005478-5iu38pr6	1026	5	this	this	DT
cord-005478-5iu38pr6	1026	6	approach	approach	NN
cord-005478-5iu38pr6	1026	7	provides	provide	VBZ
cord-005478-5iu38pr6	1026	8	a	a	DT
cord-005478-5iu38pr6	1026	9	solid	solid	JJ
cord-005478-5iu38pr6	1026	10	basis	basis	NN
cord-005478-5iu38pr6	1026	11	for	for	IN
cord-005478-5iu38pr6	1026	12	multi	multi	JJ
cord-005478-5iu38pr6	1026	13	-	-	JJ
cord-005478-5iu38pr6	1026	14	center	center	JJ
cord-005478-5iu38pr6	1026	15	academic	academic	JJ
cord-005478-5iu38pr6	1026	16	trials	trial	NNS
cord-005478-5iu38pr6	1026	17	in	in	IN
cord-005478-5iu38pr6	1026	18	the	the	DT
cord-005478-5iu38pr6	1026	19	field	field	NN
cord-005478-5iu38pr6	1026	20	of	of	IN
cord-005478-5iu38pr6	1026	21	adoptive	adoptive	JJ
cord-005478-5iu38pr6	1026	22	cell	cell	NN
cord-005478-5iu38pr6	1026	23	therapy	therapy	NN
cord-005478-5iu38pr6	1026	24	.	.	.
cord-005478-5iu38pr6	1027	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1027	2	:	:	:
cord-005478-5iu38pr6	1027	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1027	4	to	to	TO
cord-005478-5iu38pr6	1027	5	declare	declare	VB
cord-005478-5iu38pr6	1027	6	Background	background	NN
cord-005478-5iu38pr6	1027	7	:	:	:
cord-005478-5iu38pr6	1027	8	In	in	IN
cord-005478-5iu38pr6	1027	9	the	the	DT
cord-005478-5iu38pr6	1027	10	last	last	JJ
cord-005478-5iu38pr6	1027	11	decade	decade	NN
cord-005478-5iu38pr6	1027	12	,	,	,
cord-005478-5iu38pr6	1027	13	several	several	JJ
cord-005478-5iu38pr6	1027	14	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1027	15	scoring	scoring	NN
cord-005478-5iu38pr6	1027	16	models	model	NNS
cord-005478-5iu38pr6	1027	17	such	such	JJ
cord-005478-5iu38pr6	1027	18	as	as	IN
cord-005478-5iu38pr6	1027	19	the	the	DT
cord-005478-5iu38pr6	1027	20	International	International	NNP
cord-005478-5iu38pr6	1027	21	Prognostic	Prognostic	NNP
cord-005478-5iu38pr6	1027	22	Scoring	Scoring	NNP
cord-005478-5iu38pr6	1027	23	System	System	NNP
cord-005478-5iu38pr6	1027	24	(	(	-LRB-
cord-005478-5iu38pr6	1027	25	IPSS	IPSS	NNP
cord-005478-5iu38pr6	1027	26	)	)	-RRB-
cord-005478-5iu38pr6	1027	27	,	,	,
cord-005478-5iu38pr6	1027	28	the	the	DT
cord-005478-5iu38pr6	1027	29	dynamic	dynamic	JJ
cord-005478-5iu38pr6	1027	30	IPSS	IPSS	NNP
cord-005478-5iu38pr6	1027	31	(	(	-LRB-
cord-005478-5iu38pr6	1027	32	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1027	33	)	)	-RRB-
cord-005478-5iu38pr6	1027	34	or	or	CC
cord-005478-5iu38pr6	1027	35	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1027	36	-	-	HYPH
cord-005478-5iu38pr6	1027	37	plus	plus	CC
cord-005478-5iu38pr6	1027	38	have	have	VBP
cord-005478-5iu38pr6	1027	39	been	be	VBN
cord-005478-5iu38pr6	1027	40	developed	develop	VBN
cord-005478-5iu38pr6	1027	41	for	for	IN
cord-005478-5iu38pr6	1027	42	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1027	43	primary	primary	JJ
cord-005478-5iu38pr6	1027	44	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1027	45	(	(	-LRB-
cord-005478-5iu38pr6	1027	46	PMF	PMF	NNP
cord-005478-5iu38pr6	1027	47	)	)	-RRB-
cord-005478-5iu38pr6	1027	48	and	and	CC
cord-005478-5iu38pr6	1027	49	are	be	VBP
cord-005478-5iu38pr6	1027	50	currently	currently	RB
cord-005478-5iu38pr6	1027	51	used	use	VBN
cord-005478-5iu38pr6	1027	52	for	for	IN
cord-005478-5iu38pr6	1027	53	decision	decision	NN
cord-005478-5iu38pr6	1027	54	finding	finding	NN
cord-005478-5iu38pr6	1027	55	regarding	regard	VBG
cord-005478-5iu38pr6	1027	56	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1027	57	stem	stem	NN
cord-005478-5iu38pr6	1027	58	cell	cell	NN
cord-005478-5iu38pr6	1027	59	transplantation	transplantation	NN
cord-005478-5iu38pr6	1027	60	.	.	.
cord-005478-5iu38pr6	1028	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	1028	2	,	,	,
cord-005478-5iu38pr6	1028	3	the	the	DT
cord-005478-5iu38pr6	1028	4	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1028	5	relevance	relevance	NN
cord-005478-5iu38pr6	1028	6	of	of	IN
cord-005478-5iu38pr6	1028	7	mutation	mutation	NN
cord-005478-5iu38pr6	1028	8	profile	profile	NN
cord-005478-5iu38pr6	1028	9	resulted	result	VBD
cord-005478-5iu38pr6	1028	10	in	in	IN
cord-005478-5iu38pr6	1028	11	a	a	DT
cord-005478-5iu38pr6	1028	12	mutation	mutation	NN
cord-005478-5iu38pr6	1028	13	-	-	HYPH
cord-005478-5iu38pr6	1028	14	enhanced	enhance	VBN
cord-005478-5iu38pr6	1028	15	system	system	NN
cord-005478-5iu38pr6	1028	16	(	(	-LRB-
cord-005478-5iu38pr6	1028	17	MIPSS70	MIPSS70	NNP
cord-005478-5iu38pr6	1028	18	)	)	-RRB-
cord-005478-5iu38pr6	1028	19	in	in	IN
cord-005478-5iu38pr6	1028	20	transplant	transplant	NN
cord-005478-5iu38pr6	1028	21	-	-	HYPH
cord-005478-5iu38pr6	1028	22	age	age	NN
cord-005478-5iu38pr6	1028	23	PMF	PMF	NNP
cord-005478-5iu38pr6	1028	24	patients	patient	NNS
cord-005478-5iu38pr6	1028	25	(	(	-LRB-
cord-005478-5iu38pr6	1028	26	70	70	CD
cord-005478-5iu38pr6	1028	27	years	year	NNS
cord-005478-5iu38pr6	1028	28	or	or	CC
cord-005478-5iu38pr6	1028	29	younger	young	JJR
cord-005478-5iu38pr6	1028	30	)	)	-RRB-
cord-005478-5iu38pr6	1028	31	.	.	.
cord-005478-5iu38pr6	1029	1	For	for	IN
cord-005478-5iu38pr6	1029	2	secondary	secondary	JJ
cord-005478-5iu38pr6	1029	3	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1029	4	,	,	,
cord-005478-5iu38pr6	1029	5	the	the	DT
cord-005478-5iu38pr6	1029	6	MYSEC	MYSEC	NNP
cord-005478-5iu38pr6	1029	7	-	-	HYPH
cord-005478-5iu38pr6	1029	8	PM	PM	NNP
cord-005478-5iu38pr6	1029	9	was	be	VBD
cord-005478-5iu38pr6	1029	10	developed	develop	VBN
cord-005478-5iu38pr6	1029	11	.	.	.
cord-005478-5iu38pr6	1030	1	While	while	IN
cord-005478-5iu38pr6	1030	2	all	all	DT
cord-005478-5iu38pr6	1030	3	scoring	score	VBG
cord-005478-5iu38pr6	1030	4	systems	system	NNS
cord-005478-5iu38pr6	1030	5	were	be	VBD
cord-005478-5iu38pr6	1030	6	developed	develop	VBN
cord-005478-5iu38pr6	1030	7	in	in	IN
cord-005478-5iu38pr6	1030	8	nontransplant	nontransplant	JJ
cord-005478-5iu38pr6	1030	9	populations	population	NNS
cord-005478-5iu38pr6	1030	10	and	and	CC
cord-005478-5iu38pr6	1030	11	may	may	MD
cord-005478-5iu38pr6	1030	12	be	be	VB
cord-005478-5iu38pr6	1030	13	useful	useful	JJ
cord-005478-5iu38pr6	1030	14	in	in	IN
cord-005478-5iu38pr6	1030	15	decision	decision	NN
cord-005478-5iu38pr6	1030	16	finding	finding	NN
cord-005478-5iu38pr6	1030	17	regarding	regard	VBG
cord-005478-5iu38pr6	1030	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	1030	19	,	,	,
cord-005478-5iu38pr6	1030	20	uncertainty	uncertainty	NN
cord-005478-5iu38pr6	1030	21	remains	remain	VBZ
cord-005478-5iu38pr6	1030	22	regarding	regard	VBG
cord-005478-5iu38pr6	1030	23	usefulness	usefulness	NN
cord-005478-5iu38pr6	1030	24	of	of	IN
cord-005478-5iu38pr6	1030	25	these	these	DT
cord-005478-5iu38pr6	1030	26	systems	system	NNS
cord-005478-5iu38pr6	1030	27	to	to	TO
cord-005478-5iu38pr6	1030	28	predict	predict	VB
cord-005478-5iu38pr6	1030	29	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	1030	30	outcome	outcome	NN
cord-005478-5iu38pr6	1030	31	and	and	CC
cord-005478-5iu38pr6	1030	32	thus	thus	RB
cord-005478-5iu38pr6	1030	33	counseling	counsel	VBG
cord-005478-5iu38pr6	1030	34	patients	patient	NNS
cord-005478-5iu38pr6	1030	35	whether	whether	IN
cord-005478-5iu38pr6	1030	36	to	to	TO
cord-005478-5iu38pr6	1030	37	proceed	proceed	VB
cord-005478-5iu38pr6	1030	38	to	to	IN
cord-005478-5iu38pr6	1030	39	transplant	transplant	NN
cord-005478-5iu38pr6	1030	40	.	.	.
cord-005478-5iu38pr6	1031	1	Methods	method	NNS
cord-005478-5iu38pr6	1031	2	:	:	:
cord-005478-5iu38pr6	1031	3	Bone	bone	NN
cord-005478-5iu38pr6	1031	4	marrow	marrow	NN
cord-005478-5iu38pr6	1031	5	or	or	CC
cord-005478-5iu38pr6	1031	6	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1031	7	blood	blood	NN
cord-005478-5iu38pr6	1031	8	samples	sample	NNS
cord-005478-5iu38pr6	1031	9	were	be	VBD
cord-005478-5iu38pr6	1031	10	obtained	obtain	VBN
cord-005478-5iu38pr6	1031	11	before	before	IN
cord-005478-5iu38pr6	1031	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	1031	13	and	and	CC
cord-005478-5iu38pr6	1031	14	mutations	mutation	NNS
cord-005478-5iu38pr6	1031	15	were	be	VBD
cord-005478-5iu38pr6	1031	16	detected	detect	VBN
cord-005478-5iu38pr6	1031	17	using	use	VBG
cord-005478-5iu38pr6	1031	18	next	next	JJ
cord-005478-5iu38pr6	1031	19	-	-	HYPH
cord-005478-5iu38pr6	1031	20	generation	generation	NN
cord-005478-5iu38pr6	1031	21	sequencing	sequencing	NN
cord-005478-5iu38pr6	1031	22	.	.	.
cord-005478-5iu38pr6	1032	1	The	the	DT
cord-005478-5iu38pr6	1032	2	following	follow	VBG
cord-005478-5iu38pr6	1032	3	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1032	4	-	-	HYPH
cord-005478-5iu38pr6	1032	5	associated	associate	VBN
cord-005478-5iu38pr6	1032	6	genes	gene	NNS
cord-005478-5iu38pr6	1032	7	were	be	VBD
cord-005478-5iu38pr6	1032	8	sequenced	sequence	VBN
cord-005478-5iu38pr6	1032	9	:	:	:
cord-005478-5iu38pr6	1032	10	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1032	11	,	,	,
cord-005478-5iu38pr6	1032	12	CALR	CALR	NNP
cord-005478-5iu38pr6	1032	13	,	,	,
cord-005478-5iu38pr6	1032	14	MPL	MPL	NNP
cord-005478-5iu38pr6	1032	15	,	,	,
cord-005478-5iu38pr6	1032	16	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1032	17	,	,	,
cord-005478-5iu38pr6	1032	18	IDH1/2	IDH1/2	NNP
cord-005478-5iu38pr6	1032	19	,	,	,
cord-005478-5iu38pr6	1032	20	CBL	CBL	NNP
cord-005478-5iu38pr6	1032	21	,	,	,
cord-005478-5iu38pr6	1032	22	DNMT3A	DNMT3A	NNP
cord-005478-5iu38pr6	1032	23	,	,	,
cord-005478-5iu38pr6	1032	24	TET2	TET2	NNP
cord-005478-5iu38pr6	1032	25	,	,	,
cord-005478-5iu38pr6	1032	26	SF3B1	SF3B1	NNP
cord-005478-5iu38pr6	1032	27	,	,	,
cord-005478-5iu38pr6	1032	28	SRSF2	SRSF2	VBN
cord-005478-5iu38pr6	1032	29	,	,	,
cord-005478-5iu38pr6	1032	30	U2AF1	U2AF1	NNP
cord-005478-5iu38pr6	1032	31	,	,	,
cord-005478-5iu38pr6	1032	32	EZH2	EZH2	NNP
cord-005478-5iu38pr6	1032	33	,	,	,
cord-005478-5iu38pr6	1032	34	TP53	TP53	NNP
cord-005478-5iu38pr6	1032	35	,	,	,
cord-005478-5iu38pr6	1032	36	NRAS	NRAS	NNP
cord-005478-5iu38pr6	1032	37	,	,	,
cord-005478-5iu38pr6	1032	38	KRAS	KRAS	NNP
cord-005478-5iu38pr6	1032	39	,	,	,
cord-005478-5iu38pr6	1032	40	RUNX1	runx1	NN
cord-005478-5iu38pr6	1032	41	,	,	,
cord-005478-5iu38pr6	1032	42	and	and	CC
cord-005478-5iu38pr6	1032	43	FLT3	FLT3	NNP
cord-005478-5iu38pr6	1032	44	.	.	.
cord-005478-5iu38pr6	1033	1	Cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1033	2	analysis	analysis	NN
cord-005478-5iu38pr6	1033	3	and	and	CC
cord-005478-5iu38pr6	1033	4	reporting	reporting	NN
cord-005478-5iu38pr6	1033	5	were	be	VBD
cord-005478-5iu38pr6	1033	6	performed	perform	VBN
cord-005478-5iu38pr6	1033	7	according	accord	VBG
cord-005478-5iu38pr6	1033	8	to	to	IN
cord-005478-5iu38pr6	1033	9	the	the	DT
cord-005478-5iu38pr6	1033	10	International	International	NNP
cord-005478-5iu38pr6	1033	11	System	System	NNP
cord-005478-5iu38pr6	1033	12	for	for	IN
cord-005478-5iu38pr6	1033	13	Human	Human	NNP
cord-005478-5iu38pr6	1033	14	Cytogenetic	Cytogenetic	NNP
cord-005478-5iu38pr6	1033	15	Nomenclature	Nomenclature	NNP
cord-005478-5iu38pr6	1033	16	criteria	criterion	NNS
cord-005478-5iu38pr6	1033	17	using	use	VBG
cord-005478-5iu38pr6	1033	18	standardized	standardized	JJ
cord-005478-5iu38pr6	1033	19	techniques	technique	NNS
cord-005478-5iu38pr6	1033	20	.	.	.
cord-005478-5iu38pr6	1034	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1034	2	examined	examine	VBD
cord-005478-5iu38pr6	1034	3	361	361	CD
cord-005478-5iu38pr6	1034	4	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1034	5	patients	patient	NNS
cord-005478-5iu38pr6	1034	6	,	,	,
cord-005478-5iu38pr6	1034	7	of	of	IN
cord-005478-5iu38pr6	1034	8	whom	whom	WP
cord-005478-5iu38pr6	1034	9	260	260	CD
cord-005478-5iu38pr6	1034	10	had	have	VBD
cord-005478-5iu38pr6	1034	11	PMF	PMF	NNP
cord-005478-5iu38pr6	1034	12	and	and	CC
cord-005478-5iu38pr6	1034	13	101	101	CD
cord-005478-5iu38pr6	1034	14	SMF	SMF	NNP
cord-005478-5iu38pr6	1034	15	at	at	IN
cord-005478-5iu38pr6	1034	16	time	time	NN
cord-005478-5iu38pr6	1034	17	of	of	IN
cord-005478-5iu38pr6	1034	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	1034	19	.	.	.
cord-005478-5iu38pr6	1035	1	A	a	DT
cord-005478-5iu38pr6	1035	2	training	training	NN
cord-005478-5iu38pr6	1035	3	cohort	cohort	NN
cord-005478-5iu38pr6	1035	4	of	of	IN
cord-005478-5iu38pr6	1035	5	205	205	CD
cord-005478-5iu38pr6	1035	6	patients	patient	NNS
cord-005478-5iu38pr6	1035	7	was	be	VBD
cord-005478-5iu38pr6	1035	8	used	use	VBN
cord-005478-5iu38pr6	1035	9	to	to	TO
cord-005478-5iu38pr6	1035	10	create	create	VB
cord-005478-5iu38pr6	1035	11	a	a	DT
cord-005478-5iu38pr6	1035	12	clinical	clinical	JJ
cord-005478-5iu38pr6	1035	13	-	-	HYPH
cord-005478-5iu38pr6	1035	14	molecular	molecular	JJ
cord-005478-5iu38pr6	1035	15	transplant	transplant	NN
cord-005478-5iu38pr6	1035	16	scoring	scoring	NN
cord-005478-5iu38pr6	1035	17	system	system	NN
cord-005478-5iu38pr6	1035	18	(	(	-LRB-
cord-005478-5iu38pr6	1035	19	MTSS	MTSS	NNP
cord-005478-5iu38pr6	1035	20	)	)	-RRB-
cord-005478-5iu38pr6	1035	21	predicting	predict	VBG
cord-005478-5iu38pr6	1035	22	survival	survival	NN
cord-005478-5iu38pr6	1035	23	from	from	IN
cord-005478-5iu38pr6	1035	24	Cox	Cox	NNP
cord-005478-5iu38pr6	1035	25	models	model	NNS
cord-005478-5iu38pr6	1035	26	,	,	,
cord-005478-5iu38pr6	1035	27	internally	internally	RB
cord-005478-5iu38pr6	1035	28	validated	validate	VBN
cord-005478-5iu38pr6	1035	29	by	by	IN
cord-005478-5iu38pr6	1035	30	use	use	NN
cord-005478-5iu38pr6	1035	31	of	of	IN
cord-005478-5iu38pr6	1035	32	bootstrap	bootstrap	NN
cord-005478-5iu38pr6	1035	33	and	and	CC
cord-005478-5iu38pr6	1035	34	cross	cross	NN
cord-005478-5iu38pr6	1035	35	-	-	NN
cord-005478-5iu38pr6	1035	36	validation	validation	NN
cord-005478-5iu38pr6	1035	37	.	.	.
cord-005478-5iu38pr6	1036	1	Model	model	NN
cord-005478-5iu38pr6	1036	2	discrimination	discrimination	NN
cord-005478-5iu38pr6	1036	3	was	be	VBD
cord-005478-5iu38pr6	1036	4	measured	measure	VBN
cord-005478-5iu38pr6	1036	5	by	by	IN
cord-005478-5iu38pr6	1036	6	the	the	DT
cord-005478-5iu38pr6	1036	7	concordance	concordance	NN
cord-005478-5iu38pr6	1036	8	index	index	NN
cord-005478-5iu38pr6	1036	9	(	(	-LRB-
cord-005478-5iu38pr6	1036	10	C	C	NNP
cord-005478-5iu38pr6	1036	11	)	)	-RRB-
cord-005478-5iu38pr6	1036	12	.	.	.
cord-005478-5iu38pr6	1037	1	The	the	DT
cord-005478-5iu38pr6	1037	2	final	final	JJ
cord-005478-5iu38pr6	1037	3	MTSS	MTSS	NNP
cord-005478-5iu38pr6	1037	4	was	be	VBD
cord-005478-5iu38pr6	1037	5	externally	externally	RB
cord-005478-5iu38pr6	1037	6	validated	validate	VBN
cord-005478-5iu38pr6	1037	7	in	in	IN
cord-005478-5iu38pr6	1037	8	a	a	DT
cord-005478-5iu38pr6	1037	9	cohort	cohort	NN
cord-005478-5iu38pr6	1037	10	of	of	IN
cord-005478-5iu38pr6	1037	11	156	156	CD
cord-005478-5iu38pr6	1037	12	patients	patient	NNS
cord-005478-5iu38pr6	1037	13	and	and	CC
cord-005478-5iu38pr6	1037	14	was	be	VBD
cord-005478-5iu38pr6	1037	15	furthermore	furthermore	RB
cord-005478-5iu38pr6	1037	16	applied	apply	VBN
cord-005478-5iu38pr6	1037	17	to	to	IN
cord-005478-5iu38pr6	1037	18	posttransplant	posttransplant	FW
cord-005478-5iu38pr6	1037	19	non	non	JJ
cord-005478-5iu38pr6	1037	20	-	-	JJ
cord-005478-5iu38pr6	1037	21	relapse	relapse	JJ
cord-005478-5iu38pr6	1037	22	mortality	mortality	NN
cord-005478-5iu38pr6	1037	23	as	as	IN
cord-005478-5iu38pr6	1037	24	a	a	DT
cord-005478-5iu38pr6	1037	25	secondary	secondary	JJ
cord-005478-5iu38pr6	1037	26	objective	objective	NN
cord-005478-5iu38pr6	1037	27	.	.	.
cord-005478-5iu38pr6	1038	1	Results	result	NNS
cord-005478-5iu38pr6	1038	2	:	:	:
cord-005478-5iu38pr6	1039	1	Multivariable	multivariable	JJ
cord-005478-5iu38pr6	1039	2	analysis	analysis	NN
cord-005478-5iu38pr6	1039	3	on	on	IN
cord-005478-5iu38pr6	1039	4	5-year	5-year	CD
cord-005478-5iu38pr6	1039	5	survival	survival	NN
cord-005478-5iu38pr6	1039	6	identified	identify	VBD
cord-005478-5iu38pr6	1039	7	age	age	NN
cord-005478-5iu38pr6	1039	8	≥	≥	CD
cord-005478-5iu38pr6	1039	9	57	57	CD
cord-005478-5iu38pr6	1039	10	years	year	NNS
cord-005478-5iu38pr6	1039	11	,	,	,
cord-005478-5iu38pr6	1039	12	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	1039	13	performance	performance	NN
cord-005478-5iu38pr6	1039	14	status	status	NN
cord-005478-5iu38pr6	1039	15	<	<	XX
cord-005478-5iu38pr6	1039	16	90	90	CD
cord-005478-5iu38pr6	1039	17	%	%	NN
cord-005478-5iu38pr6	1040	1	,	,	,
cord-005478-5iu38pr6	1040	2	platelet	platelet	NN
cord-005478-5iu38pr6	1040	3	count	count	NN
cord-005478-5iu38pr6	1041	1	<	<	XX
cord-005478-5iu38pr6	1041	2	150	150	CD
cord-005478-5iu38pr6	1041	3	x	x	SYM
cord-005478-5iu38pr6	1041	4	10	10	CD
cord-005478-5iu38pr6	1041	5	9	9	CD
cord-005478-5iu38pr6	1041	6	/L	/L	,
cord-005478-5iu38pr6	1041	7	and	and	CC
cord-005478-5iu38pr6	1041	8	leukocyte	leukocyte	NN
cord-005478-5iu38pr6	1041	9	count	count	NN
cord-005478-5iu38pr6	1041	10	>	>	XX
cord-005478-5iu38pr6	1042	1	25	25	CD
cord-005478-5iu38pr6	1042	2	x	x	SYM
cord-005478-5iu38pr6	1042	3	10	10	CD
cord-005478-5iu38pr6	1042	4	9	9	CD
cord-005478-5iu38pr6	1042	5	/L	/L	.
cord-005478-5iu38pr6	1042	6	at	at	IN
cord-005478-5iu38pr6	1042	7	time	time	NN
cord-005478-5iu38pr6	1042	8	of	of	IN
cord-005478-5iu38pr6	1042	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	1042	10	,	,	,
cord-005478-5iu38pr6	1042	11	HLA	HLA	NNP
cord-005478-5iu38pr6	1042	12	-	-	HYPH
cord-005478-5iu38pr6	1042	13	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1042	14	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1042	15	donor	donor	NN
cord-005478-5iu38pr6	1042	16	,	,	,
cord-005478-5iu38pr6	1043	1	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1043	2	mutated	mutate	VBD
cord-005478-5iu38pr6	1043	3	and	and	CC
cord-005478-5iu38pr6	1043	4	CALR-/MPL	CALR-/MPL	NNP
cord-005478-5iu38pr6	1043	5	-	-	HYPH
cord-005478-5iu38pr6	1043	6	unmutated	unmutated	JJ
cord-005478-5iu38pr6	1043	7	genotype	genotype	NN
cord-005478-5iu38pr6	1043	8	being	be	VBG
cord-005478-5iu38pr6	1043	9	independent	independent	JJ
cord-005478-5iu38pr6	1043	10	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1043	11	factors	factor	NNS
cord-005478-5iu38pr6	1043	12	for	for	IN
cord-005478-5iu38pr6	1043	13	outcome	outcome	NN
cord-005478-5iu38pr6	1043	14	.	.	.
cord-005478-5iu38pr6	1044	1	The	the	DT
cord-005478-5iu38pr6	1044	2	uncorrected	uncorrected	JJ
cord-005478-5iu38pr6	1044	3	concordance	concordance	NN
cord-005478-5iu38pr6	1044	4	index	index	NN
cord-005478-5iu38pr6	1044	5	for	for	IN
cord-005478-5iu38pr6	1044	6	the	the	DT
cord-005478-5iu38pr6	1044	7	final	final	JJ
cord-005478-5iu38pr6	1044	8	survival	survival	NN
cord-005478-5iu38pr6	1044	9	model	model	NN
cord-005478-5iu38pr6	1044	10	was	be	VBD
cord-005478-5iu38pr6	1044	11	0.723	0.723	CD
cord-005478-5iu38pr6	1044	12	(	(	-LRB-
cord-005478-5iu38pr6	1044	13	0.713	0.713	CD
cord-005478-5iu38pr6	1044	14	-	-	SYM
cord-005478-5iu38pr6	1044	15	0.733	0.733	CD
cord-005478-5iu38pr6	1044	16	)	)	-RRB-
cord-005478-5iu38pr6	1044	17	,	,	,
cord-005478-5iu38pr6	1044	18	and	and	CC
cord-005478-5iu38pr6	1044	19	bias	bias	NN
cord-005478-5iu38pr6	1044	20	-	-	HYPH
cord-005478-5iu38pr6	1044	21	corrected	correct	VBN
cord-005478-5iu38pr6	1044	22	indices	index	NNS
cord-005478-5iu38pr6	1044	23	were	be	VBD
cord-005478-5iu38pr6	1044	24	similar	similar	JJ
cord-005478-5iu38pr6	1044	25	.	.	.
cord-005478-5iu38pr6	1045	1	A	a	DT
cord-005478-5iu38pr6	1045	2	weighted	weighted	JJ
cord-005478-5iu38pr6	1045	3	score	score	NN
cord-005478-5iu38pr6	1045	4	of	of	IN
cord-005478-5iu38pr6	1045	5	2	2	CD
cord-005478-5iu38pr6	1045	6	was	be	VBD
cord-005478-5iu38pr6	1045	7	assigned	assign	VBN
cord-005478-5iu38pr6	1045	8	to	to	IN
cord-005478-5iu38pr6	1045	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	1045	10	from	from	IN
cord-005478-5iu38pr6	1045	11	an	an	DT
cord-005478-5iu38pr6	1045	12	HLA	HLA	NNP
cord-005478-5iu38pr6	1045	13	-	-	HYPH
cord-005478-5iu38pr6	1045	14	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1045	15	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1045	16	donor	donor	NN
cord-005478-5iu38pr6	1045	17	and	and	CC
cord-005478-5iu38pr6	1045	18	an	an	DT
cord-005478-5iu38pr6	1045	19	CALR-/MPLunmutated	calr-/mplunmutated	CD
cord-005478-5iu38pr6	1045	20	genotype	genotype	NN
cord-005478-5iu38pr6	1045	21	,	,	,
cord-005478-5iu38pr6	1045	22	whereas	whereas	IN
cord-005478-5iu38pr6	1045	23	a	a	DT
cord-005478-5iu38pr6	1045	24	score	score	NN
cord-005478-5iu38pr6	1045	25	of	of	IN
cord-005478-5iu38pr6	1045	26	1	1	CD
cord-005478-5iu38pr6	1045	27	was	be	VBD
cord-005478-5iu38pr6	1045	28	assigned	assign	VBN
cord-005478-5iu38pr6	1045	29	to	to	IN
cord-005478-5iu38pr6	1045	30	older	old	JJR
cord-005478-5iu38pr6	1045	31	age	age	NN
cord-005478-5iu38pr6	1045	32	,	,	,
cord-005478-5iu38pr6	1045	33	leukocytosis	leukocytosis	NN
cord-005478-5iu38pr6	1045	34	,	,	,
cord-005478-5iu38pr6	1045	35	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	1045	36	,	,	,
cord-005478-5iu38pr6	1045	37	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1045	38	mutation	mutation	NN
cord-005478-5iu38pr6	1045	39	,	,	,
cord-005478-5iu38pr6	1045	40	and	and	CC
cord-005478-5iu38pr6	1045	41	poor	poor	JJ
cord-005478-5iu38pr6	1045	42	performance	performance	NN
cord-005478-5iu38pr6	1045	43	status	status	NN
cord-005478-5iu38pr6	1045	44	.	.	.
cord-005478-5iu38pr6	1046	1	The	the	DT
cord-005478-5iu38pr6	1046	2	MTSS	MTSS	NNP
cord-005478-5iu38pr6	1046	3	consisted	consist	VBD
cord-005478-5iu38pr6	1046	4	of	of	IN
cord-005478-5iu38pr6	1046	5	four	four	CD
cord-005478-5iu38pr6	1046	6	distinct	distinct	JJ
cord-005478-5iu38pr6	1046	7	risk	risk	NN
cord-005478-5iu38pr6	1046	8	groups	group	NNS
cord-005478-5iu38pr6	1046	9	showing	show	VBG
cord-005478-5iu38pr6	1046	10	5-year	5-year	CD
cord-005478-5iu38pr6	1046	11	survival	survival	NN
cord-005478-5iu38pr6	1046	12	in	in	IN
cord-005478-5iu38pr6	1046	13	the	the	DT
cord-005478-5iu38pr6	1046	14	validation	validation	NN
cord-005478-5iu38pr6	1046	15	cohort	cohort	NN
cord-005478-5iu38pr6	1046	16	of	of	IN
cord-005478-5iu38pr6	1046	17	83	83	CD
cord-005478-5iu38pr6	1046	18	%	%	NN
cord-005478-5iu38pr6	1046	19	(	(	-LRB-
cord-005478-5iu38pr6	1046	20	71	71	CD
cord-005478-5iu38pr6	1046	21	-	-	SYM
cord-005478-5iu38pr6	1046	22	95	95	CD
cord-005478-5iu38pr6	1046	23	%	%	NN
cord-005478-5iu38pr6	1046	24	)	)	-RRB-
cord-005478-5iu38pr6	1046	25	for	for	IN
cord-005478-5iu38pr6	1046	26	low	low	JJ
cord-005478-5iu38pr6	1046	27	(	(	-LRB-
cord-005478-5iu38pr6	1046	28	score	score	NN
cord-005478-5iu38pr6	1046	29	0	0	CD
cord-005478-5iu38pr6	1046	30	-	-	SYM
cord-005478-5iu38pr6	1046	31	2	2	CD
cord-005478-5iu38pr6	1046	32	)	)	-RRB-
cord-005478-5iu38pr6	1046	33	,	,	,
cord-005478-5iu38pr6	1046	34	64	64	CD
cord-005478-5iu38pr6	1046	35	%	%	NN
cord-005478-5iu38pr6	1046	36	(	(	-LRB-
cord-005478-5iu38pr6	1046	37	53	53	CD
cord-005478-5iu38pr6	1046	38	-	-	SYM
cord-005478-5iu38pr6	1046	39	75	75	CD
cord-005478-5iu38pr6	1046	40	%	%	NN
cord-005478-5iu38pr6	1046	41	)	)	-RRB-
cord-005478-5iu38pr6	1046	42	for	for	IN
cord-005478-5iu38pr6	1046	43	intermediate	intermediate	JJ
cord-005478-5iu38pr6	1046	44	(	(	-LRB-
cord-005478-5iu38pr6	1046	45	score	score	VB
cord-005478-5iu38pr6	1046	46	[	[	-LRB-
cord-005478-5iu38pr6	1046	47	3	3	CD
cord-005478-5iu38pr6	1046	48	]	]	-RRB-
cord-005478-5iu38pr6	1046	49	[	[	-LRB-
cord-005478-5iu38pr6	1046	50	4	4	CD
cord-005478-5iu38pr6	1046	51	]	]	-RRB-
cord-005478-5iu38pr6	1046	52	,	,	,
cord-005478-5iu38pr6	1046	53	37	37	CD
cord-005478-5iu38pr6	1046	54	%	%	NN
cord-005478-5iu38pr6	1046	55	(	(	-LRB-
cord-005478-5iu38pr6	1046	56	17	17	CD
cord-005478-5iu38pr6	1046	57	-	-	SYM
cord-005478-5iu38pr6	1046	58	57	57	CD
cord-005478-5iu38pr6	1046	59	%	%	NN
cord-005478-5iu38pr6	1046	60	)	)	-RRB-
cord-005478-5iu38pr6	1046	61	for	for	IN
cord-005478-5iu38pr6	1046	62	high	high	JJ
cord-005478-5iu38pr6	1046	63	(	(	-LRB-
cord-005478-5iu38pr6	1046	64	score	score	NN
cord-005478-5iu38pr6	1046	65	5	5	CD
cord-005478-5iu38pr6	1046	66	)	)	-RRB-
cord-005478-5iu38pr6	1046	67	,	,	,
cord-005478-5iu38pr6	1046	68	and	and	CC
cord-005478-5iu38pr6	1046	69	22	22	CD
cord-005478-5iu38pr6	1046	70	%	%	NN
cord-005478-5iu38pr6	1046	71	(	(	-LRB-
cord-005478-5iu38pr6	1046	72	4	4	CD
cord-005478-5iu38pr6	1046	73	-	-	SYM
cord-005478-5iu38pr6	1046	74	39	39	CD
cord-005478-5iu38pr6	1046	75	%	%	NN
cord-005478-5iu38pr6	1046	76	)	)	-RRB-
cord-005478-5iu38pr6	1046	77	for	for	IN
cord-005478-5iu38pr6	1046	78	very	very	RB
cord-005478-5iu38pr6	1046	79	high	high	JJ
cord-005478-5iu38pr6	1046	80	risk	risk	NN
cord-005478-5iu38pr6	1046	81	(	(	-LRB-
cord-005478-5iu38pr6	1046	82	score	score	NN
cord-005478-5iu38pr6	1046	83	>	>	XX
cord-005478-5iu38pr6	1046	84	5	5	CD
cord-005478-5iu38pr6	1046	85	)	)	-RRB-
cord-005478-5iu38pr6	1046	86	,	,	,
cord-005478-5iu38pr6	1046	87	respectively	respectively	RB
cord-005478-5iu38pr6	1046	88	(	(	-LRB-
cord-005478-5iu38pr6	1046	89	P	p	NN
cord-005478-5iu38pr6	1046	90	<	<	XX
cord-005478-5iu38pr6	1046	91	0.001	0.001	CD
cord-005478-5iu38pr6	1046	92	)	)	-RRB-
cord-005478-5iu38pr6	1046	93	.	.	.
cord-005478-5iu38pr6	1047	1	Increasing	increase	VBG
cord-005478-5iu38pr6	1047	2	score	score	NN
cord-005478-5iu38pr6	1047	3	was	be	VBD
cord-005478-5iu38pr6	1047	4	predictive	predictive	JJ
cord-005478-5iu38pr6	1047	5	of	of	IN
cord-005478-5iu38pr6	1047	6	non	non	JJ
cord-005478-5iu38pr6	1047	7	-	-	JJ
cord-005478-5iu38pr6	1047	8	relapse	relapse	JJ
cord-005478-5iu38pr6	1047	9	mortality	mortality	NN
cord-005478-5iu38pr6	1047	10	(	(	-LRB-
cord-005478-5iu38pr6	1047	11	P	p	NN
cord-005478-5iu38pr6	1047	12	<	<	XX
cord-005478-5iu38pr6	1047	13	0.001	0.001	CD
cord-005478-5iu38pr6	1047	14	)	)	-RRB-
cord-005478-5iu38pr6	1047	15	and	and	CC
cord-005478-5iu38pr6	1047	16	remained	remain	VBD
cord-005478-5iu38pr6	1047	17	applicable	applicable	JJ
cord-005478-5iu38pr6	1047	18	to	to	IN
cord-005478-5iu38pr6	1047	19	PMF	PMF	NNP
cord-005478-5iu38pr6	1047	20	(	(	-LRB-
cord-005478-5iu38pr6	1047	21	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1047	22	:	:	:
cord-005478-5iu38pr6	1048	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1048	2	show	show	VBP
cord-005478-5iu38pr6	1048	3	here	here	RB
cord-005478-5iu38pr6	1048	4	that	that	IN
cord-005478-5iu38pr6	1048	5	this	this	DT
cord-005478-5iu38pr6	1048	6	internally	internally	RB
cord-005478-5iu38pr6	1048	7	and	and	CC
cord-005478-5iu38pr6	1048	8	externally	externally	RB
cord-005478-5iu38pr6	1048	9	validated	validate	VBD
cord-005478-5iu38pr6	1048	10	MTSS	MTSS	NNP
cord-005478-5iu38pr6	1048	11	accurately	accurately	RB
cord-005478-5iu38pr6	1048	12	discriminated	discriminate	VBD
cord-005478-5iu38pr6	1048	13	different	different	JJ
cord-005478-5iu38pr6	1048	14	risk	risk	NN
cord-005478-5iu38pr6	1048	15	for	for	IN
cord-005478-5iu38pr6	1048	16	death	death	NN
cord-005478-5iu38pr6	1048	17	and	and	CC
cord-005478-5iu38pr6	1048	18	may	may	MD
cord-005478-5iu38pr6	1048	19	improve	improve	VB
cord-005478-5iu38pr6	1048	20	counseling	counseling	NN
cord-005478-5iu38pr6	1048	21	patients	patient	NNS
cord-005478-5iu38pr6	1048	22	with	with	IN
cord-005478-5iu38pr6	1048	23	respect	respect	NN
cord-005478-5iu38pr6	1048	24	to	to	IN
cord-005478-5iu38pr6	1048	25	transplant	transplant	NN
cord-005478-5iu38pr6	1048	26	compared	compare	VBN
cord-005478-5iu38pr6	1048	27	with	with	IN
cord-005478-5iu38pr6	1048	28	currently	currently	RB
cord-005478-5iu38pr6	1048	29	existing	exist	VBG
cord-005478-5iu38pr6	1048	30	systems	system	NNS
cord-005478-5iu38pr6	1048	31	,	,	,
cord-005478-5iu38pr6	1048	32	as	as	RB
cord-005478-5iu38pr6	1048	33	well	well	RB
cord-005478-5iu38pr6	1048	34	as	as	IN
cord-005478-5iu38pr6	1048	35	facilitate	facilitate	JJ
cord-005478-5iu38pr6	1048	36	design	design	NN
cord-005478-5iu38pr6	1048	37	of	of	IN
cord-005478-5iu38pr6	1048	38	clinical	clinical	JJ
cord-005478-5iu38pr6	1048	39	trials	trial	NNS
cord-005478-5iu38pr6	1048	40	in	in	IN
cord-005478-5iu38pr6	1048	41	the	the	DT
cord-005478-5iu38pr6	1048	42	transplant	transplant	NN
cord-005478-5iu38pr6	1048	43	setting	setting	NN
cord-005478-5iu38pr6	1048	44	.	.	.
cord-005478-5iu38pr6	1049	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1049	2	:	:	:
cord-005478-5iu38pr6	1049	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1049	4	to	to	TO
cord-005478-5iu38pr6	1049	5	declare	declare	VB
cord-005478-5iu38pr6	1049	6	.	.	.
cord-005478-5iu38pr6	1050	1	Response	response	NN
cord-005478-5iu38pr6	1050	2	to	to	IN
cord-005478-5iu38pr6	1050	3	up	up	IN
cord-005478-5iu38pr6	1050	4	-	-	HYPH
cord-005478-5iu38pr6	1050	5	front	front	NN
cord-005478-5iu38pr6	1050	6	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	1050	7	in	in	IN
cord-005478-5iu38pr6	1050	8	juvenile	juvenile	JJ
cord-005478-5iu38pr6	1050	9	myelomonocytic	myelomonocytic	NN
cord-005478-5iu38pr6	1050	10	leukemia	leukemia	NN
cord-005478-5iu38pr6	1050	11	(	(	-LRB-
cord-005478-5iu38pr6	1050	12	JMML	JMML	NNP
cord-005478-5iu38pr6	1050	13	)	)	-RRB-
cord-005478-5iu38pr6	1050	14	:	:	:
cord-005478-5iu38pr6	1051	1	Interim	interim	JJ
cord-005478-5iu38pr6	1051	2	analysis	analysis	NN
cord-005478-5iu38pr6	1051	3	of	of	IN
cord-005478-5iu38pr6	1051	4	the	the	DT
cord-005478-5iu38pr6	1051	5	prospective	prospective	JJ
cord-005478-5iu38pr6	1051	6	European	european	JJ
cord-005478-5iu38pr6	1051	7	multicenter	multicenter	JJ
cord-005478-5iu38pr6	1051	8	study	study	NN
cord-005478-5iu38pr6	1051	9	AZA	AZA	NNP
cord-005478-5iu38pr6	1051	10	-	-	HYPH
cord-005478-5iu38pr6	1051	11	JMML-001	JMML-001	NNP
cord-005478-5iu38pr6	1051	12	Background	Background	NNP
cord-005478-5iu38pr6	1051	13	:	:	:
cord-005478-5iu38pr6	1051	14	JMML	JMML	NNP
cord-005478-5iu38pr6	1051	15	is	be	VBZ
cord-005478-5iu38pr6	1051	16	a	a	DT
cord-005478-5iu38pr6	1051	17	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	1051	18	-	-	HYPH
cord-005478-5iu38pr6	1051	19	resistant	resistant	JJ
cord-005478-5iu38pr6	1051	20	neoplasia	neoplasia	NN
cord-005478-5iu38pr6	1051	21	of	of	IN
cord-005478-5iu38pr6	1051	22	early	early	JJ
cord-005478-5iu38pr6	1051	23	childhood	childhood	NN
cord-005478-5iu38pr6	1051	24	.	.	.
cord-005478-5iu38pr6	1052	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1052	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1052	3	stem	stem	NN
cord-005478-5iu38pr6	1052	4	cell	cell	NN
cord-005478-5iu38pr6	1052	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	1052	6	(	(	-LRB-
cord-005478-5iu38pr6	1052	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1052	8	)	)	-RRB-
cord-005478-5iu38pr6	1052	9	is	be	VBZ
cord-005478-5iu38pr6	1052	10	the	the	DT
cord-005478-5iu38pr6	1052	11	only	only	JJ
cord-005478-5iu38pr6	1052	12	curative	curative	JJ
cord-005478-5iu38pr6	1052	13	therapy	therapy	NN
cord-005478-5iu38pr6	1052	14	,	,	,
cord-005478-5iu38pr6	1052	15	saving	save	VBG
cord-005478-5iu38pr6	1052	16	approximately	approximately	RB
cord-005478-5iu38pr6	1052	17	50	50	CD
cord-005478-5iu38pr6	1052	18	%	%	NN
cord-005478-5iu38pr6	1052	19	of	of	IN
cord-005478-5iu38pr6	1052	20	these	these	DT
cord-005478-5iu38pr6	1052	21	children	child	NNS
cord-005478-5iu38pr6	1052	22	.	.	.
cord-005478-5iu38pr6	1053	1	Relapse	relapse	NN
cord-005478-5iu38pr6	1053	2	is	be	VBZ
cord-005478-5iu38pr6	1053	3	the	the	DT
cord-005478-5iu38pr6	1053	4	major	major	JJ
cord-005478-5iu38pr6	1053	5	cause	cause	NN
cord-005478-5iu38pr6	1053	6	of	of	IN
cord-005478-5iu38pr6	1053	7	treatment	treatment	NN
cord-005478-5iu38pr6	1053	8	failure	failure	NN
cord-005478-5iu38pr6	1053	9	,	,	,
cord-005478-5iu38pr6	1053	10	with	with	IN
cord-005478-5iu38pr6	1053	11	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	1053	12	prior	prior	RB
cord-005478-5iu38pr6	1053	13	to	to	IN
cord-005478-5iu38pr6	1053	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1053	15	being	be	VBG
cord-005478-5iu38pr6	1053	16	notably	notably	RB
cord-005478-5iu38pr6	1053	17	unsuccessful	unsuccessful	JJ
cord-005478-5iu38pr6	1053	18	.	.	.
cord-005478-5iu38pr6	1054	1	Novel	novel	JJ
cord-005478-5iu38pr6	1054	2	therapies	therapy	NNS
cord-005478-5iu38pr6	1054	3	controlling	control	VBG
cord-005478-5iu38pr6	1054	4	the	the	DT
cord-005478-5iu38pr6	1054	5	disorder	disorder	NN
cord-005478-5iu38pr6	1054	6	prior	prior	RB
cord-005478-5iu38pr6	1054	7	to	to	IN
cord-005478-5iu38pr6	1054	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1054	9	are	be	VBP
cord-005478-5iu38pr6	1054	10	urgently	urgently	RB
cord-005478-5iu38pr6	1054	11	needed	need	VBN
cord-005478-5iu38pr6	1054	12	.	.	.
cord-005478-5iu38pr6	1055	1	Methods	method	NNS
cord-005478-5iu38pr6	1055	2	:	:	:
cord-005478-5iu38pr6	1055	3	We	-PRON-	PRP
cord-005478-5iu38pr6	1055	4	conducted	conduct	VBD
cord-005478-5iu38pr6	1055	5	a	a	DT
cord-005478-5iu38pr6	1055	6	phase	phase	NN
cord-005478-5iu38pr6	1055	7	2	2	CD
cord-005478-5iu38pr6	1055	8	,	,	,
cord-005478-5iu38pr6	1055	9	multicenter	multicenter	JJ
cord-005478-5iu38pr6	1055	10	,	,	,
cord-005478-5iu38pr6	1055	11	open	open	JJ
cord-005478-5iu38pr6	1055	12	-	-	HYPH
cord-005478-5iu38pr6	1055	13	label	label	NN
cord-005478-5iu38pr6	1055	14	study	study	NN
cord-005478-5iu38pr6	1055	15	to	to	TO
cord-005478-5iu38pr6	1055	16	evaluate	evaluate	VB
cord-005478-5iu38pr6	1055	17	pharmacodynamics	pharmacodynamic	NNS
cord-005478-5iu38pr6	1055	18	,	,	,
cord-005478-5iu38pr6	1055	19	safety	safety	NN
cord-005478-5iu38pr6	1055	20	,	,	,
cord-005478-5iu38pr6	1055	21	and	and	CC
cord-005478-5iu38pr6	1055	22	antileukemic	antileukemic	JJ
cord-005478-5iu38pr6	1055	23	activity	activity	NN
cord-005478-5iu38pr6	1055	24	of	of	IN
cord-005478-5iu38pr6	1055	25	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	1055	26	monotherapy	monotherapy	VBD
cord-005478-5iu38pr6	1055	27	prior	prior	RB
cord-005478-5iu38pr6	1055	28	to	to	IN
cord-005478-5iu38pr6	1055	29	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1055	30	in	in	IN
cord-005478-5iu38pr6	1055	31	patients	patient	NNS
cord-005478-5iu38pr6	1055	32	with	with	IN
cord-005478-5iu38pr6	1055	33	newly	newly	RB
cord-005478-5iu38pr6	1055	34	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1055	35	JMML	JMML	NNP
cord-005478-5iu38pr6	1055	36	.	.	.
cord-005478-5iu38pr6	1056	1	Azacitidine	Azacitidine	NNP
cord-005478-5iu38pr6	1056	2	was	be	VBD
cord-005478-5iu38pr6	1056	3	administered	administer	VBN
cord-005478-5iu38pr6	1056	4	at	at	IN
cord-005478-5iu38pr6	1056	5	75	75	CD
cord-005478-5iu38pr6	1056	6	mg	mg	NNP
cord-005478-5iu38pr6	1056	7	/	/	SYM
cord-005478-5iu38pr6	1056	8	m	m	NN
cord-005478-5iu38pr6	1056	9	2	2	CD
cord-005478-5iu38pr6	1056	10	/day	/day	.
cord-005478-5iu38pr6	1056	11	intravenously	intravenously	RB
cord-005478-5iu38pr6	1056	12	on	on	IN
cord-005478-5iu38pr6	1056	13	days	day	NNS
cord-005478-5iu38pr6	1056	14	1	1	CD
cord-005478-5iu38pr6	1056	15	-	-	SYM
cord-005478-5iu38pr6	1056	16	7	7	CD
cord-005478-5iu38pr6	1056	17	of	of	IN
cord-005478-5iu38pr6	1056	18	a	a	DT
cord-005478-5iu38pr6	1056	19	28-day	28-day	CD
cord-005478-5iu38pr6	1056	20	cycle	cycle	NN
cord-005478-5iu38pr6	1056	21	for	for	IN
cord-005478-5iu38pr6	1056	22	3	3	CD
cord-005478-5iu38pr6	1056	23	to	to	TO
cord-005478-5iu38pr6	1056	24	6	6	CD
cord-005478-5iu38pr6	1056	25	cycles	cycle	NNS
cord-005478-5iu38pr6	1056	26	.	.	.
cord-005478-5iu38pr6	1057	1	The	the	DT
cord-005478-5iu38pr6	1057	2	primary	primary	JJ
cord-005478-5iu38pr6	1057	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	1057	4	was	be	VBD
cord-005478-5iu38pr6	1057	5	the	the	DT
cord-005478-5iu38pr6	1057	6	number	number	NN
cord-005478-5iu38pr6	1057	7	of	of	IN
cord-005478-5iu38pr6	1057	8	patients	patient	NNS
cord-005478-5iu38pr6	1057	9	with	with	IN
cord-005478-5iu38pr6	1057	10	clinical	clinical	JJ
cord-005478-5iu38pr6	1057	11	complete	complete	JJ
cord-005478-5iu38pr6	1057	12	remission	remission	NN
cord-005478-5iu38pr6	1057	13	or	or	CC
cord-005478-5iu38pr6	1057	14	clinical	clinical	JJ
cord-005478-5iu38pr6	1057	15	partial	partial	JJ
cord-005478-5iu38pr6	1057	16	remission	remission	NN
cord-005478-5iu38pr6	1057	17	(	(	-LRB-
cord-005478-5iu38pr6	1057	18	cPR	cpr	NN
cord-005478-5iu38pr6	1057	19	)	)	-RRB-
cord-005478-5iu38pr6	1057	20	at	at	IN
cord-005478-5iu38pr6	1057	21	Cycle	Cycle	NNP
cord-005478-5iu38pr6	1057	22	3	3	CD
cord-005478-5iu38pr6	1057	23	Day	Day	NNP
cord-005478-5iu38pr6	1057	24	28	28	CD
cord-005478-5iu38pr6	1057	25	(	(	-LRB-
cord-005478-5iu38pr6	1057	26	C3D28	C3D28	NNP
cord-005478-5iu38pr6	1057	27	)	)	-RRB-
cord-005478-5iu38pr6	1057	28	;	;	,
cord-005478-5iu38pr6	1057	29	secondary	secondary	JJ
cord-005478-5iu38pr6	1057	30	endpoints	endpoint	NNS
cord-005478-5iu38pr6	1057	31	included	include	VBD
cord-005478-5iu38pr6	1057	32	overall	overall	JJ
cord-005478-5iu38pr6	1057	33	survival	survival	NN
cord-005478-5iu38pr6	1057	34	following	follow	VBG
cord-005478-5iu38pr6	1057	35	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1057	36	.	.	.
cord-005478-5iu38pr6	1058	1	Results	result	NNS
cord-005478-5iu38pr6	1058	2	:	:	:
cord-005478-5iu38pr6	1059	1	Eighteen	eighteen	CD
cord-005478-5iu38pr6	1059	2	JMML	JMML	NNP
cord-005478-5iu38pr6	1059	3	patients	patient	NNS
cord-005478-5iu38pr6	1059	4	(	(	-LRB-
cord-005478-5iu38pr6	1059	5	13	13	CD
cord-005478-5iu38pr6	1059	6	PTPN11-	ptpn11-	JJ
cord-005478-5iu38pr6	1059	7	,	,	,
cord-005478-5iu38pr6	1059	8	3	3	CD
cord-005478-5iu38pr6	1059	9	NRAS-	NRAS-	NNS
cord-005478-5iu38pr6	1059	10	,	,	,
cord-005478-5iu38pr6	1059	11	1	1	CD
cord-005478-5iu38pr6	1059	12	KRAS-	KRAS-	NNS
cord-005478-5iu38pr6	1059	13	,	,	,
cord-005478-5iu38pr6	1059	14	1	1	CD
cord-005478-5iu38pr6	1059	15	NF1-mutated	nf1-mutated	CD
cord-005478-5iu38pr6	1059	16	)	)	-RRB-
cord-005478-5iu38pr6	1059	17	aged	age	VBN
cord-005478-5iu38pr6	1059	18	0.2	0.2	CD
cord-005478-5iu38pr6	1059	19	-	-	HYPH
cord-005478-5iu38pr6	1059	20	7.0	7.0	CD
cord-005478-5iu38pr6	1059	21	years	year	NNS
cord-005478-5iu38pr6	1059	22	were	be	VBD
cord-005478-5iu38pr6	1059	23	enrolled	enrol	VBN
cord-005478-5iu38pr6	1059	24	.	.	.
cord-005478-5iu38pr6	1060	1	Median	median	JJ
cord-005478-5iu38pr6	1061	1	(	(	-LRB-
cord-005478-5iu38pr6	1061	2	range	range	NN
cord-005478-5iu38pr6	1061	3	)	)	-RRB-
cord-005478-5iu38pr6	1061	4	WBC	WBC	NNP
cord-005478-5iu38pr6	1061	5	,	,	,
cord-005478-5iu38pr6	1061	6	platelet	platelet	NN
cord-005478-5iu38pr6	1061	7	count	count	NN
cord-005478-5iu38pr6	1061	8	and	and	CC
cord-005478-5iu38pr6	1061	9	spleen	spleen	NN
cord-005478-5iu38pr6	1061	10	size	size	NN
cord-005478-5iu38pr6	1061	11	were	be	VBD
cord-005478-5iu38pr6	1061	12	:	:	:
cord-005478-5iu38pr6	1061	13	19.7	19.7	CD
cord-005478-5iu38pr6	1061	14	(	(	-LRB-
cord-005478-5iu38pr6	1061	15	4.3	4.3	CD
cord-005478-5iu38pr6	1061	16	-	-	HYPH
cord-005478-5iu38pr6	1061	17	59.0	59.0	CD
cord-005478-5iu38pr6	1061	18	)	)	-RRB-
cord-005478-5iu38pr6	1061	19	×	×	NN
cord-005478-5iu38pr6	1061	20	10	10	CD
cord-005478-5iu38pr6	1061	21	9	9	CD
cord-005478-5iu38pr6	1061	22	/L	/l	CD
cord-005478-5iu38pr6	1061	23	,	,	,
cord-005478-5iu38pr6	1061	24	28	28	CD
cord-005478-5iu38pr6	1061	25	(	(	-LRB-
cord-005478-5iu38pr6	1061	26	7	7	CD
cord-005478-5iu38pr6	1061	27	-	-	SYM
cord-005478-5iu38pr6	1061	28	85	85	CD
cord-005478-5iu38pr6	1061	29	)	)	-RRB-
cord-005478-5iu38pr6	1061	30	×	×	NN
cord-005478-5iu38pr6	1061	31	10	10	CD
cord-005478-5iu38pr6	1061	32	9	9	CD
cord-005478-5iu38pr6	1061	33	/L	/l	CD
cord-005478-5iu38pr6	1061	34	,	,	,
cord-005478-5iu38pr6	1061	35	and	and	CC
cord-005478-5iu38pr6	1061	36	4	4	CD
cord-005478-5iu38pr6	1061	37	(	(	-LRB-
cord-005478-5iu38pr6	1061	38	2	2	CD
cord-005478-5iu38pr6	1061	39	-	-	SYM
cord-005478-5iu38pr6	1061	40	14	14	CD
cord-005478-5iu38pr6	1061	41	)	)	-RRB-
cord-005478-5iu38pr6	1061	42	cm	cm	VBP
cord-005478-5iu38pr6	1061	43	below	below	IN
cord-005478-5iu38pr6	1061	44	the	the	DT
cord-005478-5iu38pr6	1061	45	costal	costal	JJ
cord-005478-5iu38pr6	1061	46	margin	margin	NN
cord-005478-5iu38pr6	1061	47	,	,	,
cord-005478-5iu38pr6	1061	48	respectively	respectively	RB
cord-005478-5iu38pr6	1061	49	.	.	.
cord-005478-5iu38pr6	1062	1	DNA	dna	NN
cord-005478-5iu38pr6	1062	2	methylation	methylation	NN
cord-005478-5iu38pr6	1062	3	class	class	NN
cord-005478-5iu38pr6	1063	1	(	(	-LRB-
cord-005478-5iu38pr6	1063	2	Lipka	Lipka	NNP
cord-005478-5iu38pr6	1063	3	et	et	NNP
cord-005478-5iu38pr6	1063	4	al	al	NNP
cord-005478-5iu38pr6	1063	5	.	.	.
cord-005478-5iu38pr6	1064	1	Nat	Nat	NNP
cord-005478-5iu38pr6	1064	2	Comm	Comm	NNP
cord-005478-5iu38pr6	1064	3	2017	2017	CD
cord-005478-5iu38pr6	1064	4	;	;	:
cord-005478-5iu38pr6	1065	1	n=17	n=17	NNP
cord-005478-5iu38pr6	1065	2	)	)	-RRB-
cord-005478-5iu38pr6	1065	3	was	be	VBD
cord-005478-5iu38pr6	1065	4	high	high	JJ
cord-005478-5iu38pr6	1065	5	,	,	,
cord-005478-5iu38pr6	1065	6	intermediate	intermediate	JJ
cord-005478-5iu38pr6	1065	7	,	,	,
cord-005478-5iu38pr6	1065	8	or	or	CC
cord-005478-5iu38pr6	1065	9	low	low	JJ
cord-005478-5iu38pr6	1065	10	in	in	IN
cord-005478-5iu38pr6	1065	11	10	10	CD
cord-005478-5iu38pr6	1065	12	,	,	,
cord-005478-5iu38pr6	1065	13	5	5	CD
cord-005478-5iu38pr6	1065	14	,	,	,
cord-005478-5iu38pr6	1065	15	and	and	CC
cord-005478-5iu38pr6	1065	16	2	2	CD
cord-005478-5iu38pr6	1065	17	patients	patient	NNS
cord-005478-5iu38pr6	1065	18	,	,	,
cord-005478-5iu38pr6	1065	19	respectively	respectively	RB
cord-005478-5iu38pr6	1065	20	.	.	.
cord-005478-5iu38pr6	1066	1	Sixteen	sixteen	CD
cord-005478-5iu38pr6	1066	2	patients	patient	NNS
cord-005478-5iu38pr6	1066	3	completed	complete	VBD
cord-005478-5iu38pr6	1066	4	3	3	CD
cord-005478-5iu38pr6	1066	5	cycles	cycle	NNS
cord-005478-5iu38pr6	1066	6	of	of	IN
cord-005478-5iu38pr6	1066	7	therapy	therapy	NN
cord-005478-5iu38pr6	1066	8	and	and	CC
cord-005478-5iu38pr6	1066	9	5	5	CD
cord-005478-5iu38pr6	1066	10	of	of	IN
cord-005478-5iu38pr6	1066	11	them	-PRON-	PRP
cord-005478-5iu38pr6	1066	12	completed	complete	VBD
cord-005478-5iu38pr6	1066	13	6	6	CD
cord-005478-5iu38pr6	1066	14	cycles	cycle	NNS
cord-005478-5iu38pr6	1066	15	.	.	.
cord-005478-5iu38pr6	1067	1	Two	two	CD
cord-005478-5iu38pr6	1067	2	patients	patient	NNS
cord-005478-5iu38pr6	1067	3	discontinued	discontinue	VBD
cord-005478-5iu38pr6	1067	4	treatment	treatment	NN
cord-005478-5iu38pr6	1067	5	before	before	IN
cord-005478-5iu38pr6	1067	6	completing	complete	VBG
cord-005478-5iu38pr6	1067	7	3	3	CD
cord-005478-5iu38pr6	1067	8	cycles	cycle	NNS
cord-005478-5iu38pr6	1067	9	due	due	JJ
cord-005478-5iu38pr6	1067	10	to	to	IN
cord-005478-5iu38pr6	1067	11	disease	disease	NN
cord-005478-5iu38pr6	1067	12	progression	progression	NN
cord-005478-5iu38pr6	1067	13	.	.	.
cord-005478-5iu38pr6	1068	1	Six	six	CD
cord-005478-5iu38pr6	1068	2	patients	patient	NNS
cord-005478-5iu38pr6	1068	3	(	(	-LRB-
cord-005478-5iu38pr6	1068	4	33	33	CD
cord-005478-5iu38pr6	1068	5	%	%	NN
cord-005478-5iu38pr6	1068	6	)	)	-RRB-
cord-005478-5iu38pr6	1068	7	experienced	experience	VBD
cord-005478-5iu38pr6	1068	8	≥	≥	CD
cord-005478-5iu38pr6	1068	9	1	1	CD
cord-005478-5iu38pr6	1068	10	grade	grade	NN
cord-005478-5iu38pr6	1068	11	3	3	CD
cord-005478-5iu38pr6	1068	12	or	or	CC
cord-005478-5iu38pr6	1068	13	4	4	CD
cord-005478-5iu38pr6	1068	14	manageable	manageable	JJ
cord-005478-5iu38pr6	1068	15	adverse	adverse	JJ
cord-005478-5iu38pr6	1068	16	event	event	NN
cord-005478-5iu38pr6	1068	17	,	,	,
cord-005478-5iu38pr6	1068	18	consistent	consistent	JJ
cord-005478-5iu38pr6	1068	19	with	with	IN
cord-005478-5iu38pr6	1068	20	the	the	DT
cord-005478-5iu38pr6	1068	21	known	know	VBN
cord-005478-5iu38pr6	1068	22	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	1068	23	safety	safety	NN
cord-005478-5iu38pr6	1068	24	profile	profile	NN
cord-005478-5iu38pr6	1068	25	.	.	.
cord-005478-5iu38pr6	1069	1	Eleven	eleven	CD
cord-005478-5iu38pr6	1069	2	patients	patient	NNS
cord-005478-5iu38pr6	1069	3	(	(	-LRB-
cord-005478-5iu38pr6	1069	4	61	61	CD
cord-005478-5iu38pr6	1069	5	%	%	NN
cord-005478-5iu38pr6	1069	6	)	)	-RRB-
cord-005478-5iu38pr6	1069	7	achieved	achieve	VBN
cord-005478-5iu38pr6	1069	8	cPR	cPR	NNP
cord-005478-5iu38pr6	1069	9	at	at	IN
cord-005478-5iu38pr6	1069	10	C3D28	C3D28	NNP
cord-005478-5iu38pr6	1069	11	and	and	CC
cord-005478-5iu38pr6	1069	12	7	7	CD
cord-005478-5iu38pr6	1069	13	had	have	VBD
cord-005478-5iu38pr6	1069	14	progressive	progressive	JJ
cord-005478-5iu38pr6	1069	15	disease	disease	NN
cord-005478-5iu38pr6	1069	16	either	either	CC
cord-005478-5iu38pr6	1069	17	at	at	IN
cord-005478-5iu38pr6	1069	18	C3D28	C3D28	NNS
cord-005478-5iu38pr6	1069	19	or	or	CC
cord-005478-5iu38pr6	1069	20	prior	prior	RB
cord-005478-5iu38pr6	1069	21	.	.	.
cord-005478-5iu38pr6	1070	1	Importantly	importantly	RB
cord-005478-5iu38pr6	1070	2	,	,	,
cord-005478-5iu38pr6	1070	3	8	8	CD
cord-005478-5iu38pr6	1070	4	of	of	IN
cord-005478-5iu38pr6	1070	5	the	the	DT
cord-005478-5iu38pr6	1070	6	15	15	CD
cord-005478-5iu38pr6	1070	7	patients	patient	NNS
cord-005478-5iu38pr6	1070	8	who	who	WP
cord-005478-5iu38pr6	1070	9	needed	need	VBD
cord-005478-5iu38pr6	1070	10	platelet	platelet	NN
cord-005478-5iu38pr6	1070	11	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1070	12	before	before	IN
cord-005478-5iu38pr6	1070	13	or	or	CC
cord-005478-5iu38pr6	1070	14	shortly	shortly	RB
cord-005478-5iu38pr6	1070	15	after	after	IN
cord-005478-5iu38pr6	1070	16	treatment	treatment	NN
cord-005478-5iu38pr6	1070	17	initiation	initiation	NN
cord-005478-5iu38pr6	1070	18	did	do	VBD
cord-005478-5iu38pr6	1070	19	not	not	RB
cord-005478-5iu38pr6	1070	20	require	require	VB
cord-005478-5iu38pr6	1070	21	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1070	22	at	at	IN
cord-005478-5iu38pr6	1070	23	the	the	DT
cord-005478-5iu38pr6	1070	24	time	time	NN
cord-005478-5iu38pr6	1070	25	of	of	IN
cord-005478-5iu38pr6	1070	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1070	27	.	.	.
cord-005478-5iu38pr6	1071	1	Seven	seven	CD
cord-005478-5iu38pr6	1071	2	of	of	IN
cord-005478-5iu38pr6	1071	3	these	these	DT
cord-005478-5iu38pr6	1071	4	8	8	CD
cord-005478-5iu38pr6	1071	5	platelet	platelet	NN
cord-005478-5iu38pr6	1071	6	responders	responder	NNS
cord-005478-5iu38pr6	1071	7	had	have	VBD
cord-005478-5iu38pr6	1071	8	normalized	normalize	VBN
cord-005478-5iu38pr6	1071	9	their	-PRON-	PRP$
cord-005478-5iu38pr6	1071	10	platelet	platelet	NN
cord-005478-5iu38pr6	1071	11	count	count	NN
cord-005478-5iu38pr6	1071	12	(	(	-LRB-
cord-005478-5iu38pr6	1071	13	≥	≥	CD
cord-005478-5iu38pr6	1071	14	130	130	CD
cord-005478-5iu38pr6	1071	15	×	×	NN
cord-005478-5iu38pr6	1071	16	10	10	CD
cord-005478-5iu38pr6	1071	17	9	9	CD
cord-005478-5iu38pr6	1071	18	/L	/L	.
cord-005478-5iu38pr6	1071	19	)	)	-RRB-
cord-005478-5iu38pr6	1071	20	.	.	.
cord-005478-5iu38pr6	1072	1	Palpable	palpable	JJ
cord-005478-5iu38pr6	1072	2	spleen	spleen	NN
cord-005478-5iu38pr6	1072	3	size	size	NN
cord-005478-5iu38pr6	1072	4	decreased	decrease	VBD
cord-005478-5iu38pr6	1072	5	in	in	IN
cord-005478-5iu38pr6	1072	6	11	11	CD
cord-005478-5iu38pr6	1072	7	responders	responder	NNS
cord-005478-5iu38pr6	1072	8	by	by	IN
cord-005478-5iu38pr6	1072	9	a	a	DT
cord-005478-5iu38pr6	1072	10	median	median	NN
cord-005478-5iu38pr6	1072	11	of	of	IN
cord-005478-5iu38pr6	1072	12	3.5	3.5	CD
cord-005478-5iu38pr6	1072	13	cm	cm	NNS
cord-005478-5iu38pr6	1072	14	after	after	IN
cord-005478-5iu38pr6	1072	15	3	3	CD
cord-005478-5iu38pr6	1072	16	cycles	cycle	NNS
cord-005478-5iu38pr6	1072	17	and	and	CC
cord-005478-5iu38pr6	1072	18	ranged	range	VBD
cord-005478-5iu38pr6	1072	19	from	from	IN
cord-005478-5iu38pr6	1072	20	0	0	CD
cord-005478-5iu38pr6	1072	21	-	-	SYM
cord-005478-5iu38pr6	1072	22	2	2	CD
cord-005478-5iu38pr6	1072	23	cm	cm	NNS
cord-005478-5iu38pr6	1072	24	below	below	IN
cord-005478-5iu38pr6	1072	25	the	the	DT
cord-005478-5iu38pr6	1072	26	costal	costal	JJ
cord-005478-5iu38pr6	1072	27	margin	margin	NN
cord-005478-5iu38pr6	1072	28	after	after	IN
cord-005478-5iu38pr6	1072	29	6	6	CD
cord-005478-5iu38pr6	1072	30	cycles	cycle	NNS
cord-005478-5iu38pr6	1072	31	.	.	.
cord-005478-5iu38pr6	1073	1	Sixteen	sixteen	CD
cord-005478-5iu38pr6	1073	2	patients	patient	NNS
cord-005478-5iu38pr6	1073	3	received	receive	VBD
cord-005478-5iu38pr6	1073	4	allo	allo	NN
cord-005478-5iu38pr6	1073	5	-	-	HYPH
cord-005478-5iu38pr6	1073	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1073	7	from	from	IN
cord-005478-5iu38pr6	1073	8	a	a	DT
cord-005478-5iu38pr6	1073	9	family	family	NN
cord-005478-5iu38pr6	1073	10	or	or	CC
cord-005478-5iu38pr6	1073	11	compatible	compatible	JJ
cord-005478-5iu38pr6	1073	12	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1073	13	donor	donor	NN
cord-005478-5iu38pr6	1073	14	following	follow	VBG
cord-005478-5iu38pr6	1073	15	a	a	DT
cord-005478-5iu38pr6	1073	16	busulfan-(n=15	busulfan-(n=15	NNP
cord-005478-5iu38pr6	1073	17	)	)	-RRB-
cord-005478-5iu38pr6	1073	18	or	or	CC
cord-005478-5iu38pr6	1073	19	treosulfan	treosulfan	NNP
cord-005478-5iu38pr6	1073	20	-	-	HYPH
cord-005478-5iu38pr6	1073	21	based	base	VBN
cord-005478-5iu38pr6	1073	22	(	(	-LRB-
cord-005478-5iu38pr6	1073	23	n=1	n=1	JJ
cord-005478-5iu38pr6	1073	24	)	)	-RRB-
cord-005478-5iu38pr6	1073	25	preparative	preparative	JJ
cord-005478-5iu38pr6	1073	26	regimen	regimen	NN
cord-005478-5iu38pr6	1073	27	after	after	IN
cord-005478-5iu38pr6	1073	28	a	a	DT
cord-005478-5iu38pr6	1073	29	median	median	NN
cord-005478-5iu38pr6	1073	30	of	of	IN
cord-005478-5iu38pr6	1073	31	57	57	CD
cord-005478-5iu38pr6	1073	32	days	day	NNS
cord-005478-5iu38pr6	1073	33	(	(	-LRB-
cord-005478-5iu38pr6	1073	34	36	36	CD
cord-005478-5iu38pr6	1073	35	-	-	SYM
cord-005478-5iu38pr6	1073	36	112	112	CD
cord-005478-5iu38pr6	1073	37	)	)	-RRB-
cord-005478-5iu38pr6	1073	38	from	from	IN
cord-005478-5iu38pr6	1073	39	last	last	JJ
cord-005478-5iu38pr6	1073	40	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	1073	41	dose	dose	NN
cord-005478-5iu38pr6	1073	42	.	.	.
cord-005478-5iu38pr6	1074	1	Thirteen	thirteen	CD
cord-005478-5iu38pr6	1074	2	transplanted	transplant	VBN
cord-005478-5iu38pr6	1074	3	patients	patient	NNS
cord-005478-5iu38pr6	1074	4	were	be	VBD
cord-005478-5iu38pr6	1074	5	leukemia	leukemia	NN
cord-005478-5iu38pr6	1074	6	-	-	HYPH
cord-005478-5iu38pr6	1074	7	free	free	JJ
cord-005478-5iu38pr6	1074	8	at	at	IN
cord-005478-5iu38pr6	1074	9	median	median	JJ
cord-005478-5iu38pr6	1074	10	follow	follow	NN
cord-005478-5iu38pr6	1074	11	-	-	HYPH
cord-005478-5iu38pr6	1074	12	up	up	NN
cord-005478-5iu38pr6	1074	13	of	of	IN
cord-005478-5iu38pr6	1074	14	15.7	15.7	CD
cord-005478-5iu38pr6	1074	15	months	month	NNS
cord-005478-5iu38pr6	1074	16	(	(	-LRB-
cord-005478-5iu38pr6	1074	17	0.1	0.1	CD
cord-005478-5iu38pr6	1074	18	-	-	SYM
cord-005478-5iu38pr6	1074	19	31.7	31.7	CD
cord-005478-5iu38pr6	1074	20	)	)	-RRB-
cord-005478-5iu38pr6	1074	21	after	after	IN
cord-005478-5iu38pr6	1074	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1074	23	.	.	.
cord-005478-5iu38pr6	1075	1	Two	two	CD
cord-005478-5iu38pr6	1075	2	children	child	NNS
cord-005478-5iu38pr6	1075	3	(	(	-LRB-
cord-005478-5iu38pr6	1075	4	both	both	DT
cord-005478-5iu38pr6	1075	5	high	high	JJ
cord-005478-5iu38pr6	1075	6	methylation	methylation	NN
cord-005478-5iu38pr6	1075	7	class	class	NN
cord-005478-5iu38pr6	1075	8	)	)	-RRB-
cord-005478-5iu38pr6	1075	9	given	give	VBN
cord-005478-5iu38pr6	1075	10	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1075	11	relapsed	relapse	VBD
cord-005478-5iu38pr6	1075	12	after	after	IN
cord-005478-5iu38pr6	1075	13	the	the	DT
cord-005478-5iu38pr6	1075	14	allograft	allograft	NN
cord-005478-5iu38pr6	1075	15	.	.	.
cord-005478-5iu38pr6	1076	1	Sixteen	sixteen	CD
cord-005478-5iu38pr6	1076	2	of	of	IN
cord-005478-5iu38pr6	1076	3	the	the	DT
cord-005478-5iu38pr6	1076	4	18	18	CD
cord-005478-5iu38pr6	1076	5	patients	patient	NNS
cord-005478-5iu38pr6	1076	6	were	be	VBD
cord-005478-5iu38pr6	1076	7	alive	alive	JJ
cord-005478-5iu38pr6	1076	8	at	at	IN
cord-005478-5iu38pr6	1076	9	a	a	DT
cord-005478-5iu38pr6	1076	10	median	median	JJ
cord-005478-5iu38pr6	1076	11	follow	follow	NN
cord-005478-5iu38pr6	1076	12	-	-	HYPH
cord-005478-5iu38pr6	1076	13	up	up	NN
cord-005478-5iu38pr6	1076	14	of	of	IN
cord-005478-5iu38pr6	1076	15	19.8	19.8	CD
cord-005478-5iu38pr6	1076	16	months	month	NNS
cord-005478-5iu38pr6	1076	17	(	(	-LRB-
cord-005478-5iu38pr6	1076	18	2.6	2.6	CD
cord-005478-5iu38pr6	1076	19	-	-	SYM
cord-005478-5iu38pr6	1076	20	37.3	37.3	CD
cord-005478-5iu38pr6	1076	21	)	)	-RRB-
cord-005478-5iu38pr6	1076	22	.	.	.
cord-005478-5iu38pr6	1077	1	One	one	CD
cord-005478-5iu38pr6	1077	2	patient	patient	NN
cord-005478-5iu38pr6	1077	3	who	who	WP
cord-005478-5iu38pr6	1077	4	discontinued	discontinue	VBD
cord-005478-5iu38pr6	1077	5	treatment	treatment	NN
cord-005478-5iu38pr6	1077	6	before	before	IN
cord-005478-5iu38pr6	1077	7	cycle	cycle	NN
cord-005478-5iu38pr6	1077	8	3	3	CD
cord-005478-5iu38pr6	1077	9	died	die	VBD
cord-005478-5iu38pr6	1077	10	from	from	IN
cord-005478-5iu38pr6	1077	11	disease	disease	NN
cord-005478-5iu38pr6	1077	12	progression	progression	NN
cord-005478-5iu38pr6	1077	13	,	,	,
cord-005478-5iu38pr6	1077	14	and	and	CC
cord-005478-5iu38pr6	1077	15	1	1	CD
cord-005478-5iu38pr6	1077	16	non	non	JJ
cord-005478-5iu38pr6	1077	17	-	-	NN
cord-005478-5iu38pr6	1077	18	responder	responder	NN
cord-005478-5iu38pr6	1077	19	died	die	VBD
cord-005478-5iu38pr6	1077	20	from	from	IN
cord-005478-5iu38pr6	1077	21	graft	graft	NN
cord-005478-5iu38pr6	1077	22	failure	failure	NN
cord-005478-5iu38pr6	1077	23	.	.	.
cord-005478-5iu38pr6	1078	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1078	2	:	:	:
cord-005478-5iu38pr6	1079	1	This	this	DT
cord-005478-5iu38pr6	1079	2	study	study	NN
cord-005478-5iu38pr6	1079	3	shows	show	VBZ
cord-005478-5iu38pr6	1079	4	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	1079	5	monotherapy	monotherapy	NN
cord-005478-5iu38pr6	1079	6	was	be	VBD
cord-005478-5iu38pr6	1079	7	well	well	RB
cord-005478-5iu38pr6	1079	8	tolerated	tolerate	VBN
cord-005478-5iu38pr6	1079	9	in	in	IN
cord-005478-5iu38pr6	1079	10	children	child	NNS
cord-005478-5iu38pr6	1079	11	with	with	IN
cord-005478-5iu38pr6	1079	12	newly	newly	RB
cord-005478-5iu38pr6	1079	13	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1079	14	JMML	JMML	NNP
cord-005478-5iu38pr6	1079	15	.	.	.
cord-005478-5iu38pr6	1080	1	Although	although	IN
cord-005478-5iu38pr6	1080	2	the	the	DT
cord-005478-5iu38pr6	1080	3	long	long	JJ
cord-005478-5iu38pr6	1080	4	-	-	HYPH
cord-005478-5iu38pr6	1080	5	term	term	NN
cord-005478-5iu38pr6	1080	6	advantage	advantage	NN
cord-005478-5iu38pr6	1080	7	of	of	IN
cord-005478-5iu38pr6	1080	8	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	1080	9	therapy	therapy	NN
cord-005478-5iu38pr6	1080	10	remains	remain	VBZ
cord-005478-5iu38pr6	1080	11	to	to	TO
cord-005478-5iu38pr6	1080	12	be	be	VB
cord-005478-5iu38pr6	1080	13	fully	fully	RB
cord-005478-5iu38pr6	1080	14	assessed	assess	VBN
cord-005478-5iu38pr6	1080	15	,	,	,
cord-005478-5iu38pr6	1080	16	both	both	CC
cord-005478-5iu38pr6	1080	17	the	the	DT
cord-005478-5iu38pr6	1080	18	decrease	decrease	NN
cord-005478-5iu38pr6	1080	19	in	in	IN
cord-005478-5iu38pr6	1080	20	spleen	spleen	NN
cord-005478-5iu38pr6	1080	21	size	size	NN
cord-005478-5iu38pr6	1080	22	and	and	CC
cord-005478-5iu38pr6	1080	23	significant	significant	JJ
cord-005478-5iu38pr6	1080	24	platelet	platelet	NN
cord-005478-5iu38pr6	1080	25	responses	response	NNS
cord-005478-5iu38pr6	1080	26	observed	observe	VBD
cord-005478-5iu38pr6	1080	27	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	1080	28	that	that	IN
cord-005478-5iu38pr6	1080	29	the	the	DT
cord-005478-5iu38pr6	1080	30	drug	drug	NN
cord-005478-5iu38pr6	1080	31	was	be	VBD
cord-005478-5iu38pr6	1080	32	effective	effective	JJ
cord-005478-5iu38pr6	1080	33	in	in	IN
cord-005478-5iu38pr6	1080	34	JMML	JMML	NNP
cord-005478-5iu38pr6	1080	35	and	and	CC
cord-005478-5iu38pr6	1080	36	provided	provide	VBD
cord-005478-5iu38pr6	1080	37	clinical	clinical	JJ
cord-005478-5iu38pr6	1080	38	benefit	benefit	NN
cord-005478-5iu38pr6	1080	39	to	to	IN
cord-005478-5iu38pr6	1080	40	JMML	JMML	NNP
cord-005478-5iu38pr6	1080	41	patients	patient	NNS
cord-005478-5iu38pr6	1080	42	in	in	IN
cord-005478-5iu38pr6	1080	43	this	this	DT
cord-005478-5iu38pr6	1080	44	study	study	NN
cord-005478-5iu38pr6	1080	45	.	.	.
cord-005478-5iu38pr6	1081	1	This	this	DT
cord-005478-5iu38pr6	1081	2	clinical	clinical	JJ
cord-005478-5iu38pr6	1081	3	trial	trial	NN
cord-005478-5iu38pr6	1081	4	has	have	VBZ
cord-005478-5iu38pr6	1081	5	shown	show	VBN
cord-005478-5iu38pr6	1081	6	that	that	IN
cord-005478-5iu38pr6	1081	7	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	1081	8	therapy	therapy	NN
cord-005478-5iu38pr6	1081	9	prior	prior	RB
cord-005478-5iu38pr6	1081	10	to	to	IN
cord-005478-5iu38pr6	1081	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1081	12	may	may	MD
cord-005478-5iu38pr6	1081	13	be	be	VB
cord-005478-5iu38pr6	1081	14	considered	consider	VBN
cord-005478-5iu38pr6	1081	15	for	for	IN
cord-005478-5iu38pr6	1081	16	patients	patient	NNS
cord-005478-5iu38pr6	1081	17	with	with	IN
cord-005478-5iu38pr6	1081	18	JMML	JMML	NNP
cord-005478-5iu38pr6	1081	19	.	.	.
cord-005478-5iu38pr6	1082	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1082	2	Trial	Trial	NNP
cord-005478-5iu38pr6	1082	3	Registry	Registry	NNP
cord-005478-5iu38pr6	1082	4	:	:	:
cord-005478-5iu38pr6	1083	1	NCT02447666	NCT02447666	NNP
cord-005478-5iu38pr6	1083	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	1083	3	:	:	:
cord-005478-5iu38pr6	1084	1	Charlotte	Charlotte	NNP
cord-005478-5iu38pr6	1084	2	Niemeyer	Niemeyer	NNP
cord-005478-5iu38pr6	1084	3	is	be	VBZ
cord-005478-5iu38pr6	1084	4	a	a	DT
cord-005478-5iu38pr6	1084	5	member	member	NN
cord-005478-5iu38pr6	1084	6	of	of	IN
cord-005478-5iu38pr6	1084	7	a	a	DT
cord-005478-5iu38pr6	1084	8	board	board	NN
cord-005478-5iu38pr6	1084	9	of	of	IN
cord-005478-5iu38pr6	1084	10	directors	director	NNS
cord-005478-5iu38pr6	1084	11	or	or	CC
cord-005478-5iu38pr6	1084	12	advisory	advisory	JJ
cord-005478-5iu38pr6	1084	13	committee	committee	NN
cord-005478-5iu38pr6	1084	14	and	and	CC
cord-005478-5iu38pr6	1084	15	provides	provide	VBZ
cord-005478-5iu38pr6	1084	16	consultancy	consultancy	NN
cord-005478-5iu38pr6	1084	17	for	for	IN
cord-005478-5iu38pr6	1084	18	Celgene	Celgene	NNP
cord-005478-5iu38pr6	1084	19	.	.	.
cord-005478-5iu38pr6	1085	1	Claudia	Claudia	NNP
cord-005478-5iu38pr6	1085	2	Rössig	Rössig	NNP
cord-005478-5iu38pr6	1085	3	is	be	VBZ
cord-005478-5iu38pr6	1085	4	a	a	DT
cord-005478-5iu38pr6	1085	5	member	member	NN
cord-005478-5iu38pr6	1085	6	of	of	IN
cord-005478-5iu38pr6	1085	7	a	a	DT
cord-005478-5iu38pr6	1085	8	board	board	NN
cord-005478-5iu38pr6	1085	9	of	of	IN
cord-005478-5iu38pr6	1085	10	directors	director	NNS
cord-005478-5iu38pr6	1085	11	or	or	CC
cord-005478-5iu38pr6	1085	12	advisory	advisory	JJ
cord-005478-5iu38pr6	1085	13	committee	committee	NN
cord-005478-5iu38pr6	1085	14	at	at	IN
cord-005478-5iu38pr6	1085	15	Amgen	Amgen	NNP
cord-005478-5iu38pr6	1085	16	,	,	,
cord-005478-5iu38pr6	1085	17	EUSAPharm	EUSAPharm	NNP
cord-005478-5iu38pr6	1085	18	,	,	,
cord-005478-5iu38pr6	1085	19	Roche	Roche	NNP
cord-005478-5iu38pr6	1085	20	,	,	,
cord-005478-5iu38pr6	1085	21	Celgene	Celgene	NNP
cord-005478-5iu38pr6	1085	22	,	,	,
cord-005478-5iu38pr6	1085	23	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1085	24	,	,	,
cord-005478-5iu38pr6	1085	25	Pfizer	Pfizer	NNP
cord-005478-5iu38pr6	1085	26	,	,	,
cord-005478-5iu38pr6	1085	27	BMS	BMS	NNP
cord-005478-5iu38pr6	1085	28	;	;	:
cord-005478-5iu38pr6	1085	29	honoraria	honorarium	NNS
cord-005478-5iu38pr6	1085	30	from	from	IN
cord-005478-5iu38pr6	1085	31	Amgen	Amgen	NNP
cord-005478-5iu38pr6	1085	32	,	,	,
cord-005478-5iu38pr6	1085	33	Roche	Roche	NNP
cord-005478-5iu38pr6	1085	34	,	,	,
cord-005478-5iu38pr6	1085	35	Pfizer	Pfizer	NNP
cord-005478-5iu38pr6	1085	36	.	.	.
cord-005478-5iu38pr6	1086	1	André	André	NNP
cord-005478-5iu38pr6	1086	2	Baruchel	Baruchel	NNP
cord-005478-5iu38pr6	1086	3	provides	provide	VBZ
cord-005478-5iu38pr6	1086	4	consultancy	consultancy	NN
cord-005478-5iu38pr6	1086	5	(	(	-LRB-
cord-005478-5iu38pr6	1086	6	includes	include	VBZ
cord-005478-5iu38pr6	1086	7	expert	expert	JJ
cord-005478-5iu38pr6	1086	8	testimony	testimony	NN
cord-005478-5iu38pr6	1086	9	)	)	-RRB-
cord-005478-5iu38pr6	1086	10	with	with	IN
cord-005478-5iu38pr6	1086	11	Celgene	Celgene	NNP
cord-005478-5iu38pr6	1086	12	,	,	,
cord-005478-5iu38pr6	1086	13	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1086	14	,	,	,
cord-005478-5iu38pr6	1086	15	Servier	Servier	NNP
cord-005478-5iu38pr6	1086	16	,	,	,
cord-005478-5iu38pr6	1086	17	JAZZ	jazz	NN
cord-005478-5iu38pr6	1086	18	Pharma	Pharma	NNS
cord-005478-5iu38pr6	1086	19	;	;	:
cord-005478-5iu38pr6	1086	20	research	research	NN
cord-005478-5iu38pr6	1086	21	funding	funding	NN
cord-005478-5iu38pr6	1086	22	and	and	CC
cord-005478-5iu38pr6	1086	23	honoraria	honoraria	NN
cord-005478-5iu38pr6	1086	24	from	from	IN
cord-005478-5iu38pr6	1086	25	Shire	Shire	NNP
cord-005478-5iu38pr6	1086	26	;	;	:
cord-005478-5iu38pr6	1086	27	honoraria	honorarium	NNS
cord-005478-5iu38pr6	1086	28	from	from	IN
cord-005478-5iu38pr6	1086	29	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1086	30	,	,	,
cord-005478-5iu38pr6	1086	31	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1086	32	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1086	33	.	.	.
cord-005478-5iu38pr6	1087	1	Susana	Susana	NNP
cord-005478-5iu38pr6	1087	2	Rives	Rives	NNP
cord-005478-5iu38pr6	1087	3	has	have	VBZ
cord-005478-5iu38pr6	1087	4	received	receive	VBN
cord-005478-5iu38pr6	1087	5	honoraria	honorarium	NNS
cord-005478-5iu38pr6	1087	6	(	(	-LRB-
cord-005478-5iu38pr6	1087	7	for	for	IN
cord-005478-5iu38pr6	1087	8	talks	talk	NNS
cord-005478-5iu38pr6	1087	9	in	in	IN
cord-005478-5iu38pr6	1087	10	Industria	Industria	NNP
cord-005478-5iu38pr6	1087	11	sponsored	sponsor	VBD
cord-005478-5iu38pr6	1087	12	Satellite	Satellite	NNP
cord-005478-5iu38pr6	1087	13	Symposia	Symposia	NNP
cord-005478-5iu38pr6	1087	14	)	)	-RRB-
cord-005478-5iu38pr6	1087	15	from	from	IN
cord-005478-5iu38pr6	1087	16	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1087	17	,	,	,
cord-005478-5iu38pr6	1087	18	JAZZ	jazz	NN
cord-005478-5iu38pr6	1087	19	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1087	20	,	,	,
cord-005478-5iu38pr6	1087	21	Baxalta	Baxalta	NNP
cord-005478-5iu38pr6	1087	22	,	,	,
cord-005478-5iu38pr6	1087	23	Shire	Shire	NNP
cord-005478-5iu38pr6	1087	24	,	,	,
cord-005478-5iu38pr6	1087	25	Servier	Servier	NNP
cord-005478-5iu38pr6	1087	26	;	;	:
cord-005478-5iu38pr6	1087	27	Speaker	Speaker	NNP
cord-005478-5iu38pr6	1087	28	's	's	POS
cord-005478-5iu38pr6	1087	29	Bureau	Bureau	NNP
cord-005478-5iu38pr6	1087	30	at	at	IN
cord-005478-5iu38pr6	1087	31	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1087	32	,	,	,
cord-005478-5iu38pr6	1087	33	JAZZ	jazz	NN
cord-005478-5iu38pr6	1087	34	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1087	35	,	,	,
cord-005478-5iu38pr6	1087	36	Baxalta	Baxalta	NNP
cord-005478-5iu38pr6	1087	37	,	,	,
cord-005478-5iu38pr6	1087	38	Shire	Shire	NNP
cord-005478-5iu38pr6	1087	39	,	,	,
cord-005478-5iu38pr6	1087	40	Servier	Servier	NNP
cord-005478-5iu38pr6	1087	41	,	,	,
cord-005478-5iu38pr6	1087	42	Amgen	Amgen	NNP
cord-005478-5iu38pr6	1087	43	,	,	,
cord-005478-5iu38pr6	1087	44	Erytech	Erytech	NNP
cord-005478-5iu38pr6	1087	45	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1087	46	;	;	:
cord-005478-5iu38pr6	1087	47	membership	membership	NN
cord-005478-5iu38pr6	1087	48	on	on	IN
cord-005478-5iu38pr6	1087	49	an	an	DT
cord-005478-5iu38pr6	1087	50	entity´s	entity´s	NNP
cord-005478-5iu38pr6	1087	51	board	board	NN
cord-005478-5iu38pr6	1087	52	of	of	IN
cord-005478-5iu38pr6	1087	53	directors	director	NNS
cord-005478-5iu38pr6	1087	54	or	or	CC
cord-005478-5iu38pr6	1087	55	advisory	advisory	JJ
cord-005478-5iu38pr6	1087	56	committees	committee	NNS
cord-005478-5iu38pr6	1087	57	at	at	IN
cord-005478-5iu38pr6	1087	58	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1087	59	;	;	:
cord-005478-5iu38pr6	1087	60	received	receive	VBD
cord-005478-5iu38pr6	1087	61	travel	travel	NN
cord-005478-5iu38pr6	1087	62	and	and	CC
cord-005478-5iu38pr6	1087	63	accommodation	accommodation	NN
cord-005478-5iu38pr6	1087	64	expenses	expense	NNS
cord-005478-5iu38pr6	1087	65	for	for	IN
cord-005478-5iu38pr6	1087	66	medical	medical	JJ
cord-005478-5iu38pr6	1087	67	congresses	congress	NNS
cord-005478-5iu38pr6	1087	68	from	from	IN
cord-005478-5iu38pr6	1087	69	Novartis	Novartis	NNP
cord-005478-5iu38pr6	1087	70	,	,	,
cord-005478-5iu38pr6	1087	71	JAZZ	jazz	NN
cord-005478-5iu38pr6	1087	72	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1087	73	,	,	,
cord-005478-5iu38pr6	1087	74	Baxalta	Baxalta	NNP
cord-005478-5iu38pr6	1087	75	,	,	,
cord-005478-5iu38pr6	1087	76	Shire	Shire	NNP
cord-005478-5iu38pr6	1087	77	,	,	,
cord-005478-5iu38pr6	1087	78	Servier	Servier	NNP
cord-005478-5iu38pr6	1087	79	,	,	,
cord-005478-5iu38pr6	1087	80	Amgen	Amgen	NNP
cord-005478-5iu38pr6	1087	81	,	,	,
cord-005478-5iu38pr6	1087	82	Erytech	Erytech	NNP
cord-005478-5iu38pr6	1087	83	Pharma	Pharma	NNP
cord-005478-5iu38pr6	1087	84	.	.	.
cord-005478-5iu38pr6	1088	1	Marco	Marco	NNP
cord-005478-5iu38pr6	1088	2	Zecca	Zecca	NNP
cord-005478-5iu38pr6	1088	3	has	have	VBZ
cord-005478-5iu38pr6	1088	4	received	receive	VBN
cord-005478-5iu38pr6	1088	5	honoraria	honorarium	NNS
cord-005478-5iu38pr6	1088	6	from	from	IN
cord-005478-5iu38pr6	1088	7	CHIMERIX	CHIMERIX	NNP
cord-005478-5iu38pr6	1088	8	and	and	CC
cord-005478-5iu38pr6	1088	9	JAZZ	JAZZ	NNP
cord-005478-5iu38pr6	1088	10	Pharma	Pharma	NNS
cord-005478-5iu38pr6	1088	11	.	.	.
cord-005478-5iu38pr6	1089	1	Marry	marry	VB
cord-005478-5iu38pr6	1089	2	M.	M.	NNP
cord-005478-5iu38pr6	1089	3	van	van	NNP
cord-005478-5iu38pr6	1089	4	den	den	NNP
cord-005478-5iu38pr6	1089	5	Heuvel	Heuvel	NNP
cord-005478-5iu38pr6	1089	6	-	-	HYPH
cord-005478-5iu38pr6	1089	7	Eibrink	Eibrink	NNP
cord-005478-5iu38pr6	1089	8	received	receive	VBD
cord-005478-5iu38pr6	1089	9	honoraria	honorarium	NNS
cord-005478-5iu38pr6	1089	10	from	from	IN
cord-005478-5iu38pr6	1089	11	Celgene	Celgene	NNP
cord-005478-5iu38pr6	1089	12	(	(	-LRB-
cord-005478-5iu38pr6	1089	13	consultation	consultation	NN
cord-005478-5iu38pr6	1089	14	fee	fee	NN
cord-005478-5iu38pr6	1089	15	)	)	-RRB-
cord-005478-5iu38pr6	1089	16	.	.	.
cord-005478-5iu38pr6	1090	1	Bouchra	Bouchra	NNP
cord-005478-5iu38pr6	1090	2	Benettaib	Benettaib	NNP
cord-005478-5iu38pr6	1090	3	,	,	,
cord-005478-5iu38pr6	1090	4	Noha	Noha	NNP
cord-005478-5iu38pr6	1090	5	Biserna	Biserna	NNP
cord-005478-5iu38pr6	1090	6	,	,	,
cord-005478-5iu38pr6	1090	7	Jennifer	Jennifer	NNP
cord-005478-5iu38pr6	1090	8	Poon	Poon	NNP
cord-005478-5iu38pr6	1090	9	,	,	,
cord-005478-5iu38pr6	1090	10	Mathew	Mathew	NNP
cord-005478-5iu38pr6	1090	11	Simcock	Simcock	NNP
cord-005478-5iu38pr6	1090	12	,	,	,
cord-005478-5iu38pr6	1090	13	Meera	Meera	NNP
cord-005478-5iu38pr6	1090	14	Patturajan	Patturajan	NNP
cord-005478-5iu38pr6	1090	15	are	be	VBP
cord-005478-5iu38pr6	1090	16	employees	employee	NNS
cord-005478-5iu38pr6	1090	17	of	of	IN
cord-005478-5iu38pr6	1090	18	and	and	CC
cord-005478-5iu38pr6	1090	19	hold	hold	VBP
cord-005478-5iu38pr6	1090	20	stock	stock	NN
cord-005478-5iu38pr6	1090	21	or	or	CC
cord-005478-5iu38pr6	1090	22	other	other	JJ
cord-005478-5iu38pr6	1090	23	equity	equity	NN
cord-005478-5iu38pr6	1090	24	ownership	ownership	NN
cord-005478-5iu38pr6	1090	25	in	in	IN
cord-005478-5iu38pr6	1090	26	Celgene	Celgene	NNP
cord-005478-5iu38pr6	1090	27	.	.	.
cord-005478-5iu38pr6	1091	1	Christian	Christian	NNP
cord-005478-5iu38pr6	1091	2	Flotho	Flotho	NNP
cord-005478-5iu38pr6	1091	3	,	,	,
cord-005478-5iu38pr6	1091	4	Daniel	Daniel	NNP
cord-005478-5iu38pr6	1091	5	Lipka	Lipka	NNP
cord-005478-5iu38pr6	1091	6	,	,	,
cord-005478-5iu38pr6	1091	7	Jan	Jan	NNP
cord-005478-5iu38pr6	1091	8	Starý	Starý	NNP
cord-005478-5iu38pr6	1091	9	,	,	,
cord-005478-5iu38pr6	1091	10	Karsten	Karsten	NNP
cord-005478-5iu38pr6	1091	11	Nysom	Nysom	NNP
cord-005478-5iu38pr6	1091	12	,	,	,
cord-005478-5iu38pr6	1091	13	Gérard	Gérard	NNP
cord-005478-5iu38pr6	1091	14	Michel	Michel	NNP
cord-005478-5iu38pr6	1091	15	,	,	,
cord-005478-5iu38pr6	1091	16	Thomas	Thomas	NNP
cord-005478-5iu38pr6	1091	17	Kilngebiel	Kilngebiel	NNP
cord-005478-5iu38pr6	1091	18	,	,	,
cord-005478-5iu38pr6	1091	19	Franco	Franco	NNP
cord-005478-5iu38pr6	1091	20	Locatelli	Locatelli	NNP
cord-005478-5iu38pr6	1091	21	,	,	,
cord-005478-5iu38pr6	1091	22	Giuseppe	Giuseppe	NNP
cord-005478-5iu38pr6	1091	23	Basso	Basso	NNP
cord-005478-5iu38pr6	1091	24	,	,	,
cord-005478-5iu38pr6	1091	25	Concetta	Concetta	NNP
cord-005478-5iu38pr6	1091	26	Micalizzi	Micalizzi	NNP
cord-005478-5iu38pr6	1091	27	,	,	,
cord-005478-5iu38pr6	1091	28	Irith	Irith	NNP
cord-005478-5iu38pr6	1091	29	Baumann	Baumann	NNP
cord-005478-5iu38pr6	1091	30	,	,	,
cord-005478-5iu38pr6	1091	31	Markus	Markus	NNP
cord-005478-5iu38pr6	1091	32	Schmugge	Schmugge	NNP
cord-005478-5iu38pr6	1091	33	Liner	Liner	NNP
cord-005478-5iu38pr6	1091	34	have	have	VB
cord-005478-5iu38pr6	1091	35	nothing	nothing	NN
cord-005478-5iu38pr6	1091	36	to	to	TO
cord-005478-5iu38pr6	1091	37	disclose	disclose	VB
cord-005478-5iu38pr6	1091	38	.	.	.
cord-005478-5iu38pr6	1092	1	Ruxolitinib	Ruxolitinib	NNP
cord-005478-5iu38pr6	1092	2	before	before	IN
cord-005478-5iu38pr6	1092	3	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	1092	4	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1092	5	stem	stem	NN
cord-005478-5iu38pr6	1092	6	cell	cell	NN
cord-005478-5iu38pr6	1092	7	transplantation	transplantation	NN
cord-005478-5iu38pr6	1092	8	(	(	-LRB-
cord-005478-5iu38pr6	1092	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1092	10	)	)	-RRB-
cord-005478-5iu38pr6	1092	11	in	in	IN
cord-005478-5iu38pr6	1092	12	patients	patient	NNS
cord-005478-5iu38pr6	1092	13	with	with	IN
cord-005478-5iu38pr6	1092	14	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1092	15	:	:	:
cord-005478-5iu38pr6	1092	16	A	a	DT
cord-005478-5iu38pr6	1092	17	preliminary	preliminary	JJ
cord-005478-5iu38pr6	1092	18	descriptive	descriptive	JJ
cord-005478-5iu38pr6	1092	19	report	report	NN
cord-005478-5iu38pr6	1092	20	of	of	IN
cord-005478-5iu38pr6	1092	21	the	the	DT
cord-005478-5iu38pr6	1092	22	JAK	JAK	NNP
cord-005478-5iu38pr6	1092	23	ALLO	ALLO	NNP
cord-005478-5iu38pr6	1092	24	phase	phase	NN
cord-005478-5iu38pr6	1092	25	II	ii	CD
cord-005478-5iu38pr6	1092	26	study	study	NN
cord-005478-5iu38pr6	1092	27	Marie	Marie	NNP
cord-005478-5iu38pr6	1092	28	Robin	Robin	NNP
cord-005478-5iu38pr6	1092	29	1,2	1,2	CD
cord-005478-5iu38pr6	1093	1	,	,	,
cord-005478-5iu38pr6	1093	2	Raphael	Raphael	NNP
cord-005478-5iu38pr6	1093	3	Porcher	Porcher	NNP
cord-005478-5iu38pr6	1093	4	3	3	CD
cord-005478-5iu38pr6	1093	5	,	,	,
cord-005478-5iu38pr6	1093	6	Corentin	Corentin	NNP
cord-005478-5iu38pr6	1093	7	Orvain	Orvain	NNP
cord-005478-5iu38pr6	1093	8	4	4	CD
cord-005478-5iu38pr6	1093	9	,	,	,
cord-005478-5iu38pr6	1093	10	Background	background	NN
cord-005478-5iu38pr6	1093	11	:	:	:
cord-005478-5iu38pr6	1094	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1094	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1094	3	stem	stem	NN
cord-005478-5iu38pr6	1094	4	cell	cell	NN
cord-005478-5iu38pr6	1094	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	1094	6	(	(	-LRB-
cord-005478-5iu38pr6	1094	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1094	8	)	)	-RRB-
cord-005478-5iu38pr6	1094	9	is	be	VBZ
cord-005478-5iu38pr6	1094	10	the	the	DT
cord-005478-5iu38pr6	1094	11	only	only	JJ
cord-005478-5iu38pr6	1094	12	curative	curative	JJ
cord-005478-5iu38pr6	1094	13	treatment	treatment	NN
cord-005478-5iu38pr6	1094	14	for	for	IN
cord-005478-5iu38pr6	1094	15	patients	patient	NNS
cord-005478-5iu38pr6	1094	16	with	with	IN
cord-005478-5iu38pr6	1094	17	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1094	18	;	;	:
cord-005478-5iu38pr6	1094	19	OS	OS	NNP
cord-005478-5iu38pr6	1094	20	is	be	VBZ
cord-005478-5iu38pr6	1094	21	from	from	IN
cord-005478-5iu38pr6	1094	22	30	30	CD
cord-005478-5iu38pr6	1094	23	to	to	TO
cord-005478-5iu38pr6	1094	24	60	60	CD
cord-005478-5iu38pr6	1094	25	%	%	NN
cord-005478-5iu38pr6	1094	26	depending	depend	VBG
cord-005478-5iu38pr6	1094	27	on	on	IN
cord-005478-5iu38pr6	1094	28	age	age	NN
cord-005478-5iu38pr6	1094	29	,	,	,
cord-005478-5iu38pr6	1094	30	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1094	31	,	,	,
cord-005478-5iu38pr6	1094	32	disease	disease	NN
cord-005478-5iu38pr6	1094	33	status	status	NN
cord-005478-5iu38pr6	1094	34	and	and	CC
cord-005478-5iu38pr6	1094	35	type	type	NN
cord-005478-5iu38pr6	1094	36	of	of	IN
cord-005478-5iu38pr6	1094	37	donors	donor	NNS
cord-005478-5iu38pr6	1094	38	.	.	.
cord-005478-5iu38pr6	1095	1	JAK1/2	JAK1/2	NNP
cord-005478-5iu38pr6	1096	1	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	1096	2	have	have	VBP
cord-005478-5iu38pr6	1096	3	been	be	VBN
cord-005478-5iu38pr6	1096	4	reported	report	VBN
cord-005478-5iu38pr6	1096	5	to	to	TO
cord-005478-5iu38pr6	1096	6	decrease	decrease	VB
cord-005478-5iu38pr6	1096	7	constitutional	constitutional	JJ
cord-005478-5iu38pr6	1096	8	symptoms	symptom	NNS
cord-005478-5iu38pr6	1096	9	and	and	CC
cord-005478-5iu38pr6	1096	10	spleen	spleen	NN
cord-005478-5iu38pr6	1096	11	size	size	NN
cord-005478-5iu38pr6	1096	12	in	in	IN
cord-005478-5iu38pr6	1096	13	one	one	CD
cord-005478-5iu38pr6	1096	14	half	half	NN
cord-005478-5iu38pr6	1096	15	of	of	IN
cord-005478-5iu38pr6	1096	16	patients	patient	NNS
cord-005478-5iu38pr6	1096	17	with	with	IN
cord-005478-5iu38pr6	1096	18	a	a	DT
cord-005478-5iu38pr6	1096	19	possible	possible	JJ
cord-005478-5iu38pr6	1096	20	advantage	advantage	NN
cord-005478-5iu38pr6	1096	21	of	of	IN
cord-005478-5iu38pr6	1096	22	OS	OS	NNP
cord-005478-5iu38pr6	1096	23	as	as	IN
cord-005478-5iu38pr6	1096	24	compared	compare	VBN
cord-005478-5iu38pr6	1096	25	to	to	IN
cord-005478-5iu38pr6	1096	26	best	good	JJS
cord-005478-5iu38pr6	1096	27	current	current	JJ
cord-005478-5iu38pr6	1096	28	treatment	treatment	NN
cord-005478-5iu38pr6	1096	29	.	.	.
cord-005478-5iu38pr6	1097	1	Retrospective	retrospective	JJ
cord-005478-5iu38pr6	1097	2	studies	study	NNS
cord-005478-5iu38pr6	1097	3	show	show	VBP
cord-005478-5iu38pr6	1097	4	that	that	IN
cord-005478-5iu38pr6	1097	5	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1097	6	has	have	VBZ
cord-005478-5iu38pr6	1097	7	been	be	VBN
cord-005478-5iu38pr6	1097	8	used	use	VBN
cord-005478-5iu38pr6	1097	9	in	in	IN
cord-005478-5iu38pr6	1097	10	patients	patient	NNS
cord-005478-5iu38pr6	1097	11	before	before	IN
cord-005478-5iu38pr6	1097	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1097	13	with	with	IN
cord-005478-5iu38pr6	1097	14	apparent	apparent	JJ
cord-005478-5iu38pr6	1097	15	good	good	JJ
cord-005478-5iu38pr6	1097	16	tolerance	tolerance	NN
cord-005478-5iu38pr6	1097	17	.	.	.
cord-005478-5iu38pr6	1098	1	Methods	method	NNS
cord-005478-5iu38pr6	1098	2	:	:	:
cord-005478-5iu38pr6	1098	3	In	in	IN
cord-005478-5iu38pr6	1098	4	2012	2012	CD
cord-005478-5iu38pr6	1098	5	,	,	,
cord-005478-5iu38pr6	1098	6	we	-PRON-	PRP
cord-005478-5iu38pr6	1098	7	initiated	initiate	VBD
cord-005478-5iu38pr6	1098	8	a	a	DT
cord-005478-5iu38pr6	1098	9	phase	phase	NN
cord-005478-5iu38pr6	1098	10	II	ii	CD
cord-005478-5iu38pr6	1098	11	prospective	prospective	JJ
cord-005478-5iu38pr6	1098	12	French	french	JJ
cord-005478-5iu38pr6	1098	13	collaborative	collaborative	NN
cord-005478-5iu38pr6	1098	14	(	(	-LRB-
cord-005478-5iu38pr6	1098	15	FILO	FILO	NNP
cord-005478-5iu38pr6	1098	16	and	and	CC
cord-005478-5iu38pr6	1098	17	SFGM	SFGM	NNP
cord-005478-5iu38pr6	1098	18	-	-	HYPH
cord-005478-5iu38pr6	1098	19	TC	TC	NNP
cord-005478-5iu38pr6	1098	20	)	)	-RRB-
cord-005478-5iu38pr6	1098	21	trial	trial	NN
cord-005478-5iu38pr6	1098	22	testing	test	VBG
cord-005478-5iu38pr6	1098	23	the	the	DT
cord-005478-5iu38pr6	1098	24	role	role	NN
cord-005478-5iu38pr6	1098	25	of	of	IN
cord-005478-5iu38pr6	1098	26	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1098	27	given	give	VBN
cord-005478-5iu38pr6	1098	28	before	before	IN
cord-005478-5iu38pr6	1098	29	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	1098	30	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1098	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	1098	32	in	in	IN
cord-005478-5iu38pr6	1098	33	patients	patient	NNS
cord-005478-5iu38pr6	1098	34	with	with	IN
cord-005478-5iu38pr6	1098	35	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1098	36	.	.	.
cord-005478-5iu38pr6	1099	1	Patients	patient	NNS
cord-005478-5iu38pr6	1099	2	could	could	MD
cord-005478-5iu38pr6	1099	3	be	be	VB
cord-005478-5iu38pr6	1099	4	included	include	VBN
cord-005478-5iu38pr6	1099	5	if	if	IN
cord-005478-5iu38pr6	1099	6	they	-PRON-	PRP
cord-005478-5iu38pr6	1099	7	were	be	VBD
cord-005478-5iu38pr6	1099	8	intermediate	intermediate	JJ
cord-005478-5iu38pr6	1099	9	or	or	CC
cord-005478-5iu38pr6	1099	10	high	high	JJ
cord-005478-5iu38pr6	1099	11	risk	risk	NN
cord-005478-5iu38pr6	1099	12	according	accord	VBG
cord-005478-5iu38pr6	1099	13	to	to	IN
cord-005478-5iu38pr6	1099	14	Lille	Lille	NNP
cord-005478-5iu38pr6	1099	15	score	score	NN
cord-005478-5iu38pr6	1099	16	or	or	CC
cord-005478-5iu38pr6	1099	17	IPSS	IPSS	NNP
cord-005478-5iu38pr6	1099	18	.	.	.
cord-005478-5iu38pr6	1100	1	Patients	patient	NNS
cord-005478-5iu38pr6	1100	2	had	have	VBD
cord-005478-5iu38pr6	1100	3	to	to	TO
cord-005478-5iu38pr6	1100	4	start	start	VB
cord-005478-5iu38pr6	1100	5	ruxolitinib	ruxolitinib	JJ
cord-005478-5iu38pr6	1100	6	after	after	IN
cord-005478-5iu38pr6	1100	7	inclusion	inclusion	NN
cord-005478-5iu38pr6	1100	8	and	and	CC
cord-005478-5iu38pr6	1100	9	were	be	VBD
cord-005478-5iu38pr6	1100	10	transplanted	transplant	VBN
cord-005478-5iu38pr6	1100	11	in	in	IN
cord-005478-5iu38pr6	1100	12	case	case	NN
cord-005478-5iu38pr6	1100	13	a	a	DT
cord-005478-5iu38pr6	1100	14	donor	donor	NN
cord-005478-5iu38pr6	1100	15	has	have	VBZ
cord-005478-5iu38pr6	1100	16	been	be	VBN
cord-005478-5iu38pr6	1100	17	identified	identify	VBN
cord-005478-5iu38pr6	1100	18	within	within	IN
cord-005478-5iu38pr6	1100	19	4	4	CD
cord-005478-5iu38pr6	1100	20	months	month	NNS
cord-005478-5iu38pr6	1100	21	.	.	.
cord-005478-5iu38pr6	1101	1	Primary	primary	JJ
cord-005478-5iu38pr6	1101	2	aim	aim	NN
cord-005478-5iu38pr6	1101	3	was	be	VBD
cord-005478-5iu38pr6	1101	4	progression	progression	NN
cord-005478-5iu38pr6	1101	5	-	-	HYPH
cord-005478-5iu38pr6	1101	6	free	free	JJ
cord-005478-5iu38pr6	1101	7	survival	survival	NN
cord-005478-5iu38pr6	1101	8	at	at	IN
cord-005478-5iu38pr6	1101	9	one	one	CD
cord-005478-5iu38pr6	1101	10	year	year	NN
cord-005478-5iu38pr6	1101	11	after	after	IN
cord-005478-5iu38pr6	1101	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1101	13	.	.	.
cord-005478-5iu38pr6	1102	1	Results	result	NNS
cord-005478-5iu38pr6	1102	2	:	:	:
cord-005478-5iu38pr6	1102	3	76	76	CD
cord-005478-5iu38pr6	1102	4	patients	patient	NNS
cord-005478-5iu38pr6	1102	5	could	could	MD
cord-005478-5iu38pr6	1102	6	be	be	VB
cord-005478-5iu38pr6	1102	7	included	include	VBN
cord-005478-5iu38pr6	1102	8	.	.	.
cord-005478-5iu38pr6	1103	1	53	53	CD
cord-005478-5iu38pr6	1103	2	(	(	-LRB-
cord-005478-5iu38pr6	1103	3	70	70	CD
cord-005478-5iu38pr6	1103	4	%	%	NN
cord-005478-5iu38pr6	1103	5	)	)	-RRB-
cord-005478-5iu38pr6	1103	6	had	have	VBD
cord-005478-5iu38pr6	1103	7	a	a	DT
cord-005478-5iu38pr6	1103	8	primary	primary	JJ
cord-005478-5iu38pr6	1103	9	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1103	10	and	and	CC
cord-005478-5iu38pr6	1103	11	23	23	CD
cord-005478-5iu38pr6	1103	12	(	(	-LRB-
cord-005478-5iu38pr6	1103	13	30	30	CD
cord-005478-5iu38pr6	1103	14	%	%	NN
cord-005478-5iu38pr6	1103	15	)	)	-RRB-
cord-005478-5iu38pr6	1103	16	had	have	VBD
cord-005478-5iu38pr6	1103	17	a	a	DT
cord-005478-5iu38pr6	1103	18	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1103	19	secondary	secondary	JJ
cord-005478-5iu38pr6	1103	20	to	to	IN
cord-005478-5iu38pr6	1103	21	Essential	Essential	NNP
cord-005478-5iu38pr6	1103	22	Thrombocythemia	Thrombocythemia	NNP
cord-005478-5iu38pr6	1103	23	(	(	-LRB-
cord-005478-5iu38pr6	1103	24	n=10	n=10	NNP
cord-005478-5iu38pr6	1103	25	)	)	-RRB-
cord-005478-5iu38pr6	1103	26	or	or	CC
cord-005478-5iu38pr6	1103	27	Polycythemia	Polycythemia	NNP
cord-005478-5iu38pr6	1103	28	Vera	Vera	NNP
cord-005478-5iu38pr6	1103	29	(	(	-LRB-
cord-005478-5iu38pr6	1103	30	n=13	n=13	NNP
cord-005478-5iu38pr6	1103	31	)	)	-RRB-
cord-005478-5iu38pr6	1103	32	.	.	.
cord-005478-5iu38pr6	1104	1	At	at	IN
cord-005478-5iu38pr6	1104	2	time	time	NN
cord-005478-5iu38pr6	1104	3	of	of	IN
cord-005478-5iu38pr6	1104	4	inclusion	inclusion	NN
cord-005478-5iu38pr6	1104	5	,	,	,
cord-005478-5iu38pr6	1104	6	43	43	CD
cord-005478-5iu38pr6	1104	7	(	(	-LRB-
cord-005478-5iu38pr6	1104	8	57	57	CD
cord-005478-5iu38pr6	1104	9	%	%	NN
cord-005478-5iu38pr6	1104	10	)	)	-RRB-
cord-005478-5iu38pr6	1104	11	patients	patient	NNS
cord-005478-5iu38pr6	1104	12	had	have	VBD
cord-005478-5iu38pr6	1104	13	constitutional	constitutional	JJ
cord-005478-5iu38pr6	1104	14	symptoms	symptom	NNS
cord-005478-5iu38pr6	1104	15	,	,	,
cord-005478-5iu38pr6	1104	16	72	72	CD
cord-005478-5iu38pr6	1104	17	(	(	-LRB-
cord-005478-5iu38pr6	1104	18	95	95	CD
cord-005478-5iu38pr6	1104	19	%	%	NN
cord-005478-5iu38pr6	1104	20	)	)	-RRB-
cord-005478-5iu38pr6	1104	21	had	have	VBD
cord-005478-5iu38pr6	1104	22	palpable	palpable	JJ
cord-005478-5iu38pr6	1104	23	splenomegaly	splenomegaly	NN
cord-005478-5iu38pr6	1104	24	,	,	,
cord-005478-5iu38pr6	1104	25	48	48	CD
cord-005478-5iu38pr6	1104	26	(	(	-LRB-
cord-005478-5iu38pr6	1104	27	63	63	CD
cord-005478-5iu38pr6	1104	28	%	%	NN
cord-005478-5iu38pr6	1104	29	)	)	-RRB-
cord-005478-5iu38pr6	1104	30	patients	patient	NNS
cord-005478-5iu38pr6	1104	31	had	have	VBD
cord-005478-5iu38pr6	1104	32	hemoglobin	hemoglobin	NN
cord-005478-5iu38pr6	1105	1	<	<	XX
cord-005478-5iu38pr6	1105	2	10	10	CD
cord-005478-5iu38pr6	1105	3	gr	gr	NNP
cord-005478-5iu38pr6	1105	4	/	/	SYM
cord-005478-5iu38pr6	1105	5	dl	dl	NNP
cord-005478-5iu38pr6	1105	6	,	,	,
cord-005478-5iu38pr6	1105	7	23	23	CD
cord-005478-5iu38pr6	1105	8	(	(	-LRB-
cord-005478-5iu38pr6	1105	9	30	30	CD
cord-005478-5iu38pr6	1105	10	%	%	NN
cord-005478-5iu38pr6	1105	11	)	)	-RRB-
cord-005478-5iu38pr6	1106	1	patients	patient	NNS
cord-005478-5iu38pr6	1106	2	had	have	VBD
cord-005478-5iu38pr6	1106	3	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1106	4	blast	blast	NN
cord-005478-5iu38pr6	1106	5	cell	cell	NN
cord-005478-5iu38pr6	1106	6	count	count	NN
cord-005478-5iu38pr6	1106	7	>	>	XX
cord-005478-5iu38pr6	1106	8	or	or	CC
cord-005478-5iu38pr6	1106	9	=	=	NFP
cord-005478-5iu38pr6	1107	1	at	at	IN
cord-005478-5iu38pr6	1107	2	1	1	CD
cord-005478-5iu38pr6	1107	3	%	%	NN
cord-005478-5iu38pr6	1107	4	and	and	CC
cord-005478-5iu38pr6	1107	5	16	16	CD
cord-005478-5iu38pr6	1107	6	(	(	-LRB-
cord-005478-5iu38pr6	1107	7	21	21	CD
cord-005478-5iu38pr6	1107	8	%	%	NN
cord-005478-5iu38pr6	1107	9	)	)	-RRB-
cord-005478-5iu38pr6	1107	10	had	have	VBD
cord-005478-5iu38pr6	1107	11	thrombocytopenia	thrombocytopenia	VBN
cord-005478-5iu38pr6	1107	12	<	<	XX
cord-005478-5iu38pr6	1107	13	100	100	CD
cord-005478-5iu38pr6	1108	1	G	G	NNP
cord-005478-5iu38pr6	1108	2	/	/	SYM
cord-005478-5iu38pr6	1108	3	L.	L.	NNP
cord-005478-5iu38pr6	1108	4	Median	Median	NNP
cord-005478-5iu38pr6	1108	5	follow	follow	NN
cord-005478-5iu38pr6	1108	6	-	-	HYPH
cord-005478-5iu38pr6	1108	7	up	up	NN
cord-005478-5iu38pr6	1108	8	was	be	VBD
cord-005478-5iu38pr6	1108	9	31	31	CD
cord-005478-5iu38pr6	1108	10	months	month	NNS
cord-005478-5iu38pr6	1108	11	.	.	.
cord-005478-5iu38pr6	1109	1	At	at	IN
cord-005478-5iu38pr6	1109	2	4	4	CD
cord-005478-5iu38pr6	1109	3	months	month	NNS
cord-005478-5iu38pr6	1109	4	,	,	,
cord-005478-5iu38pr6	1109	5	one	one	CD
cord-005478-5iu38pr6	1109	6	patient	patient	NN
cord-005478-5iu38pr6	1109	7	has	have	VBZ
cord-005478-5iu38pr6	1109	8	died	die	VBN
cord-005478-5iu38pr6	1109	9	,	,	,
cord-005478-5iu38pr6	1109	10	11	11	CD
cord-005478-5iu38pr6	1109	11	patients	patient	NNS
cord-005478-5iu38pr6	1109	12	had	have	VBD
cord-005478-5iu38pr6	1109	13	no	no	DT
cord-005478-5iu38pr6	1109	14	donor	donor	NN
cord-005478-5iu38pr6	1109	15	,	,	,
cord-005478-5iu38pr6	1109	16	18	18	CD
cord-005478-5iu38pr6	1109	17	had	have	VBD
cord-005478-5iu38pr6	1109	18	an	an	DT
cord-005478-5iu38pr6	1109	19	HLA	HLA	NNP
cord-005478-5iu38pr6	1109	20	matched	match	VBN
cord-005478-5iu38pr6	1109	21	sibling	sibling	NN
cord-005478-5iu38pr6	1109	22	donor	donor	NN
cord-005478-5iu38pr6	1109	23	,	,	,
cord-005478-5iu38pr6	1109	24	31	31	CD
cord-005478-5iu38pr6	1109	25	had	have	VBD
cord-005478-5iu38pr6	1109	26	an	an	DT
cord-005478-5iu38pr6	1109	27	HLA	HLA	NNP
cord-005478-5iu38pr6	1109	28	matched	match	VBN
cord-005478-5iu38pr6	1109	29	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1109	30	donor	donor	NN
cord-005478-5iu38pr6	1109	31	and	and	CC
cord-005478-5iu38pr6	1109	32	15	15	CD
cord-005478-5iu38pr6	1109	33	had	have	VBD
cord-005478-5iu38pr6	1109	34	a	a	DT
cord-005478-5iu38pr6	1109	35	9/10	9/10	CD
cord-005478-5iu38pr6	1109	36	HLA	HLA	NNP
cord-005478-5iu38pr6	1109	37	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1109	38	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1109	39	donor	donor	NN
cord-005478-5iu38pr6	1109	40	.	.	.
cord-005478-5iu38pr6	1110	1	59	59	CD
cord-005478-5iu38pr6	1110	2	(	(	-LRB-
cord-005478-5iu38pr6	1110	3	78	78	CD
cord-005478-5iu38pr6	1110	4	%	%	NN
cord-005478-5iu38pr6	1110	5	)	)	-RRB-
cord-005478-5iu38pr6	1110	6	patients	patient	NNS
cord-005478-5iu38pr6	1110	7	with	with	IN
cord-005478-5iu38pr6	1110	8	a	a	DT
cord-005478-5iu38pr6	1110	9	donor	donor	NN
cord-005478-5iu38pr6	1110	10	at	at	IN
cord-005478-5iu38pr6	1110	11	4	4	CD
cord-005478-5iu38pr6	1110	12	months	month	NNS
cord-005478-5iu38pr6	1110	13	could	could	MD
cord-005478-5iu38pr6	1110	14	be	be	VB
cord-005478-5iu38pr6	1110	15	transplanted	transplant	VBN
cord-005478-5iu38pr6	1110	16	of	of	IN
cord-005478-5iu38pr6	1110	17	whom	whom	WP
cord-005478-5iu38pr6	1110	18	18	18	CD
cord-005478-5iu38pr6	1110	19	underwent	undergo	VBD
cord-005478-5iu38pr6	1110	20	a	a	DT
cord-005478-5iu38pr6	1110	21	splenectomy	splenectomy	NN
cord-005478-5iu38pr6	1110	22	before	before	IN
cord-005478-5iu38pr6	1110	23	transplantation	transplantation	NN
cord-005478-5iu38pr6	1110	24	.	.	.
cord-005478-5iu38pr6	1111	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	1111	2	regimen	regimen	NN
cord-005478-5iu38pr6	1111	3	was	be	VBD
cord-005478-5iu38pr6	1111	4	fludarabine	fludarabine	NNP
cord-005478-5iu38pr6	1111	5	90mg	90mg	NNP
cord-005478-5iu38pr6	1111	6	/	/	SYM
cord-005478-5iu38pr6	1111	7	m2	m2	NNP
cord-005478-5iu38pr6	1111	8	in	in	IN
cord-005478-5iu38pr6	1111	9	combination	combination	NN
cord-005478-5iu38pr6	1111	10	with	with	IN
cord-005478-5iu38pr6	1111	11	melphaln	melphaln	NNP
cord-005478-5iu38pr6	1111	12	140mg	140mg	NNP
cord-005478-5iu38pr6	1111	13	/	/	SYM
cord-005478-5iu38pr6	1111	14	m2	m2	NNP
cord-005478-5iu38pr6	1111	15	.	.	.
cord-005478-5iu38pr6	1112	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1112	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1112	3	was	be	VBD
cord-005478-5iu38pr6	1112	4	cyclosporine	cyclosporine	JJ
cord-005478-5iu38pr6	1112	5	and	and	CC
cord-005478-5iu38pr6	1112	6	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	1112	7	mofetil	mofetil	NNP
cord-005478-5iu38pr6	1112	8	with	with	IN
cord-005478-5iu38pr6	1112	9	ATG	ATG	NNP
cord-005478-5iu38pr6	1112	10	in	in	IN
cord-005478-5iu38pr6	1112	11	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1112	12	donor	donor	NN
cord-005478-5iu38pr6	1112	13	.	.	.
cord-005478-5iu38pr6	1113	1	Partial	partial	JJ
cord-005478-5iu38pr6	1113	2	response	response	NN
cord-005478-5iu38pr6	1113	3	under	under	IN
cord-005478-5iu38pr6	1113	4	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1113	5	was	be	VBD
cord-005478-5iu38pr6	1113	6	26	26	CD
cord-005478-5iu38pr6	1113	7	%	%	NN
cord-005478-5iu38pr6	1113	8	while	while	IN
cord-005478-5iu38pr6	1113	9	the	the	DT
cord-005478-5iu38pr6	1113	10	whole	whole	JJ
cord-005478-5iu38pr6	1113	11	complete	complete	JJ
cord-005478-5iu38pr6	1113	12	response	response	NN
cord-005478-5iu38pr6	1113	13	incidence	incidence	NN
cord-005478-5iu38pr6	1113	14	was	be	VBD
cord-005478-5iu38pr6	1113	15	46	46	CD
cord-005478-5iu38pr6	1113	16	%	%	NN
cord-005478-5iu38pr6	1113	17	at	at	IN
cord-005478-5iu38pr6	1113	18	one	one	CD
cord-005478-5iu38pr6	1113	19	year	year	NN
cord-005478-5iu38pr6	1113	20	.	.	.
cord-005478-5iu38pr6	1114	1	OS	OS	NNP
cord-005478-5iu38pr6	1114	2	and	and	CC
cord-005478-5iu38pr6	1114	3	PFS	PFS	NNP
cord-005478-5iu38pr6	1114	4	at	at	IN
cord-005478-5iu38pr6	1114	5	2	2	CD
cord-005478-5iu38pr6	1114	6	years	year	NNS
cord-005478-5iu38pr6	1114	7	were	be	VBD
cord-005478-5iu38pr6	1114	8	68	68	CD
cord-005478-5iu38pr6	1114	9	%	%	NN
cord-005478-5iu38pr6	1114	10	(	(	-LRB-
cord-005478-5iu38pr6	1114	11	95	95	CD
cord-005478-5iu38pr6	1114	12	%	%	NN
cord-005478-5iu38pr6	1114	13	CI	ci	NN
cord-005478-5iu38pr6	1114	14	:	:	:
cord-005478-5iu38pr6	1114	15	59	59	CD
cord-005478-5iu38pr6	1114	16	-	-	SYM
cord-005478-5iu38pr6	1114	17	80	80	CD
cord-005478-5iu38pr6	1114	18	)	)	-RRB-
cord-005478-5iu38pr6	1114	19	and	and	CC
cord-005478-5iu38pr6	1114	20	53	53	CD
cord-005478-5iu38pr6	1114	21	%	%	NN
cord-005478-5iu38pr6	1114	22	(	(	-LRB-
cord-005478-5iu38pr6	1114	23	95	95	CD
cord-005478-5iu38pr6	1114	24	%	%	NN
cord-005478-5iu38pr6	1114	25	CI	ci	NN
cord-005478-5iu38pr6	1114	26	:	:	:
cord-005478-5iu38pr6	1114	27	43	43	CD
cord-005478-5iu38pr6	1114	28	-	-	SYM
cord-005478-5iu38pr6	1114	29	66	66	CD
cord-005478-5iu38pr6	1114	30	)	)	-RRB-
cord-005478-5iu38pr6	1114	31	.	.	.
cord-005478-5iu38pr6	1115	1	OS	OS	NNP
cord-005478-5iu38pr6	1115	2	was	be	VBD
cord-005478-5iu38pr6	1115	3	significantly	significantly	RB
cord-005478-5iu38pr6	1115	4	better	well	JJR
cord-005478-5iu38pr6	1115	5	in	in	IN
cord-005478-5iu38pr6	1115	6	patients	patient	NNS
cord-005478-5iu38pr6	1115	7	with	with	IN
cord-005478-5iu38pr6	1115	8	HLA	HLA	NNP
cord-005478-5iu38pr6	1115	9	matched	match	VBN
cord-005478-5iu38pr6	1115	10	sibling	sibling	NN
cord-005478-5iu38pr6	1115	11	donor	donor	NN
cord-005478-5iu38pr6	1115	12	as	as	IN
cord-005478-5iu38pr6	1115	13	compared	compare	VBN
cord-005478-5iu38pr6	1115	14	to	to	IN
cord-005478-5iu38pr6	1115	15	patients	patient	NNS
cord-005478-5iu38pr6	1115	16	without	without	IN
cord-005478-5iu38pr6	1115	17	a	a	DT
cord-005478-5iu38pr6	1115	18	donor	donor	NN
cord-005478-5iu38pr6	1115	19	or	or	CC
cord-005478-5iu38pr6	1115	20	with	with	IN
cord-005478-5iu38pr6	1115	21	an	an	DT
cord-005478-5iu38pr6	1115	22	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1115	23	donor	donor	NN
cord-005478-5iu38pr6	1115	24	(	(	-LRB-
cord-005478-5iu38pr6	1115	25	p=0.008	p=0.008	NNP
cord-005478-5iu38pr6	1115	26	,	,	,
cord-005478-5iu38pr6	1115	27	figure	figure	NN
cord-005478-5iu38pr6	1115	28	1	1	CD
cord-005478-5iu38pr6	1115	29	)	)	-RRB-
cord-005478-5iu38pr6	1115	30	.	.	.
cord-005478-5iu38pr6	1116	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	1116	2	incidence	incidence	NN
cord-005478-5iu38pr6	1116	3	of	of	IN
cord-005478-5iu38pr6	1116	4	acute	acute	JJ
cord-005478-5iu38pr6	1116	5	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1116	6	on	on	IN
cord-005478-5iu38pr6	1116	7	day	day	NN
cord-005478-5iu38pr6	1116	8	100	100	CD
cord-005478-5iu38pr6	1116	9	was	be	VBD
cord-005478-5iu38pr6	1116	10	66	66	CD
cord-005478-5iu38pr6	1116	11	%	%	NN
cord-005478-5iu38pr6	1116	12	of	of	IN
cord-005478-5iu38pr6	1116	13	whom	whom	WP
cord-005478-5iu38pr6	1116	14	44	44	CD
cord-005478-5iu38pr6	1116	15	%	%	NN
cord-005478-5iu38pr6	1116	16	had	have	VBD
cord-005478-5iu38pr6	1116	17	grade	grade	NN
cord-005478-5iu38pr6	1116	18	3	3	CD
cord-005478-5iu38pr6	1116	19	-	-	SYM
cord-005478-5iu38pr6	1116	20	4	4	CD
cord-005478-5iu38pr6	1116	21	acute	acute	JJ
cord-005478-5iu38pr6	1116	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1116	23	.	.	.
cord-005478-5iu38pr6	1117	1	Cardiogenic	cardiogenic	JJ
cord-005478-5iu38pr6	1117	2	shock	shock	NN
cord-005478-5iu38pr6	1117	3	generally	generally	RB
cord-005478-5iu38pr6	1117	4	associated	associate	VBN
cord-005478-5iu38pr6	1117	5	with	with	IN
cord-005478-5iu38pr6	1117	6	severe	severe	JJ
cord-005478-5iu38pr6	1117	7	sepsis	sepsis	NN
cord-005478-5iu38pr6	1117	8	or	or	CC
cord-005478-5iu38pr6	1117	9	"	"	``
cord-005478-5iu38pr6	1117	10	sepsis	sepsis	NN
cord-005478-5iu38pr6	1117	11	like	like	IN
cord-005478-5iu38pr6	1117	12	"	"	''
cord-005478-5iu38pr6	1117	13	syndrome	syndrome	NN
cord-005478-5iu38pr6	1117	14	occurred	occur	VBD
cord-005478-5iu38pr6	1117	15	in	in	IN
cord-005478-5iu38pr6	1117	16	7	7	CD
cord-005478-5iu38pr6	1117	17	patients	patient	NNS
cord-005478-5iu38pr6	1117	18	:	:	:
cord-005478-5iu38pr6	1117	19	2	2	CD
cord-005478-5iu38pr6	1117	20	patients	patient	NNS
cord-005478-5iu38pr6	1117	21	were	be	VBD
cord-005478-5iu38pr6	1117	22	not	not	RB
cord-005478-5iu38pr6	1117	23	transplanted	transplant	VBN
cord-005478-5iu38pr6	1117	24	because	because	IN
cord-005478-5iu38pr6	1117	25	of	of	IN
cord-005478-5iu38pr6	1117	26	this	this	DT
cord-005478-5iu38pr6	1117	27	complication	complication	NN
cord-005478-5iu38pr6	1117	28	while	while	IN
cord-005478-5iu38pr6	1117	29	in	in	IN
cord-005478-5iu38pr6	1117	30	the	the	DT
cord-005478-5iu38pr6	1117	31	5	5	CD
cord-005478-5iu38pr6	1117	32	other	other	JJ
cord-005478-5iu38pr6	1117	33	patients	patient	NNS
cord-005478-5iu38pr6	1117	34	CS	CS	NNP
cord-005478-5iu38pr6	1117	35	occurred	occur	VBD
cord-005478-5iu38pr6	1117	36	within	within	IN
cord-005478-5iu38pr6	1117	37	the	the	DT
cord-005478-5iu38pr6	1117	38	15	15	CD
cord-005478-5iu38pr6	1117	39	days	day	NNS
cord-005478-5iu38pr6	1117	40	after	after	IN
cord-005478-5iu38pr6	1117	41	transplantation	transplantation	NN
cord-005478-5iu38pr6	1117	42	.	.	.
cord-005478-5iu38pr6	1118	1	Three	three	CD
cord-005478-5iu38pr6	1118	2	renal	renal	JJ
cord-005478-5iu38pr6	1118	3	failures	failure	NNS
cord-005478-5iu38pr6	1118	4	secondary	secondary	JJ
cord-005478-5iu38pr6	1118	5	to	to	TO
cord-005478-5iu38pr6	1118	6	tumor	tumor	NN
cord-005478-5iu38pr6	1118	7	lysis	lysis	NN
cord-005478-5iu38pr6	1118	8	syndrome	syndrome	NN
cord-005478-5iu38pr6	1118	9	were	be	VBD
cord-005478-5iu38pr6	1118	10	declared	declare	VBN
cord-005478-5iu38pr6	1118	11	just	just	RB
cord-005478-5iu38pr6	1118	12	after	after	IN
cord-005478-5iu38pr6	1118	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	1118	14	regimen	regimen	NN
cord-005478-5iu38pr6	1118	15	initiation	initiation	NN
cord-005478-5iu38pr6	1118	16	.	.	.
cord-005478-5iu38pr6	1119	1	Figure	figure	NN
cord-005478-5iu38pr6	1119	2	1	1	CD
cord-005478-5iu38pr6	1119	3	.	.	.
cord-005478-5iu38pr6	1120	1	Overall	overall	JJ
cord-005478-5iu38pr6	1120	2	survival	survival	NN
cord-005478-5iu38pr6	1120	3	in	in	IN
cord-005478-5iu38pr6	1120	4	JAK	JAK	NNP
cord-005478-5iu38pr6	1120	5	ALLO	ALLO	NNP
cord-005478-5iu38pr6	1120	6	patients	patient	NNS
cord-005478-5iu38pr6	1120	7	.	.	.
cord-005478-5iu38pr6	1121	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1121	2	:	:	:
cord-005478-5iu38pr6	1122	1	OS	OS	NNP
cord-005478-5iu38pr6	1122	2	was	be	VBD
cord-005478-5iu38pr6	1122	3	very	very	RB
cord-005478-5iu38pr6	1122	4	good	good	JJ
cord-005478-5iu38pr6	1122	5	in	in	IN
cord-005478-5iu38pr6	1122	6	patients	patient	NNS
cord-005478-5iu38pr6	1122	7	with	with	IN
cord-005478-5iu38pr6	1122	8	HLA	HLA	NNP
cord-005478-5iu38pr6	1122	9	matched	match	VBN
cord-005478-5iu38pr6	1122	10	related	related	JJ
cord-005478-5iu38pr6	1122	11	donor	donor	NN
cord-005478-5iu38pr6	1122	12	and	and	CC
cord-005478-5iu38pr6	1122	13	significantly	significantly	RB
cord-005478-5iu38pr6	1122	14	better	well	JJR
cord-005478-5iu38pr6	1122	15	than	than	IN
cord-005478-5iu38pr6	1122	16	in	in	IN
cord-005478-5iu38pr6	1122	17	patients	patient	NNS
cord-005478-5iu38pr6	1122	18	with	with	IN
cord-005478-5iu38pr6	1122	19	an	an	DT
cord-005478-5iu38pr6	1122	20	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1122	21	donor	donor	NN
cord-005478-5iu38pr6	1122	22	.	.	.
cord-005478-5iu38pr6	1123	1	More	More	JJR
cord-005478-5iu38pr6	1123	2	analyses	analysis	NNS
cord-005478-5iu38pr6	1123	3	are	be	VBP
cord-005478-5iu38pr6	1123	4	currently	currently	RB
cord-005478-5iu38pr6	1123	5	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1123	6	to	to	TO
cord-005478-5iu38pr6	1123	7	determinate	determinate	VB
cord-005478-5iu38pr6	1123	8	the	the	DT
cord-005478-5iu38pr6	1123	9	potential	potential	JJ
cord-005478-5iu38pr6	1123	10	role	role	NN
cord-005478-5iu38pr6	1123	11	of	of	IN
cord-005478-5iu38pr6	1123	12	cytokine	cytokine	NN
cord-005478-5iu38pr6	1123	13	release	release	NN
cord-005478-5iu38pr6	1123	14	in	in	IN
cord-005478-5iu38pr6	1123	15	peri	peri	NN
cord-005478-5iu38pr6	1123	16	-	-	HYPH
cord-005478-5iu38pr6	1123	17	transplantation	transplantation	NN
cord-005478-5iu38pr6	1123	18	time	time	NN
cord-005478-5iu38pr6	1123	19	,	,	,
cord-005478-5iu38pr6	1123	20	as	as	RB
cord-005478-5iu38pr6	1123	21	well	well	RB
cord-005478-5iu38pr6	1123	22	as	as	IN
cord-005478-5iu38pr6	1123	23	specific	specific	JJ
cord-005478-5iu38pr6	1123	24	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1123	25	and	and	CC
cord-005478-5iu38pr6	1123	26	quality	quality	NN
cord-005478-5iu38pr6	1123	27	of	of	IN
cord-005478-5iu38pr6	1123	28	life	life	NN
cord-005478-5iu38pr6	1123	29	questionnaires	questionnaire	NNS
cord-005478-5iu38pr6	1123	30	assessing	assess	VBG
cord-005478-5iu38pr6	1123	31	the	the	DT
cord-005478-5iu38pr6	1123	32	impact	impact	NN
cord-005478-5iu38pr6	1123	33	of	of	IN
cord-005478-5iu38pr6	1123	34	ruxolitinib	ruxolitinib	NN
cord-005478-5iu38pr6	1123	35	in	in	IN
cord-005478-5iu38pr6	1123	36	patients	patient	NNS
cord-005478-5iu38pr6	1123	37	.	.	.
cord-005478-5iu38pr6	1124	1	Background	background	NN
cord-005478-5iu38pr6	1124	2	:	:	:
cord-005478-5iu38pr6	1125	1	While	while	IN
cord-005478-5iu38pr6	1125	2	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	1125	3	may	may	MD
cord-005478-5iu38pr6	1125	4	influence	influence	VB
cord-005478-5iu38pr6	1125	5	outcome	outcome	NN
cord-005478-5iu38pr6	1125	6	in	in	IN
cord-005478-5iu38pr6	1125	7	primary	primary	JJ
cord-005478-5iu38pr6	1125	8	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1125	9	(	(	-LRB-
cord-005478-5iu38pr6	1125	10	PMF	PMF	NNP
cord-005478-5iu38pr6	1125	11	)	)	-RRB-
cord-005478-5iu38pr6	1125	12	from	from	IN
cord-005478-5iu38pr6	1125	13	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1125	14	which	which	WDT
cord-005478-5iu38pr6	1125	15	lead	lead	VBP
cord-005478-5iu38pr6	1125	16	to	to	IN
cord-005478-5iu38pr6	1125	17	several	several	JJ
cord-005478-5iu38pr6	1125	18	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1125	19	systems	system	NNS
cord-005478-5iu38pr6	1125	20	incorporating	incorporate	VBG
cord-005478-5iu38pr6	1125	21	different	different	JJ
cord-005478-5iu38pr6	1125	22	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1125	23	risk	risk	NN
cord-005478-5iu38pr6	1125	24	classifications	classification	NNS
cord-005478-5iu38pr6	1125	25	,	,	,
cord-005478-5iu38pr6	1125	26	its	-PRON-	PRP$
cord-005478-5iu38pr6	1125	27	definitive	definitive	JJ
cord-005478-5iu38pr6	1125	28	role	role	NN
cord-005478-5iu38pr6	1125	29	specific	specific	JJ
cord-005478-5iu38pr6	1125	30	after	after	IN
cord-005478-5iu38pr6	1125	31	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1125	32	stem	stem	NN
cord-005478-5iu38pr6	1125	33	cell	cell	NN
cord-005478-5iu38pr6	1125	34	transplantation	transplantation	NN
cord-005478-5iu38pr6	1125	35	is	be	VBZ
cord-005478-5iu38pr6	1125	36	still	still	RB
cord-005478-5iu38pr6	1125	37	unclear	unclear	JJ
cord-005478-5iu38pr6	1125	38	.	.	.
cord-005478-5iu38pr6	1126	1	Here	here	RB
cord-005478-5iu38pr6	1126	2	,	,	,
cord-005478-5iu38pr6	1126	3	we	-PRON-	PRP
cord-005478-5iu38pr6	1126	4	aim	aim	VBP
cord-005478-5iu38pr6	1126	5	to	to	TO
cord-005478-5iu38pr6	1126	6	evaluate	evaluate	VB
cord-005478-5iu38pr6	1126	7	the	the	DT
cord-005478-5iu38pr6	1126	8	role	role	NN
cord-005478-5iu38pr6	1126	9	of	of	IN
cord-005478-5iu38pr6	1126	10	currently	currently	RB
cord-005478-5iu38pr6	1126	11	existing	exist	VBG
cord-005478-5iu38pr6	1126	12	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1126	13	risk	risk	NN
cord-005478-5iu38pr6	1126	14	classifications	classification	NNS
cord-005478-5iu38pr6	1126	15	included	include	VBN
cord-005478-5iu38pr6	1126	16	in	in	IN
cord-005478-5iu38pr6	1126	17	the	the	DT
cord-005478-5iu38pr6	1126	18	Dynamic	Dynamic	NNP
cord-005478-5iu38pr6	1126	19	International	International	NNP
cord-005478-5iu38pr6	1126	20	Prognostic	Prognostic	NNP
cord-005478-5iu38pr6	1126	21	Scoring	Scoring	NNP
cord-005478-5iu38pr6	1126	22	System	System	NNP
cord-005478-5iu38pr6	1126	23	(	(	-LRB-
cord-005478-5iu38pr6	1126	24	DIPSS)-plus	DIPSS)-plus	NNP
cord-005478-5iu38pr6	1126	25	and	and	CC
cord-005478-5iu38pr6	1126	26	in	in	IN
cord-005478-5iu38pr6	1126	27	the	the	DT
cord-005478-5iu38pr6	1126	28	mutation	mutation	NN
cord-005478-5iu38pr6	1126	29	-	-	HYPH
cord-005478-5iu38pr6	1126	30	enhanced	enhance	VBN
cord-005478-5iu38pr6	1126	31	system	system	NN
cord-005478-5iu38pr6	1126	32	(	(	-LRB-
cord-005478-5iu38pr6	1126	33	MIPSS70-plus	MIPSS70-plus	NNP
cord-005478-5iu38pr6	1126	34	version	version	NN
cord-005478-5iu38pr6	1126	35	2.0	2.0	CD
cord-005478-5iu38pr6	1126	36	)	)	-RRB-
cord-005478-5iu38pr6	1126	37	.	.	.
cord-005478-5iu38pr6	1127	1	Methods	method	NNS
cord-005478-5iu38pr6	1127	2	:	:	:
cord-005478-5iu38pr6	1127	3	In	in	IN
cord-005478-5iu38pr6	1127	4	this	this	DT
cord-005478-5iu38pr6	1127	5	multicenter	multicenter	JJ
cord-005478-5iu38pr6	1127	6	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1127	7	study	study	NN
cord-005478-5iu38pr6	1127	8	,	,	,
cord-005478-5iu38pr6	1127	9	we	-PRON-	PRP
cord-005478-5iu38pr6	1127	10	examined	examine	VBD
cord-005478-5iu38pr6	1127	11	149	149	CD
cord-005478-5iu38pr6	1127	12	PMF	PMF	NNP
cord-005478-5iu38pr6	1127	13	patients	patient	NNS
cord-005478-5iu38pr6	1127	14	undergoing	undergo	VBG
cord-005478-5iu38pr6	1127	15	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1127	16	stem	stem	NN
cord-005478-5iu38pr6	1127	17	cell	cell	NN
cord-005478-5iu38pr6	1127	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	1127	19	.	.	.
cord-005478-5iu38pr6	1128	1	Current	current	JJ
cord-005478-5iu38pr6	1128	2	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1128	3	risk	risk	NN
cord-005478-5iu38pr6	1128	4	stratifications	stratification	NNS
cord-005478-5iu38pr6	1128	5	used	use	VBN
cord-005478-5iu38pr6	1128	6	in	in	IN
cord-005478-5iu38pr6	1128	7	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1128	8	-	-	HYPH
cord-005478-5iu38pr6	1128	9	plus	plus	CC
cord-005478-5iu38pr6	1128	10	and	and	CC
cord-005478-5iu38pr6	1128	11	MIPSS70-plus	MIPSS70-plus	NNP
cord-005478-5iu38pr6	1128	12	version	version	NN
cord-005478-5iu38pr6	1128	13	2.0	2.0	CD
cord-005478-5iu38pr6	1128	14	were	be	VBD
cord-005478-5iu38pr6	1128	15	evaluated	evaluate	VBN
cord-005478-5iu38pr6	1128	16	.	.	.
cord-005478-5iu38pr6	1129	1	According	accord	VBG
cord-005478-5iu38pr6	1129	2	to	to	IN
cord-005478-5iu38pr6	1129	3	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1129	4	-	-	HYPH
cord-005478-5iu38pr6	1129	5	plus	plus	CC
cord-005478-5iu38pr6	1129	6	,	,	,
cord-005478-5iu38pr6	1129	7	an	an	DT
cord-005478-5iu38pr6	1129	8	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1129	9	karyotype	karyotype	NN
cord-005478-5iu38pr6	1129	10	includes	include	NNS
cord-005478-5iu38pr6	1129	11	+8	+8	NN
cord-005478-5iu38pr6	1129	12	,	,	,
cord-005478-5iu38pr6	1129	13	-7/7q	-7/7q	NNP
cord-005478-5iu38pr6	1129	14	,	,	,
cord-005478-5iu38pr6	1129	15	i(17)q	i(17)q	NNS
cord-005478-5iu38pr6	1129	16	,	,	,
cord-005478-5iu38pr6	1129	17	-5/5q,12p-	-5/5q,12p-	UH
cord-005478-5iu38pr6	1129	18	,	,	,
cord-005478-5iu38pr6	1129	19	inv	inv	NNP
cord-005478-5iu38pr6	1129	20	(	(	-LRB-
cord-005478-5iu38pr6	1129	21	3	3	CD
cord-005478-5iu38pr6	1129	22	)	)	-RRB-
cord-005478-5iu38pr6	1129	23	,	,	,
cord-005478-5iu38pr6	1129	24	and	and	CC
cord-005478-5iu38pr6	1129	25	11q23	11q23	CD
cord-005478-5iu38pr6	1129	26	rearrangements	rearrangement	NNS
cord-005478-5iu38pr6	1129	27	while	while	IN
cord-005478-5iu38pr6	1129	28	MIPSS70-plus	MIPSS70-plus	NNP
cord-005478-5iu38pr6	1129	29	version	version	NN
cord-005478-5iu38pr6	1129	30	2.0	2.0	CD
cord-005478-5iu38pr6	1129	31	consisted	consist	VBD
cord-005478-5iu38pr6	1129	32	of	of	IN
cord-005478-5iu38pr6	1129	33	very	very	RB
cord-005478-5iu38pr6	1129	34	high	high	JJ
cord-005478-5iu38pr6	1129	35	risk	risk	NN
cord-005478-5iu38pr6	1129	36	(	(	-LRB-
cord-005478-5iu38pr6	1129	37	VHR	VHR	NNP
cord-005478-5iu38pr6	1129	38	:	:	:
cord-005478-5iu38pr6	1129	39	single	single	JJ
cord-005478-5iu38pr6	1129	40	/	/	SYM
cord-005478-5iu38pr6	1129	41	multiple	multiple	JJ
cord-005478-5iu38pr6	1129	42	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1129	43	of	of	IN
cord-005478-5iu38pr6	1129	44	-7	-7	NNP
cord-005478-5iu38pr6	1129	45	,	,	,
cord-005478-5iu38pr6	1129	46	i(17q	i(17q	CD
cord-005478-5iu38pr6	1129	47	)	)	-RRB-
cord-005478-5iu38pr6	1129	48	,	,	.
cord-005478-5iu38pr6	1130	1	inv(3)/	inv(3)/	NNP
cord-005478-5iu38pr6	1130	2	3q21	3q21	CD
cord-005478-5iu38pr6	1130	3	,	,	,
cord-005478-5iu38pr6	1130	4	12p-/12p11.2	12p-/12p11.2	CD
cord-005478-5iu38pr6	1130	5	,	,	,
cord-005478-5iu38pr6	1130	6	11q-/11q23	11q-/11q23	CD
cord-005478-5iu38pr6	1130	7	,	,	,
cord-005478-5iu38pr6	1130	8	+21	+21	XX
cord-005478-5iu38pr6	1130	9	,	,	,
cord-005478-5iu38pr6	1130	10	or	or	CC
cord-005478-5iu38pr6	1130	11	other	other	JJ
cord-005478-5iu38pr6	1130	12	autosomal	autosomal	JJ
cord-005478-5iu38pr6	1130	13	trisomy	trisomy	NN
cord-005478-5iu38pr6	1130	14	,	,	,
cord-005478-5iu38pr6	1130	15	not	not	RB
cord-005478-5iu38pr6	1130	16	including	include	VBG
cord-005478-5iu38pr6	1130	17	+8/+9	+8/+9	NNP
cord-005478-5iu38pr6	1130	18	)	)	-RRB-
cord-005478-5iu38pr6	1130	19	,	,	,
cord-005478-5iu38pr6	1130	20	favorable	favorable	JJ
cord-005478-5iu38pr6	1130	21	(	(	-LRB-
cord-005478-5iu38pr6	1130	22	normal	normal	JJ
cord-005478-5iu38pr6	1130	23	karyotype	karyotype	NN
cord-005478-5iu38pr6	1130	24	or	or	CC
cord-005478-5iu38pr6	1130	25	sole	sole	JJ
cord-005478-5iu38pr6	1130	26	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1130	27	of	of	IN
cord-005478-5iu38pr6	1130	28	13q-	13q-	CD
cord-005478-5iu38pr6	1130	29	,	,	,
cord-005478-5iu38pr6	1130	30	+9	+9	XX
cord-005478-5iu38pr6	1130	31	,	,	,
cord-005478-5iu38pr6	1130	32	20q-	20q-	CD
cord-005478-5iu38pr6	1130	33	,	,	,
cord-005478-5iu38pr6	1130	34	chromosome	chromosome	NN
cord-005478-5iu38pr6	1130	35	1	1	CD
cord-005478-5iu38pr6	1130	36	translocation	translocation	NN
cord-005478-5iu38pr6	1130	37	/	/	SYM
cord-005478-5iu38pr6	1130	38	duplication	duplication	NN
cord-005478-5iu38pr6	1130	39	or	or	CC
cord-005478-5iu38pr6	1130	40	sex	sex	NN
cord-005478-5iu38pr6	1130	41	chromosome	chromosome	NN
cord-005478-5iu38pr6	1130	42	abnormality	abnormality	NN
cord-005478-5iu38pr6	1130	43	including	include	VBG
cord-005478-5iu38pr6	1130	44	-Y	-Y	.
cord-005478-5iu38pr6	1130	45	)	)	-RRB-
cord-005478-5iu38pr6	1130	46	,	,	,
cord-005478-5iu38pr6	1130	47	and	and	CC
cord-005478-5iu38pr6	1130	48	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1130	49	(	(	-LRB-
cord-005478-5iu38pr6	1130	50	all	all	DT
cord-005478-5iu38pr6	1130	51	other	other	JJ
cord-005478-5iu38pr6	1130	52	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1130	53	)	)	-RRB-
cord-005478-5iu38pr6	1130	54	.	.	.
cord-005478-5iu38pr6	1131	1	Results	result	NNS
cord-005478-5iu38pr6	1131	2	:	:	:
cord-005478-5iu38pr6	1132	1	The	the	DT
cord-005478-5iu38pr6	1132	2	median	median	JJ
cord-005478-5iu38pr6	1132	3	follow	follow	NN
cord-005478-5iu38pr6	1132	4	-	-	HYPH
cord-005478-5iu38pr6	1132	5	up	up	NN
cord-005478-5iu38pr6	1132	6	period	period	NN
cord-005478-5iu38pr6	1132	7	of	of	IN
cord-005478-5iu38pr6	1132	8	all	all	DT
cord-005478-5iu38pr6	1132	9	149	149	CD
cord-005478-5iu38pr6	1132	10	PMF	PMF	NNP
cord-005478-5iu38pr6	1132	11	patients	patient	NNS
cord-005478-5iu38pr6	1132	12	was	be	VBD
cord-005478-5iu38pr6	1132	13	56	56	CD
cord-005478-5iu38pr6	1132	14	months	month	NNS
cord-005478-5iu38pr6	1132	15	and	and	CC
cord-005478-5iu38pr6	1132	16	the	the	DT
cord-005478-5iu38pr6	1132	17	median	median	JJ
cord-005478-5iu38pr6	1132	18	time	time	NN
cord-005478-5iu38pr6	1132	19	from	from	IN
cord-005478-5iu38pr6	1132	20	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1132	21	to	to	IN
cord-005478-5iu38pr6	1132	22	transplant	transplant	NN
cord-005478-5iu38pr6	1132	23	was	be	VBD
cord-005478-5iu38pr6	1132	24	26	26	CD
cord-005478-5iu38pr6	1132	25	months	month	NNS
cord-005478-5iu38pr6	1132	26	.	.	.
cord-005478-5iu38pr6	1133	1	After	after	IN
cord-005478-5iu38pr6	1133	2	five	five	CD
cord-005478-5iu38pr6	1133	3	years	year	NNS
cord-005478-5iu38pr6	1133	4	,	,	,
cord-005478-5iu38pr6	1133	5	51	51	CD
cord-005478-5iu38pr6	1133	6	(	(	-LRB-
cord-005478-5iu38pr6	1133	7	34	34	CD
cord-005478-5iu38pr6	1133	8	%	%	NN
cord-005478-5iu38pr6	1133	9	)	)	-RRB-
cord-005478-5iu38pr6	1133	10	patients	patient	NNS
cord-005478-5iu38pr6	1133	11	had	have	VBD
cord-005478-5iu38pr6	1133	12	died	die	VBN
cord-005478-5iu38pr6	1133	13	.	.	.
cord-005478-5iu38pr6	1134	1	The	the	DT
cord-005478-5iu38pr6	1134	2	median	median	JJ
cord-005478-5iu38pr6	1134	3	age	age	NN
cord-005478-5iu38pr6	1134	4	at	at	IN
cord-005478-5iu38pr6	1134	5	transplant	transplant	NN
cord-005478-5iu38pr6	1134	6	was	be	VBD
cord-005478-5iu38pr6	1134	7	57	57	CD
cord-005478-5iu38pr6	1134	8	years	year	NNS
cord-005478-5iu38pr6	1134	9	and	and	CC
cord-005478-5iu38pr6	1134	10	63	63	CD
cord-005478-5iu38pr6	1134	11	%	%	NN
cord-005478-5iu38pr6	1134	12	of	of	IN
cord-005478-5iu38pr6	1134	13	patients	patient	NNS
cord-005478-5iu38pr6	1134	14	were	be	VBD
cord-005478-5iu38pr6	1134	15	male	male	JJ
cord-005478-5iu38pr6	1134	16	.	.	.
cord-005478-5iu38pr6	1135	1	Most	Most	JJS
cord-005478-5iu38pr6	1135	2	allografts	allograft	NNS
cord-005478-5iu38pr6	1135	3	were	be	VBD
cord-005478-5iu38pr6	1135	4	applied	apply	VBN
cord-005478-5iu38pr6	1135	5	using	use	VBG
cord-005478-5iu38pr6	1135	6	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1135	7	blood	blood	NN
cord-005478-5iu38pr6	1135	8	(	(	-LRB-
cord-005478-5iu38pr6	1135	9	97	97	CD
cord-005478-5iu38pr6	1135	10	%	%	NN
cord-005478-5iu38pr6	1135	11	)	)	-RRB-
cord-005478-5iu38pr6	1135	12	and	and	CC
cord-005478-5iu38pr6	1135	13	were	be	VBD
cord-005478-5iu38pr6	1135	14	received	receive	VBN
cord-005478-5iu38pr6	1135	15	from	from	IN
cord-005478-5iu38pr6	1135	16	an	an	DT
cord-005478-5iu38pr6	1135	17	HLA	HLA	NNP
cord-005478-5iu38pr6	1135	18	-	-	HYPH
cord-005478-5iu38pr6	1135	19	matched	match	VBN
cord-005478-5iu38pr6	1135	20	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1135	21	donor	donor	NN
cord-005478-5iu38pr6	1135	22	(	(	-LRB-
cord-005478-5iu38pr6	1135	23	42	42	CD
cord-005478-5iu38pr6	1135	24	%	%	NN
cord-005478-5iu38pr6	1135	25	)	)	-RRB-
cord-005478-5iu38pr6	1135	26	,	,	,
cord-005478-5iu38pr6	1135	27	followed	follow	VBN
cord-005478-5iu38pr6	1135	28	by	by	IN
cord-005478-5iu38pr6	1135	29	mismatched	mismatched	JJ
cord-005478-5iu38pr6	1135	30	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1135	31	(	(	-LRB-
cord-005478-5iu38pr6	1135	32	34	34	CD
cord-005478-5iu38pr6	1135	33	%	%	NN
cord-005478-5iu38pr6	1135	34	)	)	-RRB-
cord-005478-5iu38pr6	1135	35	,	,	,
cord-005478-5iu38pr6	1135	36	matched	match	VBN
cord-005478-5iu38pr6	1135	37	related	relate	VBN
cord-005478-5iu38pr6	1135	38	(	(	-LRB-
cord-005478-5iu38pr6	1135	39	23	23	CD
cord-005478-5iu38pr6	1135	40	%	%	NN
cord-005478-5iu38pr6	1135	41	)	)	-RRB-
cord-005478-5iu38pr6	1135	42	,	,	,
cord-005478-5iu38pr6	1135	43	and	and	CC
cord-005478-5iu38pr6	1135	44	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1135	45	related	related	JJ
cord-005478-5iu38pr6	1135	46	or	or	CC
cord-005478-5iu38pr6	1135	47	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1135	48	(	(	-LRB-
cord-005478-5iu38pr6	1135	49	1	1	CD
cord-005478-5iu38pr6	1135	50	%	%	NN
cord-005478-5iu38pr6	1135	51	)	)	-RRB-
cord-005478-5iu38pr6	1135	52	.	.	.
cord-005478-5iu38pr6	1136	1	Reduced	reduced	JJ
cord-005478-5iu38pr6	1136	2	intensity	intensity	NN
cord-005478-5iu38pr6	1136	3	conditioning	conditioning	NN
cord-005478-5iu38pr6	1136	4	was	be	VBD
cord-005478-5iu38pr6	1136	5	applied	apply	VBN
cord-005478-5iu38pr6	1136	6	to	to	IN
cord-005478-5iu38pr6	1136	7	75	75	CD
cord-005478-5iu38pr6	1136	8	%	%	NN
cord-005478-5iu38pr6	1136	9	of	of	IN
cord-005478-5iu38pr6	1136	10	patients	patient	NNS
cord-005478-5iu38pr6	1136	11	.	.	.
cord-005478-5iu38pr6	1137	1	Splenectomy	Splenectomy	NNP
cord-005478-5iu38pr6	1137	2	before	before	IN
cord-005478-5iu38pr6	1137	3	transplant	transplant	NN
cord-005478-5iu38pr6	1137	4	was	be	VBD
cord-005478-5iu38pr6	1137	5	undergone	undergo	VBN
cord-005478-5iu38pr6	1137	6	in	in	IN
cord-005478-5iu38pr6	1137	7	15	15	CD
cord-005478-5iu38pr6	1137	8	%	%	NN
cord-005478-5iu38pr6	1137	9	and	and	CC
cord-005478-5iu38pr6	1137	10	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1137	11	was	be	VBD
cord-005478-5iu38pr6	1137	12	received	receive	VBN
cord-005478-5iu38pr6	1137	13	by	by	IN
cord-005478-5iu38pr6	1137	14	27	27	CD
cord-005478-5iu38pr6	1137	15	%	%	NN
cord-005478-5iu38pr6	1137	16	.	.	.
cord-005478-5iu38pr6	1138	1	Frequencies	frequency	NNS
cord-005478-5iu38pr6	1138	2	according	accord	VBG
cord-005478-5iu38pr6	1138	3	to	to	IN
cord-005478-5iu38pr6	1138	4	driver	driver	NN
cord-005478-5iu38pr6	1138	5	mutation	mutation	NN
cord-005478-5iu38pr6	1138	6	genotype	genotype	NN
cord-005478-5iu38pr6	1138	7	were	be	VBD
cord-005478-5iu38pr6	1138	8	:	:	:
cord-005478-5iu38pr6	1138	9	CALR	CALR	NNP
cord-005478-5iu38pr6	1138	10	(	(	-LRB-
cord-005478-5iu38pr6	1138	11	19	19	CD
cord-005478-5iu38pr6	1138	12	%	%	NN
cord-005478-5iu38pr6	1138	13	)	)	-RRB-
cord-005478-5iu38pr6	1138	14	,	,	,
cord-005478-5iu38pr6	1138	15	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1138	16	(	(	-LRB-
cord-005478-5iu38pr6	1138	17	59	59	CD
cord-005478-5iu38pr6	1138	18	%	%	NN
cord-005478-5iu38pr6	1138	19	)	)	-RRB-
cord-005478-5iu38pr6	1138	20	,	,	,
cord-005478-5iu38pr6	1138	21	MPL	MPL	NNP
cord-005478-5iu38pr6	1138	22	(	(	-LRB-
cord-005478-5iu38pr6	1138	23	5	5	CD
cord-005478-5iu38pr6	1138	24	%	%	NN
cord-005478-5iu38pr6	1138	25	)	)	-RRB-
cord-005478-5iu38pr6	1138	26	,	,	,
cord-005478-5iu38pr6	1138	27	and	and	CC
cord-005478-5iu38pr6	1138	28	triple	triple	JJ
cord-005478-5iu38pr6	1138	29	negative	negative	JJ
cord-005478-5iu38pr6	1138	30	(	(	-LRB-
cord-005478-5iu38pr6	1138	31	17	17	CD
cord-005478-5iu38pr6	1138	32	%	%	NN
cord-005478-5iu38pr6	1138	33	)	)	-RRB-
cord-005478-5iu38pr6	1138	34	.	.	.
cord-005478-5iu38pr6	1139	1	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1139	2	mutation	mutation	NN
cord-005478-5iu38pr6	1139	3	was	be	VBD
cord-005478-5iu38pr6	1139	4	present	present	JJ
cord-005478-5iu38pr6	1139	5	in	in	IN
cord-005478-5iu38pr6	1139	6	38	38	CD
cord-005478-5iu38pr6	1139	7	%	%	NN
cord-005478-5iu38pr6	1139	8	while	while	IN
cord-005478-5iu38pr6	1139	9	64	64	CD
cord-005478-5iu38pr6	1139	10	%	%	NN
cord-005478-5iu38pr6	1139	11	had	have	VBD
cord-005478-5iu38pr6	1139	12	more	more	JJR
cord-005478-5iu38pr6	1139	13	than	than	IN
cord-005478-5iu38pr6	1139	14	two	two	CD
cord-005478-5iu38pr6	1139	15	mutations	mutation	NNS
cord-005478-5iu38pr6	1139	16	overall	overall	RB
cord-005478-5iu38pr6	1139	17	.	.	.
cord-005478-5iu38pr6	1140	1	94	94	CD
cord-005478-5iu38pr6	1140	2	(	(	-LRB-
cord-005478-5iu38pr6	1140	3	63	63	CD
cord-005478-5iu38pr6	1140	4	%	%	NN
cord-005478-5iu38pr6	1140	5	)	)	-RRB-
cord-005478-5iu38pr6	1140	6	patients	patient	NNS
cord-005478-5iu38pr6	1140	7	had	have	VBD
cord-005478-5iu38pr6	1140	8	normal	normal	JJ
cord-005478-5iu38pr6	1140	9	karyotype	karyotype	NN
cord-005478-5iu38pr6	1140	10	.	.	.
cord-005478-5iu38pr6	1141	1	Most	Most	JJS
cord-005478-5iu38pr6	1141	2	frequent	frequent	JJ
cord-005478-5iu38pr6	1141	3	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1141	4	were	be	VBD
cord-005478-5iu38pr6	1141	5	trisomy	trisomy	NN
cord-005478-5iu38pr6	1141	6	8	8	CD
cord-005478-5iu38pr6	1141	7	in	in	IN
cord-005478-5iu38pr6	1141	8	11	11	CD
cord-005478-5iu38pr6	1141	9	(	(	-LRB-
cord-005478-5iu38pr6	1141	10	7	7	CD
cord-005478-5iu38pr6	1141	11	%	%	NN
cord-005478-5iu38pr6	1141	12	)	)	-RRB-
cord-005478-5iu38pr6	1141	13	,	,	,
cord-005478-5iu38pr6	1141	14	trisomy	trisomy	NN
cord-005478-5iu38pr6	1141	15	9	9	CD
cord-005478-5iu38pr6	1141	16	in	in	IN
cord-005478-5iu38pr6	1141	17	5	5	CD
cord-005478-5iu38pr6	1141	18	(	(	-LRB-
cord-005478-5iu38pr6	1141	19	3	3	CD
cord-005478-5iu38pr6	1141	20	%	%	NN
cord-005478-5iu38pr6	1141	21	)	)	-RRB-
cord-005478-5iu38pr6	1141	22	,	,	,
cord-005478-5iu38pr6	1141	23	deletion	deletion	NN
cord-005478-5iu38pr6	1141	24	in	in	IN
cord-005478-5iu38pr6	1141	25	20q	20q	NNS
cord-005478-5iu38pr6	1141	26	in	in	IN
cord-005478-5iu38pr6	1141	27	17	17	CD
cord-005478-5iu38pr6	1141	28	(	(	-LRB-
cord-005478-5iu38pr6	1141	29	11	11	CD
cord-005478-5iu38pr6	1141	30	%	%	NN
cord-005478-5iu38pr6	1141	31	)	)	-RRB-
cord-005478-5iu38pr6	1141	32	,	,	,
cord-005478-5iu38pr6	1141	33	deletion	deletion	NN
cord-005478-5iu38pr6	1141	34	in	in	IN
cord-005478-5iu38pr6	1141	35	13q	13q	CD
cord-005478-5iu38pr6	1141	36	in	in	IN
cord-005478-5iu38pr6	1141	37	11	11	CD
cord-005478-5iu38pr6	1141	38	(	(	-LRB-
cord-005478-5iu38pr6	1141	39	7	7	CD
cord-005478-5iu38pr6	1141	40	%	%	NN
cord-005478-5iu38pr6	1141	41	)	)	-RRB-
cord-005478-5iu38pr6	1141	42	,	,	,
cord-005478-5iu38pr6	1141	43	chromosome	chromosome	NN
cord-005478-5iu38pr6	1141	44	7	7	CD
cord-005478-5iu38pr6	1141	45	in	in	IN
cord-005478-5iu38pr6	1141	46	5	5	CD
cord-005478-5iu38pr6	1141	47	(	(	-LRB-
cord-005478-5iu38pr6	1141	48	3	3	CD
cord-005478-5iu38pr6	1141	49	%	%	NN
cord-005478-5iu38pr6	1141	50	)	)	-RRB-
cord-005478-5iu38pr6	1141	51	,	,	,
cord-005478-5iu38pr6	1141	52	chromosome	chromosome	NN
cord-005478-5iu38pr6	1141	53	5	5	CD
cord-005478-5iu38pr6	1141	54	in	in	IN
cord-005478-5iu38pr6	1141	55	5	5	CD
cord-005478-5iu38pr6	1141	56	(	(	-LRB-
cord-005478-5iu38pr6	1141	57	3	3	CD
cord-005478-5iu38pr6	1141	58	%	%	NN
cord-005478-5iu38pr6	1141	59	)	)	-RRB-
cord-005478-5iu38pr6	1141	60	,	,	,
cord-005478-5iu38pr6	1141	61	and	and	CC
cord-005478-5iu38pr6	1141	62	chromosome	chromosome	NN
cord-005478-5iu38pr6	1141	63	1	1	CD
cord-005478-5iu38pr6	1141	64	translocation	translocation	NN
cord-005478-5iu38pr6	1141	65	/	/	SYM
cord-005478-5iu38pr6	1141	66	duplication	duplication	NN
cord-005478-5iu38pr6	1141	67	in	in	IN
cord-005478-5iu38pr6	1141	68	2	2	CD
cord-005478-5iu38pr6	1141	69	(	(	-LRB-
cord-005478-5iu38pr6	1141	70	1	1	CD
cord-005478-5iu38pr6	1141	71	%	%	NN
cord-005478-5iu38pr6	1141	72	)	)	-RRB-
cord-005478-5iu38pr6	1141	73	.	.	.
cord-005478-5iu38pr6	1142	1	More	More	JJR
cord-005478-5iu38pr6	1142	2	than	than	IN
cord-005478-5iu38pr6	1142	3	two	two	CD
cord-005478-5iu38pr6	1142	4	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1142	5	were	be	VBD
cord-005478-5iu38pr6	1142	6	present	present	JJ
cord-005478-5iu38pr6	1142	7	in	in	IN
cord-005478-5iu38pr6	1142	8	9	9	CD
cord-005478-5iu38pr6	1142	9	(	(	-LRB-
cord-005478-5iu38pr6	1142	10	6	6	CD
cord-005478-5iu38pr6	1142	11	%	%	NN
cord-005478-5iu38pr6	1142	12	)	)	-RRB-
cord-005478-5iu38pr6	1142	13	patients	patient	NNS
cord-005478-5iu38pr6	1142	14	.	.	.
cord-005478-5iu38pr6	1143	1	High	high	JJ
cord-005478-5iu38pr6	1143	2	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1143	3	risk	risk	NN
cord-005478-5iu38pr6	1143	4	category	category	NN
cord-005478-5iu38pr6	1143	5	according	accord	VBG
cord-005478-5iu38pr6	1143	6	to	to	IN
cord-005478-5iu38pr6	1143	7	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1143	8	-	-	HYPH
cord-005478-5iu38pr6	1143	9	plus	plus	CC
cord-005478-5iu38pr6	1143	10	was	be	VBD
cord-005478-5iu38pr6	1143	11	present	present	JJ
cord-005478-5iu38pr6	1143	12	in	in	IN
cord-005478-5iu38pr6	1143	13	24	24	CD
cord-005478-5iu38pr6	1143	14	(	(	-LRB-
cord-005478-5iu38pr6	1143	15	16	16	CD
cord-005478-5iu38pr6	1143	16	%	%	NN
cord-005478-5iu38pr6	1143	17	)	)	-RRB-
cord-005478-5iu38pr6	1143	18	while	while	IN
cord-005478-5iu38pr6	1143	19	12	12	CD
cord-005478-5iu38pr6	1143	20	(	(	-LRB-
cord-005478-5iu38pr6	1143	21	8	8	CD
cord-005478-5iu38pr6	1143	22	%	%	NN
cord-005478-5iu38pr6	1143	23	)	)	-RRB-
cord-005478-5iu38pr6	1143	24	had	have	VBD
cord-005478-5iu38pr6	1143	25	VHR	VHR	NNP
cord-005478-5iu38pr6	1143	26	and	and	CC
cord-005478-5iu38pr6	1143	27	25	25	CD
cord-005478-5iu38pr6	1143	28	(	(	-LRB-
cord-005478-5iu38pr6	1143	29	17	17	CD
cord-005478-5iu38pr6	1143	30	%	%	NN
cord-005478-5iu38pr6	1143	31	)	)	-RRB-
cord-005478-5iu38pr6	1143	32	had	have	VBD
cord-005478-5iu38pr6	1143	33	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1143	34	risk	risk	NN
cord-005478-5iu38pr6	1143	35	according	accord	VBG
cord-005478-5iu38pr6	1143	36	to	to	IN
cord-005478-5iu38pr6	1143	37	MIPSS70-plus	MIPSS70-plus	NNP
cord-005478-5iu38pr6	1143	38	version	version	NN
cord-005478-5iu38pr6	1143	39	2.0	2.0	CD
cord-005478-5iu38pr6	1143	40	.	.	.
cord-005478-5iu38pr6	1144	1	Regarding	regard	VBG
cord-005478-5iu38pr6	1144	2	outcome	outcome	NN
cord-005478-5iu38pr6	1144	3	,	,	,
cord-005478-5iu38pr6	1144	4	an	an	DT
cord-005478-5iu38pr6	1144	5	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1144	6	karyotype	karyotype	NN
cord-005478-5iu38pr6	1144	7	according	accord	VBG
cord-005478-5iu38pr6	1144	8	to	to	IN
cord-005478-5iu38pr6	1144	9	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1144	10	-	-	HYPH
cord-005478-5iu38pr6	1144	11	plus	plus	CC
cord-005478-5iu38pr6	1144	12	showed	show	VBD
cord-005478-5iu38pr6	1144	13	5year	5year	JJ
cord-005478-5iu38pr6	1144	14	OS	os	NN
cord-005478-5iu38pr6	1144	15	of	of	IN
cord-005478-5iu38pr6	1144	16	62	62	CD
cord-005478-5iu38pr6	1144	17	%	%	NN
cord-005478-5iu38pr6	1144	18	(	(	-LRB-
cord-005478-5iu38pr6	1144	19	52	52	CD
cord-005478-5iu38pr6	1144	20	-	-	SYM
cord-005478-5iu38pr6	1144	21	72	72	CD
cord-005478-5iu38pr6	1144	22	%	%	NN
cord-005478-5iu38pr6	1144	23	)	)	-RRB-
cord-005478-5iu38pr6	1144	24	vs	vs	IN
cord-005478-5iu38pr6	1144	25	63	63	CD
cord-005478-5iu38pr6	1144	26	%	%	NN
cord-005478-5iu38pr6	1144	27	(	(	-LRB-
cord-005478-5iu38pr6	1144	28	57	57	CD
cord-005478-5iu38pr6	1144	29	-	-	SYM
cord-005478-5iu38pr6	1144	30	70	70	CD
cord-005478-5iu38pr6	1144	31	%	%	NN
cord-005478-5iu38pr6	1144	32	)	)	-RRB-
cord-005478-5iu38pr6	1144	33	,	,	,
cord-005478-5iu38pr6	1144	34	with	with	IN
cord-005478-5iu38pr6	1144	35	causespecific	causespecific	NNP
cord-005478-5iu38pr6	1144	36	hazard	hazard	NN
cord-005478-5iu38pr6	1144	37	being	be	VBG
cord-005478-5iu38pr6	1144	38	1.16	1.16	CD
cord-005478-5iu38pr6	1144	39	(	(	-LRB-
cord-005478-5iu38pr6	1144	40	P=0.69	P=0.69	NNP
cord-005478-5iu38pr6	1144	41	)	)	-RRB-
cord-005478-5iu38pr6	1144	42	.	.	.
cord-005478-5iu38pr6	1145	1	5-year	5-year	CD
cord-005478-5iu38pr6	1145	2	relapse	relapse	NN
cord-005478-5iu38pr6	1145	3	and	and	CC
cord-005478-5iu38pr6	1145	4	nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	1145	5	mortality	mortality	NN
cord-005478-5iu38pr6	1145	6	rates	rate	NNS
cord-005478-5iu38pr6	1145	7	were	be	VBD
cord-005478-5iu38pr6	1145	8	not	not	RB
cord-005478-5iu38pr6	1145	9	significantly	significantly	RB
cord-005478-5iu38pr6	1145	10	different	different	JJ
cord-005478-5iu38pr6	1145	11	showing	show	VBG
cord-005478-5iu38pr6	1145	12	9	9	CD
cord-005478-5iu38pr6	1145	13	%	%	NN
cord-005478-5iu38pr6	1145	14	and	and	CC
cord-005478-5iu38pr6	1145	15	33	33	CD
cord-005478-5iu38pr6	1145	16	%	%	NN
cord-005478-5iu38pr6	1145	17	for	for	IN
cord-005478-5iu38pr6	1145	18	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1145	19	karyotype	karyotype	NN
cord-005478-5iu38pr6	1145	20	vs	vs	IN
cord-005478-5iu38pr6	1145	21	17	17	CD
cord-005478-5iu38pr6	1145	22	%	%	NN
cord-005478-5iu38pr6	1145	23	and	and	CC
cord-005478-5iu38pr6	1145	24	28	28	CD
cord-005478-5iu38pr6	1145	25	%	%	NN
cord-005478-5iu38pr6	1145	26	(	(	-LRB-
cord-005478-5iu38pr6	1145	27	P=0.31	P=0.31	NNS
cord-005478-5iu38pr6	1145	28	and	and	CC
cord-005478-5iu38pr6	1145	29	0.52	0.52	CD
cord-005478-5iu38pr6	1145	30	)	)	-RRB-
cord-005478-5iu38pr6	1145	31	.	.	.
cord-005478-5iu38pr6	1146	1	With	with	IN
cord-005478-5iu38pr6	1146	2	respect	respect	NN
cord-005478-5iu38pr6	1146	3	to	to	IN
cord-005478-5iu38pr6	1146	4	the	the	DT
cord-005478-5iu38pr6	1146	5	three	three	CD
cord-005478-5iu38pr6	1146	6	-	-	HYPH
cord-005478-5iu38pr6	1146	7	tiered	tiered	JJ
cord-005478-5iu38pr6	1146	8	classification	classification	NN
cord-005478-5iu38pr6	1146	9	of	of	IN
cord-005478-5iu38pr6	1146	10	MIPSS70-plus	MIPSS70-plus	NNP
cord-005478-5iu38pr6	1146	11	version	version	NN
cord-005478-5iu38pr6	1146	12	2.0	2.0	CD
cord-005478-5iu38pr6	1146	13	,	,	,
cord-005478-5iu38pr6	1146	14	5-year	5-year	CD
cord-005478-5iu38pr6	1146	15	OS	os	NN
cord-005478-5iu38pr6	1146	16	of	of	IN
cord-005478-5iu38pr6	1146	17	VHR	VHR	NNP
cord-005478-5iu38pr6	1146	18	was	be	VBD
cord-005478-5iu38pr6	1146	19	74	74	CD
cord-005478-5iu38pr6	1146	20	%	%	NN
cord-005478-5iu38pr6	1146	21	(	(	-LRB-
cord-005478-5iu38pr6	1146	22	62	62	CD
cord-005478-5iu38pr6	1146	23	-	-	SYM
cord-005478-5iu38pr6	1146	24	86	86	CD
cord-005478-5iu38pr6	1146	25	%	%	NN
cord-005478-5iu38pr6	1146	26	)	)	-RRB-
cord-005478-5iu38pr6	1146	27	and	and	CC
cord-005478-5iu38pr6	1146	28	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1146	29	was	be	VBD
cord-005478-5iu38pr6	1146	30	52	52	CD
cord-005478-5iu38pr6	1146	31	%	%	NN
cord-005478-5iu38pr6	1146	32	(	(	-LRB-
cord-005478-5iu38pr6	1146	33	42	42	CD
cord-005478-5iu38pr6	1146	34	-	-	SYM
cord-005478-5iu38pr6	1146	35	62	62	CD
cord-005478-5iu38pr6	1146	36	%	%	NN
cord-005478-5iu38pr6	1146	37	)	)	-RRB-
cord-005478-5iu38pr6	1146	38	vs	vs	IN
cord-005478-5iu38pr6	1146	39	favorable	favorable	JJ
cord-005478-5iu38pr6	1146	40	risk	risk	NN
cord-005478-5iu38pr6	1146	41	of	of	IN
cord-005478-5iu38pr6	1146	42	64	64	CD
cord-005478-5iu38pr6	1146	43	%	%	NN
cord-005478-5iu38pr6	1146	44	(	(	-LRB-
cord-005478-5iu38pr6	1146	45	58	58	CD
cord-005478-5iu38pr6	1146	46	-	-	SYM
cord-005478-5iu38pr6	1146	47	70	70	CD
cord-005478-5iu38pr6	1146	48	%	%	NN
cord-005478-5iu38pr6	1146	49	)	)	-RRB-
cord-005478-5iu38pr6	1146	50	,	,	,
cord-005478-5iu38pr6	1146	51	with	with	IN
cord-005478-5iu38pr6	1146	52	cause	cause	NN
cord-005478-5iu38pr6	1146	53	-	-	HYPH
cord-005478-5iu38pr6	1146	54	specific	specific	JJ
cord-005478-5iu38pr6	1146	55	hazard	hazard	NN
cord-005478-5iu38pr6	1146	56	of	of	IN
cord-005478-5iu38pr6	1146	57	1.09	1.09	CD
cord-005478-5iu38pr6	1146	58	(	(	-LRB-
cord-005478-5iu38pr6	1146	59	P=0.74	P=0.74	NNS
cord-005478-5iu38pr6	1146	60	)	)	-RRB-
cord-005478-5iu38pr6	1146	61	.	.	.
cord-005478-5iu38pr6	1147	1	Relapse	relapse	VB
cord-005478-5iu38pr6	1147	2	and	and	CC
cord-005478-5iu38pr6	1147	3	non	non	JJ
cord-005478-5iu38pr6	1147	4	-	-	JJ
cord-005478-5iu38pr6	1147	5	relapse	relapse	JJ
cord-005478-5iu38pr6	1147	6	mortality	mortality	NN
cord-005478-5iu38pr6	1147	7	were	be	VBD
cord-005478-5iu38pr6	1147	8	9	9	CD
cord-005478-5iu38pr6	1147	9	%	%	NN
cord-005478-5iu38pr6	1147	10	and	and	CC
cord-005478-5iu38pr6	1147	11	17	17	CD
cord-005478-5iu38pr6	1147	12	%	%	NN
cord-005478-5iu38pr6	1147	13	for	for	IN
cord-005478-5iu38pr6	1147	14	VHR	VHR	NNP
cord-005478-5iu38pr6	1147	15	,	,	,
cord-005478-5iu38pr6	1147	16	4	4	CD
cord-005478-5iu38pr6	1147	17	%	%	NN
cord-005478-5iu38pr6	1147	18	and	and	CC
cord-005478-5iu38pr6	1147	19	48	48	CD
cord-005478-5iu38pr6	1147	20	%	%	NN
cord-005478-5iu38pr6	1147	21	for	for	IN
cord-005478-5iu38pr6	1147	22	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	1147	23	,	,	,
cord-005478-5iu38pr6	1147	24	and	and	CC
cord-005478-5iu38pr6	1147	25	19	19	CD
cord-005478-5iu38pr6	1147	26	%	%	NN
cord-005478-5iu38pr6	1147	27	and	and	CC
cord-005478-5iu38pr6	1147	28	26	26	CD
cord-005478-5iu38pr6	1147	29	%	%	NN
cord-005478-5iu38pr6	1147	30	for	for	IN
cord-005478-5iu38pr6	1147	31	favorable	favorable	JJ
cord-005478-5iu38pr6	1147	32	risk	risk	NN
cord-005478-5iu38pr6	1147	33	(	(	-LRB-
cord-005478-5iu38pr6	1147	34	P=0.19	P=0.19	NNP
cord-005478-5iu38pr6	1147	35	and	and	CC
cord-005478-5iu38pr6	1147	36	0.48	0.48	CD
cord-005478-5iu38pr6	1147	37	)	)	-RRB-
cord-005478-5iu38pr6	1147	38	.	.	.
cord-005478-5iu38pr6	1148	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1148	2	:	:	:
cord-005478-5iu38pr6	1149	1	Current	current	JJ
cord-005478-5iu38pr6	1149	2	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	1149	3	risk	risk	NN
cord-005478-5iu38pr6	1149	4	stratifications	stratification	NNS
cord-005478-5iu38pr6	1149	5	do	do	VBP
cord-005478-5iu38pr6	1149	6	not	not	RB
cord-005478-5iu38pr6	1149	7	predict	predict	VB
cord-005478-5iu38pr6	1149	8	outcome	outcome	NN
cord-005478-5iu38pr6	1149	9	in	in	IN
cord-005478-5iu38pr6	1149	10	PMF	PMF	NNP
cord-005478-5iu38pr6	1149	11	after	after	IN
cord-005478-5iu38pr6	1149	12	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1149	13	stem	stem	NN
cord-005478-5iu38pr6	1149	14	cell	cell	NN
cord-005478-5iu38pr6	1149	15	transplantation	transplantation	NN
cord-005478-5iu38pr6	1149	16	.	.	.
cord-005478-5iu38pr6	1150	1	[	[	-LRB-
cord-005478-5iu38pr6	1150	2	[	[	-LRB-
cord-005478-5iu38pr6	1150	3	O060	O060	NNP
cord-005478-5iu38pr6	1150	4	Image	image	NN
cord-005478-5iu38pr6	1150	5	]	]	-RRB-
cord-005478-5iu38pr6	1150	6	1	1	CD
cord-005478-5iu38pr6	1150	7	.	.	.
cord-005478-5iu38pr6	1151	1	Background	background	NN
cord-005478-5iu38pr6	1151	2	:	:	:
cord-005478-5iu38pr6	1152	1	The	the	DT
cord-005478-5iu38pr6	1152	2	aim	aim	NN
cord-005478-5iu38pr6	1152	3	of	of	IN
cord-005478-5iu38pr6	1152	4	this	this	DT
cord-005478-5iu38pr6	1152	5	study	study	NN
cord-005478-5iu38pr6	1152	6	was	be	VBD
cord-005478-5iu38pr6	1152	7	to	to	TO
cord-005478-5iu38pr6	1152	8	assess	assess	VB
cord-005478-5iu38pr6	1152	9	the	the	DT
cord-005478-5iu38pr6	1152	10	outcome	outcome	NN
cord-005478-5iu38pr6	1152	11	of	of	IN
cord-005478-5iu38pr6	1152	12	patients	patient	NNS
cord-005478-5iu38pr6	1152	13	with	with	IN
cord-005478-5iu38pr6	1152	14	Myelofibrosis	Myelofibrosis	NNP
cord-005478-5iu38pr6	1152	15	allografted	allografte	VBN
cord-005478-5iu38pr6	1152	16	before	before	IN
cord-005478-5iu38pr6	1152	17	and	and	CC
cord-005478-5iu38pr6	1152	18	after	after	IN
cord-005478-5iu38pr6	1152	19	2010	2010	CD
cord-005478-5iu38pr6	1152	20	,	,	,
cord-005478-5iu38pr6	1152	21	in	in	IN
cord-005478-5iu38pr6	1152	22	two	two	CD
cord-005478-5iu38pr6	1152	23	transplant	transplant	NN
cord-005478-5iu38pr6	1152	24	Centers	Centers	NNPS
cord-005478-5iu38pr6	1152	25	(	(	-LRB-
cord-005478-5iu38pr6	1152	26	Genova	Genova	NNP
cord-005478-5iu38pr6	1152	27	San	San	NNP
cord-005478-5iu38pr6	1152	28	Martino	Martino	NNP
cord-005478-5iu38pr6	1152	29	and	and	CC
cord-005478-5iu38pr6	1152	30	Rome	Rome	NNP
cord-005478-5iu38pr6	1152	31	Gemelli	Gemelli	NNP
cord-005478-5iu38pr6	1152	32	)	)	-RRB-
cord-005478-5iu38pr6	1152	33	.	.	.
cord-005478-5iu38pr6	1153	1	Methods	method	NNS
cord-005478-5iu38pr6	1153	2	:	:	:
cord-005478-5iu38pr6	1154	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1154	2	have	have	VBP
cord-005478-5iu38pr6	1154	3	studied	study	VBN
cord-005478-5iu38pr6	1154	4	147	147	CD
cord-005478-5iu38pr6	1154	5	patients	patient	NNS
cord-005478-5iu38pr6	1154	6	,	,	,
cord-005478-5iu38pr6	1154	7	divided	divide	VBN
cord-005478-5iu38pr6	1154	8	in	in	IN
cord-005478-5iu38pr6	1154	9	two	two	CD
cord-005478-5iu38pr6	1154	10	groups	group	NNS
cord-005478-5iu38pr6	1154	11	:	:	:
cord-005478-5iu38pr6	1154	12	2001	2001	CD
cord-005478-5iu38pr6	1154	13	-	-	SYM
cord-005478-5iu38pr6	1154	14	2010	2010	CD
cord-005478-5iu38pr6	1154	15	(	(	-LRB-
cord-005478-5iu38pr6	1154	16	n=59	n=59	NNP
cord-005478-5iu38pr6	1154	17	)	)	-RRB-
cord-005478-5iu38pr6	1154	18	and	and	CC
cord-005478-5iu38pr6	1154	19	between	between	IN
cord-005478-5iu38pr6	1154	20	2011	2011	CD
cord-005478-5iu38pr6	1154	21	and	and	CC
cord-005478-5iu38pr6	1154	22	2018	2018	CD
cord-005478-5iu38pr6	1154	23	(	(	-LRB-
cord-005478-5iu38pr6	1154	24	n=88	n=88	NN
cord-005478-5iu38pr6	1154	25	)	)	-RRB-
cord-005478-5iu38pr6	1154	26	.	.	.
cord-005478-5iu38pr6	1155	1	The	the	DT
cord-005478-5iu38pr6	1155	2	age	age	NN
cord-005478-5iu38pr6	1155	3	was	be	VBD
cord-005478-5iu38pr6	1155	4	significantly	significantly	RB
cord-005478-5iu38pr6	1155	5	older	old	JJR
cord-005478-5iu38pr6	1155	6	in	in	IN
cord-005478-5iu38pr6	1155	7	the	the	DT
cord-005478-5iu38pr6	1155	8	most	most	RBS
cord-005478-5iu38pr6	1155	9	recent	recent	JJ
cord-005478-5iu38pr6	1155	10	group	group	NN
cord-005478-5iu38pr6	1155	11	(	(	-LRB-
cord-005478-5iu38pr6	1155	12	53	53	CD
cord-005478-5iu38pr6	1155	13	vs	vs	IN
cord-005478-5iu38pr6	1155	14	58	58	CD
cord-005478-5iu38pr6	1155	15	years	year	NNS
cord-005478-5iu38pr6	1155	16	,	,	,
cord-005478-5iu38pr6	1155	17	p	p	NN
cord-005478-5iu38pr6	1155	18	<	<	XX
cord-005478-5iu38pr6	1155	19	001	001	CD
cord-005478-5iu38pr6	1155	20	)	)	-RRB-
cord-005478-5iu38pr6	1155	21	,	,	,
cord-005478-5iu38pr6	1155	22	and	and	CC
cord-005478-5iu38pr6	1155	23	there	there	EX
cord-005478-5iu38pr6	1155	24	was	be	VBD
cord-005478-5iu38pr6	1155	25	a	a	DT
cord-005478-5iu38pr6	1155	26	greater	great	JJR
cord-005478-5iu38pr6	1155	27	use	use	NN
cord-005478-5iu38pr6	1155	28	of	of	IN
cord-005478-5iu38pr6	1155	29	alternative	alternative	JJ
cord-005478-5iu38pr6	1155	30	donors	donor	NNS
cord-005478-5iu38pr6	1155	31	(	(	-LRB-
cord-005478-5iu38pr6	1155	32	38	38	CD
cord-005478-5iu38pr6	1155	33	%	%	NN
cord-005478-5iu38pr6	1155	34	vs	vs	IN
cord-005478-5iu38pr6	1155	35	80	80	CD
cord-005478-5iu38pr6	1155	36	%	%	NN
cord-005478-5iu38pr6	1155	37	,	,	,
cord-005478-5iu38pr6	1155	38	p	p	NN
cord-005478-5iu38pr6	1155	39	<	<	XX
cord-005478-5iu38pr6	1155	40	0.0001	0.0001	CD
cord-005478-5iu38pr6	1155	41	)	)	-RRB-
cord-005478-5iu38pr6	1155	42	,	,	,
cord-005478-5iu38pr6	1155	43	and	and	CC
cord-005478-5iu38pr6	1155	44	more	more	JJR
cord-005478-5iu38pr6	1155	45	patients	patient	NNS
cord-005478-5iu38pr6	1155	46	with	with	IN
cord-005478-5iu38pr6	1155	47	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1155	48	-	-	HYPH
cord-005478-5iu38pr6	1155	49	R	R	NNP
cord-005478-5iu38pr6	1155	50	high	high	JJ
cord-005478-5iu38pr6	1155	51	score	score	NN
cord-005478-5iu38pr6	1155	52	(	(	-LRB-
cord-005478-5iu38pr6	1155	53	40	40	CD
cord-005478-5iu38pr6	1155	54	%	%	NN
cord-005478-5iu38pr6	1155	55	vs	vs	IN
cord-005478-5iu38pr6	1155	56	47	47	CD
cord-005478-5iu38pr6	1155	57	%	%	NN
cord-005478-5iu38pr6	1155	58	,	,	,
cord-005478-5iu38pr6	1155	59	p=0.1	p=0.1	NNP
cord-005478-5iu38pr6	1155	60	)	)	-RRB-
cord-005478-5iu38pr6	1155	61	.	.	.
cord-005478-5iu38pr6	1156	1	The	the	DT
cord-005478-5iu38pr6	1156	2	transplant	transplant	NN
cord-005478-5iu38pr6	1156	3	score	score	NN
cord-005478-5iu38pr6	1156	4	(	(	-LRB-
cord-005478-5iu38pr6	1156	5	based	base	VBN
cord-005478-5iu38pr6	1156	6	on	on	IN
cord-005478-5iu38pr6	1156	7	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1156	8	>	>	XX
cord-005478-5iu38pr6	1156	9	20	20	CD
cord-005478-5iu38pr6	1156	10	and	and	CC
cord-005478-5iu38pr6	1156	11	splee	splee	NN
cord-005478-5iu38pr6	1156	12	size	size	NN
cord-005478-5iu38pr6	1156	13	>	>	XX
cord-005478-5iu38pr6	1156	14	22	22	CD
cord-005478-5iu38pr6	1156	15	cm	cm	NNS
cord-005478-5iu38pr6	1156	16	)	)	-RRB-
cord-005478-5iu38pr6	1156	17	was	be	VBD
cord-005478-5iu38pr6	1156	18	intermediate	intermediate	JJ
cord-005478-5iu38pr6	1156	19	-	-	HYPH
cord-005478-5iu38pr6	1156	20	high	high	JJ
cord-005478-5iu38pr6	1156	21	risk	risk	NN
cord-005478-5iu38pr6	1156	22	in	in	IN
cord-005478-5iu38pr6	1156	23	82	82	CD
cord-005478-5iu38pr6	1156	24	%	%	NN
cord-005478-5iu38pr6	1156	25	and	and	CC
cord-005478-5iu38pr6	1156	26	58	58	CD
cord-005478-5iu38pr6	1156	27	%	%	NN
cord-005478-5iu38pr6	1156	28	(	(	-LRB-
cord-005478-5iu38pr6	1156	29	p	p	NN
cord-005478-5iu38pr6	1156	30	<	<	XX
cord-005478-5iu38pr6	1156	31	0.01	0.01	CD
cord-005478-5iu38pr6	1156	32	)	)	-RRB-
cord-005478-5iu38pr6	1156	33	of	of	IN
cord-005478-5iu38pr6	1156	34	patients	patient	NNS
cord-005478-5iu38pr6	1156	35	respectively	respectively	RB
cord-005478-5iu38pr6	1156	36	.	.	.
cord-005478-5iu38pr6	1157	1	The	the	DT
cord-005478-5iu38pr6	1157	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	1157	3	regimen	regimen	NN
cord-005478-5iu38pr6	1157	4	was	be	VBD
cord-005478-5iu38pr6	1157	5	a	a	DT
cord-005478-5iu38pr6	1157	6	combination	combination	NN
cord-005478-5iu38pr6	1157	7	of	of	IN
cord-005478-5iu38pr6	1157	8	thiotepa	thiotepa	NNP
cord-005478-5iu38pr6	1157	9	,	,	,
cord-005478-5iu38pr6	1157	10	busulfan	busulfan	NNP
cord-005478-5iu38pr6	1157	11	fludarabine	fludarabine	NNP
cord-005478-5iu38pr6	1157	12	(	(	-LRB-
cord-005478-5iu38pr6	1157	13	TBF	TBF	NNP
cord-005478-5iu38pr6	1157	14	)	)	-RRB-
cord-005478-5iu38pr6	1157	15	in	in	IN
cord-005478-5iu38pr6	1157	16	1	1	CD
cord-005478-5iu38pr6	1157	17	%	%	NN
cord-005478-5iu38pr6	1157	18	and	and	CC
cord-005478-5iu38pr6	1157	19	87	87	CD
cord-005478-5iu38pr6	1157	20	%	%	NN
cord-005478-5iu38pr6	1157	21	of	of	IN
cord-005478-5iu38pr6	1157	22	patients	patient	NNS
cord-005478-5iu38pr6	1157	23	grafted	graft	VBN
cord-005478-5iu38pr6	1157	24	before	before	IN
cord-005478-5iu38pr6	1157	25	and	and	CC
cord-005478-5iu38pr6	1157	26	after	after	IN
cord-005478-5iu38pr6	1157	27	2010	2010	CD
cord-005478-5iu38pr6	1157	28	(	(	-LRB-
cord-005478-5iu38pr6	1157	29	p	p	NN
cord-005478-5iu38pr6	1157	30	<	<	XX
cord-005478-5iu38pr6	1157	31	0.00001	0.00001	CD
cord-005478-5iu38pr6	1157	32	)	)	-RRB-
cord-005478-5iu38pr6	1157	33	.	.	.
cord-005478-5iu38pr6	1158	1	The	the	DT
cord-005478-5iu38pr6	1158	2	transplant	transplant	NN
cord-005478-5iu38pr6	1158	3	risk	risk	NN
cord-005478-5iu38pr6	1158	4	score	score	NN
cord-005478-5iu38pr6	1158	5	(	(	-LRB-
cord-005478-5iu38pr6	1158	6	TS	TS	NNP
cord-005478-5iu38pr6	1158	7	)	)	-RRB-
cord-005478-5iu38pr6	1158	8	was	be	VBD
cord-005478-5iu38pr6	1158	9	based	base	VBN
cord-005478-5iu38pr6	1158	10	on	on	IN
cord-005478-5iu38pr6	1158	11	spleen	spleen	NN
cord-005478-5iu38pr6	1158	12	size	size	NN
cord-005478-5iu38pr6	1158	13	(	(	-LRB-
cord-005478-5iu38pr6	1158	14	>	>	SYM
cord-005478-5iu38pr6	1158	15	22	22	CD
cord-005478-5iu38pr6	1158	16	cm	cm	NNS
cord-005478-5iu38pr6	1158	17	)	)	-RRB-
cord-005478-5iu38pr6	1158	18	and	and	CC
cord-005478-5iu38pr6	1158	19	pre	pre	JJ
cord-005478-5iu38pr6	1158	20	-	-	JJ
cord-005478-5iu38pr6	1158	21	graft	graft	NN
cord-005478-5iu38pr6	1158	22	transfusion	transfusion	NN
cord-005478-5iu38pr6	1158	23	(	(	-LRB-
cord-005478-5iu38pr6	1158	24	>	>	NFP
cord-005478-5iu38pr6	1158	25	20	20	CD
cord-005478-5iu38pr6	1158	26	)	)	-RRB-
cord-005478-5iu38pr6	1158	27	as	as	RB
cord-005478-5iu38pr6	1158	28	previously	previously	RB
cord-005478-5iu38pr6	1158	29	described	describe	VBN
cord-005478-5iu38pr6	1158	30	(	(	-LRB-
cord-005478-5iu38pr6	1158	31	Bone	Bone	NNP
cord-005478-5iu38pr6	1158	32	Marrow	Marrow	NNP
cord-005478-5iu38pr6	1158	33	Transplant	Transplant	NNP
cord-005478-5iu38pr6	1158	34	.	.	.
cord-005478-5iu38pr6	1159	1	2010	2010	CD
cord-005478-5iu38pr6	1159	2	Mar	Mar	NNP
cord-005478-5iu38pr6	1159	3	;	;	:
cord-005478-5iu38pr6	1159	4	45(3	45(3	CD
cord-005478-5iu38pr6	1159	5	)	)	-RRB-
cord-005478-5iu38pr6	1159	6	:	:	:
cord-005478-5iu38pr6	1159	7	458	458	CD
cord-005478-5iu38pr6	1159	8	-	-	SYM
cord-005478-5iu38pr6	1159	9	63	63	CD
cord-005478-5iu38pr6	1159	10	)	)	-RRB-
cord-005478-5iu38pr6	1159	11	Results	result	NNS
cord-005478-5iu38pr6	1159	12	:	:	:
cord-005478-5iu38pr6	1160	1	Outcome	outcome	NN
cord-005478-5iu38pr6	1160	2	.	.	.
cord-005478-5iu38pr6	1161	1	The	the	DT
cord-005478-5iu38pr6	1161	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1161	3	incidence	incidence	NN
cord-005478-5iu38pr6	1161	4	(	(	-LRB-
cord-005478-5iu38pr6	1161	5	CI	CI	NNP
cord-005478-5iu38pr6	1161	6	)	)	-RRB-
cord-005478-5iu38pr6	1161	7	of	of	IN
cord-005478-5iu38pr6	1161	8	acute	acute	JJ
cord-005478-5iu38pr6	1161	9	grade	grade	NN
cord-005478-5iu38pr6	1161	10	II	II	NNP
cord-005478-5iu38pr6	1161	11	-	-	HYPH
cord-005478-5iu38pr6	1161	12	IV	IV	NNP
cord-005478-5iu38pr6	1161	13	(	(	-LRB-
cord-005478-5iu38pr6	1161	14	25	25	CD
cord-005478-5iu38pr6	1161	15	%	%	NN
cord-005478-5iu38pr6	1161	16	)	)	-RRB-
cord-005478-5iu38pr6	1161	17	and	and	CC
cord-005478-5iu38pr6	1161	18	of	of	IN
cord-005478-5iu38pr6	1161	19	chronic	chronic	JJ
cord-005478-5iu38pr6	1161	20	GvHD	GvHD	NNP
cord-005478-5iu38pr6	1161	21	(	(	-LRB-
cord-005478-5iu38pr6	1161	22	18	18	CD
cord-005478-5iu38pr6	1161	23	%	%	NN
cord-005478-5iu38pr6	1161	24	)	)	-RRB-
cord-005478-5iu38pr6	1161	25	was	be	VBD
cord-005478-5iu38pr6	1161	26	comparable	comparable	JJ
cord-005478-5iu38pr6	1161	27	in	in	IN
cord-005478-5iu38pr6	1161	28	the	the	DT
cord-005478-5iu38pr6	1161	29	two	two	CD
cord-005478-5iu38pr6	1161	30	time	time	NN
cord-005478-5iu38pr6	1161	31	periods	period	NNS
cord-005478-5iu38pr6	1161	32	.	.	.
cord-005478-5iu38pr6	1162	1	The	the	DT
cord-005478-5iu38pr6	1162	2	5	5	CD
cord-005478-5iu38pr6	1162	3	year	year	NN
cord-005478-5iu38pr6	1162	4	CI	CI	NNP
cord-005478-5iu38pr6	1162	5	of	of	IN
cord-005478-5iu38pr6	1162	6	non	non	JJ
cord-005478-5iu38pr6	1162	7	relapse	relapse	NN
cord-005478-5iu38pr6	1162	8	mortality	mortality	NN
cord-005478-5iu38pr6	1162	9	(	(	-LRB-
cord-005478-5iu38pr6	1162	10	NRM	NRM	NNP
cord-005478-5iu38pr6	1162	11	)	)	-RRB-
cord-005478-5iu38pr6	1162	12	was	be	VBD
cord-005478-5iu38pr6	1162	13	reduced	reduce	VBN
cord-005478-5iu38pr6	1162	14	overall	overall	RB
cord-005478-5iu38pr6	1162	15	from	from	IN
cord-005478-5iu38pr6	1162	16	37	37	CD
cord-005478-5iu38pr6	1162	17	%	%	NN
cord-005478-5iu38pr6	1162	18	to	to	TO
cord-005478-5iu38pr6	1162	19	20	20	CD
cord-005478-5iu38pr6	1162	20	%	%	NN
cord-005478-5iu38pr6	1162	21	(	(	-LRB-
cord-005478-5iu38pr6	1162	22	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	1162	23	)	)	-RRB-
cord-005478-5iu38pr6	1162	24	and	and	CC
cord-005478-5iu38pr6	1162	25	the	the	DT
cord-005478-5iu38pr6	1162	26	5	5	CD
cord-005478-5iu38pr6	1162	27	year	year	NN
cord-005478-5iu38pr6	1162	28	CI	CI	NNP
cord-005478-5iu38pr6	1162	29	of	of	IN
cord-005478-5iu38pr6	1162	30	relapse	relapse	NN
cord-005478-5iu38pr6	1162	31	from	from	IN
cord-005478-5iu38pr6	1162	32	47	47	CD
cord-005478-5iu38pr6	1162	33	%	%	NN
cord-005478-5iu38pr6	1162	34	to	to	TO
cord-005478-5iu38pr6	1162	35	11	11	CD
cord-005478-5iu38pr6	1162	36	%	%	NN
cord-005478-5iu38pr6	1162	37	(	(	-LRB-
cord-005478-5iu38pr6	1162	38	p=0.00006	p=0.00006	NNP
cord-005478-5iu38pr6	1162	39	)	)	-RRB-
cord-005478-5iu38pr6	1162	40	.	.	.
cord-005478-5iu38pr6	1163	1	As	as	IN
cord-005478-5iu38pr6	1163	2	a	a	DT
cord-005478-5iu38pr6	1163	3	consequence	consequence	NN
cord-005478-5iu38pr6	1163	4	the	the	DT
cord-005478-5iu38pr6	1163	5	overall	overall	JJ
cord-005478-5iu38pr6	1163	6	5	5	CD
cord-005478-5iu38pr6	1163	7	year	year	NN
cord-005478-5iu38pr6	1163	8	actuarial	actuarial	JJ
cord-005478-5iu38pr6	1163	9	survival	survival	NN
cord-005478-5iu38pr6	1163	10	has	have	VBZ
cord-005478-5iu38pr6	1163	11	improved	improve	VBN
cord-005478-5iu38pr6	1163	12	from	from	IN
cord-005478-5iu38pr6	1163	13	35	35	CD
cord-005478-5iu38pr6	1163	14	%	%	NN
cord-005478-5iu38pr6	1163	15	to	to	IN
cord-005478-5iu38pr6	1163	16	64	64	CD
cord-005478-5iu38pr6	1163	17	%	%	NN
cord-005478-5iu38pr6	1163	18	(	(	-LRB-
cord-005478-5iu38pr6	1163	19	p=0.003	p=0.003	NNP
cord-005478-5iu38pr6	1163	20	)	)	-RRB-
cord-005478-5iu38pr6	1163	21	.	.	.
cord-005478-5iu38pr6	1164	1	Predictive	predictive	JJ
cord-005478-5iu38pr6	1164	2	factors	factor	NNS
cord-005478-5iu38pr6	1164	3	.	.	.
cord-005478-5iu38pr6	1165	1	The	the	DT
cord-005478-5iu38pr6	1165	2	following	following	JJ
cord-005478-5iu38pr6	1165	3	factors	factor	NNS
cord-005478-5iu38pr6	1165	4	predicted	predict	VBD
cord-005478-5iu38pr6	1165	5	survival	survival	NN
cord-005478-5iu38pr6	1165	6	in	in	IN
cord-005478-5iu38pr6	1165	7	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1165	8	Cox	Cox	NNP
cord-005478-5iu38pr6	1165	9	analysis	analysis	NN
cord-005478-5iu38pr6	1165	10	:	:	:
cord-005478-5iu38pr6	1165	11	high	high	JJ
cord-005478-5iu38pr6	1165	12	risk	risk	NN
cord-005478-5iu38pr6	1165	13	transplant	transplant	NN
cord-005478-5iu38pr6	1165	14	score	score	NN
cord-005478-5iu38pr6	1165	15	(	(	-LRB-
cord-005478-5iu38pr6	1165	16	HR	HR	NNP
cord-005478-5iu38pr6	1165	17	2.5	2.5	CD
cord-005478-5iu38pr6	1165	18	,	,	,
cord-005478-5iu38pr6	1165	19	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	1165	20	)	)	-RRB-
cord-005478-5iu38pr6	1165	21	,	,	,
cord-005478-5iu38pr6	1165	22	high	high	JJ
cord-005478-5iu38pr6	1165	23	risk	risk	NN
cord-005478-5iu38pr6	1165	24	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1165	25	-	-	HYPH
cord-005478-5iu38pr6	1165	26	R	R	NNP
cord-005478-5iu38pr6	1165	27	(	(	-LRB-
cord-005478-5iu38pr6	1165	28	HR	HR	NNP
cord-005478-5iu38pr6	1165	29	2.0	2.0	CD
cord-005478-5iu38pr6	1165	30	,	,	,
cord-005478-5iu38pr6	1165	31	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	1165	32	)	)	-RRB-
cord-005478-5iu38pr6	1165	33	,	,	,
cord-005478-5iu38pr6	1165	34	the	the	DT
cord-005478-5iu38pr6	1165	35	use	use	NN
cord-005478-5iu38pr6	1165	36	of	of	IN
cord-005478-5iu38pr6	1165	37	TBF	tbf	NN
cord-005478-5iu38pr6	1165	38	(	(	-LRB-
cord-005478-5iu38pr6	1165	39	HR	hr	NN
cord-005478-5iu38pr6	1165	40	0,50	0,50	XX
cord-005478-5iu38pr6	1165	41	,	,	,
cord-005478-5iu38pr6	1165	42	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	1165	43	)	)	-RRB-
cord-005478-5iu38pr6	1165	44	,	,	,
cord-005478-5iu38pr6	1165	45	ALT	alt	NN
cord-005478-5iu38pr6	1165	46	donor	donor	NN
cord-005478-5iu38pr6	1165	47	(	(	-LRB-
cord-005478-5iu38pr6	1165	48	HT	HT	NNP
cord-005478-5iu38pr6	1165	49	1.8	1.8	CD
cord-005478-5iu38pr6	1165	50	m	m	CD
cord-005478-5iu38pr6	1165	51	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	1165	52	)	)	-RRB-
cord-005478-5iu38pr6	1165	53	,	,	,
cord-005478-5iu38pr6	1165	54	donor	donor	NN
cord-005478-5iu38pr6	1165	55	age	age	NN
cord-005478-5iu38pr6	1165	56	>	>	XX
cord-005478-5iu38pr6	1165	57	29	29	CD
cord-005478-5iu38pr6	1165	58	years	year	NNS
cord-005478-5iu38pr6	1165	59	(	(	-LRB-
cord-005478-5iu38pr6	1165	60	HR	HR	NNP
cord-005478-5iu38pr6	1165	61	1.8	1.8	CD
cord-005478-5iu38pr6	1165	62	,	,	,
cord-005478-5iu38pr6	1165	63	p=0	p=0	NNP
cord-005478-5iu38pr6	1165	64	.06	.06	CD
cord-005478-5iu38pr6	1165	65	)	)	-RRB-
cord-005478-5iu38pr6	1165	66	and	and	CC
cord-005478-5iu38pr6	1165	67	ABO	ABO	NNP
cord-005478-5iu38pr6	1165	68	match	match	NN
cord-005478-5iu38pr6	1165	69	(	(	-LRB-
cord-005478-5iu38pr6	1165	70	HR	HR	NNP
cord-005478-5iu38pr6	1165	71	0.64	0.64	CD
cord-005478-5iu38pr6	1165	72	,	,	,
cord-005478-5iu38pr6	1165	73	p=0.08	p=0.08	NNP
cord-005478-5iu38pr6	1165	74	)	)	-RRB-
cord-005478-5iu38pr6	1165	75	.	.	.
cord-005478-5iu38pr6	1166	1	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1166	2	and	and	CC
cord-005478-5iu38pr6	1166	3	Transplant	Transplant	NNP
cord-005478-5iu38pr6	1166	4	score	score	NN
cord-005478-5iu38pr6	1166	5	.	.	.
cord-005478-5iu38pr6	1167	1	When	when	WRB
cord-005478-5iu38pr6	1167	2	combining	combine	VBG
cord-005478-5iu38pr6	1167	3	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1167	4	-	-	HYPH
cord-005478-5iu38pr6	1167	5	R	r	NN
cord-005478-5iu38pr6	1167	6	(	(	-LRB-
cord-005478-5iu38pr6	1167	7	high	high	JJ
cord-005478-5iu38pr6	1167	8	)	)	-RRB-
cord-005478-5iu38pr6	1167	9	and	and	CC
cord-005478-5iu38pr6	1167	10	Transplant	Transplant	NNP
cord-005478-5iu38pr6	1167	11	Score	Score	NNP
cord-005478-5iu38pr6	1167	12	(	(	-LRB-
cord-005478-5iu38pr6	1167	13	int2-high	int2-high	NN
cord-005478-5iu38pr6	1167	14	)	)	-RRB-
cord-005478-5iu38pr6	1168	1	we	-PRON-	PRP
cord-005478-5iu38pr6	1168	2	could	could	MD
cord-005478-5iu38pr6	1168	3	identify	identify	VB
cord-005478-5iu38pr6	1168	4	3	3	CD
cord-005478-5iu38pr6	1168	5	groups	group	NNS
cord-005478-5iu38pr6	1168	6	:	:	:
cord-005478-5iu38pr6	1169	1	score	score	NN
cord-005478-5iu38pr6	1169	2	0	0	CD
cord-005478-5iu38pr6	1170	1	(	(	-LRB-
cord-005478-5iu38pr6	1170	2	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1170	3	not	not	RB
cord-005478-5iu38pr6	1170	4	high	high	JJ
cord-005478-5iu38pr6	1170	5	and	and	CC
cord-005478-5iu38pr6	1170	6	TS	TS	NNP
cord-005478-5iu38pr6	1170	7	not	not	RB
cord-005478-5iu38pr6	1170	8	high	high	JJ
cord-005478-5iu38pr6	1170	9	)	)	-RRB-
cord-005478-5iu38pr6	1171	1	(	(	-LRB-
cord-005478-5iu38pr6	1171	2	n=40	n=40	NNP
cord-005478-5iu38pr6	1171	3	)	)	-RRB-
cord-005478-5iu38pr6	1171	4	score	score	NN
cord-005478-5iu38pr6	1171	5	1	1	CD
cord-005478-5iu38pr6	1171	6	(	(	-LRB-
cord-005478-5iu38pr6	1171	7	either	either	DT
cord-005478-5iu38pr6	1171	8	high	high	JJ
cord-005478-5iu38pr6	1171	9	DIPSS	dipss	NN
cord-005478-5iu38pr6	1171	10	or	or	CC
cord-005478-5iu38pr6	1171	11	high	high	JJ
cord-005478-5iu38pr6	1171	12	TS	ts	NN
cord-005478-5iu38pr6	1171	13	)	)	-RRB-
cord-005478-5iu38pr6	1172	1	(	(	-LRB-
cord-005478-5iu38pr6	1172	2	n=51	n=51	NNP
cord-005478-5iu38pr6	1172	3	)	)	-RRB-
cord-005478-5iu38pr6	1172	4	,	,	,
cord-005478-5iu38pr6	1172	5	score	score	NN
cord-005478-5iu38pr6	1172	6	2	2	CD
cord-005478-5iu38pr6	1172	7	(	(	-LRB-
cord-005478-5iu38pr6	1172	8	both	both	CC
cord-005478-5iu38pr6	1172	9	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1172	10	a	a	DT
cord-005478-5iu38pr6	1172	11	TS	TS	NNP
cord-005478-5iu38pr6	1172	12	high	high	JJ
cord-005478-5iu38pr6	1172	13	risk	risk	NN
cord-005478-5iu38pr6	1172	14	)	)	-RRB-
cord-005478-5iu38pr6	1173	1	(	(	-LRB-
cord-005478-5iu38pr6	1173	2	n=55	n=55	NNP
cord-005478-5iu38pr6	1173	3	)	)	-RRB-
cord-005478-5iu38pr6	1173	4	.	.	.
cord-005478-5iu38pr6	1174	1	NRM	NRM	NNP
cord-005478-5iu38pr6	1174	2	was	be	VBD
cord-005478-5iu38pr6	1174	3	9	9	CD
cord-005478-5iu38pr6	1174	4	%	%	NN
cord-005478-5iu38pr6	1174	5	,	,	,
cord-005478-5iu38pr6	1174	6	27	27	CD
cord-005478-5iu38pr6	1174	7	%	%	NN
cord-005478-5iu38pr6	1174	8	40	40	CD
cord-005478-5iu38pr6	1174	9	%	%	NN
cord-005478-5iu38pr6	1174	10	in	in	IN
cord-005478-5iu38pr6	1174	11	these	these	DT
cord-005478-5iu38pr6	1174	12	3	3	CD
cord-005478-5iu38pr6	1174	13	group	group	NN
cord-005478-5iu38pr6	1174	14	(	(	-LRB-
cord-005478-5iu38pr6	1174	15	p=0.0004	p=0.0004	NNP
cord-005478-5iu38pr6	1174	16	)	)	-RRB-
cord-005478-5iu38pr6	1174	17	,	,	,
cord-005478-5iu38pr6	1174	18	relapse	relapse	NN
cord-005478-5iu38pr6	1174	19	was	be	VBD
cord-005478-5iu38pr6	1174	20	17	17	CD
cord-005478-5iu38pr6	1174	21	%	%	NN
cord-005478-5iu38pr6	1174	22	,	,	,
cord-005478-5iu38pr6	1174	23	29	29	CD
cord-005478-5iu38pr6	1174	24	%	%	NN
cord-005478-5iu38pr6	1174	25	,	,	,
cord-005478-5iu38pr6	1174	26	25	25	CD
cord-005478-5iu38pr6	1174	27	%	%	NN
cord-005478-5iu38pr6	1174	28	(	(	-LRB-
cord-005478-5iu38pr6	1174	29	p=0.1	p=0.1	NNP
cord-005478-5iu38pr6	1174	30	)	)	-RRB-
cord-005478-5iu38pr6	1174	31	and	and	CC
cord-005478-5iu38pr6	1174	32	5	5	CD
cord-005478-5iu38pr6	1174	33	year	year	NN
cord-005478-5iu38pr6	1174	34	survival	survival	NN
cord-005478-5iu38pr6	1174	35	was	be	VBD
cord-005478-5iu38pr6	1174	36	78	78	CD
cord-005478-5iu38pr6	1174	37	%	%	NN
cord-005478-5iu38pr6	1174	38	,	,	,
cord-005478-5iu38pr6	1174	39	55	55	CD
cord-005478-5iu38pr6	1174	40	%	%	NN
cord-005478-5iu38pr6	1174	41	,	,	,
cord-005478-5iu38pr6	1174	42	20	20	CD
cord-005478-5iu38pr6	1174	43	%	%	NN
cord-005478-5iu38pr6	1174	44	(	(	-LRB-
cord-005478-5iu38pr6	1174	45	p	p	NN
cord-005478-5iu38pr6	1174	46	<	<	XX
cord-005478-5iu38pr6	1174	47	0.00001	0.00001	CD
cord-005478-5iu38pr6	1174	48	)	)	-RRB-
cord-005478-5iu38pr6	1174	49	.	.	.
cord-005478-5iu38pr6	1175	1	In	in	IN
cord-005478-5iu38pr6	1175	2	the	the	DT
cord-005478-5iu38pr6	1175	3	current	current	JJ
cord-005478-5iu38pr6	1175	4	transplant	transplant	NN
cord-005478-5iu38pr6	1175	5	era	era	NN
cord-005478-5iu38pr6	1175	6	(	(	-LRB-
cord-005478-5iu38pr6	1175	7	>	>	NFP
cord-005478-5iu38pr6	1175	8	2010	2010	CD
cord-005478-5iu38pr6	1175	9	)	)	-RRB-
cord-005478-5iu38pr6	1175	10	the	the	DT
cord-005478-5iu38pr6	1175	11	5	5	CD
cord-005478-5iu38pr6	1175	12	year	year	NN
cord-005478-5iu38pr6	1175	13	disease	disease	NN
cord-005478-5iu38pr6	1175	14	free	free	JJ
cord-005478-5iu38pr6	1175	15	survival	survival	NN
cord-005478-5iu38pr6	1175	16	of	of	IN
cord-005478-5iu38pr6	1175	17	these	these	DT
cord-005478-5iu38pr6	1175	18	3	3	CD
cord-005478-5iu38pr6	1175	19	groups	group	NNS
cord-005478-5iu38pr6	1175	20	is	be	VBZ
cord-005478-5iu38pr6	1175	21	78	78	CD
cord-005478-5iu38pr6	1175	22	%	%	NN
cord-005478-5iu38pr6	1175	23	,	,	,
cord-005478-5iu38pr6	1175	24	70	70	CD
cord-005478-5iu38pr6	1175	25	%	%	NN
cord-005478-5iu38pr6	1175	26	,	,	,
cord-005478-5iu38pr6	1175	27	35	35	CD
cord-005478-5iu38pr6	1175	28	%	%	NN
cord-005478-5iu38pr6	1175	29	(	(	-LRB-
cord-005478-5iu38pr6	1175	30	p	p	NN
cord-005478-5iu38pr6	1175	31	<	<	XX
cord-005478-5iu38pr6	1175	32	0.00001	0.00001	CD
cord-005478-5iu38pr6	1175	33	)	)	-RRB-
cord-005478-5iu38pr6	1175	34	.	.	.
cord-005478-5iu38pr6	1176	1	ABO	ABO	NNP
cord-005478-5iu38pr6	1176	2	matching	match	VBG
cord-005478-5iu38pr6	1176	3	further	further	JJ
cord-005478-5iu38pr6	1176	4	increases	increase	VBZ
cord-005478-5iu38pr6	1176	5	DFS	DFS	NNP
cord-005478-5iu38pr6	1176	6	for	for	IN
cord-005478-5iu38pr6	1176	7	score	score	NN
cord-005478-5iu38pr6	1176	8	0	0	CD
cord-005478-5iu38pr6	1176	9	patients	patient	NNS
cord-005478-5iu38pr6	1176	10	.	.	.
cord-005478-5iu38pr6	1177	1	NRM	NRM	NNP
cord-005478-5iu38pr6	1177	2	mortality	mortality	NN
cord-005478-5iu38pr6	1177	3	for	for	IN
cord-005478-5iu38pr6	1177	4	these	these	DT
cord-005478-5iu38pr6	1177	5	3	3	CD
cord-005478-5iu38pr6	1177	6	groups	group	NNS
cord-005478-5iu38pr6	1177	7	is	be	VBZ
cord-005478-5iu38pr6	1177	8	currently	currently	RB
cord-005478-5iu38pr6	1177	9	6	6	CD
cord-005478-5iu38pr6	1177	10	%	%	NN
cord-005478-5iu38pr6	1177	11	,	,	,
cord-005478-5iu38pr6	1177	12	16	16	CD
cord-005478-5iu38pr6	1177	13	%	%	NN
cord-005478-5iu38pr6	1177	14	,	,	,
cord-005478-5iu38pr6	1177	15	36	36	CD
cord-005478-5iu38pr6	1177	16	%	%	NN
cord-005478-5iu38pr6	1177	17	(	(	-LRB-
cord-005478-5iu38pr6	1177	18	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	1177	19	)	)	-RRB-
cord-005478-5iu38pr6	1177	20	.	.	.
cord-005478-5iu38pr6	1178	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1178	2	:	:	:
cord-005478-5iu38pr6	1179	1	The	the	DT
cord-005478-5iu38pr6	1179	2	5	5	CD
cord-005478-5iu38pr6	1179	3	year	year	NN
cord-005478-5iu38pr6	1179	4	survival	survival	NN
cord-005478-5iu38pr6	1179	5	of	of	IN
cord-005478-5iu38pr6	1179	6	allografts	allograft	NNS
cord-005478-5iu38pr6	1179	7	in	in	IN
cord-005478-5iu38pr6	1179	8	patients	patient	NNS
cord-005478-5iu38pr6	1179	9	with	with	IN
cord-005478-5iu38pr6	1179	10	Myelofibrosis	Myelofibrosis	NNP
cord-005478-5iu38pr6	1179	11	has	have	VBZ
cord-005478-5iu38pr6	1179	12	improved	improve	VBN
cord-005478-5iu38pr6	1179	13	overall	overall	RB
cord-005478-5iu38pr6	1179	14	from	from	IN
cord-005478-5iu38pr6	1179	15	35	35	CD
cord-005478-5iu38pr6	1179	16	%	%	NN
cord-005478-5iu38pr6	1179	17	before	before	IN
cord-005478-5iu38pr6	1179	18	2010	2010	CD
cord-005478-5iu38pr6	1179	19	,	,	,
cord-005478-5iu38pr6	1179	20	to	to	IN
cord-005478-5iu38pr6	1179	21	64	64	CD
cord-005478-5iu38pr6	1179	22	%	%	NN
cord-005478-5iu38pr6	1179	23	beyond	beyond	IN
cord-005478-5iu38pr6	1179	24	2010	2010	CD
cord-005478-5iu38pr6	1179	25	,	,	,
cord-005478-5iu38pr6	1179	26	despite	despite	IN
cord-005478-5iu38pr6	1179	27	the	the	DT
cord-005478-5iu38pr6	1179	28	current	current	JJ
cord-005478-5iu38pr6	1179	29	use	use	NN
cord-005478-5iu38pr6	1179	30	of	of	IN
cord-005478-5iu38pr6	1179	31	80	80	CD
cord-005478-5iu38pr6	1179	32	%	%	NN
cord-005478-5iu38pr6	1179	33	ALT	alt	NN
cord-005478-5iu38pr6	1179	34	donors	donor	NNS
cord-005478-5iu38pr6	1179	35	.	.	.
cord-005478-5iu38pr6	1180	1	Predictive	predictive	JJ
cord-005478-5iu38pr6	1180	2	factors	factor	NNS
cord-005478-5iu38pr6	1180	3	are	be	VBP
cord-005478-5iu38pr6	1180	4	the	the	DT
cord-005478-5iu38pr6	1180	5	Transplant	Transplant	NNP
cord-005478-5iu38pr6	1180	6	Score	score	NN
cord-005478-5iu38pr6	1180	7	(	(	-LRB-
cord-005478-5iu38pr6	1180	8	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1180	9	and	and	CC
cord-005478-5iu38pr6	1180	10	spleen	spleen	NN
cord-005478-5iu38pr6	1180	11	size	size	NN
cord-005478-5iu38pr6	1180	12	)	)	-RRB-
cord-005478-5iu38pr6	1180	13	,	,	,
cord-005478-5iu38pr6	1180	14	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1180	15	-	-	HYPH
cord-005478-5iu38pr6	1180	16	R	R	NNP
cord-005478-5iu38pr6	1180	17	and	and	CC
cord-005478-5iu38pr6	1180	18	the	the	DT
cord-005478-5iu38pr6	1180	19	use	use	NN
cord-005478-5iu38pr6	1180	20	of	of	IN
cord-005478-5iu38pr6	1180	21	2	2	CD
cord-005478-5iu38pr6	1180	22	alkylating	alkylating	JJ
cord-005478-5iu38pr6	1180	23	agents	agent	NNS
cord-005478-5iu38pr6	1180	24	(	(	-LRB-
cord-005478-5iu38pr6	1180	25	TBF	TBF	NNP
cord-005478-5iu38pr6	1180	26	)	)	-RRB-
cord-005478-5iu38pr6	1180	27	,	,	,
cord-005478-5iu38pr6	1180	28	the	the	DT
cord-005478-5iu38pr6	1180	29	latter	latter	JJ
cord-005478-5iu38pr6	1180	30	being	be	VBG
cord-005478-5iu38pr6	1180	31	the	the	DT
cord-005478-5iu38pr6	1180	32	major	major	JJ
cord-005478-5iu38pr6	1180	33	change	change	NN
cord-005478-5iu38pr6	1180	34	in	in	IN
cord-005478-5iu38pr6	1180	35	the	the	DT
cord-005478-5iu38pr6	1180	36	2	2	CD
cord-005478-5iu38pr6	1180	37	transplant	transplant	NN
cord-005478-5iu38pr6	1180	38	eras	era	NNS
cord-005478-5iu38pr6	1180	39	.	.	.
cord-005478-5iu38pr6	1181	1	patients	patient	NNS
cord-005478-5iu38pr6	1181	2	received	receive	VBD
cord-005478-5iu38pr6	1181	3	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1181	4	before	before	IN
cord-005478-5iu38pr6	1181	5	the	the	DT
cord-005478-5iu38pr6	1181	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	1181	7	,	,	,
cord-005478-5iu38pr6	1181	8	7	7	CD
cord-005478-5iu38pr6	1181	9	were	be	VBD
cord-005478-5iu38pr6	1181	10	transfusion	transfusion	NN
cord-005478-5iu38pr6	1181	11	-	-	HYPH
cord-005478-5iu38pr6	1181	12	dependent	dependent	JJ
cord-005478-5iu38pr6	1181	13	.	.	.
cord-005478-5iu38pr6	1182	1	All	all	PDT
cord-005478-5iu38pr6	1182	2	the	the	DT
cord-005478-5iu38pr6	1182	3	patients	patient	NNS
cord-005478-5iu38pr6	1182	4	underwent	undergo	VBD
cord-005478-5iu38pr6	1182	5	PBSC	PBSC	NNP
cord-005478-5iu38pr6	1182	6	infusion	infusion	NN
cord-005478-5iu38pr6	1182	7	,	,	,
cord-005478-5iu38pr6	1182	8	except	except	IN
cord-005478-5iu38pr6	1182	9	one	one	CD
cord-005478-5iu38pr6	1182	10	who	who	WP
cord-005478-5iu38pr6	1182	11	received	receive	VBD
cord-005478-5iu38pr6	1182	12	BMSC	BMSC	NNP
cord-005478-5iu38pr6	1182	13	.	.	.
cord-005478-5iu38pr6	1183	1	In	in	IN
cord-005478-5iu38pr6	1183	2	7	7	CD
cord-005478-5iu38pr6	1183	3	cases	case	NNS
cord-005478-5iu38pr6	1183	4	the	the	DT
cord-005478-5iu38pr6	1183	5	source	source	NN
cord-005478-5iu38pr6	1183	6	was	be	VBD
cord-005478-5iu38pr6	1183	7	a	a	DT
cord-005478-5iu38pr6	1183	8	sibling	sibling	NN
cord-005478-5iu38pr6	1183	9	donor	donor	NN
cord-005478-5iu38pr6	1183	10	,	,	,
cord-005478-5iu38pr6	1183	11	in	in	IN
cord-005478-5iu38pr6	1183	12	9	9	CD
cord-005478-5iu38pr6	1183	13	a	a	DT
cord-005478-5iu38pr6	1183	14	MUD	mud	NN
cord-005478-5iu38pr6	1183	15	,	,	,
cord-005478-5iu38pr6	1183	16	in	in	IN
cord-005478-5iu38pr6	1183	17	2	2	CD
cord-005478-5iu38pr6	1183	18	a	a	DT
cord-005478-5iu38pr6	1183	19	HLA	HLA	NNP
cord-005478-5iu38pr6	1183	20	-	-	HYPH
cord-005478-5iu38pr6	1183	21	mismatched	mismatched	JJ
cord-005478-5iu38pr6	1183	22	UD	UD	NNP
cord-005478-5iu38pr6	1183	23	(	(	-LRB-
cord-005478-5iu38pr6	1183	24	1	1	CD
cord-005478-5iu38pr6	1183	25	mismatch	mismatch	NN
cord-005478-5iu38pr6	1183	26	)	)	-RRB-
cord-005478-5iu38pr6	1183	27	.	.	.
cord-005478-5iu38pr6	1184	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	1184	2	regimen	regimen	NN
cord-005478-5iu38pr6	1184	3	was	be	VBD
cord-005478-5iu38pr6	1184	4	mostly	mostly	RB
cord-005478-5iu38pr6	1184	5	based	base	VBN
cord-005478-5iu38pr6	1184	6	on	on	IN
cord-005478-5iu38pr6	1184	7	the	the	DT
cord-005478-5iu38pr6	1184	8	combination	combination	NN
cord-005478-5iu38pr6	1184	9	of	of	IN
cord-005478-5iu38pr6	1184	10	singlealkylating	singlealkylate	VBG
cord-005478-5iu38pr6	1184	11	agent	agent	NN
cord-005478-5iu38pr6	1184	12	and	and	CC
cord-005478-5iu38pr6	1184	13	Fludarabine	Fludarabine	NNP
cord-005478-5iu38pr6	1184	14	(	(	-LRB-
cord-005478-5iu38pr6	1184	15	12	12	CD
cord-005478-5iu38pr6	1184	16	Bu	Bu	NNP
cord-005478-5iu38pr6	1184	17	/	/	SYM
cord-005478-5iu38pr6	1184	18	Flu	Flu	NNP
cord-005478-5iu38pr6	1184	19	;	;	:
cord-005478-5iu38pr6	1184	20	3	3	CD
cord-005478-5iu38pr6	1184	21	Mel	Mel	NNP
cord-005478-5iu38pr6	1184	22	/	/	SYM
cord-005478-5iu38pr6	1184	23	Flu/	Flu/	NNP
cord-005478-5iu38pr6	1184	24	BCNU	BCNU	NNP
cord-005478-5iu38pr6	1184	25	;	;	:
cord-005478-5iu38pr6	1185	1	1	1	CD
cord-005478-5iu38pr6	1185	2	Mel	Mel	NNP
cord-005478-5iu38pr6	1185	3	/	/	SYM
cord-005478-5iu38pr6	1185	4	Flu	Flu	NNP
cord-005478-5iu38pr6	1185	5	;	;	:
cord-005478-5iu38pr6	1185	6	1	1	CD
cord-005478-5iu38pr6	1185	7	Treo	Treo	NNP
cord-005478-5iu38pr6	1185	8	/	/	SYM
cord-005478-5iu38pr6	1185	9	Flu	Flu	NNP
cord-005478-5iu38pr6	1185	10	)	)	-RRB-
cord-005478-5iu38pr6	1185	11	with	with	IN
cord-005478-5iu38pr6	1185	12	ATG	ATG	NNP
cord-005478-5iu38pr6	1185	13	infusion	infusion	NN
cord-005478-5iu38pr6	1185	14	.	.	.
cord-005478-5iu38pr6	1186	1	Six	six	CD
cord-005478-5iu38pr6	1186	2	patients	patient	NNS
cord-005478-5iu38pr6	1186	3	received	receive	VBD
cord-005478-5iu38pr6	1186	4	a	a	DT
cord-005478-5iu38pr6	1186	5	fully	fully	RB
cord-005478-5iu38pr6	1186	6	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1186	7	schema	schema	NNP
cord-005478-5iu38pr6	1186	8	,	,	,
cord-005478-5iu38pr6	1186	9	12	12	CD
cord-005478-5iu38pr6	1186	10	reduced	reduce	VBN
cord-005478-5iu38pr6	1186	11	-	-	HYPH
cord-005478-5iu38pr6	1186	12	intensity	intensity	NN
cord-005478-5iu38pr6	1186	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	1186	14	.	.	.
cord-005478-5iu38pr6	1187	1	Only	only	RB
cord-005478-5iu38pr6	1187	2	one	one	CD
cord-005478-5iu38pr6	1187	3	patient	patient	NN
cord-005478-5iu38pr6	1187	4	received	receive	VBD
cord-005478-5iu38pr6	1187	5	conditioning	conditioning	NN
cord-005478-5iu38pr6	1187	6	with	with	IN
cord-005478-5iu38pr6	1187	7	TBI	TBI	NNP
cord-005478-5iu38pr6	1187	8	.	.	.
cord-005478-5iu38pr6	1188	1	Results	result	NNS
cord-005478-5iu38pr6	1188	2	:	:	:
cord-005478-5iu38pr6	1189	1	Before	before	IN
cord-005478-5iu38pr6	1189	2	the	the	DT
cord-005478-5iu38pr6	1189	3	transplant	transplant	NN
cord-005478-5iu38pr6	1189	4	,	,	,
cord-005478-5iu38pr6	1189	5	a	a	DT
cord-005478-5iu38pr6	1189	6	panel	panel	NN
cord-005478-5iu38pr6	1189	7	of	of	IN
cord-005478-5iu38pr6	1189	8	molecular	molecular	JJ
cord-005478-5iu38pr6	1189	9	analysis	analysis	NN
cord-005478-5iu38pr6	1189	10	based	base	VBN
cord-005478-5iu38pr6	1189	11	on	on	IN
cord-005478-5iu38pr6	1189	12	next	next	JJ
cord-005478-5iu38pr6	1189	13	-	-	HYPH
cord-005478-5iu38pr6	1189	14	generation	generation	NN
cord-005478-5iu38pr6	1189	15	-	-	HYPH
cord-005478-5iu38pr6	1189	16	sequencing	sequencing	NN
cord-005478-5iu38pr6	1189	17	revealed	reveal	VBN
cord-005478-5iu38pr6	1189	18	,	,	,
cord-005478-5iu38pr6	1189	19	in	in	IN
cord-005478-5iu38pr6	1189	20	addition	addition	NN
cord-005478-5iu38pr6	1189	21	to	to	IN
cord-005478-5iu38pr6	1189	22	the	the	DT
cord-005478-5iu38pr6	1189	23	MPL	MPL	NNP
cord-005478-5iu38pr6	1189	24	mutation	mutation	NN
cord-005478-5iu38pr6	1189	25	,	,	,
cord-005478-5iu38pr6	1189	26	alterations	alteration	NNS
cord-005478-5iu38pr6	1189	27	in	in	IN
cord-005478-5iu38pr6	1189	28	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1189	29	(	(	-LRB-
cord-005478-5iu38pr6	1189	30	22	22	CD
cord-005478-5iu38pr6	1189	31	%	%	NN
cord-005478-5iu38pr6	1189	32	)	)	-RRB-
cord-005478-5iu38pr6	1189	33	,	,	,
cord-005478-5iu38pr6	1189	34	SRSF2	SRSF2	VBN
cord-005478-5iu38pr6	1189	35	(	(	-LRB-
cord-005478-5iu38pr6	1189	36	11	11	CD
cord-005478-5iu38pr6	1189	37	%	%	NN
cord-005478-5iu38pr6	1189	38	)	)	-RRB-
cord-005478-5iu38pr6	1189	39	,	,	,
cord-005478-5iu38pr6	1189	40	SF3B1	SF3B1	NNP
cord-005478-5iu38pr6	1189	41	(	(	-LRB-
cord-005478-5iu38pr6	1189	42	5.5	5.5	CD
cord-005478-5iu38pr6	1189	43	%	%	NN
cord-005478-5iu38pr6	1189	44	)	)	-RRB-
cord-005478-5iu38pr6	1189	45	,	,	,
cord-005478-5iu38pr6	1189	46	EZH2	EZH2	NNP
cord-005478-5iu38pr6	1189	47	(	(	-LRB-
cord-005478-5iu38pr6	1189	48	11	11	CD
cord-005478-5iu38pr6	1189	49	%	%	NN
cord-005478-5iu38pr6	1189	50	)	)	-RRB-
cord-005478-5iu38pr6	1189	51	,	,	,
cord-005478-5iu38pr6	1189	52	IDH1	IDH1	NNP
cord-005478-5iu38pr6	1189	53	(	(	-LRB-
cord-005478-5iu38pr6	1189	54	5.5	5.5	CD
cord-005478-5iu38pr6	1189	55	%	%	NN
cord-005478-5iu38pr6	1189	56	)	)	-RRB-
cord-005478-5iu38pr6	1189	57	,	,	,
cord-005478-5iu38pr6	1189	58	IDH2	IDH2	NNP
cord-005478-5iu38pr6	1189	59	(	(	-LRB-
cord-005478-5iu38pr6	1189	60	5.5	5.5	CD
cord-005478-5iu38pr6	1189	61	%	%	NN
cord-005478-5iu38pr6	1189	62	)	)	-RRB-
cord-005478-5iu38pr6	1189	63	,	,	,
cord-005478-5iu38pr6	1189	64	TET2	TET2	NNP
cord-005478-5iu38pr6	1189	65	(	(	-LRB-
cord-005478-5iu38pr6	1189	66	33.5	33.5	CD
cord-005478-5iu38pr6	1189	67	%	%	NN
cord-005478-5iu38pr6	1189	68	)	)	-RRB-
cord-005478-5iu38pr6	1189	69	,	,	,
cord-005478-5iu38pr6	1189	70	TP53	TP53	NNP
cord-005478-5iu38pr6	1189	71	(	(	-LRB-
cord-005478-5iu38pr6	1189	72	5.5	5.5	CD
cord-005478-5iu38pr6	1189	73	%	%	NN
cord-005478-5iu38pr6	1189	74	)	)	-RRB-
cord-005478-5iu38pr6	1189	75	.	.	.
cord-005478-5iu38pr6	1190	1	After	after	IN
cord-005478-5iu38pr6	1190	2	the	the	DT
cord-005478-5iu38pr6	1190	3	transplant	transplant	NN
cord-005478-5iu38pr6	1190	4	,	,	,
cord-005478-5iu38pr6	1190	5	the	the	DT
cord-005478-5iu38pr6	1190	6	incidence	incidence	NN
cord-005478-5iu38pr6	1190	7	of	of	IN
cord-005478-5iu38pr6	1190	8	acute	acute	JJ
cord-005478-5iu38pr6	1190	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1190	10	was	be	VBD
cord-005478-5iu38pr6	1190	11	72	72	CD
cord-005478-5iu38pr6	1190	12	%	%	NN
cord-005478-5iu38pr6	1190	13	;	;	:
cord-005478-5iu38pr6	1190	14	only	only	RB
cord-005478-5iu38pr6	1190	15	3	3	CD
cord-005478-5iu38pr6	1190	16	patients	patient	NNS
cord-005478-5iu38pr6	1190	17	(	(	-LRB-
cord-005478-5iu38pr6	1190	18	16.5	16.5	CD
cord-005478-5iu38pr6	1190	19	%	%	NN
cord-005478-5iu38pr6	1190	20	)	)	-RRB-
cord-005478-5iu38pr6	1190	21	experienced	experience	VBD
cord-005478-5iu38pr6	1190	22	acute	acute	JJ
cord-005478-5iu38pr6	1190	23	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1190	24	grade	grade	NN
cord-005478-5iu38pr6	1190	25	3	3	CD
cord-005478-5iu38pr6	1190	26	-	-	SYM
cord-005478-5iu38pr6	1190	27	4	4	CD
cord-005478-5iu38pr6	1190	28	.	.	.
cord-005478-5iu38pr6	1191	1	Chronic	chronic	JJ
cord-005478-5iu38pr6	1191	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1191	3	was	be	VBD
cord-005478-5iu38pr6	1191	4	registered	register	VBN
cord-005478-5iu38pr6	1191	5	in	in	IN
cord-005478-5iu38pr6	1191	6	50	50	CD
cord-005478-5iu38pr6	1191	7	%	%	NN
cord-005478-5iu38pr6	1191	8	of	of	IN
cord-005478-5iu38pr6	1191	9	cases	case	NNS
cord-005478-5iu38pr6	1191	10	(	(	-LRB-
cord-005478-5iu38pr6	1191	11	9	9	CD
cord-005478-5iu38pr6	1191	12	patients	patient	NNS
cord-005478-5iu38pr6	1191	13	:	:	:
cord-005478-5iu38pr6	1191	14	8	8	CD
cord-005478-5iu38pr6	1191	15	mild	mild	JJ
cord-005478-5iu38pr6	1191	16	,	,	,
cord-005478-5iu38pr6	1191	17	1	1	CD
cord-005478-5iu38pr6	1191	18	moderate	moderate	JJ
cord-005478-5iu38pr6	1191	19	,	,	,
cord-005478-5iu38pr6	1191	20	0	0	CD
cord-005478-5iu38pr6	1191	21	severe	severe	NN
cord-005478-5iu38pr6	1191	22	)	)	-RRB-
cord-005478-5iu38pr6	1191	23	.	.	.
cord-005478-5iu38pr6	1192	1	Relapse	relapse	NN
cord-005478-5iu38pr6	1192	2	occurred	occur	VBD
cord-005478-5iu38pr6	1192	3	in	in	IN
cord-005478-5iu38pr6	1192	4	only	only	RB
cord-005478-5iu38pr6	1192	5	1	1	CD
cord-005478-5iu38pr6	1192	6	case	case	NN
cord-005478-5iu38pr6	1192	7	.	.	.
cord-005478-5iu38pr6	1193	1	NRM	NRM	NNP
cord-005478-5iu38pr6	1193	2	incidence	incidence	NN
cord-005478-5iu38pr6	1193	3	was	be	VBD
cord-005478-5iu38pr6	1193	4	16.5	16.5	CD
cord-005478-5iu38pr6	1193	5	%	%	NN
cord-005478-5iu38pr6	1193	6	of	of	IN
cord-005478-5iu38pr6	1193	7	cases	case	NNS
cord-005478-5iu38pr6	1193	8	,	,	,
cord-005478-5iu38pr6	1193	9	occurring	occur	VBG
cord-005478-5iu38pr6	1193	10	in	in	IN
cord-005478-5iu38pr6	1193	11	the	the	DT
cord-005478-5iu38pr6	1193	12	first	first	JJ
cord-005478-5iu38pr6	1193	13	year	year	NN
cord-005478-5iu38pr6	1193	14	after	after	IN
cord-005478-5iu38pr6	1193	15	transplant	transplant	NN
cord-005478-5iu38pr6	1193	16	.	.	.
cord-005478-5iu38pr6	1194	1	With	with	IN
cord-005478-5iu38pr6	1194	2	a	a	DT
cord-005478-5iu38pr6	1194	3	median	median	NN
cord-005478-5iu38pr6	1194	4	follow	follow	NN
cord-005478-5iu38pr6	1194	5	up	up	IN
cord-005478-5iu38pr6	1194	6	of	of	IN
cord-005478-5iu38pr6	1194	7	55	55	CD
cord-005478-5iu38pr6	1194	8	months	month	NNS
cord-005478-5iu38pr6	1194	9	,	,	,
cord-005478-5iu38pr6	1194	10	5-year	5-year	CD
cord-005478-5iu38pr6	1194	11	overall	overall	JJ
cord-005478-5iu38pr6	1194	12	survival	survival	NN
cord-005478-5iu38pr6	1194	13	was	be	VBD
cord-005478-5iu38pr6	1194	14	83.5	83.5	CD
cord-005478-5iu38pr6	1194	15	%	%	NN
cord-005478-5iu38pr6	1194	16	,	,	,
cord-005478-5iu38pr6	1194	17	and	and	CC
cord-005478-5iu38pr6	1194	18	5-years	5-years	CD
cord-005478-5iu38pr6	1195	1	PFS	PFS	NNP
cord-005478-5iu38pr6	1195	2	reported	report	VBD
cord-005478-5iu38pr6	1195	3	the	the	DT
cord-005478-5iu38pr6	1195	4	same	same	JJ
cord-005478-5iu38pr6	1195	5	value	value	NN
cord-005478-5iu38pr6	1195	6	,	,	,
cord-005478-5iu38pr6	1195	7	beeing	beee	VBG
cord-005478-5iu38pr6	1195	8	the	the	DT
cord-005478-5iu38pr6	1195	9	only	only	JJ
cord-005478-5iu38pr6	1195	10	relapse	relapse	NN
cord-005478-5iu38pr6	1195	11	at	at	IN
cord-005478-5iu38pr6	1195	12	>	>	XX
cord-005478-5iu38pr6	1195	13	10	10	CD
cord-005478-5iu38pr6	1195	14	years	year	NNS
cord-005478-5iu38pr6	1195	15	after	after	IN
cord-005478-5iu38pr6	1195	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	1195	17	.	.	.
cord-005478-5iu38pr6	1196	1	The	the	DT
cord-005478-5iu38pr6	1196	2	relapse	relapse	NN
cord-005478-5iu38pr6	1196	3	occurred	occur	VBD
cord-005478-5iu38pr6	1196	4	in	in	IN
cord-005478-5iu38pr6	1196	5	the	the	DT
cord-005478-5iu38pr6	1196	6	only	only	JJ
cord-005478-5iu38pr6	1196	7	patient	patient	NN
cord-005478-5iu38pr6	1196	8	who	who	WP
cord-005478-5iu38pr6	1196	9	harbored	harbor	VBD
cord-005478-5iu38pr6	1196	10	mutations	mutation	NNS
cord-005478-5iu38pr6	1196	11	in	in	IN
cord-005478-5iu38pr6	1196	12	both	both	CC
cord-005478-5iu38pr6	1196	13	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1196	14	and	and	CC
cord-005478-5iu38pr6	1196	15	EZH2	EZH2	NNP
cord-005478-5iu38pr6	1196	16	genes	gene	NNS
cord-005478-5iu38pr6	1196	17	.	.	.
cord-005478-5iu38pr6	1197	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1197	2	:	:	:
cord-005478-5iu38pr6	1198	1	These	these	DT
cord-005478-5iu38pr6	1198	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1198	3	data	datum	NNS
cord-005478-5iu38pr6	1198	4	suggest	suggest	VBP
cord-005478-5iu38pr6	1198	5	that	that	IN
cord-005478-5iu38pr6	1198	6	the	the	DT
cord-005478-5iu38pr6	1198	7	particular	particular	JJ
cord-005478-5iu38pr6	1198	8	group	group	NN
cord-005478-5iu38pr6	1198	9	of	of	IN
cord-005478-5iu38pr6	1198	10	MPL	MPL	NNP
cord-005478-5iu38pr6	1198	11	-	-	HYPH
cord-005478-5iu38pr6	1198	12	mutated	mutate	VBN
cord-005478-5iu38pr6	1198	13	myelofibrosis	myelofibrosi	NNS
cord-005478-5iu38pr6	1198	14	may	may	MD
cord-005478-5iu38pr6	1198	15	have	have	VB
cord-005478-5iu38pr6	1198	16	a	a	DT
cord-005478-5iu38pr6	1198	17	good	good	JJ
cord-005478-5iu38pr6	1198	18	outcome	outcome	NN
cord-005478-5iu38pr6	1198	19	after	after	IN
cord-005478-5iu38pr6	1198	20	stem	stem	NN
cord-005478-5iu38pr6	1198	21	cells	cell	NNS
cord-005478-5iu38pr6	1198	22	transplantation	transplantation	NN
cord-005478-5iu38pr6	1198	23	.	.	.
cord-005478-5iu38pr6	1199	1	In	in	IN
cord-005478-5iu38pr6	1199	2	particular	particular	JJ
cord-005478-5iu38pr6	1199	3	,	,	,
cord-005478-5iu38pr6	1199	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	1199	5	data	datum	NNS
cord-005478-5iu38pr6	1199	6	revealed	reveal	VBD
cord-005478-5iu38pr6	1199	7	very	very	RB
cord-005478-5iu38pr6	1199	8	low	low	JJ
cord-005478-5iu38pr6	1199	9	rate	rate	NN
cord-005478-5iu38pr6	1199	10	of	of	IN
cord-005478-5iu38pr6	1199	11	disease	disease	NN
cord-005478-5iu38pr6	1199	12	relapse	relapse	NN
cord-005478-5iu38pr6	1199	13	(	(	-LRB-
cord-005478-5iu38pr6	1199	14	5.5	5.5	CD
cord-005478-5iu38pr6	1199	15	%	%	NN
cord-005478-5iu38pr6	1199	16	)	)	-RRB-
cord-005478-5iu38pr6	1199	17	in	in	IN
cord-005478-5iu38pr6	1199	18	comparison	comparison	NN
cord-005478-5iu38pr6	1199	19	with	with	IN
cord-005478-5iu38pr6	1199	20	the	the	DT
cord-005478-5iu38pr6	1199	21	available	available	JJ
cord-005478-5iu38pr6	1199	22	historical	historical	JJ
cord-005478-5iu38pr6	1199	23	controls	control	NNS
cord-005478-5iu38pr6	1199	24	regarding	regard	VBG
cord-005478-5iu38pr6	1199	25	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1199	26	in	in	IN
cord-005478-5iu38pr6	1199	27	toto	toto	NNP
cord-005478-5iu38pr6	1199	28	.	.	.
cord-005478-5iu38pr6	1200	1	[	[	-LRB-
cord-005478-5iu38pr6	1200	2	Background	background	NN
cord-005478-5iu38pr6	1200	3	:	:	:
cord-005478-5iu38pr6	1201	1	A	a	DT
cord-005478-5iu38pr6	1201	2	significant	significant	JJ
cord-005478-5iu38pr6	1201	3	proportion	proportion	NN
cord-005478-5iu38pr6	1201	4	of	of	IN
cord-005478-5iu38pr6	1201	5	CML	CML	NNP
cord-005478-5iu38pr6	1201	6	patients	patient	NNS
cord-005478-5iu38pr6	1201	7	undergoing	undergo	VBG
cord-005478-5iu38pr6	1201	8	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1201	9	stem	stem	NN
cord-005478-5iu38pr6	1201	10	cell	cell	NN
cord-005478-5iu38pr6	1201	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	1201	12	(	(	-LRB-
cord-005478-5iu38pr6	1201	13	allo	allo	NN
cord-005478-5iu38pr6	1201	14	-	-	HYPH
cord-005478-5iu38pr6	1201	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1201	16	)	)	-RRB-
cord-005478-5iu38pr6	1201	17	restart	restart	VBP
cord-005478-5iu38pr6	1201	18	TKI	TKI	NNP
cord-005478-5iu38pr6	1201	19	following	follow	VBG
cord-005478-5iu38pr6	1201	20	transplant	transplant	NN
cord-005478-5iu38pr6	1201	21	to	to	TO
cord-005478-5iu38pr6	1201	22	prevent	prevent	VB
cord-005478-5iu38pr6	1201	23	relapse	relapse	NN
cord-005478-5iu38pr6	1201	24	.	.	.
cord-005478-5iu38pr6	1202	1	There	there	EX
cord-005478-5iu38pr6	1202	2	is	be	VBZ
cord-005478-5iu38pr6	1202	3	however	however	RB
cord-005478-5iu38pr6	1202	4	no	no	DT
cord-005478-5iu38pr6	1202	5	data	data	NN
cord-005478-5iu38pr6	1202	6	to	to	TO
cord-005478-5iu38pr6	1202	7	support	support	VB
cord-005478-5iu38pr6	1202	8	if	if	IN
cord-005478-5iu38pr6	1202	9	TKI	TKI	NNP
cord-005478-5iu38pr6	1202	10	can	can	MD
cord-005478-5iu38pr6	1202	11	be	be	VB
cord-005478-5iu38pr6	1202	12	discontinued	discontinue	VBN
cord-005478-5iu38pr6	1202	13	following	follow	VBG
cord-005478-5iu38pr6	1202	14	allo	allo	NN
cord-005478-5iu38pr6	1202	15	-	-	HYPH
cord-005478-5iu38pr6	1202	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1202	17	and	and	CC
cord-005478-5iu38pr6	1202	18	whether	whether	IN
cord-005478-5iu38pr6	1202	19	such	such	JJ
cord-005478-5iu38pr6	1202	20	patients	patient	NNS
cord-005478-5iu38pr6	1202	21	can	can	MD
cord-005478-5iu38pr6	1202	22	safely	safely	RB
cord-005478-5iu38pr6	1202	23	discontinue	discontinue	VB
cord-005478-5iu38pr6	1202	24	TKI	TKI	NNP
cord-005478-5iu38pr6	1202	25	remains	remain	VBZ
cord-005478-5iu38pr6	1202	26	controversial	controversial	JJ
cord-005478-5iu38pr6	1202	27	.	.	.
cord-005478-5iu38pr6	1203	1	Practices	practice	NNS
cord-005478-5iu38pr6	1203	2	varies	vary	VBZ
cord-005478-5iu38pr6	1203	3	among	among	IN
cord-005478-5iu38pr6	1203	4	transplant	transplant	NN
cord-005478-5iu38pr6	1203	5	centres	centre	NNS
cord-005478-5iu38pr6	1203	6	depending	depend	VBG
cord-005478-5iu38pr6	1203	7	on	on	IN
cord-005478-5iu38pr6	1203	8	countrywide	countrywide	JJ
cord-005478-5iu38pr6	1203	9	practices	practice	NNS
cord-005478-5iu38pr6	1203	10	,	,	,
cord-005478-5iu38pr6	1203	11	centre	centre	NN
cord-005478-5iu38pr6	1203	12	experience	experience	NN
cord-005478-5iu38pr6	1203	13	,	,	,
cord-005478-5iu38pr6	1203	14	duration	duration	NN
cord-005478-5iu38pr6	1203	15	of	of	IN
cord-005478-5iu38pr6	1203	16	molecular	molecular	JJ
cord-005478-5iu38pr6	1203	17	remission	remission	NN
cord-005478-5iu38pr6	1203	18	,	,	,
cord-005478-5iu38pr6	1203	19	patients	patient	NNS
cord-005478-5iu38pr6	1203	20	'	'	POS
cord-005478-5iu38pr6	1203	21	wish	wish	NN
cord-005478-5iu38pr6	1203	22	and	and	CC
cord-005478-5iu38pr6	1203	23	analysis	analysis	NN
cord-005478-5iu38pr6	1203	24	of	of	IN
cord-005478-5iu38pr6	1203	25	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1203	26	data	datum	NNS
cord-005478-5iu38pr6	1203	27	on	on	IN
cord-005478-5iu38pr6	1203	28	the	the	DT
cord-005478-5iu38pr6	1203	29	outcome	outcome	NN
cord-005478-5iu38pr6	1203	30	of	of	IN
cord-005478-5iu38pr6	1203	31	patients	patient	NNS
cord-005478-5iu38pr6	1203	32	who	who	WP
cord-005478-5iu38pr6	1203	33	discontinue	discontinue	VBP
cord-005478-5iu38pr6	1203	34	TKI	TKI	NNP
cord-005478-5iu38pr6	1203	35	after	after	IN
cord-005478-5iu38pr6	1203	36	transplant	transplant	NN
cord-005478-5iu38pr6	1203	37	may	may	MD
cord-005478-5iu38pr6	1203	38	provide	provide	VB
cord-005478-5iu38pr6	1203	39	further	further	JJ
cord-005478-5iu38pr6	1203	40	insight	insight	NN
cord-005478-5iu38pr6	1203	41	to	to	TO
cord-005478-5iu38pr6	1203	42	help	help	VB
cord-005478-5iu38pr6	1203	43	elaborating	elaborate	VBG
cord-005478-5iu38pr6	1203	44	future	future	JJ
cord-005478-5iu38pr6	1203	45	guidelines	guideline	NNS
cord-005478-5iu38pr6	1203	46	.	.	.
cord-005478-5iu38pr6	1204	1	The	the	DT
cord-005478-5iu38pr6	1204	2	present	present	JJ
cord-005478-5iu38pr6	1204	3	study	study	NN
cord-005478-5iu38pr6	1204	4	objective	objective	NN
cord-005478-5iu38pr6	1204	5	is	be	VBZ
cord-005478-5iu38pr6	1204	6	to	to	TO
cord-005478-5iu38pr6	1204	7	investigate	investigate	VB
cord-005478-5iu38pr6	1204	8	the	the	DT
cord-005478-5iu38pr6	1204	9	outcome	outcome	NN
cord-005478-5iu38pr6	1204	10	of	of	IN
cord-005478-5iu38pr6	1204	11	patients	patient	NNS
cord-005478-5iu38pr6	1204	12	with	with	IN
cord-005478-5iu38pr6	1204	13	CML	CML	NNP
cord-005478-5iu38pr6	1204	14	who	who	WP
cord-005478-5iu38pr6	1204	15	discontinue	discontinue	VBP
cord-005478-5iu38pr6	1204	16	TKI	TKI	NNP
cord-005478-5iu38pr6	1204	17	therapy	therapy	NN
cord-005478-5iu38pr6	1204	18	after	after	IN
cord-005478-5iu38pr6	1204	19	restarting	restart	VBG
cord-005478-5iu38pr6	1204	20	TKI	TKI	NNP
cord-005478-5iu38pr6	1204	21	following	follow	VBG
cord-005478-5iu38pr6	1204	22	allo	allo	NN
cord-005478-5iu38pr6	1204	23	-	-	HYPH
cord-005478-5iu38pr6	1204	24	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1204	25	.	.	.
cord-005478-5iu38pr6	1205	1	This	this	DT
cord-005478-5iu38pr6	1205	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1205	3	study	study	NN
cord-005478-5iu38pr6	1205	4	may	may	MD
cord-005478-5iu38pr6	1205	5	be	be	VB
cord-005478-5iu38pr6	1205	6	helpful	helpful	JJ
cord-005478-5iu38pr6	1205	7	to	to	TO
cord-005478-5iu38pr6	1205	8	support	support	VB
cord-005478-5iu38pr6	1205	9	future	future	JJ
cord-005478-5iu38pr6	1205	10	guidelines	guideline	NNS
cord-005478-5iu38pr6	1205	11	.	.	.
cord-005478-5iu38pr6	1206	1	Methods	method	NNS
cord-005478-5iu38pr6	1206	2	:	:	:
cord-005478-5iu38pr6	1206	3	Through	through	IN
cord-005478-5iu38pr6	1206	4	the	the	DT
cord-005478-5iu38pr6	1206	5	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1206	6	database	database	NN
cord-005478-5iu38pr6	1206	7	of	of	IN
cord-005478-5iu38pr6	1206	8	patients	patient	NNS
cord-005478-5iu38pr6	1206	9	who	who	WP
cord-005478-5iu38pr6	1206	10	received	receive	VBD
cord-005478-5iu38pr6	1206	11	an	an	DT
cord-005478-5iu38pr6	1206	12	allo	allo	NN
cord-005478-5iu38pr6	1206	13	-	-	HYPH
cord-005478-5iu38pr6	1206	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1206	15	between	between	IN
cord-005478-5iu38pr6	1206	16	March	March	NNP
cord-005478-5iu38pr6	1206	17	2004	2004	CD
cord-005478-5iu38pr6	1206	18	and	and	CC
cord-005478-5iu38pr6	1206	19	September	September	NNP
cord-005478-5iu38pr6	1206	20	2013	2013	CD
cord-005478-5iu38pr6	1206	21	,	,	,
cord-005478-5iu38pr6	1206	22	we	-PRON-	PRP
cord-005478-5iu38pr6	1206	23	identified	identify	VBD
cord-005478-5iu38pr6	1206	24	81	81	CD
cord-005478-5iu38pr6	1206	25	CML	CML	NNP
cord-005478-5iu38pr6	1206	26	patients	patient	NNS
cord-005478-5iu38pr6	1206	27	who	who	WP
cord-005478-5iu38pr6	1206	28	restarted	restart	VBD
cord-005478-5iu38pr6	1206	29	TKI	TKI	NNP
cord-005478-5iu38pr6	1206	30	treatment	treatment	NN
cord-005478-5iu38pr6	1206	31	post	post	NN
cord-005478-5iu38pr6	1206	32	allo	allo	NN
cord-005478-5iu38pr6	1206	33	-	-	HYPH
cord-005478-5iu38pr6	1206	34	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1206	35	and	and	CC
cord-005478-5iu38pr6	1206	36	stopped	stop	VBD
cord-005478-5iu38pr6	1206	37	it	-PRON-	PRP
cord-005478-5iu38pr6	1206	38	after	after	IN
cord-005478-5iu38pr6	1206	39	at	at	RB
cord-005478-5iu38pr6	1206	40	least	least	JJS
cord-005478-5iu38pr6	1206	41	3	3	CD
cord-005478-5iu38pr6	1206	42	months	month	NNS
cord-005478-5iu38pr6	1206	43	of	of	IN
cord-005478-5iu38pr6	1206	44	TKI	TKI	NNP
cord-005478-5iu38pr6	1206	45	therapy	therapy	NN
cord-005478-5iu38pr6	1206	46	.	.	.
cord-005478-5iu38pr6	1207	1	Results	result	NNS
cord-005478-5iu38pr6	1207	2	:	:	:
cord-005478-5iu38pr6	1208	1	Out	out	IN
cord-005478-5iu38pr6	1208	2	of	of	IN
cord-005478-5iu38pr6	1208	3	81	81	CD
cord-005478-5iu38pr6	1208	4	patients	patient	NNS
cord-005478-5iu38pr6	1208	5	who	who	WP
cord-005478-5iu38pr6	1208	6	discontinued	discontinue	VBD
cord-005478-5iu38pr6	1208	7	TKI	TKI	NNP
cord-005478-5iu38pr6	1208	8	,	,	,
cord-005478-5iu38pr6	1208	9	21	21	CD
cord-005478-5iu38pr6	1208	10	were	be	VBD
cord-005478-5iu38pr6	1208	11	in	in	IN
cord-005478-5iu38pr6	1208	12	first	first	JJ
cord-005478-5iu38pr6	1208	13	chronic	chronic	JJ
cord-005478-5iu38pr6	1208	14	phase	phase	NN
cord-005478-5iu38pr6	1208	15	(	(	-LRB-
cord-005478-5iu38pr6	1208	16	CP1	CP1	NNP
cord-005478-5iu38pr6	1208	17	)	)	-RRB-
cord-005478-5iu38pr6	1208	18	at	at	IN
cord-005478-5iu38pr6	1208	19	the	the	DT
cord-005478-5iu38pr6	1208	20	time	time	NN
cord-005478-5iu38pr6	1208	21	of	of	IN
cord-005478-5iu38pr6	1208	22	transplant	transplant	NN
cord-005478-5iu38pr6	1208	23	,	,	,
cord-005478-5iu38pr6	1208	24	31	31	CD
cord-005478-5iu38pr6	1208	25	in	in	IN
cord-005478-5iu38pr6	1208	26	second	second	JJ
cord-005478-5iu38pr6	1208	27	or	or	CC
cord-005478-5iu38pr6	1208	28	third	third	JJ
cord-005478-5iu38pr6	1208	29	chronic	chronic	JJ
cord-005478-5iu38pr6	1208	30	phase	phase	NN
cord-005478-5iu38pr6	1208	31	(	(	-LRB-
cord-005478-5iu38pr6	1208	32	CP1	CP1	NNP
cord-005478-5iu38pr6	1208	33	and	and	CC
cord-005478-5iu38pr6	1208	34	CP2	CP2	NNP
cord-005478-5iu38pr6	1208	35	)	)	-RRB-
cord-005478-5iu38pr6	1208	36	and	and	CC
cord-005478-5iu38pr6	1208	37	28	28	CD
cord-005478-5iu38pr6	1208	38	in	in	IN
cord-005478-5iu38pr6	1208	39	accelerated	accelerated	JJ
cord-005478-5iu38pr6	1208	40	or	or	CC
cord-005478-5iu38pr6	1208	41	blastic	blastic	JJ
cord-005478-5iu38pr6	1208	42	phase	phase	NN
cord-005478-5iu38pr6	1208	43	(	(	-LRB-
cord-005478-5iu38pr6	1208	44	AP	AP	NNP
cord-005478-5iu38pr6	1208	45	/	/	SYM
cord-005478-5iu38pr6	1208	46	BP	BP	NNP
cord-005478-5iu38pr6	1208	47	)	)	-RRB-
cord-005478-5iu38pr6	1208	48	or	or	CC
cord-005478-5iu38pr6	1208	49	primary	primary	JJ
cord-005478-5iu38pr6	1208	50	refractory	refractory	JJ
cord-005478-5iu38pr6	1208	51	disease	disease	NN
cord-005478-5iu38pr6	1208	52	.	.	.
cord-005478-5iu38pr6	1209	1	One	one	CD
cord-005478-5iu38pr6	1209	2	patient	patient	NN
cord-005478-5iu38pr6	1209	3	had	have	VBD
cord-005478-5iu38pr6	1209	4	missing	miss	VBG
cord-005478-5iu38pr6	1209	5	data	datum	NNS
cord-005478-5iu38pr6	1209	6	at	at	IN
cord-005478-5iu38pr6	1209	7	the	the	DT
cord-005478-5iu38pr6	1209	8	time	time	NN
cord-005478-5iu38pr6	1209	9	to	to	IN
cord-005478-5iu38pr6	1209	10	transplant	transplant	NN
cord-005478-5iu38pr6	1209	11	.	.	.
cord-005478-5iu38pr6	1210	1	Allo	Allo	NNP
cord-005478-5iu38pr6	1210	2	-	-	HYPH
cord-005478-5iu38pr6	1210	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1210	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	1210	5	was	be	VBD
cord-005478-5iu38pr6	1210	6	of	of	IN
cord-005478-5iu38pr6	1210	7	reduced	reduce	VBN
cord-005478-5iu38pr6	1210	8	intensity	intensity	NN
cord-005478-5iu38pr6	1210	9	(	(	-LRB-
cord-005478-5iu38pr6	1210	10	RIC	RIC	NNP
cord-005478-5iu38pr6	1210	11	)	)	-RRB-
cord-005478-5iu38pr6	1210	12	in	in	IN
cord-005478-5iu38pr6	1210	13	27	27	CD
cord-005478-5iu38pr6	1210	14	patients	patient	NNS
cord-005478-5iu38pr6	1210	15	and	and	CC
cord-005478-5iu38pr6	1210	16	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1210	17	(	(	-LRB-
cord-005478-5iu38pr6	1210	18	MAC	MAC	NNP
cord-005478-5iu38pr6	1210	19	)	)	-RRB-
cord-005478-5iu38pr6	1210	20	in	in	IN
cord-005478-5iu38pr6	1210	21	54	54	CD
cord-005478-5iu38pr6	1210	22	patients	patient	NNS
cord-005478-5iu38pr6	1210	23	,	,	,
cord-005478-5iu38pr6	1210	24	including	include	VBG
cord-005478-5iu38pr6	1210	25	TBI	TBI	NNP
cord-005478-5iu38pr6	1210	26	in	in	IN
cord-005478-5iu38pr6	1210	27	29	29	CD
cord-005478-5iu38pr6	1210	28	patients	patient	NNS
cord-005478-5iu38pr6	1210	29	.	.	.
cord-005478-5iu38pr6	1211	1	TKI	TKI	NNP
cord-005478-5iu38pr6	1211	2	therapy	therapy	NN
cord-005478-5iu38pr6	1211	3	was	be	VBD
cord-005478-5iu38pr6	1211	4	(	(	-LRB-
cord-005478-5iu38pr6	1211	5	re)started	re)starte	VBN
cord-005478-5iu38pr6	1211	6	in	in	IN
cord-005478-5iu38pr6	1211	7	all	all	DT
cord-005478-5iu38pr6	1211	8	patients	patient	NNS
cord-005478-5iu38pr6	1211	9	after	after	IN
cord-005478-5iu38pr6	1211	10	a	a	DT
cord-005478-5iu38pr6	1211	11	median	median	JJ
cord-005478-5iu38pr6	1211	12	time	time	NN
cord-005478-5iu38pr6	1211	13	from	from	IN
cord-005478-5iu38pr6	1211	14	transplant	transplant	NN
cord-005478-5iu38pr6	1211	15	of	of	IN
cord-005478-5iu38pr6	1211	16	4.4	4.4	CD
cord-005478-5iu38pr6	1211	17	months	month	NNS
cord-005478-5iu38pr6	1211	18	(	(	-LRB-
cord-005478-5iu38pr6	1211	19	range	range	NN
cord-005478-5iu38pr6	1211	20	,	,	,
cord-005478-5iu38pr6	1211	21	0.4	0.4	CD
cord-005478-5iu38pr6	1211	22	to	to	IN
cord-005478-5iu38pr6	1211	23	57.6	57.6	CD
cord-005478-5iu38pr6	1211	24	months	month	NNS
cord-005478-5iu38pr6	1211	25	)	)	-RRB-
cord-005478-5iu38pr6	1211	26	for	for	IN
cord-005478-5iu38pr6	1211	27	a	a	DT
cord-005478-5iu38pr6	1211	28	duration	duration	NN
cord-005478-5iu38pr6	1211	29	of	of	IN
cord-005478-5iu38pr6	1211	30	9.7	9.7	CD
cord-005478-5iu38pr6	1211	31	(	(	-LRB-
cord-005478-5iu38pr6	1211	32	range	range	NN
cord-005478-5iu38pr6	1211	33	,	,	,
cord-005478-5iu38pr6	1211	34	3.1	3.1	CD
cord-005478-5iu38pr6	1211	35	-	-	HYPH
cord-005478-5iu38pr6	1211	36	62.3	62.3	CD
cord-005478-5iu38pr6	1211	37	months	month	NNS
cord-005478-5iu38pr6	1211	38	)	)	-RRB-
cord-005478-5iu38pr6	1211	39	.	.	.
cord-005478-5iu38pr6	1212	1	After	after	IN
cord-005478-5iu38pr6	1212	2	a	a	DT
cord-005478-5iu38pr6	1212	3	median	median	JJ
cord-005478-5iu38pr6	1212	4	time	time	NN
cord-005478-5iu38pr6	1212	5	from	from	IN
cord-005478-5iu38pr6	1212	6	TKI	TKI	NNP
cord-005478-5iu38pr6	1212	7	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	1212	8	of	of	IN
cord-005478-5iu38pr6	1212	9	65.8	65.8	CD
cord-005478-5iu38pr6	1212	10	months	month	NNS
cord-005478-5iu38pr6	1212	11	(	(	-LRB-
cord-005478-5iu38pr6	1212	12	range	range	VBP
cord-005478-5iu38pr6	1212	13	51.8	51.8	CD
cord-005478-5iu38pr6	1212	14	-	-	HYPH
cord-005478-5iu38pr6	1212	15	71.1	71.1	CD
cord-005478-5iu38pr6	1212	16	)	)	-RRB-
cord-005478-5iu38pr6	1212	17	,	,	,
cord-005478-5iu38pr6	1212	18	5-years	5-years	CD
cord-005478-5iu38pr6	1212	19	progression	progression	NN
cord-005478-5iu38pr6	1212	20	free	free	JJ
cord-005478-5iu38pr6	1212	21	survival	survival	NN
cord-005478-5iu38pr6	1212	22	(	(	-LRB-
cord-005478-5iu38pr6	1212	23	PFS	PFS	NNP
cord-005478-5iu38pr6	1212	24	)	)	-RRB-
cord-005478-5iu38pr6	1212	25	and	and	CC
cord-005478-5iu38pr6	1212	26	Overall	overall	JJ
cord-005478-5iu38pr6	1212	27	survival	survival	NN
cord-005478-5iu38pr6	1212	28	(	(	-LRB-
cord-005478-5iu38pr6	1212	29	OS	OS	NNP
cord-005478-5iu38pr6	1212	30	)	)	-RRB-
cord-005478-5iu38pr6	1212	31	were	be	VBD
cord-005478-5iu38pr6	1212	32	51	51	CD
cord-005478-5iu38pr6	1212	33	%	%	NN
cord-005478-5iu38pr6	1212	34	(	(	-LRB-
cord-005478-5iu38pr6	1212	35	95%CI	95%ci	CD
cord-005478-5iu38pr6	1212	36	39	39	CD
cord-005478-5iu38pr6	1212	37	to	to	TO
cord-005478-5iu38pr6	1212	38	62	62	CD
cord-005478-5iu38pr6	1212	39	%	%	NN
cord-005478-5iu38pr6	1212	40	)	)	-RRB-
cord-005478-5iu38pr6	1212	41	and	and	CC
cord-005478-5iu38pr6	1212	42	62	62	CD
cord-005478-5iu38pr6	1212	43	%	%	NN
cord-005478-5iu38pr6	1212	44	(	(	-LRB-
cord-005478-5iu38pr6	1212	45	95%CI	95%ci	CD
cord-005478-5iu38pr6	1212	46	51	51	CD
cord-005478-5iu38pr6	1212	47	to	to	TO
cord-005478-5iu38pr6	1212	48	73	73	CD
cord-005478-5iu38pr6	1212	49	%	%	NN
cord-005478-5iu38pr6	1212	50	)	)	-RRB-
cord-005478-5iu38pr6	1212	51	respectively	respectively	RB
cord-005478-5iu38pr6	1212	52	.	.	.
cord-005478-5iu38pr6	1213	1	Patients	patient	NNS
cord-005478-5iu38pr6	1213	2	in	in	IN
cord-005478-5iu38pr6	1213	3	CP1	CP1	NNP
cord-005478-5iu38pr6	1213	4	at	at	IN
cord-005478-5iu38pr6	1213	5	the	the	DT
cord-005478-5iu38pr6	1213	6	time	time	NN
cord-005478-5iu38pr6	1213	7	of	of	IN
cord-005478-5iu38pr6	1213	8	transplant	transplant	NN
cord-005478-5iu38pr6	1213	9	had	have	VBD
cord-005478-5iu38pr6	1213	10	a	a	DT
cord-005478-5iu38pr6	1213	11	significantly	significantly	RB
cord-005478-5iu38pr6	1213	12	higher	high	JJR
cord-005478-5iu38pr6	1213	13	5-years	5-years	CD
cord-005478-5iu38pr6	1213	14	OS	os	NN
cord-005478-5iu38pr6	1213	15	compared	compare	VBN
cord-005478-5iu38pr6	1213	16	to	to	IN
cord-005478-5iu38pr6	1213	17	those	those	DT
cord-005478-5iu38pr6	1213	18	in	in	IN
cord-005478-5iu38pr6	1213	19	CP2/	CP2/	NNP
cord-005478-5iu38pr6	1213	20	CP3	CP3	NNP
cord-005478-5iu38pr6	1213	21	or	or	CC
cord-005478-5iu38pr6	1213	22	AP	AP	NNP
cord-005478-5iu38pr6	1213	23	/	/	SYM
cord-005478-5iu38pr6	1213	24	BP	BP	NNP
cord-005478-5iu38pr6	1213	25	,	,	,
cord-005478-5iu38pr6	1213	26	100	100	CD
cord-005478-5iu38pr6	1213	27	%	%	NN
cord-005478-5iu38pr6	1213	28	vs	vs	IN
cord-005478-5iu38pr6	1213	29	37	37	CD
cord-005478-5iu38pr6	1213	30	%	%	NN
cord-005478-5iu38pr6	1213	31	(	(	-LRB-
cord-005478-5iu38pr6	1213	32	95%CI	95%ci	CD
cord-005478-5iu38pr6	1213	33	17	17	CD
cord-005478-5iu38pr6	1213	34	to	to	TO
cord-005478-5iu38pr6	1213	35	58	58	CD
cord-005478-5iu38pr6	1213	36	%	%	NN
cord-005478-5iu38pr6	1213	37	)	)	-RRB-
cord-005478-5iu38pr6	1213	38	and	and	CC
cord-005478-5iu38pr6	1213	39	59	59	CD
cord-005478-5iu38pr6	1213	40	%	%	NN
cord-005478-5iu38pr6	1213	41	(	(	-LRB-
cord-005478-5iu38pr6	1213	42	95%CI	95%ci	CD
cord-005478-5iu38pr6	1213	43	39	39	CD
cord-005478-5iu38pr6	1213	44	to	to	TO
cord-005478-5iu38pr6	1213	45	80	80	CD
cord-005478-5iu38pr6	1213	46	%	%	NN
cord-005478-5iu38pr6	1213	47	)	)	-RRB-
cord-005478-5iu38pr6	1213	48	respectively	respectively	RB
cord-005478-5iu38pr6	1213	49	(	(	-LRB-
cord-005478-5iu38pr6	1213	50	p	p	NN
cord-005478-5iu38pr6	1213	51	<	<	XX
cord-005478-5iu38pr6	1213	52	0.001	0.001	CD
cord-005478-5iu38pr6	1213	53	,	,	,
cord-005478-5iu38pr6	1213	54	Figure	figure	NN
cord-005478-5iu38pr6	1213	55	1	1	CD
cord-005478-5iu38pr6	1213	56	)	)	-RRB-
cord-005478-5iu38pr6	1213	57	.	.	.
cord-005478-5iu38pr6	1214	1	Causes	cause	NNS
cord-005478-5iu38pr6	1214	2	of	of	IN
cord-005478-5iu38pr6	1214	3	death	death	NN
cord-005478-5iu38pr6	1214	4	(	(	-LRB-
cord-005478-5iu38pr6	1214	5	COD	COD	NNP
cord-005478-5iu38pr6	1214	6	)	)	-RRB-
cord-005478-5iu38pr6	1214	7	in	in	IN
cord-005478-5iu38pr6	1214	8	the	the	DT
cord-005478-5iu38pr6	1214	9	CP2/3	CP2/3	NNP
cord-005478-5iu38pr6	1214	10	and	and	CC
cord-005478-5iu38pr6	1214	11	AP	AP	NNP
cord-005478-5iu38pr6	1214	12	/	/	SYM
cord-005478-5iu38pr6	1214	13	BP	BP	NNP
cord-005478-5iu38pr6	1214	14	groups	group	NNS
cord-005478-5iu38pr6	1214	15	were	be	VBD
cord-005478-5iu38pr6	1214	16	relapse	relapse	VBN
cord-005478-5iu38pr6	1214	17	(	(	-LRB-
cord-005478-5iu38pr6	1214	18	12/31	12/31	CD
cord-005478-5iu38pr6	1214	19	and	and	CC
cord-005478-5iu38pr6	1214	20	5/28	5/28	CD
cord-005478-5iu38pr6	1214	21	respectively	respectively	RB
cord-005478-5iu38pr6	1214	22	)	)	-RRB-
cord-005478-5iu38pr6	1214	23	and	and	CC
cord-005478-5iu38pr6	1214	24	NRM	NRM	NNP
cord-005478-5iu38pr6	1214	25	(	(	-LRB-
cord-005478-5iu38pr6	1214	26	4/31	4/31	CD
cord-005478-5iu38pr6	1214	27	and	and	CC
cord-005478-5iu38pr6	1214	28	4/28	4/28	CD
cord-005478-5iu38pr6	1214	29	respectively	respectively	RB
cord-005478-5iu38pr6	1214	30	,	,	,
cord-005478-5iu38pr6	1214	31	1	1	CD
cord-005478-5iu38pr6	1214	32	missing	miss	VBG
cord-005478-5iu38pr6	1214	33	COD	cod	NN
cord-005478-5iu38pr6	1214	34	in	in	IN
cord-005478-5iu38pr6	1214	35	each	each	DT
cord-005478-5iu38pr6	1214	36	group	group	NN
cord-005478-5iu38pr6	1214	37	)	)	-RRB-
cord-005478-5iu38pr6	1214	38	.	.	.
cord-005478-5iu38pr6	1215	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1215	2	:	:	:
cord-005478-5iu38pr6	1216	1	Post	post	JJ
cord-005478-5iu38pr6	1216	2	-	-	JJ
cord-005478-5iu38pr6	1216	3	transplant	transplant	NN
cord-005478-5iu38pr6	1216	4	TKI	TKI	NNP
cord-005478-5iu38pr6	1216	5	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	1216	6	appears	appear	VBZ
cord-005478-5iu38pr6	1216	7	safe	safe	JJ
cord-005478-5iu38pr6	1216	8	in	in	IN
cord-005478-5iu38pr6	1216	9	patients	patient	NNS
cord-005478-5iu38pr6	1216	10	who	who	WP
cord-005478-5iu38pr6	1216	11	receive	receive	VBP
cord-005478-5iu38pr6	1216	12	an	an	DT
cord-005478-5iu38pr6	1216	13	allo	allo	NN
cord-005478-5iu38pr6	1216	14	-	-	HYPH
cord-005478-5iu38pr6	1216	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1216	16	while	while	IN
cord-005478-5iu38pr6	1216	17	still	still	RB
cord-005478-5iu38pr6	1216	18	in	in	IN
cord-005478-5iu38pr6	1216	19	first	first	JJ
cord-005478-5iu38pr6	1216	20	chronic	chronic	JJ
cord-005478-5iu38pr6	1216	21	phase	phase	NN
cord-005478-5iu38pr6	1216	22	.	.	.
cord-005478-5iu38pr6	1217	1	However	however	RB
cord-005478-5iu38pr6	1217	2	,	,	,
cord-005478-5iu38pr6	1217	3	such	such	JJ
cord-005478-5iu38pr6	1217	4	approach	approach	NN
cord-005478-5iu38pr6	1217	5	in	in	IN
cord-005478-5iu38pr6	1217	6	patients	patient	NNS
cord-005478-5iu38pr6	1217	7	who	who	WP
cord-005478-5iu38pr6	1217	8	transform	transform	VBP
cord-005478-5iu38pr6	1217	9	to	to	IN
cord-005478-5iu38pr6	1217	10	advanced	advanced	JJ
cord-005478-5iu38pr6	1217	11	phases	phase	NNS
cord-005478-5iu38pr6	1217	12	before	before	IN
cord-005478-5iu38pr6	1217	13	allo	allo	NN
cord-005478-5iu38pr6	1217	14	-	-	HYPH
cord-005478-5iu38pr6	1217	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1217	16	remains	remain	VBZ
cord-005478-5iu38pr6	1217	17	a	a	DT
cord-005478-5iu38pr6	1217	18	matter	matter	NN
cord-005478-5iu38pr6	1217	19	of	of	IN
cord-005478-5iu38pr6	1217	20	concerns	concern	NNS
cord-005478-5iu38pr6	1217	21	given	give	VBN
cord-005478-5iu38pr6	1217	22	the	the	DT
cord-005478-5iu38pr6	1217	23	high	high	JJ
cord-005478-5iu38pr6	1217	24	incidence	incidence	NN
cord-005478-5iu38pr6	1217	25	of	of	IN
cord-005478-5iu38pr6	1217	26	post	post	FW
cord-005478-5iu38pr6	1217	27	allo	allo	NN
cord-005478-5iu38pr6	1217	28	-	-	HYPH
cord-005478-5iu38pr6	1217	29	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1217	30	relapse	relapse	NN
cord-005478-5iu38pr6	1217	31	.	.	.
cord-005478-5iu38pr6	1218	1	Further	further	JJ
cord-005478-5iu38pr6	1218	2	analysis	analysis	NN
cord-005478-5iu38pr6	1218	3	to	to	TO
cord-005478-5iu38pr6	1218	4	identify	identify	VB
cord-005478-5iu38pr6	1218	5	reason	reason	NN
cord-005478-5iu38pr6	1218	6	for	for	IN
cord-005478-5iu38pr6	1218	7	restating	restate	VBG
cord-005478-5iu38pr6	1218	8	TKI	TKI	NNP
cord-005478-5iu38pr6	1218	9	post	post	JJ
cord-005478-5iu38pr6	1218	10	-	-	NN
cord-005478-5iu38pr6	1218	11	transplant	transplant	NN
cord-005478-5iu38pr6	1218	12	and	and	CC
cord-005478-5iu38pr6	1218	13	for	for	IN
cord-005478-5iu38pr6	1218	14	subsequent	subsequent	JJ
cord-005478-5iu38pr6	1218	15	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	1218	16	will	will	MD
cord-005478-5iu38pr6	1218	17	be	be	VB
cord-005478-5iu38pr6	1218	18	performed	perform	VBN
cord-005478-5iu38pr6	1218	19	after	after	IN
cord-005478-5iu38pr6	1218	20	further	further	JJ
cord-005478-5iu38pr6	1218	21	data	data	NN
cord-005478-5iu38pr6	1218	22	is	be	VBZ
cord-005478-5iu38pr6	1218	23	collected	collect	VBN
cord-005478-5iu38pr6	1218	24	through	through	IN
cord-005478-5iu38pr6	1218	25	the	the	DT
cord-005478-5iu38pr6	1218	26	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1218	27	Data	Data	NNP
cord-005478-5iu38pr6	1218	28	Quality	Quality	NNP
cord-005478-5iu38pr6	1218	29	Initiative	Initiative	NNP
cord-005478-5iu38pr6	1218	30	(	(	-LRB-
cord-005478-5iu38pr6	1218	31	DQI	DQI	NNP
cord-005478-5iu38pr6	1218	32	)	)	-RRB-
cord-005478-5iu38pr6	1218	33	in	in	IN
cord-005478-5iu38pr6	1218	34	CML	CML	NNP
cord-005478-5iu38pr6	1218	35	.	.	.
cord-005478-5iu38pr6	1219	1	[	[	-LRB-
cord-005478-5iu38pr6	1219	2	Background	background	NN
cord-005478-5iu38pr6	1219	3	:	:	:
cord-005478-5iu38pr6	1219	4	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1219	5	stem	stem	NN
cord-005478-5iu38pr6	1219	6	-	-	HYPH
cord-005478-5iu38pr6	1219	7	cell	cell	NN
cord-005478-5iu38pr6	1219	8	transplantation	transplantation	NN
cord-005478-5iu38pr6	1219	9	(	(	-LRB-
cord-005478-5iu38pr6	1219	10	allo	allo	FW
cord-005478-5iu38pr6	1219	11	-	-	HYPH
cord-005478-5iu38pr6	1219	12	SCT	SCT	NNP
cord-005478-5iu38pr6	1219	13	)	)	-RRB-
cord-005478-5iu38pr6	1219	14	is	be	VBZ
cord-005478-5iu38pr6	1219	15	a	a	DT
cord-005478-5iu38pr6	1219	16	well	well	RB
cord-005478-5iu38pr6	1219	17	-	-	HYPH
cord-005478-5iu38pr6	1219	18	established	establish	VBN
cord-005478-5iu38pr6	1219	19	treatment	treatment	NN
cord-005478-5iu38pr6	1219	20	modality	modality	NN
cord-005478-5iu38pr6	1219	21	for	for	IN
cord-005478-5iu38pr6	1219	22	high	high	JJ
cord-005478-5iu38pr6	1219	23	-	-	HYPH
cord-005478-5iu38pr6	1219	24	risk	risk	NN
cord-005478-5iu38pr6	1219	25	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1219	26	malignancies	malignancy	NNS
cord-005478-5iu38pr6	1219	27	.	.	.
cord-005478-5iu38pr6	1220	1	However	however	RB
cord-005478-5iu38pr6	1220	2	,	,	,
cord-005478-5iu38pr6	1220	3	the	the	DT
cord-005478-5iu38pr6	1220	4	optimal	optimal	JJ
cord-005478-5iu38pr6	1220	5	intensity	intensity	NN
cord-005478-5iu38pr6	1220	6	of	of	IN
cord-005478-5iu38pr6	1220	7	myeloablation	myeloablation	NN
cord-005478-5iu38pr6	1220	8	with	with	IN
cord-005478-5iu38pr6	1220	9	a	a	DT
cord-005478-5iu38pr6	1220	10	reduced	reduce	VBN
cord-005478-5iu38pr6	1220	11	-	-	HYPH
cord-005478-5iu38pr6	1220	12	toxicity	toxicity	NN
cord-005478-5iu38pr6	1220	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	1220	14	regimen	regimen	NN
cord-005478-5iu38pr6	1220	15	to	to	TO
cord-005478-5iu38pr6	1220	16	decrease	decrease	VB
cord-005478-5iu38pr6	1220	17	relapse	relapse	NN
cord-005478-5iu38pr6	1220	18	rate	rate	NN
cord-005478-5iu38pr6	1220	19	after	after	IN
cord-005478-5iu38pr6	1220	20	allo	allo	NN
cord-005478-5iu38pr6	1220	21	-	-	HYPH
cord-005478-5iu38pr6	1220	22	SCT	SCT	NNP
cord-005478-5iu38pr6	1220	23	without	without	IN
cord-005478-5iu38pr6	1220	24	increasing	increase	VBG
cord-005478-5iu38pr6	1220	25	TRM	TRM	NNP
cord-005478-5iu38pr6	1220	26	has	have	VBZ
cord-005478-5iu38pr6	1220	27	not	not	RB
cord-005478-5iu38pr6	1220	28	been	be	VBN
cord-005478-5iu38pr6	1220	29	well	well	RB
cord-005478-5iu38pr6	1220	30	established	establish	VBN
cord-005478-5iu38pr6	1220	31	.	.	.
cord-005478-5iu38pr6	1221	1	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1221	2	is	be	VBZ
cord-005478-5iu38pr6	1221	3	an	an	DT
cord-005478-5iu38pr6	1221	4	alkylating	alkylating	JJ
cord-005478-5iu38pr6	1221	5	compound	compound	NN
cord-005478-5iu38pr6	1221	6	with	with	IN
cord-005478-5iu38pr6	1221	7	antineoplastic	antineoplastic	JJ
cord-005478-5iu38pr6	1221	8	activity	activity	NN
cord-005478-5iu38pr6	1221	9	and	and	CC
cord-005478-5iu38pr6	1221	10	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	1221	11	properties	property	NNS
cord-005478-5iu38pr6	1221	12	,	,	,
cord-005478-5iu38pr6	1221	13	as	as	RB
cord-005478-5iu38pr6	1221	14	well	well	RB
cord-005478-5iu38pr6	1221	15	as	as	IN
cord-005478-5iu38pr6	1221	16	the	the	DT
cord-005478-5iu38pr6	1221	17	ability	ability	NN
cord-005478-5iu38pr6	1221	18	to	to	TO
cord-005478-5iu38pr6	1221	19	penetrate	penetrate	VB
cord-005478-5iu38pr6	1221	20	the	the	DT
cord-005478-5iu38pr6	1221	21	blood	blood	NN
cord-005478-5iu38pr6	1221	22	brain	brain	NN
cord-005478-5iu38pr6	1221	23	barrier	barrier	NN
cord-005478-5iu38pr6	1221	24	.	.	.
cord-005478-5iu38pr6	1222	1	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1222	2	has	have	VBZ
cord-005478-5iu38pr6	1222	3	become	become	VBN
cord-005478-5iu38pr6	1222	4	an	an	DT
cord-005478-5iu38pr6	1222	5	integral	integral	JJ
cord-005478-5iu38pr6	1222	6	part	part	NN
cord-005478-5iu38pr6	1222	7	of	of	IN
cord-005478-5iu38pr6	1222	8	the	the	DT
cord-005478-5iu38pr6	1222	9	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1222	10	,	,	,
cord-005478-5iu38pr6	1222	11	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	1222	12	iv	iv	NNP
cord-005478-5iu38pr6	1222	13	(	(	-LRB-
cord-005478-5iu38pr6	1222	14	Busilvex	Busilvex	NNP
cord-005478-5iu38pr6	1222	15	)	)	-RRB-
cord-005478-5iu38pr6	1222	16	,	,	,
cord-005478-5iu38pr6	1222	17	and	and	CC
cord-005478-5iu38pr6	1222	18	fludarabine	fludarabine	NNP
cord-005478-5iu38pr6	1222	19	(	(	-LRB-
cord-005478-5iu38pr6	1222	20	TBF	tbf	NN
cord-005478-5iu38pr6	1222	21	)	)	-RRB-
cord-005478-5iu38pr6	1222	22	conditioning	conditioning	NN
cord-005478-5iu38pr6	1222	23	regimen	regimen	NN
cord-005478-5iu38pr6	1222	24	,	,	,
cord-005478-5iu38pr6	1222	25	which	which	WDT
cord-005478-5iu38pr6	1222	26	is	be	VBZ
cord-005478-5iu38pr6	1222	27	being	be	VBG
cord-005478-5iu38pr6	1222	28	used	use	VBN
cord-005478-5iu38pr6	1222	29	with	with	IN
cord-005478-5iu38pr6	1222	30	increasing	increase	VBG
cord-005478-5iu38pr6	1222	31	frequency	frequency	NN
cord-005478-5iu38pr6	1222	32	,	,	,
cord-005478-5iu38pr6	1222	33	particularly	particularly	RB
cord-005478-5iu38pr6	1222	34	for	for	IN
cord-005478-5iu38pr6	1222	35	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	1222	36	and	and	CC
cord-005478-5iu38pr6	1222	37	cord	cord	NN
cord-005478-5iu38pr6	1222	38	-	-	HYPH
cord-005478-5iu38pr6	1222	39	blood	blood	NN
cord-005478-5iu38pr6	1222	40	transplants	transplant	NNS
cord-005478-5iu38pr6	1222	41	.	.	.
cord-005478-5iu38pr6	1223	1	However	however	RB
cord-005478-5iu38pr6	1223	2	,	,	,
cord-005478-5iu38pr6	1223	3	few	few	JJ
cord-005478-5iu38pr6	1223	4	studies	study	NNS
cord-005478-5iu38pr6	1223	5	have	have	VBP
cord-005478-5iu38pr6	1223	6	focused	focus	VBN
cord-005478-5iu38pr6	1223	7	on	on	IN
cord-005478-5iu38pr6	1223	8	analyzing	analyze	VBG
cord-005478-5iu38pr6	1223	9	the	the	DT
cord-005478-5iu38pr6	1223	10	effect	effect	NN
cord-005478-5iu38pr6	1223	11	of	of	IN
cord-005478-5iu38pr6	1223	12	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1223	13	dose	dose	NN
cord-005478-5iu38pr6	1223	14	in	in	IN
cord-005478-5iu38pr6	1223	15	the	the	DT
cord-005478-5iu38pr6	1223	16	TBF	tbf	NN
cord-005478-5iu38pr6	1223	17	conditioning	conditioning	NN
cord-005478-5iu38pr6	1223	18	.	.	.
cord-005478-5iu38pr6	1224	1	Methods	method	NNS
cord-005478-5iu38pr6	1224	2	:	:	:
cord-005478-5iu38pr6	1225	1	The	the	DT
cord-005478-5iu38pr6	1225	2	aim	aim	NN
cord-005478-5iu38pr6	1225	3	of	of	IN
cord-005478-5iu38pr6	1225	4	this	this	DT
cord-005478-5iu38pr6	1225	5	study	study	NN
cord-005478-5iu38pr6	1225	6	was	be	VBD
cord-005478-5iu38pr6	1225	7	to	to	TO
cord-005478-5iu38pr6	1225	8	evaluate	evaluate	VB
cord-005478-5iu38pr6	1225	9	the	the	DT
cord-005478-5iu38pr6	1225	10	optimal	optimal	JJ
cord-005478-5iu38pr6	1225	11	dose	dose	NN
cord-005478-5iu38pr6	1225	12	of	of	IN
cord-005478-5iu38pr6	1225	13	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1225	14	,	,	,
cord-005478-5iu38pr6	1225	15	as	as	IN
cord-005478-5iu38pr6	1225	16	part	part	NN
cord-005478-5iu38pr6	1225	17	of	of	IN
cord-005478-5iu38pr6	1225	18	the	the	DT
cord-005478-5iu38pr6	1225	19	TBF	tbf	NN
cord-005478-5iu38pr6	1225	20	conditioning	conditioning	NN
cord-005478-5iu38pr6	1225	21	for	for	IN
cord-005478-5iu38pr6	1225	22	allo	allo	NN
cord-005478-5iu38pr6	1225	23	-	-	HYPH
cord-005478-5iu38pr6	1225	24	SCT	sct	NN
cord-005478-5iu38pr6	1225	25	in	in	IN
cord-005478-5iu38pr6	1225	26	adults	adult	NNS
cord-005478-5iu38pr6	1225	27	with	with	IN
cord-005478-5iu38pr6	1225	28	AML	AML	NNP
cord-005478-5iu38pr6	1225	29	transplanted	transplant	VBN
cord-005478-5iu38pr6	1225	30	in	in	IN
cord-005478-5iu38pr6	1225	31	complete	complete	JJ
cord-005478-5iu38pr6	1225	32	remission	remission	NN
cord-005478-5iu38pr6	1225	33	(	(	-LRB-
cord-005478-5iu38pr6	1225	34	CR	CR	NNP
cord-005478-5iu38pr6	1225	35	)	)	-RRB-
cord-005478-5iu38pr6	1225	36	,	,	,
cord-005478-5iu38pr6	1225	37	by	by	IN
cord-005478-5iu38pr6	1225	38	comparing	compare	VBG
cord-005478-5iu38pr6	1225	39	the	the	DT
cord-005478-5iu38pr6	1225	40	transplantation	transplantation	NN
cord-005478-5iu38pr6	1225	41	outcomes	outcome	NNS
cord-005478-5iu38pr6	1225	42	of	of	IN
cord-005478-5iu38pr6	1225	43	patients	patient	NNS
cord-005478-5iu38pr6	1225	44	who	who	WP
cord-005478-5iu38pr6	1225	45	received	receive	VBD
cord-005478-5iu38pr6	1225	46	5	5	CD
cord-005478-5iu38pr6	1225	47	mg	mg	NNP
cord-005478-5iu38pr6	1225	48	/	/	SYM
cord-005478-5iu38pr6	1225	49	kg	kg	NNP
cord-005478-5iu38pr6	1225	50	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1225	51	and	and	CC
cord-005478-5iu38pr6	1225	52	2	2	CD
cord-005478-5iu38pr6	1225	53	days	day	NNS
cord-005478-5iu38pr6	1225	54	of	of	IN
cord-005478-5iu38pr6	1225	55	Busilvex	Busilvex	NNP
cord-005478-5iu38pr6	1225	56	(	(	-LRB-
cord-005478-5iu38pr6	1225	57	6.4	6.4	CD
cord-005478-5iu38pr6	1225	58	mg	mg	NNP
cord-005478-5iu38pr6	1225	59	/	/	SYM
cord-005478-5iu38pr6	1225	60	kg	kg	NNP
cord-005478-5iu38pr6	1225	61	)	)	-RRB-
cord-005478-5iu38pr6	1226	1	(	(	-LRB-
cord-005478-5iu38pr6	1226	2	T1B2F	t1b2f	NN
cord-005478-5iu38pr6	1226	3	)	)	-RRB-
cord-005478-5iu38pr6	1226	4	versus	versus	IN
cord-005478-5iu38pr6	1226	5	those	those	DT
cord-005478-5iu38pr6	1226	6	who	who	WP
cord-005478-5iu38pr6	1226	7	received	receive	VBD
cord-005478-5iu38pr6	1226	8	10	10	CD
cord-005478-5iu38pr6	1226	9	mg	mg	NNP
cord-005478-5iu38pr6	1226	10	/	/	SYM
cord-005478-5iu38pr6	1226	11	kg	kg	NNP
cord-005478-5iu38pr6	1226	12	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1226	13	with	with	IN
cord-005478-5iu38pr6	1226	14	2	2	CD
cord-005478-5iu38pr6	1226	15	days	day	NNS
cord-005478-5iu38pr6	1226	16	of	of	IN
cord-005478-5iu38pr6	1226	17	Busilvex	Busilvex	NNP
cord-005478-5iu38pr6	1226	18	(	(	-LRB-
cord-005478-5iu38pr6	1226	19	T2B2F	T2B2F	NNP
cord-005478-5iu38pr6	1226	20	)	)	-RRB-
cord-005478-5iu38pr6	1226	21	or	or	CC
cord-005478-5iu38pr6	1226	22	3	3	CD
cord-005478-5iu38pr6	1226	23	days	day	NNS
cord-005478-5iu38pr6	1226	24	of	of	IN
cord-005478-5iu38pr6	1226	25	Busilvex	Busilvex	NNP
cord-005478-5iu38pr6	1226	26	(	(	-LRB-
cord-005478-5iu38pr6	1226	27	9.6	9.6	CD
cord-005478-5iu38pr6	1226	28	mg	mg	NNP
cord-005478-5iu38pr6	1226	29	/	/	SYM
cord-005478-5iu38pr6	1226	30	kg	kg	NNP
cord-005478-5iu38pr6	1226	31	)	)	-RRB-
cord-005478-5iu38pr6	1227	1	(	(	-LRB-
cord-005478-5iu38pr6	1227	2	T2B3F	T2B3F	NNP
cord-005478-5iu38pr6	1227	3	)	)	-RRB-
cord-005478-5iu38pr6	1227	4	using	use	VBG
cord-005478-5iu38pr6	1227	5	a	a	DT
cord-005478-5iu38pr6	1227	6	large	large	JJ
cord-005478-5iu38pr6	1227	7	dataset	dataset	NN
cord-005478-5iu38pr6	1227	8	from	from	IN
cord-005478-5iu38pr6	1227	9	the	the	DT
cord-005478-5iu38pr6	1227	10	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1227	11	registry	registry	NN
cord-005478-5iu38pr6	1227	12	.	.	.
cord-005478-5iu38pr6	1228	1	Results	result	NNS
cord-005478-5iu38pr6	1228	2	:	:	:
cord-005478-5iu38pr6	1229	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1229	2	identified	identify	VBD
cord-005478-5iu38pr6	1229	3	639	639	CD
cord-005478-5iu38pr6	1229	4	AML	AML	NNP
cord-005478-5iu38pr6	1229	5	patients	patient	NNS
cord-005478-5iu38pr6	1229	6	allotransplanted	allotransplante	VBN
cord-005478-5iu38pr6	1229	7	between	between	IN
cord-005478-5iu38pr6	1229	8	January	January	NNP
cord-005478-5iu38pr6	1229	9	2009	2009	CD
cord-005478-5iu38pr6	1229	10	and	and	CC
cord-005478-5iu38pr6	1229	11	June	June	NNP
cord-005478-5iu38pr6	1229	12	2018	2018	CD
cord-005478-5iu38pr6	1229	13	from	from	IN
cord-005478-5iu38pr6	1229	14	matched	match	VBN
cord-005478-5iu38pr6	1229	15	related	related	JJ
cord-005478-5iu38pr6	1229	16	or	or	CC
cord-005478-5iu38pr6	1229	17	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1229	18	donors	donor	NNS
cord-005478-5iu38pr6	1229	19	or	or	CC
cord-005478-5iu38pr6	1229	20	T	t	NN
cord-005478-5iu38pr6	1229	21	replete	replete	JJ
cord-005478-5iu38pr6	1229	22	haplo	haplo	NN
cord-005478-5iu38pr6	1229	23	-	-	HYPH
cord-005478-5iu38pr6	1229	24	identical	identical	JJ
cord-005478-5iu38pr6	1229	25	donors	donor	NNS
cord-005478-5iu38pr6	1229	26	.	.	.
cord-005478-5iu38pr6	1230	1	127	127	CD
cord-005478-5iu38pr6	1230	2	patients	patient	NNS
cord-005478-5iu38pr6	1230	3	(	(	-LRB-
cord-005478-5iu38pr6	1230	4	20	20	CD
cord-005478-5iu38pr6	1230	5	%	%	NN
cord-005478-5iu38pr6	1230	6	)	)	-RRB-
cord-005478-5iu38pr6	1230	7	received	receive	VBN
cord-005478-5iu38pr6	1230	8	(	(	-LRB-
cord-005478-5iu38pr6	1230	9	T1B2F	t1b2f	NN
cord-005478-5iu38pr6	1230	10	)	)	-RRB-
cord-005478-5iu38pr6	1230	11	;	;	:
cord-005478-5iu38pr6	1230	12	113	113	CD
cord-005478-5iu38pr6	1230	13	patients	patient	NNS
cord-005478-5iu38pr6	1230	14	(	(	-LRB-
cord-005478-5iu38pr6	1230	15	18	18	CD
cord-005478-5iu38pr6	1230	16	%	%	NN
cord-005478-5iu38pr6	1230	17	)	)	-RRB-
cord-005478-5iu38pr6	1230	18	received	receive	VBN
cord-005478-5iu38pr6	1230	19	(	(	-LRB-
cord-005478-5iu38pr6	1230	20	T2B2F	t2b2f	NN
cord-005478-5iu38pr6	1230	21	)	)	-RRB-
cord-005478-5iu38pr6	1230	22	;	;	:
cord-005478-5iu38pr6	1230	23	the	the	DT
cord-005478-5iu38pr6	1230	24	remaining	remain	VBG
cord-005478-5iu38pr6	1230	25	399	399	CD
cord-005478-5iu38pr6	1230	26	patients	patient	NNS
cord-005478-5iu38pr6	1230	27	(	(	-LRB-
cord-005478-5iu38pr6	1230	28	62	62	CD
cord-005478-5iu38pr6	1230	29	%	%	NN
cord-005478-5iu38pr6	1230	30	)	)	-RRB-
cord-005478-5iu38pr6	1230	31	received	receive	VBD
cord-005478-5iu38pr6	1230	32	(	(	-LRB-
cord-005478-5iu38pr6	1230	33	T2B3F	T2B3F	NNP
cord-005478-5iu38pr6	1230	34	)	)	-RRB-
cord-005478-5iu38pr6	1230	35	.	.	.
cord-005478-5iu38pr6	1231	1	all	all	PDT
cord-005478-5iu38pr6	1231	2	the	the	DT
cord-005478-5iu38pr6	1231	3	patients	patient	NNS
cord-005478-5iu38pr6	1231	4	were	be	VBD
cord-005478-5iu38pr6	1231	5	in	in	IN
cord-005478-5iu38pr6	1231	6	CR	CR	NNP
cord-005478-5iu38pr6	1231	7	at	at	IN
cord-005478-5iu38pr6	1231	8	transplant	transplant	NN
cord-005478-5iu38pr6	1231	9	.	.	.
cord-005478-5iu38pr6	1232	1	Median	median	JJ
cord-005478-5iu38pr6	1232	2	follow	follow	NN
cord-005478-5iu38pr6	1232	3	-	-	HYPH
cord-005478-5iu38pr6	1232	4	up	up	NN
cord-005478-5iu38pr6	1232	5	was	be	VBD
cord-005478-5iu38pr6	1232	6	20	20	CD
cord-005478-5iu38pr6	1232	7	months	month	NNS
cord-005478-5iu38pr6	1233	1	(	(	-LRB-
cord-005478-5iu38pr6	1233	2	IQR	IQR	NNP
cord-005478-5iu38pr6	1233	3	:	:	:
cord-005478-5iu38pr6	1233	4	9	9	CD
cord-005478-5iu38pr6	1233	5	-	-	SYM
cord-005478-5iu38pr6	1233	6	37	37	CD
cord-005478-5iu38pr6	1233	7	)	)	-RRB-
cord-005478-5iu38pr6	1233	8	.	.	.
cord-005478-5iu38pr6	1234	1	Outcomes	outcome	NNS
cord-005478-5iu38pr6	1234	2	are	be	VBP
cord-005478-5iu38pr6	1234	3	summarized	summarize	VBN
cord-005478-5iu38pr6	1234	4	in	in	IN
cord-005478-5iu38pr6	1234	5	the	the	DT
cord-005478-5iu38pr6	1234	6	table	table	NN
cord-005478-5iu38pr6	1234	7	1	1	CD
cord-005478-5iu38pr6	1234	8	.	.	.
cord-005478-5iu38pr6	1235	1	Acute	acute	JJ
cord-005478-5iu38pr6	1235	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1235	3	grade	grade	NN
cord-005478-5iu38pr6	1235	4	II	II	NNP
cord-005478-5iu38pr6	1235	5	-	-	HYPH
cord-005478-5iu38pr6	1235	6	IV	IV	NNP
cord-005478-5iu38pr6	1235	7	was	be	VBD
cord-005478-5iu38pr6	1235	8	15	15	CD
cord-005478-5iu38pr6	1235	9	%	%	NN
cord-005478-5iu38pr6	1235	10	,	,	,
cord-005478-5iu38pr6	1235	11	17	17	CD
cord-005478-5iu38pr6	1235	12	%	%	NN
cord-005478-5iu38pr6	1235	13	and	and	CC
cord-005478-5iu38pr6	1235	14	19	19	CD
cord-005478-5iu38pr6	1235	15	%	%	NN
cord-005478-5iu38pr6	1235	16	(	(	-LRB-
cord-005478-5iu38pr6	1235	17	p=0.14	p=0.14	NNP
cord-005478-5iu38pr6	1235	18	)	)	-RRB-
cord-005478-5iu38pr6	1235	19	respectively	respectively	RB
cord-005478-5iu38pr6	1235	20	.	.	.
cord-005478-5iu38pr6	1236	1	At	at	IN
cord-005478-5iu38pr6	1236	2	2	2	CD
cord-005478-5iu38pr6	1236	3	years	year	NNS
cord-005478-5iu38pr6	1236	4	the	the	DT
cord-005478-5iu38pr6	1236	5	non	non	JJ
cord-005478-5iu38pr6	1236	6	-	-	JJ
cord-005478-5iu38pr6	1236	7	relapse	relapse	JJ
cord-005478-5iu38pr6	1236	8	mortality	mortality	NN
cord-005478-5iu38pr6	1236	9	(	(	-LRB-
cord-005478-5iu38pr6	1236	10	NRM	NRM	NNP
cord-005478-5iu38pr6	1236	11	)	)	-RRB-
cord-005478-5iu38pr6	1236	12	was	be	VBD
cord-005478-5iu38pr6	1236	13	22	22	CD
cord-005478-5iu38pr6	1236	14	%	%	NN
cord-005478-5iu38pr6	1236	15	,	,	,
cord-005478-5iu38pr6	1236	16	25	25	CD
cord-005478-5iu38pr6	1236	17	%	%	NN
cord-005478-5iu38pr6	1236	18	and	and	CC
cord-005478-5iu38pr6	1236	19	21	21	CD
cord-005478-5iu38pr6	1236	20	%	%	NN
cord-005478-5iu38pr6	1236	21	respectively	respectively	RB
cord-005478-5iu38pr6	1236	22	(	(	-LRB-
cord-005478-5iu38pr6	1236	23	p=0.62	p=0.62	NN
cord-005478-5iu38pr6	1236	24	)	)	-RRB-
cord-005478-5iu38pr6	1236	25	;	;	:
cord-005478-5iu38pr6	1236	26	the	the	DT
cord-005478-5iu38pr6	1236	27	relapse	relapse	NN
cord-005478-5iu38pr6	1236	28	incidence	incidence	NN
cord-005478-5iu38pr6	1236	29	(	(	-LRB-
cord-005478-5iu38pr6	1236	30	RI	RI	NNP
cord-005478-5iu38pr6	1236	31	)	)	-RRB-
cord-005478-5iu38pr6	1236	32	was	be	VBD
cord-005478-5iu38pr6	1236	33	18	18	CD
cord-005478-5iu38pr6	1236	34	%	%	NN
cord-005478-5iu38pr6	1236	35	,	,	,
cord-005478-5iu38pr6	1236	36	19	19	CD
cord-005478-5iu38pr6	1236	37	%	%	NN
cord-005478-5iu38pr6	1236	38	and	and	CC
cord-005478-5iu38pr6	1236	39	17	17	CD
cord-005478-5iu38pr6	1236	40	%	%	NN
cord-005478-5iu38pr6	1236	41	(	(	-LRB-
cord-005478-5iu38pr6	1236	42	p=0.37	p=0.37	NNP
cord-005478-5iu38pr6	1236	43	)	)	-RRB-
cord-005478-5iu38pr6	1236	44	respectively	respectively	RB
cord-005478-5iu38pr6	1236	45	;	;	:
cord-005478-5iu38pr6	1236	46	the	the	DT
cord-005478-5iu38pr6	1236	47	leukemia	leukemia	NN
cord-005478-5iu38pr6	1236	48	free	free	JJ
cord-005478-5iu38pr6	1236	49	survival	survival	NN
cord-005478-5iu38pr6	1236	50	(	(	-LRB-
cord-005478-5iu38pr6	1236	51	LFS	LFS	NNP
cord-005478-5iu38pr6	1236	52	)	)	-RRB-
cord-005478-5iu38pr6	1236	53	was	be	VBD
cord-005478-5iu38pr6	1236	54	60	60	CD
cord-005478-5iu38pr6	1236	55	%	%	NN
cord-005478-5iu38pr6	1236	56	vs	vs	IN
cord-005478-5iu38pr6	1236	57	56	56	CD
cord-005478-5iu38pr6	1236	58	%	%	NN
cord-005478-5iu38pr6	1236	59	vs	vs	IN
cord-005478-5iu38pr6	1236	60	63	63	CD
cord-005478-5iu38pr6	1236	61	%	%	NN
cord-005478-5iu38pr6	1236	62	(	(	-LRB-
cord-005478-5iu38pr6	1236	63	p=0.21	p=0.21	NN
cord-005478-5iu38pr6	1236	64	)	)	-RRB-
cord-005478-5iu38pr6	1236	65	respectively	respectively	RB
cord-005478-5iu38pr6	1236	66	and	and	CC
cord-005478-5iu38pr6	1236	67	the	the	DT
cord-005478-5iu38pr6	1236	68	overall	overall	JJ
cord-005478-5iu38pr6	1236	69	survival	survival	NN
cord-005478-5iu38pr6	1236	70	(	(	-LRB-
cord-005478-5iu38pr6	1236	71	OS	OS	NNP
cord-005478-5iu38pr6	1236	72	)	)	-RRB-
cord-005478-5iu38pr6	1236	73	was	be	VBD
cord-005478-5iu38pr6	1236	74	67	67	CD
cord-005478-5iu38pr6	1236	75	%	%	NN
cord-005478-5iu38pr6	1236	76	vs	vs	IN
cord-005478-5iu38pr6	1236	77	62	62	CD
cord-005478-5iu38pr6	1236	78	%	%	NN
cord-005478-5iu38pr6	1236	79	vs	vs	IN
cord-005478-5iu38pr6	1236	80	67	67	CD
cord-005478-5iu38pr6	1236	81	%	%	NN
cord-005478-5iu38pr6	1236	82	(	(	-LRB-
cord-005478-5iu38pr6	1236	83	p=0.56	p=0.56	NNP
cord-005478-5iu38pr6	1236	84	)	)	-RRB-
cord-005478-5iu38pr6	1236	85	in	in	IN
cord-005478-5iu38pr6	1236	86	the	the	DT
cord-005478-5iu38pr6	1236	87	3	3	CD
cord-005478-5iu38pr6	1236	88	groups	group	NNS
cord-005478-5iu38pr6	1236	89	,	,	,
cord-005478-5iu38pr6	1236	90	respectively	respectively	RB
cord-005478-5iu38pr6	1236	91	.	.	.
cord-005478-5iu38pr6	1237	1	the	the	DT
cord-005478-5iu38pr6	1237	2	2year	2year	JJ
cord-005478-5iu38pr6	1237	3	GRFS	GRFS	NNP
cord-005478-5iu38pr6	1237	4	was	be	VBD
cord-005478-5iu38pr6	1237	5	50	50	CD
cord-005478-5iu38pr6	1237	6	%	%	NN
cord-005478-5iu38pr6	1237	7	,	,	,
cord-005478-5iu38pr6	1237	8	43	43	CD
cord-005478-5iu38pr6	1237	9	%	%	NN
cord-005478-5iu38pr6	1237	10	,	,	,
cord-005478-5iu38pr6	1237	11	and	and	CC
cord-005478-5iu38pr6	1237	12	55	55	CD
cord-005478-5iu38pr6	1237	13	%	%	NN
cord-005478-5iu38pr6	1237	14	respectively	respectively	RB
cord-005478-5iu38pr6	1237	15	(	(	-LRB-
cord-005478-5iu38pr6	1237	16	p=0.02	p=0.02	NN
cord-005478-5iu38pr6	1237	17	)	)	-RRB-
cord-005478-5iu38pr6	1237	18	.	.	.
cord-005478-5iu38pr6	1238	1	In	in	IN
cord-005478-5iu38pr6	1238	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1238	3	analysis	analysis	NN
cord-005478-5iu38pr6	1238	4	,	,	,
cord-005478-5iu38pr6	1238	5	acute	acute	JJ
cord-005478-5iu38pr6	1238	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1238	7	was	be	VBD
cord-005478-5iu38pr6	1238	8	higher	high	JJR
cord-005478-5iu38pr6	1238	9	for	for	IN
cord-005478-5iu38pr6	1238	10	patients	patient	NNS
cord-005478-5iu38pr6	1238	11	receiving	receive	VBG
cord-005478-5iu38pr6	1238	12	T2B2F	t2b2f	NN
cord-005478-5iu38pr6	1238	13	(	(	-LRB-
cord-005478-5iu38pr6	1238	14	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	1238	15	;	;	:
cord-005478-5iu38pr6	1238	16	HR	HR	NNP
cord-005478-5iu38pr6	1238	17	2.25	2.25	CD
cord-005478-5iu38pr6	1238	18	)	)	-RRB-
cord-005478-5iu38pr6	1238	19	or	or	CC
cord-005478-5iu38pr6	1238	20	T2B3F	T2B3F	NNP
cord-005478-5iu38pr6	1238	21	(	(	-LRB-
cord-005478-5iu38pr6	1238	22	p=0.02	p=0.02	NN
cord-005478-5iu38pr6	1238	23	;	;	:
cord-005478-5iu38pr6	1238	24	HR	HR	NNP
cord-005478-5iu38pr6	1238	25	2.05	2.05	CD
cord-005478-5iu38pr6	1238	26	)	)	-RRB-
cord-005478-5iu38pr6	1238	27	as	as	RB
cord-005478-5iu38pr6	1238	28	well	well	RB
cord-005478-5iu38pr6	1238	29	as	as	IN
cord-005478-5iu38pr6	1238	30	for	for	IN
cord-005478-5iu38pr6	1238	31	patients	patient	NNS
cord-005478-5iu38pr6	1238	32	receiving	receive	VBG
cord-005478-5iu38pr6	1238	33	transplant	transplant	NN
cord-005478-5iu38pr6	1238	34	from	from	IN
cord-005478-5iu38pr6	1238	35	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	1238	36	donor	donor	NN
cord-005478-5iu38pr6	1238	37	or	or	CC
cord-005478-5iu38pr6	1238	38	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1238	39	blood	blood	NN
cord-005478-5iu38pr6	1238	40	stem	stem	NN
cord-005478-5iu38pr6	1238	41	cells	cell	NNS
cord-005478-5iu38pr6	1238	42	,	,	,
cord-005478-5iu38pr6	1238	43	whereas	whereas	IN
cord-005478-5iu38pr6	1238	44	NRM	NRM	NNP
cord-005478-5iu38pr6	1238	45	was	be	VBD
cord-005478-5iu38pr6	1238	46	higher	high	JJR
cord-005478-5iu38pr6	1238	47	for	for	IN
cord-005478-5iu38pr6	1238	48	older	old	JJR
cord-005478-5iu38pr6	1238	49	patients	patient	NNS
cord-005478-5iu38pr6	1238	50	(	(	-LRB-
cord-005478-5iu38pr6	1238	51	p=0.001	p=0.001	NNS
cord-005478-5iu38pr6	1238	52	;	;	:
cord-005478-5iu38pr6	1238	53	HR	HR	NNP
cord-005478-5iu38pr6	1238	54	1.56	1.56	CD
cord-005478-5iu38pr6	1238	55	)	)	-RRB-
cord-005478-5iu38pr6	1238	56	,	,	,
cord-005478-5iu38pr6	1238	57	patients	patient	NNS
cord-005478-5iu38pr6	1238	58	receiving	receive	VBG
cord-005478-5iu38pr6	1238	59	T2B3F	T2B3F	NNP
cord-005478-5iu38pr6	1238	60	(	(	-LRB-
cord-005478-5iu38pr6	1238	61	p=0.008	p=0.008	NNP
cord-005478-5iu38pr6	1238	62	;	;	:
cord-005478-5iu38pr6	1238	63	HR	HR	NNP
cord-005478-5iu38pr6	1238	64	2.28	2.28	CD
cord-005478-5iu38pr6	1238	65	)	)	-RRB-
cord-005478-5iu38pr6	1238	66	or	or	CC
cord-005478-5iu38pr6	1238	67	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	1238	68	transplant	transplant	NN
cord-005478-5iu38pr6	1239	1	(	(	-LRB-
cord-005478-5iu38pr6	1239	2	p=0.009	p=0.009	NN
cord-005478-5iu38pr6	1239	3	;	;	:
cord-005478-5iu38pr6	1239	4	HR	HR	NNP
cord-005478-5iu38pr6	1239	5	2.2	2.2	CD
cord-005478-5iu38pr6	1239	6	)	)	-RRB-
cord-005478-5iu38pr6	1239	7	.	.	.
cord-005478-5iu38pr6	1240	1	Importantly	importantly	RB
cord-005478-5iu38pr6	1240	2	,	,	,
cord-005478-5iu38pr6	1240	3	OS	OS	NNP
cord-005478-5iu38pr6	1240	4	was	be	VBD
cord-005478-5iu38pr6	1240	5	lower	low	JJR
cord-005478-5iu38pr6	1240	6	for	for	IN
cord-005478-5iu38pr6	1240	7	older	old	JJR
cord-005478-5iu38pr6	1240	8	patients	patient	NNS
cord-005478-5iu38pr6	1240	9	(	(	-LRB-
cord-005478-5iu38pr6	1240	10	p=0.001	p=0.001	NNS
cord-005478-5iu38pr6	1240	11	;	;	:
cord-005478-5iu38pr6	1240	12	HR	HR	NNP
cord-005478-5iu38pr6	1240	13	1.4	1.4	CD
cord-005478-5iu38pr6	1240	14	)	)	-RRB-
cord-005478-5iu38pr6	1240	15	or	or	CC
cord-005478-5iu38pr6	1240	16	for	for	IN
cord-005478-5iu38pr6	1240	17	patients	patient	NNS
cord-005478-5iu38pr6	1240	18	receiving	receive	VBG
cord-005478-5iu38pr6	1240	19	T2B3F	T2B3F	NNP
cord-005478-5iu38pr6	1241	1	(	(	-LRB-
cord-005478-5iu38pr6	1241	2	p=0.004	p=0.004	NNP
cord-005478-5iu38pr6	1241	3	;	;	:
cord-005478-5iu38pr6	1241	4	HR	HR	NNP
cord-005478-5iu38pr6	1241	5	2.09	2.09	CD
cord-005478-5iu38pr6	1241	6	)	)	-RRB-
cord-005478-5iu38pr6	1241	7	.	.	.
cord-005478-5iu38pr6	1242	1	the	the	DT
cord-005478-5iu38pr6	1242	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1242	3	analysis	analysis	NN
cord-005478-5iu38pr6	1242	4	was	be	VBD
cord-005478-5iu38pr6	1242	5	adjusted	adjust	VBN
cord-005478-5iu38pr6	1242	6	to	to	IN
cord-005478-5iu38pr6	1242	7	all	all	PDT
cord-005478-5iu38pr6	1242	8	the	the	DT
cord-005478-5iu38pr6	1242	9	different	different	JJ
cord-005478-5iu38pr6	1242	10	factors	factor	NNS
cord-005478-5iu38pr6	1242	11	between	between	IN
cord-005478-5iu38pr6	1242	12	the	the	DT
cord-005478-5iu38pr6	1242	13	3	3	CD
cord-005478-5iu38pr6	1242	14	groups	group	NNS
cord-005478-5iu38pr6	1242	15	.	.	.
cord-005478-5iu38pr6	1243	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1243	2	:	:	:
cord-005478-5iu38pr6	1244	1	T2B2F	T2B2F	NNP
cord-005478-5iu38pr6	1244	2	is	be	VBZ
cord-005478-5iu38pr6	1244	3	associated	associate	VBN
cord-005478-5iu38pr6	1244	4	with	with	IN
cord-005478-5iu38pr6	1244	5	higher	high	JJR
cord-005478-5iu38pr6	1244	6	incidence	incidence	NN
cord-005478-5iu38pr6	1244	7	of	of	IN
cord-005478-5iu38pr6	1244	8	acute	acute	JJ
cord-005478-5iu38pr6	1244	9	GVHD	gvhd	NN
cord-005478-5iu38pr6	1244	10	compared	compare	VBN
cord-005478-5iu38pr6	1244	11	to	to	IN
cord-005478-5iu38pr6	1244	12	T1B1F	T1B1F	NNP
cord-005478-5iu38pr6	1244	13	whereas	whereas	IN
cord-005478-5iu38pr6	1244	14	T2B3F	t2b3f	NN
cord-005478-5iu38pr6	1244	15	associated	associate	VBN
cord-005478-5iu38pr6	1244	16	with	with	IN
cord-005478-5iu38pr6	1244	17	higher	high	JJR
cord-005478-5iu38pr6	1244	18	NRM	NRM	NNP
cord-005478-5iu38pr6	1244	19	,	,	,
cord-005478-5iu38pr6	1244	20	a	a	DT
cord-005478-5iu38pr6	1244	21	higher	high	JJR
cord-005478-5iu38pr6	1244	22	incidence	incidence	NN
cord-005478-5iu38pr6	1244	23	of	of	IN
cord-005478-5iu38pr6	1244	24	acute	acute	JJ
cord-005478-5iu38pr6	1244	25	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1244	26	and	and	CC
cord-005478-5iu38pr6	1244	27	a	a	DT
cord-005478-5iu38pr6	1244	28	lower	low	JJR
cord-005478-5iu38pr6	1244	29	OS	os	NN
cord-005478-5iu38pr6	1244	30	compared	compare	VBN
cord-005478-5iu38pr6	1244	31	to	to	IN
cord-005478-5iu38pr6	1244	32	T1B1F.	T1B1F.	NNP
cord-005478-5iu38pr6	1245	1	With	with	IN
cord-005478-5iu38pr6	1245	2	the	the	DT
cord-005478-5iu38pr6	1245	3	limitation	limitation	NN
cord-005478-5iu38pr6	1245	4	of	of	IN
cord-005478-5iu38pr6	1245	5	the	the	DT
cord-005478-5iu38pr6	1245	6	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1245	7	nature	nature	NN
cord-005478-5iu38pr6	1245	8	of	of	IN
cord-005478-5iu38pr6	1245	9	registry	registry	NN
cord-005478-5iu38pr6	1245	10	data	datum	NNS
cord-005478-5iu38pr6	1245	11	,	,	,
cord-005478-5iu38pr6	1245	12	these	these	DT
cord-005478-5iu38pr6	1245	13	results	result	NNS
cord-005478-5iu38pr6	1245	14	suggest	suggest	VBP
cord-005478-5iu38pr6	1245	15	that	that	IN
cord-005478-5iu38pr6	1245	16	a	a	DT
cord-005478-5iu38pr6	1245	17	lower	low	JJR
cord-005478-5iu38pr6	1245	18	dose	dose	NN
cord-005478-5iu38pr6	1245	19	-	-	HYPH
cord-005478-5iu38pr6	1245	20	intensity	intensity	NN
cord-005478-5iu38pr6	1245	21	of	of	IN
cord-005478-5iu38pr6	1245	22	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1245	23	and	and	CC
cord-005478-5iu38pr6	1245	24	Busilvex	Busilvex	NNP
cord-005478-5iu38pr6	1245	25	in	in	IN
cord-005478-5iu38pr6	1245	26	the	the	DT
cord-005478-5iu38pr6	1245	27	TBF	tbf	NN
cord-005478-5iu38pr6	1245	28	regimen	regimen	NN
cord-005478-5iu38pr6	1245	29	in	in	IN
cord-005478-5iu38pr6	1245	30	general	general	JJ
cord-005478-5iu38pr6	1245	31	may	may	MD
cord-005478-5iu38pr6	1245	32	yield	yield	VB
cord-005478-5iu38pr6	1245	33	better	well	JJR
cord-005478-5iu38pr6	1245	34	results	result	NNS
cord-005478-5iu38pr6	1245	35	in	in	IN
cord-005478-5iu38pr6	1245	36	AML	AML	NNP
cord-005478-5iu38pr6	1245	37	patients	patient	NNS
cord-005478-5iu38pr6	1245	38	transplanted	transplant	VBN
cord-005478-5iu38pr6	1245	39	in	in	IN
cord-005478-5iu38pr6	1245	40	complete	complete	JJ
cord-005478-5iu38pr6	1245	41	remission	remission	NN
cord-005478-5iu38pr6	1245	42	.	.	.
cord-005478-5iu38pr6	1246	1	Background	background	NN
cord-005478-5iu38pr6	1246	2	:	:	:
cord-005478-5iu38pr6	1247	1	TheThiotepa	TheThiotepa	NNP
cord-005478-5iu38pr6	1247	2	-	-	HYPH
cord-005478-5iu38pr6	1247	3	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	1247	4	-	-	HYPH
cord-005478-5iu38pr6	1247	5	Fludarabine	Fludarabine	NNP
cord-005478-5iu38pr6	1247	6	(	(	-LRB-
cord-005478-5iu38pr6	1247	7	TBF	tbf	NN
cord-005478-5iu38pr6	1247	8	)	)	-RRB-
cord-005478-5iu38pr6	1247	9	based	base	VBN
cord-005478-5iu38pr6	1247	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	1247	11	regimen	regimen	NN
cord-005478-5iu38pr6	1247	12	is	be	VBZ
cord-005478-5iu38pr6	1247	13	widely	widely	RB
cord-005478-5iu38pr6	1247	14	used	use	VBN
cord-005478-5iu38pr6	1247	15	in	in	IN
cord-005478-5iu38pr6	1247	16	T	t	NN
cord-005478-5iu38pr6	1247	17	-	-	HYPH
cord-005478-5iu38pr6	1247	18	cell	cell	NN
cord-005478-5iu38pr6	1247	19	repleted	replete	VBD
cord-005478-5iu38pr6	1247	20	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1247	21	transplantation	transplantation	NN
cord-005478-5iu38pr6	1247	22	(	(	-LRB-
cord-005478-5iu38pr6	1247	23	Haplo	Haplo	NNP
cord-005478-5iu38pr6	1247	24	)	)	-RRB-
cord-005478-5iu38pr6	1247	25	with	with	IN
cord-005478-5iu38pr6	1247	26	post	post	JJ
cord-005478-5iu38pr6	1247	27	-	-	JJ
cord-005478-5iu38pr6	1247	28	transplant	transplant	NN
cord-005478-5iu38pr6	1247	29	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	1247	30	.	.	.
cord-005478-5iu38pr6	1248	1	However	however	RB
cord-005478-5iu38pr6	1248	2	,	,	,
cord-005478-5iu38pr6	1248	3	the	the	DT
cord-005478-5iu38pr6	1248	4	use	use	NN
cord-005478-5iu38pr6	1248	5	of	of	IN
cord-005478-5iu38pr6	1248	6	Anti	anti	JJ
cord-005478-5iu38pr6	1248	7	-	-	JJ
cord-005478-5iu38pr6	1248	8	thymocyte	thymocyte	JJ
cord-005478-5iu38pr6	1248	9	globulin	globulin	NN
cord-005478-5iu38pr6	1248	10	(	(	-LRB-
cord-005478-5iu38pr6	1248	11	ATG	ATG	NNP
cord-005478-5iu38pr6	1248	12	)	)	-RRB-
cord-005478-5iu38pr6	1248	13	has	have	VBZ
cord-005478-5iu38pr6	1248	14	not	not	RB
cord-005478-5iu38pr6	1248	15	been	be	VBN
cord-005478-5iu38pr6	1248	16	well	well	RB
cord-005478-5iu38pr6	1248	17	established	establish	VBN
cord-005478-5iu38pr6	1248	18	.	.	.
cord-005478-5iu38pr6	1249	1	It	-PRON-	PRP
cord-005478-5iu38pr6	1249	2	decreases	decrease	VBZ
cord-005478-5iu38pr6	1249	3	the	the	DT
cord-005478-5iu38pr6	1249	4	incidence	incidence	NN
cord-005478-5iu38pr6	1249	5	of	of	IN
cord-005478-5iu38pr6	1249	6	graft	graft	NN
cord-005478-5iu38pr6	1249	7	versus	versus	IN
cord-005478-5iu38pr6	1249	8	host	host	NN
cord-005478-5iu38pr6	1249	9	disease	disease	NN
cord-005478-5iu38pr6	1250	1	however	however	RB
cord-005478-5iu38pr6	1250	2	some	some	DT
cord-005478-5iu38pr6	1250	3	claim	claim	VBP
cord-005478-5iu38pr6	1250	4	that	that	IN
cord-005478-5iu38pr6	1250	5	it	-PRON-	PRP
cord-005478-5iu38pr6	1250	6	's	be	VBZ
cord-005478-5iu38pr6	1250	7	at	at	IN
cord-005478-5iu38pr6	1250	8	the	the	DT
cord-005478-5iu38pr6	1250	9	cost	cost	NN
cord-005478-5iu38pr6	1250	10	of	of	IN
cord-005478-5iu38pr6	1250	11	increased	increase	VBN
cord-005478-5iu38pr6	1250	12	relapse	relapse	NN
cord-005478-5iu38pr6	1250	13	.	.	.
cord-005478-5iu38pr6	1251	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1251	2	conducted	conduct	VBD
cord-005478-5iu38pr6	1251	3	this	this	DT
cord-005478-5iu38pr6	1251	4	multi	multi	JJ
cord-005478-5iu38pr6	1251	5	centric	centric	NN
cord-005478-5iu38pr6	1251	6	study	study	NN
cord-005478-5iu38pr6	1251	7	to	to	TO
cord-005478-5iu38pr6	1251	8	compare	compare	VB
cord-005478-5iu38pr6	1251	9	the	the	DT
cord-005478-5iu38pr6	1251	10	outcomes	outcome	NNS
cord-005478-5iu38pr6	1251	11	of	of	IN
cord-005478-5iu38pr6	1251	12	patients	patient	NNS
cord-005478-5iu38pr6	1251	13	who	who	WP
cord-005478-5iu38pr6	1251	14	underwent	undergo	VBD
cord-005478-5iu38pr6	1251	15	Haplo	Haplo	NNP
cord-005478-5iu38pr6	1251	16	with	with	IN
cord-005478-5iu38pr6	1251	17	TBF	tbf	NN
cord-005478-5iu38pr6	1251	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	1251	19	regimen	regimen	NN
cord-005478-5iu38pr6	1251	20	with	with	IN
cord-005478-5iu38pr6	1251	21	ATG	ATG	NNP
cord-005478-5iu38pr6	1251	22	to	to	IN
cord-005478-5iu38pr6	1251	23	those	those	DT
cord-005478-5iu38pr6	1251	24	without	without	IN
cord-005478-5iu38pr6	1251	25	.	.	.
cord-005478-5iu38pr6	1252	1	Methods	method	NNS
cord-005478-5iu38pr6	1252	2	:	:	:
cord-005478-5iu38pr6	1252	3	This	this	DT
cord-005478-5iu38pr6	1252	4	is	be	VBZ
cord-005478-5iu38pr6	1252	5	a	a	DT
cord-005478-5iu38pr6	1252	6	multicentric	multicentric	JJ
cord-005478-5iu38pr6	1252	7	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1252	8	study	study	NN
cord-005478-5iu38pr6	1252	9	.	.	.
cord-005478-5iu38pr6	1253	1	Data	datum	NNS
cord-005478-5iu38pr6	1253	2	was	be	VBD
cord-005478-5iu38pr6	1253	3	collected	collect	VBN
cord-005478-5iu38pr6	1253	4	from	from	IN
cord-005478-5iu38pr6	1253	5	4	4	CD
cord-005478-5iu38pr6	1253	6	centers	center	NNS
cord-005478-5iu38pr6	1253	7	,	,	,
cord-005478-5iu38pr6	1253	8	the	the	DT
cord-005478-5iu38pr6	1253	9	American	American	NNP
cord-005478-5iu38pr6	1253	10	University	University	NNP
cord-005478-5iu38pr6	1253	11	of	of	IN
cord-005478-5iu38pr6	1253	12	Beirut	Beirut	NNP
cord-005478-5iu38pr6	1253	13	Medical	Medical	NNP
cord-005478-5iu38pr6	1253	14	Center	Center	NNP
cord-005478-5iu38pr6	1253	15	,	,	,
cord-005478-5iu38pr6	1253	16	Hospital	Hospital	NNP
cord-005478-5iu38pr6	1253	17	Saint	Saint	NNP
cord-005478-5iu38pr6	1253	18	Antoine	Antoine	NNP
cord-005478-5iu38pr6	1253	19	Paris	Paris	NNP
cord-005478-5iu38pr6	1253	20	,	,	,
cord-005478-5iu38pr6	1253	21	institute	institute	NN
cord-005478-5iu38pr6	1253	22	Paoli	Paoli	NNP
cord-005478-5iu38pr6	1253	23	Calmette	Calmette	NNP
cord-005478-5iu38pr6	1253	24	Marseille	Marseille	NNP
cord-005478-5iu38pr6	1253	25	,	,	,
cord-005478-5iu38pr6	1253	26	and	and	CC
cord-005478-5iu38pr6	1253	27	Humanitas	Humanitas	NNP
cord-005478-5iu38pr6	1253	28	Research	Research	NNP
cord-005478-5iu38pr6	1253	29	Hospital	Hospital	NNP
cord-005478-5iu38pr6	1253	30	Milan	Milan	NNP
cord-005478-5iu38pr6	1253	31	.	.	.
cord-005478-5iu38pr6	1254	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1254	2	included	include	VBD
cord-005478-5iu38pr6	1254	3	all	all	DT
cord-005478-5iu38pr6	1254	4	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1254	5	adult	adult	NN
cord-005478-5iu38pr6	1254	6	patients	patient	NNS
cord-005478-5iu38pr6	1254	7	who	who	WP
cord-005478-5iu38pr6	1254	8	underwent	undergo	VBD
cord-005478-5iu38pr6	1254	9	Haplo	Haplo	NNP
cord-005478-5iu38pr6	1254	10	with	with	IN
cord-005478-5iu38pr6	1254	11	TBF	tbf	NN
cord-005478-5iu38pr6	1254	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	1254	13	.	.	.
cord-005478-5iu38pr6	1255	1	The	the	DT
cord-005478-5iu38pr6	1255	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	1255	3	consisted	consist	VBD
cord-005478-5iu38pr6	1255	4	of	of	IN
cord-005478-5iu38pr6	1255	5	thiotepa	thiotepa	JJ
cord-005478-5iu38pr6	1255	6	5	5	CD
cord-005478-5iu38pr6	1255	7	mg	mg	NNP
cord-005478-5iu38pr6	1255	8	/	/	SYM
cord-005478-5iu38pr6	1255	9	kg	kg	NN
cord-005478-5iu38pr6	1255	10	per	per	IN
cord-005478-5iu38pr6	1255	11	day	day	NN
cord-005478-5iu38pr6	1255	12	infused	infuse	VBN
cord-005478-5iu38pr6	1255	13	on	on	IN
cord-005478-5iu38pr6	1255	14	days	day	NNS
cord-005478-5iu38pr6	1255	15	-7	-7	NNP
cord-005478-5iu38pr6	1255	16	and/or	and/or	CC
cord-005478-5iu38pr6	1255	17	-6	-6	NNP
cord-005478-5iu38pr6	1255	18	,	,	,
cord-005478-5iu38pr6	1255	19	fludarabine	fludarabine	NNP
cord-005478-5iu38pr6	1255	20	30	30	CD
cord-005478-5iu38pr6	1255	21	mg	mg	NNP
cord-005478-5iu38pr6	1255	22	/	/	SYM
cord-005478-5iu38pr6	1255	23	m2	m2	NNP
cord-005478-5iu38pr6	1255	24	infused	infuse	VBD
cord-005478-5iu38pr6	1255	25	on	on	IN
cord-005478-5iu38pr6	1255	26	day	day	NN
cord-005478-5iu38pr6	1255	27	-5	-5	NNP
cord-005478-5iu38pr6	1255	28	to	to	IN
cord-005478-5iu38pr6	1255	29	day	day	NN
cord-005478-5iu38pr6	1255	30	-2	-2	CD
cord-005478-5iu38pr6	1255	31	;	;	:
cord-005478-5iu38pr6	1255	32	and	and	CC
cord-005478-5iu38pr6	1255	33	busulfan	busulfan	NN
cord-005478-5iu38pr6	1255	34	130	130	CD
cord-005478-5iu38pr6	1255	35	mg	mg	NNP
cord-005478-5iu38pr6	1255	36	/	/	SYM
cord-005478-5iu38pr6	1255	37	m2	m2	NNP
cord-005478-5iu38pr6	1255	38	infused	infuse	VBD
cord-005478-5iu38pr6	1255	39	on	on	IN
cord-005478-5iu38pr6	1255	40	day	day	NN
cord-005478-5iu38pr6	1255	41	-5	-5	NNP
cord-005478-5iu38pr6	1255	42	to	to	IN
cord-005478-5iu38pr6	1255	43	day	day	NN
cord-005478-5iu38pr6	1255	44	-3	-3	NNP
cord-005478-5iu38pr6	1255	45	.	.	.
cord-005478-5iu38pr6	1256	1	Graft	graft	NN
cord-005478-5iu38pr6	1256	2	versus	versus	IN
cord-005478-5iu38pr6	1256	3	host	host	NN
cord-005478-5iu38pr6	1256	4	disease	disease	NN
cord-005478-5iu38pr6	1256	5	(	(	-LRB-
cord-005478-5iu38pr6	1256	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1256	7	)	)	-RRB-
cord-005478-5iu38pr6	1256	8	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1256	9	consisted	consist	VBD
cord-005478-5iu38pr6	1256	10	of	of	IN
cord-005478-5iu38pr6	1256	11	post	post	NN
cord-005478-5iu38pr6	1256	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	1256	13	cyclophosphamide	cyclophosphamide	IN
cord-005478-5iu38pr6	1256	14	50	50	CD
cord-005478-5iu38pr6	1256	15	mg/	mg/	NN
cord-005478-5iu38pr6	1256	16	kg	kg	NN
cord-005478-5iu38pr6	1256	17	per	per	IN
cord-005478-5iu38pr6	1256	18	day	day	NN
cord-005478-5iu38pr6	1256	19	on	on	IN
cord-005478-5iu38pr6	1256	20	day	day	NN
cord-005478-5iu38pr6	1256	21	+3	+3	NN
cord-005478-5iu38pr6	1256	22	and	and	CC
cord-005478-5iu38pr6	1256	23	day	day	NN
cord-005478-5iu38pr6	1256	24	+5	+5	XX
cord-005478-5iu38pr6	1256	25	,	,	,
cord-005478-5iu38pr6	1256	26	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	1256	27	on	on	IN
cord-005478-5iu38pr6	1256	28	day	day	NN
cord-005478-5iu38pr6	1256	29	+6	+6	XX
cord-005478-5iu38pr6	1256	30	and	and	CC
cord-005478-5iu38pr6	1256	31	readjusted	readjust	VBD
cord-005478-5iu38pr6	1256	32	according	accord	VBG
cord-005478-5iu38pr6	1256	33	to	to	IN
cord-005478-5iu38pr6	1256	34	level	level	NN
cord-005478-5iu38pr6	1256	35	,	,	,
cord-005478-5iu38pr6	1256	36	and	and	CC
cord-005478-5iu38pr6	1256	37	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	1256	38	mofetil	mofetil	NNP
cord-005478-5iu38pr6	1256	39	500	500	CD
cord-005478-5iu38pr6	1256	40	mg	mg	NN
cord-005478-5iu38pr6	1256	41	every	every	DT
cord-005478-5iu38pr6	1256	42	6	6	CD
cord-005478-5iu38pr6	1256	43	hours	hour	NNS
cord-005478-5iu38pr6	1256	44	beginning	begin	VBG
cord-005478-5iu38pr6	1256	45	on	on	IN
cord-005478-5iu38pr6	1256	46	days	day	NNS
cord-005478-5iu38pr6	1256	47	+6	+6	XX
cord-005478-5iu38pr6	1256	48	to	to	IN
cord-005478-5iu38pr6	1256	49	+28	+28	CD
cord-005478-5iu38pr6	1256	50	or	or	CC
cord-005478-5iu38pr6	1256	51	+35	+35	NN
cord-005478-5iu38pr6	1256	52	depending	depend	VBG
cord-005478-5iu38pr6	1256	53	on	on	IN
cord-005478-5iu38pr6	1256	54	the	the	DT
cord-005478-5iu38pr6	1256	55	center	center	NN
cord-005478-5iu38pr6	1256	56	.	.	.
cord-005478-5iu38pr6	1257	1	Patients	patient	NNS
cord-005478-5iu38pr6	1257	2	who	who	WP
cord-005478-5iu38pr6	1257	3	received	receive	VBD
cord-005478-5iu38pr6	1257	4	ATG	ATG	NNP
cord-005478-5iu38pr6	1257	5	received	receive	VBD
cord-005478-5iu38pr6	1257	6	a	a	DT
cord-005478-5iu38pr6	1257	7	dose	dose	NN
cord-005478-5iu38pr6	1257	8	of	of	IN
cord-005478-5iu38pr6	1257	9	2.5	2.5	CD
cord-005478-5iu38pr6	1257	10	mg	mg	NNP
cord-005478-5iu38pr6	1257	11	/	/	SYM
cord-005478-5iu38pr6	1257	12	kg	kg	NN
cord-005478-5iu38pr6	1257	13	per	per	IN
cord-005478-5iu38pr6	1257	14	day	day	NN
cord-005478-5iu38pr6	1257	15	.	.	.
cord-005478-5iu38pr6	1258	1	Results	result	NNS
cord-005478-5iu38pr6	1258	2	:	:	:
cord-005478-5iu38pr6	1259	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1259	2	included	include	VBD
cord-005478-5iu38pr6	1259	3	a	a	DT
cord-005478-5iu38pr6	1259	4	total	total	NN
cord-005478-5iu38pr6	1259	5	of	of	IN
cord-005478-5iu38pr6	1259	6	268	268	CD
cord-005478-5iu38pr6	1259	7	patients	patient	NNS
cord-005478-5iu38pr6	1259	8	,	,	,
cord-005478-5iu38pr6	1259	9	69	69	CD
cord-005478-5iu38pr6	1259	10	of	of	IN
cord-005478-5iu38pr6	1259	11	whom	whom	WP
cord-005478-5iu38pr6	1259	12	(	(	-LRB-
cord-005478-5iu38pr6	1259	13	26	26	CD
cord-005478-5iu38pr6	1259	14	%	%	NN
cord-005478-5iu38pr6	1259	15	)	)	-RRB-
cord-005478-5iu38pr6	1259	16	received	receive	VBD
cord-005478-5iu38pr6	1259	17	ATG	ATG	NNP
cord-005478-5iu38pr6	1259	18	(	(	-LRB-
cord-005478-5iu38pr6	1259	19	group	group	NN
cord-005478-5iu38pr6	1259	20	2	2	CD
cord-005478-5iu38pr6	1259	21	)	)	-RRB-
cord-005478-5iu38pr6	1259	22	as	as	IN
cord-005478-5iu38pr6	1259	23	part	part	NN
cord-005478-5iu38pr6	1259	24	of	of	IN
cord-005478-5iu38pr6	1259	25	the	the	DT
cord-005478-5iu38pr6	1259	26	conditioning	conditioning	NN
cord-005478-5iu38pr6	1259	27	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	1259	28	.	.	.
cord-005478-5iu38pr6	1260	1	Patients	patient	NNS
cord-005478-5iu38pr6	1260	2	who	who	WP
cord-005478-5iu38pr6	1260	3	received	receive	VBD
cord-005478-5iu38pr6	1260	4	ATG	ATG	NNP
cord-005478-5iu38pr6	1260	5	had	have	VBD
cord-005478-5iu38pr6	1260	6	a	a	DT
cord-005478-5iu38pr6	1260	7	younger	young	JJR
cord-005478-5iu38pr6	1260	8	median	median	NN
cord-005478-5iu38pr6	1260	9	age	age	NN
cord-005478-5iu38pr6	1260	10	compared	compare	VBN
cord-005478-5iu38pr6	1260	11	to	to	IN
cord-005478-5iu38pr6	1260	12	the	the	DT
cord-005478-5iu38pr6	1260	13	second	second	JJ
cord-005478-5iu38pr6	1260	14	group	group	NN
cord-005478-5iu38pr6	1260	15	without	without	IN
cord-005478-5iu38pr6	1260	16	ATG	ATG	NNP
cord-005478-5iu38pr6	1260	17	(	(	-LRB-
cord-005478-5iu38pr6	1260	18	group	group	NN
cord-005478-5iu38pr6	1260	19	1	1	CD
cord-005478-5iu38pr6	1260	20	)	)	-RRB-
cord-005478-5iu38pr6	1261	1	(	(	-LRB-
cord-005478-5iu38pr6	1261	2	53	53	CD
cord-005478-5iu38pr6	1261	3	and	and	CC
cord-005478-5iu38pr6	1261	4	58	58	CD
cord-005478-5iu38pr6	1261	5	years	year	NNS
cord-005478-5iu38pr6	1261	6	respectively	respectively	RB
cord-005478-5iu38pr6	1261	7	;	;	:
cord-005478-5iu38pr6	1261	8	p	p	NN
cord-005478-5iu38pr6	1261	9	value	value	NN
cord-005478-5iu38pr6	1261	10	0.004	0.004	CD
cord-005478-5iu38pr6	1261	11	)	)	-RRB-
cord-005478-5iu38pr6	1261	12	.	.	.
cord-005478-5iu38pr6	1262	1	(	(	-LRB-
cord-005478-5iu38pr6	1262	2	63	63	CD
cord-005478-5iu38pr6	1262	3	%	%	NN
cord-005478-5iu38pr6	1262	4	vs	vs	IN
cord-005478-5iu38pr6	1262	5	61	61	CD
cord-005478-5iu38pr6	1262	6	%	%	NN
cord-005478-5iu38pr6	1262	7	)	)	-RRB-
cord-005478-5iu38pr6	1262	8	of	of	IN
cord-005478-5iu38pr6	1262	9	each	each	DT
cord-005478-5iu38pr6	1262	10	group	group	NN
cord-005478-5iu38pr6	1262	11	had	have	VBD
cord-005478-5iu38pr6	1262	12	acute	acute	JJ
cord-005478-5iu38pr6	1262	13	leukemia	leukemia	NN
cord-005478-5iu38pr6	1262	14	,	,	,
cord-005478-5iu38pr6	1262	15	and	and	CC
cord-005478-5iu38pr6	1262	16	(	(	-LRB-
cord-005478-5iu38pr6	1262	17	71	71	CD
cord-005478-5iu38pr6	1262	18	%	%	NN
cord-005478-5iu38pr6	1262	19	vs	vs	IN
cord-005478-5iu38pr6	1262	20	70	70	CD
cord-005478-5iu38pr6	1262	21	%	%	NN
cord-005478-5iu38pr6	1262	22	)	)	-RRB-
cord-005478-5iu38pr6	1262	23	were	be	VBD
cord-005478-5iu38pr6	1262	24	in	in	IN
cord-005478-5iu38pr6	1262	25	complete	complete	JJ
cord-005478-5iu38pr6	1262	26	remission	remission	NN
cord-005478-5iu38pr6	1262	27	at	at	IN
cord-005478-5iu38pr6	1262	28	the	the	DT
cord-005478-5iu38pr6	1262	29	time	time	NN
cord-005478-5iu38pr6	1262	30	of	of	IN
cord-005478-5iu38pr6	1262	31	transplant	transplant	NN
cord-005478-5iu38pr6	1262	32	,	,	,
cord-005478-5iu38pr6	1262	33	while	while	IN
cord-005478-5iu38pr6	1262	34	47	47	CD
cord-005478-5iu38pr6	1262	35	patients	patient	NNS
cord-005478-5iu38pr6	1262	36	(	(	-LRB-
cord-005478-5iu38pr6	1262	37	24	24	CD
cord-005478-5iu38pr6	1262	38	%	%	NN
cord-005478-5iu38pr6	1262	39	)	)	-RRB-
cord-005478-5iu38pr6	1262	40	in	in	IN
cord-005478-5iu38pr6	1262	41	the	the	DT
cord-005478-5iu38pr6	1262	42	group	group	NN
cord-005478-5iu38pr6	1262	43	1	1	CD
cord-005478-5iu38pr6	1262	44	had	have	VBD
cord-005478-5iu38pr6	1262	45	progressive	progressive	JJ
cord-005478-5iu38pr6	1262	46	disease	disease	NN
cord-005478-5iu38pr6	1262	47	at	at	IN
cord-005478-5iu38pr6	1262	48	transplant	transplant	NN
cord-005478-5iu38pr6	1262	49	.	.	.
cord-005478-5iu38pr6	1263	1	151	151	CD
cord-005478-5iu38pr6	1263	2	patients	patient	NNS
cord-005478-5iu38pr6	1263	3	(	(	-LRB-
cord-005478-5iu38pr6	1263	4	56.5	56.5	CD
cord-005478-5iu38pr6	1263	5	%	%	NN
cord-005478-5iu38pr6	1263	6	)	)	-RRB-
cord-005478-5iu38pr6	1263	7	had	have	VBD
cord-005478-5iu38pr6	1263	8	an	an	DT
cord-005478-5iu38pr6	1263	9	intermediate	intermediate	JJ
cord-005478-5iu38pr6	1263	10	disease	disease	NN
cord-005478-5iu38pr6	1263	11	risk	risk	NN
cord-005478-5iu38pr6	1263	12	index	index	NN
cord-005478-5iu38pr6	1263	13	(	(	-LRB-
cord-005478-5iu38pr6	1263	14	DRI	DRI	NNP
cord-005478-5iu38pr6	1263	15	)	)	-RRB-
cord-005478-5iu38pr6	1263	16	.	.	.
cord-005478-5iu38pr6	1264	1	In	in	IN
cord-005478-5iu38pr6	1264	2	the	the	DT
cord-005478-5iu38pr6	1264	3	ATG	ATG	NNP
cord-005478-5iu38pr6	1264	4	group	group	NN
cord-005478-5iu38pr6	1264	5	,	,	,
cord-005478-5iu38pr6	1264	6	59	59	CD
cord-005478-5iu38pr6	1264	7	patients	patient	NNS
cord-005478-5iu38pr6	1264	8	(	(	-LRB-
cord-005478-5iu38pr6	1264	9	30	30	CD
cord-005478-5iu38pr6	1264	10	%	%	NN
cord-005478-5iu38pr6	1264	11	)	)	-RRB-
cord-005478-5iu38pr6	1264	12	compared	compare	VBN
cord-005478-5iu38pr6	1264	13	to	to	IN
cord-005478-5iu38pr6	1264	14	50	50	CD
cord-005478-5iu38pr6	1264	15	(	(	-LRB-
cord-005478-5iu38pr6	1264	16	73	73	CD
cord-005478-5iu38pr6	1264	17	%	%	NN
cord-005478-5iu38pr6	1264	18	)	)	-RRB-
cord-005478-5iu38pr6	1264	19	in	in	IN
cord-005478-5iu38pr6	1264	20	the	the	DT
cord-005478-5iu38pr6	1264	21	other	other	JJ
cord-005478-5iu38pr6	1264	22	group	group	NN
cord-005478-5iu38pr6	1264	23	received	receive	VBD
cord-005478-5iu38pr6	1264	24	5mg	5mg	NN
cord-005478-5iu38pr6	1264	25	/	/	SYM
cord-005478-5iu38pr6	1264	26	kg	kg	NN
cord-005478-5iu38pr6	1265	1	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	1265	2	,	,	,
cord-005478-5iu38pr6	1265	3	while	while	IN
cord-005478-5iu38pr6	1265	4	140	140	CD
cord-005478-5iu38pr6	1265	5	(	(	-LRB-
cord-005478-5iu38pr6	1265	6	70	70	CD
cord-005478-5iu38pr6	1265	7	)	)	-RRB-
cord-005478-5iu38pr6	1265	8	and	and	CC
cord-005478-5iu38pr6	1265	9	19	19	CD
cord-005478-5iu38pr6	1265	10	(	(	-LRB-
cord-005478-5iu38pr6	1265	11	27	27	CD
cord-005478-5iu38pr6	1265	12	%	%	NN
cord-005478-5iu38pr6	1265	13	)	)	-RRB-
cord-005478-5iu38pr6	1265	14	received	receive	VBD
cord-005478-5iu38pr6	1265	15	10mg	10mg	NNP
cord-005478-5iu38pr6	1265	16	/	/	SYM
cord-005478-5iu38pr6	1265	17	kg	kg	NN
cord-005478-5iu38pr6	1265	18	respectively	respectively	RB
cord-005478-5iu38pr6	1265	19	.	.	.
cord-005478-5iu38pr6	1266	1	Peripheral	peripheral	JJ
cord-005478-5iu38pr6	1266	2	blood	blood	NN
cord-005478-5iu38pr6	1266	3	stem	stem	NN
cord-005478-5iu38pr6	1266	4	cells	cell	NNS
cord-005478-5iu38pr6	1266	5	were	be	VBD
cord-005478-5iu38pr6	1266	6	the	the	DT
cord-005478-5iu38pr6	1266	7	most	most	RBS
cord-005478-5iu38pr6	1266	8	common	common	JJ
cord-005478-5iu38pr6	1266	9	graft	graft	NN
cord-005478-5iu38pr6	1266	10	source	source	NN
cord-005478-5iu38pr6	1266	11	in	in	IN
cord-005478-5iu38pr6	1266	12	both	both	DT
cord-005478-5iu38pr6	1266	13	groups	group	NNS
cord-005478-5iu38pr6	1266	14	(	(	-LRB-
cord-005478-5iu38pr6	1266	15	83	83	CD
cord-005478-5iu38pr6	1266	16	%	%	NN
cord-005478-5iu38pr6	1266	17	and	and	CC
cord-005478-5iu38pr6	1266	18	88	88	CD
cord-005478-5iu38pr6	1266	19	%	%	NN
cord-005478-5iu38pr6	1266	20	respectively	respectively	RB
cord-005478-5iu38pr6	1266	21	)	)	-RRB-
cord-005478-5iu38pr6	1266	22	.	.	.
cord-005478-5iu38pr6	1267	1	At	at	IN
cord-005478-5iu38pr6	1267	2	a	a	DT
cord-005478-5iu38pr6	1267	3	median	median	JJ
cord-005478-5iu38pr6	1267	4	follow	follow	NN
cord-005478-5iu38pr6	1267	5	-	-	HYPH
cord-005478-5iu38pr6	1267	6	up	up	NN
cord-005478-5iu38pr6	1267	7	of	of	IN
cord-005478-5iu38pr6	1267	8	15.4	15.4	CD
cord-005478-5iu38pr6	1267	9	months	month	NNS
cord-005478-5iu38pr6	1267	10	,	,	,
cord-005478-5iu38pr6	1267	11	patients	patient	NNS
cord-005478-5iu38pr6	1267	12	receiving	receive	VBG
cord-005478-5iu38pr6	1267	13	ATG	ATG	NNP
cord-005478-5iu38pr6	1267	14	had	have	VBD
cord-005478-5iu38pr6	1267	15	a	a	DT
cord-005478-5iu38pr6	1267	16	statistically	statistically	RB
cord-005478-5iu38pr6	1267	17	significant	significant	JJ
cord-005478-5iu38pr6	1267	18	decreased	decrease	VBN
cord-005478-5iu38pr6	1267	19	risk	risk	NN
cord-005478-5iu38pr6	1267	20	of	of	IN
cord-005478-5iu38pr6	1267	21	acute	acute	JJ
cord-005478-5iu38pr6	1267	22	graft	graft	NN
cord-005478-5iu38pr6	1267	23	versus	versus	IN
cord-005478-5iu38pr6	1267	24	host	host	NN
cord-005478-5iu38pr6	1267	25	disease	disease	NN
cord-005478-5iu38pr6	1267	26	(	(	-LRB-
cord-005478-5iu38pr6	1267	27	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1267	28	)	)	-RRB-
cord-005478-5iu38pr6	1268	1	(	(	-LRB-
cord-005478-5iu38pr6	1268	2	RR	RR	NNP
cord-005478-5iu38pr6	1268	3	0.47	0.47	CD
cord-005478-5iu38pr6	1268	4	;	;	:
cord-005478-5iu38pr6	1268	5	p	p	NN
cord-005478-5iu38pr6	1268	6	value	value	NN
cord-005478-5iu38pr6	1268	7	0.031	0.031	CD
cord-005478-5iu38pr6	1268	8	)	)	-RRB-
cord-005478-5iu38pr6	1268	9	,	,	,
cord-005478-5iu38pr6	1268	10	and	and	CC
cord-005478-5iu38pr6	1268	11	non	non	JJ
cord-005478-5iu38pr6	1268	12	-	-	JJ
cord-005478-5iu38pr6	1268	13	relapse	relapse	JJ
cord-005478-5iu38pr6	1268	14	mortality	mortality	NN
cord-005478-5iu38pr6	1268	15	(	(	-LRB-
cord-005478-5iu38pr6	1268	16	NRM	NRM	NNP
cord-005478-5iu38pr6	1268	17	)	)	-RRB-
cord-005478-5iu38pr6	1268	18	at	at	IN
cord-005478-5iu38pr6	1268	19	24	24	CD
cord-005478-5iu38pr6	1268	20	months	month	NNS
cord-005478-5iu38pr6	1269	1	(	(	-LRB-
cord-005478-5iu38pr6	1269	2	RR	RR	NNP
cord-005478-5iu38pr6	1269	3	0.5	0.5	CD
cord-005478-5iu38pr6	1269	4	;	;	:
cord-005478-5iu38pr6	1269	5	p	p	NN
cord-005478-5iu38pr6	1269	6	value	value	NN
cord-005478-5iu38pr6	1269	7	0.027	0.027	CD
cord-005478-5iu38pr6	1269	8	)	)	-RRB-
cord-005478-5iu38pr6	1269	9	.	.	.
cord-005478-5iu38pr6	1270	1	ATG	ATG	NNP
cord-005478-5iu38pr6	1270	2	also	also	RB
cord-005478-5iu38pr6	1270	3	resulted	result	VBD
cord-005478-5iu38pr6	1270	4	in	in	IN
cord-005478-5iu38pr6	1270	5	higher	high	JJR
cord-005478-5iu38pr6	1270	6	progression	progression	NN
cord-005478-5iu38pr6	1270	7	and	and	CC
cord-005478-5iu38pr6	1270	8	overall	overall	JJ
cord-005478-5iu38pr6	1270	9	survival	survival	NN
cord-005478-5iu38pr6	1270	10	at	at	IN
cord-005478-5iu38pr6	1270	11	24	24	CD
cord-005478-5iu38pr6	1270	12	months	month	NNS
cord-005478-5iu38pr6	1270	13	,	,	,
cord-005478-5iu38pr6	1270	14	which	which	WDT
cord-005478-5iu38pr6	1270	15	was	be	VBD
cord-005478-5iu38pr6	1270	16	not	not	RB
cord-005478-5iu38pr6	1270	17	statistically	statistically	RB
cord-005478-5iu38pr6	1270	18	significant	significant	JJ
cord-005478-5iu38pr6	1270	19	(	(	-LRB-
cord-005478-5iu38pr6	1270	20	66.2	66.2	CD
cord-005478-5iu38pr6	1270	21	%	%	NN
cord-005478-5iu38pr6	1270	22	and	and	CC
cord-005478-5iu38pr6	1270	23	59.8	59.8	CD
cord-005478-5iu38pr6	1270	24	%	%	NN
cord-005478-5iu38pr6	1270	25	;	;	,
cord-005478-5iu38pr6	1270	26	p	p	NN
cord-005478-5iu38pr6	1270	27	value	value	NN
cord-005478-5iu38pr6	1270	28	0.168	0.168	CD
cord-005478-5iu38pr6	1270	29	,	,	,
cord-005478-5iu38pr6	1270	30	with	with	IN
cord-005478-5iu38pr6	1270	31	76.6	76.6	CD
cord-005478-5iu38pr6	1270	32	%	%	NN
cord-005478-5iu38pr6	1270	33	and	and	CC
cord-005478-5iu38pr6	1270	34	67.8	67.8	CD
cord-005478-5iu38pr6	1270	35	%	%	NN
cord-005478-5iu38pr6	1270	36	;	;	,
cord-005478-5iu38pr6	1270	37	p	p	NN
cord-005478-5iu38pr6	1270	38	value	value	NN
cord-005478-5iu38pr6	1270	39	0.056	0.056	CD
cord-005478-5iu38pr6	1270	40	respectively	respectively	RB
cord-005478-5iu38pr6	1270	41	)	)	-RRB-
cord-005478-5iu38pr6	1270	42	.	.	.
cord-005478-5iu38pr6	1271	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1271	2	:	:	:
cord-005478-5iu38pr6	1272	1	ATG	ATG	NNP
cord-005478-5iu38pr6	1272	2	as	as	IN
cord-005478-5iu38pr6	1272	3	part	part	NN
cord-005478-5iu38pr6	1272	4	of	of	IN
cord-005478-5iu38pr6	1272	5	the	the	DT
cord-005478-5iu38pr6	1272	6	pre	pre	JJ
cord-005478-5iu38pr6	1272	7	-	-	JJ
cord-005478-5iu38pr6	1272	8	transplantation	transplantation	JJ
cord-005478-5iu38pr6	1272	9	conditioning	conditioning	NN
cord-005478-5iu38pr6	1272	10	leads	lead	VBZ
cord-005478-5iu38pr6	1272	11	to	to	IN
cord-005478-5iu38pr6	1272	12	significant	significant	JJ
cord-005478-5iu38pr6	1272	13	reduction	reduction	NN
cord-005478-5iu38pr6	1272	14	in	in	IN
cord-005478-5iu38pr6	1272	15	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1272	16	and	and	CC
cord-005478-5iu38pr6	1272	17	NRM	NRM	NNP
cord-005478-5iu38pr6	1272	18	at	at	IN
cord-005478-5iu38pr6	1272	19	24	24	CD
cord-005478-5iu38pr6	1272	20	months	month	NNS
cord-005478-5iu38pr6	1272	21	without	without	IN
cord-005478-5iu38pr6	1272	22	significant	significant	JJ
cord-005478-5iu38pr6	1272	23	effects	effect	NNS
cord-005478-5iu38pr6	1272	24	on	on	IN
cord-005478-5iu38pr6	1272	25	PFS	PFS	NNP
cord-005478-5iu38pr6	1272	26	or	or	CC
cord-005478-5iu38pr6	1272	27	OS	OS	NNP
cord-005478-5iu38pr6	1272	28	.	.	.
cord-005478-5iu38pr6	1273	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1273	2	Background	background	NN
cord-005478-5iu38pr6	1273	3	:	:	:
cord-005478-5iu38pr6	1274	1	High	high	JJ
cord-005478-5iu38pr6	1274	2	-	-	HYPH
cord-005478-5iu38pr6	1274	3	risk	risk	NN
cord-005478-5iu38pr6	1274	4	leukemia	leukemia	NN
cord-005478-5iu38pr6	1274	5	is	be	VBZ
cord-005478-5iu38pr6	1274	6	associated	associate	VBN
cord-005478-5iu38pr6	1274	7	with	with	IN
cord-005478-5iu38pr6	1274	8	poor	poor	JJ
cord-005478-5iu38pr6	1274	9	prognosis	prognosis	NN
cord-005478-5iu38pr6	1274	10	and	and	CC
cord-005478-5iu38pr6	1274	11	inferior	inferior	JJ
cord-005478-5iu38pr6	1274	12	outcome	outcome	NN
cord-005478-5iu38pr6	1274	13	.	.	.
cord-005478-5iu38pr6	1275	1	In	in	IN
cord-005478-5iu38pr6	1275	2	elderly	elderly	JJ
cord-005478-5iu38pr6	1275	3	or	or	CC
cord-005478-5iu38pr6	1275	4	comorbid	comorbid	JJ
cord-005478-5iu38pr6	1275	5	patients	patient	NNS
cord-005478-5iu38pr6	1275	6	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1275	7	SCT	SCT	NNP
cord-005478-5iu38pr6	1275	8	with	with	IN
cord-005478-5iu38pr6	1275	9	myeloablativ	myeloablativ	JJ
cord-005478-5iu38pr6	1275	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	1275	11	regimen	regimen	NN
cord-005478-5iu38pr6	1275	12	as	as	IN
cord-005478-5iu38pr6	1275	13	the	the	DT
cord-005478-5iu38pr6	1275	14	most	most	RBS
cord-005478-5iu38pr6	1275	15	effective	effective	JJ
cord-005478-5iu38pr6	1275	16	treatment	treatment	NN
cord-005478-5iu38pr6	1275	17	option	option	NN
cord-005478-5iu38pr6	1275	18	is	be	VBZ
cord-005478-5iu38pr6	1275	19	not	not	RB
cord-005478-5iu38pr6	1275	20	available	available	JJ
cord-005478-5iu38pr6	1275	21	.	.	.
cord-005478-5iu38pr6	1276	1	Sequential	sequential	JJ
cord-005478-5iu38pr6	1276	2	regimen	regimen	NN
cord-005478-5iu38pr6	1276	3	combining	combine	VBG
cord-005478-5iu38pr6	1276	4	cytoreductive	cytoreductive	JJ
cord-005478-5iu38pr6	1276	5	therapy	therapy	NN
cord-005478-5iu38pr6	1276	6	with	with	IN
cord-005478-5iu38pr6	1276	7	RIC	RIC	NNP
cord-005478-5iu38pr6	1276	8	has	have	VBZ
cord-005478-5iu38pr6	1276	9	shown	show	VBN
cord-005478-5iu38pr6	1276	10	high	high	JJ
cord-005478-5iu38pr6	1276	11	antileukemic	antileukemic	JJ
cord-005478-5iu38pr6	1276	12	activity	activity	NN
cord-005478-5iu38pr6	1276	13	for	for	IN
cord-005478-5iu38pr6	1276	14	high	high	JJ
cord-005478-5iu38pr6	1276	15	-	-	HYPH
cord-005478-5iu38pr6	1276	16	risk	risk	NN
cord-005478-5iu38pr6	1276	17	patients	patient	NNS
cord-005478-5iu38pr6	1276	18	with	with	IN
cord-005478-5iu38pr6	1276	19	acceptable	acceptable	JJ
cord-005478-5iu38pr6	1276	20	toxicity	toxicity	NN
cord-005478-5iu38pr6	1276	21	profile	profile	NN
cord-005478-5iu38pr6	1276	22	.	.	.
cord-005478-5iu38pr6	1277	1	This	this	DT
cord-005478-5iu38pr6	1277	2	study	study	NN
cord-005478-5iu38pr6	1277	3	is	be	VBZ
cord-005478-5iu38pr6	1277	4	based	base	VBN
cord-005478-5iu38pr6	1277	5	on	on	IN
cord-005478-5iu38pr6	1277	6	the	the	DT
cord-005478-5iu38pr6	1277	7	observation	observation	NN
cord-005478-5iu38pr6	1277	8	that	that	IN
cord-005478-5iu38pr6	1277	9	antileukemic	antileukemic	NNP
cord-005478-5iu38pr6	1277	10	effects	effect	NNS
cord-005478-5iu38pr6	1277	11	have	have	VBP
cord-005478-5iu38pr6	1277	12	been	be	VBN
cord-005478-5iu38pr6	1277	13	described	describe	VBN
cord-005478-5iu38pr6	1277	14	previously	previously	RB
cord-005478-5iu38pr6	1277	15	for	for	IN
cord-005478-5iu38pr6	1277	16	the	the	DT
cord-005478-5iu38pr6	1277	17	nucleoside	nucleoside	NN
cord-005478-5iu38pr6	1277	18	analogue	analogue	NN
cord-005478-5iu38pr6	1277	19	clofarabine	clofarabine	NN
cord-005478-5iu38pr6	1277	20	.	.	.
cord-005478-5iu38pr6	1278	1	Methods	method	NNS
cord-005478-5iu38pr6	1278	2	:	:	:
cord-005478-5iu38pr6	1279	1	The	the	DT
cord-005478-5iu38pr6	1279	2	trial	trial	NN
cord-005478-5iu38pr6	1279	3	was	be	VBD
cord-005478-5iu38pr6	1279	4	designed	design	VBN
cord-005478-5iu38pr6	1279	5	as	as	IN
cord-005478-5iu38pr6	1279	6	an	an	DT
cord-005478-5iu38pr6	1279	7	investigatorinitiated	investigatorinitiated	JJ
cord-005478-5iu38pr6	1279	8	prospective	prospective	JJ
cord-005478-5iu38pr6	1279	9	,	,	,
cord-005478-5iu38pr6	1279	10	multicenter	multicenter	JJ
cord-005478-5iu38pr6	1279	11	,	,	,
cord-005478-5iu38pr6	1279	12	open	open	JJ
cord-005478-5iu38pr6	1279	13	-	-	HYPH
cord-005478-5iu38pr6	1279	14	label	label	NN
cord-005478-5iu38pr6	1279	15	,	,	,
cord-005478-5iu38pr6	1279	16	two	two	CD
cord-005478-5iu38pr6	1279	17	-	-	HYPH
cord-005478-5iu38pr6	1279	18	arm	arm	NN
cord-005478-5iu38pr6	1279	19	,	,	,
cord-005478-5iu38pr6	1279	20	parallel	parallel	JJ
cord-005478-5iu38pr6	1279	21	-	-	HYPH
cord-005478-5iu38pr6	1279	22	group	group	NN
cord-005478-5iu38pr6	1279	23	phase	phase	NN
cord-005478-5iu38pr6	1279	24	II	II	NNP
cord-005478-5iu38pr6	1279	25	study	study	NN
cord-005478-5iu38pr6	1279	26	comparing	compare	VBG
cord-005478-5iu38pr6	1279	27	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1279	28	to	to	IN
cord-005478-5iu38pr6	1279	29	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1279	30	regimen	regimen	NN
cord-005478-5iu38pr6	1279	31	.	.	.
cord-005478-5iu38pr6	1280	1	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1280	2	regimen	regimen	NN
cord-005478-5iu38pr6	1280	3	consists	consist	VBZ
cord-005478-5iu38pr6	1280	4	of	of	IN
cord-005478-5iu38pr6	1280	5	Fludarabine	Fludarabine	NNP
cord-005478-5iu38pr6	1280	6	(	(	-LRB-
cord-005478-5iu38pr6	1280	7	30	30	CD
cord-005478-5iu38pr6	1280	8	mg/	mg/	NN
cord-005478-5iu38pr6	1280	9	m2	m2	NNP
cord-005478-5iu38pr6	1280	10	,	,	,
cord-005478-5iu38pr6	1280	11	days	day	NNS
cord-005478-5iu38pr6	1280	12	-13	-13	VBG
cord-005478-5iu38pr6	1280	13	to	to	IN
cord-005478-5iu38pr6	1280	14	-10	-10	NN
cord-005478-5iu38pr6	1280	15	)	)	-RRB-
cord-005478-5iu38pr6	1280	16	,	,	,
cord-005478-5iu38pr6	1280	17	Amsacrine	Amsacrine	NNP
cord-005478-5iu38pr6	1280	18	(	(	-LRB-
cord-005478-5iu38pr6	1280	19	100	100	CD
cord-005478-5iu38pr6	1280	20	mg	mg	NNP
cord-005478-5iu38pr6	1280	21	/	/	SYM
cord-005478-5iu38pr6	1280	22	m2	m2	NNP
cord-005478-5iu38pr6	1280	23	,	,	,
cord-005478-5iu38pr6	1280	24	days	day	NNS
cord-005478-5iu38pr6	1280	25	-13	-13	VBG
cord-005478-5iu38pr6	1280	26	to	to	IN
cord-005478-5iu38pr6	1280	27	-10	-10	NN
cord-005478-5iu38pr6	1280	28	)	)	-RRB-
cord-005478-5iu38pr6	1280	29	and	and	CC
cord-005478-5iu38pr6	1280	30	Cytarabine	Cytarabine	NNP
cord-005478-5iu38pr6	1280	31	(	(	-LRB-
cord-005478-5iu38pr6	1280	32	2000	2000	CD
cord-005478-5iu38pr6	1280	33	mg	mg	NNP
cord-005478-5iu38pr6	1280	34	/	/	SYM
cord-005478-5iu38pr6	1280	35	m2	m2	NNP
cord-005478-5iu38pr6	1280	36	,	,	,
cord-005478-5iu38pr6	1280	37	days	day	NNS
cord-005478-5iu38pr6	1280	38	-13	-13	VBG
cord-005478-5iu38pr6	1280	39	to	to	IN
cord-005478-5iu38pr6	1280	40	-10	-10	NN
cord-005478-5iu38pr6	1280	41	)	)	-RRB-
cord-005478-5iu38pr6	1280	42	.	.	.
cord-005478-5iu38pr6	1281	1	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1281	2	regimen	regimen	NN
cord-005478-5iu38pr6	1281	3	consists	consist	VBZ
cord-005478-5iu38pr6	1281	4	of	of	IN
cord-005478-5iu38pr6	1281	5	Clofarabine	Clofarabine	NNP
cord-005478-5iu38pr6	1281	6	(	(	-LRB-
cord-005478-5iu38pr6	1281	7	30	30	CD
cord-005478-5iu38pr6	1281	8	mg	mg	NNP
cord-005478-5iu38pr6	1281	9	/	/	SYM
cord-005478-5iu38pr6	1281	10	m2	m2	NNP
cord-005478-5iu38pr6	1281	11	,	,	,
cord-005478-5iu38pr6	1281	12	days	day	NNS
cord-005478-5iu38pr6	1281	13	-16	-16	IN
cord-005478-5iu38pr6	1281	14	to	to	IN
cord-005478-5iu38pr6	1281	15	-12	-12	CD
cord-005478-5iu38pr6	1281	16	)	)	-RRB-
cord-005478-5iu38pr6	1281	17	and	and	CC
cord-005478-5iu38pr6	1281	18	Cytarabine	Cytarabine	NNP
cord-005478-5iu38pr6	1281	19	(	(	-LRB-
cord-005478-5iu38pr6	1281	20	1000	1000	CD
cord-005478-5iu38pr6	1281	21	mg	mg	NNP
cord-005478-5iu38pr6	1281	22	/	/	SYM
cord-005478-5iu38pr6	1281	23	m2	m2	NNP
cord-005478-5iu38pr6	1281	24	,	,	,
cord-005478-5iu38pr6	1281	25	days	day	NNS
cord-005478-5iu38pr6	1281	26	-16	-16	IN
cord-005478-5iu38pr6	1281	27	to	to	IN
cord-005478-5iu38pr6	1281	28	-12	-12	CD
cord-005478-5iu38pr6	1281	29	)	)	-RRB-
cord-005478-5iu38pr6	1281	30	.	.	.
cord-005478-5iu38pr6	1282	1	Both	both	DT
cord-005478-5iu38pr6	1282	2	cytoreductive	cytoreductive	JJ
cord-005478-5iu38pr6	1282	3	therapies	therapy	NNS
cord-005478-5iu38pr6	1282	4	were	be	VBD
cord-005478-5iu38pr6	1282	5	combined	combine	VBN
cord-005478-5iu38pr6	1282	6	with	with	IN
cord-005478-5iu38pr6	1282	7	Bu	Bu	NNP
cord-005478-5iu38pr6	1282	8	/	/	SYM
cord-005478-5iu38pr6	1282	9	Cy	Cy	NNP
cord-005478-5iu38pr6	1282	10	(	(	-LRB-
cord-005478-5iu38pr6	1282	11	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	1282	12	,	,	,
cord-005478-5iu38pr6	1282	13	4	4	CD
cord-005478-5iu38pr6	1282	14	x	x	SYM
cord-005478-5iu38pr6	1282	15	0.8mg	0.8mg	CD
cord-005478-5iu38pr6	1282	16	/	/	SYM
cord-005478-5iu38pr6	1282	17	kg	kg	NNS
cord-005478-5iu38pr6	1282	18	,	,	,
cord-005478-5iu38pr6	1282	19	days	day	NNS
cord-005478-5iu38pr6	1282	20	-6	-6	JJ
cord-005478-5iu38pr6	1282	21	to	to	IN
cord-005478-5iu38pr6	1282	22	-5	-5	NNP
cord-005478-5iu38pr6	1282	23	and	and	CC
cord-005478-5iu38pr6	1282	24	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	1282	25	60	60	CD
cord-005478-5iu38pr6	1282	26	mg	mg	NNP
cord-005478-5iu38pr6	1282	27	/	/	SYM
cord-005478-5iu38pr6	1282	28	kg	kg	NNS
cord-005478-5iu38pr6	1282	29	,	,	,
cord-005478-5iu38pr6	1282	30	days	day	NNS
cord-005478-5iu38pr6	1282	31	-4	-4	XX
cord-005478-5iu38pr6	1282	32	to	to	IN
cord-005478-5iu38pr6	1282	33	-3	-3	NNP
cord-005478-5iu38pr6	1282	34	)	)	-RRB-
cord-005478-5iu38pr6	1282	35	.	.	.
cord-005478-5iu38pr6	1283	1	As	as	IN
cord-005478-5iu38pr6	1283	2	GvHD	gvhd	NN
cord-005478-5iu38pr6	1283	3	-	-	HYPH
cord-005478-5iu38pr6	1283	4	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1283	5	ATG	ATG	NNP
cord-005478-5iu38pr6	1283	6	,	,	,
cord-005478-5iu38pr6	1283	7	CsA	csa	NN
cord-005478-5iu38pr6	1283	8	and	and	CC
cord-005478-5iu38pr6	1283	9	MMF	MMF	NNP
cord-005478-5iu38pr6	1283	10	were	be	VBD
cord-005478-5iu38pr6	1283	11	used	use	VBN
cord-005478-5iu38pr6	1283	12	.	.	.
cord-005478-5iu38pr6	1284	1	Patients	patient	NNS
cord-005478-5iu38pr6	1284	2	with	with	IN
cord-005478-5iu38pr6	1284	3	high	high	JJ
cord-005478-5iu38pr6	1284	4	risk	risk	NN
cord-005478-5iu38pr6	1284	5	AML	AML	NNP
cord-005478-5iu38pr6	1284	6	or	or	CC
cord-005478-5iu38pr6	1284	7	advanced	advanced	JJ
cord-005478-5iu38pr6	1284	8	MDS	MDS	NNP
cord-005478-5iu38pr6	1284	9	(	(	-LRB-
cord-005478-5iu38pr6	1284	10	IPSS	IPSS	NNP
cord-005478-5iu38pr6	1284	11	≥	≥	CD
cord-005478-5iu38pr6	1284	12	int2	int2	NNP
cord-005478-5iu38pr6	1284	13	)	)	-RRB-
cord-005478-5iu38pr6	1284	14	with	with	IN
cord-005478-5iu38pr6	1284	15	contraindication	contraindication	NN
cord-005478-5iu38pr6	1284	16	for	for	IN
cord-005478-5iu38pr6	1284	17	conventional	conventional	JJ
cord-005478-5iu38pr6	1284	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	1284	19	or	or	CC
cord-005478-5iu38pr6	1284	20	refractory	refractory	JJ
cord-005478-5iu38pr6	1284	21	to	to	IN
cord-005478-5iu38pr6	1284	22	induction	induction	NN
cord-005478-5iu38pr6	1284	23	therapy	therapy	NN
cord-005478-5iu38pr6	1284	24	were	be	VBD
cord-005478-5iu38pr6	1284	25	eligible	eligible	JJ
cord-005478-5iu38pr6	1284	26	.	.	.
cord-005478-5iu38pr6	1285	1	Primary	primary	JJ
cord-005478-5iu38pr6	1285	2	objective	objective	NN
cord-005478-5iu38pr6	1285	3	was	be	VBD
cord-005478-5iu38pr6	1285	4	to	to	TO
cord-005478-5iu38pr6	1285	5	demonstrate	demonstrate	VB
cord-005478-5iu38pr6	1285	6	that	that	DT
cord-005478-5iu38pr6	1285	7	event	event	NN
cord-005478-5iu38pr6	1285	8	-	-	HYPH
cord-005478-5iu38pr6	1285	9	free	free	JJ
cord-005478-5iu38pr6	1285	10	survival	survival	NN
cord-005478-5iu38pr6	1285	11	is	be	VBZ
cord-005478-5iu38pr6	1285	12	improved	improve	VBN
cord-005478-5iu38pr6	1285	13	by	by	IN
cord-005478-5iu38pr6	1285	14	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1285	15	instead	instead	RB
cord-005478-5iu38pr6	1285	16	of	of	IN
cord-005478-5iu38pr6	1285	17	the	the	DT
cord-005478-5iu38pr6	1285	18	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1285	19	.	.	.
cord-005478-5iu38pr6	1286	1	Secondary	secondary	JJ
cord-005478-5iu38pr6	1286	2	objectives	objective	NNS
cord-005478-5iu38pr6	1286	3	were	be	VBD
cord-005478-5iu38pr6	1286	4	overall	overall	JJ
cord-005478-5iu38pr6	1286	5	and	and	CC
cord-005478-5iu38pr6	1286	6	relapse	relapse	NN
cord-005478-5iu38pr6	1286	7	-	-	HYPH
cord-005478-5iu38pr6	1286	8	free	free	JJ
cord-005478-5iu38pr6	1286	9	survival	survival	NN
cord-005478-5iu38pr6	1286	10	,	,	,
cord-005478-5iu38pr6	1286	11	mortality	mortality	NN
cord-005478-5iu38pr6	1286	12	rate	rate	NN
cord-005478-5iu38pr6	1286	13	,	,	,
cord-005478-5iu38pr6	1286	14	safety	safety	NN
cord-005478-5iu38pr6	1286	15	profiles	profile	NNS
cord-005478-5iu38pr6	1286	16	and	and	CC
cord-005478-5iu38pr6	1286	17	cardiac	cardiac	JJ
cord-005478-5iu38pr6	1286	18	toxicity	toxicity	NN
cord-005478-5iu38pr6	1286	19	.	.	.
cord-005478-5iu38pr6	1287	1	Results	result	NNS
cord-005478-5iu38pr6	1287	2	:	:	:
cord-005478-5iu38pr6	1288	1	Between	between	IN
cord-005478-5iu38pr6	1288	2	2011	2011	CD
cord-005478-5iu38pr6	1288	3	and	and	CC
cord-005478-5iu38pr6	1288	4	2017	2017	CD
cord-005478-5iu38pr6	1288	5	,	,	,
cord-005478-5iu38pr6	1288	6	62	62	CD
cord-005478-5iu38pr6	1288	7	patients	patient	NNS
cord-005478-5iu38pr6	1288	8	were	be	VBD
cord-005478-5iu38pr6	1288	9	recruited	recruit	VBN
cord-005478-5iu38pr6	1288	10	,	,	,
cord-005478-5iu38pr6	1288	11	2	2	CD
cord-005478-5iu38pr6	1288	12	patients	patient	NNS
cord-005478-5iu38pr6	1288	13	did	do	VBD
cord-005478-5iu38pr6	1288	14	not	not	RB
cord-005478-5iu38pr6	1288	15	meet	meet	VB
cord-005478-5iu38pr6	1288	16	the	the	DT
cord-005478-5iu38pr6	1288	17	in-/exclusion	in-/exclusion	NNP
cord-005478-5iu38pr6	1288	18	criteria	criterion	NNS
cord-005478-5iu38pr6	1288	19	.	.	.
cord-005478-5iu38pr6	1289	1	A	a	DT
cord-005478-5iu38pr6	1289	2	total	total	NN
cord-005478-5iu38pr6	1289	3	of	of	IN
cord-005478-5iu38pr6	1289	4	60	60	CD
cord-005478-5iu38pr6	1289	5	were	be	VBD
cord-005478-5iu38pr6	1289	6	randomized	randomize	VBN
cord-005478-5iu38pr6	1289	7	with	with	IN
cord-005478-5iu38pr6	1289	8	30	30	CD
cord-005478-5iu38pr6	1289	9	patients	patient	NNS
cord-005478-5iu38pr6	1289	10	each	each	DT
cord-005478-5iu38pr6	1289	11	in	in	IN
cord-005478-5iu38pr6	1289	12	the	the	DT
cord-005478-5iu38pr6	1289	13	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1289	14	and	and	CC
cord-005478-5iu38pr6	1289	15	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1289	16	group	group	NN
cord-005478-5iu38pr6	1289	17	.	.	.
cord-005478-5iu38pr6	1290	1	Mean	mean	JJ
cord-005478-5iu38pr6	1290	2	time	time	NN
cord-005478-5iu38pr6	1290	3	to	to	IN
cord-005478-5iu38pr6	1290	4	event	event	NN
cord-005478-5iu38pr6	1290	5	was	be	VBD
cord-005478-5iu38pr6	1290	6	656.6	656.6	CD
cord-005478-5iu38pr6	1290	7	±	±	NNP
cord-005478-5iu38pr6	1290	8	84.6	84.6	CD
cord-005478-5iu38pr6	1290	9	days	day	NNS
cord-005478-5iu38pr6	1290	10	for	for	IN
cord-005478-5iu38pr6	1290	11	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1290	12	and	and	CC
cord-005478-5iu38pr6	1290	13	565.6	565.6	CD
cord-005478-5iu38pr6	1290	14	±	±	CD
cord-005478-5iu38pr6	1290	15	49.2	49.2	CD
cord-005478-5iu38pr6	1290	16	days	day	NNS
cord-005478-5iu38pr6	1290	17	for	for	IN
cord-005478-5iu38pr6	1290	18	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1290	19	,	,	,
cord-005478-5iu38pr6	1290	20	respectively	respectively	RB
cord-005478-5iu38pr6	1290	21	(	(	-LRB-
cord-005478-5iu38pr6	1290	22	p=0.177	p=0.177	NN
cord-005478-5iu38pr6	1290	23	,	,	,
cord-005478-5iu38pr6	1290	24	figure	figure	NN
cord-005478-5iu38pr6	1290	25	1	1	CD
cord-005478-5iu38pr6	1290	26	)	)	-RRB-
cord-005478-5iu38pr6	1290	27	.	.	.
cord-005478-5iu38pr6	1291	1	In	in	IN
cord-005478-5iu38pr6	1291	2	total	total	JJ
cord-005478-5iu38pr6	1291	3	38	38	CD
cord-005478-5iu38pr6	1291	4	of	of	IN
cord-005478-5iu38pr6	1291	5	the	the	DT
cord-005478-5iu38pr6	1291	6	adverse	adverse	JJ
cord-005478-5iu38pr6	1291	7	events	event	NNS
cord-005478-5iu38pr6	1291	8	were	be	VBD
cord-005478-5iu38pr6	1291	9	serious	serious	JJ
cord-005478-5iu38pr6	1291	10	with	with	IN
cord-005478-5iu38pr6	1291	11	fatal	fatal	JJ
cord-005478-5iu38pr6	1291	12	outcome	outcome	NN
cord-005478-5iu38pr6	1291	13	of	of	IN
cord-005478-5iu38pr6	1291	14	3	3	CD
cord-005478-5iu38pr6	1291	15	patients	patient	NNS
cord-005478-5iu38pr6	1291	16	in	in	IN
cord-005478-5iu38pr6	1291	17	the	the	DT
cord-005478-5iu38pr6	1291	18	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1291	19	and	and	CC
cord-005478-5iu38pr6	1291	20	4	4	CD
cord-005478-5iu38pr6	1291	21	patients	patient	NNS
cord-005478-5iu38pr6	1291	22	in	in	IN
cord-005478-5iu38pr6	1291	23	the	the	DT
cord-005478-5iu38pr6	1291	24	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1291	25	group	group	NN
cord-005478-5iu38pr6	1291	26	.	.	.
cord-005478-5iu38pr6	1292	1	Cardiac	cardiac	JJ
cord-005478-5iu38pr6	1292	2	toxicity	toxicity	NN
cord-005478-5iu38pr6	1292	3	was	be	VBD
cord-005478-5iu38pr6	1292	4	observed	observe	VBN
cord-005478-5iu38pr6	1292	5	in	in	IN
cord-005478-5iu38pr6	1292	6	26	26	CD
cord-005478-5iu38pr6	1292	7	patients	patient	NNS
cord-005478-5iu38pr6	1292	8	in	in	IN
cord-005478-5iu38pr6	1292	9	the	the	DT
cord-005478-5iu38pr6	1292	10	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1292	11	treatment	treatment	NN
cord-005478-5iu38pr6	1292	12	arm	arm	NN
cord-005478-5iu38pr6	1292	13	,	,	,
cord-005478-5iu38pr6	1292	14	whereas	whereas	IN
cord-005478-5iu38pr6	1292	15	27	27	CD
cord-005478-5iu38pr6	1292	16	patients	patient	NNS
cord-005478-5iu38pr6	1292	17	were	be	VBD
cord-005478-5iu38pr6	1292	18	affected	affect	VBN
cord-005478-5iu38pr6	1292	19	in	in	IN
cord-005478-5iu38pr6	1292	20	the	the	DT
cord-005478-5iu38pr6	1292	21	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1292	22	treatment	treatment	NN
cord-005478-5iu38pr6	1292	23	arm	arm	NN
cord-005478-5iu38pr6	1292	24	(	(	-LRB-
cord-005478-5iu38pr6	1292	25	p=0.730	p=0.730	NNP
cord-005478-5iu38pr6	1292	26	)	)	-RRB-
cord-005478-5iu38pr6	1292	27	.	.	.
cord-005478-5iu38pr6	1293	1	Overall	overall	JJ
cord-005478-5iu38pr6	1293	2	survival	survival	NN
cord-005478-5iu38pr6	1293	3	for	for	IN
cord-005478-5iu38pr6	1293	4	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1293	5	was	be	VBD
cord-005478-5iu38pr6	1293	6	numerically	numerically	RB
cord-005478-5iu38pr6	1293	7	,	,	,
cord-005478-5iu38pr6	1293	8	but	but	CC
cord-005478-5iu38pr6	1293	9	not	not	RB
cord-005478-5iu38pr6	1293	10	statistically	statistically	RB
cord-005478-5iu38pr6	1293	11	inferior	inferior	JJ
cord-005478-5iu38pr6	1293	12	to	to	IN
cord-005478-5iu38pr6	1293	13	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1293	14	(	(	-LRB-
cord-005478-5iu38pr6	1293	15	p=0.134	p=0.134	NNP
cord-005478-5iu38pr6	1293	16	)	)	-RRB-
cord-005478-5iu38pr6	1293	17	.	.	.
cord-005478-5iu38pr6	1294	1	A	a	DT
cord-005478-5iu38pr6	1294	2	part	part	NN
cord-005478-5iu38pr6	1294	3	of	of	IN
cord-005478-5iu38pr6	1294	4	16/30	16/30	CD
cord-005478-5iu38pr6	1294	5	(	(	-LRB-
cord-005478-5iu38pr6	1294	6	53.3	53.3	CD
cord-005478-5iu38pr6	1294	7	%	%	NN
cord-005478-5iu38pr6	1294	8	)	)	-RRB-
cord-005478-5iu38pr6	1294	9	patients	patient	NNS
cord-005478-5iu38pr6	1294	10	died	die	VBD
cord-005478-5iu38pr6	1294	11	until	until	IN
cord-005478-5iu38pr6	1294	12	the	the	DT
cord-005478-5iu38pr6	1294	13	end	end	NN
cord-005478-5iu38pr6	1294	14	of	of	IN
cord-005478-5iu38pr6	1294	15	the	the	DT
cord-005478-5iu38pr6	1294	16	study	study	NN
cord-005478-5iu38pr6	1294	17	in	in	IN
cord-005478-5iu38pr6	1294	18	the	the	DT
cord-005478-5iu38pr6	1294	19	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1294	20	treatment	treatment	NN
cord-005478-5iu38pr6	1294	21	arm	arm	NN
cord-005478-5iu38pr6	1294	22	,	,	,
cord-005478-5iu38pr6	1294	23	whereas	whereas	IN
cord-005478-5iu38pr6	1294	24	only	only	RB
cord-005478-5iu38pr6	1294	25	12/30	12/30	CD
cord-005478-5iu38pr6	1294	26	(	(	-LRB-
cord-005478-5iu38pr6	1294	27	40.0	40.0	CD
cord-005478-5iu38pr6	1294	28	%	%	NN
cord-005478-5iu38pr6	1294	29	)	)	-RRB-
cord-005478-5iu38pr6	1294	30	died	die	VBD
cord-005478-5iu38pr6	1294	31	in	in	IN
cord-005478-5iu38pr6	1294	32	the	the	DT
cord-005478-5iu38pr6	1294	33	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1294	34	treatment	treatment	NN
cord-005478-5iu38pr6	1294	35	arm	arm	NN
cord-005478-5iu38pr6	1294	36	(	(	-LRB-
cord-005478-5iu38pr6	1294	37	p=0.134	p=0.134	NNP
cord-005478-5iu38pr6	1294	38	)	)	-RRB-
cord-005478-5iu38pr6	1294	39	.	.	.
cord-005478-5iu38pr6	1295	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1295	2	:	:	:
cord-005478-5iu38pr6	1296	1	This	this	DT
cord-005478-5iu38pr6	1296	2	study	study	NN
cord-005478-5iu38pr6	1296	3	did	do	VBD
cord-005478-5iu38pr6	1296	4	compare	compare	VB
cord-005478-5iu38pr6	1296	5	two	two	CD
cord-005478-5iu38pr6	1296	6	different	different	JJ
cord-005478-5iu38pr6	1296	7	conditioning	conditioning	NN
cord-005478-5iu38pr6	1296	8	regimens	regimen	NNS
cord-005478-5iu38pr6	1296	9	for	for	IN
cord-005478-5iu38pr6	1296	10	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1296	11	stem	stem	NN
cord-005478-5iu38pr6	1296	12	cell	cell	NN
cord-005478-5iu38pr6	1296	13	recipients	recipient	NNS
cord-005478-5iu38pr6	1296	14	with	with	IN
cord-005478-5iu38pr6	1296	15	high	high	JJ
cord-005478-5iu38pr6	1296	16	risk	risk	NN
cord-005478-5iu38pr6	1296	17	AML	AML	NNP
cord-005478-5iu38pr6	1296	18	/	/	SYM
cord-005478-5iu38pr6	1296	19	MDS	MDS	NNP
cord-005478-5iu38pr6	1296	20	.	.	.
cord-005478-5iu38pr6	1297	1	62	62	CD
cord-005478-5iu38pr6	1297	2	patients	patient	NNS
cord-005478-5iu38pr6	1297	3	have	have	VBP
cord-005478-5iu38pr6	1297	4	been	be	VBN
cord-005478-5iu38pr6	1297	5	included	include	VBN
cord-005478-5iu38pr6	1297	6	and	and	CC
cord-005478-5iu38pr6	1297	7	60	60	CD
cord-005478-5iu38pr6	1297	8	were	be	VBD
cord-005478-5iu38pr6	1297	9	randomized	randomize	VBN
cord-005478-5iu38pr6	1297	10	.	.	.
cord-005478-5iu38pr6	1298	1	The	the	DT
cord-005478-5iu38pr6	1298	2	treatment	treatment	NN
cord-005478-5iu38pr6	1298	3	arms	arm	NNS
cord-005478-5iu38pr6	1298	4	were	be	VBD
cord-005478-5iu38pr6	1298	5	wellbalanced	wellbalance	VBN
cord-005478-5iu38pr6	1298	6	at	at	IN
cord-005478-5iu38pr6	1298	7	study	study	NN
cord-005478-5iu38pr6	1298	8	baseline	baseline	NN
cord-005478-5iu38pr6	1298	9	for	for	IN
cord-005478-5iu38pr6	1298	10	relevant	relevant	JJ
cord-005478-5iu38pr6	1298	11	covariates	covariate	NNS
cord-005478-5iu38pr6	1298	12	.	.	.
cord-005478-5iu38pr6	1299	1	Superiority	superiority	NN
cord-005478-5iu38pr6	1299	2	of	of	IN
cord-005478-5iu38pr6	1299	3	the	the	DT
cord-005478-5iu38pr6	1299	4	ClAraC	ClAraC	NNP
cord-005478-5iu38pr6	1299	5	treatment	treatment	NN
cord-005478-5iu38pr6	1299	6	regimen	regimen	NN
cord-005478-5iu38pr6	1299	7	over	over	IN
cord-005478-5iu38pr6	1299	8	the	the	DT
cord-005478-5iu38pr6	1299	9	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1299	10	regimen	regimen	NN
cord-005478-5iu38pr6	1299	11	could	could	MD
cord-005478-5iu38pr6	1299	12	not	not	RB
cord-005478-5iu38pr6	1299	13	be	be	VB
cord-005478-5iu38pr6	1299	14	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	1299	15	.	.	.
cord-005478-5iu38pr6	1300	1	Consistently	consistently	RB
cord-005478-5iu38pr6	1300	2	hazard	hazard	NN
cord-005478-5iu38pr6	1300	3	ratios	ratio	NNS
cord-005478-5iu38pr6	1300	4	for	for	IN
cord-005478-5iu38pr6	1300	5	event	event	NN
cord-005478-5iu38pr6	1300	6	free	free	JJ
cord-005478-5iu38pr6	1300	7	survival	survival	NN
cord-005478-5iu38pr6	1300	8	,	,	,
cord-005478-5iu38pr6	1300	9	overall	overall	JJ
cord-005478-5iu38pr6	1300	10	survival	survival	NN
cord-005478-5iu38pr6	1300	11	and	and	CC
cord-005478-5iu38pr6	1300	12	relapsefree	relapsefree	NNP
cord-005478-5iu38pr6	1300	13	survival	survival	NN
cord-005478-5iu38pr6	1300	14	were	be	VBD
cord-005478-5iu38pr6	1300	15	in	in	IN
cord-005478-5iu38pr6	1300	16	favor	favor	NN
cord-005478-5iu38pr6	1300	17	of	of	IN
cord-005478-5iu38pr6	1300	18	the	the	DT
cord-005478-5iu38pr6	1300	19	control	control	NN
cord-005478-5iu38pr6	1300	20	group	group	NN
cord-005478-5iu38pr6	1300	21	with	with	IN
cord-005478-5iu38pr6	1300	22	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1300	23	treatment	treatment	NN
cord-005478-5iu38pr6	1300	24	.	.	.
cord-005478-5iu38pr6	1301	1	No	no	DT
cord-005478-5iu38pr6	1301	2	differences	difference	NNS
cord-005478-5iu38pr6	1301	3	were	be	VBD
cord-005478-5iu38pr6	1301	4	found	find	VBN
cord-005478-5iu38pr6	1301	5	regarding	regard	VBG
cord-005478-5iu38pr6	1301	6	cardiac	cardiac	JJ
cord-005478-5iu38pr6	1301	7	toxicity	toxicity	NN
cord-005478-5iu38pr6	1301	8	,	,	,
cord-005478-5iu38pr6	1301	9	rate	rate	NN
cord-005478-5iu38pr6	1301	10	of	of	IN
cord-005478-5iu38pr6	1301	11	engraftment	engraftment	NN
cord-005478-5iu38pr6	1301	12	,	,	,
cord-005478-5iu38pr6	1301	13	or	or	CC
cord-005478-5iu38pr6	1301	14	chimerism	chimerism	NN
cord-005478-5iu38pr6	1301	15	.	.	.
cord-005478-5iu38pr6	1302	1	Regarding	regard	VBG
cord-005478-5iu38pr6	1302	2	general	general	JJ
cord-005478-5iu38pr6	1302	3	safety	safety	NN
cord-005478-5iu38pr6	1302	4	parameters	parameter	NNS
cord-005478-5iu38pr6	1302	5	,	,	,
cord-005478-5iu38pr6	1302	6	no	no	DT
cord-005478-5iu38pr6	1302	7	relevant	relevant	JJ
cord-005478-5iu38pr6	1302	8	differences	difference	NNS
cord-005478-5iu38pr6	1302	9	between	between	IN
cord-005478-5iu38pr6	1302	10	the	the	DT
cord-005478-5iu38pr6	1302	11	two	two	CD
cord-005478-5iu38pr6	1302	12	treatment	treatment	NN
cord-005478-5iu38pr6	1302	13	strategies	strategy	NNS
cord-005478-5iu38pr6	1302	14	were	be	VBD
cord-005478-5iu38pr6	1302	15	found	find	VBN
cord-005478-5iu38pr6	1302	16	.	.	.
cord-005478-5iu38pr6	1303	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1303	2	Trial	Trial	NNP
cord-005478-5iu38pr6	1303	3	Registry	Registry	NNP
cord-005478-5iu38pr6	1303	4	:	:	:
cord-005478-5iu38pr6	1304	1	Background	background	NN
cord-005478-5iu38pr6	1304	2	:	:	:
cord-005478-5iu38pr6	1305	1	Currently	currently	RB
cord-005478-5iu38pr6	1305	2	,	,	,
cord-005478-5iu38pr6	1305	3	there	there	EX
cord-005478-5iu38pr6	1305	4	is	be	VBZ
cord-005478-5iu38pr6	1305	5	no	no	DT
cord-005478-5iu38pr6	1305	6	direct	direct	JJ
cord-005478-5iu38pr6	1305	7	evidence	evidence	NN
cord-005478-5iu38pr6	1305	8	to	to	TO
cord-005478-5iu38pr6	1305	9	recommend	recommend	VB
cord-005478-5iu38pr6	1305	10	specific	specific	JJ
cord-005478-5iu38pr6	1305	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	1305	12	intensities	intensity	NNS
cord-005478-5iu38pr6	1305	13	in	in	IN
cord-005478-5iu38pr6	1305	14	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1305	15	undergoing	undergo	VBG
cord-005478-5iu38pr6	1305	16	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1305	17	stem	stem	NN
cord-005478-5iu38pr6	1305	18	cell	cell	NN
cord-005478-5iu38pr6	1305	19	transplantation	transplantation	NN
cord-005478-5iu38pr6	1305	20	.	.	.
cord-005478-5iu38pr6	1306	1	Moreover	moreover	RB
cord-005478-5iu38pr6	1306	2	,	,	,
cord-005478-5iu38pr6	1306	3	recent	recent	JJ
cord-005478-5iu38pr6	1306	4	risk	risk	NN
cord-005478-5iu38pr6	1306	5	stratifications	stratification	NNS
cord-005478-5iu38pr6	1306	6	for	for	IN
cord-005478-5iu38pr6	1306	7	diagnosed	diagnosed	JJ
cord-005478-5iu38pr6	1306	8	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1306	9	(	(	-LRB-
cord-005478-5iu38pr6	1306	10	MF	MF	NNP
cord-005478-5iu38pr6	1306	11	)	)	-RRB-
cord-005478-5iu38pr6	1306	12	included	include	VBD
cord-005478-5iu38pr6	1306	13	specific	specific	JJ
cord-005478-5iu38pr6	1306	14	mutation	mutation	NN
cord-005478-5iu38pr6	1306	15	profiles	profile	NNS
cord-005478-5iu38pr6	1306	16	as	as	IN
cord-005478-5iu38pr6	1306	17	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1306	18	factors	factor	NNS
cord-005478-5iu38pr6	1306	19	.	.	.
cord-005478-5iu38pr6	1307	1	Using	use	VBG
cord-005478-5iu38pr6	1307	2	clinical	clinical	JJ
cord-005478-5iu38pr6	1307	3	-	-	HYPH
cord-005478-5iu38pr6	1307	4	molecular	molecular	JJ
cord-005478-5iu38pr6	1307	5	data	datum	NNS
cord-005478-5iu38pr6	1307	6	from	from	IN
cord-005478-5iu38pr6	1307	7	four	four	CD
cord-005478-5iu38pr6	1307	8	different	different	JJ
cord-005478-5iu38pr6	1307	9	centers	center	NNS
cord-005478-5iu38pr6	1307	10	from	from	IN
cord-005478-5iu38pr6	1307	11	Germany	Germany	NNP
cord-005478-5iu38pr6	1307	12	and	and	CC
cord-005478-5iu38pr6	1307	13	France	France	NNP
cord-005478-5iu38pr6	1307	14	,	,	,
cord-005478-5iu38pr6	1307	15	we	-PRON-	PRP
cord-005478-5iu38pr6	1307	16	sought	seek	VBD
cord-005478-5iu38pr6	1307	17	to	to	TO
cord-005478-5iu38pr6	1307	18	determine	determine	VB
cord-005478-5iu38pr6	1307	19	whether	whether	IN
cord-005478-5iu38pr6	1307	20	molecular	molecular	JJ
cord-005478-5iu38pr6	1307	21	genetics	genetic	NNS
cord-005478-5iu38pr6	1307	22	have	have	VBP
cord-005478-5iu38pr6	1307	23	an	an	DT
cord-005478-5iu38pr6	1307	24	impact	impact	NN
cord-005478-5iu38pr6	1307	25	on	on	IN
cord-005478-5iu38pr6	1307	26	outcome	outcome	NN
cord-005478-5iu38pr6	1307	27	after	after	IN
cord-005478-5iu38pr6	1307	28	reduced	reduce	VBN
cord-005478-5iu38pr6	1307	29	intensity	intensity	NN
cord-005478-5iu38pr6	1307	30	(	(	-LRB-
cord-005478-5iu38pr6	1307	31	RIC	RIC	NNP
cord-005478-5iu38pr6	1307	32	)	)	-RRB-
cord-005478-5iu38pr6	1307	33	and	and	CC
cord-005478-5iu38pr6	1307	34	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1307	35	conditioning	conditioning	NNP
cord-005478-5iu38pr6	1307	36	(	(	-LRB-
cord-005478-5iu38pr6	1307	37	MAC	MAC	NNP
cord-005478-5iu38pr6	1307	38	)	)	-RRB-
cord-005478-5iu38pr6	1307	39	stem	stem	NN
cord-005478-5iu38pr6	1307	40	cell	cell	NN
cord-005478-5iu38pr6	1307	41	transplantation	transplantation	NN
cord-005478-5iu38pr6	1307	42	in	in	IN
cord-005478-5iu38pr6	1307	43	MF	MF	NNP
cord-005478-5iu38pr6	1307	44	.	.	.
cord-005478-5iu38pr6	1308	1	Methods	method	NNS
cord-005478-5iu38pr6	1308	2	:	:	:
cord-005478-5iu38pr6	1308	3	Previously	previously	RB
cord-005478-5iu38pr6	1308	4	published	publish	VBN
cord-005478-5iu38pr6	1308	5	methods	method	NNS
cord-005478-5iu38pr6	1308	6	were	be	VBD
cord-005478-5iu38pr6	1308	7	used	use	VBN
cord-005478-5iu38pr6	1308	8	to	to	TO
cord-005478-5iu38pr6	1308	9	sequence	sequence	VB
cord-005478-5iu38pr6	1308	10	myelofibrosis	myelofibrosis	NNP
cord-005478-5iu38pr6	1308	11	-	-	HYPH
cord-005478-5iu38pr6	1308	12	associated	associate	VBN
cord-005478-5iu38pr6	1308	13	genes	gene	NNS
cord-005478-5iu38pr6	1308	14	(	(	-LRB-
cord-005478-5iu38pr6	1308	15	i.a	i.a	NNP
cord-005478-5iu38pr6	1308	16	.	.	NNP
cord-005478-5iu38pr6	1308	17	CALR	CALR	NNP
cord-005478-5iu38pr6	1308	18	,	,	,
cord-005478-5iu38pr6	1308	19	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1308	20	,	,	,
cord-005478-5iu38pr6	1308	21	MPL	MPL	NNP
cord-005478-5iu38pr6	1308	22	,	,	,
cord-005478-5iu38pr6	1308	23	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1308	24	,	,	,
cord-005478-5iu38pr6	1308	25	SRSF2	SRSF2	VBN
cord-005478-5iu38pr6	1308	26	,	,	,
cord-005478-5iu38pr6	1309	1	EZH2	EZH2	NNP
cord-005478-5iu38pr6	1309	2	,	,	,
cord-005478-5iu38pr6	1309	3	IDH1/2	idh1/2	UH
cord-005478-5iu38pr6	1309	4	,	,	,
cord-005478-5iu38pr6	1309	5	DNMT3A	DNMT3A	NNP
cord-005478-5iu38pr6	1309	6	,	,	,
cord-005478-5iu38pr6	1309	7	TET2	TET2	NNP
cord-005478-5iu38pr6	1309	8	,	,	,
cord-005478-5iu38pr6	1309	9	TP53	TP53	NNP
cord-005478-5iu38pr6	1309	10	)	)	-RRB-
cord-005478-5iu38pr6	1309	11	.	.	.
cord-005478-5iu38pr6	1310	1	Risk	risk	NN
cord-005478-5iu38pr6	1310	2	stratifications	stratification	NNS
cord-005478-5iu38pr6	1310	3	according	accord	VBG
cord-005478-5iu38pr6	1310	4	to	to	IN
cord-005478-5iu38pr6	1310	5	Dynamic	Dynamic	NNP
cord-005478-5iu38pr6	1310	6	International	International	NNP
cord-005478-5iu38pr6	1310	7	Prognostic	Prognostic	NNP
cord-005478-5iu38pr6	1310	8	Scoring	Scoring	NNP
cord-005478-5iu38pr6	1310	9	System	System	NNP
cord-005478-5iu38pr6	1310	10	(	(	-LRB-
cord-005478-5iu38pr6	1310	11	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1310	12	)	)	-RRB-
cord-005478-5iu38pr6	1310	13	,	,	,
cord-005478-5iu38pr6	1310	14	mutation	mutation	NN
cord-005478-5iu38pr6	1310	15	-	-	HYPH
cord-005478-5iu38pr6	1310	16	enhanced	enhance	VBN
cord-005478-5iu38pr6	1310	17	system	system	NN
cord-005478-5iu38pr6	1310	18	(	(	-LRB-
cord-005478-5iu38pr6	1310	19	MIPSS70	MIPSS70	NNP
cord-005478-5iu38pr6	1310	20	)	)	-RRB-
cord-005478-5iu38pr6	1310	21	,	,	,
cord-005478-5iu38pr6	1310	22	genetic	genetic	JJ
cord-005478-5iu38pr6	1310	23	inspired	inspire	VBD
cord-005478-5iu38pr6	1310	24	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1310	25	system	system	NN
cord-005478-5iu38pr6	1310	26	(	(	-LRB-
cord-005478-5iu38pr6	1310	27	GIPSS	GIPSS	NNP
cord-005478-5iu38pr6	1310	28	)	)	-RRB-
cord-005478-5iu38pr6	1310	29	,	,	,
cord-005478-5iu38pr6	1310	30	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1310	31	model	model	NN
cord-005478-5iu38pr6	1310	32	for	for	IN
cord-005478-5iu38pr6	1310	33	secondary	secondary	JJ
cord-005478-5iu38pr6	1310	34	myelofibrosis	myelofibrosis	NN
cord-005478-5iu38pr6	1310	35	(	(	-LRB-
cord-005478-5iu38pr6	1310	36	MYSEC	MYSEC	NNP
cord-005478-5iu38pr6	1310	37	-	-	HYPH
cord-005478-5iu38pr6	1310	38	PM	PM	NNP
cord-005478-5iu38pr6	1310	39	)	)	-RRB-
cord-005478-5iu38pr6	1310	40	,	,	,
cord-005478-5iu38pr6	1310	41	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	1310	42	as	as	RB
cord-005478-5iu38pr6	1310	43	well	well	RB
cord-005478-5iu38pr6	1310	44	as	as	IN
cord-005478-5iu38pr6	1310	45	other	other	JJ
cord-005478-5iu38pr6	1310	46	clinical	clinical	JJ
cord-005478-5iu38pr6	1310	47	and	and	CC
cord-005478-5iu38pr6	1310	48	transplant	transplant	NN
cord-005478-5iu38pr6	1310	49	-	-	HYPH
cord-005478-5iu38pr6	1310	50	specific	specific	JJ
cord-005478-5iu38pr6	1310	51	variables	variable	NNS
cord-005478-5iu38pr6	1310	52	were	be	VBD
cord-005478-5iu38pr6	1310	53	included	include	VBN
cord-005478-5iu38pr6	1310	54	in	in	IN
cord-005478-5iu38pr6	1310	55	analyses	analysis	NNS
cord-005478-5iu38pr6	1310	56	.	.	.
cord-005478-5iu38pr6	1311	1	Cox	Cox	NNP
cord-005478-5iu38pr6	1311	2	model	model	NN
cord-005478-5iu38pr6	1311	3	with	with	IN
cord-005478-5iu38pr6	1311	4	hazard	hazard	NN
cord-005478-5iu38pr6	1311	5	ratios	ratio	NNS
cord-005478-5iu38pr6	1311	6	(	(	-LRB-
cord-005478-5iu38pr6	1311	7	HR	HR	NNP
cord-005478-5iu38pr6	1311	8	)	)	-RRB-
cord-005478-5iu38pr6	1311	9	was	be	VBD
cord-005478-5iu38pr6	1311	10	used	use	VBN
cord-005478-5iu38pr6	1311	11	for	for	IN
cord-005478-5iu38pr6	1311	12	survival	survival	NN
cord-005478-5iu38pr6	1311	13	(	(	-LRB-
cord-005478-5iu38pr6	1311	14	OS	OS	NNP
cord-005478-5iu38pr6	1311	15	)	)	-RRB-
cord-005478-5iu38pr6	1311	16	and	and	CC
cord-005478-5iu38pr6	1311	17	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1311	18	incidence	incidence	NN
cord-005478-5iu38pr6	1311	19	for	for	IN
cord-005478-5iu38pr6	1311	20	relapse	relapse	NN
cord-005478-5iu38pr6	1311	21	and	and	CC
cord-005478-5iu38pr6	1311	22	non	non	JJ
cord-005478-5iu38pr6	1311	23	-	-	JJ
cord-005478-5iu38pr6	1311	24	relapse	relapse	JJ
cord-005478-5iu38pr6	1311	25	mortality	mortality	NN
cord-005478-5iu38pr6	1311	26	(	(	-LRB-
cord-005478-5iu38pr6	1311	27	NRM	NRM	NNP
cord-005478-5iu38pr6	1311	28	)	)	-RRB-
cord-005478-5iu38pr6	1311	29	.	.	.
cord-005478-5iu38pr6	1312	1	Risk	risk	NN
cord-005478-5iu38pr6	1312	2	ratios	ratio	NNS
cord-005478-5iu38pr6	1312	3	(	(	-LRB-
cord-005478-5iu38pr6	1312	4	RR	rr	NN
cord-005478-5iu38pr6	1312	5	)	)	-RRB-
cord-005478-5iu38pr6	1312	6	were	be	VBD
cord-005478-5iu38pr6	1312	7	obtained	obtain	VBN
cord-005478-5iu38pr6	1312	8	for	for	IN
cord-005478-5iu38pr6	1312	9	subgroup	subgroup	NN
cord-005478-5iu38pr6	1312	10	analysis	analysis	NN
cord-005478-5iu38pr6	1312	11	.	.	.
cord-005478-5iu38pr6	1313	1	Results	result	NNS
cord-005478-5iu38pr6	1313	2	:	:	:
cord-005478-5iu38pr6	1314	1	The	the	DT
cord-005478-5iu38pr6	1314	2	study	study	NN
cord-005478-5iu38pr6	1314	3	included	include	VBD
cord-005478-5iu38pr6	1314	4	361	361	CD
cord-005478-5iu38pr6	1314	5	MF	MF	NNP
cord-005478-5iu38pr6	1314	6	patients	patient	NNS
cord-005478-5iu38pr6	1314	7	(	(	-LRB-
cord-005478-5iu38pr6	1314	8	260	260	CD
cord-005478-5iu38pr6	1314	9	primary	primary	JJ
cord-005478-5iu38pr6	1314	10	and	and	CC
cord-005478-5iu38pr6	1314	11	101	101	CD
cord-005478-5iu38pr6	1314	12	secondary	secondary	JJ
cord-005478-5iu38pr6	1314	13	MF	MF	NNP
cord-005478-5iu38pr6	1314	14	)	)	-RRB-
cord-005478-5iu38pr6	1314	15	of	of	IN
cord-005478-5iu38pr6	1314	16	whom	whom	WP
cord-005478-5iu38pr6	1314	17	230	230	CD
cord-005478-5iu38pr6	1314	18	received	receive	VBD
cord-005478-5iu38pr6	1314	19	RIC	RIC	NNP
cord-005478-5iu38pr6	1314	20	and	and	CC
cord-005478-5iu38pr6	1314	21	131	131	CD
cord-005478-5iu38pr6	1314	22	MAC	MAC	NNP
cord-005478-5iu38pr6	1314	23	.	.	.
cord-005478-5iu38pr6	1315	1	The	the	DT
cord-005478-5iu38pr6	1315	2	median	median	JJ
cord-005478-5iu38pr6	1315	3	follow	follow	NN
cord-005478-5iu38pr6	1315	4	-	-	HYPH
cord-005478-5iu38pr6	1315	5	up	up	NN
cord-005478-5iu38pr6	1315	6	was	be	VBD
cord-005478-5iu38pr6	1315	7	61	61	CD
cord-005478-5iu38pr6	1315	8	months	month	NNS
cord-005478-5iu38pr6	1315	9	in	in	IN
cord-005478-5iu38pr6	1315	10	RIC	RIC	NNP
cord-005478-5iu38pr6	1315	11	and	and	CC
cord-005478-5iu38pr6	1316	1	73	73	CD
cord-005478-5iu38pr6	1316	2	months	month	NNS
cord-005478-5iu38pr6	1316	3	in	in	IN
cord-005478-5iu38pr6	1316	4	MAC	MAC	NNP
cord-005478-5iu38pr6	1316	5	and	and	CC
cord-005478-5iu38pr6	1316	6	the	the	DT
cord-005478-5iu38pr6	1316	7	median	median	JJ
cord-005478-5iu38pr6	1316	8	age	age	NN
cord-005478-5iu38pr6	1316	9	was	be	VBD
cord-005478-5iu38pr6	1316	10	57	57	CD
cord-005478-5iu38pr6	1316	11	and	and	CC
cord-005478-5iu38pr6	1316	12	54	54	CD
cord-005478-5iu38pr6	1316	13	years	year	NNS
cord-005478-5iu38pr6	1316	14	.	.	.
cord-005478-5iu38pr6	1317	1	Patients	patient	NNS
cord-005478-5iu38pr6	1317	2	receiving	receive	VBG
cord-005478-5iu38pr6	1317	3	RIC	RIC	NNP
cord-005478-5iu38pr6	1317	4	were	be	VBD
cord-005478-5iu38pr6	1317	5	at	at	IN
cord-005478-5iu38pr6	1317	6	higher	high	JJR
cord-005478-5iu38pr6	1317	7	risk	risk	NN
cord-005478-5iu38pr6	1317	8	according	accord	VBG
cord-005478-5iu38pr6	1317	9	to	to	IN
cord-005478-5iu38pr6	1317	10	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1317	11	,	,	,
cord-005478-5iu38pr6	1317	12	MIPSS70	MIPSS70	NNP
cord-005478-5iu38pr6	1317	13	,	,	,
cord-005478-5iu38pr6	1317	14	and	and	CC
cord-005478-5iu38pr6	1317	15	MYSEC	MYSEC	NNP
cord-005478-5iu38pr6	1317	16	-	-	HYPH
cord-005478-5iu38pr6	1317	17	PM	PM	NNP
cord-005478-5iu38pr6	1317	18	,	,	,
cord-005478-5iu38pr6	1317	19	whereas	whereas	IN
cord-005478-5iu38pr6	1317	20	frequencies	frequency	NNS
cord-005478-5iu38pr6	1317	21	of	of	IN
cord-005478-5iu38pr6	1317	22	driver	driver	NN
cord-005478-5iu38pr6	1317	23	mutation	mutation	NN
cord-005478-5iu38pr6	1317	24	genotype	genotype	NN
cord-005478-5iu38pr6	1317	25	(	(	-LRB-
cord-005478-5iu38pr6	1317	26	CALR	CALR	NNP
cord-005478-5iu38pr6	1317	27	,	,	,
cord-005478-5iu38pr6	1317	28	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1317	29	,	,	,
cord-005478-5iu38pr6	1317	30	MPL	MPL	NNP
cord-005478-5iu38pr6	1317	31	,	,	,
cord-005478-5iu38pr6	1317	32	triple	triple	JJ
cord-005478-5iu38pr6	1317	33	negative	negative	JJ
cord-005478-5iu38pr6	1317	34	)	)	-RRB-
cord-005478-5iu38pr6	1317	35	as	as	RB
cord-005478-5iu38pr6	1317	36	well	well	RB
cord-005478-5iu38pr6	1317	37	as	as	IN
cord-005478-5iu38pr6	1317	38	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1317	39	mutation	mutation	NN
cord-005478-5iu38pr6	1317	40	were	be	VBD
cord-005478-5iu38pr6	1317	41	similar	similar	JJ
cord-005478-5iu38pr6	1317	42	.	.	.
cord-005478-5iu38pr6	1318	1	HLA	HLA	NNP
cord-005478-5iu38pr6	1318	2	-	-	HYPH
cord-005478-5iu38pr6	1318	3	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1318	4	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1318	5	donors	donor	NNS
cord-005478-5iu38pr6	1318	6	were	be	VBD
cord-005478-5iu38pr6	1318	7	more	more	RBR
cord-005478-5iu38pr6	1318	8	frequent	frequent	JJ
cord-005478-5iu38pr6	1318	9	in	in	IN
cord-005478-5iu38pr6	1318	10	RIC	RIC	NNP
cord-005478-5iu38pr6	1318	11	.	.	.
cord-005478-5iu38pr6	1319	1	Most	Most	JJS
cord-005478-5iu38pr6	1319	2	common	common	JJ
cord-005478-5iu38pr6	1319	3	conditioning	conditioning	NN
cord-005478-5iu38pr6	1319	4	regimens	regimen	NNS
cord-005478-5iu38pr6	1319	5	for	for	IN
cord-005478-5iu38pr6	1319	6	RIC	RIC	NNP
cord-005478-5iu38pr6	1319	7	were	be	VBD
cord-005478-5iu38pr6	1319	8	Bu	Bu	NNP
cord-005478-5iu38pr6	1319	9	/	/	SYM
cord-005478-5iu38pr6	1319	10	Flu	Flu	NNP
cord-005478-5iu38pr6	1319	11	(	(	-LRB-
cord-005478-5iu38pr6	1319	12	83	83	CD
cord-005478-5iu38pr6	1319	13	%	%	NN
cord-005478-5iu38pr6	1319	14	)	)	-RRB-
cord-005478-5iu38pr6	1319	15	and	and	CC
cord-005478-5iu38pr6	1319	16	Flamsa	Flamsa	NNP
cord-005478-5iu38pr6	1319	17	(	(	-LRB-
cord-005478-5iu38pr6	1319	18	12	12	CD
cord-005478-5iu38pr6	1319	19	%	%	NN
cord-005478-5iu38pr6	1319	20	)	)	-RRB-
cord-005478-5iu38pr6	1319	21	,	,	,
cord-005478-5iu38pr6	1319	22	and	and	CC
cord-005478-5iu38pr6	1319	23	Flu	Flu	NNP
cord-005478-5iu38pr6	1319	24	/	/	SYM
cord-005478-5iu38pr6	1319	25	Mel	Mel	NNP
cord-005478-5iu38pr6	1319	26	(	(	-LRB-
cord-005478-5iu38pr6	1319	27	37	37	CD
cord-005478-5iu38pr6	1319	28	%	%	NN
cord-005478-5iu38pr6	1319	29	)	)	-RRB-
cord-005478-5iu38pr6	1319	30	,	,	,
cord-005478-5iu38pr6	1319	31	Treo	Treo	NNP
cord-005478-5iu38pr6	1319	32	/	/	SYM
cord-005478-5iu38pr6	1319	33	Flu	Flu	NNP
cord-005478-5iu38pr6	1319	34	and	and	CC
cord-005478-5iu38pr6	1319	35	TBI	TBI	NNP
cord-005478-5iu38pr6	1319	36	/	/	SYM
cord-005478-5iu38pr6	1319	37	Flu	Flu	NNP
cord-005478-5iu38pr6	1319	38	(	(	-LRB-
cord-005478-5iu38pr6	1319	39	21	21	CD
cord-005478-5iu38pr6	1319	40	%	%	NN
cord-005478-5iu38pr6	1319	41	,	,	,
cord-005478-5iu38pr6	1319	42	respectively	respectively	RB
cord-005478-5iu38pr6	1319	43	)	)	-RRB-
cord-005478-5iu38pr6	1319	44	for	for	IN
cord-005478-5iu38pr6	1319	45	MAC	MAC	NNP
cord-005478-5iu38pr6	1319	46	.	.	.
cord-005478-5iu38pr6	1320	1	No	no	DT
cord-005478-5iu38pr6	1320	2	significant	significant	JJ
cord-005478-5iu38pr6	1320	3	difference	difference	NN
cord-005478-5iu38pr6	1320	4	was	be	VBD
cord-005478-5iu38pr6	1320	5	found	find	VBN
cord-005478-5iu38pr6	1320	6	for	for	IN
cord-005478-5iu38pr6	1320	7	RIC	RIC	NNP
cord-005478-5iu38pr6	1320	8	versus	versus	IN
cord-005478-5iu38pr6	1320	9	MAC	MAC	NNP
cord-005478-5iu38pr6	1320	10	with	with	IN
cord-005478-5iu38pr6	1320	11	respect	respect	NN
cord-005478-5iu38pr6	1320	12	to	to	IN
cord-005478-5iu38pr6	1320	13	OS	OS	NNP
cord-005478-5iu38pr6	1320	14	(	(	-LRB-
cord-005478-5iu38pr6	1320	15	62	62	CD
cord-005478-5iu38pr6	1320	16	%	%	NN
cord-005478-5iu38pr6	1320	17	vs	vs	IN
cord-005478-5iu38pr6	1320	18	57	57	CD
cord-005478-5iu38pr6	1320	19	%	%	NN
cord-005478-5iu38pr6	1320	20	;	;	:
cord-005478-5iu38pr6	1320	21	p=0.35	p=0.35	NNP
cord-005478-5iu38pr6	1320	22	)	)	-RRB-
cord-005478-5iu38pr6	1320	23	,	,	,
cord-005478-5iu38pr6	1320	24	relapse	relapse	NN
cord-005478-5iu38pr6	1320	25	(	(	-LRB-
cord-005478-5iu38pr6	1320	26	16	16	CD
cord-005478-5iu38pr6	1320	27	%	%	NN
cord-005478-5iu38pr6	1320	28	vs	vs	IN
cord-005478-5iu38pr6	1320	29	13	13	CD
cord-005478-5iu38pr6	1320	30	%	%	NN
cord-005478-5iu38pr6	1320	31	;	;	:
cord-005478-5iu38pr6	1320	32	p=0.60	p=0.60	NNP
cord-005478-5iu38pr6	1320	33	)	)	-RRB-
cord-005478-5iu38pr6	1320	34	or	or	CC
cord-005478-5iu38pr6	1320	35	NRM	NRM	NNP
cord-005478-5iu38pr6	1320	36	(	(	-LRB-
cord-005478-5iu38pr6	1320	37	28	28	CD
cord-005478-5iu38pr6	1320	38	%	%	NN
cord-005478-5iu38pr6	1320	39	vs	vs	IN
cord-005478-5iu38pr6	1320	40	30	30	CD
cord-005478-5iu38pr6	1320	41	%	%	NN
cord-005478-5iu38pr6	1320	42	;	;	,
cord-005478-5iu38pr6	1320	43	p=0.68	p=0.68	NN
cord-005478-5iu38pr6	1320	44	)	)	-RRB-
cord-005478-5iu38pr6	1320	45	.	.	.
cord-005478-5iu38pr6	1321	1	Early	early	JJ
cord-005478-5iu38pr6	1321	2	relapse	relapse	NN
cord-005478-5iu38pr6	1321	3	within	within	IN
cord-005478-5iu38pr6	1321	4	five	five	CD
cord-005478-5iu38pr6	1321	5	months	month	NNS
cord-005478-5iu38pr6	1321	6	was	be	VBD
cord-005478-5iu38pr6	1321	7	increased	increase	VBN
cord-005478-5iu38pr6	1321	8	after	after	IN
cord-005478-5iu38pr6	1321	9	RIC	RIC	NNP
cord-005478-5iu38pr6	1321	10	(	(	-LRB-
cord-005478-5iu38pr6	1321	11	7	7	CD
cord-005478-5iu38pr6	1321	12	%	%	NN
cord-005478-5iu38pr6	1321	13	vs	vs	IN
cord-005478-5iu38pr6	1321	14	3	3	CD
cord-005478-5iu38pr6	1321	15	%	%	NN
cord-005478-5iu38pr6	1321	16	)	)	-RRB-
cord-005478-5iu38pr6	1321	17	.	.	.
cord-005478-5iu38pr6	1322	1	Including	include	VBG
cord-005478-5iu38pr6	1322	2	molecular	molecular	JJ
cord-005478-5iu38pr6	1322	3	variables	variable	NNS
cord-005478-5iu38pr6	1322	4	,	,	,
cord-005478-5iu38pr6	1322	5	RIC	RIC	NNP
cord-005478-5iu38pr6	1322	6	showed	show	VBD
cord-005478-5iu38pr6	1322	7	higher	higher	RBR
cord-005478-5iu38pr6	1322	8	but	but	CC
cord-005478-5iu38pr6	1322	9	not	not	RB
cord-005478-5iu38pr6	1322	10	significantly	significantly	RB
cord-005478-5iu38pr6	1322	11	different	different	JJ
cord-005478-5iu38pr6	1322	12	OS	os	NN
cord-005478-5iu38pr6	1322	13	rates	rate	NNS
cord-005478-5iu38pr6	1322	14	in	in	IN
cord-005478-5iu38pr6	1322	15	patients	patient	NNS
cord-005478-5iu38pr6	1322	16	with	with	IN
cord-005478-5iu38pr6	1322	17	<	<	NNP
cord-005478-5iu38pr6	1322	18	3	3	CD
cord-005478-5iu38pr6	1322	19	mutations	mutation	NNS
cord-005478-5iu38pr6	1322	20	,	,	,
cord-005478-5iu38pr6	1322	21	in	in	IN
cord-005478-5iu38pr6	1322	22	triple	triple	JJ
cord-005478-5iu38pr6	1322	23	negative	negative	JJ
cord-005478-5iu38pr6	1322	24	driver	driver	NN
cord-005478-5iu38pr6	1322	25	mutation	mutation	NN
cord-005478-5iu38pr6	1322	26	genotype	genotype	NN
cord-005478-5iu38pr6	1322	27	,	,	,
cord-005478-5iu38pr6	1322	28	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1322	29	mutation	mutation	NN
cord-005478-5iu38pr6	1322	30	(	(	-LRB-
cord-005478-5iu38pr6	1322	31	Figure	figure	NN
cord-005478-5iu38pr6	1322	32	1	1	CD
cord-005478-5iu38pr6	1322	33	)	)	-RRB-
cord-005478-5iu38pr6	1322	34	.	.	.
cord-005478-5iu38pr6	1323	1	When	when	WRB
cord-005478-5iu38pr6	1323	2	evaluating	evaluate	VBG
cord-005478-5iu38pr6	1323	3	patients	patient	NNS
cord-005478-5iu38pr6	1323	4	with	with	IN
cord-005478-5iu38pr6	1323	5	an	an	DT
cord-005478-5iu38pr6	1323	6	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1323	7	mutation	mutation	NN
cord-005478-5iu38pr6	1323	8	,	,	,
cord-005478-5iu38pr6	1323	9	those	those	DT
cord-005478-5iu38pr6	1323	10	88	88	CD
cord-005478-5iu38pr6	1323	11	patients	patient	NNS
cord-005478-5iu38pr6	1323	12	who	who	WP
cord-005478-5iu38pr6	1323	13	had	have	VBD
cord-005478-5iu38pr6	1323	14	only	only	RB
cord-005478-5iu38pr6	1323	15	one	one	CD
cord-005478-5iu38pr6	1323	16	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1323	17	or	or	CC
cord-005478-5iu38pr6	1323	18	one	one	CD
cord-005478-5iu38pr6	1323	19	additional	additional	JJ
cord-005478-5iu38pr6	1323	20	mutation	mutation	NN
cord-005478-5iu38pr6	1323	21	seemed	seem	VBD
cord-005478-5iu38pr6	1323	22	to	to	TO
cord-005478-5iu38pr6	1323	23	benefit	benefit	VB
cord-005478-5iu38pr6	1323	24	from	from	IN
cord-005478-5iu38pr6	1323	25	RIC	RIC	NNP
cord-005478-5iu38pr6	1323	26	showing	show	VBG
cord-005478-5iu38pr6	1323	27	5-year	5-year	CD
cord-005478-5iu38pr6	1323	28	OS	os	NN
cord-005478-5iu38pr6	1323	29	of	of	IN
cord-005478-5iu38pr6	1323	30	65	65	CD
cord-005478-5iu38pr6	1323	31	%	%	NN
cord-005478-5iu38pr6	1323	32	vs	vs	IN
cord-005478-5iu38pr6	1323	33	20	20	CD
cord-005478-5iu38pr6	1323	34	%	%	NN
cord-005478-5iu38pr6	1323	35	for	for	IN
cord-005478-5iu38pr6	1323	36	MAC	MAC	NNP
cord-005478-5iu38pr6	1323	37	(	(	-LRB-
cord-005478-5iu38pr6	1323	38	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	1323	39	)	)	-RRB-
cord-005478-5iu38pr6	1323	40	,	,	,
cord-005478-5iu38pr6	1323	41	whereas	whereas	IN
cord-005478-5iu38pr6	1323	42	no	no	DT
cord-005478-5iu38pr6	1323	43	difference	difference	NN
cord-005478-5iu38pr6	1323	44	was	be	VBD
cord-005478-5iu38pr6	1323	45	identified	identify	VBN
cord-005478-5iu38pr6	1323	46	when	when	WRB
cord-005478-5iu38pr6	1323	47	more	more	JJR
cord-005478-5iu38pr6	1323	48	than	than	IN
cord-005478-5iu38pr6	1323	49	two	two	CD
cord-005478-5iu38pr6	1323	50	additional	additional	JJ
cord-005478-5iu38pr6	1323	51	mutations	mutation	NNS
cord-005478-5iu38pr6	1323	52	were	be	VBD
cord-005478-5iu38pr6	1323	53	present	present	JJ
cord-005478-5iu38pr6	1323	54	(	(	-LRB-
cord-005478-5iu38pr6	1323	55	57	57	CD
cord-005478-5iu38pr6	1323	56	%	%	NN
cord-005478-5iu38pr6	1323	57	vs	vs	IN
cord-005478-5iu38pr6	1323	58	65	65	CD
cord-005478-5iu38pr6	1323	59	%	%	NN
cord-005478-5iu38pr6	1323	60	;	;	:
cord-005478-5iu38pr6	1323	61	p=0.27	p=0.27	NNP
cord-005478-5iu38pr6	1323	62	)	)	-RRB-
cord-005478-5iu38pr6	1323	63	.	.	.
cord-005478-5iu38pr6	1324	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	1324	2	,	,	,
cord-005478-5iu38pr6	1324	3	in	in	IN
cord-005478-5iu38pr6	1324	4	patients	patient	NNS
cord-005478-5iu38pr6	1324	5	with	with	IN
cord-005478-5iu38pr6	1324	6	an	an	DT
cord-005478-5iu38pr6	1324	7	ASXL1	asxl1	NN
cord-005478-5iu38pr6	1324	8	mutation	mutation	NN
cord-005478-5iu38pr6	1324	9	and	and	CC
cord-005478-5iu38pr6	1324	10	one	one	CD
cord-005478-5iu38pr6	1324	11	additional	additional	JJ
cord-005478-5iu38pr6	1324	12	driver	driver	NN
cord-005478-5iu38pr6	1324	13	mutation	mutation	NN
cord-005478-5iu38pr6	1324	14	(	(	-LRB-
cord-005478-5iu38pr6	1324	15	CALR	CALR	NNP
cord-005478-5iu38pr6	1324	16	,	,	,
cord-005478-5iu38pr6	1324	17	MPL	MPL	NNP
cord-005478-5iu38pr6	1324	18	,	,	,
cord-005478-5iu38pr6	1324	19	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1324	20	)	)	-RRB-
cord-005478-5iu38pr6	1324	21	,	,	,
cord-005478-5iu38pr6	1324	22	5year	5year	JJ
cord-005478-5iu38pr6	1324	23	OS	OS	NNP
cord-005478-5iu38pr6	1324	24	was	be	VBD
cord-005478-5iu38pr6	1324	25	significantly	significantly	RB
cord-005478-5iu38pr6	1324	26	different	different	JJ
cord-005478-5iu38pr6	1324	27	showing	show	VBG
cord-005478-5iu38pr6	1324	28	63	63	CD
cord-005478-5iu38pr6	1324	29	%	%	NN
cord-005478-5iu38pr6	1324	30	in	in	IN
cord-005478-5iu38pr6	1324	31	RIC	RIC	NNP
cord-005478-5iu38pr6	1324	32	vs	vs	IN
cord-005478-5iu38pr6	1324	33	18	18	CD
cord-005478-5iu38pr6	1324	34	%	%	NN
cord-005478-5iu38pr6	1324	35	in	in	IN
cord-005478-5iu38pr6	1324	36	MAC	MAC	NNP
cord-005478-5iu38pr6	1324	37	(	(	-LRB-
cord-005478-5iu38pr6	1324	38	p=0.005	p=0.005	NNP
cord-005478-5iu38pr6	1324	39	)	)	-RRB-
cord-005478-5iu38pr6	1324	40	.	.	.
cord-005478-5iu38pr6	1325	1	Regarding	regard	VBG
cord-005478-5iu38pr6	1325	2	current	current	JJ
cord-005478-5iu38pr6	1325	3	risk	risk	NN
cord-005478-5iu38pr6	1325	4	stratifications	stratification	NNS
cord-005478-5iu38pr6	1325	5	,	,	,
cord-005478-5iu38pr6	1325	6	RIC	RIC	NNP
cord-005478-5iu38pr6	1325	7	showed	show	VBD
cord-005478-5iu38pr6	1325	8	significantly	significantly	RB
cord-005478-5iu38pr6	1325	9	improved	improve	VBN
cord-005478-5iu38pr6	1325	10	OS	OS	NNP
cord-005478-5iu38pr6	1325	11	only	only	RB
cord-005478-5iu38pr6	1325	12	in	in	IN
cord-005478-5iu38pr6	1325	13	high	high	JJ
cord-005478-5iu38pr6	1325	14	risk	risk	NN
cord-005478-5iu38pr6	1325	15	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1325	16	and	and	CC
cord-005478-5iu38pr6	1325	17	MYSEC	MYSEC	NNP
cord-005478-5iu38pr6	1325	18	-	-	HYPH
cord-005478-5iu38pr6	1325	19	PM	PM	NNP
cord-005478-5iu38pr6	1325	20	,	,	,
cord-005478-5iu38pr6	1325	21	whereas	whereas	IN
cord-005478-5iu38pr6	1325	22	no	no	DT
cord-005478-5iu38pr6	1325	23	difference	difference	NN
cord-005478-5iu38pr6	1325	24	was	be	VBD
cord-005478-5iu38pr6	1325	25	found	find	VBN
cord-005478-5iu38pr6	1325	26	regarding	regard	VBG
cord-005478-5iu38pr6	1325	27	the	the	DT
cord-005478-5iu38pr6	1325	28	remaining	remain	VBG
cord-005478-5iu38pr6	1325	29	systems	system	NNS
cord-005478-5iu38pr6	1325	30	such	such	JJ
cord-005478-5iu38pr6	1325	31	as	as	IN
cord-005478-5iu38pr6	1325	32	DIPSS	DIPSS	NNP
cord-005478-5iu38pr6	1325	33	-	-	HYPH
cord-005478-5iu38pr6	1325	34	plus	plus	CC
cord-005478-5iu38pr6	1325	35	,	,	,
cord-005478-5iu38pr6	1325	36	MIPSS70	MIPSS70	NNP
cord-005478-5iu38pr6	1325	37	and	and	CC
cord-005478-5iu38pr6	1325	38	GIPSS	GIPSS	NNP
cord-005478-5iu38pr6	1326	1	(	(	-LRB-
cord-005478-5iu38pr6	1326	2	Figure	figure	NN
cord-005478-5iu38pr6	1326	3	1	1	CD
cord-005478-5iu38pr6	1326	4	)	)	-RRB-
cord-005478-5iu38pr6	1326	5	.	.	.
cord-005478-5iu38pr6	1327	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1327	2	:	:	:
cord-005478-5iu38pr6	1328	1	The	the	DT
cord-005478-5iu38pr6	1328	2	evaluation	evaluation	NN
cord-005478-5iu38pr6	1328	3	of	of	IN
cord-005478-5iu38pr6	1328	4	different	different	JJ
cord-005478-5iu38pr6	1328	5	conditioning	conditioning	NN
cord-005478-5iu38pr6	1328	6	intensities	intensity	NNS
cord-005478-5iu38pr6	1328	7	in	in	IN
cord-005478-5iu38pr6	1328	8	MF	MF	NNP
cord-005478-5iu38pr6	1328	9	did	do	VBD
cord-005478-5iu38pr6	1328	10	not	not	RB
cord-005478-5iu38pr6	1328	11	favor	favor	VB
cord-005478-5iu38pr6	1328	12	RIC	RIC	NNP
cord-005478-5iu38pr6	1328	13	or	or	CC
cord-005478-5iu38pr6	1328	14	MAC	MAC	NNP
cord-005478-5iu38pr6	1328	15	regarding	regard	VBG
cord-005478-5iu38pr6	1328	16	currently	currently	RB
cord-005478-5iu38pr6	1328	17	existing	exist	VBG
cord-005478-5iu38pr6	1328	18	risk	risk	NN
cord-005478-5iu38pr6	1328	19	stratifications	stratification	NNS
cord-005478-5iu38pr6	1328	20	.	.	.
cord-005478-5iu38pr6	1329	1	With	with	IN
cord-005478-5iu38pr6	1329	2	respect	respect	NN
cord-005478-5iu38pr6	1329	3	to	to	IN
cord-005478-5iu38pr6	1329	4	molecular	molecular	JJ
cord-005478-5iu38pr6	1329	5	genetics	genetic	NNS
cord-005478-5iu38pr6	1329	6	,	,	,
cord-005478-5iu38pr6	1329	7	a	a	DT
cord-005478-5iu38pr6	1329	8	proportion	proportion	NN
cord-005478-5iu38pr6	1329	9	of	of	IN
cord-005478-5iu38pr6	1329	10	patients	patient	NNS
cord-005478-5iu38pr6	1329	11	specifically	specifically	RB
cord-005478-5iu38pr6	1329	12	harboring	harbor	VBG
cord-005478-5iu38pr6	1329	13	up	up	RP
cord-005478-5iu38pr6	1329	14	to	to	TO
cord-005478-5iu38pr6	1329	15	two	two	CD
cord-005478-5iu38pr6	1329	16	mutations	mutation	NNS
cord-005478-5iu38pr6	1329	17	including	include	VBG
cord-005478-5iu38pr6	1329	18	ASXL1	ASXL1	NNP
cord-005478-5iu38pr6	1329	19	may	may	MD
cord-005478-5iu38pr6	1329	20	benefit	benefit	VB
cord-005478-5iu38pr6	1329	21	from	from	IN
cord-005478-5iu38pr6	1329	22	RIC	RIC	NNP
cord-005478-5iu38pr6	1329	23	with	with	IN
cord-005478-5iu38pr6	1329	24	respect	respect	NN
cord-005478-5iu38pr6	1329	25	to	to	IN
cord-005478-5iu38pr6	1329	26	OS	OS	NNP
cord-005478-5iu38pr6	1329	27	.	.	.
cord-005478-5iu38pr6	1330	1	[	[	-LRB-
cord-005478-5iu38pr6	1330	2	Background	background	NN
cord-005478-5iu38pr6	1330	3	:	:	:
cord-005478-5iu38pr6	1331	1	Sequential	sequential	JJ
cord-005478-5iu38pr6	1331	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	1331	3	regimens	regimen	NNS
cord-005478-5iu38pr6	1331	4	(	(	-LRB-
cord-005478-5iu38pr6	1331	5	SR	SR	NNP
cord-005478-5iu38pr6	1331	6	)	)	-RRB-
cord-005478-5iu38pr6	1331	7	have	have	VBP
cord-005478-5iu38pr6	1331	8	shown	show	VBN
cord-005478-5iu38pr6	1331	9	substantial	substantial	JJ
cord-005478-5iu38pr6	1331	10	activity	activity	NN
cord-005478-5iu38pr6	1331	11	in	in	IN
cord-005478-5iu38pr6	1331	12	relapsed	relapse	VBN
cord-005478-5iu38pr6	1331	13	/	/	SYM
cord-005478-5iu38pr6	1331	14	refractory	refractory	JJ
cord-005478-5iu38pr6	1331	15	acute	acute	JJ
cord-005478-5iu38pr6	1331	16	myeloid	myeloid	NN
cord-005478-5iu38pr6	1331	17	leukemia	leukemia	NN
cord-005478-5iu38pr6	1331	18	(	(	-LRB-
cord-005478-5iu38pr6	1331	19	r	r	NN
cord-005478-5iu38pr6	1331	20	/	/	SYM
cord-005478-5iu38pr6	1331	21	rAML	raml	NN
cord-005478-5iu38pr6	1331	22	)	)	-RRB-
cord-005478-5iu38pr6	1331	23	.	.	.
cord-005478-5iu38pr6	1332	1	The	the	DT
cord-005478-5iu38pr6	1332	2	original	original	JJ
cord-005478-5iu38pr6	1332	3	prototype	prototype	NN
cord-005478-5iu38pr6	1332	4	SR	SR	NNP
cord-005478-5iu38pr6	1332	5	is	be	VBZ
cord-005478-5iu38pr6	1332	6	the	the	DT
cord-005478-5iu38pr6	1332	7	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1332	8	-	-	HYPH
cord-005478-5iu38pr6	1332	9	CYTBI	CYTBI	NNP
cord-005478-5iu38pr6	1332	10	regimen	regimen	NN
cord-005478-5iu38pr6	1332	11	.	.	.
cord-005478-5iu38pr6	1333	1	Various	various	JJ
cord-005478-5iu38pr6	1333	2	modifications	modification	NNS
cord-005478-5iu38pr6	1333	3	of	of	IN
cord-005478-5iu38pr6	1333	4	this	this	DT
cord-005478-5iu38pr6	1333	5	protocol	protocol	NN
cord-005478-5iu38pr6	1333	6	have	have	VBP
cord-005478-5iu38pr6	1333	7	been	be	VBN
cord-005478-5iu38pr6	1333	8	developed	develop	VBN
cord-005478-5iu38pr6	1333	9	in	in	IN
cord-005478-5iu38pr6	1333	10	recent	recent	JJ
cord-005478-5iu38pr6	1333	11	years	year	NNS
cord-005478-5iu38pr6	1333	12	(	(	-LRB-
cord-005478-5iu38pr6	1333	13	see	see	VB
cord-005478-5iu38pr6	1333	14	table	table	NN
cord-005478-5iu38pr6	1333	15	1	1	CD
cord-005478-5iu38pr6	1333	16	)	)	-RRB-
cord-005478-5iu38pr6	1333	17	.	.	.
cord-005478-5iu38pr6	1334	1	In	in	IN
cord-005478-5iu38pr6	1334	2	the	the	DT
cord-005478-5iu38pr6	1334	3	current	current	JJ
cord-005478-5iu38pr6	1334	4	study	study	NN
cord-005478-5iu38pr6	1334	5	,	,	,
cord-005478-5iu38pr6	1334	6	we	-PRON-	PRP
cord-005478-5iu38pr6	1334	7	compared	compare	VBD
cord-005478-5iu38pr6	1334	8	the	the	DT
cord-005478-5iu38pr6	1334	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	1334	10	of	of	IN
cord-005478-5iu38pr6	1334	11	patients	patient	NNS
cord-005478-5iu38pr6	1334	12	suffering	suffer	VBG
cord-005478-5iu38pr6	1334	13	from	from	IN
cord-005478-5iu38pr6	1335	1	r	r	LS
cord-005478-5iu38pr6	1335	2	/	/	SYM
cord-005478-5iu38pr6	1335	3	rAML	raml	NN
cord-005478-5iu38pr6	1335	4	that	that	WDT
cord-005478-5iu38pr6	1335	5	had	have	VBD
cord-005478-5iu38pr6	1335	6	received	receive	VBN
cord-005478-5iu38pr6	1335	7	their	-PRON-	PRP$
cord-005478-5iu38pr6	1335	8	first	first	JJ
cord-005478-5iu38pr6	1335	9	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1335	10	stem	stem	NN
cord-005478-5iu38pr6	1335	11	cell	cell	NN
cord-005478-5iu38pr6	1335	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	1335	13	(	(	-LRB-
cord-005478-5iu38pr6	1335	14	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1335	15	)	)	-RRB-
cord-005478-5iu38pr6	1335	16	after	after	IN
cord-005478-5iu38pr6	1335	17	conditioning	condition	VBG
cord-005478-5iu38pr6	1335	18	with	with	IN
cord-005478-5iu38pr6	1335	19	a	a	DT
cord-005478-5iu38pr6	1335	20	SR	SR	NNP
cord-005478-5iu38pr6	1335	21	.	.	.
cord-005478-5iu38pr6	1336	1	Methods	method	NNS
cord-005478-5iu38pr6	1336	2	:	:	:
cord-005478-5iu38pr6	1336	3	Adult	adult	NN
cord-005478-5iu38pr6	1336	4	patients	patient	NNS
cord-005478-5iu38pr6	1336	5	with	with	IN
cord-005478-5iu38pr6	1336	6	r	r	NN
cord-005478-5iu38pr6	1336	7	/	/	SYM
cord-005478-5iu38pr6	1336	8	rAML	raml	NN
cord-005478-5iu38pr6	1336	9	who	who	WP
cord-005478-5iu38pr6	1336	10	had	have	VBD
cord-005478-5iu38pr6	1336	11	received	receive	VBN
cord-005478-5iu38pr6	1336	12	their	-PRON-	PRP$
cord-005478-5iu38pr6	1336	13	first	first	JJ
cord-005478-5iu38pr6	1336	14	alloSCT	allosct	NN
cord-005478-5iu38pr6	1336	15	following	follow	VBG
cord-005478-5iu38pr6	1336	16	SR	SR	NNP
cord-005478-5iu38pr6	1336	17	conditioning	conditioning	NN
cord-005478-5iu38pr6	1336	18	between	between	IN
cord-005478-5iu38pr6	1336	19	2000	2000	CD
cord-005478-5iu38pr6	1336	20	and	and	CC
cord-005478-5iu38pr6	1336	21	2017	2017	CD
cord-005478-5iu38pr6	1336	22	and	and	CC
cord-005478-5iu38pr6	1336	23	were	be	VBD
cord-005478-5iu38pr6	1336	24	reported	report	VBN
cord-005478-5iu38pr6	1336	25	to	to	IN
cord-005478-5iu38pr6	1336	26	the	the	DT
cord-005478-5iu38pr6	1336	27	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1336	28	registry	registry	NN
cord-005478-5iu38pr6	1336	29	were	be	VBD
cord-005478-5iu38pr6	1336	30	analyzed	analyze	VBN
cord-005478-5iu38pr6	1336	31	.	.	.
cord-005478-5iu38pr6	1337	1	Patients	patient	NNS
cord-005478-5iu38pr6	1337	2	were	be	VBD
cord-005478-5iu38pr6	1337	3	grouped	group	VBN
cord-005478-5iu38pr6	1337	4	according	accord	VBG
cord-005478-5iu38pr6	1337	5	to	to	IN
cord-005478-5iu38pr6	1337	6	the	the	DT
cord-005478-5iu38pr6	1337	7	type	type	NN
cord-005478-5iu38pr6	1337	8	of	of	IN
cord-005478-5iu38pr6	1337	9	SR	SR	NNP
cord-005478-5iu38pr6	1337	10	used	use	VBN
cord-005478-5iu38pr6	1337	11	as	as	IN
cord-005478-5iu38pr6	1337	12	shown	show	VBN
cord-005478-5iu38pr6	1337	13	in	in	IN
cord-005478-5iu38pr6	1337	14	table1	table1	NN
cord-005478-5iu38pr6	1337	15	.	.	.
cord-005478-5iu38pr6	1338	1	The	the	DT
cord-005478-5iu38pr6	1338	2	FLAMSA	FLAMSA	NNP
cord-005478-5iu38pr6	1338	3	-	-	HYPH
cord-005478-5iu38pr6	1338	4	CYTBI	CYTBI	NNP
cord-005478-5iu38pr6	1338	5	group	group	NN
cord-005478-5iu38pr6	1338	6	served	serve	VBD
cord-005478-5iu38pr6	1338	7	as	as	IN
cord-005478-5iu38pr6	1338	8	comparator	comparator	NN
cord-005478-5iu38pr6	1338	9	for	for	IN
cord-005478-5iu38pr6	1338	10	all	all	DT
cord-005478-5iu38pr6	1338	11	others	other	NNS
cord-005478-5iu38pr6	1338	12	.	.	.
cord-005478-5iu38pr6	1339	1	The	the	DT
cord-005478-5iu38pr6	1339	2	primary	primary	JJ
cord-005478-5iu38pr6	1339	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	1339	4	was	be	VBD
cord-005478-5iu38pr6	1339	5	leukemia	leukemia	NN
cord-005478-5iu38pr6	1339	6	-	-	HYPH
cord-005478-5iu38pr6	1339	7	free	free	JJ
cord-005478-5iu38pr6	1339	8	survival	survival	NN
cord-005478-5iu38pr6	1339	9	(	(	-LRB-
cord-005478-5iu38pr6	1339	10	LFS	LFS	NNP
cord-005478-5iu38pr6	1339	11	)	)	-RRB-
cord-005478-5iu38pr6	1339	12	.	.	.
cord-005478-5iu38pr6	1340	1	Secondary	secondary	JJ
cord-005478-5iu38pr6	1340	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	1340	3	were	be	VBD
cord-005478-5iu38pr6	1340	4	overall	overall	JJ
cord-005478-5iu38pr6	1340	5	survival	survival	NN
cord-005478-5iu38pr6	1340	6	(	(	-LRB-
cord-005478-5iu38pr6	1340	7	OS	OS	NNP
cord-005478-5iu38pr6	1340	8	)	)	-RRB-
cord-005478-5iu38pr6	1340	9	,	,	,
cord-005478-5iu38pr6	1340	10	relapse	relapse	NN
cord-005478-5iu38pr6	1340	11	incidence	incidence	NN
cord-005478-5iu38pr6	1340	12	(	(	-LRB-
cord-005478-5iu38pr6	1340	13	RI	RI	NNP
cord-005478-5iu38pr6	1340	14	)	)	-RRB-
cord-005478-5iu38pr6	1340	15	,	,	,
cord-005478-5iu38pr6	1340	16	nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	1340	17	mortality	mortality	NN
cord-005478-5iu38pr6	1340	18	(	(	-LRB-
cord-005478-5iu38pr6	1340	19	NRM	NRM	NNP
cord-005478-5iu38pr6	1340	20	)	)	-RRB-
cord-005478-5iu38pr6	1340	21	,	,	,
cord-005478-5iu38pr6	1340	22	refined	refined	JJ
cord-005478-5iu38pr6	1340	23	graft	graft	NN
cord-005478-5iu38pr6	1340	24	-	-	HYPH
cord-005478-5iu38pr6	1340	25	versus	versus	IN
cord-005478-5iu38pr6	1340	26	-	-	HYPH
cord-005478-5iu38pr6	1340	27	host	host	NN
cord-005478-5iu38pr6	1340	28	-	-	HYPH
cord-005478-5iu38pr6	1340	29	diseasefree	diseasefree	JJ
cord-005478-5iu38pr6	1340	30	,	,	,
cord-005478-5iu38pr6	1340	31	relapse	relapse	NN
cord-005478-5iu38pr6	1340	32	-	-	HYPH
cord-005478-5iu38pr6	1340	33	free	free	JJ
cord-005478-5iu38pr6	1340	34	survival	survival	NN
cord-005478-5iu38pr6	1340	35	(	(	-LRB-
cord-005478-5iu38pr6	1340	36	GRFS	GRFS	NNP
cord-005478-5iu38pr6	1340	37	)	)	-RRB-
cord-005478-5iu38pr6	1340	38	,	,	,
cord-005478-5iu38pr6	1340	39	acute	acute	JJ
cord-005478-5iu38pr6	1340	40	(	(	-LRB-
cord-005478-5iu38pr6	1340	41	a)GVHD	a)gvhd	JJ
cord-005478-5iu38pr6	1340	42	and	and	CC
cord-005478-5iu38pr6	1340	43	chronic	chronic	JJ
cord-005478-5iu38pr6	1340	44	(	(	-LRB-
cord-005478-5iu38pr6	1340	45	c)GVHD	c)GVHD	NNP
cord-005478-5iu38pr6	1340	46	.	.	.
cord-005478-5iu38pr6	1341	1	Multivariate	multivariate	JJ
cord-005478-5iu38pr6	1341	2	analysis	analysis	NN
cord-005478-5iu38pr6	1341	3	was	be	VBD
cord-005478-5iu38pr6	1341	4	done	do	VBN
cord-005478-5iu38pr6	1341	5	using	use	VBG
cord-005478-5iu38pr6	1341	6	Cox	Cox	NNP
cord-005478-5iu38pr6	1341	7	regression	regression	NN
cord-005478-5iu38pr6	1341	8	.	.	.
cord-005478-5iu38pr6	1342	1	Results	result	NNS
cord-005478-5iu38pr6	1342	2	:	:	:
cord-005478-5iu38pr6	1343	1	Patients	patient	NNS
cord-005478-5iu38pr6	1343	2	'	'	POS
cord-005478-5iu38pr6	1343	3	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1343	4	are	be	VBP
cord-005478-5iu38pr6	1343	5	detailed	detail	VBN
cord-005478-5iu38pr6	1343	6	in	in	IN
cord-005478-5iu38pr6	1343	7	Table	Table	NNP
cord-005478-5iu38pr6	1343	8	1	1	CD
cord-005478-5iu38pr6	1343	9	.	.	.
cord-005478-5iu38pr6	1344	1	There	there	EX
cord-005478-5iu38pr6	1344	2	were	be	VBD
cord-005478-5iu38pr6	1344	3	more	more	JJR
cord-005478-5iu38pr6	1344	4	patients	patient	NNS
cord-005478-5iu38pr6	1344	5	with	with	IN
cord-005478-5iu38pr6	1344	6	transformed	transform	VBN
cord-005478-5iu38pr6	1344	7	NHL	NHL	NNP
cord-005478-5iu38pr6	1344	8	in	in	IN
cord-005478-5iu38pr6	1344	9	the	the	DT
cord-005478-5iu38pr6	1344	10	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1344	11	(	(	-LRB-
cord-005478-5iu38pr6	1344	12	18%vs7	18%vs7	CD
cord-005478-5iu38pr6	1344	13	%	%	NN
cord-005478-5iu38pr6	1344	14	)	)	-RRB-
cord-005478-5iu38pr6	1344	15	.	.	.
cord-005478-5iu38pr6	1345	1	The	the	DT
cord-005478-5iu38pr6	1345	2	median	median	JJ
cord-005478-5iu38pr6	1345	3	time	time	NN
cord-005478-5iu38pr6	1345	4	to	to	IN
cord-005478-5iu38pr6	1345	5	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1345	6	count	count	NN
cord-005478-5iu38pr6	1345	7	>	>	XX
cord-005478-5iu38pr6	1345	8	0.5	0.5	CD
cord-005478-5iu38pr6	1345	9	G	g	NN
cord-005478-5iu38pr6	1345	10	/	/	SYM
cord-005478-5iu38pr6	1345	11	l	l	NN
cord-005478-5iu38pr6	1345	12	and	and	CC
cord-005478-5iu38pr6	1345	13	platelet	platelet	NN
cord-005478-5iu38pr6	1345	14	counts	count	VBZ
cord-005478-5iu38pr6	1345	15	>	>	XX
cord-005478-5iu38pr6	1346	1	50	50	CD
cord-005478-5iu38pr6	1346	2	G	g	NN
cord-005478-5iu38pr6	1346	3	/	/	SYM
cord-005478-5iu38pr6	1346	4	l	l	NN
cord-005478-5iu38pr6	1346	5	were	be	VBD
cord-005478-5iu38pr6	1346	6	10	10	CD
cord-005478-5iu38pr6	1346	7	(	(	-LRB-
cord-005478-5iu38pr6	1346	8	4	4	CD
cord-005478-5iu38pr6	1346	9	-24	-24	,
cord-005478-5iu38pr6	1346	10	)	)	-RRB-
cord-005478-5iu38pr6	1346	11	and	and	CC
cord-005478-5iu38pr6	1346	12	10	10	CD
cord-005478-5iu38pr6	1346	13	(	(	-LRB-
cord-005478-5iu38pr6	1346	14	1	1	CD
cord-005478-5iu38pr6	1346	15	-	-	SYM
cord-005478-5iu38pr6	1346	16	124	124	CD
cord-005478-5iu38pr6	1346	17	)	)	-RRB-
cord-005478-5iu38pr6	1346	18	days	day	NNS
cord-005478-5iu38pr6	1346	19	for	for	IN
cord-005478-5iu38pr6	1346	20	BeEAM	beeam	JJ
cord-005478-5iu38pr6	1346	21	and	and	CC
cord-005478-5iu38pr6	1346	22	12	12	CD
cord-005478-5iu38pr6	1346	23	(	(	-LRB-
cord-005478-5iu38pr6	1346	24	1	1	CD
cord-005478-5iu38pr6	1346	25	-	-	SYM
cord-005478-5iu38pr6	1346	26	34	34	CD
cord-005478-5iu38pr6	1346	27	)	)	-RRB-
cord-005478-5iu38pr6	1346	28	and	and	CC
cord-005478-5iu38pr6	1346	29	12	12	CD
cord-005478-5iu38pr6	1346	30	(	(	-LRB-
cord-005478-5iu38pr6	1346	31	9	9	CD
cord-005478-5iu38pr6	1346	32	-	-	SYM
cord-005478-5iu38pr6	1346	33	50	50	CD
cord-005478-5iu38pr6	1346	34	)	)	-RRB-
cord-005478-5iu38pr6	1346	35	days	day	NNS
cord-005478-5iu38pr6	1346	36	for	for	IN
cord-005478-5iu38pr6	1346	37	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1346	38	,	,	,
cord-005478-5iu38pr6	1346	39	respectively	respectively	RB
cord-005478-5iu38pr6	1346	40	.	.	.
cord-005478-5iu38pr6	1347	1	Twenty	twenty	CD
cord-005478-5iu38pr6	1347	2	-	-	HYPH
cord-005478-5iu38pr6	1347	3	nine	nine	CD
cord-005478-5iu38pr6	1347	4	(	(	-LRB-
cord-005478-5iu38pr6	1347	5	22	22	CD
cord-005478-5iu38pr6	1347	6	%	%	NN
cord-005478-5iu38pr6	1347	7	)	)	-RRB-
cord-005478-5iu38pr6	1347	8	patients	patient	NNS
cord-005478-5iu38pr6	1347	9	in	in	IN
cord-005478-5iu38pr6	1347	10	the	the	DT
cord-005478-5iu38pr6	1347	11	BeEAM	beeam	JJ
cord-005478-5iu38pr6	1347	12	and	and	CC
cord-005478-5iu38pr6	1347	13	35	35	CD
cord-005478-5iu38pr6	1347	14	(	(	-LRB-
cord-005478-5iu38pr6	1347	15	15	15	CD
cord-005478-5iu38pr6	1347	16	%	%	NN
cord-005478-5iu38pr6	1347	17	)	)	-RRB-
cord-005478-5iu38pr6	1347	18	patients	patient	NNS
cord-005478-5iu38pr6	1347	19	in	in	IN
cord-005478-5iu38pr6	1347	20	the	the	DT
cord-005478-5iu38pr6	1347	21	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1347	22	groups	group	NNS
cord-005478-5iu38pr6	1347	23	relapsed	relapse	VBD
cord-005478-5iu38pr6	1347	24	after	after	IN
cord-005478-5iu38pr6	1347	25	a	a	DT
cord-005478-5iu38pr6	1347	26	median	median	JJ
cord-005478-5iu38pr6	1347	27	time	time	NN
cord-005478-5iu38pr6	1347	28	to	to	TO
cord-005478-5iu38pr6	1347	29	relapse	relapse	VB
cord-005478-5iu38pr6	1347	30	of	of	IN
cord-005478-5iu38pr6	1347	31	6	6	CD
cord-005478-5iu38pr6	1347	32	and	and	CC
cord-005478-5iu38pr6	1347	33	9	9	CD
cord-005478-5iu38pr6	1347	34	months	month	NNS
cord-005478-5iu38pr6	1347	35	,	,	,
cord-005478-5iu38pr6	1347	36	respectively	respectively	RB
cord-005478-5iu38pr6	1347	37	.	.	.
cord-005478-5iu38pr6	1348	1	After	after	IN
cord-005478-5iu38pr6	1348	2	a	a	DT
cord-005478-5iu38pr6	1348	3	median	median	JJ
cord-005478-5iu38pr6	1348	4	follow	follow	NN
cord-005478-5iu38pr6	1348	5	-	-	HYPH
cord-005478-5iu38pr6	1348	6	up	up	NN
cord-005478-5iu38pr6	1348	7	from	from	IN
cord-005478-5iu38pr6	1348	8	transplant	transplant	NN
cord-005478-5iu38pr6	1348	9	of	of	IN
cord-005478-5iu38pr6	1348	10	33	33	CD
cord-005478-5iu38pr6	1348	11	months	month	NNS
cord-005478-5iu38pr6	1348	12	,	,	,
cord-005478-5iu38pr6	1348	13	54	54	CD
cord-005478-5iu38pr6	1348	14	(	(	-LRB-
cord-005478-5iu38pr6	1348	15	15	15	CD
cord-005478-5iu38pr6	1348	16	%	%	NN
cord-005478-5iu38pr6	1348	17	)	)	-RRB-
cord-005478-5iu38pr6	1348	18	patients	patient	NNS
cord-005478-5iu38pr6	1348	19	died	die	VBD
cord-005478-5iu38pr6	1348	20	,	,	,
cord-005478-5iu38pr6	1348	21	24	24	CD
cord-005478-5iu38pr6	1348	22	(	(	-LRB-
cord-005478-5iu38pr6	1348	23	18	18	CD
cord-005478-5iu38pr6	1348	24	%	%	NN
cord-005478-5iu38pr6	1348	25	)	)	-RRB-
cord-005478-5iu38pr6	1348	26	in	in	IN
cord-005478-5iu38pr6	1348	27	the	the	DT
cord-005478-5iu38pr6	1348	28	BeEAM	BeEAM	NNP
cord-005478-5iu38pr6	1348	29	and	and	CC
cord-005478-5iu38pr6	1348	30	30	30	CD
cord-005478-5iu38pr6	1348	31	(	(	-LRB-
cord-005478-5iu38pr6	1348	32	13	13	CD
cord-005478-5iu38pr6	1348	33	%	%	NN
cord-005478-5iu38pr6	1348	34	)	)	-RRB-
cord-005478-5iu38pr6	1348	35	in	in	IN
cord-005478-5iu38pr6	1348	36	the	the	DT
cord-005478-5iu38pr6	1348	37	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1348	38	groups	group	NNS
cord-005478-5iu38pr6	1348	39	,	,	,
cord-005478-5iu38pr6	1348	40	respectively	respectively	RB
cord-005478-5iu38pr6	1348	41	.	.	.
cord-005478-5iu38pr6	1349	1	The	the	DT
cord-005478-5iu38pr6	1349	2	main	main	JJ
cord-005478-5iu38pr6	1349	3	causes	cause	NNS
cord-005478-5iu38pr6	1349	4	of	of	IN
cord-005478-5iu38pr6	1349	5	death	death	NN
cord-005478-5iu38pr6	1349	6	was	be	VBD
cord-005478-5iu38pr6	1349	7	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1349	8	in	in	IN
cord-005478-5iu38pr6	1349	9	31	31	CD
cord-005478-5iu38pr6	1349	10	patients	patient	NNS
cord-005478-5iu38pr6	1349	11	,	,	,
cord-005478-5iu38pr6	1349	12	(	(	-LRB-
cord-005478-5iu38pr6	1349	13	BeEAM:13	BeEAM:13	NNP
cord-005478-5iu38pr6	1349	14	,	,	,
cord-005478-5iu38pr6	1349	15	BEAM:18	BEAM:18	NNP
cord-005478-5iu38pr6	1349	16	)	)	-RRB-
cord-005478-5iu38pr6	1349	17	,	,	,
cord-005478-5iu38pr6	1349	18	infections	infection	NNS
cord-005478-5iu38pr6	1349	19	in	in	IN
cord-005478-5iu38pr6	1349	20	16	16	CD
cord-005478-5iu38pr6	1349	21	,	,	,
cord-005478-5iu38pr6	1349	22	(	(	-LRB-
cord-005478-5iu38pr6	1349	23	BeEAM:7	beeam:7	UH
cord-005478-5iu38pr6	1349	24	,	,	,
cord-005478-5iu38pr6	1349	25	BEAM:9	BEAM:9	NNP
cord-005478-5iu38pr6	1349	26	)	)	-RRB-
cord-005478-5iu38pr6	1349	27	,	,	,
cord-005478-5iu38pr6	1349	28	secondary	secondary	JJ
cord-005478-5iu38pr6	1349	29	cancers	cancer	NNS
cord-005478-5iu38pr6	1349	30	in	in	IN
cord-005478-5iu38pr6	1349	31	2	2	CD
cord-005478-5iu38pr6	1349	32	patients	patient	NNS
cord-005478-5iu38pr6	1349	33	(	(	-LRB-
cord-005478-5iu38pr6	1349	34	BeEAM	beeam	RB
cord-005478-5iu38pr6	1349	35	)	)	-RRB-
cord-005478-5iu38pr6	1349	36	.	.	.
cord-005478-5iu38pr6	1350	1	There	there	EX
cord-005478-5iu38pr6	1350	2	were	be	VBD
cord-005478-5iu38pr6	1350	3	no	no	DT
cord-005478-5iu38pr6	1350	4	significant	significant	JJ
cord-005478-5iu38pr6	1350	5	differences	difference	NNS
cord-005478-5iu38pr6	1350	6	between	between	IN
cord-005478-5iu38pr6	1350	7	BeEAM	beeam	JJ
cord-005478-5iu38pr6	1350	8	and	and	CC
cord-005478-5iu38pr6	1350	9	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1350	10	regimens	regimen	NNS
cord-005478-5iu38pr6	1350	11	for	for	IN
cord-005478-5iu38pr6	1350	12	OS	OS	NNP
cord-005478-5iu38pr6	1350	13	:	:	:
cord-005478-5iu38pr6	1351	1	HR=1.02	hr=1.02	JJ
cord-005478-5iu38pr6	1351	2	[	[	-LRB-
cord-005478-5iu38pr6	1352	1	(	(	-LRB-
cord-005478-5iu38pr6	1352	2	0.55	0.55	CD
cord-005478-5iu38pr6	1352	3	-	-	SYM
cord-005478-5iu38pr6	1352	4	1.86	1.86	CD
cord-005478-5iu38pr6	1352	5	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1352	6	:	:	:
cord-005478-5iu38pr6	1352	7	In	in	IN
cord-005478-5iu38pr6	1352	8	this	this	DT
cord-005478-5iu38pr6	1352	9	matched	match	VBN
cord-005478-5iu38pr6	1352	10	pair	pair	NN
cord-005478-5iu38pr6	1352	11	analysis	analysis	NN
cord-005478-5iu38pr6	1352	12	,	,	,
cord-005478-5iu38pr6	1352	13	BeEAM	beeam	JJ
cord-005478-5iu38pr6	1352	14	and	and	CC
cord-005478-5iu38pr6	1352	15	BEAM	BEAM	NNP
cord-005478-5iu38pr6	1352	16	resulted	result	VBD
cord-005478-5iu38pr6	1352	17	in	in	IN
cord-005478-5iu38pr6	1352	18	equivalent	equivalent	JJ
cord-005478-5iu38pr6	1352	19	NRM	NRM	NNP
cord-005478-5iu38pr6	1352	20	,	,	,
cord-005478-5iu38pr6	1352	21	LFS	LFS	NNP
cord-005478-5iu38pr6	1352	22	and	and	CC
cord-005478-5iu38pr6	1352	23	OS	OS	NNP
cord-005478-5iu38pr6	1352	24	suggesting	suggest	VBG
cord-005478-5iu38pr6	1352	25	that	that	IN
cord-005478-5iu38pr6	1352	26	both	both	DT
cord-005478-5iu38pr6	1352	27	conditioning	conditioning	NN
cord-005478-5iu38pr6	1352	28	regimens	regimen	NNS
cord-005478-5iu38pr6	1352	29	may	may	MD
cord-005478-5iu38pr6	1352	30	reasonably	reasonably	RB
cord-005478-5iu38pr6	1352	31	be	be	VB
cord-005478-5iu38pr6	1352	32	employed	employ	VBN
cord-005478-5iu38pr6	1352	33	in	in	IN
cord-005478-5iu38pr6	1352	34	patients	patient	NNS
cord-005478-5iu38pr6	1352	35	with	with	IN
cord-005478-5iu38pr6	1352	36	DLBCL	DLBCL	NNP
cord-005478-5iu38pr6	1352	37	.	.	.
cord-005478-5iu38pr6	1353	1	The	the	DT
cord-005478-5iu38pr6	1353	2	higher	high	JJR
cord-005478-5iu38pr6	1353	3	relapse	relapse	NN
cord-005478-5iu38pr6	1353	4	rate	rate	NN
cord-005478-5iu38pr6	1353	5	following	follow	VBG
cord-005478-5iu38pr6	1353	6	BeEAM	BeEAM	NNP
cord-005478-5iu38pr6	1353	7	requires	require	VBZ
cord-005478-5iu38pr6	1353	8	further	further	JJ
cord-005478-5iu38pr6	1353	9	evaluation	evaluation	NN
cord-005478-5iu38pr6	1353	10	.	.	.
cord-005478-5iu38pr6	1354	1	A	a	DT
cord-005478-5iu38pr6	1354	2	prospective	prospective	JJ
cord-005478-5iu38pr6	1354	3	randomized	randomized	JJ
cord-005478-5iu38pr6	1354	4	study	study	NN
cord-005478-5iu38pr6	1354	5	will	will	MD
cord-005478-5iu38pr6	1354	6	be	be	VB
cord-005478-5iu38pr6	1354	7	required	require	VBN
cord-005478-5iu38pr6	1354	8	to	to	TO
cord-005478-5iu38pr6	1354	9	confirm	confirm	VB
cord-005478-5iu38pr6	1354	10	the	the	DT
cord-005478-5iu38pr6	1354	11	equivalence	equivalence	NN
cord-005478-5iu38pr6	1354	12	of	of	IN
cord-005478-5iu38pr6	1354	13	the	the	DT
cord-005478-5iu38pr6	1354	14	two	two	CD
cord-005478-5iu38pr6	1354	15	regimens	regimen	NNS
cord-005478-5iu38pr6	1354	16	.	.	.
cord-005478-5iu38pr6	1355	1	[	[	-LRB-
cord-005478-5iu38pr6	1355	2	[	[	-LRB-
cord-005478-5iu38pr6	1355	3	O071	O071	NNP
cord-005478-5iu38pr6	1355	4	Table	table	NN
cord-005478-5iu38pr6	1355	5	]	]	-RRB-
cord-005478-5iu38pr6	1355	6	1	1	CD
cord-005478-5iu38pr6	1355	7	.	.	.
cord-005478-5iu38pr6	1356	1	Background	background	NN
cord-005478-5iu38pr6	1356	2	:	:	:
cord-005478-5iu38pr6	1357	1	Inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	1357	2	bowel	bowel	NN
cord-005478-5iu38pr6	1357	3	diseases	disease	NNS
cord-005478-5iu38pr6	1357	4	(	(	-LRB-
cord-005478-5iu38pr6	1357	5	IBD	IBD	NNP
cord-005478-5iu38pr6	1357	6	)	)	-RRB-
cord-005478-5iu38pr6	1357	7	are	be	VBP
cord-005478-5iu38pr6	1357	8	thought	think	VBN
cord-005478-5iu38pr6	1357	9	to	to	TO
cord-005478-5iu38pr6	1357	10	increase	increase	VB
cord-005478-5iu38pr6	1357	11	the	the	DT
cord-005478-5iu38pr6	1357	12	risk	risk	NN
cord-005478-5iu38pr6	1357	13	and	and	CC
cord-005478-5iu38pr6	1357	14	severity	severity	NN
cord-005478-5iu38pr6	1357	15	of	of	IN
cord-005478-5iu38pr6	1357	16	graft	graft	NN
cord-005478-5iu38pr6	1357	17	-	-	HYPH
cord-005478-5iu38pr6	1357	18	versus	versus	IN
cord-005478-5iu38pr6	1357	19	-	-	HYPH
cord-005478-5iu38pr6	1357	20	host	host	NN
cord-005478-5iu38pr6	1357	21	disease	disease	NN
cord-005478-5iu38pr6	1357	22	(	(	-LRB-
cord-005478-5iu38pr6	1357	23	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1357	24	)	)	-RRB-
cord-005478-5iu38pr6	1357	25	and	and	CC
cord-005478-5iu38pr6	1357	26	non	non	JJ
cord-005478-5iu38pr6	1357	27	-	-	JJ
cord-005478-5iu38pr6	1357	28	relapse	relapse	JJ
cord-005478-5iu38pr6	1357	29	mortality	mortality	NN
cord-005478-5iu38pr6	1357	30	(	(	-LRB-
cord-005478-5iu38pr6	1357	31	NRM	NRM	NNP
cord-005478-5iu38pr6	1357	32	)	)	-RRB-
cord-005478-5iu38pr6	1357	33	after	after	IN
cord-005478-5iu38pr6	1357	34	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	1357	35	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1357	36	stem	stem	NN
cord-005478-5iu38pr6	1357	37	cell	cell	NN
cord-005478-5iu38pr6	1357	38	transplantation	transplantation	NN
cord-005478-5iu38pr6	1357	39	(	(	-LRB-
cord-005478-5iu38pr6	1357	40	allo	allo	NN
cord-005478-5iu38pr6	1357	41	-	-	HYPH
cord-005478-5iu38pr6	1357	42	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1357	43	)	)	-RRB-
cord-005478-5iu38pr6	1357	44	.	.	.
cord-005478-5iu38pr6	1358	1	Thus	thus	RB
cord-005478-5iu38pr6	1358	2	,	,	,
cord-005478-5iu38pr6	1358	3	IBD	IBD	NNP
cord-005478-5iu38pr6	1358	4	have	have	VBP
cord-005478-5iu38pr6	1358	5	been	be	VBN
cord-005478-5iu38pr6	1358	6	included	include	VBN
cord-005478-5iu38pr6	1358	7	in	in	IN
cord-005478-5iu38pr6	1358	8	pre	pre	JJ
cord-005478-5iu38pr6	1358	9	-	-	JJ
cord-005478-5iu38pr6	1358	10	transplant	transplant	JJ
cord-005478-5iu38pr6	1358	11	comorbidity	comorbidity	NN
cord-005478-5iu38pr6	1358	12	risk	risk	NN
cord-005478-5iu38pr6	1358	13	scores	score	NNS
cord-005478-5iu38pr6	1358	14	,	,	,
cord-005478-5iu38pr6	1358	15	although	although	IN
cord-005478-5iu38pr6	1358	16	formal	formal	JJ
cord-005478-5iu38pr6	1358	17	analysis	analysis	NN
cord-005478-5iu38pr6	1358	18	of	of	IN
cord-005478-5iu38pr6	1358	19	allo	allo	NN
cord-005478-5iu38pr6	1358	20	-	-	HYPH
cord-005478-5iu38pr6	1358	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1358	22	outcomes	outcome	NNS
cord-005478-5iu38pr6	1358	23	in	in	IN
cord-005478-5iu38pr6	1358	24	patients	patient	NNS
cord-005478-5iu38pr6	1358	25	with	with	IN
cord-005478-5iu38pr6	1358	26	IBD	IBD	NNP
cord-005478-5iu38pr6	1358	27	are	be	VBP
cord-005478-5iu38pr6	1358	28	lacking	lack	VBG
cord-005478-5iu38pr6	1358	29	.	.	.
cord-005478-5iu38pr6	1359	1	Methods	method	NNS
cord-005478-5iu38pr6	1359	2	:	:	:
cord-005478-5iu38pr6	1359	3	With	with	IN
cord-005478-5iu38pr6	1359	4	this	this	DT
cord-005478-5iu38pr6	1359	5	background	background	NN
cord-005478-5iu38pr6	1359	6	,	,	,
cord-005478-5iu38pr6	1359	7	we	-PRON-	PRP
cord-005478-5iu38pr6	1359	8	designed	design	VBD
cord-005478-5iu38pr6	1359	9	an	an	DT
cord-005478-5iu38pr6	1359	10	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1359	11	registry	registry	NN
cord-005478-5iu38pr6	1359	12	retrospective	retrospective	JJ
cord-005478-5iu38pr6	1359	13	case	case	NN
cord-005478-5iu38pr6	1359	14	-	-	HYPH
cord-005478-5iu38pr6	1359	15	controlled	control	VBN
cord-005478-5iu38pr6	1359	16	analysis	analysis	NN
cord-005478-5iu38pr6	1359	17	to	to	TO
cord-005478-5iu38pr6	1359	18	assess	assess	VB
cord-005478-5iu38pr6	1359	19	outcomes	outcome	NNS
cord-005478-5iu38pr6	1359	20	of	of	IN
cord-005478-5iu38pr6	1359	21	allo	allo	NN
cord-005478-5iu38pr6	1359	22	-	-	HYPH
cord-005478-5iu38pr6	1359	23	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1359	24	in	in	IN
cord-005478-5iu38pr6	1359	25	patients	patient	NNS
cord-005478-5iu38pr6	1359	26	with	with	IN
cord-005478-5iu38pr6	1359	27	IBD	IBD	NNP
cord-005478-5iu38pr6	1359	28	.	.	.
cord-005478-5iu38pr6	1360	1	The	the	DT
cord-005478-5iu38pr6	1360	2	aim	aim	NN
cord-005478-5iu38pr6	1360	3	was	be	VBD
cord-005478-5iu38pr6	1360	4	to	to	TO
cord-005478-5iu38pr6	1360	5	compare	compare	VB
cord-005478-5iu38pr6	1360	6	the	the	DT
cord-005478-5iu38pr6	1360	7	incidence	incidence	NN
cord-005478-5iu38pr6	1360	8	of	of	IN
cord-005478-5iu38pr6	1360	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1360	10	,	,	,
cord-005478-5iu38pr6	1360	11	NRM	NRM	NNP
cord-005478-5iu38pr6	1360	12	and	and	CC
cord-005478-5iu38pr6	1360	13	overall	overall	JJ
cord-005478-5iu38pr6	1360	14	survival	survival	NN
cord-005478-5iu38pr6	1360	15	(	(	-LRB-
cord-005478-5iu38pr6	1360	16	OS	OS	NNP
cord-005478-5iu38pr6	1360	17	)	)	-RRB-
cord-005478-5iu38pr6	1360	18	after	after	IN
cord-005478-5iu38pr6	1360	19	allo	allo	NN
cord-005478-5iu38pr6	1360	20	-	-	HYPH
cord-005478-5iu38pr6	1360	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1360	22	in	in	IN
cord-005478-5iu38pr6	1360	23	the	the	DT
cord-005478-5iu38pr6	1360	24	2	2	CD
cord-005478-5iu38pr6	1360	25	groups	group	NNS
cord-005478-5iu38pr6	1360	26	of	of	IN
cord-005478-5iu38pr6	1360	27	patients	patient	NNS
cord-005478-5iu38pr6	1360	28	.	.	.
cord-005478-5iu38pr6	1361	1	Each	each	DT
cord-005478-5iu38pr6	1361	2	patient	patient	JJ
cord-005478-5iu38pr6	1361	3	with	with	IN
cord-005478-5iu38pr6	1361	4	IBD	IBD	NNP
cord-005478-5iu38pr6	1361	5	was	be	VBD
cord-005478-5iu38pr6	1361	6	matched	match	VBN
cord-005478-5iu38pr6	1361	7	with	with	IN
cord-005478-5iu38pr6	1361	8	3	3	CD
cord-005478-5iu38pr6	1361	9	controls	control	NNS
cord-005478-5iu38pr6	1361	10	according	accord	VBG
cord-005478-5iu38pr6	1361	11	to	to	IN
cord-005478-5iu38pr6	1361	12	following	follow	VBG
cord-005478-5iu38pr6	1361	13	factors	factor	NNS
cord-005478-5iu38pr6	1361	14	:	:	:
cord-005478-5iu38pr6	1361	15	patient	patient	JJ
cord-005478-5iu38pr6	1361	16	sex	sex	NN
cord-005478-5iu38pr6	1361	17	,	,	,
cord-005478-5iu38pr6	1361	18	patient	patient	JJ
cord-005478-5iu38pr6	1361	19	age	age	NN
cord-005478-5iu38pr6	1361	20	,	,	,
cord-005478-5iu38pr6	1361	21	disease	disease	NN
cord-005478-5iu38pr6	1361	22	,	,	,
cord-005478-5iu38pr6	1361	23	intensity	intensity	NN
cord-005478-5iu38pr6	1361	24	of	of	IN
cord-005478-5iu38pr6	1361	25	conditioning	conditioning	NN
cord-005478-5iu38pr6	1361	26	,	,	,
cord-005478-5iu38pr6	1361	27	donor	donor	NN
cord-005478-5iu38pr6	1361	28	type	type	NN
cord-005478-5iu38pr6	1361	29	and	and	CC
cord-005478-5iu38pr6	1361	30	HLA	HLA	NNP
cord-005478-5iu38pr6	1361	31	disparity	disparity	NN
cord-005478-5iu38pr6	1361	32	,	,	,
cord-005478-5iu38pr6	1361	33	cell	cell	NN
cord-005478-5iu38pr6	1361	34	source	source	NN
cord-005478-5iu38pr6	1361	35	and	and	CC
cord-005478-5iu38pr6	1361	36	year	year	NN
cord-005478-5iu38pr6	1361	37	of	of	IN
cord-005478-5iu38pr6	1361	38	transplant	transplant	NN
cord-005478-5iu38pr6	1361	39	.	.	.
cord-005478-5iu38pr6	1362	1	Group	group	NN
cord-005478-5iu38pr6	1362	2	comparisons	comparison	NNS
cord-005478-5iu38pr6	1362	3	were	be	VBD
cord-005478-5iu38pr6	1362	4	done	do	VBN
cord-005478-5iu38pr6	1362	5	using	use	VBG
cord-005478-5iu38pr6	1362	6	logrank	logrank	NN
cord-005478-5iu38pr6	1362	7	test	test	NN
cord-005478-5iu38pr6	1362	8	or	or	CC
cord-005478-5iu38pr6	1362	9	Gray	gray	JJ
cord-005478-5iu38pr6	1362	10	test	test	NN
cord-005478-5iu38pr6	1362	11	for	for	IN
cord-005478-5iu38pr6	1362	12	competing	compete	VBG
cord-005478-5iu38pr6	1362	13	risks	risk	NNS
cord-005478-5iu38pr6	1362	14	outcomes	outcome	NNS
cord-005478-5iu38pr6	1362	15	.	.	.
cord-005478-5iu38pr6	1363	1	Results	result	NNS
cord-005478-5iu38pr6	1363	2	:	:	:
cord-005478-5iu38pr6	1364	1	Between	between	IN
cord-005478-5iu38pr6	1364	2	2011	2011	CD
cord-005478-5iu38pr6	1364	3	and	and	CC
cord-005478-5iu38pr6	1364	4	2015	2015	CD
cord-005478-5iu38pr6	1364	5	,	,	,
cord-005478-5iu38pr6	1364	6	175	175	CD
cord-005478-5iu38pr6	1364	7	patients	patient	NNS
cord-005478-5iu38pr6	1364	8	with	with	IN
cord-005478-5iu38pr6	1364	9	IBD	IBD	NNP
cord-005478-5iu38pr6	1364	10	who	who	WP
cord-005478-5iu38pr6	1364	11	underwent	undergo	VBD
cord-005478-5iu38pr6	1364	12	allo	allo	NN
cord-005478-5iu38pr6	1364	13	-	-	HYPH
cord-005478-5iu38pr6	1364	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1364	15	for	for	IN
cord-005478-5iu38pr6	1364	16	a	a	DT
cord-005478-5iu38pr6	1364	17	hematologic	hematologic	JJ
cord-005478-5iu38pr6	1364	18	malignancy	malignancy	NN
cord-005478-5iu38pr6	1364	19	were	be	VBD
cord-005478-5iu38pr6	1364	20	reported	report	VBN
cord-005478-5iu38pr6	1364	21	to	to	IN
cord-005478-5iu38pr6	1364	22	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1364	23	.	.	.
cord-005478-5iu38pr6	1365	1	The	the	DT
cord-005478-5iu38pr6	1365	2	cohort	cohort	NN
cord-005478-5iu38pr6	1365	3	comprised	comprise	VBD
cord-005478-5iu38pr6	1365	4	94	94	CD
cord-005478-5iu38pr6	1365	5	males	male	NNS
cord-005478-5iu38pr6	1365	6	and	and	CC
cord-005478-5iu38pr6	1365	7	81	81	CD
cord-005478-5iu38pr6	1365	8	females	female	NNS
cord-005478-5iu38pr6	1365	9	,	,	,
cord-005478-5iu38pr6	1365	10	with	with	IN
cord-005478-5iu38pr6	1365	11	a	a	DT
cord-005478-5iu38pr6	1365	12	median	median	JJ
cord-005478-5iu38pr6	1365	13	age	age	NN
cord-005478-5iu38pr6	1365	14	of	of	IN
cord-005478-5iu38pr6	1365	15	53	53	CD
cord-005478-5iu38pr6	1365	16	years	year	NNS
cord-005478-5iu38pr6	1365	17	(	(	-LRB-
cord-005478-5iu38pr6	1365	18	range	range	NN
cord-005478-5iu38pr6	1365	19	,	,	,
cord-005478-5iu38pr6	1365	20	18	18	CD
cord-005478-5iu38pr6	1365	21	to	to	TO
cord-005478-5iu38pr6	1365	22	69	69	CD
cord-005478-5iu38pr6	1365	23	years	year	NNS
cord-005478-5iu38pr6	1365	24	)	)	-RRB-
cord-005478-5iu38pr6	1365	25	at	at	IN
cord-005478-5iu38pr6	1365	26	the	the	DT
cord-005478-5iu38pr6	1365	27	time	time	NN
cord-005478-5iu38pr6	1365	28	of	of	IN
cord-005478-5iu38pr6	1365	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	1365	30	.	.	.
cord-005478-5iu38pr6	1366	1	The	the	DT
cord-005478-5iu38pr6	1366	2	most	most	RBS
cord-005478-5iu38pr6	1366	3	frequent	frequent	JJ
cord-005478-5iu38pr6	1366	4	malignancies	malignancy	NNS
cord-005478-5iu38pr6	1366	5	in	in	IN
cord-005478-5iu38pr6	1366	6	the	the	DT
cord-005478-5iu38pr6	1366	7	IBD	IBD	NNP
cord-005478-5iu38pr6	1366	8	group	group	NN
cord-005478-5iu38pr6	1366	9	were	be	VBD
cord-005478-5iu38pr6	1366	10	acute	acute	JJ
cord-005478-5iu38pr6	1366	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	1366	12	(	(	-LRB-
cord-005478-5iu38pr6	1366	13	106	106	CD
cord-005478-5iu38pr6	1366	14	patients	patient	NNS
cord-005478-5iu38pr6	1366	15	;	;	:
cord-005478-5iu38pr6	1366	16	61	61	CD
cord-005478-5iu38pr6	1366	17	%	%	NN
cord-005478-5iu38pr6	1366	18	)	)	-RRB-
cord-005478-5iu38pr6	1366	19	and	and	CC
cord-005478-5iu38pr6	1366	20	myelodysplastic	myelodysplastic	JJ
cord-005478-5iu38pr6	1366	21	/	/	SYM
cord-005478-5iu38pr6	1366	22	myeloproliferative	myeloproliferative	JJ
cord-005478-5iu38pr6	1366	23	neoplasm	neoplasm	NN
cord-005478-5iu38pr6	1366	24	(	(	-LRB-
cord-005478-5iu38pr6	1366	25	42	42	CD
cord-005478-5iu38pr6	1366	26	patients	patient	NNS
cord-005478-5iu38pr6	1366	27	;	;	:
cord-005478-5iu38pr6	1366	28	24	24	CD
cord-005478-5iu38pr6	1366	29	%	%	NN
cord-005478-5iu38pr6	1366	30	)	)	-RRB-
cord-005478-5iu38pr6	1366	31	.	.	.
cord-005478-5iu38pr6	1367	1	The	the	DT
cord-005478-5iu38pr6	1367	2	donor	donor	NN
cord-005478-5iu38pr6	1367	3	was	be	VBD
cord-005478-5iu38pr6	1367	4	an	an	DT
cord-005478-5iu38pr6	1367	5	identical	identical	JJ
cord-005478-5iu38pr6	1367	6	sibling	sibling	NN
cord-005478-5iu38pr6	1367	7	for	for	IN
cord-005478-5iu38pr6	1367	8	66	66	CD
cord-005478-5iu38pr6	1367	9	patients	patient	NNS
cord-005478-5iu38pr6	1367	10	(	(	-LRB-
cord-005478-5iu38pr6	1367	11	38	38	CD
cord-005478-5iu38pr6	1367	12	%	%	NN
cord-005478-5iu38pr6	1367	13	)	)	-RRB-
cord-005478-5iu38pr6	1367	14	,	,	,
cord-005478-5iu38pr6	1367	15	and	and	CC
cord-005478-5iu38pr6	1367	16	a	a	DT
cord-005478-5iu38pr6	1367	17	matched	match	VBN
cord-005478-5iu38pr6	1367	18	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1367	19	donor	donor	NN
cord-005478-5iu38pr6	1367	20	for	for	IN
cord-005478-5iu38pr6	1367	21	56	56	CD
cord-005478-5iu38pr6	1367	22	patients	patient	NNS
cord-005478-5iu38pr6	1367	23	(	(	-LRB-
cord-005478-5iu38pr6	1367	24	32	32	CD
cord-005478-5iu38pr6	1367	25	%	%	NN
cord-005478-5iu38pr6	1367	26	)	)	-RRB-
cord-005478-5iu38pr6	1367	27	.	.	.
cord-005478-5iu38pr6	1368	1	93	93	CD
cord-005478-5iu38pr6	1368	2	patients	patient	NNS
cord-005478-5iu38pr6	1368	3	(	(	-LRB-
cord-005478-5iu38pr6	1368	4	53	53	CD
cord-005478-5iu38pr6	1368	5	%	%	NN
cord-005478-5iu38pr6	1368	6	)	)	-RRB-
cord-005478-5iu38pr6	1368	7	received	receive	VBD
cord-005478-5iu38pr6	1368	8	a	a	DT
cord-005478-5iu38pr6	1368	9	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1368	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	1368	11	regimen	regimen	NN
cord-005478-5iu38pr6	1368	12	while	while	IN
cord-005478-5iu38pr6	1368	13	82	82	CD
cord-005478-5iu38pr6	1368	14	patients	patient	NNS
cord-005478-5iu38pr6	1368	15	(	(	-LRB-
cord-005478-5iu38pr6	1368	16	47	47	CD
cord-005478-5iu38pr6	1368	17	%	%	NN
cord-005478-5iu38pr6	1368	18	)	)	-RRB-
cord-005478-5iu38pr6	1368	19	received	receive	VBD
cord-005478-5iu38pr6	1368	20	a	a	DT
cord-005478-5iu38pr6	1368	21	reduced	reduce	VBN
cord-005478-5iu38pr6	1368	22	-	-	HYPH
cord-005478-5iu38pr6	1368	23	intensity	intensity	NN
cord-005478-5iu38pr6	1368	24	conditioning	conditioning	NN
cord-005478-5iu38pr6	1368	25	regimen	regimen	NN
cord-005478-5iu38pr6	1368	26	.	.	.
cord-005478-5iu38pr6	1369	1	With	with	IN
cord-005478-5iu38pr6	1369	2	a	a	DT
cord-005478-5iu38pr6	1369	3	median	median	JJ
cord-005478-5iu38pr6	1369	4	follow	follow	NN
cord-005478-5iu38pr6	1369	5	-	-	HYPH
cord-005478-5iu38pr6	1369	6	up	up	NN
cord-005478-5iu38pr6	1369	7	of	of	IN
cord-005478-5iu38pr6	1369	8	37	37	CD
cord-005478-5iu38pr6	1369	9	months	month	NNS
cord-005478-5iu38pr6	1369	10	(	(	-LRB-
cord-005478-5iu38pr6	1369	11	range	range	NN
cord-005478-5iu38pr6	1369	12	,	,	,
cord-005478-5iu38pr6	1369	13	32	32	CD
cord-005478-5iu38pr6	1369	14	-	-	SYM
cord-005478-5iu38pr6	1369	15	45	45	CD
cord-005478-5iu38pr6	1369	16	)	)	-RRB-
cord-005478-5iu38pr6	1369	17	for	for	IN
cord-005478-5iu38pr6	1369	18	the	the	DT
cord-005478-5iu38pr6	1369	19	patients	patient	NNS
cord-005478-5iu38pr6	1369	20	with	with	IN
cord-005478-5iu38pr6	1369	21	IBD	IBD	NNP
cord-005478-5iu38pr6	1369	22	and	and	CC
cord-005478-5iu38pr6	1369	23	36	36	CD
cord-005478-5iu38pr6	1369	24	months	month	NNS
cord-005478-5iu38pr6	1369	25	(	(	-LRB-
cord-005478-5iu38pr6	1369	26	range	range	NN
cord-005478-5iu38pr6	1369	27	,	,	,
cord-005478-5iu38pr6	1369	28	33	33	CD
cord-005478-5iu38pr6	1369	29	-	-	SYM
cord-005478-5iu38pr6	1369	30	39	39	CD
cord-005478-5iu38pr6	1369	31	)	)	-RRB-
cord-005478-5iu38pr6	1369	32	for	for	IN
cord-005478-5iu38pr6	1369	33	controls	control	NNS
cord-005478-5iu38pr6	1369	34	,	,	,
cord-005478-5iu38pr6	1369	35	the	the	DT
cord-005478-5iu38pr6	1369	36	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1369	37	incidence	incidence	NN
cord-005478-5iu38pr6	1369	38	of	of	IN
cord-005478-5iu38pr6	1369	39	grade	grade	NN
cord-005478-5iu38pr6	1369	40	II	II	NNP
cord-005478-5iu38pr6	1369	41	-	-	HYPH
cord-005478-5iu38pr6	1369	42	IV	IV	NNP
cord-005478-5iu38pr6	1369	43	acute	acute	JJ
cord-005478-5iu38pr6	1369	44	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1369	45	was	be	VBD
cord-005478-5iu38pr6	1369	46	27	27	CD
cord-005478-5iu38pr6	1369	47	%	%	NN
cord-005478-5iu38pr6	1369	48	for	for	IN
cord-005478-5iu38pr6	1369	49	the	the	DT
cord-005478-5iu38pr6	1369	50	patients	patient	NNS
cord-005478-5iu38pr6	1369	51	with	with	IN
cord-005478-5iu38pr6	1369	52	IBD	IBD	NNP
cord-005478-5iu38pr6	1369	53	and	and	CC
cord-005478-5iu38pr6	1369	54	28	28	CD
cord-005478-5iu38pr6	1369	55	%	%	NN
cord-005478-5iu38pr6	1369	56	for	for	IN
cord-005478-5iu38pr6	1369	57	controls	control	NNS
cord-005478-5iu38pr6	1369	58	(	(	-LRB-
cord-005478-5iu38pr6	1369	59	hazard	hazard	NN
cord-005478-5iu38pr6	1369	60	ratio	ratio	NN
cord-005478-5iu38pr6	1369	61	(	(	-LRB-
cord-005478-5iu38pr6	1369	62	HR	HR	NNP
cord-005478-5iu38pr6	1369	63	)	)	-RRB-
cord-005478-5iu38pr6	1369	64	for	for	IN
cord-005478-5iu38pr6	1369	65	IBD	IBD	NNP
cord-005478-5iu38pr6	1369	66	versus	versus	IN
cord-005478-5iu38pr6	1369	67	controls	control	NNS
cord-005478-5iu38pr6	1369	68	,	,	,
cord-005478-5iu38pr6	1369	69	0.95	0.95	CD
cord-005478-5iu38pr6	1369	70	;	;	:
cord-005478-5iu38pr6	1369	71	95	95	CD
cord-005478-5iu38pr6	1369	72	%	%	NN
cord-005478-5iu38pr6	1369	73	CI	CI	NNP
cord-005478-5iu38pr6	1369	74	,	,	,
cord-005478-5iu38pr6	1369	75	0.66	0.66	CD
cord-005478-5iu38pr6	1369	76	to	to	IN
cord-005478-5iu38pr6	1369	77	1.36	1.36	CD
cord-005478-5iu38pr6	1369	78	;	;	:
cord-005478-5iu38pr6	1369	79	p=0.77	p=0.77	NN
cord-005478-5iu38pr6	1369	80	)	)	-RRB-
cord-005478-5iu38pr6	1369	81	.	.	.
cord-005478-5iu38pr6	1370	1	The	the	DT
cord-005478-5iu38pr6	1370	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1370	3	incidence	incidence	NN
cord-005478-5iu38pr6	1370	4	of	of	IN
cord-005478-5iu38pr6	1370	5	extensive	extensive	JJ
cord-005478-5iu38pr6	1370	6	chronic	chronic	JJ
cord-005478-5iu38pr6	1370	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1370	8	at	at	IN
cord-005478-5iu38pr6	1370	9	36	36	CD
cord-005478-5iu38pr6	1370	10	months	month	NNS
cord-005478-5iu38pr6	1370	11	was	be	VBD
cord-005478-5iu38pr6	1370	12	25	25	CD
cord-005478-5iu38pr6	1370	13	%	%	NN
cord-005478-5iu38pr6	1370	14	in	in	IN
cord-005478-5iu38pr6	1370	15	patients	patient	NNS
cord-005478-5iu38pr6	1370	16	with	with	IN
cord-005478-5iu38pr6	1370	17	IBD	IBD	NNP
cord-005478-5iu38pr6	1370	18	and	and	CC
cord-005478-5iu38pr6	1370	19	17	17	CD
cord-005478-5iu38pr6	1370	20	%	%	NN
cord-005478-5iu38pr6	1370	21	in	in	IN
cord-005478-5iu38pr6	1370	22	controls	control	NNS
cord-005478-5iu38pr6	1370	23	(	(	-LRB-
cord-005478-5iu38pr6	1370	24	HR	HR	NNP
cord-005478-5iu38pr6	1370	25	,	,	,
cord-005478-5iu38pr6	1370	26	1.54	1.54	CD
cord-005478-5iu38pr6	1370	27	;	;	:
cord-005478-5iu38pr6	1370	28	95	95	CD
cord-005478-5iu38pr6	1370	29	%	%	NN
cord-005478-5iu38pr6	1370	30	CI	CI	NNP
cord-005478-5iu38pr6	1370	31	,	,	,
cord-005478-5iu38pr6	1370	32	1.03	1.03	CD
cord-005478-5iu38pr6	1370	33	to	to	IN
cord-005478-5iu38pr6	1370	34	2.28	2.28	CD
cord-005478-5iu38pr6	1370	35	;	;	:
cord-005478-5iu38pr6	1370	36	p=0.03	p=0.03	NN
cord-005478-5iu38pr6	1370	37	)	)	-RRB-
cord-005478-5iu38pr6	1370	38	.	.	.
cord-005478-5iu38pr6	1371	1	NRM	NRM	NNP
cord-005478-5iu38pr6	1371	2	at	at	IN
cord-005478-5iu38pr6	1371	3	36	36	CD
cord-005478-5iu38pr6	1371	4	months	month	NNS
cord-005478-5iu38pr6	1371	5	was	be	VBD
cord-005478-5iu38pr6	1371	6	27	27	CD
cord-005478-5iu38pr6	1371	7	%	%	NN
cord-005478-5iu38pr6	1371	8	for	for	IN
cord-005478-5iu38pr6	1371	9	the	the	DT
cord-005478-5iu38pr6	1371	10	patients	patient	NNS
cord-005478-5iu38pr6	1371	11	with	with	IN
cord-005478-5iu38pr6	1371	12	IBD	IBD	NNP
cord-005478-5iu38pr6	1371	13	and	and	CC
cord-005478-5iu38pr6	1371	14	25	25	CD
cord-005478-5iu38pr6	1371	15	%	%	NN
cord-005478-5iu38pr6	1371	16	for	for	IN
cord-005478-5iu38pr6	1371	17	controls	control	NNS
cord-005478-5iu38pr6	1371	18	(	(	-LRB-
cord-005478-5iu38pr6	1371	19	HR	HR	NNP
cord-005478-5iu38pr6	1371	20	,	,	,
cord-005478-5iu38pr6	1371	21	1.07	1.07	CD
cord-005478-5iu38pr6	1371	22	;	;	:
cord-005478-5iu38pr6	1371	23	95	95	CD
cord-005478-5iu38pr6	1371	24	%	%	NN
cord-005478-5iu38pr6	1371	25	CI	ci	NN
cord-005478-5iu38pr6	1371	26	,	,	,
cord-005478-5iu38pr6	1371	27	0.76	0.76	CD
cord-005478-5iu38pr6	1371	28	-	-	HYPH
cord-005478-5iu38pr6	1371	29	1.52	1.52	CD
cord-005478-5iu38pr6	1371	30	;	;	:
cord-005478-5iu38pr6	1371	31	p=0.68	p=0.68	NN
cord-005478-5iu38pr6	1371	32	)	)	-RRB-
cord-005478-5iu38pr6	1371	33	.	.	.
cord-005478-5iu38pr6	1372	1	The	the	DT
cord-005478-5iu38pr6	1372	2	relapse	relapse	NN
cord-005478-5iu38pr6	1372	3	incidence	incidence	NN
cord-005478-5iu38pr6	1372	4	at	at	IN
cord-005478-5iu38pr6	1372	5	36	36	CD
cord-005478-5iu38pr6	1372	6	months	month	NNS
cord-005478-5iu38pr6	1372	7	was	be	VBD
cord-005478-5iu38pr6	1372	8	32	32	CD
cord-005478-5iu38pr6	1372	9	%	%	NN
cord-005478-5iu38pr6	1372	10	in	in	IN
cord-005478-5iu38pr6	1372	11	patients	patient	NNS
cord-005478-5iu38pr6	1372	12	with	with	IN
cord-005478-5iu38pr6	1372	13	IBD	IBD	NNP
cord-005478-5iu38pr6	1372	14	and	and	CC
cord-005478-5iu38pr6	1372	15	33	33	CD
cord-005478-5iu38pr6	1372	16	%	%	NN
cord-005478-5iu38pr6	1372	17	in	in	IN
cord-005478-5iu38pr6	1372	18	patients	patient	NNS
cord-005478-5iu38pr6	1372	19	without	without	IN
cord-005478-5iu38pr6	1372	20	IBD	IBD	NNP
cord-005478-5iu38pr6	1372	21	(	(	-LRB-
cord-005478-5iu38pr6	1372	22	HR	HR	NNP
cord-005478-5iu38pr6	1372	23	,	,	,
cord-005478-5iu38pr6	1372	24	1.19	1.19	CD
cord-005478-5iu38pr6	1372	25	;	;	:
cord-005478-5iu38pr6	1372	26	95	95	CD
cord-005478-5iu38pr6	1372	27	%	%	NN
cord-005478-5iu38pr6	1372	28	CI	CI	NNP
cord-005478-5iu38pr6	1372	29	,	,	,
cord-005478-5iu38pr6	1372	30	0.94	0.94	CD
cord-005478-5iu38pr6	1372	31	-	-	SYM
cord-005478-5iu38pr6	1372	32	1.49	1.49	CD
cord-005478-5iu38pr6	1372	33	;	;	:
cord-005478-5iu38pr6	1372	34	p=0.82	p=0.82	NNP
cord-005478-5iu38pr6	1372	35	)	)	-RRB-
cord-005478-5iu38pr6	1372	36	.	.	.
cord-005478-5iu38pr6	1373	1	OS	OS	NNP
cord-005478-5iu38pr6	1373	2	at	at	IN
cord-005478-5iu38pr6	1373	3	36	36	CD
cord-005478-5iu38pr6	1373	4	months	month	NNS
cord-005478-5iu38pr6	1373	5	was	be	VBD
cord-005478-5iu38pr6	1373	6	47	47	CD
cord-005478-5iu38pr6	1373	7	%	%	NN
cord-005478-5iu38pr6	1373	8	for	for	IN
cord-005478-5iu38pr6	1373	9	the	the	DT
cord-005478-5iu38pr6	1373	10	patients	patient	NNS
cord-005478-5iu38pr6	1373	11	with	with	IN
cord-005478-5iu38pr6	1373	12	IBD	IBD	NNP
cord-005478-5iu38pr6	1373	13	and	and	CC
cord-005478-5iu38pr6	1373	14	49	49	CD
cord-005478-5iu38pr6	1373	15	%	%	NN
cord-005478-5iu38pr6	1373	16	for	for	IN
cord-005478-5iu38pr6	1373	17	matched	matched	JJ
cord-005478-5iu38pr6	1373	18	controls	control	NNS
cord-005478-5iu38pr6	1373	19	(	(	-LRB-
cord-005478-5iu38pr6	1373	20	HR	HR	NNP
cord-005478-5iu38pr6	1373	21	,	,	,
cord-005478-5iu38pr6	1373	22	1.04	1.04	CD
cord-005478-5iu38pr6	1373	23	;	;	:
cord-005478-5iu38pr6	1373	24	95	95	CD
cord-005478-5iu38pr6	1373	25	%	%	NN
cord-005478-5iu38pr6	1373	26	CI	CI	NNP
cord-005478-5iu38pr6	1373	27	,	,	,
cord-005478-5iu38pr6	1373	28	0.81	0.81	CD
cord-005478-5iu38pr6	1373	29	-	-	SYM
cord-005478-5iu38pr6	1373	30	1.33	1.33	CD
cord-005478-5iu38pr6	1373	31	;	;	:
cord-005478-5iu38pr6	1373	32	p=0.79	p=0.79	NN
cord-005478-5iu38pr6	1373	33	)	)	-RRB-
cord-005478-5iu38pr6	1373	34	.	.	.
cord-005478-5iu38pr6	1374	1	Finally	finally	RB
cord-005478-5iu38pr6	1374	2	,	,	,
cord-005478-5iu38pr6	1374	3	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1374	4	-	-	HYPH
cord-005478-5iu38pr6	1374	5	free	free	JJ
cord-005478-5iu38pr6	1374	6	relapse	relapse	NN
cord-005478-5iu38pr6	1374	7	-	-	HYPH
cord-005478-5iu38pr6	1374	8	free	free	JJ
cord-005478-5iu38pr6	1374	9	survival	survival	NN
cord-005478-5iu38pr6	1374	10	(	(	-LRB-
cord-005478-5iu38pr6	1374	11	GRFS	GRFS	NNP
cord-005478-5iu38pr6	1374	12	)	)	-RRB-
cord-005478-5iu38pr6	1374	13	at	at	IN
cord-005478-5iu38pr6	1374	14	36	36	CD
cord-005478-5iu38pr6	1374	15	months	month	NNS
cord-005478-5iu38pr6	1374	16	was	be	VBD
cord-005478-5iu38pr6	1374	17	29	29	CD
cord-005478-5iu38pr6	1374	18	%	%	NN
cord-005478-5iu38pr6	1374	19	for	for	IN
cord-005478-5iu38pr6	1374	20	the	the	DT
cord-005478-5iu38pr6	1374	21	patients	patient	NNS
cord-005478-5iu38pr6	1374	22	with	with	IN
cord-005478-5iu38pr6	1374	23	IBD	IBD	NNP
cord-005478-5iu38pr6	1374	24	and	and	CC
cord-005478-5iu38pr6	1374	25	34	34	CD
cord-005478-5iu38pr6	1374	26	%	%	NN
cord-005478-5iu38pr6	1374	27	for	for	IN
cord-005478-5iu38pr6	1374	28	matched	matched	JJ
cord-005478-5iu38pr6	1374	29	controls	control	NNS
cord-005478-5iu38pr6	1374	30	(	(	-LRB-
cord-005478-5iu38pr6	1374	31	HR	HR	NNP
cord-005478-5iu38pr6	1374	32	,	,	,
cord-005478-5iu38pr6	1374	33	1.19	1.19	CD
cord-005478-5iu38pr6	1374	34	;	;	:
cord-005478-5iu38pr6	1374	35	95	95	CD
cord-005478-5iu38pr6	1374	36	%	%	NN
cord-005478-5iu38pr6	1374	37	CI	CI	NNP
cord-005478-5iu38pr6	1374	38	,	,	,
cord-005478-5iu38pr6	1374	39	0.94	0.94	CD
cord-005478-5iu38pr6	1374	40	-	-	SYM
cord-005478-5iu38pr6	1374	41	1.49	1.49	CD
cord-005478-5iu38pr6	1374	42	;	;	:
cord-005478-5iu38pr6	1374	43	p=0.14	p=0.14	NNP
cord-005478-5iu38pr6	1374	44	)	)	-RRB-
cord-005478-5iu38pr6	1374	45	.	.	.
cord-005478-5iu38pr6	1375	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1375	2	:	:	:
cord-005478-5iu38pr6	1376	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1376	2	report	report	VBP
cord-005478-5iu38pr6	1376	3	the	the	DT
cord-005478-5iu38pr6	1376	4	largest	large	JJS
cord-005478-5iu38pr6	1376	5	matched	match	VBN
cord-005478-5iu38pr6	1376	6	-	-	HYPH
cord-005478-5iu38pr6	1376	7	controlled	control	VBN
cord-005478-5iu38pr6	1376	8	study	study	NN
cord-005478-5iu38pr6	1376	9	of	of	IN
cord-005478-5iu38pr6	1376	10	allo	allo	NN
cord-005478-5iu38pr6	1376	11	-	-	HYPH
cord-005478-5iu38pr6	1376	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1376	13	in	in	IN
cord-005478-5iu38pr6	1376	14	patients	patient	NNS
cord-005478-5iu38pr6	1376	15	with	with	IN
cord-005478-5iu38pr6	1376	16	IBD	IBD	NNP
cord-005478-5iu38pr6	1376	17	conducted	conduct	VBN
cord-005478-5iu38pr6	1376	18	so	so	RB
cord-005478-5iu38pr6	1376	19	far	far	RB
cord-005478-5iu38pr6	1376	20	.	.	.
cord-005478-5iu38pr6	1377	1	Contrary	contrary	JJ
cord-005478-5iu38pr6	1377	2	to	to	IN
cord-005478-5iu38pr6	1377	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	1377	4	expectations	expectation	NNS
cord-005478-5iu38pr6	1377	5	,	,	,
cord-005478-5iu38pr6	1377	6	we	-PRON-	PRP
cord-005478-5iu38pr6	1377	7	found	find	VBD
cord-005478-5iu38pr6	1377	8	no	no	DT
cord-005478-5iu38pr6	1377	9	significant	significant	JJ
cord-005478-5iu38pr6	1377	10	differences	difference	NNS
cord-005478-5iu38pr6	1377	11	in	in	IN
cord-005478-5iu38pr6	1377	12	acute	acute	JJ
cord-005478-5iu38pr6	1377	13	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1377	14	,	,	,
cord-005478-5iu38pr6	1377	15	NRM	NRM	NNP
cord-005478-5iu38pr6	1377	16	or	or	CC
cord-005478-5iu38pr6	1377	17	OS	OS	NNP
cord-005478-5iu38pr6	1377	18	between	between	IN
cord-005478-5iu38pr6	1377	19	the	the	DT
cord-005478-5iu38pr6	1377	20	IBD	IBD	NNP
cord-005478-5iu38pr6	1377	21	group	group	NN
cord-005478-5iu38pr6	1377	22	and	and	CC
cord-005478-5iu38pr6	1377	23	controls	control	NNS
cord-005478-5iu38pr6	1377	24	.	.	.
cord-005478-5iu38pr6	1378	1	However	however	RB
cord-005478-5iu38pr6	1378	2	,	,	,
cord-005478-5iu38pr6	1378	3	IBD	IBD	NNP
cord-005478-5iu38pr6	1378	4	patients	patient	NNS
cord-005478-5iu38pr6	1378	5	had	have	VBD
cord-005478-5iu38pr6	1378	6	significantly	significantly	RB
cord-005478-5iu38pr6	1378	7	more	more	RBR
cord-005478-5iu38pr6	1378	8	extensive	extensive	JJ
cord-005478-5iu38pr6	1378	9	chronic	chronic	JJ
cord-005478-5iu38pr6	1378	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1378	11	than	than	IN
cord-005478-5iu38pr6	1378	12	the	the	DT
cord-005478-5iu38pr6	1378	13	control	control	NN
cord-005478-5iu38pr6	1378	14	group	group	NN
cord-005478-5iu38pr6	1378	15	.	.	.
cord-005478-5iu38pr6	1379	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	1379	2	results	result	NNS
cord-005478-5iu38pr6	1379	3	suggest	suggest	VBP
cord-005478-5iu38pr6	1379	4	that	that	IN
cord-005478-5iu38pr6	1379	5	allo	allo	NN
cord-005478-5iu38pr6	1379	6	-	-	HYPH
cord-005478-5iu38pr6	1379	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1379	8	should	should	MD
cord-005478-5iu38pr6	1379	9	not	not	RB
cord-005478-5iu38pr6	1379	10	be	be	VB
cord-005478-5iu38pr6	1379	11	contraindicated	contraindicate	VBN
cord-005478-5iu38pr6	1379	12	if	if	IN
cord-005478-5iu38pr6	1379	13	IBD	IBD	NNP
cord-005478-5iu38pr6	1379	14	alone	alone	RB
cord-005478-5iu38pr6	1379	15	is	be	VBZ
cord-005478-5iu38pr6	1379	16	considered	consider	VBN
cord-005478-5iu38pr6	1379	17	a	a	DT
cord-005478-5iu38pr6	1379	18	comorbidity	comorbidity	NN
cord-005478-5iu38pr6	1379	19	.	.	.
cord-005478-5iu38pr6	1380	1	However	however	RB
cord-005478-5iu38pr6	1380	2	,	,	,
cord-005478-5iu38pr6	1380	3	IBD	IBD	NNP
cord-005478-5iu38pr6	1380	4	patients	patient	NNS
cord-005478-5iu38pr6	1380	5	have	have	VBP
cord-005478-5iu38pr6	1380	6	a	a	DT
cord-005478-5iu38pr6	1380	7	higher	high	JJR
cord-005478-5iu38pr6	1380	8	risk	risk	NN
cord-005478-5iu38pr6	1380	9	for	for	IN
cord-005478-5iu38pr6	1380	10	developing	develop	VBG
cord-005478-5iu38pr6	1380	11	severe	severe	JJ
cord-005478-5iu38pr6	1380	12	forms	form	NNS
cord-005478-5iu38pr6	1380	13	of	of	IN
cord-005478-5iu38pr6	1380	14	chronic	chronic	JJ
cord-005478-5iu38pr6	1380	15	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1380	16	,	,	,
cord-005478-5iu38pr6	1380	17	which	which	WDT
cord-005478-5iu38pr6	1380	18	could	could	MD
cord-005478-5iu38pr6	1380	19	considerably	considerably	RB
cord-005478-5iu38pr6	1380	20	impair	impair	VB
cord-005478-5iu38pr6	1380	21	their	-PRON-	PRP$
cord-005478-5iu38pr6	1380	22	long	long	JJ
cord-005478-5iu38pr6	1380	23	-	-	HYPH
cord-005478-5iu38pr6	1380	24	term	term	NN
cord-005478-5iu38pr6	1380	25	quality	quality	NN
cord-005478-5iu38pr6	1380	26	of	of	IN
cord-005478-5iu38pr6	1380	27	life	life	NN
cord-005478-5iu38pr6	1380	28	.	.	.
cord-005478-5iu38pr6	1381	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1381	2	Background	background	NN
cord-005478-5iu38pr6	1381	3	:	:	:
cord-005478-5iu38pr6	1382	1	The	the	DT
cord-005478-5iu38pr6	1382	2	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1382	3	(	(	-LRB-
cord-005478-5iu38pr6	1382	4	Endothelial	Endothelial	NNP
cord-005478-5iu38pr6	1382	5	Activation	Activation	NNP
cord-005478-5iu38pr6	1382	6	and	and	CC
cord-005478-5iu38pr6	1382	7	Stress	Stress	NNP
cord-005478-5iu38pr6	1382	8	Index	Index	NNP
cord-005478-5iu38pr6	1382	9	)	)	-RRB-
cord-005478-5iu38pr6	1382	10	score	score	NN
cord-005478-5iu38pr6	1382	11	is	be	VBZ
cord-005478-5iu38pr6	1382	12	associated	associate	VBN
cord-005478-5iu38pr6	1382	13	with	with	IN
cord-005478-5iu38pr6	1382	14	non	non	JJ
cord-005478-5iu38pr6	1382	15	-	-	JJ
cord-005478-5iu38pr6	1382	16	relapse	relapse	JJ
cord-005478-5iu38pr6	1382	17	mortality	mortality	NN
cord-005478-5iu38pr6	1382	18	(	(	-LRB-
cord-005478-5iu38pr6	1382	19	NRM	NRM	NNP
cord-005478-5iu38pr6	1382	20	)	)	-RRB-
cord-005478-5iu38pr6	1382	21	and	and	CC
cord-005478-5iu38pr6	1382	22	overall	overall	JJ
cord-005478-5iu38pr6	1382	23	survival	survival	NN
cord-005478-5iu38pr6	1382	24	(	(	-LRB-
cord-005478-5iu38pr6	1382	25	OS	OS	NNP
cord-005478-5iu38pr6	1382	26	)	)	-RRB-
cord-005478-5iu38pr6	1382	27	after	after	IN
cord-005478-5iu38pr6	1382	28	reduced	reduce	VBN
cord-005478-5iu38pr6	1382	29	intensity	intensity	NN
cord-005478-5iu38pr6	1382	30	(	(	-LRB-
cord-005478-5iu38pr6	1382	31	RIC	RIC	NNP
cord-005478-5iu38pr6	1382	32	)	)	-RRB-
cord-005478-5iu38pr6	1382	33	AlloHCT	AlloHCT	NNP
cord-005478-5iu38pr6	1382	34	(	(	-LRB-
cord-005478-5iu38pr6	1382	35	Luft	Luft	NNP
cord-005478-5iu38pr6	1382	36	et	et	NNP
cord-005478-5iu38pr6	1382	37	al	al	NNP
cord-005478-5iu38pr6	1382	38	,	,	,
cord-005478-5iu38pr6	1382	39	Lancet	Lancet	NNP
cord-005478-5iu38pr6	1382	40	Haematol	Haematol	NNP
cord-005478-5iu38pr6	1382	41	2017	2017	CD
cord-005478-5iu38pr6	1382	42	)	)	-RRB-
cord-005478-5iu38pr6	1382	43	.	.	.
cord-005478-5iu38pr6	1383	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1383	2	aimed	aim	VBD
cord-005478-5iu38pr6	1383	3	to	to	TO
cord-005478-5iu38pr6	1383	4	validate	validate	VB
cord-005478-5iu38pr6	1383	5	the	the	DT
cord-005478-5iu38pr6	1383	6	prognostic	prognostic	JJ
cord-005478-5iu38pr6	1383	7	ability	ability	NN
cord-005478-5iu38pr6	1383	8	of	of	IN
cord-005478-5iu38pr6	1383	9	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1383	10	in	in	IN
cord-005478-5iu38pr6	1383	11	a	a	DT
cord-005478-5iu38pr6	1383	12	cohort	cohort	NN
cord-005478-5iu38pr6	1383	13	of	of	IN
cord-005478-5iu38pr6	1383	14	both	both	CC
cord-005478-5iu38pr6	1383	15	unmodified	unmodified	JJ
cord-005478-5iu38pr6	1383	16	and	and	CC
cord-005478-5iu38pr6	1383	17	CD34-selected	cd34-selected	JJ
cord-005478-5iu38pr6	1383	18	alloHCT	allohct	FW
cord-005478-5iu38pr6	1383	19	.	.	.
cord-005478-5iu38pr6	1384	1	Methods	method	NNS
cord-005478-5iu38pr6	1384	2	:	:	:
cord-005478-5iu38pr6	1385	1	Between	between	IN
cord-005478-5iu38pr6	1385	2	April	April	NNP
cord-005478-5iu38pr6	1385	3	2008	2008	CD
cord-005478-5iu38pr6	1385	4	and	and	CC
cord-005478-5iu38pr6	1385	5	December	December	NNP
cord-005478-5iu38pr6	1385	6	2016	2016	CD
cord-005478-5iu38pr6	1385	7	,	,	,
cord-005478-5iu38pr6	1385	8	509	509	CD
cord-005478-5iu38pr6	1385	9	adult	adult	NN
cord-005478-5iu38pr6	1385	10	patients	patient	NNS
cord-005478-5iu38pr6	1385	11	(	(	-LRB-
cord-005478-5iu38pr6	1385	12	pts	pt	NNS
cord-005478-5iu38pr6	1385	13	)	)	-RRB-
cord-005478-5iu38pr6	1385	14	underwent	undergo	VBD
cord-005478-5iu38pr6	1385	15	unmodified	unmodified	JJ
cord-005478-5iu38pr6	1385	16	RIC	RIC	NNP
cord-005478-5iu38pr6	1385	17	or	or	CC
cord-005478-5iu38pr6	1385	18	non	non	JJ
cord-005478-5iu38pr6	1385	19	-	-	JJ
cord-005478-5iu38pr6	1385	20	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1385	21	(	(	-LRB-
cord-005478-5iu38pr6	1385	22	NMA	NMA	NNP
cord-005478-5iu38pr6	1385	23	)	)	-RRB-
cord-005478-5iu38pr6	1386	1	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	1387	1	(	(	-LRB-
cord-005478-5iu38pr6	1387	2	N=149	n=149	JJ
cord-005478-5iu38pr6	1387	3	)	)	-RRB-
cord-005478-5iu38pr6	1387	4	with	with	IN
cord-005478-5iu38pr6	1387	5	uniform	uniform	JJ
cord-005478-5iu38pr6	1387	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1387	7	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1387	8	of	of	IN
cord-005478-5iu38pr6	1387	9	sirolimus	sirolimus	NN
cord-005478-5iu38pr6	1387	10	/	/	SYM
cord-005478-5iu38pr6	1387	11	tacrolimus	tacrolimus	NNP
cord-005478-5iu38pr6	1387	12	and	and	CC
cord-005478-5iu38pr6	1387	13	low/	low/	NNP
cord-005478-5iu38pr6	1387	14	dose	dose	NN
cord-005478-5iu38pr6	1387	15	MTX	MTX	NNP
cord-005478-5iu38pr6	1387	16	or	or	CC
cord-005478-5iu38pr6	1387	17	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1387	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	1387	19	(	(	-LRB-
cord-005478-5iu38pr6	1387	20	MAC	MAC	NNP
cord-005478-5iu38pr6	1387	21	)	)	-RRB-
cord-005478-5iu38pr6	1388	1	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	1389	1	using	use	VBG
cord-005478-5iu38pr6	1389	2	ex	ex	FW
cord-005478-5iu38pr6	1389	3	vivo	vivo	NN
cord-005478-5iu38pr6	1389	4	CD34-selection	cd34-selection	NN
cord-005478-5iu38pr6	1389	5	(	(	-LRB-
cord-005478-5iu38pr6	1389	6	N=360	n=360	UH
cord-005478-5iu38pr6	1389	7	)	)	-RRB-
cord-005478-5iu38pr6	1389	8	with	with	IN
cord-005478-5iu38pr6	1389	9	the	the	DT
cord-005478-5iu38pr6	1389	10	CliniMACS	CliniMACS	NNP
cord-005478-5iu38pr6	1389	11	CD34	CD34	NNP
cord-005478-5iu38pr6	1389	12	Reagent	Reagent	NNP
cord-005478-5iu38pr6	1389	13	System	System	NNP
cord-005478-5iu38pr6	1389	14	(	(	-LRB-
cord-005478-5iu38pr6	1389	15	Miltenyi	Miltenyi	NNP
cord-005478-5iu38pr6	1389	16	Biotech	Biotech	NNP
cord-005478-5iu38pr6	1389	17	)	)	-RRB-
cord-005478-5iu38pr6	1389	18	as	as	IN
cord-005478-5iu38pr6	1389	19	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1389	20	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1389	21	.	.	.
cord-005478-5iu38pr6	1390	1	The	the	DT
cord-005478-5iu38pr6	1390	2	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1390	3	formula	formula	NN
cord-005478-5iu38pr6	1390	4	(	(	-LRB-
cord-005478-5iu38pr6	1390	5	LDH*Creatinine	LDH*Creatinine	NNP
cord-005478-5iu38pr6	1390	6	/	/	SYM
cord-005478-5iu38pr6	1390	7	Thrombocytes	Thrombocytes	NNP
cord-005478-5iu38pr6	1390	8	)	)	-RRB-
cord-005478-5iu38pr6	1390	9	was	be	VBD
cord-005478-5iu38pr6	1390	10	calculated	calculate	VBN
cord-005478-5iu38pr6	1390	11	at	at	IN
cord-005478-5iu38pr6	1390	12	multiple	multiple	JJ
cord-005478-5iu38pr6	1390	13	timepoints	timepoint	NNS
cord-005478-5iu38pr6	1390	14	(	(	-LRB-
cord-005478-5iu38pr6	1390	15	pre	pre	JJ
cord-005478-5iu38pr6	1390	16	-	-	JJ
cord-005478-5iu38pr6	1390	17	alloHCT	allohct	JJ
cord-005478-5iu38pr6	1390	18	,	,	,
cord-005478-5iu38pr6	1390	19	day	day	NN
cord-005478-5iu38pr6	1390	20	30	30	CD
cord-005478-5iu38pr6	1390	21	,	,	,
cord-005478-5iu38pr6	1390	22	day	day	NN
cord-005478-5iu38pr6	1390	23	100	100	CD
cord-005478-5iu38pr6	1390	24	and	and	CC
cord-005478-5iu38pr6	1390	25	onset	onset	NN
cord-005478-5iu38pr6	1390	26	of	of	IN
cord-005478-5iu38pr6	1390	27	acute	acute	JJ
cord-005478-5iu38pr6	1390	28	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1390	29	)	)	-RRB-
cord-005478-5iu38pr6	1390	30	.	.	.
cord-005478-5iu38pr6	1391	1	A	a	DT
cord-005478-5iu38pr6	1391	2	log	log	NN
cord-005478-5iu38pr6	1391	3	transformation	transformation	NN
cord-005478-5iu38pr6	1391	4	using	use	VBG
cord-005478-5iu38pr6	1391	5	base	base	NN
cord-005478-5iu38pr6	1391	6	2	2	CD
cord-005478-5iu38pr6	1391	7	(	(	-LRB-
cord-005478-5iu38pr6	1391	8	log2	log2	NN
cord-005478-5iu38pr6	1391	9	)	)	-RRB-
cord-005478-5iu38pr6	1391	10	was	be	VBD
cord-005478-5iu38pr6	1391	11	applied	apply	VBN
cord-005478-5iu38pr6	1391	12	to	to	IN
cord-005478-5iu38pr6	1391	13	all	all	DT
cord-005478-5iu38pr6	1391	14	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1391	15	variables	variable	NNS
cord-005478-5iu38pr6	1391	16	to	to	TO
cord-005478-5iu38pr6	1391	17	reduce	reduce	VB
cord-005478-5iu38pr6	1391	18	skew	skew	NNS
cord-005478-5iu38pr6	1391	19	.	.	.
cord-005478-5iu38pr6	1392	1	A	a	DT
cord-005478-5iu38pr6	1392	2	one	one	CD
cord-005478-5iu38pr6	1392	3	unit	unit	NN
cord-005478-5iu38pr6	1392	4	increase	increase	NN
cord-005478-5iu38pr6	1392	5	in	in	IN
cord-005478-5iu38pr6	1392	6	log2	log2	NN
cord-005478-5iu38pr6	1392	7	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1392	8	is	be	VBZ
cord-005478-5iu38pr6	1392	9	associated	associate	VBN
cord-005478-5iu38pr6	1392	10	with	with	IN
cord-005478-5iu38pr6	1392	11	a	a	DT
cord-005478-5iu38pr6	1392	12	doubling	double	VBG
cord-005478-5iu38pr6	1392	13	(	(	-LRB-
cord-005478-5iu38pr6	1392	14	one	one	CD
cord-005478-5iu38pr6	1392	15	-	-	HYPH
cord-005478-5iu38pr6	1392	16	fold	fold	NN
cord-005478-5iu38pr6	1392	17	increase	increase	NN
cord-005478-5iu38pr6	1392	18	)	)	-RRB-
cord-005478-5iu38pr6	1392	19	of	of	IN
cord-005478-5iu38pr6	1392	20	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1392	21	on	on	IN
cord-005478-5iu38pr6	1392	22	the	the	DT
cord-005478-5iu38pr6	1392	23	original	original	JJ
cord-005478-5iu38pr6	1392	24	scale	scale	NN
cord-005478-5iu38pr6	1392	25	.	.	.
cord-005478-5iu38pr6	1393	1	Relapse	relapse	NN
cord-005478-5iu38pr6	1393	2	and	and	CC
cord-005478-5iu38pr6	1393	3	death	death	NN
cord-005478-5iu38pr6	1393	4	or	or	CC
cord-005478-5iu38pr6	1393	5	relapse	relapse	NN
cord-005478-5iu38pr6	1393	6	,	,	,
cord-005478-5iu38pr6	1393	7	were	be	VBD
cord-005478-5iu38pr6	1393	8	considered	consider	VBN
cord-005478-5iu38pr6	1393	9	competing	compete	VBG
cord-005478-5iu38pr6	1393	10	risks	risk	NNS
cord-005478-5iu38pr6	1393	11	for	for	IN
cord-005478-5iu38pr6	1393	12	NRM	NRM	NNP
cord-005478-5iu38pr6	1393	13	and	and	CC
cord-005478-5iu38pr6	1393	14	acute	acute	JJ
cord-005478-5iu38pr6	1393	15	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1393	16	,	,	,
cord-005478-5iu38pr6	1393	17	respectively	respectively	RB
cord-005478-5iu38pr6	1393	18	.	.	.
cord-005478-5iu38pr6	1394	1	Results	result	NNS
cord-005478-5iu38pr6	1394	2	:	:	:
cord-005478-5iu38pr6	1395	1	Median	median	JJ
cord-005478-5iu38pr6	1395	2	age	age	NN
cord-005478-5iu38pr6	1395	3	was	be	VBD
cord-005478-5iu38pr6	1395	4	55.6	55.6	CD
cord-005478-5iu38pr6	1395	5	years	year	NNS
cord-005478-5iu38pr6	1395	6	(	(	-LRB-
cord-005478-5iu38pr6	1395	7	19.6	19.6	CD
cord-005478-5iu38pr6	1395	8	-	-	HYPH
cord-005478-5iu38pr6	1395	9	78.7	78.7	CD
cord-005478-5iu38pr6	1395	10	)	)	-RRB-
cord-005478-5iu38pr6	1395	11	and	and	CC
cord-005478-5iu38pr6	1395	12	most	most	JJS
cord-005478-5iu38pr6	1395	13	pts	pt	NNS
cord-005478-5iu38pr6	1395	14	were	be	VBD
cord-005478-5iu38pr6	1395	15	male	male	JJ
cord-005478-5iu38pr6	1395	16	(	(	-LRB-
cord-005478-5iu38pr6	1395	17	59	59	CD
cord-005478-5iu38pr6	1395	18	%	%	NN
cord-005478-5iu38pr6	1395	19	)	)	-RRB-
cord-005478-5iu38pr6	1395	20	.	.	.
cord-005478-5iu38pr6	1396	1	Most	Most	JJS
cord-005478-5iu38pr6	1396	2	pts	pt	NNS
cord-005478-5iu38pr6	1396	3	had	have	VBD
cord-005478-5iu38pr6	1396	4	myeloid	myeloid	JJ
cord-005478-5iu38pr6	1396	5	malignancies	malignancy	NNS
cord-005478-5iu38pr6	1396	6	(	(	-LRB-
cord-005478-5iu38pr6	1396	7	72	72	CD
cord-005478-5iu38pr6	1396	8	%	%	NN
cord-005478-5iu38pr6	1396	9	)	)	-RRB-
cord-005478-5iu38pr6	1396	10	and	and	CC
cord-005478-5iu38pr6	1396	11	received	receive	VBD
cord-005478-5iu38pr6	1396	12	MAC	MAC	NNP
cord-005478-5iu38pr6	1396	13	(	(	-LRB-
cord-005478-5iu38pr6	1396	14	70	70	CD
cord-005478-5iu38pr6	1396	15	%	%	NN
cord-005478-5iu38pr6	1396	16	)	)	-RRB-
cord-005478-5iu38pr6	1396	17	.	.	.
cord-005478-5iu38pr6	1397	1	With	with	IN
cord-005478-5iu38pr6	1397	2	a	a	DT
cord-005478-5iu38pr6	1397	3	median	median	NN
cord-005478-5iu38pr6	1397	4	follow	follow	NN
cord-005478-5iu38pr6	1397	5	up	up	IN
cord-005478-5iu38pr6	1397	6	of	of	IN
cord-005478-5iu38pr6	1397	7	4.8	4.8	CD
cord-005478-5iu38pr6	1397	8	years	year	NNS
cord-005478-5iu38pr6	1397	9	(	(	-LRB-
cord-005478-5iu38pr6	1397	10	0.7	0.7	CD
cord-005478-5iu38pr6	1397	11	-	-	SYM
cord-005478-5iu38pr6	1397	12	10	10	CD
cord-005478-5iu38pr6	1397	13	)	)	-RRB-
cord-005478-5iu38pr6	1397	14	among	among	IN
cord-005478-5iu38pr6	1397	15	survivors	survivor	NNS
cord-005478-5iu38pr6	1397	16	,	,	,
cord-005478-5iu38pr6	1397	17	1	1	CD
cord-005478-5iu38pr6	1397	18	and	and	CC
cord-005478-5iu38pr6	1397	19	3-year	3-year	CD
cord-005478-5iu38pr6	1397	20	OS	OS	NNP
cord-005478-5iu38pr6	1397	21	were	be	VBD
cord-005478-5iu38pr6	1397	22	79.9	79.9	CD
cord-005478-5iu38pr6	1397	23	%	%	NN
cord-005478-5iu38pr6	1397	24	(	(	-LRB-
cord-005478-5iu38pr6	1397	25	95	95	CD
cord-005478-5iu38pr6	1397	26	%	%	NN
cord-005478-5iu38pr6	1397	27	CI	CI	NNP
cord-005478-5iu38pr6	1397	28	,	,	,
cord-005478-5iu38pr6	1397	29	76.2	76.2	CD
cord-005478-5iu38pr6	1397	30	-	-	HYPH
cord-005478-5iu38pr6	1397	31	83.2	83.2	CD
cord-005478-5iu38pr6	1397	32	)	)	-RRB-
cord-005478-5iu38pr6	1397	33	and	and	CC
cord-005478-5iu38pr6	1397	34	63.2	63.2	CD
cord-005478-5iu38pr6	1397	35	%	%	NN
cord-005478-5iu38pr6	1397	36	(	(	-LRB-
cord-005478-5iu38pr6	1397	37	95	95	CD
cord-005478-5iu38pr6	1397	38	%	%	NN
cord-005478-5iu38pr6	1397	39	CI	CI	NNP
cord-005478-5iu38pr6	1397	40	,	,	,
cord-005478-5iu38pr6	1397	41	5.7	5.7	CD
cord-005478-5iu38pr6	1397	42	-	-	SYM
cord-005478-5iu38pr6	1397	43	67.3	67.3	CD
cord-005478-5iu38pr6	1397	44	)	)	-RRB-
cord-005478-5iu38pr6	1397	45	,	,	,
cord-005478-5iu38pr6	1397	46	respectively	respectively	RB
cord-005478-5iu38pr6	1397	47	.	.	.
cord-005478-5iu38pr6	1398	1	The	the	DT
cord-005478-5iu38pr6	1398	2	1	1	CD
cord-005478-5iu38pr6	1398	3	and	and	CC
cord-005478-5iu38pr6	1398	4	3-year	3-year	CD
cord-005478-5iu38pr6	1398	5	NRM	NRM	NNP
cord-005478-5iu38pr6	1398	6	were	be	VBD
cord-005478-5iu38pr6	1398	7	13.2	13.2	CD
cord-005478-5iu38pr6	1398	8	%	%	NN
cord-005478-5iu38pr6	1398	9	(	(	-LRB-
cord-005478-5iu38pr6	1398	10	95	95	CD
cord-005478-5iu38pr6	1398	11	%	%	NN
cord-005478-5iu38pr6	1398	12	CI	CI	NNP
cord-005478-5iu38pr6	1398	13	,	,	,
cord-005478-5iu38pr6	1398	14	10.4	10.4	CD
cord-005478-5iu38pr6	1398	15	-	-	SYM
cord-005478-5iu38pr6	1398	16	16.3	16.3	CD
cord-005478-5iu38pr6	1398	17	)	)	-RRB-
cord-005478-5iu38pr6	1398	18	and	and	CC
cord-005478-5iu38pr6	1398	19	22.2	22.2	CD
cord-005478-5iu38pr6	1398	20	%	%	NN
cord-005478-5iu38pr6	1398	21	(	(	-LRB-
cord-005478-5iu38pr6	1398	22	95	95	CD
cord-005478-5iu38pr6	1398	23	%	%	NN
cord-005478-5iu38pr6	1398	24	CI	CI	NNP
cord-005478-5iu38pr6	1398	25	,	,	,
cord-005478-5iu38pr6	1398	26	18.6	18.6	CD
cord-005478-5iu38pr6	1398	27	-	-	SYM
cord-005478-5iu38pr6	1398	28	25.9	25.9	CD
cord-005478-5iu38pr6	1398	29	)	)	-RRB-
cord-005478-5iu38pr6	1398	30	,	,	,
cord-005478-5iu38pr6	1398	31	respectively	respectively	RB
cord-005478-5iu38pr6	1398	32	.	.	.
cord-005478-5iu38pr6	1399	1	The	the	DT
cord-005478-5iu38pr6	1399	2	1-year	1-year	CD
cord-005478-5iu38pr6	1399	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1399	4	incidence	incidence	NN
cord-005478-5iu38pr6	1399	5	of	of	IN
cord-005478-5iu38pr6	1399	6	grade	grade	NN
cord-005478-5iu38pr6	1399	7	1	1	CD
cord-005478-5iu38pr6	1399	8	-	-	SYM
cord-005478-5iu38pr6	1399	9	4	4	CD
cord-005478-5iu38pr6	1399	10	,	,	,
cord-005478-5iu38pr6	1399	11	2	2	CD
cord-005478-5iu38pr6	1399	12	-	-	SYM
cord-005478-5iu38pr6	1399	13	4	4	CD
cord-005478-5iu38pr6	1399	14	and	and	CC
cord-005478-5iu38pr6	1399	15	3	3	CD
cord-005478-5iu38pr6	1399	16	-	-	SYM
cord-005478-5iu38pr6	1399	17	4	4	CD
cord-005478-5iu38pr6	1399	18	acute	acute	JJ
cord-005478-5iu38pr6	1399	19	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1399	20	was	be	VBD
cord-005478-5iu38pr6	1399	21	44.4	44.4	CD
cord-005478-5iu38pr6	1399	22	%	%	NN
cord-005478-5iu38pr6	1399	23	(	(	-LRB-
cord-005478-5iu38pr6	1399	24	95	95	CD
cord-005478-5iu38pr6	1399	25	%	%	NN
cord-005478-5iu38pr6	1399	26	CI	CI	NNP
cord-005478-5iu38pr6	1399	27	,	,	,
cord-005478-5iu38pr6	1399	28	40.0	40.0	CD
cord-005478-5iu38pr6	1399	29	-	-	HYPH
cord-005478-5iu38pr6	1399	30	48.7	48.7	CD
cord-005478-5iu38pr6	1399	31	)	)	-RRB-
cord-005478-5iu38pr6	1399	32	,	,	,
cord-005478-5iu38pr6	1399	33	33.0	33.0	CD
cord-005478-5iu38pr6	1399	34	%	%	NN
cord-005478-5iu38pr6	1399	35	(	(	-LRB-
cord-005478-5iu38pr6	1399	36	95	95	CD
cord-005478-5iu38pr6	1399	37	%	%	NN
cord-005478-5iu38pr6	1399	38	CI	CI	NNP
cord-005478-5iu38pr6	1399	39	,	,	,
cord-005478-5iu38pr6	1399	40	29.0	29.0	CD
cord-005478-5iu38pr6	1399	41	-	-	HYPH
cord-005478-5iu38pr6	1399	42	37.1	37.1	CD
cord-005478-5iu38pr6	1399	43	)	)	-RRB-
cord-005478-5iu38pr6	1399	44	and	and	CC
cord-005478-5iu38pr6	1399	45	10.4	10.4	CD
cord-005478-5iu38pr6	1399	46	%	%	NN
cord-005478-5iu38pr6	1399	47	(	(	-LRB-
cord-005478-5iu38pr6	1399	48	95	95	CD
cord-005478-5iu38pr6	1399	49	%	%	NN
cord-005478-5iu38pr6	1399	50	CI	ci	NN
cord-005478-5iu38pr6	1399	51	,	,	,
cord-005478-5iu38pr6	1399	52	8.0	8.0	CD
cord-005478-5iu38pr6	1399	53	-	-	SYM
cord-005478-5iu38pr6	1399	54	13.3	13.3	CD
cord-005478-5iu38pr6	1399	55	)	)	-RRB-
cord-005478-5iu38pr6	1399	56	,	,	,
cord-005478-5iu38pr6	1399	57	respectively	respectively	RB
cord-005478-5iu38pr6	1399	58	.	.	.
cord-005478-5iu38pr6	1400	1	Causes	cause	NNS
cord-005478-5iu38pr6	1400	2	of	of	IN
cord-005478-5iu38pr6	1400	3	death	death	NN
cord-005478-5iu38pr6	1400	4	in	in	IN
cord-005478-5iu38pr6	1400	5	211	211	CD
cord-005478-5iu38pr6	1400	6	pts	pt	NNS
cord-005478-5iu38pr6	1400	7	at	at	IN
cord-005478-5iu38pr6	1400	8	last	last	JJ
cord-005478-5iu38pr6	1400	9	follow	follow	NN
cord-005478-5iu38pr6	1400	10	up	up	RP
cord-005478-5iu38pr6	1400	11	included	include	VBD
cord-005478-5iu38pr6	1400	12	relapse	relapse	NN
cord-005478-5iu38pr6	1400	13	(	(	-LRB-
cord-005478-5iu38pr6	1400	14	34	34	CD
cord-005478-5iu38pr6	1400	15	%	%	NN
cord-005478-5iu38pr6	1400	16	)	)	-RRB-
cord-005478-5iu38pr6	1400	17	,	,	,
cord-005478-5iu38pr6	1400	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1400	19	(	(	-LRB-
cord-005478-5iu38pr6	1400	20	25	25	CD
cord-005478-5iu38pr6	1400	21	%	%	NN
cord-005478-5iu38pr6	1400	22	)	)	-RRB-
cord-005478-5iu38pr6	1400	23	and	and	CC
cord-005478-5iu38pr6	1400	24	infection	infection	NN
cord-005478-5iu38pr6	1400	25	(	(	-LRB-
cord-005478-5iu38pr6	1400	26	20	20	CD
cord-005478-5iu38pr6	1400	27	%	%	NN
cord-005478-5iu38pr6	1400	28	Higher	high	JJR
cord-005478-5iu38pr6	1400	29	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1400	30	score	score	NN
cord-005478-5iu38pr6	1400	31	at	at	IN
cord-005478-5iu38pr6	1400	32	d30	d30	NNP
cord-005478-5iu38pr6	1400	33	,	,	,
cord-005478-5iu38pr6	1400	34	d100	d100	NNP
cord-005478-5iu38pr6	1400	35	and	and	CC
cord-005478-5iu38pr6	1400	36	at	at	IN
cord-005478-5iu38pr6	1400	37	onset	onset	NN
cord-005478-5iu38pr6	1400	38	of	of	IN
cord-005478-5iu38pr6	1400	39	acute	acute	JJ
cord-005478-5iu38pr6	1400	40	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1400	41	was	be	VBD
cord-005478-5iu38pr6	1400	42	significantly	significantly	RB
cord-005478-5iu38pr6	1400	43	associated	associate	VBN
cord-005478-5iu38pr6	1400	44	with	with	IN
cord-005478-5iu38pr6	1400	45	increased	increase	VBN
cord-005478-5iu38pr6	1400	46	risk	risk	NN
cord-005478-5iu38pr6	1400	47	of	of	IN
cord-005478-5iu38pr6	1400	48	death	death	NN
cord-005478-5iu38pr6	1400	49	and	and	CC
cord-005478-5iu38pr6	1400	50	NRM	NRM	NNP
cord-005478-5iu38pr6	1400	51	(	(	-LRB-
cord-005478-5iu38pr6	1400	52	table	table	NN
cord-005478-5iu38pr6	1400	53	1	1	CD
cord-005478-5iu38pr6	1400	54	and	and	CC
cord-005478-5iu38pr6	1400	55	figure	figure	NN
cord-005478-5iu38pr6	1400	56	1	1	CD
cord-005478-5iu38pr6	1400	57	)	)	-RRB-
cord-005478-5iu38pr6	1400	58	.	.	.
cord-005478-5iu38pr6	1401	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1401	2	:	:	:
cord-005478-5iu38pr6	1402	1	Higher	high	JJR
cord-005478-5iu38pr6	1402	2	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1402	3	scores	score	NNS
cord-005478-5iu38pr6	1402	4	at	at	IN
cord-005478-5iu38pr6	1402	5	day	day	NN
cord-005478-5iu38pr6	1402	6	30	30	CD
cord-005478-5iu38pr6	1402	7	,	,	,
cord-005478-5iu38pr6	1402	8	day	day	NN
cord-005478-5iu38pr6	1402	9	100	100	CD
cord-005478-5iu38pr6	1402	10	,	,	,
cord-005478-5iu38pr6	1402	11	and	and	CC
cord-005478-5iu38pr6	1403	1	at	at	IN
cord-005478-5iu38pr6	1403	2	onset	onset	NN
cord-005478-5iu38pr6	1403	3	of	of	IN
cord-005478-5iu38pr6	1403	4	acute	acute	JJ
cord-005478-5iu38pr6	1403	5	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1403	6	are	be	VBP
cord-005478-5iu38pr6	1403	7	associated	associate	VBN
cord-005478-5iu38pr6	1403	8	with	with	IN
cord-005478-5iu38pr6	1403	9	higher	high	JJR
cord-005478-5iu38pr6	1403	10	NRM	NRM	NNP
cord-005478-5iu38pr6	1403	11	and	and	CC
cord-005478-5iu38pr6	1403	12	inferior	inferior	JJ
cord-005478-5iu38pr6	1403	13	OS	os	NN
cord-005478-5iu38pr6	1403	14	with	with	IN
cord-005478-5iu38pr6	1403	15	a	a	DT
cord-005478-5iu38pr6	1403	16	more	more	RBR
cord-005478-5iu38pr6	1403	17	prominent	prominent	JJ
cord-005478-5iu38pr6	1403	18	association	association	NN
cord-005478-5iu38pr6	1403	19	in	in	IN
cord-005478-5iu38pr6	1403	20	calcineurin	calcineurin	NNP
cord-005478-5iu38pr6	1403	21	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	1403	22	-	-	HYPH
cord-005478-5iu38pr6	1403	23	based	base	VBN
cord-005478-5iu38pr6	1403	24	unmodified	unmodified	JJ
cord-005478-5iu38pr6	1403	25	alloHCT	alloHCT	NNS
cord-005478-5iu38pr6	1403	26	compared	compare	VBN
cord-005478-5iu38pr6	1403	27	to	to	IN
cord-005478-5iu38pr6	1403	28	CD34-selected	CD34-selected	NNP
cord-005478-5iu38pr6	1403	29	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	1403	30	.	.	.
cord-005478-5iu38pr6	1404	1	Endothelial	endothelial	JJ
cord-005478-5iu38pr6	1404	2	damage	damage	NN
cord-005478-5iu38pr6	1404	3	is	be	VBZ
cord-005478-5iu38pr6	1404	4	an	an	DT
cord-005478-5iu38pr6	1404	5	important	important	JJ
cord-005478-5iu38pr6	1404	6	contributor	contributor	NN
cord-005478-5iu38pr6	1404	7	to	to	IN
cord-005478-5iu38pr6	1404	8	poorer	poor	JJR
cord-005478-5iu38pr6	1404	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	1404	10	after	after	IN
cord-005478-5iu38pr6	1404	11	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	1404	12	and	and	CC
cord-005478-5iu38pr6	1404	13	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1404	14	formula	formula	NN
cord-005478-5iu38pr6	1404	15	provides	provide	VBZ
cord-005478-5iu38pr6	1404	16	an	an	DT
cord-005478-5iu38pr6	1404	17	easy	easy	JJ
cord-005478-5iu38pr6	1404	18	complimentary	complimentary	JJ
cord-005478-5iu38pr6	1404	19	tool	tool	NN
cord-005478-5iu38pr6	1404	20	to	to	TO
cord-005478-5iu38pr6	1404	21	predict	predict	VB
cord-005478-5iu38pr6	1404	22	outcomes	outcome	NNS
cord-005478-5iu38pr6	1404	23	in	in	IN
cord-005478-5iu38pr6	1404	24	these	these	DT
cord-005478-5iu38pr6	1404	25	patients	patient	NNS
cord-005478-5iu38pr6	1404	26	.	.	.
cord-005478-5iu38pr6	1405	1	Background	background	NN
cord-005478-5iu38pr6	1405	2	:	:	:
cord-005478-5iu38pr6	1406	1	Subsequent	subsequent	JJ
cord-005478-5iu38pr6	1406	2	malignant	malignant	JJ
cord-005478-5iu38pr6	1406	3	neoplasms	neoplasm	NNS
cord-005478-5iu38pr6	1406	4	(	(	-LRB-
cord-005478-5iu38pr6	1406	5	SMNs	SMNs	NNP
cord-005478-5iu38pr6	1406	6	)	)	-RRB-
cord-005478-5iu38pr6	1406	7	are	be	VBP
cord-005478-5iu38pr6	1406	8	one	one	CD
cord-005478-5iu38pr6	1406	9	of	of	IN
cord-005478-5iu38pr6	1406	10	the	the	DT
cord-005478-5iu38pr6	1406	11	most	most	RBS
cord-005478-5iu38pr6	1406	12	important	important	JJ
cord-005478-5iu38pr6	1406	13	complications	complication	NNS
cord-005478-5iu38pr6	1406	14	of	of	IN
cord-005478-5iu38pr6	1406	15	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1406	16	stem	stem	NN
cord-005478-5iu38pr6	1406	17	cell	cell	NN
cord-005478-5iu38pr6	1406	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	1406	19	(	(	-LRB-
cord-005478-5iu38pr6	1406	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1406	21	)	)	-RRB-
cord-005478-5iu38pr6	1406	22	and	and	CC
cord-005478-5iu38pr6	1406	23	result	result	VB
cord-005478-5iu38pr6	1406	24	in	in	IN
cord-005478-5iu38pr6	1406	25	considerable	considerable	JJ
cord-005478-5iu38pr6	1406	26	morbidity	morbidity	NN
cord-005478-5iu38pr6	1406	27	and	and	CC
cord-005478-5iu38pr6	1406	28	mortality	mortality	NN
cord-005478-5iu38pr6	1406	29	.	.	.
cord-005478-5iu38pr6	1407	1	The	the	DT
cord-005478-5iu38pr6	1407	2	reported	report	VBN
cord-005478-5iu38pr6	1407	3	rate	rate	NN
cord-005478-5iu38pr6	1407	4	of	of	IN
cord-005478-5iu38pr6	1407	5	SMNs	smn	NNS
cord-005478-5iu38pr6	1407	6	after	after	IN
cord-005478-5iu38pr6	1407	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1407	8	in	in	IN
cord-005478-5iu38pr6	1407	9	adults	adult	NNS
cord-005478-5iu38pr6	1407	10	ranges	range	VBZ
cord-005478-5iu38pr6	1407	11	between	between	IN
cord-005478-5iu38pr6	1407	12	1	1	CD
cord-005478-5iu38pr6	1407	13	-	-	SYM
cord-005478-5iu38pr6	1407	14	11	11	CD
cord-005478-5iu38pr6	1407	15	%	%	NN
cord-005478-5iu38pr6	1407	16	at	at	IN
cord-005478-5iu38pr6	1407	17	10-years	10-years	CD
cord-005478-5iu38pr6	1407	18	.	.	.
cord-005478-5iu38pr6	1408	1	There	there	EX
cord-005478-5iu38pr6	1408	2	is	be	VBZ
cord-005478-5iu38pr6	1408	3	limited	limited	JJ
cord-005478-5iu38pr6	1408	4	data	datum	NNS
cord-005478-5iu38pr6	1408	5	on	on	IN
cord-005478-5iu38pr6	1408	6	SMNs	smn	NNS
cord-005478-5iu38pr6	1408	7	after	after	IN
cord-005478-5iu38pr6	1408	8	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1408	9	,	,	,
cord-005478-5iu38pr6	1408	10	adolescent	adolescent	JJ
cord-005478-5iu38pr6	1408	11	and	and	CC
cord-005478-5iu38pr6	1408	12	young	young	JJ
cord-005478-5iu38pr6	1408	13	adult	adult	NN
cord-005478-5iu38pr6	1408	14	(	(	-LRB-
cord-005478-5iu38pr6	1408	15	AYA	AYA	NNP
cord-005478-5iu38pr6	1408	16	)	)	-RRB-
cord-005478-5iu38pr6	1408	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1408	18	,	,	,
cord-005478-5iu38pr6	1408	19	where	where	WRB
cord-005478-5iu38pr6	1408	20	the	the	DT
cord-005478-5iu38pr6	1408	21	potential	potential	JJ
cord-005478-5iu38pr6	1408	22	years	year	NNS
cord-005478-5iu38pr6	1408	23	of	of	IN
cord-005478-5iu38pr6	1408	24	life	life	NN
cord-005478-5iu38pr6	1408	25	gained	gain	VBD
cord-005478-5iu38pr6	1408	26	is	be	VBZ
cord-005478-5iu38pr6	1408	27	greater	great	JJR
cord-005478-5iu38pr6	1408	28	than	than	IN
cord-005478-5iu38pr6	1408	29	among	among	IN
cord-005478-5iu38pr6	1408	30	older	old	JJR
cord-005478-5iu38pr6	1408	31	adults	adult	NNS
cord-005478-5iu38pr6	1408	32	.	.	.
cord-005478-5iu38pr6	1409	1	The	the	DT
cord-005478-5iu38pr6	1409	2	objective	objective	NN
cord-005478-5iu38pr6	1409	3	of	of	IN
cord-005478-5iu38pr6	1409	4	this	this	DT
cord-005478-5iu38pr6	1409	5	study	study	NN
cord-005478-5iu38pr6	1409	6	was	be	VBD
cord-005478-5iu38pr6	1409	7	to	to	TO
cord-005478-5iu38pr6	1409	8	assess	assess	VB
cord-005478-5iu38pr6	1409	9	the	the	DT
cord-005478-5iu38pr6	1409	10	incidence	incidence	NN
cord-005478-5iu38pr6	1409	11	and	and	CC
cord-005478-5iu38pr6	1409	12	types	type	NNS
cord-005478-5iu38pr6	1409	13	of	of	IN
cord-005478-5iu38pr6	1409	14	SMNs	smn	NNS
cord-005478-5iu38pr6	1409	15	in	in	IN
cord-005478-5iu38pr6	1409	16	a	a	DT
cord-005478-5iu38pr6	1409	17	cohort	cohort	NN
cord-005478-5iu38pr6	1409	18	of	of	IN
cord-005478-5iu38pr6	1409	19	survivors	survivor	NNS
cord-005478-5iu38pr6	1409	20	of	of	IN
cord-005478-5iu38pr6	1409	21	childhood	childhood	NN
cord-005478-5iu38pr6	1409	22	and	and	CC
cord-005478-5iu38pr6	1409	23	AYA	AYA	NNP
cord-005478-5iu38pr6	1409	24	HSCTs	HSCTs	NNPS
cord-005478-5iu38pr6	1409	25	that	that	WDT
cord-005478-5iu38pr6	1409	26	were	be	VBD
cord-005478-5iu38pr6	1409	27	performed	perform	VBN
cord-005478-5iu38pr6	1409	28	for	for	IN
cord-005478-5iu38pr6	1409	29	malignant	malignant	JJ
cord-005478-5iu38pr6	1409	30	indications	indication	NNS
cord-005478-5iu38pr6	1409	31	.	.	.
cord-005478-5iu38pr6	1410	1	Methods	method	NNS
cord-005478-5iu38pr6	1410	2	:	:	:
cord-005478-5iu38pr6	1410	3	All	all	DT
cord-005478-5iu38pr6	1410	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1410	5	patients	patient	NNS
cord-005478-5iu38pr6	1410	6	(	(	-LRB-
cord-005478-5iu38pr6	1410	7	age	age	NN
cord-005478-5iu38pr6	1410	8	0	0	CD
cord-005478-5iu38pr6	1410	9	-	-	SYM
cord-005478-5iu38pr6	1410	10	30	30	CD
cord-005478-5iu38pr6	1410	11	years	year	NNS
cord-005478-5iu38pr6	1410	12	at	at	IN
cord-005478-5iu38pr6	1410	13	time	time	NN
cord-005478-5iu38pr6	1410	14	of	of	IN
cord-005478-5iu38pr6	1410	15	transplant	transplant	NN
cord-005478-5iu38pr6	1410	16	)	)	-RRB-
cord-005478-5iu38pr6	1410	17	who	who	WP
cord-005478-5iu38pr6	1410	18	survived	survive	VBD
cord-005478-5iu38pr6	1410	19	at	at	IN
cord-005478-5iu38pr6	1410	20	least	least	JJS
cord-005478-5iu38pr6	1410	21	2-years	2-years	CD
cord-005478-5iu38pr6	1410	22	after	after	IN
cord-005478-5iu38pr6	1410	23	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1410	24	in	in	IN
cord-005478-5iu38pr6	1410	25	the	the	DT
cord-005478-5iu38pr6	1410	26	province	province	NN
cord-005478-5iu38pr6	1410	27	of	of	IN
cord-005478-5iu38pr6	1410	28	Ontario	Ontario	NNP
cord-005478-5iu38pr6	1410	29	,	,	,
cord-005478-5iu38pr6	1410	30	Canada	Canada	NNP
cord-005478-5iu38pr6	1410	31	between	between	IN
cord-005478-5iu38pr6	1410	32	1994	1994	CD
cord-005478-5iu38pr6	1410	33	and	and	CC
cord-005478-5iu38pr6	1410	34	2017	2017	CD
cord-005478-5iu38pr6	1410	35	were	be	VBD
cord-005478-5iu38pr6	1410	36	identified	identify	VBN
cord-005478-5iu38pr6	1410	37	from	from	IN
cord-005478-5iu38pr6	1410	38	3	3	CD
cord-005478-5iu38pr6	1410	39	transplant	transplant	NN
cord-005478-5iu38pr6	1410	40	centers	center	NNS
cord-005478-5iu38pr6	1410	41	.	.	.
cord-005478-5iu38pr6	1411	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1411	2	data	datum	NNS
cord-005478-5iu38pr6	1411	3	were	be	VBD
cord-005478-5iu38pr6	1411	4	linked	link	VBN
cord-005478-5iu38pr6	1411	5	to	to	IN
cord-005478-5iu38pr6	1411	6	provincial	provincial	JJ
cord-005478-5iu38pr6	1411	7	administrative	administrative	JJ
cord-005478-5iu38pr6	1411	8	databases	database	NNS
cord-005478-5iu38pr6	1411	9	and	and	CC
cord-005478-5iu38pr6	1411	10	the	the	DT
cord-005478-5iu38pr6	1411	11	Ontario	Ontario	NNP
cord-005478-5iu38pr6	1411	12	Cancer	Cancer	NNP
cord-005478-5iu38pr6	1411	13	Registry	Registry	NNP
cord-005478-5iu38pr6	1411	14	that	that	WDT
cord-005478-5iu38pr6	1411	15	identifies	identify	VBZ
cord-005478-5iu38pr6	1411	16	cancer	cancer	NN
cord-005478-5iu38pr6	1411	17	cases	case	NNS
cord-005478-5iu38pr6	1411	18	based	base	VBN
cord-005478-5iu38pr6	1411	19	on	on	IN
cord-005478-5iu38pr6	1411	20	pathology	pathology	NN
cord-005478-5iu38pr6	1411	21	reports	report	NNS
cord-005478-5iu38pr6	1411	22	and	and	CC
cord-005478-5iu38pr6	1411	23	electronic	electronic	JJ
cord-005478-5iu38pr6	1411	24	patient	patient	NN
cord-005478-5iu38pr6	1411	25	records	record	NNS
cord-005478-5iu38pr6	1411	26	.	.	.
cord-005478-5iu38pr6	1412	1	Results	result	NNS
cord-005478-5iu38pr6	1412	2	:	:	:
cord-005478-5iu38pr6	1413	1	Four	four	CD
cord-005478-5iu38pr6	1413	2	-	-	HYPH
cord-005478-5iu38pr6	1413	3	hundred	hundred	CD
cord-005478-5iu38pr6	1413	4	and	and	CC
cord-005478-5iu38pr6	1413	5	forty	forty	CD
cord-005478-5iu38pr6	1413	6	-	-	HYPH
cord-005478-5iu38pr6	1413	7	six	six	CD
cord-005478-5iu38pr6	1414	1	2-year	2-year	CD
cord-005478-5iu38pr6	1414	2	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1414	3	HCST	HCST	NNP
cord-005478-5iu38pr6	1414	4	survivors	survivor	NNS
cord-005478-5iu38pr6	1414	5	were	be	VBD
cord-005478-5iu38pr6	1414	6	included	include	VBN
cord-005478-5iu38pr6	1414	7	in	in	IN
cord-005478-5iu38pr6	1414	8	this	this	DT
cord-005478-5iu38pr6	1414	9	study	study	NN
cord-005478-5iu38pr6	1414	10	.	.	.
cord-005478-5iu38pr6	1415	1	Of	of	IN
cord-005478-5iu38pr6	1415	2	them	-PRON-	PRP
cord-005478-5iu38pr6	1415	3	,	,	,
cord-005478-5iu38pr6	1415	4	36	36	CD
cord-005478-5iu38pr6	1415	5	(	(	-LRB-
cord-005478-5iu38pr6	1415	6	8	8	CD
cord-005478-5iu38pr6	1415	7	%	%	NN
cord-005478-5iu38pr6	1415	8	)	)	-RRB-
cord-005478-5iu38pr6	1415	9	developed	develop	VBD
cord-005478-5iu38pr6	1415	10	45	45	CD
cord-005478-5iu38pr6	1415	11	SMNs	smn	NNS
cord-005478-5iu38pr6	1415	12	at	at	IN
cord-005478-5iu38pr6	1415	13	a	a	DT
cord-005478-5iu38pr6	1415	14	median	median	NN
cord-005478-5iu38pr6	1415	15	follow	follow	NN
cord-005478-5iu38pr6	1415	16	up	up	IN
cord-005478-5iu38pr6	1415	17	of	of	IN
cord-005478-5iu38pr6	1415	18	13.1	13.1	CD
cord-005478-5iu38pr6	1415	19	years	year	NNS
cord-005478-5iu38pr6	1415	20	(	(	-LRB-
cord-005478-5iu38pr6	1415	21	range	range	NN
cord-005478-5iu38pr6	1415	22	:	:	:
cord-005478-5iu38pr6	1415	23	0.25	0.25	CD
cord-005478-5iu38pr6	1415	24	-	-	HYPH
cord-005478-5iu38pr6	1415	25	22.8	22.8	CD
cord-005478-5iu38pr6	1415	26	years	year	NNS
cord-005478-5iu38pr6	1415	27	)	)	-RRB-
cord-005478-5iu38pr6	1415	28	.	.	.
cord-005478-5iu38pr6	1416	1	The	the	DT
cord-005478-5iu38pr6	1416	2	10-year	10-year	CD
cord-005478-5iu38pr6	1416	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1416	4	incidence	incidence	NN
cord-005478-5iu38pr6	1416	5	of	of	IN
cord-005478-5iu38pr6	1416	6	SMN	SMN	NNP
cord-005478-5iu38pr6	1416	7	was	be	VBD
cord-005478-5iu38pr6	1416	8	4	4	CD
cord-005478-5iu38pr6	1416	9	%	%	NN
cord-005478-5iu38pr6	1416	10	(	(	-LRB-
cord-005478-5iu38pr6	1416	11	2.1	2.1	CD
cord-005478-5iu38pr6	1416	12	-	-	SYM
cord-005478-5iu38pr6	1416	13	6.3	6.3	CD
cord-005478-5iu38pr6	1416	14	%	%	NN
cord-005478-5iu38pr6	1416	15	)	)	-RRB-
cord-005478-5iu38pr6	1416	16	and	and	CC
cord-005478-5iu38pr6	1416	17	the	the	DT
cord-005478-5iu38pr6	1416	18	20-year	20-year	JJ
cord-005478-5iu38pr6	1416	19	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1416	20	incidence	incidence	NN
cord-005478-5iu38pr6	1416	21	of	of	IN
cord-005478-5iu38pr6	1416	22	SMN	SMN	NNP
cord-005478-5iu38pr6	1416	23	was	be	VBD
cord-005478-5iu38pr6	1416	24	18	18	CD
cord-005478-5iu38pr6	1416	25	%	%	NN
cord-005478-5iu38pr6	1416	26	(	(	-LRB-
cord-005478-5iu38pr6	1416	27	12.4	12.4	CD
cord-005478-5iu38pr6	1416	28	-	-	SYM
cord-005478-5iu38pr6	1416	29	24.6	24.6	CD
cord-005478-5iu38pr6	1416	30	%	%	NN
cord-005478-5iu38pr6	1416	31	)	)	-RRB-
cord-005478-5iu38pr6	1416	32	.	.	.
cord-005478-5iu38pr6	1417	1	Several	several	JJ
cord-005478-5iu38pr6	1417	2	patients	patient	NNS
cord-005478-5iu38pr6	1417	3	developed	develop	VBD
cord-005478-5iu38pr6	1417	4	more	more	JJR
cord-005478-5iu38pr6	1417	5	than	than	IN
cord-005478-5iu38pr6	1417	6	1	1	CD
cord-005478-5iu38pr6	1417	7	SMN	smn	NN
cord-005478-5iu38pr6	1417	8	.	.	.
cord-005478-5iu38pr6	1418	1	The	the	DT
cord-005478-5iu38pr6	1418	2	most	most	RBS
cord-005478-5iu38pr6	1418	3	common	common	JJ
cord-005478-5iu38pr6	1418	4	SMNs	smn	NNS
cord-005478-5iu38pr6	1418	5	were	be	VBD
cord-005478-5iu38pr6	1418	6	:	:	:
cord-005478-5iu38pr6	1418	7	papillary	papillary	JJ
cord-005478-5iu38pr6	1418	8	carcinoma	carcinoma	NN
cord-005478-5iu38pr6	1418	9	of	of	IN
cord-005478-5iu38pr6	1418	10	the	the	DT
cord-005478-5iu38pr6	1418	11	thyroid	thyroid	NN
cord-005478-5iu38pr6	1418	12	(	(	-LRB-
cord-005478-5iu38pr6	1418	13	n=11	n=11	NNP
cord-005478-5iu38pr6	1418	14	)	)	-RRB-
cord-005478-5iu38pr6	1418	15	;	;	,
cord-005478-5iu38pr6	1418	16	secondary	secondary	JJ
cord-005478-5iu38pr6	1418	17	leukemia	leukemia	NN
cord-005478-5iu38pr6	1418	18	/	/	SYM
cord-005478-5iu38pr6	1418	19	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1418	20	(	(	-LRB-
cord-005478-5iu38pr6	1418	21	n=10	n=10	NNP
cord-005478-5iu38pr6	1418	22	)	)	-RRB-
cord-005478-5iu38pr6	1418	23	;	;	:
cord-005478-5iu38pr6	1418	24	squamous	squamous	JJ
cord-005478-5iu38pr6	1418	25	cell	cell	NN
cord-005478-5iu38pr6	1418	26	carcinoma	carcinoma	NN
cord-005478-5iu38pr6	1418	27	of	of	IN
cord-005478-5iu38pr6	1418	28	the	the	DT
cord-005478-5iu38pr6	1418	29	skin	skin	NN
cord-005478-5iu38pr6	1418	30	/	/	SYM
cord-005478-5iu38pr6	1418	31	oral	oral	JJ
cord-005478-5iu38pr6	1418	32	mucosa	mucosa	NN
cord-005478-5iu38pr6	1418	33	(	(	-LRB-
cord-005478-5iu38pr6	1418	34	n=9	n=9	NN
cord-005478-5iu38pr6	1418	35	)	)	-RRB-
cord-005478-5iu38pr6	1418	36	;	;	:
cord-005478-5iu38pr6	1418	37	and	and	CC
cord-005478-5iu38pr6	1418	38	adenocarcinoma	adenocarcinoma	NN
cord-005478-5iu38pr6	1418	39	of	of	IN
cord-005478-5iu38pr6	1418	40	colon	colon	NN
cord-005478-5iu38pr6	1418	41	/	/	SYM
cord-005478-5iu38pr6	1418	42	lung	lung	NN
cord-005478-5iu38pr6	1418	43	(	(	-LRB-
cord-005478-5iu38pr6	1418	44	n=5	n=5	NNP
cord-005478-5iu38pr6	1418	45	)	)	-RRB-
cord-005478-5iu38pr6	1418	46	.	.	.
cord-005478-5iu38pr6	1419	1	Ten	ten	CD
cord-005478-5iu38pr6	1419	2	other	other	JJ
cord-005478-5iu38pr6	1419	3	types	type	NNS
cord-005478-5iu38pr6	1419	4	of	of	IN
cord-005478-5iu38pr6	1419	5	SMNs	smn	NNS
cord-005478-5iu38pr6	1419	6	were	be	VBD
cord-005478-5iu38pr6	1419	7	found	find	VBN
cord-005478-5iu38pr6	1419	8	including	include	VBG
cord-005478-5iu38pr6	1419	9	sarcoma	sarcoma	NN
cord-005478-5iu38pr6	1419	10	,	,	,
cord-005478-5iu38pr6	1419	11	melanoma	melanoma	NN
cord-005478-5iu38pr6	1419	12	,	,	,
cord-005478-5iu38pr6	1419	13	nerve	nerve	NN
cord-005478-5iu38pr6	1419	14	sheath	sheath	NN
cord-005478-5iu38pr6	1419	15	tumor	tumor	NN
cord-005478-5iu38pr6	1419	16	and	and	CC
cord-005478-5iu38pr6	1419	17	breast	breast	NN
cord-005478-5iu38pr6	1419	18	cancer	cancer	NN
cord-005478-5iu38pr6	1419	19	.	.	.
cord-005478-5iu38pr6	1420	1	Nine	nine	CD
cord-005478-5iu38pr6	1420	2	survivors	survivor	NNS
cord-005478-5iu38pr6	1420	3	died	die	VBD
cord-005478-5iu38pr6	1420	4	at	at	IN
cord-005478-5iu38pr6	1420	5	a	a	DT
cord-005478-5iu38pr6	1420	6	median	median	NN
cord-005478-5iu38pr6	1420	7	of	of	IN
cord-005478-5iu38pr6	1420	8	7.7	7.7	CD
cord-005478-5iu38pr6	1420	9	months	month	NNS
cord-005478-5iu38pr6	1420	10	after	after	IN
cord-005478-5iu38pr6	1420	11	SMN	smn	NN
cord-005478-5iu38pr6	1420	12	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1420	13	.	.	.
cord-005478-5iu38pr6	1421	1	The	the	DT
cord-005478-5iu38pr6	1421	2	10-year	10-year	CD
cord-005478-5iu38pr6	1421	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1421	4	incidence	incidence	NN
cord-005478-5iu38pr6	1421	5	of	of	IN
cord-005478-5iu38pr6	1421	6	SMN	SMN	NNP
cord-005478-5iu38pr6	1421	7	for	for	IN
cord-005478-5iu38pr6	1421	8	190	190	CD
cord-005478-5iu38pr6	1421	9	acute	acute	JJ
cord-005478-5iu38pr6	1421	10	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	1421	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	1421	12	survivors	survivor	NNS
cord-005478-5iu38pr6	1421	13	who	who	WP
cord-005478-5iu38pr6	1421	14	received	receive	VBD
cord-005478-5iu38pr6	1421	15	total	total	JJ
cord-005478-5iu38pr6	1421	16	-	-	HYPH
cord-005478-5iu38pr6	1421	17	body	body	NN
cord-005478-5iu38pr6	1421	18	irradiation	irradiation	NN
cord-005478-5iu38pr6	1421	19	was	be	VBD
cord-005478-5iu38pr6	1421	20	5	5	CD
cord-005478-5iu38pr6	1421	21	%	%	NN
cord-005478-5iu38pr6	1421	22	(	(	-LRB-
cord-005478-5iu38pr6	1421	23	2.4%-10.6	2.4%-10.6	CD
cord-005478-5iu38pr6	1421	24	%	%	NN
cord-005478-5iu38pr6	1421	25	)	)	-RRB-
cord-005478-5iu38pr6	1421	26	.	.	.
cord-005478-5iu38pr6	1422	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1422	2	:	:	:
cord-005478-5iu38pr6	1423	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	1423	2	findings	finding	NNS
cord-005478-5iu38pr6	1423	3	corroborate	corroborate	VBP
cord-005478-5iu38pr6	1423	4	the	the	DT
cord-005478-5iu38pr6	1423	5	observation	observation	NN
cord-005478-5iu38pr6	1423	6	that	that	IN
cord-005478-5iu38pr6	1423	7	children	child	NNS
cord-005478-5iu38pr6	1423	8	and	and	CC
cord-005478-5iu38pr6	1423	9	AYA	AYA	NNP
cord-005478-5iu38pr6	1423	10	who	who	WP
cord-005478-5iu38pr6	1423	11	undergo	undergo	VBP
cord-005478-5iu38pr6	1423	12	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1423	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1423	14	are	be	VBP
cord-005478-5iu38pr6	1423	15	at	at	IN
cord-005478-5iu38pr6	1423	16	a	a	DT
cord-005478-5iu38pr6	1423	17	significant	significant	JJ
cord-005478-5iu38pr6	1423	18	risk	risk	NN
cord-005478-5iu38pr6	1423	19	for	for	IN
cord-005478-5iu38pr6	1423	20	developing	develop	VBG
cord-005478-5iu38pr6	1423	21	SMN	SMN	NNP
cord-005478-5iu38pr6	1423	22	.	.	.
cord-005478-5iu38pr6	1424	1	Careful	careful	JJ
cord-005478-5iu38pr6	1424	2	observation	observation	NN
cord-005478-5iu38pr6	1424	3	in	in	IN
cord-005478-5iu38pr6	1424	4	the	the	DT
cord-005478-5iu38pr6	1424	5	survivorship	survivorship	NN
cord-005478-5iu38pr6	1424	6	period	period	NN
cord-005478-5iu38pr6	1424	7	is	be	VBZ
cord-005478-5iu38pr6	1424	8	required	require	VBN
cord-005478-5iu38pr6	1424	9	for	for	IN
cord-005478-5iu38pr6	1424	10	potential	potential	JJ
cord-005478-5iu38pr6	1424	11	early	early	JJ
cord-005478-5iu38pr6	1424	12	detection	detection	NN
cord-005478-5iu38pr6	1424	13	.	.	.
cord-005478-5iu38pr6	1425	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1425	2	1979	1979	CD
cord-005478-5iu38pr6	1425	3	and	and	CC
cord-005478-5iu38pr6	1425	4	1998	1998	CD
cord-005478-5iu38pr6	1425	5	and	and	CC
cord-005478-5iu38pr6	1425	6	who	who	WP
cord-005478-5iu38pr6	1425	7	survived	survive	VBD
cord-005478-5iu38pr6	1425	8	at	at	IN
cord-005478-5iu38pr6	1425	9	least	least	RBS
cord-005478-5iu38pr6	1425	10	20	20	CD
cord-005478-5iu38pr6	1425	11	years	year	NNS
cord-005478-5iu38pr6	1425	12	post	post	NN
cord-005478-5iu38pr6	1425	13	-	-	NN
cord-005478-5iu38pr6	1425	14	HCT	hct	JJ
cord-005478-5iu38pr6	1425	15	while	while	IN
cord-005478-5iu38pr6	1425	16	continuing	continue	VBG
cord-005478-5iu38pr6	1425	17	follow	follow	NN
cord-005478-5iu38pr6	1425	18	-	-	HYPH
cord-005478-5iu38pr6	1425	19	up	up	NN
cord-005478-5iu38pr6	1425	20	at	at	IN
cord-005478-5iu38pr6	1425	21	our	-PRON-	PRP$
cord-005478-5iu38pr6	1425	22	centre	centre	NN
cord-005478-5iu38pr6	1425	23	.	.	.
cord-005478-5iu38pr6	1426	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1426	2	documented	document	VBD
cord-005478-5iu38pr6	1426	3	performance	performance	NN
cord-005478-5iu38pr6	1426	4	status	status	NN
cord-005478-5iu38pr6	1426	5	,	,	,
cord-005478-5iu38pr6	1426	6	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1426	7	,	,	,
cord-005478-5iu38pr6	1426	8	number	number	NN
cord-005478-5iu38pr6	1426	9	of	of	IN
cord-005478-5iu38pr6	1426	10	medications	medication	NNS
cord-005478-5iu38pr6	1426	11	and	and	CC
cord-005478-5iu38pr6	1426	12	occurrence	occurrence	NN
cord-005478-5iu38pr6	1426	13	of	of	IN
cord-005478-5iu38pr6	1426	14	secondary	secondary	JJ
cord-005478-5iu38pr6	1426	15	malignancies	malignancy	NNS
cord-005478-5iu38pr6	1426	16	at	at	IN
cord-005478-5iu38pr6	1426	17	20	20	CD
cord-005478-5iu38pr6	1426	18	years	year	NNS
cord-005478-5iu38pr6	1426	19	,	,	,
cord-005478-5iu38pr6	1426	20	as	as	RB
cord-005478-5iu38pr6	1426	21	well	well	RB
cord-005478-5iu38pr6	1426	22	as	as	IN
cord-005478-5iu38pr6	1426	23	survival	survival	NN
cord-005478-5iu38pr6	1426	24	following	follow	VBG
cord-005478-5iu38pr6	1426	25	the	the	DT
cord-005478-5iu38pr6	1426	26	20-year	20-year	JJ
cord-005478-5iu38pr6	1426	27	time	time	NN
cord-005478-5iu38pr6	1426	28	-	-	HYPH
cord-005478-5iu38pr6	1426	29	point	point	NN
cord-005478-5iu38pr6	1426	30	.	.	.
cord-005478-5iu38pr6	1427	1	Results	result	NNS
cord-005478-5iu38pr6	1427	2	:	:	:
cord-005478-5iu38pr6	1428	1	The	the	DT
cord-005478-5iu38pr6	1428	2	median	median	JJ
cord-005478-5iu38pr6	1428	3	age	age	NN
cord-005478-5iu38pr6	1428	4	of	of	IN
cord-005478-5iu38pr6	1428	5	the	the	DT
cord-005478-5iu38pr6	1428	6	cohort	cohort	NN
cord-005478-5iu38pr6	1428	7	at	at	IN
cord-005478-5iu38pr6	1428	8	20	20	CD
cord-005478-5iu38pr6	1428	9	years	year	NNS
cord-005478-5iu38pr6	1428	10	post	post	NN
cord-005478-5iu38pr6	1428	11	-	-	NN
cord-005478-5iu38pr6	1428	12	HCT	HCT	NNP
cord-005478-5iu38pr6	1428	13	was	be	VBD
cord-005478-5iu38pr6	1428	14	56	56	CD
cord-005478-5iu38pr6	1428	15	years	year	NNS
cord-005478-5iu38pr6	1429	1	(	(	-LRB-
cord-005478-5iu38pr6	1429	2	range	range	NNP
cord-005478-5iu38pr6	1429	3	37	37	CD
cord-005478-5iu38pr6	1429	4	-	-	SYM
cord-005478-5iu38pr6	1429	5	77	77	CD
cord-005478-5iu38pr6	1429	6	)	)	-RRB-
cord-005478-5iu38pr6	1429	7	,	,	,
cord-005478-5iu38pr6	1429	8	157	157	CD
cord-005478-5iu38pr6	1429	9	(	(	-LRB-
cord-005478-5iu38pr6	1429	10	91	91	CD
cord-005478-5iu38pr6	1429	11	%	%	NN
cord-005478-5iu38pr6	1429	12	)	)	-RRB-
cord-005478-5iu38pr6	1429	13	of	of	IN
cord-005478-5iu38pr6	1429	14	patients	patient	NNS
cord-005478-5iu38pr6	1429	15	underwent	undergo	VBD
cord-005478-5iu38pr6	1429	16	transplant	transplant	NN
cord-005478-5iu38pr6	1429	17	using	use	VBG
cord-005478-5iu38pr6	1429	18	a	a	DT
cord-005478-5iu38pr6	1429	19	related	related	JJ
cord-005478-5iu38pr6	1429	20	donor	donor	NN
cord-005478-5iu38pr6	1429	21	.	.	.
cord-005478-5iu38pr6	1430	1	Eighty	eighty	CD
cord-005478-5iu38pr6	1430	2	patients	patient	NNS
cord-005478-5iu38pr6	1430	3	(	(	-LRB-
cord-005478-5iu38pr6	1430	4	46	46	CD
cord-005478-5iu38pr6	1430	5	%	%	NN
cord-005478-5iu38pr6	1430	6	)	)	-RRB-
cord-005478-5iu38pr6	1430	7	underwent	undergo	VBD
cord-005478-5iu38pr6	1430	8	HCT	hct	NN
cord-005478-5iu38pr6	1430	9	for	for	IN
cord-005478-5iu38pr6	1430	10	CML	CML	NNP
cord-005478-5iu38pr6	1430	11	,	,	,
cord-005478-5iu38pr6	1430	12	44	44	CD
cord-005478-5iu38pr6	1430	13	(	(	-LRB-
cord-005478-5iu38pr6	1430	14	25	25	CD
cord-005478-5iu38pr6	1430	15	%	%	NN
cord-005478-5iu38pr6	1430	16	)	)	-RRB-
cord-005478-5iu38pr6	1430	17	for	for	IN
cord-005478-5iu38pr6	1430	18	AML	AML	NNP
cord-005478-5iu38pr6	1430	19	,	,	,
cord-005478-5iu38pr6	1430	20	14	14	CD
cord-005478-5iu38pr6	1430	21	(	(	-LRB-
cord-005478-5iu38pr6	1430	22	8	8	CD
cord-005478-5iu38pr6	1430	23	%	%	NN
cord-005478-5iu38pr6	1430	24	)	)	-RRB-
cord-005478-5iu38pr6	1430	25	for	for	IN
cord-005478-5iu38pr6	1430	26	ALL	all	DT
cord-005478-5iu38pr6	1430	27	,	,	,
cord-005478-5iu38pr6	1430	28	12	12	CD
cord-005478-5iu38pr6	1430	29	(	(	-LRB-
cord-005478-5iu38pr6	1430	30	7	7	CD
cord-005478-5iu38pr6	1430	31	%	%	NN
cord-005478-5iu38pr6	1430	32	)	)	-RRB-
cord-005478-5iu38pr6	1430	33	for	for	IN
cord-005478-5iu38pr6	1430	34	aplastic	aplastic	JJ
cord-005478-5iu38pr6	1430	35	anemia	anemia	NN
cord-005478-5iu38pr6	1430	36	,	,	,
cord-005478-5iu38pr6	1430	37	23	23	CD
cord-005478-5iu38pr6	1430	38	(	(	-LRB-
cord-005478-5iu38pr6	1430	39	13	13	CD
cord-005478-5iu38pr6	1430	40	%	%	NN
cord-005478-5iu38pr6	1430	41	)	)	-RRB-
cord-005478-5iu38pr6	1430	42	for	for	IN
cord-005478-5iu38pr6	1430	43	other	other	JJ
cord-005478-5iu38pr6	1430	44	indications	indication	NNS
cord-005478-5iu38pr6	1430	45	.	.	.
cord-005478-5iu38pr6	1431	1	Bone	bone	NN
cord-005478-5iu38pr6	1431	2	marrow	marrow	NN
cord-005478-5iu38pr6	1431	3	grafts	graft	NNS
cord-005478-5iu38pr6	1431	4	were	be	VBD
cord-005478-5iu38pr6	1431	5	used	use	VBN
cord-005478-5iu38pr6	1431	6	in	in	IN
cord-005478-5iu38pr6	1431	7	163	163	CD
cord-005478-5iu38pr6	1431	8	(	(	-LRB-
cord-005478-5iu38pr6	1431	9	94	94	CD
cord-005478-5iu38pr6	1431	10	%	%	NN
cord-005478-5iu38pr6	1431	11	)	)	-RRB-
cord-005478-5iu38pr6	1431	12	patients	patient	NNS
cord-005478-5iu38pr6	1431	13	.	.	.
cord-005478-5iu38pr6	1432	1	Myeloablative	Myeloablative	NNP
cord-005478-5iu38pr6	1432	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	1432	3	was	be	VBD
cord-005478-5iu38pr6	1432	4	used	use	VBN
cord-005478-5iu38pr6	1432	5	in	in	IN
cord-005478-5iu38pr6	1432	6	163	163	CD
cord-005478-5iu38pr6	1432	7	(	(	-LRB-
cord-005478-5iu38pr6	1432	8	94	94	CD
cord-005478-5iu38pr6	1432	9	%	%	NN
cord-005478-5iu38pr6	1432	10	)	)	-RRB-
cord-005478-5iu38pr6	1432	11	patients	patient	NNS
cord-005478-5iu38pr6	1432	12	.	.	.
cord-005478-5iu38pr6	1433	1	Individual	individual	JJ
cord-005478-5iu38pr6	1433	2	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1433	3	were	be	VBD
cord-005478-5iu38pr6	1433	4	categorized	categorize	VBN
cord-005478-5iu38pr6	1433	5	into	into	IN
cord-005478-5iu38pr6	1433	6	five	five	CD
cord-005478-5iu38pr6	1433	7	major	major	JJ
cord-005478-5iu38pr6	1433	8	groups	group	NNS
cord-005478-5iu38pr6	1433	9	:	:	:
cord-005478-5iu38pr6	1433	10	endocrine	endocrine	JJ
cord-005478-5iu38pr6	1433	11	79	79	CD
cord-005478-5iu38pr6	1433	12	(	(	-LRB-
cord-005478-5iu38pr6	1433	13	46	46	CD
cord-005478-5iu38pr6	1433	14	%	%	NN
cord-005478-5iu38pr6	1433	15	)	)	-RRB-
cord-005478-5iu38pr6	1433	16	,	,	,
cord-005478-5iu38pr6	1433	17	cardiac	cardiac	JJ
cord-005478-5iu38pr6	1433	18	59	59	CD
cord-005478-5iu38pr6	1433	19	(	(	-LRB-
cord-005478-5iu38pr6	1433	20	34	34	CD
cord-005478-5iu38pr6	1433	21	%	%	NN
cord-005478-5iu38pr6	1433	22	)	)	-RRB-
cord-005478-5iu38pr6	1433	23	,	,	,
cord-005478-5iu38pr6	1433	24	secondary	secondary	JJ
cord-005478-5iu38pr6	1433	25	cancer	cancer	NN
cord-005478-5iu38pr6	1433	26	46	46	CD
cord-005478-5iu38pr6	1433	27	(	(	-LRB-
cord-005478-5iu38pr6	1433	28	27	27	CD
cord-005478-5iu38pr6	1433	29	%	%	NN
cord-005478-5iu38pr6	1433	30	)	)	-RRB-
cord-005478-5iu38pr6	1433	31	,	,	,
cord-005478-5iu38pr6	1433	32	psychosocial	psychosocial	JJ
cord-005478-5iu38pr6	1433	33	39	39	CD
cord-005478-5iu38pr6	1433	34	(	(	-LRB-
cord-005478-5iu38pr6	1433	35	23	23	CD
cord-005478-5iu38pr6	1433	36	%	%	NN
cord-005478-5iu38pr6	1433	37	)	)	-RRB-
cord-005478-5iu38pr6	1433	38	,	,	,
cord-005478-5iu38pr6	1433	39	and	and	CC
cord-005478-5iu38pr6	1433	40	other	other	JJ
cord-005478-5iu38pr6	1433	41	organ	organ	NN
cord-005478-5iu38pr6	1433	42	dysfunctions	dysfunction	NNS
cord-005478-5iu38pr6	1433	43	94	94	CD
cord-005478-5iu38pr6	1433	44	(	(	-LRB-
cord-005478-5iu38pr6	1433	45	54	54	CD
cord-005478-5iu38pr6	1433	46	%	%	NN
cord-005478-5iu38pr6	1433	47	)	)	-RRB-
cord-005478-5iu38pr6	1433	48	.	.	.
cord-005478-5iu38pr6	1434	1	At	at	IN
cord-005478-5iu38pr6	1434	2	the	the	DT
cord-005478-5iu38pr6	1434	3	20	20	CD
cord-005478-5iu38pr6	1434	4	year	year	NN
cord-005478-5iu38pr6	1434	5	mark	mark	NN
cord-005478-5iu38pr6	1434	6	,	,	,
cord-005478-5iu38pr6	1434	7	median	median	JJ
cord-005478-5iu38pr6	1434	8	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	1434	9	Performance	Performance	NNP
cord-005478-5iu38pr6	1434	10	Status	Status	NNP
cord-005478-5iu38pr6	1434	11	was	be	VBD
cord-005478-5iu38pr6	1434	12	100	100	CD
cord-005478-5iu38pr6	1435	1	(	(	-LRB-
cord-005478-5iu38pr6	1435	2	range	range	NNP
cord-005478-5iu38pr6	1435	3	30	30	CD
cord-005478-5iu38pr6	1435	4	-	-	SYM
cord-005478-5iu38pr6	1435	5	100	100	CD
cord-005478-5iu38pr6	1435	6	)	)	-RRB-
cord-005478-5iu38pr6	1435	7	.	.	.
cord-005478-5iu38pr6	1436	1	No	no	DT
cord-005478-5iu38pr6	1436	2	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1436	3	were	be	VBD
cord-005478-5iu38pr6	1436	4	seen	see	VBN
cord-005478-5iu38pr6	1436	5	in	in	IN
cord-005478-5iu38pr6	1436	6	24	24	CD
cord-005478-5iu38pr6	1436	7	(	(	-LRB-
cord-005478-5iu38pr6	1436	8	14	14	CD
cord-005478-5iu38pr6	1436	9	%	%	NN
cord-005478-5iu38pr6	1436	10	)	)	-RRB-
cord-005478-5iu38pr6	1436	11	patients	patient	NNS
cord-005478-5iu38pr6	1436	12	.	.	.
cord-005478-5iu38pr6	1437	1	The	the	DT
cord-005478-5iu38pr6	1437	2	most	most	RBS
cord-005478-5iu38pr6	1437	3	frequent	frequent	JJ
cord-005478-5iu38pr6	1437	4	individual	individual	JJ
cord-005478-5iu38pr6	1437	5	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1437	6	were	be	VBD
cord-005478-5iu38pr6	1437	7	dyslipidemia	dyslipidemia	NN
cord-005478-5iu38pr6	1437	8	(	(	-LRB-
cord-005478-5iu38pr6	1437	9	n=54	n=54	JJ
cord-005478-5iu38pr6	1437	10	,	,	,
cord-005478-5iu38pr6	1437	11	31	31	CD
cord-005478-5iu38pr6	1437	12	%	%	NN
cord-005478-5iu38pr6	1437	13	)	)	-RRB-
cord-005478-5iu38pr6	1437	14	,	,	,
cord-005478-5iu38pr6	1437	15	hypertension	hypertension	NN
cord-005478-5iu38pr6	1437	16	(	(	-LRB-
cord-005478-5iu38pr6	1437	17	n=54	n=54	JJ
cord-005478-5iu38pr6	1437	18	,	,	,
cord-005478-5iu38pr6	1437	19	31	31	CD
cord-005478-5iu38pr6	1437	20	%	%	NN
cord-005478-5iu38pr6	1437	21	)	)	-RRB-
cord-005478-5iu38pr6	1437	22	,	,	,
cord-005478-5iu38pr6	1437	23	osteoporosis	osteoporosis	NN
cord-005478-5iu38pr6	1437	24	(	(	-LRB-
cord-005478-5iu38pr6	1437	25	n=31	n=31	NNP
cord-005478-5iu38pr6	1437	26	,	,	,
cord-005478-5iu38pr6	1437	27	18	18	CD
cord-005478-5iu38pr6	1437	28	%	%	NN
cord-005478-5iu38pr6	1437	29	)	)	-RRB-
cord-005478-5iu38pr6	1437	30	and	and	CC
cord-005478-5iu38pr6	1437	31	hypothyroidism	hypothyroidism	NN
cord-005478-5iu38pr6	1437	32	(	(	-LRB-
cord-005478-5iu38pr6	1437	33	n=28	n=28	NN
cord-005478-5iu38pr6	1437	34	,	,	,
cord-005478-5iu38pr6	1437	35	16	16	CD
cord-005478-5iu38pr6	1437	36	%	%	NN
cord-005478-5iu38pr6	1437	37	)	)	-RRB-
cord-005478-5iu38pr6	1437	38	.	.	.
cord-005478-5iu38pr6	1438	1	At	at	IN
cord-005478-5iu38pr6	1438	2	the	the	DT
cord-005478-5iu38pr6	1438	3	time	time	NN
cord-005478-5iu38pr6	1438	4	of	of	IN
cord-005478-5iu38pr6	1438	5	the	the	DT
cord-005478-5iu38pr6	1438	6	20-year	20-year	JJ
cord-005478-5iu38pr6	1438	7	post	post	JJ
cord-005478-5iu38pr6	1438	8	-	-	JJ
cord-005478-5iu38pr6	1438	9	HCT	hct	JJ
cord-005478-5iu38pr6	1438	10	follow	follow	NN
cord-005478-5iu38pr6	1438	11	-	-	HYPH
cord-005478-5iu38pr6	1438	12	up	up	NN
cord-005478-5iu38pr6	1438	13	,	,	,
cord-005478-5iu38pr6	1438	14	the	the	DT
cord-005478-5iu38pr6	1438	15	median	median	JJ
cord-005478-5iu38pr6	1438	16	number	number	NN
cord-005478-5iu38pr6	1438	17	of	of	IN
cord-005478-5iu38pr6	1438	18	medications	medication	NNS
cord-005478-5iu38pr6	1438	19	patients	patient	NNS
cord-005478-5iu38pr6	1438	20	were	be	VBD
cord-005478-5iu38pr6	1438	21	taking	take	VBG
cord-005478-5iu38pr6	1438	22	was	be	VBD
cord-005478-5iu38pr6	1438	23	2	2	CD
cord-005478-5iu38pr6	1439	1	(	(	-LRB-
cord-005478-5iu38pr6	1439	2	range	range	NN
cord-005478-5iu38pr6	1439	3	0	0	CD
cord-005478-5iu38pr6	1439	4	-	-	SYM
cord-005478-5iu38pr6	1439	5	25	25	CD
cord-005478-5iu38pr6	1439	6	)	)	-RRB-
cord-005478-5iu38pr6	1439	7	.	.	.
cord-005478-5iu38pr6	1440	1	Follow	follow	VB
cord-005478-5iu38pr6	1440	2	-	-	HYPH
cord-005478-5iu38pr6	1440	3	up	up	RP
cord-005478-5iu38pr6	1440	4	data	datum	NNS
cord-005478-5iu38pr6	1440	5	after	after	IN
cord-005478-5iu38pr6	1440	6	the	the	DT
cord-005478-5iu38pr6	1440	7	20-year	20-year	JJ
cord-005478-5iu38pr6	1440	8	mark	mark	NN
cord-005478-5iu38pr6	1440	9	was	be	VBD
cord-005478-5iu38pr6	1440	10	available	available	JJ
cord-005478-5iu38pr6	1440	11	for	for	IN
cord-005478-5iu38pr6	1440	12	146	146	CD
cord-005478-5iu38pr6	1440	13	(	(	-LRB-
cord-005478-5iu38pr6	1440	14	84	84	CD
cord-005478-5iu38pr6	1440	15	%	%	NN
cord-005478-5iu38pr6	1440	16	)	)	-RRB-
cord-005478-5iu38pr6	1440	17	patients	patient	NNS
cord-005478-5iu38pr6	1440	18	.	.	.
cord-005478-5iu38pr6	1441	1	Median	median	JJ
cord-005478-5iu38pr6	1441	2	follow	follow	NN
cord-005478-5iu38pr6	1441	3	-	-	HYPH
cord-005478-5iu38pr6	1441	4	up	up	NN
cord-005478-5iu38pr6	1441	5	of	of	IN
cord-005478-5iu38pr6	1441	6	survivors	survivor	NNS
cord-005478-5iu38pr6	1441	7	after	after	IN
cord-005478-5iu38pr6	1441	8	the	the	DT
cord-005478-5iu38pr6	1441	9	20-year	20-year	JJ
cord-005478-5iu38pr6	1441	10	mark	mark	NN
cord-005478-5iu38pr6	1441	11	was	be	VBD
cord-005478-5iu38pr6	1441	12	59	59	CD
cord-005478-5iu38pr6	1441	13	months	month	NNS
cord-005478-5iu38pr6	1442	1	(	(	-LRB-
cord-005478-5iu38pr6	1442	2	range	range	NNP
cord-005478-5iu38pr6	1442	3	4	4	CD
cord-005478-5iu38pr6	1442	4	-	-	SYM
cord-005478-5iu38pr6	1442	5	219	219	CD
cord-005478-5iu38pr6	1442	6	months	month	NNS
cord-005478-5iu38pr6	1442	7	)	)	-RRB-
cord-005478-5iu38pr6	1442	8	.	.	.
cord-005478-5iu38pr6	1443	1	Fiveyear	fiveyear	JJ
cord-005478-5iu38pr6	1443	2	overall	overall	JJ
cord-005478-5iu38pr6	1443	3	survival	survival	NN
cord-005478-5iu38pr6	1443	4	of	of	IN
cord-005478-5iu38pr6	1443	5	the	the	DT
cord-005478-5iu38pr6	1443	6	146	146	CD
cord-005478-5iu38pr6	1443	7	patients	patient	NNS
cord-005478-5iu38pr6	1443	8	was	be	VBD
cord-005478-5iu38pr6	1443	9	92	92	CD
cord-005478-5iu38pr6	1443	10	%	%	NN
cord-005478-5iu38pr6	1443	11	(	(	-LRB-
cord-005478-5iu38pr6	1443	12	95%CI	95%ci	CD
cord-005478-5iu38pr6	1443	13	85	85	CD
cord-005478-5iu38pr6	1443	14	-	-	SYM
cord-005478-5iu38pr6	1443	15	96	96	CD
cord-005478-5iu38pr6	1443	16	%	%	NN
cord-005478-5iu38pr6	1443	17	)	)	-RRB-
cord-005478-5iu38pr6	1443	18	and	and	CC
cord-005478-5iu38pr6	1443	19	at	at	IN
cord-005478-5iu38pr6	1443	20	10	10	CD
cord-005478-5iu38pr6	1443	21	years	year	NNS
cord-005478-5iu38pr6	1443	22	was	be	VBD
cord-005478-5iu38pr6	1443	23	89	89	CD
cord-005478-5iu38pr6	1443	24	%	%	NN
cord-005478-5iu38pr6	1443	25	(	(	-LRB-
cord-005478-5iu38pr6	1443	26	95	95	CD
cord-005478-5iu38pr6	1443	27	%	%	NN
cord-005478-5iu38pr6	1443	28	CI	CI	NNP
cord-005478-5iu38pr6	1443	29	79	79	CD
cord-005478-5iu38pr6	1443	30	-	-	SYM
cord-005478-5iu38pr6	1443	31	94	94	CD
cord-005478-5iu38pr6	1443	32	%	%	NN
cord-005478-5iu38pr6	1443	33	)	)	-RRB-
cord-005478-5iu38pr6	1443	34	.	.	.
cord-005478-5iu38pr6	1444	1	When	when	WRB
cord-005478-5iu38pr6	1444	2	grouped	group	VBN
cord-005478-5iu38pr6	1444	3	by	by	IN
cord-005478-5iu38pr6	1444	4	age	age	NN
cord-005478-5iu38pr6	1444	5	at	at	IN
cord-005478-5iu38pr6	1444	6	the	the	DT
cord-005478-5iu38pr6	1444	7	20-year	20-year	JJ
cord-005478-5iu38pr6	1444	8	mark	mark	NN
cord-005478-5iu38pr6	1444	9	,	,	,
cord-005478-5iu38pr6	1444	10	there	there	EX
cord-005478-5iu38pr6	1444	11	was	be	VBD
cord-005478-5iu38pr6	1444	12	no	no	DT
cord-005478-5iu38pr6	1444	13	significant	significant	JJ
cord-005478-5iu38pr6	1444	14	difference	difference	NN
cord-005478-5iu38pr6	1444	15	in	in	IN
cord-005478-5iu38pr6	1444	16	5-year	5-year	CD
cord-005478-5iu38pr6	1444	17	OS	OS	NNP
cord-005478-5iu38pr6	1444	18	survival	survival	NN
cord-005478-5iu38pr6	1444	19	between	between	IN
cord-005478-5iu38pr6	1444	20	ages	age	NNS
cord-005478-5iu38pr6	1444	21	35	35	CD
cord-005478-5iu38pr6	1444	22	-	-	SYM
cord-005478-5iu38pr6	1444	23	49	49	CD
cord-005478-5iu38pr6	1444	24	(	(	-LRB-
cord-005478-5iu38pr6	1444	25	n=48	n=48	NN
cord-005478-5iu38pr6	1444	26	,	,	,
cord-005478-5iu38pr6	1444	27	5-year	5-year	CD
cord-005478-5iu38pr6	1444	28	OS	OS	NNP
cord-005478-5iu38pr6	1444	29	91	91	CD
cord-005478-5iu38pr6	1444	30	%	%	NN
cord-005478-5iu38pr6	1444	31	)	)	-RRB-
cord-005478-5iu38pr6	1444	32	,	,	,
cord-005478-5iu38pr6	1444	33	50	50	CD
cord-005478-5iu38pr6	1444	34	-	-	SYM
cord-005478-5iu38pr6	1444	35	60	60	CD
cord-005478-5iu38pr6	1444	36	(	(	-LRB-
cord-005478-5iu38pr6	1444	37	n=58	n=58	NNS
cord-005478-5iu38pr6	1444	38	,	,	,
cord-005478-5iu38pr6	1444	39	5-year	5-year	CD
cord-005478-5iu38pr6	1444	40	OS	OS	NNP
cord-005478-5iu38pr6	1444	41	95	95	CD
cord-005478-5iu38pr6	1444	42	%	%	NN
cord-005478-5iu38pr6	1444	43	)	)	-RRB-
cord-005478-5iu38pr6	1444	44	and	and	CC
cord-005478-5iu38pr6	1444	45	61	61	CD
cord-005478-5iu38pr6	1444	46	-	-	SYM
cord-005478-5iu38pr6	1444	47	75	75	CD
cord-005478-5iu38pr6	1444	48	(	(	-LRB-
cord-005478-5iu38pr6	1444	49	n=40	n=40	NNP
cord-005478-5iu38pr6	1444	50	,	,	,
cord-005478-5iu38pr6	1444	51	5-year	5-year	CD
cord-005478-5iu38pr6	1444	52	OS	OS	NNP
cord-005478-5iu38pr6	1444	53	87	87	CD
cord-005478-5iu38pr6	1444	54	%	%	NN
cord-005478-5iu38pr6	1444	55	)	)	-RRB-
cord-005478-5iu38pr6	1445	1	(	(	-LRB-
cord-005478-5iu38pr6	1445	2	p=0.90	p=0.90	NNP
cord-005478-5iu38pr6	1445	3	)	)	-RRB-
cord-005478-5iu38pr6	1445	4	.	.	.
cord-005478-5iu38pr6	1446	1	When	when	WRB
cord-005478-5iu38pr6	1446	2	grouped	group	VBN
cord-005478-5iu38pr6	1446	3	by	by	IN
cord-005478-5iu38pr6	1446	4	the	the	DT
cord-005478-5iu38pr6	1446	5	number	number	NN
cord-005478-5iu38pr6	1446	6	of	of	IN
cord-005478-5iu38pr6	1446	7	concurrent	concurrent	JJ
cord-005478-5iu38pr6	1446	8	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1446	9	,	,	,
cord-005478-5iu38pr6	1446	10	there	there	EX
cord-005478-5iu38pr6	1446	11	was	be	VBD
cord-005478-5iu38pr6	1446	12	a	a	DT
cord-005478-5iu38pr6	1446	13	significant	significant	JJ
cord-005478-5iu38pr6	1446	14	difference	difference	NN
cord-005478-5iu38pr6	1446	15	in	in	IN
cord-005478-5iu38pr6	1446	16	OS	os	NN
cord-005478-5iu38pr6	1446	17	between	between	IN
cord-005478-5iu38pr6	1446	18	the	the	DT
cord-005478-5iu38pr6	1446	19	groups	group	NNS
cord-005478-5iu38pr6	1446	20	with	with	IN
cord-005478-5iu38pr6	1446	21	0	0	CD
cord-005478-5iu38pr6	1446	22	-	-	SYM
cord-005478-5iu38pr6	1446	23	1	1	CD
cord-005478-5iu38pr6	1446	24	(	(	-LRB-
cord-005478-5iu38pr6	1446	25	n=54	n=54	NN
cord-005478-5iu38pr6	1446	26	)	)	-RRB-
cord-005478-5iu38pr6	1446	27	,	,	,
cord-005478-5iu38pr6	1446	28	2	2	CD
cord-005478-5iu38pr6	1446	29	-	-	SYM
cord-005478-5iu38pr6	1446	30	3	3	CD
cord-005478-5iu38pr6	1446	31	(	(	-LRB-
cord-005478-5iu38pr6	1446	32	n=53	n=53	NNP
cord-005478-5iu38pr6	1446	33	)	)	-RRB-
cord-005478-5iu38pr6	1446	34	and	and	CC
cord-005478-5iu38pr6	1446	35	≥4	≥4	JJ
cord-005478-5iu38pr6	1446	36	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1446	37	(	(	-LRB-
cord-005478-5iu38pr6	1446	38	n=39	n=39	NNP
cord-005478-5iu38pr6	1446	39	)	)	-RRB-
cord-005478-5iu38pr6	1446	40	(	(	-LRB-
cord-005478-5iu38pr6	1446	41	10-year	10-year	CD
cord-005478-5iu38pr6	1446	42	OS	OS	NNP
cord-005478-5iu38pr6	1446	43	98	98	CD
cord-005478-5iu38pr6	1446	44	%	%	NN
cord-005478-5iu38pr6	1446	45	,	,	,
cord-005478-5iu38pr6	1446	46	87	87	CD
cord-005478-5iu38pr6	1446	47	%	%	NN
cord-005478-5iu38pr6	1446	48	and	and	CC
cord-005478-5iu38pr6	1446	49	67	67	CD
cord-005478-5iu38pr6	1446	50	%	%	NN
cord-005478-5iu38pr6	1446	51	respectively	respectively	RB
cord-005478-5iu38pr6	1446	52	,	,	,
cord-005478-5iu38pr6	1446	53	p=0.0001	p=0.0001	NNS
cord-005478-5iu38pr6	1446	54	,	,	,
cord-005478-5iu38pr6	1446	55	Figure	figure	NN
cord-005478-5iu38pr6	1446	56	1	1	CD
cord-005478-5iu38pr6	1446	57	)	)	-RRB-
cord-005478-5iu38pr6	1446	58	.	.	.
cord-005478-5iu38pr6	1447	1	When	when	WRB
cord-005478-5iu38pr6	1447	2	grouped	group	VBN
cord-005478-5iu38pr6	1447	3	by	by	IN
cord-005478-5iu38pr6	1447	4	the	the	DT
cord-005478-5iu38pr6	1447	5	number	number	NN
cord-005478-5iu38pr6	1447	6	of	of	IN
cord-005478-5iu38pr6	1447	7	medications	medication	NNS
cord-005478-5iu38pr6	1447	8	patients	patient	NNS
cord-005478-5iu38pr6	1447	9	were	be	VBD
cord-005478-5iu38pr6	1447	10	on	on	RP
cord-005478-5iu38pr6	1447	11	at	at	IN
cord-005478-5iu38pr6	1447	12	the	the	DT
cord-005478-5iu38pr6	1447	13	20-year	20-year	JJ
cord-005478-5iu38pr6	1447	14	mark	mark	NN
cord-005478-5iu38pr6	1447	15	,	,	,
cord-005478-5iu38pr6	1447	16	there	there	EX
cord-005478-5iu38pr6	1447	17	was	be	VBD
cord-005478-5iu38pr6	1447	18	a	a	DT
cord-005478-5iu38pr6	1447	19	borderline	borderline	JJ
cord-005478-5iu38pr6	1447	20	significant	significant	JJ
cord-005478-5iu38pr6	1447	21	difference	difference	NN
cord-005478-5iu38pr6	1447	22	between	between	IN
cord-005478-5iu38pr6	1447	23	the	the	DT
cord-005478-5iu38pr6	1447	24	groups	group	NNS
cord-005478-5iu38pr6	1447	25	on	on	IN
cord-005478-5iu38pr6	1447	26	0	0	CD
cord-005478-5iu38pr6	1447	27	-	-	SYM
cord-005478-5iu38pr6	1447	28	1	1	CD
cord-005478-5iu38pr6	1447	29	(	(	-LRB-
cord-005478-5iu38pr6	1447	30	n=61	n=61	NNP
cord-005478-5iu38pr6	1447	31	)	)	-RRB-
cord-005478-5iu38pr6	1447	32	,	,	,
cord-005478-5iu38pr6	1447	33	2	2	CD
cord-005478-5iu38pr6	1447	34	-	-	SYM
cord-005478-5iu38pr6	1447	35	4	4	CD
cord-005478-5iu38pr6	1447	36	(	(	-LRB-
cord-005478-5iu38pr6	1447	37	n=46	n=46	JJ
cord-005478-5iu38pr6	1447	38	)	)	-RRB-
cord-005478-5iu38pr6	1448	1	and	and	CC
cord-005478-5iu38pr6	1448	2	≥5	≥5	NNP
cord-005478-5iu38pr6	1448	3	(	(	-LRB-
cord-005478-5iu38pr6	1448	4	n=39	n=39	NNP
cord-005478-5iu38pr6	1448	5	)	)	-RRB-
cord-005478-5iu38pr6	1449	1	different	different	JJ
cord-005478-5iu38pr6	1449	2	medications	medication	NNS
cord-005478-5iu38pr6	1449	3	(	(	-LRB-
cord-005478-5iu38pr6	1449	4	10-year	10-year	CD
cord-005478-5iu38pr6	1449	5	OS	OS	NNP
cord-005478-5iu38pr6	1449	6	93	93	CD
cord-005478-5iu38pr6	1449	7	%	%	NN
cord-005478-5iu38pr6	1449	8	,	,	,
cord-005478-5iu38pr6	1449	9	93	93	CD
cord-005478-5iu38pr6	1449	10	%	%	NN
cord-005478-5iu38pr6	1449	11	and	and	CC
cord-005478-5iu38pr6	1449	12	76	76	CD
cord-005478-5iu38pr6	1449	13	%	%	NN
cord-005478-5iu38pr6	1449	14	respectively	respectively	RB
cord-005478-5iu38pr6	1449	15	,	,	,
cord-005478-5iu38pr6	1449	16	p=0.05	p=0.05	NNP
cord-005478-5iu38pr6	1449	17	)	)	-RRB-
cord-005478-5iu38pr6	1449	18	.	.	.
cord-005478-5iu38pr6	1450	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1450	2	:	:	:
cord-005478-5iu38pr6	1451	1	Long	long	JJ
cord-005478-5iu38pr6	1451	2	-	-	HYPH
cord-005478-5iu38pr6	1451	3	term	term	NN
cord-005478-5iu38pr6	1451	4	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1451	5	HCT	hct	NN
cord-005478-5iu38pr6	1451	6	recipients	recipient	NNS
cord-005478-5iu38pr6	1451	7	may	may	MD
cord-005478-5iu38pr6	1451	8	develop	develop	VB
cord-005478-5iu38pr6	1451	9	a	a	DT
cord-005478-5iu38pr6	1451	10	number	number	NN
cord-005478-5iu38pr6	1451	11	of	of	IN
cord-005478-5iu38pr6	1451	12	long	long	JJ
cord-005478-5iu38pr6	1451	13	-	-	HYPH
cord-005478-5iu38pr6	1451	14	term	term	NN
cord-005478-5iu38pr6	1451	15	comorbidities	comorbiditie	NNS
cord-005478-5iu38pr6	1451	16	that	that	WDT
cord-005478-5iu38pr6	1451	17	negatively	negatively	RB
cord-005478-5iu38pr6	1451	18	influence	influence	VBP
cord-005478-5iu38pr6	1451	19	survival	survival	NN
cord-005478-5iu38pr6	1451	20	even	even	RB
cord-005478-5iu38pr6	1451	21	past	past	IN
cord-005478-5iu38pr6	1451	22	the	the	DT
cord-005478-5iu38pr6	1451	23	20-year	20-year	JJ
cord-005478-5iu38pr6	1451	24	mark	mark	NN
cord-005478-5iu38pr6	1451	25	.	.	.
cord-005478-5iu38pr6	1452	1	These	these	DT
cord-005478-5iu38pr6	1452	2	findings	finding	NNS
cord-005478-5iu38pr6	1452	3	warrant	warrant	VBP
cord-005478-5iu38pr6	1452	4	the	the	DT
cord-005478-5iu38pr6	1452	5	continuous	continuous	JJ
cord-005478-5iu38pr6	1452	6	long	long	JJ
cord-005478-5iu38pr6	1452	7	-	-	HYPH
cord-005478-5iu38pr6	1452	8	term	term	NN
cord-005478-5iu38pr6	1452	9	medical	medical	JJ
cord-005478-5iu38pr6	1452	10	followup	followup	NN
cord-005478-5iu38pr6	1452	11	of	of	IN
cord-005478-5iu38pr6	1452	12	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1452	13	transplant	transplant	NN
cord-005478-5iu38pr6	1452	14	patients	patient	NNS
cord-005478-5iu38pr6	1452	15	,	,	,
cord-005478-5iu38pr6	1452	16	regardless	regardless	RB
cord-005478-5iu38pr6	1452	17	of	of	IN
cord-005478-5iu38pr6	1452	18	age	age	NN
cord-005478-5iu38pr6	1452	19	or	or	CC
cord-005478-5iu38pr6	1452	20	time	time	NN
cord-005478-5iu38pr6	1452	21	that	that	WDT
cord-005478-5iu38pr6	1452	22	has	have	VBZ
cord-005478-5iu38pr6	1452	23	lapsed	lapse	VBN
cord-005478-5iu38pr6	1452	24	post	post	JJ
cord-005478-5iu38pr6	1452	25	-	-	JJ
cord-005478-5iu38pr6	1452	26	HCT	hct	NN
cord-005478-5iu38pr6	1452	27	.	.	.
cord-005478-5iu38pr6	1453	1	Background	background	NN
cord-005478-5iu38pr6	1453	2	:	:	:
cord-005478-5iu38pr6	1454	1	No	no	DT
cord-005478-5iu38pr6	1454	2	standard	standard	JJ
cord-005478-5iu38pr6	1454	3	procedure	procedure	NN
cord-005478-5iu38pr6	1454	4	is	be	VBZ
cord-005478-5iu38pr6	1454	5	in	in	IN
cord-005478-5iu38pr6	1454	6	use	use	NN
cord-005478-5iu38pr6	1454	7	to	to	TO
cord-005478-5iu38pr6	1454	8	predict	predict	VB
cord-005478-5iu38pr6	1454	9	sinusoidal	sinusoidal	JJ
cord-005478-5iu38pr6	1454	10	obstruction	obstruction	NN
cord-005478-5iu38pr6	1454	11	syndrome	syndrome	NN
cord-005478-5iu38pr6	1454	12	/	/	SYM
cord-005478-5iu38pr6	1454	13	venoocclusive	venoocclusive	JJ
cord-005478-5iu38pr6	1454	14	disease	disease	NN
cord-005478-5iu38pr6	1454	15	(	(	-LRB-
cord-005478-5iu38pr6	1454	16	SOS/	SOS/	NNP
cord-005478-5iu38pr6	1454	17	VOD	VOD	NNP
cord-005478-5iu38pr6	1454	18	)	)	-RRB-
cord-005478-5iu38pr6	1454	19	.	.	.
cord-005478-5iu38pr6	1455	1	Recently	recently	RB
cord-005478-5iu38pr6	1455	2	the	the	DT
cord-005478-5iu38pr6	1455	3	SOS	SOS	NNP
cord-005478-5iu38pr6	1455	4	/	/	SYM
cord-005478-5iu38pr6	1455	5	VOD	VOD	NNP
cord-005478-5iu38pr6	1455	6	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1455	7	clinical	clinical	JJ
cord-005478-5iu38pr6	1455	8	risk	risk	NN
cord-005478-5iu38pr6	1455	9	score	score	NN
cord-005478-5iu38pr6	1455	10	(	(	-LRB-
cord-005478-5iu38pr6	1455	11	age	age	NN
cord-005478-5iu38pr6	1455	12	,	,	,
cord-005478-5iu38pr6	1455	13	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	1455	14	,	,	,
cord-005478-5iu38pr6	1455	15	Sirolimus	Sirolimus	NNP
cord-005478-5iu38pr6	1455	16	,	,	,
cord-005478-5iu38pr6	1455	17	Hepatitis	Hepatitis	NNP
cord-005478-5iu38pr6	1455	18	B	B	NNP
cord-005478-5iu38pr6	1455	19	/	/	SYM
cord-005478-5iu38pr6	1455	20	C	C	NNP
cord-005478-5iu38pr6	1455	21	,	,	,
cord-005478-5iu38pr6	1455	22	conditioning	conditioning	NN
cord-005478-5iu38pr6	1455	23	regimen	regimen	NN
cord-005478-5iu38pr6	1455	24	,	,	,
cord-005478-5iu38pr6	1455	25	disease	disease	NN
cord-005478-5iu38pr6	1455	26	type	type	NN
cord-005478-5iu38pr6	1455	27	)	)	-RRB-
cord-005478-5iu38pr6	1455	28	has	have	VBZ
cord-005478-5iu38pr6	1455	29	been	be	VBN
cord-005478-5iu38pr6	1455	30	established	establish	VBN
cord-005478-5iu38pr6	1455	31	using	use	VBG
cord-005478-5iu38pr6	1455	32	the	the	DT
cord-005478-5iu38pr6	1455	33	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1455	34	database	database	NN
cord-005478-5iu38pr6	1455	35	(	(	-LRB-
cord-005478-5iu38pr6	1455	36	Biol	Biol	NNP
cord-005478-5iu38pr6	1455	37	Blood	Blood	NNP
cord-005478-5iu38pr6	1455	38	Marrow	Marrow	NNP
cord-005478-5iu38pr6	1455	39	Transplant	Transplant	NNP
cord-005478-5iu38pr6	1455	40	.	.	.
cord-005478-5iu38pr6	1456	1	2018	2018	CD
cord-005478-5iu38pr6	1456	2	;	;	:
cord-005478-5iu38pr6	1456	3	24:2072	24:2072	CD
cord-005478-5iu38pr6	1456	4	)	)	-RRB-
cord-005478-5iu38pr6	1456	5	.	.	.
cord-005478-5iu38pr6	1457	1	The	the	DT
cord-005478-5iu38pr6	1457	2	Endothelial	Endothelial	NNP
cord-005478-5iu38pr6	1457	3	Activation	Activation	NNP
cord-005478-5iu38pr6	1457	4	and	and	CC
cord-005478-5iu38pr6	1457	5	Stress	Stress	NNP
cord-005478-5iu38pr6	1457	6	Index	Index	NNP
cord-005478-5iu38pr6	1457	7	(	(	-LRB-
cord-005478-5iu38pr6	1457	8	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1457	9	)	)	-RRB-
cord-005478-5iu38pr6	1457	10	,	,	,
cord-005478-5iu38pr6	1457	11	based	base	VBN
cord-005478-5iu38pr6	1457	12	on	on	IN
cord-005478-5iu38pr6	1457	13	the	the	DT
cord-005478-5iu38pr6	1457	14	simple	simple	JJ
cord-005478-5iu38pr6	1457	15	formula	formula	NN
cord-005478-5iu38pr6	1457	16	'	'	''
cord-005478-5iu38pr6	1457	17	LDH(U	LDH(U	NNP
cord-005478-5iu38pr6	1457	18	/	/	SYM
cord-005478-5iu38pr6	1457	19	l	l	NN
cord-005478-5iu38pr6	1457	20	)	)	-RRB-
cord-005478-5iu38pr6	1457	21	x	x	NNP
cord-005478-5iu38pr6	1457	22	Creatinine(mg	Creatinine(mg	NNP
cord-005478-5iu38pr6	1457	23	/	/	SYM
cord-005478-5iu38pr6	1457	24	dl	dl	NN
cord-005478-5iu38pr6	1457	25	)	)	-RRB-
cord-005478-5iu38pr6	1457	26	/	/	SYM
cord-005478-5iu38pr6	1457	27	Thrombocytes	Thrombocytes	NNPS
cord-005478-5iu38pr6	1457	28	(	(	-LRB-
cord-005478-5iu38pr6	1457	29	10	10	CD
cord-005478-5iu38pr6	1457	30	9	9	CD
cord-005478-5iu38pr6	1457	31	/l	/l	NN
cord-005478-5iu38pr6	1457	32	)	)	-RRB-
cord-005478-5iu38pr6	1457	33	'	'	''
cord-005478-5iu38pr6	1457	34	,	,	,
cord-005478-5iu38pr6	1457	35	has	have	VBZ
cord-005478-5iu38pr6	1457	36	been	be	VBN
cord-005478-5iu38pr6	1457	37	proven	prove	VBN
cord-005478-5iu38pr6	1457	38	to	to	TO
cord-005478-5iu38pr6	1457	39	predict	predict	VB
cord-005478-5iu38pr6	1457	40	mortality	mortality	NN
cord-005478-5iu38pr6	1457	41	after	after	IN
cord-005478-5iu38pr6	1457	42	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1458	1	(	(	-LRB-
cord-005478-5iu38pr6	1458	2	Lancet	Lancet	NNP
cord-005478-5iu38pr6	1458	3	Haematol	Haematol	NNP
cord-005478-5iu38pr6	1458	4	2017	2017	CD
cord-005478-5iu38pr6	1458	5	;	;	:
cord-005478-5iu38pr6	1459	1	4	4	LS
cord-005478-5iu38pr6	1459	2	:	:	:
cord-005478-5iu38pr6	1459	3	e414	e414	NNP
cord-005478-5iu38pr6	1459	4	)	)	-RRB-
cord-005478-5iu38pr6	1459	5	.	.	.
cord-005478-5iu38pr6	1460	1	The	the	DT
cord-005478-5iu38pr6	1460	2	aim	aim	NN
cord-005478-5iu38pr6	1460	3	of	of	IN
cord-005478-5iu38pr6	1460	4	the	the	DT
cord-005478-5iu38pr6	1460	5	current	current	JJ
cord-005478-5iu38pr6	1460	6	study	study	NN
cord-005478-5iu38pr6	1460	7	was	be	VBD
cord-005478-5iu38pr6	1460	8	to	to	TO
cord-005478-5iu38pr6	1460	9	test	test	VB
cord-005478-5iu38pr6	1460	10	prediction	prediction	NN
cord-005478-5iu38pr6	1460	11	of	of	IN
cord-005478-5iu38pr6	1460	12	SOS	SOS	NNP
cord-005478-5iu38pr6	1460	13	/	/	SYM
cord-005478-5iu38pr6	1460	14	VOD	VOD	NNP
cord-005478-5iu38pr6	1460	15	by	by	IN
cord-005478-5iu38pr6	1460	16	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1460	17	compared	compare	VBN
cord-005478-5iu38pr6	1460	18	with	with	IN
cord-005478-5iu38pr6	1460	19	the	the	DT
cord-005478-5iu38pr6	1460	20	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1460	21	score	score	NN
cord-005478-5iu38pr6	1460	22	in	in	IN
cord-005478-5iu38pr6	1460	23	two	two	CD
cord-005478-5iu38pr6	1460	24	independent	independent	JJ
cord-005478-5iu38pr6	1460	25	European	european	JJ
cord-005478-5iu38pr6	1460	26	cohorts	cohort	NNS
cord-005478-5iu38pr6	1460	27	.	.	.
cord-005478-5iu38pr6	1461	1	Methods	method	NNS
cord-005478-5iu38pr6	1461	2	:	:	:
cord-005478-5iu38pr6	1462	1	SOS	SOS	NNP
cord-005478-5iu38pr6	1462	2	/	/	SYM
cord-005478-5iu38pr6	1462	3	VOD	VOD	NNP
cord-005478-5iu38pr6	1462	4	was	be	VBD
cord-005478-5iu38pr6	1462	5	defined	define	VBN
cord-005478-5iu38pr6	1462	6	according	accord	VBG
cord-005478-5iu38pr6	1462	7	to	to	IN
cord-005478-5iu38pr6	1462	8	the	the	DT
cord-005478-5iu38pr6	1462	9	2016	2016	CD
cord-005478-5iu38pr6	1462	10	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1462	11	criteria	criterion	NNS
cord-005478-5iu38pr6	1462	12	.	.	.
cord-005478-5iu38pr6	1463	1	The	the	DT
cord-005478-5iu38pr6	1463	2	capacity	capacity	NN
cord-005478-5iu38pr6	1463	3	of	of	IN
cord-005478-5iu38pr6	1463	4	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1463	5	and	and	CC
cord-005478-5iu38pr6	1463	6	of	of	IN
cord-005478-5iu38pr6	1463	7	the	the	DT
cord-005478-5iu38pr6	1463	8	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1463	9	score	score	NN
cord-005478-5iu38pr6	1463	10	for	for	IN
cord-005478-5iu38pr6	1463	11	predicting	predict	VBG
cord-005478-5iu38pr6	1463	12	SOS	SOS	NNP
cord-005478-5iu38pr6	1463	13	/	/	SYM
cord-005478-5iu38pr6	1463	14	VOD	VOD	NNP
cord-005478-5iu38pr6	1463	15	was	be	VBD
cord-005478-5iu38pr6	1463	16	tested	test	VBN
cord-005478-5iu38pr6	1463	17	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	1463	18	in	in	IN
cord-005478-5iu38pr6	1463	19	556	556	CD
cord-005478-5iu38pr6	1463	20	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1463	21	adult	adult	NN
cord-005478-5iu38pr6	1463	22	patients	patient	NNS
cord-005478-5iu38pr6	1463	23	undergoing	undergo	VBG
cord-005478-5iu38pr6	1463	24	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1463	25	at	at	IN
cord-005478-5iu38pr6	1463	26	a	a	DT
cord-005478-5iu38pr6	1463	27	single	single	JJ
cord-005478-5iu38pr6	1463	28	institution	institution	NN
cord-005478-5iu38pr6	1463	29	between	between	IN
cord-005478-5iu38pr6	1463	30	2001	2001	CD
cord-005478-5iu38pr6	1463	31	and	and	CC
cord-005478-5iu38pr6	1463	32	2013	2013	CD
cord-005478-5iu38pr6	1464	1	(	(	-LRB-
cord-005478-5iu38pr6	1464	2	training	train	VBG
cord-005478-5iu38pr6	1464	3	cohort	cohort	NN
cord-005478-5iu38pr6	1464	4	)	)	-RRB-
cord-005478-5iu38pr6	1464	5	.	.	.
cord-005478-5iu38pr6	1465	1	The	the	DT
cord-005478-5iu38pr6	1465	2	primary	primary	JJ
cord-005478-5iu38pr6	1465	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	1465	4	was	be	VBD
cord-005478-5iu38pr6	1465	5	prediction	prediction	NN
cord-005478-5iu38pr6	1465	6	of	of	IN
cord-005478-5iu38pr6	1465	7	SOS	SOS	NNP
cord-005478-5iu38pr6	1465	8	/	/	SYM
cord-005478-5iu38pr6	1465	9	VOD	VOD	NNP
cord-005478-5iu38pr6	1465	10	by	by	IN
cord-005478-5iu38pr6	1465	11	the	the	DT
cord-005478-5iu38pr6	1465	12	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1465	13	score	score	NN
cord-005478-5iu38pr6	1465	14	or	or	CC
cord-005478-5iu38pr6	1465	15	by	by	IN
cord-005478-5iu38pr6	1465	16	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1465	17	-	-	HYPH
cord-005478-5iu38pr6	1465	18	d0	d0	NNP
cord-005478-5iu38pr6	1465	19	(	(	-LRB-
cord-005478-5iu38pr6	1465	20	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1465	21	measured	measure	VBD
cord-005478-5iu38pr6	1465	22	at	at	IN
cord-005478-5iu38pr6	1465	23	the	the	DT
cord-005478-5iu38pr6	1465	24	day	day	NN
cord-005478-5iu38pr6	1465	25	of	of	IN
cord-005478-5iu38pr6	1465	26	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1465	27	)	)	-RRB-
cord-005478-5iu38pr6	1465	28	.	.	.
cord-005478-5iu38pr6	1466	1	Results	result	NNS
cord-005478-5iu38pr6	1466	2	were	be	VBD
cord-005478-5iu38pr6	1466	3	validated	validate	VBN
cord-005478-5iu38pr6	1466	4	in	in	IN
cord-005478-5iu38pr6	1466	5	an	an	DT
cord-005478-5iu38pr6	1466	6	independent	independent	JJ
cord-005478-5iu38pr6	1466	7	cohort	cohort	NN
cord-005478-5iu38pr6	1466	8	of	of	IN
cord-005478-5iu38pr6	1466	9	446	446	CD
cord-005478-5iu38pr6	1466	10	adult	adult	NN
cord-005478-5iu38pr6	1466	11	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1466	12	recipients	recipient	NNS
cord-005478-5iu38pr6	1466	13	from	from	IN
cord-005478-5iu38pr6	1466	14	another	another	DT
cord-005478-5iu38pr6	1466	15	single	single	JJ
cord-005478-5iu38pr6	1466	16	institution	institution	NN
cord-005478-5iu38pr6	1466	17	transplanted	transplant	VBN
cord-005478-5iu38pr6	1466	18	between	between	IN
cord-005478-5iu38pr6	1466	19	2013	2013	CD
cord-005478-5iu38pr6	1466	20	and	and	CC
cord-005478-5iu38pr6	1466	21	2015	2015	CD
cord-005478-5iu38pr6	1466	22	.	.	.
cord-005478-5iu38pr6	1467	1	Incidence	incidence	NN
cord-005478-5iu38pr6	1467	2	of	of	IN
cord-005478-5iu38pr6	1467	3	SOS	SOS	NNP
cord-005478-5iu38pr6	1467	4	/	/	SYM
cord-005478-5iu38pr6	1467	5	VOD	VOD	NNP
cord-005478-5iu38pr6	1467	6	was	be	VBD
cord-005478-5iu38pr6	1467	7	assessed	assess	VBN
cord-005478-5iu38pr6	1467	8	by	by	IN
cord-005478-5iu38pr6	1467	9	uni	uni	NN
cord-005478-5iu38pr6	1467	10	-	-	HYPH
cord-005478-5iu38pr6	1467	11	and	and	CC
cord-005478-5iu38pr6	1467	12	multivariable	multivariable	JJ
cord-005478-5iu38pr6	1467	13	Cox	Cox	NNP
cord-005478-5iu38pr6	1467	14	regression	regression	NN
cord-005478-5iu38pr6	1467	15	analyses	analysis	NNS
cord-005478-5iu38pr6	1467	16	using	use	VBG
cord-005478-5iu38pr6	1467	17	age	age	NN
cord-005478-5iu38pr6	1467	18	,	,	,
cord-005478-5iu38pr6	1467	19	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1467	20	and	and	CC
cord-005478-5iu38pr6	1467	21	the	the	DT
cord-005478-5iu38pr6	1467	22	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1467	23	score	score	NN
cord-005478-5iu38pr6	1467	24	as	as	IN
cord-005478-5iu38pr6	1467	25	confounders	confounder	NNS
cord-005478-5iu38pr6	1467	26	.	.	.
cord-005478-5iu38pr6	1468	1	Results	result	NNS
cord-005478-5iu38pr6	1468	2	:	:	:
cord-005478-5iu38pr6	1469	1	SOS	SOS	NNP
cord-005478-5iu38pr6	1469	2	/	/	SYM
cord-005478-5iu38pr6	1469	3	VOD	VOD	NNP
cord-005478-5iu38pr6	1469	4	was	be	VBD
cord-005478-5iu38pr6	1469	5	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1469	6	in	in	IN
cord-005478-5iu38pr6	1469	7	35	35	CD
cord-005478-5iu38pr6	1469	8	patients	patient	NNS
cord-005478-5iu38pr6	1469	9	(	(	-LRB-
cord-005478-5iu38pr6	1469	10	6.3	6.3	CD
cord-005478-5iu38pr6	1469	11	%	%	NN
cord-005478-5iu38pr6	1469	12	,	,	,
cord-005478-5iu38pr6	1469	13	median	median	JJ
cord-005478-5iu38pr6	1469	14	onset	onset	NN
cord-005478-5iu38pr6	1469	15	day	day	NN
cord-005478-5iu38pr6	1469	16	+8	+8	NNS
cord-005478-5iu38pr6	1469	17	)	)	-RRB-
cord-005478-5iu38pr6	1469	18	in	in	IN
cord-005478-5iu38pr6	1469	19	the	the	DT
cord-005478-5iu38pr6	1469	20	training	training	NN
cord-005478-5iu38pr6	1469	21	cohort	cohort	NN
cord-005478-5iu38pr6	1469	22	and	and	CC
cord-005478-5iu38pr6	1469	23	in	in	IN
cord-005478-5iu38pr6	1469	24	45	45	CD
cord-005478-5iu38pr6	1469	25	patients	patient	NNS
cord-005478-5iu38pr6	1469	26	(	(	-LRB-
cord-005478-5iu38pr6	1469	27	10.1	10.1	CD
cord-005478-5iu38pr6	1469	28	%	%	NN
cord-005478-5iu38pr6	1469	29	,	,	,
cord-005478-5iu38pr6	1469	30	median	median	JJ
cord-005478-5iu38pr6	1469	31	onset	onset	NN
cord-005478-5iu38pr6	1469	32	d	d	NN
cord-005478-5iu38pr6	1469	33	+9	+9	NN
cord-005478-5iu38pr6	1469	34	)	)	-RRB-
cord-005478-5iu38pr6	1469	35	in	in	IN
cord-005478-5iu38pr6	1469	36	the	the	DT
cord-005478-5iu38pr6	1469	37	validation	validation	NN
cord-005478-5iu38pr6	1469	38	cohort	cohort	NN
cord-005478-5iu38pr6	1469	39	,	,	,
cord-005478-5iu38pr6	1469	40	respectively	respectively	RB
cord-005478-5iu38pr6	1469	41	.	.	.
cord-005478-5iu38pr6	1470	1	In	in	IN
cord-005478-5iu38pr6	1470	2	the	the	DT
cord-005478-5iu38pr6	1470	3	training	training	NN
cord-005478-5iu38pr6	1470	4	cohort	cohort	NN
cord-005478-5iu38pr6	1470	5	,	,	,
cord-005478-5iu38pr6	1470	6	increasing	increase	VBG
cord-005478-5iu38pr6	1470	7	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1470	8	-	-	HYPH
cord-005478-5iu38pr6	1470	9	d0	d0	NNP
cord-005478-5iu38pr6	1470	10	was	be	VBD
cord-005478-5iu38pr6	1470	11	significantly	significantly	RB
cord-005478-5iu38pr6	1470	12	associated	associate	VBN
cord-005478-5iu38pr6	1470	13	with	with	IN
cord-005478-5iu38pr6	1470	14	SOS	SOS	NNP
cord-005478-5iu38pr6	1470	15	/	/	SYM
cord-005478-5iu38pr6	1470	16	VOD	VOD	NNP
cord-005478-5iu38pr6	1470	17	incidence	incidence	NN
cord-005478-5iu38pr6	1470	18	on	on	IN
cord-005478-5iu38pr6	1470	19	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1470	20	analysis	analysis	NN
cord-005478-5iu38pr6	1470	21	(	(	-LRB-
cord-005478-5iu38pr6	1470	22	HR	hr	NN
cord-005478-5iu38pr6	1470	23	per	per	IN
cord-005478-5iu38pr6	1470	24	log2	log2	NN
cord-005478-5iu38pr6	1470	25	increase	increase	NN
cord-005478-5iu38pr6	1470	26	1.27	1.27	CD
cord-005478-5iu38pr6	1470	27	,	,	,
cord-005478-5iu38pr6	1470	28	95%CI	95%ci	CD
cord-005478-5iu38pr6	1470	29	1	1	CD
cord-005478-5iu38pr6	1470	30	.	.	.
cord-005478-5iu38pr6	1471	1	03	03	CD
cord-005478-5iu38pr6	1471	2	-	-	SYM
cord-005478-5iu38pr6	1471	3	1.57	1.57	CD
cord-005478-5iu38pr6	1471	4	,	,	,
cord-005478-5iu38pr6	1471	5	p=0.023	p=0.023	NNP
cord-005478-5iu38pr6	1471	6	)	)	-RRB-
cord-005478-5iu38pr6	1471	7	.	.	.
cord-005478-5iu38pr6	1472	1	Similarly	similarly	RB
cord-005478-5iu38pr6	1472	2	,	,	,
cord-005478-5iu38pr6	1472	3	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1472	4	-	-	HYPH
cord-005478-5iu38pr6	1472	5	d0	d0	NNP
cord-005478-5iu38pr6	1472	6	predicted	predict	VBD
cord-005478-5iu38pr6	1472	7	the	the	DT
cord-005478-5iu38pr6	1472	8	incidence	incidence	NN
cord-005478-5iu38pr6	1472	9	of	of	IN
cord-005478-5iu38pr6	1472	10	SOS	SOS	NNP
cord-005478-5iu38pr6	1472	11	/	/	SYM
cord-005478-5iu38pr6	1472	12	VOD	VOD	NNP
cord-005478-5iu38pr6	1472	13	in	in	IN
cord-005478-5iu38pr6	1472	14	the	the	DT
cord-005478-5iu38pr6	1472	15	validation	validation	NN
cord-005478-5iu38pr6	1472	16	cohort	cohort	NN
cord-005478-5iu38pr6	1472	17	(	(	-LRB-
cord-005478-5iu38pr6	1472	18	HR	hr	NN
cord-005478-5iu38pr6	1472	19	per	per	IN
cord-005478-5iu38pr6	1472	20	log2	log2	NN
cord-005478-5iu38pr6	1472	21	increase	increase	NN
cord-005478-5iu38pr6	1472	22	1.35	1.35	CD
cord-005478-5iu38pr6	1472	23	,	,	,
cord-005478-5iu38pr6	1472	24	95	95	CD
cord-005478-5iu38pr6	1472	25	%	%	NN
cord-005478-5iu38pr6	1473	1	CI	CI	NNP
cord-005478-5iu38pr6	1473	2	1.14	1.14	CD
cord-005478-5iu38pr6	1473	3	-	-	SYM
cord-005478-5iu38pr6	1473	4	1.59	1.59	CD
cord-005478-5iu38pr6	1473	5	,	,	,
cord-005478-5iu38pr6	1473	6	p	p	NN
cord-005478-5iu38pr6	1473	7	<	<	XX
cord-005478-5iu38pr6	1473	8	0.001	0.001	CD
cord-005478-5iu38pr6	1473	9	)	)	-RRB-
cord-005478-5iu38pr6	1473	10	.	.	.
cord-005478-5iu38pr6	1474	1	Also	also	RB
cord-005478-5iu38pr6	1474	2	,	,	,
cord-005478-5iu38pr6	1474	3	the	the	DT
cord-005478-5iu38pr6	1474	4	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1474	5	score	score	NN
cord-005478-5iu38pr6	1474	6	showed	show	VBD
cord-005478-5iu38pr6	1474	7	an	an	DT
cord-005478-5iu38pr6	1474	8	association	association	NN
cord-005478-5iu38pr6	1474	9	with	with	IN
cord-005478-5iu38pr6	1474	10	SOS	SOS	NNP
cord-005478-5iu38pr6	1474	11	/	/	SYM
cord-005478-5iu38pr6	1474	12	VOD	VOD	NNP
cord-005478-5iu38pr6	1474	13	incidence	incidence	NN
cord-005478-5iu38pr6	1474	14	which	which	WDT
cord-005478-5iu38pr6	1474	15	was	be	VBD
cord-005478-5iu38pr6	1474	16	however	however	RB
cord-005478-5iu38pr6	1474	17	significant	significant	JJ
cord-005478-5iu38pr6	1474	18	only	only	RB
cord-005478-5iu38pr6	1474	19	in	in	IN
cord-005478-5iu38pr6	1474	20	the	the	DT
cord-005478-5iu38pr6	1474	21	training	training	NN
cord-005478-5iu38pr6	1474	22	cohort	cohort	NN
cord-005478-5iu38pr6	1474	23	(	(	-LRB-
cord-005478-5iu38pr6	1474	24	HR	hr	NN
cord-005478-5iu38pr6	1474	25	per	per	IN
cord-005478-5iu38pr6	1474	26	log2	log2	NN
cord-005478-5iu38pr6	1474	27	increase	increase	NN
cord-005478-5iu38pr6	1474	28	1.55	1.55	CD
cord-005478-5iu38pr6	1474	29	,	,	,
cord-005478-5iu38pr6	1474	30	95	95	CD
cord-005478-5iu38pr6	1474	31	%	%	NN
cord-005478-5iu38pr6	1474	32	CI	CI	NNP
cord-005478-5iu38pr6	1474	33	1.09	1.09	CD
cord-005478-5iu38pr6	1474	34	-	-	SYM
cord-005478-5iu38pr6	1474	35	1.62	1.62	CD
cord-005478-5iu38pr6	1474	36	,	,	,
cord-005478-5iu38pr6	1474	37	p=0.016	p=0.016	JJS
cord-005478-5iu38pr6	1474	38	)	)	-RRB-
cord-005478-5iu38pr6	1474	39	but	but	CC
cord-005478-5iu38pr6	1474	40	not	not	RB
cord-005478-5iu38pr6	1474	41	in	in	IN
cord-005478-5iu38pr6	1474	42	the	the	DT
cord-005478-5iu38pr6	1474	43	validation	validation	NN
cord-005478-5iu38pr6	1474	44	cohort	cohort	NN
cord-005478-5iu38pr6	1474	45	,	,	,
cord-005478-5iu38pr6	1474	46	(	(	-LRB-
cord-005478-5iu38pr6	1474	47	HR	hr	NN
cord-005478-5iu38pr6	1474	48	per	per	IN
cord-005478-5iu38pr6	1474	49	log2	log2	NN
cord-005478-5iu38pr6	1474	50	increase	increase	NN
cord-005478-5iu38pr6	1474	51	1.43	1.43	CD
cord-005478-5iu38pr6	1474	52	,	,	,
cord-005478-5iu38pr6	1474	53	95	95	CD
cord-005478-5iu38pr6	1474	54	%	%	NN
cord-005478-5iu38pr6	1475	1	CI	CI	NNP
cord-005478-5iu38pr6	1475	2	0.98	0.98	CD
cord-005478-5iu38pr6	1475	3	-	-	SYM
cord-005478-5iu38pr6	1475	4	2.08	2.08	CD
cord-005478-5iu38pr6	1475	5	,	,	,
cord-005478-5iu38pr6	1475	6	p=0.060	p=0.060	NNPS
cord-005478-5iu38pr6	1475	7	)	)	-RRB-
cord-005478-5iu38pr6	1475	8	.	.	.
cord-005478-5iu38pr6	1476	1	These	these	DT
cord-005478-5iu38pr6	1476	2	results	result	NNS
cord-005478-5iu38pr6	1476	3	are	be	VBP
cord-005478-5iu38pr6	1476	4	visualized	visualize	VBN
cord-005478-5iu38pr6	1476	5	by	by	IN
cord-005478-5iu38pr6	1476	6	comparing	compare	VBG
cord-005478-5iu38pr6	1476	7	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1476	8	-	-	HYPH
cord-005478-5iu38pr6	1476	9	d0	d0	NNP
cord-005478-5iu38pr6	1476	10	and	and	CC
cord-005478-5iu38pr6	1476	11	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1476	12	-	-	HYPH
cord-005478-5iu38pr6	1476	13	VOD	VOD	NNP
cord-005478-5iu38pr6	1476	14	scores	score	NNS
cord-005478-5iu38pr6	1476	15	in	in	IN
cord-005478-5iu38pr6	1476	16	patients	patient	NNS
cord-005478-5iu38pr6	1476	17	grouped	group	VBN
cord-005478-5iu38pr6	1476	18	according	accord	VBG
cord-005478-5iu38pr6	1476	19	to	to	IN
cord-005478-5iu38pr6	1476	20	later	later	RB
cord-005478-5iu38pr6	1476	21	VOD	VOD	NNP
cord-005478-5iu38pr6	1476	22	development	development	NN
cord-005478-5iu38pr6	1476	23	within	within	IN
cord-005478-5iu38pr6	1476	24	the	the	DT
cord-005478-5iu38pr6	1476	25	observation	observation	NN
cord-005478-5iu38pr6	1476	26	period	period	NN
cord-005478-5iu38pr6	1476	27	(	(	-LRB-
cord-005478-5iu38pr6	1476	28	Figure	figure	NN
cord-005478-5iu38pr6	1476	29	1	1	CD
cord-005478-5iu38pr6	1476	30	,	,	,
cord-005478-5iu38pr6	1476	31	Kruskal	Kruskal	NNP
cord-005478-5iu38pr6	1476	32	-	-	HYPH
cord-005478-5iu38pr6	1476	33	Wallis	Wallis	NNP
cord-005478-5iu38pr6	1476	34	tests	test	VBZ
cord-005478-5iu38pr6	1476	35	;	;	:
cord-005478-5iu38pr6	1476	36	1A	1a	LS
cord-005478-5iu38pr6	1476	37	-	-	HYPH
cord-005478-5iu38pr6	1476	38	B	b	NN
cord-005478-5iu38pr6	1476	39	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1476	40	-	-	HYPH
cord-005478-5iu38pr6	1476	41	d0	d0	NNP
cord-005478-5iu38pr6	1476	42	and	and	CC
cord-005478-5iu38pr6	1476	43	1C	1C	NNP
cord-005478-5iu38pr6	1476	44	-	-	HYPH
cord-005478-5iu38pr6	1476	45	D	D	NNP
cord-005478-5iu38pr6	1476	46	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1476	47	risk	risk	NN
cord-005478-5iu38pr6	1476	48	score	score	NN
cord-005478-5iu38pr6	1476	49	)	)	-RRB-
cord-005478-5iu38pr6	1476	50	.	.	.
cord-005478-5iu38pr6	1477	1	The	the	DT
cord-005478-5iu38pr6	1477	2	association	association	NN
cord-005478-5iu38pr6	1477	3	of	of	IN
cord-005478-5iu38pr6	1477	4	EASIXd0	EASIXd0	NNP
cord-005478-5iu38pr6	1477	5	with	with	IN
cord-005478-5iu38pr6	1477	6	VOD	VOD	NNP
cord-005478-5iu38pr6	1477	7	incidence	incidence	NN
cord-005478-5iu38pr6	1477	8	was	be	VBD
cord-005478-5iu38pr6	1477	9	independent	independent	JJ
cord-005478-5iu38pr6	1477	10	from	from	IN
cord-005478-5iu38pr6	1477	11	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1477	12	score	score	NN
cord-005478-5iu38pr6	1477	13	.	.	.
cord-005478-5iu38pr6	1478	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1478	2	:	:	:
cord-005478-5iu38pr6	1478	3	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1478	4	-	-	HYPH
cord-005478-5iu38pr6	1478	5	d0	d0	NNP
cord-005478-5iu38pr6	1478	6	is	be	VBZ
cord-005478-5iu38pr6	1478	7	very	very	RB
cord-005478-5iu38pr6	1478	8	easy	easy	JJ
cord-005478-5iu38pr6	1478	9	to	to	TO
cord-005478-5iu38pr6	1478	10	test	test	VB
cord-005478-5iu38pr6	1478	11	and	and	CC
cord-005478-5iu38pr6	1478	12	predicted	predict	VBD
cord-005478-5iu38pr6	1478	13	SOS	SOS	NNP
cord-005478-5iu38pr6	1478	14	/	/	SYM
cord-005478-5iu38pr6	1478	15	VOD	VOD	NNP
cord-005478-5iu38pr6	1478	16	in	in	IN
cord-005478-5iu38pr6	1478	17	two	two	CD
cord-005478-5iu38pr6	1478	18	separate	separate	JJ
cord-005478-5iu38pr6	1478	19	cohorts	cohort	NNS
cord-005478-5iu38pr6	1478	20	of	of	IN
cord-005478-5iu38pr6	1478	21	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1478	22	recipients	recipient	NNS
cord-005478-5iu38pr6	1478	23	independent	independent	JJ
cord-005478-5iu38pr6	1478	24	of	of	IN
cord-005478-5iu38pr6	1478	25	the	the	DT
cord-005478-5iu38pr6	1478	26	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1478	27	-	-	HYPH
cord-005478-5iu38pr6	1478	28	VOD	VOD	NNP
cord-005478-5iu38pr6	1478	29	score	score	NN
cord-005478-5iu38pr6	1478	30	.	.	.
cord-005478-5iu38pr6	1479	1	Patients	patient	NNS
cord-005478-5iu38pr6	1479	2	with	with	IN
cord-005478-5iu38pr6	1479	3	high	high	JJ
cord-005478-5iu38pr6	1479	4	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1479	5	-	-	HYPH
cord-005478-5iu38pr6	1479	6	d0	d0	NN
cord-005478-5iu38pr6	1479	7	scores	score	NNS
cord-005478-5iu38pr6	1479	8	might	may	MD
cord-005478-5iu38pr6	1479	9	be	be	VB
cord-005478-5iu38pr6	1479	10	candidates	candidate	NNS
cord-005478-5iu38pr6	1479	11	for	for	IN
cord-005478-5iu38pr6	1479	12	clinical	clinical	JJ
cord-005478-5iu38pr6	1479	13	evaluation	evaluation	NN
cord-005478-5iu38pr6	1479	14	of	of	IN
cord-005478-5iu38pr6	1479	15	intensified	intensify	VBN
cord-005478-5iu38pr6	1479	16	strategies	strategy	NNS
cord-005478-5iu38pr6	1479	17	to	to	TO
cord-005478-5iu38pr6	1479	18	prevent	prevent	VB
cord-005478-5iu38pr6	1479	19	SOS	SOS	NNP
cord-005478-5iu38pr6	1479	20	/	/	SYM
cord-005478-5iu38pr6	1479	21	VOD	VOD	NNP
cord-005478-5iu38pr6	1479	22	after	after	IN
cord-005478-5iu38pr6	1479	23	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1479	24	.	.	.
cord-005478-5iu38pr6	1480	1	[	[	-LRB-
cord-005478-5iu38pr6	1480	2	[	[	-LRB-
cord-005478-5iu38pr6	1480	3	O076	O076	NNP
cord-005478-5iu38pr6	1480	4	Image	image	NN
cord-005478-5iu38pr6	1480	5	]	]	-RRB-
cord-005478-5iu38pr6	1480	6	1	1	CD
cord-005478-5iu38pr6	1480	7	.	.	.
cord-005478-5iu38pr6	1481	1	Figure	figure	NN
cord-005478-5iu38pr6	1481	2	1	1	CD
cord-005478-5iu38pr6	1481	3	]	]	-RRB-
cord-005478-5iu38pr6	1482	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1482	2	:	:	:
cord-005478-5iu38pr6	1482	3	The	the	DT
cord-005478-5iu38pr6	1482	4	authors	author	NNS
cord-005478-5iu38pr6	1482	5	thank	thank	VBP
cord-005478-5iu38pr6	1482	6	Jazz	jazz	NN
cord-005478-5iu38pr6	1482	7	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1482	8	for	for	IN
cord-005478-5iu38pr6	1482	9	providing	provide	VBG
cord-005478-5iu38pr6	1482	10	financial	financial	JJ
cord-005478-5iu38pr6	1482	11	support	support	NN
cord-005478-5iu38pr6	1482	12	that	that	WDT
cord-005478-5iu38pr6	1482	13	was	be	VBD
cord-005478-5iu38pr6	1482	14	used	use	VBN
cord-005478-5iu38pr6	1482	15	for	for	IN
cord-005478-5iu38pr6	1482	16	data	datum	NNS
cord-005478-5iu38pr6	1482	17	collection	collection	NN
cord-005478-5iu38pr6	1482	18	.	.	.
cord-005478-5iu38pr6	1483	1	The	the	DT
cord-005478-5iu38pr6	1483	2	company	company	NN
cord-005478-5iu38pr6	1483	3	had	have	VBD
cord-005478-5iu38pr6	1483	4	no	no	DT
cord-005478-5iu38pr6	1483	5	active	active	JJ
cord-005478-5iu38pr6	1483	6	part	part	NN
cord-005478-5iu38pr6	1483	7	in	in	IN
cord-005478-5iu38pr6	1483	8	this	this	DT
cord-005478-5iu38pr6	1483	9	project	project	NN
cord-005478-5iu38pr6	1483	10	,	,	,
cord-005478-5iu38pr6	1483	11	did	do	VBD
cord-005478-5iu38pr6	1483	12	not	not	RB
cord-005478-5iu38pr6	1483	13	have	have	VB
cord-005478-5iu38pr6	1483	14	access	access	NN
cord-005478-5iu38pr6	1483	15	to	to	IN
cord-005478-5iu38pr6	1483	16	data	datum	NNS
cord-005478-5iu38pr6	1483	17	and	and	CC
cord-005478-5iu38pr6	1483	18	was	be	VBD
cord-005478-5iu38pr6	1483	19	not	not	RB
cord-005478-5iu38pr6	1483	20	involved	involve	VBN
cord-005478-5iu38pr6	1483	21	in	in	IN
cord-005478-5iu38pr6	1483	22	analyses	analysis	NNS
cord-005478-5iu38pr6	1483	23	or	or	CC
cord-005478-5iu38pr6	1483	24	writing	writing	NN
cord-005478-5iu38pr6	1483	25	/	/	SYM
cord-005478-5iu38pr6	1483	26	editing	editing	NN
cord-005478-5iu38pr6	1483	27	of	of	IN
cord-005478-5iu38pr6	1483	28	this	this	DT
cord-005478-5iu38pr6	1483	29	abstract	abstract	NN
cord-005478-5iu38pr6	1483	30	.	.	.
cord-005478-5iu38pr6	1484	1	Early	early	JJ
cord-005478-5iu38pr6	1484	2	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1484	3	without	without	IN
cord-005478-5iu38pr6	1484	4	SOS	SOS	NNP
cord-005478-5iu38pr6	1484	5	/	/	SYM
cord-005478-5iu38pr6	1484	6	VOD	VOD	NNP
cord-005478-5iu38pr6	1484	7	-A	-A	NNS
cord-005478-5iu38pr6	1484	8	link	link	NN
cord-005478-5iu38pr6	1484	9	between	between	IN
cord-005478-5iu38pr6	1484	10	endothelial	endothelial	JJ
cord-005478-5iu38pr6	1484	11	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1484	12	and	and	CC
cord-005478-5iu38pr6	1484	13	early	early	JJ
cord-005478-5iu38pr6	1484	14	mortality	mortality	NN
cord-005478-5iu38pr6	1484	15	after	after	IN
cord-005478-5iu38pr6	1484	16	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1484	17	transplantation	transplantation	NN
cord-005478-5iu38pr6	1484	18	Thomas	Thomas	NNP
cord-005478-5iu38pr6	1484	19	Luft	Luft	NNP
cord-005478-5iu38pr6	1484	20	1	1	CD
cord-005478-5iu38pr6	1484	21	,	,	,
cord-005478-5iu38pr6	1484	22	David	David	NNP
cord-005478-5iu38pr6	1484	23	Schult	Schult	NNP
cord-005478-5iu38pr6	1484	24	1	1	CD
cord-005478-5iu38pr6	1484	25	,	,	,
cord-005478-5iu38pr6	1484	26	Joshua	Joshua	NNP
cord-005478-5iu38pr6	1484	27	Majer	Majer	NNP
cord-005478-5iu38pr6	1484	28	-	-	HYPH
cord-005478-5iu38pr6	1484	29	Lauterbach	Lauterbach	NNP
cord-005478-5iu38pr6	1484	30	1	1	CD
cord-005478-5iu38pr6	1484	31	,	,	,
cord-005478-5iu38pr6	1484	32	Sihe	Sihe	NNP
cord-005478-5iu38pr6	1484	33	Jiang	Jiang	NNP
cord-005478-5iu38pr6	1484	34	2	2	CD
cord-005478-5iu38pr6	1484	35	,	,	,
cord-005478-5iu38pr6	1484	36	Aleksandar	Aleksandar	NNP
cord-005478-5iu38pr6	1484	37	Radujkovic	Radujkovic	NNP
cord-005478-5iu38pr6	1484	38	1	1	CD
cord-005478-5iu38pr6	1484	39	,	,	,
cord-005478-5iu38pr6	1484	40	Peter	Peter	NNP
cord-005478-5iu38pr6	1484	41	Dreger	Dreger	NNP
cord-005478-5iu38pr6	1484	42	1	1	CD
cord-005478-5iu38pr6	1485	1	,	,	,
cord-005478-5iu38pr6	1485	2	Olaf	Olaf	NNP
cord-005478-5iu38pr6	1485	3	Penack	Penack	NNP
cord-005478-5iu38pr6	1485	4	2	2	CD
cord-005478-5iu38pr6	1485	5	1	1	CD
cord-005478-5iu38pr6	1485	6	University	University	NNP
cord-005478-5iu38pr6	1485	7	Hospital	Hospital	NNP
cord-005478-5iu38pr6	1485	8	Heidelberg	Heidelberg	NNP
cord-005478-5iu38pr6	1485	9	,	,	,
cord-005478-5iu38pr6	1485	10	Heidelberg	Heidelberg	NNP
cord-005478-5iu38pr6	1485	11	,	,	,
cord-005478-5iu38pr6	1485	12	Germany	Germany	NNP
cord-005478-5iu38pr6	1485	13	,	,	,
cord-005478-5iu38pr6	1485	14	2	2	CD
cord-005478-5iu38pr6	1485	15	Charité	Charité	NNP
cord-005478-5iu38pr6	1485	16	Universitätsmedizin	Universitätsmedizin	NNP
cord-005478-5iu38pr6	1485	17	Berlin	Berlin	NNP
cord-005478-5iu38pr6	1485	18	,	,	,
cord-005478-5iu38pr6	1485	19	Berlin	Berlin	NNP
cord-005478-5iu38pr6	1485	20	,	,	,
cord-005478-5iu38pr6	1485	21	Germany	Germany	NNP
cord-005478-5iu38pr6	1485	22	Background	Background	NNP
cord-005478-5iu38pr6	1485	23	:	:	:
cord-005478-5iu38pr6	1486	1	Endothelial	endothelial	JJ
cord-005478-5iu38pr6	1486	2	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1486	3	is	be	VBZ
cord-005478-5iu38pr6	1486	4	a	a	DT
cord-005478-5iu38pr6	1486	5	risk	risk	NN
cord-005478-5iu38pr6	1486	6	factor	factor	NN
cord-005478-5iu38pr6	1486	7	for	for	IN
cord-005478-5iu38pr6	1486	8	early	early	JJ
cord-005478-5iu38pr6	1486	9	mortality	mortality	NN
cord-005478-5iu38pr6	1486	10	after	after	IN
cord-005478-5iu38pr6	1486	11	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1486	12	stem	stem	NN
cord-005478-5iu38pr6	1486	13	cell	cell	NN
cord-005478-5iu38pr6	1486	14	transplantation	transplantation	NN
cord-005478-5iu38pr6	1486	15	(	(	-LRB-
cord-005478-5iu38pr6	1486	16	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1486	17	)	)	-RRB-
cord-005478-5iu38pr6	1486	18	and	and	CC
cord-005478-5iu38pr6	1486	19	is	be	VBZ
cord-005478-5iu38pr6	1486	20	linked	link	VBN
cord-005478-5iu38pr6	1486	21	to	to	IN
cord-005478-5iu38pr6	1486	22	transplant	transplant	NN
cord-005478-5iu38pr6	1486	23	-	-	HYPH
cord-005478-5iu38pr6	1486	24	associated	associate	VBN
cord-005478-5iu38pr6	1486	25	thrombotic	thrombotic	JJ
cord-005478-5iu38pr6	1486	26	microangiopathy	microangiopathy	NNP
cord-005478-5iu38pr6	1486	27	(	(	-LRB-
cord-005478-5iu38pr6	1486	28	TAM	TAM	NNP
cord-005478-5iu38pr6	1486	29	)	)	-RRB-
cord-005478-5iu38pr6	1486	30	.	.	.
cord-005478-5iu38pr6	1487	1	Similar	similar	JJ
cord-005478-5iu38pr6	1487	2	to	to	IN
cord-005478-5iu38pr6	1487	3	TAM	TAM	NNP
cord-005478-5iu38pr6	1487	4	,	,	,
cord-005478-5iu38pr6	1487	5	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1487	6	of	of	IN
cord-005478-5iu38pr6	1487	7	sinusoidal	sinusoidal	JJ
cord-005478-5iu38pr6	1487	8	obstruction	obstruction	NN
cord-005478-5iu38pr6	1487	9	syndrome	syndrome	NN
cord-005478-5iu38pr6	1487	10	/	/	SYM
cord-005478-5iu38pr6	1487	11	venoocclusive	venoocclusive	JJ
cord-005478-5iu38pr6	1487	12	disease	disease	NN
cord-005478-5iu38pr6	1487	13	(	(	-LRB-
cord-005478-5iu38pr6	1487	14	SOS	SOS	NNP
cord-005478-5iu38pr6	1487	15	/	/	SYM
cord-005478-5iu38pr6	1487	16	VOD	VOD	NNP
cord-005478-5iu38pr6	1487	17	)	)	-RRB-
cord-005478-5iu38pr6	1487	18	is	be	VBZ
cord-005478-5iu38pr6	1487	19	based	base	VBN
cord-005478-5iu38pr6	1487	20	on	on	IN
cord-005478-5iu38pr6	1487	21	consensus	consensus	NN
cord-005478-5iu38pr6	1487	22	criteria	criterion	NNS
cord-005478-5iu38pr6	1487	23	,	,	,
cord-005478-5iu38pr6	1487	24	and	and	CC
cord-005478-5iu38pr6	1487	25	several	several	JJ
cord-005478-5iu38pr6	1487	26	scores	score	NNS
cord-005478-5iu38pr6	1487	27	have	have	VBP
cord-005478-5iu38pr6	1487	28	been	be	VBN
cord-005478-5iu38pr6	1487	29	proposed	propose	VBN
cord-005478-5iu38pr6	1487	30	that	that	WDT
cord-005478-5iu38pr6	1487	31	include	include	VBP
cord-005478-5iu38pr6	1487	32	earlier	early	RBR
cord-005478-5iu38pr6	1487	33	or	or	CC
cord-005478-5iu38pr6	1487	34	later	later	JJ
cord-005478-5iu38pr6	1487	35	stages	stage	NNS
cord-005478-5iu38pr6	1487	36	of	of	IN
cord-005478-5iu38pr6	1487	37	the	the	DT
cord-005478-5iu38pr6	1487	38	diseases	disease	NNS
cord-005478-5iu38pr6	1487	39	.	.	.
cord-005478-5iu38pr6	1488	1	Early	early	JJ
cord-005478-5iu38pr6	1488	2	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1488	3	occurs	occur	VBZ
cord-005478-5iu38pr6	1488	4	frequently	frequently	RB
cord-005478-5iu38pr6	1488	5	after	after	IN
cord-005478-5iu38pr6	1488	6	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1488	7	.	.	.
cord-005478-5iu38pr6	1489	1	The	the	DT
cord-005478-5iu38pr6	1489	2	pathophysiology	pathophysiology	NN
cord-005478-5iu38pr6	1489	3	is	be	VBZ
cord-005478-5iu38pr6	1489	4	often	often	RB
cord-005478-5iu38pr6	1489	5	elusive	elusive	JJ
cord-005478-5iu38pr6	1489	6	,	,	,
cord-005478-5iu38pr6	1489	7	and	and	CC
cord-005478-5iu38pr6	1489	8	only	only	RB
cord-005478-5iu38pr6	1489	9	in	in	IN
cord-005478-5iu38pr6	1489	10	a	a	DT
cord-005478-5iu38pr6	1489	11	subset	subset	NN
cord-005478-5iu38pr6	1489	12	of	of	IN
cord-005478-5iu38pr6	1489	13	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1489	14	recipients	recipient	NNS
cord-005478-5iu38pr6	1489	15	with	with	IN
cord-005478-5iu38pr6	1489	16	hyperbilirubinaemia	hyperbilirubinaemia	NNP
cord-005478-5iu38pr6	1489	17	SOS	SOS	NNP
cord-005478-5iu38pr6	1489	18	/	/	SYM
cord-005478-5iu38pr6	1489	19	VOD	VOD	NNP
cord-005478-5iu38pr6	1489	20	is	be	VBZ
cord-005478-5iu38pr6	1489	21	identified	identify	VBN
cord-005478-5iu38pr6	1489	22	as	as	IN
cord-005478-5iu38pr6	1489	23	the	the	DT
cord-005478-5iu38pr6	1489	24	underlying	underlying	JJ
cord-005478-5iu38pr6	1489	25	mechanism	mechanism	NN
cord-005478-5iu38pr6	1489	26	.	.	.
cord-005478-5iu38pr6	1490	1	The	the	DT
cord-005478-5iu38pr6	1490	2	aim	aim	NN
cord-005478-5iu38pr6	1490	3	of	of	IN
cord-005478-5iu38pr6	1490	4	the	the	DT
cord-005478-5iu38pr6	1490	5	current	current	JJ
cord-005478-5iu38pr6	1490	6	study	study	NN
cord-005478-5iu38pr6	1490	7	was	be	VBD
cord-005478-5iu38pr6	1490	8	to	to	TO
cord-005478-5iu38pr6	1490	9	explore	explore	VB
cord-005478-5iu38pr6	1490	10	clinical	clinical	JJ
cord-005478-5iu38pr6	1490	11	impact	impact	NN
cord-005478-5iu38pr6	1490	12	and	and	CC
cord-005478-5iu38pr6	1490	13	pathophysiological	pathophysiological	JJ
cord-005478-5iu38pr6	1490	14	context	context	NN
cord-005478-5iu38pr6	1490	15	of	of	IN
cord-005478-5iu38pr6	1490	16	early	early	JJ
cord-005478-5iu38pr6	1490	17	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1490	18	without	without	IN
cord-005478-5iu38pr6	1490	19	SOS	SOS	NNP
cord-005478-5iu38pr6	1490	20	/	/	SYM
cord-005478-5iu38pr6	1490	21	VOD	VOD	NNP
cord-005478-5iu38pr6	1490	22	.	.	.
cord-005478-5iu38pr6	1491	1	Methods	method	NNS
cord-005478-5iu38pr6	1491	2	:	:	:
cord-005478-5iu38pr6	1491	3	In	in	IN
cord-005478-5iu38pr6	1491	4	two	two	CD
cord-005478-5iu38pr6	1491	5	independent	independent	JJ
cord-005478-5iu38pr6	1491	6	cohorts	cohort	NNS
cord-005478-5iu38pr6	1491	7	of	of	IN
cord-005478-5iu38pr6	1491	8	864	864	CD
cord-005478-5iu38pr6	1491	9	and	and	CC
cord-005478-5iu38pr6	1491	10	446	446	CD
cord-005478-5iu38pr6	1491	11	patients	patient	NNS
cord-005478-5iu38pr6	1491	12	,	,	,
cord-005478-5iu38pr6	1491	13	serum	serum	NN
cord-005478-5iu38pr6	1491	14	bilirubin	bilirubin	NN
cord-005478-5iu38pr6	1491	15	levels	level	NNS
cord-005478-5iu38pr6	1491	16	before	before	IN
cord-005478-5iu38pr6	1491	17	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1491	18	and	and	CC
cord-005478-5iu38pr6	1491	19	on	on	IN
cord-005478-5iu38pr6	1491	20	days	day	NNS
cord-005478-5iu38pr6	1491	21	0	0	CD
cord-005478-5iu38pr6	1491	22	,	,	,
cord-005478-5iu38pr6	1491	23	3	3	CD
cord-005478-5iu38pr6	1491	24	,	,	,
cord-005478-5iu38pr6	1491	25	5	5	CD
cord-005478-5iu38pr6	1491	26	,	,	,
cord-005478-5iu38pr6	1491	27	7	7	CD
cord-005478-5iu38pr6	1491	28	,	,	,
cord-005478-5iu38pr6	1491	29	14	14	CD
cord-005478-5iu38pr6	1491	30	,	,	,
cord-005478-5iu38pr6	1491	31	21	21	CD
cord-005478-5iu38pr6	1491	32	and	and	CC
cord-005478-5iu38pr6	1491	33	28	28	CD
cord-005478-5iu38pr6	1491	34	were	be	VBD
cord-005478-5iu38pr6	1491	35	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	1491	36	retrieved	retrieve	VBN
cord-005478-5iu38pr6	1491	37	.	.	.
cord-005478-5iu38pr6	1492	1	SOS	SOS	NNP
cord-005478-5iu38pr6	1492	2	/	/	SYM
cord-005478-5iu38pr6	1492	3	VOD	VOD	NNP
cord-005478-5iu38pr6	1492	4	was	be	VBD
cord-005478-5iu38pr6	1492	5	defined	define	VBN
cord-005478-5iu38pr6	1492	6	according	accord	VBG
cord-005478-5iu38pr6	1492	7	to	to	IN
cord-005478-5iu38pr6	1492	8	the	the	DT
cord-005478-5iu38pr6	1492	9	2016	2016	CD
cord-005478-5iu38pr6	1492	10	EBMT	EBMT	NNP
cord-005478-5iu38pr6	1492	11	criteria	criterion	NNS
cord-005478-5iu38pr6	1492	12	.	.	.
cord-005478-5iu38pr6	1493	1	Patients	patient	NNS
cord-005478-5iu38pr6	1493	2	with	with	IN
cord-005478-5iu38pr6	1493	3	at	at	RB
cord-005478-5iu38pr6	1493	4	least	least	RBS
cord-005478-5iu38pr6	1493	5	one	one	CD
cord-005478-5iu38pr6	1493	6	bilirubin	bilirubin	NN
cord-005478-5iu38pr6	1493	7	value	value	NN
cord-005478-5iu38pr6	1493	8	of	of	IN
cord-005478-5iu38pr6	1493	9	>	>	XX
cord-005478-5iu38pr6	1494	1	3mg	3mg	NNP
cord-005478-5iu38pr6	1494	2	/	/	SYM
cord-005478-5iu38pr6	1494	3	dl	dl	NNP
cord-005478-5iu38pr6	1494	4	between	between	IN
cord-005478-5iu38pr6	1494	5	days	day	NNS
cord-005478-5iu38pr6	1494	6	0	0	CD
cord-005478-5iu38pr6	1494	7	-	-	SYM
cord-005478-5iu38pr6	1494	8	28	28	CD
cord-005478-5iu38pr6	1494	9	were	be	VBD
cord-005478-5iu38pr6	1494	10	grouped	group	VBN
cord-005478-5iu38pr6	1494	11	as	as	IN
cord-005478-5iu38pr6	1494	12	"	"	``
cord-005478-5iu38pr6	1494	13	early	early	JJ
cord-005478-5iu38pr6	1494	14	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1494	15	"	"	''
cord-005478-5iu38pr6	1494	16	.	.	.
cord-005478-5iu38pr6	1495	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1495	2	assessed	assess	VBD
cord-005478-5iu38pr6	1495	3	overall	overall	JJ
cord-005478-5iu38pr6	1495	4	survival	survival	NN
cord-005478-5iu38pr6	1495	5	(	(	-LRB-
cord-005478-5iu38pr6	1495	6	OS	OS	NNP
cord-005478-5iu38pr6	1495	7	)	)	-RRB-
cord-005478-5iu38pr6	1495	8	,	,	,
cord-005478-5iu38pr6	1495	9	non	non	JJ
cord-005478-5iu38pr6	1495	10	-	-	JJ
cord-005478-5iu38pr6	1495	11	relapse	relapse	JJ
cord-005478-5iu38pr6	1495	12	mortality	mortality	NN
cord-005478-5iu38pr6	1495	13	(	(	-LRB-
cord-005478-5iu38pr6	1495	14	NRM	NRM	NNP
cord-005478-5iu38pr6	1495	15	)	)	-RRB-
cord-005478-5iu38pr6	1495	16	and	and	CC
cord-005478-5iu38pr6	1495	17	time	time	NN
cord-005478-5iu38pr6	1495	18	to	to	TO
cord-005478-5iu38pr6	1495	19	relapse	relapse	VB
cord-005478-5iu38pr6	1495	20	(	(	-LRB-
cord-005478-5iu38pr6	1495	21	TTR	TTR	NNP
cord-005478-5iu38pr6	1495	22	)	)	-RRB-
cord-005478-5iu38pr6	1495	23	with	with	IN
cord-005478-5iu38pr6	1495	24	and	and	CC
cord-005478-5iu38pr6	1495	25	without	without	IN
cord-005478-5iu38pr6	1495	26	early	early	JJ
cord-005478-5iu38pr6	1495	27	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1495	28	depending	depend	VBG
cord-005478-5iu38pr6	1495	29	on	on	IN
cord-005478-5iu38pr6	1495	30	coincident	coincident	JJ
cord-005478-5iu38pr6	1495	31	SOS	SOS	NNP
cord-005478-5iu38pr6	1495	32	/	/	SYM
cord-005478-5iu38pr6	1495	33	VOD	VOD	NNP
cord-005478-5iu38pr6	1495	34	,	,	,
cord-005478-5iu38pr6	1495	35	TAM	TAM	NNP
cord-005478-5iu38pr6	1495	36	,	,	,
cord-005478-5iu38pr6	1495	37	and	and	CC
cord-005478-5iu38pr6	1495	38	refractory	refractory	JJ
cord-005478-5iu38pr6	1495	39	acute	acute	JJ
cord-005478-5iu38pr6	1495	40	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1495	41	,	,	,
cord-005478-5iu38pr6	1495	42	and	and	CC
cord-005478-5iu38pr6	1495	43	we	-PRON-	PRP
cord-005478-5iu38pr6	1495	44	investigated	investigate	VBD
cord-005478-5iu38pr6	1495	45	the	the	DT
cord-005478-5iu38pr6	1495	46	impact	impact	NN
cord-005478-5iu38pr6	1495	47	of	of	IN
cord-005478-5iu38pr6	1495	48	statin	statin	NN
cord-005478-5iu38pr6	1495	49	-	-	HYPH
cord-005478-5iu38pr6	1495	50	based	base	VBN
cord-005478-5iu38pr6	1495	51	endothelial	endothelial	JJ
cord-005478-5iu38pr6	1495	52	cell	cell	NN
cord-005478-5iu38pr6	1495	53	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1495	54	(	(	-LRB-
cord-005478-5iu38pr6	1495	55	pravastatin	pravastatin	NN
cord-005478-5iu38pr6	1495	56	plus	plus	CC
cord-005478-5iu38pr6	1495	57	ursodeoxycholic	ursodeoxycholic	JJ
cord-005478-5iu38pr6	1495	58	acid	acid	NN
cord-005478-5iu38pr6	1495	59	)	)	-RRB-
cord-005478-5iu38pr6	1495	60	.	.	.
cord-005478-5iu38pr6	1496	1	Serum	serum	NN
cord-005478-5iu38pr6	1496	2	bilirubin	bilirubin	NN
cord-005478-5iu38pr6	1496	3	levels	level	NNS
cord-005478-5iu38pr6	1496	4	were	be	VBD
cord-005478-5iu38pr6	1496	5	correlated	correlate	VBN
cord-005478-5iu38pr6	1496	6	with	with	IN
cord-005478-5iu38pr6	1496	7	the	the	DT
cord-005478-5iu38pr6	1496	8	Endothelial	Endothelial	NNP
cord-005478-5iu38pr6	1496	9	Activation	Activation	NNP
cord-005478-5iu38pr6	1496	10	and	and	CC
cord-005478-5iu38pr6	1496	11	Stress	Stress	NNP
cord-005478-5iu38pr6	1496	12	Index	Index	NNP
cord-005478-5iu38pr6	1496	13	(	(	-LRB-
cord-005478-5iu38pr6	1496	14	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1496	15	,	,	,
cord-005478-5iu38pr6	1496	16	'	'	''
cord-005478-5iu38pr6	1496	17	LDH(U	LDH(U	NNP
cord-005478-5iu38pr6	1496	18	/	/	SYM
cord-005478-5iu38pr6	1496	19	l	l	NN
cord-005478-5iu38pr6	1496	20	)	)	-RRB-
cord-005478-5iu38pr6	1496	21	x	x	NNP
cord-005478-5iu38pr6	1496	22	Creatinine(mg	Creatinine(mg	NNP
cord-005478-5iu38pr6	1496	23	/	/	SYM
cord-005478-5iu38pr6	1496	24	dl	dl	NN
cord-005478-5iu38pr6	1496	25	)	)	-RRB-
cord-005478-5iu38pr6	1497	1	/	/	SYM
cord-005478-5iu38pr6	1497	2	Thrombocytes(10	thrombocytes(10	NN
cord-005478-5iu38pr6	1497	3	9	9	CD
cord-005478-5iu38pr6	1497	4	/l	/l	NN
cord-005478-5iu38pr6	1497	5	)	)	-RRB-
cord-005478-5iu38pr6	1497	6	'	'	''
cord-005478-5iu38pr6	1497	7	)	)	-RRB-
cord-005478-5iu38pr6	1497	8	,	,	,
cord-005478-5iu38pr6	1497	9	measured	measure	VBN
cord-005478-5iu38pr6	1497	10	before	before	IN
cord-005478-5iu38pr6	1497	11	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1498	1	(	(	-LRB-
cord-005478-5iu38pr6	1498	2	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1498	3	-	-	HYPH
cord-005478-5iu38pr6	1498	4	pre	pre	NNP
cord-005478-5iu38pr6	1498	5	)	)	-RRB-
cord-005478-5iu38pr6	1498	6	or	or	CC
cord-005478-5iu38pr6	1498	7	on	on	IN
cord-005478-5iu38pr6	1498	8	the	the	DT
cord-005478-5iu38pr6	1498	9	day	day	NN
cord-005478-5iu38pr6	1498	10	of	of	IN
cord-005478-5iu38pr6	1498	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	1498	12	(	(	-LRB-
cord-005478-5iu38pr6	1498	13	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1498	14	-	-	HYPH
cord-005478-5iu38pr6	1498	15	d0	d0	NNP
cord-005478-5iu38pr6	1498	16	)	)	-RRB-
cord-005478-5iu38pr6	1498	17	.	.	.
cord-005478-5iu38pr6	1499	1	Similarly	similarly	RB
cord-005478-5iu38pr6	1499	2	,	,	,
cord-005478-5iu38pr6	1499	3	bilirubin	bilirubin	NN
cord-005478-5iu38pr6	1499	4	levels	level	NNS
cord-005478-5iu38pr6	1499	5	were	be	VBD
cord-005478-5iu38pr6	1499	6	correlated	correlate	VBN
cord-005478-5iu38pr6	1499	7	with	with	IN
cord-005478-5iu38pr6	1499	8	the	the	DT
cord-005478-5iu38pr6	1499	9	SOS	SOS	NNP
cord-005478-5iu38pr6	1499	10	/	/	SYM
cord-005478-5iu38pr6	1499	11	VOD	VOD	NNP
cord-005478-5iu38pr6	1499	12	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1499	13	clinical	clinical	JJ
cord-005478-5iu38pr6	1499	14	risk	risk	NN
cord-005478-5iu38pr6	1499	15	score	score	NN
cord-005478-5iu38pr6	1499	16	,	,	,
cord-005478-5iu38pr6	1499	17	and	and	CC
cord-005478-5iu38pr6	1499	18	with	with	IN
cord-005478-5iu38pr6	1499	19	serum	serum	NN
cord-005478-5iu38pr6	1499	20	markers	marker	NNS
cord-005478-5iu38pr6	1499	21	of	of	IN
cord-005478-5iu38pr6	1499	22	liver	liver	NN
cord-005478-5iu38pr6	1499	23	damage	damage	NN
cord-005478-5iu38pr6	1499	24	(	(	-LRB-
cord-005478-5iu38pr6	1499	25	alanine	alanine	NN
cord-005478-5iu38pr6	1499	26	transaminase	transaminase	NN
cord-005478-5iu38pr6	1499	27	,	,	,
cord-005478-5iu38pr6	1499	28	ALT	ALT	NNP
cord-005478-5iu38pr6	1499	29	,	,	,
cord-005478-5iu38pr6	1499	30	Gamma	Gamma	NNP
cord-005478-5iu38pr6	1499	31	-	-	HYPH
cord-005478-5iu38pr6	1499	32	glutamyltransferase	glutamyltransferase	NNP
cord-005478-5iu38pr6	1499	33	,	,	,
cord-005478-5iu38pr6	1499	34	GGT	GGT	NNP
cord-005478-5iu38pr6	1499	35	)	)	-RRB-
cord-005478-5iu38pr6	1499	36	and	and	CC
cord-005478-5iu38pr6	1499	37	endothelial	endothelial	JJ
cord-005478-5iu38pr6	1499	38	cell	cell	NN
cord-005478-5iu38pr6	1499	39	distress	distress	NN
cord-005478-5iu38pr6	1499	40	markers	marker	NNS
cord-005478-5iu38pr6	1499	41	(	(	-LRB-
cord-005478-5iu38pr6	1499	42	Angiopoietin-2	Angiopoietin-2	NNP
cord-005478-5iu38pr6	1499	43	)	)	-RRB-
cord-005478-5iu38pr6	1499	44	.	.	.
cord-005478-5iu38pr6	1500	1	Results	result	NNS
cord-005478-5iu38pr6	1500	2	:	:	:
cord-005478-5iu38pr6	1501	1	Early	early	JJ
cord-005478-5iu38pr6	1501	2	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1501	3	was	be	VBD
cord-005478-5iu38pr6	1501	4	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1501	5	in	in	IN
cord-005478-5iu38pr6	1501	6	156	156	CD
cord-005478-5iu38pr6	1501	7	(	(	-LRB-
cord-005478-5iu38pr6	1501	8	18	18	CD
cord-005478-5iu38pr6	1501	9	%	%	NN
cord-005478-5iu38pr6	1501	10	)	)	-RRB-
cord-005478-5iu38pr6	1501	11	and	and	CC
cord-005478-5iu38pr6	1501	12	141	141	CD
cord-005478-5iu38pr6	1501	13	(	(	-LRB-
cord-005478-5iu38pr6	1501	14	32	32	CD
cord-005478-5iu38pr6	1501	15	%	%	NN
cord-005478-5iu38pr6	1501	16	)	)	-RRB-
cord-005478-5iu38pr6	1501	17	patients	patient	NNS
cord-005478-5iu38pr6	1501	18	of	of	IN
cord-005478-5iu38pr6	1501	19	the	the	DT
cord-005478-5iu38pr6	1501	20	training	training	NN
cord-005478-5iu38pr6	1501	21	and	and	CC
cord-005478-5iu38pr6	1501	22	validation	validation	NN
cord-005478-5iu38pr6	1501	23	cohort	cohort	NN
cord-005478-5iu38pr6	1501	24	,	,	,
cord-005478-5iu38pr6	1501	25	and	and	CC
cord-005478-5iu38pr6	1501	26	VOD	VOD	NNP
cord-005478-5iu38pr6	1501	27	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	1501	28	criteria	criterion	NNS
cord-005478-5iu38pr6	1501	29	were	be	VBD
cord-005478-5iu38pr6	1501	30	met	meet	VBN
cord-005478-5iu38pr6	1501	31	by	by	IN
cord-005478-5iu38pr6	1501	32	23	23	CD
cord-005478-5iu38pr6	1501	33	%	%	NN
cord-005478-5iu38pr6	1501	34	and	and	CC
cord-005478-5iu38pr6	1501	35	30	30	CD
cord-005478-5iu38pr6	1501	36	%	%	NN
cord-005478-5iu38pr6	1501	37	of	of	IN
cord-005478-5iu38pr6	1501	38	patients	patient	NNS
cord-005478-5iu38pr6	1501	39	with	with	IN
cord-005478-5iu38pr6	1501	40	early	early	JJ
cord-005478-5iu38pr6	1501	41	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1501	42	,	,	,
cord-005478-5iu38pr6	1501	43	respectively	respectively	RB
cord-005478-5iu38pr6	1501	44	.	.	.
cord-005478-5iu38pr6	1502	1	In	in	IN
cord-005478-5iu38pr6	1502	2	all	all	DT
cord-005478-5iu38pr6	1502	3	patients	patient	NNS
cord-005478-5iu38pr6	1502	4	,	,	,
cord-005478-5iu38pr6	1502	5	early	early	JJ
cord-005478-5iu38pr6	1502	6	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1502	7	was	be	VBD
cord-005478-5iu38pr6	1502	8	associated	associate	VBN
cord-005478-5iu38pr6	1502	9	with	with	IN
cord-005478-5iu38pr6	1502	10	increased	increase	VBN
cord-005478-5iu38pr6	1502	11	NRM	NRM	NNP
cord-005478-5iu38pr6	1502	12	and	and	CC
cord-005478-5iu38pr6	1502	13	OS	OS	NNP
cord-005478-5iu38pr6	1502	14	(	(	-LRB-
cord-005478-5iu38pr6	1502	15	NRM	NRM	NNP
cord-005478-5iu38pr6	1502	16	,	,	,
cord-005478-5iu38pr6	1502	17	training	training	NN
cord-005478-5iu38pr6	1502	18	:	:	:
cord-005478-5iu38pr6	1502	19	HR	HR	NNP
cord-005478-5iu38pr6	1502	20	2.03	2.03	CD
cord-005478-5iu38pr6	1502	21	,	,	,
cord-005478-5iu38pr6	1502	22	95%CI	95%ci	CD
cord-005478-5iu38pr6	1502	23	1.47	1.47	CD
cord-005478-5iu38pr6	1502	24	-	-	SYM
cord-005478-5iu38pr6	1502	25	2.80	2.80	CD
cord-005478-5iu38pr6	1502	26	,	,	,
cord-005478-5iu38pr6	1502	27	p	p	NN
cord-005478-5iu38pr6	1502	28	<	<	XX
cord-005478-5iu38pr6	1502	29	0.001	0.001	CD
cord-005478-5iu38pr6	1502	30	;	;	:
cord-005478-5iu38pr6	1502	31	NRM	NRM	NNP
cord-005478-5iu38pr6	1502	32	validation	validation	NN
cord-005478-5iu38pr6	1502	33	:	:	:
cord-005478-5iu38pr6	1502	34	HR	HR	NNP
cord-005478-5iu38pr6	1502	35	2.12	2.12	CD
cord-005478-5iu38pr6	1502	36	,	,	,
cord-005478-5iu38pr6	1502	37	95%CI	95%ci	CD
cord-005478-5iu38pr6	1502	38	1.48	1.48	CD
cord-005478-5iu38pr6	1502	39	-	-	HYPH
cord-005478-5iu38pr6	1502	40	3.06	3.06	CD
cord-005478-5iu38pr6	1502	41	,	,	,
cord-005478-5iu38pr6	1502	42	p	p	NN
cord-005478-5iu38pr6	1502	43	<	<	XX
cord-005478-5iu38pr6	1502	44	0.001	0.001	CD
cord-005478-5iu38pr6	1502	45	)	)	-RRB-
cord-005478-5iu38pr6	1502	46	.	.	.
cord-005478-5iu38pr6	1503	1	Increased	increase	VBN
cord-005478-5iu38pr6	1503	2	NRM	NRM	NNP
cord-005478-5iu38pr6	1503	3	in	in	IN
cord-005478-5iu38pr6	1503	4	recipients	recipient	NNS
cord-005478-5iu38pr6	1503	5	with	with	IN
cord-005478-5iu38pr6	1503	6	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1503	7	without	without	IN
cord-005478-5iu38pr6	1503	8	SOS	SOS	NNP
cord-005478-5iu38pr6	1503	9	/	/	SYM
cord-005478-5iu38pr6	1503	10	VOD	VOD	NNP
cord-005478-5iu38pr6	1503	11	was	be	VBD
cord-005478-5iu38pr6	1503	12	independent	independent	JJ
cord-005478-5iu38pr6	1503	13	from	from	IN
cord-005478-5iu38pr6	1503	14	TMA	TMA	NNP
cord-005478-5iu38pr6	1503	15	or	or	CC
cord-005478-5iu38pr6	1503	16	refractory	refractory	JJ
cord-005478-5iu38pr6	1503	17	acute	acute	JJ
cord-005478-5iu38pr6	1503	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1504	1	(	(	-LRB-
cord-005478-5iu38pr6	1504	2	Figure	figure	NN
cord-005478-5iu38pr6	1504	3	 	 	_SP
cord-005478-5iu38pr6	1504	4	1	1	CD
cord-005478-5iu38pr6	1504	5	)	)	-RRB-
cord-005478-5iu38pr6	1504	6	.	.	.
cord-005478-5iu38pr6	1505	1	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1505	2	-	-	HYPH
cord-005478-5iu38pr6	1505	3	pre	pre	JJ
cord-005478-5iu38pr6	1505	4	and	and	CC
cord-005478-5iu38pr6	1505	5	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1505	6	-	-	HYPH
cord-005478-5iu38pr6	1505	7	d0	d0	NNP
cord-005478-5iu38pr6	1505	8	correlated	correlate	VBD
cord-005478-5iu38pr6	1505	9	with	with	IN
cord-005478-5iu38pr6	1505	10	day	day	NN
cord-005478-5iu38pr6	1505	11	0	0	CD
cord-005478-5iu38pr6	1505	12	-	-	SYM
cord-005478-5iu38pr6	1505	13	28	28	CD
cord-005478-5iu38pr6	1505	14	bilirubin	bilirubin	NN
cord-005478-5iu38pr6	1505	15	in	in	IN
cord-005478-5iu38pr6	1505	16	both	both	DT
cord-005478-5iu38pr6	1505	17	cohorts	cohort	NNS
cord-005478-5iu38pr6	1505	18	.	.	.
cord-005478-5iu38pr6	1506	1	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1506	2	-	-	HYPH
cord-005478-5iu38pr6	1506	3	pre	pre	JJ
cord-005478-5iu38pr6	1506	4	,	,	,
cord-005478-5iu38pr6	1506	5	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1506	6	-	-	HYPH
cord-005478-5iu38pr6	1506	7	d0	d0	NNP
cord-005478-5iu38pr6	1506	8	and	and	CC
cord-005478-5iu38pr6	1506	9	the	the	DT
cord-005478-5iu38pr6	1506	10	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1506	11	-	-	HYPH
cord-005478-5iu38pr6	1506	12	VOD	VOD	NNP
cord-005478-5iu38pr6	1506	13	score	score	NN
cord-005478-5iu38pr6	1506	14	predicted	predict	VBD
cord-005478-5iu38pr6	1506	15	risk	risk	NN
cord-005478-5iu38pr6	1506	16	of	of	IN
cord-005478-5iu38pr6	1506	17	early	early	JJ
cord-005478-5iu38pr6	1506	18	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1506	19	.	.	.
cord-005478-5iu38pr6	1507	1	However	however	RB
cord-005478-5iu38pr6	1507	2	,	,	,
cord-005478-5iu38pr6	1507	3	only	only	RB
cord-005478-5iu38pr6	1507	4	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1507	5	predicted	predict	VBD
cord-005478-5iu38pr6	1507	6	risk	risk	NN
cord-005478-5iu38pr6	1507	7	of	of	IN
cord-005478-5iu38pr6	1507	8	NRM	NRM	NNP
cord-005478-5iu38pr6	1507	9	in	in	IN
cord-005478-5iu38pr6	1507	10	patients	patient	NNS
cord-005478-5iu38pr6	1507	11	without	without	IN
cord-005478-5iu38pr6	1507	12	SOS	SOS	NNP
cord-005478-5iu38pr6	1507	13	/	/	SYM
cord-005478-5iu38pr6	1507	14	VOD	VOD	NNP
cord-005478-5iu38pr6	1507	15	.	.	.
cord-005478-5iu38pr6	1508	1	Endothelial	endothelial	JJ
cord-005478-5iu38pr6	1508	2	protection	protection	NN
cord-005478-5iu38pr6	1508	3	with	with	IN
cord-005478-5iu38pr6	1508	4	statins	statin	NNS
cord-005478-5iu38pr6	1508	5	and	and	CC
cord-005478-5iu38pr6	1508	6	ursodeoxycholic	ursodeoxycholic	JJ
cord-005478-5iu38pr6	1508	7	acid	acid	NN
cord-005478-5iu38pr6	1508	8	was	be	VBD
cord-005478-5iu38pr6	1508	9	associated	associate	VBN
cord-005478-5iu38pr6	1508	10	with	with	IN
cord-005478-5iu38pr6	1508	11	reduced	reduce	VBN
cord-005478-5iu38pr6	1508	12	incidence	incidence	NN
cord-005478-5iu38pr6	1508	13	of	of	IN
cord-005478-5iu38pr6	1508	14	and	and	CC
cord-005478-5iu38pr6	1508	15	reduced	reduce	VBN
cord-005478-5iu38pr6	1508	16	NRM	NRM	NNP
cord-005478-5iu38pr6	1508	17	after	after	IN
cord-005478-5iu38pr6	1508	18	early	early	JJ
cord-005478-5iu38pr6	1508	19	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1508	20	.	.	.
cord-005478-5iu38pr6	1509	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	1509	2	,	,	,
cord-005478-5iu38pr6	1509	3	pre	pre	JJ
cord-005478-5iu38pr6	1509	4	-	-	NN
cord-005478-5iu38pr6	1509	5	transplant	transplant	NN
cord-005478-5iu38pr6	1509	6	Angiopoietin-2	Angiopoietin-2	NNP
cord-005478-5iu38pr6	1509	7	correlated	correlate	VBD
cord-005478-5iu38pr6	1509	8	with	with	IN
cord-005478-5iu38pr6	1509	9	early	early	JJ
cord-005478-5iu38pr6	1509	10	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1509	11	,	,	,
cord-005478-5iu38pr6	1509	12	whereas	whereas	IN
cord-005478-5iu38pr6	1509	13	ALT	ALT	NNP
cord-005478-5iu38pr6	1509	14	and	and	CC
cord-005478-5iu38pr6	1509	15	GGT	GGT	NNP
cord-005478-5iu38pr6	1509	16	did	do	VBD
cord-005478-5iu38pr6	1509	17	not	not	RB
cord-005478-5iu38pr6	1509	18	.	.	.
cord-005478-5iu38pr6	1510	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1510	2	:	:	:
cord-005478-5iu38pr6	1511	1	Early	early	JJ
cord-005478-5iu38pr6	1511	2	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1511	3	represents	represent	VBZ
cord-005478-5iu38pr6	1511	4	a	a	DT
cord-005478-5iu38pr6	1511	5	novel	novel	JJ
cord-005478-5iu38pr6	1511	6	risk	risk	NN
cord-005478-5iu38pr6	1511	7	factor	factor	NN
cord-005478-5iu38pr6	1511	8	for	for	IN
cord-005478-5iu38pr6	1511	9	NRM	NRM	NNP
cord-005478-5iu38pr6	1511	10	independent	independent	JJ
cord-005478-5iu38pr6	1511	11	of	of	IN
cord-005478-5iu38pr6	1511	12	TMA	TMA	NNP
cord-005478-5iu38pr6	1511	13	and	and	CC
cord-005478-5iu38pr6	1511	14	refractory	refractory	JJ
cord-005478-5iu38pr6	1511	15	acute	acute	JJ
cord-005478-5iu38pr6	1511	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1511	17	,	,	,
cord-005478-5iu38pr6	1511	18	even	even	RB
cord-005478-5iu38pr6	1511	19	in	in	IN
cord-005478-5iu38pr6	1511	20	patients	patient	NNS
cord-005478-5iu38pr6	1511	21	not	not	RB
cord-005478-5iu38pr6	1511	22	meeting	meet	VBG
cord-005478-5iu38pr6	1511	23	the	the	DT
cord-005478-5iu38pr6	1511	24	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	1511	25	criteria	criterion	NNS
cord-005478-5iu38pr6	1511	26	for	for	IN
cord-005478-5iu38pr6	1511	27	VOD	VOD	NNP
cord-005478-5iu38pr6	1511	28	.	.	.
cord-005478-5iu38pr6	1512	1	The	the	DT
cord-005478-5iu38pr6	1512	2	endothelial	endothelial	JJ
cord-005478-5iu38pr6	1512	3	relationship	relationship	NN
cord-005478-5iu38pr6	1512	4	of	of	IN
cord-005478-5iu38pr6	1512	5	this	this	DT
cord-005478-5iu38pr6	1512	6	condition	condition	NN
cord-005478-5iu38pr6	1512	7	is	be	VBZ
cord-005478-5iu38pr6	1512	8	underlined	underline	VBN
cord-005478-5iu38pr6	1512	9	by	by	IN
cord-005478-5iu38pr6	1512	10	the	the	DT
cord-005478-5iu38pr6	1512	11	observation	observation	NN
cord-005478-5iu38pr6	1512	12	that	that	IN
cord-005478-5iu38pr6	1512	13	Angiopoietin-2	Angiopoietin-2	NNP
cord-005478-5iu38pr6	1512	14	,	,	,
cord-005478-5iu38pr6	1512	15	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1512	16	-	-	HYPH
cord-005478-5iu38pr6	1512	17	pre	pre	JJ
cord-005478-5iu38pr6	1512	18	and	and	CC
cord-005478-5iu38pr6	1512	19	EASIX	EASIX	NNP
cord-005478-5iu38pr6	1512	20	-	-	HYPH
cord-005478-5iu38pr6	1512	21	d0	d0	NNP
cord-005478-5iu38pr6	1512	22	but	but	CC
cord-005478-5iu38pr6	1512	23	not	not	RB
cord-005478-5iu38pr6	1512	24	markers	marker	NNS
cord-005478-5iu38pr6	1512	25	of	of	IN
cord-005478-5iu38pr6	1512	26	liver	liver	NN
cord-005478-5iu38pr6	1512	27	damage	damage	NN
cord-005478-5iu38pr6	1512	28	associate	associate	NN
cord-005478-5iu38pr6	1512	29	with	with	IN
cord-005478-5iu38pr6	1512	30	the	the	DT
cord-005478-5iu38pr6	1512	31	incidence	incidence	NN
cord-005478-5iu38pr6	1512	32	of	of	IN
cord-005478-5iu38pr6	1512	33	early	early	JJ
cord-005478-5iu38pr6	1512	34	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1512	35	.	.	.
cord-005478-5iu38pr6	1513	1	Therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1513	2	strategies	strategy	NNS
cord-005478-5iu38pr6	1513	3	aiming	aim	VBG
cord-005478-5iu38pr6	1513	4	at	at	IN
cord-005478-5iu38pr6	1513	5	normalization	normalization	NN
cord-005478-5iu38pr6	1513	6	of	of	IN
cord-005478-5iu38pr6	1513	7	endothelial	endothelial	JJ
cord-005478-5iu38pr6	1513	8	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1513	9	after	after	IN
cord-005478-5iu38pr6	1513	10	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1513	11	are	be	VBP
cord-005478-5iu38pr6	1513	12	attractive	attractive	JJ
cord-005478-5iu38pr6	1513	13	.	.	.
cord-005478-5iu38pr6	1514	1	As	as	IN
cord-005478-5iu38pr6	1514	2	a	a	DT
cord-005478-5iu38pr6	1514	3	first	first	JJ
cord-005478-5iu38pr6	1514	4	example	example	NN
cord-005478-5iu38pr6	1514	5	,	,	,
cord-005478-5iu38pr6	1514	6	our	-PRON-	PRP$
cord-005478-5iu38pr6	1514	7	data	datum	NNS
cord-005478-5iu38pr6	1514	8	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	1514	9	reduced	reduce	VBN
cord-005478-5iu38pr6	1514	10	incidence	incidence	NN
cord-005478-5iu38pr6	1514	11	of	of	IN
cord-005478-5iu38pr6	1514	12	early	early	JJ
cord-005478-5iu38pr6	1514	13	hyperbilirubinaemia	hyperbilirubinaemia	NN
cord-005478-5iu38pr6	1514	14	and	and	CC
cord-005478-5iu38pr6	1514	15	reduced	reduce	VBN
cord-005478-5iu38pr6	1514	16	NRM	NRM	NNP
cord-005478-5iu38pr6	1514	17	thereafter	thereafter	RB
cord-005478-5iu38pr6	1514	18	in	in	IN
cord-005478-5iu38pr6	1514	19	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	1514	20	recipients	recipient	NNS
cord-005478-5iu38pr6	1514	21	prophylactically	prophylactically	RB
cord-005478-5iu38pr6	1514	22	treated	treat	VBN
cord-005478-5iu38pr6	1514	23	with	with	IN
cord-005478-5iu38pr6	1514	24	statins	statin	NNS
cord-005478-5iu38pr6	1514	25	and	and	CC
cord-005478-5iu38pr6	1514	26	ursodeoxycholic	ursodeoxycholic	JJ
cord-005478-5iu38pr6	1514	27	acid	acid	NN
cord-005478-5iu38pr6	1514	28	in	in	IN
cord-005478-5iu38pr6	1514	29	the	the	DT
cord-005478-5iu38pr6	1514	30	peri	peri	NN
cord-005478-5iu38pr6	1514	31	-	-	HYPH
cord-005478-5iu38pr6	1514	32	transplant	transplant	NN
cord-005478-5iu38pr6	1514	33	period	period	NN
cord-005478-5iu38pr6	1514	34	.	.	.
cord-005478-5iu38pr6	1515	1	[	[	-LRB-
cord-005478-5iu38pr6	1515	2	[	[	-LRB-
cord-005478-5iu38pr6	1515	3	O077	o077	NN
cord-005478-5iu38pr6	1515	4	Image	image	NN
cord-005478-5iu38pr6	1515	5	]	]	-RRB-
cord-005478-5iu38pr6	1515	6	1	1	CD
cord-005478-5iu38pr6	1515	7	.	.	.
cord-005478-5iu38pr6	1516	1	Figure	figure	NN
cord-005478-5iu38pr6	1516	2	1	1	CD
cord-005478-5iu38pr6	1516	3	Background	background	NN
cord-005478-5iu38pr6	1516	4	:	:	:
cord-005478-5iu38pr6	1517	1	Accumulating	accumulate	VBG
cord-005478-5iu38pr6	1517	2	evidence	evidence	NN
cord-005478-5iu38pr6	1517	3	has	have	VBZ
cord-005478-5iu38pr6	1517	4	suggested	suggest	VBN
cord-005478-5iu38pr6	1517	5	complement	complement	JJ
cord-005478-5iu38pr6	1517	6	activation	activation	NN
cord-005478-5iu38pr6	1517	7	in	in	IN
cord-005478-5iu38pr6	1517	8	transplant	transplant	NN
cord-005478-5iu38pr6	1517	9	-	-	HYPH
cord-005478-5iu38pr6	1517	10	associated	associate	VBN
cord-005478-5iu38pr6	1517	11	thrombotic	thrombotic	JJ
cord-005478-5iu38pr6	1517	12	microangiopathy	microangiopathy	NNP
cord-005478-5iu38pr6	1517	13	(	(	-LRB-
cord-005478-5iu38pr6	1517	14	TA	TA	NNP
cord-005478-5iu38pr6	1517	15	-	-	HYPH
cord-005478-5iu38pr6	1517	16	TMA	TMA	NNP
cord-005478-5iu38pr6	1517	17	)	)	-RRB-
cord-005478-5iu38pr6	1517	18	,	,	,
cord-005478-5iu38pr6	1517	19	mainly	mainly	RB
cord-005478-5iu38pr6	1517	20	in	in	IN
cord-005478-5iu38pr6	1517	21	the	the	DT
cord-005478-5iu38pr6	1517	22	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1517	23	setting	setting	NN
cord-005478-5iu38pr6	1517	24	.	.	.
cord-005478-5iu38pr6	1518	1	To	to	TO
cord-005478-5iu38pr6	1518	2	further	further	RB
cord-005478-5iu38pr6	1518	3	understand	understand	VB
cord-005478-5iu38pr6	1518	4	its	-PRON-	PRP$
cord-005478-5iu38pr6	1518	5	pathogenesis	pathogenesis	NN
cord-005478-5iu38pr6	1518	6	in	in	IN
cord-005478-5iu38pr6	1518	7	adults	adult	NNS
cord-005478-5iu38pr6	1518	8	,	,	,
cord-005478-5iu38pr6	1518	9	we	-PRON-	PRP
cord-005478-5iu38pr6	1518	10	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	1518	11	that	that	IN
cord-005478-5iu38pr6	1518	12	both	both	DT
cord-005478-5iu38pr6	1518	13	complement	complement	NN
cord-005478-5iu38pr6	1518	14	and	and	CC
cord-005478-5iu38pr6	1518	15	neutrophils	neutrophil	NNS
cord-005478-5iu38pr6	1518	16	are	be	VBP
cord-005478-5iu38pr6	1518	17	activated	activate	VBN
cord-005478-5iu38pr6	1518	18	in	in	IN
cord-005478-5iu38pr6	1518	19	TA	TA	NNP
cord-005478-5iu38pr6	1518	20	-	-	HYPH
cord-005478-5iu38pr6	1518	21	TMA	TMA	NNP
cord-005478-5iu38pr6	1518	22	as	as	IN
cord-005478-5iu38pr6	1518	23	previously	previously	RB
cord-005478-5iu38pr6	1518	24	observed	observe	VBN
cord-005478-5iu38pr6	1518	25	in	in	IN
cord-005478-5iu38pr6	1518	26	distinct	distinct	JJ
cord-005478-5iu38pr6	1518	27	thrombotic	thrombotic	JJ
cord-005478-5iu38pr6	1518	28	disorders	disorder	NNS
cord-005478-5iu38pr6	1518	29	.	.	.
cord-005478-5iu38pr6	1519	1	Methods	method	NNS
cord-005478-5iu38pr6	1519	2	:	:	:
cord-005478-5iu38pr6	1519	3	We	-PRON-	PRP
cord-005478-5iu38pr6	1519	4	enrolled	enrol	VBD
cord-005478-5iu38pr6	1519	5	adult	adult	NN
cord-005478-5iu38pr6	1519	6	TA	TA	NNP
cord-005478-5iu38pr6	1519	7	-	-	HYPH
cord-005478-5iu38pr6	1519	8	TMA	TMA	NNP
cord-005478-5iu38pr6	1519	9	(	(	-LRB-
cord-005478-5iu38pr6	1519	10	International	International	NNP
cord-005478-5iu38pr6	1519	11	Working	Working	NNP
cord-005478-5iu38pr6	1519	12	Group	Group	NNP
cord-005478-5iu38pr6	1519	13	/	/	SYM
cord-005478-5iu38pr6	1519	14	IWG	IWG	NNP
cord-005478-5iu38pr6	1519	15	criteria	criterion	NNS
cord-005478-5iu38pr6	1519	16	)	)	-RRB-
cord-005478-5iu38pr6	1519	17	,	,	,
cord-005478-5iu38pr6	1519	18	acute	acute	JJ
cord-005478-5iu38pr6	1519	19	and/or	and/or	CC
cord-005478-5iu38pr6	1519	20	chronic	chronic	JJ
cord-005478-5iu38pr6	1519	21	graftversus	graftversus	NN
cord-005478-5iu38pr6	1519	22	-	-	HYPH
cord-005478-5iu38pr6	1519	23	host	host	NN
cord-005478-5iu38pr6	1519	24	-	-	HYPH
cord-005478-5iu38pr6	1519	25	disease	disease	NN
cord-005478-5iu38pr6	1519	26	(	(	-LRB-
cord-005478-5iu38pr6	1519	27	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1519	28	)	)	-RRB-
cord-005478-5iu38pr6	1519	29	and	and	CC
cord-005478-5iu38pr6	1519	30	control	control	VB
cord-005478-5iu38pr6	1519	31	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1519	32	cell	cell	NN
cord-005478-5iu38pr6	1519	33	transplantation	transplantation	NN
cord-005478-5iu38pr6	1519	34	(	(	-LRB-
cord-005478-5iu38pr6	1519	35	HCT	HCT	NNP
cord-005478-5iu38pr6	1519	36	)	)	-RRB-
cord-005478-5iu38pr6	1519	37	recipients	recipient	NNS
cord-005478-5iu38pr6	1519	38	in	in	IN
cord-005478-5iu38pr6	1519	39	a	a	DT
cord-005478-5iu38pr6	1519	40	1:1:1	1:1:1	CD
cord-005478-5iu38pr6	1519	41	ratio	ratio	NN
cord-005478-5iu38pr6	1519	42	(	(	-LRB-
cord-005478-5iu38pr6	1519	43	January	January	NNP
cord-005478-5iu38pr6	1519	44	2015-June	2015-june	CD
cord-005478-5iu38pr6	1519	45	2018	2018	CD
cord-005478-5iu38pr6	1519	46	)	)	-RRB-
cord-005478-5iu38pr6	1519	47	.	.	.
cord-005478-5iu38pr6	1520	1	Complement	complement	JJ
cord-005478-5iu38pr6	1520	2	activation	activation	NN
cord-005478-5iu38pr6	1520	3	was	be	VBD
cord-005478-5iu38pr6	1520	4	detected	detect	VBN
cord-005478-5iu38pr6	1520	5	in	in	IN
cord-005478-5iu38pr6	1520	6	patient	patient	NN
cord-005478-5iu38pr6	1520	7	sera	sera	NNP
cord-005478-5iu38pr6	1520	8	and	and	CC
cord-005478-5iu38pr6	1520	9	plasma	plasma	NN
cord-005478-5iu38pr6	1520	10	with	with	IN
cord-005478-5iu38pr6	1520	11	the	the	DT
cord-005478-5iu38pr6	1520	12	modified	modify	VBN
cord-005478-5iu38pr6	1520	13	Ham	Ham	NNP
cord-005478-5iu38pr6	1520	14	test	test	NN
cord-005478-5iu38pr6	1520	15	(	(	-LRB-
cord-005478-5iu38pr6	1520	16	mHam	mHam	NNP
cord-005478-5iu38pr6	1520	17	)	)	-RRB-
cord-005478-5iu38pr6	1520	18	,	,	,
cord-005478-5iu38pr6	1520	19	soluble	soluble	JJ
cord-005478-5iu38pr6	1520	20	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1520	21	and	and	CC
cord-005478-5iu38pr6	1520	22	activated	activate	VBN
cord-005478-5iu38pr6	1520	23	C3	c3	NN
cord-005478-5iu38pr6	1520	24	fragments	fragment	NNS
cord-005478-5iu38pr6	1520	25	;	;	:
cord-005478-5iu38pr6	1520	26	while	while	IN
cord-005478-5iu38pr6	1520	27	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1520	28	activation	activation	NN
cord-005478-5iu38pr6	1520	29	with	with	IN
cord-005478-5iu38pr6	1520	30	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1520	31	extracellular	extracellular	JJ
cord-005478-5iu38pr6	1520	32	traps	trap	NNS
cord-005478-5iu38pr6	1520	33	(	(	-LRB-
cord-005478-5iu38pr6	1520	34	NETs	nets	NN
cord-005478-5iu38pr6	1520	35	)	)	-RRB-
cord-005478-5iu38pr6	1520	36	using	use	VBG
cord-005478-5iu38pr6	1520	37	extracellular	extracellular	JJ
cord-005478-5iu38pr6	1520	38	DNA	dna	NN
cord-005478-5iu38pr6	1520	39	and	and	CC
cord-005478-5iu38pr6	1520	40	myeloperoxidase/	myeloperoxidase/	JJS
cord-005478-5iu38pr6	1520	41	MPO	MPO	NNP
cord-005478-5iu38pr6	1520	42	-	-	HYPH
cord-005478-5iu38pr6	1520	43	DNA	DNA	NNP
cord-005478-5iu38pr6	1520	44	.	.	.
cord-005478-5iu38pr6	1521	1	Results	result	NNS
cord-005478-5iu38pr6	1521	2	:	:	:
cord-005478-5iu38pr6	1522	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1522	2	studied	study	VBD
cord-005478-5iu38pr6	1522	3	10	10	CD
cord-005478-5iu38pr6	1522	4	TA	TA	NNP
cord-005478-5iu38pr6	1522	5	-	-	HYPH
cord-005478-5iu38pr6	1522	6	TMA	TMA	NNP
cord-005478-5iu38pr6	1522	7	,	,	,
cord-005478-5iu38pr6	1522	8	10	10	CD
cord-005478-5iu38pr6	1522	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1522	10	and	and	CC
cord-005478-5iu38pr6	1522	11	10	10	CD
cord-005478-5iu38pr6	1522	12	control	control	NN
cord-005478-5iu38pr6	1522	13	patients	patient	NNS
cord-005478-5iu38pr6	1522	14	.	.	.
cord-005478-5iu38pr6	1523	1	TA	TA	NNP
cord-005478-5iu38pr6	1523	2	-	-	HYPH
cord-005478-5iu38pr6	1523	3	TMA	TMA	NNP
cord-005478-5iu38pr6	1523	4	patients	patient	NNS
cord-005478-5iu38pr6	1523	5	suffered	suffer	VBD
cord-005478-5iu38pr6	1523	6	from	from	IN
cord-005478-5iu38pr6	1523	7	severe	severe	JJ
cord-005478-5iu38pr6	1523	8	acute	acute	JJ
cord-005478-5iu38pr6	1523	9	and/or	and/or	CC
cord-005478-5iu38pr6	1523	10	extensive	extensive	JJ
cord-005478-5iu38pr6	1523	11	chronic	chronic	JJ
cord-005478-5iu38pr6	1523	12	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1523	13	.	.	.
cord-005478-5iu38pr6	1524	1	TA	TA	NNP
cord-005478-5iu38pr6	1524	2	-	-	HYPH
cord-005478-5iu38pr6	1524	3	TMA	TMA	NNP
cord-005478-5iu38pr6	1524	4	presented	present	VBD
cord-005478-5iu38pr6	1524	5	at	at	IN
cord-005478-5iu38pr6	1524	6	median	median	NN
cord-005478-5iu38pr6	1524	7	+109	+109	NNP
cord-005478-5iu38pr6	1524	8	(	(	-LRB-
cord-005478-5iu38pr6	1524	9	9	9	CD
cord-005478-5iu38pr6	1524	10	-	-	SYM
cord-005478-5iu38pr6	1524	11	930	930	CD
cord-005478-5iu38pr6	1524	12	)	)	-RRB-
cord-005478-5iu38pr6	1524	13	day	day	NN
cord-005478-5iu38pr6	1524	14	post	post	NN
cord-005478-5iu38pr6	1524	15	-	-	NN
cord-005478-5iu38pr6	1524	16	transplant	transplant	NN
cord-005478-5iu38pr6	1524	17	.	.	.
cord-005478-5iu38pr6	1525	1	Full	full	JJ
cord-005478-5iu38pr6	1525	2	donor	donor	NN
cord-005478-5iu38pr6	1525	3	chimerism	chimerism	NN
cord-005478-5iu38pr6	1525	4	was	be	VBD
cord-005478-5iu38pr6	1525	5	evident	evident	JJ
cord-005478-5iu38pr6	1525	6	in	in	IN
cord-005478-5iu38pr6	1525	7	all	all	DT
cord-005478-5iu38pr6	1525	8	patients	patient	NNS
cord-005478-5iu38pr6	1525	9	.	.	.
cord-005478-5iu38pr6	1526	1	No	no	DT
cord-005478-5iu38pr6	1526	2	significant	significant	JJ
cord-005478-5iu38pr6	1526	3	difference	difference	NN
cord-005478-5iu38pr6	1526	4	in	in	IN
cord-005478-5iu38pr6	1526	5	transplant	transplant	NN
cord-005478-5iu38pr6	1526	6	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1526	7	was	be	VBD
cord-005478-5iu38pr6	1526	8	observed	observe	VBN
cord-005478-5iu38pr6	1526	9	among	among	IN
cord-005478-5iu38pr6	1526	10	groups	group	NNS
cord-005478-5iu38pr6	1526	11	,	,	,
cord-005478-5iu38pr6	1526	12	except	except	IN
cord-005478-5iu38pr6	1526	13	for	for	IN
cord-005478-5iu38pr6	1526	14	the	the	DT
cord-005478-5iu38pr6	1526	15	significantly	significantly	RB
cord-005478-5iu38pr6	1526	16	lower	low	JJR
cord-005478-5iu38pr6	1526	17	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1526	18	rate	rate	NN
cord-005478-5iu38pr6	1526	19	in	in	IN
cord-005478-5iu38pr6	1526	20	the	the	DT
cord-005478-5iu38pr6	1526	21	control	control	NN
cord-005478-5iu38pr6	1526	22	group	group	NN
cord-005478-5iu38pr6	1526	23	.	.	.
cord-005478-5iu38pr6	1527	1	C5b-9	c5b-9	JJ
cord-005478-5iu38pr6	1527	2	and	and	CC
cord-005478-5iu38pr6	1527	3	mHam	mham	JJ
cord-005478-5iu38pr6	1527	4	levels	level	NNS
cord-005478-5iu38pr6	1527	5	were	be	VBD
cord-005478-5iu38pr6	1527	6	significantly	significantly	RB
cord-005478-5iu38pr6	1527	7	increased	increase	VBN
cord-005478-5iu38pr6	1527	8	in	in	IN
cord-005478-5iu38pr6	1527	9	TA	TA	NNP
cord-005478-5iu38pr6	1527	10	-	-	HYPH
cord-005478-5iu38pr6	1527	11	TMA	TMA	NNP
cord-005478-5iu38pr6	1527	12	compared	compare	VBN
cord-005478-5iu38pr6	1527	13	to	to	IN
cord-005478-5iu38pr6	1527	14	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1527	15	(	(	-LRB-
cord-005478-5iu38pr6	1527	16	p=0.004	p=0.004	NNP
cord-005478-5iu38pr6	1528	1	and	and	CC
cord-005478-5iu38pr6	1528	2	p=0.006	p=0.006	NNS
cord-005478-5iu38pr6	1528	3	,	,	,
cord-005478-5iu38pr6	1528	4	Figure	Figure	NNP
cord-005478-5iu38pr6	1528	5	A	a	NN
cord-005478-5iu38pr6	1528	6	)	)	-RRB-
cord-005478-5iu38pr6	1528	7	and	and	CC
cord-005478-5iu38pr6	1528	8	control	control	NN
cord-005478-5iu38pr6	1528	9	patients	patient	NNS
cord-005478-5iu38pr6	1528	10	(	(	-LRB-
cord-005478-5iu38pr6	1528	11	p=0.001	p=0.001	NNS
cord-005478-5iu38pr6	1528	12	and	and	CC
cord-005478-5iu38pr6	1528	13	p=0.005	p=0.005	NNP
cord-005478-5iu38pr6	1528	14	,	,	,
cord-005478-5iu38pr6	1528	15	Figure	figure	NN
cord-005478-5iu38pr6	1528	16	B	B	NNP
cord-005478-5iu38pr6	1528	17	)	)	-RRB-
cord-005478-5iu38pr6	1528	18	,	,	,
cord-005478-5iu38pr6	1528	19	while	while	IN
cord-005478-5iu38pr6	1528	20	no	no	DT
cord-005478-5iu38pr6	1528	21	significant	significant	JJ
cord-005478-5iu38pr6	1528	22	difference	difference	NN
cord-005478-5iu38pr6	1528	23	was	be	VBD
cord-005478-5iu38pr6	1528	24	observed	observe	VBN
cord-005478-5iu38pr6	1528	25	in	in	IN
cord-005478-5iu38pr6	1528	26	activated	activate	VBN
cord-005478-5iu38pr6	1528	27	plasma	plasma	NN
cord-005478-5iu38pr6	1528	28	C3	c3	NN
cord-005478-5iu38pr6	1528	29	levels	level	NNS
cord-005478-5iu38pr6	1528	30	in	in	IN
cord-005478-5iu38pr6	1528	31	the	the	DT
cord-005478-5iu38pr6	1528	32	plasma	plasma	NN
cord-005478-5iu38pr6	1528	33	.	.	.
cord-005478-5iu38pr6	1529	1	In	in	IN
cord-005478-5iu38pr6	1529	2	the	the	DT
cord-005478-5iu38pr6	1529	3	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1529	4	analysis	analysis	NN
cord-005478-5iu38pr6	1529	5	,	,	,
cord-005478-5iu38pr6	1529	6	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1529	7	levels	level	NNS
cord-005478-5iu38pr6	1529	8	were	be	VBD
cord-005478-5iu38pr6	1529	9	an	an	DT
cord-005478-5iu38pr6	1529	10	independent	independent	JJ
cord-005478-5iu38pr6	1529	11	predictor	predictor	NN
cord-005478-5iu38pr6	1529	12	of	of	IN
cord-005478-5iu38pr6	1529	13	TA	TA	NNP
cord-005478-5iu38pr6	1529	14	-	-	HYPH
cord-005478-5iu38pr6	1529	15	TMA	TMA	NNP
cord-005478-5iu38pr6	1529	16	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1529	17	(	(	-LRB-
cord-005478-5iu38pr6	1529	18	p=0.026	p=0.026	NNP
cord-005478-5iu38pr6	1529	19	)	)	-RRB-
cord-005478-5iu38pr6	1529	20	.	.	.
cord-005478-5iu38pr6	1530	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1530	2	next	next	RB
cord-005478-5iu38pr6	1530	3	sought	seek	VBD
cord-005478-5iu38pr6	1530	4	to	to	TO
cord-005478-5iu38pr6	1530	5	determine	determine	VB
cord-005478-5iu38pr6	1530	6	the	the	DT
cord-005478-5iu38pr6	1530	7	cutoff	cutoff	NN
cord-005478-5iu38pr6	1530	8	value	value	NN
cord-005478-5iu38pr6	1530	9	of	of	IN
cord-005478-5iu38pr6	1530	10	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1530	11	that	that	WDT
cord-005478-5iu38pr6	1530	12	distinguishes	distinguish	VBZ
cord-005478-5iu38pr6	1530	13	TA	TA	NNP
cord-005478-5iu38pr6	1530	14	-	-	HYPH
cord-005478-5iu38pr6	1530	15	TMA	TMA	NNP
cord-005478-5iu38pr6	1530	16	from	from	IN
cord-005478-5iu38pr6	1530	17	other	other	JJ
cord-005478-5iu38pr6	1530	18	HCT	HCT	NNP
cord-005478-5iu38pr6	1530	19	recipients	recipient	NNS
cord-005478-5iu38pr6	1530	20	.	.	.
cord-005478-5iu38pr6	1531	1	In	in	IN
cord-005478-5iu38pr6	1531	2	the	the	DT
cord-005478-5iu38pr6	1531	3	receiver	receiver	NN
cord-005478-5iu38pr6	1531	4	-	-	HYPH
cord-005478-5iu38pr6	1531	5	operating	operate	VBG
cord-005478-5iu38pr6	1531	6	characteristic	characteristic	JJ
cord-005478-5iu38pr6	1531	7	curve	curve	NN
cord-005478-5iu38pr6	1531	8	,	,	,
cord-005478-5iu38pr6	1531	9	we	-PRON-	PRP
cord-005478-5iu38pr6	1531	10	found	find	VBD
cord-005478-5iu38pr6	1531	11	a	a	DT
cord-005478-5iu38pr6	1531	12	significantly	significantly	RB
cord-005478-5iu38pr6	1531	13	high	high	JJ
cord-005478-5iu38pr6	1531	14	area	area	NN
cord-005478-5iu38pr6	1531	15	under	under	IN
cord-005478-5iu38pr6	1531	16	the	the	DT
cord-005478-5iu38pr6	1531	17	curve	curve	NN
cord-005478-5iu38pr6	1531	18	(	(	-LRB-
cord-005478-5iu38pr6	1531	19	0.823	0.823	CD
cord-005478-5iu38pr6	1531	20	,	,	,
cord-005478-5iu38pr6	1531	21	p=003	p=003	NNP
cord-005478-5iu38pr6	1531	22	)	)	-RRB-
cord-005478-5iu38pr6	1531	23	.	.	.
cord-005478-5iu38pr6	1532	1	Values	value	NNS
cord-005478-5iu38pr6	1532	2	higher	high	JJR
cord-005478-5iu38pr6	1532	3	than	than	IN
cord-005478-5iu38pr6	1532	4	321.5	321.5	CD
cord-005478-5iu38pr6	1532	5	ng	ng	NN
cord-005478-5iu38pr6	1532	6	/	/	SYM
cord-005478-5iu38pr6	1532	7	ml	ml	NNS
cord-005478-5iu38pr6	1532	8	conferred	confer	VBD
cord-005478-5iu38pr6	1532	9	a	a	DT
cord-005478-5iu38pr6	1532	10	specificity	specificity	NN
cord-005478-5iu38pr6	1532	11	of	of	IN
cord-005478-5iu38pr6	1532	12	70	70	CD
cord-005478-5iu38pr6	1532	13	%	%	NN
cord-005478-5iu38pr6	1532	14	with	with	IN
cord-005478-5iu38pr6	1532	15	a	a	DT
cord-005478-5iu38pr6	1532	16	very	very	RB
cord-005478-5iu38pr6	1532	17	high	high	JJ
cord-005478-5iu38pr6	1532	18	sensitivity	sensitivity	NN
cord-005478-5iu38pr6	1532	19	of	of	IN
cord-005478-5iu38pr6	1532	20	91.7	91.7	CD
cord-005478-5iu38pr6	1532	21	%	%	NN
cord-005478-5iu38pr6	1532	22	for	for	IN
cord-005478-5iu38pr6	1532	23	TA	TA	NNP
cord-005478-5iu38pr6	1532	24	-	-	HYPH
cord-005478-5iu38pr6	1532	25	TMA	TMA	NNP
cord-005478-5iu38pr6	1532	26	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1532	27	.	.	.
cord-005478-5iu38pr6	1533	1	Regarding	regard	VBG
cord-005478-5iu38pr6	1533	2	NETs	net	NNS
cord-005478-5iu38pr6	1533	3	,	,	,
cord-005478-5iu38pr6	1533	4	both	both	CC
cord-005478-5iu38pr6	1533	5	extracellular	extracellular	JJ
cord-005478-5iu38pr6	1533	6	and	and	CC
cord-005478-5iu38pr6	1533	7	MPO	MPO	NNP
cord-005478-5iu38pr6	1533	8	-	-	HYPH
cord-005478-5iu38pr6	1533	9	DNA	DNA	NNP
cord-005478-5iu38pr6	1533	10	were	be	VBD
cord-005478-5iu38pr6	1533	11	significantly	significantly	RB
cord-005478-5iu38pr6	1533	12	increased	increase	VBN
cord-005478-5iu38pr6	1533	13	in	in	IN
cord-005478-5iu38pr6	1533	14	patients	patient	NNS
cord-005478-5iu38pr6	1533	15	with	with	IN
cord-005478-5iu38pr6	1533	16	TA	TA	NNP
cord-005478-5iu38pr6	1533	17	-	-	HYPH
cord-005478-5iu38pr6	1533	18	TMA	TMA	NNP
cord-005478-5iu38pr6	1533	19	compared	compare	VBN
cord-005478-5iu38pr6	1533	20	to	to	IN
cord-005478-5iu38pr6	1533	21	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1533	22	(	(	-LRB-
cord-005478-5iu38pr6	1533	23	p	p	NN
cord-005478-5iu38pr6	1533	24	<	<	XX
cord-005478-5iu38pr6	1533	25	0.001	0.001	CD
cord-005478-5iu38pr6	1533	26	and	and	CC
cord-005478-5iu38pr6	1533	27	p=0.042	p=0.042	NNP
cord-005478-5iu38pr6	1533	28	,	,	,
cord-005478-5iu38pr6	1533	29	Figure	figure	NN
cord-005478-5iu38pr6	1533	30	C	C	NNP
cord-005478-5iu38pr6	1533	31	)	)	-RRB-
cord-005478-5iu38pr6	1533	32	and	and	CC
cord-005478-5iu38pr6	1533	33	control	control	NN
cord-005478-5iu38pr6	1533	34	patients	patient	NNS
cord-005478-5iu38pr6	1533	35	(	(	-LRB-
cord-005478-5iu38pr6	1533	36	p	p	NN
cord-005478-5iu38pr6	1533	37	<	<	XX
cord-005478-5iu38pr6	1533	38	0.001	0.001	CD
cord-005478-5iu38pr6	1533	39	and	and	CC
cord-005478-5iu38pr6	1533	40	p=0.029	p=0.029	NNP
cord-005478-5iu38pr6	1533	41	,	,	,
cord-005478-5iu38pr6	1533	42	Figure	figure	NN
cord-005478-5iu38pr6	1533	43	D	d	NN
cord-005478-5iu38pr6	1533	44	)	)	-RRB-
cord-005478-5iu38pr6	1533	45	.	.	.
cord-005478-5iu38pr6	1534	1	Interestingly	interestingly	RB
cord-005478-5iu38pr6	1534	2	,	,	,
cord-005478-5iu38pr6	1534	3	increased	increase	VBN
cord-005478-5iu38pr6	1534	4	complement	complement	NN
cord-005478-5iu38pr6	1534	5	activation	activation	NN
cord-005478-5iu38pr6	1534	6	markers	marker	NNS
cord-005478-5iu38pr6	1534	7	(	(	-LRB-
cord-005478-5iu38pr6	1534	8	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1534	9	and	and	CC
cord-005478-5iu38pr6	1534	10	mHam	mHam	NNP
cord-005478-5iu38pr6	1534	11	)	)	-RRB-
cord-005478-5iu38pr6	1534	12	were	be	VBD
cord-005478-5iu38pr6	1534	13	strongly	strongly	RB
cord-005478-5iu38pr6	1534	14	associated	associate	VBN
cord-005478-5iu38pr6	1534	15	with	with	IN
cord-005478-5iu38pr6	1534	16	MPO	MPO	NNP
cord-005478-5iu38pr6	1534	17	-	-	HYPH
cord-005478-5iu38pr6	1534	18	DNA	DNA	NNP
cord-005478-5iu38pr6	1534	19	(	(	-LRB-
cord-005478-5iu38pr6	1534	20	r	r	NN
cord-005478-5iu38pr6	1534	21	2	2	CD
cord-005478-5iu38pr6	1534	22	=	=	SYM
cord-005478-5iu38pr6	1534	23	0.461	0.461	CD
cord-005478-5iu38pr6	1534	24	,	,	,
cord-005478-5iu38pr6	1534	25	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	1534	26	and	and	CC
cord-005478-5iu38pr6	1534	27	r	r	NN
cord-005478-5iu38pr6	1534	28	2	2	CD
cord-005478-5iu38pr6	1534	29	=	=	SYM
cord-005478-5iu38pr6	1534	30	0.403	0.403	CD
cord-005478-5iu38pr6	1534	31	,	,	,
cord-005478-5iu38pr6	1534	32	p=0.018	p=0.018	NNP
cord-005478-5iu38pr6	1534	33	,	,	,
cord-005478-5iu38pr6	1534	34	respectively	respectively	RB
cord-005478-5iu38pr6	1534	35	)	)	-RRB-
cord-005478-5iu38pr6	1534	36	and	and	CC
cord-005478-5iu38pr6	1534	37	extracellular	extracellular	JJ
cord-005478-5iu38pr6	1534	38	DNA	dna	NN
cord-005478-5iu38pr6	1534	39	(	(	-LRB-
cord-005478-5iu38pr6	1534	40	r	r	NN
cord-005478-5iu38pr6	1534	41	2	2	CD
cord-005478-5iu38pr6	1534	42	=	=	SYM
cord-005478-5iu38pr6	1534	43	0.555	0.555	CD
cord-005478-5iu38pr6	1534	44	,	,	,
cord-005478-5iu38pr6	1534	45	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	1534	46	and	and	CC
cord-005478-5iu38pr6	1534	47	r	r	NN
cord-005478-5iu38pr6	1534	48	2	2	CD
cord-005478-5iu38pr6	1534	49	=	=	SYM
cord-005478-5iu38pr6	1534	50	0.502	0.502	CD
cord-005478-5iu38pr6	1534	51	,	,	,
cord-005478-5iu38pr6	1534	52	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	1534	53	,	,	,
cord-005478-5iu38pr6	1534	54	respectively	respectively	RB
cord-005478-5iu38pr6	1534	55	)	)	-RRB-
cord-005478-5iu38pr6	1534	56	.	.	.
cord-005478-5iu38pr6	1535	1	Lastly	lastly	RB
cord-005478-5iu38pr6	1535	2	,	,	,
cord-005478-5iu38pr6	1535	3	we	-PRON-	PRP
cord-005478-5iu38pr6	1535	4	studied	study	VBD
cord-005478-5iu38pr6	1535	5	changes	change	NNS
cord-005478-5iu38pr6	1535	6	of	of	IN
cord-005478-5iu38pr6	1535	7	complement	complement	NN
cord-005478-5iu38pr6	1535	8	and	and	CC
cord-005478-5iu38pr6	1535	9	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1535	10	activation	activation	NN
cord-005478-5iu38pr6	1535	11	in	in	IN
cord-005478-5iu38pr6	1535	12	3	3	CD
cord-005478-5iu38pr6	1535	13	patients	patient	NNS
cord-005478-5iu38pr6	1535	14	that	that	WDT
cord-005478-5iu38pr6	1535	15	received	receive	VBD
cord-005478-5iu38pr6	1535	16	complement	complement	JJ
cord-005478-5iu38pr6	1535	17	inhibition	inhibition	NN
cord-005478-5iu38pr6	1535	18	by	by	IN
cord-005478-5iu38pr6	1535	19	eculizumab	eculizumab	NNS
cord-005478-5iu38pr6	1535	20	.	.	.
cord-005478-5iu38pr6	1536	1	Despite	despite	IN
cord-005478-5iu38pr6	1536	2	delayed	delayed	JJ
cord-005478-5iu38pr6	1536	3	initiation	initiation	NN
cord-005478-5iu38pr6	1536	4	in	in	IN
cord-005478-5iu38pr6	1536	5	the	the	DT
cord-005478-5iu38pr6	1536	6	first	first	JJ
cord-005478-5iu38pr6	1536	7	two	two	CD
cord-005478-5iu38pr6	1536	8	patients	patient	NNS
cord-005478-5iu38pr6	1536	9	(	(	-LRB-
cord-005478-5iu38pr6	1536	10	28	28	CD
cord-005478-5iu38pr6	1536	11	and	and	CC
cord-005478-5iu38pr6	1536	12	18	18	CD
cord-005478-5iu38pr6	1536	13	days	day	NNS
cord-005478-5iu38pr6	1536	14	post	post	NN
cord-005478-5iu38pr6	1536	15	TA	TA	NNP
cord-005478-5iu38pr6	1536	16	-	-	HYPH
cord-005478-5iu38pr6	1536	17	TMA	TMA	NNP
cord-005478-5iu38pr6	1536	18	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1536	19	respectively	respectively	RB
cord-005478-5iu38pr6	1536	20	)	)	-RRB-
cord-005478-5iu38pr6	1536	21	,	,	,
cord-005478-5iu38pr6	1536	22	we	-PRON-	PRP
cord-005478-5iu38pr6	1536	23	observed	observe	VBD
cord-005478-5iu38pr6	1536	24	laboratory	laboratory	NN
cord-005478-5iu38pr6	1536	25	response	response	NN
cord-005478-5iu38pr6	1536	26	including	include	VBG
cord-005478-5iu38pr6	1536	27	evidence	evidence	NN
cord-005478-5iu38pr6	1536	28	of	of	IN
cord-005478-5iu38pr6	1536	29	reduced	reduced	JJ
cord-005478-5iu38pr6	1536	30	hemolysis	hemolysis	NN
cord-005478-5iu38pr6	1536	31	,	,	,
cord-005478-5iu38pr6	1536	32	schistocytosis	schistocytosis	NN
cord-005478-5iu38pr6	1536	33	and	and	CC
cord-005478-5iu38pr6	1536	34	transfusion	transfusion	NN
cord-005478-5iu38pr6	1536	35	needs	need	NNS
cord-005478-5iu38pr6	1536	36	.	.	.
cord-005478-5iu38pr6	1537	1	Both	both	DT
cord-005478-5iu38pr6	1537	2	extracellular	extracellular	JJ
cord-005478-5iu38pr6	1537	3	DNA	dna	NN
cord-005478-5iu38pr6	1537	4	and	and	CC
cord-005478-5iu38pr6	1537	5	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1537	6	levels	level	NNS
cord-005478-5iu38pr6	1537	7	were	be	VBD
cord-005478-5iu38pr6	1537	8	significantly	significantly	RB
cord-005478-5iu38pr6	1537	9	reduced	reduce	VBN
cord-005478-5iu38pr6	1537	10	post	post	NN
cord-005478-5iu38pr6	1537	11	2	2	CD
cord-005478-5iu38pr6	1537	12	doses	dose	NNS
cord-005478-5iu38pr6	1537	13	of	of	IN
cord-005478-5iu38pr6	1537	14	eculizumab	eculizumab	NNS
cord-005478-5iu38pr6	1537	15	(	(	-LRB-
cord-005478-5iu38pr6	1537	16	p	p	NN
cord-005478-5iu38pr6	1537	17	<	<	XX
cord-005478-5iu38pr6	1537	18	0.001	0.001	CD
cord-005478-5iu38pr6	1537	19	)	)	-RRB-
cord-005478-5iu38pr6	1537	20	.	.	.
cord-005478-5iu38pr6	1538	1	However	however	RB
cord-005478-5iu38pr6	1538	2	,	,	,
cord-005478-5iu38pr6	1538	3	all	all	DT
cord-005478-5iu38pr6	1538	4	patients	patient	NNS
cord-005478-5iu38pr6	1538	5	succumbed	succumb	VBD
cord-005478-5iu38pr6	1538	6	to	to	IN
cord-005478-5iu38pr6	1538	7	complications	complication	NNS
cord-005478-5iu38pr6	1538	8	of	of	IN
cord-005478-5iu38pr6	1538	9	endstage	endstage	NN
cord-005478-5iu38pr6	1538	10	renal	renal	JJ
cord-005478-5iu38pr6	1538	11	disease	disease	NN
cord-005478-5iu38pr6	1538	12	and	and	CC
cord-005478-5iu38pr6	1538	13	infections	infection	NNS
cord-005478-5iu38pr6	1538	14	after	after	IN
cord-005478-5iu38pr6	1538	15	a	a	DT
cord-005478-5iu38pr6	1538	16	median	median	NN
cord-005478-5iu38pr6	1538	17	of	of	IN
cord-005478-5iu38pr6	1538	18	3	3	CD
cord-005478-5iu38pr6	1538	19	(	(	-LRB-
cord-005478-5iu38pr6	1538	20	2	2	CD
cord-005478-5iu38pr6	1538	21	)	)	-RRB-
cord-005478-5iu38pr6	1538	22	(	(	-LRB-
cord-005478-5iu38pr6	1538	23	3	3	LS
cord-005478-5iu38pr6	1538	24	)	)	-RRB-
cord-005478-5iu38pr6	1538	25	(	(	-LRB-
cord-005478-5iu38pr6	1538	26	4	4	LS
cord-005478-5iu38pr6	1538	27	)	)	-RRB-
cord-005478-5iu38pr6	1538	28	(	(	-LRB-
cord-005478-5iu38pr6	1538	29	5	5	LS
cord-005478-5iu38pr6	1538	30	)	)	-RRB-
cord-005478-5iu38pr6	1538	31	(	(	-LRB-
cord-005478-5iu38pr6	1538	32	6	6	LS
cord-005478-5iu38pr6	1538	33	)	)	-RRB-
cord-005478-5iu38pr6	1538	34	(	(	-LRB-
cord-005478-5iu38pr6	1538	35	7	7	LS
cord-005478-5iu38pr6	1538	36	)	)	-RRB-
cord-005478-5iu38pr6	1538	37	(	(	-LRB-
cord-005478-5iu38pr6	1538	38	8)	8)	NNP
cord-005478-5iu38pr6	1538	39	doses	dose	NNS
cord-005478-5iu38pr6	1538	40	of	of	IN
cord-005478-5iu38pr6	1538	41	eculizumab	eculizumab	NNS
cord-005478-5iu38pr6	1538	42	.	.	.
cord-005478-5iu38pr6	1539	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1539	2	:	:	:
cord-005478-5iu38pr6	1540	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	1540	2	findings	finding	NNS
cord-005478-5iu38pr6	1540	3	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	1540	4	for	for	IN
cord-005478-5iu38pr6	1540	5	the	the	DT
cord-005478-5iu38pr6	1540	6	first	first	JJ
cord-005478-5iu38pr6	1540	7	time	time	NN
cord-005478-5iu38pr6	1540	8	a	a	DT
cord-005478-5iu38pr6	1540	9	crosstalk	crosstalk	NN
cord-005478-5iu38pr6	1540	10	between	between	IN
cord-005478-5iu38pr6	1540	11	complement	complement	NN
cord-005478-5iu38pr6	1540	12	and	and	CC
cord-005478-5iu38pr6	1540	13	neutrophils	neutrophil	NNS
cord-005478-5iu38pr6	1540	14	in	in	IN
cord-005478-5iu38pr6	1540	15	adult	adult	NN
cord-005478-5iu38pr6	1540	16	TA	TA	NNP
cord-005478-5iu38pr6	1540	17	-	-	HYPH
cord-005478-5iu38pr6	1540	18	TMA	TMA	NNP
cord-005478-5iu38pr6	1540	19	.	.	.
cord-005478-5iu38pr6	1541	1	In	in	IN
cord-005478-5iu38pr6	1541	2	addition	addition	NN
cord-005478-5iu38pr6	1541	3	,	,	,
cord-005478-5iu38pr6	1541	4	we	-PRON-	PRP
cord-005478-5iu38pr6	1541	5	were	be	VBD
cord-005478-5iu38pr6	1541	6	able	able	JJ
cord-005478-5iu38pr6	1541	7	to	to	TO
cord-005478-5iu38pr6	1541	8	set	set	VB
cord-005478-5iu38pr6	1541	9	a	a	DT
cord-005478-5iu38pr6	1541	10	cut	cut	VB
cord-005478-5iu38pr6	1541	11	-	-	HYPH
cord-005478-5iu38pr6	1541	12	off	off	RP
cord-005478-5iu38pr6	1541	13	C5b-9	c5b-9	NN
cord-005478-5iu38pr6	1541	14	value	value	NN
cord-005478-5iu38pr6	1541	15	for	for	IN
cord-005478-5iu38pr6	1541	16	distinguishing	distinguish	VBG
cord-005478-5iu38pr6	1541	17	complement	complement	JJ
cord-005478-5iu38pr6	1541	18	activation	activation	NN
cord-005478-5iu38pr6	1541	19	in	in	IN
cord-005478-5iu38pr6	1541	20	unselected	unselected	JJ
cord-005478-5iu38pr6	1541	21	patients	patient	NNS
cord-005478-5iu38pr6	1541	22	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	1541	23	with	with	IN
cord-005478-5iu38pr6	1541	24	the	the	DT
cord-005478-5iu38pr6	1541	25	IWG	IWG	NNP
cord-005478-5iu38pr6	1541	26	criteria	criterion	NNS
cord-005478-5iu38pr6	1541	27	.	.	.
cord-005478-5iu38pr6	1542	1	Although	although	IN
cord-005478-5iu38pr6	1542	2	complement	complement	JJ
cord-005478-5iu38pr6	1542	3	inhibition	inhibition	NN
cord-005478-5iu38pr6	1542	4	by	by	IN
cord-005478-5iu38pr6	1542	5	eculizumab	eculizumab	NNP
cord-005478-5iu38pr6	1542	6	seems	seem	VBZ
cord-005478-5iu38pr6	1542	7	to	to	TO
cord-005478-5iu38pr6	1542	8	hinder	hinder	VB
cord-005478-5iu38pr6	1542	9	this	this	DT
cord-005478-5iu38pr6	1542	10	pathophysiological	pathophysiological	JJ
cord-005478-5iu38pr6	1542	11	process	process	NN
cord-005478-5iu38pr6	1542	12	,	,	,
cord-005478-5iu38pr6	1542	13	further	further	JJ
cord-005478-5iu38pr6	1542	14	studies	study	NNS
cord-005478-5iu38pr6	1542	15	are	be	VBP
cord-005478-5iu38pr6	1542	16	needed	need	VBN
cord-005478-5iu38pr6	1542	17	to	to	TO
cord-005478-5iu38pr6	1542	18	clarify	clarify	VB
cord-005478-5iu38pr6	1542	19	changes	change	NNS
cord-005478-5iu38pr6	1542	20	and	and	CC
cord-005478-5iu38pr6	1542	21	identify	identify	VB
cord-005478-5iu38pr6	1542	22	optimal	optimal	JJ
cord-005478-5iu38pr6	1542	23	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1542	24	targets	target	NNS
cord-005478-5iu38pr6	1542	25	in	in	IN
cord-005478-5iu38pr6	1542	26	this	this	DT
cord-005478-5iu38pr6	1542	27	complex	complex	JJ
cord-005478-5iu38pr6	1542	28	setting	setting	NN
cord-005478-5iu38pr6	1542	29	.	.	.
cord-005478-5iu38pr6	1543	1	[	[	-LRB-
cord-005478-5iu38pr6	1543	2	[	[	-LRB-
cord-005478-5iu38pr6	1543	3	O078	O078	NNP
cord-005478-5iu38pr6	1543	4	Image	image	NN
cord-005478-5iu38pr6	1543	5	]	]	-RRB-
cord-005478-5iu38pr6	1543	6	1	1	CD
cord-005478-5iu38pr6	1543	7	.	.	.
cord-005478-5iu38pr6	1544	1	Background	background	NN
cord-005478-5iu38pr6	1544	2	:	:	:
cord-005478-5iu38pr6	1545	1	Hepatic	hepatic	JJ
cord-005478-5iu38pr6	1545	2	VOD	VOD	NNP
cord-005478-5iu38pr6	1545	3	/	/	SYM
cord-005478-5iu38pr6	1545	4	SOS	SOS	NNP
cord-005478-5iu38pr6	1545	5	with	with	IN
cord-005478-5iu38pr6	1545	6	multi	multi	JJ
cord-005478-5iu38pr6	1545	7	-	-	JJ
cord-005478-5iu38pr6	1545	8	organ	organ	JJ
cord-005478-5iu38pr6	1545	9	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1545	10	(	(	-LRB-
cord-005478-5iu38pr6	1545	11	MOD	mod	NN
cord-005478-5iu38pr6	1546	1	;	;	:
cord-005478-5iu38pr6	1546	2	typically	typically	RB
cord-005478-5iu38pr6	1546	3	,	,	,
cord-005478-5iu38pr6	1546	4	renal	renal	JJ
cord-005478-5iu38pr6	1546	5	or	or	CC
cord-005478-5iu38pr6	1546	6	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1546	7	)	)	-RRB-
cord-005478-5iu38pr6	1546	8	may	may	MD
cord-005478-5iu38pr6	1546	9	be	be	VB
cord-005478-5iu38pr6	1546	10	associated	associate	VBN
cord-005478-5iu38pr6	1546	11	with	with	IN
cord-005478-5iu38pr6	1546	12	>	>	XX
cord-005478-5iu38pr6	1546	13	80	80	CD
cord-005478-5iu38pr6	1546	14	%	%	NN
cord-005478-5iu38pr6	1546	15	mortality	mortality	NN
cord-005478-5iu38pr6	1546	16	.	.	.
cord-005478-5iu38pr6	1547	1	Defibrotide	Defibrotide	NNP
cord-005478-5iu38pr6	1547	2	is	be	VBZ
cord-005478-5iu38pr6	1547	3	approved	approve	VBN
cord-005478-5iu38pr6	1547	4	for	for	IN
cord-005478-5iu38pr6	1547	5	treating	treat	VBG
cord-005478-5iu38pr6	1547	6	severe	severe	JJ
cord-005478-5iu38pr6	1547	7	hepatic	hepatic	JJ
cord-005478-5iu38pr6	1547	8	VOD	VOD	NNP
cord-005478-5iu38pr6	1547	9	/	/	SYM
cord-005478-5iu38pr6	1547	10	SOS	SOS	NNP
cord-005478-5iu38pr6	1547	11	post	post	JJ
cord-005478-5iu38pr6	1547	12	-	-	JJ
cord-005478-5iu38pr6	1547	13	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1547	14	stem	stem	NN
cord-005478-5iu38pr6	1547	15	cell	cell	NN
cord-005478-5iu38pr6	1547	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	1547	17	(	(	-LRB-
cord-005478-5iu38pr6	1547	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1547	19	)	)	-RRB-
cord-005478-5iu38pr6	1547	20	in	in	IN
cord-005478-5iu38pr6	1547	21	patients	patient	NNS
cord-005478-5iu38pr6	1547	22	aged	age	VBN
cord-005478-5iu38pr6	1547	23	>	>	SYM
cord-005478-5iu38pr6	1547	24	1	1	CD
cord-005478-5iu38pr6	1547	25	month	month	NN
cord-005478-5iu38pr6	1547	26	in	in	IN
cord-005478-5iu38pr6	1547	27	the	the	DT
cord-005478-5iu38pr6	1547	28	European	European	NNP
cord-005478-5iu38pr6	1547	29	Union	Union	NNP
cord-005478-5iu38pr6	1547	30	,	,	,
cord-005478-5iu38pr6	1547	31	and	and	CC
cord-005478-5iu38pr6	1547	32	for	for	IN
cord-005478-5iu38pr6	1547	33	hepatic	hepatic	JJ
cord-005478-5iu38pr6	1547	34	VOD	VOD	NNP
cord-005478-5iu38pr6	1547	35	/	/	SYM
cord-005478-5iu38pr6	1547	36	SOS	SOS	NNP
cord-005478-5iu38pr6	1547	37	with	with	IN
cord-005478-5iu38pr6	1547	38	renal	renal	JJ
cord-005478-5iu38pr6	1547	39	or	or	CC
cord-005478-5iu38pr6	1547	40	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1547	41	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1547	42	post	post	NN
cord-005478-5iu38pr6	1547	43	-	-	JJ
cord-005478-5iu38pr6	1547	44	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1547	45	in	in	IN
cord-005478-5iu38pr6	1547	46	the	the	DT
cord-005478-5iu38pr6	1547	47	United	United	NNP
cord-005478-5iu38pr6	1547	48	States	States	NNP
cord-005478-5iu38pr6	1547	49	and	and	CC
cord-005478-5iu38pr6	1547	50	Canada	Canada	NNP
cord-005478-5iu38pr6	1547	51	.	.	.
cord-005478-5iu38pr6	1548	1	Per	per	IN
cord-005478-5iu38pr6	1548	2	prescribing	prescribe	VBG
cord-005478-5iu38pr6	1548	3	guidelines	guideline	NNS
cord-005478-5iu38pr6	1548	4	,	,	,
cord-005478-5iu38pr6	1548	5	defibrotide	defibrotide	NNP
cord-005478-5iu38pr6	1548	6	25	25	CD
cord-005478-5iu38pr6	1548	7	mg	mg	NNP
cord-005478-5iu38pr6	1548	8	/	/	SYM
cord-005478-5iu38pr6	1548	9	kg	kg	NNP
cord-005478-5iu38pr6	1548	10	/	/	SYM
cord-005478-5iu38pr6	1548	11	day	day	NN
cord-005478-5iu38pr6	1548	12	(	(	-LRB-
cord-005478-5iu38pr6	1548	13	4	4	CD
cord-005478-5iu38pr6	1548	14	divided	divide	VBN
cord-005478-5iu38pr6	1548	15	doses	dose	NNS
cord-005478-5iu38pr6	1548	16	)	)	-RRB-
cord-005478-5iu38pr6	1548	17	is	be	VBZ
cord-005478-5iu38pr6	1548	18	recommended	recommend	VBN
cord-005478-5iu38pr6	1548	19	for	for	IN
cord-005478-5iu38pr6	1548	20	≥21	≥21	NNP
cord-005478-5iu38pr6	1548	21	days	day	NNS
cord-005478-5iu38pr6	1548	22	.	.	.
cord-005478-5iu38pr6	1549	1	This	this	DT
cord-005478-5iu38pr6	1549	2	pooled	pool	VBN
cord-005478-5iu38pr6	1549	3	analysis	analysis	NN
cord-005478-5iu38pr6	1549	4	examined	examine	VBD
cord-005478-5iu38pr6	1549	5	time	time	NN
cord-005478-5iu38pr6	1549	6	to	to	TO
cord-005478-5iu38pr6	1549	7	complete	complete	VB
cord-005478-5iu38pr6	1549	8	response	response	NN
cord-005478-5iu38pr6	1549	9	(	(	-LRB-
cord-005478-5iu38pr6	1549	10	CR	cr	NN
cord-005478-5iu38pr6	1549	11	)	)	-RRB-
cord-005478-5iu38pr6	1549	12	of	of	IN
cord-005478-5iu38pr6	1549	13	VOD/	VOD/	NNP
cord-005478-5iu38pr6	1549	14	SOS	SOS	NNP
cord-005478-5iu38pr6	1549	15	and	and	CC
cord-005478-5iu38pr6	1549	16	MOD	mod	NN
cord-005478-5iu38pr6	1549	17	symptoms	symptom	NNS
cord-005478-5iu38pr6	1549	18	relative	relative	JJ
cord-005478-5iu38pr6	1549	19	to	to	IN
cord-005478-5iu38pr6	1549	20	day	day	NN
cord-005478-5iu38pr6	1549	21	of	of	IN
cord-005478-5iu38pr6	1549	22	defibrotide	defibrotide	NN
cord-005478-5iu38pr6	1549	23	initiation	initiation	NN
cord-005478-5iu38pr6	1549	24	in	in	IN
cord-005478-5iu38pr6	1549	25	patients	patient	NNS
cord-005478-5iu38pr6	1549	26	who	who	WP
cord-005478-5iu38pr6	1549	27	received	receive	VBD
cord-005478-5iu38pr6	1549	28	defibrotide	defibrotide	NNP
cord-005478-5iu38pr6	1549	29	25	25	CD
cord-005478-5iu38pr6	1549	30	mg	mg	NNP
cord-005478-5iu38pr6	1549	31	/	/	SYM
cord-005478-5iu38pr6	1549	32	kg	kg	NNP
cord-005478-5iu38pr6	1549	33	/	/	SYM
cord-005478-5iu38pr6	1549	34	day	day	NN
cord-005478-5iu38pr6	1549	35	.	.	.
cord-005478-5iu38pr6	1550	1	Methods	method	NNS
cord-005478-5iu38pr6	1550	2	:	:	:
cord-005478-5iu38pr6	1550	3	Time	time	NN
cord-005478-5iu38pr6	1550	4	to	to	IN
cord-005478-5iu38pr6	1550	5	CR	CR	NNP
cord-005478-5iu38pr6	1550	6	and	and	CC
cord-005478-5iu38pr6	1550	7	safety	safety	NN
cord-005478-5iu38pr6	1550	8	data	datum	NNS
cord-005478-5iu38pr6	1550	9	were	be	VBD
cord-005478-5iu38pr6	1550	10	pooled	pool	VBN
cord-005478-5iu38pr6	1550	11	from	from	IN
cord-005478-5iu38pr6	1550	12	2	2	CD
cord-005478-5iu38pr6	1550	13	studies	study	NNS
cord-005478-5iu38pr6	1550	14	that	that	WDT
cord-005478-5iu38pr6	1550	15	included	include	VBD
cord-005478-5iu38pr6	1550	16	patients	patient	NNS
cord-005478-5iu38pr6	1550	17	with	with	IN
cord-005478-5iu38pr6	1550	18	VOD	VOD	NNP
cord-005478-5iu38pr6	1550	19	/	/	SYM
cord-005478-5iu38pr6	1550	20	SOS	SOS	NNP
cord-005478-5iu38pr6	1550	21	and	and	CC
cord-005478-5iu38pr6	1550	22	MOD	MOD	NNP
cord-005478-5iu38pr6	1550	23	post	post	JJ
cord-005478-5iu38pr6	1550	24	-	-	JJ
cord-005478-5iu38pr6	1550	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1550	26	who	who	WP
cord-005478-5iu38pr6	1550	27	were	be	VBD
cord-005478-5iu38pr6	1550	28	treated	treat	VBN
cord-005478-5iu38pr6	1550	29	with	with	IN
cord-005478-5iu38pr6	1550	30	defibrotide	defibrotide	NNP
cord-005478-5iu38pr6	1550	31	:	:	:
cord-005478-5iu38pr6	1550	32	a	a	DT
cord-005478-5iu38pr6	1550	33	phase	phase	NN
cord-005478-5iu38pr6	1550	34	3	3	CD
cord-005478-5iu38pr6	1550	35	trial	trial	NN
cord-005478-5iu38pr6	1550	36	(	(	-LRB-
cord-005478-5iu38pr6	1550	37	n=102	n=102	NNP
cord-005478-5iu38pr6	1550	38	)	)	-RRB-
cord-005478-5iu38pr6	1550	39	and	and	CC
cord-005478-5iu38pr6	1550	40	a	a	DT
cord-005478-5iu38pr6	1550	41	phase	phase	NN
cord-005478-5iu38pr6	1550	42	2	2	CD
cord-005478-5iu38pr6	1550	43	,	,	,
cord-005478-5iu38pr6	1550	44	randomized	randomized	JJ
cord-005478-5iu38pr6	1550	45	dose	dose	NN
cord-005478-5iu38pr6	1550	46	-	-	HYPH
cord-005478-5iu38pr6	1550	47	finding	find	VBG
cord-005478-5iu38pr6	1550	48	trial	trial	NN
cord-005478-5iu38pr6	1550	49	(	(	-LRB-
cord-005478-5iu38pr6	1550	50	n=74	n=74	NNP
cord-005478-5iu38pr6	1550	51	receiving	receive	VBG
cord-005478-5iu38pr6	1550	52	25	25	CD
cord-005478-5iu38pr6	1550	53	mg	mg	NNP
cord-005478-5iu38pr6	1550	54	/	/	SYM
cord-005478-5iu38pr6	1550	55	kg	kg	NNP
cord-005478-5iu38pr6	1550	56	/	/	SYM
cord-005478-5iu38pr6	1550	57	day	day	NN
cord-005478-5iu38pr6	1550	58	)	)	-RRB-
cord-005478-5iu38pr6	1550	59	.	.	.
cord-005478-5iu38pr6	1551	1	Duration	duration	NN
cord-005478-5iu38pr6	1551	2	of	of	IN
cord-005478-5iu38pr6	1551	3	therapy	therapy	NN
cord-005478-5iu38pr6	1551	4	in	in	IN
cord-005478-5iu38pr6	1551	5	patients	patient	NNS
cord-005478-5iu38pr6	1551	6	who	who	WP
cord-005478-5iu38pr6	1551	7	discontinued	discontinue	VBD
cord-005478-5iu38pr6	1551	8	due	due	IN
cord-005478-5iu38pr6	1551	9	to	to	IN
cord-005478-5iu38pr6	1551	10	CR	CR	NNP
cord-005478-5iu38pr6	1551	11	in	in	IN
cord-005478-5iu38pr6	1551	12	an	an	DT
cord-005478-5iu38pr6	1551	13	expanded	expand	VBN
cord-005478-5iu38pr6	1551	14	-	-	HYPH
cord-005478-5iu38pr6	1551	15	access	access	NN
cord-005478-5iu38pr6	1551	16	program	program	NN
cord-005478-5iu38pr6	1551	17	(	(	-LRB-
cord-005478-5iu38pr6	1551	18	T	T	NNP
cord-005478-5iu38pr6	1551	19	-	-	HYPH
cord-005478-5iu38pr6	1551	20	IND	IND	NNP
cord-005478-5iu38pr6	1551	21	)	)	-RRB-
cord-005478-5iu38pr6	1551	22	in	in	IN
cord-005478-5iu38pr6	1551	23	VOD	VOD	NNP
cord-005478-5iu38pr6	1551	24	/	/	SYM
cord-005478-5iu38pr6	1551	25	SOS	SOS	NNP
cord-005478-5iu38pr6	1551	26	patients	patient	NNS
cord-005478-5iu38pr6	1551	27	with	with	IN
cord-005478-5iu38pr6	1551	28	and	and	CC
cord-005478-5iu38pr6	1551	29	without	without	IN
cord-005478-5iu38pr6	1551	30	MOD	mod	NN
cord-005478-5iu38pr6	1551	31	post	post	JJ
cord-005478-5iu38pr6	1551	32	-	-	JJ
cord-005478-5iu38pr6	1551	33	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1551	34	(	(	-LRB-
cord-005478-5iu38pr6	1551	35	n=1000	n=1000	NFP
cord-005478-5iu38pr6	1551	36	)	)	-RRB-
cord-005478-5iu38pr6	1551	37	was	be	VBD
cord-005478-5iu38pr6	1551	38	analyzed	analyze	VBN
cord-005478-5iu38pr6	1551	39	separately	separately	RB
cord-005478-5iu38pr6	1551	40	due	due	JJ
cord-005478-5iu38pr6	1551	41	to	to	IN
cord-005478-5iu38pr6	1551	42	differences	difference	NNS
cord-005478-5iu38pr6	1551	43	in	in	IN
cord-005478-5iu38pr6	1551	44	the	the	DT
cord-005478-5iu38pr6	1551	45	patient	patient	JJ
cord-005478-5iu38pr6	1551	46	population	population	NN
cord-005478-5iu38pr6	1551	47	and	and	CC
cord-005478-5iu38pr6	1551	48	data	datum	NNS
cord-005478-5iu38pr6	1551	49	monitoring	monitoring	NN
cord-005478-5iu38pr6	1551	50	protocol	protocol	NN
cord-005478-5iu38pr6	1551	51	(	(	-LRB-
cord-005478-5iu38pr6	1551	52	eg	eg	RB
cord-005478-5iu38pr6	1551	53	,	,	,
cord-005478-5iu38pr6	1551	54	CR	CR	NNP
cord-005478-5iu38pr6	1551	55	data	datum	NNS
cord-005478-5iu38pr6	1551	56	by	by	IN
cord-005478-5iu38pr6	1551	57	day	day	NN
cord-005478-5iu38pr6	1551	58	were	be	VBD
cord-005478-5iu38pr6	1551	59	not	not	RB
cord-005478-5iu38pr6	1551	60	collected	collect	VBN
cord-005478-5iu38pr6	1551	61	)	)	-RRB-
cord-005478-5iu38pr6	1551	62	.	.	.
cord-005478-5iu38pr6	1552	1	VOD	VOD	NNP
cord-005478-5iu38pr6	1552	2	/	/	SYM
cord-005478-5iu38pr6	1552	3	SOS	SOS	NNP
cord-005478-5iu38pr6	1552	4	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1552	5	was	be	VBD
cord-005478-5iu38pr6	1552	6	defined	define	VBN
cord-005478-5iu38pr6	1552	7	by	by	IN
cord-005478-5iu38pr6	1552	8	Baltimore	Baltimore	NNP
cord-005478-5iu38pr6	1552	9	criteria	criterion	NNS
cord-005478-5iu38pr6	1552	10	/	/	SYM
cord-005478-5iu38pr6	1552	11	biopsy	biopsy	NN
cord-005478-5iu38pr6	1552	12	for	for	IN
cord-005478-5iu38pr6	1552	13	the	the	DT
cord-005478-5iu38pr6	1552	14	phase	phase	NN
cord-005478-5iu38pr6	1552	15	2	2	CD
cord-005478-5iu38pr6	1552	16	and	and	CC
cord-005478-5iu38pr6	1552	17	3	3	CD
cord-005478-5iu38pr6	1552	18	studies	study	NNS
cord-005478-5iu38pr6	1552	19	;	;	:
cord-005478-5iu38pr6	1552	20	in	in	IN
cord-005478-5iu38pr6	1552	21	the	the	DT
cord-005478-5iu38pr6	1552	22	T	T	NNP
cord-005478-5iu38pr6	1552	23	-	-	HYPH
cord-005478-5iu38pr6	1552	24	IND	IND	NNP
cord-005478-5iu38pr6	1552	25	,	,	,
cord-005478-5iu38pr6	1552	26	modified	modify	VBN
cord-005478-5iu38pr6	1552	27	Seattle	Seattle	NNP
cord-005478-5iu38pr6	1552	28	criteria	criterion	NNS
cord-005478-5iu38pr6	1552	29	also	also	RB
cord-005478-5iu38pr6	1552	30	was	be	VBD
cord-005478-5iu38pr6	1552	31	permitted	permit	VBN
cord-005478-5iu38pr6	1552	32	.	.	.
cord-005478-5iu38pr6	1553	1	Minimum	minimum	JJ
cord-005478-5iu38pr6	1553	2	recommended	recommend	VBN
cord-005478-5iu38pr6	1553	3	treatment	treatment	NN
cord-005478-5iu38pr6	1553	4	duration	duration	NN
cord-005478-5iu38pr6	1553	5	was	be	VBD
cord-005478-5iu38pr6	1553	6	≥14	≥14	JJ
cord-005478-5iu38pr6	1553	7	days	day	NNS
cord-005478-5iu38pr6	1553	8	(	(	-LRB-
cord-005478-5iu38pr6	1553	9	phase	phase	NN
cord-005478-5iu38pr6	1553	10	2	2	CD
cord-005478-5iu38pr6	1553	11	)	)	-RRB-
cord-005478-5iu38pr6	1553	12	or	or	CC
cord-005478-5iu38pr6	1553	13	≥21	≥21	NNP
cord-005478-5iu38pr6	1553	14	days	day	NNS
cord-005478-5iu38pr6	1553	15	(	(	-LRB-
cord-005478-5iu38pr6	1553	16	phase	phase	NN
cord-005478-5iu38pr6	1553	17	3	3	CD
cord-005478-5iu38pr6	1553	18	,	,	,
cord-005478-5iu38pr6	1553	19	T	T	NNP
cord-005478-5iu38pr6	1553	20	-	-	HYPH
cord-005478-5iu38pr6	1553	21	IND	IND	NNP
cord-005478-5iu38pr6	1553	22	)	)	-RRB-
cord-005478-5iu38pr6	1553	23	.	.	.
cord-005478-5iu38pr6	1554	1	Results	result	NNS
cord-005478-5iu38pr6	1554	2	:	:	:
cord-005478-5iu38pr6	1555	1	The	the	DT
cord-005478-5iu38pr6	1555	2	pooled	pooled	JJ
cord-005478-5iu38pr6	1555	3	phase	phase	NN
cord-005478-5iu38pr6	1555	4	2	2	CD
cord-005478-5iu38pr6	1555	5	and	and	CC
cord-005478-5iu38pr6	1555	6	3	3	CD
cord-005478-5iu38pr6	1555	7	trials	trial	NNS
cord-005478-5iu38pr6	1555	8	had	have	VBD
cord-005478-5iu38pr6	1555	9	60	60	CD
cord-005478-5iu38pr6	1555	10	patients	patient	NNS
cord-005478-5iu38pr6	1555	11	with	with	IN
cord-005478-5iu38pr6	1555	12	CR	CR	NNP
cord-005478-5iu38pr6	1555	13	(	(	-LRB-
cord-005478-5iu38pr6	1555	14	n=34	n=34	NNP
cord-005478-5iu38pr6	1555	15	and	and	CC
cord-005478-5iu38pr6	1555	16	n=26	n=26	RB
cord-005478-5iu38pr6	1555	17	,	,	,
cord-005478-5iu38pr6	1555	18	respectively	respectively	RB
cord-005478-5iu38pr6	1555	19	)	)	-RRB-
cord-005478-5iu38pr6	1555	20	and	and	CC
cord-005478-5iu38pr6	1555	21	116	116	CD
cord-005478-5iu38pr6	1555	22	patients	patient	NNS
cord-005478-5iu38pr6	1555	23	without	without	IN
cord-005478-5iu38pr6	1555	24	CR	CR	NNP
cord-005478-5iu38pr6	1555	25	(	(	-LRB-
cord-005478-5iu38pr6	1555	26	n=40	n=40	JJ
cord-005478-5iu38pr6	1555	27	and	and	CC
cord-005478-5iu38pr6	1555	28	n=76	n=76	XX
cord-005478-5iu38pr6	1555	29	,	,	,
cord-005478-5iu38pr6	1555	30	respectively	respectively	RB
cord-005478-5iu38pr6	1555	31	)	)	-RRB-
cord-005478-5iu38pr6	1555	32	.	.	.
cord-005478-5iu38pr6	1556	1	Of	of	IN
cord-005478-5iu38pr6	1556	2	60	60	CD
cord-005478-5iu38pr6	1556	3	patients	patient	NNS
cord-005478-5iu38pr6	1556	4	with	with	IN
cord-005478-5iu38pr6	1556	5	CR	CR	NNP
cord-005478-5iu38pr6	1556	6	(	(	-LRB-
cord-005478-5iu38pr6	1556	7	Figure	figure	NN
cord-005478-5iu38pr6	1556	8	)	)	-RRB-
cord-005478-5iu38pr6	1556	9	in	in	IN
cord-005478-5iu38pr6	1556	10	the	the	DT
cord-005478-5iu38pr6	1556	11	phase	phase	NN
cord-005478-5iu38pr6	1556	12	2	2	CD
cord-005478-5iu38pr6	1556	13	and	and	CC
cord-005478-5iu38pr6	1556	14	3	3	CD
cord-005478-5iu38pr6	1556	15	trials	trial	NNS
cord-005478-5iu38pr6	1556	16	,	,	,
cord-005478-5iu38pr6	1556	17	the	the	DT
cord-005478-5iu38pr6	1556	18	median	median	JJ
cord-005478-5iu38pr6	1556	19	time	time	NN
cord-005478-5iu38pr6	1556	20	to	to	IN
cord-005478-5iu38pr6	1556	21	CR	CR	NNP
cord-005478-5iu38pr6	1556	22	was	be	VBD
cord-005478-5iu38pr6	1556	23	24.5	24.5	CD
cord-005478-5iu38pr6	1556	24	days	day	NNS
cord-005478-5iu38pr6	1557	1	(	(	-LRB-
cord-005478-5iu38pr6	1557	2	range	range	NN
cord-005478-5iu38pr6	1557	3	:	:	:
cord-005478-5iu38pr6	1557	4	7	7	CD
cord-005478-5iu38pr6	1557	5	-	-	SYM
cord-005478-5iu38pr6	1557	6	123	123	CD
cord-005478-5iu38pr6	1557	7	)	)	-RRB-
cord-005478-5iu38pr6	1557	8	;	;	:
cord-005478-5iu38pr6	1558	1	of	of	IN
cord-005478-5iu38pr6	1558	2	these	these	DT
cord-005478-5iu38pr6	1558	3	,	,	,
cord-005478-5iu38pr6	1558	4	53.3	53.3	CD
cord-005478-5iu38pr6	1558	5	%	%	NN
cord-005478-5iu38pr6	1558	6	achieved	achieve	VBD
cord-005478-5iu38pr6	1558	7	CR	CR	NNP
cord-005478-5iu38pr6	1558	8	after	after	IN
cord-005478-5iu38pr6	1558	9	4	4	CD
cord-005478-5iu38pr6	1558	10	or	or	CC
cord-005478-5iu38pr6	1558	11	more	more	JJR
cord-005478-5iu38pr6	1558	12	weeks	week	NNS
cord-005478-5iu38pr6	1558	13	of	of	IN
cord-005478-5iu38pr6	1558	14	treatment	treatment	NN
cord-005478-5iu38pr6	1558	15	.	.	.
cord-005478-5iu38pr6	1559	1	In	in	IN
cord-005478-5iu38pr6	1559	2	the	the	DT
cord-005478-5iu38pr6	1559	3	T	T	NNP
cord-005478-5iu38pr6	1559	4	-	-	HYPH
cord-005478-5iu38pr6	1559	5	IND	IND	NNP
cord-005478-5iu38pr6	1559	6	,	,	,
cord-005478-5iu38pr6	1559	7	390	390	CD
cord-005478-5iu38pr6	1559	8	patients	patient	NNS
cord-005478-5iu38pr6	1559	9	discontinued	discontinue	VBD
cord-005478-5iu38pr6	1559	10	treatment	treatment	NN
cord-005478-5iu38pr6	1559	11	due	due	IN
cord-005478-5iu38pr6	1559	12	to	to	IN
cord-005478-5iu38pr6	1559	13	CR	CR	NNP
cord-005478-5iu38pr6	1559	14	(	(	-LRB-
cord-005478-5iu38pr6	1559	15	median	median	JJ
cord-005478-5iu38pr6	1559	16	time	time	NN
cord-005478-5iu38pr6	1559	17	to	to	IN
cord-005478-5iu38pr6	1559	18	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	1559	19	,	,	,
cord-005478-5iu38pr6	1559	20	22	22	CD
cord-005478-5iu38pr6	1559	21	days	day	NNS
cord-005478-5iu38pr6	1559	22	after	after	IN
cord-005478-5iu38pr6	1559	23	initiation	initiation	NN
cord-005478-5iu38pr6	1559	24	of	of	IN
cord-005478-5iu38pr6	1559	25	defibrotide	defibrotide	NN
cord-005478-5iu38pr6	1559	26	;	;	:
cord-005478-5iu38pr6	1559	27	range	range	NN
cord-005478-5iu38pr6	1559	28	,	,	,
cord-005478-5iu38pr6	1559	29	2	2	CD
cord-005478-5iu38pr6	1559	30	-	-	SYM
cord-005478-5iu38pr6	1559	31	64	64	CD
cord-005478-5iu38pr6	1559	32	)	)	-RRB-
cord-005478-5iu38pr6	1559	33	,	,	,
cord-005478-5iu38pr6	1559	34	with	with	IN
cord-005478-5iu38pr6	1559	35	57	57	CD
cord-005478-5iu38pr6	1559	36	patients	patient	NNS
cord-005478-5iu38pr6	1559	37	(	(	-LRB-
cord-005478-5iu38pr6	1559	38	14.6	14.6	CD
cord-005478-5iu38pr6	1559	39	%	%	NN
cord-005478-5iu38pr6	1559	40	)	)	-RRB-
cord-005478-5iu38pr6	1559	41	discontinuing	discontinue	VBG
cord-005478-5iu38pr6	1559	42	on	on	IN
cord-005478-5iu38pr6	1559	43	or	or	CC
cord-005478-5iu38pr6	1559	44	after	after	IN
cord-005478-5iu38pr6	1559	45	week	week	NN
cord-005478-5iu38pr6	1559	46	4	4	CD
cord-005478-5iu38pr6	1559	47	of	of	IN
cord-005478-5iu38pr6	1559	48	treatment	treatment	NN
cord-005478-5iu38pr6	1559	49	.	.	.
cord-005478-5iu38pr6	1560	1	In	in	IN
cord-005478-5iu38pr6	1560	2	the	the	DT
cord-005478-5iu38pr6	1560	3	phase	phase	NN
cord-005478-5iu38pr6	1560	4	2	2	CD
cord-005478-5iu38pr6	1560	5	and	and	CC
cord-005478-5iu38pr6	1560	6	3	3	CD
cord-005478-5iu38pr6	1560	7	studies	study	NNS
cord-005478-5iu38pr6	1560	8	(	(	-LRB-
cord-005478-5iu38pr6	1560	9	n=176	n=176	NNP
cord-005478-5iu38pr6	1560	10	)	)	-RRB-
cord-005478-5iu38pr6	1560	11	,	,	,
cord-005478-5iu38pr6	1560	12	58	58	CD
cord-005478-5iu38pr6	1560	13	patients	patient	NNS
cord-005478-5iu38pr6	1560	14	(	(	-LRB-
cord-005478-5iu38pr6	1560	15	33	33	CD
cord-005478-5iu38pr6	1560	16	%	%	NN
cord-005478-5iu38pr6	1560	17	)	)	-RRB-
cord-005478-5iu38pr6	1560	18	had	have	VBD
cord-005478-5iu38pr6	1560	19	treatment	treatment	NN
cord-005478-5iu38pr6	1560	20	-	-	HYPH
cord-005478-5iu38pr6	1560	21	related	relate	VBN
cord-005478-5iu38pr6	1560	22	adverse	adverse	JJ
cord-005478-5iu38pr6	1560	23	events	event	NNS
cord-005478-5iu38pr6	1560	24	(	(	-LRB-
cord-005478-5iu38pr6	1560	25	TRAEs	trae	NNS
cord-005478-5iu38pr6	1560	26	)	)	-RRB-
cord-005478-5iu38pr6	1560	27	;	;	:
cord-005478-5iu38pr6	1560	28	most	most	RBS
cord-005478-5iu38pr6	1560	29	common	common	JJ
cord-005478-5iu38pr6	1560	30	were	be	VBD
cord-005478-5iu38pr6	1560	31	gastrointestinal	gastrointestinal	JJ
cord-005478-5iu38pr6	1560	32	(	(	-LRB-
cord-005478-5iu38pr6	1560	33	GI	GI	NNP
cord-005478-5iu38pr6	1560	34	)	)	-RRB-
cord-005478-5iu38pr6	1560	35	hemorrhage	hemorrhage	NN
cord-005478-5iu38pr6	1560	36	(	(	-LRB-
cord-005478-5iu38pr6	1560	37	4.0	4.0	CD
cord-005478-5iu38pr6	1560	38	%	%	NN
cord-005478-5iu38pr6	1560	39	)	)	-RRB-
cord-005478-5iu38pr6	1560	40	,	,	,
cord-005478-5iu38pr6	1560	41	epistaxis	epistaxis	NN
cord-005478-5iu38pr6	1560	42	(	(	-LRB-
cord-005478-5iu38pr6	1560	43	4.5	4.5	CD
cord-005478-5iu38pr6	1560	44	%	%	NN
cord-005478-5iu38pr6	1560	45	)	)	-RRB-
cord-005478-5iu38pr6	1560	46	,	,	,
cord-005478-5iu38pr6	1560	47	hypotension	hypotension	NN
cord-005478-5iu38pr6	1560	48	(	(	-LRB-
cord-005478-5iu38pr6	1560	49	5.7	5.7	CD
cord-005478-5iu38pr6	1560	50	%	%	NN
cord-005478-5iu38pr6	1560	51	)	)	-RRB-
cord-005478-5iu38pr6	1560	52	,	,	,
cord-005478-5iu38pr6	1560	53	and	and	CC
cord-005478-5iu38pr6	1560	54	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1560	55	alveolar	alveolar	NN
cord-005478-5iu38pr6	1560	56	hemorrhage	hemorrhage	NN
cord-005478-5iu38pr6	1560	57	(	(	-LRB-
cord-005478-5iu38pr6	1560	58	5.7	5.7	CD
cord-005478-5iu38pr6	1560	59	%	%	NN
cord-005478-5iu38pr6	1560	60	)	)	-RRB-
cord-005478-5iu38pr6	1560	61	.	.	.
cord-005478-5iu38pr6	1561	1	In	in	IN
cord-005478-5iu38pr6	1561	2	the	the	DT
cord-005478-5iu38pr6	1561	3	T	T	NNP
cord-005478-5iu38pr6	1561	4	-	-	HYPH
cord-005478-5iu38pr6	1561	5	IND	IND	NNP
cord-005478-5iu38pr6	1561	6	(	(	-LRB-
cord-005478-5iu38pr6	1561	7	n=1000	n=1000	CD
cord-005478-5iu38pr6	1561	8	)	)	-RRB-
cord-005478-5iu38pr6	1561	9	,	,	,
cord-005478-5iu38pr6	1561	10	210	210	CD
cord-005478-5iu38pr6	1561	11	patients	patient	NNS
cord-005478-5iu38pr6	1561	12	(	(	-LRB-
cord-005478-5iu38pr6	1561	13	21.0	21.0	CD
cord-005478-5iu38pr6	1561	14	%	%	NN
cord-005478-5iu38pr6	1561	15	)	)	-RRB-
cord-005478-5iu38pr6	1561	16	had	have	VBD
cord-005478-5iu38pr6	1561	17	≥1	≥1	$
cord-005478-5iu38pr6	1561	18	TRAE	TRAE	NNP
cord-005478-5iu38pr6	1561	19	;	;	:
cord-005478-5iu38pr6	1561	20	most	most	RBS
cord-005478-5iu38pr6	1561	21	common	common	JJ
cord-005478-5iu38pr6	1561	22	were	be	VBD
cord-005478-5iu38pr6	1561	23	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1561	24	hemorrhage	hemorrhage	NN
cord-005478-5iu38pr6	1561	25	(	(	-LRB-
cord-005478-5iu38pr6	1561	26	4.6	4.6	CD
cord-005478-5iu38pr6	1561	27	%	%	NN
cord-005478-5iu38pr6	1561	28	)	)	-RRB-
cord-005478-5iu38pr6	1561	29	,	,	,
cord-005478-5iu38pr6	1561	30	GI	GI	NNP
cord-005478-5iu38pr6	1561	31	hemorrhage	hemorrhage	NN
cord-005478-5iu38pr6	1561	32	(	(	-LRB-
cord-005478-5iu38pr6	1561	33	3.0	3.0	CD
cord-005478-5iu38pr6	1561	34	%	%	NN
cord-005478-5iu38pr6	1561	35	)	)	-RRB-
cord-005478-5iu38pr6	1561	36	,	,	,
cord-005478-5iu38pr6	1561	37	epistaxis	epistaxis	NN
cord-005478-5iu38pr6	1561	38	(	(	-LRB-
cord-005478-5iu38pr6	1561	39	2.3	2.3	CD
cord-005478-5iu38pr6	1561	40	%	%	NN
cord-005478-5iu38pr6	1561	41	)	)	-RRB-
cord-005478-5iu38pr6	1561	42	,	,	,
cord-005478-5iu38pr6	1561	43	and	and	CC
cord-005478-5iu38pr6	1561	44	hypotension	hypotension	NN
cord-005478-5iu38pr6	1561	45	(	(	-LRB-
cord-005478-5iu38pr6	1561	46	2.0	2.0	CD
cord-005478-5iu38pr6	1561	47	%	%	NN
cord-005478-5iu38pr6	1561	48	)	)	-RRB-
cord-005478-5iu38pr6	1561	49	.	.	.
cord-005478-5iu38pr6	1562	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1562	2	:	:	:
cord-005478-5iu38pr6	1563	1	Among	among	IN
cord-005478-5iu38pr6	1563	2	patients	patient	NNS
cord-005478-5iu38pr6	1563	3	with	with	IN
cord-005478-5iu38pr6	1563	4	CR	CR	NNP
cord-005478-5iu38pr6	1563	5	in	in	IN
cord-005478-5iu38pr6	1563	6	the	the	DT
cord-005478-5iu38pr6	1563	7	phase	phase	NN
cord-005478-5iu38pr6	1563	8	2	2	CD
cord-005478-5iu38pr6	1563	9	and	and	CC
cord-005478-5iu38pr6	1563	10	3	3	CD
cord-005478-5iu38pr6	1563	11	studies	study	NNS
cord-005478-5iu38pr6	1563	12	,	,	,
cord-005478-5iu38pr6	1563	13	a	a	DT
cord-005478-5iu38pr6	1563	14	significant	significant	JJ
cord-005478-5iu38pr6	1563	15	number	number	NN
cord-005478-5iu38pr6	1563	16	of	of	IN
cord-005478-5iu38pr6	1563	17	patients	patient	NNS
cord-005478-5iu38pr6	1563	18	achieve	achieve	VBP
cord-005478-5iu38pr6	1563	19	CR	CR	NNP
cord-005478-5iu38pr6	1563	20	(	(	-LRB-
cord-005478-5iu38pr6	1563	21	40	40	CD
cord-005478-5iu38pr6	1563	22	%	%	NN
cord-005478-5iu38pr6	1563	23	)	)	-RRB-
cord-005478-5iu38pr6	1563	24	after	after	IN
cord-005478-5iu38pr6	1563	25	4	4	CD
cord-005478-5iu38pr6	1563	26	weeks	week	NNS
cord-005478-5iu38pr6	1563	27	of	of	IN
cord-005478-5iu38pr6	1563	28	persistent	persistent	JJ
cord-005478-5iu38pr6	1563	29	treatment	treatment	NN
cord-005478-5iu38pr6	1563	30	,	,	,
cord-005478-5iu38pr6	1563	31	highlighting	highlight	VBG
cord-005478-5iu38pr6	1563	32	the	the	DT
cord-005478-5iu38pr6	1563	33	importance	importance	NN
cord-005478-5iu38pr6	1563	34	of	of	IN
cord-005478-5iu38pr6	1563	35	continued	continue	VBN
cord-005478-5iu38pr6	1563	36	therapy	therapy	NN
cord-005478-5iu38pr6	1563	37	as	as	IN
cord-005478-5iu38pr6	1563	38	per	per	IN
cord-005478-5iu38pr6	1563	39	label	label	NN
cord-005478-5iu38pr6	1563	40	indication	indication	NN
cord-005478-5iu38pr6	1563	41	.	.	.
cord-005478-5iu38pr6	1564	1	Support	support	NN
cord-005478-5iu38pr6	1564	2	:	:	:
cord-005478-5iu38pr6	1564	3	Jazz	jazz	NN
cord-005478-5iu38pr6	1564	4	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1564	5	Figure	Figure	NNP
cord-005478-5iu38pr6	1564	6	.	.	.
cord-005478-5iu38pr6	1565	1	Time	time	NN
cord-005478-5iu38pr6	1565	2	to	to	IN
cord-005478-5iu38pr6	1565	3	CR	cr	NN
cord-005478-5iu38pr6	1566	1	Among	among	IN
cord-005478-5iu38pr6	1566	2	60	60	CD
cord-005478-5iu38pr6	1566	3	Patients	patient	NNS
cord-005478-5iu38pr6	1566	4	Achieving	achieve	VBG
cord-005478-5iu38pr6	1566	5	CR	cr	NN
cord-005478-5iu38pr6	1566	6	in	in	IN
cord-005478-5iu38pr6	1566	7	Defibrotide	Defibrotide	NNP
cord-005478-5iu38pr6	1566	8	Phase	Phase	NNP
cord-005478-5iu38pr6	1566	9	2	2	CD
cord-005478-5iu38pr6	1566	10	and	and	CC
cord-005478-5iu38pr6	1566	11	3	3	CD
cord-005478-5iu38pr6	1566	12	Studies	Studies	NNPS
cord-005478-5iu38pr6	1566	13	]	]	-RRB-
cord-005478-5iu38pr6	1567	1	Trial	trial	NN
cord-005478-5iu38pr6	1567	2	Registry	registry	NN
cord-005478-5iu38pr6	1567	3	:	:	:
cord-005478-5iu38pr6	1568	1	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-005478-5iu38pr6	1568	2	:	:	:
cord-005478-5iu38pr6	1568	3	NCT00003966	NCT00003966	NNP
cord-005478-5iu38pr6	1568	4	,	,	,
cord-005478-5iu38pr6	1568	5	NCT00358501	NCT00358501	NNP
cord-005478-5iu38pr6	1568	6	,	,	,
cord-005478-5iu38pr6	1568	7	and	and	CC
cord-005478-5iu38pr6	1568	8	NCT00628498	NCT00628498	NNP
cord-005478-5iu38pr6	1569	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1569	2	:	:	:
cord-005478-5iu38pr6	1570	1	Paul	Paul	NNP
cord-005478-5iu38pr6	1570	2	G.	G.	NNP
cord-005478-5iu38pr6	1570	3	Richardson	Richardson	NNP
cord-005478-5iu38pr6	1570	4	has	have	VBZ
cord-005478-5iu38pr6	1570	5	served	serve	VBN
cord-005478-5iu38pr6	1570	6	on	on	IN
cord-005478-5iu38pr6	1570	7	advisory	advisory	JJ
cord-005478-5iu38pr6	1570	8	committees	committee	NNS
cord-005478-5iu38pr6	1570	9	and	and	CC
cord-005478-5iu38pr6	1570	10	as	as	IN
cord-005478-5iu38pr6	1570	11	a	a	DT
cord-005478-5iu38pr6	1570	12	consultant	consultant	NN
cord-005478-5iu38pr6	1570	13	,	,	,
cord-005478-5iu38pr6	1570	14	and	and	CC
cord-005478-5iu38pr6	1570	15	has	have	VBZ
cord-005478-5iu38pr6	1570	16	received	receive	VBN
cord-005478-5iu38pr6	1570	17	research	research	NN
cord-005478-5iu38pr6	1570	18	funding	funding	NN
cord-005478-5iu38pr6	1570	19	from	from	IN
cord-005478-5iu38pr6	1570	20	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1570	21	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1570	22	.	.	.
cord-005478-5iu38pr6	1571	1	Angela	Angela	NNP
cord-005478-5iu38pr6	1571	2	R.	R.	NNP
cord-005478-5iu38pr6	1571	3	Smith	Smith	NNP
cord-005478-5iu38pr6	1571	4	and	and	CC
cord-005478-5iu38pr6	1571	5	Leslie	Leslie	NNP
cord-005478-5iu38pr6	1571	6	Lehmann	Lehmann	NNP
cord-005478-5iu38pr6	1571	7	have	have	VBP
cord-005478-5iu38pr6	1571	8	nothing	nothing	NN
cord-005478-5iu38pr6	1571	9	to	to	TO
cord-005478-5iu38pr6	1571	10	disclose	disclose	VB
cord-005478-5iu38pr6	1571	11	.	.	.
cord-005478-5iu38pr6	1572	1	Nancy	Nancy	NNP
cord-005478-5iu38pr6	1572	2	A.	A.	NNP
cord-005478-5iu38pr6	1572	3	Kernan	Kernan	NNP
cord-005478-5iu38pr6	1572	4	received	receive	VBD
cord-005478-5iu38pr6	1572	5	grants	grant	NNS
cord-005478-5iu38pr6	1572	6	from	from	IN
cord-005478-5iu38pr6	1572	7	Gentium	Gentium	NNP
cord-005478-5iu38pr6	1572	8	during	during	IN
cord-005478-5iu38pr6	1572	9	the	the	DT
cord-005478-5iu38pr6	1572	10	conduct	conduct	NN
cord-005478-5iu38pr6	1572	11	of	of	IN
cord-005478-5iu38pr6	1572	12	the	the	DT
cord-005478-5iu38pr6	1572	13	study	study	NN
cord-005478-5iu38pr6	1572	14	,	,	,
cord-005478-5iu38pr6	1572	15	and	and	CC
cord-005478-5iu38pr6	1572	16	her	-PRON-	PRP$
cord-005478-5iu38pr6	1572	17	research	research	NN
cord-005478-5iu38pr6	1572	18	was	be	VBD
cord-005478-5iu38pr6	1572	19	supported	support	VBN
cord-005478-5iu38pr6	1572	20	by	by	IN
cord-005478-5iu38pr6	1572	21	The	the	DT
cord-005478-5iu38pr6	1572	22	National	National	NNP
cord-005478-5iu38pr6	1572	23	Cancer	Cancer	NNP
cord-005478-5iu38pr6	1572	24	Institute	Institute	NNP
cord-005478-5iu38pr6	1572	25	of	of	IN
cord-005478-5iu38pr6	1572	26	the	the	DT
cord-005478-5iu38pr6	1572	27	National	National	NNP
cord-005478-5iu38pr6	1572	28	Institutes	Institutes	NNPS
cord-005478-5iu38pr6	1572	29	of	of	IN
cord-005478-5iu38pr6	1572	30	Health	Health	NNP
cord-005478-5iu38pr6	1572	31	under	under	IN
cord-005478-5iu38pr6	1572	32	award	award	NN
cord-005478-5iu38pr6	1572	33	number	number	NN
cord-005478-5iu38pr6	1572	34	P30	P30	NNP
cord-005478-5iu38pr6	1572	35	CA008748	CA008748	NNP
cord-005478-5iu38pr6	1572	36	;	;	:
cord-005478-5iu38pr6	1572	37	the	the	DT
cord-005478-5iu38pr6	1572	38	content	content	NN
cord-005478-5iu38pr6	1572	39	is	be	VBZ
cord-005478-5iu38pr6	1572	40	solely	solely	RB
cord-005478-5iu38pr6	1572	41	the	the	DT
cord-005478-5iu38pr6	1572	42	responsibility	responsibility	NN
cord-005478-5iu38pr6	1572	43	of	of	IN
cord-005478-5iu38pr6	1572	44	the	the	DT
cord-005478-5iu38pr6	1572	45	author	author	NN
cord-005478-5iu38pr6	1572	46	and	and	CC
cord-005478-5iu38pr6	1572	47	does	do	VBZ
cord-005478-5iu38pr6	1572	48	not	not	RB
cord-005478-5iu38pr6	1572	49	necessarily	necessarily	RB
cord-005478-5iu38pr6	1572	50	represent	represent	VB
cord-005478-5iu38pr6	1572	51	the	the	DT
cord-005478-5iu38pr6	1572	52	official	official	JJ
cord-005478-5iu38pr6	1572	53	views	view	NNS
cord-005478-5iu38pr6	1572	54	of	of	IN
cord-005478-5iu38pr6	1572	55	the	the	DT
cord-005478-5iu38pr6	1572	56	National	National	NNP
cord-005478-5iu38pr6	1572	57	Institutes	Institutes	NNPS
cord-005478-5iu38pr6	1572	58	of	of	IN
cord-005478-5iu38pr6	1572	59	Health	Health	NNP
cord-005478-5iu38pr6	1572	60	.	.	.
cord-005478-5iu38pr6	1573	1	She	-PRON-	PRP
cord-005478-5iu38pr6	1573	2	has	have	VBZ
cord-005478-5iu38pr6	1573	3	a	a	DT
cord-005478-5iu38pr6	1573	4	research	research	NN
cord-005478-5iu38pr6	1573	5	grant	grant	NN
cord-005478-5iu38pr6	1573	6	from	from	IN
cord-005478-5iu38pr6	1573	7	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1573	8	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1573	9	.	.	.
cord-005478-5iu38pr6	1574	1	Robert	Robert	NNP
cord-005478-5iu38pr6	1574	2	Ryan	Ryan	NNP
cord-005478-5iu38pr6	1574	3	and	and	CC
cord-005478-5iu38pr6	1574	4	William	William	NNP
cord-005478-5iu38pr6	1574	5	Tappe	Tappe	NNP
cord-005478-5iu38pr6	1574	6	are	be	VBP
cord-005478-5iu38pr6	1574	7	employees	employee	NNS
cord-005478-5iu38pr6	1574	8	of	of	IN
cord-005478-5iu38pr6	1574	9	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1574	10	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1574	11	and	and	CC
cord-005478-5iu38pr6	1574	12	hold	hold	VB
cord-005478-5iu38pr6	1574	13	stock	stock	NN
cord-005478-5iu38pr6	1574	14	and/or	and/or	CC
cord-005478-5iu38pr6	1574	15	stock	stock	NN
cord-005478-5iu38pr6	1574	16	options	option	NNS
cord-005478-5iu38pr6	1574	17	in	in	IN
cord-005478-5iu38pr6	1574	18	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1574	19	Pharmaceuticals	Pharmaceuticals	NNP
cord-005478-5iu38pr6	1574	20	plc	plc	NNP
cord-005478-5iu38pr6	1574	21	.	.	.
cord-005478-5iu38pr6	1575	1	Stephan	Stephan	NNP
cord-005478-5iu38pr6	1575	2	A.	A.	NNP
cord-005478-5iu38pr6	1575	3	Grupp	Grupp	NNP
cord-005478-5iu38pr6	1575	4	has	have	VBZ
cord-005478-5iu38pr6	1575	5	served	serve	VBN
cord-005478-5iu38pr6	1575	6	on	on	IN
cord-005478-5iu38pr6	1575	7	a	a	DT
cord-005478-5iu38pr6	1575	8	steering	steering	NN
cord-005478-5iu38pr6	1575	9	committee	committee	NN
cord-005478-5iu38pr6	1575	10	and	and	CC
cord-005478-5iu38pr6	1575	11	as	as	IN
cord-005478-5iu38pr6	1575	12	a	a	DT
cord-005478-5iu38pr6	1575	13	consultant	consultant	NN
cord-005478-5iu38pr6	1575	14	to	to	IN
cord-005478-5iu38pr6	1575	15	Jazz	Jazz	NNP
cord-005478-5iu38pr6	1575	16	Pharmaceuticals	Pharmaceuticals	NNPS
cord-005478-5iu38pr6	1575	17	.	.	.
cord-005478-5iu38pr6	1576	1	Sperm	sperm	NN
cord-005478-5iu38pr6	1576	2	counts	count	NNS
cord-005478-5iu38pr6	1576	3	and	and	CC
cord-005478-5iu38pr6	1576	4	prevalence	prevalence	NN
cord-005478-5iu38pr6	1576	5	of	of	IN
cord-005478-5iu38pr6	1576	6	testosterone	testosterone	NN
cord-005478-5iu38pr6	1576	7	substitution	substitution	NN
cord-005478-5iu38pr6	1576	8	at	at	IN
cord-005478-5iu38pr6	1576	9	long	long	JJ
cord-005478-5iu38pr6	1576	10	-	-	HYPH
cord-005478-5iu38pr6	1576	11	term	term	NN
cord-005478-5iu38pr6	1576	12	follow	follow	NN
cord-005478-5iu38pr6	1576	13	-	-	HYPH
cord-005478-5iu38pr6	1576	14	up	up	NN
cord-005478-5iu38pr6	1576	15	after	after	IN
cord-005478-5iu38pr6	1576	16	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1576	17	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1576	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1576	19	in	in	IN
cord-005478-5iu38pr6	1576	20	childhood	childhood	NN
cord-005478-5iu38pr6	1576	21	Background	background	NN
cord-005478-5iu38pr6	1576	22	:	:	:
cord-005478-5iu38pr6	1576	23	Little	little	JJ
cord-005478-5iu38pr6	1576	24	is	be	VBZ
cord-005478-5iu38pr6	1576	25	known	know	VBN
cord-005478-5iu38pr6	1576	26	about	about	IN
cord-005478-5iu38pr6	1576	27	the	the	DT
cord-005478-5iu38pr6	1576	28	long	long	JJ
cord-005478-5iu38pr6	1576	29	-	-	HYPH
cord-005478-5iu38pr6	1576	30	term	term	NN
cord-005478-5iu38pr6	1576	31	effects	effect	NNS
cord-005478-5iu38pr6	1576	32	of	of	IN
cord-005478-5iu38pr6	1576	33	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1576	34	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1576	35	on	on	IN
cord-005478-5iu38pr6	1576	36	the	the	DT
cord-005478-5iu38pr6	1576	37	male	male	JJ
cord-005478-5iu38pr6	1576	38	reproductive	reproductive	JJ
cord-005478-5iu38pr6	1576	39	axis	axis	NN
cord-005478-5iu38pr6	1576	40	.	.	.
cord-005478-5iu38pr6	1577	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1577	2	investigated	investigate	VBD
cord-005478-5iu38pr6	1577	3	sperm	sperm	NN
cord-005478-5iu38pr6	1577	4	counts	count	NNS
cord-005478-5iu38pr6	1577	5	and	and	CC
cord-005478-5iu38pr6	1577	6	prevalence	prevalence	NN
cord-005478-5iu38pr6	1577	7	of	of	IN
cord-005478-5iu38pr6	1577	8	testosterone	testosterone	NN
cord-005478-5iu38pr6	1577	9	substitution	substitution	NN
cord-005478-5iu38pr6	1577	10	twenty	twenty	CD
cord-005478-5iu38pr6	1577	11	years	year	NNS
cord-005478-5iu38pr6	1577	12	after	after	IN
cord-005478-5iu38pr6	1577	13	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1577	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1577	15	and	and	CC
cord-005478-5iu38pr6	1577	16	aimed	aim	VBN
cord-005478-5iu38pr6	1577	17	at	at	IN
cord-005478-5iu38pr6	1577	18	identifying	identify	VBG
cord-005478-5iu38pr6	1577	19	risk	risk	NN
cord-005478-5iu38pr6	1577	20	factors	factor	NNS
cord-005478-5iu38pr6	1577	21	for	for	IN
cord-005478-5iu38pr6	1577	22	azoospermia	azoospermia	NN
cord-005478-5iu38pr6	1577	23	and	and	CC
cord-005478-5iu38pr6	1577	24	testosterone	testosterone	NN
cord-005478-5iu38pr6	1577	25	substitution	substitution	NN
cord-005478-5iu38pr6	1577	26	.	.	.
cord-005478-5iu38pr6	1578	1	Methods	method	NNS
cord-005478-5iu38pr6	1578	2	:	:	:
cord-005478-5iu38pr6	1579	1	This	this	DT
cord-005478-5iu38pr6	1579	2	cross	cross	JJ
cord-005478-5iu38pr6	1579	3	-	-	JJ
cord-005478-5iu38pr6	1579	4	sectional	sectional	JJ
cord-005478-5iu38pr6	1579	5	follow	follow	NN
cord-005478-5iu38pr6	1579	6	-	-	HYPH
cord-005478-5iu38pr6	1579	7	up	up	NN
cord-005478-5iu38pr6	1579	8	study	study	NN
cord-005478-5iu38pr6	1579	9	included	include	VBD
cord-005478-5iu38pr6	1579	10	two	two	CD
cord-005478-5iu38pr6	1579	11	national	national	JJ
cord-005478-5iu38pr6	1579	12	cohorts	cohort	NNS
cord-005478-5iu38pr6	1579	13	of	of	IN
cord-005478-5iu38pr6	1579	14	adult	adult	NN
cord-005478-5iu38pr6	1579	15	males	male	NNS
cord-005478-5iu38pr6	1579	16	(	(	-LRB-
cord-005478-5iu38pr6	1579	17	≥	≥	CD
cord-005478-5iu38pr6	1579	18	18	18	CD
cord-005478-5iu38pr6	1579	19	years	year	NNS
cord-005478-5iu38pr6	1579	20	)	)	-RRB-
cord-005478-5iu38pr6	1579	21	treated	treat	VBN
cord-005478-5iu38pr6	1579	22	with	with	IN
cord-005478-5iu38pr6	1579	23	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1579	24	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	1579	25	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1579	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1579	27	before	before	IN
cord-005478-5iu38pr6	1579	28	age	age	NN
cord-005478-5iu38pr6	1579	29	17	17	CD
cord-005478-5iu38pr6	1579	30	between	between	IN
cord-005478-5iu38pr6	1579	31	1980	1980	CD
cord-005478-5iu38pr6	1579	32	-	-	SYM
cord-005478-5iu38pr6	1579	33	2010	2010	CD
cord-005478-5iu38pr6	1579	34	in	in	IN
cord-005478-5iu38pr6	1579	35	Denmark	Denmark	NNP
cord-005478-5iu38pr6	1579	36	and	and	CC
cord-005478-5iu38pr6	1579	37	Finland	Finland	NNP
cord-005478-5iu38pr6	1579	38	.	.	.
cord-005478-5iu38pr6	1580	1	The	the	DT
cord-005478-5iu38pr6	1580	2	study	study	NN
cord-005478-5iu38pr6	1580	3	included	include	VBD
cord-005478-5iu38pr6	1580	4	medical	medical	JJ
cord-005478-5iu38pr6	1580	5	history	history	NN
cord-005478-5iu38pr6	1580	6	;	;	,
cord-005478-5iu38pr6	1580	7	physical	physical	JJ
cord-005478-5iu38pr6	1580	8	examination	examination	NN
cord-005478-5iu38pr6	1580	9	including	include	VBG
cord-005478-5iu38pr6	1580	10	testicular	testicular	JJ
cord-005478-5iu38pr6	1580	11	volume	volume	NN
cord-005478-5iu38pr6	1580	12	and	and	CC
cord-005478-5iu38pr6	1580	13	screening	screening	NN
cord-005478-5iu38pr6	1580	14	for	for	IN
cord-005478-5iu38pr6	1580	15	chronic	chronic	JJ
cord-005478-5iu38pr6	1580	16	graft	graft	NN
cord-005478-5iu38pr6	1580	17	-	-	HYPH
cord-005478-5iu38pr6	1580	18	versushost	versushost	NN
cord-005478-5iu38pr6	1580	19	-	-	HYPH
cord-005478-5iu38pr6	1580	20	disease	disease	NN
cord-005478-5iu38pr6	1580	21	(	(	-LRB-
cord-005478-5iu38pr6	1580	22	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	1580	23	)	)	-RRB-
cord-005478-5iu38pr6	1580	24	;	;	:
cord-005478-5iu38pr6	1580	25	sex	sex	NN
cord-005478-5iu38pr6	1580	26	hormones	hormone	NNS
cord-005478-5iu38pr6	1580	27	and	and	CC
cord-005478-5iu38pr6	1580	28	a	a	DT
cord-005478-5iu38pr6	1580	29	semen	semen	NN
cord-005478-5iu38pr6	1580	30	sample	sample	NN
cord-005478-5iu38pr6	1580	31	.	.	.
cord-005478-5iu38pr6	1581	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	1581	2	(	(	-LRB-
cord-005478-5iu38pr6	1581	3	pre	pre	JJ
cord-005478-5iu38pr6	1581	4	-	-	JJ
cord-005478-5iu38pr6	1581	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1581	6	and	and	CC
cord-005478-5iu38pr6	1581	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1581	8	)	)	-RRB-
cord-005478-5iu38pr6	1582	1	gonadal	gonadal	JJ
cord-005478-5iu38pr6	1582	2	irradiation	irradiation	NN
cord-005478-5iu38pr6	1582	3	including	include	VBG
cord-005478-5iu38pr6	1582	4	TBI	TBI	NNP
cord-005478-5iu38pr6	1582	5	and	and	CC
cord-005478-5iu38pr6	1582	6	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1582	7	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	1582	8	equivalent	equivalent	JJ
cord-005478-5iu38pr6	1582	9	doses	dose	NNS
cord-005478-5iu38pr6	1582	10	(	(	-LRB-
cord-005478-5iu38pr6	1582	11	CED	CED	NNP
cord-005478-5iu38pr6	1582	12	)	)	-RRB-
cord-005478-5iu38pr6	1582	13	were	be	VBD
cord-005478-5iu38pr6	1582	14	estimated	estimate	VBN
cord-005478-5iu38pr6	1582	15	from	from	IN
cord-005478-5iu38pr6	1582	16	patient	patient	JJ
cord-005478-5iu38pr6	1582	17	files	file	NNS
cord-005478-5iu38pr6	1582	18	.	.	.
cord-005478-5iu38pr6	1583	1	Results	result	NNS
cord-005478-5iu38pr6	1583	2	:	:	:
cord-005478-5iu38pr6	1583	3	98/181	98/181	CD
cord-005478-5iu38pr6	1583	4	(	(	-LRB-
cord-005478-5iu38pr6	1583	5	54	54	CD
cord-005478-5iu38pr6	1583	6	%	%	NN
cord-005478-5iu38pr6	1583	7	)	)	-RRB-
cord-005478-5iu38pr6	1583	8	of	of	IN
cord-005478-5iu38pr6	1583	9	eligible	eligible	JJ
cord-005478-5iu38pr6	1583	10	patients	patient	NNS
cord-005478-5iu38pr6	1583	11	(	(	-LRB-
cord-005478-5iu38pr6	1583	12	age	age	NN
cord-005478-5iu38pr6	1583	13	18	18	CD
cord-005478-5iu38pr6	1583	14	-	-	SYM
cord-005478-5iu38pr6	1583	15	47	47	CD
cord-005478-5iu38pr6	1583	16	years	year	NNS
cord-005478-5iu38pr6	1583	17	)	)	-RRB-
cord-005478-5iu38pr6	1583	18	participated	participate	VBD
cord-005478-5iu38pr6	1583	19	with	with	IN
cord-005478-5iu38pr6	1583	20	a	a	DT
cord-005478-5iu38pr6	1583	21	median	median	NN
cord-005478-5iu38pr6	1583	22	(	(	-LRB-
cord-005478-5iu38pr6	1583	23	range	range	NN
cord-005478-5iu38pr6	1583	24	)	)	-RRB-
cord-005478-5iu38pr6	1583	25	follow	follow	VB
cord-005478-5iu38pr6	1583	26	up	up	RP
cord-005478-5iu38pr6	1583	27	time	time	NN
cord-005478-5iu38pr6	1583	28	of	of	IN
cord-005478-5iu38pr6	1583	29	18	18	CD
cord-005478-5iu38pr6	1583	30	years	year	NNS
cord-005478-5iu38pr6	1583	31	.	.	.
cord-005478-5iu38pr6	1584	1	76	76	CD
cord-005478-5iu38pr6	1584	2	%	%	NN
cord-005478-5iu38pr6	1584	3	had	have	VBD
cord-005478-5iu38pr6	1584	4	malignant	malignant	JJ
cord-005478-5iu38pr6	1584	5	diagnoses	diagnosis	NNS
cord-005478-5iu38pr6	1584	6	and	and	CC
cord-005478-5iu38pr6	1584	7	74	74	CD
cord-005478-5iu38pr6	1584	8	%	%	NN
cord-005478-5iu38pr6	1584	9	were	be	VBD
cord-005478-5iu38pr6	1584	10	treated	treat	VBN
cord-005478-5iu38pr6	1584	11	with	with	IN
cord-005478-5iu38pr6	1584	12	TBI	tbi	NN
cord-005478-5iu38pr6	1584	13	-	-	HYPH
cord-005478-5iu38pr6	1584	14	conditioning	conditioning	NN
cord-005478-5iu38pr6	1584	15	.	.	.
cord-005478-5iu38pr6	1585	1	91	91	CD
cord-005478-5iu38pr6	1585	2	delivered	deliver	VBD
cord-005478-5iu38pr6	1585	3	a	a	DT
cord-005478-5iu38pr6	1585	4	semen	semen	NN
cord-005478-5iu38pr6	1585	5	sample	sample	NN
cord-005478-5iu38pr6	1585	6	.	.	.
cord-005478-5iu38pr6	1586	1	Results	result	NNS
cord-005478-5iu38pr6	1586	2	of	of	IN
cord-005478-5iu38pr6	1586	3	semen	semen	NN
cord-005478-5iu38pr6	1586	4	and	and	CC
cord-005478-5iu38pr6	1586	5	sex	sex	NN
cord-005478-5iu38pr6	1586	6	hormone	hormone	NN
cord-005478-5iu38pr6	1586	7	analyses	analysis	NNS
cord-005478-5iu38pr6	1586	8	are	be	VBP
cord-005478-5iu38pr6	1586	9	listed	list	VBN
cord-005478-5iu38pr6	1586	10	in	in	IN
cord-005478-5iu38pr6	1586	11	table	table	NN
cord-005478-5iu38pr6	1586	12	1	1	CD
cord-005478-5iu38pr6	1586	13	.	.	.
cord-005478-5iu38pr6	1587	1	30/98	30/98	CD
cord-005478-5iu38pr6	1587	2	(	(	-LRB-
cord-005478-5iu38pr6	1587	3	31	31	CD
cord-005478-5iu38pr6	1587	4	%	%	NN
cord-005478-5iu38pr6	1587	5	)	)	-RRB-
cord-005478-5iu38pr6	1587	6	had	have	VBD
cord-005478-5iu38pr6	1587	7	detectable	detectable	JJ
cord-005478-5iu38pr6	1587	8	sperm	sperm	NN
cord-005478-5iu38pr6	1587	9	counts	count	NNS
cord-005478-5iu38pr6	1587	10	(	(	-LRB-
cord-005478-5iu38pr6	1587	11	0.010	0.010	CD
cord-005478-5iu38pr6	1587	12	-	-	SYM
cord-005478-5iu38pr6	1587	13	524.8	524.8	CD
cord-005478-5iu38pr6	1587	14	million	million	CD
cord-005478-5iu38pr6	1587	15	)	)	-RRB-
cord-005478-5iu38pr6	1587	16	,	,	,
cord-005478-5iu38pr6	1587	17	of	of	IN
cord-005478-5iu38pr6	1587	18	these	these	DT
cord-005478-5iu38pr6	1587	19	15	15	CD
cord-005478-5iu38pr6	1587	20	were	be	VBD
cord-005478-5iu38pr6	1587	21	treated	treat	VBN
cord-005478-5iu38pr6	1587	22	with	with	IN
cord-005478-5iu38pr6	1587	23	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	1587	24	only	only	RB
cord-005478-5iu38pr6	1587	25	and	and	CC
cord-005478-5iu38pr6	1587	26	15	15	CD
cord-005478-5iu38pr6	1587	27	with	with	IN
cord-005478-5iu38pr6	1587	28	TBI	TBI	NNP
cord-005478-5iu38pr6	1587	29	(	(	-LRB-
cord-005478-5iu38pr6	1587	30	2	2	CD
cord-005478-5iu38pr6	1587	31	with	with	IN
cord-005478-5iu38pr6	1587	32	2	2	CD
cord-005478-5iu38pr6	1587	33	Gy	Gy	NNP
cord-005478-5iu38pr6	1587	34	TBI	TBI	NNP
cord-005478-5iu38pr6	1587	35	and	and	CC
cord-005478-5iu38pr6	1587	36	13	13	CD
cord-005478-5iu38pr6	1587	37	with	with	IN
cord-005478-5iu38pr6	1587	38	10	10	CD
cord-005478-5iu38pr6	1587	39	-	-	SYM
cord-005478-5iu38pr6	1587	40	12	12	CD
cord-005478-5iu38pr6	1587	41	Gy	Gy	NNP
cord-005478-5iu38pr6	1587	42	TBI	TBI	NNP
cord-005478-5iu38pr6	1587	43	including	include	VBG
cord-005478-5iu38pr6	1587	44	5	5	CD
cord-005478-5iu38pr6	1587	45	with	with	IN
cord-005478-5iu38pr6	1587	46	gonadal	gonadal	JJ
cord-005478-5iu38pr6	1587	47	shielding	shielding	NN
cord-005478-5iu38pr6	1587	48	)	)	-RRB-
cord-005478-5iu38pr6	1587	49	.	.	.
cord-005478-5iu38pr6	1588	1	In	in	IN
cord-005478-5iu38pr6	1588	2	patients	patient	NNS
cord-005478-5iu38pr6	1588	3	with	with	IN
cord-005478-5iu38pr6	1588	4	detectable	detectable	JJ
cord-005478-5iu38pr6	1588	5	sperm	sperm	NN
cord-005478-5iu38pr6	1588	6	in	in	IN
cord-005478-5iu38pr6	1588	7	the	the	DT
cord-005478-5iu38pr6	1588	8	ejaculate	ejaculate	NN
cord-005478-5iu38pr6	1588	9	,	,	,
cord-005478-5iu38pr6	1588	10	increase	increase	VBP
cord-005478-5iu38pr6	1588	11	in	in	IN
cord-005478-5iu38pr6	1588	12	sperm	sperm	NN
cord-005478-5iu38pr6	1588	13	counts	count	NNS
cord-005478-5iu38pr6	1588	14	was	be	VBD
cord-005478-5iu38pr6	1588	15	associated	associate	VBN
cord-005478-5iu38pr6	1588	16	with	with	IN
cord-005478-5iu38pr6	1588	17	time	time	NN
cord-005478-5iu38pr6	1588	18	from	from	IN
cord-005478-5iu38pr6	1588	19	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1589	1	(	(	-LRB-
cord-005478-5iu38pr6	1589	2	β=6.6	β=6.6	NNP
cord-005478-5iu38pr6	1589	3	million	million	CD
cord-005478-5iu38pr6	1589	4	per	per	IN
cord-005478-5iu38pr6	1589	5	year	year	NN
cord-005478-5iu38pr6	1589	6	95%CI	95%ci	CD
cord-005478-5iu38pr6	1589	7	(	(	-LRB-
cord-005478-5iu38pr6	1589	8	(	(	-LRB-
cord-005478-5iu38pr6	1589	9	-0.18)-13.32	-0.18)-13.32	NFP
cord-005478-5iu38pr6	1589	10	)	)	-RRB-
cord-005478-5iu38pr6	1589	11	,	,	,
cord-005478-5iu38pr6	1589	12	p=0.056	p=0.056	NNP
cord-005478-5iu38pr6	1589	13	,	,	,
cord-005478-5iu38pr6	1589	14	time	time	NN
cord-005478-5iu38pr6	1589	15	range	range	NN
cord-005478-5iu38pr6	1589	16	9	9	CD
cord-005478-5iu38pr6	1589	17	-	-	SYM
cord-005478-5iu38pr6	1589	18	32	32	CD
cord-005478-5iu38pr6	1589	19	years	year	NNS
cord-005478-5iu38pr6	1589	20	)	)	-RRB-
cord-005478-5iu38pr6	1589	21	indicating	indicate	VBG
cord-005478-5iu38pr6	1589	22	late	late	JJ
cord-005478-5iu38pr6	1589	23	spermatogenic	spermatogenic	NNP
cord-005478-5iu38pr6	1589	24	recovery	recovery	NN
cord-005478-5iu38pr6	1589	25	.	.	.
cord-005478-5iu38pr6	1590	1	Testicular	testicular	JJ
cord-005478-5iu38pr6	1590	2	irradiation	irradiation	NN
cord-005478-5iu38pr6	1590	3	was	be	VBD
cord-005478-5iu38pr6	1590	4	a	a	DT
cord-005478-5iu38pr6	1590	5	strong	strong	JJ
cord-005478-5iu38pr6	1590	6	risk	risk	NN
cord-005478-5iu38pr6	1590	7	factor	factor	NN
cord-005478-5iu38pr6	1590	8	for	for	IN
cord-005478-5iu38pr6	1590	9	azoospermia	azoospermia	NN
cord-005478-5iu38pr6	1590	10	(	(	-LRB-
cord-005478-5iu38pr6	1590	11	OR=6.2	OR=6.2	NNP
cord-005478-5iu38pr6	1591	1	95%CI	95%ci	CD
cord-005478-5iu38pr6	1592	1	(	(	-LRB-
cord-005478-5iu38pr6	1592	2	2.0	2.0	CD
cord-005478-5iu38pr6	1592	3	-	-	SYM
cord-005478-5iu38pr6	1592	4	20.7	20.7	CD
cord-005478-5iu38pr6	1592	5	)	)	-RRB-
cord-005478-5iu38pr6	1592	6	,	,	,
cord-005478-5iu38pr6	1592	7	p	p	NN
cord-005478-5iu38pr6	1592	8	<	<	XX
cord-005478-5iu38pr6	1592	9	0.001	0.001	CD
cord-005478-5iu38pr6	1592	10	)	)	-RRB-
cord-005478-5iu38pr6	1592	11	and	and	CC
cord-005478-5iu38pr6	1592	12	testosterone	testosterone	NN
cord-005478-5iu38pr6	1592	13	substitution	substitution	NN
cord-005478-5iu38pr6	1592	14	(	(	-LRB-
cord-005478-5iu38pr6	1592	15	OR=5.0	or=5.0	NN
cord-005478-5iu38pr6	1592	16	95%CI	95%ci	CD
cord-005478-5iu38pr6	1593	1	(	(	-LRB-
cord-005478-5iu38pr6	1593	2	1.3	1.3	CD
cord-005478-5iu38pr6	1593	3	-	-	SYM
cord-005478-5iu38pr6	1593	4	28.3	28.3	CD
cord-005478-5iu38pr6	1593	5	)	)	-RRB-
cord-005478-5iu38pr6	1593	6	,	,	,
cord-005478-5iu38pr6	1593	7	p=0.012	p=0.012	NNP
cord-005478-5iu38pr6	1593	8	)	)	-RRB-
cord-005478-5iu38pr6	1594	1	and	and	CC
cord-005478-5iu38pr6	1594	2	no	no	DT
cord-005478-5iu38pr6	1594	3	patients	patient	NNS
cord-005478-5iu38pr6	1594	4	with	with	IN
cord-005478-5iu38pr6	1594	5	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1594	6	testicular	testicular	JJ
cord-005478-5iu38pr6	1594	7	irradiation	irradiation	NN
cord-005478-5iu38pr6	1594	8	doses	dose	NNS
cord-005478-5iu38pr6	1594	9	>	>	XX
cord-005478-5iu38pr6	1595	1	12	12	CD
cord-005478-5iu38pr6	1595	2	Gy	Gy	NNP
cord-005478-5iu38pr6	1595	3	had	have	VBD
cord-005478-5iu38pr6	1595	4	detectable	detectable	JJ
cord-005478-5iu38pr6	1595	5	sperms	sperm	NNS
cord-005478-5iu38pr6	1595	6	,	,	,
cord-005478-5iu38pr6	1595	7	figure	figure	NN
cord-005478-5iu38pr6	1595	8	1	1	CD
cord-005478-5iu38pr6	1595	9	.	.	.
cord-005478-5iu38pr6	1596	1	Pre	pre	JJ
cord-005478-5iu38pr6	1596	2	-	-	JJ
cord-005478-5iu38pr6	1596	3	pubertal	pubertal	JJ
cord-005478-5iu38pr6	1596	4	stage	stage	NN
cord-005478-5iu38pr6	1596	5	at	at	IN
cord-005478-5iu38pr6	1596	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1596	7	was	be	VBD
cord-005478-5iu38pr6	1596	8	a	a	DT
cord-005478-5iu38pr6	1596	9	risk	risk	NN
cord-005478-5iu38pr6	1596	10	factor	factor	NN
cord-005478-5iu38pr6	1596	11	for	for	IN
cord-005478-5iu38pr6	1596	12	later	later	JJ
cord-005478-5iu38pr6	1596	13	testosterone	testosterone	NN
cord-005478-5iu38pr6	1596	14	substitution	substitution	NN
cord-005478-5iu38pr6	1596	15	(	(	-LRB-
cord-005478-5iu38pr6	1596	16	OR=10.4	or=10.4	FW
cord-005478-5iu38pr6	1596	17	95%CI	95%ci	CD
cord-005478-5iu38pr6	1596	18	(	(	-LRB-
cord-005478-5iu38pr6	1596	19	1.5	1.5	CD
cord-005478-5iu38pr6	1596	20	-	-	SYM
cord-005478-5iu38pr6	1596	21	453	453	CD
cord-005478-5iu38pr6	1596	22	)	)	-RRB-
cord-005478-5iu38pr6	1596	23	,	,	,
cord-005478-5iu38pr6	1596	24	p=0.0060	p=0.0060	NNP
cord-005478-5iu38pr6	1596	25	)	)	-RRB-
cord-005478-5iu38pr6	1596	26	.	.	.
cord-005478-5iu38pr6	1597	1	Risk	risk	NN
cord-005478-5iu38pr6	1597	2	of	of	IN
cord-005478-5iu38pr6	1597	3	testosterone	testosterone	NN
cord-005478-5iu38pr6	1597	4	substitution	substitution	NN
cord-005478-5iu38pr6	1597	5	was	be	VBD
cord-005478-5iu38pr6	1597	6	associated	associate	VBN
cord-005478-5iu38pr6	1597	7	with	with	IN
cord-005478-5iu38pr6	1597	8	time	time	NN
cord-005478-5iu38pr6	1597	9	from	from	IN
cord-005478-5iu38pr6	1597	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	1597	11	(	(	-LRB-
cord-005478-5iu38pr6	1597	12	OR	or	CC
cord-005478-5iu38pr6	1597	13	for	for	IN
cord-005478-5iu38pr6	1597	14	+1	+1	NFP
cord-005478-5iu38pr6	1597	15	year	year	NN
cord-005478-5iu38pr6	1597	16	1.1	1.1	CD
cord-005478-5iu38pr6	1597	17	95%CI	95%ci	CD
cord-005478-5iu38pr6	1597	18	(	(	-LRB-
cord-005478-5iu38pr6	1597	19	1.0	1.0	CD
cord-005478-5iu38pr6	1597	20	-	-	SYM
cord-005478-5iu38pr6	1597	21	1.2	1.2	CD
cord-005478-5iu38pr6	1597	22	)	)	-RRB-
cord-005478-5iu38pr6	1597	23	,	,	,
cord-005478-5iu38pr6	1597	24	p=0.025	p=0.025	NNP
cord-005478-5iu38pr6	1597	25	)	)	-RRB-
cord-005478-5iu38pr6	1597	26	.	.	.
cord-005478-5iu38pr6	1598	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	1598	2	CED	CED	NNP
cord-005478-5iu38pr6	1598	3	adjusted	adjust	VBD
cord-005478-5iu38pr6	1598	4	for	for	IN
cord-005478-5iu38pr6	1598	5	testicular	testicular	JJ
cord-005478-5iu38pr6	1598	6	irradiation	irradiation	NN
cord-005478-5iu38pr6	1598	7	was	be	VBD
cord-005478-5iu38pr6	1598	8	not	not	RB
cord-005478-5iu38pr6	1598	9	a	a	DT
cord-005478-5iu38pr6	1598	10	risk	risk	NN
cord-005478-5iu38pr6	1598	11	factor	factor	NN
cord-005478-5iu38pr6	1598	12	for	for	IN
cord-005478-5iu38pr6	1598	13	azoospermia	azoospermia	NN
cord-005478-5iu38pr6	1598	14	or	or	CC
cord-005478-5iu38pr6	1598	15	testosterone	testosterone	NN
cord-005478-5iu38pr6	1598	16	substitution	substitution	NN
cord-005478-5iu38pr6	1598	17	,	,	,
cord-005478-5iu38pr6	1598	18	nor	nor	CC
cord-005478-5iu38pr6	1598	19	was	be	VBD
cord-005478-5iu38pr6	1598	20	cGvHD	cGvHD	VBN
cord-005478-5iu38pr6	1598	21	.	.	.
cord-005478-5iu38pr6	1599	1	[	[	-LRB-
cord-005478-5iu38pr6	1599	2	[	[	-LRB-
cord-005478-5iu38pr6	1599	3	O080	O080	NNP
cord-005478-5iu38pr6	1599	4	Image	Image	NNP
cord-005478-5iu38pr6	1599	5	]	]	-RRB-
cord-005478-5iu38pr6	1599	6	1	1	CD
cord-005478-5iu38pr6	1599	7	.	.	.
cord-005478-5iu38pr6	1600	1	Figure	figure	NN
cord-005478-5iu38pr6	1600	2	1	1	CD
cord-005478-5iu38pr6	1600	3	]	]	-RRB-
cord-005478-5iu38pr6	1601	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1601	2	:	:	:
cord-005478-5iu38pr6	1602	1	Late	late	JJ
cord-005478-5iu38pr6	1602	2	spermatogenic	spermatogenic	JJ
cord-005478-5iu38pr6	1602	3	recovery	recovery	NN
cord-005478-5iu38pr6	1602	4	is	be	VBZ
cord-005478-5iu38pr6	1602	5	possible	possible	JJ
cord-005478-5iu38pr6	1602	6	10	10	CD
cord-005478-5iu38pr6	1602	7	-	-	SYM
cord-005478-5iu38pr6	1602	8	30	30	CD
cord-005478-5iu38pr6	1602	9	years	year	NNS
cord-005478-5iu38pr6	1602	10	following	follow	VBG
cord-005478-5iu38pr6	1602	11	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1602	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1602	13	but	but	CC
cord-005478-5iu38pr6	1602	14	depends	depend	VBZ
cord-005478-5iu38pr6	1602	15	on	on	IN
cord-005478-5iu38pr6	1602	16	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1602	17	testicular	testicular	JJ
cord-005478-5iu38pr6	1602	18	irradiation	irradiation	NN
cord-005478-5iu38pr6	1602	19	dose	dose	NN
cord-005478-5iu38pr6	1602	20	;	;	:
cord-005478-5iu38pr6	1602	21	azoospermia	azoospermia	NN
cord-005478-5iu38pr6	1602	22	was	be	VBD
cord-005478-5iu38pr6	1602	23	present	present	JJ
cord-005478-5iu38pr6	1602	24	in	in	IN
cord-005478-5iu38pr6	1602	25	all	all	DT
cord-005478-5iu38pr6	1602	26	patients	patient	NNS
cord-005478-5iu38pr6	1602	27	treated	treat	VBN
cord-005478-5iu38pr6	1602	28	with	with	IN
cord-005478-5iu38pr6	1602	29	>	>	XX
cord-005478-5iu38pr6	1602	30	12	12	CD
cord-005478-5iu38pr6	1602	31	Gy	Gy	NNS
cord-005478-5iu38pr6	1602	32	.	.	.
cord-005478-5iu38pr6	1603	1	Pre	pre	JJ
cord-005478-5iu38pr6	1603	2	-	-	JJ
cord-005478-5iu38pr6	1603	3	pubertal	pubertal	JJ
cord-005478-5iu38pr6	1603	4	stage	stage	NN
cord-005478-5iu38pr6	1603	5	at	at	IN
cord-005478-5iu38pr6	1603	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1603	7	increases	increase	VBZ
cord-005478-5iu38pr6	1603	8	the	the	DT
cord-005478-5iu38pr6	1603	9	risk	risk	NN
cord-005478-5iu38pr6	1603	10	for	for	IN
cord-005478-5iu38pr6	1603	11	later	later	JJ
cord-005478-5iu38pr6	1603	12	testosterone	testosterone	NN
cord-005478-5iu38pr6	1603	13	substitution	substitution	NN
cord-005478-5iu38pr6	1603	14	supporting	support	VBG
cord-005478-5iu38pr6	1603	15	the	the	DT
cord-005478-5iu38pr6	1603	16	hypothesis	hypothesis	NN
cord-005478-5iu38pr6	1603	17	that	that	IN
cord-005478-5iu38pr6	1603	18	pre	pre	JJ
cord-005478-5iu38pr6	1603	19	-	-	JJ
cord-005478-5iu38pr6	1603	20	pubertal	pubertal	JJ
cord-005478-5iu38pr6	1603	21	Leydig	Leydig	NNP
cord-005478-5iu38pr6	1603	22	cells	cell	NNS
cord-005478-5iu38pr6	1603	23	are	be	VBP
cord-005478-5iu38pr6	1603	24	more	more	RBR
cord-005478-5iu38pr6	1603	25	sensitive	sensitive	JJ
cord-005478-5iu38pr6	1603	26	to	to	IN
cord-005478-5iu38pr6	1603	27	irradiation	irradiation	NN
cord-005478-5iu38pr6	1603	28	than	than	IN
cord-005478-5iu38pr6	1603	29	more	more	JJR
cord-005478-5iu38pr6	1603	30	mature	mature	JJ
cord-005478-5iu38pr6	1603	31	ones	one	NNS
cord-005478-5iu38pr6	1603	32	.	.	.
cord-005478-5iu38pr6	1604	1	Additionally	additionally	RB
cord-005478-5iu38pr6	1604	2	,	,	,
cord-005478-5iu38pr6	1604	3	the	the	DT
cord-005478-5iu38pr6	1604	4	risk	risk	NN
cord-005478-5iu38pr6	1604	5	of	of	IN
cord-005478-5iu38pr6	1604	6	testosterone	testosterone	NN
cord-005478-5iu38pr6	1604	7	substitution	substitution	NN
cord-005478-5iu38pr6	1604	8	increased	increase	VBD
cord-005478-5iu38pr6	1604	9	with	with	IN
cord-005478-5iu38pr6	1604	10	time	time	NN
cord-005478-5iu38pr6	1604	11	from	from	IN
cord-005478-5iu38pr6	1604	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	1604	13	indicating	indicate	VBG
cord-005478-5iu38pr6	1604	14	a	a	DT
cord-005478-5iu38pr6	1604	15	potential	potential	JJ
cord-005478-5iu38pr6	1604	16	early	early	JJ
cord-005478-5iu38pr6	1604	17	androgen	androgen	NN
cord-005478-5iu38pr6	1604	18	insufficiency	insufficiency	NN
cord-005478-5iu38pr6	1604	19	in	in	IN
cord-005478-5iu38pr6	1604	20	male	male	JJ
cord-005478-5iu38pr6	1604	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1604	22	recipients	recipient	NNS
cord-005478-5iu38pr6	1604	23	.	.	.
cord-005478-5iu38pr6	1605	1	Thus	thus	RB
cord-005478-5iu38pr6	1605	2	,	,	,
cord-005478-5iu38pr6	1605	3	close	close	JJ
cord-005478-5iu38pr6	1605	4	follow	follow	NN
cord-005478-5iu38pr6	1605	5	-	-	HYPH
cord-005478-5iu38pr6	1605	6	up	up	NN
cord-005478-5iu38pr6	1605	7	and	and	CC
cord-005478-5iu38pr6	1605	8	focus	focus	VB
cord-005478-5iu38pr6	1605	9	on	on	IN
cord-005478-5iu38pr6	1605	10	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1605	11	irradiation	irradiation	NN
cord-005478-5iu38pr6	1605	12	doses	dose	NNS
cord-005478-5iu38pr6	1605	13	are	be	VBP
cord-005478-5iu38pr6	1605	14	needed	need	VBN
cord-005478-5iu38pr6	1605	15	.	.	.
cord-005478-5iu38pr6	1606	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1606	2	Background	background	NN
cord-005478-5iu38pr6	1606	3	:	:	:
cord-005478-5iu38pr6	1606	4	Hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1606	5	stem	stem	NN
cord-005478-5iu38pr6	1606	6	cell	cell	NN
cord-005478-5iu38pr6	1606	7	transplantation	transplantation	NN
cord-005478-5iu38pr6	1606	8	(	(	-LRB-
cord-005478-5iu38pr6	1606	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1606	10	)	)	-RRB-
cord-005478-5iu38pr6	1606	11	has	have	VBZ
cord-005478-5iu38pr6	1606	12	become	become	VBN
cord-005478-5iu38pr6	1606	13	a	a	DT
cord-005478-5iu38pr6	1606	14	standard	standard	JJ
cord-005478-5iu38pr6	1606	15	component	component	NN
cord-005478-5iu38pr6	1606	16	of	of	IN
cord-005478-5iu38pr6	1606	17	therapy	therapy	NN
cord-005478-5iu38pr6	1606	18	for	for	IN
cord-005478-5iu38pr6	1606	19	several	several	JJ
cord-005478-5iu38pr6	1606	20	malignant	malignant	JJ
cord-005478-5iu38pr6	1606	21	indications	indication	NNS
cord-005478-5iu38pr6	1606	22	.	.	.
cord-005478-5iu38pr6	1607	1	As	as	IN
cord-005478-5iu38pr6	1607	2	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1607	3	may	may	MD
cord-005478-5iu38pr6	1607	4	improve	improve	VB
cord-005478-5iu38pr6	1607	5	survival	survival	NN
cord-005478-5iu38pr6	1607	6	for	for	IN
cord-005478-5iu38pr6	1607	7	some	some	DT
cord-005478-5iu38pr6	1607	8	cancers	cancer	NNS
cord-005478-5iu38pr6	1607	9	,	,	,
cord-005478-5iu38pr6	1607	10	the	the	DT
cord-005478-5iu38pr6	1607	11	risk	risk	NN
cord-005478-5iu38pr6	1607	12	for	for	IN
cord-005478-5iu38pr6	1607	13	late	late	JJ
cord-005478-5iu38pr6	1607	14	complications	complication	NNS
cord-005478-5iu38pr6	1607	15	is	be	VBZ
cord-005478-5iu38pr6	1607	16	of	of	IN
cord-005478-5iu38pr6	1607	17	increasing	increase	VBG
cord-005478-5iu38pr6	1607	18	concern	concern	NN
cord-005478-5iu38pr6	1607	19	.	.	.
cord-005478-5iu38pr6	1608	1	The	the	DT
cord-005478-5iu38pr6	1608	2	frequency	frequency	NN
cord-005478-5iu38pr6	1608	3	of	of	IN
cord-005478-5iu38pr6	1608	4	hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1608	5	can	can	MD
cord-005478-5iu38pr6	1608	6	serve	serve	VB
cord-005478-5iu38pr6	1608	7	as	as	IN
cord-005478-5iu38pr6	1608	8	a	a	DT
cord-005478-5iu38pr6	1608	9	proxy	proxy	JJ
cord-005478-5iu38pr6	1608	10	measure	measure	NN
cord-005478-5iu38pr6	1608	11	of	of	IN
cord-005478-5iu38pr6	1608	12	severe	severe	JJ
cord-005478-5iu38pr6	1608	13	morbidity	morbidity	NN
cord-005478-5iu38pr6	1608	14	.	.	.
cord-005478-5iu38pr6	1609	1	However	however	RB
cord-005478-5iu38pr6	1609	2	,	,	,
cord-005478-5iu38pr6	1609	3	knowledge	knowledge	NN
cord-005478-5iu38pr6	1609	4	regarding	regard	VBG
cord-005478-5iu38pr6	1609	5	late	late	JJ
cord-005478-5iu38pr6	1609	6	hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1609	7	is	be	VBZ
cord-005478-5iu38pr6	1609	8	limited	limited	JJ
cord-005478-5iu38pr6	1609	9	.	.	.
cord-005478-5iu38pr6	1610	1	The	the	DT
cord-005478-5iu38pr6	1610	2	objectives	objective	NNS
cord-005478-5iu38pr6	1610	3	of	of	IN
cord-005478-5iu38pr6	1610	4	the	the	DT
cord-005478-5iu38pr6	1610	5	study	study	NN
cord-005478-5iu38pr6	1610	6	were	be	VBD
cord-005478-5iu38pr6	1610	7	to	to	TO
cord-005478-5iu38pr6	1610	8	describe	describe	VB
cord-005478-5iu38pr6	1610	9	health	health	NN
cord-005478-5iu38pr6	1610	10	care	care	NN
cord-005478-5iu38pr6	1610	11	utilization	utilization	NN
cord-005478-5iu38pr6	1610	12	as	as	IN
cord-005478-5iu38pr6	1610	13	measured	measure	VBN
cord-005478-5iu38pr6	1610	14	by	by	IN
cord-005478-5iu38pr6	1610	15	hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1610	16	beyond	beyond	IN
cord-005478-5iu38pr6	1610	17	2	2	CD
cord-005478-5iu38pr6	1610	18	years	year	NNS
cord-005478-5iu38pr6	1610	19	following	follow	VBG
cord-005478-5iu38pr6	1610	20	transplant	transplant	NN
cord-005478-5iu38pr6	1610	21	in	in	IN
cord-005478-5iu38pr6	1610	22	survivors	survivor	NNS
cord-005478-5iu38pr6	1610	23	of	of	IN
cord-005478-5iu38pr6	1610	24	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1610	25	/	/	SYM
cord-005478-5iu38pr6	1610	26	adolescent	adolescent	JJ
cord-005478-5iu38pr6	1610	27	and	and	CC
cord-005478-5iu38pr6	1610	28	young	young	JJ
cord-005478-5iu38pr6	1610	29	adult	adult	NN
cord-005478-5iu38pr6	1610	30	(	(	-LRB-
cord-005478-5iu38pr6	1610	31	AYA	AYA	NNP
cord-005478-5iu38pr6	1610	32	)	)	-RRB-
cord-005478-5iu38pr6	1610	33	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1610	34	for	for	IN
cord-005478-5iu38pr6	1610	35	a	a	DT
cord-005478-5iu38pr6	1610	36	malignant	malignant	JJ
cord-005478-5iu38pr6	1610	37	indication	indication	NN
cord-005478-5iu38pr6	1610	38	.	.	.
cord-005478-5iu38pr6	1611	1	Methods	method	NNS
cord-005478-5iu38pr6	1611	2	:	:	:
cord-005478-5iu38pr6	1611	3	We	-PRON-	PRP
cord-005478-5iu38pr6	1611	4	linked	link	VBD
cord-005478-5iu38pr6	1611	5	data	datum	NNS
cord-005478-5iu38pr6	1611	6	from	from	IN
cord-005478-5iu38pr6	1611	7	3	3	CD
cord-005478-5iu38pr6	1611	8	Ontario	Ontario	NNP
cord-005478-5iu38pr6	1611	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1611	10	centers	center	NNS
cord-005478-5iu38pr6	1611	11	and	and	CC
cord-005478-5iu38pr6	1611	12	provincial	provincial	JJ
cord-005478-5iu38pr6	1611	13	health	health	NN
cord-005478-5iu38pr6	1611	14	care	care	NN
cord-005478-5iu38pr6	1611	15	utilization	utilization	NN
cord-005478-5iu38pr6	1611	16	data	datum	NNS
cord-005478-5iu38pr6	1611	17	housed	house	VBN
cord-005478-5iu38pr6	1611	18	at	at	IN
cord-005478-5iu38pr6	1611	19	Institute	Institute	NNP
cord-005478-5iu38pr6	1611	20	for	for	IN
cord-005478-5iu38pr6	1611	21	Clinical	Clinical	NNP
cord-005478-5iu38pr6	1611	22	Evaluative	Evaluative	NNP
cord-005478-5iu38pr6	1611	23	Sciences	Sciences	NNPS
cord-005478-5iu38pr6	1611	24	(	(	-LRB-
cord-005478-5iu38pr6	1611	25	ICES	ICES	NNP
cord-005478-5iu38pr6	1611	26	)	)	-RRB-
cord-005478-5iu38pr6	1611	27	to	to	TO
cord-005478-5iu38pr6	1611	28	describe	describe	VB
cord-005478-5iu38pr6	1611	29	all	all	DT
cord-005478-5iu38pr6	1611	30	hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1611	31	and	and	CC
cord-005478-5iu38pr6	1611	32	their	-PRON-	PRP$
cord-005478-5iu38pr6	1611	33	indications	indication	NNS
cord-005478-5iu38pr6	1611	34	.	.	.
cord-005478-5iu38pr6	1612	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1612	2	also	also	RB
cord-005478-5iu38pr6	1612	3	described	describe	VBD
cord-005478-5iu38pr6	1612	4	intensive	intensive	JJ
cord-005478-5iu38pr6	1612	5	-	-	HYPH
cord-005478-5iu38pr6	1612	6	care	care	NN
cord-005478-5iu38pr6	1612	7	unit	unit	NN
cord-005478-5iu38pr6	1612	8	admissions	admission	NNS
cord-005478-5iu38pr6	1612	9	.	.	.
cord-005478-5iu38pr6	1613	1	The	the	DT
cord-005478-5iu38pr6	1613	2	study	study	NN
cord-005478-5iu38pr6	1613	3	population	population	NN
cord-005478-5iu38pr6	1613	4	included	include	VBD
cord-005478-5iu38pr6	1613	5	Ontario	Ontario	NNP
cord-005478-5iu38pr6	1613	6	residents	resident	NNS
cord-005478-5iu38pr6	1613	7	with	with	IN
cord-005478-5iu38pr6	1613	8	cancer	cancer	NN
cord-005478-5iu38pr6	1613	9	age	age	NN
cord-005478-5iu38pr6	1613	10	0	0	CD
cord-005478-5iu38pr6	1613	11	-	-	SYM
cord-005478-5iu38pr6	1613	12	30	30	CD
cord-005478-5iu38pr6	1613	13	years	year	NNS
cord-005478-5iu38pr6	1613	14	who	who	WP
cord-005478-5iu38pr6	1613	15	underwent	undergo	VBD
cord-005478-5iu38pr6	1613	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1613	17	between	between	IN
cord-005478-5iu38pr6	1613	18	1992	1992	CD
cord-005478-5iu38pr6	1613	19	and	and	CC
cord-005478-5iu38pr6	1613	20	2015	2015	CD
cord-005478-5iu38pr6	1613	21	,	,	,
cord-005478-5iu38pr6	1613	22	who	who	WP
cord-005478-5iu38pr6	1613	23	survived	survive	VBD
cord-005478-5iu38pr6	1613	24	more	more	JJR
cord-005478-5iu38pr6	1613	25	than	than	IN
cord-005478-5iu38pr6	1613	26	2	2	CD
cord-005478-5iu38pr6	1613	27	years	year	NNS
cord-005478-5iu38pr6	1613	28	from	from	IN
cord-005478-5iu38pr6	1613	29	transplant	transplant	NN
cord-005478-5iu38pr6	1613	30	(	(	-LRB-
cord-005478-5iu38pr6	1613	31	index	index	NN
cord-005478-5iu38pr6	1613	32	date	date	NN
cord-005478-5iu38pr6	1613	33	)	)	-RRB-
cord-005478-5iu38pr6	1613	34	.	.	.
cord-005478-5iu38pr6	1614	1	Hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1614	2	were	be	VBD
cord-005478-5iu38pr6	1614	3	described	describe	VBN
cord-005478-5iu38pr6	1614	4	from	from	IN
cord-005478-5iu38pr6	1614	5	the	the	DT
cord-005478-5iu38pr6	1614	6	index	index	NN
cord-005478-5iu38pr6	1614	7	date	date	NN
cord-005478-5iu38pr6	1614	8	until	until	IN
cord-005478-5iu38pr6	1614	9	Dec	Dec	NNP
cord-005478-5iu38pr6	1614	10	2017	2017	CD
cord-005478-5iu38pr6	1614	11	or	or	CC
cord-005478-5iu38pr6	1614	12	death	death	NN
cord-005478-5iu38pr6	1614	13	.	.	.
cord-005478-5iu38pr6	1615	1	Results	result	NNS
cord-005478-5iu38pr6	1615	2	:	:	:
cord-005478-5iu38pr6	1616	1	The	the	DT
cord-005478-5iu38pr6	1616	2	cohort	cohort	NN
cord-005478-5iu38pr6	1616	3	consisted	consist	VBD
cord-005478-5iu38pr6	1616	4	of	of	IN
cord-005478-5iu38pr6	1616	5	446	446	CD
cord-005478-5iu38pr6	1616	6	survivors	survivor	NNS
cord-005478-5iu38pr6	1616	7	who	who	WP
cord-005478-5iu38pr6	1616	8	were	be	VBD
cord-005478-5iu38pr6	1616	9	followed	follow	VBN
cord-005478-5iu38pr6	1616	10	for	for	IN
cord-005478-5iu38pr6	1616	11	a	a	DT
cord-005478-5iu38pr6	1616	12	median	median	NN
cord-005478-5iu38pr6	1616	13	of	of	IN
cord-005478-5iu38pr6	1616	14	11.4	11.4	CD
cord-005478-5iu38pr6	1616	15	years	year	NNS
cord-005478-5iu38pr6	1616	16	from	from	IN
cord-005478-5iu38pr6	1616	17	index	index	NN
cord-005478-5iu38pr6	1616	18	date	date	NN
cord-005478-5iu38pr6	1616	19	(	(	-LRB-
cord-005478-5iu38pr6	1616	20	interquartile	interquartile	JJ
cord-005478-5iu38pr6	1616	21	range	range	NN
cord-005478-5iu38pr6	1616	22	(	(	-LRB-
cord-005478-5iu38pr6	1616	23	IQR	IQR	NNP
cord-005478-5iu38pr6	1616	24	)	)	-RRB-
cord-005478-5iu38pr6	1616	25	2.6	2.6	CD
cord-005478-5iu38pr6	1616	26	-	-	HYPH
cord-005478-5iu38pr6	1616	27	18.5	18.5	CD
cord-005478-5iu38pr6	1616	28	)	)	-RRB-
cord-005478-5iu38pr6	1616	29	.	.	.
cord-005478-5iu38pr6	1617	1	Indications	indication	NNS
cord-005478-5iu38pr6	1617	2	for	for	IN
cord-005478-5iu38pr6	1617	3	transplant	transplant	NN
cord-005478-5iu38pr6	1617	4	included	include	VBN
cord-005478-5iu38pr6	1617	5	:	:	:
cord-005478-5iu38pr6	1617	6	acute	acute	JJ
cord-005478-5iu38pr6	1617	7	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	1617	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	1617	9	(	(	-LRB-
cord-005478-5iu38pr6	1617	10	n=190	n=190	CD
cord-005478-5iu38pr6	1617	11	,	,	,
cord-005478-5iu38pr6	1617	12	42.6	42.6	CD
cord-005478-5iu38pr6	1617	13	%	%	NN
cord-005478-5iu38pr6	1617	14	)	)	-RRB-
cord-005478-5iu38pr6	1617	15	;	;	,
cord-005478-5iu38pr6	1617	16	myeloid	myeloid	JJ
cord-005478-5iu38pr6	1617	17	malignancy	malignancy	NN
cord-005478-5iu38pr6	1617	18	(	(	-LRB-
cord-005478-5iu38pr6	1617	19	n=231	n=231	CD
cord-005478-5iu38pr6	1617	20	,	,	,
cord-005478-5iu38pr6	1617	21	51.8	51.8	CD
cord-005478-5iu38pr6	1617	22	%	%	NN
cord-005478-5iu38pr6	1617	23	)	)	-RRB-
cord-005478-5iu38pr6	1617	24	;	;	:
cord-005478-5iu38pr6	1617	25	and	and	CC
cord-005478-5iu38pr6	1617	26	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1617	27	(	(	-LRB-
cord-005478-5iu38pr6	1617	28	n=25	n=25	NN
cord-005478-5iu38pr6	1617	29	,	,	,
cord-005478-5iu38pr6	1617	30	5.6	5.6	CD
cord-005478-5iu38pr6	1617	31	%	%	NN
cord-005478-5iu38pr6	1617	32	)	)	-RRB-
cord-005478-5iu38pr6	1617	33	.	.	.
cord-005478-5iu38pr6	1618	1	Of	of	IN
cord-005478-5iu38pr6	1618	2	these	these	DT
cord-005478-5iu38pr6	1618	3	,	,	,
cord-005478-5iu38pr6	1618	4	150	150	CD
cord-005478-5iu38pr6	1618	5	(	(	-LRB-
cord-005478-5iu38pr6	1618	6	33.6	33.6	CD
cord-005478-5iu38pr6	1618	7	%	%	NN
cord-005478-5iu38pr6	1618	8	)	)	-RRB-
cord-005478-5iu38pr6	1618	9	received	receive	VBD
cord-005478-5iu38pr6	1618	10	a	a	DT
cord-005478-5iu38pr6	1618	11	related	relate	VBN
cord-005478-5iu38pr6	1618	12	-	-	HYPH
cord-005478-5iu38pr6	1618	13	donor	donor	NN
cord-005478-5iu38pr6	1618	14	bone	bone	NN
cord-005478-5iu38pr6	1618	15	-	-	HYPH
cord-005478-5iu38pr6	1618	16	marrow	marrow	NN
cord-005478-5iu38pr6	1618	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1618	18	.	.	.
cord-005478-5iu38pr6	1619	1	At	at	IN
cord-005478-5iu38pr6	1619	2	the	the	DT
cord-005478-5iu38pr6	1619	3	time	time	NN
cord-005478-5iu38pr6	1619	4	of	of	IN
cord-005478-5iu38pr6	1619	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1619	6	,	,	,
cord-005478-5iu38pr6	1619	7	ages	age	NNS
cord-005478-5iu38pr6	1619	8	were	be	VBD
cord-005478-5iu38pr6	1619	9	:	:	:
cord-005478-5iu38pr6	1619	10	0	0	CD
cord-005478-5iu38pr6	1619	11	-	-	SYM
cord-005478-5iu38pr6	1619	12	9	9	CD
cord-005478-5iu38pr6	1619	13	(	(	-LRB-
cord-005478-5iu38pr6	1619	14	n=132	n=132	UH
cord-005478-5iu38pr6	1619	15	,	,	,
cord-005478-5iu38pr6	1619	16	29.6	29.6	CD
cord-005478-5iu38pr6	1619	17	%	%	NN
cord-005478-5iu38pr6	1619	18	)	)	-RRB-
cord-005478-5iu38pr6	1619	19	;	;	:
cord-005478-5iu38pr6	1619	20	10	10	CD
cord-005478-5iu38pr6	1619	21	-	-	SYM
cord-005478-5iu38pr6	1619	22	18	18	CD
cord-005478-5iu38pr6	1619	23	(	(	-LRB-
cord-005478-5iu38pr6	1619	24	n=137	n=137	CD
cord-005478-5iu38pr6	1619	25	,	,	,
cord-005478-5iu38pr6	1619	26	30.7	30.7	CD
cord-005478-5iu38pr6	1619	27	%	%	NN
cord-005478-5iu38pr6	1619	28	)	)	-RRB-
cord-005478-5iu38pr6	1619	29	;	;	:
cord-005478-5iu38pr6	1619	30	and	and	CC
cord-005478-5iu38pr6	1619	31	19	19	CD
cord-005478-5iu38pr6	1619	32	-	-	SYM
cord-005478-5iu38pr6	1619	33	29	29	CD
cord-005478-5iu38pr6	1619	34	(	(	-LRB-
cord-005478-5iu38pr6	1619	35	n=177	n=177	NNP
cord-005478-5iu38pr6	1619	36	,	,	,
cord-005478-5iu38pr6	1619	37	39.7	39.7	CD
cord-005478-5iu38pr6	1619	38	%	%	NN
cord-005478-5iu38pr6	1619	39	)	)	-RRB-
cord-005478-5iu38pr6	1619	40	years	year	NNS
cord-005478-5iu38pr6	1619	41	.	.	.
cord-005478-5iu38pr6	1620	1	There	there	EX
cord-005478-5iu38pr6	1620	2	were	be	VBD
cord-005478-5iu38pr6	1620	3	269	269	CD
cord-005478-5iu38pr6	1620	4	patients	patient	NNS
cord-005478-5iu38pr6	1620	5	(	(	-LRB-
cord-005478-5iu38pr6	1620	6	60	60	CD
cord-005478-5iu38pr6	1620	7	%	%	NN
cord-005478-5iu38pr6	1620	8	)	)	-RRB-
cord-005478-5iu38pr6	1620	9	with	with	IN
cord-005478-5iu38pr6	1620	10	at	at	RB
cord-005478-5iu38pr6	1620	11	least	least	JJS
cord-005478-5iu38pr6	1620	12	1	1	CD
cord-005478-5iu38pr6	1620	13	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1620	14	beyond	beyond	IN
cord-005478-5iu38pr6	1620	15	2	2	CD
cord-005478-5iu38pr6	1620	16	years	year	NNS
cord-005478-5iu38pr6	1620	17	from	from	IN
cord-005478-5iu38pr6	1620	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1620	19	.	.	.
cord-005478-5iu38pr6	1621	1	There	there	EX
cord-005478-5iu38pr6	1621	2	were	be	VBD
cord-005478-5iu38pr6	1621	3	a	a	DT
cord-005478-5iu38pr6	1621	4	total	total	NN
cord-005478-5iu38pr6	1621	5	of	of	IN
cord-005478-5iu38pr6	1621	6	1879	1879	CD
cord-005478-5iu38pr6	1621	7	hospitalizations	hospitalization	NNS
cord-005478-5iu38pr6	1621	8	,	,	,
cord-005478-5iu38pr6	1621	9	resulting	result	VBG
cord-005478-5iu38pr6	1621	10	in	in	IN
cord-005478-5iu38pr6	1621	11	a	a	DT
cord-005478-5iu38pr6	1621	12	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1621	13	rate	rate	NN
cord-005478-5iu38pr6	1621	14	of	of	IN
cord-005478-5iu38pr6	1621	15	0.43	0.43	CD
cord-005478-5iu38pr6	1621	16	per	per	IN
cord-005478-5iu38pr6	1621	17	follow	follow	NN
cord-005478-5iu38pr6	1621	18	-	-	HYPH
cord-005478-5iu38pr6	1621	19	up	up	NN
cord-005478-5iu38pr6	1621	20	year	year	NN
cord-005478-5iu38pr6	1621	21	.	.	.
cord-005478-5iu38pr6	1622	1	Average	average	JJ
cord-005478-5iu38pr6	1622	2	length	length	NN
cord-005478-5iu38pr6	1622	3	of	of	IN
cord-005478-5iu38pr6	1622	4	hospital	hospital	NN
cord-005478-5iu38pr6	1622	5	stay	stay	NN
cord-005478-5iu38pr6	1622	6	was	be	VBD
cord-005478-5iu38pr6	1622	7	6.1	6.1	CD
cord-005478-5iu38pr6	1622	8	days	day	NNS
cord-005478-5iu38pr6	1622	9	.	.	.
cord-005478-5iu38pr6	1623	1	A	a	DT
cord-005478-5iu38pr6	1623	2	total	total	NN
cord-005478-5iu38pr6	1623	3	of	of	IN
cord-005478-5iu38pr6	1623	4	97	97	CD
cord-005478-5iu38pr6	1623	5	intensivecare	intensivecare	JJ
cord-005478-5iu38pr6	1623	6	unit	unit	NN
cord-005478-5iu38pr6	1623	7	admissions	admission	NNS
cord-005478-5iu38pr6	1623	8	were	be	VBD
cord-005478-5iu38pr6	1623	9	documented	document	VBN
cord-005478-5iu38pr6	1623	10	among	among	IN
cord-005478-5iu38pr6	1623	11	57	57	CD
cord-005478-5iu38pr6	1623	12	(	(	-LRB-
cord-005478-5iu38pr6	1623	13	12.8	12.8	CD
cord-005478-5iu38pr6	1623	14	%	%	NN
cord-005478-5iu38pr6	1623	15	)	)	-RRB-
cord-005478-5iu38pr6	1623	16	patients	patient	NNS
cord-005478-5iu38pr6	1623	17	.	.	.
cord-005478-5iu38pr6	1624	1	The	the	DT
cord-005478-5iu38pr6	1624	2	most	most	RBS
cord-005478-5iu38pr6	1624	3	common	common	JJ
cord-005478-5iu38pr6	1624	4	indications	indication	NNS
cord-005478-5iu38pr6	1624	5	for	for	IN
cord-005478-5iu38pr6	1624	6	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1624	7	were	be	VBD
cord-005478-5iu38pr6	1624	8	:	:	:
cord-005478-5iu38pr6	1625	1	graft	graft	NN
cord-005478-5iu38pr6	1625	2	-	-	HYPH
cord-005478-5iu38pr6	1625	3	versus	versus	IN
cord-005478-5iu38pr6	1625	4	-	-	HYPH
cord-005478-5iu38pr6	1625	5	host	host	NN
cord-005478-5iu38pr6	1625	6	disease	disease	NN
cord-005478-5iu38pr6	1625	7	(	(	-LRB-
cord-005478-5iu38pr6	1625	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1625	9	)	)	-RRB-
cord-005478-5iu38pr6	1625	10	(	(	-LRB-
cord-005478-5iu38pr6	1625	11	n=486	n=486	NNP
cord-005478-5iu38pr6	1625	12	,	,	,
cord-005478-5iu38pr6	1625	13	25.9	25.9	CD
cord-005478-5iu38pr6	1625	14	%	%	NN
cord-005478-5iu38pr6	1625	15	)	)	-RRB-
cord-005478-5iu38pr6	1625	16	,	,	,
cord-005478-5iu38pr6	1625	17	relapse	relapse	NN
cord-005478-5iu38pr6	1625	18	(	(	-LRB-
cord-005478-5iu38pr6	1625	19	n=303	n=303	UH
cord-005478-5iu38pr6	1625	20	,	,	,
cord-005478-5iu38pr6	1625	21	16.1	16.1	CD
cord-005478-5iu38pr6	1625	22	%	%	NN
cord-005478-5iu38pr6	1625	23	)	)	-RRB-
cord-005478-5iu38pr6	1625	24	,	,	,
cord-005478-5iu38pr6	1625	25	infection	infection	NN
cord-005478-5iu38pr6	1625	26	(	(	-LRB-
cord-005478-5iu38pr6	1625	27	n=186	n=186	NNP
cord-005478-5iu38pr6	1625	28	,	,	,
cord-005478-5iu38pr6	1625	29	9.8	9.8	CD
cord-005478-5iu38pr6	1625	30	%	%	NN
cord-005478-5iu38pr6	1625	31	)	)	-RRB-
cord-005478-5iu38pr6	1625	32	,	,	,
cord-005478-5iu38pr6	1625	33	orthopedic	orthopedic	NN
cord-005478-5iu38pr6	1625	34	procedures	procedure	NNS
cord-005478-5iu38pr6	1625	35	/	/	SYM
cord-005478-5iu38pr6	1625	36	fractures	fracture	NNS
cord-005478-5iu38pr6	1625	37	(	(	-LRB-
cord-005478-5iu38pr6	1625	38	n=90	n=90	NNP
cord-005478-5iu38pr6	1625	39	,	,	,
cord-005478-5iu38pr6	1625	40	5.4	5.4	CD
cord-005478-5iu38pr6	1625	41	%	%	NN
cord-005478-5iu38pr6	1625	42	)	)	-RRB-
cord-005478-5iu38pr6	1625	43	,	,	,
cord-005478-5iu38pr6	1625	44	benign	benign	JJ
cord-005478-5iu38pr6	1625	45	neoplasm	neoplasm	NN
cord-005478-5iu38pr6	1625	46	(	(	-LRB-
cord-005478-5iu38pr6	1625	47	n=96	n=96	FW
cord-005478-5iu38pr6	1625	48	,	,	,
cord-005478-5iu38pr6	1625	49	5.3	5.3	CD
cord-005478-5iu38pr6	1625	50	%	%	NN
cord-005478-5iu38pr6	1625	51	)	)	-RRB-
cord-005478-5iu38pr6	1625	52	and	and	CC
cord-005478-5iu38pr6	1625	53	subsequent	subsequent	JJ
cord-005478-5iu38pr6	1625	54	malignant	malignant	JJ
cord-005478-5iu38pr6	1625	55	neoplasm	neoplasm	NN
cord-005478-5iu38pr6	1625	56	(	(	-LRB-
cord-005478-5iu38pr6	1625	57	n=83	n=83	NN
cord-005478-5iu38pr6	1625	58	,	,	,
cord-005478-5iu38pr6	1625	59	4.7	4.7	CD
cord-005478-5iu38pr6	1625	60	%	%	NN
cord-005478-5iu38pr6	1625	61	)	)	-RRB-
cord-005478-5iu38pr6	1625	62	.	.	.
cord-005478-5iu38pr6	1626	1	Among	among	IN
cord-005478-5iu38pr6	1626	2	those	those	DT
cord-005478-5iu38pr6	1626	3	who	who	WP
cord-005478-5iu38pr6	1626	4	did	do	VBD
cord-005478-5iu38pr6	1626	5	not	not	RB
cord-005478-5iu38pr6	1626	6	relapse	relapse	VB
cord-005478-5iu38pr6	1626	7	,	,	,
cord-005478-5iu38pr6	1626	8	190/320	190/320	CD
cord-005478-5iu38pr6	1626	9	(	(	-LRB-
cord-005478-5iu38pr6	1626	10	59	59	CD
cord-005478-5iu38pr6	1626	11	%	%	NN
cord-005478-5iu38pr6	1626	12	)	)	-RRB-
cord-005478-5iu38pr6	1626	13	were	be	VBD
cord-005478-5iu38pr6	1626	14	hospitalized	hospitalize	VBN
cord-005478-5iu38pr6	1626	15	.	.	.
cord-005478-5iu38pr6	1627	1	At	at	IN
cord-005478-5iu38pr6	1627	2	10	10	CD
cord-005478-5iu38pr6	1627	3	years	year	NNS
cord-005478-5iu38pr6	1627	4	following	follow	VBG
cord-005478-5iu38pr6	1627	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1627	6	,	,	,
cord-005478-5iu38pr6	1627	7	the	the	DT
cord-005478-5iu38pr6	1627	8	proportion	proportion	NN
cord-005478-5iu38pr6	1627	9	of	of	IN
cord-005478-5iu38pr6	1627	10	patients	patient	NNS
cord-005478-5iu38pr6	1627	11	hospitalized	hospitalize	VBN
cord-005478-5iu38pr6	1627	12	was	be	VBD
cord-005478-5iu38pr6	1627	13	10.5	10.5	CD
cord-005478-5iu38pr6	1627	14	%	%	NN
cord-005478-5iu38pr6	1627	15	.	.	.
cord-005478-5iu38pr6	1628	1	An	an	DT
cord-005478-5iu38pr6	1628	2	underlying	underlie	VBG
cord-005478-5iu38pr6	1628	3	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1628	4	of	of	IN
cord-005478-5iu38pr6	1628	5	acute	acute	JJ
cord-005478-5iu38pr6	1628	6	myeloid	myeloid	NN
cord-005478-5iu38pr6	1628	7	leukemia	leukemia	NN
cord-005478-5iu38pr6	1628	8	(	(	-LRB-
cord-005478-5iu38pr6	1628	9	AML	AML	NNP
cord-005478-5iu38pr6	1628	10	)	)	-RRB-
cord-005478-5iu38pr6	1628	11	(	(	-LRB-
cord-005478-5iu38pr6	1628	12	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	1628	13	)	)	-RRB-
cord-005478-5iu38pr6	1628	14	and	and	CC
cord-005478-5iu38pr6	1628	15	chronic	chronic	JJ
cord-005478-5iu38pr6	1628	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1628	17	(	(	-LRB-
cord-005478-5iu38pr6	1628	18	p=0.014	p=0.014	NNS
cord-005478-5iu38pr6	1628	19	)	)	-RRB-
cord-005478-5iu38pr6	1628	20	were	be	VBD
cord-005478-5iu38pr6	1628	21	associated	associate	VBN
cord-005478-5iu38pr6	1628	22	with	with	IN
cord-005478-5iu38pr6	1628	23	increased	increase	VBN
cord-005478-5iu38pr6	1628	24	rate	rate	NN
cord-005478-5iu38pr6	1628	25	of	of	IN
cord-005478-5iu38pr6	1628	26	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1628	27	.	.	.
cord-005478-5iu38pr6	1629	1	In	in	IN
cord-005478-5iu38pr6	1629	2	the	the	DT
cord-005478-5iu38pr6	1629	3	follow	follow	NN
cord-005478-5iu38pr6	1629	4	-	-	HYPH
cord-005478-5iu38pr6	1629	5	up	up	NN
cord-005478-5iu38pr6	1629	6	period	period	NN
cord-005478-5iu38pr6	1629	7	,	,	,
cord-005478-5iu38pr6	1629	8	73	73	CD
cord-005478-5iu38pr6	1629	9	(	(	-LRB-
cord-005478-5iu38pr6	1629	10	16.4	16.4	CD
cord-005478-5iu38pr6	1629	11	%	%	NN
cord-005478-5iu38pr6	1629	12	)	)	-RRB-
cord-005478-5iu38pr6	1629	13	patients	patient	NNS
cord-005478-5iu38pr6	1629	14	died	die	VBD
cord-005478-5iu38pr6	1629	15	.	.	.
cord-005478-5iu38pr6	1630	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1630	2	:	:	:
cord-005478-5iu38pr6	1631	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1631	2	identified	identify	VBD
cord-005478-5iu38pr6	1631	3	a	a	DT
cord-005478-5iu38pr6	1631	4	high	high	JJ
cord-005478-5iu38pr6	1631	5	rate	rate	NN
cord-005478-5iu38pr6	1631	6	of	of	IN
cord-005478-5iu38pr6	1631	7	late	late	JJ
cord-005478-5iu38pr6	1631	8	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1631	9	in	in	IN
cord-005478-5iu38pr6	1631	10	pediatric	pediatric	JJ
cord-005478-5iu38pr6	1631	11	/	/	SYM
cord-005478-5iu38pr6	1631	12	AYA	AYA	NNP
cord-005478-5iu38pr6	1631	13	survivors	survivor	NNS
cord-005478-5iu38pr6	1631	14	who	who	WP
cord-005478-5iu38pr6	1631	15	underwent	undergo	VBD
cord-005478-5iu38pr6	1631	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1631	17	for	for	IN
cord-005478-5iu38pr6	1631	18	a	a	DT
cord-005478-5iu38pr6	1631	19	malignant	malignant	JJ
cord-005478-5iu38pr6	1631	20	indication	indication	NN
cord-005478-5iu38pr6	1631	21	,	,	,
cord-005478-5iu38pr6	1631	22	even	even	RB
cord-005478-5iu38pr6	1631	23	among	among	IN
cord-005478-5iu38pr6	1631	24	those	those	DT
cord-005478-5iu38pr6	1631	25	without	without	IN
cord-005478-5iu38pr6	1631	26	relapse	relapse	NN
cord-005478-5iu38pr6	1631	27	.	.	.
cord-005478-5iu38pr6	1632	1	A	a	DT
cord-005478-5iu38pr6	1632	2	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1632	3	of	of	IN
cord-005478-5iu38pr6	1632	4	AML	AML	NNP
cord-005478-5iu38pr6	1632	5	and	and	CC
cord-005478-5iu38pr6	1632	6	chronic	chronic	JJ
cord-005478-5iu38pr6	1632	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1632	8	were	be	VBD
cord-005478-5iu38pr6	1632	9	associated	associate	VBN
cord-005478-5iu38pr6	1632	10	with	with	IN
cord-005478-5iu38pr6	1632	11	increased	increase	VBN
cord-005478-5iu38pr6	1632	12	risk	risk	NN
cord-005478-5iu38pr6	1632	13	for	for	IN
cord-005478-5iu38pr6	1632	14	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1632	15	.	.	.
cord-005478-5iu38pr6	1633	1	Careful	careful	JJ
cord-005478-5iu38pr6	1633	2	observation	observation	NN
cord-005478-5iu38pr6	1633	3	in	in	IN
cord-005478-5iu38pr6	1633	4	the	the	DT
cord-005478-5iu38pr6	1633	5	survivorship	survivorship	NN
cord-005478-5iu38pr6	1633	6	period	period	NN
cord-005478-5iu38pr6	1633	7	is	be	VBZ
cord-005478-5iu38pr6	1633	8	required	require	VBN
cord-005478-5iu38pr6	1633	9	for	for	IN
cord-005478-5iu38pr6	1633	10	potential	potential	JJ
cord-005478-5iu38pr6	1633	11	prevention	prevention	NN
cord-005478-5iu38pr6	1633	12	of	of	IN
cord-005478-5iu38pr6	1633	13	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1633	14	.	.	.
cord-005478-5iu38pr6	1634	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1634	2	Background	background	NN
cord-005478-5iu38pr6	1634	3	:	:	:
cord-005478-5iu38pr6	1635	1	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	1635	2	syndrome	syndrome	NN
cord-005478-5iu38pr6	1635	3	(	(	-LRB-
cord-005478-5iu38pr6	1635	4	ES	ES	NNP
cord-005478-5iu38pr6	1635	5	)	)	-RRB-
cord-005478-5iu38pr6	1635	6	is	be	VBZ
cord-005478-5iu38pr6	1635	7	a	a	DT
cord-005478-5iu38pr6	1635	8	clinical	clinical	JJ
cord-005478-5iu38pr6	1635	9	complication	complication	NN
cord-005478-5iu38pr6	1635	10	characterized	characterize	VBN
cord-005478-5iu38pr6	1635	11	by	by	IN
cord-005478-5iu38pr6	1635	12	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	1635	13	signs	sign	NNS
cord-005478-5iu38pr6	1635	14	and	and	CC
cord-005478-5iu38pr6	1635	15	symptoms	symptom	NNS
cord-005478-5iu38pr6	1635	16	occurring	occur	VBG
cord-005478-5iu38pr6	1635	17	during	during	IN
cord-005478-5iu38pr6	1635	18	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1635	19	recovery	recovery	NN
cord-005478-5iu38pr6	1635	20	after	after	IN
cord-005478-5iu38pr6	1635	21	stem	stem	NN
cord-005478-5iu38pr6	1635	22	cell	cell	NN
cord-005478-5iu38pr6	1635	23	transplantation	transplantation	NN
cord-005478-5iu38pr6	1635	24	(	(	-LRB-
cord-005478-5iu38pr6	1635	25	SCT	SCT	NNP
cord-005478-5iu38pr6	1635	26	)	)	-RRB-
cord-005478-5iu38pr6	1635	27	.	.	.
cord-005478-5iu38pr6	1636	1	Its	-PRON-	PRP$
cord-005478-5iu38pr6	1636	2	incidence	incidence	NN
cord-005478-5iu38pr6	1636	3	varies	vary	VBZ
cord-005478-5iu38pr6	1636	4	depending	depend	VBG
cord-005478-5iu38pr6	1636	5	on	on	IN
cord-005478-5iu38pr6	1636	6	the	the	DT
cord-005478-5iu38pr6	1636	7	clinical	clinical	JJ
cord-005478-5iu38pr6	1636	8	criteria	criterion	NNS
cord-005478-5iu38pr6	1636	9	used	use	VBN
cord-005478-5iu38pr6	1636	10	.	.	.
cord-005478-5iu38pr6	1637	1	The	the	DT
cord-005478-5iu38pr6	1637	2	objective	objective	NN
cord-005478-5iu38pr6	1637	3	of	of	IN
cord-005478-5iu38pr6	1637	4	this	this	DT
cord-005478-5iu38pr6	1637	5	study	study	NN
cord-005478-5iu38pr6	1637	6	was	be	VBD
cord-005478-5iu38pr6	1637	7	to	to	TO
cord-005478-5iu38pr6	1637	8	analyze	analyze	VB
cord-005478-5iu38pr6	1637	9	the	the	DT
cord-005478-5iu38pr6	1637	10	incidence	incidence	NN
cord-005478-5iu38pr6	1637	11	,	,	,
cord-005478-5iu38pr6	1637	12	clinical	clinical	JJ
cord-005478-5iu38pr6	1637	13	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1637	14	,	,	,
cord-005478-5iu38pr6	1637	15	risk	risk	NN
cord-005478-5iu38pr6	1637	16	factors	factor	NNS
cord-005478-5iu38pr6	1637	17	and	and	CC
cord-005478-5iu38pr6	1637	18	clinical	clinical	JJ
cord-005478-5iu38pr6	1637	19	outcomes	outcome	NNS
cord-005478-5iu38pr6	1637	20	of	of	IN
cord-005478-5iu38pr6	1637	21	ES	ES	NNP
cord-005478-5iu38pr6	1637	22	after	after	IN
cord-005478-5iu38pr6	1637	23	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1637	24	-	-	HYPH
cord-005478-5iu38pr6	1637	25	SCT	SCT	NNP
cord-005478-5iu38pr6	1637	26	with	with	IN
cord-005478-5iu38pr6	1637	27	post	post	JJ
cord-005478-5iu38pr6	1637	28	-	-	JJ
cord-005478-5iu38pr6	1637	29	transplant	transplant	NN
cord-005478-5iu38pr6	1637	30	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	1637	31	(	(	-LRB-
cord-005478-5iu38pr6	1637	32	HaploSCT	HaploSCT	NNP
cord-005478-5iu38pr6	1637	33	)	)	-RRB-
cord-005478-5iu38pr6	1637	34	in	in	IN
cord-005478-5iu38pr6	1637	35	a	a	DT
cord-005478-5iu38pr6	1637	36	single	single	JJ
cord-005478-5iu38pr6	1637	37	center	center	NN
cord-005478-5iu38pr6	1637	38	.	.	.
cord-005478-5iu38pr6	1638	1	Methods	method	NNS
cord-005478-5iu38pr6	1638	2	:	:	:
cord-005478-5iu38pr6	1638	3	105	105	CD
cord-005478-5iu38pr6	1638	4	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1638	5	Haplo	Haplo	NNP
cord-005478-5iu38pr6	1638	6	-	-	HYPH
cord-005478-5iu38pr6	1638	7	SCT	SCT	NNP
cord-005478-5iu38pr6	1638	8	performed	perform	VBN
cord-005478-5iu38pr6	1638	9	between	between	IN
cord-005478-5iu38pr6	1638	10	2010	2010	CD
cord-005478-5iu38pr6	1638	11	-	-	SYM
cord-005478-5iu38pr6	1638	12	2016	2016	CD
cord-005478-5iu38pr6	1638	13	in	in	IN
cord-005478-5iu38pr6	1638	14	our	-PRON-	PRP$
cord-005478-5iu38pr6	1638	15	center	center	NN
cord-005478-5iu38pr6	1638	16	were	be	VBD
cord-005478-5iu38pr6	1638	17	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	1638	18	reviewed	review	VBN
cord-005478-5iu38pr6	1638	19	.	.	.
cord-005478-5iu38pr6	1639	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1639	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1639	3	was	be	VBD
cord-005478-5iu38pr6	1639	4	performed	perform	VBN
cord-005478-5iu38pr6	1639	5	with	with	IN
cord-005478-5iu38pr6	1639	6	cyclophosphamide	cyclophosphamide	JJ
cord-005478-5iu38pr6	1639	7	50mg	50mg	NN
cord-005478-5iu38pr6	1639	8	/	/	SYM
cord-005478-5iu38pr6	1639	9	kg	kg	NN
cord-005478-5iu38pr6	1639	10	/	/	SYM
cord-005478-5iu38pr6	1639	11	day	day	NN
cord-005478-5iu38pr6	1639	12	days	day	NNS
cord-005478-5iu38pr6	1639	13	+4	+4	-RRB-
cord-005478-5iu38pr6	1639	14	and	and	CC
cord-005478-5iu38pr6	1639	15	+5	+5	XX
cord-005478-5iu38pr6	1639	16	,	,	,
cord-005478-5iu38pr6	1639	17	MMF	mmf	NN
cord-005478-5iu38pr6	1639	18	and	and	CC
cord-005478-5iu38pr6	1639	19	CsA	csa	NN
cord-005478-5iu38pr6	1639	20	from	from	IN
cord-005478-5iu38pr6	1639	21	day	day	NN
cord-005478-5iu38pr6	1639	22	+5	+5	NFP
cord-005478-5iu38pr6	1639	23	.	.	.
cord-005478-5iu38pr6	1640	1	G	G	NNP
cord-005478-5iu38pr6	1640	2	-	-	HYPH
cord-005478-5iu38pr6	1640	3	CSF	CSF	NNP
cord-005478-5iu38pr6	1640	4	was	be	VBD
cord-005478-5iu38pr6	1640	5	started	start	VBN
cord-005478-5iu38pr6	1640	6	in	in	IN
cord-005478-5iu38pr6	1640	7	all	all	DT
cord-005478-5iu38pr6	1640	8	cases	case	NNS
cord-005478-5iu38pr6	1640	9	from	from	IN
cord-005478-5iu38pr6	1640	10	day	day	NN
cord-005478-5iu38pr6	1640	11	+5	+5	NN
cord-005478-5iu38pr6	1640	12	until	until	IN
cord-005478-5iu38pr6	1640	13	engraftment	engraftment	NN
cord-005478-5iu38pr6	1640	14	.	.	.
cord-005478-5iu38pr6	1641	1	11	11	CD
cord-005478-5iu38pr6	1641	2	cases	case	NNS
cord-005478-5iu38pr6	1641	3	were	be	VBD
cord-005478-5iu38pr6	1641	4	excluded	exclude	VBN
cord-005478-5iu38pr6	1641	5	from	from	IN
cord-005478-5iu38pr6	1641	6	the	the	DT
cord-005478-5iu38pr6	1641	7	analysis	analysis	NN
cord-005478-5iu38pr6	1641	8	(	(	-LRB-
cord-005478-5iu38pr6	1641	9	9	9	CD
cord-005478-5iu38pr6	1641	10	due	due	IN
cord-005478-5iu38pr6	1641	11	to	to	IN
cord-005478-5iu38pr6	1641	12	death	death	NN
cord-005478-5iu38pr6	1641	13	before	before	IN
cord-005478-5iu38pr6	1641	14	engraftment	engraftment	NN
cord-005478-5iu38pr6	1641	15	and	and	CC
cord-005478-5iu38pr6	1641	16	2	2	CD
cord-005478-5iu38pr6	1641	17	due	due	IN
cord-005478-5iu38pr6	1641	18	to	to	IN
cord-005478-5iu38pr6	1641	19	primary	primary	JJ
cord-005478-5iu38pr6	1641	20	graft	graft	NN
cord-005478-5iu38pr6	1641	21	failure	failure	NN
cord-005478-5iu38pr6	1641	22	)	)	-RRB-
cord-005478-5iu38pr6	1641	23	.	.	.
cord-005478-5iu38pr6	1642	1	Maiolino	Maiolino	NNP
cord-005478-5iu38pr6	1642	2	and	and	CC
cord-005478-5iu38pr6	1642	3	Spitzer´s	spitzer´s	JJ
cord-005478-5iu38pr6	1642	4	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	1642	5	criteria	criterion	NNS
cord-005478-5iu38pr6	1642	6	were	be	VBD
cord-005478-5iu38pr6	1642	7	used	use	VBN
cord-005478-5iu38pr6	1642	8	to	to	TO
cord-005478-5iu38pr6	1642	9	define	define	VB
cord-005478-5iu38pr6	1642	10	ES	ES	NNP
cord-005478-5iu38pr6	1642	11	.	.	.
cord-005478-5iu38pr6	1643	1	Results	result	NNS
cord-005478-5iu38pr6	1643	2	:	:	:
cord-005478-5iu38pr6	1644	1	Characteristics	characteristic	NNS
cord-005478-5iu38pr6	1644	2	of	of	IN
cord-005478-5iu38pr6	1644	3	the	the	DT
cord-005478-5iu38pr6	1644	4	94	94	CD
cord-005478-5iu38pr6	1644	5	transplant	transplant	NN
cord-005478-5iu38pr6	1644	6	included	include	VBN
cord-005478-5iu38pr6	1644	7	are	be	VBP
cord-005478-5iu38pr6	1644	8	shown	show	VBN
cord-005478-5iu38pr6	1644	9	in	in	IN
cord-005478-5iu38pr6	1644	10	Table	Table	NNP
cord-005478-5iu38pr6	1644	11	1	1	CD
cord-005478-5iu38pr6	1644	12	.	.	.
cord-005478-5iu38pr6	1645	1	The	the	DT
cord-005478-5iu38pr6	1645	2	ES	ES	NNP
cord-005478-5iu38pr6	1645	3	incidence	incidence	NN
cord-005478-5iu38pr6	1645	4	was	be	VBD
cord-005478-5iu38pr6	1645	5	27.6	27.6	CD
cord-005478-5iu38pr6	1645	6	%	%	NN
cord-005478-5iu38pr6	1645	7	,	,	,
cord-005478-5iu38pr6	1645	8	with	with	IN
cord-005478-5iu38pr6	1645	9	median	median	JJ
cord-005478-5iu38pr6	1645	10	time	time	NN
cord-005478-5iu38pr6	1645	11	to	to	IN
cord-005478-5iu38pr6	1645	12	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1645	13	of	of	IN
cord-005478-5iu38pr6	1645	14	17	17	CD
cord-005478-5iu38pr6	1645	15	days	day	NNS
cord-005478-5iu38pr6	1645	16	(	(	-LRB-
cord-005478-5iu38pr6	1645	17	IQR	IQR	NNP
cord-005478-5iu38pr6	1645	18	,	,	,
cord-005478-5iu38pr6	1645	19	(	(	-LRB-
cord-005478-5iu38pr6	1645	20	15	15	CD
cord-005478-5iu38pr6	1645	21	)	)	-RRB-
cord-005478-5iu38pr6	1646	1	(	(	-LRB-
cord-005478-5iu38pr6	1646	2	16	16	CD
cord-005478-5iu38pr6	1646	3	)	)	-RRB-
cord-005478-5iu38pr6	1647	1	(	(	-LRB-
cord-005478-5iu38pr6	1647	2	17	17	CD
cord-005478-5iu38pr6	1647	3	)	)	-RRB-
cord-005478-5iu38pr6	1648	1	(	(	-LRB-
cord-005478-5iu38pr6	1648	2	18	18	CD
cord-005478-5iu38pr6	1648	3	)	)	-RRB-
cord-005478-5iu38pr6	1648	4	(	(	-LRB-
cord-005478-5iu38pr6	1648	5	19	19	CD
cord-005478-5iu38pr6	1648	6	)	)	-RRB-
cord-005478-5iu38pr6	1648	7	.	.	.
cord-005478-5iu38pr6	1649	1	Median	median	JJ
cord-005478-5iu38pr6	1649	2	time	time	NN
cord-005478-5iu38pr6	1649	3	to	to	IN
cord-005478-5iu38pr6	1649	4	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1649	5	engraftment	engraftment	NN
cord-005478-5iu38pr6	1649	6	in	in	IN
cord-005478-5iu38pr6	1649	7	the	the	DT
cord-005478-5iu38pr6	1649	8	ES	ES	NNP
cord-005478-5iu38pr6	1649	9	cohort	cohort	NN
cord-005478-5iu38pr6	1649	10	was	be	VBD
cord-005478-5iu38pr6	1649	11	17	17	CD
cord-005478-5iu38pr6	1649	12	days	day	NNS
cord-005478-5iu38pr6	1649	13	(	(	-LRB-
cord-005478-5iu38pr6	1649	14	IQR	IQR	NNP
cord-005478-5iu38pr6	1649	15	,	,	,
cord-005478-5iu38pr6	1649	16	(	(	-LRB-
cord-005478-5iu38pr6	1649	17	14	14	CD
cord-005478-5iu38pr6	1649	18	)	)	-RRB-
cord-005478-5iu38pr6	1650	1	(	(	-LRB-
cord-005478-5iu38pr6	1650	2	15	15	CD
cord-005478-5iu38pr6	1650	3	)	)	-RRB-
cord-005478-5iu38pr6	1650	4	(	(	-LRB-
cord-005478-5iu38pr6	1650	5	16	16	CD
cord-005478-5iu38pr6	1650	6	)	)	-RRB-
cord-005478-5iu38pr6	1650	7	(	(	-LRB-
cord-005478-5iu38pr6	1650	8	17	17	CD
cord-005478-5iu38pr6	1650	9	)	)	-RRB-
cord-005478-5iu38pr6	1650	10	(	(	-LRB-
cord-005478-5iu38pr6	1650	11	18	18	CD
cord-005478-5iu38pr6	1650	12	)	)	-RRB-
cord-005478-5iu38pr6	1650	13	(	(	-LRB-
cord-005478-5iu38pr6	1650	14	19	19	CD
cord-005478-5iu38pr6	1650	15	)	)	-RRB-
cord-005478-5iu38pr6	1650	16	(	(	-LRB-
cord-005478-5iu38pr6	1650	17	20	20	CD
cord-005478-5iu38pr6	1650	18	)	)	-RRB-
cord-005478-5iu38pr6	1650	19	.	.	.
cord-005478-5iu38pr6	1651	1	Fever	fever	NN
cord-005478-5iu38pr6	1651	2	(	(	-LRB-
cord-005478-5iu38pr6	1651	3	100	100	CD
cord-005478-5iu38pr6	1651	4	%	%	NN
cord-005478-5iu38pr6	1651	5	)	)	-RRB-
cord-005478-5iu38pr6	1651	6	and	and	CC
cord-005478-5iu38pr6	1651	7	skin	skin	NN
cord-005478-5iu38pr6	1651	8	rash	rash	NN
cord-005478-5iu38pr6	1651	9	(	(	-LRB-
cord-005478-5iu38pr6	1651	10	77	77	CD
cord-005478-5iu38pr6	1651	11	%	%	NN
cord-005478-5iu38pr6	1651	12	)	)	-RRB-
cord-005478-5iu38pr6	1651	13	were	be	VBD
cord-005478-5iu38pr6	1651	14	the	the	DT
cord-005478-5iu38pr6	1651	15	most	most	RBS
cord-005478-5iu38pr6	1651	16	frequent	frequent	JJ
cord-005478-5iu38pr6	1651	17	clinical	clinical	JJ
cord-005478-5iu38pr6	1651	18	findings	finding	NNS
cord-005478-5iu38pr6	1651	19	.	.	.
cord-005478-5iu38pr6	1652	1	There	there	EX
cord-005478-5iu38pr6	1652	2	were	be	VBD
cord-005478-5iu38pr6	1652	3	other	other	JJ
cord-005478-5iu38pr6	1652	4	5	5	CD
cord-005478-5iu38pr6	1652	5	cases	case	NNS
cord-005478-5iu38pr6	1652	6	of	of	IN
cord-005478-5iu38pr6	1652	7	fever	fever	NN
cord-005478-5iu38pr6	1652	8	and	and	CC
cord-005478-5iu38pr6	1652	9	skin	skin	NN
cord-005478-5iu38pr6	1652	10	rash	rash	NN
cord-005478-5iu38pr6	1652	11	during	during	IN
cord-005478-5iu38pr6	1652	12	the	the	DT
cord-005478-5iu38pr6	1652	13	peri	peri	NNP
cord-005478-5iu38pr6	1652	14	-	-	HYPH
cord-005478-5iu38pr6	1652	15	engraftment	engraftment	JJ
cord-005478-5iu38pr6	1652	16	period	period	NN
cord-005478-5iu38pr6	1652	17	with	with	IN
cord-005478-5iu38pr6	1652	18	a	a	DT
cord-005478-5iu38pr6	1652	19	final	final	JJ
cord-005478-5iu38pr6	1652	20	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	1652	21	of	of	IN
cord-005478-5iu38pr6	1652	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1652	23	considering	consider	VBG
cord-005478-5iu38pr6	1652	24	clinical	clinical	JJ
cord-005478-5iu38pr6	1652	25	outcome	outcome	NN
cord-005478-5iu38pr6	1652	26	.	.	.
cord-005478-5iu38pr6	1653	1	18	18	CD
cord-005478-5iu38pr6	1653	2	patients	patient	NNS
cord-005478-5iu38pr6	1653	3	(	(	-LRB-
cord-005478-5iu38pr6	1653	4	69	69	CD
cord-005478-5iu38pr6	1653	5	%	%	NN
cord-005478-5iu38pr6	1653	6	)	)	-RRB-
cord-005478-5iu38pr6	1653	7	received	receive	VBD
cord-005478-5iu38pr6	1653	8	high	high	JJ
cord-005478-5iu38pr6	1653	9	doses	dose	NNS
cord-005478-5iu38pr6	1653	10	of	of	IN
cord-005478-5iu38pr6	1653	11	corticosteroids	corticosteroid	NNS
cord-005478-5iu38pr6	1653	12	,	,	,
cord-005478-5iu38pr6	1653	13	with	with	IN
cord-005478-5iu38pr6	1653	14	favorable	favorable	JJ
cord-005478-5iu38pr6	1653	15	response	response	NN
cord-005478-5iu38pr6	1653	16	in	in	IN
cord-005478-5iu38pr6	1653	17	78	78	CD
cord-005478-5iu38pr6	1653	18	%	%	NN
cord-005478-5iu38pr6	1653	19	of	of	IN
cord-005478-5iu38pr6	1653	20	cases	case	NNS
cord-005478-5iu38pr6	1653	21	.	.	.
cord-005478-5iu38pr6	1654	1	Of	of	IN
cord-005478-5iu38pr6	1654	2	note	note	NN
cord-005478-5iu38pr6	1654	3	,	,	,
cord-005478-5iu38pr6	1654	4	28	28	CD
cord-005478-5iu38pr6	1654	5	%	%	NN
cord-005478-5iu38pr6	1654	6	cases	case	NNS
cord-005478-5iu38pr6	1654	7	also	also	RB
cord-005478-5iu38pr6	1654	8	needed	need	VBD
cord-005478-5iu38pr6	1654	9	intensive	intensive	JJ
cord-005478-5iu38pr6	1654	10	supportive	supportive	JJ
cord-005478-5iu38pr6	1654	11	care	care	NN
cord-005478-5iu38pr6	1654	12	.	.	.
cord-005478-5iu38pr6	1655	1	There	there	EX
cord-005478-5iu38pr6	1655	2	were	be	VBD
cord-005478-5iu38pr6	1655	3	no	no	DT
cord-005478-5iu38pr6	1655	4	deaths	death	NNS
cord-005478-5iu38pr6	1655	5	secondary	secondary	JJ
cord-005478-5iu38pr6	1655	6	to	to	IN
cord-005478-5iu38pr6	1655	7	ES	ES	NNP
cord-005478-5iu38pr6	1655	8	.	.	.
cord-005478-5iu38pr6	1656	1	Univariable	univariable	JJ
cord-005478-5iu38pr6	1656	2	analysis	analysis	NN
cord-005478-5iu38pr6	1656	3	showed	show	VBD
cord-005478-5iu38pr6	1656	4	a	a	DT
cord-005478-5iu38pr6	1656	5	higher	high	JJR
cord-005478-5iu38pr6	1656	6	risk	risk	NN
cord-005478-5iu38pr6	1656	7	of	of	IN
cord-005478-5iu38pr6	1656	8	ES	ES	NNP
cord-005478-5iu38pr6	1656	9	with	with	IN
cord-005478-5iu38pr6	1656	10	use	use	NN
cord-005478-5iu38pr6	1656	11	of	of	IN
cord-005478-5iu38pr6	1656	12	brother	brother	NN
cord-005478-5iu38pr6	1656	13	/	/	SYM
cord-005478-5iu38pr6	1656	14	sister	sister	NN
cord-005478-5iu38pr6	1656	15	as	as	IN
cord-005478-5iu38pr6	1656	16	cell	cell	NN
cord-005478-5iu38pr6	1656	17	donor	donor	NN
cord-005478-5iu38pr6	1656	18	(	(	-LRB-
cord-005478-5iu38pr6	1656	19	61	61	CD
cord-005478-5iu38pr6	1656	20	%	%	NN
cord-005478-5iu38pr6	1656	21	cases	case	NNS
cord-005478-5iu38pr6	1656	22	of	of	IN
cord-005478-5iu38pr6	1656	23	ES	ES	NNP
cord-005478-5iu38pr6	1656	24	;	;	:
cord-005478-5iu38pr6	1656	25	p=0,003	p=0,003	NNP
cord-005478-5iu38pr6	1656	26	)	)	-RRB-
cord-005478-5iu38pr6	1656	27	.	.	.
cord-005478-5iu38pr6	1657	1	No	no	DT
cord-005478-5iu38pr6	1657	2	other	other	JJ
cord-005478-5iu38pr6	1657	3	risk	risk	NN
cord-005478-5iu38pr6	1657	4	factors	factor	NNS
cord-005478-5iu38pr6	1657	5	were	be	VBD
cord-005478-5iu38pr6	1657	6	identified	identify	VBN
cord-005478-5iu38pr6	1657	7	.	.	.
cord-005478-5iu38pr6	1658	1	No	no	DT
cord-005478-5iu38pr6	1658	2	association	association	NN
cord-005478-5iu38pr6	1658	3	was	be	VBD
cord-005478-5iu38pr6	1658	4	noted	note	VBN
cord-005478-5iu38pr6	1658	5	with	with	IN
cord-005478-5iu38pr6	1658	6	acute	acute	JJ
cord-005478-5iu38pr6	1658	7	or	or	CC
cord-005478-5iu38pr6	1658	8	chronic	chronic	JJ
cord-005478-5iu38pr6	1658	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1658	10	.	.	.
cord-005478-5iu38pr6	1659	1	There	there	EX
cord-005478-5iu38pr6	1659	2	was	be	VBD
cord-005478-5iu38pr6	1659	3	no	no	DT
cord-005478-5iu38pr6	1659	4	significant	significant	JJ
cord-005478-5iu38pr6	1659	5	difference	difference	NN
cord-005478-5iu38pr6	1659	6	in	in	IN
cord-005478-5iu38pr6	1659	7	NRM	NRM	NNP
cord-005478-5iu38pr6	1659	8	,	,	,
cord-005478-5iu38pr6	1659	9	overall	overall	JJ
cord-005478-5iu38pr6	1659	10	survival	survival	NN
cord-005478-5iu38pr6	1659	11	and	and	CC
cord-005478-5iu38pr6	1659	12	progression	progression	NN
cord-005478-5iu38pr6	1659	13	-	-	HYPH
cord-005478-5iu38pr6	1659	14	free	free	JJ
cord-005478-5iu38pr6	1659	15	survival	survival	NN
cord-005478-5iu38pr6	1659	16	between	between	IN
cord-005478-5iu38pr6	1659	17	ES	ES	NNP
cord-005478-5iu38pr6	1659	18	and	and	CC
cord-005478-5iu38pr6	1659	19	non	non	JJ
cord-005478-5iu38pr6	1659	20	-	-	JJ
cord-005478-5iu38pr6	1659	21	ES	es	JJ
cord-005478-5iu38pr6	1659	22	patients	patient	NNS
cord-005478-5iu38pr6	1659	23	.	.	.
cord-005478-5iu38pr6	1660	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1660	2	:	:	:
cord-005478-5iu38pr6	1661	1	In	in	IN
cord-005478-5iu38pr6	1661	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	1661	3	experience	experience	NN
cord-005478-5iu38pr6	1661	4	,	,	,
cord-005478-5iu38pr6	1661	5	ES	ES	NNP
cord-005478-5iu38pr6	1661	6	is	be	VBZ
cord-005478-5iu38pr6	1661	7	a	a	DT
cord-005478-5iu38pr6	1661	8	frequent	frequent	JJ
cord-005478-5iu38pr6	1661	9	complication	complication	NN
cord-005478-5iu38pr6	1661	10	of	of	IN
cord-005478-5iu38pr6	1661	11	HaploSCT	HaploSCT	NNP
cord-005478-5iu38pr6	1661	12	with	with	IN
cord-005478-5iu38pr6	1661	13	post	post	JJ
cord-005478-5iu38pr6	1661	14	-	-	JJ
cord-005478-5iu38pr6	1661	15	transplant	transplant	NN
cord-005478-5iu38pr6	1661	16	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	1661	17	.	.	.
cord-005478-5iu38pr6	1662	1	To	to	IN
cord-005478-5iu38pr6	1662	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	1662	3	knowledge	knowledge	NN
cord-005478-5iu38pr6	1662	4	,	,	,
cord-005478-5iu38pr6	1662	5	this	this	DT
cord-005478-5iu38pr6	1662	6	is	be	VBZ
cord-005478-5iu38pr6	1662	7	the	the	DT
cord-005478-5iu38pr6	1662	8	largest	large	JJS
cord-005478-5iu38pr6	1662	9	study	study	NN
cord-005478-5iu38pr6	1662	10	including	include	VBG
cord-005478-5iu38pr6	1662	11	only	only	RB
cord-005478-5iu38pr6	1662	12	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1662	13	SCT	SCT	NNP
cord-005478-5iu38pr6	1662	14	.	.	.
cord-005478-5iu38pr6	1663	1	Most	Most	JJS
cord-005478-5iu38pr6	1663	2	cases	case	NNS
cord-005478-5iu38pr6	1663	3	of	of	IN
cord-005478-5iu38pr6	1663	4	ES	ES	NNP
cord-005478-5iu38pr6	1663	5	had	have	VBD
cord-005478-5iu38pr6	1663	6	a	a	DT
cord-005478-5iu38pr6	1663	7	self	self	NN
cord-005478-5iu38pr6	1663	8	-	-	HYPH
cord-005478-5iu38pr6	1663	9	limited	limit	VBN
cord-005478-5iu38pr6	1663	10	course	course	NN
cord-005478-5iu38pr6	1663	11	or	or	CC
cord-005478-5iu38pr6	1663	12	good	good	JJ
cord-005478-5iu38pr6	1663	13	response	response	NN
cord-005478-5iu38pr6	1663	14	to	to	IN
cord-005478-5iu38pr6	1663	15	corticosteroids	corticosteroid	NNS
cord-005478-5iu38pr6	1663	16	,	,	,
cord-005478-5iu38pr6	1663	17	and	and	CC
cord-005478-5iu38pr6	1663	18	there	there	EX
cord-005478-5iu38pr6	1663	19	were	be	VBD
cord-005478-5iu38pr6	1663	20	no	no	DT
cord-005478-5iu38pr6	1663	21	associated	associate	VBN
cord-005478-5iu38pr6	1663	22	mortality	mortality	NN
cord-005478-5iu38pr6	1663	23	.	.	.
cord-005478-5iu38pr6	1664	1	However	however	RB
cord-005478-5iu38pr6	1664	2	ES	ES	NNP
cord-005478-5iu38pr6	1664	3	can	can	MD
cord-005478-5iu38pr6	1664	4	progress	progress	VB
cord-005478-5iu38pr6	1664	5	to	to	IN
cord-005478-5iu38pr6	1664	6	multi	multi	JJ
cord-005478-5iu38pr6	1664	7	-	-	JJ
cord-005478-5iu38pr6	1664	8	organ	organ	JJ
cord-005478-5iu38pr6	1664	9	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1664	10	with	with	IN
cord-005478-5iu38pr6	1664	11	need	need	NN
cord-005478-5iu38pr6	1664	12	of	of	IN
cord-005478-5iu38pr6	1664	13	intensive	intensive	JJ
cord-005478-5iu38pr6	1664	14	supportive	supportive	JJ
cord-005478-5iu38pr6	1664	15	care	care	NN
cord-005478-5iu38pr6	1664	16	.	.	.
cord-005478-5iu38pr6	1665	1	In	in	IN
cord-005478-5iu38pr6	1665	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	1665	3	analysis	analysis	NN
cord-005478-5iu38pr6	1665	4	,	,	,
cord-005478-5iu38pr6	1665	5	incidence	incidence	NN
cord-005478-5iu38pr6	1665	6	of	of	IN
cord-005478-5iu38pr6	1665	7	ES	ES	NNP
cord-005478-5iu38pr6	1665	8	was	be	VBD
cord-005478-5iu38pr6	1665	9	higher	high	JJR
cord-005478-5iu38pr6	1665	10	with	with	IN
cord-005478-5iu38pr6	1665	11	the	the	DT
cord-005478-5iu38pr6	1665	12	use	use	NN
cord-005478-5iu38pr6	1665	13	of	of	IN
cord-005478-5iu38pr6	1665	14	sibling	sible	VBG
cord-005478-5iu38pr6	1665	15	haplo	haplo	NNS
cord-005478-5iu38pr6	1665	16	-	-	HYPH
cord-005478-5iu38pr6	1665	17	donors	donor	NNS
cord-005478-5iu38pr6	1665	18	,	,	,
cord-005478-5iu38pr6	1665	19	and	and	CC
cord-005478-5iu38pr6	1665	20	further	further	JJ
cord-005478-5iu38pr6	1665	21	studies	study	NNS
cord-005478-5iu38pr6	1665	22	are	be	VBP
cord-005478-5iu38pr6	1665	23	needed	need	VBN
cord-005478-5iu38pr6	1665	24	to	to	TO
cord-005478-5iu38pr6	1665	25	confirm	confirm	VB
cord-005478-5iu38pr6	1665	26	these	these	DT
cord-005478-5iu38pr6	1665	27	results	result	NNS
cord-005478-5iu38pr6	1665	28	.	.	.
cord-005478-5iu38pr6	1666	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1666	2	have	have	VBP
cord-005478-5iu38pr6	1666	3	not	not	RB
cord-005478-5iu38pr6	1666	4	found	find	VBN
cord-005478-5iu38pr6	1666	5	relationship	relationship	NN
cord-005478-5iu38pr6	1666	6	between	between	IN
cord-005478-5iu38pr6	1666	7	ES	ES	NNP
cord-005478-5iu38pr6	1666	8	and	and	CC
cord-005478-5iu38pr6	1666	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1666	10	.	.	.
cord-005478-5iu38pr6	1667	1	Specific	specific	JJ
cord-005478-5iu38pr6	1667	2	biomarkers	biomarker	NNS
cord-005478-5iu38pr6	1667	3	may	may	MD
cord-005478-5iu38pr6	1667	4	contribute	contribute	VB
cord-005478-5iu38pr6	1667	5	to	to	IN
cord-005478-5iu38pr6	1667	6	an	an	DT
cord-005478-5iu38pr6	1667	7	early	early	JJ
cord-005478-5iu38pr6	1667	8	identification	identification	NN
cord-005478-5iu38pr6	1667	9	of	of	IN
cord-005478-5iu38pr6	1667	10	this	this	DT
cord-005478-5iu38pr6	1667	11	entity	entity	NN
cord-005478-5iu38pr6	1667	12	in	in	IN
cord-005478-5iu38pr6	1667	13	order	order	NN
cord-005478-5iu38pr6	1667	14	to	to	TO
cord-005478-5iu38pr6	1667	15	install	install	VB
cord-005478-5iu38pr6	1667	16	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1667	17	measures	measure	NNS
cord-005478-5iu38pr6	1667	18	.	.	.
cord-005478-5iu38pr6	1668	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1668	2	:	:	:
cord-005478-5iu38pr6	1668	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1668	4	to	to	TO
cord-005478-5iu38pr6	1668	5	declare	declare	VB
cord-005478-5iu38pr6	1668	6	Features	feature	NNS
cord-005478-5iu38pr6	1668	7	and	and	CC
cord-005478-5iu38pr6	1668	8	outcome	outcome	NN
cord-005478-5iu38pr6	1668	9	of	of	IN
cord-005478-5iu38pr6	1668	10	early	early	JJ
cord-005478-5iu38pr6	1668	11	cardiac	cardiac	JJ
cord-005478-5iu38pr6	1668	12	toxicity	toxicity	NN
cord-005478-5iu38pr6	1668	13	associated	associate	VBN
cord-005478-5iu38pr6	1668	14	with	with	IN
cord-005478-5iu38pr6	1668	15	post	post	JJ
cord-005478-5iu38pr6	1668	16	-	-	JJ
cord-005478-5iu38pr6	1668	17	transplant	transplant	JJ
cord-005478-5iu38pr6	1668	18	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	1668	19	in	in	IN
cord-005478-5iu38pr6	1668	20	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1668	21	stem	stem	NN
cord-005478-5iu38pr6	1668	22	cell	cell	NN
cord-005478-5iu38pr6	1668	23	transplantatioN	transplantatioN	NNP
cord-005478-5iu38pr6	1668	24	Background	Background	NNP
cord-005478-5iu38pr6	1668	25	:	:	:
cord-005478-5iu38pr6	1669	1	Data	datum	NNS
cord-005478-5iu38pr6	1669	2	on	on	IN
cord-005478-5iu38pr6	1669	3	risk	risk	NN
cord-005478-5iu38pr6	1669	4	factors	factor	NNS
cord-005478-5iu38pr6	1669	5	and	and	CC
cord-005478-5iu38pr6	1669	6	incidence	incidence	NN
cord-005478-5iu38pr6	1669	7	of	of	IN
cord-005478-5iu38pr6	1669	8	early	early	JJ
cord-005478-5iu38pr6	1669	9	cardiac	cardiac	JJ
cord-005478-5iu38pr6	1669	10	events	event	NNS
cord-005478-5iu38pr6	1669	11	(	(	-LRB-
cord-005478-5iu38pr6	1669	12	ECE	ECE	NNP
cord-005478-5iu38pr6	1669	13	)	)	-RRB-
cord-005478-5iu38pr6	1669	14	after	after	IN
cord-005478-5iu38pr6	1669	15	post	post	JJ
cord-005478-5iu38pr6	1669	16	-	-	JJ
cord-005478-5iu38pr6	1669	17	transplant	transplant	NN
cord-005478-5iu38pr6	1669	18	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	1669	19	(	(	-LRB-
cord-005478-5iu38pr6	1669	20	PT	PT	NNP
cord-005478-5iu38pr6	1669	21	-	-	HYPH
cord-005478-5iu38pr6	1669	22	Cy	Cy	NNP
cord-005478-5iu38pr6	1669	23	)	)	-RRB-
cord-005478-5iu38pr6	1669	24	are	be	VBP
cord-005478-5iu38pr6	1669	25	scarce	scarce	JJ
cord-005478-5iu38pr6	1669	26	.	.	.
cord-005478-5iu38pr6	1670	1	Thus	thus	RB
cord-005478-5iu38pr6	1670	2	,	,	,
cord-005478-5iu38pr6	1670	3	we	-PRON-	PRP
cord-005478-5iu38pr6	1670	4	compared	compare	VBD
cord-005478-5iu38pr6	1670	5	clinical	clinical	JJ
cord-005478-5iu38pr6	1670	6	outcomes	outcome	NNS
cord-005478-5iu38pr6	1670	7	between	between	IN
cord-005478-5iu38pr6	1670	8	patients	patient	NNS
cord-005478-5iu38pr6	1670	9	who	who	WP
cord-005478-5iu38pr6	1670	10	received	receive	VBD
cord-005478-5iu38pr6	1670	11	PT	PT	NNP
cord-005478-5iu38pr6	1670	12	-	-	HYPH
cord-005478-5iu38pr6	1670	13	Cy	Cy	NNP
cord-005478-5iu38pr6	1670	14	and	and	CC
cord-005478-5iu38pr6	1670	15	patients	patient	NNS
cord-005478-5iu38pr6	1670	16	who	who	WP
cord-005478-5iu38pr6	1670	17	did	do	VBD
cord-005478-5iu38pr6	1670	18	not	not	RB
cord-005478-5iu38pr6	1670	19	in	in	IN
cord-005478-5iu38pr6	1670	20	a	a	DT
cord-005478-5iu38pr6	1670	21	cohort	cohort	NN
cord-005478-5iu38pr6	1670	22	study	study	NN
cord-005478-5iu38pr6	1670	23	including	include	VBG
cord-005478-5iu38pr6	1670	24	all	all	DT
cord-005478-5iu38pr6	1670	25	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1670	26	patients	patient	NNS
cord-005478-5iu38pr6	1670	27	allografted	allografte	VBN
cord-005478-5iu38pr6	1670	28	in	in	IN
cord-005478-5iu38pr6	1670	29	our	-PRON-	PRP$
cord-005478-5iu38pr6	1670	30	center	center	NN
cord-005478-5iu38pr6	1670	31	.	.	.
cord-005478-5iu38pr6	1671	1	Methods	method	NNS
cord-005478-5iu38pr6	1672	1	:	:	:
cord-005478-5iu38pr6	1672	2	We	-PRON-	PRP
cord-005478-5iu38pr6	1672	3	analyzed	analyze	VBD
cord-005478-5iu38pr6	1672	4	all	all	DT
cord-005478-5iu38pr6	1672	5	ECE	ECE	NNP
cord-005478-5iu38pr6	1672	6	occurring	occur	VBG
cord-005478-5iu38pr6	1672	7	within	within	IN
cord-005478-5iu38pr6	1672	8	3	3	CD
cord-005478-5iu38pr6	1672	9	months	month	NNS
cord-005478-5iu38pr6	1672	10	after	after	IN
cord-005478-5iu38pr6	1672	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1672	12	in	in	IN
cord-005478-5iu38pr6	1672	13	331	331	CD
cord-005478-5iu38pr6	1672	14	patients	patient	NNS
cord-005478-5iu38pr6	1672	15	.	.	.
cord-005478-5iu38pr6	1673	1	Transthoracic	Transthoracic	NNP
cord-005478-5iu38pr6	1673	2	echocardiography	echocardiography	NN
cord-005478-5iu38pr6	1673	3	and	and	CC
cord-005478-5iu38pr6	1673	4	EKG	EKG	NNP
cord-005478-5iu38pr6	1673	5	were	be	VBD
cord-005478-5iu38pr6	1673	6	performed	perform	VBN
cord-005478-5iu38pr6	1673	7	before	before	IN
cord-005478-5iu38pr6	1673	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1673	9	,	,	,
cord-005478-5iu38pr6	1673	10	at	at	IN
cord-005478-5iu38pr6	1673	11	day	day	NN
cord-005478-5iu38pr6	1673	12	+90	+90	CD
cord-005478-5iu38pr6	1673	13	and	and	CC
cord-005478-5iu38pr6	1673	14	in	in	IN
cord-005478-5iu38pr6	1673	15	case	case	NN
cord-005478-5iu38pr6	1673	16	of	of	IN
cord-005478-5iu38pr6	1673	17	ECE	ECE	NNP
cord-005478-5iu38pr6	1673	18	.	.	.
cord-005478-5iu38pr6	1674	1	Prior	prior	RB
cord-005478-5iu38pr6	1674	2	to	to	IN
cord-005478-5iu38pr6	1674	3	transplant	transplant	NN
cord-005478-5iu38pr6	1674	4	,	,	,
cord-005478-5iu38pr6	1674	5	276	276	CD
cord-005478-5iu38pr6	1674	6	patients	patient	NNS
cord-005478-5iu38pr6	1674	7	(	(	-LRB-
cord-005478-5iu38pr6	1674	8	83.4	83.4	CD
cord-005478-5iu38pr6	1674	9	%	%	NN
cord-005478-5iu38pr6	1674	10	)	)	-RRB-
cord-005478-5iu38pr6	1674	11	had	have	VBD
cord-005478-5iu38pr6	1674	12	at	at	RB
cord-005478-5iu38pr6	1674	13	least	least	RBS
cord-005478-5iu38pr6	1674	14	one	one	CD
cord-005478-5iu38pr6	1674	15	cardiovascular	cardiovascular	JJ
cord-005478-5iu38pr6	1674	16	risk	risk	NN
cord-005478-5iu38pr6	1674	17	factor	factor	NN
cord-005478-5iu38pr6	1674	18	,	,	,
cord-005478-5iu38pr6	1674	19	72	72	CD
cord-005478-5iu38pr6	1674	20	(	(	-LRB-
cord-005478-5iu38pr6	1674	21	21.8	21.8	CD
cord-005478-5iu38pr6	1674	22	%	%	NN
cord-005478-5iu38pr6	1674	23	)	)	-RRB-
cord-005478-5iu38pr6	1674	24	cardiovascular	cardiovascular	JJ
cord-005478-5iu38pr6	1674	25	disease	disease	NN
cord-005478-5iu38pr6	1674	26	history	history	NN
cord-005478-5iu38pr6	1674	27	and	and	CC
cord-005478-5iu38pr6	1674	28	31	31	CD
cord-005478-5iu38pr6	1674	29	(	(	-LRB-
cord-005478-5iu38pr6	1674	30	9.4	9.4	CD
cord-005478-5iu38pr6	1674	31	%	%	NN
cord-005478-5iu38pr6	1674	32	)	)	-RRB-
cord-005478-5iu38pr6	1674	33	left	leave	VBD
cord-005478-5iu38pr6	1674	34	ventricular	ventricular	JJ
cord-005478-5iu38pr6	1674	35	systolic	systolic	JJ
cord-005478-5iu38pr6	1674	36	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1674	37	(	(	-LRB-
cord-005478-5iu38pr6	1674	38	LVSD	LVSD	NNP
cord-005478-5iu38pr6	1674	39	)	)	-RRB-
cord-005478-5iu38pr6	1674	40	(	(	-LRB-
cord-005478-5iu38pr6	1674	41	defined	define	VBN
cord-005478-5iu38pr6	1674	42	by	by	IN
cord-005478-5iu38pr6	1674	43	left	left	JJ
cord-005478-5iu38pr6	1674	44	ventricular	ventricular	JJ
cord-005478-5iu38pr6	1674	45	ejection	ejection	NN
cord-005478-5iu38pr6	1674	46	fraction	fraction	NN
cord-005478-5iu38pr6	1674	47	<	<	XX
cord-005478-5iu38pr6	1674	48	53	53	CD
cord-005478-5iu38pr6	1674	49	%	%	NN
cord-005478-5iu38pr6	1674	50	)	)	-RRB-
cord-005478-5iu38pr6	1674	51	.	.	.
cord-005478-5iu38pr6	1675	1	Median	median	JJ
cord-005478-5iu38pr6	1675	2	age	age	NN
cord-005478-5iu38pr6	1675	3	was	be	VBD
cord-005478-5iu38pr6	1675	4	55	55	CD
cord-005478-5iu38pr6	1675	5	years	year	NNS
cord-005478-5iu38pr6	1675	6	(	(	-LRB-
cord-005478-5iu38pr6	1675	7	range	range	NN
cord-005478-5iu38pr6	1675	8	,	,	,
cord-005478-5iu38pr6	1675	9	15	15	CD
cord-005478-5iu38pr6	1675	10	-	-	SYM
cord-005478-5iu38pr6	1675	11	76	76	CD
cord-005478-5iu38pr6	1675	12	)	)	-RRB-
cord-005478-5iu38pr6	1675	13	and	and	CC
cord-005478-5iu38pr6	1675	14	60.4	60.4	CD
cord-005478-5iu38pr6	1675	15	%	%	NN
cord-005478-5iu38pr6	1675	16	of	of	IN
cord-005478-5iu38pr6	1675	17	patients	patient	NNS
cord-005478-5iu38pr6	1675	18	were	be	VBD
cord-005478-5iu38pr6	1675	19	males	male	NNS
cord-005478-5iu38pr6	1675	20	.	.	.
cord-005478-5iu38pr6	1676	1	Patients	patient	NNS
cord-005478-5iu38pr6	1676	2	were	be	VBD
cord-005478-5iu38pr6	1676	3	transplanted	transplant	VBN
cord-005478-5iu38pr6	1676	4	for	for	IN
cord-005478-5iu38pr6	1676	5	AML	AML	NNP
cord-005478-5iu38pr6	1676	6	(	(	-LRB-
cord-005478-5iu38pr6	1676	7	n=153	n=153	CD
cord-005478-5iu38pr6	1676	8	,	,	,
cord-005478-5iu38pr6	1676	9	46	46	CD
cord-005478-5iu38pr6	1676	10	%	%	NN
cord-005478-5iu38pr6	1676	11	)	)	-RRB-
cord-005478-5iu38pr6	1676	12	,	,	,
cord-005478-5iu38pr6	1676	13	ALL	all	DT
cord-005478-5iu38pr6	1676	14	(	(	-LRB-
cord-005478-5iu38pr6	1676	15	n=49	n=49	NNP
cord-005478-5iu38pr6	1676	16	,	,	,
cord-005478-5iu38pr6	1676	17	15	15	CD
cord-005478-5iu38pr6	1676	18	%	%	NN
cord-005478-5iu38pr6	1676	19	)	)	-RRB-
cord-005478-5iu38pr6	1676	20	,	,	,
cord-005478-5iu38pr6	1676	21	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1676	22	(	(	-LRB-
cord-005478-5iu38pr6	1676	23	n=44	n=44	NNP
cord-005478-5iu38pr6	1676	24	,	,	,
cord-005478-5iu38pr6	1676	25	13	13	CD
cord-005478-5iu38pr6	1676	26	%	%	NN
cord-005478-5iu38pr6	1676	27	)	)	-RRB-
cord-005478-5iu38pr6	1676	28	,	,	,
cord-005478-5iu38pr6	1676	29	multiple	multiple	JJ
cord-005478-5iu38pr6	1676	30	myeloma	myeloma	NN
cord-005478-5iu38pr6	1676	31	(	(	-LRB-
cord-005478-5iu38pr6	1676	32	n=8	n=8	NN
cord-005478-5iu38pr6	1676	33	,	,	,
cord-005478-5iu38pr6	1676	34	2.4	2.4	CD
cord-005478-5iu38pr6	1676	35	%	%	NN
cord-005478-5iu38pr6	1676	36	)	)	-RRB-
cord-005478-5iu38pr6	1676	37	,	,	,
cord-005478-5iu38pr6	1676	38	MDS	MDS	NNP
cord-005478-5iu38pr6	1676	39	(	(	-LRB-
cord-005478-5iu38pr6	1676	40	n=35	n=35	NNP
cord-005478-5iu38pr6	1676	41	,	,	,
cord-005478-5iu38pr6	1676	42	11	11	CD
cord-005478-5iu38pr6	1676	43	%	%	NN
cord-005478-5iu38pr6	1676	44	)	)	-RRB-
cord-005478-5iu38pr6	1676	45	and	and	CC
cord-005478-5iu38pr6	1676	46	MPN	MPN	NNP
cord-005478-5iu38pr6	1676	47	(	(	-LRB-
cord-005478-5iu38pr6	1676	48	n=42	n=42	NN
cord-005478-5iu38pr6	1676	49	,	,	,
cord-005478-5iu38pr6	1676	50	13	13	CD
cord-005478-5iu38pr6	1676	51	%	%	NN
cord-005478-5iu38pr6	1676	52	)	)	-RRB-
cord-005478-5iu38pr6	1676	53	.	.	.
cord-005478-5iu38pr6	1677	1	Disease	Disease	NNP
cord-005478-5iu38pr6	1677	2	risk	risk	NN
cord-005478-5iu38pr6	1677	3	index	index	NN
cord-005478-5iu38pr6	1677	4	was	be	VBD
cord-005478-5iu38pr6	1677	5	high	high	JJ
cord-005478-5iu38pr6	1677	6	or	or	CC
cord-005478-5iu38pr6	1677	7	very	very	RB
cord-005478-5iu38pr6	1677	8	-	-	HYPH
cord-005478-5iu38pr6	1677	9	high	high	JJ
cord-005478-5iu38pr6	1677	10	in	in	IN
cord-005478-5iu38pr6	1677	11	93	93	CD
cord-005478-5iu38pr6	1677	12	patients	patient	NNS
cord-005478-5iu38pr6	1677	13	(	(	-LRB-
cord-005478-5iu38pr6	1677	14	28	28	CD
cord-005478-5iu38pr6	1677	15	%	%	NN
cord-005478-5iu38pr6	1677	16	)	)	-RRB-
cord-005478-5iu38pr6	1677	17	.	.	.
cord-005478-5iu38pr6	1678	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	1678	2	regimen	regimen	NN
cord-005478-5iu38pr6	1678	3	were	be	VBD
cord-005478-5iu38pr6	1678	4	MAC	MAC	NNP
cord-005478-5iu38pr6	1678	5	(	(	-LRB-
cord-005478-5iu38pr6	1678	6	n=131	n=131	NNP
cord-005478-5iu38pr6	1678	7	,	,	,
cord-005478-5iu38pr6	1678	8	40	40	CD
cord-005478-5iu38pr6	1678	9	%	%	NN
cord-005478-5iu38pr6	1678	10	)	)	-RRB-
cord-005478-5iu38pr6	1678	11	,	,	,
cord-005478-5iu38pr6	1678	12	RIC	RIC	NNP
cord-005478-5iu38pr6	1678	13	(	(	-LRB-
cord-005478-5iu38pr6	1678	14	n=85	n=85	NNP
cord-005478-5iu38pr6	1678	15	,	,	,
cord-005478-5iu38pr6	1678	16	26	26	CD
cord-005478-5iu38pr6	1678	17	%	%	NN
cord-005478-5iu38pr6	1678	18	)	)	-RRB-
cord-005478-5iu38pr6	1678	19	or	or	CC
cord-005478-5iu38pr6	1678	20	sequential	sequential	JJ
cord-005478-5iu38pr6	1678	21	(	(	-LRB-
cord-005478-5iu38pr6	1678	22	Flamsa	Flamsa	NNP
cord-005478-5iu38pr6	1678	23	-	-	HYPH
cord-005478-5iu38pr6	1678	24	like	like	JJ
cord-005478-5iu38pr6	1678	25	)	)	-RRB-
cord-005478-5iu38pr6	1678	26	(	(	-LRB-
cord-005478-5iu38pr6	1678	27	n=115	n=115	NNPS
cord-005478-5iu38pr6	1678	28	,	,	,
cord-005478-5iu38pr6	1678	29	35	35	CD
cord-005478-5iu38pr6	1678	30	%	%	NN
cord-005478-5iu38pr6	1678	31	)	)	-RRB-
cord-005478-5iu38pr6	1678	32	.	.	.
cord-005478-5iu38pr6	1679	1	Donors	donor	NNS
cord-005478-5iu38pr6	1679	2	were	be	VBD
cord-005478-5iu38pr6	1679	3	matched	match	VBN
cord-005478-5iu38pr6	1679	4	related	relate	VBN
cord-005478-5iu38pr6	1679	5	(	(	-LRB-
cord-005478-5iu38pr6	1679	6	n=89	n=89	NN
cord-005478-5iu38pr6	1679	7	,	,	,
cord-005478-5iu38pr6	1679	8	27	27	CD
cord-005478-5iu38pr6	1679	9	%	%	NN
cord-005478-5iu38pr6	1679	10	)	)	-RRB-
cord-005478-5iu38pr6	1679	11	,	,	,
cord-005478-5iu38pr6	1679	12	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1679	13	(	(	-LRB-
cord-005478-5iu38pr6	1679	14	n=124	n=124	CD
cord-005478-5iu38pr6	1679	15	,	,	,
cord-005478-5iu38pr6	1679	16	37	37	CD
cord-005478-5iu38pr6	1679	17	%	%	NN
cord-005478-5iu38pr6	1679	18	)	)	-RRB-
cord-005478-5iu38pr6	1679	19	or	or	CC
cord-005478-5iu38pr6	1679	20	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1679	21	(	(	-LRB-
cord-005478-5iu38pr6	1679	22	n=118	n=118	NNP
cord-005478-5iu38pr6	1679	23	,	,	,
cord-005478-5iu38pr6	1679	24	36	36	CD
cord-005478-5iu38pr6	1679	25	%	%	NN
cord-005478-5iu38pr6	1679	26	)	)	-RRB-
cord-005478-5iu38pr6	1679	27	.	.	.
cord-005478-5iu38pr6	1680	1	Stem	stem	JJ
cord-005478-5iu38pr6	1680	2	cell	cell	NN
cord-005478-5iu38pr6	1680	3	source	source	NN
cord-005478-5iu38pr6	1680	4	was	be	VBD
cord-005478-5iu38pr6	1680	5	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1680	6	blood	blood	NN
cord-005478-5iu38pr6	1680	7	(	(	-LRB-
cord-005478-5iu38pr6	1680	8	n=310	n=310	NNP
cord-005478-5iu38pr6	1680	9	,	,	,
cord-005478-5iu38pr6	1680	10	94	94	CD
cord-005478-5iu38pr6	1680	11	%	%	NN
cord-005478-5iu38pr6	1680	12	)	)	-RRB-
cord-005478-5iu38pr6	1680	13	or	or	CC
cord-005478-5iu38pr6	1680	14	bone	bone	NN
cord-005478-5iu38pr6	1680	15	marrow	marrow	NN
cord-005478-5iu38pr6	1680	16	(	(	-LRB-
cord-005478-5iu38pr6	1680	17	n=21	n=21	NNP
cord-005478-5iu38pr6	1680	18	,	,	,
cord-005478-5iu38pr6	1680	19	6	6	CD
cord-005478-5iu38pr6	1680	20	%	%	NN
cord-005478-5iu38pr6	1680	21	)	)	-RRB-
cord-005478-5iu38pr6	1680	22	.	.	.
cord-005478-5iu38pr6	1681	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1681	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	1681	3	included	include	VBD
cord-005478-5iu38pr6	1681	4	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	1681	5	in	in	IN
cord-005478-5iu38pr6	1681	6	all	all	DT
cord-005478-5iu38pr6	1681	7	patients	patient	NNS
cord-005478-5iu38pr6	1681	8	associated	associate	VBN
cord-005478-5iu38pr6	1681	9	with	with	IN
cord-005478-5iu38pr6	1681	10	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	1681	11	mofetil	mofetil	NNP
cord-005478-5iu38pr6	1681	12	(	(	-LRB-
cord-005478-5iu38pr6	1681	13	n=267	n=267	NNP
cord-005478-5iu38pr6	1681	14	,	,	,
cord-005478-5iu38pr6	1681	15	81	81	CD
cord-005478-5iu38pr6	1681	16	%	%	NN
cord-005478-5iu38pr6	1681	17	)	)	-RRB-
cord-005478-5iu38pr6	1681	18	,	,	,
cord-005478-5iu38pr6	1681	19	short	short	JJ
cord-005478-5iu38pr6	1681	20	courses	course	NNS
cord-005478-5iu38pr6	1681	21	of	of	IN
cord-005478-5iu38pr6	1681	22	methotrexate	methotrexate	NNP
cord-005478-5iu38pr6	1681	23	(	(	-LRB-
cord-005478-5iu38pr6	1681	24	n=23	n=23	NNP
cord-005478-5iu38pr6	1681	25	,	,	,
cord-005478-5iu38pr6	1681	26	7	7	CD
cord-005478-5iu38pr6	1681	27	%	%	NN
cord-005478-5iu38pr6	1681	28	)	)	-RRB-
cord-005478-5iu38pr6	1682	1	and/or	and/or	CC
cord-005478-5iu38pr6	1682	2	antithymocyte	antithymocyte	NNP
cord-005478-5iu38pr6	1682	3	globulin	globulin	NNP
cord-005478-5iu38pr6	1682	4	(	(	-LRB-
cord-005478-5iu38pr6	1682	5	n=312	n=312	NNP
cord-005478-5iu38pr6	1682	6	,	,	,
cord-005478-5iu38pr6	1682	7	94	94	CD
cord-005478-5iu38pr6	1682	8	%	%	NN
cord-005478-5iu38pr6	1682	9	)	)	-RRB-
cord-005478-5iu38pr6	1682	10	.	.	.
cord-005478-5iu38pr6	1683	1	In	in	IN
cord-005478-5iu38pr6	1683	2	the	the	DT
cord-005478-5iu38pr6	1683	3	PT	PT	NNP
cord-005478-5iu38pr6	1683	4	-	-	HYPH
cord-005478-5iu38pr6	1683	5	Cy	Cy	NNP
cord-005478-5iu38pr6	1683	6	group	group	NN
cord-005478-5iu38pr6	1683	7	,	,	,
cord-005478-5iu38pr6	1683	8	136	136	CD
cord-005478-5iu38pr6	1683	9	patients	patient	NNS
cord-005478-5iu38pr6	1683	10	received	receive	VBD
cord-005478-5iu38pr6	1683	11	PT	PT	NNP
cord-005478-5iu38pr6	1683	12	-	-	HYPH
cord-005478-5iu38pr6	1683	13	Cy	Cy	NNP
cord-005478-5iu38pr6	1683	14	at	at	IN
cord-005478-5iu38pr6	1683	15	50	50	CD
cord-005478-5iu38pr6	1683	16	mg	mg	NNP
cord-005478-5iu38pr6	1683	17	/	/	SYM
cord-005478-5iu38pr6	1683	18	kg	kg	NNP
cord-005478-5iu38pr6	1683	19	/	/	SYM
cord-005478-5iu38pr6	1683	20	day	day	NN
cord-005478-5iu38pr6	1683	21	for	for	IN
cord-005478-5iu38pr6	1683	22	at	at	RB
cord-005478-5iu38pr6	1683	23	least	least	JJS
cord-005478-5iu38pr6	1683	24	1	1	CD
cord-005478-5iu38pr6	1683	25	day	day	NN
cord-005478-5iu38pr6	1683	26	and	and	CC
cord-005478-5iu38pr6	1683	27	100	100	CD
cord-005478-5iu38pr6	1683	28	patients	patient	NNS
cord-005478-5iu38pr6	1683	29	for	for	IN
cord-005478-5iu38pr6	1683	30	2	2	CD
cord-005478-5iu38pr6	1683	31	days	day	NNS
cord-005478-5iu38pr6	1683	32	,	,	,
cord-005478-5iu38pr6	1683	33	including	include	VBG
cord-005478-5iu38pr6	1683	34	13	13	CD
cord-005478-5iu38pr6	1683	35	patients	patient	NNS
cord-005478-5iu38pr6	1683	36	with	with	IN
cord-005478-5iu38pr6	1683	37	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1683	38	donor	donor	NN
cord-005478-5iu38pr6	1683	39	and	and	CC
cord-005478-5iu38pr6	1683	40	6	6	CD
cord-005478-5iu38pr6	1683	41	patients	patient	NNS
cord-005478-5iu38pr6	1683	42	with	with	IN
cord-005478-5iu38pr6	1683	43	matched	match	VBN
cord-005478-5iu38pr6	1683	44	related	related	JJ
cord-005478-5iu38pr6	1683	45	donor	donor	NN
cord-005478-5iu38pr6	1683	46	,	,	,
cord-005478-5iu38pr6	1683	47	either	either	CC
cord-005478-5iu38pr6	1683	48	because	because	IN
cord-005478-5iu38pr6	1683	49	of	of	IN
cord-005478-5iu38pr6	1683	50	HLA	hla	NN
cord-005478-5iu38pr6	1683	51	-	-	HYPH
cord-005478-5iu38pr6	1683	52	mismatch	mismatch	NN
cord-005478-5iu38pr6	1683	53	or	or	CC
cord-005478-5iu38pr6	1683	54	renal	renal	JJ
cord-005478-5iu38pr6	1683	55	insufficiency	insufficiency	NN
cord-005478-5iu38pr6	1683	56	,	,	,
cord-005478-5iu38pr6	1683	57	or	or	CC
cord-005478-5iu38pr6	1683	58	inclusion	inclusion	NN
cord-005478-5iu38pr6	1683	59	in	in	IN
cord-005478-5iu38pr6	1683	60	a	a	DT
cord-005478-5iu38pr6	1683	61	clinical	clinical	JJ
cord-005478-5iu38pr6	1683	62	trial	trial	NN
cord-005478-5iu38pr6	1683	63	.	.	.
cord-005478-5iu38pr6	1684	1	Results	result	NNS
cord-005478-5iu38pr6	1684	2	:	:	:
cord-005478-5iu38pr6	1685	1	In	in	IN
cord-005478-5iu38pr6	1685	2	univariate	univariate	JJ
cord-005478-5iu38pr6	1685	3	analysis	analysis	NN
cord-005478-5iu38pr6	1685	4	,	,	,
cord-005478-5iu38pr6	1685	5	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1685	6	incidence	incidence	NN
cord-005478-5iu38pr6	1685	7	of	of	IN
cord-005478-5iu38pr6	1685	8	ECE	ECE	NNP
cord-005478-5iu38pr6	1685	9	was	be	VBD
cord-005478-5iu38pr6	1685	10	21.3	21.3	CD
cord-005478-5iu38pr6	1685	11	%	%	NN
cord-005478-5iu38pr6	1685	12	in	in	IN
cord-005478-5iu38pr6	1685	13	the	the	DT
cord-005478-5iu38pr6	1685	14	PT	PT	NNP
cord-005478-5iu38pr6	1685	15	-	-	HYPH
cord-005478-5iu38pr6	1685	16	Cy	Cy	NNP
cord-005478-5iu38pr6	1685	17	group	group	NN
cord-005478-5iu38pr6	1685	18	and	and	CC
cord-005478-5iu38pr6	1685	19	8.2	8.2	CD
cord-005478-5iu38pr6	1685	20	%	%	NN
cord-005478-5iu38pr6	1685	21	in	in	IN
cord-005478-5iu38pr6	1685	22	the	the	DT
cord-005478-5iu38pr6	1685	23	no	no	DT
cord-005478-5iu38pr6	1685	24	PT	PT	NNP
cord-005478-5iu38pr6	1685	25	-	-	HYPH
cord-005478-5iu38pr6	1685	26	Cy	Cy	NNP
cord-005478-5iu38pr6	1685	27	group	group	NN
cord-005478-5iu38pr6	1685	28	(	(	-LRB-
cord-005478-5iu38pr6	1685	29	p	p	NN
cord-005478-5iu38pr6	1685	30	<	<	XX
cord-005478-5iu38pr6	1685	31	0.001	0.001	CD
cord-005478-5iu38pr6	1685	32	)	)	-RRB-
cord-005478-5iu38pr6	1685	33	.	.	.
cord-005478-5iu38pr6	1686	1	The	the	DT
cord-005478-5iu38pr6	1686	2	main	main	JJ
cord-005478-5iu38pr6	1686	3	complication	complication	NN
cord-005478-5iu38pr6	1686	4	was	be	VBD
cord-005478-5iu38pr6	1686	5	LVSD	LVSD	NNP
cord-005478-5iu38pr6	1686	6	(	(	-LRB-
cord-005478-5iu38pr6	1686	7	15	15	CD
cord-005478-5iu38pr6	1686	8	%	%	NN
cord-005478-5iu38pr6	1686	9	of	of	IN
cord-005478-5iu38pr6	1686	10	patients	patient	NNS
cord-005478-5iu38pr6	1686	11	in	in	IN
cord-005478-5iu38pr6	1686	12	the	the	DT
cord-005478-5iu38pr6	1686	13	PT	PT	NNP
cord-005478-5iu38pr6	1686	14	-	-	HYPH
cord-005478-5iu38pr6	1686	15	Cy	Cy	NNP
cord-005478-5iu38pr6	1686	16	group	group	NN
cord-005478-5iu38pr6	1686	17	and	and	CC
cord-005478-5iu38pr6	1686	18	3	3	CD
cord-005478-5iu38pr6	1686	19	%	%	NN
cord-005478-5iu38pr6	1686	20	in	in	IN
cord-005478-5iu38pr6	1686	21	the	the	DT
cord-005478-5iu38pr6	1686	22	no	no	DT
cord-005478-5iu38pr6	1686	23	PT	PT	NNP
cord-005478-5iu38pr6	1686	24	-	-	HYPH
cord-005478-5iu38pr6	1686	25	Cy	Cy	NNP
cord-005478-5iu38pr6	1686	26	group	group	NN
cord-005478-5iu38pr6	1686	27	,	,	,
cord-005478-5iu38pr6	1686	28	p	p	NN
cord-005478-5iu38pr6	1686	29	<	<	XX
cord-005478-5iu38pr6	1686	30	0.001	0.001	CD
cord-005478-5iu38pr6	1686	31	)	)	-RRB-
cord-005478-5iu38pr6	1686	32	.	.	.
cord-005478-5iu38pr6	1687	1	Other	other	JJ
cord-005478-5iu38pr6	1687	2	ECE	ECE	NNP
cord-005478-5iu38pr6	1687	3	included	include	VBD
cord-005478-5iu38pr6	1687	4	acute	acute	JJ
cord-005478-5iu38pr6	1687	5	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1687	6	edema	edema	NN
cord-005478-5iu38pr6	1687	7	(	(	-LRB-
cord-005478-5iu38pr6	1687	8	n=13	n=13	NNP
cord-005478-5iu38pr6	1687	9	,	,	,
cord-005478-5iu38pr6	1687	10	4	4	CD
cord-005478-5iu38pr6	1687	11	%	%	NN
cord-005478-5iu38pr6	1687	12	)	)	-RRB-
cord-005478-5iu38pr6	1687	13	,	,	,
cord-005478-5iu38pr6	1687	14	arrhythmia	arrhythmia	NN
cord-005478-5iu38pr6	1687	15	(	(	-LRB-
cord-005478-5iu38pr6	1688	1	n=12	n=12	NNP
cord-005478-5iu38pr6	1688	2	,	,	,
cord-005478-5iu38pr6	1688	3	4	4	CD
cord-005478-5iu38pr6	1688	4	%	%	NN
cord-005478-5iu38pr6	1688	5	)	)	-RRB-
cord-005478-5iu38pr6	1688	6	,	,	,
cord-005478-5iu38pr6	1688	7	pericarditis	pericarditis	NN
cord-005478-5iu38pr6	1688	8	(	(	-LRB-
cord-005478-5iu38pr6	1688	9	n=7	n=7	NNS
cord-005478-5iu38pr6	1688	10	,	,	,
cord-005478-5iu38pr6	1688	11	2	2	CD
cord-005478-5iu38pr6	1688	12	%	%	NN
cord-005478-5iu38pr6	1688	13	)	)	-RRB-
cord-005478-5iu38pr6	1688	14	and	and	CC
cord-005478-5iu38pr6	1688	15	coronary	coronary	JJ
cord-005478-5iu38pr6	1688	16	artery	artery	NN
cord-005478-5iu38pr6	1688	17	syndrome	syndrome	NN
cord-005478-5iu38pr6	1688	18	(	(	-LRB-
cord-005478-5iu38pr6	1688	19	n=3	n=3	NN
cord-005478-5iu38pr6	1688	20	,	,	,
cord-005478-5iu38pr6	1688	21	1	1	CD
cord-005478-5iu38pr6	1688	22	%	%	NN
cord-005478-5iu38pr6	1688	23	)	)	-RRB-
cord-005478-5iu38pr6	1688	24	in	in	IN
cord-005478-5iu38pr6	1688	25	the	the	DT
cord-005478-5iu38pr6	1688	26	whole	whole	JJ
cord-005478-5iu38pr6	1688	27	patient	patient	NN
cord-005478-5iu38pr6	1688	28	group	group	NN
cord-005478-5iu38pr6	1688	29	.	.	.
cord-005478-5iu38pr6	1689	1	ECE	ECE	NNP
cord-005478-5iu38pr6	1689	2	resolved	resolve	VBD
cord-005478-5iu38pr6	1689	3	in	in	IN
cord-005478-5iu38pr6	1689	4	38	38	CD
cord-005478-5iu38pr6	1689	5	patients	patient	NNS
cord-005478-5iu38pr6	1689	6	(	(	-LRB-
cord-005478-5iu38pr6	1689	7	78	78	CD
cord-005478-5iu38pr6	1689	8	%	%	NN
cord-005478-5iu38pr6	1689	9	)	)	-RRB-
cord-005478-5iu38pr6	1689	10	.	.	.
cord-005478-5iu38pr6	1690	1	Cardiovascular	cardiovascular	JJ
cord-005478-5iu38pr6	1690	2	risk	risk	NN
cord-005478-5iu38pr6	1690	3	factors	factor	NNS
cord-005478-5iu38pr6	1690	4	and	and	CC
cord-005478-5iu38pr6	1690	5	the	the	DT
cord-005478-5iu38pr6	1690	6	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1690	7	doses	dose	NNS
cord-005478-5iu38pr6	1690	8	of	of	IN
cord-005478-5iu38pr6	1690	9	anthracycline	anthracycline	NNP
cord-005478-5iu38pr6	1690	10	were	be	VBD
cord-005478-5iu38pr6	1690	11	not	not	RB
cord-005478-5iu38pr6	1690	12	significantly	significantly	RB
cord-005478-5iu38pr6	1690	13	associated	associate	VBN
cord-005478-5iu38pr6	1690	14	with	with	IN
cord-005478-5iu38pr6	1690	15	the	the	DT
cord-005478-5iu38pr6	1690	16	incidence	incidence	NN
cord-005478-5iu38pr6	1690	17	of	of	IN
cord-005478-5iu38pr6	1690	18	ECE	ECE	NNP
cord-005478-5iu38pr6	1690	19	.	.	.
cord-005478-5iu38pr6	1691	1	In	in	IN
cord-005478-5iu38pr6	1691	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	1691	3	analysis	analysis	NN
cord-005478-5iu38pr6	1691	4	,	,	,
cord-005478-5iu38pr6	1691	5	the	the	DT
cord-005478-5iu38pr6	1691	6	main	main	JJ
cord-005478-5iu38pr6	1691	7	factors	factor	NNS
cord-005478-5iu38pr6	1691	8	associated	associate	VBN
cord-005478-5iu38pr6	1691	9	with	with	IN
cord-005478-5iu38pr6	1691	10	ECE	ECE	NNP
cord-005478-5iu38pr6	1691	11	were	be	VBD
cord-005478-5iu38pr6	1691	12	the	the	DT
cord-005478-5iu38pr6	1691	13	use	use	NN
cord-005478-5iu38pr6	1691	14	of	of	IN
cord-005478-5iu38pr6	1691	15	PT	PT	NNP
cord-005478-5iu38pr6	1691	16	-	-	HYPH
cord-005478-5iu38pr6	1691	17	Cy	Cy	NNP
cord-005478-5iu38pr6	1691	18	[	[	-LRB-
cord-005478-5iu38pr6	1691	19	HR=2.8	HR=2.8	NNP
cord-005478-5iu38pr6	1691	20	,	,	,
cord-005478-5iu38pr6	1691	21	95	95	CD
cord-005478-5iu38pr6	1691	22	%	%	NN
cord-005478-5iu38pr6	1691	23	CI	CI	NNP
cord-005478-5iu38pr6	1691	24	1	1	CD
cord-005478-5iu38pr6	1691	25	.	.	.
cord-005478-5iu38pr6	1692	1	After	after	IN
cord-005478-5iu38pr6	1692	2	a	a	DT
cord-005478-5iu38pr6	1692	3	median	median	JJ
cord-005478-5iu38pr6	1692	4	follow	follow	NN
cord-005478-5iu38pr6	1692	5	-	-	HYPH
cord-005478-5iu38pr6	1692	6	up	up	NN
cord-005478-5iu38pr6	1692	7	of	of	IN
cord-005478-5iu38pr6	1692	8	36.5	36.5	CD
cord-005478-5iu38pr6	1692	9	months	month	NNS
cord-005478-5iu38pr6	1692	10	(	(	-LRB-
cord-005478-5iu38pr6	1692	11	IQR	IQR	NNP
cord-005478-5iu38pr6	1692	12	,	,	,
cord-005478-5iu38pr6	1692	13	32	32	CD
cord-005478-5iu38pr6	1692	14	-	-	SYM
cord-005478-5iu38pr6	1692	15	40	40	CD
cord-005478-5iu38pr6	1692	16	)	)	-RRB-
cord-005478-5iu38pr6	1692	17	,	,	,
cord-005478-5iu38pr6	1692	18	the	the	DT
cord-005478-5iu38pr6	1692	19	2-year	2-year	CD
cord-005478-5iu38pr6	1692	20	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1692	21	incidences	incidence	NNS
cord-005478-5iu38pr6	1692	22	of	of	IN
cord-005478-5iu38pr6	1692	23	NRM	NRM	NNP
cord-005478-5iu38pr6	1692	24	,	,	,
cord-005478-5iu38pr6	1692	25	relapse	relapse	NN
cord-005478-5iu38pr6	1692	26	,	,	,
cord-005478-5iu38pr6	1692	27	OS	OS	NNP
cord-005478-5iu38pr6	1692	28	and	and	CC
cord-005478-5iu38pr6	1692	29	DFS	DFS	NNP
cord-005478-5iu38pr6	1692	30	were	be	VBD
cord-005478-5iu38pr6	1692	31	28	28	CD
cord-005478-5iu38pr6	1692	32	%	%	NN
cord-005478-5iu38pr6	1692	33	vs.	vs.	IN
cord-005478-5iu38pr6	1692	34	22	22	CD
cord-005478-5iu38pr6	1692	35	%	%	NN
cord-005478-5iu38pr6	1692	36	;	;	:
cord-005478-5iu38pr6	1692	37	23	23	CD
cord-005478-5iu38pr6	1692	38	%	%	NN
cord-005478-5iu38pr6	1692	39	vs.	vs.	IN
cord-005478-5iu38pr6	1692	40	19	19	CD
cord-005478-5iu38pr6	1692	41	%	%	NN
cord-005478-5iu38pr6	1692	42	;	;	:
cord-005478-5iu38pr6	1692	43	56	56	CD
cord-005478-5iu38pr6	1692	44	%	%	NN
cord-005478-5iu38pr6	1692	45	vs.	vs.	CC
cord-005478-5iu38pr6	1692	46	63	63	CD
cord-005478-5iu38pr6	1692	47	%	%	NN
cord-005478-5iu38pr6	1692	48	;	;	:
cord-005478-5iu38pr6	1692	49	49	49	CD
cord-005478-5iu38pr6	1692	50	%	%	NN
cord-005478-5iu38pr6	1692	51	vs.	vs.	IN
cord-005478-5iu38pr6	1692	52	59	59	CD
cord-005478-5iu38pr6	1692	53	%	%	NN
cord-005478-5iu38pr6	1692	54	in	in	IN
cord-005478-5iu38pr6	1692	55	the	the	DT
cord-005478-5iu38pr6	1692	56	PT	PT	NNP
cord-005478-5iu38pr6	1692	57	-	-	HYPH
cord-005478-5iu38pr6	1692	58	Cy	Cy	NNP
cord-005478-5iu38pr6	1692	59	and	and	CC
cord-005478-5iu38pr6	1692	60	no	no	DT
cord-005478-5iu38pr6	1692	61	PT	PT	NNP
cord-005478-5iu38pr6	1692	62	-	-	HYPH
cord-005478-5iu38pr6	1692	63	CY	CY	NNP
cord-005478-5iu38pr6	1692	64	groups	group	NNS
cord-005478-5iu38pr6	1692	65	,	,	,
cord-005478-5iu38pr6	1692	66	respectively	respectively	RB
cord-005478-5iu38pr6	1692	67	(	(	-LRB-
cord-005478-5iu38pr6	1692	68	p	p	IN
cord-005478-5iu38pr6	1692	69	values	value	NNS
cord-005478-5iu38pr6	1692	70	non	non	JJ
cord-005478-5iu38pr6	1692	71	significant	significant	JJ
cord-005478-5iu38pr6	1692	72	)	)	-RRB-
cord-005478-5iu38pr6	1692	73	.	.	.
cord-005478-5iu38pr6	1693	1	At	at	IN
cord-005478-5iu38pr6	1693	2	last	last	JJ
cord-005478-5iu38pr6	1693	3	-	-	HYPH
cord-005478-5iu38pr6	1693	4	follow	follow	NN
cord-005478-5iu38pr6	1693	5	-	-	HYPH
cord-005478-5iu38pr6	1693	6	up	up	NN
cord-005478-5iu38pr6	1693	7	,	,	,
cord-005478-5iu38pr6	1693	8	136	136	CD
cord-005478-5iu38pr6	1693	9	patients	patient	NNS
cord-005478-5iu38pr6	1693	10	have	have	VBP
cord-005478-5iu38pr6	1693	11	died	die	VBN
cord-005478-5iu38pr6	1693	12	.	.	.
cord-005478-5iu38pr6	1694	1	The	the	DT
cord-005478-5iu38pr6	1694	2	main	main	JJ
cord-005478-5iu38pr6	1694	3	causes	cause	NNS
cord-005478-5iu38pr6	1694	4	of	of	IN
cord-005478-5iu38pr6	1694	5	death	death	NN
cord-005478-5iu38pr6	1694	6	were	be	VBD
cord-005478-5iu38pr6	1694	7	disease	disease	NN
cord-005478-5iu38pr6	1694	8	relapse	relapse	NN
cord-005478-5iu38pr6	1694	9	(	(	-LRB-
cord-005478-5iu38pr6	1694	10	n=51	n=51	NNP
cord-005478-5iu38pr6	1694	11	)	)	-RRB-
cord-005478-5iu38pr6	1694	12	,	,	.
cord-005478-5iu38pr6	1695	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1695	2	/	/	SYM
cord-005478-5iu38pr6	1695	3	infection	infection	NN
cord-005478-5iu38pr6	1695	4	(	(	-LRB-
cord-005478-5iu38pr6	1695	5	n=48	n=48	NNP
cord-005478-5iu38pr6	1695	6	)	)	-RRB-
cord-005478-5iu38pr6	1695	7	and	and	CC
cord-005478-5iu38pr6	1695	8	ECE	ECE	NNP
cord-005478-5iu38pr6	1695	9	(	(	-LRB-
cord-005478-5iu38pr6	1695	10	n=8	n=8	NNP
cord-005478-5iu38pr6	1695	11	)	)	-RRB-
cord-005478-5iu38pr6	1695	12	.	.	.
cord-005478-5iu38pr6	1696	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1696	2	:	:	:
cord-005478-5iu38pr6	1697	1	Incidence	incidence	NN
cord-005478-5iu38pr6	1697	2	of	of	IN
cord-005478-5iu38pr6	1697	3	ECE	ECE	NNP
cord-005478-5iu38pr6	1697	4	is	be	VBZ
cord-005478-5iu38pr6	1697	5	significantly	significantly	RB
cord-005478-5iu38pr6	1697	6	higher	high	JJR
cord-005478-5iu38pr6	1697	7	in	in	IN
cord-005478-5iu38pr6	1697	8	the	the	DT
cord-005478-5iu38pr6	1697	9	PT	PT	NNP
cord-005478-5iu38pr6	1697	10	-	-	HYPH
cord-005478-5iu38pr6	1697	11	Cy	Cy	NNP
cord-005478-5iu38pr6	1697	12	group	group	NN
cord-005478-5iu38pr6	1697	13	.	.	.
cord-005478-5iu38pr6	1698	1	In	in	IN
cord-005478-5iu38pr6	1698	2	elderly	elderly	JJ
cord-005478-5iu38pr6	1698	3	patients	patient	NNS
cord-005478-5iu38pr6	1698	4	or	or	CC
cord-005478-5iu38pr6	1698	5	with	with	IN
cord-005478-5iu38pr6	1698	6	a	a	DT
cord-005478-5iu38pr6	1698	7	history	history	NN
cord-005478-5iu38pr6	1698	8	of	of	IN
cord-005478-5iu38pr6	1698	9	pretransplant	pretransplant	JJ
cord-005478-5iu38pr6	1698	10	cardiac	cardiac	NN
cord-005478-5iu38pr6	1698	11	event	event	NN
cord-005478-5iu38pr6	1698	12	,	,	,
cord-005478-5iu38pr6	1698	13	an	an	DT
cord-005478-5iu38pr6	1698	14	alternative	alternative	NN
cord-005478-5iu38pr6	1698	15	to	to	IN
cord-005478-5iu38pr6	1698	16	PT	PT	NNP
cord-005478-5iu38pr6	1698	17	-	-	HYPH
cord-005478-5iu38pr6	1698	18	Cy	Cy	NNP
cord-005478-5iu38pr6	1698	19	should	should	MD
cord-005478-5iu38pr6	1698	20	be	be	VB
cord-005478-5iu38pr6	1698	21	considered	consider	VBN
cord-005478-5iu38pr6	1698	22	to	to	TO
cord-005478-5iu38pr6	1698	23	prevent	prevent	VB
cord-005478-5iu38pr6	1698	24	ECE	ECE	NNP
cord-005478-5iu38pr6	1698	25	.	.	.
cord-005478-5iu38pr6	1699	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1699	2	:	:	:
cord-005478-5iu38pr6	1699	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1699	4	to	to	TO
cord-005478-5iu38pr6	1699	5	declare	declare	VB
cord-005478-5iu38pr6	1699	6	Severe	severe	JJ
cord-005478-5iu38pr6	1699	7	iron	iron	NN
cord-005478-5iu38pr6	1699	8	overload	overload	NN
cord-005478-5iu38pr6	1699	9	,	,	,
cord-005478-5iu38pr6	1699	10	measured	measure	VBN
cord-005478-5iu38pr6	1699	11	by	by	IN
cord-005478-5iu38pr6	1699	12	liver	liver	NN
cord-005478-5iu38pr6	1699	13	MRI	MRI	NNP
cord-005478-5iu38pr6	1699	14	at	at	IN
cord-005478-5iu38pr6	1699	15	the	the	DT
cord-005478-5iu38pr6	1699	16	preallo	preallo	NNP
cord-005478-5iu38pr6	1699	17	-	-	HYPH
cord-005478-5iu38pr6	1699	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1699	19	,	,	,
cord-005478-5iu38pr6	1699	20	significantly	significantly	RB
cord-005478-5iu38pr6	1699	21	impaired	impair	VBD
cord-005478-5iu38pr6	1699	22	the	the	DT
cord-005478-5iu38pr6	1699	23	long	long	JJ
cord-005478-5iu38pr6	1699	24	-	-	HYPH
cord-005478-5iu38pr6	1699	25	term	term	NN
cord-005478-5iu38pr6	1699	26	outcome	outcome	NN
cord-005478-5iu38pr6	1699	27	of	of	IN
cord-005478-5iu38pr6	1699	28	the	the	DT
cord-005478-5iu38pr6	1699	29	procedure	procedure	NN
cord-005478-5iu38pr6	1699	30	Methods	method	NNS
cord-005478-5iu38pr6	1699	31	:	:	:
cord-005478-5iu38pr6	1699	32	Once	once	RB
cord-005478-5iu38pr6	1699	33	approved	approve	VBN
cord-005478-5iu38pr6	1699	34	by	by	IN
cord-005478-5iu38pr6	1699	35	the	the	DT
cord-005478-5iu38pr6	1699	36	Clinical	Clinical	NNP
cord-005478-5iu38pr6	1699	37	Trials	Trials	NNPS
cord-005478-5iu38pr6	1699	38	and	and	CC
cord-005478-5iu38pr6	1699	39	Ethics	Ethics	NNP
cord-005478-5iu38pr6	1699	40	Committee	Committee	NNP
cord-005478-5iu38pr6	1699	41	,	,	,
cord-005478-5iu38pr6	1699	42	a	a	DT
cord-005478-5iu38pr6	1699	43	liver	liver	NN
cord-005478-5iu38pr6	1699	44	MRI	MRI	NNP
cord-005478-5iu38pr6	1699	45	was	be	VBD
cord-005478-5iu38pr6	1699	46	systematically	systematically	RB
cord-005478-5iu38pr6	1699	47	offered	offer	VBN
cord-005478-5iu38pr6	1699	48	to	to	IN
cord-005478-5iu38pr6	1699	49	patients	patient	NNS
cord-005478-5iu38pr6	1699	50	who	who	WP
cord-005478-5iu38pr6	1699	51	were	be	VBD
cord-005478-5iu38pr6	1699	52	admitted	admit	VBN
cord-005478-5iu38pr6	1699	53	to	to	TO
cord-005478-5iu38pr6	1699	54	undergo	undergo	VB
cord-005478-5iu38pr6	1699	55	an	an	DT
cord-005478-5iu38pr6	1699	56	allo	allo	NN
cord-005478-5iu38pr6	1699	57	-	-	HYPH
cord-005478-5iu38pr6	1699	58	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1699	59	in	in	IN
cord-005478-5iu38pr6	1699	60	our	-PRON-	PRP$
cord-005478-5iu38pr6	1699	61	Center	Center	NNP
cord-005478-5iu38pr6	1699	62	.	.	.
cord-005478-5iu38pr6	1700	1	Among	among	IN
cord-005478-5iu38pr6	1700	2	the	the	DT
cord-005478-5iu38pr6	1700	3	131	131	CD
cord-005478-5iu38pr6	1700	4	pts	pt	NNS
cord-005478-5iu38pr6	1700	5	consecutively	consecutively	RB
cord-005478-5iu38pr6	1700	6	transplanted	transplant	VBN
cord-005478-5iu38pr6	1700	7	between	between	IN
cord-005478-5iu38pr6	1700	8	June	June	NNP
cord-005478-5iu38pr6	1700	9	2015	2015	CD
cord-005478-5iu38pr6	1700	10	and	and	CC
cord-005478-5iu38pr6	1700	11	July	July	NNP
cord-005478-5iu38pr6	1700	12	2018	2018	CD
cord-005478-5iu38pr6	1700	13	,	,	,
cord-005478-5iu38pr6	1700	14	100	100	CD
cord-005478-5iu38pr6	1700	15	pts	pt	NNS
cord-005478-5iu38pr6	1700	16	signed	sign	VBD
cord-005478-5iu38pr6	1700	17	the	the	DT
cord-005478-5iu38pr6	1700	18	informed	informed	JJ
cord-005478-5iu38pr6	1700	19	consent	consent	NN
cord-005478-5iu38pr6	1700	20	and	and	CC
cord-005478-5iu38pr6	1700	21	underwent	undergo	VBD
cord-005478-5iu38pr6	1700	22	a	a	DT
cord-005478-5iu38pr6	1700	23	pre	pre	JJ
cord-005478-5iu38pr6	1700	24	-	-	JJ
cord-005478-5iu38pr6	1700	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1700	26	MRI	MRI	NNP
cord-005478-5iu38pr6	1700	27	to	to	TO
cord-005478-5iu38pr6	1700	28	assess	assess	VB
cord-005478-5iu38pr6	1700	29	the	the	DT
cord-005478-5iu38pr6	1700	30	hepatic	hepatic	JJ
cord-005478-5iu38pr6	1700	31	iron	iron	NN
cord-005478-5iu38pr6	1700	32	load	load	NN
cord-005478-5iu38pr6	1700	33	.	.	.
cord-005478-5iu38pr6	1701	1	A	a	DT
cord-005478-5iu38pr6	1701	2	Signal	Signal	NNP
cord-005478-5iu38pr6	1701	3	Intensity	intensity	NN
cord-005478-5iu38pr6	1701	4	Ratio	ratio	NN
cord-005478-5iu38pr6	1701	5	(	(	-LRB-
cord-005478-5iu38pr6	1701	6	SIR	SIR	NNP
cord-005478-5iu38pr6	1701	7	)	)	-RRB-
cord-005478-5iu38pr6	1701	8	method	method	NN
cord-005478-5iu38pr6	1701	9	was	be	VBD
cord-005478-5iu38pr6	1701	10	employed	employ	VBN
cord-005478-5iu38pr6	1701	11	for	for	IN
cord-005478-5iu38pr6	1701	12	the	the	DT
cord-005478-5iu38pr6	1701	13	measurement	measurement	NN
cord-005478-5iu38pr6	1701	14	.	.	.
cord-005478-5iu38pr6	1702	1	Results	result	NNS
cord-005478-5iu38pr6	1702	2	:	:	:
cord-005478-5iu38pr6	1703	1	64	64	CD
cord-005478-5iu38pr6	1703	2	pts	pt	NNS
cord-005478-5iu38pr6	1703	3	were	be	VBD
cord-005478-5iu38pr6	1703	4	male	male	JJ
cord-005478-5iu38pr6	1703	5	,	,	,
cord-005478-5iu38pr6	1703	6	and	and	CC
cord-005478-5iu38pr6	1703	7	36	36	CD
cord-005478-5iu38pr6	1703	8	were	be	VBD
cord-005478-5iu38pr6	1703	9	female	female	JJ
cord-005478-5iu38pr6	1703	10	.	.	.
cord-005478-5iu38pr6	1704	1	Median	median	JJ
cord-005478-5iu38pr6	1704	2	age	age	NN
cord-005478-5iu38pr6	1704	3	was	be	VBD
cord-005478-5iu38pr6	1704	4	54	54	CD
cord-005478-5iu38pr6	1704	5	years	year	NNS
cord-005478-5iu38pr6	1705	1	(	(	-LRB-
cord-005478-5iu38pr6	1705	2	range	range	NN
cord-005478-5iu38pr6	1705	3	:	:	:
cord-005478-5iu38pr6	1705	4	12	12	CD
cord-005478-5iu38pr6	1705	5	-	-	SYM
cord-005478-5iu38pr6	1705	6	69	69	CD
cord-005478-5iu38pr6	1705	7	)	)	-RRB-
cord-005478-5iu38pr6	1705	8	.	.	.
cord-005478-5iu38pr6	1706	1	The	the	DT
cord-005478-5iu38pr6	1706	2	baseline	baseline	JJ
cord-005478-5iu38pr6	1706	3	diseases	disease	NNS
cord-005478-5iu38pr6	1706	4	were	be	VBD
cord-005478-5iu38pr6	1706	5	:	:	:
cord-005478-5iu38pr6	1706	6	37	37	CD
cord-005478-5iu38pr6	1706	7	AML	AML	NNP
cord-005478-5iu38pr6	1706	8	,	,	,
cord-005478-5iu38pr6	1706	9	24	24	CD
cord-005478-5iu38pr6	1706	10	NHL	NHL	NNP
cord-005478-5iu38pr6	1706	11	,	,	,
cord-005478-5iu38pr6	1706	12	16	16	CD
cord-005478-5iu38pr6	1706	13	ALL	all	DT
cord-005478-5iu38pr6	1706	14	,	,	,
cord-005478-5iu38pr6	1706	15	8	8	CD
cord-005478-5iu38pr6	1706	16	MDS	MDS	NNP
cord-005478-5iu38pr6	1706	17	,	,	,
cord-005478-5iu38pr6	1706	18	8	8	CD
cord-005478-5iu38pr6	1706	19	cMPD	cmpd	NN
cord-005478-5iu38pr6	1706	20	,	,	,
cord-005478-5iu38pr6	1706	21	6	6	CD
cord-005478-5iu38pr6	1706	22	MM	MM	NNP
cord-005478-5iu38pr6	1706	23	,	,	,
cord-005478-5iu38pr6	1706	24	and	and	CC
cord-005478-5iu38pr6	1706	25	1	1	CD
cord-005478-5iu38pr6	1706	26	BMF	bmf	NN
cord-005478-5iu38pr6	1706	27	.	.	.
cord-005478-5iu38pr6	1707	1	67	67	CD
cord-005478-5iu38pr6	1707	2	underwent	undergo	VBD
cord-005478-5iu38pr6	1707	3	alternative	alternative	JJ
cord-005478-5iu38pr6	1707	4	donor	donor	NN
cord-005478-5iu38pr6	1707	5	transplants	transplant	NNS
cord-005478-5iu38pr6	1707	6	(	(	-LRB-
cord-005478-5iu38pr6	1707	7	56	56	CD
cord-005478-5iu38pr6	1707	8	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1707	9	,	,	,
cord-005478-5iu38pr6	1707	10	and	and	CC
cord-005478-5iu38pr6	1707	11	11	11	CD
cord-005478-5iu38pr6	1707	12	haplo	haplo	NN
cord-005478-5iu38pr6	1707	13	-	-	HYPH
cord-005478-5iu38pr6	1707	14	identical	identical	JJ
cord-005478-5iu38pr6	1707	15	)	)	-RRB-
cord-005478-5iu38pr6	1707	16	,	,	,
cord-005478-5iu38pr6	1707	17	and	and	CC
cord-005478-5iu38pr6	1707	18	33	33	CD
cord-005478-5iu38pr6	1707	19	HLA	HLA	NNP
cord-005478-5iu38pr6	1707	20	-	-	HYPH
cord-005478-5iu38pr6	1707	21	id	id	NNP
cord-005478-5iu38pr6	1707	22	family	family	NN
cord-005478-5iu38pr6	1707	23	donor	donor	NN
cord-005478-5iu38pr6	1707	24	transplants	transplant	NNS
cord-005478-5iu38pr6	1707	25	.	.	.
cord-005478-5iu38pr6	1708	1	Stem	stem	JJ
cord-005478-5iu38pr6	1708	2	cell	cell	NN
cord-005478-5iu38pr6	1708	3	source	source	NN
cord-005478-5iu38pr6	1708	4	was	be	VBD
cord-005478-5iu38pr6	1708	5	PB	PB	NNP
cord-005478-5iu38pr6	1708	6	in	in	IN
cord-005478-5iu38pr6	1708	7	96	96	CD
cord-005478-5iu38pr6	1708	8	,	,	,
cord-005478-5iu38pr6	1708	9	and	and	CC
cord-005478-5iu38pr6	1708	10	BM	BM	NNP
cord-005478-5iu38pr6	1708	11	in	in	IN
cord-005478-5iu38pr6	1708	12	4	4	CD
cord-005478-5iu38pr6	1708	13	cases	case	NNS
cord-005478-5iu38pr6	1708	14	.	.	.
cord-005478-5iu38pr6	1709	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	1709	2	regimen	regimen	NN
cord-005478-5iu38pr6	1709	3	was	be	VBD
cord-005478-5iu38pr6	1709	4	intensive	intensive	JJ
cord-005478-5iu38pr6	1709	5	in	in	IN
cord-005478-5iu38pr6	1709	6	51	51	CD
cord-005478-5iu38pr6	1709	7	pts	pt	NNS
cord-005478-5iu38pr6	1709	8	,	,	,
cord-005478-5iu38pr6	1709	9	and	and	CC
cord-005478-5iu38pr6	1709	10	RIC	RIC	NNP
cord-005478-5iu38pr6	1709	11	in	in	IN
cord-005478-5iu38pr6	1709	12	49	49	CD
cord-005478-5iu38pr6	1709	13	;	;	:
cord-005478-5iu38pr6	1709	14	no	no	DT
cord-005478-5iu38pr6	1709	15	non	non	JJ
cord-005478-5iu38pr6	1709	16	-	-	JJ
cord-005478-5iu38pr6	1709	17	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1709	18	allo	allo	NN
cord-005478-5iu38pr6	1709	19	-	-	HYPH
cord-005478-5iu38pr6	1709	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1709	21	were	be	VBD
cord-005478-5iu38pr6	1709	22	performed	perform	VBN
cord-005478-5iu38pr6	1709	23	.	.	.
cord-005478-5iu38pr6	1710	1	Based	base	VBN
cord-005478-5iu38pr6	1710	2	on	on	IN
cord-005478-5iu38pr6	1710	3	hepatic	hepatic	JJ
cord-005478-5iu38pr6	1710	4	iron	iron	NN
cord-005478-5iu38pr6	1710	5	overload	overload	NN
cord-005478-5iu38pr6	1710	6	at	at	IN
cord-005478-5iu38pr6	1710	7	pre	pre	JJ
cord-005478-5iu38pr6	1710	8	-	-	JJ
cord-005478-5iu38pr6	1710	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1710	10	MRI	MRI	NNP
cord-005478-5iu38pr6	1710	11	,	,	,
cord-005478-5iu38pr6	1710	12	the	the	DT
cord-005478-5iu38pr6	1710	13	patients	patient	NNS
cord-005478-5iu38pr6	1710	14	were	be	VBD
cord-005478-5iu38pr6	1710	15	classified	classify	VBN
cord-005478-5iu38pr6	1710	16	into	into	IN
cord-005478-5iu38pr6	1710	17	the	the	DT
cord-005478-5iu38pr6	1710	18	following	follow	VBG
cord-005478-5iu38pr6	1710	19	groups	group	NNS
cord-005478-5iu38pr6	1710	20	:	:	:
cord-005478-5iu38pr6	1711	1	23	23	CD
cord-005478-5iu38pr6	1711	2	pts	pt	NNS
cord-005478-5iu38pr6	1711	3	(	(	-LRB-
cord-005478-5iu38pr6	1711	4	23	23	CD
cord-005478-5iu38pr6	1711	5	%	%	NN
cord-005478-5iu38pr6	1711	6	)	)	-RRB-
cord-005478-5iu38pr6	1711	7	showed	show	VBD
cord-005478-5iu38pr6	1711	8	severe	severe	JJ
cord-005478-5iu38pr6	1711	9	IO	IO	NNP
cord-005478-5iu38pr6	1711	10	(	(	-LRB-
cord-005478-5iu38pr6	1711	11	LIC	LIC	NNP
cord-005478-5iu38pr6	1711	12	>	>	XX
cord-005478-5iu38pr6	1711	13	80	80	CD
cord-005478-5iu38pr6	1711	14	micromol	micromol	JJ
cord-005478-5iu38pr6	1711	15	/	/	SYM
cord-005478-5iu38pr6	1711	16	g	g	NN
cord-005478-5iu38pr6	1711	17	or	or	CC
cord-005478-5iu38pr6	1711	18	4.5	4.5	CD
cord-005478-5iu38pr6	1711	19	mg	mg	NNP
cord-005478-5iu38pr6	1711	20	/	/	SYM
cord-005478-5iu38pr6	1711	21	g	g	NNP
cord-005478-5iu38pr6	1711	22	)	)	-RRB-
cord-005478-5iu38pr6	1711	23	,	,	,
cord-005478-5iu38pr6	1711	24	25	25	CD
cord-005478-5iu38pr6	1711	25	pts	pt	NNS
cord-005478-5iu38pr6	1711	26	(	(	-LRB-
cord-005478-5iu38pr6	1711	27	25	25	CD
cord-005478-5iu38pr6	1711	28	%	%	NN
cord-005478-5iu38pr6	1711	29	)	)	-RRB-
cord-005478-5iu38pr6	1711	30	moderate	moderate	JJ
cord-005478-5iu38pr6	1711	31	IO	IO	NNP
cord-005478-5iu38pr6	1712	1	(	(	-LRB-
cord-005478-5iu38pr6	1712	2	LIC	LIC	NNP
cord-005478-5iu38pr6	1712	3	36	36	CD
cord-005478-5iu38pr6	1712	4	-	-	SYM
cord-005478-5iu38pr6	1712	5	80	80	CD
cord-005478-5iu38pr6	1712	6	micromol	micromol	JJ
cord-005478-5iu38pr6	1712	7	/	/	SYM
cord-005478-5iu38pr6	1712	8	g	g	NN
cord-005478-5iu38pr6	1712	9	or	or	CC
cord-005478-5iu38pr6	1712	10	2.1	2.1	CD
cord-005478-5iu38pr6	1712	11	-	-	SYM
cord-005478-5iu38pr6	1712	12	4.4	4.4	CD
cord-005478-5iu38pr6	1712	13	mg	mg	NNP
cord-005478-5iu38pr6	1712	14	/	/	SYM
cord-005478-5iu38pr6	1712	15	g	g	NNP
cord-005478-5iu38pr6	1712	16	)	)	-RRB-
cord-005478-5iu38pr6	1712	17	and	and	CC
cord-005478-5iu38pr6	1712	18	52	52	CD
cord-005478-5iu38pr6	1712	19	pts	pt	NNS
cord-005478-5iu38pr6	1712	20	(	(	-LRB-
cord-005478-5iu38pr6	1712	21	52	52	CD
cord-005478-5iu38pr6	1712	22	%	%	NN
cord-005478-5iu38pr6	1712	23	)	)	-RRB-
cord-005478-5iu38pr6	1713	1	no	no	DT
cord-005478-5iu38pr6	1713	2	significant	significant	JJ
cord-005478-5iu38pr6	1713	3	IO	IO	NNP
cord-005478-5iu38pr6	1713	4	(	(	-LRB-
cord-005478-5iu38pr6	1713	5	LIC	LIC	NNP
cord-005478-5iu38pr6	1713	6	<	<	XX
cord-005478-5iu38pr6	1713	7	36	36	CD
cord-005478-5iu38pr6	1713	8	micromol	micromol	JJ
cord-005478-5iu38pr6	1713	9	/	/	SYM
cord-005478-5iu38pr6	1713	10	g	g	NN
cord-005478-5iu38pr6	1713	11	or	or	CC
cord-005478-5iu38pr6	1713	12	2.1	2.1	CD
cord-005478-5iu38pr6	1713	13	mg	mg	NNP
cord-005478-5iu38pr6	1713	14	/	/	SYM
cord-005478-5iu38pr6	1713	15	g	g	NN
cord-005478-5iu38pr6	1713	16	)	)	-RRB-
cord-005478-5iu38pr6	1713	17	.	.	.
cord-005478-5iu38pr6	1714	1	As	as	IN
cord-005478-5iu38pr6	1714	2	shown	show	VBN
cord-005478-5iu38pr6	1714	3	in	in	IN
cord-005478-5iu38pr6	1714	4	table	table	NN
cord-005478-5iu38pr6	1714	5	1	1	CD
cord-005478-5iu38pr6	1714	6	,	,	,
cord-005478-5iu38pr6	1714	7	majority	majority	NN
cord-005478-5iu38pr6	1714	8	of	of	IN
cord-005478-5iu38pr6	1714	9	patients	patient	NNS
cord-005478-5iu38pr6	1714	10	with	with	IN
cord-005478-5iu38pr6	1714	11	severe	severe	JJ
cord-005478-5iu38pr6	1714	12	iron	iron	NN
cord-005478-5iu38pr6	1714	13	overload	overload	NN
cord-005478-5iu38pr6	1714	14	had	have	VBD
cord-005478-5iu38pr6	1714	15	been	be	VBN
cord-005478-5iu38pr6	1714	16	heavily	heavily	RB
cord-005478-5iu38pr6	1714	17	transfused	transfuse	VBN
cord-005478-5iu38pr6	1714	18	,	,	,
cord-005478-5iu38pr6	1714	19	and	and	CC
cord-005478-5iu38pr6	1714	20	had	have	VBD
cord-005478-5iu38pr6	1714	21	a	a	DT
cord-005478-5iu38pr6	1714	22	high	high	JJ
cord-005478-5iu38pr6	1714	23	pre	pre	JJ
cord-005478-5iu38pr6	1714	24	-	-	JJ
cord-005478-5iu38pr6	1714	25	HCST	hcst	JJ
cord-005478-5iu38pr6	1714	26	ferritin	ferritin	NN
cord-005478-5iu38pr6	1714	27	level	level	NN
cord-005478-5iu38pr6	1714	28	.	.	.
cord-005478-5iu38pr6	1715	1	Surprisingly	surprisingly	RB
cord-005478-5iu38pr6	1715	2	,	,	,
cord-005478-5iu38pr6	1715	3	pre	pre	JJ
cord-005478-5iu38pr6	1715	4	-	-	JJ
cord-005478-5iu38pr6	1715	5	HSCT	hsct	JJ
cord-005478-5iu38pr6	1715	6	chelation	chelation	NN
cord-005478-5iu38pr6	1715	7	had	have	VBD
cord-005478-5iu38pr6	1715	8	been	be	VBN
cord-005478-5iu38pr6	1715	9	employed	employ	VBN
cord-005478-5iu38pr6	1715	10	only	only	RB
cord-005478-5iu38pr6	1715	11	in	in	IN
cord-005478-5iu38pr6	1715	12	3	3	CD
cord-005478-5iu38pr6	1715	13	pts	pts	NN
cord-005478-5iu38pr6	1715	14	(	(	-LRB-
cord-005478-5iu38pr6	1715	15	13	13	CD
cord-005478-5iu38pr6	1715	16	%	%	NN
cord-005478-5iu38pr6	1715	17	)	)	-RRB-
cord-005478-5iu38pr6	1715	18	of	of	IN
cord-005478-5iu38pr6	1715	19	this	this	DT
cord-005478-5iu38pr6	1715	20	group	group	NN
cord-005478-5iu38pr6	1715	21	.	.	.
cord-005478-5iu38pr6	1716	1	Overall	overall	JJ
cord-005478-5iu38pr6	1716	2	mortalities	mortality	NNS
cord-005478-5iu38pr6	1716	3	at	at	IN
cord-005478-5iu38pr6	1716	4	days	day	NNS
cord-005478-5iu38pr6	1716	5	+100	+100	NNS
cord-005478-5iu38pr6	1716	6	,	,	,
cord-005478-5iu38pr6	1716	7	+180	+180	NNP
cord-005478-5iu38pr6	1716	8	and	and	CC
cord-005478-5iu38pr6	1716	9	+365	+365	NNP
cord-005478-5iu38pr6	1716	10	in	in	IN
cord-005478-5iu38pr6	1716	11	the	the	DT
cord-005478-5iu38pr6	1716	12	global	global	JJ
cord-005478-5iu38pr6	1716	13	series	series	NN
cord-005478-5iu38pr6	1716	14	,	,	,
cord-005478-5iu38pr6	1716	15	and	and	CC
cord-005478-5iu38pr6	1716	16	in	in	IN
cord-005478-5iu38pr6	1716	17	severe	severe	JJ
cord-005478-5iu38pr6	1716	18	versus	versus	IN
cord-005478-5iu38pr6	1716	19	non	non	JJ
cord-005478-5iu38pr6	1716	20	-	-	JJ
cord-005478-5iu38pr6	1716	21	severe	severe	JJ
cord-005478-5iu38pr6	1716	22	IO	IO	NNP
cord-005478-5iu38pr6	1716	23	group	group	NN
cord-005478-5iu38pr6	1716	24	are	be	VBP
cord-005478-5iu38pr6	1716	25	reflexed	reflexe	VBN
cord-005478-5iu38pr6	1716	26	in	in	IN
cord-005478-5iu38pr6	1716	27	table	table	NN
cord-005478-5iu38pr6	1716	28	2	2	CD
cord-005478-5iu38pr6	1716	29	.	.	.
cord-005478-5iu38pr6	1717	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1717	2	:	:	:
cord-005478-5iu38pr6	1718	1	1	1	LS
cord-005478-5iu38pr6	1718	2	)	)	-RRB-
cord-005478-5iu38pr6	1718	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	1718	4	data	datum	NNS
cord-005478-5iu38pr6	1718	5	shows	show	VBZ
cord-005478-5iu38pr6	1718	6	that	that	IN
cord-005478-5iu38pr6	1718	7	pre	pre	JJ
cord-005478-5iu38pr6	1718	8	-	-	JJ
cord-005478-5iu38pr6	1718	9	allo	allo	JJ
cord-005478-5iu38pr6	1718	10	-	-	HYPH
cord-005478-5iu38pr6	1718	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1718	12	iron	iron	NN
cord-005478-5iu38pr6	1718	13	-	-	HYPH
cord-005478-5iu38pr6	1718	14	overload	overload	NN
cord-005478-5iu38pr6	1718	15	correlates	correlate	VBZ
cord-005478-5iu38pr6	1718	16	with	with	IN
cord-005478-5iu38pr6	1718	17	previous	previous	JJ
cord-005478-5iu38pr6	1718	18	PRBC	PRBC	NNP
cord-005478-5iu38pr6	1718	19	transfusion	transfusion	NN
cord-005478-5iu38pr6	1718	20	load	load	NN
cord-005478-5iu38pr6	1718	21	;	;	:
cord-005478-5iu38pr6	1718	22	2	2	LS
cord-005478-5iu38pr6	1718	23	)	)	-RRB-
cord-005478-5iu38pr6	1718	24	it	-PRON-	PRP
cord-005478-5iu38pr6	1718	25	also	also	RB
cord-005478-5iu38pr6	1718	26	makes	make	VBZ
cord-005478-5iu38pr6	1718	27	evident	evident	JJ
cord-005478-5iu38pr6	1718	28	that	that	IN
cord-005478-5iu38pr6	1718	29	IO	IO	NNP
cord-005478-5iu38pr6	1718	30	is	be	VBZ
cord-005478-5iu38pr6	1718	31	an	an	DT
cord-005478-5iu38pr6	1718	32	important	important	JJ
cord-005478-5iu38pr6	1718	33	risk	risk	NN
cord-005478-5iu38pr6	1718	34	factors	factor	NNS
cord-005478-5iu38pr6	1718	35	for	for	IN
cord-005478-5iu38pr6	1718	36	post	post	JJ
cord-005478-5iu38pr6	1718	37	-	-	JJ
cord-005478-5iu38pr6	1718	38	transplant	transplant	JJ
cord-005478-5iu38pr6	1718	39	mortality	mortality	NN
cord-005478-5iu38pr6	1718	40	.	.	.
cord-005478-5iu38pr6	1719	1	3	3	LS
cord-005478-5iu38pr6	1719	2	)	)	-RRB-
cord-005478-5iu38pr6	1720	1	our	-PRON-	PRP$
cord-005478-5iu38pr6	1720	2	real	real	JJ
cord-005478-5iu38pr6	1720	3	-	-	HYPH
cord-005478-5iu38pr6	1720	4	life	life	NN
cord-005478-5iu38pr6	1720	5	study	study	NN
cord-005478-5iu38pr6	1720	6	reflects	reflect	VBZ
cord-005478-5iu38pr6	1720	7	that	that	IN
cord-005478-5iu38pr6	1720	8	only	only	RB
cord-005478-5iu38pr6	1720	9	a	a	DT
cord-005478-5iu38pr6	1720	10	minority	minority	NN
cord-005478-5iu38pr6	1720	11	of	of	IN
cord-005478-5iu38pr6	1720	12	heavily	heavily	RB
cord-005478-5iu38pr6	1720	13	transfused	transfuse	VBN
cord-005478-5iu38pr6	1720	14	pts	pt	NNS
cord-005478-5iu38pr6	1720	15	had	have	VBD
cord-005478-5iu38pr6	1720	16	received	receive	VBN
cord-005478-5iu38pr6	1720	17	chelation	chelation	NN
cord-005478-5iu38pr6	1720	18	therapy	therapy	NN
cord-005478-5iu38pr6	1720	19	previously	previously	RB
cord-005478-5iu38pr6	1720	20	to	to	IN
cord-005478-5iu38pr6	1720	21	the	the	DT
cord-005478-5iu38pr6	1720	22	allo	allo	NN
cord-005478-5iu38pr6	1720	23	-	-	HYPH
cord-005478-5iu38pr6	1720	24	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1720	25	.	.	.
cord-005478-5iu38pr6	1721	1	4	4	LS
cord-005478-5iu38pr6	1721	2	)	)	-RRB-
cord-005478-5iu38pr6	1721	3	considering	consider	VBG
cord-005478-5iu38pr6	1721	4	the	the	DT
cord-005478-5iu38pr6	1721	5	relevance	relevance	NN
cord-005478-5iu38pr6	1721	6	of	of	IN
cord-005478-5iu38pr6	1721	7	pre	pre	JJ
cord-005478-5iu38pr6	1721	8	-	-	JJ
cord-005478-5iu38pr6	1721	9	allo	allo	JJ
cord-005478-5iu38pr6	1721	10	-	-	HYPH
cord-005478-5iu38pr6	1721	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1721	12	iron	iron	NN
cord-005478-5iu38pr6	1721	13	overload	overload	NN
cord-005478-5iu38pr6	1721	14	,	,	,
cord-005478-5iu38pr6	1721	15	we	-PRON-	PRP
cord-005478-5iu38pr6	1721	16	strongly	strongly	RB
cord-005478-5iu38pr6	1721	17	suggest	suggest	VBP
cord-005478-5iu38pr6	1721	18	to	to	IN
cord-005478-5iu38pr6	1721	19	referring	refer	VBG
cord-005478-5iu38pr6	1721	20	physicians	physician	NNS
cord-005478-5iu38pr6	1721	21	to	to	TO
cord-005478-5iu38pr6	1721	22	employ	employ	VB
cord-005478-5iu38pr6	1721	23	chelation	chelation	NN
cord-005478-5iu38pr6	1721	24	therapy	therapy	NN
cord-005478-5iu38pr6	1721	25	for	for	IN
cord-005478-5iu38pr6	1721	26	patient	patient	JJ
cord-005478-5iu38pr6	1721	27	candidates	candidate	NNS
cord-005478-5iu38pr6	1721	28	to	to	TO
cord-005478-5iu38pr6	1721	29	transplant	transplant	VB
cord-005478-5iu38pr6	1721	30	during	during	IN
cord-005478-5iu38pr6	1721	31	the	the	DT
cord-005478-5iu38pr6	1721	32	treatment	treatment	NN
cord-005478-5iu38pr6	1721	33	of	of	IN
cord-005478-5iu38pr6	1721	34	the	the	DT
cord-005478-5iu38pr6	1721	35	underline	underline	NNP
cord-005478-5iu38pr6	1721	36	disease	disease	NN
cord-005478-5iu38pr6	1721	37	.	.	.
cord-005478-5iu38pr6	1722	1	Background	background	NN
cord-005478-5iu38pr6	1722	2	:	:	:
cord-005478-5iu38pr6	1723	1	Neurologic	neurologic	JJ
cord-005478-5iu38pr6	1723	2	complications	complication	NNS
cord-005478-5iu38pr6	1723	3	(	(	-LRB-
cord-005478-5iu38pr6	1723	4	NCs	NCs	NNP
cord-005478-5iu38pr6	1723	5	)	)	-RRB-
cord-005478-5iu38pr6	1723	6	are	be	VBP
cord-005478-5iu38pr6	1723	7	associated	associate	VBN
cord-005478-5iu38pr6	1723	8	with	with	IN
cord-005478-5iu38pr6	1723	9	relevant	relevant	JJ
cord-005478-5iu38pr6	1723	10	morbidity	morbidity	NN
cord-005478-5iu38pr6	1723	11	and	and	CC
cord-005478-5iu38pr6	1723	12	mortality	mortality	NN
cord-005478-5iu38pr6	1723	13	after	after	IN
cord-005478-5iu38pr6	1723	14	allo	allo	NN
cord-005478-5iu38pr6	1723	15	-	-	HYPH
cord-005478-5iu38pr6	1723	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1723	17	.	.	.
cord-005478-5iu38pr6	1724	1	The	the	DT
cord-005478-5iu38pr6	1724	2	aim	aim	NN
cord-005478-5iu38pr6	1724	3	of	of	IN
cord-005478-5iu38pr6	1724	4	this	this	DT
cord-005478-5iu38pr6	1724	5	study	study	NN
cord-005478-5iu38pr6	1724	6	was	be	VBD
cord-005478-5iu38pr6	1724	7	to	to	TO
cord-005478-5iu38pr6	1724	8	analyze	analyze	VB
cord-005478-5iu38pr6	1724	9	the	the	DT
cord-005478-5iu38pr6	1724	10	incidence	incidence	NN
cord-005478-5iu38pr6	1724	11	,	,	,
cord-005478-5iu38pr6	1724	12	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1724	13	,	,	,
cord-005478-5iu38pr6	1724	14	risk	risk	NN
cord-005478-5iu38pr6	1724	15	factors	factor	NNS
cord-005478-5iu38pr6	1724	16	and	and	CC
cord-005478-5iu38pr6	1724	17	outcomes	outcome	NNS
cord-005478-5iu38pr6	1724	18	of	of	IN
cord-005478-5iu38pr6	1724	19	patients	patient	NNS
cord-005478-5iu38pr6	1724	20	developing	develop	VBG
cord-005478-5iu38pr6	1724	21	NCs	NCs	NNP
cord-005478-5iu38pr6	1724	22	after	after	IN
cord-005478-5iu38pr6	1724	23	allo	allo	NN
cord-005478-5iu38pr6	1724	24	-	-	HYPH
cord-005478-5iu38pr6	1724	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1724	26	.	.	.
cord-005478-5iu38pr6	1725	1	Methods	method	NNS
cord-005478-5iu38pr6	1725	2	:	:	:
cord-005478-5iu38pr6	1725	3	We	-PRON-	PRP
cord-005478-5iu38pr6	1725	4	evaluated	evaluate	VBD
cord-005478-5iu38pr6	1725	5	971	971	CD
cord-005478-5iu38pr6	1725	6	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1725	7	adult	adult	NN
cord-005478-5iu38pr6	1725	8	patients	patient	NNS
cord-005478-5iu38pr6	1725	9	(	(	-LRB-
cord-005478-5iu38pr6	1725	10	>	>	NFP
cord-005478-5iu38pr6	1725	11	17	17	CD
cord-005478-5iu38pr6	1725	12	years	year	NNS
cord-005478-5iu38pr6	1725	13	)	)	-RRB-
cord-005478-5iu38pr6	1725	14	who	who	WP
cord-005478-5iu38pr6	1725	15	underwent	undergo	VBD
cord-005478-5iu38pr6	1725	16	allo	allo	NN
cord-005478-5iu38pr6	1725	17	-	-	HYPH
cord-005478-5iu38pr6	1725	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1725	19	at	at	IN
cord-005478-5iu38pr6	1725	20	our	-PRON-	PRP$
cord-005478-5iu38pr6	1725	21	center	center	NN
cord-005478-5iu38pr6	1725	22	between	between	IN
cord-005478-5iu38pr6	1725	23	January	January	NNP
cord-005478-5iu38pr6	1725	24	2000	2000	CD
cord-005478-5iu38pr6	1725	25	and	and	CC
cord-005478-5iu38pr6	1725	26	December	December	NNP
cord-005478-5iu38pr6	1725	27	2016	2016	CD
cord-005478-5iu38pr6	1725	28	.	.	.
cord-005478-5iu38pr6	1726	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1726	2	collected	collect	VBD
cord-005478-5iu38pr6	1726	3	data	datum	NNS
cord-005478-5iu38pr6	1726	4	on	on	IN
cord-005478-5iu38pr6	1726	5	neurological	neurological	JJ
cord-005478-5iu38pr6	1726	6	symptoms	symptom	NNS
cord-005478-5iu38pr6	1726	7	,	,	,
cord-005478-5iu38pr6	1726	8	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	1726	9	methods	method	NNS
cord-005478-5iu38pr6	1726	10	,	,	,
cord-005478-5iu38pr6	1726	11	time	time	NN
cord-005478-5iu38pr6	1726	12	of	of	IN
cord-005478-5iu38pr6	1726	13	onset	onset	NN
cord-005478-5iu38pr6	1726	14	and	and	CC
cord-005478-5iu38pr6	1726	15	cause	cause	NN
cord-005478-5iu38pr6	1726	16	.	.	.
cord-005478-5iu38pr6	1727	1	NC	NC	NNP
cord-005478-5iu38pr6	1727	2	was	be	VBD
cord-005478-5iu38pr6	1727	3	defined	define	VBN
cord-005478-5iu38pr6	1727	4	as	as	IN
cord-005478-5iu38pr6	1727	5	any	any	DT
cord-005478-5iu38pr6	1727	6	neurological	neurological	JJ
cord-005478-5iu38pr6	1727	7	event	event	NN
cord-005478-5iu38pr6	1727	8	that	that	WDT
cord-005478-5iu38pr6	1727	9	occurred	occur	VBD
cord-005478-5iu38pr6	1727	10	after	after	IN
cord-005478-5iu38pr6	1727	11	starting	start	VBG
cord-005478-5iu38pr6	1727	12	the	the	DT
cord-005478-5iu38pr6	1727	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	1727	14	regimen	regimen	NN
cord-005478-5iu38pr6	1727	15	and	and	CC
cord-005478-5iu38pr6	1727	16	before	before	IN
cord-005478-5iu38pr6	1727	17	relapse	relapse	NN
cord-005478-5iu38pr6	1727	18	.	.	.
cord-005478-5iu38pr6	1728	1	NC	NC	NNP
cord-005478-5iu38pr6	1728	2	due	due	JJ
cord-005478-5iu38pr6	1728	3	to	to	IN
cord-005478-5iu38pr6	1728	4	central	central	JJ
cord-005478-5iu38pr6	1728	5	nervous	nervous	JJ
cord-005478-5iu38pr6	1728	6	system	system	NN
cord-005478-5iu38pr6	1728	7	(	(	-LRB-
cord-005478-5iu38pr6	1728	8	CNS	CNS	NNP
cord-005478-5iu38pr6	1728	9	)	)	-RRB-
cord-005478-5iu38pr6	1728	10	infections	infection	NNS
cord-005478-5iu38pr6	1729	1	o	o	UH
cord-005478-5iu38pr6	1730	1	neoplastic	neoplastic	JJ
cord-005478-5iu38pr6	1730	2	infiltration	infiltration	NN
cord-005478-5iu38pr6	1730	3	were	be	VBD
cord-005478-5iu38pr6	1730	4	excluded	exclude	VBN
cord-005478-5iu38pr6	1730	5	.	.	.
cord-005478-5iu38pr6	1731	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1731	2	considered	consider	VBD
cord-005478-5iu38pr6	1731	3	both	both	DT
cord-005478-5iu38pr6	1731	4	CNS	CNS	NNP
cord-005478-5iu38pr6	1731	5	and	and	CC
cord-005478-5iu38pr6	1731	6	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1731	7	nervous	nervous	JJ
cord-005478-5iu38pr6	1731	8	system	system	NN
cord-005478-5iu38pr6	1731	9	(	(	-LRB-
cord-005478-5iu38pr6	1731	10	PNS	PNS	NNP
cord-005478-5iu38pr6	1731	11	)	)	-RRB-
cord-005478-5iu38pr6	1731	12	complications	complication	NNS
cord-005478-5iu38pr6	1731	13	.	.	.
cord-005478-5iu38pr6	1732	1	Results	result	NNS
cord-005478-5iu38pr6	1732	2	:	:	:
cord-005478-5iu38pr6	1733	1	The	the	DT
cord-005478-5iu38pr6	1733	2	current	current	JJ
cord-005478-5iu38pr6	1733	3	series	series	NN
cord-005478-5iu38pr6	1733	4	comprised	comprise	VBD
cord-005478-5iu38pr6	1733	5	467	467	CD
cord-005478-5iu38pr6	1733	6	allo	allo	NN
cord-005478-5iu38pr6	1733	7	-	-	HYPH
cord-005478-5iu38pr6	1733	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1733	9	from	from	IN
cord-005478-5iu38pr6	1733	10	matched	match	VBN
cord-005478-5iu38pr6	1733	11	sibling	sibling	NN
cord-005478-5iu38pr6	1733	12	donor	donor	NN
cord-005478-5iu38pr6	1733	13	(	(	-LRB-
cord-005478-5iu38pr6	1733	14	MSD	MSD	NNP
cord-005478-5iu38pr6	1733	15	)	)	-RRB-
cord-005478-5iu38pr6	1733	16	,	,	,
cord-005478-5iu38pr6	1733	17	381	381	CD
cord-005478-5iu38pr6	1733	18	from	from	IN
cord-005478-5iu38pr6	1733	19	umbilical	umbilical	JJ
cord-005478-5iu38pr6	1733	20	cord	cord	NN
cord-005478-5iu38pr6	1733	21	blood	blood	NN
cord-005478-5iu38pr6	1733	22	(	(	-LRB-
cord-005478-5iu38pr6	1733	23	UCB	UCB	NNP
cord-005478-5iu38pr6	1733	24	)	)	-RRB-
cord-005478-5iu38pr6	1733	25	,	,	,
cord-005478-5iu38pr6	1733	26	49	49	CD
cord-005478-5iu38pr6	1733	27	matched	match	VBD
cord-005478-5iu38pr6	1733	28	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1733	29	donor	donor	NN
cord-005478-5iu38pr6	1733	30	(	(	-LRB-
cord-005478-5iu38pr6	1733	31	MUD	MUD	NNP
cord-005478-5iu38pr6	1733	32	)	)	-RRB-
cord-005478-5iu38pr6	1733	33	and	and	CC
cord-005478-5iu38pr6	1733	34	74	74	CD
cord-005478-5iu38pr6	1733	35	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	1733	36	donor	donor	NN
cord-005478-5iu38pr6	1733	37	(	(	-LRB-
cord-005478-5iu38pr6	1733	38	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	1733	39	)	)	-RRB-
cord-005478-5iu38pr6	1733	40	.	.	.
cord-005478-5iu38pr6	1734	1	Median	median	JJ
cord-005478-5iu38pr6	1734	2	age	age	NN
cord-005478-5iu38pr6	1734	3	was	be	VBD
cord-005478-5iu38pr6	1734	4	41	41	CD
cord-005478-5iu38pr6	1734	5	years	year	NNS
cord-005478-5iu38pr6	1734	6	and	and	CC
cord-005478-5iu38pr6	1734	7	most	most	JJS
cord-005478-5iu38pr6	1734	8	patients	patient	NNS
cord-005478-5iu38pr6	1734	9	had	have	VBD
cord-005478-5iu38pr6	1734	10	acute	acute	JJ
cord-005478-5iu38pr6	1734	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	1734	12	(	(	-LRB-
cord-005478-5iu38pr6	1734	13	63	63	CD
cord-005478-5iu38pr6	1734	14	%	%	NN
cord-005478-5iu38pr6	1734	15	)	)	-RRB-
cord-005478-5iu38pr6	1734	16	.	.	.
cord-005478-5iu38pr6	1735	1	Median	median	JJ
cord-005478-5iu38pr6	1735	2	follow	follow	NN
cord-005478-5iu38pr6	1735	3	-	-	HYPH
cord-005478-5iu38pr6	1735	4	up	up	NN
cord-005478-5iu38pr6	1735	5	of	of	IN
cord-005478-5iu38pr6	1735	6	surviving	survive	VBG
cord-005478-5iu38pr6	1735	7	patients	patient	NNS
cord-005478-5iu38pr6	1735	8	was	be	VBD
cord-005478-5iu38pr6	1735	9	71	71	CD
cord-005478-5iu38pr6	1735	10	months	month	NNS
cord-005478-5iu38pr6	1735	11	(	(	-LRB-
cord-005478-5iu38pr6	1735	12	range	range	NN
cord-005478-5iu38pr6	1735	13	,	,	,
cord-005478-5iu38pr6	1735	14	11	11	CD
cord-005478-5iu38pr6	1735	15	-	-	SYM
cord-005478-5iu38pr6	1735	16	213	213	CD
cord-005478-5iu38pr6	1735	17	)	)	-RRB-
cord-005478-5iu38pr6	1735	18	.	.	.
cord-005478-5iu38pr6	1736	1	There	there	EX
cord-005478-5iu38pr6	1736	2	were	be	VBD
cord-005478-5iu38pr6	1736	3	differences	difference	NNS
cord-005478-5iu38pr6	1736	4	in	in	IN
cord-005478-5iu38pr6	1736	5	median	median	JJ
cord-005478-5iu38pr6	1736	6	follow	follow	NN
cord-005478-5iu38pr6	1736	7	-	-	HYPH
cord-005478-5iu38pr6	1736	8	up	up	NN
cord-005478-5iu38pr6	1736	9	according	accord	VBG
cord-005478-5iu38pr6	1736	10	to	to	IN
cord-005478-5iu38pr6	1736	11	the	the	DT
cord-005478-5iu38pr6	1736	12	donor	donor	NN
cord-005478-5iu38pr6	1736	13	source	source	NN
cord-005478-5iu38pr6	1736	14	,	,	,
cord-005478-5iu38pr6	1736	15	being	be	VBG
cord-005478-5iu38pr6	1736	16	longer	long	RBR
cord-005478-5iu38pr6	1736	17	in	in	IN
cord-005478-5iu38pr6	1736	18	UCB	UCB	NNP
cord-005478-5iu38pr6	1736	19	and	and	CC
cord-005478-5iu38pr6	1736	20	MSD	MSD	NNP
cord-005478-5iu38pr6	1736	21	,	,	,
cord-005478-5iu38pr6	1736	22	87	87	CD
cord-005478-5iu38pr6	1736	23	and	and	CC
cord-005478-5iu38pr6	1736	24	67	67	CD
cord-005478-5iu38pr6	1736	25	months	month	NNS
cord-005478-5iu38pr6	1736	26	respectively	respectively	RB
cord-005478-5iu38pr6	1736	27	,	,	,
cord-005478-5iu38pr6	1736	28	and	and	CC
cord-005478-5iu38pr6	1736	29	shorter	short	JJR
cord-005478-5iu38pr6	1736	30	in	in	IN
cord-005478-5iu38pr6	1736	31	MUD	mud	NN
cord-005478-5iu38pr6	1736	32	and	and	CC
cord-005478-5iu38pr6	1736	33	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	1736	34	,	,	,
cord-005478-5iu38pr6	1736	35	23	23	CD
cord-005478-5iu38pr6	1736	36	and	and	CC
cord-005478-5iu38pr6	1736	37	24	24	CD
cord-005478-5iu38pr6	1736	38	months	month	NNS
cord-005478-5iu38pr6	1736	39	respectively	respectively	RB
cord-005478-5iu38pr6	1736	40	(	(	-LRB-
cord-005478-5iu38pr6	1736	41	P	p	NN
cord-005478-5iu38pr6	1736	42	<	<	XX
cord-005478-5iu38pr6	1736	43	0.0001	0.0001	CD
cord-005478-5iu38pr6	1736	44	)	)	-RRB-
cord-005478-5iu38pr6	1736	45	.	.	.
cord-005478-5iu38pr6	1737	1	Overall	overall	RB
cord-005478-5iu38pr6	1737	2	,	,	,
cord-005478-5iu38pr6	1737	3	NCs	NCs	NNP
cord-005478-5iu38pr6	1737	4	were	be	VBD
cord-005478-5iu38pr6	1737	5	documented	document	VBN
cord-005478-5iu38pr6	1737	6	in	in	IN
cord-005478-5iu38pr6	1737	7	149	149	CD
cord-005478-5iu38pr6	1737	8	cases	case	NNS
cord-005478-5iu38pr6	1737	9	,	,	,
cord-005478-5iu38pr6	1737	10	64	64	CD
cord-005478-5iu38pr6	1737	11	after	after	IN
cord-005478-5iu38pr6	1737	12	MSD	MSD	NNP
cord-005478-5iu38pr6	1737	13	transplants	transplant	NNS
cord-005478-5iu38pr6	1737	14	,	,	,
cord-005478-5iu38pr6	1737	15	74	74	CD
cord-005478-5iu38pr6	1737	16	after	after	IN
cord-005478-5iu38pr6	1737	17	UCB	UCB	NNP
cord-005478-5iu38pr6	1737	18	,	,	,
cord-005478-5iu38pr6	1737	19	9	9	CD
cord-005478-5iu38pr6	1737	20	after	after	IN
cord-005478-5iu38pr6	1737	21	MUD	mud	NN
cord-005478-5iu38pr6	1737	22	,	,	,
cord-005478-5iu38pr6	1737	23	and	and	CC
cord-005478-5iu38pr6	1737	24	5	5	CD
cord-005478-5iu38pr6	1737	25	after	after	IN
cord-005478-5iu38pr6	1737	26	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	1737	27	.	.	.
cord-005478-5iu38pr6	1738	1	CNS	CNS	NNP
cord-005478-5iu38pr6	1738	2	complications	complication	NNS
cord-005478-5iu38pr6	1738	3	(	(	-LRB-
cord-005478-5iu38pr6	1738	4	68	68	CD
cord-005478-5iu38pr6	1738	5	%	%	NN
cord-005478-5iu38pr6	1738	6	)	)	-RRB-
cord-005478-5iu38pr6	1738	7	were	be	VBD
cord-005478-5iu38pr6	1738	8	more	more	RBR
cord-005478-5iu38pr6	1738	9	common	common	JJ
cord-005478-5iu38pr6	1738	10	than	than	IN
cord-005478-5iu38pr6	1738	11	PNS	PNS	NNP
cord-005478-5iu38pr6	1738	12	events	event	NNS
cord-005478-5iu38pr6	1738	13	.	.	.
cord-005478-5iu38pr6	1739	1	The	the	DT
cord-005478-5iu38pr6	1739	2	most	most	RBS
cord-005478-5iu38pr6	1739	3	frequent	frequent	JJ
cord-005478-5iu38pr6	1739	4	NC	NC	NNP
cord-005478-5iu38pr6	1739	5	was	be	VBD
cord-005478-5iu38pr6	1739	6	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	1739	7	(	(	-LRB-
cord-005478-5iu38pr6	1739	8	31	31	CD
cord-005478-5iu38pr6	1739	9	%	%	NN
cord-005478-5iu38pr6	1739	10	)	)	-RRB-
cord-005478-5iu38pr6	1739	11	followed	follow	VBN
cord-005478-5iu38pr6	1739	12	by	by	IN
cord-005478-5iu38pr6	1739	13	myopathy	myopathy	NN
cord-005478-5iu38pr6	1739	14	(	(	-LRB-
cord-005478-5iu38pr6	1739	15	13	13	CD
cord-005478-5iu38pr6	1739	16	%	%	NN
cord-005478-5iu38pr6	1739	17	)	)	-RRB-
cord-005478-5iu38pr6	1739	18	1-year	1-year	CD
cord-005478-5iu38pr6	1739	19	and	and	CC
cord-005478-5iu38pr6	1739	20	5-year	5-year	CD
cord-005478-5iu38pr6	1739	21	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1739	22	incidence	incidence	NN
cord-005478-5iu38pr6	1739	23	of	of	IN
cord-005478-5iu38pr6	1739	24	NCs	NCs	NNP
cord-005478-5iu38pr6	1740	1	was	be	VBD
cord-005478-5iu38pr6	1740	2	11	11	CD
cord-005478-5iu38pr6	1740	3	%	%	NN
cord-005478-5iu38pr6	1740	4	and	and	CC
cord-005478-5iu38pr6	1740	5	13	13	CD
cord-005478-5iu38pr6	1740	6	%	%	NN
cord-005478-5iu38pr6	1740	7	,	,	,
cord-005478-5iu38pr6	1740	8	respectively	respectively	RB
cord-005478-5iu38pr6	1740	9	.	.	.
cord-005478-5iu38pr6	1741	1	5-year	5-year	CD
cord-005478-5iu38pr6	1741	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	1741	3	incidence	incidence	NN
cord-005478-5iu38pr6	1741	4	was	be	VBD
cord-005478-5iu38pr6	1741	5	11	11	CD
cord-005478-5iu38pr6	1741	6	%	%	NN
cord-005478-5iu38pr6	1741	7	after	after	IN
cord-005478-5iu38pr6	1741	8	MSD	MSD	NNP
cord-005478-5iu38pr6	1741	9	,	,	,
cord-005478-5iu38pr6	1741	10	17	17	CD
cord-005478-5iu38pr6	1741	11	%	%	NN
cord-005478-5iu38pr6	1741	12	after	after	IN
cord-005478-5iu38pr6	1741	13	UCB	UCB	NNP
cord-005478-5iu38pr6	1741	14	,	,	,
cord-005478-5iu38pr6	1741	15	16	16	CD
cord-005478-5iu38pr6	1741	16	%	%	NN
cord-005478-5iu38pr6	1741	17	after	after	IN
cord-005478-5iu38pr6	1741	18	MUD	mud	NN
cord-005478-5iu38pr6	1741	19	,	,	,
cord-005478-5iu38pr6	1741	20	and	and	CC
cord-005478-5iu38pr6	1741	21	6	6	CD
cord-005478-5iu38pr6	1741	22	%	%	NN
cord-005478-5iu38pr6	1741	23	after	after	IN
cord-005478-5iu38pr6	1741	24	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	1741	25	transplants	transplant	NNS
cord-005478-5iu38pr6	1741	26	(	(	-LRB-
cord-005478-5iu38pr6	1741	27	P=0.014	P=0.014	NNS
cord-005478-5iu38pr6	1741	28	)	)	-RRB-
cord-005478-5iu38pr6	1741	29	.	.	.
cord-005478-5iu38pr6	1742	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1742	2	:	:	:
cord-005478-5iu38pr6	1743	1	NCs	NCs	NNP
cord-005478-5iu38pr6	1743	2	are	be	VBP
cord-005478-5iu38pr6	1743	3	common	common	JJ
cord-005478-5iu38pr6	1743	4	and	and	CC
cord-005478-5iu38pr6	1743	5	diverse	diverse	JJ
cord-005478-5iu38pr6	1743	6	after	after	IN
cord-005478-5iu38pr6	1743	7	allo	allo	NN
cord-005478-5iu38pr6	1743	8	-	-	HYPH
cord-005478-5iu38pr6	1743	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1743	10	.	.	.
cord-005478-5iu38pr6	1744	1	NCs	NCs	NNP
cord-005478-5iu38pr6	1744	2	were	be	VBD
cord-005478-5iu38pr6	1744	3	more	more	RBR
cord-005478-5iu38pr6	1744	4	frequent	frequent	JJ
cord-005478-5iu38pr6	1744	5	in	in	IN
cord-005478-5iu38pr6	1744	6	recipients	recipient	NNS
cord-005478-5iu38pr6	1744	7	allografted	allografte	VBN
cord-005478-5iu38pr6	1744	8	from	from	IN
cord-005478-5iu38pr6	1744	9	alternative	alternative	JJ
cord-005478-5iu38pr6	1744	10	donors	donor	NNS
cord-005478-5iu38pr6	1744	11	,	,	,
cord-005478-5iu38pr6	1744	12	recipients	recipient	NNS
cord-005478-5iu38pr6	1744	13	older	old	JJR
cord-005478-5iu38pr6	1744	14	than	than	IN
cord-005478-5iu38pr6	1744	15	40	40	CD
cord-005478-5iu38pr6	1744	16	years	year	NNS
cord-005478-5iu38pr6	1744	17	,	,	,
cord-005478-5iu38pr6	1744	18	and	and	CC
cord-005478-5iu38pr6	1744	19	in	in	IN
cord-005478-5iu38pr6	1744	20	those	those	DT
cord-005478-5iu38pr6	1744	21	developing	develop	VBG
cord-005478-5iu38pr6	1744	22	GvHD	GvHD	NNP
cord-005478-5iu38pr6	1744	23	.	.	.
cord-005478-5iu38pr6	1745	1	CNS	CNS	NNP
cord-005478-5iu38pr6	1745	2	complications	complication	NNS
cord-005478-5iu38pr6	1745	3	,	,	,
cord-005478-5iu38pr6	1745	4	but	but	CC
cord-005478-5iu38pr6	1745	5	not	not	RB
cord-005478-5iu38pr6	1745	6	PNS	PNS	NNP
cord-005478-5iu38pr6	1745	7	,	,	,
cord-005478-5iu38pr6	1745	8	are	be	VBP
cord-005478-5iu38pr6	1745	9	associated	associate	VBN
cord-005478-5iu38pr6	1745	10	with	with	IN
cord-005478-5iu38pr6	1745	11	poor	poor	JJ
cord-005478-5iu38pr6	1745	12	OS	os	NN
cord-005478-5iu38pr6	1745	13	.	.	.
cord-005478-5iu38pr6	1746	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1746	2	:	:	:
cord-005478-5iu38pr6	1746	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1746	4	to	to	TO
cord-005478-5iu38pr6	1746	5	declare	declare	VB
cord-005478-5iu38pr6	1746	6	.	.	.
cord-005478-5iu38pr6	1747	1	Abstract	Abstract	NNP
cord-005478-5iu38pr6	1747	2	already	already	RB
cord-005478-5iu38pr6	1747	3	published	publish	VBN
cord-005478-5iu38pr6	1747	4	.	.	.
cord-005478-5iu38pr6	1748	1	Using	use	VBG
cord-005478-5iu38pr6	1748	2	ciclosporin	ciclosporin	NNP
cord-005478-5iu38pr6	1748	3	's	's	POS
cord-005478-5iu38pr6	1748	4	area	area	NN
cord-005478-5iu38pr6	1748	5	under	under	IN
cord-005478-5iu38pr6	1748	6	the	the	DT
cord-005478-5iu38pr6	1748	7	curve	curve	NN
cord-005478-5iu38pr6	1748	8	(	(	-LRB-
cord-005478-5iu38pr6	1748	9	AUC	AUC	NNP
cord-005478-5iu38pr6	1748	10	)	)	-RRB-
cord-005478-5iu38pr6	1748	11	to	to	TO
cord-005478-5iu38pr6	1748	12	predict	predict	VB
cord-005478-5iu38pr6	1748	13	risk	risk	NN
cord-005478-5iu38pr6	1748	14	of	of	IN
cord-005478-5iu38pr6	1748	15	acute	acute	JJ
cord-005478-5iu38pr6	1748	16	kidney	kidney	NN
cord-005478-5iu38pr6	1748	17	injury	injury	NN
cord-005478-5iu38pr6	1748	18	in	in	IN
cord-005478-5iu38pr6	1748	19	non	non	JJ
cord-005478-5iu38pr6	1748	20	-	-	JJ
cord-005478-5iu38pr6	1748	21	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1748	22	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	1748	23	stem	stem	NN
cord-005478-5iu38pr6	1748	24	cell	cell	NN
cord-005478-5iu38pr6	1748	25	transplantation	transplantation	NN
cord-005478-5iu38pr6	1748	26	VAIDIE	VAIDIE	NNP
cord-005478-5iu38pr6	1748	27	Julien	Julien	NNP
cord-005478-5iu38pr6	1748	28	1	1	CD
cord-005478-5iu38pr6	1749	1	,	,	,
cord-005478-5iu38pr6	1749	2	Jean	Jean	NNP
cord-005478-5iu38pr6	1749	3	-	-	HYPH
cord-005478-5iu38pr6	1749	4	Baptiste	Baptiste	NNP
cord-005478-5iu38pr6	1749	5	Woillard	Woillard	NNP
cord-005478-5iu38pr6	1749	6	1	1	CD
cord-005478-5iu38pr6	1749	7	,	,	,
cord-005478-5iu38pr6	1749	8	Stéphane	Stéphane	NNP
cord-005478-5iu38pr6	1749	9	Girault	Girault	NNP
cord-005478-5iu38pr6	1749	10	1	1	CD
cord-005478-5iu38pr6	1749	11	,	,	,
cord-005478-5iu38pr6	1749	12	Pierre	Pierre	NNP
cord-005478-5iu38pr6	1749	13	Marquet	Marquet	NNP
cord-005478-5iu38pr6	1749	14	1	1	CD
cord-005478-5iu38pr6	1749	15	,	,	,
cord-005478-5iu38pr6	1749	16	Franck	Franck	NNP
cord-005478-5iu38pr6	1749	17	Saint	Saint	NNP
cord-005478-5iu38pr6	1749	18	-	-	HYPH
cord-005478-5iu38pr6	1749	19	Marcoux	Marcoux	NNP
cord-005478-5iu38pr6	1749	20	1	1	CD
cord-005478-5iu38pr6	1749	21	,	,	,
cord-005478-5iu38pr6	1749	22	Arnaud	Arnaud	NNP
cord-005478-5iu38pr6	1749	23	Jaccard	Jaccard	NNP
cord-005478-5iu38pr6	1749	24	1	1	CD
cord-005478-5iu38pr6	1749	25	,	,	,
cord-005478-5iu38pr6	1749	26	Pascal	Pascal	NNP
cord-005478-5iu38pr6	1749	27	Turlure	Turlure	NNP
cord-005478-5iu38pr6	1749	28	1	1	CD
cord-005478-5iu38pr6	1749	29	Background	Background	NNP
cord-005478-5iu38pr6	1749	30	:	:	:
cord-005478-5iu38pr6	1750	1	Non	non	JJ
cord-005478-5iu38pr6	1750	2	myeloablative	myeloablative	NN
cord-005478-5iu38pr6	1750	3	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1750	4	stem	stem	NN
cord-005478-5iu38pr6	1750	5	cell	cell	NN
cord-005478-5iu38pr6	1750	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	1750	7	(	(	-LRB-
cord-005478-5iu38pr6	1750	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1750	9	)	)	-RRB-
cord-005478-5iu38pr6	1750	10	by	by	IN
cord-005478-5iu38pr6	1750	11	limiting	limit	VBG
cord-005478-5iu38pr6	1750	12	toxicity	toxicity	NN
cord-005478-5iu38pr6	1750	13	,	,	,
cord-005478-5iu38pr6	1750	14	can	can	MD
cord-005478-5iu38pr6	1750	15	be	be	VB
cord-005478-5iu38pr6	1750	16	proposed	propose	VBN
cord-005478-5iu38pr6	1750	17	to	to	IN
cord-005478-5iu38pr6	1750	18	elderly	elderly	JJ
cord-005478-5iu38pr6	1750	19	patients	patient	NNS
cord-005478-5iu38pr6	1750	20	.	.	.
cord-005478-5iu38pr6	1751	1	However	however	RB
cord-005478-5iu38pr6	1751	2	,	,	,
cord-005478-5iu38pr6	1751	3	acute	acute	JJ
cord-005478-5iu38pr6	1751	4	renal	renal	JJ
cord-005478-5iu38pr6	1751	5	injuries	injury	NNS
cord-005478-5iu38pr6	1751	6	related	relate	VBN
cord-005478-5iu38pr6	1751	7	to	to	IN
cord-005478-5iu38pr6	1751	8	anti	anti	JJ
cord-005478-5iu38pr6	1751	9	-	-	JJ
cord-005478-5iu38pr6	1751	10	calcineurin	calcineurin	JJ
cord-005478-5iu38pr6	1751	11	,	,	,
cord-005478-5iu38pr6	1751	12	which	which	WDT
cord-005478-5iu38pr6	1751	13	are	be	VBP
cord-005478-5iu38pr6	1751	14	frequent	frequent	JJ
cord-005478-5iu38pr6	1751	15	in	in	IN
cord-005478-5iu38pr6	1751	16	this	this	DT
cord-005478-5iu38pr6	1751	17	population	population	NN
cord-005478-5iu38pr6	1751	18	,	,	,
cord-005478-5iu38pr6	1751	19	can	can	MD
cord-005478-5iu38pr6	1751	20	negatively	negatively	RB
cord-005478-5iu38pr6	1751	21	impact	impact	VB
cord-005478-5iu38pr6	1751	22	the	the	DT
cord-005478-5iu38pr6	1751	23	outcome	outcome	NN
cord-005478-5iu38pr6	1751	24	.	.	.
cord-005478-5iu38pr6	1752	1	Currently	currently	RB
cord-005478-5iu38pr6	1752	2	,	,	,
cord-005478-5iu38pr6	1752	3	the	the	DT
cord-005478-5iu38pr6	1752	4	exposure	exposure	NN
cord-005478-5iu38pr6	1752	5	indexes	index	NNS
cord-005478-5iu38pr6	1752	6	to	to	TO
cord-005478-5iu38pr6	1752	7	follow	follow	VB
cord-005478-5iu38pr6	1752	8	and	and	CC
cord-005478-5iu38pr6	1752	9	the	the	DT
cord-005478-5iu38pr6	1752	10	target	target	NN
cord-005478-5iu38pr6	1752	11	to	to	TO
cord-005478-5iu38pr6	1752	12	use	use	NN
cord-005478-5iu38pr6	1752	13	are	be	VBP
cord-005478-5iu38pr6	1752	14	not	not	RB
cord-005478-5iu38pr6	1752	15	consensually	consensually	RB
cord-005478-5iu38pr6	1752	16	established	establish	VBN
cord-005478-5iu38pr6	1752	17	.	.	.
cord-005478-5iu38pr6	1753	1	However	however	RB
cord-005478-5iu38pr6	1753	2	,	,	,
cord-005478-5iu38pr6	1753	3	using	use	VBG
cord-005478-5iu38pr6	1753	4	the	the	DT
cord-005478-5iu38pr6	1753	5	area	area	NN
cord-005478-5iu38pr6	1753	6	under	under	IN
cord-005478-5iu38pr6	1753	7	the	the	DT
cord-005478-5iu38pr6	1753	8	curve	curve	NN
cord-005478-5iu38pr6	1753	9	(	(	-LRB-
cord-005478-5iu38pr6	1753	10	AUC	AUC	NNP
cord-005478-5iu38pr6	1753	11	)	)	-RRB-
cord-005478-5iu38pr6	1753	12	for	for	IN
cord-005478-5iu38pr6	1753	13	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1753	14	drug	drug	NN
cord-005478-5iu38pr6	1753	15	monitoring	monitoring	NN
cord-005478-5iu38pr6	1753	16	(	(	-LRB-
cord-005478-5iu38pr6	1753	17	TDM	TDM	NNP
cord-005478-5iu38pr6	1753	18	)	)	-RRB-
cord-005478-5iu38pr6	1753	19	is	be	VBZ
cord-005478-5iu38pr6	1753	20	theoretically	theoretically	RB
cord-005478-5iu38pr6	1753	21	the	the	DT
cord-005478-5iu38pr6	1753	22	best	good	JJS
cord-005478-5iu38pr6	1753	23	method	method	NN
cord-005478-5iu38pr6	1753	24	to	to	TO
cord-005478-5iu38pr6	1753	25	describe	describe	VB
cord-005478-5iu38pr6	1753	26	the	the	DT
cord-005478-5iu38pr6	1753	27	patient	patient	NN
cord-005478-5iu38pr6	1753	28	's	's	POS
cord-005478-5iu38pr6	1753	29	exposure	exposure	NN
cord-005478-5iu38pr6	1753	30	.	.	.
cord-005478-5iu38pr6	1754	1	The	the	DT
cord-005478-5iu38pr6	1754	2	primary	primary	JJ
cord-005478-5iu38pr6	1754	3	objective	objective	NN
cord-005478-5iu38pr6	1754	4	of	of	IN
cord-005478-5iu38pr6	1754	5	this	this	DT
cord-005478-5iu38pr6	1754	6	study	study	NN
cord-005478-5iu38pr6	1754	7	was	be	VBD
cord-005478-5iu38pr6	1754	8	to	to	TO
cord-005478-5iu38pr6	1754	9	determine	determine	VB
cord-005478-5iu38pr6	1754	10	an	an	DT
cord-005478-5iu38pr6	1754	11	AUC	AUC	NNP
cord-005478-5iu38pr6	1754	12	target	target	NN
cord-005478-5iu38pr6	1754	13	for	for	IN
cord-005478-5iu38pr6	1754	14	ciclosporin	ciclosporin	NN
cord-005478-5iu38pr6	1754	15	associated	associate	VBN
cord-005478-5iu38pr6	1754	16	to	to	IN
cord-005478-5iu38pr6	1754	17	the	the	DT
cord-005478-5iu38pr6	1754	18	occurrence	occurrence	NN
cord-005478-5iu38pr6	1754	19	of	of	IN
cord-005478-5iu38pr6	1754	20	acute	acute	JJ
cord-005478-5iu38pr6	1754	21	kidney	kidney	NN
cord-005478-5iu38pr6	1754	22	injury	injury	NN
cord-005478-5iu38pr6	1754	23	in	in	IN
cord-005478-5iu38pr6	1754	24	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1754	25	patients	patient	NNS
cord-005478-5iu38pr6	1754	26	.	.	.
cord-005478-5iu38pr6	1755	1	Methods	method	NNS
cord-005478-5iu38pr6	1755	2	:	:	:
cord-005478-5iu38pr6	1756	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1756	2	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	1756	3	studied	study	VBD
cord-005478-5iu38pr6	1756	4	all	all	DT
cord-005478-5iu38pr6	1756	5	consecutive	consecutive	JJ
cord-005478-5iu38pr6	1756	6	patients	patient	NNS
cord-005478-5iu38pr6	1756	7	who	who	WP
cord-005478-5iu38pr6	1756	8	received	receive	VBD
cord-005478-5iu38pr6	1756	9	a	a	DT
cord-005478-5iu38pr6	1756	10	non	non	JJ
cord-005478-5iu38pr6	1756	11	-	-	JJ
cord-005478-5iu38pr6	1756	12	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1756	13	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1756	14	stem	stem	NN
cord-005478-5iu38pr6	1756	15	cell	cell	NN
cord-005478-5iu38pr6	1756	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	1756	17	at	at	IN
cord-005478-5iu38pr6	1756	18	Limoges	Limoges	NNP
cord-005478-5iu38pr6	1756	19	University	University	NNP
cord-005478-5iu38pr6	1756	20	Hospital	Hospital	NNP
cord-005478-5iu38pr6	1756	21	from	from	IN
cord-005478-5iu38pr6	1756	22	June	June	NNP
cord-005478-5iu38pr6	1756	23	2009	2009	CD
cord-005478-5iu38pr6	1756	24	to	to	IN
cord-005478-5iu38pr6	1756	25	December	December	NNP
cord-005478-5iu38pr6	1756	26	2015	2015	CD
cord-005478-5iu38pr6	1756	27	.	.	.
cord-005478-5iu38pr6	1757	1	Patients	patient	NNS
cord-005478-5iu38pr6	1757	2	received	receive	VBD
cord-005478-5iu38pr6	1757	3	Fludarabine	Fludarabine	NNP
cord-005478-5iu38pr6	1757	4	30	30	CD
cord-005478-5iu38pr6	1757	5	mg	mg	NNP
cord-005478-5iu38pr6	1757	6	/	/	SYM
cord-005478-5iu38pr6	1757	7	m2	m2	NNP
cord-005478-5iu38pr6	1757	8	/	/	SYM
cord-005478-5iu38pr6	1757	9	day	day	NN
cord-005478-5iu38pr6	1757	10	between	between	IN
cord-005478-5iu38pr6	1757	11	D-6	D-6	NNP
cord-005478-5iu38pr6	1757	12	and	and	CC
cord-005478-5iu38pr6	1757	13	D-2	D-2	NNP
cord-005478-5iu38pr6	1757	14	before	before	IN
cord-005478-5iu38pr6	1757	15	allograft	allograft	NN
cord-005478-5iu38pr6	1757	16	and	and	CC
cord-005478-5iu38pr6	1757	17	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	1757	18	3.2	3.2	CD
cord-005478-5iu38pr6	1757	19	mg	mg	NNP
cord-005478-5iu38pr6	1757	20	/	/	SYM
cord-005478-5iu38pr6	1757	21	kg	kg	NNP
cord-005478-5iu38pr6	1757	22	/	/	SYM
cord-005478-5iu38pr6	1757	23	day	day	NN
cord-005478-5iu38pr6	1757	24	at	at	IN
cord-005478-5iu38pr6	1757	25	D-4	D-4	NNP
cord-005478-5iu38pr6	1757	26	and	and	CC
cord-005478-5iu38pr6	1757	27	D-3	D-3	NNP
cord-005478-5iu38pr6	1757	28	.	.	.
cord-005478-5iu38pr6	1758	1	GvH	GvH	NNP
cord-005478-5iu38pr6	1758	2	prophylaxis	prophylaxis	NNP
cord-005478-5iu38pr6	1758	3	consisted	consist	VBD
cord-005478-5iu38pr6	1758	4	in	in	IN
cord-005478-5iu38pr6	1758	5	rabbit	rabbit	NN
cord-005478-5iu38pr6	1758	6	anti	anti	JJ
cord-005478-5iu38pr6	1758	7	-	-	JJ
cord-005478-5iu38pr6	1758	8	lymphocyte	lymphocyte	JJ
cord-005478-5iu38pr6	1758	9	serum	serum	NN
cord-005478-5iu38pr6	1758	10	at	at	IN
cord-005478-5iu38pr6	1758	11	the	the	DT
cord-005478-5iu38pr6	1758	12	dose	dose	NN
cord-005478-5iu38pr6	1758	13	of	of	IN
cord-005478-5iu38pr6	1758	14	2.5	2.5	CD
cord-005478-5iu38pr6	1758	15	mg	mg	NNP
cord-005478-5iu38pr6	1758	16	/	/	SYM
cord-005478-5iu38pr6	1758	17	kg	kg	NNS
cord-005478-5iu38pr6	1758	18	at	at	IN
cord-005478-5iu38pr6	1758	19	D-2	D-2	NNP
cord-005478-5iu38pr6	1758	20	and	and	CC
cord-005478-5iu38pr6	1758	21	D-1	D-1	NNP
cord-005478-5iu38pr6	1758	22	,	,	,
cord-005478-5iu38pr6	1758	23	and	and	CC
cord-005478-5iu38pr6	1758	24	ciclosporin	ciclosporin	NN
cord-005478-5iu38pr6	1758	25	at	at	IN
cord-005478-5iu38pr6	1758	26	the	the	DT
cord-005478-5iu38pr6	1758	27	beginning	beginning	NN
cord-005478-5iu38pr6	1758	28	dose	dose	NN
cord-005478-5iu38pr6	1758	29	of	of	IN
cord-005478-5iu38pr6	1758	30	3mg	3mg	NN
cord-005478-5iu38pr6	1758	31	/	/	SYM
cord-005478-5iu38pr6	1758	32	kg	kg	NN
cord-005478-5iu38pr6	1758	33	per	per	IN
cord-005478-5iu38pr6	1758	34	os	os	NN
cord-005478-5iu38pr6	1758	35	twice	twice	PDT
cord-005478-5iu38pr6	1758	36	a	a	DT
cord-005478-5iu38pr6	1758	37	day	day	NN
cord-005478-5iu38pr6	1758	38	.	.	.
cord-005478-5iu38pr6	1759	1	Mycophenolate	Mycophenolate	NNP
cord-005478-5iu38pr6	1759	2	mofetil	mofetil	NNP
cord-005478-5iu38pr6	1759	3	was	be	VBD
cord-005478-5iu38pr6	1759	4	added	add	VBN
cord-005478-5iu38pr6	1759	5	for	for	IN
cord-005478-5iu38pr6	1759	6	patients	patient	NNS
cord-005478-5iu38pr6	1759	7	with	with	IN
cord-005478-5iu38pr6	1759	8	HLA	HLA	NNP
cord-005478-5iu38pr6	1759	9	-	-	HYPH
cord-005478-5iu38pr6	1759	10	matched	match	VBN
cord-005478-5iu38pr6	1759	11	or	or	CC
cord-005478-5iu38pr6	1759	12	mismatched	mismatch	VBN
cord-005478-5iu38pr6	1759	13	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1759	14	donors	donor	NNS
cord-005478-5iu38pr6	1759	15	.	.	.
cord-005478-5iu38pr6	1760	1	TDM	TDM	NNP
cord-005478-5iu38pr6	1760	2	of	of	IN
cord-005478-5iu38pr6	1760	3	ciclosporin	ciclosporin	NN
cord-005478-5iu38pr6	1760	4	was	be	VBD
cord-005478-5iu38pr6	1760	5	done	do	VBN
cord-005478-5iu38pr6	1760	6	based	base	VBN
cord-005478-5iu38pr6	1760	7	on	on	IN
cord-005478-5iu38pr6	1760	8	trough	trough	NN
cord-005478-5iu38pr6	1760	9	concentration	concentration	NN
cord-005478-5iu38pr6	1760	10	(	(	-LRB-
cord-005478-5iu38pr6	1760	11	C0	C0	NNP
cord-005478-5iu38pr6	1760	12	)	)	-RRB-
cord-005478-5iu38pr6	1760	13	twice	twice	PDT
cord-005478-5iu38pr6	1760	14	a	a	DT
cord-005478-5iu38pr6	1760	15	week	week	NN
cord-005478-5iu38pr6	1760	16	with	with	IN
cord-005478-5iu38pr6	1760	17	concomitant	concomitant	JJ
cord-005478-5iu38pr6	1760	18	renal	renal	JJ
cord-005478-5iu38pr6	1760	19	evaluation	evaluation	NN
cord-005478-5iu38pr6	1760	20	using	use	VBG
cord-005478-5iu38pr6	1760	21	creatininemia	creatininemia	NNP
cord-005478-5iu38pr6	1760	22	.	.	.
cord-005478-5iu38pr6	1761	1	Dose	dose	NN
cord-005478-5iu38pr6	1761	2	adjustments	adjustment	NNS
cord-005478-5iu38pr6	1761	3	were	be	VBD
cord-005478-5iu38pr6	1761	4	done	do	VBN
cord-005478-5iu38pr6	1761	5	in	in	IN
cord-005478-5iu38pr6	1761	6	according	accord	VBG
cord-005478-5iu38pr6	1761	7	to	to	IN
cord-005478-5iu38pr6	1761	8	the	the	DT
cord-005478-5iu38pr6	1761	9	SFGM	SFGM	NNP
cord-005478-5iu38pr6	1761	10	-	-	HYPH
cord-005478-5iu38pr6	1761	11	TC	TC	NNP
cord-005478-5iu38pr6	1761	12	recommendations	recommendation	NNS
cord-005478-5iu38pr6	1761	13	and	and	CC
cord-005478-5iu38pr6	1761	14	renal	renal	JJ
cord-005478-5iu38pr6	1761	15	tolerance	tolerance	NN
cord-005478-5iu38pr6	1761	16	.	.	.
cord-005478-5iu38pr6	1762	1	Ciclosporin	Ciclosporin	NNP
cord-005478-5iu38pr6	1762	2	's	's	POS
cord-005478-5iu38pr6	1762	3	AUC	AUC	NNP
cord-005478-5iu38pr6	1762	4	was	be	VBD
cord-005478-5iu38pr6	1762	5	evaluated	evaluate	VBN
cord-005478-5iu38pr6	1762	6	at	at	IN
cord-005478-5iu38pr6	1762	7	day	day	NN
cord-005478-5iu38pr6	1762	8	1	1	CD
cord-005478-5iu38pr6	1762	9	,	,	,
cord-005478-5iu38pr6	1762	10	day	day	NN
cord-005478-5iu38pr6	1762	11	14	14	CD
cord-005478-5iu38pr6	1762	12	and	and	CC
cord-005478-5iu38pr6	1762	13	day	day	NN
cord-005478-5iu38pr6	1762	14	28	28	CD
cord-005478-5iu38pr6	1762	15	after	after	IN
cord-005478-5iu38pr6	1762	16	allograft	allograft	NN
cord-005478-5iu38pr6	1762	17	using	use	VBG
cord-005478-5iu38pr6	1762	18	bayesian	bayesian	JJ
cord-005478-5iu38pr6	1762	19	estimation	estimation	NN
cord-005478-5iu38pr6	1762	20	from	from	IN
cord-005478-5iu38pr6	1762	21	a	a	DT
cord-005478-5iu38pr6	1762	22	limited	limited	JJ
cord-005478-5iu38pr6	1762	23	sampling	sampling	NN
cord-005478-5iu38pr6	1762	24	strategy	strategy	NN
cord-005478-5iu38pr6	1762	25	and	and	CC
cord-005478-5iu38pr6	1762	26	a	a	DT
cord-005478-5iu38pr6	1762	27	population	population	NN
cord-005478-5iu38pr6	1762	28	pharmacokinetics	pharmacokinetic	NNS
cord-005478-5iu38pr6	1762	29	model	model	VBP
cord-005478-5iu38pr6	1762	30	previously	previously	RB
cord-005478-5iu38pr6	1762	31	published	publish	VBN
cord-005478-5iu38pr6	1762	32	.	.	.
cord-005478-5iu38pr6	1763	1	The	the	DT
cord-005478-5iu38pr6	1763	2	association	association	NN
cord-005478-5iu38pr6	1763	3	between	between	IN
cord-005478-5iu38pr6	1763	4	ciclosporin	ciclosporin	NNP
cord-005478-5iu38pr6	1763	5	AUC	AUC	NNP
cord-005478-5iu38pr6	1763	6	and	and	CC
cord-005478-5iu38pr6	1763	7	acute	acute	JJ
cord-005478-5iu38pr6	1763	8	kidney	kidney	NN
cord-005478-5iu38pr6	1763	9	injury	injury	NN
cord-005478-5iu38pr6	1763	10	was	be	VBD
cord-005478-5iu38pr6	1763	11	investigated	investigate	VBN
cord-005478-5iu38pr6	1763	12	using	use	VBG
cord-005478-5iu38pr6	1763	13	a	a	DT
cord-005478-5iu38pr6	1763	14	joint	joint	JJ
cord-005478-5iu38pr6	1763	15	model	model	NN
cord-005478-5iu38pr6	1763	16	.	.	.
cord-005478-5iu38pr6	1764	1	A	a	DT
cord-005478-5iu38pr6	1764	2	ROC	ROC	NNP
cord-005478-5iu38pr6	1764	3	curve	curve	NN
cord-005478-5iu38pr6	1764	4	was	be	VBD
cord-005478-5iu38pr6	1764	5	then	then	RB
cord-005478-5iu38pr6	1764	6	constructed	construct	VBN
cord-005478-5iu38pr6	1764	7	to	to	TO
cord-005478-5iu38pr6	1764	8	investigate	investigate	VB
cord-005478-5iu38pr6	1764	9	an	an	DT
cord-005478-5iu38pr6	1764	10	AUC	AUC	NNP
cord-005478-5iu38pr6	1764	11	threshold	threshold	NN
cord-005478-5iu38pr6	1764	12	associated	associate	VBN
cord-005478-5iu38pr6	1764	13	with	with	IN
cord-005478-5iu38pr6	1764	14	the	the	DT
cord-005478-5iu38pr6	1764	15	best	good	JJS
cord-005478-5iu38pr6	1764	16	sensibility	sensibility	NN
cord-005478-5iu38pr6	1764	17	/	/	SYM
cord-005478-5iu38pr6	1764	18	specificity	specificity	NN
cord-005478-5iu38pr6	1764	19	ratio	ratio	NN
cord-005478-5iu38pr6	1764	20	for	for	IN
cord-005478-5iu38pr6	1764	21	acute	acute	JJ
cord-005478-5iu38pr6	1764	22	kidney	kidney	NN
cord-005478-5iu38pr6	1764	23	injury	injury	NN
cord-005478-5iu38pr6	1764	24	(	(	-LRB-
cord-005478-5iu38pr6	1764	25	AKI	AKI	NNP
cord-005478-5iu38pr6	1764	26	.	.	.
cord-005478-5iu38pr6	1765	1	Interestingly	interestingly	RB
cord-005478-5iu38pr6	1765	2	,	,	,
cord-005478-5iu38pr6	1765	3	a	a	DT
cord-005478-5iu38pr6	1765	4	very	very	RB
cord-005478-5iu38pr6	1765	5	low	low	JJ
cord-005478-5iu38pr6	1765	6	correlation	correlation	NN
cord-005478-5iu38pr6	1765	7	was	be	VBD
cord-005478-5iu38pr6	1765	8	observed	observe	VBN
cord-005478-5iu38pr6	1765	9	between	between	IN
cord-005478-5iu38pr6	1765	10	ciclosporin	ciclosporin	NNP
cord-005478-5iu38pr6	1765	11	C0	C0	NNP
cord-005478-5iu38pr6	1765	12	and	and	CC
cord-005478-5iu38pr6	1765	13	AUC	AUC	NNP
cord-005478-5iu38pr6	1765	14	(	(	-LRB-
cord-005478-5iu38pr6	1765	15	r²	r²	NNP
cord-005478-5iu38pr6	1765	16	=	=	SYM
cord-005478-5iu38pr6	1765	17	0.55	0.55	CD
cord-005478-5iu38pr6	1765	18	for	for	IN
cord-005478-5iu38pr6	1765	19	the	the	DT
cord-005478-5iu38pr6	1765	20	overall	overall	JJ
cord-005478-5iu38pr6	1765	21	period	period	NN
cord-005478-5iu38pr6	1765	22	)	)	-RRB-
cord-005478-5iu38pr6	1765	23	.	.	.
cord-005478-5iu38pr6	1766	1	Additionally	additionally	RB
cord-005478-5iu38pr6	1766	2	,	,	,
cord-005478-5iu38pr6	1766	3	an	an	DT
cord-005478-5iu38pr6	1766	4	higher	high	JJR
cord-005478-5iu38pr6	1766	5	intra	intra	JJ
cord-005478-5iu38pr6	1766	6	-	-	JJ
cord-005478-5iu38pr6	1766	7	individual	individual	JJ
cord-005478-5iu38pr6	1766	8	variability	variability	NN
cord-005478-5iu38pr6	1766	9	was	be	VBD
cord-005478-5iu38pr6	1766	10	observed	observe	VBN
cord-005478-5iu38pr6	1766	11	with	with	IN
cord-005478-5iu38pr6	1766	12	C0	C0	NNP
cord-005478-5iu38pr6	1766	13	than	than	IN
cord-005478-5iu38pr6	1766	14	AUC	AUC	NNP
cord-005478-5iu38pr6	1766	15	(	(	-LRB-
cord-005478-5iu38pr6	1766	16	coefficient	coefficient	NN
cord-005478-5iu38pr6	1766	17	of	of	IN
cord-005478-5iu38pr6	1766	18	variation=	variation=	NNP
cord-005478-5iu38pr6	1766	19	36	36	CD
cord-005478-5iu38pr6	1766	20	%	%	NN
cord-005478-5iu38pr6	1766	21	and	and	CC
cord-005478-5iu38pr6	1766	22	26	26	CD
cord-005478-5iu38pr6	1766	23	%	%	NN
cord-005478-5iu38pr6	1766	24	respectively	respectively	RB
cord-005478-5iu38pr6	1766	25	)	)	-RRB-
cord-005478-5iu38pr6	1766	26	.	.	.
cord-005478-5iu38pr6	1767	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1767	2	:	:	:
cord-005478-5iu38pr6	1768	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1768	2	report	report	VBP
cord-005478-5iu38pr6	1768	3	in	in	IN
cord-005478-5iu38pr6	1768	4	this	this	DT
cord-005478-5iu38pr6	1768	5	study	study	NN
cord-005478-5iu38pr6	1768	6	that	that	IN
cord-005478-5iu38pr6	1768	7	a	a	DT
cord-005478-5iu38pr6	1768	8	ciclosporin	ciclosporin	NN
cord-005478-5iu38pr6	1768	9	AUC=5.15	AUC=5.15	NNP
cord-005478-5iu38pr6	1768	10	mg*h	mg*h	NNP
cord-005478-5iu38pr6	1768	11	/	/	SYM
cord-005478-5iu38pr6	1768	12	L	L	NNP
cord-005478-5iu38pr6	1768	13	could	could	MD
cord-005478-5iu38pr6	1768	14	be	be	VB
cord-005478-5iu38pr6	1768	15	used	use	VBN
cord-005478-5iu38pr6	1768	16	as	as	IN
cord-005478-5iu38pr6	1768	17	a	a	DT
cord-005478-5iu38pr6	1768	18	high	high	JJ
cord-005478-5iu38pr6	1768	19	threshold	threshold	NN
cord-005478-5iu38pr6	1768	20	for	for	IN
cord-005478-5iu38pr6	1768	21	AKI	AKI	NNP
cord-005478-5iu38pr6	1768	22	.	.	.
cord-005478-5iu38pr6	1769	1	New	new	JJ
cord-005478-5iu38pr6	1769	2	evaluations	evaluation	NNS
cord-005478-5iu38pr6	1769	3	of	of	IN
cord-005478-5iu38pr6	1769	4	AUC	AUC	NNP
cord-005478-5iu38pr6	1769	5	in	in	IN
cord-005478-5iu38pr6	1769	6	prospective	prospective	JJ
cord-005478-5iu38pr6	1769	7	studies	study	NNS
cord-005478-5iu38pr6	1769	8	are	be	VBP
cord-005478-5iu38pr6	1769	9	needed	need	VBN
cord-005478-5iu38pr6	1769	10	to	to	TO
cord-005478-5iu38pr6	1769	11	better	better	RB
cord-005478-5iu38pr6	1769	12	define	define	VB
cord-005478-5iu38pr6	1769	13	the	the	DT
cord-005478-5iu38pr6	1769	14	relevance	relevance	NN
cord-005478-5iu38pr6	1769	15	of	of	IN
cord-005478-5iu38pr6	1769	16	this	this	DT
cord-005478-5iu38pr6	1769	17	marker	marker	NN
cord-005478-5iu38pr6	1769	18	in	in	IN
cord-005478-5iu38pr6	1769	19	clinical	clinical	JJ
cord-005478-5iu38pr6	1769	20	practice	practice	NN
cord-005478-5iu38pr6	1769	21	.	.	.
cord-005478-5iu38pr6	1770	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1770	2	Background	background	NN
cord-005478-5iu38pr6	1770	3	:	:	:
cord-005478-5iu38pr6	1770	4	Human	human	JJ
cord-005478-5iu38pr6	1770	5	cord	cord	NN
cord-005478-5iu38pr6	1770	6	blood	blood	NN
cord-005478-5iu38pr6	1770	7	(	(	-LRB-
cord-005478-5iu38pr6	1770	8	CB	CB	NNP
cord-005478-5iu38pr6	1770	9	)	)	-RRB-
cord-005478-5iu38pr6	1770	10	provides	provide	VBZ
cord-005478-5iu38pr6	1770	11	an	an	DT
cord-005478-5iu38pr6	1770	12	attractive	attractive	JJ
cord-005478-5iu38pr6	1770	13	source	source	NN
cord-005478-5iu38pr6	1770	14	of	of	IN
cord-005478-5iu38pr6	1770	15	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1770	16	stem	stem	NN
cord-005478-5iu38pr6	1770	17	cells	cell	NNS
cord-005478-5iu38pr6	1770	18	for	for	IN
cord-005478-5iu38pr6	1770	19	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1770	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	1770	21	of	of	IN
cord-005478-5iu38pr6	1770	22	patients	patient	NNS
cord-005478-5iu38pr6	1770	23	with	with	IN
cord-005478-5iu38pr6	1770	24	a	a	DT
cord-005478-5iu38pr6	1770	25	variety	variety	NN
cord-005478-5iu38pr6	1770	26	of	of	IN
cord-005478-5iu38pr6	1770	27	diseases	disease	NNS
cord-005478-5iu38pr6	1770	28	.	.	.
cord-005478-5iu38pr6	1771	1	A	a	DT
cord-005478-5iu38pr6	1771	2	sufficient	sufficient	JJ
cord-005478-5iu38pr6	1771	3	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1771	4	stem	stem	NN
cord-005478-5iu38pr6	1771	5	cell	cell	NN
cord-005478-5iu38pr6	1771	6	(	(	-LRB-
cord-005478-5iu38pr6	1771	7	HSC	HSC	NNP
cord-005478-5iu38pr6	1771	8	)	)	-RRB-
cord-005478-5iu38pr6	1771	9	dose	dose	NN
cord-005478-5iu38pr6	1771	10	,	,	,
cord-005478-5iu38pr6	1771	11	currently	currently	RB
cord-005478-5iu38pr6	1771	12	measured	measure	VBN
cord-005478-5iu38pr6	1771	13	as	as	IN
cord-005478-5iu38pr6	1771	14	CD34	CD34	NNP
cord-005478-5iu38pr6	1771	15	+	+	CC
cord-005478-5iu38pr6	1771	16	cells	cell	NNS
cord-005478-5iu38pr6	1771	17	/	/	SYM
cord-005478-5iu38pr6	1771	18	kg	kg	NN
cord-005478-5iu38pr6	1771	19	recipient	recipient	NN
cord-005478-5iu38pr6	1771	20	,	,	,
cord-005478-5iu38pr6	1771	21	is	be	VBZ
cord-005478-5iu38pr6	1771	22	essential	essential	JJ
cord-005478-5iu38pr6	1771	23	for	for	IN
cord-005478-5iu38pr6	1771	24	successful	successful	JJ
cord-005478-5iu38pr6	1771	25	engraftment	engraftment	NN
cord-005478-5iu38pr6	1771	26	.	.	.
cord-005478-5iu38pr6	1772	1	Nevertheless	nevertheless	RB
cord-005478-5iu38pr6	1772	2	,	,	,
cord-005478-5iu38pr6	1772	3	the	the	DT
cord-005478-5iu38pr6	1772	4	frequency	frequency	NN
cord-005478-5iu38pr6	1772	5	of	of	IN
cord-005478-5iu38pr6	1772	6	true	true	JJ
cord-005478-5iu38pr6	1772	7	HSC	HSC	NNP
cord-005478-5iu38pr6	1772	8	within	within	IN
cord-005478-5iu38pr6	1772	9	the	the	DT
cord-005478-5iu38pr6	1772	10	CD34	CD34	NNP
cord-005478-5iu38pr6	1772	11	+	+	CC
cord-005478-5iu38pr6	1772	12	population	population	NN
cord-005478-5iu38pr6	1772	13	and	and	CC
cord-005478-5iu38pr6	1772	14	the	the	DT
cord-005478-5iu38pr6	1772	15	dynamics	dynamic	NNS
cord-005478-5iu38pr6	1772	16	of	of	IN
cord-005478-5iu38pr6	1772	17	their	-PRON-	PRP$
cord-005478-5iu38pr6	1772	18	clonal	clonal	JJ
cord-005478-5iu38pr6	1772	19	offspring	offspring	NN
cord-005478-5iu38pr6	1772	20	remain	remain	VBP
cord-005478-5iu38pr6	1772	21	poorly	poorly	RB
cord-005478-5iu38pr6	1772	22	understood	understand	VBN
cord-005478-5iu38pr6	1772	23	and	and	CC
cord-005478-5iu38pr6	1772	24	may	may	MD
cord-005478-5iu38pr6	1772	25	differ	differ	VB
cord-005478-5iu38pr6	1772	26	between	between	IN
cord-005478-5iu38pr6	1772	27	donors	donor	NNS
cord-005478-5iu38pr6	1772	28	.	.	.
cord-005478-5iu38pr6	1773	1	Methods	method	NNS
cord-005478-5iu38pr6	1773	2	:	:	:
cord-005478-5iu38pr6	1774	1	Here	here	RB
cord-005478-5iu38pr6	1774	2	,	,	,
cord-005478-5iu38pr6	1774	3	we	-PRON-	PRP
cord-005478-5iu38pr6	1774	4	use	use	VBP
cord-005478-5iu38pr6	1774	5	cellular	cellular	JJ
cord-005478-5iu38pr6	1774	6	barcoding	barcoding	NN
cord-005478-5iu38pr6	1774	7	and	and	CC
cord-005478-5iu38pr6	1774	8	multiplexed	multiplexed	JJ
cord-005478-5iu38pr6	1774	9	high	high	JJ
cord-005478-5iu38pr6	1774	10	-	-	HYPH
cord-005478-5iu38pr6	1774	11	throughput	throughput	NN
cord-005478-5iu38pr6	1774	12	sequencing	sequencing	NN
cord-005478-5iu38pr6	1774	13	to	to	TO
cord-005478-5iu38pr6	1774	14	determine	determine	VB
cord-005478-5iu38pr6	1774	15	the	the	DT
cord-005478-5iu38pr6	1774	16	frequency	frequency	NN
cord-005478-5iu38pr6	1774	17	of	of	IN
cord-005478-5iu38pr6	1774	18	repopulating	repopulate	VBG
cord-005478-5iu38pr6	1774	19	cells	cell	NNS
cord-005478-5iu38pr6	1774	20	among	among	IN
cord-005478-5iu38pr6	1774	21	CD34	CD34	NNP
cord-005478-5iu38pr6	1774	22	+	+	CC
cord-005478-5iu38pr6	1774	23	cells	cell	NNS
cord-005478-5iu38pr6	1774	24	from	from	IN
cord-005478-5iu38pr6	1774	25	20	20	CD
cord-005478-5iu38pr6	1774	26	individual	individual	JJ
cord-005478-5iu38pr6	1774	27	human	human	JJ
cord-005478-5iu38pr6	1774	28	CB	CB	NNP
cord-005478-5iu38pr6	1774	29	donors	donor	NNS
cord-005478-5iu38pr6	1774	30	,	,	,
cord-005478-5iu38pr6	1774	31	and	and	CC
cord-005478-5iu38pr6	1774	32	to	to	TO
cord-005478-5iu38pr6	1774	33	quantify	quantify	VB
cord-005478-5iu38pr6	1774	34	their	-PRON-	PRP$
cord-005478-5iu38pr6	1774	35	contribution	contribution	NN
cord-005478-5iu38pr6	1774	36	to	to	IN
cord-005478-5iu38pr6	1774	37	each	each	DT
cord-005478-5iu38pr6	1774	38	of	of	IN
cord-005478-5iu38pr6	1774	39	the	the	DT
cord-005478-5iu38pr6	1774	40	blood	blood	NN
cord-005478-5iu38pr6	1774	41	lineages	lineage	NNS
cord-005478-5iu38pr6	1774	42	over	over	IN
cord-005478-5iu38pr6	1774	43	time	time	NN
cord-005478-5iu38pr6	1774	44	in	in	IN
cord-005478-5iu38pr6	1774	45	murine	murine	JJ
cord-005478-5iu38pr6	1774	46	NOD	NOD	NNP
cord-005478-5iu38pr6	1774	47	/	/	SYM
cord-005478-5iu38pr6	1774	48	Scid	Scid	NNP
cord-005478-5iu38pr6	1774	49	/	/	SYM
cord-005478-5iu38pr6	1774	50	IL2Ry	IL2Ry	NNP
cord-005478-5iu38pr6	1774	51	-/-(NSG	-/-(NSG	NNP
cord-005478-5iu38pr6	1774	52	)	)	-RRB-
cord-005478-5iu38pr6	1774	53	xenografts	xenograft	NNS
cord-005478-5iu38pr6	1774	54	.	.	.
cord-005478-5iu38pr6	1775	1	Results	result	NNS
cord-005478-5iu38pr6	1775	2	:	:	:
cord-005478-5iu38pr6	1776	1	In	in	IN
cord-005478-5iu38pr6	1776	2	total	total	NN
cord-005478-5iu38pr6	1776	3	,	,	,
cord-005478-5iu38pr6	1776	4	we	-PRON-	PRP
cord-005478-5iu38pr6	1776	5	detected	detect	VBD
cord-005478-5iu38pr6	1776	6	a	a	DT
cord-005478-5iu38pr6	1776	7	median	median	NN
cord-005478-5iu38pr6	1776	8	of	of	IN
cord-005478-5iu38pr6	1776	9	14.3	14.3	CD
cord-005478-5iu38pr6	1776	10	(	(	-LRB-
cord-005478-5iu38pr6	1776	11	range	range	NNP
cord-005478-5iu38pr6	1776	12	5	5	CD
cord-005478-5iu38pr6	1776	13	-	-	SYM
cord-005478-5iu38pr6	1776	14	168	168	CD
cord-005478-5iu38pr6	1776	15	)	)	-RRB-
cord-005478-5iu38pr6	1776	16	clones	clone	NNS
cord-005478-5iu38pr6	1776	17	in	in	IN
cord-005478-5iu38pr6	1776	18	blood	blood	NN
cord-005478-5iu38pr6	1776	19	and	and	CC
cord-005478-5iu38pr6	1776	20	15.0	15.0	CD
cord-005478-5iu38pr6	1776	21	(	(	-LRB-
cord-005478-5iu38pr6	1776	22	range	range	VBP
cord-005478-5iu38pr6	1776	23	1.7	1.7	CD
cord-005478-5iu38pr6	1776	24	-	-	SYM
cord-005478-5iu38pr6	1776	25	85	85	CD
cord-005478-5iu38pr6	1776	26	)	)	-RRB-
cord-005478-5iu38pr6	1776	27	clones	clone	NNS
cord-005478-5iu38pr6	1776	28	in	in	IN
cord-005478-5iu38pr6	1776	29	bone	bone	NN
cord-005478-5iu38pr6	1776	30	marrow	marrow	NN
cord-005478-5iu38pr6	1776	31	,	,	,
cord-005478-5iu38pr6	1776	32	corresponding	correspond	VBG
cord-005478-5iu38pr6	1776	33	to	to	IN
cord-005478-5iu38pr6	1776	34	HSPC	HSPC	NNP
cord-005478-5iu38pr6	1776	35	frequencies	frequency	NNS
cord-005478-5iu38pr6	1776	36	of	of	IN
cord-005478-5iu38pr6	1776	37	1:100	1:100	CD
cord-005478-5iu38pr6	1776	38	to	to	IN
cord-005478-5iu38pr6	1776	39	1:1000	1:1000	CD
cord-005478-5iu38pr6	1776	40	.	.	.
cord-005478-5iu38pr6	1777	1	The	the	DT
cord-005478-5iu38pr6	1777	2	number	number	NN
cord-005478-5iu38pr6	1777	3	of	of	IN
cord-005478-5iu38pr6	1777	4	retrieved	retrieve	VBN
cord-005478-5iu38pr6	1777	5	clones	clone	NNS
cord-005478-5iu38pr6	1777	6	correlated	correlate	VBN
cord-005478-5iu38pr6	1777	7	to	to	IN
cord-005478-5iu38pr6	1777	8	barcoded	barcode	VBN
cord-005478-5iu38pr6	1777	9	CD34	CD34	NNP
cord-005478-5iu38pr6	1777	10	+	+	CC
cord-005478-5iu38pr6	1777	11	cell	cell	NN
cord-005478-5iu38pr6	1777	12	dose	dose	NN
cord-005478-5iu38pr6	1777	13	(	(	-LRB-
cord-005478-5iu38pr6	1777	14	Spearman	Spearman	NNP
cord-005478-5iu38pr6	1777	15	R=0.85	R=0.85	NNP
cord-005478-5iu38pr6	1777	16	,	,	,
cord-005478-5iu38pr6	1777	17	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	1777	18	)	)	-RRB-
cord-005478-5iu38pr6	1777	19	,	,	,
cord-005478-5iu38pr6	1777	20	yet	yet	CC
cord-005478-5iu38pr6	1777	21	could	could	MD
cord-005478-5iu38pr6	1777	22	vary	vary	VB
cord-005478-5iu38pr6	1777	23	up	up	IN
cord-005478-5iu38pr6	1777	24	to	to	TO
cord-005478-5iu38pr6	1777	25	four	four	CD
cord-005478-5iu38pr6	1777	26	-	-	NN
cord-005478-5iu38pr6	1777	27	fold	fold	RB
cord-005478-5iu38pr6	1777	28	between	between	IN
cord-005478-5iu38pr6	1777	29	mice	mouse	NNS
cord-005478-5iu38pr6	1777	30	transplanted	transplant	VBN
cord-005478-5iu38pr6	1777	31	with	with	IN
cord-005478-5iu38pr6	1777	32	the	the	DT
cord-005478-5iu38pr6	1777	33	same	same	JJ
cord-005478-5iu38pr6	1777	34	cell	cell	NN
cord-005478-5iu38pr6	1777	35	dose	dose	NN
cord-005478-5iu38pr6	1777	36	.	.	.
cord-005478-5iu38pr6	1778	1	Clonal	clonal	JJ
cord-005478-5iu38pr6	1778	2	patterns	pattern	NNS
cord-005478-5iu38pr6	1778	3	in	in	IN
cord-005478-5iu38pr6	1778	4	blood	blood	NN
cord-005478-5iu38pr6	1778	5	early	early	RB
cord-005478-5iu38pr6	1778	6	after	after	IN
cord-005478-5iu38pr6	1778	7	transplant	transplant	NN
cord-005478-5iu38pr6	1778	8	differed	differ	VBD
cord-005478-5iu38pr6	1778	9	markedly	markedly	RB
cord-005478-5iu38pr6	1778	10	from	from	IN
cord-005478-5iu38pr6	1778	11	those	those	DT
cord-005478-5iu38pr6	1778	12	at	at	IN
cord-005478-5iu38pr6	1778	13	later	later	JJ
cord-005478-5iu38pr6	1778	14	time	time	NN
cord-005478-5iu38pr6	1778	15	points	point	NNS
cord-005478-5iu38pr6	1778	16	,	,	,
cord-005478-5iu38pr6	1778	17	and	and	CC
cord-005478-5iu38pr6	1778	18	became	become	VBD
cord-005478-5iu38pr6	1778	19	increasingly	increasingly	RB
cord-005478-5iu38pr6	1778	20	deterministic	deterministic	JJ
cord-005478-5iu38pr6	1778	21	over	over	IN
cord-005478-5iu38pr6	1778	22	time	time	NN
cord-005478-5iu38pr6	1778	23	.	.	.
cord-005478-5iu38pr6	1779	1	The	the	DT
cord-005478-5iu38pr6	1779	2	majority	majority	NN
cord-005478-5iu38pr6	1779	3	of	of	IN
cord-005478-5iu38pr6	1779	4	clones	clone	NNS
cord-005478-5iu38pr6	1779	5	displayed	display	VBD
cord-005478-5iu38pr6	1779	6	multilineage	multilineage	NN
cord-005478-5iu38pr6	1779	7	output	output	NN
cord-005478-5iu38pr6	1779	8	,	,	,
cord-005478-5iu38pr6	1779	9	yet	yet	CC
cord-005478-5iu38pr6	1779	10	clones	clone	NNS
cord-005478-5iu38pr6	1779	11	with	with	IN
cord-005478-5iu38pr6	1779	12	bias	bias	NN
cord-005478-5iu38pr6	1779	13	towards	towards	IN
cord-005478-5iu38pr6	1779	14	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	1779	15	or	or	CC
cord-005478-5iu38pr6	1779	16	myeloid	myeloid	JJ
cord-005478-5iu38pr6	1779	17	lineages	lineage	NNS
cord-005478-5iu38pr6	1779	18	were	be	VBD
cord-005478-5iu38pr6	1779	19	also	also	RB
cord-005478-5iu38pr6	1779	20	present	present	JJ
cord-005478-5iu38pr6	1779	21	.	.	.
cord-005478-5iu38pr6	1780	1	Similar	similar	JJ
cord-005478-5iu38pr6	1780	2	to	to	IN
cord-005478-5iu38pr6	1780	3	recent	recent	JJ
cord-005478-5iu38pr6	1780	4	data	datum	NNS
cord-005478-5iu38pr6	1780	5	on	on	IN
cord-005478-5iu38pr6	1780	6	murine	murine	JJ
cord-005478-5iu38pr6	1780	7	HSC	HSC	NNP
cord-005478-5iu38pr6	1780	8	clones	clone	NNS
cord-005478-5iu38pr6	1780	9	,	,	,
cord-005478-5iu38pr6	1780	10	human	human	JJ
cord-005478-5iu38pr6	1780	11	CB	CB	NNP
cord-005478-5iu38pr6	1780	12	clones	clone	NNS
cord-005478-5iu38pr6	1780	13	were	be	VBD
cord-005478-5iu38pr6	1780	14	distributed	distribute	VBN
cord-005478-5iu38pr6	1780	15	asymmetrically	asymmetrically	RB
cord-005478-5iu38pr6	1780	16	across	across	IN
cord-005478-5iu38pr6	1780	17	different	different	JJ
cord-005478-5iu38pr6	1780	18	bone	bone	NN
cord-005478-5iu38pr6	1780	19	marrow	marrow	NN
cord-005478-5iu38pr6	1780	20	sites	site	NNS
cord-005478-5iu38pr6	1780	21	.	.	.
cord-005478-5iu38pr6	1781	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1781	2	:	:	:
cord-005478-5iu38pr6	1782	1	In	in	IN
cord-005478-5iu38pr6	1782	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	1782	3	,	,	,
cord-005478-5iu38pr6	1782	4	the	the	DT
cord-005478-5iu38pr6	1782	5	frequency	frequency	NN
cord-005478-5iu38pr6	1782	6	of	of	IN
cord-005478-5iu38pr6	1782	7	NSGrepopulating	nsgrepopulating	NN
cord-005478-5iu38pr6	1782	8	cells	cell	NNS
cord-005478-5iu38pr6	1782	9	among	among	IN
cord-005478-5iu38pr6	1782	10	cord	cord	NN
cord-005478-5iu38pr6	1782	11	blood	blood	NN
cord-005478-5iu38pr6	1782	12	CD34	CD34	NNP
cord-005478-5iu38pr6	1782	13	+	+	CC
cord-005478-5iu38pr6	1782	14	cells	cell	NNS
cord-005478-5iu38pr6	1782	15	is	be	VBZ
cord-005478-5iu38pr6	1782	16	low	low	JJ
cord-005478-5iu38pr6	1782	17	,	,	,
cord-005478-5iu38pr6	1782	18	and	and	CC
cord-005478-5iu38pr6	1782	19	highly	highly	RB
cord-005478-5iu38pr6	1782	20	variable	variable	JJ
cord-005478-5iu38pr6	1782	21	between	between	IN
cord-005478-5iu38pr6	1782	22	individual	individual	JJ
cord-005478-5iu38pr6	1782	23	CB	CB	NNP
cord-005478-5iu38pr6	1782	24	donors	donor	NNS
cord-005478-5iu38pr6	1782	25	.	.	.
cord-005478-5iu38pr6	1783	1	Heterogeneity	heterogeneity	NN
cord-005478-5iu38pr6	1783	2	in	in	IN
cord-005478-5iu38pr6	1783	3	HSC	HSC	NNP
cord-005478-5iu38pr6	1783	4	frequency	frequency	NN
cord-005478-5iu38pr6	1783	5	,	,	,
cord-005478-5iu38pr6	1784	1	proliferation	proliferation	NN
cord-005478-5iu38pr6	1784	2	and	and	CC
cord-005478-5iu38pr6	1784	3	lineage	lineage	NN
cord-005478-5iu38pr6	1784	4	fate	fate	NN
cord-005478-5iu38pr6	1784	5	decisions	decision	NNS
cord-005478-5iu38pr6	1784	6	may	may	MD
cord-005478-5iu38pr6	1784	7	contribute	contribute	VB
cord-005478-5iu38pr6	1784	8	to	to	IN
cord-005478-5iu38pr6	1784	9	(	(	-LRB-
cord-005478-5iu38pr6	1784	10	non-)engraftment	non-)engraftment	NN
cord-005478-5iu38pr6	1784	11	upon	upon	IN
cord-005478-5iu38pr6	1784	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1784	13	.	.	.
cord-005478-5iu38pr6	1785	1	Future	future	JJ
cord-005478-5iu38pr6	1785	2	research	research	NN
cord-005478-5iu38pr6	1785	3	will	will	MD
cord-005478-5iu38pr6	1785	4	be	be	VB
cord-005478-5iu38pr6	1785	5	aimed	aim	VBN
cord-005478-5iu38pr6	1785	6	at	at	IN
cord-005478-5iu38pr6	1785	7	identifying	identify	VBG
cord-005478-5iu38pr6	1785	8	the	the	DT
cord-005478-5iu38pr6	1785	9	underlying	underlie	VBG
cord-005478-5iu38pr6	1785	10	mechanisms	mechanism	NNS
cord-005478-5iu38pr6	1785	11	guiding	guide	VBG
cord-005478-5iu38pr6	1785	12	HSC	HSC	NNP
cord-005478-5iu38pr6	1785	13	behavior	behavior	NN
cord-005478-5iu38pr6	1785	14	upon	upon	IN
cord-005478-5iu38pr6	1785	15	transplantation	transplantation	NN
cord-005478-5iu38pr6	1785	16	and	and	CC
cord-005478-5iu38pr6	1785	17	expanding	expand	VBG
cord-005478-5iu38pr6	1785	18	our	-PRON-	PRP$
cord-005478-5iu38pr6	1785	19	findings	finding	NNS
cord-005478-5iu38pr6	1785	20	to	to	IN
cord-005478-5iu38pr6	1785	21	human	human	JJ
cord-005478-5iu38pr6	1785	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1785	23	recipients	recipient	NNS
cord-005478-5iu38pr6	1785	24	.	.	.
cord-005478-5iu38pr6	1786	1	[	[	-LRB-
cord-005478-5iu38pr6	1786	2	[	[	-LRB-
cord-005478-5iu38pr6	1786	3	O089	o089	NN
cord-005478-5iu38pr6	1786	4	Image	image	NN
cord-005478-5iu38pr6	1786	5	]	]	-RRB-
cord-005478-5iu38pr6	1786	6	1	1	CD
cord-005478-5iu38pr6	1786	7	.	.	.
cord-005478-5iu38pr6	1787	1	Background	background	NN
cord-005478-5iu38pr6	1787	2	:	:	:
cord-005478-5iu38pr6	1788	1	Chronic	Chronic	NNP
cord-005478-5iu38pr6	1788	2	Granulomatous	granulomatous	JJ
cord-005478-5iu38pr6	1788	3	Disease	Disease	NNP
cord-005478-5iu38pr6	1788	4	(	(	-LRB-
cord-005478-5iu38pr6	1788	5	CGD	CGD	NNP
cord-005478-5iu38pr6	1788	6	)	)	-RRB-
cord-005478-5iu38pr6	1788	7	is	be	VBZ
cord-005478-5iu38pr6	1788	8	a	a	DT
cord-005478-5iu38pr6	1788	9	rare	rare	JJ
cord-005478-5iu38pr6	1788	10	genetic	genetic	JJ
cord-005478-5iu38pr6	1788	11	immune	immune	JJ
cord-005478-5iu38pr6	1788	12	disorder	disorder	NN
cord-005478-5iu38pr6	1788	13	that	that	WDT
cord-005478-5iu38pr6	1788	14	leaves	leave	VBZ
cord-005478-5iu38pr6	1788	15	patients	patient	NNS
cord-005478-5iu38pr6	1788	16	susceptible	susceptible	JJ
cord-005478-5iu38pr6	1788	17	to	to	IN
cord-005478-5iu38pr6	1788	18	life	life	NN
cord-005478-5iu38pr6	1788	19	-	-	HYPH
cord-005478-5iu38pr6	1788	20	threatening	threaten	VBG
cord-005478-5iu38pr6	1788	21	infections	infection	NNS
cord-005478-5iu38pr6	1788	22	,	,	,
cord-005478-5iu38pr6	1788	23	chronic	chronic	JJ
cord-005478-5iu38pr6	1788	24	inflammation	inflammation	NN
cord-005478-5iu38pr6	1788	25	and	and	CC
cord-005478-5iu38pr6	1788	26	often	often	RB
cord-005478-5iu38pr6	1788	27	long	long	JJ
cord-005478-5iu38pr6	1788	28	hospital	hospital	NN
cord-005478-5iu38pr6	1788	29	stays	stay	VBZ
cord-005478-5iu38pr6	1788	30	.	.	.
cord-005478-5iu38pr6	1789	1	X	X	NNS
cord-005478-5iu38pr6	1789	2	-	-	HYPH
cord-005478-5iu38pr6	1789	3	linked	link	VBN
cord-005478-5iu38pr6	1789	4	CGD	CGD	NNP
cord-005478-5iu38pr6	1789	5	(	(	-LRB-
cord-005478-5iu38pr6	1789	6	X	X	NNP
cord-005478-5iu38pr6	1789	7	-	-	NNP
cord-005478-5iu38pr6	1789	8	CGD	CGD	NNP
cord-005478-5iu38pr6	1789	9	)	)	-RRB-
cord-005478-5iu38pr6	1789	10	is	be	VBZ
cord-005478-5iu38pr6	1789	11	caused	cause	VBN
cord-005478-5iu38pr6	1789	12	by	by	IN
cord-005478-5iu38pr6	1789	13	mutations	mutation	NNS
cord-005478-5iu38pr6	1789	14	in	in	IN
cord-005478-5iu38pr6	1789	15	CYBB	CYBB	NNP
cord-005478-5iu38pr6	1789	16	encoding	encode	VBG
cord-005478-5iu38pr6	1789	17	the	the	DT
cord-005478-5iu38pr6	1789	18	gp91phox	gp91phox	NN
cord-005478-5iu38pr6	1789	19	subunit	subunit	NN
cord-005478-5iu38pr6	1789	20	of	of	IN
cord-005478-5iu38pr6	1789	21	the	the	DT
cord-005478-5iu38pr6	1789	22	phagocyte	phagocyte	NNP
cord-005478-5iu38pr6	1789	23	NADPH	NADPH	NNP
cord-005478-5iu38pr6	1789	24	-	-	HYPH
cord-005478-5iu38pr6	1789	25	oxidase	oxidase	NN
cord-005478-5iu38pr6	1789	26	,	,	,
cord-005478-5iu38pr6	1789	27	which	which	WDT
cord-005478-5iu38pr6	1789	28	regulates	regulate	VBZ
cord-005478-5iu38pr6	1789	29	cell	cell	NN
cord-005478-5iu38pr6	1789	30	pH	ph	NN
cord-005478-5iu38pr6	1789	31	and	and	CC
cord-005478-5iu38pr6	1789	32	ionic	ionic	JJ
cord-005478-5iu38pr6	1789	33	content	content	NN
cord-005478-5iu38pr6	1789	34	for	for	IN
cord-005478-5iu38pr6	1789	35	efficient	efficient	JJ
cord-005478-5iu38pr6	1789	36	microbial	microbial	JJ
cord-005478-5iu38pr6	1789	37	killing	killing	NN
cord-005478-5iu38pr6	1789	38	.	.	.
cord-005478-5iu38pr6	1790	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1790	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1790	3	stem	stem	NN
cord-005478-5iu38pr6	1790	4	cell	cell	NN
cord-005478-5iu38pr6	1790	5	transplant	transplant	NN
cord-005478-5iu38pr6	1790	6	(	(	-LRB-
cord-005478-5iu38pr6	1790	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1790	8	)	)	-RRB-
cord-005478-5iu38pr6	1790	9	has	have	VBZ
cord-005478-5iu38pr6	1790	10	been	be	VBN
cord-005478-5iu38pr6	1790	11	a	a	DT
cord-005478-5iu38pr6	1790	12	potentially	potentially	RB
cord-005478-5iu38pr6	1790	13	curative	curative	JJ
cord-005478-5iu38pr6	1790	14	approach	approach	NN
cord-005478-5iu38pr6	1790	15	for	for	IN
cord-005478-5iu38pr6	1790	16	X	X	NNP
cord-005478-5iu38pr6	1790	17	-	-	NNP
cord-005478-5iu38pr6	1790	18	CGD	CGD	NNP
cord-005478-5iu38pr6	1790	19	patients	patient	NNS
cord-005478-5iu38pr6	1790	20	,	,	,
cord-005478-5iu38pr6	1790	21	but	but	CC
cord-005478-5iu38pr6	1790	22	is	be	VBZ
cord-005478-5iu38pr6	1790	23	often	often	RB
cord-005478-5iu38pr6	1790	24	complicated	complicate	VBN
cord-005478-5iu38pr6	1790	25	by	by	IN
cord-005478-5iu38pr6	1790	26	lack	lack	NN
cord-005478-5iu38pr6	1790	27	of	of	IN
cord-005478-5iu38pr6	1790	28	HLA	HLA	NNP
cord-005478-5iu38pr6	1790	29	-	-	HYPH
cord-005478-5iu38pr6	1790	30	matched	match	VBN
cord-005478-5iu38pr6	1790	31	donors	donor	NNS
cord-005478-5iu38pr6	1790	32	and	and	CC
cord-005478-5iu38pr6	1790	33	risks	risk	NNS
cord-005478-5iu38pr6	1790	34	of	of	IN
cord-005478-5iu38pr6	1790	35	graft	graft	NN
cord-005478-5iu38pr6	1790	36	versus	versus	IN
cord-005478-5iu38pr6	1790	37	host	host	NN
cord-005478-5iu38pr6	1790	38	disease	disease	NN
cord-005478-5iu38pr6	1790	39	,	,	,
cord-005478-5iu38pr6	1790	40	graft	graft	NN
cord-005478-5iu38pr6	1790	41	rejection	rejection	NN
cord-005478-5iu38pr6	1790	42	,	,	,
cord-005478-5iu38pr6	1790	43	and	and	CC
cord-005478-5iu38pr6	1790	44	procedure	procedure	NN
cord-005478-5iu38pr6	1790	45	-	-	HYPH
cord-005478-5iu38pr6	1790	46	related	relate	VBN
cord-005478-5iu38pr6	1790	47	fatality	fatality	NN
cord-005478-5iu38pr6	1790	48	.	.	.
cord-005478-5iu38pr6	1791	1	Previous	previous	JJ
cord-005478-5iu38pr6	1791	2	attempts	attempt	NNS
cord-005478-5iu38pr6	1791	3	at	at	IN
cord-005478-5iu38pr6	1791	4	autologous	autologous	JJ
cord-005478-5iu38pr6	1791	5	ex	ex	FW
cord-005478-5iu38pr6	1791	6	vivo	vivo	NN
cord-005478-5iu38pr6	1791	7	gene	gene	NN
cord-005478-5iu38pr6	1791	8	therapy	therapy	NN
cord-005478-5iu38pr6	1791	9	for	for	IN
cord-005478-5iu38pr6	1791	10	X	X	NNP
cord-005478-5iu38pr6	1791	11	-	-	NNP
cord-005478-5iu38pr6	1791	12	CGD	CGD	NNP
cord-005478-5iu38pr6	1791	13	using	use	VBG
cord-005478-5iu38pr6	1791	14	gammaretroviral	gammaretroviral	JJ
cord-005478-5iu38pr6	1791	15	vectors	vector	NNS
cord-005478-5iu38pr6	1791	16	have	have	VBP
cord-005478-5iu38pr6	1791	17	met	meet	VBN
cord-005478-5iu38pr6	1791	18	with	with	IN
cord-005478-5iu38pr6	1791	19	limited	limited	JJ
cord-005478-5iu38pr6	1791	20	efficacy	efficacy	NN
cord-005478-5iu38pr6	1791	21	due	due	IN
cord-005478-5iu38pr6	1791	22	to	to	IN
cord-005478-5iu38pr6	1791	23	transient	transient	JJ
cord-005478-5iu38pr6	1791	24	engraftment	engraftment	NN
cord-005478-5iu38pr6	1791	25	of	of	IN
cord-005478-5iu38pr6	1791	26	gene	gene	NN
cord-005478-5iu38pr6	1791	27	corrected	correct	VBD
cord-005478-5iu38pr6	1791	28	cells	cell	NNS
cord-005478-5iu38pr6	1791	29	,	,	,
cord-005478-5iu38pr6	1791	30	gene	gene	NN
cord-005478-5iu38pr6	1791	31	silencing	silencing	NN
cord-005478-5iu38pr6	1791	32	,	,	,
cord-005478-5iu38pr6	1791	33	and	and	CC
cord-005478-5iu38pr6	1791	34	mutagenic	mutagenic	JJ
cord-005478-5iu38pr6	1791	35	activation	activation	NN
cord-005478-5iu38pr6	1791	36	leading	lead	VBG
cord-005478-5iu38pr6	1791	37	to	to	IN
cord-005478-5iu38pr6	1791	38	myelodysplasia	myelodysplasia	NNP
cord-005478-5iu38pr6	1791	39	.	.	.
cord-005478-5iu38pr6	1792	1	Here	here	RB
cord-005478-5iu38pr6	1792	2	we	-PRON-	PRP
cord-005478-5iu38pr6	1792	3	report	report	VBP
cord-005478-5iu38pr6	1792	4	on	on	IN
cord-005478-5iu38pr6	1792	5	9	9	CD
cord-005478-5iu38pr6	1792	6	patients	patient	NNS
cord-005478-5iu38pr6	1792	7	with	with	IN
cord-005478-5iu38pr6	1792	8	a	a	DT
cord-005478-5iu38pr6	1792	9	history	history	NN
cord-005478-5iu38pr6	1792	10	of	of	IN
cord-005478-5iu38pr6	1792	11	severe	severe	JJ
cord-005478-5iu38pr6	1792	12	X	X	NNP
cord-005478-5iu38pr6	1792	13	-	-	NN
cord-005478-5iu38pr6	1792	14	CGD	CGD	NNP
cord-005478-5iu38pr6	1792	15	-	-	HYPH
cord-005478-5iu38pr6	1792	16	related	relate	VBN
cord-005478-5iu38pr6	1792	17	complications	complication	NNS
cord-005478-5iu38pr6	1792	18	,	,	,
cord-005478-5iu38pr6	1792	19	who	who	WP
cord-005478-5iu38pr6	1792	20	received	receive	VBD
cord-005478-5iu38pr6	1792	21	autologous	autologous	JJ
cord-005478-5iu38pr6	1792	22	ex	ex	FW
cord-005478-5iu38pr6	1792	23	vivo	vivo	NN
cord-005478-5iu38pr6	1792	24	gene	gene	NN
cord-005478-5iu38pr6	1792	25	therapy	therapy	NN
cord-005478-5iu38pr6	1792	26	(	(	-LRB-
cord-005478-5iu38pr6	1792	27	GT	GT	NNP
cord-005478-5iu38pr6	1792	28	)	)	-RRB-
cord-005478-5iu38pr6	1792	29	using	use	VBG
cord-005478-5iu38pr6	1792	30	a	a	DT
cord-005478-5iu38pr6	1792	31	novel	novel	JJ
cord-005478-5iu38pr6	1792	32	self	self	NN
cord-005478-5iu38pr6	1792	33	-	-	HYPH
cord-005478-5iu38pr6	1792	34	inactivating	inactivate	VBG
cord-005478-5iu38pr6	1792	35	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	1792	36	vector	vector	NN
cord-005478-5iu38pr6	1792	37	(	(	-LRB-
cord-005478-5iu38pr6	1792	38	G1XCGD	G1XCGD	NNP
cord-005478-5iu38pr6	1792	39	LV	LV	NNP
cord-005478-5iu38pr6	1792	40	)	)	-RRB-
cord-005478-5iu38pr6	1792	41	designed	design	VBN
cord-005478-5iu38pr6	1792	42	to	to	TO
cord-005478-5iu38pr6	1792	43	limit	limit	VB
cord-005478-5iu38pr6	1792	44	the	the	DT
cord-005478-5iu38pr6	1792	45	risk	risk	NN
cord-005478-5iu38pr6	1792	46	of	of	IN
cord-005478-5iu38pr6	1792	47	mutagenesis	mutagenesis	NN
cord-005478-5iu38pr6	1792	48	through	through	IN
cord-005478-5iu38pr6	1792	49	preferential	preferential	JJ
cord-005478-5iu38pr6	1792	50	expression	expression	NN
cord-005478-5iu38pr6	1792	51	of	of	IN
cord-005478-5iu38pr6	1792	52	the	the	DT
cord-005478-5iu38pr6	1792	53	missing	miss	VBG
cord-005478-5iu38pr6	1792	54	g91phox	g91phox	JJ
cord-005478-5iu38pr6	1792	55	subunit	subunit	NN
cord-005478-5iu38pr6	1792	56	in	in	IN
cord-005478-5iu38pr6	1792	57	mature	mature	JJ
cord-005478-5iu38pr6	1792	58	myeloid	myeloid	NN
cord-005478-5iu38pr6	1792	59	cells	cell	NNS
cord-005478-5iu38pr6	1792	60	.	.	.
cord-005478-5iu38pr6	1793	1	Methods	method	NNS
cord-005478-5iu38pr6	1793	2	:	:	:
cord-005478-5iu38pr6	1793	3	Similar	similar	JJ
cord-005478-5iu38pr6	1793	4	trials	trial	NNS
cord-005478-5iu38pr6	1793	5	of	of	IN
cord-005478-5iu38pr6	1793	6	GT	GT	NNP
cord-005478-5iu38pr6	1793	7	with	with	IN
cord-005478-5iu38pr6	1793	8	G1XCGD	G1XCGD	NNP
cord-005478-5iu38pr6	1793	9	LV	LV	NNP
cord-005478-5iu38pr6	1793	10	were	be	VBD
cord-005478-5iu38pr6	1793	11	initiated	initiate	VBN
cord-005478-5iu38pr6	1793	12	in	in	IN
cord-005478-5iu38pr6	1793	13	the	the	DT
cord-005478-5iu38pr6	1793	14	UK	UK	NNP
cord-005478-5iu38pr6	1793	15	(	(	-LRB-
cord-005478-5iu38pr6	1793	16	n=3	n=3	NN
cord-005478-5iu38pr6	1793	17	,	,	,
cord-005478-5iu38pr6	1793	18	plus	plus	CC
cord-005478-5iu38pr6	1793	19	1	1	CD
cord-005478-5iu38pr6	1793	20	compassionate	compassionate	JJ
cord-005478-5iu38pr6	1793	21	use	use	NN
cord-005478-5iu38pr6	1793	22	patient	patient	NN
cord-005478-5iu38pr6	1793	23	)	)	-RRB-
cord-005478-5iu38pr6	1793	24	and	and	CC
cord-005478-5iu38pr6	1793	25	in	in	IN
cord-005478-5iu38pr6	1793	26	the	the	DT
cord-005478-5iu38pr6	1793	27	USA	USA	NNP
cord-005478-5iu38pr6	1793	28	(	(	-LRB-
cord-005478-5iu38pr6	1793	29	n=5	n=5	JJ
cord-005478-5iu38pr6	1793	30	,	,	,
cord-005478-5iu38pr6	1793	31	3	3	CD
cord-005478-5iu38pr6	1793	32	sites	site	NNS
cord-005478-5iu38pr6	1793	33	)	)	-RRB-
cord-005478-5iu38pr6	1793	34	.	.	.
cord-005478-5iu38pr6	1794	1	All	all	DT
cord-005478-5iu38pr6	1794	2	patients	patient	NNS
cord-005478-5iu38pr6	1794	3	had	have	VBD
cord-005478-5iu38pr6	1794	4	histories	history	NNS
cord-005478-5iu38pr6	1794	5	of	of	IN
cord-005478-5iu38pr6	1794	6	severe	severe	JJ
cord-005478-5iu38pr6	1794	7	,	,	,
cord-005478-5iu38pr6	1794	8	persistent	persistent	JJ
cord-005478-5iu38pr6	1794	9	infections	infection	NNS
cord-005478-5iu38pr6	1794	10	,	,	,
cord-005478-5iu38pr6	1794	11	and	and	CC
cord-005478-5iu38pr6	1794	12	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	1794	13	disease	disease	NN
cord-005478-5iu38pr6	1794	14	.	.	.
cord-005478-5iu38pr6	1795	1	G	G	NNP
cord-005478-5iu38pr6	1795	2	-	-	HYPH
cord-005478-5iu38pr6	1795	3	CSF	CSF	NNP
cord-005478-5iu38pr6	1795	4	and	and	CC
cord-005478-5iu38pr6	1795	5	Plerixafor	Plerixafor	NNP
cord-005478-5iu38pr6	1795	6	-	-	HYPH
cord-005478-5iu38pr6	1795	7	mobilized	mobilize	VBN
cord-005478-5iu38pr6	1795	8	CD34	CD34	NNP
cord-005478-5iu38pr6	1795	9	+	+	SYM
cord-005478-5iu38pr6	1795	10	selected	select	VBN
cord-005478-5iu38pr6	1795	11	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1795	12	stem	stem	NN
cord-005478-5iu38pr6	1795	13	and	and	CC
cord-005478-5iu38pr6	1795	14	progenitor	progenitor	NN
cord-005478-5iu38pr6	1795	15	cells	cell	NNS
cord-005478-5iu38pr6	1795	16	were	be	VBD
cord-005478-5iu38pr6	1795	17	transduced	transduce	VBN
cord-005478-5iu38pr6	1795	18	ex	ex	IN
cord-005478-5iu38pr6	1795	19	vivo	vivo	NN
cord-005478-5iu38pr6	1795	20	with	with	IN
cord-005478-5iu38pr6	1795	21	G1XCGD	G1XCGD	NNP
cord-005478-5iu38pr6	1795	22	LV	LV	NNP
cord-005478-5iu38pr6	1795	23	.	.	.
cord-005478-5iu38pr6	1796	1	Subjects	subject	NNS
cord-005478-5iu38pr6	1796	2	received	receive	VBD
cord-005478-5iu38pr6	1796	3	near	near	RB
cord-005478-5iu38pr6	1796	4	-	-	HYPH
cord-005478-5iu38pr6	1796	5	myeloablative	myeloablative	NN
cord-005478-5iu38pr6	1796	6	conditioning	conditioning	NN
cord-005478-5iu38pr6	1796	7	with	with	IN
cord-005478-5iu38pr6	1796	8	single	single	JJ
cord-005478-5iu38pr6	1796	9	agent	agent	NN
cord-005478-5iu38pr6	1796	10	busulfan	busulfan	NN
cord-005478-5iu38pr6	1796	11	,	,	,
cord-005478-5iu38pr6	1796	12	targeted	target	VBN
cord-005478-5iu38pr6	1796	13	to	to	IN
cord-005478-5iu38pr6	1796	14	net	net	JJ
cord-005478-5iu38pr6	1796	15	area	area	NN
cord-005478-5iu38pr6	1796	16	-	-	HYPH
cord-005478-5iu38pr6	1796	17	under	under	IN
cord-005478-5iu38pr6	1796	18	-	-	HYPH
cord-005478-5iu38pr6	1796	19	the	the	DT
cord-005478-5iu38pr6	1796	20	-	-	HYPH
cord-005478-5iu38pr6	1796	21	curve	curve	NN
cord-005478-5iu38pr6	1796	22	of	of	IN
cord-005478-5iu38pr6	1796	23	70,000	70,000	CD
cord-005478-5iu38pr6	1796	24	ng	ng	NNP
cord-005478-5iu38pr6	1796	25	/	/	SYM
cord-005478-5iu38pr6	1796	26	ml*hr	ml*hr	NNP
cord-005478-5iu38pr6	1796	27	.	.	.
cord-005478-5iu38pr6	1797	1	Freshly	freshly	RB
cord-005478-5iu38pr6	1797	2	prepared	prepare	VBN
cord-005478-5iu38pr6	1797	3	or	or	CC
cord-005478-5iu38pr6	1797	4	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	1797	5	quality	quality	NN
cord-005478-5iu38pr6	1797	6	-	-	HYPH
cord-005478-5iu38pr6	1797	7	tested	test	VBN
cord-005478-5iu38pr6	1797	8	gene	gene	NN
cord-005478-5iu38pr6	1797	9	-	-	HYPH
cord-005478-5iu38pr6	1797	10	modified	modify	VBN
cord-005478-5iu38pr6	1797	11	cells	cell	NNS
cord-005478-5iu38pr6	1797	12	,	,	,
cord-005478-5iu38pr6	1797	13	manufactured	manufacture	VBN
cord-005478-5iu38pr6	1797	14	on	on	IN
cord-005478-5iu38pr6	1797	15	-	-	HYPH
cord-005478-5iu38pr6	1797	16	site	site	NN
cord-005478-5iu38pr6	1797	17	,	,	,
cord-005478-5iu38pr6	1797	18	were	be	VBD
cord-005478-5iu38pr6	1797	19	administered	administer	VBN
cord-005478-5iu38pr6	1797	20	intravenously	intravenously	RB
cord-005478-5iu38pr6	1797	21	.	.	.
cord-005478-5iu38pr6	1798	1	Primary	primary	JJ
cord-005478-5iu38pr6	1798	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	1798	3	were	be	VBD
cord-005478-5iu38pr6	1798	4	efficacy	efficacy	NN
cord-005478-5iu38pr6	1798	5	,	,	,
cord-005478-5iu38pr6	1798	6	as	as	IN
cord-005478-5iu38pr6	1798	7	determined	determine	VBN
cord-005478-5iu38pr6	1798	8	by	by	IN
cord-005478-5iu38pr6	1798	9	percent	percent	NN
cord-005478-5iu38pr6	1798	10	of	of	IN
cord-005478-5iu38pr6	1798	11	oxidase	oxidase	NN
cord-005478-5iu38pr6	1798	12	positive	positive	JJ
cord-005478-5iu38pr6	1798	13	granulocytes	granulocyte	NNS
cord-005478-5iu38pr6	1798	14	by	by	IN
cord-005478-5iu38pr6	1798	15	dihydrorhodamine	dihydrorhodamine	NN
cord-005478-5iu38pr6	1798	16	[	[	-LRB-
cord-005478-5iu38pr6	1798	17	DHR	DHR	NNP
cord-005478-5iu38pr6	1798	18	]	]	-RRB-
cord-005478-5iu38pr6	1798	19	flow	flow	NN
cord-005478-5iu38pr6	1798	20	cytometry	cytometry	NN
cord-005478-5iu38pr6	1798	21	,	,	,
cord-005478-5iu38pr6	1798	22	and	and	CC
cord-005478-5iu38pr6	1798	23	safety	safety	NN
cord-005478-5iu38pr6	1798	24	at	at	IN
cord-005478-5iu38pr6	1798	25	12	12	CD
cord-005478-5iu38pr6	1798	26	months	month	NNS
cord-005478-5iu38pr6	1798	27	.	.	.
cord-005478-5iu38pr6	1799	1	Results	result	NNS
cord-005478-5iu38pr6	1799	2	:	:	:
cord-005478-5iu38pr6	1800	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1800	2	report	report	VBP
cord-005478-5iu38pr6	1800	3	results	result	NNS
cord-005478-5iu38pr6	1800	4	for	for	IN
cord-005478-5iu38pr6	1800	5	7	7	CD
cord-005478-5iu38pr6	1800	6	patients	patient	NNS
cord-005478-5iu38pr6	1800	7	(	(	-LRB-
cord-005478-5iu38pr6	1800	8	2	2	CD
cord-005478-5iu38pr6	1800	9	-	-	SYM
cord-005478-5iu38pr6	1800	10	27	27	CD
cord-005478-5iu38pr6	1800	11	years	year	NNS
cord-005478-5iu38pr6	1800	12	)	)	-RRB-
cord-005478-5iu38pr6	1800	13	with	with	IN
cord-005478-5iu38pr6	1800	14	1	1	CD
cord-005478-5iu38pr6	1800	15	-	-	SYM
cord-005478-5iu38pr6	1800	16	2.5	2.5	CD
cord-005478-5iu38pr6	1800	17	years	year	NNS
cord-005478-5iu38pr6	1800	18	of	of	IN
cord-005478-5iu38pr6	1800	19	follow	follow	NN
cord-005478-5iu38pr6	1800	20	-	-	HYPH
cord-005478-5iu38pr6	1800	21	up	up	NN
cord-005478-5iu38pr6	1800	22	;	;	:
cord-005478-5iu38pr6	1800	23	2	2	CD
cord-005478-5iu38pr6	1800	24	additional	additional	JJ
cord-005478-5iu38pr6	1800	25	patients	patient	NNS
cord-005478-5iu38pr6	1800	26	were	be	VBD
cord-005478-5iu38pr6	1800	27	treated	treat	VBN
cord-005478-5iu38pr6	1800	28	but	but	CC
cord-005478-5iu38pr6	1800	29	died	die	VBD
cord-005478-5iu38pr6	1800	30	within	within	IN
cord-005478-5iu38pr6	1800	31	3	3	CD
cord-005478-5iu38pr6	1800	32	months	month	NNS
cord-005478-5iu38pr6	1800	33	of	of	IN
cord-005478-5iu38pr6	1800	34	GT	GT	NNP
cord-005478-5iu38pr6	1800	35	from	from	IN
cord-005478-5iu38pr6	1800	36	complications	complication	NNS
cord-005478-5iu38pr6	1800	37	deemed	deem	VBD
cord-005478-5iu38pr6	1800	38	related	related	JJ
cord-005478-5iu38pr6	1800	39	to	to	IN
cord-005478-5iu38pr6	1800	40	pre	pre	VB
cord-005478-5iu38pr6	1800	41	-	-	JJ
cord-005478-5iu38pr6	1800	42	existing	existing	JJ
cord-005478-5iu38pr6	1800	43	disease	disease	NN
cord-005478-5iu38pr6	1800	44	-	-	HYPH
cord-005478-5iu38pr6	1800	45	related	relate	VBN
cord-005478-5iu38pr6	1800	46	co	co	NNS
cord-005478-5iu38pr6	1800	47	-	-	NNS
cord-005478-5iu38pr6	1800	48	morbidities	morbidities	JJ
cord-005478-5iu38pr6	1800	49	(	(	-LRB-
cord-005478-5iu38pr6	1800	50	severe	severe	JJ
cord-005478-5iu38pr6	1800	51	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1800	52	disease	disease	NN
cord-005478-5iu38pr6	1800	53	,	,	,
cord-005478-5iu38pr6	1800	54	anti	anti	JJ
cord-005478-5iu38pr6	1800	55	-	-	JJ
cord-005478-5iu38pr6	1800	56	platelet	platelet	JJ
cord-005478-5iu38pr6	1800	57	antibodies	antibody	NNS
cord-005478-5iu38pr6	1800	58	)	)	-RRB-
cord-005478-5iu38pr6	1800	59	.	.	.
cord-005478-5iu38pr6	1801	1	GT	GT	NNP
cord-005478-5iu38pr6	1801	2	was	be	VBD
cord-005478-5iu38pr6	1801	3	welltolerated	welltolerate	VBN
cord-005478-5iu38pr6	1801	4	,	,	,
cord-005478-5iu38pr6	1801	5	only	only	RB
cord-005478-5iu38pr6	1801	6	one	one	CD
cord-005478-5iu38pr6	1801	7	serious	serious	JJ
cord-005478-5iu38pr6	1801	8	adverse	adverse	JJ
cord-005478-5iu38pr6	1801	9	reaction	reaction	NN
cord-005478-5iu38pr6	1801	10	(	(	-LRB-
cord-005478-5iu38pr6	1801	11	a	a	DT
cord-005478-5iu38pr6	1801	12	systemic	systemic	JJ
cord-005478-5iu38pr6	1801	13	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	1801	14	process	process	NN
cord-005478-5iu38pr6	1801	15	at	at	IN
cord-005478-5iu38pr6	1801	16	engraftment	engraftment	NN
cord-005478-5iu38pr6	1801	17	of	of	IN
cord-005478-5iu38pr6	1801	18	functional	functional	JJ
cord-005478-5iu38pr6	1801	19	neutrophils	neutrophil	NNS
cord-005478-5iu38pr6	1801	20	)	)	-RRB-
cord-005478-5iu38pr6	1801	21	was	be	VBD
cord-005478-5iu38pr6	1801	22	reported	report	VBN
cord-005478-5iu38pr6	1801	23	as	as	RB
cord-005478-5iu38pr6	1801	24	possibly	possibly	RB
cord-005478-5iu38pr6	1801	25	related	relate	VBN
cord-005478-5iu38pr6	1801	26	to	to	IN
cord-005478-5iu38pr6	1801	27	GT	GT	NNP
cord-005478-5iu38pr6	1801	28	.	.	.
cord-005478-5iu38pr6	1802	1	Patients	patient	NNS
cord-005478-5iu38pr6	1802	2	experienced	experience	VBD
cord-005478-5iu38pr6	1802	3	typical	typical	JJ
cord-005478-5iu38pr6	1802	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	1802	5	-	-	HYPH
cord-005478-5iu38pr6	1802	6	related	relate	VBN
cord-005478-5iu38pr6	1802	7	transient	transient	JJ
cord-005478-5iu38pr6	1802	8	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	1802	9	,	,	,
cord-005478-5iu38pr6	1802	10	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	1802	11	and	and	CC
cord-005478-5iu38pr6	1802	12	mucositis	mucositis	NNP
cord-005478-5iu38pr6	1802	13	.	.	.
cord-005478-5iu38pr6	1803	1	There	there	EX
cord-005478-5iu38pr6	1803	2	has	have	VBZ
cord-005478-5iu38pr6	1803	3	been	be	VBN
cord-005478-5iu38pr6	1803	4	no	no	DT
cord-005478-5iu38pr6	1803	5	molecular	molecular	JJ
cord-005478-5iu38pr6	1803	6	evidence	evidence	NN
cord-005478-5iu38pr6	1803	7	for	for	IN
cord-005478-5iu38pr6	1803	8	clonal	clonal	JJ
cord-005478-5iu38pr6	1803	9	dysregulation	dysregulation	NN
cord-005478-5iu38pr6	1803	10	or	or	CC
cord-005478-5iu38pr6	1803	11	gene	gene	NN
cord-005478-5iu38pr6	1803	12	silencing	silence	VBG
cord-005478-5iu38pr6	1803	13	through	through	IN
cord-005478-5iu38pr6	1803	14	CpG	CpG	NNP
cord-005478-5iu38pr6	1803	15	dinucleotide	dinucleotide	NNP
cord-005478-5iu38pr6	1803	16	methylation	methylation	NNP
cord-005478-5iu38pr6	1803	17	.	.	.
cord-005478-5iu38pr6	1804	1	Followup	Followup	NNP
cord-005478-5iu38pr6	1804	2	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	1804	3	sustained	sustain	VBD
cord-005478-5iu38pr6	1804	4	stable	stable	JJ
cord-005478-5iu38pr6	1804	5	persistence	persistence	NN
cord-005478-5iu38pr6	1804	6	of	of	IN
cord-005478-5iu38pr6	1804	7	12	12	CD
cord-005478-5iu38pr6	1804	8	-	-	SYM
cord-005478-5iu38pr6	1804	9	46	46	CD
cord-005478-5iu38pr6	1804	10	%	%	NN
cord-005478-5iu38pr6	1804	11	oxidase	oxidase	NN
cord-005478-5iu38pr6	1804	12	(	(	-LRB-
cord-005478-5iu38pr6	1804	13	+	+	NN
cord-005478-5iu38pr6	1804	14	)	)	-RRB-
cord-005478-5iu38pr6	1804	15	neutrophils	neutrophil	NNS
cord-005478-5iu38pr6	1804	16	for	for	IN
cord-005478-5iu38pr6	1804	17	>	>	$
cord-005478-5iu38pr6	1804	18	12	12	CD
cord-005478-5iu38pr6	1804	19	months	month	NNS
cord-005478-5iu38pr6	1804	20	in	in	IN
cord-005478-5iu38pr6	1804	21	6/7	6/7	CD
cord-005478-5iu38pr6	1804	22	surviving	survive	VBG
cord-005478-5iu38pr6	1804	23	patients	patient	NNS
cord-005478-5iu38pr6	1804	24	(	(	-LRB-
cord-005478-5iu38pr6	1804	25	one	one	CD
cord-005478-5iu38pr6	1804	26	,	,	,
cord-005478-5iu38pr6	1804	27	who	who	WP
cord-005478-5iu38pr6	1804	28	remains	remain	VBZ
cord-005478-5iu38pr6	1804	29	clinically	clinically	RB
cord-005478-5iu38pr6	1804	30	well	well	RB
cord-005478-5iu38pr6	1804	31	,	,	,
cord-005478-5iu38pr6	1804	32	had	have	VBD
cord-005478-5iu38pr6	1804	33	a	a	DT
cord-005478-5iu38pr6	1804	34	decline	decline	NN
cord-005478-5iu38pr6	1804	35	to	to	IN
cord-005478-5iu38pr6	1804	36	<	<	XX
cord-005478-5iu38pr6	1804	37	5	5	CD
cord-005478-5iu38pr6	1804	38	%	%	NN
cord-005478-5iu38pr6	1804	39	after	after	IN
cord-005478-5iu38pr6	1804	40	3	3	CD
cord-005478-5iu38pr6	1804	41	months	month	NNS
cord-005478-5iu38pr6	1804	42	)	)	-RRB-
cord-005478-5iu38pr6	1805	1	[	[	-LRB-
cord-005478-5iu38pr6	1805	2	Figure	figure	NN
cord-005478-5iu38pr6	1805	3	]	]	-RRB-
cord-005478-5iu38pr6	1805	4	.	.	.
cord-005478-5iu38pr6	1806	1	These	these	DT
cord-005478-5iu38pr6	1806	2	patients	patient	NNS
cord-005478-5iu38pr6	1806	3	have	have	VBP
cord-005478-5iu38pr6	1806	4	maintained	maintain	VBN
cord-005478-5iu38pr6	1806	5	restoration	restoration	NN
cord-005478-5iu38pr6	1806	6	of	of	IN
cord-005478-5iu38pr6	1806	7	biochemical	biochemical	JJ
cord-005478-5iu38pr6	1806	8	function	function	NN
cord-005478-5iu38pr6	1806	9	and	and	CC
cord-005478-5iu38pr6	1806	10	immunity	immunity	NN
cord-005478-5iu38pr6	1806	11	(	(	-LRB-
cord-005478-5iu38pr6	1806	12	defined	define	VBN
cord-005478-5iu38pr6	1806	13	as	as	IN
cord-005478-5iu38pr6	1806	14	≥10	≥10	NNP
cord-005478-5iu38pr6	1806	15	%	%	NN
cord-005478-5iu38pr6	1806	16	of	of	IN
cord-005478-5iu38pr6	1806	17	oxidase	oxidase	NN
cord-005478-5iu38pr6	1806	18	(	(	-LRB-
cord-005478-5iu38pr6	1806	19	+	+	NN
cord-005478-5iu38pr6	1806	20	)	)	-RRB-
cord-005478-5iu38pr6	1806	21	by	by	IN
cord-005478-5iu38pr6	1806	22	DHR	DHR	NNP
cord-005478-5iu38pr6	1806	23	)	)	-RRB-
cord-005478-5iu38pr6	1806	24	as	as	IN
cord-005478-5iu38pr6	1806	25	of	of	IN
cord-005478-5iu38pr6	1806	26	December	December	NNP
cord-005478-5iu38pr6	1806	27	2018	2018	CD
cord-005478-5iu38pr6	1806	28	.	.	.
cord-005478-5iu38pr6	1807	1	Patients	patient	NNS
cord-005478-5iu38pr6	1807	2	have	have	VBP
cord-005478-5iu38pr6	1807	3	been	be	VBN
cord-005478-5iu38pr6	1807	4	well	well	JJ
cord-005478-5iu38pr6	1807	5	,	,	,
cord-005478-5iu38pr6	1807	6	without	without	IN
cord-005478-5iu38pr6	1807	7	new	new	JJ
cord-005478-5iu38pr6	1807	8	X	X	NNP
cord-005478-5iu38pr6	1807	9	-	-	NN
cord-005478-5iu38pr6	1807	10	CGD	CGD	NNP
cord-005478-5iu38pr6	1807	11	-	-	HYPH
cord-005478-5iu38pr6	1807	12	related	relate	VBN
cord-005478-5iu38pr6	1807	13	infections	infection	NNS
cord-005478-5iu38pr6	1807	14	,	,	,
cord-005478-5iu38pr6	1807	15	and	and	CC
cord-005478-5iu38pr6	1807	16	4	4	CD
cord-005478-5iu38pr6	1807	17	are	be	VBP
cord-005478-5iu38pr6	1807	18	successfully	successfully	RB
cord-005478-5iu38pr6	1807	19	weaned	wean	VBN
cord-005478-5iu38pr6	1807	20	off	off	RP
cord-005478-5iu38pr6	1807	21	prophylactic	prophylactic	JJ
cord-005478-5iu38pr6	1807	22	antibiotics	antibiotic	NNS
cord-005478-5iu38pr6	1807	23	.	.	.
cord-005478-5iu38pr6	1808	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1808	2	:	:	:
cord-005478-5iu38pr6	1809	1	These	these	DT
cord-005478-5iu38pr6	1809	2	results	result	NNS
cord-005478-5iu38pr6	1809	3	are	be	VBP
cord-005478-5iu38pr6	1809	4	the	the	DT
cord-005478-5iu38pr6	1809	5	first	first	JJ
cord-005478-5iu38pr6	1809	6	demonstration	demonstration	NN
cord-005478-5iu38pr6	1809	7	of	of	IN
cord-005478-5iu38pr6	1809	8	effective	effective	JJ
cord-005478-5iu38pr6	1809	9	autologous	autologous	JJ
cord-005478-5iu38pr6	1809	10	lentiviral	lentiviral	NN
cord-005478-5iu38pr6	1809	11	GT	gt	NN
cord-005478-5iu38pr6	1809	12	at	at	IN
cord-005478-5iu38pr6	1809	13	12	12	CD
cord-005478-5iu38pr6	1809	14	months	month	NNS
cord-005478-5iu38pr6	1809	15	in	in	IN
cord-005478-5iu38pr6	1809	16	severely	severely	RB
cord-005478-5iu38pr6	1809	17	affected	affect	VBN
cord-005478-5iu38pr6	1809	18	X	X	NNP
cord-005478-5iu38pr6	1809	19	-	-	NN
cord-005478-5iu38pr6	1809	20	CGD	CGD	NNP
cord-005478-5iu38pr6	1809	21	patients	patient	NNS
cord-005478-5iu38pr6	1809	22	without	without	IN
cord-005478-5iu38pr6	1809	23	evidence	evidence	NN
cord-005478-5iu38pr6	1809	24	of	of	IN
cord-005478-5iu38pr6	1809	25	genotoxicity	genotoxicity	NN
cord-005478-5iu38pr6	1809	26	.	.	.
cord-005478-5iu38pr6	1810	1	Corrected	correct	VBN
cord-005478-5iu38pr6	1810	2	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1810	3	function	function	NN
cord-005478-5iu38pr6	1810	4	has	have	VBZ
cord-005478-5iu38pr6	1810	5	been	be	VBN
cord-005478-5iu38pr6	1810	6	observed	observe	VBN
cord-005478-5iu38pr6	1810	7	in	in	IN
cord-005478-5iu38pr6	1810	8	6	6	CD
cord-005478-5iu38pr6	1810	9	patients	patient	NNS
cord-005478-5iu38pr6	1810	10	for	for	IN
cord-005478-5iu38pr6	1810	11	>	>	$
cord-005478-5iu38pr6	1810	12	12	12	CD
cord-005478-5iu38pr6	1810	13	months	month	NNS
cord-005478-5iu38pr6	1810	14	and	and	CC
cord-005478-5iu38pr6	1810	15	has	have	VBZ
cord-005478-5iu38pr6	1810	16	been	be	VBN
cord-005478-5iu38pr6	1810	17	associated	associate	VBN
cord-005478-5iu38pr6	1810	18	with	with	IN
cord-005478-5iu38pr6	1810	19	significant	significant	JJ
cord-005478-5iu38pr6	1810	20	clinical	clinical	JJ
cord-005478-5iu38pr6	1810	21	improvement	improvement	NN
cord-005478-5iu38pr6	1810	22	,	,	,
cord-005478-5iu38pr6	1810	23	freedom	freedom	NN
cord-005478-5iu38pr6	1810	24	from	from	IN
cord-005478-5iu38pr6	1810	25	infections	infection	NNS
cord-005478-5iu38pr6	1810	26	,	,	,
cord-005478-5iu38pr6	1810	27	and	and	CC
cord-005478-5iu38pr6	1810	28	resolution	resolution	NN
cord-005478-5iu38pr6	1810	29	of	of	IN
cord-005478-5iu38pr6	1810	30	chronic	chronic	JJ
cord-005478-5iu38pr6	1810	31	inflammation	inflammation	NN
cord-005478-5iu38pr6	1810	32	.	.	.
cord-005478-5iu38pr6	1811	1	Results	result	NNS
cord-005478-5iu38pr6	1811	2	are	be	VBP
cord-005478-5iu38pr6	1811	3	supportive	supportive	JJ
cord-005478-5iu38pr6	1811	4	of	of	IN
cord-005478-5iu38pr6	1811	5	extended	extended	JJ
cord-005478-5iu38pr6	1811	6	clinical	clinical	JJ
cord-005478-5iu38pr6	1811	7	trials	trial	NNS
cord-005478-5iu38pr6	1811	8	evaluating	evaluate	VBG
cord-005478-5iu38pr6	1811	9	the	the	DT
cord-005478-5iu38pr6	1811	10	safety	safety	NN
cord-005478-5iu38pr6	1811	11	and	and	CC
cord-005478-5iu38pr6	1811	12	efficacy	efficacy	NN
cord-005478-5iu38pr6	1811	13	of	of	IN
cord-005478-5iu38pr6	1811	14	G1XCGD	G1XCGD	NNP
cord-005478-5iu38pr6	1811	15	LV	LV	NNP
cord-005478-5iu38pr6	1811	16	-	-	HYPH
cord-005478-5iu38pr6	1811	17	based	base	VBN
cord-005478-5iu38pr6	1811	18	gene	gene	NN
cord-005478-5iu38pr6	1811	19	therapy	therapy	NN
cord-005478-5iu38pr6	1811	20	.	.	.
cord-005478-5iu38pr6	1811	21	 	 	_SP
cord-005478-5iu38pr6	1812	1	Updated	update	VBN
cord-005478-5iu38pr6	1812	2	results	result	NNS
cord-005478-5iu38pr6	1812	3	from	from	IN
cord-005478-5iu38pr6	1812	4	the	the	DT
cord-005478-5iu38pr6	1812	5	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1812	6	northstar-2	northstar-2	NNP
cord-005478-5iu38pr6	1812	7	(	(	-LRB-
cord-005478-5iu38pr6	1812	8	HGB-207	HGB-207	NNP
cord-005478-5iu38pr6	1812	9	)	)	-RRB-
cord-005478-5iu38pr6	1812	10	trial	trial	NN
cord-005478-5iu38pr6	1812	11	of	of	IN
cord-005478-5iu38pr6	1812	12	lentiglobin	lentiglobin	NNP
cord-005478-5iu38pr6	1812	13	gene	gene	NNP
cord-005478-5iu38pr6	1812	14	therapy	therapy	NN
cord-005478-5iu38pr6	1812	15	in	in	IN
cord-005478-5iu38pr6	1812	16	patients	patient	NNS
cord-005478-5iu38pr6	1812	17	with	with	IN
cord-005478-5iu38pr6	1812	18	transfusion	transfusion	NN
cord-005478-5iu38pr6	1812	19	-	-	HYPH
cord-005478-5iu38pr6	1812	20	dependent	dependent	JJ
cord-005478-5iu38pr6	1812	21	β	β	NN
cord-005478-5iu38pr6	1812	22	-	-	HYPH
cord-005478-5iu38pr6	1812	23	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	1812	24	and	and	CC
cord-005478-5iu38pr6	1812	25	non	non	NNS
cord-005478-5iu38pr6	1812	26	-	-	JJ
cord-005478-5iu38pr6	1812	27	β	β	JJ
cord-005478-5iu38pr6	1812	28	0	0	CD
cord-005478-5iu38pr6	1812	29	/β	/β	NN
cord-005478-5iu38pr6	1812	30	0	0	NFP
cord-005478-5iu38pr6	1812	31	genotypes	genotype	NNS
cord-005478-5iu38pr6	1812	32	Franco	Franco	NNP
cord-005478-5iu38pr6	1812	33	Locatelli	Locatelli	NNP
cord-005478-5iu38pr6	1812	34	1	1	CD
cord-005478-5iu38pr6	1812	35	,	,	,
cord-005478-5iu38pr6	1812	36	Alexis	Alexis	NNP
cord-005478-5iu38pr6	1812	37	Thompson	Thompson	NNP
cord-005478-5iu38pr6	1812	38	2,3	2,3	CD
cord-005478-5iu38pr6	1812	39	,	,	,
cord-005478-5iu38pr6	1813	1	Janet	Janet	NNP
cord-005478-5iu38pr6	1813	2	Kwiatkowski	Kwiatkowski	NNP
cord-005478-5iu38pr6	1813	3	4,5	4,5	CD
cord-005478-5iu38pr6	1813	4	,	,	,
cord-005478-5iu38pr6	1813	5	Suradej	Suradej	NNP
cord-005478-5iu38pr6	1813	6	Hongeng	Hongeng	NNP
cord-005478-5iu38pr6	1813	7	6	6	CD
cord-005478-5iu38pr6	1813	8	,	,	,
cord-005478-5iu38pr6	1813	9	John	John	NNP
cord-005478-5iu38pr6	1813	10	Porter	Porter	NNP
cord-005478-5iu38pr6	1813	11	7	7	CD
cord-005478-5iu38pr6	1813	12	,	,	,
cord-005478-5iu38pr6	1813	13	Martin	Martin	NNP
cord-005478-5iu38pr6	1813	14	Sauer	Sauer	NNP
cord-005478-5iu38pr6	1813	15	8	8	CD
cord-005478-5iu38pr6	1813	16	,	,	,
cord-005478-5iu38pr6	1813	17	Adrian	Adrian	NNP
cord-005478-5iu38pr6	1813	18	Thrasher	Thrasher	NNP
cord-005478-5iu38pr6	1813	19	9	9	CD
cord-005478-5iu38pr6	1813	20	,	,	,
cord-005478-5iu38pr6	1814	1	Isabelle	Isabelle	NNP
cord-005478-5iu38pr6	1814	2	Thuret	Thuret	NNP
cord-005478-5iu38pr6	1814	3	10	10	CD
cord-005478-5iu38pr6	1814	4	,	,	,
cord-005478-5iu38pr6	1814	5	Heidi	Heidi	NNP
cord-005478-5iu38pr6	1814	6	Elliot	Elliot	NNP
cord-005478-5iu38pr6	1814	7	11	11	CD
cord-005478-5iu38pr6	1815	1	,	,	,
cord-005478-5iu38pr6	1815	2	Ge	Ge	NNP
cord-005478-5iu38pr6	1815	3	Tao	Tao	NNP
cord-005478-5iu38pr6	1815	4	Background	Background	NNP
cord-005478-5iu38pr6	1815	5	:	:	:
cord-005478-5iu38pr6	1816	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	1816	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1816	3	stem	stem	NN
cord-005478-5iu38pr6	1816	4	cell	cell	NN
cord-005478-5iu38pr6	1816	5	(	(	-LRB-
cord-005478-5iu38pr6	1816	6	HSC	HSC	NNP
cord-005478-5iu38pr6	1816	7	)	)	-RRB-
cord-005478-5iu38pr6	1816	8	transplantation	transplantation	NN
cord-005478-5iu38pr6	1816	9	is	be	VBZ
cord-005478-5iu38pr6	1816	10	potentially	potentially	RB
cord-005478-5iu38pr6	1816	11	curative	curative	JJ
cord-005478-5iu38pr6	1816	12	for	for	IN
cord-005478-5iu38pr6	1816	13	patients	patient	NNS
cord-005478-5iu38pr6	1816	14	with	with	IN
cord-005478-5iu38pr6	1816	15	transfusion	transfusion	NN
cord-005478-5iu38pr6	1816	16	dependent	dependent	JJ
cord-005478-5iu38pr6	1816	17	β	β	NN
cord-005478-5iu38pr6	1816	18	-	-	HYPH
cord-005478-5iu38pr6	1816	19	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	1816	20	(	(	-LRB-
cord-005478-5iu38pr6	1816	21	TDT	TDT	NNP
cord-005478-5iu38pr6	1816	22	)	)	-RRB-
cord-005478-5iu38pr6	1816	23	;	;	:
cord-005478-5iu38pr6	1816	24	however	however	RB
cord-005478-5iu38pr6	1816	25	,	,	,
cord-005478-5iu38pr6	1816	26	it	-PRON-	PRP
cord-005478-5iu38pr6	1816	27	is	be	VBZ
cord-005478-5iu38pr6	1816	28	associated	associate	VBN
cord-005478-5iu38pr6	1816	29	with	with	IN
cord-005478-5iu38pr6	1816	30	risks	risk	NNS
cord-005478-5iu38pr6	1816	31	of	of	IN
cord-005478-5iu38pr6	1816	32	morbidity	morbidity	NN
cord-005478-5iu38pr6	1816	33	and	and	CC
cord-005478-5iu38pr6	1816	34	mortality	mortality	NN
cord-005478-5iu38pr6	1816	35	and	and	CC
cord-005478-5iu38pr6	1816	36	is	be	VBZ
cord-005478-5iu38pr6	1816	37	limited	limit	VBN
cord-005478-5iu38pr6	1816	38	by	by	IN
cord-005478-5iu38pr6	1816	39	donor	donor	NN
cord-005478-5iu38pr6	1816	40	availability	availability	NN
cord-005478-5iu38pr6	1816	41	.	.	.
cord-005478-5iu38pr6	1817	1	Gene	gene	NN
cord-005478-5iu38pr6	1817	2	therapy	therapy	NN
cord-005478-5iu38pr6	1817	3	has	have	VBZ
cord-005478-5iu38pr6	1817	4	the	the	DT
cord-005478-5iu38pr6	1817	5	potential	potential	NN
cord-005478-5iu38pr6	1817	6	to	to	TO
cord-005478-5iu38pr6	1817	7	be	be	VB
cord-005478-5iu38pr6	1817	8	an	an	DT
cord-005478-5iu38pr6	1817	9	effective	effective	JJ
cord-005478-5iu38pr6	1817	10	treatment	treatment	NN
cord-005478-5iu38pr6	1817	11	option	option	NN
cord-005478-5iu38pr6	1817	12	for	for	IN
cord-005478-5iu38pr6	1817	13	patients	patient	NNS
cord-005478-5iu38pr6	1817	14	with	with	IN
cord-005478-5iu38pr6	1817	15	TDT	TDT	NNP
cord-005478-5iu38pr6	1817	16	,	,	,
cord-005478-5iu38pr6	1817	17	but	but	CC
cord-005478-5iu38pr6	1817	18	without	without	IN
cord-005478-5iu38pr6	1817	19	some	some	DT
cord-005478-5iu38pr6	1817	20	of	of	IN
cord-005478-5iu38pr6	1817	21	these	these	DT
cord-005478-5iu38pr6	1817	22	limitations	limitation	NNS
cord-005478-5iu38pr6	1817	23	.	.	.
cord-005478-5iu38pr6	1818	1	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1818	2	gene	gene	NN
cord-005478-5iu38pr6	1818	3	therapy	therapy	NN
cord-005478-5iu38pr6	1818	4	contains	contain	VBZ
cord-005478-5iu38pr6	1818	5	autologous	autologous	JJ
cord-005478-5iu38pr6	1818	6	CD34	CD34	NNP
cord-005478-5iu38pr6	1819	1	+	+	CC
cord-005478-5iu38pr6	1819	2	HSCs	hscs	NN
cord-005478-5iu38pr6	1819	3	transduced	transduce	VBD
cord-005478-5iu38pr6	1819	4	ex	ex	NN
cord-005478-5iu38pr6	1819	5	vivo	vivo	NN
cord-005478-5iu38pr6	1819	6	with	with	IN
cord-005478-5iu38pr6	1819	7	the	the	DT
cord-005478-5iu38pr6	1819	8	BB305	BB305	NNP
cord-005478-5iu38pr6	1819	9	lentiviral	lentiviral	NN
cord-005478-5iu38pr6	1819	10	vector	vector	NN
cord-005478-5iu38pr6	1819	11	encoding	encode	VBG
cord-005478-5iu38pr6	1819	12	β	β	NN
cord-005478-5iu38pr6	1819	13	-	-	HYPH
cord-005478-5iu38pr6	1819	14	globin	globin	NN
cord-005478-5iu38pr6	1819	15	with	with	IN
cord-005478-5iu38pr6	1819	16	the	the	DT
cord-005478-5iu38pr6	1819	17	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1819	18	amino	amino	NN
cord-005478-5iu38pr6	1819	19	-	-	HYPH
cord-005478-5iu38pr6	1819	20	acid	acid	NN
cord-005478-5iu38pr6	1819	21	substitution	substitution	NN
cord-005478-5iu38pr6	1819	22	.	.	.
cord-005478-5iu38pr6	1820	1	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1820	2	is	be	VBZ
cord-005478-5iu38pr6	1820	3	being	be	VBG
cord-005478-5iu38pr6	1820	4	studied	study	VBN
cord-005478-5iu38pr6	1820	5	in	in	IN
cord-005478-5iu38pr6	1820	6	patients	patient	NNS
cord-005478-5iu38pr6	1820	7	with	with	IN
cord-005478-5iu38pr6	1820	8	TDT	TDT	NNP
cord-005478-5iu38pr6	1820	9	and	and	CC
cord-005478-5iu38pr6	1820	10	non	non	NNS
cord-005478-5iu38pr6	1820	11	-	-	JJ
cord-005478-5iu38pr6	1820	12	β	β	JJ
cord-005478-5iu38pr6	1820	13	0	0	CD
cord-005478-5iu38pr6	1820	14	/β	/β	NN
cord-005478-5iu38pr6	1820	15	0	0	NFP
cord-005478-5iu38pr6	1820	16	genotypes	genotype	NNS
cord-005478-5iu38pr6	1820	17	in	in	IN
cord-005478-5iu38pr6	1820	18	the	the	DT
cord-005478-5iu38pr6	1820	19	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1820	20	,	,	,
cord-005478-5iu38pr6	1820	21	phase	phase	NN
cord-005478-5iu38pr6	1820	22	3	3	CD
cord-005478-5iu38pr6	1820	23	Northstar-2	Northstar-2	NNP
cord-005478-5iu38pr6	1820	24	study	study	NN
cord-005478-5iu38pr6	1820	25	(	(	-LRB-
cord-005478-5iu38pr6	1820	26	HGB-207	HGB-207	NNP
cord-005478-5iu38pr6	1820	27	;	;	:
cord-005478-5iu38pr6	1820	28	NCT02906202	NCT02906202	NNP
cord-005478-5iu38pr6	1820	29	)	)	-RRB-
cord-005478-5iu38pr6	1820	30	.	.	.
cord-005478-5iu38pr6	1821	1	Methods	method	NNS
cord-005478-5iu38pr6	1821	2	:	:	:
cord-005478-5iu38pr6	1821	3	Northstar-2	Northstar-2	NNP
cord-005478-5iu38pr6	1821	4	is	be	VBZ
cord-005478-5iu38pr6	1821	5	enrolling	enrol	VBG
cord-005478-5iu38pr6	1821	6	patients	patient	NNS
cord-005478-5iu38pr6	1821	7	with	with	IN
cord-005478-5iu38pr6	1821	8	TDT	TDT	NNP
cord-005478-5iu38pr6	1821	9	who	who	WP
cord-005478-5iu38pr6	1821	10	had	have	VBD
cord-005478-5iu38pr6	1821	11	a	a	DT
cord-005478-5iu38pr6	1821	12	history	history	NN
cord-005478-5iu38pr6	1821	13	of	of	IN
cord-005478-5iu38pr6	1821	14	≥100	≥100	CD
cord-005478-5iu38pr6	1821	15	mL	ml	NN
cord-005478-5iu38pr6	1821	16	/	/	SYM
cord-005478-5iu38pr6	1821	17	kg	kg	NN
cord-005478-5iu38pr6	1821	18	/	/	SYM
cord-005478-5iu38pr6	1821	19	year	year	NN
cord-005478-5iu38pr6	1821	20	of	of	IN
cord-005478-5iu38pr6	1821	21	red	red	JJ
cord-005478-5iu38pr6	1821	22	blood	blood	NN
cord-005478-5iu38pr6	1821	23	cells	cell	NNS
cord-005478-5iu38pr6	1821	24	(	(	-LRB-
cord-005478-5iu38pr6	1821	25	RBCs	rbc	NNS
cord-005478-5iu38pr6	1821	26	)	)	-RRB-
cord-005478-5iu38pr6	1821	27	or	or	CC
cord-005478-5iu38pr6	1821	28	≥8	≥8	NNP
cord-005478-5iu38pr6	1821	29	RBC	RBC	NNP
cord-005478-5iu38pr6	1821	30	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1821	31	/	/	SYM
cord-005478-5iu38pr6	1821	32	year	year	NN
cord-005478-5iu38pr6	1821	33	.	.	.
cord-005478-5iu38pr6	1822	1	To	to	TO
cord-005478-5iu38pr6	1822	2	generate	generate	VB
cord-005478-5iu38pr6	1822	3	drug	drug	NN
cord-005478-5iu38pr6	1822	4	product	product	NN
cord-005478-5iu38pr6	1822	5	(	(	-LRB-
cord-005478-5iu38pr6	1822	6	DP	DP	NNP
cord-005478-5iu38pr6	1822	7	)	)	-RRB-
cord-005478-5iu38pr6	1822	8	,	,	,
cord-005478-5iu38pr6	1822	9	autologous	autologous	JJ
cord-005478-5iu38pr6	1822	10	CD34	CD34	NNP
cord-005478-5iu38pr6	1822	11	+	+	CC
cord-005478-5iu38pr6	1822	12	cells	cell	NNS
cord-005478-5iu38pr6	1822	13	were	be	VBD
cord-005478-5iu38pr6	1822	14	collected	collect	VBN
cord-005478-5iu38pr6	1822	15	by	by	IN
cord-005478-5iu38pr6	1822	16	apheresis	apheresis	NN
cord-005478-5iu38pr6	1822	17	after	after	IN
cord-005478-5iu38pr6	1822	18	G	G	NNP
cord-005478-5iu38pr6	1822	19	-	-	HYPH
cord-005478-5iu38pr6	1822	20	CSF	CSF	NNP
cord-005478-5iu38pr6	1822	21	and	and	CC
cord-005478-5iu38pr6	1822	22	plerixafor	plerixafor	NN
cord-005478-5iu38pr6	1822	23	mobilization	mobilization	NN
cord-005478-5iu38pr6	1822	24	and	and	CC
cord-005478-5iu38pr6	1822	25	transduced	transduce	VBN
cord-005478-5iu38pr6	1822	26	with	with	IN
cord-005478-5iu38pr6	1822	27	the	the	DT
cord-005478-5iu38pr6	1822	28	BB305	BB305	NNP
cord-005478-5iu38pr6	1822	29	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	1822	30	vector	vector	NN
cord-005478-5iu38pr6	1822	31	.	.	.
cord-005478-5iu38pr6	1823	1	Patients	patient	NNS
cord-005478-5iu38pr6	1823	2	received	receive	VBD
cord-005478-5iu38pr6	1823	3	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1823	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	1823	5	with	with	IN
cord-005478-5iu38pr6	1823	6	single	single	JJ
cord-005478-5iu38pr6	1823	7	-	-	HYPH
cord-005478-5iu38pr6	1823	8	agent	agent	NN
cord-005478-5iu38pr6	1823	9	busulfan	busulfan	NN
cord-005478-5iu38pr6	1823	10	before	before	IN
cord-005478-5iu38pr6	1823	11	DP	DP	NNP
cord-005478-5iu38pr6	1823	12	infusion	infusion	NN
cord-005478-5iu38pr6	1823	13	.	.	.
cord-005478-5iu38pr6	1824	1	Primary	primary	JJ
cord-005478-5iu38pr6	1824	2	endpoint	endpoint	NN
cord-005478-5iu38pr6	1824	3	was	be	VBD
cord-005478-5iu38pr6	1824	4	the	the	DT
cord-005478-5iu38pr6	1824	5	proportion	proportion	NN
cord-005478-5iu38pr6	1824	6	of	of	IN
cord-005478-5iu38pr6	1824	7	patients	patient	NNS
cord-005478-5iu38pr6	1824	8	achieving	achieve	VBG
cord-005478-5iu38pr6	1824	9	transfusion	transfusion	NN
cord-005478-5iu38pr6	1824	10	independence	independence	NN
cord-005478-5iu38pr6	1824	11	(	(	-LRB-
cord-005478-5iu38pr6	1824	12	TI	TI	NNP
cord-005478-5iu38pr6	1824	13	,	,	,
cord-005478-5iu38pr6	1824	14	weighted	weighted	JJ
cord-005478-5iu38pr6	1824	15	average	average	JJ
cord-005478-5iu38pr6	1824	16	hemoglobin	hemoglobin	NN
cord-005478-5iu38pr6	1824	17	[	[	-LRB-
cord-005478-5iu38pr6	1824	18	Hb	Hb	NNP
cord-005478-5iu38pr6	1824	19	]	]	-RRB-
cord-005478-5iu38pr6	1824	20	≥	≥	NNP
cord-005478-5iu38pr6	1824	21	9	9	CD
cord-005478-5iu38pr6	1824	22	g	g	NN
cord-005478-5iu38pr6	1824	23	/	/	SYM
cord-005478-5iu38pr6	1824	24	dL	dl	NN
cord-005478-5iu38pr6	1824	25	without	without	IN
cord-005478-5iu38pr6	1824	26	RBC	RBC	NNP
cord-005478-5iu38pr6	1824	27	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1824	28	for	for	IN
cord-005478-5iu38pr6	1824	29	≥	≥	CD
cord-005478-5iu38pr6	1824	30	12	12	CD
cord-005478-5iu38pr6	1824	31	months	month	NNS
cord-005478-5iu38pr6	1824	32	)	)	-RRB-
cord-005478-5iu38pr6	1824	33	.	.	.
cord-005478-5iu38pr6	1825	1	Patients	patient	NNS
cord-005478-5iu38pr6	1825	2	are	be	VBP
cord-005478-5iu38pr6	1825	3	followed	follow	VBN
cord-005478-5iu38pr6	1825	4	for	for	IN
cord-005478-5iu38pr6	1825	5	2	2	CD
cord-005478-5iu38pr6	1825	6	years	year	NNS
cord-005478-5iu38pr6	1825	7	and	and	CC
cord-005478-5iu38pr6	1825	8	offered	offer	VBD
cord-005478-5iu38pr6	1825	9	participation	participation	NN
cord-005478-5iu38pr6	1825	10	in	in	IN
cord-005478-5iu38pr6	1825	11	a	a	DT
cord-005478-5iu38pr6	1825	12	long	long	JJ
cord-005478-5iu38pr6	1825	13	-	-	HYPH
cord-005478-5iu38pr6	1825	14	term	term	NN
cord-005478-5iu38pr6	1825	15	followup	followup	JJ
cord-005478-5iu38pr6	1825	16	study	study	NN
cord-005478-5iu38pr6	1825	17	.	.	.
cord-005478-5iu38pr6	1826	1	Statistics	statistic	NNS
cord-005478-5iu38pr6	1826	2	are	be	VBP
cord-005478-5iu38pr6	1826	3	presented	present	VBN
cord-005478-5iu38pr6	1826	4	as	as	IN
cord-005478-5iu38pr6	1826	5	median	median	JJ
cord-005478-5iu38pr6	1826	6	(	(	-LRB-
cord-005478-5iu38pr6	1826	7	min	min	NNP
cord-005478-5iu38pr6	1826	8	-	-	HYPH
cord-005478-5iu38pr6	1826	9	max	max	NNP
cord-005478-5iu38pr6	1826	10	)	)	-RRB-
cord-005478-5iu38pr6	1826	11	.	.	.
cord-005478-5iu38pr6	1827	1	Results	result	NNS
cord-005478-5iu38pr6	1827	2	:	:	:
cord-005478-5iu38pr6	1828	1	As	as	IN
cord-005478-5iu38pr6	1828	2	of	of	IN
cord-005478-5iu38pr6	1828	3	14	14	CD
cord-005478-5iu38pr6	1828	4	September	September	NNP
cord-005478-5iu38pr6	1828	5	2018	2018	CD
cord-005478-5iu38pr6	1828	6	,	,	,
cord-005478-5iu38pr6	1828	7	16	16	CD
cord-005478-5iu38pr6	1828	8	patients	patient	NNS
cord-005478-5iu38pr6	1828	9	(	(	-LRB-
cord-005478-5iu38pr6	1828	10	age	age	NN
cord-005478-5iu38pr6	1828	11	19	19	CD
cord-005478-5iu38pr6	1828	12	years	year	NNS
cord-005478-5iu38pr6	1828	13	;	;	:
cord-005478-5iu38pr6	1828	14	9	9	CD
cord-005478-5iu38pr6	1828	15	patients	patient	NNS
cord-005478-5iu38pr6	1828	16	≥	≥	CD
cord-005478-5iu38pr6	1828	17	18	18	CD
cord-005478-5iu38pr6	1828	18	years	year	NNS
cord-005478-5iu38pr6	1828	19	)	)	-RRB-
cord-005478-5iu38pr6	1828	20	have	have	VBP
cord-005478-5iu38pr6	1828	21	been	be	VBN
cord-005478-5iu38pr6	1828	22	treated	treat	VBN
cord-005478-5iu38pr6	1828	23	(	(	-LRB-
cord-005478-5iu38pr6	1828	24	follow	follow	VB
cord-005478-5iu38pr6	1828	25	-	-	HYPH
cord-005478-5iu38pr6	1828	26	up	up	NN
cord-005478-5iu38pr6	1828	27	9.3	9.3	CD
cord-005478-5iu38pr6	1828	28	[	[	-LRB-
cord-005478-5iu38pr6	1828	29	0.7	0.7	CD
cord-005478-5iu38pr6	1828	30	-	-	HYPH
cord-005478-5iu38pr6	1828	31	20.4	20.4	CD
cord-005478-5iu38pr6	1828	32	]	]	-RRB-
cord-005478-5iu38pr6	1828	33	months	month	NNS
cord-005478-5iu38pr6	1828	34	)	)	-RRB-
cord-005478-5iu38pr6	1828	35	.	.	.
cord-005478-5iu38pr6	1829	1	Patients	patient	NNS
cord-005478-5iu38pr6	1829	2	received	receive	VBD
cord-005478-5iu38pr6	1829	3	a	a	DT
cord-005478-5iu38pr6	1829	4	cell	cell	NN
cord-005478-5iu38pr6	1829	5	dose	dose	NN
cord-005478-5iu38pr6	1829	6	of	of	IN
cord-005478-5iu38pr6	1829	7	7.7x10	7.7x10	CD
cord-005478-5iu38pr6	1829	8	6	6	CD
cord-005478-5iu38pr6	1829	9	(	(	-LRB-
cord-005478-5iu38pr6	1829	10	5.0	5.0	CD
cord-005478-5iu38pr6	1829	11	-	-	SYM
cord-005478-5iu38pr6	1829	12	19.4	19.4	CD
cord-005478-5iu38pr6	1829	13	)	)	-RRB-
cord-005478-5iu38pr6	1830	1	CD34	CD34	NNP
cord-005478-5iu38pr6	1830	2	+	+	CC
cord-005478-5iu38pr6	1830	3	cells	cell	NNS
cord-005478-5iu38pr6	1830	4	/	/	SYM
cord-005478-5iu38pr6	1830	5	kg	kg	NNS
cord-005478-5iu38pr6	1830	6	with	with	IN
cord-005478-5iu38pr6	1830	7	a	a	DT
cord-005478-5iu38pr6	1830	8	DP	dp	NN
cord-005478-5iu38pr6	1830	9	vector	vector	NN
cord-005478-5iu38pr6	1830	10	copy	copy	NN
cord-005478-5iu38pr6	1830	11	number	number	NN
cord-005478-5iu38pr6	1830	12	of	of	IN
cord-005478-5iu38pr6	1830	13	3.1	3.1	CD
cord-005478-5iu38pr6	1830	14	(	(	-LRB-
cord-005478-5iu38pr6	1830	15	2.1	2.1	CD
cord-005478-5iu38pr6	1830	16	-	-	SYM
cord-005478-5iu38pr6	1830	17	5.6	5.6	CD
cord-005478-5iu38pr6	1830	18	)	)	-RRB-
cord-005478-5iu38pr6	1830	19	vector	vector	NN
cord-005478-5iu38pr6	1830	20	copies	copy	NNS
cord-005478-5iu38pr6	1830	21	/	/	SYM
cord-005478-5iu38pr6	1830	22	diploid	diploid	JJ
cord-005478-5iu38pr6	1830	23	genome	genome	NN
cord-005478-5iu38pr6	1830	24	and	and	CC
cord-005478-5iu38pr6	1830	25	82	82	CD
cord-005478-5iu38pr6	1830	26	%	%	NN
cord-005478-5iu38pr6	1830	27	(	(	-LRB-
cord-005478-5iu38pr6	1830	28	53	53	CD
cord-005478-5iu38pr6	1830	29	-	-	SYM
cord-005478-5iu38pr6	1830	30	90	90	CD
cord-005478-5iu38pr6	1830	31	%	%	NN
cord-005478-5iu38pr6	1830	32	)	)	-RRB-
cord-005478-5iu38pr6	1830	33	of	of	IN
cord-005478-5iu38pr6	1830	34	cells	cell	NNS
cord-005478-5iu38pr6	1830	35	were	be	VBD
cord-005478-5iu38pr6	1830	36	transduced	transduce	VBN
cord-005478-5iu38pr6	1830	37	.	.	.
cord-005478-5iu38pr6	1831	1	Baseline	baseline	JJ
cord-005478-5iu38pr6	1831	2	liver	liver	NN
cord-005478-5iu38pr6	1831	3	iron	iron	NN
cord-005478-5iu38pr6	1831	4	content	content	NN
cord-005478-5iu38pr6	1831	5	(	(	-LRB-
cord-005478-5iu38pr6	1831	6	LIC	LIC	NNP
cord-005478-5iu38pr6	1831	7	)	)	-RRB-
cord-005478-5iu38pr6	1831	8	was	be	VBD
cord-005478-5iu38pr6	1831	9	6.4	6.4	CD
cord-005478-5iu38pr6	1831	10	(	(	-LRB-
cord-005478-5iu38pr6	1831	11	1.0	1.0	CD
cord-005478-5iu38pr6	1831	12	-	-	HYPH
cord-005478-5iu38pr6	1831	13	41.0	41.0	CD
cord-005478-5iu38pr6	1831	14	)	)	-RRB-
cord-005478-5iu38pr6	1832	1	mg	mg	NNP
cord-005478-5iu38pr6	1833	1	Fe	Fe	NNP
cord-005478-5iu38pr6	1833	2	/	/	SYM
cord-005478-5iu38pr6	1833	3	g	g	NN
cord-005478-5iu38pr6	1833	4	dw	dw	NNP
cord-005478-5iu38pr6	1833	5	.	.	.
cord-005478-5iu38pr6	1834	1	Outcomes	outcome	NNS
cord-005478-5iu38pr6	1834	2	by	by	IN
cord-005478-5iu38pr6	1834	3	age	age	NN
cord-005478-5iu38pr6	1834	4	and	and	CC
cord-005478-5iu38pr6	1834	5	baseline	baseline	JJ
cord-005478-5iu38pr6	1834	6	LIC	LIC	NNP
cord-005478-5iu38pr6	1834	7	will	will	MD
cord-005478-5iu38pr6	1834	8	be	be	VB
cord-005478-5iu38pr6	1834	9	reported	report	VBN
cord-005478-5iu38pr6	1834	10	.	.	.
cord-005478-5iu38pr6	1835	1	Times	time	NNS
cord-005478-5iu38pr6	1835	2	to	to	IN
cord-005478-5iu38pr6	1835	3	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1835	4	and	and	CC
cord-005478-5iu38pr6	1835	5	platelet	platelet	NN
cord-005478-5iu38pr6	1835	6	engraftment	engraftment	NN
cord-005478-5iu38pr6	1835	7	were	be	VBD
cord-005478-5iu38pr6	1835	8	19	19	CD
cord-005478-5iu38pr6	1835	9	(	(	-LRB-
cord-005478-5iu38pr6	1835	10	13	13	CD
cord-005478-5iu38pr6	1835	11	-	-	SYM
cord-005478-5iu38pr6	1835	12	32	32	CD
cord-005478-5iu38pr6	1835	13	)	)	-RRB-
cord-005478-5iu38pr6	1835	14	and	and	CC
cord-005478-5iu38pr6	1835	15	44.5	44.5	CD
cord-005478-5iu38pr6	1835	16	(	(	-LRB-
cord-005478-5iu38pr6	1835	17	20	20	CD
cord-005478-5iu38pr6	1835	18	-	-	SYM
cord-005478-5iu38pr6	1835	19	84	84	CD
cord-005478-5iu38pr6	1835	20	)	)	-RRB-
cord-005478-5iu38pr6	1835	21	days	day	NNS
cord-005478-5iu38pr6	1835	22	,	,	,
cord-005478-5iu38pr6	1835	23	respectively	respectively	RB
cord-005478-5iu38pr6	1835	24	;	;	:
cord-005478-5iu38pr6	1835	25	1	1	CD
cord-005478-5iu38pr6	1835	26	patient	patient	NN
cord-005478-5iu38pr6	1835	27	(	(	-LRB-
cord-005478-5iu38pr6	1835	28	1.0month	1.0month	CD
cord-005478-5iu38pr6	1835	29	follow	follow	VB
cord-005478-5iu38pr6	1835	30	-	-	HYPH
cord-005478-5iu38pr6	1835	31	up	up	NN
cord-005478-5iu38pr6	1835	32	)	)	-RRB-
cord-005478-5iu38pr6	1835	33	and	and	CC
cord-005478-5iu38pr6	1835	34	4	4	CD
cord-005478-5iu38pr6	1835	35	patients	patient	NNS
cord-005478-5iu38pr6	1835	36	(	(	-LRB-
cord-005478-5iu38pr6	1835	37	1.0	1.0	CD
cord-005478-5iu38pr6	1835	38	-	-	SYM
cord-005478-5iu38pr6	1835	39	2.1	2.1	CD
cord-005478-5iu38pr6	1835	40	months	month	NNS
cord-005478-5iu38pr6	1835	41	follow	follow	NN
cord-005478-5iu38pr6	1835	42	-	-	HYPH
cord-005478-5iu38pr6	1835	43	up	up	NN
cord-005478-5iu38pr6	1835	44	)	)	-RRB-
cord-005478-5iu38pr6	1835	45	had	have	VBD
cord-005478-5iu38pr6	1835	46	not	not	RB
cord-005478-5iu38pr6	1835	47	achieved	achieve	VBN
cord-005478-5iu38pr6	1835	48	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	1835	49	and	and	CC
cord-005478-5iu38pr6	1835	50	platelet	platelet	NN
cord-005478-5iu38pr6	1835	51	engraftment	engraftment	NN
cord-005478-5iu38pr6	1835	52	,	,	,
cord-005478-5iu38pr6	1835	53	respectively	respectively	RB
cord-005478-5iu38pr6	1835	54	,	,	,
cord-005478-5iu38pr6	1835	55	at	at	IN
cord-005478-5iu38pr6	1835	56	time	time	NN
cord-005478-5iu38pr6	1835	57	of	of	IN
cord-005478-5iu38pr6	1835	58	analysis	analysis	NN
cord-005478-5iu38pr6	1835	59	.	.	.
cord-005478-5iu38pr6	1836	1	Of	of	IN
cord-005478-5iu38pr6	1836	2	11	11	CD
cord-005478-5iu38pr6	1836	3	patients	patient	NNS
cord-005478-5iu38pr6	1836	4	with	with	IN
cord-005478-5iu38pr6	1836	5	≥	≥	CD
cord-005478-5iu38pr6	1836	6	3	3	CD
cord-005478-5iu38pr6	1836	7	months	month	NNS
cord-005478-5iu38pr6	1836	8	of	of	IN
cord-005478-5iu38pr6	1836	9	follow	follow	NN
cord-005478-5iu38pr6	1836	10	-	-	HYPH
cord-005478-5iu38pr6	1836	11	up	up	NN
cord-005478-5iu38pr6	1836	12	,	,	,
cord-005478-5iu38pr6	1836	13	10	10	CD
cord-005478-5iu38pr6	1836	14	(	(	-LRB-
cord-005478-5iu38pr6	1836	15	6	6	CD
cord-005478-5iu38pr6	1836	16	≥	≥	CD
cord-005478-5iu38pr6	1836	17	18	18	CD
cord-005478-5iu38pr6	1836	18	years	year	NNS
cord-005478-5iu38pr6	1836	19	old	old	JJ
cord-005478-5iu38pr6	1836	20	)	)	-RRB-
cord-005478-5iu38pr6	1836	21	stopped	stop	VBD
cord-005478-5iu38pr6	1836	22	chronic	chronic	JJ
cord-005478-5iu38pr6	1836	23	RBC	RBC	NNP
cord-005478-5iu38pr6	1836	24	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1836	25	and	and	CC
cord-005478-5iu38pr6	1836	26	two	two	CD
cord-005478-5iu38pr6	1836	27	have	have	VBP
cord-005478-5iu38pr6	1836	28	achieved	achieve	VBN
cord-005478-5iu38pr6	1836	29	TI	TI	NNP
cord-005478-5iu38pr6	1836	30	.	.	.
cord-005478-5iu38pr6	1837	1	At	at	IN
cord-005478-5iu38pr6	1837	2	last	last	JJ
cord-005478-5iu38pr6	1837	3	study	study	NN
cord-005478-5iu38pr6	1837	4	visit	visit	NN
cord-005478-5iu38pr6	1837	5	,	,	,
cord-005478-5iu38pr6	1837	6	total	total	JJ
cord-005478-5iu38pr6	1837	7	Hb	Hb	NNP
cord-005478-5iu38pr6	1837	8	in	in	IN
cord-005478-5iu38pr6	1837	9	these	these	DT
cord-005478-5iu38pr6	1837	10	10	10	CD
cord-005478-5iu38pr6	1837	11	patients	patient	NNS
cord-005478-5iu38pr6	1837	12	was	be	VBD
cord-005478-5iu38pr6	1837	13	11.1	11.1	CD
cord-005478-5iu38pr6	1837	14	-	-	SYM
cord-005478-5iu38pr6	1837	15	13.3	13.3	CD
cord-005478-5iu38pr6	1837	16	g	g	NN
cord-005478-5iu38pr6	1837	17	/	/	SYM
cord-005478-5iu38pr6	1837	18	dL	dl	NN
cord-005478-5iu38pr6	1837	19	consisting	consisting	NN
cord-005478-5iu38pr6	1837	20	of	of	IN
cord-005478-5iu38pr6	1837	21	7.7	7.7	CD
cord-005478-5iu38pr6	1837	22	-	-	HYPH
cord-005478-5iu38pr6	1837	23	10.6	10.6	CD
cord-005478-5iu38pr6	1838	1	g	g	NNP
cord-005478-5iu38pr6	1838	2	/	/	SYM
cord-005478-5iu38pr6	1838	3	dL	dl	NN
cord-005478-5iu38pr6	1838	4	gene	gene	NN
cord-005478-5iu38pr6	1838	5	therapy	therapy	NN
cord-005478-5iu38pr6	1838	6	-	-	HYPH
cord-005478-5iu38pr6	1838	7	derived	derive	VBN
cord-005478-5iu38pr6	1838	8	Hb	Hb	NNP
cord-005478-5iu38pr6	1838	9	,	,	,
cord-005478-5iu38pr6	1838	10	HbA	HbA	NNP
cord-005478-5iu38pr6	1838	11	T87Q	t87q	RB
cord-005478-5iu38pr6	1838	12	.	.	.
cord-005478-5iu38pr6	1839	1	One	one	CD
cord-005478-5iu38pr6	1839	2	treated	treat	VBN
cord-005478-5iu38pr6	1839	3	patient	patient	NN
cord-005478-5iu38pr6	1839	4	had	have	VBD
cord-005478-5iu38pr6	1839	5	no	no	DT
cord-005478-5iu38pr6	1839	6	RBC	RBC	NNP
cord-005478-5iu38pr6	1839	7	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1839	8	for	for	IN
cord-005478-5iu38pr6	1839	9	11	11	CD
cord-005478-5iu38pr6	1839	10	months	month	NNS
cord-005478-5iu38pr6	1839	11	,	,	,
cord-005478-5iu38pr6	1839	12	then	then	RB
cord-005478-5iu38pr6	1839	13	re	re	VB
cord-005478-5iu38pr6	1839	14	-	-	VBN
cord-005478-5iu38pr6	1839	15	initiated	initiate	VBN
cord-005478-5iu38pr6	1839	16	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1839	17	due	due	JJ
cord-005478-5iu38pr6	1839	18	to	to	IN
cord-005478-5iu38pr6	1839	19	low	low	JJ
cord-005478-5iu38pr6	1839	20	Hb	Hb	NNP
cord-005478-5iu38pr6	1839	21	.	.	.
cord-005478-5iu38pr6	1840	1	Non	non	JJ
cord-005478-5iu38pr6	1840	2	-	-	JJ
cord-005478-5iu38pr6	1840	3	hematologic	hematologic	JJ
cord-005478-5iu38pr6	1840	4	grade	grade	NN
cord-005478-5iu38pr6	1841	1	≥	≥	CD
cord-005478-5iu38pr6	1841	2	3	3	CD
cord-005478-5iu38pr6	1841	3	adverse	adverse	JJ
cord-005478-5iu38pr6	1841	4	events	event	NNS
cord-005478-5iu38pr6	1841	5	post	post	NN
cord-005478-5iu38pr6	1841	6	-	-	NN
cord-005478-5iu38pr6	1841	7	infusion	infusion	NN
cord-005478-5iu38pr6	1841	8	in	in	IN
cord-005478-5iu38pr6	1841	9	≥	≥	CD
cord-005478-5iu38pr6	1841	10	3	3	CD
cord-005478-5iu38pr6	1841	11	patients	patient	NNS
cord-005478-5iu38pr6	1841	12	included	include	VBD
cord-005478-5iu38pr6	1841	13	stomatitis	stomatitis	NN
cord-005478-5iu38pr6	1841	14	,	,	,
cord-005478-5iu38pr6	1841	15	febrile	febrile	JJ
cord-005478-5iu38pr6	1841	16	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	1841	17	,	,	,
cord-005478-5iu38pr6	1841	18	epistaxis	epistaxis	NN
cord-005478-5iu38pr6	1841	19	,	,	,
cord-005478-5iu38pr6	1841	20	pyrexia	pyrexia	NNP
cord-005478-5iu38pr6	1841	21	,	,	,
cord-005478-5iu38pr6	1841	22	and	and	CC
cord-005478-5iu38pr6	1841	23	veno	veno	NNP
cord-005478-5iu38pr6	1841	24	-	-	HYPH
cord-005478-5iu38pr6	1841	25	occlusive	occlusive	JJ
cord-005478-5iu38pr6	1841	26	liver	liver	NN
cord-005478-5iu38pr6	1841	27	disease	disease	NN
cord-005478-5iu38pr6	1841	28	(	(	-LRB-
cord-005478-5iu38pr6	1841	29	VOD	VOD	NNP
cord-005478-5iu38pr6	1841	30	)	)	-RRB-
cord-005478-5iu38pr6	1841	31	.	.	.
cord-005478-5iu38pr6	1842	1	One	one	CD
cord-005478-5iu38pr6	1842	2	grade	grade	NN
cord-005478-5iu38pr6	1842	3	3	3	CD
cord-005478-5iu38pr6	1842	4	event	event	NN
cord-005478-5iu38pr6	1842	5	of	of	IN
cord-005478-5iu38pr6	1842	6	serious	serious	JJ
cord-005478-5iu38pr6	1842	7	prolonged	prolonged	JJ
cord-005478-5iu38pr6	1842	8	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	1842	9	after	after	IN
cord-005478-5iu38pr6	1842	10	platelet	platelet	NN
cord-005478-5iu38pr6	1842	11	engraftment	engraftment	NN
cord-005478-5iu38pr6	1842	12	was	be	VBD
cord-005478-5iu38pr6	1842	13	considered	consider	VBN
cord-005478-5iu38pr6	1842	14	possibly	possibly	RB
cord-005478-5iu38pr6	1842	15	related	relate	VBN
cord-005478-5iu38pr6	1842	16	to	to	IN
cord-005478-5iu38pr6	1842	17	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1842	18	.	.	.
cord-005478-5iu38pr6	1843	1	The	the	DT
cord-005478-5iu38pr6	1843	2	three	three	CD
cord-005478-5iu38pr6	1843	3	grade	grade	NN
cord-005478-5iu38pr6	1843	4	4	4	CD
cord-005478-5iu38pr6	1843	5	serious	serious	JJ
cord-005478-5iu38pr6	1843	6	VOD	VOD	NNP
cord-005478-5iu38pr6	1843	7	events	event	NNS
cord-005478-5iu38pr6	1843	8	were	be	VBD
cord-005478-5iu38pr6	1843	9	attributed	attribute	VBN
cord-005478-5iu38pr6	1843	10	to	to	IN
cord-005478-5iu38pr6	1843	11	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1843	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	1843	13	(	(	-LRB-
cord-005478-5iu38pr6	1843	14	Table	table	NN
cord-005478-5iu38pr6	1843	15	1	1	CD
cord-005478-5iu38pr6	1843	16	)	)	-RRB-
cord-005478-5iu38pr6	1843	17	.	.	.
cord-005478-5iu38pr6	1844	1	The	the	DT
cord-005478-5iu38pr6	1844	2	events	event	NNS
cord-005478-5iu38pr6	1844	3	resulted	result	VBD
cord-005478-5iu38pr6	1844	4	in	in	IN
cord-005478-5iu38pr6	1844	5	extended	extended	JJ
cord-005478-5iu38pr6	1844	6	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	1844	7	and	and	CC
cord-005478-5iu38pr6	1844	8	resolved	resolve	VBD
cord-005478-5iu38pr6	1844	9	following	follow	VBG
cord-005478-5iu38pr6	1844	10	defibrotide	defibrotide	NN
cord-005478-5iu38pr6	1844	11	treatment	treatment	NN
cord-005478-5iu38pr6	1844	12	.	.	.
cord-005478-5iu38pr6	1845	1	There	there	EX
cord-005478-5iu38pr6	1845	2	were	be	VBD
cord-005478-5iu38pr6	1845	3	no	no	DT
cord-005478-5iu38pr6	1845	4	deaths	death	NNS
cord-005478-5iu38pr6	1845	5	or	or	CC
cord-005478-5iu38pr6	1845	6	graft	graft	NN
cord-005478-5iu38pr6	1845	7	failure	failure	NN
cord-005478-5iu38pr6	1845	8	and	and	CC
cord-005478-5iu38pr6	1845	9	no	no	DT
cord-005478-5iu38pr6	1845	10	evidence	evidence	NN
cord-005478-5iu38pr6	1845	11	of	of	IN
cord-005478-5iu38pr6	1845	12	vector	vector	NN
cord-005478-5iu38pr6	1845	13	-	-	HYPH
cord-005478-5iu38pr6	1845	14	mediated	mediate	VBN
cord-005478-5iu38pr6	1845	15	replication	replication	NN
cord-005478-5iu38pr6	1845	16	of	of	IN
cord-005478-5iu38pr6	1845	17	competent	competent	JJ
cord-005478-5iu38pr6	1845	18	lentivirus	lentivirus	NN
cord-005478-5iu38pr6	1845	19	or	or	CC
cord-005478-5iu38pr6	1845	20	clonal	clonal	JJ
cord-005478-5iu38pr6	1845	21	dominance	dominance	NN
cord-005478-5iu38pr6	1845	22	.	.	.
cord-005478-5iu38pr6	1846	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1846	2	:	:	:
cord-005478-5iu38pr6	1847	1	In	in	IN
cord-005478-5iu38pr6	1847	2	Northstar-2	Northstar-2	NNP
cord-005478-5iu38pr6	1847	3	,	,	,
cord-005478-5iu38pr6	1847	4	10/11	10/11	CD
cord-005478-5iu38pr6	1847	5	patients	patient	NNS
cord-005478-5iu38pr6	1847	6	with	with	IN
cord-005478-5iu38pr6	1847	7	TDT	TDT	NNP
cord-005478-5iu38pr6	1847	8	and	and	CC
cord-005478-5iu38pr6	1847	9	non	non	NNS
cord-005478-5iu38pr6	1847	10	-	-	JJ
cord-005478-5iu38pr6	1847	11	β	β	JJ
cord-005478-5iu38pr6	1847	12	0	0	CD
cord-005478-5iu38pr6	1847	13	/β	/β	NN
cord-005478-5iu38pr6	1847	14	0	0	NFP
cord-005478-5iu38pr6	1847	15	genotypes	genotype	NNS
cord-005478-5iu38pr6	1847	16	treated	treat	VBN
cord-005478-5iu38pr6	1847	17	to	to	IN
cord-005478-5iu38pr6	1847	18	date	date	NN
cord-005478-5iu38pr6	1847	19	produced	produce	VBN
cord-005478-5iu38pr6	1847	20	sufficient	sufficient	JJ
cord-005478-5iu38pr6	1847	21	gene	gene	NN
cord-005478-5iu38pr6	1847	22	therapy	therapy	NN
cord-005478-5iu38pr6	1847	23	-	-	HYPH
cord-005478-5iu38pr6	1847	24	derived	derive	VBN
cord-005478-5iu38pr6	1847	25	Hb	Hb	NNP
cord-005478-5iu38pr6	1847	26	,	,	,
cord-005478-5iu38pr6	1847	27	HbA	HbA	NNP
cord-005478-5iu38pr6	1847	28	T87Q	t87q	RB
cord-005478-5iu38pr6	1847	29	,	,	,
cord-005478-5iu38pr6	1847	30	to	to	TO
cord-005478-5iu38pr6	1847	31	stop	stop	VB
cord-005478-5iu38pr6	1847	32	chronic	chronic	JJ
cord-005478-5iu38pr6	1847	33	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1847	34	following	follow	VBG
cord-005478-5iu38pr6	1847	35	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1847	36	gene	gene	NN
cord-005478-5iu38pr6	1847	37	therapy	therapy	NN
cord-005478-5iu38pr6	1847	38	.	.	.
cord-005478-5iu38pr6	1848	1	Total	total	JJ
cord-005478-5iu38pr6	1848	2	Hb	Hb	NNP
cord-005478-5iu38pr6	1848	3	in	in	IN
cord-005478-5iu38pr6	1848	4	patients	patient	NNS
cord-005478-5iu38pr6	1848	5	off	off	IN
cord-005478-5iu38pr6	1848	6	RBC	RBC	NNP
cord-005478-5iu38pr6	1848	7	transfusions	transfusion	NNS
cord-005478-5iu38pr6	1848	8	remains	remain	VBZ
cord-005478-5iu38pr6	1848	9	stable	stable	JJ
cord-005478-5iu38pr6	1848	10	at	at	IN
cord-005478-5iu38pr6	1848	11	>	>	$
cord-005478-5iu38pr6	1848	12	11	11	CD
cord-005478-5iu38pr6	1848	13	g	g	NN
cord-005478-5iu38pr6	1848	14	/	/	SYM
cord-005478-5iu38pr6	1848	15	dL.	dl.	NN
cord-005478-5iu38pr6	1849	1	The	the	DT
cord-005478-5iu38pr6	1849	2	safety	safety	NN
cord-005478-5iu38pr6	1849	3	profile	profile	NN
cord-005478-5iu38pr6	1849	4	of	of	IN
cord-005478-5iu38pr6	1849	5	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1849	6	remains	remain	VBZ
cord-005478-5iu38pr6	1849	7	generally	generally	RB
cord-005478-5iu38pr6	1849	8	consistent	consistent	JJ
cord-005478-5iu38pr6	1849	9	with	with	IN
cord-005478-5iu38pr6	1849	10	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1849	11	busulfan	busulfan	NNP
cord-005478-5iu38pr6	1849	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	1849	13	.	.	.
cord-005478-5iu38pr6	1850	1	Background	background	NN
cord-005478-5iu38pr6	1850	2	:	:	:
cord-005478-5iu38pr6	1851	1	Metachromatic	metachromatic	JJ
cord-005478-5iu38pr6	1851	2	leukodystrophy	leukodystrophy	NN
cord-005478-5iu38pr6	1851	3	(	(	-LRB-
cord-005478-5iu38pr6	1851	4	MLD	MLD	NNP
cord-005478-5iu38pr6	1851	5	)	)	-RRB-
cord-005478-5iu38pr6	1851	6	is	be	VBZ
cord-005478-5iu38pr6	1851	7	an	an	DT
cord-005478-5iu38pr6	1851	8	ultra	ultra	JJ
cord-005478-5iu38pr6	1851	9	-	-	JJ
cord-005478-5iu38pr6	1851	10	rare	rare	JJ
cord-005478-5iu38pr6	1851	11	and	and	CC
cord-005478-5iu38pr6	1851	12	devastating	devastating	JJ
cord-005478-5iu38pr6	1851	13	demyelinating	demyelinating	JJ
cord-005478-5iu38pr6	1851	14	lysosomal	lysosomal	JJ
cord-005478-5iu38pr6	1851	15	storage	storage	NN
cord-005478-5iu38pr6	1851	16	disease	disease	NN
cord-005478-5iu38pr6	1851	17	caused	cause	VBN
cord-005478-5iu38pr6	1851	18	by	by	IN
cord-005478-5iu38pr6	1851	19	mutations	mutation	NNS
cord-005478-5iu38pr6	1851	20	in	in	IN
cord-005478-5iu38pr6	1851	21	the	the	DT
cord-005478-5iu38pr6	1851	22	Arylsulfatase	Arylsulfatase	NNP
cord-005478-5iu38pr6	1851	23	A	A	NNP
cord-005478-5iu38pr6	1851	24	(	(	-LRB-
cord-005478-5iu38pr6	1851	25	ARSA	arsa	NN
cord-005478-5iu38pr6	1851	26	)	)	-RRB-
cord-005478-5iu38pr6	1851	27	gene	gene	NN
cord-005478-5iu38pr6	1851	28	,	,	,
cord-005478-5iu38pr6	1851	29	currently	currently	RB
cord-005478-5iu38pr6	1851	30	with	with	IN
cord-005478-5iu38pr6	1851	31	no	no	DT
cord-005478-5iu38pr6	1851	32	approved	approve	VBN
cord-005478-5iu38pr6	1851	33	treatment	treatment	NN
cord-005478-5iu38pr6	1851	34	.	.	.
cord-005478-5iu38pr6	1852	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1852	2	report	report	VBP
cord-005478-5iu38pr6	1852	3	an	an	DT
cord-005478-5iu38pr6	1852	4	interim	interim	JJ
cord-005478-5iu38pr6	1852	5	analysis	analysis	NN
cord-005478-5iu38pr6	1852	6	of	of	IN
cord-005478-5iu38pr6	1852	7	the	the	DT
cord-005478-5iu38pr6	1852	8	safety	safety	NN
cord-005478-5iu38pr6	1852	9	and	and	CC
cord-005478-5iu38pr6	1852	10	efficacy	efficacy	NN
cord-005478-5iu38pr6	1852	11	results	result	NNS
cord-005478-5iu38pr6	1852	12	of	of	IN
cord-005478-5iu38pr6	1852	13	20	20	CD
cord-005478-5iu38pr6	1852	14	early	early	JJ
cord-005478-5iu38pr6	1852	15	-	-	HYPH
cord-005478-5iu38pr6	1852	16	onset	onset	NN
cord-005478-5iu38pr6	1852	17	MLD	MLD	NNP
cord-005478-5iu38pr6	1852	18	subjects	subject	NNS
cord-005478-5iu38pr6	1852	19	treated	treat	VBN
cord-005478-5iu38pr6	1852	20	with	with	IN
cord-005478-5iu38pr6	1852	21	experimental	experimental	JJ
cord-005478-5iu38pr6	1852	22	autologous	autologous	JJ
cord-005478-5iu38pr6	1852	23	,	,	,
cord-005478-5iu38pr6	1852	24	ex	ex	NN
cord-005478-5iu38pr6	1852	25	-	-	NN
cord-005478-5iu38pr6	1852	26	vivo	vivo	JJ
cord-005478-5iu38pr6	1852	27	,	,	,
cord-005478-5iu38pr6	1852	28	lentiviral	lentiviral	RB
cord-005478-5iu38pr6	1852	29	-	-	HYPH
cord-005478-5iu38pr6	1852	30	mediated	mediate	VBN
cord-005478-5iu38pr6	1852	31	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1852	32	stem	stem	NN
cord-005478-5iu38pr6	1852	33	cell	cell	NN
cord-005478-5iu38pr6	1852	34	gene	gene	NN
cord-005478-5iu38pr6	1852	35	therapy	therapy	NN
cord-005478-5iu38pr6	1852	36	(	(	-LRB-
cord-005478-5iu38pr6	1852	37	HSC	HSC	NNP
cord-005478-5iu38pr6	1852	38	-	-	HYPH
cord-005478-5iu38pr6	1852	39	GT	GT	NNP
cord-005478-5iu38pr6	1852	40	)	)	-RRB-
cord-005478-5iu38pr6	1852	41	followed	follow	VBD
cord-005478-5iu38pr6	1852	42	for	for	IN
cord-005478-5iu38pr6	1852	43	up	up	IN
cord-005478-5iu38pr6	1852	44	to	to	TO
cord-005478-5iu38pr6	1852	45	8	8	CD
cord-005478-5iu38pr6	1852	46	years	year	NNS
cord-005478-5iu38pr6	1852	47	posttreatment	posttreatment	NN
cord-005478-5iu38pr6	1852	48	,	,	,
cord-005478-5iu38pr6	1852	49	as	as	IN
cord-005478-5iu38pr6	1852	50	part	part	NN
cord-005478-5iu38pr6	1852	51	of	of	IN
cord-005478-5iu38pr6	1852	52	an	an	DT
cord-005478-5iu38pr6	1852	53	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1852	54	,	,	,
cord-005478-5iu38pr6	1852	55	open	open	JJ
cord-005478-5iu38pr6	1852	56	-	-	HYPH
cord-005478-5iu38pr6	1852	57	label	label	NN
cord-005478-5iu38pr6	1852	58	,	,	,
cord-005478-5iu38pr6	1852	59	study	study	NN
cord-005478-5iu38pr6	1852	60	.	.	.
cord-005478-5iu38pr6	1853	1	The	the	DT
cord-005478-5iu38pr6	1853	2	study	study	NN
cord-005478-5iu38pr6	1853	3	has	have	VBZ
cord-005478-5iu38pr6	1853	4	completed	complete	VBN
cord-005478-5iu38pr6	1853	5	the	the	DT
cord-005478-5iu38pr6	1853	6	enrollment	enrollment	NN
cord-005478-5iu38pr6	1853	7	period	period	NN
cord-005478-5iu38pr6	1853	8	;	;	:
cord-005478-5iu38pr6	1853	9	follow	follow	VB
cord-005478-5iu38pr6	1853	10	up	up	RP
cord-005478-5iu38pr6	1853	11	visits	visit	NNS
cord-005478-5iu38pr6	1853	12	are	be	VBP
cord-005478-5iu38pr6	1853	13	currently	currently	RB
cord-005478-5iu38pr6	1853	14	on	on	RB
cord-005478-5iu38pr6	1853	15	-	-	HYPH
cord-005478-5iu38pr6	1853	16	going	going	NN
cord-005478-5iu38pr6	1853	17	.	.	.
cord-005478-5iu38pr6	1854	1	Methods	method	NNS
cord-005478-5iu38pr6	1854	2	:	:	:
cord-005478-5iu38pr6	1854	3	GT	GT	NNP
cord-005478-5iu38pr6	1854	4	consists	consist	VBZ
cord-005478-5iu38pr6	1854	5	of	of	IN
cord-005478-5iu38pr6	1854	6	a	a	DT
cord-005478-5iu38pr6	1854	7	formulation	formulation	NN
cord-005478-5iu38pr6	1854	8	of	of	IN
cord-005478-5iu38pr6	1854	9	autologous	autologous	JJ
cord-005478-5iu38pr6	1854	10	CD34	CD34	NNP
cord-005478-5iu38pr6	1854	11	+	+	CC
cord-005478-5iu38pr6	1854	12	cells	cell	NNS
cord-005478-5iu38pr6	1854	13	transduced	transduce	VBN
cord-005478-5iu38pr6	1854	14	ex	ex	FW
cord-005478-5iu38pr6	1854	15	vivo	vivo	FW
cord-005478-5iu38pr6	1854	16	with	with	IN
cord-005478-5iu38pr6	1854	17	a	a	DT
cord-005478-5iu38pr6	1854	18	self	self	NN
cord-005478-5iu38pr6	1854	19	-	-	HYPH
cord-005478-5iu38pr6	1854	20	inactivating	inactivate	VBG
cord-005478-5iu38pr6	1854	21	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	1854	22	vector	vector	NN
cord-005478-5iu38pr6	1854	23	encoding	encoding	NN
cord-005478-5iu38pr6	1854	24	for	for	IN
cord-005478-5iu38pr6	1854	25	the	the	DT
cord-005478-5iu38pr6	1854	26	human	human	JJ
cord-005478-5iu38pr6	1854	27	ARSA	ARSA	NNP
cord-005478-5iu38pr6	1854	28	gene	gene	NN
cord-005478-5iu38pr6	1854	29	and	and	CC
cord-005478-5iu38pr6	1854	30	administered	administer	VBN
cord-005478-5iu38pr6	1854	31	intravenously	intravenously	RB
cord-005478-5iu38pr6	1854	32	after	after	IN
cord-005478-5iu38pr6	1854	33	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	1854	34	conditioning	conditioning	NN
cord-005478-5iu38pr6	1854	35	.	.	.
cord-005478-5iu38pr6	1855	1	Twenty	twenty	CD
cord-005478-5iu38pr6	1855	2	early	early	JJ
cord-005478-5iu38pr6	1855	3	-	-	HYPH
cord-005478-5iu38pr6	1855	4	onset	onset	NN
cord-005478-5iu38pr6	1855	5	MLD	MLD	NNP
cord-005478-5iu38pr6	1855	6	subjects	subject	NNS
cord-005478-5iu38pr6	1855	7	(	(	-LRB-
cord-005478-5iu38pr6	1855	8	pre	pre	JJ
cord-005478-5iu38pr6	1855	9	-	-	JJ
cord-005478-5iu38pr6	1855	10	symptomatic	symptomatic	JJ
cord-005478-5iu38pr6	1855	11	or	or	CC
cord-005478-5iu38pr6	1855	12	early	early	JJ
cord-005478-5iu38pr6	1855	13	symptomatic	symptomatic	JJ
cord-005478-5iu38pr6	1855	14	)	)	-RRB-
cord-005478-5iu38pr6	1855	15	were	be	VBD
cord-005478-5iu38pr6	1855	16	enrolled	enrol	VBN
cord-005478-5iu38pr6	1855	17	and	and	CC
cord-005478-5iu38pr6	1855	18	treated	treat	VBN
cord-005478-5iu38pr6	1855	19	(	(	-LRB-
cord-005478-5iu38pr6	1855	20	9	9	CD
cord-005478-5iu38pr6	1855	21	Late	late	JJ
cord-005478-5iu38pr6	1855	22	Infantile	infantile	JJ
cord-005478-5iu38pr6	1855	23	[	[	-LRB-
cord-005478-5iu38pr6	1855	24	LI	LI	NNP
cord-005478-5iu38pr6	1855	25	]	]	-RRB-
cord-005478-5iu38pr6	1855	26	and	and	CC
cord-005478-5iu38pr6	1855	27	11	11	CD
cord-005478-5iu38pr6	1855	28	Early	early	JJ
cord-005478-5iu38pr6	1855	29	Juvenile	Juvenile	NNP
cord-005478-5iu38pr6	1855	30	[	[	-LRB-
cord-005478-5iu38pr6	1855	31	EJ	EJ	NNP
cord-005478-5iu38pr6	1855	32	]	]	-RRB-
cord-005478-5iu38pr6	1855	33	)	)	-RRB-
cord-005478-5iu38pr6	1855	34	.	.	.
cord-005478-5iu38pr6	1856	1	Co	co	JJ
cord-005478-5iu38pr6	1856	2	-	-	JJ
cord-005478-5iu38pr6	1856	3	primary	primary	JJ
cord-005478-5iu38pr6	1856	4	efficacy	efficacy	NN
cord-005478-5iu38pr6	1856	5	endpoints	endpoint	NNS
cord-005478-5iu38pr6	1856	6	were	be	VBD
cord-005478-5iu38pr6	1856	7	improvement	improvement	NN
cord-005478-5iu38pr6	1856	8	in	in	IN
cord-005478-5iu38pr6	1856	9	Gross	Gross	NNP
cord-005478-5iu38pr6	1856	10	Motor	Motor	NNP
cord-005478-5iu38pr6	1856	11	Function	Function	NNP
cord-005478-5iu38pr6	1856	12	Measure	measure	NN
cord-005478-5iu38pr6	1856	13	(	(	-LRB-
cord-005478-5iu38pr6	1856	14	GMFM	GMFM	NNP
cord-005478-5iu38pr6	1856	15	)	)	-RRB-
cord-005478-5iu38pr6	1856	16	score	score	NN
cord-005478-5iu38pr6	1856	17	(	(	-LRB-
cord-005478-5iu38pr6	1856	18	10	10	CD
cord-005478-5iu38pr6	1856	19	%	%	NN
cord-005478-5iu38pr6	1856	20	)	)	-RRB-
cord-005478-5iu38pr6	1856	21	and	and	CC
cord-005478-5iu38pr6	1856	22	a	a	DT
cord-005478-5iu38pr6	1856	23	significant	significant	JJ
cord-005478-5iu38pr6	1856	24	increase	increase	NN
cord-005478-5iu38pr6	1856	25	in	in	IN
cord-005478-5iu38pr6	1856	26	ARSA	ARSA	NNP
cord-005478-5iu38pr6	1856	27	activity	activity	NN
cord-005478-5iu38pr6	1856	28	in	in	IN
cord-005478-5iu38pr6	1856	29	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1856	30	blood	blood	NN
cord-005478-5iu38pr6	1856	31	mononuclear	mononuclear	NN
cord-005478-5iu38pr6	1856	32	cells	cell	NNS
cord-005478-5iu38pr6	1856	33	(	(	-LRB-
cord-005478-5iu38pr6	1856	34	PBMCs	pbmc	NNS
cord-005478-5iu38pr6	1856	35	)	)	-RRB-
cord-005478-5iu38pr6	1856	36	,	,	,
cord-005478-5iu38pr6	1856	37	evaluated	evaluate	VBD
cord-005478-5iu38pr6	1856	38	24	24	CD
cord-005478-5iu38pr6	1856	39	months	month	NNS
cord-005478-5iu38pr6	1856	40	after	after	IN
cord-005478-5iu38pr6	1856	41	treatment	treatment	NN
cord-005478-5iu38pr6	1856	42	.	.	.
cord-005478-5iu38pr6	1857	1	Safety	safety	NN
cord-005478-5iu38pr6	1857	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	1857	3	include	include	VBP
cord-005478-5iu38pr6	1857	4	engraftment	engraftment	NN
cord-005478-5iu38pr6	1857	5	failure	failure	NN
cord-005478-5iu38pr6	1857	6	and	and	CC
cord-005478-5iu38pr6	1857	7	long	long	JJ
cord-005478-5iu38pr6	1857	8	-	-	HYPH
cord-005478-5iu38pr6	1857	9	term	term	NN
cord-005478-5iu38pr6	1857	10	safety	safety	NN
cord-005478-5iu38pr6	1857	11	and	and	CC
cord-005478-5iu38pr6	1857	12	tolerability	tolerability	NN
cord-005478-5iu38pr6	1857	13	of	of	IN
cord-005478-5iu38pr6	1857	14	lentiviral	lentiviral	NN
cord-005478-5iu38pr6	1857	15	-	-	HYPH
cord-005478-5iu38pr6	1857	16	transduction	transduction	NN
cord-005478-5iu38pr6	1857	17	.	.	.
cord-005478-5iu38pr6	1858	1	Results	result	NNS
cord-005478-5iu38pr6	1858	2	:	:	:
cord-005478-5iu38pr6	1859	1	18/20	18/20	CD
cord-005478-5iu38pr6	1859	2	subjects	subject	NNS
cord-005478-5iu38pr6	1859	3	are	be	VBP
cord-005478-5iu38pr6	1859	4	alive	alive	JJ
cord-005478-5iu38pr6	1859	5	after	after	IN
cord-005478-5iu38pr6	1859	6	a	a	DT
cord-005478-5iu38pr6	1859	7	clinical	clinical	JJ
cord-005478-5iu38pr6	1859	8	follow	follow	NN
cord-005478-5iu38pr6	1859	9	-	-	HYPH
cord-005478-5iu38pr6	1859	10	up	up	NN
cord-005478-5iu38pr6	1859	11	of	of	IN
cord-005478-5iu38pr6	1859	12	3	3	CD
cord-005478-5iu38pr6	1859	13	-	-	SYM
cord-005478-5iu38pr6	1859	14	8	8	CD
cord-005478-5iu38pr6	1859	15	years	year	NNS
cord-005478-5iu38pr6	1859	16	.	.	.
cord-005478-5iu38pr6	1860	1	Two	two	CD
cord-005478-5iu38pr6	1860	2	EJ	EJ	NNP
cord-005478-5iu38pr6	1860	3	subjects	subject	NNS
cord-005478-5iu38pr6	1860	4	,	,	,
cord-005478-5iu38pr6	1860	5	treated	treat	VBN
cord-005478-5iu38pr6	1860	6	after	after	IN
cord-005478-5iu38pr6	1860	7	onset	onset	NN
cord-005478-5iu38pr6	1860	8	of	of	IN
cord-005478-5iu38pr6	1860	9	symptoms	symptom	NNS
cord-005478-5iu38pr6	1860	10	,	,	,
cord-005478-5iu38pr6	1860	11	died	die	VBD
cord-005478-5iu38pr6	1860	12	due	due	JJ
cord-005478-5iu38pr6	1860	13	to	to	IN
cord-005478-5iu38pr6	1860	14	rapid	rapid	JJ
cord-005478-5iu38pr6	1860	15	disease	disease	NN
cord-005478-5iu38pr6	1860	16	progression	progression	NN
cord-005478-5iu38pr6	1860	17	8-and	8-and	NNP
cord-005478-5iu38pr6	1860	18	15months	15months	CD
cord-005478-5iu38pr6	1860	19	post	post	NN
cord-005478-5iu38pr6	1860	20	-	-	NN
cord-005478-5iu38pr6	1860	21	treatment	treatment	NN
cord-005478-5iu38pr6	1860	22	.	.	.
cord-005478-5iu38pr6	1861	1	There	there	EX
cord-005478-5iu38pr6	1861	2	was	be	VBD
cord-005478-5iu38pr6	1861	3	no	no	DT
cord-005478-5iu38pr6	1861	4	treatment	treatment	NN
cord-005478-5iu38pr6	1861	5	-	-	HYPH
cord-005478-5iu38pr6	1861	6	related	relate	VBN
cord-005478-5iu38pr6	1861	7	mortality	mortality	NN
cord-005478-5iu38pr6	1861	8	,	,	,
cord-005478-5iu38pr6	1861	9	no	no	DT
cord-005478-5iu38pr6	1861	10	evidence	evidence	NN
cord-005478-5iu38pr6	1861	11	of	of	IN
cord-005478-5iu38pr6	1861	12	abnormal	abnormal	JJ
cord-005478-5iu38pr6	1861	13	clonal	clonal	JJ
cord-005478-5iu38pr6	1861	14	expansion	expansion	NN
cord-005478-5iu38pr6	1861	15	,	,	,
cord-005478-5iu38pr6	1861	16	and	and	CC
cord-005478-5iu38pr6	1861	17	no	no	DT
cord-005478-5iu38pr6	1861	18	adverse	adverse	JJ
cord-005478-5iu38pr6	1861	19	events	event	NNS
cord-005478-5iu38pr6	1861	20	related	relate	VBN
cord-005478-5iu38pr6	1861	21	to	to	IN
cord-005478-5iu38pr6	1861	22	the	the	DT
cord-005478-5iu38pr6	1861	23	Medicinal	Medicinal	NNP
cord-005478-5iu38pr6	1861	24	Product	Product	NNP
cord-005478-5iu38pr6	1861	25	.	.	.
cord-005478-5iu38pr6	1862	1	Durable	durable	JJ
cord-005478-5iu38pr6	1862	2	and	and	CC
cord-005478-5iu38pr6	1862	3	stable	stable	JJ
cord-005478-5iu38pr6	1862	4	engraftment	engraftment	NN
cord-005478-5iu38pr6	1862	5	of	of	IN
cord-005478-5iu38pr6	1862	6	gene	gene	NN
cord-005478-5iu38pr6	1862	7	-	-	HYPH
cord-005478-5iu38pr6	1862	8	corrected	correct	VBN
cord-005478-5iu38pr6	1862	9	cells	cell	NNS
cord-005478-5iu38pr6	1862	10	were	be	VBD
cord-005478-5iu38pr6	1862	11	observed	observe	VBN
cord-005478-5iu38pr6	1862	12	beginning	begin	VBG
cord-005478-5iu38pr6	1862	13	1-month	1-month	CD
cord-005478-5iu38pr6	1862	14	post	post	JJ
cord-005478-5iu38pr6	1862	15	-	-	JJ
cord-005478-5iu38pr6	1862	16	treatment	treatment	JJ
cord-005478-5iu38pr6	1862	17	,	,	,
cord-005478-5iu38pr6	1862	18	with	with	IN
cord-005478-5iu38pr6	1862	19	persistent	persistent	JJ
cord-005478-5iu38pr6	1862	20	vector	vector	NN
cord-005478-5iu38pr6	1862	21	copy	copy	NN
cord-005478-5iu38pr6	1862	22	number	number	NN
cord-005478-5iu38pr6	1862	23	in	in	IN
cord-005478-5iu38pr6	1862	24	CD34	CD34	NNP
cord-005478-5iu38pr6	1862	25	+	+	CC
cord-005478-5iu38pr6	1862	26	bone	bone	NN
cord-005478-5iu38pr6	1862	27	marrow	marrow	NN
cord-005478-5iu38pr6	1862	28	cells	cell	NNS
cord-005478-5iu38pr6	1862	29	and	and	CC
cord-005478-5iu38pr6	1862	30	PBMCs	pbmc	NNS
cord-005478-5iu38pr6	1862	31	throughout	throughout	IN
cord-005478-5iu38pr6	1862	32	the	the	DT
cord-005478-5iu38pr6	1862	33	follow	follow	NN
cord-005478-5iu38pr6	1862	34	-	-	HYPH
cord-005478-5iu38pr6	1862	35	up	up	NN
cord-005478-5iu38pr6	1862	36	for	for	IN
cord-005478-5iu38pr6	1862	37	all	all	DT
cord-005478-5iu38pr6	1862	38	18	18	CD
cord-005478-5iu38pr6	1862	39	subjects	subject	NNS
cord-005478-5iu38pr6	1862	40	.	.	.
cord-005478-5iu38pr6	1863	1	Reconstitution	reconstitution	NN
cord-005478-5iu38pr6	1863	2	of	of	IN
cord-005478-5iu38pr6	1863	3	ARSA	ARSA	NNP
cord-005478-5iu38pr6	1863	4	activity	activity	NN
cord-005478-5iu38pr6	1863	5	in	in	IN
cord-005478-5iu38pr6	1863	6	the	the	DT
cord-005478-5iu38pr6	1863	7	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1863	8	system	system	NN
cord-005478-5iu38pr6	1863	9	was	be	VBD
cord-005478-5iu38pr6	1863	10	observed	observe	VBN
cord-005478-5iu38pr6	1863	11	in	in	IN
cord-005478-5iu38pr6	1863	12	both	both	DT
cord-005478-5iu38pr6	1863	13	populations	population	NNS
cord-005478-5iu38pr6	1863	14	(	(	-LRB-
cord-005478-5iu38pr6	1863	15	LI	LI	NNP
cord-005478-5iu38pr6	1863	16	and	and	CC
cord-005478-5iu38pr6	1863	17	EJ	EJ	NNP
cord-005478-5iu38pr6	1863	18	)	)	-RRB-
cord-005478-5iu38pr6	1863	19	,	,	,
cord-005478-5iu38pr6	1863	20	stabilizing	stabilize	VBG
cord-005478-5iu38pr6	1863	21	at	at	IN
cord-005478-5iu38pr6	1863	22	normal	normal	JJ
cord-005478-5iu38pr6	1863	23	to	to	IN
cord-005478-5iu38pr6	1863	24	supranormal	supranormal	JJ
cord-005478-5iu38pr6	1863	25	levels	level	NNS
cord-005478-5iu38pr6	1863	26	within	within	IN
cord-005478-5iu38pr6	1863	27	three	three	CD
cord-005478-5iu38pr6	1863	28	months	month	NNS
cord-005478-5iu38pr6	1863	29	.	.	.
cord-005478-5iu38pr6	1864	1	ARSA	ARSA	NNP
cord-005478-5iu38pr6	1864	2	activity	activity	NN
cord-005478-5iu38pr6	1864	3	in	in	IN
cord-005478-5iu38pr6	1864	4	CSF	CSF	NNP
cord-005478-5iu38pr6	1864	5	showed	show	VBD
cord-005478-5iu38pr6	1864	6	a	a	DT
cord-005478-5iu38pr6	1864	7	similar	similar	JJ
cord-005478-5iu38pr6	1864	8	pattern	pattern	NN
cord-005478-5iu38pr6	1864	9	;	;	:
cord-005478-5iu38pr6	1864	10	normal	normal	JJ
cord-005478-5iu38pr6	1864	11	levels	level	NNS
cord-005478-5iu38pr6	1864	12	were	be	VBD
cord-005478-5iu38pr6	1864	13	observed	observe	VBN
cord-005478-5iu38pr6	1864	14	9	9	CD
cord-005478-5iu38pr6	1864	15	-	-	SYM
cord-005478-5iu38pr6	1864	16	12	12	CD
cord-005478-5iu38pr6	1864	17	months	month	NNS
cord-005478-5iu38pr6	1864	18	post	post	NN
cord-005478-5iu38pr6	1864	19	-	-	NN
cord-005478-5iu38pr6	1864	20	treatment	treatment	JJ
cord-005478-5iu38pr6	1864	21	,	,	,
cord-005478-5iu38pr6	1864	22	demonstrating	demonstrate	VBG
cord-005478-5iu38pr6	1864	23	effective	effective	JJ
cord-005478-5iu38pr6	1864	24	enzymatic	enzymatic	JJ
cord-005478-5iu38pr6	1864	25	production	production	NN
cord-005478-5iu38pr6	1864	26	in	in	IN
cord-005478-5iu38pr6	1864	27	the	the	DT
cord-005478-5iu38pr6	1864	28	central	central	JJ
cord-005478-5iu38pr6	1864	29	nervous	nervous	JJ
cord-005478-5iu38pr6	1864	30	system	system	NN
cord-005478-5iu38pr6	1864	31	(	(	-LRB-
cord-005478-5iu38pr6	1864	32	CNS	CNS	NNP
cord-005478-5iu38pr6	1864	33	)	)	-RRB-
cord-005478-5iu38pr6	1864	34	.	.	.
cord-005478-5iu38pr6	1865	1	The	the	DT
cord-005478-5iu38pr6	1865	2	majority	majority	NN
cord-005478-5iu38pr6	1865	3	of	of	IN
cord-005478-5iu38pr6	1865	4	LI	LI	NNP
cord-005478-5iu38pr6	1865	5	and	and	CC
cord-005478-5iu38pr6	1865	6	EJ	EJ	NNP
cord-005478-5iu38pr6	1865	7	subjects	subject	NNS
cord-005478-5iu38pr6	1865	8	treated	treat	VBN
cord-005478-5iu38pr6	1865	9	before	before	IN
cord-005478-5iu38pr6	1865	10	the	the	DT
cord-005478-5iu38pr6	1865	11	onset	onset	NN
cord-005478-5iu38pr6	1865	12	of	of	IN
cord-005478-5iu38pr6	1865	13	overt	overt	JJ
cord-005478-5iu38pr6	1865	14	symptoms	symptom	NNS
cord-005478-5iu38pr6	1865	15	showed	show	VBD
cord-005478-5iu38pr6	1865	16	normal	normal	JJ
cord-005478-5iu38pr6	1865	17	motor	motor	NN
cord-005478-5iu38pr6	1865	18	development	development	NN
cord-005478-5iu38pr6	1865	19	,	,	,
cord-005478-5iu38pr6	1865	20	stabilization	stabilization	NN
cord-005478-5iu38pr6	1865	21	of	of	IN
cord-005478-5iu38pr6	1865	22	motor	motor	NN
cord-005478-5iu38pr6	1865	23	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	1865	24	or	or	CC
cord-005478-5iu38pr6	1865	25	a	a	DT
cord-005478-5iu38pr6	1865	26	significant	significant	JJ
cord-005478-5iu38pr6	1865	27	delay	delay	NN
cord-005478-5iu38pr6	1865	28	in	in	IN
cord-005478-5iu38pr6	1865	29	disease	disease	NN
cord-005478-5iu38pr6	1865	30	progression	progression	NN
cord-005478-5iu38pr6	1865	31	,	,	,
cord-005478-5iu38pr6	1865	32	as	as	IN
cord-005478-5iu38pr6	1865	33	measured	measure	VBN
cord-005478-5iu38pr6	1865	34	by	by	IN
cord-005478-5iu38pr6	1865	35	GMFM	GMFM	NNP
cord-005478-5iu38pr6	1865	36	total	total	JJ
cord-005478-5iu38pr6	1865	37	score	score	NN
cord-005478-5iu38pr6	1865	38	and	and	CC
cord-005478-5iu38pr6	1865	39	gross	gross	JJ
cord-005478-5iu38pr6	1865	40	motor	motor	NN
cord-005478-5iu38pr6	1865	41	function	function	NN
cord-005478-5iu38pr6	1865	42	classification	classification	NN
cord-005478-5iu38pr6	1865	43	(	(	-LRB-
cord-005478-5iu38pr6	1865	44	GMFC)-MLD	GMFC)-MLD	NNP
cord-005478-5iu38pr6	1865	45	.	.	.
cord-005478-5iu38pr6	1866	1	Cognitive	cognitive	JJ
cord-005478-5iu38pr6	1866	2	function	function	NN
cord-005478-5iu38pr6	1866	3	(	(	-LRB-
cord-005478-5iu38pr6	1866	4	measurements	measurement	NNS
cord-005478-5iu38pr6	1866	5	included	include	VBD
cord-005478-5iu38pr6	1866	6	performance	performance	NN
cord-005478-5iu38pr6	1866	7	and	and	CC
cord-005478-5iu38pr6	1866	8	verbal	verbal	JJ
cord-005478-5iu38pr6	1866	9	IQ	iq	NN
cord-005478-5iu38pr6	1866	10	scores	score	NNS
cord-005478-5iu38pr6	1866	11	)	)	-RRB-
cord-005478-5iu38pr6	1866	12	was	be	VBD
cord-005478-5iu38pr6	1866	13	maintained	maintain	VBN
cord-005478-5iu38pr6	1866	14	within	within	IN
cord-005478-5iu38pr6	1866	15	normal	normal	JJ
cord-005478-5iu38pr6	1866	16	range	range	NN
cord-005478-5iu38pr6	1866	17	for	for	IN
cord-005478-5iu38pr6	1866	18	most	most	JJS
cord-005478-5iu38pr6	1866	19	subjects	subject	NNS
cord-005478-5iu38pr6	1866	20	,	,	,
cord-005478-5iu38pr6	1866	21	independent	independent	JJ
cord-005478-5iu38pr6	1866	22	of	of	IN
cord-005478-5iu38pr6	1866	23	their	-PRON-	PRP$
cord-005478-5iu38pr6	1866	24	symptomatic	symptomatic	JJ
cord-005478-5iu38pr6	1866	25	status	status	NN
cord-005478-5iu38pr6	1866	26	at	at	IN
cord-005478-5iu38pr6	1866	27	the	the	DT
cord-005478-5iu38pr6	1866	28	time	time	NN
cord-005478-5iu38pr6	1866	29	of	of	IN
cord-005478-5iu38pr6	1866	30	treatment	treatment	NN
cord-005478-5iu38pr6	1866	31	.	.	.
cord-005478-5iu38pr6	1867	1	Improvement	improvement	NN
cord-005478-5iu38pr6	1867	2	or	or	CC
cord-005478-5iu38pr6	1867	3	stabilization	stabilization	NN
cord-005478-5iu38pr6	1867	4	of	of	IN
cord-005478-5iu38pr6	1867	5	central	central	JJ
cord-005478-5iu38pr6	1867	6	demyelination	demyelination	NN
cord-005478-5iu38pr6	1867	7	and	and	CC
cord-005478-5iu38pr6	1867	8	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1867	9	nervous	nervous	JJ
cord-005478-5iu38pr6	1867	10	system	system	NN
cord-005478-5iu38pr6	1867	11	(	(	-LRB-
cord-005478-5iu38pr6	1867	12	PNS	PNS	NNP
cord-005478-5iu38pr6	1867	13	)	)	-RRB-
cord-005478-5iu38pr6	1867	14	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	1867	15	were	be	VBD
cord-005478-5iu38pr6	1867	16	observed	observe	VBN
cord-005478-5iu38pr6	1867	17	in	in	IN
cord-005478-5iu38pr6	1867	18	most	most	JJS
cord-005478-5iu38pr6	1867	19	subjects	subject	NNS
cord-005478-5iu38pr6	1867	20	treated	treat	VBN
cord-005478-5iu38pr6	1867	21	.	.	.
cord-005478-5iu38pr6	1868	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1868	2	:	:	:
cord-005478-5iu38pr6	1869	1	This	this	DT
cord-005478-5iu38pr6	1869	2	interim	interim	JJ
cord-005478-5iu38pr6	1869	3	analysis	analysis	NN
cord-005478-5iu38pr6	1869	4	demonstrates	demonstrate	VBZ
cord-005478-5iu38pr6	1869	5	that	that	IN
cord-005478-5iu38pr6	1869	6	HSC	HSC	NNP
cord-005478-5iu38pr6	1869	7	-	-	HYPH
cord-005478-5iu38pr6	1869	8	GT	GT	NNP
cord-005478-5iu38pr6	1869	9	continues	continue	VBZ
cord-005478-5iu38pr6	1869	10	to	to	TO
cord-005478-5iu38pr6	1869	11	be	be	VB
cord-005478-5iu38pr6	1869	12	a	a	DT
cord-005478-5iu38pr6	1869	13	safe	safe	JJ
cord-005478-5iu38pr6	1869	14	and	and	CC
cord-005478-5iu38pr6	1869	15	well	well	RB
cord-005478-5iu38pr6	1869	16	-	-	HYPH
cord-005478-5iu38pr6	1869	17	tolerated	tolerate	VBN
cord-005478-5iu38pr6	1869	18	treatment	treatment	NN
cord-005478-5iu38pr6	1869	19	for	for	IN
cord-005478-5iu38pr6	1869	20	all	all	DT
cord-005478-5iu38pr6	1869	21	MLD	MLD	NNP
cord-005478-5iu38pr6	1869	22	subjects	subject	NNS
cord-005478-5iu38pr6	1869	23	treated	treat	VBN
cord-005478-5iu38pr6	1869	24	with	with	IN
cord-005478-5iu38pr6	1869	25	a	a	DT
cord-005478-5iu38pr6	1869	26	clinical	clinical	JJ
cord-005478-5iu38pr6	1869	27	follow	follow	NN
cord-005478-5iu38pr6	1869	28	-	-	HYPH
cord-005478-5iu38pr6	1869	29	up	up	NN
cord-005478-5iu38pr6	1869	30	≤8	≤8	NN
cord-005478-5iu38pr6	1869	31	years	year	NNS
cord-005478-5iu38pr6	1869	32	.	.	.
cord-005478-5iu38pr6	1870	1	All	all	DT
cord-005478-5iu38pr6	1870	2	subjects	subject	NNS
cord-005478-5iu38pr6	1870	3	achieved	achieve	VBD
cord-005478-5iu38pr6	1870	4	high	high	JJ
cord-005478-5iu38pr6	1870	5	levels	level	NNS
cord-005478-5iu38pr6	1870	6	of	of	IN
cord-005478-5iu38pr6	1870	7	multi	multi	JJ
cord-005478-5iu38pr6	1870	8	-	-	JJ
cord-005478-5iu38pr6	1870	9	linage	linage	NN
cord-005478-5iu38pr6	1870	10	engraftment	engraftment	NN
cord-005478-5iu38pr6	1870	11	,	,	,
cord-005478-5iu38pr6	1870	12	polyclonal	polyclonal	JJ
cord-005478-5iu38pr6	1870	13	hematological	hematological	JJ
cord-005478-5iu38pr6	1870	14	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	1870	15	and	and	CC
cord-005478-5iu38pr6	1870	16	central	central	JJ
cord-005478-5iu38pr6	1870	17	and	and	CC
cord-005478-5iu38pr6	1870	18	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1870	19	ARSA	ARSA	NNP
cord-005478-5iu38pr6	1870	20	activity	activity	NN
cord-005478-5iu38pr6	1870	21	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	1870	22	within	within	IN
cord-005478-5iu38pr6	1870	23	or	or	CC
cord-005478-5iu38pr6	1870	24	above	above	IN
cord-005478-5iu38pr6	1870	25	normal	normal	JJ
cord-005478-5iu38pr6	1870	26	levels	level	NNS
cord-005478-5iu38pr6	1870	27	.	.	.
cord-005478-5iu38pr6	1871	1	Patients	patient	NNS
cord-005478-5iu38pr6	1871	2	treated	treat	VBN
cord-005478-5iu38pr6	1871	3	prior	prior	RB
cord-005478-5iu38pr6	1871	4	to	to	IN
cord-005478-5iu38pr6	1871	5	symptom	symptom	NN
cord-005478-5iu38pr6	1871	6	onset	onset	NN
cord-005478-5iu38pr6	1871	7	achieved	achieve	VBD
cord-005478-5iu38pr6	1871	8	a	a	DT
cord-005478-5iu38pr6	1871	9	sustained	sustained	JJ
cord-005478-5iu38pr6	1871	10	clinical	clinical	JJ
cord-005478-5iu38pr6	1871	11	benefit	benefit	NN
cord-005478-5iu38pr6	1871	12	in	in	IN
cord-005478-5iu38pr6	1871	13	motor	motor	NN
cord-005478-5iu38pr6	1871	14	and	and	CC
cord-005478-5iu38pr6	1871	15	cognitive	cognitive	JJ
cord-005478-5iu38pr6	1871	16	function	function	NN
cord-005478-5iu38pr6	1871	17	as	as	RB
cord-005478-5iu38pr6	1871	18	well	well	RB
cord-005478-5iu38pr6	1871	19	as	as	IN
cord-005478-5iu38pr6	1871	20	on	on	IN
cord-005478-5iu38pr6	1871	21	instrumental	instrumental	JJ
cord-005478-5iu38pr6	1871	22	biomarkers	biomarker	NNS
cord-005478-5iu38pr6	1871	23	of	of	IN
cord-005478-5iu38pr6	1871	24	PNS	PNS	NNP
cord-005478-5iu38pr6	1871	25	and	and	CC
cord-005478-5iu38pr6	1871	26	CNS	CNS	NNP
cord-005478-5iu38pr6	1871	27	demyelination	demyelination	NN
cord-005478-5iu38pr6	1871	28	,	,	,
cord-005478-5iu38pr6	1871	29	suggesting	suggest	VBG
cord-005478-5iu38pr6	1871	30	that	that	IN
cord-005478-5iu38pr6	1871	31	autologous	autologous	JJ
cord-005478-5iu38pr6	1871	32	,	,	,
cord-005478-5iu38pr6	1871	33	ex	ex	JJ
cord-005478-5iu38pr6	1871	34	-	-	NN
cord-005478-5iu38pr6	1871	35	vivo	vivo	JJ
cord-005478-5iu38pr6	1871	36	HSC	HSC	NNP
cord-005478-5iu38pr6	1871	37	-	-	HYPH
cord-005478-5iu38pr6	1871	38	GT	GT	NNP
cord-005478-5iu38pr6	1871	39	is	be	VBZ
cord-005478-5iu38pr6	1871	40	a	a	DT
cord-005478-5iu38pr6	1871	41	highly	highly	RB
cord-005478-5iu38pr6	1871	42	promising	promising	JJ
cord-005478-5iu38pr6	1871	43	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1871	44	approach	approach	NN
cord-005478-5iu38pr6	1871	45	for	for	IN
cord-005478-5iu38pr6	1871	46	LI	LI	NNP
cord-005478-5iu38pr6	1871	47	and	and	CC
cord-005478-5iu38pr6	1871	48	EJ	EJ	NNP
cord-005478-5iu38pr6	1871	49	MLD	MLD	NNP
cord-005478-5iu38pr6	1871	50	pre	pre	JJ
cord-005478-5iu38pr6	1871	51	-	-	JJ
cord-005478-5iu38pr6	1871	52	symptomatic	symptomatic	JJ
cord-005478-5iu38pr6	1871	53	subjects	subject	NNS
cord-005478-5iu38pr6	1871	54	.	.	.
cord-005478-5iu38pr6	1872	1	Further	further	JJ
cord-005478-5iu38pr6	1872	2	research	research	NN
cord-005478-5iu38pr6	1872	3	is	be	VBZ
cord-005478-5iu38pr6	1872	4	needed	need	VBN
cord-005478-5iu38pr6	1872	5	to	to	TO
cord-005478-5iu38pr6	1872	6	support	support	VB
cord-005478-5iu38pr6	1872	7	the	the	DT
cord-005478-5iu38pr6	1872	8	benefit	benefit	NN
cord-005478-5iu38pr6	1872	9	:	:	:
cord-005478-5iu38pr6	1872	10	risk	risk	NN
cord-005478-5iu38pr6	1872	11	profile	profile	NN
cord-005478-5iu38pr6	1872	12	in	in	IN
cord-005478-5iu38pr6	1872	13	EJ	EJ	NNP
cord-005478-5iu38pr6	1872	14	patients	patient	NNS
cord-005478-5iu38pr6	1872	15	.	.	.
cord-005478-5iu38pr6	1873	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	1873	2	Trial	Trial	NNP
cord-005478-5iu38pr6	1873	3	Registry	Registry	NNP
cord-005478-5iu38pr6	1873	4	:	:	:
cord-005478-5iu38pr6	1874	1	NCT01560182	NCT01560182	NNP
cord-005478-5iu38pr6	1875	1	https://www.clinicaltrials.gov/ct2/show/NCT01560182	https://www.clinicaltrials.gov/ct2/show/nct01560182	VB
cord-005478-5iu38pr6	1875	2	?	?	.
cord-005478-5iu38pr6	1876	1	term=	term=	NNP
cord-005478-5iu38pr6	1877	1	NCT01560182&rank=1	NCT01560182&rank=1	NNP
cord-005478-5iu38pr6	1877	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	1877	3	:	:	:
cord-005478-5iu38pr6	1878	1	The	the	DT
cord-005478-5iu38pr6	1878	2	San	San	NNP
cord-005478-5iu38pr6	1878	3	Raffaele	Raffaele	NNP
cord-005478-5iu38pr6	1878	4	Telethon	Telethon	NNP
cord-005478-5iu38pr6	1878	5	Institute	Institute	NNP
cord-005478-5iu38pr6	1878	6	for	for	IN
cord-005478-5iu38pr6	1878	7	Gene	Gene	NNP
cord-005478-5iu38pr6	1878	8	Therapy	Therapy	NNP
cord-005478-5iu38pr6	1878	9	(	(	-LRB-
cord-005478-5iu38pr6	1878	10	SR	SR	NNP
cord-005478-5iu38pr6	1878	11	-	-	HYPH
cord-005478-5iu38pr6	1878	12	TIGET	TIGET	NNP
cord-005478-5iu38pr6	1878	13	)	)	-RRB-
cord-005478-5iu38pr6	1878	14	is	be	VBZ
cord-005478-5iu38pr6	1878	15	a	a	DT
cord-005478-5iu38pr6	1878	16	joint	joint	JJ
cord-005478-5iu38pr6	1878	17	venture	venture	NN
cord-005478-5iu38pr6	1878	18	between	between	IN
cord-005478-5iu38pr6	1878	19	Telethon	Telethon	NNP
cord-005478-5iu38pr6	1878	20	and	and	CC
cord-005478-5iu38pr6	1878	21	Ospedale	Ospedale	NNP
cord-005478-5iu38pr6	1878	22	San	San	NNP
cord-005478-5iu38pr6	1878	23	Raffaele	Raffaele	NNP
cord-005478-5iu38pr6	1878	24	(	(	-LRB-
cord-005478-5iu38pr6	1878	25	OSR	OSR	NNP
cord-005478-5iu38pr6	1878	26	)	)	-RRB-
cord-005478-5iu38pr6	1878	27	.	.	.
cord-005478-5iu38pr6	1879	1	ADA	ADA	NNP
cord-005478-5iu38pr6	1879	2	-	-	HYPH
cord-005478-5iu38pr6	1879	3	SCID	SCID	NNP
cord-005478-5iu38pr6	1879	4	gene	gene	NN
cord-005478-5iu38pr6	1879	5	therapy	therapy	NN
cord-005478-5iu38pr6	1879	6	(	(	-LRB-
cord-005478-5iu38pr6	1879	7	Strimvelis	Strimvelis	NNP
cord-005478-5iu38pr6	1879	8	)	)	-RRB-
cord-005478-5iu38pr6	1879	9	was	be	VBD
cord-005478-5iu38pr6	1879	10	licensed	license	VBN
cord-005478-5iu38pr6	1879	11	to	to	IN
cord-005478-5iu38pr6	1879	12	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-005478-5iu38pr6	1879	13	(	(	-LRB-
cord-005478-5iu38pr6	1879	14	GSK	GSK	NNP
cord-005478-5iu38pr6	1879	15	)	)	-RRB-
cord-005478-5iu38pr6	1879	16	in	in	IN
cord-005478-5iu38pr6	1879	17	2010	2010	CD
cord-005478-5iu38pr6	1879	18	and	and	CC
cord-005478-5iu38pr6	1879	19	received	receive	VBD
cord-005478-5iu38pr6	1879	20	European	european	JJ
cord-005478-5iu38pr6	1879	21	marketing	marketing	NN
cord-005478-5iu38pr6	1879	22	authorization	authorization	NN
cord-005478-5iu38pr6	1879	23	in	in	IN
cord-005478-5iu38pr6	1879	24	2016	2016	CD
cord-005478-5iu38pr6	1879	25	.	.	.
cord-005478-5iu38pr6	1880	1	Alessandro	Alessandro	NNP
cord-005478-5iu38pr6	1880	2	Aiuti	Aiuti	NNP
cord-005478-5iu38pr6	1880	3	is	be	VBZ
cord-005478-5iu38pr6	1880	4	the	the	DT
cord-005478-5iu38pr6	1880	5	PI	pi	NN
cord-005478-5iu38pr6	1880	6	of	of	IN
cord-005478-5iu38pr6	1880	7	the	the	DT
cord-005478-5iu38pr6	1880	8	ADA	ADA	NNP
cord-005478-5iu38pr6	1880	9	-	-	HYPH
cord-005478-5iu38pr6	1880	10	SCID	SCID	NNP
cord-005478-5iu38pr6	1880	11	long	long	JJ
cord-005478-5iu38pr6	1880	12	-	-	HYPH
cord-005478-5iu38pr6	1880	13	term	term	NN
cord-005478-5iu38pr6	1880	14	follow	follow	VB
cord-005478-5iu38pr6	1880	15	up	up	RP
cord-005478-5iu38pr6	1880	16	clinical	clinical	JJ
cord-005478-5iu38pr6	1880	17	trial	trial	NN
cord-005478-5iu38pr6	1880	18	sponsored	sponsor	VBN
cord-005478-5iu38pr6	1880	19	by	by	IN
cord-005478-5iu38pr6	1880	20	GSK	GSK	NNP
cord-005478-5iu38pr6	1880	21	.	.	.
cord-005478-5iu38pr6	1881	1	Strimvelis	Strimvelis	NNP
cord-005478-5iu38pr6	1881	2	was	be	VBD
cord-005478-5iu38pr6	1881	3	licensed	license	VBN
cord-005478-5iu38pr6	1881	4	to	to	IN
cord-005478-5iu38pr6	1881	5	Orchard	Orchard	NNP
cord-005478-5iu38pr6	1881	6	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	1881	7	(	(	-LRB-
cord-005478-5iu38pr6	1881	8	OTL	OTL	NNP
cord-005478-5iu38pr6	1881	9	)	)	-RRB-
cord-005478-5iu38pr6	1881	10	in	in	IN
cord-005478-5iu38pr6	1881	11	April	April	NNP
cord-005478-5iu38pr6	1881	12	2018	2018	CD
cord-005478-5iu38pr6	1881	13	.	.	.
cord-005478-5iu38pr6	1882	1	Lentiglobin	Lentiglobin	NNP
cord-005478-5iu38pr6	1882	2	gene	gene	NN
cord-005478-5iu38pr6	1882	3	therapy	therapy	NN
cord-005478-5iu38pr6	1882	4	in	in	IN
cord-005478-5iu38pr6	1882	5	patients	patient	NNS
cord-005478-5iu38pr6	1882	6	with	with	IN
cord-005478-5iu38pr6	1882	7	sickle	sickle	NN
cord-005478-5iu38pr6	1882	8	cell	cell	NN
cord-005478-5iu38pr6	1882	9	disease	disease	NN
cord-005478-5iu38pr6	1882	10	:	:	:
cord-005478-5iu38pr6	1883	1	Updated	update	VBN
cord-005478-5iu38pr6	1883	2	interim	interim	JJ
cord-005478-5iu38pr6	1883	3	results	result	NNS
cord-005478-5iu38pr6	1883	4	from	from	IN
cord-005478-5iu38pr6	1883	5	HGB-206	HGB-206	NNP
cord-005478-5iu38pr6	1883	6	Background	Background	NNP
cord-005478-5iu38pr6	1883	7	:	:	:
cord-005478-5iu38pr6	1884	1	β	β	NN
cord-005478-5iu38pr6	1884	2	-	-	HYPH
cord-005478-5iu38pr6	1884	3	globin	globin	NN
cord-005478-5iu38pr6	1884	4	gene	gene	NN
cord-005478-5iu38pr6	1884	5	transfer	transfer	NN
cord-005478-5iu38pr6	1884	6	may	may	MD
cord-005478-5iu38pr6	1884	7	reduce	reduce	VB
cord-005478-5iu38pr6	1884	8	or	or	CC
cord-005478-5iu38pr6	1884	9	eliminate	eliminate	VB
cord-005478-5iu38pr6	1884	10	complications	complication	NNS
cord-005478-5iu38pr6	1884	11	in	in	IN
cord-005478-5iu38pr6	1884	12	patients	patient	NNS
cord-005478-5iu38pr6	1884	13	with	with	IN
cord-005478-5iu38pr6	1884	14	sickle	sickle	NN
cord-005478-5iu38pr6	1884	15	cell	cell	NN
cord-005478-5iu38pr6	1884	16	disease	disease	NN
cord-005478-5iu38pr6	1884	17	(	(	-LRB-
cord-005478-5iu38pr6	1884	18	SCD	SCD	NNP
cord-005478-5iu38pr6	1884	19	)	)	-RRB-
cord-005478-5iu38pr6	1884	20	.	.	.
cord-005478-5iu38pr6	1885	1	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1885	2	gene	gene	NN
cord-005478-5iu38pr6	1885	3	therapy	therapy	NN
cord-005478-5iu38pr6	1885	4	(	(	-LRB-
cord-005478-5iu38pr6	1885	5	GT	GT	NNP
cord-005478-5iu38pr6	1885	6	)	)	-RRB-
cord-005478-5iu38pr6	1885	7	comprises	comprise	VBZ
cord-005478-5iu38pr6	1885	8	drug	drug	NN
cord-005478-5iu38pr6	1885	9	product	product	NN
cord-005478-5iu38pr6	1885	10	(	(	-LRB-
cord-005478-5iu38pr6	1885	11	DP	DP	NNP
cord-005478-5iu38pr6	1885	12	)	)	-RRB-
cord-005478-5iu38pr6	1885	13	made	make	VBN
cord-005478-5iu38pr6	1885	14	from	from	IN
cord-005478-5iu38pr6	1885	15	autologous	autologous	JJ
cord-005478-5iu38pr6	1885	16	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1885	17	stem	stem	NN
cord-005478-5iu38pr6	1885	18	cells	cell	NNS
cord-005478-5iu38pr6	1885	19	(	(	-LRB-
cord-005478-5iu38pr6	1885	20	HSCs	hscs	NN
cord-005478-5iu38pr6	1885	21	)	)	-RRB-
cord-005478-5iu38pr6	1885	22	transduced	transduce	VBN
cord-005478-5iu38pr6	1885	23	with	with	IN
cord-005478-5iu38pr6	1885	24	the	the	DT
cord-005478-5iu38pr6	1885	25	BB305	BB305	NNP
cord-005478-5iu38pr6	1885	26	lentiviral	lentiviral	NNP
cord-005478-5iu38pr6	1885	27	vector	vector	NN
cord-005478-5iu38pr6	1885	28	(	(	-LRB-
cord-005478-5iu38pr6	1885	29	LVV	LVV	NNP
cord-005478-5iu38pr6	1885	30	)	)	-RRB-
cord-005478-5iu38pr6	1885	31	encoding	encode	VBG
cord-005478-5iu38pr6	1885	32	β	β	NN
cord-005478-5iu38pr6	1885	33	-	-	HYPH
cord-005478-5iu38pr6	1885	34	globin	globin	NN
cord-005478-5iu38pr6	1885	35	with	with	IN
cord-005478-5iu38pr6	1885	36	an	an	DT
cord-005478-5iu38pr6	1885	37	anti	anti	JJ
cord-005478-5iu38pr6	1885	38	-	-	JJ
cord-005478-5iu38pr6	1885	39	sickling	sickling	JJ
cord-005478-5iu38pr6	1885	40	T87Q	t87q	JJ
cord-005478-5iu38pr6	1885	41	substitution	substitution	NN
cord-005478-5iu38pr6	1885	42	(	(	-LRB-
cord-005478-5iu38pr6	1885	43	HbA	HbA	NNP
cord-005478-5iu38pr6	1885	44	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1885	45	)	)	-RRB-
cord-005478-5iu38pr6	1885	46	.	.	.
cord-005478-5iu38pr6	1886	1	The	the	DT
cord-005478-5iu38pr6	1886	2	safety	safety	NN
cord-005478-5iu38pr6	1886	3	and	and	CC
cord-005478-5iu38pr6	1886	4	efficacy	efficacy	NN
cord-005478-5iu38pr6	1886	5	of	of	IN
cord-005478-5iu38pr6	1886	6	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1886	7	GT	GT	NNP
cord-005478-5iu38pr6	1886	8	in	in	IN
cord-005478-5iu38pr6	1886	9	adults	adult	NNS
cord-005478-5iu38pr6	1886	10	with	with	IN
cord-005478-5iu38pr6	1886	11	SCD	SCD	NNP
cord-005478-5iu38pr6	1886	12	is	be	VBZ
cord-005478-5iu38pr6	1886	13	being	be	VBG
cord-005478-5iu38pr6	1886	14	evaluated	evaluate	VBN
cord-005478-5iu38pr6	1886	15	in	in	IN
cord-005478-5iu38pr6	1886	16	a	a	DT
cord-005478-5iu38pr6	1886	17	phase	phase	NN
cord-005478-5iu38pr6	1886	18	1	1	CD
cord-005478-5iu38pr6	1886	19	study	study	NN
cord-005478-5iu38pr6	1886	20	,	,	,
cord-005478-5iu38pr6	1886	21	HGB-206	HGB-206	NNP
cord-005478-5iu38pr6	1886	22	(	(	-LRB-
cord-005478-5iu38pr6	1886	23	NCT02140554	NCT02140554	NNP
cord-005478-5iu38pr6	1886	24	)	)	-RRB-
cord-005478-5iu38pr6	1886	25	.	.	.
cord-005478-5iu38pr6	1887	1	Patients	patient	NNS
cord-005478-5iu38pr6	1887	2	were	be	VBD
cord-005478-5iu38pr6	1887	3	initially	initially	RB
cord-005478-5iu38pr6	1887	4	treated	treat	VBN
cord-005478-5iu38pr6	1887	5	with	with	IN
cord-005478-5iu38pr6	1887	6	DP	DP	NNP
cord-005478-5iu38pr6	1887	7	made	make	VBN
cord-005478-5iu38pr6	1887	8	from	from	IN
cord-005478-5iu38pr6	1887	9	bone	bone	NN
cord-005478-5iu38pr6	1887	10	marrow	marrow	NN
cord-005478-5iu38pr6	1887	11	harvested	harvest	VBN
cord-005478-5iu38pr6	1887	12	(	(	-LRB-
cord-005478-5iu38pr6	1887	13	BMH	BMH	NNP
cord-005478-5iu38pr6	1887	14	)	)	-RRB-
cord-005478-5iu38pr6	1887	15	HSCs	HSCs	.
cord-005478-5iu38pr6	1887	16	(	(	-LRB-
cord-005478-5iu38pr6	1887	17	Group	Group	NNP
cord-005478-5iu38pr6	1887	18	A	A	NNP
cord-005478-5iu38pr6	1887	19	,	,	,
cord-005478-5iu38pr6	1887	20	fully	fully	RB
cord-005478-5iu38pr6	1887	21	enrolled	enrol	VBN
cord-005478-5iu38pr6	1887	22	)	)	-RRB-
cord-005478-5iu38pr6	1887	23	,	,	,
cord-005478-5iu38pr6	1887	24	then	then	RB
cord-005478-5iu38pr6	1887	25	from	from	IN
cord-005478-5iu38pr6	1887	26	DP	DP	NNP
cord-005478-5iu38pr6	1887	27	made	make	VBN
cord-005478-5iu38pr6	1887	28	from	from	IN
cord-005478-5iu38pr6	1887	29	BMH	BMH	NNP
cord-005478-5iu38pr6	1887	30	HSCs	HSCs	.
cord-005478-5iu38pr6	1887	31	but	but	CC
cord-005478-5iu38pr6	1887	32	using	use	VBG
cord-005478-5iu38pr6	1887	33	a	a	DT
cord-005478-5iu38pr6	1887	34	refined	refined	JJ
cord-005478-5iu38pr6	1887	35	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	1887	36	process	process	NN
cord-005478-5iu38pr6	1887	37	(	(	-LRB-
cord-005478-5iu38pr6	1887	38	Group	Group	NNP
cord-005478-5iu38pr6	1887	39	B	B	NNP
cord-005478-5iu38pr6	1887	40	,	,	,
cord-005478-5iu38pr6	1887	41	fully	fully	RB
cord-005478-5iu38pr6	1887	42	enrolled	enrol	VBN
cord-005478-5iu38pr6	1887	43	)	)	-RRB-
cord-005478-5iu38pr6	1887	44	,	,	,
cord-005478-5iu38pr6	1887	45	and	and	CC
cord-005478-5iu38pr6	1887	46	subsequently	subsequently	RB
cord-005478-5iu38pr6	1887	47	from	from	IN
cord-005478-5iu38pr6	1887	48	plerixafor	plerixafor	NN
cord-005478-5iu38pr6	1887	49	mobilized	mobilize	VBD
cord-005478-5iu38pr6	1887	50	HSCs	HSCs	.
cord-005478-5iu38pr6	1887	51	(	(	-LRB-
cord-005478-5iu38pr6	1887	52	Group	Group	NNP
cord-005478-5iu38pr6	1887	53	C	C	NNP
cord-005478-5iu38pr6	1887	54	,	,	,
cord-005478-5iu38pr6	1887	55	currently	currently	RB
cord-005478-5iu38pr6	1887	56	enrolling	enrol	VBG
cord-005478-5iu38pr6	1887	57	)	)	-RRB-
cord-005478-5iu38pr6	1887	58	.	.	.
cord-005478-5iu38pr6	1888	1	Methods	method	NNS
cord-005478-5iu38pr6	1888	2	:	:	:
cord-005478-5iu38pr6	1888	3	Adults	adult	NNS
cord-005478-5iu38pr6	1888	4	with	with	IN
cord-005478-5iu38pr6	1888	5	severe	severe	JJ
cord-005478-5iu38pr6	1888	6	SCD	SCD	NNP
cord-005478-5iu38pr6	1888	7	(	(	-LRB-
cord-005478-5iu38pr6	1888	8	history	history	NN
cord-005478-5iu38pr6	1888	9	of	of	IN
cord-005478-5iu38pr6	1888	10	recurrent	recurrent	JJ
cord-005478-5iu38pr6	1888	11	vaso	vaso	JJ
cord-005478-5iu38pr6	1888	12	-	-	HYPH
cord-005478-5iu38pr6	1888	13	occlusive	occlusive	JJ
cord-005478-5iu38pr6	1888	14	crisis	crisis	NN
cord-005478-5iu38pr6	1888	15	,	,	,
cord-005478-5iu38pr6	1888	16	acute	acute	JJ
cord-005478-5iu38pr6	1888	17	chest	chest	NN
cord-005478-5iu38pr6	1888	18	syndrome	syndrome	NN
cord-005478-5iu38pr6	1888	19	,	,	,
cord-005478-5iu38pr6	1888	20	stroke	stroke	NN
cord-005478-5iu38pr6	1888	21	,	,	,
cord-005478-5iu38pr6	1888	22	or	or	CC
cord-005478-5iu38pr6	1888	23	tricuspid	tricuspid	JJ
cord-005478-5iu38pr6	1888	24	regurgitant	regurgitant	JJ
cord-005478-5iu38pr6	1888	25	jet	jet	NN
cord-005478-5iu38pr6	1888	26	velocity	velocity	NN
cord-005478-5iu38pr6	1888	27	of	of	IN
cord-005478-5iu38pr6	1888	28	>	>	$
cord-005478-5iu38pr6	1888	29	2.5	2.5	CD
cord-005478-5iu38pr6	1888	30	m	m	NN
cord-005478-5iu38pr6	1888	31	/	/	SYM
cord-005478-5iu38pr6	1888	32	s	s	NN
cord-005478-5iu38pr6	1888	33	)	)	-RRB-
cord-005478-5iu38pr6	1888	34	were	be	VBD
cord-005478-5iu38pr6	1888	35	enrolled	enrol	VBN
cord-005478-5iu38pr6	1888	36	.	.	.
cord-005478-5iu38pr6	1889	1	Autologous	autologous	JJ
cord-005478-5iu38pr6	1889	2	CD34	CD34	NNP
cord-005478-5iu38pr6	1889	3	+	+	CC
cord-005478-5iu38pr6	1889	4	cells	cell	NNS
cord-005478-5iu38pr6	1889	5	,	,	,
cord-005478-5iu38pr6	1889	6	collected	collect	VBN
cord-005478-5iu38pr6	1889	7	by	by	IN
cord-005478-5iu38pr6	1889	8	BMH	BMH	NNP
cord-005478-5iu38pr6	1889	9	or	or	CC
cord-005478-5iu38pr6	1889	10	apheresis	apheresis	NN
cord-005478-5iu38pr6	1889	11	following	follow	VBG
cord-005478-5iu38pr6	1889	12	mobilization	mobilization	NN
cord-005478-5iu38pr6	1889	13	with	with	IN
cord-005478-5iu38pr6	1889	14	240	240	CD
cord-005478-5iu38pr6	1889	15	μg	μg	NNP
cord-005478-5iu38pr6	1889	16	/	/	SYM
cord-005478-5iu38pr6	1889	17	kg	kg	NN
cord-005478-5iu38pr6	1889	18	plerixafor	plerixafor	NN
cord-005478-5iu38pr6	1889	19	,	,	,
cord-005478-5iu38pr6	1889	20	were	be	VBD
cord-005478-5iu38pr6	1889	21	transduced	transduce	VBN
cord-005478-5iu38pr6	1889	22	with	with	IN
cord-005478-5iu38pr6	1889	23	BB305	BB305	NNP
cord-005478-5iu38pr6	1889	24	LVV	LVV	NNP
cord-005478-5iu38pr6	1889	25	.	.	.
cord-005478-5iu38pr6	1890	1	After	after	IN
cord-005478-5iu38pr6	1890	2	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	1890	3	busulfan	busulfan	NN
cord-005478-5iu38pr6	1890	4	conditioning	conditioning	NNP
cord-005478-5iu38pr6	1890	5	(	(	-LRB-
cord-005478-5iu38pr6	1890	6	area	area	NN
cord-005478-5iu38pr6	1890	7	under	under	IN
cord-005478-5iu38pr6	1890	8	the	the	DT
cord-005478-5iu38pr6	1890	9	curve	curve	NN
cord-005478-5iu38pr6	1890	10	goal	goal	NN
cord-005478-5iu38pr6	1890	11	of	of	IN
cord-005478-5iu38pr6	1890	12	5000	5000	CD
cord-005478-5iu38pr6	1890	13	[	[	-LRB-
cord-005478-5iu38pr6	1890	14	range	range	NN
cord-005478-5iu38pr6	1890	15	4400	4400	CD
cord-005478-5iu38pr6	1890	16	-5400	-5400	NN
cord-005478-5iu38pr6	1890	17	]	]	-RRB-
cord-005478-5iu38pr6	1891	1	μM*min	μM*min	NFP
cord-005478-5iu38pr6	1892	1	daily	daily	NNP
cord-005478-5iu38pr6	1892	2	)	)	-RRB-
cord-005478-5iu38pr6	1892	3	,	,	,
cord-005478-5iu38pr6	1892	4	patients	patient	NNS
cord-005478-5iu38pr6	1892	5	were	be	VBD
cord-005478-5iu38pr6	1892	6	infused	infuse	VBN
cord-005478-5iu38pr6	1892	7	with	with	IN
cord-005478-5iu38pr6	1892	8	the	the	DT
cord-005478-5iu38pr6	1892	9	transduced	transduce	VBN
cord-005478-5iu38pr6	1892	10	cells	cell	NNS
cord-005478-5iu38pr6	1892	11	and	and	CC
cord-005478-5iu38pr6	1892	12	monitored	monitor	VBD
cord-005478-5iu38pr6	1892	13	for	for	IN
cord-005478-5iu38pr6	1892	14	safety	safety	NN
cord-005478-5iu38pr6	1892	15	and	and	CC
cord-005478-5iu38pr6	1892	16	efficacy	efficacy	NN
cord-005478-5iu38pr6	1892	17	.	.	.
cord-005478-5iu38pr6	1893	1	Summary	summary	NN
cord-005478-5iu38pr6	1893	2	statistics	statistic	NNS
cord-005478-5iu38pr6	1893	3	are	be	VBP
cord-005478-5iu38pr6	1893	4	median	median	JJ
cord-005478-5iu38pr6	1893	5	(	(	-LRB-
cord-005478-5iu38pr6	1893	6	min	min	NNP
cord-005478-5iu38pr6	1893	7	-	-	HYPH
cord-005478-5iu38pr6	1893	8	max	max	NNP
cord-005478-5iu38pr6	1893	9	)	)	-RRB-
cord-005478-5iu38pr6	1893	10	.	.	.
cord-005478-5iu38pr6	1894	1	Results	result	NNS
cord-005478-5iu38pr6	1894	2	:	:	:
cord-005478-5iu38pr6	1895	1	As	as	IN
cord-005478-5iu38pr6	1895	2	of	of	IN
cord-005478-5iu38pr6	1895	3	May	May	NNP
cord-005478-5iu38pr6	1895	4	15	15	CD
cord-005478-5iu38pr6	1895	5	,	,	,
cord-005478-5iu38pr6	1895	6	2018	2018	CD
cord-005478-5iu38pr6	1895	7	,	,	,
cord-005478-5iu38pr6	1895	8	22	22	CD
cord-005478-5iu38pr6	1895	9	patients	patient	NNS
cord-005478-5iu38pr6	1895	10	had	have	VBD
cord-005478-5iu38pr6	1895	11	HSCs	hsc	NNS
cord-005478-5iu38pr6	1895	12	collected	collect	VBN
cord-005478-5iu38pr6	1895	13	,	,	,
cord-005478-5iu38pr6	1895	14	18	18	CD
cord-005478-5iu38pr6	1895	15	patients	patient	NNS
cord-005478-5iu38pr6	1895	16	had	have	VBD
cord-005478-5iu38pr6	1895	17	DP	DP	NNP
cord-005478-5iu38pr6	1895	18	manufactured	manufacture	VBN
cord-005478-5iu38pr6	1895	19	and	and	CC
cord-005478-5iu38pr6	1895	20	15	15	CD
cord-005478-5iu38pr6	1895	21	patients	patient	NNS
cord-005478-5iu38pr6	1895	22	were	be	VBD
cord-005478-5iu38pr6	1895	23	treated	treat	VBN
cord-005478-5iu38pr6	1895	24	.	.	.
cord-005478-5iu38pr6	1896	1	Eleven	eleven	CD
cord-005478-5iu38pr6	1896	2	patients	patient	NNS
cord-005478-5iu38pr6	1896	3	(	(	-LRB-
cord-005478-5iu38pr6	1896	4	9	9	CD
cord-005478-5iu38pr6	1896	5	in	in	IN
cord-005478-5iu38pr6	1896	6	Group	Group	NNP
cord-005478-5iu38pr6	1896	7	A	A	NNP
cord-005478-5iu38pr6	1896	8	,	,	,
cord-005478-5iu38pr6	1896	9	2	2	CD
cord-005478-5iu38pr6	1896	10	in	in	IN
cord-005478-5iu38pr6	1896	11	Group	Group	NNP
cord-005478-5iu38pr6	1896	12	B	B	NNP
cord-005478-5iu38pr6	1896	13	)	)	-RRB-
cord-005478-5iu38pr6	1896	14	underwent	undergo	VBD
cord-005478-5iu38pr6	1896	15	BMH	BMH	NNP
cord-005478-5iu38pr6	1896	16	and	and	CC
cord-005478-5iu38pr6	1896	17	12	12	CD
cord-005478-5iu38pr6	1896	18	patients	patient	NNS
cord-005478-5iu38pr6	1896	19	(	(	-LRB-
cord-005478-5iu38pr6	1896	20	1	1	CD
cord-005478-5iu38pr6	1896	21	in	in	IN
cord-005478-5iu38pr6	1896	22	Group	Group	NNP
cord-005478-5iu38pr6	1896	23	B	B	NNP
cord-005478-5iu38pr6	1896	24	[	[	-LRB-
cord-005478-5iu38pr6	1896	25	who	who	WP
cord-005478-5iu38pr6	1896	26	also	also	RB
cord-005478-5iu38pr6	1896	27	had	have	VBD
cord-005478-5iu38pr6	1896	28	BMH	BMH	NNP
cord-005478-5iu38pr6	1896	29	]	]	-RRB-
cord-005478-5iu38pr6	1896	30	,	,	,
cord-005478-5iu38pr6	1896	31	11	11	CD
cord-005478-5iu38pr6	1896	32	in	in	IN
cord-005478-5iu38pr6	1896	33	Group	Group	NNP
cord-005478-5iu38pr6	1896	34	C	C	NNP
cord-005478-5iu38pr6	1896	35	)	)	-RRB-
cord-005478-5iu38pr6	1896	36	underwent	undergo	VBD
cord-005478-5iu38pr6	1896	37	mobilization/	mobilization/	CD
cord-005478-5iu38pr6	1896	38	apheresis	apheresis	NN
cord-005478-5iu38pr6	1896	39	.	.	.
cord-005478-5iu38pr6	1897	1	Median	median	NN
cord-005478-5iu38pr6	1897	2	of	of	IN
cord-005478-5iu38pr6	1897	3	4.3	4.3	CD
cord-005478-5iu38pr6	1897	4	(	(	-LRB-
cord-005478-5iu38pr6	1897	5	0.1	0.1	CD
cord-005478-5iu38pr6	1897	6	-	-	SYM
cord-005478-5iu38pr6	1897	7	10.8	10.8	CD
cord-005478-5iu38pr6	1897	8	)	)	-RRB-
cord-005478-5iu38pr6	1897	9	x	x	SYM
cord-005478-5iu38pr6	1897	10	10	10	CD
cord-005478-5iu38pr6	1897	11	6	6	CD
cord-005478-5iu38pr6	1897	12	and	and	CC
cord-005478-5iu38pr6	1897	13	10.4	10.4	CD
cord-005478-5iu38pr6	1897	14	(	(	-LRB-
cord-005478-5iu38pr6	1897	15	3.8	3.8	CD
cord-005478-5iu38pr6	1897	16	-21.6	-21.6	JJS
cord-005478-5iu38pr6	1897	17	)	)	-RRB-
cord-005478-5iu38pr6	1898	1	x	x	LS
cord-005478-5iu38pr6	1898	2	10	10	CD
cord-005478-5iu38pr6	1899	1	6	6	CD
cord-005478-5iu38pr6	1899	2	CD34	CD34	NNP
cord-005478-5iu38pr6	1899	3	+	+	CC
cord-005478-5iu38pr6	1899	4	cells	cell	NNS
cord-005478-5iu38pr6	1899	5	/	/	SYM
cord-005478-5iu38pr6	1899	6	kg	kg	NNS
cord-005478-5iu38pr6	1899	7	were	be	VBD
cord-005478-5iu38pr6	1899	8	collected	collect	VBN
cord-005478-5iu38pr6	1899	9	per	per	IN
cord-005478-5iu38pr6	1899	10	BMH	BMH	NNP
cord-005478-5iu38pr6	1899	11	(	(	-LRB-
cord-005478-5iu38pr6	1899	12	N=26	N=26	NNP
cord-005478-5iu38pr6	1899	13	)	)	-RRB-
cord-005478-5iu38pr6	1899	14	and	and	CC
cord-005478-5iu38pr6	1899	15	per	per	IN
cord-005478-5iu38pr6	1899	16	mobilization	mobilization	NN
cord-005478-5iu38pr6	1899	17	cycle	cycle	NN
cord-005478-5iu38pr6	1899	18	(	(	-LRB-
cord-005478-5iu38pr6	1899	19	N=17	N=17	NNP
cord-005478-5iu38pr6	1899	20	)	)	-RRB-
cord-005478-5iu38pr6	1899	21	,	,	,
cord-005478-5iu38pr6	1899	22	respectively	respectively	RB
cord-005478-5iu38pr6	1899	23	.	.	.
cord-005478-5iu38pr6	1900	1	Eighteen	eighteen	CD
cord-005478-5iu38pr6	1900	2	grade	grade	NN
cord-005478-5iu38pr6	1900	3	3	3	CD
cord-005478-5iu38pr6	1900	4	adverse	adverse	JJ
cord-005478-5iu38pr6	1900	5	events	event	NNS
cord-005478-5iu38pr6	1900	6	(	(	-LRB-
cord-005478-5iu38pr6	1900	7	AEs	AEs	NNP
cord-005478-5iu38pr6	1900	8	)	)	-RRB-
cord-005478-5iu38pr6	1900	9	in	in	IN
cord-005478-5iu38pr6	1900	10	6	6	CD
cord-005478-5iu38pr6	1900	11	patients	patient	NNS
cord-005478-5iu38pr6	1900	12	were	be	VBD
cord-005478-5iu38pr6	1900	13	attributed	attribute	VBN
cord-005478-5iu38pr6	1900	14	to	to	IN
cord-005478-5iu38pr6	1900	15	BMH	BMH	NNP
cord-005478-5iu38pr6	1900	16	and	and	CC
cord-005478-5iu38pr6	1900	17	5	5	CD
cord-005478-5iu38pr6	1900	18	grade	grade	NN
cord-005478-5iu38pr6	1900	19	3	3	CD
cord-005478-5iu38pr6	1900	20	AEs	ae	NNS
cord-005478-5iu38pr6	1900	21	in	in	IN
cord-005478-5iu38pr6	1900	22	3	3	CD
cord-005478-5iu38pr6	1900	23	patients	patient	NNS
cord-005478-5iu38pr6	1900	24	to	to	IN
cord-005478-5iu38pr6	1900	25	mobilization	mobilization	NN
cord-005478-5iu38pr6	1900	26	/	/	SYM
cord-005478-5iu38pr6	1900	27	apheresis	apheresis	NN
cord-005478-5iu38pr6	1900	28	.	.	.
cord-005478-5iu38pr6	1901	1	DP	dp	NN
cord-005478-5iu38pr6	1901	2	and	and	CC
cord-005478-5iu38pr6	1901	3	treatment	treatment	NN
cord-005478-5iu38pr6	1901	4	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1901	5	are	be	VBP
cord-005478-5iu38pr6	1901	6	shown	show	VBN
cord-005478-5iu38pr6	1901	7	in	in	IN
cord-005478-5iu38pr6	1901	8	Table	Table	NNP
cord-005478-5iu38pr6	1901	9	1	1	CD
cord-005478-5iu38pr6	1901	10	.	.	.
cord-005478-5iu38pr6	1902	1	DP	DP	NNP
cord-005478-5iu38pr6	1902	2	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1902	3	were	be	VBD
cord-005478-5iu38pr6	1902	4	improved	improve	VBN
cord-005478-5iu38pr6	1902	5	in	in	IN
cord-005478-5iu38pr6	1902	6	Group	Group	NNP
cord-005478-5iu38pr6	1902	7	B	B	NNP
cord-005478-5iu38pr6	1902	8	and	and	CC
cord-005478-5iu38pr6	1902	9	Group	Group	NNP
cord-005478-5iu38pr6	1902	10	C	C	NNP
cord-005478-5iu38pr6	1902	11	vs	vs	IN
cord-005478-5iu38pr6	1902	12	Group	Group	NNP
cord-005478-5iu38pr6	1902	13	A.	a.	NN
cord-005478-5iu38pr6	1903	1	The	the	DT
cord-005478-5iu38pr6	1903	2	safety	safety	NN
cord-005478-5iu38pr6	1903	3	profile	profile	NN
cord-005478-5iu38pr6	1903	4	post	post	JJ
cord-005478-5iu38pr6	1903	5	-	-	JJ
cord-005478-5iu38pr6	1903	6	DP	dp	JJ
cord-005478-5iu38pr6	1903	7	infusion	infusion	NN
cord-005478-5iu38pr6	1903	8	was	be	VBD
cord-005478-5iu38pr6	1903	9	consistent	consistent	JJ
cord-005478-5iu38pr6	1903	10	with	with	IN
cord-005478-5iu38pr6	1903	11	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	1903	12	conditioning	conditioning	NN
cord-005478-5iu38pr6	1903	13	and	and	CC
cord-005478-5iu38pr6	1903	14	underlying	underlie	VBG
cord-005478-5iu38pr6	1903	15	SCD	SCD	NNP
cord-005478-5iu38pr6	1903	16	;	;	:
cord-005478-5iu38pr6	1903	17	most	most	RBS
cord-005478-5iu38pr6	1903	18	common	common	JJ
cord-005478-5iu38pr6	1903	19	non	non	JJ
cord-005478-5iu38pr6	1903	20	-	-	JJ
cord-005478-5iu38pr6	1903	21	hematologic	hematologic	JJ
cord-005478-5iu38pr6	1903	22	grade	grade	NN
cord-005478-5iu38pr6	1903	23	≥	≥	NNP
cord-005478-5iu38pr6	1903	24	3	3	CD
cord-005478-5iu38pr6	1903	25	AEs	ae	NNS
cord-005478-5iu38pr6	1903	26	were	be	VBD
cord-005478-5iu38pr6	1903	27	stomatitis	stomatitis	JJ
cord-005478-5iu38pr6	1903	28	,	,	,
cord-005478-5iu38pr6	1903	29	febrile	febrile	JJ
cord-005478-5iu38pr6	1903	30	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	1903	31	,	,	,
cord-005478-5iu38pr6	1903	32	and	and	CC
cord-005478-5iu38pr6	1903	33	vasoocclusive	vasoocclusive	JJ
cord-005478-5iu38pr6	1903	34	pain	pain	NN
cord-005478-5iu38pr6	1903	35	.	.	.
cord-005478-5iu38pr6	1904	1	No	no	DT
cord-005478-5iu38pr6	1904	2	grade	grade	NN
cord-005478-5iu38pr6	1904	3	≥	≥	CD
cord-005478-5iu38pr6	1904	4	3	3	CD
cord-005478-5iu38pr6	1904	5	DP	dp	NN
cord-005478-5iu38pr6	1904	6	-	-	HYPH
cord-005478-5iu38pr6	1904	7	related	relate	VBN
cord-005478-5iu38pr6	1904	8	AEs	ae	NNS
cord-005478-5iu38pr6	1904	9	,	,	,
cord-005478-5iu38pr6	1904	10	graft	graft	NN
cord-005478-5iu38pr6	1904	11	failure	failure	NN
cord-005478-5iu38pr6	1904	12	,	,	,
cord-005478-5iu38pr6	1904	13	veno	veno	NNP
cord-005478-5iu38pr6	1904	14	-	-	HYPH
cord-005478-5iu38pr6	1904	15	occlusive	occlusive	JJ
cord-005478-5iu38pr6	1904	16	liver	liver	NN
cord-005478-5iu38pr6	1904	17	disease	disease	NN
cord-005478-5iu38pr6	1904	18	,	,	,
cord-005478-5iu38pr6	1904	19	replication	replication	NN
cord-005478-5iu38pr6	1904	20	competent	competent	JJ
cord-005478-5iu38pr6	1904	21	lentivirus	lentivirus	NN
cord-005478-5iu38pr6	1904	22	detection	detection	NN
cord-005478-5iu38pr6	1904	23	or	or	CC
cord-005478-5iu38pr6	1904	24	clonal	clonal	JJ
cord-005478-5iu38pr6	1904	25	dominance	dominance	NN
cord-005478-5iu38pr6	1904	26	were	be	VBD
cord-005478-5iu38pr6	1904	27	reported	report	VBN
cord-005478-5iu38pr6	1904	28	.	.	.
cord-005478-5iu38pr6	1905	1	At	at	IN
cord-005478-5iu38pr6	1905	2	last	last	JJ
cord-005478-5iu38pr6	1905	3	visit	visit	NN
cord-005478-5iu38pr6	1905	4	(	(	-LRB-
cord-005478-5iu38pr6	1905	5	Table	table	NN
cord-005478-5iu38pr6	1905	6	1	1	CD
cord-005478-5iu38pr6	1905	7	)	)	-RRB-
cord-005478-5iu38pr6	1905	8	,	,	,
cord-005478-5iu38pr6	1905	9	HbA	HbA	NNP
cord-005478-5iu38pr6	1905	10	T87Q	t87q	DT
cord-005478-5iu38pr6	1905	11	levels	level	NNS
cord-005478-5iu38pr6	1905	12	were	be	VBD
cord-005478-5iu38pr6	1905	13	higher	high	JJR
cord-005478-5iu38pr6	1905	14	in	in	IN
cord-005478-5iu38pr6	1905	15	Group	Group	NNP
cord-005478-5iu38pr6	1905	16	B	B	NNP
cord-005478-5iu38pr6	1905	17	(	(	-LRB-
cord-005478-5iu38pr6	1905	18	3.2	3.2	CD
cord-005478-5iu38pr6	1905	19	-	-	HYPH
cord-005478-5iu38pr6	1905	20	7.2	7.2	CD
cord-005478-5iu38pr6	1905	21	g	g	NN
cord-005478-5iu38pr6	1905	22	/	/	SYM
cord-005478-5iu38pr6	1905	23	dL	dl	NN
cord-005478-5iu38pr6	1905	24	)	)	-RRB-
cord-005478-5iu38pr6	1905	25	vs	vs	IN
cord-005478-5iu38pr6	1905	26	Group	Group	NNP
cord-005478-5iu38pr6	1905	27	A	A	NNP
cord-005478-5iu38pr6	1905	28	(	(	-LRB-
cord-005478-5iu38pr6	1905	29	0.5	0.5	CD
cord-005478-5iu38pr6	1905	30	-	-	SYM
cord-005478-5iu38pr6	1905	31	1.2	1.2	CD
cord-005478-5iu38pr6	1905	32	g	g	NN
cord-005478-5iu38pr6	1905	33	/	/	SYM
cord-005478-5iu38pr6	1905	34	dL	dl	NN
cord-005478-5iu38pr6	1905	35	)	)	-RRB-
cord-005478-5iu38pr6	1905	36	.	.	.
cord-005478-5iu38pr6	1906	1	In	in	IN
cord-005478-5iu38pr6	1906	2	4	4	CD
cord-005478-5iu38pr6	1906	3	Group	Group	NNP
cord-005478-5iu38pr6	1906	4	C	C	NNP
cord-005478-5iu38pr6	1906	5	patients	patient	NNS
cord-005478-5iu38pr6	1906	6	at	at	IN
cord-005478-5iu38pr6	1906	7	the	the	DT
cord-005478-5iu38pr6	1906	8	3-month	3-month	CD
cord-005478-5iu38pr6	1906	9	visit	visit	NN
cord-005478-5iu38pr6	1906	10	,	,	,
cord-005478-5iu38pr6	1906	11	HbA	HbA	NNP
cord-005478-5iu38pr6	1906	12	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1906	13	(	(	-LRB-
cord-005478-5iu38pr6	1906	14	4.1	4.1	CD
cord-005478-5iu38pr6	1906	15	[	[	-LRB-
cord-005478-5iu38pr6	1906	16	3.2	3.2	CD
cord-005478-5iu38pr6	1906	17	-	-	SYM
cord-005478-5iu38pr6	1906	18	6	6	CD
cord-005478-5iu38pr6	1906	19	.0	.0	CD
cord-005478-5iu38pr6	1906	20	]	]	-RRB-
cord-005478-5iu38pr6	1907	1	g	g	NNP
cord-005478-5iu38pr6	1907	2	/	/	SYM
cord-005478-5iu38pr6	1907	3	dL	dl	NN
cord-005478-5iu38pr6	1907	4	)	)	-RRB-
cord-005478-5iu38pr6	1907	5	levels	level	NNS
cord-005478-5iu38pr6	1907	6	were	be	VBD
cord-005478-5iu38pr6	1907	7	equal	equal	JJ
cord-005478-5iu38pr6	1907	8	to	to	IN
cord-005478-5iu38pr6	1907	9	or	or	CC
cord-005478-5iu38pr6	1907	10	exceeded	exceed	VBN
cord-005478-5iu38pr6	1907	11	HbS	hb	VBN
cord-005478-5iu38pr6	1907	12	levels	level	NNS
cord-005478-5iu38pr6	1907	13	(	(	-LRB-
cord-005478-5iu38pr6	1907	14	3.3	3.3	CD
cord-005478-5iu38pr6	1907	15	[	[	-LRB-
cord-005478-5iu38pr6	1907	16	2.8	2.8	CD
cord-005478-5iu38pr6	1907	17	-	-	SYM
cord-005478-5iu38pr6	1907	18	3.8	3.8	CD
cord-005478-5iu38pr6	1907	19	]	]	-RRB-
cord-005478-5iu38pr6	1907	20	g	g	NN
cord-005478-5iu38pr6	1907	21	/	/	SYM
cord-005478-5iu38pr6	1907	22	dL	dl	NN
cord-005478-5iu38pr6	1907	23	)	)	-RRB-
cord-005478-5iu38pr6	1907	24	.	.	.
cord-005478-5iu38pr6	1908	1	In	in	IN
cord-005478-5iu38pr6	1908	2	1	1	CD
cord-005478-5iu38pr6	1908	3	Group	Group	NNP
cord-005478-5iu38pr6	1908	4	C	C	NNP
cord-005478-5iu38pr6	1908	5	patient	patient	NN
cord-005478-5iu38pr6	1908	6	at	at	IN
cord-005478-5iu38pr6	1908	7	the	the	DT
cord-005478-5iu38pr6	1908	8	6-month	6-month	CD
cord-005478-5iu38pr6	1908	9	visit	visit	NN
cord-005478-5iu38pr6	1908	10	,	,	,
cord-005478-5iu38pr6	1908	11	HbA	HbA	NNP
cord-005478-5iu38pr6	1908	12	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1908	13	was	be	VBD
cord-005478-5iu38pr6	1908	14	8.8	8.8	CD
cord-005478-5iu38pr6	1908	15	g	g	NN
cord-005478-5iu38pr6	1908	16	/	/	SYM
cord-005478-5iu38pr6	1908	17	dL	dl	NN
cord-005478-5iu38pr6	1908	18	and	and	CC
cord-005478-5iu38pr6	1908	19	total	total	NN
cord-005478-5iu38pr6	1909	1	Hb	Hb	NNP
cord-005478-5iu38pr6	1909	2	was	be	VBD
cord-005478-5iu38pr6	1909	3	14.2	14.2	CD
cord-005478-5iu38pr6	1909	4	g	g	NN
cord-005478-5iu38pr6	1909	5	/	/	SYM
cord-005478-5iu38pr6	1909	6	dL.	dL.	NNS
cord-005478-5iu38pr6	1909	7	Conclusions	Conclusions	NNPS
cord-005478-5iu38pr6	1909	8	:	:	:
cord-005478-5iu38pr6	1910	1	These	these	DT
cord-005478-5iu38pr6	1910	2	data	datum	NNS
cord-005478-5iu38pr6	1910	3	support	support	VBP
cord-005478-5iu38pr6	1910	4	the	the	DT
cord-005478-5iu38pr6	1910	5	safety	safety	NN
cord-005478-5iu38pr6	1910	6	and	and	CC
cord-005478-5iu38pr6	1910	7	feasibility	feasibility	NN
cord-005478-5iu38pr6	1910	8	of	of	IN
cord-005478-5iu38pr6	1910	9	plerixafor	plerixafor	NN
cord-005478-5iu38pr6	1910	10	-	-	HYPH
cord-005478-5iu38pr6	1910	11	mediated	mediate	VBN
cord-005478-5iu38pr6	1910	12	HSC	HSC	NNP
cord-005478-5iu38pr6	1910	13	collection	collection	NN
cord-005478-5iu38pr6	1910	14	in	in	IN
cord-005478-5iu38pr6	1910	15	patients	patient	NNS
cord-005478-5iu38pr6	1910	16	with	with	IN
cord-005478-5iu38pr6	1910	17	SCD	SCD	NNP
cord-005478-5iu38pr6	1910	18	.	.	.
cord-005478-5iu38pr6	1911	1	HGB-206	hgb-206	DT
cord-005478-5iu38pr6	1911	2	protocol	protocol	NN
cord-005478-5iu38pr6	1911	3	changes	change	NNS
cord-005478-5iu38pr6	1911	4	have	have	VBP
cord-005478-5iu38pr6	1911	5	improved	improve	VBN
cord-005478-5iu38pr6	1911	6	LentiGlobin	LentiGlobin	NNP
cord-005478-5iu38pr6	1911	7	DP	DP	NNP
cord-005478-5iu38pr6	1911	8	characteristics	characteristic	NNS
cord-005478-5iu38pr6	1911	9	yielding	yield	VBG
cord-005478-5iu38pr6	1911	10	higher	high	JJR
cord-005478-5iu38pr6	1911	11	HbA	hba	JJ
cord-005478-5iu38pr6	1911	12	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1911	13	levels	level	NNS
cord-005478-5iu38pr6	1911	14	.	.	.
cord-005478-5iu38pr6	1912	1	Additional	additional	JJ
cord-005478-5iu38pr6	1912	2	data	datum	NNS
cord-005478-5iu38pr6	1912	3	will	will	MD
cord-005478-5iu38pr6	1912	4	determine	determine	VB
cord-005478-5iu38pr6	1912	5	the	the	DT
cord-005478-5iu38pr6	1912	6	clinical	clinical	JJ
cord-005478-5iu38pr6	1912	7	effect	effect	NN
cord-005478-5iu38pr6	1912	8	of	of	IN
cord-005478-5iu38pr6	1913	1	increased	increase	VBN
cord-005478-5iu38pr6	1913	2	HbA	HbA	NNP
cord-005478-5iu38pr6	1913	3	T87Q	T87Q	NNP
cord-005478-5iu38pr6	1913	4	/HbS	/hbs	CD
cord-005478-5iu38pr6	1913	5	ratios	ratio	NNS
cord-005478-5iu38pr6	1913	6	.	.	.
cord-005478-5iu38pr6	1914	1	Background	background	NN
cord-005478-5iu38pr6	1914	2	:	:	:
cord-005478-5iu38pr6	1915	1	The	the	DT
cord-005478-5iu38pr6	1915	2	prognosis	prognosis	NN
cord-005478-5iu38pr6	1915	3	of	of	IN
cord-005478-5iu38pr6	1915	4	most	most	JJS
cord-005478-5iu38pr6	1915	5	patients	patient	NNS
cord-005478-5iu38pr6	1915	6	with	with	IN
cord-005478-5iu38pr6	1915	7	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	1915	8	-	-	HYPH
cord-005478-5iu38pr6	1915	9	refractory	refractory	JJ
cord-005478-5iu38pr6	1915	10	or	or	CC
cord-005478-5iu38pr6	1915	11	multiply	multiply	NN
cord-005478-5iu38pr6	1915	12	-	-	HYPH
cord-005478-5iu38pr6	1915	13	relapsed	relapse	VBN
cord-005478-5iu38pr6	1915	14	CD30	CD30	NNP
cord-005478-5iu38pr6	1915	15	+	+	CC
cord-005478-5iu38pr6	1915	16	(	(	-LRB-
cord-005478-5iu38pr6	1915	17	a	a	DT
cord-005478-5iu38pr6	1915	18	cell	cell	NN
cord-005478-5iu38pr6	1915	19	membrane	membrane	NN
cord-005478-5iu38pr6	1915	20	protein	protein	NN
cord-005478-5iu38pr6	1915	21	)	)	-RRB-
cord-005478-5iu38pr6	1916	1	Non	Non	NNP
cord-005478-5iu38pr6	1916	2	-	-	NNP
cord-005478-5iu38pr6	1916	3	Hodgkin	Hodgkin	NNP
cord-005478-5iu38pr6	1916	4	's	's	POS
cord-005478-5iu38pr6	1916	5	Lymphoma	Lymphoma	NNP
cord-005478-5iu38pr6	1916	6	(	(	-LRB-
cord-005478-5iu38pr6	1916	7	NHL	NHL	NNP
cord-005478-5iu38pr6	1916	8	)	)	-RRB-
cord-005478-5iu38pr6	1916	9	or	or	CC
cord-005478-5iu38pr6	1916	10	Hodgkin	Hodgkin	NNP
cord-005478-5iu38pr6	1916	11	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1916	12	(	(	-LRB-
cord-005478-5iu38pr6	1916	13	HL	HL	NNP
cord-005478-5iu38pr6	1916	14	)	)	-RRB-
cord-005478-5iu38pr6	1916	15	still	still	RB
cord-005478-5iu38pr6	1916	16	remain	remain	VBP
cord-005478-5iu38pr6	1916	17	poor	poor	JJ
cord-005478-5iu38pr6	1916	18	.	.	.
cord-005478-5iu38pr6	1917	1	Targeting	target	VBG
cord-005478-5iu38pr6	1917	2	CD30	CD30	NNP
cord-005478-5iu38pr6	1917	3	with	with	IN
cord-005478-5iu38pr6	1917	4	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	1917	5	antibodies	antibody	NNS
cord-005478-5iu38pr6	1917	6	in	in	IN
cord-005478-5iu38pr6	1917	7	HL	HL	NNP
cord-005478-5iu38pr6	1917	8	and	and	CC
cord-005478-5iu38pr6	1917	9	anaplastic	anaplastic	JJ
cord-005478-5iu38pr6	1917	10	large	large	JJ
cord-005478-5iu38pr6	1917	11	cell	cell	NN
cord-005478-5iu38pr6	1917	12	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1917	13	(	(	-LRB-
cord-005478-5iu38pr6	1917	14	ALCL	ALCL	NNP
cord-005478-5iu38pr6	1917	15	)	)	-RRB-
cord-005478-5iu38pr6	1917	16	was	be	VBD
cord-005478-5iu38pr6	1917	17	shown	show	VBN
cord-005478-5iu38pr6	1917	18	to	to	TO
cord-005478-5iu38pr6	1917	19	induce	induce	VB
cord-005478-5iu38pr6	1917	20	remarkable	remarkable	JJ
cord-005478-5iu38pr6	1917	21	clinical	clinical	JJ
cord-005478-5iu38pr6	1917	22	activity	activity	NN
cord-005478-5iu38pr6	1917	23	;	;	:
cord-005478-5iu38pr6	1917	24	however	however	RB
cord-005478-5iu38pr6	1917	25	,	,	,
cord-005478-5iu38pr6	1917	26	occurrence	occurrence	NN
cord-005478-5iu38pr6	1917	27	of	of	IN
cord-005478-5iu38pr6	1917	28	adverse	adverse	JJ
cord-005478-5iu38pr6	1917	29	events	event	NNS
cord-005478-5iu38pr6	1917	30	(	(	-LRB-
cord-005478-5iu38pr6	1917	31	mainly	mainly	RB
cord-005478-5iu38pr6	1917	32	neuropathy	neuropathy	NN
cord-005478-5iu38pr6	1917	33	)	)	-RRB-
cord-005478-5iu38pr6	1917	34	may	may	MD
cord-005478-5iu38pr6	1917	35	result	result	VB
cord-005478-5iu38pr6	1917	36	into	into	IN
cord-005478-5iu38pr6	1917	37	treatment	treatment	NN
cord-005478-5iu38pr6	1917	38	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	1917	39	in	in	IN
cord-005478-5iu38pr6	1917	40	many	many	JJ
cord-005478-5iu38pr6	1917	41	patients	patient	NNS
cord-005478-5iu38pr6	1917	42	.	.	.
cord-005478-5iu38pr6	1918	1	Immunotherapeutic	Immunotherapeutic	NNP
cord-005478-5iu38pr6	1918	2	approaches	approach	NNS
cord-005478-5iu38pr6	1918	3	targeting	target	VBG
cord-005478-5iu38pr6	1918	4	CD30	CD30	NNP
cord-005478-5iu38pr6	1918	5	by	by	IN
cord-005478-5iu38pr6	1918	6	chimeric	chimeric	JJ
cord-005478-5iu38pr6	1918	7	antigen	antigen	NN
cord-005478-5iu38pr6	1918	8	receptor	receptor	NN
cord-005478-5iu38pr6	1918	9	(	(	-LRB-
cord-005478-5iu38pr6	1918	10	CAR	car	NN
cord-005478-5iu38pr6	1918	11	)	)	-RRB-
cord-005478-5iu38pr6	1918	12	has	have	VBZ
cord-005478-5iu38pr6	1918	13	been	be	VBN
cord-005478-5iu38pr6	1918	14	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	1918	15	to	to	TO
cord-005478-5iu38pr6	1918	16	be	be	VB
cord-005478-5iu38pr6	1918	17	of	of	IN
cord-005478-5iu38pr6	1918	18	value	value	NN
cord-005478-5iu38pr6	1918	19	in	in	IN
cord-005478-5iu38pr6	1918	20	two	two	CD
cord-005478-5iu38pr6	1918	21	independent	independent	JJ
cord-005478-5iu38pr6	1918	22	clinical	clinical	JJ
cord-005478-5iu38pr6	1918	23	trials	trial	NNS
cord-005478-5iu38pr6	1918	24	(	(	-LRB-
cord-005478-5iu38pr6	1918	25	PMID	PMID	NNP
cord-005478-5iu38pr6	1918	26	:	:	:
cord-005478-5iu38pr6	1918	27	27582488	27582488	CD
cord-005478-5iu38pr6	1918	28	)	)	-RRB-
cord-005478-5iu38pr6	1918	29	(	(	-LRB-
cord-005478-5iu38pr6	1918	30	PMID:28805662	PMID:28805662	NNP
cord-005478-5iu38pr6	1918	31	)	)	-RRB-
cord-005478-5iu38pr6	1918	32	,	,	,
cord-005478-5iu38pr6	1918	33	although	although	IN
cord-005478-5iu38pr6	1918	34	clinical	clinical	JJ
cord-005478-5iu38pr6	1918	35	benefit	benefit	NN
cord-005478-5iu38pr6	1918	36	was	be	VBD
cord-005478-5iu38pr6	1918	37	sub	sub	NN
cord-005478-5iu38pr6	1918	38	-	-	JJ
cord-005478-5iu38pr6	1918	39	optimal	optimal	JJ
cord-005478-5iu38pr6	1918	40	.	.	.
cord-005478-5iu38pr6	1919	1	Methods	method	NNS
cord-005478-5iu38pr6	1919	2	:	:	:
cord-005478-5iu38pr6	1919	3	We	-PRON-	PRP
cord-005478-5iu38pr6	1919	4	designed	design	VBD
cord-005478-5iu38pr6	1919	5	two	two	CD
cord-005478-5iu38pr6	1919	6	3	3	CD
cord-005478-5iu38pr6	1919	7	rd	rd	NN
cord-005478-5iu38pr6	1919	8	generation	generation	NN
cord-005478-5iu38pr6	1919	9	,	,	,
cord-005478-5iu38pr6	1919	10	clinical	clinical	JJ
cord-005478-5iu38pr6	1919	11	-	-	HYPH
cord-005478-5iu38pr6	1919	12	grade	grade	NN
cord-005478-5iu38pr6	1919	13	retroviral	retroviral	NN
cord-005478-5iu38pr6	1919	14	vectors	vector	NNS
cord-005478-5iu38pr6	1919	15	carrying	carry	VBG
cord-005478-5iu38pr6	1919	16	the	the	DT
cord-005478-5iu38pr6	1919	17	cassette	cassette	NN
cord-005478-5iu38pr6	1919	18	anti	anti	JJ
cord-005478-5iu38pr6	1919	19	-	-	JJ
cord-005478-5iu38pr6	1919	20	CD30	CD30	NNP
cord-005478-5iu38pr6	1919	21	singlechain	singlechain	NN
cord-005478-5iu38pr6	1919	22	variable	variable	JJ
cord-005478-5iu38pr6	1919	23	fragment	fragment	NN
cord-005478-5iu38pr6	1919	24	linked	link	VBN
cord-005478-5iu38pr6	1919	25	via	via	IN
cord-005478-5iu38pr6	1919	26	CD8	CD8	NNP
cord-005478-5iu38pr6	1919	27	hingetransmembrane	hingetransmembrane	NNP
cord-005478-5iu38pr6	1919	28	domain	domain	NN
cord-005478-5iu38pr6	1919	29	,	,	,
cord-005478-5iu38pr6	1919	30	to	to	IN
cord-005478-5iu38pr6	1919	31	the	the	DT
cord-005478-5iu38pr6	1919	32	signaling	signal	VBG
cord-005478-5iu38pr6	1919	33	domains	domain	NNS
cord-005478-5iu38pr6	1919	34	of	of	IN
cord-005478-5iu38pr6	1919	35	two	two	CD
cord-005478-5iu38pr6	1919	36	costimulatory	costimulatory	NN
cord-005478-5iu38pr6	1919	37	domains	domain	NNS
cord-005478-5iu38pr6	1919	38	,	,	,
cord-005478-5iu38pr6	1919	39	namely	namely	RB
cord-005478-5iu38pr6	1919	40	either	either	CC
cord-005478-5iu38pr6	1919	41	CD28/4	CD28/4	NNP
cord-005478-5iu38pr6	1919	42	-	-	HYPH
cord-005478-5iu38pr6	1919	43	1BB	1BB	NNP
cord-005478-5iu38pr6	1919	44	or	or	CC
cord-005478-5iu38pr6	1919	45	CD28	CD28	NNP
cord-005478-5iu38pr6	1919	46	/	/	SYM
cord-005478-5iu38pr6	1919	47	OX40	OX40	NNP
cord-005478-5iu38pr6	1919	48	and	and	CC
cord-005478-5iu38pr6	1919	49	CD3-ζ	CD3-ζ	NNP
cord-005478-5iu38pr6	1919	50	.	.	.
cord-005478-5iu38pr6	1920	1	The	the	DT
cord-005478-5iu38pr6	1920	2	inducible	inducible	JJ
cord-005478-5iu38pr6	1920	3	Caspase-9	Caspase-9	NNPS
cord-005478-5iu38pr6	1920	4	(	(	-LRB-
cord-005478-5iu38pr6	1920	5	iCasp9	iCasp9	NNP
cord-005478-5iu38pr6	1920	6	)	)	-RRB-
cord-005478-5iu38pr6	1920	7	safety	safety	NN
cord-005478-5iu38pr6	1920	8	switch	switch	NN
cord-005478-5iu38pr6	1920	9	was	be	VBD
cord-005478-5iu38pr6	1920	10	also	also	RB
cord-005478-5iu38pr6	1920	11	included	include	VBN
cord-005478-5iu38pr6	1920	12	in	in	IN
cord-005478-5iu38pr6	1920	13	the	the	DT
cord-005478-5iu38pr6	1920	14	constructs	construct	NNS
cord-005478-5iu38pr6	1920	15	with	with	IN
cord-005478-5iu38pr6	1920	16	the	the	DT
cord-005478-5iu38pr6	1920	17	goal	goal	NN
cord-005478-5iu38pr6	1920	18	of	of	IN
cord-005478-5iu38pr6	1920	19	promptly	promptly	RB
cord-005478-5iu38pr6	1920	20	controlling	control	VBG
cord-005478-5iu38pr6	1920	21	undue	undue	JJ
cord-005478-5iu38pr6	1920	22	toxicity	toxicity	NN
cord-005478-5iu38pr6	1920	23	.	.	.
cord-005478-5iu38pr6	1921	1	As	as	IN
cord-005478-5iu38pr6	1921	2	a	a	DT
cord-005478-5iu38pr6	1921	3	selectable	selectable	JJ
cord-005478-5iu38pr6	1921	4	marker	marker	NN
cord-005478-5iu38pr6	1921	5	,	,	,
cord-005478-5iu38pr6	1921	6	we	-PRON-	PRP
cord-005478-5iu38pr6	1921	7	added	add	VBD
cord-005478-5iu38pr6	1921	8	,	,	,
cord-005478-5iu38pr6	1921	9	in	in	IN
cord-005478-5iu38pr6	1921	10	frame	frame	NN
cord-005478-5iu38pr6	1921	11	with	with	IN
cord-005478-5iu38pr6	1921	12	the	the	DT
cord-005478-5iu38pr6	1921	13	CAR	car	NN
cord-005478-5iu38pr6	1921	14	molecule	molecule	NN
cord-005478-5iu38pr6	1921	15	,	,	,
cord-005478-5iu38pr6	1921	16	a	a	DT
cord-005478-5iu38pr6	1921	17	peptide	peptide	NN
cord-005478-5iu38pr6	1921	18	derived	derive	VBN
cord-005478-5iu38pr6	1921	19	from	from	IN
cord-005478-5iu38pr6	1921	20	CD34	CD34	NNP
cord-005478-5iu38pr6	1921	21	antigen	antigen	NN
cord-005478-5iu38pr6	1921	22	.	.	.
cord-005478-5iu38pr6	1922	1	The	the	DT
cord-005478-5iu38pr6	1922	2	in	in	FW
cord-005478-5iu38pr6	1922	3	vitro	vitro	FW
cord-005478-5iu38pr6	1922	4	anti	anti	JJ
cord-005478-5iu38pr6	1922	5	-	-	JJ
cord-005478-5iu38pr6	1922	6	tumor	tumor	JJ
cord-005478-5iu38pr6	1922	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	1922	8	was	be	VBD
cord-005478-5iu38pr6	1922	9	evaluated	evaluate	VBN
cord-005478-5iu38pr6	1922	10	by	by	IN
cord-005478-5iu38pr6	1922	11	using	use	VBG
cord-005478-5iu38pr6	1922	12	Karpas299	Karpas299	NNP
cord-005478-5iu38pr6	1922	13	,	,	,
cord-005478-5iu38pr6	1922	14	L428	L428	NNP
cord-005478-5iu38pr6	1922	15	or	or	CC
cord-005478-5iu38pr6	1922	16	HDML-2	HDML-2	NNP
cord-005478-5iu38pr6	1922	17	,	,	,
cord-005478-5iu38pr6	1922	18	in	in	IN
cord-005478-5iu38pr6	1922	19	both	both	DT
cord-005478-5iu38pr6	1922	20	short	short	JJ
cord-005478-5iu38pr6	1922	21	-	-	HYPH
cord-005478-5iu38pr6	1922	22	term	term	NN
cord-005478-5iu38pr6	1922	23	cytotoxic	cytotoxic	JJ
cord-005478-5iu38pr6	1922	24	assay	assay	NN
cord-005478-5iu38pr6	1922	25	(	(	-LRB-
cord-005478-5iu38pr6	1922	26	represented	represent	VBN
cord-005478-5iu38pr6	1922	27	by	by	IN
cord-005478-5iu38pr6	1922	28	Cr	Cr	NNP
cord-005478-5iu38pr6	1922	29	51	51	CD
cord-005478-5iu38pr6	1922	30	release	release	NN
cord-005478-5iu38pr6	1922	31	assays	assay	NNS
cord-005478-5iu38pr6	1922	32	)	)	-RRB-
cord-005478-5iu38pr6	1922	33	and	and	CC
cord-005478-5iu38pr6	1922	34	long	long	JJ
cord-005478-5iu38pr6	1922	35	-	-	HYPH
cord-005478-5iu38pr6	1922	36	term	term	NN
cord-005478-5iu38pr6	1922	37	co	co	NNS
cord-005478-5iu38pr6	1922	38	-	-	NNS
cord-005478-5iu38pr6	1922	39	cultures	culture	NNS
cord-005478-5iu38pr6	1922	40	(	(	-LRB-
cord-005478-5iu38pr6	1922	41	7	7	CD
cord-005478-5iu38pr6	1922	42	days	day	NNS
cord-005478-5iu38pr6	1922	43	)	)	-RRB-
cord-005478-5iu38pr6	1922	44	.	.	.
cord-005478-5iu38pr6	1923	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	1923	2	profile	profile	NN
cord-005478-5iu38pr6	1923	3	upon	upon	IN
cord-005478-5iu38pr6	1923	4	antigen	antigen	NN
cord-005478-5iu38pr6	1923	5	stimulation	stimulation	NN
cord-005478-5iu38pr6	1923	6	was	be	VBD
cord-005478-5iu38pr6	1923	7	characterized	characterize	VBN
cord-005478-5iu38pr6	1923	8	,	,	,
cord-005478-5iu38pr6	1923	9	as	as	RB
cord-005478-5iu38pr6	1923	10	well	well	RB
cord-005478-5iu38pr6	1923	11	as	as	IN
cord-005478-5iu38pr6	1923	12	Tcell	Tcell	NNP
cord-005478-5iu38pr6	1923	13	exhaustion	exhaustion	NN
cord-005478-5iu38pr6	1923	14	and	and	CC
cord-005478-5iu38pr6	1923	15	memory	memory	NN
cord-005478-5iu38pr6	1923	16	marker	marker	NN
cord-005478-5iu38pr6	1923	17	profile	profile	NN
cord-005478-5iu38pr6	1923	18	.	.	.
cord-005478-5iu38pr6	1924	1	To	to	TO
cord-005478-5iu38pr6	1924	2	assess	assess	VB
cord-005478-5iu38pr6	1924	3	the	the	DT
cord-005478-5iu38pr6	1924	4	expansion	expansion	NN
cord-005478-5iu38pr6	1924	5	,	,	,
cord-005478-5iu38pr6	1924	6	persistence	persistence	NN
cord-005478-5iu38pr6	1924	7	,	,	,
cord-005478-5iu38pr6	1924	8	and	and	CC
cord-005478-5iu38pr6	1924	9	antitumor	antitumor	JJ
cord-005478-5iu38pr6	1924	10	effect	effect	NN
cord-005478-5iu38pr6	1924	11	of	of	IN
cord-005478-5iu38pr6	1924	12	CAR.CD30	CAR.CD30	NNP
cord-005478-5iu38pr6	1924	13	T	T	NNP
cord-005478-5iu38pr6	1924	14	cells	cell	NNS
cord-005478-5iu38pr6	1924	15	in	in	IN
cord-005478-5iu38pr6	1924	16	vivo	vivo	NN
cord-005478-5iu38pr6	1924	17	,	,	,
cord-005478-5iu38pr6	1924	18	we	-PRON-	PRP
cord-005478-5iu38pr6	1924	19	used	use	VBD
cord-005478-5iu38pr6	1924	20	a	a	DT
cord-005478-5iu38pr6	1924	21	NSG	NSG	NNP
cord-005478-5iu38pr6	1924	22	mouse	mouse	NN
cord-005478-5iu38pr6	1924	23	model	model	NN
cord-005478-5iu38pr6	1924	24	engrafted	engraft	VBD
cord-005478-5iu38pr6	1924	25	i.v	i.v	NNP
cord-005478-5iu38pr6	1924	26	.	.	.
cord-005478-5iu38pr6	1925	1	with	with	IN
cord-005478-5iu38pr6	1925	2	human	human	JJ
cord-005478-5iu38pr6	1925	3	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1925	4	cell	cell	NN
cord-005478-5iu38pr6	1925	5	lines	line	NNS
cord-005478-5iu38pr6	1925	6	(	(	-LRB-
cord-005478-5iu38pr6	1925	7	Karpas299	Karpas299	NNP
cord-005478-5iu38pr6	1925	8	and	and	CC
cord-005478-5iu38pr6	1925	9	L428	L428	NNP
cord-005478-5iu38pr6	1925	10	)	)	-RRB-
cord-005478-5iu38pr6	1925	11	genetically	genetically	RB
cord-005478-5iu38pr6	1925	12	modified	modify	VBN
cord-005478-5iu38pr6	1925	13	with	with	IN
cord-005478-5iu38pr6	1925	14	FF	ff	NN
cord-005478-5iu38pr6	1925	15	-	-	HYPH
cord-005478-5iu38pr6	1925	16	luciferase	luciferase	NN
cord-005478-5iu38pr6	1925	17	,	,	,
cord-005478-5iu38pr6	1925	18	this	this	DT
cord-005478-5iu38pr6	1925	19	allowing	allow	VBG
cord-005478-5iu38pr6	1925	20	the	the	DT
cord-005478-5iu38pr6	1925	21	monitoring	monitoring	NN
cord-005478-5iu38pr6	1925	22	of	of	IN
cord-005478-5iu38pr6	1925	23	tumor	tumor	NN
cord-005478-5iu38pr6	1925	24	growth	growth	NN
cord-005478-5iu38pr6	1925	25	by	by	IN
cord-005478-5iu38pr6	1925	26	IVIS	IVIS	NNP
cord-005478-5iu38pr6	1925	27	Imaging	Imaging	NNP
cord-005478-5iu38pr6	1925	28	system	system	NN
cord-005478-5iu38pr6	1925	29	.	.	.
cord-005478-5iu38pr6	1926	1	Persistence	persistence	NN
cord-005478-5iu38pr6	1926	2	of	of	IN
cord-005478-5iu38pr6	1926	3	CAR.CD30	CAR.CD30	NNP
cord-005478-5iu38pr6	1926	4	T	T	NNP
cord-005478-5iu38pr6	1926	5	cells	cell	NNS
cord-005478-5iu38pr6	1926	6	was	be	VBD
cord-005478-5iu38pr6	1926	7	evaluated	evaluate	VBN
cord-005478-5iu38pr6	1926	8	every	every	DT
cord-005478-5iu38pr6	1926	9	15	15	CD
cord-005478-5iu38pr6	1926	10	days	day	NNS
cord-005478-5iu38pr6	1926	11	,	,	,
cord-005478-5iu38pr6	1926	12	together	together	RB
cord-005478-5iu38pr6	1926	13	with	with	IN
cord-005478-5iu38pr6	1926	14	a	a	DT
cord-005478-5iu38pr6	1926	15	deep	deep	JJ
cord-005478-5iu38pr6	1926	16	characterization	characterization	NN
cord-005478-5iu38pr6	1926	17	of	of	IN
cord-005478-5iu38pr6	1926	18	memory	memory	NN
cord-005478-5iu38pr6	1926	19	profile	profile	NN
cord-005478-5iu38pr6	1926	20	and	and	CC
cord-005478-5iu38pr6	1926	21	policlonality	policlonality	NN
cord-005478-5iu38pr6	1926	22	of	of	IN
cord-005478-5iu38pr6	1926	23	persisting	persist	VBG
cord-005478-5iu38pr6	1926	24	T	t	NN
cord-005478-5iu38pr6	1926	25	cells	cell	NNS
cord-005478-5iu38pr6	1926	26	.	.	.
cord-005478-5iu38pr6	1927	1	Results	result	NNS
cord-005478-5iu38pr6	1927	2	:	:	:
cord-005478-5iu38pr6	1928	1	Independently	independently	RB
cord-005478-5iu38pr6	1928	2	from	from	IN
cord-005478-5iu38pr6	1928	3	the	the	DT
cord-005478-5iu38pr6	1928	4	costimulatory	costimulatory	NNP
cord-005478-5iu38pr6	1928	5	domains	domain	NNS
cord-005478-5iu38pr6	1928	6	CD28	CD28	NNP
cord-005478-5iu38pr6	1928	7	/	/	SYM
cord-005478-5iu38pr6	1928	8	OX40	OX40	NNP
cord-005478-5iu38pr6	1928	9	or	or	CC
cord-005478-5iu38pr6	1928	10	CD28/4	CD28/4	NNP
cord-005478-5iu38pr6	1928	11	-	-	HYPH
cord-005478-5iu38pr6	1928	12	1BB	1BB	NNP
cord-005478-5iu38pr6	1928	13	,	,	,
cord-005478-5iu38pr6	1929	1	the	the	DT
cord-005478-5iu38pr6	1929	2	generated	generate	VBN
cord-005478-5iu38pr6	1929	3	retroviral	retroviral	NN
cord-005478-5iu38pr6	1929	4	vectors	vector	NNS
cord-005478-5iu38pr6	1929	5	showed	show	VBD
cord-005478-5iu38pr6	1929	6	similar	similar	JJ
cord-005478-5iu38pr6	1929	7	transduction	transduction	NN
cord-005478-5iu38pr6	1929	8	efficiency	efficiency	NN
cord-005478-5iu38pr6	1929	9	of	of	IN
cord-005478-5iu38pr6	1929	10	T	t	NN
cord-005478-5iu38pr6	1929	11	cells	cell	NNS
cord-005478-5iu38pr6	1929	12	(	(	-LRB-
cord-005478-5iu38pr6	1929	13	86.50±5.08	86.50±5.08	CD
cord-005478-5iu38pr6	1929	14	%	%	NN
cord-005478-5iu38pr6	1929	15	and	and	CC
cord-005478-5iu38pr6	1929	16	79.30±5.33	79.30±5.33	CD
cord-005478-5iu38pr6	1929	17	%	%	NN
cord-005478-5iu38pr6	1929	18	,	,	,
cord-005478-5iu38pr6	1929	19	respectively	respectively	RB
cord-005478-5iu38pr6	1929	20	)	)	-RRB-
cord-005478-5iu38pr6	1929	21	.	.	.
cord-005478-5iu38pr6	1930	1	Nevertheless	nevertheless	RB
cord-005478-5iu38pr6	1930	2	,	,	,
cord-005478-5iu38pr6	1930	3	CAR.CD30	CAR.CD30	NNP
cord-005478-5iu38pr6	1930	4	incorporating	incorporate	VBG
cord-005478-5iu38pr6	1930	5	CD28.OX40	CD28.OX40	NNP
cord-005478-5iu38pr6	1930	6	costimulatory	costimulatory	NNP
cord-005478-5iu38pr6	1930	7	domains	domain	NNS
cord-005478-5iu38pr6	1930	8	was	be	VBD
cord-005478-5iu38pr6	1930	9	associated	associate	VBN
cord-005478-5iu38pr6	1930	10	with	with	IN
cord-005478-5iu38pr6	1930	11	more	more	RBR
cord-005478-5iu38pr6	1930	12	stable	stable	JJ
cord-005478-5iu38pr6	1930	13	expression	expression	NN
cord-005478-5iu38pr6	1930	14	of	of	IN
cord-005478-5iu38pr6	1930	15	the	the	DT
cord-005478-5iu38pr6	1930	16	CAR	car	NN
cord-005478-5iu38pr6	1930	17	over	over	IN
cord-005478-5iu38pr6	1930	18	time	time	NN
cord-005478-5iu38pr6	1930	19	,	,	,
cord-005478-5iu38pr6	1930	20	during	during	IN
cord-005478-5iu38pr6	1930	21	extensive	extensive	JJ
cord-005478-5iu38pr6	1930	22	in	in	IN
cord-005478-5iu38pr6	1930	23	vitro	vitro	FW
cord-005478-5iu38pr6	1930	24	culture	culture	NN
cord-005478-5iu38pr6	1930	25	(	(	-LRB-
cord-005478-5iu38pr6	1930	26	84.72	84.72	CD
cord-005478-5iu38pr6	1930	27	±5.30	±5.30	JJ
cord-005478-5iu38pr6	1930	28	%	%	NN
cord-005478-5iu38pr6	1930	29	vs	vs	IN
cord-005478-5iu38pr6	1930	30	63.98±11.51	63.98±11.51	CD
cord-005478-5iu38pr6	1930	31	%	%	NN
cord-005478-5iu38pr6	1930	32	CAR+	CAR+	NNP
cord-005478-5iu38pr6	1930	33	T	T	NNP
cord-005478-5iu38pr6	1930	34	cells	cell	NNS
cord-005478-5iu38pr6	1930	35	at	at	IN
cord-005478-5iu38pr6	1930	36	30	30	CD
cord-005478-5iu38pr6	1930	37	days	day	NNS
cord-005478-5iu38pr6	1930	38	after	after	IN
cord-005478-5iu38pr6	1930	39	transduction	transduction	NN
cord-005478-5iu38pr6	1930	40	;	;	:
cord-005478-5iu38pr6	1930	41	p=0.002	p=0.002	ADD
cord-005478-5iu38pr6	1930	42	)	)	-RRB-
cord-005478-5iu38pr6	1930	43	.	.	.
cord-005478-5iu38pr6	1931	1	This	this	DT
cord-005478-5iu38pr6	1931	2	finding	finding	NN
cord-005478-5iu38pr6	1931	3	was	be	VBD
cord-005478-5iu38pr6	1931	4	also	also	RB
cord-005478-5iu38pr6	1931	5	associated	associate	VBN
cord-005478-5iu38pr6	1931	6	with	with	IN
cord-005478-5iu38pr6	1931	7	the	the	DT
cord-005478-5iu38pr6	1931	8	evidence	evidence	NN
cord-005478-5iu38pr6	1931	9	that	that	IN
cord-005478-5iu38pr6	1931	10	CAR.CD30-CD28.OX40	CAR.CD30-CD28.OX40	NNP
cord-005478-5iu38pr6	1931	11	T	T	NNP
cord-005478-5iu38pr6	1931	12	cells	cell	NNS
cord-005478-5iu38pr6	1931	13	showed	show	VBD
cord-005478-5iu38pr6	1931	14	a	a	DT
cord-005478-5iu38pr6	1931	15	superior	superior	JJ
cord-005478-5iu38pr6	1931	16	anti	anti	JJ
cord-005478-5iu38pr6	1931	17	-	-	JJ
cord-005478-5iu38pr6	1931	18	lymphoma	lymphoma	JJ
cord-005478-5iu38pr6	1931	19	in	in	IN
cord-005478-5iu38pr6	1931	20	vitro	vitro	FW
cord-005478-5iu38pr6	1931	21	activity	activity	NN
cord-005478-5iu38pr6	1931	22	as	as	IN
cord-005478-5iu38pr6	1931	23	compared	compare	VBN
cord-005478-5iu38pr6	1931	24	to	to	IN
cord-005478-5iu38pr6	1931	25	CAR.CD30-CD28.41BB	CAR.CD30-CD28.41BB	NNP
cord-005478-5iu38pr6	1931	26	T	t	NN
cord-005478-5iu38pr6	1931	27	cells	cell	NNS
cord-005478-5iu38pr6	1931	28	,	,	,
cord-005478-5iu38pr6	1931	29	when	when	WRB
cord-005478-5iu38pr6	1931	30	challenged	challenge	VBN
cord-005478-5iu38pr6	1931	31	at	at	IN
cord-005478-5iu38pr6	1931	32	very	very	RB
cord-005478-5iu38pr6	1931	33	high	high	JJ
cord-005478-5iu38pr6	1931	34	tumor	tumor	NN
cord-005478-5iu38pr6	1931	35	/	/	SYM
cord-005478-5iu38pr6	1931	36	effector	effector	NN
cord-005478-5iu38pr6	1931	37	ratio	ratio	NN
cord-005478-5iu38pr6	1931	38	(	(	-LRB-
cord-005478-5iu38pr6	1931	39	8:1	8:1	CD
cord-005478-5iu38pr6	1931	40	)	)	-RRB-
cord-005478-5iu38pr6	1931	41	.	.	.
cord-005478-5iu38pr6	1932	1	Moreover	moreover	RB
cord-005478-5iu38pr6	1932	2	,	,	,
cord-005478-5iu38pr6	1932	3	antigen	antigen	NN
cord-005478-5iu38pr6	1932	4	-	-	HYPH
cord-005478-5iu38pr6	1932	5	specific	specific	JJ
cord-005478-5iu38pr6	1932	6	stimulation	stimulation	NN
cord-005478-5iu38pr6	1932	7	was	be	VBD
cord-005478-5iu38pr6	1932	8	associated	associate	VBN
cord-005478-5iu38pr6	1932	9	to	to	IN
cord-005478-5iu38pr6	1932	10	high	high	JJ
cord-005478-5iu38pr6	1932	11	levels	level	NNS
cord-005478-5iu38pr6	1932	12	of	of	IN
cord-005478-5iu38pr6	1932	13	Th1	th1	CD
cord-005478-5iu38pr6	1932	14	cytokine	cytokine	NN
cord-005478-5iu38pr6	1932	15	production	production	NN
cord-005478-5iu38pr6	1932	16	,	,	,
cord-005478-5iu38pr6	1932	17	with	with	IN
cord-005478-5iu38pr6	1932	18	CAR.CD30-CD28.OX40	CAR.CD30-CD28.OX40	NNP
cord-005478-5iu38pr6	1932	19	T	T	NNP
cord-005478-5iu38pr6	1932	20	cells	cell	NNS
cord-005478-5iu38pr6	1932	21	secreting	secrete	VBG
cord-005478-5iu38pr6	1932	22	a	a	DT
cord-005478-5iu38pr6	1932	23	significantly	significantly	RB
cord-005478-5iu38pr6	1932	24	higher	high	JJR
cord-005478-5iu38pr6	1932	25	amount	amount	NN
cord-005478-5iu38pr6	1932	26	of	of	IN
cord-005478-5iu38pr6	1932	27	IFNγ	IFNγ	NNS
cord-005478-5iu38pr6	1932	28	(	(	-LRB-
cord-005478-5iu38pr6	1932	29	8306.03±3745.85	8306.03±3745.85	CD
cord-005478-5iu38pr6	1932	30	pg	pg	NNP
cord-005478-5iu38pr6	1932	31	/	/	SYM
cord-005478-5iu38pr6	1932	32	ml	ml	NNP
cord-005478-5iu38pr6	1932	33	)	)	-RRB-
cord-005478-5iu38pr6	1932	34	,	,	,
cord-005478-5iu38pr6	1932	35	IL2	IL2	NNP
cord-005478-5iu38pr6	1932	36	(	(	-LRB-
cord-005478-5iu38pr6	1932	37	13492.68±5837.77	13492.68±5837.77	CD
cord-005478-5iu38pr6	1932	38	pg	pg	NNP
cord-005478-5iu38pr6	1932	39	/	/	SYM
cord-005478-5iu38pr6	1932	40	ml	ml	NNP
cord-005478-5iu38pr6	1932	41	)	)	-RRB-
cord-005478-5iu38pr6	1932	42	and	and	CC
cord-005478-5iu38pr6	1932	43	TNFα	TNFα	NNS
cord-005478-5iu38pr6	1932	44	(	(	-LRB-
cord-005478-5iu38pr6	1932	45	17661.00±11113.27	17661.00±11113.27	CD
cord-005478-5iu38pr6	1932	46	pg	pg	NNP
cord-005478-5iu38pr6	1932	47	/	/	SYM
cord-005478-5iu38pr6	1932	48	ml	ml	NNP
cord-005478-5iu38pr6	1932	49	)	)	-RRB-
cord-005478-5iu38pr6	1932	50	as	as	IN
cord-005478-5iu38pr6	1932	51	compared	compare	VBN
cord-005478-5iu38pr6	1932	52	to	to	IN
cord-005478-5iu38pr6	1932	53	CAR.CD30-CD28.41BB	CAR.CD30-CD28.41BB	NNP
cord-005478-5iu38pr6	1932	54	T	t	NN
cord-005478-5iu38pr6	1932	55	cells	cell	NNS
cord-005478-5iu38pr6	1932	56	(	(	-LRB-
cord-005478-5iu38pr6	1932	57	6617.81±3025.67	6617.81±3025.67	CD
cord-005478-5iu38pr6	1932	58	pg/	pg/	NNS
cord-005478-5iu38pr6	1932	59	ml	ml	XX
cord-005478-5iu38pr6	1932	60	,	,	,
cord-005478-5iu38pr6	1932	61	p=	p=	NNP
cord-005478-5iu38pr6	1932	62	0.040	0.040	CD
cord-005478-5iu38pr6	1932	63	;	;	:
cord-005478-5iu38pr6	1932	64	7616.67±4464.06	7616.67±4464.06	CD
cord-005478-5iu38pr6	1932	65	pg	pg	NNP
cord-005478-5iu38pr6	1932	66	/	/	SYM
cord-005478-5iu38pr6	1932	67	ml	ml	NNP
cord-005478-5iu38pr6	1932	68	,	,	,
cord-005478-5iu38pr6	1932	69	p=0.008	p=0.008	NNP
cord-005478-5iu38pr6	1932	70	;	;	:
cord-005478-5iu38pr6	1932	71	5824.63	5824.63	CD
cord-005478-5iu38pr6	1932	72	±1823.73	±1823.73	NN
cord-005478-5iu38pr6	1932	73	pg	pg	NNP
cord-005478-5iu38pr6	1932	74	/	/	SYM
cord-005478-5iu38pr6	1932	75	ml	ml	XX
cord-005478-5iu38pr6	1932	76	,	,	,
cord-005478-5iu38pr6	1932	77	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	1932	78	;	;	,
cord-005478-5iu38pr6	1932	79	respectively	respectively	RB
cord-005478-5iu38pr6	1932	80	)	)	-RRB-
cord-005478-5iu38pr6	1932	81	.	.	.
cord-005478-5iu38pr6	1933	1	In	in	IN
cord-005478-5iu38pr6	1933	2	NSG	NSG	NNP
cord-005478-5iu38pr6	1933	3	mouse	mouse	NN
cord-005478-5iu38pr6	1933	4	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	1933	5	models	model	NNS
cord-005478-5iu38pr6	1933	6	,	,	,
cord-005478-5iu38pr6	1933	7	we	-PRON-	PRP
cord-005478-5iu38pr6	1933	8	proved	prove	VBD
cord-005478-5iu38pr6	1933	9	that	that	IN
cord-005478-5iu38pr6	1933	10	CAR.CD30-CD28	CAR.CD30-CD28	NNP
cord-005478-5iu38pr6	1933	11	.	.	.
cord-005478-5iu38pr6	1934	1	OX40	OX40	NNP
cord-005478-5iu38pr6	1934	2	T	t	NN
cord-005478-5iu38pr6	1934	3	cells	cell	NNS
cord-005478-5iu38pr6	1934	4	had	have	VBD
cord-005478-5iu38pr6	1934	5	an	an	DT
cord-005478-5iu38pr6	1934	6	extensive	extensive	JJ
cord-005478-5iu38pr6	1934	7	superior	superior	JJ
cord-005478-5iu38pr6	1934	8	anti	anti	JJ
cord-005478-5iu38pr6	1934	9	-	-	JJ
cord-005478-5iu38pr6	1934	10	tumor	tumor	JJ
cord-005478-5iu38pr6	1934	11	control	control	NN
cord-005478-5iu38pr6	1934	12	than	than	IN
cord-005478-5iu38pr6	1934	13	CAR.CD30-CD28.41BB	CAR.CD30-CD28.41BB	NNP
cord-005478-5iu38pr6	1934	14	T	t	NN
cord-005478-5iu38pr6	1934	15	cells	cell	NNS
cord-005478-5iu38pr6	1934	16	,	,	,
cord-005478-5iu38pr6	1934	17	leading	lead	VBG
cord-005478-5iu38pr6	1934	18	to	to	IN
cord-005478-5iu38pr6	1934	19	a	a	DT
cord-005478-5iu38pr6	1934	20	significant	significant	JJ
cord-005478-5iu38pr6	1934	21	reduction	reduction	NN
cord-005478-5iu38pr6	1934	22	of	of	IN
cord-005478-5iu38pr6	1934	23	bioluminescence	bioluminescence	NN
cord-005478-5iu38pr6	1934	24	at	at	IN
cord-005478-5iu38pr6	1934	25	day	day	NN
cord-005478-5iu38pr6	1934	26	45	45	CD
cord-005478-5iu38pr6	1934	27	(	(	-LRB-
cord-005478-5iu38pr6	1934	28	3.32x10	3.32x10	CD
cord-005478-5iu38pr6	1934	29	6	6	CD
cord-005478-5iu38pr6	1934	30	vs	vs	IN
cord-005478-5iu38pr6	1934	31	2.29x10	2.29x10	CD
cord-005478-5iu38pr6	1934	32	10	10	CD
cord-005478-5iu38pr6	1934	33	,	,	,
cord-005478-5iu38pr6	1934	34	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	1934	35	)	)	-RRB-
cord-005478-5iu38pr6	1934	36	and	and	CC
cord-005478-5iu38pr6	1934	37	an	an	DT
cord-005478-5iu38pr6	1934	38	increased	increased	JJ
cord-005478-5iu38pr6	1934	39	overall	overall	JJ
cord-005478-5iu38pr6	1934	40	survival	survival	NN
cord-005478-5iu38pr6	1934	41	of	of	IN
cord-005478-5iu38pr6	1934	42	the	the	DT
cord-005478-5iu38pr6	1934	43	treated	treat	VBN
cord-005478-5iu38pr6	1934	44	mice	mouse	NNS
cord-005478-5iu38pr6	1934	45	(	(	-LRB-
cord-005478-5iu38pr6	1934	46	60	60	CD
cord-005478-5iu38pr6	1934	47	%	%	NN
cord-005478-5iu38pr6	1934	48	vs	vs	IN
cord-005478-5iu38pr6	1934	49	10	10	CD
cord-005478-5iu38pr6	1934	50	%	%	NN
cord-005478-5iu38pr6	1934	51	,	,	,
cord-005478-5iu38pr6	1934	52	at	at	IN
cord-005478-5iu38pr6	1934	53	180	180	CD
cord-005478-5iu38pr6	1934	54	days	day	NNS
cord-005478-5iu38pr6	1934	55	,	,	,
cord-005478-5iu38pr6	1934	56	p=0.0014	p=0.0014	NNPS
cord-005478-5iu38pr6	1934	57	)	)	-RRB-
cord-005478-5iu38pr6	1934	58	.	.	.
cord-005478-5iu38pr6	1935	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1935	2	:	:	:
cord-005478-5iu38pr6	1936	1	Overall	overall	RB
cord-005478-5iu38pr6	1936	2	,	,	,
cord-005478-5iu38pr6	1936	3	these	these	DT
cord-005478-5iu38pr6	1936	4	data	datum	NNS
cord-005478-5iu38pr6	1936	5	indicate	indicate	VBP
cord-005478-5iu38pr6	1936	6	that	that	IN
cord-005478-5iu38pr6	1936	7	,	,	,
cord-005478-5iu38pr6	1936	8	in	in	IN
cord-005478-5iu38pr6	1936	9	the	the	DT
cord-005478-5iu38pr6	1936	10	context	context	NN
cord-005478-5iu38pr6	1936	11	of	of	IN
cord-005478-5iu38pr6	1936	12	CAR.CD30	CAR.CD30	NNP
cord-005478-5iu38pr6	1936	13	T	T	NNP
cord-005478-5iu38pr6	1936	14	cells	cell	NNS
cord-005478-5iu38pr6	1936	15	,	,	,
cord-005478-5iu38pr6	1936	16	the	the	DT
cord-005478-5iu38pr6	1936	17	costimulatory	costimulatory	NNP
cord-005478-5iu38pr6	1936	18	machinery	machinery	NN
cord-005478-5iu38pr6	1936	19	of	of	IN
cord-005478-5iu38pr6	1936	20	CD28.OX40	CD28.OX40	NNP
cord-005478-5iu38pr6	1936	21	is	be	VBZ
cord-005478-5iu38pr6	1936	22	crucial	crucial	JJ
cord-005478-5iu38pr6	1936	23	for	for	IN
cord-005478-5iu38pr6	1936	24	improving	improve	VBG
cord-005478-5iu38pr6	1936	25	both	both	DT
cord-005478-5iu38pr6	1936	26	persistence	persistence	NN
cord-005478-5iu38pr6	1936	27	and	and	CC
cord-005478-5iu38pr6	1936	28	ultimately	ultimately	RB
cord-005478-5iu38pr6	1936	29	the	the	DT
cord-005478-5iu38pr6	1936	30	antitumor	antitumor	JJ
cord-005478-5iu38pr6	1936	31	efficacy	efficacy	NN
cord-005478-5iu38pr6	1936	32	of	of	IN
cord-005478-5iu38pr6	1936	33	the	the	DT
cord-005478-5iu38pr6	1936	34	approach	approach	NN
cord-005478-5iu38pr6	1936	35	.	.	.
cord-005478-5iu38pr6	1937	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1937	2	:	:	:
cord-005478-5iu38pr6	1937	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1937	4	to	to	TO
cord-005478-5iu38pr6	1937	5	declare	declare	VB
cord-005478-5iu38pr6	1937	6	Background	background	NN
cord-005478-5iu38pr6	1937	7	:	:	:
cord-005478-5iu38pr6	1938	1	Acute	acute	JJ
cord-005478-5iu38pr6	1938	2	graft	graft	NN
cord-005478-5iu38pr6	1938	3	-	-	HYPH
cord-005478-5iu38pr6	1938	4	vs	vs	IN
cord-005478-5iu38pr6	1938	5	-	-	HYPH
cord-005478-5iu38pr6	1938	6	host	host	NN
cord-005478-5iu38pr6	1938	7	disease	disease	NN
cord-005478-5iu38pr6	1938	8	(	(	-LRB-
cord-005478-5iu38pr6	1938	9	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1938	10	)	)	-RRB-
cord-005478-5iu38pr6	1938	11	is	be	VBZ
cord-005478-5iu38pr6	1938	12	a	a	DT
cord-005478-5iu38pr6	1938	13	serious	serious	JJ
cord-005478-5iu38pr6	1938	14	complication	complication	NN
cord-005478-5iu38pr6	1938	15	of	of	IN
cord-005478-5iu38pr6	1938	16	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	1938	17	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1938	18	stem	stem	NN
cord-005478-5iu38pr6	1938	19	cell	cell	NN
cord-005478-5iu38pr6	1938	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	1938	21	(	(	-LRB-
cord-005478-5iu38pr6	1938	22	allo	allo	NN
cord-005478-5iu38pr6	1938	23	-	-	HYPH
cord-005478-5iu38pr6	1938	24	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1938	25	)	)	-RRB-
cord-005478-5iu38pr6	1938	26	.	.	.
cord-005478-5iu38pr6	1939	1	Less	Less	JJR
cord-005478-5iu38pr6	1939	2	than	than	IN
cord-005478-5iu38pr6	1939	3	50	50	CD
cord-005478-5iu38pr6	1939	4	%	%	NN
cord-005478-5iu38pr6	1939	5	of	of	IN
cord-005478-5iu38pr6	1939	6	patients	patient	NNS
cord-005478-5iu38pr6	1939	7	(	(	-LRB-
cord-005478-5iu38pr6	1939	8	pts	pt	NNS
cord-005478-5iu38pr6	1939	9	)	)	-RRB-
cord-005478-5iu38pr6	1939	10	achieve	achieve	VBP
cord-005478-5iu38pr6	1939	11	sustained	sustained	JJ
cord-005478-5iu38pr6	1939	12	responses	response	NNS
cord-005478-5iu38pr6	1939	13	with	with	IN
cord-005478-5iu38pr6	1939	14	first	first	JJ
cord-005478-5iu38pr6	1939	15	-	-	HYPH
cord-005478-5iu38pr6	1939	16	line	line	NN
cord-005478-5iu38pr6	1939	17	corticosteroid	corticosteroid	NN
cord-005478-5iu38pr6	1939	18	(	(	-LRB-
cord-005478-5iu38pr6	1939	19	CS	CS	NNP
cord-005478-5iu38pr6	1939	20	)	)	-RRB-
cord-005478-5iu38pr6	1939	21	treatment	treatment	NN
cord-005478-5iu38pr6	1939	22	.	.	.
cord-005478-5iu38pr6	1940	1	Retrospective	retrospective	JJ
cord-005478-5iu38pr6	1940	2	studies	study	NNS
cord-005478-5iu38pr6	1940	3	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	1940	4	clinical	clinical	JJ
cord-005478-5iu38pr6	1940	5	benefit	benefit	NN
cord-005478-5iu38pr6	1940	6	with	with	IN
cord-005478-5iu38pr6	1940	7	the	the	DT
cord-005478-5iu38pr6	1940	8	Janus	Janus	NNP
cord-005478-5iu38pr6	1940	9	kinase	kinase	NN
cord-005478-5iu38pr6	1940	10	(	(	-LRB-
cord-005478-5iu38pr6	1940	11	JAK)1	JAK)1	NNP
cord-005478-5iu38pr6	1940	12	/	/	SYM
cord-005478-5iu38pr6	1940	13	JAK2	JAK2	NNP
cord-005478-5iu38pr6	1940	14	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	1940	15	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	1940	16	(	(	-LRB-
cord-005478-5iu38pr6	1940	17	RUX	RUX	NNP
cord-005478-5iu38pr6	1940	18	)	)	-RRB-
cord-005478-5iu38pr6	1940	19	in	in	IN
cord-005478-5iu38pr6	1940	20	pts	pts	NN
cord-005478-5iu38pr6	1940	21	with	with	IN
cord-005478-5iu38pr6	1940	22	steroid	steroid	NN
cord-005478-5iu38pr6	1940	23	-	-	HYPH
cord-005478-5iu38pr6	1940	24	refractory	refractory	JJ
cord-005478-5iu38pr6	1940	25	(	(	-LRB-
cord-005478-5iu38pr6	1940	26	SR	SR	NNP
cord-005478-5iu38pr6	1940	27	)	)	-RRB-
cord-005478-5iu38pr6	1940	28	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1940	29	.	.	.
cord-005478-5iu38pr6	1941	1	Here	here	RB
cord-005478-5iu38pr6	1941	2	we	-PRON-	PRP
cord-005478-5iu38pr6	1941	3	present	present	VBP
cord-005478-5iu38pr6	1941	4	6-month	6-month	CD
cord-005478-5iu38pr6	1941	5	follow	follow	NN
cord-005478-5iu38pr6	1941	6	-	-	HYPH
cord-005478-5iu38pr6	1941	7	up	up	NN
cord-005478-5iu38pr6	1941	8	data	datum	NNS
cord-005478-5iu38pr6	1941	9	from	from	IN
cord-005478-5iu38pr6	1941	10	patients	patient	NNS
cord-005478-5iu38pr6	1941	11	enrolled	enrol	VBN
cord-005478-5iu38pr6	1941	12	in	in	IN
cord-005478-5iu38pr6	1941	13	REACH1	REACH1	NNP
cord-005478-5iu38pr6	1941	14	(	(	-LRB-
cord-005478-5iu38pr6	1941	15	NCT02953678	NCT02953678	NNP
cord-005478-5iu38pr6	1941	16	)	)	-RRB-
cord-005478-5iu38pr6	1941	17	,	,	,
cord-005478-5iu38pr6	1941	18	a	a	DT
cord-005478-5iu38pr6	1941	19	phase	phase	NN
cord-005478-5iu38pr6	1941	20	2	2	CD
cord-005478-5iu38pr6	1941	21	trial	trial	NN
cord-005478-5iu38pr6	1941	22	evaluating	evaluate	VBG
cord-005478-5iu38pr6	1941	23	RUX	RUX	NNP
cord-005478-5iu38pr6	1941	24	plus	plus	CC
cord-005478-5iu38pr6	1941	25	CS	CS	NNP
cord-005478-5iu38pr6	1941	26	in	in	IN
cord-005478-5iu38pr6	1941	27	SR	SR	NNP
cord-005478-5iu38pr6	1941	28	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1941	29	.	.	.
cord-005478-5iu38pr6	1942	1	Methods	method	NNS
cord-005478-5iu38pr6	1942	2	:	:	:
cord-005478-5iu38pr6	1943	1	REACH1	REACH1	NNP
cord-005478-5iu38pr6	1943	2	was	be	VBD
cord-005478-5iu38pr6	1943	3	a	a	DT
cord-005478-5iu38pr6	1943	4	single	single	JJ
cord-005478-5iu38pr6	1943	5	-	-	HYPH
cord-005478-5iu38pr6	1943	6	arm	arm	NN
cord-005478-5iu38pr6	1943	7	,	,	,
cord-005478-5iu38pr6	1943	8	open	open	JJ
cord-005478-5iu38pr6	1943	9	-	-	HYPH
cord-005478-5iu38pr6	1943	10	label	label	NN
cord-005478-5iu38pr6	1943	11	,	,	,
cord-005478-5iu38pr6	1943	12	multicenter	multicenter	JJ
cord-005478-5iu38pr6	1943	13	study	study	NN
cord-005478-5iu38pr6	1943	14	.	.	.
cord-005478-5iu38pr6	1944	1	Eligible	eligible	JJ
cord-005478-5iu38pr6	1944	2	pts	pt	NNS
cord-005478-5iu38pr6	1944	3	were	be	VBD
cord-005478-5iu38pr6	1944	4	aged	age	VBN
cord-005478-5iu38pr6	1944	5	≥12	≥12	NNP
cord-005478-5iu38pr6	1944	6	years	year	NNS
cord-005478-5iu38pr6	1944	7	and	and	CC
cord-005478-5iu38pr6	1944	8	developed	develop	VBD
cord-005478-5iu38pr6	1944	9	grade	grade	NN
cord-005478-5iu38pr6	1944	10	II	II	NNP
cord-005478-5iu38pr6	1944	11	-	-	HYPH
cord-005478-5iu38pr6	1944	12	IV	IV	NNP
cord-005478-5iu38pr6	1944	13	SR	SR	NNP
cord-005478-5iu38pr6	1944	14	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1944	15	following	follow	VBG
cord-005478-5iu38pr6	1944	16	allo	allo	NN
cord-005478-5iu38pr6	1944	17	-	-	HYPH
cord-005478-5iu38pr6	1944	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1944	19	from	from	IN
cord-005478-5iu38pr6	1944	20	any	any	DT
cord-005478-5iu38pr6	1944	21	donor	donor	NN
cord-005478-5iu38pr6	1944	22	source	source	NN
cord-005478-5iu38pr6	1944	23	for	for	IN
cord-005478-5iu38pr6	1944	24	hematologic	hematologic	JJ
cord-005478-5iu38pr6	1944	25	malignancies	malignancy	NNS
cord-005478-5iu38pr6	1944	26	.	.	.
cord-005478-5iu38pr6	1945	1	SR	SR	NNP
cord-005478-5iu38pr6	1945	2	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1945	3	was	be	VBD
cord-005478-5iu38pr6	1945	4	defined	define	VBN
cord-005478-5iu38pr6	1945	5	as	as	IN
cord-005478-5iu38pr6	1945	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1945	7	that	that	WDT
cord-005478-5iu38pr6	1945	8	progressed	progress	VBD
cord-005478-5iu38pr6	1945	9	after	after	IN
cord-005478-5iu38pr6	1945	10	3	3	CD
cord-005478-5iu38pr6	1945	11	days	day	NNS
cord-005478-5iu38pr6	1945	12	or	or	CC
cord-005478-5iu38pr6	1945	13	had	have	VBD
cord-005478-5iu38pr6	1945	14	not	not	RB
cord-005478-5iu38pr6	1945	15	improved	improve	VBN
cord-005478-5iu38pr6	1945	16	after	after	IN
cord-005478-5iu38pr6	1945	17	7	7	CD
cord-005478-5iu38pr6	1945	18	days	day	NNS
cord-005478-5iu38pr6	1945	19	of	of	IN
cord-005478-5iu38pr6	1945	20	primary	primary	JJ
cord-005478-5iu38pr6	1945	21	treatment	treatment	NN
cord-005478-5iu38pr6	1945	22	with	with	IN
cord-005478-5iu38pr6	1945	23	methylprednisolone	methylprednisolone	JJ
cord-005478-5iu38pr6	1945	24	≥2	≥2	NNP
cord-005478-5iu38pr6	1945	25	mg	mg	NNP
cord-005478-5iu38pr6	1945	26	/	/	SYM
cord-005478-5iu38pr6	1945	27	kg	kg	NNP
cord-005478-5iu38pr6	1945	28	/	/	SYM
cord-005478-5iu38pr6	1945	29	d	d	NN
cord-005478-5iu38pr6	1945	30	(	(	-LRB-
cord-005478-5iu38pr6	1945	31	or	or	CC
cord-005478-5iu38pr6	1945	32	equivalent	equivalent	JJ
cord-005478-5iu38pr6	1945	33	)	)	-RRB-
cord-005478-5iu38pr6	1945	34	,	,	,
cord-005478-5iu38pr6	1945	35	development	development	NN
cord-005478-5iu38pr6	1945	36	of	of	IN
cord-005478-5iu38pr6	1945	37	GVHD	GVHD	NNP
cord-005478-5iu38pr6	1945	38	in	in	IN
cord-005478-5iu38pr6	1945	39	another	another	DT
cord-005478-5iu38pr6	1945	40	organ	organ	NN
cord-005478-5iu38pr6	1945	41	after	after	IN
cord-005478-5iu38pr6	1945	42	receiving	receive	VBG
cord-005478-5iu38pr6	1945	43	≥1	≥1	NNP
cord-005478-5iu38pr6	1945	44	mg	mg	NNP
cord-005478-5iu38pr6	1945	45	/	/	SYM
cord-005478-5iu38pr6	1945	46	kg	kg	NNP
cord-005478-5iu38pr6	1945	47	/	/	SYM
cord-005478-5iu38pr6	1945	48	d	d	NN
cord-005478-5iu38pr6	1945	49	methylprednisolone	methylprednisolone	NN
cord-005478-5iu38pr6	1945	50	for	for	IN
cord-005478-5iu38pr6	1945	51	skin	skin	NN
cord-005478-5iu38pr6	1945	52	or	or	CC
cord-005478-5iu38pr6	1945	53	skin	skin	NN
cord-005478-5iu38pr6	1945	54	plus	plus	CC
cord-005478-5iu38pr6	1945	55	upper	upper	JJ
cord-005478-5iu38pr6	1945	56	gastrointestinal	gastrointestinal	JJ
cord-005478-5iu38pr6	1945	57	GVHD	gvhd	NN
cord-005478-5iu38pr6	1945	58	,	,	,
cord-005478-5iu38pr6	1945	59	or	or	CC
cord-005478-5iu38pr6	1945	60	inability	inability	NN
cord-005478-5iu38pr6	1945	61	to	to	TO
cord-005478-5iu38pr6	1945	62	tolerate	tolerate	VB
cord-005478-5iu38pr6	1945	63	CS	CS	NNP
cord-005478-5iu38pr6	1945	64	taper	taper	NN
cord-005478-5iu38pr6	1945	65	.	.	.
cord-005478-5iu38pr6	1946	1	Pts	Pts	NNP
cord-005478-5iu38pr6	1946	2	received	receive	VBD
cord-005478-5iu38pr6	1946	3	RUX	RUX	NNP
cord-005478-5iu38pr6	1946	4	5	5	CD
cord-005478-5iu38pr6	1946	5	mg	mg	NNP
cord-005478-5iu38pr6	1946	6	twice	twice	RB
cord-005478-5iu38pr6	1946	7	daily	daily	JJ
cord-005478-5iu38pr6	1946	8	(	(	-LRB-
cord-005478-5iu38pr6	1946	9	BID	BID	NNP
cord-005478-5iu38pr6	1946	10	)	)	-RRB-
cord-005478-5iu38pr6	1946	11	,	,	,
cord-005478-5iu38pr6	1946	12	with	with	IN
cord-005478-5iu38pr6	1946	13	optional	optional	JJ
cord-005478-5iu38pr6	1946	14	increase	increase	NN
cord-005478-5iu38pr6	1946	15	to	to	IN
cord-005478-5iu38pr6	1946	16	10	10	CD
cord-005478-5iu38pr6	1946	17	mg	mg	NNP
cord-005478-5iu38pr6	1946	18	BID	BID	NNP
cord-005478-5iu38pr6	1946	19	in	in	IN
cord-005478-5iu38pr6	1946	20	the	the	DT
cord-005478-5iu38pr6	1946	21	absence	absence	NN
cord-005478-5iu38pr6	1946	22	of	of	IN
cord-005478-5iu38pr6	1946	23	cytopenias	cytopenia	NNS
cord-005478-5iu38pr6	1946	24	.	.	.
cord-005478-5iu38pr6	1947	1	The	the	DT
cord-005478-5iu38pr6	1947	2	primary	primary	JJ
cord-005478-5iu38pr6	1947	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	1947	4	was	be	VBD
cord-005478-5iu38pr6	1947	5	Day	day	NN
cord-005478-5iu38pr6	1947	6	28	28	CD
cord-005478-5iu38pr6	1947	7	overall	overall	JJ
cord-005478-5iu38pr6	1947	8	response	response	NN
cord-005478-5iu38pr6	1947	9	rate	rate	NN
cord-005478-5iu38pr6	1947	10	(	(	-LRB-
cord-005478-5iu38pr6	1947	11	ORR	ORR	NNP
cord-005478-5iu38pr6	1947	12	)	)	-RRB-
cord-005478-5iu38pr6	1947	13	,	,	,
cord-005478-5iu38pr6	1947	14	and	and	CC
cord-005478-5iu38pr6	1947	15	the	the	DT
cord-005478-5iu38pr6	1947	16	key	key	JJ
cord-005478-5iu38pr6	1947	17	secondary	secondary	JJ
cord-005478-5iu38pr6	1947	18	endpoint	endpoint	NN
cord-005478-5iu38pr6	1947	19	was	be	VBD
cord-005478-5iu38pr6	1947	20	6-month	6-month	CD
cord-005478-5iu38pr6	1947	21	duration	duration	NN
cord-005478-5iu38pr6	1947	22	of	of	IN
cord-005478-5iu38pr6	1947	23	response	response	NN
cord-005478-5iu38pr6	1947	24	(	(	-LRB-
cord-005478-5iu38pr6	1947	25	DOR	DOR	NNP
cord-005478-5iu38pr6	1947	26	)	)	-RRB-
cord-005478-5iu38pr6	1947	27	.	.	.
cord-005478-5iu38pr6	1948	1	ORR	ORR	NNP
cord-005478-5iu38pr6	1948	2	was	be	VBD
cord-005478-5iu38pr6	1948	3	defined	define	VBN
cord-005478-5iu38pr6	1948	4	as	as	IN
cord-005478-5iu38pr6	1948	5	the	the	DT
cord-005478-5iu38pr6	1948	6	proportion	proportion	NN
cord-005478-5iu38pr6	1948	7	of	of	IN
cord-005478-5iu38pr6	1948	8	patients	patient	NNS
cord-005478-5iu38pr6	1948	9	demonstrating	demonstrate	VBG
cord-005478-5iu38pr6	1948	10	a	a	DT
cord-005478-5iu38pr6	1948	11	complete	complete	JJ
cord-005478-5iu38pr6	1948	12	response	response	NN
cord-005478-5iu38pr6	1948	13	(	(	-LRB-
cord-005478-5iu38pr6	1948	14	CR	CR	NNP
cord-005478-5iu38pr6	1948	15	)	)	-RRB-
cord-005478-5iu38pr6	1948	16	,	,	,
cord-005478-5iu38pr6	1948	17	very	very	RB
cord-005478-5iu38pr6	1948	18	good	good	JJ
cord-005478-5iu38pr6	1948	19	partial	partial	JJ
cord-005478-5iu38pr6	1948	20	response	response	NN
cord-005478-5iu38pr6	1948	21	,	,	,
cord-005478-5iu38pr6	1948	22	or	or	CC
cord-005478-5iu38pr6	1948	23	partial	partial	JJ
cord-005478-5iu38pr6	1948	24	response	response	NN
cord-005478-5iu38pr6	1948	25	.	.	.
cord-005478-5iu38pr6	1949	1	Results	result	NNS
cord-005478-5iu38pr6	1949	2	:	:	:
cord-005478-5iu38pr6	1950	1	The	the	DT
cord-005478-5iu38pr6	1950	2	study	study	NN
cord-005478-5iu38pr6	1950	3	enrolled	enrol	VBD
cord-005478-5iu38pr6	1950	4	71	71	CD
cord-005478-5iu38pr6	1950	5	pts	pt	NNS
cord-005478-5iu38pr6	1950	6	.	.	.
cord-005478-5iu38pr6	1951	1	Median	median	JJ
cord-005478-5iu38pr6	1951	2	age	age	NN
cord-005478-5iu38pr6	1951	3	was	be	VBD
cord-005478-5iu38pr6	1951	4	58	58	CD
cord-005478-5iu38pr6	1951	5	years	year	NNS
cord-005478-5iu38pr6	1951	6	,	,	,
cord-005478-5iu38pr6	1951	7	and	and	CC
cord-005478-5iu38pr6	1951	8	49.3	49.3	CD
cord-005478-5iu38pr6	1951	9	%	%	NN
cord-005478-5iu38pr6	1951	10	were	be	VBD
cord-005478-5iu38pr6	1951	11	male	male	JJ
cord-005478-5iu38pr6	1951	12	.	.	.
cord-005478-5iu38pr6	1952	1	Treatment	treatment	NN
cord-005478-5iu38pr6	1952	2	was	be	VBD
cord-005478-5iu38pr6	1952	3	ongoing	ongoing	JJ
cord-005478-5iu38pr6	1952	4	in	in	IN
cord-005478-5iu38pr6	1952	5	11	11	CD
cord-005478-5iu38pr6	1952	6	pts	pt	NNS
cord-005478-5iu38pr6	1952	7	(	(	-LRB-
cord-005478-5iu38pr6	1952	8	15.5	15.5	CD
cord-005478-5iu38pr6	1952	9	%	%	NN
cord-005478-5iu38pr6	1952	10	)	)	-RRB-
cord-005478-5iu38pr6	1952	11	at	at	IN
cord-005478-5iu38pr6	1952	12	data	datum	NNS
cord-005478-5iu38pr6	1952	13	cutoff	cutoff	NNP
cord-005478-5iu38pr6	1952	14	(	(	-LRB-
cord-005478-5iu38pr6	1952	15	2	2	CD
cord-005478-5iu38pr6	1952	16	Jul	Jul	NNP
cord-005478-5iu38pr6	1952	17	2018	2018	CD
cord-005478-5iu38pr6	1952	18	)	)	-RRB-
cord-005478-5iu38pr6	1952	19	.	.	.
cord-005478-5iu38pr6	1953	1	At	at	IN
cord-005478-5iu38pr6	1953	2	Day	day	NN
cord-005478-5iu38pr6	1953	3	28	28	CD
cord-005478-5iu38pr6	1953	4	,	,	,
cord-005478-5iu38pr6	1953	5	ORR	ORR	NNP
cord-005478-5iu38pr6	1953	6	was	be	VBD
cord-005478-5iu38pr6	1953	7	54.9	54.9	CD
cord-005478-5iu38pr6	1953	8	%	%	NN
cord-005478-5iu38pr6	1953	9	(	(	-LRB-
cord-005478-5iu38pr6	1953	10	CR	CR	NNP
cord-005478-5iu38pr6	1953	11	,	,	,
cord-005478-5iu38pr6	1953	12	26.8	26.8	CD
cord-005478-5iu38pr6	1953	13	%	%	NN
cord-005478-5iu38pr6	1953	14	)	)	-RRB-
cord-005478-5iu38pr6	1953	15	.	.	.
cord-005478-5iu38pr6	1954	1	Responses	response	NNS
cord-005478-5iu38pr6	1954	2	were	be	VBD
cord-005478-5iu38pr6	1954	3	observed	observe	VBN
cord-005478-5iu38pr6	1954	4	irrespective	irrespective	RB
cord-005478-5iu38pr6	1954	5	of	of	IN
cord-005478-5iu38pr6	1954	6	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1954	7	grade	grade	NN
cord-005478-5iu38pr6	1954	8	and	and	CC
cord-005478-5iu38pr6	1954	9	SR	SR	NNP
cord-005478-5iu38pr6	1954	10	criteria	criterion	NNS
cord-005478-5iu38pr6	1954	11	.	.	.
cord-005478-5iu38pr6	1955	1	Best	Best	NNP
cord-005478-5iu38pr6	1955	2	ORR	ORR	NNP
cord-005478-5iu38pr6	1955	3	at	at	IN
cord-005478-5iu38pr6	1955	4	any	any	DT
cord-005478-5iu38pr6	1955	5	time	time	NN
cord-005478-5iu38pr6	1955	6	during	during	IN
cord-005478-5iu38pr6	1955	7	treatment	treatment	NN
cord-005478-5iu38pr6	1955	8	was	be	VBD
cord-005478-5iu38pr6	1955	9	73.2	73.2	CD
cord-005478-5iu38pr6	1955	10	%	%	NN
cord-005478-5iu38pr6	1955	11	(	(	-LRB-
cord-005478-5iu38pr6	1955	12	CR	CR	NNP
cord-005478-5iu38pr6	1955	13	,	,	,
cord-005478-5iu38pr6	1955	14	56.3	56.3	CD
cord-005478-5iu38pr6	1955	15	%	%	NN
cord-005478-5iu38pr6	1955	16	)	)	-RRB-
cord-005478-5iu38pr6	1955	17	.	.	.
cord-005478-5iu38pr6	1956	1	Median	median	JJ
cord-005478-5iu38pr6	1956	2	(	(	-LRB-
cord-005478-5iu38pr6	1956	3	range	range	NN
cord-005478-5iu38pr6	1956	4	)	)	-RRB-
cord-005478-5iu38pr6	1956	5	time	time	NN
cord-005478-5iu38pr6	1956	6	to	to	IN
cord-005478-5iu38pr6	1956	7	response	response	NN
cord-005478-5iu38pr6	1956	8	was	be	VBD
cord-005478-5iu38pr6	1956	9	7	7	CD
cord-005478-5iu38pr6	1956	10	(	(	-LRB-
cord-005478-5iu38pr6	1956	11	6	6	CD
cord-005478-5iu38pr6	1956	12	-	-	SYM
cord-005478-5iu38pr6	1956	13	49	49	CD
cord-005478-5iu38pr6	1956	14	)	)	-RRB-
cord-005478-5iu38pr6	1956	15	days	day	NNS
cord-005478-5iu38pr6	1956	16	.	.	.
cord-005478-5iu38pr6	1957	1	Median	median	JJ
cord-005478-5iu38pr6	1957	2	DOR	DOR	NNP
cord-005478-5iu38pr6	1957	3	with	with	IN
cord-005478-5iu38pr6	1957	4	minimum	minimum	JJ
cord-005478-5iu38pr6	1957	5	6	6	CD
cord-005478-5iu38pr6	1957	6	months	month	NNS
cord-005478-5iu38pr6	1957	7	follow	follow	NN
cord-005478-5iu38pr6	1957	8	-	-	HYPH
cord-005478-5iu38pr6	1957	9	up	up	NN
cord-005478-5iu38pr6	1957	10	was	be	VBD
cord-005478-5iu38pr6	1957	11	345	345	CD
cord-005478-5iu38pr6	1957	12	days	day	NNS
cord-005478-5iu38pr6	1957	13	for	for	IN
cord-005478-5iu38pr6	1957	14	both	both	DT
cord-005478-5iu38pr6	1957	15	Day	day	NN
cord-005478-5iu38pr6	1957	16	28	28	CD
cord-005478-5iu38pr6	1957	17	responders	responder	NNS
cord-005478-5iu38pr6	1957	18	(	(	-LRB-
cord-005478-5iu38pr6	1957	19	Figure	figure	NN
cord-005478-5iu38pr6	1957	20	1	1	CD
cord-005478-5iu38pr6	1957	21	)	)	-RRB-
cord-005478-5iu38pr6	1957	22	and	and	CC
cord-005478-5iu38pr6	1957	23	for	for	IN
cord-005478-5iu38pr6	1957	24	pts	pt	NNS
cord-005478-5iu38pr6	1957	25	who	who	WP
cord-005478-5iu38pr6	1957	26	had	have	VBD
cord-005478-5iu38pr6	1957	27	a	a	DT
cord-005478-5iu38pr6	1957	28	best	good	JJS
cord-005478-5iu38pr6	1957	29	overall	overall	JJ
cord-005478-5iu38pr6	1957	30	response	response	NN
cord-005478-5iu38pr6	1957	31	at	at	IN
cord-005478-5iu38pr6	1957	32	any	any	DT
cord-005478-5iu38pr6	1957	33	time	time	NN
cord-005478-5iu38pr6	1957	34	during	during	IN
cord-005478-5iu38pr6	1957	35	treatment	treatment	NN
cord-005478-5iu38pr6	1957	36	.	.	.
cord-005478-5iu38pr6	1958	1	Four	four	CD
cord-005478-5iu38pr6	1958	2	pts	pt	NNS
cord-005478-5iu38pr6	1958	3	(	(	-LRB-
cord-005478-5iu38pr6	1958	4	5.6	5.6	CD
cord-005478-5iu38pr6	1958	5	%	%	NN
cord-005478-5iu38pr6	1958	6	)	)	-RRB-
cord-005478-5iu38pr6	1958	7	had	have	VBD
cord-005478-5iu38pr6	1958	8	malignancy	malignancy	NN
cord-005478-5iu38pr6	1958	9	relapse	relapse	NN
cord-005478-5iu38pr6	1958	10	.	.	.
cord-005478-5iu38pr6	1959	1	Overall	overall	JJ
cord-005478-5iu38pr6	1959	2	,	,	,
cord-005478-5iu38pr6	1959	3	nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	1959	4	mortality	mortality	NN
cord-005478-5iu38pr6	1959	5	at	at	IN
cord-005478-5iu38pr6	1959	6	6	6	CD
cord-005478-5iu38pr6	1959	7	months	month	NNS
cord-005478-5iu38pr6	1959	8	was	be	VBD
cord-005478-5iu38pr6	1959	9	44.4	44.4	CD
cord-005478-5iu38pr6	1959	10	%	%	NN
cord-005478-5iu38pr6	1959	11	;	;	:
cord-005478-5iu38pr6	1959	12	results	result	NNS
cord-005478-5iu38pr6	1959	13	varied	vary	VBN
cord-005478-5iu38pr6	1959	14	by	by	IN
cord-005478-5iu38pr6	1959	15	Day	day	NN
cord-005478-5iu38pr6	1959	16	28	28	CD
cord-005478-5iu38pr6	1959	17	response	response	NN
cord-005478-5iu38pr6	1959	18	(	(	-LRB-
cord-005478-5iu38pr6	1959	19	Day	day	NN
cord-005478-5iu38pr6	1959	20	28	28	CD
cord-005478-5iu38pr6	1959	21	responders	responder	NNS
cord-005478-5iu38pr6	1959	22	,	,	,
cord-005478-5iu38pr6	1959	23	21.2	21.2	CD
cord-005478-5iu38pr6	1959	24	%	%	NN
cord-005478-5iu38pr6	1959	25	;	;	,
cord-005478-5iu38pr6	1959	26	other	other	JJ
cord-005478-5iu38pr6	1959	27	responders	responder	NNS
cord-005478-5iu38pr6	1959	28	,	,	,
cord-005478-5iu38pr6	1959	29	64.1	64.1	CD
cord-005478-5iu38pr6	1959	30	%	%	NN
cord-005478-5iu38pr6	1959	31	;	;	:
cord-005478-5iu38pr6	1959	32	nonresponders	nonresponder	NNS
cord-005478-5iu38pr6	1959	33	,	,	,
cord-005478-5iu38pr6	1959	34	78.9	78.9	CD
cord-005478-5iu38pr6	1959	35	%	%	NN
cord-005478-5iu38pr6	1959	36	)	)	-RRB-
cord-005478-5iu38pr6	1959	37	.	.	.
cord-005478-5iu38pr6	1960	1	Median	median	JJ
cord-005478-5iu38pr6	1960	2	overall	overall	JJ
cord-005478-5iu38pr6	1960	3	survival	survival	NN
cord-005478-5iu38pr6	1960	4	had	have	VBD
cord-005478-5iu38pr6	1960	5	not	not	RB
cord-005478-5iu38pr6	1960	6	been	be	VBN
cord-005478-5iu38pr6	1960	7	reached	reach	VBN
cord-005478-5iu38pr6	1960	8	for	for	IN
cord-005478-5iu38pr6	1960	9	Day	day	NN
cord-005478-5iu38pr6	1960	10	28	28	CD
cord-005478-5iu38pr6	1960	11	responders	responder	NNS
cord-005478-5iu38pr6	1960	12	.	.	.
cord-005478-5iu38pr6	1961	1	The	the	DT
cord-005478-5iu38pr6	1961	2	most	most	RBS
cord-005478-5iu38pr6	1961	3	frequently	frequently	RB
cord-005478-5iu38pr6	1961	4	reported	report	VBD
cord-005478-5iu38pr6	1961	5	hematologic	hematologic	JJ
cord-005478-5iu38pr6	1961	6	treatment	treatment	NN
cord-005478-5iu38pr6	1961	7	-	-	HYPH
cord-005478-5iu38pr6	1961	8	emergent	emergent	JJ
cord-005478-5iu38pr6	1961	9	adverse	adverse	JJ
cord-005478-5iu38pr6	1961	10	events	event	NNS
cord-005478-5iu38pr6	1961	11	(	(	-LRB-
cord-005478-5iu38pr6	1961	12	TEAEs	teae	NNS
cord-005478-5iu38pr6	1961	13	)	)	-RRB-
cord-005478-5iu38pr6	1961	14	were	be	VBD
cord-005478-5iu38pr6	1961	15	anemia	anemia	NN
cord-005478-5iu38pr6	1961	16	(	(	-LRB-
cord-005478-5iu38pr6	1961	17	64.8	64.8	CD
cord-005478-5iu38pr6	1961	18	%	%	NN
cord-005478-5iu38pr6	1961	19	)	)	-RRB-
cord-005478-5iu38pr6	1961	20	,	,	,
cord-005478-5iu38pr6	1961	21	thrombocytopenia	thrombocytopenia	NN
cord-005478-5iu38pr6	1961	22	(	(	-LRB-
cord-005478-5iu38pr6	1961	23	62.0	62.0	CD
cord-005478-5iu38pr6	1961	24	%	%	NN
cord-005478-5iu38pr6	1961	25	)	)	-RRB-
cord-005478-5iu38pr6	1961	26	,	,	,
cord-005478-5iu38pr6	1961	27	and	and	CC
cord-005478-5iu38pr6	1961	28	neutropenia	neutropenia	NN
cord-005478-5iu38pr6	1961	29	(	(	-LRB-
cord-005478-5iu38pr6	1961	30	47.9	47.9	CD
cord-005478-5iu38pr6	1961	31	%	%	NN
cord-005478-5iu38pr6	1961	32	)	)	-RRB-
cord-005478-5iu38pr6	1961	33	.	.	.
cord-005478-5iu38pr6	1962	1	Cytomegalovirus	Cytomegalovirus	NNP
cord-005478-5iu38pr6	1962	2	infection	infection	NN
cord-005478-5iu38pr6	1962	3	(	(	-LRB-
cord-005478-5iu38pr6	1962	4	12.7	12.7	CD
cord-005478-5iu38pr6	1962	5	%	%	NN
cord-005478-5iu38pr6	1962	6	)	)	-RRB-
cord-005478-5iu38pr6	1962	7	,	,	,
cord-005478-5iu38pr6	1962	8	sepsis	sepsis	NN
cord-005478-5iu38pr6	1962	9	(	(	-LRB-
cord-005478-5iu38pr6	1962	10	12.7	12.7	CD
cord-005478-5iu38pr6	1962	11	%	%	NN
cord-005478-5iu38pr6	1962	12	)	)	-RRB-
cord-005478-5iu38pr6	1962	13	,	,	,
cord-005478-5iu38pr6	1962	14	and	and	CC
cord-005478-5iu38pr6	1962	15	bacteremia	bacteremia	NN
cord-005478-5iu38pr6	1962	16	(	(	-LRB-
cord-005478-5iu38pr6	1962	17	9.9	9.9	CD
cord-005478-5iu38pr6	1962	18	%	%	NN
cord-005478-5iu38pr6	1962	19	)	)	-RRB-
cord-005478-5iu38pr6	1962	20	were	be	VBD
cord-005478-5iu38pr6	1962	21	the	the	DT
cord-005478-5iu38pr6	1962	22	most	most	RBS
cord-005478-5iu38pr6	1962	23	frequently	frequently	RB
cord-005478-5iu38pr6	1962	24	reported	report	VBN
cord-005478-5iu38pr6	1962	25	infections	infection	NNS
cord-005478-5iu38pr6	1962	26	.	.	.
cord-005478-5iu38pr6	1963	1	Fatal	fatal	JJ
cord-005478-5iu38pr6	1963	2	RUX	RUX	NNP
cord-005478-5iu38pr6	1963	3	-	-	HYPH
cord-005478-5iu38pr6	1963	4	related	relate	VBN
cord-005478-5iu38pr6	1963	5	TEAEs	teae	NNS
cord-005478-5iu38pr6	1963	6	were	be	VBD
cord-005478-5iu38pr6	1963	7	sepsis	sepsis	NN
cord-005478-5iu38pr6	1963	8	and	and	CC
cord-005478-5iu38pr6	1963	9	pulmonary	pulmonary	JJ
cord-005478-5iu38pr6	1963	10	hemorrhage	hemorrhage	NN
cord-005478-5iu38pr6	1963	11	(	(	-LRB-
cord-005478-5iu38pr6	1963	12	1	1	CD
cord-005478-5iu38pr6	1963	13	pt	pt	NN
cord-005478-5iu38pr6	1963	14	each	each	DT
cord-005478-5iu38pr6	1963	15	)	)	-RRB-
cord-005478-5iu38pr6	1963	16	and	and	CC
cord-005478-5iu38pr6	1963	17	were	be	VBD
cord-005478-5iu38pr6	1963	18	attributed	attribute	VBN
cord-005478-5iu38pr6	1963	19	to	to	IN
cord-005478-5iu38pr6	1963	20	both	both	DT
cord-005478-5iu38pr6	1963	21	RUX	RUX	NNP
cord-005478-5iu38pr6	1963	22	and	and	CC
cord-005478-5iu38pr6	1963	23	CS	CS	NNP
cord-005478-5iu38pr6	1963	24	.	.	.
cord-005478-5iu38pr6	1964	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1964	2	:	:	:
cord-005478-5iu38pr6	1965	1	In	in	IN
cord-005478-5iu38pr6	1965	2	this	this	DT
cord-005478-5iu38pr6	1965	3	first	first	JJ
cord-005478-5iu38pr6	1965	4	prospective	prospective	JJ
cord-005478-5iu38pr6	1965	5	trial	trial	NN
cord-005478-5iu38pr6	1965	6	of	of	IN
cord-005478-5iu38pr6	1965	7	RUX	RUX	NNP
cord-005478-5iu38pr6	1965	8	in	in	IN
cord-005478-5iu38pr6	1965	9	SR	SR	NNP
cord-005478-5iu38pr6	1965	10	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1965	11	,	,	,
cord-005478-5iu38pr6	1965	12	ORR	ORR	NNP
cord-005478-5iu38pr6	1965	13	was	be	VBD
cord-005478-5iu38pr6	1965	14	54.9	54.9	CD
cord-005478-5iu38pr6	1965	15	%	%	NN
cord-005478-5iu38pr6	1965	16	by	by	IN
cord-005478-5iu38pr6	1965	17	Day	Day	NNP
cord-005478-5iu38pr6	1965	18	28	28	CD
cord-005478-5iu38pr6	1965	19	and	and	CC
cord-005478-5iu38pr6	1965	20	73.2	73.2	CD
cord-005478-5iu38pr6	1965	21	%	%	NN
cord-005478-5iu38pr6	1965	22	at	at	IN
cord-005478-5iu38pr6	1965	23	any	any	DT
cord-005478-5iu38pr6	1965	24	time	time	NN
cord-005478-5iu38pr6	1965	25	during	during	IN
cord-005478-5iu38pr6	1965	26	treatment	treatment	NN
cord-005478-5iu38pr6	1965	27	.	.	.
cord-005478-5iu38pr6	1966	1	Responses	response	NNS
cord-005478-5iu38pr6	1966	2	were	be	VBD
cord-005478-5iu38pr6	1966	3	rapid	rapid	JJ
cord-005478-5iu38pr6	1966	4	and	and	CC
cord-005478-5iu38pr6	1966	5	durable	durable	JJ
cord-005478-5iu38pr6	1966	6	.	.	.
cord-005478-5iu38pr6	1967	1	The	the	DT
cord-005478-5iu38pr6	1967	2	AE	AE	NNP
cord-005478-5iu38pr6	1967	3	profile	profile	NN
cord-005478-5iu38pr6	1967	4	was	be	VBD
cord-005478-5iu38pr6	1967	5	consistent	consistent	JJ
cord-005478-5iu38pr6	1967	6	with	with	IN
cord-005478-5iu38pr6	1967	7	expectations	expectation	NNS
cord-005478-5iu38pr6	1967	8	for	for	IN
cord-005478-5iu38pr6	1967	9	RUX	RUX	NNP
cord-005478-5iu38pr6	1967	10	and	and	CC
cord-005478-5iu38pr6	1967	11	pts	pt	NNS
cord-005478-5iu38pr6	1967	12	with	with	IN
cord-005478-5iu38pr6	1967	13	SR	SR	NNP
cord-005478-5iu38pr6	1967	14	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	1967	15	.	.	.
cord-005478-5iu38pr6	1968	1	RUX	RUX	NNP
cord-005478-5iu38pr6	1968	2	represents	represent	VBZ
cord-005478-5iu38pr6	1968	3	a	a	DT
cord-005478-5iu38pr6	1968	4	promising	promising	JJ
cord-005478-5iu38pr6	1968	5	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1968	6	strategy	strategy	NN
cord-005478-5iu38pr6	1968	7	.	.	.
cord-005478-5iu38pr6	1969	1	Background	background	NN
cord-005478-5iu38pr6	1969	2	:	:	:
cord-005478-5iu38pr6	1970	1	Chronic	chronic	JJ
cord-005478-5iu38pr6	1970	2	graft	graft	NN
cord-005478-5iu38pr6	1970	3	-	-	HYPH
cord-005478-5iu38pr6	1970	4	versus	versus	IN
cord-005478-5iu38pr6	1970	5	-	-	HYPH
cord-005478-5iu38pr6	1970	6	host	host	NN
cord-005478-5iu38pr6	1970	7	disease	disease	NN
cord-005478-5iu38pr6	1970	8	(	(	-LRB-
cord-005478-5iu38pr6	1970	9	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1970	10	)	)	-RRB-
cord-005478-5iu38pr6	1970	11	remains	remain	VBZ
cord-005478-5iu38pr6	1970	12	a	a	DT
cord-005478-5iu38pr6	1970	13	major	major	JJ
cord-005478-5iu38pr6	1970	14	complication	complication	NN
cord-005478-5iu38pr6	1970	15	after	after	IN
cord-005478-5iu38pr6	1970	16	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	1970	17	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	1970	18	cell	cell	NN
cord-005478-5iu38pr6	1970	19	transplantation	transplantation	NN
cord-005478-5iu38pr6	1970	20	(	(	-LRB-
cord-005478-5iu38pr6	1970	21	allo	allo	NN
cord-005478-5iu38pr6	1970	22	-	-	HYPH
cord-005478-5iu38pr6	1970	23	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1970	24	)	)	-RRB-
cord-005478-5iu38pr6	1970	25	.	.	.
cord-005478-5iu38pr6	1971	1	Over	over	IN
cord-005478-5iu38pr6	1971	2	the	the	DT
cord-005478-5iu38pr6	1971	3	last	last	JJ
cord-005478-5iu38pr6	1971	4	decade	decade	NN
cord-005478-5iu38pr6	1971	5	,	,	,
cord-005478-5iu38pr6	1971	6	clinical	clinical	JJ
cord-005478-5iu38pr6	1971	7	success	success	NN
cord-005478-5iu38pr6	1971	8	in	in	IN
cord-005478-5iu38pr6	1971	9	patients	patient	NNS
cord-005478-5iu38pr6	1971	10	with	with	IN
cord-005478-5iu38pr6	1971	11	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1971	12	has	have	VBZ
cord-005478-5iu38pr6	1971	13	been	be	VBN
cord-005478-5iu38pr6	1971	14	hampered	hamper	VBN
cord-005478-5iu38pr6	1971	15	by	by	IN
cord-005478-5iu38pr6	1971	16	the	the	DT
cord-005478-5iu38pr6	1971	17	lack	lack	NN
cord-005478-5iu38pr6	1971	18	of	of	IN
cord-005478-5iu38pr6	1971	19	insight	insight	NN
cord-005478-5iu38pr6	1971	20	into	into	IN
cord-005478-5iu38pr6	1971	21	the	the	DT
cord-005478-5iu38pr6	1971	22	complex	complex	JJ
cord-005478-5iu38pr6	1971	23	pathobiological	pathobiological	JJ
cord-005478-5iu38pr6	1971	24	mechanisms	mechanism	NNS
cord-005478-5iu38pr6	1971	25	of	of	IN
cord-005478-5iu38pr6	1971	26	the	the	DT
cord-005478-5iu38pr6	1971	27	disease	disease	NN
cord-005478-5iu38pr6	1971	28	and	and	CC
cord-005478-5iu38pr6	1971	29	the	the	DT
cord-005478-5iu38pr6	1971	30	paucity	paucity	NN
cord-005478-5iu38pr6	1971	31	of	of	IN
cord-005478-5iu38pr6	1971	32	specific	specific	JJ
cord-005478-5iu38pr6	1971	33	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	1971	34	targets	target	NNS
cord-005478-5iu38pr6	1971	35	.	.	.
cord-005478-5iu38pr6	1972	1	Although	although	IN
cord-005478-5iu38pr6	1972	2	,	,	,
cord-005478-5iu38pr6	1972	3	it	-PRON-	PRP
cord-005478-5iu38pr6	1972	4	is	be	VBZ
cord-005478-5iu38pr6	1972	5	now	now	RB
cord-005478-5iu38pr6	1972	6	evident	evident	JJ
cord-005478-5iu38pr6	1972	7	that	that	IN
cord-005478-5iu38pr6	1972	8	the	the	DT
cord-005478-5iu38pr6	1972	9	clinical	clinical	JJ
cord-005478-5iu38pr6	1972	10	manifestations	manifestation	NNS
cord-005478-5iu38pr6	1972	11	of	of	IN
cord-005478-5iu38pr6	1972	12	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1972	13	are	be	VBP
cord-005478-5iu38pr6	1972	14	the	the	DT
cord-005478-5iu38pr6	1972	15	result	result	NN
cord-005478-5iu38pr6	1972	16	of	of	IN
cord-005478-5iu38pr6	1972	17	a	a	DT
cord-005478-5iu38pr6	1972	18	highly	highly	RB
cord-005478-5iu38pr6	1972	19	complex	complex	JJ
cord-005478-5iu38pr6	1972	20	immune	immune	JJ
cord-005478-5iu38pr6	1972	21	pathology	pathology	NN
cord-005478-5iu38pr6	1972	22	involving	involve	VBG
cord-005478-5iu38pr6	1972	23	both	both	DT
cord-005478-5iu38pr6	1972	24	donor	donor	NN
cord-005478-5iu38pr6	1972	25	B	b	NN
cord-005478-5iu38pr6	1972	26	cells	cell	NNS
cord-005478-5iu38pr6	1972	27	and	and	CC
cord-005478-5iu38pr6	1972	28	T	t	NN
cord-005478-5iu38pr6	1972	29	cells	cell	NNS
cord-005478-5iu38pr6	1972	30	as	as	RB
cord-005478-5iu38pr6	1972	31	well	well	RB
cord-005478-5iu38pr6	1972	32	as	as	IN
cord-005478-5iu38pr6	1972	33	other	other	JJ
cord-005478-5iu38pr6	1972	34	cells	cell	NNS
cord-005478-5iu38pr6	1972	35	.	.	.
cord-005478-5iu38pr6	1973	1	Current	current	JJ
cord-005478-5iu38pr6	1973	2	work	work	NN
cord-005478-5iu38pr6	1973	3	on	on	IN
cord-005478-5iu38pr6	1973	4	immune	immune	JJ
cord-005478-5iu38pr6	1973	5	cells	cell	NNS
cord-005478-5iu38pr6	1973	6	involved	involve	VBN
cord-005478-5iu38pr6	1973	7	in	in	IN
cord-005478-5iu38pr6	1973	8	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1973	9	pathobiology	pathobiology	NN
cord-005478-5iu38pr6	1973	10	is	be	VBZ
cord-005478-5iu38pr6	1973	11	limited	limit	VBN
cord-005478-5iu38pr6	1973	12	by	by	IN
cord-005478-5iu38pr6	1973	13	the	the	DT
cord-005478-5iu38pr6	1973	14	number	number	NN
cord-005478-5iu38pr6	1973	15	of	of	IN
cord-005478-5iu38pr6	1973	16	parameters	parameter	NNS
cord-005478-5iu38pr6	1973	17	that	that	IN
cord-005478-5iu38pr6	1973	18	conventional	conventional	JJ
cord-005478-5iu38pr6	1973	19	flow	flow	NN
cord-005478-5iu38pr6	1973	20	cytometry	cytometry	NN
cord-005478-5iu38pr6	1973	21	(	(	-LRB-
cord-005478-5iu38pr6	1973	22	FCM	FCM	NNP
cord-005478-5iu38pr6	1973	23	)	)	-RRB-
cord-005478-5iu38pr6	1973	24	can	can	MD
cord-005478-5iu38pr6	1973	25	analyze	analyze	VB
cord-005478-5iu38pr6	1973	26	because	because	IN
cord-005478-5iu38pr6	1973	27	of	of	IN
cord-005478-5iu38pr6	1973	28	cell	cell	NN
cord-005478-5iu38pr6	1973	29	autofluorescence	autofluorescence	NN
cord-005478-5iu38pr6	1973	30	and	and	CC
cord-005478-5iu38pr6	1973	31	fluorescent	fluorescent	JJ
cord-005478-5iu38pr6	1973	32	dye	dye	NN
cord-005478-5iu38pr6	1973	33	spectral	spectral	JJ
cord-005478-5iu38pr6	1973	34	overlap	overlap	NN
cord-005478-5iu38pr6	1973	35	.	.	.
cord-005478-5iu38pr6	1974	1	Mass	mass	JJ
cord-005478-5iu38pr6	1974	2	cytometry	cytometry	NN
cord-005478-5iu38pr6	1974	3	time	time	NN
cord-005478-5iu38pr6	1974	4	-	-	HYPH
cord-005478-5iu38pr6	1974	5	offlight	offlight	VBN
cord-005478-5iu38pr6	1974	6	(	(	-LRB-
cord-005478-5iu38pr6	1974	7	CyTOF	CyTOF	NNP
cord-005478-5iu38pr6	1974	8	)	)	-RRB-
cord-005478-5iu38pr6	1974	9	substitutes	substitute	VBZ
cord-005478-5iu38pr6	1974	10	rare	rare	JJ
cord-005478-5iu38pr6	1974	11	earth	earth	NN
cord-005478-5iu38pr6	1974	12	elements	element	NNS
cord-005478-5iu38pr6	1974	13	for	for	IN
cord-005478-5iu38pr6	1974	14	fluorophores	fluorophore	NNS
cord-005478-5iu38pr6	1974	15	to	to	TO
cord-005478-5iu38pr6	1974	16	label	label	VB
cord-005478-5iu38pr6	1974	17	antibodies	antibody	NNS
cord-005478-5iu38pr6	1974	18	,	,	,
cord-005478-5iu38pr6	1974	19	which	which	WDT
cord-005478-5iu38pr6	1974	20	allows	allow	VBZ
cord-005478-5iu38pr6	1974	21	simultaneous	simultaneous	JJ
cord-005478-5iu38pr6	1974	22	measurements	measurement	NNS
cord-005478-5iu38pr6	1974	23	of	of	IN
cord-005478-5iu38pr6	1974	24	more	more	JJR
cord-005478-5iu38pr6	1974	25	than	than	IN
cord-005478-5iu38pr6	1974	26	40	40	CD
cord-005478-5iu38pr6	1974	27	parameters	parameter	NNS
cord-005478-5iu38pr6	1974	28	in	in	IN
cord-005478-5iu38pr6	1974	29	single	single	JJ
cord-005478-5iu38pr6	1974	30	cells	cell	NNS
cord-005478-5iu38pr6	1974	31	without	without	IN
cord-005478-5iu38pr6	1974	32	correction	correction	NN
cord-005478-5iu38pr6	1974	33	for	for	IN
cord-005478-5iu38pr6	1974	34	spectral	spectral	JJ
cord-005478-5iu38pr6	1974	35	overlap	overlap	NN
cord-005478-5iu38pr6	1974	36	,	,	,
cord-005478-5iu38pr6	1974	37	and	and	CC
cord-005478-5iu38pr6	1974	38	empowers	empower	VBZ
cord-005478-5iu38pr6	1974	39	us	-PRON-	PRP
cord-005478-5iu38pr6	1974	40	to	to	TO
cord-005478-5iu38pr6	1974	41	understand	understand	VB
cord-005478-5iu38pr6	1974	42	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1974	43	biology	biology	NN
cord-005478-5iu38pr6	1974	44	at	at	IN
cord-005478-5iu38pr6	1974	45	the	the	DT
cord-005478-5iu38pr6	1974	46	single	single	JJ
cord-005478-5iu38pr6	1974	47	-	-	HYPH
cord-005478-5iu38pr6	1974	48	cell	cell	NN
cord-005478-5iu38pr6	1974	49	level	level	NN
cord-005478-5iu38pr6	1974	50	.	.	.
cord-005478-5iu38pr6	1975	1	Methods	method	NNS
cord-005478-5iu38pr6	1975	2	:	:	:
cord-005478-5iu38pr6	1976	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1976	2	used	use	VBD
cord-005478-5iu38pr6	1976	3	mass	mass	NN
cord-005478-5iu38pr6	1976	4	cytometry	cytometry	NN
cord-005478-5iu38pr6	1976	5	with	with	IN
cord-005478-5iu38pr6	1976	6	extensive	extensive	JJ
cord-005478-5iu38pr6	1976	7	antibody	antibody	NN
cord-005478-5iu38pr6	1976	8	panels	panel	NNS
cord-005478-5iu38pr6	1976	9	to	to	TO
cord-005478-5iu38pr6	1976	10	perform	perform	VB
cord-005478-5iu38pr6	1976	11	in	in	IN
cord-005478-5iu38pr6	1976	12	-	-	HYPH
cord-005478-5iu38pr6	1976	13	depth	depth	NN
cord-005478-5iu38pr6	1976	14	immune	immune	JJ
cord-005478-5iu38pr6	1976	15	profiling	profiling	NN
cord-005478-5iu38pr6	1976	16	of	of	IN
cord-005478-5iu38pr6	1976	17	peripheral	peripheral	JJ
cord-005478-5iu38pr6	1976	18	blood	blood	NN
cord-005478-5iu38pr6	1976	19	samples	sample	NNS
cord-005478-5iu38pr6	1976	20	from	from	IN
cord-005478-5iu38pr6	1976	21	34	34	CD
cord-005478-5iu38pr6	1976	22	patients	patient	NNS
cord-005478-5iu38pr6	1976	23	following	follow	VBG
cord-005478-5iu38pr6	1976	24	allo	allo	NN
cord-005478-5iu38pr6	1976	25	-	-	HYPH
cord-005478-5iu38pr6	1976	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	1976	27	,	,	,
cord-005478-5iu38pr6	1976	28	in	in	IN
cord-005478-5iu38pr6	1976	29	which	which	WDT
cord-005478-5iu38pr6	1976	30	11	11	CD
cord-005478-5iu38pr6	1976	31	patients	patient	NNS
cord-005478-5iu38pr6	1976	32	were	be	VBD
cord-005478-5iu38pr6	1976	33	without	without	IN
cord-005478-5iu38pr6	1976	34	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1976	35	,	,	,
cord-005478-5iu38pr6	1976	36	7	7	CD
cord-005478-5iu38pr6	1976	37	patients	patient	NNS
cord-005478-5iu38pr6	1976	38	experienced	experience	VBD
cord-005478-5iu38pr6	1976	39	moderate	moderate	JJ
cord-005478-5iu38pr6	1976	40	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	1976	41	and	and	CC
cord-005478-5iu38pr6	1976	42	16	16	CD
cord-005478-5iu38pr6	1976	43	patients	patient	NNS
cord-005478-5iu38pr6	1976	44	experienced	experience	VBD
cord-005478-5iu38pr6	1976	45	severe	severe	JJ
cord-005478-5iu38pr6	1976	46	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	1976	47	.	.	.
cord-005478-5iu38pr6	1977	1	The	the	DT
cord-005478-5iu38pr6	1977	2	involved	involved	JJ
cord-005478-5iu38pr6	1977	3	organs	organ	NNS
cord-005478-5iu38pr6	1977	4	in	in	IN
cord-005478-5iu38pr6	1977	5	patients	patient	NNS
cord-005478-5iu38pr6	1977	6	with	with	IN
cord-005478-5iu38pr6	1977	7	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1977	8	are	be	VBP
cord-005478-5iu38pr6	1977	9	skin	skin	NN
cord-005478-5iu38pr6	1977	10	,	,	,
cord-005478-5iu38pr6	1977	11	liver	liver	NN
cord-005478-5iu38pr6	1977	12	and	and	CC
cord-005478-5iu38pr6	1977	13	lung	lung	NN
cord-005478-5iu38pr6	1977	14	.	.	.
cord-005478-5iu38pr6	1978	1	Results	result	NNS
cord-005478-5iu38pr6	1978	2	:	:	:
cord-005478-5iu38pr6	1979	1	We	-PRON-	PRP
cord-005478-5iu38pr6	1979	2	simultaneously	simultaneously	RB
cord-005478-5iu38pr6	1979	3	stained	stain	VBD
cord-005478-5iu38pr6	1979	4	cells	cell	NNS
cord-005478-5iu38pr6	1979	5	with	with	IN
cord-005478-5iu38pr6	1979	6	42	42	CD
cord-005478-5iu38pr6	1979	7	antibody	antibody	NN
cord-005478-5iu38pr6	1979	8	panels	panel	NNS
cord-005478-5iu38pr6	1979	9	created	create	VBN
cord-005478-5iu38pr6	1979	10	for	for	IN
cord-005478-5iu38pr6	1979	11	this	this	DT
cord-005478-5iu38pr6	1979	12	study	study	NN
cord-005478-5iu38pr6	1979	13	.	.	.
cord-005478-5iu38pr6	1980	1	The	the	DT
cord-005478-5iu38pr6	1980	2	T	T	NNP
cord-005478-5iu38pr6	1980	3	cell	cell	NN
cord-005478-5iu38pr6	1980	4	panel	panel	NN
cord-005478-5iu38pr6	1980	5	was	be	VBD
cord-005478-5iu38pr6	1980	6	designed	design	VBN
cord-005478-5iu38pr6	1980	7	to	to	TO
cord-005478-5iu38pr6	1980	8	identify	identify	VB
cord-005478-5iu38pr6	1980	9	different	different	JJ
cord-005478-5iu38pr6	1980	10	populations	population	NNS
cord-005478-5iu38pr6	1980	11	of	of	IN
cord-005478-5iu38pr6	1980	12	naive	naive	JJ
cord-005478-5iu38pr6	1980	13	,	,	,
cord-005478-5iu38pr6	1980	14	memory	memory	NN
cord-005478-5iu38pr6	1980	15	,	,	,
cord-005478-5iu38pr6	1980	16	effector	effector	NN
cord-005478-5iu38pr6	1980	17	,	,	,
cord-005478-5iu38pr6	1980	18	regulatory	regulatory	JJ
cord-005478-5iu38pr6	1980	19	,	,	,
cord-005478-5iu38pr6	1980	20	and	and	CC
cord-005478-5iu38pr6	1980	21	exhausted	exhaust	VBN
cord-005478-5iu38pr6	1980	22	T	t	NN
cord-005478-5iu38pr6	1980	23	cells	cell	NNS
cord-005478-5iu38pr6	1980	24	.	.	.
cord-005478-5iu38pr6	1981	1	The	the	DT
cord-005478-5iu38pr6	1981	2	panels	panel	NNS
cord-005478-5iu38pr6	1981	3	also	also	RB
cord-005478-5iu38pr6	1981	4	included	include	VBD
cord-005478-5iu38pr6	1981	5	markers	marker	NNS
cord-005478-5iu38pr6	1981	6	for	for	IN
cord-005478-5iu38pr6	1981	7	the	the	DT
cord-005478-5iu38pr6	1981	8	identification	identification	NN
cord-005478-5iu38pr6	1981	9	of	of	IN
cord-005478-5iu38pr6	1981	10	B	b	NN
cord-005478-5iu38pr6	1981	11	cells	cell	NNS
cord-005478-5iu38pr6	1981	12	,	,	,
cord-005478-5iu38pr6	1981	13	natural	natural	JJ
cord-005478-5iu38pr6	1981	14	killer	killer	NN
cord-005478-5iu38pr6	1981	15	cells	cell	NNS
cord-005478-5iu38pr6	1981	16	,	,	,
cord-005478-5iu38pr6	1981	17	NKT	NKT	NNP
cord-005478-5iu38pr6	1981	18	cells	cell	NNS
cord-005478-5iu38pr6	1981	19	,	,	,
cord-005478-5iu38pr6	1981	20	DC	DC	NNP
cord-005478-5iu38pr6	1981	21	cells	cell	NNS
cord-005478-5iu38pr6	1981	22	,	,	,
cord-005478-5iu38pr6	1981	23	plasma	plasma	NN
cord-005478-5iu38pr6	1981	24	cells	cell	NNS
cord-005478-5iu38pr6	1981	25	,	,	,
cord-005478-5iu38pr6	1981	26	granulocytes	granulocyte	NNS
cord-005478-5iu38pr6	1981	27	,	,	,
cord-005478-5iu38pr6	1981	28	and	and	CC
cord-005478-5iu38pr6	1981	29	myeloid	myeloid	NN
cord-005478-5iu38pr6	1981	30	cells	cell	NNS
cord-005478-5iu38pr6	1981	31	.	.	.
cord-005478-5iu38pr6	1982	1	In	in	IN
cord-005478-5iu38pr6	1982	2	4	4	CD
cord-005478-5iu38pr6	1982	3	million	million	CD
cord-005478-5iu38pr6	1982	4	measured	measure	VBN
cord-005478-5iu38pr6	1982	5	cells	cell	NNS
cord-005478-5iu38pr6	1982	6	,	,	,
cord-005478-5iu38pr6	1982	7	we	-PRON-	PRP
cord-005478-5iu38pr6	1982	8	identified	identify	VBD
cord-005478-5iu38pr6	1982	9	40	40	CD
cord-005478-5iu38pr6	1982	10	immune	immune	JJ
cord-005478-5iu38pr6	1982	11	cell	cell	NN
cord-005478-5iu38pr6	1982	12	phenotypes	phenotype	NNS
cord-005478-5iu38pr6	1982	13	,	,	,
cord-005478-5iu38pr6	1982	14	in	in	IN
cord-005478-5iu38pr6	1982	15	which	which	WDT
cord-005478-5iu38pr6	1982	16	there	there	EX
cord-005478-5iu38pr6	1982	17	were	be	VBD
cord-005478-5iu38pr6	1982	18	22	22	CD
cord-005478-5iu38pr6	1982	19	T	t	NN
cord-005478-5iu38pr6	1982	20	cell	cell	NN
cord-005478-5iu38pr6	1982	21	phenotypes	phenotype	NNS
cord-005478-5iu38pr6	1982	22	,	,	,
cord-005478-5iu38pr6	1982	23	6	6	CD
cord-005478-5iu38pr6	1982	24	B	b	NN
cord-005478-5iu38pr6	1982	25	cell	cell	NN
cord-005478-5iu38pr6	1982	26	phenotypes	phenotype	NNS
cord-005478-5iu38pr6	1982	27	,	,	,
cord-005478-5iu38pr6	1982	28	6	6	CD
cord-005478-5iu38pr6	1982	29	monocyte	monocyte	NNP
cord-005478-5iu38pr6	1982	30	phenotypes	phenotype	NNS
cord-005478-5iu38pr6	1982	31	and	and	CC
cord-005478-5iu38pr6	1982	32	6	6	CD
cord-005478-5iu38pr6	1982	33	granulocyte	granulocyte	NN
cord-005478-5iu38pr6	1982	34	phenotypes	phenotype	NNS
cord-005478-5iu38pr6	1982	35	.	.	.
cord-005478-5iu38pr6	1983	1	To	to	TO
cord-005478-5iu38pr6	1983	2	generate	generate	VB
cord-005478-5iu38pr6	1983	3	a	a	DT
cord-005478-5iu38pr6	1983	4	comprehensive	comprehensive	JJ
cord-005478-5iu38pr6	1983	5	view	view	NN
cord-005478-5iu38pr6	1983	6	of	of	IN
cord-005478-5iu38pr6	1983	7	the	the	DT
cord-005478-5iu38pr6	1983	8	immune	immune	JJ
cord-005478-5iu38pr6	1983	9	ecosystem	ecosystem	NN
cord-005478-5iu38pr6	1983	10	of	of	IN
cord-005478-5iu38pr6	1983	11	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1983	12	,	,	,
cord-005478-5iu38pr6	1983	13	we	-PRON-	PRP
cord-005478-5iu38pr6	1983	14	generated	generate	VBD
cord-005478-5iu38pr6	1983	15	two	two	CD
cord-005478-5iu38pr6	1983	16	-	-	HYPH
cord-005478-5iu38pr6	1983	17	dimensional	dimensional	JJ
cord-005478-5iu38pr6	1983	18	maps	map	NNS
cord-005478-5iu38pr6	1983	19	of	of	IN
cord-005478-5iu38pr6	1983	20	the	the	DT
cord-005478-5iu38pr6	1983	21	data	datum	NNS
cord-005478-5iu38pr6	1983	22	using	use	VBG
cord-005478-5iu38pr6	1983	23	the	the	DT
cord-005478-5iu38pr6	1983	24	dimensionality	dimensionality	NN
cord-005478-5iu38pr6	1983	25	reduction	reduction	NN
cord-005478-5iu38pr6	1983	26	algorithm	algorithm	NN
cord-005478-5iu38pr6	1983	27	t	t	NNP
cord-005478-5iu38pr6	1983	28	-	-	HYPH
cord-005478-5iu38pr6	1983	29	SNE	SNE	NNP
cord-005478-5iu38pr6	1983	30	.	.	.
cord-005478-5iu38pr6	1984	1	This	this	DT
cord-005478-5iu38pr6	1984	2	analysis	analysis	NN
cord-005478-5iu38pr6	1984	3	showed	show	VBD
cord-005478-5iu38pr6	1984	4	a	a	DT
cord-005478-5iu38pr6	1984	5	strong	strong	JJ
cord-005478-5iu38pr6	1984	6	overlap	overlap	NN
cord-005478-5iu38pr6	1984	7	between	between	IN
cord-005478-5iu38pr6	1984	8	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	1984	9	of	of	IN
cord-005478-5iu38pr6	1984	10	moderate	moderate	JJ
cord-005478-5iu38pr6	1984	11	and	and	CC
cord-005478-5iu38pr6	1984	12	severe	severe	JJ
cord-005478-5iu38pr6	1984	13	grades	grade	NNS
cord-005478-5iu38pr6	1984	14	,	,	,
cord-005478-5iu38pr6	1984	15	but	but	CC
cord-005478-5iu38pr6	1984	16	seperation	seperation	NN
cord-005478-5iu38pr6	1984	17	from	from	IN
cord-005478-5iu38pr6	1984	18	patients	patient	NNS
cord-005478-5iu38pr6	1984	19	without	without	IN
cord-005478-5iu38pr6	1984	20	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1984	21	.	.	.
cord-005478-5iu38pr6	1985	1	Seven	seven	CD
cord-005478-5iu38pr6	1985	2	immune	immune	JJ
cord-005478-5iu38pr6	1985	3	compositions	composition	NNS
cord-005478-5iu38pr6	1985	4	were	be	VBD
cord-005478-5iu38pr6	1985	5	identified	identify	VBN
cord-005478-5iu38pr6	1985	6	to	to	TO
cord-005478-5iu38pr6	1985	7	be	be	VB
cord-005478-5iu38pr6	1985	8	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1985	9	-	-	HYPH
cord-005478-5iu38pr6	1985	10	associated	associate	VBN
cord-005478-5iu38pr6	1985	11	.	.	.
cord-005478-5iu38pr6	1986	1	Five	five	CD
cord-005478-5iu38pr6	1986	2	distinct	distinct	JJ
cord-005478-5iu38pr6	1986	3	immune	immune	JJ
cord-005478-5iu38pr6	1986	4	cells	cell	NNS
cord-005478-5iu38pr6	1986	5	were	be	VBD
cord-005478-5iu38pr6	1986	6	correlated	correlate	VBN
cord-005478-5iu38pr6	1986	7	with	with	IN
cord-005478-5iu38pr6	1986	8	specific	specific	JJ
cord-005478-5iu38pr6	1986	9	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	1986	10	-	-	HYPH
cord-005478-5iu38pr6	1986	11	involved	involve	VBN
cord-005478-5iu38pr6	1986	12	organs	organ	NNS
cord-005478-5iu38pr6	1986	13	(	(	-LRB-
cord-005478-5iu38pr6	1986	14	skin	skin	NN
cord-005478-5iu38pr6	1986	15	or	or	CC
cord-005478-5iu38pr6	1986	16	lung	lung	NN
cord-005478-5iu38pr6	1986	17	)	)	-RRB-
cord-005478-5iu38pr6	1986	18	,	,	,
cord-005478-5iu38pr6	1986	19	thereby	thereby	RB
cord-005478-5iu38pr6	1986	20	presenting	present	VBG
cord-005478-5iu38pr6	1986	21	an	an	DT
cord-005478-5iu38pr6	1986	22	in	in	IN
cord-005478-5iu38pr6	1986	23	-	-	HYPH
cord-005478-5iu38pr6	1986	24	depth	depth	NN
cord-005478-5iu38pr6	1986	25	human	human	JJ
cord-005478-5iu38pr6	1986	26	atlas	atlas	NN
cord-005478-5iu38pr6	1986	27	of	of	IN
cord-005478-5iu38pr6	1986	28	the	the	DT
cord-005478-5iu38pr6	1986	29	immune	immune	JJ
cord-005478-5iu38pr6	1986	30	cells	cell	NNS
cord-005478-5iu38pr6	1986	31	in	in	IN
cord-005478-5iu38pr6	1986	32	this	this	DT
cord-005478-5iu38pr6	1986	33	disease	disease	NN
cord-005478-5iu38pr6	1986	34	.	.	.
cord-005478-5iu38pr6	1987	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	1987	2	:	:	:
cord-005478-5iu38pr6	1988	1	This	this	DT
cord-005478-5iu38pr6	1988	2	study	study	NN
cord-005478-5iu38pr6	1988	3	revealed	reveal	VBD
cord-005478-5iu38pr6	1988	4	potential	potential	JJ
cord-005478-5iu38pr6	1988	5	biomarkers	biomarker	NNS
cord-005478-5iu38pr6	1988	6	and	and	CC
cord-005478-5iu38pr6	1988	7	targets	target	NNS
cord-005478-5iu38pr6	1988	8	for	for	IN
cord-005478-5iu38pr6	1988	9	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	1988	10	of	of	IN
cord-005478-5iu38pr6	1988	11	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1988	12	and	and	CC
cord-005478-5iu38pr6	1988	13	validated	validate	VBD
cord-005478-5iu38pr6	1988	14	CyTOF	CyTOF	NNP
cord-005478-5iu38pr6	1988	15	as	as	IN
cord-005478-5iu38pr6	1988	16	a	a	DT
cord-005478-5iu38pr6	1988	17	valuable	valuable	JJ
cord-005478-5iu38pr6	1988	18	tool	tool	NN
cord-005478-5iu38pr6	1988	19	that	that	WDT
cord-005478-5iu38pr6	1988	20	can	can	MD
cord-005478-5iu38pr6	1988	21	be	be	VB
cord-005478-5iu38pr6	1988	22	used	use	VBN
cord-005478-5iu38pr6	1988	23	for	for	IN
cord-005478-5iu38pr6	1988	24	immune	immune	JJ
cord-005478-5iu38pr6	1988	25	profiling	profiling	NN
cord-005478-5iu38pr6	1988	26	of	of	IN
cord-005478-5iu38pr6	1988	27	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	1988	28	.	.	.
cord-005478-5iu38pr6	1989	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	1989	2	:	:	:
cord-005478-5iu38pr6	1989	3	Nothing	nothing	NN
cord-005478-5iu38pr6	1989	4	to	to	TO
cord-005478-5iu38pr6	1989	5	declare	declare	VB
cord-005478-5iu38pr6	1989	6	O100	O100	NNP
cord-005478-5iu38pr6	1989	7	T	T	NNP
cord-005478-5iu38pr6	1989	8	cell	cell	NN
cord-005478-5iu38pr6	1989	9	costimulation	costimulation	NN
cord-005478-5iu38pr6	1989	10	blockade	blockade	NN
cord-005478-5iu38pr6	1989	11	with	with	IN
cord-005478-5iu38pr6	1989	12	abatacept	abatacept	NNP
cord-005478-5iu38pr6	1989	13	for	for	IN
cord-005478-5iu38pr6	1989	14	acute	acute	JJ
cord-005478-5iu38pr6	1989	15	graft	graft	NN
cord-005478-5iu38pr6	1989	16	-	-	HYPH
cord-005478-5iu38pr6	1989	17	versus	versus	IN
cord-005478-5iu38pr6	1989	18	-	-	HYPH
cord-005478-5iu38pr6	1989	19	host	host	NN
cord-005478-5iu38pr6	1989	20	disease	disease	NN
cord-005478-5iu38pr6	1989	21	prevention	prevention	NN
cord-005478-5iu38pr6	1989	22	in	in	IN
cord-005478-5iu38pr6	1989	23	matched	match	VBN
cord-005478-5iu38pr6	1989	24	and	and	CC
cord-005478-5iu38pr6	1989	25	mismatched	mismatched	JJ
cord-005478-5iu38pr6	1989	26	unrelated	unrelated	JJ
cord-005478-5iu38pr6	1989	27	donor	donor	NN
cord-005478-5iu38pr6	1989	28	transplantation	transplantation	NN
cord-005478-5iu38pr6	1989	29	:	:	:
cord-005478-5iu38pr6	1989	30	Results	result	NNS
cord-005478-5iu38pr6	1989	31	of	of	IN
cord-005478-5iu38pr6	1989	32	the	the	DT
cord-005478-5iu38pr6	1989	33	first	first	JJ
cord-005478-5iu38pr6	1989	34	phase	phase	NN
cord-005478-5iu38pr6	1989	35	2	2	CD
cord-005478-5iu38pr6	1989	36	trial	trial	NN
cord-005478-5iu38pr6	1989	37	Background	background	NN
cord-005478-5iu38pr6	1990	1	:	:	:
cord-005478-5iu38pr6	1990	2	We	-PRON-	PRP
cord-005478-5iu38pr6	1990	3	performed	perform	VBD
cord-005478-5iu38pr6	1990	4	a	a	DT
cord-005478-5iu38pr6	1990	5	Phase	phase	NN
cord-005478-5iu38pr6	1990	6	2	2	CD
cord-005478-5iu38pr6	1990	7	trial	trial	NN
cord-005478-5iu38pr6	1990	8	in	in	IN
cord-005478-5iu38pr6	1990	9	adults	adult	NNS
cord-005478-5iu38pr6	1990	10	and	and	CC
cord-005478-5iu38pr6	1990	11	children	child	NNS
cord-005478-5iu38pr6	1990	12	to	to	TO
cord-005478-5iu38pr6	1990	13	test	test	VB
cord-005478-5iu38pr6	1990	14	abatacept	abatacept	NN
cord-005478-5iu38pr6	1990	15	for	for	IN
cord-005478-5iu38pr6	1990	16	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	1990	17	prevention	prevention	NN
cord-005478-5iu38pr6	1990	18	(	(	-LRB-
cord-005478-5iu38pr6	1990	19	'	'	``
cord-005478-5iu38pr6	1990	20	ABA2	ABA2	NNP
cord-005478-5iu38pr6	1990	21	'	'	''
cord-005478-5iu38pr6	1990	22	)	)	-RRB-
cord-005478-5iu38pr6	1990	23	,	,	,
cord-005478-5iu38pr6	1990	24	based	base	VBN
cord-005478-5iu38pr6	1990	25	on	on	IN
cord-005478-5iu38pr6	1990	26	our	-PRON-	PRP$
cord-005478-5iu38pr6	1990	27	promising	promising	JJ
cord-005478-5iu38pr6	1990	28	preclinical	preclinical	JJ
cord-005478-5iu38pr6	1990	29	and	and	CC
cord-005478-5iu38pr6	1990	30	pilot	pilot	NN
cord-005478-5iu38pr6	1990	31	patient	patient	NN
cord-005478-5iu38pr6	1990	32	data	datum	NNS
cord-005478-5iu38pr6	1990	33	.	.	.
cord-005478-5iu38pr6	1991	1	Methods	method	NNS
cord-005478-5iu38pr6	1991	2	:	:	:
cord-005478-5iu38pr6	1991	3	ABA2	ABA2	NNP
cord-005478-5iu38pr6	1991	4	had	have	VBD
cord-005478-5iu38pr6	1991	5	2	2	CD
cord-005478-5iu38pr6	1991	6	cohorts	cohort	NNS
cord-005478-5iu38pr6	1991	7	:	:	:
cord-005478-5iu38pr6	1991	8	A	a	LS
cord-005478-5iu38pr6	1991	9	)	)	-RRB-
cord-005478-5iu38pr6	1991	10	HLA	HLA	NNP
cord-005478-5iu38pr6	1991	11	mismatched	mismatch	VBD
cord-005478-5iu38pr6	1991	12	(	(	-LRB-
cord-005478-5iu38pr6	1991	13	'	'	``
cord-005478-5iu38pr6	1991	14	7/	7/	CD
cord-005478-5iu38pr6	1991	15	8	8	CD
cord-005478-5iu38pr6	1991	16	'	'	''
cord-005478-5iu38pr6	1991	17	,	,	,
cord-005478-5iu38pr6	1991	18	n=	n=	NNP
cord-005478-5iu38pr6	1991	19	43	43	CD
cord-005478-5iu38pr6	1991	20	)	)	-RRB-
cord-005478-5iu38pr6	1991	21	,	,	,
cord-005478-5iu38pr6	1991	22	a	a	DT
cord-005478-5iu38pr6	1991	23	single	single	JJ
cord-005478-5iu38pr6	1991	24	-	-	HYPH
cord-005478-5iu38pr6	1991	25	arm	arm	NN
cord-005478-5iu38pr6	1991	26	study	study	NN
cord-005478-5iu38pr6	1991	27	with	with	IN
cord-005478-5iu38pr6	1991	28	pre	pre	JJ
cord-005478-5iu38pr6	1991	29	-	-	JJ
cord-005478-5iu38pr6	1991	30	specified	specified	JJ
cord-005478-5iu38pr6	1991	31	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	1991	32	matched	match	VBN
cord-005478-5iu38pr6	1991	33	analysis	analysis	NN
cord-005478-5iu38pr6	1991	34	(	(	-LRB-
cord-005478-5iu38pr6	1991	35	vs	vs	IN
cord-005478-5iu38pr6	1991	36	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	1991	37	or	or	CC
cord-005478-5iu38pr6	1991	38	CNI+MTX+ATG	cni+mtx+atg	CD
cord-005478-5iu38pr6	1991	39	)	)	-RRB-
cord-005478-5iu38pr6	1991	40	.	.	.
cord-005478-5iu38pr6	1992	1	B	b	NN
cord-005478-5iu38pr6	1992	2	)	)	-RRB-
cord-005478-5iu38pr6	1993	1	HLA	HLA	NNP
cord-005478-5iu38pr6	1993	2	-	-	HYPH
cord-005478-5iu38pr6	1993	3	matched	match	VBN
cord-005478-5iu38pr6	1993	4	(	(	-LRB-
cord-005478-5iu38pr6	1993	5	'	'	``
cord-005478-5iu38pr6	1993	6	8/8	8/8	CD
cord-005478-5iu38pr6	1993	7	'	'	''
cord-005478-5iu38pr6	1993	8	,	,	,
cord-005478-5iu38pr6	1993	9	n=	n=	NNP
cord-005478-5iu38pr6	1993	10	142	142	CD
cord-005478-5iu38pr6	1993	11	)	)	-RRB-
cord-005478-5iu38pr6	1993	12	,	,	,
cord-005478-5iu38pr6	1993	13	randomized	randomize	VBN
cord-005478-5iu38pr6	1993	14	double	double	JJ
cord-005478-5iu38pr6	1993	15	-	-	HYPH
cord-005478-5iu38pr6	1993	16	blind	blind	JJ
cord-005478-5iu38pr6	1993	17	,	,	,
cord-005478-5iu38pr6	1993	18	comparing	compare	VBG
cord-005478-5iu38pr6	1993	19	CNI+MTX+placebo	cni+mtx+placebo	NN
cord-005478-5iu38pr6	1993	20	vs	vs	IN
cord-005478-5iu38pr6	1993	21	CNI+MTX+ABA	cni+mtx+aba	ADD
cord-005478-5iu38pr6	1993	22	(	(	-LRB-
cord-005478-5iu38pr6	1993	23	'	'	``
cord-005478-5iu38pr6	1993	24	ABA	ABA	NNP
cord-005478-5iu38pr6	1993	25	'	'	''
cord-005478-5iu38pr6	1993	26	)	)	-RRB-
cord-005478-5iu38pr6	1993	27	.	.	.
cord-005478-5iu38pr6	1994	1	Abatacept	Abatacept	NNP
cord-005478-5iu38pr6	1994	2	dosing	dosing	NN
cord-005478-5iu38pr6	1994	3	was	be	VBD
cord-005478-5iu38pr6	1994	4	10mg	10mg	NN
cord-005478-5iu38pr6	1994	5	/	/	SYM
cord-005478-5iu38pr6	1994	6	kg	kg	NN
cord-005478-5iu38pr6	1994	7	on	on	IN
cord-005478-5iu38pr6	1994	8	d	d	NNP
cord-005478-5iu38pr6	1994	9	-1	-1	NN
cord-005478-5iu38pr6	1994	10	,	,	,
cord-005478-5iu38pr6	1994	11	+5	+5	NNP
cord-005478-5iu38pr6	1994	12	,	,	,
cord-005478-5iu38pr6	1994	13	+14	+14	CD
cord-005478-5iu38pr6	1994	14	,	,	,
cord-005478-5iu38pr6	1994	15	+28	+28	NNS
cord-005478-5iu38pr6	1994	16	.	.	.
cord-005478-5iu38pr6	1995	1	ABA2	ABA2	NNP
cord-005478-5iu38pr6	1995	2	was	be	VBD
cord-005478-5iu38pr6	1995	3	designed	design	VBN
cord-005478-5iu38pr6	1995	4	as	as	IN
cord-005478-5iu38pr6	1995	5	a	a	DT
cord-005478-5iu38pr6	1995	6	screening	screening	NN
cord-005478-5iu38pr6	1995	7	Phase	phase	NN
cord-005478-5iu38pr6	1995	8	2	2	CD
cord-005478-5iu38pr6	1995	9	trial	trial	NN
cord-005478-5iu38pr6	1995	10	,	,	,
cord-005478-5iu38pr6	1995	11	with	with	IN
cord-005478-5iu38pr6	1995	12	relaxed	relaxed	JJ
cord-005478-5iu38pr6	1995	13	Type	type	NN
cord-005478-5iu38pr6	1995	14	1	1	CD
cord-005478-5iu38pr6	1995	15	error	error	NN
cord-005478-5iu38pr6	1995	16	(	(	-LRB-
cord-005478-5iu38pr6	1995	17	0.2	0.2	CD
cord-005478-5iu38pr6	1995	18	)	)	-RRB-
cord-005478-5iu38pr6	1995	19	and	and	CC
cord-005478-5iu38pr6	1995	20	standard	standard	JJ
cord-005478-5iu38pr6	1995	21	Type	type	NN
cord-005478-5iu38pr6	1995	22	2	2	CD
cord-005478-5iu38pr6	1995	23	error	error	NN
cord-005478-5iu38pr6	1995	24	(	(	-LRB-
cord-005478-5iu38pr6	1995	25	0.2	0.2	CD
cord-005478-5iu38pr6	1995	26	)	)	-RRB-
cord-005478-5iu38pr6	1995	27	.	.	.
cord-005478-5iu38pr6	1996	1	Power	power	NN
cord-005478-5iu38pr6	1996	2	analysis	analysis	NN
cord-005478-5iu38pr6	1996	3	assumed	assume	VBD
cord-005478-5iu38pr6	1996	4	reduction	reduction	NN
cord-005478-5iu38pr6	1996	5	of	of	IN
cord-005478-5iu38pr6	1996	6	Gr	Gr	NNP
cord-005478-5iu38pr6	1996	7	3	3	CD
cord-005478-5iu38pr6	1996	8	-	-	SYM
cord-005478-5iu38pr6	1996	9	4	4	CD
cord-005478-5iu38pr6	1996	10	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	1996	11	from	from	IN
cord-005478-5iu38pr6	1996	12	30%-->10	30%-->10	CD
cord-005478-5iu38pr6	1996	13	%	%	NN
cord-005478-5iu38pr6	1996	14	in	in	IN
cord-005478-5iu38pr6	1996	15	7/8s	7/8s	CD
cord-005478-5iu38pr6	1996	16	and	and	CC
cord-005478-5iu38pr6	1996	17	20%-->10	20%-->10	CD
cord-005478-5iu38pr6	1996	18	%	%	NN
cord-005478-5iu38pr6	1996	19	in	in	IN
cord-005478-5iu38pr6	1996	20	8/8s	8/8s	CD
cord-005478-5iu38pr6	1996	21	.	.	.
cord-005478-5iu38pr6	1997	1	Median	median	JJ
cord-005478-5iu38pr6	1997	2	follow	follow	VBP
cord-005478-5iu38pr6	1997	3	up	up	RB
cord-005478-5iu38pr6	1997	4	=	=	SYM
cord-005478-5iu38pr6	1997	5	708	708	CD
cord-005478-5iu38pr6	1997	6	days	day	NNS
cord-005478-5iu38pr6	1997	7	(	(	-LRB-
cord-005478-5iu38pr6	1997	8	7/8s	7/8s	NN
cord-005478-5iu38pr6	1997	9	)	)	-RRB-
cord-005478-5iu38pr6	1997	10	and	and	CC
cord-005478-5iu38pr6	1997	11	369	369	CD
cord-005478-5iu38pr6	1997	12	days	day	NNS
cord-005478-5iu38pr6	1997	13	(	(	-LRB-
cord-005478-5iu38pr6	1997	14	8/8s	8/8s	NN
cord-005478-5iu38pr6	1997	15	)	)	-RRB-
cord-005478-5iu38pr6	1997	16	.	.	.
cord-005478-5iu38pr6	1998	1	Results	result	NNS
cord-005478-5iu38pr6	1998	2	:	:	:
cord-005478-5iu38pr6	1999	1	Reduced	reduce	VBN
cord-005478-5iu38pr6	1999	2	grade	grade	NN
cord-005478-5iu38pr6	1999	3	3	3	CD
cord-005478-5iu38pr6	1999	4	-	-	SYM
cord-005478-5iu38pr6	1999	5	4	4	CD
cord-005478-5iu38pr6	1999	6	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	1999	7	:	:	:
cord-005478-5iu38pr6	2000	1	ABA	ABA	NNP
cord-005478-5iu38pr6	2000	2	was	be	VBD
cord-005478-5iu38pr6	2000	3	associated	associate	VBN
cord-005478-5iu38pr6	2000	4	with	with	IN
cord-005478-5iu38pr6	2000	5	decreased	decrease	VBN
cord-005478-5iu38pr6	2000	6	d180	d180	NN
cord-005478-5iu38pr6	2000	7	Gr	Gr	NNP
cord-005478-5iu38pr6	2000	8	3	3	CD
cord-005478-5iu38pr6	2000	9	-	-	SYM
cord-005478-5iu38pr6	2000	10	4	4	CD
cord-005478-5iu38pr6	2000	11	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2000	12	.	.	.
cord-005478-5iu38pr6	2001	1	In	in	IN
cord-005478-5iu38pr6	2001	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2001	3	,	,	,
cord-005478-5iu38pr6	2001	4	Gr	Gr	NNP
cord-005478-5iu38pr6	2001	5	3	3	CD
cord-005478-5iu38pr6	2001	6	-	-	SYM
cord-005478-5iu38pr6	2001	7	4	4	CD
cord-005478-5iu38pr6	2001	8	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2001	9	=	=	SYM
cord-005478-5iu38pr6	2001	10	2.5	2.5	CD
cord-005478-5iu38pr6	2001	11	%	%	NN
cord-005478-5iu38pr6	2001	12	(	(	-LRB-
cord-005478-5iu38pr6	2001	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2001	14	)	)	-RRB-
cord-005478-5iu38pr6	2001	15	vs	vs	IN
cord-005478-5iu38pr6	2001	16	31	31	CD
cord-005478-5iu38pr6	2001	17	%	%	NN
cord-005478-5iu38pr6	2001	18	(	(	-LRB-
cord-005478-5iu38pr6	2001	19	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2001	20	)	)	-RRB-
cord-005478-5iu38pr6	2001	21	and	and	CC
cord-005478-5iu38pr6	2001	22	22	22	CD
cord-005478-5iu38pr6	2001	23	%	%	NN
cord-005478-5iu38pr6	2001	24	(	(	-LRB-
cord-005478-5iu38pr6	2001	25	+	+	CC
cord-005478-5iu38pr6	2001	26	ATG	ATG	NNP
cord-005478-5iu38pr6	2001	27	)	)	-RRB-
cord-005478-5iu38pr6	2001	28	,	,	,
cord-005478-5iu38pr6	2001	29	(	(	-LRB-
cord-005478-5iu38pr6	2001	30	1-sided	1-sided	CD
cord-005478-5iu38pr6	2001	31	p	p	NN
cord-005478-5iu38pr6	2001	32	=	=	SYM
cord-005478-5iu38pr6	2001	33	0.001	0.001	CD
cord-005478-5iu38pr6	2001	34	,	,	,
cord-005478-5iu38pr6	2001	35	0.005	0.005	CD
cord-005478-5iu38pr6	2001	36	)	)	-RRB-
cord-005478-5iu38pr6	2001	37	.	.	.
cord-005478-5iu38pr6	2002	1	In	in	IN
cord-005478-5iu38pr6	2002	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2002	3	,	,	,
cord-005478-5iu38pr6	2002	4	Gr	Gr	NNP
cord-005478-5iu38pr6	2002	5	3	3	CD
cord-005478-5iu38pr6	2002	6	-	-	SYM
cord-005478-5iu38pr6	2002	7	4	4	CD
cord-005478-5iu38pr6	2002	8	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2002	9	=	=	SYM
cord-005478-5iu38pr6	2002	10	6.85	6.85	CD
cord-005478-5iu38pr6	2002	11	%	%	NN
cord-005478-5iu38pr6	2002	12	in	in	IN
cord-005478-5iu38pr6	2002	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2002	14	vs	vs	IN
cord-005478-5iu38pr6	2002	15	14.6	14.6	CD
cord-005478-5iu38pr6	2002	16	%	%	NN
cord-005478-5iu38pr6	2002	17	in	in	IN
cord-005478-5iu38pr6	2002	18	placebo	placebo	NN
cord-005478-5iu38pr6	2002	19	,	,	,
cord-005478-5iu38pr6	2002	20	(	(	-LRB-
cord-005478-5iu38pr6	2002	21	1-sided	1-sided	CD
cord-005478-5iu38pr6	2002	22	p	p	NN
cord-005478-5iu38pr6	2002	23	=	=	SYM
cord-005478-5iu38pr6	2002	24	0.068	0.068	CD
cord-005478-5iu38pr6	2002	25	)	)	-RRB-
cord-005478-5iu38pr6	2002	26	.	.	.
cord-005478-5iu38pr6	2003	1	Reduced	reduce	VBN
cord-005478-5iu38pr6	2003	2	grade	grade	NN
cord-005478-5iu38pr6	2003	3	2	2	CD
cord-005478-5iu38pr6	2003	4	-	-	SYM
cord-005478-5iu38pr6	2003	5	4	4	CD
cord-005478-5iu38pr6	2003	6	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2003	7	in	in	IN
cord-005478-5iu38pr6	2003	8	8/8s	8/8s	CD
cord-005478-5iu38pr6	2003	9	:	:	:
cord-005478-5iu38pr6	2004	1	ABA	ABA	NNP
cord-005478-5iu38pr6	2004	2	was	be	VBD
cord-005478-5iu38pr6	2004	3	associated	associate	VBN
cord-005478-5iu38pr6	2004	4	with	with	IN
cord-005478-5iu38pr6	2004	5	decreased	decrease	VBN
cord-005478-5iu38pr6	2004	6	d180	d180	NN
cord-005478-5iu38pr6	2004	7	Gr	Gr	NNP
cord-005478-5iu38pr6	2004	8	2	2	CD
cord-005478-5iu38pr6	2004	9	-	-	SYM
cord-005478-5iu38pr6	2004	10	4	4	CD
cord-005478-5iu38pr6	2004	11	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2004	12	.	.	.
cord-005478-5iu38pr6	2005	1	In	in	IN
cord-005478-5iu38pr6	2005	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2005	3	,	,	,
cord-005478-5iu38pr6	2005	4	Gr	Gr	NNP
cord-005478-5iu38pr6	2005	5	2	2	CD
cord-005478-5iu38pr6	2005	6	-	-	SYM
cord-005478-5iu38pr6	2005	7	4	4	CD
cord-005478-5iu38pr6	2005	8	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2005	9	=	=	SYM
cord-005478-5iu38pr6	2005	10	42	42	CD
cord-005478-5iu38pr6	2005	11	%	%	NN
cord-005478-5iu38pr6	2005	12	(	(	-LRB-
cord-005478-5iu38pr6	2005	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2005	14	)	)	-RRB-
cord-005478-5iu38pr6	2005	15	vs	vs	IN
cord-005478-5iu38pr6	2005	16	54	54	CD
cord-005478-5iu38pr6	2005	17	%	%	NN
cord-005478-5iu38pr6	2005	18	(	(	-LRB-
cord-005478-5iu38pr6	2005	19	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2005	20	)	)	-RRB-
cord-005478-5iu38pr6	2005	21	and	and	CC
cord-005478-5iu38pr6	2005	22	45	45	CD
cord-005478-5iu38pr6	2005	23	%	%	NN
cord-005478-5iu38pr6	2005	24	(	(	-LRB-
cord-005478-5iu38pr6	2005	25	+	+	CC
cord-005478-5iu38pr6	2005	26	ATG	ATG	NNP
cord-005478-5iu38pr6	2005	27	,	,	,
cord-005478-5iu38pr6	2005	28	1-sided	1-sided	CD
cord-005478-5iu38pr6	2005	29	p	p	NN
cord-005478-5iu38pr6	2005	30	=	=	SYM
cord-005478-5iu38pr6	2005	31	0.098	0.098	CD
cord-005478-5iu38pr6	2005	32	,	,	,
cord-005478-5iu38pr6	2005	33	0.25	0.25	CD
cord-005478-5iu38pr6	2005	34	)	)	-RRB-
cord-005478-5iu38pr6	2005	35	.	.	.
cord-005478-5iu38pr6	2006	1	In	in	IN
cord-005478-5iu38pr6	2006	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2006	3	,	,	,
cord-005478-5iu38pr6	2006	4	Gr	Gr	NNP
cord-005478-5iu38pr6	2006	5	2	2	CD
cord-005478-5iu38pr6	2006	6	-	-	SYM
cord-005478-5iu38pr6	2006	7	4	4	CD
cord-005478-5iu38pr6	2006	8	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2006	9	=	=	SYM
cord-005478-5iu38pr6	2006	10	44.5	44.5	CD
cord-005478-5iu38pr6	2006	11	%	%	NN
cord-005478-5iu38pr6	2006	12	in	in	IN
cord-005478-5iu38pr6	2006	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2006	14	vs	vs	IN
cord-005478-5iu38pr6	2006	15	62.3	62.3	CD
cord-005478-5iu38pr6	2006	16	%	%	NN
cord-005478-5iu38pr6	2006	17	in	in	IN
cord-005478-5iu38pr6	2006	18	placebo	placebo	NN
cord-005478-5iu38pr6	2006	19	(	(	-LRB-
cord-005478-5iu38pr6	2006	20	1-sided	1-sided	CD
cord-005478-5iu38pr6	2006	21	p	p	NN
cord-005478-5iu38pr6	2006	22	=	=	SYM
cord-005478-5iu38pr6	2006	23	0.004	0.004	CD
cord-005478-5iu38pr6	2006	24	)	)	-RRB-
cord-005478-5iu38pr6	2006	25	.	.	.
cord-005478-5iu38pr6	2007	1	Chronic	chronic	JJ
cord-005478-5iu38pr6	2007	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2007	3	:	:	:
cord-005478-5iu38pr6	2008	1	For	for	IN
cord-005478-5iu38pr6	2008	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2008	3	,	,	,
cord-005478-5iu38pr6	2008	4	1	1	CD
cord-005478-5iu38pr6	2008	5	yr	yr	NN
cord-005478-5iu38pr6	2008	6	CGVHD	CGVHD	NNP
cord-005478-5iu38pr6	2008	7	=	=	SYM
cord-005478-5iu38pr6	2008	8	38.8	38.8	CD
cord-005478-5iu38pr6	2008	9	%	%	NN
cord-005478-5iu38pr6	2008	10	(	(	-LRB-
cord-005478-5iu38pr6	2008	11	ABA	ABA	NNP
cord-005478-5iu38pr6	2008	12	)	)	-RRB-
cord-005478-5iu38pr6	2008	13	vs	vs	IN
cord-005478-5iu38pr6	2008	14	43.5	43.5	CD
cord-005478-5iu38pr6	2008	15	%	%	NN
cord-005478-5iu38pr6	2008	16	(	(	-LRB-
cord-005478-5iu38pr6	2008	17	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2008	18	)	)	-RRB-
cord-005478-5iu38pr6	2008	19	and	and	CC
cord-005478-5iu38pr6	2008	20	35.5	35.5	CD
cord-005478-5iu38pr6	2008	21	%	%	NN
cord-005478-5iu38pr6	2008	22	(	(	-LRB-
cord-005478-5iu38pr6	2008	23	+	+	CC
cord-005478-5iu38pr6	2008	24	ATG	ATG	NNP
cord-005478-5iu38pr6	2008	25	,	,	,
cord-005478-5iu38pr6	2008	26	p	p	NN
cord-005478-5iu38pr6	2008	27	=	=	SYM
cord-005478-5iu38pr6	2008	28	0.4	0.4	CD
cord-005478-5iu38pr6	2008	29	,	,	,
cord-005478-5iu38pr6	2008	30	0.99	0.99	CD
cord-005478-5iu38pr6	2008	31	)	)	-RRB-
cord-005478-5iu38pr6	2008	32	.	.	.
cord-005478-5iu38pr6	2009	1	In	in	IN
cord-005478-5iu38pr6	2009	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2009	3	,	,	,
cord-005478-5iu38pr6	2009	4	data	datum	NNS
cord-005478-5iu38pr6	2009	5	collection	collection	NN
cord-005478-5iu38pr6	2009	6	is	be	VBZ
cord-005478-5iu38pr6	2009	7	ongoing	ongoing	JJ
cord-005478-5iu38pr6	2009	8	.	.	.
cord-005478-5iu38pr6	2010	1	Safety	safety	NN
cord-005478-5iu38pr6	2010	2	indicators	indicator	NNS
cord-005478-5iu38pr6	2010	3	:	:	:
cord-005478-5iu38pr6	2011	1	There	there	EX
cord-005478-5iu38pr6	2011	2	was	be	VBD
cord-005478-5iu38pr6	2011	3	no	no	DT
cord-005478-5iu38pr6	2011	4	difference	difference	NN
cord-005478-5iu38pr6	2011	5	in	in	IN
cord-005478-5iu38pr6	2011	6	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2011	7	or	or	CC
cord-005478-5iu38pr6	2011	8	platelet	platelet	NN
cord-005478-5iu38pr6	2011	9	engraftment	engraftment	NN
cord-005478-5iu38pr6	2011	10	,	,	,
cord-005478-5iu38pr6	2011	11	CMV	CMV	NNP
cord-005478-5iu38pr6	2011	12	and	and	CC
cord-005478-5iu38pr6	2011	13	EBV	EBV	NNP
cord-005478-5iu38pr6	2011	14	reactivation	reactivation	NN
cord-005478-5iu38pr6	2011	15	between	between	IN
cord-005478-5iu38pr6	2011	16	ABA	ABA	NNP
cord-005478-5iu38pr6	2011	17	and	and	CC
cord-005478-5iu38pr6	2011	18	controls	control	NNS
cord-005478-5iu38pr6	2011	19	.	.	.
cord-005478-5iu38pr6	2012	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2012	2	incidence	incidence	NN
cord-005478-5iu38pr6	2012	3	of	of	IN
cord-005478-5iu38pr6	2012	4	relapse	relapse	NN
cord-005478-5iu38pr6	2012	5	in	in	IN
cord-005478-5iu38pr6	2012	6	7/8s	7/8s	CD
cord-005478-5iu38pr6	2012	7	at	at	IN
cord-005478-5iu38pr6	2012	8	2	2	CD
cord-005478-5iu38pr6	2012	9	yr	yr	CD
cord-005478-5iu38pr6	2012	10	9.4	9.4	CD
cord-005478-5iu38pr6	2012	11	%	%	NN
cord-005478-5iu38pr6	2012	12	(	(	-LRB-
cord-005478-5iu38pr6	2012	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2012	14	)	)	-RRB-
cord-005478-5iu38pr6	2012	15	vs	vs	IN
cord-005478-5iu38pr6	2012	16	20.6	20.6	CD
cord-005478-5iu38pr6	2012	17	%	%	NN
cord-005478-5iu38pr6	2012	18	(	(	-LRB-
cord-005478-5iu38pr6	2012	19	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2012	20	)	)	-RRB-
cord-005478-5iu38pr6	2012	21	and	and	CC
cord-005478-5iu38pr6	2012	22	23.4	23.4	CD
cord-005478-5iu38pr6	2012	23	%	%	NN
cord-005478-5iu38pr6	2012	24	(	(	-LRB-
cord-005478-5iu38pr6	2012	25	+	+	``
cord-005478-5iu38pr6	2012	26	ATG	ATG	NNP
cord-005478-5iu38pr6	2012	27	)	)	-RRB-
cord-005478-5iu38pr6	2012	28	(	(	-LRB-
cord-005478-5iu38pr6	2012	29	p=0.115	p=0.115	NNP
cord-005478-5iu38pr6	2012	30	,	,	,
cord-005478-5iu38pr6	2012	31	0.085	0.085	CD
cord-005478-5iu38pr6	2012	32	)	)	-RRB-
cord-005478-5iu38pr6	2012	33	.	.	.
cord-005478-5iu38pr6	2013	1	In	in	IN
cord-005478-5iu38pr6	2013	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2013	3	,	,	,
cord-005478-5iu38pr6	2013	4	at	at	IN
cord-005478-5iu38pr6	2013	5	1	1	CD
cord-005478-5iu38pr6	2013	6	yr	yr	NN
cord-005478-5iu38pr6	2013	7	,	,	,
cord-005478-5iu38pr6	2013	8	it	-PRON-	PRP
cord-005478-5iu38pr6	2013	9	was	be	VBD
cord-005478-5iu38pr6	2013	10	13.8	13.8	CD
cord-005478-5iu38pr6	2013	11	%	%	NN
cord-005478-5iu38pr6	2013	12	(	(	-LRB-
cord-005478-5iu38pr6	2013	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2013	14	)	)	-RRB-
cord-005478-5iu38pr6	2013	15	vs	vs	IN
cord-005478-5iu38pr6	2013	16	20.5	20.5	CD
cord-005478-5iu38pr6	2013	17	%	%	NN
cord-005478-5iu38pr6	2013	18	(	(	-LRB-
cord-005478-5iu38pr6	2013	19	Placebo	Placebo	NNP
cord-005478-5iu38pr6	2013	20	,	,	,
cord-005478-5iu38pr6	2013	21	p	p	NN
cord-005478-5iu38pr6	2013	22	=	=	SYM
cord-005478-5iu38pr6	2013	23	0.7	0.7	CD
cord-005478-5iu38pr6	2013	24	)	)	-RRB-
cord-005478-5iu38pr6	2013	25	.	.	.
cord-005478-5iu38pr6	2014	1	Statistically	statistically	RB
cord-005478-5iu38pr6	2014	2	significant	significant	JJ
cord-005478-5iu38pr6	2014	3	survival	survival	NN
cord-005478-5iu38pr6	2014	4	advantage	advantage	NN
cord-005478-5iu38pr6	2014	5	in	in	IN
cord-005478-5iu38pr6	2015	1	7/8s	7/8s	NN
cord-005478-5iu38pr6	2015	2	:	:	:
cord-005478-5iu38pr6	2016	1	For	for	IN
cord-005478-5iu38pr6	2016	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2016	3	,	,	,
cord-005478-5iu38pr6	2016	4	1	1	CD
cord-005478-5iu38pr6	2016	5	yr	yr	NN
cord-005478-5iu38pr6	2016	6	non	non	JJ
cord-005478-5iu38pr6	2016	7	-	-	JJ
cord-005478-5iu38pr6	2016	8	relapse	relapse	JJ
cord-005478-5iu38pr6	2016	9	mortality	mortality	NN
cord-005478-5iu38pr6	2016	10	(	(	-LRB-
cord-005478-5iu38pr6	2016	11	NRM	NRM	NNP
cord-005478-5iu38pr6	2016	12	)	)	-RRB-
cord-005478-5iu38pr6	2016	13	=	=	SYM
cord-005478-5iu38pr6	2016	14	10.5	10.5	CD
cord-005478-5iu38pr6	2016	15	%	%	NN
cord-005478-5iu38pr6	2016	16	(	(	-LRB-
cord-005478-5iu38pr6	2016	17	ABA	ABA	NNP
cord-005478-5iu38pr6	2016	18	)	)	-RRB-
cord-005478-5iu38pr6	2016	19	vs	vs	IN
cord-005478-5iu38pr6	2016	20	32.7	32.7	CD
cord-005478-5iu38pr6	2016	21	%	%	NN
cord-005478-5iu38pr6	2016	22	(	(	-LRB-
cord-005478-5iu38pr6	2016	23	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2016	24	)	)	-RRB-
cord-005478-5iu38pr6	2016	25	and	and	CC
cord-005478-5iu38pr6	2016	26	26	26	CD
cord-005478-5iu38pr6	2016	27	%	%	NN
cord-005478-5iu38pr6	2016	28	(	(	-LRB-
cord-005478-5iu38pr6	2016	29	+	+	CC
cord-005478-5iu38pr6	2016	30	ATG	ATG	NNP
cord-005478-5iu38pr6	2016	31	,	,	,
cord-005478-5iu38pr6	2016	32	p	p	NN
cord-005478-5iu38pr6	2016	33	=	=	SYM
cord-005478-5iu38pr6	2016	34	0.024	0.024	CD
cord-005478-5iu38pr6	2016	35	,	,	,
cord-005478-5iu38pr6	2016	36	0.365	0.365	CD
cord-005478-5iu38pr6	2016	37	)	)	-RRB-
cord-005478-5iu38pr6	2016	38	.	.	.
cord-005478-5iu38pr6	2017	1	For	for	IN
cord-005478-5iu38pr6	2017	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2017	3	,	,	,
cord-005478-5iu38pr6	2017	4	NRM	NRM	NNP
cord-005478-5iu38pr6	2017	5	=	=	SYM
cord-005478-5iu38pr6	2017	6	7.1	7.1	CD
cord-005478-5iu38pr6	2017	7	%	%	NN
cord-005478-5iu38pr6	2017	8	vs	vs	IN
cord-005478-5iu38pr6	2017	9	14.6	14.6	CD
cord-005478-5iu38pr6	2017	10	%	%	NN
cord-005478-5iu38pr6	2017	11	at	at	IN
cord-005478-5iu38pr6	2017	12	1	1	CD
cord-005478-5iu38pr6	2017	13	yr	yr	NN
cord-005478-5iu38pr6	2017	14	(	(	-LRB-
cord-005478-5iu38pr6	2017	15	p	p	NN
cord-005478-5iu38pr6	2017	16	=	=	SYM
cord-005478-5iu38pr6	2017	17	0.5	0.5	CD
cord-005478-5iu38pr6	2017	18	)	)	-RRB-
cord-005478-5iu38pr6	2017	19	.	.	.
cord-005478-5iu38pr6	2018	1	Severe	severe	JJ
cord-005478-5iu38pr6	2018	2	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2018	3	free	free	JJ
cord-005478-5iu38pr6	2018	4	survival	survival	NN
cord-005478-5iu38pr6	2018	5	at	at	IN
cord-005478-5iu38pr6	2018	6	6	6	CD
cord-005478-5iu38pr6	2018	7	months	month	NNS
cord-005478-5iu38pr6	2018	8	for	for	IN
cord-005478-5iu38pr6	2018	9	7/	7/	CD
cord-005478-5iu38pr6	2018	10	8s	8	NNS
cord-005478-5iu38pr6	2018	11	=	=	SYM
cord-005478-5iu38pr6	2018	12	97	97	CD
cord-005478-5iu38pr6	2018	13	%	%	NN
cord-005478-5iu38pr6	2019	1	(	(	-LRB-
cord-005478-5iu38pr6	2019	2	ABA	ABA	NNP
cord-005478-5iu38pr6	2019	3	)	)	-RRB-
cord-005478-5iu38pr6	2019	4	vs	vs	IN
cord-005478-5iu38pr6	2019	5	55	55	CD
cord-005478-5iu38pr6	2019	6	%	%	NN
cord-005478-5iu38pr6	2019	7	(	(	-LRB-
cord-005478-5iu38pr6	2019	8	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2019	9	)	)	-RRB-
cord-005478-5iu38pr6	2019	10	and	and	CC
cord-005478-5iu38pr6	2019	11	59	59	CD
cord-005478-5iu38pr6	2019	12	%	%	NN
cord-005478-5iu38pr6	2019	13	(	(	-LRB-
cord-005478-5iu38pr6	2020	1	+	+	CC
cord-005478-5iu38pr6	2020	2	ATG	ATG	NNP
cord-005478-5iu38pr6	2020	3	,	,	,
cord-005478-5iu38pr6	2020	4	p	p	NN
cord-005478-5iu38pr6	2020	5	=	=	SYM
cord-005478-5iu38pr6	2020	6	0.001	0.001	CD
cord-005478-5iu38pr6	2020	7	,	,	,
cord-005478-5iu38pr6	2020	8	0.006	0.006	CD
cord-005478-5iu38pr6	2020	9	)	)	-RRB-
cord-005478-5iu38pr6	2020	10	.	.	.
cord-005478-5iu38pr6	2021	1	For	for	IN
cord-005478-5iu38pr6	2021	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2021	3	=	=	SYM
cord-005478-5iu38pr6	2021	4	89.0	89.0	CD
cord-005478-5iu38pr6	2021	5	%	%	NN
cord-005478-5iu38pr6	2021	6	(	(	-LRB-
cord-005478-5iu38pr6	2021	7	ABA	ABA	NNP
cord-005478-5iu38pr6	2021	8	)	)	-RRB-
cord-005478-5iu38pr6	2021	9	vs	vs	IN
cord-005478-5iu38pr6	2021	10	76.8	76.8	CD
cord-005478-5iu38pr6	2021	11	%	%	NN
cord-005478-5iu38pr6	2021	12	(	(	-LRB-
cord-005478-5iu38pr6	2021	13	Placebo	Placebo	NNP
cord-005478-5iu38pr6	2021	14	,	,	,
cord-005478-5iu38pr6	2021	15	p	p	NN
cord-005478-5iu38pr6	2021	16	=	=	SYM
cord-005478-5iu38pr6	2021	17	0.049	0.049	CD
cord-005478-5iu38pr6	2021	18	)	)	-RRB-
cord-005478-5iu38pr6	2021	19	.	.	.
cord-005478-5iu38pr6	2022	1	For	for	IN
cord-005478-5iu38pr6	2022	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2022	3	,	,	,
cord-005478-5iu38pr6	2022	4	relapse	relapse	NN
cord-005478-5iu38pr6	2022	5	-	-	HYPH
cord-005478-5iu38pr6	2022	6	free	free	JJ
cord-005478-5iu38pr6	2022	7	survival	survival	NN
cord-005478-5iu38pr6	2022	8	(	(	-LRB-
cord-005478-5iu38pr6	2022	9	RFS	RFS	NNP
cord-005478-5iu38pr6	2022	10	)	)	-RRB-
cord-005478-5iu38pr6	2022	11	=	=	SYM
cord-005478-5iu38pr6	2022	12	73.7	73.7	CD
cord-005478-5iu38pr6	2022	13	%	%	NN
cord-005478-5iu38pr6	2022	14	(	(	-LRB-
cord-005478-5iu38pr6	2022	15	ABA	ABA	NNP
cord-005478-5iu38pr6	2022	16	)	)	-RRB-
cord-005478-5iu38pr6	2022	17	vs	vs	IN
cord-005478-5iu38pr6	2022	18	38.7	38.7	CD
cord-005478-5iu38pr6	2022	19	%	%	NN
cord-005478-5iu38pr6	2022	20	in	in	IN
cord-005478-5iu38pr6	2022	21	CNI+MTX	cni+mtx	NN
cord-005478-5iu38pr6	2022	22	and	and	CC
cord-005478-5iu38pr6	2022	23	48.7	48.7	CD
cord-005478-5iu38pr6	2022	24	%	%	NN
cord-005478-5iu38pr6	2022	25	in	in	IN
cord-005478-5iu38pr6	2022	26	+	+	CC
cord-005478-5iu38pr6	2022	27	ATG	ATG	NNP
cord-005478-5iu38pr6	2022	28	(	(	-LRB-
cord-005478-5iu38pr6	2022	29	p	p	NN
cord-005478-5iu38pr6	2022	30	=	=	SYM
cord-005478-5iu38pr6	2022	31	0.001	0.001	CD
cord-005478-5iu38pr6	2022	32	,	,	,
cord-005478-5iu38pr6	2022	33	0.027	0.027	CD
cord-005478-5iu38pr6	2022	34	)	)	-RRB-
cord-005478-5iu38pr6	2022	35	.	.	.
cord-005478-5iu38pr6	2023	1	For	for	IN
cord-005478-5iu38pr6	2023	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2023	3	,	,	,
cord-005478-5iu38pr6	2023	4	RFS	RFS	NNP
cord-005478-5iu38pr6	2023	5	=	=	SYM
cord-005478-5iu38pr6	2023	6	79.1	79.1	CD
cord-005478-5iu38pr6	2023	7	%	%	NN
cord-005478-5iu38pr6	2023	8	for	for	IN
cord-005478-5iu38pr6	2023	9	ABA	ABA	NNP
cord-005478-5iu38pr6	2023	10	vs	vs	IN
cord-005478-5iu38pr6	2023	11	64.9	64.9	CD
cord-005478-5iu38pr6	2023	12	%	%	NN
cord-005478-5iu38pr6	2023	13	(	(	-LRB-
cord-005478-5iu38pr6	2023	14	placebo	placebo	NN
cord-005478-5iu38pr6	2023	15	,	,	,
cord-005478-5iu38pr6	2023	16	p	p	NN
cord-005478-5iu38pr6	2023	17	=	=	SYM
cord-005478-5iu38pr6	2023	18	0.38	0.38	CD
cord-005478-5iu38pr6	2023	19	)	)	-RRB-
cord-005478-5iu38pr6	2023	20	.	.	.
cord-005478-5iu38pr6	2024	1	For	for	IN
cord-005478-5iu38pr6	2024	2	7/8s	7/8s	CD
cord-005478-5iu38pr6	2024	3	,	,	,
cord-005478-5iu38pr6	2024	4	overall	overall	JJ
cord-005478-5iu38pr6	2024	5	survival	survival	NN
cord-005478-5iu38pr6	2024	6	(	(	-LRB-
cord-005478-5iu38pr6	2024	7	OS	OS	NNP
cord-005478-5iu38pr6	2024	8	)	)	-RRB-
cord-005478-5iu38pr6	2024	9	=	=	SYM
cord-005478-5iu38pr6	2024	10	71	71	CD
cord-005478-5iu38pr6	2024	11	%	%	NN
cord-005478-5iu38pr6	2024	12	(	(	-LRB-
cord-005478-5iu38pr6	2024	13	ABA	ABA	NNP
cord-005478-5iu38pr6	2024	14	)	)	-RRB-
cord-005478-5iu38pr6	2024	15	vs	vs	IN
cord-005478-5iu38pr6	2024	16	47.5	47.5	CD
cord-005478-5iu38pr6	2024	17	%	%	NN
cord-005478-5iu38pr6	2024	18	(	(	-LRB-
cord-005478-5iu38pr6	2024	19	CNI+MTX	CNI+MTX	NNP
cord-005478-5iu38pr6	2024	20	)	)	-RRB-
cord-005478-5iu38pr6	2024	21	and	and	CC
cord-005478-5iu38pr6	2024	22	58	58	CD
cord-005478-5iu38pr6	2024	23	%	%	NN
cord-005478-5iu38pr6	2024	24	(	(	-LRB-
cord-005478-5iu38pr6	2024	25	+	+	CC
cord-005478-5iu38pr6	2024	26	ATG	ATG	NNP
cord-005478-5iu38pr6	2024	27	,	,	,
cord-005478-5iu38pr6	2024	28	p	p	NN
cord-005478-5iu38pr6	2024	29	=	=	SYM
cord-005478-5iu38pr6	2024	30	0.01	0.01	CD
cord-005478-5iu38pr6	2024	31	,	,	,
cord-005478-5iu38pr6	2024	32	0.145	0.145	CD
cord-005478-5iu38pr6	2024	33	)	)	-RRB-
cord-005478-5iu38pr6	2024	34	.	.	.
cord-005478-5iu38pr6	2025	1	For	for	IN
cord-005478-5iu38pr6	2025	2	8/8s	8/8s	CD
cord-005478-5iu38pr6	2025	3	,	,	,
cord-005478-5iu38pr6	2025	4	OS	OS	NNP
cord-005478-5iu38pr6	2025	5	=	=	SYM
cord-005478-5iu38pr6	2025	6	83.2	83.2	CD
cord-005478-5iu38pr6	2025	7	%	%	NN
cord-005478-5iu38pr6	2025	8	(	(	-LRB-
cord-005478-5iu38pr6	2025	9	ABA	ABA	NNP
cord-005478-5iu38pr6	2025	10	)	)	-RRB-
cord-005478-5iu38pr6	2025	11	vs	vs	IN
cord-005478-5iu38pr6	2025	12	76.6	76.6	CD
cord-005478-5iu38pr6	2025	13	(	(	-LRB-
cord-005478-5iu38pr6	2025	14	placebo	placebo	NN
cord-005478-5iu38pr6	2025	15	,	,	,
cord-005478-5iu38pr6	2025	16	p	p	NN
cord-005478-5iu38pr6	2025	17	=	=	SYM
cord-005478-5iu38pr6	2025	18	0.32	0.32	CD
cord-005478-5iu38pr6	2025	19	)	)	-RRB-
cord-005478-5iu38pr6	2025	20	.	.	.
cord-005478-5iu38pr6	2026	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2026	2	:	:	:
cord-005478-5iu38pr6	2027	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2027	2	results	result	NNS
cord-005478-5iu38pr6	2027	3	suggest	suggest	VBP
cord-005478-5iu38pr6	2027	4	that	that	IN
cord-005478-5iu38pr6	2027	5	short	short	JJ
cord-005478-5iu38pr6	2027	6	-	-	HYPH
cord-005478-5iu38pr6	2027	7	course	course	NN
cord-005478-5iu38pr6	2027	8	ABA	ABA	NNP
cord-005478-5iu38pr6	2027	9	can	can	MD
cord-005478-5iu38pr6	2027	10	safely	safely	RB
cord-005478-5iu38pr6	2027	11	prevent	prevent	VB
cord-005478-5iu38pr6	2027	12	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2027	13	without	without	IN
cord-005478-5iu38pr6	2027	14	compromising	compromise	VBG
cord-005478-5iu38pr6	2027	15	relapse	relapse	NN
cord-005478-5iu38pr6	2027	16	.	.	.
cord-005478-5iu38pr6	2028	1	Despite	despite	IN
cord-005478-5iu38pr6	2028	2	the	the	DT
cord-005478-5iu38pr6	2028	3	modestly	modestly	RB
cord-005478-5iu38pr6	2028	4	sized	sized	JJ
cord-005478-5iu38pr6	2028	5	study	study	NN
cord-005478-5iu38pr6	2028	6	,	,	,
cord-005478-5iu38pr6	2028	7	the	the	DT
cord-005478-5iu38pr6	2028	8	comparative	comparative	JJ
cord-005478-5iu38pr6	2028	9	event	event	NN
cord-005478-5iu38pr6	2028	10	size	size	NN
cord-005478-5iu38pr6	2028	11	for	for	IN
cord-005478-5iu38pr6	2028	12	7/8s	7/8s	NN
cord-005478-5iu38pr6	2028	13	was	be	VBD
cord-005478-5iu38pr6	2028	14	high	high	JJ
cord-005478-5iu38pr6	2028	15	enough	enough	RB
cord-005478-5iu38pr6	2028	16	that	that	IN
cord-005478-5iu38pr6	2028	17	the	the	DT
cord-005478-5iu38pr6	2028	18	protective	protective	JJ
cord-005478-5iu38pr6	2028	19	effect	effect	NN
cord-005478-5iu38pr6	2028	20	of	of	IN
cord-005478-5iu38pr6	2028	21	ABA	ABA	NNP
cord-005478-5iu38pr6	2028	22	against	against	IN
cord-005478-5iu38pr6	2028	23	Gr3	gr3	CD
cord-005478-5iu38pr6	2028	24	-	-	SYM
cord-005478-5iu38pr6	2028	25	4	4	CD
cord-005478-5iu38pr6	2028	26	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2028	27	was	be	VBD
cord-005478-5iu38pr6	2028	28	highly	highly	RB
cord-005478-5iu38pr6	2028	29	significant	significant	JJ
cord-005478-5iu38pr6	2028	30	.	.	.
cord-005478-5iu38pr6	2029	1	For	for	IN
cord-005478-5iu38pr6	2029	2	8/	8/	CD
cord-005478-5iu38pr6	2029	3	8s	8	NNS
cord-005478-5iu38pr6	2029	4	,	,	,
cord-005478-5iu38pr6	2029	5	there	there	EX
cord-005478-5iu38pr6	2029	6	was	be	VBD
cord-005478-5iu38pr6	2029	7	a	a	DT
cord-005478-5iu38pr6	2029	8	statistically	statistically	RB
cord-005478-5iu38pr6	2029	9	significant	significant	JJ
cord-005478-5iu38pr6	2029	10	improvement	improvement	NN
cord-005478-5iu38pr6	2029	11	for	for	IN
cord-005478-5iu38pr6	2029	12	Gr	Gr	NNP
cord-005478-5iu38pr6	2029	13	2	2	CD
cord-005478-5iu38pr6	2029	14	-	-	SYM
cord-005478-5iu38pr6	2029	15	4	4	CD
cord-005478-5iu38pr6	2029	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2029	17	and	and	CC
cord-005478-5iu38pr6	2029	18	a	a	DT
cord-005478-5iu38pr6	2029	19	trend	trend	NN
cord-005478-5iu38pr6	2029	20	toward	toward	IN
cord-005478-5iu38pr6	2029	21	an	an	DT
cord-005478-5iu38pr6	2029	22	advantage	advantage	NN
cord-005478-5iu38pr6	2029	23	in	in	IN
cord-005478-5iu38pr6	2029	24	all	all	DT
cord-005478-5iu38pr6	2029	25	parameters	parameter	NNS
cord-005478-5iu38pr6	2029	26	.	.	.
cord-005478-5iu38pr6	2030	1	For	for	IN
cord-005478-5iu38pr6	2030	2	both	both	DT
cord-005478-5iu38pr6	2030	3	cohorts	cohort	NNS
cord-005478-5iu38pr6	2030	4	,	,	,
cord-005478-5iu38pr6	2030	5	severe	severe	JJ
cord-005478-5iu38pr6	2030	6	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2030	7	free	free	JJ
cord-005478-5iu38pr6	2030	8	survival	survival	NN
cord-005478-5iu38pr6	2030	9	was	be	VBD
cord-005478-5iu38pr6	2030	10	statistically	statistically	RB
cord-005478-5iu38pr6	2030	11	-	-	HYPH
cord-005478-5iu38pr6	2030	12	significantly	significantly	RB
cord-005478-5iu38pr6	2030	13	improved	improve	VBN
cord-005478-5iu38pr6	2030	14	.	.	.
cord-005478-5iu38pr6	2031	1	These	these	DT
cord-005478-5iu38pr6	2031	2	results	result	NNS
cord-005478-5iu38pr6	2031	3	are	be	VBP
cord-005478-5iu38pr6	2031	4	the	the	DT
cord-005478-5iu38pr6	2031	5	first	first	JJ
cord-005478-5iu38pr6	2031	6	to	to	TO
cord-005478-5iu38pr6	2031	7	demonstrate	demonstrate	VB
cord-005478-5iu38pr6	2031	8	efficacy	efficacy	NN
cord-005478-5iu38pr6	2031	9	of	of	IN
cord-005478-5iu38pr6	2031	10	in	in	IN
cord-005478-5iu38pr6	2031	11	vivo	vivo	NNP
cord-005478-5iu38pr6	2031	12	T	T	NNP
cord-005478-5iu38pr6	2031	13	cell	cell	NN
cord-005478-5iu38pr6	2031	14	costimulation	costimulation	NN
cord-005478-5iu38pr6	2031	15	blockade	blockade	NN
cord-005478-5iu38pr6	2031	16	in	in	IN
cord-005478-5iu38pr6	2031	17	preventing	prevent	VBG
cord-005478-5iu38pr6	2031	18	AGVHD	AGVHD	NNP
cord-005478-5iu38pr6	2031	19	.	.	.
cord-005478-5iu38pr6	2032	1	Background	background	NN
cord-005478-5iu38pr6	2032	2	:	:	:
cord-005478-5iu38pr6	2033	1	In	in	IN
cord-005478-5iu38pr6	2033	2	the	the	DT
cord-005478-5iu38pr6	2033	3	NIH	NIH	NNP
cord-005478-5iu38pr6	2033	4	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2033	5	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	2033	6	classification	classification	NN
cord-005478-5iu38pr6	2033	7	,	,	,
cord-005478-5iu38pr6	2033	8	patients	patient	NNS
cord-005478-5iu38pr6	2033	9	with	with	IN
cord-005478-5iu38pr6	2033	10	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2033	11	after	after	IN
cord-005478-5iu38pr6	2033	12	3	3	CD
cord-005478-5iu38pr6	2033	13	months	month	NNS
cord-005478-5iu38pr6	2033	14	are	be	VBP
cord-005478-5iu38pr6	2033	15	classified	classify	VBN
cord-005478-5iu38pr6	2033	16	as	as	IN
cord-005478-5iu38pr6	2033	17	either	either	DT
cord-005478-5iu38pr6	2033	18	late	late	JJ
cord-005478-5iu38pr6	2033	19	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2033	20	or	or	CC
cord-005478-5iu38pr6	2033	21	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2033	22	.	.	.
cord-005478-5iu38pr6	2034	1	To	to	IN
cord-005478-5iu38pr6	2034	2	date	date	NN
cord-005478-5iu38pr6	2034	3	,	,	,
cord-005478-5iu38pr6	2034	4	this	this	DT
cord-005478-5iu38pr6	2034	5	is	be	VBZ
cord-005478-5iu38pr6	2034	6	only	only	RB
cord-005478-5iu38pr6	2034	7	a	a	DT
cord-005478-5iu38pr6	2034	8	clinical	clinical	JJ
cord-005478-5iu38pr6	2034	9	classification	classification	NN
cord-005478-5iu38pr6	2034	10	,	,	,
cord-005478-5iu38pr6	2034	11	with	with	IN
cord-005478-5iu38pr6	2034	12	no	no	DT
cord-005478-5iu38pr6	2034	13	biological	biological	JJ
cord-005478-5iu38pr6	2034	14	differences	difference	NNS
cord-005478-5iu38pr6	2034	15	identified	identify	VBD
cord-005478-5iu38pr6	2034	16	.	.	.
cord-005478-5iu38pr6	2035	1	Recently	recently	RB
cord-005478-5iu38pr6	2035	2	,	,	,
cord-005478-5iu38pr6	2035	3	the	the	DT
cord-005478-5iu38pr6	2035	4	PBMTC	PBMTC	NNP
cord-005478-5iu38pr6	2035	5	1202/	1202/	CD
cord-005478-5iu38pr6	2035	6	Applied	Applied	NNP
cord-005478-5iu38pr6	2035	7	Biomarker	Biomarker	NNP
cord-005478-5iu38pr6	2035	8	in	in	IN
cord-005478-5iu38pr6	2035	9	Late	late	JJ
cord-005478-5iu38pr6	2035	10	Effects	effect	NNS
cord-005478-5iu38pr6	2035	11	of	of	IN
cord-005478-5iu38pr6	2035	12	Children	Children	NNPS
cord-005478-5iu38pr6	2035	13	and	and	CC
cord-005478-5iu38pr6	2035	14	Adolescent	Adolescent	NNP
cord-005478-5iu38pr6	2035	15	(	(	-LRB-
cord-005478-5iu38pr6	2035	16	ABLE	ABLE	NNP
cord-005478-5iu38pr6	2035	17	)	)	-RRB-
cord-005478-5iu38pr6	2035	18	study	study	NN
cord-005478-5iu38pr6	2035	19	completed	complete	VBD
cord-005478-5iu38pr6	2035	20	accrual	accrual	NN
cord-005478-5iu38pr6	2035	21	of	of	IN
cord-005478-5iu38pr6	2035	22	302	302	CD
cord-005478-5iu38pr6	2035	23	pediatric	pediatric	JJ
cord-005478-5iu38pr6	2035	24	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2035	25	Hematopoietic	Hematopoietic	NNP
cord-005478-5iu38pr6	2035	26	Cell	Cell	NNP
cord-005478-5iu38pr6	2035	27	Transplantation	Transplantation	NNP
cord-005478-5iu38pr6	2035	28	(	(	-LRB-
cord-005478-5iu38pr6	2035	29	HCT	HCT	NNP
cord-005478-5iu38pr6	2035	30	)	)	-RRB-
cord-005478-5iu38pr6	2035	31	patients	patient	NNS
cord-005478-5iu38pr6	2035	32	.	.	.
cord-005478-5iu38pr6	2036	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2036	2	used	use	VBD
cord-005478-5iu38pr6	2036	3	day	day	NN
cord-005478-5iu38pr6	2036	4	100	100	CD
cord-005478-5iu38pr6	2036	5	biomarkers	biomarker	NNS
cord-005478-5iu38pr6	2036	6	to	to	TO
cord-005478-5iu38pr6	2036	7	identify	identify	VB
cord-005478-5iu38pr6	2036	8	biological	biological	JJ
cord-005478-5iu38pr6	2036	9	differences	difference	NNS
cord-005478-5iu38pr6	2036	10	between	between	IN
cord-005478-5iu38pr6	2036	11	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2036	12	and	and	CC
cord-005478-5iu38pr6	2036	13	late	late	JJ
cord-005478-5iu38pr6	2036	14	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2036	15	.	.	.
cord-005478-5iu38pr6	2037	1	Methods	method	NNS
cord-005478-5iu38pr6	2037	2	:	:	:
cord-005478-5iu38pr6	2038	1	The	the	DT
cord-005478-5iu38pr6	2038	2	PBMTC1202	PBMTC1202	NNP
cord-005478-5iu38pr6	2038	3	/	/	SYM
cord-005478-5iu38pr6	2038	4	ABLE	able	RB
cord-005478-5iu38pr6	2038	5	study	study	VBP
cord-005478-5iu38pr6	2038	6	with	with	IN
cord-005478-5iu38pr6	2038	7	26	26	CD
cord-005478-5iu38pr6	2038	8	centers	center	NNS
cord-005478-5iu38pr6	2038	9	in	in	IN
cord-005478-5iu38pr6	2038	10	Canada	Canada	NNP
cord-005478-5iu38pr6	2038	11	,	,	,
cord-005478-5iu38pr6	2038	12	US	US	NNP
cord-005478-5iu38pr6	2038	13	,	,	,
cord-005478-5iu38pr6	2038	14	and	and	CC
cord-005478-5iu38pr6	2038	15	Europe	Europe	NNP
cord-005478-5iu38pr6	2038	16	prospectively	prospectively	RB
cord-005478-5iu38pr6	2038	17	collected	collect	VBD
cord-005478-5iu38pr6	2038	18	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2038	19	blood	blood	NN
cord-005478-5iu38pr6	2038	20	samples	sample	NNS
cord-005478-5iu38pr6	2038	21	at	at	IN
cord-005478-5iu38pr6	2038	22	3	3	CD
cord-005478-5iu38pr6	2038	23	,	,	,
cord-005478-5iu38pr6	2038	24	6	6	CD
cord-005478-5iu38pr6	2038	25	,	,	,
cord-005478-5iu38pr6	2038	26	12	12	CD
cord-005478-5iu38pr6	2038	27	month	month	NN
cord-005478-5iu38pr6	2038	28	post	post	NN
cord-005478-5iu38pr6	2038	29	HCT	hct	NN
cord-005478-5iu38pr6	2038	30	and	and	CC
cord-005478-5iu38pr6	2038	31	at	at	IN
cord-005478-5iu38pr6	2038	32	the	the	DT
cord-005478-5iu38pr6	2038	33	onset	onset	NN
cord-005478-5iu38pr6	2038	34	of	of	IN
cord-005478-5iu38pr6	2038	35	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2038	36	in	in	IN
cord-005478-5iu38pr6	2038	37	302	302	CD
cord-005478-5iu38pr6	2038	38	children	child	NNS
cord-005478-5iu38pr6	2038	39	.	.	.
cord-005478-5iu38pr6	2039	1	A	a	DT
cord-005478-5iu38pr6	2039	2	comprehensive	comprehensive	JJ
cord-005478-5iu38pr6	2039	3	analysis	analysis	NN
cord-005478-5iu38pr6	2039	4	for	for	IN
cord-005478-5iu38pr6	2039	5	previously	previously	RB
cord-005478-5iu38pr6	2039	6	identified	identify	VBN
cord-005478-5iu38pr6	2039	7	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2039	8	immune	immune	JJ
cord-005478-5iu38pr6	2039	9	cell	cell	NN
cord-005478-5iu38pr6	2039	10	markers	marker	NNS
cord-005478-5iu38pr6	2039	11	by	by	IN
cord-005478-5iu38pr6	2039	12	flow	flow	NN
cord-005478-5iu38pr6	2039	13	and	and	CC
cord-005478-5iu38pr6	2039	14	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2039	15	by	by	IN
cord-005478-5iu38pr6	2039	16	ELISA	ELISA	NNP
cord-005478-5iu38pr6	2039	17	on	on	IN
cord-005478-5iu38pr6	2039	18	plasma	plasma	NN
cord-005478-5iu38pr6	2039	19	and	and	CC
cord-005478-5iu38pr6	2039	20	STRECK	STRECK	NNP
cord-005478-5iu38pr6	2039	21	tubes	tube	NNS
cord-005478-5iu38pr6	2039	22	shipped	ship	VBN
cord-005478-5iu38pr6	2039	23	overnight	overnight	RB
cord-005478-5iu38pr6	2039	24	and	and	CC
cord-005478-5iu38pr6	2039	25	centrally	centrally	RB
cord-005478-5iu38pr6	2039	26	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2039	27	at	at	IN
cord-005478-5iu38pr6	2039	28	BC	BC	NNP
cord-005478-5iu38pr6	2039	29	Children	Children	NNP
cord-005478-5iu38pr6	2039	30	's	's	POS
cord-005478-5iu38pr6	2039	31	Hospital	Hospital	NNP
cord-005478-5iu38pr6	2039	32	.	.	.
cord-005478-5iu38pr6	2040	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2040	2	data	datum	NNS
cord-005478-5iu38pr6	2040	3	was	be	VBD
cord-005478-5iu38pr6	2040	4	collected	collect	VBN
cord-005478-5iu38pr6	2040	5	centrally	centrally	RB
cord-005478-5iu38pr6	2040	6	with	with	IN
cord-005478-5iu38pr6	2040	7	a	a	DT
cord-005478-5iu38pr6	2040	8	thorough	thorough	JJ
cord-005478-5iu38pr6	2040	9	central	central	JJ
cord-005478-5iu38pr6	2040	10	clinical	clinical	JJ
cord-005478-5iu38pr6	2040	11	adjudication	adjudication	NN
cord-005478-5iu38pr6	2040	12	by	by	IN
cord-005478-5iu38pr6	2040	13	the	the	DT
cord-005478-5iu38pr6	2040	14	PBMTC	PBMTC	NNP
cord-005478-5iu38pr6	2040	15	study	study	NN
cord-005478-5iu38pr6	2040	16	committee	committee	NN
cord-005478-5iu38pr6	2040	17	.	.	.
cord-005478-5iu38pr6	2041	1	Of	of	IN
cord-005478-5iu38pr6	2041	2	those	those	DT
cord-005478-5iu38pr6	2041	3	enrolled	enrol	VBN
cord-005478-5iu38pr6	2041	4	,	,	,
cord-005478-5iu38pr6	2041	5	228	228	CD
cord-005478-5iu38pr6	2041	6	were	be	VBD
cord-005478-5iu38pr6	2041	7	evaluable	evaluable	JJ
cord-005478-5iu38pr6	2041	8	at	at	IN
cord-005478-5iu38pr6	2041	9	day	day	NN
cord-005478-5iu38pr6	2041	10	100	100	CD
cord-005478-5iu38pr6	2041	11	and	and	CC
cord-005478-5iu38pr6	2041	12	classified	classify	VBD
cord-005478-5iu38pr6	2041	13	as	as	IN
cord-005478-5iu38pr6	2041	14	a	a	DT
cord-005478-5iu38pr6	2041	15	)	)	-RRB-
cord-005478-5iu38pr6	2041	16	late	late	JJ
cord-005478-5iu38pr6	2041	17	aGvHD	aGvHD	.
cord-005478-5iu38pr6	2041	18	(	(	-LRB-
cord-005478-5iu38pr6	2041	19	N	n	NN
cord-005478-5iu38pr6	2041	20	=	=	SYM
cord-005478-5iu38pr6	2041	21	58	58	CD
cord-005478-5iu38pr6	2041	22	)	)	-RRB-
cord-005478-5iu38pr6	2041	23	,	,	,
cord-005478-5iu38pr6	2041	24	b	b	LS
cord-005478-5iu38pr6	2041	25	)	)	-RRB-
cord-005478-5iu38pr6	2041	26	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2041	27	(	(	-LRB-
cord-005478-5iu38pr6	2041	28	N	n	NN
cord-005478-5iu38pr6	2041	29	=	=	SYM
cord-005478-5iu38pr6	2041	30	44	44	CD
cord-005478-5iu38pr6	2041	31	)	)	-RRB-
cord-005478-5iu38pr6	2041	32	,	,	,
cord-005478-5iu38pr6	2041	33	and	and	CC
cord-005478-5iu38pr6	2041	34	c	c	LS
cord-005478-5iu38pr6	2041	35	)	)	-RRB-
cord-005478-5iu38pr6	2041	36	controls	control	VBZ
cord-005478-5iu38pr6	2041	37	that	that	WDT
cord-005478-5iu38pr6	2041	38	did	do	VBD
cord-005478-5iu38pr6	2041	39	not	not	RB
cord-005478-5iu38pr6	2041	40	develop	develop	VB
cord-005478-5iu38pr6	2041	41	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2041	42	(	(	-LRB-
cord-005478-5iu38pr6	2041	43	N	n	NN
cord-005478-5iu38pr6	2041	44	=	=	SYM
cord-005478-5iu38pr6	2041	45	132	132	CD
cord-005478-5iu38pr6	2041	46	)	)	-RRB-
cord-005478-5iu38pr6	2041	47	.	.	.
cord-005478-5iu38pr6	2042	1	Univariate	Univariate	NNP
cord-005478-5iu38pr6	2042	2	analysis	analysis	NN
cord-005478-5iu38pr6	2042	3	was	be	VBD
cord-005478-5iu38pr6	2042	4	performed	perform	VBN
cord-005478-5iu38pr6	2042	5	comparing	compare	VBG
cord-005478-5iu38pr6	2042	6	late	late	JJ
cord-005478-5iu38pr6	2042	7	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2042	8	,	,	,
cord-005478-5iu38pr6	2042	9	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2042	10	,	,	,
cord-005478-5iu38pr6	2042	11	and	and	CC
cord-005478-5iu38pr6	2042	12	no	no	DT
cord-005478-5iu38pr6	2042	13	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2042	14	controls	control	VBZ
cord-005478-5iu38pr6	2042	15	.	.	.
cord-005478-5iu38pr6	2043	1	Significant	significant	JJ
cord-005478-5iu38pr6	2043	2	differences	difference	NNS
cord-005478-5iu38pr6	2043	3	were	be	VBD
cord-005478-5iu38pr6	2043	4	defined	define	VBN
cord-005478-5iu38pr6	2043	5	as	as	IN
cord-005478-5iu38pr6	2043	6	a	a	DT
cord-005478-5iu38pr6	2043	7	biomarker	biomarker	NN
cord-005478-5iu38pr6	2043	8	with	with	IN
cord-005478-5iu38pr6	2043	9	both	both	CC
cord-005478-5iu38pr6	2043	10	a	a	DT
cord-005478-5iu38pr6	2043	11	ROC	ROC	NNP
cord-005478-5iu38pr6	2043	12	AUC	AUC	NNP
cord-005478-5iu38pr6	2043	13	≥0.60	≥0.60	NNP
cord-005478-5iu38pr6	2043	14	and	and	CC
cord-005478-5iu38pr6	2043	15	p	p	NN
cord-005478-5iu38pr6	2043	16	value	value	NN
cord-005478-5iu38pr6	2043	17	≤0.05	≤0.05	NNS
cord-005478-5iu38pr6	2043	18	compared	compare	VBN
cord-005478-5iu38pr6	2043	19	to	to	IN
cord-005478-5iu38pr6	2043	20	controls	control	NNS
cord-005478-5iu38pr6	2043	21	.	.	.
cord-005478-5iu38pr6	2044	1	Results	result	NNS
cord-005478-5iu38pr6	2044	2	:	:	:
cord-005478-5iu38pr6	2045	1	The	the	DT
cord-005478-5iu38pr6	2045	2	profile	profile	NN
cord-005478-5iu38pr6	2045	3	of	of	IN
cord-005478-5iu38pr6	2045	4	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2045	5	included	include	VBD
cord-005478-5iu38pr6	2045	6	a	a	DT
cord-005478-5iu38pr6	2045	7	cluster	cluster	NN
cord-005478-5iu38pr6	2045	8	of	of	IN
cord-005478-5iu38pr6	2045	9	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	2045	10	in	in	IN
cord-005478-5iu38pr6	2045	11	memory	memory	NN
cord-005478-5iu38pr6	2045	12	and	and	CC
cord-005478-5iu38pr6	2045	13	transitional	transitional	JJ
cord-005478-5iu38pr6	2045	14	B	b	NN
cord-005478-5iu38pr6	2045	15	cells	cell	NNS
cord-005478-5iu38pr6	2045	16	,	,	,
cord-005478-5iu38pr6	2045	17	conventional	conventional	JJ
cord-005478-5iu38pr6	2045	18	naïve	naïve	JJ
cord-005478-5iu38pr6	2045	19	and	and	CC
cord-005478-5iu38pr6	2045	20	follicular	follicular	JJ
cord-005478-5iu38pr6	2045	21	helper	helper	NN
cord-005478-5iu38pr6	2045	22	T	t	NN
cord-005478-5iu38pr6	2045	23	cells	cell	NNS
cord-005478-5iu38pr6	2045	24	,	,	,
cord-005478-5iu38pr6	2045	25	and	and	CC
cord-005478-5iu38pr6	2045	26	a	a	DT
cord-005478-5iu38pr6	2045	27	loss	loss	NN
cord-005478-5iu38pr6	2045	28	of	of	IN
cord-005478-5iu38pr6	2045	29	both	both	CC
cord-005478-5iu38pr6	2045	30	recent	recent	JJ
cord-005478-5iu38pr6	2045	31	thymic	thymic	JJ
cord-005478-5iu38pr6	2045	32	emigrant	emigrant	NN
cord-005478-5iu38pr6	2045	33	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2045	34	T	t	NN
cord-005478-5iu38pr6	2045	35	cells	cell	NNS
cord-005478-5iu38pr6	2045	36	and	and	CC
cord-005478-5iu38pr6	2045	37	CD56	CD56	NNP
cord-005478-5iu38pr6	2045	38	bright	bright	JJ
cord-005478-5iu38pr6	2045	39	NK	NK	NNP
cord-005478-5iu38pr6	2045	40	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2045	41	cells	cell	NNS
cord-005478-5iu38pr6	2045	42	.	.	.
cord-005478-5iu38pr6	2046	1	Four	four	CD
cord-005478-5iu38pr6	2046	2	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2046	3	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2046	4	,	,	,
cord-005478-5iu38pr6	2046	5	ST2	ST2	NNP
cord-005478-5iu38pr6	2046	6	,	,	,
cord-005478-5iu38pr6	2046	7	Aminopeptidase	Aminopeptidase	NNP
cord-005478-5iu38pr6	2046	8	N	N	NNP
cord-005478-5iu38pr6	2046	9	,	,	,
cord-005478-5iu38pr6	2046	10	CXCL9	CXCL9	NNP
cord-005478-5iu38pr6	2046	11	and	and	CC
cord-005478-5iu38pr6	2046	12	MMP3	MMP3	NNP
cord-005478-5iu38pr6	2047	1	(	(	-LRB-
cord-005478-5iu38pr6	2047	2	See	see	VB
cord-005478-5iu38pr6	2047	3	Table	table	NN
cord-005478-5iu38pr6	2047	4	1	1	CD
cord-005478-5iu38pr6	2047	5	)	)	-RRB-
cord-005478-5iu38pr6	2047	6	were	be	VBD
cord-005478-5iu38pr6	2047	7	increased	increase	VBN
cord-005478-5iu38pr6	2047	8	.	.	.
cord-005478-5iu38pr6	2048	1	Patients	patient	NNS
cord-005478-5iu38pr6	2048	2	clinically	clinically	RB
cord-005478-5iu38pr6	2048	3	identified	identify	VBN
cord-005478-5iu38pr6	2048	4	as	as	IN
cord-005478-5iu38pr6	2048	5	late	late	JJ
cord-005478-5iu38pr6	2048	6	aGvHD	aGvHD	NNP
cord-005478-5iu38pr6	2048	7	had	have	VBD
cord-005478-5iu38pr6	2048	8	a	a	DT
cord-005478-5iu38pr6	2048	9	more	more	RBR
cord-005478-5iu38pr6	2048	10	restricted	restrict	VBN
cord-005478-5iu38pr6	2048	11	biomarker	biomarker	NN
cord-005478-5iu38pr6	2048	12	pattern	pattern	NN
cord-005478-5iu38pr6	2048	13	of	of	IN
cord-005478-5iu38pr6	2048	14	limited	limited	JJ
cord-005478-5iu38pr6	2048	15	B	b	NN
cord-005478-5iu38pr6	2048	16	cell	cell	NN
cord-005478-5iu38pr6	2048	17	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	2048	18	and	and	CC
cord-005478-5iu38pr6	2048	19	ST2	ST2	NNP
cord-005478-5iu38pr6	2048	20	.	.	.
cord-005478-5iu38pr6	2049	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2049	2	:	:	:
cord-005478-5iu38pr6	2050	1	Late	late	JJ
cord-005478-5iu38pr6	2050	2	acute	acute	JJ
cord-005478-5iu38pr6	2050	3	GvHD	gvhd	NN
cord-005478-5iu38pr6	2050	4	is	be	VBZ
cord-005478-5iu38pr6	2050	5	limited	limit	VBN
cord-005478-5iu38pr6	2050	6	to	to	IN
cord-005478-5iu38pr6	2050	7	restricted	restricted	JJ
cord-005478-5iu38pr6	2050	8	B	b	NN
cord-005478-5iu38pr6	2050	9	cell	cell	NN
cord-005478-5iu38pr6	2050	10	and	and	CC
cord-005478-5iu38pr6	2050	11	elevation	elevation	NN
cord-005478-5iu38pr6	2050	12	of	of	IN
cord-005478-5iu38pr6	2050	13	ST2	ST2	NNP
cord-005478-5iu38pr6	2050	14	.	.	.
cord-005478-5iu38pr6	2051	1	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2051	2	is	be	VBZ
cord-005478-5iu38pr6	2051	3	characterized	characterize	VBN
cord-005478-5iu38pr6	2051	4	by	by	IN
cord-005478-5iu38pr6	2051	5	the	the	DT
cord-005478-5iu38pr6	2051	6	identical	identical	JJ
cord-005478-5iu38pr6	2051	7	B	b	NN
cord-005478-5iu38pr6	2051	8	cell	cell	NN
cord-005478-5iu38pr6	2051	9	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	2051	10	but	but	CC
cord-005478-5iu38pr6	2051	11	with	with	IN
cord-005478-5iu38pr6	2051	12	the	the	DT
cord-005478-5iu38pr6	2051	13	additional	additional	JJ
cord-005478-5iu38pr6	2051	14	loss	loss	NN
cord-005478-5iu38pr6	2051	15	of	of	IN
cord-005478-5iu38pr6	2051	16	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2051	17	function	function	NN
cord-005478-5iu38pr6	2051	18	in	in	IN
cord-005478-5iu38pr6	2051	19	CD56bright	CD56bright	NNP
cord-005478-5iu38pr6	2051	20	NKregs	NKregs	NNP
cord-005478-5iu38pr6	2051	21	and	and	CC
cord-005478-5iu38pr6	2051	22	RTE	RTE	NNP
cord-005478-5iu38pr6	2051	23	Treg	Treg	NNP
cord-005478-5iu38pr6	2051	24	cells	cell	NNS
cord-005478-5iu38pr6	2051	25	.	.	.
cord-005478-5iu38pr6	2052	1	With	with	IN
cord-005478-5iu38pr6	2052	2	the	the	DT
cord-005478-5iu38pr6	2052	3	loss	loss	NN
cord-005478-5iu38pr6	2052	4	of	of	IN
cord-005478-5iu38pr6	2052	5	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2052	6	function	function	NN
cord-005478-5iu38pr6	2052	7	in	in	IN
cord-005478-5iu38pr6	2052	8	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2052	9	,	,	,
cord-005478-5iu38pr6	2052	10	there	there	EX
cord-005478-5iu38pr6	2052	11	is	be	VBZ
cord-005478-5iu38pr6	2052	12	an	an	DT
cord-005478-5iu38pr6	2052	13	increase	increase	NN
cord-005478-5iu38pr6	2052	14	in	in	IN
cord-005478-5iu38pr6	2052	15	CD21	CD21	NNP
cord-005478-5iu38pr6	2052	16	lo	lo	NNP
cord-005478-5iu38pr6	2052	17	B	B	NNP
cord-005478-5iu38pr6	2052	18	cells	cell	NNS
cord-005478-5iu38pr6	2052	19	,	,	,
cord-005478-5iu38pr6	2052	20	follicular	follicular	JJ
cord-005478-5iu38pr6	2052	21	T	T	NNP
cord-005478-5iu38pr6	2052	22	helper	helper	NN
cord-005478-5iu38pr6	2052	23	cells	cell	NNS
cord-005478-5iu38pr6	2052	24	,	,	,
cord-005478-5iu38pr6	2052	25	and	and	CC
cord-005478-5iu38pr6	2052	26	additional	additional	JJ
cord-005478-5iu38pr6	2052	27	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2052	28	.	.	.
cord-005478-5iu38pr6	2053	1	These	these	DT
cord-005478-5iu38pr6	2053	2	prognostic	prognostic	JJ
cord-005478-5iu38pr6	2053	3	markers	marker	NNS
cord-005478-5iu38pr6	2053	4	findings	finding	NNS
cord-005478-5iu38pr6	2053	5	may	may	MD
cord-005478-5iu38pr6	2053	6	suggest	suggest	VB
cord-005478-5iu38pr6	2053	7	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	2053	8	targets	target	NNS
cord-005478-5iu38pr6	2053	9	that	that	WDT
cord-005478-5iu38pr6	2053	10	differ	differ	VBP
cord-005478-5iu38pr6	2053	11	for	for	IN
cord-005478-5iu38pr6	2053	12	late	late	JJ
cord-005478-5iu38pr6	2053	13	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2053	14	compared	compare	VBN
cord-005478-5iu38pr6	2053	15	to	to	IN
cord-005478-5iu38pr6	2053	16	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2053	17	.	.	.
cord-005478-5iu38pr6	2054	1	Background	background	NN
cord-005478-5iu38pr6	2054	2	:	:	:
cord-005478-5iu38pr6	2055	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2055	2	are	be	VBP
cord-005478-5iu38pr6	2055	3	reporting	report	VBG
cord-005478-5iu38pr6	2055	4	the	the	DT
cord-005478-5iu38pr6	2055	5	outcome	outcome	NN
cord-005478-5iu38pr6	2055	6	of	of	IN
cord-005478-5iu38pr6	2055	7	69	69	CD
cord-005478-5iu38pr6	2055	8	patients	patient	NNS
cord-005478-5iu38pr6	2055	9	with	with	IN
cord-005478-5iu38pr6	2055	10	steroid	steroid	NN
cord-005478-5iu38pr6	2055	11	refractory	refractory	JJ
cord-005478-5iu38pr6	2055	12	acute	acute	JJ
cord-005478-5iu38pr6	2055	13	graft	graft	NN
cord-005478-5iu38pr6	2055	14	versus	versus	IN
cord-005478-5iu38pr6	2055	15	host	host	NN
cord-005478-5iu38pr6	2055	16	disease	disease	NN
cord-005478-5iu38pr6	2055	17	(	(	-LRB-
cord-005478-5iu38pr6	2055	18	SR	SR	NNP
cord-005478-5iu38pr6	2055	19	-	-	HYPH
cord-005478-5iu38pr6	2055	20	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2055	21	)	)	-RRB-
cord-005478-5iu38pr6	2055	22	,	,	,
cord-005478-5iu38pr6	2055	23	treated	treat	VBN
cord-005478-5iu38pr6	2055	24	with	with	IN
cord-005478-5iu38pr6	2055	25	an	an	DT
cord-005478-5iu38pr6	2055	26	anti	anti	JJ
cord-005478-5iu38pr6	2055	27	-	-	JJ
cord-005478-5iu38pr6	2055	28	CD26	cd26	JJ
cord-005478-5iu38pr6	2055	29	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	2055	30	antibody	antibody	NN
cord-005478-5iu38pr6	2055	31	(	(	-LRB-
cord-005478-5iu38pr6	2055	32	Begelomab	Begelomab	NNP
cord-005478-5iu38pr6	2055	33	R	R	NNP
cord-005478-5iu38pr6	2055	34	)	)	-RRB-
cord-005478-5iu38pr6	2055	35	.	.	.
cord-005478-5iu38pr6	2056	1	Methods	method	NNS
cord-005478-5iu38pr6	2056	2	:	:	:
cord-005478-5iu38pr6	2056	3	Twenty	twenty	CD
cord-005478-5iu38pr6	2056	4	-	-	HYPH
cord-005478-5iu38pr6	2056	5	eight	eight	CD
cord-005478-5iu38pr6	2056	6	patients	patient	NNS
cord-005478-5iu38pr6	2056	7	were	be	VBD
cord-005478-5iu38pr6	2056	8	enrolled	enrol	VBN
cord-005478-5iu38pr6	2056	9	in	in	IN
cord-005478-5iu38pr6	2056	10	two	two	CD
cord-005478-5iu38pr6	2056	11	pilot	pilot	NN
cord-005478-5iu38pr6	2056	12	studies	study	NNS
cord-005478-5iu38pr6	2056	13	EudraCT	eudract	VB
cord-005478-5iu38pr6	2056	14	No	no	UH
cord-005478-5iu38pr6	2056	15	.	.	.
cord-005478-5iu38pr6	2057	1	2007	2007	CD
cord-005478-5iu38pr6	2057	2	-	-	SYM
cord-005478-5iu38pr6	2057	3	005809	005809	CD
cord-005478-5iu38pr6	2057	4	-	-	SYM
cord-005478-5iu38pr6	2057	5	21	21	CD
cord-005478-5iu38pr6	2057	6	and	and	CC
cord-005478-5iu38pr6	2057	7	No	no	NN
cord-005478-5iu38pr6	2057	8	.	.	.
cord-005478-5iu38pr6	2058	1	2012	2012	CD
cord-005478-5iu38pr6	2058	2	-	-	HYPH
cord-005478-5iu38pr6	2058	3	001353	001353	CD
cord-005478-5iu38pr6	2058	4	-	-	SYM
cord-005478-5iu38pr6	2058	5	19	19	CD
cord-005478-5iu38pr6	2058	6	,	,	,
cord-005478-5iu38pr6	2058	7	whereas	whereas	IN
cord-005478-5iu38pr6	2058	8	41	41	CD
cord-005478-5iu38pr6	2058	9	patient	patient	NN
cord-005478-5iu38pr6	2058	10	were	be	VBD
cord-005478-5iu38pr6	2058	11	treated	treat	VBN
cord-005478-5iu38pr6	2058	12	on	on	IN
cord-005478-5iu38pr6	2058	13	a	a	DT
cord-005478-5iu38pr6	2058	14	multicenter	multicenter	JJ
cord-005478-5iu38pr6	2058	15	follow	follow	VB
cord-005478-5iu38pr6	2058	16	up	up	RP
cord-005478-5iu38pr6	2058	17	compassionate	compassionate	JJ
cord-005478-5iu38pr6	2058	18	use	use	NN
cord-005478-5iu38pr6	2058	19	of	of	IN
cord-005478-5iu38pr6	2058	20	the	the	DT
cord-005478-5iu38pr6	2058	21	antibody	antibody	NN
cord-005478-5iu38pr6	2058	22	.	.	.
cord-005478-5iu38pr6	2059	1	The	the	DT
cord-005478-5iu38pr6	2059	2	median	median	JJ
cord-005478-5iu38pr6	2059	3	age	age	NN
cord-005478-5iu38pr6	2059	4	of	of	IN
cord-005478-5iu38pr6	2059	5	the	the	DT
cord-005478-5iu38pr6	2059	6	patients	patient	NNS
cord-005478-5iu38pr6	2059	7	was	be	VBD
cord-005478-5iu38pr6	2059	8	respectively	respectively	RB
cord-005478-5iu38pr6	2059	9	42	42	CD
cord-005478-5iu38pr6	2059	10	and	and	CC
cord-005478-5iu38pr6	2059	11	44	44	CD
cord-005478-5iu38pr6	2059	12	years	year	NNS
cord-005478-5iu38pr6	2059	13	.	.	.
cord-005478-5iu38pr6	2060	1	At	at	IN
cord-005478-5iu38pr6	2060	2	the	the	DT
cord-005478-5iu38pr6	2060	3	time	time	NN
cord-005478-5iu38pr6	2060	4	of	of	IN
cord-005478-5iu38pr6	2060	5	anti	anti	JJ
cord-005478-5iu38pr6	2060	6	-	-	JJ
cord-005478-5iu38pr6	2060	7	CD26	CD26	NNP
cord-005478-5iu38pr6	2060	8	treatment	treatment	NN
cord-005478-5iu38pr6	2060	9	,	,	,
cord-005478-5iu38pr6	2060	10	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2060	11	was	be	VBD
cord-005478-5iu38pr6	2060	12	overall	overall	RB
cord-005478-5iu38pr6	2060	13	recorded	record	VBN
cord-005478-5iu38pr6	2060	14	as	as	IN
cord-005478-5iu38pr6	2060	15	grade	grade	NN
cord-005478-5iu38pr6	2060	16	II	II	NNP
cord-005478-5iu38pr6	2060	17	in	in	IN
cord-005478-5iu38pr6	2060	18	8	8	CD
cord-005478-5iu38pr6	2060	19	patients	patient	NNS
cord-005478-5iu38pr6	2060	20	,	,	,
cord-005478-5iu38pr6	2060	21	grade	grade	NN
cord-005478-5iu38pr6	2060	22	III	iii	CD
cord-005478-5iu38pr6	2060	23	in	in	IN
cord-005478-5iu38pr6	2060	24	33	33	CD
cord-005478-5iu38pr6	2060	25	and	and	CC
cord-005478-5iu38pr6	2060	26	grade	grade	NN
cord-005478-5iu38pr6	2060	27	IV	IV	NNP
cord-005478-5iu38pr6	2060	28	in	in	IN
cord-005478-5iu38pr6	2060	29	28	28	CD
cord-005478-5iu38pr6	2060	30	patients	patient	NNS
cord-005478-5iu38pr6	2060	31	.	.	.
cord-005478-5iu38pr6	2061	1	In	in	IN
cord-005478-5iu38pr6	2061	2	the	the	DT
cord-005478-5iu38pr6	2061	3	pilot	pilot	NN
cord-005478-5iu38pr6	2061	4	sudies	sudie	NNS
cord-005478-5iu38pr6	2061	5	patients	patient	NNS
cord-005478-5iu38pr6	2061	6	had	have	VBD
cord-005478-5iu38pr6	2061	7	failed	fail	VBN
cord-005478-5iu38pr6	2061	8	1	1	CD
cord-005478-5iu38pr6	2061	9	line	line	NN
cord-005478-5iu38pr6	2061	10	of	of	IN
cord-005478-5iu38pr6	2061	11	treatment	treatment	NN
cord-005478-5iu38pr6	2061	12	,	,	,
cord-005478-5iu38pr6	2061	13	wheas	wheas	NNP
cord-005478-5iu38pr6	2061	14	in	in	IN
cord-005478-5iu38pr6	2061	15	the	the	DT
cord-005478-5iu38pr6	2061	16	follow	follow	NN
cord-005478-5iu38pr6	2061	17	up	up	RP
cord-005478-5iu38pr6	2061	18	compassionate	compassionate	JJ
cord-005478-5iu38pr6	2061	19	use	use	NN
cord-005478-5iu38pr6	2061	20	,	,	,
cord-005478-5iu38pr6	2061	21	patients	patient	NNS
cord-005478-5iu38pr6	2061	22	had	have	VBD
cord-005478-5iu38pr6	2061	23	failed	fail	VBN
cord-005478-5iu38pr6	2061	24	one	one	CD
cord-005478-5iu38pr6	2061	25	line	line	NN
cord-005478-5iu38pr6	2061	26	(	(	-LRB-
cord-005478-5iu38pr6	2061	27	n=18	n=18	RB
cord-005478-5iu38pr6	2061	28	)	)	-RRB-
cord-005478-5iu38pr6	2061	29	,	,	,
cord-005478-5iu38pr6	2061	30	two	two	CD
cord-005478-5iu38pr6	2061	31	lines	line	NNS
cord-005478-5iu38pr6	2061	32	(	(	-LRB-
cord-005478-5iu38pr6	2061	33	n=11	n=11	NNP
cord-005478-5iu38pr6	2061	34	)	)	-RRB-
cord-005478-5iu38pr6	2061	35	,	,	,
cord-005478-5iu38pr6	2061	36	three	three	CD
cord-005478-5iu38pr6	2061	37	lines	line	NNS
cord-005478-5iu38pr6	2061	38	(	(	-LRB-
cord-005478-5iu38pr6	2061	39	n=11	n=11	NNP
cord-005478-5iu38pr6	2061	40	)	)	-RRB-
cord-005478-5iu38pr6	2061	41	or	or	CC
cord-005478-5iu38pr6	2061	42	4	4	CD
cord-005478-5iu38pr6	2061	43	lines	line	NNS
cord-005478-5iu38pr6	2061	44	of	of	IN
cord-005478-5iu38pr6	2061	45	treatment	treatment	NN
cord-005478-5iu38pr6	2061	46	(	(	-LRB-
cord-005478-5iu38pr6	2061	47	n=1	n=1	NN
cord-005478-5iu38pr6	2061	48	)	)	-RRB-
cord-005478-5iu38pr6	2061	49	.	.	.
cord-005478-5iu38pr6	2062	1	Results	result	NNS
cord-005478-5iu38pr6	2062	2	:	:	:
cord-005478-5iu38pr6	2063	1	There	there	EX
cord-005478-5iu38pr6	2063	2	were	be	VBD
cord-005478-5iu38pr6	2063	3	no	no	DT
cord-005478-5iu38pr6	2063	4	adverse	adverse	JJ
cord-005478-5iu38pr6	2063	5	events	event	NNS
cord-005478-5iu38pr6	2063	6	attributable	attributable	JJ
cord-005478-5iu38pr6	2063	7	to	to	IN
cord-005478-5iu38pr6	2063	8	the	the	DT
cord-005478-5iu38pr6	2063	9	antibody	antibody	NN
cord-005478-5iu38pr6	2063	10	.	.	.
cord-005478-5iu38pr6	2064	1	Day	day	NN
cord-005478-5iu38pr6	2064	2	28	28	CD
cord-005478-5iu38pr6	2064	3	response	response	NN
cord-005478-5iu38pr6	2064	4	was	be	VBD
cord-005478-5iu38pr6	2064	5	recorded	record	VBN
cord-005478-5iu38pr6	2064	6	in	in	IN
cord-005478-5iu38pr6	2064	7	75	75	CD
cord-005478-5iu38pr6	2064	8	%	%	NN
cord-005478-5iu38pr6	2064	9	and	and	CC
cord-005478-5iu38pr6	2064	10	63	63	CD
cord-005478-5iu38pr6	2064	11	%	%	NN
cord-005478-5iu38pr6	2064	12	in	in	IN
cord-005478-5iu38pr6	2064	13	the	the	DT
cord-005478-5iu38pr6	2064	14	pilot	pilot	NN
cord-005478-5iu38pr6	2064	15	studies	study	NNS
cord-005478-5iu38pr6	2064	16	and	and	CC
cord-005478-5iu38pr6	2064	17	follow	follow	VB
cord-005478-5iu38pr6	2064	18	up	up	RP
cord-005478-5iu38pr6	2064	19	patients	patient	NNS
cord-005478-5iu38pr6	2064	20	.	.	.
cord-005478-5iu38pr6	2065	1	Response	response	NN
cord-005478-5iu38pr6	2065	2	in	in	IN
cord-005478-5iu38pr6	2065	3	grade	grade	NN
cord-005478-5iu38pr6	2065	4	II	II	NNP
cord-005478-5iu38pr6	2065	5	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2065	6	was	be	VBD
cord-005478-5iu38pr6	2065	7	evaluable	evaluable	JJ
cord-005478-5iu38pr6	2065	8	only	only	RB
cord-005478-5iu38pr6	2065	9	in	in	IN
cord-005478-5iu38pr6	2065	10	the	the	DT
cord-005478-5iu38pr6	2065	11	pilot	pilot	NN
cord-005478-5iu38pr6	2065	12	studies	study	NNS
cord-005478-5iu38pr6	2065	13	(	(	-LRB-
cord-005478-5iu38pr6	2065	14	57	57	CD
cord-005478-5iu38pr6	2065	15	%	%	NN
cord-005478-5iu38pr6	2065	16	)	)	-RRB-
cord-005478-5iu38pr6	2065	17	;	;	:
cord-005478-5iu38pr6	2065	18	response	response	NN
cord-005478-5iu38pr6	2065	19	in	in	IN
cord-005478-5iu38pr6	2065	20	grade	grade	NN
cord-005478-5iu38pr6	2065	21	III	iii	CD
cord-005478-5iu38pr6	2065	22	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2065	23	was	be	VBD
cord-005478-5iu38pr6	2065	24	recorded	record	VBN
cord-005478-5iu38pr6	2065	25	in	in	IN
cord-005478-5iu38pr6	2065	26	80	80	CD
cord-005478-5iu38pr6	2065	27	%	%	NN
cord-005478-5iu38pr6	2065	28	and	and	CC
cord-005478-5iu38pr6	2065	29	83	83	CD
cord-005478-5iu38pr6	2065	30	%	%	NN
cord-005478-5iu38pr6	2065	31	patients	patient	NNS
cord-005478-5iu38pr6	2065	32	in	in	IN
cord-005478-5iu38pr6	2065	33	the	the	DT
cord-005478-5iu38pr6	2065	34	two	two	CD
cord-005478-5iu38pr6	2065	35	groups	group	NNS
cord-005478-5iu38pr6	2065	36	;	;	:
cord-005478-5iu38pr6	2065	37	response	response	NN
cord-005478-5iu38pr6	2065	38	in	in	IN
cord-005478-5iu38pr6	2065	39	grade	grade	NN
cord-005478-5iu38pr6	2065	40	IV	IV	NNP
cord-005478-5iu38pr6	2065	41	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2065	42	was	be	VBD
cord-005478-5iu38pr6	2065	43	recorded	record	VBN
cord-005478-5iu38pr6	2065	44	in	in	IN
cord-005478-5iu38pr6	2065	45	66	66	CD
cord-005478-5iu38pr6	2065	46	%	%	NN
cord-005478-5iu38pr6	2065	47	and	and	CC
cord-005478-5iu38pr6	2065	48	56	56	CD
cord-005478-5iu38pr6	2065	49	%	%	NN
cord-005478-5iu38pr6	2065	50	of	of	IN
cord-005478-5iu38pr6	2065	51	patients	patient	NNS
cord-005478-5iu38pr6	2065	52	in	in	IN
cord-005478-5iu38pr6	2065	53	the	the	DT
cord-005478-5iu38pr6	2065	54	two	two	CD
cord-005478-5iu38pr6	2065	55	groups	group	NNS
cord-005478-5iu38pr6	2065	56	.	.	.
cord-005478-5iu38pr6	2066	1	Overall	overall	RB
cord-005478-5iu38pr6	2066	2	there	there	EX
cord-005478-5iu38pr6	2066	3	were	be	VBD
cord-005478-5iu38pr6	2066	4	60	60	CD
cord-005478-5iu38pr6	2066	5	%	%	NN
cord-005478-5iu38pr6	2066	6	responses	response	NNS
cord-005478-5iu38pr6	2066	7	for	for	IN
cord-005478-5iu38pr6	2066	8	skin	skin	NN
cord-005478-5iu38pr6	2066	9	and	and	CC
cord-005478-5iu38pr6	2066	10	liver	liver	NN
cord-005478-5iu38pr6	2066	11	stage	stage	NN
cord-005478-5iu38pr6	2066	12	3	3	CD
cord-005478-5iu38pr6	2066	13	-	-	SYM
cord-005478-5iu38pr6	2066	14	4	4	CD
cord-005478-5iu38pr6	2066	15	,	,	,
cord-005478-5iu38pr6	2066	16	and	and	CC
cord-005478-5iu38pr6	2066	17	70	70	CD
cord-005478-5iu38pr6	2066	18	%	%	NN
cord-005478-5iu38pr6	2066	19	responses	response	NNS
cord-005478-5iu38pr6	2066	20	for	for	IN
cord-005478-5iu38pr6	2066	21	gut	gut	NN
cord-005478-5iu38pr6	2066	22	stage	stage	NN
cord-005478-5iu38pr6	2066	23	3	3	CD
cord-005478-5iu38pr6	2066	24	-	-	SYM
cord-005478-5iu38pr6	2066	25	4	4	CD
cord-005478-5iu38pr6	2066	26	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2066	27	.	.	.
cord-005478-5iu38pr6	2067	1	The	the	DT
cord-005478-5iu38pr6	2067	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2067	3	incidence	incidence	NN
cord-005478-5iu38pr6	2067	4	of	of	IN
cord-005478-5iu38pr6	2067	5	non	non	JJ
cord-005478-5iu38pr6	2067	6	relapse	relapse	NN
cord-005478-5iu38pr6	2067	7	mortality	mortality	NN
cord-005478-5iu38pr6	2067	8	(	(	-LRB-
cord-005478-5iu38pr6	2067	9	NRM	NRM	NNP
cord-005478-5iu38pr6	2067	10	)	)	-RRB-
cord-005478-5iu38pr6	2067	11	at	at	IN
cord-005478-5iu38pr6	2067	12	6	6	CD
cord-005478-5iu38pr6	2067	13	months	month	NNS
cord-005478-5iu38pr6	2067	14	was	be	VBD
cord-005478-5iu38pr6	2067	15	28	28	CD
cord-005478-5iu38pr6	2067	16	%	%	NN
cord-005478-5iu38pr6	2067	17	and	and	CC
cord-005478-5iu38pr6	2067	18	38	38	CD
cord-005478-5iu38pr6	2067	19	%	%	NN
cord-005478-5iu38pr6	2067	20	.	.	.
cord-005478-5iu38pr6	2068	1	For	for	IN
cord-005478-5iu38pr6	2068	2	day	day	NN
cord-005478-5iu38pr6	2068	3	28	28	CD
cord-005478-5iu38pr6	2068	4	responders	responder	NNS
cord-005478-5iu38pr6	2068	5	,	,	,
cord-005478-5iu38pr6	2068	6	this	this	DT
cord-005478-5iu38pr6	2068	7	figure	figure	NN
cord-005478-5iu38pr6	2068	8	was	be	VBD
cord-005478-5iu38pr6	2068	9	19	19	CD
cord-005478-5iu38pr6	2068	10	%	%	NN
cord-005478-5iu38pr6	2068	11	and	and	CC
cord-005478-5iu38pr6	2068	12	22	22	CD
cord-005478-5iu38pr6	2068	13	%	%	NN
cord-005478-5iu38pr6	2068	14	,	,	,
cord-005478-5iu38pr6	2068	15	for	for	IN
cord-005478-5iu38pr6	2068	16	non	non	JJ
cord-005478-5iu38pr6	2068	17	responders	responder	NNS
cord-005478-5iu38pr6	2068	18	it	-PRON-	PRP
cord-005478-5iu38pr6	2068	19	was	be	VBD
cord-005478-5iu38pr6	2068	20	57	57	CD
cord-005478-5iu38pr6	2068	21	%	%	NN
cord-005478-5iu38pr6	2068	22	and	and	CC
cord-005478-5iu38pr6	2068	23	66	66	CD
cord-005478-5iu38pr6	2068	24	%	%	NN
cord-005478-5iu38pr6	2068	25	in	in	IN
cord-005478-5iu38pr6	2068	26	the	the	DT
cord-005478-5iu38pr6	2068	27	two	two	CD
cord-005478-5iu38pr6	2068	28	groups	group	NNS
cord-005478-5iu38pr6	2068	29	.	.	.
cord-005478-5iu38pr6	2069	1	The	the	DT
cord-005478-5iu38pr6	2069	2	overall	overall	JJ
cord-005478-5iu38pr6	2069	3	survival	survival	NN
cord-005478-5iu38pr6	2069	4	at	at	IN
cord-005478-5iu38pr6	2069	5	1	1	CD
cord-005478-5iu38pr6	2069	6	year	year	NN
cord-005478-5iu38pr6	2069	7	was	be	VBD
cord-005478-5iu38pr6	2069	8	50	50	CD
cord-005478-5iu38pr6	2069	9	%	%	NN
cord-005478-5iu38pr6	2069	10	for	for	IN
cord-005478-5iu38pr6	2069	11	the	the	DT
cord-005478-5iu38pr6	2069	12	pilot	pilot	NN
cord-005478-5iu38pr6	2069	13	studies	study	NNS
cord-005478-5iu38pr6	2069	14	and	and	CC
cord-005478-5iu38pr6	2069	15	33	33	CD
cord-005478-5iu38pr6	2069	16	%	%	NN
cord-005478-5iu38pr6	2069	17	for	for	IN
cord-005478-5iu38pr6	2069	18	the	the	DT
cord-005478-5iu38pr6	2069	19	follow	follow	NN
cord-005478-5iu38pr6	2069	20	up	up	RP
cord-005478-5iu38pr6	2069	21	patients	patient	NNS
cord-005478-5iu38pr6	2069	22	.	.	.
cord-005478-5iu38pr6	2070	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2070	2	:	:	:
cord-005478-5iu38pr6	2071	1	In	in	IN
cord-005478-5iu38pr6	2071	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	2071	3	,	,	,
cord-005478-5iu38pr6	2071	4	Begelomab	Begelomab	NNP
cord-005478-5iu38pr6	2071	5	induces	induce	VBZ
cord-005478-5iu38pr6	2071	6	a	a	DT
cord-005478-5iu38pr6	2071	7	high	high	JJ
cord-005478-5iu38pr6	2071	8	remission	remission	NN
cord-005478-5iu38pr6	2071	9	rate	rate	NN
cord-005478-5iu38pr6	2071	10	on	on	IN
cord-005478-5iu38pr6	2071	11	day+28	day+28	NNPS
cord-005478-5iu38pr6	2071	12	in	in	IN
cord-005478-5iu38pr6	2071	13	patients	patient	NNS
cord-005478-5iu38pr6	2071	14	with	with	IN
cord-005478-5iu38pr6	2071	15	SR	SR	NNP
cord-005478-5iu38pr6	2071	16	-	-	HYPH
cord-005478-5iu38pr6	2071	17	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2071	18	,	,	,
cord-005478-5iu38pr6	2071	19	including	include	VBG
cord-005478-5iu38pr6	2071	20	a	a	DT
cord-005478-5iu38pr6	2071	21	significant	significant	JJ
cord-005478-5iu38pr6	2071	22	proportion	proportion	NN
cord-005478-5iu38pr6	2071	23	of	of	IN
cord-005478-5iu38pr6	2071	24	patients	patient	NNS
cord-005478-5iu38pr6	2071	25	wih	wih	IN
cord-005478-5iu38pr6	2071	26	severe	severe	JJ
cord-005478-5iu38pr6	2071	27	gut	gut	NN
cord-005478-5iu38pr6	2071	28	and	and	CC
cord-005478-5iu38pr6	2071	29	liver	liver	NN
cord-005478-5iu38pr6	2071	30	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2071	31	.	.	.
cord-005478-5iu38pr6	2072	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2072	2	Background	background	NN
cord-005478-5iu38pr6	2072	3	:	:	:
cord-005478-5iu38pr6	2073	1	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2073	2	is	be	VBZ
cord-005478-5iu38pr6	2073	3	characterized	characterize	VBN
cord-005478-5iu38pr6	2073	4	by	by	IN
cord-005478-5iu38pr6	2073	5	an	an	DT
cord-005478-5iu38pr6	2073	6	imbalance	imbalance	NN
cord-005478-5iu38pr6	2073	7	between	between	IN
cord-005478-5iu38pr6	2073	8	effector	effector	NN
cord-005478-5iu38pr6	2073	9	and	and	CC
cord-005478-5iu38pr6	2073	10	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2073	11	arms	arm	NNS
cord-005478-5iu38pr6	2073	12	of	of	IN
cord-005478-5iu38pr6	2073	13	the	the	DT
cord-005478-5iu38pr6	2073	14	immune	immune	JJ
cord-005478-5iu38pr6	2073	15	system	system	NN
cord-005478-5iu38pr6	2073	16	that	that	WDT
cord-005478-5iu38pr6	2073	17	results	result	VBZ
cord-005478-5iu38pr6	2073	18	in	in	IN
cord-005478-5iu38pr6	2073	19	overproduction	overproduction	NN
cord-005478-5iu38pr6	2073	20	of	of	IN
cord-005478-5iu38pr6	2073	21	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2073	22	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2073	23	including	include	VBG
cord-005478-5iu38pr6	2073	24	IL-17	IL-17	NNP
cord-005478-5iu38pr6	2073	25	and	and	CC
cord-005478-5iu38pr6	2073	26	IL-21	IL-21	NNP
cord-005478-5iu38pr6	2073	27	.	.	.
cord-005478-5iu38pr6	2074	1	Moreover	moreover	RB
cord-005478-5iu38pr6	2074	2	,	,	,
cord-005478-5iu38pr6	2074	3	a	a	DT
cord-005478-5iu38pr6	2074	4	persistent	persistent	JJ
cord-005478-5iu38pr6	2074	5	reduction	reduction	NN
cord-005478-5iu38pr6	2074	6	in	in	IN
cord-005478-5iu38pr6	2074	7	the	the	DT
cord-005478-5iu38pr6	2074	8	number	number	NN
cord-005478-5iu38pr6	2074	9	of	of	IN
cord-005478-5iu38pr6	2074	10	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2074	11	T	T	NNP
cord-005478-5iu38pr6	2074	12	(	(	-LRB-
cord-005478-5iu38pr6	2074	13	Treg	Treg	NNP
cord-005478-5iu38pr6	2074	14	)	)	-RRB-
cord-005478-5iu38pr6	2074	15	cells	cell	NNS
cord-005478-5iu38pr6	2074	16	limits	limit	VBZ
cord-005478-5iu38pr6	2074	17	the	the	DT
cord-005478-5iu38pr6	2074	18	ability	ability	NN
cord-005478-5iu38pr6	2074	19	of	of	IN
cord-005478-5iu38pr6	2074	20	the	the	DT
cord-005478-5iu38pr6	2074	21	immune	immune	JJ
cord-005478-5iu38pr6	2074	22	system	system	NN
cord-005478-5iu38pr6	2074	23	to	to	TO
cord-005478-5iu38pr6	2074	24	recalibrate	recalibrate	VB
cord-005478-5iu38pr6	2074	25	this	this	DT
cord-005478-5iu38pr6	2074	26	pro	pro	JJ
cord-005478-5iu38pr6	2074	27	-	-	JJ
cord-005478-5iu38pr6	2074	28	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2074	29	environment	environment	NN
cord-005478-5iu38pr6	2074	30	.	.	.
cord-005478-5iu38pr6	2075	1	KD025	KD025	NNP
cord-005478-5iu38pr6	2075	2	is	be	VBZ
cord-005478-5iu38pr6	2075	3	an	an	DT
cord-005478-5iu38pr6	2075	4	orally	orally	RB
cord-005478-5iu38pr6	2075	5	available	available	JJ
cord-005478-5iu38pr6	2075	6	Rho	rho	NN
cord-005478-5iu38pr6	2075	7	-	-	HYPH
cord-005478-5iu38pr6	2075	8	associated	associate	VBN
cord-005478-5iu38pr6	2075	9	coiled	coil	VBN
cord-005478-5iu38pr6	2075	10	-	-	HYPH
cord-005478-5iu38pr6	2075	11	coil	coil	NN
cord-005478-5iu38pr6	2075	12	kinase	kinase	NN
cord-005478-5iu38pr6	2075	13	2	2	CD
cord-005478-5iu38pr6	2075	14	(	(	-LRB-
cord-005478-5iu38pr6	2075	15	ROCK2	ROCK2	''
cord-005478-5iu38pr6	2075	16	)	)	-RRB-
cord-005478-5iu38pr6	2075	17	selective	selective	JJ
cord-005478-5iu38pr6	2075	18	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	2075	19	.	.	.
cord-005478-5iu38pr6	2076	1	In	in	IN
cord-005478-5iu38pr6	2076	2	vitro	vitro	FW
cord-005478-5iu38pr6	2076	3	data	datum	NNS
cord-005478-5iu38pr6	2076	4	suggest	suggest	VBP
cord-005478-5iu38pr6	2076	5	that	that	IN
cord-005478-5iu38pr6	2076	6	KD025	KD025	NNP
cord-005478-5iu38pr6	2076	7	modulates	modulate	VBZ
cord-005478-5iu38pr6	2076	8	immune	immune	JJ
cord-005478-5iu38pr6	2076	9	homeostasis	homeostasis	NN
cord-005478-5iu38pr6	2076	10	by	by	IN
cord-005478-5iu38pr6	2076	11	shifting	shift	VBG
cord-005478-5iu38pr6	2076	12	the	the	DT
cord-005478-5iu38pr6	2076	13	TH17	TH17	NNP
cord-005478-5iu38pr6	2076	14	/	/	SYM
cord-005478-5iu38pr6	2076	15	Treg	Treg	NNP
cord-005478-5iu38pr6	2076	16	balance	balance	NN
cord-005478-5iu38pr6	2076	17	towards	towards	IN
cord-005478-5iu38pr6	2076	18	a	a	DT
cord-005478-5iu38pr6	2076	19	Treg	Treg	NNP
cord-005478-5iu38pr6	2076	20	phenotype	phenotype	NN
cord-005478-5iu38pr6	2076	21	.	.	.
cord-005478-5iu38pr6	2077	1	Methods	method	NNS
cord-005478-5iu38pr6	2077	2	:	:	:
cord-005478-5iu38pr6	2078	1	KD025	KD025	NNP
cord-005478-5iu38pr6	2078	2	-	-	HYPH
cord-005478-5iu38pr6	2078	3	208	208	CD
cord-005478-5iu38pr6	2078	4	is	be	VBZ
cord-005478-5iu38pr6	2078	5	an	an	DT
cord-005478-5iu38pr6	2078	6	open	open	JJ
cord-005478-5iu38pr6	2078	7	-	-	HYPH
cord-005478-5iu38pr6	2078	8	label	label	NN
cord-005478-5iu38pr6	2078	9	Phase	Phase	NNP
cord-005478-5iu38pr6	2078	10	2a	2a	CD
cord-005478-5iu38pr6	2078	11	study	study	NN
cord-005478-5iu38pr6	2078	12	in	in	IN
cord-005478-5iu38pr6	2078	13	patients	patient	NNS
cord-005478-5iu38pr6	2078	14	with	with	IN
cord-005478-5iu38pr6	2078	15	steroid	steroid	NN
cord-005478-5iu38pr6	2078	16	-	-	HYPH
cord-005478-5iu38pr6	2078	17	dependent	dependent	JJ
cord-005478-5iu38pr6	2078	18	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2079	1	after	after	IN
cord-005478-5iu38pr6	2079	2	no	no	DT
cord-005478-5iu38pr6	2079	3	more	more	JJR
cord-005478-5iu38pr6	2079	4	than	than	IN
cord-005478-5iu38pr6	2079	5	3	3	CD
cord-005478-5iu38pr6	2079	6	prior	prior	JJ
cord-005478-5iu38pr6	2079	7	lines	line	NNS
cord-005478-5iu38pr6	2079	8	of	of	IN
cord-005478-5iu38pr6	2079	9	treatment	treatment	NN
cord-005478-5iu38pr6	2079	10	.	.	.
cord-005478-5iu38pr6	2080	1	Three	three	CD
cord-005478-5iu38pr6	2080	2	cohorts	cohort	NNS
cord-005478-5iu38pr6	2080	3	(	(	-LRB-
cord-005478-5iu38pr6	2080	4	C1	C1	NNP
cord-005478-5iu38pr6	2080	5	:	:	:
cord-005478-5iu38pr6	2080	6	200	200	CD
cord-005478-5iu38pr6	2080	7	mg	mg	NNP
cord-005478-5iu38pr6	2080	8	QD	QD	NNP
cord-005478-5iu38pr6	2080	9	(	(	-LRB-
cord-005478-5iu38pr6	2080	10	n=17	n=17	NNP
cord-005478-5iu38pr6	2080	11	)	)	-RRB-
cord-005478-5iu38pr6	2080	12	,	,	,
cord-005478-5iu38pr6	2080	13	C2	C2	NNP
cord-005478-5iu38pr6	2080	14	:	:	:
cord-005478-5iu38pr6	2080	15	200	200	CD
cord-005478-5iu38pr6	2080	16	mg	mg	NNP
cord-005478-5iu38pr6	2080	17	BID	BID	NNP
cord-005478-5iu38pr6	2080	18	(	(	-LRB-
cord-005478-5iu38pr6	2080	19	n=16	n=16	NNP
cord-005478-5iu38pr6	2080	20	)	)	-RRB-
cord-005478-5iu38pr6	2080	21	,	,	,
cord-005478-5iu38pr6	2080	22	and	and	CC
cord-005478-5iu38pr6	2080	23	C3	c3	NN
cord-005478-5iu38pr6	2080	24	:	:	:
cord-005478-5iu38pr6	2080	25	400	400	CD
cord-005478-5iu38pr6	2080	26	mg	mg	NNP
cord-005478-5iu38pr6	2080	27	QD	QD	NNP
cord-005478-5iu38pr6	2080	28	(	(	-LRB-
cord-005478-5iu38pr6	2080	29	n=21	n=21	NNP
cord-005478-5iu38pr6	2080	30	)	)	-RRB-
cord-005478-5iu38pr6	2080	31	)	)	-RRB-
cord-005478-5iu38pr6	2080	32	were	be	VBD
cord-005478-5iu38pr6	2080	33	enrolled	enrol	VBN
cord-005478-5iu38pr6	2080	34	.	.	.
cord-005478-5iu38pr6	2081	1	The	the	DT
cord-005478-5iu38pr6	2081	2	primary	primary	JJ
cord-005478-5iu38pr6	2081	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	2081	4	is	be	VBZ
cord-005478-5iu38pr6	2081	5	Overall	overall	JJ
cord-005478-5iu38pr6	2081	6	Response	response	NN
cord-005478-5iu38pr6	2081	7	Rate	rate	NN
cord-005478-5iu38pr6	2081	8	(	(	-LRB-
cord-005478-5iu38pr6	2081	9	ORR	ORR	NNP
cord-005478-5iu38pr6	2081	10	)	)	-RRB-
cord-005478-5iu38pr6	2081	11	,	,	,
cord-005478-5iu38pr6	2081	12	defined	define	VBN
cord-005478-5iu38pr6	2081	13	per	per	IN
cord-005478-5iu38pr6	2081	14	the	the	DT
cord-005478-5iu38pr6	2081	15	2014	2014	CD
cord-005478-5iu38pr6	2081	16	NIH	NIH	NNP
cord-005478-5iu38pr6	2081	17	Consensus	Consensus	NNP
cord-005478-5iu38pr6	2081	18	criteria	criterion	NNS
cord-005478-5iu38pr6	2081	19	.	.	.
cord-005478-5iu38pr6	2082	1	Results	result	NNS
cord-005478-5iu38pr6	2082	2	:	:	:
cord-005478-5iu38pr6	2083	1	As	as	IN
cord-005478-5iu38pr6	2083	2	of	of	IN
cord-005478-5iu38pr6	2083	3	13-September-2018	13-september-2018	CD
cord-005478-5iu38pr6	2083	4	,	,	,
cord-005478-5iu38pr6	2083	5	the	the	DT
cord-005478-5iu38pr6	2083	6	median	median	JJ
cord-005478-5iu38pr6	2083	7	duration	duration	NN
cord-005478-5iu38pr6	2083	8	of	of	IN
cord-005478-5iu38pr6	2083	9	treatment	treatment	NN
cord-005478-5iu38pr6	2083	10	was	be	VBD
cord-005478-5iu38pr6	2083	11	37	37	CD
cord-005478-5iu38pr6	2083	12	,	,	,
cord-005478-5iu38pr6	2083	13	33	33	CD
cord-005478-5iu38pr6	2083	14	and	and	CC
cord-005478-5iu38pr6	2083	15	27	27	CD
cord-005478-5iu38pr6	2083	16	weeks	week	NNS
cord-005478-5iu38pr6	2083	17	for	for	IN
cord-005478-5iu38pr6	2083	18	C1	C1	NNP
cord-005478-5iu38pr6	2083	19	,	,	,
cord-005478-5iu38pr6	2083	20	C2	C2	NNP
cord-005478-5iu38pr6	2083	21	and	and	CC
cord-005478-5iu38pr6	2083	22	C3	C3	NNP
cord-005478-5iu38pr6	2083	23	,	,	,
cord-005478-5iu38pr6	2083	24	respectively	respectively	RB
cord-005478-5iu38pr6	2083	25	.	.	.
cord-005478-5iu38pr6	2084	1	The	the	DT
cord-005478-5iu38pr6	2084	2	median	median	JJ
cord-005478-5iu38pr6	2084	3	age	age	NN
cord-005478-5iu38pr6	2084	4	was	be	VBD
cord-005478-5iu38pr6	2084	5	52	52	CD
cord-005478-5iu38pr6	2084	6	years	year	NNS
cord-005478-5iu38pr6	2085	1	(	(	-LRB-
cord-005478-5iu38pr6	2085	2	range	range	NN
cord-005478-5iu38pr6	2085	3	20	20	CD
cord-005478-5iu38pr6	2085	4	-	-	SYM
cord-005478-5iu38pr6	2085	5	75	75	CD
cord-005478-5iu38pr6	2085	6	)	)	-RRB-
cord-005478-5iu38pr6	2085	7	and	and	CC
cord-005478-5iu38pr6	2085	8	median	median	JJ
cord-005478-5iu38pr6	2085	9	time	time	NN
cord-005478-5iu38pr6	2085	10	from	from	IN
cord-005478-5iu38pr6	2085	11	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2085	12	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2085	13	to	to	IN
cord-005478-5iu38pr6	2085	14	KD025	KD025	NNP
cord-005478-5iu38pr6	2085	15	treatment	treatment	NN
cord-005478-5iu38pr6	2085	16	was	be	VBD
cord-005478-5iu38pr6	2085	17	19	19	CD
cord-005478-5iu38pr6	2085	18	months	month	NNS
cord-005478-5iu38pr6	2085	19	.	.	.
cord-005478-5iu38pr6	2086	1	67	67	CD
cord-005478-5iu38pr6	2086	2	%	%	NN
cord-005478-5iu38pr6	2086	3	of	of	IN
cord-005478-5iu38pr6	2086	4	patients	patient	NNS
cord-005478-5iu38pr6	2086	5	had	have	VBD
cord-005478-5iu38pr6	2086	6	received	receive	VBN
cord-005478-5iu38pr6	2086	7	≥2	≥2	NNP
cord-005478-5iu38pr6	2086	8	prior	prior	JJ
cord-005478-5iu38pr6	2086	9	lines	line	NNS
cord-005478-5iu38pr6	2086	10	of	of	IN
cord-005478-5iu38pr6	2086	11	therapy	therapy	NN
cord-005478-5iu38pr6	2086	12	and	and	CC
cord-005478-5iu38pr6	2086	13	48	48	CD
cord-005478-5iu38pr6	2086	14	%	%	NN
cord-005478-5iu38pr6	2086	15	had	have	VBD
cord-005478-5iu38pr6	2086	16	≥4	≥4	JJ
cord-005478-5iu38pr6	2086	17	organs	organ	NNS
cord-005478-5iu38pr6	2086	18	involved	involve	VBN
cord-005478-5iu38pr6	2086	19	at	at	IN
cord-005478-5iu38pr6	2086	20	baseline	baseline	NN
cord-005478-5iu38pr6	2086	21	.	.	.
cord-005478-5iu38pr6	2087	1	20	20	CD
cord-005478-5iu38pr6	2087	2	patients	patient	NNS
cord-005478-5iu38pr6	2087	3	remain	remain	VBP
cord-005478-5iu38pr6	2087	4	on	on	IN
cord-005478-5iu38pr6	2087	5	treatment	treatment	NN
cord-005478-5iu38pr6	2087	6	with	with	IN
cord-005478-5iu38pr6	2087	7	KD025	KD025	NNP
cord-005478-5iu38pr6	2087	8	,	,	,
cord-005478-5iu38pr6	2087	9	with	with	IN
cord-005478-5iu38pr6	2087	10	median	median	JJ
cord-005478-5iu38pr6	2087	11	duration	duration	NN
cord-005478-5iu38pr6	2087	12	of	of	IN
cord-005478-5iu38pr6	2087	13	treatment	treatment	NN
cord-005478-5iu38pr6	2087	14	of	of	IN
cord-005478-5iu38pr6	2087	15	89	89	CD
cord-005478-5iu38pr6	2087	16	weeks	week	NNS
cord-005478-5iu38pr6	2087	17	(	(	-LRB-
cord-005478-5iu38pr6	2087	18	n=6	n=6	NNP
cord-005478-5iu38pr6	2087	19	)	)	-RRB-
cord-005478-5iu38pr6	2087	20	,	,	,
cord-005478-5iu38pr6	2087	21	68	68	CD
cord-005478-5iu38pr6	2087	22	weeks	week	NNS
cord-005478-5iu38pr6	2087	23	(	(	-LRB-
cord-005478-5iu38pr6	2087	24	n=3	n=3	NN
cord-005478-5iu38pr6	2087	25	)	)	-RRB-
cord-005478-5iu38pr6	2087	26	and	and	CC
cord-005478-5iu38pr6	2087	27	34	34	CD
cord-005478-5iu38pr6	2087	28	weeks	week	NNS
cord-005478-5iu38pr6	2087	29	(	(	-LRB-
cord-005478-5iu38pr6	2087	30	n=11	n=11	NNP
cord-005478-5iu38pr6	2087	31	)	)	-RRB-
cord-005478-5iu38pr6	2087	32	for	for	IN
cord-005478-5iu38pr6	2087	33	each	each	DT
cord-005478-5iu38pr6	2087	34	cohort	cohort	NN
cord-005478-5iu38pr6	2087	35	,	,	,
cord-005478-5iu38pr6	2087	36	respectively	respectively	RB
cord-005478-5iu38pr6	2087	37	.	.	.
cord-005478-5iu38pr6	2088	1	The	the	DT
cord-005478-5iu38pr6	2088	2	ORR	ORR	NNP
cord-005478-5iu38pr6	2088	3	was	be	VBD
cord-005478-5iu38pr6	2088	4	65	65	CD
cord-005478-5iu38pr6	2088	5	%	%	NN
cord-005478-5iu38pr6	2088	6	in	in	IN
cord-005478-5iu38pr6	2088	7	C1	C1	NNP
cord-005478-5iu38pr6	2088	8	,	,	,
cord-005478-5iu38pr6	2088	9	63	63	CD
cord-005478-5iu38pr6	2088	10	%	%	NN
cord-005478-5iu38pr6	2088	11	in	in	IN
cord-005478-5iu38pr6	2088	12	C2	C2	NNP
cord-005478-5iu38pr6	2088	13	and	and	CC
cord-005478-5iu38pr6	2088	14	52	52	CD
cord-005478-5iu38pr6	2088	15	%	%	NN
cord-005478-5iu38pr6	2088	16	in	in	IN
cord-005478-5iu38pr6	2088	17	C3	C3	NNP
cord-005478-5iu38pr6	2088	18	.	.	.
cord-005478-5iu38pr6	2089	1	Responses	response	NNS
cord-005478-5iu38pr6	2089	2	were	be	VBD
cord-005478-5iu38pr6	2089	3	rapid	rapid	JJ
cord-005478-5iu38pr6	2089	4	,	,	,
cord-005478-5iu38pr6	2089	5	with	with	IN
cord-005478-5iu38pr6	2089	6	75	75	CD
cord-005478-5iu38pr6	2089	7	%	%	NN
cord-005478-5iu38pr6	2089	8	of	of	IN
cord-005478-5iu38pr6	2089	9	responders	responder	NNS
cord-005478-5iu38pr6	2089	10	achieving	achieve	VBG
cord-005478-5iu38pr6	2089	11	a	a	DT
cord-005478-5iu38pr6	2089	12	response	response	NN
cord-005478-5iu38pr6	2089	13	at	at	IN
cord-005478-5iu38pr6	2089	14	the	the	DT
cord-005478-5iu38pr6	2089	15	first	first	JJ
cord-005478-5iu38pr6	2089	16	assessment	assessment	NN
cord-005478-5iu38pr6	2089	17	(	(	-LRB-
cord-005478-5iu38pr6	2089	18	8	8	CD
cord-005478-5iu38pr6	2089	19	weeks	week	NNS
cord-005478-5iu38pr6	2089	20	)	)	-RRB-
cord-005478-5iu38pr6	2089	21	.	.	.
cord-005478-5iu38pr6	2090	1	Among	among	IN
cord-005478-5iu38pr6	2090	2	responders	responder	NNS
cord-005478-5iu38pr6	2090	3	,	,	,
cord-005478-5iu38pr6	2090	4	82	82	CD
cord-005478-5iu38pr6	2090	5	%	%	NN
cord-005478-5iu38pr6	2090	6	,	,	,
cord-005478-5iu38pr6	2090	7	50	50	CD
cord-005478-5iu38pr6	2090	8	%	%	NN
cord-005478-5iu38pr6	2090	9	and	and	CC
cord-005478-5iu38pr6	2090	10	36	36	CD
cord-005478-5iu38pr6	2090	11	%	%	NN
cord-005478-5iu38pr6	2090	12	have	have	VBP
cord-005478-5iu38pr6	2090	13	sustained	sustain	VBN
cord-005478-5iu38pr6	2090	14	responses	response	NNS
cord-005478-5iu38pr6	2090	15	for	for	IN
cord-005478-5iu38pr6	2090	16	≥20	≥20	NNP
cord-005478-5iu38pr6	2090	17	weeks	week	NNS
cord-005478-5iu38pr6	2090	18	in	in	IN
cord-005478-5iu38pr6	2090	19	each	each	DT
cord-005478-5iu38pr6	2090	20	cohort	cohort	NN
cord-005478-5iu38pr6	2090	21	,	,	,
cord-005478-5iu38pr6	2090	22	respectively	respectively	RB
cord-005478-5iu38pr6	2090	23	.	.	.
cord-005478-5iu38pr6	2091	1	Responses	response	NNS
cord-005478-5iu38pr6	2091	2	were	be	VBD
cord-005478-5iu38pr6	2091	3	observed	observe	VBN
cord-005478-5iu38pr6	2091	4	across	across	IN
cord-005478-5iu38pr6	2091	5	all	all	DT
cord-005478-5iu38pr6	2091	6	affected	affect	VBN
cord-005478-5iu38pr6	2091	7	organ	organ	NN
cord-005478-5iu38pr6	2091	8	systems	system	NNS
cord-005478-5iu38pr6	2091	9	,	,	,
cord-005478-5iu38pr6	2091	10	including	include	VBG
cord-005478-5iu38pr6	2091	11	CRs	CRs	NNP
cord-005478-5iu38pr6	2091	12	in	in	IN
cord-005478-5iu38pr6	2091	13	upper	upper	JJ
cord-005478-5iu38pr6	2091	14	GI	GI	NNP
cord-005478-5iu38pr6	2091	15	,	,	,
cord-005478-5iu38pr6	2091	16	lower	low	JJR
cord-005478-5iu38pr6	2091	17	GI	GI	NNP
cord-005478-5iu38pr6	2091	18	,	,	,
cord-005478-5iu38pr6	2091	19	esophagus	esophagus	NN
cord-005478-5iu38pr6	2091	20	,	,	,
cord-005478-5iu38pr6	2091	21	mouth	mouth	NN
cord-005478-5iu38pr6	2091	22	,	,	,
cord-005478-5iu38pr6	2091	23	skin	skin	NN
cord-005478-5iu38pr6	2091	24	,	,	,
cord-005478-5iu38pr6	2091	25	joints	joint	NNS
cord-005478-5iu38pr6	2091	26	/	/	SYM
cord-005478-5iu38pr6	2091	27	fascia	fascia	NNS
cord-005478-5iu38pr6	2091	28	,	,	,
cord-005478-5iu38pr6	2091	29	eyes	eye	NNS
cord-005478-5iu38pr6	2091	30	,	,	,
cord-005478-5iu38pr6	2091	31	and	and	CC
cord-005478-5iu38pr6	2091	32	liver	liver	NN
cord-005478-5iu38pr6	2091	33	.	.	.
cord-005478-5iu38pr6	2092	1	Two	two	CD
cord-005478-5iu38pr6	2092	2	patients	patient	NNS
cord-005478-5iu38pr6	2092	3	with	with	IN
cord-005478-5iu38pr6	2092	4	lung	lung	NN
cord-005478-5iu38pr6	2092	5	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2092	6	achieved	achieve	VBD
cord-005478-5iu38pr6	2092	7	PR	PR	NNP
cord-005478-5iu38pr6	2092	8	.	.	.
cord-005478-5iu38pr6	2093	1	69	69	CD
cord-005478-5iu38pr6	2093	2	%	%	NN
cord-005478-5iu38pr6	2093	3	of	of	IN
cord-005478-5iu38pr6	2093	4	patients	patient	NNS
cord-005478-5iu38pr6	2093	5	achieved	achieve	VBD
cord-005478-5iu38pr6	2093	6	reductions	reduction	NNS
cord-005478-5iu38pr6	2093	7	in	in	IN
cord-005478-5iu38pr6	2093	8	corticosteroid	corticosteroid	NN
cord-005478-5iu38pr6	2093	9	dose	dose	NN
cord-005478-5iu38pr6	2093	10	and	and	CC
cord-005478-5iu38pr6	2093	11	7	7	CD
cord-005478-5iu38pr6	2093	12	patients	patient	NNS
cord-005478-5iu38pr6	2093	13	discontinued	discontinue	VBD
cord-005478-5iu38pr6	2093	14	corticosteroid	corticosteroid	JJ
cord-005478-5iu38pr6	2093	15	treatment	treatment	NN
cord-005478-5iu38pr6	2093	16	while	while	IN
cord-005478-5iu38pr6	2093	17	receiving	receive	VBG
cord-005478-5iu38pr6	2093	18	KD025	KD025	NNP
cord-005478-5iu38pr6	2093	19	.	.	.
cord-005478-5iu38pr6	2094	1	72	72	CD
cord-005478-5iu38pr6	2094	2	%	%	NN
cord-005478-5iu38pr6	2094	3	of	of	IN
cord-005478-5iu38pr6	2094	4	responders	responder	NNS
cord-005478-5iu38pr6	2094	5	achieved	achieve	VBD
cord-005478-5iu38pr6	2094	6	a	a	DT
cord-005478-5iu38pr6	2094	7	clinically	clinically	RB
cord-005478-5iu38pr6	2094	8	meaningful	meaningful	JJ
cord-005478-5iu38pr6	2094	9	improvement	improvement	NN
cord-005478-5iu38pr6	2094	10	(	(	-LRB-
cord-005478-5iu38pr6	2094	11	≥7-point	≥7-point	NNP
cord-005478-5iu38pr6	2094	12	reduction	reduction	NN
cord-005478-5iu38pr6	2094	13	)	)	-RRB-
cord-005478-5iu38pr6	2094	14	in	in	IN
cord-005478-5iu38pr6	2094	15	the	the	DT
cord-005478-5iu38pr6	2094	16	Lee	Lee	NNP
cord-005478-5iu38pr6	2094	17	Symptom	Symptom	NNP
cord-005478-5iu38pr6	2094	18	Scale	Scale	NNP
cord-005478-5iu38pr6	2094	19	(	(	-LRB-
cord-005478-5iu38pr6	2094	20	LSS	LSS	NNP
cord-005478-5iu38pr6	2094	21	)	)	-RRB-
cord-005478-5iu38pr6	2094	22	score	score	NN
cord-005478-5iu38pr6	2094	23	.	.	.
cord-005478-5iu38pr6	2095	1	KD025	KD025	NNP
cord-005478-5iu38pr6	2095	2	has	have	VBZ
cord-005478-5iu38pr6	2095	3	been	be	VBN
cord-005478-5iu38pr6	2095	4	well	well	RB
cord-005478-5iu38pr6	2095	5	tolerated	tolerate	VBN
cord-005478-5iu38pr6	2095	6	.	.	.
cord-005478-5iu38pr6	2096	1	Commonly	commonly	RB
cord-005478-5iu38pr6	2096	2	reported	report	VBN
cord-005478-5iu38pr6	2096	3	AEs	AEs	NNP
cord-005478-5iu38pr6	2096	4	(	(	-LRB-
cord-005478-5iu38pr6	2096	5	≥20	≥20	NNP
cord-005478-5iu38pr6	2096	6	%	%	NN
cord-005478-5iu38pr6	2096	7	patients	patient	NNS
cord-005478-5iu38pr6	2096	8	)	)	-RRB-
cord-005478-5iu38pr6	2096	9	were	be	VBD
cord-005478-5iu38pr6	2096	10	URTI	URTI	NNP
cord-005478-5iu38pr6	2096	11	,	,	,
cord-005478-5iu38pr6	2096	12	AST	AST	NNP
cord-005478-5iu38pr6	2096	13	/	/	SYM
cord-005478-5iu38pr6	2096	14	ALT	alt	NN
cord-005478-5iu38pr6	2096	15	elevations	elevation	NNS
cord-005478-5iu38pr6	2096	16	,	,	,
cord-005478-5iu38pr6	2096	17	fatigue	fatigue	NN
cord-005478-5iu38pr6	2096	18	,	,	,
cord-005478-5iu38pr6	2096	19	nausea	nausea	NN
cord-005478-5iu38pr6	2096	20	and	and	CC
cord-005478-5iu38pr6	2096	21	diarrhea	diarrhea	NN
cord-005478-5iu38pr6	2096	22	.	.	.
cord-005478-5iu38pr6	2097	1	Grade	grade	NN
cord-005478-5iu38pr6	2097	2	≥3	≥3	NNP
cord-005478-5iu38pr6	2097	3	AEs	ae	NNS
cord-005478-5iu38pr6	2097	4	occurring	occur	VBG
cord-005478-5iu38pr6	2097	5	in	in	IN
cord-005478-5iu38pr6	2097	6	>	>	$
cord-005478-5iu38pr6	2097	7	3	3	CD
cord-005478-5iu38pr6	2097	8	patients	patient	NNS
cord-005478-5iu38pr6	2097	9	were	be	VBD
cord-005478-5iu38pr6	2097	10	GGT	GGT	NNP
cord-005478-5iu38pr6	2097	11	elevations	elevation	NNS
cord-005478-5iu38pr6	2097	12	(	(	-LRB-
cord-005478-5iu38pr6	2097	13	n=6	n=6	NNP
cord-005478-5iu38pr6	2097	14	)	)	-RRB-
cord-005478-5iu38pr6	2097	15	and	and	CC
cord-005478-5iu38pr6	2097	16	hyperglycemia	hyperglycemia	NN
cord-005478-5iu38pr6	2097	17	(	(	-LRB-
cord-005478-5iu38pr6	2097	18	n=4	n=4	NNS
cord-005478-5iu38pr6	2097	19	)	)	-RRB-
cord-005478-5iu38pr6	2097	20	.	.	.
cord-005478-5iu38pr6	2098	1	No	no	DT
cord-005478-5iu38pr6	2098	2	SAEs	SAEs	NNP
cord-005478-5iu38pr6	2098	3	were	be	VBD
cord-005478-5iu38pr6	2098	4	considered	consider	VBN
cord-005478-5iu38pr6	2098	5	related	related	JJ
cord-005478-5iu38pr6	2098	6	to	to	TO
cord-005478-5iu38pr6	2098	7	study	study	VB
cord-005478-5iu38pr6	2098	8	drug	drug	NN
cord-005478-5iu38pr6	2098	9	.	.	.
cord-005478-5iu38pr6	2099	1	Two	two	CD
cord-005478-5iu38pr6	2099	2	patients	patient	NNS
cord-005478-5iu38pr6	2099	3	discontinued	discontinue	VBD
cord-005478-5iu38pr6	2099	4	treatment	treatment	NN
cord-005478-5iu38pr6	2099	5	due	due	IN
cord-005478-5iu38pr6	2099	6	to	to	IN
cord-005478-5iu38pr6	2099	7	AEs	AEs	NNP
cord-005478-5iu38pr6	2099	8	considered	consider	VBN
cord-005478-5iu38pr6	2099	9	possibly	possibly	RB
cord-005478-5iu38pr6	2099	10	related	relate	VBN
cord-005478-5iu38pr6	2099	11	to	to	IN
cord-005478-5iu38pr6	2099	12	KD025	KD025	NNP
cord-005478-5iu38pr6	2099	13	(	(	-LRB-
cord-005478-5iu38pr6	2099	14	headache	headache	NN
cord-005478-5iu38pr6	2099	15	,	,	,
cord-005478-5iu38pr6	2099	16	diarrhea	diarrhea	NN
cord-005478-5iu38pr6	2099	17	)	)	-RRB-
cord-005478-5iu38pr6	2099	18	.	.	.
cord-005478-5iu38pr6	2100	1	Three	three	CD
cord-005478-5iu38pr6	2100	2	fatal	fatal	JJ
cord-005478-5iu38pr6	2100	3	events	event	NNS
cord-005478-5iu38pr6	2100	4	occurred	occur	VBD
cord-005478-5iu38pr6	2100	5	(	(	-LRB-
cord-005478-5iu38pr6	2100	6	relapse	relapse	NN
cord-005478-5iu38pr6	2100	7	of	of	IN
cord-005478-5iu38pr6	2100	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	2100	9	;	;	:
cord-005478-5iu38pr6	2100	10	lung	lung	NN
cord-005478-5iu38pr6	2100	11	infection	infection	NN
cord-005478-5iu38pr6	2100	12	;	;	:
cord-005478-5iu38pr6	2100	13	cardiac	cardiac	JJ
cord-005478-5iu38pr6	2100	14	arrest	arrest	NN
cord-005478-5iu38pr6	2100	15	)	)	-RRB-
cord-005478-5iu38pr6	2100	16	;	;	:
cord-005478-5iu38pr6	2100	17	none	none	NN
cord-005478-5iu38pr6	2100	18	were	be	VBD
cord-005478-5iu38pr6	2100	19	considered	consider	VBN
cord-005478-5iu38pr6	2100	20	related	related	JJ
cord-005478-5iu38pr6	2100	21	to	to	IN
cord-005478-5iu38pr6	2100	22	KD025	KD025	NNP
cord-005478-5iu38pr6	2100	23	.	.	.
cord-005478-5iu38pr6	2101	1	No	no	DT
cord-005478-5iu38pr6	2101	2	increase	increase	NN
cord-005478-5iu38pr6	2101	3	in	in	IN
cord-005478-5iu38pr6	2101	4	incidence	incidence	NN
cord-005478-5iu38pr6	2101	5	of	of	IN
cord-005478-5iu38pr6	2101	6	infection	infection	NN
cord-005478-5iu38pr6	2101	7	was	be	VBD
cord-005478-5iu38pr6	2101	8	observed	observe	VBN
cord-005478-5iu38pr6	2101	9	.	.	.
cord-005478-5iu38pr6	2102	1	Consistent	consistent	JJ
cord-005478-5iu38pr6	2102	2	with	with	IN
cord-005478-5iu38pr6	2102	3	the	the	DT
cord-005478-5iu38pr6	2102	4	postulated	postulate	VBN
cord-005478-5iu38pr6	2102	5	KD025	KD025	NNP
cord-005478-5iu38pr6	2102	6	mechanism	mechanism	NN
cord-005478-5iu38pr6	2102	7	of	of	IN
cord-005478-5iu38pr6	2102	8	action	action	NN
cord-005478-5iu38pr6	2102	9	,	,	,
cord-005478-5iu38pr6	2102	10	TH17	TH17	NNP
cord-005478-5iu38pr6	2102	11	cells	cell	NNS
cord-005478-5iu38pr6	2102	12	decreased	decrease	VBD
cord-005478-5iu38pr6	2102	13	and	and	CC
cord-005478-5iu38pr6	2102	14	Treg	Treg	NNP
cord-005478-5iu38pr6	2102	15	cells	cell	NNS
cord-005478-5iu38pr6	2102	16	increased	increase	VBD
cord-005478-5iu38pr6	2102	17	in	in	IN
cord-005478-5iu38pr6	2102	18	patients	patient	NNS
cord-005478-5iu38pr6	2102	19	receiving	receive	VBG
cord-005478-5iu38pr6	2102	20	KD025	KD025	NNP
cord-005478-5iu38pr6	2102	21	Background	Background	NNP
cord-005478-5iu38pr6	2102	22	:	:	:
cord-005478-5iu38pr6	2103	1	Antithymocyte	Antithymocyte	NNP
cord-005478-5iu38pr6	2103	2	globulin	globulin	NN
cord-005478-5iu38pr6	2103	3	(	(	-LRB-
cord-005478-5iu38pr6	2103	4	ATG	ATG	NNP
cord-005478-5iu38pr6	2103	5	)	)	-RRB-
cord-005478-5iu38pr6	2103	6	treatment	treatment	NN
cord-005478-5iu38pr6	2103	7	significantly	significantly	RB
cord-005478-5iu38pr6	2103	8	decreases	decrease	VBZ
cord-005478-5iu38pr6	2103	9	later	later	RB
cord-005478-5iu38pr6	2103	10	development	development	NN
cord-005478-5iu38pr6	2103	11	of	of	IN
cord-005478-5iu38pr6	2103	12	chronic	chronic	JJ
cord-005478-5iu38pr6	2103	13	graftversus	graftversus	NN
cord-005478-5iu38pr6	2103	14	-	-	HYPH
cord-005478-5iu38pr6	2103	15	host	host	NN
cord-005478-5iu38pr6	2103	16	disease	disease	NN
cord-005478-5iu38pr6	2103	17	(	(	-LRB-
cord-005478-5iu38pr6	2103	18	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2103	19	)	)	-RRB-
cord-005478-5iu38pr6	2103	20	.	.	.
cord-005478-5iu38pr6	2104	1	One	one	CD
cord-005478-5iu38pr6	2104	2	phase	phase	NN
cord-005478-5iu38pr6	2104	3	3	3	CD
cord-005478-5iu38pr6	2104	4	trial	trial	NN
cord-005478-5iu38pr6	2104	5	evaluating	evaluate	VBG
cord-005478-5iu38pr6	2104	6	ATG	ATG	NNP
cord-005478-5iu38pr6	2104	7	was	be	VBD
cord-005478-5iu38pr6	2104	8	the	the	DT
cord-005478-5iu38pr6	2104	9	Canadian	canadian	JJ
cord-005478-5iu38pr6	2104	10	BMT	BMT	NNP
cord-005478-5iu38pr6	2104	11	Group	Group	NNP
cord-005478-5iu38pr6	2104	12	(	(	-LRB-
cord-005478-5iu38pr6	2104	13	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2104	14	)	)	-RRB-
cord-005478-5iu38pr6	2104	15	0801	0801	CD
cord-005478-5iu38pr6	2104	16	study	study	NN
cord-005478-5iu38pr6	2104	17	that	that	WDT
cord-005478-5iu38pr6	2104	18	found	find	VBD
cord-005478-5iu38pr6	2104	19	that	that	IN
cord-005478-5iu38pr6	2104	20	ATG	ATG	NNP
cord-005478-5iu38pr6	2104	21	treatment	treatment	NN
cord-005478-5iu38pr6	2104	22	resulted	result	VBD
cord-005478-5iu38pr6	2104	23	in	in	IN
cord-005478-5iu38pr6	2104	24	significantly	significantly	RB
cord-005478-5iu38pr6	2104	25	less	less	JJR
cord-005478-5iu38pr6	2104	26	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2104	27	and	and	CC
cord-005478-5iu38pr6	2104	28	dependence	dependence	NN
cord-005478-5iu38pr6	2104	29	on	on	IN
cord-005478-5iu38pr6	2104	30	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2104	31	treatment	treatment	NN
cord-005478-5iu38pr6	2104	32	at	at	IN
cord-005478-5iu38pr6	2104	33	1	1	CD
cord-005478-5iu38pr6	2104	34	year	year	NN
cord-005478-5iu38pr6	2104	35	.	.	.
cord-005478-5iu38pr6	2105	1	The	the	DT
cord-005478-5iu38pr6	2105	2	exact	exact	JJ
cord-005478-5iu38pr6	2105	3	mechanism	mechanism	NN
cord-005478-5iu38pr6	2105	4	by	by	IN
cord-005478-5iu38pr6	2105	5	which	which	WDT
cord-005478-5iu38pr6	2105	6	ATG	ATG	NNP
cord-005478-5iu38pr6	2105	7	decreases	decrease	VBZ
cord-005478-5iu38pr6	2105	8	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2105	9	is	be	VBZ
cord-005478-5iu38pr6	2105	10	not	not	RB
cord-005478-5iu38pr6	2105	11	known	know	VBN
cord-005478-5iu38pr6	2105	12	.	.	.
cord-005478-5iu38pr6	2106	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2106	2	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	2106	3	that	that	IN
cord-005478-5iu38pr6	2106	4	using	use	VBG
cord-005478-5iu38pr6	2106	5	known	know	VBN
cord-005478-5iu38pr6	2106	6	prognostic	prognostic	JJ
cord-005478-5iu38pr6	2106	7	day	day	NN
cord-005478-5iu38pr6	2106	8	100	100	CD
cord-005478-5iu38pr6	2106	9	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2106	10	biomarkers	biomarker	NNS
cord-005478-5iu38pr6	2106	11	in	in	IN
cord-005478-5iu38pr6	2106	12	the	the	DT
cord-005478-5iu38pr6	2106	13	wellcontrolled	wellcontrolled	JJ
cord-005478-5iu38pr6	2106	14	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2106	15	0801	0801	CD
cord-005478-5iu38pr6	2106	16	trial	trial	NN
cord-005478-5iu38pr6	2106	17	represented	represent	VBD
cord-005478-5iu38pr6	2106	18	an	an	DT
cord-005478-5iu38pr6	2106	19	optimal	optimal	JJ
cord-005478-5iu38pr6	2106	20	approach	approach	NN
cord-005478-5iu38pr6	2106	21	to	to	TO
cord-005478-5iu38pr6	2106	22	understand	understand	VB
cord-005478-5iu38pr6	2106	23	ATG	ATG	NNP
cord-005478-5iu38pr6	2106	24	's	's	POS
cord-005478-5iu38pr6	2106	25	biological	biological	JJ
cord-005478-5iu38pr6	2106	26	impact	impact	NN
cord-005478-5iu38pr6	2106	27	on	on	IN
cord-005478-5iu38pr6	2106	28	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2106	29	in	in	IN
cord-005478-5iu38pr6	2106	30	humans	human	NNS
cord-005478-5iu38pr6	2106	31	.	.	.
cord-005478-5iu38pr6	2107	1	Methods	method	NNS
cord-005478-5iu38pr6	2107	2	:	:	:
cord-005478-5iu38pr6	2108	1	A	a	DT
cord-005478-5iu38pr6	2108	2	separately	separately	RB
cord-005478-5iu38pr6	2108	3	developed	develop	VBN
cord-005478-5iu38pr6	2108	4	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2108	5	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2108	6	biomarker	biomarker	NN
cord-005478-5iu38pr6	2108	7	study	study	NN
cord-005478-5iu38pr6	2108	8	opened	open	VBD
cord-005478-5iu38pr6	2108	9	while	while	IN
cord-005478-5iu38pr6	2108	10	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2108	11	0801	0801	CD
cord-005478-5iu38pr6	2108	12	was	be	VBD
cord-005478-5iu38pr6	2108	13	ongoing	ongoing	JJ
cord-005478-5iu38pr6	2108	14	and	and	CC
cord-005478-5iu38pr6	2108	15	accrued	accrue	VBN
cord-005478-5iu38pr6	2108	16	40	40	CD
cord-005478-5iu38pr6	2108	17	patients	patient	NNS
cord-005478-5iu38pr6	2108	18	(	(	-LRB-
cord-005478-5iu38pr6	2108	19	N	n	NN
cord-005478-5iu38pr6	2108	20	=	=	SYM
cord-005478-5iu38pr6	2108	21	25	25	CD
cord-005478-5iu38pr6	2108	22	;	;	:
cord-005478-5iu38pr6	2108	23	ATG	ATG	NNP
cord-005478-5iu38pr6	2108	24	treated	treat	VBD
cord-005478-5iu38pr6	2108	25	and	and	CC
cord-005478-5iu38pr6	2108	26	N	n	NN
cord-005478-5iu38pr6	2108	27	=	=	SYM
cord-005478-5iu38pr6	2108	28	15	15	CD
cord-005478-5iu38pr6	2108	29	controls	control	NNS
cord-005478-5iu38pr6	2108	30	)	)	-RRB-
cord-005478-5iu38pr6	2108	31	of	of	IN
cord-005478-5iu38pr6	2108	32	the	the	DT
cord-005478-5iu38pr6	2108	33	203	203	CD
cord-005478-5iu38pr6	2108	34	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2108	35	0801	0801	CD
cord-005478-5iu38pr6	2108	36	patients	patient	NNS
cord-005478-5iu38pr6	2108	37	.	.	.
cord-005478-5iu38pr6	2109	1	Samples	sample	NNS
cord-005478-5iu38pr6	2109	2	were	be	VBD
cord-005478-5iu38pr6	2109	3	collected	collect	VBN
cord-005478-5iu38pr6	2109	4	at	at	IN
cord-005478-5iu38pr6	2109	5	3	3	CD
cord-005478-5iu38pr6	2109	6	,	,	,
cord-005478-5iu38pr6	2109	7	6	6	CD
cord-005478-5iu38pr6	2109	8	,	,	,
cord-005478-5iu38pr6	2109	9	and	and	CC
cord-005478-5iu38pr6	2109	10	12	12	CD
cord-005478-5iu38pr6	2109	11	months	month	NNS
cord-005478-5iu38pr6	2109	12	and	and	CC
cord-005478-5iu38pr6	2109	13	at	at	IN
cord-005478-5iu38pr6	2109	14	the	the	DT
cord-005478-5iu38pr6	2109	15	onset	onset	NN
cord-005478-5iu38pr6	2109	16	of	of	IN
cord-005478-5iu38pr6	2109	17	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2109	18	and	and	CC
cord-005478-5iu38pr6	2109	19	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2109	20	at	at	IN
cord-005478-5iu38pr6	2109	21	BC	BC	NNP
cord-005478-5iu38pr6	2109	22	Children	Children	NNP
cord-005478-5iu38pr6	2109	23	's	's	POS
cord-005478-5iu38pr6	2109	24	'	'	``
cord-005478-5iu38pr6	2109	25	Hospital	Hospital	NNP
cord-005478-5iu38pr6	2109	26	Research	Research	NNP
cord-005478-5iu38pr6	2109	27	Institute	Institute	NNP
cord-005478-5iu38pr6	2109	28	,	,	,
cord-005478-5iu38pr6	2109	29	Vancouver	Vancouver	NNP
cord-005478-5iu38pr6	2109	30	,	,	,
cord-005478-5iu38pr6	2109	31	BC	BC	NNP
cord-005478-5iu38pr6	2109	32	.	.	.
cord-005478-5iu38pr6	2110	1	Patients	patient	NNS
cord-005478-5iu38pr6	2110	2	were	be	VBD
cord-005478-5iu38pr6	2110	3	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2110	4	for	for	IN
cord-005478-5iu38pr6	2110	5	day	day	NN
cord-005478-5iu38pr6	2110	6	100	100	CD
cord-005478-5iu38pr6	2110	7	immune	immune	JJ
cord-005478-5iu38pr6	2110	8	cellular	cellular	JJ
cord-005478-5iu38pr6	2110	9	markers	marker	NNS
cord-005478-5iu38pr6	2110	10	previously	previously	RB
cord-005478-5iu38pr6	2110	11	associated	associate	VBN
cord-005478-5iu38pr6	2110	12	with	with	IN
cord-005478-5iu38pr6	2110	13	later	later	JJ
cord-005478-5iu38pr6	2110	14	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2110	15	including	include	VBG
cord-005478-5iu38pr6	2110	16	:	:	:
cord-005478-5iu38pr6	2110	17	a	a	LS
cord-005478-5iu38pr6	2110	18	)	)	-RRB-
cord-005478-5iu38pr6	2110	19	Naive	naive	JJ
cord-005478-5iu38pr6	2110	20	helper	helper	NN
cord-005478-5iu38pr6	2110	21	T	t	NN
cord-005478-5iu38pr6	2110	22	(	(	-LRB-
cord-005478-5iu38pr6	2110	23	Th	Th	NNP
cord-005478-5iu38pr6	2110	24	)	)	-RRB-
cord-005478-5iu38pr6	2110	25	cells	cell	NNS
cord-005478-5iu38pr6	2110	26	,	,	,
cord-005478-5iu38pr6	2110	27	b	b	LS
cord-005478-5iu38pr6	2110	28	)	)	-RRB-
cord-005478-5iu38pr6	2110	29	recent	recent	JJ
cord-005478-5iu38pr6	2110	30	thymic	thymic	JJ
cord-005478-5iu38pr6	2110	31	emigrant	emigrant	NN
cord-005478-5iu38pr6	2110	32	(	(	-LRB-
cord-005478-5iu38pr6	2110	33	RTE	RTE	NNP
cord-005478-5iu38pr6	2110	34	)	)	-RRB-
cord-005478-5iu38pr6	2111	1	Th	th	DT
cord-005478-5iu38pr6	2111	2	cells	cell	NNS
cord-005478-5iu38pr6	2111	3	;	;	:
cord-005478-5iu38pr6	2111	4	c	c	LS
cord-005478-5iu38pr6	2111	5	)	)	-RRB-
cord-005478-5iu38pr6	2111	6	CD21	CD21	NNP
cord-005478-5iu38pr6	2111	7	low	low	JJ
cord-005478-5iu38pr6	2111	8	B	b	NN
cord-005478-5iu38pr6	2111	9	cells	cell	NNS
cord-005478-5iu38pr6	2111	10	;	;	:
cord-005478-5iu38pr6	2111	11	d	d	LS
cord-005478-5iu38pr6	2111	12	)	)	-RRB-
cord-005478-5iu38pr6	2111	13	CD56	cd56	NN
cord-005478-5iu38pr6	2111	14	bright	bright	JJ
cord-005478-5iu38pr6	2111	15	NKreg	NKreg	NNP
cord-005478-5iu38pr6	2111	16	cells	cell	NNS
cord-005478-5iu38pr6	2111	17	;	;	:
cord-005478-5iu38pr6	2111	18	and	and	CC
cord-005478-5iu38pr6	2111	19	e	e	LS
cord-005478-5iu38pr6	2111	20	)	)	-RRB-
cord-005478-5iu38pr6	2111	21	Treg	Treg	NNP
cord-005478-5iu38pr6	2111	22	cells	cell	NNS
cord-005478-5iu38pr6	2111	23	.	.	.
cord-005478-5iu38pr6	2112	1	Frequencies	frequency	NNS
cord-005478-5iu38pr6	2112	2	in	in	IN
cord-005478-5iu38pr6	2112	3	the	the	DT
cord-005478-5iu38pr6	2112	4	ATG	ATG	NNP
cord-005478-5iu38pr6	2112	5	treated	treat	VBD
cord-005478-5iu38pr6	2112	6	and	and	CC
cord-005478-5iu38pr6	2112	7	control	control	NN
cord-005478-5iu38pr6	2112	8	group	group	NN
cord-005478-5iu38pr6	2112	9	were	be	VBD
cord-005478-5iu38pr6	2112	10	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2112	11	to	to	TO
cord-005478-5iu38pr6	2112	12	detect	detect	VB
cord-005478-5iu38pr6	2112	13	significant	significant	JJ
cord-005478-5iu38pr6	2112	14	difference	difference	NN
cord-005478-5iu38pr6	2112	15	using	use	VBG
cord-005478-5iu38pr6	2112	16	non	non	JJ
cord-005478-5iu38pr6	2112	17	-	-	JJ
cord-005478-5iu38pr6	2112	18	parametric	parametric	JJ
cord-005478-5iu38pr6	2112	19	t	t	NN
cord-005478-5iu38pr6	2112	20	-	-	HYPH
cord-005478-5iu38pr6	2112	21	test	test	NN
cord-005478-5iu38pr6	2112	22	Mann	Mann	NNP
cord-005478-5iu38pr6	2112	23	-	-	HYPH
cord-005478-5iu38pr6	2112	24	Whitney	Whitney	NNP
cord-005478-5iu38pr6	2112	25	test	test	NN
cord-005478-5iu38pr6	2112	26	.	.	.
cord-005478-5iu38pr6	2113	1	Results	result	NNS
cord-005478-5iu38pr6	2113	2	:	:	:
cord-005478-5iu38pr6	2114	1	Patients	patient	NNS
cord-005478-5iu38pr6	2114	2	of	of	IN
cord-005478-5iu38pr6	2114	3	this	this	DT
cord-005478-5iu38pr6	2114	4	subpopulation	subpopulation	NN
cord-005478-5iu38pr6	2114	5	(	(	-LRB-
cord-005478-5iu38pr6	2114	6	aged	age	VBN
cord-005478-5iu38pr6	2114	7	16	16	CD
cord-005478-5iu38pr6	2114	8	-	-	SYM
cord-005478-5iu38pr6	2114	9	70	70	CD
cord-005478-5iu38pr6	2114	10	years	year	NNS
cord-005478-5iu38pr6	2114	11	)	)	-RRB-
cord-005478-5iu38pr6	2114	12	were	be	VBD
cord-005478-5iu38pr6	2114	13	shown	show	VBN
cord-005478-5iu38pr6	2114	14	to	to	TO
cord-005478-5iu38pr6	2114	15	be	be	VB
cord-005478-5iu38pr6	2114	16	representative	representative	JJ
cord-005478-5iu38pr6	2114	17	of	of	IN
cord-005478-5iu38pr6	2114	18	the	the	DT
cord-005478-5iu38pr6	2114	19	larger	large	JJR
cord-005478-5iu38pr6	2114	20	CBMTG	CBMTG	NNP
cord-005478-5iu38pr6	2114	21	0801	0801	CD
cord-005478-5iu38pr6	2114	22	study	study	NN
cord-005478-5iu38pr6	2114	23	population	population	NN
cord-005478-5iu38pr6	2114	24	.	.	.
cord-005478-5iu38pr6	2115	1	The	the	DT
cord-005478-5iu38pr6	2115	2	ATG	ATG	NNP
cord-005478-5iu38pr6	2115	3	treated	treat	VBN
cord-005478-5iu38pr6	2115	4	group	group	NN
cord-005478-5iu38pr6	2115	5	had	have	VBD
cord-005478-5iu38pr6	2115	6	a	a	DT
cord-005478-5iu38pr6	2115	7	significant	significant	JJ
cord-005478-5iu38pr6	2115	8	decrease	decrease	NN
cord-005478-5iu38pr6	2115	9	in	in	IN
cord-005478-5iu38pr6	2115	10	total	total	JJ
cord-005478-5iu38pr6	2115	11	T	t	NN
cord-005478-5iu38pr6	2115	12	cells	cell	NNS
cord-005478-5iu38pr6	2115	13	,	,	,
cord-005478-5iu38pr6	2116	1	RTE	RTE	NNP
cord-005478-5iu38pr6	2116	2	Th	Th	NNP
cord-005478-5iu38pr6	2116	3	cells	cell	NNS
cord-005478-5iu38pr6	2116	4	,	,	,
cord-005478-5iu38pr6	2116	5	and	and	CC
cord-005478-5iu38pr6	2116	6	naïve	naïve	JJ
cord-005478-5iu38pr6	2116	7	Th	Th	NNP
cord-005478-5iu38pr6	2116	8	cells	cell	NNS
cord-005478-5iu38pr6	2116	9	at	at	IN
cord-005478-5iu38pr6	2116	10	day	day	NN
cord-005478-5iu38pr6	2116	11	100	100	CD
cord-005478-5iu38pr6	2116	12	compared	compare	VBN
cord-005478-5iu38pr6	2116	13	to	to	IN
cord-005478-5iu38pr6	2116	14	the	the	DT
cord-005478-5iu38pr6	2116	15	control	control	NN
cord-005478-5iu38pr6	2116	16	population	population	NN
cord-005478-5iu38pr6	2116	17	(	(	-LRB-
cord-005478-5iu38pr6	2116	18	p	p	NN
cord-005478-5iu38pr6	2116	19	<	<	XX
cord-005478-5iu38pr6	2116	20	0.0001	0.0001	CD
cord-005478-5iu38pr6	2116	21	each	each	DT
cord-005478-5iu38pr6	2116	22	population	population	NN
cord-005478-5iu38pr6	2116	23	-See	-see	NN
cord-005478-5iu38pr6	2116	24	Table	Table	NNP
cord-005478-5iu38pr6	2116	25	1	1	CD
cord-005478-5iu38pr6	2116	26	)	)	-RRB-
cord-005478-5iu38pr6	2116	27	.	.	.
cord-005478-5iu38pr6	2117	1	ATG	ATG	NNP
cord-005478-5iu38pr6	2117	2	treatment	treatment	NN
cord-005478-5iu38pr6	2117	3	had	have	VBD
cord-005478-5iu38pr6	2117	4	no	no	DT
cord-005478-5iu38pr6	2117	5	impact	impact	NN
cord-005478-5iu38pr6	2117	6	on	on	IN
cord-005478-5iu38pr6	2117	7	Tregcells	Tregcells	NNP
cord-005478-5iu38pr6	2117	8	,	,	,
cord-005478-5iu38pr6	2117	9	CD19	CD19	NNP
cord-005478-5iu38pr6	2117	10	+	+	CC
cord-005478-5iu38pr6	2117	11	B	b	NN
cord-005478-5iu38pr6	2117	12	cells	cell	NNS
cord-005478-5iu38pr6	2117	13	,	,	,
cord-005478-5iu38pr6	2117	14	and	and	CC
cord-005478-5iu38pr6	2117	15	CD21lowB	cd21lowb	NN
cord-005478-5iu38pr6	2117	16	cells	cell	NNS
cord-005478-5iu38pr6	2118	1	but	but	CC
cord-005478-5iu38pr6	2118	2	there	there	EX
cord-005478-5iu38pr6	2118	3	was	be	VBD
cord-005478-5iu38pr6	2118	4	a	a	DT
cord-005478-5iu38pr6	2118	5	significant	significant	JJ
cord-005478-5iu38pr6	2118	6	increase	increase	NN
cord-005478-5iu38pr6	2118	7	in	in	IN
cord-005478-5iu38pr6	2118	8	CD56bright	CD56bright	NNP
cord-005478-5iu38pr6	2118	9	NKreg	NKreg	NNP
cord-005478-5iu38pr6	2118	10	cells	cell	NNS
cord-005478-5iu38pr6	2118	11	(	(	-LRB-
cord-005478-5iu38pr6	2118	12	p	p	NN
cord-005478-5iu38pr6	2118	13	<	<	XX
cord-005478-5iu38pr6	2118	14	0.0001	0.0001	CD
cord-005478-5iu38pr6	2118	15	)	)	-RRB-
cord-005478-5iu38pr6	2118	16	.	.	.
cord-005478-5iu38pr6	2119	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2119	2	evaluated	evaluate	VBD
cord-005478-5iu38pr6	2119	3	the	the	DT
cord-005478-5iu38pr6	2119	4	ratio	ratio	NN
cord-005478-5iu38pr6	2119	5	of	of	IN
cord-005478-5iu38pr6	2119	6	Naïve	Naïve	NNP
cord-005478-5iu38pr6	2119	7	Th	Th	NNP
cord-005478-5iu38pr6	2119	8	effector	effector	NN
cord-005478-5iu38pr6	2119	9	cells	cell	NNS
cord-005478-5iu38pr6	2119	10	to	to	IN
cord-005478-5iu38pr6	2119	11	the	the	DT
cord-005478-5iu38pr6	2119	12	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2119	13	NKregcell	NKregcell	NNP
cord-005478-5iu38pr6	2119	14	population	population	NN
cord-005478-5iu38pr6	2119	15	and	and	CC
cord-005478-5iu38pr6	2119	16	saw	see	VBD
cord-005478-5iu38pr6	2119	17	a	a	DT
cord-005478-5iu38pr6	2119	18	>	>	XX
cord-005478-5iu38pr6	2119	19	100	100	CD
cord-005478-5iu38pr6	2119	20	fold	fold	NN
cord-005478-5iu38pr6	2119	21	difference	difference	NN
cord-005478-5iu38pr6	2119	22	the	the	DT
cord-005478-5iu38pr6	2119	23	ATG	ATG	NNP
cord-005478-5iu38pr6	2119	24	treated	treat	VBN
cord-005478-5iu38pr6	2119	25	group	group	NN
cord-005478-5iu38pr6	2119	26	(	(	-LRB-
cord-005478-5iu38pr6	2119	27	Naïve	Naïve	NNP
cord-005478-5iu38pr6	2119	28	Th	Th	NNP
cord-005478-5iu38pr6	2119	29	cell	cell	NN
cord-005478-5iu38pr6	2119	30	:	:	:
cord-005478-5iu38pr6	2119	31	NKregcell	NKregcell	NNP
cord-005478-5iu38pr6	2119	32	ratio	ratio	NN
cord-005478-5iu38pr6	2119	33	=	=	SYM
cord-005478-5iu38pr6	2119	34	0.06	0.06	CD
cord-005478-5iu38pr6	2119	35	)	)	-RRB-
cord-005478-5iu38pr6	2119	36	compared	compare	VBN
cord-005478-5iu38pr6	2119	37	to	to	IN
cord-005478-5iu38pr6	2119	38	untreated	untreated	JJ
cord-005478-5iu38pr6	2119	39	patients	patient	NNS
cord-005478-5iu38pr6	2119	40	(	(	-LRB-
cord-005478-5iu38pr6	2119	41	ratio	ratio	NN
cord-005478-5iu38pr6	2119	42	of	of	IN
cord-005478-5iu38pr6	2119	43	9.2	9.2	CD
cord-005478-5iu38pr6	2119	44	;	;	:
cord-005478-5iu38pr6	2119	45	p	p	NN
cord-005478-5iu38pr6	2119	46	<	<	XX
cord-005478-5iu38pr6	2119	47	0.0001	0.0001	CD
cord-005478-5iu38pr6	2119	48	)	)	-RRB-
cord-005478-5iu38pr6	2119	49	.	.	.
cord-005478-5iu38pr6	2120	1	In	in	IN
cord-005478-5iu38pr6	2120	2	this	this	DT
cord-005478-5iu38pr6	2120	3	small	small	JJ
cord-005478-5iu38pr6	2120	4	population	population	NN
cord-005478-5iu38pr6	2120	5	we	-PRON-	PRP
cord-005478-5iu38pr6	2120	6	found	find	VBD
cord-005478-5iu38pr6	2120	7	that	that	IN
cord-005478-5iu38pr6	2120	8	the	the	DT
cord-005478-5iu38pr6	2120	9	Naïve	naïve	JJ
cord-005478-5iu38pr6	2120	10	Th	Th	NNP
cord-005478-5iu38pr6	2120	11	cell	cell	NN
cord-005478-5iu38pr6	2120	12	:	:	:
cord-005478-5iu38pr6	2120	13	NKregcell	NKregcell	NNP
cord-005478-5iu38pr6	2120	14	ratio	ratio	NN
cord-005478-5iu38pr6	2120	15	was	be	VBD
cord-005478-5iu38pr6	2120	16	also	also	RB
cord-005478-5iu38pr6	2120	17	high	high	JJ
cord-005478-5iu38pr6	2120	18	prognostic	prognostic	JJ
cord-005478-5iu38pr6	2120	19	for	for	IN
cord-005478-5iu38pr6	2120	20	later	later	JJ
cord-005478-5iu38pr6	2120	21	development	development	NN
cord-005478-5iu38pr6	2120	22	of	of	IN
cord-005478-5iu38pr6	2120	23	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2120	24	(	(	-LRB-
cord-005478-5iu38pr6	2120	25	1.37	1.37	CD
cord-005478-5iu38pr6	2120	26	vs.	vs.	IN
cord-005478-5iu38pr6	2120	27	0.13	0.13	CD
cord-005478-5iu38pr6	2120	28	;	;	:
cord-005478-5iu38pr6	2120	29	p	p	NN
cord-005478-5iu38pr6	2120	30	<	<	XX
cord-005478-5iu38pr6	2120	31	0.0001	0.0001	CD
cord-005478-5iu38pr6	2120	32	)	)	-RRB-
cord-005478-5iu38pr6	2120	33	.	.	.
cord-005478-5iu38pr6	2121	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2121	2	:	:	:
cord-005478-5iu38pr6	2122	1	These	these	DT
cord-005478-5iu38pr6	2122	2	results	result	NNS
cord-005478-5iu38pr6	2122	3	suggest	suggest	VBP
cord-005478-5iu38pr6	2122	4	that	that	IN
cord-005478-5iu38pr6	2122	5	ATG	ATG	NNP
cord-005478-5iu38pr6	2122	6	's	's	POS
cord-005478-5iu38pr6	2122	7	major	major	JJ
cord-005478-5iu38pr6	2122	8	mechanism	mechanism	NN
cord-005478-5iu38pr6	2122	9	of	of	IN
cord-005478-5iu38pr6	2122	10	action	action	NN
cord-005478-5iu38pr6	2122	11	is	be	VBZ
cord-005478-5iu38pr6	2122	12	related	relate	VBN
cord-005478-5iu38pr6	2122	13	to	to	IN
cord-005478-5iu38pr6	2122	14	its	-PRON-	PRP$
cord-005478-5iu38pr6	2122	15	ability	ability	NN
cord-005478-5iu38pr6	2122	16	to	to	TO
cord-005478-5iu38pr6	2122	17	simultaneously	simultaneously	RB
cord-005478-5iu38pr6	2122	18	inhibit	inhibit	VB
cord-005478-5iu38pr6	2122	19	Naïve	naïve	JJ
cord-005478-5iu38pr6	2122	20	Th	Th	NNP
cord-005478-5iu38pr6	2122	21	cells	cell	NNS
cord-005478-5iu38pr6	2122	22	and	and	CC
cord-005478-5iu38pr6	2122	23	enhance	enhance	VB
cord-005478-5iu38pr6	2122	24	CD56	cd56	NN
cord-005478-5iu38pr6	2122	25	bright	bright	JJ
cord-005478-5iu38pr6	2122	26	NKreg	NKreg	NNP
cord-005478-5iu38pr6	2122	27	cells	cell	NNS
cord-005478-5iu38pr6	2122	28	after	after	IN
cord-005478-5iu38pr6	2122	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	2122	30	.	.	.
cord-005478-5iu38pr6	2123	1	While	while	IN
cord-005478-5iu38pr6	2123	2	these	these	DT
cord-005478-5iu38pr6	2123	3	results	result	NNS
cord-005478-5iu38pr6	2123	4	require	require	VBP
cord-005478-5iu38pr6	2123	5	confirmation	confirmation	NN
cord-005478-5iu38pr6	2123	6	,	,	,
cord-005478-5iu38pr6	2123	7	they	-PRON-	PRP
cord-005478-5iu38pr6	2123	8	support	support	VBP
cord-005478-5iu38pr6	2123	9	strategies	strategy	NNS
cord-005478-5iu38pr6	2123	10	that	that	WDT
cord-005478-5iu38pr6	2123	11	target	target	VBP
cord-005478-5iu38pr6	2123	12	the	the	DT
cord-005478-5iu38pr6	2123	13	ratio	ratio	NN
cord-005478-5iu38pr6	2123	14	of	of	IN
cord-005478-5iu38pr6	2123	15	NK	NK	NNP
cord-005478-5iu38pr6	2123	16	reg	reg	NN
cord-005478-5iu38pr6	2123	17	cell	cell	NN
cord-005478-5iu38pr6	2123	18	and	and	CC
cord-005478-5iu38pr6	2123	19	Naive	Naive	NNP
cord-005478-5iu38pr6	2123	20	CD4	CD4	NNP
cord-005478-5iu38pr6	2123	21	+	+	CC
cord-005478-5iu38pr6	2123	22	T	t	NN
cord-005478-5iu38pr6	2123	23	cells	cell	NNS
cord-005478-5iu38pr6	2123	24	to	to	TO
cord-005478-5iu38pr6	2123	25	modulate	modulate	VB
cord-005478-5iu38pr6	2123	26	cGvHD	cGvHD	NNS
cord-005478-5iu38pr6	2123	27	.	.	.
cord-005478-5iu38pr6	2124	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2124	2	Trial	Trial	NNP
cord-005478-5iu38pr6	2124	3	Registry	Registry	NNP
cord-005478-5iu38pr6	2124	4	:	:	:
cord-005478-5iu38pr6	2125	1	NCT01217723	NCT01217723	NNP
cord-005478-5iu38pr6	2126	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2126	2	:	:	:
cord-005478-5iu38pr6	2127	1	None	none	NN
cord-005478-5iu38pr6	2127	2	of	of	IN
cord-005478-5iu38pr6	2127	3	the	the	DT
cord-005478-5iu38pr6	2127	4	Authors	author	NNS
cord-005478-5iu38pr6	2127	5	have	have	VBP
cord-005478-5iu38pr6	2127	6	any	any	DT
cord-005478-5iu38pr6	2127	7	conflicts	conflict	NNS
cord-005478-5iu38pr6	2127	8	of	of	IN
cord-005478-5iu38pr6	2127	9	interest	interest	NN
cord-005478-5iu38pr6	2127	10	to	to	TO
cord-005478-5iu38pr6	2127	11	declare	declare	VB
cord-005478-5iu38pr6	2128	1	O105	O105	NNP
cord-005478-5iu38pr6	2128	2	Immune	Immune	NNP
cord-005478-5iu38pr6	2128	3	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2128	4	-based	-based	JJ
cord-005478-5iu38pr6	2128	5	score	score	NN
cord-005478-5iu38pr6	2128	6	at	at	IN
cord-005478-5iu38pr6	2128	7	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2128	8	of	of	IN
cord-005478-5iu38pr6	2128	9	CGVHD	CGVHD	NNP
cord-005478-5iu38pr6	2128	10	predicts	predict	VBZ
cord-005478-5iu38pr6	2128	11	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2128	12	severity	severity	NN
cord-005478-5iu38pr6	2128	13	and	and	CC
cord-005478-5iu38pr6	2128	14	overall	overall	JJ
cord-005478-5iu38pr6	2128	15	-	-	HYPH
cord-005478-5iu38pr6	2128	16	survival	survival	NN
cord-005478-5iu38pr6	2128	17	:	:	:
cord-005478-5iu38pr6	2128	18	A	a	DT
cord-005478-5iu38pr6	2128	19	novel	novel	JJ
cord-005478-5iu38pr6	2128	20	prognostication	prognostication	NN
cord-005478-5iu38pr6	2128	21	tool	tool	NN
cord-005478-5iu38pr6	2128	22	for	for	IN
cord-005478-5iu38pr6	2128	23	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2128	24	treatment	treatment	NN
cord-005478-5iu38pr6	2128	25	tailoring	tailor	VBG
cord-005478-5iu38pr6	2128	26	Background	background	NN
cord-005478-5iu38pr6	2128	27	:	:	:
cord-005478-5iu38pr6	2129	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2129	2	stem	stem	VBP
cord-005478-5iu38pr6	2129	3	cell	cell	NN
cord-005478-5iu38pr6	2129	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2129	5	(	(	-LRB-
cord-005478-5iu38pr6	2129	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2129	7	)	)	-RRB-
cord-005478-5iu38pr6	2130	1	survivors	survivor	NNS
cord-005478-5iu38pr6	2130	2	are	be	VBP
cord-005478-5iu38pr6	2130	3	at	at	IN
cord-005478-5iu38pr6	2130	4	a	a	DT
cord-005478-5iu38pr6	2130	5	relevant	relevant	JJ
cord-005478-5iu38pr6	2130	6	risk	risk	NN
cord-005478-5iu38pr6	2130	7	of	of	IN
cord-005478-5iu38pr6	2130	8	developing	develop	VBG
cord-005478-5iu38pr6	2130	9	chronic	chronic	JJ
cord-005478-5iu38pr6	2130	10	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2130	11	(	(	-LRB-
cord-005478-5iu38pr6	2130	12	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2130	13	)	)	-RRB-
cord-005478-5iu38pr6	2130	14	,	,	,
cord-005478-5iu38pr6	2130	15	which	which	WDT
cord-005478-5iu38pr6	2130	16	importantly	importantly	RB
cord-005478-5iu38pr6	2130	17	affects	affect	VBZ
cord-005478-5iu38pr6	2130	18	quality	quality	NN
cord-005478-5iu38pr6	2130	19	of	of	IN
cord-005478-5iu38pr6	2130	20	life	life	NN
cord-005478-5iu38pr6	2130	21	and	and	CC
cord-005478-5iu38pr6	2130	22	increases	increase	VBZ
cord-005478-5iu38pr6	2130	23	morbidity	morbidity	NN
cord-005478-5iu38pr6	2130	24	and	and	CC
cord-005478-5iu38pr6	2130	25	mortality	mortality	NN
cord-005478-5iu38pr6	2130	26	.	.	.
cord-005478-5iu38pr6	2131	1	Early	early	JJ
cord-005478-5iu38pr6	2131	2	identification	identification	NN
cord-005478-5iu38pr6	2131	3	of	of	IN
cord-005478-5iu38pr6	2131	4	patients	patient	NNS
cord-005478-5iu38pr6	2131	5	at	at	IN
cord-005478-5iu38pr6	2131	6	risk	risk	NN
cord-005478-5iu38pr6	2131	7	of	of	IN
cord-005478-5iu38pr6	2131	8	development	development	NN
cord-005478-5iu38pr6	2131	9	of	of	IN
cord-005478-5iu38pr6	2131	10	severe	severe	JJ
cord-005478-5iu38pr6	2131	11	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2131	12	related	relate	VBN
cord-005478-5iu38pr6	2131	13	morbidity	morbidity	NN
cord-005478-5iu38pr6	2131	14	would	would	MD
cord-005478-5iu38pr6	2131	15	be	be	VB
cord-005478-5iu38pr6	2131	16	a	a	DT
cord-005478-5iu38pr6	2131	17	relevant	relevant	JJ
cord-005478-5iu38pr6	2131	18	tool	tool	NN
cord-005478-5iu38pr6	2131	19	to	to	TO
cord-005478-5iu38pr6	2131	20	tailor	tailor	VB
cord-005478-5iu38pr6	2131	21	preventive	preventive	JJ
cord-005478-5iu38pr6	2131	22	strategies	strategy	NNS
cord-005478-5iu38pr6	2131	23	.	.	.
cord-005478-5iu38pr6	2132	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2132	2	have	have	VBP
cord-005478-5iu38pr6	2132	3	previously	previously	RB
cord-005478-5iu38pr6	2132	4	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	2132	5	the	the	DT
cord-005478-5iu38pr6	2132	6	role	role	NN
cord-005478-5iu38pr6	2132	7	of	of	IN
cord-005478-5iu38pr6	2132	8	immune	immune	JJ
cord-005478-5iu38pr6	2132	9	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2132	10	(	(	-LRB-
cord-005478-5iu38pr6	2132	11	IR	IR	NNP
cord-005478-5iu38pr6	2132	12	)	)	-RRB-
cord-005478-5iu38pr6	2132	13	as	as	IN
cord-005478-5iu38pr6	2132	14	predictive	predictive	JJ
cord-005478-5iu38pr6	2132	15	biomarker	biomarker	NN
cord-005478-5iu38pr6	2132	16	of	of	IN
cord-005478-5iu38pr6	2132	17	occurrence	occurrence	NN
cord-005478-5iu38pr6	2132	18	of	of	IN
cord-005478-5iu38pr6	2132	19	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2132	20	.	.	.
cord-005478-5iu38pr6	2133	1	The	the	DT
cord-005478-5iu38pr6	2133	2	aim	aim	NN
cord-005478-5iu38pr6	2133	3	of	of	IN
cord-005478-5iu38pr6	2133	4	this	this	DT
cord-005478-5iu38pr6	2133	5	study	study	NN
cord-005478-5iu38pr6	2133	6	was	be	VBD
cord-005478-5iu38pr6	2133	7	to	to	TO
cord-005478-5iu38pr6	2133	8	evaluate	evaluate	VB
cord-005478-5iu38pr6	2133	9	the	the	DT
cord-005478-5iu38pr6	2133	10	prognostication	prognostication	NN
cord-005478-5iu38pr6	2133	11	power	power	NN
cord-005478-5iu38pr6	2133	12	of	of	IN
cord-005478-5iu38pr6	2133	13	IR	IR	NNP
cord-005478-5iu38pr6	2133	14	at	at	IN
cord-005478-5iu38pr6	2133	15	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2133	16	onset	onset	NN
cord-005478-5iu38pr6	2133	17	through	through	IN
cord-005478-5iu38pr6	2133	18	a	a	DT
cord-005478-5iu38pr6	2133	19	new	new	JJ
cord-005478-5iu38pr6	2133	20	IR	IR	NNP
cord-005478-5iu38pr6	2133	21	-	-	HYPH
cord-005478-5iu38pr6	2133	22	based	base	VBN
cord-005478-5iu38pr6	2133	23	score	score	NN
cord-005478-5iu38pr6	2133	24	.	.	.
cord-005478-5iu38pr6	2134	1	Methods	method	NNS
cord-005478-5iu38pr6	2134	2	:	:	:
cord-005478-5iu38pr6	2134	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2134	4	analyzed	analyze	VBD
cord-005478-5iu38pr6	2134	5	clinical	clinical	JJ
cord-005478-5iu38pr6	2134	6	data	datum	NNS
cord-005478-5iu38pr6	2134	7	from	from	IN
cord-005478-5iu38pr6	2134	8	383	383	CD
cord-005478-5iu38pr6	2134	9	adult	adult	NN
cord-005478-5iu38pr6	2134	10	patients	patient	NNS
cord-005478-5iu38pr6	2134	11	consecutively	consecutively	RB
cord-005478-5iu38pr6	2134	12	undergoing	undergo	VBG
cord-005478-5iu38pr6	2134	13	first	first	JJ
cord-005478-5iu38pr6	2134	14	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2134	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2134	16	transplant	transplant	NN
cord-005478-5iu38pr6	2134	17	between	between	IN
cord-005478-5iu38pr6	2134	18	January	January	NNP
cord-005478-5iu38pr6	2134	19	2011	2011	CD
cord-005478-5iu38pr6	2134	20	and	and	CC
cord-005478-5iu38pr6	2134	21	December	December	NNP
cord-005478-5iu38pr6	2134	22	2016	2016	CD
cord-005478-5iu38pr6	2134	23	at	at	IN
cord-005478-5iu38pr6	2134	24	our	-PRON-	PRP$
cord-005478-5iu38pr6	2134	25	Institution	Institution	NNP
cord-005478-5iu38pr6	2134	26	.	.	.
cord-005478-5iu38pr6	2135	1	A	a	DT
cord-005478-5iu38pr6	2135	2	written	write	VBN
cord-005478-5iu38pr6	2135	3	consent	consent	NN
cord-005478-5iu38pr6	2135	4	was	be	VBD
cord-005478-5iu38pr6	2135	5	given	give	VBN
cord-005478-5iu38pr6	2135	6	for	for	IN
cord-005478-5iu38pr6	2135	7	the	the	DT
cord-005478-5iu38pr6	2135	8	use	use	NN
cord-005478-5iu38pr6	2135	9	of	of	IN
cord-005478-5iu38pr6	2135	10	medical	medical	JJ
cord-005478-5iu38pr6	2135	11	records	record	NNS
cord-005478-5iu38pr6	2135	12	for	for	IN
cord-005478-5iu38pr6	2135	13	research	research	NN
cord-005478-5iu38pr6	2135	14	.	.	.
cord-005478-5iu38pr6	2136	1	Patients	patient	NNS
cord-005478-5iu38pr6	2136	2	were	be	VBD
cord-005478-5iu38pr6	2136	3	divided	divide	VBN
cord-005478-5iu38pr6	2136	4	into	into	IN
cord-005478-5iu38pr6	2136	5	a	a	DT
cord-005478-5iu38pr6	2136	6	test	test	NN
cord-005478-5iu38pr6	2136	7	cohort	cohort	NN
cord-005478-5iu38pr6	2136	8	(	(	-LRB-
cord-005478-5iu38pr6	2136	9	307	307	CD
cord-005478-5iu38pr6	2136	10	pts	pts	CD
cord-005478-5iu38pr6	2136	11	)	)	-RRB-
cord-005478-5iu38pr6	2136	12	and	and	CC
cord-005478-5iu38pr6	2136	13	a	a	DT
cord-005478-5iu38pr6	2136	14	validation	validation	NN
cord-005478-5iu38pr6	2136	15	cohort	cohort	NN
cord-005478-5iu38pr6	2136	16	(	(	-LRB-
cord-005478-5iu38pr6	2136	17	76	76	CD
cord-005478-5iu38pr6	2136	18	pts	pts	CD
cord-005478-5iu38pr6	2136	19	)	)	-RRB-
cord-005478-5iu38pr6	2136	20	.	.	.
cord-005478-5iu38pr6	2137	1	Median	median	JJ
cord-005478-5iu38pr6	2137	2	follow	follow	NN
cord-005478-5iu38pr6	2137	3	-	-	HYPH
cord-005478-5iu38pr6	2137	4	up	up	NN
cord-005478-5iu38pr6	2137	5	for	for	IN
cord-005478-5iu38pr6	2137	6	surviving	survive	VBG
cord-005478-5iu38pr6	2137	7	patients	patient	NNS
cord-005478-5iu38pr6	2137	8	was	be	VBD
cord-005478-5iu38pr6	2137	9	4	4	CD
cord-005478-5iu38pr6	2137	10	years	year	NNS
cord-005478-5iu38pr6	2137	11	.	.	.
cord-005478-5iu38pr6	2138	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2138	2	built	build	VBD
cord-005478-5iu38pr6	2138	3	a	a	DT
cord-005478-5iu38pr6	2138	4	Cox	Cox	NNP
cord-005478-5iu38pr6	2138	5	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2138	6	models	model	NNS
cord-005478-5iu38pr6	2138	7	for	for	IN
cord-005478-5iu38pr6	2138	8	OS	OS	NNP
cord-005478-5iu38pr6	2138	9	in	in	IN
cord-005478-5iu38pr6	2138	10	patients	patient	NNS
cord-005478-5iu38pr6	2138	11	with	with	IN
cord-005478-5iu38pr6	2138	12	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2138	13	of	of	IN
cord-005478-5iu38pr6	2138	14	any	any	DT
cord-005478-5iu38pr6	2138	15	severity	severity	NN
cord-005478-5iu38pr6	2138	16	.	.	.
cord-005478-5iu38pr6	2139	1	Variables	variable	NNS
cord-005478-5iu38pr6	2139	2	included	include	VBN
cord-005478-5iu38pr6	2139	3	in	in	IN
cord-005478-5iu38pr6	2139	4	the	the	DT
cord-005478-5iu38pr6	2139	5	models	model	NNS
cord-005478-5iu38pr6	2139	6	were	be	VBD
cord-005478-5iu38pr6	2139	7	:	:	:
cord-005478-5iu38pr6	2139	8	patient	patient	JJ
cord-005478-5iu38pr6	2139	9	age	age	NN
cord-005478-5iu38pr6	2139	10	(	(	-LRB-
cord-005478-5iu38pr6	2139	11	according	accord	VBG
cord-005478-5iu38pr6	2139	12	to	to	IN
cord-005478-5iu38pr6	2139	13	median	median	JJ
cord-005478-5iu38pr6	2139	14	value	value	NN
cord-005478-5iu38pr6	2139	15	)	)	-RRB-
cord-005478-5iu38pr6	2140	1	,	,	,
cord-005478-5iu38pr6	2140	2	R	r	NN
cord-005478-5iu38pr6	2140	3	-	-	HYPH
cord-005478-5iu38pr6	2140	4	DRI	dri	NN
cord-005478-5iu38pr6	2140	5	score	score	NN
cord-005478-5iu38pr6	2140	6	,	,	,
cord-005478-5iu38pr6	2140	7	type	type	NN
cord-005478-5iu38pr6	2140	8	of	of	IN
cord-005478-5iu38pr6	2140	9	donor	donor	NN
cord-005478-5iu38pr6	2140	10	(	(	-LRB-
cord-005478-5iu38pr6	2140	11	matched	match	VBN
cord-005478-5iu38pr6	2140	12	related	related	JJ
cord-005478-5iu38pr6	2140	13	donor	donor	NN
cord-005478-5iu38pr6	2140	14	vs	vs	IN
cord-005478-5iu38pr6	2140	15	matched	match	VBN
cord-005478-5iu38pr6	2140	16	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2140	17	vs	vs	IN
cord-005478-5iu38pr6	2140	18	haploidentical	haploidentical	NNP
cord-005478-5iu38pr6	2140	19	)	)	-RRB-
cord-005478-5iu38pr6	2140	20	,	,	,
cord-005478-5iu38pr6	2140	21	main	main	JJ
cord-005478-5iu38pr6	2140	22	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2140	23	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2140	24	platform	platform	NN
cord-005478-5iu38pr6	2140	25	(	(	-LRB-
cord-005478-5iu38pr6	2140	26	ATG	ATG	NNP
cord-005478-5iu38pr6	2140	27	-	-	HYPH
cord-005478-5iu38pr6	2140	28	based	base	VBN
cord-005478-5iu38pr6	2140	29	vs	vs	IN
cord-005478-5iu38pr6	2140	30	PtCy	ptcy	RB
cord-005478-5iu38pr6	2140	31	-	-	HYPH
cord-005478-5iu38pr6	2140	32	based	base	VBN
cord-005478-5iu38pr6	2140	33	vs	vs	IN
cord-005478-5iu38pr6	2140	34	neither	neither	DT
cord-005478-5iu38pr6	2140	35	of	of	IN
cord-005478-5iu38pr6	2140	36	the	the	DT
cord-005478-5iu38pr6	2140	37	two	two	CD
cord-005478-5iu38pr6	2140	38	)	)	-RRB-
cord-005478-5iu38pr6	2140	39	,	,	,
cord-005478-5iu38pr6	2140	40	IR	IR	NNP
cord-005478-5iu38pr6	2140	41	values	value	NNS
cord-005478-5iu38pr6	2140	42	(	(	-LRB-
cord-005478-5iu38pr6	2140	43	CD4	CD4	NNP
cord-005478-5iu38pr6	2140	44	,	,	,
cord-005478-5iu38pr6	2140	45	CD19	CD19	NNP
cord-005478-5iu38pr6	2140	46	,	,	,
cord-005478-5iu38pr6	2140	47	NK	NK	NNP
cord-005478-5iu38pr6	2140	48	,	,	,
cord-005478-5iu38pr6	2140	49	IgA	IgA	NNP
cord-005478-5iu38pr6	2140	50	,	,	,
cord-005478-5iu38pr6	2140	51	IgM	IgM	NNP
cord-005478-5iu38pr6	2140	52	according	accord	VBG
cord-005478-5iu38pr6	2140	53	to	to	IN
cord-005478-5iu38pr6	2140	54	median	median	JJ
cord-005478-5iu38pr6	2140	55	values	value	NNS
cord-005478-5iu38pr6	2140	56	)	)	-RRB-
cord-005478-5iu38pr6	2140	57	at	at	IN
cord-005478-5iu38pr6	2140	58	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2140	59	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2140	60	,	,	,
cord-005478-5iu38pr6	2140	61	history	history	NN
cord-005478-5iu38pr6	2140	62	of	of	IN
cord-005478-5iu38pr6	2140	63	prior	prior	JJ
cord-005478-5iu38pr6	2140	64	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2140	65	,	,	,
cord-005478-5iu38pr6	2140	66	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	2140	67	PS	PS	NNP
cord-005478-5iu38pr6	2140	68	,	,	,
cord-005478-5iu38pr6	2141	1	Plt	Plt	NNP
cord-005478-5iu38pr6	2141	2	<	<	XX
cord-005478-5iu38pr6	2142	1	100.000	100.000	CD
cord-005478-5iu38pr6	2142	2	/	/	SYM
cord-005478-5iu38pr6	2142	3	μL	μL	NNP
cord-005478-5iu38pr6	2142	4	,	,	,
cord-005478-5iu38pr6	2143	1	ALC	ALC	NNP
cord-005478-5iu38pr6	2143	2	<	<	XX
cord-005478-5iu38pr6	2144	1	1000	1000	CD
cord-005478-5iu38pr6	2145	1	/μL	/μL	NFP
cord-005478-5iu38pr6	2145	2	,	,	,
cord-005478-5iu38pr6	2146	1	Eos	Eos	NNP
cord-005478-5iu38pr6	2146	2	<	<	XX
cord-005478-5iu38pr6	2146	3	500/	500/	NNP
cord-005478-5iu38pr6	2147	1	μL.Once	μl.once	IN
cord-005478-5iu38pr6	2147	2	we	-PRON-	PRP
cord-005478-5iu38pr6	2147	3	identified	identify	VBD
cord-005478-5iu38pr6	2147	4	the	the	DT
cord-005478-5iu38pr6	2147	5	variables	variable	NNS
cord-005478-5iu38pr6	2147	6	independently	independently	RB
cord-005478-5iu38pr6	2147	7	predicting	predict	VBG
cord-005478-5iu38pr6	2147	8	OS	OS	NNP
cord-005478-5iu38pr6	2147	9	by	by	IN
cord-005478-5iu38pr6	2147	10	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2147	11	analysis	analysis	NN
cord-005478-5iu38pr6	2147	12	,	,	,
cord-005478-5iu38pr6	2147	13	we	-PRON-	PRP
cord-005478-5iu38pr6	2147	14	derived	derive	VBD
cord-005478-5iu38pr6	2147	15	a	a	DT
cord-005478-5iu38pr6	2147	16	formula	formula	NN
cord-005478-5iu38pr6	2147	17	for	for	IN
cord-005478-5iu38pr6	2147	18	a	a	DT
cord-005478-5iu38pr6	2147	19	prognostic	prognostic	JJ
cord-005478-5iu38pr6	2147	20	risk	risk	NN
cord-005478-5iu38pr6	2147	21	index	index	NN
cord-005478-5iu38pr6	2147	22	by	by	IN
cord-005478-5iu38pr6	2147	23	using	use	VBG
cord-005478-5iu38pr6	2147	24	the	the	DT
cord-005478-5iu38pr6	2147	25	β	β	NN
cord-005478-5iu38pr6	2147	26	coefficients	coefficient	NNS
cord-005478-5iu38pr6	2147	27	found	find	VBN
cord-005478-5iu38pr6	2147	28	in	in	IN
cord-005478-5iu38pr6	2147	29	the	the	DT
cord-005478-5iu38pr6	2147	30	model	model	NN
cord-005478-5iu38pr6	2147	31	.	.	.
cord-005478-5iu38pr6	2148	1	Each	each	DT
cord-005478-5iu38pr6	2148	2	patient	patient	NN
cord-005478-5iu38pr6	2148	3	was	be	VBD
cord-005478-5iu38pr6	2148	4	then	then	RB
cord-005478-5iu38pr6	2148	5	assigned	assign	VBN
cord-005478-5iu38pr6	2148	6	a	a	DT
cord-005478-5iu38pr6	2148	7	score	score	NN
cord-005478-5iu38pr6	2149	1	and	and	CC
cord-005478-5iu38pr6	2149	2	we	-PRON-	PRP
cord-005478-5iu38pr6	2149	3	defined	define	VBD
cord-005478-5iu38pr6	2149	4	three	three	CD
cord-005478-5iu38pr6	2149	5	groups	group	NNS
cord-005478-5iu38pr6	2149	6	of	of	IN
cord-005478-5iu38pr6	2149	7	OS	OS	NNP
cord-005478-5iu38pr6	2149	8	risk	risk	NN
cord-005478-5iu38pr6	2149	9	(	(	-LRB-
cord-005478-5iu38pr6	2149	10	low	low	JJ
cord-005478-5iu38pr6	2149	11	,	,	,
cord-005478-5iu38pr6	2149	12	intermediate	intermediate	JJ
cord-005478-5iu38pr6	2149	13	and	and	CC
cord-005478-5iu38pr6	2149	14	high	high	JJ
cord-005478-5iu38pr6	2149	15	)	)	-RRB-
cord-005478-5iu38pr6	2149	16	by	by	IN
cord-005478-5iu38pr6	2149	17	dividing	divide	VBG
cord-005478-5iu38pr6	2149	18	the	the	DT
cord-005478-5iu38pr6	2149	19	score	score	NN
cord-005478-5iu38pr6	2149	20	into	into	IN
cord-005478-5iu38pr6	2149	21	three	three	CD
cord-005478-5iu38pr6	2149	22	classes	class	NNS
cord-005478-5iu38pr6	2149	23	using	use	VBG
cord-005478-5iu38pr6	2149	24	the	the	DT
cord-005478-5iu38pr6	2149	25	first	first	JJ
cord-005478-5iu38pr6	2149	26	and	and	CC
cord-005478-5iu38pr6	2149	27	third	third	JJ
cord-005478-5iu38pr6	2149	28	quartiles	quartile	NNS
cord-005478-5iu38pr6	2149	29	.	.	.
cord-005478-5iu38pr6	2150	1	Finally	finally	RB
cord-005478-5iu38pr6	2150	2	,	,	,
cord-005478-5iu38pr6	2150	3	to	to	TO
cord-005478-5iu38pr6	2150	4	evaluate	evaluate	VB
cord-005478-5iu38pr6	2150	5	predictive	predictive	JJ
cord-005478-5iu38pr6	2150	6	performance	performance	NN
cord-005478-5iu38pr6	2150	7	of	of	IN
cord-005478-5iu38pr6	2150	8	the	the	DT
cord-005478-5iu38pr6	2150	9	IR	IR	NNP
cord-005478-5iu38pr6	2150	10	-	-	HYPH
cord-005478-5iu38pr6	2150	11	score	score	NN
cord-005478-5iu38pr6	2150	12	we	-PRON-	PRP
cord-005478-5iu38pr6	2150	13	calculated	calculate	VBD
cord-005478-5iu38pr6	2150	14	the	the	DT
cord-005478-5iu38pr6	2150	15	receiver	receiver	NN
cord-005478-5iu38pr6	2150	16	operating	operate	VBG
cord-005478-5iu38pr6	2150	17	characteristics	characteristic	NNS
cord-005478-5iu38pr6	2150	18	(	(	-LRB-
cord-005478-5iu38pr6	2150	19	ROC	ROC	NNP
cord-005478-5iu38pr6	2150	20	)	)	-RRB-
cord-005478-5iu38pr6	2150	21	curve	curve	NN
cord-005478-5iu38pr6	2150	22	via	via	IN
cord-005478-5iu38pr6	2150	23	the	the	DT
cord-005478-5iu38pr6	2150	24	area	area	NN
cord-005478-5iu38pr6	2150	25	under	under	IN
cord-005478-5iu38pr6	2150	26	the	the	DT
cord-005478-5iu38pr6	2150	27	curve	curve	NN
cord-005478-5iu38pr6	2150	28	(	(	-LRB-
cord-005478-5iu38pr6	2150	29	AUC	AUC	NNP
cord-005478-5iu38pr6	2150	30	)	)	-RRB-
cord-005478-5iu38pr6	2150	31	,	,	,
cord-005478-5iu38pr6	2150	32	to	to	TO
cord-005478-5iu38pr6	2150	33	summarize	summarize	VB
cord-005478-5iu38pr6	2150	34	the	the	DT
cord-005478-5iu38pr6	2150	35	IR	IR	NNP
cord-005478-5iu38pr6	2150	36	-	-	HYPH
cord-005478-5iu38pr6	2150	37	score	score	NN
cord-005478-5iu38pr6	2150	38	ability	ability	NN
cord-005478-5iu38pr6	2150	39	to	to	TO
cord-005478-5iu38pr6	2150	40	correctly	correctly	RB
cord-005478-5iu38pr6	2150	41	classify	classify	VB
cord-005478-5iu38pr6	2150	42	events	event	NNS
cord-005478-5iu38pr6	2150	43	and	and	CC
cord-005478-5iu38pr6	2150	44	non	non	NNS
cord-005478-5iu38pr6	2150	45	-	-	NNS
cord-005478-5iu38pr6	2150	46	events	event	NNS
cord-005478-5iu38pr6	2150	47	.	.	.
cord-005478-5iu38pr6	2151	1	Results	result	NNS
cord-005478-5iu38pr6	2151	2	:	:	:
cord-005478-5iu38pr6	2152	1	115	115	CD
cord-005478-5iu38pr6	2152	2	patients	patient	NNS
cord-005478-5iu38pr6	2152	3	(	(	-LRB-
cord-005478-5iu38pr6	2152	4	87	87	CD
cord-005478-5iu38pr6	2152	5	test	test	NN
cord-005478-5iu38pr6	2152	6	-	-	HYPH
cord-005478-5iu38pr6	2152	7	cohort	cohort	NN
cord-005478-5iu38pr6	2152	8	,	,	,
cord-005478-5iu38pr6	2152	9	28	28	CD
cord-005478-5iu38pr6	2152	10	validationcohort	validationcohort	NN
cord-005478-5iu38pr6	2152	11	)	)	-RRB-
cord-005478-5iu38pr6	2152	12	were	be	VBD
cord-005478-5iu38pr6	2152	13	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2152	14	for	for	IN
cord-005478-5iu38pr6	2152	15	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2152	16	and	and	CC
cord-005478-5iu38pr6	2152	17	outcome	outcome	NN
cord-005478-5iu38pr6	2152	18	.	.	.
cord-005478-5iu38pr6	2153	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2153	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2153	3	model	model	NN
cord-005478-5iu38pr6	2153	4	defined	define	VBD
cord-005478-5iu38pr6	2153	5	the	the	DT
cord-005478-5iu38pr6	2153	6	variables	variable	NNS
cord-005478-5iu38pr6	2153	7	independently	independently	RB
cord-005478-5iu38pr6	2153	8	predicting	predict	VBG
cord-005478-5iu38pr6	2153	9	OS	OS	NNP
cord-005478-5iu38pr6	2153	10	at	at	IN
cord-005478-5iu38pr6	2153	11	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2153	12	onset	onset	NN
cord-005478-5iu38pr6	2153	13	:	:	:
cord-005478-5iu38pr6	2154	1	CD4	CD4	NNP
cord-005478-5iu38pr6	2154	2	+	+	CC
cord-005478-5iu38pr6	2154	3	count	count	NN
cord-005478-5iu38pr6	2154	4	>	>	XX
cord-005478-5iu38pr6	2155	1	233/	233/	CD
cord-005478-5iu38pr6	2155	2	mcl	mcl	NNP
cord-005478-5iu38pr6	2155	3	,	,	,
cord-005478-5iu38pr6	2156	1	NK	NK	NNP
cord-005478-5iu38pr6	2156	2	count	count	VB
cord-005478-5iu38pr6	2156	3	<	<	XX
cord-005478-5iu38pr6	2156	4	115	115	CD
cord-005478-5iu38pr6	2156	5	/	/	SYM
cord-005478-5iu38pr6	2156	6	mcl	mcl	NNP
cord-005478-5iu38pr6	2156	7	,	,	,
cord-005478-5iu38pr6	2156	8	IgM	IgM	NNP
cord-005478-5iu38pr6	2156	9	<	<	XX
cord-005478-5iu38pr6	2156	10	0.45	0.45	CD
cord-005478-5iu38pr6	2156	11	g	g	NNP
cord-005478-5iu38pr6	2156	12	/	/	SYM
cord-005478-5iu38pr6	2156	13	L	L	NNP
cord-005478-5iu38pr6	2156	14	,	,	,
cord-005478-5iu38pr6	2156	15	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	2156	16	PS	PS	NNP
cord-005478-5iu38pr6	2156	17	<	<	XX
cord-005478-5iu38pr6	2156	18	80	80	CD
cord-005478-5iu38pr6	2156	19	%	%	NN
cord-005478-5iu38pr6	2156	20	.	.	.
cord-005478-5iu38pr6	2157	1	Final	final	JJ
cord-005478-5iu38pr6	2157	2	score	score	NN
cord-005478-5iu38pr6	2157	3	was	be	VBD
cord-005478-5iu38pr6	2157	4	calculated	calculate	VBN
cord-005478-5iu38pr6	2157	5	as	as	IN
cord-005478-5iu38pr6	2157	6	follows	follow	VBZ
cord-005478-5iu38pr6	2157	7	:	:	:
cord-005478-5iu38pr6	2157	8	2,4	2,4	LS
cord-005478-5iu38pr6	2157	9	(	(	-LRB-
cord-005478-5iu38pr6	2157	10	if	if	IN
cord-005478-5iu38pr6	2157	11	CD4	CD4	NNP
cord-005478-5iu38pr6	2157	12	>	>	XX
cord-005478-5iu38pr6	2157	13	233/	233/	CD
cord-005478-5iu38pr6	2157	14	mcL	mcl	NN
cord-005478-5iu38pr6	2157	15	)	)	-RRB-
cord-005478-5iu38pr6	2158	1	+	+	CC
cord-005478-5iu38pr6	2158	2	2,1	2,1	CD
cord-005478-5iu38pr6	2158	3	(	(	-LRB-
cord-005478-5iu38pr6	2158	4	if	if	IN
cord-005478-5iu38pr6	2158	5	NK	NK	NNP
cord-005478-5iu38pr6	2158	6	<	<	XX
cord-005478-5iu38pr6	2158	7	115	115	CD
cord-005478-5iu38pr6	2158	8	/	/	SYM
cord-005478-5iu38pr6	2158	9	mcL	mcl	NN
cord-005478-5iu38pr6	2158	10	)	)	-RRB-
cord-005478-5iu38pr6	2159	1	+	+	CC
cord-005478-5iu38pr6	2159	2	2,1	2,1	CD
cord-005478-5iu38pr6	2159	3	(	(	-LRB-
cord-005478-5iu38pr6	2159	4	if	if	IN
cord-005478-5iu38pr6	2159	5	IgM	IgM	NNP
cord-005478-5iu38pr6	2159	6	<	<	XX
cord-005478-5iu38pr6	2159	7	0,45	0,45	CD
cord-005478-5iu38pr6	2159	8	)	)	-RRB-
cord-005478-5iu38pr6	2160	1	+	+	CC
cord-005478-5iu38pr6	2160	2	4,3	4,3	CD
cord-005478-5iu38pr6	2160	3	(	(	-LRB-
cord-005478-5iu38pr6	2160	4	if	if	IN
cord-005478-5iu38pr6	2160	5	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	2160	6	<	<	XX
cord-005478-5iu38pr6	2160	7	80	80	CD
cord-005478-5iu38pr6	2160	8	)	)	-RRB-
cord-005478-5iu38pr6	2160	9	.	.	.
cord-005478-5iu38pr6	2161	1	Low	low	JJ
cord-005478-5iu38pr6	2161	2	risk	risk	NN
cord-005478-5iu38pr6	2161	3	patients	patient	NNS
cord-005478-5iu38pr6	2161	4	were	be	VBD
cord-005478-5iu38pr6	2161	5	defined	define	VBN
cord-005478-5iu38pr6	2161	6	as	as	IN
cord-005478-5iu38pr6	2161	7	having	have	VBG
cord-005478-5iu38pr6	2161	8	a	a	DT
cord-005478-5iu38pr6	2161	9	score	score	NN
cord-005478-5iu38pr6	2161	10	≤2.4	≤2.4	NN
cord-005478-5iu38pr6	2161	11	,	,	,
cord-005478-5iu38pr6	2161	12	intermediate	intermediate	JJ
cord-005478-5iu38pr6	2161	13	>	>	XX
cord-005478-5iu38pr6	2161	14	2,4	2,4	CD
cord-005478-5iu38pr6	2162	1	and	and	CC
cord-005478-5iu38pr6	2162	2	≤4.5	≤4.5	DT
cord-005478-5iu38pr6	2162	3	,	,	,
cord-005478-5iu38pr6	2162	4	high	high	JJ
cord-005478-5iu38pr6	2162	5	risk	risk	NN
cord-005478-5iu38pr6	2162	6	>	>	XX
cord-005478-5iu38pr6	2162	7	4.5	4.5	CD
cord-005478-5iu38pr6	2162	8	.	.	.
cord-005478-5iu38pr6	2163	1	The	the	DT
cord-005478-5iu38pr6	2163	2	3y	3y	CD
cord-005478-5iu38pr6	2163	3	-	-	HYPH
cord-005478-5iu38pr6	2163	4	OS	os	NN
cord-005478-5iu38pr6	2163	5	for	for	IN
cord-005478-5iu38pr6	2163	6	low	low	JJ
cord-005478-5iu38pr6	2163	7	risk	risk	NN
cord-005478-5iu38pr6	2163	8	patients	patient	NNS
cord-005478-5iu38pr6	2163	9	was	be	VBD
cord-005478-5iu38pr6	2163	10	96	96	CD
cord-005478-5iu38pr6	2163	11	%	%	NN
cord-005478-5iu38pr6	2163	12	,	,	,
cord-005478-5iu38pr6	2163	13	for	for	IN
cord-005478-5iu38pr6	2163	14	intermediate	intermediate	JJ
cord-005478-5iu38pr6	2163	15	76	76	CD
cord-005478-5iu38pr6	2163	16	%	%	NN
cord-005478-5iu38pr6	2163	17	and	and	CC
cord-005478-5iu38pr6	2163	18	for	for	IN
cord-005478-5iu38pr6	2163	19	high	high	JJ
cord-005478-5iu38pr6	2163	20	risk	risk	NN
cord-005478-5iu38pr6	2163	21	27	27	CD
cord-005478-5iu38pr6	2163	22	%	%	NN
cord-005478-5iu38pr6	2163	23	in	in	IN
cord-005478-5iu38pr6	2163	24	the	the	DT
cord-005478-5iu38pr6	2163	25	test	test	NN
cord-005478-5iu38pr6	2163	26	-	-	HYPH
cord-005478-5iu38pr6	2163	27	cohort	cohort	NN
cord-005478-5iu38pr6	2163	28	and	and	CC
cord-005478-5iu38pr6	2163	29	100	100	CD
cord-005478-5iu38pr6	2163	30	%	%	NN
cord-005478-5iu38pr6	2163	31	,	,	,
cord-005478-5iu38pr6	2163	32	66	66	CD
cord-005478-5iu38pr6	2163	33	%	%	NN
cord-005478-5iu38pr6	2163	34	and	and	CC
cord-005478-5iu38pr6	2163	35	35	35	CD
cord-005478-5iu38pr6	2163	36	%	%	NN
cord-005478-5iu38pr6	2163	37	in	in	IN
cord-005478-5iu38pr6	2163	38	the	the	DT
cord-005478-5iu38pr6	2163	39	validation	validation	NN
cord-005478-5iu38pr6	2163	40	-	-	HYPH
cord-005478-5iu38pr6	2163	41	cohort	cohort	NN
cord-005478-5iu38pr6	2163	42	(	(	-LRB-
cord-005478-5iu38pr6	2163	43	figure	figure	VB
cord-005478-5iu38pr6	2163	44	 	 	_SP
cord-005478-5iu38pr6	2163	45	1a	1a	NNP
cord-005478-5iu38pr6	2163	46	-	-	HYPH
cord-005478-5iu38pr6	2163	47	b	b	NN
cord-005478-5iu38pr6	2163	48	)	)	-RRB-
cord-005478-5iu38pr6	2163	49	.	.	.
cord-005478-5iu38pr6	2164	1	The	the	DT
cord-005478-5iu38pr6	2164	2	ROC	ROC	NNP
cord-005478-5iu38pr6	2164	3	curve	curve	NN
cord-005478-5iu38pr6	2164	4	analysis	analysis	NN
cord-005478-5iu38pr6	2164	5	supports	support	VBZ
cord-005478-5iu38pr6	2164	6	the	the	DT
cord-005478-5iu38pr6	2164	7	validity	validity	NN
cord-005478-5iu38pr6	2164	8	of	of	IN
cord-005478-5iu38pr6	2164	9	the	the	DT
cord-005478-5iu38pr6	2164	10	IR	IR	NNP
cord-005478-5iu38pr6	2164	11	-	-	HYPH
cord-005478-5iu38pr6	2164	12	score	score	NN
cord-005478-5iu38pr6	2164	13	in	in	IN
cord-005478-5iu38pr6	2164	14	our	-PRON-	PRP$
cord-005478-5iu38pr6	2164	15	cohort	cohort	NN
cord-005478-5iu38pr6	2164	16	of	of	IN
cord-005478-5iu38pr6	2164	17	patients	patient	NNS
cord-005478-5iu38pr6	2164	18	-AUC	-auc	SYM
cord-005478-5iu38pr6	2164	19	85.5	85.5	CD
cord-005478-5iu38pr6	2164	20	%	%	NN
cord-005478-5iu38pr6	2164	21	,	,	,
cord-005478-5iu38pr6	2164	22	with	with	IN
cord-005478-5iu38pr6	2164	23	95	95	CD
cord-005478-5iu38pr6	2164	24	%	%	NN
cord-005478-5iu38pr6	2164	25	confidence	confidence	NN
cord-005478-5iu38pr6	2164	26	intervals	interval	NNS
cord-005478-5iu38pr6	2164	27	higher	high	JJR
cord-005478-5iu38pr6	2164	28	than	than	IN
cord-005478-5iu38pr6	2164	29	50	50	CD
cord-005478-5iu38pr6	2164	30	%	%	NN
cord-005478-5iu38pr6	2164	31	.	.	.
cord-005478-5iu38pr6	2165	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	2165	2	IR	IR	NNP
cord-005478-5iu38pr6	2165	3	-	-	HYPH
cord-005478-5iu38pr6	2165	4	score	score	NN
cord-005478-5iu38pr6	2165	5	was	be	VBD
cord-005478-5iu38pr6	2165	6	able	able	JJ
cord-005478-5iu38pr6	2165	7	to	to	TO
cord-005478-5iu38pr6	2165	8	stratify	stratify	VB
cord-005478-5iu38pr6	2165	9	across	across	IN
cord-005478-5iu38pr6	2165	10	NIH	NIH	NNP
cord-005478-5iu38pr6	2165	11	-	-	HYPH
cord-005478-5iu38pr6	2165	12	severity	severity	NN
cord-005478-5iu38pr6	2165	13	classification	classification	NN
cord-005478-5iu38pr6	2165	14	(	(	-LRB-
cord-005478-5iu38pr6	2165	15	figure	figure	NN
cord-005478-5iu38pr6	2165	16	1c	1c	CD
cord-005478-5iu38pr6	2165	17	)	)	-RRB-
cord-005478-5iu38pr6	2165	18	.	.	.
cord-005478-5iu38pr6	2166	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2166	2	:	:	:
cord-005478-5iu38pr6	2167	1	Immune	immune	NN
cord-005478-5iu38pr6	2167	2	-	-	HYPH
cord-005478-5iu38pr6	2167	3	Reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2167	4	score	score	NN
cord-005478-5iu38pr6	2167	5	at	at	IN
cord-005478-5iu38pr6	2167	6	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2167	7	of	of	IN
cord-005478-5iu38pr6	2167	8	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	2167	9	predicts	predict	VBZ
cord-005478-5iu38pr6	2167	10	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2167	11	severity	severity	NN
cord-005478-5iu38pr6	2167	12	and	and	CC
cord-005478-5iu38pr6	2167	13	overall	overall	JJ
cord-005478-5iu38pr6	2167	14	-	-	HYPH
cord-005478-5iu38pr6	2167	15	survival	survival	NN
cord-005478-5iu38pr6	2167	16	.	.	.
cord-005478-5iu38pr6	2168	1	IRscore	IRscore	NNP
cord-005478-5iu38pr6	2168	2	could	could	MD
cord-005478-5iu38pr6	2168	3	be	be	VB
cord-005478-5iu38pr6	2168	4	adopted	adopt	VBN
cord-005478-5iu38pr6	2168	5	to	to	TO
cord-005478-5iu38pr6	2168	6	identify	identify	VB
cord-005478-5iu38pr6	2168	7	patients	patient	NNS
cord-005478-5iu38pr6	2168	8	at	at	IN
cord-005478-5iu38pr6	2168	9	high	high	JJ
cord-005478-5iu38pr6	2168	10	risk	risk	NN
cord-005478-5iu38pr6	2168	11	and	and	CC
cord-005478-5iu38pr6	2168	12	modulate	modulate	VB
cord-005478-5iu38pr6	2168	13	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2168	14	treatments	treatment	NNS
cord-005478-5iu38pr6	2168	15	accordingly	accordingly	RB
cord-005478-5iu38pr6	2168	16	.	.	.
cord-005478-5iu38pr6	2169	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2169	2	:	:	:
cord-005478-5iu38pr6	2170	1	Chiara	Chiara	NNP
cord-005478-5iu38pr6	2170	2	Bonini	Bonini	NNP
cord-005478-5iu38pr6	2170	3	has	have	VBZ
cord-005478-5iu38pr6	2170	4	research	research	NN
cord-005478-5iu38pr6	2170	5	contract	contract	NN
cord-005478-5iu38pr6	2170	6	with	with	IN
cord-005478-5iu38pr6	2170	7	Intellia	Intellia	NNP
cord-005478-5iu38pr6	2170	8	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	2170	9	.	.	.
cord-005478-5iu38pr6	2171	1	The	the	DT
cord-005478-5iu38pr6	2171	2	other	other	JJ
cord-005478-5iu38pr6	2171	3	authors	author	NNS
cord-005478-5iu38pr6	2171	4	declare	declare	VBP
cord-005478-5iu38pr6	2171	5	that	that	IN
cord-005478-5iu38pr6	2171	6	they	-PRON-	PRP
cord-005478-5iu38pr6	2171	7	have	have	VBP
cord-005478-5iu38pr6	2171	8	no	no	DT
cord-005478-5iu38pr6	2171	9	conflicts	conflict	NNS
cord-005478-5iu38pr6	2171	10	of	of	IN
cord-005478-5iu38pr6	2171	11	interest	interest	NN
cord-005478-5iu38pr6	2171	12	.	.	.
cord-005478-5iu38pr6	2172	1	Haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2172	2	transplantation	transplantation	NN
cord-005478-5iu38pr6	2172	3	with	with	IN
cord-005478-5iu38pr6	2172	4	sirolimus	sirolimus	NN
cord-005478-5iu38pr6	2172	5	-	-	HYPH
cord-005478-5iu38pr6	2172	6	based	base	VBN
cord-005478-5iu38pr6	2172	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2172	8	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2172	9	and	and	CC
cord-005478-5iu38pr6	2172	10	unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	2172	11	PBSC	PBSC	NNP
cord-005478-5iu38pr6	2172	12	graft	graft	NN
cord-005478-5iu38pr6	2173	1	:	:	:
cord-005478-5iu38pr6	2173	2	Background	background	NN
cord-005478-5iu38pr6	2173	3	:	:	:
cord-005478-5iu38pr6	2174	1	Haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2174	2	transplantation	transplantation	NN
cord-005478-5iu38pr6	2174	3	has	have	VBZ
cord-005478-5iu38pr6	2174	4	emerged	emerge	VBN
cord-005478-5iu38pr6	2174	5	as	as	IN
cord-005478-5iu38pr6	2174	6	a	a	DT
cord-005478-5iu38pr6	2174	7	viable	viable	JJ
cord-005478-5iu38pr6	2174	8	option	option	NN
cord-005478-5iu38pr6	2174	9	for	for	IN
cord-005478-5iu38pr6	2174	10	patients	patient	NNS
cord-005478-5iu38pr6	2174	11	lacking	lack	VBG
cord-005478-5iu38pr6	2174	12	a	a	DT
cord-005478-5iu38pr6	2174	13	fully	fully	RB
cord-005478-5iu38pr6	2174	14	matched	match	VBN
cord-005478-5iu38pr6	2174	15	donor	donor	NN
cord-005478-5iu38pr6	2174	16	.	.	.
cord-005478-5iu38pr6	2175	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2175	2	firstly	firstly	RB
cord-005478-5iu38pr6	2175	3	explored	explore	VBD
cord-005478-5iu38pr6	2175	4	the	the	DT
cord-005478-5iu38pr6	2175	5	association	association	NNP
cord-005478-5iu38pr6	2175	6	of	of	IN
cord-005478-5iu38pr6	2175	7	sirolimus	sirolimus	NNP
cord-005478-5iu38pr6	2175	8	and	and	CC
cord-005478-5iu38pr6	2175	9	ATG	ATG	NNP
cord-005478-5iu38pr6	2175	10	,	,	,
cord-005478-5iu38pr6	2175	11	later	later	RB
cord-005478-5iu38pr6	2175	12	followed	follow	VBN
cord-005478-5iu38pr6	2175	13	by	by	IN
cord-005478-5iu38pr6	2175	14	sirolimus	sirolimus	NNP
cord-005478-5iu38pr6	2175	15	with	with	IN
cord-005478-5iu38pr6	2175	16	PT	PT	NNP
cord-005478-5iu38pr6	2175	17	-	-	HYPH
cord-005478-5iu38pr6	2175	18	Cy	Cy	NNP
cord-005478-5iu38pr6	2175	19	as	as	IN
cord-005478-5iu38pr6	2175	20	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2175	21	strategy	strategy	NN
cord-005478-5iu38pr6	2175	22	.	.	.
cord-005478-5iu38pr6	2176	1	Herein	herein	RB
cord-005478-5iu38pr6	2176	2	,	,	,
cord-005478-5iu38pr6	2176	3	we	-PRON-	PRP
cord-005478-5iu38pr6	2176	4	describe	describe	VBP
cord-005478-5iu38pr6	2176	5	long	long	JJ
cord-005478-5iu38pr6	2176	6	-	-	HYPH
cord-005478-5iu38pr6	2176	7	term	term	NN
cord-005478-5iu38pr6	2176	8	outcomes	outcome	NNS
cord-005478-5iu38pr6	2176	9	of	of	IN
cord-005478-5iu38pr6	2176	10	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2176	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2176	12	using	use	VBG
cord-005478-5iu38pr6	2176	13	sirolimus	sirolimus	NN
cord-005478-5iu38pr6	2176	14	-	-	HYPH
cord-005478-5iu38pr6	2176	15	based	base	VBN
cord-005478-5iu38pr6	2176	16	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2176	17	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2176	18	.	.	.
cord-005478-5iu38pr6	2177	1	Methods	method	NNS
cord-005478-5iu38pr6	2178	1	All	all	DT
cord-005478-5iu38pr6	2178	2	patients	patient	NNS
cord-005478-5iu38pr6	2178	3	received	receive	VBD
cord-005478-5iu38pr6	2178	4	sirolimus	sirolimus	NN
cord-005478-5iu38pr6	2178	5	and	and	CC
cord-005478-5iu38pr6	2178	6	MMF	MMF	NNP
cord-005478-5iu38pr6	2178	7	as	as	IN
cord-005478-5iu38pr6	2178	8	GvHD	gvhd	NN
cord-005478-5iu38pr6	2178	9	backbone	backbone	NN
cord-005478-5iu38pr6	2178	10	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2178	11	plus	plus	CC
cord-005478-5iu38pr6	2178	12	ATG	ATG	NNP
cord-005478-5iu38pr6	2178	13	in	in	IN
cord-005478-5iu38pr6	2178	14	203	203	CD
cord-005478-5iu38pr6	2178	15	patients	patient	NNS
cord-005478-5iu38pr6	2178	16	,	,	,
cord-005478-5iu38pr6	2178	17	and	and	CC
cord-005478-5iu38pr6	2178	18	PT	PT	NNP
cord-005478-5iu38pr6	2178	19	-	-	HYPH
cord-005478-5iu38pr6	2178	20	Cy	Cy	NNP
cord-005478-5iu38pr6	2178	21	in	in	IN
cord-005478-5iu38pr6	2178	22	151	151	CD
cord-005478-5iu38pr6	2178	23	.	.	.
cord-005478-5iu38pr6	2179	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	2179	2	regimen	regimen	NN
cord-005478-5iu38pr6	2179	3	was	be	VBD
cord-005478-5iu38pr6	2179	4	based	base	VBN
cord-005478-5iu38pr6	2179	5	on	on	IN
cord-005478-5iu38pr6	2179	6	treosulfanfludarabine	treosulfanfludarabine	NN
cord-005478-5iu38pr6	2179	7	;	;	:
cord-005478-5iu38pr6	2179	8	recipients	recipient	NNS
cord-005478-5iu38pr6	2179	9	of	of	IN
cord-005478-5iu38pr6	2179	10	PT	PT	NNP
cord-005478-5iu38pr6	2179	11	-	-	HYPH
cord-005478-5iu38pr6	2179	12	Cy	Cy	NNP
cord-005478-5iu38pr6	2179	13	transplants	transplant	NNS
cord-005478-5iu38pr6	2179	14	were	be	VBD
cord-005478-5iu38pr6	2179	15	more	more	RBR
cord-005478-5iu38pr6	2179	16	likely	likely	JJ
cord-005478-5iu38pr6	2179	17	to	to	TO
cord-005478-5iu38pr6	2179	18	receive	receive	VB
cord-005478-5iu38pr6	2179	19	a	a	DT
cord-005478-5iu38pr6	2179	20	regimen	regimen	NN
cord-005478-5iu38pr6	2179	21	intensified	intensify	VBN
cord-005478-5iu38pr6	2179	22	by	by	IN
cord-005478-5iu38pr6	2179	23	a	a	DT
cord-005478-5iu38pr6	2179	24	2	2	CD
cord-005478-5iu38pr6	2179	25	nd	nd	NNP
cord-005478-5iu38pr6	2179	26	alkylating	alkylating	NN
cord-005478-5iu38pr6	2179	27	agent	agent	NN
cord-005478-5iu38pr6	2179	28	(	(	-LRB-
cord-005478-5iu38pr6	2179	29	melphalan	melphalan	NNP
cord-005478-5iu38pr6	2179	30	or	or	CC
cord-005478-5iu38pr6	2179	31	thiotepa	thiotepa	NNP
cord-005478-5iu38pr6	2179	32	)	)	-RRB-
cord-005478-5iu38pr6	2179	33	.	.	.
cord-005478-5iu38pr6	2180	1	Median	median	JJ
cord-005478-5iu38pr6	2180	2	follow	follow	VBP
cord-005478-5iu38pr6	2180	3	up	up	RP
cord-005478-5iu38pr6	2180	4	was	be	VBD
cord-005478-5iu38pr6	2180	5	longer	long	JJR
cord-005478-5iu38pr6	2180	6	in	in	IN
cord-005478-5iu38pr6	2180	7	ATG	ATG	NNP
cord-005478-5iu38pr6	2180	8	group	group	NN
cord-005478-5iu38pr6	2180	9	(	(	-LRB-
cord-005478-5iu38pr6	2180	10	70	70	CD
cord-005478-5iu38pr6	2180	11	vs	vs	IN
cord-005478-5iu38pr6	2180	12	26	26	CD
cord-005478-5iu38pr6	2180	13	monhs	monh	NNS
cord-005478-5iu38pr6	2180	14	,	,	,
cord-005478-5iu38pr6	2181	1	p	p	NN
cord-005478-5iu38pr6	2181	2	<	<	NNP
cord-005478-5iu38pr6	2181	3	0.01	0.01	CD
cord-005478-5iu38pr6	2181	4	)	)	-RRB-
cord-005478-5iu38pr6	2181	5	.	.	.
cord-005478-5iu38pr6	2182	1	There	there	EX
cord-005478-5iu38pr6	2182	2	were	be	VBD
cord-005478-5iu38pr6	2182	3	no	no	DT
cord-005478-5iu38pr6	2182	4	differences	difference	NNS
cord-005478-5iu38pr6	2182	5	in	in	IN
cord-005478-5iu38pr6	2182	6	DRI	DRI	NNP
cord-005478-5iu38pr6	2182	7	.	.	.
cord-005478-5iu38pr6	2183	1	Results	result	NNS
cord-005478-5iu38pr6	2183	2	:	:	:
cord-005478-5iu38pr6	2184	1	The	the	DT
cord-005478-5iu38pr6	2184	2	majority	majority	NN
cord-005478-5iu38pr6	2184	3	of	of	IN
cord-005478-5iu38pr6	2184	4	patients	patient	NNS
cord-005478-5iu38pr6	2184	5	reached	reach	VBD
cord-005478-5iu38pr6	2184	6	the	the	DT
cord-005478-5iu38pr6	2184	7	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2184	8	(	(	-LRB-
cord-005478-5iu38pr6	2184	9	89	89	CD
cord-005478-5iu38pr6	2184	10	%	%	NN
cord-005478-5iu38pr6	2184	11	in	in	IN
cord-005478-5iu38pr6	2184	12	ATG	ATG	NNP
cord-005478-5iu38pr6	2184	13	group	group	NN
cord-005478-5iu38pr6	2184	14	vs	vs	IN
cord-005478-5iu38pr6	2184	15	86	86	CD
cord-005478-5iu38pr6	2184	16	%	%	NN
cord-005478-5iu38pr6	2184	17	in	in	IN
cord-005478-5iu38pr6	2184	18	PT	PT	NNP
cord-005478-5iu38pr6	2184	19	-	-	HYPH
cord-005478-5iu38pr6	2184	20	Cy	Cy	NNP
cord-005478-5iu38pr6	2184	21	group	group	NN
cord-005478-5iu38pr6	2184	22	)	)	-RRB-
cord-005478-5iu38pr6	2184	23	and	and	CC
cord-005478-5iu38pr6	2184	24	platelet	platelet	NN
cord-005478-5iu38pr6	2184	25	(	(	-LRB-
cord-005478-5iu38pr6	2184	26	76	76	CD
cord-005478-5iu38pr6	2184	27	%	%	NN
cord-005478-5iu38pr6	2184	28	vs	vs	IN
cord-005478-5iu38pr6	2184	29	77	77	CD
cord-005478-5iu38pr6	2184	30	%	%	NN
cord-005478-5iu38pr6	2184	31	)	)	-RRB-
cord-005478-5iu38pr6	2184	32	engraftment	engraftment	NN
cord-005478-5iu38pr6	2184	33	within	within	IN
cord-005478-5iu38pr6	2184	34	30	30	CD
cord-005478-5iu38pr6	2184	35	days	day	NNS
cord-005478-5iu38pr6	2184	36	after	after	IN
cord-005478-5iu38pr6	2184	37	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2184	38	.	.	.
cord-005478-5iu38pr6	2185	1	Immune	immune	NN
cord-005478-5iu38pr6	2185	2	-	-	HYPH
cord-005478-5iu38pr6	2185	3	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2185	4	was	be	VBD
cord-005478-5iu38pr6	2185	5	broad	broad	JJ
cord-005478-5iu38pr6	2185	6	and	and	CC
cord-005478-5iu38pr6	2185	7	fast	fast	JJ
cord-005478-5iu38pr6	2185	8	,	,	,
cord-005478-5iu38pr6	2185	9	reaching	reach	VBG
cord-005478-5iu38pr6	2185	10	more	more	JJR
cord-005478-5iu38pr6	2185	11	than	than	IN
cord-005478-5iu38pr6	2185	12	100	100	CD
cord-005478-5iu38pr6	2186	1	/ml	/ml	NFP
cord-005478-5iu38pr6	2186	2	CD3	CD3	NNP
cord-005478-5iu38pr6	2186	3	+	+	CC
cord-005478-5iu38pr6	2186	4	T	T	NNP
cord-005478-5iu38pr6	2186	5	cells	cell	NNS
cord-005478-5iu38pr6	2186	6	within	within	IN
cord-005478-5iu38pr6	2186	7	a	a	DT
cord-005478-5iu38pr6	2186	8	median	median	NN
cord-005478-5iu38pr6	2186	9	of	of	IN
cord-005478-5iu38pr6	2186	10	35	35	CD
cord-005478-5iu38pr6	2186	11	vs	vs	IN
cord-005478-5iu38pr6	2186	12	33	33	CD
cord-005478-5iu38pr6	2186	13	days	day	NNS
cord-005478-5iu38pr6	2186	14	.	.	.
cord-005478-5iu38pr6	2187	1	The	the	DT
cord-005478-5iu38pr6	2187	2	two	two	CD
cord-005478-5iu38pr6	2187	3	groups	group	NNS
cord-005478-5iu38pr6	2187	4	were	be	VBD
cord-005478-5iu38pr6	2187	5	similar	similar	JJ
cord-005478-5iu38pr6	2187	6	in	in	IN
cord-005478-5iu38pr6	2187	7	terms	term	NNS
cord-005478-5iu38pr6	2187	8	of	of	IN
cord-005478-5iu38pr6	2187	9	survival	survival	NN
cord-005478-5iu38pr6	2187	10	and	and	CC
cord-005478-5iu38pr6	2187	11	main	main	JJ
cord-005478-5iu38pr6	2187	12	transplant	transplant	NN
cord-005478-5iu38pr6	2187	13	outcomes	outcome	NNS
cord-005478-5iu38pr6	2187	14	.	.	.
cord-005478-5iu38pr6	2188	1	In	in	IN
cord-005478-5iu38pr6	2188	2	the	the	DT
cord-005478-5iu38pr6	2188	3	ATG	ATG	NNP
cord-005478-5iu38pr6	2188	4	group	group	NN
cord-005478-5iu38pr6	2188	5	,	,	,
cord-005478-5iu38pr6	2188	6	the	the	DT
cord-005478-5iu38pr6	2188	7	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2188	8	incidence	incidence	NN
cord-005478-5iu38pr6	2188	9	of	of	IN
cord-005478-5iu38pr6	2188	10	grades	grade	NNS
cord-005478-5iu38pr6	2188	11	II	II	NNP
cord-005478-5iu38pr6	2188	12	-	-	HYPH
cord-005478-5iu38pr6	2188	13	IV	IV	NNP
cord-005478-5iu38pr6	2188	14	and	and	CC
cord-005478-5iu38pr6	2188	15	III	III	NNP
cord-005478-5iu38pr6	2188	16	-	-	HYPH
cord-005478-5iu38pr6	2188	17	IV	IV	NNP
cord-005478-5iu38pr6	2188	18	acute	acute	JJ
cord-005478-5iu38pr6	2188	19	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2188	20	at	at	IN
cord-005478-5iu38pr6	2188	21	100	100	CD
cord-005478-5iu38pr6	2188	22	days	day	NNS
cord-005478-5iu38pr6	2188	23	was	be	VBD
cord-005478-5iu38pr6	2188	24	26	26	CD
cord-005478-5iu38pr6	2188	25	%	%	NN
cord-005478-5iu38pr6	2188	26	and	and	CC
cord-005478-5iu38pr6	2188	27	20	20	CD
cord-005478-5iu38pr6	2188	28	%	%	NN
cord-005478-5iu38pr6	2188	29	.	.	.
cord-005478-5iu38pr6	2189	1	Corresponding	correspond	VBG
cord-005478-5iu38pr6	2189	2	rates	rate	NNS
cord-005478-5iu38pr6	2189	3	after	after	IN
cord-005478-5iu38pr6	2189	4	PT	PT	NNP
cord-005478-5iu38pr6	2189	5	-	-	HYPH
cord-005478-5iu38pr6	2189	6	Cy	Cy	NNP
cord-005478-5iu38pr6	2189	7	were	be	VBD
cord-005478-5iu38pr6	2189	8	35	35	CD
cord-005478-5iu38pr6	2189	9	%	%	NN
cord-005478-5iu38pr6	2189	10	and	and	CC
cord-005478-5iu38pr6	2189	11	20	20	CD
cord-005478-5iu38pr6	2189	12	%	%	NN
cord-005478-5iu38pr6	2189	13	.	.	.
cord-005478-5iu38pr6	2190	1	The	the	DT
cord-005478-5iu38pr6	2190	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2190	3	incidence	incidence	NN
cord-005478-5iu38pr6	2190	4	of	of	IN
cord-005478-5iu38pr6	2190	5	overall	overall	JJ
cord-005478-5iu38pr6	2190	6	and	and	CC
cord-005478-5iu38pr6	2190	7	severe	severe	JJ
cord-005478-5iu38pr6	2190	8	chronic	chronic	JJ
cord-005478-5iu38pr6	2190	9	GvHD	gvhd	NN
cord-005478-5iu38pr6	2190	10	was	be	VBD
cord-005478-5iu38pr6	2190	11	31	31	CD
cord-005478-5iu38pr6	2190	12	%	%	NN
cord-005478-5iu38pr6	2190	13	and	and	CC
cord-005478-5iu38pr6	2190	14	10	10	CD
cord-005478-5iu38pr6	2190	15	%	%	NN
cord-005478-5iu38pr6	2190	16	at	at	IN
cord-005478-5iu38pr6	2190	17	3	3	CD
cord-005478-5iu38pr6	2190	18	years	year	NNS
cord-005478-5iu38pr6	2190	19	in	in	IN
cord-005478-5iu38pr6	2190	20	ATG	ATG	NNP
cord-005478-5iu38pr6	2190	21	group	group	NN
cord-005478-5iu38pr6	2190	22	and	and	CC
cord-005478-5iu38pr6	2190	23	42	42	CD
cord-005478-5iu38pr6	2190	24	%	%	NN
cord-005478-5iu38pr6	2190	25	and	and	CC
cord-005478-5iu38pr6	2190	26	16	16	CD
cord-005478-5iu38pr6	2190	27	%	%	NN
cord-005478-5iu38pr6	2190	28	after	after	IN
cord-005478-5iu38pr6	2190	29	PT	PT	NNP
cord-005478-5iu38pr6	2190	30	-	-	HYPH
cord-005478-5iu38pr6	2190	31	Cy	Cy	NNP
cord-005478-5iu38pr6	2191	1	.The	.The	.
cord-005478-5iu38pr6	2192	1	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2192	2	incidences	incidence	NNS
cord-005478-5iu38pr6	2192	3	of	of	IN
cord-005478-5iu38pr6	2192	4	relapse	relapse	NN
cord-005478-5iu38pr6	2192	5	and	and	CC
cord-005478-5iu38pr6	2192	6	NRM	NRM	NNP
cord-005478-5iu38pr6	2192	7	in	in	IN
cord-005478-5iu38pr6	2192	8	ATG	ATG	NNP
cord-005478-5iu38pr6	2192	9	group	group	NN
cord-005478-5iu38pr6	2192	10	were	be	VBD
cord-005478-5iu38pr6	2192	11	respectively	respectively	RB
cord-005478-5iu38pr6	2192	12	41	41	CD
cord-005478-5iu38pr6	2192	13	%	%	NN
cord-005478-5iu38pr6	2192	14	and	and	CC
cord-005478-5iu38pr6	2192	15	31	31	CD
cord-005478-5iu38pr6	2192	16	%	%	NN
cord-005478-5iu38pr6	2192	17	at	at	IN
cord-005478-5iu38pr6	2192	18	3	3	CD
cord-005478-5iu38pr6	2192	19	years	year	NNS
cord-005478-5iu38pr6	2192	20	.	.	.
cord-005478-5iu38pr6	2193	1	Corresponding	correspond	VBG
cord-005478-5iu38pr6	2193	2	rates	rate	NNS
cord-005478-5iu38pr6	2193	3	after	after	IN
cord-005478-5iu38pr6	2193	4	PT	PT	NNP
cord-005478-5iu38pr6	2193	5	-	-	HYPH
cord-005478-5iu38pr6	2193	6	Cy	Cy	NNP
cord-005478-5iu38pr6	2193	7	were	be	VBD
cord-005478-5iu38pr6	2193	8	35	35	CD
cord-005478-5iu38pr6	2193	9	%	%	NN
cord-005478-5iu38pr6	2193	10	and	and	CC
cord-005478-5iu38pr6	2193	11	27	27	CD
cord-005478-5iu38pr6	2193	12	%	%	NN
cord-005478-5iu38pr6	2193	13	.	.	.
cord-005478-5iu38pr6	2194	1	In	in	IN
cord-005478-5iu38pr6	2194	2	ATG	ATG	NNP
cord-005478-5iu38pr6	2194	3	group	group	NN
cord-005478-5iu38pr6	2194	4	,	,	,
cord-005478-5iu38pr6	2195	1	3-year	3-year	JJ
cord-005478-5iu38pr6	2195	2	OS	OS	NNP
cord-005478-5iu38pr6	2195	3	was	be	VBD
cord-005478-5iu38pr6	2195	4	36	36	CD
cord-005478-5iu38pr6	2195	5	%	%	NN
cord-005478-5iu38pr6	2195	6	,	,	,
cord-005478-5iu38pr6	2195	7	while	while	IN
cord-005478-5iu38pr6	2195	8	GRFS	GRFS	NNP
cord-005478-5iu38pr6	2195	9	was	be	VBD
cord-005478-5iu38pr6	2195	10	24	24	CD
cord-005478-5iu38pr6	2195	11	%	%	NN
cord-005478-5iu38pr6	2195	12	.	.	.
cord-005478-5iu38pr6	2196	1	The	the	DT
cord-005478-5iu38pr6	2196	2	corresponding	correspond	VBG
cord-005478-5iu38pr6	2196	3	probabilities	probability	NNS
cord-005478-5iu38pr6	2196	4	after	after	IN
cord-005478-5iu38pr6	2196	5	PT	PT	NNP
cord-005478-5iu38pr6	2196	6	-	-	HYPH
cord-005478-5iu38pr6	2196	7	Cy	Cy	NNP
cord-005478-5iu38pr6	2196	8	were	be	VBD
cord-005478-5iu38pr6	2196	9	44	44	CD
cord-005478-5iu38pr6	2196	10	%	%	NN
cord-005478-5iu38pr6	2196	11	and	and	CC
cord-005478-5iu38pr6	2196	12	24	24	CD
cord-005478-5iu38pr6	2196	13	%	%	NN
cord-005478-5iu38pr6	2196	14	.	.	.
cord-005478-5iu38pr6	2197	1	The	the	DT
cord-005478-5iu38pr6	2197	2	only	only	JJ
cord-005478-5iu38pr6	2197	3	difference	difference	NN
cord-005478-5iu38pr6	2197	4	reported	report	VBN
cord-005478-5iu38pr6	2197	5	was	be	VBD
cord-005478-5iu38pr6	2197	6	a	a	DT
cord-005478-5iu38pr6	2197	7	better	well	JJR
cord-005478-5iu38pr6	2197	8	PFS	PFS	NNP
cord-005478-5iu38pr6	2197	9	in	in	IN
cord-005478-5iu38pr6	2197	10	favour	favour	NN
cord-005478-5iu38pr6	2197	11	of	of	IN
cord-005478-5iu38pr6	2197	12	PT	PT	NNP
cord-005478-5iu38pr6	2197	13	-	-	HYPH
cord-005478-5iu38pr6	2197	14	Cy	Cy	NNP
cord-005478-5iu38pr6	2197	15	(	(	-LRB-
cord-005478-5iu38pr6	2197	16	38	38	CD
cord-005478-5iu38pr6	2197	17	%	%	NN
cord-005478-5iu38pr6	2197	18	vs	vs	IN
cord-005478-5iu38pr6	2197	19	29	29	CD
cord-005478-5iu38pr6	2197	20	%	%	NN
cord-005478-5iu38pr6	2197	21	,	,	,
cord-005478-5iu38pr6	2197	22	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	2197	23	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2197	24	:	:	:
cord-005478-5iu38pr6	2198	1	Extended	extend	VBN
cord-005478-5iu38pr6	2198	2	follow	follow	NN
cord-005478-5iu38pr6	2198	3	-	-	HYPH
cord-005478-5iu38pr6	2198	4	up	up	NN
cord-005478-5iu38pr6	2198	5	in	in	IN
cord-005478-5iu38pr6	2198	6	354	354	CD
cord-005478-5iu38pr6	2198	7	patients	patient	NNS
cord-005478-5iu38pr6	2198	8	confirms	confirm	VBZ
cord-005478-5iu38pr6	2198	9	Sirolimus	Sirolimus	NNP
cord-005478-5iu38pr6	2198	10	-	-	HYPH
cord-005478-5iu38pr6	2198	11	based	base	VBN
cord-005478-5iu38pr6	2198	12	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2198	13	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2198	14	as	as	IN
cord-005478-5iu38pr6	2198	15	feasible	feasible	JJ
cord-005478-5iu38pr6	2198	16	and	and	CC
cord-005478-5iu38pr6	2198	17	safe	safe	JJ
cord-005478-5iu38pr6	2198	18	in	in	IN
cord-005478-5iu38pr6	2198	19	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2198	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2198	21	based	base	VBN
cord-005478-5iu38pr6	2198	22	on	on	IN
cord-005478-5iu38pr6	2198	23	unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	2198	24	PBSC	PBSC	NNP
cord-005478-5iu38pr6	2198	25	graft	graft	NN
cord-005478-5iu38pr6	2198	26	.	.	.
cord-005478-5iu38pr6	2199	1	Both	both	DT
cord-005478-5iu38pr6	2199	2	ATG	ATG	NNP
cord-005478-5iu38pr6	2199	3	and	and	CC
cord-005478-5iu38pr6	2199	4	PTCy	PTCy	NNP
cord-005478-5iu38pr6	2199	5	association	association	NNP
cord-005478-5iu38pr6	2199	6	to	to	TO
cord-005478-5iu38pr6	2199	7	sirolimus	sirolimus	NNP
cord-005478-5iu38pr6	2199	8	provide	provide	VB
cord-005478-5iu38pr6	2199	9	an	an	DT
cord-005478-5iu38pr6	2199	10	effective	effective	JJ
cord-005478-5iu38pr6	2199	11	prevention	prevention	NN
cord-005478-5iu38pr6	2199	12	of	of	IN
cord-005478-5iu38pr6	2199	13	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2199	14	and	and	CC
cord-005478-5iu38pr6	2199	15	translate	translate	VB
cord-005478-5iu38pr6	2199	16	into	into	IN
cord-005478-5iu38pr6	2199	17	a	a	DT
cord-005478-5iu38pr6	2199	18	similar	similar	JJ
cord-005478-5iu38pr6	2199	19	long	long	JJ
cord-005478-5iu38pr6	2199	20	-	-	HYPH
cord-005478-5iu38pr6	2199	21	term	term	NN
cord-005478-5iu38pr6	2199	22	overall	overall	JJ
cord-005478-5iu38pr6	2199	23	survival	survival	NN
cord-005478-5iu38pr6	2199	24	.	.	.
cord-005478-5iu38pr6	2200	1	A	a	DT
cord-005478-5iu38pr6	2200	2	significant	significant	JJ
cord-005478-5iu38pr6	2200	3	advantage	advantage	NN
cord-005478-5iu38pr6	2200	4	of	of	IN
cord-005478-5iu38pr6	2200	5	Sir	Sir	NNP
cord-005478-5iu38pr6	2200	6	-	-	HYPH
cord-005478-5iu38pr6	2200	7	PT	PT	NNP
cord-005478-5iu38pr6	2200	8	-	-	HYPH
cord-005478-5iu38pr6	2200	9	Cy	Cy	NNP
cord-005478-5iu38pr6	2200	10	on	on	IN
cord-005478-5iu38pr6	2200	11	relapse	relapse	NN
cord-005478-5iu38pr6	2200	12	rate	rate	NN
cord-005478-5iu38pr6	2200	13	warrants	warrant	NNS
cord-005478-5iu38pr6	2200	14	further	further	JJ
cord-005478-5iu38pr6	2200	15	investigation	investigation	NN
cord-005478-5iu38pr6	2200	16	.	.	.
cord-005478-5iu38pr6	2201	1	Background	background	NN
cord-005478-5iu38pr6	2201	2	:	:	:
cord-005478-5iu38pr6	2202	1	Steroid	steroid	JJ
cord-005478-5iu38pr6	2202	2	-	-	HYPH
cord-005478-5iu38pr6	2202	3	refractory	refractory	JJ
cord-005478-5iu38pr6	2202	4	graft	graft	NN
cord-005478-5iu38pr6	2202	5	-	-	HYPH
cord-005478-5iu38pr6	2202	6	versus	versus	IN
cord-005478-5iu38pr6	2202	7	-	-	HYPH
cord-005478-5iu38pr6	2202	8	host	host	NN
cord-005478-5iu38pr6	2202	9	disease	disease	NN
cord-005478-5iu38pr6	2202	10	(	(	-LRB-
cord-005478-5iu38pr6	2202	11	SR	SR	NNP
cord-005478-5iu38pr6	2202	12	-	-	HYPH
cord-005478-5iu38pr6	2202	13	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2202	14	)	)	-RRB-
cord-005478-5iu38pr6	2202	15	is	be	VBZ
cord-005478-5iu38pr6	2202	16	still	still	RB
cord-005478-5iu38pr6	2202	17	responsible	responsible	JJ
cord-005478-5iu38pr6	2202	18	for	for	IN
cord-005478-5iu38pr6	2202	19	high	high	JJ
cord-005478-5iu38pr6	2202	20	mortality	mortality	NN
cord-005478-5iu38pr6	2202	21	in	in	IN
cord-005478-5iu38pr6	2202	22	patients	patient	NNS
cord-005478-5iu38pr6	2202	23	undergoing	undergo	VBG
cord-005478-5iu38pr6	2202	24	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2202	25	stem	stem	NN
cord-005478-5iu38pr6	2202	26	cell	cell	NN
cord-005478-5iu38pr6	2202	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	2202	28	;	;	:
cord-005478-5iu38pr6	2202	29	a	a	DT
cord-005478-5iu38pr6	2202	30	number	number	NN
cord-005478-5iu38pr6	2202	31	of	of	IN
cord-005478-5iu38pr6	2202	32	agents	agent	NNS
cord-005478-5iu38pr6	2202	33	is	be	VBZ
cord-005478-5iu38pr6	2202	34	currently	currently	RB
cord-005478-5iu38pr6	2202	35	available	available	JJ
cord-005478-5iu38pr6	2202	36	in	in	IN
cord-005478-5iu38pr6	2202	37	case	case	NN
cord-005478-5iu38pr6	2202	38	of	of	IN
cord-005478-5iu38pr6	2202	39	steroid	steroid	NN
cord-005478-5iu38pr6	2202	40	-	-	HYPH
cord-005478-5iu38pr6	2202	41	refractoriness	refractoriness	RB
cord-005478-5iu38pr6	2202	42	,	,	,
cord-005478-5iu38pr6	2202	43	yet	yet	CC
cord-005478-5iu38pr6	2202	44	there	there	EX
cord-005478-5iu38pr6	2202	45	is	be	VBZ
cord-005478-5iu38pr6	2202	46	so	so	RB
cord-005478-5iu38pr6	2202	47	far	far	RB
cord-005478-5iu38pr6	2202	48	no	no	DT
cord-005478-5iu38pr6	2202	49	consensus	consensus	NN
cord-005478-5iu38pr6	2202	50	about	about	IN
cord-005478-5iu38pr6	2202	51	a	a	DT
cord-005478-5iu38pr6	2202	52	standard	standard	JJ
cord-005478-5iu38pr6	2202	53	second	second	JJ
cord-005478-5iu38pr6	2202	54	-	-	HYPH
cord-005478-5iu38pr6	2202	55	line	line	NN
cord-005478-5iu38pr6	2202	56	treatment	treatment	NN
cord-005478-5iu38pr6	2202	57	and	and	CC
cord-005478-5iu38pr6	2202	58	overall	overall	JJ
cord-005478-5iu38pr6	2202	59	survival	survival	NN
cord-005478-5iu38pr6	2202	60	(	(	-LRB-
cord-005478-5iu38pr6	2202	61	OS	OS	NNP
cord-005478-5iu38pr6	2202	62	)	)	-RRB-
cord-005478-5iu38pr6	2202	63	remains	remain	VBZ
cord-005478-5iu38pr6	2202	64	poor.α1-antitripsyn	poor.α1-antitripsyn	NNP
cord-005478-5iu38pr6	2202	65	(	(	-LRB-
cord-005478-5iu38pr6	2202	66	αAT	αat	NN
cord-005478-5iu38pr6	2202	67	)	)	-RRB-
cord-005478-5iu38pr6	2203	1	is	be	VBZ
cord-005478-5iu38pr6	2203	2	a	a	DT
cord-005478-5iu38pr6	2203	3	circulating	circulate	VBG
cord-005478-5iu38pr6	2203	4	52-kDa	52-kda	CD
cord-005478-5iu38pr6	2203	5	serine	serine	NN
cord-005478-5iu38pr6	2203	6	protease	protease	NN
cord-005478-5iu38pr6	2203	7	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	2203	8	found	find	VBD
cord-005478-5iu38pr6	2203	9	to	to	TO
cord-005478-5iu38pr6	2203	10	enhance	enhance	VB
cord-005478-5iu38pr6	2203	11	the	the	DT
cord-005478-5iu38pr6	2203	12	production	production	NN
cord-005478-5iu38pr6	2203	13	of	of	IN
cord-005478-5iu38pr6	2203	14	anti	anti	JJ
cord-005478-5iu38pr6	2203	15	-	-	JJ
cord-005478-5iu38pr6	2203	16	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2203	17	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2203	18	and	and	CC
cord-005478-5iu38pr6	2203	19	to	to	TO
cord-005478-5iu38pr6	2203	20	favor	favor	VB
cord-005478-5iu38pr6	2203	21	the	the	DT
cord-005478-5iu38pr6	2203	22	expansion	expansion	NN
cord-005478-5iu38pr6	2203	23	of	of	IN
cord-005478-5iu38pr6	2203	24	regulatory	regulatory	JJ
cord-005478-5iu38pr6	2203	25	T	t	NN
cord-005478-5iu38pr6	2203	26	-	-	HYPH
cord-005478-5iu38pr6	2203	27	cells	cell	NNS
cord-005478-5iu38pr6	2203	28	;	;	:
cord-005478-5iu38pr6	2203	29	it	-PRON-	PRP
cord-005478-5iu38pr6	2203	30	has	have	VBZ
cord-005478-5iu38pr6	2203	31	therefore	therefore	RB
cord-005478-5iu38pr6	2203	32	been	be	VBN
cord-005478-5iu38pr6	2203	33	tested	test	VBN
cord-005478-5iu38pr6	2203	34	in	in	IN
cord-005478-5iu38pr6	2203	35	situations	situation	NNS
cord-005478-5iu38pr6	2203	36	of	of	IN
cord-005478-5iu38pr6	2203	37	altered	altered	JJ
cord-005478-5iu38pr6	2203	38	tolerance	tolerance	NN
cord-005478-5iu38pr6	2203	39	and	and	CC
cord-005478-5iu38pr6	2203	40	disproportionate	disproportionate	JJ
cord-005478-5iu38pr6	2203	41	inflammation	inflammation	NN
cord-005478-5iu38pr6	2203	42	,	,	,
cord-005478-5iu38pr6	2203	43	including	include	VBG
cord-005478-5iu38pr6	2203	44	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2203	45	.	.	.
cord-005478-5iu38pr6	2204	1	Two	two	CD
cord-005478-5iu38pr6	2204	2	studies	study	NNS
cord-005478-5iu38pr6	2204	3	showed	show	VBD
cord-005478-5iu38pr6	2204	4	that	that	IN
cord-005478-5iu38pr6	2204	5	treatment	treatment	NN
cord-005478-5iu38pr6	2204	6	of	of	IN
cord-005478-5iu38pr6	2204	7	SR	SR	NNP
cord-005478-5iu38pr6	2204	8	acute	acute	JJ
cord-005478-5iu38pr6	2204	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2204	10	with	with	IN
cord-005478-5iu38pr6	2204	11	αAT	αat	NN
cord-005478-5iu38pr6	2204	12	is	be	VBZ
cord-005478-5iu38pr6	2204	13	feasible	feasible	JJ
cord-005478-5iu38pr6	2204	14	and	and	CC
cord-005478-5iu38pr6	2204	15	effective	effective	JJ
cord-005478-5iu38pr6	2204	16	.	.	.
cord-005478-5iu38pr6	2205	1	Methods	method	NNS
cord-005478-5iu38pr6	2205	2	:	:	:
cord-005478-5iu38pr6	2205	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2205	4	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	2205	5	analyzed	analyze	VBD
cord-005478-5iu38pr6	2205	6	a	a	DT
cord-005478-5iu38pr6	2205	7	series	series	NN
cord-005478-5iu38pr6	2205	8	of	of	IN
cord-005478-5iu38pr6	2205	9	patients	patient	NNS
cord-005478-5iu38pr6	2205	10	who	who	WP
cord-005478-5iu38pr6	2205	11	received	receive	VBD
cord-005478-5iu38pr6	2205	12	exogenous	exogenous	JJ
cord-005478-5iu38pr6	2205	13	αAT	αat	NN
cord-005478-5iu38pr6	2205	14	for	for	IN
cord-005478-5iu38pr6	2205	15	SR	SR	NNP
cord-005478-5iu38pr6	2205	16	acute	acute	JJ
cord-005478-5iu38pr6	2205	17	gastrointestinal	gastrointestinal	JJ
cord-005478-5iu38pr6	2205	18	GVHD	gvhd	NN
cord-005478-5iu38pr6	2205	19	or	or	CC
cord-005478-5iu38pr6	2205	20	overlap	overlap	VB
cord-005478-5iu38pr6	2205	21	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2205	22	with	with	IN
cord-005478-5iu38pr6	2205	23	acute	acute	JJ
cord-005478-5iu38pr6	2205	24	gut	gut	NN
cord-005478-5iu38pr6	2205	25	features	feature	NNS
cord-005478-5iu38pr6	2205	26	.	.	.
cord-005478-5iu38pr6	2206	1	SR	SR	NNP
cord-005478-5iu38pr6	2206	2	-	-	HYPH
cord-005478-5iu38pr6	2206	3	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2206	4	was	be	VBD
cord-005478-5iu38pr6	2206	5	defined	define	VBN
cord-005478-5iu38pr6	2206	6	and	and	CC
cord-005478-5iu38pr6	2206	7	graded	grade	VBN
cord-005478-5iu38pr6	2206	8	according	accord	VBG
cord-005478-5iu38pr6	2206	9	to	to	IN
cord-005478-5iu38pr6	2206	10	standard	standard	JJ
cord-005478-5iu38pr6	2206	11	criteria	criterion	NNS
cord-005478-5iu38pr6	2206	12	.	.	.
cord-005478-5iu38pr6	2207	1	αAT	αAT	VBG
cord-005478-5iu38pr6	2207	2	was	be	VBD
cord-005478-5iu38pr6	2207	3	administered	administer	VBN
cord-005478-5iu38pr6	2207	4	intravenously	intravenously	RB
cord-005478-5iu38pr6	2207	5	at	at	IN
cord-005478-5iu38pr6	2207	6	a	a	DT
cord-005478-5iu38pr6	2207	7	loading	loading	NN
cord-005478-5iu38pr6	2207	8	dose	dose	NN
cord-005478-5iu38pr6	2207	9	of	of	IN
cord-005478-5iu38pr6	2207	10	90	90	CD
cord-005478-5iu38pr6	2207	11	mg	mg	NNP
cord-005478-5iu38pr6	2207	12	/	/	SYM
cord-005478-5iu38pr6	2207	13	kg	kg	NN
cord-005478-5iu38pr6	2207	14	at	at	IN
cord-005478-5iu38pr6	2207	15	day	day	NN
cord-005478-5iu38pr6	2207	16	1	1	CD
cord-005478-5iu38pr6	2207	17	followed	follow	VBD
cord-005478-5iu38pr6	2207	18	by	by	IN
cord-005478-5iu38pr6	2207	19	30	30	CD
cord-005478-5iu38pr6	2207	20	mg	mg	NN
cord-005478-5iu38pr6	2207	21	/	/	SYM
cord-005478-5iu38pr6	2207	22	kg	kg	NN
cord-005478-5iu38pr6	2207	23	/day	/day	.
cord-005478-5iu38pr6	2208	1	every	every	DT
cord-005478-5iu38pr6	2208	2	other	other	JJ
cord-005478-5iu38pr6	2208	3	day	day	NN
cord-005478-5iu38pr6	2208	4	for	for	IN
cord-005478-5iu38pr6	2208	5	a	a	DT
cord-005478-5iu38pr6	2208	6	total	total	NN
cord-005478-5iu38pr6	2208	7	of	of	IN
cord-005478-5iu38pr6	2208	8	8	8	CD
cord-005478-5iu38pr6	2208	9	doses	dose	NNS
cord-005478-5iu38pr6	2208	10	.	.	.
cord-005478-5iu38pr6	2209	1	Response	response	NN
cord-005478-5iu38pr6	2209	2	to	to	IN
cord-005478-5iu38pr6	2209	3	treatment	treatment	NN
cord-005478-5iu38pr6	2209	4	was	be	VBD
cord-005478-5iu38pr6	2209	5	defined	define	VBN
cord-005478-5iu38pr6	2209	6	according	accord	VBG
cord-005478-5iu38pr6	2209	7	to	to	IN
cord-005478-5iu38pr6	2209	8	published	publish	VBN
cord-005478-5iu38pr6	2209	9	criteria	criterion	NNS
cord-005478-5iu38pr6	2209	10	;	;	:
cord-005478-5iu38pr6	2209	11	OS	OS	NNP
cord-005478-5iu38pr6	2209	12	was	be	VBD
cord-005478-5iu38pr6	2209	13	estimated	estimate	VBN
cord-005478-5iu38pr6	2209	14	with	with	IN
cord-005478-5iu38pr6	2209	15	the	the	DT
cord-005478-5iu38pr6	2209	16	Kaplan	Kaplan	NNP
cord-005478-5iu38pr6	2209	17	-	-	HYPH
cord-005478-5iu38pr6	2209	18	Meier	Meier	NNP
cord-005478-5iu38pr6	2209	19	method	method	NN
cord-005478-5iu38pr6	2209	20	.	.	.
cord-005478-5iu38pr6	2210	1	A	a	DT
cord-005478-5iu38pr6	2210	2	panel	panel	NN
cord-005478-5iu38pr6	2210	3	of	of	IN
cord-005478-5iu38pr6	2210	4	46	46	CD
cord-005478-5iu38pr6	2210	5	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2210	6	and	and	CC
cord-005478-5iu38pr6	2210	7	immune	immune	JJ
cord-005478-5iu38pr6	2210	8	cell	cell	NN
cord-005478-5iu38pr6	2210	9	subsets	subset	NNS
cord-005478-5iu38pr6	2210	10	were	be	VBD
cord-005478-5iu38pr6	2210	11	measured	measure	VBN
cord-005478-5iu38pr6	2210	12	before	before	IN
cord-005478-5iu38pr6	2210	13	treatment	treatment	NN
cord-005478-5iu38pr6	2210	14	and	and	CC
cord-005478-5iu38pr6	2210	15	once	once	RB
cord-005478-5iu38pr6	2210	16	weekly	weekly	RB
cord-005478-5iu38pr6	2210	17	during	during	IN
cord-005478-5iu38pr6	2210	18	treatment	treatment	NN
cord-005478-5iu38pr6	2210	19	by	by	IN
cord-005478-5iu38pr6	2210	20	a	a	DT
cord-005478-5iu38pr6	2210	21	Luminex	Luminex	NNP
cord-005478-5iu38pr6	2210	22	assay	assay	NN
cord-005478-5iu38pr6	2210	23	and	and	CC
cord-005478-5iu38pr6	2210	24	by	by	IN
cord-005478-5iu38pr6	2210	25	flow	flow	NN
cord-005478-5iu38pr6	2210	26	cytometry	cytometry	NN
cord-005478-5iu38pr6	2210	27	,	,	,
cord-005478-5iu38pr6	2210	28	respectively	respectively	RB
cord-005478-5iu38pr6	2210	29	.	.	.
cord-005478-5iu38pr6	2211	1	Results	result	NNS
cord-005478-5iu38pr6	2211	2	:	:	:
cord-005478-5iu38pr6	2212	1	Sixteen	sixteen	CD
cord-005478-5iu38pr6	2212	2	patients	patient	NNS
cord-005478-5iu38pr6	2212	3	were	be	VBD
cord-005478-5iu38pr6	2212	4	treated	treat	VBN
cord-005478-5iu38pr6	2212	5	for	for	IN
cord-005478-5iu38pr6	2212	6	gut	gut	NN
cord-005478-5iu38pr6	2212	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2212	8	between	between	IN
cord-005478-5iu38pr6	2212	9	September	September	NNP
cord-005478-5iu38pr6	2212	10	2016	2016	CD
cord-005478-5iu38pr6	2212	11	and	and	CC
cord-005478-5iu38pr6	2212	12	March	March	NNP
cord-005478-5iu38pr6	2212	13	2018	2018	CD
cord-005478-5iu38pr6	2212	14	.	.	.
cord-005478-5iu38pr6	2213	1	Median	median	JJ
cord-005478-5iu38pr6	2213	2	age	age	NN
cord-005478-5iu38pr6	2213	3	was	be	VBD
cord-005478-5iu38pr6	2213	4	50	50	CD
cord-005478-5iu38pr6	2213	5	years	year	NNS
cord-005478-5iu38pr6	2214	1	(	(	-LRB-
cord-005478-5iu38pr6	2214	2	range	range	NNP
cord-005478-5iu38pr6	2214	3	18	18	CD
cord-005478-5iu38pr6	2214	4	-	-	SYM
cord-005478-5iu38pr6	2214	5	56	56	CD
cord-005478-5iu38pr6	2214	6	)	)	-RRB-
cord-005478-5iu38pr6	2214	7	.	.	.
cord-005478-5iu38pr6	2215	1	αAT	αAT	VBG
cord-005478-5iu38pr6	2215	2	was	be	VBD
cord-005478-5iu38pr6	2215	3	administered	administer	VBN
cord-005478-5iu38pr6	2215	4	at	at	IN
cord-005478-5iu38pr6	2215	5	a	a	DT
cord-005478-5iu38pr6	2215	6	median	median	JJ
cord-005478-5iu38pr6	2215	7	time	time	NN
cord-005478-5iu38pr6	2215	8	of	of	IN
cord-005478-5iu38pr6	2215	9	104	104	CD
cord-005478-5iu38pr6	2215	10	days	day	NNS
cord-005478-5iu38pr6	2215	11	from	from	IN
cord-005478-5iu38pr6	2215	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	2215	13	(	(	-LRB-
cord-005478-5iu38pr6	2215	14	range	range	NNP
cord-005478-5iu38pr6	2215	15	38	38	CD
cord-005478-5iu38pr6	2215	16	-	-	SYM
cord-005478-5iu38pr6	2215	17	215	215	CD
cord-005478-5iu38pr6	2215	18	)	)	-RRB-
cord-005478-5iu38pr6	2215	19	and	and	CC
cord-005478-5iu38pr6	2215	20	of	of	IN
cord-005478-5iu38pr6	2215	21	65	65	CD
cord-005478-5iu38pr6	2215	22	days	day	NNS
cord-005478-5iu38pr6	2215	23	from	from	IN
cord-005478-5iu38pr6	2215	24	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2215	25	onset	onset	NN
cord-005478-5iu38pr6	2216	1	(	(	-LRB-
cord-005478-5iu38pr6	2216	2	range	range	NNP
cord-005478-5iu38pr6	2216	3	12	12	CD
cord-005478-5iu38pr6	2216	4	-	-	SYM
cord-005478-5iu38pr6	2216	5	198	198	CD
cord-005478-5iu38pr6	2216	6	)	)	-RRB-
cord-005478-5iu38pr6	2216	7	.	.	.
cord-005478-5iu38pr6	2217	1	Acute	acute	JJ
cord-005478-5iu38pr6	2217	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2217	3	was	be	VBD
cord-005478-5iu38pr6	2217	4	scored	score	VBN
cord-005478-5iu38pr6	2217	5	as	as	IN
cord-005478-5iu38pr6	2217	6	grade	grade	NN
cord-005478-5iu38pr6	2217	7	II	II	NNP
cord-005478-5iu38pr6	2217	8	in	in	IN
cord-005478-5iu38pr6	2217	9	28	28	CD
cord-005478-5iu38pr6	2217	10	%	%	NN
cord-005478-5iu38pr6	2217	11	of	of	IN
cord-005478-5iu38pr6	2217	12	patients	patient	NNS
cord-005478-5iu38pr6	2217	13	,	,	,
cord-005478-5iu38pr6	2217	14	grade	grade	NN
cord-005478-5iu38pr6	2217	15	III	iii	CD
cord-005478-5iu38pr6	2217	16	in	in	IN
cord-005478-5iu38pr6	2217	17	66	66	CD
cord-005478-5iu38pr6	2217	18	%	%	NN
cord-005478-5iu38pr6	2217	19	,	,	,
cord-005478-5iu38pr6	2217	20	grade	grade	NN
cord-005478-5iu38pr6	2217	21	IV	IV	NNP
cord-005478-5iu38pr6	2217	22	in	in	IN
cord-005478-5iu38pr6	2217	23	6	6	CD
cord-005478-5iu38pr6	2217	24	%	%	NN
cord-005478-5iu38pr6	2217	25	.	.	.
cord-005478-5iu38pr6	2218	1	Sixty	sixty	CD
cord-005478-5iu38pr6	2218	2	-	-	HYPH
cord-005478-5iu38pr6	2218	3	seven	seven	CD
cord-005478-5iu38pr6	2218	4	percent	percent	NN
cord-005478-5iu38pr6	2218	5	of	of	IN
cord-005478-5iu38pr6	2218	6	patients	patient	NNS
cord-005478-5iu38pr6	2218	7	had	have	VBD
cord-005478-5iu38pr6	2218	8	already	already	RB
cord-005478-5iu38pr6	2218	9	received	receive	VBN
cord-005478-5iu38pr6	2218	10	one	one	CD
cord-005478-5iu38pr6	2218	11	or	or	CC
cord-005478-5iu38pr6	2218	12	more	more	JJR
cord-005478-5iu38pr6	2218	13	lines	line	NNS
cord-005478-5iu38pr6	2218	14	of	of	IN
cord-005478-5iu38pr6	2218	15	treatment	treatment	NN
cord-005478-5iu38pr6	2218	16	other	other	JJ
cord-005478-5iu38pr6	2218	17	than	than	IN
cord-005478-5iu38pr6	2218	18	steroids	steroid	NNS
cord-005478-5iu38pr6	2218	19	,	,	,
cord-005478-5iu38pr6	2218	20	including	include	VBG
cord-005478-5iu38pr6	2218	21	ruxolitinib	ruxolitinib	NNP
cord-005478-5iu38pr6	2218	22	,	,	,
cord-005478-5iu38pr6	2218	23	etanercept	etanercept	NNP
cord-005478-5iu38pr6	2218	24	,	,	,
cord-005478-5iu38pr6	2218	25	ATG	ATG	NNP
cord-005478-5iu38pr6	2218	26	;	;	:
cord-005478-5iu38pr6	2218	27	ORR	ORR	NNP
cord-005478-5iu38pr6	2218	28	was	be	VBD
cord-005478-5iu38pr6	2218	29	44	44	CD
cord-005478-5iu38pr6	2218	30	%	%	NN
cord-005478-5iu38pr6	2218	31	with	with	IN
cord-005478-5iu38pr6	2218	32	a	a	DT
cord-005478-5iu38pr6	2218	33	CR	cr	NN
cord-005478-5iu38pr6	2218	34	rate	rate	NN
cord-005478-5iu38pr6	2218	35	of	of	IN
cord-005478-5iu38pr6	2218	36	27	27	CD
cord-005478-5iu38pr6	2218	37	%	%	NN
cord-005478-5iu38pr6	2218	38	;	;	,
cord-005478-5iu38pr6	2218	39	median	median	JJ
cord-005478-5iu38pr6	2218	40	time	time	NN
cord-005478-5iu38pr6	2218	41	to	to	IN
cord-005478-5iu38pr6	2218	42	best	good	JJS
cord-005478-5iu38pr6	2218	43	response	response	NN
cord-005478-5iu38pr6	2218	44	was	be	VBD
cord-005478-5iu38pr6	2218	45	21	21	CD
cord-005478-5iu38pr6	2218	46	days	day	NNS
cord-005478-5iu38pr6	2219	1	(	(	-LRB-
cord-005478-5iu38pr6	2219	2	range	range	NNP
cord-005478-5iu38pr6	2219	3	6	6	CD
cord-005478-5iu38pr6	2219	4	-	-	SYM
cord-005478-5iu38pr6	2219	5	26	26	CD
cord-005478-5iu38pr6	2219	6	)	)	-RRB-
cord-005478-5iu38pr6	2219	7	,	,	,
cord-005478-5iu38pr6	2219	8	with	with	IN
cord-005478-5iu38pr6	2219	9	a	a	DT
cord-005478-5iu38pr6	2219	10	continued	continue	VBN
cord-005478-5iu38pr6	2219	11	ORR	ORR	NNP
cord-005478-5iu38pr6	2219	12	at	at	IN
cord-005478-5iu38pr6	2219	13	day	day	NN
cord-005478-5iu38pr6	2219	14	56	56	CD
cord-005478-5iu38pr6	2219	15	of	of	IN
cord-005478-5iu38pr6	2219	16	39	39	CD
cord-005478-5iu38pr6	2219	17	%	%	NN
cord-005478-5iu38pr6	2219	18	.	.	.
cord-005478-5iu38pr6	2220	1	The	the	DT
cord-005478-5iu38pr6	2220	2	overall	overall	JJ
cord-005478-5iu38pr6	2220	3	rate	rate	NN
cord-005478-5iu38pr6	2220	4	of	of	IN
cord-005478-5iu38pr6	2220	5	gastrointestinal	gastrointestinal	JJ
cord-005478-5iu38pr6	2220	6	responses	response	NNS
cord-005478-5iu38pr6	2220	7	was	be	VBD
cord-005478-5iu38pr6	2220	8	61	61	CD
cord-005478-5iu38pr6	2220	9	%	%	NN
cord-005478-5iu38pr6	2220	10	.	.	.
cord-005478-5iu38pr6	2221	1	Median	median	JJ
cord-005478-5iu38pr6	2221	2	follow	follow	NN
cord-005478-5iu38pr6	2221	3	-	-	HYPH
cord-005478-5iu38pr6	2221	4	up	up	NN
cord-005478-5iu38pr6	2221	5	of	of	IN
cord-005478-5iu38pr6	2221	6	living	live	VBG
cord-005478-5iu38pr6	2221	7	patients	patient	NNS
cord-005478-5iu38pr6	2221	8	was	be	VBD
cord-005478-5iu38pr6	2221	9	440	440	CD
cord-005478-5iu38pr6	2221	10	days	day	NNS
cord-005478-5iu38pr6	2221	11	(	(	-LRB-
cord-005478-5iu38pr6	2221	12	range	range	NNP
cord-005478-5iu38pr6	2221	13	84	84	CD
cord-005478-5iu38pr6	2221	14	-	-	SYM
cord-005478-5iu38pr6	2221	15	602	602	CD
cord-005478-5iu38pr6	2221	16	)	)	-RRB-
cord-005478-5iu38pr6	2221	17	;	;	:
cord-005478-5iu38pr6	2221	18	median	median	JJ
cord-005478-5iu38pr6	2221	19	OS	OS	NNP
cord-005478-5iu38pr6	2221	20	was	be	VBD
cord-005478-5iu38pr6	2222	1	138	138	CD
cord-005478-5iu38pr6	2222	2	days	day	NNS
cord-005478-5iu38pr6	2222	3	and	and	CC
cord-005478-5iu38pr6	2222	4	1-year	1-year	CD
cord-005478-5iu38pr6	2222	5	OS	OS	NNP
cord-005478-5iu38pr6	2222	6	was	be	VBD
cord-005478-5iu38pr6	2222	7	48	48	CD
cord-005478-5iu38pr6	2222	8	%	%	NN
cord-005478-5iu38pr6	2222	9	(	(	-LRB-
cord-005478-5iu38pr6	2222	10	95	95	CD
cord-005478-5iu38pr6	2222	11	%	%	NN
cord-005478-5iu38pr6	2222	12	CI	CI	NNP
cord-005478-5iu38pr6	2222	13	26	26	CD
cord-005478-5iu38pr6	2222	14	%	%	NN
cord-005478-5iu38pr6	2222	15	-74%).The	-74%).the	NN
cord-005478-5iu38pr6	2223	1	most	most	RBS
cord-005478-5iu38pr6	2223	2	common	common	JJ
cord-005478-5iu38pr6	2223	3	infectious	infectious	JJ
cord-005478-5iu38pr6	2223	4	event	event	NN
cord-005478-5iu38pr6	2223	5	was	be	VBD
cord-005478-5iu38pr6	2223	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2223	7	reactivation	reactivation	NN
cord-005478-5iu38pr6	2223	8	(	(	-LRB-
cord-005478-5iu38pr6	2223	9	29	29	CD
cord-005478-5iu38pr6	2223	10	%	%	NN
cord-005478-5iu38pr6	2223	11	)	)	-RRB-
cord-005478-5iu38pr6	2223	12	;	;	:
cord-005478-5iu38pr6	2223	13	2	2	CD
cord-005478-5iu38pr6	2223	14	grade	grade	NN
cord-005478-5iu38pr6	2223	15	3	3	CD
cord-005478-5iu38pr6	2223	16	-	-	SYM
cord-005478-5iu38pr6	2223	17	4	4	CD
cord-005478-5iu38pr6	2223	18	infectious	infectious	JJ
cord-005478-5iu38pr6	2223	19	complications	complication	NNS
cord-005478-5iu38pr6	2223	20	were	be	VBD
cord-005478-5iu38pr6	2223	21	recorded	record	VBN
cord-005478-5iu38pr6	2223	22	.	.	.
cord-005478-5iu38pr6	2224	1	There	there	EX
cord-005478-5iu38pr6	2224	2	was	be	VBD
cord-005478-5iu38pr6	2224	3	no	no	DT
cord-005478-5iu38pr6	2224	4	quantitative	quantitative	JJ
cord-005478-5iu38pr6	2224	5	deficiency	deficiency	NN
cord-005478-5iu38pr6	2224	6	of	of	IN
cord-005478-5iu38pr6	2224	7	blood	blood	NN
cord-005478-5iu38pr6	2224	8	AAT	AAT	NNP
cord-005478-5iu38pr6	2224	9	levels	level	NNS
cord-005478-5iu38pr6	2224	10	before	before	IN
cord-005478-5iu38pr6	2224	11	treatment	treatment	NN
cord-005478-5iu38pr6	2224	12	(	(	-LRB-
cord-005478-5iu38pr6	2224	13	1.72	1.72	CD
cord-005478-5iu38pr6	2224	14	g	g	NN
cord-005478-5iu38pr6	2224	15	/	/	SYM
cord-005478-5iu38pr6	2224	16	L	L	NNP
cord-005478-5iu38pr6	2224	17	±	±	NNP
cord-005478-5iu38pr6	2224	18	0.46	0.46	CD
cord-005478-5iu38pr6	2224	19	)	)	-RRB-
cord-005478-5iu38pr6	2224	20	;	;	:
cord-005478-5iu38pr6	2224	21	blood	blood	NN
cord-005478-5iu38pr6	2224	22	αAT	αat	PRP
cord-005478-5iu38pr6	2224	23	rose	rise	VBD
cord-005478-5iu38pr6	2224	24	significantly	significantly	RB
cord-005478-5iu38pr6	2224	25	during	during	IN
cord-005478-5iu38pr6	2224	26	and	and	CC
cord-005478-5iu38pr6	2224	27	after	after	IN
cord-005478-5iu38pr6	2224	28	treatment	treatment	NN
cord-005478-5iu38pr6	2224	29	.	.	.
cord-005478-5iu38pr6	2225	1	Baseline	Baseline	NNP
cord-005478-5iu38pr6	2225	2	αAT	αat	IN
cord-005478-5iu38pr6	2225	3	level	level	NN
cord-005478-5iu38pr6	2225	4	didn´t	didn´t	TO
cord-005478-5iu38pr6	2225	5	differ	differ	VB
cord-005478-5iu38pr6	2225	6	between	between	IN
cord-005478-5iu38pr6	2225	7	responding	respond	VBG
cord-005478-5iu38pr6	2225	8	and	and	CC
cord-005478-5iu38pr6	2225	9	nonresponding	nonresponde	VBG
cord-005478-5iu38pr6	2225	10	patients	patient	NNS
cord-005478-5iu38pr6	2225	11	.	.	.
cord-005478-5iu38pr6	2226	1	A	a	DT
cord-005478-5iu38pr6	2226	2	cytokine	cytokine	NN
cord-005478-5iu38pr6	2226	3	profile	profile	NN
cord-005478-5iu38pr6	2226	4	was	be	VBD
cord-005478-5iu38pr6	2226	5	evaluable	evaluable	JJ
cord-005478-5iu38pr6	2226	6	in	in	IN
cord-005478-5iu38pr6	2226	7	12	12	CD
cord-005478-5iu38pr6	2226	8	patients	patient	NNS
cord-005478-5iu38pr6	2226	9	;	;	:
cord-005478-5iu38pr6	2226	10	no	no	DT
cord-005478-5iu38pr6	2226	11	statistically	statistically	RB
cord-005478-5iu38pr6	2226	12	significant	significant	JJ
cord-005478-5iu38pr6	2226	13	increase	increase	NN
cord-005478-5iu38pr6	2226	14	or	or	CC
cord-005478-5iu38pr6	2226	15	decrease	decrease	NN
cord-005478-5iu38pr6	2226	16	in	in	IN
cord-005478-5iu38pr6	2226	17	cytokine	cytokine	NN
cord-005478-5iu38pr6	2226	18	plasma	plasma	NN
cord-005478-5iu38pr6	2226	19	concentration	concentration	NN
cord-005478-5iu38pr6	2226	20	after	after	IN
cord-005478-5iu38pr6	2226	21	αAT	αAT	''
cord-005478-5iu38pr6	2226	22	infusion	infusion	NN
cord-005478-5iu38pr6	2226	23	was	be	VBD
cord-005478-5iu38pr6	2226	24	observed	observe	VBN
cord-005478-5iu38pr6	2226	25	.	.	.
cord-005478-5iu38pr6	2227	1	Surprisingly	surprisingly	RB
cord-005478-5iu38pr6	2227	2	,	,	,
cord-005478-5iu38pr6	2227	3	a	a	DT
cord-005478-5iu38pr6	2227	4	decrease	decrease	NN
cord-005478-5iu38pr6	2227	5	in	in	IN
cord-005478-5iu38pr6	2227	6	circulating	circulate	VBG
cord-005478-5iu38pr6	2227	7	T	T	NNP
cord-005478-5iu38pr6	2227	8	regs	reg	NNS
cord-005478-5iu38pr6	2227	9	after	after	IN
cord-005478-5iu38pr6	2227	10	exposure	exposure	NN
cord-005478-5iu38pr6	2227	11	was	be	VBD
cord-005478-5iu38pr6	2227	12	found	find	VBN
cord-005478-5iu38pr6	2227	13	(	(	-LRB-
cord-005478-5iu38pr6	2227	14	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	2227	15	)	)	-RRB-
cord-005478-5iu38pr6	2227	16	,	,	,
cord-005478-5iu38pr6	2227	17	regardless	regardless	RB
cord-005478-5iu38pr6	2227	18	of	of	IN
cord-005478-5iu38pr6	2227	19	patients´responding	patients´responde	VBG
cord-005478-5iu38pr6	2227	20	status	status	NN
cord-005478-5iu38pr6	2227	21	.	.	.
cord-005478-5iu38pr6	2228	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2228	2	:	:	:
cord-005478-5iu38pr6	2229	1	Treatment	treatment	NN
cord-005478-5iu38pr6	2229	2	with	with	IN
cord-005478-5iu38pr6	2229	3	αAT	αAT	''
cord-005478-5iu38pr6	2229	4	was	be	VBD
cord-005478-5iu38pr6	2229	5	safe	safe	JJ
cord-005478-5iu38pr6	2229	6	and	and	CC
cord-005478-5iu38pr6	2229	7	effective	effective	JJ
cord-005478-5iu38pr6	2229	8	in	in	IN
cord-005478-5iu38pr6	2229	9	a	a	DT
cord-005478-5iu38pr6	2229	10	cohort	cohort	NN
cord-005478-5iu38pr6	2229	11	of	of	IN
cord-005478-5iu38pr6	2229	12	SR	SR	NNP
cord-005478-5iu38pr6	2229	13	-	-	HYPH
cord-005478-5iu38pr6	2229	14	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2229	15	high	high	JJ
cord-005478-5iu38pr6	2229	16	risk	risk	NN
cord-005478-5iu38pr6	2229	17	,	,	,
cord-005478-5iu38pr6	2229	18	pre	pre	VB
cord-005478-5iu38pr6	2229	19	-	-	VBN
cord-005478-5iu38pr6	2229	20	treated	treat	VBN
cord-005478-5iu38pr6	2229	21	patients	patient	NNS
cord-005478-5iu38pr6	2229	22	and	and	CC
cord-005478-5iu38pr6	2229	23	should	should	MD
cord-005478-5iu38pr6	2229	24	be	be	VB
cord-005478-5iu38pr6	2229	25	considered	consider	VBN
cord-005478-5iu38pr6	2229	26	as	as	IN
cord-005478-5iu38pr6	2229	27	a	a	DT
cord-005478-5iu38pr6	2229	28	possible	possible	JJ
cord-005478-5iu38pr6	2229	29	alternative	alternative	NN
cord-005478-5iu38pr6	2229	30	.	.	.
cord-005478-5iu38pr6	2230	1	Changes	change	NNS
cord-005478-5iu38pr6	2230	2	in	in	IN
cord-005478-5iu38pr6	2230	3	the	the	DT
cord-005478-5iu38pr6	2230	4	cytokine	cytokine	NN
cord-005478-5iu38pr6	2230	5	milieu	milieu	NN
cord-005478-5iu38pr6	2230	6	and	and	CC
cord-005478-5iu38pr6	2230	7	T	t	NN
cord-005478-5iu38pr6	2230	8	-	-	HYPH
cord-005478-5iu38pr6	2230	9	cell	cell	NN
cord-005478-5iu38pr6	2230	10	subsets	subset	NNS
cord-005478-5iu38pr6	2230	11	shown	show	VBN
cord-005478-5iu38pr6	2230	12	in	in	IN
cord-005478-5iu38pr6	2230	13	murine	murine	JJ
cord-005478-5iu38pr6	2230	14	models	model	NNS
cord-005478-5iu38pr6	2230	15	were	be	VBD
cord-005478-5iu38pr6	2230	16	not	not	RB
cord-005478-5iu38pr6	2230	17	observed	observe	VBN
cord-005478-5iu38pr6	2230	18	in	in	IN
cord-005478-5iu38pr6	2230	19	a	a	DT
cord-005478-5iu38pr6	2230	20	real	real	JJ
cord-005478-5iu38pr6	2230	21	-	-	HYPH
cord-005478-5iu38pr6	2230	22	life	life	NN
cord-005478-5iu38pr6	2230	23	setting	setting	NN
cord-005478-5iu38pr6	2230	24	.	.	.
cord-005478-5iu38pr6	2231	1	Table	table	NN
cord-005478-5iu38pr6	2231	2	1	1	CD
cord-005478-5iu38pr6	2231	3	.	.	.
cord-005478-5iu38pr6	2232	1	Peripheral	peripheral	JJ
cord-005478-5iu38pr6	2232	2	blood	blood	NN
cord-005478-5iu38pr6	2232	3	was	be	VBD
cord-005478-5iu38pr6	2232	4	used	use	VBN
cord-005478-5iu38pr6	2232	5	as	as	IN
cord-005478-5iu38pr6	2232	6	graft	graft	NN
cord-005478-5iu38pr6	2232	7	source	source	NN
cord-005478-5iu38pr6	2232	8	in	in	IN
cord-005478-5iu38pr6	2232	9	87	87	CD
cord-005478-5iu38pr6	2232	10	%	%	NN
cord-005478-5iu38pr6	2232	11	of	of	IN
cord-005478-5iu38pr6	2232	12	the	the	DT
cord-005478-5iu38pr6	2232	13	patients	patient	NNS
cord-005478-5iu38pr6	2232	14	in	in	IN
cord-005478-5iu38pr6	2232	15	the	the	DT
cord-005478-5iu38pr6	2232	16	ATG	ATG	NNP
cord-005478-5iu38pr6	2232	17	group	group	NN
cord-005478-5iu38pr6	2232	18	and	and	CC
cord-005478-5iu38pr6	2232	19	in	in	IN
cord-005478-5iu38pr6	2232	20	78	78	CD
cord-005478-5iu38pr6	2232	21	%	%	NN
cord-005478-5iu38pr6	2232	22	in	in	IN
cord-005478-5iu38pr6	2232	23	the	the	DT
cord-005478-5iu38pr6	2232	24	PT	PT	NNP
cord-005478-5iu38pr6	2232	25	-	-	HYPH
cord-005478-5iu38pr6	2232	26	CY	CY	NNP
cord-005478-5iu38pr6	2232	27	group	group	NN
cord-005478-5iu38pr6	2232	28	.	.	.
cord-005478-5iu38pr6	2233	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2233	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2233	3	consisted	consist	VBD
cord-005478-5iu38pr6	2233	4	in	in	IN
cord-005478-5iu38pr6	2233	5	ATG	ATG	NNP
cord-005478-5iu38pr6	2233	6	2mg	2mg	NNP
cord-005478-5iu38pr6	2233	7	/	/	SYM
cord-005478-5iu38pr6	2233	8	m	m	NN
cord-005478-5iu38pr6	2233	9	2	2	CD
cord-005478-5iu38pr6	2233	10	days	day	NNS
cord-005478-5iu38pr6	2233	11	-4	-4	ADD
cord-005478-5iu38pr6	2233	12	to	to	IN
cord-005478-5iu38pr6	2233	13	-2	-2	NNP
cord-005478-5iu38pr6	2233	14	,	,	,
cord-005478-5iu38pr6	2233	15	MTX	MTX	NNP
cord-005478-5iu38pr6	2233	16	days	day	NNS
cord-005478-5iu38pr6	2233	17	+1	+1	HYPH
cord-005478-5iu38pr6	2233	18	,	,	,
cord-005478-5iu38pr6	2233	19	+3	+3	NNP
cord-005478-5iu38pr6	2233	20	,	,	,
cord-005478-5iu38pr6	2233	21	+6	+6	NN
cord-005478-5iu38pr6	2233	22	and	and	CC
cord-005478-5iu38pr6	2233	23	+11	+11	NNS
cord-005478-5iu38pr6	2233	24	,	,	,
cord-005478-5iu38pr6	2233	25	and	and	CC
cord-005478-5iu38pr6	2233	26	CsA	csa	NN
cord-005478-5iu38pr6	2233	27	from	from	IN
cord-005478-5iu38pr6	2233	28	day	day	NN
cord-005478-5iu38pr6	2233	29	-1	-1	CD
cord-005478-5iu38pr6	2233	30	in	in	IN
cord-005478-5iu38pr6	2233	31	the	the	DT
cord-005478-5iu38pr6	2233	32	ATG	ATG	NNP
cord-005478-5iu38pr6	2233	33	group	group	NN
cord-005478-5iu38pr6	2233	34	.	.	.
cord-005478-5iu38pr6	2234	1	The	the	DT
cord-005478-5iu38pr6	2234	2	PT	PT	NNP
cord-005478-5iu38pr6	2234	3	-	-	HYPH
cord-005478-5iu38pr6	2234	4	CY	CY	NNP
cord-005478-5iu38pr6	2234	5	group	group	NN
cord-005478-5iu38pr6	2234	6	received	receive	VBD
cord-005478-5iu38pr6	2234	7	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2234	8	50	50	CD
cord-005478-5iu38pr6	2234	9	mg	mg	NNP
cord-005478-5iu38pr6	2234	10	/	/	SYM
cord-005478-5iu38pr6	2234	11	kg	kg	NNP
cord-005478-5iu38pr6	2234	12	/	/	SYM
cord-005478-5iu38pr6	2234	13	d	d	NN
cord-005478-5iu38pr6	2234	14	on	on	IN
cord-005478-5iu38pr6	2234	15	days	day	NNS
cord-005478-5iu38pr6	2234	16	+3	+3	NNP
cord-005478-5iu38pr6	2234	17	and	and	CC
cord-005478-5iu38pr6	2234	18	+4	+4	NN
cord-005478-5iu38pr6	2234	19	,	,	,
cord-005478-5iu38pr6	2234	20	followed	follow	VBN
cord-005478-5iu38pr6	2234	21	by	by	IN
cord-005478-5iu38pr6	2234	22	either	either	CC
cord-005478-5iu38pr6	2234	23	CsA	csa	NN
cord-005478-5iu38pr6	2234	24	or	or	CC
cord-005478-5iu38pr6	2234	25	tacrolimus	tacrolimus	NNP
cord-005478-5iu38pr6	2234	26	and	and	CC
cord-005478-5iu38pr6	2234	27	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	2234	28	mofetil	mofetil	NNP
cord-005478-5iu38pr6	2234	29	(	(	-LRB-
cord-005478-5iu38pr6	2234	30	MMF	MMF	NNP
cord-005478-5iu38pr6	2234	31	)	)	-RRB-
cord-005478-5iu38pr6	2234	32	from	from	IN
cord-005478-5iu38pr6	2234	33	day	day	NN
cord-005478-5iu38pr6	2234	34	+5	+5	NN
cord-005478-5iu38pr6	2234	35	in	in	IN
cord-005478-5iu38pr6	2234	36	30	30	CD
cord-005478-5iu38pr6	2234	37	patients	patient	NNS
cord-005478-5iu38pr6	2234	38	(	(	-LRB-
cord-005478-5iu38pr6	2234	39	42	42	CD
cord-005478-5iu38pr6	2234	40	%	%	NN
cord-005478-5iu38pr6	2234	41	)	)	-RRB-
cord-005478-5iu38pr6	2234	42	,	,	,
cord-005478-5iu38pr6	2234	43	cyclophosphamide	cyclophosphamide	RB
cord-005478-5iu38pr6	2234	44	on	on	IN
cord-005478-5iu38pr6	2234	45	days	day	NNS
cord-005478-5iu38pr6	2234	46	+3	+3	NNP
cord-005478-5iu38pr6	2234	47	and	and	CC
cord-005478-5iu38pr6	2234	48	+5	+5	HYPH
cord-005478-5iu38pr6	2234	49	combined	combine	VBN
cord-005478-5iu38pr6	2234	50	with	with	IN
cord-005478-5iu38pr6	2234	51	CsA	csa	NN
cord-005478-5iu38pr6	2234	52	or	or	CC
cord-005478-5iu38pr6	2234	53	tacrolimus	tacrolimus	NN
cord-005478-5iu38pr6	2234	54	from	from	IN
cord-005478-5iu38pr6	2234	55	day	day	NN
cord-005478-5iu38pr6	2234	56	0	0	CD
cord-005478-5iu38pr6	2234	57	in	in	IN
cord-005478-5iu38pr6	2234	58	26	26	CD
cord-005478-5iu38pr6	2234	59	patients	patient	NNS
cord-005478-5iu38pr6	2234	60	(	(	-LRB-
cord-005478-5iu38pr6	2234	61	36	36	CD
cord-005478-5iu38pr6	2234	62	%	%	NN
cord-005478-5iu38pr6	2234	63	)	)	-RRB-
cord-005478-5iu38pr6	2234	64	,	,	,
cord-005478-5iu38pr6	2234	65	or	or	CC
cord-005478-5iu38pr6	2234	66	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2234	67	on	on	IN
cord-005478-5iu38pr6	2234	68	days	day	NNS
cord-005478-5iu38pr6	2234	69	+3	+3	NNP
cord-005478-5iu38pr6	2234	70	and	and	CC
cord-005478-5iu38pr6	2234	71	+5	+5	XX
cord-005478-5iu38pr6	2234	72	combined	combine	VBN
cord-005478-5iu38pr6	2234	73	with	with	IN
cord-005478-5iu38pr6	2234	74	tacrolimus	tacrolimus	NN
cord-005478-5iu38pr6	2234	75	and	and	CC
cord-005478-5iu38pr6	2234	76	sirolimus	sirolimus	NN
cord-005478-5iu38pr6	2234	77	from	from	IN
cord-005478-5iu38pr6	2234	78	day	day	NN
cord-005478-5iu38pr6	2234	79	+5	+5	.
cord-005478-5iu38pr6	2234	80	in	in	IN
cord-005478-5iu38pr6	2234	81	16	16	CD
cord-005478-5iu38pr6	2234	82	patients	patient	NNS
cord-005478-5iu38pr6	2234	83	(	(	-LRB-
cord-005478-5iu38pr6	2234	84	22	22	CD
cord-005478-5iu38pr6	2234	85	%	%	NN
cord-005478-5iu38pr6	2234	86	)	)	-RRB-
cord-005478-5iu38pr6	2234	87	.	.	.
cord-005478-5iu38pr6	2235	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2235	2	incidence	incidence	NN
cord-005478-5iu38pr6	2235	3	at	at	IN
cord-005478-5iu38pr6	2235	4	100	100	CD
cord-005478-5iu38pr6	2235	5	days	day	NNS
cord-005478-5iu38pr6	2235	6	of	of	IN
cord-005478-5iu38pr6	2235	7	grade	grade	NN
cord-005478-5iu38pr6	2235	8	II	II	NNP
cord-005478-5iu38pr6	2235	9	-	-	HYPH
cord-005478-5iu38pr6	2235	10	IV	IV	NNP
cord-005478-5iu38pr6	2235	11	(	(	-LRB-
cord-005478-5iu38pr6	2235	12	67	67	CD
cord-005478-5iu38pr6	2235	13	%	%	NN
cord-005478-5iu38pr6	2235	14	vs	vs	IN
cord-005478-5iu38pr6	2235	15	46	46	CD
cord-005478-5iu38pr6	2235	16	%	%	NN
cord-005478-5iu38pr6	2235	17	,	,	,
cord-005478-5iu38pr6	2235	18	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	2235	19	)	)	-RRB-
cord-005478-5iu38pr6	2235	20	and	and	CC
cord-005478-5iu38pr6	2235	21	III	III	NNP
cord-005478-5iu38pr6	2235	22	-	-	HYPH
cord-005478-5iu38pr6	2235	23	IV	IV	NNP
cord-005478-5iu38pr6	2235	24	(	(	-LRB-
cord-005478-5iu38pr6	2235	25	41	41	CD
cord-005478-5iu38pr6	2235	26	%	%	NN
cord-005478-5iu38pr6	2235	27	vs	vs	IN
cord-005478-5iu38pr6	2235	28	3	3	CD
cord-005478-5iu38pr6	2235	29	%	%	NN
cord-005478-5iu38pr6	2235	30	,	,	,
cord-005478-5iu38pr6	2235	31	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	2235	32	)	)	-RRB-
cord-005478-5iu38pr6	2236	1	acute	acute	JJ
cord-005478-5iu38pr6	2236	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2236	3	,	,	,
cord-005478-5iu38pr6	2236	4	were	be	VBD
cord-005478-5iu38pr6	2236	5	significantly	significantly	RB
cord-005478-5iu38pr6	2236	6	higher	high	JJR
cord-005478-5iu38pr6	2236	7	in	in	IN
cord-005478-5iu38pr6	2236	8	the	the	DT
cord-005478-5iu38pr6	2236	9	MTX	MTX	NNP
cord-005478-5iu38pr6	2236	10	-	-	HYPH
cord-005478-5iu38pr6	2236	11	CsA	CsA	NNP
cord-005478-5iu38pr6	2236	12	group	group	NN
cord-005478-5iu38pr6	2236	13	(	(	-LRB-
cord-005478-5iu38pr6	2236	14	Figure	Figure	NNP
cord-005478-5iu38pr6	2236	15	1A	1a	NN
cord-005478-5iu38pr6	2236	16	)	)	-RRB-
cord-005478-5iu38pr6	2236	17	.	.	.
cord-005478-5iu38pr6	2237	1	There	there	EX
cord-005478-5iu38pr6	2237	2	were	be	VBD
cord-005478-5iu38pr6	2237	3	no	no	DT
cord-005478-5iu38pr6	2237	4	differences	difference	NNS
cord-005478-5iu38pr6	2237	5	in	in	IN
cord-005478-5iu38pr6	2237	6	the	the	DT
cord-005478-5iu38pr6	2237	7	2-year	2-year	CD
cord-005478-5iu38pr6	2237	8	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2237	9	incidence	incidence	NN
cord-005478-5iu38pr6	2237	10	of	of	IN
cord-005478-5iu38pr6	2237	11	chronic	chronic	JJ
cord-005478-5iu38pr6	2237	12	moderate	moderate	JJ
cord-005478-5iu38pr6	2237	13	to	to	IN
cord-005478-5iu38pr6	2237	14	severe	severe	JJ
cord-005478-5iu38pr6	2237	15	GVHD	gvhd	NN
cord-005478-5iu38pr6	2237	16	between	between	IN
cord-005478-5iu38pr6	2237	17	the	the	DT
cord-005478-5iu38pr6	2237	18	ATG	ATG	NNP
cord-005478-5iu38pr6	2237	19	and	and	CC
cord-005478-5iu38pr6	2237	20	the	the	DT
cord-005478-5iu38pr6	2237	21	PT	PT	NNP
cord-005478-5iu38pr6	2237	22	-	-	HYPH
cord-005478-5iu38pr6	2237	23	CY	CY	NNP
cord-005478-5iu38pr6	2237	24	group	group	NN
cord-005478-5iu38pr6	2237	25	(	(	-LRB-
cord-005478-5iu38pr6	2237	26	30	30	CD
cord-005478-5iu38pr6	2237	27	%	%	NN
cord-005478-5iu38pr6	2237	28	vs	vs	IN
cord-005478-5iu38pr6	2237	29	24	24	CD
cord-005478-5iu38pr6	2237	30	%	%	NN
cord-005478-5iu38pr6	2237	31	,	,	,
cord-005478-5iu38pr6	2237	32	p=0.6	p=0.6	NNP
cord-005478-5iu38pr6	2237	33	)	)	-RRB-
cord-005478-5iu38pr6	2237	34	.	.	.
cord-005478-5iu38pr6	2238	1	After	after	IN
cord-005478-5iu38pr6	2238	2	a	a	DT
cord-005478-5iu38pr6	2238	3	median	median	JJ
cord-005478-5iu38pr6	2238	4	follow	follow	NN
cord-005478-5iu38pr6	2238	5	-	-	HYPH
cord-005478-5iu38pr6	2238	6	up	up	NN
cord-005478-5iu38pr6	2238	7	of	of	IN
cord-005478-5iu38pr6	2238	8	90	90	CD
cord-005478-5iu38pr6	2238	9	months	month	NNS
cord-005478-5iu38pr6	2238	10	for	for	IN
cord-005478-5iu38pr6	2238	11	the	the	DT
cord-005478-5iu38pr6	2238	12	ATG	ATG	NNP
cord-005478-5iu38pr6	2238	13	group	group	NN
cord-005478-5iu38pr6	2238	14	and	and	CC
cord-005478-5iu38pr6	2238	15	26	26	CD
cord-005478-5iu38pr6	2238	16	months	month	NNS
cord-005478-5iu38pr6	2238	17	for	for	IN
cord-005478-5iu38pr6	2238	18	the	the	DT
cord-005478-5iu38pr6	2238	19	PT	PT	NNP
cord-005478-5iu38pr6	2238	20	-	-	HYPH
cord-005478-5iu38pr6	2238	21	CY	CY	NNP
cord-005478-5iu38pr6	2238	22	group	group	NN
cord-005478-5iu38pr6	2238	23	,	,	,
cord-005478-5iu38pr6	2238	24	2-year	2-year	JJ
cord-005478-5iu38pr6	2238	25	overall	overall	JJ
cord-005478-5iu38pr6	2238	26	survival	survival	NN
cord-005478-5iu38pr6	2238	27	(	(	-LRB-
cord-005478-5iu38pr6	2238	28	OS	OS	NNP
cord-005478-5iu38pr6	2238	29	)	)	-RRB-
cord-005478-5iu38pr6	2238	30	was	be	VBD
cord-005478-5iu38pr6	2238	31	higher	high	JJR
cord-005478-5iu38pr6	2238	32	in	in	IN
cord-005478-5iu38pr6	2238	33	the	the	DT
cord-005478-5iu38pr6	2238	34	PT	PT	NNP
cord-005478-5iu38pr6	2238	35	-	-	HYPH
cord-005478-5iu38pr6	2238	36	CY	CY	NNP
cord-005478-5iu38pr6	2238	37	group	group	NN
cord-005478-5iu38pr6	2238	38	(	(	-LRB-
cord-005478-5iu38pr6	2238	39	45	45	CD
cord-005478-5iu38pr6	2238	40	%	%	NN
cord-005478-5iu38pr6	2238	41	vs	vs	IN
cord-005478-5iu38pr6	2238	42	60	60	CD
cord-005478-5iu38pr6	2238	43	%	%	NN
cord-005478-5iu38pr6	2238	44	)	)	-RRB-
cord-005478-5iu38pr6	2238	45	although	although	IN
cord-005478-5iu38pr6	2238	46	not	not	RB
cord-005478-5iu38pr6	2238	47	statistically	statistically	RB
cord-005478-5iu38pr6	2238	48	significant	significant	JJ
cord-005478-5iu38pr6	2238	49	(	(	-LRB-
cord-005478-5iu38pr6	2238	50	p=0.09	p=0.09	NN
cord-005478-5iu38pr6	2238	51	)	)	-RRB-
cord-005478-5iu38pr6	2238	52	(	(	-LRB-
cord-005478-5iu38pr6	2239	1	Figure	figure	NN
cord-005478-5iu38pr6	2239	2	1B	1b	CD
cord-005478-5iu38pr6	2239	3	)	)	-RRB-
cord-005478-5iu38pr6	2239	4	.	.	.
cord-005478-5iu38pr6	2240	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2240	2	found	find	VBD
cord-005478-5iu38pr6	2240	3	no	no	DT
cord-005478-5iu38pr6	2240	4	differences	difference	NNS
cord-005478-5iu38pr6	2240	5	between	between	IN
cord-005478-5iu38pr6	2240	6	both	both	DT
cord-005478-5iu38pr6	2240	7	cohorts	cohort	NNS
cord-005478-5iu38pr6	2240	8	in	in	IN
cord-005478-5iu38pr6	2240	9	2-year	2-year	CD
cord-005478-5iu38pr6	2240	10	event	event	NN
cord-005478-5iu38pr6	2240	11	-	-	HYPH
cord-005478-5iu38pr6	2240	12	free	free	JJ
cord-005478-5iu38pr6	2240	13	survival	survival	NN
cord-005478-5iu38pr6	2240	14	(	(	-LRB-
cord-005478-5iu38pr6	2240	15	EFS	EFS	NNP
cord-005478-5iu38pr6	2240	16	)	)	-RRB-
cord-005478-5iu38pr6	2240	17	(	(	-LRB-
cord-005478-5iu38pr6	2240	18	46	46	CD
cord-005478-5iu38pr6	2240	19	%	%	NN
cord-005478-5iu38pr6	2240	20	and	and	CC
cord-005478-5iu38pr6	2240	21	50	50	CD
cord-005478-5iu38pr6	2240	22	%	%	NN
cord-005478-5iu38pr6	2240	23	,	,	,
cord-005478-5iu38pr6	2240	24	p=0.55	p=0.55	NNP
cord-005478-5iu38pr6	2240	25	)	)	-RRB-
cord-005478-5iu38pr6	2240	26	and	and	CC
cord-005478-5iu38pr6	2240	27	the	the	DT
cord-005478-5iu38pr6	2240	28	composite	composite	JJ
cord-005478-5iu38pr6	2240	29	endpoint	endpoint	NN
cord-005478-5iu38pr6	2240	30	of	of	IN
cord-005478-5iu38pr6	2240	31	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2240	32	-	-	HYPH
cord-005478-5iu38pr6	2240	33	free	free	JJ
cord-005478-5iu38pr6	2240	34	and	and	CC
cord-005478-5iu38pr6	2240	35	relapse	relapse	NN
cord-005478-5iu38pr6	2240	36	-	-	HYPH
cord-005478-5iu38pr6	2240	37	free	free	JJ
cord-005478-5iu38pr6	2240	38	survival	survival	NN
cord-005478-5iu38pr6	2240	39	(	(	-LRB-
cord-005478-5iu38pr6	2240	40	GFRS	GFRS	NNP
cord-005478-5iu38pr6	2240	41	)	)	-RRB-
cord-005478-5iu38pr6	2240	42	(	(	-LRB-
cord-005478-5iu38pr6	2240	43	38	38	CD
cord-005478-5iu38pr6	2240	44	%	%	NN
cord-005478-5iu38pr6	2240	45	vs	vs	IN
cord-005478-5iu38pr6	2240	46	40	40	CD
cord-005478-5iu38pr6	2240	47	%	%	NN
cord-005478-5iu38pr6	2240	48	,	,	,
cord-005478-5iu38pr6	2240	49	p=0.253	p=0.253	NNP
cord-005478-5iu38pr6	2240	50	)	)	-RRB-
cord-005478-5iu38pr6	2240	51	.	.	.
cord-005478-5iu38pr6	2241	1	The	the	DT
cord-005478-5iu38pr6	2241	2	2-year	2-year	CD
cord-005478-5iu38pr6	2241	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2241	4	incidence	incidence	NN
cord-005478-5iu38pr6	2241	5	of	of	IN
cord-005478-5iu38pr6	2241	6	relapse	relapse	NN
cord-005478-5iu38pr6	2241	7	was	be	VBD
cord-005478-5iu38pr6	2241	8	significantly	significantly	RB
cord-005478-5iu38pr6	2241	9	higher	high	JJR
cord-005478-5iu38pr6	2241	10	in	in	IN
cord-005478-5iu38pr6	2241	11	the	the	DT
cord-005478-5iu38pr6	2241	12	PT	PT	NNP
cord-005478-5iu38pr6	2241	13	-	-	HYPH
cord-005478-5iu38pr6	2241	14	CY	CY	NNP
cord-005478-5iu38pr6	2241	15	group	group	NN
cord-005478-5iu38pr6	2241	16	(	(	-LRB-
cord-005478-5iu38pr6	2241	17	26	26	CD
cord-005478-5iu38pr6	2241	18	%	%	NN
cord-005478-5iu38pr6	2241	19	vs	vs	IN
cord-005478-5iu38pr6	2241	20	6.6	6.6	CD
cord-005478-5iu38pr6	2241	21	%	%	NN
cord-005478-5iu38pr6	2241	22	,	,	,
cord-005478-5iu38pr6	2241	23	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	2241	24	)	)	-RRB-
cord-005478-5iu38pr6	2241	25	and	and	CC
cord-005478-5iu38pr6	2241	26	non	non	JJ
cord-005478-5iu38pr6	2241	27	-	-	JJ
cord-005478-5iu38pr6	2241	28	relapse	relapse	JJ
cord-005478-5iu38pr6	2241	29	mortality	mortality	NN
cord-005478-5iu38pr6	2241	30	(	(	-LRB-
cord-005478-5iu38pr6	2241	31	NRM	NRM	NNP
cord-005478-5iu38pr6	2241	32	)	)	-RRB-
cord-005478-5iu38pr6	2242	1	at	at	IN
cord-005478-5iu38pr6	2242	2	2-years	2-years	CD
cord-005478-5iu38pr6	2242	3	was	be	VBD
cord-005478-5iu38pr6	2242	4	higher	high	JJR
cord-005478-5iu38pr6	2242	5	in	in	IN
cord-005478-5iu38pr6	2242	6	the	the	DT
cord-005478-5iu38pr6	2242	7	ATG	ATG	NNP
cord-005478-5iu38pr6	2242	8	group	group	NN
cord-005478-5iu38pr6	2242	9	(	(	-LRB-
cord-005478-5iu38pr6	2242	10	40	40	CD
cord-005478-5iu38pr6	2242	11	%	%	NN
cord-005478-5iu38pr6	2242	12	vs	vs	IN
cord-005478-5iu38pr6	2242	13	22	22	CD
cord-005478-5iu38pr6	2242	14	%	%	NN
cord-005478-5iu38pr6	2242	15	)	)	-RRB-
cord-005478-5iu38pr6	2242	16	but	but	CC
cord-005478-5iu38pr6	2242	17	not	not	RB
cord-005478-5iu38pr6	2242	18	statistically	statistically	RB
cord-005478-5iu38pr6	2242	19	significant	significant	JJ
cord-005478-5iu38pr6	2242	20	(	(	-LRB-
cord-005478-5iu38pr6	2242	21	p=0.06	p=0.06	NNP
cord-005478-5iu38pr6	2242	22	)	)	-RRB-
cord-005478-5iu38pr6	2242	23	.	.	.
cord-005478-5iu38pr6	2243	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2243	2	:	:	:
cord-005478-5iu38pr6	2244	1	In	in	IN
cord-005478-5iu38pr6	2244	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	2244	3	experience	experience	NN
cord-005478-5iu38pr6	2244	4	,	,	,
cord-005478-5iu38pr6	2244	5	in	in	IN
cord-005478-5iu38pr6	2244	6	spite	spite	NN
cord-005478-5iu38pr6	2244	7	of	of	IN
cord-005478-5iu38pr6	2244	8	the	the	DT
cord-005478-5iu38pr6	2244	9	limited	limited	JJ
cord-005478-5iu38pr6	2244	10	number	number	NN
cord-005478-5iu38pr6	2244	11	of	of	IN
cord-005478-5iu38pr6	2244	12	patients	patient	NNS
cord-005478-5iu38pr6	2244	13	,	,	,
cord-005478-5iu38pr6	2244	14	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2244	15	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2244	16	using	use	VBG
cord-005478-5iu38pr6	2244	17	PT	PT	NNP
cord-005478-5iu38pr6	2244	18	-	-	HYPH
cord-005478-5iu38pr6	2244	19	CY	CY	NNP
cord-005478-5iu38pr6	2244	20	combined	combine	VBN
cord-005478-5iu38pr6	2244	21	with	with	IN
cord-005478-5iu38pr6	2244	22	additional	additional	JJ
cord-005478-5iu38pr6	2244	23	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2244	24	after	after	IN
cord-005478-5iu38pr6	2244	25	MUD	mud	NN
cord-005478-5iu38pr6	2244	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2244	27	,	,	,
cord-005478-5iu38pr6	2244	28	using	use	VBG
cord-005478-5iu38pr6	2244	29	mostly	mostly	RB
cord-005478-5iu38pr6	2244	30	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2244	31	blood	blood	NN
cord-005478-5iu38pr6	2244	32	as	as	IN
cord-005478-5iu38pr6	2244	33	graft	graft	NN
cord-005478-5iu38pr6	2244	34	source	source	NN
cord-005478-5iu38pr6	2244	35	,	,	,
cord-005478-5iu38pr6	2244	36	reduced	reduce	VBD
cord-005478-5iu38pr6	2244	37	the	the	DT
cord-005478-5iu38pr6	2244	38	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2244	39	incidence	incidence	NN
cord-005478-5iu38pr6	2244	40	of	of	IN
cord-005478-5iu38pr6	2244	41	aGVHD	agvhd	NN
cord-005478-5iu38pr6	2244	42	compared	compare	VBN
cord-005478-5iu38pr6	2244	43	to	to	IN
cord-005478-5iu38pr6	2244	44	standard	standard	JJ
cord-005478-5iu38pr6	2244	45	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2244	46	with	with	IN
cord-005478-5iu38pr6	2244	47	MTX	MTX	NNP
cord-005478-5iu38pr6	2244	48	-	-	HYPH
cord-005478-5iu38pr6	2244	49	CsA.	CsA.	NNP
cord-005478-5iu38pr6	2244	50	Prospective	prospective	JJ
cord-005478-5iu38pr6	2244	51	studies	study	NNS
cord-005478-5iu38pr6	2244	52	with	with	IN
cord-005478-5iu38pr6	2244	53	longer	long	JJR
cord-005478-5iu38pr6	2244	54	follow	follow	NN
cord-005478-5iu38pr6	2244	55	-	-	HYPH
cord-005478-5iu38pr6	2244	56	up	up	NN
cord-005478-5iu38pr6	2244	57	are	be	VBP
cord-005478-5iu38pr6	2244	58	needed	need	VBN
cord-005478-5iu38pr6	2244	59	to	to	TO
cord-005478-5iu38pr6	2244	60	confirm	confirm	VB
cord-005478-5iu38pr6	2244	61	these	these	DT
cord-005478-5iu38pr6	2244	62	observations	observation	NNS
cord-005478-5iu38pr6	2244	63	.	.	.
cord-005478-5iu38pr6	2245	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2245	2	:	:	:
cord-005478-5iu38pr6	2245	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2245	4	to	to	TO
cord-005478-5iu38pr6	2245	5	declare	declare	VB
cord-005478-5iu38pr6	2245	6	O109	O109	NNP
cord-005478-5iu38pr6	2245	7	Abstract	Abstract	NNP
cord-005478-5iu38pr6	2245	8	already	already	RB
cord-005478-5iu38pr6	2245	9	published	publish	VBN
cord-005478-5iu38pr6	2245	10	.	.	.
cord-005478-5iu38pr6	2246	1	Methods	method	NNS
cord-005478-5iu38pr6	2246	2	:	:	:
cord-005478-5iu38pr6	2246	3	44	44	CD
cord-005478-5iu38pr6	2246	4	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2246	5	patients	patient	NNS
cord-005478-5iu38pr6	2246	6	who	who	WP
cord-005478-5iu38pr6	2246	7	underwent	undergo	VBD
cord-005478-5iu38pr6	2246	8	allo	allo	NN
cord-005478-5iu38pr6	2246	9	-	-	HYPH
cord-005478-5iu38pr6	2246	10	SCT	SCT	NNP
cord-005478-5iu38pr6	2246	11	for	for	IN
cord-005478-5iu38pr6	2246	12	hematological	hematological	JJ
cord-005478-5iu38pr6	2246	13	malignancies	malignancy	NNS
cord-005478-5iu38pr6	2246	14	between	between	IN
cord-005478-5iu38pr6	2246	15	January	January	NNP
cord-005478-5iu38pr6	2246	16	2016	2016	CD
cord-005478-5iu38pr6	2246	17	and	and	CC
cord-005478-5iu38pr6	2246	18	August	August	NNP
cord-005478-5iu38pr6	2246	19	2018	2018	CD
cord-005478-5iu38pr6	2246	20	were	be	VBD
cord-005478-5iu38pr6	2246	21	included	include	VBN
cord-005478-5iu38pr6	2246	22	in	in	IN
cord-005478-5iu38pr6	2246	23	this	this	DT
cord-005478-5iu38pr6	2246	24	prospective	prospective	JJ
cord-005478-5iu38pr6	2246	25	singlecentre	singlecentre	NNP
cord-005478-5iu38pr6	2246	26	protocol	protocol	NN
cord-005478-5iu38pr6	2246	27	.	.	.
cord-005478-5iu38pr6	2247	1	All	all	DT
cord-005478-5iu38pr6	2247	2	patients	patient	NNS
cord-005478-5iu38pr6	2247	3	had	have	VBD
cord-005478-5iu38pr6	2247	4	at	at	RB
cord-005478-5iu38pr6	2247	5	least	least	RBS
cord-005478-5iu38pr6	2247	6	one	one	CD
cord-005478-5iu38pr6	2247	7	baseline	baseline	JJ
cord-005478-5iu38pr6	2247	8	risk	risk	NN
cord-005478-5iu38pr6	2247	9	factor	factor	NN
cord-005478-5iu38pr6	2247	10	predicting	predict	VBG
cord-005478-5iu38pr6	2247	11	development	development	NN
cord-005478-5iu38pr6	2247	12	of	of	IN
cord-005478-5iu38pr6	2247	13	severe	severe	JJ
cord-005478-5iu38pr6	2247	14	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2248	1	(	(	-LRB-
cord-005478-5iu38pr6	2248	2	e.g.	e.g.	DT
cord-005478-5iu38pr6	2248	3	HLA	HLA	NNP
cord-005478-5iu38pr6	2248	4	mismatch	mismatch	NN
cord-005478-5iu38pr6	2248	5	,	,	,
cord-005478-5iu38pr6	2248	6	Fem	Fem	NNP
cord-005478-5iu38pr6	2248	7	-	-	HYPH
cord-005478-5iu38pr6	2248	8	to	to	IN
cord-005478-5iu38pr6	2248	9	-	-	HYPH
cord-005478-5iu38pr6	2248	10	Male	male	NN
cord-005478-5iu38pr6	2248	11	sex	sex	NN
cord-005478-5iu38pr6	2248	12	mismatch	mismatch	NN
cord-005478-5iu38pr6	2248	13	)	)	-RRB-
cord-005478-5iu38pr6	2248	14	.	.	.
cord-005478-5iu38pr6	2249	1	PT	PT	NNP
cord-005478-5iu38pr6	2249	2	-	-	HYPH
cord-005478-5iu38pr6	2249	3	CY	CY	NNP
cord-005478-5iu38pr6	2249	4	in	in	IN
cord-005478-5iu38pr6	2249	5	combination	combination	NN
cord-005478-5iu38pr6	2249	6	with	with	IN
cord-005478-5iu38pr6	2249	7	a	a	DT
cord-005478-5iu38pr6	2249	8	second	second	JJ
cord-005478-5iu38pr6	2249	9	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2249	10	drug	drug	NN
cord-005478-5iu38pr6	2249	11	was	be	VBD
cord-005478-5iu38pr6	2249	12	used	use	VBN
cord-005478-5iu38pr6	2249	13	as	as	IN
cord-005478-5iu38pr6	2249	14	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2249	15	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2249	16	.	.	.
cord-005478-5iu38pr6	2250	1	Results	result	NNS
cord-005478-5iu38pr6	2250	2	:	:	:
cord-005478-5iu38pr6	2251	1	Patients	patient	NNS
cord-005478-5iu38pr6	2251	2	characteristics	characteristic	NNS
cord-005478-5iu38pr6	2251	3	are	be	VBP
cord-005478-5iu38pr6	2251	4	summarized	summarize	VBN
cord-005478-5iu38pr6	2251	5	in	in	IN
cord-005478-5iu38pr6	2251	6	Table	Table	NNP
cord-005478-5iu38pr6	2251	7	 	 	_SP
cord-005478-5iu38pr6	2251	8	1	1	CD
cord-005478-5iu38pr6	2251	9	.	.	.
cord-005478-5iu38pr6	2252	1	Median	median	JJ
cord-005478-5iu38pr6	2252	2	age	age	NN
cord-005478-5iu38pr6	2252	3	was	be	VBD
cord-005478-5iu38pr6	2252	4	56	56	CD
cord-005478-5iu38pr6	2253	1	(	(	-LRB-
cord-005478-5iu38pr6	2253	2	range	range	NN
cord-005478-5iu38pr6	2253	3	,	,	,
cord-005478-5iu38pr6	2253	4	19	19	CD
cord-005478-5iu38pr6	2253	5	-	-	SYM
cord-005478-5iu38pr6	2253	6	67	67	CD
cord-005478-5iu38pr6	2253	7	)	)	-RRB-
cord-005478-5iu38pr6	2253	8	years	year	NNS
cord-005478-5iu38pr6	2253	9	,	,	,
cord-005478-5iu38pr6	2253	10	with	with	IN
cord-005478-5iu38pr6	2253	11	6	6	CD
cord-005478-5iu38pr6	2253	12	male	male	JJ
cord-005478-5iu38pr6	2253	13	patients	patient	NNS
cord-005478-5iu38pr6	2253	14	(	(	-LRB-
cord-005478-5iu38pr6	2253	15	14	14	CD
cord-005478-5iu38pr6	2253	16	%	%	NN
cord-005478-5iu38pr6	2253	17	)	)	-RRB-
cord-005478-5iu38pr6	2253	18	receiving	receive	VBG
cord-005478-5iu38pr6	2253	19	a	a	DT
cord-005478-5iu38pr6	2253	20	graft	graft	NN
cord-005478-5iu38pr6	2253	21	from	from	IN
cord-005478-5iu38pr6	2253	22	a	a	DT
cord-005478-5iu38pr6	2253	23	female	female	JJ
cord-005478-5iu38pr6	2253	24	donor	donor	NN
cord-005478-5iu38pr6	2253	25	.	.	.
cord-005478-5iu38pr6	2254	1	More	more	RBR
cord-005478-5iu38pr6	2254	2	frequent	frequent	JJ
cord-005478-5iu38pr6	2254	3	allo	allo	NN
cord-005478-5iu38pr6	2254	4	-	-	HYPH
cord-005478-5iu38pr6	2254	5	SCT	SCT	NNP
cord-005478-5iu38pr6	2254	6	indications	indication	NNS
cord-005478-5iu38pr6	2254	7	were	be	VBD
cord-005478-5iu38pr6	2254	8	acute	acute	JJ
cord-005478-5iu38pr6	2254	9	leukemia	leukemia	NN
cord-005478-5iu38pr6	2254	10	and	and	CC
cord-005478-5iu38pr6	2254	11	MDS	MDS	NNP
cord-005478-5iu38pr6	2254	12	(	(	-LRB-
cord-005478-5iu38pr6	2254	13	54.5	54.5	CD
cord-005478-5iu38pr6	2254	14	%	%	NN
cord-005478-5iu38pr6	2254	15	)	)	-RRB-
cord-005478-5iu38pr6	2254	16	followed	follow	VBN
cord-005478-5iu38pr6	2254	17	by	by	IN
cord-005478-5iu38pr6	2254	18	NHL	NHL	NNP
cord-005478-5iu38pr6	2254	19	(	(	-LRB-
cord-005478-5iu38pr6	2254	20	18	18	CD
cord-005478-5iu38pr6	2254	21	%	%	NN
cord-005478-5iu38pr6	2254	22	)	)	-RRB-
cord-005478-5iu38pr6	2254	23	.	.	.
cord-005478-5iu38pr6	2255	1	Eleven	eleven	CD
cord-005478-5iu38pr6	2255	2	patients	patient	NNS
cord-005478-5iu38pr6	2255	3	(	(	-LRB-
cord-005478-5iu38pr6	2255	4	25	25	CD
cord-005478-5iu38pr6	2255	5	%	%	NN
cord-005478-5iu38pr6	2255	6	)	)	-RRB-
cord-005478-5iu38pr6	2255	7	were	be	VBD
cord-005478-5iu38pr6	2255	8	transplanted	transplant	VBN
cord-005478-5iu38pr6	2255	9	in	in	IN
cord-005478-5iu38pr6	2255	10	advanced	advanced	JJ
cord-005478-5iu38pr6	2255	11	status	status	NN
cord-005478-5iu38pr6	2255	12	.	.	.
cord-005478-5iu38pr6	2256	1	Donor	donor	NN
cord-005478-5iu38pr6	2256	2	was	be	VBD
cord-005478-5iu38pr6	2256	3	a	a	DT
cord-005478-5iu38pr6	2256	4	sibling	sibling	NN
cord-005478-5iu38pr6	2256	5	,	,	,
cord-005478-5iu38pr6	2256	6	matched	match	VBN
cord-005478-5iu38pr6	2256	7	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2256	8	or	or	CC
cord-005478-5iu38pr6	2256	9	mismatched	mismatched	JJ
cord-005478-5iu38pr6	2256	10	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2256	11	in	in	IN
cord-005478-5iu38pr6	2256	12	34	34	CD
cord-005478-5iu38pr6	2256	13	%	%	NN
cord-005478-5iu38pr6	2256	14	,	,	,
cord-005478-5iu38pr6	2256	15	25	25	CD
cord-005478-5iu38pr6	2256	16	%	%	NN
cord-005478-5iu38pr6	2256	17	and	and	CC
cord-005478-5iu38pr6	2256	18	41	41	CD
cord-005478-5iu38pr6	2256	19	%	%	NN
cord-005478-5iu38pr6	2256	20	respectively	respectively	RB
cord-005478-5iu38pr6	2256	21	.	.	.
cord-005478-5iu38pr6	2257	1	Seven	seven	CD
cord-005478-5iu38pr6	2257	2	patients	patient	NNS
cord-005478-5iu38pr6	2257	3	(	(	-LRB-
cord-005478-5iu38pr6	2257	4	16	16	CD
cord-005478-5iu38pr6	2257	5	%	%	NN
cord-005478-5iu38pr6	2257	6	)	)	-RRB-
cord-005478-5iu38pr6	2257	7	received	receive	VBD
cord-005478-5iu38pr6	2257	8	a	a	DT
cord-005478-5iu38pr6	2257	9	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2257	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	2257	11	regimen	regimen	NN
cord-005478-5iu38pr6	2257	12	including	include	VBG
cord-005478-5iu38pr6	2257	13	TBI	TBI	NNP
cord-005478-5iu38pr6	2257	14	(	(	-LRB-
cord-005478-5iu38pr6	2257	15	8	8	CD
cord-005478-5iu38pr6	2257	16	or	or	CC
cord-005478-5iu38pr6	2257	17	13.5	13.5	CD
cord-005478-5iu38pr6	2257	18	Gy	Gy	NNS
cord-005478-5iu38pr6	2257	19	)	)	-RRB-
cord-005478-5iu38pr6	2257	20	while	while	IN
cord-005478-5iu38pr6	2257	21	the	the	DT
cord-005478-5iu38pr6	2257	22	remaining	remain	VBG
cord-005478-5iu38pr6	2257	23	(	(	-LRB-
cord-005478-5iu38pr6	2257	24	84	84	CD
cord-005478-5iu38pr6	2257	25	%	%	NN
cord-005478-5iu38pr6	2257	26	)	)	-RRB-
cord-005478-5iu38pr6	2257	27	received	receive	VBD
cord-005478-5iu38pr6	2257	28	a	a	DT
cord-005478-5iu38pr6	2257	29	RIC	RIC	NNP
cord-005478-5iu38pr6	2257	30	/	/	SYM
cord-005478-5iu38pr6	2257	31	RTC	RTC	NNP
cord-005478-5iu38pr6	2257	32	regimen	regimen	NN
cord-005478-5iu38pr6	2257	33	based	base	VBN
cord-005478-5iu38pr6	2257	34	on	on	IN
cord-005478-5iu38pr6	2257	35	Fludarabine	Fludarabine	NNP
cord-005478-5iu38pr6	2257	36	,	,	,
cord-005478-5iu38pr6	2257	37	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	2257	38	or	or	CC
cord-005478-5iu38pr6	2257	39	Melphalan	Melphalan	NNP
cord-005478-5iu38pr6	2257	40	+	+	CC
cord-005478-5iu38pr6	2257	41	/-Thiotepa	/-Thiotepa	NNP
cord-005478-5iu38pr6	2257	42	(	(	-LRB-
cord-005478-5iu38pr6	2257	43	3mg	3mg	NNP
cord-005478-5iu38pr6	2257	44	/	/	SYM
cord-005478-5iu38pr6	2257	45	kg	kg	NNP
cord-005478-5iu38pr6	2257	46	)	)	-RRB-
cord-005478-5iu38pr6	2257	47	.	.	.
cord-005478-5iu38pr6	2258	1	Median	median	JJ
cord-005478-5iu38pr6	2258	2	follow	follow	NN
cord-005478-5iu38pr6	2258	3	-	-	HYPH
cord-005478-5iu38pr6	2258	4	up	up	NN
cord-005478-5iu38pr6	2258	5	for	for	IN
cord-005478-5iu38pr6	2258	6	survivors	survivor	NNS
cord-005478-5iu38pr6	2258	7	was	be	VBD
cord-005478-5iu38pr6	2258	8	365	365	CD
cord-005478-5iu38pr6	2258	9	days	day	NNS
cord-005478-5iu38pr6	2258	10	(	(	-LRB-
cord-005478-5iu38pr6	2258	11	range:64	range:64	NNP
cord-005478-5iu38pr6	2258	12	-	-	HYPH
cord-005478-5iu38pr6	2258	13	959	959	CD
cord-005478-5iu38pr6	2258	14	)	)	-RRB-
cord-005478-5iu38pr6	2258	15	.	.	.
cord-005478-5iu38pr6	2259	1	Median	median	JJ
cord-005478-5iu38pr6	2259	2	time	time	NN
cord-005478-5iu38pr6	2259	3	to	to	IN
cord-005478-5iu38pr6	2259	4	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2259	5	and	and	CC
cord-005478-5iu38pr6	2259	6	platelet	platelet	NN
cord-005478-5iu38pr6	2259	7	engrafment	engrafment	NN
cord-005478-5iu38pr6	2259	8	were	be	VBD
cord-005478-5iu38pr6	2259	9	+23	+23	NNS
cord-005478-5iu38pr6	2259	10	(	(	-LRB-
cord-005478-5iu38pr6	2259	11	12	12	CD
cord-005478-5iu38pr6	2259	12	-	-	SYM
cord-005478-5iu38pr6	2259	13	36	36	CD
cord-005478-5iu38pr6	2259	14	)	)	-RRB-
cord-005478-5iu38pr6	2259	15	and	and	CC
cord-005478-5iu38pr6	2259	16	+22	+22	NNS
cord-005478-5iu38pr6	2259	17	(	(	-LRB-
cord-005478-5iu38pr6	2259	18	10	10	CD
cord-005478-5iu38pr6	2259	19	-	-	SYM
cord-005478-5iu38pr6	2259	20	50	50	CD
cord-005478-5iu38pr6	2259	21	)	)	-RRB-
cord-005478-5iu38pr6	2259	22	days	day	NNS
cord-005478-5iu38pr6	2259	23	,	,	,
cord-005478-5iu38pr6	2259	24	respectively	respectively	RB
cord-005478-5iu38pr6	2259	25	(	(	-LRB-
cord-005478-5iu38pr6	2259	26	G	G	NNP
cord-005478-5iu38pr6	2259	27	-	-	HYPH
cord-005478-5iu38pr6	2259	28	CSF	CSF	NNP
cord-005478-5iu38pr6	2259	29	not	not	RB
cord-005478-5iu38pr6	2259	30	routinely	routinely	RB
cord-005478-5iu38pr6	2259	31	used	use	VBN
cord-005478-5iu38pr6	2259	32	)	)	-RRB-
cord-005478-5iu38pr6	2259	33	.	.	.
cord-005478-5iu38pr6	2260	1	Early	early	JJ
cord-005478-5iu38pr6	2260	2	toxicity	toxicity	NN
cord-005478-5iu38pr6	2260	3	was	be	VBD
cord-005478-5iu38pr6	2260	4	low	low	JJ
cord-005478-5iu38pr6	2260	5	,	,	,
cord-005478-5iu38pr6	2260	6	without	without	IN
cord-005478-5iu38pr6	2260	7	cases	case	NNS
cord-005478-5iu38pr6	2260	8	of	of	IN
cord-005478-5iu38pr6	2260	9	thrombotic	thrombotic	JJ
cord-005478-5iu38pr6	2260	10	microangiopathy	microangiopathy	NN
cord-005478-5iu38pr6	2260	11	,	,	,
cord-005478-5iu38pr6	2260	12	only	only	RB
cord-005478-5iu38pr6	2260	13	2	2	CD
cord-005478-5iu38pr6	2260	14	cases	case	NNS
cord-005478-5iu38pr6	2260	15	of	of	IN
cord-005478-5iu38pr6	2260	16	drug	drug	NN
cord-005478-5iu38pr6	2260	17	-	-	HYPH
cord-005478-5iu38pr6	2260	18	related	relate	VBN
cord-005478-5iu38pr6	2260	19	renal	renal	JJ
cord-005478-5iu38pr6	2260	20	failure	failure	NN
cord-005478-5iu38pr6	2260	21	(	(	-LRB-
cord-005478-5iu38pr6	2260	22	4.5	4.5	CD
cord-005478-5iu38pr6	2260	23	%	%	NN
cord-005478-5iu38pr6	2260	24	)	)	-RRB-
cord-005478-5iu38pr6	2260	25	and	and	CC
cord-005478-5iu38pr6	2260	26	1	1	CD
cord-005478-5iu38pr6	2260	27	case	case	NN
cord-005478-5iu38pr6	2260	28	of	of	IN
cord-005478-5iu38pr6	2260	29	possible	possible	JJ
cord-005478-5iu38pr6	2260	30	VOD	vod	NN
cord-005478-5iu38pr6	2260	31	.	.	.
cord-005478-5iu38pr6	2261	1	Before	before	IN
cord-005478-5iu38pr6	2261	2	the	the	DT
cord-005478-5iu38pr6	2261	3	introduction	introduction	NN
cord-005478-5iu38pr6	2261	4	of	of	IN
cord-005478-5iu38pr6	2261	5	mini	mini	JJ
cord-005478-5iu38pr6	2261	6	-	-	NNP
cord-005478-5iu38pr6	2261	7	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	2261	8	in	in	IN
cord-005478-5iu38pr6	2261	9	the	the	DT
cord-005478-5iu38pr6	2261	10	RIC	RIC	NNP
cord-005478-5iu38pr6	2261	11	protocols	protocol	NNS
cord-005478-5iu38pr6	2261	12	(	(	-LRB-
cord-005478-5iu38pr6	2261	13	FluBu/	FluBu/	NNP
cord-005478-5iu38pr6	2261	14	FluMel	FluMel	NNP
cord-005478-5iu38pr6	2261	15	)	)	-RRB-
cord-005478-5iu38pr6	2261	16	there	there	EX
cord-005478-5iu38pr6	2261	17	was	be	VBD
cord-005478-5iu38pr6	2261	18	1	1	CD
cord-005478-5iu38pr6	2261	19	case	case	NN
cord-005478-5iu38pr6	2261	20	of	of	IN
cord-005478-5iu38pr6	2261	21	primary	primary	JJ
cord-005478-5iu38pr6	2261	22	graft	graft	NN
cord-005478-5iu38pr6	2261	23	failure	failure	NN
cord-005478-5iu38pr6	2261	24	(	(	-LRB-
cord-005478-5iu38pr6	2261	25	GF	GF	NNP
cord-005478-5iu38pr6	2261	26	)	)	-RRB-
cord-005478-5iu38pr6	2261	27	and	and	CC
cord-005478-5iu38pr6	2261	28	5	5	CD
cord-005478-5iu38pr6	2261	29	cases	case	NNS
cord-005478-5iu38pr6	2261	30	of	of	IN
cord-005478-5iu38pr6	2261	31	late	late	JJ
cord-005478-5iu38pr6	2261	32	graft	graft	NN
cord-005478-5iu38pr6	2261	33	failure	failure	NN
cord-005478-5iu38pr6	2261	34	(	(	-LRB-
cord-005478-5iu38pr6	2261	35	6/28	6/28	CD
cord-005478-5iu38pr6	2261	36	;	;	:
cord-005478-5iu38pr6	2261	37	21	21	CD
cord-005478-5iu38pr6	2261	38	%	%	NN
cord-005478-5iu38pr6	2261	39	)	)	-RRB-
cord-005478-5iu38pr6	2261	40	;	;	:
cord-005478-5iu38pr6	2261	41	4	4	CD
cord-005478-5iu38pr6	2261	42	cases	case	NNS
cord-005478-5iu38pr6	2261	43	were	be	VBD
cord-005478-5iu38pr6	2261	44	successfully	successfully	RB
cord-005478-5iu38pr6	2261	45	regrafted	regrafte	VBN
cord-005478-5iu38pr6	2261	46	with	with	IN
cord-005478-5iu38pr6	2261	47	the	the	DT
cord-005478-5iu38pr6	2261	48	mini	mini	NN
cord-005478-5iu38pr6	2261	49	-	-	NNP
cord-005478-5iu38pr6	2261	50	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	2261	51	RIC	RIC	NNP
cord-005478-5iu38pr6	2261	52	.	.	.
cord-005478-5iu38pr6	2262	1	There	there	EX
cord-005478-5iu38pr6	2262	2	have	have	VBP
cord-005478-5iu38pr6	2262	3	been	be	VBN
cord-005478-5iu38pr6	2262	4	no	no	DT
cord-005478-5iu38pr6	2262	5	further	further	JJ
cord-005478-5iu38pr6	2262	6	cases	case	NNS
cord-005478-5iu38pr6	2262	7	of	of	IN
cord-005478-5iu38pr6	2262	8	GF	GF	NNP
cord-005478-5iu38pr6	2262	9	after	after	IN
cord-005478-5iu38pr6	2262	10	its	-PRON-	PRP$
cord-005478-5iu38pr6	2262	11	introduction	introduction	NN
cord-005478-5iu38pr6	2262	12	(	(	-LRB-
cord-005478-5iu38pr6	2262	13	n=8	n=8	NN
cord-005478-5iu38pr6	2262	14	evaluable	evaluable	JJ
cord-005478-5iu38pr6	2262	15	cases	case	NNS
cord-005478-5iu38pr6	2262	16	+	+	SYM
cord-005478-5iu38pr6	2262	17	4	4	CD
cord-005478-5iu38pr6	2262	18	second	second	JJ
cord-005478-5iu38pr6	2262	19	salvage	salvage	NN
cord-005478-5iu38pr6	2262	20	alloRICs	allorics	NN
cord-005478-5iu38pr6	2262	21	)	)	-RRB-
cord-005478-5iu38pr6	2262	22	.	.	.
cord-005478-5iu38pr6	2263	1	Additional	additional	JJ
cord-005478-5iu38pr6	2263	2	potential	potential	JJ
cord-005478-5iu38pr6	2263	3	risk	risk	NN
cord-005478-5iu38pr6	2263	4	factors	factor	NNS
cord-005478-5iu38pr6	2263	5	for	for	IN
cord-005478-5iu38pr6	2263	6	GF	GF	NNP
cord-005478-5iu38pr6	2263	7	were	be	VBD
cord-005478-5iu38pr6	2263	8	CD34	CD34	NNP
cord-005478-5iu38pr6	2263	9	+	+	CC
cord-005478-5iu38pr6	2263	10	≤3x10e6	≤3x10e6	NNS
cord-005478-5iu38pr6	2263	11	/	/	SYM
cord-005478-5iu38pr6	2263	12	kg	kg	NN
cord-005478-5iu38pr6	2263	13	(	(	-LRB-
cord-005478-5iu38pr6	2263	14	p=0.07	p=0.07	NNP
cord-005478-5iu38pr6	2263	15	)	)	-RRB-
cord-005478-5iu38pr6	2263	16	and	and	CC
cord-005478-5iu38pr6	2263	17	a	a	DT
cord-005478-5iu38pr6	2263	18	high	high	JJ
cord-005478-5iu38pr6	2263	19	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	2263	20	count	count	NN
cord-005478-5iu38pr6	2263	21	at	at	IN
cord-005478-5iu38pr6	2263	22	stem	stem	NN
cord-005478-5iu38pr6	2263	23	cell	cell	NN
cord-005478-5iu38pr6	2263	24	infusion	infusion	NN
cord-005478-5iu38pr6	2263	25	(	(	-LRB-
cord-005478-5iu38pr6	2263	26	p=0.06	p=0.06	NNP
cord-005478-5iu38pr6	2263	27	)	)	-RRB-
cord-005478-5iu38pr6	2263	28	.	.	.
cord-005478-5iu38pr6	2264	1	The	the	DT
cord-005478-5iu38pr6	2264	2	CI	ci	NN
cord-005478-5iu38pr6	2264	3	of	of	IN
cord-005478-5iu38pr6	2264	4	grade	grade	NN
cord-005478-5iu38pr6	2264	5	2	2	CD
cord-005478-5iu38pr6	2264	6	-	-	SYM
cord-005478-5iu38pr6	2264	7	4	4	CD
cord-005478-5iu38pr6	2264	8	acute	acute	JJ
cord-005478-5iu38pr6	2264	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2264	10	at	at	IN
cord-005478-5iu38pr6	2264	11	day	day	NN
cord-005478-5iu38pr6	2264	12	+	+	CC
cord-005478-5iu38pr6	2264	13	120	120	CD
cord-005478-5iu38pr6	2264	14	was	be	VBD
cord-005478-5iu38pr6	2264	15	28	28	CD
cord-005478-5iu38pr6	2264	16	%	%	NN
cord-005478-5iu38pr6	2264	17	(	(	-LRB-
cord-005478-5iu38pr6	2264	18	95%CI	95%ci	CD
cord-005478-5iu38pr6	2264	19	:	:	:
cord-005478-5iu38pr6	2264	20	14	14	CD
cord-005478-5iu38pr6	2264	21	-	-	SYM
cord-005478-5iu38pr6	2264	22	48	48	CD
cord-005478-5iu38pr6	2264	23	)	)	-RRB-
cord-005478-5iu38pr6	2264	24	with	with	IN
cord-005478-5iu38pr6	2264	25	only	only	RB
cord-005478-5iu38pr6	2264	26	2	2	CD
cord-005478-5iu38pr6	2264	27	cases	case	NNS
cord-005478-5iu38pr6	2264	28	of	of	IN
cord-005478-5iu38pr6	2264	29	refractoriness	refractoriness	NN
cord-005478-5iu38pr6	2264	30	to	to	IN
cord-005478-5iu38pr6	2264	31	steroids	steroid	NNS
cord-005478-5iu38pr6	2264	32	.	.	.
cord-005478-5iu38pr6	2265	1	Of	of	IN
cord-005478-5iu38pr6	2265	2	the	the	DT
cord-005478-5iu38pr6	2265	3	37	37	CD
cord-005478-5iu38pr6	2265	4	evaluable	evaluable	JJ
cord-005478-5iu38pr6	2265	5	patients	patient	NNS
cord-005478-5iu38pr6	2265	6	,	,	,
cord-005478-5iu38pr6	2265	7	only	only	RB
cord-005478-5iu38pr6	2265	8	1	1	CD
cord-005478-5iu38pr6	2265	9	developed	develop	VBD
cord-005478-5iu38pr6	2265	10	moderate	moderate	JJ
cord-005478-5iu38pr6	2265	11	chronic	chronic	JJ
cord-005478-5iu38pr6	2265	12	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2265	13	leading	lead	VBG
cord-005478-5iu38pr6	2265	14	to	to	IN
cord-005478-5iu38pr6	2265	15	a	a	DT
cord-005478-5iu38pr6	2265	16	1yr	1yr	JJ
cord-005478-5iu38pr6	2265	17	-	-	HYPH
cord-005478-5iu38pr6	2265	18	CI	ci	NN
cord-005478-5iu38pr6	2265	19	of	of	IN
cord-005478-5iu38pr6	2265	20	3	3	CD
cord-005478-5iu38pr6	2265	21	%	%	NN
cord-005478-5iu38pr6	2265	22	.	.	.
cord-005478-5iu38pr6	2266	1	NRM	NRM	NNP
cord-005478-5iu38pr6	2266	2	was	be	VBD
cord-005478-5iu38pr6	2266	3	10.5	10.5	CD
cord-005478-5iu38pr6	2266	4	%	%	NN
cord-005478-5iu38pr6	2266	5	at	at	IN
cord-005478-5iu38pr6	2266	6	1yr	1yr	NN
cord-005478-5iu38pr6	2266	7	and	and	CC
cord-005478-5iu38pr6	2266	8	the	the	DT
cord-005478-5iu38pr6	2266	9	CI	CI	NNP
cord-005478-5iu38pr6	2266	10	of	of	IN
cord-005478-5iu38pr6	2266	11	relapse	relapse	NN
cord-005478-5iu38pr6	2266	12	was	be	VBD
cord-005478-5iu38pr6	2266	13	31	31	CD
cord-005478-5iu38pr6	2266	14	%	%	NN
cord-005478-5iu38pr6	2266	15	(	(	-LRB-
cord-005478-5iu38pr6	2266	16	95	95	CD
cord-005478-5iu38pr6	2266	17	%	%	NN
cord-005478-5iu38pr6	2266	18	CI	ci	NN
cord-005478-5iu38pr6	2266	19	:	:	:
cord-005478-5iu38pr6	2266	20	21	21	CD
cord-005478-5iu38pr6	2266	21	-	-	SYM
cord-005478-5iu38pr6	2266	22	40	40	CD
cord-005478-5iu38pr6	2266	23	)	)	-RRB-
cord-005478-5iu38pr6	2266	24	.	.	.
cord-005478-5iu38pr6	2267	1	All	all	DT
cord-005478-5iu38pr6	2267	2	relapses	relapse	NNS
cord-005478-5iu38pr6	2267	3	occurred	occur	VBD
cord-005478-5iu38pr6	2267	4	in	in	IN
cord-005478-5iu38pr6	2267	5	patients	patient	NNS
cord-005478-5iu38pr6	2267	6	with	with	IN
cord-005478-5iu38pr6	2267	7	intermediate/	intermediate/	JJ
cord-005478-5iu38pr6	2267	8	high	high	JJ
cord-005478-5iu38pr6	2267	9	rDRI	rDRI	NNS
cord-005478-5iu38pr6	2267	10	.	.	.
cord-005478-5iu38pr6	2268	1	1yr	1yr	JJ
cord-005478-5iu38pr6	2268	2	-	-	HYPH
cord-005478-5iu38pr6	2268	3	OS	OS	NNP
cord-005478-5iu38pr6	2268	4	was	be	VBD
cord-005478-5iu38pr6	2268	5	76	76	CD
cord-005478-5iu38pr6	2268	6	%	%	NN
cord-005478-5iu38pr6	2268	7	and	and	CC
cord-005478-5iu38pr6	2268	8	the	the	DT
cord-005478-5iu38pr6	2268	9	estimated	estimate	VBN
cord-005478-5iu38pr6	2268	10	1-year	1-year	CD
cord-005478-5iu38pr6	2268	11	DFS	DFS	NNP
cord-005478-5iu38pr6	2268	12	was	be	VBD
cord-005478-5iu38pr6	2268	13	63.6	63.6	CD
cord-005478-5iu38pr6	2268	14	%	%	NN
cord-005478-5iu38pr6	2268	15	.	.	.
cord-005478-5iu38pr6	2269	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2269	2	:	:	:
cord-005478-5iu38pr6	2270	1	These	these	DT
cord-005478-5iu38pr6	2270	2	outcomes	outcome	NNS
cord-005478-5iu38pr6	2270	3	confirmed	confirm	VBD
cord-005478-5iu38pr6	2270	4	the	the	DT
cord-005478-5iu38pr6	2270	5	feasibility	feasibility	NN
cord-005478-5iu38pr6	2270	6	of	of	IN
cord-005478-5iu38pr6	2270	7	both	both	CC
cord-005478-5iu38pr6	2270	8	RIC	RIC	NNP
cord-005478-5iu38pr6	2270	9	and	and	CC
cord-005478-5iu38pr6	2270	10	MAC	MAC	NNP
cord-005478-5iu38pr6	2270	11	allo	allo	NNP
cord-005478-5iu38pr6	2270	12	-	-	HYPH
cord-005478-5iu38pr6	2270	13	SCT	SCT	NNP
cord-005478-5iu38pr6	2270	14	using	use	VBG
cord-005478-5iu38pr6	2270	15	PT	PT	NNP
cord-005478-5iu38pr6	2270	16	-	-	HYPH
cord-005478-5iu38pr6	2270	17	Cy	Cy	NNP
cord-005478-5iu38pr6	2270	18	as	as	IN
cord-005478-5iu38pr6	2270	19	SOC	SOC	NNP
cord-005478-5iu38pr6	2270	20	with	with	IN
cord-005478-5iu38pr6	2270	21	a	a	DT
cord-005478-5iu38pr6	2270	22	single	single	JJ
cord-005478-5iu38pr6	2270	23	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2270	24	drug	drug	NN
cord-005478-5iu38pr6	2270	25	in	in	IN
cord-005478-5iu38pr6	2270	26	patients	patient	NNS
cord-005478-5iu38pr6	2270	27	at	at	IN
cord-005478-5iu38pr6	2270	28	high	high	JJ
cord-005478-5iu38pr6	2270	29	risk	risk	NN
cord-005478-5iu38pr6	2270	30	of	of	IN
cord-005478-5iu38pr6	2270	31	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2270	32	.	.	.
cord-005478-5iu38pr6	2271	1	An	an	DT
cord-005478-5iu38pr6	2271	2	important	important	JJ
cord-005478-5iu38pr6	2271	3	observation	observation	NN
cord-005478-5iu38pr6	2271	4	was	be	VBD
cord-005478-5iu38pr6	2271	5	the	the	DT
cord-005478-5iu38pr6	2271	6	high	high	JJ
cord-005478-5iu38pr6	2271	7	rate	rate	NN
cord-005478-5iu38pr6	2271	8	of	of	IN
cord-005478-5iu38pr6	2271	9	GF	gf	NN
cord-005478-5iu38pr6	2271	10	with	with	IN
cord-005478-5iu38pr6	2271	11	"	"	``
cord-005478-5iu38pr6	2271	12	classical	classical	JJ
cord-005478-5iu38pr6	2271	13	"	"	''
cord-005478-5iu38pr6	2271	14	alloRIC	alloric	FW
cord-005478-5iu38pr6	2271	15	platforms	platform	NNS
cord-005478-5iu38pr6	2271	16	(	(	-LRB-
cord-005478-5iu38pr6	2271	17	FluBu	FluBu	NNP
cord-005478-5iu38pr6	2271	18	/	/	SYM
cord-005478-5iu38pr6	2271	19	FluMel	FluMel	NNP
cord-005478-5iu38pr6	2271	20	)	)	-RRB-
cord-005478-5iu38pr6	2271	21	,	,	,
cord-005478-5iu38pr6	2271	22	which	which	WDT
cord-005478-5iu38pr6	2271	23	appears	appear	VBZ
cord-005478-5iu38pr6	2271	24	to	to	TO
cord-005478-5iu38pr6	2271	25	be	be	VB
cord-005478-5iu38pr6	2271	26	lower	low	JJR
cord-005478-5iu38pr6	2271	27	after	after	IN
cord-005478-5iu38pr6	2271	28	introducing	introduce	VBG
cord-005478-5iu38pr6	2271	29	the	the	DT
cord-005478-5iu38pr6	2271	30	mini	mini	NN
cord-005478-5iu38pr6	2271	31	-	-	NNP
cord-005478-5iu38pr6	2271	32	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	2271	33	.	.	.
cord-005478-5iu38pr6	2272	1	Although	although	IN
cord-005478-5iu38pr6	2272	2	these	these	DT
cord-005478-5iu38pr6	2272	3	data	datum	NNS
cord-005478-5iu38pr6	2272	4	need	need	VBP
cord-005478-5iu38pr6	2272	5	confirmation	confirmation	NN
cord-005478-5iu38pr6	2272	6	in	in	IN
cord-005478-5iu38pr6	2272	7	larger	large	JJR
cord-005478-5iu38pr6	2272	8	cohorts	cohort	NNS
cord-005478-5iu38pr6	2272	9	,	,	,
cord-005478-5iu38pr6	2272	10	the	the	DT
cord-005478-5iu38pr6	2272	11	current	current	JJ
cord-005478-5iu38pr6	2272	12	results	result	NNS
cord-005478-5iu38pr6	2272	13	suggests	suggest	VBZ
cord-005478-5iu38pr6	2272	14	that	that	IN
cord-005478-5iu38pr6	2272	15	PT	PT	NNP
cord-005478-5iu38pr6	2272	16	-	-	HYPH
cord-005478-5iu38pr6	2272	17	CY	CY	NNP
cord-005478-5iu38pr6	2272	18	may	may	MD
cord-005478-5iu38pr6	2272	19	pave	pave	VB
cord-005478-5iu38pr6	2272	20	the	the	DT
cord-005478-5iu38pr6	2272	21	way	way	NN
cord-005478-5iu38pr6	2272	22	to	to	IN
cord-005478-5iu38pr6	2272	23	improving	improve	VBG
cord-005478-5iu38pr6	2272	24	the	the	DT
cord-005478-5iu38pr6	2272	25	quality	quality	NN
cord-005478-5iu38pr6	2272	26	of	of	IN
cord-005478-5iu38pr6	2272	27	life	life	NN
cord-005478-5iu38pr6	2272	28	of	of	IN
cord-005478-5iu38pr6	2272	29	transplant	transplant	NN
cord-005478-5iu38pr6	2272	30	survivors	survivor	NNS
cord-005478-5iu38pr6	2272	31	by	by	IN
cord-005478-5iu38pr6	2272	32	markedly	markedly	RB
cord-005478-5iu38pr6	2272	33	reducing	reduce	VBG
cord-005478-5iu38pr6	2272	34	severe	severe	JJ
cord-005478-5iu38pr6	2272	35	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2272	36	.	.	.
cord-005478-5iu38pr6	2273	1	Protection	protection	NN
cord-005478-5iu38pr6	2273	2	of	of	IN
cord-005478-5iu38pr6	2273	3	the	the	DT
cord-005478-5iu38pr6	2273	4	endothelium	endothelium	NN
cord-005478-5iu38pr6	2273	5	during	during	IN
cord-005478-5iu38pr6	2273	6	steroid	steroid	JJ
cord-005478-5iu38pr6	2273	7	-	-	HYPH
cord-005478-5iu38pr6	2273	8	refractory	refractory	JJ
cord-005478-5iu38pr6	2273	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2273	10	Background	background	NN
cord-005478-5iu38pr6	2273	11	:	:	:
cord-005478-5iu38pr6	2274	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2274	2	data	datum	NNS
cord-005478-5iu38pr6	2274	3	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	2274	4	that	that	IN
cord-005478-5iu38pr6	2274	5	endothelium	endothelium	NN
cord-005478-5iu38pr6	2274	6	related	relate	VBN
cord-005478-5iu38pr6	2274	7	factors	factor	NNS
cord-005478-5iu38pr6	2274	8	predict	predict	VBP
cord-005478-5iu38pr6	2274	9	mortality	mortality	NN
cord-005478-5iu38pr6	2274	10	after	after	IN
cord-005478-5iu38pr6	2274	11	the	the	DT
cord-005478-5iu38pr6	2274	12	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2274	13	of	of	IN
cord-005478-5iu38pr6	2274	14	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2274	15	,	,	,
cord-005478-5iu38pr6	2274	16	suggesting	suggest	VBG
cord-005478-5iu38pr6	2274	17	that	that	IN
cord-005478-5iu38pr6	2274	18	the	the	DT
cord-005478-5iu38pr6	2274	19	endothelium	endothelium	NN
cord-005478-5iu38pr6	2274	20	may	may	MD
cord-005478-5iu38pr6	2274	21	be	be	VB
cord-005478-5iu38pr6	2274	22	involved	involve	VBN
cord-005478-5iu38pr6	2274	23	in	in	IN
cord-005478-5iu38pr6	2274	24	the	the	DT
cord-005478-5iu38pr6	2274	25	pathobiology	pathobiology	NN
cord-005478-5iu38pr6	2274	26	of	of	IN
cord-005478-5iu38pr6	2274	27	steroid	steroid	NN
cord-005478-5iu38pr6	2274	28	-	-	HYPH
cord-005478-5iu38pr6	2274	29	refractory	refractory	JJ
cord-005478-5iu38pr6	2275	1	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2275	2	(	(	-LRB-
cord-005478-5iu38pr6	2275	3	SR	SR	NNP
cord-005478-5iu38pr6	2275	4	-	-	HYPH
cord-005478-5iu38pr6	2275	5	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2275	6	)	)	-RRB-
cord-005478-5iu38pr6	2275	7	(	(	-LRB-
cord-005478-5iu38pr6	2275	8	J	J	NNP
cord-005478-5iu38pr6	2275	9	Clin	Clin	NNP
cord-005478-5iu38pr6	2275	10	Oncol	Oncol	NNP
cord-005478-5iu38pr6	2275	11	.	.	.
cord-005478-5iu38pr6	2276	1	2018	2018	CD
cord-005478-5iu38pr6	2277	1	Mar	Mar	NNP
cord-005478-5iu38pr6	2277	2	10;36	10;36	CD
cord-005478-5iu38pr6	2277	3	(	(	-LRB-
cord-005478-5iu38pr6	2277	4	8)	8)	NNP
cord-005478-5iu38pr6	2277	5	Methods	method	NNS
cord-005478-5iu38pr6	2277	6	:	:	:
cord-005478-5iu38pr6	2278	1	Intestinal	intestinal	JJ
cord-005478-5iu38pr6	2278	2	biopsies	biopsy	NNS
cord-005478-5iu38pr6	2278	3	from	from	IN
cord-005478-5iu38pr6	2278	4	patients	patient	NNS
cord-005478-5iu38pr6	2278	5	after	after	IN
cord-005478-5iu38pr6	2278	6	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2278	7	.	.	.
cord-005478-5iu38pr6	2279	1	Murine	murine	JJ
cord-005478-5iu38pr6	2279	2	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2279	3	models	model	NNS
cord-005478-5iu38pr6	2280	1	Balb	Balb	NNP
cord-005478-5iu38pr6	2280	2	/	/	SYM
cord-005478-5iu38pr6	2280	3	c→B6	c→B6	''
cord-005478-5iu38pr6	2280	4	,	,	,
cord-005478-5iu38pr6	2280	5	B6→BDF	B6→BDF	NNP
cord-005478-5iu38pr6	2280	6	and	and	CC
cord-005478-5iu38pr6	2280	7	LP/	lp/	NN
cord-005478-5iu38pr6	2280	8	J→B6	j→b6	XX
cord-005478-5iu38pr6	2280	9	with	with	IN
cord-005478-5iu38pr6	2280	10	and	and	CC
cord-005478-5iu38pr6	2280	11	without	without	IN
cord-005478-5iu38pr6	2280	12	steroid	steroid	NN
cord-005478-5iu38pr6	2280	13	treatment	treatment	NN
cord-005478-5iu38pr6	2280	14	.	.	.
cord-005478-5iu38pr6	2281	1	Immunostaining	immunostaining	NN
cord-005478-5iu38pr6	2281	2	,	,	,
cord-005478-5iu38pr6	2281	3	electron	electron	NN
cord-005478-5iu38pr6	2281	4	microscopy	microscopy	NN
cord-005478-5iu38pr6	2281	5	,	,	,
cord-005478-5iu38pr6	2281	6	light	light	JJ
cord-005478-5iu38pr6	2281	7	sheet	sheet	NN
cord-005478-5iu38pr6	2281	8	fluorescence	fluorescence	NN
cord-005478-5iu38pr6	2281	9	microscopy	microscopy	NN
cord-005478-5iu38pr6	2281	10	(	(	-LRB-
cord-005478-5iu38pr6	2281	11	LSFM	LSFM	NNP
cord-005478-5iu38pr6	2281	12	)	)	-RRB-
cord-005478-5iu38pr6	2281	13	,	,	,
cord-005478-5iu38pr6	2281	14	FACS	FACS	NNP
cord-005478-5iu38pr6	2281	15	.	.	.
cord-005478-5iu38pr6	2282	1	In	in	IN
cord-005478-5iu38pr6	2282	2	vivo	vivo	NN
cord-005478-5iu38pr6	2282	3	and	and	CC
cord-005478-5iu38pr6	2282	4	in	in	IN
cord-005478-5iu38pr6	2282	5	vitro	vitro	FW
cord-005478-5iu38pr6	2282	6	assays	assay	NNS
cord-005478-5iu38pr6	2282	7	for	for	IN
cord-005478-5iu38pr6	2282	8	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2282	9	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	2282	10	.	.	.
cord-005478-5iu38pr6	2283	1	Treatment	treatment	NN
cord-005478-5iu38pr6	2283	2	with	with	IN
cord-005478-5iu38pr6	2283	3	phosphodiesterase	phosphodiesterase	NN
cord-005478-5iu38pr6	2283	4	type	type	NN
cord-005478-5iu38pr6	2283	5	5	5	CD
cord-005478-5iu38pr6	2283	6	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	2283	7	(	(	-LRB-
cord-005478-5iu38pr6	2283	8	PDE5	PDE5	NNP
cord-005478-5iu38pr6	2283	9	)	)	-RRB-
cord-005478-5iu38pr6	2283	10	in	in	IN
cord-005478-5iu38pr6	2283	11	SR	SR	NNP
cord-005478-5iu38pr6	2283	12	-	-	HYPH
cord-005478-5iu38pr6	2283	13	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2283	14	models	model	NNS
cord-005478-5iu38pr6	2283	15	.	.	.
cord-005478-5iu38pr6	2284	1	Results	result	NNS
cord-005478-5iu38pr6	2285	1	:	:	:
cord-005478-5iu38pr6	2285	2	We	-PRON-	PRP
cord-005478-5iu38pr6	2285	3	found	find	VBD
cord-005478-5iu38pr6	2285	4	a	a	DT
cord-005478-5iu38pr6	2285	5	significant	significant	JJ
cord-005478-5iu38pr6	2285	6	higher	high	JJR
cord-005478-5iu38pr6	2285	7	percentage	percentage	NN
cord-005478-5iu38pr6	2285	8	of	of	IN
cord-005478-5iu38pr6	2285	9	apoptotic	apoptotic	JJ
cord-005478-5iu38pr6	2285	10	vessels	vessel	NNS
cord-005478-5iu38pr6	2285	11	in	in	IN
cord-005478-5iu38pr6	2285	12	duodenal	duodenal	JJ
cord-005478-5iu38pr6	2285	13	and	and	CC
cord-005478-5iu38pr6	2285	14	colonic	colonic	JJ
cord-005478-5iu38pr6	2285	15	mucosa	mucosa	JJ
cord-005478-5iu38pr6	2285	16	biopsies	biopsy	NNS
cord-005478-5iu38pr6	2285	17	of	of	IN
cord-005478-5iu38pr6	2285	18	patients	patient	NNS
cord-005478-5iu38pr6	2285	19	with	with	IN
cord-005478-5iu38pr6	2285	20	grade	grade	NN
cord-005478-5iu38pr6	2285	21	III	III	NNP
cord-005478-5iu38pr6	2285	22	-	-	HYPH
cord-005478-5iu38pr6	2285	23	IV	IV	NNP
cord-005478-5iu38pr6	2285	24	aGVHD	agvhd	NN
cord-005478-5iu38pr6	2285	25	compared	compare	VBN
cord-005478-5iu38pr6	2285	26	to	to	IN
cord-005478-5iu38pr6	2285	27	no	no	DT
cord-005478-5iu38pr6	2285	28	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2285	29	(	(	-LRB-
cord-005478-5iu38pr6	2285	30	Figure	figure	NN
cord-005478-5iu38pr6	2285	31	1A	1a	NN
cord-005478-5iu38pr6	2285	32	)	)	-RRB-
cord-005478-5iu38pr6	2285	33	.	.	.
cord-005478-5iu38pr6	2286	1	In	in	IN
cord-005478-5iu38pr6	2286	2	murine	murine	JJ
cord-005478-5iu38pr6	2286	3	experimental	experimental	JJ
cord-005478-5iu38pr6	2286	4	aGVHD	agvhd	NN
cord-005478-5iu38pr6	2286	5	,	,	,
cord-005478-5iu38pr6	2286	6	we	-PRON-	PRP
cord-005478-5iu38pr6	2286	7	detected	detect	VBD
cord-005478-5iu38pr6	2286	8	severe	severe	JJ
cord-005478-5iu38pr6	2286	9	microstructural	microstructural	JJ
cord-005478-5iu38pr6	2286	10	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2286	11	damage	damage	NN
cord-005478-5iu38pr6	2286	12	and	and	CC
cord-005478-5iu38pr6	2286	13	reduced	reduce	VBN
cord-005478-5iu38pr6	2286	14	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2286	15	pericyte	pericyte	NN
cord-005478-5iu38pr6	2286	16	coverage	coverage	NN
cord-005478-5iu38pr6	2286	17	accompanied	accompany	VBN
cord-005478-5iu38pr6	2286	18	by	by	IN
cord-005478-5iu38pr6	2286	19	reduced	reduce	VBN
cord-005478-5iu38pr6	2286	20	expression	expression	NN
cord-005478-5iu38pr6	2286	21	of	of	IN
cord-005478-5iu38pr6	2286	22	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2286	23	tight	tight	JJ
cord-005478-5iu38pr6	2286	24	junction	junction	NN
cord-005478-5iu38pr6	2286	25	proteins	protein	NNS
cord-005478-5iu38pr6	2286	26	leading	lead	VBG
cord-005478-5iu38pr6	2286	27	to	to	IN
cord-005478-5iu38pr6	2286	28	increased	increase	VBN
cord-005478-5iu38pr6	2286	29	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2286	30	leakage	leakage	NN
cord-005478-5iu38pr6	2286	31	in	in	IN
cord-005478-5iu38pr6	2286	32	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2286	33	target	target	NN
cord-005478-5iu38pr6	2286	34	organs	organ	NNS
cord-005478-5iu38pr6	2286	35	.	.	.
cord-005478-5iu38pr6	2287	1	During	during	IN
cord-005478-5iu38pr6	2287	2	intestinal	intestinal	JJ
cord-005478-5iu38pr6	2287	3	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2287	4	,	,	,
cord-005478-5iu38pr6	2287	5	colonic	colonic	JJ
cord-005478-5iu38pr6	2287	6	vasculature	vasculature	NN
cord-005478-5iu38pr6	2287	7	structurally	structurally	RB
cord-005478-5iu38pr6	2287	8	changed	change	VBN
cord-005478-5iu38pr6	2287	9	,	,	,
cord-005478-5iu38pr6	2287	10	reflected	reflect	VBN
cord-005478-5iu38pr6	2287	11	by	by	IN
cord-005478-5iu38pr6	2287	12	increased	increase	VBN
cord-005478-5iu38pr6	2287	13	vessel	vessel	NN
cord-005478-5iu38pr6	2287	14	branching	branching	NN
cord-005478-5iu38pr6	2287	15	and	and	CC
cord-005478-5iu38pr6	2287	16	vessel	vessel	NN
cord-005478-5iu38pr6	2287	17	diameter	diameter	NN
cord-005478-5iu38pr6	2287	18	(	(	-LRB-
cord-005478-5iu38pr6	2287	19	Figure	figure	NN
cord-005478-5iu38pr6	2287	20	1B	1b	CD
cord-005478-5iu38pr6	2287	21	)	)	-RRB-
cord-005478-5iu38pr6	2287	22	.	.	.
cord-005478-5iu38pr6	2288	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2288	2	analysed	analyse	VBD
cord-005478-5iu38pr6	2288	3	human	human	JJ
cord-005478-5iu38pr6	2288	4	biopsies	biopsy	NNS
cord-005478-5iu38pr6	2288	5	and	and	CC
cord-005478-5iu38pr6	2288	6	murine	murine	JJ
cord-005478-5iu38pr6	2288	7	tissues	tissue	NNS
cord-005478-5iu38pr6	2288	8	from	from	IN
cord-005478-5iu38pr6	2288	9	SR	SR	NNP
cord-005478-5iu38pr6	2288	10	-	-	HYPH
cord-005478-5iu38pr6	2288	11	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2288	12	vs.	vs.	FW
cord-005478-5iu38pr6	2288	13	naive	naive	JJ
cord-005478-5iu38pr6	2288	14	(	(	-LRB-
cord-005478-5iu38pr6	2288	15	untreated	untreated	JJ
cord-005478-5iu38pr6	2288	16	)	)	-RRB-
cord-005478-5iu38pr6	2288	17	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2288	18	and	and	CC
cord-005478-5iu38pr6	2288	19	found	find	VBD
cord-005478-5iu38pr6	2288	20	significantly	significantly	RB
cord-005478-5iu38pr6	2288	21	lower	low	JJR
cord-005478-5iu38pr6	2288	22	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	2288	23	infiltration	infiltration	NN
cord-005478-5iu38pr6	2288	24	in	in	IN
cord-005478-5iu38pr6	2288	25	SR	SR	NNP
cord-005478-5iu38pr6	2288	26	-	-	HYPH
cord-005478-5iu38pr6	2288	27	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2288	28	,	,	,
cord-005478-5iu38pr6	2288	29	demonstrating	demonstrate	VBG
cord-005478-5iu38pr6	2288	30	low	low	JJ
cord-005478-5iu38pr6	2288	31	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2288	32	activity	activity	NN
cord-005478-5iu38pr6	2288	33	(	(	-LRB-
cord-005478-5iu38pr6	2288	34	Figure	figure	NN
cord-005478-5iu38pr6	2288	35	 	 	_SP
cord-005478-5iu38pr6	2288	36	1C	1c	NN
cord-005478-5iu38pr6	2288	37	)	)	-RRB-
cord-005478-5iu38pr6	2288	38	.	.	.
cord-005478-5iu38pr6	2289	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2289	2	findings	finding	NNS
cord-005478-5iu38pr6	2289	3	suggest	suggest	VBP
cord-005478-5iu38pr6	2289	4	that	that	IN
cord-005478-5iu38pr6	2289	5	endothelium	endothelium	NN
cord-005478-5iu38pr6	2289	6	-	-	HYPH
cord-005478-5iu38pr6	2289	7	related	relate	VBN
cord-005478-5iu38pr6	2289	8	and	and	CC
cord-005478-5iu38pr6	2289	9	T	T	NNP
cord-005478-5iu38pr6	2289	10	cell	cell	NN
cord-005478-5iu38pr6	2289	11	independent	independent	JJ
cord-005478-5iu38pr6	2289	12	mechanisms	mechanism	NNS
cord-005478-5iu38pr6	2289	13	play	play	VBP
cord-005478-5iu38pr6	2289	14	a	a	DT
cord-005478-5iu38pr6	2289	15	previously	previously	RB
cord-005478-5iu38pr6	2289	16	unrecognized	unrecognized	JJ
cord-005478-5iu38pr6	2289	17	role	role	NN
cord-005478-5iu38pr6	2289	18	during	during	IN
cord-005478-5iu38pr6	2289	19	SR	SR	NNP
cord-005478-5iu38pr6	2289	20	-	-	HYPH
cord-005478-5iu38pr6	2289	21	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2289	22	,	,	,
cord-005478-5iu38pr6	2289	23	providing	provide	VBG
cord-005478-5iu38pr6	2289	24	the	the	DT
cord-005478-5iu38pr6	2289	25	rationale	rationale	NN
cord-005478-5iu38pr6	2289	26	for	for	IN
cord-005478-5iu38pr6	2289	27	T	t	NN
cord-005478-5iu38pr6	2289	28	-	-	HYPH
cord-005478-5iu38pr6	2289	29	cell	cell	NN
cord-005478-5iu38pr6	2289	30	independent	independent	JJ
cord-005478-5iu38pr6	2289	31	treatment	treatment	NN
cord-005478-5iu38pr6	2289	32	strategies	strategy	NNS
cord-005478-5iu38pr6	2289	33	.	.	.
cord-005478-5iu38pr6	2290	1	As	as	IN
cord-005478-5iu38pr6	2290	2	a	a	DT
cord-005478-5iu38pr6	2290	3	first	first	JJ
cord-005478-5iu38pr6	2290	4	example	example	NN
cord-005478-5iu38pr6	2290	5	for	for	IN
cord-005478-5iu38pr6	2290	6	such	such	PDT
cord-005478-5iu38pr6	2290	7	an	an	DT
cord-005478-5iu38pr6	2290	8	approach	approach	NN
cord-005478-5iu38pr6	2290	9	,	,	,
cord-005478-5iu38pr6	2290	10	we	-PRON-	PRP
cord-005478-5iu38pr6	2290	11	tested	test	VBD
cord-005478-5iu38pr6	2290	12	the	the	DT
cord-005478-5iu38pr6	2290	13	endothelium	endothelium	NN
cord-005478-5iu38pr6	2290	14	-	-	HYPH
cord-005478-5iu38pr6	2290	15	effective	effective	JJ
cord-005478-5iu38pr6	2290	16	PDE5	PDE5	NNP
cord-005478-5iu38pr6	2290	17	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	2290	18	sildenafil	sildenafil	NN
cord-005478-5iu38pr6	2290	19	and	and	CC
cord-005478-5iu38pr6	2290	20	found	find	VBD
cord-005478-5iu38pr6	2290	21	reduced	reduce	VBN
cord-005478-5iu38pr6	2290	22	apoptosis	apoptosis	NN
cord-005478-5iu38pr6	2290	23	as	as	RB
cord-005478-5iu38pr6	2290	24	well	well	RB
cord-005478-5iu38pr6	2290	25	as	as	IN
cord-005478-5iu38pr6	2290	26	improved	improve	VBN
cord-005478-5iu38pr6	2290	27	metabolic	metabolic	JJ
cord-005478-5iu38pr6	2290	28	activity	activity	NN
cord-005478-5iu38pr6	2290	29	of	of	IN
cord-005478-5iu38pr6	2290	30	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2290	31	cells	cell	NNS
cord-005478-5iu38pr6	2290	32	in	in	IN
cord-005478-5iu38pr6	2290	33	vitro	vitro	FW
cord-005478-5iu38pr6	2290	34	.	.	.
cord-005478-5iu38pr6	2291	1	In	in	IN
cord-005478-5iu38pr6	2291	2	accordance	accordance	NN
cord-005478-5iu38pr6	2291	3	,	,	,
cord-005478-5iu38pr6	2291	4	sildenafil	sildenafil	NN
cord-005478-5iu38pr6	2291	5	treatment	treatment	NN
cord-005478-5iu38pr6	2291	6	resulted	result	VBD
cord-005478-5iu38pr6	2291	7	in	in	IN
cord-005478-5iu38pr6	2291	8	improved	improve	VBN
cord-005478-5iu38pr6	2291	9	survival	survival	NN
cord-005478-5iu38pr6	2291	10	and	and	CC
cord-005478-5iu38pr6	2291	11	reduced	reduce	VBN
cord-005478-5iu38pr6	2291	12	target	target	NN
cord-005478-5iu38pr6	2291	13	organ	organ	NN
cord-005478-5iu38pr6	2291	14	damage	damage	NN
cord-005478-5iu38pr6	2291	15	during	during	IN
cord-005478-5iu38pr6	2291	16	experimental	experimental	JJ
cord-005478-5iu38pr6	2291	17	SR	SR	NNP
cord-005478-5iu38pr6	2291	18	-	-	HYPH
cord-005478-5iu38pr6	2291	19	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2291	20	(	(	-LRB-
cord-005478-5iu38pr6	2291	21	Figure	figure	NN
cord-005478-5iu38pr6	2291	22	1D	1d	CD
cord-005478-5iu38pr6	2291	23	)	)	-RRB-
cord-005478-5iu38pr6	2291	24	.	.	.
cord-005478-5iu38pr6	2292	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2292	2	:	:	:
cord-005478-5iu38pr6	2293	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2293	2	show	show	VBP
cord-005478-5iu38pr6	2293	3	profound	profound	JJ
cord-005478-5iu38pr6	2293	4	endothelial	endothelial	JJ
cord-005478-5iu38pr6	2293	5	involvement	involvement	NN
cord-005478-5iu38pr6	2293	6	after	after	IN
cord-005478-5iu38pr6	2293	7	allo	allo	NN
cord-005478-5iu38pr6	2293	8	-	-	HYPH
cord-005478-5iu38pr6	2293	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2293	10	and	and	CC
cord-005478-5iu38pr6	2293	11	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	2293	12	that	that	IN
cord-005478-5iu38pr6	2293	13	endothelialprotection	endothelialprotection	NN
cord-005478-5iu38pr6	2293	14	with	with	IN
cord-005478-5iu38pr6	2293	15	sildenafil	sildenafil	NNP
cord-005478-5iu38pr6	2293	16	ameliorates	ameliorate	VBZ
cord-005478-5iu38pr6	2293	17	SR	SR	NNP
cord-005478-5iu38pr6	2293	18	-	-	HYPH
cord-005478-5iu38pr6	2293	19	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2293	20	,	,	,
cord-005478-5iu38pr6	2293	21	providing	provide	VBG
cord-005478-5iu38pr6	2293	22	a	a	DT
cord-005478-5iu38pr6	2293	23	novel	novel	JJ
cord-005478-5iu38pr6	2293	24	non	non	JJ
cord-005478-5iu38pr6	2293	25	-	-	JJ
cord-005478-5iu38pr6	2293	26	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2293	27	treatment	treatment	NN
cord-005478-5iu38pr6	2293	28	approach	approach	NN
cord-005478-5iu38pr6	2293	29	.	.	.
cord-005478-5iu38pr6	2294	1	These	these	DT
cord-005478-5iu38pr6	2294	2	results	result	NNS
cord-005478-5iu38pr6	2294	3	can	can	MD
cord-005478-5iu38pr6	2294	4	serve	serve	VB
cord-005478-5iu38pr6	2294	5	as	as	IN
cord-005478-5iu38pr6	2294	6	rationale	rationale	NN
cord-005478-5iu38pr6	2294	7	for	for	IN
cord-005478-5iu38pr6	2294	8	translational	translational	JJ
cord-005478-5iu38pr6	2294	9	development	development	NN
cord-005478-5iu38pr6	2294	10	of	of	IN
cord-005478-5iu38pr6	2294	11	endothelium	endothelium	NN
cord-005478-5iu38pr6	2294	12	-	-	HYPH
cord-005478-5iu38pr6	2294	13	based	base	VBN
cord-005478-5iu38pr6	2294	14	therapies	therapy	NNS
cord-005478-5iu38pr6	2294	15	for	for	IN
cord-005478-5iu38pr6	2294	16	SR	SR	NNP
cord-005478-5iu38pr6	2294	17	-	-	HYPH
cord-005478-5iu38pr6	2294	18	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2294	19	.	.	.
cord-005478-5iu38pr6	2295	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2295	2	:	:	:
cord-005478-5iu38pr6	2296	1	The	the	DT
cord-005478-5iu38pr6	2296	2	authors	author	NNS
cord-005478-5iu38pr6	2296	3	declare	declare	VBP
cord-005478-5iu38pr6	2296	4	no	no	DT
cord-005478-5iu38pr6	2296	5	confilct	confilct	NN
cord-005478-5iu38pr6	2296	6	of	of	IN
cord-005478-5iu38pr6	2296	7	interest	interest	NN
cord-005478-5iu38pr6	2296	8	relevant	relevant	JJ
cord-005478-5iu38pr6	2296	9	to	to	IN
cord-005478-5iu38pr6	2296	10	this	this	DT
cord-005478-5iu38pr6	2296	11	study	study	NN
cord-005478-5iu38pr6	2297	1	O113	O113	NNP
cord-005478-5iu38pr6	2297	2	Abstract	Abstract	NNP
cord-005478-5iu38pr6	2297	3	already	already	RB
cord-005478-5iu38pr6	2297	4	published	publish	VBN
cord-005478-5iu38pr6	2297	5	.	.	.
cord-005478-5iu38pr6	2298	1	The	the	DT
cord-005478-5iu38pr6	2298	2	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	2298	3	effect	effect	NN
cord-005478-5iu38pr6	2298	4	of	of	IN
cord-005478-5iu38pr6	2298	5	immune	immune	NN
cord-005478-5iu38pr6	2298	6	-	-	HYPH
cord-005478-5iu38pr6	2298	7	modifying	modify	VBG
cord-005478-5iu38pr6	2298	8	microparticles	microparticle	NNS
cord-005478-5iu38pr6	2298	9	in	in	IN
cord-005478-5iu38pr6	2298	10	an	an	DT
cord-005478-5iu38pr6	2298	11	acute	acute	JJ
cord-005478-5iu38pr6	2298	12	graft	graft	NN
cord-005478-5iu38pr6	2298	13	-	-	HYPH
cord-005478-5iu38pr6	2298	14	versus	versus	IN
cord-005478-5iu38pr6	2298	15	-	-	HYPH
cord-005478-5iu38pr6	2298	16	host	host	NN
cord-005478-5iu38pr6	2298	17	disease	disease	NN
cord-005478-5iu38pr6	2298	18	model	model	NN
cord-005478-5iu38pr6	2298	19	John	John	NNP
cord-005478-5iu38pr6	2298	20	Galvin	Galvin	NNP
cord-005478-5iu38pr6	2298	21	1	1	CD
cord-005478-5iu38pr6	2298	22	,	,	,
cord-005478-5iu38pr6	2298	23	Sara	Sara	NNP
cord-005478-5iu38pr6	2298	24	Beddow	Beddow	NNP
cord-005478-5iu38pr6	2298	25	2	2	CD
cord-005478-5iu38pr6	2298	26	,	,	,
cord-005478-5iu38pr6	2298	27	Stephen	Stephen	NNP
cord-005478-5iu38pr6	2298	28	Miller	Miller	NNP
cord-005478-5iu38pr6	2298	29	2	2	CD
cord-005478-5iu38pr6	2298	30	1	1	CD
cord-005478-5iu38pr6	2298	31	University	University	NNP
cord-005478-5iu38pr6	2298	32	of	of	IN
cord-005478-5iu38pr6	2298	33	Illinois	Illinois	NNP
cord-005478-5iu38pr6	2298	34	Chicago	Chicago	NNP
cord-005478-5iu38pr6	2298	35	,	,	,
cord-005478-5iu38pr6	2298	36	Chicago	Chicago	NNP
cord-005478-5iu38pr6	2298	37	,	,	,
cord-005478-5iu38pr6	2298	38	IL	IL	NNP
cord-005478-5iu38pr6	2298	39	,	,	,
cord-005478-5iu38pr6	2298	40	United	United	NNP
cord-005478-5iu38pr6	2298	41	States	States	NNP
cord-005478-5iu38pr6	2298	42	,	,	,
cord-005478-5iu38pr6	2298	43	2	2	CD
cord-005478-5iu38pr6	2298	44	Northwestern	Northwestern	NNP
cord-005478-5iu38pr6	2298	45	University	University	NNP
cord-005478-5iu38pr6	2298	46	,	,	,
cord-005478-5iu38pr6	2298	47	Chicago	Chicago	NNP
cord-005478-5iu38pr6	2298	48	,	,	,
cord-005478-5iu38pr6	2298	49	IL	IL	NNP
cord-005478-5iu38pr6	2298	50	,	,	,
cord-005478-5iu38pr6	2298	51	United	United	NNP
cord-005478-5iu38pr6	2298	52	States	States	NNP
cord-005478-5iu38pr6	2298	53	Background	Background	NNP
cord-005478-5iu38pr6	2298	54	:	:	:
cord-005478-5iu38pr6	2298	55	Inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2298	56	monocytes	monocyte	NNS
cord-005478-5iu38pr6	2298	57	are	be	VBP
cord-005478-5iu38pr6	2298	58	recruited	recruit	VBN
cord-005478-5iu38pr6	2298	59	to	to	TO
cord-005478-5iu38pr6	2298	60	target	target	VB
cord-005478-5iu38pr6	2298	61	organs	organ	NNS
cord-005478-5iu38pr6	2298	62	during	during	IN
cord-005478-5iu38pr6	2298	63	acute	acute	JJ
cord-005478-5iu38pr6	2298	64	Graft	graft	NN
cord-005478-5iu38pr6	2298	65	versus	versus	IN
cord-005478-5iu38pr6	2298	66	Host	Host	NNP
cord-005478-5iu38pr6	2298	67	Disease	Disease	NNP
cord-005478-5iu38pr6	2298	68	(	(	-LRB-
cord-005478-5iu38pr6	2298	69	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2298	70	)	)	-RRB-
cord-005478-5iu38pr6	2298	71	.	.	.
cord-005478-5iu38pr6	2299	1	As	as	IN
cord-005478-5iu38pr6	2299	2	seen	see	VBN
cord-005478-5iu38pr6	2299	3	in	in	IN
cord-005478-5iu38pr6	2299	4	other	other	JJ
cord-005478-5iu38pr6	2299	5	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	2299	6	disorders	disorder	NNS
cord-005478-5iu38pr6	2299	7	,	,	,
cord-005478-5iu38pr6	2299	8	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2299	9	monocytes	monocyte	NNS
cord-005478-5iu38pr6	2299	10	play	play	VBP
cord-005478-5iu38pr6	2299	11	an	an	DT
cord-005478-5iu38pr6	2299	12	important	important	JJ
cord-005478-5iu38pr6	2299	13	role	role	NN
cord-005478-5iu38pr6	2299	14	in	in	IN
cord-005478-5iu38pr6	2299	15	antigen	antigen	NN
cord-005478-5iu38pr6	2299	16	presentation	presentation	NN
cord-005478-5iu38pr6	2299	17	and	and	CC
cord-005478-5iu38pr6	2299	18	cytokine	cytokine	NN
cord-005478-5iu38pr6	2299	19	production	production	NN
cord-005478-5iu38pr6	2299	20	.	.	.
cord-005478-5iu38pr6	2300	1	These	these	DT
cord-005478-5iu38pr6	2300	2	actions	action	NNS
cord-005478-5iu38pr6	2300	3	allow	allow	VBP
cord-005478-5iu38pr6	2300	4	for	for	IN
cord-005478-5iu38pr6	2300	5	a	a	DT
cord-005478-5iu38pr6	2300	6	sustained	sustained	JJ
cord-005478-5iu38pr6	2300	7	activation	activation	NN
cord-005478-5iu38pr6	2300	8	and	and	CC
cord-005478-5iu38pr6	2300	9	proliferation	proliferation	NN
cord-005478-5iu38pr6	2300	10	signal	signal	NN
cord-005478-5iu38pr6	2300	11	to	to	IN
cord-005478-5iu38pr6	2300	12	T	t	NN
cord-005478-5iu38pr6	2300	13	-	-	HYPH
cord-005478-5iu38pr6	2300	14	cells	cell	NNS
cord-005478-5iu38pr6	2300	15	.	.	.
cord-005478-5iu38pr6	2301	1	Previous	previous	JJ
cord-005478-5iu38pr6	2301	2	studies	study	NNS
cord-005478-5iu38pr6	2301	3	have	have	VBP
cord-005478-5iu38pr6	2301	4	shown	show	VBN
cord-005478-5iu38pr6	2301	5	that	that	IN
cord-005478-5iu38pr6	2301	6	IMP	IMP	NNP
cord-005478-5iu38pr6	2301	7	treatment	treatment	NN
cord-005478-5iu38pr6	2301	8	in	in	IN
cord-005478-5iu38pr6	2301	9	mouse	mouse	NN
cord-005478-5iu38pr6	2301	10	models	model	NNS
cord-005478-5iu38pr6	2301	11	of	of	IN
cord-005478-5iu38pr6	2301	12	colitis	colitis	NN
cord-005478-5iu38pr6	2301	13	,	,	,
cord-005478-5iu38pr6	2301	14	encephalitis	encephalitis	RB
cord-005478-5iu38pr6	2301	15	,	,	,
cord-005478-5iu38pr6	2301	16	myocardial	myocardial	JJ
cord-005478-5iu38pr6	2301	17	infarction	infarction	NN
cord-005478-5iu38pr6	2301	18	and	and	CC
cord-005478-5iu38pr6	2301	19	peritonitis	peritonitis	NN
cord-005478-5iu38pr6	2301	20	markedly	markedly	RB
cord-005478-5iu38pr6	2301	21	reduced	reduce	VBD
cord-005478-5iu38pr6	2301	22	monocyte	monocyte	NNP
cord-005478-5iu38pr6	2301	23	accumulation	accumulation	NN
cord-005478-5iu38pr6	2301	24	in	in	IN
cord-005478-5iu38pr6	2301	25	the	the	DT
cord-005478-5iu38pr6	2301	26	affected	affected	JJ
cord-005478-5iu38pr6	2301	27	end	end	NN
cord-005478-5iu38pr6	2301	28	-	-	HYPH
cord-005478-5iu38pr6	2301	29	organs	organ	NNS
cord-005478-5iu38pr6	2302	1	--promoting	--promote	VBG
cord-005478-5iu38pr6	2302	2	tissue	tissue	NN
cord-005478-5iu38pr6	2302	3	repair	repair	NN
cord-005478-5iu38pr6	2302	4	;	;	:
cord-005478-5iu38pr6	2302	5	reducing	reduce	VBG
cord-005478-5iu38pr6	2302	6	disease	disease	NN
cord-005478-5iu38pr6	2302	7	symptoms	symptom	NNS
cord-005478-5iu38pr6	2302	8	and	and	CC
cord-005478-5iu38pr6	2302	9	increasing	increase	VBG
cord-005478-5iu38pr6	2302	10	survival	survival	NN
cord-005478-5iu38pr6	2302	11	.	.	.
cord-005478-5iu38pr6	2303	1	Therefore	therefore	RB
cord-005478-5iu38pr6	2303	2	,	,	,
cord-005478-5iu38pr6	2303	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	2303	4	objective	objective	NN
cord-005478-5iu38pr6	2303	5	was	be	VBD
cord-005478-5iu38pr6	2303	6	to	to	TO
cord-005478-5iu38pr6	2303	7	test	test	VB
cord-005478-5iu38pr6	2303	8	clinical	clinical	JJ
cord-005478-5iu38pr6	2303	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	2303	10	after	after	IN
cord-005478-5iu38pr6	2303	11	IMP	imp	JJ
cord-005478-5iu38pr6	2303	12	treatment	treatment	NN
cord-005478-5iu38pr6	2303	13	in	in	IN
cord-005478-5iu38pr6	2303	14	a	a	DT
cord-005478-5iu38pr6	2303	15	mouse	mouse	NN
cord-005478-5iu38pr6	2303	16	model	model	NN
cord-005478-5iu38pr6	2303	17	of	of	IN
cord-005478-5iu38pr6	2303	18	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2303	19	.	.	.
cord-005478-5iu38pr6	2304	1	Methods	method	NNS
cord-005478-5iu38pr6	2304	2	:	:	:
cord-005478-5iu38pr6	2304	3	Murine	Murine	NNP
cord-005478-5iu38pr6	2304	4	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2304	5	model	model	NN
cord-005478-5iu38pr6	2304	6	:	:	:
cord-005478-5iu38pr6	2305	1	BALB	BALB	NNP
cord-005478-5iu38pr6	2305	2	/	/	SYM
cord-005478-5iu38pr6	2305	3	c	c	NN
cord-005478-5iu38pr6	2305	4	mice	mouse	NNS
cord-005478-5iu38pr6	2305	5	were	be	VBD
cord-005478-5iu38pr6	2305	6	given	give	VBN
cord-005478-5iu38pr6	2305	7	800	800	CD
cord-005478-5iu38pr6	2305	8	cGy	cGy	NNS
cord-005478-5iu38pr6	2305	9	total	total	JJ
cord-005478-5iu38pr6	2305	10	body	body	NN
cord-005478-5iu38pr6	2305	11	irradiation	irradiation	NN
cord-005478-5iu38pr6	2305	12	,	,	,
cord-005478-5iu38pr6	2305	13	irradiated	irradiate	VBN
cord-005478-5iu38pr6	2305	14	BALB	BALB	NNP
cord-005478-5iu38pr6	2305	15	/	/	SYM
cord-005478-5iu38pr6	2305	16	c	c	NN
cord-005478-5iu38pr6	2305	17	mice	mouse	NNS
cord-005478-5iu38pr6	2305	18	were	be	VBD
cord-005478-5iu38pr6	2305	19	transplanted	transplant	VBN
cord-005478-5iu38pr6	2305	20	with	with	IN
cord-005478-5iu38pr6	2305	21	5×10	5×10	CD
cord-005478-5iu38pr6	2305	22	6	6	CD
cord-005478-5iu38pr6	2305	23	C57BL/6	C57BL/6	NNP
cord-005478-5iu38pr6	2305	24	bone	bone	NN
cord-005478-5iu38pr6	2305	25	marrow	marrow	NN
cord-005478-5iu38pr6	2305	26	cells	cell	NNS
cord-005478-5iu38pr6	2305	27	and	and	CC
cord-005478-5iu38pr6	2305	28	1×10	1×10	CD
cord-005478-5iu38pr6	2305	29	6	6	CD
cord-005478-5iu38pr6	2305	30	C57BL/6	c57bl/6	CD
cord-005478-5iu38pr6	2305	31	spleen	spleen	NN
cord-005478-5iu38pr6	2305	32	cells	cell	NNS
cord-005478-5iu38pr6	2305	33	via	via	IN
cord-005478-5iu38pr6	2305	34	tail	tail	NN
cord-005478-5iu38pr6	2305	35	vein	vein	NN
cord-005478-5iu38pr6	2305	36	.	.	.
cord-005478-5iu38pr6	2306	1	IMP	IMP	NNP
cord-005478-5iu38pr6	2306	2	treatment	treatment	NN
cord-005478-5iu38pr6	2306	3	:	:	:
cord-005478-5iu38pr6	2307	1	IMPs	imp	NNS
cord-005478-5iu38pr6	2307	2	were	be	VBD
cord-005478-5iu38pr6	2307	3	made	make	VBN
cord-005478-5iu38pr6	2307	4	with	with	IN
cord-005478-5iu38pr6	2307	5	PLGA	PLGA	NNP
cord-005478-5iu38pr6	2307	6	(	(	-LRB-
cord-005478-5iu38pr6	2307	7	Phosphorex	Phosphorex	NNP
cord-005478-5iu38pr6	2307	8	Inc	Inc	NNP
cord-005478-5iu38pr6	2307	9	,	,	,
cord-005478-5iu38pr6	2307	10	Hopkinton	Hopkinton	NNP
cord-005478-5iu38pr6	2307	11	MA	MA	NNP
cord-005478-5iu38pr6	2307	12	)	)	-RRB-
cord-005478-5iu38pr6	2307	13	was	be	VBD
cord-005478-5iu38pr6	2307	14	administered	administer	VBN
cord-005478-5iu38pr6	2307	15	to	to	IN
cord-005478-5iu38pr6	2307	16	the	the	DT
cord-005478-5iu38pr6	2307	17	recipient	recipient	NN
cord-005478-5iu38pr6	2307	18	mice	mouse	NNS
cord-005478-5iu38pr6	2307	19	(	(	-LRB-
cord-005478-5iu38pr6	2307	20	1.4	1.4	CD
cord-005478-5iu38pr6	2307	21	mg	mg	NNP
cord-005478-5iu38pr6	2307	22	/	/	SYM
cord-005478-5iu38pr6	2307	23	kg	kg	NN
cord-005478-5iu38pr6	2307	24	body	body	NN
cord-005478-5iu38pr6	2307	25	weight	weight	NN
cord-005478-5iu38pr6	2307	26	)	)	-RRB-
cord-005478-5iu38pr6	2307	27	by	by	IN
cord-005478-5iu38pr6	2307	28	IV	IV	NNP
cord-005478-5iu38pr6	2307	29	daily	daily	RB
cord-005478-5iu38pr6	2307	30	starting	start	VBG
cord-005478-5iu38pr6	2307	31	from	from	IN
cord-005478-5iu38pr6	2307	32	day	day	NN
cord-005478-5iu38pr6	2307	33	5	5	CD
cord-005478-5iu38pr6	2307	34	to	to	IN
cord-005478-5iu38pr6	2307	35	day	day	NN
cord-005478-5iu38pr6	2307	36	10	10	CD
cord-005478-5iu38pr6	2307	37	after	after	IN
cord-005478-5iu38pr6	2307	38	bone	bone	NN
cord-005478-5iu38pr6	2307	39	marrow	marrow	NN
cord-005478-5iu38pr6	2307	40	transplantation	transplantation	NN
cord-005478-5iu38pr6	2307	41	(	(	-LRB-
cord-005478-5iu38pr6	2307	42	BMT	BMT	NNP
cord-005478-5iu38pr6	2307	43	)	)	-RRB-
cord-005478-5iu38pr6	2307	44	.	.	.
cord-005478-5iu38pr6	2308	1	PBS	PBS	NNP
cord-005478-5iu38pr6	2308	2	at	at	IN
cord-005478-5iu38pr6	2308	3	the	the	DT
cord-005478-5iu38pr6	2308	4	same	same	JJ
cord-005478-5iu38pr6	2308	5	volume	volume	NN
cord-005478-5iu38pr6	2308	6	was	be	VBD
cord-005478-5iu38pr6	2308	7	used	use	VBN
cord-005478-5iu38pr6	2308	8	as	as	IN
cord-005478-5iu38pr6	2308	9	vehicle	vehicle	NN
cord-005478-5iu38pr6	2308	10	control	control	NN
cord-005478-5iu38pr6	2308	11	.	.	.
cord-005478-5iu38pr6	2309	1	In	in	IN
cord-005478-5iu38pr6	2309	2	vivo	vivo	NN
cord-005478-5iu38pr6	2309	3	bioluminescence	bioluminescence	NN
cord-005478-5iu38pr6	2309	4	imaging	imaging	NN
cord-005478-5iu38pr6	2309	5	:	:	:
cord-005478-5iu38pr6	2309	6	Mice	mouse	NNS
cord-005478-5iu38pr6	2309	7	were	be	VBD
cord-005478-5iu38pr6	2309	8	given	give	VBN
cord-005478-5iu38pr6	2309	9	an	an	DT
cord-005478-5iu38pr6	2309	10	intraperitoneal	intraperitoneal	JJ
cord-005478-5iu38pr6	2309	11	injection	injection	NN
cord-005478-5iu38pr6	2309	12	of	of	IN
cord-005478-5iu38pr6	2309	13	luciferin	luciferin	NN
cord-005478-5iu38pr6	2309	14	(	(	-LRB-
cord-005478-5iu38pr6	2309	15	150	150	CD
cord-005478-5iu38pr6	2309	16	mg	mg	NNP
cord-005478-5iu38pr6	2309	17	/	/	SYM
cord-005478-5iu38pr6	2309	18	kg	kg	NN
cord-005478-5iu38pr6	2309	19	body	body	NN
cord-005478-5iu38pr6	2309	20	weight	weight	NN
cord-005478-5iu38pr6	2309	21	)	)	-RRB-
cord-005478-5iu38pr6	2309	22	and	and	CC
cord-005478-5iu38pr6	2309	23	then	then	RB
cord-005478-5iu38pr6	2309	24	anesthetized	anesthetize	VBN
cord-005478-5iu38pr6	2309	25	and	and	CC
cord-005478-5iu38pr6	2309	26	imaged	image	VBD
cord-005478-5iu38pr6	2309	27	using	use	VBG
cord-005478-5iu38pr6	2309	28	the	the	DT
cord-005478-5iu38pr6	2309	29	IVIS	IVIS	NNP
cord-005478-5iu38pr6	2309	30	Imaging	Imaging	NNP
cord-005478-5iu38pr6	2309	31	system	system	NN
cord-005478-5iu38pr6	2309	32	(	(	-LRB-
cord-005478-5iu38pr6	2309	33	Xenogen	Xenogen	NNP
cord-005478-5iu38pr6	2309	34	)	)	-RRB-
cord-005478-5iu38pr6	2309	35	.	.	.
cord-005478-5iu38pr6	2310	1	Imaging	imaging	NN
cord-005478-5iu38pr6	2310	2	data	datum	NNS
cord-005478-5iu38pr6	2310	3	were	be	VBD
cord-005478-5iu38pr6	2310	4	analyzed	analyze	VBN
cord-005478-5iu38pr6	2310	5	and	and	CC
cord-005478-5iu38pr6	2310	6	quantified	quantify	VBN
cord-005478-5iu38pr6	2310	7	with	with	IN
cord-005478-5iu38pr6	2310	8	Living	Living	NNP
cord-005478-5iu38pr6	2310	9	Image	image	NN
cord-005478-5iu38pr6	2310	10	Software	Software	NNP
cord-005478-5iu38pr6	2310	11	(	(	-LRB-
cord-005478-5iu38pr6	2310	12	Xenogen	Xenogen	NNP
cord-005478-5iu38pr6	2310	13	)	)	-RRB-
cord-005478-5iu38pr6	2310	14	.	.	.
cord-005478-5iu38pr6	2311	1	Results	result	NNS
cord-005478-5iu38pr6	2311	2	:	:	:
cord-005478-5iu38pr6	2312	1	IMP	IMP	NNP
cord-005478-5iu38pr6	2312	2	treated	treat	VBD
cord-005478-5iu38pr6	2313	1	mice	mouse	NNS
cord-005478-5iu38pr6	2313	2	had	have	VBD
cord-005478-5iu38pr6	2313	3	significantly	significantly	RB
cord-005478-5iu38pr6	2313	4	less	less	RBR
cord-005478-5iu38pr6	2313	5	severe	severe	JJ
cord-005478-5iu38pr6	2313	6	acute	acute	JJ
cord-005478-5iu38pr6	2313	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2313	8	symptoms	symptom	NNS
cord-005478-5iu38pr6	2313	9	(	(	-LRB-
cord-005478-5iu38pr6	2313	10	average	average	JJ
cord-005478-5iu38pr6	2313	11	score	score	NN
cord-005478-5iu38pr6	2313	12	of	of	IN
cord-005478-5iu38pr6	2313	13	2.48	2.48	CD
cord-005478-5iu38pr6	2313	14	)	)	-RRB-
cord-005478-5iu38pr6	2313	15	than	than	IN
cord-005478-5iu38pr6	2313	16	the	the	DT
cord-005478-5iu38pr6	2313	17	untreated	untreated	JJ
cord-005478-5iu38pr6	2313	18	BM+Sp	BM+Sp	NNP
cord-005478-5iu38pr6	2313	19	group	group	NN
cord-005478-5iu38pr6	2313	20	(	(	-LRB-
cord-005478-5iu38pr6	2313	21	average	average	JJ
cord-005478-5iu38pr6	2313	22	score	score	NN
cord-005478-5iu38pr6	2313	23	3.96	3.96	CD
cord-005478-5iu38pr6	2313	24	)	)	-RRB-
cord-005478-5iu38pr6	2313	25	starting	start	VBG
cord-005478-5iu38pr6	2313	26	at	at	IN
cord-005478-5iu38pr6	2313	27	the	the	DT
cord-005478-5iu38pr6	2313	28	time	time	NN
cord-005478-5iu38pr6	2313	29	of	of	IN
cord-005478-5iu38pr6	2313	30	IMP	IMP	NNP
cord-005478-5iu38pr6	2313	31	treatment	treatment	NN
cord-005478-5iu38pr6	2313	32	(	(	-LRB-
cord-005478-5iu38pr6	2313	33	days	day	NNS
cord-005478-5iu38pr6	2313	34	5	5	CD
cord-005478-5iu38pr6	2313	35	-	-	SYM
cord-005478-5iu38pr6	2313	36	10	10	CD
cord-005478-5iu38pr6	2313	37	)	)	-RRB-
cord-005478-5iu38pr6	2313	38	and	and	CC
cord-005478-5iu38pr6	2313	39	remained	remain	VBD
cord-005478-5iu38pr6	2313	40	with	with	IN
cord-005478-5iu38pr6	2313	41	significantly	significantly	RB
cord-005478-5iu38pr6	2313	42	reduced	reduce	VBN
cord-005478-5iu38pr6	2313	43	symptoms	symptom	NNS
cord-005478-5iu38pr6	2313	44	for	for	IN
cord-005478-5iu38pr6	2313	45	the	the	DT
cord-005478-5iu38pr6	2313	46	30	30	CD
cord-005478-5iu38pr6	2313	47	day	day	NN
cord-005478-5iu38pr6	2313	48	course	course	NN
cord-005478-5iu38pr6	2314	1	(	(	-LRB-
cord-005478-5iu38pr6	2314	2	Figure	figure	NN
cord-005478-5iu38pr6	2314	3	1	1	CD
cord-005478-5iu38pr6	2314	4	)	)	-RRB-
cord-005478-5iu38pr6	2314	5	.	.	.
cord-005478-5iu38pr6	2315	1	IMP	IMP	NNP
cord-005478-5iu38pr6	2315	2	treatment	treatment	NN
cord-005478-5iu38pr6	2315	3	also	also	RB
cord-005478-5iu38pr6	2315	4	rescued	rescue	VBD
cord-005478-5iu38pr6	2315	5	BM+Sp	bm+sp	DT
cord-005478-5iu38pr6	2315	6	mice	mouse	NNS
cord-005478-5iu38pr6	2315	7	from	from	IN
cord-005478-5iu38pr6	2315	8	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2315	9	associated	associate	VBN
cord-005478-5iu38pr6	2315	10	mortality	mortality	NN
cord-005478-5iu38pr6	2315	11	with	with	IN
cord-005478-5iu38pr6	2315	12	a	a	DT
cord-005478-5iu38pr6	2315	13	30-day	30-day	CD
cord-005478-5iu38pr6	2315	14	overall	overall	JJ
cord-005478-5iu38pr6	2315	15	survival	survival	NN
cord-005478-5iu38pr6	2315	16	of	of	IN
cord-005478-5iu38pr6	2315	17	62	62	CD
cord-005478-5iu38pr6	2315	18	%	%	NN
cord-005478-5iu38pr6	2315	19	compared	compare	VBN
cord-005478-5iu38pr6	2315	20	to	to	IN
cord-005478-5iu38pr6	2315	21	4	4	CD
cord-005478-5iu38pr6	2315	22	%	%	NN
cord-005478-5iu38pr6	2315	23	in	in	IN
cord-005478-5iu38pr6	2315	24	the	the	DT
cord-005478-5iu38pr6	2315	25	untreated	untreated	JJ
cord-005478-5iu38pr6	2315	26	BM+Sp	BM+Sp	NNP
cord-005478-5iu38pr6	2315	27	group	group	NN
cord-005478-5iu38pr6	2315	28	(	(	-LRB-
cord-005478-5iu38pr6	2315	29	Figure	figure	NN
cord-005478-5iu38pr6	2315	30	2	2	CD
cord-005478-5iu38pr6	2315	31	)	)	-RRB-
cord-005478-5iu38pr6	2315	32	.	.	.
cord-005478-5iu38pr6	2316	1	Intestinal	intestinal	JJ
cord-005478-5iu38pr6	2316	2	tissue	tissue	NN
cord-005478-5iu38pr6	2316	3	from	from	IN
cord-005478-5iu38pr6	2316	4	the	the	DT
cord-005478-5iu38pr6	2316	5	IMP	IMP	NNP
cord-005478-5iu38pr6	2316	6	treated	treat	VBD
cord-005478-5iu38pr6	2316	7	mice	mouse	NNS
cord-005478-5iu38pr6	2316	8	compared	compare	VBN
cord-005478-5iu38pr6	2316	9	to	to	IN
cord-005478-5iu38pr6	2316	10	the	the	DT
cord-005478-5iu38pr6	2316	11	BM+Sp	BM+Sp	NNP
cord-005478-5iu38pr6	2316	12	mice	mouse	NNS
cord-005478-5iu38pr6	2316	13	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	2316	14	less	less	JJR
cord-005478-5iu38pr6	2316	15	evidence	evidence	NN
cord-005478-5iu38pr6	2316	16	of	of	IN
cord-005478-5iu38pr6	2316	17	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2316	18	(	(	-LRB-
cord-005478-5iu38pr6	2316	19	an	an	DT
cord-005478-5iu38pr6	2316	20	average	average	JJ
cord-005478-5iu38pr6	2316	21	score	score	NN
cord-005478-5iu38pr6	2316	22	of	of	IN
cord-005478-5iu38pr6	2316	23	1.25	1.25	CD
cord-005478-5iu38pr6	2316	24	and	and	CC
cord-005478-5iu38pr6	2316	25	2.75	2.75	CD
cord-005478-5iu38pr6	2316	26	,	,	,
cord-005478-5iu38pr6	2316	27	respectively	respectively	RB
cord-005478-5iu38pr6	2316	28	)	)	-RRB-
cord-005478-5iu38pr6	2316	29	.	.	.
cord-005478-5iu38pr6	2317	1	Hepatic	hepatic	JJ
cord-005478-5iu38pr6	2317	2	tissue	tissue	NN
cord-005478-5iu38pr6	2317	3	from	from	IN
cord-005478-5iu38pr6	2317	4	the	the	DT
cord-005478-5iu38pr6	2317	5	IMP	IMP	NNP
cord-005478-5iu38pr6	2317	6	treated	treat	VBD
cord-005478-5iu38pr6	2317	7	mice	mouse	NNS
cord-005478-5iu38pr6	2317	8	compared	compare	VBN
cord-005478-5iu38pr6	2317	9	to	to	IN
cord-005478-5iu38pr6	2317	10	the	the	DT
cord-005478-5iu38pr6	2317	11	BM+Sp	BM+Sp	NNP
cord-005478-5iu38pr6	2317	12	mice	mouse	NNS
cord-005478-5iu38pr6	2317	13	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	2317	14	less	less	JJR
cord-005478-5iu38pr6	2317	15	evidence	evidence	NN
cord-005478-5iu38pr6	2317	16	of	of	IN
cord-005478-5iu38pr6	2317	17	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2317	18	(	(	-LRB-
cord-005478-5iu38pr6	2317	19	an	an	DT
cord-005478-5iu38pr6	2317	20	average	average	JJ
cord-005478-5iu38pr6	2317	21	score	score	NN
cord-005478-5iu38pr6	2317	22	of	of	IN
cord-005478-5iu38pr6	2317	23	1.5	1.5	CD
cord-005478-5iu38pr6	2317	24	and	and	CC
cord-005478-5iu38pr6	2317	25	2.42	2.42	CD
cord-005478-5iu38pr6	2317	26	,	,	,
cord-005478-5iu38pr6	2317	27	respectively	respectively	RB
cord-005478-5iu38pr6	2317	28	)	)	-RRB-
cord-005478-5iu38pr6	2317	29	.	.	.
cord-005478-5iu38pr6	2318	1	IMP	IMP	NNP
cord-005478-5iu38pr6	2318	2	treatment	treatment	NN
cord-005478-5iu38pr6	2318	3	also	also	RB
cord-005478-5iu38pr6	2318	4	significantly	significantly	RB
cord-005478-5iu38pr6	2318	5	reduced	reduce	VBD
cord-005478-5iu38pr6	2318	6	INF	inf	NN
cord-005478-5iu38pr6	2318	7	-	-	HYPH
cord-005478-5iu38pr6	2318	8	γ	γ	NN
cord-005478-5iu38pr6	2318	9	levels	level	NNS
cord-005478-5iu38pr6	2318	10	in	in	IN
cord-005478-5iu38pr6	2318	11	the	the	DT
cord-005478-5iu38pr6	2318	12	intestinal	intestinal	JJ
cord-005478-5iu38pr6	2318	13	tissues	tissue	NNS
cord-005478-5iu38pr6	2318	14	of	of	IN
cord-005478-5iu38pr6	2318	15	treated	treat	VBN
cord-005478-5iu38pr6	2318	16	mice	mouse	NNS
cord-005478-5iu38pr6	2318	17	compared	compare	VBN
cord-005478-5iu38pr6	2318	18	to	to	IN
cord-005478-5iu38pr6	2318	19	untreated	untreated	JJ
cord-005478-5iu38pr6	2318	20	BM	bm	NN
cord-005478-5iu38pr6	2318	21	+	+	CC
cord-005478-5iu38pr6	2319	1	Sp	Sp	NNP
cord-005478-5iu38pr6	2319	2	mice	mouse	NNS
cord-005478-5iu38pr6	2319	3	.	.	.
cord-005478-5iu38pr6	2320	1	In	in	IN
cord-005478-5iu38pr6	2320	2	the	the	DT
cord-005478-5iu38pr6	2320	3	mice	mouse	NNS
cord-005478-5iu38pr6	2320	4	infused	infuse	VBN
cord-005478-5iu38pr6	2320	5	with	with	IN
cord-005478-5iu38pr6	2320	6	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2320	7	cells	cell	NNS
cord-005478-5iu38pr6	2320	8	(	(	-LRB-
cord-005478-5iu38pr6	2320	9	A20-luc	A20-luc	NNP
cord-005478-5iu38pr6	2320	10	)	)	-RRB-
cord-005478-5iu38pr6	2320	11	,	,	,
cord-005478-5iu38pr6	2320	12	IMP	IMP	NNP
cord-005478-5iu38pr6	2320	13	treatment	treatment	NN
cord-005478-5iu38pr6	2320	14	reduced	reduce	VBD
cord-005478-5iu38pr6	2320	15	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2320	16	symptoms	symptom	NNS
cord-005478-5iu38pr6	2320	17	and	and	CC
cord-005478-5iu38pr6	2320	18	death	death	NN
cord-005478-5iu38pr6	2320	19	while	while	IN
cord-005478-5iu38pr6	2320	20	preserving	preserve	VBG
cord-005478-5iu38pr6	2320	21	the	the	DT
cord-005478-5iu38pr6	2320	22	GVL	GVL	NNP
cord-005478-5iu38pr6	2320	23	effect	effect	NN
cord-005478-5iu38pr6	2320	24	.	.	.
cord-005478-5iu38pr6	2321	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2321	2	:	:	:
cord-005478-5iu38pr6	2322	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2322	2	results	result	NNS
cord-005478-5iu38pr6	2322	3	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	2322	4	that	that	IN
cord-005478-5iu38pr6	2322	5	IMPs	imp	NNS
cord-005478-5iu38pr6	2322	6	significantly	significantly	RB
cord-005478-5iu38pr6	2322	7	reduce	reduce	VBP
cord-005478-5iu38pr6	2322	8	symptoms	symptom	NNS
cord-005478-5iu38pr6	2322	9	and	and	CC
cord-005478-5iu38pr6	2322	10	mortality	mortality	NN
cord-005478-5iu38pr6	2322	11	in	in	IN
cord-005478-5iu38pr6	2322	12	a	a	DT
cord-005478-5iu38pr6	2322	13	murine	murine	JJ
cord-005478-5iu38pr6	2322	14	model	model	NN
cord-005478-5iu38pr6	2322	15	of	of	IN
cord-005478-5iu38pr6	2322	16	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2322	17	while	while	IN
cord-005478-5iu38pr6	2322	18	preserving	preserve	VBG
cord-005478-5iu38pr6	2322	19	GVL	GVL	NNP
cord-005478-5iu38pr6	2322	20	.	.	.
cord-005478-5iu38pr6	2323	1	The	the	DT
cord-005478-5iu38pr6	2323	2	reduction	reduction	NN
cord-005478-5iu38pr6	2323	3	in	in	IN
cord-005478-5iu38pr6	2323	4	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2323	5	monocytes	monocyte	NNS
cord-005478-5iu38pr6	2323	6	with	with	IN
cord-005478-5iu38pr6	2323	7	IMPs	imp	NNS
cord-005478-5iu38pr6	2323	8	leads	lead	VBZ
cord-005478-5iu38pr6	2323	9	to	to	IN
cord-005478-5iu38pr6	2323	10	a	a	DT
cord-005478-5iu38pr6	2323	11	reduction	reduction	NN
cord-005478-5iu38pr6	2323	12	in	in	IN
cord-005478-5iu38pr6	2323	13	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2323	14	cytokines	cytokine	NNS
cord-005478-5iu38pr6	2323	15	,	,	,
cord-005478-5iu38pr6	2323	16	hepatic	hepatic	JJ
cord-005478-5iu38pr6	2323	17	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	2323	18	infiltration	infiltration	NN
cord-005478-5iu38pr6	2323	19	and	and	CC
cord-005478-5iu38pr6	2323	20	intestinal	intestinal	JJ
cord-005478-5iu38pr6	2323	21	mucosal	mucosal	JJ
cord-005478-5iu38pr6	2323	22	denudation	denudation	NN
cord-005478-5iu38pr6	2323	23	.	.	.
cord-005478-5iu38pr6	2324	1	These	these	DT
cord-005478-5iu38pr6	2324	2	findings	finding	NNS
cord-005478-5iu38pr6	2324	3	highlight	highlight	VBP
cord-005478-5iu38pr6	2324	4	the	the	DT
cord-005478-5iu38pr6	2324	5	potential	potential	NN
cord-005478-5iu38pr6	2324	6	of	of	IN
cord-005478-5iu38pr6	2324	7	IMP	IMP	NNP
cord-005478-5iu38pr6	2324	8	therapy	therapy	NN
cord-005478-5iu38pr6	2324	9	as	as	IN
cord-005478-5iu38pr6	2324	10	a	a	DT
cord-005478-5iu38pr6	2324	11	specific	specific	JJ
cord-005478-5iu38pr6	2324	12	and	and	CC
cord-005478-5iu38pr6	2324	13	potentially	potentially	RB
cord-005478-5iu38pr6	2324	14	safe	safe	JJ
cord-005478-5iu38pr6	2324	15	treatment	treatment	NN
cord-005478-5iu38pr6	2324	16	in	in	IN
cord-005478-5iu38pr6	2324	17	acute	acute	JJ
cord-005478-5iu38pr6	2324	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2324	19	.	.	.
cord-005478-5iu38pr6	2325	1	[	[	-LRB-
cord-005478-5iu38pr6	2325	2	[	[	-LRB-
cord-005478-5iu38pr6	2325	3	O114	O114	NNP
cord-005478-5iu38pr6	2325	4	Image	Image	NNP
cord-005478-5iu38pr6	2325	5	]	]	-RRB-
cord-005478-5iu38pr6	2325	6	1	1	CD
cord-005478-5iu38pr6	2325	7	.	.	.
cord-005478-5iu38pr6	2326	1	Figure	figure	NN
cord-005478-5iu38pr6	2326	2	1	1	CD
cord-005478-5iu38pr6	2326	3	Background	background	NN
cord-005478-5iu38pr6	2326	4	:	:	:
cord-005478-5iu38pr6	2327	1	Despite	despite	IN
cord-005478-5iu38pr6	2327	2	significant	significant	JJ
cord-005478-5iu38pr6	2327	3	improvements	improvement	NNS
cord-005478-5iu38pr6	2327	4	in	in	IN
cord-005478-5iu38pr6	2327	5	the	the	DT
cord-005478-5iu38pr6	2327	6	supportive	supportive	JJ
cord-005478-5iu38pr6	2327	7	Sickle	Sickle	NNP
cord-005478-5iu38pr6	2327	8	cell	cell	NN
cord-005478-5iu38pr6	2327	9	disease	disease	NN
cord-005478-5iu38pr6	2327	10	(	(	-LRB-
cord-005478-5iu38pr6	2327	11	SCD	SCD	NNP
cord-005478-5iu38pr6	2327	12	)	)	-RRB-
cord-005478-5iu38pr6	2327	13	causes	cause	VBZ
cord-005478-5iu38pr6	2327	14	substantial	substantial	JJ
cord-005478-5iu38pr6	2327	15	morbidity	morbidity	NN
cord-005478-5iu38pr6	2327	16	and	and	CC
cord-005478-5iu38pr6	2327	17	mortality	mortality	NN
cord-005478-5iu38pr6	2327	18	.	.	.
cord-005478-5iu38pr6	2328	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2328	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2328	3	stem	stem	NN
cord-005478-5iu38pr6	2328	4	cell	cell	NN
cord-005478-5iu38pr6	2328	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	2328	6	(	(	-LRB-
cord-005478-5iu38pr6	2328	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2328	8	)	)	-RRB-
cord-005478-5iu38pr6	2328	9	is	be	VBZ
cord-005478-5iu38pr6	2328	10	currently	currently	RB
cord-005478-5iu38pr6	2328	11	the	the	DT
cord-005478-5iu38pr6	2328	12	only	only	JJ
cord-005478-5iu38pr6	2328	13	curative	curative	JJ
cord-005478-5iu38pr6	2328	14	option	option	NN
cord-005478-5iu38pr6	2328	15	but	but	CC
cord-005478-5iu38pr6	2328	16	is	be	VBZ
cord-005478-5iu38pr6	2328	17	only	only	RB
cord-005478-5iu38pr6	2328	18	offered	offer	VBN
cord-005478-5iu38pr6	2328	19	if	if	IN
cord-005478-5iu38pr6	2328	20	a	a	DT
cord-005478-5iu38pr6	2328	21	matched	match	VBN
cord-005478-5iu38pr6	2328	22	sibling	sibling	NN
cord-005478-5iu38pr6	2328	23	donor	donor	NN
cord-005478-5iu38pr6	2328	24	(	(	-LRB-
cord-005478-5iu38pr6	2328	25	MSD	MSD	NNP
cord-005478-5iu38pr6	2328	26	)	)	-RRB-
cord-005478-5iu38pr6	2328	27	is	be	VBZ
cord-005478-5iu38pr6	2328	28	available	available	JJ
cord-005478-5iu38pr6	2328	29	.	.	.
cord-005478-5iu38pr6	2329	1	With	with	IN
cord-005478-5iu38pr6	2329	2	a	a	DT
cord-005478-5iu38pr6	2329	3	MSD	MSD	NNP
cord-005478-5iu38pr6	2329	4	availability	availability	NN
cord-005478-5iu38pr6	2329	5	of	of	IN
cord-005478-5iu38pr6	2329	6	<	<	$
cord-005478-5iu38pr6	2329	7	20	20	CD
cord-005478-5iu38pr6	2329	8	%	%	NN
cord-005478-5iu38pr6	2329	9	T	t	NN
cord-005478-5iu38pr6	2329	10	cell	cell	NN
cord-005478-5iu38pr6	2329	11	depleted	deplete	VBD
cord-005478-5iu38pr6	2329	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2329	13	from	from	IN
cord-005478-5iu38pr6	2329	14	a	a	DT
cord-005478-5iu38pr6	2329	15	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2329	16	donor	donor	NN
cord-005478-5iu38pr6	2329	17	(	(	-LRB-
cord-005478-5iu38pr6	2329	18	T	t	NN
cord-005478-5iu38pr6	2329	19	-	-	HYPH
cord-005478-5iu38pr6	2329	20	haplo	haplo	NNP
cord-005478-5iu38pr6	2329	21	-	-	HYPH
cord-005478-5iu38pr6	2329	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2329	23	)	)	-RRB-
cord-005478-5iu38pr6	2329	24	is	be	VBZ
cord-005478-5iu38pr6	2329	25	a	a	DT
cord-005478-5iu38pr6	2329	26	potential	potential	JJ
cord-005478-5iu38pr6	2329	27	alternative	alternative	NN
cord-005478-5iu38pr6	2329	28	.	.	.
cord-005478-5iu38pr6	2330	1	Methods	method	NNS
cord-005478-5iu38pr6	2330	2	:	:	:
cord-005478-5iu38pr6	2330	3	29	29	CD
cord-005478-5iu38pr6	2330	4	patients	patient	NNS
cord-005478-5iu38pr6	2330	5	(	(	-LRB-
cord-005478-5iu38pr6	2330	6	pts	pt	NNS
cord-005478-5iu38pr6	2330	7	)	)	-RRB-
cord-005478-5iu38pr6	2330	8	with	with	IN
cord-005478-5iu38pr6	2330	9	advanced	advanced	JJ
cord-005478-5iu38pr6	2330	10	stage	stage	NN
cord-005478-5iu38pr6	2330	11	SCD	SCD	NNP
cord-005478-5iu38pr6	2330	12	(	(	-LRB-
cord-005478-5iu38pr6	2330	13	asSCD	asSCD	NNS
cord-005478-5iu38pr6	2330	14	)	)	-RRB-
cord-005478-5iu38pr6	2330	15	were	be	VBD
cord-005478-5iu38pr6	2330	16	transplanted	transplant	VBN
cord-005478-5iu38pr6	2330	17	with	with	IN
cord-005478-5iu38pr6	2330	18	a	a	DT
cord-005478-5iu38pr6	2330	19	CD3	cd3	NN
cord-005478-5iu38pr6	2331	1	+	+	CC
cord-005478-5iu38pr6	2332	1	/CD19	/CD19	.
cord-005478-5iu38pr6	2333	1	+	+	CC
cord-005478-5iu38pr6	2334	1	or	or	CC
cord-005478-5iu38pr6	2334	2	αβ	αβ	NN
cord-005478-5iu38pr6	2334	3	/	/	NFP
cord-005478-5iu38pr6	2334	4	CD19	CD19	NNP
cord-005478-5iu38pr6	2335	1	+	+	CC
cord-005478-5iu38pr6	2335	2	depleted	deplete	VBN
cord-005478-5iu38pr6	2335	3	T	T	NNP
cord-005478-5iu38pr6	2335	4	-	-	HYPH
cord-005478-5iu38pr6	2335	5	haplo	haplo	NNP
cord-005478-5iu38pr6	2335	6	-	-	HYPH
cord-005478-5iu38pr6	2335	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2335	8	(	(	-LRB-
cord-005478-5iu38pr6	2335	9	20	20	CD
cord-005478-5iu38pr6	2335	10	pts	pt	NNS
cord-005478-5iu38pr6	2335	11	,	,	,
cord-005478-5iu38pr6	2335	12	median	median	JJ
cord-005478-5iu38pr6	2335	13	age	age	NN
cord-005478-5iu38pr6	2335	14	13	13	CD
cord-005478-5iu38pr6	2335	15	years	year	NNS
cord-005478-5iu38pr6	2335	16	,	,	,
cord-005478-5iu38pr6	2335	17	range	range	VBP
cord-005478-5iu38pr6	2335	18	3	3	CD
cord-005478-5iu38pr6	2335	19	-	-	SYM
cord-005478-5iu38pr6	2335	20	31	31	CD
cord-005478-5iu38pr6	2335	21	years	year	NNS
cord-005478-5iu38pr6	2335	22	)	)	-RRB-
cord-005478-5iu38pr6	2335	23	or	or	CC
cord-005478-5iu38pr6	2335	24	with	with	IN
cord-005478-5iu38pr6	2335	25	bone	bone	NN
cord-005478-5iu38pr6	2335	26	marrow	marrow	NN
cord-005478-5iu38pr6	2335	27	(	(	-LRB-
cord-005478-5iu38pr6	2335	28	BM	BM	NNP
cord-005478-5iu38pr6	2335	29	)	)	-RRB-
cord-005478-5iu38pr6	2335	30	from	from	IN
cord-005478-5iu38pr6	2335	31	a	a	DT
cord-005478-5iu38pr6	2335	32	MSD	MSD	NNP
cord-005478-5iu38pr6	2335	33	,	,	,
cord-005478-5iu38pr6	2335	34	9	9	CD
cord-005478-5iu38pr6	2335	35	pts	pt	NNS
cord-005478-5iu38pr6	2335	36	,	,	,
cord-005478-5iu38pr6	2335	37	median	median	JJ
cord-005478-5iu38pr6	2335	38	age	age	NN
cord-005478-5iu38pr6	2335	39	14	14	CD
cord-005478-5iu38pr6	2335	40	,	,	,
cord-005478-5iu38pr6	2335	41	range	range	VBP
cord-005478-5iu38pr6	2335	42	9	9	CD
cord-005478-5iu38pr6	2335	43	-	-	SYM
cord-005478-5iu38pr6	2335	44	25	25	CD
cord-005478-5iu38pr6	2335	45	years	year	NNS
cord-005478-5iu38pr6	2335	46	)	)	-RRB-
cord-005478-5iu38pr6	2335	47	.	.	.
cord-005478-5iu38pr6	2336	1	Indication	indication	NN
cord-005478-5iu38pr6	2336	2	for	for	IN
cord-005478-5iu38pr6	2336	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2336	4	was	be	VBD
cord-005478-5iu38pr6	2336	5	asSCD	asscd	RB
cord-005478-5iu38pr6	2336	6	with	with	IN
cord-005478-5iu38pr6	2336	7	multiple	multiple	JJ
cord-005478-5iu38pr6	2336	8	SCD	SCD	NNP
cord-005478-5iu38pr6	2336	9	related	relate	VBN
cord-005478-5iu38pr6	2336	10	complications	complication	NNS
cord-005478-5iu38pr6	2336	11	.	.	.
cord-005478-5iu38pr6	2337	1	All	all	DT
cord-005478-5iu38pr6	2337	2	pts	pt	NNS
cord-005478-5iu38pr6	2337	3	underwent	undergo	VBD
cord-005478-5iu38pr6	2337	4	exchange	exchange	NN
cord-005478-5iu38pr6	2337	5	transfusion	transfusion	NN
cord-005478-5iu38pr6	2337	6	before	before	IN
cord-005478-5iu38pr6	2337	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2337	8	.	.	.
cord-005478-5iu38pr6	2338	1	In	in	IN
cord-005478-5iu38pr6	2338	2	all	all	DT
cord-005478-5iu38pr6	2338	3	pts	pt	NNS
cord-005478-5iu38pr6	2338	4	the	the	DT
cord-005478-5iu38pr6	2338	5	conditioning	conditioning	NN
cord-005478-5iu38pr6	2338	6	regimen	regimen	NN
cord-005478-5iu38pr6	2338	7	consisted	consist	VBD
cord-005478-5iu38pr6	2338	8	of	of	IN
cord-005478-5iu38pr6	2338	9	treosulfan	treosulfan	NNP
cord-005478-5iu38pr6	2338	10	,	,	,
cord-005478-5iu38pr6	2338	11	thiotepa	thiotepa	JJ
cord-005478-5iu38pr6	2338	12	,	,	,
cord-005478-5iu38pr6	2338	13	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	2338	14	and	and	CC
cord-005478-5iu38pr6	2338	15	ATG	ATG	NNP
cord-005478-5iu38pr6	2338	16	.	.	.
cord-005478-5iu38pr6	2339	1	Immunosuppression	Immunosuppression	NNP
cord-005478-5iu38pr6	2339	2	was	be	VBD
cord-005478-5iu38pr6	2339	3	carried	carry	VBN
cord-005478-5iu38pr6	2339	4	out	out	RP
cord-005478-5iu38pr6	2339	5	with	with	IN
cord-005478-5iu38pr6	2339	6	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	2339	7	A	a	NN
cord-005478-5iu38pr6	2339	8	or	or	CC
cord-005478-5iu38pr6	2339	9	tacrolimus	tacrolimus	NNP
cord-005478-5iu38pr6	2339	10	and	and	CC
cord-005478-5iu38pr6	2339	11	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	2339	12	mofetil	mofetil	NNP
cord-005478-5iu38pr6	2339	13	.	.	.
cord-005478-5iu38pr6	2340	1	The	the	DT
cord-005478-5iu38pr6	2340	2	control	control	NN
cord-005478-5iu38pr6	2340	3	group	group	NN
cord-005478-5iu38pr6	2340	4	received	receive	VBD
cord-005478-5iu38pr6	2340	5	a	a	DT
cord-005478-5iu38pr6	2340	6	MSD	MSD	NNP
cord-005478-5iu38pr6	2340	7	BM	BM	NNP
cord-005478-5iu38pr6	2340	8	allograft	allograft	NN
cord-005478-5iu38pr6	2340	9	.	.	.
cord-005478-5iu38pr6	2341	1	Results	result	NNS
cord-005478-5iu38pr6	2341	2	:	:	:
cord-005478-5iu38pr6	2342	1	In	in	IN
cord-005478-5iu38pr6	2342	2	the	the	DT
cord-005478-5iu38pr6	2342	3	T	t	NN
cord-005478-5iu38pr6	2342	4	-	-	HYPH
cord-005478-5iu38pr6	2342	5	haplo	haplo	NNP
cord-005478-5iu38pr6	2342	6	-	-	HYPH
cord-005478-5iu38pr6	2342	7	SCT	SCT	NNP
cord-005478-5iu38pr6	2342	8	group	group	NN
cord-005478-5iu38pr6	2342	9	the	the	DT
cord-005478-5iu38pr6	2342	10	pts	pts	NN
cord-005478-5iu38pr6	2342	11	received	receive	VBD
cord-005478-5iu38pr6	2342	12	a	a	DT
cord-005478-5iu38pr6	2342	13	CD3	cd3	NN
cord-005478-5iu38pr6	2342	14	+	+	CC
cord-005478-5iu38pr6	2343	1	or	or	CC
cord-005478-5iu38pr6	2343	2	αβ	αβ	NN
cord-005478-5iu38pr6	2344	1	+	+	CC
cord-005478-5iu38pr6	2344	2	T	t	NN
cord-005478-5iu38pr6	2344	3	-	-	HYPH
cord-005478-5iu38pr6	2344	4	and	and	CC
cord-005478-5iu38pr6	2344	5	CD19	CD19	NNP
cord-005478-5iu38pr6	2344	6	+	+	CC
cord-005478-5iu38pr6	2344	7	B	b	NN
cord-005478-5iu38pr6	2344	8	-	-	HYPH
cord-005478-5iu38pr6	2344	9	cell	cell	NN
cord-005478-5iu38pr6	2344	10	depleted	deplete	VBD
cord-005478-5iu38pr6	2344	11	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2344	12	stem	stem	NN
cord-005478-5iu38pr6	2344	13	cell	cell	NN
cord-005478-5iu38pr6	2344	14	allograft	allograft	NN
cord-005478-5iu38pr6	2344	15	with	with	IN
cord-005478-5iu38pr6	2344	16	13,1	13,1	CD
cord-005478-5iu38pr6	2344	17	x	x	SYM
cord-005478-5iu38pr6	2344	18	10	10	CD
cord-005478-5iu38pr6	2344	19	6	6	CD
cord-005478-5iu38pr6	2344	20	CD34	CD34	NNP
cord-005478-5iu38pr6	2344	21	+	+	CC
cord-005478-5iu38pr6	2344	22	cells	cell	NNS
cord-005478-5iu38pr6	2344	23	/	/	SYM
cord-005478-5iu38pr6	2344	24	kg	kg	NN
cord-005478-5iu38pr6	2344	25	body	body	NN
cord-005478-5iu38pr6	2344	26	weight	weight	NN
cord-005478-5iu38pr6	2344	27	(	(	-LRB-
cord-005478-5iu38pr6	2344	28	range	range	NN
cord-005478-5iu38pr6	2344	29	8,1	8,1	CD
cord-005478-5iu38pr6	2344	30	to	to	IN
cord-005478-5iu38pr6	2344	31	77,9	77,9	CD
cord-005478-5iu38pr6	2344	32	)	)	-RRB-
cord-005478-5iu38pr6	2344	33	.	.	.
cord-005478-5iu38pr6	2345	1	All	all	DT
cord-005478-5iu38pr6	2345	2	pts	pt	NNS
cord-005478-5iu38pr6	2345	3	with	with	IN
cord-005478-5iu38pr6	2345	4	a	a	DT
cord-005478-5iu38pr6	2345	5	median	median	NN
cord-005478-5iu38pr6	2345	6	follow	follow	NN
cord-005478-5iu38pr6	2345	7	up	up	IN
cord-005478-5iu38pr6	2345	8	of	of	IN
cord-005478-5iu38pr6	2345	9	22	22	CD
cord-005478-5iu38pr6	2345	10	months	month	NNS
cord-005478-5iu38pr6	2345	11	(	(	-LRB-
cord-005478-5iu38pr6	2345	12	range	range	VBP
cord-005478-5iu38pr6	2345	13	4	4	CD
cord-005478-5iu38pr6	2345	14	-	-	SYM
cord-005478-5iu38pr6	2345	15	57	57	CD
cord-005478-5iu38pr6	2345	16	months	month	NNS
cord-005478-5iu38pr6	2345	17	)	)	-RRB-
cord-005478-5iu38pr6	2345	18	in	in	IN
cord-005478-5iu38pr6	2345	19	the	the	DT
cord-005478-5iu38pr6	2345	20	MSD	MSD	NNP
cord-005478-5iu38pr6	2345	21	group	group	NN
cord-005478-5iu38pr6	2345	22	and	and	CC
cord-005478-5iu38pr6	2345	23	18	18	CD
cord-005478-5iu38pr6	2345	24	from	from	IN
cord-005478-5iu38pr6	2345	25	20	20	CD
cord-005478-5iu38pr6	2345	26	pts	pt	NNS
cord-005478-5iu38pr6	2345	27	with	with	IN
cord-005478-5iu38pr6	2345	28	a	a	DT
cord-005478-5iu38pr6	2345	29	median	median	NN
cord-005478-5iu38pr6	2345	30	follow	follow	NN
cord-005478-5iu38pr6	2345	31	up	up	IN
cord-005478-5iu38pr6	2345	32	of	of	IN
cord-005478-5iu38pr6	2345	33	17	17	CD
cord-005478-5iu38pr6	2345	34	months	month	NNS
cord-005478-5iu38pr6	2345	35	(	(	-LRB-
cord-005478-5iu38pr6	2345	36	range	range	VBP
cord-005478-5iu38pr6	2345	37	5	5	CD
cord-005478-5iu38pr6	2345	38	-	-	SYM
cord-005478-5iu38pr6	2345	39	58	58	CD
cord-005478-5iu38pr6	2345	40	months	month	NNS
cord-005478-5iu38pr6	2345	41	)	)	-RRB-
cord-005478-5iu38pr6	2345	42	in	in	IN
cord-005478-5iu38pr6	2345	43	the	the	DT
cord-005478-5iu38pr6	2345	44	T	T	NNP
cord-005478-5iu38pr6	2345	45	-	-	HYPH
cord-005478-5iu38pr6	2345	46	haplo	haplo	NNP
cord-005478-5iu38pr6	2345	47	-	-	HYPH
cord-005478-5iu38pr6	2345	48	SCT	SCT	NNP
cord-005478-5iu38pr6	2345	49	group	group	NN
cord-005478-5iu38pr6	2345	50	are	be	VBP
cord-005478-5iu38pr6	2345	51	alive	alive	JJ
cord-005478-5iu38pr6	2345	52	.	.	.
cord-005478-5iu38pr6	2346	1	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	2346	2	was	be	VBD
cord-005478-5iu38pr6	2346	3	achieved	achieve	VBN
cord-005478-5iu38pr6	2346	4	in	in	IN
cord-005478-5iu38pr6	2346	5	all	all	DT
cord-005478-5iu38pr6	2346	6	pts	pt	NNS
cord-005478-5iu38pr6	2346	7	with	with	IN
cord-005478-5iu38pr6	2346	8	stable	stable	JJ
cord-005478-5iu38pr6	2346	9	chimerism	chimerism	NN
cord-005478-5iu38pr6	2346	10	over	over	IN
cord-005478-5iu38pr6	2346	11	90	90	CD
cord-005478-5iu38pr6	2346	12	%	%	NN
cord-005478-5iu38pr6	2346	13	,	,	,
cord-005478-5iu38pr6	2346	14	except	except	IN
cord-005478-5iu38pr6	2346	15	for	for	IN
cord-005478-5iu38pr6	2346	16	4	4	CD
cord-005478-5iu38pr6	2346	17	pts	pt	NNS
cord-005478-5iu38pr6	2346	18	with	with	IN
cord-005478-5iu38pr6	2346	19	a	a	DT
cord-005478-5iu38pr6	2346	20	stable	stable	JJ
cord-005478-5iu38pr6	2346	21	MC	MC	NNP
cord-005478-5iu38pr6	2346	22	in	in	IN
cord-005478-5iu38pr6	2346	23	the	the	DT
cord-005478-5iu38pr6	2346	24	T	T	NNP
cord-005478-5iu38pr6	2346	25	-	-	HYPH
cord-005478-5iu38pr6	2346	26	haplo	haplo	NNP
cord-005478-5iu38pr6	2346	27	SCT	SCT	NNP
cord-005478-5iu38pr6	2346	28	group	group	NN
cord-005478-5iu38pr6	2346	29	and	and	CC
cord-005478-5iu38pr6	2346	30	1	1	CD
cord-005478-5iu38pr6	2346	31	patient	patient	NN
cord-005478-5iu38pr6	2346	32	in	in	IN
cord-005478-5iu38pr6	2346	33	the	the	DT
cord-005478-5iu38pr6	2346	34	MSD	MSD	NNP
cord-005478-5iu38pr6	2346	35	group	group	NN
cord-005478-5iu38pr6	2346	36	,	,	,
cord-005478-5iu38pr6	2346	37	but	but	CC
cord-005478-5iu38pr6	2346	38	complete	complete	JJ
cord-005478-5iu38pr6	2346	39	engraftment	engraftment	NN
cord-005478-5iu38pr6	2346	40	of	of	IN
cord-005478-5iu38pr6	2346	41	red	red	JJ
cord-005478-5iu38pr6	2346	42	cell	cell	NN
cord-005478-5iu38pr6	2346	43	precursor	precursor	NN
cord-005478-5iu38pr6	2346	44	in	in	IN
cord-005478-5iu38pr6	2346	45	the	the	DT
cord-005478-5iu38pr6	2346	46	BM	BM	NNP
cord-005478-5iu38pr6	2346	47	.	.	.
cord-005478-5iu38pr6	2347	1	All	all	DT
cord-005478-5iu38pr6	2347	2	pts	pt	NNS
cord-005478-5iu38pr6	2347	3	are	be	VBP
cord-005478-5iu38pr6	2347	4	off	off	IN
cord-005478-5iu38pr6	2347	5	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2347	6	with	with	IN
cord-005478-5iu38pr6	2347	7	a	a	DT
cord-005478-5iu38pr6	2347	8	stable	stable	JJ
cord-005478-5iu38pr6	2347	9	almost	almost	RB
cord-005478-5iu38pr6	2347	10	complete	complete	JJ
cord-005478-5iu38pr6	2347	11	chimerism	chimerism	NN
cord-005478-5iu38pr6	2347	12	.	.	.
cord-005478-5iu38pr6	2348	1	The	the	DT
cord-005478-5iu38pr6	2348	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	2348	3	regimen	regimen	NN
cord-005478-5iu38pr6	2348	4	was	be	VBD
cord-005478-5iu38pr6	2348	5	well	well	RB
cord-005478-5iu38pr6	2348	6	tolerated	tolerate	VBN
cord-005478-5iu38pr6	2348	7	with	with	IN
cord-005478-5iu38pr6	2348	8	no	no	DT
cord-005478-5iu38pr6	2348	9	case	case	NN
cord-005478-5iu38pr6	2348	10	of	of	IN
cord-005478-5iu38pr6	2348	11	high	high	JJ
cord-005478-5iu38pr6	2348	12	-	-	HYPH
cord-005478-5iu38pr6	2348	13	grade	grade	NN
cord-005478-5iu38pr6	2348	14	transplant	transplant	NN
cord-005478-5iu38pr6	2348	15	related	relate	VBN
cord-005478-5iu38pr6	2348	16	morbidity	morbidity	NN
cord-005478-5iu38pr6	2348	17	.	.	.
cord-005478-5iu38pr6	2349	1	The	the	DT
cord-005478-5iu38pr6	2349	2	post	post	JJ
cord-005478-5iu38pr6	2349	3	-	-	JJ
cord-005478-5iu38pr6	2349	4	transplantation	transplantation	JJ
cord-005478-5iu38pr6	2349	5	complications	complication	NNS
cord-005478-5iu38pr6	2349	6	were	be	VBD
cord-005478-5iu38pr6	2349	7	comparable	comparable	JJ
cord-005478-5iu38pr6	2349	8	in	in	IN
cord-005478-5iu38pr6	2349	9	both	both	DT
cord-005478-5iu38pr6	2349	10	groups	group	NNS
cord-005478-5iu38pr6	2349	11	.	.	.
cord-005478-5iu38pr6	2350	1	One	one	CD
cord-005478-5iu38pr6	2350	2	patient	patient	NN
cord-005478-5iu38pr6	2350	3	developed	develop	VBN
cord-005478-5iu38pr6	2350	4	after	after	IN
cord-005478-5iu38pr6	2350	5	severe	severe	JJ
cord-005478-5iu38pr6	2350	6	rotavirus	rotavirus	JJ
cord-005478-5iu38pr6	2350	7	gastroenteritis	gastroenteritis	NN
cord-005478-5iu38pr6	2350	8	a	a	DT
cord-005478-5iu38pr6	2350	9	severe	severe	JJ
cord-005478-5iu38pr6	2350	10	CMV	CMV	NNP
cord-005478-5iu38pr6	2350	11	pneumonitis	pneumonitis	NN
cord-005478-5iu38pr6	2350	12	and	and	CC
cord-005478-5iu38pr6	2350	13	succumbed	succumb	VBD
cord-005478-5iu38pr6	2350	14	to	to	IN
cord-005478-5iu38pr6	2350	15	an	an	DT
cord-005478-5iu38pr6	2350	16	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	2350	17	CMV	CMV	NNP
cord-005478-5iu38pr6	2350	18	pneumonitis	pneumonitis	NN
cord-005478-5iu38pr6	2350	19	.	.	.
cord-005478-5iu38pr6	2351	1	One	one	CD
cord-005478-5iu38pr6	2351	2	patient	patient	NN
cord-005478-5iu38pr6	2351	3	in	in	IN
cord-005478-5iu38pr6	2351	4	the	the	DT
cord-005478-5iu38pr6	2351	5	T	T	NNP
cord-005478-5iu38pr6	2351	6	-	-	HYPH
cord-005478-5iu38pr6	2351	7	haplo	haplo	NNP
cord-005478-5iu38pr6	2351	8	SCT	SCT	NNP
cord-005478-5iu38pr6	2351	9	group	group	NN
cord-005478-5iu38pr6	2351	10	suffered	suffer	VBD
cord-005478-5iu38pr6	2351	11	from	from	IN
cord-005478-5iu38pr6	2351	12	a	a	DT
cord-005478-5iu38pr6	2351	13	late	late	JJ
cord-005478-5iu38pr6	2351	14	graft	graft	NN
cord-005478-5iu38pr6	2351	15	failure	failure	NN
cord-005478-5iu38pr6	2351	16	and	and	CC
cord-005478-5iu38pr6	2351	17	developed	develop	VBD
cord-005478-5iu38pr6	2351	18	a	a	DT
cord-005478-5iu38pr6	2351	19	macrophage	macrophage	NN
cord-005478-5iu38pr6	2351	20	activation	activation	NN
cord-005478-5iu38pr6	2351	21	syndrome	syndrome	NN
cord-005478-5iu38pr6	2351	22	.	.	.
cord-005478-5iu38pr6	2352	1	He	-PRON-	PRP
cord-005478-5iu38pr6	2352	2	died	die	VBD
cord-005478-5iu38pr6	2352	3	in	in	IN
cord-005478-5iu38pr6	2352	4	a	a	DT
cord-005478-5iu38pr6	2352	5	septic	septic	JJ
cord-005478-5iu38pr6	2352	6	event	event	NN
cord-005478-5iu38pr6	2352	7	.	.	.
cord-005478-5iu38pr6	2353	1	None	none	NN
cord-005478-5iu38pr6	2353	2	developed	develop	VBD
cord-005478-5iu38pr6	2353	3	a	a	DT
cord-005478-5iu38pr6	2353	4	Glucksberg	Glucksberg	NNP
cord-005478-5iu38pr6	2353	5	Grade	Grade	NNP
cord-005478-5iu38pr6	2353	6	III	III	NNP
cord-005478-5iu38pr6	2353	7	-	-	HYPH
cord-005478-5iu38pr6	2353	8	IV	IV	NNP
cord-005478-5iu38pr6	2353	9	aGvHD	agvhd	NN
cord-005478-5iu38pr6	2353	10	and	and	CC
cord-005478-5iu38pr6	2353	11	in	in	IN
cord-005478-5iu38pr6	2353	12	the	the	DT
cord-005478-5iu38pr6	2353	13	T	T	NNP
cord-005478-5iu38pr6	2353	14	-	-	HYPH
cord-005478-5iu38pr6	2353	15	haplo	haplo	NNP
cord-005478-5iu38pr6	2353	16	SCT	SCT	NNP
cord-005478-5iu38pr6	2353	17	group	group	NN
cord-005478-5iu38pr6	2353	18	4	4	CD
cord-005478-5iu38pr6	2353	19	pts	pt	NNS
cord-005478-5iu38pr6	2353	20	(	(	-LRB-
cord-005478-5iu38pr6	2353	21	20	20	CD
cord-005478-5iu38pr6	2353	22	%	%	NN
cord-005478-5iu38pr6	2353	23	)	)	-RRB-
cord-005478-5iu38pr6	2353	24	and	and	CC
cord-005478-5iu38pr6	2353	25	in	in	IN
cord-005478-5iu38pr6	2353	26	the	the	DT
cord-005478-5iu38pr6	2353	27	MSD	MSD	NNP
cord-005478-5iu38pr6	2353	28	group	group	NN
cord-005478-5iu38pr6	2353	29	2	2	CD
cord-005478-5iu38pr6	2353	30	pts	pt	NNS
cord-005478-5iu38pr6	2353	31	(	(	-LRB-
cord-005478-5iu38pr6	2353	32	22	22	CD
cord-005478-5iu38pr6	2353	33	%	%	NN
cord-005478-5iu38pr6	2353	34	)	)	-RRB-
cord-005478-5iu38pr6	2353	35	developed	develop	VBD
cord-005478-5iu38pr6	2353	36	a	a	DT
cord-005478-5iu38pr6	2353	37	steroid	steroid	NN
cord-005478-5iu38pr6	2353	38	sensitive	sensitive	JJ
cord-005478-5iu38pr6	2353	39	mild	mild	NN
cord-005478-5iu38pr6	2353	40	to	to	TO
cord-005478-5iu38pr6	2353	41	moderate	moderate	JJ
cord-005478-5iu38pr6	2353	42	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2353	43	with	with	IN
cord-005478-5iu38pr6	2353	44	symptoms	symptom	NNS
cord-005478-5iu38pr6	2353	45	of	of	IN
cord-005478-5iu38pr6	2353	46	fasciitis	fasciitis	NN
cord-005478-5iu38pr6	2353	47	,	,	,
cord-005478-5iu38pr6	2353	48	oral	oral	JJ
cord-005478-5iu38pr6	2353	49	as	as	RB
cord-005478-5iu38pr6	2353	50	well	well	RB
cord-005478-5iu38pr6	2353	51	as	as	IN
cord-005478-5iu38pr6	2353	52	mild	mild	JJ
cord-005478-5iu38pr6	2353	53	cutaneous	cutaneous	JJ
cord-005478-5iu38pr6	2353	54	GvHD	gvhd	NN
cord-005478-5iu38pr6	2353	55	.	.	.
cord-005478-5iu38pr6	2354	1	In	in	IN
cord-005478-5iu38pr6	2354	2	both	both	DT
cord-005478-5iu38pr6	2354	3	groups	group	NNS
cord-005478-5iu38pr6	2354	4	no	no	DT
cord-005478-5iu38pr6	2354	5	severe	severe	JJ
cord-005478-5iu38pr6	2354	6	or	or	CC
cord-005478-5iu38pr6	2354	7	steroid	steroid	NN
cord-005478-5iu38pr6	2354	8	refractory	refractory	JJ
cord-005478-5iu38pr6	2354	9	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	2354	10	was	be	VBD
cord-005478-5iu38pr6	2354	11	observed	observe	VBN
cord-005478-5iu38pr6	2354	12	.	.	.
cord-005478-5iu38pr6	2355	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2355	2	:	:	:
cord-005478-5iu38pr6	2356	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2356	2	results	result	NNS
cord-005478-5iu38pr6	2356	3	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	2356	4	increasing	increase	VBG
cord-005478-5iu38pr6	2356	5	evidence	evidence	NN
cord-005478-5iu38pr6	2356	6	for	for	IN
cord-005478-5iu38pr6	2356	7	the	the	DT
cord-005478-5iu38pr6	2356	8	safety	safety	NN
cord-005478-5iu38pr6	2356	9	and	and	CC
cord-005478-5iu38pr6	2356	10	efficacy	efficacy	NN
cord-005478-5iu38pr6	2356	11	of	of	IN
cord-005478-5iu38pr6	2356	12	CD3	CD3	NNP
cord-005478-5iu38pr6	2357	1	+	+	CC
cord-005478-5iu38pr6	2358	1	/CD19	/CD19	.
cord-005478-5iu38pr6	2359	1	+	+	CC
cord-005478-5iu38pr6	2360	1	or	or	CC
cord-005478-5iu38pr6	2360	2	αβ	αβ	NN
cord-005478-5iu38pr6	2361	1	+	+	CC
cord-005478-5iu38pr6	2362	1	/CD19	/CD19	NNP
cord-005478-5iu38pr6	2362	2	+	+	CC
cord-005478-5iu38pr6	2362	3	depleted	deplete	VBD
cord-005478-5iu38pr6	2362	4	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2362	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2362	6	in	in	IN
cord-005478-5iu38pr6	2362	7	asSCD	asSCD	NNS
cord-005478-5iu38pr6	2362	8	.	.	.
cord-005478-5iu38pr6	2363	1	The	the	DT
cord-005478-5iu38pr6	2363	2	treosulfan	treosulfan	NN
cord-005478-5iu38pr6	2363	3	based	base	VBN
cord-005478-5iu38pr6	2363	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	2363	5	regimen	regimen	NN
cord-005478-5iu38pr6	2363	6	was	be	VBD
cord-005478-5iu38pr6	2363	7	an	an	DT
cord-005478-5iu38pr6	2363	8	excellent	excellent	JJ
cord-005478-5iu38pr6	2363	9	alternative	alternative	NN
cord-005478-5iu38pr6	2363	10	to	to	IN
cord-005478-5iu38pr6	2363	11	busulfan	busulfan	NN
cord-005478-5iu38pr6	2363	12	with	with	IN
cord-005478-5iu38pr6	2363	13	a	a	DT
cord-005478-5iu38pr6	2363	14	low	low	JJ
cord-005478-5iu38pr6	2363	15	incidence	incidence	NN
cord-005478-5iu38pr6	2363	16	of	of	IN
cord-005478-5iu38pr6	2363	17	transplant	transplant	NN
cord-005478-5iu38pr6	2363	18	related	relate	VBN
cord-005478-5iu38pr6	2363	19	morbidities	morbidity	NNS
cord-005478-5iu38pr6	2363	20	and	and	CC
cord-005478-5iu38pr6	2363	21	therefore	therefore	RB
cord-005478-5iu38pr6	2363	22	most	most	RBS
cord-005478-5iu38pr6	2363	23	suitable	suitable	JJ
cord-005478-5iu38pr6	2363	24	for	for	IN
cord-005478-5iu38pr6	2363	25	pts	pt	NNS
cord-005478-5iu38pr6	2363	26	with	with	IN
cord-005478-5iu38pr6	2363	27	SCD	SCD	NNP
cord-005478-5iu38pr6	2363	28	.	.	.
cord-005478-5iu38pr6	2364	1	These	these	DT
cord-005478-5iu38pr6	2364	2	results	result	NNS
cord-005478-5iu38pr6	2364	3	open	open	VBP
cord-005478-5iu38pr6	2364	4	the	the	DT
cord-005478-5iu38pr6	2364	5	option	option	NN
cord-005478-5iu38pr6	2364	6	of	of	IN
cord-005478-5iu38pr6	2364	7	a	a	DT
cord-005478-5iu38pr6	2364	8	curative	curative	JJ
cord-005478-5iu38pr6	2364	9	therapy	therapy	NN
cord-005478-5iu38pr6	2364	10	for	for	IN
cord-005478-5iu38pr6	2364	11	almost	almost	RB
cord-005478-5iu38pr6	2364	12	all	all	DT
cord-005478-5iu38pr6	2364	13	SCD	SCD	NNP
cord-005478-5iu38pr6	2364	14	pts	pt	NNS
cord-005478-5iu38pr6	2364	15	without	without	IN
cord-005478-5iu38pr6	2364	16	a	a	DT
cord-005478-5iu38pr6	2364	17	MSD	msd	NN
cord-005478-5iu38pr6	2364	18	.	.	.
cord-005478-5iu38pr6	2365	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2365	2	:	:	:
cord-005478-5iu38pr6	2365	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2365	4	to	to	TO
cord-005478-5iu38pr6	2365	5	declare	declare	VB
cord-005478-5iu38pr6	2365	6	.	.	.
cord-005478-5iu38pr6	2366	1	Abstract	Abstract	NNP
cord-005478-5iu38pr6	2366	2	already	already	RB
cord-005478-5iu38pr6	2366	3	published	publish	VBN
cord-005478-5iu38pr6	2366	4	.	.	.
cord-005478-5iu38pr6	2367	1	Hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2367	2	stem	stem	NN
cord-005478-5iu38pr6	2367	3	cells	cell	NNS
cord-005478-5iu38pr6	2367	4	O117	o117	CC
cord-005478-5iu38pr6	2367	5	Abstract	Abstract	NNP
cord-005478-5iu38pr6	2367	6	already	already	RB
cord-005478-5iu38pr6	2367	7	published	publish	VBN
cord-005478-5iu38pr6	2367	8	.	.	.
cord-005478-5iu38pr6	2368	1	Comparison	comparison	NN
cord-005478-5iu38pr6	2368	2	of	of	IN
cord-005478-5iu38pr6	2368	3	outcomes	outcome	NNS
cord-005478-5iu38pr6	2368	4	post	post	VBP
cord-005478-5iu38pr6	2368	5	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2368	6	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2368	7	cell	cell	NN
cord-005478-5iu38pr6	2368	8	transplantation	transplantation	NN
cord-005478-5iu38pr6	2368	9	using	use	VBG
cord-005478-5iu38pr6	2368	10	fresh	fresh	JJ
cord-005478-5iu38pr6	2368	11	versus	versus	IN
cord-005478-5iu38pr6	2368	12	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2368	13	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2368	14	blood	blood	NN
cord-005478-5iu38pr6	2368	15	stem	stem	NN
cord-005478-5iu38pr6	2368	16	cell	cell	NN
cord-005478-5iu38pr6	2368	17	grafts	graft	NNS
cord-005478-5iu38pr6	2368	18	Background	Background	NNP
cord-005478-5iu38pr6	2368	19	:	:	:
cord-005478-5iu38pr6	2368	20	Cryopreservation	Cryopreservation	NNP
cord-005478-5iu38pr6	2368	21	is	be	VBZ
cord-005478-5iu38pr6	2368	22	routine	routine	JJ
cord-005478-5iu38pr6	2368	23	practice	practice	NN
cord-005478-5iu38pr6	2368	24	with	with	IN
cord-005478-5iu38pr6	2368	25	autografts	autografts	NNP
cord-005478-5iu38pr6	2368	26	,	,	,
cord-005478-5iu38pr6	2368	27	however	however	RB
cord-005478-5iu38pr6	2368	28	in	in	IN
cord-005478-5iu38pr6	2368	29	the	the	DT
cord-005478-5iu38pr6	2368	30	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2368	31	HCT	hct	NN
cord-005478-5iu38pr6	2368	32	setting	set	VBG
cord-005478-5iu38pr6	2368	33	the	the	DT
cord-005478-5iu38pr6	2368	34	effects	effect	NNS
cord-005478-5iu38pr6	2368	35	of	of	IN
cord-005478-5iu38pr6	2368	36	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	2368	37	have	have	VBP
cord-005478-5iu38pr6	2368	38	not	not	RB
cord-005478-5iu38pr6	2368	39	been	be	VBN
cord-005478-5iu38pr6	2368	40	thoroughly	thoroughly	RB
cord-005478-5iu38pr6	2368	41	investigated	investigate	VBN
cord-005478-5iu38pr6	2368	42	.	.	.
cord-005478-5iu38pr6	2369	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2369	2	sought	seek	VBD
cord-005478-5iu38pr6	2369	3	to	to	TO
cord-005478-5iu38pr6	2369	4	compare	compare	VB
cord-005478-5iu38pr6	2369	5	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2369	6	HCT	hct	NN
cord-005478-5iu38pr6	2369	7	outcomes	outcome	NNS
cord-005478-5iu38pr6	2369	8	using	use	VBG
cord-005478-5iu38pr6	2369	9	fresh	fresh	JJ
cord-005478-5iu38pr6	2369	10	versus	versus	IN
cord-005478-5iu38pr6	2369	11	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	2369	12	grafts	graft	NNS
cord-005478-5iu38pr6	2369	13	in	in	IN
cord-005478-5iu38pr6	2369	14	a	a	DT
cord-005478-5iu38pr6	2369	15	large	large	JJ
cord-005478-5iu38pr6	2369	16	single	single	JJ
cord-005478-5iu38pr6	2369	17	centre	centre	NN
cord-005478-5iu38pr6	2369	18	cohort	cohort	NN
cord-005478-5iu38pr6	2369	19	.	.	.
cord-005478-5iu38pr6	2370	1	Methods	method	NNS
cord-005478-5iu38pr6	2370	2	:	:	:
cord-005478-5iu38pr6	2371	1	Between	between	IN
cord-005478-5iu38pr6	2371	2	2003	2003	CD
cord-005478-5iu38pr6	2371	3	and	and	CC
cord-005478-5iu38pr6	2371	4	2017	2017	CD
cord-005478-5iu38pr6	2371	5	,	,	,
cord-005478-5iu38pr6	2371	6	we	-PRON-	PRP
cord-005478-5iu38pr6	2371	7	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	2371	8	reviewed	review	VBD
cord-005478-5iu38pr6	2371	9	951	951	CD
cord-005478-5iu38pr6	2371	10	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2371	11	adult	adult	NN
cord-005478-5iu38pr6	2371	12	patients	patient	NNS
cord-005478-5iu38pr6	2371	13	who	who	WP
cord-005478-5iu38pr6	2371	14	underwent	undergo	VBD
cord-005478-5iu38pr6	2371	15	allogenic	allogenic	JJ
cord-005478-5iu38pr6	2371	16	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2371	17	blood	blood	NN
cord-005478-5iu38pr6	2371	18	HCT	hct	NN
cord-005478-5iu38pr6	2371	19	at	at	IN
cord-005478-5iu38pr6	2371	20	our	-PRON-	PRP$
cord-005478-5iu38pr6	2371	21	centre	centre	NN
cord-005478-5iu38pr6	2371	22	.	.	.
cord-005478-5iu38pr6	2372	1	Outcomes	outcome	NNS
cord-005478-5iu38pr6	2372	2	assessed	assess	VBD
cord-005478-5iu38pr6	2372	3	included	include	VBN
cord-005478-5iu38pr6	2372	4	platelet	platelet	NN
cord-005478-5iu38pr6	2372	5	(	(	-LRB-
cord-005478-5iu38pr6	2372	6	≥20x10e9	≥20x10e9	NNP
cord-005478-5iu38pr6	2372	7	/	/	SYM
cord-005478-5iu38pr6	2372	8	L	l	NN
cord-005478-5iu38pr6	2372	9	)	)	-RRB-
cord-005478-5iu38pr6	2372	10	and	and	CC
cord-005478-5iu38pr6	2372	11	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2372	12	(	(	-LRB-
cord-005478-5iu38pr6	2372	13	≥0.5x10e9	≥0.5x10e9	NNP
cord-005478-5iu38pr6	2372	14	/	/	SYM
cord-005478-5iu38pr6	2372	15	L	L	NNP
cord-005478-5iu38pr6	2372	16	)	)	-RRB-
cord-005478-5iu38pr6	2372	17	engraftment	engraftment	NN
cord-005478-5iu38pr6	2372	18	,	,	,
cord-005478-5iu38pr6	2372	19	occurrence	occurrence	NN
cord-005478-5iu38pr6	2372	20	of	of	IN
cord-005478-5iu38pr6	2372	21	acute	acute	JJ
cord-005478-5iu38pr6	2372	22	graft	graft	NN
cord-005478-5iu38pr6	2372	23	-	-	HYPH
cord-005478-5iu38pr6	2372	24	versushost	versushost	NN
cord-005478-5iu38pr6	2372	25	disease	disease	NN
cord-005478-5iu38pr6	2372	26	(	(	-LRB-
cord-005478-5iu38pr6	2372	27	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2372	28	)	)	-RRB-
cord-005478-5iu38pr6	2372	29	in	in	IN
cord-005478-5iu38pr6	2372	30	the	the	DT
cord-005478-5iu38pr6	2372	31	first	first	JJ
cord-005478-5iu38pr6	2372	32	100	100	CD
cord-005478-5iu38pr6	2372	33	days	day	NNS
cord-005478-5iu38pr6	2372	34	,	,	,
cord-005478-5iu38pr6	2372	35	overall	overall	JJ
cord-005478-5iu38pr6	2372	36	survival	survival	NN
cord-005478-5iu38pr6	2372	37	(	(	-LRB-
cord-005478-5iu38pr6	2372	38	OS	OS	NNP
cord-005478-5iu38pr6	2372	39	)	)	-RRB-
cord-005478-5iu38pr6	2372	40	,	,	,
cord-005478-5iu38pr6	2372	41	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2372	42	incidence	incidence	NN
cord-005478-5iu38pr6	2372	43	of	of	IN
cord-005478-5iu38pr6	2372	44	relapse	relapse	NN
cord-005478-5iu38pr6	2372	45	(	(	-LRB-
cord-005478-5iu38pr6	2372	46	CIR	CIR	NNP
cord-005478-5iu38pr6	2372	47	)	)	-RRB-
cord-005478-5iu38pr6	2372	48	and	and	CC
cord-005478-5iu38pr6	2372	49	non	non	JJ
cord-005478-5iu38pr6	2372	50	-	-	JJ
cord-005478-5iu38pr6	2372	51	relapse	relapse	JJ
cord-005478-5iu38pr6	2372	52	mortality	mortality	NN
cord-005478-5iu38pr6	2372	53	.	.	.
cord-005478-5iu38pr6	2373	1	Results	result	NNS
cord-005478-5iu38pr6	2373	2	:	:	:
cord-005478-5iu38pr6	2374	1	Median	median	JJ
cord-005478-5iu38pr6	2374	2	follow	follow	VBP
cord-005478-5iu38pr6	2374	3	up	up	IN
cord-005478-5iu38pr6	2374	4	of	of	IN
cord-005478-5iu38pr6	2374	5	survivors	survivor	NNS
cord-005478-5iu38pr6	2374	6	was	be	VBD
cord-005478-5iu38pr6	2374	7	47	47	CD
cord-005478-5iu38pr6	2374	8	months	month	NNS
cord-005478-5iu38pr6	2375	1	(	(	-LRB-
cord-005478-5iu38pr6	2375	2	range	range	NNP
cord-005478-5iu38pr6	2375	3	4	4	CD
cord-005478-5iu38pr6	2375	4	-	-	SYM
cord-005478-5iu38pr6	2375	5	177	177	CD
cord-005478-5iu38pr6	2375	6	months	month	NNS
cord-005478-5iu38pr6	2375	7	)	)	-RRB-
cord-005478-5iu38pr6	2375	8	.	.	.
cord-005478-5iu38pr6	2376	1	Fresh	fresh	JJ
cord-005478-5iu38pr6	2376	2	grafts	graft	NNS
cord-005478-5iu38pr6	2376	3	were	be	VBD
cord-005478-5iu38pr6	2376	4	received	receive	VBN
cord-005478-5iu38pr6	2376	5	by	by	IN
cord-005478-5iu38pr6	2376	6	525	525	CD
cord-005478-5iu38pr6	2376	7	patients	patient	NNS
cord-005478-5iu38pr6	2376	8	,	,	,
cord-005478-5iu38pr6	2376	9	426	426	CD
cord-005478-5iu38pr6	2376	10	received	receive	VBD
cord-005478-5iu38pr6	2376	11	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2376	12	grafts	graft	NNS
cord-005478-5iu38pr6	2376	13	,	,	,
cord-005478-5iu38pr6	2376	14	median	median	JJ
cord-005478-5iu38pr6	2376	15	age	age	NN
cord-005478-5iu38pr6	2376	16	at	at	IN
cord-005478-5iu38pr6	2376	17	HCT	HCT	NNP
cord-005478-5iu38pr6	2376	18	was	be	VBD
cord-005478-5iu38pr6	2376	19	53	53	CD
cord-005478-5iu38pr6	2376	20	and	and	CC
cord-005478-5iu38pr6	2376	21	54	54	CD
cord-005478-5iu38pr6	2376	22	years	year	NNS
cord-005478-5iu38pr6	2376	23	respectively	respectively	RB
cord-005478-5iu38pr6	2376	24	.	.	.
cord-005478-5iu38pr6	2377	1	Transplant	transplant	NN
cord-005478-5iu38pr6	2377	2	indication	indication	NN
cord-005478-5iu38pr6	2377	3	was	be	VBD
cord-005478-5iu38pr6	2377	4	myeloid	myeloid	JJ
cord-005478-5iu38pr6	2377	5	malignancy	malignancy	NN
cord-005478-5iu38pr6	2377	6	in	in	IN
cord-005478-5iu38pr6	2377	7	711	711	CD
cord-005478-5iu38pr6	2377	8	(	(	-LRB-
cord-005478-5iu38pr6	2377	9	75	75	CD
cord-005478-5iu38pr6	2377	10	%	%	NN
cord-005478-5iu38pr6	2377	11	)	)	-RRB-
cord-005478-5iu38pr6	2377	12	,	,	,
cord-005478-5iu38pr6	2377	13	lymphoid	lymphoid	NN
cord-005478-5iu38pr6	2377	14	in	in	IN
cord-005478-5iu38pr6	2377	15	229	229	CD
cord-005478-5iu38pr6	2377	16	(	(	-LRB-
cord-005478-5iu38pr6	2377	17	24	24	CD
cord-005478-5iu38pr6	2377	18	%	%	NN
cord-005478-5iu38pr6	2377	19	)	)	-RRB-
cord-005478-5iu38pr6	2377	20	patients	patient	NNS
cord-005478-5iu38pr6	2377	21	.	.	.
cord-005478-5iu38pr6	2378	1	Myeloablative	Myeloablative	NNP
cord-005478-5iu38pr6	2378	2	regimens	regimen	NNS
cord-005478-5iu38pr6	2378	3	were	be	VBD
cord-005478-5iu38pr6	2378	4	used	use	VBN
cord-005478-5iu38pr6	2378	5	in	in	IN
cord-005478-5iu38pr6	2378	6	506	506	CD
cord-005478-5iu38pr6	2378	7	(	(	-LRB-
cord-005478-5iu38pr6	2378	8	53	53	CD
cord-005478-5iu38pr6	2378	9	%	%	NN
cord-005478-5iu38pr6	2378	10	)	)	-RRB-
cord-005478-5iu38pr6	2378	11	patients	patient	NNS
cord-005478-5iu38pr6	2378	12	.	.	.
cord-005478-5iu38pr6	2379	1	The	the	DT
cord-005478-5iu38pr6	2379	2	majority	majority	NN
cord-005478-5iu38pr6	2379	3	of	of	IN
cord-005478-5iu38pr6	2379	4	fresh	fresh	JJ
cord-005478-5iu38pr6	2379	5	grafts	graft	NNS
cord-005478-5iu38pr6	2379	6	were	be	VBD
cord-005478-5iu38pr6	2379	7	from	from	IN
cord-005478-5iu38pr6	2379	8	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2379	9	donors	donor	NNS
cord-005478-5iu38pr6	2379	10	(	(	-LRB-
cord-005478-5iu38pr6	2379	11	82	82	CD
cord-005478-5iu38pr6	2379	12	%	%	NN
cord-005478-5iu38pr6	2379	13	)	)	-RRB-
cord-005478-5iu38pr6	2379	14	while	while	IN
cord-005478-5iu38pr6	2379	15	most	most	RBS
cord-005478-5iu38pr6	2379	16	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2379	17	grafts	graft	NNS
cord-005478-5iu38pr6	2379	18	were	be	VBD
cord-005478-5iu38pr6	2379	19	from	from	IN
cord-005478-5iu38pr6	2379	20	matched	match	VBN
cord-005478-5iu38pr6	2379	21	related	related	JJ
cord-005478-5iu38pr6	2379	22	donors	donor	NNS
cord-005478-5iu38pr6	2379	23	(	(	-LRB-
cord-005478-5iu38pr6	2379	24	90	90	CD
cord-005478-5iu38pr6	2379	25	%	%	NN
cord-005478-5iu38pr6	2379	26	)	)	-RRB-
cord-005478-5iu38pr6	2379	27	.	.	.
cord-005478-5iu38pr6	2380	1	In	in	IN
cord-005478-5iu38pr6	2380	2	vivo	vivo	NNP
cord-005478-5iu38pr6	2380	3	T	t	NN
cord-005478-5iu38pr6	2380	4	-	-	HYPH
cord-005478-5iu38pr6	2380	5	cell	cell	NN
cord-005478-5iu38pr6	2380	6	depletion	depletion	NN
cord-005478-5iu38pr6	2380	7	was	be	VBD
cord-005478-5iu38pr6	2380	8	performed	perform	VBN
cord-005478-5iu38pr6	2380	9	in	in	IN
cord-005478-5iu38pr6	2380	10	65	65	CD
cord-005478-5iu38pr6	2380	11	%	%	NN
cord-005478-5iu38pr6	2380	12	of	of	IN
cord-005478-5iu38pr6	2380	13	fresh	fresh	JJ
cord-005478-5iu38pr6	2380	14	and	and	CC
cord-005478-5iu38pr6	2380	15	18	18	CD
cord-005478-5iu38pr6	2380	16	%	%	NN
cord-005478-5iu38pr6	2380	17	of	of	IN
cord-005478-5iu38pr6	2380	18	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2380	19	transplants	transplant	NNS
cord-005478-5iu38pr6	2380	20	.	.	.
cord-005478-5iu38pr6	2381	1	Median	median	JJ
cord-005478-5iu38pr6	2381	2	time	time	NN
cord-005478-5iu38pr6	2381	3	to	to	IN
cord-005478-5iu38pr6	2381	4	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2381	5	engraftment	engraftment	NN
cord-005478-5iu38pr6	2381	6	for	for	IN
cord-005478-5iu38pr6	2381	7	fresh	fresh	JJ
cord-005478-5iu38pr6	2381	8	versus	versus	IN
cord-005478-5iu38pr6	2381	9	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	2381	10	grafts	graft	NNS
cord-005478-5iu38pr6	2381	11	was	be	VBD
cord-005478-5iu38pr6	2381	12	15	15	CD
cord-005478-5iu38pr6	2381	13	and	and	CC
cord-005478-5iu38pr6	2381	14	15	15	CD
cord-005478-5iu38pr6	2381	15	(	(	-LRB-
cord-005478-5iu38pr6	2381	16	10	10	CD
cord-005478-5iu38pr6	2381	17	-	-	SYM
cord-005478-5iu38pr6	2381	18	48	48	CD
cord-005478-5iu38pr6	2381	19	)	)	-RRB-
cord-005478-5iu38pr6	2381	20	days	day	NNS
cord-005478-5iu38pr6	2381	21	respectively	respectively	RB
cord-005478-5iu38pr6	2381	22	,	,	,
cord-005478-5iu38pr6	2381	23	while	while	IN
cord-005478-5iu38pr6	2381	24	median	median	JJ
cord-005478-5iu38pr6	2381	25	time	time	NN
cord-005478-5iu38pr6	2381	26	to	to	IN
cord-005478-5iu38pr6	2381	27	platelet	platelet	NN
cord-005478-5iu38pr6	2381	28	recovery	recovery	NN
cord-005478-5iu38pr6	2381	29	was	be	VBD
cord-005478-5iu38pr6	2381	30	16	16	CD
cord-005478-5iu38pr6	2381	31	(	(	-LRB-
cord-005478-5iu38pr6	2381	32	12	12	CD
cord-005478-5iu38pr6	2381	33	-	-	SYM
cord-005478-5iu38pr6	2381	34	186	186	CD
cord-005478-5iu38pr6	2381	35	)	)	-RRB-
cord-005478-5iu38pr6	2381	36	and	and	CC
cord-005478-5iu38pr6	2381	37	17	17	CD
cord-005478-5iu38pr6	2381	38	days	day	NNS
cord-005478-5iu38pr6	2381	39	,	,	,
cord-005478-5iu38pr6	2381	40	respectively	respectively	RB
cord-005478-5iu38pr6	2381	41	.	.	.
cord-005478-5iu38pr6	2382	1	For	for	IN
cord-005478-5iu38pr6	2382	2	fresh	fresh	JJ
cord-005478-5iu38pr6	2382	3	versus	versus	IN
cord-005478-5iu38pr6	2382	4	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	2382	5	grafts	graft	NNS
cord-005478-5iu38pr6	2382	6	,	,	,
cord-005478-5iu38pr6	2382	7	grade	grade	NN
cord-005478-5iu38pr6	2382	8	II	II	NNP
cord-005478-5iu38pr6	2382	9	-	-	HYPH
cord-005478-5iu38pr6	2382	10	IV	IV	NNP
cord-005478-5iu38pr6	2382	11	acute	acute	JJ
cord-005478-5iu38pr6	2382	12	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2382	13	was	be	VBD
cord-005478-5iu38pr6	2382	14	seen	see	VBN
cord-005478-5iu38pr6	2382	15	in	in	IN
cord-005478-5iu38pr6	2382	16	51	51	CD
cord-005478-5iu38pr6	2382	17	%	%	NN
cord-005478-5iu38pr6	2382	18	and	and	CC
cord-005478-5iu38pr6	2382	19	54	54	CD
cord-005478-5iu38pr6	2382	20	%	%	NN
cord-005478-5iu38pr6	2382	21	,	,	,
cord-005478-5iu38pr6	2382	22	respectively	respectively	RB
cord-005478-5iu38pr6	2382	23	(	(	-LRB-
cord-005478-5iu38pr6	2382	24	p=0.42	p=0.42	NN
cord-005478-5iu38pr6	2382	25	)	)	-RRB-
cord-005478-5iu38pr6	2382	26	while	while	IN
cord-005478-5iu38pr6	2382	27	grade	grade	NN
cord-005478-5iu38pr6	2382	28	III	III	NNP
cord-005478-5iu38pr6	2382	29	-	-	HYPH
cord-005478-5iu38pr6	2382	30	IV	IV	NNP
cord-005478-5iu38pr6	2382	31	acute	acute	JJ
cord-005478-5iu38pr6	2382	32	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2382	33	was	be	VBD
cord-005478-5iu38pr6	2382	34	seen	see	VBN
cord-005478-5iu38pr6	2382	35	in	in	IN
cord-005478-5iu38pr6	2382	36	28	28	CD
cord-005478-5iu38pr6	2382	37	%	%	NN
cord-005478-5iu38pr6	2382	38	of	of	IN
cord-005478-5iu38pr6	2382	39	patients	patient	NNS
cord-005478-5iu38pr6	2382	40	in	in	IN
cord-005478-5iu38pr6	2382	41	both	both	DT
cord-005478-5iu38pr6	2382	42	groups	group	NNS
cord-005478-5iu38pr6	2382	43	(	(	-LRB-
cord-005478-5iu38pr6	2382	44	p=0.96	p=0.96	NNP
cord-005478-5iu38pr6	2382	45	)	)	-RRB-
cord-005478-5iu38pr6	2382	46	.	.	.
cord-005478-5iu38pr6	2383	1	On	on	IN
cord-005478-5iu38pr6	2383	2	univariate	univariate	JJ
cord-005478-5iu38pr6	2383	3	analysis	analysis	NN
cord-005478-5iu38pr6	2383	4	,	,	,
cord-005478-5iu38pr6	2383	5	OS	OS	NNP
cord-005478-5iu38pr6	2383	6	for	for	IN
cord-005478-5iu38pr6	2383	7	the	the	DT
cord-005478-5iu38pr6	2383	8	entire	entire	JJ
cord-005478-5iu38pr6	2383	9	cohort	cohort	NN
cord-005478-5iu38pr6	2383	10	at	at	IN
cord-005478-5iu38pr6	2383	11	2	2	CD
cord-005478-5iu38pr6	2383	12	years	year	NNS
cord-005478-5iu38pr6	2383	13	was	be	VBD
cord-005478-5iu38pr6	2383	14	50	50	CD
cord-005478-5iu38pr6	2383	15	%	%	NN
cord-005478-5iu38pr6	2383	16	(	(	-LRB-
cord-005478-5iu38pr6	2383	17	95%CI	95%ci	CD
cord-005478-5iu38pr6	2383	18	47	47	CD
cord-005478-5iu38pr6	2383	19	-	-	SYM
cord-005478-5iu38pr6	2383	20	54	54	CD
cord-005478-5iu38pr6	2383	21	%	%	NN
cord-005478-5iu38pr6	2383	22	)	)	-RRB-
cord-005478-5iu38pr6	2383	23	and	and	CC
cord-005478-5iu38pr6	2383	24	at	at	IN
cord-005478-5iu38pr6	2383	25	5	5	CD
cord-005478-5iu38pr6	2383	26	years	year	NNS
cord-005478-5iu38pr6	2383	27	was	be	VBD
cord-005478-5iu38pr6	2383	28	40	40	CD
cord-005478-5iu38pr6	2383	29	%	%	NN
cord-005478-5iu38pr6	2383	30	(	(	-LRB-
cord-005478-5iu38pr6	2383	31	95%CI	95%ci	CD
cord-005478-5iu38pr6	2383	32	36	36	CD
cord-005478-5iu38pr6	2383	33	-	-	SYM
cord-005478-5iu38pr6	2383	34	43	43	CD
cord-005478-5iu38pr6	2383	35	%	%	NN
cord-005478-5iu38pr6	2383	36	)	)	-RRB-
cord-005478-5iu38pr6	2383	37	.	.	.
cord-005478-5iu38pr6	2384	1	Two	two	CD
cord-005478-5iu38pr6	2384	2	and	and	CC
cord-005478-5iu38pr6	2384	3	5	5	CD
cord-005478-5iu38pr6	2384	4	year	year	NN
cord-005478-5iu38pr6	2384	5	OS	OS	NNP
cord-005478-5iu38pr6	2384	6	was	be	VBD
cord-005478-5iu38pr6	2384	7	47	47	CD
cord-005478-5iu38pr6	2384	8	%	%	NN
cord-005478-5iu38pr6	2384	9	(	(	-LRB-
cord-005478-5iu38pr6	2384	10	95%CI	95%ci	CD
cord-005478-5iu38pr6	2384	11	43	43	CD
cord-005478-5iu38pr6	2384	12	-	-	SYM
cord-005478-5iu38pr6	2384	13	52	52	CD
cord-005478-5iu38pr6	2384	14	%	%	NN
cord-005478-5iu38pr6	2384	15	)	)	-RRB-
cord-005478-5iu38pr6	2384	16	and	and	CC
cord-005478-5iu38pr6	2384	17	39	39	CD
cord-005478-5iu38pr6	2384	18	%	%	NN
cord-005478-5iu38pr6	2384	19	(	(	-LRB-
cord-005478-5iu38pr6	2384	20	95%CI	95%ci	CD
cord-005478-5iu38pr6	2384	21	34	34	CD
cord-005478-5iu38pr6	2384	22	-	-	SYM
cord-005478-5iu38pr6	2384	23	44	44	CD
cord-005478-5iu38pr6	2384	24	%	%	NN
cord-005478-5iu38pr6	2384	25	)	)	-RRB-
cord-005478-5iu38pr6	2384	26	respectively	respectively	RB
cord-005478-5iu38pr6	2384	27	for	for	IN
cord-005478-5iu38pr6	2384	28	fresh	fresh	JJ
cord-005478-5iu38pr6	2384	29	grafts	graft	NNS
cord-005478-5iu38pr6	2384	30	and	and	CC
cord-005478-5iu38pr6	2384	31	54	54	CD
cord-005478-5iu38pr6	2384	32	%	%	NN
cord-005478-5iu38pr6	2384	33	(	(	-LRB-
cord-005478-5iu38pr6	2384	34	95%CI	95%ci	CD
cord-005478-5iu38pr6	2384	35	49	49	CD
cord-005478-5iu38pr6	2384	36	-	-	SYM
cord-005478-5iu38pr6	2384	37	59	59	CD
cord-005478-5iu38pr6	2384	38	%	%	NN
cord-005478-5iu38pr6	2384	39	)	)	-RRB-
cord-005478-5iu38pr6	2384	40	and	and	CC
cord-005478-5iu38pr6	2384	41	41	41	CD
cord-005478-5iu38pr6	2384	42	%	%	NN
cord-005478-5iu38pr6	2384	43	(	(	-LRB-
cord-005478-5iu38pr6	2384	44	95%CI	95%ci	CD
cord-005478-5iu38pr6	2384	45	36	36	CD
cord-005478-5iu38pr6	2384	46	-	-	SYM
cord-005478-5iu38pr6	2384	47	46	46	CD
cord-005478-5iu38pr6	2384	48	%	%	NN
cord-005478-5iu38pr6	2384	49	)	)	-RRB-
cord-005478-5iu38pr6	2384	50	respectively	respectively	RB
cord-005478-5iu38pr6	2384	51	for	for	IN
cord-005478-5iu38pr6	2384	52	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2384	53	grafts	graft	NNS
cord-005478-5iu38pr6	2384	54	(	(	-LRB-
cord-005478-5iu38pr6	2384	55	p=0.21	p=0.21	NN
cord-005478-5iu38pr6	2384	56	)	)	-RRB-
cord-005478-5iu38pr6	2384	57	.	.	.
cord-005478-5iu38pr6	2385	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2385	2	incidence	incidence	NN
cord-005478-5iu38pr6	2385	3	of	of	IN
cord-005478-5iu38pr6	2385	4	relapse	relapse	NN
cord-005478-5iu38pr6	2385	5	(	(	-LRB-
cord-005478-5iu38pr6	2385	6	CIR	CIR	NNP
cord-005478-5iu38pr6	2385	7	)	)	-RRB-
cord-005478-5iu38pr6	2385	8	of	of	IN
cord-005478-5iu38pr6	2385	9	the	the	DT
cord-005478-5iu38pr6	2385	10	entire	entire	JJ
cord-005478-5iu38pr6	2385	11	cohort	cohort	NN
cord-005478-5iu38pr6	2385	12	at	at	IN
cord-005478-5iu38pr6	2385	13	2	2	CD
cord-005478-5iu38pr6	2385	14	years	year	NNS
cord-005478-5iu38pr6	2385	15	was	be	VBD
cord-005478-5iu38pr6	2385	16	18	18	CD
cord-005478-5iu38pr6	2385	17	%	%	NN
cord-005478-5iu38pr6	2385	18	(	(	-LRB-
cord-005478-5iu38pr6	2385	19	95%CI	95%ci	CD
cord-005478-5iu38pr6	2385	20	16	16	CD
cord-005478-5iu38pr6	2385	21	-	-	SYM
cord-005478-5iu38pr6	2385	22	21	21	CD
cord-005478-5iu38pr6	2385	23	%	%	NN
cord-005478-5iu38pr6	2385	24	)	)	-RRB-
cord-005478-5iu38pr6	2385	25	and	and	CC
cord-005478-5iu38pr6	2385	26	at	at	IN
cord-005478-5iu38pr6	2385	27	5	5	CD
cord-005478-5iu38pr6	2385	28	years	year	NNS
cord-005478-5iu38pr6	2385	29	was	be	VBD
cord-005478-5iu38pr6	2385	30	21	21	CD
cord-005478-5iu38pr6	2385	31	%	%	NN
cord-005478-5iu38pr6	2385	32	(	(	-LRB-
cord-005478-5iu38pr6	2385	33	95%CI	95%ci	CD
cord-005478-5iu38pr6	2385	34	19	19	CD
cord-005478-5iu38pr6	2385	35	-	-	SYM
cord-005478-5iu38pr6	2385	36	24	24	CD
cord-005478-5iu38pr6	2385	37	%	%	NN
cord-005478-5iu38pr6	2385	38	)	)	-RRB-
cord-005478-5iu38pr6	2385	39	.	.	.
cord-005478-5iu38pr6	2386	1	Two	two	CD
cord-005478-5iu38pr6	2386	2	and	and	CC
cord-005478-5iu38pr6	2386	3	5	5	CD
cord-005478-5iu38pr6	2386	4	year	year	NN
cord-005478-5iu38pr6	2386	5	CIR	CIR	NNP
cord-005478-5iu38pr6	2386	6	was	be	VBD
cord-005478-5iu38pr6	2386	7	16	16	CD
cord-005478-5iu38pr6	2386	8	%	%	NN
cord-005478-5iu38pr6	2386	9	(	(	-LRB-
cord-005478-5iu38pr6	2386	10	95%CI	95%ci	CD
cord-005478-5iu38pr6	2386	11	13	13	CD
cord-005478-5iu38pr6	2386	12	-	-	SYM
cord-005478-5iu38pr6	2386	13	20	20	CD
cord-005478-5iu38pr6	2386	14	%	%	NN
cord-005478-5iu38pr6	2386	15	)	)	-RRB-
cord-005478-5iu38pr6	2386	16	and	and	CC
cord-005478-5iu38pr6	2386	17	19	19	CD
cord-005478-5iu38pr6	2386	18	%	%	NN
cord-005478-5iu38pr6	2386	19	(	(	-LRB-
cord-005478-5iu38pr6	2386	20	95%CI	95%ci	CD
cord-005478-5iu38pr6	2386	21	15	15	CD
cord-005478-5iu38pr6	2386	22	-	-	SYM
cord-005478-5iu38pr6	2386	23	22	22	CD
cord-005478-5iu38pr6	2386	24	%	%	NN
cord-005478-5iu38pr6	2386	25	)	)	-RRB-
cord-005478-5iu38pr6	2386	26	respectively	respectively	RB
cord-005478-5iu38pr6	2386	27	for	for	IN
cord-005478-5iu38pr6	2386	28	fresh	fresh	JJ
cord-005478-5iu38pr6	2386	29	grafts	graft	NNS
cord-005478-5iu38pr6	2386	30	and	and	CC
cord-005478-5iu38pr6	2386	31	21	21	CD
cord-005478-5iu38pr6	2386	32	%	%	NN
cord-005478-5iu38pr6	2386	33	(	(	-LRB-
cord-005478-5iu38pr6	2386	34	95%CI	95%ci	CD
cord-005478-5iu38pr6	2386	35	17	17	CD
cord-005478-5iu38pr6	2386	36	-	-	SYM
cord-005478-5iu38pr6	2386	37	25	25	CD
cord-005478-5iu38pr6	2386	38	%	%	NN
cord-005478-5iu38pr6	2386	39	)	)	-RRB-
cord-005478-5iu38pr6	2386	40	and	and	CC
cord-005478-5iu38pr6	2386	41	25	25	CD
cord-005478-5iu38pr6	2386	42	%	%	NN
cord-005478-5iu38pr6	2386	43	(	(	-LRB-
cord-005478-5iu38pr6	2386	44	95%CI	95%ci	CD
cord-005478-5iu38pr6	2386	45	21	21	CD
cord-005478-5iu38pr6	2386	46	-	-	SYM
cord-005478-5iu38pr6	2386	47	29	29	CD
cord-005478-5iu38pr6	2386	48	%	%	NN
cord-005478-5iu38pr6	2386	49	)	)	-RRB-
cord-005478-5iu38pr6	2386	50	respectively	respectively	RB
cord-005478-5iu38pr6	2386	51	for	for	IN
cord-005478-5iu38pr6	2386	52	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2386	53	grafts	graft	NNS
cord-005478-5iu38pr6	2386	54	(	(	-LRB-
cord-005478-5iu38pr6	2386	55	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	2386	56	,	,	,
cord-005478-5iu38pr6	2386	57	Figure	figure	NN
cord-005478-5iu38pr6	2386	58	1	1	CD
cord-005478-5iu38pr6	2386	59	)	)	-RRB-
cord-005478-5iu38pr6	2386	60	.	.	.
cord-005478-5iu38pr6	2387	1	[	[	-LRB-
cord-005478-5iu38pr6	2387	2	[	[	-LRB-
cord-005478-5iu38pr6	2387	3	O118	O118	NNP
cord-005478-5iu38pr6	2387	4	Image	image	NN
cord-005478-5iu38pr6	2387	5	]	]	-RRB-
cord-005478-5iu38pr6	2387	6	1	1	CD
cord-005478-5iu38pr6	2387	7	.	.	.
cord-005478-5iu38pr6	2388	1	Figure	figure	NN
cord-005478-5iu38pr6	2388	2	1	1	CD
cord-005478-5iu38pr6	2388	3	]	]	-RRB-
cord-005478-5iu38pr6	2389	1	Multivariable	multivariable	JJ
cord-005478-5iu38pr6	2389	2	analysis	analysis	NN
cord-005478-5iu38pr6	2389	3	for	for	IN
cord-005478-5iu38pr6	2389	4	OS	OS	NNP
cord-005478-5iu38pr6	2389	5	verified	verify	VBD
cord-005478-5iu38pr6	2389	6	no	no	DT
cord-005478-5iu38pr6	2389	7	significant	significant	JJ
cord-005478-5iu38pr6	2389	8	difference	difference	NN
cord-005478-5iu38pr6	2389	9	between	between	IN
cord-005478-5iu38pr6	2389	10	fresh	fresh	JJ
cord-005478-5iu38pr6	2389	11	versus	versus	IN
cord-005478-5iu38pr6	2389	12	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	2389	13	grafts	graft	NNS
cord-005478-5iu38pr6	2389	14	(	(	-LRB-
cord-005478-5iu38pr6	2389	15	p=0.25	p=0.25	NNP
cord-005478-5iu38pr6	2389	16	)	)	-RRB-
cord-005478-5iu38pr6	2389	17	.	.	.
cord-005478-5iu38pr6	2390	1	For	for	IN
cord-005478-5iu38pr6	2390	2	CIR	CIR	NNP
cord-005478-5iu38pr6	2390	3	however	however	RB
cord-005478-5iu38pr6	2390	4	,	,	,
cord-005478-5iu38pr6	2390	5	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	2390	6	was	be	VBD
cord-005478-5iu38pr6	2390	7	the	the	DT
cord-005478-5iu38pr6	2390	8	only	only	JJ
cord-005478-5iu38pr6	2390	9	independent	independent	JJ
cord-005478-5iu38pr6	2390	10	predictor	predictor	NN
cord-005478-5iu38pr6	2390	11	of	of	IN
cord-005478-5iu38pr6	2390	12	relapse	relapse	NN
cord-005478-5iu38pr6	2390	13	(	(	-LRB-
cord-005478-5iu38pr6	2390	14	HR	hr	NN
cord-005478-5iu38pr6	2390	15	1.43	1.43	CD
cord-005478-5iu38pr6	2390	16	for	for	IN
cord-005478-5iu38pr6	2390	17	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2390	18	,	,	,
cord-005478-5iu38pr6	2390	19	95%CI	95%ci	CD
cord-005478-5iu38pr6	2390	20	1.07	1.07	CD
cord-005478-5iu38pr6	2390	21	-	-	SYM
cord-005478-5iu38pr6	2390	22	1.91	1.91	CD
cord-005478-5iu38pr6	2390	23	,	,	,
cord-005478-5iu38pr6	2390	24	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	2390	25	)	)	-RRB-
cord-005478-5iu38pr6	2390	26	,	,	,
cord-005478-5iu38pr6	2390	27	while	while	IN
cord-005478-5iu38pr6	2390	28	for	for	IN
cord-005478-5iu38pr6	2390	29	NRM	NRM	NNP
cord-005478-5iu38pr6	2390	30	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	2390	31	was	be	VBD
cord-005478-5iu38pr6	2390	32	not	not	RB
cord-005478-5iu38pr6	2390	33	an	an	DT
cord-005478-5iu38pr6	2390	34	independent	independent	JJ
cord-005478-5iu38pr6	2390	35	predictor	predictor	NN
cord-005478-5iu38pr6	2390	36	of	of	IN
cord-005478-5iu38pr6	2390	37	increased	increased	JJ
cord-005478-5iu38pr6	2390	38	risk	risk	NN
cord-005478-5iu38pr6	2390	39	(	(	-LRB-
cord-005478-5iu38pr6	2390	40	p=0.06	p=0.06	NNP
cord-005478-5iu38pr6	2390	41	)	)	-RRB-
cord-005478-5iu38pr6	2390	42	.	.	.
cord-005478-5iu38pr6	2391	1	When	when	WRB
cord-005478-5iu38pr6	2391	2	the	the	DT
cord-005478-5iu38pr6	2391	3	multivariable	multivariable	JJ
cord-005478-5iu38pr6	2391	4	analysis	analysis	NN
cord-005478-5iu38pr6	2391	5	was	be	VBD
cord-005478-5iu38pr6	2391	6	repeated	repeat	VBN
cord-005478-5iu38pr6	2391	7	for	for	IN
cord-005478-5iu38pr6	2391	8	related	related	JJ
cord-005478-5iu38pr6	2391	9	donor	donor	NN
cord-005478-5iu38pr6	2391	10	transplants	transplant	NNS
cord-005478-5iu38pr6	2391	11	only	only	RB
cord-005478-5iu38pr6	2391	12	(	(	-LRB-
cord-005478-5iu38pr6	2391	13	n=474	n=474	NNP
cord-005478-5iu38pr6	2391	14	,	,	,
cord-005478-5iu38pr6	2391	15	385	385	CD
cord-005478-5iu38pr6	2391	16	cryopreserved	cryopreserve	VBN
cord-005478-5iu38pr6	2391	17	grafts	graft	NNS
cord-005478-5iu38pr6	2391	18	,	,	,
cord-005478-5iu38pr6	2391	19	89	89	CD
cord-005478-5iu38pr6	2391	20	fresh	fresh	JJ
cord-005478-5iu38pr6	2391	21	)	)	-RRB-
cord-005478-5iu38pr6	2391	22	,	,	,
cord-005478-5iu38pr6	2391	23	this	this	DT
cord-005478-5iu38pr6	2391	24	confirmed	confirm	VBD
cord-005478-5iu38pr6	2391	25	the	the	DT
cord-005478-5iu38pr6	2391	26	independent	independent	JJ
cord-005478-5iu38pr6	2391	27	increased	increase	VBN
cord-005478-5iu38pr6	2391	28	relapse	relapse	NN
cord-005478-5iu38pr6	2391	29	risk	risk	NN
cord-005478-5iu38pr6	2391	30	for	for	IN
cord-005478-5iu38pr6	2391	31	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2391	32	grafts	graft	NNS
cord-005478-5iu38pr6	2391	33	(	(	-LRB-
cord-005478-5iu38pr6	2391	34	HR	HR	NNP
cord-005478-5iu38pr6	2391	35	2.30	2.30	CD
cord-005478-5iu38pr6	2391	36	,	,	,
cord-005478-5iu38pr6	2391	37	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	2391	38	)	)	-RRB-
cord-005478-5iu38pr6	2391	39	.	.	.
cord-005478-5iu38pr6	2392	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2392	2	:	:	:
cord-005478-5iu38pr6	2393	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2393	2	confirmed	confirm	VBD
cord-005478-5iu38pr6	2393	3	on	on	IN
cord-005478-5iu38pr6	2393	4	univariate	univariate	JJ
cord-005478-5iu38pr6	2393	5	and	and	CC
cord-005478-5iu38pr6	2393	6	multivariable	multivariable	JJ
cord-005478-5iu38pr6	2393	7	analysis	analysis	NN
cord-005478-5iu38pr6	2393	8	that	that	IN
cord-005478-5iu38pr6	2393	9	there	there	EX
cord-005478-5iu38pr6	2393	10	is	be	VBZ
cord-005478-5iu38pr6	2393	11	no	no	DT
cord-005478-5iu38pr6	2393	12	significant	significant	JJ
cord-005478-5iu38pr6	2393	13	difference	difference	NN
cord-005478-5iu38pr6	2393	14	in	in	IN
cord-005478-5iu38pr6	2393	15	OS	os	NN
cord-005478-5iu38pr6	2393	16	between	between	IN
cord-005478-5iu38pr6	2393	17	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2393	18	transplants	transplant	NNS
cord-005478-5iu38pr6	2393	19	performed	perform	VBN
cord-005478-5iu38pr6	2393	20	with	with	IN
cord-005478-5iu38pr6	2393	21	fresh	fresh	JJ
cord-005478-5iu38pr6	2393	22	versus	versus	IN
cord-005478-5iu38pr6	2393	23	cryopreserved	cryopreserved	JJ
cord-005478-5iu38pr6	2393	24	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2393	25	blood	blood	NN
cord-005478-5iu38pr6	2393	26	stem	stem	NN
cord-005478-5iu38pr6	2393	27	cell	cell	NN
cord-005478-5iu38pr6	2393	28	grafts	graft	NNS
cord-005478-5iu38pr6	2393	29	,	,	,
cord-005478-5iu38pr6	2393	30	however	however	WRB
cord-005478-5iu38pr6	2393	31	there	there	EX
cord-005478-5iu38pr6	2393	32	is	be	VBZ
cord-005478-5iu38pr6	2393	33	a	a	DT
cord-005478-5iu38pr6	2393	34	significant	significant	JJ
cord-005478-5iu38pr6	2393	35	increase	increase	NN
cord-005478-5iu38pr6	2393	36	in	in	IN
cord-005478-5iu38pr6	2393	37	relapse	relapse	NN
cord-005478-5iu38pr6	2393	38	risk	risk	NN
cord-005478-5iu38pr6	2393	39	associated	associate	VBN
cord-005478-5iu38pr6	2393	40	with	with	IN
cord-005478-5iu38pr6	2393	41	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	2393	42	.	.	.
cord-005478-5iu38pr6	2394	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2394	2	:	:	:
cord-005478-5iu38pr6	2394	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2394	4	to	to	TO
cord-005478-5iu38pr6	2394	5	declare	declare	VB
cord-005478-5iu38pr6	2394	6	.	.	.
cord-005478-5iu38pr6	2395	1	Background	background	NN
cord-005478-5iu38pr6	2395	2	:	:	:
cord-005478-5iu38pr6	2396	1	High	high	JJ
cord-005478-5iu38pr6	2396	2	dose	dose	NN
cord-005478-5iu38pr6	2396	3	post	post	JJ
cord-005478-5iu38pr6	2396	4	-	-	JJ
cord-005478-5iu38pr6	2396	5	transplantation	transplantation	JJ
cord-005478-5iu38pr6	2396	6	Cyclophosphamide(PTCY	Cyclophosphamide(PTCY	NNP
cord-005478-5iu38pr6	2396	7	)	)	-RRB-
cord-005478-5iu38pr6	2396	8	used	use	VBD
cord-005478-5iu38pr6	2396	9	in	in	IN
cord-005478-5iu38pr6	2396	10	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2396	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	2397	1	(	(	-LRB-
cord-005478-5iu38pr6	2397	2	haplo	haplo	NNP
cord-005478-5iu38pr6	2397	3	-	-	HYPH
cord-005478-5iu38pr6	2397	4	SCT	SCT	NNP
cord-005478-5iu38pr6	2397	5	)	)	-RRB-
cord-005478-5iu38pr6	2397	6	has	have	VBZ
cord-005478-5iu38pr6	2397	7	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	2397	8	to	to	TO
cord-005478-5iu38pr6	2397	9	be	be	VB
cord-005478-5iu38pr6	2397	10	highly	highly	RB
cord-005478-5iu38pr6	2397	11	effective	effective	JJ
cord-005478-5iu38pr6	2397	12	in	in	IN
cord-005478-5iu38pr6	2397	13	acute	acute	JJ
cord-005478-5iu38pr6	2397	14	and	and	CC
cord-005478-5iu38pr6	2397	15	chronic	chronic	JJ
cord-005478-5iu38pr6	2397	16	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2397	17	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2397	18	;	;	:
cord-005478-5iu38pr6	2397	19	however	however	RB
cord-005478-5iu38pr6	2397	20	it	-PRON-	PRP
cord-005478-5iu38pr6	2397	21	is	be	VBZ
cord-005478-5iu38pr6	2397	22	associated	associate	VBN
cord-005478-5iu38pr6	2397	23	with	with	IN
cord-005478-5iu38pr6	2397	24	high	high	JJ
cord-005478-5iu38pr6	2397	25	relapse	relapse	NN
cord-005478-5iu38pr6	2397	26	rates	rate	NNS
cord-005478-5iu38pr6	2397	27	.	.	.
cord-005478-5iu38pr6	2398	1	Anti	Anti	NNP
cord-005478-5iu38pr6	2398	2	-	-	JJ
cord-005478-5iu38pr6	2398	3	T	t	JJ
cord-005478-5iu38pr6	2398	4	-	-	HYPH
cord-005478-5iu38pr6	2398	5	Lymphocyte	Lymphocyte	NNP
cord-005478-5iu38pr6	2398	6	Globulin	globulin	NN
cord-005478-5iu38pr6	2399	1	(	(	-LRB-
cord-005478-5iu38pr6	2399	2	ATG	ATG	NNP
cord-005478-5iu38pr6	2399	3	-	-	HYPH
cord-005478-5iu38pr6	2399	4	Fresenius	Fresenius	NNP
cord-005478-5iu38pr6	2399	5	®	®	.
cord-005478-5iu38pr6	2399	6	)	)	-RRB-
cord-005478-5iu38pr6	2399	7	is	be	VBZ
cord-005478-5iu38pr6	2399	8	also	also	RB
cord-005478-5iu38pr6	2399	9	effective	effective	JJ
cord-005478-5iu38pr6	2399	10	as	as	IN
cord-005478-5iu38pr6	2399	11	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2399	12	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2399	13	but	but	CC
cord-005478-5iu38pr6	2400	1	its	-PRON-	PRP$
cord-005478-5iu38pr6	2400	2	benefit	benefit	NN
cord-005478-5iu38pr6	2400	3	in	in	IN
cord-005478-5iu38pr6	2400	4	Overall	Overall	NNP
cord-005478-5iu38pr6	2400	5	Survival	Survival	NNP
cord-005478-5iu38pr6	2400	6	(	(	-LRB-
cord-005478-5iu38pr6	2400	7	OS	OS	NNP
cord-005478-5iu38pr6	2400	8	)	)	-RRB-
cord-005478-5iu38pr6	2400	9	and	and	CC
cord-005478-5iu38pr6	2400	10	Relapse	Relapse	NNP
cord-005478-5iu38pr6	2400	11	Free	Free	NNP
cord-005478-5iu38pr6	2400	12	Survival	Survival	NNP
cord-005478-5iu38pr6	2400	13	(	(	-LRB-
cord-005478-5iu38pr6	2400	14	RFS	RFS	NNP
cord-005478-5iu38pr6	2400	15	)	)	-RRB-
cord-005478-5iu38pr6	2400	16	is	be	VBZ
cord-005478-5iu38pr6	2400	17	unclear	unclear	JJ
cord-005478-5iu38pr6	2400	18	.	.	.
cord-005478-5iu38pr6	2401	1	The	the	DT
cord-005478-5iu38pr6	2401	2	aim	aim	NN
cord-005478-5iu38pr6	2401	3	of	of	IN
cord-005478-5iu38pr6	2401	4	this	this	DT
cord-005478-5iu38pr6	2401	5	study	study	NN
cord-005478-5iu38pr6	2401	6	was	be	VBD
cord-005478-5iu38pr6	2401	7	to	to	TO
cord-005478-5iu38pr6	2401	8	compare	compare	VB
cord-005478-5iu38pr6	2401	9	the	the	DT
cord-005478-5iu38pr6	2401	10	effectiveness	effectiveness	NN
cord-005478-5iu38pr6	2401	11	of	of	IN
cord-005478-5iu38pr6	2401	12	two	two	CD
cord-005478-5iu38pr6	2401	13	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2401	14	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2401	15	regimen	regimen	NN
cord-005478-5iu38pr6	2401	16	employed	employ	VBN
cord-005478-5iu38pr6	2401	17	in	in	IN
cord-005478-5iu38pr6	2401	18	high	high	JJ
cord-005478-5iu38pr6	2401	19	risk	risk	NN
cord-005478-5iu38pr6	2401	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	2401	21	:	:	:
cord-005478-5iu38pr6	2401	22	PTCY	ptcy	NN
cord-005478-5iu38pr6	2401	23	-	-	HYPH
cord-005478-5iu38pr6	2401	24	haplo	haplo	NNP
cord-005478-5iu38pr6	2401	25	-	-	HYPH
cord-005478-5iu38pr6	2401	26	SCT	SCT	NNP
cord-005478-5iu38pr6	2401	27	and	and	CC
cord-005478-5iu38pr6	2401	28	low	low	JJ
cord-005478-5iu38pr6	2401	29	doses	dose	NNS
cord-005478-5iu38pr6	2401	30	of	of	IN
cord-005478-5iu38pr6	2401	31	ATG	ATG	NNP
cord-005478-5iu38pr6	2401	32	-	-	HYPH
cord-005478-5iu38pr6	2401	33	F	F	NNP
cord-005478-5iu38pr6	2401	34	used	use	VBD
cord-005478-5iu38pr6	2401	35	in	in	IN
cord-005478-5iu38pr6	2401	36	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2401	37	blood(PB	blood(PB	NNP
cord-005478-5iu38pr6	2401	38	)	)	-RRB-
cord-005478-5iu38pr6	2401	39	and	and	CC
cord-005478-5iu38pr6	2401	40	mismatched	mismatch	VBD
cord-005478-5iu38pr6	2401	41	transplantation	transplantation	NN
cord-005478-5iu38pr6	2401	42	.	.	.
cord-005478-5iu38pr6	2402	1	The	the	DT
cord-005478-5iu38pr6	2402	2	primary	primary	JJ
cord-005478-5iu38pr6	2402	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	2402	4	was	be	VBD
cord-005478-5iu38pr6	2402	5	to	to	TO
cord-005478-5iu38pr6	2402	6	evaluate	evaluate	VB
cord-005478-5iu38pr6	2402	7	the	the	DT
cord-005478-5iu38pr6	2402	8	incidence	incidence	NN
cord-005478-5iu38pr6	2402	9	and	and	CC
cord-005478-5iu38pr6	2402	10	severity	severity	NN
cord-005478-5iu38pr6	2402	11	of	of	IN
cord-005478-5iu38pr6	2402	12	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2402	13	and	and	CC
cord-005478-5iu38pr6	2402	14	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2402	15	.	.	.
cord-005478-5iu38pr6	2403	1	As	as	IN
cord-005478-5iu38pr6	2403	2	secondary	secondary	JJ
cord-005478-5iu38pr6	2403	3	endpoints	endpoint	NNS
cord-005478-5iu38pr6	2403	4	we	-PRON-	PRP
cord-005478-5iu38pr6	2403	5	analysed	analyse	VBD
cord-005478-5iu38pr6	2403	6	the	the	DT
cord-005478-5iu38pr6	2403	7	OS	OS	NNP
cord-005478-5iu38pr6	2403	8	,	,	,
cord-005478-5iu38pr6	2403	9	RFS	RFS	NNP
cord-005478-5iu38pr6	2403	10	and	and	CC
cord-005478-5iu38pr6	2403	11	GRFS	GRFS	NNP
cord-005478-5iu38pr6	2403	12	(	(	-LRB-
cord-005478-5iu38pr6	2403	13	considering	consider	VBG
cord-005478-5iu38pr6	2403	14	as	as	IN
cord-005478-5iu38pr6	2403	15	events	event	NNS
cord-005478-5iu38pr6	2403	16	severe	severe	JJ
cord-005478-5iu38pr6	2403	17	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2403	18	,	,	,
cord-005478-5iu38pr6	2403	19	systemic	systemic	JJ
cord-005478-5iu38pr6	2403	20	therapy	therapy	NN
cord-005478-5iu38pr6	2403	21	-	-	HYPH
cord-005478-5iu38pr6	2403	22	requiring	require	VBG
cord-005478-5iu38pr6	2403	23	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2403	24	,	,	,
cord-005478-5iu38pr6	2403	25	relapse	relapse	NN
cord-005478-5iu38pr6	2403	26	or	or	CC
cord-005478-5iu38pr6	2403	27	death	death	NN
cord-005478-5iu38pr6	2403	28	)	)	-RRB-
cord-005478-5iu38pr6	2403	29	.	.	.
cord-005478-5iu38pr6	2404	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2404	2	also	also	RB
cord-005478-5iu38pr6	2404	3	evaluated	evaluate	VBD
cord-005478-5iu38pr6	2404	4	mortality	mortality	NN
cord-005478-5iu38pr6	2404	5	related	relate	VBN
cord-005478-5iu38pr6	2404	6	to	to	IN
cord-005478-5iu38pr6	2404	7	transplantation(TRM	transplantation(trm	CD
cord-005478-5iu38pr6	2404	8	)	)	-RRB-
cord-005478-5iu38pr6	2404	9	and	and	CC
cord-005478-5iu38pr6	2404	10	post	post	JJ
cord-005478-5iu38pr6	2404	11	-	-	JJ
cord-005478-5iu38pr6	2404	12	transplant	transplant	JJ
cord-005478-5iu38pr6	2404	13	complications	complication	NNS
cord-005478-5iu38pr6	2404	14	.	.	.
cord-005478-5iu38pr6	2405	1	Methods	method	NNS
cord-005478-5iu38pr6	2405	2	:	:	:
cord-005478-5iu38pr6	2405	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2405	4	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	2405	5	analysed	analyse	VBD
cord-005478-5iu38pr6	2405	6	111	111	CD
cord-005478-5iu38pr6	2405	7	allo	allo	NN
cord-005478-5iu38pr6	2405	8	-	-	HYPH
cord-005478-5iu38pr6	2405	9	SCT	SCT	NNP
cord-005478-5iu38pr6	2405	10	performed	perform	VBN
cord-005478-5iu38pr6	2405	11	in	in	IN
cord-005478-5iu38pr6	2405	12	our	-PRON-	PRP$
cord-005478-5iu38pr6	2405	13	institution	institution	NN
cord-005478-5iu38pr6	2405	14	between	between	IN
cord-005478-5iu38pr6	2405	15	2012	2012	CD
cord-005478-5iu38pr6	2405	16	and	and	CC
cord-005478-5iu38pr6	2405	17	2017	2017	CD
cord-005478-5iu38pr6	2405	18	.	.	.
cord-005478-5iu38pr6	2406	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2406	2	analysed	analyse	VBD
cord-005478-5iu38pr6	2406	3	two	two	CD
cord-005478-5iu38pr6	2406	4	cohorts	cohort	NNS
cord-005478-5iu38pr6	2406	5	:	:	:
cord-005478-5iu38pr6	2406	6	49	49	CD
cord-005478-5iu38pr6	2406	7	haplo	haplo	NNP
cord-005478-5iu38pr6	2406	8	-	-	HYPH
cord-005478-5iu38pr6	2406	9	SCT	SCT	NNP
cord-005478-5iu38pr6	2406	10	with	with	IN
cord-005478-5iu38pr6	2406	11	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2406	12	(	(	-LRB-
cord-005478-5iu38pr6	2406	13	50	50	CD
cord-005478-5iu38pr6	2406	14	mg/	mg/	NN
cord-005478-5iu38pr6	2406	15	kg	kg	NN
cord-005478-5iu38pr6	2406	16	,	,	,
cord-005478-5iu38pr6	2406	17	days	day	NNS
cord-005478-5iu38pr6	2406	18	+3,+4	+3,+4	NNS
cord-005478-5iu38pr6	2406	19	)	)	-RRB-
cord-005478-5iu38pr6	2406	20	followed	follow	VBN
cord-005478-5iu38pr6	2406	21	by	by	IN
cord-005478-5iu38pr6	2406	22	Tacrolimus	Tacrolimus	NNP
cord-005478-5iu38pr6	2406	23	and	and	CC
cord-005478-5iu38pr6	2406	24	Mycophenolate	Mycophenolate	NNP
cord-005478-5iu38pr6	2406	25	(	(	-LRB-
cord-005478-5iu38pr6	2406	26	MMF	MMF	NNP
cord-005478-5iu38pr6	2406	27	)	)	-RRB-
cord-005478-5iu38pr6	2406	28	;	;	:
cord-005478-5iu38pr6	2406	29	and	and	CC
cord-005478-5iu38pr6	2406	30	62	62	CD
cord-005478-5iu38pr6	2406	31	PB	PB	NNP
cord-005478-5iu38pr6	2406	32	and/or	and/or	CC
cord-005478-5iu38pr6	2406	33	mismatched	mismatched	JJ
cord-005478-5iu38pr6	2406	34	transplants	transplant	NNS
cord-005478-5iu38pr6	2406	35	with	with	IN
cord-005478-5iu38pr6	2406	36	low	low	JJ
cord-005478-5iu38pr6	2406	37	dose	dose	NN
cord-005478-5iu38pr6	2406	38	ATG	ATG	NNP
cord-005478-5iu38pr6	2406	39	-	-	HYPH
cord-005478-5iu38pr6	2406	40	F	F	NNP
cord-005478-5iu38pr6	2406	41	(	(	-LRB-
cord-005478-5iu38pr6	2406	42	7	7	CD
cord-005478-5iu38pr6	2406	43	mg	mg	NNP
cord-005478-5iu38pr6	2406	44	/	/	SYM
cord-005478-5iu38pr6	2406	45	Kg	Kg	NNP
cord-005478-5iu38pr6	2406	46	days	day	NNS
cord-005478-5iu38pr6	2406	47	-3,-2,-1	-3,-2,-1	JJ
cord-005478-5iu38pr6	2406	48	)	)	-RRB-
cord-005478-5iu38pr6	2407	1	associated	associate	VBN
cord-005478-5iu38pr6	2407	2	to	to	IN
cord-005478-5iu38pr6	2407	3	calcineurin	calcineurin	NNP
cord-005478-5iu38pr6	2407	4	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	2407	5	starting	start	VBG
cord-005478-5iu38pr6	2407	6	on	on	IN
cord-005478-5iu38pr6	2407	7	day	day	NN
cord-005478-5iu38pr6	2407	8	-1	-1	CD
cord-005478-5iu38pr6	2407	9	,	,	,
cord-005478-5iu38pr6	2407	10	with	with	IN
cord-005478-5iu38pr6	2407	11	short	short	JJ
cord-005478-5iu38pr6	2407	12	course	course	NN
cord-005478-5iu38pr6	2407	13	MTX	MTX	NNP
cord-005478-5iu38pr6	2407	14	(	(	-LRB-
cord-005478-5iu38pr6	2407	15	days	day	NNS
cord-005478-5iu38pr6	2407	16	+1,+3,+6	+1,+3,+6	NNP
cord-005478-5iu38pr6	2407	17	)	)	-RRB-
cord-005478-5iu38pr6	2407	18	or	or	CC
cord-005478-5iu38pr6	2407	19	MMF	mmf	NN
cord-005478-5iu38pr6	2407	20	.	.	.
cord-005478-5iu38pr6	2408	1	In	in	IN
cord-005478-5iu38pr6	2408	2	both	both	DT
cord-005478-5iu38pr6	2408	3	cohorts	cohort	NNS
cord-005478-5iu38pr6	2408	4	,	,	,
cord-005478-5iu38pr6	2408	5	MMF	MMF	NNP
cord-005478-5iu38pr6	2408	6	was	be	VBD
cord-005478-5iu38pr6	2408	7	stopped	stop	VBN
cord-005478-5iu38pr6	2408	8	on	on	IN
cord-005478-5iu38pr6	2408	9	day	day	NN
cord-005478-5iu38pr6	2408	10	+28	+28	NNP
cord-005478-5iu38pr6	2408	11	and	and	CC
cord-005478-5iu38pr6	2408	12	calcineurin	calcineurin	NNP
cord-005478-5iu38pr6	2408	13	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	2408	14	were	be	VBD
cord-005478-5iu38pr6	2408	15	tappered	tappere	VBN
cord-005478-5iu38pr6	2408	16	on	on	IN
cord-005478-5iu38pr6	2408	17	day	day	NN
cord-005478-5iu38pr6	2408	18	+50	+50	NN
cord-005478-5iu38pr6	2408	19	.	.	.
cord-005478-5iu38pr6	2409	1	Comparing	compare	VBG
cord-005478-5iu38pr6	2409	2	both	both	DT
cord-005478-5iu38pr6	2409	3	groups	group	NNS
cord-005478-5iu38pr6	2409	4	,	,	,
cord-005478-5iu38pr6	2409	5	we	-PRON-	PRP
cord-005478-5iu38pr6	2409	6	found	find	VBD
cord-005478-5iu38pr6	2409	7	differences	difference	NNS
cord-005478-5iu38pr6	2409	8	in	in	IN
cord-005478-5iu38pr6	2409	9	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2409	10	(	(	-LRB-
cord-005478-5iu38pr6	2409	11	lymphoproliferative	lymphoproliferative	JJ
cord-005478-5iu38pr6	2409	12	disorders	disorder	NNS
cord-005478-5iu38pr6	2409	13	16	16	CD
cord-005478-5iu38pr6	2409	14	vs	vs	IN
cord-005478-5iu38pr6	2409	15	4,p=0.003	4,p=0.003	CD
cord-005478-5iu38pr6	2409	16	)	)	-RRB-
cord-005478-5iu38pr6	2409	17	,	,	,
cord-005478-5iu38pr6	2409	18	high	high	JJ
cord-005478-5iu38pr6	2409	19	DRI	dri	NN
cord-005478-5iu38pr6	2409	20	-	-	HYPH
cord-005478-5iu38pr6	2409	21	score	score	NN
cord-005478-5iu38pr6	2409	22	(	(	-LRB-
cord-005478-5iu38pr6	2409	23	18	18	CD
cord-005478-5iu38pr6	2409	24	vs	vs	IN
cord-005478-5iu38pr6	2409	25	11	11	CD
cord-005478-5iu38pr6	2409	26	,	,	,
cord-005478-5iu38pr6	2409	27	p=0.04	p=0.04	NNP
cord-005478-5iu38pr6	2409	28	)	)	-RRB-
cord-005478-5iu38pr6	2409	29	,	,	,
cord-005478-5iu38pr6	2409	30	previous	previous	JJ
cord-005478-5iu38pr6	2409	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	2409	32	(	(	-LRB-
cord-005478-5iu38pr6	2409	33	12	12	CD
cord-005478-5iu38pr6	2409	34	vs	vs	IN
cord-005478-5iu38pr6	2409	35	5,p=0.02	5,p=0.02	CD
cord-005478-5iu38pr6	2409	36	)	)	-RRB-
cord-005478-5iu38pr6	2409	37	,	,	,
cord-005478-5iu38pr6	2409	38	reduced	reduce	VBN
cord-005478-5iu38pr6	2409	39	-	-	HYPH
cord-005478-5iu38pr6	2409	40	intensity	intensity	NN
cord-005478-5iu38pr6	2409	41	conditioning	conditioning	NN
cord-005478-5iu38pr6	2409	42	regimen	regimen	NN
cord-005478-5iu38pr6	2409	43	(	(	-LRB-
cord-005478-5iu38pr6	2409	44	36	36	CD
cord-005478-5iu38pr6	2409	45	vs	vs	IN
cord-005478-5iu38pr6	2409	46	20,p	20,p	CD
cord-005478-5iu38pr6	2409	47	<	<	XX
cord-005478-5iu38pr6	2409	48	0.001	0.001	CD
cord-005478-5iu38pr6	2409	49	)	)	-RRB-
cord-005478-5iu38pr6	2409	50	and	and	CC
cord-005478-5iu38pr6	2409	51	bone	bone	NN
cord-005478-5iu38pr6	2409	52	marrow	marrow	NN
cord-005478-5iu38pr6	2409	53	as	as	IN
cord-005478-5iu38pr6	2409	54	stem	stem	NN
cord-005478-5iu38pr6	2409	55	cells	cell	NNS
cord-005478-5iu38pr6	2409	56	source	source	NN
cord-005478-5iu38pr6	2409	57	(	(	-LRB-
cord-005478-5iu38pr6	2409	58	38	38	CD
cord-005478-5iu38pr6	2409	59	vs	vs	IN
cord-005478-5iu38pr6	2409	60	9	9	CD
cord-005478-5iu38pr6	2409	61	,	,	,
cord-005478-5iu38pr6	2409	62	p	p	NN
cord-005478-5iu38pr6	2409	63	<	<	XX
cord-005478-5iu38pr6	2409	64	0.001	0.001	CD
cord-005478-5iu38pr6	2409	65	)	)	-RRB-
cord-005478-5iu38pr6	2409	66	.	.	.
cord-005478-5iu38pr6	2410	1	Results	result	NNS
cord-005478-5iu38pr6	2410	2	:	:	:
cord-005478-5iu38pr6	2411	1	Median	median	JJ
cord-005478-5iu38pr6	2411	2	time	time	NN
cord-005478-5iu38pr6	2411	3	to	to	IN
cord-005478-5iu38pr6	2411	4	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2411	5	engraftment	engraftment	NN
cord-005478-5iu38pr6	2411	6	was	be	VBD
cord-005478-5iu38pr6	2411	7	similar	similar	JJ
cord-005478-5iu38pr6	2411	8	in	in	IN
cord-005478-5iu38pr6	2411	9	both	both	DT
cord-005478-5iu38pr6	2411	10	groups	group	NNS
cord-005478-5iu38pr6	2411	11	:	:	:
cord-005478-5iu38pr6	2411	12	17	17	CD
cord-005478-5iu38pr6	2411	13	vs	vs	IN
cord-005478-5iu38pr6	2411	14	16	16	CD
cord-005478-5iu38pr6	2411	15	days	day	NNS
cord-005478-5iu38pr6	2411	16	.	.	.
cord-005478-5iu38pr6	2412	1	Conversely	conversely	RB
cord-005478-5iu38pr6	2412	2	,	,	,
cord-005478-5iu38pr6	2412	3	median	median	JJ
cord-005478-5iu38pr6	2412	4	time	time	NN
cord-005478-5iu38pr6	2412	5	to	to	IN
cord-005478-5iu38pr6	2412	6	platelet	platelet	NN
cord-005478-5iu38pr6	2412	7	recovery	recovery	NN
cord-005478-5iu38pr6	2412	8	was	be	VBD
cord-005478-5iu38pr6	2412	9	longer	long	JJR
cord-005478-5iu38pr6	2412	10	in	in	IN
cord-005478-5iu38pr6	2412	11	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2412	12	cohort	cohort	NN
cord-005478-5iu38pr6	2412	13	(	(	-LRB-
cord-005478-5iu38pr6	2412	14	33vs18	33vs18	CD
cord-005478-5iu38pr6	2412	15	days	day	NNS
cord-005478-5iu38pr6	2412	16	,	,	,
cord-005478-5iu38pr6	2412	17	p=0.016	p=0.016	RB
cord-005478-5iu38pr6	2412	18	)	)	-RRB-
cord-005478-5iu38pr6	2412	19	.	.	.
cord-005478-5iu38pr6	2413	1	There	there	EX
cord-005478-5iu38pr6	2413	2	were	be	VBD
cord-005478-5iu38pr6	2413	3	no	no	DT
cord-005478-5iu38pr6	2413	4	differences	difference	NNS
cord-005478-5iu38pr6	2413	5	in	in	IN
cord-005478-5iu38pr6	2413	6	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2413	7	incidence	incidence	NN
cord-005478-5iu38pr6	2413	8	(	(	-LRB-
cord-005478-5iu38pr6	2413	9	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2413	10	30.6	30.6	CD
cord-005478-5iu38pr6	2413	11	%	%	NN
cord-005478-5iu38pr6	2413	12	vs	vs	IN
cord-005478-5iu38pr6	2413	13	ATG	ATG	NNP
cord-005478-5iu38pr6	2413	14	36.4	36.4	CD
cord-005478-5iu38pr6	2413	15	%	%	NN
cord-005478-5iu38pr6	2413	16	)	)	-RRB-
cord-005478-5iu38pr6	2413	17	or	or	CC
cord-005478-5iu38pr6	2413	18	severe	severe	JJ
cord-005478-5iu38pr6	2413	19	aGVHD	agvhd	NN
cord-005478-5iu38pr6	2414	1	(	(	-LRB-
cord-005478-5iu38pr6	2414	2	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2414	3	4.1	4.1	CD
cord-005478-5iu38pr6	2414	4	%	%	NN
cord-005478-5iu38pr6	2414	5	vs	vs	IN
cord-005478-5iu38pr6	2414	6	ATG	ATG	NNP
cord-005478-5iu38pr6	2414	7	9	9	CD
cord-005478-5iu38pr6	2414	8	%	%	NN
cord-005478-5iu38pr6	2414	9	,	,	,
cord-005478-5iu38pr6	2414	10	p=	p=	NNP
cord-005478-5iu38pr6	2414	11	0.852	0.852	CD
cord-005478-5iu38pr6	2414	12	)	)	-RRB-
cord-005478-5iu38pr6	2414	13	.	.	.
cord-005478-5iu38pr6	2415	1	The	the	DT
cord-005478-5iu38pr6	2415	2	global	global	JJ
cord-005478-5iu38pr6	2415	3	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2415	4	incidence	incidence	NN
cord-005478-5iu38pr6	2415	5	was	be	VBD
cord-005478-5iu38pr6	2415	6	PCTY	PCTY	NNP
cord-005478-5iu38pr6	2415	7	56.1	56.1	CD
cord-005478-5iu38pr6	2415	8	%	%	NN
cord-005478-5iu38pr6	2415	9	vs	vs	IN
cord-005478-5iu38pr6	2415	10	ATG	ATG	NNP
cord-005478-5iu38pr6	2415	11	66	66	CD
cord-005478-5iu38pr6	2415	12	%	%	NN
cord-005478-5iu38pr6	2415	13	.	.	.
cord-005478-5iu38pr6	2416	1	Mild	mild	JJ
cord-005478-5iu38pr6	2416	2	,	,	,
cord-005478-5iu38pr6	2416	3	moderate	moderate	JJ
cord-005478-5iu38pr6	2416	4	and	and	CC
cord-005478-5iu38pr6	2416	5	severe	severe	JJ
cord-005478-5iu38pr6	2416	6	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2416	7	incidence	incidence	NN
cord-005478-5iu38pr6	2416	8	was	be	VBD
cord-005478-5iu38pr6	2416	9	31.7	31.7	CD
cord-005478-5iu38pr6	2416	10	%	%	NN
cord-005478-5iu38pr6	2416	11	,	,	,
cord-005478-5iu38pr6	2416	12	19.5	19.5	CD
cord-005478-5iu38pr6	2416	13	%	%	NN
cord-005478-5iu38pr6	2416	14	and	and	CC
cord-005478-5iu38pr6	2416	15	4.8	4.8	CD
cord-005478-5iu38pr6	2416	16	%	%	NN
cord-005478-5iu38pr6	2416	17	,	,	,
cord-005478-5iu38pr6	2416	18	for	for	IN
cord-005478-5iu38pr6	2416	19	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2416	20	vs	vs	IN
cord-005478-5iu38pr6	2416	21	28	28	CD
cord-005478-5iu38pr6	2416	22	%	%	NN
cord-005478-5iu38pr6	2416	23	,	,	,
cord-005478-5iu38pr6	2416	24	26	26	CD
cord-005478-5iu38pr6	2416	25	%	%	NN
cord-005478-5iu38pr6	2417	1	y	y	NNP
cord-005478-5iu38pr6	2417	2	12	12	CD
cord-005478-5iu38pr6	2417	3	%	%	NN
cord-005478-5iu38pr6	2417	4	for	for	IN
cord-005478-5iu38pr6	2417	5	ATG(p=0.475).With	atg(p=0.475).with	NN
cord-005478-5iu38pr6	2417	6	a	a	DT
cord-005478-5iu38pr6	2417	7	median	median	JJ
cord-005478-5iu38pr6	2417	8	follow	follow	NN
cord-005478-5iu38pr6	2417	9	-	-	HYPH
cord-005478-5iu38pr6	2417	10	up	up	NN
cord-005478-5iu38pr6	2417	11	of	of	IN
cord-005478-5iu38pr6	2417	12	27	27	CD
cord-005478-5iu38pr6	2417	13	months	month	NNS
cord-005478-5iu38pr6	2417	14	(	(	-LRB-
cord-005478-5iu38pr6	2417	15	28	28	CD
cord-005478-5iu38pr6	2417	16	months	month	NNS
cord-005478-5iu38pr6	2417	17	for	for	IN
cord-005478-5iu38pr6	2417	18	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2417	19	and	and	CC
cord-005478-5iu38pr6	2417	20	22	22	CD
cord-005478-5iu38pr6	2417	21	months	month	NNS
cord-005478-5iu38pr6	2417	22	for	for	IN
cord-005478-5iu38pr6	2417	23	ATG	ATG	NNP
cord-005478-5iu38pr6	2417	24	)	)	-RRB-
cord-005478-5iu38pr6	2418	1	the	the	DT
cord-005478-5iu38pr6	2418	2	OS	OS	NNP
cord-005478-5iu38pr6	2418	3	at	at	IN
cord-005478-5iu38pr6	2418	4	12	12	CD
cord-005478-5iu38pr6	2418	5	and	and	CC
cord-005478-5iu38pr6	2418	6	24	24	CD
cord-005478-5iu38pr6	2418	7	was	be	VBD
cord-005478-5iu38pr6	2418	8	:	:	:
cord-005478-5iu38pr6	2418	9	PCTY	PCTY	NNP
cord-005478-5iu38pr6	2418	10	67.8	67.8	CD
cord-005478-5iu38pr6	2418	11	%	%	NN
cord-005478-5iu38pr6	2418	12	and	and	CC
cord-005478-5iu38pr6	2418	13	61	61	CD
cord-005478-5iu38pr6	2418	14	%	%	NN
cord-005478-5iu38pr6	2418	15	,	,	,
cord-005478-5iu38pr6	2418	16	and	and	CC
cord-005478-5iu38pr6	2418	17	ATG	ATG	NNP
cord-005478-5iu38pr6	2418	18	68.8	68.8	CD
cord-005478-5iu38pr6	2418	19	%	%	NN
cord-005478-5iu38pr6	2418	20	and	and	CC
cord-005478-5iu38pr6	2418	21	59.9%,p=0.971	59.9%,p=0.971	CD
cord-005478-5iu38pr6	2418	22	)	)	-RRB-
cord-005478-5iu38pr6	2418	23	.	.	.
cord-005478-5iu38pr6	2419	1	RFS	RFS	NNP
cord-005478-5iu38pr6	2419	2	(	(	-LRB-
cord-005478-5iu38pr6	2419	3	12	12	CD
cord-005478-5iu38pr6	2419	4	and	and	CC
cord-005478-5iu38pr6	2419	5	24	24	CD
cord-005478-5iu38pr6	2419	6	months	month	NNS
cord-005478-5iu38pr6	2419	7	)	)	-RRB-
cord-005478-5iu38pr6	2419	8	was	be	VBD
cord-005478-5iu38pr6	2419	9	:	:	:
cord-005478-5iu38pr6	2419	10	61	61	CD
cord-005478-5iu38pr6	2419	11	%	%	NN
cord-005478-5iu38pr6	2419	12	and	and	CC
cord-005478-5iu38pr6	2419	13	57.9	57.9	CD
cord-005478-5iu38pr6	2419	14	%	%	NN
cord-005478-5iu38pr6	2419	15	for	for	IN
cord-005478-5iu38pr6	2419	16	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2419	17	,	,	,
cord-005478-5iu38pr6	2419	18	and,69	and,69	NN
cord-005478-5iu38pr6	2419	19	%	%	NN
cord-005478-5iu38pr6	2419	20	and	and	CC
cord-005478-5iu38pr6	2419	21	54	54	CD
cord-005478-5iu38pr6	2419	22	%	%	NN
cord-005478-5iu38pr6	2419	23	for	for	IN
cord-005478-5iu38pr6	2419	24	ATG(p=0.839	atg(p=0.839	NN
cord-005478-5iu38pr6	2419	25	)	)	-RRB-
cord-005478-5iu38pr6	2419	26	.	.	.
cord-005478-5iu38pr6	2420	1	GRFS	GRFS	NNP
cord-005478-5iu38pr6	2420	2	at	at	IN
cord-005478-5iu38pr6	2420	3	12	12	CD
cord-005478-5iu38pr6	2420	4	and	and	CC
cord-005478-5iu38pr6	2420	5	24	24	CD
cord-005478-5iu38pr6	2420	6	months	month	NNS
cord-005478-5iu38pr6	2420	7	was	be	VBD
cord-005478-5iu38pr6	2420	8	46.5	46.5	CD
cord-005478-5iu38pr6	2420	9	%	%	NN
cord-005478-5iu38pr6	2420	10	and	and	CC
cord-005478-5iu38pr6	2420	11	42.9	42.9	CD
cord-005478-5iu38pr6	2420	12	%	%	NN
cord-005478-5iu38pr6	2420	13	,	,	,
cord-005478-5iu38pr6	2420	14	for	for	IN
cord-005478-5iu38pr6	2420	15	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2420	16	patients	patient	NNS
cord-005478-5iu38pr6	2420	17	and	and	CC
cord-005478-5iu38pr6	2420	18	40.7	40.7	CD
cord-005478-5iu38pr6	2420	19	%	%	NN
cord-005478-5iu38pr6	2420	20	and	and	CC
cord-005478-5iu38pr6	2420	21	33	33	CD
cord-005478-5iu38pr6	2420	22	%	%	NN
cord-005478-5iu38pr6	2420	23	for	for	IN
cord-005478-5iu38pr6	2420	24	ATG	ATG	NNP
cord-005478-5iu38pr6	2420	25	patients	patient	NNS
cord-005478-5iu38pr6	2420	26	(	(	-LRB-
cord-005478-5iu38pr6	2420	27	p=0.433	p=0.433	NNP
cord-005478-5iu38pr6	2420	28	)	)	-RRB-
cord-005478-5iu38pr6	2420	29	.	.	.
cord-005478-5iu38pr6	2421	1	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2421	2	cohort	cohort	NN
cord-005478-5iu38pr6	2421	3	seemed	seem	VBD
cord-005478-5iu38pr6	2421	4	to	to	TO
cord-005478-5iu38pr6	2421	5	develop	develop	VB
cord-005478-5iu38pr6	2421	6	more	more	RBR
cord-005478-5iu38pr6	2421	7	relevant	relevant	JJ
cord-005478-5iu38pr6	2421	8	non	non	JJ
cord-005478-5iu38pr6	2421	9	-	-	JJ
cord-005478-5iu38pr6	2421	10	infectious	infectious	JJ
cord-005478-5iu38pr6	2421	11	complications	complication	NNS
cord-005478-5iu38pr6	2421	12	,	,	,
cord-005478-5iu38pr6	2421	13	but	but	CC
cord-005478-5iu38pr6	2421	14	there	there	EX
cord-005478-5iu38pr6	2421	15	were	be	VBD
cord-005478-5iu38pr6	2421	16	no	no	DT
cord-005478-5iu38pr6	2421	17	differences	difference	NNS
cord-005478-5iu38pr6	2421	18	among	among	IN
cord-005478-5iu38pr6	2421	19	infectious	infectious	JJ
cord-005478-5iu38pr6	2421	20	complications	complication	NNS
cord-005478-5iu38pr6	2421	21	.	.	.
cord-005478-5iu38pr6	2422	1	Image	image	NN
cord-005478-5iu38pr6	2422	2	1	1	CD
cord-005478-5iu38pr6	2422	3	.	.	.
cord-005478-5iu38pr6	2423	1	TRM	TRM	NNP
cord-005478-5iu38pr6	2423	2	was	be	VBD
cord-005478-5iu38pr6	2423	3	similar	similar	JJ
cord-005478-5iu38pr6	2423	4	in	in	IN
cord-005478-5iu38pr6	2423	5	both	both	DT
cord-005478-5iu38pr6	2423	6	cohorts	cohort	NNS
cord-005478-5iu38pr6	2423	7	:	:	:
cord-005478-5iu38pr6	2423	8	PCTY	PCTY	NNP
cord-005478-5iu38pr6	2423	9	18.4	18.4	CD
cord-005478-5iu38pr6	2423	10	%	%	NN
cord-005478-5iu38pr6	2423	11	vs	vs	IN
cord-005478-5iu38pr6	2423	12	ATG	ATG	NNP
cord-005478-5iu38pr6	2423	13	22.5	22.5	CD
cord-005478-5iu38pr6	2423	14	%	%	NN
cord-005478-5iu38pr6	2423	15	(	(	-LRB-
cord-005478-5iu38pr6	2423	16	p=0.250	p=0.250	NNP
cord-005478-5iu38pr6	2423	17	)	)	-RRB-
cord-005478-5iu38pr6	2423	18	.	.	.
cord-005478-5iu38pr6	2424	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2424	2	neither	neither	CC
cord-005478-5iu38pr6	2424	3	found	find	VBD
cord-005478-5iu38pr6	2424	4	differences	difference	NNS
cord-005478-5iu38pr6	2424	5	in	in	IN
cord-005478-5iu38pr6	2424	6	early	early	JJ
cord-005478-5iu38pr6	2424	7	toxic	toxic	JJ
cord-005478-5iu38pr6	2424	8	mortality	mortality	NN
cord-005478-5iu38pr6	2424	9	(	(	-LRB-
cord-005478-5iu38pr6	2424	10	<	<	NNP
cord-005478-5iu38pr6	2424	11	100	100	CD
cord-005478-5iu38pr6	2424	12	days	day	NNS
cord-005478-5iu38pr6	2424	13	)	)	-RRB-
cord-005478-5iu38pr6	2424	14	:	:	:
cord-005478-5iu38pr6	2424	15	PCTY	PCTY	NNP
cord-005478-5iu38pr6	2424	16	16.3	16.3	CD
cord-005478-5iu38pr6	2424	17	%	%	NN
cord-005478-5iu38pr6	2424	18	vs	vs	IN
cord-005478-5iu38pr6	2424	19	ATG	ATG	NNP
cord-005478-5iu38pr6	2424	20	14.5	14.5	CD
cord-005478-5iu38pr6	2424	21	%	%	NN
cord-005478-5iu38pr6	2424	22	for	for	IN
cord-005478-5iu38pr6	2424	23	ATG	ATG	NNP
cord-005478-5iu38pr6	2424	24	(	(	-LRB-
cord-005478-5iu38pr6	2424	25	p=0,421	p=0,421	NNP
cord-005478-5iu38pr6	2424	26	)	)	-RRB-
cord-005478-5iu38pr6	2424	27	.	.	.
cord-005478-5iu38pr6	2425	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2425	2	:	:	:
cord-005478-5iu38pr6	2426	1	Regardless	regardless	RB
cord-005478-5iu38pr6	2426	2	the	the	DT
cord-005478-5iu38pr6	2426	3	different	different	JJ
cord-005478-5iu38pr6	2426	4	transplant	transplant	NN
cord-005478-5iu38pr6	2426	5	scenarios	scenario	NNS
cord-005478-5iu38pr6	2426	6	in	in	IN
cord-005478-5iu38pr6	2426	7	which	which	WDT
cord-005478-5iu38pr6	2426	8	they	-PRON-	PRP
cord-005478-5iu38pr6	2426	9	were	be	VBD
cord-005478-5iu38pr6	2426	10	used	use	VBN
cord-005478-5iu38pr6	2426	11	,	,	,
cord-005478-5iu38pr6	2426	12	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2426	13	and	and	CC
cord-005478-5iu38pr6	2426	14	low	low	JJ
cord-005478-5iu38pr6	2426	15	dose	dose	NN
cord-005478-5iu38pr6	2426	16	ATG	ATG	NNP
cord-005478-5iu38pr6	2426	17	seem	seem	VBP
cord-005478-5iu38pr6	2426	18	to	to	TO
cord-005478-5iu38pr6	2426	19	be	be	VB
cord-005478-5iu38pr6	2426	20	equally	equally	RB
cord-005478-5iu38pr6	2426	21	effective	effective	JJ
cord-005478-5iu38pr6	2426	22	in	in	IN
cord-005478-5iu38pr6	2426	23	the	the	DT
cord-005478-5iu38pr6	2426	24	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2426	25	of	of	IN
cord-005478-5iu38pr6	2426	26	severe	severe	JJ
cord-005478-5iu38pr6	2426	27	forms	form	NNS
cord-005478-5iu38pr6	2426	28	of	of	IN
cord-005478-5iu38pr6	2426	29	acute	acute	JJ
cord-005478-5iu38pr6	2426	30	and	and	CC
cord-005478-5iu38pr6	2426	31	chronic	chronic	JJ
cord-005478-5iu38pr6	2426	32	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2426	33	,	,	,
cord-005478-5iu38pr6	2426	34	offering	offer	VBG
cord-005478-5iu38pr6	2426	35	similar	similar	JJ
cord-005478-5iu38pr6	2426	36	GRFS	grfs	NN
cord-005478-5iu38pr6	2426	37	.	.	.
cord-005478-5iu38pr6	2427	1	Moreover	moreover	RB
cord-005478-5iu38pr6	2427	2	,	,	,
cord-005478-5iu38pr6	2427	3	they	-PRON-	PRP
cord-005478-5iu38pr6	2427	4	show	show	VBP
cord-005478-5iu38pr6	2427	5	similar	similar	JJ
cord-005478-5iu38pr6	2427	6	early	early	JJ
cord-005478-5iu38pr6	2427	7	toxicity	toxicity	NN
cord-005478-5iu38pr6	2427	8	and	and	CC
cord-005478-5iu38pr6	2427	9	rate	rate	NN
cord-005478-5iu38pr6	2427	10	of	of	IN
cord-005478-5iu38pr6	2427	11	infectious	infectious	JJ
cord-005478-5iu38pr6	2427	12	events	event	NNS
cord-005478-5iu38pr6	2427	13	.	.	.
cord-005478-5iu38pr6	2428	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2428	2	:	:	:
cord-005478-5iu38pr6	2428	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2428	4	have	have	VBP
cord-005478-5iu38pr6	2428	5	nothing	nothing	NN
cord-005478-5iu38pr6	2428	6	to	to	TO
cord-005478-5iu38pr6	2428	7	disclose	disclose	VB
cord-005478-5iu38pr6	2428	8	.	.	.
cord-005478-5iu38pr6	2429	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2429	2	:	:	:
cord-005478-5iu38pr6	2430	1	Emapalumab	Emapalumab	NNP
cord-005478-5iu38pr6	2430	2	treatment	treatment	NN
cord-005478-5iu38pr6	2430	3	promoted	promote	VBD
cord-005478-5iu38pr6	2430	4	disease	disease	NN
cord-005478-5iu38pr6	2430	5	control	control	NN
cord-005478-5iu38pr6	2430	6	,	,	,
cord-005478-5iu38pr6	2430	7	blunting	blunt	VBG
cord-005478-5iu38pr6	2430	8	the	the	DT
cord-005478-5iu38pr6	2430	9	exacerbated	exacerbate	VBN
cord-005478-5iu38pr6	2430	10	immune	immune	JJ
cord-005478-5iu38pr6	2430	11	response	response	NN
cord-005478-5iu38pr6	2430	12	typical	typical	JJ
cord-005478-5iu38pr6	2430	13	of	of	IN
cord-005478-5iu38pr6	2430	14	the	the	DT
cord-005478-5iu38pr6	2430	15	disease	disease	NN
cord-005478-5iu38pr6	2430	16	,	,	,
cord-005478-5iu38pr6	2430	17	with	with	IN
cord-005478-5iu38pr6	2430	18	a	a	DT
cord-005478-5iu38pr6	2430	19	favorable	favorable	JJ
cord-005478-5iu38pr6	2430	20	safety	safety	NN
cord-005478-5iu38pr6	2430	21	and	and	CC
cord-005478-5iu38pr6	2430	22	tolerability	tolerability	NN
cord-005478-5iu38pr6	2430	23	profile	profile	NN
cord-005478-5iu38pr6	2430	24	.	.	.
cord-005478-5iu38pr6	2431	1	The	the	DT
cord-005478-5iu38pr6	2431	2	results	result	NNS
cord-005478-5iu38pr6	2431	3	of	of	IN
cord-005478-5iu38pr6	2431	4	the	the	DT
cord-005478-5iu38pr6	2431	5	study	study	NN
cord-005478-5iu38pr6	2431	6	also	also	RB
cord-005478-5iu38pr6	2431	7	suggest	suggest	VBP
cord-005478-5iu38pr6	2431	8	that	that	IN
cord-005478-5iu38pr6	2431	9	emapalumab	emapalumab	NNP
cord-005478-5iu38pr6	2431	10	may	may	MD
cord-005478-5iu38pr6	2431	11	contribute	contribute	VB
cord-005478-5iu38pr6	2431	12	to	to	TO
cord-005478-5iu38pr6	2431	13	optimize	optimize	VB
cord-005478-5iu38pr6	2431	14	post	post	JJ
cord-005478-5iu38pr6	2431	15	-	-	JJ
cord-005478-5iu38pr6	2431	16	transplant	transplant	JJ
cord-005478-5iu38pr6	2431	17	outcome	outcome	NN
cord-005478-5iu38pr6	2431	18	of	of	IN
cord-005478-5iu38pr6	2431	19	patients	patient	NNS
cord-005478-5iu38pr6	2431	20	given	give	VBN
cord-005478-5iu38pr6	2431	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2431	22	.	.	.
cord-005478-5iu38pr6	2432	1	Based	base	VBN
cord-005478-5iu38pr6	2432	2	on	on	IN
cord-005478-5iu38pr6	2432	3	these	these	DT
cord-005478-5iu38pr6	2432	4	data	datum	NNS
cord-005478-5iu38pr6	2432	5	,	,	,
cord-005478-5iu38pr6	2432	6	emapalumab	emapalumab	NNP
cord-005478-5iu38pr6	2432	7	received	receive	VBD
cord-005478-5iu38pr6	2432	8	marketing	marketing	NN
cord-005478-5iu38pr6	2432	9	authorization	authorization	NN
cord-005478-5iu38pr6	2432	10	in	in	IN
cord-005478-5iu38pr6	2432	11	the	the	DT
cord-005478-5iu38pr6	2432	12	US	US	NNP
cord-005478-5iu38pr6	2432	13	from	from	IN
cord-005478-5iu38pr6	2432	14	the	the	DT
cord-005478-5iu38pr6	2432	15	Food	Food	NNP
cord-005478-5iu38pr6	2432	16	and	and	CC
cord-005478-5iu38pr6	2432	17	Drug	Drug	NNP
cord-005478-5iu38pr6	2432	18	Administration	Administration	NNP
cord-005478-5iu38pr6	2432	19	for	for	IN
cord-005478-5iu38pr6	2432	20	the	the	DT
cord-005478-5iu38pr6	2432	21	treatment	treatment	NN
cord-005478-5iu38pr6	2432	22	of	of	IN
cord-005478-5iu38pr6	2432	23	patients	patient	NNS
cord-005478-5iu38pr6	2432	24	with	with	IN
cord-005478-5iu38pr6	2432	25	primary	primary	JJ
cord-005478-5iu38pr6	2432	26	HLH	HLH	NNP
cord-005478-5iu38pr6	2432	27	with	with	IN
cord-005478-5iu38pr6	2432	28	refractory	refractory	JJ
cord-005478-5iu38pr6	2432	29	,	,	,
cord-005478-5iu38pr6	2432	30	recurrent	recurrent	JJ
cord-005478-5iu38pr6	2432	31	or	or	CC
cord-005478-5iu38pr6	2432	32	progressive	progressive	JJ
cord-005478-5iu38pr6	2432	33	disease	disease	NN
cord-005478-5iu38pr6	2432	34	or	or	CC
cord-005478-5iu38pr6	2432	35	intolerance	intolerance	NN
cord-005478-5iu38pr6	2432	36	with	with	IN
cord-005478-5iu38pr6	2432	37	conventional	conventional	JJ
cord-005478-5iu38pr6	2432	38	therapy	therapy	NN
cord-005478-5iu38pr6	2432	39	.	.	.
cord-005478-5iu38pr6	2433	1	Background	background	NN
cord-005478-5iu38pr6	2433	2	:	:	:
cord-005478-5iu38pr6	2434	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2434	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2434	3	stem	stem	NN
cord-005478-5iu38pr6	2434	4	cell	cell	NN
cord-005478-5iu38pr6	2434	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	2434	6	(	(	-LRB-
cord-005478-5iu38pr6	2434	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2434	8	)	)	-RRB-
cord-005478-5iu38pr6	2434	9	is	be	VBZ
cord-005478-5iu38pr6	2434	10	a	a	DT
cord-005478-5iu38pr6	2434	11	potentially	potentially	RB
cord-005478-5iu38pr6	2434	12	curative	curative	JJ
cord-005478-5iu38pr6	2434	13	treatment	treatment	NN
cord-005478-5iu38pr6	2434	14	for	for	IN
cord-005478-5iu38pr6	2434	15	some	some	DT
cord-005478-5iu38pr6	2434	16	inherited	inherit	VBN
cord-005478-5iu38pr6	2434	17	disorders	disorder	NNS
cord-005478-5iu38pr6	2434	18	,	,	,
cord-005478-5iu38pr6	2434	19	including	include	VBG
cord-005478-5iu38pr6	2434	20	selected	select	VBN
cord-005478-5iu38pr6	2434	21	primary	primary	JJ
cord-005478-5iu38pr6	2434	22	immunodeficiencies	immunodeficiency	NNS
cord-005478-5iu38pr6	2434	23	(	(	-LRB-
cord-005478-5iu38pr6	2434	24	PIDs	PIDs	NNP
cord-005478-5iu38pr6	2434	25	)	)	-RRB-
cord-005478-5iu38pr6	2434	26	.	.	.
cord-005478-5iu38pr6	2435	1	In	in	IN
cord-005478-5iu38pr6	2435	2	the	the	DT
cord-005478-5iu38pr6	2435	3	absence	absence	NN
cord-005478-5iu38pr6	2435	4	of	of	IN
cord-005478-5iu38pr6	2435	5	a	a	DT
cord-005478-5iu38pr6	2435	6	wellmatched	wellmatched	NN
cord-005478-5iu38pr6	2435	7	donor	donor	NN
cord-005478-5iu38pr6	2435	8	,	,	,
cord-005478-5iu38pr6	2435	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2435	10	from	from	IN
cord-005478-5iu38pr6	2435	11	a	a	DT
cord-005478-5iu38pr6	2435	12	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2435	13	family	family	NN
cord-005478-5iu38pr6	2435	14	donor	donor	NN
cord-005478-5iu38pr6	2435	15	(	(	-LRB-
cord-005478-5iu38pr6	2435	16	HIFD	HIFD	NNP
cord-005478-5iu38pr6	2435	17	)	)	-RRB-
cord-005478-5iu38pr6	2435	18	may	may	MD
cord-005478-5iu38pr6	2435	19	be	be	VB
cord-005478-5iu38pr6	2435	20	considered	consider	VBN
cord-005478-5iu38pr6	2435	21	.	.	.
cord-005478-5iu38pr6	2436	1	Various	various	JJ
cord-005478-5iu38pr6	2436	2	approaches	approach	NNS
cord-005478-5iu38pr6	2436	3	are	be	VBP
cord-005478-5iu38pr6	2436	4	being	be	VBG
cord-005478-5iu38pr6	2436	5	developed	develop	VBN
cord-005478-5iu38pr6	2436	6	to	to	TO
cord-005478-5iu38pr6	2436	7	mitigate	mitigate	VB
cord-005478-5iu38pr6	2436	8	the	the	DT
cord-005478-5iu38pr6	2436	9	risks	risk	NNS
cord-005478-5iu38pr6	2436	10	of	of	IN
cord-005478-5iu38pr6	2436	11	graft	graft	NN
cord-005478-5iu38pr6	2436	12	failure	failure	NN
cord-005478-5iu38pr6	2436	13	and	and	CC
cord-005478-5iu38pr6	2436	14	graftversus	graftversus	NN
cord-005478-5iu38pr6	2436	15	-	-	HYPH
cord-005478-5iu38pr6	2436	16	host	host	NN
cord-005478-5iu38pr6	2436	17	disease	disease	NN
cord-005478-5iu38pr6	2436	18	(	(	-LRB-
cord-005478-5iu38pr6	2436	19	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2436	20	)	)	-RRB-
cord-005478-5iu38pr6	2436	21	and	and	CC
cord-005478-5iu38pr6	2436	22	to	to	TO
cord-005478-5iu38pr6	2436	23	speed	speed	VB
cord-005478-5iu38pr6	2436	24	-	-	HYPH
cord-005478-5iu38pr6	2436	25	up	up	RP
cord-005478-5iu38pr6	2436	26	immune	immune	JJ
cord-005478-5iu38pr6	2436	27	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2436	28	.	.	.
cord-005478-5iu38pr6	2437	1	Among	among	IN
cord-005478-5iu38pr6	2437	2	those	those	DT
cord-005478-5iu38pr6	2437	3	,	,	,
cord-005478-5iu38pr6	2437	4	high	high	JJ
cord-005478-5iu38pr6	2437	5	-	-	HYPH
cord-005478-5iu38pr6	2437	6	dose	dose	NN
cord-005478-5iu38pr6	2437	7	,	,	,
cord-005478-5iu38pr6	2437	8	post	post	JJ
cord-005478-5iu38pr6	2437	9	-	-	JJ
cord-005478-5iu38pr6	2437	10	transplant	transplant	NN
cord-005478-5iu38pr6	2437	11	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2437	12	(	(	-LRB-
cord-005478-5iu38pr6	2437	13	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2437	14	)	)	-RRB-
cord-005478-5iu38pr6	2437	15	is	be	VBZ
cord-005478-5iu38pr6	2437	16	increasingly	increasingly	RB
cord-005478-5iu38pr6	2437	17	used	use	VBN
cord-005478-5iu38pr6	2437	18	in	in	IN
cord-005478-5iu38pr6	2437	19	adult	adult	NN
cord-005478-5iu38pr6	2437	20	recipients	recipient	NNS
cord-005478-5iu38pr6	2437	21	.	.	.
cord-005478-5iu38pr6	2438	1	However	however	RB
cord-005478-5iu38pr6	2438	2	,	,	,
cord-005478-5iu38pr6	2438	3	data	datum	NNS
cord-005478-5iu38pr6	2438	4	on	on	IN
cord-005478-5iu38pr6	2438	5	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2438	6	in	in	IN
cord-005478-5iu38pr6	2438	7	children	child	NNS
cord-005478-5iu38pr6	2438	8	and	and	CC
cord-005478-5iu38pr6	2438	9	those	those	DT
cord-005478-5iu38pr6	2438	10	with	with	IN
cord-005478-5iu38pr6	2438	11	inherited	inherit	VBN
cord-005478-5iu38pr6	2438	12	disorders	disorder	NNS
cord-005478-5iu38pr6	2438	13	in	in	IN
cord-005478-5iu38pr6	2438	14	particular	particular	JJ
cord-005478-5iu38pr6	2438	15	are	be	VBP
cord-005478-5iu38pr6	2438	16	scarce	scarce	JJ
cord-005478-5iu38pr6	2438	17	.	.	.
cord-005478-5iu38pr6	2439	1	Methods	method	NNS
cord-005478-5iu38pr6	2439	2	:	:	:
cord-005478-5iu38pr6	2439	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2439	4	reviewed	review	VBD
cord-005478-5iu38pr6	2439	5	the	the	DT
cord-005478-5iu38pr6	2439	6	outcome	outcome	NN
cord-005478-5iu38pr6	2439	7	of	of	IN
cord-005478-5iu38pr6	2439	8	27	27	CD
cord-005478-5iu38pr6	2439	9	children	child	NNS
cord-005478-5iu38pr6	2439	10	transplanted	transplant	VBN
cord-005478-5iu38pr6	2439	11	with	with	IN
cord-005478-5iu38pr6	2439	12	HIFD	HIFD	NNP
cord-005478-5iu38pr6	2439	13	and	and	CC
cord-005478-5iu38pr6	2439	14	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2439	15	for	for	IN
cord-005478-5iu38pr6	2439	16	PID	PID	NNP
cord-005478-5iu38pr6	2440	1	(	(	-LRB-
cord-005478-5iu38pr6	2440	2	n=	n=	NNP
cord-005478-5iu38pr6	2440	3	22	22	CD
cord-005478-5iu38pr6	2440	4	)	)	-RRB-
cord-005478-5iu38pr6	2440	5	or	or	CC
cord-005478-5iu38pr6	2440	6	osteopetrosis	osteopetrosis	NNP
cord-005478-5iu38pr6	2441	1	(	(	-LRB-
cord-005478-5iu38pr6	2441	2	n=	n=	NNP
cord-005478-5iu38pr6	2441	3	5	5	CD
cord-005478-5iu38pr6	2441	4	)	)	-RRB-
cord-005478-5iu38pr6	2441	5	in	in	IN
cord-005478-5iu38pr6	2441	6	a	a	DT
cord-005478-5iu38pr6	2441	7	single	single	JJ
cord-005478-5iu38pr6	2441	8	center	center	NN
cord-005478-5iu38pr6	2441	9	.	.	.
cord-005478-5iu38pr6	2442	1	Median	median	JJ
cord-005478-5iu38pr6	2442	2	(	(	-LRB-
cord-005478-5iu38pr6	2442	3	range	range	NN
cord-005478-5iu38pr6	2442	4	)	)	-RRB-
cord-005478-5iu38pr6	2442	5	age	age	NN
cord-005478-5iu38pr6	2442	6	was	be	VBD
cord-005478-5iu38pr6	2442	7	1.5	1.5	CD
cord-005478-5iu38pr6	2442	8	years	year	NNS
cord-005478-5iu38pr6	2442	9	(	(	-LRB-
cord-005478-5iu38pr6	2442	10	0.2	0.2	CD
cord-005478-5iu38pr6	2442	11	to	to	IN
cord-005478-5iu38pr6	2442	12	17	17	CD
cord-005478-5iu38pr6	2442	13	)	)	-RRB-
cord-005478-5iu38pr6	2442	14	)	)	-RRB-
cord-005478-5iu38pr6	2442	15	.	.	.
cord-005478-5iu38pr6	2443	1	Patients	patient	NNS
cord-005478-5iu38pr6	2443	2	in	in	IN
cord-005478-5iu38pr6	2443	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	2443	4	series	series	NN
cord-005478-5iu38pr6	2443	5	had	have	VBD
cord-005478-5iu38pr6	2443	6	major	major	JJ
cord-005478-5iu38pr6	2443	7	risk	risk	NN
cord-005478-5iu38pr6	2443	8	factors	factor	NNS
cord-005478-5iu38pr6	2443	9	for	for	IN
cord-005478-5iu38pr6	2443	10	poor	poor	JJ
cord-005478-5iu38pr6	2443	11	post	post	JJ
cord-005478-5iu38pr6	2443	12	-	-	JJ
cord-005478-5iu38pr6	2443	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2443	14	outcome	outcome	NN
cord-005478-5iu38pr6	2443	15	such	such	JJ
cord-005478-5iu38pr6	2443	16	as	as	IN
cord-005478-5iu38pr6	2443	17	active	active	JJ
cord-005478-5iu38pr6	2443	18	viral	viral	JJ
cord-005478-5iu38pr6	2443	19	infections	infection	NNS
cord-005478-5iu38pr6	2443	20	at	at	IN
cord-005478-5iu38pr6	2443	21	the	the	DT
cord-005478-5iu38pr6	2443	22	time	time	NN
cord-005478-5iu38pr6	2443	23	of	of	IN
cord-005478-5iu38pr6	2443	24	transplantation	transplantation	NN
cord-005478-5iu38pr6	2443	25	(	(	-LRB-
cord-005478-5iu38pr6	2443	26	n=9	n=9	NN
cord-005478-5iu38pr6	2443	27	)	)	-RRB-
cord-005478-5iu38pr6	2443	28	,	,	,
cord-005478-5iu38pr6	2443	29	EBVrelated	EBVrelated	NNP
cord-005478-5iu38pr6	2443	30	lymphoproliferation	lymphoproliferation	NN
cord-005478-5iu38pr6	2443	31	in	in	IN
cord-005478-5iu38pr6	2443	32	partial	partial	JJ
cord-005478-5iu38pr6	2443	33	remission	remission	NN
cord-005478-5iu38pr6	2443	34	(	(	-LRB-
cord-005478-5iu38pr6	2443	35	n=3	n=3	NN
cord-005478-5iu38pr6	2443	36	)	)	-RRB-
cord-005478-5iu38pr6	2443	37	,	,	,
cord-005478-5iu38pr6	2443	38	previous	previous	JJ
cord-005478-5iu38pr6	2443	39	kidney	kidney	NN
cord-005478-5iu38pr6	2443	40	transplant	transplant	NN
cord-005478-5iu38pr6	2443	41	(	(	-LRB-
cord-005478-5iu38pr6	2443	42	n=1	n=1	FW
cord-005478-5iu38pr6	2443	43	)	)	-RRB-
cord-005478-5iu38pr6	2443	44	.	.	.
cord-005478-5iu38pr6	2444	1	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2444	2	with	with	IN
cord-005478-5iu38pr6	2444	3	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2444	4	was	be	VBD
cord-005478-5iu38pr6	2444	5	a	a	DT
cord-005478-5iu38pr6	2444	6	primary	primary	JJ
cord-005478-5iu38pr6	2444	7	(	(	-LRB-
cord-005478-5iu38pr6	2444	8	n=21	n=21	NN
cord-005478-5iu38pr6	2444	9	)	)	-RRB-
cord-005478-5iu38pr6	2444	10	or	or	CC
cord-005478-5iu38pr6	2444	11	a	a	DT
cord-005478-5iu38pr6	2444	12	rescue	rescue	NN
cord-005478-5iu38pr6	2444	13	procedure	procedure	NN
cord-005478-5iu38pr6	2444	14	after	after	IN
cord-005478-5iu38pr6	2444	15	graft	graft	NN
cord-005478-5iu38pr6	2444	16	failure	failure	NN
cord-005478-5iu38pr6	2444	17	(	(	-LRB-
cord-005478-5iu38pr6	2444	18	n=6	n=6	NNP
cord-005478-5iu38pr6	2444	19	)	)	-RRB-
cord-005478-5iu38pr6	2444	20	.	.	.
cord-005478-5iu38pr6	2445	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	2445	2	regimen	regimen	NN
cord-005478-5iu38pr6	2445	3	was	be	VBD
cord-005478-5iu38pr6	2445	4	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2445	5	in	in	IN
cord-005478-5iu38pr6	2445	6	most	most	JJS
cord-005478-5iu38pr6	2445	7	primary	primary	JJ
cord-005478-5iu38pr6	2445	8	HSCTs	hsct	NNS
cord-005478-5iu38pr6	2445	9	and	and	CC
cord-005478-5iu38pr6	2445	10	non	non	JJ
cord-005478-5iu38pr6	2445	11	-	-	JJ
cord-005478-5iu38pr6	2445	12	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2445	13	in	in	IN
cord-005478-5iu38pr6	2445	14	all	all	DT
cord-005478-5iu38pr6	2445	15	rescue	rescue	NN
cord-005478-5iu38pr6	2445	16	procedures	procedure	NNS
cord-005478-5iu38pr6	2445	17	.	.	.
cord-005478-5iu38pr6	2446	1	Results	result	NNS
cord-005478-5iu38pr6	2446	2	:	:	:
cord-005478-5iu38pr6	2447	1	After	after	IN
cord-005478-5iu38pr6	2447	2	a	a	DT
cord-005478-5iu38pr6	2447	3	median	median	JJ
cord-005478-5iu38pr6	2447	4	follow	follow	NN
cord-005478-5iu38pr6	2447	5	-	-	HYPH
cord-005478-5iu38pr6	2447	6	up	up	NN
cord-005478-5iu38pr6	2447	7	of	of	IN
cord-005478-5iu38pr6	2447	8	17.3	17.3	CD
cord-005478-5iu38pr6	2447	9	months	month	NNS
cord-005478-5iu38pr6	2447	10	,	,	,
cord-005478-5iu38pr6	2447	11	24	24	CD
cord-005478-5iu38pr6	2447	12	of	of	IN
cord-005478-5iu38pr6	2447	13	the	the	DT
cord-005478-5iu38pr6	2447	14	27	27	CD
cord-005478-5iu38pr6	2447	15	patients	patient	NNS
cord-005478-5iu38pr6	2447	16	engrafted	engraft	VBN
cord-005478-5iu38pr6	2447	17	.	.	.
cord-005478-5iu38pr6	2448	1	Twenty	twenty	CD
cord-005478-5iu38pr6	2448	2	-	-	HYPH
cord-005478-5iu38pr6	2448	3	one	one	CD
cord-005478-5iu38pr6	2448	4	patients	patient	NNS
cord-005478-5iu38pr6	2448	5	are	be	VBP
cord-005478-5iu38pr6	2448	6	alive	alive	JJ
cord-005478-5iu38pr6	2448	7	and	and	CC
cord-005478-5iu38pr6	2448	8	have	have	VBP
cord-005478-5iu38pr6	2448	9	been	be	VBN
cord-005478-5iu38pr6	2448	10	cured	cure	VBN
cord-005478-5iu38pr6	2448	11	of	of	IN
cord-005478-5iu38pr6	2448	12	the	the	DT
cord-005478-5iu38pr6	2448	13	underlying	underlie	VBG
cord-005478-5iu38pr6	2448	14	disease	disease	NN
cord-005478-5iu38pr6	2448	15	.	.	.
cord-005478-5iu38pr6	2449	1	The	the	DT
cord-005478-5iu38pr6	2449	2	two	two	CD
cord-005478-5iu38pr6	2449	3	-	-	HYPH
cord-005478-5iu38pr6	2449	4	year	year	NN
cord-005478-5iu38pr6	2449	5	overall	overall	JJ
cord-005478-5iu38pr6	2449	6	survival	survival	NN
cord-005478-5iu38pr6	2449	7	rate	rate	NN
cord-005478-5iu38pr6	2449	8	was	be	VBD
cord-005478-5iu38pr6	2449	9	77.7	77.7	CD
cord-005478-5iu38pr6	2449	10	%	%	NN
cord-005478-5iu38pr6	2449	11	.	.	.
cord-005478-5iu38pr6	2450	1	The	the	DT
cord-005478-5iu38pr6	2450	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2450	3	incidences	incidence	NNS
cord-005478-5iu38pr6	2450	4	of	of	IN
cord-005478-5iu38pr6	2450	5	acute	acute	JJ
cord-005478-5iu38pr6	2450	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2450	7	grade	grade	NN
cord-005478-5iu38pr6	2450	8	≥	≥	NNP
cord-005478-5iu38pr6	2450	9	II	II	NNP
cord-005478-5iu38pr6	2450	10	,	,	,
cord-005478-5iu38pr6	2450	11	chronic	chronic	JJ
cord-005478-5iu38pr6	2450	12	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2450	13	and	and	CC
cord-005478-5iu38pr6	2450	14	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	2450	15	disease	disease	NN
cord-005478-5iu38pr6	2450	16	were	be	VBD
cord-005478-5iu38pr6	2450	17	49	49	CD
cord-005478-5iu38pr6	2450	18	%	%	NN
cord-005478-5iu38pr6	2450	19	,	,	,
cord-005478-5iu38pr6	2450	20	26.6	26.6	CD
cord-005478-5iu38pr6	2450	21	%	%	NN
cord-005478-5iu38pr6	2450	22	,	,	,
cord-005478-5iu38pr6	2450	23	and	and	CC
cord-005478-5iu38pr6	2450	24	26.5	26.5	CD
cord-005478-5iu38pr6	2450	25	%	%	NN
cord-005478-5iu38pr6	2450	26	,	,	,
cord-005478-5iu38pr6	2450	27	respectively	respectively	RB
cord-005478-5iu38pr6	2450	28	.	.	.
cord-005478-5iu38pr6	2451	1	There	there	EX
cord-005478-5iu38pr6	2451	2	were	be	VBD
cord-005478-5iu38pr6	2451	3	only	only	RB
cord-005478-5iu38pr6	2451	4	two	two	CD
cord-005478-5iu38pr6	2451	5	cases	case	NNS
cord-005478-5iu38pr6	2451	6	of	of	IN
cord-005478-5iu38pr6	2451	7	grade	grade	NN
cord-005478-5iu38pr6	2451	8	III	iii	CD
cord-005478-5iu38pr6	2451	9	acute	acute	JJ
cord-005478-5iu38pr6	2451	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2451	11	,	,	,
cord-005478-5iu38pr6	2451	12	all	all	DT
cord-005478-5iu38pr6	2451	13	cases	case	NNS
cord-005478-5iu38pr6	2451	14	of	of	IN
cord-005478-5iu38pr6	2451	15	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2451	16	were	be	VBD
cord-005478-5iu38pr6	2451	17	limited	limit	VBN
cord-005478-5iu38pr6	2451	18	and	and	CC
cord-005478-5iu38pr6	2451	19	allowed	allow	VBN
cord-005478-5iu38pr6	2451	20	to	to	TO
cord-005478-5iu38pr6	2451	21	stop	stop	VB
cord-005478-5iu38pr6	2451	22	systemic	systemic	JJ
cord-005478-5iu38pr6	2451	23	immune	immune	JJ
cord-005478-5iu38pr6	2451	24	-	-	HYPH
cord-005478-5iu38pr6	2451	25	supression	supression	NN
cord-005478-5iu38pr6	2451	26	,	,	,
cord-005478-5iu38pr6	2451	27	autoimmunity	autoimmunity	NN
cord-005478-5iu38pr6	2451	28	consisted	consist	VBD
cord-005478-5iu38pr6	2451	29	in	in	IN
cord-005478-5iu38pr6	2451	30	2	2	CD
cord-005478-5iu38pr6	2451	31	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	2451	32	hemolytic	hemolytic	JJ
cord-005478-5iu38pr6	2451	33	anemia	anemia	NN
cord-005478-5iu38pr6	2451	34	in	in	IN
cord-005478-5iu38pr6	2451	35	remission	remission	NN
cord-005478-5iu38pr6	2451	36	at	at	IN
cord-005478-5iu38pr6	2451	37	last	last	JJ
cord-005478-5iu38pr6	2451	38	follow	follow	NN
cord-005478-5iu38pr6	2451	39	up	up	RB
cord-005478-5iu38pr6	2451	40	,	,	,
cord-005478-5iu38pr6	2451	41	1	1	CD
cord-005478-5iu38pr6	2451	42	vitiligo	vitiligo	NN
cord-005478-5iu38pr6	2451	43	and	and	CC
cord-005478-5iu38pr6	2451	44	2	2	CD
cord-005478-5iu38pr6	2451	45	thyroiditis	thyroiditis	NN
cord-005478-5iu38pr6	2451	46	.	.	.
cord-005478-5iu38pr6	2452	1	The	the	DT
cord-005478-5iu38pr6	2452	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2452	3	incidence	incidence	NN
cord-005478-5iu38pr6	2452	4	of	of	IN
cord-005478-5iu38pr6	2452	5	blood	blood	NN
cord-005478-5iu38pr6	2452	6	viral	viral	JJ
cord-005478-5iu38pr6	2452	7	replication	replication	NN
cord-005478-5iu38pr6	2452	8	and	and	CC
cord-005478-5iu38pr6	2452	9	life	life	NN
cord-005478-5iu38pr6	2452	10	-	-	HYPH
cord-005478-5iu38pr6	2452	11	threatening	threaten	VBG
cord-005478-5iu38pr6	2452	12	viral	viral	JJ
cord-005478-5iu38pr6	2452	13	events	event	NNS
cord-005478-5iu38pr6	2452	14	were	be	VBD
cord-005478-5iu38pr6	2452	15	58	58	CD
cord-005478-5iu38pr6	2452	16	%	%	NN
cord-005478-5iu38pr6	2452	17	and	and	CC
cord-005478-5iu38pr6	2452	18	15.5	15.5	CD
cord-005478-5iu38pr6	2452	19	%	%	NN
cord-005478-5iu38pr6	2452	20	,	,	,
cord-005478-5iu38pr6	2452	21	respectively	respectively	RB
cord-005478-5iu38pr6	2452	22	.	.	.
cord-005478-5iu38pr6	2453	1	There	there	EX
cord-005478-5iu38pr6	2453	2	was	be	VBD
cord-005478-5iu38pr6	2453	3	evidence	evidence	NN
cord-005478-5iu38pr6	2453	4	of	of	IN
cord-005478-5iu38pr6	2453	5	early	early	JJ
cord-005478-5iu38pr6	2453	6	T	t	NN
cord-005478-5iu38pr6	2453	7	cell	cell	NN
cord-005478-5iu38pr6	2453	8	immune	immune	NN
cord-005478-5iu38pr6	2453	9	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2453	10	including	include	VBG
cord-005478-5iu38pr6	2453	11	early	early	JJ
cord-005478-5iu38pr6	2453	12	anti	anti	JJ
cord-005478-5iu38pr6	2453	13	-	-	JJ
cord-005478-5iu38pr6	2453	14	viral	viral	JJ
cord-005478-5iu38pr6	2453	15	responses	response	NNS
cord-005478-5iu38pr6	2453	16	.	.	.
cord-005478-5iu38pr6	2454	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2454	2	:	:	:
cord-005478-5iu38pr6	2455	1	In	in	IN
cord-005478-5iu38pr6	2455	2	the	the	DT
cord-005478-5iu38pr6	2455	3	absence	absence	NN
cord-005478-5iu38pr6	2455	4	of	of	IN
cord-005478-5iu38pr6	2455	5	an	an	DT
cord-005478-5iu38pr6	2455	6	HLA	HLA	NNP
cord-005478-5iu38pr6	2455	7	-	-	HYPH
cord-005478-5iu38pr6	2455	8	identical	identical	JJ
cord-005478-5iu38pr6	2455	9	donor	donor	NN
cord-005478-5iu38pr6	2455	10	,	,	,
cord-005478-5iu38pr6	2455	11	HIFD	HIFD	NNP
cord-005478-5iu38pr6	2455	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2455	13	with	with	IN
cord-005478-5iu38pr6	2455	14	PTCY	PTCY	NNP
cord-005478-5iu38pr6	2455	15	is	be	VBZ
cord-005478-5iu38pr6	2455	16	a	a	DT
cord-005478-5iu38pr6	2455	17	viable	viable	JJ
cord-005478-5iu38pr6	2455	18	option	option	NN
cord-005478-5iu38pr6	2455	19	for	for	IN
cord-005478-5iu38pr6	2455	20	patients	patient	NNS
cord-005478-5iu38pr6	2455	21	with	with	IN
cord-005478-5iu38pr6	2455	22	life	life	NN
cord-005478-5iu38pr6	2455	23	-	-	HYPH
cord-005478-5iu38pr6	2455	24	threatening	threaten	VBG
cord-005478-5iu38pr6	2455	25	inherited	inherit	VBN
cord-005478-5iu38pr6	2455	26	disorders	disorder	NNS
cord-005478-5iu38pr6	2455	27	.	.	.
cord-005478-5iu38pr6	2456	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2456	2	:	:	:
cord-005478-5iu38pr6	2456	3	nothing	nothing	NN
cord-005478-5iu38pr6	2456	4	to	to	TO
cord-005478-5iu38pr6	2456	5	declare	declare	VB
cord-005478-5iu38pr6	2456	6	Background	background	NN
cord-005478-5iu38pr6	2456	7	:	:	:
cord-005478-5iu38pr6	2457	1	Griscelli	Griscelli	NNP
cord-005478-5iu38pr6	2457	2	Syndrome	Syndrome	NNP
cord-005478-5iu38pr6	2457	3	(	(	-LRB-
cord-005478-5iu38pr6	2457	4	GS	GS	NNP
cord-005478-5iu38pr6	2457	5	)	)	-RRB-
cord-005478-5iu38pr6	2457	6	is	be	VBZ
cord-005478-5iu38pr6	2457	7	a	a	DT
cord-005478-5iu38pr6	2457	8	very	very	RB
cord-005478-5iu38pr6	2457	9	rare	rare	JJ
cord-005478-5iu38pr6	2457	10	autosomal	autosomal	JJ
cord-005478-5iu38pr6	2457	11	recessive	recessive	JJ
cord-005478-5iu38pr6	2457	12	disease	disease	NN
cord-005478-5iu38pr6	2457	13	,	,	,
cord-005478-5iu38pr6	2457	14	characterized	characterize	VBN
cord-005478-5iu38pr6	2457	15	by	by	IN
cord-005478-5iu38pr6	2457	16	skin	skin	NN
cord-005478-5iu38pr6	2457	17	hypopigmentation	hypopigmentation	NN
cord-005478-5iu38pr6	2457	18	and	and	CC
cord-005478-5iu38pr6	2457	19	silvery	silvery	JJ
cord-005478-5iu38pr6	2457	20	-	-	HYPH
cord-005478-5iu38pr6	2457	21	gray	gray	JJ
cord-005478-5iu38pr6	2457	22	hair	hair	NN
cord-005478-5iu38pr6	2457	23	.	.	.
cord-005478-5iu38pr6	2458	1	GS	GS	NNP
cord-005478-5iu38pr6	2458	2	type	type	NN
cord-005478-5iu38pr6	2458	3	2	2	CD
cord-005478-5iu38pr6	2458	4	(	(	-LRB-
cord-005478-5iu38pr6	2458	5	GS2	GS2	NNP
cord-005478-5iu38pr6	2458	6	)	)	-RRB-
cord-005478-5iu38pr6	2458	7	patients	patient	NNS
cord-005478-5iu38pr6	2458	8	suffer	suffer	VBP
cord-005478-5iu38pr6	2458	9	immunodeficiency	immunodeficiency	NN
cord-005478-5iu38pr6	2458	10	and	and	CC
cord-005478-5iu38pr6	2458	11	potentially	potentially	RB
cord-005478-5iu38pr6	2458	12	fatal	fatal	JJ
cord-005478-5iu38pr6	2458	13	episodes	episode	NNS
cord-005478-5iu38pr6	2458	14	of	of	IN
cord-005478-5iu38pr6	2458	15	macrophage	macrophage	NN
cord-005478-5iu38pr6	2458	16	activation	activation	NN
cord-005478-5iu38pr6	2458	17	known	know	VBN
cord-005478-5iu38pr6	2458	18	as	as	IN
cord-005478-5iu38pr6	2458	19	accelerated	accelerate	VBN
cord-005478-5iu38pr6	2458	20	phases	phase	NNS
cord-005478-5iu38pr6	2458	21	during	during	IN
cord-005478-5iu38pr6	2458	22	early	early	JJ
cord-005478-5iu38pr6	2458	23	childhood	childhood	NN
cord-005478-5iu38pr6	2458	24	.	.	.
cord-005478-5iu38pr6	2459	1	The	the	DT
cord-005478-5iu38pr6	2459	2	only	only	JJ
cord-005478-5iu38pr6	2459	3	curative	curative	JJ
cord-005478-5iu38pr6	2459	4	treatment	treatment	NN
cord-005478-5iu38pr6	2459	5	modality	modality	NN
cord-005478-5iu38pr6	2459	6	for	for	IN
cord-005478-5iu38pr6	2459	7	these	these	DT
cord-005478-5iu38pr6	2459	8	patients	patient	NNS
cord-005478-5iu38pr6	2459	9	is	be	VBZ
cord-005478-5iu38pr6	2459	10	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2459	11	Hematopoietic	Hematopoietic	NNP
cord-005478-5iu38pr6	2459	12	Stem	Stem	NNP
cord-005478-5iu38pr6	2459	13	Cell	cell	NN
cord-005478-5iu38pr6	2459	14	Transplantation	transplantation	NN
cord-005478-5iu38pr6	2459	15	(	(	-LRB-
cord-005478-5iu38pr6	2459	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2459	17	)	)	-RRB-
cord-005478-5iu38pr6	2459	18	.	.	.
cord-005478-5iu38pr6	2460	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2460	2	report	report	VBP
cord-005478-5iu38pr6	2460	3	the	the	DT
cord-005478-5iu38pr6	2460	4	outcome	outcome	NN
cord-005478-5iu38pr6	2460	5	of	of	IN
cord-005478-5iu38pr6	2460	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2460	7	in	in	IN
cord-005478-5iu38pr6	2460	8	35	35	CD
cord-005478-5iu38pr6	2460	9	children	child	NNS
cord-005478-5iu38pr6	2460	10	with	with	IN
cord-005478-5iu38pr6	2460	11	GS2	GS2	NNP
cord-005478-5iu38pr6	2460	12	.	.	.
cord-005478-5iu38pr6	2461	1	To	to	IN
cord-005478-5iu38pr6	2461	2	date	date	NN
cord-005478-5iu38pr6	2461	3	,	,	,
cord-005478-5iu38pr6	2461	4	this	this	DT
cord-005478-5iu38pr6	2461	5	is	be	VBZ
cord-005478-5iu38pr6	2461	6	the	the	DT
cord-005478-5iu38pr6	2461	7	largest	large	JJS
cord-005478-5iu38pr6	2461	8	cohort	cohort	NN
cord-005478-5iu38pr6	2461	9	of	of	IN
cord-005478-5iu38pr6	2461	10	GS	GS	NNP
cord-005478-5iu38pr6	2461	11	patients	patient	NNS
cord-005478-5iu38pr6	2461	12	who	who	WP
cord-005478-5iu38pr6	2461	13	have	have	VBP
cord-005478-5iu38pr6	2461	14	undergone	undergo	VBN
cord-005478-5iu38pr6	2461	15	transplantation	transplantation	NN
cord-005478-5iu38pr6	2461	16	at	at	IN
cord-005478-5iu38pr6	2461	17	a	a	DT
cord-005478-5iu38pr6	2461	18	single	single	JJ
cord-005478-5iu38pr6	2461	19	center	center	NN
cord-005478-5iu38pr6	2461	20	.	.	.
cord-005478-5iu38pr6	2462	1	Methods	method	NNS
cord-005478-5iu38pr6	2462	2	:	:	:
cord-005478-5iu38pr6	2462	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2462	4	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	2462	5	reviewed	review	VBD
cord-005478-5iu38pr6	2462	6	35	35	CD
cord-005478-5iu38pr6	2462	7	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2462	8	patients	patient	NNS
cord-005478-5iu38pr6	2462	9	with	with	IN
cord-005478-5iu38pr6	2462	10	GS2	GS2	NNP
cord-005478-5iu38pr6	2462	11	who	who	WP
cord-005478-5iu38pr6	2462	12	underwent	undergo	VBD
cord-005478-5iu38pr6	2462	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2462	14	at	at	IN
cord-005478-5iu38pr6	2462	15	our	-PRON-	PRP$
cord-005478-5iu38pr6	2462	16	institution	institution	NN
cord-005478-5iu38pr6	2462	17	between	between	IN
cord-005478-5iu38pr6	2462	18	January	January	NNP
cord-005478-5iu38pr6	2462	19	1993-December	1993-december	CD
cord-005478-5iu38pr6	2462	20	2017	2017	CD
cord-005478-5iu38pr6	2462	21	.	.	.
cord-005478-5iu38pr6	2463	1	Median	median	JJ
cord-005478-5iu38pr6	2463	2	age	age	NN
cord-005478-5iu38pr6	2463	3	at	at	IN
cord-005478-5iu38pr6	2463	4	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2463	5	and	and	CC
cord-005478-5iu38pr6	2463	6	at	at	IN
cord-005478-5iu38pr6	2463	7	transplant	transplant	NN
cord-005478-5iu38pr6	2463	8	was	be	VBD
cord-005478-5iu38pr6	2463	9	0.3	0.3	CD
cord-005478-5iu38pr6	2463	10	(	(	-LRB-
cord-005478-5iu38pr6	2463	11	0	0	CD
cord-005478-5iu38pr6	2463	12	-	-	SYM
cord-005478-5iu38pr6	2463	13	12	12	CD
cord-005478-5iu38pr6	2463	14	)	)	-RRB-
cord-005478-5iu38pr6	2463	15	and	and	CC
cord-005478-5iu38pr6	2463	16	0.9	0.9	CD
cord-005478-5iu38pr6	2463	17	(	(	-LRB-
cord-005478-5iu38pr6	2463	18	0.3	0.3	CD
cord-005478-5iu38pr6	2463	19	-	-	SYM
cord-005478-5iu38pr6	2463	20	15.1	15.1	CD
cord-005478-5iu38pr6	2463	21	)	)	-RRB-
cord-005478-5iu38pr6	2463	22	years	year	NNS
cord-005478-5iu38pr6	2463	23	respectively	respectively	RB
cord-005478-5iu38pr6	2463	24	.	.	.
cord-005478-5iu38pr6	2464	1	Prior	prior	RB
cord-005478-5iu38pr6	2464	2	to	to	IN
cord-005478-5iu38pr6	2464	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2464	4	,	,	,
cord-005478-5iu38pr6	2464	5	28	28	CD
cord-005478-5iu38pr6	2464	6	(	(	-LRB-
cord-005478-5iu38pr6	2464	7	80	80	CD
cord-005478-5iu38pr6	2464	8	%	%	NN
cord-005478-5iu38pr6	2464	9	)	)	-RRB-
cord-005478-5iu38pr6	2464	10	and	and	CC
cord-005478-5iu38pr6	2464	11	16	16	CD
cord-005478-5iu38pr6	2464	12	(	(	-LRB-
cord-005478-5iu38pr6	2464	13	46	46	CD
cord-005478-5iu38pr6	2464	14	%	%	NN
cord-005478-5iu38pr6	2464	15	)	)	-RRB-
cord-005478-5iu38pr6	2464	16	patients	patient	NNS
cord-005478-5iu38pr6	2464	17	had	have	VBD
cord-005478-5iu38pr6	2464	18	life	life	NN
cord-005478-5iu38pr6	2464	19	-	-	HYPH
cord-005478-5iu38pr6	2464	20	threatening	threaten	VBG
cord-005478-5iu38pr6	2464	21	accelerated	accelerate	VBN
cord-005478-5iu38pr6	2464	22	phases	phase	NNS
cord-005478-5iu38pr6	2464	23	(	(	-LRB-
cord-005478-5iu38pr6	2464	24	HLH	HLH	NNP
cord-005478-5iu38pr6	2464	25	)	)	-RRB-
cord-005478-5iu38pr6	2464	26	and	and	CC
cord-005478-5iu38pr6	2464	27	CNS	CNS	NNP
cord-005478-5iu38pr6	2464	28	involvement	involvement	NN
cord-005478-5iu38pr6	2464	29	respectively	respectively	RB
cord-005478-5iu38pr6	2464	30	.	.	.
cord-005478-5iu38pr6	2465	1	All	all	DT
cord-005478-5iu38pr6	2465	2	such	such	JJ
cord-005478-5iu38pr6	2465	3	patients	patient	NNS
cord-005478-5iu38pr6	2465	4	were	be	VBD
cord-005478-5iu38pr6	2465	5	treated	treat	VBN
cord-005478-5iu38pr6	2465	6	with	with	IN
cord-005478-5iu38pr6	2465	7	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2465	8	and	and	CC
cord-005478-5iu38pr6	2465	9	achieved	achieve	VBD
cord-005478-5iu38pr6	2465	10	remission	remission	NN
cord-005478-5iu38pr6	2465	11	at	at	IN
cord-005478-5iu38pr6	2465	12	the	the	DT
cord-005478-5iu38pr6	2465	13	time	time	NN
cord-005478-5iu38pr6	2465	14	of	of	IN
cord-005478-5iu38pr6	2465	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2465	16	.	.	.
cord-005478-5iu38pr6	2466	1	The	the	DT
cord-005478-5iu38pr6	2466	2	source	source	NN
cord-005478-5iu38pr6	2466	3	of	of	IN
cord-005478-5iu38pr6	2466	4	grafts	graft	NNS
cord-005478-5iu38pr6	2466	5	was	be	VBD
cord-005478-5iu38pr6	2466	6	matched	match	VBN
cord-005478-5iu38pr6	2466	7	related	relate	VBN
cord-005478-5iu38pr6	2466	8	marrows	marrow	NNS
cord-005478-5iu38pr6	2466	9	in	in	IN
cord-005478-5iu38pr6	2466	10	19	19	CD
cord-005478-5iu38pr6	2466	11	(	(	-LRB-
cord-005478-5iu38pr6	2466	12	54.3	54.3	CD
cord-005478-5iu38pr6	2466	13	%	%	NN
cord-005478-5iu38pr6	2466	14	)	)	-RRB-
cord-005478-5iu38pr6	2466	15	pts	pts	NN
cord-005478-5iu38pr6	2466	16	and	and	CC
cord-005478-5iu38pr6	2466	17	partially	partially	RB
cord-005478-5iu38pr6	2466	18	mismatched	mismatched	JJ
cord-005478-5iu38pr6	2466	19	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2466	20	cord	cord	NN
cord-005478-5iu38pr6	2466	21	in	in	IN
cord-005478-5iu38pr6	2466	22	14	14	CD
cord-005478-5iu38pr6	2466	23	(	(	-LRB-
cord-005478-5iu38pr6	2466	24	40	40	CD
cord-005478-5iu38pr6	2466	25	%	%	NN
cord-005478-5iu38pr6	2466	26	)	)	-RRB-
cord-005478-5iu38pr6	2466	27	pts	pts	NN
cord-005478-5iu38pr6	2466	28	.	.	.
cord-005478-5iu38pr6	2467	1	Two	two	CD
cord-005478-5iu38pr6	2467	2	patients	patient	NNS
cord-005478-5iu38pr6	2467	3	received	receive	VBD
cord-005478-5iu38pr6	2467	4	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2467	5	and	and	CC
cord-005478-5iu38pr6	2467	6	matched	match	VBD
cord-005478-5iu38pr6	2467	7	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2467	8	marrows	marrow	NNS
cord-005478-5iu38pr6	2467	9	respectively	respectively	RB
cord-005478-5iu38pr6	2467	10	.	.	.
cord-005478-5iu38pr6	2468	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	2468	2	regimens	regimen	NNS
cord-005478-5iu38pr6	2468	3	were	be	VBD
cord-005478-5iu38pr6	2468	4	myloablative	myloablative	JJ
cord-005478-5iu38pr6	2468	5	doses	dose	NNS
cord-005478-5iu38pr6	2468	6	of	of	IN
cord-005478-5iu38pr6	2468	7	busulfan	busulfan	NN
cord-005478-5iu38pr6	2468	8	/	/	,
cord-005478-5iu38pr6	2468	9	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2468	10	and	and	CC
cord-005478-5iu38pr6	2468	11	busulfan	busulfan	NN
cord-005478-5iu38pr6	2468	12	/	/	SYM
cord-005478-5iu38pr6	2468	13	fludaribine	fludaribine	NN
cord-005478-5iu38pr6	2468	14	in	in	IN
cord-005478-5iu38pr6	2468	15	27	27	CD
cord-005478-5iu38pr6	2468	16	(	(	-LRB-
cord-005478-5iu38pr6	2468	17	77	77	CD
cord-005478-5iu38pr6	2468	18	%	%	NN
cord-005478-5iu38pr6	2468	19	)	)	-RRB-
cord-005478-5iu38pr6	2468	20	and	and	CC
cord-005478-5iu38pr6	2468	21	8(23	8(23	CD
cord-005478-5iu38pr6	2468	22	%	%	NN
cord-005478-5iu38pr6	2468	23	)	)	-RRB-
cord-005478-5iu38pr6	2468	24	patients	patient	NNS
cord-005478-5iu38pr6	2468	25	respectively	respectively	RB
cord-005478-5iu38pr6	2468	26	.	.	.
cord-005478-5iu38pr6	2469	1	All	all	DT
cord-005478-5iu38pr6	2469	2	patients	patient	NNS
cord-005478-5iu38pr6	2469	3	received	receive	VBD
cord-005478-5iu38pr6	2469	4	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2469	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2469	6	.	.	.
cord-005478-5iu38pr6	2470	1	Growth	growth	NN
cord-005478-5iu38pr6	2470	2	factors	factor	NNS
cord-005478-5iu38pr6	2470	3	were	be	VBD
cord-005478-5iu38pr6	2470	4	administered	administer	VBN
cord-005478-5iu38pr6	2470	5	in	in	IN
cord-005478-5iu38pr6	2470	6	33	33	CD
cord-005478-5iu38pr6	2470	7	(	(	-LRB-
cord-005478-5iu38pr6	2470	8	94.3	94.3	CD
cord-005478-5iu38pr6	2470	9	%	%	NN
cord-005478-5iu38pr6	2470	10	)	)	-RRB-
cord-005478-5iu38pr6	2470	11	and	and	CC
cord-005478-5iu38pr6	2470	12	median	median	JJ
cord-005478-5iu38pr6	2470	13	CD34	CD34	NNP
cord-005478-5iu38pr6	2470	14	dose	dose	NN
cord-005478-5iu38pr6	2470	15	used	use	VBN
cord-005478-5iu38pr6	2470	16	was	be	VBD
cord-005478-5iu38pr6	2470	17	5.46	5.46	CD
cord-005478-5iu38pr6	2470	18	(	(	-LRB-
cord-005478-5iu38pr6	2470	19	2.14	2.14	CD
cord-005478-5iu38pr6	2470	20	-	-	SYM
cord-005478-5iu38pr6	2470	21	11.94	11.94	CD
cord-005478-5iu38pr6	2470	22	)	)	-RRB-
cord-005478-5iu38pr6	2470	23	10	10	CD
cord-005478-5iu38pr6	2470	24	^	^	SYM
cord-005478-5iu38pr6	2470	25	6	6	CD
cord-005478-5iu38pr6	2470	26	and	and	CC
cord-005478-5iu38pr6	2470	27	5.45	5.45	CD
cord-005478-5iu38pr6	2470	28	(	(	-LRB-
cord-005478-5iu38pr6	2470	29	1.8	1.8	CD
cord-005478-5iu38pr6	2470	30	-	-	SYM
cord-005478-5iu38pr6	2470	31	13	13	CD
cord-005478-5iu38pr6	2470	32	.5	.5	CD
cord-005478-5iu38pr6	2470	33	)	)	-RRB-
cord-005478-5iu38pr6	2471	1	10	10	CD
cord-005478-5iu38pr6	2471	2	^	^	SYM
cord-005478-5iu38pr6	2471	3	5	5	CD
cord-005478-5iu38pr6	2471	4	per	per	IN
cord-005478-5iu38pr6	2471	5	Kg	Kg	NNP
cord-005478-5iu38pr6	2471	6	of	of	IN
cord-005478-5iu38pr6	2471	7	body	body	NN
cord-005478-5iu38pr6	2471	8	weight	weight	NN
cord-005478-5iu38pr6	2471	9	for	for	IN
cord-005478-5iu38pr6	2471	10	marrow	marrow	NN
cord-005478-5iu38pr6	2471	11	and	and	CC
cord-005478-5iu38pr6	2471	12	cord	cord	NN
cord-005478-5iu38pr6	2471	13	respectively	respectively	RB
cord-005478-5iu38pr6	2471	14	.	.	.
cord-005478-5iu38pr6	2472	1	Results	result	NNS
cord-005478-5iu38pr6	2472	2	:	:	:
cord-005478-5iu38pr6	2473	1	Post	post	JJ
cord-005478-5iu38pr6	2473	2	infusion	infusion	NN
cord-005478-5iu38pr6	2473	3	rate	rate	NN
cord-005478-5iu38pr6	2473	4	of	of	IN
cord-005478-5iu38pr6	2473	5	engraftment	engraftment	NN
cord-005478-5iu38pr6	2473	6	was	be	VBD
cord-005478-5iu38pr6	2473	7	88.6	88.6	CD
cord-005478-5iu38pr6	2473	8	%	%	NN
cord-005478-5iu38pr6	2473	9	(	(	-LRB-
cord-005478-5iu38pr6	2473	10	31	31	CD
cord-005478-5iu38pr6	2473	11	cases	case	NNS
cord-005478-5iu38pr6	2473	12	)	)	-RRB-
cord-005478-5iu38pr6	2473	13	with	with	IN
cord-005478-5iu38pr6	2473	14	median	median	JJ
cord-005478-5iu38pr6	2473	15	time	time	NN
cord-005478-5iu38pr6	2473	16	to	to	IN
cord-005478-5iu38pr6	2473	17	neutrophil	neutrophil	NN
cord-005478-5iu38pr6	2473	18	and	and	CC
cord-005478-5iu38pr6	2473	19	platelets	platelet	NNS
cord-005478-5iu38pr6	2473	20	recovery	recovery	NN
cord-005478-5iu38pr6	2473	21	were	be	VBD
cord-005478-5iu38pr6	2473	22	15	15	CD
cord-005478-5iu38pr6	2473	23	(	(	-LRB-
cord-005478-5iu38pr6	2473	24	8	8	CD
cord-005478-5iu38pr6	2473	25	-	-	SYM
cord-005478-5iu38pr6	2473	26	30	30	CD
cord-005478-5iu38pr6	2473	27	)	)	-RRB-
cord-005478-5iu38pr6	2473	28	and	and	CC
cord-005478-5iu38pr6	2473	29	29	29	CD
cord-005478-5iu38pr6	2473	30	(	(	-LRB-
cord-005478-5iu38pr6	2473	31	14	14	CD
cord-005478-5iu38pr6	2473	32	-	-	SYM
cord-005478-5iu38pr6	2473	33	61	61	CD
cord-005478-5iu38pr6	2473	34	)	)	-RRB-
cord-005478-5iu38pr6	2473	35	days	day	NNS
cord-005478-5iu38pr6	2473	36	respectively	respectively	RB
cord-005478-5iu38pr6	2473	37	.	.	.
cord-005478-5iu38pr6	2474	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2474	2	incidence	incidence	NN
cord-005478-5iu38pr6	2474	3	of	of	IN
cord-005478-5iu38pr6	2474	4	acute	acute	JJ
cord-005478-5iu38pr6	2474	5	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2474	6	was	be	VBD
cord-005478-5iu38pr6	2474	7	28.6	28.6	CD
cord-005478-5iu38pr6	2474	8	%	%	NN
cord-005478-5iu38pr6	2474	9	(	(	-LRB-
cord-005478-5iu38pr6	2474	10	10	10	CD
cord-005478-5iu38pr6	2474	11	)	)	-RRB-
cord-005478-5iu38pr6	2474	12	,	,	,
cord-005478-5iu38pr6	2474	13	with	with	IN
cord-005478-5iu38pr6	2474	14	an	an	DT
cord-005478-5iu38pr6	2474	15	overall	overall	JJ
cord-005478-5iu38pr6	2474	16	Grade	grade	NN
cord-005478-5iu38pr6	2474	17	of	of	IN
cord-005478-5iu38pr6	2474	18	I	I	NNP
cord-005478-5iu38pr6	2474	19	,	,	,
cord-005478-5iu38pr6	2474	20	II	II	NNP
cord-005478-5iu38pr6	2474	21	and	and	CC
cord-005478-5iu38pr6	2474	22	IV	IV	NNP
cord-005478-5iu38pr6	2474	23	as	as	IN
cord-005478-5iu38pr6	2474	24	20	20	CD
cord-005478-5iu38pr6	2474	25	%	%	NN
cord-005478-5iu38pr6	2474	26	,	,	,
cord-005478-5iu38pr6	2474	27	60	60	CD
cord-005478-5iu38pr6	2474	28	%	%	NN
cord-005478-5iu38pr6	2474	29	and	and	CC
cord-005478-5iu38pr6	2474	30	20	20	CD
cord-005478-5iu38pr6	2474	31	%	%	NN
cord-005478-5iu38pr6	2474	32	respectively	respectively	RB
cord-005478-5iu38pr6	2474	33	.	.	.
cord-005478-5iu38pr6	2475	1	The	the	DT
cord-005478-5iu38pr6	2475	2	post	post	JJ
cord-005478-5iu38pr6	2475	3	-	-	JJ
cord-005478-5iu38pr6	2475	4	transplant	transplant	NN
cord-005478-5iu38pr6	2475	5	course	course	NN
cord-005478-5iu38pr6	2475	6	was	be	VBD
cord-005478-5iu38pr6	2475	7	complicated	complicate	VBN
cord-005478-5iu38pr6	2475	8	by	by	IN
cord-005478-5iu38pr6	2475	9	CMV	CMV	NNP
cord-005478-5iu38pr6	2475	10	infection	infection	NN
cord-005478-5iu38pr6	2475	11	,	,	,
cord-005478-5iu38pr6	2475	12	EBV	EBV	NNP
cord-005478-5iu38pr6	2475	13	viremia	viremia	NN
cord-005478-5iu38pr6	2475	14	and	and	CC
cord-005478-5iu38pr6	2475	15	veno	veno	NNP
cord-005478-5iu38pr6	2475	16	-	-	HYPH
cord-005478-5iu38pr6	2475	17	occlussive	occlussive	JJ
cord-005478-5iu38pr6	2475	18	disease	disease	NN
cord-005478-5iu38pr6	2475	19	in	in	IN
cord-005478-5iu38pr6	2475	20	14(40	14(40	CD
cord-005478-5iu38pr6	2475	21	%	%	NN
cord-005478-5iu38pr6	2475	22	)	)	-RRB-
cord-005478-5iu38pr6	2475	23	,	,	,
cord-005478-5iu38pr6	2475	24	7(20	7(20	CD
cord-005478-5iu38pr6	2475	25	%	%	NN
cord-005478-5iu38pr6	2475	26	)	)	-RRB-
cord-005478-5iu38pr6	2475	27	and	and	CC
cord-005478-5iu38pr6	2475	28	7(20	7(20	CD
cord-005478-5iu38pr6	2475	29	%	%	NN
cord-005478-5iu38pr6	2475	30	)	)	-RRB-
cord-005478-5iu38pr6	2475	31	patients	patient	NNS
cord-005478-5iu38pr6	2475	32	respectively	respectively	RB
cord-005478-5iu38pr6	2475	33	.	.	.
cord-005478-5iu38pr6	2476	1	Chimerism	chimerism	NN
cord-005478-5iu38pr6	2476	2	studies	study	NNS
cord-005478-5iu38pr6	2476	3	at	at	IN
cord-005478-5iu38pr6	2476	4	the	the	DT
cord-005478-5iu38pr6	2476	5	last	last	JJ
cord-005478-5iu38pr6	2476	6	contact	contact	NN
cord-005478-5iu38pr6	2476	7	were	be	VBD
cord-005478-5iu38pr6	2476	8	available	available	JJ
cord-005478-5iu38pr6	2476	9	for	for	IN
cord-005478-5iu38pr6	2476	10	24	24	CD
cord-005478-5iu38pr6	2476	11	patients	patient	NNS
cord-005478-5iu38pr6	2476	12	.	.	.
cord-005478-5iu38pr6	2477	1	Full	full	JJ
cord-005478-5iu38pr6	2477	2	donor	donor	NN
cord-005478-5iu38pr6	2477	3	cell	cell	NN
cord-005478-5iu38pr6	2477	4	chimerism	chimerism	NN
cord-005478-5iu38pr6	2477	5	(	(	-LRB-
cord-005478-5iu38pr6	2477	6	100	100	CD
cord-005478-5iu38pr6	2477	7	%	%	NN
cord-005478-5iu38pr6	2477	8	)	)	-RRB-
cord-005478-5iu38pr6	2477	9	was	be	VBD
cord-005478-5iu38pr6	2477	10	seen	see	VBN
cord-005478-5iu38pr6	2477	11	in	in	IN
cord-005478-5iu38pr6	2477	12	16	16	CD
cord-005478-5iu38pr6	2477	13	(	(	-LRB-
cord-005478-5iu38pr6	2477	14	67	67	CD
cord-005478-5iu38pr6	2477	15	%	%	NN
cord-005478-5iu38pr6	2477	16	)	)	-RRB-
cord-005478-5iu38pr6	2477	17	of	of	IN
cord-005478-5iu38pr6	2477	18	the	the	DT
cord-005478-5iu38pr6	2477	19	transplanted	transplanted	JJ
cord-005478-5iu38pr6	2477	20	patients	patient	NNS
cord-005478-5iu38pr6	2477	21	.	.	.
cord-005478-5iu38pr6	2478	1	Post	post	JJ
cord-005478-5iu38pr6	2478	2	-	-	JJ
cord-005478-5iu38pr6	2478	3	transplant	transplant	JJ
cord-005478-5iu38pr6	2478	4	two	two	CD
cord-005478-5iu38pr6	2478	5	patients	patient	NNS
cord-005478-5iu38pr6	2478	6	experienced	experience	VBD
cord-005478-5iu38pr6	2478	7	disease	disease	NN
cord-005478-5iu38pr6	2478	8	reactivation	reactivation	NN
cord-005478-5iu38pr6	2478	9	at	at	IN
cord-005478-5iu38pr6	2478	10	a	a	DT
cord-005478-5iu38pr6	2478	11	median	median	JJ
cord-005478-5iu38pr6	2478	12	time	time	NN
cord-005478-5iu38pr6	2478	13	45.5	45.5	CD
cord-005478-5iu38pr6	2478	14	(	(	-LRB-
cord-005478-5iu38pr6	2478	15	28	28	CD
cord-005478-5iu38pr6	2478	16	-	-	SYM
cord-005478-5iu38pr6	2478	17	63	63	CD
cord-005478-5iu38pr6	2478	18	)	)	-RRB-
cord-005478-5iu38pr6	2478	19	days	day	NNS
cord-005478-5iu38pr6	2478	20	.	.	.
cord-005478-5iu38pr6	2479	1	With	with	IN
cord-005478-5iu38pr6	2479	2	a	a	DT
cord-005478-5iu38pr6	2479	3	mortality	mortality	NN
cord-005478-5iu38pr6	2479	4	rate	rate	NN
cord-005478-5iu38pr6	2479	5	of	of	IN
cord-005478-5iu38pr6	2479	6	37.1	37.1	CD
cord-005478-5iu38pr6	2479	7	%	%	NN
cord-005478-5iu38pr6	2479	8	(	(	-LRB-
cord-005478-5iu38pr6	2479	9	13	13	CD
cord-005478-5iu38pr6	2479	10	)	)	-RRB-
cord-005478-5iu38pr6	2479	11	and	and	CC
cord-005478-5iu38pr6	2479	12	a	a	DT
cord-005478-5iu38pr6	2479	13	median	median	JJ
cord-005478-5iu38pr6	2479	14	follow	follow	NN
cord-005478-5iu38pr6	2479	15	-	-	HYPH
cord-005478-5iu38pr6	2479	16	up	up	NN
cord-005478-5iu38pr6	2479	17	time	time	NN
cord-005478-5iu38pr6	2479	18	of	of	IN
cord-005478-5iu38pr6	2479	19	87.7	87.7	CD
cord-005478-5iu38pr6	2479	20	months	month	NNS
cord-005478-5iu38pr6	2479	21	,	,	,
cord-005478-5iu38pr6	2479	22	five	five	CD
cord-005478-5iu38pr6	2479	23	-	-	HYPH
cord-005478-5iu38pr6	2479	24	year	year	NN
cord-005478-5iu38pr6	2479	25	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2479	26	probability	probability	NN
cord-005478-5iu38pr6	2479	27	of	of	IN
cord-005478-5iu38pr6	2479	28	overall	overall	JJ
cord-005478-5iu38pr6	2479	29	survival	survival	NN
cord-005478-5iu38pr6	2479	30	(	(	-LRB-
cord-005478-5iu38pr6	2479	31	OS	OS	NNP
cord-005478-5iu38pr6	2479	32	)	)	-RRB-
cord-005478-5iu38pr6	2479	33	for	for	IN
cord-005478-5iu38pr6	2479	34	our	-PRON-	PRP$
cord-005478-5iu38pr6	2479	35	cohort	cohort	NN
cord-005478-5iu38pr6	2479	36	of	of	IN
cord-005478-5iu38pr6	2479	37	patients	patient	NNS
cord-005478-5iu38pr6	2479	38	was	be	VBD
cord-005478-5iu38pr6	2479	39	0.625	0.625	CD
cord-005478-5iu38pr6	2479	40	±	±	NNP
cord-005478-5iu38pr6	2479	41	0.083	0.083	CD
cord-005478-5iu38pr6	2479	42	.	.	.
cord-005478-5iu38pr6	2480	1	Transplant	transplant	NN
cord-005478-5iu38pr6	2480	2	related	relate	VBN
cord-005478-5iu38pr6	2480	3	mortality	mortality	NN
cord-005478-5iu38pr6	2480	4	counted	count	VBD
cord-005478-5iu38pr6	2480	5	as	as	IN
cord-005478-5iu38pr6	2480	6	death	death	NN
cord-005478-5iu38pr6	2480	7	within	within	IN
cord-005478-5iu38pr6	2480	8	day	day	NN
cord-005478-5iu38pr6	2480	9	100	100	CD
cord-005478-5iu38pr6	2480	10	was	be	VBD
cord-005478-5iu38pr6	2480	11	28.6	28.6	CD
cord-005478-5iu38pr6	2480	12	%	%	NN
cord-005478-5iu38pr6	2480	13	(	(	-LRB-
cord-005478-5iu38pr6	2480	14	10	10	CD
cord-005478-5iu38pr6	2480	15	)	)	-RRB-
cord-005478-5iu38pr6	2480	16	.	.	.
cord-005478-5iu38pr6	2481	1	Prominent	prominent	JJ
cord-005478-5iu38pr6	2481	2	causes	cause	NNS
cord-005478-5iu38pr6	2481	3	of	of	IN
cord-005478-5iu38pr6	2481	4	death	death	NN
cord-005478-5iu38pr6	2481	5	were	be	VBD
cord-005478-5iu38pr6	2481	6	septic	septic	JJ
cord-005478-5iu38pr6	2481	7	shock	shock	NN
cord-005478-5iu38pr6	2481	8	followed	follow	VBN
cord-005478-5iu38pr6	2481	9	by	by	IN
cord-005478-5iu38pr6	2481	10	ARDS	ARDS	NNP
cord-005478-5iu38pr6	2481	11	.	.	.
cord-005478-5iu38pr6	2482	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2482	2	probability	probability	NN
cord-005478-5iu38pr6	2482	3	of	of	IN
cord-005478-5iu38pr6	2482	4	five	five	CD
cord-005478-5iu38pr6	2482	5	years	year	NNS
cord-005478-5iu38pr6	2482	6	overall	overall	JJ
cord-005478-5iu38pr6	2482	7	survival	survival	NN
cord-005478-5iu38pr6	2482	8	was	be	VBD
cord-005478-5iu38pr6	2482	9	significantly	significantly	RB
cord-005478-5iu38pr6	2482	10	better	well	JJR
cord-005478-5iu38pr6	2482	11	in	in	IN
cord-005478-5iu38pr6	2482	12	those	those	DT
cord-005478-5iu38pr6	2482	13	who	who	WP
cord-005478-5iu38pr6	2482	14	did	do	VBD
cord-005478-5iu38pr6	2482	15	not	not	RB
cord-005478-5iu38pr6	2482	16	have	have	VB
cord-005478-5iu38pr6	2482	17	HLH	HLH	NNP
cord-005478-5iu38pr6	2482	18	prior	prior	RB
cord-005478-5iu38pr6	2482	19	to	to	IN
cord-005478-5iu38pr6	2482	20	SCT	SCT	NNP
cord-005478-5iu38pr6	2482	21	(	(	-LRB-
cord-005478-5iu38pr6	2482	22	1.0±0.0	1.0±0.0	CD
cord-005478-5iu38pr6	2482	23	vs.	vs.	IN
cord-005478-5iu38pr6	2482	24	0.529±0.096	0.529±0.096	CD
cord-005478-5iu38pr6	2482	25	,	,	,
cord-005478-5iu38pr6	2482	26	P	p	NN
cord-005478-5iu38pr6	2482	27	-	-	HYPH
cord-005478-5iu38pr6	2482	28	value	value	NN
cord-005478-5iu38pr6	2482	29	:	:	:
cord-005478-5iu38pr6	2482	30	0.037	0.037	CD
cord-005478-5iu38pr6	2482	31	)	)	-RRB-
cord-005478-5iu38pr6	2482	32	.	.	.
cord-005478-5iu38pr6	2483	1	Of	of	IN
cord-005478-5iu38pr6	2483	2	the	the	DT
cord-005478-5iu38pr6	2483	3	16	16	CD
cord-005478-5iu38pr6	2483	4	patients	patient	NNS
cord-005478-5iu38pr6	2483	5	with	with	IN
cord-005478-5iu38pr6	2483	6	neurological	neurological	JJ
cord-005478-5iu38pr6	2483	7	involvement	involvement	NN
cord-005478-5iu38pr6	2483	8	before	before	IN
cord-005478-5iu38pr6	2483	9	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2483	10	,	,	,
cord-005478-5iu38pr6	2483	11	8	8	CD
cord-005478-5iu38pr6	2483	12	survived	survive	VBD
cord-005478-5iu38pr6	2483	13	with	with	IN
cord-005478-5iu38pr6	2483	14	residual	residual	JJ
cord-005478-5iu38pr6	2483	15	sequelae	sequela	NNS
cord-005478-5iu38pr6	2483	16	in	in	IN
cord-005478-5iu38pr6	2483	17	3	3	CD
cord-005478-5iu38pr6	2483	18	patients	patient	NNS
cord-005478-5iu38pr6	2483	19	.	.	.
cord-005478-5iu38pr6	2484	1	OS	OS	NNP
cord-005478-5iu38pr6	2484	2	at	at	IN
cord-005478-5iu38pr6	2484	3	five	five	CD
cord-005478-5iu38pr6	2484	4	years	year	NNS
cord-005478-5iu38pr6	2484	5	was	be	VBD
cord-005478-5iu38pr6	2484	6	0.500±0.125	0.500±0.125	CD
cord-005478-5iu38pr6	2485	1	and	and	CC
cord-005478-5iu38pr6	2485	2	0.729±0.104(P	0.729±0.104(p	CD
cord-005478-5iu38pr6	2485	3	-	-	HYPH
cord-005478-5iu38pr6	2485	4	Value	value	NN
cord-005478-5iu38pr6	2485	5	:	:	:
cord-005478-5iu38pr6	2485	6	0.328	0.328	CD
cord-005478-5iu38pr6	2485	7	)	)	-RRB-
cord-005478-5iu38pr6	2485	8	in	in	IN
cord-005478-5iu38pr6	2485	9	pts	pts	NN
cord-005478-5iu38pr6	2485	10	with	with	IN
cord-005478-5iu38pr6	2485	11	and	and	CC
cord-005478-5iu38pr6	2485	12	without	without	IN
cord-005478-5iu38pr6	2485	13	CNS	CNS	NNP
cord-005478-5iu38pr6	2485	14	involvement	involvement	NN
cord-005478-5iu38pr6	2485	15	at	at	IN
cord-005478-5iu38pr6	2485	16	presentation	presentation	NN
cord-005478-5iu38pr6	2485	17	respectively	respectively	RB
cord-005478-5iu38pr6	2485	18	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2485	19	:	:	:
cord-005478-5iu38pr6	2486	1	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2486	2	in	in	IN
cord-005478-5iu38pr6	2486	3	patients	patient	NNS
cord-005478-5iu38pr6	2486	4	with	with	IN
cord-005478-5iu38pr6	2486	5	GS	GS	NNP
cord-005478-5iu38pr6	2486	6	is	be	VBZ
cord-005478-5iu38pr6	2486	7	potentially	potentially	RB
cord-005478-5iu38pr6	2486	8	curative	curative	JJ
cord-005478-5iu38pr6	2486	9	with	with	IN
cord-005478-5iu38pr6	2486	10	long	long	JJ
cord-005478-5iu38pr6	2486	11	-	-	HYPH
cord-005478-5iu38pr6	2486	12	term	term	NN
cord-005478-5iu38pr6	2486	13	,	,	,
cord-005478-5iu38pr6	2486	14	disease	disease	NN
cord-005478-5iu38pr6	2486	15	-	-	HYPH
cord-005478-5iu38pr6	2486	16	free	free	JJ
cord-005478-5iu38pr6	2486	17	survival	survival	NN
cord-005478-5iu38pr6	2486	18	.	.	.
cord-005478-5iu38pr6	2487	1	Early	early	JJ
cord-005478-5iu38pr6	2487	2	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2487	3	before	before	IN
cord-005478-5iu38pr6	2487	4	the	the	DT
cord-005478-5iu38pr6	2487	5	development	development	NN
cord-005478-5iu38pr6	2487	6	of	of	IN
cord-005478-5iu38pr6	2487	7	the	the	DT
cord-005478-5iu38pr6	2487	8	accelerated	accelerated	JJ
cord-005478-5iu38pr6	2487	9	phase	phase	NN
cord-005478-5iu38pr6	2487	10	showed	show	VBD
cord-005478-5iu38pr6	2487	11	better	well	JJR
cord-005478-5iu38pr6	2487	12	result	result	NN
cord-005478-5iu38pr6	2487	13	.	.	.
cord-005478-5iu38pr6	2488	1	[	[	-LRB-
cord-005478-5iu38pr6	2488	2	Background	background	NN
cord-005478-5iu38pr6	2488	3	:	:	:
cord-005478-5iu38pr6	2488	4	Primary	primary	JJ
cord-005478-5iu38pr6	2488	5	immunodeficiencies	immunodeficiency	NNS
cord-005478-5iu38pr6	2488	6	(	(	-LRB-
cord-005478-5iu38pr6	2488	7	PIDs	PIDs	NNP
cord-005478-5iu38pr6	2488	8	)	)	-RRB-
cord-005478-5iu38pr6	2488	9	are	be	VBP
cord-005478-5iu38pr6	2488	10	heterogeneous	heterogeneous	JJ
cord-005478-5iu38pr6	2488	11	inborn	inborn	JJ
cord-005478-5iu38pr6	2488	12	disorders	disorder	NNS
cord-005478-5iu38pr6	2488	13	resulting	result	VBG
cord-005478-5iu38pr6	2488	14	in	in	IN
cord-005478-5iu38pr6	2488	15	impaired	impaired	JJ
cord-005478-5iu38pr6	2488	16	cellular	cellular	JJ
cord-005478-5iu38pr6	2488	17	and/or	and/or	CC
cord-005478-5iu38pr6	2488	18	humoral	humoral	JJ
cord-005478-5iu38pr6	2488	19	responses	response	NNS
cord-005478-5iu38pr6	2488	20	.	.	.
cord-005478-5iu38pr6	2489	1	PID	PID	NNP
cord-005478-5iu38pr6	2489	2	present	present	VBP
cord-005478-5iu38pr6	2489	3	a	a	DT
cord-005478-5iu38pr6	2489	4	wide	wide	JJ
cord-005478-5iu38pr6	2489	5	range	range	NN
cord-005478-5iu38pr6	2489	6	of	of	IN
cord-005478-5iu38pr6	2489	7	clinical	clinical	JJ
cord-005478-5iu38pr6	2489	8	manifestations	manifestation	NNS
cord-005478-5iu38pr6	2489	9	,	,	,
cord-005478-5iu38pr6	2489	10	ranging	range	VBG
cord-005478-5iu38pr6	2489	11	from	from	IN
cord-005478-5iu38pr6	2489	12	infections	infection	NNS
cord-005478-5iu38pr6	2489	13	to	to	IN
cord-005478-5iu38pr6	2489	14	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	2489	15	,	,	,
cord-005478-5iu38pr6	2489	16	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2489	17	and/or	and/or	CC
cord-005478-5iu38pr6	2489	18	malignant	malignant	JJ
cord-005478-5iu38pr6	2489	19	complications	complication	NNS
cord-005478-5iu38pr6	2489	20	.	.	.
cord-005478-5iu38pr6	2490	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2490	2	stem	stem	VBP
cord-005478-5iu38pr6	2490	3	cell	cell	NN
cord-005478-5iu38pr6	2490	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2490	5	(	(	-LRB-
cord-005478-5iu38pr6	2490	6	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2490	7	)	)	-RRB-
cord-005478-5iu38pr6	2490	8	is	be	VBZ
cord-005478-5iu38pr6	2490	9	curative	curative	JJ
cord-005478-5iu38pr6	2490	10	for	for	IN
cord-005478-5iu38pr6	2490	11	pediatric	pediatric	JJ
cord-005478-5iu38pr6	2490	12	PID	pid	NN
cord-005478-5iu38pr6	2490	13	with	with	IN
cord-005478-5iu38pr6	2490	14	an	an	DT
cord-005478-5iu38pr6	2490	15	excellent	excellent	JJ
cord-005478-5iu38pr6	2490	16	safety	safety	NN
cord-005478-5iu38pr6	2490	17	.	.	.
cord-005478-5iu38pr6	2491	1	In	in	IN
cord-005478-5iu38pr6	2491	2	adults	adult	NNS
cord-005478-5iu38pr6	2491	3	on	on	IN
cord-005478-5iu38pr6	2491	4	the	the	DT
cord-005478-5iu38pr6	2491	5	other	other	JJ
cord-005478-5iu38pr6	2491	6	hand	hand	NN
cord-005478-5iu38pr6	2491	7	,	,	,
cord-005478-5iu38pr6	2491	8	this	this	DT
cord-005478-5iu38pr6	2491	9	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	2491	10	approach	approach	NN
cord-005478-5iu38pr6	2491	11	remains	remain	VBZ
cord-005478-5iu38pr6	2491	12	controversial	controversial	JJ
cord-005478-5iu38pr6	2491	13	.	.	.
cord-005478-5iu38pr6	2492	1	Methods	method	NNS
cord-005478-5iu38pr6	2492	2	:	:	:
cord-005478-5iu38pr6	2493	1	This	this	DT
cord-005478-5iu38pr6	2493	2	is	be	VBZ
cord-005478-5iu38pr6	2493	3	a	a	DT
cord-005478-5iu38pr6	2493	4	retrospective	retrospective	JJ
cord-005478-5iu38pr6	2493	5	,	,	,
cord-005478-5iu38pr6	2493	6	monocentric	monocentric	JJ
cord-005478-5iu38pr6	2493	7	study	study	NN
cord-005478-5iu38pr6	2493	8	of	of	IN
cord-005478-5iu38pr6	2493	9	26	26	CD
cord-005478-5iu38pr6	2493	10	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2493	11	adult	adult	NN
cord-005478-5iu38pr6	2493	12	patients	patient	NNS
cord-005478-5iu38pr6	2493	13	with	with	IN
cord-005478-5iu38pr6	2493	14	PID	PID	NNP
cord-005478-5iu38pr6	2493	15	who	who	WP
cord-005478-5iu38pr6	2493	16	underwent	undergo	VBD
cord-005478-5iu38pr6	2493	17	an	an	DT
cord-005478-5iu38pr6	2493	18	alloSCT	allosct	NN
cord-005478-5iu38pr6	2493	19	between	between	IN
cord-005478-5iu38pr6	2493	20	2011	2011	CD
cord-005478-5iu38pr6	2493	21	and	and	CC
cord-005478-5iu38pr6	2493	22	2018	2018	CD
cord-005478-5iu38pr6	2493	23	.	.	.
cord-005478-5iu38pr6	2494	1	The	the	DT
cord-005478-5iu38pr6	2494	2	objective	objective	NN
cord-005478-5iu38pr6	2494	3	was	be	VBD
cord-005478-5iu38pr6	2494	4	to	to	TO
cord-005478-5iu38pr6	2494	5	assess	assess	VB
cord-005478-5iu38pr6	2494	6	the	the	DT
cord-005478-5iu38pr6	2494	7	feasibility	feasibility	NN
cord-005478-5iu38pr6	2494	8	,	,	,
cord-005478-5iu38pr6	2494	9	effectiveness	effectiveness	NN
cord-005478-5iu38pr6	2494	10	and	and	CC
cord-005478-5iu38pr6	2494	11	safety	safety	NN
cord-005478-5iu38pr6	2494	12	of	of	IN
cord-005478-5iu38pr6	2494	13	this	this	DT
cord-005478-5iu38pr6	2494	14	procedure	procedure	NN
cord-005478-5iu38pr6	2494	15	.	.	.
cord-005478-5iu38pr6	2495	1	Results	result	NNS
cord-005478-5iu38pr6	2495	2	:	:	:
cord-005478-5iu38pr6	2496	1	Twenty	twenty	CD
cord-005478-5iu38pr6	2496	2	-	-	HYPH
cord-005478-5iu38pr6	2496	3	two	two	CD
cord-005478-5iu38pr6	2496	4	(	(	-LRB-
cord-005478-5iu38pr6	2496	5	85	85	CD
cord-005478-5iu38pr6	2496	6	%	%	NN
cord-005478-5iu38pr6	2496	7	)	)	-RRB-
cord-005478-5iu38pr6	2496	8	of	of	IN
cord-005478-5iu38pr6	2496	9	26	26	CD
cord-005478-5iu38pr6	2496	10	patients	patient	NNS
cord-005478-5iu38pr6	2496	11	presented	present	VBD
cord-005478-5iu38pr6	2496	12	an	an	DT
cord-005478-5iu38pr6	2496	13	inherited	inherit	VBN
cord-005478-5iu38pr6	2496	14	T	t	NN
cord-005478-5iu38pr6	2496	15	or	or	CC
cord-005478-5iu38pr6	2496	16	B	b	NN
cord-005478-5iu38pr6	2496	17	cell	cell	NN
cord-005478-5iu38pr6	2496	18	deficiency	deficiency	NN
cord-005478-5iu38pr6	2496	19	and	and	CC
cord-005478-5iu38pr6	2496	20	4	4	CD
cord-005478-5iu38pr6	2496	21	(	(	-LRB-
cord-005478-5iu38pr6	2496	22	15	15	CD
cord-005478-5iu38pr6	2496	23	%	%	NN
cord-005478-5iu38pr6	2496	24	)	)	-RRB-
cord-005478-5iu38pr6	2496	25	a	a	DT
cord-005478-5iu38pr6	2496	26	phagocyte	phagocyte	NN
cord-005478-5iu38pr6	2496	27	impairment	impairment	NN
cord-005478-5iu38pr6	2496	28	.	.	.
cord-005478-5iu38pr6	2497	1	Twenty	twenty	CD
cord-005478-5iu38pr6	2497	2	(	(	-LRB-
cord-005478-5iu38pr6	2497	3	77	77	CD
cord-005478-5iu38pr6	2497	4	%	%	NN
cord-005478-5iu38pr6	2497	5	)	)	-RRB-
cord-005478-5iu38pr6	2497	6	patients	patient	NNS
cord-005478-5iu38pr6	2497	7	had	have	VBD
cord-005478-5iu38pr6	2497	8	a	a	DT
cord-005478-5iu38pr6	2497	9	genetic	genetic	JJ
cord-005478-5iu38pr6	2497	10	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2497	11	.	.	.
cord-005478-5iu38pr6	2498	1	Besides	besides	IN
cord-005478-5iu38pr6	2498	2	infectious	infectious	JJ
cord-005478-5iu38pr6	2498	3	complications	complication	NNS
cord-005478-5iu38pr6	2498	4	,	,	,
cord-005478-5iu38pr6	2498	5	8	8	CD
cord-005478-5iu38pr6	2498	6	(	(	-LRB-
cord-005478-5iu38pr6	2498	7	31	31	CD
cord-005478-5iu38pr6	2498	8	%	%	NN
cord-005478-5iu38pr6	2498	9	)	)	-RRB-
cord-005478-5iu38pr6	2498	10	patients	patient	NNS
cord-005478-5iu38pr6	2498	11	had	have	VBD
cord-005478-5iu38pr6	2498	12	an	an	DT
cord-005478-5iu38pr6	2498	13	history	history	NN
cord-005478-5iu38pr6	2498	14	of	of	IN
cord-005478-5iu38pr6	2498	15	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2498	16	and	and	CC
cord-005478-5iu38pr6	2498	17	13	13	CD
cord-005478-5iu38pr6	2498	18	(	(	-LRB-
cord-005478-5iu38pr6	2498	19	50	50	CD
cord-005478-5iu38pr6	2498	20	%	%	NN
cord-005478-5iu38pr6	2498	21	)	)	-RRB-
cord-005478-5iu38pr6	2499	1	an	an	DT
cord-005478-5iu38pr6	2499	2	history	history	NN
cord-005478-5iu38pr6	2499	3	of	of	IN
cord-005478-5iu38pr6	2499	4	autoimmune/	autoimmune/	CD
cord-005478-5iu38pr6	2499	5	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2499	6	complication	complication	NN
cord-005478-5iu38pr6	2499	7	.	.	.
cord-005478-5iu38pr6	2500	1	The	the	DT
cord-005478-5iu38pr6	2500	2	median	median	JJ
cord-005478-5iu38pr6	2500	3	age	age	NN
cord-005478-5iu38pr6	2500	4	at	at	IN
cord-005478-5iu38pr6	2500	5	transplant	transplant	NN
cord-005478-5iu38pr6	2500	6	was	be	VBD
cord-005478-5iu38pr6	2500	7	24	24	CD
cord-005478-5iu38pr6	2500	8	years	year	NNS
cord-005478-5iu38pr6	2501	1	(	(	-LRB-
cord-005478-5iu38pr6	2501	2	range	range	NNP
cord-005478-5iu38pr6	2501	3	17	17	CD
cord-005478-5iu38pr6	2501	4	-	-	SYM
cord-005478-5iu38pr6	2501	5	37	37	CD
cord-005478-5iu38pr6	2501	6	)	)	-RRB-
cord-005478-5iu38pr6	2501	7	.	.	.
cord-005478-5iu38pr6	2502	1	Twelve	twelve	CD
cord-005478-5iu38pr6	2502	2	(	(	-LRB-
cord-005478-5iu38pr6	2502	3	46	46	CD
cord-005478-5iu38pr6	2502	4	%	%	NN
cord-005478-5iu38pr6	2502	5	)	)	-RRB-
cord-005478-5iu38pr6	2502	6	patients	patient	NNS
cord-005478-5iu38pr6	2502	7	received	receive	VBD
cord-005478-5iu38pr6	2502	8	a	a	DT
cord-005478-5iu38pr6	2502	9	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2502	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	2502	11	(	(	-LRB-
cord-005478-5iu38pr6	2502	12	MAC	MAC	NNP
cord-005478-5iu38pr6	2502	13	)	)	-RRB-
cord-005478-5iu38pr6	2502	14	,	,	,
cord-005478-5iu38pr6	2502	15	12	12	CD
cord-005478-5iu38pr6	2502	16	(	(	-LRB-
cord-005478-5iu38pr6	2502	17	46	46	CD
cord-005478-5iu38pr6	2502	18	%	%	NN
cord-005478-5iu38pr6	2502	19	)	)	-RRB-
cord-005478-5iu38pr6	2503	1	a	a	DT
cord-005478-5iu38pr6	2503	2	reduced	reduce	VBN
cord-005478-5iu38pr6	2503	3	intensity	intensity	NN
cord-005478-5iu38pr6	2503	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	2503	5	(	(	-LRB-
cord-005478-5iu38pr6	2503	6	RIC	RIC	NNP
cord-005478-5iu38pr6	2503	7	)	)	-RRB-
cord-005478-5iu38pr6	2503	8	and	and	CC
cord-005478-5iu38pr6	2503	9	2	2	CD
cord-005478-5iu38pr6	2503	10	(	(	-LRB-
cord-005478-5iu38pr6	2503	11	8	8	CD
cord-005478-5iu38pr6	2503	12	%	%	NN
cord-005478-5iu38pr6	2503	13	)	)	-RRB-
cord-005478-5iu38pr6	2503	14	had	have	VBD
cord-005478-5iu38pr6	2503	15	no	no	DT
cord-005478-5iu38pr6	2503	16	conditioning	conditioning	NN
cord-005478-5iu38pr6	2503	17	(	(	-LRB-
cord-005478-5iu38pr6	2503	18	second	second	JJ
cord-005478-5iu38pr6	2503	19	transplant	transplant	NN
cord-005478-5iu38pr6	2503	20	for	for	IN
cord-005478-5iu38pr6	2503	21	severe	severe	JJ
cord-005478-5iu38pr6	2503	22	combined	combined	JJ
cord-005478-5iu38pr6	2503	23	deficiency	deficiency	NN
cord-005478-5iu38pr6	2503	24	)	)	-RRB-
cord-005478-5iu38pr6	2503	25	.	.	.
cord-005478-5iu38pr6	2504	1	MAC	MAC	NNP
cord-005478-5iu38pr6	2504	2	included	include	VBD
cord-005478-5iu38pr6	2504	3	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	2504	4	(	(	-LRB-
cord-005478-5iu38pr6	2504	5	Flu)/Buslfan	Flu)/Buslfan	NNP
cord-005478-5iu38pr6	2504	6	(	(	-LRB-
cord-005478-5iu38pr6	2504	7	Bu	Bu	NNP
cord-005478-5iu38pr6	2504	8	,	,	,
cord-005478-5iu38pr6	2504	9	dosage	dosage	NN
cord-005478-5iu38pr6	2504	10	:	:	:
cord-005478-5iu38pr6	2504	11	12.8	12.8	CD
cord-005478-5iu38pr6	2504	12	mg	mg	NNP
cord-005478-5iu38pr6	2504	13	/	/	SYM
cord-005478-5iu38pr6	2504	14	kg	kg	NNP
cord-005478-5iu38pr6	2504	15	)	)	-RRB-
cord-005478-5iu38pr6	2504	16	based	base	VBN
cord-005478-5iu38pr6	2504	17	regimen	regimen	NN
cord-005478-5iu38pr6	2504	18	(	(	-LRB-
cord-005478-5iu38pr6	2504	19	n=11	n=11	FW
cord-005478-5iu38pr6	2504	20	)	)	-RRB-
cord-005478-5iu38pr6	2504	21	and	and	CC
cord-005478-5iu38pr6	2504	22	Bu	Bu	NNP
cord-005478-5iu38pr6	2504	23	(	(	-LRB-
cord-005478-5iu38pr6	2504	24	12.8	12.8	CD
cord-005478-5iu38pr6	2504	25	mg	mg	NNP
cord-005478-5iu38pr6	2504	26	/	/	SYM
cord-005478-5iu38pr6	2504	27	kg)/Cyclophosphamide	kg)/cyclophosphamide	NN
cord-005478-5iu38pr6	2504	28	(	(	-LRB-
cord-005478-5iu38pr6	2504	29	Cy	Cy	NNP
cord-005478-5iu38pr6	2504	30	)	)	-RRB-
cord-005478-5iu38pr6	2504	31	based	base	VBN
cord-005478-5iu38pr6	2504	32	regimen	regimen	NN
cord-005478-5iu38pr6	2504	33	(	(	-LRB-
cord-005478-5iu38pr6	2504	34	n=1	n=1	FW
cord-005478-5iu38pr6	2504	35	)	)	-RRB-
cord-005478-5iu38pr6	2504	36	.	.	.
cord-005478-5iu38pr6	2505	1	RIC	RIC	NNP
cord-005478-5iu38pr6	2505	2	included	include	VBD
cord-005478-5iu38pr6	2505	3	based	base	VBN
cord-005478-5iu38pr6	2505	4	Flu	Flu	NNP
cord-005478-5iu38pr6	2505	5	/	/	SYM
cord-005478-5iu38pr6	2505	6	Bu	Bu	NNP
cord-005478-5iu38pr6	2506	1	(	(	-LRB-
cord-005478-5iu38pr6	2506	2	range	range	NNP
cord-005478-5iu38pr6	2506	3	dosage	dosage	NNP
cord-005478-5iu38pr6	2506	4	:	:	:
cord-005478-5iu38pr6	2507	1	6.4	6.4	CD
cord-005478-5iu38pr6	2507	2	-	-	SYM
cord-005478-5iu38pr6	2507	3	9.6	9.6	CD
cord-005478-5iu38pr6	2507	4	mg	mg	NNP
cord-005478-5iu38pr6	2507	5	/	/	SYM
cord-005478-5iu38pr6	2507	6	kg	kg	NNP
cord-005478-5iu38pr6	2507	7	)	)	-RRB-
cord-005478-5iu38pr6	2507	8	regimen	regimen	NN
cord-005478-5iu38pr6	2507	9	(	(	-LRB-
cord-005478-5iu38pr6	2507	10	n=9	n=9	NN
cord-005478-5iu38pr6	2507	11	)	)	-RRB-
cord-005478-5iu38pr6	2507	12	,	,	,
cord-005478-5iu38pr6	2507	13	Flu	Flu	NNP
cord-005478-5iu38pr6	2507	14	/	/	SYM
cord-005478-5iu38pr6	2507	15	Cy	Cy	NNP
cord-005478-5iu38pr6	2507	16	based	base	VBN
cord-005478-5iu38pr6	2507	17	regimen	regimen	NN
cord-005478-5iu38pr6	2507	18	(	(	-LRB-
cord-005478-5iu38pr6	2507	19	n=1	n=1	CD
cord-005478-5iu38pr6	2507	20	)	)	-RRB-
cord-005478-5iu38pr6	2507	21	,	,	.
cord-005478-5iu38pr6	2508	1	Thiotepa	Thiotepa	NNP
cord-005478-5iu38pr6	2508	2	/	/	SYM
cord-005478-5iu38pr6	2508	3	Flu	Flu	NNP
cord-005478-5iu38pr6	2508	4	/	/	SYM
cord-005478-5iu38pr6	2508	5	Bu	Bu	NNP
cord-005478-5iu38pr6	2508	6	regimen	regimen	NN
cord-005478-5iu38pr6	2508	7	(	(	-LRB-
cord-005478-5iu38pr6	2508	8	n=1	n=1	FW
cord-005478-5iu38pr6	2508	9	)	)	-RRB-
cord-005478-5iu38pr6	2508	10	and	and	CC
cord-005478-5iu38pr6	2508	11	low	low	JJ
cord-005478-5iu38pr6	2508	12	dose	dose	NN
cord-005478-5iu38pr6	2508	13	TBI	TBI	NNP
cord-005478-5iu38pr6	2508	14	based	base	VBN
cord-005478-5iu38pr6	2508	15	regimen	regimen	NN
cord-005478-5iu38pr6	2508	16	(	(	-LRB-
cord-005478-5iu38pr6	2508	17	n=1	n=1	FW
cord-005478-5iu38pr6	2508	18	)	)	-RRB-
cord-005478-5iu38pr6	2508	19	.	.	.
cord-005478-5iu38pr6	2509	1	Among	among	IN
cord-005478-5iu38pr6	2509	2	the	the	DT
cord-005478-5iu38pr6	2509	3	24	24	CD
cord-005478-5iu38pr6	2509	4	patients	patient	NNS
cord-005478-5iu38pr6	2509	5	who	who	WP
cord-005478-5iu38pr6	2509	6	received	receive	VBD
cord-005478-5iu38pr6	2509	7	a	a	DT
cord-005478-5iu38pr6	2509	8	conditioning	conditioning	NN
cord-005478-5iu38pr6	2509	9	,	,	,
cord-005478-5iu38pr6	2509	10	4	4	CD
cord-005478-5iu38pr6	2509	11	(	(	-LRB-
cord-005478-5iu38pr6	2509	12	17	17	CD
cord-005478-5iu38pr6	2509	13	%	%	NN
cord-005478-5iu38pr6	2509	14	)	)	-RRB-
cord-005478-5iu38pr6	2509	15	received	receive	VBD
cord-005478-5iu38pr6	2509	16	Alemtuzumab	Alemtuzumab	NNP
cord-005478-5iu38pr6	2509	17	and	and	CC
cord-005478-5iu38pr6	2509	18	11	11	CD
cord-005478-5iu38pr6	2509	19	(	(	-LRB-
cord-005478-5iu38pr6	2509	20	46	46	CD
cord-005478-5iu38pr6	2509	21	%	%	NN
cord-005478-5iu38pr6	2509	22	)	)	-RRB-
cord-005478-5iu38pr6	2509	23	received	receive	VBD
cord-005478-5iu38pr6	2509	24	antithymocyte	antithymocyte	NNP
cord-005478-5iu38pr6	2509	25	globulin	globulin	NN
cord-005478-5iu38pr6	2509	26	as	as	IN
cord-005478-5iu38pr6	2509	27	part	part	NN
cord-005478-5iu38pr6	2509	28	of	of	IN
cord-005478-5iu38pr6	2509	29	the	the	DT
cord-005478-5iu38pr6	2509	30	conditioning	conditioning	NN
cord-005478-5iu38pr6	2509	31	.	.	.
cord-005478-5iu38pr6	2510	1	The	the	DT
cord-005478-5iu38pr6	2510	2	stem	stem	NN
cord-005478-5iu38pr6	2510	3	cell	cell	NN
cord-005478-5iu38pr6	2510	4	source	source	NN
cord-005478-5iu38pr6	2510	5	was	be	VBD
cord-005478-5iu38pr6	2510	6	bone	bone	NN
cord-005478-5iu38pr6	2510	7	marrow	marrow	NN
cord-005478-5iu38pr6	2510	8	for	for	IN
cord-005478-5iu38pr6	2510	9	8	8	CD
cord-005478-5iu38pr6	2510	10	(	(	-LRB-
cord-005478-5iu38pr6	2510	11	31	31	CD
cord-005478-5iu38pr6	2510	12	%	%	NN
cord-005478-5iu38pr6	2510	13	)	)	-RRB-
cord-005478-5iu38pr6	2510	14	and	and	CC
cord-005478-5iu38pr6	2510	15	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2510	16	blood	blood	NN
cord-005478-5iu38pr6	2510	17	stem	stem	NN
cord-005478-5iu38pr6	2510	18	cells	cell	NNS
cord-005478-5iu38pr6	2510	19	for	for	IN
cord-005478-5iu38pr6	2510	20	18	18	CD
cord-005478-5iu38pr6	2510	21	(	(	-LRB-
cord-005478-5iu38pr6	2510	22	69	69	CD
cord-005478-5iu38pr6	2510	23	%	%	NN
cord-005478-5iu38pr6	2510	24	)	)	-RRB-
cord-005478-5iu38pr6	2510	25	.	.	.
cord-005478-5iu38pr6	2511	1	The	the	DT
cord-005478-5iu38pr6	2511	2	donor	donor	NN
cord-005478-5iu38pr6	2511	3	was	be	VBD
cord-005478-5iu38pr6	2511	4	matched	match	VBN
cord-005478-5iu38pr6	2511	5	related	relate	VBN
cord-005478-5iu38pr6	2511	6	for	for	IN
cord-005478-5iu38pr6	2511	7	10	10	CD
cord-005478-5iu38pr6	2511	8	(	(	-LRB-
cord-005478-5iu38pr6	2511	9	38	38	CD
cord-005478-5iu38pr6	2511	10	%	%	NN
cord-005478-5iu38pr6	2511	11	)	)	-RRB-
cord-005478-5iu38pr6	2511	12	,	,	,
cord-005478-5iu38pr6	2511	13	matched	match	VBN
cord-005478-5iu38pr6	2511	14	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2511	15	for	for	IN
cord-005478-5iu38pr6	2511	16	12	12	CD
cord-005478-5iu38pr6	2511	17	(	(	-LRB-
cord-005478-5iu38pr6	2511	18	46	46	CD
cord-005478-5iu38pr6	2511	19	%	%	NN
cord-005478-5iu38pr6	2511	20	)	)	-RRB-
cord-005478-5iu38pr6	2511	21	,	,	,
cord-005478-5iu38pr6	2511	22	mismatch	mismatch	NN
cord-005478-5iu38pr6	2511	23	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2511	24	for	for	IN
cord-005478-5iu38pr6	2511	25	2	2	CD
cord-005478-5iu38pr6	2511	26	(	(	-LRB-
cord-005478-5iu38pr6	2511	27	8	8	CD
cord-005478-5iu38pr6	2511	28	%	%	NN
cord-005478-5iu38pr6	2511	29	)	)	-RRB-
cord-005478-5iu38pr6	2511	30	,	,	,
cord-005478-5iu38pr6	2511	31	and	and	CC
cord-005478-5iu38pr6	2511	32	haplo	haplo	NN
cord-005478-5iu38pr6	2511	33	-	-	HYPH
cord-005478-5iu38pr6	2511	34	identical	identical	JJ
cord-005478-5iu38pr6	2511	35	for	for	IN
cord-005478-5iu38pr6	2511	36	2	2	CD
cord-005478-5iu38pr6	2511	37	(	(	-LRB-
cord-005478-5iu38pr6	2511	38	8	8	CD
cord-005478-5iu38pr6	2511	39	%	%	NN
cord-005478-5iu38pr6	2511	40	)	)	-RRB-
cord-005478-5iu38pr6	2511	41	.	.	.
cord-005478-5iu38pr6	2512	1	All	all	DT
cord-005478-5iu38pr6	2512	2	assessable	assessable	JJ
cord-005478-5iu38pr6	2512	3	patients	patient	NNS
cord-005478-5iu38pr6	2512	4	had	have	VBD
cord-005478-5iu38pr6	2512	5	a	a	DT
cord-005478-5iu38pr6	2512	6	successful	successful	JJ
cord-005478-5iu38pr6	2512	7	engraftment	engraftment	NN
cord-005478-5iu38pr6	2512	8	.	.	.
cord-005478-5iu38pr6	2513	1	Eight	eight	CD
cord-005478-5iu38pr6	2513	2	(	(	-LRB-
cord-005478-5iu38pr6	2513	3	31	31	CD
cord-005478-5iu38pr6	2513	4	%	%	NN
cord-005478-5iu38pr6	2513	5	)	)	-RRB-
cord-005478-5iu38pr6	2513	6	presented	present	VBD
cord-005478-5iu38pr6	2513	7	a	a	DT
cord-005478-5iu38pr6	2513	8	grade	grade	NN
cord-005478-5iu38pr6	2513	9	II	II	NNP
cord-005478-5iu38pr6	2513	10	-	-	HYPH
cord-005478-5iu38pr6	2513	11	IV	IV	NNP
cord-005478-5iu38pr6	2513	12	acute	acute	JJ
cord-005478-5iu38pr6	2513	13	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2513	14	(	(	-LRB-
cord-005478-5iu38pr6	2513	15	one	one	CD
cord-005478-5iu38pr6	2513	16	grade	grade	NN
cord-005478-5iu38pr6	2513	17	III	III	NNP
cord-005478-5iu38pr6	2513	18	,	,	,
cord-005478-5iu38pr6	2513	19	0	0	CD
cord-005478-5iu38pr6	2513	20	grade	grade	NN
cord-005478-5iu38pr6	2513	21	IV	IV	NNP
cord-005478-5iu38pr6	2513	22	)	)	-RRB-
cord-005478-5iu38pr6	2513	23	,	,	,
cord-005478-5iu38pr6	2513	24	and	and	CC
cord-005478-5iu38pr6	2513	25	5	5	CD
cord-005478-5iu38pr6	2513	26	(	(	-LRB-
cord-005478-5iu38pr6	2513	27	23	23	CD
cord-005478-5iu38pr6	2513	28	%	%	NN
cord-005478-5iu38pr6	2513	29	)	)	-RRB-
cord-005478-5iu38pr6	2514	1	a	a	DT
cord-005478-5iu38pr6	2514	2	chronic	chronic	JJ
cord-005478-5iu38pr6	2514	3	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2514	4	(	(	-LRB-
cord-005478-5iu38pr6	2514	5	2	2	CD
cord-005478-5iu38pr6	2514	6	limited	limit	VBN
cord-005478-5iu38pr6	2514	7	and	and	CC
cord-005478-5iu38pr6	2514	8	3	3	CD
cord-005478-5iu38pr6	2514	9	extensive	extensive	JJ
cord-005478-5iu38pr6	2514	10	)	)	-RRB-
cord-005478-5iu38pr6	2514	11	.	.	.
cord-005478-5iu38pr6	2515	1	With	with	IN
cord-005478-5iu38pr6	2515	2	a	a	DT
cord-005478-5iu38pr6	2515	3	median	median	JJ
cord-005478-5iu38pr6	2515	4	follow	follow	NN
cord-005478-5iu38pr6	2515	5	-	-	HYPH
cord-005478-5iu38pr6	2515	6	up	up	NN
cord-005478-5iu38pr6	2515	7	of	of	IN
cord-005478-5iu38pr6	2515	8	29	29	CD
cord-005478-5iu38pr6	2515	9	months	month	NNS
cord-005478-5iu38pr6	2515	10	(	(	-LRB-
cord-005478-5iu38pr6	2515	11	3	3	CD
cord-005478-5iu38pr6	2515	12	-	-	SYM
cord-005478-5iu38pr6	2515	13	90	90	CD
cord-005478-5iu38pr6	2515	14	months	month	NNS
cord-005478-5iu38pr6	2515	15	)	)	-RRB-
cord-005478-5iu38pr6	2515	16	post	post	JJ
cord-005478-5iu38pr6	2515	17	-	-	NN
cord-005478-5iu38pr6	2515	18	transplant	transplant	NN
cord-005478-5iu38pr6	2515	19	,	,	,
cord-005478-5iu38pr6	2515	20	the	the	DT
cord-005478-5iu38pr6	2515	21	3-years	3-years	CD
cord-005478-5iu38pr6	2515	22	overall	overall	JJ
cord-005478-5iu38pr6	2515	23	survival	survival	NN
cord-005478-5iu38pr6	2515	24	(	(	-LRB-
cord-005478-5iu38pr6	2515	25	OS	OS	NNP
cord-005478-5iu38pr6	2515	26	)	)	-RRB-
cord-005478-5iu38pr6	2515	27	was	be	VBD
cord-005478-5iu38pr6	2515	28	80.8	80.8	CD
cord-005478-5iu38pr6	2515	29	%	%	NN
cord-005478-5iu38pr6	2515	30	.	.	.
cord-005478-5iu38pr6	2516	1	The	the	DT
cord-005478-5iu38pr6	2516	2	transplant	transplant	NN
cord-005478-5iu38pr6	2516	3	related	relate	VBN
cord-005478-5iu38pr6	2516	4	mortality	mortality	NN
cord-005478-5iu38pr6	2516	5	was	be	VBD
cord-005478-5iu38pr6	2516	6	19.2	19.2	CD
cord-005478-5iu38pr6	2516	7	%	%	NN
cord-005478-5iu38pr6	2516	8	with	with	IN
cord-005478-5iu38pr6	2516	9	5	5	CD
cord-005478-5iu38pr6	2516	10	deaths	death	NNS
cord-005478-5iu38pr6	2516	11	.	.	.
cord-005478-5iu38pr6	2517	1	Among	among	IN
cord-005478-5iu38pr6	2517	2	them	-PRON-	PRP
cord-005478-5iu38pr6	2517	3	,	,	,
cord-005478-5iu38pr6	2517	4	both	both	DT
cord-005478-5iu38pr6	2517	5	patients	patient	NNS
cord-005478-5iu38pr6	2517	6	transplanted	transplant	VBN
cord-005478-5iu38pr6	2517	7	with	with	IN
cord-005478-5iu38pr6	2517	8	an	an	DT
cord-005478-5iu38pr6	2517	9	haplo	haplo	NN
cord-005478-5iu38pr6	2517	10	-	-	HYPH
cord-005478-5iu38pr6	2517	11	identical	identical	JJ
cord-005478-5iu38pr6	2517	12	donor	donor	NN
cord-005478-5iu38pr6	2517	13	died	die	VBD
cord-005478-5iu38pr6	2517	14	.	.	.
cord-005478-5iu38pr6	2518	1	All	all	DT
cord-005478-5iu38pr6	2518	2	deaths	death	NNS
cord-005478-5iu38pr6	2518	3	occurred	occur	VBD
cord-005478-5iu38pr6	2518	4	in	in	IN
cord-005478-5iu38pr6	2518	5	the	the	DT
cord-005478-5iu38pr6	2518	6	firstyear	firstyear	FW
cord-005478-5iu38pr6	2518	7	post	post	NN
cord-005478-5iu38pr6	2518	8	-	-	NN
cord-005478-5iu38pr6	2518	9	transplant	transplant	NN
cord-005478-5iu38pr6	2518	10	.	.	.
cord-005478-5iu38pr6	2519	1	Thus	thus	RB
cord-005478-5iu38pr6	2519	2	,	,	,
cord-005478-5iu38pr6	2519	3	the	the	DT
cord-005478-5iu38pr6	2519	4	use	use	NN
cord-005478-5iu38pr6	2519	5	of	of	IN
cord-005478-5iu38pr6	2519	6	an	an	DT
cord-005478-5iu38pr6	2519	7	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2519	8	donor	donor	NN
cord-005478-5iu38pr6	2519	9	was	be	VBD
cord-005478-5iu38pr6	2519	10	associated	associate	VBN
cord-005478-5iu38pr6	2519	11	with	with	IN
cord-005478-5iu38pr6	2519	12	an	an	DT
cord-005478-5iu38pr6	2519	13	adverse	adverse	JJ
cord-005478-5iu38pr6	2519	14	outcome	outcome	NN
cord-005478-5iu38pr6	2519	15	.	.	.
cord-005478-5iu38pr6	2520	1	Conversely	conversely	RB
cord-005478-5iu38pr6	2520	2	,	,	,
cord-005478-5iu38pr6	2520	3	neither	neither	CC
cord-005478-5iu38pr6	2520	4	the	the	DT
cord-005478-5iu38pr6	2520	5	conditioning	conditioning	NN
cord-005478-5iu38pr6	2520	6	nor	nor	CC
cord-005478-5iu38pr6	2520	7	the	the	DT
cord-005478-5iu38pr6	2520	8	stem	stem	NN
cord-005478-5iu38pr6	2520	9	cell	cell	NN
cord-005478-5iu38pr6	2520	10	source	source	NN
cord-005478-5iu38pr6	2520	11	was	be	VBD
cord-005478-5iu38pr6	2520	12	associated	associate	VBN
cord-005478-5iu38pr6	2520	13	with	with	IN
cord-005478-5iu38pr6	2520	14	a	a	DT
cord-005478-5iu38pr6	2520	15	worse	bad	JJR
cord-005478-5iu38pr6	2520	16	outcome	outcome	NN
cord-005478-5iu38pr6	2520	17	.	.	.
cord-005478-5iu38pr6	2521	1	Except	except	IN
cord-005478-5iu38pr6	2521	2	one	one	CD
cord-005478-5iu38pr6	2521	3	patient	patient	NN
cord-005478-5iu38pr6	2521	4	with	with	IN
cord-005478-5iu38pr6	2521	5	an	an	DT
cord-005478-5iu38pr6	2521	6	history	history	NN
cord-005478-5iu38pr6	2521	7	of	of	IN
cord-005478-5iu38pr6	2521	8	aggressive	aggressive	JJ
cord-005478-5iu38pr6	2521	9	B	b	NN
cord-005478-5iu38pr6	2521	10	cell	cell	NN
cord-005478-5iu38pr6	2521	11	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2521	12	who	who	WP
cord-005478-5iu38pr6	2521	13	relapsed	relapse	VBD
cord-005478-5iu38pr6	2521	14	few	few	JJ
cord-005478-5iu38pr6	2521	15	months	month	NNS
cord-005478-5iu38pr6	2521	16	after	after	IN
cord-005478-5iu38pr6	2521	17	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2521	18	,	,	,
cord-005478-5iu38pr6	2521	19	no	no	DT
cord-005478-5iu38pr6	2521	20	patient	patient	NN
cord-005478-5iu38pr6	2521	21	with	with	IN
cord-005478-5iu38pr6	2521	22	an	an	DT
cord-005478-5iu38pr6	2521	23	history	history	NN
cord-005478-5iu38pr6	2521	24	of	of	IN
cord-005478-5iu38pr6	2521	25	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2521	26	relapsed	relapse	VBN
cord-005478-5iu38pr6	2521	27	.	.	.
cord-005478-5iu38pr6	2522	1	After	after	IN
cord-005478-5iu38pr6	2522	2	a	a	DT
cord-005478-5iu38pr6	2522	3	salvage	salvage	NN
cord-005478-5iu38pr6	2522	4	treatment	treatment	NN
cord-005478-5iu38pr6	2522	5	,	,	,
cord-005478-5iu38pr6	2522	6	the	the	DT
cord-005478-5iu38pr6	2522	7	relapsing	relapse	VBG
cord-005478-5iu38pr6	2522	8	patient	patient	NN
cord-005478-5iu38pr6	2522	9	remained	remain	VBD
cord-005478-5iu38pr6	2522	10	in	in	IN
cord-005478-5iu38pr6	2522	11	complete	complete	JJ
cord-005478-5iu38pr6	2522	12	remission	remission	NN
cord-005478-5iu38pr6	2522	13	5	5	CD
cord-005478-5iu38pr6	2522	14	years	year	NNS
cord-005478-5iu38pr6	2522	15	later	later	RB
cord-005478-5iu38pr6	2522	16	.	.	.
cord-005478-5iu38pr6	2523	1	At	at	IN
cord-005478-5iu38pr6	2523	2	last	last	JJ
cord-005478-5iu38pr6	2523	3	follow	follow	NN
cord-005478-5iu38pr6	2523	4	-	-	HYPH
cord-005478-5iu38pr6	2523	5	up	up	NN
cord-005478-5iu38pr6	2523	6	,	,	,
cord-005478-5iu38pr6	2523	7	all	all	DT
cord-005478-5iu38pr6	2523	8	surviving	survive	VBG
cord-005478-5iu38pr6	2523	9	patients	patient	NNS
cord-005478-5iu38pr6	2523	10	had	have	VBD
cord-005478-5iu38pr6	2523	11	a	a	DT
cord-005478-5iu38pr6	2523	12	stable	stable	JJ
cord-005478-5iu38pr6	2523	13	,	,	,
cord-005478-5iu38pr6	2523	14	mixed	mixed	JJ
cord-005478-5iu38pr6	2523	15	donorrecipient	donorrecipient	NN
cord-005478-5iu38pr6	2523	16	or	or	CC
cord-005478-5iu38pr6	2523	17	full	full	JJ
cord-005478-5iu38pr6	2523	18	donor	donor	NN
cord-005478-5iu38pr6	2523	19	chimerism	chimerism	NN
cord-005478-5iu38pr6	2523	20	without	without	IN
cord-005478-5iu38pr6	2523	21	any	any	DT
cord-005478-5iu38pr6	2523	22	sign	sign	NN
cord-005478-5iu38pr6	2523	23	of	of	IN
cord-005478-5iu38pr6	2523	24	active	active	JJ
cord-005478-5iu38pr6	2523	25	infection	infection	NN
cord-005478-5iu38pr6	2523	26	.	.	.
cord-005478-5iu38pr6	2524	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2524	2	:	:	:
cord-005478-5iu38pr6	2525	1	AlloSCT	AlloSCT	NNP
cord-005478-5iu38pr6	2525	2	in	in	IN
cord-005478-5iu38pr6	2525	3	the	the	DT
cord-005478-5iu38pr6	2525	4	PID	pid	NN
cord-005478-5iu38pr6	2525	5	setting	setting	NN
cord-005478-5iu38pr6	2525	6	is	be	VBZ
cord-005478-5iu38pr6	2525	7	an	an	DT
cord-005478-5iu38pr6	2525	8	effective	effective	JJ
cord-005478-5iu38pr6	2525	9	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	2525	10	with	with	IN
cord-005478-5iu38pr6	2525	11	an	an	DT
cord-005478-5iu38pr6	2525	12	acceptable	acceptable	JJ
cord-005478-5iu38pr6	2525	13	toxicity	toxicity	NN
cord-005478-5iu38pr6	2525	14	and	and	CC
cord-005478-5iu38pr6	2525	15	should	should	MD
cord-005478-5iu38pr6	2525	16	be	be	VB
cord-005478-5iu38pr6	2525	17	considered	consider	VBN
cord-005478-5iu38pr6	2525	18	in	in	IN
cord-005478-5iu38pr6	2525	19	case	case	NN
cord-005478-5iu38pr6	2525	20	of	of	IN
cord-005478-5iu38pr6	2525	21	severe	severe	JJ
cord-005478-5iu38pr6	2525	22	infectious	infectious	JJ
cord-005478-5iu38pr6	2525	23	,	,	,
cord-005478-5iu38pr6	2525	24	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	2525	25	and/or	and/or	CC
cord-005478-5iu38pr6	2525	26	malignant	malignant	JJ
cord-005478-5iu38pr6	2525	27	complications	complication	NNS
cord-005478-5iu38pr6	2525	28	in	in	IN
cord-005478-5iu38pr6	2525	29	young	young	JJ
cord-005478-5iu38pr6	2525	30	adult	adult	NN
cord-005478-5iu38pr6	2525	31	patients	patient	NNS
cord-005478-5iu38pr6	2525	32	with	with	IN
cord-005478-5iu38pr6	2525	33	PID	PID	NNP
cord-005478-5iu38pr6	2525	34	when	when	WRB
cord-005478-5iu38pr6	2525	35	an	an	DT
cord-005478-5iu38pr6	2525	36	appropriate	appropriate	JJ
cord-005478-5iu38pr6	2525	37	donor	donor	NN
cord-005478-5iu38pr6	2525	38	is	be	VBZ
cord-005478-5iu38pr6	2525	39	available	available	JJ
cord-005478-5iu38pr6	2525	40	.	.	.
cord-005478-5iu38pr6	2526	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2526	2	Methods	method	NNS
cord-005478-5iu38pr6	2527	1	:	:	:
cord-005478-5iu38pr6	2527	2	We	-PRON-	PRP
cord-005478-5iu38pr6	2527	3	analyzed	analyze	VBD
cord-005478-5iu38pr6	2527	4	the	the	DT
cord-005478-5iu38pr6	2527	5	results	result	NNS
cord-005478-5iu38pr6	2527	6	of	of	IN
cord-005478-5iu38pr6	2527	7	allogenic	allogenic	JJ
cord-005478-5iu38pr6	2527	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2527	9	with	with	IN
cord-005478-5iu38pr6	2527	10	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	2528	1	/CD19	/CD19	NNP
cord-005478-5iu38pr6	2528	2	graft	graft	NN
cord-005478-5iu38pr6	2528	3	depletion	depletion	NN
cord-005478-5iu38pr6	2528	4	in	in	IN
cord-005478-5iu38pr6	2528	5	148	148	CD
cord-005478-5iu38pr6	2528	6	patients	patient	NNS
cord-005478-5iu38pr6	2528	7	with	with	IN
cord-005478-5iu38pr6	2528	8	various	various	JJ
cord-005478-5iu38pr6	2528	9	PID	pid	NN
cord-005478-5iu38pr6	2528	10	(	(	-LRB-
cord-005478-5iu38pr6	2528	11	excluding	exclude	VBG
cord-005478-5iu38pr6	2528	12	classic	classic	JJ
cord-005478-5iu38pr6	2528	13	SCID	SCID	NNP
cord-005478-5iu38pr6	2528	14	)	)	-RRB-
cord-005478-5iu38pr6	2528	15	who	who	WP
cord-005478-5iu38pr6	2528	16	received	receive	VBD
cord-005478-5iu38pr6	2528	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2528	18	from	from	IN
cord-005478-5iu38pr6	2528	19	May	May	NNP
cord-005478-5iu38pr6	2528	20	2012	2012	CD
cord-005478-5iu38pr6	2528	21	to	to	IN
cord-005478-5iu38pr6	2528	22	September	September	NNP
cord-005478-5iu38pr6	2528	23	2018	2018	CD
cord-005478-5iu38pr6	2528	24	in	in	IN
cord-005478-5iu38pr6	2528	25	our	-PRON-	PRP$
cord-005478-5iu38pr6	2528	26	center	center	NN
cord-005478-5iu38pr6	2528	27	.	.	.
cord-005478-5iu38pr6	2529	1	The	the	DT
cord-005478-5iu38pr6	2529	2	median	median	JJ
cord-005478-5iu38pr6	2529	3	age	age	NN
cord-005478-5iu38pr6	2529	4	at	at	IN
cord-005478-5iu38pr6	2529	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2529	6	was	be	VBD
cord-005478-5iu38pr6	2529	7	3,5	3,5	CD
cord-005478-5iu38pr6	2529	8	years	year	NNS
cord-005478-5iu38pr6	2530	1	(	(	-LRB-
cord-005478-5iu38pr6	2530	2	range	range	VB
cord-005478-5iu38pr6	2530	3	0,43	0,43	CD
cord-005478-5iu38pr6	2530	4	-	-	HYPH
cord-005478-5iu38pr6	2530	5	17,63	17,63	CD
cord-005478-5iu38pr6	2530	6	)	)	-RRB-
cord-005478-5iu38pr6	2530	7	.	.	.
cord-005478-5iu38pr6	2531	1	112	112	CD
cord-005478-5iu38pr6	2531	2	patients	patient	NNS
cord-005478-5iu38pr6	2531	3	received	receive	VBD
cord-005478-5iu38pr6	2531	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2531	5	from	from	IN
cord-005478-5iu38pr6	2531	6	matched	match	VBN
cord-005478-5iu38pr6	2531	7	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2531	8	,	,	,
cord-005478-5iu38pr6	2531	9	31haploidentical	31haploidentical	CD
cord-005478-5iu38pr6	2531	10	donors	donor	NNS
cord-005478-5iu38pr6	2531	11	,	,	,
cord-005478-5iu38pr6	2531	12	5	5	CD
cord-005478-5iu38pr6	2531	13	-siblings	-sibling	NNS
cord-005478-5iu38pr6	2531	14	.	.	.
cord-005478-5iu38pr6	2532	1	The	the	DT
cord-005478-5iu38pr6	2532	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	2532	3	regimens	regimen	NNS
cord-005478-5iu38pr6	2532	4	included	include	VBD
cord-005478-5iu38pr6	2532	5	:	:	:
cord-005478-5iu38pr6	2533	1	Fludarabin	Fludarabin	NNP
cord-005478-5iu38pr6	2533	2	(	(	-LRB-
cord-005478-5iu38pr6	2533	3	Flu	Flu	NNP
cord-005478-5iu38pr6	2533	4	)	)	-RRB-
cord-005478-5iu38pr6	2533	5	150mg	150mg	NNP
cord-005478-5iu38pr6	2533	6	/	/	SYM
cord-005478-5iu38pr6	2533	7	m2	m2	NNP
cord-005478-5iu38pr6	2533	8	with	with	IN
cord-005478-5iu38pr6	2533	9	1	1	CD
cord-005478-5iu38pr6	2533	10	alkylator	alkylator	NN
cord-005478-5iu38pr6	2533	11	(	(	-LRB-
cord-005478-5iu38pr6	2533	12	Treosulfan	Treosulfan	NNP
cord-005478-5iu38pr6	2533	13	(	(	-LRB-
cord-005478-5iu38pr6	2533	14	Treo	Treo	NNP
cord-005478-5iu38pr6	2533	15	)	)	-RRB-
cord-005478-5iu38pr6	2533	16	36	36	CD
cord-005478-5iu38pr6	2533	17	-	-	HYPH
cord-005478-5iu38pr6	2533	18	42g	42g	NNS
cord-005478-5iu38pr6	2533	19	/	/	SYM
cord-005478-5iu38pr6	2533	20	m2	m2	NNP
cord-005478-5iu38pr6	2533	21	)	)	-RRB-
cord-005478-5iu38pr6	2533	22	in	in	IN
cord-005478-5iu38pr6	2533	23	33	33	CD
cord-005478-5iu38pr6	2533	24	patients	patient	NNS
cord-005478-5iu38pr6	2533	25	,	,	,
cord-005478-5iu38pr6	2533	26	with	with	IN
cord-005478-5iu38pr6	2533	27	2	2	CD
cord-005478-5iu38pr6	2533	28	alkylators	alkylator	NNS
cord-005478-5iu38pr6	2533	29	(	(	-LRB-
cord-005478-5iu38pr6	2533	30	Treo	Treo	NNP
cord-005478-5iu38pr6	2533	31	36	36	CD
cord-005478-5iu38pr6	2533	32	-	-	HYPH
cord-005478-5iu38pr6	2533	33	42g	42g	NNS
cord-005478-5iu38pr6	2533	34	/	/	SYM
cord-005478-5iu38pr6	2533	35	m2	m2	NNP
cord-005478-5iu38pr6	2533	36	with	with	IN
cord-005478-5iu38pr6	2533	37	Melphalan	Melphalan	NNP
cord-005478-5iu38pr6	2533	38	140mg	140mg	NNP
cord-005478-5iu38pr6	2533	39	/	/	SYM
cord-005478-5iu38pr6	2533	40	m2	m2	NNP
cord-005478-5iu38pr6	2533	41	or	or	CC
cord-005478-5iu38pr6	2533	42	Thyotepa	Thyotepa	NNP
cord-005478-5iu38pr6	2533	43	10mg	10mg	NNP
cord-005478-5iu38pr6	2533	44	/	/	SYM
cord-005478-5iu38pr6	2533	45	kg	kg	NNP
cord-005478-5iu38pr6	2533	46	)	)	-RRB-
cord-005478-5iu38pr6	2533	47	in	in	IN
cord-005478-5iu38pr6	2533	48	74	74	CD
cord-005478-5iu38pr6	2533	49	.	.	.
cord-005478-5iu38pr6	2534	1	Twenty	twenty	CD
cord-005478-5iu38pr6	2534	2	-	-	HYPH
cord-005478-5iu38pr6	2534	3	five	five	CD
cord-005478-5iu38pr6	2534	4	patients	patient	NNS
cord-005478-5iu38pr6	2534	5	received	receive	VBD
cord-005478-5iu38pr6	2534	6	2	2	CD
cord-005478-5iu38pr6	2534	7	alkylators	alkylator	NNS
cord-005478-5iu38pr6	2534	8	with	with	IN
cord-005478-5iu38pr6	2534	9	addition	addition	NN
cord-005478-5iu38pr6	2534	10	of	of	IN
cord-005478-5iu38pr6	2534	11	G	G	NNP
cord-005478-5iu38pr6	2534	12	-	-	HYPH
cord-005478-5iu38pr6	2534	13	CSF	CSF	NNP
cord-005478-5iu38pr6	2534	14	30mg	30mg	NNP
cord-005478-5iu38pr6	2534	15	/	/	SYM
cord-005478-5iu38pr6	2534	16	kg	kg	NNP
cord-005478-5iu38pr6	2534	17	and	and	CC
cord-005478-5iu38pr6	2534	18	Plerixafor	Plerixafor	NNP
cord-005478-5iu38pr6	2534	19	24mg	24mg	NNP
cord-005478-5iu38pr6	2534	20	/	/	SYM
cord-005478-5iu38pr6	2534	21	kg	kg	NN
cord-005478-5iu38pr6	2534	22	.	.	.
cord-005478-5iu38pr6	2535	1	Seventeen	seventeen	CD
cord-005478-5iu38pr6	2535	2	patients	patient	NNS
cord-005478-5iu38pr6	2535	3	with	with	IN
cord-005478-5iu38pr6	2535	4	Nijmegen	Nijmegen	NNP
cord-005478-5iu38pr6	2535	5	breakage	breakage	NN
cord-005478-5iu38pr6	2535	6	syndrome	syndrome	NN
cord-005478-5iu38pr6	2535	7	(	(	-LRB-
cord-005478-5iu38pr6	2535	8	NBS	NBS	NNP
cord-005478-5iu38pr6	2535	9	)	)	-RRB-
cord-005478-5iu38pr6	2535	10	received	receive	VBD
cord-005478-5iu38pr6	2535	11	reduced	reduced	JJ
cord-005478-5iu38pr6	2535	12	intensity	intensity	NN
cord-005478-5iu38pr6	2535	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	2535	14	with	with	IN
cord-005478-5iu38pr6	2535	15	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	2535	16	4mg	4mg	NNP
cord-005478-5iu38pr6	2535	17	/	/	SYM
cord-005478-5iu38pr6	2535	18	kg	kg	NN
cord-005478-5iu38pr6	2535	19	or	or	CC
cord-005478-5iu38pr6	2535	20	Treo	Treo	NNP
cord-005478-5iu38pr6	2535	21	30mg	30mg	NNP
cord-005478-5iu38pr6	2535	22	/	/	SYM
cord-005478-5iu38pr6	2535	23	m2	m2	NNP
cord-005478-5iu38pr6	2535	24	,	,	,
cord-005478-5iu38pr6	2535	25	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	2535	26	40mg	40mg	NNP
cord-005478-5iu38pr6	2535	27	/	/	SYM
cord-005478-5iu38pr6	2535	28	kg	kg	NNP
cord-005478-5iu38pr6	2535	29	and	and	CC
cord-005478-5iu38pr6	2535	30	Flu	Flu	NNP
cord-005478-5iu38pr6	2535	31	150mg	150mg	NNP
cord-005478-5iu38pr6	2535	32	/	/	SYM
cord-005478-5iu38pr6	2535	33	m2	m2	NNP
cord-005478-5iu38pr6	2535	34	.	.	.
cord-005478-5iu38pr6	2536	1	In	in	IN
cord-005478-5iu38pr6	2536	2	all	all	DT
cord-005478-5iu38pr6	2536	3	but	but	CC
cord-005478-5iu38pr6	2536	4	2	2	CD
cord-005478-5iu38pr6	2536	5	patients	patient	NNS
cord-005478-5iu38pr6	2536	6	serotherapy	serotherapy	NNP
cord-005478-5iu38pr6	2536	7	was	be	VBD
cord-005478-5iu38pr6	2536	8	used	use	VBN
cord-005478-5iu38pr6	2536	9	:	:	:
cord-005478-5iu38pr6	2536	10	10	10	CD
cord-005478-5iu38pr6	2536	11	patients	patient	NNS
cord-005478-5iu38pr6	2536	12	-horse	-horse	NNP
cord-005478-5iu38pr6	2536	13	ATG	ATG	NNP
cord-005478-5iu38pr6	2536	14	-90	-90	NN
cord-005478-5iu38pr6	2536	15	mg	mg	NN
cord-005478-5iu38pr6	2537	1	/kg	/kg	NFP
cord-005478-5iu38pr6	2537	2	,	,	,
cord-005478-5iu38pr6	2537	3	133	133	CD
cord-005478-5iu38pr6	2537	4	-rabbit	-rabbit	NNP
cord-005478-5iu38pr6	2537	5	ATG	ATG	NNP
cord-005478-5iu38pr6	2537	6	(	(	-LRB-
cord-005478-5iu38pr6	2537	7	Thymoglobulin	Thymoglobulin	NNP
cord-005478-5iu38pr6	2537	8	)	)	-RRB-
cord-005478-5iu38pr6	2537	9	5mg	5mg	NN
cord-005478-5iu38pr6	2537	10	/	/	SYM
cord-005478-5iu38pr6	2537	11	kg	kg	NN
cord-005478-5iu38pr6	2537	12	,	,	,
cord-005478-5iu38pr6	2537	13	3	3	CD
cord-005478-5iu38pr6	2537	14	-1mg	-1mg	CD
cord-005478-5iu38pr6	2537	15	/	/	SYM
cord-005478-5iu38pr6	2537	16	kg	kg	CC
cord-005478-5iu38pr6	2537	17	anti	anti	JJ
cord-005478-5iu38pr6	2537	18	CD52	CD52	NNP
cord-005478-5iu38pr6	2537	19	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	2537	20	antibodies	antibody	NNS
cord-005478-5iu38pr6	2537	21	.	.	.
cord-005478-5iu38pr6	2538	1	In	in	IN
cord-005478-5iu38pr6	2538	2	55	55	CD
cord-005478-5iu38pr6	2538	3	patients	patient	NNS
cord-005478-5iu38pr6	2538	4	two	two	CD
cord-005478-5iu38pr6	2538	5	or	or	CC
cord-005478-5iu38pr6	2538	6	more	more	RBR
cord-005478-5iu38pr6	2538	7	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2538	8	drugs	drug	NNS
cord-005478-5iu38pr6	2538	9	were	be	VBD
cord-005478-5iu38pr6	2538	10	used	use	VBN
cord-005478-5iu38pr6	2538	11	after	after	IN
cord-005478-5iu38pr6	2538	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	2538	13	(	(	-LRB-
cord-005478-5iu38pr6	2538	14	combination	combination	NN
cord-005478-5iu38pr6	2538	15	of	of	IN
cord-005478-5iu38pr6	2538	16	calcineurin	calcineurin	JJ
cord-005478-5iu38pr6	2538	17	inhibitor	inhibitor	NN
cord-005478-5iu38pr6	2538	18	(	(	-LRB-
cord-005478-5iu38pr6	2538	19	CNI	CNI	NNP
cord-005478-5iu38pr6	2538	20	)	)	-RRB-
cord-005478-5iu38pr6	2538	21	with	with	IN
cord-005478-5iu38pr6	2538	22	short	short	JJ
cord-005478-5iu38pr6	2538	23	course	course	NN
cord-005478-5iu38pr6	2538	24	of	of	IN
cord-005478-5iu38pr6	2538	25	methotrexate	methotrexate	NNP
cord-005478-5iu38pr6	2538	26	,	,	,
cord-005478-5iu38pr6	2538	27	or	or	CC
cord-005478-5iu38pr6	2538	28	mycophenolate	mycophenolate	NNP
cord-005478-5iu38pr6	2538	29	mofetil	mofetil	NNP
cord-005478-5iu38pr6	2538	30	,	,	,
cord-005478-5iu38pr6	2538	31	or	or	CC
cord-005478-5iu38pr6	2538	32	abatacept	abatacept	NNP
cord-005478-5iu38pr6	2538	33	)	)	-RRB-
cord-005478-5iu38pr6	2538	34	,	,	,
cord-005478-5iu38pr6	2538	35	66	66	CD
cord-005478-5iu38pr6	2538	36	patients	patient	NNS
cord-005478-5iu38pr6	2538	37	received	receive	VBD
cord-005478-5iu38pr6	2538	38	one	one	CD
cord-005478-5iu38pr6	2538	39	immunosupressive	immunosupressive	JJ
cord-005478-5iu38pr6	2538	40	agent	agent	NN
cord-005478-5iu38pr6	2538	41	(	(	-LRB-
cord-005478-5iu38pr6	2538	42	CNI	CNI	NNP
cord-005478-5iu38pr6	2538	43	)	)	-RRB-
cord-005478-5iu38pr6	2538	44	.	.	.
cord-005478-5iu38pr6	2539	1	From	from	IN
cord-005478-5iu38pr6	2539	2	November	November	NNP
cord-005478-5iu38pr6	2539	3	2017	2017	CD
cord-005478-5iu38pr6	2539	4	no	no	DT
cord-005478-5iu38pr6	2539	5	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	2539	6	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2539	7	was	be	VBD
cord-005478-5iu38pr6	2539	8	used	use	VBN
cord-005478-5iu38pr6	2539	9	(	(	-LRB-
cord-005478-5iu38pr6	2539	10	27	27	CD
cord-005478-5iu38pr6	2539	11	patients	patient	NNS
cord-005478-5iu38pr6	2539	12	)	)	-RRB-
cord-005478-5iu38pr6	2539	13	.	.	.
cord-005478-5iu38pr6	2540	1	Primary	primary	JJ
cord-005478-5iu38pr6	2540	2	end	end	NN
cord-005478-5iu38pr6	2540	3	points	point	NNS
cord-005478-5iu38pr6	2540	4	were	be	VBD
cord-005478-5iu38pr6	2540	5	:	:	:
cord-005478-5iu38pr6	2540	6	incidence	incidence	NN
cord-005478-5iu38pr6	2540	7	of	of	IN
cord-005478-5iu38pr6	2540	8	acute	acute	JJ
cord-005478-5iu38pr6	2540	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2540	10	,	,	,
cord-005478-5iu38pr6	2540	11	graft	graft	NN
cord-005478-5iu38pr6	2540	12	failure	failure	NN
cord-005478-5iu38pr6	2540	13	(	(	-LRB-
cord-005478-5iu38pr6	2540	14	GF	GF	NNP
cord-005478-5iu38pr6	2540	15	)	)	-RRB-
cord-005478-5iu38pr6	2540	16	and	and	CC
cord-005478-5iu38pr6	2540	17	transplant	transplant	NN
cord-005478-5iu38pr6	2540	18	related	relate	VBN
cord-005478-5iu38pr6	2540	19	mortality	mortality	NN
cord-005478-5iu38pr6	2540	20	(	(	-LRB-
cord-005478-5iu38pr6	2540	21	TRM	TRM	NNP
cord-005478-5iu38pr6	2540	22	)	)	-RRB-
cord-005478-5iu38pr6	2540	23	.	.	.
cord-005478-5iu38pr6	2541	1	Because	because	IN
cord-005478-5iu38pr6	2541	2	of	of	IN
cord-005478-5iu38pr6	2541	3	the	the	DT
cord-005478-5iu38pr6	2541	4	supposed	suppose	VBN
cord-005478-5iu38pr6	2541	5	influence	influence	NN
cord-005478-5iu38pr6	2541	6	of	of	IN
cord-005478-5iu38pr6	2541	7	conditioning	conditioning	NN
cord-005478-5iu38pr6	2541	8	regimen	regimen	NN
cord-005478-5iu38pr6	2541	9	on	on	IN
cord-005478-5iu38pr6	2541	10	GF	GF	NNP
cord-005478-5iu38pr6	2541	11	and	and	CC
cord-005478-5iu38pr6	2541	12	TRM	TRM	NNP
cord-005478-5iu38pr6	2541	13	incidence	incidence	NN
cord-005478-5iu38pr6	2541	14	,	,	,
cord-005478-5iu38pr6	2541	15	to	to	IN
cord-005478-5iu38pr6	2541	16	the	the	DT
cord-005478-5iu38pr6	2541	17	analysis	analysis	NN
cord-005478-5iu38pr6	2541	18	of	of	IN
cord-005478-5iu38pr6	2541	19	GF	GF	NNP
cord-005478-5iu38pr6	2541	20	and	and	CC
cord-005478-5iu38pr6	2541	21	TRM	TRM	NNP
cord-005478-5iu38pr6	2541	22	were	be	VBD
cord-005478-5iu38pr6	2541	23	included	include	VBN
cord-005478-5iu38pr6	2541	24	only	only	RB
cord-005478-5iu38pr6	2541	25	74	74	CD
cord-005478-5iu38pr6	2541	26	patients	patient	NNS
cord-005478-5iu38pr6	2541	27	with	with	IN
cord-005478-5iu38pr6	2541	28	similar	similar	JJ
cord-005478-5iu38pr6	2541	29	conditioning	conditioning	NN
cord-005478-5iu38pr6	2541	30	regimen	regimen	NN
cord-005478-5iu38pr6	2541	31	with	with	IN
cord-005478-5iu38pr6	2541	32	2	2	CD
cord-005478-5iu38pr6	2541	33	alkylators	alkylator	NNS
cord-005478-5iu38pr6	2541	34	(	(	-LRB-
cord-005478-5iu38pr6	2541	35	excluding	exclude	VBG
cord-005478-5iu38pr6	2541	36	patients	patient	NNS
cord-005478-5iu38pr6	2541	37	with	with	IN
cord-005478-5iu38pr6	2541	38	NBS	NBS	NNP
cord-005478-5iu38pr6	2541	39	,	,	,
cord-005478-5iu38pr6	2541	40	with	with	IN
cord-005478-5iu38pr6	2541	41	1	1	CD
cord-005478-5iu38pr6	2541	42	alkylator	alkylator	NN
cord-005478-5iu38pr6	2541	43	and	and	CC
cord-005478-5iu38pr6	2541	44	addition	addition	NN
cord-005478-5iu38pr6	2541	45	of	of	IN
cord-005478-5iu38pr6	2541	46	G	G	NNP
cord-005478-5iu38pr6	2541	47	-	-	HYPH
cord-005478-5iu38pr6	2541	48	CSF	CSF	NNP
cord-005478-5iu38pr6	2541	49	and	and	CC
cord-005478-5iu38pr6	2541	50	plerixafor	plerixafor	NN
cord-005478-5iu38pr6	2541	51	in	in	IN
cord-005478-5iu38pr6	2541	52	conditioning	conditioning	NN
cord-005478-5iu38pr6	2541	53	regimen	regimen	NN
cord-005478-5iu38pr6	2541	54	)	)	-RRB-
cord-005478-5iu38pr6	2541	55	.	.	.
cord-005478-5iu38pr6	2542	1	Median	median	JJ
cord-005478-5iu38pr6	2542	2	follow	follow	VBP
cord-005478-5iu38pr6	2542	3	up	up	RP
cord-005478-5iu38pr6	2542	4	after	after	IN
cord-005478-5iu38pr6	2542	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2542	6	was	be	VBD
cord-005478-5iu38pr6	2542	7	1,95	1,95	CD
cord-005478-5iu38pr6	2542	8	years	year	NNS
cord-005478-5iu38pr6	2543	1	(	(	-LRB-
cord-005478-5iu38pr6	2543	2	range	range	NNP
cord-005478-5iu38pr6	2543	3	0,04	0,04	CD
cord-005478-5iu38pr6	2543	4	-	-	HYPH
cord-005478-5iu38pr6	2543	5	6,3	6,3	CD
cord-005478-5iu38pr6	2543	6	years	year	NNS
cord-005478-5iu38pr6	2543	7	)	)	-RRB-
cord-005478-5iu38pr6	2543	8	.	.	.
cord-005478-5iu38pr6	2544	1	Results	result	NNS
cord-005478-5iu38pr6	2544	2	:	:	:
cord-005478-5iu38pr6	2545	1	Overall	overall	JJ
cord-005478-5iu38pr6	2545	2	survival	survival	NN
cord-005478-5iu38pr6	2545	3	(	(	-LRB-
cord-005478-5iu38pr6	2545	4	OS	OS	NNP
cord-005478-5iu38pr6	2545	5	)	)	-RRB-
cord-005478-5iu38pr6	2545	6	in	in	IN
cord-005478-5iu38pr6	2545	7	148	148	CD
cord-005478-5iu38pr6	2545	8	patients	patient	NNS
cord-005478-5iu38pr6	2545	9	was	be	VBD
cord-005478-5iu38pr6	2545	10	0,85	0,85	CD
cord-005478-5iu38pr6	2545	11	(	(	-LRB-
cord-005478-5iu38pr6	2545	12	95	95	CD
cord-005478-5iu38pr6	2545	13	%	%	NN
cord-005478-5iu38pr6	2545	14	CI	CI	NNP
cord-005478-5iu38pr6	2545	15	0,79	0,79	CD
cord-005478-5iu38pr6	2545	16	-	-	HYPH
cord-005478-5iu38pr6	2545	17	0,91	0,91	CD
cord-005478-5iu38pr6	2545	18	)	)	-RRB-
cord-005478-5iu38pr6	2545	19	.	.	.
cord-005478-5iu38pr6	2546	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2546	2	incidence	incidence	NN
cord-005478-5iu38pr6	2546	3	(	(	-LRB-
cord-005478-5iu38pr6	2546	4	CI	CI	NNP
cord-005478-5iu38pr6	2546	5	)	)	-RRB-
cord-005478-5iu38pr6	2546	6	of	of	IN
cord-005478-5iu38pr6	2546	7	acute	acute	JJ
cord-005478-5iu38pr6	2546	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2546	9	in	in	IN
cord-005478-5iu38pr6	2546	10	patients	patient	NNS
cord-005478-5iu38pr6	2546	11	with	with	IN
cord-005478-5iu38pr6	2546	12	two	two	CD
cord-005478-5iu38pr6	2546	13	and	and	CC
cord-005478-5iu38pr6	2546	14	more	more	JJR
cord-005478-5iu38pr6	2546	15	immunosupressants	immunosupressant	NNS
cord-005478-5iu38pr6	2546	16	was	be	VBD
cord-005478-5iu38pr6	2546	17	0,164	0,164	CD
cord-005478-5iu38pr6	2546	18	(	(	-LRB-
cord-005478-5iu38pr6	2546	19	95	95	CD
cord-005478-5iu38pr6	2546	20	%	%	NN
cord-005478-5iu38pr6	2547	1	CI	CI	NNP
cord-005478-5iu38pr6	2547	2	0,09	0,09	CD
cord-005478-5iu38pr6	2547	3	-0,3	-0,3	NNP
cord-005478-5iu38pr6	2547	4	)	)	-RRB-
cord-005478-5iu38pr6	2547	5	,	,	,
cord-005478-5iu38pr6	2547	6	with	with	IN
cord-005478-5iu38pr6	2547	7	one	one	CD
cord-005478-5iu38pr6	2547	8	-0,17	-0,17	:
cord-005478-5iu38pr6	2547	9	(	(	-LRB-
cord-005478-5iu38pr6	2547	10	95	95	CD
cord-005478-5iu38pr6	2547	11	%	%	NN
cord-005478-5iu38pr6	2547	12	CI	CI	NNP
cord-005478-5iu38pr6	2547	13	0,1	0,1	CD
cord-005478-5iu38pr6	2547	14	-0,29	-0,29	CD
cord-005478-5iu38pr6	2547	15	)	)	-RRB-
cord-005478-5iu38pr6	2548	1	,	,	,
cord-005478-5iu38pr6	2548	2	with	with	IN
cord-005478-5iu38pr6	2548	3	no	no	DT
cord-005478-5iu38pr6	2548	4	immunosupression	immunosupression	NN
cord-005478-5iu38pr6	2548	5	-0,11	-0,11	.
cord-005478-5iu38pr6	2548	6	(	(	-LRB-
cord-005478-5iu38pr6	2548	7	95	95	CD
cord-005478-5iu38pr6	2548	8	%	%	NN
cord-005478-5iu38pr6	2548	9	CI	CI	NNP
cord-005478-5iu38pr6	2548	10	0,04	0,04	NNP
cord-005478-5iu38pr6	2548	11	-0,32	-0,32	NN
cord-005478-5iu38pr6	2548	12	)	)	-RRB-
cord-005478-5iu38pr6	2549	1	,	,	,
cord-005478-5iu38pr6	2549	2	p=0,843	p=0,843	NNP
cord-005478-5iu38pr6	2549	3	.	.	.
cord-005478-5iu38pr6	2550	1	CI	CI	NNP
cord-005478-5iu38pr6	2550	2	of	of	IN
cord-005478-5iu38pr6	2550	3	graft	graft	NN
cord-005478-5iu38pr6	2550	4	failure	failure	NN
cord-005478-5iu38pr6	2550	5	was	be	VBD
cord-005478-5iu38pr6	2550	6	:	:	:
cord-005478-5iu38pr6	2550	7	in	in	IN
cord-005478-5iu38pr6	2550	8	patients	patient	NNS
cord-005478-5iu38pr6	2550	9	with	with	IN
cord-005478-5iu38pr6	2550	10	two	two	CD
cord-005478-5iu38pr6	2550	11	and	and	CC
cord-005478-5iu38pr6	2550	12	more	more	RBR
cord-005478-5iu38pr6	2550	13	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2550	14	agents	agent	NNS
cord-005478-5iu38pr6	2550	15	(	(	-LRB-
cord-005478-5iu38pr6	2550	16	n=25	n=25	NNP
cord-005478-5iu38pr6	2550	17	)	)	-RRB-
cord-005478-5iu38pr6	2550	18	-0,24	-0,24	:
cord-005478-5iu38pr6	2550	19	(	(	-LRB-
cord-005478-5iu38pr6	2550	20	95	95	CD
cord-005478-5iu38pr6	2550	21	%	%	NN
cord-005478-5iu38pr6	2550	22	CI	CI	NNP
cord-005478-5iu38pr6	2550	23	0,12	0,12	CD
cord-005478-5iu38pr6	2550	24	-0,48	-0,48	NFP
cord-005478-5iu38pr6	2550	25	)	)	-RRB-
cord-005478-5iu38pr6	2550	26	,	,	,
cord-005478-5iu38pr6	2550	27	with	with	IN
cord-005478-5iu38pr6	2550	28	one	one	CD
cord-005478-5iu38pr6	2550	29	(	(	-LRB-
cord-005478-5iu38pr6	2550	30	n=32	n=32	NNP
cord-005478-5iu38pr6	2550	31	)	)	-RRB-
cord-005478-5iu38pr6	2550	32	-0,17	-0,17	.
cord-005478-5iu38pr6	2551	1	(	(	-LRB-
cord-005478-5iu38pr6	2551	2	95	95	CD
cord-005478-5iu38pr6	2551	3	%	%	NN
cord-005478-5iu38pr6	2551	4	CI	CI	NNP
cord-005478-5iu38pr6	2551	5	0,1	0,1	CD
cord-005478-5iu38pr6	2551	6	-0,29	-0,29	CD
cord-005478-5iu38pr6	2551	7	)	)	-RRB-
cord-005478-5iu38pr6	2551	8	,	,	,
cord-005478-5iu38pr6	2551	9	without	without	IN
cord-005478-5iu38pr6	2551	10	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2551	11	(	(	-LRB-
cord-005478-5iu38pr6	2551	12	n=17	n=17	NNP
cord-005478-5iu38pr6	2551	13	)	)	-RRB-
cord-005478-5iu38pr6	2551	14	-0,06	-0,06	NFP
cord-005478-5iu38pr6	2551	15	(	(	-LRB-
cord-005478-5iu38pr6	2551	16	95	95	CD
cord-005478-5iu38pr6	2551	17	%	%	NN
cord-005478-5iu38pr6	2551	18	CI	CI	NNP
cord-005478-5iu38pr6	2551	19	0,01	0,01	NN
cord-005478-5iu38pr6	2551	20	-0,44	-0,44	:
cord-005478-5iu38pr6	2551	21	)	)	-RRB-
cord-005478-5iu38pr6	2551	22	,	,	,
cord-005478-5iu38pr6	2551	23	p=0,172	p=0,172	NNP
cord-005478-5iu38pr6	2551	24	.	.	.
cord-005478-5iu38pr6	2552	1	CI	CI	NNP
cord-005478-5iu38pr6	2552	2	of	of	IN
cord-005478-5iu38pr6	2552	3	TRM	TRM	NNP
cord-005478-5iu38pr6	2552	4	in	in	IN
cord-005478-5iu38pr6	2552	5	patients	patient	NNS
cord-005478-5iu38pr6	2552	6	with	with	IN
cord-005478-5iu38pr6	2552	7	two	two	CD
cord-005478-5iu38pr6	2552	8	and	and	CC
cord-005478-5iu38pr6	2552	9	more	more	JJR
cord-005478-5iu38pr6	2552	10	immunosuppressants	immunosuppressant	NNS
cord-005478-5iu38pr6	2552	11	was	be	VBD
cord-005478-5iu38pr6	2552	12	0,22	0,22	CD
cord-005478-5iu38pr6	2552	13	(	(	-LRB-
cord-005478-5iu38pr6	2552	14	95	95	CD
cord-005478-5iu38pr6	2552	15	%	%	NN
cord-005478-5iu38pr6	2552	16	CI	ci	NN
cord-005478-5iu38pr6	2552	17	0,1	0,1	CD
cord-005478-5iu38pr6	2552	18	-0,47	-0,47	CD
cord-005478-5iu38pr6	2552	19	)	)	-RRB-
cord-005478-5iu38pr6	2552	20	,	,	,
cord-005478-5iu38pr6	2552	21	with	with	IN
cord-005478-5iu38pr6	2552	22	one	one	CD
cord-005478-5iu38pr6	2552	23	-0,1	-0,1	:
cord-005478-5iu38pr6	2552	24	(	(	-LRB-
cord-005478-5iu38pr6	2552	25	95	95	CD
cord-005478-5iu38pr6	2552	26	%	%	NN
cord-005478-5iu38pr6	2552	27	CI	CI	NNP
cord-005478-5iu38pr6	2552	28	0,02	0,02	NNP
cord-005478-5iu38pr6	2552	29	-0,28	-0,28	CD
cord-005478-5iu38pr6	2552	30	)	)	-RRB-
cord-005478-5iu38pr6	2552	31	,	,	,
cord-005478-5iu38pr6	2552	32	without	without	IN
cord-005478-5iu38pr6	2552	33	immunosuppression-0,26	immunosuppression-0,26	PRP
cord-005478-5iu38pr6	2552	34	(	(	-LRB-
cord-005478-5iu38pr6	2552	35	95	95	CD
cord-005478-5iu38pr6	2552	36	%	%	NN
cord-005478-5iu38pr6	2553	1	CI	CI	NNP
cord-005478-5iu38pr6	2553	2	0,09	0,09	CD
cord-005478-5iu38pr6	2553	3	-0,73	-0,73	NFP
cord-005478-5iu38pr6	2553	4	)	)	-RRB-
cord-005478-5iu38pr6	2554	1	,	,	,
cord-005478-5iu38pr6	2554	2	p=0,42	p=0,42	NNP
cord-005478-5iu38pr6	2554	3	.	.	.
cord-005478-5iu38pr6	2555	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2555	2	:	:	:
cord-005478-5iu38pr6	2556	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2556	2	conclude	conclude	VBP
cord-005478-5iu38pr6	2556	3	that	that	IN
cord-005478-5iu38pr6	2556	4	in	in	IN
cord-005478-5iu38pr6	2556	5	our	-PRON-	PRP$
cord-005478-5iu38pr6	2556	6	group	group	NN
cord-005478-5iu38pr6	2556	7	of	of	IN
cord-005478-5iu38pr6	2556	8	PID	PID	NNP
cord-005478-5iu38pr6	2556	9	patients	patient	NNS
cord-005478-5iu38pr6	2556	10	presence	presence	NN
cord-005478-5iu38pr6	2556	11	or	or	CC
cord-005478-5iu38pr6	2556	12	absence	absence	NN
cord-005478-5iu38pr6	2556	13	of	of	IN
cord-005478-5iu38pr6	2556	14	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2556	15	after	after	IN
cord-005478-5iu38pr6	2556	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2556	17	with	with	IN
cord-005478-5iu38pr6	2556	18	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	2557	1	/CD19	/CD19	NNP
cord-005478-5iu38pr6	2557	2	graft	graft	NN
cord-005478-5iu38pr6	2557	3	depletion	depletion	NN
cord-005478-5iu38pr6	2557	4	and	and	CC
cord-005478-5iu38pr6	2557	5	its	-PRON-	PRP$
cord-005478-5iu38pr6	2557	6	extent	extent	NN
cord-005478-5iu38pr6	2557	7	made	make	VBD
cord-005478-5iu38pr6	2557	8	no	no	DT
cord-005478-5iu38pr6	2557	9	significant	significant	JJ
cord-005478-5iu38pr6	2557	10	difference	difference	NN
cord-005478-5iu38pr6	2557	11	on	on	IN
cord-005478-5iu38pr6	2557	12	the	the	DT
cord-005478-5iu38pr6	2557	13	incidence	incidence	NN
cord-005478-5iu38pr6	2557	14	of	of	IN
cord-005478-5iu38pr6	2557	15	acute	acute	JJ
cord-005478-5iu38pr6	2557	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2557	17	,	,	,
cord-005478-5iu38pr6	2557	18	graft	graft	NN
cord-005478-5iu38pr6	2557	19	failure	failure	NN
cord-005478-5iu38pr6	2557	20	and	and	CC
cord-005478-5iu38pr6	2557	21	TRM	TRM	NNP
cord-005478-5iu38pr6	2557	22	.	.	.
cord-005478-5iu38pr6	2558	1	Considering	consider	VBG
cord-005478-5iu38pr6	2558	2	these	these	DT
cord-005478-5iu38pr6	2558	3	results	result	NNS
cord-005478-5iu38pr6	2558	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2558	5	with	with	IN
cord-005478-5iu38pr6	2558	6	TCRαβ	TCRαβ	NNP
cord-005478-5iu38pr6	2559	1	/CD19	/CD19	NNP
cord-005478-5iu38pr6	2559	2	graft	graft	NN
cord-005478-5iu38pr6	2559	3	depletion	depletion	NN
cord-005478-5iu38pr6	2559	4	without	without	IN
cord-005478-5iu38pr6	2559	5	posttransplant	posttransplant	NNP
cord-005478-5iu38pr6	2559	6	immunosupression	immunosupression	NNP
cord-005478-5iu38pr6	2559	7	could	could	MD
cord-005478-5iu38pr6	2559	8	be	be	VB
cord-005478-5iu38pr6	2559	9	recommended	recommend	VBN
cord-005478-5iu38pr6	2559	10	for	for	IN
cord-005478-5iu38pr6	2559	11	patients	patient	NNS
cord-005478-5iu38pr6	2559	12	with	with	IN
cord-005478-5iu38pr6	2559	13	PID	PID	NNP
cord-005478-5iu38pr6	2559	14	.	.	.
cord-005478-5iu38pr6	2560	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2560	2	Background	background	NN
cord-005478-5iu38pr6	2560	3	:	:	:
cord-005478-5iu38pr6	2560	4	LPS	LPS	NNP
cord-005478-5iu38pr6	2560	5	-	-	HYPH
cord-005478-5iu38pr6	2560	6	responsive	responsive	JJ
cord-005478-5iu38pr6	2560	7	beige	beige	JJ
cord-005478-5iu38pr6	2560	8	-	-	HYPH
cord-005478-5iu38pr6	2560	9	like	like	JJ
cord-005478-5iu38pr6	2560	10	anchor	anchor	NN
cord-005478-5iu38pr6	2560	11	protein	protein	NN
cord-005478-5iu38pr6	2560	12	(	(	-LRB-
cord-005478-5iu38pr6	2560	13	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2560	14	)	)	-RRB-
cord-005478-5iu38pr6	2560	15	deficiency	deficiency	NN
cord-005478-5iu38pr6	2560	16	is	be	VBZ
cord-005478-5iu38pr6	2560	17	a	a	DT
cord-005478-5iu38pr6	2560	18	severe	severe	JJ
cord-005478-5iu38pr6	2560	19	primary	primary	JJ
cord-005478-5iu38pr6	2560	20	immunodeficiency	immunodeficiency	NN
cord-005478-5iu38pr6	2560	21	with	with	IN
cord-005478-5iu38pr6	2560	22	a	a	DT
cord-005478-5iu38pr6	2560	23	variable	variable	JJ
cord-005478-5iu38pr6	2560	24	clinical	clinical	JJ
cord-005478-5iu38pr6	2560	25	phenotype	phenotype	NN
cord-005478-5iu38pr6	2560	26	,	,	,
cord-005478-5iu38pr6	2560	27	including	include	VBG
cord-005478-5iu38pr6	2560	28	features	feature	NNS
cord-005478-5iu38pr6	2560	29	overlapping	overlap	VBG
cord-005478-5iu38pr6	2560	30	with	with	IN
cord-005478-5iu38pr6	2560	31	common	common	JJ
cord-005478-5iu38pr6	2560	32	variable	variable	JJ
cord-005478-5iu38pr6	2560	33	immunodeficiency	immunodeficiency	NN
cord-005478-5iu38pr6	2560	34	,	,	,
cord-005478-5iu38pr6	2560	35	autoimmune	autoimmune	JJ
cord-005478-5iu38pr6	2560	36	lymphoproliferative	lymphoproliferative	JJ
cord-005478-5iu38pr6	2560	37	syndrome	syndrome	NN
cord-005478-5iu38pr6	2560	38	,	,	,
cord-005478-5iu38pr6	2560	39	and	and	CC
cord-005478-5iu38pr6	2560	40	immune	immune	JJ
cord-005478-5iu38pr6	2560	41	dysregulation	dysregulation	NN
cord-005478-5iu38pr6	2560	42	polyendocrinopathy	polyendocrinopathy	NN
cord-005478-5iu38pr6	2560	43	enteropathy	enteropathy	NNP
cord-005478-5iu38pr6	2560	44	X	x	NN
cord-005478-5iu38pr6	2560	45	-	-	HYPH
cord-005478-5iu38pr6	2560	46	linked	link	VBN
cord-005478-5iu38pr6	2560	47	syndrome	syndrome	NN
cord-005478-5iu38pr6	2560	48	and	and	CC
cord-005478-5iu38pr6	2560	49	an	an	DT
cord-005478-5iu38pr6	2560	50	association	association	NN
cord-005478-5iu38pr6	2560	51	with	with	IN
cord-005478-5iu38pr6	2560	52	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2560	53	.	.	.
cord-005478-5iu38pr6	2561	1	Recent	recent	JJ
cord-005478-5iu38pr6	2561	2	findings	finding	NNS
cord-005478-5iu38pr6	2561	3	strongly	strongly	RB
cord-005478-5iu38pr6	2561	4	support	support	VBP
cord-005478-5iu38pr6	2561	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2561	6	in	in	IN
cord-005478-5iu38pr6	2561	7	patients	patient	NNS
cord-005478-5iu38pr6	2561	8	with	with	IN
cord-005478-5iu38pr6	2561	9	severe	severe	JJ
cord-005478-5iu38pr6	2561	10	presentation	presentation	NN
cord-005478-5iu38pr6	2561	11	of	of	IN
cord-005478-5iu38pr6	2561	12	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2561	13	deficiency	deficiency	NN
cord-005478-5iu38pr6	2561	14	.	.	.
cord-005478-5iu38pr6	2562	1	However	however	RB
cord-005478-5iu38pr6	2562	2	,	,	,
cord-005478-5iu38pr6	2562	3	there	there	EX
cord-005478-5iu38pr6	2562	4	are	be	VBP
cord-005478-5iu38pr6	2562	5	no	no	DT
cord-005478-5iu38pr6	2562	6	up	up	IN
cord-005478-5iu38pr6	2562	7	-	-	HYPH
cord-005478-5iu38pr6	2562	8	to	to	IN
cord-005478-5iu38pr6	2562	9	-	-	HYPH
cord-005478-5iu38pr6	2562	10	date	date	NN
cord-005478-5iu38pr6	2562	11	follow	follow	NN
cord-005478-5iu38pr6	2562	12	-	-	HYPH
cord-005478-5iu38pr6	2562	13	up	up	NN
cord-005478-5iu38pr6	2562	14	and	and	CC
cord-005478-5iu38pr6	2562	15	survival	survival	NN
cord-005478-5iu38pr6	2562	16	data	datum	NNS
cord-005478-5iu38pr6	2562	17	of	of	IN
cord-005478-5iu38pr6	2562	18	patients	patient	NNS
cord-005478-5iu38pr6	2562	19	not	not	RB
cord-005478-5iu38pr6	2562	20	undergoing	undergo	VBG
cord-005478-5iu38pr6	2562	21	transplantation	transplantation	NN
cord-005478-5iu38pr6	2562	22	beyond	beyond	IN
cord-005478-5iu38pr6	2562	23	previous	previous	JJ
cord-005478-5iu38pr6	2562	24	publications	publication	NNS
cord-005478-5iu38pr6	2562	25	of	of	IN
cord-005478-5iu38pr6	2562	26	large	large	JJ
cord-005478-5iu38pr6	2562	27	cohort	cohort	NN
cord-005478-5iu38pr6	2562	28	studies	study	NNS
cord-005478-5iu38pr6	2562	29	.	.	.
cord-005478-5iu38pr6	2563	1	This	this	DT
cord-005478-5iu38pr6	2563	2	study	study	NN
cord-005478-5iu38pr6	2563	3	was	be	VBD
cord-005478-5iu38pr6	2563	4	conducted	conduct	VBN
cord-005478-5iu38pr6	2563	5	to	to	TO
cord-005478-5iu38pr6	2563	6	increase	increase	VB
cord-005478-5iu38pr6	2563	7	the	the	DT
cord-005478-5iu38pr6	2563	8	knowledge	knowledge	NN
cord-005478-5iu38pr6	2563	9	on	on	IN
cord-005478-5iu38pr6	2563	10	transplant	transplant	NN
cord-005478-5iu38pr6	2563	11	experience	experience	NN
cord-005478-5iu38pr6	2563	12	and	and	CC
cord-005478-5iu38pr6	2563	13	to	to	TO
cord-005478-5iu38pr6	2563	14	elucidate	elucidate	VB
cord-005478-5iu38pr6	2563	15	the	the	DT
cord-005478-5iu38pr6	2563	16	clinical	clinical	JJ
cord-005478-5iu38pr6	2563	17	course	course	NN
cord-005478-5iu38pr6	2563	18	of	of	IN
cord-005478-5iu38pr6	2563	19	both	both	CC
cord-005478-5iu38pr6	2563	20	transplanted	transplant	VBN
cord-005478-5iu38pr6	2563	21	and	and	CC
cord-005478-5iu38pr6	2563	22	untransplanted	untransplante	VBN
cord-005478-5iu38pr6	2563	23	patients	patient	NNS
cord-005478-5iu38pr6	2563	24	with	with	IN
cord-005478-5iu38pr6	2563	25	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2563	26	deficiency	deficiency	NN
cord-005478-5iu38pr6	2563	27	under	under	IN
cord-005478-5iu38pr6	2563	28	various	various	JJ
cord-005478-5iu38pr6	2563	29	targeted	target	VBN
cord-005478-5iu38pr6	2563	30	treatment	treatment	NN
cord-005478-5iu38pr6	2563	31	modalities	modality	NNS
cord-005478-5iu38pr6	2563	32	.	.	.
cord-005478-5iu38pr6	2564	1	Methods	method	NNS
cord-005478-5iu38pr6	2564	2	:	:	:
cord-005478-5iu38pr6	2564	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2564	4	performed	perform	VBD
cord-005478-5iu38pr6	2564	5	an	an	DT
cord-005478-5iu38pr6	2564	6	international	international	JJ
cord-005478-5iu38pr6	2564	7	Inborn	inborn	JJ
cord-005478-5iu38pr6	2564	8	errors	error	NNS
cord-005478-5iu38pr6	2564	9	working	work	VBG
cord-005478-5iu38pr6	2564	10	party	party	NN
cord-005478-5iu38pr6	2564	11	-	-	HYPH
cord-005478-5iu38pr6	2564	12	and	and	CC
cord-005478-5iu38pr6	2564	13	European	European	NNP
cord-005478-5iu38pr6	2564	14	Society	Society	NNP
cord-005478-5iu38pr6	2564	15	for	for	IN
cord-005478-5iu38pr6	2564	16	Immunodeficiencies	Immunodeficiencies	NNP
cord-005478-5iu38pr6	2564	17	-	-	HYPH
cord-005478-5iu38pr6	2564	18	wide	wide	JJ
cord-005478-5iu38pr6	2564	19	survey	survey	NN
cord-005478-5iu38pr6	2564	20	in	in	IN
cord-005478-5iu38pr6	2564	21	2018	2018	CD
cord-005478-5iu38pr6	2564	22	to	to	TO
cord-005478-5iu38pr6	2564	23	collect	collect	VB
cord-005478-5iu38pr6	2564	24	information	information	NN
cord-005478-5iu38pr6	2564	25	about	about	IN
cord-005478-5iu38pr6	2564	26	the	the	DT
cord-005478-5iu38pr6	2564	27	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2564	28	experience	experience	NN
cord-005478-5iu38pr6	2564	29	and	and	CC
cord-005478-5iu38pr6	2564	30	the	the	DT
cord-005478-5iu38pr6	2564	31	clinical	clinical	JJ
cord-005478-5iu38pr6	2564	32	course	course	NN
cord-005478-5iu38pr6	2564	33	of	of	IN
cord-005478-5iu38pr6	2564	34	both	both	CC
cord-005478-5iu38pr6	2564	35	transplanted	transplant	VBN
cord-005478-5iu38pr6	2564	36	and	and	CC
cord-005478-5iu38pr6	2564	37	untransplanted	untransplante	VBN
cord-005478-5iu38pr6	2564	38	patients	patient	NNS
cord-005478-5iu38pr6	2564	39	with	with	IN
cord-005478-5iu38pr6	2564	40	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2564	41	deficiency	deficiency	NN
cord-005478-5iu38pr6	2564	42	.	.	.
cord-005478-5iu38pr6	2565	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2565	2	included	include	VBD
cord-005478-5iu38pr6	2565	3	an	an	DT
cord-005478-5iu38pr6	2565	4	assessment	assessment	NN
cord-005478-5iu38pr6	2565	5	of	of	IN
cord-005478-5iu38pr6	2565	6	the	the	DT
cord-005478-5iu38pr6	2565	7	disease	disease	NN
cord-005478-5iu38pr6	2565	8	activity	activity	NN
cord-005478-5iu38pr6	2565	9	and	and	CC
cord-005478-5iu38pr6	2565	10	treatment	treatment	NN
cord-005478-5iu38pr6	2565	11	responses	response	NNS
cord-005478-5iu38pr6	2565	12	with	with	IN
cord-005478-5iu38pr6	2565	13	a	a	DT
cord-005478-5iu38pr6	2565	14	specially	specially	RB
cord-005478-5iu38pr6	2565	15	developed	develop	VBN
cord-005478-5iu38pr6	2565	16	immune	immune	JJ
cord-005478-5iu38pr6	2565	17	deficiency	deficiency	NN
cord-005478-5iu38pr6	2565	18	and	and	CC
cord-005478-5iu38pr6	2565	19	dysregulation	dysregulation	NN
cord-005478-5iu38pr6	2565	20	activity	activity	NN
cord-005478-5iu38pr6	2565	21	(	(	-LRB-
cord-005478-5iu38pr6	2565	22	IDDA	IDDA	NNP
cord-005478-5iu38pr6	2565	23	)	)	-RRB-
cord-005478-5iu38pr6	2565	24	score	score	NN
cord-005478-5iu38pr6	2565	25	,	,	,
cord-005478-5iu38pr6	2565	26	which	which	WDT
cord-005478-5iu38pr6	2565	27	weighs	weigh	VBZ
cord-005478-5iu38pr6	2565	28	the	the	DT
cord-005478-5iu38pr6	2565	29	sum	sum	NN
cord-005478-5iu38pr6	2565	30	of	of	IN
cord-005478-5iu38pr6	2565	31	organ	organ	NN
cord-005478-5iu38pr6	2565	32	involvement	involvement	NN
cord-005478-5iu38pr6	2565	33	(	(	-LRB-
cord-005478-5iu38pr6	2565	34	scored	score	VBN
cord-005478-5iu38pr6	2565	35	by	by	IN
cord-005478-5iu38pr6	2565	36	0	0	CD
cord-005478-5iu38pr6	2565	37	-	-	SYM
cord-005478-5iu38pr6	2565	38	4	4	CD
cord-005478-5iu38pr6	2565	39	)	)	-RRB-
cord-005478-5iu38pr6	2565	40	by	by	IN
cord-005478-5iu38pr6	2565	41	days	day	NNS
cord-005478-5iu38pr6	2565	42	of	of	IN
cord-005478-5iu38pr6	2565	43	hospitalization	hospitalization	NN
cord-005478-5iu38pr6	2565	44	and	and	CC
cord-005478-5iu38pr6	2565	45	performance	performance	NN
cord-005478-5iu38pr6	2565	46	scores	score	NNS
cord-005478-5iu38pr6	2565	47	,	,	,
cord-005478-5iu38pr6	2565	48	taking	take	VBG
cord-005478-5iu38pr6	2565	49	into	into	IN
cord-005478-5iu38pr6	2565	50	account	account	NN
cord-005478-5iu38pr6	2565	51	the	the	DT
cord-005478-5iu38pr6	2565	52	type	type	NN
cord-005478-5iu38pr6	2565	53	of	of	IN
cord-005478-5iu38pr6	2565	54	therapy	therapy	NN
cord-005478-5iu38pr6	2565	55	and	and	CC
cord-005478-5iu38pr6	2565	56	response	response	NN
cord-005478-5iu38pr6	2565	57	per	per	IN
cord-005478-5iu38pr6	2565	58	treatment	treatment	NN
cord-005478-5iu38pr6	2565	59	phase	phase	NN
cord-005478-5iu38pr6	2565	60	,	,	,
cord-005478-5iu38pr6	2565	61	which	which	WDT
cord-005478-5iu38pr6	2565	62	we	-PRON-	PRP
cord-005478-5iu38pr6	2565	63	herewith	herewith	VBP
cord-005478-5iu38pr6	2565	64	introduce	introduce	VB
cord-005478-5iu38pr6	2565	65	.	.	.
cord-005478-5iu38pr6	2566	1	Data	datum	NNS
cord-005478-5iu38pr6	2566	2	were	be	VBD
cord-005478-5iu38pr6	2566	3	obtained	obtain	VBN
cord-005478-5iu38pr6	2566	4	in	in	IN
cord-005478-5iu38pr6	2566	5	accordance	accordance	NN
cord-005478-5iu38pr6	2566	6	with	with	IN
cord-005478-5iu38pr6	2566	7	the	the	DT
cord-005478-5iu38pr6	2566	8	Declaration	Declaration	NNP
cord-005478-5iu38pr6	2566	9	of	of	IN
cord-005478-5iu38pr6	2566	10	Helsinki	Helsinki	NNP
cord-005478-5iu38pr6	2566	11	and	and	CC
cord-005478-5iu38pr6	2566	12	an	an	DT
cord-005478-5iu38pr6	2566	13	institutional	institutional	JJ
cord-005478-5iu38pr6	2566	14	review	review	NN
cord-005478-5iu38pr6	2566	15	board	board	NN
cord-005478-5iu38pr6	2566	16	review	review	NN
cord-005478-5iu38pr6	2566	17	by	by	IN
cord-005478-5iu38pr6	2566	18	means	mean	NNS
cord-005478-5iu38pr6	2566	19	of	of	IN
cord-005478-5iu38pr6	2566	20	retrospective	retrospective	JJ
cord-005478-5iu38pr6	2566	21	chart	chart	NN
cord-005478-5iu38pr6	2566	22	review	review	NN
cord-005478-5iu38pr6	2566	23	by	by	IN
cord-005478-5iu38pr6	2566	24	local	local	JJ
cord-005478-5iu38pr6	2566	25	physicians	physician	NNS
cord-005478-5iu38pr6	2566	26	.	.	.
cord-005478-5iu38pr6	2567	1	Results	result	NNS
cord-005478-5iu38pr6	2567	2	:	:	:
cord-005478-5iu38pr6	2568	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2568	2	analyzed	analyze	VBD
cord-005478-5iu38pr6	2568	3	the	the	DT
cord-005478-5iu38pr6	2568	4	data	datum	NNS
cord-005478-5iu38pr6	2568	5	of	of	IN
cord-005478-5iu38pr6	2568	6	68	68	CD
cord-005478-5iu38pr6	2568	7	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2568	8	deficient	deficient	JJ
cord-005478-5iu38pr6	2568	9	patients	patient	NNS
cord-005478-5iu38pr6	2568	10	from	from	IN
cord-005478-5iu38pr6	2568	11	23	23	CD
cord-005478-5iu38pr6	2568	12	centers	center	NNS
cord-005478-5iu38pr6	2568	13	,	,	,
cord-005478-5iu38pr6	2568	14	including	include	VBG
cord-005478-5iu38pr6	2568	15	35	35	CD
cord-005478-5iu38pr6	2568	16	unpublished	unpublished	JJ
cord-005478-5iu38pr6	2568	17	patients	patient	NNS
cord-005478-5iu38pr6	2568	18	.	.	.
cord-005478-5iu38pr6	2569	1	20	20	CD
cord-005478-5iu38pr6	2569	2	patients	patient	NNS
cord-005478-5iu38pr6	2569	3	of	of	IN
cord-005478-5iu38pr6	2569	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	2569	5	cohort	cohort	NN
cord-005478-5iu38pr6	2569	6	underwent	undergo	VBD
cord-005478-5iu38pr6	2569	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2569	8	between	between	IN
cord-005478-5iu38pr6	2569	9	2005	2005	CD
cord-005478-5iu38pr6	2569	10	and	and	CC
cord-005478-5iu38pr6	2569	11	2018	2018	CD
cord-005478-5iu38pr6	2569	12	.	.	.
cord-005478-5iu38pr6	2570	1	Overall	overall	JJ
cord-005478-5iu38pr6	2570	2	survival	survival	NN
cord-005478-5iu38pr6	2570	3	of	of	IN
cord-005478-5iu38pr6	2570	4	patients	patient	NNS
cord-005478-5iu38pr6	2570	5	undergoing	undergo	VBG
cord-005478-5iu38pr6	2570	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	2570	7	(	(	-LRB-
cord-005478-5iu38pr6	2570	8	median	median	JJ
cord-005478-5iu38pr6	2570	9	FU	FU	NNP
cord-005478-5iu38pr6	2570	10	30	30	CD
cord-005478-5iu38pr6	2570	11	months	month	NNS
cord-005478-5iu38pr6	2570	12	)	)	-RRB-
cord-005478-5iu38pr6	2570	13	was	be	VBD
cord-005478-5iu38pr6	2570	14	70	70	CD
cord-005478-5iu38pr6	2570	15	%	%	NN
cord-005478-5iu38pr6	2570	16	(	(	-LRB-
cord-005478-5iu38pr6	2570	17	14/20	14/20	CD
cord-005478-5iu38pr6	2570	18	patients	patient	NNS
cord-005478-5iu38pr6	2570	19	)	)	-RRB-
cord-005478-5iu38pr6	2570	20	;	;	:
cord-005478-5iu38pr6	2570	21	all	all	DT
cord-005478-5iu38pr6	2570	22	deaths	death	NNS
cord-005478-5iu38pr6	2570	23	were	be	VBD
cord-005478-5iu38pr6	2570	24	due	due	JJ
cord-005478-5iu38pr6	2570	25	to	to	IN
cord-005478-5iu38pr6	2570	26	transplant	transplant	NN
cord-005478-5iu38pr6	2570	27	-	-	HYPH
cord-005478-5iu38pr6	2570	28	related	relate	VBN
cord-005478-5iu38pr6	2570	29	mortality	mortality	NN
cord-005478-5iu38pr6	2570	30	and	and	CC
cord-005478-5iu38pr6	2570	31	occurred	occur	VBD
cord-005478-5iu38pr6	2570	32	within	within	IN
cord-005478-5iu38pr6	2570	33	3	3	CD
cord-005478-5iu38pr6	2570	34	months	month	NNS
cord-005478-5iu38pr6	2570	35	of	of	IN
cord-005478-5iu38pr6	2570	36	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2570	37	.	.	.
cord-005478-5iu38pr6	2571	1	83.3	83.3	CD
cord-005478-5iu38pr6	2571	2	%	%	NN
cord-005478-5iu38pr6	2571	3	(	(	-LRB-
cord-005478-5iu38pr6	2571	4	40/48	40/48	CD
cord-005478-5iu38pr6	2571	5	)	)	-RRB-
cord-005478-5iu38pr6	2571	6	of	of	IN
cord-005478-5iu38pr6	2571	7	untransplanted	untransplante	VBN
cord-005478-5iu38pr6	2571	8	patients	patient	NNS
cord-005478-5iu38pr6	2571	9	(	(	-LRB-
cord-005478-5iu38pr6	2571	10	2	2	CD
cord-005478-5iu38pr6	2571	11	-	-	SYM
cord-005478-5iu38pr6	2571	12	68	68	CD
cord-005478-5iu38pr6	2571	13	years	year	NNS
cord-005478-5iu38pr6	2571	14	)	)	-RRB-
cord-005478-5iu38pr6	2571	15	are	be	VBP
cord-005478-5iu38pr6	2571	16	currently	currently	RB
cord-005478-5iu38pr6	2571	17	alive	alive	JJ
cord-005478-5iu38pr6	2571	18	.	.	.
cord-005478-5iu38pr6	2572	1	Out	out	IN
cord-005478-5iu38pr6	2572	2	of	of	IN
cord-005478-5iu38pr6	2572	3	the	the	DT
cord-005478-5iu38pr6	2572	4	surviving	survive	VBG
cord-005478-5iu38pr6	2572	5	transplanted	transplanted	JJ
cord-005478-5iu38pr6	2572	6	patients	patient	NNS
cord-005478-5iu38pr6	2572	7	(	(	-LRB-
cord-005478-5iu38pr6	2572	8	n=14	n=14	NNP
cord-005478-5iu38pr6	2572	9	)	)	-RRB-
cord-005478-5iu38pr6	2572	10	6	6	CD
cord-005478-5iu38pr6	2572	11	are	be	VBP
cord-005478-5iu38pr6	2572	12	in	in	IN
cord-005478-5iu38pr6	2572	13	complete	complete	JJ
cord-005478-5iu38pr6	2572	14	remission	remission	NN
cord-005478-5iu38pr6	2572	15	,	,	,
cord-005478-5iu38pr6	2572	16	4	4	CD
cord-005478-5iu38pr6	2572	17	in	in	IN
cord-005478-5iu38pr6	2572	18	good	good	JJ
cord-005478-5iu38pr6	2572	19	partial	partial	JJ
cord-005478-5iu38pr6	2572	20	remission	remission	NN
cord-005478-5iu38pr6	2572	21	(	(	-LRB-
cord-005478-5iu38pr6	2572	22	no	no	DT
cord-005478-5iu38pr6	2572	23	treatment	treatment	NN
cord-005478-5iu38pr6	2572	24	)	)	-RRB-
cord-005478-5iu38pr6	2572	25	and	and	CC
cord-005478-5iu38pr6	2572	26	4	4	CD
cord-005478-5iu38pr6	2572	27	in	in	IN
cord-005478-5iu38pr6	2572	28	partial	partial	JJ
cord-005478-5iu38pr6	2572	29	remission	remission	NN
cord-005478-5iu38pr6	2572	30	(	(	-LRB-
cord-005478-5iu38pr6	2572	31	receiving	receive	VBG
cord-005478-5iu38pr6	2572	32	therapy	therapy	NN
cord-005478-5iu38pr6	2572	33	)	)	-RRB-
cord-005478-5iu38pr6	2572	34	,	,	,
cord-005478-5iu38pr6	2572	35	implying	imply	VBG
cord-005478-5iu38pr6	2572	36	that	that	IN
cord-005478-5iu38pr6	2572	37	10	10	CD
cord-005478-5iu38pr6	2572	38	out	out	IN
cord-005478-5iu38pr6	2572	39	of	of	IN
cord-005478-5iu38pr6	2572	40	14	14	CD
cord-005478-5iu38pr6	2572	41	transplanted	transplant	VBN
cord-005478-5iu38pr6	2572	42	patients	patient	NNS
cord-005478-5iu38pr6	2572	43	(	(	-LRB-
cord-005478-5iu38pr6	2572	44	71.4	71.4	CD
cord-005478-5iu38pr6	2572	45	%	%	NN
cord-005478-5iu38pr6	2572	46	)	)	-RRB-
cord-005478-5iu38pr6	2572	47	are	be	VBP
cord-005478-5iu38pr6	2572	48	currently	currently	RB
cord-005478-5iu38pr6	2572	49	without	without	IN
cord-005478-5iu38pr6	2572	50	treatment	treatment	NN
cord-005478-5iu38pr6	2572	51	.	.	.
cord-005478-5iu38pr6	2573	1	Only	only	RB
cord-005478-5iu38pr6	2573	2	5	5	CD
cord-005478-5iu38pr6	2573	3	out	out	IN
cord-005478-5iu38pr6	2573	4	of	of	IN
cord-005478-5iu38pr6	2573	5	40	40	CD
cord-005478-5iu38pr6	2573	6	living	live	VBG
cord-005478-5iu38pr6	2573	7	untransplanted	untransplante	VBN
cord-005478-5iu38pr6	2573	8	patients	patient	NNS
cord-005478-5iu38pr6	2573	9	(	(	-LRB-
cord-005478-5iu38pr6	2573	10	12.5	12.5	CD
cord-005478-5iu38pr6	2573	11	%	%	NN
cord-005478-5iu38pr6	2573	12	)	)	-RRB-
cord-005478-5iu38pr6	2573	13	do	do	VBP
cord-005478-5iu38pr6	2573	14	currently	currently	RB
cord-005478-5iu38pr6	2573	15	not	not	RB
cord-005478-5iu38pr6	2573	16	receive	receive	VB
cord-005478-5iu38pr6	2573	17	therapy	therapy	NN
cord-005478-5iu38pr6	2573	18	.	.	.
cord-005478-5iu38pr6	2574	1	Most	most	RBS
cord-005478-5iu38pr6	2574	2	commonly	commonly	RB
cord-005478-5iu38pr6	2574	3	used	use	VBN
cord-005478-5iu38pr6	2574	4	drugs	drug	NNS
cord-005478-5iu38pr6	2574	5	in	in	IN
cord-005478-5iu38pr6	2574	6	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2574	7	deficiency	deficiency	NN
cord-005478-5iu38pr6	2574	8	were	be	VBD
cord-005478-5iu38pr6	2574	9	Steroids	steroid	NNS
cord-005478-5iu38pr6	2574	10	(	(	-LRB-
cord-005478-5iu38pr6	2574	11	27.7	27.7	CD
cord-005478-5iu38pr6	2574	12	%	%	NN
cord-005478-5iu38pr6	2574	13	)	)	-RRB-
cord-005478-5iu38pr6	2574	14	,	,	,
cord-005478-5iu38pr6	2574	15	Sirolimus	Sirolimus	NNP
cord-005478-5iu38pr6	2574	16	(	(	-LRB-
cord-005478-5iu38pr6	2574	17	18.8	18.8	CD
cord-005478-5iu38pr6	2574	18	%	%	NN
cord-005478-5iu38pr6	2574	19	)	)	-RRB-
cord-005478-5iu38pr6	2574	20	and	and	CC
cord-005478-5iu38pr6	2574	21	Abatacept	Abatacept	NNP
cord-005478-5iu38pr6	2574	22	(	(	-LRB-
cord-005478-5iu38pr6	2574	23	18.8	18.8	CD
cord-005478-5iu38pr6	2574	24	%	%	NN
cord-005478-5iu38pr6	2574	25	)	)	-RRB-
cord-005478-5iu38pr6	2574	26	.	.	.
cord-005478-5iu38pr6	2575	1	Disease	disease	NN
cord-005478-5iu38pr6	2575	2	activity	activity	NN
cord-005478-5iu38pr6	2575	3	,	,	,
cord-005478-5iu38pr6	2575	4	measured	measure	VBN
cord-005478-5iu38pr6	2575	5	by	by	IN
cord-005478-5iu38pr6	2575	6	IDDA	IDDA	NNP
cord-005478-5iu38pr6	2575	7	score	score	NN
cord-005478-5iu38pr6	2575	8	,	,	,
cord-005478-5iu38pr6	2575	9	was	be	VBD
cord-005478-5iu38pr6	2575	10	significantly	significantly	RB
cord-005478-5iu38pr6	2575	11	lower	low	JJR
cord-005478-5iu38pr6	2575	12	in	in	IN
cord-005478-5iu38pr6	2575	13	patients	patient	NNS
cord-005478-5iu38pr6	2575	14	treated	treat	VBN
cord-005478-5iu38pr6	2575	15	with	with	IN
cord-005478-5iu38pr6	2575	16	Abatacept	Abatacept	NNP
cord-005478-5iu38pr6	2575	17	(	(	-LRB-
cord-005478-5iu38pr6	2575	18	p	p	NN
cord-005478-5iu38pr6	2575	19	<	<	XX
cord-005478-5iu38pr6	2575	20	0.0001	0.0001	CD
cord-005478-5iu38pr6	2575	21	)	)	-RRB-
cord-005478-5iu38pr6	2575	22	.	.	.
cord-005478-5iu38pr6	2576	1	No	no	DT
cord-005478-5iu38pr6	2576	2	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2576	3	-	-	HYPH
cord-005478-5iu38pr6	2576	4	associated	associate	VBN
cord-005478-5iu38pr6	2576	5	malignancy	malignancy	NN
cord-005478-5iu38pr6	2576	6	was	be	VBD
cord-005478-5iu38pr6	2576	7	detected	detect	VBN
cord-005478-5iu38pr6	2576	8	in	in	IN
cord-005478-5iu38pr6	2576	9	our	-PRON-	PRP$
cord-005478-5iu38pr6	2576	10	cohort	cohort	NN
cord-005478-5iu38pr6	2576	11	.	.	.
cord-005478-5iu38pr6	2577	1	Analyzation	analyzation	NN
cord-005478-5iu38pr6	2577	2	of	of	IN
cord-005478-5iu38pr6	2577	3	the	the	DT
cord-005478-5iu38pr6	2577	4	IDDA	IDDA	NNP
cord-005478-5iu38pr6	2577	5	score	score	NN
cord-005478-5iu38pr6	2577	6	of	of	IN
cord-005478-5iu38pr6	2577	7	all	all	DT
cord-005478-5iu38pr6	2577	8	living	live	VBG
cord-005478-5iu38pr6	2577	9	patients	patient	NNS
cord-005478-5iu38pr6	2577	10	revealed	reveal	VBD
cord-005478-5iu38pr6	2577	11	significantly	significantly	RB
cord-005478-5iu38pr6	2577	12	lower	low	JJR
cord-005478-5iu38pr6	2577	13	disease	disease	NN
cord-005478-5iu38pr6	2577	14	activity	activity	NN
cord-005478-5iu38pr6	2577	15	in	in	IN
cord-005478-5iu38pr6	2577	16	patients	patient	NNS
cord-005478-5iu38pr6	2577	17	transplanted	transplant	VBN
cord-005478-5iu38pr6	2577	18	and	and	CC
cord-005478-5iu38pr6	2577	19	alive	alive	JJ
cord-005478-5iu38pr6	2577	20	,	,	,
cord-005478-5iu38pr6	2577	21	than	than	IN
cord-005478-5iu38pr6	2577	22	in	in	IN
cord-005478-5iu38pr6	2577	23	those	those	DT
cord-005478-5iu38pr6	2577	24	who	who	WP
cord-005478-5iu38pr6	2577	25	did	do	VBD
cord-005478-5iu38pr6	2577	26	not	not	RB
cord-005478-5iu38pr6	2577	27	undergo	undergo	VB
cord-005478-5iu38pr6	2577	28	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2577	29	(	(	-LRB-
cord-005478-5iu38pr6	2577	30	p=	p=	NNP
cord-005478-5iu38pr6	2577	31	0.01	0.01	CD
cord-005478-5iu38pr6	2577	32	)	)	-RRB-
cord-005478-5iu38pr6	2577	33	.	.	.
cord-005478-5iu38pr6	2578	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2578	2	:	:	:
cord-005478-5iu38pr6	2579	1	In	in	IN
cord-005478-5iu38pr6	2579	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	2579	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	2579	4	findings	finding	NNS
cord-005478-5iu38pr6	2579	5	do	do	VBP
cord-005478-5iu38pr6	2579	6	,	,	,
cord-005478-5iu38pr6	2579	7	concordant	concordant	JJ
cord-005478-5iu38pr6	2579	8	with	with	IN
cord-005478-5iu38pr6	2579	9	previous	previous	JJ
cord-005478-5iu38pr6	2579	10	results	result	NNS
cord-005478-5iu38pr6	2579	11	,	,	,
cord-005478-5iu38pr6	2579	12	support	support	VBP
cord-005478-5iu38pr6	2579	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2579	14	,	,	,
cord-005478-5iu38pr6	2579	15	especially	especially	RB
cord-005478-5iu38pr6	2579	16	in	in	IN
cord-005478-5iu38pr6	2579	17	patients	patient	NNS
cord-005478-5iu38pr6	2579	18	with	with	IN
cord-005478-5iu38pr6	2579	19	a	a	DT
cord-005478-5iu38pr6	2579	20	severe	severe	JJ
cord-005478-5iu38pr6	2579	21	phenotype	phenotype	NN
cord-005478-5iu38pr6	2579	22	of	of	IN
cord-005478-5iu38pr6	2579	23	LRBA	LRBA	NNP
cord-005478-5iu38pr6	2579	24	deficiency	deficiency	NN
cord-005478-5iu38pr6	2579	25	.	.	.
cord-005478-5iu38pr6	2580	1	However	however	RB
cord-005478-5iu38pr6	2580	2	,	,	,
cord-005478-5iu38pr6	2580	3	the	the	DT
cord-005478-5iu38pr6	2580	4	question	question	NN
cord-005478-5iu38pr6	2580	5	of	of	IN
cord-005478-5iu38pr6	2580	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2580	7	indication	indication	NN
cord-005478-5iu38pr6	2580	8	and	and	CC
cord-005478-5iu38pr6	2580	9	optimal	optimal	JJ
cord-005478-5iu38pr6	2580	10	time	time	NN
cord-005478-5iu38pr6	2580	11	point	point	NN
cord-005478-5iu38pr6	2580	12	can	can	MD
cord-005478-5iu38pr6	2580	13	not	not	RB
cord-005478-5iu38pr6	2580	14	yet	yet	RB
cord-005478-5iu38pr6	2580	15	be	be	VB
cord-005478-5iu38pr6	2580	16	generally	generally	RB
cord-005478-5iu38pr6	2580	17	resolved	resolve	VBN
cord-005478-5iu38pr6	2580	18	.	.	.
cord-005478-5iu38pr6	2581	1	In	in	IN
cord-005478-5iu38pr6	2581	2	terms	term	NNS
cord-005478-5iu38pr6	2581	3	of	of	IN
cord-005478-5iu38pr6	2581	4	conventional	conventional	JJ
cord-005478-5iu38pr6	2581	5	treatment	treatment	NN
cord-005478-5iu38pr6	2581	6	,	,	,
cord-005478-5iu38pr6	2581	7	Abatacept	Abatacept	NNP
cord-005478-5iu38pr6	2581	8	is	be	VBZ
cord-005478-5iu38pr6	2581	9	clearly	clearly	RB
cord-005478-5iu38pr6	2581	10	favorable	favorable	JJ
cord-005478-5iu38pr6	2581	11	in	in	IN
cord-005478-5iu38pr6	2581	12	untransplanted	untransplanted	JJ
cord-005478-5iu38pr6	2581	13	patients	patient	NNS
cord-005478-5iu38pr6	2581	14	.	.	.
cord-005478-5iu38pr6	2582	1	Nevertheless	nevertheless	RB
cord-005478-5iu38pr6	2582	2	,	,	,
cord-005478-5iu38pr6	2582	3	it	-PRON-	PRP
cord-005478-5iu38pr6	2582	4	is	be	VBZ
cord-005478-5iu38pr6	2582	5	not	not	RB
cord-005478-5iu38pr6	2582	6	available	available	JJ
cord-005478-5iu38pr6	2582	7	in	in	IN
cord-005478-5iu38pr6	2582	8	many	many	JJ
cord-005478-5iu38pr6	2582	9	countries	country	NNS
cord-005478-5iu38pr6	2582	10	and	and	CC
cord-005478-5iu38pr6	2582	11	the	the	DT
cord-005478-5iu38pr6	2582	12	long	long	JJ
cord-005478-5iu38pr6	2582	13	-	-	HYPH
cord-005478-5iu38pr6	2582	14	term	term	NN
cord-005478-5iu38pr6	2582	15	dependency	dependency	NN
cord-005478-5iu38pr6	2582	16	on	on	IN
cord-005478-5iu38pr6	2582	17	this	this	DT
cord-005478-5iu38pr6	2582	18	treatment	treatment	NN
cord-005478-5iu38pr6	2582	19	with	with	IN
cord-005478-5iu38pr6	2582	20	its	-PRON-	PRP$
cord-005478-5iu38pr6	2582	21	associated	associate	VBN
cord-005478-5iu38pr6	2582	22	potential	potential	JJ
cord-005478-5iu38pr6	2582	23	risks	risk	NNS
cord-005478-5iu38pr6	2582	24	remains	remain	VBZ
cord-005478-5iu38pr6	2582	25	.	.	.
cord-005478-5iu38pr6	2583	1	Finally	finally	RB
cord-005478-5iu38pr6	2583	2	,	,	,
cord-005478-5iu38pr6	2583	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	2583	4	newly	newly	RB
cord-005478-5iu38pr6	2583	5	introduced	introduce	VBN
cord-005478-5iu38pr6	2583	6	IDDA	IDDA	NNP
cord-005478-5iu38pr6	2583	7	score	score	NN
cord-005478-5iu38pr6	2583	8	for	for	IN
cord-005478-5iu38pr6	2583	9	assessment	assessment	NN
cord-005478-5iu38pr6	2583	10	of	of	IN
cord-005478-5iu38pr6	2583	11	disease	disease	NN
cord-005478-5iu38pr6	2583	12	activity	activity	NN
cord-005478-5iu38pr6	2583	13	may	may	MD
cord-005478-5iu38pr6	2583	14	also	also	RB
cord-005478-5iu38pr6	2583	15	prove	prove	VB
cord-005478-5iu38pr6	2583	16	useful	useful	JJ
cord-005478-5iu38pr6	2583	17	for	for	IN
cord-005478-5iu38pr6	2583	18	other	other	JJ
cord-005478-5iu38pr6	2583	19	syndromes	syndrome	NNS
cord-005478-5iu38pr6	2583	20	with	with	IN
cord-005478-5iu38pr6	2583	21	immune	immune	JJ
cord-005478-5iu38pr6	2583	22	dysregulation	dysregulation	NN
cord-005478-5iu38pr6	2583	23	.	.	.
cord-005478-5iu38pr6	2584	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2584	2	:	:	:
cord-005478-5iu38pr6	2584	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2584	4	to	to	TO
cord-005478-5iu38pr6	2584	5	declare	declare	VB
cord-005478-5iu38pr6	2584	6	Background	background	NN
cord-005478-5iu38pr6	2584	7	:	:	:
cord-005478-5iu38pr6	2584	8	Cytomegalovirus	Cytomegalovirus	NNP
cord-005478-5iu38pr6	2584	9	(	(	-LRB-
cord-005478-5iu38pr6	2584	10	CMV	CMV	NNP
cord-005478-5iu38pr6	2584	11	)	)	-RRB-
cord-005478-5iu38pr6	2584	12	,	,	,
cord-005478-5iu38pr6	2584	13	is	be	VBZ
cord-005478-5iu38pr6	2584	14	a	a	DT
cord-005478-5iu38pr6	2584	15	major	major	JJ
cord-005478-5iu38pr6	2584	16	complication	complication	NN
cord-005478-5iu38pr6	2584	17	of	of	IN
cord-005478-5iu38pr6	2584	18	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2584	19	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2584	20	stem	stem	NN
cord-005478-5iu38pr6	2584	21	cell	cell	NN
cord-005478-5iu38pr6	2584	22	transplant	transplant	NN
cord-005478-5iu38pr6	2584	23	(	(	-LRB-
cord-005478-5iu38pr6	2584	24	HCT	HCT	NNP
cord-005478-5iu38pr6	2584	25	)	)	-RRB-
cord-005478-5iu38pr6	2584	26	recipients	recipient	NNS
cord-005478-5iu38pr6	2584	27	.	.	.
cord-005478-5iu38pr6	2585	1	To	to	TO
cord-005478-5iu38pr6	2585	2	overcome	overcome	VB
cord-005478-5iu38pr6	2585	3	morbidity	morbidity	NN
cord-005478-5iu38pr6	2585	4	associated	associate	VBN
cord-005478-5iu38pr6	2585	5	with	with	IN
cord-005478-5iu38pr6	2585	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2585	7	infection	infection	NN
cord-005478-5iu38pr6	2585	8	,	,	,
cord-005478-5iu38pr6	2585	9	antivirals	antiviral	NNS
cord-005478-5iu38pr6	2585	10	are	be	VBP
cord-005478-5iu38pr6	2585	11	given	give	VBN
cord-005478-5iu38pr6	2585	12	,	,	,
cord-005478-5iu38pr6	2585	13	and	and	CC
cord-005478-5iu38pr6	2585	14	while	while	IN
cord-005478-5iu38pr6	2585	15	they	-PRON-	PRP
cord-005478-5iu38pr6	2585	16	successfully	successfully	RB
cord-005478-5iu38pr6	2585	17	suppress	suppress	VBP
cord-005478-5iu38pr6	2585	18	viremia	viremia	NN
cord-005478-5iu38pr6	2585	19	,	,	,
cord-005478-5iu38pr6	2585	20	they	-PRON-	PRP
cord-005478-5iu38pr6	2585	21	do	do	VBP
cord-005478-5iu38pr6	2585	22	so	so	RB
cord-005478-5iu38pr6	2585	23	in	in	IN
cord-005478-5iu38pr6	2585	24	the	the	DT
cord-005478-5iu38pr6	2585	25	absence	absence	NN
cord-005478-5iu38pr6	2585	26	of	of	IN
cord-005478-5iu38pr6	2585	27	immune	immune	JJ
cord-005478-5iu38pr6	2585	28	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2585	29	.	.	.
cord-005478-5iu38pr6	2586	1	A	a	DT
cord-005478-5iu38pr6	2586	2	different	different	JJ
cord-005478-5iu38pr6	2586	3	approach	approach	NN
cord-005478-5iu38pr6	2586	4	is	be	VBZ
cord-005478-5iu38pr6	2586	5	to	to	TO
cord-005478-5iu38pr6	2586	6	use	use	VB
cord-005478-5iu38pr6	2586	7	a	a	DT
cord-005478-5iu38pr6	2586	8	vaccine	vaccine	NN
cord-005478-5iu38pr6	2586	9	to	to	TO
cord-005478-5iu38pr6	2586	10	bolster	bolster	VB
cord-005478-5iu38pr6	2586	11	immunity	immunity	NN
cord-005478-5iu38pr6	2586	12	to	to	IN
cord-005478-5iu38pr6	2586	13	CMV	CMV	NNP
cord-005478-5iu38pr6	2586	14	early	early	JJ
cord-005478-5iu38pr6	2586	15	post	post	JJ
cord-005478-5iu38pr6	2586	16	-	-	JJ
cord-005478-5iu38pr6	2586	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2586	18	and	and	CC
cord-005478-5iu38pr6	2586	19	sustain	sustain	VB
cord-005478-5iu38pr6	2586	20	it	-PRON-	PRP
cord-005478-5iu38pr6	2586	21	at	at	IN
cord-005478-5iu38pr6	2586	22	least	least	JJS
cord-005478-5iu38pr6	2586	23	until	until	IN
cord-005478-5iu38pr6	2586	24	the	the	DT
cord-005478-5iu38pr6	2586	25	patient	patient	NN
cord-005478-5iu38pr6	2586	26	is	be	VBZ
cord-005478-5iu38pr6	2586	27	immune	immune	JJ
cord-005478-5iu38pr6	2586	28	reconstituted	reconstitute	VBN
cord-005478-5iu38pr6	2586	29	.	.	.
cord-005478-5iu38pr6	2587	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2587	2	selected	select	VBD
cord-005478-5iu38pr6	2587	3	a	a	DT
cord-005478-5iu38pr6	2587	4	highly	highly	RB
cord-005478-5iu38pr6	2587	5	attenuated	attenuated	JJ
cord-005478-5iu38pr6	2587	6	,	,	,
cord-005478-5iu38pr6	2587	7	non	non	JJ
cord-005478-5iu38pr6	2587	8	-	-	JJ
cord-005478-5iu38pr6	2587	9	proliferating	proliferating	JJ
cord-005478-5iu38pr6	2587	10	viral	viral	JJ
cord-005478-5iu38pr6	2587	11	vector	vector	NN
cord-005478-5iu38pr6	2587	12	referred	refer	VBN
cord-005478-5iu38pr6	2587	13	to	to	IN
cord-005478-5iu38pr6	2587	14	as	as	RB
cord-005478-5iu38pr6	2587	15	modified	modify	VBN
cord-005478-5iu38pr6	2587	16	vaccinia	vaccinia	NN
cord-005478-5iu38pr6	2587	17	Ankara	Ankara	NNP
cord-005478-5iu38pr6	2587	18	(	(	-LRB-
cord-005478-5iu38pr6	2587	19	MVA	MVA	NNP
cord-005478-5iu38pr6	2587	20	)	)	-RRB-
cord-005478-5iu38pr6	2587	21	to	to	TO
cord-005478-5iu38pr6	2587	22	insert	insert	VB
cord-005478-5iu38pr6	2587	23	3	3	CD
cord-005478-5iu38pr6	2587	24	immunodominant	immunodominant	JJ
cord-005478-5iu38pr6	2587	25	CMV	CMV	NNP
cord-005478-5iu38pr6	2587	26	antigens	antigen	NNS
cord-005478-5iu38pr6	2587	27	pp65	pp65	RB
cord-005478-5iu38pr6	2587	28	,	,	,
cord-005478-5iu38pr6	2587	29	IE1-exon4	IE1-exon4	NNP
cord-005478-5iu38pr6	2587	30	,	,	,
cord-005478-5iu38pr6	2587	31	and	and	CC
cord-005478-5iu38pr6	2587	32	IE2-exon5	IE2-exon5	NNP
cord-005478-5iu38pr6	2587	33	.	.	.
cord-005478-5iu38pr6	2588	1	This	this	DT
cord-005478-5iu38pr6	2588	2	novel	novel	JJ
cord-005478-5iu38pr6	2588	3	vaccine	vaccine	NN
cord-005478-5iu38pr6	2588	4	(	(	-LRB-
cord-005478-5iu38pr6	2588	5	Triplex	Triplex	NNP
cord-005478-5iu38pr6	2588	6	)	)	-RRB-
cord-005478-5iu38pr6	2588	7	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	2588	8	excellent	excellent	JJ
cord-005478-5iu38pr6	2588	9	tolerability	tolerability	NN
cord-005478-5iu38pr6	2588	10	and	and	CC
cord-005478-5iu38pr6	2588	11	immunogenicity	immunogenicity	NN
cord-005478-5iu38pr6	2588	12	in	in	IN
cord-005478-5iu38pr6	2588	13	a	a	DT
cord-005478-5iu38pr6	2588	14	clinical	clinical	JJ
cord-005478-5iu38pr6	2588	15	study	study	NN
cord-005478-5iu38pr6	2588	16	of	of	IN
cord-005478-5iu38pr6	2588	17	24	24	CD
cord-005478-5iu38pr6	2588	18	healthy	healthy	JJ
cord-005478-5iu38pr6	2588	19	adults	adult	NNS
cord-005478-5iu38pr6	2588	20	(	(	-LRB-
cord-005478-5iu38pr6	2588	21	La	La	NNP
cord-005478-5iu38pr6	2588	22	Rosa	Rosa	NNP
cord-005478-5iu38pr6	2588	23	,	,	,
cord-005478-5iu38pr6	2588	24	et	et	NNP
cord-005478-5iu38pr6	2588	25	al	al	NNP
cord-005478-5iu38pr6	2588	26	.	.	.
cord-005478-5iu38pr6	2589	1	Blood	blood	NN
cord-005478-5iu38pr6	2589	2	2017	2017	CD
cord-005478-5iu38pr6	2589	3	)	)	-RRB-
cord-005478-5iu38pr6	2589	4	.	.	.
cord-005478-5iu38pr6	2590	1	These	these	DT
cord-005478-5iu38pr6	2590	2	findings	finding	NNS
cord-005478-5iu38pr6	2590	3	prompted	prompt	VBD
cord-005478-5iu38pr6	2590	4	us	-PRON-	PRP
cord-005478-5iu38pr6	2590	5	to	to	TO
cord-005478-5iu38pr6	2590	6	conduct	conduct	VB
cord-005478-5iu38pr6	2590	7	a	a	DT
cord-005478-5iu38pr6	2590	8	test	test	NN
cord-005478-5iu38pr6	2590	9	of	of	IN
cord-005478-5iu38pr6	2590	10	vaccine	vaccine	NN
cord-005478-5iu38pr6	2590	11	protective	protective	JJ
cord-005478-5iu38pr6	2590	12	efficacy	efficacy	NN
cord-005478-5iu38pr6	2590	13	in	in	IN
cord-005478-5iu38pr6	2590	14	at	at	IN
cord-005478-5iu38pr6	2590	15	-	-	HYPH
cord-005478-5iu38pr6	2590	16	risk	risk	NN
cord-005478-5iu38pr6	2590	17	HCT	hct	NN
cord-005478-5iu38pr6	2590	18	recipients	recipient	NNS
cord-005478-5iu38pr6	2590	19	in	in	IN
cord-005478-5iu38pr6	2590	20	a	a	DT
cord-005478-5iu38pr6	2590	21	multi	multi	JJ
cord-005478-5iu38pr6	2590	22	-	-	JJ
cord-005478-5iu38pr6	2590	23	center	center	JJ
cord-005478-5iu38pr6	2590	24	,	,	,
cord-005478-5iu38pr6	2590	25	randomized	randomized	JJ
cord-005478-5iu38pr6	2590	26	and	and	CC
cord-005478-5iu38pr6	2590	27	placebo	placebo	NN
cord-005478-5iu38pr6	2590	28	-	-	HYPH
cord-005478-5iu38pr6	2590	29	controlled	control	VBN
cord-005478-5iu38pr6	2590	30	Phase	Phase	NNP
cord-005478-5iu38pr6	2590	31	2	2	CD
cord-005478-5iu38pr6	2590	32	clinical	clinical	JJ
cord-005478-5iu38pr6	2590	33	trial	trial	NN
cord-005478-5iu38pr6	2590	34	(	(	-LRB-
cord-005478-5iu38pr6	2590	35	NCT02506933	NCT02506933	NNP
cord-005478-5iu38pr6	2590	36	)	)	-RRB-
cord-005478-5iu38pr6	2590	37	.	.	.
cord-005478-5iu38pr6	2591	1	Methods	method	NNS
cord-005478-5iu38pr6	2591	2	:	:	:
cord-005478-5iu38pr6	2592	1	Eligible	eligible	JJ
cord-005478-5iu38pr6	2592	2	patients	patient	NNS
cord-005478-5iu38pr6	2592	3	were	be	VBD
cord-005478-5iu38pr6	2592	4	CMV	CMV	NNP
cord-005478-5iu38pr6	2592	5	-	-	HYPH
cord-005478-5iu38pr6	2592	6	seropositive	seropositive	JJ
cord-005478-5iu38pr6	2592	7	and	and	CC
cord-005478-5iu38pr6	2592	8	undergoing	undergo	VBG
cord-005478-5iu38pr6	2592	9	HCT	hct	NN
cord-005478-5iu38pr6	2592	10	for	for	IN
cord-005478-5iu38pr6	2592	11	hematologic	hematologic	JJ
cord-005478-5iu38pr6	2592	12	malignancies	malignancy	NNS
cord-005478-5iu38pr6	2592	13	from	from	IN
cord-005478-5iu38pr6	2592	14	matched	match	VBN
cord-005478-5iu38pr6	2592	15	related	related	JJ
cord-005478-5iu38pr6	2592	16	/	/	SYM
cord-005478-5iu38pr6	2592	17	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2592	18	donors	donor	NNS
cord-005478-5iu38pr6	2592	19	without	without	IN
cord-005478-5iu38pr6	2592	20	the	the	DT
cord-005478-5iu38pr6	2592	21	use	use	NN
cord-005478-5iu38pr6	2592	22	of	of	IN
cord-005478-5iu38pr6	2592	23	exvivo	exvivo	NN
cord-005478-5iu38pr6	2592	24	or	or	CC
cord-005478-5iu38pr6	2592	25	in	in	IN
cord-005478-5iu38pr6	2592	26	-	-	HYPH
cord-005478-5iu38pr6	2592	27	vivo	vivo	NN
cord-005478-5iu38pr6	2592	28	T	t	NN
cord-005478-5iu38pr6	2592	29	cell	cell	NN
cord-005478-5iu38pr6	2592	30	depletion	depletion	NN
cord-005478-5iu38pr6	2592	31	.	.	.
cord-005478-5iu38pr6	2593	1	The	the	DT
cord-005478-5iu38pr6	2593	2	randomization	randomization	NN
cord-005478-5iu38pr6	2593	3	(	(	-LRB-
cord-005478-5iu38pr6	2593	4	1:1	1:1	LS
cord-005478-5iu38pr6	2593	5	)	)	-RRB-
cord-005478-5iu38pr6	2593	6	was	be	VBD
cord-005478-5iu38pr6	2593	7	stratified	stratify	VBN
cord-005478-5iu38pr6	2593	8	by	by	IN
cord-005478-5iu38pr6	2593	9	donor	donor	NN
cord-005478-5iu38pr6	2593	10	serostatus	serostatus	NN
cord-005478-5iu38pr6	2593	11	and	and	CC
cord-005478-5iu38pr6	2593	12	HCT	HCT	NNP
cord-005478-5iu38pr6	2593	13	center	center	NN
cord-005478-5iu38pr6	2593	14	.	.	.
cord-005478-5iu38pr6	2594	1	Patients	patient	NNS
cord-005478-5iu38pr6	2594	2	were	be	VBD
cord-005478-5iu38pr6	2594	3	enrolled	enrol	VBN
cord-005478-5iu38pr6	2594	4	pre	pre	JJ
cord-005478-5iu38pr6	2594	5	-	-	NN
cord-005478-5iu38pr6	2594	6	HCT	HCT	NNP
cord-005478-5iu38pr6	2594	7	,	,	,
cord-005478-5iu38pr6	2594	8	and	and	CC
cord-005478-5iu38pr6	2594	9	on	on	IN
cord-005478-5iu38pr6	2594	10	d28	d28	NNP
cord-005478-5iu38pr6	2594	11	were	be	VBD
cord-005478-5iu38pr6	2594	12	requalified	requalifie	VBN
cord-005478-5iu38pr6	2594	13	for	for	IN
cord-005478-5iu38pr6	2594	14	eligibility	eligibility	NN
cord-005478-5iu38pr6	2594	15	based	base	VBN
cord-005478-5iu38pr6	2594	16	on	on	IN
cord-005478-5iu38pr6	2594	17	lack	lack	NN
cord-005478-5iu38pr6	2594	18	of	of	IN
cord-005478-5iu38pr6	2594	19	prior	prior	JJ
cord-005478-5iu38pr6	2594	20	CMV	CMV	NNP
cord-005478-5iu38pr6	2594	21	reactivation	reactivation	NN
cord-005478-5iu38pr6	2594	22	,	,	,
cord-005478-5iu38pr6	2594	23	≥Grade	≥grade	CD
cord-005478-5iu38pr6	2594	24	3	3	CD
cord-005478-5iu38pr6	2594	25	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2594	26	,	,	,
cord-005478-5iu38pr6	2594	27	high	high	JJ
cord-005478-5iu38pr6	2594	28	-	-	HYPH
cord-005478-5iu38pr6	2594	29	dose	dose	NN
cord-005478-5iu38pr6	2594	30	steroids	steroid	NNS
cord-005478-5iu38pr6	2594	31	,	,	,
cord-005478-5iu38pr6	2594	32	or	or	CC
cord-005478-5iu38pr6	2594	33	other	other	JJ
cord-005478-5iu38pr6	2594	34	significant	significant	JJ
cord-005478-5iu38pr6	2594	35	transplantrelated	transplantrelate	VBN
cord-005478-5iu38pr6	2594	36	morbidity	morbidity	NN
cord-005478-5iu38pr6	2594	37	.	.	.
cord-005478-5iu38pr6	2595	1	After	after	IN
cord-005478-5iu38pr6	2595	2	randomization	randomization	NN
cord-005478-5iu38pr6	2595	3	patients	patient	NNS
cord-005478-5iu38pr6	2595	4	received	receive	VBD
cord-005478-5iu38pr6	2595	5	Triplex	Triplex	NNP
cord-005478-5iu38pr6	2595	6	or	or	CC
cord-005478-5iu38pr6	2595	7	placebo	placebo	NN
cord-005478-5iu38pr6	2595	8	injections	injection	NNS
cord-005478-5iu38pr6	2595	9	on	on	IN
cord-005478-5iu38pr6	2595	10	d28	d28	NN
cord-005478-5iu38pr6	2595	11	and	and	CC
cord-005478-5iu38pr6	2595	12	d56	d56	CD
cord-005478-5iu38pr6	2595	13	post	post	JJ
cord-005478-5iu38pr6	2595	14	-	-	JJ
cord-005478-5iu38pr6	2595	15	HCT	hct	JJ
cord-005478-5iu38pr6	2595	16	and	and	CC
cord-005478-5iu38pr6	2595	17	followed	follow	VBD
cord-005478-5iu38pr6	2595	18	for	for	IN
cord-005478-5iu38pr6	2595	19	one	one	CD
cord-005478-5iu38pr6	2595	20	year	year	NN
cord-005478-5iu38pr6	2595	21	.	.	.
cord-005478-5iu38pr6	2596	1	The	the	DT
cord-005478-5iu38pr6	2596	2	primary	primary	JJ
cord-005478-5iu38pr6	2596	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	2596	4	is	be	VBZ
cord-005478-5iu38pr6	2596	5	defined	define	VBN
cord-005478-5iu38pr6	2596	6	as	as	IN
cord-005478-5iu38pr6	2596	7	any	any	DT
cord-005478-5iu38pr6	2596	8	CMV	CMV	NNP
cord-005478-5iu38pr6	2596	9	reactivation	reactivation	NN
cord-005478-5iu38pr6	2596	10	[	[	-LRB-
cord-005478-5iu38pr6	2596	11	≥500	≥500	DT
cord-005478-5iu38pr6	2596	12	CMV	CMV	NNP
cord-005478-5iu38pr6	2596	13	genome	genome	NN
cord-005478-5iu38pr6	2596	14	copies	copy	NNS
cord-005478-5iu38pr6	2596	15	(	(	-LRB-
cord-005478-5iu38pr6	2596	16	gc)/	gc)/	NNP
cord-005478-5iu38pr6	2596	17	mL	mL	NNP
cord-005478-5iu38pr6	2596	18	]	]	-RRB-
cord-005478-5iu38pr6	2596	19	,	,	,
cord-005478-5iu38pr6	2596	20	low	low	JJ
cord-005478-5iu38pr6	2596	21	-	-	HYPH
cord-005478-5iu38pr6	2596	22	level	level	NN
cord-005478-5iu38pr6	2596	23	reactivation	reactivation	NN
cord-005478-5iu38pr6	2596	24	prompting	prompt	VBG
cord-005478-5iu38pr6	2596	25	antiviral	antiviral	JJ
cord-005478-5iu38pr6	2596	26	therapy	therapy	NN
cord-005478-5iu38pr6	2596	27	,	,	,
cord-005478-5iu38pr6	2596	28	or	or	CC
cord-005478-5iu38pr6	2596	29	CMV	CMV	NNP
cord-005478-5iu38pr6	2596	30	disease	disease	NN
cord-005478-5iu38pr6	2596	31	prior	prior	RB
cord-005478-5iu38pr6	2596	32	to	to	IN
cord-005478-5iu38pr6	2596	33	d100	d100	NNP
cord-005478-5iu38pr6	2596	34	post	post	NNP
cord-005478-5iu38pr6	2596	35	-	-	NN
cord-005478-5iu38pr6	2596	36	HCT	HCT	NNP
cord-005478-5iu38pr6	2596	37	.	.	.
cord-005478-5iu38pr6	2597	1	Based	base	VBN
cord-005478-5iu38pr6	2597	2	on	on	IN
cord-005478-5iu38pr6	2597	3	the	the	DT
cord-005478-5iu38pr6	2597	4	objective	objective	NN
cord-005478-5iu38pr6	2597	5	of	of	IN
cord-005478-5iu38pr6	2597	6	reducing	reduce	VBG
cord-005478-5iu38pr6	2597	7	reactivation	reactivation	NN
cord-005478-5iu38pr6	2597	8	from	from	IN
cord-005478-5iu38pr6	2597	9	30	30	CD
cord-005478-5iu38pr6	2597	10	%	%	NN
cord-005478-5iu38pr6	2597	11	to	to	TO
cord-005478-5iu38pr6	2597	12	10	10	CD
cord-005478-5iu38pr6	2597	13	%	%	NN
cord-005478-5iu38pr6	2597	14	or	or	CC
cord-005478-5iu38pr6	2597	15	from	from	IN
cord-005478-5iu38pr6	2597	16	40	40	CD
cord-005478-5iu38pr6	2597	17	%	%	NN
cord-005478-5iu38pr6	2597	18	to	to	TO
cord-005478-5iu38pr6	2597	19	15	15	CD
cord-005478-5iu38pr6	2597	20	%	%	NN
cord-005478-5iu38pr6	2597	21	on	on	IN
cord-005478-5iu38pr6	2597	22	the	the	DT
cord-005478-5iu38pr6	2597	23	vaccine	vaccine	NN
cord-005478-5iu38pr6	2597	24	arm	arm	NN
cord-005478-5iu38pr6	2597	25	,	,	,
cord-005478-5iu38pr6	2597	26	a	a	DT
cord-005478-5iu38pr6	2597	27	sample	sample	NN
cord-005478-5iu38pr6	2597	28	size	size	NN
cord-005478-5iu38pr6	2597	29	of	of	IN
cord-005478-5iu38pr6	2597	30	102	102	CD
cord-005478-5iu38pr6	2597	31	was	be	VBD
cord-005478-5iu38pr6	2597	32	determined	determine	VBN
cord-005478-5iu38pr6	2597	33	to	to	TO
cord-005478-5iu38pr6	2597	34	provide	provide	VB
cord-005478-5iu38pr6	2597	35	at	at	IN
cord-005478-5iu38pr6	2597	36	least	least	RBS
cord-005478-5iu38pr6	2597	37	90	90	CD
cord-005478-5iu38pr6	2597	38	%	%	NN
cord-005478-5iu38pr6	2597	39	power	power	NN
cord-005478-5iu38pr6	2597	40	at	at	IN
cord-005478-5iu38pr6	2597	41	a	a	DT
cord-005478-5iu38pr6	2597	42	one	one	CD
cord-005478-5iu38pr6	2597	43	-	-	HYPH
cord-005478-5iu38pr6	2597	44	sided	side	VBN
cord-005478-5iu38pr6	2597	45	0.10	0.10	CD
cord-005478-5iu38pr6	2597	46	level	level	NN
cord-005478-5iu38pr6	2597	47	of	of	IN
cord-005478-5iu38pr6	2597	48	significance	significance	NN
cord-005478-5iu38pr6	2597	49	by	by	IN
cord-005478-5iu38pr6	2597	50	log	log	NN
cord-005478-5iu38pr6	2597	51	-	-	HYPH
cord-005478-5iu38pr6	2597	52	rank	rank	NN
cord-005478-5iu38pr6	2597	53	test	test	NN
cord-005478-5iu38pr6	2597	54	.	.	.
cord-005478-5iu38pr6	2598	1	Results	result	NNS
cord-005478-5iu38pr6	2598	2	:	:	:
cord-005478-5iu38pr6	2599	1	The	the	DT
cord-005478-5iu38pr6	2599	2	patient	patient	JJ
cord-005478-5iu38pr6	2599	3	clinical	clinical	JJ
cord-005478-5iu38pr6	2599	4	/	/	SYM
cord-005478-5iu38pr6	2599	5	HCT	hct	NN
cord-005478-5iu38pr6	2599	6	characteristics	characteristic	NNS
cord-005478-5iu38pr6	2599	7	were	be	VBD
cord-005478-5iu38pr6	2599	8	balanced	balance	VBN
cord-005478-5iu38pr6	2599	9	between	between	IN
cord-005478-5iu38pr6	2599	10	the	the	DT
cord-005478-5iu38pr6	2599	11	vaccine	vaccine	NN
cord-005478-5iu38pr6	2599	12	arm	arm	NN
cord-005478-5iu38pr6	2599	13	(	(	-LRB-
cord-005478-5iu38pr6	2599	14	n=51	n=51	NNP
cord-005478-5iu38pr6	2599	15	)	)	-RRB-
cord-005478-5iu38pr6	2599	16	and	and	CC
cord-005478-5iu38pr6	2599	17	placebo	placebo	NN
cord-005478-5iu38pr6	2599	18	arm	arm	NN
cord-005478-5iu38pr6	2599	19	(	(	-LRB-
cord-005478-5iu38pr6	2599	20	n=51	n=51	NNP
cord-005478-5iu38pr6	2599	21	)	)	-RRB-
cord-005478-5iu38pr6	2599	22	.	.	.
cord-005478-5iu38pr6	2600	1	The	the	DT
cord-005478-5iu38pr6	2600	2	vaccine	vaccine	NN
cord-005478-5iu38pr6	2600	3	was	be	VBD
cord-005478-5iu38pr6	2600	4	well	well	RB
cord-005478-5iu38pr6	2600	5	tolerated	tolerate	VBN
cord-005478-5iu38pr6	2600	6	with	with	IN
cord-005478-5iu38pr6	2600	7	no	no	DT
cord-005478-5iu38pr6	2600	8	significant	significant	JJ
cord-005478-5iu38pr6	2600	9	difference	difference	NN
cord-005478-5iu38pr6	2600	10	in	in	IN
cord-005478-5iu38pr6	2600	11	grade	grade	NN
cord-005478-5iu38pr6	2600	12	3	3	CD
cord-005478-5iu38pr6	2600	13	-	-	SYM
cord-005478-5iu38pr6	2600	14	4	4	CD
cord-005478-5iu38pr6	2600	15	AEs	AEs	NNPS
cord-005478-5iu38pr6	2600	16	or	or	CC
cord-005478-5iu38pr6	2600	17	SAEs	SAEs	NNP
cord-005478-5iu38pr6	2600	18	in	in	IN
cord-005478-5iu38pr6	2600	19	both	both	DT
cord-005478-5iu38pr6	2600	20	arms	arm	NNS
cord-005478-5iu38pr6	2600	21	.	.	.
cord-005478-5iu38pr6	2601	1	Triplex	Triplex	NNP
cord-005478-5iu38pr6	2601	2	displayed	display	VBD
cord-005478-5iu38pr6	2601	3	potent	potent	JJ
cord-005478-5iu38pr6	2601	4	immunogenicity	immunogenicity	NN
cord-005478-5iu38pr6	2601	5	,	,	,
cord-005478-5iu38pr6	2601	6	as	as	IN
cord-005478-5iu38pr6	2601	7	many	many	JJ
cord-005478-5iu38pr6	2601	8	vaccine	vaccine	NN
cord-005478-5iu38pr6	2601	9	recipients	recipient	NNS
cord-005478-5iu38pr6	2601	10	with	with	IN
cord-005478-5iu38pr6	2601	11	either	either	CC
cord-005478-5iu38pr6	2601	12	CMV	CMV	NNP
cord-005478-5iu38pr6	2601	13	-	-	HYPH
cord-005478-5iu38pr6	2601	14	positive	positive	JJ
cord-005478-5iu38pr6	2601	15	or	or	CC
cord-005478-5iu38pr6	2601	16	-negative	-negative	JJ
cord-005478-5iu38pr6	2602	1	donors	donor	NNS
cord-005478-5iu38pr6	2602	2	showed	show	VBD
cord-005478-5iu38pr6	2602	3	strong	strong	JJ
cord-005478-5iu38pr6	2602	4	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2602	5	of	of	IN
cord-005478-5iu38pr6	2602	6	both	both	CC
cord-005478-5iu38pr6	2602	7	CD4	CD4	NNP
cord-005478-5iu38pr6	2602	8	and	and	CC
cord-005478-5iu38pr6	2602	9	CD8	CD8	NNP
cord-005478-5iu38pr6	2602	10	CMV	CMV	NNP
cord-005478-5iu38pr6	2602	11	-	-	HYPH
cord-005478-5iu38pr6	2602	12	specific	specific	JJ
cord-005478-5iu38pr6	2602	13	immunity	immunity	NN
cord-005478-5iu38pr6	2602	14	that	that	WDT
cord-005478-5iu38pr6	2602	15	initiated	initiate	VBD
cord-005478-5iu38pr6	2602	16	soon	soon	RB
cord-005478-5iu38pr6	2602	17	after	after	IN
cord-005478-5iu38pr6	2602	18	the	the	DT
cord-005478-5iu38pr6	2602	19	first	first	JJ
cord-005478-5iu38pr6	2602	20	injection	injection	NN
cord-005478-5iu38pr6	2602	21	and	and	CC
cord-005478-5iu38pr6	2602	22	was	be	VBD
cord-005478-5iu38pr6	2602	23	elevated	elevate	VBN
cord-005478-5iu38pr6	2602	24	for	for	IN
cord-005478-5iu38pr6	2602	25	at	at	RB
cord-005478-5iu38pr6	2602	26	least	least	JJS
cord-005478-5iu38pr6	2602	27	100d	100d	CD
cord-005478-5iu38pr6	2602	28	post	post	JJ
cord-005478-5iu38pr6	2602	29	-	-	NN
cord-005478-5iu38pr6	2602	30	HCT	hct	NN
cord-005478-5iu38pr6	2602	31	.	.	.
cord-005478-5iu38pr6	2603	1	Most	most	RBS
cord-005478-5iu38pr6	2603	2	notably	notably	RB
cord-005478-5iu38pr6	2603	3	there	there	EX
cord-005478-5iu38pr6	2603	4	was	be	VBD
cord-005478-5iu38pr6	2603	5	a	a	DT
cord-005478-5iu38pr6	2603	6	reduction	reduction	NN
cord-005478-5iu38pr6	2603	7	of	of	IN
cord-005478-5iu38pr6	2603	8	primary	primary	JJ
cord-005478-5iu38pr6	2603	9	endpoint	endpoint	NN
cord-005478-5iu38pr6	2603	10	-	-	HYPH
cord-005478-5iu38pr6	2603	11	defining	define	VBG
cord-005478-5iu38pr6	2603	12	reactivation	reactivation	NN
cord-005478-5iu38pr6	2603	13	through	through	IN
cord-005478-5iu38pr6	2603	14	d100	d100	NNP
cord-005478-5iu38pr6	2603	15	in	in	IN
cord-005478-5iu38pr6	2603	16	the	the	DT
cord-005478-5iu38pr6	2603	17	vaccine	vaccine	NN
cord-005478-5iu38pr6	2603	18	arm	arm	NN
cord-005478-5iu38pr6	2603	19	(	(	-LRB-
cord-005478-5iu38pr6	2603	20	5	5	CD
cord-005478-5iu38pr6	2603	21	events	event	NNS
cord-005478-5iu38pr6	2603	22	,	,	,
cord-005478-5iu38pr6	2603	23	9.8	9.8	CD
cord-005478-5iu38pr6	2603	24	%	%	NN
cord-005478-5iu38pr6	2603	25	)	)	-RRB-
cord-005478-5iu38pr6	2603	26	compared	compare	VBN
cord-005478-5iu38pr6	2603	27	to	to	IN
cord-005478-5iu38pr6	2603	28	the	the	DT
cord-005478-5iu38pr6	2603	29	placebo	placebo	NN
cord-005478-5iu38pr6	2603	30	arm	arm	NN
cord-005478-5iu38pr6	2603	31	(	(	-LRB-
cord-005478-5iu38pr6	2603	32	10	10	CD
cord-005478-5iu38pr6	2603	33	events	event	NNS
cord-005478-5iu38pr6	2603	34	,	,	,
cord-005478-5iu38pr6	2603	35	19.6	19.6	CD
cord-005478-5iu38pr6	2603	36	%	%	NN
cord-005478-5iu38pr6	2603	37	,	,	,
cord-005478-5iu38pr6	2603	38	p=0.08	p=0.08	NNP
cord-005478-5iu38pr6	2603	39	)	)	-RRB-
cord-005478-5iu38pr6	2603	40	.	.	.
cord-005478-5iu38pr6	2604	1	Greater	great	JJR
cord-005478-5iu38pr6	2604	2	detail	detail	NN
cord-005478-5iu38pr6	2604	3	regarding	regard	VBG
cord-005478-5iu38pr6	2604	4	protocol	protocol	NN
cord-005478-5iu38pr6	2604	5	-	-	HYPH
cord-005478-5iu38pr6	2604	6	specified	specify	VBN
cord-005478-5iu38pr6	2604	7	secondary	secondary	JJ
cord-005478-5iu38pr6	2604	8	endpoints	endpoint	NNS
cord-005478-5iu38pr6	2604	9	including	include	VBG
cord-005478-5iu38pr6	2604	10	time	time	NN
cord-005478-5iu38pr6	2604	11	to	to	IN
cord-005478-5iu38pr6	2604	12	viremia	viremia	NNP
cord-005478-5iu38pr6	2604	13	,	,	,
cord-005478-5iu38pr6	2604	14	its	-PRON-	PRP$
cord-005478-5iu38pr6	2604	15	duration	duration	NN
cord-005478-5iu38pr6	2604	16	,	,	,
cord-005478-5iu38pr6	2604	17	frequency	frequency	NN
cord-005478-5iu38pr6	2604	18	and	and	CC
cord-005478-5iu38pr6	2604	19	duration	duration	NN
cord-005478-5iu38pr6	2604	20	of	of	IN
cord-005478-5iu38pr6	2604	21	antiviral	antiviral	JJ
cord-005478-5iu38pr6	2604	22	drug	drug	NN
cord-005478-5iu38pr6	2604	23	treatment	treatment	NN
cord-005478-5iu38pr6	2604	24	,	,	,
cord-005478-5iu38pr6	2604	25	late	late	JJ
cord-005478-5iu38pr6	2604	26	CMV	CMV	NNP
cord-005478-5iu38pr6	2604	27	viremia	viremia	NN
cord-005478-5iu38pr6	2604	28	,	,	,
cord-005478-5iu38pr6	2604	29	time	time	NN
cord-005478-5iu38pr6	2604	30	to	to	IN
cord-005478-5iu38pr6	2604	31	engraftment	engraftment	NN
cord-005478-5iu38pr6	2604	32	and	and	CC
cord-005478-5iu38pr6	2604	33	incidence	incidence	NN
cord-005478-5iu38pr6	2604	34	of	of	IN
cord-005478-5iu38pr6	2604	35	acute	acute	JJ
cord-005478-5iu38pr6	2604	36	and	and	CC
cord-005478-5iu38pr6	2604	37	chronic	chronic	JJ
cord-005478-5iu38pr6	2604	38	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2604	39	,	,	,
cord-005478-5iu38pr6	2604	40	relapse	relapse	NN
cord-005478-5iu38pr6	2604	41	and	and	CC
cord-005478-5iu38pr6	2604	42	non	non	JJ
cord-005478-5iu38pr6	2604	43	-	-	JJ
cord-005478-5iu38pr6	2604	44	relapse	relapse	JJ
cord-005478-5iu38pr6	2604	45	mortality	mortality	NN
cord-005478-5iu38pr6	2604	46	will	will	MD
cord-005478-5iu38pr6	2604	47	be	be	VB
cord-005478-5iu38pr6	2604	48	presented	present	VBN
cord-005478-5iu38pr6	2604	49	.	.	.
cord-005478-5iu38pr6	2605	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2605	2	:	:	:
cord-005478-5iu38pr6	2606	1	In	in	IN
cord-005478-5iu38pr6	2606	2	summary	summary	NN
cord-005478-5iu38pr6	2606	3	,	,	,
cord-005478-5iu38pr6	2606	4	Triplex	Triplex	NNP
cord-005478-5iu38pr6	2606	5	was	be	VBD
cord-005478-5iu38pr6	2606	6	well	well	RB
cord-005478-5iu38pr6	2606	7	tolerated	tolerate	VBN
cord-005478-5iu38pr6	2606	8	in	in	IN
cord-005478-5iu38pr6	2606	9	seropositive	seropositive	JJ
cord-005478-5iu38pr6	2606	10	HCT	hct	NN
cord-005478-5iu38pr6	2606	11	recipients	recipient	NNS
cord-005478-5iu38pr6	2606	12	,	,	,
cord-005478-5iu38pr6	2606	13	and	and	CC
cord-005478-5iu38pr6	2606	14	was	be	VBD
cord-005478-5iu38pr6	2606	15	significantly	significantly	RB
cord-005478-5iu38pr6	2606	16	better	well	JJR
cord-005478-5iu38pr6	2606	17	than	than	IN
cord-005478-5iu38pr6	2606	18	placebo	placebo	NN
cord-005478-5iu38pr6	2606	19	in	in	IN
cord-005478-5iu38pr6	2606	20	preventing	prevent	VBG
cord-005478-5iu38pr6	2606	21	viremia	viremia	NN
cord-005478-5iu38pr6	2606	22	cases	case	NNS
cord-005478-5iu38pr6	2606	23	accompanied	accompany	VBN
cord-005478-5iu38pr6	2606	24	by	by	IN
cord-005478-5iu38pr6	2606	25	improved	improve	VBN
cord-005478-5iu38pr6	2606	26	CMV	CMV	NNP
cord-005478-5iu38pr6	2606	27	-	-	HYPH
cord-005478-5iu38pr6	2606	28	specific	specific	JJ
cord-005478-5iu38pr6	2606	29	T	T	NNP
cord-005478-5iu38pr6	2606	30	cell	cell	NN
cord-005478-5iu38pr6	2606	31	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2606	32	.	.	.
cord-005478-5iu38pr6	2607	1	Background	background	NN
cord-005478-5iu38pr6	2607	2	:	:	:
cord-005478-5iu38pr6	2608	1	Due	due	IN
cord-005478-5iu38pr6	2608	2	to	to	IN
cord-005478-5iu38pr6	2608	3	the	the	DT
cord-005478-5iu38pr6	2608	4	risk	risk	NN
cord-005478-5iu38pr6	2608	5	of	of	IN
cord-005478-5iu38pr6	2608	6	invasive	invasive	JJ
cord-005478-5iu38pr6	2608	7	pneumococcal	pneumococcal	JJ
cord-005478-5iu38pr6	2608	8	disease	disease	NN
cord-005478-5iu38pr6	2608	9	(	(	-LRB-
cord-005478-5iu38pr6	2608	10	IPD	IPD	NNP
cord-005478-5iu38pr6	2608	11	)	)	-RRB-
cord-005478-5iu38pr6	2608	12	after	after	IN
cord-005478-5iu38pr6	2608	13	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2608	14	transplant	transplant	NN
cord-005478-5iu38pr6	2608	15	,	,	,
cord-005478-5iu38pr6	2608	16	the	the	DT
cord-005478-5iu38pr6	2608	17	ECIL7	ECIL7	NNS
cord-005478-5iu38pr6	2608	18	guidelines	guideline	NNS
cord-005478-5iu38pr6	2608	19	recommend	recommend	VBP
cord-005478-5iu38pr6	2608	20	3	3	CD
cord-005478-5iu38pr6	2608	21	doses	dose	NNS
cord-005478-5iu38pr6	2608	22	of	of	IN
cord-005478-5iu38pr6	2608	23	pneumococcal	pneumococcal	JJ
cord-005478-5iu38pr6	2608	24	conjugate	conjugate	JJ
cord-005478-5iu38pr6	2608	25	vaccine	vaccine	NN
cord-005478-5iu38pr6	2608	26	(	(	-LRB-
cord-005478-5iu38pr6	2608	27	PCV	pcv	NN
cord-005478-5iu38pr6	2608	28	)	)	-RRB-
cord-005478-5iu38pr6	2608	29	starting	start	VBG
cord-005478-5iu38pr6	2608	30	3	3	CD
cord-005478-5iu38pr6	2608	31	months	month	NNS
cord-005478-5iu38pr6	2608	32	after	after	IN
cord-005478-5iu38pr6	2608	33	transplant	transplant	NN
cord-005478-5iu38pr6	2608	34	,	,	,
cord-005478-5iu38pr6	2608	35	followed	follow	VBN
cord-005478-5iu38pr6	2608	36	by	by	IN
cord-005478-5iu38pr6	2608	37	either	either	DT
cord-005478-5iu38pr6	2608	38	one	one	CD
cord-005478-5iu38pr6	2608	39	polysaccharide	polysaccharide	NN
cord-005478-5iu38pr6	2608	40	23-valent	23-valent	CD
cord-005478-5iu38pr6	2608	41	vaccine	vaccine	NN
cord-005478-5iu38pr6	2608	42	(	(	-LRB-
cord-005478-5iu38pr6	2608	43	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2608	44	)	)	-RRB-
cord-005478-5iu38pr6	2608	45	dose	dose	NN
cord-005478-5iu38pr6	2608	46	or	or	CC
cord-005478-5iu38pr6	2608	47	a	a	DT
cord-005478-5iu38pr6	2608	48	4th	4th	JJ
cord-005478-5iu38pr6	2608	49	PCV	pcv	NN
cord-005478-5iu38pr6	2608	50	in	in	IN
cord-005478-5iu38pr6	2608	51	case	case	NN
cord-005478-5iu38pr6	2608	52	of	of	IN
cord-005478-5iu38pr6	2608	53	chronic	chronic	JJ
cord-005478-5iu38pr6	2608	54	GvHD	GvHD	NNP
cord-005478-5iu38pr6	2608	55	.	.	.
cord-005478-5iu38pr6	2609	1	However	however	RB
cord-005478-5iu38pr6	2609	2	,	,	,
cord-005478-5iu38pr6	2609	3	no	no	DT
cord-005478-5iu38pr6	2609	4	data	datum	NNS
cord-005478-5iu38pr6	2609	5	strongly	strongly	RB
cord-005478-5iu38pr6	2609	6	support	support	VBP
cord-005478-5iu38pr6	2609	7	recommendations	recommendation	NNS
cord-005478-5iu38pr6	2609	8	from	from	IN
cord-005478-5iu38pr6	2609	9	the	the	DT
cord-005478-5iu38pr6	2609	10	2	2	CD
cord-005478-5iu38pr6	2609	11	nd	nd	NNP
cord-005478-5iu38pr6	2609	12	year	year	NN
cord-005478-5iu38pr6	2609	13	.	.	.
cord-005478-5iu38pr6	2610	1	The	the	DT
cord-005478-5iu38pr6	2610	2	aim	aim	NN
cord-005478-5iu38pr6	2610	3	of	of	IN
cord-005478-5iu38pr6	2610	4	this	this	DT
cord-005478-5iu38pr6	2610	5	study	study	NN
cord-005478-5iu38pr6	2610	6	was	be	VBD
cord-005478-5iu38pr6	2610	7	to	to	TO
cord-005478-5iu38pr6	2610	8	assess	assess	VB
cord-005478-5iu38pr6	2610	9	the	the	DT
cord-005478-5iu38pr6	2610	10	anti	anti	JJ
cord-005478-5iu38pr6	2610	11	-	-	JJ
cord-005478-5iu38pr6	2610	12	pneumococcal	pneumococcal	JJ
cord-005478-5iu38pr6	2610	13	antibody	antibody	NN
cord-005478-5iu38pr6	2610	14	(	(	-LRB-
cord-005478-5iu38pr6	2610	15	Ab	Ab	NNP
cord-005478-5iu38pr6	2610	16	)	)	-RRB-
cord-005478-5iu38pr6	2610	17	concentrations	concentration	NNS
cord-005478-5iu38pr6	2610	18	,	,	,
cord-005478-5iu38pr6	2610	19	years	year	NNS
cord-005478-5iu38pr6	2610	20	after	after	IN
cord-005478-5iu38pr6	2610	21	different	different	JJ
cord-005478-5iu38pr6	2610	22	schedules	schedule	NNS
cord-005478-5iu38pr6	2610	23	of	of	IN
cord-005478-5iu38pr6	2610	24	vaccination	vaccination	NN
cord-005478-5iu38pr6	2610	25	.	.	.
cord-005478-5iu38pr6	2611	1	Methods	method	NNS
cord-005478-5iu38pr6	2611	2	:	:	:
cord-005478-5iu38pr6	2611	3	Patients	patient	NNS
cord-005478-5iu38pr6	2611	4	who	who	WP
cord-005478-5iu38pr6	2611	5	received	receive	VBD
cord-005478-5iu38pr6	2611	6	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2611	7	HCT	hct	NN
cord-005478-5iu38pr6	2611	8	more	more	JJR
cord-005478-5iu38pr6	2611	9	than	than	IN
cord-005478-5iu38pr6	2611	10	18	18	CD
cord-005478-5iu38pr6	2611	11	months	month	NNS
cord-005478-5iu38pr6	2611	12	ago	ago	RB
cord-005478-5iu38pr6	2611	13	and	and	CC
cord-005478-5iu38pr6	2611	14	were	be	VBD
cord-005478-5iu38pr6	2611	15	seen	see	VBN
cord-005478-5iu38pr6	2611	16	in	in	IN
cord-005478-5iu38pr6	2611	17	consultation	consultation	NN
cord-005478-5iu38pr6	2611	18	between	between	IN
cord-005478-5iu38pr6	2611	19	Jan	Jan	NNP
cord-005478-5iu38pr6	2611	20	-	-	HYPH
cord-005478-5iu38pr6	2611	21	Nov	Nov	NNP
cord-005478-5iu38pr6	2611	22	2018	2018	CD
cord-005478-5iu38pr6	2611	23	were	be	VBD
cord-005478-5iu38pr6	2611	24	screened	screen	VBN
cord-005478-5iu38pr6	2611	25	for	for	IN
cord-005478-5iu38pr6	2611	26	IgG	IgG	NNP
cord-005478-5iu38pr6	2611	27	Ab	Ab	NNP
cord-005478-5iu38pr6	2611	28	concentrations	concentration	NNS
cord-005478-5iu38pr6	2611	29	for	for	IN
cord-005478-5iu38pr6	2611	30	the	the	DT
cord-005478-5iu38pr6	2611	31	7	7	CD
cord-005478-5iu38pr6	2611	32	pneumococcal	pneumococcal	JJ
cord-005478-5iu38pr6	2611	33	serotypes	serotype	NNS
cord-005478-5iu38pr6	2611	34	shared	share	VBN
cord-005478-5iu38pr6	2611	35	by	by	IN
cord-005478-5iu38pr6	2611	36	PCV7	PCV7	NNP
cord-005478-5iu38pr6	2611	37	,	,	,
cord-005478-5iu38pr6	2611	38	PCV13	PCV13	NNP
cord-005478-5iu38pr6	2611	39	,	,	,
cord-005478-5iu38pr6	2611	40	and	and	CC
cord-005478-5iu38pr6	2611	41	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2611	42	(	(	-LRB-
cord-005478-5iu38pr6	2611	43	4	4	CD
cord-005478-5iu38pr6	2611	44	,	,	,
cord-005478-5iu38pr6	2611	45	6B	6b	CD
cord-005478-5iu38pr6	2611	46	,	,	,
cord-005478-5iu38pr6	2611	47	9V	9v	CD
cord-005478-5iu38pr6	2611	48	,	,	,
cord-005478-5iu38pr6	2611	49	14	14	CD
cord-005478-5iu38pr6	2611	50	,	,	,
cord-005478-5iu38pr6	2611	51	18C	18C	NNP
cord-005478-5iu38pr6	2611	52	,	,	,
cord-005478-5iu38pr6	2611	53	19F	19F	NNP
cord-005478-5iu38pr6	2611	54	,	,	,
cord-005478-5iu38pr6	2611	55	23F	23F	NNP
cord-005478-5iu38pr6	2611	56	)	)	-RRB-
cord-005478-5iu38pr6	2611	57	,	,	,
cord-005478-5iu38pr6	2611	58	using	use	VBG
cord-005478-5iu38pr6	2611	59	modified	modify	VBN
cord-005478-5iu38pr6	2611	60	enzyme	enzyme	NN
cord-005478-5iu38pr6	2611	61	linked	link	VBN
cord-005478-5iu38pr6	2611	62	immunosorbent	immunosorbent	JJ
cord-005478-5iu38pr6	2611	63	assay	assay	NN
cord-005478-5iu38pr6	2611	64	(	(	-LRB-
cord-005478-5iu38pr6	2611	65	Wernette	Wernette	NNP
cord-005478-5iu38pr6	2611	66	et	et	NNP
cord-005478-5iu38pr6	2611	67	al.2003	al.2003	NNP
cord-005478-5iu38pr6	2611	68	)	)	-RRB-
cord-005478-5iu38pr6	2611	69	.	.	.
cord-005478-5iu38pr6	2612	1	Patients	patient	NNS
cord-005478-5iu38pr6	2612	2	were	be	VBD
cord-005478-5iu38pr6	2612	3	considered	consider	VBN
cord-005478-5iu38pr6	2612	4	protected	protect	VBN
cord-005478-5iu38pr6	2612	5	if	if	IN
cord-005478-5iu38pr6	2612	6	their	-PRON-	PRP$
cord-005478-5iu38pr6	2612	7	Ab	Ab	NNP
cord-005478-5iu38pr6	2612	8	concentrations	concentration	NNS
cord-005478-5iu38pr6	2612	9	were	be	VBD
cord-005478-5iu38pr6	2612	10	>	>	XX
cord-005478-5iu38pr6	2613	1	0.35μg	0.35μg	CD
cord-005478-5iu38pr6	2613	2	/	/	SYM
cord-005478-5iu38pr6	2613	3	mL	ml	NN
cord-005478-5iu38pr6	2613	4	for	for	IN
cord-005478-5iu38pr6	2613	5	the	the	DT
cord-005478-5iu38pr6	2613	6	7	7	CD
cord-005478-5iu38pr6	2613	7	serotypes	serotype	NNS
cord-005478-5iu38pr6	2613	8	tested	test	VBN
cord-005478-5iu38pr6	2613	9	.	.	.
cord-005478-5iu38pr6	2614	1	From	from	IN
cord-005478-5iu38pr6	2614	2	2001	2001	CD
cord-005478-5iu38pr6	2614	3	,	,	,
cord-005478-5iu38pr6	2614	4	all	all	DT
cord-005478-5iu38pr6	2614	5	patients	patient	NNS
cord-005478-5iu38pr6	2614	6	received	receive	VBD
cord-005478-5iu38pr6	2614	7	3	3	CD
cord-005478-5iu38pr6	2614	8	PCVs	pcv	NNS
cord-005478-5iu38pr6	2614	9	during	during	IN
cord-005478-5iu38pr6	2614	10	the	the	DT
cord-005478-5iu38pr6	2614	11	1	1	CD
cord-005478-5iu38pr6	2614	12	st	st	NNP
cord-005478-5iu38pr6	2614	13	year	year	NN
cord-005478-5iu38pr6	2614	14	of	of	IN
cord-005478-5iu38pr6	2614	15	transplant	transplant	NN
cord-005478-5iu38pr6	2614	16	,	,	,
cord-005478-5iu38pr6	2614	17	then	then	RB
cord-005478-5iu38pr6	2614	18	either	either	DT
cord-005478-5iu38pr6	2614	19	one	one	CD
cord-005478-5iu38pr6	2614	20	dose	dose	NN
cord-005478-5iu38pr6	2614	21	of	of	IN
cord-005478-5iu38pr6	2614	22	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2614	23	or	or	CC
cord-005478-5iu38pr6	2614	24	(	(	-LRB-
cord-005478-5iu38pr6	2614	25	from	from	IN
cord-005478-5iu38pr6	2614	26	2009	2009	CD
cord-005478-5iu38pr6	2614	27	)	)	-RRB-
cord-005478-5iu38pr6	2615	1	a	a	DT
cord-005478-5iu38pr6	2615	2	4	4	CD
cord-005478-5iu38pr6	2615	3	th	th	NN
cord-005478-5iu38pr6	2615	4	PCV	pcv	NN
cord-005478-5iu38pr6	2615	5	.	.	.
cord-005478-5iu38pr6	2616	1	For	for	IN
cord-005478-5iu38pr6	2616	2	patients	patient	NNS
cord-005478-5iu38pr6	2616	3	transplanted	transplant	VBN
cord-005478-5iu38pr6	2616	4	for	for	IN
cord-005478-5iu38pr6	2616	5	more	more	JJR
cord-005478-5iu38pr6	2616	6	than	than	IN
cord-005478-5iu38pr6	2616	7	12	12	CD
cord-005478-5iu38pr6	2616	8	months	month	NNS
cord-005478-5iu38pr6	2616	9	when	when	WRB
cord-005478-5iu38pr6	2616	10	PCV	PCV	NNP
cord-005478-5iu38pr6	2616	11	became	become	VBD
cord-005478-5iu38pr6	2616	12	available	available	JJ
cord-005478-5iu38pr6	2616	13	,	,	,
cord-005478-5iu38pr6	2616	14	we	-PRON-	PRP
cord-005478-5iu38pr6	2616	15	locally	locally	RB
cord-005478-5iu38pr6	2616	16	recommended	recommend	VBD
cord-005478-5iu38pr6	2616	17	>	>	XX
cord-005478-5iu38pr6	2616	18	2	2	CD
cord-005478-5iu38pr6	2616	19	PCV	pcv	NN
cord-005478-5iu38pr6	2616	20	and	and	CC
cord-005478-5iu38pr6	2616	21	one	one	CD
cord-005478-5iu38pr6	2616	22	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2616	23	.	.	.
cord-005478-5iu38pr6	2617	1	Results	result	NNS
cord-005478-5iu38pr6	2617	2	:	:	:
cord-005478-5iu38pr6	2618	1	Sixty	sixty	CD
cord-005478-5iu38pr6	2618	2	-	-	HYPH
cord-005478-5iu38pr6	2618	3	one	one	CD
cord-005478-5iu38pr6	2618	4	patients	patient	NNS
cord-005478-5iu38pr6	2618	5	were	be	VBD
cord-005478-5iu38pr6	2618	6	assessed	assess	VBN
cord-005478-5iu38pr6	2618	7	at	at	IN
cord-005478-5iu38pr6	2618	8	a	a	DT
cord-005478-5iu38pr6	2618	9	median	median	NN
cord-005478-5iu38pr6	2618	10	of	of	IN
cord-005478-5iu38pr6	2618	11	8.3	8.3	CD
cord-005478-5iu38pr6	2618	12	years	year	NNS
cord-005478-5iu38pr6	2618	13	(	(	-LRB-
cord-005478-5iu38pr6	2618	14	range	range	NN
cord-005478-5iu38pr6	2618	15	:	:	:
cord-005478-5iu38pr6	2618	16	1.7	1.7	CD
cord-005478-5iu38pr6	2618	17	-	-	SYM
cord-005478-5iu38pr6	2618	18	39.1	39.1	CD
cord-005478-5iu38pr6	2618	19	)	)	-RRB-
cord-005478-5iu38pr6	2618	20	after	after	IN
cord-005478-5iu38pr6	2618	21	transplant	transplant	NN
cord-005478-5iu38pr6	2618	22	.	.	.
cord-005478-5iu38pr6	2619	1	The	the	DT
cord-005478-5iu38pr6	2619	2	mean	mean	JJ
cord-005478-5iu38pr6	2619	3	age	age	NN
cord-005478-5iu38pr6	2619	4	was	be	VBD
cord-005478-5iu38pr6	2619	5	53	53	CD
cord-005478-5iu38pr6	2619	6	years	year	NNS
cord-005478-5iu38pr6	2620	1	(	(	-LRB-
cord-005478-5iu38pr6	2620	2	range	range	NN
cord-005478-5iu38pr6	2620	3	:	:	:
cord-005478-5iu38pr6	2620	4	21	21	CD
cord-005478-5iu38pr6	2620	5	-	-	SYM
cord-005478-5iu38pr6	2620	6	79	79	CD
cord-005478-5iu38pr6	2620	7	)	)	-RRB-
cord-005478-5iu38pr6	2620	8	,	,	,
cord-005478-5iu38pr6	2620	9	M	M	NNP
cord-005478-5iu38pr6	2620	10	/	/	SYM
cord-005478-5iu38pr6	2620	11	F	F	NNP
cord-005478-5iu38pr6	2620	12	sex	sex	NN
cord-005478-5iu38pr6	2620	13	ratio	ratio	NN
cord-005478-5iu38pr6	2620	14	0,85	0,85	CD
cord-005478-5iu38pr6	2620	15	.	.	.
cord-005478-5iu38pr6	2621	1	Most	Most	JJS
cord-005478-5iu38pr6	2621	2	patients	patient	NNS
cord-005478-5iu38pr6	2621	3	had	have	VBD
cord-005478-5iu38pr6	2621	4	acute	acute	JJ
cord-005478-5iu38pr6	2621	5	leukemia	leukemia	NN
cord-005478-5iu38pr6	2621	6	(	(	-LRB-
cord-005478-5iu38pr6	2621	7	32	32	CD
cord-005478-5iu38pr6	2621	8	,	,	,
cord-005478-5iu38pr6	2621	9	52.5	52.5	CD
cord-005478-5iu38pr6	2621	10	%	%	NN
cord-005478-5iu38pr6	2621	11	)	)	-RRB-
cord-005478-5iu38pr6	2621	12	or	or	CC
cord-005478-5iu38pr6	2621	13	lymphoproliferative	lymphoproliferative	JJ
cord-005478-5iu38pr6	2621	14	diseases	disease	NNS
cord-005478-5iu38pr6	2621	15	(	(	-LRB-
cord-005478-5iu38pr6	2621	16	13	13	CD
cord-005478-5iu38pr6	2621	17	,	,	,
cord-005478-5iu38pr6	2621	18	21.5	21.5	CD
cord-005478-5iu38pr6	2621	19	%	%	NN
cord-005478-5iu38pr6	2621	20	)	)	-RRB-
cord-005478-5iu38pr6	2621	21	.	.	.
cord-005478-5iu38pr6	2622	1	The	the	DT
cord-005478-5iu38pr6	2622	2	donor	donor	NN
cord-005478-5iu38pr6	2622	3	was	be	VBD
cord-005478-5iu38pr6	2622	4	HLA	HLA	NNP
cord-005478-5iu38pr6	2622	5	-	-	HYPH
cord-005478-5iu38pr6	2622	6	identical	identical	JJ
cord-005478-5iu38pr6	2622	7	in	in	IN
cord-005478-5iu38pr6	2622	8	42	42	CD
cord-005478-5iu38pr6	2622	9	(	(	-LRB-
cord-005478-5iu38pr6	2622	10	69	69	CD
cord-005478-5iu38pr6	2622	11	%	%	NN
cord-005478-5iu38pr6	2622	12	)	)	-RRB-
cord-005478-5iu38pr6	2622	13	cases	case	NNS
cord-005478-5iu38pr6	2622	14	.	.	.
cord-005478-5iu38pr6	2623	1	Conditioning	conditioning	NN
cord-005478-5iu38pr6	2623	2	regimen	regimen	NN
cord-005478-5iu38pr6	2623	3	was	be	VBD
cord-005478-5iu38pr6	2623	4	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2623	5	in	in	IN
cord-005478-5iu38pr6	2623	6	37	37	CD
cord-005478-5iu38pr6	2623	7	(	(	-LRB-
cord-005478-5iu38pr6	2623	8	61	61	CD
cord-005478-5iu38pr6	2623	9	%	%	NN
cord-005478-5iu38pr6	2623	10	)	)	-RRB-
cord-005478-5iu38pr6	2623	11	,	,	,
cord-005478-5iu38pr6	2623	12	reduced	reduce	VBN
cord-005478-5iu38pr6	2623	13	-	-	HYPH
cord-005478-5iu38pr6	2623	14	intensity	intensity	NN
cord-005478-5iu38pr6	2623	15	or	or	CC
cord-005478-5iu38pr6	2623	16	non	non	JJ
cord-005478-5iu38pr6	2623	17	-	-	JJ
cord-005478-5iu38pr6	2623	18	MA	MA	NNP
cord-005478-5iu38pr6	2623	19	in	in	IN
cord-005478-5iu38pr6	2623	20	12	12	CD
cord-005478-5iu38pr6	2623	21	(	(	-LRB-
cord-005478-5iu38pr6	2623	22	19.5	19.5	CD
cord-005478-5iu38pr6	2623	23	%	%	NN
cord-005478-5iu38pr6	2623	24	)	)	-RRB-
cord-005478-5iu38pr6	2623	25	each	each	DT
cord-005478-5iu38pr6	2623	26	.	.	.
cord-005478-5iu38pr6	2624	1	None	none	NN
cord-005478-5iu38pr6	2624	2	patient	patient	NN
cord-005478-5iu38pr6	2624	3	had	have	VBD
cord-005478-5iu38pr6	2624	4	experienced	experience	VBN
cord-005478-5iu38pr6	2624	5	IPD	ipd	NN
cord-005478-5iu38pr6	2624	6	since	since	IN
cord-005478-5iu38pr6	2624	7	transplant	transplant	NN
cord-005478-5iu38pr6	2624	8	nor	nor	CC
cord-005478-5iu38pr6	2624	9	had	have	VBD
cord-005478-5iu38pr6	2624	10	received	receive	VBN
cord-005478-5iu38pr6	2624	11	immunoglobulins	immunoglobulin	NNS
cord-005478-5iu38pr6	2624	12	for	for	IN
cord-005478-5iu38pr6	2624	13	at	at	RB
cord-005478-5iu38pr6	2624	14	least	least	RBS
cord-005478-5iu38pr6	2624	15	6	6	CD
cord-005478-5iu38pr6	2624	16	months	month	NNS
cord-005478-5iu38pr6	2624	17	or	or	CC
cord-005478-5iu38pr6	2624	18	rituximab	rituximab	VBN
cord-005478-5iu38pr6	2624	19	for	for	IN
cord-005478-5iu38pr6	2624	20	at	at	RB
cord-005478-5iu38pr6	2624	21	least	least	RBS
cord-005478-5iu38pr6	2624	22	23	23	CD
cord-005478-5iu38pr6	2624	23	months	month	NNS
cord-005478-5iu38pr6	2624	24	at	at	IN
cord-005478-5iu38pr6	2624	25	time	time	NN
cord-005478-5iu38pr6	2624	26	of	of	IN
cord-005478-5iu38pr6	2624	27	assessment	assessment	NN
cord-005478-5iu38pr6	2624	28	.	.	.
cord-005478-5iu38pr6	2625	1	Fifty	fifty	CD
cord-005478-5iu38pr6	2625	2	-	-	HYPH
cord-005478-5iu38pr6	2625	3	four	four	CD
cord-005478-5iu38pr6	2625	4	patients	patient	NNS
cord-005478-5iu38pr6	2625	5	(	(	-LRB-
cord-005478-5iu38pr6	2625	6	88.5	88.5	CD
cord-005478-5iu38pr6	2625	7	%	%	NN
cord-005478-5iu38pr6	2625	8	)	)	-RRB-
cord-005478-5iu38pr6	2625	9	received	receive	VBD
cord-005478-5iu38pr6	2625	10	3	3	CD
cord-005478-5iu38pr6	2625	11	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2625	12	PCV	pcv	NN
cord-005478-5iu38pr6	2625	13	:	:	:
cord-005478-5iu38pr6	2625	14	46	46	CD
cord-005478-5iu38pr6	2625	15	(	(	-LRB-
cord-005478-5iu38pr6	2625	16	75.5	75.5	CD
cord-005478-5iu38pr6	2625	17	%	%	NN
cord-005478-5iu38pr6	2625	18	)	)	-RRB-
cord-005478-5iu38pr6	2625	19	during	during	IN
cord-005478-5iu38pr6	2625	20	the	the	DT
cord-005478-5iu38pr6	2625	21	first	first	JJ
cord-005478-5iu38pr6	2625	22	12	12	CD
cord-005478-5iu38pr6	2625	23	months	month	NNS
cord-005478-5iu38pr6	2625	24	and	and	CC
cord-005478-5iu38pr6	2625	25	8	8	CD
cord-005478-5iu38pr6	2625	26	(	(	-LRB-
cord-005478-5iu38pr6	2625	27	13	13	CD
cord-005478-5iu38pr6	2625	28	%	%	NN
cord-005478-5iu38pr6	2625	29	)	)	-RRB-
cord-005478-5iu38pr6	2625	30	thereafter	thereafter	RB
cord-005478-5iu38pr6	2625	31	.	.	.
cord-005478-5iu38pr6	2626	1	Five	five	CD
cord-005478-5iu38pr6	2626	2	(	(	-LRB-
cord-005478-5iu38pr6	2626	3	8	8	CD
cord-005478-5iu38pr6	2626	4	%	%	NN
cord-005478-5iu38pr6	2626	5	)	)	-RRB-
cord-005478-5iu38pr6	2626	6	patients	patient	NNS
cord-005478-5iu38pr6	2626	7	received	receive	VBD
cord-005478-5iu38pr6	2626	8	2	2	CD
cord-005478-5iu38pr6	2626	9	PCV	pcv	NN
cord-005478-5iu38pr6	2626	10	and	and	CC
cord-005478-5iu38pr6	2626	11	only	only	RB
cord-005478-5iu38pr6	2626	12	one	one	CD
cord-005478-5iu38pr6	2626	13	patient	patient	NN
cord-005478-5iu38pr6	2626	14	(	(	-LRB-
cord-005478-5iu38pr6	2626	15	1.5	1.5	CD
cord-005478-5iu38pr6	2626	16	%	%	NN
cord-005478-5iu38pr6	2626	17	)	)	-RRB-
cord-005478-5iu38pr6	2626	18	received	receive	VBD
cord-005478-5iu38pr6	2626	19	a	a	DT
cord-005478-5iu38pr6	2626	20	unique	unique	JJ
cord-005478-5iu38pr6	2626	21	dose	dose	NN
cord-005478-5iu38pr6	2626	22	of	of	IN
cord-005478-5iu38pr6	2626	23	PCV	pcv	NN
cord-005478-5iu38pr6	2626	24	.	.	.
cord-005478-5iu38pr6	2627	1	The	the	DT
cord-005478-5iu38pr6	2627	2	1	1	CD
cord-005478-5iu38pr6	2627	3	st	st	NNP
cord-005478-5iu38pr6	2627	4	PCV	PCV	NNP
cord-005478-5iu38pr6	2627	5	was	be	VBD
cord-005478-5iu38pr6	2627	6	administered	administer	VBN
cord-005478-5iu38pr6	2627	7	at	at	IN
cord-005478-5iu38pr6	2627	8	a	a	DT
cord-005478-5iu38pr6	2627	9	median	median	NN
cord-005478-5iu38pr6	2627	10	of	of	IN
cord-005478-5iu38pr6	2627	11	3.5	3.5	CD
cord-005478-5iu38pr6	2627	12	(	(	-LRB-
cord-005478-5iu38pr6	2627	13	range	range	NN
cord-005478-5iu38pr6	2627	14	:	:	:
cord-005478-5iu38pr6	2627	15	3	3	CD
cord-005478-5iu38pr6	2627	16	-	-	SYM
cord-005478-5iu38pr6	2627	17	201	201	CD
cord-005478-5iu38pr6	2627	18	)	)	-RRB-
cord-005478-5iu38pr6	2627	19	months	month	NNS
cord-005478-5iu38pr6	2627	20	after	after	IN
cord-005478-5iu38pr6	2627	21	HCT	HCT	NNP
cord-005478-5iu38pr6	2627	22	.	.	.
cord-005478-5iu38pr6	2628	1	Fifty	fifty	CD
cord-005478-5iu38pr6	2628	2	-	-	HYPH
cord-005478-5iu38pr6	2628	3	seven	seven	CD
cord-005478-5iu38pr6	2628	4	(	(	-LRB-
cord-005478-5iu38pr6	2628	5	93.5	93.5	CD
cord-005478-5iu38pr6	2628	6	%	%	NN
cord-005478-5iu38pr6	2628	7	)	)	-RRB-
cord-005478-5iu38pr6	2628	8	patients	patient	NNS
cord-005478-5iu38pr6	2628	9	received	receive	VBD
cord-005478-5iu38pr6	2628	10	one	one	CD
cord-005478-5iu38pr6	2628	11	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2628	12	at	at	IN
cord-005478-5iu38pr6	2628	13	a	a	DT
cord-005478-5iu38pr6	2628	14	median	median	NN
cord-005478-5iu38pr6	2628	15	of	of	IN
cord-005478-5iu38pr6	2628	16	13	13	CD
cord-005478-5iu38pr6	2628	17	months	month	NNS
cord-005478-5iu38pr6	2628	18	(	(	-LRB-
cord-005478-5iu38pr6	2628	19	range	range	NN
cord-005478-5iu38pr6	2628	20	:	:	:
cord-005478-5iu38pr6	2628	21	0.9	0.9	CD
cord-005478-5iu38pr6	2628	22	-	-	SYM
cord-005478-5iu38pr6	2628	23	385	385	CD
cord-005478-5iu38pr6	2628	24	)	)	-RRB-
cord-005478-5iu38pr6	2628	25	and	and	CC
cord-005478-5iu38pr6	2628	26	33	33	CD
cord-005478-5iu38pr6	2628	27	(	(	-LRB-
cord-005478-5iu38pr6	2628	28	54	54	CD
cord-005478-5iu38pr6	2628	29	%	%	NN
cord-005478-5iu38pr6	2628	30	)	)	-RRB-
cord-005478-5iu38pr6	2628	31	of	of	IN
cord-005478-5iu38pr6	2628	32	them	-PRON-	PRP
cord-005478-5iu38pr6	2628	33	received	receive	VBD
cord-005478-5iu38pr6	2628	34	a	a	DT
cord-005478-5iu38pr6	2628	35	2nd	2nd	JJ
cord-005478-5iu38pr6	2628	36	PSV23	PSV23	NNP
cord-005478-5iu38pr6	2628	37	thereafter	thereafter	RB
cord-005478-5iu38pr6	2628	38	.	.	.
cord-005478-5iu38pr6	2629	1	Finally	finally	RB
cord-005478-5iu38pr6	2629	2	,	,	,
cord-005478-5iu38pr6	2629	3	39/	39/	CD
cord-005478-5iu38pr6	2629	4	61	61	CD
cord-005478-5iu38pr6	2629	5	(	(	-LRB-
cord-005478-5iu38pr6	2629	6	64	64	CD
cord-005478-5iu38pr6	2629	7	%	%	NN
cord-005478-5iu38pr6	2629	8	)	)	-RRB-
cord-005478-5iu38pr6	2629	9	patients	patient	NNS
cord-005478-5iu38pr6	2629	10	received	receive	VBD
cord-005478-5iu38pr6	2629	11	the	the	DT
cord-005478-5iu38pr6	2629	12	recommended	recommend	VBN
cord-005478-5iu38pr6	2629	13	program	program	NN
cord-005478-5iu38pr6	2629	14	.	.	.
cord-005478-5iu38pr6	2630	1	The	the	DT
cord-005478-5iu38pr6	2630	2	overall	overall	JJ
cord-005478-5iu38pr6	2630	3	protection	protection	NN
cord-005478-5iu38pr6	2630	4	rate	rate	NN
cord-005478-5iu38pr6	2630	5	was	be	VBD
cord-005478-5iu38pr6	2630	6	29/61	29/61	CD
cord-005478-5iu38pr6	2630	7	(	(	-LRB-
cord-005478-5iu38pr6	2630	8	47.5	47.5	CD
cord-005478-5iu38pr6	2630	9	%	%	NN
cord-005478-5iu38pr6	2630	10	)	)	-RRB-
cord-005478-5iu38pr6	2630	11	at	at	IN
cord-005478-5iu38pr6	2630	12	a	a	DT
cord-005478-5iu38pr6	2630	13	median	median	JJ
cord-005478-5iu38pr6	2630	14	time	time	NN
cord-005478-5iu38pr6	2630	15	of	of	IN
cord-005478-5iu38pr6	2630	16	8.3	8.3	CD
cord-005478-5iu38pr6	2630	17	years	year	NNS
cord-005478-5iu38pr6	2630	18	after	after	IN
cord-005478-5iu38pr6	2630	19	HCT	HCT	NNP
cord-005478-5iu38pr6	2630	20	.	.	.
cord-005478-5iu38pr6	2631	1	No	no	DT
cord-005478-5iu38pr6	2631	2	differences	difference	NNS
cord-005478-5iu38pr6	2631	3	were	be	VBD
cord-005478-5iu38pr6	2631	4	observed	observe	VBN
cord-005478-5iu38pr6	2631	5	between	between	IN
cord-005478-5iu38pr6	2631	6	patients	patient	NNS
cord-005478-5iu38pr6	2631	7	who	who	WP
cord-005478-5iu38pr6	2631	8	received	receive	VBD
cord-005478-5iu38pr6	2631	9	the	the	DT
cord-005478-5iu38pr6	2631	10	recommended	recommend	VBN
cord-005478-5iu38pr6	2631	11	program	program	NN
cord-005478-5iu38pr6	2631	12	(	(	-LRB-
cord-005478-5iu38pr6	2631	13	18/39	18/39	CD
cord-005478-5iu38pr6	2631	14	,	,	,
cord-005478-5iu38pr6	2631	15	46	46	CD
cord-005478-5iu38pr6	2631	16	%	%	NN
cord-005478-5iu38pr6	2631	17	)	)	-RRB-
cord-005478-5iu38pr6	2631	18	and	and	CC
cord-005478-5iu38pr6	2631	19	the	the	DT
cord-005478-5iu38pr6	2631	20	others	other	NNS
cord-005478-5iu38pr6	2631	21	(	(	-LRB-
cord-005478-5iu38pr6	2631	22	11/22	11/22	CD
cord-005478-5iu38pr6	2631	23	,	,	,
cord-005478-5iu38pr6	2631	24	50	50	CD
cord-005478-5iu38pr6	2631	25	%	%	NN
cord-005478-5iu38pr6	2631	26	)	)	-RRB-
cord-005478-5iu38pr6	2631	27	.	.	.
cord-005478-5iu38pr6	2632	1	However	however	RB
cord-005478-5iu38pr6	2632	2	,	,	,
cord-005478-5iu38pr6	2632	3	this	this	DT
cord-005478-5iu38pr6	2632	4	latter	latter	JJ
cord-005478-5iu38pr6	2632	5	group	group	NN
cord-005478-5iu38pr6	2632	6	was	be	VBD
cord-005478-5iu38pr6	2632	7	often	often	RB
cord-005478-5iu38pr6	2632	8	vaccinated	vaccinate	VBN
cord-005478-5iu38pr6	2632	9	>	>	XX
cord-005478-5iu38pr6	2632	10	10	10	CD
cord-005478-5iu38pr6	2632	11	years	year	NNS
cord-005478-5iu38pr6	2632	12	after	after	IN
cord-005478-5iu38pr6	2632	13	HCT	hct	NN
cord-005478-5iu38pr6	2632	14	and	and	CC
cord-005478-5iu38pr6	2632	15	therefore	therefore	RB
cord-005478-5iu38pr6	2632	16	not	not	RB
cord-005478-5iu38pr6	2632	17	protected	protect	VBN
cord-005478-5iu38pr6	2632	18	for	for	IN
cord-005478-5iu38pr6	2632	19	years	year	NNS
cord-005478-5iu38pr6	2632	20	,	,	,
cord-005478-5iu38pr6	2632	21	but	but	CC
cord-005478-5iu38pr6	2632	22	may	may	MD
cord-005478-5iu38pr6	2632	23	have	have	VB
cord-005478-5iu38pr6	2632	24	developed	develop	VBN
cord-005478-5iu38pr6	2632	25	a	a	DT
cord-005478-5iu38pr6	2632	26	better	well	JJR
cord-005478-5iu38pr6	2632	27	response	response	NN
cord-005478-5iu38pr6	2632	28	to	to	IN
cord-005478-5iu38pr6	2632	29	only	only	RB
cord-005478-5iu38pr6	2632	30	one	one	CD
cord-005478-5iu38pr6	2632	31	or	or	CC
cord-005478-5iu38pr6	2632	32	2	2	CD
cord-005478-5iu38pr6	2632	33	PCV	pcv	NN
cord-005478-5iu38pr6	2632	34	.	.	.
cord-005478-5iu38pr6	2633	1	In	in	IN
cord-005478-5iu38pr6	2633	2	all	all	DT
cord-005478-5iu38pr6	2633	3	groups	group	NNS
cord-005478-5iu38pr6	2633	4	,	,	,
cord-005478-5iu38pr6	2633	5	the	the	DT
cord-005478-5iu38pr6	2633	6	Ab	Ab	NNP
cord-005478-5iu38pr6	2633	7	concentrations	concentration	NNS
cord-005478-5iu38pr6	2633	8	were	be	VBD
cord-005478-5iu38pr6	2633	9	heterogeneous	heterogeneous	JJ
cord-005478-5iu38pr6	2633	10	from	from	IN
cord-005478-5iu38pr6	2633	11	one	one	CD
cord-005478-5iu38pr6	2633	12	serotype	serotype	NN
cord-005478-5iu38pr6	2633	13	to	to	IN
cord-005478-5iu38pr6	2633	14	an	an	DT
cord-005478-5iu38pr6	2633	15	other	other	JJ
cord-005478-5iu38pr6	2633	16	.	.	.
cord-005478-5iu38pr6	2634	1	Recipient	recipient	NN
cord-005478-5iu38pr6	2634	2	age	age	NN
cord-005478-5iu38pr6	2634	3	,	,	,
cord-005478-5iu38pr6	2634	4	donor	donor	NN
cord-005478-5iu38pr6	2634	5	age	age	NN
cord-005478-5iu38pr6	2634	6	,	,	,
cord-005478-5iu38pr6	2634	7	underlying	underlie	VBG
cord-005478-5iu38pr6	2634	8	disease	disease	NN
cord-005478-5iu38pr6	2634	9	,	,	,
cord-005478-5iu38pr6	2634	10	conditioning	conditioning	NN
cord-005478-5iu38pr6	2634	11	,	,	,
cord-005478-5iu38pr6	2634	12	donor	donor	NN
cord-005478-5iu38pr6	2634	13	type	type	NN
cord-005478-5iu38pr6	2634	14	,	,	,
cord-005478-5iu38pr6	2634	15	previous	previous	JJ
cord-005478-5iu38pr6	2634	16	GvHD	gvhd	NN
cord-005478-5iu38pr6	2634	17	,	,	,
cord-005478-5iu38pr6	2634	18	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	2634	19	count	count	NN
cord-005478-5iu38pr6	2634	20	or	or	CC
cord-005478-5iu38pr6	2634	21	gammaglobulin	gammaglobulin	NN
cord-005478-5iu38pr6	2634	22	serum	serum	NN
cord-005478-5iu38pr6	2634	23	levels	level	NNS
cord-005478-5iu38pr6	2634	24	were	be	VBD
cord-005478-5iu38pr6	2634	25	not	not	RB
cord-005478-5iu38pr6	2634	26	associated	associate	VBN
cord-005478-5iu38pr6	2634	27	with	with	IN
cord-005478-5iu38pr6	2634	28	seroprotection	seroprotection	NN
cord-005478-5iu38pr6	2634	29	.	.	.
cord-005478-5iu38pr6	2635	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2635	2	:	:	:
cord-005478-5iu38pr6	2636	1	Although	although	IN
cord-005478-5iu38pr6	2636	2	the	the	DT
cord-005478-5iu38pr6	2636	3	early	early	JJ
cord-005478-5iu38pr6	2636	4	antipneumococcal	antipneumococcal	JJ
cord-005478-5iu38pr6	2636	5	vaccination	vaccination	NN
cord-005478-5iu38pr6	2636	6	program	program	NN
cord-005478-5iu38pr6	2636	7	is	be	VBZ
cord-005478-5iu38pr6	2636	8	now	now	RB
cord-005478-5iu38pr6	2636	9	well	well	RB
cord-005478-5iu38pr6	2636	10	established	establish	VBN
cord-005478-5iu38pr6	2636	11	,	,	,
cord-005478-5iu38pr6	2636	12	half	half	NN
cord-005478-5iu38pr6	2636	13	of	of	IN
cord-005478-5iu38pr6	2636	14	the	the	DT
cord-005478-5iu38pr6	2636	15	patients	patient	NNS
cord-005478-5iu38pr6	2636	16	vaccinated	vaccinate	VBN
cord-005478-5iu38pr6	2636	17	according	accord	VBG
cord-005478-5iu38pr6	2636	18	to	to	IN
cord-005478-5iu38pr6	2636	19	the	the	DT
cord-005478-5iu38pr6	2636	20	guidelines	guideline	NNS
cord-005478-5iu38pr6	2636	21	were	be	VBD
cord-005478-5iu38pr6	2636	22	not	not	RB
cord-005478-5iu38pr6	2636	23	protected	protect	VBN
cord-005478-5iu38pr6	2636	24	anymore	anymore	RB
cord-005478-5iu38pr6	2636	25	years	year	NNS
cord-005478-5iu38pr6	2636	26	later	later	RB
cord-005478-5iu38pr6	2636	27	.	.	.
cord-005478-5iu38pr6	2637	1	Prospective	prospective	JJ
cord-005478-5iu38pr6	2637	2	studies	study	NNS
cord-005478-5iu38pr6	2637	3	are	be	VBP
cord-005478-5iu38pr6	2637	4	needed	need	VBN
cord-005478-5iu38pr6	2637	5	to	to	TO
cord-005478-5iu38pr6	2637	6	establish	establish	VB
cord-005478-5iu38pr6	2637	7	an	an	DT
cord-005478-5iu38pr6	2637	8	optimal	optimal	JJ
cord-005478-5iu38pr6	2637	9	long	long	JJ
cord-005478-5iu38pr6	2637	10	-	-	HYPH
cord-005478-5iu38pr6	2637	11	term	term	NN
cord-005478-5iu38pr6	2637	12	programme	programme	NN
cord-005478-5iu38pr6	2637	13	.	.	.
cord-005478-5iu38pr6	2638	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2638	2	:	:	:
cord-005478-5iu38pr6	2638	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2638	4	to	to	TO
cord-005478-5iu38pr6	2638	5	declare	declare	VB
cord-005478-5iu38pr6	2638	6	,	,	,
cord-005478-5iu38pr6	2638	7	letermovir	letermovir	NNP
cord-005478-5iu38pr6	2638	8	vs.	vs.	IN
cord-005478-5iu38pr6	2638	9	placebo	placebo	NN
cord-005478-5iu38pr6	2638	10	)	)	-RRB-
cord-005478-5iu38pr6	2638	11	and	and	CC
cord-005478-5iu38pr6	2638	12	was	be	VBD
cord-005478-5iu38pr6	2638	13	well	well	RB
cord-005478-5iu38pr6	2638	14	tolerated	tolerate	VBN
cord-005478-5iu38pr6	2638	15	overall	overall	RB
cord-005478-5iu38pr6	2638	16	.	.	.
cord-005478-5iu38pr6	2639	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2639	2	evaluated	evaluate	VBD
cord-005478-5iu38pr6	2639	3	risk	risk	NN
cord-005478-5iu38pr6	2639	4	factors	factor	NNS
cord-005478-5iu38pr6	2639	5	associated	associate	VBN
cord-005478-5iu38pr6	2639	6	with	with	IN
cord-005478-5iu38pr6	2639	7	development	development	NN
cord-005478-5iu38pr6	2639	8	of	of	IN
cord-005478-5iu38pr6	2639	9	cs	cs	NNP
cord-005478-5iu38pr6	2639	10	-	-	HYPH
cord-005478-5iu38pr6	2639	11	CMVi	CMVi	NNPS
cord-005478-5iu38pr6	2639	12	to	to	TO
cord-005478-5iu38pr6	2639	13	further	further	RB
cord-005478-5iu38pr6	2639	14	inform	inform	VB
cord-005478-5iu38pr6	2639	15	the	the	DT
cord-005478-5iu38pr6	2639	16	clinical	clinical	JJ
cord-005478-5iu38pr6	2639	17	use	use	NN
cord-005478-5iu38pr6	2639	18	of	of	IN
cord-005478-5iu38pr6	2639	19	letermovir	letermovir	NNS
cord-005478-5iu38pr6	2639	20	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2639	21	and	and	CC
cord-005478-5iu38pr6	2639	22	future	future	JJ
cord-005478-5iu38pr6	2639	23	trial	trial	NN
cord-005478-5iu38pr6	2639	24	designs	design	NNS
cord-005478-5iu38pr6	2639	25	.	.	.
cord-005478-5iu38pr6	2640	1	Methods	method	NNS
cord-005478-5iu38pr6	2640	2	:	:	:
cord-005478-5iu38pr6	2641	1	The	the	DT
cord-005478-5iu38pr6	2641	2	495	495	CD
cord-005478-5iu38pr6	2641	3	participants	participant	NNS
cord-005478-5iu38pr6	2641	4	without	without	IN
cord-005478-5iu38pr6	2641	5	detectable	detectable	JJ
cord-005478-5iu38pr6	2641	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2641	7	DNA	dna	NN
cord-005478-5iu38pr6	2641	8	at	at	IN
cord-005478-5iu38pr6	2641	9	randomization	randomization	NN
cord-005478-5iu38pr6	2641	10	(	(	-LRB-
cord-005478-5iu38pr6	2641	11	primary	primary	JJ
cord-005478-5iu38pr6	2641	12	efficacy	efficacy	NN
cord-005478-5iu38pr6	2641	13	population	population	NN
cord-005478-5iu38pr6	2641	14	)	)	-RRB-
cord-005478-5iu38pr6	2641	15	were	be	VBD
cord-005478-5iu38pr6	2641	16	analyzed	analyze	VBN
cord-005478-5iu38pr6	2641	17	.	.	.
cord-005478-5iu38pr6	2642	1	CS	CS	NNP
cord-005478-5iu38pr6	2642	2	-	-	HYPH
cord-005478-5iu38pr6	2642	3	CMVi	CMVi	NNP
cord-005478-5iu38pr6	2642	4	was	be	VBD
cord-005478-5iu38pr6	2642	5	defined	define	VBN
cord-005478-5iu38pr6	2642	6	as	as	IN
cord-005478-5iu38pr6	2642	7	CMV	CMV	NNP
cord-005478-5iu38pr6	2642	8	viremia	viremia	NN
cord-005478-5iu38pr6	2642	9	requiring	require	VBG
cord-005478-5iu38pr6	2642	10	antiviral	antiviral	JJ
cord-005478-5iu38pr6	2642	11	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2642	12	therapy	therapy	NN
cord-005478-5iu38pr6	2642	13	(	(	-LRB-
cord-005478-5iu38pr6	2642	14	PET	PET	NNP
cord-005478-5iu38pr6	2642	15	)	)	-RRB-
cord-005478-5iu38pr6	2642	16	or	or	CC
cord-005478-5iu38pr6	2642	17	CMV	CMV	NNP
cord-005478-5iu38pr6	2642	18	diseasepatients	diseasepatient	NNS
cord-005478-5iu38pr6	2642	19	without	without	IN
cord-005478-5iu38pr6	2642	20	cs	cs	NNP
cord-005478-5iu38pr6	2642	21	-	-	HYPH
cord-005478-5iu38pr6	2642	22	CMVi	CMVi	NNP
cord-005478-5iu38pr6	2642	23	who	who	WP
cord-005478-5iu38pr6	2642	24	died	die	VBD
cord-005478-5iu38pr6	2642	25	or	or	CC
cord-005478-5iu38pr6	2642	26	withdrew	withdraw	VBD
cord-005478-5iu38pr6	2642	27	from	from	IN
cord-005478-5iu38pr6	2642	28	the	the	DT
cord-005478-5iu38pr6	2642	29	trial	trial	NN
cord-005478-5iu38pr6	2642	30	on	on	IN
cord-005478-5iu38pr6	2642	31	or	or	CC
cord-005478-5iu38pr6	2642	32	before	before	IN
cord-005478-5iu38pr6	2642	33	Week	week	NN
cord-005478-5iu38pr6	2642	34	24	24	CD
cord-005478-5iu38pr6	2642	35	were	be	VBD
cord-005478-5iu38pr6	2642	36	censored	censor	VBN
cord-005478-5iu38pr6	2642	37	at	at	IN
cord-005478-5iu38pr6	2642	38	the	the	DT
cord-005478-5iu38pr6	2642	39	time	time	NN
cord-005478-5iu38pr6	2642	40	of	of	IN
cord-005478-5iu38pr6	2642	41	those	those	DT
cord-005478-5iu38pr6	2642	42	events	event	NNS
cord-005478-5iu38pr6	2642	43	for	for	IN
cord-005478-5iu38pr6	2642	44	this	this	DT
cord-005478-5iu38pr6	2642	45	analysis	analysis	NN
cord-005478-5iu38pr6	2642	46	.	.	.
cord-005478-5iu38pr6	2643	1	Potential	potential	JJ
cord-005478-5iu38pr6	2643	2	risk	risk	NN
cord-005478-5iu38pr6	2643	3	factors	factor	NNS
cord-005478-5iu38pr6	2643	4	for	for	IN
cord-005478-5iu38pr6	2643	5	cs	cs	NNP
cord-005478-5iu38pr6	2643	6	-	-	HYPH
cord-005478-5iu38pr6	2643	7	CMVi	CMVi	NNP
cord-005478-5iu38pr6	2643	8	by	by	IN
cord-005478-5iu38pr6	2643	9	Week	week	NN
cord-005478-5iu38pr6	2643	10	24	24	CD
cord-005478-5iu38pr6	2643	11	post	post	NN
cord-005478-5iu38pr6	2643	12	HCT	hct	NN
cord-005478-5iu38pr6	2643	13	were	be	VBD
cord-005478-5iu38pr6	2643	14	examined	examine	VBN
cord-005478-5iu38pr6	2643	15	using	use	VBG
cord-005478-5iu38pr6	2643	16	univariate	univariate	JJ
cord-005478-5iu38pr6	2643	17	and	and	CC
cord-005478-5iu38pr6	2643	18	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2643	19	Cox	Cox	NNP
cord-005478-5iu38pr6	2643	20	proportional	proportional	JJ
cord-005478-5iu38pr6	2643	21	hazards	hazard	NNS
cord-005478-5iu38pr6	2643	22	models	model	NNS
cord-005478-5iu38pr6	2643	23	.	.	.
cord-005478-5iu38pr6	2644	1	Candidate	candidate	NN
cord-005478-5iu38pr6	2644	2	covariates	covariate	NNS
cord-005478-5iu38pr6	2644	3	were	be	VBD
cord-005478-5iu38pr6	2644	4	included	include	VBN
cord-005478-5iu38pr6	2644	5	in	in	IN
cord-005478-5iu38pr6	2644	6	the	the	DT
cord-005478-5iu38pr6	2644	7	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2644	8	Cox	Cox	NNP
cord-005478-5iu38pr6	2644	9	model	model	NN
cord-005478-5iu38pr6	2644	10	if	if	IN
cord-005478-5iu38pr6	2644	11	they	-PRON-	PRP
cord-005478-5iu38pr6	2644	12	were	be	VBD
cord-005478-5iu38pr6	2644	13	associated	associate	VBN
cord-005478-5iu38pr6	2644	14	with	with	IN
cord-005478-5iu38pr6	2644	15	cs	cs	NNP
cord-005478-5iu38pr6	2644	16	-	-	HYPH
cord-005478-5iu38pr6	2644	17	CMVi	CMVi	NNP
cord-005478-5iu38pr6	2644	18	in	in	IN
cord-005478-5iu38pr6	2644	19	the	the	DT
cord-005478-5iu38pr6	2644	20	univariate	univariate	JJ
cord-005478-5iu38pr6	2644	21	analysis	analysis	NN
cord-005478-5iu38pr6	2644	22	or	or	CC
cord-005478-5iu38pr6	2644	23	had	have	VBD
cord-005478-5iu38pr6	2644	24	been	be	VBN
cord-005478-5iu38pr6	2644	25	previously	previously	RB
cord-005478-5iu38pr6	2644	26	identified	identify	VBN
cord-005478-5iu38pr6	2644	27	in	in	IN
cord-005478-5iu38pr6	2644	28	the	the	DT
cord-005478-5iu38pr6	2644	29	literature	literature	NN
cord-005478-5iu38pr6	2644	30	as	as	IN
cord-005478-5iu38pr6	2644	31	significant	significant	JJ
cord-005478-5iu38pr6	2644	32	risk	risk	NN
cord-005478-5iu38pr6	2644	33	factors	factor	NNS
cord-005478-5iu38pr6	2644	34	.	.	.
cord-005478-5iu38pr6	2645	1	To	to	TO
cord-005478-5iu38pr6	2645	2	avoid	avoid	VB
cord-005478-5iu38pr6	2645	3	collinearity	collinearity	NN
cord-005478-5iu38pr6	2645	4	,	,	,
cord-005478-5iu38pr6	2645	5	the	the	DT
cord-005478-5iu38pr6	2645	6	trial	trial	JJ
cord-005478-5iu38pr6	2645	7	high	high	JJ
cord-005478-5iu38pr6	2645	8	-	-	HYPH
cord-005478-5iu38pr6	2645	9	risk	risk	NN
cord-005478-5iu38pr6	2645	10	for	for	IN
cord-005478-5iu38pr6	2645	11	reactivation	reactivation	NN
cord-005478-5iu38pr6	2645	12	of	of	IN
cord-005478-5iu38pr6	2645	13	CMV	CMV	NNP
cord-005478-5iu38pr6	2645	14	stratification	stratification	NN
cord-005478-5iu38pr6	2645	15	covariate	covariate	NN
cord-005478-5iu38pr6	2645	16	was	be	VBD
cord-005478-5iu38pr6	2645	17	replaced	replace	VBN
cord-005478-5iu38pr6	2645	18	with	with	IN
cord-005478-5iu38pr6	2645	19	an	an	DT
cord-005478-5iu38pr6	2645	20	updated	update	VBN
cord-005478-5iu38pr6	2645	21	covariate	covariate	NN
cord-005478-5iu38pr6	2645	22	that	that	WDT
cord-005478-5iu38pr6	2645	23	only	only	RB
cord-005478-5iu38pr6	2645	24	included	include	VBD
cord-005478-5iu38pr6	2645	25	patients	patient	NNS
cord-005478-5iu38pr6	2645	26	who	who	WP
cord-005478-5iu38pr6	2645	27	underwent	undergo	VBD
cord-005478-5iu38pr6	2645	28	HCT	hct	NN
cord-005478-5iu38pr6	2645	29	with	with	IN
cord-005478-5iu38pr6	2645	30	a	a	DT
cord-005478-5iu38pr6	2645	31	mismatched	mismatched	JJ
cord-005478-5iu38pr6	2645	32	donor	donor	NN
cord-005478-5iu38pr6	2645	33	,	,	,
cord-005478-5iu38pr6	2645	34	cord	cord	NN
cord-005478-5iu38pr6	2645	35	blood	blood	NN
cord-005478-5iu38pr6	2645	36	,	,	,
cord-005478-5iu38pr6	2645	37	ex	ex	NN
cord-005478-5iu38pr6	2645	38	-	-	JJ
cord-005478-5iu38pr6	2645	39	vivo	vivo	JJ
cord-005478-5iu38pr6	2645	40	T	t	NN
cord-005478-5iu38pr6	2645	41	-	-	HYPH
cord-005478-5iu38pr6	2645	42	cell	cell	NN
cord-005478-5iu38pr6	2645	43	depletion	depletion	NN
cord-005478-5iu38pr6	2645	44	,	,	,
cord-005478-5iu38pr6	2645	45	or	or	CC
cord-005478-5iu38pr6	2645	46	received	receive	VBD
cord-005478-5iu38pr6	2645	47	alemtuzumab	alemtuzumab	NNS
cord-005478-5iu38pr6	2645	48	.	.	.
cord-005478-5iu38pr6	2646	1	The	the	DT
cord-005478-5iu38pr6	2646	2	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2646	3	HCT	hct	NN
cord-005478-5iu38pr6	2646	4	and	and	CC
cord-005478-5iu38pr6	2646	5	matched	match	VBD
cord-005478-5iu38pr6	2646	6	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2646	7	donor	donor	NN
cord-005478-5iu38pr6	2646	8	type	type	NN
cord-005478-5iu38pr6	2646	9	were	be	VBD
cord-005478-5iu38pr6	2646	10	considered	consider	VBN
cord-005478-5iu38pr6	2646	11	separately	separately	RB
cord-005478-5iu38pr6	2646	12	from	from	IN
cord-005478-5iu38pr6	2646	13	the	the	DT
cord-005478-5iu38pr6	2646	14	trial	trial	JJ
cord-005478-5iu38pr6	2646	15	high	high	JJ
cord-005478-5iu38pr6	2646	16	-	-	HYPH
cord-005478-5iu38pr6	2646	17	risk	risk	NN
cord-005478-5iu38pr6	2646	18	CMV	CMV	NNP
cord-005478-5iu38pr6	2646	19	categories	category	NNS
cord-005478-5iu38pr6	2646	20	.	.	.
cord-005478-5iu38pr6	2647	1	Graft	graft	NN
cord-005478-5iu38pr6	2647	2	-	-	HYPH
cord-005478-5iu38pr6	2647	3	versus	versus	IN
cord-005478-5iu38pr6	2647	4	-	-	HYPH
cord-005478-5iu38pr6	2647	5	host	host	NN
cord-005478-5iu38pr6	2647	6	disease	disease	NN
cord-005478-5iu38pr6	2647	7	(	(	-LRB-
cord-005478-5iu38pr6	2647	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2647	9	)	)	-RRB-
cord-005478-5iu38pr6	2647	10	and	and	CC
cord-005478-5iu38pr6	2647	11	systemic	systemic	JJ
cord-005478-5iu38pr6	2647	12	glucocorticoid	glucocorticoid	NN
cord-005478-5iu38pr6	2647	13	exposure	exposure	NN
cord-005478-5iu38pr6	2647	14	were	be	VBD
cord-005478-5iu38pr6	2647	15	modeled	model	VBN
cord-005478-5iu38pr6	2647	16	as	as	IN
cord-005478-5iu38pr6	2647	17	time	time	NN
cord-005478-5iu38pr6	2647	18	-	-	HYPH
cord-005478-5iu38pr6	2647	19	dependent	dependent	JJ
cord-005478-5iu38pr6	2647	20	covariates	covariate	NNS
cord-005478-5iu38pr6	2647	21	.	.	.
cord-005478-5iu38pr6	2648	1	Race	race	NN
cord-005478-5iu38pr6	2648	2	was	be	VBD
cord-005478-5iu38pr6	2648	3	dichotomized	dichotomize	VBN
cord-005478-5iu38pr6	2648	4	into	into	IN
cord-005478-5iu38pr6	2648	5	Asian	asian	JJ
cord-005478-5iu38pr6	2648	6	and	and	CC
cord-005478-5iu38pr6	2648	7	non	non	JJ
cord-005478-5iu38pr6	2648	8	-	-	JJ
cord-005478-5iu38pr6	2648	9	Asian	asian	JJ
cord-005478-5iu38pr6	2648	10	.	.	.
cord-005478-5iu38pr6	2649	1	The	the	DT
cord-005478-5iu38pr6	2649	2	effect	effect	NN
cord-005478-5iu38pr6	2649	3	of	of	IN
cord-005478-5iu38pr6	2649	4	study	study	NN
cord-005478-5iu38pr6	2649	5	treatment	treatment	NN
cord-005478-5iu38pr6	2649	6	was	be	VBD
cord-005478-5iu38pr6	2649	7	not	not	RB
cord-005478-5iu38pr6	2649	8	included	include	VBN
cord-005478-5iu38pr6	2649	9	in	in	IN
cord-005478-5iu38pr6	2649	10	the	the	DT
cord-005478-5iu38pr6	2649	11	model	model	NN
cord-005478-5iu38pr6	2649	12	due	due	JJ
cord-005478-5iu38pr6	2649	13	to	to	IN
cord-005478-5iu38pr6	2649	14	nonproportional	nonproportional	JJ
cord-005478-5iu38pr6	2649	15	hazards	hazard	NNS
cord-005478-5iu38pr6	2649	16	.	.	.
cord-005478-5iu38pr6	2650	1	Instead	instead	RB
cord-005478-5iu38pr6	2650	2	,	,	,
cord-005478-5iu38pr6	2650	3	letermovir	letermovir	NNP
cord-005478-5iu38pr6	2650	4	treatment	treatment	NN
cord-005478-5iu38pr6	2650	5	was	be	VBD
cord-005478-5iu38pr6	2650	6	used	use	VBN
cord-005478-5iu38pr6	2650	7	as	as	IN
cord-005478-5iu38pr6	2650	8	a	a	DT
cord-005478-5iu38pr6	2650	9	stratification	stratification	NN
cord-005478-5iu38pr6	2650	10	variable	variable	NN
cord-005478-5iu38pr6	2650	11	.	.	.
cord-005478-5iu38pr6	2651	1	Hazard	hazard	NN
cord-005478-5iu38pr6	2651	2	ratios	ratio	NNS
cord-005478-5iu38pr6	2651	3	and	and	CC
cord-005478-5iu38pr6	2651	4	95	95	CD
cord-005478-5iu38pr6	2651	5	%	%	NN
cord-005478-5iu38pr6	2651	6	confidence	confidence	NN
cord-005478-5iu38pr6	2651	7	intervals	interval	NNS
cord-005478-5iu38pr6	2651	8	(	(	-LRB-
cord-005478-5iu38pr6	2651	9	CI	CI	NNP
cord-005478-5iu38pr6	2651	10	)	)	-RRB-
cord-005478-5iu38pr6	2651	11	were	be	VBD
cord-005478-5iu38pr6	2651	12	calculated	calculate	VBN
cord-005478-5iu38pr6	2651	13	.	.	.
cord-005478-5iu38pr6	2652	1	Results	result	NNS
cord-005478-5iu38pr6	2652	2	:	:	:
cord-005478-5iu38pr6	2653	1	There	there	EX
cord-005478-5iu38pr6	2653	2	were	be	VBD
cord-005478-5iu38pr6	2653	3	128	128	CD
cord-005478-5iu38pr6	2653	4	cs	cs	NNP
cord-005478-5iu38pr6	2653	5	-	-	HYPH
cord-005478-5iu38pr6	2653	6	CMVi	CMVi	NNP
cord-005478-5iu38pr6	2653	7	events	event	NNS
cord-005478-5iu38pr6	2653	8	(	(	-LRB-
cord-005478-5iu38pr6	2653	9	25.9	25.9	CD
cord-005478-5iu38pr6	2653	10	%	%	NN
cord-005478-5iu38pr6	2653	11	)	)	-RRB-
cord-005478-5iu38pr6	2653	12	among	among	IN
cord-005478-5iu38pr6	2653	13	495	495	CD
cord-005478-5iu38pr6	2653	14	patients	patient	NNS
cord-005478-5iu38pr6	2653	15	by	by	IN
cord-005478-5iu38pr6	2653	16	Week	week	NN
cord-005478-5iu38pr6	2653	17	24	24	CD
cord-005478-5iu38pr6	2653	18	post	post	NN
cord-005478-5iu38pr6	2653	19	-	-	JJ
cord-005478-5iu38pr6	2653	20	HCT	hct	NN
cord-005478-5iu38pr6	2653	21	for	for	IN
cord-005478-5iu38pr6	2653	22	an	an	DT
cord-005478-5iu38pr6	2653	23	incidence	incidence	NN
cord-005478-5iu38pr6	2653	24	rate	rate	NN
cord-005478-5iu38pr6	2653	25	of	of	IN
cord-005478-5iu38pr6	2653	26	0.19/100	0.19/100	CD
cord-005478-5iu38pr6	2653	27	patient	patient	NN
cord-005478-5iu38pr6	2653	28	-	-	HYPH
cord-005478-5iu38pr6	2653	29	days	day	NNS
cord-005478-5iu38pr6	2653	30	(	(	-LRB-
cord-005478-5iu38pr6	2653	31	95	95	CD
cord-005478-5iu38pr6	2653	32	%	%	NN
cord-005478-5iu38pr6	2653	33	CI	ci	NN
cord-005478-5iu38pr6	2653	34	,	,	,
cord-005478-5iu38pr6	2653	35	0	0	CD
cord-005478-5iu38pr6	2653	36	.	.	.
cord-005478-5iu38pr6	2654	1	16	16	CD
cord-005478-5iu38pr6	2654	2	-	-	SYM
cord-005478-5iu38pr6	2654	3	0.22	0.22	CD
cord-005478-5iu38pr6	2654	4	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2654	5	:	:	:
cord-005478-5iu38pr6	2655	1	Donor	donor	NN
cord-005478-5iu38pr6	2655	2	CMV	CMV	NNP
cord-005478-5iu38pr6	2655	3	seronegativity	seronegativity	NN
cord-005478-5iu38pr6	2655	4	,	,	,
cord-005478-5iu38pr6	2655	5	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2655	6	HCT	hct	NN
cord-005478-5iu38pr6	2655	7	,	,	,
cord-005478-5iu38pr6	2655	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2655	9	,	,	,
cord-005478-5iu38pr6	2655	10	glucocorticoid	glucocorticoid	NN
cord-005478-5iu38pr6	2655	11	use	use	NN
cord-005478-5iu38pr6	2655	12	,	,	,
cord-005478-5iu38pr6	2655	13	ATG	ATG	NNP
cord-005478-5iu38pr6	2655	14	use	use	NN
cord-005478-5iu38pr6	2655	15	,	,	,
cord-005478-5iu38pr6	2655	16	and	and	CC
cord-005478-5iu38pr6	2655	17	Asian	asian	JJ
cord-005478-5iu38pr6	2655	18	race	race	NN
cord-005478-5iu38pr6	2655	19	conferred	confer	VBD
cord-005478-5iu38pr6	2655	20	significant	significant	JJ
cord-005478-5iu38pr6	2655	21	risk	risk	NN
cord-005478-5iu38pr6	2655	22	of	of	IN
cord-005478-5iu38pr6	2655	23	cs	cs	NNP
cord-005478-5iu38pr6	2655	24	-	-	HYPH
cord-005478-5iu38pr6	2655	25	CMVi	CMVi	NNPS
cord-005478-5iu38pr6	2655	26	through	through	IN
cord-005478-5iu38pr6	2655	27	Week	week	NN
cord-005478-5iu38pr6	2655	28	24	24	CD
cord-005478-5iu38pr6	2655	29	post	post	NN
cord-005478-5iu38pr6	2655	30	-	-	JJ
cord-005478-5iu38pr6	2655	31	HCT	hct	NN
cord-005478-5iu38pr6	2655	32	in	in	IN
cord-005478-5iu38pr6	2655	33	a	a	DT
cord-005478-5iu38pr6	2655	34	phase	phase	NN
cord-005478-5iu38pr6	2655	35	3	3	CD
cord-005478-5iu38pr6	2655	36	study	study	NN
cord-005478-5iu38pr6	2655	37	of	of	IN
cord-005478-5iu38pr6	2655	38	letermovir	letermovir	NNP
cord-005478-5iu38pr6	2655	39	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2655	40	.	.	.
cord-005478-5iu38pr6	2656	1	These	these	DT
cord-005478-5iu38pr6	2656	2	results	result	NNS
cord-005478-5iu38pr6	2656	3	identify	identify	VBP
cord-005478-5iu38pr6	2656	4	HCT	hct	NN
cord-005478-5iu38pr6	2656	5	patient	patient	JJ
cord-005478-5iu38pr6	2656	6	groups	group	NNS
cord-005478-5iu38pr6	2656	7	that	that	WDT
cord-005478-5iu38pr6	2656	8	would	would	MD
cord-005478-5iu38pr6	2656	9	benefit	benefit	VB
cord-005478-5iu38pr6	2656	10	the	the	DT
cord-005478-5iu38pr6	2656	11	most	most	JJS
cord-005478-5iu38pr6	2656	12	from	from	IN
cord-005478-5iu38pr6	2656	13	letermovir	letermovir	NNP
cord-005478-5iu38pr6	2656	14	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2656	15	.	.	.
cord-005478-5iu38pr6	2657	1	Methods	method	NNS
cord-005478-5iu38pr6	2657	2	:	:	:
cord-005478-5iu38pr6	2657	3	769	769	CD
cord-005478-5iu38pr6	2657	4	adult	adult	NN
cord-005478-5iu38pr6	2657	5	patients	patient	NNS
cord-005478-5iu38pr6	2657	6	(	(	-LRB-
cord-005478-5iu38pr6	2657	7	age	age	NN
cord-005478-5iu38pr6	2657	8	18	18	CD
cord-005478-5iu38pr6	2657	9	-	-	SYM
cord-005478-5iu38pr6	2657	10	60	60	CD
cord-005478-5iu38pr6	2657	11	)	)	-RRB-
cord-005478-5iu38pr6	2657	12	with	with	IN
cord-005478-5iu38pr6	2657	13	de	de	NNP
cord-005478-5iu38pr6	2657	14	novo	novo	NNP
cord-005478-5iu38pr6	2657	15	AML	AML	NNP
cord-005478-5iu38pr6	2657	16	in	in	IN
cord-005478-5iu38pr6	2657	17	complete	complete	JJ
cord-005478-5iu38pr6	2657	18	remission	remission	NN
cord-005478-5iu38pr6	2657	19	(	(	-LRB-
cord-005478-5iu38pr6	2657	20	CR	cr	NN
cord-005478-5iu38pr6	2657	21	)	)	-RRB-
cord-005478-5iu38pr6	2657	22	perusing	peruse	VBG
cord-005478-5iu38pr6	2657	23	T	t	NN
cord-005478-5iu38pr6	2657	24	-	-	HYPH
cord-005478-5iu38pr6	2657	25	cell	cell	NN
cord-005478-5iu38pr6	2657	26	replete	replete	JJ
cord-005478-5iu38pr6	2657	27	haplo	haplo	NN
cord-005478-5iu38pr6	2657	28	-	-	HYPH
cord-005478-5iu38pr6	2657	29	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2657	30	with	with	IN
cord-005478-5iu38pr6	2657	31	ATG+G	ATG+G	NNP
cord-005478-5iu38pr6	2657	32	-	-	HYPH
cord-005478-5iu38pr6	2657	33	CSF	csf	NN
cord-005478-5iu38pr6	2657	34	protocol	protocol	NN
cord-005478-5iu38pr6	2657	35	were	be	VBD
cord-005478-5iu38pr6	2657	36	consecutively	consecutively	RB
cord-005478-5iu38pr6	2657	37	enrolled	enrol	VBN
cord-005478-5iu38pr6	2657	38	at	at	IN
cord-005478-5iu38pr6	2657	39	Peking	Peking	NNP
cord-005478-5iu38pr6	2657	40	University	University	NNP
cord-005478-5iu38pr6	2657	41	People	People	NNPS
cord-005478-5iu38pr6	2657	42	's	's	POS
cord-005478-5iu38pr6	2657	43	Hospital	Hospital	NNP
cord-005478-5iu38pr6	2657	44	between	between	IN
cord-005478-5iu38pr6	2657	45	2010	2010	CD
cord-005478-5iu38pr6	2657	46	and	and	CC
cord-005478-5iu38pr6	2657	47	2016	2016	CD
cord-005478-5iu38pr6	2657	48	.	.	.
cord-005478-5iu38pr6	2658	1	All	all	DT
cord-005478-5iu38pr6	2658	2	patients	patient	NNS
cord-005478-5iu38pr6	2658	3	were	be	VBD
cord-005478-5iu38pr6	2658	4	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2658	5	for	for	IN
cord-005478-5iu38pr6	2658	6	donor	donor	NN
cord-005478-5iu38pr6	2658	7	-	-	HYPH
cord-005478-5iu38pr6	2658	8	patient	patient	NN
cord-005478-5iu38pr6	2658	9	CMV	CMV	NNP
cord-005478-5iu38pr6	2658	10	serostatus	serostatus	NN
cord-005478-5iu38pr6	2658	11	before	before	IN
cord-005478-5iu38pr6	2658	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2658	13	.	.	.
cord-005478-5iu38pr6	2659	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2659	2	DNA	DNA	NNP
cord-005478-5iu38pr6	2659	3	emia	emia	NN
cord-005478-5iu38pr6	2659	4	were	be	VBD
cord-005478-5iu38pr6	2659	5	positive	positive	JJ
cord-005478-5iu38pr6	2659	6	for	for	IN
cord-005478-5iu38pr6	2659	7	>	>	XX
cord-005478-5iu38pr6	2660	1	1000	1000	CD
cord-005478-5iu38pr6	2660	2	copies	copy	NNS
cord-005478-5iu38pr6	2660	3	/	/	SYM
cord-005478-5iu38pr6	2660	4	mL	ml	NN
cord-005478-5iu38pr6	2660	5	CMV	CMV	NNP
cord-005478-5iu38pr6	2660	6	by	by	IN
cord-005478-5iu38pr6	2660	7	PCR	PCR	NNP
cord-005478-5iu38pr6	2660	8	tests	test	NNS
cord-005478-5iu38pr6	2660	9	on	on	IN
cord-005478-5iu38pr6	2660	10	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2660	11	blood	blood	NN
cord-005478-5iu38pr6	2660	12	(	(	-LRB-
cord-005478-5iu38pr6	2660	13	PB	PB	NNP
cord-005478-5iu38pr6	2660	14	)	)	-RRB-
cord-005478-5iu38pr6	2660	15	.	.	.
cord-005478-5iu38pr6	2661	1	Refractory	refractory	JJ
cord-005478-5iu38pr6	2661	2	CMV	CMV	NNP
cord-005478-5iu38pr6	2661	3	infection	infection	NN
cord-005478-5iu38pr6	2661	4	was	be	VBD
cord-005478-5iu38pr6	2661	5	defined	define	VBN
cord-005478-5iu38pr6	2661	6	as	as	IN
cord-005478-5iu38pr6	2661	7	CMV	CMV	NNP
cord-005478-5iu38pr6	2661	8	DNAemia	dnaemia	NN
cord-005478-5iu38pr6	2661	9	lasting	last	VBG
cord-005478-5iu38pr6	2661	10	for	for	IN
cord-005478-5iu38pr6	2661	11	>	>	$
cord-005478-5iu38pr6	2661	12	2	2	CD
cord-005478-5iu38pr6	2661	13	weeks	week	NNS
cord-005478-5iu38pr6	2661	14	in	in	IN
cord-005478-5iu38pr6	2661	15	spite	spite	NN
cord-005478-5iu38pr6	2661	16	of	of	IN
cord-005478-5iu38pr6	2661	17	treatment	treatment	NN
cord-005478-5iu38pr6	2661	18	.	.	.
cord-005478-5iu38pr6	2662	1	PB	PB	NNP
cord-005478-5iu38pr6	2662	2	samples	sample	NNS
cord-005478-5iu38pr6	2662	3	of	of	IN
cord-005478-5iu38pr6	2662	4	8	8	CD
cord-005478-5iu38pr6	2662	5	patients	patient	NNS
cord-005478-5iu38pr6	2662	6	with	with	IN
cord-005478-5iu38pr6	2662	7	refractory	refractory	JJ
cord-005478-5iu38pr6	2662	8	CMV	CMV	NNP
cord-005478-5iu38pr6	2662	9	infection	infection	NN
cord-005478-5iu38pr6	2662	10	(	(	-LRB-
cord-005478-5iu38pr6	2662	11	4	4	CD
cord-005478-5iu38pr6	2662	12	relapse	relapse	NN
cord-005478-5iu38pr6	2662	13	and	and	CC
cord-005478-5iu38pr6	2662	14	4	4	CD
cord-005478-5iu38pr6	2662	15	without	without	IN
cord-005478-5iu38pr6	2662	16	AML	AML	NNP
cord-005478-5iu38pr6	2662	17	relapse	relapse	NN
cord-005478-5iu38pr6	2662	18	)	)	-RRB-
cord-005478-5iu38pr6	2662	19	were	be	VBD
cord-005478-5iu38pr6	2662	20	sequencing	sequence	VBG
cord-005478-5iu38pr6	2662	21	for	for	IN
cord-005478-5iu38pr6	2662	22	CMV	CMV	NNP
cord-005478-5iu38pr6	2662	23	derived	derive	VBD
cord-005478-5iu38pr6	2662	24	small	small	JJ
cord-005478-5iu38pr6	2662	25	RNA	RNA	NNP
cord-005478-5iu38pr6	2662	26	.	.	.
cord-005478-5iu38pr6	2663	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2663	2	-	-	HYPH
cord-005478-5iu38pr6	2663	3	miR	miR	NNP
cord-005478-5iu38pr6	2663	4	-	-	HYPH
cord-005478-5iu38pr6	2663	5	US4	US4	NNP
cord-005478-5iu38pr6	2663	6	-	-	HYPH
cord-005478-5iu38pr6	2663	7	1	1	CD
cord-005478-5iu38pr6	2663	8	/	/	SYM
cord-005478-5iu38pr6	2663	9	UL-148D	UL-148D	NNP
cord-005478-5iu38pr6	2663	10	were	be	VBD
cord-005478-5iu38pr6	2663	11	then	then	RB
cord-005478-5iu38pr6	2663	12	chosen	choose	VBN
cord-005478-5iu38pr6	2663	13	as	as	IN
cord-005478-5iu38pr6	2663	14	target	target	NN
cord-005478-5iu38pr6	2663	15	miRNAs	miRNAs	NNP
cord-005478-5iu38pr6	2663	16	and	and	CC
cord-005478-5iu38pr6	2663	17	tested	test	VBN
cord-005478-5iu38pr6	2663	18	by	by	IN
cord-005478-5iu38pr6	2663	19	stem	stem	NN
cord-005478-5iu38pr6	2663	20	-	-	HYPH
cord-005478-5iu38pr6	2663	21	loop	loop	NN
cord-005478-5iu38pr6	2663	22	Taqman	Taqman	NNP
cord-005478-5iu38pr6	2663	23	qPCR	qpcr	NN
cord-005478-5iu38pr6	2663	24	in	in	IN
cord-005478-5iu38pr6	2663	25	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2663	26	patients	patient	NNS
cord-005478-5iu38pr6	2663	27	(	(	-LRB-
cord-005478-5iu38pr6	2663	28	n=157	n=157	NNP
cord-005478-5iu38pr6	2663	29	)	)	-RRB-
cord-005478-5iu38pr6	2663	30	.	.	.
cord-005478-5iu38pr6	2664	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	2664	2	incidence	incidence	NN
cord-005478-5iu38pr6	2664	3	of	of	IN
cord-005478-5iu38pr6	2664	4	relapse	relapse	NN
cord-005478-5iu38pr6	2664	5	(	(	-LRB-
cord-005478-5iu38pr6	2664	6	CIR	CIR	NNP
cord-005478-5iu38pr6	2664	7	)	)	-RRB-
cord-005478-5iu38pr6	2664	8	and	and	CC
cord-005478-5iu38pr6	2664	9	treatment	treatment	NN
cord-005478-5iu38pr6	2664	10	related	relate	VBN
cord-005478-5iu38pr6	2664	11	mortality	mortality	NN
cord-005478-5iu38pr6	2664	12	(	(	-LRB-
cord-005478-5iu38pr6	2664	13	TRM	TRM	NNP
cord-005478-5iu38pr6	2664	14	)	)	-RRB-
cord-005478-5iu38pr6	2664	15	were	be	VBD
cord-005478-5iu38pr6	2664	16	calculated	calculate	VBN
cord-005478-5iu38pr6	2664	17	using	use	VBG
cord-005478-5iu38pr6	2664	18	competing	compete	VBG
cord-005478-5iu38pr6	2664	19	risks	risk	NNS
cord-005478-5iu38pr6	2664	20	,	,	,
cord-005478-5iu38pr6	2664	21	Cox	Cox	NNP
cord-005478-5iu38pr6	2664	22	model	model	NN
cord-005478-5iu38pr6	2664	23	was	be	VBD
cord-005478-5iu38pr6	2664	24	tested	test	VBN
cord-005478-5iu38pr6	2664	25	with	with	IN
cord-005478-5iu38pr6	2664	26	patient	patient	JJ
cord-005478-5iu38pr6	2664	27	age	age	NN
cord-005478-5iu38pr6	2664	28	,	,	,
cord-005478-5iu38pr6	2664	29	sex	sex	NN
cord-005478-5iu38pr6	2664	30	,	,	,
cord-005478-5iu38pr6	2664	31	WBC	WBC	NNP
cord-005478-5iu38pr6	2664	32	count	count	NN
cord-005478-5iu38pr6	2664	33	at	at	IN
cord-005478-5iu38pr6	2664	34	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2664	35	,	,	,
cord-005478-5iu38pr6	2664	36	CR	cr	NN
cord-005478-5iu38pr6	2664	37	status	status	NN
cord-005478-5iu38pr6	2664	38	,	,	,
cord-005478-5iu38pr6	2664	39	courses	course	NNS
cord-005478-5iu38pr6	2664	40	to	to	IN
cord-005478-5iu38pr6	2664	41	achieving	achieve	VBG
cord-005478-5iu38pr6	2664	42	CR	cr	NN
cord-005478-5iu38pr6	2664	43	,	,	,
cord-005478-5iu38pr6	2664	44	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	2664	45	risk	risk	NN
cord-005478-5iu38pr6	2664	46	group	group	NN
cord-005478-5iu38pr6	2664	47	,	,	,
cord-005478-5iu38pr6	2664	48	minimal	minimal	JJ
cord-005478-5iu38pr6	2664	49	residual	residual	JJ
cord-005478-5iu38pr6	2664	50	diseases	disease	NNS
cord-005478-5iu38pr6	2664	51	before	before	IN
cord-005478-5iu38pr6	2664	52	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2664	53	,	,	,
cord-005478-5iu38pr6	2664	54	CMV	CMV	NNP
cord-005478-5iu38pr6	2664	55	infection	infection	NN
cord-005478-5iu38pr6	2664	56	,	,	,
cord-005478-5iu38pr6	2664	57	CMV	CMV	NNP
cord-005478-5iu38pr6	2664	58	-	-	HYPH
cord-005478-5iu38pr6	2664	59	miR	miR	NNP
cord-005478-5iu38pr6	2664	60	-	-	HYPH
cord-005478-5iu38pr6	2664	61	US4	US4	NNP
cord-005478-5iu38pr6	2664	62	-	-	HYPH
cord-005478-5iu38pr6	2664	63	1/	1/	CD
cord-005478-5iu38pr6	2664	64	UL-148D	ul-148d	JJ
cord-005478-5iu38pr6	2664	65	expression	expression	NN
cord-005478-5iu38pr6	2664	66	.	.	.
cord-005478-5iu38pr6	2665	1	US4	US4	NNP
cord-005478-5iu38pr6	2665	2	-	-	HYPH
cord-005478-5iu38pr6	2665	3	1	1	CD
cord-005478-5iu38pr6	2666	1	/UL-148D	/UL-148D	:
cord-005478-5iu38pr6	2666	2	were	be	VBD
cord-005478-5iu38pr6	2666	3	further	further	RB
cord-005478-5iu38pr6	2666	4	explored	explore	VBN
cord-005478-5iu38pr6	2666	5	for	for	IN
cord-005478-5iu38pr6	2666	6	the	the	DT
cord-005478-5iu38pr6	2666	7	association	association	NN
cord-005478-5iu38pr6	2666	8	with	with	IN
cord-005478-5iu38pr6	2666	9	T	T	NNP
cord-005478-5iu38pr6	2666	10	cells	cell	NNS
cord-005478-5iu38pr6	2666	11	and	and	CC
cord-005478-5iu38pr6	2666	12	natural	natural	JJ
cord-005478-5iu38pr6	2666	13	killer	killer	NN
cord-005478-5iu38pr6	2666	14	(	(	-LRB-
cord-005478-5iu38pr6	2666	15	NK	NK	NNP
cord-005478-5iu38pr6	2666	16	)	)	-RRB-
cord-005478-5iu38pr6	2666	17	cells	cell	NNS
cord-005478-5iu38pr6	2666	18	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2666	19	and	and	CC
cord-005478-5iu38pr6	2666	20	target	target	NN
cord-005478-5iu38pr6	2666	21	mRNA	mRNA	NNP
cord-005478-5iu38pr6	2666	22	validation	validation	NN
cord-005478-5iu38pr6	2666	23	.	.	.
cord-005478-5iu38pr6	2667	1	Results	result	NNS
cord-005478-5iu38pr6	2667	2	:	:	:
cord-005478-5iu38pr6	2668	1	In	in	IN
cord-005478-5iu38pr6	2668	2	the	the	DT
cord-005478-5iu38pr6	2668	3	total	total	JJ
cord-005478-5iu38pr6	2668	4	cohort	cohort	NN
cord-005478-5iu38pr6	2668	5	of	of	IN
cord-005478-5iu38pr6	2668	6	769	769	CD
cord-005478-5iu38pr6	2668	7	patients	patient	NNS
cord-005478-5iu38pr6	2668	8	,	,	,
cord-005478-5iu38pr6	2668	9	the	the	DT
cord-005478-5iu38pr6	2668	10	3-year	3-year	JJ
cord-005478-5iu38pr6	2668	11	overall	overall	JJ
cord-005478-5iu38pr6	2668	12	survival	survival	NN
cord-005478-5iu38pr6	2668	13	(	(	-LRB-
cord-005478-5iu38pr6	2668	14	OS	OS	NNP
cord-005478-5iu38pr6	2668	15	)	)	-RRB-
cord-005478-5iu38pr6	2668	16	and	and	CC
cord-005478-5iu38pr6	2668	17	Leukemia	leukemia	NN
cord-005478-5iu38pr6	2668	18	-	-	HYPH
cord-005478-5iu38pr6	2668	19	free	free	JJ
cord-005478-5iu38pr6	2668	20	survival	survival	NN
cord-005478-5iu38pr6	2668	21	(	(	-LRB-
cord-005478-5iu38pr6	2668	22	LFS	LFS	NNP
cord-005478-5iu38pr6	2668	23	)	)	-RRB-
cord-005478-5iu38pr6	2668	24	were	be	VBD
cord-005478-5iu38pr6	2668	25	75.3	75.3	CD
cord-005478-5iu38pr6	2668	26	%	%	NN
cord-005478-5iu38pr6	2668	27	and	and	CC
cord-005478-5iu38pr6	2668	28	78.4	78.4	CD
cord-005478-5iu38pr6	2668	29	%	%	NN
cord-005478-5iu38pr6	2668	30	,	,	,
cord-005478-5iu38pr6	2668	31	CIR	CIR	NNP
cord-005478-5iu38pr6	2668	32	and	and	CC
cord-005478-5iu38pr6	2668	33	TRM	TRM	NNP
cord-005478-5iu38pr6	2668	34	were	be	VBD
cord-005478-5iu38pr6	2668	35	15.9	15.9	CD
cord-005478-5iu38pr6	2668	36	%	%	NN
cord-005478-5iu38pr6	2668	37	and	and	CC
cord-005478-5iu38pr6	2668	38	8.8	8.8	CD
cord-005478-5iu38pr6	2668	39	%	%	NN
cord-005478-5iu38pr6	2668	40	.	.	.
cord-005478-5iu38pr6	2669	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2669	2	infection	infection	NN
cord-005478-5iu38pr6	2669	3	occurred	occur	VBD
cord-005478-5iu38pr6	2669	4	in	in	IN
cord-005478-5iu38pr6	2669	5	71.5	71.5	CD
cord-005478-5iu38pr6	2669	6	%	%	NN
cord-005478-5iu38pr6	2669	7	recipients	recipient	NNS
cord-005478-5iu38pr6	2669	8	at	at	IN
cord-005478-5iu38pr6	2669	9	a	a	DT
cord-005478-5iu38pr6	2669	10	median	median	JJ
cord-005478-5iu38pr6	2669	11	time	time	NN
cord-005478-5iu38pr6	2669	12	of	of	IN
cord-005478-5iu38pr6	2669	13	4	4	CD
cord-005478-5iu38pr6	2669	14	weeks	week	NNS
cord-005478-5iu38pr6	2669	15	after	after	IN
cord-005478-5iu38pr6	2669	16	haplo	haplo	NN
cord-005478-5iu38pr6	2669	17	-	-	HYPH
cord-005478-5iu38pr6	2669	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2669	19	,	,	,
cord-005478-5iu38pr6	2669	20	and	and	CC
cord-005478-5iu38pr6	2669	21	the	the	DT
cord-005478-5iu38pr6	2669	22	duration	duration	NN
cord-005478-5iu38pr6	2669	23	was	be	VBD
cord-005478-5iu38pr6	2669	24	2	2	CD
cord-005478-5iu38pr6	2669	25	weeks	week	NNS
cord-005478-5iu38pr6	2669	26	.	.	.
cord-005478-5iu38pr6	2670	1	49.7	49.7	CD
cord-005478-5iu38pr6	2670	2	%	%	NN
cord-005478-5iu38pr6	2670	3	recipients	recipient	NNS
cord-005478-5iu38pr6	2670	4	experienced	experience	VBD
cord-005478-5iu38pr6	2670	5	refractory	refractory	JJ
cord-005478-5iu38pr6	2670	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2670	7	infection	infection	NN
cord-005478-5iu38pr6	2670	8	.	.	.
cord-005478-5iu38pr6	2671	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2671	2	infection	infection	NN
cord-005478-5iu38pr6	2671	3	(	(	-LRB-
cord-005478-5iu38pr6	2671	4	yes	yes	UH
cord-005478-5iu38pr6	2671	5	vs.	vs.	FW
cord-005478-5iu38pr6	2671	6	no	no	UH
cord-005478-5iu38pr6	2671	7	,	,	,
cord-005478-5iu38pr6	2671	8	refractory	refractory	JJ
cord-005478-5iu38pr6	2671	9	vs	vs	IN
cord-005478-5iu38pr6	2671	10	no	no	DT
cord-005478-5iu38pr6	2671	11	)	)	-RRB-
cord-005478-5iu38pr6	2671	12	did	do	VBD
cord-005478-5iu38pr6	2671	13	not	not	RB
cord-005478-5iu38pr6	2671	14	affect	affect	VB
cord-005478-5iu38pr6	2671	15	CIR	CIR	NNP
cord-005478-5iu38pr6	2671	16	in	in	IN
cord-005478-5iu38pr6	2671	17	univariate	univariate	JJ
cord-005478-5iu38pr6	2671	18	analysis	analysis	NN
cord-005478-5iu38pr6	2671	19	,	,	,
cord-005478-5iu38pr6	2671	20	while	while	IN
cord-005478-5iu38pr6	2671	21	in	in	IN
cord-005478-5iu38pr6	2671	22	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2671	23	analysis	analysis	NN
cord-005478-5iu38pr6	2671	24	,	,	,
cord-005478-5iu38pr6	2671	25	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	2671	26	risk	risk	NN
cord-005478-5iu38pr6	2671	27	group	group	NN
cord-005478-5iu38pr6	2671	28	was	be	VBD
cord-005478-5iu38pr6	2671	29	identified	identify	VBN
cord-005478-5iu38pr6	2671	30	as	as	IN
cord-005478-5iu38pr6	2671	31	the	the	DT
cord-005478-5iu38pr6	2671	32	only	only	JJ
cord-005478-5iu38pr6	2671	33	independent	independent	JJ
cord-005478-5iu38pr6	2671	34	prognostic	prognostic	JJ
cord-005478-5iu38pr6	2671	35	factor	factor	NN
cord-005478-5iu38pr6	2671	36	affecting	affect	VBG
cord-005478-5iu38pr6	2671	37	CIR	CIR	NNP
cord-005478-5iu38pr6	2671	38	(	(	-LRB-
cord-005478-5iu38pr6	2671	39	HR	HR	NNP
cord-005478-5iu38pr6	2671	40	1.72	1.72	CD
cord-005478-5iu38pr6	2671	41	,	,	,
cord-005478-5iu38pr6	2671	42	95	95	CD
cord-005478-5iu38pr6	2671	43	%	%	NN
cord-005478-5iu38pr6	2671	44	CI	CI	NNP
cord-005478-5iu38pr6	2671	45	,	,	,
cord-005478-5iu38pr6	2671	46	p=0.032	p=0.032	NNP
cord-005478-5iu38pr6	2671	47	)	)	-RRB-
cord-005478-5iu38pr6	2671	48	.	.	.
cord-005478-5iu38pr6	2672	1	In	in	IN
cord-005478-5iu38pr6	2672	2	the	the	DT
cord-005478-5iu38pr6	2672	3	cohort	cohort	NN
cord-005478-5iu38pr6	2672	4	testing	testing	NN
cord-005478-5iu38pr6	2672	5	for	for	IN
cord-005478-5iu38pr6	2672	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2672	7	microRNA	microRNA	NNP
cord-005478-5iu38pr6	2672	8	,	,	,
cord-005478-5iu38pr6	2672	9	35.0	35.0	CD
cord-005478-5iu38pr6	2672	10	%	%	NN
cord-005478-5iu38pr6	2672	11	patients	patient	NNS
cord-005478-5iu38pr6	2672	12	were	be	VBD
cord-005478-5iu38pr6	2672	13	identified	identify	VBN
cord-005478-5iu38pr6	2672	14	expression	expression	NN
cord-005478-5iu38pr6	2672	15	of	of	IN
cord-005478-5iu38pr6	2672	16	US4	US4	NNP
cord-005478-5iu38pr6	2672	17	-	-	HYPH
cord-005478-5iu38pr6	2672	18	1	1	CD
cord-005478-5iu38pr6	2672	19	,	,	,
cord-005478-5iu38pr6	2672	20	40.1	40.1	CD
cord-005478-5iu38pr6	2672	21	%	%	NN
cord-005478-5iu38pr6	2672	22	patients	patient	NNS
cord-005478-5iu38pr6	2672	23	for	for	IN
cord-005478-5iu38pr6	2672	24	UL-148D	UL-148D	NNP
cord-005478-5iu38pr6	2672	25	,	,	,
cord-005478-5iu38pr6	2672	26	while	while	IN
cord-005478-5iu38pr6	2672	27	29.3	29.3	CD
cord-005478-5iu38pr6	2672	28	%	%	NN
cord-005478-5iu38pr6	2672	29	patients	patient	NNS
cord-005478-5iu38pr6	2672	30	had	have	VBD
cord-005478-5iu38pr6	2672	31	co	co	NN
cord-005478-5iu38pr6	2672	32	-	-	NN
cord-005478-5iu38pr6	2672	33	expression	expression	NN
cord-005478-5iu38pr6	2672	34	.	.	.
cord-005478-5iu38pr6	2673	1	The	the	DT
cord-005478-5iu38pr6	2673	2	relapse	relapse	NN
cord-005478-5iu38pr6	2673	3	incidence	incidence	NN
cord-005478-5iu38pr6	2673	4	was	be	VBD
cord-005478-5iu38pr6	2673	5	significantly	significantly	RB
cord-005478-5iu38pr6	2673	6	lower	low	JJR
cord-005478-5iu38pr6	2673	7	in	in	IN
cord-005478-5iu38pr6	2673	8	patients	patient	NNS
cord-005478-5iu38pr6	2673	9	with	with	IN
cord-005478-5iu38pr6	2673	10	vs.	vs.	NN
cord-005478-5iu38pr6	2673	11	without	without	IN
cord-005478-5iu38pr6	2673	12	co	co	NN
cord-005478-5iu38pr6	2673	13	-	-	NN
cord-005478-5iu38pr6	2673	14	expression	expression	NN
cord-005478-5iu38pr6	2674	1	of	of	IN
cord-005478-5iu38pr6	2674	2	miR	miR	NNP
cord-005478-5iu38pr6	2674	3	-	-	HYPH
cord-005478-5iu38pr6	2674	4	US4	US4	NNP
cord-005478-5iu38pr6	2674	5	-	-	HYPH
cord-005478-5iu38pr6	2674	6	1	1	CD
cord-005478-5iu38pr6	2674	7	/	/	SYM
cord-005478-5iu38pr6	2674	8	UL-148D.	UL-148D.	NNP
cord-005478-5iu38pr6	2674	9	Co	co	NN
cord-005478-5iu38pr6	2674	10	-	-	NN
cord-005478-5iu38pr6	2674	11	expression	expression	NN
cord-005478-5iu38pr6	2674	12	of	of	IN
cord-005478-5iu38pr6	2674	13	miR	mir	JJ
cord-005478-5iu38pr6	2674	14	-	-	HYPH
cord-005478-5iu38pr6	2674	15	US4	US4	NNP
cord-005478-5iu38pr6	2674	16	-	-	HYPH
cord-005478-5iu38pr6	2674	17	1	1	CD
cord-005478-5iu38pr6	2674	18	/	/	SYM
cord-005478-5iu38pr6	2674	19	UL-148D	UL-148D	NNP
cord-005478-5iu38pr6	2674	20	was	be	VBD
cord-005478-5iu38pr6	2674	21	the	the	DT
cord-005478-5iu38pr6	2674	22	only	only	JJ
cord-005478-5iu38pr6	2674	23	independent	independent	JJ
cord-005478-5iu38pr6	2674	24	risk	risk	NN
cord-005478-5iu38pr6	2674	25	factor	factor	NN
cord-005478-5iu38pr6	2674	26	for	for	IN
cord-005478-5iu38pr6	2674	27	reducing	reduce	VBG
cord-005478-5iu38pr6	2674	28	CIR	CIR	NNP
cord-005478-5iu38pr6	2674	29	(	(	-LRB-
cord-005478-5iu38pr6	2674	30	HR	HR	NNP
cord-005478-5iu38pr6	2674	31	0.414	0.414	CD
cord-005478-5iu38pr6	2674	32	,	,	,
cord-005478-5iu38pr6	2674	33	95	95	CD
cord-005478-5iu38pr6	2674	34	%	%	NN
cord-005478-5iu38pr6	2674	35	CI	ci	NN
cord-005478-5iu38pr6	2674	36	,	,	,
cord-005478-5iu38pr6	2674	37	0.165	0.165	CD
cord-005478-5iu38pr6	2674	38	-	-	SYM
cord-005478-5iu38pr6	2674	39	1.036	1.036	CD
cord-005478-5iu38pr6	2674	40	;	;	:
cord-005478-5iu38pr6	2674	41	p=0.019	p=0.019	NNP
cord-005478-5iu38pr6	2674	42	)	)	-RRB-
cord-005478-5iu38pr6	2674	43	.	.	.
cord-005478-5iu38pr6	2675	1	US4	US4	NNP
cord-005478-5iu38pr6	2675	2	-	-	HYPH
cord-005478-5iu38pr6	2675	3	1	1	CD
cord-005478-5iu38pr6	2675	4	/	/	SYM
cord-005478-5iu38pr6	2675	5	UL-148D	UL-148D	NNP
cord-005478-5iu38pr6	2675	6	as	as	RB
cord-005478-5iu38pr6	2675	7	also	also	RB
cord-005478-5iu38pr6	2675	8	found	find	VBN
cord-005478-5iu38pr6	2675	9	to	to	TO
cord-005478-5iu38pr6	2675	10	promote	promote	VB
cord-005478-5iu38pr6	2675	11	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2675	12	of	of	IN
cord-005478-5iu38pr6	2675	13	NKG2C+	NKG2C+	NNP
cord-005478-5iu38pr6	2675	14	NKs	NKs	NNP
cord-005478-5iu38pr6	2675	15	.	.	.
cord-005478-5iu38pr6	2676	1	Luciferase	luciferase	NN
cord-005478-5iu38pr6	2676	2	assay	assay	NN
cord-005478-5iu38pr6	2676	3	identify	identify	VB
cord-005478-5iu38pr6	2676	4	PLZF	PLZF	NNS
cord-005478-5iu38pr6	2676	5	as	as	IN
cord-005478-5iu38pr6	2676	6	target	target	NN
cord-005478-5iu38pr6	2676	7	of	of	IN
cord-005478-5iu38pr6	2676	8	US4	US4	NNP
cord-005478-5iu38pr6	2676	9	-	-	HYPH
cord-005478-5iu38pr6	2676	10	1	1	CD
cord-005478-5iu38pr6	2676	11	while	while	IN
cord-005478-5iu38pr6	2676	12	KLRC1	klrc1	NN
cord-005478-5iu38pr6	2676	13	targeted	target	VBN
cord-005478-5iu38pr6	2676	14	by	by	IN
cord-005478-5iu38pr6	2676	15	miR	miR	NNP
cord-005478-5iu38pr6	2676	16	-	-	HYPH
cord-005478-5iu38pr6	2676	17	UL-148D	UL-148D	NNP
cord-005478-5iu38pr6	2676	18	,	,	,
cord-005478-5iu38pr6	2676	19	which	which	WDT
cord-005478-5iu38pr6	2676	20	suggest	suggest	VBP
cord-005478-5iu38pr6	2676	21	potential	potential	JJ
cord-005478-5iu38pr6	2676	22	role	role	NN
cord-005478-5iu38pr6	2676	23	of	of	IN
cord-005478-5iu38pr6	2676	24	shifting	shift	VBG
cord-005478-5iu38pr6	2676	25	NKG2C	NKG2C	NNP
cord-005478-5iu38pr6	2676	26	/	/	SYM
cord-005478-5iu38pr6	2676	27	NKG2A	nkg2a	CD
cord-005478-5iu38pr6	2676	28	balance	balance	NN
cord-005478-5iu38pr6	2676	29	to	to	IN
cord-005478-5iu38pr6	2676	30	NKG2C	nkg2c	JJ
cord-005478-5iu38pr6	2676	31	domination	domination	NN
cord-005478-5iu38pr6	2676	32	.	.	.
cord-005478-5iu38pr6	2677	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2677	2	:	:	:
cord-005478-5iu38pr6	2678	1	The	the	DT
cord-005478-5iu38pr6	2678	2	present	present	JJ
cord-005478-5iu38pr6	2678	3	study	study	NN
cord-005478-5iu38pr6	2678	4	is	be	VBZ
cord-005478-5iu38pr6	2678	5	the	the	DT
cord-005478-5iu38pr6	2678	6	first	first	JJ
cord-005478-5iu38pr6	2678	7	prospective	prospective	JJ
cord-005478-5iu38pr6	2678	8	trial	trial	NN
cord-005478-5iu38pr6	2678	9	to	to	TO
cord-005478-5iu38pr6	2678	10	evaluate	evaluate	VB
cord-005478-5iu38pr6	2678	11	CMV	CMV	NNP
cord-005478-5iu38pr6	2678	12	infection	infection	NN
cord-005478-5iu38pr6	2678	13	on	on	IN
cord-005478-5iu38pr6	2678	14	relapse	relapse	NN
cord-005478-5iu38pr6	2678	15	for	for	IN
cord-005478-5iu38pr6	2678	16	AML	AML	NNP
cord-005478-5iu38pr6	2678	17	patients	patient	NNS
cord-005478-5iu38pr6	2678	18	following	follow	VBG
cord-005478-5iu38pr6	2678	19	T	t	NN
cord-005478-5iu38pr6	2678	20	-	-	HYPH
cord-005478-5iu38pr6	2678	21	cell	cell	NN
cord-005478-5iu38pr6	2678	22	replete	replete	JJ
cord-005478-5iu38pr6	2678	23	haplo	haplo	NN
cord-005478-5iu38pr6	2678	24	-	-	HYPH
cord-005478-5iu38pr6	2678	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2678	26	with	with	IN
cord-005478-5iu38pr6	2678	27	ATG+	ATG+	NNP
cord-005478-5iu38pr6	2678	28	G	G	NNP
cord-005478-5iu38pr6	2678	29	-	-	HYPH
cord-005478-5iu38pr6	2678	30	CSF	csf	NN
cord-005478-5iu38pr6	2678	31	protocol	protocol	NN
cord-005478-5iu38pr6	2678	32	.	.	.
cord-005478-5iu38pr6	2679	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	2679	2	results	result	NNS
cord-005478-5iu38pr6	2679	3	suggested	suggest	VBD
cord-005478-5iu38pr6	2679	4	CMV	CMV	NNP
cord-005478-5iu38pr6	2679	5	-	-	HYPH
cord-005478-5iu38pr6	2679	6	miR	miR	NNP
cord-005478-5iu38pr6	2679	7	-	-	HYPH
cord-005478-5iu38pr6	2679	8	US4	US4	NNP
cord-005478-5iu38pr6	2679	9	-	-	HYPH
cord-005478-5iu38pr6	2679	10	1	1	CD
cord-005478-5iu38pr6	2679	11	/	/	SYM
cord-005478-5iu38pr6	2679	12	UL-148D	ul-148d	JJ
cord-005478-5iu38pr6	2679	13	co	co	NN
cord-005478-5iu38pr6	2679	14	-	-	NN
cord-005478-5iu38pr6	2679	15	expression	expression	NN
cord-005478-5iu38pr6	2679	16	rather	rather	RB
cord-005478-5iu38pr6	2679	17	than	than	IN
cord-005478-5iu38pr6	2679	18	CMV	CMV	NNP
cord-005478-5iu38pr6	2679	19	infection	infection	NN
cord-005478-5iu38pr6	2679	20	reduces	reduce	VBZ
cord-005478-5iu38pr6	2679	21	the	the	DT
cord-005478-5iu38pr6	2679	22	relapse	relapse	NN
cord-005478-5iu38pr6	2679	23	incidence	incidence	NN
cord-005478-5iu38pr6	2679	24	,	,	,
cord-005478-5iu38pr6	2679	25	the	the	DT
cord-005478-5iu38pr6	2679	26	stronger	strong	JJR
cord-005478-5iu38pr6	2679	27	GVL	GVL	NNP
cord-005478-5iu38pr6	2679	28	effect	effect	NN
cord-005478-5iu38pr6	2679	29	might	may	MD
cord-005478-5iu38pr6	2679	30	be	be	VB
cord-005478-5iu38pr6	2679	31	associated	associate	VBN
cord-005478-5iu38pr6	2679	32	with	with	IN
cord-005478-5iu38pr6	2679	33	strengthening	strengthen	VBG
cord-005478-5iu38pr6	2679	34	NKG2C+	NKG2C+	NNP
cord-005478-5iu38pr6	2679	35	NK	NK	NNP
cord-005478-5iu38pr6	2679	36	cells	cell	NNS
cord-005478-5iu38pr6	2679	37	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2679	38	and	and	CC
cord-005478-5iu38pr6	2679	39	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	2679	40	via	via	IN
cord-005478-5iu38pr6	2679	41	PLZF	PLZF	NNP
cord-005478-5iu38pr6	2679	42	/	/	SYM
cord-005478-5iu38pr6	2679	43	KLRC1	KLRC1	NNP
cord-005478-5iu38pr6	2679	44	pathway	pathway	NN
cord-005478-5iu38pr6	2679	45	.	.	.
cord-005478-5iu38pr6	2680	1	[	[	-LRB-
cord-005478-5iu38pr6	2680	2	[	[	-LRB-
cord-005478-5iu38pr6	2680	3	O129	O129	NNP
cord-005478-5iu38pr6	2680	4	Image	Image	NNP
cord-005478-5iu38pr6	2680	5	]	]	-RRB-
cord-005478-5iu38pr6	2680	6	1	1	CD
cord-005478-5iu38pr6	2680	7	.	.	.
cord-005478-5iu38pr6	2681	1	miR	miR	NNP
cord-005478-5iu38pr6	2681	2	-	-	HYPH
cord-005478-5iu38pr6	2681	3	US4	US4	NNP
cord-005478-5iu38pr6	2681	4	-	-	HYPH
cord-005478-5iu38pr6	2681	5	1	1	CD
cord-005478-5iu38pr6	2681	6	/	/	SYM
cord-005478-5iu38pr6	2681	7	UL-148D	ul-148d	NN
cord-005478-5iu38pr6	2681	8	reduces	reduce	VBZ
cord-005478-5iu38pr6	2681	9	relapse	relapse	NN
cord-005478-5iu38pr6	2681	10	in	in	IN
cord-005478-5iu38pr6	2681	11	AML	AML	NNP
cord-005478-5iu38pr6	2681	12	after	after	IN
cord-005478-5iu38pr6	2681	13	haplo	haplo	NN
cord-005478-5iu38pr6	2681	14	-	-	HYPH
cord-005478-5iu38pr6	2681	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2681	16	]	]	-RRB-
cord-005478-5iu38pr6	2682	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2682	2	Trial	Trial	NNP
cord-005478-5iu38pr6	2682	3	Registry	Registry	NNP
cord-005478-5iu38pr6	2682	4	:	:	:
cord-005478-5iu38pr6	2683	1	ChiCTR	chictr	JJ
cord-005478-5iu38pr6	2683	2	-	-	:
cord-005478-5iu38pr6	2683	3	OCH-10000940	OCH-10000940	NNP
cord-005478-5iu38pr6	2683	4	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2683	5	:	:	:
cord-005478-5iu38pr6	2683	6	Nothing	nothing	NN
cord-005478-5iu38pr6	2683	7	to	to	TO
cord-005478-5iu38pr6	2683	8	declare	declare	VB
cord-005478-5iu38pr6	2683	9	O130	O130	NNS
cord-005478-5iu38pr6	2684	1	A	a	DT
cord-005478-5iu38pr6	2684	2	randomised	randomised	JJ
cord-005478-5iu38pr6	2684	3	,	,	,
cord-005478-5iu38pr6	2684	4	placebo	placebo	NN
cord-005478-5iu38pr6	2684	5	-	-	HYPH
cord-005478-5iu38pr6	2684	6	controlled	control	VBN
cord-005478-5iu38pr6	2684	7	phase	phase	NN
cord-005478-5iu38pr6	2684	8	3	3	CD
cord-005478-5iu38pr6	2684	9	study	study	NN
cord-005478-5iu38pr6	2684	10	to	to	TO
cord-005478-5iu38pr6	2684	11	evaluate	evaluate	VB
cord-005478-5iu38pr6	2684	12	the	the	DT
cord-005478-5iu38pr6	2684	13	efficacy	efficacy	NN
cord-005478-5iu38pr6	2684	14	and	and	CC
cord-005478-5iu38pr6	2684	15	safety	safety	NN
cord-005478-5iu38pr6	2684	16	of	of	IN
cord-005478-5iu38pr6	2684	17	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	2684	18	,	,	,
cord-005478-5iu38pr6	2684	19	a	a	DT
cord-005478-5iu38pr6	2684	20	first	first	JJ
cord-005478-5iu38pr6	2684	21	-	-	HYPH
cord-005478-5iu38pr6	2684	22	inclass	inclass	NN
cord-005478-5iu38pr6	2684	23	,	,	,
cord-005478-5iu38pr6	2684	24	DNA	dna	NN
cord-005478-5iu38pr6	2684	25	-	-	HYPH
cord-005478-5iu38pr6	2684	26	based	base	VBN
cord-005478-5iu38pr6	2684	27	vaccine	vaccine	NN
cord-005478-5iu38pr6	2684	28	in	in	IN
cord-005478-5iu38pr6	2684	29	CMV	CMV	NNP
cord-005478-5iu38pr6	2684	30	-	-	HYPH
cord-005478-5iu38pr6	2684	31	seropositive	seropositive	JJ
cord-005478-5iu38pr6	2684	32	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2684	33	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	2684	34	cell	cell	NN
cord-005478-5iu38pr6	2684	35	transplant	transplant	NN
cord-005478-5iu38pr6	2684	36	recipients	recipient	NNS
cord-005478-5iu38pr6	2684	37	adjudicated	adjudicate	VBD
cord-005478-5iu38pr6	2684	38	CMV	CMV	NNP
cord-005478-5iu38pr6	2684	39	-	-	HYPH
cord-005478-5iu38pr6	2684	40	specific	specific	JJ
cord-005478-5iu38pr6	2684	41	AVT	AVT	NNP
cord-005478-5iu38pr6	2684	42	or	or	CC
cord-005478-5iu38pr6	2684	43	adjudicated	adjudicate	VBN
cord-005478-5iu38pr6	2684	44	CMV	CMV	NNP
cord-005478-5iu38pr6	2684	45	EOD	EOD	NNP
cord-005478-5iu38pr6	2684	46	and	and	CC
cord-005478-5iu38pr6	2684	47	mortality	mortality	NN
cord-005478-5iu38pr6	2684	48	through	through	IN
cord-005478-5iu38pr6	2684	49	1	1	CD
cord-005478-5iu38pr6	2684	50	year	year	NN
cord-005478-5iu38pr6	2684	51	post	post	NN
cord-005478-5iu38pr6	2684	52	transplant	transplant	NN
cord-005478-5iu38pr6	2684	53	.	.	.
cord-005478-5iu38pr6	2685	1	Results	result	NNS
cord-005478-5iu38pr6	2685	2	:	:	:
cord-005478-5iu38pr6	2686	1	Overall	overall	RB
cord-005478-5iu38pr6	2686	2	,	,	,
cord-005478-5iu38pr6	2686	3	514	514	CD
cord-005478-5iu38pr6	2686	4	patients	patient	NNS
cord-005478-5iu38pr6	2686	5	were	be	VBD
cord-005478-5iu38pr6	2686	6	randomized	randomize	VBN
cord-005478-5iu38pr6	2686	7	,	,	,
cord-005478-5iu38pr6	2686	8	of	of	IN
cord-005478-5iu38pr6	2686	9	whom	whom	WP
cord-005478-5iu38pr6	2686	10	501	501	CD
cord-005478-5iu38pr6	2686	11	received	receive	VBN
cord-005478-5iu38pr6	2686	12	≥1	≥1	NNP
cord-005478-5iu38pr6	2686	13	dose	dose	NN
cord-005478-5iu38pr6	2686	14	of	of	IN
cord-005478-5iu38pr6	2686	15	randomized	randomized	JJ
cord-005478-5iu38pr6	2686	16	treatment	treatment	NN
cord-005478-5iu38pr6	2686	17	(	(	-LRB-
cord-005478-5iu38pr6	2686	18	ASP0113	ASP0113	VBZ
cord-005478-5iu38pr6	2686	19	n=246	n=246	NNPS
cord-005478-5iu38pr6	2686	20	;	;	:
cord-005478-5iu38pr6	2686	21	placebo	placebo	NN
cord-005478-5iu38pr6	2686	22	n=255	n=255	CD
cord-005478-5iu38pr6	2686	23	)	)	-RRB-
cord-005478-5iu38pr6	2686	24	.	.	.
cord-005478-5iu38pr6	2687	1	There	there	EX
cord-005478-5iu38pr6	2687	2	was	be	VBD
cord-005478-5iu38pr6	2687	3	no	no	DT
cord-005478-5iu38pr6	2687	4	statistically	statistically	RB
cord-005478-5iu38pr6	2687	5	significant	significant	JJ
cord-005478-5iu38pr6	2687	6	difference	difference	NN
cord-005478-5iu38pr6	2687	7	in	in	IN
cord-005478-5iu38pr6	2687	8	the	the	DT
cord-005478-5iu38pr6	2687	9	proportion	proportion	NN
cord-005478-5iu38pr6	2687	10	of	of	IN
cord-005478-5iu38pr6	2687	11	patients	patient	NNS
cord-005478-5iu38pr6	2687	12	who	who	WP
cord-005478-5iu38pr6	2687	13	achieved	achieve	VBD
cord-005478-5iu38pr6	2687	14	the	the	DT
cord-005478-5iu38pr6	2687	15	primary	primary	JJ
cord-005478-5iu38pr6	2687	16	endpoint	endpoint	NN
cord-005478-5iu38pr6	2687	17	between	between	IN
cord-005478-5iu38pr6	2687	18	the	the	DT
cord-005478-5iu38pr6	2687	19	ASP0113	ASP0113	NNS
cord-005478-5iu38pr6	2687	20	(	(	-LRB-
cord-005478-5iu38pr6	2687	21	n=87	n=87	JJ
cord-005478-5iu38pr6	2687	22	[	[	-LRB-
cord-005478-5iu38pr6	2687	23	35.4	35.4	CD
cord-005478-5iu38pr6	2687	24	%	%	NN
cord-005478-5iu38pr6	2687	25	]	]	-RRB-
cord-005478-5iu38pr6	2687	26	)	)	-RRB-
cord-005478-5iu38pr6	2687	27	and	and	CC
cord-005478-5iu38pr6	2687	28	placebo	placebo	NN
cord-005478-5iu38pr6	2687	29	(	(	-LRB-
cord-005478-5iu38pr6	2687	30	n=77	n=77	JJ
cord-005478-5iu38pr6	2687	31	[	[	-LRB-
cord-005478-5iu38pr6	2687	32	30.2	30.2	CD
cord-005478-5iu38pr6	2687	33	%	%	NN
cord-005478-5iu38pr6	2687	34	]	]	-RRB-
cord-005478-5iu38pr6	2687	35	)	)	-RRB-
cord-005478-5iu38pr6	2687	36	groups	group	NNS
cord-005478-5iu38pr6	2687	37	,	,	,
cord-005478-5iu38pr6	2687	38	respectively	respectively	RB
cord-005478-5iu38pr6	2687	39	(	(	-LRB-
cord-005478-5iu38pr6	2687	40	odds	odd	NNS
cord-005478-5iu38pr6	2687	41	ratio	ratio	NN
cord-005478-5iu38pr6	2687	42	1.27	1.27	CD
cord-005478-5iu38pr6	2687	43	;	;	:
cord-005478-5iu38pr6	2687	44	95	95	CD
cord-005478-5iu38pr6	2687	45	%	%	NN
cord-005478-5iu38pr6	2687	46	confidence	confidence	NN
cord-005478-5iu38pr6	2687	47	interval	interval	NN
cord-005478-5iu38pr6	2687	48	p=0.205	p=0.205	NNP
cord-005478-5iu38pr6	2687	49	)	)	-RRB-
cord-005478-5iu38pr6	2687	50	.	.	.
cord-005478-5iu38pr6	2688	1	There	there	EX
cord-005478-5iu38pr6	2688	2	were	be	VBD
cord-005478-5iu38pr6	2688	3	no	no	DT
cord-005478-5iu38pr6	2688	4	statistically	statistically	RB
cord-005478-5iu38pr6	2688	5	significant	significant	JJ
cord-005478-5iu38pr6	2688	6	differences	difference	NNS
cord-005478-5iu38pr6	2688	7	between	between	IN
cord-005478-5iu38pr6	2688	8	groups	group	NNS
cord-005478-5iu38pr6	2688	9	for	for	IN
cord-005478-5iu38pr6	2688	10	any	any	DT
cord-005478-5iu38pr6	2688	11	secondary	secondary	JJ
cord-005478-5iu38pr6	2688	12	endpoints	endpoint	NNS
cord-005478-5iu38pr6	2688	13	(	(	-LRB-
cord-005478-5iu38pr6	2688	14	Table	table	NN
cord-005478-5iu38pr6	2688	15	)	)	-RRB-
cord-005478-5iu38pr6	2688	16	.	.	.
cord-005478-5iu38pr6	2689	1	The	the	DT
cord-005478-5iu38pr6	2689	2	incidence	incidence	NN
cord-005478-5iu38pr6	2689	3	of	of	IN
cord-005478-5iu38pr6	2689	4	TEAEs	teae	NNS
cord-005478-5iu38pr6	2689	5	was	be	VBD
cord-005478-5iu38pr6	2689	6	similar	similar	JJ
cord-005478-5iu38pr6	2689	7	between	between	IN
cord-005478-5iu38pr6	2689	8	groups	group	NNS
cord-005478-5iu38pr6	2689	9	,	,	,
cord-005478-5iu38pr6	2689	10	except	except	IN
cord-005478-5iu38pr6	2689	11	for	for	IN
cord-005478-5iu38pr6	2689	12	a	a	DT
cord-005478-5iu38pr6	2689	13	greater	great	JJR
cord-005478-5iu38pr6	2689	14	incidence	incidence	NN
cord-005478-5iu38pr6	2689	15	of	of	IN
cord-005478-5iu38pr6	2689	16	drugrelated	drugrelated	JJ
cord-005478-5iu38pr6	2689	17	TEAEs	TEAEs	NNPS
cord-005478-5iu38pr6	2689	18	in	in	IN
cord-005478-5iu38pr6	2689	19	the	the	DT
cord-005478-5iu38pr6	2689	20	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	2689	21	group	group	NN
cord-005478-5iu38pr6	2689	22	(	(	-LRB-
cord-005478-5iu38pr6	2689	23	n=194	n=194	CD
cord-005478-5iu38pr6	2689	24	[	[	-LRB-
cord-005478-5iu38pr6	2689	25	78.9	78.9	CD
cord-005478-5iu38pr6	2689	26	%	%	NN
cord-005478-5iu38pr6	2689	27	]	]	-RRB-
cord-005478-5iu38pr6	2689	28	)	)	-RRB-
cord-005478-5iu38pr6	2689	29	compared	compare	VBN
cord-005478-5iu38pr6	2689	30	with	with	IN
cord-005478-5iu38pr6	2689	31	placebo	placebo	NN
cord-005478-5iu38pr6	2689	32	(	(	-LRB-
cord-005478-5iu38pr6	2689	33	n=74	n=74	NNP
cord-005478-5iu38pr6	2689	34	[	[	-LRB-
cord-005478-5iu38pr6	2689	35	29	29	CD
cord-005478-5iu38pr6	2689	36	.	.	.
cord-005478-5iu38pr6	2689	37	0	0	CD
cord-005478-5iu38pr6	2689	38	%	%	NN
cord-005478-5iu38pr6	2689	39	]	]	-RRB-
cord-005478-5iu38pr6	2689	40	)	)	-RRB-
cord-005478-5iu38pr6	2689	41	attributed	attribute	VBN
cord-005478-5iu38pr6	2689	42	to	to	IN
cord-005478-5iu38pr6	2689	43	injection	injection	NN
cord-005478-5iu38pr6	2689	44	site	site	NN
cord-005478-5iu38pr6	2689	45	-	-	HYPH
cord-005478-5iu38pr6	2689	46	related	relate	VBN
cord-005478-5iu38pr6	2689	47	TEAEs	teae	NNS
cord-005478-5iu38pr6	2689	48	.	.	.
cord-005478-5iu38pr6	2690	1	Mean	mean	JJ
cord-005478-5iu38pr6	2690	2	T	t	NN
cord-005478-5iu38pr6	2690	3	-	-	HYPH
cord-005478-5iu38pr6	2690	4	cell	cell	NN
cord-005478-5iu38pr6	2690	5	response	response	NN
cord-005478-5iu38pr6	2690	6	to	to	IN
cord-005478-5iu38pr6	2690	7	pp65	pp65	NNP
cord-005478-5iu38pr6	2690	8	increased	increase	VBN
cord-005478-5iu38pr6	2690	9	over	over	IN
cord-005478-5iu38pr6	2690	10	time	time	NN
cord-005478-5iu38pr6	2690	11	in	in	IN
cord-005478-5iu38pr6	2690	12	both	both	DT
cord-005478-5iu38pr6	2690	13	groups	group	NNS
cord-005478-5iu38pr6	2690	14	and	and	CC
cord-005478-5iu38pr6	2690	15	was	be	VBD
cord-005478-5iu38pr6	2690	16	significantly	significantly	RB
cord-005478-5iu38pr6	2690	17	greater	great	JJR
cord-005478-5iu38pr6	2690	18	with	with	IN
cord-005478-5iu38pr6	2690	19	placebo	placebo	NN
cord-005478-5iu38pr6	2690	20	compared	compare	VBN
cord-005478-5iu38pr6	2690	21	with	with	IN
cord-005478-5iu38pr6	2690	22	ASP0113	ASP0113	NNS
cord-005478-5iu38pr6	2690	23	(	(	-LRB-
cord-005478-5iu38pr6	2690	24	p=0.027	p=0.027	RB
cord-005478-5iu38pr6	2690	25	)	)	-RRB-
cord-005478-5iu38pr6	2690	26	.	.	.
cord-005478-5iu38pr6	2691	1	There	there	EX
cord-005478-5iu38pr6	2691	2	was	be	VBD
cord-005478-5iu38pr6	2691	3	no	no	DT
cord-005478-5iu38pr6	2691	4	statistically	statistically	RB
cord-005478-5iu38pr6	2691	5	significant	significant	JJ
cord-005478-5iu38pr6	2691	6	difference	difference	NN
cord-005478-5iu38pr6	2691	7	between	between	IN
cord-005478-5iu38pr6	2691	8	groups	group	NNS
cord-005478-5iu38pr6	2691	9	for	for	IN
cord-005478-5iu38pr6	2691	10	mean	mean	JJ
cord-005478-5iu38pr6	2691	11	gB	gB	NNP
cord-005478-5iu38pr6	2691	12	-	-	JJ
cord-005478-5iu38pr6	2691	13	specific	specific	JJ
cord-005478-5iu38pr6	2691	14	antibody	antibody	NN
cord-005478-5iu38pr6	2691	15	response	response	NN
cord-005478-5iu38pr6	2691	16	.	.	.
cord-005478-5iu38pr6	2692	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2692	2	:	:	:
cord-005478-5iu38pr6	2692	3	ASP0113	ASP0113	NNS
cord-005478-5iu38pr6	2692	4	did	do	VBD
cord-005478-5iu38pr6	2692	5	not	not	RB
cord-005478-5iu38pr6	2692	6	demonstrate	demonstrate	VB
cord-005478-5iu38pr6	2692	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	2692	8	in	in	IN
cord-005478-5iu38pr6	2692	9	the	the	DT
cord-005478-5iu38pr6	2692	10	reduction	reduction	NN
cord-005478-5iu38pr6	2692	11	of	of	IN
cord-005478-5iu38pr6	2692	12	overall	overall	JJ
cord-005478-5iu38pr6	2692	13	mortality	mortality	NN
cord-005478-5iu38pr6	2692	14	and	and	CC
cord-005478-5iu38pr6	2692	15	CMV	CMV	NNP
cord-005478-5iu38pr6	2692	16	EOD	EOD	NNP
cord-005478-5iu38pr6	2692	17	through	through	IN
cord-005478-5iu38pr6	2692	18	1	1	CD
cord-005478-5iu38pr6	2692	19	year	year	NN
cord-005478-5iu38pr6	2692	20	post	post	NN
cord-005478-5iu38pr6	2692	21	transplant	transplant	NN
cord-005478-5iu38pr6	2692	22	.	.	.
cord-005478-5iu38pr6	2693	1	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	2693	2	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	2693	3	a	a	DT
cord-005478-5iu38pr6	2693	4	similar	similar	JJ
cord-005478-5iu38pr6	2693	5	safety	safety	NN
cord-005478-5iu38pr6	2693	6	profile	profile	NN
cord-005478-5iu38pr6	2693	7	to	to	IN
cord-005478-5iu38pr6	2693	8	placebo	placebo	NN
cord-005478-5iu38pr6	2693	9	,	,	,
cord-005478-5iu38pr6	2693	10	with	with	IN
cord-005478-5iu38pr6	2693	11	the	the	DT
cord-005478-5iu38pr6	2693	12	exception	exception	NN
cord-005478-5iu38pr6	2693	13	of	of	IN
cord-005478-5iu38pr6	2693	14	injection	injection	NN
cord-005478-5iu38pr6	2693	15	siterelated	siterelate	VBN
cord-005478-5iu38pr6	2693	16	TEAEs	TEAEs	NNPS
cord-005478-5iu38pr6	2693	17	that	that	WDT
cord-005478-5iu38pr6	2693	18	were	be	VBD
cord-005478-5iu38pr6	2693	19	more	more	RBR
cord-005478-5iu38pr6	2693	20	frequent	frequent	JJ
cord-005478-5iu38pr6	2693	21	in	in	IN
cord-005478-5iu38pr6	2693	22	the	the	DT
cord-005478-5iu38pr6	2693	23	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	2693	24	group	group	NN
cord-005478-5iu38pr6	2693	25	.	.	.
cord-005478-5iu38pr6	2694	1	Participants	participant	NNS
cord-005478-5iu38pr6	2694	2	in	in	IN
cord-005478-5iu38pr6	2694	3	this	this	DT
cord-005478-5iu38pr6	2694	4	study	study	NN
cord-005478-5iu38pr6	2694	5	will	will	MD
cord-005478-5iu38pr6	2694	6	be	be	VB
cord-005478-5iu38pr6	2694	7	followed	follow	VBN
cord-005478-5iu38pr6	2694	8	up	up	RP
cord-005478-5iu38pr6	2694	9	to	to	TO
cord-005478-5iu38pr6	2694	10	5.5	5.5	CD
cord-005478-5iu38pr6	2694	11	years	year	NNS
cord-005478-5iu38pr6	2694	12	post	post	NN
cord-005478-5iu38pr6	2694	13	transplant	transplant	NN
cord-005478-5iu38pr6	2694	14	for	for	IN
cord-005478-5iu38pr6	2694	15	long	long	JJ
cord-005478-5iu38pr6	2694	16	-	-	HYPH
cord-005478-5iu38pr6	2694	17	term	term	NN
cord-005478-5iu38pr6	2694	18	safety	safety	NN
cord-005478-5iu38pr6	2694	19	assessments	assessment	NNS
cord-005478-5iu38pr6	2694	20	.	.	.
cord-005478-5iu38pr6	2695	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2695	2	:	:	:
cord-005478-5iu38pr6	2695	3	JM	JM	NNP
cord-005478-5iu38pr6	2695	4	:	:	:
cord-005478-5iu38pr6	2695	5	Personal	personal	JJ
cord-005478-5iu38pr6	2695	6	fees	fee	NNS
cord-005478-5iu38pr6	2695	7	and	and	CC
cord-005478-5iu38pr6	2695	8	non	non	JJ
cord-005478-5iu38pr6	2695	9	-	-	JJ
cord-005478-5iu38pr6	2695	10	financial	financial	JJ
cord-005478-5iu38pr6	2695	11	support	support	NN
cord-005478-5iu38pr6	2695	12	from	from	IN
cord-005478-5iu38pr6	2695	13	Astellas	Astellas	NNP
cord-005478-5iu38pr6	2695	14	,	,	,
cord-005478-5iu38pr6	2695	15	Basilea	Basilea	NNP
cord-005478-5iu38pr6	2695	16	,	,	,
cord-005478-5iu38pr6	2695	17	Cidara	Cidara	NNP
cord-005478-5iu38pr6	2695	18	,	,	,
cord-005478-5iu38pr6	2695	19	F2	F2	NNP
cord-005478-5iu38pr6	2695	20	G	G	NNP
cord-005478-5iu38pr6	2695	21	,	,	,
cord-005478-5iu38pr6	2695	22	Gilead	Gilead	NNP
cord-005478-5iu38pr6	2695	23	,	,	,
cord-005478-5iu38pr6	2695	24	Merck	Merck	NNP
cord-005478-5iu38pr6	2695	25	and	and	CC
cord-005478-5iu38pr6	2695	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2695	27	)	)	-RRB-
cord-005478-5iu38pr6	2695	28	and	and	CC
cord-005478-5iu38pr6	2695	29	893	893	CD
cord-005478-5iu38pr6	2695	30	autologous	autologous	JJ
cord-005478-5iu38pr6	2695	31	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2695	32	(	(	-LRB-
cord-005478-5iu38pr6	2695	33	auto	auto	NN
cord-005478-5iu38pr6	2695	34	-	-	HYPH
cord-005478-5iu38pr6	2695	35	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2695	36	)	)	-RRB-
cord-005478-5iu38pr6	2695	37	.	.	.
cord-005478-5iu38pr6	2696	1	During	during	IN
cord-005478-5iu38pr6	2696	2	the	the	DT
cord-005478-5iu38pr6	2696	3	observation	observation	NN
cord-005478-5iu38pr6	2696	4	period	period	NN
cord-005478-5iu38pr6	2696	5	40	40	CD
cord-005478-5iu38pr6	2696	6	probable	probable	JJ
cord-005478-5iu38pr6	2696	7	and	and	CC
cord-005478-5iu38pr6	2696	8	proven	prove	VBN
cord-005478-5iu38pr6	2696	9	rare	rare	JJ
cord-005478-5iu38pr6	2696	10	IFD	ifd	NN
cord-005478-5iu38pr6	2696	11	(	(	-LRB-
cord-005478-5iu38pr6	2696	12	EORTC	EORTC	NNP
cord-005478-5iu38pr6	2696	13	/	/	SYM
cord-005478-5iu38pr6	2696	14	MSG	MSG	NNP
cord-005478-5iu38pr6	2696	15	2008	2008	CD
cord-005478-5iu38pr6	2696	16	criteria	criterion	NNS
cord-005478-5iu38pr6	2696	17	)	)	-RRB-
cord-005478-5iu38pr6	2696	18	cases	case	NNS
cord-005478-5iu38pr6	2696	19	were	be	VBD
cord-005478-5iu38pr6	2696	20	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	2696	21	in	in	IN
cord-005478-5iu38pr6	2696	22	children	child	NNS
cord-005478-5iu38pr6	2696	23	and	and	CC
cord-005478-5iu38pr6	2696	24	adults	adult	NNS
cord-005478-5iu38pr6	2696	25	with	with	IN
cord-005478-5iu38pr6	2696	26	hematological	hematological	JJ
cord-005478-5iu38pr6	2696	27	malignances	malignance	NNS
cord-005478-5iu38pr6	2696	28	and	and	CC
cord-005478-5iu38pr6	2696	29	non	non	JJ
cord-005478-5iu38pr6	2696	30	-	-	JJ
cord-005478-5iu38pr6	2696	31	malignant	malignant	JJ
cord-005478-5iu38pr6	2696	32	hematological	hematological	JJ
cord-005478-5iu38pr6	2696	33	diseases	disease	NNS
cord-005478-5iu38pr6	2696	34	after	after	IN
cord-005478-5iu38pr6	2696	35	allo	allo	NN
cord-005478-5iu38pr6	2696	36	-	-	HYPH
cord-005478-5iu38pr6	2696	37	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2696	38	(	(	-LRB-
cord-005478-5iu38pr6	2696	39	n=30	n=30	NNP
cord-005478-5iu38pr6	2696	40	)	)	-RRB-
cord-005478-5iu38pr6	2696	41	,	,	,
cord-005478-5iu38pr6	2696	42	auto	auto	NN
cord-005478-5iu38pr6	2696	43	-	-	HYPH
cord-005478-5iu38pr6	2696	44	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2696	45	(	(	-LRB-
cord-005478-5iu38pr6	2696	46	n=2	n=2	NNS
cord-005478-5iu38pr6	2696	47	)	)	-RRB-
cord-005478-5iu38pr6	2696	48	,	,	,
cord-005478-5iu38pr6	2696	49	and	and	CC
cord-005478-5iu38pr6	2696	50	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2696	51	(	(	-LRB-
cord-005478-5iu38pr6	2696	52	n=8	n=8	NN
cord-005478-5iu38pr6	2696	53	)	)	-RRB-
cord-005478-5iu38pr6	2696	54	.	.	.
cord-005478-5iu38pr6	2697	1	The	the	DT
cord-005478-5iu38pr6	2697	2	median	median	JJ
cord-005478-5iu38pr6	2697	3	age	age	NN
cord-005478-5iu38pr6	2697	4	was	be	VBD
cord-005478-5iu38pr6	2697	5	23	23	CD
cord-005478-5iu38pr6	2697	6	(	(	-LRB-
cord-005478-5iu38pr6	2697	7	2	2	CD
cord-005478-5iu38pr6	2697	8	-	-	SYM
cord-005478-5iu38pr6	2697	9	59	59	CD
cord-005478-5iu38pr6	2697	10	)	)	-RRB-
cord-005478-5iu38pr6	2698	1	y.o	y.o	NNP
cord-005478-5iu38pr6	2698	2	.	.	NNP
cord-005478-5iu38pr6	2698	3	,	,	,
cord-005478-5iu38pr6	2698	4	males	male	NNS
cord-005478-5iu38pr6	2698	5	-60%(n=24	-60%(n=24	VBP
cord-005478-5iu38pr6	2698	6	)	)	-RRB-
cord-005478-5iu38pr6	2698	7	.	.	.
cord-005478-5iu38pr6	2699	1	The	the	DT
cord-005478-5iu38pr6	2699	2	median	median	NN
cord-005478-5iu38pr6	2699	3	follow	follow	VBP
cord-005478-5iu38pr6	2699	4	up	up	RP
cord-005478-5iu38pr6	2699	5	time	time	NN
cord-005478-5iu38pr6	2699	6	for	for	IN
cord-005478-5iu38pr6	2699	7	rare	rare	JJ
cord-005478-5iu38pr6	2699	8	IFD	IFD	NNP
cord-005478-5iu38pr6	2699	9	cases	case	NNS
cord-005478-5iu38pr6	2699	10	was	be	VBD
cord-005478-5iu38pr6	2699	11	3	3	CD
cord-005478-5iu38pr6	2699	12	months	month	NNS
cord-005478-5iu38pr6	2699	13	;	;	:
cord-005478-5iu38pr6	2699	14	for	for	IN
cord-005478-5iu38pr6	2699	15	survivors	survivor	NNS
cord-005478-5iu38pr6	2699	16	-30	-30	CD
cord-005478-5iu38pr6	2699	17	months	month	NNS
cord-005478-5iu38pr6	2699	18	.	.	.
cord-005478-5iu38pr6	2700	1	Results	result	NNS
cord-005478-5iu38pr6	2700	2	:	:	:
cord-005478-5iu38pr6	2701	1	Incidence	incidence	NN
cord-005478-5iu38pr6	2701	2	of	of	IN
cord-005478-5iu38pr6	2701	3	rare	rare	JJ
cord-005478-5iu38pr6	2701	4	IFD	ifd	NN
cord-005478-5iu38pr6	2701	5	in	in	IN
cord-005478-5iu38pr6	2701	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2701	7	recipients	recipient	NNS
cord-005478-5iu38pr6	2701	8	was	be	VBD
cord-005478-5iu38pr6	2701	9	1,5	1,5	CD
cord-005478-5iu38pr6	2701	10	%	%	NN
cord-005478-5iu38pr6	2701	11	,	,	,
cord-005478-5iu38pr6	2701	12	it	-PRON-	PRP
cord-005478-5iu38pr6	2701	13	was	be	VBD
cord-005478-5iu38pr6	2701	14	higher	high	JJR
cord-005478-5iu38pr6	2701	15	after	after	IN
cord-005478-5iu38pr6	2701	16	allo	allo	NN
cord-005478-5iu38pr6	2701	17	-	-	HYPH
cord-005478-5iu38pr6	2701	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2701	19	(	(	-LRB-
cord-005478-5iu38pr6	2701	20	1,6	1,6	CD
cord-005478-5iu38pr6	2701	21	%	%	NN
cord-005478-5iu38pr6	2701	22	)	)	-RRB-
cord-005478-5iu38pr6	2701	23	than	than	IN
cord-005478-5iu38pr6	2701	24	auto	auto	NN
cord-005478-5iu38pr6	2701	25	-	-	HYPH
cord-005478-5iu38pr6	2701	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2701	27	(	(	-LRB-
cord-005478-5iu38pr6	2701	28	0,2	0,2	CD
cord-005478-5iu38pr6	2701	29	%	%	NN
cord-005478-5iu38pr6	2701	30	)	)	-RRB-
cord-005478-5iu38pr6	2702	1	(	(	-LRB-
cord-005478-5iu38pr6	2702	2	p	p	NN
cord-005478-5iu38pr6	2702	3	<	<	XX
cord-005478-5iu38pr6	2702	4	0,01	0,01	NN
cord-005478-5iu38pr6	2702	5	)	)	-RRB-
cord-005478-5iu38pr6	2702	6	.	.	.
cord-005478-5iu38pr6	2703	1	In	in	IN
cord-005478-5iu38pr6	2703	2	eight	eight	CD
cord-005478-5iu38pr6	2703	3	patients	patient	NNS
cord-005478-5iu38pr6	2703	4	,	,	,
cord-005478-5iu38pr6	2703	5	this	this	DT
cord-005478-5iu38pr6	2703	6	complication	complication	NN
cord-005478-5iu38pr6	2703	7	developed	develop	VBN
cord-005478-5iu38pr6	2703	8	after	after	IN
cord-005478-5iu38pr6	2703	9	CT	CT	NNP
cord-005478-5iu38pr6	2703	10	and	and	CC
cord-005478-5iu38pr6	2703	11	four	four	CD
cord-005478-5iu38pr6	2703	12	of	of	IN
cord-005478-5iu38pr6	2703	13	them	-PRON-	PRP
cord-005478-5iu38pr6	2703	14	proceed	proceed	VBP
cord-005478-5iu38pr6	2703	15	to	to	IN
cord-005478-5iu38pr6	2703	16	allo	allo	NN
cord-005478-5iu38pr6	2703	17	-	-	HYPH
cord-005478-5iu38pr6	2703	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2703	19	.	.	.
cord-005478-5iu38pr6	2704	1	The	the	DT
cord-005478-5iu38pr6	2704	2	most	most	RBS
cord-005478-5iu38pr6	2704	3	frequent	frequent	JJ
cord-005478-5iu38pr6	2704	4	underlying	underlie	VBG
cord-005478-5iu38pr6	2704	5	diseases	disease	NNS
cord-005478-5iu38pr6	2704	6	were	be	VBD
cord-005478-5iu38pr6	2704	7	acute	acute	JJ
cord-005478-5iu38pr6	2704	8	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	2704	9	leukemia	leukemia	NN
cord-005478-5iu38pr6	2704	10	(	(	-LRB-
cord-005478-5iu38pr6	2704	11	33	33	CD
cord-005478-5iu38pr6	2704	12	%	%	NN
cord-005478-5iu38pr6	2704	13	)	)	-RRB-
cord-005478-5iu38pr6	2704	14	and	and	CC
cord-005478-5iu38pr6	2704	15	acute	acute	JJ
cord-005478-5iu38pr6	2704	16	myeloid	myeloid	NN
cord-005478-5iu38pr6	2704	17	leukemia	leukemia	NN
cord-005478-5iu38pr6	2704	18	(	(	-LRB-
cord-005478-5iu38pr6	2704	19	30	30	CD
cord-005478-5iu38pr6	2704	20	%	%	NN
cord-005478-5iu38pr6	2704	21	)	)	-RRB-
cord-005478-5iu38pr6	2704	22	.	.	.
cord-005478-5iu38pr6	2705	1	The	the	DT
cord-005478-5iu38pr6	2705	2	median	median	JJ
cord-005478-5iu38pr6	2705	3	time	time	NN
cord-005478-5iu38pr6	2705	4	of	of	IN
cord-005478-5iu38pr6	2705	5	onset	onset	NN
cord-005478-5iu38pr6	2705	6	of	of	IN
cord-005478-5iu38pr6	2705	7	rare	rare	JJ
cord-005478-5iu38pr6	2705	8	IFD	ifd	NN
cord-005478-5iu38pr6	2705	9	after	after	IN
cord-005478-5iu38pr6	2705	10	allo	allo	NN
cord-005478-5iu38pr6	2705	11	-	-	HYPH
cord-005478-5iu38pr6	2705	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2705	13	was	be	VBD
cord-005478-5iu38pr6	2705	14	104	104	CD
cord-005478-5iu38pr6	2706	1	(	(	-LRB-
cord-005478-5iu38pr6	2706	2	21	21	CD
cord-005478-5iu38pr6	2706	3	-	-	SYM
cord-005478-5iu38pr6	2706	4	1057	1057	CD
cord-005478-5iu38pr6	2706	5	)	)	-RRB-
cord-005478-5iu38pr6	2706	6	days	day	NNS
cord-005478-5iu38pr6	2706	7	,	,	,
cord-005478-5iu38pr6	2706	8	auto	auto	NN
cord-005478-5iu38pr6	2706	9	-	-	HYPH
cord-005478-5iu38pr6	2706	10	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2706	11	-138	-138	NN
cord-005478-5iu38pr6	2706	12	(	(	-LRB-
cord-005478-5iu38pr6	2706	13	60	60	CD
cord-005478-5iu38pr6	2706	14	-	-	SYM
cord-005478-5iu38pr6	2706	15	216	216	CD
cord-005478-5iu38pr6	2706	16	)	)	-RRB-
cord-005478-5iu38pr6	2706	17	,	,	,
cord-005478-5iu38pr6	2706	18	after	after	IN
cord-005478-5iu38pr6	2706	19	start	start	NN
cord-005478-5iu38pr6	2706	20	of	of	IN
cord-005478-5iu38pr6	2706	21	.	.	.
cord-005478-5iu38pr6	2707	1	Etiology	etiology	NN
cord-005478-5iu38pr6	2707	2	of	of	IN
cord-005478-5iu38pr6	2707	3	rare	rare	JJ
cord-005478-5iu38pr6	2707	4	IFD	IFD	NNP
cord-005478-5iu38pr6	2707	5	was	be	VBD
cord-005478-5iu38pr6	2707	6	identified	identify	VBN
cord-005478-5iu38pr6	2707	7	by	by	IN
cord-005478-5iu38pr6	2707	8	culture	culture	NN
cord-005478-5iu38pr6	2707	9	in	in	IN
cord-005478-5iu38pr6	2707	10	65	65	CD
cord-005478-5iu38pr6	2707	11	%	%	NN
cord-005478-5iu38pr6	2707	12	cases	case	NNS
cord-005478-5iu38pr6	2707	13	:	:	:
cord-005478-5iu38pr6	2707	14	Rhizopus	Rhizopus	NNP
cord-005478-5iu38pr6	2707	15	spp	spp	NNS
cord-005478-5iu38pr6	2707	16	.	.	.
cord-005478-5iu38pr6	2708	1	-27	-27	CD
cord-005478-5iu38pr6	2708	2	%	%	NN
cord-005478-5iu38pr6	2708	3	,	,	,
cord-005478-5iu38pr6	2708	4	Paecilomyces	Paecilomyces	NNP
cord-005478-5iu38pr6	2708	5	spp	spp	NNS
cord-005478-5iu38pr6	2708	6	.	.	.
cord-005478-5iu38pr6	2709	1	-7	-7	.
cord-005478-5iu38pr6	2710	1	%	%	NN
cord-005478-5iu38pr6	2710	2	,	,	,
cord-005478-5iu38pr6	2710	3	Fuzarium	Fuzarium	NNP
cord-005478-5iu38pr6	2710	4	spp	spp	NNS
cord-005478-5iu38pr6	2710	5	.	.	.
cord-005478-5iu38pr6	2711	1	-5	-5	NNP
cord-005478-5iu38pr6	2711	2	%	%	NN
cord-005478-5iu38pr6	2711	3	,	,	,
cord-005478-5iu38pr6	2711	4	Malassezia	Malassezia	NNP
cord-005478-5iu38pr6	2711	5	furfur	furfur	JJ
cord-005478-5iu38pr6	2711	6	-5	-5	NNP
cord-005478-5iu38pr6	2711	7	%	%	NN
cord-005478-5iu38pr6	2711	8	,	,	,
cord-005478-5iu38pr6	2711	9	Trichosporon	Trichosporon	NNP
cord-005478-5iu38pr6	2711	10	asahii	asahii	NNP
cord-005478-5iu38pr6	2711	11	-3	-3	NNP
cord-005478-5iu38pr6	2711	12	%	%	NN
cord-005478-5iu38pr6	2711	13	,	,	,
cord-005478-5iu38pr6	2711	14	Scedosporium	Scedosporium	NNP
cord-005478-5iu38pr6	2711	15	apiosperium	apiosperium	NN
cord-005478-5iu38pr6	2711	16	-2	-2	CD
cord-005478-5iu38pr6	2711	17	%	%	NN
cord-005478-5iu38pr6	2711	18	,	,	,
cord-005478-5iu38pr6	2711	19	Scopulariopsis	Scopulariopsis	NNP
cord-005478-5iu38pr6	2711	20	gracilis	gracilis	NNP
cord-005478-5iu38pr6	2711	21	-2	-2	NNP
cord-005478-5iu38pr6	2711	22	%	%	NN
cord-005478-5iu38pr6	2711	23	,	,	,
cord-005478-5iu38pr6	2711	24	Rhizomucor	Rhizomucor	NNP
cord-005478-5iu38pr6	2711	25	pusillus	pusillus	NN
cord-005478-5iu38pr6	2711	26	-2	-2	CD
cord-005478-5iu38pr6	2711	27	%	%	NN
cord-005478-5iu38pr6	2711	28	,	,	,
cord-005478-5iu38pr6	2711	29	Lichtheimia	Lichtheimia	NNP
cord-005478-5iu38pr6	2711	30	corymbifera	corymbifera	NN
cord-005478-5iu38pr6	2711	31	-2	-2	CD
cord-005478-5iu38pr6	2711	32	%	%	NN
cord-005478-5iu38pr6	2711	33	,	,	,
cord-005478-5iu38pr6	2711	34	mix	mix	VB
cord-005478-5iu38pr6	2711	35	rare	rare	JJ
cord-005478-5iu38pr6	2711	36	IFD	ifd	NN
cord-005478-5iu38pr6	2711	37	with	with	IN
cord-005478-5iu38pr6	2711	38	Rhizopus	Rhizopus	NNP
cord-005478-5iu38pr6	2711	39	spp	spp	NNS
cord-005478-5iu38pr6	2711	40	.	.	.
cord-005478-5iu38pr6	2712	1	+	+	CC
cord-005478-5iu38pr6	2713	1	Paecilomyces	paecilomyce	NNS
cord-005478-5iu38pr6	2713	2	spp	spp	NNS
cord-005478-5iu38pr6	2713	3	.	.	.
cord-005478-5iu38pr6	2714	1	-5	-5	NNP
cord-005478-5iu38pr6	2714	2	%	%	NN
cord-005478-5iu38pr6	2714	3	,	,	,
cord-005478-5iu38pr6	2714	4	Paecilomyces	Paecilomyces	NNP
cord-005478-5iu38pr6	2714	5	spp	spp	NNS
cord-005478-5iu38pr6	2714	6	.	.	.
cord-005478-5iu38pr6	2715	1	+	+	CC
cord-005478-5iu38pr6	2716	1	Fuzarium	Fuzarium	NNP
cord-005478-5iu38pr6	2716	2	spp	spp	NNS
cord-005478-5iu38pr6	2716	3	.	.	.
cord-005478-5iu38pr6	2717	1	-5	-5	NNP
cord-005478-5iu38pr6	2717	2	%	%	NN
cord-005478-5iu38pr6	2717	3	.	.	.
cord-005478-5iu38pr6	2718	1	35	35	CD
cord-005478-5iu38pr6	2718	2	%	%	NN
cord-005478-5iu38pr6	2718	3	cases	case	NNS
cord-005478-5iu38pr6	2718	4	(	(	-LRB-
cord-005478-5iu38pr6	2718	5	mucormycosis	mucormycosis	NN
cord-005478-5iu38pr6	2718	6	)	)	-RRB-
cord-005478-5iu38pr6	2718	7	were	be	VBD
cord-005478-5iu38pr6	2718	8	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	2718	9	by	by	IN
cord-005478-5iu38pr6	2718	10	microscopy	microscopy	NNS
cord-005478-5iu38pr6	2718	11	.	.	.
cord-005478-5iu38pr6	2719	1	In	in	IN
cord-005478-5iu38pr6	2719	2	45	45	CD
cord-005478-5iu38pr6	2719	3	%	%	NN
cord-005478-5iu38pr6	2719	4	cases	case	NNS
cord-005478-5iu38pr6	2719	5	rare	rare	JJ
cord-005478-5iu38pr6	2719	6	IFD	IFD	NNP
cord-005478-5iu38pr6	2719	7	developed	develop	VBD
cord-005478-5iu38pr6	2719	8	after	after	IN
cord-005478-5iu38pr6	2719	9	or	or	CC
cord-005478-5iu38pr6	2719	10	in	in	IN
cord-005478-5iu38pr6	2719	11	combination	combination	NN
cord-005478-5iu38pr6	2719	12	with	with	IN
cord-005478-5iu38pr6	2719	13	invasive	invasive	JJ
cord-005478-5iu38pr6	2719	14	aspergillosis	aspergillosis	NN
cord-005478-5iu38pr6	2719	15	,	,	,
cord-005478-5iu38pr6	2719	16	and	and	CC
cord-005478-5iu38pr6	2719	17	2	2	CD
cord-005478-5iu38pr6	2719	18	patients	patient	NNS
cord-005478-5iu38pr6	2719	19	had	have	VBD
cord-005478-5iu38pr6	2719	20	both	both	DT
cord-005478-5iu38pr6	2719	21	preexisting	preexist	VBG
cord-005478-5iu38pr6	2719	22	invasive	invasive	JJ
cord-005478-5iu38pr6	2719	23	aspergillosis	aspergillosis	NN
cord-005478-5iu38pr6	2719	24	and	and	CC
cord-005478-5iu38pr6	2719	25	co	co	NN
cord-005478-5iu38pr6	2719	26	-	-	NN
cord-005478-5iu38pr6	2719	27	infection	infection	NN
cord-005478-5iu38pr6	2719	28	with	with	IN
cord-005478-5iu38pr6	2719	29	mucormycosis	mucormycosis	NN
cord-005478-5iu38pr6	2719	30	.	.	.
cord-005478-5iu38pr6	2720	1	The	the	DT
cord-005478-5iu38pr6	2720	2	main	main	JJ
cord-005478-5iu38pr6	2720	3	site	site	NN
cord-005478-5iu38pr6	2720	4	of	of	IN
cord-005478-5iu38pr6	2720	5	infection	infection	NN
cord-005478-5iu38pr6	2720	6	were	be	VBD
cord-005478-5iu38pr6	2720	7	lungs	lung	NNS
cord-005478-5iu38pr6	2720	8	(	(	-LRB-
cord-005478-5iu38pr6	2720	9	82	82	CD
cord-005478-5iu38pr6	2720	10	%	%	NN
cord-005478-5iu38pr6	2720	11	)	)	-RRB-
cord-005478-5iu38pr6	2720	12	,	,	,
cord-005478-5iu38pr6	2720	13	the	the	DT
cord-005478-5iu38pr6	2720	14	main	main	JJ
cord-005478-5iu38pr6	2720	15	clinical	clinical	JJ
cord-005478-5iu38pr6	2720	16	symptom	symptom	NN
cord-005478-5iu38pr6	2720	17	-febrile	-febrile	NN
cord-005478-5iu38pr6	2720	18	fever	fever	NN
cord-005478-5iu38pr6	2720	19	(	(	-LRB-
cord-005478-5iu38pr6	2720	20	95	95	CD
cord-005478-5iu38pr6	2720	21	%	%	NN
cord-005478-5iu38pr6	2720	22	)	)	-RRB-
cord-005478-5iu38pr6	2720	23	.	.	.
cord-005478-5iu38pr6	2721	1	Antifungal	antifungal	JJ
cord-005478-5iu38pr6	2721	2	therapy	therapy	NN
cord-005478-5iu38pr6	2721	3	was	be	VBD
cord-005478-5iu38pr6	2721	4	used	use	VBN
cord-005478-5iu38pr6	2721	5	in	in	IN
cord-005478-5iu38pr6	2721	6	all	all	DT
cord-005478-5iu38pr6	2721	7	patients	patient	NNS
cord-005478-5iu38pr6	2721	8	:	:	:
cord-005478-5iu38pr6	2722	1	lipid	lipid	NN
cord-005478-5iu38pr6	2722	2	amphotericin	amphotericin	NNS
cord-005478-5iu38pr6	2722	3	B	B	NNP
cord-005478-5iu38pr6	2723	1	-30	-30	CD
cord-005478-5iu38pr6	2723	2	%	%	NN
cord-005478-5iu38pr6	2723	3	,	,	,
cord-005478-5iu38pr6	2723	4	lipid	lipid	NN
cord-005478-5iu38pr6	2723	5	amphotericin	amphotericin	NNS
cord-005478-5iu38pr6	2723	6	B	b	NN
cord-005478-5iu38pr6	2723	7	+	+	CC
cord-005478-5iu38pr6	2723	8	caspofungin	caspofungin	FW
cord-005478-5iu38pr6	2723	9	-22,5	-22,5	XX
cord-005478-5iu38pr6	2723	10	%	%	NN
cord-005478-5iu38pr6	2723	11	,	,	,
cord-005478-5iu38pr6	2723	12	voriconazole	voriconazole	NN
cord-005478-5iu38pr6	2723	13	-17,5	-17,5	CD
cord-005478-5iu38pr6	2723	14	%	%	NN
cord-005478-5iu38pr6	2723	15	,	,	,
cord-005478-5iu38pr6	2723	16	posaconazole	posaconazole	NNP
cord-005478-5iu38pr6	2723	17	-12,5	-12,5	NNP
cord-005478-5iu38pr6	2723	18	%	%	NN
cord-005478-5iu38pr6	2723	19	,	,	,
cord-005478-5iu38pr6	2723	20	lipid	lipid	NN
cord-005478-5iu38pr6	2723	21	amphotericin	amphotericin	NNS
cord-005478-5iu38pr6	2723	22	B	b	NN
cord-005478-5iu38pr6	2723	23	+	+	CC
cord-005478-5iu38pr6	2723	24	posaconazole	posaconazole	NN
cord-005478-5iu38pr6	2723	25	-10	-10	NN
cord-005478-5iu38pr6	2723	26	%	%	NN
cord-005478-5iu38pr6	2723	27	,	,	,
cord-005478-5iu38pr6	2723	28	and	and	CC
cord-005478-5iu38pr6	2723	29	echinocandins	echinocandin	NNS
cord-005478-5iu38pr6	2723	30	-7,5	-7,5	CD
cord-005478-5iu38pr6	2723	31	%	%	NN
cord-005478-5iu38pr6	2723	32	.	.	.
cord-005478-5iu38pr6	2724	1	Surgery	surgery	NN
cord-005478-5iu38pr6	2724	2	was	be	VBD
cord-005478-5iu38pr6	2724	3	used	use	VBN
cord-005478-5iu38pr6	2724	4	in	in	IN
cord-005478-5iu38pr6	2724	5	10	10	CD
cord-005478-5iu38pr6	2724	6	%	%	NN
cord-005478-5iu38pr6	2724	7	patients	patient	NNS
cord-005478-5iu38pr6	2724	8	.	.	.
cord-005478-5iu38pr6	2725	1	Overall	overall	JJ
cord-005478-5iu38pr6	2725	2	survival	survival	NN
cord-005478-5iu38pr6	2725	3	at	at	IN
cord-005478-5iu38pr6	2725	4	12	12	CD
cord-005478-5iu38pr6	2725	5	weeks	week	NNS
cord-005478-5iu38pr6	2725	6	from	from	IN
cord-005478-5iu38pr6	2725	7	the	the	DT
cord-005478-5iu38pr6	2725	8	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2725	9	of	of	IN
cord-005478-5iu38pr6	2725	10	rare	rare	JJ
cord-005478-5iu38pr6	2725	11	IFD	IFD	NNP
cord-005478-5iu38pr6	2725	12	was	be	VBD
cord-005478-5iu38pr6	2725	13	50	50	CD
cord-005478-5iu38pr6	2725	14	%	%	NN
cord-005478-5iu38pr6	2725	15	.	.	.
cord-005478-5iu38pr6	2726	1	The	the	DT
cord-005478-5iu38pr6	2726	2	12-weeks	12-weeks	CD
cord-005478-5iu38pr6	2726	3	overall	overall	JJ
cord-005478-5iu38pr6	2726	4	survival	survival	NN
cord-005478-5iu38pr6	2726	5	was	be	VBD
cord-005478-5iu38pr6	2726	6	better	well	JJR
cord-005478-5iu38pr6	2726	7	in	in	IN
cord-005478-5iu38pr6	2726	8	patients	patient	NNS
cord-005478-5iu38pr6	2726	9	after	after	IN
cord-005478-5iu38pr6	2726	10	CT	CT	NNP
cord-005478-5iu38pr6	2726	11	and	and	CC
cord-005478-5iu38pr6	2726	12	auto	auto	NN
cord-005478-5iu38pr6	2726	13	-	-	HYPH
cord-005478-5iu38pr6	2726	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2726	15	(	(	-LRB-
cord-005478-5iu38pr6	2726	16	80	80	CD
cord-005478-5iu38pr6	2726	17	%	%	NN
cord-005478-5iu38pr6	2726	18	)	)	-RRB-
cord-005478-5iu38pr6	2726	19	than	than	IN
cord-005478-5iu38pr6	2726	20	allo	allo	NN
cord-005478-5iu38pr6	2726	21	-	-	HYPH
cord-005478-5iu38pr6	2726	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2726	23	(	(	-LRB-
cord-005478-5iu38pr6	2726	24	42	42	CD
cord-005478-5iu38pr6	2726	25	%	%	NN
cord-005478-5iu38pr6	2726	26	)	)	-RRB-
cord-005478-5iu38pr6	2726	27	,	,	,
cord-005478-5iu38pr6	2726	28	p=0,048	p=0,048	NNP
cord-005478-5iu38pr6	2726	29	.	.	.
cord-005478-5iu38pr6	2727	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2727	2	:	:	:
cord-005478-5iu38pr6	2728	1	The	the	DT
cord-005478-5iu38pr6	2728	2	incidence	incidence	NN
cord-005478-5iu38pr6	2728	3	of	of	IN
cord-005478-5iu38pr6	2728	4	rare	rare	JJ
cord-005478-5iu38pr6	2728	5	IFD	ifd	NN
cord-005478-5iu38pr6	2728	6	in	in	IN
cord-005478-5iu38pr6	2728	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2728	8	recipients	recipient	NNS
cord-005478-5iu38pr6	2728	9	was	be	VBD
cord-005478-5iu38pr6	2728	10	1,5	1,5	CD
cord-005478-5iu38pr6	2728	11	%	%	NN
cord-005478-5iu38pr6	2728	12	and	and	CC
cord-005478-5iu38pr6	2728	13	depends	depend	VBZ
cord-005478-5iu38pr6	2728	14	on	on	IN
cord-005478-5iu38pr6	2728	15	type	type	NN
cord-005478-5iu38pr6	2728	16	of	of	IN
cord-005478-5iu38pr6	2728	17	transplantation	transplantation	NN
cord-005478-5iu38pr6	2728	18	.	.	.
cord-005478-5iu38pr6	2729	1	Rare	rare	JJ
cord-005478-5iu38pr6	2729	2	IFD	IFD	NNP
cord-005478-5iu38pr6	2729	3	is	be	VBZ
cord-005478-5iu38pr6	2729	4	a	a	DT
cord-005478-5iu38pr6	2729	5	late	late	JJ
cord-005478-5iu38pr6	2729	6	complication	complication	NN
cord-005478-5iu38pr6	2729	7	after	after	IN
cord-005478-5iu38pr6	2729	8	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2729	9	and	and	CC
cord-005478-5iu38pr6	2729	10	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2729	11	and	and	CC
cord-005478-5iu38pr6	2729	12	usually	usually	RB
cord-005478-5iu38pr6	2729	13	develops	develop	VBZ
cord-005478-5iu38pr6	2729	14	after	after	IN
cord-005478-5iu38pr6	2729	15	or	or	CC
cord-005478-5iu38pr6	2729	16	in	in	IN
cord-005478-5iu38pr6	2729	17	combination	combination	NN
cord-005478-5iu38pr6	2729	18	with	with	IN
cord-005478-5iu38pr6	2729	19	invasive	invasive	JJ
cord-005478-5iu38pr6	2729	20	aspergillosis	aspergillosis	NN
cord-005478-5iu38pr6	2729	21	.	.	.
cord-005478-5iu38pr6	2730	1	Higher	high	JJR
cord-005478-5iu38pr6	2730	2	incidence	incidence	NN
cord-005478-5iu38pr6	2730	3	and	and	CC
cord-005478-5iu38pr6	2730	4	worst	bad	JJS
cord-005478-5iu38pr6	2730	5	prognosis	prognosis	NN
cord-005478-5iu38pr6	2731	1	rare	rare	JJ
cord-005478-5iu38pr6	2731	2	IFD	IFD	NNP
cord-005478-5iu38pr6	2731	3	is	be	VBZ
cord-005478-5iu38pr6	2731	4	observed	observe	VBN
cord-005478-5iu38pr6	2731	5	in	in	IN
cord-005478-5iu38pr6	2731	6	allo	allo	NN
cord-005478-5iu38pr6	2731	7	-	-	HYPH
cord-005478-5iu38pr6	2731	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2731	9	recipients	recipient	NNS
cord-005478-5iu38pr6	2731	10	.	.	.
cord-005478-5iu38pr6	2732	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2732	2	:	:	:
cord-005478-5iu38pr6	2732	3	Nothing	nothing	NN
cord-005478-5iu38pr6	2732	4	to	to	TO
cord-005478-5iu38pr6	2732	5	declare	declare	VB
cord-005478-5iu38pr6	2732	6	O133	O133	NNP
cord-005478-5iu38pr6	2732	7	Incidence	incidence	NN
cord-005478-5iu38pr6	2732	8	and	and	CC
cord-005478-5iu38pr6	2732	9	outcome	outcome	NN
cord-005478-5iu38pr6	2732	10	of	of	IN
cord-005478-5iu38pr6	2732	11	kaposi	kaposi	NNP
cord-005478-5iu38pr6	2732	12	sarcoma	sarcoma	NN
cord-005478-5iu38pr6	2732	13	after	after	IN
cord-005478-5iu38pr6	2732	14	hsct	hsct	NNP
cord-005478-5iu38pr6	2732	15	:	:	:
cord-005478-5iu38pr6	2732	16	A	a	DT
cord-005478-5iu38pr6	2732	17	retrospective	retrospective	JJ
cord-005478-5iu38pr6	2732	18	analysis	analysis	NN
cord-005478-5iu38pr6	2732	19	on	on	IN
cord-005478-5iu38pr6	2732	20	behalf	behalf	NN
cord-005478-5iu38pr6	2732	21	of	of	IN
cord-005478-5iu38pr6	2732	22	IDWP	IDWP	NNP
cord-005478-5iu38pr6	2732	23	Background	Background	NNP
cord-005478-5iu38pr6	2732	24	:	:	:
cord-005478-5iu38pr6	2732	25	Kaposi	Kaposi	NNP
cord-005478-5iu38pr6	2732	26	's	's	POS
cord-005478-5iu38pr6	2732	27	sarcoma	sarcoma	NN
cord-005478-5iu38pr6	2732	28	(	(	-LRB-
cord-005478-5iu38pr6	2732	29	KS	KS	NNP
cord-005478-5iu38pr6	2732	30	)	)	-RRB-
cord-005478-5iu38pr6	2732	31	is	be	VBZ
cord-005478-5iu38pr6	2732	32	an	an	DT
cord-005478-5iu38pr6	2732	33	angioprolipherative	angioprolipherative	JJ
cord-005478-5iu38pr6	2732	34	disease	disease	NN
cord-005478-5iu38pr6	2732	35	which	which	WDT
cord-005478-5iu38pr6	2732	36	occurs	occur	VBZ
cord-005478-5iu38pr6	2732	37	in	in	IN
cord-005478-5iu38pr6	2732	38	immunosuppressed	immunosuppressed	JJ
cord-005478-5iu38pr6	2732	39	patients	patient	NNS
cord-005478-5iu38pr6	2732	40	,	,	,
cord-005478-5iu38pr6	2732	41	often	often	RB
cord-005478-5iu38pr6	2732	42	associated	associate	VBN
cord-005478-5iu38pr6	2732	43	with	with	IN
cord-005478-5iu38pr6	2732	44	infection	infection	NN
cord-005478-5iu38pr6	2732	45	by	by	IN
cord-005478-5iu38pr6	2732	46	Human	Human	NNP
cord-005478-5iu38pr6	2732	47	Herpes	Herpes	NNP
cord-005478-5iu38pr6	2732	48	.	.	.
cord-005478-5iu38pr6	2733	1	In	in	IN
cord-005478-5iu38pr6	2733	2	solid	solid	JJ
cord-005478-5iu38pr6	2733	3	organ	organ	NN
cord-005478-5iu38pr6	2733	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2733	5	(	(	-LRB-
cord-005478-5iu38pr6	2733	6	SOT	SOT	NNP
cord-005478-5iu38pr6	2733	7	)	)	-RRB-
cord-005478-5iu38pr6	2733	8	KS	KS	NNP
cord-005478-5iu38pr6	2733	9	is	be	VBZ
cord-005478-5iu38pr6	2733	10	relatively	relatively	RB
cord-005478-5iu38pr6	2733	11	common	common	JJ
cord-005478-5iu38pr6	2733	12	,	,	,
cord-005478-5iu38pr6	2733	13	the	the	DT
cord-005478-5iu38pr6	2733	14	risk	risk	NN
cord-005478-5iu38pr6	2733	15	being	be	VBG
cord-005478-5iu38pr6	2733	16	60	60	CD
cord-005478-5iu38pr6	2733	17	-	-	SYM
cord-005478-5iu38pr6	2733	18	500	500	CD
cord-005478-5iu38pr6	2733	19	folds	fold	NNS
cord-005478-5iu38pr6	2733	20	higher	high	JJR
cord-005478-5iu38pr6	2733	21	than	than	IN
cord-005478-5iu38pr6	2733	22	that	that	DT
cord-005478-5iu38pr6	2733	23	of	of	IN
cord-005478-5iu38pr6	2733	24	general	general	JJ
cord-005478-5iu38pr6	2733	25	population	population	NN
cord-005478-5iu38pr6	2733	26	and	and	CC
cord-005478-5iu38pr6	2733	27	representing	represent	VBG
cord-005478-5iu38pr6	2733	28	around	around	IN
cord-005478-5iu38pr6	2733	29	23	23	CD
cord-005478-5iu38pr6	2733	30	%	%	NN
cord-005478-5iu38pr6	2733	31	of	of	IN
cord-005478-5iu38pr6	2733	32	secondary	secondary	JJ
cord-005478-5iu38pr6	2733	33	cancers	cancer	NNS
cord-005478-5iu38pr6	2733	34	.	.	.
cord-005478-5iu38pr6	2734	1	Also	also	RB
cord-005478-5iu38pr6	2734	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2734	3	stem	stem	NN
cord-005478-5iu38pr6	2734	4	cell	cell	NN
cord-005478-5iu38pr6	2734	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	2734	6	(	(	-LRB-
cord-005478-5iu38pr6	2734	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2734	8	)	)	-RRB-
cord-005478-5iu38pr6	2734	9	is	be	VBZ
cord-005478-5iu38pr6	2734	10	a	a	DT
cord-005478-5iu38pr6	2734	11	risk	risk	NN
cord-005478-5iu38pr6	2734	12	factor	factor	NN
cord-005478-5iu38pr6	2734	13	for	for	IN
cord-005478-5iu38pr6	2734	14	the	the	DT
cord-005478-5iu38pr6	2734	15	development	development	NN
cord-005478-5iu38pr6	2734	16	of	of	IN
cord-005478-5iu38pr6	2734	17	KS	KS	NNP
cord-005478-5iu38pr6	2734	18	but	but	CC
cord-005478-5iu38pr6	2734	19	until	until	IN
cord-005478-5iu38pr6	2734	20	now	now	RB
cord-005478-5iu38pr6	2734	21	only	only	RB
cord-005478-5iu38pr6	2734	22	few	few	JJ
cord-005478-5iu38pr6	2734	23	case	case	NN
cord-005478-5iu38pr6	2734	24	reports	report	NNS
cord-005478-5iu38pr6	2734	25	were	be	VBD
cord-005478-5iu38pr6	2734	26	published	publish	VBN
cord-005478-5iu38pr6	2734	27	.	.	.
cord-005478-5iu38pr6	2735	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2735	2	assessed	assess	VBD
cord-005478-5iu38pr6	2735	3	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	2735	4	the	the	DT
cord-005478-5iu38pr6	2735	5	incidence	incidence	NN
cord-005478-5iu38pr6	2735	6	,	,	,
cord-005478-5iu38pr6	2735	7	the	the	DT
cord-005478-5iu38pr6	2735	8	clinical	clinical	JJ
cord-005478-5iu38pr6	2735	9	characteristics	characteristic	NNS
cord-005478-5iu38pr6	2735	10	,	,	,
cord-005478-5iu38pr6	2735	11	and	and	CC
cord-005478-5iu38pr6	2735	12	the	the	DT
cord-005478-5iu38pr6	2735	13	outcome	outcome	NN
cord-005478-5iu38pr6	2735	14	of	of	IN
cord-005478-5iu38pr6	2735	15	KS	KS	NNP
cord-005478-5iu38pr6	2735	16	in	in	IN
cord-005478-5iu38pr6	2735	17	the	the	DT
cord-005478-5iu38pr6	2735	18	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2735	19	database	database	NN
cord-005478-5iu38pr6	2735	20	.	.	.
cord-005478-5iu38pr6	2736	1	Methods	method	NNS
cord-005478-5iu38pr6	2736	2	:	:	:
cord-005478-5iu38pr6	2736	3	The	the	DT
cord-005478-5iu38pr6	2736	4	cases	case	NNS
cord-005478-5iu38pr6	2736	5	of	of	IN
cord-005478-5iu38pr6	2736	6	KS	KS	NNP
cord-005478-5iu38pr6	2736	7	were	be	VBD
cord-005478-5iu38pr6	2736	8	identified	identify	VBN
cord-005478-5iu38pr6	2736	9	by	by	IN
cord-005478-5iu38pr6	2736	10	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2736	11	registry	registry	NN
cord-005478-5iu38pr6	2736	12	(	(	-LRB-
cord-005478-5iu38pr6	2736	13	ProMISe	promise	NN
cord-005478-5iu38pr6	2736	14	)	)	-RRB-
cord-005478-5iu38pr6	2736	15	and	and	CC
cord-005478-5iu38pr6	2736	16	by	by	IN
cord-005478-5iu38pr6	2736	17	inviting	invite	VBG
cord-005478-5iu38pr6	2736	18	all	all	DT
cord-005478-5iu38pr6	2736	19	569	569	CD
cord-005478-5iu38pr6	2736	20	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2736	21	centers	center	NNS
cord-005478-5iu38pr6	2736	22	to	to	TO
cord-005478-5iu38pr6	2736	23	notify	notify	VB
cord-005478-5iu38pr6	2736	24	KS	KS	NNP
cord-005478-5iu38pr6	2736	25	cases	case	NNS
cord-005478-5iu38pr6	2736	26	.	.	.
cord-005478-5iu38pr6	2737	1	The	the	DT
cord-005478-5iu38pr6	2737	2	clinical	clinical	JJ
cord-005478-5iu38pr6	2737	3	features	feature	NNS
cord-005478-5iu38pr6	2737	4	,	,	,
cord-005478-5iu38pr6	2737	5	type	type	NN
cord-005478-5iu38pr6	2737	6	of	of	IN
cord-005478-5iu38pr6	2737	7	therapy	therapy	NN
cord-005478-5iu38pr6	2737	8	,	,	,
cord-005478-5iu38pr6	2737	9	survival	survival	NN
cord-005478-5iu38pr6	2737	10	rate	rate	NN
cord-005478-5iu38pr6	2737	11	and	and	CC
cord-005478-5iu38pr6	2737	12	causes	cause	NNS
cord-005478-5iu38pr6	2737	13	of	of	IN
cord-005478-5iu38pr6	2737	14	death	death	NN
cord-005478-5iu38pr6	2737	15	were	be	VBD
cord-005478-5iu38pr6	2737	16	retrieved	retrieve	VBN
cord-005478-5iu38pr6	2737	17	from	from	IN
cord-005478-5iu38pr6	2737	18	of	of	IN
cord-005478-5iu38pr6	2737	19	ProMise	ProMise	NNP
cord-005478-5iu38pr6	2737	20	or	or	CC
cord-005478-5iu38pr6	2737	21	,	,	,
cord-005478-5iu38pr6	2737	22	if	if	IN
cord-005478-5iu38pr6	2737	23	lacking	lack	VBG
cord-005478-5iu38pr6	2737	24	,	,	,
cord-005478-5iu38pr6	2737	25	by	by	IN
cord-005478-5iu38pr6	2737	26	specific	specific	JJ
cord-005478-5iu38pr6	2737	27	case	case	NN
cord-005478-5iu38pr6	2737	28	report	report	NN
cord-005478-5iu38pr6	2737	29	form	form	NN
cord-005478-5iu38pr6	2737	30	sent	send	VBN
cord-005478-5iu38pr6	2737	31	to	to	IN
cord-005478-5iu38pr6	2737	32	participating	participate	VBG
cord-005478-5iu38pr6	2737	33	centers	center	NNS
cord-005478-5iu38pr6	2737	34	.	.	.
cord-005478-5iu38pr6	2738	1	The	the	DT
cord-005478-5iu38pr6	2738	2	center	center	NN
cord-005478-5iu38pr6	2738	3	response	response	NN
cord-005478-5iu38pr6	2738	4	rate	rate	NN
cord-005478-5iu38pr6	2738	5	was	be	VBD
cord-005478-5iu38pr6	2738	6	74/	74/	CD
cord-005478-5iu38pr6	2738	7	569	569	CD
cord-005478-5iu38pr6	2738	8	(	(	-LRB-
cord-005478-5iu38pr6	2738	9	13	13	CD
cord-005478-5iu38pr6	2738	10	%	%	NN
cord-005478-5iu38pr6	2738	11	)	)	-RRB-
cord-005478-5iu38pr6	2738	12	.	.	.
cord-005478-5iu38pr6	2739	1	Results	result	NNS
cord-005478-5iu38pr6	2739	2	:	:	:
cord-005478-5iu38pr6	2740	1	Fourteen	fourteen	CD
cord-005478-5iu38pr6	2740	2	centers	center	NNS
cord-005478-5iu38pr6	2740	3	reported	report	VBD
cord-005478-5iu38pr6	2740	4	17	17	CD
cord-005478-5iu38pr6	2740	5	patients	patient	NNS
cord-005478-5iu38pr6	2740	6	with	with	IN
cord-005478-5iu38pr6	2740	7	KS	KS	NNP
cord-005478-5iu38pr6	2740	8	,	,	,
cord-005478-5iu38pr6	2740	9	all	all	DT
cord-005478-5iu38pr6	2740	10	KS	KS	NNP
cord-005478-5iu38pr6	2740	11	were	be	VBD
cord-005478-5iu38pr6	2740	12	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	2740	13	from	from	IN
cord-005478-5iu38pr6	2740	14	2004	2004	CD
cord-005478-5iu38pr6	2740	15	to	to	IN
cord-005478-5iu38pr6	2740	16	2017	2017	CD
cord-005478-5iu38pr6	2740	17	,	,	,
cord-005478-5iu38pr6	2740	18	but	but	CC
cord-005478-5iu38pr6	2740	19	one	one	CD
cord-005478-5iu38pr6	2740	20	case	case	NN
cord-005478-5iu38pr6	2740	21	that	that	WDT
cord-005478-5iu38pr6	2740	22	was	be	VBD
cord-005478-5iu38pr6	2740	23	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	2740	24	in	in	IN
cord-005478-5iu38pr6	2740	25	1987	1987	CD
cord-005478-5iu38pr6	2740	26	.	.	.
cord-005478-5iu38pr6	2741	1	The	the	DT
cord-005478-5iu38pr6	2741	2	analysis	analysis	NN
cord-005478-5iu38pr6	2741	3	was	be	VBD
cord-005478-5iu38pr6	2741	4	limited	limit	VBN
cord-005478-5iu38pr6	2741	5	to	to	IN
cord-005478-5iu38pr6	2741	6	13/17	13/17	CD
cord-005478-5iu38pr6	2741	7	patients	patient	NNS
cord-005478-5iu38pr6	2741	8	because	because	IN
cord-005478-5iu38pr6	2741	9	KS	KS	NNP
cord-005478-5iu38pr6	2741	10	was	be	VBD
cord-005478-5iu38pr6	2741	11	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	2741	12	before	before	IN
cord-005478-5iu38pr6	2741	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2741	14	in	in	IN
cord-005478-5iu38pr6	2741	15	4	4	CD
cord-005478-5iu38pr6	2741	16	patients	patient	NNS
cord-005478-5iu38pr6	2741	17	:	:	:
cord-005478-5iu38pr6	2741	18	they	-PRON-	PRP
cord-005478-5iu38pr6	2741	19	were	be	VBD
cord-005478-5iu38pr6	2741	20	13	13	CD
cord-005478-5iu38pr6	2741	21	patients	patient	NNS
cord-005478-5iu38pr6	2741	22	,	,	,
cord-005478-5iu38pr6	2741	23	3	3	CD
cord-005478-5iu38pr6	2741	24	females	female	NNS
cord-005478-5iu38pr6	2741	25	and	and	CC
cord-005478-5iu38pr6	2741	26	10	10	CD
cord-005478-5iu38pr6	2741	27	males	male	NNS
cord-005478-5iu38pr6	2741	28	who	who	WP
cord-005478-5iu38pr6	2741	29	developed	develop	VBD
cord-005478-5iu38pr6	2741	30	KS	KS	NNP
cord-005478-5iu38pr6	2741	31	after	after	IN
cord-005478-5iu38pr6	2741	32	allo	allo	NNP
cord-005478-5iu38pr6	2741	33	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2741	34	(	(	-LRB-
cord-005478-5iu38pr6	2741	35	10	10	CD
cord-005478-5iu38pr6	2741	36	)	)	-RRB-
cord-005478-5iu38pr6	2741	37	and	and	CC
cord-005478-5iu38pr6	2741	38	auto	auto	NN
cord-005478-5iu38pr6	2741	39	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2741	40	(	(	-LRB-
cord-005478-5iu38pr6	2741	41	3	3	CD
cord-005478-5iu38pr6	2741	42	)	)	-RRB-
cord-005478-5iu38pr6	2741	43	;	;	:
cord-005478-5iu38pr6	2741	44	moreover	moreover	RB
cord-005478-5iu38pr6	2741	45	,	,	,
cord-005478-5iu38pr6	2741	46	KS	KS	NNP
cord-005478-5iu38pr6	2741	47	occurred	occur	VBD
cord-005478-5iu38pr6	2741	48	after	after	IN
cord-005478-5iu38pr6	2741	49	a	a	DT
cord-005478-5iu38pr6	2741	50	second	second	JJ
cord-005478-5iu38pr6	2741	51	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2741	52	in	in	IN
cord-005478-5iu38pr6	2741	53	2	2	CD
cord-005478-5iu38pr6	2741	54	patients	patient	NNS
cord-005478-5iu38pr6	2741	55	and	and	CC
cord-005478-5iu38pr6	2741	56	after	after	IN
cord-005478-5iu38pr6	2741	57	a	a	DT
cord-005478-5iu38pr6	2741	58	third	third	JJ
cord-005478-5iu38pr6	2741	59	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2741	60	in	in	IN
cord-005478-5iu38pr6	2741	61	1	1	CD
cord-005478-5iu38pr6	2741	62	patient	patient	NN
cord-005478-5iu38pr6	2741	63	.	.	.
cord-005478-5iu38pr6	2742	1	The	the	DT
cord-005478-5iu38pr6	2742	2	search	search	NN
cord-005478-5iu38pr6	2742	3	of	of	IN
cord-005478-5iu38pr6	2742	4	HHV8	HHV8	NNP
cord-005478-5iu38pr6	2742	5	in	in	IN
cord-005478-5iu38pr6	2742	6	tumour	tumour	NN
cord-005478-5iu38pr6	2742	7	tissue	tissue	NN
cord-005478-5iu38pr6	2742	8	was	be	VBD
cord-005478-5iu38pr6	2742	9	done	do	VBN
cord-005478-5iu38pr6	2742	10	in	in	IN
cord-005478-5iu38pr6	2742	11	9	9	CD
cord-005478-5iu38pr6	2742	12	cases	case	NNS
cord-005478-5iu38pr6	2742	13	and	and	CC
cord-005478-5iu38pr6	2742	14	resulted	result	VBD
cord-005478-5iu38pr6	2742	15	positive	positive	JJ
cord-005478-5iu38pr6	2742	16	in	in	IN
cord-005478-5iu38pr6	2742	17	8/	8/	CD
cord-005478-5iu38pr6	2742	18	9	9	CD
cord-005478-5iu38pr6	2742	19	.	.	.
cord-005478-5iu38pr6	2743	1	The	the	DT
cord-005478-5iu38pr6	2743	2	underlying	underlie	VBG
cord-005478-5iu38pr6	2743	3	disease	disease	NN
cord-005478-5iu38pr6	2743	4	were	be	VBD
cord-005478-5iu38pr6	2743	5	:	:	:
cord-005478-5iu38pr6	2743	6	46	46	CD
cord-005478-5iu38pr6	2743	7	%	%	NN
cord-005478-5iu38pr6	2743	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	2743	9	,	,	,
cord-005478-5iu38pr6	2743	10	23	23	CD
cord-005478-5iu38pr6	2743	11	%	%	NN
cord-005478-5iu38pr6	2743	12	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2743	13	,	,	,
cord-005478-5iu38pr6	2743	14	15	15	CD
cord-005478-5iu38pr6	2743	15	%	%	NN
cord-005478-5iu38pr6	2743	16	myeloma	myeloma	NN
cord-005478-5iu38pr6	2743	17	,	,	,
cord-005478-5iu38pr6	2743	18	8	8	CD
cord-005478-5iu38pr6	2743	19	%	%	NN
cord-005478-5iu38pr6	2743	20	myelodysplastic	myelodysplastic	JJ
cord-005478-5iu38pr6	2743	21	syndrome	syndrome	NN
cord-005478-5iu38pr6	2743	22	(	(	-LRB-
cord-005478-5iu38pr6	2743	23	MDS	MDS	NNP
cord-005478-5iu38pr6	2743	24	)	)	-RRB-
cord-005478-5iu38pr6	2743	25	,	,	,
cord-005478-5iu38pr6	2743	26	8	8	CD
cord-005478-5iu38pr6	2743	27	%	%	NN
cord-005478-5iu38pr6	2743	28	bone	bone	NN
cord-005478-5iu38pr6	2743	29	marrow	marrow	NN
cord-005478-5iu38pr6	2743	30	failure	failure	NN
cord-005478-5iu38pr6	2743	31	.	.	.
cord-005478-5iu38pr6	2744	1	The	the	DT
cord-005478-5iu38pr6	2744	2	source	source	NN
cord-005478-5iu38pr6	2744	3	of	of	IN
cord-005478-5iu38pr6	2744	4	stem	stem	NN
cord-005478-5iu38pr6	2744	5	cells	cell	NNS
cord-005478-5iu38pr6	2744	6	was	be	VBD
cord-005478-5iu38pr6	2744	7	bone	bone	NN
cord-005478-5iu38pr6	2744	8	marrow	marrow	NN
cord-005478-5iu38pr6	2744	9	in	in	IN
cord-005478-5iu38pr6	2744	10	4	4	CD
cord-005478-5iu38pr6	2744	11	patients	patient	NNS
cord-005478-5iu38pr6	2744	12	(	(	-LRB-
cord-005478-5iu38pr6	2744	13	31	31	CD
cord-005478-5iu38pr6	2744	14	%	%	NN
cord-005478-5iu38pr6	2744	15	)	)	-RRB-
cord-005478-5iu38pr6	2744	16	and	and	CC
cord-005478-5iu38pr6	2744	17	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2744	18	blood	blood	NN
cord-005478-5iu38pr6	2744	19	in	in	IN
cord-005478-5iu38pr6	2744	20	9	9	CD
cord-005478-5iu38pr6	2744	21	patients	patient	NNS
cord-005478-5iu38pr6	2744	22	(	(	-LRB-
cord-005478-5iu38pr6	2744	23	69	69	CD
cord-005478-5iu38pr6	2744	24	%	%	NN
cord-005478-5iu38pr6	2744	25	)	)	-RRB-
cord-005478-5iu38pr6	2744	26	.	.	.
cord-005478-5iu38pr6	2745	1	The	the	DT
cord-005478-5iu38pr6	2745	2	median	median	JJ
cord-005478-5iu38pr6	2745	3	age	age	NN
cord-005478-5iu38pr6	2745	4	at	at	IN
cord-005478-5iu38pr6	2745	5	KS	KS	NNP
cord-005478-5iu38pr6	2745	6	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2745	7	was	be	VBD
cord-005478-5iu38pr6	2745	8	49.7	49.7	CD
cord-005478-5iu38pr6	2745	9	years	year	NNS
cord-005478-5iu38pr6	2746	1	(	(	-LRB-
cord-005478-5iu38pr6	2746	2	range	range	NNP
cord-005478-5iu38pr6	2746	3	6	6	CD
cord-005478-5iu38pr6	2746	4	.	.	.
cord-005478-5iu38pr6	2747	1	3	3	LS
cord-005478-5iu38pr6	2747	2	-	-	SYM
cord-005478-5iu38pr6	2747	3	61.4	61.4	CD
cord-005478-5iu38pr6	2747	4	)	)	-RRB-
cord-005478-5iu38pr6	2747	5	.	.	.
cord-005478-5iu38pr6	2748	1	Considering	consider	VBG
cord-005478-5iu38pr6	2748	2	the	the	DT
cord-005478-5iu38pr6	2748	3	number	number	NN
cord-005478-5iu38pr6	2748	4	of	of	IN
cord-005478-5iu38pr6	2748	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2748	6	performed	perform	VBN
cord-005478-5iu38pr6	2748	7	in	in	IN
cord-005478-5iu38pr6	2748	8	the	the	DT
cord-005478-5iu38pr6	2748	9	participating	participate	VBG
cord-005478-5iu38pr6	2748	10	center	center	NN
cord-005478-5iu38pr6	2748	11	from	from	IN
cord-005478-5iu38pr6	2748	12	2004	2004	CD
cord-005478-5iu38pr6	2748	13	to	to	IN
cord-005478-5iu38pr6	2748	14	2017	2017	CD
cord-005478-5iu38pr6	2748	15	,	,	,
cord-005478-5iu38pr6	2748	16	the	the	DT
cord-005478-5iu38pr6	2748	17	incidence	incidence	NN
cord-005478-5iu38pr6	2748	18	rate	rate	NN
cord-005478-5iu38pr6	2748	19	was	be	VBD
cord-005478-5iu38pr6	2748	20	0.17	0.17	CD
cord-005478-5iu38pr6	2748	21	%	%	NN
cord-005478-5iu38pr6	2748	22	in	in	IN
cord-005478-5iu38pr6	2748	23	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2748	24	transplantations	transplantation	NNS
cord-005478-5iu38pr6	2748	25	(	(	-LRB-
cord-005478-5iu38pr6	2748	26	9/5345	9/5345	NNP
cord-005478-5iu38pr6	2748	27	)	)	-RRB-
cord-005478-5iu38pr6	2748	28	,	,	,
cord-005478-5iu38pr6	2748	29	0.05	0.05	CD
cord-005478-5iu38pr6	2748	30	%	%	NN
cord-005478-5iu38pr6	2748	31	in	in	IN
cord-005478-5iu38pr6	2748	32	autologous	autologous	JJ
cord-005478-5iu38pr6	2748	33	transplantations	transplantation	NNS
cord-005478-5iu38pr6	2748	34	(	(	-LRB-
cord-005478-5iu38pr6	2748	35	3/5857	3/5857	NNP
cord-005478-5iu38pr6	2748	36	)	)	-RRB-
cord-005478-5iu38pr6	2748	37	and	and	CC
cord-005478-5iu38pr6	2748	38	0.11	0.11	CD
cord-005478-5iu38pr6	2748	39	%	%	NN
cord-005478-5iu38pr6	2748	40	(	(	-LRB-
cord-005478-5iu38pr6	2748	41	12/11202	12/11202	CD
cord-005478-5iu38pr6	2748	42	)	)	-RRB-
cord-005478-5iu38pr6	2748	43	in	in	IN
cord-005478-5iu38pr6	2748	44	the	the	DT
cord-005478-5iu38pr6	2748	45	whole	whole	JJ
cord-005478-5iu38pr6	2748	46	group	group	NN
cord-005478-5iu38pr6	2748	47	.	.	.
cord-005478-5iu38pr6	2749	1	The	the	DT
cord-005478-5iu38pr6	2749	2	interval	interval	NN
cord-005478-5iu38pr6	2749	3	of	of	IN
cord-005478-5iu38pr6	2749	4	time	time	NN
cord-005478-5iu38pr6	2749	5	between	between	IN
cord-005478-5iu38pr6	2749	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2749	7	and	and	CC
cord-005478-5iu38pr6	2749	8	the	the	DT
cord-005478-5iu38pr6	2749	9	development	development	NN
cord-005478-5iu38pr6	2749	10	of	of	IN
cord-005478-5iu38pr6	2749	11	KS	KS	NNP
cord-005478-5iu38pr6	2749	12	was	be	VBD
cord-005478-5iu38pr6	2749	13	7	7	CD
cord-005478-5iu38pr6	2749	14	months	month	NNS
cord-005478-5iu38pr6	2749	15	(	(	-LRB-
cord-005478-5iu38pr6	2749	16	range	range	VBP
cord-005478-5iu38pr6	2749	17	-0	-0	NNP
cord-005478-5iu38pr6	2749	18	.	.	.
cord-005478-5iu38pr6	2750	1	3	3	LS
cord-005478-5iu38pr6	2750	2	-	-	SYM
cord-005478-5iu38pr6	2750	3	61.2	61.2	CD
cord-005478-5iu38pr6	2750	4	)	)	-RRB-
cord-005478-5iu38pr6	2750	5	.	.	.
cord-005478-5iu38pr6	2751	1	The	the	DT
cord-005478-5iu38pr6	2751	2	organ	organ	NN
cord-005478-5iu38pr6	2751	3	involvement	involvement	NN
cord-005478-5iu38pr6	2751	4	was	be	VBD
cord-005478-5iu38pr6	2751	5	:	:	:
cord-005478-5iu38pr6	2751	6	62	62	CD
cord-005478-5iu38pr6	2751	7	%	%	NN
cord-005478-5iu38pr6	2751	8	skin	skin	NN
cord-005478-5iu38pr6	2751	9	(	(	-LRB-
cord-005478-5iu38pr6	2751	10	8	8	CD
cord-005478-5iu38pr6	2751	11	patients	patient	NNS
cord-005478-5iu38pr6	2751	12	)	)	-RRB-
cord-005478-5iu38pr6	2751	13	,	,	,
cord-005478-5iu38pr6	2751	14	31	31	CD
cord-005478-5iu38pr6	2751	15	%	%	NN
cord-005478-5iu38pr6	2751	16	lymph	lymph	NN
cord-005478-5iu38pr6	2751	17	nodes	node	NNS
cord-005478-5iu38pr6	2751	18	(	(	-LRB-
cord-005478-5iu38pr6	2751	19	4	4	CD
cord-005478-5iu38pr6	2751	20	)	)	-RRB-
cord-005478-5iu38pr6	2751	21	,	,	,
cord-005478-5iu38pr6	2751	22	8	8	CD
cord-005478-5iu38pr6	2751	23	%	%	NN
cord-005478-5iu38pr6	2751	24	gingival	gingival	NN
cord-005478-5iu38pr6	2751	25	(	(	-LRB-
cord-005478-5iu38pr6	2751	26	1	1	CD
cord-005478-5iu38pr6	2751	27	)	)	-RRB-
cord-005478-5iu38pr6	2751	28	.	.	.
cord-005478-5iu38pr6	2752	1	Apart	apart	RB
cord-005478-5iu38pr6	2752	2	from	from	IN
cord-005478-5iu38pr6	2752	3	withdrawal	withdrawal	NN
cord-005478-5iu38pr6	2752	4	of	of	IN
cord-005478-5iu38pr6	2752	5	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	2752	6	,	,	,
cord-005478-5iu38pr6	2752	7	2	2	CD
cord-005478-5iu38pr6	2752	8	patients	patient	NNS
cord-005478-5iu38pr6	2752	9	received	receive	VBD
cord-005478-5iu38pr6	2752	10	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2752	11	,	,	,
cord-005478-5iu38pr6	2752	12	3	3	CD
cord-005478-5iu38pr6	2752	13	patients	patient	NNS
cord-005478-5iu38pr6	2752	14	received	receive	VBD
cord-005478-5iu38pr6	2752	15	radiotherapy	radiotherapy	NN
cord-005478-5iu38pr6	2752	16	,	,	,
cord-005478-5iu38pr6	2752	17	and	and	CC
cord-005478-5iu38pr6	2752	18	1	1	CD
cord-005478-5iu38pr6	2752	19	patient	patient	NN
cord-005478-5iu38pr6	2752	20	received	receive	VBD
cord-005478-5iu38pr6	2752	21	radio	radio	NN
cord-005478-5iu38pr6	2752	22	and	and	CC
cord-005478-5iu38pr6	2752	23	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2752	24	;	;	:
cord-005478-5iu38pr6	2752	25	moreover	moreover	RB
cord-005478-5iu38pr6	2752	26	5	5	CD
cord-005478-5iu38pr6	2752	27	patients	patient	NNS
cord-005478-5iu38pr6	2752	28	received	receive	VBD
cord-005478-5iu38pr6	2752	29	antiviral	antiviral	JJ
cord-005478-5iu38pr6	2752	30	treatment	treatment	NN
cord-005478-5iu38pr6	2752	31	with	with	IN
cord-005478-5iu38pr6	2752	32	ganciclovir	ganciclovir	NNP
cord-005478-5iu38pr6	2752	33	or	or	CC
cord-005478-5iu38pr6	2752	34	foscarnet	foscarnet	NN
cord-005478-5iu38pr6	2752	35	.	.	.
cord-005478-5iu38pr6	2753	1	Eight	eight	CD
cord-005478-5iu38pr6	2753	2	patients	patient	NNS
cord-005478-5iu38pr6	2753	3	(	(	-LRB-
cord-005478-5iu38pr6	2753	4	62	62	CD
cord-005478-5iu38pr6	2753	5	%	%	NN
cord-005478-5iu38pr6	2753	6	)	)	-RRB-
cord-005478-5iu38pr6	2753	7	are	be	VBP
cord-005478-5iu38pr6	2753	8	alive	alive	JJ
cord-005478-5iu38pr6	2753	9	whereas	whereas	IN
cord-005478-5iu38pr6	2753	10	5	5	CD
cord-005478-5iu38pr6	2753	11	patients	patient	NNS
cord-005478-5iu38pr6	2753	12	(	(	-LRB-
cord-005478-5iu38pr6	2753	13	38	38	CD
cord-005478-5iu38pr6	2753	14	%	%	NN
cord-005478-5iu38pr6	2753	15	)	)	-RRB-
cord-005478-5iu38pr6	2753	16	died	die	VBD
cord-005478-5iu38pr6	2753	17	at	at	IN
cord-005478-5iu38pr6	2753	18	a	a	DT
cord-005478-5iu38pr6	2753	19	median	median	JJ
cord-005478-5iu38pr6	2753	20	time	time	NN
cord-005478-5iu38pr6	2753	21	of	of	IN
cord-005478-5iu38pr6	2753	22	8.1	8.1	CD
cord-005478-5iu38pr6	2753	23	months	month	NNS
cord-005478-5iu38pr6	2753	24	,	,	,
cord-005478-5iu38pr6	2753	25	range	range	VBP
cord-005478-5iu38pr6	2753	26	0.5	0.5	CD
cord-005478-5iu38pr6	2753	27	-	-	HYPH
cord-005478-5iu38pr6	2753	28	12.3	12.3	CD
cord-005478-5iu38pr6	2753	29	.	.	.
cord-005478-5iu38pr6	2754	1	The	the	DT
cord-005478-5iu38pr6	2754	2	causes	cause	NNS
cord-005478-5iu38pr6	2754	3	of	of	IN
cord-005478-5iu38pr6	2754	4	death	death	NN
cord-005478-5iu38pr6	2754	5	were	be	VBD
cord-005478-5iu38pr6	2754	6	infection	infection	NN
cord-005478-5iu38pr6	2754	7	in	in	IN
cord-005478-5iu38pr6	2754	8	2	2	CD
cord-005478-5iu38pr6	2754	9	cases	case	NNS
cord-005478-5iu38pr6	2754	10	,	,	,
cord-005478-5iu38pr6	2754	11	secondary	secondary	JJ
cord-005478-5iu38pr6	2754	12	malignancy	malignancy	NN
cord-005478-5iu38pr6	2754	13	/	/	SYM
cord-005478-5iu38pr6	2754	14	PTLD	PTLD	NNP
cord-005478-5iu38pr6	2754	15	in	in	IN
cord-005478-5iu38pr6	2754	16	2	2	CD
cord-005478-5iu38pr6	2754	17	and	and	CC
cord-005478-5iu38pr6	2754	18	relapse	relapse	NN
cord-005478-5iu38pr6	2754	19	/	/	SYM
cord-005478-5iu38pr6	2754	20	progression	progression	NN
cord-005478-5iu38pr6	2754	21	in	in	IN
cord-005478-5iu38pr6	2754	22	1	1	CD
cord-005478-5iu38pr6	2754	23	whereas	whereas	IN
cord-005478-5iu38pr6	2754	24	no	no	DT
cord-005478-5iu38pr6	2754	25	case	case	NN
cord-005478-5iu38pr6	2754	26	of	of	IN
cord-005478-5iu38pr6	2754	27	death	death	NN
cord-005478-5iu38pr6	2754	28	directly	directly	RB
cord-005478-5iu38pr6	2754	29	associated	associate	VBN
cord-005478-5iu38pr6	2754	30	to	to	IN
cord-005478-5iu38pr6	2754	31	KS	KS	NNP
cord-005478-5iu38pr6	2754	32	.	.	.
cord-005478-5iu38pr6	2755	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2755	2	:	:	:
cord-005478-5iu38pr6	2756	1	KS	KS	NNP
cord-005478-5iu38pr6	2756	2	is	be	VBZ
cord-005478-5iu38pr6	2756	3	a	a	DT
cord-005478-5iu38pr6	2756	4	rare	rare	JJ
cord-005478-5iu38pr6	2756	5	complication	complication	NN
cord-005478-5iu38pr6	2756	6	of	of	IN
cord-005478-5iu38pr6	2756	7	the	the	DT
cord-005478-5iu38pr6	2756	8	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	2756	9	status	status	NN
cord-005478-5iu38pr6	2756	10	related	relate	VBN
cord-005478-5iu38pr6	2756	11	to	to	IN
cord-005478-5iu38pr6	2756	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2756	13	that	that	WDT
cord-005478-5iu38pr6	2756	14	generally	generally	RB
cord-005478-5iu38pr6	2756	15	occurs	occur	VBZ
cord-005478-5iu38pr6	2756	16	within	within	IN
cord-005478-5iu38pr6	2756	17	the	the	DT
cord-005478-5iu38pr6	2756	18	first	first	JJ
cord-005478-5iu38pr6	2756	19	year	year	NN
cord-005478-5iu38pr6	2756	20	after	after	IN
cord-005478-5iu38pr6	2756	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2756	22	.	.	.
cord-005478-5iu38pr6	2757	1	The	the	DT
cord-005478-5iu38pr6	2757	2	low	low	JJ
cord-005478-5iu38pr6	2757	3	prevalence	prevalence	NN
cord-005478-5iu38pr6	2757	4	and	and	CC
cord-005478-5iu38pr6	2757	5	the	the	DT
cord-005478-5iu38pr6	2757	6	rarity	rarity	NN
cord-005478-5iu38pr6	2757	7	of	of	IN
cord-005478-5iu38pr6	2757	8	this	this	DT
cord-005478-5iu38pr6	2757	9	complication	complication	NN
cord-005478-5iu38pr6	2757	10	do	do	VBP
cord-005478-5iu38pr6	2757	11	not	not	RB
cord-005478-5iu38pr6	2757	12	justify	justify	VB
cord-005478-5iu38pr6	2757	13	the	the	DT
cord-005478-5iu38pr6	2757	14	adoption	adoption	NN
cord-005478-5iu38pr6	2757	15	of	of	IN
cord-005478-5iu38pr6	2757	16	screening	screening	NN
cord-005478-5iu38pr6	2757	17	program	program	NN
cord-005478-5iu38pr6	2757	18	for	for	IN
cord-005478-5iu38pr6	2757	19	HHV-8	HHV-8	NNP
cord-005478-5iu38pr6	2757	20	.	.	.
cord-005478-5iu38pr6	2758	1	On	on	IN
cord-005478-5iu38pr6	2758	2	the	the	DT
cord-005478-5iu38pr6	2758	3	other	other	JJ
cord-005478-5iu38pr6	2758	4	hand	hand	NN
cord-005478-5iu38pr6	2758	5	,	,	,
cord-005478-5iu38pr6	2758	6	the	the	DT
cord-005478-5iu38pr6	2758	7	role	role	NN
cord-005478-5iu38pr6	2758	8	of	of	IN
cord-005478-5iu38pr6	2758	9	the	the	DT
cord-005478-5iu38pr6	2758	10	virus	virus	NN
cord-005478-5iu38pr6	2758	11	in	in	IN
cord-005478-5iu38pr6	2758	12	febrile	febrile	JJ
cord-005478-5iu38pr6	2758	13	status	status	NN
cord-005478-5iu38pr6	2758	14	in	in	IN
cord-005478-5iu38pr6	2758	15	immunosuppressed	immunosuppressed	JJ
cord-005478-5iu38pr6	2758	16	patients	patient	NNS
cord-005478-5iu38pr6	2758	17	and	and	CC
cord-005478-5iu38pr6	2758	18	the	the	DT
cord-005478-5iu38pr6	2758	19	risk	risk	NN
cord-005478-5iu38pr6	2758	20	factors	factor	NNS
cord-005478-5iu38pr6	2758	21	for	for	IN
cord-005478-5iu38pr6	2758	22	the	the	DT
cord-005478-5iu38pr6	2758	23	development	development	NN
cord-005478-5iu38pr6	2758	24	of	of	IN
cord-005478-5iu38pr6	2758	25	KS	KS	NNP
cord-005478-5iu38pr6	2758	26	are	be	VBP
cord-005478-5iu38pr6	2758	27	not	not	RB
cord-005478-5iu38pr6	2758	28	well	well	RB
cord-005478-5iu38pr6	2758	29	known	known	JJ
cord-005478-5iu38pr6	2758	30	.	.	.
cord-005478-5iu38pr6	2759	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2759	2	Background	background	NN
cord-005478-5iu38pr6	2759	3	:	:	:
cord-005478-5iu38pr6	2760	1	Autologous	autologous	JJ
cord-005478-5iu38pr6	2760	2	stem	stem	NN
cord-005478-5iu38pr6	2760	3	cell	cell	NN
cord-005478-5iu38pr6	2760	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2760	5	(	(	-LRB-
cord-005478-5iu38pr6	2760	6	auto	auto	NN
cord-005478-5iu38pr6	2760	7	-	-	HYPH
cord-005478-5iu38pr6	2760	8	SCT	SCT	NNP
cord-005478-5iu38pr6	2760	9	)	)	-RRB-
cord-005478-5iu38pr6	2760	10	is	be	VBZ
cord-005478-5iu38pr6	2760	11	considered	consider	VBN
cord-005478-5iu38pr6	2760	12	the	the	DT
cord-005478-5iu38pr6	2760	13	standard	standard	JJ
cord-005478-5iu38pr6	2760	14	treatment	treatment	NN
cord-005478-5iu38pr6	2760	15	for	for	IN
cord-005478-5iu38pr6	2760	16	patients	patient	NNS
cord-005478-5iu38pr6	2760	17	with	with	IN
cord-005478-5iu38pr6	2760	18	relapsed	relapsed	JJ
cord-005478-5iu38pr6	2760	19	or	or	CC
cord-005478-5iu38pr6	2760	20	refractory	refractory	JJ
cord-005478-5iu38pr6	2760	21	(	(	-LRB-
cord-005478-5iu38pr6	2760	22	R	r	NN
cord-005478-5iu38pr6	2760	23	/	/	SYM
cord-005478-5iu38pr6	2760	24	R	r	NN
cord-005478-5iu38pr6	2760	25	)	)	-RRB-
cord-005478-5iu38pr6	2760	26	Hodgkin	Hodgkin	NNP
cord-005478-5iu38pr6	2760	27	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2760	28	(	(	-LRB-
cord-005478-5iu38pr6	2760	29	HL	HL	NNP
cord-005478-5iu38pr6	2760	30	)	)	-RRB-
cord-005478-5iu38pr6	2760	31	.	.	.
cord-005478-5iu38pr6	2761	1	For	for	IN
cord-005478-5iu38pr6	2761	2	those	those	DT
cord-005478-5iu38pr6	2761	3	with	with	IN
cord-005478-5iu38pr6	2761	4	high	high	JJ
cord-005478-5iu38pr6	2761	5	-	-	HYPH
cord-005478-5iu38pr6	2761	6	risk	risk	NN
cord-005478-5iu38pr6	2761	7	disease	disease	NN
cord-005478-5iu38pr6	2761	8	,	,	,
cord-005478-5iu38pr6	2761	9	an	an	DT
cord-005478-5iu38pr6	2761	10	alternative	alternative	JJ
cord-005478-5iu38pr6	2761	11	consolidation	consolidation	NN
cord-005478-5iu38pr6	2761	12	strategy	strategy	NN
cord-005478-5iu38pr6	2761	13	with	with	IN
cord-005478-5iu38pr6	2761	14	allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2761	15	SCT	SCT	NNP
cord-005478-5iu38pr6	2761	16	(	(	-LRB-
cord-005478-5iu38pr6	2761	17	allo	allo	NN
cord-005478-5iu38pr6	2761	18	-	-	HYPH
cord-005478-5iu38pr6	2761	19	SCT	SCT	NNP
cord-005478-5iu38pr6	2761	20	)	)	-RRB-
cord-005478-5iu38pr6	2761	21	could	could	MD
cord-005478-5iu38pr6	2761	22	be	be	VB
cord-005478-5iu38pr6	2761	23	a	a	DT
cord-005478-5iu38pr6	2761	24	potential	potential	JJ
cord-005478-5iu38pr6	2761	25	option	option	NN
cord-005478-5iu38pr6	2761	26	to	to	TO
cord-005478-5iu38pr6	2761	27	improve	improve	VB
cord-005478-5iu38pr6	2761	28	the	the	DT
cord-005478-5iu38pr6	2761	29	outcome	outcome	NN
cord-005478-5iu38pr6	2761	30	.	.	.
cord-005478-5iu38pr6	2762	1	However	however	RB
cord-005478-5iu38pr6	2762	2	,	,	,
cord-005478-5iu38pr6	2762	3	allo	allo	NN
cord-005478-5iu38pr6	2762	4	-	-	HYPH
cord-005478-5iu38pr6	2762	5	SCT	SCT	NNP
cord-005478-5iu38pr6	2762	6	with	with	IN
cord-005478-5iu38pr6	2762	7	a	a	DT
cord-005478-5iu38pr6	2762	8	reduced	reduce	VBN
cord-005478-5iu38pr6	2762	9	-	-	HYPH
cord-005478-5iu38pr6	2762	10	intensity	intensity	NN
cord-005478-5iu38pr6	2762	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	2762	12	(	(	-LRB-
cord-005478-5iu38pr6	2762	13	RIC	RIC	NNP
cord-005478-5iu38pr6	2762	14	)	)	-RRB-
cord-005478-5iu38pr6	2762	15	needs	need	VBZ
cord-005478-5iu38pr6	2762	16	around	around	RB
cord-005478-5iu38pr6	2762	17	3	3	CD
cord-005478-5iu38pr6	2762	18	months	month	NNS
cord-005478-5iu38pr6	2762	19	for	for	IN
cord-005478-5iu38pr6	2762	20	the	the	DT
cord-005478-5iu38pr6	2762	21	graft	graft	NN
cord-005478-5iu38pr6	2762	22	-	-	HYPH
cord-005478-5iu38pr6	2762	23	versus	versus	IN
cord-005478-5iu38pr6	2762	24	-	-	HYPH
cord-005478-5iu38pr6	2762	25	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2762	26	effect	effect	NN
cord-005478-5iu38pr6	2762	27	(	(	-LRB-
cord-005478-5iu38pr6	2762	28	GVL	GVL	NNP
cord-005478-5iu38pr6	2762	29	)	)	-RRB-
cord-005478-5iu38pr6	2762	30	to	to	TO
cord-005478-5iu38pr6	2762	31	develop	develop	VB
cord-005478-5iu38pr6	2762	32	,	,	,
cord-005478-5iu38pr6	2762	33	thus	thus	RB
cord-005478-5iu38pr6	2762	34	in	in	IN
cord-005478-5iu38pr6	2762	35	patients	patient	NNS
cord-005478-5iu38pr6	2762	36	with	with	IN
cord-005478-5iu38pr6	2762	37	an	an	DT
cord-005478-5iu38pr6	2762	38	aggressive	aggressive	JJ
cord-005478-5iu38pr6	2762	39	HL	HL	NNP
cord-005478-5iu38pr6	2762	40	the	the	DT
cord-005478-5iu38pr6	2762	41	disease	disease	NN
cord-005478-5iu38pr6	2762	42	might	may	MD
cord-005478-5iu38pr6	2762	43	progress	progress	VB
cord-005478-5iu38pr6	2762	44	before	before	IN
cord-005478-5iu38pr6	2762	45	this	this	DT
cord-005478-5iu38pr6	2762	46	happens	happen	VBZ
cord-005478-5iu38pr6	2762	47	.	.	.
cord-005478-5iu38pr6	2763	1	In	in	IN
cord-005478-5iu38pr6	2763	2	this	this	DT
cord-005478-5iu38pr6	2763	3	setting	setting	NN
cord-005478-5iu38pr6	2763	4	,	,	,
cord-005478-5iu38pr6	2763	5	a	a	DT
cord-005478-5iu38pr6	2763	6	tandem	tandem	JJ
cord-005478-5iu38pr6	2763	7	auto	auto	NN
cord-005478-5iu38pr6	2763	8	-	-	HYPH
cord-005478-5iu38pr6	2763	9	RIC	RIC	NNP
cord-005478-5iu38pr6	2763	10	-	-	HYPH
cord-005478-5iu38pr6	2763	11	SCT	SCT	NNP
cord-005478-5iu38pr6	2763	12	approach	approach	NN
cord-005478-5iu38pr6	2763	13	has	have	VBZ
cord-005478-5iu38pr6	2763	14	the	the	DT
cord-005478-5iu38pr6	2763	15	potential	potential	NN
cord-005478-5iu38pr6	2763	16	of	of	IN
cord-005478-5iu38pr6	2763	17	combining	combine	VBG
cord-005478-5iu38pr6	2763	18	cytoreduction	cytoreduction	NN
cord-005478-5iu38pr6	2763	19	to	to	TO
cord-005478-5iu38pr6	2763	20	keep	keep	VB
cord-005478-5iu38pr6	2763	21	the	the	DT
cord-005478-5iu38pr6	2763	22	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2763	23	under	under	IN
cord-005478-5iu38pr6	2763	24	control	control	NN
cord-005478-5iu38pr6	2763	25	and	and	CC
cord-005478-5iu38pr6	2763	26	the	the	DT
cord-005478-5iu38pr6	2763	27	potential	potential	JJ
cord-005478-5iu38pr6	2763	28	benefit	benefit	NN
cord-005478-5iu38pr6	2763	29	of	of	IN
cord-005478-5iu38pr6	2763	30	a	a	DT
cord-005478-5iu38pr6	2763	31	GVL	GVL	NNP
cord-005478-5iu38pr6	2763	32	effect	effect	NN
cord-005478-5iu38pr6	2763	33	.	.	.
cord-005478-5iu38pr6	2764	1	To	to	TO
cord-005478-5iu38pr6	2764	2	better	well	RBR
cord-005478-5iu38pr6	2764	3	understand	understand	VB
cord-005478-5iu38pr6	2764	4	the	the	DT
cord-005478-5iu38pr6	2764	5	safety	safety	NN
cord-005478-5iu38pr6	2764	6	and	and	CC
cord-005478-5iu38pr6	2764	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	2764	8	of	of	IN
cord-005478-5iu38pr6	2764	9	a	a	DT
cord-005478-5iu38pr6	2764	10	tandem	tandem	JJ
cord-005478-5iu38pr6	2764	11	auto	auto	NN
cord-005478-5iu38pr6	2764	12	-	-	HYPH
cord-005478-5iu38pr6	2764	13	RIC	RIC	NNP
cord-005478-5iu38pr6	2764	14	-	-	HYPH
cord-005478-5iu38pr6	2764	15	SCT	SCT	NNP
cord-005478-5iu38pr6	2764	16	approach	approach	NN
cord-005478-5iu38pr6	2764	17	we	-PRON-	PRP
cord-005478-5iu38pr6	2764	18	conducted	conduct	VBD
cord-005478-5iu38pr6	2764	19	a	a	DT
cord-005478-5iu38pr6	2764	20	retrospective	retrospective	JJ
cord-005478-5iu38pr6	2764	21	analysis	analysis	NN
cord-005478-5iu38pr6	2764	22	of	of	IN
cord-005478-5iu38pr6	2764	23	patients	patient	NNS
cord-005478-5iu38pr6	2764	24	treated	treat	VBN
cord-005478-5iu38pr6	2764	25	with	with	IN
cord-005478-5iu38pr6	2764	26	this	this	DT
cord-005478-5iu38pr6	2764	27	strategy	strategy	NN
cord-005478-5iu38pr6	2764	28	between	between	IN
cord-005478-5iu38pr6	2764	29	January	January	NNP
cord-005478-5iu38pr6	2764	30	2004	2004	CD
cord-005478-5iu38pr6	2764	31	and	and	CC
cord-005478-5iu38pr6	2764	32	December	December	NNP
cord-005478-5iu38pr6	2764	33	2015	2015	CD
cord-005478-5iu38pr6	2764	34	and	and	CC
cord-005478-5iu38pr6	2764	35	reported	report	VBD
cord-005478-5iu38pr6	2764	36	to	to	IN
cord-005478-5iu38pr6	2764	37	the	the	DT
cord-005478-5iu38pr6	2764	38	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2764	39	registry	registry	NN
cord-005478-5iu38pr6	2764	40	.	.	.
cord-005478-5iu38pr6	2765	1	Methods	method	NNS
cord-005478-5iu38pr6	2765	2	:	:	:
cord-005478-5iu38pr6	2765	3	Patients	patient	NNS
cord-005478-5iu38pr6	2765	4	were	be	VBD
cord-005478-5iu38pr6	2765	5	included	include	VBN
cord-005478-5iu38pr6	2765	6	if	if	IN
cord-005478-5iu38pr6	2765	7	they	-PRON-	PRP
cord-005478-5iu38pr6	2765	8	had	have	VBD
cord-005478-5iu38pr6	2765	9	received	receive	VBN
cord-005478-5iu38pr6	2765	10	an	an	DT
cord-005478-5iu38pr6	2765	11	auto	auto	NN
cord-005478-5iu38pr6	2765	12	-	-	HYPH
cord-005478-5iu38pr6	2765	13	SCT	SCT	NNP
cord-005478-5iu38pr6	2765	14	followed	follow	VBN
cord-005478-5iu38pr6	2765	15	by	by	IN
cord-005478-5iu38pr6	2765	16	a	a	DT
cord-005478-5iu38pr6	2765	17	planned	plan	VBN
cord-005478-5iu38pr6	2765	18	RIC	RIC	NNP
cord-005478-5iu38pr6	2765	19	-	-	HYPH
cord-005478-5iu38pr6	2765	20	SCT	SCT	NNP
cord-005478-5iu38pr6	2765	21	in	in	IN
cord-005478-5iu38pr6	2765	22	<	<	NNP
cord-005478-5iu38pr6	2765	23	6	6	CD
cord-005478-5iu38pr6	2765	24	months	month	NNS
cord-005478-5iu38pr6	2765	25	with	with	IN
cord-005478-5iu38pr6	2765	26	no	no	DT
cord-005478-5iu38pr6	2765	27	disease	disease	NN
cord-005478-5iu38pr6	2765	28	relapse	relapse	VB
cord-005478-5iu38pr6	2765	29	between	between	IN
cord-005478-5iu38pr6	2765	30	the	the	DT
cord-005478-5iu38pr6	2765	31	procedures	procedure	NNS
cord-005478-5iu38pr6	2765	32	.	.	.
cord-005478-5iu38pr6	2766	1	The	the	DT
cord-005478-5iu38pr6	2766	2	primary	primary	JJ
cord-005478-5iu38pr6	2766	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	2766	4	was	be	VBD
cord-005478-5iu38pr6	2766	5	progression	progression	NN
cord-005478-5iu38pr6	2766	6	-	-	HYPH
cord-005478-5iu38pr6	2766	7	free	free	JJ
cord-005478-5iu38pr6	2766	8	survival	survival	NN
cord-005478-5iu38pr6	2766	9	(	(	-LRB-
cord-005478-5iu38pr6	2766	10	PFS	PFS	NNP
cord-005478-5iu38pr6	2766	11	)	)	-RRB-
cord-005478-5iu38pr6	2766	12	after	after	IN
cord-005478-5iu38pr6	2766	13	the	the	DT
cord-005478-5iu38pr6	2766	14	tandem	tandem	NN
cord-005478-5iu38pr6	2766	15	procedure	procedure	NN
cord-005478-5iu38pr6	2766	16	.	.	.
cord-005478-5iu38pr6	2767	1	Secondary	secondary	JJ
cord-005478-5iu38pr6	2767	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	2767	3	were	be	VBD
cord-005478-5iu38pr6	2767	4	overall	overall	JJ
cord-005478-5iu38pr6	2767	5	survival	survival	NN
cord-005478-5iu38pr6	2767	6	(	(	-LRB-
cord-005478-5iu38pr6	2767	7	OS	OS	NNP
cord-005478-5iu38pr6	2767	8	)	)	-RRB-
cord-005478-5iu38pr6	2767	9	,	,	,
cord-005478-5iu38pr6	2767	10	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2767	11	incidence	incidence	NN
cord-005478-5iu38pr6	2767	12	of	of	IN
cord-005478-5iu38pr6	2767	13	non	non	JJ
cord-005478-5iu38pr6	2767	14	-	-	JJ
cord-005478-5iu38pr6	2767	15	relapse	relapse	JJ
cord-005478-5iu38pr6	2767	16	mortality	mortality	NN
cord-005478-5iu38pr6	2767	17	(	(	-LRB-
cord-005478-5iu38pr6	2767	18	NRM	NRM	NNP
cord-005478-5iu38pr6	2767	19	)	)	-RRB-
cord-005478-5iu38pr6	2767	20	,	,	,
cord-005478-5iu38pr6	2767	21	incidence	incidence	NN
cord-005478-5iu38pr6	2767	22	of	of	IN
cord-005478-5iu38pr6	2767	23	relapse	relapse	NN
cord-005478-5iu38pr6	2767	24	(	(	-LRB-
cord-005478-5iu38pr6	2767	25	IR	IR	NNP
cord-005478-5iu38pr6	2767	26	)	)	-RRB-
cord-005478-5iu38pr6	2767	27	and	and	CC
cord-005478-5iu38pr6	2767	28	graft	graft	NN
cord-005478-5iu38pr6	2767	29	versus	versus	IN
cord-005478-5iu38pr6	2767	30	host	host	NN
cord-005478-5iu38pr6	2767	31	disease	disease	NN
cord-005478-5iu38pr6	2767	32	(	(	-LRB-
cord-005478-5iu38pr6	2767	33	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2767	34	)	)	-RRB-
cord-005478-5iu38pr6	2767	35	.	.	.
cord-005478-5iu38pr6	2768	1	Results	result	NNS
cord-005478-5iu38pr6	2768	2	:	:	:
cord-005478-5iu38pr6	2769	1	One	one	CD
cord-005478-5iu38pr6	2769	2	-	-	HYPH
cord-005478-5iu38pr6	2769	3	hundred	hundred	CD
cord-005478-5iu38pr6	2769	4	and	and	CC
cord-005478-5iu38pr6	2769	5	thirty	thirty	CD
cord-005478-5iu38pr6	2769	6	patients	patient	NNS
cord-005478-5iu38pr6	2769	7	[	[	-LRB-
cord-005478-5iu38pr6	2769	8	58	58	CD
cord-005478-5iu38pr6	2769	9	%	%	NN
cord-005478-5iu38pr6	2769	10	male	male	NN
cord-005478-5iu38pr6	2769	11	,	,	,
cord-005478-5iu38pr6	2769	12	median	median	JJ
cord-005478-5iu38pr6	2769	13	age	age	NN
cord-005478-5iu38pr6	2769	14	at	at	IN
cord-005478-5iu38pr6	2769	15	auto	auto	NN
cord-005478-5iu38pr6	2769	16	-	-	HYPH
cord-005478-5iu38pr6	2769	17	SCT	SCT	NNP
cord-005478-5iu38pr6	2769	18	,	,	,
cord-005478-5iu38pr6	2770	1	30	30	CD
cord-005478-5iu38pr6	2770	2	years	year	NNS
cord-005478-5iu38pr6	2770	3	(	(	-LRB-
cord-005478-5iu38pr6	2770	4	range	range	NN
cord-005478-5iu38pr6	2770	5	:	:	:
cord-005478-5iu38pr6	2770	6	18	18	CD
cord-005478-5iu38pr6	2770	7	-	-	SYM
cord-005478-5iu38pr6	2770	8	65	65	CD
cord-005478-5iu38pr6	2770	9	)	)	-RRB-
cord-005478-5iu38pr6	2770	10	]	]	-RRB-
cord-005478-5iu38pr6	2770	11	fulfilled	fulfil	VBD
cord-005478-5iu38pr6	2770	12	the	the	DT
cord-005478-5iu38pr6	2770	13	inclusion	inclusion	NN
cord-005478-5iu38pr6	2770	14	criteria	criterion	NNS
cord-005478-5iu38pr6	2770	15	.	.	.
cord-005478-5iu38pr6	2771	1	The	the	DT
cord-005478-5iu38pr6	2771	2	median	median	JJ
cord-005478-5iu38pr6	2771	3	time	time	NN
cord-005478-5iu38pr6	2771	4	between	between	IN
cord-005478-5iu38pr6	2771	5	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2771	6	and	and	CC
cord-005478-5iu38pr6	2771	7	auto	auto	NN
cord-005478-5iu38pr6	2771	8	-	-	HYPH
cord-005478-5iu38pr6	2771	9	SCT	SCT	NNP
cord-005478-5iu38pr6	2771	10	was	be	VBD
cord-005478-5iu38pr6	2771	11	16	16	CD
cord-005478-5iu38pr6	2771	12	months	month	NNS
cord-005478-5iu38pr6	2772	1	(	(	-LRB-
cord-005478-5iu38pr6	2772	2	range	range	NN
cord-005478-5iu38pr6	2772	3	:	:	:
cord-005478-5iu38pr6	2772	4	2	2	CD
cord-005478-5iu38pr6	2772	5	-	-	SYM
cord-005478-5iu38pr6	2772	6	174	174	CD
cord-005478-5iu38pr6	2772	7	)	)	-RRB-
cord-005478-5iu38pr6	2772	8	and	and	CC
cord-005478-5iu38pr6	2772	9	the	the	DT
cord-005478-5iu38pr6	2772	10	median	median	JJ
cord-005478-5iu38pr6	2772	11	number	number	NN
cord-005478-5iu38pr6	2772	12	of	of	IN
cord-005478-5iu38pr6	2772	13	lines	line	NNS
cord-005478-5iu38pr6	2772	14	prior	prior	RB
cord-005478-5iu38pr6	2772	15	to	to	IN
cord-005478-5iu38pr6	2772	16	auto	auto	NN
cord-005478-5iu38pr6	2772	17	-	-	HYPH
cord-005478-5iu38pr6	2772	18	SCT	SCT	NNP
cord-005478-5iu38pr6	2772	19	2	2	CD
cord-005478-5iu38pr6	2772	20	(	(	-LRB-
cord-005478-5iu38pr6	2772	21	2	2	CD
cord-005478-5iu38pr6	2772	22	)	)	-RRB-
cord-005478-5iu38pr6	2772	23	(	(	-LRB-
cord-005478-5iu38pr6	2772	24	3	3	LS
cord-005478-5iu38pr6	2772	25	)	)	-RRB-
cord-005478-5iu38pr6	2772	26	(	(	-LRB-
cord-005478-5iu38pr6	2772	27	4	4	LS
cord-005478-5iu38pr6	2772	28	)	)	-RRB-
cord-005478-5iu38pr6	2772	29	.	.	.
cord-005478-5iu38pr6	2773	1	Disease	disease	NN
cord-005478-5iu38pr6	2773	2	status	status	NN
cord-005478-5iu38pr6	2773	3	at	at	IN
cord-005478-5iu38pr6	2773	4	auto	auto	NN
cord-005478-5iu38pr6	2773	5	-	-	HYPH
cord-005478-5iu38pr6	2773	6	SCT	SCT	NNP
cord-005478-5iu38pr6	2773	7	was	be	VBD
cord-005478-5iu38pr6	2773	8	complete	complete	JJ
cord-005478-5iu38pr6	2773	9	response	response	NN
cord-005478-5iu38pr6	2773	10	in	in	IN
cord-005478-5iu38pr6	2773	11	32	32	CD
cord-005478-5iu38pr6	2773	12	%	%	NN
cord-005478-5iu38pr6	2773	13	,	,	,
cord-005478-5iu38pr6	2773	14	partial	partial	JJ
cord-005478-5iu38pr6	2773	15	response	response	NN
cord-005478-5iu38pr6	2773	16	in	in	IN
cord-005478-5iu38pr6	2773	17	27	27	CD
cord-005478-5iu38pr6	2773	18	%	%	NN
cord-005478-5iu38pr6	2773	19	and	and	CC
cord-005478-5iu38pr6	2773	20	the	the	DT
cord-005478-5iu38pr6	2773	21	remaining	remain	VBG
cord-005478-5iu38pr6	2773	22	41	41	CD
cord-005478-5iu38pr6	2773	23	%	%	NN
cord-005478-5iu38pr6	2773	24	were	be	VBD
cord-005478-5iu38pr6	2773	25	transplanted	transplant	VBN
cord-005478-5iu38pr6	2773	26	with	with	IN
cord-005478-5iu38pr6	2773	27	active	active	JJ
cord-005478-5iu38pr6	2773	28	disease	disease	NN
cord-005478-5iu38pr6	2773	29	.	.	.
cord-005478-5iu38pr6	2774	1	The	the	DT
cord-005478-5iu38pr6	2774	2	median	median	JJ
cord-005478-5iu38pr6	2774	3	time	time	NN
cord-005478-5iu38pr6	2774	4	from	from	IN
cord-005478-5iu38pr6	2774	5	auto	auto	NN
cord-005478-5iu38pr6	2774	6	to	to	IN
cord-005478-5iu38pr6	2774	7	allo	allo	NNP
cord-005478-5iu38pr6	2774	8	-	-	HYPH
cord-005478-5iu38pr6	2774	9	SCT	SCT	NNP
cord-005478-5iu38pr6	2774	10	was	be	VBD
cord-005478-5iu38pr6	2774	11	3	3	CD
cord-005478-5iu38pr6	2774	12	months	month	NNS
cord-005478-5iu38pr6	2774	13	(	(	-LRB-
cord-005478-5iu38pr6	2774	14	1	1	CD
cord-005478-5iu38pr6	2774	15	-	-	SYM
cord-005478-5iu38pr6	2774	16	6	6	CD
cord-005478-5iu38pr6	2774	17	)	)	-RRB-
cord-005478-5iu38pr6	2774	18	.	.	.
cord-005478-5iu38pr6	2775	1	Forty	forty	CD
cord-005478-5iu38pr6	2775	2	percent	percent	NN
cord-005478-5iu38pr6	2775	3	underwent	undergo	VBD
cord-005478-5iu38pr6	2775	4	an	an	DT
cord-005478-5iu38pr6	2775	5	identical	identical	JJ
cord-005478-5iu38pr6	2775	6	sibling	sibling	NN
cord-005478-5iu38pr6	2775	7	allo	allo	NN
cord-005478-5iu38pr6	2775	8	-	-	HYPH
cord-005478-5iu38pr6	2775	9	SCT	SCT	NNP
cord-005478-5iu38pr6	2775	10	,	,	,
cord-005478-5iu38pr6	2775	11	39	39	CD
cord-005478-5iu38pr6	2775	12	%	%	NN
cord-005478-5iu38pr6	2775	13	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2775	14	and	and	CC
cord-005478-5iu38pr6	2775	15	21	21	CD
cord-005478-5iu38pr6	2775	16	%	%	NN
cord-005478-5iu38pr6	2775	17	haplo	haplo	NN
cord-005478-5iu38pr6	2775	18	.	.	.
cord-005478-5iu38pr6	2776	1	TBI	TBI	NNP
cord-005478-5iu38pr6	2776	2	was	be	VBD
cord-005478-5iu38pr6	2776	3	used	use	VBN
cord-005478-5iu38pr6	2776	4	in	in	IN
cord-005478-5iu38pr6	2776	5	35	35	CD
cord-005478-5iu38pr6	2776	6	%	%	NN
cord-005478-5iu38pr6	2776	7	of	of	IN
cord-005478-5iu38pr6	2776	8	the	the	DT
cord-005478-5iu38pr6	2776	9	patients	patient	NNS
cord-005478-5iu38pr6	2776	10	as	as	IN
cord-005478-5iu38pr6	2776	11	a	a	DT
cord-005478-5iu38pr6	2776	12	part	part	NN
cord-005478-5iu38pr6	2776	13	of	of	IN
cord-005478-5iu38pr6	2776	14	RIC	RIC	NNP
cord-005478-5iu38pr6	2776	15	.	.	.
cord-005478-5iu38pr6	2777	1	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2777	2	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2777	3	was	be	VBD
cord-005478-5iu38pr6	2777	4	cyclosporine	cyclosporine	NN
cord-005478-5iu38pr6	2777	5	-	-	HYPH
cord-005478-5iu38pr6	2777	6	methotrexate	methotrexate	NN
cord-005478-5iu38pr6	2777	7	in	in	IN
cord-005478-5iu38pr6	2777	8	36	36	CD
cord-005478-5iu38pr6	2777	9	%	%	NN
cord-005478-5iu38pr6	2777	10	of	of	IN
cord-005478-5iu38pr6	2777	11	the	the	DT
cord-005478-5iu38pr6	2777	12	patients	patient	NNS
cord-005478-5iu38pr6	2777	13	,	,	,
cord-005478-5iu38pr6	2777	14	cyclosporine	cyclosporine	JJ
cord-005478-5iu38pr6	2777	15	-	-	HYPH
cord-005478-5iu38pr6	2777	16	micofenolate	micofenolate	NNP
cord-005478-5iu38pr6	2777	17	mofetil	mofetil	NNP
cord-005478-5iu38pr6	2777	18	in	in	IN
cord-005478-5iu38pr6	2777	19	16	16	CD
cord-005478-5iu38pr6	2777	20	%	%	NN
cord-005478-5iu38pr6	2777	21	and	and	CC
cord-005478-5iu38pr6	2777	22	post	post	JJ
cord-005478-5iu38pr6	2777	23	-	-	JJ
cord-005478-5iu38pr6	2777	24	transplant	transplant	NN
cord-005478-5iu38pr6	2777	25	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2777	26	in	in	IN
cord-005478-5iu38pr6	2777	27	the	the	DT
cord-005478-5iu38pr6	2777	28	remaining	remain	VBG
cord-005478-5iu38pr6	2777	29	17	17	CD
cord-005478-5iu38pr6	2777	30	%	%	NN
cord-005478-5iu38pr6	2777	31	.	.	.
cord-005478-5iu38pr6	2778	1	91	91	CD
cord-005478-5iu38pr6	2778	2	%	%	NN
cord-005478-5iu38pr6	2778	3	of	of	IN
cord-005478-5iu38pr6	2778	4	the	the	DT
cord-005478-5iu38pr6	2778	5	patients	patient	NNS
cord-005478-5iu38pr6	2778	6	engrafted	engraft	VBN
cord-005478-5iu38pr6	2778	7	after	after	IN
cord-005478-5iu38pr6	2778	8	RIC	RIC	NNP
cord-005478-5iu38pr6	2778	9	-	-	HYPH
cord-005478-5iu38pr6	2778	10	SCT	SCT	NNP
cord-005478-5iu38pr6	2778	11	.	.	.
cord-005478-5iu38pr6	2779	1	After	after	IN
cord-005478-5iu38pr6	2779	2	a	a	DT
cord-005478-5iu38pr6	2779	3	median	median	JJ
cord-005478-5iu38pr6	2779	4	follow	follow	NN
cord-005478-5iu38pr6	2779	5	-	-	HYPH
cord-005478-5iu38pr6	2779	6	up	up	NN
cord-005478-5iu38pr6	2779	7	of	of	IN
cord-005478-5iu38pr6	2779	8	44	44	CD
cord-005478-5iu38pr6	2779	9	months	month	NNS
cord-005478-5iu38pr6	2779	10	(	(	-LRB-
cord-005478-5iu38pr6	2779	11	6	6	CD
cord-005478-5iu38pr6	2779	12	-	-	SYM
cord-005478-5iu38pr6	2779	13	130	130	CD
cord-005478-5iu38pr6	2779	14	)	)	-RRB-
cord-005478-5iu38pr6	2779	15	,	,	,
cord-005478-5iu38pr6	2779	16	33	33	CD
cord-005478-5iu38pr6	2779	17	%	%	NN
cord-005478-5iu38pr6	2779	18	of	of	IN
cord-005478-5iu38pr6	2779	19	the	the	DT
cord-005478-5iu38pr6	2779	20	patients	patient	NNS
cord-005478-5iu38pr6	2779	21	Background	Background	NNP
cord-005478-5iu38pr6	2779	22	:	:	:
cord-005478-5iu38pr6	2780	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2780	2	stem	stem	VBP
cord-005478-5iu38pr6	2780	3	cell	cell	NN
cord-005478-5iu38pr6	2780	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2780	5	(	(	-LRB-
cord-005478-5iu38pr6	2780	6	allo	allo	FW
cord-005478-5iu38pr6	2780	7	-	-	HYPH
cord-005478-5iu38pr6	2780	8	SCT	SCT	NNP
cord-005478-5iu38pr6	2780	9	)	)	-RRB-
cord-005478-5iu38pr6	2780	10	is	be	VBZ
cord-005478-5iu38pr6	2780	11	a	a	DT
cord-005478-5iu38pr6	2780	12	valid	valid	JJ
cord-005478-5iu38pr6	2780	13	option	option	NN
cord-005478-5iu38pr6	2780	14	in	in	IN
cord-005478-5iu38pr6	2780	15	patients	patient	NNS
cord-005478-5iu38pr6	2780	16	with	with	IN
cord-005478-5iu38pr6	2780	17	refractory	refractory	JJ
cord-005478-5iu38pr6	2780	18	/	/	SYM
cord-005478-5iu38pr6	2780	19	relapsed	relapse	VBN
cord-005478-5iu38pr6	2780	20	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2780	21	but	but	CC
cord-005478-5iu38pr6	2780	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2780	23	remains	remain	VBZ
cord-005478-5iu38pr6	2780	24	the	the	DT
cord-005478-5iu38pr6	2780	25	major	major	JJ
cord-005478-5iu38pr6	2780	26	cause	cause	NN
cord-005478-5iu38pr6	2780	27	of	of	IN
cord-005478-5iu38pr6	2780	28	mortality	mortality	NN
cord-005478-5iu38pr6	2780	29	and	and	CC
cord-005478-5iu38pr6	2780	30	morbidity	morbidity	NN
cord-005478-5iu38pr6	2780	31	.	.	.
cord-005478-5iu38pr6	2781	1	Calcineurin	Calcineurin	NNP
cord-005478-5iu38pr6	2781	2	-	-	HYPH
cord-005478-5iu38pr6	2781	3	inhibitors	inhibitor	NNS
cord-005478-5iu38pr6	2781	4	(	(	-LRB-
cord-005478-5iu38pr6	2781	5	CNI	CNI	NNP
cord-005478-5iu38pr6	2781	6	)	)	-RRB-
cord-005478-5iu38pr6	2781	7	combined	combine	VBN
cord-005478-5iu38pr6	2781	8	with	with	IN
cord-005478-5iu38pr6	2781	9	methotrexate	methotrexate	NNP
cord-005478-5iu38pr6	2781	10	or	or	CC
cord-005478-5iu38pr6	2781	11	ATG	ATG	NNP
cord-005478-5iu38pr6	2781	12	is	be	VBZ
cord-005478-5iu38pr6	2781	13	the	the	DT
cord-005478-5iu38pr6	2781	14	conventional	conventional	JJ
cord-005478-5iu38pr6	2781	15	strategy	strategy	NN
cord-005478-5iu38pr6	2781	16	for	for	IN
cord-005478-5iu38pr6	2781	17	preventing	prevent	VBG
cord-005478-5iu38pr6	2781	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2781	19	,	,	,
cord-005478-5iu38pr6	2781	20	resulting	result	VBG
cord-005478-5iu38pr6	2781	21	in	in	IN
cord-005478-5iu38pr6	2781	22	an	an	DT
cord-005478-5iu38pr6	2781	23	incidence	incidence	NN
cord-005478-5iu38pr6	2781	24	of	of	IN
cord-005478-5iu38pr6	2781	25	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2781	26	of	of	IN
cord-005478-5iu38pr6	2781	27	41	41	CD
cord-005478-5iu38pr6	2781	28	-	-	SYM
cord-005478-5iu38pr6	2781	29	60	60	CD
cord-005478-5iu38pr6	2781	30	%	%	NN
cord-005478-5iu38pr6	2781	31	.	.	.
cord-005478-5iu38pr6	2782	1	Post	post	JJ
cord-005478-5iu38pr6	2782	2	-	-	JJ
cord-005478-5iu38pr6	2782	3	transplant	transplant	NN
cord-005478-5iu38pr6	2782	4	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	2782	5	(	(	-LRB-
cord-005478-5iu38pr6	2782	6	PT	PT	NNP
cord-005478-5iu38pr6	2782	7	-	-	HYPH
cord-005478-5iu38pr6	2782	8	Cy	Cy	NNP
cord-005478-5iu38pr6	2782	9	)	)	-RRB-
cord-005478-5iu38pr6	2782	10	reduces	reduce	VBZ
cord-005478-5iu38pr6	2782	11	the	the	DT
cord-005478-5iu38pr6	2782	12	risk	risk	NN
cord-005478-5iu38pr6	2782	13	of	of	IN
cord-005478-5iu38pr6	2782	14	severe	severe	JJ
cord-005478-5iu38pr6	2782	15	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2782	16	and	and	CC
cord-005478-5iu38pr6	2782	17	improves	improve	VBZ
cord-005478-5iu38pr6	2782	18	survival	survival	NN
cord-005478-5iu38pr6	2782	19	in	in	IN
cord-005478-5iu38pr6	2782	20	acute	acute	JJ
cord-005478-5iu38pr6	2782	21	leukemia	leukemia	NN
cord-005478-5iu38pr6	2782	22	patients	patient	NNS
cord-005478-5iu38pr6	2782	23	receiving	receive	VBG
cord-005478-5iu38pr6	2782	24	allo	allo	NNP
cord-005478-5iu38pr6	2782	25	-	-	HYPH
cord-005478-5iu38pr6	2782	26	SCT	SCT	NNP
cord-005478-5iu38pr6	2782	27	from	from	IN
cord-005478-5iu38pr6	2782	28	matched	match	VBN
cord-005478-5iu38pr6	2782	29	sibling	sibling	NN
cord-005478-5iu38pr6	2782	30	(	(	-LRB-
cord-005478-5iu38pr6	2782	31	MSD	MSD	NNP
cord-005478-5iu38pr6	2782	32	)	)	-RRB-
cord-005478-5iu38pr6	2782	33	or	or	CC
cord-005478-5iu38pr6	2782	34	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2782	35	donors	donor	NNS
cord-005478-5iu38pr6	2782	36	(	(	-LRB-
cord-005478-5iu38pr6	2782	37	UD	UD	NNP
cord-005478-5iu38pr6	2782	38	)	)	-RRB-
cord-005478-5iu38pr6	2782	39	.	.	.
cord-005478-5iu38pr6	2783	1	The	the	DT
cord-005478-5iu38pr6	2783	2	aim	aim	NN
cord-005478-5iu38pr6	2783	3	of	of	IN
cord-005478-5iu38pr6	2783	4	this	this	DT
cord-005478-5iu38pr6	2783	5	retrospective	retrospective	JJ
cord-005478-5iu38pr6	2783	6	registry	registry	NN
cord-005478-5iu38pr6	2783	7	-	-	HYPH
cord-005478-5iu38pr6	2783	8	based	base	VBN
cord-005478-5iu38pr6	2783	9	study	study	NN
cord-005478-5iu38pr6	2783	10	was	be	VBD
cord-005478-5iu38pr6	2783	11	to	to	TO
cord-005478-5iu38pr6	2783	12	compare	compare	VB
cord-005478-5iu38pr6	2783	13	PT	PT	NNP
cord-005478-5iu38pr6	2783	14	-	-	HYPH
cord-005478-5iu38pr6	2783	15	Cy	Cy	NNP
cord-005478-5iu38pr6	2783	16	-	-	HYPH
cord-005478-5iu38pr6	2783	17	based	base	VBN
cord-005478-5iu38pr6	2783	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2783	19	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2783	20	to	to	IN
cord-005478-5iu38pr6	2783	21	standard	standard	JJ
cord-005478-5iu38pr6	2783	22	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2783	23	in	in	IN
cord-005478-5iu38pr6	2783	24	the	the	DT
cord-005478-5iu38pr6	2783	25	setting	setting	NN
cord-005478-5iu38pr6	2783	26	of	of	IN
cord-005478-5iu38pr6	2783	27	MSD	MSD	NNP
cord-005478-5iu38pr6	2783	28	or	or	CC
cord-005478-5iu38pr6	2783	29	UD	UD	NNP
cord-005478-5iu38pr6	2783	30	for	for	IN
cord-005478-5iu38pr6	2783	31	patients	patient	NNS
cord-005478-5iu38pr6	2783	32	with	with	IN
cord-005478-5iu38pr6	2783	33	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2783	34	.	.	.
cord-005478-5iu38pr6	2784	1	Methods	method	NNS
cord-005478-5iu38pr6	2784	2	:	:	:
cord-005478-5iu38pr6	2785	1	Three	three	CD
cord-005478-5iu38pr6	2785	2	thousand	thousand	CD
cord-005478-5iu38pr6	2785	3	eight	eight	CD
cord-005478-5iu38pr6	2785	4	hundred	hundred	CD
cord-005478-5iu38pr6	2785	5	sixty	sixty	CD
cord-005478-5iu38pr6	2785	6	-	-	HYPH
cord-005478-5iu38pr6	2785	7	four	four	CD
cord-005478-5iu38pr6	2785	8	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2785	9	patients	patient	NNS
cord-005478-5iu38pr6	2785	10	undergoing	undergo	VBG
cord-005478-5iu38pr6	2785	11	an	an	DT
cord-005478-5iu38pr6	2785	12	HLA	HLA	NNP
cord-005478-5iu38pr6	2785	13	-id	-id	NN
cord-005478-5iu38pr6	2785	14	SCT(HLA	SCT(HLA	NNP
cord-005478-5iu38pr6	2785	15	identical	identical	JJ
cord-005478-5iu38pr6	2785	16	stem	stem	NN
cord-005478-5iu38pr6	2785	17	cell	cell	NN
cord-005478-5iu38pr6	2785	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	2785	19	)	)	-RRB-
cord-005478-5iu38pr6	2786	1	registered	register	VBN
cord-005478-5iu38pr6	2786	2	in	in	IN
cord-005478-5iu38pr6	2786	3	Promise	Promise	NNP
cord-005478-5iu38pr6	2786	4	were	be	VBD
cord-005478-5iu38pr6	2786	5	included	include	VBN
cord-005478-5iu38pr6	2786	6	in	in	IN
cord-005478-5iu38pr6	2786	7	the	the	DT
cord-005478-5iu38pr6	2786	8	study	study	NN
cord-005478-5iu38pr6	2786	9	(	(	-LRB-
cord-005478-5iu38pr6	2786	10	Table	Table	NNP
cord-005478-5iu38pr6	2786	11	1	1	CD
cord-005478-5iu38pr6	2786	12	)	)	-RRB-
cord-005478-5iu38pr6	2786	13	.	.	.
cord-005478-5iu38pr6	2787	1	Outcomes	outcome	NNS
cord-005478-5iu38pr6	2787	2	between	between	IN
cord-005478-5iu38pr6	2787	3	PT	PT	NNP
cord-005478-5iu38pr6	2787	4	-	-	HYPH
cord-005478-5iu38pr6	2787	5	Cy	Cy	NNP
cord-005478-5iu38pr6	2787	6	vs	vs	IN
cord-005478-5iu38pr6	2787	7	no	no	DT
cord-005478-5iu38pr6	2787	8	-	-	HYPH
cord-005478-5iu38pr6	2787	9	PT	PT	NNP
cord-005478-5iu38pr6	2787	10	-	-	HYPH
cord-005478-5iu38pr6	2787	11	Cy	Cy	NNP
cord-005478-5iu38pr6	2787	12	were	be	VBD
cord-005478-5iu38pr6	2787	13	compared	compare	VBN
cord-005478-5iu38pr6	2787	14	a	a	LS
cord-005478-5iu38pr6	2787	15	)	)	-RRB-
cord-005478-5iu38pr6	2787	16	with	with	IN
cord-005478-5iu38pr6	2787	17	a	a	DT
cord-005478-5iu38pr6	2787	18	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2787	19	cause	cause	NN
cord-005478-5iu38pr6	2787	20	-	-	HYPH
cord-005478-5iu38pr6	2787	21	specific	specific	JJ
cord-005478-5iu38pr6	2787	22	cox	cox	NNP
cord-005478-5iu38pr6	2787	23	model	model	NN
cord-005478-5iu38pr6	2787	24	adjusted	adjust	VBN
cord-005478-5iu38pr6	2787	25	on	on	IN
cord-005478-5iu38pr6	2787	26	RIC	RIC	NNP
cord-005478-5iu38pr6	2787	27	/	/	SYM
cord-005478-5iu38pr6	2787	28	MAC	MAC	NNP
cord-005478-5iu38pr6	2787	29	,	,	,
cord-005478-5iu38pr6	2787	30	donor	donor	NN
cord-005478-5iu38pr6	2787	31	type	type	NN
cord-005478-5iu38pr6	2787	32	,	,	,
cord-005478-5iu38pr6	2787	33	source	source	NN
cord-005478-5iu38pr6	2787	34	of	of	IN
cord-005478-5iu38pr6	2787	35	stem	stem	NN
cord-005478-5iu38pr6	2787	36	cell	cell	NN
cord-005478-5iu38pr6	2787	37	,	,	,
cord-005478-5iu38pr6	2787	38	age	age	NN
cord-005478-5iu38pr6	2787	39	of	of	IN
cord-005478-5iu38pr6	2787	40	the	the	DT
cord-005478-5iu38pr6	2787	41	patient	patient	NN
cord-005478-5iu38pr6	2787	42	,	,	,
cord-005478-5iu38pr6	2787	43	donor	donor	NN
cord-005478-5iu38pr6	2787	44	gender	gender	NN
cord-005478-5iu38pr6	2787	45	,	,	,
cord-005478-5iu38pr6	2787	46	patient	patient	JJ
cord-005478-5iu38pr6	2787	47	gender	gender	NN
cord-005478-5iu38pr6	2787	48	,	,	,
cord-005478-5iu38pr6	2787	49	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2787	50	and	and	CC
cord-005478-5iu38pr6	2787	51	,	,	,
cord-005478-5iu38pr6	2787	52	disease	disease	NN
cord-005478-5iu38pr6	2787	53	status	status	NN
cord-005478-5iu38pr6	2787	54	at	at	IN
cord-005478-5iu38pr6	2787	55	SCT	SCT	NNP
cord-005478-5iu38pr6	2787	56	;	;	:
cord-005478-5iu38pr6	2787	57	and	and	CC
cord-005478-5iu38pr6	2787	58	b	b	LS
cord-005478-5iu38pr6	2787	59	)	)	-RRB-
cord-005478-5iu38pr6	2787	60	by	by	IN
cord-005478-5iu38pr6	2787	61	matching	match	VBG
cord-005478-5iu38pr6	2787	62	one	one	CD
cord-005478-5iu38pr6	2787	63	PT	PT	NNP
cord-005478-5iu38pr6	2787	64	-	-	HYPH
cord-005478-5iu38pr6	2787	65	Cy	Cy	NNP
cord-005478-5iu38pr6	2787	66	patient	patient	NN
cord-005478-5iu38pr6	2787	67	(	(	-LRB-
cord-005478-5iu38pr6	2787	68	118	118	CD
cord-005478-5iu38pr6	2787	69	)	)	-RRB-
cord-005478-5iu38pr6	2787	70	with	with	IN
cord-005478-5iu38pr6	2787	71	two	two	CD
cord-005478-5iu38pr6	2787	72	no	no	DT
cord-005478-5iu38pr6	2787	73	-	-	HYPH
cord-005478-5iu38pr6	2787	74	PT	PT	NNP
cord-005478-5iu38pr6	2787	75	-	-	HYPH
cord-005478-5iu38pr6	2787	76	Cy	Cy	NNP
cord-005478-5iu38pr6	2787	77	patients	patient	NNS
cord-005478-5iu38pr6	2787	78	(	(	-LRB-
cord-005478-5iu38pr6	2787	79	217	217	CD
cord-005478-5iu38pr6	2787	80	)	)	-RRB-
cord-005478-5iu38pr6	2787	81	using	use	VBG
cord-005478-5iu38pr6	2787	82	the	the	DT
cord-005478-5iu38pr6	2787	83	same	same	JJ
cord-005478-5iu38pr6	2787	84	covariates	covariate	NNS
cord-005478-5iu38pr6	2787	85	.	.	.
cord-005478-5iu38pr6	2788	1	Results	result	NNS
cord-005478-5iu38pr6	2788	2	:	:	:
cord-005478-5iu38pr6	2789	1	In	in	IN
cord-005478-5iu38pr6	2789	2	univariate	univariate	JJ
cord-005478-5iu38pr6	2789	3	analysis	analysis	NN
cord-005478-5iu38pr6	2789	4	,	,	,
cord-005478-5iu38pr6	2789	5	comparing	compare	VBG
cord-005478-5iu38pr6	2789	6	PT	PT	NNP
cord-005478-5iu38pr6	2789	7	-	-	HYPH
cord-005478-5iu38pr6	2789	8	Cy	Cy	NNP
cord-005478-5iu38pr6	2789	9	and	and	CC
cord-005478-5iu38pr6	2789	10	no	no	DT
cord-005478-5iu38pr6	2789	11	-	-	HYPH
cord-005478-5iu38pr6	2789	12	PT	PT	NNP
cord-005478-5iu38pr6	2789	13	-	-	HYPH
cord-005478-5iu38pr6	2789	14	Cy	Cy	NNP
cord-005478-5iu38pr6	2789	15	,	,	,
cord-005478-5iu38pr6	2789	16	the	the	DT
cord-005478-5iu38pr6	2789	17	100-day	100-day	JJ
cord-005478-5iu38pr6	2789	18	CI	ci	NN
cord-005478-5iu38pr6	2789	19	of	of	IN
cord-005478-5iu38pr6	2789	20	grade	grade	NN
cord-005478-5iu38pr6	2789	21	2	2	CD
cord-005478-5iu38pr6	2789	22	-	-	SYM
cord-005478-5iu38pr6	2789	23	4	4	CD
cord-005478-5iu38pr6	2789	24	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2789	25	was	be	VBD
cord-005478-5iu38pr6	2789	26	26	26	CD
cord-005478-5iu38pr6	2789	27	%	%	NN
cord-005478-5iu38pr6	2789	28	and	and	CC
cord-005478-5iu38pr6	2789	29	27	27	CD
cord-005478-5iu38pr6	2789	30	%	%	NN
cord-005478-5iu38pr6	2789	31	(	(	-LRB-
cord-005478-5iu38pr6	2789	32	p=0.7	p=0.7	NNP
cord-005478-5iu38pr6	2789	33	)	)	-RRB-
cord-005478-5iu38pr6	2789	34	,	,	,
cord-005478-5iu38pr6	2789	35	the	the	DT
cord-005478-5iu38pr6	2789	36	1-year	1-year	CD
cord-005478-5iu38pr6	2789	37	CI	CI	NNP
cord-005478-5iu38pr6	2789	38	of	of	IN
cord-005478-5iu38pr6	2789	39	non	non	JJ
cord-005478-5iu38pr6	2789	40	-	-	JJ
cord-005478-5iu38pr6	2789	41	relapse	relapse	JJ
cord-005478-5iu38pr6	2789	42	mortality	mortality	NN
cord-005478-5iu38pr6	2789	43	(	(	-LRB-
cord-005478-5iu38pr6	2789	44	NRM	NRM	NNP
cord-005478-5iu38pr6	2789	45	)	)	-RRB-
cord-005478-5iu38pr6	2789	46	was	be	VBD
cord-005478-5iu38pr6	2789	47	12	12	CD
cord-005478-5iu38pr6	2789	48	%	%	NN
cord-005478-5iu38pr6	2789	49	and	and	CC
cord-005478-5iu38pr6	2789	50	16	16	CD
cord-005478-5iu38pr6	2789	51	%	%	NN
cord-005478-5iu38pr6	2789	52	(	(	-LRB-
cord-005478-5iu38pr6	2789	53	p=0.6	p=0.6	NNP
cord-005478-5iu38pr6	2789	54	)	)	-RRB-
cord-005478-5iu38pr6	2789	55	and	and	CC
cord-005478-5iu38pr6	2789	56	the	the	DT
cord-005478-5iu38pr6	2789	57	3-year	3-year	CD
cord-005478-5iu38pr6	2789	58	relapse	relapse	NN
cord-005478-5iu38pr6	2789	59	incidence	incidence	NN
cord-005478-5iu38pr6	2789	60	(	(	-LRB-
cord-005478-5iu38pr6	2789	61	RI	RI	NNP
cord-005478-5iu38pr6	2789	62	)	)	-RRB-
cord-005478-5iu38pr6	2789	63	was	be	VBD
cord-005478-5iu38pr6	2789	64	38	38	CD
cord-005478-5iu38pr6	2789	65	%	%	NN
cord-005478-5iu38pr6	2789	66	and	and	CC
cord-005478-5iu38pr6	2789	67	33	33	CD
cord-005478-5iu38pr6	2789	68	%	%	NN
cord-005478-5iu38pr6	2789	69	(	(	-LRB-
cord-005478-5iu38pr6	2789	70	p=0.2	p=0.2	NNP
cord-005478-5iu38pr6	2789	71	)	)	-RRB-
cord-005478-5iu38pr6	2789	72	,	,	,
cord-005478-5iu38pr6	2789	73	respectively	respectively	RB
cord-005478-5iu38pr6	2789	74	.	.	.
cord-005478-5iu38pr6	2790	1	The	the	DT
cord-005478-5iu38pr6	2790	2	1-year	1-year	CD
cord-005478-5iu38pr6	2790	3	CI	CI	NNP
cord-005478-5iu38pr6	2790	4	of	of	IN
cord-005478-5iu38pr6	2790	5	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2790	6	was	be	VBD
cord-005478-5iu38pr6	2790	7	32	32	CD
cord-005478-5iu38pr6	2790	8	%	%	NN
cord-005478-5iu38pr6	2790	9	vs	vs	IN
cord-005478-5iu38pr6	2790	10	42	42	CD
cord-005478-5iu38pr6	2790	11	%	%	NN
cord-005478-5iu38pr6	2790	12	(	(	-LRB-
cord-005478-5iu38pr6	2790	13	p=0.1	p=0.1	NN
cord-005478-5iu38pr6	2790	14	)	)	-RRB-
cord-005478-5iu38pr6	2791	1	,	,	,
cord-005478-5iu38pr6	2791	2	3-year	3-year	CD
cord-005478-5iu38pr6	2791	3	PFS	PFS	NNP
cord-005478-5iu38pr6	2791	4	for	for	IN
cord-005478-5iu38pr6	2791	5	PT	PT	NNP
cord-005478-5iu38pr6	2791	6	-	-	HYPH
cord-005478-5iu38pr6	2791	7	Cy	Cy	NNP
cord-005478-5iu38pr6	2791	8	and	and	CC
cord-005478-5iu38pr6	2791	9	no	no	DT
cord-005478-5iu38pr6	2791	10	-	-	HYPH
cord-005478-5iu38pr6	2791	11	PT	PT	NNP
cord-005478-5iu38pr6	2791	12	-	-	HYPH
cord-005478-5iu38pr6	2791	13	Cy	Cy	NNP
cord-005478-5iu38pr6	2791	14	was	be	VBD
cord-005478-5iu38pr6	2791	15	43	43	CD
cord-005478-5iu38pr6	2791	16	%	%	NN
cord-005478-5iu38pr6	2791	17	and	and	CC
cord-005478-5iu38pr6	2791	18	46	46	CD
cord-005478-5iu38pr6	2791	19	%	%	NN
cord-005478-5iu38pr6	2791	20	(	(	-LRB-
cord-005478-5iu38pr6	2791	21	p=0.5	p=0.5	NNP
cord-005478-5iu38pr6	2791	22	)	)	-RRB-
cord-005478-5iu38pr6	2791	23	and	and	CC
cord-005478-5iu38pr6	2791	24	54	54	CD
cord-005478-5iu38pr6	2791	25	%	%	NN
cord-005478-5iu38pr6	2791	26	and	and	CC
cord-005478-5iu38pr6	2791	27	57	57	CD
cord-005478-5iu38pr6	2791	28	%	%	NN
cord-005478-5iu38pr6	2791	29	(	(	-LRB-
cord-005478-5iu38pr6	2791	30	p=0.9	p=0.9	NNP
cord-005478-5iu38pr6	2791	31	)	)	-RRB-
cord-005478-5iu38pr6	2791	32	,	,	,
cord-005478-5iu38pr6	2791	33	respectively	respectively	RB
cord-005478-5iu38pr6	2791	34	.	.	.
cord-005478-5iu38pr6	2792	1	In	in	IN
cord-005478-5iu38pr6	2792	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2792	3	analysis	analysis	NN
cord-005478-5iu38pr6	2792	4	,	,	,
cord-005478-5iu38pr6	2792	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	2792	6	with	with	IN
cord-005478-5iu38pr6	2792	7	PT	PT	NNP
cord-005478-5iu38pr6	2792	8	-	-	HYPH
cord-005478-5iu38pr6	2792	9	Cy	Cy	NNP
cord-005478-5iu38pr6	2792	10	was	be	VBD
cord-005478-5iu38pr6	2792	11	not	not	RB
cord-005478-5iu38pr6	2792	12	associated	associate	VBN
cord-005478-5iu38pr6	2792	13	with	with	IN
cord-005478-5iu38pr6	2792	14	a	a	DT
cord-005478-5iu38pr6	2792	15	reduced	reduce	VBN
cord-005478-5iu38pr6	2792	16	risk	risk	NN
cord-005478-5iu38pr6	2792	17	of	of	IN
cord-005478-5iu38pr6	2792	18	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	2792	19	,	,	,
cord-005478-5iu38pr6	2792	20	overall	overall	JJ
cord-005478-5iu38pr6	2792	21	or	or	CC
cord-005478-5iu38pr6	2792	22	extensive	extensive	JJ
cord-005478-5iu38pr6	2792	23	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2792	24	,	,	,
cord-005478-5iu38pr6	2792	25	NRM	NRM	NNP
cord-005478-5iu38pr6	2792	26	,	,	,
cord-005478-5iu38pr6	2792	27	RI	RI	NNP
cord-005478-5iu38pr6	2792	28	,	,	,
cord-005478-5iu38pr6	2792	29	nor	nor	CC
cord-005478-5iu38pr6	2792	30	with	with	IN
cord-005478-5iu38pr6	2792	31	an	an	DT
cord-005478-5iu38pr6	2792	32	improved	improved	JJ
cord-005478-5iu38pr6	2792	33	PFS	PFS	NNP
cord-005478-5iu38pr6	2792	34	or	or	CC
cord-005478-5iu38pr6	2792	35	OS	OS	NNP
cord-005478-5iu38pr6	2792	36	.	.	.
cord-005478-5iu38pr6	2793	1	Likewise	likewise	RB
cord-005478-5iu38pr6	2793	2	,	,	,
cord-005478-5iu38pr6	2793	3	in	in	IN
cord-005478-5iu38pr6	2793	4	the	the	DT
cord-005478-5iu38pr6	2793	5	matched	match	VBN
cord-005478-5iu38pr6	2793	6	-	-	HYPH
cord-005478-5iu38pr6	2793	7	pair	pair	NN
cord-005478-5iu38pr6	2793	8	analysis	analysis	NN
cord-005478-5iu38pr6	2793	9	PT	PT	NNP
cord-005478-5iu38pr6	2793	10	-	-	HYPH
cord-005478-5iu38pr6	2793	11	Cy	Cy	NNP
cord-005478-5iu38pr6	2793	12	did	do	VBD
cord-005478-5iu38pr6	2793	13	not	not	RB
cord-005478-5iu38pr6	2793	14	impact	impact	VB
cord-005478-5iu38pr6	2793	15	on	on	IN
cord-005478-5iu38pr6	2793	16	any	any	DT
cord-005478-5iu38pr6	2793	17	of	of	IN
cord-005478-5iu38pr6	2793	18	these	these	DT
cord-005478-5iu38pr6	2793	19	outcomes	outcome	NNS
cord-005478-5iu38pr6	2793	20	.	.	.
cord-005478-5iu38pr6	2794	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2794	2	:	:	:
cord-005478-5iu38pr6	2795	1	This	this	DT
cord-005478-5iu38pr6	2795	2	study	study	NN
cord-005478-5iu38pr6	2795	3	demonstrates	demonstrate	VBZ
cord-005478-5iu38pr6	2795	4	that	that	IN
cord-005478-5iu38pr6	2795	5	in	in	IN
cord-005478-5iu38pr6	2795	6	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2795	7	patients	patient	NNS
cord-005478-5iu38pr6	2795	8	who	who	WP
cord-005478-5iu38pr6	2795	9	underwent	undergo	VBD
cord-005478-5iu38pr6	2795	10	an	an	DT
cord-005478-5iu38pr6	2795	11	HLA	HLA	NNP
cord-005478-5iu38pr6	2795	12	-	-	HYPH
cord-005478-5iu38pr6	2795	13	id	id	NNP
cord-005478-5iu38pr6	2795	14	SCT	SCT	NNP
cord-005478-5iu38pr6	2795	15	,	,	,
cord-005478-5iu38pr6	2795	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2795	17	prohphylaxis	prohphylaxis	NN
cord-005478-5iu38pr6	2795	18	strategies	strategy	NNS
cord-005478-5iu38pr6	2795	19	employing	employ	VBG
cord-005478-5iu38pr6	2795	20	PT	PT	NNP
cord-005478-5iu38pr6	2795	21	-	-	HYPH
cord-005478-5iu38pr6	2795	22	Cy	Cy	NNP
cord-005478-5iu38pr6	2795	23	-	-	HYPH
cord-005478-5iu38pr6	2795	24	based	base	VBN
cord-005478-5iu38pr6	2795	25	achieve	achieve	VBP
cord-005478-5iu38pr6	2795	26	equivalent	equivalent	JJ
cord-005478-5iu38pr6	2795	27	transplant	transplant	NN
cord-005478-5iu38pr6	2795	28	outcomes	outcome	NNS
cord-005478-5iu38pr6	2795	29	to	to	IN
cord-005478-5iu38pr6	2795	30	those	those	DT
cord-005478-5iu38pr6	2795	31	seen	see	VBN
cord-005478-5iu38pr6	2795	32	with	with	IN
cord-005478-5iu38pr6	2795	33	CNI	CNI	NNP
cord-005478-5iu38pr6	2795	34	-	-	HYPH
cord-005478-5iu38pr6	2795	35	based	base	VBN
cord-005478-5iu38pr6	2795	36	strategies	strategy	NNS
cord-005478-5iu38pr6	2795	37	.	.	.
cord-005478-5iu38pr6	2796	1	Myeloablative	Myeloablative	NNP
cord-005478-5iu38pr6	2796	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	2796	3	may	may	MD
cord-005478-5iu38pr6	2796	4	contribute	contribute	VB
cord-005478-5iu38pr6	2796	5	to	to	IN
cord-005478-5iu38pr6	2796	6	disease	disease	NN
cord-005478-5iu38pr6	2796	7	control	control	NN
cord-005478-5iu38pr6	2796	8	after	after	IN
cord-005478-5iu38pr6	2796	9	stem	stem	NN
cord-005478-5iu38pr6	2796	10	cell	cell	NN
cord-005478-5iu38pr6	2796	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	2796	12	in	in	IN
cord-005478-5iu38pr6	2796	13	blastic	blastic	JJ
cord-005478-5iu38pr6	2796	14	plasmacytoid	plasmacytoid	NNP
cord-005478-5iu38pr6	2797	1	dentric	dentric	JJ
cord-005478-5iu38pr6	2797	2	cell	cell	NN
cord-005478-5iu38pr6	2797	3	neoplasia	neoplasia	NN
cord-005478-5iu38pr6	2797	4	Background	background	NN
cord-005478-5iu38pr6	2797	5	:	:	:
cord-005478-5iu38pr6	2798	1	Blastic	Blastic	NNP
cord-005478-5iu38pr6	2798	2	plasmacytoid	plasmacytoid	NNP
cord-005478-5iu38pr6	2798	3	dentric	dentric	JJ
cord-005478-5iu38pr6	2798	4	cell	cell	NN
cord-005478-5iu38pr6	2798	5	neoplasia	neoplasia	NN
cord-005478-5iu38pr6	2798	6	(	(	-LRB-
cord-005478-5iu38pr6	2798	7	BPDCN	BPDCN	NNP
cord-005478-5iu38pr6	2798	8	)	)	-RRB-
cord-005478-5iu38pr6	2798	9	is	be	VBZ
cord-005478-5iu38pr6	2798	10	a	a	DT
cord-005478-5iu38pr6	2798	11	rare	rare	JJ
cord-005478-5iu38pr6	2798	12	and	and	CC
cord-005478-5iu38pr6	2798	13	clinically	clinically	RB
cord-005478-5iu38pr6	2798	14	aggressive	aggressive	JJ
cord-005478-5iu38pr6	2798	15	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2798	16	malignancy	malignancy	NN
cord-005478-5iu38pr6	2798	17	,	,	,
cord-005478-5iu38pr6	2798	18	which	which	WDT
cord-005478-5iu38pr6	2798	19	preferentially	preferentially	RB
cord-005478-5iu38pr6	2798	20	involves	involve	VBZ
cord-005478-5iu38pr6	2798	21	the	the	DT
cord-005478-5iu38pr6	2798	22	skin	skin	NN
cord-005478-5iu38pr6	2798	23	,	,	,
cord-005478-5iu38pr6	2798	24	the	the	DT
cord-005478-5iu38pr6	2798	25	bone	bone	NN
cord-005478-5iu38pr6	2798	26	marrow	marrow	NN
cord-005478-5iu38pr6	2798	27	,	,	,
cord-005478-5iu38pr6	2798	28	and	and	CC
cord-005478-5iu38pr6	2798	29	,	,	,
cord-005478-5iu38pr6	2798	30	occasionally	occasionally	RB
cord-005478-5iu38pr6	2798	31	,	,	,
cord-005478-5iu38pr6	2798	32	the	the	DT
cord-005478-5iu38pr6	2798	33	lymph	lymph	NN
cord-005478-5iu38pr6	2798	34	nodes	node	NNS
cord-005478-5iu38pr6	2798	35	.	.	.
cord-005478-5iu38pr6	2799	1	It	-PRON-	PRP
cord-005478-5iu38pr6	2799	2	mainly	mainly	RB
cord-005478-5iu38pr6	2799	3	affects	affect	VBZ
cord-005478-5iu38pr6	2799	4	elderly	elderly	JJ
cord-005478-5iu38pr6	2799	5	patients	patient	NNS
cord-005478-5iu38pr6	2799	6	and	and	CC
cord-005478-5iu38pr6	2799	7	has	have	VBZ
cord-005478-5iu38pr6	2799	8	a	a	DT
cord-005478-5iu38pr6	2799	9	poor	poor	JJ
cord-005478-5iu38pr6	2799	10	prognosis	prognosis	NN
cord-005478-5iu38pr6	2799	11	with	with	IN
cord-005478-5iu38pr6	2799	12	conventional	conventional	JJ
cord-005478-5iu38pr6	2799	13	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2799	14	.	.	.
cord-005478-5iu38pr6	2800	1	The	the	DT
cord-005478-5iu38pr6	2800	2	treatment	treatment	NN
cord-005478-5iu38pr6	2800	3	for	for	IN
cord-005478-5iu38pr6	2800	4	this	this	DT
cord-005478-5iu38pr6	2800	5	condition	condition	NN
cord-005478-5iu38pr6	2800	6	is	be	VBZ
cord-005478-5iu38pr6	2800	7	heterogeneous	heterogeneous	JJ
cord-005478-5iu38pr6	2800	8	,	,	,
cord-005478-5iu38pr6	2800	9	some	some	DT
cord-005478-5iu38pr6	2800	10	patients	patient	NNS
cord-005478-5iu38pr6	2800	11	treated	treat	VBN
cord-005478-5iu38pr6	2800	12	with	with	IN
cord-005478-5iu38pr6	2800	13	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2800	14	-	-	HYPH
cord-005478-5iu38pr6	2800	15	type	type	NN
cord-005478-5iu38pr6	2800	16	regimens	regimen	NNS
cord-005478-5iu38pr6	2800	17	and	and	CC
cord-005478-5iu38pr6	2800	18	others	other	NNS
cord-005478-5iu38pr6	2800	19	receiving	receive	VBG
cord-005478-5iu38pr6	2800	20	intensive	intensive	JJ
cord-005478-5iu38pr6	2800	21	acute	acute	JJ
cord-005478-5iu38pr6	2800	22	leukemiatype	leukemiatype	NN
cord-005478-5iu38pr6	2800	23	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2800	24	.	.	.
cord-005478-5iu38pr6	2801	1	Although	although	IN
cord-005478-5iu38pr6	2801	2	preliminary	preliminary	JJ
cord-005478-5iu38pr6	2801	3	case	case	NN
cord-005478-5iu38pr6	2801	4	series	serie	NNS
cord-005478-5iu38pr6	2801	5	suggest	suggest	VBP
cord-005478-5iu38pr6	2801	6	that	that	IN
cord-005478-5iu38pr6	2801	7	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2801	8	stem	stem	NN
cord-005478-5iu38pr6	2801	9	cell	cell	NN
cord-005478-5iu38pr6	2801	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	2801	11	(	(	-LRB-
cord-005478-5iu38pr6	2801	12	SCT	SCT	NNP
cord-005478-5iu38pr6	2801	13	)	)	-RRB-
cord-005478-5iu38pr6	2801	14	could	could	MD
cord-005478-5iu38pr6	2801	15	provide	provide	VB
cord-005478-5iu38pr6	2801	16	sustained	sustained	JJ
cord-005478-5iu38pr6	2801	17	disease	disease	NN
cord-005478-5iu38pr6	2801	18	control	control	NN
cord-005478-5iu38pr6	2801	19	in	in	IN
cord-005478-5iu38pr6	2801	20	patients	patient	NNS
cord-005478-5iu38pr6	2801	21	with	with	IN
cord-005478-5iu38pr6	2801	22	BPDCN	BPDCN	NNP
cord-005478-5iu38pr6	2801	23	,	,	,
cord-005478-5iu38pr6	2801	24	the	the	DT
cord-005478-5iu38pr6	2801	25	role	role	NN
cord-005478-5iu38pr6	2801	26	of	of	IN
cord-005478-5iu38pr6	2801	27	SCT	SCT	NNP
cord-005478-5iu38pr6	2801	28	and	and	CC
cord-005478-5iu38pr6	2801	29	potential	potential	JJ
cord-005478-5iu38pr6	2801	30	graft	graft	NN
cord-005478-5iu38pr6	2801	31	-	-	HYPH
cord-005478-5iu38pr6	2801	32	versus	versus	IN
cord-005478-5iu38pr6	2801	33	-	-	HYPH
cord-005478-5iu38pr6	2801	34	tumor	tumor	NN
cord-005478-5iu38pr6	2801	35	effects	effect	NNS
cord-005478-5iu38pr6	2801	36	(	(	-LRB-
cord-005478-5iu38pr6	2801	37	GVT	GVT	NNP
cord-005478-5iu38pr6	2801	38	)	)	-RRB-
cord-005478-5iu38pr6	2801	39	in	in	IN
cord-005478-5iu38pr6	2801	40	this	this	DT
cord-005478-5iu38pr6	2801	41	condition	condition	NN
cord-005478-5iu38pr6	2801	42	is	be	VBZ
cord-005478-5iu38pr6	2801	43	yet	yet	RB
cord-005478-5iu38pr6	2801	44	undefined	undefined	JJ
cord-005478-5iu38pr6	2801	45	.	.	.
cord-005478-5iu38pr6	2802	1	Methods	method	NNS
cord-005478-5iu38pr6	2802	2	:	:	:
cord-005478-5iu38pr6	2803	1	Between	between	IN
cord-005478-5iu38pr6	2803	2	2009	2009	CD
cord-005478-5iu38pr6	2803	3	and	and	CC
cord-005478-5iu38pr6	2803	4	2017	2017	CD
cord-005478-5iu38pr6	2803	5	26	26	CD
cord-005478-5iu38pr6	2803	6	patients	patient	NNS
cord-005478-5iu38pr6	2803	7	were	be	VBD
cord-005478-5iu38pr6	2803	8	included	include	VBN
cord-005478-5iu38pr6	2803	9	in	in	IN
cord-005478-5iu38pr6	2803	10	an	an	DT
cord-005478-5iu38pr6	2803	11	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2803	12	prospective	prospective	JJ
cord-005478-5iu38pr6	2803	13	non	non	JJ
cord-005478-5iu38pr6	2803	14	-	-	JJ
cord-005478-5iu38pr6	2803	15	interventional	interventional	JJ
cord-005478-5iu38pr6	2803	16	study	study	NN
cord-005478-5iu38pr6	2803	17	(	(	-LRB-
cord-005478-5iu38pr6	2803	18	NIS	NIS	NNP
cord-005478-5iu38pr6	2803	19	)	)	-RRB-
cord-005478-5iu38pr6	2803	20	on	on	IN
cord-005478-5iu38pr6	2803	21	the	the	DT
cord-005478-5iu38pr6	2803	22	value	value	NN
cord-005478-5iu38pr6	2803	23	of	of	IN
cord-005478-5iu38pr6	2803	24	SCT	SCT	NNP
cord-005478-5iu38pr6	2803	25	in	in	IN
cord-005478-5iu38pr6	2803	26	BPDCN	BPDCN	NNP
cord-005478-5iu38pr6	2803	27	.	.	.
cord-005478-5iu38pr6	2804	1	These	these	DT
cord-005478-5iu38pr6	2804	2	were	be	VBD
cord-005478-5iu38pr6	2804	3	compared	compare	VBN
cord-005478-5iu38pr6	2804	4	with	with	IN
cord-005478-5iu38pr6	2804	5	133	133	CD
cord-005478-5iu38pr6	2804	6	patients	patient	NNS
cord-005478-5iu38pr6	2804	7	with	with	IN
cord-005478-5iu38pr6	2804	8	BPDCN	BPDCN	NNP
cord-005478-5iu38pr6	2804	9	registered	register	VBN
cord-005478-5iu38pr6	2804	10	with	with	IN
cord-005478-5iu38pr6	2804	11	the	the	DT
cord-005478-5iu38pr6	2804	12	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2804	13	during	during	IN
cord-005478-5iu38pr6	2804	14	the	the	DT
cord-005478-5iu38pr6	2804	15	same	same	JJ
cord-005478-5iu38pr6	2804	16	time	time	NN
cord-005478-5iu38pr6	2804	17	period	period	NN
cord-005478-5iu38pr6	2804	18	outside	outside	IN
cord-005478-5iu38pr6	2804	19	the	the	DT
cord-005478-5iu38pr6	2804	20	NIS	NIS	NNP
cord-005478-5iu38pr6	2804	21	.	.	.
cord-005478-5iu38pr6	2805	1	No	no	DT
cord-005478-5iu38pr6	2805	2	differences	difference	NNS
cord-005478-5iu38pr6	2805	3	with	with	IN
cord-005478-5iu38pr6	2805	4	regard	regard	NN
cord-005478-5iu38pr6	2805	5	to	to	IN
cord-005478-5iu38pr6	2805	6	overall	overall	JJ
cord-005478-5iu38pr6	2805	7	survival	survival	NN
cord-005478-5iu38pr6	2805	8	(	(	-LRB-
cord-005478-5iu38pr6	2805	9	OS	OS	NNP
cord-005478-5iu38pr6	2805	10	)	)	-RRB-
cord-005478-5iu38pr6	2805	11	,	,	,
cord-005478-5iu38pr6	2805	12	line	line	NN
cord-005478-5iu38pr6	2805	13	of	of	IN
cord-005478-5iu38pr6	2805	14	treatment	treatment	NN
cord-005478-5iu38pr6	2805	15	or	or	CC
cord-005478-5iu38pr6	2805	16	year	year	NN
cord-005478-5iu38pr6	2805	17	of	of	IN
cord-005478-5iu38pr6	2805	18	transplant	transplant	NN
cord-005478-5iu38pr6	2805	19	was	be	VBD
cord-005478-5iu38pr6	2805	20	observed	observe	VBN
cord-005478-5iu38pr6	2805	21	between	between	IN
cord-005478-5iu38pr6	2805	22	patients	patient	NNS
cord-005478-5iu38pr6	2805	23	included	include	VBN
cord-005478-5iu38pr6	2805	24	in	in	IN
cord-005478-5iu38pr6	2805	25	the	the	DT
cord-005478-5iu38pr6	2805	26	NIS	NIS	NNP
cord-005478-5iu38pr6	2805	27	and	and	CC
cord-005478-5iu38pr6	2805	28	the	the	DT
cord-005478-5iu38pr6	2805	29	remainder	remainder	NN
cord-005478-5iu38pr6	2805	30	from	from	IN
cord-005478-5iu38pr6	2805	31	the	the	DT
cord-005478-5iu38pr6	2805	32	EBMT	EBMT	NNP
cord-005478-5iu38pr6	2805	33	database	database	NN
cord-005478-5iu38pr6	2805	34	,	,	,
cord-005478-5iu38pr6	2805	35	and	and	CC
cord-005478-5iu38pr6	2805	36	they	-PRON-	PRP
cord-005478-5iu38pr6	2805	37	were	be	VBD
cord-005478-5iu38pr6	2805	38	therefore	therefore	RB
cord-005478-5iu38pr6	2805	39	analyzed	analyze	VBN
cord-005478-5iu38pr6	2805	40	together	together	RB
cord-005478-5iu38pr6	2805	41	.	.	.
cord-005478-5iu38pr6	2806	1	Results	result	NNS
cord-005478-5iu38pr6	2806	2	:	:	:
cord-005478-5iu38pr6	2807	1	One	one	CD
cord-005478-5iu38pr6	2807	2	hundred	hundred	CD
cord-005478-5iu38pr6	2807	3	and	and	CC
cord-005478-5iu38pr6	2807	4	forty	forty	CD
cord-005478-5iu38pr6	2807	5	-	-	HYPH
cord-005478-5iu38pr6	2807	6	two	two	CD
cord-005478-5iu38pr6	2807	7	patients	patient	NNS
cord-005478-5iu38pr6	2807	8	were	be	VBD
cord-005478-5iu38pr6	2807	9	treated	treat	VBN
cord-005478-5iu38pr6	2807	10	with	with	IN
cord-005478-5iu38pr6	2807	11	an	an	DT
cord-005478-5iu38pr6	2807	12	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2807	13	SCT	sct	NN
cord-005478-5iu38pr6	2807	14	(	(	-LRB-
cord-005478-5iu38pr6	2807	15	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2807	16	)	)	-RRB-
cord-005478-5iu38pr6	2807	17	and	and	CC
cord-005478-5iu38pr6	2807	18	17	17	CD
cord-005478-5iu38pr6	2807	19	patients	patient	NNS
cord-005478-5iu38pr6	2807	20	with	with	IN
cord-005478-5iu38pr6	2807	21	autologous	autologous	JJ
cord-005478-5iu38pr6	2807	22	or	or	CC
cord-005478-5iu38pr6	2807	23	syngeneic	syngeneic	NNS
cord-005478-5iu38pr6	2807	24	SCT	SCT	NNP
cord-005478-5iu38pr6	2807	25	(	(	-LRB-
cord-005478-5iu38pr6	2807	26	AUTOSYN	AUTOSYN	NNP
cord-005478-5iu38pr6	2807	27	)	)	-RRB-
cord-005478-5iu38pr6	2807	28	.	.	.
cord-005478-5iu38pr6	2808	1	The	the	DT
cord-005478-5iu38pr6	2808	2	median	median	JJ
cord-005478-5iu38pr6	2808	3	follow	follow	NN
cord-005478-5iu38pr6	2808	4	-	-	HYPH
cord-005478-5iu38pr6	2808	5	up	up	NN
cord-005478-5iu38pr6	2808	6	was	be	VBD
cord-005478-5iu38pr6	2808	7	17	17	CD
cord-005478-5iu38pr6	2808	8	months	month	NNS
cord-005478-5iu38pr6	2808	9	with	with	IN
cord-005478-5iu38pr6	2808	10	no	no	DT
cord-005478-5iu38pr6	2808	11	differences	difference	NNS
cord-005478-5iu38pr6	2808	12	between	between	IN
cord-005478-5iu38pr6	2808	13	the	the	DT
cord-005478-5iu38pr6	2808	14	alloSCT	allosct	NN
cord-005478-5iu38pr6	2808	15	and	and	CC
cord-005478-5iu38pr6	2808	16	AUTOSYN	AUTOSYN	NNP
cord-005478-5iu38pr6	2808	17	groups	group	NNS
cord-005478-5iu38pr6	2808	18	.	.	.
cord-005478-5iu38pr6	2809	1	Disease	disease	NN
cord-005478-5iu38pr6	2809	2	status	status	NN
cord-005478-5iu38pr6	2809	3	at	at	IN
cord-005478-5iu38pr6	2809	4	SCT	SCT	NNP
cord-005478-5iu38pr6	2809	5	was	be	VBD
cord-005478-5iu38pr6	2809	6	complete	complete	JJ
cord-005478-5iu38pr6	2809	7	remission	remission	NN
cord-005478-5iu38pr6	2809	8	(	(	-LRB-
cord-005478-5iu38pr6	2809	9	CR	CR	NNP
cord-005478-5iu38pr6	2809	10	)	)	-RRB-
cord-005478-5iu38pr6	2809	11	in	in	IN
cord-005478-5iu38pr6	2809	12	88	88	CD
cord-005478-5iu38pr6	2809	13	%	%	NN
cord-005478-5iu38pr6	2809	14	,	,	,
cord-005478-5iu38pr6	2809	15	and	and	CC
cord-005478-5iu38pr6	2809	16	90	90	CD
cord-005478-5iu38pr6	2809	17	%	%	NN
cord-005478-5iu38pr6	2809	18	patients	patient	NNS
cord-005478-5iu38pr6	2809	19	received	receive	VBD
cord-005478-5iu38pr6	2809	20	the	the	DT
cord-005478-5iu38pr6	2809	21	SCT	SCT	NNP
cord-005478-5iu38pr6	2809	22	as	as	IN
cord-005478-5iu38pr6	2809	23	part	part	NN
cord-005478-5iu38pr6	2809	24	of	of	IN
cord-005478-5iu38pr6	2809	25	first	first	JJ
cord-005478-5iu38pr6	2809	26	-	-	HYPH
cord-005478-5iu38pr6	2809	27	line	line	NN
cord-005478-5iu38pr6	2809	28	treatment	treatment	NN
cord-005478-5iu38pr6	2809	29	.	.	.
cord-005478-5iu38pr6	2810	1	Two	two	CD
cord-005478-5iu38pr6	2810	2	-	-	HYPH
cord-005478-5iu38pr6	2810	3	year	year	NN
cord-005478-5iu38pr6	2810	4	OS	os	NN
cord-005478-5iu38pr6	2810	5	after	after	IN
cord-005478-5iu38pr6	2810	6	AUTOSYN	AUTOSYN	NNP
cord-005478-5iu38pr6	2810	7	was	be	VBD
cord-005478-5iu38pr6	2810	8	70	70	CD
cord-005478-5iu38pr6	2810	9	%	%	NN
cord-005478-5iu38pr6	2810	10	(	(	-LRB-
cord-005478-5iu38pr6	2810	11	95	95	CD
cord-005478-5iu38pr6	2810	12	%	%	NN
cord-005478-5iu38pr6	2810	13	CI	CI	NNP
cord-005478-5iu38pr6	2810	14	46	46	CD
cord-005478-5iu38pr6	2810	15	-	-	SYM
cord-005478-5iu38pr6	2810	16	99	99	CD
cord-005478-5iu38pr6	2810	17	%	%	NN
cord-005478-5iu38pr6	2810	18	)	)	-RRB-
cord-005478-5iu38pr6	2810	19	,	,	,
cord-005478-5iu38pr6	2810	20	whereas	whereas	IN
cord-005478-5iu38pr6	2810	21	it	-PRON-	PRP
cord-005478-5iu38pr6	2810	22	was	be	VBD
cord-005478-5iu38pr6	2810	23	65	65	CD
cord-005478-5iu38pr6	2810	24	%	%	NN
cord-005478-5iu38pr6	2810	25	(	(	-LRB-
cord-005478-5iu38pr6	2810	26	95	95	CD
cord-005478-5iu38pr6	2810	27	%	%	NN
cord-005478-5iu38pr6	2810	28	CI	CI	NNP
cord-005478-5iu38pr6	2810	29	53	53	CD
cord-005478-5iu38pr6	2810	30	-	-	SYM
cord-005478-5iu38pr6	2810	31	83	83	CD
cord-005478-5iu38pr6	2810	32	%	%	NN
cord-005478-5iu38pr6	2810	33	)	)	-RRB-
cord-005478-5iu38pr6	2810	34	following	follow	VBG
cord-005478-5iu38pr6	2810	35	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2810	36	.	.	.
cord-005478-5iu38pr6	2811	1	Of	of	IN
cord-005478-5iu38pr6	2811	2	those	those	DT
cord-005478-5iu38pr6	2811	3	patients	patient	NNS
cord-005478-5iu38pr6	2811	4	who	who	WP
cord-005478-5iu38pr6	2811	5	received	receive	VBD
cord-005478-5iu38pr6	2811	6	an	an	DT
cord-005478-5iu38pr6	2811	7	alloSCT	allosct	NN
cord-005478-5iu38pr6	2811	8	,	,	,
cord-005478-5iu38pr6	2811	9	71	71	CD
cord-005478-5iu38pr6	2811	10	%	%	NN
cord-005478-5iu38pr6	2811	11	were	be	VBD
cord-005478-5iu38pr6	2811	12	transplanted	transplant	VBN
cord-005478-5iu38pr6	2811	13	from	from	IN
cord-005478-5iu38pr6	2811	14	an	an	DT
cord-005478-5iu38pr6	2811	15	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2811	16	donor	donor	NN
cord-005478-5iu38pr6	2811	17	(	(	-LRB-
cord-005478-5iu38pr6	2811	18	UD	UD	NNP
cord-005478-5iu38pr6	2811	19	)	)	-RRB-
cord-005478-5iu38pr6	2811	20	,	,	,
cord-005478-5iu38pr6	2811	21	and	and	CC
cord-005478-5iu38pr6	2811	22	29	29	CD
cord-005478-5iu38pr6	2811	23	%	%	NN
cord-005478-5iu38pr6	2811	24	from	from	IN
cord-005478-5iu38pr6	2811	25	an	an	DT
cord-005478-5iu38pr6	2811	26	identical	identical	JJ
cord-005478-5iu38pr6	2811	27	sibling	sibling	NN
cord-005478-5iu38pr6	2811	28	donor	donor	NN
cord-005478-5iu38pr6	2811	29	(	(	-LRB-
cord-005478-5iu38pr6	2811	30	SIB	SIB	NNP
cord-005478-5iu38pr6	2811	31	)	)	-RRB-
cord-005478-5iu38pr6	2811	32	.	.	.
cord-005478-5iu38pr6	2812	1	Reduced	reduced	JJ
cord-005478-5iu38pr6	2812	2	intensity	intensity	NN
cord-005478-5iu38pr6	2812	3	conditioning	conditioning	NN
cord-005478-5iu38pr6	2812	4	(	(	-LRB-
cord-005478-5iu38pr6	2812	5	RIC	RIC	NNP
cord-005478-5iu38pr6	2812	6	)	)	-RRB-
cord-005478-5iu38pr6	2812	7	was	be	VBD
cord-005478-5iu38pr6	2812	8	used	use	VBN
cord-005478-5iu38pr6	2812	9	in	in	IN
cord-005478-5iu38pr6	2812	10	47	47	CD
cord-005478-5iu38pr6	2812	11	%	%	NN
cord-005478-5iu38pr6	2812	12	and	and	CC
cord-005478-5iu38pr6	2812	13	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	2812	14	conditioning	conditioning	NN
cord-005478-5iu38pr6	2812	15	(	(	-LRB-
cord-005478-5iu38pr6	2812	16	MAC	MAC	NNP
cord-005478-5iu38pr6	2812	17	)	)	-RRB-
cord-005478-5iu38pr6	2812	18	in	in	IN
cord-005478-5iu38pr6	2812	19	53	53	CD
cord-005478-5iu38pr6	2812	20	%	%	NN
cord-005478-5iu38pr6	2812	21	of	of	IN
cord-005478-5iu38pr6	2812	22	the	the	DT
cord-005478-5iu38pr6	2812	23	patients	patient	NNS
cord-005478-5iu38pr6	2812	24	.	.	.
cord-005478-5iu38pr6	2813	1	In	in	IN
cord-005478-5iu38pr6	2813	2	allotransplanted	allotransplante	VBN
cord-005478-5iu38pr6	2813	3	patients	patient	NNS
cord-005478-5iu38pr6	2813	4	,	,	,
cord-005478-5iu38pr6	2813	5	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2813	6	competitive	competitive	JJ
cord-005478-5iu38pr6	2813	7	risk	risk	NN
cord-005478-5iu38pr6	2813	8	analysis	analysis	NN
cord-005478-5iu38pr6	2813	9	of	of	IN
cord-005478-5iu38pr6	2813	10	NRM	NRM	NNP
cord-005478-5iu38pr6	2813	11	and	and	CC
cord-005478-5iu38pr6	2813	12	relapse	relapse	NN
cord-005478-5iu38pr6	2813	13	incidence	incidence	NN
cord-005478-5iu38pr6	2813	14	considering	consider	VBG
cord-005478-5iu38pr6	2813	15	age	age	NN
cord-005478-5iu38pr6	2813	16	,	,	,
cord-005478-5iu38pr6	2813	17	conditioning	conditioning	NN
cord-005478-5iu38pr6	2813	18	intensity	intensity	NN
cord-005478-5iu38pr6	2813	19	,	,	,
cord-005478-5iu38pr6	2813	20	line	line	NN
cord-005478-5iu38pr6	2813	21	of	of	IN
cord-005478-5iu38pr6	2813	22	treatment	treatment	NN
cord-005478-5iu38pr6	2813	23	,	,	,
cord-005478-5iu38pr6	2813	24	remission	remission	NN
cord-005478-5iu38pr6	2813	25	status	status	NN
cord-005478-5iu38pr6	2813	26	prior	prior	RB
cord-005478-5iu38pr6	2813	27	to	to	IN
cord-005478-5iu38pr6	2813	28	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2813	29	and	and	CC
cord-005478-5iu38pr6	2813	30	donor	donor	NN
cord-005478-5iu38pr6	2813	31	type	type	NN
cord-005478-5iu38pr6	2813	32	revealed	reveal	VBD
cord-005478-5iu38pr6	2813	33	a	a	DT
cord-005478-5iu38pr6	2813	34	statistically	statistically	RB
cord-005478-5iu38pr6	2813	35	significant	significant	JJ
cord-005478-5iu38pr6	2813	36	reduction	reduction	NN
cord-005478-5iu38pr6	2813	37	of	of	IN
cord-005478-5iu38pr6	2813	38	relapse	relapse	NN
cord-005478-5iu38pr6	2813	39	incidence	incidence	NN
cord-005478-5iu38pr6	2813	40	(	(	-LRB-
cord-005478-5iu38pr6	2813	41	p=0.02	p=0.02	NNP
cord-005478-5iu38pr6	2813	42	,	,	,
cord-005478-5iu38pr6	2813	43	HR	HR	NNP
cord-005478-5iu38pr6	2813	44	0.2	0.2	CD
cord-005478-5iu38pr6	2813	45	CI	CI	NNP
cord-005478-5iu38pr6	2813	46	0.1	0.1	CD
cord-005478-5iu38pr6	2813	47	-	-	HYPH
cord-005478-5iu38pr6	2813	48	0.7	0.7	CD
cord-005478-5iu38pr6	2813	49	)	)	-RRB-
cord-005478-5iu38pr6	2813	50	without	without	IN
cord-005478-5iu38pr6	2813	51	increased	increase	VBN
cord-005478-5iu38pr6	2813	52	NRM	NRM	NNP
cord-005478-5iu38pr6	2813	53	for	for	IN
cord-005478-5iu38pr6	2813	54	patients	patient	NNS
cord-005478-5iu38pr6	2813	55	who	who	WP
cord-005478-5iu38pr6	2813	56	received	receive	VBD
cord-005478-5iu38pr6	2813	57	MAC	MAC	NNP
cord-005478-5iu38pr6	2813	58	compared	compare	VBN
cord-005478-5iu38pr6	2813	59	to	to	IN
cord-005478-5iu38pr6	2813	60	RIC	RIC	NNP
cord-005478-5iu38pr6	2813	61	.	.	.
cord-005478-5iu38pr6	2814	1	Multivariate	Multivariate	NNP
cord-005478-5iu38pr6	2814	2	cox	cox	NNP
cord-005478-5iu38pr6	2814	3	regression	regression	NN
cord-005478-5iu38pr6	2814	4	analysis	analysis	NN
cord-005478-5iu38pr6	2814	5	for	for	IN
cord-005478-5iu38pr6	2814	6	OS	OS	NNP
cord-005478-5iu38pr6	2814	7	considering	consider	VBG
cord-005478-5iu38pr6	2814	8	the	the	DT
cord-005478-5iu38pr6	2814	9	same	same	JJ
cord-005478-5iu38pr6	2814	10	co	co	NNS
cord-005478-5iu38pr6	2814	11	-	-	NNS
cord-005478-5iu38pr6	2814	12	variates	variate	NNS
cord-005478-5iu38pr6	2814	13	confirmed	confirm	VBD
cord-005478-5iu38pr6	2814	14	that	that	IN
cord-005478-5iu38pr6	2814	15	MAC	MAC	NNP
cord-005478-5iu38pr6	2814	16	was	be	VBD
cord-005478-5iu38pr6	2814	17	associated	associate	VBN
cord-005478-5iu38pr6	2814	18	with	with	IN
cord-005478-5iu38pr6	2814	19	a	a	DT
cord-005478-5iu38pr6	2814	20	significantly	significantly	RB
cord-005478-5iu38pr6	2814	21	reduced	reduce	VBN
cord-005478-5iu38pr6	2814	22	mortality	mortality	NN
cord-005478-5iu38pr6	2814	23	risk	risk	NN
cord-005478-5iu38pr6	2814	24	(	(	-LRB-
cord-005478-5iu38pr6	2814	25	p=0.05	p=0.05	NNP
cord-005478-5iu38pr6	2814	26	,	,	,
cord-005478-5iu38pr6	2814	27	CI	CI	NNP
cord-005478-5iu38pr6	2814	28	0.4	0.4	CD
cord-005478-5iu38pr6	2814	29	,	,	,
cord-005478-5iu38pr6	2814	30	HR	HR	NNP
cord-005478-5iu38pr6	2814	31	0.1	0.1	CD
cord-005478-5iu38pr6	2814	32	-	-	HYPH
cord-005478-5iu38pr6	2814	33	0.99	0.99	CD
cord-005478-5iu38pr6	2814	34	)	)	-RRB-
cord-005478-5iu38pr6	2814	35	along	along	IN
cord-005478-5iu38pr6	2814	36	with	with	IN
cord-005478-5iu38pr6	2814	37	being	be	VBG
cord-005478-5iu38pr6	2814	38	in	in	IN
cord-005478-5iu38pr6	2814	39	CR	CR	NNP
cord-005478-5iu38pr6	2814	40	at	at	IN
cord-005478-5iu38pr6	2814	41	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	2814	42	(	(	-LRB-
cord-005478-5iu38pr6	2814	43	p	p	NN
cord-005478-5iu38pr6	2814	44	<	<	XX
cord-005478-5iu38pr6	2814	45	0.001	0.001	CD
cord-005478-5iu38pr6	2814	46	,	,	,
cord-005478-5iu38pr6	2814	47	HR	HR	NNP
cord-005478-5iu38pr6	2814	48	9.1	9.1	CD
cord-005478-5iu38pr6	2814	49	,	,	,
cord-005478-5iu38pr6	2814	50	.	.	.
cord-005478-5iu38pr6	2815	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2815	2	:	:	:
cord-005478-5iu38pr6	2816	1	This	this	DT
cord-005478-5iu38pr6	2816	2	study	study	NN
cord-005478-5iu38pr6	2816	3	confirms	confirm	VBZ
cord-005478-5iu38pr6	2816	4	on	on	IN
cord-005478-5iu38pr6	2816	5	a	a	DT
cord-005478-5iu38pr6	2816	6	large	large	JJ
cord-005478-5iu38pr6	2816	7	data	datum	NNS
cord-005478-5iu38pr6	2816	8	set	set	NN
cord-005478-5iu38pr6	2816	9	that	that	IN
cord-005478-5iu38pr6	2816	10	SCT	SCT	NNP
cord-005478-5iu38pr6	2816	11	is	be	VBZ
cord-005478-5iu38pr6	2816	12	an	an	DT
cord-005478-5iu38pr6	2816	13	effective	effective	JJ
cord-005478-5iu38pr6	2816	14	and	and	CC
cord-005478-5iu38pr6	2816	15	potentially	potentially	RB
cord-005478-5iu38pr6	2816	16	curative	curative	JJ
cord-005478-5iu38pr6	2816	17	treatment	treatment	NN
cord-005478-5iu38pr6	2816	18	for	for	IN
cord-005478-5iu38pr6	2816	19	patients	patient	NNS
cord-005478-5iu38pr6	2816	20	with	with	IN
cord-005478-5iu38pr6	2816	21	BPDCN	BPDCN	NNP
cord-005478-5iu38pr6	2816	22	.	.	.
cord-005478-5iu38pr6	2817	1	The	the	DT
cord-005478-5iu38pr6	2817	2	superiority	superiority	NN
cord-005478-5iu38pr6	2817	3	of	of	IN
cord-005478-5iu38pr6	2817	4	MAC	MAC	NNP
cord-005478-5iu38pr6	2817	5	and	and	CC
cord-005478-5iu38pr6	2817	6	the	the	DT
cord-005478-5iu38pr6	2817	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	2817	8	of	of	IN
cord-005478-5iu38pr6	2817	9	AUTOSYN	AUTOSYN	NNP
cord-005478-5iu38pr6	2817	10	suggest	suggest	VBP
cord-005478-5iu38pr6	2817	11	that	that	IN
cord-005478-5iu38pr6	2817	12	apart	apart	RB
cord-005478-5iu38pr6	2817	13	from	from	IN
cord-005478-5iu38pr6	2817	14	GVT	GVT	NNP
cord-005478-5iu38pr6	2817	15	,	,	,
cord-005478-5iu38pr6	2817	16	highdose	highdose	NN
cord-005478-5iu38pr6	2817	17	therapy	therapy	NN
cord-005478-5iu38pr6	2817	18	might	may	MD
cord-005478-5iu38pr6	2817	19	be	be	VB
cord-005478-5iu38pr6	2817	20	an	an	DT
cord-005478-5iu38pr6	2817	21	important	important	JJ
cord-005478-5iu38pr6	2817	22	contributor	contributor	NN
cord-005478-5iu38pr6	2817	23	to	to	IN
cord-005478-5iu38pr6	2817	24	long	long	JJ
cord-005478-5iu38pr6	2817	25	-	-	HYPH
cord-005478-5iu38pr6	2817	26	term	term	NN
cord-005478-5iu38pr6	2817	27	disease	disease	NN
cord-005478-5iu38pr6	2817	28	control	control	NN
cord-005478-5iu38pr6	2817	29	in	in	IN
cord-005478-5iu38pr6	2817	30	this	this	DT
cord-005478-5iu38pr6	2817	31	condition	condition	NN
cord-005478-5iu38pr6	2817	32	.	.	.
cord-005478-5iu38pr6	2818	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2818	2	Background	background	NN
cord-005478-5iu38pr6	2818	3	:	:	:
cord-005478-5iu38pr6	2819	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2819	2	hematopoetic	hematopoetic	JJ
cord-005478-5iu38pr6	2819	3	cell	cell	NN
cord-005478-5iu38pr6	2819	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	2819	5	(	(	-LRB-
cord-005478-5iu38pr6	2819	6	allo	allo	NN
cord-005478-5iu38pr6	2819	7	-	-	HYPH
cord-005478-5iu38pr6	2819	8	HCT	HCT	NNP
cord-005478-5iu38pr6	2819	9	)	)	-RRB-
cord-005478-5iu38pr6	2819	10	is	be	VBZ
cord-005478-5iu38pr6	2819	11	a	a	DT
cord-005478-5iu38pr6	2819	12	curative	curative	JJ
cord-005478-5iu38pr6	2819	13	therapy	therapy	NN
cord-005478-5iu38pr6	2819	14	for	for	IN
cord-005478-5iu38pr6	2819	15	patients	patient	NNS
cord-005478-5iu38pr6	2819	16	with	with	IN
cord-005478-5iu38pr6	2819	17	relapsed/	relapsed/	NN
cord-005478-5iu38pr6	2819	18	refractory	refractory	JJ
cord-005478-5iu38pr6	2819	19	and	and	CC
cord-005478-5iu38pr6	2819	20	high	high	JJ
cord-005478-5iu38pr6	2819	21	-	-	HYPH
cord-005478-5iu38pr6	2819	22	risk	risk	NN
cord-005478-5iu38pr6	2819	23	non	non	JJ
cord-005478-5iu38pr6	2819	24	-	-	JJ
cord-005478-5iu38pr6	2819	25	Hodgkin	hodgkin	JJ
cord-005478-5iu38pr6	2819	26	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2819	27	(	(	-LRB-
cord-005478-5iu38pr6	2819	28	NHL	NHL	NNP
cord-005478-5iu38pr6	2819	29	)	)	-RRB-
cord-005478-5iu38pr6	2819	30	.	.	.
cord-005478-5iu38pr6	2820	1	However	however	RB
cord-005478-5iu38pr6	2820	2	,	,	,
cord-005478-5iu38pr6	2820	3	no	no	DT
cord-005478-5iu38pr6	2820	4	large	large	JJ
cord-005478-5iu38pr6	2820	5	studies	study	NNS
cord-005478-5iu38pr6	2820	6	have	have	VBP
cord-005478-5iu38pr6	2820	7	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2820	8	the	the	DT
cord-005478-5iu38pr6	2820	9	trends	trend	NNS
cord-005478-5iu38pr6	2820	10	in	in	IN
cord-005478-5iu38pr6	2820	11	the	the	DT
cord-005478-5iu38pr6	2820	12	utilization	utilization	NN
cord-005478-5iu38pr6	2820	13	of	of	IN
cord-005478-5iu38pr6	2820	14	allo	allo	NN
cord-005478-5iu38pr6	2820	15	-	-	HYPH
cord-005478-5iu38pr6	2820	16	HCT	hct	NN
cord-005478-5iu38pr6	2820	17	in	in	IN
cord-005478-5iu38pr6	2820	18	elderly	elderly	JJ
cord-005478-5iu38pr6	2820	19	NHL	NHL	NNP
cord-005478-5iu38pr6	2820	20	patients	patient	NNS
cord-005478-5iu38pr6	2820	21	(	(	-LRB-
cord-005478-5iu38pr6	2820	22	≥65	≥65	IN
cord-005478-5iu38pr6	2820	23	years	year	NNS
cord-005478-5iu38pr6	2820	24	)	)	-RRB-
cord-005478-5iu38pr6	2820	25	.	.	.
cord-005478-5iu38pr6	2821	1	Using	use	VBG
cord-005478-5iu38pr6	2821	2	the	the	DT
cord-005478-5iu38pr6	2821	3	CIBMTR	CIBMTR	NNP
cord-005478-5iu38pr6	2821	4	registry	registry	NN
cord-005478-5iu38pr6	2821	5	we	-PRON-	PRP
cord-005478-5iu38pr6	2821	6	report	report	VBP
cord-005478-5iu38pr6	2821	7	here	here	RB
cord-005478-5iu38pr6	2821	8	a	a	DT
cord-005478-5iu38pr6	2821	9	time	time	NN
cord-005478-5iu38pr6	2821	10	trends	trend	NNS
cord-005478-5iu38pr6	2821	11	analysis	analysis	NN
cord-005478-5iu38pr6	2821	12	of	of	IN
cord-005478-5iu38pr6	2821	13	allo	allo	NN
cord-005478-5iu38pr6	2821	14	-	-	HYPH
cord-005478-5iu38pr6	2821	15	HCT	hct	NN
cord-005478-5iu38pr6	2821	16	use	use	NN
cord-005478-5iu38pr6	2821	17	in	in	IN
cord-005478-5iu38pr6	2821	18	elderly	elderly	JJ
cord-005478-5iu38pr6	2821	19	NHL	NHL	NNP
cord-005478-5iu38pr6	2821	20	subjects	subject	NNS
cord-005478-5iu38pr6	2822	1	Methods	method	NNS
cord-005478-5iu38pr6	2823	1	:	:	:
cord-005478-5iu38pr6	2823	2	We	-PRON-	PRP
cord-005478-5iu38pr6	2823	3	identified	identify	VBD
cord-005478-5iu38pr6	2823	4	727	727	CD
cord-005478-5iu38pr6	2823	5	NHL	NHL	NNP
cord-005478-5iu38pr6	2823	6	patients	patient	NNS
cord-005478-5iu38pr6	2823	7	(	(	-LRB-
cord-005478-5iu38pr6	2823	8	≥65	≥65	IN
cord-005478-5iu38pr6	2823	9	years	year	NNS
cord-005478-5iu38pr6	2823	10	of	of	IN
cord-005478-5iu38pr6	2823	11	age	age	NN
cord-005478-5iu38pr6	2823	12	)	)	-RRB-
cord-005478-5iu38pr6	2823	13	undergoing	undergo	VBG
cord-005478-5iu38pr6	2823	14	a	a	DT
cord-005478-5iu38pr6	2823	15	first	first	JJ
cord-005478-5iu38pr6	2823	16	alloHCT	allohct	NN
cord-005478-5iu38pr6	2823	17	during	during	IN
cord-005478-5iu38pr6	2823	18	2000	2000	CD
cord-005478-5iu38pr6	2823	19	-	-	SYM
cord-005478-5iu38pr6	2823	20	2015	2015	CD
cord-005478-5iu38pr6	2823	21	in	in	IN
cord-005478-5iu38pr6	2823	22	the	the	DT
cord-005478-5iu38pr6	2823	23	United	United	NNP
cord-005478-5iu38pr6	2823	24	States	States	NNP
cord-005478-5iu38pr6	2823	25	(	(	-LRB-
cord-005478-5iu38pr6	2823	26	U.S.	U.S.	NNP
cord-005478-5iu38pr6	2823	27	)	)	-RRB-
cord-005478-5iu38pr6	2823	28	.	.	.
cord-005478-5iu38pr6	2824	1	Study	study	NN
cord-005478-5iu38pr6	2824	2	cohort	cohort	NN
cord-005478-5iu38pr6	2824	3	was	be	VBD
cord-005478-5iu38pr6	2824	4	divided	divide	VBN
cord-005478-5iu38pr6	2824	5	into	into	IN
cord-005478-5iu38pr6	2824	6	the	the	DT
cord-005478-5iu38pr6	2824	7	following	following	JJ
cord-005478-5iu38pr6	2824	8	time	time	NN
cord-005478-5iu38pr6	2824	9	-	-	HYPH
cord-005478-5iu38pr6	2824	10	periods	period	NNS
cord-005478-5iu38pr6	2824	11	for	for	IN
cord-005478-5iu38pr6	2824	12	analysis	analysis	NN
cord-005478-5iu38pr6	2824	13	;	;	:
cord-005478-5iu38pr6	2824	14	2000	2000	CD
cord-005478-5iu38pr6	2824	15	-	-	SYM
cord-005478-5iu38pr6	2824	16	2005	2005	CD
cord-005478-5iu38pr6	2824	17	vs.	vs.	IN
cord-005478-5iu38pr6	2824	18	2006	2006	CD
cord-005478-5iu38pr6	2824	19	-	-	SYM
cord-005478-5iu38pr6	2824	20	2010	2010	CD
cord-005478-5iu38pr6	2824	21	vs.	vs.	IN
cord-005478-5iu38pr6	2824	22	2011	2011	CD
cord-005478-5iu38pr6	2824	23	-	-	SYM
cord-005478-5iu38pr6	2824	24	2015	2015	CD
cord-005478-5iu38pr6	2824	25	.	.	.
cord-005478-5iu38pr6	2825	1	Primary	primary	JJ
cord-005478-5iu38pr6	2825	2	outcome	outcome	NN
cord-005478-5iu38pr6	2825	3	was	be	VBD
cord-005478-5iu38pr6	2825	4	overall	overall	JJ
cord-005478-5iu38pr6	2825	5	survival	survival	NN
cord-005478-5iu38pr6	2825	6	(	(	-LRB-
cord-005478-5iu38pr6	2825	7	OS	OS	NNP
cord-005478-5iu38pr6	2825	8	)	)	-RRB-
cord-005478-5iu38pr6	2825	9	.	.	.
cord-005478-5iu38pr6	2826	1	Secondary	secondary	JJ
cord-005478-5iu38pr6	2826	2	outcomes	outcome	NNS
cord-005478-5iu38pr6	2826	3	included	include	VBD
cord-005478-5iu38pr6	2826	4	progression	progression	NN
cord-005478-5iu38pr6	2826	5	-	-	HYPH
cord-005478-5iu38pr6	2826	6	free	free	JJ
cord-005478-5iu38pr6	2826	7	survival	survival	NN
cord-005478-5iu38pr6	2826	8	(	(	-LRB-
cord-005478-5iu38pr6	2826	9	PFS	PFS	NNP
cord-005478-5iu38pr6	2826	10	)	)	-RRB-
cord-005478-5iu38pr6	2826	11	,	,	,
cord-005478-5iu38pr6	2826	12	relapse	relapse	NN
cord-005478-5iu38pr6	2826	13	/	/	SYM
cord-005478-5iu38pr6	2826	14	progression	progression	NN
cord-005478-5iu38pr6	2826	15	(	(	-LRB-
cord-005478-5iu38pr6	2826	16	R	r	NN
cord-005478-5iu38pr6	2826	17	/	/	SYM
cord-005478-5iu38pr6	2826	18	P	p	NN
cord-005478-5iu38pr6	2826	19	)	)	-RRB-
cord-005478-5iu38pr6	2826	20	and	and	CC
cord-005478-5iu38pr6	2826	21	non	non	JJ
cord-005478-5iu38pr6	2826	22	-	-	JJ
cord-005478-5iu38pr6	2826	23	relapse	relapse	JJ
cord-005478-5iu38pr6	2826	24	mortality	mortality	NN
cord-005478-5iu38pr6	2826	25	(	(	-LRB-
cord-005478-5iu38pr6	2826	26	NRM	NRM	NNP
cord-005478-5iu38pr6	2826	27	)	)	-RRB-
cord-005478-5iu38pr6	2826	28	.	.	.
cord-005478-5iu38pr6	2827	1	Results	result	NNS
cord-005478-5iu38pr6	2827	2	:	:	:
cord-005478-5iu38pr6	2828	1	Baseline	baseline	JJ
cord-005478-5iu38pr6	2828	2	patient	patient	NN
cord-005478-5iu38pr6	2828	3	characteristics	characteristic	NNS
cord-005478-5iu38pr6	2828	4	are	be	VBP
cord-005478-5iu38pr6	2828	5	shown	show	VBN
cord-005478-5iu38pr6	2828	6	in	in	IN
cord-005478-5iu38pr6	2828	7	Table-	Table-	NNP
cord-005478-5iu38pr6	2828	8	1	1	CD
cord-005478-5iu38pr6	2828	9	.	.	.
cord-005478-5iu38pr6	2829	1	During	during	IN
cord-005478-5iu38pr6	2829	2	the	the	DT
cord-005478-5iu38pr6	2829	3	three	three	CD
cord-005478-5iu38pr6	2829	4	study	study	NN
cord-005478-5iu38pr6	2829	5	time	time	NN
cord-005478-5iu38pr6	2829	6	-	-	HYPH
cord-005478-5iu38pr6	2829	7	periods	periods	NN
cord-005478-5iu38pr6	2829	8	median	median	JJ
cord-005478-5iu38pr6	2829	9	patient	patient	NN
cord-005478-5iu38pr6	2829	10	age	age	NN
cord-005478-5iu38pr6	2829	11	(	(	-LRB-
cord-005478-5iu38pr6	2829	12	67	67	CD
cord-005478-5iu38pr6	2829	13	-	-	HYPH
cord-005478-5iu38pr6	2829	14	68-year	68-year	JJ
cord-005478-5iu38pr6	2829	15	)	)	-RRB-
cord-005478-5iu38pr6	2829	16	,	,	,
cord-005478-5iu38pr6	2829	17	use	use	NN
cord-005478-5iu38pr6	2829	18	of	of	IN
cord-005478-5iu38pr6	2829	19	reduced	reduce	VBN
cord-005478-5iu38pr6	2829	20	-	-	HYPH
cord-005478-5iu38pr6	2829	21	intensity	intensity	NN
cord-005478-5iu38pr6	2829	22	conditioning	conditioning	NN
cord-005478-5iu38pr6	2829	23	regimens	regimen	NNS
cord-005478-5iu38pr6	2829	24	and	and	CC
cord-005478-5iu38pr6	2829	25	proportion	proportion	NN
cord-005478-5iu38pr6	2829	26	of	of	IN
cord-005478-5iu38pr6	2829	27	patients	patient	NNS
cord-005478-5iu38pr6	2829	28	with	with	IN
cord-005478-5iu38pr6	2829	29	chemosensitive	chemosensitive	JJ
cord-005478-5iu38pr6	2829	30	disease	disease	NN
cord-005478-5iu38pr6	2829	31	remained	remain	VBD
cord-005478-5iu38pr6	2829	32	stable	stable	JJ
cord-005478-5iu38pr6	2829	33	.	.	.
cord-005478-5iu38pr6	2830	1	In	in	IN
cord-005478-5iu38pr6	2830	2	the	the	DT
cord-005478-5iu38pr6	2830	3	most	most	RBS
cord-005478-5iu38pr6	2830	4	recent	recent	JJ
cord-005478-5iu38pr6	2830	5	era	era	NN
cord-005478-5iu38pr6	2830	6	(	(	-LRB-
cord-005478-5iu38pr6	2830	7	2011	2011	CD
cord-005478-5iu38pr6	2830	8	-	-	SYM
cord-005478-5iu38pr6	2830	9	2015	2015	CD
cord-005478-5iu38pr6	2830	10	)	)	-RRB-
cord-005478-5iu38pr6	2830	11	a	a	DT
cord-005478-5iu38pr6	2830	12	higher	high	JJR
cord-005478-5iu38pr6	2830	13	proportion	proportion	NN
cord-005478-5iu38pr6	2830	14	of	of	IN
cord-005478-5iu38pr6	2830	15	patients	patient	NNS
cord-005478-5iu38pr6	2830	16	had	have	VBD
cord-005478-5iu38pr6	2830	17	T	t	NN
cord-005478-5iu38pr6	2830	18	-	-	HYPH
cord-005478-5iu38pr6	2830	19	cell	cell	NN
cord-005478-5iu38pr6	2830	20	NHL	NHL	NNP
cord-005478-5iu38pr6	2830	21	,	,	,
cord-005478-5iu38pr6	2830	22	history	history	NN
cord-005478-5iu38pr6	2830	23	of	of	IN
cord-005478-5iu38pr6	2830	24	prior	prior	JJ
cord-005478-5iu38pr6	2830	25	autografts	autografts	NNP
cord-005478-5iu38pr6	2830	26	,	,	,
cord-005478-5iu38pr6	2830	27	good	good	JJ
cord-005478-5iu38pr6	2830	28	performance	performance	NN
cord-005478-5iu38pr6	2830	29	status	status	NN
cord-005478-5iu38pr6	2831	1	(	(	-LRB-
cord-005478-5iu38pr6	2831	2	KPS	KPS	NNP
cord-005478-5iu38pr6	2831	3	90	90	CD
cord-005478-5iu38pr6	2831	4	-	-	SYM
cord-005478-5iu38pr6	2831	5	100	100	CD
cord-005478-5iu38pr6	2831	6	)	)	-RRB-
cord-005478-5iu38pr6	2831	7	and	and	CC
cord-005478-5iu38pr6	2831	8	high	high	JJ
cord-005478-5iu38pr6	2831	9	HCT	HCT	NNP
cord-005478-5iu38pr6	2831	10	-	-	HYPH
cord-005478-5iu38pr6	2831	11	CI	CI	NNP
cord-005478-5iu38pr6	2831	12	,	,	,
cord-005478-5iu38pr6	2831	13	while	while	IN
cord-005478-5iu38pr6	2831	14	fewer	few	JJR
cord-005478-5iu38pr6	2831	15	subjects	subject	NNS
cord-005478-5iu38pr6	2831	16	received	receive	VBD
cord-005478-5iu38pr6	2831	17	a	a	DT
cord-005478-5iu38pr6	2831	18	HLAmatched	hlamatche	VBN
cord-005478-5iu38pr6	2831	19	sibling	sibling	NN
cord-005478-5iu38pr6	2831	20	HCT	hct	NN
cord-005478-5iu38pr6	2831	21	.	.	.
cord-005478-5iu38pr6	2832	1	The	the	DT
cord-005478-5iu38pr6	2832	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2832	3	incidence	incidence	NN
cord-005478-5iu38pr6	2832	4	of	of	IN
cord-005478-5iu38pr6	2832	5	day100	day100	JJ
cord-005478-5iu38pr6	2832	6	grade	grade	NN
cord-005478-5iu38pr6	2832	7	2	2	CD
cord-005478-5iu38pr6	2832	8	-	-	SYM
cord-005478-5iu38pr6	2832	9	4	4	CD
cord-005478-5iu38pr6	2832	10	acute	acute	JJ
cord-005478-5iu38pr6	2832	11	graft	graft	NN
cord-005478-5iu38pr6	2832	12	-	-	HYPH
cord-005478-5iu38pr6	2832	13	versus	versus	IN
cord-005478-5iu38pr6	2832	14	-	-	HYPH
cord-005478-5iu38pr6	2832	15	host	host	NN
cord-005478-5iu38pr6	2832	16	disease	disease	NN
cord-005478-5iu38pr6	2832	17	(	(	-LRB-
cord-005478-5iu38pr6	2832	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2832	19	)	)	-RRB-
cord-005478-5iu38pr6	2832	20	for	for	IN
cord-005478-5iu38pr6	2832	21	2000	2000	CD
cord-005478-5iu38pr6	2832	22	-	-	SYM
cord-005478-5iu38pr6	2832	23	2005	2005	CD
cord-005478-5iu38pr6	2832	24	vs.	vs.	IN
cord-005478-5iu38pr6	2832	25	2006	2006	CD
cord-005478-5iu38pr6	2832	26	-	-	SYM
cord-005478-5iu38pr6	2832	27	2010	2010	CD
cord-005478-5iu38pr6	2832	28	vs.	vs.	IN
cord-005478-5iu38pr6	2832	29	2011	2011	CD
cord-005478-5iu38pr6	2832	30	-	-	SYM
cord-005478-5iu38pr6	2832	31	2015	2015	CD
cord-005478-5iu38pr6	2833	1	cohorts	cohort	NNS
cord-005478-5iu38pr6	2833	2	was	be	VBD
cord-005478-5iu38pr6	2833	3	25	25	CD
cord-005478-5iu38pr6	2833	4	%	%	NN
cord-005478-5iu38pr6	2833	5	vs.	vs.	CC
cord-005478-5iu38pr6	2833	6	35	35	CD
cord-005478-5iu38pr6	2833	7	%	%	NN
cord-005478-5iu38pr6	2833	8	vs.	vs.	IN
cord-005478-5iu38pr6	2833	9	31	31	CD
cord-005478-5iu38pr6	2833	10	%	%	NN
cord-005478-5iu38pr6	2833	11	respectively	respectively	RB
cord-005478-5iu38pr6	2833	12	(	(	-LRB-
cord-005478-5iu38pr6	2833	13	p=0.47	p=0.47	NNP
cord-005478-5iu38pr6	2833	14	)	)	-RRB-
cord-005478-5iu38pr6	2833	15	.	.	.
cord-005478-5iu38pr6	2834	1	The	the	DT
cord-005478-5iu38pr6	2834	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2834	3	incidence	incidence	NN
cord-005478-5iu38pr6	2834	4	of	of	IN
cord-005478-5iu38pr6	2834	5	chronic	chronic	JJ
cord-005478-5iu38pr6	2834	6	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2834	7	at	at	IN
cord-005478-5iu38pr6	2834	8	1	1	CD
cord-005478-5iu38pr6	2834	9	year	year	NN
cord-005478-5iu38pr6	2834	10	was	be	VBD
cord-005478-5iu38pr6	2834	11	21	21	CD
cord-005478-5iu38pr6	2834	12	%	%	NN
cord-005478-5iu38pr6	2834	13	vs.	vs.	IN
cord-005478-5iu38pr6	2834	14	34	34	CD
cord-005478-5iu38pr6	2834	15	%	%	NN
cord-005478-5iu38pr6	2834	16	vs.	vs.	IN
cord-005478-5iu38pr6	2834	17	31	31	CD
cord-005478-5iu38pr6	2834	18	%	%	NN
cord-005478-5iu38pr6	2834	19	,	,	,
cord-005478-5iu38pr6	2834	20	in	in	IN
cord-005478-5iu38pr6	2834	21	similar	similar	JJ
cord-005478-5iu38pr6	2834	22	order	order	NN
cord-005478-5iu38pr6	2834	23	(	(	-LRB-
cord-005478-5iu38pr6	2834	24	p=0.07	p=0.07	NNP
cord-005478-5iu38pr6	2834	25	)	)	-RRB-
cord-005478-5iu38pr6	2834	26	.	.	.
cord-005478-5iu38pr6	2835	1	The	the	DT
cord-005478-5iu38pr6	2835	2	4-year	4-year	CD
cord-005478-5iu38pr6	2835	3	probabilities	probability	NNS
cord-005478-5iu38pr6	2835	4	of	of	IN
cord-005478-5iu38pr6	2835	5	NRM	NRM	NNP
cord-005478-5iu38pr6	2835	6	and	and	CC
cord-005478-5iu38pr6	2835	7	R	R	NNP
cord-005478-5iu38pr6	2835	8	/	/	SYM
cord-005478-5iu38pr6	2835	9	P	p	NN
cord-005478-5iu38pr6	2835	10	of	of	IN
cord-005478-5iu38pr6	2835	11	2000	2000	CD
cord-005478-5iu38pr6	2835	12	-	-	SYM
cord-005478-5iu38pr6	2835	13	2005	2005	CD
cord-005478-5iu38pr6	2835	14	vs.	vs.	IN
cord-005478-5iu38pr6	2835	15	2006	2006	CD
cord-005478-5iu38pr6	2835	16	-	-	SYM
cord-005478-5iu38pr6	2835	17	2010	2010	CD
cord-005478-5iu38pr6	2835	18	vs.	vs.	IN
cord-005478-5iu38pr6	2835	19	2011	2011	CD
cord-005478-5iu38pr6	2835	20	-	-	SYM
cord-005478-5iu38pr6	2835	21	2015	2015	CD
cord-005478-5iu38pr6	2835	22	time	time	NN
cord-005478-5iu38pr6	2835	23	-	-	HYPH
cord-005478-5iu38pr6	2835	24	periods	period	NNS
cord-005478-5iu38pr6	2835	25	were	be	VBD
cord-005478-5iu38pr6	2835	26	34	34	CD
cord-005478-5iu38pr6	2835	27	%	%	NN
cord-005478-5iu38pr6	2835	28	vs.	vs.	IN
cord-005478-5iu38pr6	2835	29	29	29	CD
cord-005478-5iu38pr6	2835	30	%	%	NN
cord-005478-5iu38pr6	2835	31	vs.	vs.	IN
cord-005478-5iu38pr6	2835	32	30	30	CD
cord-005478-5iu38pr6	2835	33	%	%	NN
cord-005478-5iu38pr6	2835	34	(	(	-LRB-
cord-005478-5iu38pr6	2835	35	p=0.69	p=0.69	NNP
cord-005478-5iu38pr6	2835	36	)	)	-RRB-
cord-005478-5iu38pr6	2835	37	and	and	CC
cord-005478-5iu38pr6	2835	38	48	48	CD
cord-005478-5iu38pr6	2835	39	%	%	NN
cord-005478-5iu38pr6	2835	40	vs.	vs.	IN
cord-005478-5iu38pr6	2835	41	40	40	CD
cord-005478-5iu38pr6	2835	42	%	%	NN
cord-005478-5iu38pr6	2835	43	vs.	vs.	IN
cord-005478-5iu38pr6	2835	44	40	40	CD
cord-005478-5iu38pr6	2835	45	%	%	NN
cord-005478-5iu38pr6	2835	46	(	(	-LRB-
cord-005478-5iu38pr6	2835	47	p=0.39	p=0.39	NNP
cord-005478-5iu38pr6	2835	48	)	)	-RRB-
cord-005478-5iu38pr6	2835	49	,	,	,
cord-005478-5iu38pr6	2835	50	respectively	respectively	RB
cord-005478-5iu38pr6	2835	51	(	(	-LRB-
cord-005478-5iu38pr6	2835	52	Figure	figure	NN
cord-005478-5iu38pr6	2835	53	)	)	-RRB-
cord-005478-5iu38pr6	2835	54	.	.	.
cord-005478-5iu38pr6	2836	1	The	the	DT
cord-005478-5iu38pr6	2836	2	4-year	4-year	CD
cord-005478-5iu38pr6	2836	3	probabilities	probability	NNS
cord-005478-5iu38pr6	2836	4	of	of	IN
cord-005478-5iu38pr6	2836	5	PFS	PFS	NNP
cord-005478-5iu38pr6	2836	6	and	and	CC
cord-005478-5iu38pr6	2836	7	OS	OS	NNP
cord-005478-5iu38pr6	2836	8	(	(	-LRB-
cord-005478-5iu38pr6	2836	9	2000	2000	CD
cord-005478-5iu38pr6	2836	10	-2005	-2005	CC
cord-005478-5iu38pr6	2836	11	vs.	vs.	IN
cord-005478-5iu38pr6	2836	12	2006	2006	CD
cord-005478-5iu38pr6	2836	13	-2010	-2010	,
cord-005478-5iu38pr6	2836	14	vs.	vs.	IN
cord-005478-5iu38pr6	2836	15	2011	2011	CD
cord-005478-5iu38pr6	2836	16	-2015	-2015	NNS
cord-005478-5iu38pr6	2836	17	showed	show	VBD
cord-005478-5iu38pr6	2836	18	significantly	significantly	RB
cord-005478-5iu38pr6	2836	19	improved	improve	VBN
cord-005478-5iu38pr6	2836	20	outcomes	outcome	NNS
cord-005478-5iu38pr6	2836	21	in	in	IN
cord-005478-5iu38pr6	2836	22	the	the	DT
cord-005478-5iu38pr6	2836	23	most	most	RBS
cord-005478-5iu38pr6	2836	24	recent	recent	JJ
cord-005478-5iu38pr6	2836	25	time	time	NN
cord-005478-5iu38pr6	2836	26	-	-	HYPH
cord-005478-5iu38pr6	2836	27	periods	period	NNS
cord-005478-5iu38pr6	2836	28	as	as	IN
cord-005478-5iu38pr6	2836	29	following	follow	VBG
cord-005478-5iu38pr6	2836	30	:	:	:
cord-005478-5iu38pr6	2836	31	17	17	CD
cord-005478-5iu38pr6	2836	32	%	%	NN
cord-005478-5iu38pr6	2836	33	vs.	vs.	CC
cord-005478-5iu38pr6	2836	34	31	31	CD
cord-005478-5iu38pr6	2836	35	%	%	NN
cord-005478-5iu38pr6	2836	36	vs.	vs.	IN
cord-005478-5iu38pr6	2836	37	30	30	CD
cord-005478-5iu38pr6	2836	38	%	%	NN
cord-005478-5iu38pr6	2836	39	(	(	-LRB-
cord-005478-5iu38pr6	2836	40	p=0.02	p=0.02	NN
cord-005478-5iu38pr6	2836	41	)	)	-RRB-
cord-005478-5iu38pr6	2836	42	and	and	CC
cord-005478-5iu38pr6	2836	43	21	21	CD
cord-005478-5iu38pr6	2836	44	%	%	NN
cord-005478-5iu38pr6	2836	45	vs.	vs.	IN
cord-005478-5iu38pr6	2836	46	42	42	CD
cord-005478-5iu38pr6	2836	47	%	%	NN
cord-005478-5iu38pr6	2836	48	vs.	vs.	IN
cord-005478-5iu38pr6	2836	49	44	44	CD
cord-005478-5iu38pr6	2836	50	%	%	NN
cord-005478-5iu38pr6	2837	1	(	(	-LRB-
cord-005478-5iu38pr6	2837	2	p	p	NN
cord-005478-5iu38pr6	2837	3	<	<	XX
cord-005478-5iu38pr6	2837	4	0.001	0.001	CD
cord-005478-5iu38pr6	2837	5	)	)	-RRB-
cord-005478-5iu38pr6	2837	6	,	,	,
cord-005478-5iu38pr6	2837	7	respectively	respectively	RB
cord-005478-5iu38pr6	2837	8	(	(	-LRB-
cord-005478-5iu38pr6	2837	9	Figure	figure	NN
cord-005478-5iu38pr6	2837	10	)	)	-RRB-
cord-005478-5iu38pr6	2837	11	.	.	.
cord-005478-5iu38pr6	2838	1	On	on	IN
cord-005478-5iu38pr6	2838	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2838	3	analysis	analysis	NN
cord-005478-5iu38pr6	2838	4	,	,	,
cord-005478-5iu38pr6	2838	5	compared	compare	VBN
cord-005478-5iu38pr6	2838	6	to	to	IN
cord-005478-5iu38pr6	2838	7	the	the	DT
cord-005478-5iu38pr6	2838	8	2000	2000	CD
cord-005478-5iu38pr6	2838	9	-	-	SYM
cord-005478-5iu38pr6	2838	10	2005	2005	CD
cord-005478-5iu38pr6	2838	11	cohort	cohort	NN
cord-005478-5iu38pr6	2838	12	,	,	,
cord-005478-5iu38pr6	2838	13	the	the	DT
cord-005478-5iu38pr6	2838	14	2011	2011	CD
cord-005478-5iu38pr6	2838	15	-	-	SYM
cord-005478-5iu38pr6	2838	16	2015	2015	CD
cord-005478-5iu38pr6	2838	17	cohort	cohort	NN
cord-005478-5iu38pr6	2838	18	showed	show	VBD
cord-005478-5iu38pr6	2838	19	a	a	DT
cord-005478-5iu38pr6	2838	20	28	28	CD
cord-005478-5iu38pr6	2838	21	%	%	NN
cord-005478-5iu38pr6	2838	22	reduction	reduction	NN
cord-005478-5iu38pr6	2838	23	in	in	IN
cord-005478-5iu38pr6	2838	24	the	the	DT
cord-005478-5iu38pr6	2838	25	risk	risk	NN
cord-005478-5iu38pr6	2838	26	of	of	IN
cord-005478-5iu38pr6	2838	27	mortality	mortality	NN
cord-005478-5iu38pr6	2838	28	(	(	-LRB-
cord-005478-5iu38pr6	2838	29	RR=0.72	RR=0.72	NNS
cord-005478-5iu38pr6	2838	30	,	,	,
cord-005478-5iu38pr6	2838	31	95%CI=0.52	95%ci=0.52	CD
cord-005478-5iu38pr6	2838	32	-	-	SYM
cord-005478-5iu38pr6	2838	33	1.008	1.008	CD
cord-005478-5iu38pr6	2838	34	,	,	,
cord-005478-5iu38pr6	2838	35	p=0.056	p=0.056	NNP
cord-005478-5iu38pr6	2838	36	)	)	-RRB-
cord-005478-5iu38pr6	2838	37	.	.	.
cord-005478-5iu38pr6	2839	1	The	the	DT
cord-005478-5iu38pr6	2839	2	most	most	RBS
cord-005478-5iu38pr6	2839	3	common	common	JJ
cord-005478-5iu38pr6	2839	4	cause	cause	NN
cord-005478-5iu38pr6	2839	5	of	of	IN
cord-005478-5iu38pr6	2839	6	death	death	NN
cord-005478-5iu38pr6	2839	7	was	be	VBD
cord-005478-5iu38pr6	2839	8	relapse	relapse	NN
cord-005478-5iu38pr6	2839	9	of	of	IN
cord-005478-5iu38pr6	2839	10	primary	primary	JJ
cord-005478-5iu38pr6	2839	11	disease	disease	NN
cord-005478-5iu38pr6	2839	12	in	in	IN
cord-005478-5iu38pr6	2839	13	all	all	DT
cord-005478-5iu38pr6	2839	14	time	time	NN
cord-005478-5iu38pr6	2839	15	-	-	HYPH
cord-005478-5iu38pr6	2839	16	periods	period	NNS
cord-005478-5iu38pr6	2839	17	.	.	.
cord-005478-5iu38pr6	2840	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2840	2	:	:	:
cord-005478-5iu38pr6	2841	1	Utilization	utilization	NN
cord-005478-5iu38pr6	2841	2	of	of	IN
cord-005478-5iu38pr6	2841	3	allo	allo	NN
cord-005478-5iu38pr6	2841	4	-	-	HYPH
cord-005478-5iu38pr6	2841	5	HCT	HCT	NNP
cord-005478-5iu38pr6	2841	6	has	have	VBZ
cord-005478-5iu38pr6	2841	7	steadily	steadily	RB
cord-005478-5iu38pr6	2841	8	increased	increase	VBN
cord-005478-5iu38pr6	2841	9	in	in	IN
cord-005478-5iu38pr6	2841	10	elderly	elderly	JJ
cord-005478-5iu38pr6	2841	11	NHL	NHL	NNP
cord-005478-5iu38pr6	2841	12	patients	patient	NNS
cord-005478-5iu38pr6	2841	13	in	in	IN
cord-005478-5iu38pr6	2841	14	the	the	DT
cord-005478-5iu38pr6	2841	15	U.S.	U.S.	NNP
cord-005478-5iu38pr6	2841	16	since	since	IN
cord-005478-5iu38pr6	2841	17	2000	2000	CD
cord-005478-5iu38pr6	2841	18	.	.	.
cord-005478-5iu38pr6	2842	1	In	in	IN
cord-005478-5iu38pr6	2842	2	the	the	DT
cord-005478-5iu38pr6	2842	3	recent	recent	JJ
cord-005478-5iu38pr6	2842	4	years	year	NNS
cord-005478-5iu38pr6	2842	5	despite	despite	IN
cord-005478-5iu38pr6	2842	6	decline	decline	NN
cord-005478-5iu38pr6	2842	7	in	in	IN
cord-005478-5iu38pr6	2842	8	the	the	DT
cord-005478-5iu38pr6	2842	9	use	use	NN
cord-005478-5iu38pr6	2842	10	of	of	IN
cord-005478-5iu38pr6	2842	11	HLAmatched	hlamatche	VBN
cord-005478-5iu38pr6	2842	12	sibling	sibling	NN
cord-005478-5iu38pr6	2842	13	donors	donor	NNS
cord-005478-5iu38pr6	2842	14	and	and	CC
cord-005478-5iu38pr6	2842	15	transplanting	transplant	VBG
cord-005478-5iu38pr6	2842	16	elderly	elderly	JJ
cord-005478-5iu38pr6	2842	17	patients	patient	NNS
cord-005478-5iu38pr6	2842	18	with	with	IN
cord-005478-5iu38pr6	2842	19	higher	high	JJR
cord-005478-5iu38pr6	2842	20	HCT	HCT	NNP
cord-005478-5iu38pr6	2842	21	-	-	HYPH
cord-005478-5iu38pr6	2842	22	CI	ci	NN
cord-005478-5iu38pr6	2842	23	and	and	CC
cord-005478-5iu38pr6	2842	24	more	more	RBR
cord-005478-5iu38pr6	2842	25	heavily	heavily	RB
cord-005478-5iu38pr6	2842	26	pretreated	pretreate	VBN
cord-005478-5iu38pr6	2842	27	disease	disease	NN
cord-005478-5iu38pr6	2842	28	,	,	,
cord-005478-5iu38pr6	2842	29	survival	survival	NN
cord-005478-5iu38pr6	2842	30	outcomes	outcome	NNS
cord-005478-5iu38pr6	2842	31	have	have	VBP
cord-005478-5iu38pr6	2842	32	improved	improve	VBN
cord-005478-5iu38pr6	2842	33	.	.	.
cord-005478-5iu38pr6	2843	1	Age	age	NN
cord-005478-5iu38pr6	2843	2	alone	alone	RB
cord-005478-5iu38pr6	2843	3	should	should	MD
cord-005478-5iu38pr6	2843	4	not	not	RB
cord-005478-5iu38pr6	2843	5	be	be	VB
cord-005478-5iu38pr6	2843	6	a	a	DT
cord-005478-5iu38pr6	2843	7	determinant	determinant	NN
cord-005478-5iu38pr6	2843	8	for	for	IN
cord-005478-5iu38pr6	2843	9	allo	allo	NN
cord-005478-5iu38pr6	2843	10	-	-	HYPH
cord-005478-5iu38pr6	2843	11	HCT	hct	NN
cord-005478-5iu38pr6	2843	12	eligibility	eligibility	NN
cord-005478-5iu38pr6	2843	13	in	in	IN
cord-005478-5iu38pr6	2843	14	NHL	NHL	NNP
cord-005478-5iu38pr6	2843	15	.	.	.
cord-005478-5iu38pr6	2844	1	Methods	method	NNS
cord-005478-5iu38pr6	2844	2	:	:	:
cord-005478-5iu38pr6	2844	3	Four	four	CD
cord-005478-5iu38pr6	2844	4	medical	medical	JJ
cord-005478-5iu38pr6	2844	5	experts	expert	NNS
cord-005478-5iu38pr6	2844	6	who	who	WP
cord-005478-5iu38pr6	2844	7	had	have	VBD
cord-005478-5iu38pr6	2844	8	managed	manage	VBN
cord-005478-5iu38pr6	2844	9	patients	patient	NNS
cord-005478-5iu38pr6	2844	10	with	with	IN
cord-005478-5iu38pr6	2844	11	DLBCL	dlbcl	RB
cord-005478-5iu38pr6	2844	12	using	use	VBG
cord-005478-5iu38pr6	2844	13	different	different	JJ
cord-005478-5iu38pr6	2844	14	CAR	car	NN
cord-005478-5iu38pr6	2844	15	T	t	NN
cord-005478-5iu38pr6	2844	16	-	-	HYPH
cord-005478-5iu38pr6	2844	17	cell	cell	NN
cord-005478-5iu38pr6	2844	18	therapy	therapy	NN
cord-005478-5iu38pr6	2844	19	protocols	protocol	NNS
cord-005478-5iu38pr6	2844	20	and	and	CC
cord-005478-5iu38pr6	2844	21	products	product	NNS
cord-005478-5iu38pr6	2844	22	independently	independently	RB
cord-005478-5iu38pr6	2844	23	reviewed	review	VBD
cord-005478-5iu38pr6	2844	24	the	the	DT
cord-005478-5iu38pr6	2844	25	extracted	extract	VBN
cord-005478-5iu38pr6	2844	26	adverse	adverse	JJ
cord-005478-5iu38pr6	2844	27	event	event	NN
cord-005478-5iu38pr6	2844	28	data	datum	NNS
cord-005478-5iu38pr6	2844	29	from	from	IN
cord-005478-5iu38pr6	2844	30	the	the	DT
cord-005478-5iu38pr6	2844	31	case	case	NN
cord-005478-5iu38pr6	2844	32	report	report	NN
cord-005478-5iu38pr6	2844	33	forms	form	NNS
cord-005478-5iu38pr6	2844	34	and	and	CC
cord-005478-5iu38pr6	2844	35	re	re	NNS
cord-005478-5iu38pr6	2844	36	-	-	VBN
cord-005478-5iu38pr6	2844	37	graded	grade	VBN
cord-005478-5iu38pr6	2844	38	CRS	CRS	NNP
cord-005478-5iu38pr6	2844	39	using	use	VBG
cord-005478-5iu38pr6	2844	40	the	the	DT
cord-005478-5iu38pr6	2844	41	more	more	RBR
cord-005478-5iu38pr6	2844	42	commonly	commonly	RB
cord-005478-5iu38pr6	2844	43	used	use	VBN
cord-005478-5iu38pr6	2844	44	Lee	Lee	NNP
cord-005478-5iu38pr6	2844	45	scale	scale	NN
cord-005478-5iu38pr6	2844	46	(	(	-LRB-
cord-005478-5iu38pr6	2844	47	Lee	Lee	NNP
cord-005478-5iu38pr6	2844	48	,	,	,
cord-005478-5iu38pr6	2844	49	Blood	blood	NN
cord-005478-5iu38pr6	2844	50	,	,	,
cord-005478-5iu38pr6	2844	51	2014	2014	CD
cord-005478-5iu38pr6	2844	52	)	)	-RRB-
cord-005478-5iu38pr6	2844	53	and	and	CC
cord-005478-5iu38pr6	2844	54	the	the	DT
cord-005478-5iu38pr6	2844	55	NT	NT	NNP
cord-005478-5iu38pr6	2844	56	grading	grading	NN
cord-005478-5iu38pr6	2844	57	for	for	IN
cord-005478-5iu38pr6	2844	58	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	2844	59	(	(	-LRB-
cord-005478-5iu38pr6	2844	60	modified	modify	VBN
cord-005478-5iu38pr6	2844	61	Car	car	NN
cord-005478-5iu38pr6	2844	62	T	T	NNP
cord-005478-5iu38pr6	2844	63	related	relate	VBN
cord-005478-5iu38pr6	2844	64	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	2844	65	syndrome	syndrome	NN
cord-005478-5iu38pr6	2844	66	(	(	-LRB-
cord-005478-5iu38pr6	2845	1	mCRES	mcres	LS
cord-005478-5iu38pr6	2845	2	)	)	-RRB-
cord-005478-5iu38pr6	2846	1	(	(	-LRB-
cord-005478-5iu38pr6	2846	2	Neelapu	Neelapu	NNP
cord-005478-5iu38pr6	2846	3	,	,	,
cord-005478-5iu38pr6	2846	4	Nature	Nature	NNP
cord-005478-5iu38pr6	2846	5	Reviews	Reviews	NNPS
cord-005478-5iu38pr6	2846	6	in	in	IN
cord-005478-5iu38pr6	2846	7	Clinical	Clinical	NNP
cord-005478-5iu38pr6	2846	8	Oncology	Oncology	NNP
cord-005478-5iu38pr6	2846	9	,	,	,
cord-005478-5iu38pr6	2846	10	2018	2018	CD
cord-005478-5iu38pr6	2846	11	)	)	-RRB-
cord-005478-5iu38pr6	2846	12	while	while	IN
cord-005478-5iu38pr6	2846	13	blinded	blind	VBN
cord-005478-5iu38pr6	2846	14	to	to	IN
cord-005478-5iu38pr6	2846	15	the	the	DT
cord-005478-5iu38pr6	2846	16	original	original	JJ
cord-005478-5iu38pr6	2846	17	trial	trial	NN
cord-005478-5iu38pr6	2846	18	grading	grading	NN
cord-005478-5iu38pr6	2846	19	and	and	CC
cord-005478-5iu38pr6	2846	20	other	other	JJ
cord-005478-5iu38pr6	2846	21	experts	expert	NNS
cord-005478-5iu38pr6	2846	22	'	'	POS
cord-005478-5iu38pr6	2846	23	grading	grading	NN
cord-005478-5iu38pr6	2846	24	.	.	.
cord-005478-5iu38pr6	2847	1	Re	Re	VBG
cord-005478-5iu38pr6	2847	2	-	-	JJ
cord-005478-5iu38pr6	2847	3	grading	grade	VBG
cord-005478-5iu38pr6	2847	4	assessments	assessment	NNS
cord-005478-5iu38pr6	2847	5	and	and	CC
cord-005478-5iu38pr6	2847	6	disagreements	disagreement	NNS
cord-005478-5iu38pr6	2847	7	concerning	concern	VBG
cord-005478-5iu38pr6	2847	8	the	the	DT
cord-005478-5iu38pr6	2847	9	assigned	assign	VBN
cord-005478-5iu38pr6	2847	10	Lee	Lee	NNP
cord-005478-5iu38pr6	2847	11	and	and	CC
cord-005478-5iu38pr6	2847	12	NCI	NCI	NNP
cord-005478-5iu38pr6	2847	13	CTC	CTC	NNP
cord-005478-5iu38pr6	2847	14	grades	grade	NNS
cord-005478-5iu38pr6	2847	15	were	be	VBD
cord-005478-5iu38pr6	2847	16	later	later	RB
cord-005478-5iu38pr6	2847	17	discussed	discuss	VBN
cord-005478-5iu38pr6	2847	18	and	and	CC
cord-005478-5iu38pr6	2847	19	reconciled	reconcile	VBN
cord-005478-5iu38pr6	2847	20	among	among	IN
cord-005478-5iu38pr6	2847	21	reviewers	reviewer	NNS
cord-005478-5iu38pr6	2847	22	during	during	IN
cord-005478-5iu38pr6	2847	23	a	a	DT
cord-005478-5iu38pr6	2847	24	live	live	JJ
cord-005478-5iu38pr6	2847	25	meeting	meeting	NN
cord-005478-5iu38pr6	2847	26	.	.	.
cord-005478-5iu38pr6	2848	1	As	as	IN
cord-005478-5iu38pr6	2848	2	per	per	IN
cord-005478-5iu38pr6	2848	3	the	the	DT
cord-005478-5iu38pr6	2848	4	investigational	investigational	JJ
cord-005478-5iu38pr6	2848	5	charter	charter	NN
cord-005478-5iu38pr6	2848	6	,	,	,
cord-005478-5iu38pr6	2848	7	in	in	IN
cord-005478-5iu38pr6	2848	8	cases	case	NNS
cord-005478-5iu38pr6	2848	9	that	that	WDT
cord-005478-5iu38pr6	2848	10	could	could	MD
cord-005478-5iu38pr6	2848	11	not	not	RB
cord-005478-5iu38pr6	2848	12	be	be	VB
cord-005478-5iu38pr6	2848	13	reconciled	reconcile	VBN
cord-005478-5iu38pr6	2848	14	,	,	,
cord-005478-5iu38pr6	2848	15	the	the	DT
cord-005478-5iu38pr6	2848	16	most	most	RBS
cord-005478-5iu38pr6	2848	17	conservative	conservative	JJ
cord-005478-5iu38pr6	2848	18	final	final	JJ
cord-005478-5iu38pr6	2848	19	assessment	assessment	NN
cord-005478-5iu38pr6	2848	20	of	of	IN
cord-005478-5iu38pr6	2848	21	any	any	DT
cord-005478-5iu38pr6	2848	22	reviewer	reviewer	NN
cord-005478-5iu38pr6	2848	23	determined	determine	VBD
cord-005478-5iu38pr6	2848	24	the	the	DT
cord-005478-5iu38pr6	2848	25	final	final	JJ
cord-005478-5iu38pr6	2848	26	grading	grading	NN
cord-005478-5iu38pr6	2848	27	for	for	IN
cord-005478-5iu38pr6	2848	28	any	any	DT
cord-005478-5iu38pr6	2848	29	individual	individual	JJ
cord-005478-5iu38pr6	2848	30	case	case	NN
cord-005478-5iu38pr6	2848	31	.	.	.
cord-005478-5iu38pr6	2849	1	Results	result	NNS
cord-005478-5iu38pr6	2849	2	:	:	:
cord-005478-5iu38pr6	2849	3	CRS	CRS	NNP
cord-005478-5iu38pr6	2849	4	:	:	:
cord-005478-5iu38pr6	2849	5	64	64	CD
cord-005478-5iu38pr6	2849	6	of	of	IN
cord-005478-5iu38pr6	2849	7	111	111	CD
cord-005478-5iu38pr6	2849	8	(	(	-LRB-
cord-005478-5iu38pr6	2849	9	58	58	CD
cord-005478-5iu38pr6	2849	10	%	%	NN
cord-005478-5iu38pr6	2849	11	)	)	-RRB-
cord-005478-5iu38pr6	2850	1	patients	patient	NNS
cord-005478-5iu38pr6	2850	2	were	be	VBD
cord-005478-5iu38pr6	2850	3	originally	originally	RB
cord-005478-5iu38pr6	2850	4	recorded	record	VBN
cord-005478-5iu38pr6	2850	5	as	as	IN
cord-005478-5iu38pr6	2850	6	CRS	CRS	NNP
cord-005478-5iu38pr6	2850	7	by	by	IN
cord-005478-5iu38pr6	2850	8	Penn	Penn	NNP
cord-005478-5iu38pr6	2850	9	Scale	Scale	NNP
cord-005478-5iu38pr6	2850	10	,	,	,
cord-005478-5iu38pr6	2850	11	and	and	CC
cord-005478-5iu38pr6	2850	12	63	63	CD
cord-005478-5iu38pr6	2850	13	were	be	VBD
cord-005478-5iu38pr6	2850	14	regraded	regrade	VBN
cord-005478-5iu38pr6	2850	15	as	as	IN
cord-005478-5iu38pr6	2850	16	CRS	CRS	NNP
cord-005478-5iu38pr6	2850	17	by	by	IN
cord-005478-5iu38pr6	2850	18	Lee	Lee	NNP
cord-005478-5iu38pr6	2850	19	criteria	criterion	NNS
cord-005478-5iu38pr6	2850	20	.	.	.
cord-005478-5iu38pr6	2851	1	18	18	CD
cord-005478-5iu38pr6	2851	2	of	of	IN
cord-005478-5iu38pr6	2851	3	64	64	CD
cord-005478-5iu38pr6	2851	4	subjects	subject	NNS
cord-005478-5iu38pr6	2851	5	received	receive	VBD
cord-005478-5iu38pr6	2851	6	anticytokine	anticytokine	JJ
cord-005478-5iu38pr6	2851	7	therapy	therapy	NN
cord-005478-5iu38pr6	2851	8	overall	overall	RB
cord-005478-5iu38pr6	2851	9	.	.	.
cord-005478-5iu38pr6	2852	1	With	with	IN
cord-005478-5iu38pr6	2852	2	this	this	DT
cord-005478-5iu38pr6	2852	3	blinded	blinded	JJ
cord-005478-5iu38pr6	2852	4	reassessment	reassessment	NN
cord-005478-5iu38pr6	2852	5	,	,	,
cord-005478-5iu38pr6	2852	6	more	more	JJR
cord-005478-5iu38pr6	2852	7	patients	patient	NNS
cord-005478-5iu38pr6	2852	8	were	be	VBD
cord-005478-5iu38pr6	2852	9	categorized	categorize	VBN
cord-005478-5iu38pr6	2852	10	as	as	IN
cord-005478-5iu38pr6	2852	11	grade	grade	NN
cord-005478-5iu38pr6	2852	12	1	1	CD
cord-005478-5iu38pr6	2852	13	(	(	-LRB-
cord-005478-5iu38pr6	2852	14	Lee	Lee	NNP
cord-005478-5iu38pr6	2852	15	vs	vs	IN
cord-005478-5iu38pr6	2852	16	Penn	Penn	NNP
cord-005478-5iu38pr6	2852	17	:	:	:
cord-005478-5iu38pr6	2852	18	26	26	CD
cord-005478-5iu38pr6	2852	19	vs	vs	IN
cord-005478-5iu38pr6	2852	20	17	17	CD
cord-005478-5iu38pr6	2852	21	)	)	-RRB-
cord-005478-5iu38pr6	2852	22	,	,	,
cord-005478-5iu38pr6	2852	23	fewer	few	JJR
cord-005478-5iu38pr6	2852	24	patients	patient	NNS
cord-005478-5iu38pr6	2852	25	as	as	IN
cord-005478-5iu38pr6	2852	26	grades	grade	NNS
cord-005478-5iu38pr6	2852	27	2	2	CD
cord-005478-5iu38pr6	2852	28	and	and	CC
cord-005478-5iu38pr6	2852	29	3	3	CD
cord-005478-5iu38pr6	2852	30	(	(	-LRB-
cord-005478-5iu38pr6	2852	31	18	18	CD
cord-005478-5iu38pr6	2852	32	vs	vs	IN
cord-005478-5iu38pr6	2852	33	23	23	CD
cord-005478-5iu38pr6	2852	34	and	and	CC
cord-005478-5iu38pr6	2852	35	10	10	CD
cord-005478-5iu38pr6	2852	36	vs	vs	IN
cord-005478-5iu38pr6	2852	37	15	15	CD
cord-005478-5iu38pr6	2852	38	,	,	,
cord-005478-5iu38pr6	2852	39	respectively	respectively	RB
cord-005478-5iu38pr6	2852	40	)	)	-RRB-
cord-005478-5iu38pr6	2852	41	and	and	CC
cord-005478-5iu38pr6	2852	42	the	the	DT
cord-005478-5iu38pr6	2852	43	same	same	JJ
cord-005478-5iu38pr6	2852	44	number	number	NN
cord-005478-5iu38pr6	2852	45	of	of	IN
cord-005478-5iu38pr6	2852	46	patients	patient	NNS
cord-005478-5iu38pr6	2852	47	as	as	IN
cord-005478-5iu38pr6	2852	48	grade	grade	NN
cord-005478-5iu38pr6	2852	49	4	4	CD
cord-005478-5iu38pr6	2852	50	(	(	-LRB-
cord-005478-5iu38pr6	2852	51	9	9	CD
cord-005478-5iu38pr6	2852	52	vs	vs	IN
cord-005478-5iu38pr6	2852	53	9	9	CD
cord-005478-5iu38pr6	2852	54	)	)	-RRB-
cord-005478-5iu38pr6	2852	55	.	.	.
cord-005478-5iu38pr6	2853	1	NT	NT	NNP
cord-005478-5iu38pr6	2853	2	:	:	:
cord-005478-5iu38pr6	2854	1	Results	result	NNS
cord-005478-5iu38pr6	2854	2	were	be	VBD
cord-005478-5iu38pr6	2854	3	compared	compare	VBN
cord-005478-5iu38pr6	2854	4	with	with	IN
cord-005478-5iu38pr6	2854	5	data	datum	NNS
cord-005478-5iu38pr6	2854	6	on	on	IN
cord-005478-5iu38pr6	2854	7	NT	NT	NNP
cord-005478-5iu38pr6	2854	8	determined	determine	VBN
cord-005478-5iu38pr6	2854	9	by	by	IN
cord-005478-5iu38pr6	2854	10	NCI	NCI	NNP
cord-005478-5iu38pr6	2854	11	CTC	CTC	NNP
cord-005478-5iu38pr6	2854	12	criteria	criterion	NNS
cord-005478-5iu38pr6	2854	13	of	of	IN
cord-005478-5iu38pr6	2854	14	tisagenlecleucel	tisagenlecleucel	NNP
cord-005478-5iu38pr6	2854	15	,	,	,
cord-005478-5iu38pr6	2854	16	in	in	IN
cord-005478-5iu38pr6	2854	17	which	which	WDT
cord-005478-5iu38pr6	2854	18	NT	NT	NNP
cord-005478-5iu38pr6	2854	19	was	be	VBD
cord-005478-5iu38pr6	2854	20	broadly	broadly	RB
cord-005478-5iu38pr6	2854	21	defined	define	VBN
cord-005478-5iu38pr6	2854	22	as	as	IN
cord-005478-5iu38pr6	2854	23	the	the	DT
cord-005478-5iu38pr6	2854	24	occurrence	occurrence	NN
cord-005478-5iu38pr6	2854	25	of	of	IN
cord-005478-5iu38pr6	2854	26	any	any	DT
cord-005478-5iu38pr6	2854	27	nervous	nervous	JJ
cord-005478-5iu38pr6	2854	28	system	system	NN
cord-005478-5iu38pr6	2854	29	or	or	CC
cord-005478-5iu38pr6	2854	30	psychiatric	psychiatric	JJ
cord-005478-5iu38pr6	2854	31	AE	AE	NNP
cord-005478-5iu38pr6	2854	32	(	(	-LRB-
cord-005478-5iu38pr6	2854	33	eg	eg	RB
cord-005478-5iu38pr6	2854	34	,	,	,
cord-005478-5iu38pr6	2854	35	anxiety	anxiety	NN
cord-005478-5iu38pr6	2854	36	,	,	,
cord-005478-5iu38pr6	2854	37	dizziness	dizziness	NN
cord-005478-5iu38pr6	2854	38	,	,	,
cord-005478-5iu38pr6	2854	39	headache	headache	NN
cord-005478-5iu38pr6	2854	40	,	,	,
cord-005478-5iu38pr6	2854	41	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2854	42	neuropathy	neuropathy	NN
cord-005478-5iu38pr6	2854	43	,	,	,
cord-005478-5iu38pr6	2854	44	and	and	CC
cord-005478-5iu38pr6	2854	45	sleep	sleep	NN
cord-005478-5iu38pr6	2854	46	disorder	disorder	NN
cord-005478-5iu38pr6	2854	47	)	)	-RRB-
cord-005478-5iu38pr6	2854	48	.	.	.
cord-005478-5iu38pr6	2855	1	68	68	CD
cord-005478-5iu38pr6	2855	2	of	of	IN
cord-005478-5iu38pr6	2855	3	111	111	CD
cord-005478-5iu38pr6	2855	4	subjects	subject	NNS
cord-005478-5iu38pr6	2855	5	were	be	VBD
cord-005478-5iu38pr6	2855	6	identified	identify	VBN
cord-005478-5iu38pr6	2855	7	as	as	IN
cord-005478-5iu38pr6	2855	8	having	have	VBG
cord-005478-5iu38pr6	2855	9	NT	NT	NNP
cord-005478-5iu38pr6	2855	10	by	by	IN
cord-005478-5iu38pr6	2855	11	CTC	CTC	NNP
cord-005478-5iu38pr6	2855	12	criteria	criterion	NNS
cord-005478-5iu38pr6	2855	13	:	:	:
cord-005478-5iu38pr6	2855	14	34	34	CD
cord-005478-5iu38pr6	2855	15	(	(	-LRB-
cord-005478-5iu38pr6	2855	16	30.6	30.6	CD
cord-005478-5iu38pr6	2855	17	%	%	NN
cord-005478-5iu38pr6	2855	18	)	)	-RRB-
cord-005478-5iu38pr6	2855	19	patients	patient	NNS
cord-005478-5iu38pr6	2855	20	were	be	VBD
cord-005478-5iu38pr6	2855	21	identified	identify	VBN
cord-005478-5iu38pr6	2855	22	as	as	IN
cord-005478-5iu38pr6	2855	23	having	have	VBG
cord-005478-5iu38pr6	2855	24	grade	grade	NN
cord-005478-5iu38pr6	2855	25	1/2	1/2	CD
cord-005478-5iu38pr6	2855	26	NT	NT	NNP
cord-005478-5iu38pr6	2855	27	,	,	,
cord-005478-5iu38pr6	2855	28	11	11	CD
cord-005478-5iu38pr6	2855	29	(	(	-LRB-
cord-005478-5iu38pr6	2855	30	9.9	9.9	CD
cord-005478-5iu38pr6	2855	31	%	%	NN
cord-005478-5iu38pr6	2855	32	)	)	-RRB-
cord-005478-5iu38pr6	2855	33	patients	patient	NNS
cord-005478-5iu38pr6	2855	34	as	as	IN
cord-005478-5iu38pr6	2855	35	having	have	VBG
cord-005478-5iu38pr6	2855	36	grade	grade	NN
cord-005478-5iu38pr6	2855	37	3	3	CD
cord-005478-5iu38pr6	2855	38	NT	NT	NNP
cord-005478-5iu38pr6	2855	39	,	,	,
cord-005478-5iu38pr6	2855	40	&	&	CC
cord-005478-5iu38pr6	2855	41	5	5	CD
cord-005478-5iu38pr6	2855	42	(	(	-LRB-
cord-005478-5iu38pr6	2855	43	4.5	4.5	CD
cord-005478-5iu38pr6	2855	44	%	%	NN
cord-005478-5iu38pr6	2855	45	)	)	-RRB-
cord-005478-5iu38pr6	2855	46	patients	patient	NNS
cord-005478-5iu38pr6	2855	47	as	as	IN
cord-005478-5iu38pr6	2855	48	having	have	VBG
cord-005478-5iu38pr6	2855	49	grade	grade	NN
cord-005478-5iu38pr6	2855	50	4	4	CD
cord-005478-5iu38pr6	2855	51	NT	NT	NNP
cord-005478-5iu38pr6	2855	52	.	.	.
cord-005478-5iu38pr6	2856	1	Evalution	evalution	NN
cord-005478-5iu38pr6	2856	2	by	by	IN
cord-005478-5iu38pr6	2856	3	mCRES	mcres	NN
cord-005478-5iu38pr6	2856	4	grading	grading	NN
cord-005478-5iu38pr6	2856	5	system	system	NN
cord-005478-5iu38pr6	2856	6	revealed	reveal	VBD
cord-005478-5iu38pr6	2856	7	low	low	JJ
cord-005478-5iu38pr6	2856	8	rates	rate	NNS
cord-005478-5iu38pr6	2856	9	of	of	IN
cord-005478-5iu38pr6	2856	10	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	2856	11	/	/	SYM
cord-005478-5iu38pr6	2856	12	delirium	delirium	NN
cord-005478-5iu38pr6	2856	13	:	:	:
cord-005478-5iu38pr6	2856	14	5	5	CD
cord-005478-5iu38pr6	2856	15	(	(	-LRB-
cord-005478-5iu38pr6	2856	16	4.5	4.5	CD
cord-005478-5iu38pr6	2856	17	%	%	NN
cord-005478-5iu38pr6	2856	18	)	)	-RRB-
cord-005478-5iu38pr6	2856	19	patients	patient	NNS
cord-005478-5iu38pr6	2856	20	had	have	VBD
cord-005478-5iu38pr6	2856	21	grade	grade	NN
cord-005478-5iu38pr6	2856	22	1/2	1/2	CD
cord-005478-5iu38pr6	2856	23	NT	NT	NNP
cord-005478-5iu38pr6	2856	24	,	,	,
cord-005478-5iu38pr6	2856	25	6	6	CD
cord-005478-5iu38pr6	2856	26	(	(	-LRB-
cord-005478-5iu38pr6	2856	27	5.4	5.4	CD
cord-005478-5iu38pr6	2856	28	%	%	NN
cord-005478-5iu38pr6	2856	29	)	)	-RRB-
cord-005478-5iu38pr6	2857	1	patients	patient	NNS
cord-005478-5iu38pr6	2857	2	had	have	VBD
cord-005478-5iu38pr6	2857	3	grade	grade	NN
cord-005478-5iu38pr6	2857	4	3	3	CD
cord-005478-5iu38pr6	2857	5	NT	NT	NNP
cord-005478-5iu38pr6	2857	6	,	,	,
cord-005478-5iu38pr6	2857	7	and	and	CC
cord-005478-5iu38pr6	2857	8	8	8	CD
cord-005478-5iu38pr6	2857	9	(	(	-LRB-
cord-005478-5iu38pr6	2857	10	7.2	7.2	CD
cord-005478-5iu38pr6	2857	11	%	%	NN
cord-005478-5iu38pr6	2857	12	)	)	-RRB-
cord-005478-5iu38pr6	2858	1	patients	patient	NNS
cord-005478-5iu38pr6	2858	2	had	have	VBD
cord-005478-5iu38pr6	2858	3	grade	grade	NN
cord-005478-5iu38pr6	2858	4	4	4	CD
cord-005478-5iu38pr6	2858	5	NT	NT	NNP
cord-005478-5iu38pr6	2858	6	.	.	.
cord-005478-5iu38pr6	2859	1	No	no	DT
cord-005478-5iu38pr6	2859	2	grade	grade	NN
cord-005478-5iu38pr6	2859	3	5	5	CD
cord-005478-5iu38pr6	2859	4	events	event	NNS
cord-005478-5iu38pr6	2859	5	were	be	VBD
cord-005478-5iu38pr6	2859	6	seen	see	VBN
cord-005478-5iu38pr6	2859	7	and	and	CC
cord-005478-5iu38pr6	2859	8	the	the	DT
cord-005478-5iu38pr6	2859	9	presence	presence	NN
cord-005478-5iu38pr6	2859	10	of	of	IN
cord-005478-5iu38pr6	2859	11	CRS	CRS	NNP
cord-005478-5iu38pr6	2859	12	was	be	VBD
cord-005478-5iu38pr6	2859	13	associated	associate	VBN
cord-005478-5iu38pr6	2859	14	with	with	IN
cord-005478-5iu38pr6	2859	15	higher	high	JJR
cord-005478-5iu38pr6	2859	16	likelihood	likelihood	NN
cord-005478-5iu38pr6	2859	17	of	of	IN
cord-005478-5iu38pr6	2859	18	concomitant	concomitant	JJ
cord-005478-5iu38pr6	2859	19	NT	NT	NNP
cord-005478-5iu38pr6	2859	20	.	.	.
cord-005478-5iu38pr6	2860	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2860	2	:	:	:
cord-005478-5iu38pr6	2861	1	These	these	DT
cord-005478-5iu38pr6	2861	2	results	result	NNS
cord-005478-5iu38pr6	2861	3	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	2861	4	difficulties	difficulty	NNS
cord-005478-5iu38pr6	2861	5	in	in	IN
cord-005478-5iu38pr6	2861	6	identifying	identify	VBG
cord-005478-5iu38pr6	2861	7	cross	cross	NN
cord-005478-5iu38pr6	2861	8	protocol	protocol	NN
cord-005478-5iu38pr6	2861	9	toxicity	toxicity	NN
cord-005478-5iu38pr6	2861	10	assessments	assessment	NNS
cord-005478-5iu38pr6	2861	11	.	.	.
cord-005478-5iu38pr6	2862	1	Harmonized	harmonize	VBN
cord-005478-5iu38pr6	2862	2	grading	grading	NN
cord-005478-5iu38pr6	2862	3	scales	scale	NNS
cord-005478-5iu38pr6	2862	4	being	be	VBG
cord-005478-5iu38pr6	2862	5	developed	develop	VBN
cord-005478-5iu38pr6	2862	6	for	for	IN
cord-005478-5iu38pr6	2862	7	future	future	JJ
cord-005478-5iu38pr6	2862	8	studies	study	NNS
cord-005478-5iu38pr6	2862	9	will	will	MD
cord-005478-5iu38pr6	2862	10	facilitate	facilitate	VB
cord-005478-5iu38pr6	2862	11	comparison	comparison	NN
cord-005478-5iu38pr6	2862	12	of	of	IN
cord-005478-5iu38pr6	2862	13	the	the	DT
cord-005478-5iu38pr6	2862	14	safety	safety	NN
cord-005478-5iu38pr6	2862	15	profiles	profile	NNS
cord-005478-5iu38pr6	2862	16	of	of	IN
cord-005478-5iu38pr6	2862	17	different	different	JJ
cord-005478-5iu38pr6	2862	18	CAR	car	NN
cord-005478-5iu38pr6	2862	19	T	t	NN
cord-005478-5iu38pr6	2862	20	-	-	HYPH
cord-005478-5iu38pr6	2862	21	cell	cell	NN
cord-005478-5iu38pr6	2862	22	and	and	CC
cord-005478-5iu38pr6	2862	23	other	other	JJ
cord-005478-5iu38pr6	2862	24	immune	immune	JJ
cord-005478-5iu38pr6	2862	25	effector	effector	NN
cord-005478-5iu38pr6	2862	26	cell	cell	NN
cord-005478-5iu38pr6	2862	27	products	product	NNS
cord-005478-5iu38pr6	2862	28	.	.	.
cord-005478-5iu38pr6	2863	1	Further	further	JJ
cord-005478-5iu38pr6	2863	2	analyses	analysis	NNS
cord-005478-5iu38pr6	2863	3	are	be	VBP
cord-005478-5iu38pr6	2863	4	ongoing	ongoing	JJ
cord-005478-5iu38pr6	2863	5	of	of	IN
cord-005478-5iu38pr6	2863	6	these	these	DT
cord-005478-5iu38pr6	2863	7	data	datum	NNS
cord-005478-5iu38pr6	2863	8	with	with	IN
cord-005478-5iu38pr6	2863	9	the	the	DT
cord-005478-5iu38pr6	2863	10	new	new	JJ
cord-005478-5iu38pr6	2863	11	ASBMT	ASBMT	NNP
cord-005478-5iu38pr6	2863	12	consensus	consensus	NN
cord-005478-5iu38pr6	2863	13	CRS	CRS	NNP
cord-005478-5iu38pr6	2863	14	guidelines	guideline	NNS
cord-005478-5iu38pr6	2863	15	.	.	.
cord-005478-5iu38pr6	2864	1	Recent	recent	JJ
cord-005478-5iu38pr6	2864	2	studies	study	NNS
cord-005478-5iu38pr6	2864	3	show	show	VBP
cord-005478-5iu38pr6	2864	4	that	that	IN
cord-005478-5iu38pr6	2864	5	mouse	mouse	NN
cord-005478-5iu38pr6	2864	6	bone	bone	NN
cord-005478-5iu38pr6	2864	7	marrow	marrow	NN
cord-005478-5iu38pr6	2864	8	Tregs	Tregs	NNP
cord-005478-5iu38pr6	2864	9	localize	localize	VBP
cord-005478-5iu38pr6	2864	10	in	in	IN
cord-005478-5iu38pr6	2864	11	the	the	DT
cord-005478-5iu38pr6	2864	12	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2864	13	stem	stem	NN
cord-005478-5iu38pr6	2864	14	cell	cell	NN
cord-005478-5iu38pr6	2864	15	(	(	-LRB-
cord-005478-5iu38pr6	2864	16	HSC	HSC	NNP
cord-005478-5iu38pr6	2864	17	)	)	-RRB-
cord-005478-5iu38pr6	2864	18	niche	niche	NN
cord-005478-5iu38pr6	2864	19	,	,	,
cord-005478-5iu38pr6	2864	20	where	where	WRB
cord-005478-5iu38pr6	2864	21	they	-PRON-	PRP
cord-005478-5iu38pr6	2864	22	contribute	contribute	VBP
cord-005478-5iu38pr6	2864	23	to	to	IN
cord-005478-5iu38pr6	2864	24	HSCs	hscs	NN
cord-005478-5iu38pr6	2864	25	maintenance	maintenance	NN
cord-005478-5iu38pr6	2864	26	and	and	CC
cord-005478-5iu38pr6	2864	27	promote	promote	VB
cord-005478-5iu38pr6	2864	28	donor	donor	NN
cord-005478-5iu38pr6	2864	29	engraftment	engraftment	NN
cord-005478-5iu38pr6	2864	30	and	and	CC
cord-005478-5iu38pr6	2864	31	B	B	NNP
cord-005478-5iu38pr6	2864	32	cell	cell	NN
cord-005478-5iu38pr6	2864	33	lymphopoiesis	lymphopoiesis	NN
cord-005478-5iu38pr6	2864	34	.	.	.
cord-005478-5iu38pr6	2865	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2865	2	are	be	VBP
cord-005478-5iu38pr6	2865	3	investigating	investigate	VBG
cord-005478-5iu38pr6	2865	4	if	if	IN
cord-005478-5iu38pr6	2865	5	human	human	JJ
cord-005478-5iu38pr6	2865	6	Tregs	Tregs	NNP
cord-005478-5iu38pr6	2865	7	promote	promote	VBP
cord-005478-5iu38pr6	2865	8	B	b	NN
cord-005478-5iu38pr6	2865	9	cell	cell	NN
cord-005478-5iu38pr6	2865	10	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2865	11	and	and	CC
cord-005478-5iu38pr6	2865	12	immunity	immunity	NN
cord-005478-5iu38pr6	2865	13	in	in	IN
cord-005478-5iu38pr6	2865	14	preclinical	preclinical	JJ
cord-005478-5iu38pr6	2865	15	models	model	NNS
cord-005478-5iu38pr6	2865	16	and	and	CC
cord-005478-5iu38pr6	2865	17	in	in	IN
cord-005478-5iu38pr6	2865	18	haplo	haplo	NNP
cord-005478-5iu38pr6	2865	19	-	-	HYPH
cord-005478-5iu38pr6	2865	20	HCT	HCT	NNP
cord-005478-5iu38pr6	2865	21	patients	patient	NNS
cord-005478-5iu38pr6	2865	22	.	.	.
cord-005478-5iu38pr6	2866	1	Methods	method	NNS
cord-005478-5iu38pr6	2866	2	:	:	:
cord-005478-5iu38pr6	2867	1	B	b	NN
cord-005478-5iu38pr6	2867	2	cell	cell	NN
cord-005478-5iu38pr6	2867	3	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2867	4	was	be	VBD
cord-005478-5iu38pr6	2867	5	analysed	analyse	VBN
cord-005478-5iu38pr6	2867	6	monthly	monthly	RB
cord-005478-5iu38pr6	2867	7	by	by	IN
cord-005478-5iu38pr6	2867	8	FACS	FACS	NNP
cord-005478-5iu38pr6	2867	9	in	in	IN
cord-005478-5iu38pr6	2867	10	bone	bone	NN
cord-005478-5iu38pr6	2867	11	marrow	marrow	NN
cord-005478-5iu38pr6	2867	12	(	(	-LRB-
cord-005478-5iu38pr6	2867	13	BM	BM	NNP
cord-005478-5iu38pr6	2867	14	)	)	-RRB-
cord-005478-5iu38pr6	2867	15	and	and	CC
cord-005478-5iu38pr6	2867	16	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2867	17	blood	blood	NN
cord-005478-5iu38pr6	2867	18	(	(	-LRB-
cord-005478-5iu38pr6	2867	19	PB	PB	NNP
cord-005478-5iu38pr6	2867	20	)	)	-RRB-
cord-005478-5iu38pr6	2867	21	samples	sample	NNS
cord-005478-5iu38pr6	2867	22	from	from	IN
cord-005478-5iu38pr6	2867	23	51	51	CD
cord-005478-5iu38pr6	2867	24	patients	patient	NNS
cord-005478-5iu38pr6	2867	25	who	who	WP
cord-005478-5iu38pr6	2867	26	underwent	undergo	VBD
cord-005478-5iu38pr6	2867	27	either	either	CC
cord-005478-5iu38pr6	2867	28	Treg	Treg	NNP
cord-005478-5iu38pr6	2867	29	/	/	SYM
cord-005478-5iu38pr6	2867	30	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2867	31	haplo	haplo	NN
cord-005478-5iu38pr6	2867	32	-	-	HYPH
cord-005478-5iu38pr6	2867	33	HCT	HCT	NNP
cord-005478-5iu38pr6	2867	34	(	(	-LRB-
cord-005478-5iu38pr6	2867	35	33	33	CD
cord-005478-5iu38pr6	2867	36	patients	patient	NNS
cord-005478-5iu38pr6	2867	37	)	)	-RRB-
cord-005478-5iu38pr6	2867	38	,	,	,
cord-005478-5iu38pr6	2867	39	or	or	CC
cord-005478-5iu38pr6	2867	40	T	t	NN
cord-005478-5iu38pr6	2867	41	-	-	HYPH
cord-005478-5iu38pr6	2867	42	cell	cell	NN
cord-005478-5iu38pr6	2867	43	depleted	deplete	VBN
cord-005478-5iu38pr6	2867	44	haplo	haplo	NN
cord-005478-5iu38pr6	2867	45	-	-	HYPH
cord-005478-5iu38pr6	2867	46	HCT	HCT	NNP
cord-005478-5iu38pr6	2867	47	(	(	-LRB-
cord-005478-5iu38pr6	2867	48	8	8	CD
cord-005478-5iu38pr6	2867	49	patients	patient	NNS
cord-005478-5iu38pr6	2867	50	)	)	-RRB-
cord-005478-5iu38pr6	2867	51	or	or	CC
cord-005478-5iu38pr6	2867	52	haplo	haplo	NN
cord-005478-5iu38pr6	2867	53	-	-	HYPH
cord-005478-5iu38pr6	2867	54	HCT	HCT	NNP
cord-005478-5iu38pr6	2867	55	with	with	IN
cord-005478-5iu38pr6	2867	56	high	high	JJ
cord-005478-5iu38pr6	2867	57	dose	dose	NN
cord-005478-5iu38pr6	2867	58	post	post	JJ
cord-005478-5iu38pr6	2867	59	-	-	JJ
cord-005478-5iu38pr6	2867	60	transplant	transplant	NN
cord-005478-5iu38pr6	2867	61	Cy	Cy	NNP
cord-005478-5iu38pr6	2867	62	(	(	-LRB-
cord-005478-5iu38pr6	2867	63	PTCy	PTCy	NNP
cord-005478-5iu38pr6	2867	64	,	,	,
cord-005478-5iu38pr6	2867	65	10	10	CD
cord-005478-5iu38pr6	2867	66	patients	patient	NNS
cord-005478-5iu38pr6	2867	67	)	)	-RRB-
cord-005478-5iu38pr6	2867	68	.	.	.
cord-005478-5iu38pr6	2868	1	Diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2868	2	was	be	VBD
cord-005478-5iu38pr6	2868	3	acute	acute	JJ
cord-005478-5iu38pr6	2868	4	leukemia	leukemia	NN
cord-005478-5iu38pr6	2868	5	in	in	IN
cord-005478-5iu38pr6	2868	6	39	39	CD
cord-005478-5iu38pr6	2868	7	patients	patient	NNS
cord-005478-5iu38pr6	2868	8	,	,	,
cord-005478-5iu38pr6	2868	9	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	2868	10	in	in	IN
cord-005478-5iu38pr6	2868	11	9	9	CD
cord-005478-5iu38pr6	2868	12	and	and	CC
cord-005478-5iu38pr6	2868	13	multiple	multiple	JJ
cord-005478-5iu38pr6	2868	14	myeloma	myeloma	NN
cord-005478-5iu38pr6	2868	15	in	in	IN
cord-005478-5iu38pr6	2868	16	3	3	CD
cord-005478-5iu38pr6	2868	17	.	.	.
cord-005478-5iu38pr6	2869	1	PB	PB	NNP
cord-005478-5iu38pr6	2869	2	total	total	JJ
cord-005478-5iu38pr6	2869	3	immunoglobulin	immunoglobulin	NN
cord-005478-5iu38pr6	2869	4	(	(	-LRB-
cord-005478-5iu38pr6	2869	5	Ig	Ig	NNP
cord-005478-5iu38pr6	2869	6	)	)	-RRB-
cord-005478-5iu38pr6	2869	7	and	and	CC
cord-005478-5iu38pr6	2869	8	anti	anti	JJ
cord-005478-5iu38pr6	2869	9	-	-	JJ
cord-005478-5iu38pr6	2869	10	Cytomegalovirus	cytomegalovirus	JJ
cord-005478-5iu38pr6	2869	11	(	(	-LRB-
cord-005478-5iu38pr6	2869	12	CMV	CMV	NNP
cord-005478-5iu38pr6	2869	13	)	)	-RRB-
cord-005478-5iu38pr6	2869	14	IgM	IgM	NNP
cord-005478-5iu38pr6	2869	15	were	be	VBD
cord-005478-5iu38pr6	2869	16	also	also	RB
cord-005478-5iu38pr6	2869	17	monitored	monitor	VBN
cord-005478-5iu38pr6	2869	18	together	together	RB
cord-005478-5iu38pr6	2869	19	with	with	IN
cord-005478-5iu38pr6	2869	20	CMV	CMV	NNP
cord-005478-5iu38pr6	2869	21	viremia	viremia	NN
cord-005478-5iu38pr6	2869	22	.	.	.
cord-005478-5iu38pr6	2870	1	For	for	IN
cord-005478-5iu38pr6	2870	2	the	the	DT
cord-005478-5iu38pr6	2870	3	mouse	mouse	NN
cord-005478-5iu38pr6	2870	4	model	model	NN
cord-005478-5iu38pr6	2870	5	,	,	,
cord-005478-5iu38pr6	2870	6	donor	donor	NN
cord-005478-5iu38pr6	2870	7	derived	derive	VBD
cord-005478-5iu38pr6	2870	8	human	human	JJ
cord-005478-5iu38pr6	2870	9	Treg	Treg	NNP
cord-005478-5iu38pr6	2870	10	and	and	CC
cord-005478-5iu38pr6	2870	11	CD34	CD34	NNP
cord-005478-5iu38pr6	2870	12	+	+	CC
cord-005478-5iu38pr6	2870	13	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2870	14	stem	stem	NN
cord-005478-5iu38pr6	2870	15	cells	cell	NNS
cord-005478-5iu38pr6	2870	16	(	(	-LRB-
cord-005478-5iu38pr6	2870	17	HSCs	HSCs	NNP
cord-005478-5iu38pr6	2870	18	)	)	-RRB-
cord-005478-5iu38pr6	2870	19	were	be	VBD
cord-005478-5iu38pr6	2870	20	coinfused	coinfuse	VBN
cord-005478-5iu38pr6	2870	21	in	in	IN
cord-005478-5iu38pr6	2870	22	sublethally	sublethally	RB
cord-005478-5iu38pr6	2870	23	irradiated	irradiate	VBN
cord-005478-5iu38pr6	2870	24	(	(	-LRB-
cord-005478-5iu38pr6	2870	25	2	2	CD
cord-005478-5iu38pr6	2870	26	Gy	gy	NN
cord-005478-5iu38pr6	2870	27	)	)	-RRB-
cord-005478-5iu38pr6	2870	28	immune	immune	NN
cord-005478-5iu38pr6	2870	29	-	-	HYPH
cord-005478-5iu38pr6	2870	30	deficient	deficient	JJ
cord-005478-5iu38pr6	2870	31	NSG	NSG	NNP
cord-005478-5iu38pr6	2870	32	mice	mouse	NNS
cord-005478-5iu38pr6	2870	33	and	and	CC
cord-005478-5iu38pr6	2870	34	donor	donor	NN
cord-005478-5iu38pr6	2870	35	engraftment	engraftment	NN
cord-005478-5iu38pr6	2870	36	and	and	CC
cord-005478-5iu38pr6	2870	37	B	b	NN
cord-005478-5iu38pr6	2870	38	cell	cell	NN
cord-005478-5iu38pr6	2870	39	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2870	40	were	be	VBD
cord-005478-5iu38pr6	2870	41	analysed	analyse	VBN
cord-005478-5iu38pr6	2870	42	in	in	IN
cord-005478-5iu38pr6	2870	43	mouse	mouse	NN
cord-005478-5iu38pr6	2870	44	PB	PB	NNP
cord-005478-5iu38pr6	2870	45	twice	twice	PDT
cord-005478-5iu38pr6	2870	46	a	a	DT
cord-005478-5iu38pr6	2870	47	month	month	NN
cord-005478-5iu38pr6	2870	48	by	by	IN
cord-005478-5iu38pr6	2870	49	FACS	FACS	NNP
cord-005478-5iu38pr6	2870	50	.	.	.
cord-005478-5iu38pr6	2871	1	Results	result	NNS
cord-005478-5iu38pr6	2871	2	:	:	:
cord-005478-5iu38pr6	2872	1	B	b	NN
cord-005478-5iu38pr6	2872	2	cell	cell	NN
cord-005478-5iu38pr6	2872	3	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2872	4	was	be	VBD
cord-005478-5iu38pr6	2872	5	faster	fast	JJR
cord-005478-5iu38pr6	2872	6	after	after	RB
cord-005478-5iu38pr6	2873	1	Treg	Treg	NNP
cord-005478-5iu38pr6	2873	2	/	/	SYM
cord-005478-5iu38pr6	2873	3	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2873	4	haplo	haplo	NN
cord-005478-5iu38pr6	2873	5	-	-	HYPH
cord-005478-5iu38pr6	2873	6	HCT	HCT	NNP
cord-005478-5iu38pr6	2874	1	when	when	WRB
cord-005478-5iu38pr6	2874	2	compared	compare	VBN
cord-005478-5iu38pr6	2874	3	to	to	IN
cord-005478-5iu38pr6	2874	4	other	other	JJ
cord-005478-5iu38pr6	2874	5	haplo	haplo	NN
cord-005478-5iu38pr6	2874	6	-	-	HYPH
cord-005478-5iu38pr6	2874	7	HCT	HCT	NNP
cord-005478-5iu38pr6	2874	8	protocols	protocol	NNS
cord-005478-5iu38pr6	2874	9	.	.	.
cord-005478-5iu38pr6	2875	1	B	b	NN
cord-005478-5iu38pr6	2875	2	cell	cell	NN
cord-005478-5iu38pr6	2875	3	counts	count	NNS
cord-005478-5iu38pr6	2875	4	were	be	VBD
cord-005478-5iu38pr6	2875	5	higher	high	JJR
cord-005478-5iu38pr6	2875	6	in	in	IN
cord-005478-5iu38pr6	2875	7	PB	PB	NNP
cord-005478-5iu38pr6	2875	8	of	of	IN
cord-005478-5iu38pr6	2875	9	patients	patient	NNS
cord-005478-5iu38pr6	2875	10	that	that	WDT
cord-005478-5iu38pr6	2875	11	received	receive	VBD
cord-005478-5iu38pr6	2875	12	Treg/	Treg/	NNP
cord-005478-5iu38pr6	2875	13	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2875	14	haplo	haplo	NN
cord-005478-5iu38pr6	2875	15	-	-	HYPH
cord-005478-5iu38pr6	2875	16	HCT	HCT	NNP
cord-005478-5iu38pr6	2875	17	(	(	-LRB-
cord-005478-5iu38pr6	2875	18	p	p	NN
cord-005478-5iu38pr6	2875	19	=	=	SYM
cord-005478-5iu38pr6	2875	20	.02	.02	NFP
cord-005478-5iu38pr6	2875	21	)	)	-RRB-
cord-005478-5iu38pr6	2875	22	and	and	CC
cord-005478-5iu38pr6	2875	23	were	be	VBD
cord-005478-5iu38pr6	2875	24	comparable	comparable	JJ
cord-005478-5iu38pr6	2875	25	to	to	IN
cord-005478-5iu38pr6	2875	26	those	those	DT
cord-005478-5iu38pr6	2875	27	of	of	IN
cord-005478-5iu38pr6	2875	28	healthy	healthy	JJ
cord-005478-5iu38pr6	2875	29	subjects	subject	NNS
cord-005478-5iu38pr6	2875	30	by	by	IN
cord-005478-5iu38pr6	2875	31	4	4	CD
cord-005478-5iu38pr6	2875	32	months	month	NNS
cord-005478-5iu38pr6	2875	33	after	after	IN
cord-005478-5iu38pr6	2875	34	transplant	transplant	NN
cord-005478-5iu38pr6	2875	35	(	(	-LRB-
cord-005478-5iu38pr6	2875	36	131±121	131±121	CD
cord-005478-5iu38pr6	2875	37	cells/	cells/	SYM
cord-005478-5iu38pr6	2875	38	mm	mm	NNP
cord-005478-5iu38pr6	2875	39	3	3	CD
cord-005478-5iu38pr6	2875	40	,	,	,
cord-005478-5iu38pr6	2875	41	Fig.1A	Fig.1A	NNP
cord-005478-5iu38pr6	2875	42	)	)	-RRB-
cord-005478-5iu38pr6	2875	43	.	.	.
cord-005478-5iu38pr6	2876	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2876	2	could	could	MD
cord-005478-5iu38pr6	2876	3	detect	detect	VB
cord-005478-5iu38pr6	2876	4	early	early	JJ
cord-005478-5iu38pr6	2876	5	frequencies	frequency	NNS
cord-005478-5iu38pr6	2876	6	of	of	IN
cord-005478-5iu38pr6	2876	7	CD34	CD34	NNP
cord-005478-5iu38pr6	2876	8	+	+	CC
cord-005478-5iu38pr6	2877	1	CD38	CD38	NNP
cord-005478-5iu38pr6	2877	2	+	+	SYM
cord-005478-5iu38pr6	2877	3	CD10	CD10	NNP
cord-005478-5iu38pr6	2877	4	+	+	CC
cord-005478-5iu38pr6	2877	5	CD127	cd127	NN
cord-005478-5iu38pr6	2877	6	+	+	CC
cord-005478-5iu38pr6	2877	7	common	common	JJ
cord-005478-5iu38pr6	2877	8	lymphoid	lymphoid	JJ
cord-005478-5iu38pr6	2877	9	progenitors	progenitor	NNS
cord-005478-5iu38pr6	2877	10	,	,	,
cord-005478-5iu38pr6	2878	1	CD45	CD45	NNP
cord-005478-5iu38pr6	2878	2	+	+	CC
cord-005478-5iu38pr6	2878	3	CD10	CD10	NNP
cord-005478-5iu38pr6	2878	4	+	+	CC
cord-005478-5iu38pr6	2878	5	CD38	CD38	NNP
cord-005478-5iu38pr6	2878	6	+	+	CC
cord-005478-5iu38pr6	2879	1	CD19	CD19	NNP
cord-005478-5iu38pr6	2879	2	-Pre	-Pre	VBZ
cord-005478-5iu38pr6	2879	3	/	/	,
cord-005478-5iu38pr6	2879	4	Pro	pro	NN
cord-005478-5iu38pr6	2879	5	-	-	NN
cord-005478-5iu38pr6	2879	6	B	b	NN
cord-005478-5iu38pr6	2880	1	,	,	,
cord-005478-5iu38pr6	2880	2	CD45	CD45	NNP
cord-005478-5iu38pr6	2880	3	+	+	CC
cord-005478-5iu38pr6	2881	1	CD10	CD10	NNP
cord-005478-5iu38pr6	2881	2	+	+	CC
cord-005478-5iu38pr6	2881	3	CD38	CD38	NNP
cord-005478-5iu38pr6	2881	4	+	+	SYM
cord-005478-5iu38pr6	2881	5	CD19	CD19	NNP
cord-005478-5iu38pr6	2881	6	+	+	CC
cord-005478-5iu38pr6	2881	7	Pre	pre	NN
cord-005478-5iu38pr6	2881	8	-	-	NN
cord-005478-5iu38pr6	2881	9	B	B	NNP
cord-005478-5iu38pr6	2881	10	,	,	,
cord-005478-5iu38pr6	2881	11	and	and	CC
cord-005478-5iu38pr6	2881	12	Pro	pro	JJ
cord-005478-5iu38pr6	2881	13	-	-	HYPH
cord-005478-5iu38pr6	2881	14	B	b	NN
cord-005478-5iu38pr6	2881	15	cells	cell	NNS
cord-005478-5iu38pr6	2881	16	in	in	IN
cord-005478-5iu38pr6	2881	17	the	the	DT
cord-005478-5iu38pr6	2881	18	BM	bm	NN
cord-005478-5iu38pr6	2881	19	of	of	IN
cord-005478-5iu38pr6	2881	20	these	these	DT
cord-005478-5iu38pr6	2881	21	patients	patient	NNS
cord-005478-5iu38pr6	2881	22	,	,	,
cord-005478-5iu38pr6	2881	23	that	that	WDT
cord-005478-5iu38pr6	2881	24	resulted	result	VBD
cord-005478-5iu38pr6	2881	25	in	in	IN
cord-005478-5iu38pr6	2881	26	an	an	DT
cord-005478-5iu38pr6	2881	27	increased	increase	VBN
cord-005478-5iu38pr6	2881	28	production	production	NN
cord-005478-5iu38pr6	2881	29	of	of	IN
cord-005478-5iu38pr6	2881	30	CD38	CD38	NNP
cord-005478-5iu38pr6	2881	31	+	+	SYM
cord-005478-5iu38pr6	2881	32	CD19	CD19	NNP
cord-005478-5iu38pr6	2881	33	+	+	CC
cord-005478-5iu38pr6	2881	34	CD5	cd5	NN
cord-005478-5iu38pr6	2881	35	-IgM	-igm	ADD
cord-005478-5iu38pr6	2881	36	+	+	CC
cord-005478-5iu38pr6	2881	37	immature	immature	JJ
cord-005478-5iu38pr6	2881	38	B	b	NN
cord-005478-5iu38pr6	2881	39	cells	cell	NNS
cord-005478-5iu38pr6	2881	40	,	,	,
cord-005478-5iu38pr6	2881	41	CD38	CD38	NNP
cord-005478-5iu38pr6	2881	42	+	+	SYM
cord-005478-5iu38pr6	2881	43	CD19	CD19	NNP
cord-005478-5iu38pr6	2881	44	+	+	CC
cord-005478-5iu38pr6	2881	45	CD5	CD5	NNP
cord-005478-5iu38pr6	2881	46	+	+	CC
cord-005478-5iu38pr6	2881	47	IgM	IgM	NNP
cord-005478-5iu38pr6	2881	48	+	+	CC
cord-005478-5iu38pr6	2881	49	transitional	transitional	NNP
cord-005478-5iu38pr6	2881	50	B	B	NNP
cord-005478-5iu38pr6	2881	51	cells	cell	NNS
cord-005478-5iu38pr6	2881	52	and	and	CC
cord-005478-5iu38pr6	2881	53	CD19	CD19	NNP
cord-005478-5iu38pr6	2881	54	+	+	CC
cord-005478-5iu38pr6	2881	55	CD20	cd20	NN
cord-005478-5iu38pr6	2881	56	+	+	CC
cord-005478-5iu38pr6	2881	57	mature	mature	VB
cord-005478-5iu38pr6	2881	58	B	b	NN
cord-005478-5iu38pr6	2881	59	cells	cell	NNS
cord-005478-5iu38pr6	2881	60	.	.	.
cord-005478-5iu38pr6	2882	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2882	2	used	use	VBD
cord-005478-5iu38pr6	2882	3	a	a	DT
cord-005478-5iu38pr6	2882	4	mouse	mouse	NN
cord-005478-5iu38pr6	2882	5	model	model	NN
cord-005478-5iu38pr6	2882	6	of	of	IN
cord-005478-5iu38pr6	2882	7	xenotransplantation	xenotransplantation	NN
cord-005478-5iu38pr6	2882	8	to	to	TO
cord-005478-5iu38pr6	2882	9	understand	understand	VB
cord-005478-5iu38pr6	2882	10	whether	whether	IN
cord-005478-5iu38pr6	2882	11	donor	donor	NN
cord-005478-5iu38pr6	2882	12	B	b	NN
cord-005478-5iu38pr6	2882	13	cell	cell	NN
cord-005478-5iu38pr6	2882	14	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2882	15	in	in	IN
cord-005478-5iu38pr6	2882	16	Treg/	Treg/	NNP
cord-005478-5iu38pr6	2882	17	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2882	18	haplo	haplo	NN
cord-005478-5iu38pr6	2882	19	-	-	HYPH
cord-005478-5iu38pr6	2882	20	HCT	HCT	NNP
cord-005478-5iu38pr6	2882	21	is	be	VBZ
cord-005478-5iu38pr6	2882	22	boosted	boost	VBN
cord-005478-5iu38pr6	2882	23	by	by	IN
cord-005478-5iu38pr6	2882	24	a	a	DT
cord-005478-5iu38pr6	2882	25	Treg	Treg	NNP
cord-005478-5iu38pr6	2882	26	-	-	HYPH
cord-005478-5iu38pr6	2882	27	mediated	mediate	VBN
cord-005478-5iu38pr6	2882	28	effect	effect	NN
cord-005478-5iu38pr6	2882	29	on	on	IN
cord-005478-5iu38pr6	2882	30	donor	donor	NN
cord-005478-5iu38pr6	2882	31	human	human	NN
cord-005478-5iu38pr6	2882	32	HSCs	hscs	NN
cord-005478-5iu38pr6	2882	33	.	.	.
cord-005478-5iu38pr6	2883	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2883	2	found	find	VBD
cord-005478-5iu38pr6	2883	3	that	that	DT
cord-005478-5iu38pr6	2883	4	infusion	infusion	NN
cord-005478-5iu38pr6	2883	5	of	of	IN
cord-005478-5iu38pr6	2883	6	human	human	JJ
cord-005478-5iu38pr6	2883	7	Tregs	Tregs	NNP
cord-005478-5iu38pr6	2883	8	facilitated	facilitate	VBD
cord-005478-5iu38pr6	2883	9	donor	donor	NN
cord-005478-5iu38pr6	2883	10	HSC	HSC	NNP
cord-005478-5iu38pr6	2883	11	engraftment	engraftment	NN
cord-005478-5iu38pr6	2883	12	.	.	.
cord-005478-5iu38pr6	2884	1	HSC	HSC	NNP
cord-005478-5iu38pr6	2884	2	-	-	HYPH
cord-005478-5iu38pr6	2884	3	derived	derive	VBN
cord-005478-5iu38pr6	2884	4	mature	mature	NN
cord-005478-5iu38pr6	2884	5	B	b	NN
cord-005478-5iu38pr6	2884	6	cells	cell	NNS
cord-005478-5iu38pr6	2884	7	were	be	VBD
cord-005478-5iu38pr6	2884	8	rapidly	rapidly	RB
cord-005478-5iu38pr6	2884	9	abundant	abundant	JJ
cord-005478-5iu38pr6	2884	10	and	and	CC
cord-005478-5iu38pr6	2884	11	easily	easily	RB
cord-005478-5iu38pr6	2884	12	detectable	detectable	JJ
cord-005478-5iu38pr6	2884	13	60	60	CD
cord-005478-5iu38pr6	2884	14	days	day	NNS
cord-005478-5iu38pr6	2884	15	after	after	IN
cord-005478-5iu38pr6	2884	16	HSC	HSC	NNP
cord-005478-5iu38pr6	2884	17	infusion	infusion	NN
cord-005478-5iu38pr6	2884	18	in	in	IN
cord-005478-5iu38pr6	2884	19	PB	PB	NNP
cord-005478-5iu38pr6	2884	20	of	of	IN
cord-005478-5iu38pr6	2884	21	Treg	Treg	NNP
cord-005478-5iu38pr6	2884	22	-	-	HYPH
cord-005478-5iu38pr6	2884	23	treated	treat	VBN
cord-005478-5iu38pr6	2884	24	animals	animal	NNS
cord-005478-5iu38pr6	2884	25	.	.	.
cord-005478-5iu38pr6	2885	1	To	to	TO
cord-005478-5iu38pr6	2885	2	evaluate	evaluate	VB
cord-005478-5iu38pr6	2885	3	donor	donor	NN
cord-005478-5iu38pr6	2885	4	B	b	NN
cord-005478-5iu38pr6	2885	5	cell	cell	NN
cord-005478-5iu38pr6	2885	6	function	function	NN
cord-005478-5iu38pr6	2885	7	we	-PRON-	PRP
cord-005478-5iu38pr6	2885	8	analysed	analyse	VBD
cord-005478-5iu38pr6	2885	9	Ig	ig	JJ
cord-005478-5iu38pr6	2885	10	production	production	NN
cord-005478-5iu38pr6	2885	11	in	in	IN
cord-005478-5iu38pr6	2885	12	response	response	NN
cord-005478-5iu38pr6	2885	13	to	to	IN
cord-005478-5iu38pr6	2885	14	CMV	CMV	NNP
cord-005478-5iu38pr6	2885	15	reactivation	reactivation	NN
cord-005478-5iu38pr6	2885	16	in	in	IN
cord-005478-5iu38pr6	2885	17	transplanted	transplanted	JJ
cord-005478-5iu38pr6	2885	18	patients	patient	NNS
cord-005478-5iu38pr6	2885	19	.	.	.
cord-005478-5iu38pr6	2886	1	Post	post	JJ
cord-005478-5iu38pr6	2886	2	-	-	JJ
cord-005478-5iu38pr6	2886	3	transplant	transplant	NN
cord-005478-5iu38pr6	2886	4	hypogammaglobulinemia	hypogammaglobulinemia	NN
cord-005478-5iu38pr6	2886	5	was	be	VBD
cord-005478-5iu38pr6	2886	6	rapidly	rapidly	RB
cord-005478-5iu38pr6	2886	7	corrected	correct	VBN
cord-005478-5iu38pr6	2886	8	in	in	IN
cord-005478-5iu38pr6	2886	9	Treg	Treg	NNP
cord-005478-5iu38pr6	2886	10	/	/	SYM
cord-005478-5iu38pr6	2886	11	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2886	12	haplo	haplo	NN
cord-005478-5iu38pr6	2886	13	-	-	HYPH
cord-005478-5iu38pr6	2886	14	HCT	HCT	NNP
cord-005478-5iu38pr6	2886	15	patients	patient	NNS
cord-005478-5iu38pr6	2886	16	.	.	.
cord-005478-5iu38pr6	2887	1	Total	total	JJ
cord-005478-5iu38pr6	2887	2	IgM	igm	NN
cord-005478-5iu38pr6	2887	3	were	be	VBD
cord-005478-5iu38pr6	2887	4	higher	high	JJR
cord-005478-5iu38pr6	2887	5	compared	compare	VBN
cord-005478-5iu38pr6	2887	6	to	to	IN
cord-005478-5iu38pr6	2887	7	other	other	JJ
cord-005478-5iu38pr6	2887	8	haplo	haplo	NN
cord-005478-5iu38pr6	2887	9	-	-	HYPH
cord-005478-5iu38pr6	2887	10	HCT	HCT	NNP
cord-005478-5iu38pr6	2887	11	protocols	protocol	NNS
cord-005478-5iu38pr6	2887	12	and	and	CC
cord-005478-5iu38pr6	2887	13	reached	reach	VBD
cord-005478-5iu38pr6	2887	14	normal	normal	JJ
cord-005478-5iu38pr6	2887	15	levels	level	NNS
cord-005478-5iu38pr6	2887	16	by	by	IN
cord-005478-5iu38pr6	2887	17	3	3	CD
cord-005478-5iu38pr6	2887	18	months	month	NNS
cord-005478-5iu38pr6	2887	19	after	after	IN
cord-005478-5iu38pr6	2887	20	transplant	transplant	NN
cord-005478-5iu38pr6	2887	21	(	(	-LRB-
cord-005478-5iu38pr6	2887	22	152	152	CD
cord-005478-5iu38pr6	2887	23	±194	±194	NNP
cord-005478-5iu38pr6	2887	24	mg	mg	NNP
cord-005478-5iu38pr6	2887	25	/	/	SYM
cord-005478-5iu38pr6	2887	26	dL	dL	NNP
cord-005478-5iu38pr6	2887	27	,	,	,
cord-005478-5iu38pr6	2887	28	Fig.1B	Fig.1B	NNP
cord-005478-5iu38pr6	2887	29	)	)	-RRB-
cord-005478-5iu38pr6	2887	30	.	.	.
cord-005478-5iu38pr6	2888	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2888	2	reactivation	reactivation	NN
cord-005478-5iu38pr6	2888	3	rate	rate	NN
cord-005478-5iu38pr6	2888	4	was	be	VBD
cord-005478-5iu38pr6	2888	5	similar	similar	JJ
cord-005478-5iu38pr6	2888	6	among	among	IN
cord-005478-5iu38pr6	2888	7	haplo	haplo	NN
cord-005478-5iu38pr6	2888	8	-	-	HYPH
cord-005478-5iu38pr6	2888	9	HCT	HCT	NNP
cord-005478-5iu38pr6	2888	10	protocols	protocol	NNS
cord-005478-5iu38pr6	2888	11	(	(	-LRB-
cord-005478-5iu38pr6	2888	12	~73	~73	CD
cord-005478-5iu38pr6	2888	13	%	%	NN
cord-005478-5iu38pr6	2888	14	)	)	-RRB-
cord-005478-5iu38pr6	2888	15	,	,	,
cord-005478-5iu38pr6	2888	16	but	but	CC
cord-005478-5iu38pr6	2888	17	it	-PRON-	PRP
cord-005478-5iu38pr6	2888	18	occurred	occur	VBD
cord-005478-5iu38pr6	2888	19	later	later	RB
cord-005478-5iu38pr6	2888	20	after	after	RB
cord-005478-5iu38pr6	2889	1	Treg	Treg	NNP
cord-005478-5iu38pr6	2889	2	/	/	SYM
cord-005478-5iu38pr6	2889	3	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2889	4	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	2889	5	(	(	-LRB-
cord-005478-5iu38pr6	2889	6	45+/-17	45+/-17	CD
cord-005478-5iu38pr6	2889	7	days	day	NNS
cord-005478-5iu38pr6	2889	8	vs	vs	IN
cord-005478-5iu38pr6	2889	9	33	33	CD
cord-005478-5iu38pr6	2889	10	+	+	SYM
cord-005478-5iu38pr6	2889	11	/-11	/-11	CD
cord-005478-5iu38pr6	2889	12	days	day	NNS
cord-005478-5iu38pr6	2889	13	)	)	-RRB-
cord-005478-5iu38pr6	2889	14	.	.	.
cord-005478-5iu38pr6	2890	1	New	new	JJ
cord-005478-5iu38pr6	2890	2	production	production	NN
cord-005478-5iu38pr6	2890	3	of	of	IN
cord-005478-5iu38pr6	2890	4	anti	anti	JJ
cord-005478-5iu38pr6	2890	5	-	-	JJ
cord-005478-5iu38pr6	2890	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2890	7	specific	specific	JJ
cord-005478-5iu38pr6	2890	8	IgM	igm	NN
cord-005478-5iu38pr6	2890	9	was	be	VBD
cord-005478-5iu38pr6	2890	10	documented	document	VBN
cord-005478-5iu38pr6	2890	11	in	in	IN
cord-005478-5iu38pr6	2890	12	60	60	CD
cord-005478-5iu38pr6	2890	13	%	%	NN
cord-005478-5iu38pr6	2890	14	of	of	IN
cord-005478-5iu38pr6	2890	15	CMV	CMV	NNP
cord-005478-5iu38pr6	2890	16	seropositive	seropositive	JJ
cord-005478-5iu38pr6	2890	17	patients	patient	NNS
cord-005478-5iu38pr6	2891	1	76	76	CD
cord-005478-5iu38pr6	2891	2	+	+	CC
cord-005478-5iu38pr6	2892	1	/-33	/-33	NFP
cord-005478-5iu38pr6	2892	2	days	day	NNS
cord-005478-5iu38pr6	2892	3	after	after	RB
cord-005478-5iu38pr6	2893	1	Treg	Treg	NNP
cord-005478-5iu38pr6	2893	2	/	/	SYM
cord-005478-5iu38pr6	2893	3	Tcon	Tcon	NNP
cord-005478-5iu38pr6	2893	4	haplo	haplo	NN
cord-005478-5iu38pr6	2893	5	-	-	HYPH
cord-005478-5iu38pr6	2893	6	HCT	HCT	NNP
cord-005478-5iu38pr6	2893	7	,	,	,
cord-005478-5iu38pr6	2893	8	while	while	IN
cord-005478-5iu38pr6	2893	9	anti	anti	JJ
cord-005478-5iu38pr6	2893	10	-	-	JJ
cord-005478-5iu38pr6	2893	11	CMV	CMV	NNP
cord-005478-5iu38pr6	2893	12	specific	specific	JJ
cord-005478-5iu38pr6	2893	13	IgM	IgM	NNP
cord-005478-5iu38pr6	2893	14	were	be	VBD
cord-005478-5iu38pr6	2893	15	undetectable	undetectable	JJ
cord-005478-5iu38pr6	2893	16	after	after	IN
cord-005478-5iu38pr6	2893	17	other	other	JJ
cord-005478-5iu38pr6	2893	18	haplo	haplo	NN
cord-005478-5iu38pr6	2893	19	-	-	HYPH
cord-005478-5iu38pr6	2893	20	HCT	HCT	NNP
cord-005478-5iu38pr6	2893	21	protocols	protocol	NNS
cord-005478-5iu38pr6	2893	22	within	within	IN
cord-005478-5iu38pr6	2893	23	the	the	DT
cord-005478-5iu38pr6	2893	24	first	first	JJ
cord-005478-5iu38pr6	2893	25	6	6	CD
cord-005478-5iu38pr6	2893	26	months	month	NNS
cord-005478-5iu38pr6	2893	27	after	after	IN
cord-005478-5iu38pr6	2893	28	transplant	transplant	NN
cord-005478-5iu38pr6	2893	29	.	.	.
cord-005478-5iu38pr6	2894	1	[	[	-LRB-
cord-005478-5iu38pr6	2894	2	Background	background	NN
cord-005478-5iu38pr6	2894	3	:	:	:
cord-005478-5iu38pr6	2894	4	Allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2894	5	cell	cell	NN
cord-005478-5iu38pr6	2894	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	2894	7	(	(	-LRB-
cord-005478-5iu38pr6	2894	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2894	9	)	)	-RRB-
cord-005478-5iu38pr6	2894	10	success	success	NN
cord-005478-5iu38pr6	2894	11	prediction	prediction	NN
cord-005478-5iu38pr6	2894	12	is	be	VBZ
cord-005478-5iu38pr6	2894	13	partly	partly	RB
cord-005478-5iu38pr6	2894	14	based	base	VBN
cord-005478-5iu38pr6	2894	15	on	on	IN
cord-005478-5iu38pr6	2894	16	minimal	minimal	JJ
cord-005478-5iu38pr6	2894	17	residual	residual	JJ
cord-005478-5iu38pr6	2894	18	disease	disease	NN
cord-005478-5iu38pr6	2894	19	(	(	-LRB-
cord-005478-5iu38pr6	2894	20	MRD	MRD	NNP
cord-005478-5iu38pr6	2894	21	)	)	-RRB-
cord-005478-5iu38pr6	2894	22	and	and	CC
cord-005478-5iu38pr6	2894	23	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2894	24	chimerism	chimerism	NN
cord-005478-5iu38pr6	2894	25	testing	testing	NN
cord-005478-5iu38pr6	2894	26	.	.	.
cord-005478-5iu38pr6	2895	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2895	2	developed	develop	VBD
cord-005478-5iu38pr6	2895	3	a	a	DT
cord-005478-5iu38pr6	2895	4	droplet	droplet	NN
cord-005478-5iu38pr6	2895	5	digital	digital	JJ
cord-005478-5iu38pr6	2895	6	PCR	PCR	NNP
cord-005478-5iu38pr6	2895	7	platform	platform	NN
cord-005478-5iu38pr6	2895	8	(	(	-LRB-
cord-005478-5iu38pr6	2895	9	dPCR	dPCR	NNP
cord-005478-5iu38pr6	2895	10	)	)	-RRB-
cord-005478-5iu38pr6	2895	11	for	for	IN
cord-005478-5iu38pr6	2895	12	the	the	DT
cord-005478-5iu38pr6	2895	13	simultaneous	simultaneous	JJ
cord-005478-5iu38pr6	2895	14	detection	detection	NN
cord-005478-5iu38pr6	2895	15	of	of	IN
cord-005478-5iu38pr6	2895	16	MRD	MRD	NNP
cord-005478-5iu38pr6	2895	17	and	and	CC
cord-005478-5iu38pr6	2895	18	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2895	19	chimerism	chimerism	NN
cord-005478-5iu38pr6	2895	20	.	.	.
cord-005478-5iu38pr6	2896	1	Methods	method	NNS
cord-005478-5iu38pr6	2896	2	:	:	:
cord-005478-5iu38pr6	2897	1	A	a	DT
cord-005478-5iu38pr6	2897	2	panel	panel	NN
cord-005478-5iu38pr6	2897	3	of	of	IN
cord-005478-5iu38pr6	2897	4	12	12	CD
cord-005478-5iu38pr6	2897	5	deletion	deletion	NN
cord-005478-5iu38pr6	2897	6	/	/	SYM
cord-005478-5iu38pr6	2897	7	insertion	insertion	NN
cord-005478-5iu38pr6	2897	8	polymorphic	polymorphic	JJ
cord-005478-5iu38pr6	2897	9	markers	marker	NNS
cord-005478-5iu38pr6	2897	10	and	and	CC
cord-005478-5iu38pr6	2897	11	frequent	frequent	JJ
cord-005478-5iu38pr6	2897	12	molecular	molecular	JJ
cord-005478-5iu38pr6	2897	13	targets	target	NNS
cord-005478-5iu38pr6	2897	14	used	use	VBN
cord-005478-5iu38pr6	2897	15	for	for	IN
cord-005478-5iu38pr6	2897	16	MRD	MRD	NNP
cord-005478-5iu38pr6	2897	17	testing	testing	NN
cord-005478-5iu38pr6	2897	18	:	:	:
cord-005478-5iu38pr6	2897	19	NPM1	NPM1	NNP
cord-005478-5iu38pr6	2897	20	,	,	,
cord-005478-5iu38pr6	2897	21	RUNX1-RUNX1T1	runx1-runx1t1	NN
cord-005478-5iu38pr6	2897	22	(	(	-LRB-
cord-005478-5iu38pr6	2897	23	t	t	NN
cord-005478-5iu38pr6	2897	24	8;21	8;21	CD
cord-005478-5iu38pr6	2897	25	)	)	-RRB-
cord-005478-5iu38pr6	2897	26	,	,	,
cord-005478-5iu38pr6	2897	27	DNMT3A	DNMT3A	NNP
cord-005478-5iu38pr6	2897	28	,	,	,
cord-005478-5iu38pr6	2897	29	MLL	MLL	NNP
cord-005478-5iu38pr6	2897	30	-	-	HYPH
cord-005478-5iu38pr6	2897	31	PTD	PTD	NNP
cord-005478-5iu38pr6	2897	32	,	,	,
cord-005478-5iu38pr6	2897	33	CBFß	CBFß	NNP
cord-005478-5iu38pr6	2897	34	-	-	HYPH
cord-005478-5iu38pr6	2897	35	MYH11	MYH11	NNP
cord-005478-5iu38pr6	2898	1	(	(	-LRB-
cord-005478-5iu38pr6	2898	2	Inv	Inv	NNP
cord-005478-5iu38pr6	2898	3	16	16	CD
cord-005478-5iu38pr6	2898	4	)	)	-RRB-
cord-005478-5iu38pr6	2898	5	,	,	,
cord-005478-5iu38pr6	2898	6	KRAS	KRAS	NNP
cord-005478-5iu38pr6	2898	7	,	,	,
cord-005478-5iu38pr6	2898	8	MLL	MLL	NNP
cord-005478-5iu38pr6	2898	9	-	-	HYPH
cord-005478-5iu38pr6	2898	10	AF10	AF10	NNP
cord-005478-5iu38pr6	2898	11	,	,	,
cord-005478-5iu38pr6	2898	12	IDH	IDH	NNP
cord-005478-5iu38pr6	2898	13	1/2	1/2	CD
cord-005478-5iu38pr6	2898	14	,	,	,
cord-005478-5iu38pr6	2899	1	cKIT	cKIT	NNP
cord-005478-5iu38pr6	2899	2	,	,	,
cord-005478-5iu38pr6	2899	3	BCR	BCR	NNP
cord-005478-5iu38pr6	2899	4	-	-	HYPH
cord-005478-5iu38pr6	2899	5	ABL	ABL	NNP
cord-005478-5iu38pr6	2899	6	(	(	-LRB-
cord-005478-5iu38pr6	2899	7	t9	t9	NNP
cord-005478-5iu38pr6	2899	8	;	;	:
cord-005478-5iu38pr6	2899	9	22	22	CD
cord-005478-5iu38pr6	2899	10	)	)	-RRB-
cord-005478-5iu38pr6	2899	11	,	,	,
cord-005478-5iu38pr6	2899	12	EVI1	EVI1	NNP
cord-005478-5iu38pr6	2899	13	and	and	CC
cord-005478-5iu38pr6	2899	14	WT1	WT1	NNP
cord-005478-5iu38pr6	2899	15	expression	expression	NN
cord-005478-5iu38pr6	2899	16	were	be	VBD
cord-005478-5iu38pr6	2899	17	included	include	VBN
cord-005478-5iu38pr6	2899	18	in	in	IN
cord-005478-5iu38pr6	2899	19	a	a	DT
cord-005478-5iu38pr6	2899	20	single	single	JJ
cord-005478-5iu38pr6	2899	21	dPCR	dpcr	NN
cord-005478-5iu38pr6	2899	22	platform	platform	NN
cord-005478-5iu38pr6	2899	23	for	for	IN
cord-005478-5iu38pr6	2899	24	MRD	MRD	NNP
cord-005478-5iu38pr6	2899	25	and	and	CC
cord-005478-5iu38pr6	2899	26	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2899	27	chimerism	chimerism	NN
cord-005478-5iu38pr6	2899	28	analysis	analysis	NN
cord-005478-5iu38pr6	2899	29	.	.	.
cord-005478-5iu38pr6	2900	1	A	a	DT
cord-005478-5iu38pr6	2900	2	total	total	NN
cord-005478-5iu38pr6	2900	3	of	of	IN
cord-005478-5iu38pr6	2900	4	225	225	CD
cord-005478-5iu38pr6	2900	5	patients	patient	NNS
cord-005478-5iu38pr6	2900	6	were	be	VBD
cord-005478-5iu38pr6	2900	7	evaluated	evaluate	VBN
cord-005478-5iu38pr6	2900	8	with	with	IN
cord-005478-5iu38pr6	2900	9	a	a	DT
cord-005478-5iu38pr6	2900	10	mean	mean	JJ
cord-005478-5iu38pr6	2900	11	follow	follow	NN
cord-005478-5iu38pr6	2900	12	-	-	HYPH
cord-005478-5iu38pr6	2900	13	up	up	NN
cord-005478-5iu38pr6	2900	14	of	of	IN
cord-005478-5iu38pr6	2900	15	653	653	CD
cord-005478-5iu38pr6	2900	16	days	day	NNS
cord-005478-5iu38pr6	2900	17	(	(	-LRB-
cord-005478-5iu38pr6	2900	18	range	range	NN
cord-005478-5iu38pr6	2900	19	:	:	:
cord-005478-5iu38pr6	2900	20	30	30	CD
cord-005478-5iu38pr6	2900	21	-	-	SYM
cord-005478-5iu38pr6	2900	22	5895	5895	CD
cord-005478-5iu38pr6	2900	23	days	day	NNS
cord-005478-5iu38pr6	2900	24	)	)	-RRB-
cord-005478-5iu38pr6	2900	25	.	.	.
cord-005478-5iu38pr6	2901	1	Results	result	NNS
cord-005478-5iu38pr6	2901	2	:	:	:
cord-005478-5iu38pr6	2902	1	Hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2902	2	chimerism	chimerism	NN
cord-005478-5iu38pr6	2902	3	analysis	analysis	NN
cord-005478-5iu38pr6	2902	4	revealed	reveal	VBD
cord-005478-5iu38pr6	2902	5	mixed	mixed	JJ
cord-005478-5iu38pr6	2902	6	chimerism	chimerism	NN
cord-005478-5iu38pr6	2902	7	(	(	-LRB-
cord-005478-5iu38pr6	2902	8	MC	MC	NNP
cord-005478-5iu38pr6	2902	9	)	)	-RRB-
cord-005478-5iu38pr6	2902	10	in	in	IN
cord-005478-5iu38pr6	2902	11	93	93	CD
cord-005478-5iu38pr6	2902	12	patients	patient	NNS
cord-005478-5iu38pr6	2902	13	(	(	-LRB-
cord-005478-5iu38pr6	2902	14	41	41	CD
cord-005478-5iu38pr6	2902	15	%	%	NN
cord-005478-5iu38pr6	2902	16	of	of	IN
cord-005478-5iu38pr6	2902	17	all	all	DT
cord-005478-5iu38pr6	2902	18	patients	patient	NNS
cord-005478-5iu38pr6	2902	19	)	)	-RRB-
cord-005478-5iu38pr6	2902	20	.	.	.
cord-005478-5iu38pr6	2903	1	MC	MC	NNP
cord-005478-5iu38pr6	2903	2	was	be	VBD
cord-005478-5iu38pr6	2903	3	detected	detect	VBN
cord-005478-5iu38pr6	2903	4	more	more	RBR
cord-005478-5iu38pr6	2903	5	frequently	frequently	RB
cord-005478-5iu38pr6	2903	6	in	in	IN
cord-005478-5iu38pr6	2903	7	patients	patient	NNS
cord-005478-5iu38pr6	2903	8	with	with	IN
cord-005478-5iu38pr6	2903	9	reduced	reduce	VBN
cord-005478-5iu38pr6	2903	10	intensity	intensity	NN
cord-005478-5iu38pr6	2903	11	conditioning	conditioning	NN
cord-005478-5iu38pr6	2903	12	(	(	-LRB-
cord-005478-5iu38pr6	2903	13	68	68	CD
cord-005478-5iu38pr6	2903	14	%	%	NN
cord-005478-5iu38pr6	2903	15	)	)	-RRB-
cord-005478-5iu38pr6	2903	16	when	when	WRB
cord-005478-5iu38pr6	2903	17	compared	compare	VBN
cord-005478-5iu38pr6	2903	18	with	with	IN
cord-005478-5iu38pr6	2903	19	full	full	JJ
cord-005478-5iu38pr6	2903	20	conditioning	conditioning	NN
cord-005478-5iu38pr6	2903	21	(	(	-LRB-
cord-005478-5iu38pr6	2903	22	47	47	CD
cord-005478-5iu38pr6	2903	23	%	%	NN
cord-005478-5iu38pr6	2903	24	)	)	-RRB-
cord-005478-5iu38pr6	2903	25	.	.	.
cord-005478-5iu38pr6	2904	1	The	the	DT
cord-005478-5iu38pr6	2904	2	mean	mean	JJ
cord-005478-5iu38pr6	2904	3	percentage	percentage	NN
cord-005478-5iu38pr6	2904	4	of	of	IN
cord-005478-5iu38pr6	2904	5	host	host	NN
cord-005478-5iu38pr6	2904	6	derived	derive	VBN
cord-005478-5iu38pr6	2904	7	DNA	dna	NN
cord-005478-5iu38pr6	2904	8	in	in	IN
cord-005478-5iu38pr6	2904	9	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2904	10	blood	blood	NN
cord-005478-5iu38pr6	2904	11	was	be	VBD
cord-005478-5iu38pr6	2904	12	13	13	CD
cord-005478-5iu38pr6	2904	13	%	%	NN
cord-005478-5iu38pr6	2904	14	(	(	-LRB-
cord-005478-5iu38pr6	2904	15	range	range	NN
cord-005478-5iu38pr6	2904	16	:	:	:
cord-005478-5iu38pr6	2904	17	0.1	0.1	CD
cord-005478-5iu38pr6	2904	18	-	-	SYM
cord-005478-5iu38pr6	2904	19	90	90	CD
cord-005478-5iu38pr6	2904	20	%	%	NN
cord-005478-5iu38pr6	2904	21	)	)	-RRB-
cord-005478-5iu38pr6	2904	22	.	.	.
cord-005478-5iu38pr6	2905	1	Three	three	CD
cord-005478-5iu38pr6	2905	2	different	different	JJ
cord-005478-5iu38pr6	2905	3	patterns	pattern	NNS
cord-005478-5iu38pr6	2905	4	of	of	IN
cord-005478-5iu38pr6	2905	5	MC	MC	NNP
cord-005478-5iu38pr6	2905	6	were	be	VBD
cord-005478-5iu38pr6	2905	7	observed	observe	VBN
cord-005478-5iu38pr6	2905	8	:	:	:
cord-005478-5iu38pr6	2905	9	increasing	increase	VBG
cord-005478-5iu38pr6	2905	10	,	,	,
cord-005478-5iu38pr6	2905	11	decreasing	decrease	VBG
cord-005478-5iu38pr6	2905	12	or	or	CC
cord-005478-5iu38pr6	2905	13	stable	stable	JJ
cord-005478-5iu38pr6	2905	14	MC	MC	NNP
cord-005478-5iu38pr6	2905	15	.	.	.
cord-005478-5iu38pr6	2906	1	In	in	IN
cord-005478-5iu38pr6	2906	2	those	those	DT
cord-005478-5iu38pr6	2906	3	patients	patient	NNS
cord-005478-5iu38pr6	2906	4	with	with	IN
cord-005478-5iu38pr6	2906	5	stable	stable	JJ
cord-005478-5iu38pr6	2906	6	or	or	CC
cord-005478-5iu38pr6	2906	7	decreasing	decrease	VBG
cord-005478-5iu38pr6	2906	8	MC	MC	NNP
cord-005478-5iu38pr6	2906	9	(	(	-LRB-
cord-005478-5iu38pr6	2906	10	n=46	n=46	JJ
cord-005478-5iu38pr6	2906	11	)	)	-RRB-
cord-005478-5iu38pr6	2906	12	,	,	,
cord-005478-5iu38pr6	2906	13	as	as	RB
cord-005478-5iu38pr6	2906	14	well	well	RB
cord-005478-5iu38pr6	2906	15	as	as	IN
cord-005478-5iu38pr6	2906	16	patients	patient	NNS
cord-005478-5iu38pr6	2906	17	with	with	IN
cord-005478-5iu38pr6	2906	18	complete	complete	JJ
cord-005478-5iu38pr6	2906	19	donor	donor	NN
cord-005478-5iu38pr6	2906	20	chimerism	chimerism	NN
cord-005478-5iu38pr6	2906	21	(	(	-LRB-
cord-005478-5iu38pr6	2906	22	n=132	n=132	UH
cord-005478-5iu38pr6	2906	23	)	)	-RRB-
cord-005478-5iu38pr6	2906	24	the	the	DT
cord-005478-5iu38pr6	2906	25	molecular	molecular	JJ
cord-005478-5iu38pr6	2906	26	targets	target	NNS
cord-005478-5iu38pr6	2906	27	used	use	VBN
cord-005478-5iu38pr6	2906	28	for	for	IN
cord-005478-5iu38pr6	2906	29	MRD	MRD	NNP
cord-005478-5iu38pr6	2906	30	monitoring	monitoring	NN
cord-005478-5iu38pr6	2906	31	were	be	VBD
cord-005478-5iu38pr6	2906	32	not	not	RB
cord-005478-5iu38pr6	2906	33	detectable	detectable	JJ
cord-005478-5iu38pr6	2906	34	.	.	.
cord-005478-5iu38pr6	2907	1	In	in	IN
cord-005478-5iu38pr6	2907	2	47	47	CD
cord-005478-5iu38pr6	2907	3	out	out	IN
cord-005478-5iu38pr6	2907	4	of	of	IN
cord-005478-5iu38pr6	2907	5	93	93	CD
cord-005478-5iu38pr6	2907	6	patients	patient	NNS
cord-005478-5iu38pr6	2907	7	,	,	,
cord-005478-5iu38pr6	2907	8	increasing	increase	VBG
cord-005478-5iu38pr6	2907	9	MC	MC	NNP
cord-005478-5iu38pr6	2907	10	was	be	VBD
cord-005478-5iu38pr6	2907	11	detected	detect	VBN
cord-005478-5iu38pr6	2907	12	.	.	.
cord-005478-5iu38pr6	2908	1	This	this	DT
cord-005478-5iu38pr6	2908	2	group	group	NN
cord-005478-5iu38pr6	2908	3	of	of	IN
cord-005478-5iu38pr6	2908	4	patient	patient	NN
cord-005478-5iu38pr6	2908	5	showed	show	VBD
cord-005478-5iu38pr6	2908	6	in	in	IN
cord-005478-5iu38pr6	2908	7	addition	addition	NN
cord-005478-5iu38pr6	2908	8	either	either	CC
cord-005478-5iu38pr6	2908	9	a	a	DT
cord-005478-5iu38pr6	2908	10	positive	positive	JJ
cord-005478-5iu38pr6	2908	11	MRD	MRD	NNP
cord-005478-5iu38pr6	2908	12	marker	marker	NN
cord-005478-5iu38pr6	2908	13	,	,	,
cord-005478-5iu38pr6	2908	14	increased	increase	VBD
cord-005478-5iu38pr6	2908	15	WT1	wt1	JJ
cord-005478-5iu38pr6	2908	16	expression	expression	NN
cord-005478-5iu38pr6	2908	17	or	or	CC
cord-005478-5iu38pr6	2908	18	both	both	DT
cord-005478-5iu38pr6	2908	19	.	.	.
cord-005478-5iu38pr6	2909	1	In	in	IN
cord-005478-5iu38pr6	2909	2	37	37	CD
cord-005478-5iu38pr6	2909	3	patients	patient	NNS
cord-005478-5iu38pr6	2909	4	with	with	IN
cord-005478-5iu38pr6	2909	5	increasing	increase	VBG
cord-005478-5iu38pr6	2909	6	MC	MC	NNP
cord-005478-5iu38pr6	2909	7	,	,	,
cord-005478-5iu38pr6	2909	8	a	a	DT
cord-005478-5iu38pr6	2909	9	positive	positive	JJ
cord-005478-5iu38pr6	2909	10	MRD	MRD	NNP
cord-005478-5iu38pr6	2909	11	marker	marker	NN
cord-005478-5iu38pr6	2909	12	and	and	CC
cord-005478-5iu38pr6	2909	13	increased	increase	VBD
cord-005478-5iu38pr6	2909	14	WT1	wt1	JJ
cord-005478-5iu38pr6	2909	15	expression	expression	NN
cord-005478-5iu38pr6	2909	16	hematologic	hematologic	JJ
cord-005478-5iu38pr6	2909	17	relapse	relapse	NN
cord-005478-5iu38pr6	2909	18	of	of	IN
cord-005478-5iu38pr6	2909	19	the	the	DT
cord-005478-5iu38pr6	2909	20	underlying	underlying	JJ
cord-005478-5iu38pr6	2909	21	disease	disease	NN
cord-005478-5iu38pr6	2909	22	was	be	VBD
cord-005478-5iu38pr6	2909	23	observed	observe	VBN
cord-005478-5iu38pr6	2909	24	.	.	.
cord-005478-5iu38pr6	2910	1	In	in	IN
cord-005478-5iu38pr6	2910	2	patients	patient	NNS
cord-005478-5iu38pr6	2910	3	with	with	IN
cord-005478-5iu38pr6	2910	4	increasing	increase	VBG
cord-005478-5iu38pr6	2910	5	MC	MC	NNP
cord-005478-5iu38pr6	2910	6	and	and	CC
cord-005478-5iu38pr6	2910	7	a	a	DT
cord-005478-5iu38pr6	2910	8	positive	positive	JJ
cord-005478-5iu38pr6	2910	9	MRD	MRD	NNP
cord-005478-5iu38pr6	2910	10	marker	marker	NN
cord-005478-5iu38pr6	2910	11	,	,	,
cord-005478-5iu38pr6	2910	12	we	-PRON-	PRP
cord-005478-5iu38pr6	2910	13	analysed	analyse	VBD
cord-005478-5iu38pr6	2910	14	whether	whether	IN
cord-005478-5iu38pr6	2910	15	MC	MC	NNP
cord-005478-5iu38pr6	2910	16	or	or	CC
cord-005478-5iu38pr6	2910	17	the	the	DT
cord-005478-5iu38pr6	2910	18	molecular	molecular	JJ
cord-005478-5iu38pr6	2910	19	target	target	NN
cord-005478-5iu38pr6	2910	20	for	for	IN
cord-005478-5iu38pr6	2910	21	MRD	MRD	NNP
cord-005478-5iu38pr6	2910	22	was	be	VBD
cord-005478-5iu38pr6	2910	23	first	first	RB
cord-005478-5iu38pr6	2910	24	detected	detect	VBN
cord-005478-5iu38pr6	2910	25	.	.	.
cord-005478-5iu38pr6	2911	1	In	in	IN
cord-005478-5iu38pr6	2911	2	40	40	CD
cord-005478-5iu38pr6	2911	3	%	%	NN
cord-005478-5iu38pr6	2911	4	of	of	IN
cord-005478-5iu38pr6	2911	5	the	the	DT
cord-005478-5iu38pr6	2911	6	cases	case	NNS
cord-005478-5iu38pr6	2911	7	MC	MC	NNP
cord-005478-5iu38pr6	2911	8	was	be	VBD
cord-005478-5iu38pr6	2911	9	detected	detect	VBN
cord-005478-5iu38pr6	2911	10	before	before	IN
cord-005478-5iu38pr6	2911	11	the	the	DT
cord-005478-5iu38pr6	2911	12	molecular	molecular	JJ
cord-005478-5iu38pr6	2911	13	marker	marker	NN
cord-005478-5iu38pr6	2911	14	used	use	VBN
cord-005478-5iu38pr6	2911	15	for	for	IN
cord-005478-5iu38pr6	2911	16	MRD	MRD	NNP
cord-005478-5iu38pr6	2911	17	assessment	assessment	NN
cord-005478-5iu38pr6	2911	18	,	,	,
cord-005478-5iu38pr6	2911	19	while	while	IN
cord-005478-5iu38pr6	2911	20	in	in	IN
cord-005478-5iu38pr6	2911	21	13	13	CD
cord-005478-5iu38pr6	2911	22	%	%	NN
cord-005478-5iu38pr6	2911	23	of	of	IN
cord-005478-5iu38pr6	2911	24	the	the	DT
cord-005478-5iu38pr6	2911	25	patients	patient	NNS
cord-005478-5iu38pr6	2911	26	MRD	MRD	NNP
cord-005478-5iu38pr6	2911	27	positivity	positivity	NN
cord-005478-5iu38pr6	2911	28	was	be	VBD
cord-005478-5iu38pr6	2911	29	detected	detect	VBN
cord-005478-5iu38pr6	2911	30	before	before	IN
cord-005478-5iu38pr6	2911	31	MC	MC	NNP
cord-005478-5iu38pr6	2911	32	.	.	.
cord-005478-5iu38pr6	2912	1	In	in	IN
cord-005478-5iu38pr6	2912	2	the	the	DT
cord-005478-5iu38pr6	2912	3	remaining	remain	VBG
cord-005478-5iu38pr6	2912	4	patients	patient	NNS
cord-005478-5iu38pr6	2912	5	(	(	-LRB-
cord-005478-5iu38pr6	2912	6	47	47	CD
cord-005478-5iu38pr6	2912	7	%	%	NN
cord-005478-5iu38pr6	2912	8	of	of	IN
cord-005478-5iu38pr6	2912	9	the	the	DT
cord-005478-5iu38pr6	2912	10	patients	patient	NNS
cord-005478-5iu38pr6	2912	11	)	)	-RRB-
cord-005478-5iu38pr6	2913	1	MC	MC	NNP
cord-005478-5iu38pr6	2913	2	and	and	CC
cord-005478-5iu38pr6	2913	3	MRD	MRD	NNP
cord-005478-5iu38pr6	2913	4	positivity	positivity	NN
cord-005478-5iu38pr6	2913	5	were	be	VBD
cord-005478-5iu38pr6	2913	6	detected	detect	VBN
cord-005478-5iu38pr6	2913	7	simultaneously	simultaneously	RB
cord-005478-5iu38pr6	2913	8	.	.	.
cord-005478-5iu38pr6	2914	1	The	the	DT
cord-005478-5iu38pr6	2914	2	mean	mean	JJ
cord-005478-5iu38pr6	2914	3	time	time	NN
cord-005478-5iu38pr6	2914	4	between	between	IN
cord-005478-5iu38pr6	2914	5	either	either	DT
cord-005478-5iu38pr6	2914	6	MC	MC	NNP
cord-005478-5iu38pr6	2914	7	or	or	CC
cord-005478-5iu38pr6	2914	8	MRD	MRD	NNP
cord-005478-5iu38pr6	2914	9	detection	detection	NN
cord-005478-5iu38pr6	2914	10	in	in	IN
cord-005478-5iu38pr6	2914	11	peripheral	peripheral	JJ
cord-005478-5iu38pr6	2914	12	blood	blood	NN
cord-005478-5iu38pr6	2914	13	and	and	CC
cord-005478-5iu38pr6	2914	14	relapse	relapse	NN
cord-005478-5iu38pr6	2914	15	was	be	VBD
cord-005478-5iu38pr6	2914	16	116	116	CD
cord-005478-5iu38pr6	2914	17	days	day	NNS
cord-005478-5iu38pr6	2914	18	(	(	-LRB-
cord-005478-5iu38pr6	2914	19	range	range	NN
cord-005478-5iu38pr6	2914	20	:	:	:
cord-005478-5iu38pr6	2914	21	15	15	CD
cord-005478-5iu38pr6	2914	22	-	-	SYM
cord-005478-5iu38pr6	2914	23	385	385	CD
cord-005478-5iu38pr6	2914	24	days	day	NNS
cord-005478-5iu38pr6	2914	25	)	)	-RRB-
cord-005478-5iu38pr6	2914	26	.	.	.
cord-005478-5iu38pr6	2915	1	Patients	patient	NNS
cord-005478-5iu38pr6	2915	2	with	with	IN
cord-005478-5iu38pr6	2915	3	increasing	increase	VBG
cord-005478-5iu38pr6	2915	4	MC	MC	NNP
cord-005478-5iu38pr6	2915	5	and	and	CC
cord-005478-5iu38pr6	2915	6	MRD	MRD	NNP
cord-005478-5iu38pr6	2915	7	positivity	positivity	NN
cord-005478-5iu38pr6	2915	8	,	,	,
cord-005478-5iu38pr6	2915	9	whether	whether	IN
cord-005478-5iu38pr6	2915	10	or	or	CC
cord-005478-5iu38pr6	2915	11	not	not	RB
cord-005478-5iu38pr6	2915	12	they	-PRON-	PRP
cord-005478-5iu38pr6	2915	13	responded	respond	VBD
cord-005478-5iu38pr6	2915	14	to	to	IN
cord-005478-5iu38pr6	2915	15	treatment	treatment	NN
cord-005478-5iu38pr6	2915	16	,	,	,
cord-005478-5iu38pr6	2915	17	showed	show	VBD
cord-005478-5iu38pr6	2915	18	a	a	DT
cord-005478-5iu38pr6	2915	19	similar	similar	JJ
cord-005478-5iu38pr6	2915	20	kinetic	kinetic	JJ
cord-005478-5iu38pr6	2915	21	pattern	pattern	NN
cord-005478-5iu38pr6	2915	22	for	for	IN
cord-005478-5iu38pr6	2915	23	the	the	DT
cord-005478-5iu38pr6	2915	24	chimerism	chimerism	NN
cord-005478-5iu38pr6	2915	25	and	and	CC
cord-005478-5iu38pr6	2915	26	MRD	MRD	NNP
cord-005478-5iu38pr6	2915	27	markers	marker	NNS
cord-005478-5iu38pr6	2915	28	.	.	.
cord-005478-5iu38pr6	2916	1	In	in	IN
cord-005478-5iu38pr6	2916	2	those	those	DT
cord-005478-5iu38pr6	2916	3	patients	patient	NNS
cord-005478-5iu38pr6	2916	4	that	that	WDT
cord-005478-5iu38pr6	2916	5	responded	respond	VBD
cord-005478-5iu38pr6	2916	6	to	to	IN
cord-005478-5iu38pr6	2916	7	molecular	molecular	JJ
cord-005478-5iu38pr6	2916	8	relapse	relapse	NN
cord-005478-5iu38pr6	2916	9	treatment	treatment	NN
cord-005478-5iu38pr6	2916	10	(	(	-LRB-
cord-005478-5iu38pr6	2916	11	n=10	n=10	NNP
cord-005478-5iu38pr6	2916	12	)	)	-RRB-
cord-005478-5iu38pr6	2916	13	the	the	DT
cord-005478-5iu38pr6	2916	14	mean	mean	JJ
cord-005478-5iu38pr6	2916	15	time	time	NN
cord-005478-5iu38pr6	2916	16	to	to	TO
cord-005478-5iu38pr6	2916	17	achieve	achieve	VB
cord-005478-5iu38pr6	2916	18	complete	complete	JJ
cord-005478-5iu38pr6	2916	19	donor	donor	NN
cord-005478-5iu38pr6	2916	20	chimerism	chimerism	NN
cord-005478-5iu38pr6	2916	21	or	or	CC
cord-005478-5iu38pr6	2916	22	MRD	MRD	NNP
cord-005478-5iu38pr6	2916	23	PCR	PCR	NNP
cord-005478-5iu38pr6	2916	24	negativity	negativity	NN
cord-005478-5iu38pr6	2916	25	was	be	VBD
cord-005478-5iu38pr6	2916	26	305	305	CD
cord-005478-5iu38pr6	2916	27	days	day	NNS
cord-005478-5iu38pr6	2916	28	and	and	CC
cord-005478-5iu38pr6	2916	29	294	294	CD
cord-005478-5iu38pr6	2916	30	days	day	NNS
cord-005478-5iu38pr6	2916	31	respectively	respectively	RB
cord-005478-5iu38pr6	2916	32	.	.	.
cord-005478-5iu38pr6	2917	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2917	2	:	:	:
cord-005478-5iu38pr6	2918	1	The	the	DT
cord-005478-5iu38pr6	2918	2	combination	combination	NN
cord-005478-5iu38pr6	2918	3	of	of	IN
cord-005478-5iu38pr6	2918	4	MRD	MRD	NNP
cord-005478-5iu38pr6	2918	5	and	and	CC
cord-005478-5iu38pr6	2918	6	chimerism	chimerism	NN
cord-005478-5iu38pr6	2918	7	markers	marker	NNS
cord-005478-5iu38pr6	2918	8	in	in	IN
cord-005478-5iu38pr6	2918	9	a	a	DT
cord-005478-5iu38pr6	2918	10	dCPR	dcpr	JJ
cord-005478-5iu38pr6	2918	11	platform	platform	NN
cord-005478-5iu38pr6	2918	12	represents	represent	VBZ
cord-005478-5iu38pr6	2918	13	a	a	DT
cord-005478-5iu38pr6	2918	14	sensitive	sensitive	JJ
cord-005478-5iu38pr6	2918	15	and	and	CC
cord-005478-5iu38pr6	2918	16	accurate	accurate	JJ
cord-005478-5iu38pr6	2918	17	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	2918	18	tool	tool	NN
cord-005478-5iu38pr6	2918	19	for	for	IN
cord-005478-5iu38pr6	2918	20	the	the	DT
cord-005478-5iu38pr6	2918	21	comprehensive	comprehensive	JJ
cord-005478-5iu38pr6	2918	22	assessment	assessment	NN
cord-005478-5iu38pr6	2918	23	of	of	IN
cord-005478-5iu38pr6	2918	24	the	the	DT
cord-005478-5iu38pr6	2918	25	molecular	molecular	JJ
cord-005478-5iu38pr6	2918	26	remission	remission	NN
cord-005478-5iu38pr6	2918	27	status	status	NN
cord-005478-5iu38pr6	2918	28	after	after	IN
cord-005478-5iu38pr6	2918	29	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2918	30	.	.	.
cord-005478-5iu38pr6	2919	1	In	in	IN
cord-005478-5iu38pr6	2919	2	addition	addition	NN
cord-005478-5iu38pr6	2919	3	,	,	,
cord-005478-5iu38pr6	2919	4	by	by	IN
cord-005478-5iu38pr6	2919	5	using	use	VBG
cord-005478-5iu38pr6	2919	6	the	the	DT
cord-005478-5iu38pr6	2919	7	developed	develop	VBN
cord-005478-5iu38pr6	2919	8	dPCR	dpcr	NN
cord-005478-5iu38pr6	2919	9	platform	platform	NN
cord-005478-5iu38pr6	2919	10	costs	cost	NNS
cord-005478-5iu38pr6	2919	11	and	and	CC
cord-005478-5iu38pr6	2919	12	turnaround	turnaround	NN
cord-005478-5iu38pr6	2919	13	times	time	NNS
cord-005478-5iu38pr6	2919	14	can	can	MD
cord-005478-5iu38pr6	2919	15	be	be	VB
cord-005478-5iu38pr6	2919	16	reduced	reduce	VBN
cord-005478-5iu38pr6	2919	17	.	.	.
cord-005478-5iu38pr6	2920	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2920	2	Background	background	NN
cord-005478-5iu38pr6	2920	3	:	:	:
cord-005478-5iu38pr6	2920	4	Minimal	minimal	JJ
cord-005478-5iu38pr6	2920	5	residual	residual	JJ
cord-005478-5iu38pr6	2920	6	disease	disease	NN
cord-005478-5iu38pr6	2920	7	(	(	-LRB-
cord-005478-5iu38pr6	2920	8	MRD	MRD	NNP
cord-005478-5iu38pr6	2920	9	)	)	-RRB-
cord-005478-5iu38pr6	2920	10	monitoring	monitoring	NN
cord-005478-5iu38pr6	2920	11	can	can	MD
cord-005478-5iu38pr6	2920	12	help	help	VB
cord-005478-5iu38pr6	2920	13	to	to	TO
cord-005478-5iu38pr6	2920	14	indicate	indicate	VB
cord-005478-5iu38pr6	2920	15	impending	impending	JJ
cord-005478-5iu38pr6	2920	16	relapse	relapse	NN
cord-005478-5iu38pr6	2920	17	of	of	IN
cord-005478-5iu38pr6	2920	18	acute	acute	JJ
cord-005478-5iu38pr6	2920	19	leukemia	leukemia	NN
cord-005478-5iu38pr6	2920	20	after	after	IN
cord-005478-5iu38pr6	2920	21	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2920	22	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2920	23	stem	stem	NN
cord-005478-5iu38pr6	2920	24	cell	cell	NN
cord-005478-5iu38pr6	2920	25	transplantation	transplantation	NN
cord-005478-5iu38pr6	2920	26	(	(	-LRB-
cord-005478-5iu38pr6	2920	27	allo	allo	NN
cord-005478-5iu38pr6	2920	28	-	-	HYPH
cord-005478-5iu38pr6	2920	29	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2920	30	)	)	-RRB-
cord-005478-5iu38pr6	2920	31	.	.	.
cord-005478-5iu38pr6	2921	1	Because	because	IN
cord-005478-5iu38pr6	2921	2	impending	impending	JJ
cord-005478-5iu38pr6	2921	3	relapse	relapse	NN
cord-005478-5iu38pr6	2921	4	can	can	MD
cord-005478-5iu38pr6	2921	5	be	be	VB
cord-005478-5iu38pr6	2921	6	altered	alter	VBN
cord-005478-5iu38pr6	2921	7	with	with	IN
cord-005478-5iu38pr6	2921	8	early	early	JJ
cord-005478-5iu38pr6	2921	9	detection	detection	NN
cord-005478-5iu38pr6	2921	10	of	of	IN
cord-005478-5iu38pr6	2921	11	low	low	JJ
cord-005478-5iu38pr6	2921	12	-	-	HYPH
cord-005478-5iu38pr6	2921	13	volume	volume	NN
cord-005478-5iu38pr6	2921	14	disease	disease	NN
cord-005478-5iu38pr6	2921	15	and	and	CC
cord-005478-5iu38pr6	2921	16	timely	timely	JJ
cord-005478-5iu38pr6	2921	17	therapies	therapy	NNS
cord-005478-5iu38pr6	2921	18	,	,	,
cord-005478-5iu38pr6	2921	19	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2921	20	intervention	intervention	NN
cord-005478-5iu38pr6	2921	21	is	be	VBZ
cord-005478-5iu38pr6	2921	22	a	a	DT
cord-005478-5iu38pr6	2921	23	reasonable	reasonable	JJ
cord-005478-5iu38pr6	2921	24	option	option	NN
cord-005478-5iu38pr6	2921	25	for	for	IN
cord-005478-5iu38pr6	2921	26	patients	patient	NNS
cord-005478-5iu38pr6	2921	27	with	with	IN
cord-005478-5iu38pr6	2921	28	MRD	MRD	NNP
cord-005478-5iu38pr6	2921	29	which	which	WDT
cord-005478-5iu38pr6	2921	30	can	can	MD
cord-005478-5iu38pr6	2921	31	spare	spare	VB
cord-005478-5iu38pr6	2921	32	those	those	DT
cord-005478-5iu38pr6	2921	33	in	in	IN
cord-005478-5iu38pr6	2921	34	remission	remission	NN
cord-005478-5iu38pr6	2921	35	from	from	IN
cord-005478-5iu38pr6	2921	36	further	further	JJ
cord-005478-5iu38pr6	2921	37	therapy	therapy	NN
cord-005478-5iu38pr6	2921	38	.	.	.
cord-005478-5iu38pr6	2922	1	Chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2922	2	plus	plus	CC
cord-005478-5iu38pr6	2922	3	donor	donor	NN
cord-005478-5iu38pr6	2922	4	leukocyte	leukocyte	NN
cord-005478-5iu38pr6	2922	5	infusion	infusion	NN
cord-005478-5iu38pr6	2922	6	(	(	-LRB-
cord-005478-5iu38pr6	2922	7	Chemo	Chemo	NNP
cord-005478-5iu38pr6	2922	8	-	-	HYPH
cord-005478-5iu38pr6	2922	9	DLI	DLI	NNP
cord-005478-5iu38pr6	2922	10	)	)	-RRB-
cord-005478-5iu38pr6	2922	11	is	be	VBZ
cord-005478-5iu38pr6	2922	12	the	the	DT
cord-005478-5iu38pr6	2922	13	most	most	RBS
cord-005478-5iu38pr6	2922	14	important	important	JJ
cord-005478-5iu38pr6	2922	15	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2922	16	intervention	intervention	NN
cord-005478-5iu38pr6	2922	17	,	,	,
cord-005478-5iu38pr6	2922	18	but	but	CC
cord-005478-5iu38pr6	2922	19	it	-PRON-	PRP
cord-005478-5iu38pr6	2922	20	may	may	MD
cord-005478-5iu38pr6	2922	21	lead	lead	VB
cord-005478-5iu38pr6	2922	22	to	to	IN
cord-005478-5iu38pr6	2922	23	several	several	JJ
cord-005478-5iu38pr6	2922	24	complications	complication	NNS
cord-005478-5iu38pr6	2922	25	,	,	,
cord-005478-5iu38pr6	2922	26	such	such	JJ
cord-005478-5iu38pr6	2922	27	as	as	IN
cord-005478-5iu38pr6	2922	28	severe	severe	JJ
cord-005478-5iu38pr6	2922	29	graft	graft	NN
cord-005478-5iu38pr6	2922	30	-	-	HYPH
cord-005478-5iu38pr6	2922	31	versus	versus	IN
cord-005478-5iu38pr6	2922	32	-	-	HYPH
cord-005478-5iu38pr6	2922	33	host	host	NN
cord-005478-5iu38pr6	2922	34	disease	disease	NN
cord-005478-5iu38pr6	2922	35	(	(	-LRB-
cord-005478-5iu38pr6	2922	36	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2922	37	)	)	-RRB-
cord-005478-5iu38pr6	2922	38	and	and	CC
cord-005478-5iu38pr6	2922	39	pancytopenia	pancytopenia	NNP
cord-005478-5iu38pr6	2922	40	.	.	.
cord-005478-5iu38pr6	2923	1	Hypomethylating	hypomethylating	NN
cord-005478-5iu38pr6	2923	2	agents	agent	NNS
cord-005478-5iu38pr6	2923	3	(	(	-LRB-
cord-005478-5iu38pr6	2923	4	HMAs	HMAs	NNP
cord-005478-5iu38pr6	2923	5	)	)	-RRB-
cord-005478-5iu38pr6	2923	6	represent	represent	VBP
cord-005478-5iu38pr6	2923	7	another	another	DT
cord-005478-5iu38pr6	2923	8	potential	potential	JJ
cord-005478-5iu38pr6	2923	9	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2923	10	intervention	intervention	NN
cord-005478-5iu38pr6	2923	11	,	,	,
cord-005478-5iu38pr6	2923	12	but	but	CC
cord-005478-5iu38pr6	2923	13	it	-PRON-	PRP
cord-005478-5iu38pr6	2923	14	only	only	RB
cord-005478-5iu38pr6	2923	15	delayed	delay	VBD
cord-005478-5iu38pr6	2923	16	the	the	DT
cord-005478-5iu38pr6	2923	17	time	time	NN
cord-005478-5iu38pr6	2923	18	to	to	IN
cord-005478-5iu38pr6	2923	19	hematologic	hematologic	JJ
cord-005478-5iu38pr6	2923	20	relapse	relapse	NN
cord-005478-5iu38pr6	2923	21	and	and	CC
cord-005478-5iu38pr6	2923	22	the	the	DT
cord-005478-5iu38pr6	2923	23	long	long	JJ
cord-005478-5iu38pr6	2923	24	-	-	HYPH
cord-005478-5iu38pr6	2923	25	term	term	NN
cord-005478-5iu38pr6	2923	26	efficacy	efficacy	NN
cord-005478-5iu38pr6	2923	27	may	may	MD
cord-005478-5iu38pr6	2923	28	be	be	VB
cord-005478-5iu38pr6	2923	29	unsatisfactory	unsatisfactory	JJ
cord-005478-5iu38pr6	2923	30	.	.	.
cord-005478-5iu38pr6	2924	1	Thus	thus	RB
cord-005478-5iu38pr6	2924	2	far	far	RB
cord-005478-5iu38pr6	2924	3	,	,	,
cord-005478-5iu38pr6	2924	4	few	few	JJ
cord-005478-5iu38pr6	2924	5	studies	study	NNS
cord-005478-5iu38pr6	2924	6	had	have	VBD
cord-005478-5iu38pr6	2924	7	identified	identify	VBN
cord-005478-5iu38pr6	2924	8	the	the	DT
cord-005478-5iu38pr6	2924	9	longterm	longterm	JJ
cord-005478-5iu38pr6	2924	10	efficacy	efficacy	NN
cord-005478-5iu38pr6	2924	11	of	of	IN
cord-005478-5iu38pr6	2924	12	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2924	13	intervention	intervention	NN
cord-005478-5iu38pr6	2924	14	with	with	IN
cord-005478-5iu38pr6	2924	15	drugs	drug	NNS
cord-005478-5iu38pr6	2924	16	in	in	IN
cord-005478-5iu38pr6	2924	17	patients	patient	NNS
cord-005478-5iu38pr6	2924	18	with	with	IN
cord-005478-5iu38pr6	2924	19	MRD	MRD	NNP
cord-005478-5iu38pr6	2924	20	after	after	IN
cord-005478-5iu38pr6	2924	21	allo	allo	NN
cord-005478-5iu38pr6	2924	22	-	-	HYPH
cord-005478-5iu38pr6	2924	23	HSCT.Two	HSCT.Two	NNP
cord-005478-5iu38pr6	2924	24	prospective	prospective	JJ
cord-005478-5iu38pr6	2924	25	studies	study	NNS
cord-005478-5iu38pr6	2924	26	(	(	-LRB-
cord-005478-5iu38pr6	2924	27	NCT02027064	nct02027064	NN
cord-005478-5iu38pr6	2924	28	and	and	CC
cord-005478-5iu38pr6	2924	29	NCT02185261	NCT02185261	NNS
cord-005478-5iu38pr6	2924	30	)	)	-RRB-
cord-005478-5iu38pr6	2924	31	reported	report	VBD
cord-005478-5iu38pr6	2924	32	that	that	IN
cord-005478-5iu38pr6	2924	33	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2924	34	interferon	interferon	NN
cord-005478-5iu38pr6	2924	35	-	-	HYPH
cord-005478-5iu38pr6	2924	36	α	α	NN
cord-005478-5iu38pr6	2924	37	(	(	-LRB-
cord-005478-5iu38pr6	2924	38	IFN	IFN	NNP
cord-005478-5iu38pr6	2924	39	-	-	HYPH
cord-005478-5iu38pr6	2924	40	α	α	NNP
cord-005478-5iu38pr6	2924	41	)	)	-RRB-
cord-005478-5iu38pr6	2924	42	treatment	treatment	NN
cord-005478-5iu38pr6	2924	43	can	can	MD
cord-005478-5iu38pr6	2924	44	help	help	VB
cord-005478-5iu38pr6	2924	45	clear	clear	VB
cord-005478-5iu38pr6	2924	46	minimal	minimal	JJ
cord-005478-5iu38pr6	2924	47	residual	residual	JJ
cord-005478-5iu38pr6	2924	48	disease	disease	NN
cord-005478-5iu38pr6	2924	49	(	(	-LRB-
cord-005478-5iu38pr6	2924	50	MRD	MRD	NNP
cord-005478-5iu38pr6	2924	51	)	)	-RRB-
cord-005478-5iu38pr6	2924	52	and	and	CC
cord-005478-5iu38pr6	2924	53	prevent	prevent	VB
cord-005478-5iu38pr6	2924	54	relapse	relapse	NN
cord-005478-5iu38pr6	2924	55	after	after	IN
cord-005478-5iu38pr6	2924	56	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2924	57	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2924	58	stem	stem	NN
cord-005478-5iu38pr6	2924	59	cell	cell	NN
cord-005478-5iu38pr6	2924	60	transplantation	transplantation	NN
cord-005478-5iu38pr6	2924	61	(	(	-LRB-
cord-005478-5iu38pr6	2924	62	allo	allo	NN
cord-005478-5iu38pr6	2924	63	-	-	HYPH
cord-005478-5iu38pr6	2924	64	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2924	65	)	)	-RRB-
cord-005478-5iu38pr6	2924	66	.	.	.
cord-005478-5iu38pr6	2925	1	In	in	IN
cord-005478-5iu38pr6	2925	2	this	this	DT
cord-005478-5iu38pr6	2925	3	extension	extension	NN
cord-005478-5iu38pr6	2925	4	study	study	NN
cord-005478-5iu38pr6	2925	5	,	,	,
cord-005478-5iu38pr6	2925	6	we	-PRON-	PRP
cord-005478-5iu38pr6	2925	7	aimed	aim	VBD
cord-005478-5iu38pr6	2925	8	to	to	TO
cord-005478-5iu38pr6	2925	9	identify	identify	VB
cord-005478-5iu38pr6	2925	10	the	the	DT
cord-005478-5iu38pr6	2925	11	long	long	JJ
cord-005478-5iu38pr6	2925	12	-	-	HYPH
cord-005478-5iu38pr6	2925	13	term	term	NN
cord-005478-5iu38pr6	2925	14	clinical	clinical	JJ
cord-005478-5iu38pr6	2925	15	outcomes	outcome	NNS
cord-005478-5iu38pr6	2925	16	of	of	IN
cord-005478-5iu38pr6	2925	17	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2925	18	IFN	IFN	NNP
cord-005478-5iu38pr6	2925	19	-	-	HYPH
cord-005478-5iu38pr6	2925	20	α	α	NNP
cord-005478-5iu38pr6	2925	21	treatment	treatment	NN
cord-005478-5iu38pr6	2925	22	in	in	IN
cord-005478-5iu38pr6	2925	23	acute	acute	JJ
cord-005478-5iu38pr6	2925	24	leukemia	leukemia	NN
cord-005478-5iu38pr6	2925	25	patients	patient	NNS
cord-005478-5iu38pr6	2925	26	who	who	WP
cord-005478-5iu38pr6	2925	27	were	be	VBD
cord-005478-5iu38pr6	2925	28	MRD	MRD	NNP
cord-005478-5iu38pr6	2925	29	positive	positive	JJ
cord-005478-5iu38pr6	2925	30	after	after	IN
cord-005478-5iu38pr6	2925	31	allo	allo	NN
cord-005478-5iu38pr6	2925	32	-	-	HYPH
cord-005478-5iu38pr6	2925	33	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2925	34	(	(	-LRB-
cord-005478-5iu38pr6	2925	35	n=118	n=118	NNP
cord-005478-5iu38pr6	2925	36	)	)	-RRB-
cord-005478-5iu38pr6	2925	37	.	.	.
cord-005478-5iu38pr6	2926	1	Methods	method	NNS
cord-005478-5iu38pr6	2926	2	:	:	:
cord-005478-5iu38pr6	2926	3	MRD	MRD	NNP
cord-005478-5iu38pr6	2926	4	was	be	VBD
cord-005478-5iu38pr6	2926	5	monitored	monitor	VBN
cord-005478-5iu38pr6	2926	6	by	by	IN
cord-005478-5iu38pr6	2926	7	multiparameter	multiparameter	NNP
cord-005478-5iu38pr6	2926	8	flow	flow	NN
cord-005478-5iu38pr6	2926	9	cytometry	cytometry	NNP
cord-005478-5iu38pr6	2926	10	(	(	-LRB-
cord-005478-5iu38pr6	2926	11	MFC	MFC	NNP
cord-005478-5iu38pr6	2926	12	)	)	-RRB-
cord-005478-5iu38pr6	2926	13	and	and	CC
cord-005478-5iu38pr6	2926	14	TaqMan	TaqMan	NNP
cord-005478-5iu38pr6	2926	15	-	-	HYPH
cord-005478-5iu38pr6	2926	16	based	base	VBN
cord-005478-5iu38pr6	2926	17	reverse	reverse	NN
cord-005478-5iu38pr6	2926	18	transcriptionreal	transcriptionreal	NN
cord-005478-5iu38pr6	2926	19	time	time	NN
cord-005478-5iu38pr6	2926	20	polymerase	polymerase	NN
cord-005478-5iu38pr6	2926	21	chain	chain	NN
cord-005478-5iu38pr6	2926	22	reaction	reaction	NN
cord-005478-5iu38pr6	2926	23	(	(	-LRB-
cord-005478-5iu38pr6	2926	24	PCR	PCR	NNP
cord-005478-5iu38pr6	2926	25	)	)	-RRB-
cord-005478-5iu38pr6	2926	26	.	.	.
cord-005478-5iu38pr6	2927	1	A	a	DT
cord-005478-5iu38pr6	2927	2	patient	patient	NN
cord-005478-5iu38pr6	2927	3	was	be	VBD
cord-005478-5iu38pr6	2927	4	considered	consider	VBN
cord-005478-5iu38pr6	2927	5	to	to	TO
cord-005478-5iu38pr6	2927	6	be	be	VB
cord-005478-5iu38pr6	2927	7	MRD	MRD	NNP
cord-005478-5iu38pr6	2927	8	-	-	HYPH
cord-005478-5iu38pr6	2927	9	positive	positive	JJ
cord-005478-5iu38pr6	2927	10	when	when	WRB
cord-005478-5iu38pr6	2927	11	a	a	DT
cord-005478-5iu38pr6	2927	12	single	single	JJ
cord-005478-5iu38pr6	2927	13	bone	bone	NN
cord-005478-5iu38pr6	2927	14	marrow	marrow	NN
cord-005478-5iu38pr6	2927	15	sample	sample	NN
cord-005478-5iu38pr6	2927	16	tested	test	VBD
cord-005478-5iu38pr6	2927	17	positive	positive	JJ
cord-005478-5iu38pr6	2927	18	by	by	IN
cord-005478-5iu38pr6	2927	19	PCR	PCR	NNP
cord-005478-5iu38pr6	2927	20	or	or	CC
cord-005478-5iu38pr6	2927	21	MFC	MFC	NNP
cord-005478-5iu38pr6	2927	22	.	.	.
cord-005478-5iu38pr6	2928	1	Recombinant	recombinant	JJ
cord-005478-5iu38pr6	2928	2	human	human	NN
cord-005478-5iu38pr6	2928	3	IFN	IFN	NNP
cord-005478-5iu38pr6	2928	4	-	-	HYPH
cord-005478-5iu38pr6	2928	5	α-2b	α-2b	JJ
cord-005478-5iu38pr6	2928	6	injections	injection	NNS
cord-005478-5iu38pr6	2928	7	were	be	VBD
cord-005478-5iu38pr6	2928	8	administered	administer	VBN
cord-005478-5iu38pr6	2928	9	subcutaneously	subcutaneously	RB
cord-005478-5iu38pr6	2928	10	for	for	IN
cord-005478-5iu38pr6	2928	11	6	6	CD
cord-005478-5iu38pr6	2928	12	cycles	cycle	NNS
cord-005478-5iu38pr6	2928	13	(	(	-LRB-
cord-005478-5iu38pr6	2928	14	twice	twice	RB
cord-005478-5iu38pr6	2928	15	or	or	CC
cord-005478-5iu38pr6	2928	16	thrice	thrice	RB
cord-005478-5iu38pr6	2928	17	weekly	weekly	RB
cord-005478-5iu38pr6	2928	18	in	in	IN
cord-005478-5iu38pr6	2928	19	every	every	DT
cord-005478-5iu38pr6	2928	20	4-week	4-week	CD
cord-005478-5iu38pr6	2928	21	cycle	cycle	NN
cord-005478-5iu38pr6	2928	22	)	)	-RRB-
cord-005478-5iu38pr6	2928	23	.	.	.
cord-005478-5iu38pr6	2929	1	Results	result	NNS
cord-005478-5iu38pr6	2929	2	:	:	:
cord-005478-5iu38pr6	2930	1	The	the	DT
cord-005478-5iu38pr6	2930	2	4-year	4-year	CD
cord-005478-5iu38pr6	2930	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2930	4	incidence	incidence	NN
cord-005478-5iu38pr6	2930	5	of	of	IN
cord-005478-5iu38pr6	2930	6	total	total	JJ
cord-005478-5iu38pr6	2930	7	chronic	chronic	JJ
cord-005478-5iu38pr6	2930	8	graft	graft	NN
cord-005478-5iu38pr6	2930	9	-	-	HYPH
cord-005478-5iu38pr6	2930	10	versus	versus	IN
cord-005478-5iu38pr6	2930	11	-	-	HYPH
cord-005478-5iu38pr6	2930	12	host	host	NN
cord-005478-5iu38pr6	2930	13	disease	disease	NN
cord-005478-5iu38pr6	2930	14	(	(	-LRB-
cord-005478-5iu38pr6	2930	15	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2930	16	)	)	-RRB-
cord-005478-5iu38pr6	2930	17	and	and	CC
cord-005478-5iu38pr6	2930	18	severe	severe	JJ
cord-005478-5iu38pr6	2930	19	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	2930	20	after	after	IN
cord-005478-5iu38pr6	2930	21	IFN	IFN	NNP
cord-005478-5iu38pr6	2930	22	-	-	HYPH
cord-005478-5iu38pr6	2930	23	α	α	NNP
cord-005478-5iu38pr6	2930	24	treatment	treatment	NN
cord-005478-5iu38pr6	2930	25	was	be	VBD
cord-005478-5iu38pr6	2930	26	58.5	58.5	CD
cord-005478-5iu38pr6	2930	27	%	%	NN
cord-005478-5iu38pr6	2930	28	(	(	-LRB-
cord-005478-5iu38pr6	2930	29	95	95	CD
cord-005478-5iu38pr6	2930	30	%	%	NN
cord-005478-5iu38pr6	2930	31	CI	CI	NNP
cord-005478-5iu38pr6	2930	32	,	,	,
cord-005478-5iu38pr6	2930	33	49.5	49.5	CD
cord-005478-5iu38pr6	2930	34	-	-	HYPH
cord-005478-5iu38pr6	2930	35	67.5	67.5	CD
cord-005478-5iu38pr6	2930	36	%	%	NN
cord-005478-5iu38pr6	2930	37	)	)	-RRB-
cord-005478-5iu38pr6	2930	38	and	and	CC
cord-005478-5iu38pr6	2930	39	10.2	10.2	CD
cord-005478-5iu38pr6	2930	40	%	%	NN
cord-005478-5iu38pr6	2930	41	(	(	-LRB-
cord-005478-5iu38pr6	2930	42	95	95	CD
cord-005478-5iu38pr6	2930	43	%	%	NN
cord-005478-5iu38pr6	2930	44	CI	CI	NNP
cord-005478-5iu38pr6	2930	45	,	,	,
cord-005478-5iu38pr6	2930	46	4.7	4.7	CD
cord-005478-5iu38pr6	2930	47	-	-	SYM
cord-005478-5iu38pr6	2930	48	15.7	15.7	CD
cord-005478-5iu38pr6	2930	49	%	%	NN
cord-005478-5iu38pr6	2930	50	)	)	-RRB-
cord-005478-5iu38pr6	2930	51	,	,	,
cord-005478-5iu38pr6	2930	52	respectively	respectively	RB
cord-005478-5iu38pr6	2930	53	.	.	.
cord-005478-5iu38pr6	2931	1	The	the	DT
cord-005478-5iu38pr6	2931	2	4-year	4-year	CD
cord-005478-5iu38pr6	2931	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	2931	4	incidence	incidence	NN
cord-005478-5iu38pr6	2931	5	of	of	IN
cord-005478-5iu38pr6	2931	6	relapse	relapse	NN
cord-005478-5iu38pr6	2931	7	and	and	CC
cord-005478-5iu38pr6	2931	8	non	non	JJ
cord-005478-5iu38pr6	2931	9	-	-	JJ
cord-005478-5iu38pr6	2931	10	relapse	relapse	JJ
cord-005478-5iu38pr6	2931	11	mortality	mortality	NN
cord-005478-5iu38pr6	2931	12	(	(	-LRB-
cord-005478-5iu38pr6	2931	13	NRM	NRM	NNP
cord-005478-5iu38pr6	2931	14	)	)	-RRB-
cord-005478-5iu38pr6	2931	15	after	after	IN
cord-005478-5iu38pr6	2931	16	IFN	IFN	NNP
cord-005478-5iu38pr6	2931	17	-	-	HYPH
cord-005478-5iu38pr6	2931	18	α	α	NNP
cord-005478-5iu38pr6	2931	19	treatment	treatment	NN
cord-005478-5iu38pr6	2931	20	was	be	VBD
cord-005478-5iu38pr6	2931	21	16.1	16.1	CD
cord-005478-5iu38pr6	2931	22	%	%	NN
cord-005478-5iu38pr6	2931	23	(	(	-LRB-
cord-005478-5iu38pr6	2931	24	95	95	CD
cord-005478-5iu38pr6	2931	25	%	%	NN
cord-005478-5iu38pr6	2931	26	CI	CI	NNP
cord-005478-5iu38pr6	2931	27	,	,	,
cord-005478-5iu38pr6	2931	28	9.4	9.4	CD
cord-005478-5iu38pr6	2931	29	-	-	HYPH
cord-005478-5iu38pr6	2931	30	22.8	22.8	CD
cord-005478-5iu38pr6	2931	31	%	%	NN
cord-005478-5iu38pr6	2931	32	)	)	-RRB-
cord-005478-5iu38pr6	2931	33	and	and	CC
cord-005478-5iu38pr6	2931	34	5.6	5.6	CD
cord-005478-5iu38pr6	2931	35	%	%	NN
cord-005478-5iu38pr6	2931	36	(	(	-LRB-
cord-005478-5iu38pr6	2931	37	95	95	CD
cord-005478-5iu38pr6	2931	38	%	%	NN
cord-005478-5iu38pr6	2931	39	CI	CI	NNP
cord-005478-5iu38pr6	2931	40	,	,	,
cord-005478-5iu38pr6	2931	41	1.1	1.1	CD
cord-005478-5iu38pr6	2931	42	-	-	SYM
cord-005478-5iu38pr6	2931	43	10.1	10.1	CD
cord-005478-5iu38pr6	2931	44	%	%	NN
cord-005478-5iu38pr6	2931	45	)	)	-RRB-
cord-005478-5iu38pr6	2931	46	,	,	,
cord-005478-5iu38pr6	2931	47	respectively	respectively	RB
cord-005478-5iu38pr6	2931	48	.	.	.
cord-005478-5iu38pr6	2932	1	The	the	DT
cord-005478-5iu38pr6	2932	2	4year	4year	CD
cord-005478-5iu38pr6	2932	3	probabilities	probability	NNS
cord-005478-5iu38pr6	2932	4	of	of	IN
cord-005478-5iu38pr6	2932	5	disease	disease	NN
cord-005478-5iu38pr6	2932	6	-	-	HYPH
cord-005478-5iu38pr6	2932	7	free	free	JJ
cord-005478-5iu38pr6	2932	8	survival	survival	NN
cord-005478-5iu38pr6	2932	9	and	and	CC
cord-005478-5iu38pr6	2932	10	overall	overall	JJ
cord-005478-5iu38pr6	2932	11	survival	survival	NN
cord-005478-5iu38pr6	2932	12	(	(	-LRB-
cord-005478-5iu38pr6	2932	13	OS	OS	NNP
cord-005478-5iu38pr6	2932	14	)	)	-RRB-
cord-005478-5iu38pr6	2932	15	after	after	IN
cord-005478-5iu38pr6	2932	16	IFN	IFN	NNP
cord-005478-5iu38pr6	2932	17	-	-	HYPH
cord-005478-5iu38pr6	2932	18	α	α	NNP
cord-005478-5iu38pr6	2932	19	treatment	treatment	NN
cord-005478-5iu38pr6	2932	20	were	be	VBD
cord-005478-5iu38pr6	2932	21	78.3	78.3	CD
cord-005478-5iu38pr6	2932	22	%	%	NN
cord-005478-5iu38pr6	2932	23	(	(	-LRB-
cord-005478-5iu38pr6	2932	24	95	95	CD
cord-005478-5iu38pr6	2932	25	%	%	NN
cord-005478-5iu38pr6	2932	26	CI	CI	NNP
cord-005478-5iu38pr6	2932	27	,	,	,
cord-005478-5iu38pr6	2932	28	70.6	70.6	CD
cord-005478-5iu38pr6	2932	29	-	-	HYPH
cord-005478-5iu38pr6	2932	30	86.0	86.0	CD
cord-005478-5iu38pr6	2932	31	%	%	NN
cord-005478-5iu38pr6	2932	32	)	)	-RRB-
cord-005478-5iu38pr6	2932	33	and	and	CC
cord-005478-5iu38pr6	2932	34	84.0	84.0	CD
cord-005478-5iu38pr6	2932	35	%	%	NN
cord-005478-5iu38pr6	2932	36	(	(	-LRB-
cord-005478-5iu38pr6	2932	37	95	95	CD
cord-005478-5iu38pr6	2932	38	%	%	NN
cord-005478-5iu38pr6	2932	39	CI	ci	NN
cord-005478-5iu38pr6	2932	40	,	,	,
cord-005478-5iu38pr6	2932	41	77.1	77.1	CD
cord-005478-5iu38pr6	2932	42	-	-	HYPH
cord-005478-5iu38pr6	2932	43	90.9	90.9	CD
cord-005478-5iu38pr6	2932	44	%	%	NN
cord-005478-5iu38pr6	2932	45	)	)	-RRB-
cord-005478-5iu38pr6	2932	46	.	.	.
cord-005478-5iu38pr6	2933	1	In	in	IN
cord-005478-5iu38pr6	2933	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	2933	3	analysis	analysis	NN
cord-005478-5iu38pr6	2933	4	,	,	,
cord-005478-5iu38pr6	2933	5	severe	severe	JJ
cord-005478-5iu38pr6	2933	6	acute	acute	JJ
cord-005478-5iu38pr6	2933	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	2933	8	was	be	VBD
cord-005478-5iu38pr6	2933	9	associated	associate	VBN
cord-005478-5iu38pr6	2933	10	with	with	IN
cord-005478-5iu38pr6	2933	11	a	a	DT
cord-005478-5iu38pr6	2933	12	higher	high	JJR
cord-005478-5iu38pr6	2933	13	risk	risk	NN
cord-005478-5iu38pr6	2933	14	of	of	IN
cord-005478-5iu38pr6	2933	15	NRM	NRM	NNP
cord-005478-5iu38pr6	2933	16	and	and	CC
cord-005478-5iu38pr6	2933	17	poorer	poor	JJR
cord-005478-5iu38pr6	2933	18	OS	OS	NNP
cord-005478-5iu38pr6	2933	19	,	,	,
cord-005478-5iu38pr6	2933	20	and	and	CC
cord-005478-5iu38pr6	2933	21	mild	mild	JJ
cord-005478-5iu38pr6	2933	22	to	to	TO
cord-005478-5iu38pr6	2933	23	moderate	moderate	JJ
cord-005478-5iu38pr6	2933	24	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	2933	25	was	be	VBD
cord-005478-5iu38pr6	2933	26	associated	associate	VBN
cord-005478-5iu38pr6	2933	27	with	with	IN
cord-005478-5iu38pr6	2933	28	a	a	DT
cord-005478-5iu38pr6	2933	29	lower	low	JJR
cord-005478-5iu38pr6	2933	30	risk	risk	NN
cord-005478-5iu38pr6	2933	31	of	of	IN
cord-005478-5iu38pr6	2933	32	relapse	relapse	NN
cord-005478-5iu38pr6	2933	33	and	and	CC
cord-005478-5iu38pr6	2933	34	better	well	JJR
cord-005478-5iu38pr6	2933	35	survival	survival	NN
cord-005478-5iu38pr6	2933	36	.	.	.
cord-005478-5iu38pr6	2934	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2934	2	:	:	:
cord-005478-5iu38pr6	2935	1	These	these	DT
cord-005478-5iu38pr6	2935	2	data	datum	NNS
cord-005478-5iu38pr6	2935	3	confirmed	confirm	VBD
cord-005478-5iu38pr6	2935	4	that	that	IN
cord-005478-5iu38pr6	2935	5	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2935	6	IFNα	IFNα	NNP
cord-005478-5iu38pr6	2935	7	treatment	treatment	NN
cord-005478-5iu38pr6	2935	8	showed	show	VBD
cord-005478-5iu38pr6	2935	9	long	long	JJ
cord-005478-5iu38pr6	2935	10	-	-	HYPH
cord-005478-5iu38pr6	2935	11	term	term	NN
cord-005478-5iu38pr6	2935	12	efficacy	efficacy	NN
cord-005478-5iu38pr6	2935	13	in	in	IN
cord-005478-5iu38pr6	2935	14	patients	patient	NNS
cord-005478-5iu38pr6	2935	15	who	who	WP
cord-005478-5iu38pr6	2935	16	were	be	VBD
cord-005478-5iu38pr6	2935	17	MRD	MRD	NNP
cord-005478-5iu38pr6	2935	18	-	-	HYPH
cord-005478-5iu38pr6	2935	19	positive	positive	JJ
cord-005478-5iu38pr6	2935	20	after	after	IN
cord-005478-5iu38pr6	2935	21	allo	allo	NN
cord-005478-5iu38pr6	2935	22	-	-	HYPH
cord-005478-5iu38pr6	2935	23	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2935	24	.	.	.
cord-005478-5iu38pr6	2936	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	2936	2	Trial	Trial	NNP
cord-005478-5iu38pr6	2936	3	Registry	Registry	NNP
cord-005478-5iu38pr6	2936	4	:	:	:
cord-005478-5iu38pr6	2936	5	The	the	DT
cord-005478-5iu38pr6	2936	6	study	study	NN
cord-005478-5iu38pr6	2936	7	was	be	VBD
cord-005478-5iu38pr6	2936	8	registered	register	VBN
cord-005478-5iu38pr6	2936	9	at	at	IN
cord-005478-5iu38pr6	2936	10	http://clinicaltrials.gov	http://clinicaltrials.gov	ADD
cord-005478-5iu38pr6	2936	11	as	as	IN
cord-005478-5iu38pr6	2936	12	#	#	$
cord-005478-5iu38pr6	2936	13	NCT02185261	NCT02185261	NNS
cord-005478-5iu38pr6	2936	14	and	and	CC
cord-005478-5iu38pr6	2936	15	#	#	NN
cord-005478-5iu38pr6	2936	16	NCT02027064	nct02027064	NN
cord-005478-5iu38pr6	2936	17	.	.	.
cord-005478-5iu38pr6	2937	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2937	2	:	:	:
cord-005478-5iu38pr6	2938	1	The	the	DT
cord-005478-5iu38pr6	2938	2	authors	author	NNS
cord-005478-5iu38pr6	2938	3	declare	declare	VBP
cord-005478-5iu38pr6	2938	4	no	no	DT
cord-005478-5iu38pr6	2938	5	competing	compete	VBG
cord-005478-5iu38pr6	2938	6	financial	financial	JJ
cord-005478-5iu38pr6	2938	7	interests	interest	NNS
cord-005478-5iu38pr6	2938	8	.	.	.
cord-005478-5iu38pr6	2939	1	A	a	DT
cord-005478-5iu38pr6	2939	2	phase	phase	NN
cord-005478-5iu38pr6	2939	3	II	ii	CD
cord-005478-5iu38pr6	2939	4	clinical	clinical	JJ
cord-005478-5iu38pr6	2939	5	trial	trial	NN
cord-005478-5iu38pr6	2939	6	of	of	IN
cord-005478-5iu38pr6	2939	7	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	2939	8	for	for	IN
cord-005478-5iu38pr6	2939	9	enhancement	enhancement	NN
cord-005478-5iu38pr6	2939	10	of	of	IN
cord-005478-5iu38pr6	2939	11	immune	immune	JJ
cord-005478-5iu38pr6	2939	12	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2939	13	after	after	IN
cord-005478-5iu38pr6	2939	14	ex	ex	FW
cord-005478-5iu38pr6	2939	15	vivo	vivo	NN
cord-005478-5iu38pr6	2939	16	CD34	CD34	NNP
cord-005478-5iu38pr6	2939	17	+	+	CC
cord-005478-5iu38pr6	2939	18	cell	cell	NN
cord-005478-5iu38pr6	2939	19	-	-	HYPH
cord-005478-5iu38pr6	2939	20	selected	select	VBN
cord-005478-5iu38pr6	2939	21	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2939	22	HCT	hct	NN
cord-005478-5iu38pr6	2939	23	with	with	IN
cord-005478-5iu38pr6	2939	24	TBI	tbi	NN
cord-005478-5iu38pr6	2939	25	-	-	HYPH
cord-005478-5iu38pr6	2939	26	based	base	VBN
cord-005478-5iu38pr6	2939	27	conditioning	conditioning	NN
cord-005478-5iu38pr6	2939	28	GnRH	gnrh	NN
cord-005478-5iu38pr6	2939	29	agonist	agonist	NN
cord-005478-5iu38pr6	2939	30	use	use	NN
cord-005478-5iu38pr6	2939	31	,	,	,
cord-005478-5iu38pr6	2939	32	which	which	WDT
cord-005478-5iu38pr6	2939	33	has	have	VBZ
cord-005478-5iu38pr6	2939	34	been	be	VBN
cord-005478-5iu38pr6	2939	35	associated	associate	VBN
cord-005478-5iu38pr6	2939	36	with	with	IN
cord-005478-5iu38pr6	2939	37	thymic	thymic	JJ
cord-005478-5iu38pr6	2939	38	cellular	cellular	JJ
cord-005478-5iu38pr6	2939	39	degeneration	degeneration	NN
cord-005478-5iu38pr6	2939	40	in	in	IN
cord-005478-5iu38pr6	2939	41	mouse	mouse	NN
cord-005478-5iu38pr6	2939	42	(	(	-LRB-
cord-005478-5iu38pr6	2939	43	Velardi	Velardi	NNP
cord-005478-5iu38pr6	2939	44	,	,	,
cord-005478-5iu38pr6	2939	45	JEM	JEM	NNP
cord-005478-5iu38pr6	2939	46	2014	2014	CD
cord-005478-5iu38pr6	2939	47	)	)	-RRB-
cord-005478-5iu38pr6	2939	48	.	.	.
cord-005478-5iu38pr6	2940	1	As	as	IN
cord-005478-5iu38pr6	2940	2	direct	direct	JJ
cord-005478-5iu38pr6	2940	3	GnRH	gnrh	JJ
cord-005478-5iu38pr6	2940	4	antagonism	antagonism	NN
cord-005478-5iu38pr6	2940	5	might	may	MD
cord-005478-5iu38pr6	2940	6	circumvent	circumvent	VB
cord-005478-5iu38pr6	2940	7	this	this	DT
cord-005478-5iu38pr6	2940	8	effect	effect	NN
cord-005478-5iu38pr6	2940	9	,	,	,
cord-005478-5iu38pr6	2940	10	a	a	DT
cord-005478-5iu38pr6	2940	11	follow	follow	NN
cord-005478-5iu38pr6	2940	12	-	-	HYPH
cord-005478-5iu38pr6	2940	13	up	up	NN
cord-005478-5iu38pr6	2940	14	phase	phase	NN
cord-005478-5iu38pr6	2940	15	II	II	NNP
cord-005478-5iu38pr6	2940	16	trial	trial	NN
cord-005478-5iu38pr6	2940	17	evaluating	evaluate	VBG
cord-005478-5iu38pr6	2940	18	peri	peri	NN
cord-005478-5iu38pr6	2940	19	-	-	HYPH
cord-005478-5iu38pr6	2940	20	transplant	transplant	NN
cord-005478-5iu38pr6	2940	21	degarelix	degarelix	VBN
cord-005478-5iu38pr6	2940	22	for	for	IN
cord-005478-5iu38pr6	2940	23	enhancement	enhancement	NN
cord-005478-5iu38pr6	2940	24	of	of	IN
cord-005478-5iu38pr6	2940	25	immune	immune	JJ
cord-005478-5iu38pr6	2940	26	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2940	27	is	be	VBZ
cord-005478-5iu38pr6	2940	28	in	in	IN
cord-005478-5iu38pr6	2940	29	progress	progress	NN
cord-005478-5iu38pr6	2940	30	.	.	.
cord-005478-5iu38pr6	2941	1	Background	background	NN
cord-005478-5iu38pr6	2941	2	:	:	:
cord-005478-5iu38pr6	2942	1	In	in	IN
cord-005478-5iu38pr6	2942	2	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	2942	3	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	2942	4	stem	stem	NN
cord-005478-5iu38pr6	2942	5	cell	cell	NN
cord-005478-5iu38pr6	2942	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	2942	7	(	(	-LRB-
cord-005478-5iu38pr6	2942	8	allo	allo	NN
cord-005478-5iu38pr6	2942	9	-	-	HYPH
cord-005478-5iu38pr6	2942	10	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2942	11	)	)	-RRB-
cord-005478-5iu38pr6	2942	12	recipients	recipient	NNS
cord-005478-5iu38pr6	2942	13	,	,	,
cord-005478-5iu38pr6	2942	14	Cytomegalovirus	Cytomegalovirus	NNP
cord-005478-5iu38pr6	2942	15	(	(	-LRB-
cord-005478-5iu38pr6	2942	16	CMV	CMV	NNP
cord-005478-5iu38pr6	2942	17	)	)	-RRB-
cord-005478-5iu38pr6	2942	18	reactivation	reactivation	NN
cord-005478-5iu38pr6	2942	19	and	and	CC
cord-005478-5iu38pr6	2942	20	disease	disease	NN
cord-005478-5iu38pr6	2942	21	are	be	VBP
cord-005478-5iu38pr6	2942	22	frequent	frequent	JJ
cord-005478-5iu38pr6	2942	23	causes	cause	NNS
cord-005478-5iu38pr6	2942	24	of	of	IN
cord-005478-5iu38pr6	2942	25	morbidity	morbidity	NN
cord-005478-5iu38pr6	2942	26	and	and	CC
cord-005478-5iu38pr6	2942	27	mortality	mortality	NN
cord-005478-5iu38pr6	2942	28	,	,	,
cord-005478-5iu38pr6	2942	29	that	that	WDT
cord-005478-5iu38pr6	2942	30	may	may	MD
cord-005478-5iu38pr6	2942	31	be	be	VB
cord-005478-5iu38pr6	2942	32	evaded	evade	VBN
cord-005478-5iu38pr6	2942	33	by	by	IN
cord-005478-5iu38pr6	2942	34	CMV	CMV	NNP
cord-005478-5iu38pr6	2942	35	-	-	HYPH
cord-005478-5iu38pr6	2942	36	specific	specific	JJ
cord-005478-5iu38pr6	2942	37	T	T	NNP
cord-005478-5iu38pr6	2942	38	cell	cell	NN
cord-005478-5iu38pr6	2942	39	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2942	40	.	.	.
cord-005478-5iu38pr6	2943	1	Methods	method	NNS
cord-005478-5iu38pr6	2943	2	:	:	:
cord-005478-5iu38pr6	2943	3	We	-PRON-	PRP
cord-005478-5iu38pr6	2943	4	designed	design	VBD
cord-005478-5iu38pr6	2943	5	a	a	DT
cord-005478-5iu38pr6	2943	6	prospective	prospective	JJ
cord-005478-5iu38pr6	2943	7	,	,	,
cord-005478-5iu38pr6	2943	8	single	single	JJ
cord-005478-5iu38pr6	2943	9	-	-	HYPH
cord-005478-5iu38pr6	2943	10	center	center	NN
cord-005478-5iu38pr6	2943	11	observational	observational	JJ
cord-005478-5iu38pr6	2943	12	study	study	NN
cord-005478-5iu38pr6	2943	13	to	to	TO
cord-005478-5iu38pr6	2943	14	assess	assess	VB
cord-005478-5iu38pr6	2943	15	if	if	IN
cord-005478-5iu38pr6	2943	16	the	the	DT
cord-005478-5iu38pr6	2943	17	kinetic	kinetic	JJ
cord-005478-5iu38pr6	2943	18	and	and	CC
cord-005478-5iu38pr6	2943	19	quality	quality	NN
cord-005478-5iu38pr6	2943	20	of	of	IN
cord-005478-5iu38pr6	2943	21	CMV	CMV	NNP
cord-005478-5iu38pr6	2943	22	specific	specific	JJ
cord-005478-5iu38pr6	2943	23	T	t	NN
cord-005478-5iu38pr6	2943	24	-	-	HYPH
cord-005478-5iu38pr6	2943	25	cell	cell	NN
cord-005478-5iu38pr6	2943	26	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2943	27	impact	impact	NN
cord-005478-5iu38pr6	2943	28	the	the	DT
cord-005478-5iu38pr6	2943	29	incidence	incidence	NN
cord-005478-5iu38pr6	2943	30	and	and	CC
cord-005478-5iu38pr6	2943	31	severity	severity	NN
cord-005478-5iu38pr6	2943	32	of	of	IN
cord-005478-5iu38pr6	2943	33	CMV	CMV	NNP
cord-005478-5iu38pr6	2943	34	reactivations	reactivation	NNS
cord-005478-5iu38pr6	2943	35	.	.	.
cord-005478-5iu38pr6	2944	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2944	2	report	report	VBP
cord-005478-5iu38pr6	2944	3	data	datum	NNS
cord-005478-5iu38pr6	2944	4	on	on	IN
cord-005478-5iu38pr6	2944	5	the	the	DT
cord-005478-5iu38pr6	2944	6	first	first	JJ
cord-005478-5iu38pr6	2944	7	54	54	CD
cord-005478-5iu38pr6	2944	8	consecutive	consecutive	JJ
cord-005478-5iu38pr6	2944	9	patients	patient	NNS
cord-005478-5iu38pr6	2944	10	affected	affect	VBN
cord-005478-5iu38pr6	2944	11	by	by	IN
cord-005478-5iu38pr6	2944	12	hematological	hematological	JJ
cord-005478-5iu38pr6	2944	13	malignancies	malignancy	NNS
cord-005478-5iu38pr6	2944	14	receiving	receive	VBG
cord-005478-5iu38pr6	2944	15	allo	allo	NN
cord-005478-5iu38pr6	2944	16	-	-	HYPH
cord-005478-5iu38pr6	2944	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2944	18	followed	follow	VBD
cord-005478-5iu38pr6	2944	19	by	by	IN
cord-005478-5iu38pr6	2944	20	Cyclophosphamide	Cyclophosphamide	NNP
cord-005478-5iu38pr6	2944	21	and	and	CC
cord-005478-5iu38pr6	2944	22	Rapamycin	Rapamycin	NNP
cord-005478-5iu38pr6	2944	23	between	between	IN
cord-005478-5iu38pr6	2944	24	December	December	NNP
cord-005478-5iu38pr6	2944	25	2017	2017	CD
cord-005478-5iu38pr6	2944	26	and	and	CC
cord-005478-5iu38pr6	2944	27	August	August	NNP
cord-005478-5iu38pr6	2944	28	2018	2018	CD
cord-005478-5iu38pr6	2944	29	.	.	.
cord-005478-5iu38pr6	2945	1	Patients	patient	NNS
cord-005478-5iu38pr6	2945	2	received	receive	VBD
cord-005478-5iu38pr6	2945	3	allo	allo	NN
cord-005478-5iu38pr6	2945	4	-	-	HYPH
cord-005478-5iu38pr6	2945	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2945	6	from	from	IN
cord-005478-5iu38pr6	2945	7	family	family	NN
cord-005478-5iu38pr6	2945	8	(	(	-LRB-
cord-005478-5iu38pr6	2945	9	sib	sib	NN
cord-005478-5iu38pr6	2945	10	-	-	HYPH
cord-005478-5iu38pr6	2945	11	lings=9	lings=9	NN
cord-005478-5iu38pr6	2945	12	;	;	:
cord-005478-5iu38pr6	2945	13	HLA	HLA	NNP
cord-005478-5iu38pr6	2945	14	haploidentical=21	haploidentical=21	NNP
cord-005478-5iu38pr6	2945	15	)	)	-RRB-
cord-005478-5iu38pr6	2945	16	,	,	,
cord-005478-5iu38pr6	2945	17	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2945	18	HLA	HLA	NNP
cord-005478-5iu38pr6	2945	19	matched	match	VBD
cord-005478-5iu38pr6	2945	20	(	(	-LRB-
cord-005478-5iu38pr6	2945	21	n=	n=	NNP
cord-005478-5iu38pr6	2945	22	23	23	CD
cord-005478-5iu38pr6	2945	23	)	)	-RRB-
cord-005478-5iu38pr6	2945	24	donors	donor	NNS
cord-005478-5iu38pr6	2945	25	or	or	CC
cord-005478-5iu38pr6	2945	26	cord	cord	NN
cord-005478-5iu38pr6	2945	27	blood	blood	NN
cord-005478-5iu38pr6	2945	28	(	(	-LRB-
cord-005478-5iu38pr6	2945	29	n=1	n=1	FW
cord-005478-5iu38pr6	2945	30	)	)	-RRB-
cord-005478-5iu38pr6	2945	31	.	.	.
cord-005478-5iu38pr6	2946	1	The	the	DT
cord-005478-5iu38pr6	2946	2	CMV	CMV	NNP
cord-005478-5iu38pr6	2946	3	serostatus	serostatus	NN
cord-005478-5iu38pr6	2946	4	of	of	IN
cord-005478-5iu38pr6	2946	5	host	host	NN
cord-005478-5iu38pr6	2946	6	(	(	-LRB-
cord-005478-5iu38pr6	2946	7	H	H	NNP
cord-005478-5iu38pr6	2946	8	)	)	-RRB-
cord-005478-5iu38pr6	2946	9	and	and	CC
cord-005478-5iu38pr6	2946	10	donor	donor	NN
cord-005478-5iu38pr6	2946	11	(	(	-LRB-
cord-005478-5iu38pr6	2946	12	D	D	NNP
cord-005478-5iu38pr6	2946	13	)	)	-RRB-
cord-005478-5iu38pr6	2946	14	pairs	pair	NNS
cord-005478-5iu38pr6	2946	15	was	be	VBD
cord-005478-5iu38pr6	2946	16	:	:	:
cord-005478-5iu38pr6	2947	1	H	h	NN
cord-005478-5iu38pr6	2947	2	+	+	CC
cord-005478-5iu38pr6	2947	3	/D	/D	.
cord-005478-5iu38pr6	2948	1	+	+	CC
cord-005478-5iu38pr6	2949	1	(	(	-LRB-
cord-005478-5iu38pr6	2949	2	n=36	n=36	NNS
cord-005478-5iu38pr6	2949	3	,	,	,
cord-005478-5iu38pr6	2949	4	67	67	CD
cord-005478-5iu38pr6	2949	5	%	%	NN
cord-005478-5iu38pr6	2949	6	)	)	-RRB-
cord-005478-5iu38pr6	2949	7	,	,	,
cord-005478-5iu38pr6	2949	8	H	h	NN
cord-005478-5iu38pr6	2949	9	+	+	CC
cord-005478-5iu38pr6	2949	10	/D	/d	NN
cord-005478-5iu38pr6	2949	11	-(n=17	-(n=17	ADD
cord-005478-5iu38pr6	2949	12	,	,	,
cord-005478-5iu38pr6	2949	13	31	31	CD
cord-005478-5iu38pr6	2949	14	%	%	NN
cord-005478-5iu38pr6	2949	15	)	)	-RRB-
cord-005478-5iu38pr6	2949	16	and	and	CC
cord-005478-5iu38pr6	2949	17	H	h	NN
cord-005478-5iu38pr6	2949	18	-/D	-/d	NN
cord-005478-5iu38pr6	2949	19	+	+	CC
cord-005478-5iu38pr6	2950	1	(	(	-LRB-
cord-005478-5iu38pr6	2950	2	n=1	n=1	UH
cord-005478-5iu38pr6	2950	3	,	,	,
cord-005478-5iu38pr6	2950	4	2	2	CD
cord-005478-5iu38pr6	2950	5	%	%	NN
cord-005478-5iu38pr6	2950	6	)	)	-RRB-
cord-005478-5iu38pr6	2950	7	;	;	:
cord-005478-5iu38pr6	2950	8	H	H	NNP
cord-005478-5iu38pr6	2950	9	-/Dwere	-/dwere	RB
cord-005478-5iu38pr6	2950	10	excluded	exclude	VBN
cord-005478-5iu38pr6	2950	11	.	.	.
cord-005478-5iu38pr6	2951	1	CMV	CMV	NNP
cord-005478-5iu38pr6	2951	2	DNAemia	DNAemia	NNP
cord-005478-5iu38pr6	2951	3	was	be	VBD
cord-005478-5iu38pr6	2951	4	assessed	assess	VBN
cord-005478-5iu38pr6	2951	5	weekly	weekly	RB
cord-005478-5iu38pr6	2951	6	in	in	IN
cord-005478-5iu38pr6	2951	7	whole	whole	JJ
cord-005478-5iu38pr6	2951	8	blood	blood	NN
cord-005478-5iu38pr6	2951	9	(	(	-LRB-
cord-005478-5iu38pr6	2951	10	WB	WB	NNP
cord-005478-5iu38pr6	2951	11	)	)	-RRB-
cord-005478-5iu38pr6	2951	12	.	.	.
cord-005478-5iu38pr6	2952	1	Absolute	absolute	JJ
cord-005478-5iu38pr6	2952	2	numbers	number	NNS
cord-005478-5iu38pr6	2952	3	of	of	IN
cord-005478-5iu38pr6	2952	4	polyclonal	polyclonal	JJ
cord-005478-5iu38pr6	2952	5	and	and	CC
cord-005478-5iu38pr6	2952	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2952	7	-	-	HYPH
cord-005478-5iu38pr6	2952	8	specific	specific	JJ
cord-005478-5iu38pr6	2952	9	T	t	NN
cord-005478-5iu38pr6	2952	10	cells	cell	NNS
cord-005478-5iu38pr6	2952	11	were	be	VBD
cord-005478-5iu38pr6	2952	12	quantified	quantify	VBN
cord-005478-5iu38pr6	2952	13	by	by	IN
cord-005478-5iu38pr6	2952	14	flow	flow	NN
cord-005478-5iu38pr6	2952	15	cytometry	cytometry	NN
cord-005478-5iu38pr6	2952	16	using	use	VBG
cord-005478-5iu38pr6	2952	17	Trou	Trou	NNP
cord-005478-5iu38pr6	2952	18	-	-	HYPH
cord-005478-5iu38pr6	2952	19	count	count	NN
cord-005478-5iu38pr6	2952	20	™	™	NN
cord-005478-5iu38pr6	2952	21	Tubes	tube	NNS
cord-005478-5iu38pr6	2952	22	(	(	-LRB-
cord-005478-5iu38pr6	2952	23	BD	BD	NNP
cord-005478-5iu38pr6	2952	24	)	)	-RRB-
cord-005478-5iu38pr6	2952	25	and	and	CC
cord-005478-5iu38pr6	2952	26	Dextramer	Dextramer	NNP
cord-005478-5iu38pr6	2952	27	®	®	NNP
cord-005478-5iu38pr6	2952	28	CMV	CMV	NNP
cord-005478-5iu38pr6	2952	29	-	-	HYPH
cord-005478-5iu38pr6	2952	30	Kit	Kit	NNP
cord-005478-5iu38pr6	2952	31	(	(	-LRB-
cord-005478-5iu38pr6	2952	32	IMMU	IMMU	NNP
cord-005478-5iu38pr6	2952	33	-	-	HYPH
cord-005478-5iu38pr6	2952	34	DEX	DEX	NNP
cord-005478-5iu38pr6	2952	35	)	)	-RRB-
cord-005478-5iu38pr6	2952	36	,	,	,
cord-005478-5iu38pr6	2952	37	respectively	respectively	RB
cord-005478-5iu38pr6	2952	38	,	,	,
cord-005478-5iu38pr6	2952	39	in	in	IN
cord-005478-5iu38pr6	2952	40	the	the	DT
cord-005478-5iu38pr6	2952	41	graft	graft	NN
cord-005478-5iu38pr6	2952	42	and	and	CC
cord-005478-5iu38pr6	2952	43	fresh	fresh	JJ
cord-005478-5iu38pr6	2952	44	WB	WB	NNP
cord-005478-5iu38pr6	2952	45	at	at	IN
cord-005478-5iu38pr6	2952	46	days	day	NNS
cord-005478-5iu38pr6	2952	47	-7	-7	NNP
cord-005478-5iu38pr6	2952	48	,	,	,
cord-005478-5iu38pr6	2952	49	+30	+30	CD
cord-005478-5iu38pr6	2952	50	,	,	,
cord-005478-5iu38pr6	2952	51	+45	+45	NNP
cord-005478-5iu38pr6	2952	52	,	,	,
cord-005478-5iu38pr6	2952	53	+60	+60	NNP
cord-005478-5iu38pr6	2952	54	,	,	,
cord-005478-5iu38pr6	2952	55	+90	+90	CD
cord-005478-5iu38pr6	2952	56	,	,	,
cord-005478-5iu38pr6	2952	57	+120	+120	NNP
cord-005478-5iu38pr6	2952	58	,	,	,
cord-005478-5iu38pr6	2952	59	+150	+150	NNP
cord-005478-5iu38pr6	2952	60	and	and	CC
cord-005478-5iu38pr6	2952	61	+180	+180	NNP
cord-005478-5iu38pr6	2952	62	.	.	.
cord-005478-5iu38pr6	2953	1	Dextramers	dextramer	NNS
cord-005478-5iu38pr6	2953	2	permit	permit	VBP
cord-005478-5iu38pr6	2953	3	the	the	DT
cord-005478-5iu38pr6	2953	4	identification	identification	NN
cord-005478-5iu38pr6	2953	5	of	of	IN
cord-005478-5iu38pr6	2953	6	CMV	CMV	NNP
cord-005478-5iu38pr6	2953	7	-	-	HYPH
cord-005478-5iu38pr6	2953	8	specific	specific	JJ
cord-005478-5iu38pr6	2953	9	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2953	10	restricted	restrict	VBN
cord-005478-5iu38pr6	2953	11	for	for	IN
cord-005478-5iu38pr6	2953	12	several	several	JJ
cord-005478-5iu38pr6	2953	13	HLA	HLA	NNP
cord-005478-5iu38pr6	2953	14	class	class	NN
cord-005478-5iu38pr6	2954	1	I	-PRON-	PRP
cord-005478-5iu38pr6	2954	2	molecules	molecule	VBZ
cord-005478-5iu38pr6	2954	3	:	:	:
cord-005478-5iu38pr6	2955	1	A*01:01/	a*01:01/	LS
cord-005478-5iu38pr6	2955	2	*	*	NFP
cord-005478-5iu38pr6	2955	3	02:01/*03:01/*24:02	02:01/*03:01/*24:02	CD
cord-005478-5iu38pr6	2955	4	and	and	CC
cord-005478-5iu38pr6	2955	5	B*07:02/*08:01/*35:01	B*07:02/*08:01/*35:01	NNS
cord-005478-5iu38pr6	2955	6	.	.	.
cord-005478-5iu38pr6	2956	1	These	these	DT
cord-005478-5iu38pr6	2956	2	alleles	allele	NNS
cord-005478-5iu38pr6	2956	3	allowed	allow	VBD
cord-005478-5iu38pr6	2956	4	the	the	DT
cord-005478-5iu38pr6	2956	5	longitudinal	longitudinal	JJ
cord-005478-5iu38pr6	2956	6	evaluation	evaluation	NN
cord-005478-5iu38pr6	2956	7	of	of	IN
cord-005478-5iu38pr6	2956	8	48	48	CD
cord-005478-5iu38pr6	2956	9	(	(	-LRB-
cord-005478-5iu38pr6	2956	10	89	89	CD
cord-005478-5iu38pr6	2956	11	%	%	NN
cord-005478-5iu38pr6	2956	12	)	)	-RRB-
cord-005478-5iu38pr6	2956	13	patients	patient	NNS
cord-005478-5iu38pr6	2956	14	.	.	.
cord-005478-5iu38pr6	2957	1	Results	result	NNS
cord-005478-5iu38pr6	2957	2	:	:	:
cord-005478-5iu38pr6	2958	1	At	at	IN
cord-005478-5iu38pr6	2958	2	a	a	DT
cord-005478-5iu38pr6	2958	3	median	median	JJ
cord-005478-5iu38pr6	2958	4	follow	follow	NN
cord-005478-5iu38pr6	2958	5	-	-	HYPH
cord-005478-5iu38pr6	2958	6	up	up	NN
cord-005478-5iu38pr6	2958	7	of	of	IN
cord-005478-5iu38pr6	2958	8	150	150	CD
cord-005478-5iu38pr6	2958	9	days	day	NNS
cord-005478-5iu38pr6	2958	10	post	post	NN
cord-005478-5iu38pr6	2958	11	-	-	JJ
cord-005478-5iu38pr6	2958	12	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2958	13	,	,	,
cord-005478-5iu38pr6	2958	14	28	28	CD
cord-005478-5iu38pr6	2958	15	(	(	-LRB-
cord-005478-5iu38pr6	2958	16	58	58	CD
cord-005478-5iu38pr6	2958	17	%	%	NN
cord-005478-5iu38pr6	2958	18	)	)	-RRB-
cord-005478-5iu38pr6	2958	19	patients	patient	NNS
cord-005478-5iu38pr6	2958	20	experienced	experience	VBD
cord-005478-5iu38pr6	2958	21	a	a	DT
cord-005478-5iu38pr6	2958	22	CMV	CMV	NNP
cord-005478-5iu38pr6	2958	23	-	-	HYPH
cord-005478-5iu38pr6	2958	24	related	relate	VBN
cord-005478-5iu38pr6	2958	25	clinically	clinically	RB
cord-005478-5iu38pr6	2958	26	relevant	relevant	JJ
cord-005478-5iu38pr6	2958	27	event	event	NN
cord-005478-5iu38pr6	2958	28	(	(	-LRB-
cord-005478-5iu38pr6	2958	29	CRE	CRE	NNP
cord-005478-5iu38pr6	2958	30	,	,	,
cord-005478-5iu38pr6	2958	31	median	median	JJ
cord-005478-5iu38pr6	2958	32	+50	+50	CD
cord-005478-5iu38pr6	2958	33	days	day	NNS
cord-005478-5iu38pr6	2958	34	)	)	-RRB-
cord-005478-5iu38pr6	2958	35	,	,	,
cord-005478-5iu38pr6	2958	36	including	include	VBG
cord-005478-5iu38pr6	2958	37	7	7	CD
cord-005478-5iu38pr6	2958	38	patients	patient	NNS
cord-005478-5iu38pr6	2958	39	(	(	-LRB-
cord-005478-5iu38pr6	2958	40	15	15	CD
cord-005478-5iu38pr6	2958	41	%	%	NN
cord-005478-5iu38pr6	2958	42	)	)	-RRB-
cord-005478-5iu38pr6	2958	43	with	with	IN
cord-005478-5iu38pr6	2958	44	CMV	CMV	NNP
cord-005478-5iu38pr6	2958	45	disease	disease	NN
cord-005478-5iu38pr6	2958	46	.	.	.
cord-005478-5iu38pr6	2959	1	For	for	IN
cord-005478-5iu38pr6	2959	2	each	each	DT
cord-005478-5iu38pr6	2959	3	time	time	NN
cord-005478-5iu38pr6	2959	4	-	-	HYPH
cord-005478-5iu38pr6	2959	5	point	point	NN
cord-005478-5iu38pr6	2959	6	,	,	,
cord-005478-5iu38pr6	2959	7	we	-PRON-	PRP
cord-005478-5iu38pr6	2959	8	compared	compare	VBD
cord-005478-5iu38pr6	2959	9	the	the	DT
cord-005478-5iu38pr6	2959	10	absolute	absolute	JJ
cord-005478-5iu38pr6	2959	11	number	number	NN
cord-005478-5iu38pr6	2959	12	of	of	IN
cord-005478-5iu38pr6	2959	13	CMV	CMV	NNP
cord-005478-5iu38pr6	2959	14	-	-	HYPH
cord-005478-5iu38pr6	2959	15	specific	specific	JJ
cord-005478-5iu38pr6	2959	16	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2959	17	in	in	IN
cord-005478-5iu38pr6	2959	18	patients	patient	NNS
cord-005478-5iu38pr6	2959	19	experiencing	experience	VBG
cord-005478-5iu38pr6	2959	20	or	or	CC
cord-005478-5iu38pr6	2959	21	not	not	RB
cord-005478-5iu38pr6	2959	22	a	a	DT
cord-005478-5iu38pr6	2959	23	subsequent	subsequent	JJ
cord-005478-5iu38pr6	2959	24	CRE	cre	NN
cord-005478-5iu38pr6	2959	25	.	.	.
cord-005478-5iu38pr6	2960	1	At	at	IN
cord-005478-5iu38pr6	2960	2	+45	+45	NNP
cord-005478-5iu38pr6	2960	3	days	day	NNS
cord-005478-5iu38pr6	2960	4	,	,	,
cord-005478-5iu38pr6	2960	5	we	-PRON-	PRP
cord-005478-5iu38pr6	2960	6	observed	observe	VBD
cord-005478-5iu38pr6	2960	7	lower	low	JJR
cord-005478-5iu38pr6	2960	8	CMV	CMV	NNP
cord-005478-5iu38pr6	2960	9	-	-	HYPH
cord-005478-5iu38pr6	2960	10	specific	specific	JJ
cord-005478-5iu38pr6	2960	11	CD8	CD8	NNP
cord-005478-5iu38pr6	2960	12	+	+	CC
cord-005478-5iu38pr6	2960	13	T	t	NN
cord-005478-5iu38pr6	2960	14	cells	cell	NNS
cord-005478-5iu38pr6	2960	15	in	in	IN
cord-005478-5iu38pr6	2960	16	patients	patient	NNS
cord-005478-5iu38pr6	2960	17	prone	prone	JJ
cord-005478-5iu38pr6	2960	18	to	to	TO
cord-005478-5iu38pr6	2960	19	reactivate	reactivate	VB
cord-005478-5iu38pr6	2960	20	CMV	CMV	NNP
cord-005478-5iu38pr6	2960	21	than	than	IN
cord-005478-5iu38pr6	2960	22	in	in	IN
cord-005478-5iu38pr6	2960	23	not	not	RB
cord-005478-5iu38pr6	2960	24	reactivating	reactivate	VBG
cord-005478-5iu38pr6	2960	25	patients	patient	NNS
cord-005478-5iu38pr6	2960	26	(	(	-LRB-
cord-005478-5iu38pr6	2960	27	median	median	JJ
cord-005478-5iu38pr6	2960	28	CMV	CMV	NNP
cord-005478-5iu38pr6	2960	29	-	-	HYPH
cord-005478-5iu38pr6	2960	30	specific	specific	JJ
cord-005478-5iu38pr6	2960	31	CD8	CD8	NNP
cord-005478-5iu38pr6	2960	32	+	+	CC
cord-005478-5iu38pr6	2960	33	cells/	cells/	CD
cord-005478-5iu38pr6	2961	1	mL=	mL=	NNP
cord-005478-5iu38pr6	2961	2	0.125	0.125	CD
cord-005478-5iu38pr6	2961	3	vs	vs	IN
cord-005478-5iu38pr6	2961	4	1.69	1.69	CD
cord-005478-5iu38pr6	2961	5	,	,	,
cord-005478-5iu38pr6	2961	6	p=0.026	p=0.026	NNP
cord-005478-5iu38pr6	2961	7	)	)	-RRB-
cord-005478-5iu38pr6	2961	8	.	.	.
cord-005478-5iu38pr6	2962	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	2962	2	,	,	,
cord-005478-5iu38pr6	2962	3	patients	patient	NNS
cord-005478-5iu38pr6	2962	4	with	with	IN
cord-005478-5iu38pr6	2962	5	any	any	DT
cord-005478-5iu38pr6	2962	6	Dextramer	Dextramer	NNP
cord-005478-5iu38pr6	2962	7	positivity	positivity	NN
cord-005478-5iu38pr6	2962	8	at	at	IN
cord-005478-5iu38pr6	2962	9	+45	+45	NNP
cord-005478-5iu38pr6	2962	10	days	day	NNS
cord-005478-5iu38pr6	2962	11	displayed	display	VBD
cord-005478-5iu38pr6	2962	12	a	a	DT
cord-005478-5iu38pr6	2962	13	lower	low	JJR
cord-005478-5iu38pr6	2962	14	incidence	incidence	NN
cord-005478-5iu38pr6	2962	15	of	of	IN
cord-005478-5iu38pr6	2962	16	CRE	cre	NN
cord-005478-5iu38pr6	2962	17	compared	compare	VBN
cord-005478-5iu38pr6	2962	18	with	with	IN
cord-005478-5iu38pr6	2962	19	subjects	subject	NNS
cord-005478-5iu38pr6	2962	20	who	who	WP
cord-005478-5iu38pr6	2962	21	were	be	VBD
cord-005478-5iu38pr6	2962	22	negative	negative	JJ
cord-005478-5iu38pr6	2963	1	(	(	-LRB-
cord-005478-5iu38pr6	2963	2	CRE	CRE	NNP
cord-005478-5iu38pr6	2963	3	probability	probability	NN
cord-005478-5iu38pr6	2963	4	:	:	:
cord-005478-5iu38pr6	2963	5	0.55	0.55	CD
cord-005478-5iu38pr6	2963	6	vs	vs	IN
cord-005478-5iu38pr6	2963	7	0.83	0.83	CD
cord-005478-5iu38pr6	2963	8	,	,	,
cord-005478-5iu38pr6	2963	9	p=0.038	p=0.038	NNP
cord-005478-5iu38pr6	2963	10	)	)	-RRB-
cord-005478-5iu38pr6	2963	11	.	.	.
cord-005478-5iu38pr6	2964	1	Patient	patient	JJ
cord-005478-5iu38pr6	2964	2	stratification	stratification	NN
cord-005478-5iu38pr6	2964	3	based	base	VBN
cord-005478-5iu38pr6	2964	4	on	on	IN
cord-005478-5iu38pr6	2964	5	different	different	JJ
cord-005478-5iu38pr6	2964	6	thresholds	threshold	NNS
cord-005478-5iu38pr6	2964	7	of	of	IN
cord-005478-5iu38pr6	2964	8	Dextramerpositive	Dextramerpositive	NNP
cord-005478-5iu38pr6	2964	9	cells	cell	NNS
cord-005478-5iu38pr6	2964	10	confirms	confirm	VBZ
cord-005478-5iu38pr6	2964	11	the	the	DT
cord-005478-5iu38pr6	2964	12	inverse	inverse	NN
cord-005478-5iu38pr6	2964	13	association	association	NN
cord-005478-5iu38pr6	2964	14	between	between	IN
cord-005478-5iu38pr6	2964	15	CRE	CRE	NNP
cord-005478-5iu38pr6	2964	16	and	and	CC
cord-005478-5iu38pr6	2964	17	CMV	CMV	NNP
cord-005478-5iu38pr6	2964	18	-	-	HYPH
cord-005478-5iu38pr6	2964	19	specific	specific	JJ
cord-005478-5iu38pr6	2964	20	immunity	immunity	NN
cord-005478-5iu38pr6	2964	21	(	(	-LRB-
cord-005478-5iu38pr6	2964	22	CRE	cre	NN
cord-005478-5iu38pr6	2964	23	incidence	incidence	NN
cord-005478-5iu38pr6	2964	24	in	in	IN
cord-005478-5iu38pr6	2964	25	patients	patient	NNS
cord-005478-5iu38pr6	2964	26	with	with	IN
cord-005478-5iu38pr6	2964	27	:	:	:
cord-005478-5iu38pr6	2964	28	0	0	CD
cord-005478-5iu38pr6	2964	29	cells	cell	NNS
cord-005478-5iu38pr6	2964	30	/	/	SYM
cord-005478-5iu38pr6	2964	31	mL=0.83	ml=0.83	NN
cord-005478-5iu38pr6	2964	32	,	,	,
cord-005478-5iu38pr6	2964	33	<	<	NNP
cord-005478-5iu38pr6	2964	34	1	1	CD
cord-005478-5iu38pr6	2964	35	cells	cell	NNS
cord-005478-5iu38pr6	2964	36	/	/	SYM
cord-005478-5iu38pr6	2964	37	mL=	ml=	CD
cord-005478-5iu38pr6	2964	38	0.66	0.66	CD
cord-005478-5iu38pr6	2964	39	,	,	,
cord-005478-5iu38pr6	2964	40	≥	≥	CD
cord-005478-5iu38pr6	2964	41	1	1	CD
cord-005478-5iu38pr6	2964	42	cells	cell	NNS
cord-005478-5iu38pr6	2964	43	/	/	SYM
cord-005478-5iu38pr6	2964	44	mL=	ml=	CD
cord-005478-5iu38pr6	2964	45	0.36	0.36	CD
cord-005478-5iu38pr6	2964	46	;	;	:
cord-005478-5iu38pr6	2964	47	p=0.046	p=0.046	NNP
cord-005478-5iu38pr6	2964	48	)	)	-RRB-
cord-005478-5iu38pr6	2964	49	.	.	.
cord-005478-5iu38pr6	2965	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2965	2	observed	observe	VBD
cord-005478-5iu38pr6	2965	3	a	a	DT
cord-005478-5iu38pr6	2965	4	higher	high	JJR
cord-005478-5iu38pr6	2965	5	CRE	cre	NN
cord-005478-5iu38pr6	2965	6	incidence	incidence	NN
cord-005478-5iu38pr6	2965	7	in	in	IN
cord-005478-5iu38pr6	2965	8	CMV	CMV	NNP
cord-005478-5iu38pr6	2965	9	H	H	NNP
cord-005478-5iu38pr6	2965	10	+	+	CC
cord-005478-5iu38pr6	2965	11	/Dpairs	/dpair	NNS
cord-005478-5iu38pr6	2965	12	than	than	IN
cord-005478-5iu38pr6	2965	13	in	in	IN
cord-005478-5iu38pr6	2965	14	H	h	NN
cord-005478-5iu38pr6	2965	15	+	+	CC
cord-005478-5iu38pr6	2965	16	/D	/d	NN
cord-005478-5iu38pr6	2965	17	+	+	NN
cord-005478-5iu38pr6	2965	18	(	(	-LRB-
cord-005478-5iu38pr6	2965	19	0.89	0.89	CD
cord-005478-5iu38pr6	2965	20	vs	vs	IN
cord-005478-5iu38pr6	2965	21	0.44	0.44	CD
cord-005478-5iu38pr6	2965	22	,	,	,
cord-005478-5iu38pr6	2965	23	p=0.03	p=0.03	NNP
cord-005478-5iu38pr6	2965	24	)	)	-RRB-
cord-005478-5iu38pr6	2965	25	.	.	.
cord-005478-5iu38pr6	2966	1	Taking	take	VBG
cord-005478-5iu38pr6	2966	2	advantage	advantage	NN
cord-005478-5iu38pr6	2966	3	of	of	IN
cord-005478-5iu38pr6	2966	4	the	the	DT
cord-005478-5iu38pr6	2966	5	HLA	HLA	NNP
cord-005478-5iu38pr6	2966	6	mismatched	mismatch	VBN
cord-005478-5iu38pr6	2966	7	-	-	HYPH
cord-005478-5iu38pr6	2966	8	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2966	9	setting	setting	NN
cord-005478-5iu38pr6	2966	10	,	,	,
cord-005478-5iu38pr6	2966	11	we	-PRON-	PRP
cord-005478-5iu38pr6	2966	12	then	then	RB
cord-005478-5iu38pr6	2966	13	dissected	dissect	VBD
cord-005478-5iu38pr6	2966	14	CMV	CMV	NNP
cord-005478-5iu38pr6	2966	15	-	-	HYPH
cord-005478-5iu38pr6	2966	16	specific	specific	JJ
cord-005478-5iu38pr6	2966	17	T	t	NN
cord-005478-5iu38pr6	2966	18	-	-	HYPH
cord-005478-5iu38pr6	2966	19	cell	cell	NN
cord-005478-5iu38pr6	2966	20	response	response	NN
cord-005478-5iu38pr6	2966	21	according	accord	VBG
cord-005478-5iu38pr6	2966	22	to	to	IN
cord-005478-5iu38pr6	2966	23	HLA	HLA	NNP
cord-005478-5iu38pr6	2966	24	restriction	restriction	NN
cord-005478-5iu38pr6	2966	25	elements	element	NNS
cord-005478-5iu38pr6	2966	26	(	(	-LRB-
cord-005478-5iu38pr6	2966	27	H	h	NN
cord-005478-5iu38pr6	2966	28	/	/	SYM
cord-005478-5iu38pr6	2966	29	D	d	NN
cord-005478-5iu38pr6	2966	30	=	=	SYM
cord-005478-5iu38pr6	2966	31	shared	share	VBN
cord-005478-5iu38pr6	2966	32	n=40	n=40	NN
cord-005478-5iu38pr6	2966	33	,	,	,
cord-005478-5iu38pr6	2966	34	Drestricted	Drestricted	NNP
cord-005478-5iu38pr6	2966	35	n=12	n=12	NN
cord-005478-5iu38pr6	2966	36	,	,	,
cord-005478-5iu38pr6	2966	37	H	h	NN
cord-005478-5iu38pr6	2966	38	-	-	HYPH
cord-005478-5iu38pr6	2966	39	restricted	restrict	VBN
cord-005478-5iu38pr6	2966	40	n=19	n=19	NN
cord-005478-5iu38pr6	2966	41	)	)	-RRB-
cord-005478-5iu38pr6	2966	42	.	.	.
cord-005478-5iu38pr6	2967	1	In	in	IN
cord-005478-5iu38pr6	2967	2	H	h	NN
cord-005478-5iu38pr6	2967	3	+	+	CC
cord-005478-5iu38pr6	2967	4	/D	/d	NN
cord-005478-5iu38pr6	2967	5	+	+	CC
cord-005478-5iu38pr6	2967	6	pairs	pair	NNS
cord-005478-5iu38pr6	2967	7	,	,	,
cord-005478-5iu38pr6	2967	8	we	-PRON-	PRP
cord-005478-5iu38pr6	2967	9	observed	observe	VBD
cord-005478-5iu38pr6	2967	10	a	a	DT
cord-005478-5iu38pr6	2967	11	fast	fast	JJ
cord-005478-5iu38pr6	2967	12	and	and	CC
cord-005478-5iu38pr6	2967	13	similar	similar	JJ
cord-005478-5iu38pr6	2967	14	kinetic	kinetic	NN
cord-005478-5iu38pr6	2967	15	of	of	IN
cord-005478-5iu38pr6	2967	16	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2967	17	of	of	IN
cord-005478-5iu38pr6	2967	18	CMV	CMV	NNP
cord-005478-5iu38pr6	2967	19	-	-	HYPH
cord-005478-5iu38pr6	2967	20	specific	specific	JJ
cord-005478-5iu38pr6	2967	21	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2967	22	restricted	restrict	VBN
cord-005478-5iu38pr6	2967	23	by	by	IN
cord-005478-5iu38pr6	2967	24	H	H	NNP
cord-005478-5iu38pr6	2967	25	/	/	SYM
cord-005478-5iu38pr6	2967	26	D	D	NNP
cord-005478-5iu38pr6	2967	27	and	and	CC
cord-005478-5iu38pr6	2967	28	D	D	NNP
cord-005478-5iu38pr6	2967	29	HLAs	HLAs	NNP
cord-005478-5iu38pr6	2967	30	.	.	.
cord-005478-5iu38pr6	2968	1	Conversely	conversely	RB
cord-005478-5iu38pr6	2968	2	,	,	,
cord-005478-5iu38pr6	2968	3	in	in	IN
cord-005478-5iu38pr6	2968	4	H	h	NN
cord-005478-5iu38pr6	2968	5	+	+	CC
cord-005478-5iu38pr6	2968	6	/Dpairs	/dpair	NNS
cord-005478-5iu38pr6	2968	7	,	,	,
cord-005478-5iu38pr6	2968	8	we	-PRON-	PRP
cord-005478-5iu38pr6	2968	9	detected	detect	VBD
cord-005478-5iu38pr6	2968	10	only	only	RB
cord-005478-5iu38pr6	2968	11	CMV	CMV	NNP
cord-005478-5iu38pr6	2968	12	-	-	HYPH
cord-005478-5iu38pr6	2968	13	specific	specific	JJ
cord-005478-5iu38pr6	2968	14	CD8	CD8	NNP
cord-005478-5iu38pr6	2968	15	+	+	SYM
cord-005478-5iu38pr6	2968	16	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2968	17	restricted	restrict	VBN
cord-005478-5iu38pr6	2968	18	for	for	IN
cord-005478-5iu38pr6	2968	19	H	h	NN
cord-005478-5iu38pr6	2968	20	/	/	SYM
cord-005478-5iu38pr6	2968	21	D	D	NNP
cord-005478-5iu38pr6	2968	22	haplotypes	haplotype	NNS
cord-005478-5iu38pr6	2968	23	.	.	.
cord-005478-5iu38pr6	2969	1	Hostrestricted	hostrestricte	VBN
cord-005478-5iu38pr6	2969	2	cells	cell	NNS
cord-005478-5iu38pr6	2969	3	remained	remain	VBD
cord-005478-5iu38pr6	2969	4	undetectable	undetectable	JJ
cord-005478-5iu38pr6	2969	5	for	for	IN
cord-005478-5iu38pr6	2969	6	the	the	DT
cord-005478-5iu38pr6	2969	7	first	first	JJ
cord-005478-5iu38pr6	2969	8	150	150	CD
cord-005478-5iu38pr6	2969	9	days	day	NNS
cord-005478-5iu38pr6	2969	10	after	after	IN
cord-005478-5iu38pr6	2969	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2969	12	.	.	.
cord-005478-5iu38pr6	2970	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	2970	2	:	:	:
cord-005478-5iu38pr6	2971	1	When	when	WRB
cord-005478-5iu38pr6	2971	2	the	the	DT
cord-005478-5iu38pr6	2971	3	donor	donor	NN
cord-005478-5iu38pr6	2971	4	is	be	VBZ
cord-005478-5iu38pr6	2971	5	CMV	CMV	NNP
cord-005478-5iu38pr6	2971	6	seropositive	seropositive	JJ
cord-005478-5iu38pr6	2971	7	,	,	,
cord-005478-5iu38pr6	2971	8	a	a	DT
cord-005478-5iu38pr6	2971	9	rapid	rapid	JJ
cord-005478-5iu38pr6	2971	10	and	and	CC
cord-005478-5iu38pr6	2971	11	effective	effective	JJ
cord-005478-5iu38pr6	2971	12	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	2971	13	of	of	IN
cord-005478-5iu38pr6	2971	14	CMV	CMV	NNP
cord-005478-5iu38pr6	2971	15	-	-	HYPH
cord-005478-5iu38pr6	2971	16	specific	specific	JJ
cord-005478-5iu38pr6	2971	17	D	d	NN
cord-005478-5iu38pr6	2971	18	-	-	:
cord-005478-5iu38pr6	2971	19	and	and	CC
cord-005478-5iu38pr6	2971	20	H	H	NNP
cord-005478-5iu38pr6	2971	21	/	/	SYM
cord-005478-5iu38pr6	2971	22	D	d	NN
cord-005478-5iu38pr6	2971	23	-	-	HYPH
cord-005478-5iu38pr6	2971	24	restricted	restricted	JJ
cord-005478-5iu38pr6	2971	25	memory	memory	NN
cord-005478-5iu38pr6	2971	26	T	t	NN
cord-005478-5iu38pr6	2971	27	cells	cell	NNS
cord-005478-5iu38pr6	2971	28	occurs	occur	VBZ
cord-005478-5iu38pr6	2971	29	.	.	.
cord-005478-5iu38pr6	2972	1	If	if	IN
cord-005478-5iu38pr6	2972	2	the	the	DT
cord-005478-5iu38pr6	2972	3	donor	donor	NN
cord-005478-5iu38pr6	2972	4	is	be	VBZ
cord-005478-5iu38pr6	2972	5	CMV	CMV	NNP
cord-005478-5iu38pr6	2972	6	seronegative	seronegative	JJ
cord-005478-5iu38pr6	2972	7	,	,	,
cord-005478-5iu38pr6	2972	8	only	only	RB
cord-005478-5iu38pr6	2972	9	H	h	NN
cord-005478-5iu38pr6	2972	10	/	/	SYM
cord-005478-5iu38pr6	2972	11	D	d	NN
cord-005478-5iu38pr6	2972	12	-	-	HYPH
cord-005478-5iu38pr6	2972	13	restricted	restrict	VBN
cord-005478-5iu38pr6	2972	14	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2972	15	are	be	VBP
cord-005478-5iu38pr6	2972	16	observed	observe	VBN
cord-005478-5iu38pr6	2972	17	early	early	RB
cord-005478-5iu38pr6	2972	18	after	after	IN
cord-005478-5iu38pr6	2972	19	allo	allo	NN
cord-005478-5iu38pr6	2972	20	-	-	HYPH
cord-005478-5iu38pr6	2972	21	HSCT	HSCT	NNP
cord-005478-5iu38pr6	2972	22	in	in	IN
cord-005478-5iu38pr6	2972	23	H	H	NNP
cord-005478-5iu38pr6	2972	24	+	+	CC
cord-005478-5iu38pr6	2972	25	/Dpairs	/dpair	NNS
cord-005478-5iu38pr6	2972	26	.	.	.
cord-005478-5iu38pr6	2973	1	These	these	DT
cord-005478-5iu38pr6	2973	2	findings	finding	NNS
cord-005478-5iu38pr6	2973	3	indicate	indicate	VBP
cord-005478-5iu38pr6	2973	4	that	that	IN
cord-005478-5iu38pr6	2973	5	CMV	CMV	NNP
cord-005478-5iu38pr6	2973	6	reactivation	reactivation	NN
cord-005478-5iu38pr6	2973	7	can	can	MD
cord-005478-5iu38pr6	2973	8	prime	prime	JJ
cord-005478-5iu38pr6	2973	9	H	H	NNP
cord-005478-5iu38pr6	2973	10	/	/	SYM
cord-005478-5iu38pr6	2973	11	D	d	NN
cord-005478-5iu38pr6	2973	12	-	-	HYPH
cord-005478-5iu38pr6	2973	13	restricted	restrict	VBN
cord-005478-5iu38pr6	2973	14	T	t	NN
cord-005478-5iu38pr6	2973	15	cells	cell	NNS
cord-005478-5iu38pr6	2973	16	presumably	presumably	RB
cord-005478-5iu38pr6	2973	17	educated	educate	VBN
cord-005478-5iu38pr6	2973	18	in	in	IN
cord-005478-5iu38pr6	2973	19	the	the	DT
cord-005478-5iu38pr6	2973	20	donor	donor	NN
cord-005478-5iu38pr6	2973	21	thymus	thymus	NN
cord-005478-5iu38pr6	2973	22	;	;	:
cord-005478-5iu38pr6	2973	23	conversely	conversely	RB
cord-005478-5iu38pr6	2973	24	,	,	,
cord-005478-5iu38pr6	2973	25	D	D	NNP
cord-005478-5iu38pr6	2973	26	-	-	:
cord-005478-5iu38pr6	2973	27	and	and	CC
cord-005478-5iu38pr6	2973	28	H	h	NN
cord-005478-5iu38pr6	2973	29	-	-	HYPH
cord-005478-5iu38pr6	2973	30	restricted	restrict	VBN
cord-005478-5iu38pr6	2973	31	donor	donor	NN
cord-005478-5iu38pr6	2973	32	-	-	HYPH
cord-005478-5iu38pr6	2973	33	derived	derive	VBN
cord-005478-5iu38pr6	2973	34	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	2973	35	have	have	VBP
cord-005478-5iu38pr6	2973	36	not	not	RB
cord-005478-5iu38pr6	2973	37	yet	yet	RB
cord-005478-5iu38pr6	2973	38	undergone	undergo	VBN
cord-005478-5iu38pr6	2973	39	neither	neither	CC
cord-005478-5iu38pr6	2973	40	cross	cross	NN
cord-005478-5iu38pr6	2973	41	-	-	JJ
cord-005478-5iu38pr6	2973	42	priming	priming	JJ
cord-005478-5iu38pr6	2973	43	nor	nor	CC
cord-005478-5iu38pr6	2973	44	thymic	thymic	JJ
cord-005478-5iu38pr6	2973	45	education	education	NN
cord-005478-5iu38pr6	2973	46	,	,	,
cord-005478-5iu38pr6	2973	47	which	which	WDT
cord-005478-5iu38pr6	2973	48	might	may	MD
cord-005478-5iu38pr6	2973	49	be	be	VB
cord-005478-5iu38pr6	2973	50	required	require	VBN
cord-005478-5iu38pr6	2973	51	for	for	IN
cord-005478-5iu38pr6	2973	52	full	full	JJ
cord-005478-5iu38pr6	2973	53	protection	protection	NN
cord-005478-5iu38pr6	2973	54	from	from	IN
cord-005478-5iu38pr6	2973	55	CMV	CMV	NNP
cord-005478-5iu38pr6	2973	56	.	.	.
cord-005478-5iu38pr6	2974	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	2974	2	:	:	:
cord-005478-5iu38pr6	2975	1	C.B.	C.B.	NNP
cord-005478-5iu38pr6	2975	2	received	receive	VBD
cord-005478-5iu38pr6	2975	3	research	research	NN
cord-005478-5iu38pr6	2975	4	support	support	NN
cord-005478-5iu38pr6	2975	5	from	from	IN
cord-005478-5iu38pr6	2975	6	Molmed	Molmed	NNP
cord-005478-5iu38pr6	2975	7	s.p.a	s.p.a	NN
cord-005478-5iu38pr6	2975	8	.	.	.
cord-005478-5iu38pr6	2975	9	and	and	CC
cord-005478-5iu38pr6	2975	10	Intellia	Intellia	NNP
cord-005478-5iu38pr6	2975	11	Therapeutics	Therapeutics	NNP
cord-005478-5iu38pr6	2975	12	.	.	.
cord-005478-5iu38pr6	2976	1	L.B.	L.B.	NNP
cord-005478-5iu38pr6	2976	2	is	be	VBZ
cord-005478-5iu38pr6	2976	3	employed	employ	VBN
cord-005478-5iu38pr6	2976	4	by	by	IN
cord-005478-5iu38pr6	2976	5	Immudex	Immudex	NNP
cord-005478-5iu38pr6	2976	6	ApS.	ApS.	NNP
cord-005478-5iu38pr6	2976	7	Non	Non	NNP
cord-005478-5iu38pr6	2976	8	of	of	IN
cord-005478-5iu38pr6	2976	9	the	the	DT
cord-005478-5iu38pr6	2976	10	other	other	JJ
cord-005478-5iu38pr6	2976	11	authors	author	NNS
cord-005478-5iu38pr6	2976	12	has	have	VBZ
cord-005478-5iu38pr6	2976	13	any	any	DT
cord-005478-5iu38pr6	2976	14	relevant	relevant	JJ
cord-005478-5iu38pr6	2976	15	conflict	conflict	NN
cord-005478-5iu38pr6	2976	16	of	of	IN
cord-005478-5iu38pr6	2976	17	interest	interest	NN
cord-005478-5iu38pr6	2976	18	to	to	TO
cord-005478-5iu38pr6	2976	19	disclose	disclose	VB
cord-005478-5iu38pr6	2976	20	.	.	.
cord-005478-5iu38pr6	2977	1	O148	O148	NNS
cord-005478-5iu38pr6	2977	2	5-Azactidine	5-azactidine	CD
cord-005478-5iu38pr6	2977	3	is	be	VBZ
cord-005478-5iu38pr6	2977	4	safe	safe	JJ
cord-005478-5iu38pr6	2977	5	and	and	CC
cord-005478-5iu38pr6	2977	6	effective	effective	JJ
cord-005478-5iu38pr6	2977	7	therapy	therapy	NN
cord-005478-5iu38pr6	2977	8	for	for	IN
cord-005478-5iu38pr6	2977	9	prevention	prevention	NN
cord-005478-5iu38pr6	2977	10	of	of	IN
cord-005478-5iu38pr6	2977	11	disease	disease	NN
cord-005478-5iu38pr6	2977	12	relapse	relapse	NN
cord-005478-5iu38pr6	2977	13	in	in	IN
cord-005478-5iu38pr6	2977	14	high	high	JJ
cord-005478-5iu38pr6	2977	15	-	-	HYPH
cord-005478-5iu38pr6	2977	16	risk	risk	NN
cord-005478-5iu38pr6	2977	17	patients	patient	NNS
cord-005478-5iu38pr6	2977	18	with	with	IN
cord-005478-5iu38pr6	2977	19	acute	acute	JJ
cord-005478-5iu38pr6	2977	20	myeloid	myeloid	JJ
cord-005478-5iu38pr6	2977	21	leukemia	leukemia	NN
cord-005478-5iu38pr6	2977	22	and	and	CC
cord-005478-5iu38pr6	2977	23	myelodysplastic	myelodysplastic	JJ
cord-005478-5iu38pr6	2977	24	syndrome	syndrome	NN
cord-005478-5iu38pr6	2977	25	following	follow	VBG
cord-005478-5iu38pr6	2977	26	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	2977	27	stem	stem	NN
cord-005478-5iu38pr6	2977	28	-	-	HYPH
cord-005478-5iu38pr6	2977	29	cell	cell	NN
cord-005478-5iu38pr6	2977	30	transplantation	transplantation	NN
cord-005478-5iu38pr6	2977	31	Ivetta	Ivetta	NNP
cord-005478-5iu38pr6	2977	32	Danylesko	Danylesko	NNP
cord-005478-5iu38pr6	2977	33	1	1	CD
cord-005478-5iu38pr6	2978	1	,	,	,
cord-005478-5iu38pr6	2978	2	Noga	Noga	NNP
cord-005478-5iu38pr6	2978	3	Shem	Shem	NNP
cord-005478-5iu38pr6	2978	4	-	-	HYPH
cord-005478-5iu38pr6	2978	5	Tov	Tov	NNP
cord-005478-5iu38pr6	2978	6	1	1	CD
cord-005478-5iu38pr6	2978	7	,	,	,
cord-005478-5iu38pr6	2978	8	Adriana	Adriana	NNP
cord-005478-5iu38pr6	2978	9	Del	Del	NNP
cord-005478-5iu38pr6	2978	10	-	-	HYPH
cord-005478-5iu38pr6	2978	11	Giglio	Giglio	NNP
cord-005478-5iu38pr6	2978	12	1	1	CD
cord-005478-5iu38pr6	2978	13	,	,	,
cord-005478-5iu38pr6	2978	14	Ronit	Ronit	NNP
cord-005478-5iu38pr6	2978	15	Yerushalmi	Yerushalmi	NNP
cord-005478-5iu38pr6	2978	16	1	1	CD
cord-005478-5iu38pr6	2978	17	,	,	,
cord-005478-5iu38pr6	2978	18	Arnon	Arnon	NNP
cord-005478-5iu38pr6	2978	19	Nagler	Nagler	NNP
cord-005478-5iu38pr6	2978	20	1	1	CD
cord-005478-5iu38pr6	2978	21	,	,	,
cord-005478-5iu38pr6	2978	22	Avichai	Avichai	NNP
cord-005478-5iu38pr6	2978	23	Shimoni	Shimoni	NNP
cord-005478-5iu38pr6	2978	24	1	1	CD
cord-005478-5iu38pr6	2978	25	Background	Background	NNP
cord-005478-5iu38pr6	2978	26	:	:	:
cord-005478-5iu38pr6	2978	27	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	2978	28	stem	stem	NN
cord-005478-5iu38pr6	2978	29	-	-	HYPH
cord-005478-5iu38pr6	2978	30	cell	cell	NN
cord-005478-5iu38pr6	2978	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	2978	32	(	(	-LRB-
cord-005478-5iu38pr6	2978	33	SCT	SCT	NNP
cord-005478-5iu38pr6	2978	34	)	)	-RRB-
cord-005478-5iu38pr6	2978	35	is	be	VBZ
cord-005478-5iu38pr6	2978	36	curative	curative	JJ
cord-005478-5iu38pr6	2978	37	approach	approach	NN
cord-005478-5iu38pr6	2978	38	in	in	IN
cord-005478-5iu38pr6	2978	39	patients	patient	NNS
cord-005478-5iu38pr6	2978	40	with	with	IN
cord-005478-5iu38pr6	2978	41	AML	AML	NNP
cord-005478-5iu38pr6	2978	42	or	or	CC
cord-005478-5iu38pr6	2978	43	MDS	MDS	NNP
cord-005478-5iu38pr6	2978	44	.	.	.
cord-005478-5iu38pr6	2979	1	However	however	RB
cord-005478-5iu38pr6	2979	2	,	,	,
cord-005478-5iu38pr6	2979	3	disease	disease	NN
cord-005478-5iu38pr6	2979	4	recurrence	recurrence	NN
cord-005478-5iu38pr6	2979	5	is	be	VBZ
cord-005478-5iu38pr6	2979	6	the	the	DT
cord-005478-5iu38pr6	2979	7	major	major	JJ
cord-005478-5iu38pr6	2979	8	cause	cause	NN
cord-005478-5iu38pr6	2979	9	of	of	IN
cord-005478-5iu38pr6	2979	10	treatment	treatment	NN
cord-005478-5iu38pr6	2979	11	failure	failure	NN
cord-005478-5iu38pr6	2979	12	.	.	.
cord-005478-5iu38pr6	2980	1	5azacitidine	5azacitidine	CD
cord-005478-5iu38pr6	2980	2	has	have	VBZ
cord-005478-5iu38pr6	2980	3	been	be	VBN
cord-005478-5iu38pr6	2980	4	used	use	VBN
cord-005478-5iu38pr6	2980	5	in	in	IN
cord-005478-5iu38pr6	2980	6	standard	standard	JJ
cord-005478-5iu38pr6	2980	7	treatment	treatment	NN
cord-005478-5iu38pr6	2980	8	of	of	IN
cord-005478-5iu38pr6	2980	9	MDS	MDS	NNP
cord-005478-5iu38pr6	2980	10	and	and	CC
cord-005478-5iu38pr6	2980	11	also	also	RB
cord-005478-5iu38pr6	2980	12	in	in	IN
cord-005478-5iu38pr6	2980	13	AML	AML	NNP
cord-005478-5iu38pr6	2980	14	patients	patient	NNS
cord-005478-5iu38pr6	2980	15	not	not	RB
cord-005478-5iu38pr6	2980	16	eligible	eligible	JJ
cord-005478-5iu38pr6	2980	17	for	for	IN
cord-005478-5iu38pr6	2980	18	standard	standard	JJ
cord-005478-5iu38pr6	2980	19	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2980	20	.	.	.
cord-005478-5iu38pr6	2981	1	There	there	EX
cord-005478-5iu38pr6	2981	2	is	be	VBZ
cord-005478-5iu38pr6	2981	3	limited	limited	JJ
cord-005478-5iu38pr6	2981	4	data	datum	NNS
cord-005478-5iu38pr6	2981	5	on	on	IN
cord-005478-5iu38pr6	2981	6	the	the	DT
cord-005478-5iu38pr6	2981	7	safety	safety	NN
cord-005478-5iu38pr6	2981	8	and	and	CC
cord-005478-5iu38pr6	2981	9	efficacy	efficacy	NN
cord-005478-5iu38pr6	2981	10	of	of	IN
cord-005478-5iu38pr6	2981	11	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2981	12	after	after	IN
cord-005478-5iu38pr6	2981	13	SCT	SCT	NNP
cord-005478-5iu38pr6	2981	14	.	.	.
cord-005478-5iu38pr6	2982	1	We	-PRON-	PRP
cord-005478-5iu38pr6	2982	2	explored	explore	VBD
cord-005478-5iu38pr6	2982	3	the	the	DT
cord-005478-5iu38pr6	2982	4	use	use	NN
cord-005478-5iu38pr6	2982	5	of	of	IN
cord-005478-5iu38pr6	2982	6	low	low	JJ
cord-005478-5iu38pr6	2982	7	-	-	HYPH
cord-005478-5iu38pr6	2982	8	dose	dose	NN
cord-005478-5iu38pr6	2982	9	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	2982	10	for	for	IN
cord-005478-5iu38pr6	2982	11	prevention	prevention	NN
cord-005478-5iu38pr6	2982	12	and	and	CC
cord-005478-5iu38pr6	2982	13	treatment	treatment	NN
cord-005478-5iu38pr6	2982	14	of	of	IN
cord-005478-5iu38pr6	2982	15	relapse	relapse	NN
cord-005478-5iu38pr6	2982	16	of	of	IN
cord-005478-5iu38pr6	2982	17	AML/	AML/	NNP
cord-005478-5iu38pr6	2982	18	MDS	MDS	NNP
cord-005478-5iu38pr6	2982	19	after	after	IN
cord-005478-5iu38pr6	2982	20	SCT	SCT	NNP
cord-005478-5iu38pr6	2982	21	.	.	.
cord-005478-5iu38pr6	2983	1	Methods	method	NNS
cord-005478-5iu38pr6	2983	2	:	:	:
cord-005478-5iu38pr6	2983	3	Patients	patient	NNS
cord-005478-5iu38pr6	2983	4	in	in	IN
cord-005478-5iu38pr6	2983	5	CR	CR	NNP
cord-005478-5iu38pr6	2983	6	after	after	IN
cord-005478-5iu38pr6	2983	7	SCT	SCT	NNP
cord-005478-5iu38pr6	2983	8	who	who	WP
cord-005478-5iu38pr6	2983	9	were	be	VBD
cord-005478-5iu38pr6	2983	10	considered	consider	VBN
cord-005478-5iu38pr6	2983	11	to	to	TO
cord-005478-5iu38pr6	2983	12	be	be	VB
cord-005478-5iu38pr6	2983	13	at	at	IN
cord-005478-5iu38pr6	2983	14	high	high	JJ
cord-005478-5iu38pr6	2983	15	-	-	HYPH
cord-005478-5iu38pr6	2983	16	risk	risk	NN
cord-005478-5iu38pr6	2983	17	for	for	IN
cord-005478-5iu38pr6	2983	18	relapse	relapse	NN
cord-005478-5iu38pr6	2983	19	were	be	VBD
cord-005478-5iu38pr6	2983	20	given	give	VBN
cord-005478-5iu38pr6	2983	21	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2983	22	at	at	IN
cord-005478-5iu38pr6	2983	23	32mg	32mg	NNP
cord-005478-5iu38pr6	2983	24	/	/	SYM
cord-005478-5iu38pr6	2983	25	m	m	NNP
cord-005478-5iu38pr6	2983	26	2	2	CD
cord-005478-5iu38pr6	2983	27	for	for	IN
cord-005478-5iu38pr6	2983	28	5	5	CD
cord-005478-5iu38pr6	2983	29	days	day	NNS
cord-005478-5iu38pr6	2983	30	every	every	DT
cord-005478-5iu38pr6	2983	31	28	28	CD
cord-005478-5iu38pr6	2983	32	days	day	NNS
cord-005478-5iu38pr6	2983	33	,	,	,
cord-005478-5iu38pr6	2983	34	planned	plan	VBN
cord-005478-5iu38pr6	2983	35	for	for	IN
cord-005478-5iu38pr6	2983	36	2	2	CD
cord-005478-5iu38pr6	2983	37	years	year	NNS
cord-005478-5iu38pr6	2983	38	.	.	.
cord-005478-5iu38pr6	2984	1	Patients	patient	NNS
cord-005478-5iu38pr6	2984	2	with	with	IN
cord-005478-5iu38pr6	2984	3	overt	overt	JJ
cord-005478-5iu38pr6	2984	4	relapse	relapse	NN
cord-005478-5iu38pr6	2984	5	after	after	IN
cord-005478-5iu38pr6	2984	6	SCT	SCT	NNP
cord-005478-5iu38pr6	2984	7	were	be	VBD
cord-005478-5iu38pr6	2984	8	given	give	VBN
cord-005478-5iu38pr6	2984	9	32	32	CD
cord-005478-5iu38pr6	2984	10	-	-	SYM
cord-005478-5iu38pr6	2984	11	75	75	CD
cord-005478-5iu38pr6	2984	12	mg/	mg/	NN
cord-005478-5iu38pr6	2984	13	m	m	NN
cord-005478-5iu38pr6	2984	14	2	2	CD
cord-005478-5iu38pr6	2984	15	for	for	IN
cord-005478-5iu38pr6	2984	16	5	5	CD
cord-005478-5iu38pr6	2984	17	days	day	NNS
cord-005478-5iu38pr6	2984	18	until	until	IN
cord-005478-5iu38pr6	2984	19	progression	progression	NN
cord-005478-5iu38pr6	2984	20	.	.	.
cord-005478-5iu38pr6	2985	1	Results	result	NNS
cord-005478-5iu38pr6	2985	2	:	:	:
cord-005478-5iu38pr6	2986	1	Ninety	ninety	CD
cord-005478-5iu38pr6	2986	2	-	-	HYPH
cord-005478-5iu38pr6	2986	3	four	four	CD
cord-005478-5iu38pr6	2986	4	patients	patient	NNS
cord-005478-5iu38pr6	2986	5	,	,	,
cord-005478-5iu38pr6	2986	6	median	median	JJ
cord-005478-5iu38pr6	2986	7	age	age	NN
cord-005478-5iu38pr6	2986	8	64	64	CD
cord-005478-5iu38pr6	2986	9	years	year	NNS
cord-005478-5iu38pr6	2986	10	(	(	-LRB-
cord-005478-5iu38pr6	2986	11	24	24	CD
cord-005478-5iu38pr6	2986	12	-	-	SYM
cord-005478-5iu38pr6	2986	13	77	77	CD
cord-005478-5iu38pr6	2986	14	)	)	-RRB-
cord-005478-5iu38pr6	2986	15	were	be	VBD
cord-005478-5iu38pr6	2986	16	given	give	VBN
cord-005478-5iu38pr6	2986	17	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	2986	18	after	after	IN
cord-005478-5iu38pr6	2986	19	SCT	SCT	NNP
cord-005478-5iu38pr6	2986	20	from	from	IN
cord-005478-5iu38pr6	2986	21	HLA	HLA	NNP
cord-005478-5iu38pr6	2986	22	-	-	HYPH
cord-005478-5iu38pr6	2986	23	matched	match	VBN
cord-005478-5iu38pr6	2986	24	sibling	sibling	NN
cord-005478-5iu38pr6	2986	25	(	(	-LRB-
cord-005478-5iu38pr6	2986	26	n=29	n=29	NNP
cord-005478-5iu38pr6	2986	27	)	)	-RRB-
cord-005478-5iu38pr6	2986	28	,	,	,
cord-005478-5iu38pr6	2986	29	matched	match	VBN
cord-005478-5iu38pr6	2986	30	-	-	HYPH
cord-005478-5iu38pr6	2986	31	unrelated	unrelated	JJ
cord-005478-5iu38pr6	2986	32	(	(	-LRB-
cord-005478-5iu38pr6	2986	33	n=64	n=64	NNP
cord-005478-5iu38pr6	2986	34	)	)	-RRB-
cord-005478-5iu38pr6	2986	35	or	or	CC
cord-005478-5iu38pr6	2986	36	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	2986	37	(	(	-LRB-
cord-005478-5iu38pr6	2986	38	n=1	n=1	NNS
cord-005478-5iu38pr6	2986	39	)	)	-RRB-
cord-005478-5iu38pr6	2986	40	donors	donor	NNS
cord-005478-5iu38pr6	2986	41	.	.	.
cord-005478-5iu38pr6	2987	1	Diagnosis	diagnosis	NN
cord-005478-5iu38pr6	2987	2	was	be	VBD
cord-005478-5iu38pr6	2987	3	AML	AML	NNP
cord-005478-5iu38pr6	2987	4	(	(	-LRB-
cord-005478-5iu38pr6	2987	5	n=66	n=66	NN
cord-005478-5iu38pr6	2987	6	)	)	-RRB-
cord-005478-5iu38pr6	2987	7	or	or	CC
cord-005478-5iu38pr6	2987	8	MDS	MDS	NNP
cord-005478-5iu38pr6	2987	9	(	(	-LRB-
cord-005478-5iu38pr6	2987	10	n=28	n=28	NN
cord-005478-5iu38pr6	2987	11	)	)	-RRB-
cord-005478-5iu38pr6	2987	12	.	.	.
cord-005478-5iu38pr6	2988	1	The	the	DT
cord-005478-5iu38pr6	2988	2	conditioning	conditioning	NN
cord-005478-5iu38pr6	2988	3	regimen	regimen	NN
cord-005478-5iu38pr6	2988	4	was	be	VBD
cord-005478-5iu38pr6	2988	5	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	2988	6	(	(	-LRB-
cord-005478-5iu38pr6	2988	7	n=56	n=56	NNP
cord-005478-5iu38pr6	2988	8	)	)	-RRB-
cord-005478-5iu38pr6	2988	9	or	or	CC
cord-005478-5iu38pr6	2988	10	reduced	reduce	VBN
cord-005478-5iu38pr6	2988	11	-	-	HYPH
cord-005478-5iu38pr6	2988	12	intensity	intensity	NN
cord-005478-5iu38pr6	2988	13	(	(	-LRB-
cord-005478-5iu38pr6	2988	14	n=38	n=38	NNP
cord-005478-5iu38pr6	2988	15	)	)	-RRB-
cord-005478-5iu38pr6	2988	16	.	.	.
cord-005478-5iu38pr6	2989	1	22	22	CD
cord-005478-5iu38pr6	2989	2	patients	patient	NNS
cord-005478-5iu38pr6	2989	3	were	be	VBD
cord-005478-5iu38pr6	2989	4	given	give	VBN
cord-005478-5iu38pr6	2989	5	prophylactic	prophylactic	JJ
cord-005478-5iu38pr6	2989	6	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	2989	7	;	;	:
cord-005478-5iu38pr6	2989	8	15	15	CD
cord-005478-5iu38pr6	2989	9	were	be	VBD
cord-005478-5iu38pr6	2989	10	in	in	IN
cord-005478-5iu38pr6	2989	11	CR	CR	NNP
cord-005478-5iu38pr6	2989	12	after	after	IN
cord-005478-5iu38pr6	2989	13	SCT	SCT	NNP
cord-005478-5iu38pr6	2989	14	but	but	CC
cord-005478-5iu38pr6	2989	15	at	at	IN
cord-005478-5iu38pr6	2989	16	high	high	JJ
cord-005478-5iu38pr6	2989	17	-	-	HYPH
cord-005478-5iu38pr6	2989	18	risk	risk	NN
cord-005478-5iu38pr6	2989	19	for	for	IN
cord-005478-5iu38pr6	2989	20	relapse	relapse	NN
cord-005478-5iu38pr6	2989	21	due	due	IN
cord-005478-5iu38pr6	2989	22	to	to	IN
cord-005478-5iu38pr6	2989	23	active	active	JJ
cord-005478-5iu38pr6	2989	24	disease	disease	NN
cord-005478-5iu38pr6	2989	25	(	(	-LRB-
cord-005478-5iu38pr6	2989	26	n=7	n=7	NNS
cord-005478-5iu38pr6	2989	27	)	)	-RRB-
cord-005478-5iu38pr6	2989	28	or	or	CC
cord-005478-5iu38pr6	2989	29	positive	positive	JJ
cord-005478-5iu38pr6	2989	30	minimal	minimal	JJ
cord-005478-5iu38pr6	2989	31	-	-	HYPH
cord-005478-5iu38pr6	2989	32	residual	residual	JJ
cord-005478-5iu38pr6	2989	33	disease	disease	NN
cord-005478-5iu38pr6	2989	34	(	(	-LRB-
cord-005478-5iu38pr6	2989	35	MRD	MRD	NNP
cord-005478-5iu38pr6	2989	36	)	)	-RRB-
cord-005478-5iu38pr6	2990	1	(	(	-LRB-
cord-005478-5iu38pr6	2990	2	n=3	n=3	NN
cord-005478-5iu38pr6	2990	3	)	)	-RRB-
cord-005478-5iu38pr6	2990	4	prior	prior	RB
cord-005478-5iu38pr6	2990	5	to	to	IN
cord-005478-5iu38pr6	2990	6	SCT	SCT	NNP
cord-005478-5iu38pr6	2990	7	,	,	,
cord-005478-5iu38pr6	2990	8	or	or	CC
cord-005478-5iu38pr6	2990	9	poor	poor	JJ
cord-005478-5iu38pr6	2990	10	-	-	HYPH
cord-005478-5iu38pr6	2990	11	risk	risk	NN
cord-005478-5iu38pr6	2990	12	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	2990	13	(	(	-LRB-
cord-005478-5iu38pr6	2990	14	n=5	n=5	NNP
cord-005478-5iu38pr6	2990	15	)	)	-RRB-
cord-005478-5iu38pr6	2990	16	.	.	.
cord-005478-5iu38pr6	2991	1	Seven	seven	CD
cord-005478-5iu38pr6	2991	2	patients	patient	NNS
cord-005478-5iu38pr6	2991	3	were	be	VBD
cord-005478-5iu38pr6	2991	4	given	give	VBN
cord-005478-5iu38pr6	2991	5	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2991	6	as	as	IN
cord-005478-5iu38pr6	2991	7	secondary	secondary	JJ
cord-005478-5iu38pr6	2991	8	prevention	prevention	NN
cord-005478-5iu38pr6	2991	9	after	after	IN
cord-005478-5iu38pr6	2991	10	achieving	achieve	VBG
cord-005478-5iu38pr6	2991	11	CR	CR	NNP
cord-005478-5iu38pr6	2991	12	with	with	IN
cord-005478-5iu38pr6	2991	13	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	2991	14	for	for	IN
cord-005478-5iu38pr6	2991	15	post	post	JJ
cord-005478-5iu38pr6	2991	16	-	-	JJ
cord-005478-5iu38pr6	2991	17	transplant	transplant	JJ
cord-005478-5iu38pr6	2991	18	relapse	relapse	NN
cord-005478-5iu38pr6	2991	19	.	.	.
cord-005478-5iu38pr6	2992	1	19	19	CD
cord-005478-5iu38pr6	2992	2	patients	patient	NNS
cord-005478-5iu38pr6	2992	3	were	be	VBD
cord-005478-5iu38pr6	2992	4	given	give	VBN
cord-005478-5iu38pr6	2992	5	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2992	6	pre	pre	JJ
cord-005478-5iu38pr6	2992	7	-	-	NN
cord-005478-5iu38pr6	2992	8	emptively	emptively	RB
cord-005478-5iu38pr6	2992	9	for	for	IN
cord-005478-5iu38pr6	2992	10	mixed	mix	VBN
cord-005478-5iu38pr6	2992	11	-	-	HYPH
cord-005478-5iu38pr6	2992	12	chimerism	chimerism	NN
cord-005478-5iu38pr6	2992	13	,	,	,
cord-005478-5iu38pr6	2992	14	positive	positive	JJ
cord-005478-5iu38pr6	2992	15	MRD	MRD	NNP
cord-005478-5iu38pr6	2992	16	after	after	IN
cord-005478-5iu38pr6	2992	17	SCT	SCT	NNP
cord-005478-5iu38pr6	2992	18	or	or	CC
cord-005478-5iu38pr6	2992	19	early	early	JJ
cord-005478-5iu38pr6	2992	20	relapse	relapse	NN
cord-005478-5iu38pr6	2992	21	(	(	-LRB-
cord-005478-5iu38pr6	2992	22	<	<	XX
cord-005478-5iu38pr6	2992	23	10	10	CD
cord-005478-5iu38pr6	2992	24	%	%	NN
cord-005478-5iu38pr6	2992	25	marrow	marrow	NN
cord-005478-5iu38pr6	2992	26	blasts	blast	NNS
cord-005478-5iu38pr6	2992	27	)	)	-RRB-
cord-005478-5iu38pr6	2992	28	.	.	.
cord-005478-5iu38pr6	2993	1	Patients	patient	NNS
cord-005478-5iu38pr6	2993	2	in	in	IN
cord-005478-5iu38pr6	2993	3	the	the	DT
cord-005478-5iu38pr6	2993	4	combined	combine	VBN
cord-005478-5iu38pr6	2993	5	prophylactic/	prophylactic/	NN
cord-005478-5iu38pr6	2993	6	preemptive	preemptive	JJ
cord-005478-5iu38pr6	2993	7	group	group	NN
cord-005478-5iu38pr6	2993	8	(	(	-LRB-
cord-005478-5iu38pr6	2993	9	n=41	n=41	RB
cord-005478-5iu38pr6	2993	10	)	)	-RRB-
cord-005478-5iu38pr6	2993	11	started	start	VBD
cord-005478-5iu38pr6	2993	12	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2993	13	in	in	IN
cord-005478-5iu38pr6	2993	14	a	a	DT
cord-005478-5iu38pr6	2993	15	median	median	NN
cord-005478-5iu38pr6	2993	16	of	of	IN
cord-005478-5iu38pr6	2993	17	2.4	2.4	CD
cord-005478-5iu38pr6	2993	18	months	month	NNS
cord-005478-5iu38pr6	2993	19	(	(	-LRB-
cord-005478-5iu38pr6	2993	20	1.2	1.2	CD
cord-005478-5iu38pr6	2993	21	-	-	SYM
cord-005478-5iu38pr6	2993	22	14.9	14.9	CD
cord-005478-5iu38pr6	2993	23	)	)	-RRB-
cord-005478-5iu38pr6	2993	24	after	after	IN
cord-005478-5iu38pr6	2993	25	SCT	SCT	NNP
cord-005478-5iu38pr6	2993	26	and	and	CC
cord-005478-5iu38pr6	2993	27	received	receive	VBD
cord-005478-5iu38pr6	2993	28	a	a	DT
cord-005478-5iu38pr6	2993	29	median	median	NN
cord-005478-5iu38pr6	2993	30	of	of	IN
cord-005478-5iu38pr6	2993	31	8	8	CD
cord-005478-5iu38pr6	2993	32	courses	course	NNS
cord-005478-5iu38pr6	2993	33	.	.	.
cord-005478-5iu38pr6	2994	1	4	4	CD
cord-005478-5iu38pr6	2994	2	patients	patient	NNS
cord-005478-5iu38pr6	2994	3	were	be	VBD
cord-005478-5iu38pr6	2994	4	also	also	RB
cord-005478-5iu38pr6	2994	5	given	give	VBN
cord-005478-5iu38pr6	2994	6	donor	donor	NN
cord-005478-5iu38pr6	2994	7	-	-	HYPH
cord-005478-5iu38pr6	2994	8	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	2994	9	infusions	infusion	NNS
cord-005478-5iu38pr6	2994	10	(	(	-LRB-
cord-005478-5iu38pr6	2994	11	DLI	DLI	NNP
cord-005478-5iu38pr6	2994	12	)	)	-RRB-
cord-005478-5iu38pr6	2994	13	concomitantly	concomitantly	RB
cord-005478-5iu38pr6	2994	14	with	with	IN
cord-005478-5iu38pr6	2994	15	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2994	16	.	.	.
cord-005478-5iu38pr6	2995	1	23	23	CD
cord-005478-5iu38pr6	2995	2	are	be	VBP
cord-005478-5iu38pr6	2995	3	still	still	RB
cord-005478-5iu38pr6	2995	4	on	on	IN
cord-005478-5iu38pr6	2995	5	therapy	therapy	NN
cord-005478-5iu38pr6	2995	6	,	,	,
cord-005478-5iu38pr6	2995	7	12	12	CD
cord-005478-5iu38pr6	2995	8	died	die	VBD
cord-005478-5iu38pr6	2995	9	or	or	CC
cord-005478-5iu38pr6	2995	10	progressed	progress	VBD
cord-005478-5iu38pr6	2995	11	,	,	,
cord-005478-5iu38pr6	2995	12	2	2	CD
cord-005478-5iu38pr6	2995	13	stopped	stop	VBD
cord-005478-5iu38pr6	2995	14	after	after	IN
cord-005478-5iu38pr6	2995	15	long	long	JJ
cord-005478-5iu38pr6	2995	16	remission	remission	NN
cord-005478-5iu38pr6	2995	17	,	,	,
cord-005478-5iu38pr6	2995	18	3	3	CD
cord-005478-5iu38pr6	2995	19	stopped	stop	VBD
cord-005478-5iu38pr6	2995	20	due	due	JJ
cord-005478-5iu38pr6	2995	21	to	to	IN
cord-005478-5iu38pr6	2995	22	patient	patient	JJ
cord-005478-5iu38pr6	2995	23	request	request	NN
cord-005478-5iu38pr6	2995	24	and	and	CC
cord-005478-5iu38pr6	2995	25	only	only	RB
cord-005478-5iu38pr6	2995	26	1	1	CD
cord-005478-5iu38pr6	2995	27	discontinued	discontinue	VBD
cord-005478-5iu38pr6	2995	28	due	due	IN
cord-005478-5iu38pr6	2995	29	to	to	IN
cord-005478-5iu38pr6	2995	30	toxicity	toxicity	NN
cord-005478-5iu38pr6	2995	31	.	.	.
cord-005478-5iu38pr6	2996	1	17	17	CD
cord-005478-5iu38pr6	2996	2	of	of	IN
cord-005478-5iu38pr6	2996	3	22	22	CD
cord-005478-5iu38pr6	2996	4	patients	patient	NNS
cord-005478-5iu38pr6	2996	5	given	give	VBN
cord-005478-5iu38pr6	2996	6	prophylactic	prophylactic	JJ
cord-005478-5iu38pr6	2996	7	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	2996	8	remained	remain	VBD
cord-005478-5iu38pr6	2996	9	in	in	IN
cord-005478-5iu38pr6	2996	10	CR	CR	NNP
cord-005478-5iu38pr6	2996	11	.	.	.
cord-005478-5iu38pr6	2997	1	16	16	CD
cord-005478-5iu38pr6	2997	2	of	of	IN
cord-005478-5iu38pr6	2997	3	19	19	CD
cord-005478-5iu38pr6	2997	4	patients	patient	NNS
cord-005478-5iu38pr6	2997	5	given	give	VBN
cord-005478-5iu38pr6	2997	6	azacitidine	azacitidine	NNP
cord-005478-5iu38pr6	2997	7	preemptively	preemptively	RB
cord-005478-5iu38pr6	2997	8	achieved	achieve	VBD
cord-005478-5iu38pr6	2997	9	CR	CR	NNP
cord-005478-5iu38pr6	2997	10	and	and	CC
cord-005478-5iu38pr6	2997	11	10	10	CD
cord-005478-5iu38pr6	2997	12	remained	remain	VBD
cord-005478-5iu38pr6	2997	13	in	in	IN
cord-005478-5iu38pr6	2997	14	CR	CR	NNP
cord-005478-5iu38pr6	2997	15	.	.	.
cord-005478-5iu38pr6	2998	1	With	with	IN
cord-005478-5iu38pr6	2998	2	median	median	JJ
cord-005478-5iu38pr6	2998	3	follow	follow	NN
cord-005478-5iu38pr6	2998	4	-	-	HYPH
cord-005478-5iu38pr6	2998	5	up	up	NN
cord-005478-5iu38pr6	2998	6	of	of	IN
cord-005478-5iu38pr6	2998	7	14	14	CD
cord-005478-5iu38pr6	2998	8	months	month	NNS
cord-005478-5iu38pr6	2998	9	,	,	,
cord-005478-5iu38pr6	2998	10	30	30	CD
cord-005478-5iu38pr6	2998	11	of	of	IN
cord-005478-5iu38pr6	2998	12	the	the	DT
cord-005478-5iu38pr6	2998	13	41	41	CD
cord-005478-5iu38pr6	2998	14	patients	patient	NNS
cord-005478-5iu38pr6	2998	15	in	in	IN
cord-005478-5iu38pr6	2998	16	the	the	DT
cord-005478-5iu38pr6	2998	17	prophylactic/	prophylactic/	NN
cord-005478-5iu38pr6	2998	18	pre	pre	JJ
cord-005478-5iu38pr6	2998	19	-	-	JJ
cord-005478-5iu38pr6	2998	20	emptive	emptive	JJ
cord-005478-5iu38pr6	2998	21	group	group	NN
cord-005478-5iu38pr6	2998	22	are	be	VBP
cord-005478-5iu38pr6	2998	23	alive	alive	JJ
cord-005478-5iu38pr6	2998	24	and	and	CC
cord-005478-5iu38pr6	2998	25	11	11	CD
cord-005478-5iu38pr6	2998	26	died	die	VBD
cord-005478-5iu38pr6	2998	27	.	.	.
cord-005478-5iu38pr6	2999	1	The	the	DT
cord-005478-5iu38pr6	2999	2	estimated	estimate	VBN
cord-005478-5iu38pr6	2999	3	3-year	3-year	CD
cord-005478-5iu38pr6	2999	4	OS	OS	NNP
cord-005478-5iu38pr6	2999	5	and	and	CC
cord-005478-5iu38pr6	2999	6	PFS	PFS	NNP
cord-005478-5iu38pr6	2999	7	are	be	VBP
cord-005478-5iu38pr6	2999	8	58	58	CD
cord-005478-5iu38pr6	2999	9	%	%	NN
cord-005478-5iu38pr6	2999	10	(	(	-LRB-
cord-005478-5iu38pr6	2999	11	95%CI	95%ci	CD
cord-005478-5iu38pr6	2999	12	,	,	,
cord-005478-5iu38pr6	2999	13	29	29	CD
cord-005478-5iu38pr6	2999	14	-	-	SYM
cord-005478-5iu38pr6	2999	15	86	86	CD
cord-005478-5iu38pr6	2999	16	)	)	-RRB-
cord-005478-5iu38pr6	2999	17	and	and	CC
cord-005478-5iu38pr6	2999	18	50	50	CD
cord-005478-5iu38pr6	2999	19	%	%	NN
cord-005478-5iu38pr6	2999	20	(	(	-LRB-
cord-005478-5iu38pr6	2999	21	95%CI	95%ci	CD
cord-005478-5iu38pr6	2999	22	,	,	,
cord-005478-5iu38pr6	2999	23	27	27	CD
cord-005478-5iu38pr6	2999	24	-	-	SYM
cord-005478-5iu38pr6	2999	25	74	74	CD
cord-005478-5iu38pr6	2999	26	)	)	-RRB-
cord-005478-5iu38pr6	2999	27	,	,	,
cord-005478-5iu38pr6	2999	28	respectively	respectively	RB
cord-005478-5iu38pr6	2999	29	.	.	.
cord-005478-5iu38pr6	3000	1	The	the	DT
cord-005478-5iu38pr6	3000	2	expected	expected	JJ
cord-005478-5iu38pr6	3000	3	PFS	PFS	NNP
cord-005478-5iu38pr6	3000	4	in	in	IN
cord-005478-5iu38pr6	3000	5	this	this	DT
cord-005478-5iu38pr6	3000	6	group	group	NN
cord-005478-5iu38pr6	3000	7	of	of	IN
cord-005478-5iu38pr6	3000	8	high	high	JJ
cord-005478-5iu38pr6	3000	9	-	-	HYPH
cord-005478-5iu38pr6	3000	10	risk	risk	NN
cord-005478-5iu38pr6	3000	11	patients	patient	NNS
cord-005478-5iu38pr6	3000	12	is	be	VBZ
cord-005478-5iu38pr6	3000	13	less	less	JJR
cord-005478-5iu38pr6	3000	14	than	than	IN
cord-005478-5iu38pr6	3000	15	20	20	CD
cord-005478-5iu38pr6	3000	16	%	%	NN
cord-005478-5iu38pr6	3000	17	.	.	.
cord-005478-5iu38pr6	3001	1	53	53	CD
cord-005478-5iu38pr6	3001	2	patients	patient	NNS
cord-005478-5iu38pr6	3001	3	were	be	VBD
cord-005478-5iu38pr6	3001	4	given	give	VBN
cord-005478-5iu38pr6	3001	5	azacitidine	azacitidine	NN
cord-005478-5iu38pr6	3001	6	for	for	IN
cord-005478-5iu38pr6	3001	7	overt	overt	JJ
cord-005478-5iu38pr6	3001	8	relapse	relapse	NN
cord-005478-5iu38pr6	3001	9	after	after	IN
cord-005478-5iu38pr6	3001	10	SCT	SCT	NNP
cord-005478-5iu38pr6	3001	11	.	.	.
cord-005478-5iu38pr6	3002	1	Patients	patient	NNS
cord-005478-5iu38pr6	3002	2	were	be	VBD
cord-005478-5iu38pr6	3002	3	given	give	VBN
cord-005478-5iu38pr6	3002	4	a	a	DT
cord-005478-5iu38pr6	3002	5	median	median	NN
cord-005478-5iu38pr6	3002	6	of	of	IN
cord-005478-5iu38pr6	3002	7	3	3	CD
cord-005478-5iu38pr6	3002	8	courses	course	NNS
cord-005478-5iu38pr6	3002	9	(	(	-LRB-
cord-005478-5iu38pr6	3002	10	2	2	CD
cord-005478-5iu38pr6	3002	11	-	-	SYM
cord-005478-5iu38pr6	3002	12	36	36	CD
cord-005478-5iu38pr6	3002	13	)	)	-RRB-
cord-005478-5iu38pr6	3002	14	and	and	CC
cord-005478-5iu38pr6	3002	15	16	16	CD
cord-005478-5iu38pr6	3002	16	were	be	VBD
cord-005478-5iu38pr6	3002	17	also	also	RB
cord-005478-5iu38pr6	3002	18	given	give	VBN
cord-005478-5iu38pr6	3002	19	DLI	DLI	NNP
cord-005478-5iu38pr6	3002	20	.	.	.
cord-005478-5iu38pr6	3003	1	10	10	CD
cord-005478-5iu38pr6	3003	2	patients	patient	NNS
cord-005478-5iu38pr6	3003	3	achieved	achieve	VBD
cord-005478-5iu38pr6	3003	4	CR	CR	NNP
cord-005478-5iu38pr6	3003	5	,	,	,
cord-005478-5iu38pr6	3003	6	10	10	CD
cord-005478-5iu38pr6	3003	7	stable	stable	JJ
cord-005478-5iu38pr6	3003	8	disease	disease	NN
cord-005478-5iu38pr6	3003	9	and	and	CC
cord-005478-5iu38pr6	3003	10	33	33	CD
cord-005478-5iu38pr6	3003	11	progressive	progressive	JJ
cord-005478-5iu38pr6	3003	12	disease	disease	NN
cord-005478-5iu38pr6	3003	13	.	.	.
cord-005478-5iu38pr6	3004	1	5	5	CD
cord-005478-5iu38pr6	3004	2	patients	patient	NNS
cord-005478-5iu38pr6	3004	3	are	be	VBP
cord-005478-5iu38pr6	3004	4	still	still	RB
cord-005478-5iu38pr6	3004	5	on	on	IN
cord-005478-5iu38pr6	3004	6	therapy	therapy	NN
cord-005478-5iu38pr6	3004	7	,	,	,
cord-005478-5iu38pr6	3004	8	44	44	CD
cord-005478-5iu38pr6	3004	9	died	die	VBD
cord-005478-5iu38pr6	3004	10	or	or	CC
cord-005478-5iu38pr6	3004	11	progressed	progress	VBN
cord-005478-5iu38pr6	3004	12	and	and	CC
cord-005478-5iu38pr6	3004	13	4	4	CD
cord-005478-5iu38pr6	3004	14	had	have	VBD
cord-005478-5iu38pr6	3004	15	to	to	TO
cord-005478-5iu38pr6	3004	16	discontinue	discontinue	VB
cord-005478-5iu38pr6	3004	17	due	due	IN
cord-005478-5iu38pr6	3004	18	to	to	IN
cord-005478-5iu38pr6	3004	19	hematological	hematological	JJ
cord-005478-5iu38pr6	3004	20	toxicity	toxicity	NN
cord-005478-5iu38pr6	3004	21	.	.	.
cord-005478-5iu38pr6	3005	1	With	with	IN
cord-005478-5iu38pr6	3005	2	median	median	JJ
cord-005478-5iu38pr6	3005	3	follow	follow	NN
cord-005478-5iu38pr6	3005	4	-	-	HYPH
cord-005478-5iu38pr6	3005	5	up	up	NN
cord-005478-5iu38pr6	3005	6	of	of	IN
cord-005478-5iu38pr6	3005	7	15	15	CD
cord-005478-5iu38pr6	3005	8	months	month	NNS
cord-005478-5iu38pr6	3005	9	,	,	,
cord-005478-5iu38pr6	3005	10	12	12	CD
cord-005478-5iu38pr6	3005	11	are	be	VBP
cord-005478-5iu38pr6	3005	12	alive	alive	JJ
cord-005478-5iu38pr6	3005	13	and	and	CC
cord-005478-5iu38pr6	3005	14	5	5	CD
cord-005478-5iu38pr6	3005	15	are	be	VBP
cord-005478-5iu38pr6	3005	16	progression	progression	NN
cord-005478-5iu38pr6	3005	17	-	-	HYPH
cord-005478-5iu38pr6	3005	18	free	free	JJ
cord-005478-5iu38pr6	3005	19	.	.	.
cord-005478-5iu38pr6	3006	1	and	and	CC
cord-005478-5iu38pr6	3006	2	7	7	CD
cord-005478-5iu38pr6	3006	3	%	%	NN
cord-005478-5iu38pr6	3006	4	(	(	-LRB-
cord-005478-5iu38pr6	3006	5	95%CI	95%ci	CD
cord-005478-5iu38pr6	3006	6	,	,	,
cord-005478-5iu38pr6	3006	7	0	0	CD
cord-005478-5iu38pr6	3006	8	-	-	SYM
cord-005478-5iu38pr6	3006	9	13	13	CD
cord-005478-5iu38pr6	3006	10	)	)	-RRB-
cord-005478-5iu38pr6	3006	11	,	,	,
cord-005478-5iu38pr6	3006	12	respectively	respectively	RB
cord-005478-5iu38pr6	3006	13	.	.	.
cord-005478-5iu38pr6	3007	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3007	2	:	:	:
cord-005478-5iu38pr6	3008	1	Azacitidine	Azacitidine	NNP
cord-005478-5iu38pr6	3008	2	is	be	VBZ
cord-005478-5iu38pr6	3008	3	safe	safe	JJ
cord-005478-5iu38pr6	3008	4	and	and	CC
cord-005478-5iu38pr6	3008	5	effective	effective	JJ
cord-005478-5iu38pr6	3008	6	therapy	therapy	NN
cord-005478-5iu38pr6	3008	7	when	when	WRB
cord-005478-5iu38pr6	3008	8	used	use	VBN
cord-005478-5iu38pr6	3008	9	prophylactically	prophylactically	RB
cord-005478-5iu38pr6	3008	10	in	in	IN
cord-005478-5iu38pr6	3008	11	high	high	JJ
cord-005478-5iu38pr6	3008	12	-	-	HYPH
cord-005478-5iu38pr6	3008	13	risk	risk	NN
cord-005478-5iu38pr6	3008	14	AML	AML	NNP
cord-005478-5iu38pr6	3008	15	/	/	SYM
cord-005478-5iu38pr6	3008	16	MDS	MDS	NNP
cord-005478-5iu38pr6	3008	17	patients	patient	NNS
cord-005478-5iu38pr6	3008	18	to	to	TO
cord-005478-5iu38pr6	3008	19	prevent	prevent	VB
cord-005478-5iu38pr6	3008	20	relapse	relapse	NN
cord-005478-5iu38pr6	3008	21	or	or	CC
cord-005478-5iu38pr6	3008	22	preemptively	preemptively	RB
cord-005478-5iu38pr6	3008	23	to	to	TO
cord-005478-5iu38pr6	3008	24	treat	treat	VB
cord-005478-5iu38pr6	3008	25	MRD	MRD	NNP
cord-005478-5iu38pr6	3008	26	or	or	CC
cord-005478-5iu38pr6	3008	27	early	early	JJ
cord-005478-5iu38pr6	3008	28	relapse	relapse	NN
cord-005478-5iu38pr6	3008	29	after	after	IN
cord-005478-5iu38pr6	3008	30	SCT	SCT	NNP
cord-005478-5iu38pr6	3008	31	.	.	.
cord-005478-5iu38pr6	3009	1	Azacitidine	azacitidine	JJ
cord-005478-5iu38pr6	3009	2	maintenance	maintenance	NN
cord-005478-5iu38pr6	3009	3	may	may	MD
cord-005478-5iu38pr6	3009	4	improve	improve	VB
cord-005478-5iu38pr6	3009	5	outcome	outcome	NN
cord-005478-5iu38pr6	3009	6	in	in	IN
cord-005478-5iu38pr6	3009	7	this	this	DT
cord-005478-5iu38pr6	3009	8	high	high	JJ
cord-005478-5iu38pr6	3009	9	-	-	HYPH
cord-005478-5iu38pr6	3009	10	risk	risk	NN
cord-005478-5iu38pr6	3009	11	patient	patient	NN
cord-005478-5iu38pr6	3009	12	group	group	NN
cord-005478-5iu38pr6	3009	13	and	and	CC
cord-005478-5iu38pr6	3009	14	should	should	MD
cord-005478-5iu38pr6	3009	15	be	be	VB
cord-005478-5iu38pr6	3009	16	further	further	RB
cord-005478-5iu38pr6	3009	17	explored	explore	VBN
cord-005478-5iu38pr6	3009	18	.	.	.
cord-005478-5iu38pr6	3010	1	Results	result	NNS
cord-005478-5iu38pr6	3010	2	of	of	IN
cord-005478-5iu38pr6	3010	3	azacitidine	azacitidine	JJ
cord-005478-5iu38pr6	3010	4	treatment	treatment	NN
cord-005478-5iu38pr6	3010	5	in	in	IN
cord-005478-5iu38pr6	3010	6	overt	overt	JJ
cord-005478-5iu38pr6	3010	7	post	post	JJ
cord-005478-5iu38pr6	3010	8	-	-	JJ
cord-005478-5iu38pr6	3010	9	transplant	transplant	JJ
cord-005478-5iu38pr6	3010	10	relapse	relapse	NN
cord-005478-5iu38pr6	3010	11	are	be	VBP
cord-005478-5iu38pr6	3010	12	limited	limit	VBN
cord-005478-5iu38pr6	3010	13	.	.	.
cord-005478-5iu38pr6	3011	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3011	2	:	:	:
cord-005478-5iu38pr6	3011	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3011	4	to	to	TO
cord-005478-5iu38pr6	3011	5	declare	declare	VB
cord-005478-5iu38pr6	3011	6	Novel	Novel	NNP
cord-005478-5iu38pr6	3011	7	mass	mass	NN
cord-005478-5iu38pr6	3011	8	cytometry	cytometry	NN
cord-005478-5iu38pr6	3011	9	analysis	analysis	NN
cord-005478-5iu38pr6	3011	10	identifies	identify	VBZ
cord-005478-5iu38pr6	3011	11	reciprocal	reciprocal	JJ
cord-005478-5iu38pr6	3011	12	changes	change	NNS
cord-005478-5iu38pr6	3011	13	in	in	IN
cord-005478-5iu38pr6	3011	14	NKREG	NKREG	NNP
cord-005478-5iu38pr6	3011	15	and	and	CC
cord-005478-5iu38pr6	3011	16	CD4	CD4	NNP
cord-005478-5iu38pr6	3011	17	EM	EM	NNP
cord-005478-5iu38pr6	3011	18	as	as	IN
cord-005478-5iu38pr6	3011	19	the	the	DT
cord-005478-5iu38pr6	3011	20	dominant	dominant	JJ
cord-005478-5iu38pr6	3011	21	early	early	JJ
cord-005478-5iu38pr6	3011	22	immune	immune	JJ
cord-005478-5iu38pr6	3011	23	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3011	24	signature	signature	NN
cord-005478-5iu38pr6	3011	25	associated	associate	VBN
cord-005478-5iu38pr6	3011	26	with	with	IN
cord-005478-5iu38pr6	3011	27	subsequent	subsequent	JJ
cord-005478-5iu38pr6	3011	28	acute	acute	JJ
cord-005478-5iu38pr6	3011	29	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3011	30	after	after	IN
cord-005478-5iu38pr6	3011	31	RIC	RIC	NNP
cord-005478-5iu38pr6	3011	32	-	-	HYPH
cord-005478-5iu38pr6	3011	33	AHST	AHST	NNP
cord-005478-5iu38pr6	3011	34	Background	Background	NNP
cord-005478-5iu38pr6	3011	35	:	:	:
cord-005478-5iu38pr6	3012	1	Treatment	treatment	NN
cord-005478-5iu38pr6	3012	2	failure	failure	NN
cord-005478-5iu38pr6	3012	3	after	after	IN
cord-005478-5iu38pr6	3012	4	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	3012	5	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	3012	6	stem	stem	NN
cord-005478-5iu38pr6	3012	7	-	-	HYPH
cord-005478-5iu38pr6	3012	8	cell	cell	NN
cord-005478-5iu38pr6	3012	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	3012	10	(	(	-LRB-
cord-005478-5iu38pr6	3012	11	AHST	AHST	NNP
cord-005478-5iu38pr6	3012	12	)	)	-RRB-
cord-005478-5iu38pr6	3013	1	using	use	VBG
cord-005478-5iu38pr6	3013	2	reducedintensity	reducedintensity	NN
cord-005478-5iu38pr6	3013	3	conditioning	conditioning	NN
cord-005478-5iu38pr6	3013	4	(	(	-LRB-
cord-005478-5iu38pr6	3013	5	RIC	RIC	NNP
cord-005478-5iu38pr6	3013	6	)	)	-RRB-
cord-005478-5iu38pr6	3013	7	results	result	VBZ
cord-005478-5iu38pr6	3013	8	from	from	IN
cord-005478-5iu38pr6	3013	9	either	either	CC
cord-005478-5iu38pr6	3013	10	too	too	RB
cord-005478-5iu38pr6	3013	11	much	much	JJ
cord-005478-5iu38pr6	3013	12	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	3013	13	and	and	CC
cord-005478-5iu38pr6	3013	14	harmful	harmful	JJ
cord-005478-5iu38pr6	3013	15	acute	acute	JJ
cord-005478-5iu38pr6	3013	16	Graft	graft	NN
cord-005478-5iu38pr6	3013	17	-	-	HYPH
cord-005478-5iu38pr6	3013	18	versus	versus	IN
cord-005478-5iu38pr6	3013	19	-	-	HYPH
cord-005478-5iu38pr6	3013	20	Host	host	NN
cord-005478-5iu38pr6	3013	21	Disease	Disease	NNP
cord-005478-5iu38pr6	3013	22	(	(	-LRB-
cord-005478-5iu38pr6	3013	23	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3013	24	)	)	-RRB-
cord-005478-5iu38pr6	3013	25	or	or	CC
cord-005478-5iu38pr6	3013	26	not	not	RB
cord-005478-5iu38pr6	3013	27	enough	enough	JJ
cord-005478-5iu38pr6	3014	1	(	(	-LRB-
cord-005478-5iu38pr6	3014	2	reducing	reduce	VBG
cord-005478-5iu38pr6	3014	3	Graft	graft	NN
cord-005478-5iu38pr6	3014	4	-	-	HYPH
cord-005478-5iu38pr6	3014	5	versus	versus	IN
cord-005478-5iu38pr6	3014	6	-	-	HYPH
cord-005478-5iu38pr6	3014	7	Tumour	tumour	NN
cord-005478-5iu38pr6	3014	8	effects	effect	NNS
cord-005478-5iu38pr6	3014	9	)	)	-RRB-
cord-005478-5iu38pr6	3014	10	.	.	.
cord-005478-5iu38pr6	3015	1	Studies	study	NNS
cord-005478-5iu38pr6	3015	2	have	have	VBP
cord-005478-5iu38pr6	3015	3	identified	identify	VBN
cord-005478-5iu38pr6	3015	4	individual	individual	JJ
cord-005478-5iu38pr6	3015	5	reconstituting	reconstitute	VBG
cord-005478-5iu38pr6	3015	6	immune	immune	JJ
cord-005478-5iu38pr6	3015	7	cell	cell	NN
cord-005478-5iu38pr6	3015	8	subsets	subset	NNS
cord-005478-5iu38pr6	3015	9	associated	associate	VBN
cord-005478-5iu38pr6	3015	10	with	with	IN
cord-005478-5iu38pr6	3015	11	development	development	NN
cord-005478-5iu38pr6	3015	12	of	of	IN
cord-005478-5iu38pr6	3015	13	clinical	clinical	JJ
cord-005478-5iu38pr6	3015	14	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	3015	15	but	but	CC
cord-005478-5iu38pr6	3015	16	the	the	DT
cord-005478-5iu38pr6	3015	17	functionally	functionally	RB
cord-005478-5iu38pr6	3015	18	dominant	dominant	JJ
cord-005478-5iu38pr6	3015	19	parameters	parameter	NNS
cord-005478-5iu38pr6	3015	20	remain	remain	VBP
cord-005478-5iu38pr6	3015	21	unknown	unknown	JJ
cord-005478-5iu38pr6	3015	22	.	.	.
cord-005478-5iu38pr6	3016	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3016	2	therefore	therefore	RB
cord-005478-5iu38pr6	3016	3	used	use	VBD
cord-005478-5iu38pr6	3016	4	mass	mass	NN
cord-005478-5iu38pr6	3016	5	cytometry	cytometry	NN
cord-005478-5iu38pr6	3016	6	(	(	-LRB-
cord-005478-5iu38pr6	3016	7	MS	MS	NNP
cord-005478-5iu38pr6	3016	8	)	)	-RRB-
cord-005478-5iu38pr6	3016	9	technology	technology	NN
cord-005478-5iu38pr6	3016	10	to	to	TO
cord-005478-5iu38pr6	3016	11	determine	determine	VB
cord-005478-5iu38pr6	3016	12	multiple	multiple	JJ
cord-005478-5iu38pr6	3016	13	parameters	parameter	NNS
cord-005478-5iu38pr6	3016	14	simultaneously	simultaneously	RB
cord-005478-5iu38pr6	3016	15	to	to	TO
cord-005478-5iu38pr6	3016	16	identify	identify	VB
cord-005478-5iu38pr6	3016	17	dominant	dominant	JJ
cord-005478-5iu38pr6	3016	18	cellular	cellular	JJ
cord-005478-5iu38pr6	3016	19	immune	immune	JJ
cord-005478-5iu38pr6	3016	20	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3016	21	signatures	signature	NNS
cord-005478-5iu38pr6	3016	22	associated	associate	VBN
cord-005478-5iu38pr6	3016	23	with	with	IN
cord-005478-5iu38pr6	3016	24	development	development	NN
cord-005478-5iu38pr6	3016	25	of	of	IN
cord-005478-5iu38pr6	3016	26	clinical	clinical	JJ
cord-005478-5iu38pr6	3016	27	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	3016	28	after	after	IN
cord-005478-5iu38pr6	3016	29	AHST	AHST	NNP
cord-005478-5iu38pr6	3016	30	.	.	.
cord-005478-5iu38pr6	3017	1	Methods	method	NNS
cord-005478-5iu38pr6	3017	2	:	:	:
cord-005478-5iu38pr6	3017	3	Phenotypic	phenotypic	JJ
cord-005478-5iu38pr6	3017	4	markers	marker	NNS
cord-005478-5iu38pr6	3017	5	identifying	identify	VBG
cord-005478-5iu38pr6	3017	6	>	>	SYM
cord-005478-5iu38pr6	3017	7	30	30	CD
cord-005478-5iu38pr6	3017	8	T	t	NN
cord-005478-5iu38pr6	3017	9	,	,	,
cord-005478-5iu38pr6	3017	10	B	B	NNP
cord-005478-5iu38pr6	3017	11	and	and	CC
cord-005478-5iu38pr6	3017	12	NK	NK	NNP
cord-005478-5iu38pr6	3017	13	cell	cell	NN
cord-005478-5iu38pr6	3017	14	subsets	subset	NNS
cord-005478-5iu38pr6	3017	15	known	know	VBN
cord-005478-5iu38pr6	3017	16	to	to	TO
cord-005478-5iu38pr6	3017	17	influence	influence	VB
cord-005478-5iu38pr6	3017	18	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	3017	19	were	be	VBD
cord-005478-5iu38pr6	3017	20	combined	combine	VBN
cord-005478-5iu38pr6	3017	21	in	in	IN
cord-005478-5iu38pr6	3017	22	a	a	DT
cord-005478-5iu38pr6	3017	23	single	single	JJ
cord-005478-5iu38pr6	3017	24	MS	MS	NNP
cord-005478-5iu38pr6	3017	25	panel	panel	NN
cord-005478-5iu38pr6	3017	26	.	.	.
cord-005478-5iu38pr6	3018	1	Peripheral	peripheral	JJ
cord-005478-5iu38pr6	3018	2	blood	blood	NN
cord-005478-5iu38pr6	3018	3	from	from	IN
cord-005478-5iu38pr6	3018	4	52	52	CD
cord-005478-5iu38pr6	3018	5	patients	patient	NNS
cord-005478-5iu38pr6	3018	6	with	with	IN
cord-005478-5iu38pr6	3018	7	haematological	haematological	JJ
cord-005478-5iu38pr6	3018	8	cancer	cancer	NN
cord-005478-5iu38pr6	3018	9	was	be	VBD
cord-005478-5iu38pr6	3018	10	analysed	analyse	VBN
cord-005478-5iu38pr6	3018	11	at	at	IN
cord-005478-5iu38pr6	3018	12	D+30	d+30	NN
cord-005478-5iu38pr6	3018	13	after	after	IN
cord-005478-5iu38pr6	3018	14	T	t	NN
cord-005478-5iu38pr6	3018	15	-	-	HYPH
cord-005478-5iu38pr6	3018	16	replete	replete	JJ
cord-005478-5iu38pr6	3018	17	HLA	HLA	NNP
cord-005478-5iu38pr6	3018	18	-	-	HYPH
cord-005478-5iu38pr6	3018	19	matched	match	VBN
cord-005478-5iu38pr6	3018	20	RIC	RIC	NNP
cord-005478-5iu38pr6	3018	21	-	-	HYPH
cord-005478-5iu38pr6	3018	22	AHST	AHST	NNP
cord-005478-5iu38pr6	3018	23	using	use	VBG
cord-005478-5iu38pr6	3018	24	uniform	uniform	JJ
cord-005478-5iu38pr6	3018	25	conditioning	conditioning	NN
cord-005478-5iu38pr6	3018	26	.	.	.
cord-005478-5iu38pr6	3019	1	Test	test	NN
cord-005478-5iu38pr6	3019	2	samples	sample	NNS
cord-005478-5iu38pr6	3019	3	were	be	VBD
cord-005478-5iu38pr6	3019	4	spiked	spike	VBN
cord-005478-5iu38pr6	3019	5	with	with	IN
cord-005478-5iu38pr6	3019	6	CD45barcoded	cd45barcoded	JJ
cord-005478-5iu38pr6	3019	7	healthy	healthy	JJ
cord-005478-5iu38pr6	3019	8	control	control	NN
cord-005478-5iu38pr6	3019	9	cells	cell	NNS
cord-005478-5iu38pr6	3019	10	.	.	.
cord-005478-5iu38pr6	3020	1	Three	three	CD
cord-005478-5iu38pr6	3020	2	complementary	complementary	JJ
cord-005478-5iu38pr6	3020	3	high	high	JJ
cord-005478-5iu38pr6	3020	4	-	-	HYPH
cord-005478-5iu38pr6	3020	5	dimensional	dimensional	JJ
cord-005478-5iu38pr6	3020	6	analytic	analytic	JJ
cord-005478-5iu38pr6	3020	7	tools	tool	NNS
cord-005478-5iu38pr6	3020	8	were	be	VBD
cord-005478-5iu38pr6	3020	9	used	use	VBN
cord-005478-5iu38pr6	3020	10	to	to	TO
cord-005478-5iu38pr6	3020	11	identify	identify	VB
cord-005478-5iu38pr6	3020	12	immune	immune	JJ
cord-005478-5iu38pr6	3020	13	signatures	signature	NNS
cord-005478-5iu38pr6	3020	14	in	in	IN
cord-005478-5iu38pr6	3020	15	CD45	CD45	NNP
cord-005478-5iu38pr6	3020	16	+	+	CC
cord-005478-5iu38pr6	3020	17	lineage	lineage	NN
cord-005478-5iu38pr6	3020	18	+	+	CC
cord-005478-5iu38pr6	3020	19	cells	cell	NNS
cord-005478-5iu38pr6	3020	20	across	across	IN
cord-005478-5iu38pr6	3020	21	the	the	DT
cord-005478-5iu38pr6	3020	22	whole	whole	JJ
cord-005478-5iu38pr6	3020	23	cohort	cohort	NN
cord-005478-5iu38pr6	3020	24	and	and	CC
cord-005478-5iu38pr6	3020	25	identify	identify	VB
cord-005478-5iu38pr6	3020	26	differences	difference	NNS
cord-005478-5iu38pr6	3020	27	between	between	IN
cord-005478-5iu38pr6	3020	28	patients	patient	NNS
cord-005478-5iu38pr6	3020	29	grouped	group	VBN
cord-005478-5iu38pr6	3020	30	by	by	IN
cord-005478-5iu38pr6	3020	31	subsequent	subsequent	JJ
cord-005478-5iu38pr6	3020	32	occurrence	occurrence	NN
cord-005478-5iu38pr6	3020	33	of	of	IN
cord-005478-5iu38pr6	3020	34	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3020	35	.	.	.
cord-005478-5iu38pr6	3021	1	Results	result	NNS
cord-005478-5iu38pr6	3021	2	:	:	:
cord-005478-5iu38pr6	3022	1	Significant	significant	JJ
cord-005478-5iu38pr6	3022	2	batch	batch	NN
cord-005478-5iu38pr6	3022	3	effects	effect	NNS
cord-005478-5iu38pr6	3022	4	were	be	VBD
cord-005478-5iu38pr6	3022	5	effectively	effectively	RB
cord-005478-5iu38pr6	3022	6	reduced	reduce	VBN
cord-005478-5iu38pr6	3022	7	with	with	IN
cord-005478-5iu38pr6	3022	8	a	a	DT
cord-005478-5iu38pr6	3022	9	novel	novel	JJ
cord-005478-5iu38pr6	3022	10	R	r	NN
cord-005478-5iu38pr6	3022	11	-	-	HYPH
cord-005478-5iu38pr6	3022	12	based	base	VBN
cord-005478-5iu38pr6	3022	13	algorithm	algorithm	NN
cord-005478-5iu38pr6	3022	14	normalising	normalise	VBG
cord-005478-5iu38pr6	3022	15	data	datum	NNS
cord-005478-5iu38pr6	3022	16	to	to	TO
cord-005478-5iu38pr6	3022	17	control	control	VB
cord-005478-5iu38pr6	3022	18	cells	cell	NNS
cord-005478-5iu38pr6	3022	19	.	.	.
cord-005478-5iu38pr6	3023	1	Unsupervised	unsupervised	JJ
cord-005478-5iu38pr6	3023	2	clustering	clustering	NN
cord-005478-5iu38pr6	3023	3	analysis	analysis	NN
cord-005478-5iu38pr6	3023	4	using	use	VBG
cord-005478-5iu38pr6	3023	5	Phenograph	Phenograph	NNP
cord-005478-5iu38pr6	3023	6	and	and	CC
cord-005478-5iu38pr6	3023	7	FlowSOM	FlowSOM	NNP
cord-005478-5iu38pr6	3023	8	algorithms	algorithm	NNS
cord-005478-5iu38pr6	3023	9	identified	identify	VBD
cord-005478-5iu38pr6	3023	10	24	24	CD
cord-005478-5iu38pr6	3023	11	and	and	CC
cord-005478-5iu38pr6	3023	12	40	40	CD
cord-005478-5iu38pr6	3023	13	phenotypically	phenotypically	RB
cord-005478-5iu38pr6	3023	14	distinct	distinct	JJ
cord-005478-5iu38pr6	3023	15	clusters	cluster	NNS
cord-005478-5iu38pr6	3023	16	respectively	respectively	RB
cord-005478-5iu38pr6	3023	17	.	.	.
cord-005478-5iu38pr6	3024	1	Diversity	diversity	NN
cord-005478-5iu38pr6	3024	2	analysis	analysis	NN
cord-005478-5iu38pr6	3024	3	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	3024	4	lower	low	JJR
cord-005478-5iu38pr6	3024	5	cluster	cluster	NN
cord-005478-5iu38pr6	3024	6	diversity	diversity	NN
cord-005478-5iu38pr6	3024	7	(	(	-LRB-
cord-005478-5iu38pr6	3024	8	P=0.06	P=0.06	NNP
cord-005478-5iu38pr6	3024	9	)	)	-RRB-
cord-005478-5iu38pr6	3024	10	in	in	IN
cord-005478-5iu38pr6	3024	11	the	the	DT
cord-005478-5iu38pr6	3024	12	20	20	CD
cord-005478-5iu38pr6	3024	13	patients	patient	NNS
cord-005478-5iu38pr6	3024	14	who	who	WP
cord-005478-5iu38pr6	3024	15	subsequently	subsequently	RB
cord-005478-5iu38pr6	3024	16	developed	develop	VBD
cord-005478-5iu38pr6	3024	17	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3024	18	consistent	consistent	JJ
cord-005478-5iu38pr6	3024	19	with	with	IN
cord-005478-5iu38pr6	3024	20	perturbation	perturbation	NN
cord-005478-5iu38pr6	3024	21	of	of	IN
cord-005478-5iu38pr6	3024	22	phenotypic	phenotypic	JJ
cord-005478-5iu38pr6	3024	23	clusters	cluster	NNS
cord-005478-5iu38pr6	3024	24	in	in	IN
cord-005478-5iu38pr6	3024	25	these	these	DT
cord-005478-5iu38pr6	3024	26	patients	patient	NNS
cord-005478-5iu38pr6	3024	27	.	.	.
cord-005478-5iu38pr6	3025	1	Comparison	comparison	NN
cord-005478-5iu38pr6	3025	2	of	of	IN
cord-005478-5iu38pr6	3025	3	individual	individual	JJ
cord-005478-5iu38pr6	3025	4	cluster	cluster	NN
cord-005478-5iu38pr6	3025	5	abundance	abundance	NN
cord-005478-5iu38pr6	3025	6	identified	identify	VBD
cord-005478-5iu38pr6	3025	7	2	2	CD
cord-005478-5iu38pr6	3025	8	cluster	cluster	NN
cord-005478-5iu38pr6	3025	9	groups	group	NNS
cord-005478-5iu38pr6	3025	10	significantly	significantly	RB
cord-005478-5iu38pr6	3025	11	different	different	JJ
cord-005478-5iu38pr6	3025	12	between	between	IN
cord-005478-5iu38pr6	3025	13	patients	patient	NNS
cord-005478-5iu38pr6	3025	14	who	who	WP
cord-005478-5iu38pr6	3025	15	subsequently	subsequently	RB
cord-005478-5iu38pr6	3025	16	developed	develop	VBD
cord-005478-5iu38pr6	3025	17	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3025	18	and	and	CC
cord-005478-5iu38pr6	3025	19	those	those	DT
cord-005478-5iu38pr6	3025	20	who	who	WP
cord-005478-5iu38pr6	3025	21	did	do	VBD
cord-005478-5iu38pr6	3025	22	not	not	RB
cord-005478-5iu38pr6	3025	23	.	.	.
cord-005478-5iu38pr6	3026	1	A	a	DT
cord-005478-5iu38pr6	3026	2	cluster	cluster	NN
cord-005478-5iu38pr6	3026	3	containing	contain	VBG
cord-005478-5iu38pr6	3026	4	cells	cell	NNS
cord-005478-5iu38pr6	3026	5	with	with	IN
cord-005478-5iu38pr6	3026	6	a	a	DT
cord-005478-5iu38pr6	3026	7	CD56	CD56	NNP
cord-005478-5iu38pr6	3026	8	bright	bright	JJ
cord-005478-5iu38pr6	3026	9	CD16	CD16	NNP
cord-005478-5iu38pr6	3026	10	neg	neg	NN
cord-005478-5iu38pr6	3026	11	CD27	CD27	NNP
cord-005478-5iu38pr6	3027	1	+	+	CC
cord-005478-5iu38pr6	3028	1	/regulatory	/regulatory	JJ
cord-005478-5iu38pr6	3028	2	/	/	SYM
cord-005478-5iu38pr6	3028	3	tolerant	tolerant	JJ
cord-005478-5iu38pr6	3028	4	NK	NK	NNP
cord-005478-5iu38pr6	3028	5	cell	cell	NN
cord-005478-5iu38pr6	3028	6	(	(	-LRB-
cord-005478-5iu38pr6	3028	7	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3028	8	)	)	-RRB-
cord-005478-5iu38pr6	3028	9	phenotype	phenotype	NN
cord-005478-5iu38pr6	3028	10	was	be	VBD
cord-005478-5iu38pr6	3028	11	significantly	significantly	RB
cord-005478-5iu38pr6	3028	12	reduced	reduce	VBN
cord-005478-5iu38pr6	3028	13	in	in	IN
cord-005478-5iu38pr6	3028	14	patients	patient	NNS
cord-005478-5iu38pr6	3028	15	who	who	WP
cord-005478-5iu38pr6	3028	16	subsequently	subsequently	RB
cord-005478-5iu38pr6	3028	17	developed	develop	VBD
cord-005478-5iu38pr6	3028	18	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3028	19	using	use	VBG
cord-005478-5iu38pr6	3028	20	both	both	DT
cord-005478-5iu38pr6	3028	21	Phenograph	Phenograph	NNP
cord-005478-5iu38pr6	3028	22	and	and	CC
cord-005478-5iu38pr6	3028	23	FlowSOM	FlowSOM	NNP
cord-005478-5iu38pr6	3028	24	algorithms	algorithm	NNS
cord-005478-5iu38pr6	3028	25	(	(	-LRB-
cord-005478-5iu38pr6	3028	26	p	p	NN
cord-005478-5iu38pr6	3028	27	<	<	XX
cord-005478-5iu38pr6	3028	28	0.001	0.001	CD
cord-005478-5iu38pr6	3028	29	)	)	-RRB-
cord-005478-5iu38pr6	3028	30	.	.	.
cord-005478-5iu38pr6	3029	1	A	a	DT
cord-005478-5iu38pr6	3029	2	differentiating	differentiate	VBG
cord-005478-5iu38pr6	3029	3	cell	cell	NN
cord-005478-5iu38pr6	3029	4	population	population	NN
cord-005478-5iu38pr6	3029	5	with	with	IN
cord-005478-5iu38pr6	3029	6	this	this	DT
cord-005478-5iu38pr6	3029	7	phenotype	phenotype	NN
cord-005478-5iu38pr6	3029	8	was	be	VBD
cord-005478-5iu38pr6	3029	9	also	also	RB
cord-005478-5iu38pr6	3029	10	identified	identify	VBN
cord-005478-5iu38pr6	3029	11	in	in	IN
cord-005478-5iu38pr6	3029	12	forward	forward	JJ
cord-005478-5iu38pr6	3029	13	analysis	analysis	NN
cord-005478-5iu38pr6	3029	14	using	use	VBG
cord-005478-5iu38pr6	3029	15	the	the	DT
cord-005478-5iu38pr6	3029	16	CITRUS	CITRUS	NNP
cord-005478-5iu38pr6	3029	17	algorithm	algorithm	NN
cord-005478-5iu38pr6	3029	18	.	.	.
cord-005478-5iu38pr6	3030	1	Notably	notably	RB
cord-005478-5iu38pr6	3030	2	,	,	,
cord-005478-5iu38pr6	3030	3	this	this	DT
cord-005478-5iu38pr6	3030	4	reduction	reduction	NN
cord-005478-5iu38pr6	3030	5	in	in	IN
cord-005478-5iu38pr6	3030	6	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3030	7	was	be	VBD
cord-005478-5iu38pr6	3030	8	accompanied	accompany	VBN
cord-005478-5iu38pr6	3030	9	by	by	IN
cord-005478-5iu38pr6	3030	10	a	a	DT
cord-005478-5iu38pr6	3030	11	significant	significant	JJ
cord-005478-5iu38pr6	3030	12	increase	increase	NN
cord-005478-5iu38pr6	3030	13	in	in	IN
cord-005478-5iu38pr6	3030	14	abundance	abundance	NN
cord-005478-5iu38pr6	3030	15	of	of	IN
cord-005478-5iu38pr6	3030	16	a	a	DT
cord-005478-5iu38pr6	3030	17	cluster	cluster	NN
cord-005478-5iu38pr6	3030	18	of	of	IN
cord-005478-5iu38pr6	3030	19	CCR5	CCR5	NNP
cord-005478-5iu38pr6	3031	1	+	+	CC
cord-005478-5iu38pr6	3032	1	CD45RA	cd45ra	NN
cord-005478-5iu38pr6	3032	2	-CCR7	-CCR7	NNP
cord-005478-5iu38pr6	3032	3	-CD4	-CD4	NNP
cord-005478-5iu38pr6	3032	4	effector	effector	NN
cord-005478-5iu38pr6	3032	5	memory	memory	NN
cord-005478-5iu38pr6	3032	6	T	t	NN
cord-005478-5iu38pr6	3032	7	-	-	HYPH
cord-005478-5iu38pr6	3032	8	cells	cell	NNS
cord-005478-5iu38pr6	3032	9	(	(	-LRB-
cord-005478-5iu38pr6	3032	10	Tem	Tem	NNP
cord-005478-5iu38pr6	3032	11	)	)	-RRB-
cord-005478-5iu38pr6	3032	12	in	in	IN
cord-005478-5iu38pr6	3032	13	patients	patient	NNS
cord-005478-5iu38pr6	3032	14	who	who	WP
cord-005478-5iu38pr6	3032	15	subsequently	subsequently	RB
cord-005478-5iu38pr6	3032	16	developed	develop	VBD
cord-005478-5iu38pr6	3032	17	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3032	18	.	.	.
cord-005478-5iu38pr6	3033	1	There	there	EX
cord-005478-5iu38pr6	3033	2	was	be	VBD
cord-005478-5iu38pr6	3033	3	a	a	DT
cord-005478-5iu38pr6	3033	4	significant	significant	JJ
cord-005478-5iu38pr6	3033	5	negative	negative	JJ
cord-005478-5iu38pr6	3033	6	correlation	correlation	NN
cord-005478-5iu38pr6	3033	7	(	(	-LRB-
cord-005478-5iu38pr6	3033	8	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	3033	9	)	)	-RRB-
cord-005478-5iu38pr6	3033	10	between	between	IN
cord-005478-5iu38pr6	3033	11	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3033	12	and	and	CC
cord-005478-5iu38pr6	3033	13	Tem	Tem	NNP
cord-005478-5iu38pr6	3033	14	.	.	.
cord-005478-5iu38pr6	3034	1	In	in	IN
cord-005478-5iu38pr6	3034	2	contrast	contrast	NN
cord-005478-5iu38pr6	3034	3	there	there	EX
cord-005478-5iu38pr6	3034	4	was	be	VBD
cord-005478-5iu38pr6	3034	5	no	no	DT
cord-005478-5iu38pr6	3034	6	inverse	inverse	JJ
cord-005478-5iu38pr6	3034	7	correlation	correlation	NN
cord-005478-5iu38pr6	3034	8	between	between	IN
cord-005478-5iu38pr6	3034	9	CD4	CD4	NNP
cord-005478-5iu38pr6	3034	10	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3034	11	T	T	NNP
cord-005478-5iu38pr6	3034	12	-	-	HYPH
cord-005478-5iu38pr6	3034	13	cells	cell	NNS
cord-005478-5iu38pr6	3034	14	and	and	CC
cord-005478-5iu38pr6	3034	15	CD4em	CD4em	NNS
cord-005478-5iu38pr6	3034	16	.	.	.
cord-005478-5iu38pr6	3035	1	These	these	DT
cord-005478-5iu38pr6	3035	2	changes	change	NNS
cord-005478-5iu38pr6	3035	3	were	be	VBD
cord-005478-5iu38pr6	3035	4	independent	independent	JJ
cord-005478-5iu38pr6	3035	5	of	of	IN
cord-005478-5iu38pr6	3035	6	clinically	clinically	RB
cord-005478-5iu38pr6	3035	7	significant	significant	JJ
cord-005478-5iu38pr6	3035	8	CMV	CMV	NNP
cord-005478-5iu38pr6	3035	9	reactivation	reactivation	NN
cord-005478-5iu38pr6	3035	10	.	.	.
cord-005478-5iu38pr6	3036	1	Finally	finally	RB
cord-005478-5iu38pr6	3036	2	,	,	,
cord-005478-5iu38pr6	3036	3	we	-PRON-	PRP
cord-005478-5iu38pr6	3036	4	determined	determine	VBD
cord-005478-5iu38pr6	3036	5	the	the	DT
cord-005478-5iu38pr6	3036	6	impact	impact	NN
cord-005478-5iu38pr6	3036	7	of	of	IN
cord-005478-5iu38pr6	3036	8	time	time	NN
cord-005478-5iu38pr6	3036	9	to	to	IN
cord-005478-5iu38pr6	3036	10	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3036	11	on	on	IN
cord-005478-5iu38pr6	3036	12	this	this	DT
cord-005478-5iu38pr6	3036	13	novel	novel	JJ
cord-005478-5iu38pr6	3036	14	immune	immune	NN
cord-005478-5iu38pr6	3036	15	signature	signature	NN
cord-005478-5iu38pr6	3036	16	.	.	.
cord-005478-5iu38pr6	3037	1	Reciprocal	reciprocal	JJ
cord-005478-5iu38pr6	3037	2	changes	change	NNS
cord-005478-5iu38pr6	3037	3	in	in	IN
cord-005478-5iu38pr6	3037	4	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3037	5	and	and	CC
cord-005478-5iu38pr6	3037	6	CD4	CD4	NNP
cord-005478-5iu38pr6	3037	7	Tem	Tem	NNP
cord-005478-5iu38pr6	3037	8	abundance	abundance	NN
cord-005478-5iu38pr6	3037	9	were	be	VBD
cord-005478-5iu38pr6	3037	10	more	more	RBR
cord-005478-5iu38pr6	3037	11	significant	significant	JJ
cord-005478-5iu38pr6	3037	12	in	in	IN
cord-005478-5iu38pr6	3037	13	patients	patient	NNS
cord-005478-5iu38pr6	3037	14	who	who	WP
cord-005478-5iu38pr6	3037	15	developed	develop	VBD
cord-005478-5iu38pr6	3037	16	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3037	17	before	before	IN
cord-005478-5iu38pr6	3037	18	D60	D60	NNP
cord-005478-5iu38pr6	3037	19	,	,	,
cord-005478-5iu38pr6	3037	20	consistent	consistent	JJ
cord-005478-5iu38pr6	3037	21	with	with	IN
cord-005478-5iu38pr6	3037	22	a	a	DT
cord-005478-5iu38pr6	3037	23	dynamically	dynamically	RB
cord-005478-5iu38pr6	3037	24	evolving	evolve	VBG
cord-005478-5iu38pr6	3037	25	immune	immune	JJ
cord-005478-5iu38pr6	3037	26	signature	signature	NN
cord-005478-5iu38pr6	3037	27	.	.	.
cord-005478-5iu38pr6	3038	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3038	2	:	:	:
cord-005478-5iu38pr6	3039	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3039	2	show	show	VBP
cord-005478-5iu38pr6	3039	3	proof	proof	NN
cord-005478-5iu38pr6	3039	4	-	-	HYPH
cord-005478-5iu38pr6	3039	5	of	of	IN
cord-005478-5iu38pr6	3039	6	-	-	HYPH
cord-005478-5iu38pr6	3039	7	concept	concept	NN
cord-005478-5iu38pr6	3039	8	that	that	IN
cord-005478-5iu38pr6	3039	9	a	a	DT
cord-005478-5iu38pr6	3039	10	novel	novel	JJ
cord-005478-5iu38pr6	3039	11	pipeline	pipeline	NN
cord-005478-5iu38pr6	3039	12	can	can	MD
cord-005478-5iu38pr6	3039	13	be	be	VB
cord-005478-5iu38pr6	3039	14	applied	apply	VBN
cord-005478-5iu38pr6	3039	15	to	to	IN
cord-005478-5iu38pr6	3039	16	MS	MS	NNP
cord-005478-5iu38pr6	3039	17	data	datum	NNS
cord-005478-5iu38pr6	3039	18	to	to	TO
cord-005478-5iu38pr6	3039	19	measure	measure	VB
cord-005478-5iu38pr6	3039	20	multiple	multiple	JJ
cord-005478-5iu38pr6	3039	21	immune	immune	JJ
cord-005478-5iu38pr6	3039	22	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3039	23	parameters	parameter	NNS
cord-005478-5iu38pr6	3039	24	after	after	IN
cord-005478-5iu38pr6	3039	25	AHST	AHST	NNP
cord-005478-5iu38pr6	3039	26	.	.	.
cord-005478-5iu38pr6	3040	1	Importantly	importantly	RB
cord-005478-5iu38pr6	3040	2	,	,	,
cord-005478-5iu38pr6	3040	3	this	this	DT
cord-005478-5iu38pr6	3040	4	pipeline	pipeline	NN
cord-005478-5iu38pr6	3040	5	identified	identify	VBD
cord-005478-5iu38pr6	3040	6	concomitant	concomitant	JJ
cord-005478-5iu38pr6	3040	7	loss	loss	NN
cord-005478-5iu38pr6	3040	8	of	of	IN
cord-005478-5iu38pr6	3040	9	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3040	10	and	and	CC
cord-005478-5iu38pr6	3040	11	increase	increase	NN
cord-005478-5iu38pr6	3040	12	of	of	IN
cord-005478-5iu38pr6	3040	13	CD4	CD4	NNP
cord-005478-5iu38pr6	3040	14	Tem	Tem	NNP
cord-005478-5iu38pr6	3040	15	in	in	IN
cord-005478-5iu38pr6	3040	16	patients	patient	NNS
cord-005478-5iu38pr6	3040	17	who	who	WP
cord-005478-5iu38pr6	3040	18	subsequently	subsequently	RB
cord-005478-5iu38pr6	3040	19	developed	develop	VBD
cord-005478-5iu38pr6	3040	20	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3040	21	.	.	.
cord-005478-5iu38pr6	3041	1	This	this	DT
cord-005478-5iu38pr6	3041	2	is	be	VBZ
cord-005478-5iu38pr6	3041	3	consistent	consistent	JJ
cord-005478-5iu38pr6	3041	4	with	with	IN
cord-005478-5iu38pr6	3041	5	loss	loss	NN
cord-005478-5iu38pr6	3041	6	of	of	IN
cord-005478-5iu38pr6	3041	7	NK	NK	NNP
cord-005478-5iu38pr6	3041	8	cell	cell	NN
cord-005478-5iu38pr6	3041	9	-	-	HYPH
cord-005478-5iu38pr6	3041	10	mediated	mediate	VBN
cord-005478-5iu38pr6	3041	11	control	control	NN
cord-005478-5iu38pr6	3041	12	of	of	IN
cord-005478-5iu38pr6	3041	13	alloreactive	alloreactive	JJ
cord-005478-5iu38pr6	3041	14	CD4	CD4	NNP
cord-005478-5iu38pr6	3041	15	Tem	Tem	NNP
cord-005478-5iu38pr6	3041	16	cells	cell	NNS
cord-005478-5iu38pr6	3041	17	as	as	IN
cord-005478-5iu38pr6	3041	18	the	the	DT
cord-005478-5iu38pr6	3041	19	dominant	dominant	JJ
cord-005478-5iu38pr6	3041	20	immune	immune	JJ
cord-005478-5iu38pr6	3041	21	process	process	NN
cord-005478-5iu38pr6	3041	22	preceding	precede	VBG
cord-005478-5iu38pr6	3041	23	the	the	DT
cord-005478-5iu38pr6	3041	24	development	development	NN
cord-005478-5iu38pr6	3041	25	of	of	IN
cord-005478-5iu38pr6	3041	26	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3041	27	after	after	IN
cord-005478-5iu38pr6	3041	28	RIC	RIC	NNP
cord-005478-5iu38pr6	3041	29	-	-	HYPH
cord-005478-5iu38pr6	3041	30	AHST	AHST	NNP
cord-005478-5iu38pr6	3041	31	.	.	.
cord-005478-5iu38pr6	3042	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	3042	2	data	datum	NNS
cord-005478-5iu38pr6	3042	3	provide	provide	VBP
cord-005478-5iu38pr6	3042	4	mechanistic	mechanistic	JJ
cord-005478-5iu38pr6	3042	5	insight	insight	NN
cord-005478-5iu38pr6	3042	6	into	into	IN
cord-005478-5iu38pr6	3042	7	evolution	evolution	NN
cord-005478-5iu38pr6	3042	8	of	of	IN
cord-005478-5iu38pr6	3042	9	alloreactivity	alloreactivity	NN
cord-005478-5iu38pr6	3042	10	and	and	CC
cord-005478-5iu38pr6	3042	11	support	support	VB
cord-005478-5iu38pr6	3042	12	the	the	DT
cord-005478-5iu38pr6	3042	13	development	development	NN
cord-005478-5iu38pr6	3042	14	of	of	IN
cord-005478-5iu38pr6	3042	15	strategies	strategy	NNS
cord-005478-5iu38pr6	3042	16	to	to	TO
cord-005478-5iu38pr6	3042	17	maintain	maintain	VB
cord-005478-5iu38pr6	3042	18	or	or	CC
cord-005478-5iu38pr6	3042	19	expand	expand	VB
cord-005478-5iu38pr6	3042	20	NKreg	NKreg	NNP
cord-005478-5iu38pr6	3042	21	numbers	number	NNS
cord-005478-5iu38pr6	3042	22	early	early	JJ
cord-005478-5iu38pr6	3042	23	post	post	JJ
cord-005478-5iu38pr6	3042	24	-	-	NN
cord-005478-5iu38pr6	3042	25	transplant	transplant	NN
cord-005478-5iu38pr6	3042	26	to	to	TO
cord-005478-5iu38pr6	3042	27	reduce	reduce	VB
cord-005478-5iu38pr6	3042	28	harmful	harmful	JJ
cord-005478-5iu38pr6	3042	29	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3042	30	.	.	.
cord-005478-5iu38pr6	3043	1	[	[	-LRB-
cord-005478-5iu38pr6	3043	2	[	[	-LRB-
cord-005478-5iu38pr6	3043	3	O149	o149	CD
cord-005478-5iu38pr6	3043	4	Image	image	NN
cord-005478-5iu38pr6	3043	5	]	]	-RRB-
cord-005478-5iu38pr6	3043	6	1	1	CD
cord-005478-5iu38pr6	3043	7	.	.	.
cord-005478-5iu38pr6	3044	1	Dominant	dominant	JJ
cord-005478-5iu38pr6	3044	2	immune	immune	JJ
cord-005478-5iu38pr6	3044	3	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3044	4	signature	signature	NN
cord-005478-5iu38pr6	3044	5	early	early	RB
cord-005478-5iu38pr6	3044	6	after	after	IN
cord-005478-5iu38pr6	3044	7	RIC	RIC	NNP
cord-005478-5iu38pr6	3044	8	-	-	HYPH
cord-005478-5iu38pr6	3044	9	AHST	AHST	NNP
cord-005478-5iu38pr6	3044	10	associated	associate	VBN
cord-005478-5iu38pr6	3044	11	with	with	IN
cord-005478-5iu38pr6	3044	12	subsequent	subsequent	JJ
cord-005478-5iu38pr6	3044	13	acute	acute	JJ
cord-005478-5iu38pr6	3044	14	GvHD	gvhd	NN
cord-005478-5iu38pr6	3044	15	]	]	-RRB-
cord-005478-5iu38pr6	3045	1	Multiple	multiple	JJ
cord-005478-5iu38pr6	3045	2	myeloma	myeloma	NN
cord-005478-5iu38pr6	3045	3	O150	O150	NNP
cord-005478-5iu38pr6	3045	4	Abstract	Abstract	NNP
cord-005478-5iu38pr6	3045	5	already	already	RB
cord-005478-5iu38pr6	3045	6	published	publish	VBN
cord-005478-5iu38pr6	3045	7	.	.	.
cord-005478-5iu38pr6	3046	1	Impact	impact	NN
cord-005478-5iu38pr6	3046	2	of	of	IN
cord-005478-5iu38pr6	3046	3	high	high	JJ
cord-005478-5iu38pr6	3046	4	-	-	HYPH
cord-005478-5iu38pr6	3046	5	risk	risk	NN
cord-005478-5iu38pr6	3046	6	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	3046	7	in	in	IN
cord-005478-5iu38pr6	3046	8	newly	newly	RB
cord-005478-5iu38pr6	3046	9	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	3046	10	multiple	multiple	JJ
cord-005478-5iu38pr6	3046	11	myeloma	myeloma	NN
cord-005478-5iu38pr6	3046	12	undergoing	undergo	VBG
cord-005478-5iu38pr6	3046	13	upfront	upfront	JJ
cord-005478-5iu38pr6	3046	14	stem	stem	NN
cord-005478-5iu38pr6	3046	15	cell	cell	NN
cord-005478-5iu38pr6	3046	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	3046	17	:	:	:
cord-005478-5iu38pr6	3046	18	A	a	DT
cord-005478-5iu38pr6	3046	19	study	study	NN
cord-005478-5iu38pr6	3046	20	from	from	IN
cord-005478-5iu38pr6	3046	21	the	the	DT
cord-005478-5iu38pr6	3046	22	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3046	23	chronic	chronic	JJ
cord-005478-5iu38pr6	3046	24	malignancies	malignancy	NNS
cord-005478-5iu38pr6	3046	25	working	work	VBG
cord-005478-5iu38pr6	3046	26	party	party	NN
cord-005478-5iu38pr6	3046	27	Background	Background	NNP
cord-005478-5iu38pr6	3046	28	:	:	:
cord-005478-5iu38pr6	3046	29	Current	current	JJ
cord-005478-5iu38pr6	3046	30	consensus	consensus	NN
cord-005478-5iu38pr6	3046	31	identifies	identify	VBZ
cord-005478-5iu38pr6	3046	32	t(4;14	t(4;14	NN
cord-005478-5iu38pr6	3046	33	)	)	-RRB-
cord-005478-5iu38pr6	3046	34	,	,	,
cord-005478-5iu38pr6	3046	35	t(14;16	t(14;16	NNP
cord-005478-5iu38pr6	3046	36	)	)	-RRB-
cord-005478-5iu38pr6	3046	37	,	,	,
cord-005478-5iu38pr6	3046	38	t(14;20	t(14;20	ADD
cord-005478-5iu38pr6	3046	39	)	)	-RRB-
cord-005478-5iu38pr6	3046	40	,	,	,
cord-005478-5iu38pr6	3046	41	gain	gain	NN
cord-005478-5iu38pr6	3046	42	and/or	and/or	CC
cord-005478-5iu38pr6	3046	43	deletion	deletion	NN
cord-005478-5iu38pr6	3046	44	in	in	IN
cord-005478-5iu38pr6	3046	45	chromosome	chromosome	NN
cord-005478-5iu38pr6	3046	46	1	1	CD
cord-005478-5iu38pr6	3046	47	,	,	,
cord-005478-5iu38pr6	3046	48	and	and	CC
cord-005478-5iu38pr6	3046	49	del(17/	del(17/	NNS
cord-005478-5iu38pr6	3046	50	17p	17p	CD
cord-005478-5iu38pr6	3046	51	)	)	-RRB-
cord-005478-5iu38pr6	3046	52	as	as	IN
cord-005478-5iu38pr6	3046	53	high	high	JJ
cord-005478-5iu38pr6	3046	54	-	-	HYPH
cord-005478-5iu38pr6	3046	55	risk	risk	NN
cord-005478-5iu38pr6	3046	56	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	3046	57	in	in	IN
cord-005478-5iu38pr6	3046	58	newly	newly	RB
cord-005478-5iu38pr6	3046	59	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	3046	60	multiple	multiple	JJ
cord-005478-5iu38pr6	3046	61	myeloma	myeloma	NN
cord-005478-5iu38pr6	3046	62	(	(	-LRB-
cord-005478-5iu38pr6	3046	63	NDMM	NDMM	NNP
cord-005478-5iu38pr6	3046	64	)	)	-RRB-
cord-005478-5iu38pr6	3046	65	.	.	.
cord-005478-5iu38pr6	3047	1	However	however	RB
cord-005478-5iu38pr6	3047	2	,	,	,
cord-005478-5iu38pr6	3047	3	evidence	evidence	NN
cord-005478-5iu38pr6	3047	4	on	on	IN
cord-005478-5iu38pr6	3047	5	outcome	outcome	NN
cord-005478-5iu38pr6	3047	6	of	of	IN
cord-005478-5iu38pr6	3047	7	specific	specific	JJ
cord-005478-5iu38pr6	3047	8	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	3047	9	after	after	IN
cord-005478-5iu38pr6	3047	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	3047	11	as	as	IN
cord-005478-5iu38pr6	3047	12	first	first	JJ
cord-005478-5iu38pr6	3047	13	-	-	HYPH
cord-005478-5iu38pr6	3047	14	line	line	NN
cord-005478-5iu38pr6	3047	15	treatment	treatment	NN
cord-005478-5iu38pr6	3047	16	is	be	VBZ
cord-005478-5iu38pr6	3047	17	limited	limit	VBN
cord-005478-5iu38pr6	3047	18	.	.	.
cord-005478-5iu38pr6	3048	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3048	2	analyzed	analyze	VBD
cord-005478-5iu38pr6	3048	3	high	high	JJ
cord-005478-5iu38pr6	3048	4	-	-	HYPH
cord-005478-5iu38pr6	3048	5	risk	risk	NN
cord-005478-5iu38pr6	3048	6	NDMM	NDMM	NNP
cord-005478-5iu38pr6	3048	7	patients	patient	NNS
cord-005478-5iu38pr6	3048	8	reported	report	VBD
cord-005478-5iu38pr6	3048	9	to	to	IN
cord-005478-5iu38pr6	3048	10	the	the	DT
cord-005478-5iu38pr6	3048	11	European	European	NNP
cord-005478-5iu38pr6	3048	12	Society	Society	NNP
cord-005478-5iu38pr6	3048	13	for	for	IN
cord-005478-5iu38pr6	3048	14	Blood	blood	NN
cord-005478-5iu38pr6	3048	15	and	and	CC
cord-005478-5iu38pr6	3048	16	Marrow	marrow	NN
cord-005478-5iu38pr6	3048	17	Transplantation	transplantation	NN
cord-005478-5iu38pr6	3048	18	(	(	-LRB-
cord-005478-5iu38pr6	3048	19	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3048	20	)	)	-RRB-
cord-005478-5iu38pr6	3048	21	registry	registry	NN
cord-005478-5iu38pr6	3048	22	undergoing	undergo	VBG
cord-005478-5iu38pr6	3048	23	upfront	upfront	JJ
cord-005478-5iu38pr6	3048	24	stem	stem	NN
cord-005478-5iu38pr6	3048	25	cell	cell	NN
cord-005478-5iu38pr6	3048	26	transplantation	transplantation	NN
cord-005478-5iu38pr6	3048	27	.	.	.
cord-005478-5iu38pr6	3049	1	Methods	method	NNS
cord-005478-5iu38pr6	3049	2	:	:	:
cord-005478-5iu38pr6	3049	3	Upfront	upfront	NN
cord-005478-5iu38pr6	3049	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	3049	5	was	be	VBD
cord-005478-5iu38pr6	3049	6	defined	define	VBN
cord-005478-5iu38pr6	3049	7	as	as	IN
cord-005478-5iu38pr6	3049	8	first	first	JJ
cord-005478-5iu38pr6	3049	9	autologous	autologous	JJ
cord-005478-5iu38pr6	3049	10	transplant	transplant	NN
cord-005478-5iu38pr6	3049	11	within	within	IN
cord-005478-5iu38pr6	3049	12	12	12	CD
cord-005478-5iu38pr6	3049	13	months	month	NNS
cord-005478-5iu38pr6	3049	14	from	from	IN
cord-005478-5iu38pr6	3049	15	MM	MM	NNP
cord-005478-5iu38pr6	3049	16	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3049	17	.	.	.
cord-005478-5iu38pr6	3050	1	Survival	survival	NN
cord-005478-5iu38pr6	3050	2	and	and	CC
cord-005478-5iu38pr6	3050	3	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3050	4	incidence	incidence	NN
cord-005478-5iu38pr6	3050	5	were	be	VBD
cord-005478-5iu38pr6	3050	6	calculated	calculate	VBN
cord-005478-5iu38pr6	3050	7	from	from	IN
cord-005478-5iu38pr6	3050	8	date	date	NN
cord-005478-5iu38pr6	3050	9	of	of	IN
cord-005478-5iu38pr6	3050	10	first	first	JJ
cord-005478-5iu38pr6	3050	11	transplant	transplant	NN
cord-005478-5iu38pr6	3050	12	(	(	-LRB-
cord-005478-5iu38pr6	3050	13	95	95	CD
cord-005478-5iu38pr6	3050	14	%	%	NN
cord-005478-5iu38pr6	3050	15	confidence	confidence	NN
cord-005478-5iu38pr6	3050	16	interval	interval	NN
cord-005478-5iu38pr6	3050	17	)	)	-RRB-
cord-005478-5iu38pr6	3050	18	.	.	.
cord-005478-5iu38pr6	3051	1	End	end	NN
cord-005478-5iu38pr6	3051	2	points	point	NNS
cord-005478-5iu38pr6	3051	3	were	be	VBD
cord-005478-5iu38pr6	3051	4	progression	progression	NN
cord-005478-5iu38pr6	3051	5	-	-	HYPH
cord-005478-5iu38pr6	3051	6	free	free	JJ
cord-005478-5iu38pr6	3051	7	survival	survival	NN
cord-005478-5iu38pr6	3051	8	(	(	-LRB-
cord-005478-5iu38pr6	3051	9	PFS	PFS	NNP
cord-005478-5iu38pr6	3051	10	)	)	-RRB-
cord-005478-5iu38pr6	3051	11	,	,	,
cord-005478-5iu38pr6	3051	12	overall	overall	JJ
cord-005478-5iu38pr6	3051	13	survival	survival	NN
cord-005478-5iu38pr6	3051	14	(	(	-LRB-
cord-005478-5iu38pr6	3051	15	OS	OS	NNP
cord-005478-5iu38pr6	3051	16	)	)	-RRB-
cord-005478-5iu38pr6	3051	17	,	,	,
cord-005478-5iu38pr6	3051	18	relapse	relapse	NN
cord-005478-5iu38pr6	3051	19	and	and	CC
cord-005478-5iu38pr6	3051	20	non	non	JJ
cord-005478-5iu38pr6	3051	21	-	-	JJ
cord-005478-5iu38pr6	3051	22	relapse	relapse	JJ
cord-005478-5iu38pr6	3051	23	mortality	mortality	NN
cord-005478-5iu38pr6	3051	24	(	(	-LRB-
cord-005478-5iu38pr6	3051	25	NRM	NRM	NNP
cord-005478-5iu38pr6	3051	26	)	)	-RRB-
cord-005478-5iu38pr6	3051	27	.	.	.
cord-005478-5iu38pr6	3052	1	Cox	Cox	NNP
cord-005478-5iu38pr6	3052	2	model	model	NN
cord-005478-5iu38pr6	3052	3	with	with	IN
cord-005478-5iu38pr6	3052	4	hazard	hazard	NN
cord-005478-5iu38pr6	3052	5	ratios	ratio	NNS
cord-005478-5iu38pr6	3052	6	(	(	-LRB-
cord-005478-5iu38pr6	3052	7	HR	HR	NNP
cord-005478-5iu38pr6	3052	8	)	)	-RRB-
cord-005478-5iu38pr6	3052	9	was	be	VBD
cord-005478-5iu38pr6	3052	10	used	use	VBN
cord-005478-5iu38pr6	3052	11	for	for	IN
cord-005478-5iu38pr6	3052	12	multivariable	multivariable	JJ
cord-005478-5iu38pr6	3052	13	OS	OS	NNP
cord-005478-5iu38pr6	3052	14	analyses	analysis	NNS
cord-005478-5iu38pr6	3052	15	and	and	CC
cord-005478-5iu38pr6	3052	16	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3052	17	incidence	incidence	NN
cord-005478-5iu38pr6	3052	18	method	method	NN
cord-005478-5iu38pr6	3052	19	for	for	IN
cord-005478-5iu38pr6	3052	20	relapse	relapse	NN
cord-005478-5iu38pr6	3052	21	incidence	incidence	NN
cord-005478-5iu38pr6	3052	22	and	and	CC
cord-005478-5iu38pr6	3052	23	NRM	NRM	NNP
cord-005478-5iu38pr6	3052	24	.	.	.
cord-005478-5iu38pr6	3053	1	Results	result	NNS
cord-005478-5iu38pr6	3053	2	:	:	:
cord-005478-5iu38pr6	3054	1	Within	within	IN
cord-005478-5iu38pr6	3054	2	the	the	DT
cord-005478-5iu38pr6	3054	3	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3054	4	registry	registry	NN
cord-005478-5iu38pr6	3054	5	,	,	,
cord-005478-5iu38pr6	3054	6	623	623	CD
cord-005478-5iu38pr6	3054	7	high	high	JJ
cord-005478-5iu38pr6	3054	8	-	-	HYPH
cord-005478-5iu38pr6	3054	9	risk	risk	NN
cord-005478-5iu38pr6	3054	10	NDMM	NDMM	NNP
cord-005478-5iu38pr6	3054	11	patients	patient	NNS
cord-005478-5iu38pr6	3054	12	according	accord	VBG
cord-005478-5iu38pr6	3054	13	to	to	IN
cord-005478-5iu38pr6	3054	14	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	3054	15	underwent	undergo	VBD
cord-005478-5iu38pr6	3054	16	single	single	JJ
cord-005478-5iu38pr6	3054	17	autologous	autologous	NN
cord-005478-5iu38pr6	3054	18	(	(	-LRB-
cord-005478-5iu38pr6	3054	19	n=446	n=446	CD
cord-005478-5iu38pr6	3054	20	)	)	-RRB-
cord-005478-5iu38pr6	3054	21	,	,	,
cord-005478-5iu38pr6	3054	22	tandem	tandem	JJ
cord-005478-5iu38pr6	3054	23	autologous	autologous	JJ
cord-005478-5iu38pr6	3054	24	(	(	-LRB-
cord-005478-5iu38pr6	3054	25	n=105	n=105	NNP
cord-005478-5iu38pr6	3054	26	)	)	-RRB-
cord-005478-5iu38pr6	3054	27	,	,	,
cord-005478-5iu38pr6	3054	28	autologous	autologous	JJ
cord-005478-5iu38pr6	3054	29	-	-	HYPH
cord-005478-5iu38pr6	3054	30	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	3054	31	(	(	-LRB-
cord-005478-5iu38pr6	3054	32	n=72	n=72	NN
cord-005478-5iu38pr6	3054	33	)	)	-RRB-
cord-005478-5iu38pr6	3054	34	stem	stem	NN
cord-005478-5iu38pr6	3054	35	cell	cell	NN
cord-005478-5iu38pr6	3054	36	transplantation	transplantation	NN
cord-005478-5iu38pr6	3054	37	between	between	IN
cord-005478-5iu38pr6	3054	38	2000	2000	CD
cord-005478-5iu38pr6	3054	39	and	and	CC
cord-005478-5iu38pr6	3054	40	2015	2015	CD
cord-005478-5iu38pr6	3054	41	.	.	.
cord-005478-5iu38pr6	3055	1	The	the	DT
cord-005478-5iu38pr6	3055	2	median	median	JJ
cord-005478-5iu38pr6	3055	3	follow	follow	NN
cord-005478-5iu38pr6	3055	4	-	-	HYPH
cord-005478-5iu38pr6	3055	5	up	up	NN
cord-005478-5iu38pr6	3055	6	of	of	IN
cord-005478-5iu38pr6	3055	7	all	all	DT
cord-005478-5iu38pr6	3055	8	patients	patient	NNS
cord-005478-5iu38pr6	3055	9	was	be	VBD
cord-005478-5iu38pr6	3055	10	58	58	CD
cord-005478-5iu38pr6	3055	11	months	month	NNS
cord-005478-5iu38pr6	3055	12	(	(	-LRB-
cord-005478-5iu38pr6	3055	13	95	95	CD
cord-005478-5iu38pr6	3055	14	%	%	NN
cord-005478-5iu38pr6	3055	15	CI	CI	NNP
cord-005478-5iu38pr6	3055	16	,	,	,
cord-005478-5iu38pr6	3055	17	52	52	CD
cord-005478-5iu38pr6	3055	18	-	-	SYM
cord-005478-5iu38pr6	3055	19	63	63	CD
cord-005478-5iu38pr6	3055	20	months	month	NNS
cord-005478-5iu38pr6	3055	21	)	)	-RRB-
cord-005478-5iu38pr6	3055	22	,	,	,
cord-005478-5iu38pr6	3055	23	the	the	DT
cord-005478-5iu38pr6	3055	24	median	median	JJ
cord-005478-5iu38pr6	3055	25	age	age	NN
cord-005478-5iu38pr6	3055	26	was	be	VBD
cord-005478-5iu38pr6	3055	27	59	59	CD
cord-005478-5iu38pr6	3055	28	years	year	NNS
cord-005478-5iu38pr6	3056	1	(	(	-LRB-
cord-005478-5iu38pr6	3056	2	range	range	NN
cord-005478-5iu38pr6	3056	3	,	,	,
cord-005478-5iu38pr6	3056	4	25	25	CD
cord-005478-5iu38pr6	3056	5	-	-	SYM
cord-005478-5iu38pr6	3056	6	76	76	CD
cord-005478-5iu38pr6	3056	7	years	year	NNS
cord-005478-5iu38pr6	3056	8	)	)	-RRB-
cord-005478-5iu38pr6	3056	9	and	and	CC
cord-005478-5iu38pr6	3056	10	the	the	DT
cord-005478-5iu38pr6	3056	11	median	median	JJ
cord-005478-5iu38pr6	3056	12	time	time	NN
cord-005478-5iu38pr6	3056	13	between	between	IN
cord-005478-5iu38pr6	3056	14	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3056	15	and	and	CC
cord-005478-5iu38pr6	3056	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	3056	17	was	be	VBD
cord-005478-5iu38pr6	3056	18	5.6	5.6	CD
cord-005478-5iu38pr6	3056	19	months	month	NNS
cord-005478-5iu38pr6	3056	20	(	(	-LRB-
cord-005478-5iu38pr6	3056	21	range	range	NN
cord-005478-5iu38pr6	3056	22	,	,	,
cord-005478-5iu38pr6	3056	23	2.2	2.2	CD
cord-005478-5iu38pr6	3056	24	-	-	SYM
cord-005478-5iu38pr6	3056	25	11.7	11.7	CD
cord-005478-5iu38pr6	3056	26	months	month	NNS
cord-005478-5iu38pr6	3056	27	)	)	-RRB-
cord-005478-5iu38pr6	3056	28	.	.	.
cord-005478-5iu38pr6	3057	1	Frequencies	frequency	NNS
cord-005478-5iu38pr6	3057	2	according	accord	VBG
cord-005478-5iu38pr6	3057	3	to	to	IN
cord-005478-5iu38pr6	3057	4	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3057	5	were	be	VBD
cord-005478-5iu38pr6	3057	6	:	:	:
cord-005478-5iu38pr6	3057	7	del(17	del(17	NNP
cord-005478-5iu38pr6	3057	8	)	)	-RRB-
cord-005478-5iu38pr6	3058	1	(	(	-LRB-
cord-005478-5iu38pr6	3058	2	n=333	n=333	NNP
cord-005478-5iu38pr6	3058	3	,	,	,
cord-005478-5iu38pr6	3058	4	54	54	CD
cord-005478-5iu38pr6	3058	5	%	%	NN
cord-005478-5iu38pr6	3058	6	)	)	-RRB-
cord-005478-5iu38pr6	3058	7	,	,	,
cord-005478-5iu38pr6	3058	8	t	t	NNP
cord-005478-5iu38pr6	3058	9	(	(	-LRB-
cord-005478-5iu38pr6	3058	10	4;14	4;14	CD
cord-005478-5iu38pr6	3058	11	)	)	-RRB-
cord-005478-5iu38pr6	3058	12	(	(	-LRB-
cord-005478-5iu38pr6	3058	13	n=344	n=344	NNP
cord-005478-5iu38pr6	3058	14	,	,	,
cord-005478-5iu38pr6	3058	15	55	55	CD
cord-005478-5iu38pr6	3058	16	%	%	NN
cord-005478-5iu38pr6	3058	17	)	)	-RRB-
cord-005478-5iu38pr6	3058	18	,	,	,
cord-005478-5iu38pr6	3058	19	gain	gain	NN
cord-005478-5iu38pr6	3058	20	or	or	CC
cord-005478-5iu38pr6	3058	21	deletion	deletion	NN
cord-005478-5iu38pr6	3058	22	in	in	IN
cord-005478-5iu38pr6	3058	23	chromosome	chromosome	NN
cord-005478-5iu38pr6	3058	24	1	1	CD
cord-005478-5iu38pr6	3058	25	(	(	-LRB-
cord-005478-5iu38pr6	3058	26	n=85	n=85	NNP
cord-005478-5iu38pr6	3058	27	,	,	,
cord-005478-5iu38pr6	3058	28	14	14	CD
cord-005478-5iu38pr6	3058	29	%	%	NN
cord-005478-5iu38pr6	3058	30	)	)	-RRB-
cord-005478-5iu38pr6	3058	31	,	,	,
cord-005478-5iu38pr6	3058	32	t(14;16	t(14;16	ADD
cord-005478-5iu38pr6	3058	33	)	)	-RRB-
cord-005478-5iu38pr6	3058	34	(	(	-LRB-
cord-005478-5iu38pr6	3058	35	n=19	n=19	JJ
cord-005478-5iu38pr6	3058	36	,	,	,
cord-005478-5iu38pr6	3058	37	3	3	CD
cord-005478-5iu38pr6	3058	38	%	%	NN
cord-005478-5iu38pr6	3058	39	)	)	-RRB-
cord-005478-5iu38pr6	3058	40	.	.	.
cord-005478-5iu38pr6	3059	1	Two	two	CD
cord-005478-5iu38pr6	3059	2	or	or	CC
cord-005478-5iu38pr6	3059	3	more	more	JJR
cord-005478-5iu38pr6	3059	4	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3059	5	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	3059	6	were	be	VBD
cord-005478-5iu38pr6	3059	7	documented	document	VBN
cord-005478-5iu38pr6	3059	8	in	in	IN
cord-005478-5iu38pr6	3059	9	143	143	CD
cord-005478-5iu38pr6	3059	10	patients	patient	NNS
cord-005478-5iu38pr6	3059	11	(	(	-LRB-
cord-005478-5iu38pr6	3059	12	23	23	CD
cord-005478-5iu38pr6	3059	13	%	%	NN
cord-005478-5iu38pr6	3059	14	)	)	-RRB-
cord-005478-5iu38pr6	3059	15	.	.	.
cord-005478-5iu38pr6	3060	1	56	56	CD
cord-005478-5iu38pr6	3060	2	%	%	NN
cord-005478-5iu38pr6	3060	3	of	of	IN
cord-005478-5iu38pr6	3060	4	patients	patient	NNS
cord-005478-5iu38pr6	3060	5	were	be	VBD
cord-005478-5iu38pr6	3061	1	male	male	JJ
cord-005478-5iu38pr6	3061	2	and	and	CC
cord-005478-5iu38pr6	3061	3	most	most	JJS
cord-005478-5iu38pr6	3061	4	patients	patient	NNS
cord-005478-5iu38pr6	3061	5	had	have	VBD
cord-005478-5iu38pr6	3061	6	IgG	IgG	NNP
cord-005478-5iu38pr6	3061	7	(	(	-LRB-
cord-005478-5iu38pr6	3061	8	53	53	CD
cord-005478-5iu38pr6	3061	9	%	%	NN
cord-005478-5iu38pr6	3061	10	)	)	-RRB-
cord-005478-5iu38pr6	3061	11	or	or	CC
cord-005478-5iu38pr6	3061	12	IgA	IgA	NNP
cord-005478-5iu38pr6	3061	13	(	(	-LRB-
cord-005478-5iu38pr6	3061	14	26	26	CD
cord-005478-5iu38pr6	3061	15	%	%	NN
cord-005478-5iu38pr6	3061	16	)	)	-RRB-
cord-005478-5iu38pr6	3061	17	paraproteins	paraprotein	NNS
cord-005478-5iu38pr6	3061	18	.	.	.
cord-005478-5iu38pr6	3062	1	A	a	DT
cord-005478-5iu38pr6	3062	2	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	3062	3	performance	performance	NN
cord-005478-5iu38pr6	3062	4	status	status	NN
cord-005478-5iu38pr6	3062	5	<	<	XX
cord-005478-5iu38pr6	3062	6	90	90	CD
cord-005478-5iu38pr6	3062	7	%	%	NN
cord-005478-5iu38pr6	3062	8	had	have	VBD
cord-005478-5iu38pr6	3062	9	29	29	CD
cord-005478-5iu38pr6	3062	10	%	%	NN
cord-005478-5iu38pr6	3062	11	of	of	IN
cord-005478-5iu38pr6	3062	12	patients	patient	NNS
cord-005478-5iu38pr6	3062	13	while	while	IN
cord-005478-5iu38pr6	3062	14	frequencies	frequency	NNS
cord-005478-5iu38pr6	3062	15	according	accord	VBG
cord-005478-5iu38pr6	3062	16	to	to	IN
cord-005478-5iu38pr6	3062	17	International	International	NNP
cord-005478-5iu38pr6	3062	18	Staging	Staging	NNP
cord-005478-5iu38pr6	3062	19	System	System	NNP
cord-005478-5iu38pr6	3062	20	(	(	-LRB-
cord-005478-5iu38pr6	3062	21	ISS	ISS	NNP
cord-005478-5iu38pr6	3062	22	)	)	-RRB-
cord-005478-5iu38pr6	3062	23	I	I	NNP
cord-005478-5iu38pr6	3062	24	/	/	SYM
cord-005478-5iu38pr6	3062	25	II	II	NNP
cord-005478-5iu38pr6	3062	26	/	/	SYM
cord-005478-5iu38pr6	3062	27	III	III	NNP
cord-005478-5iu38pr6	3062	28	were	be	VBD
cord-005478-5iu38pr6	3062	29	21%/57%/22	21%/57%/22	CD
cord-005478-5iu38pr6	3062	30	%	%	NN
cord-005478-5iu38pr6	3062	31	.	.	.
cord-005478-5iu38pr6	3063	1	Complete	complete	JJ
cord-005478-5iu38pr6	3063	2	remission	remission	NN
cord-005478-5iu38pr6	3063	3	(	(	-LRB-
cord-005478-5iu38pr6	3063	4	CR	cr	NN
cord-005478-5iu38pr6	3063	5	)	)	-RRB-
cord-005478-5iu38pr6	3063	6	at	at	IN
cord-005478-5iu38pr6	3063	7	time	time	NN
cord-005478-5iu38pr6	3063	8	of	of	IN
cord-005478-5iu38pr6	3063	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	3063	10	was	be	VBD
cord-005478-5iu38pr6	3063	11	achieved	achieve	VBN
cord-005478-5iu38pr6	3063	12	by	by	IN
cord-005478-5iu38pr6	3063	13	18	18	CD
cord-005478-5iu38pr6	3063	14	%	%	NN
cord-005478-5iu38pr6	3063	15	.	.	.
cord-005478-5iu38pr6	3064	1	In	in	IN
cord-005478-5iu38pr6	3064	2	univariable	univariable	JJ
cord-005478-5iu38pr6	3064	3	analysis	analysis	NN
cord-005478-5iu38pr6	3064	4	,	,	,
cord-005478-5iu38pr6	3064	5	presence	presence	NN
cord-005478-5iu38pr6	3064	6	vs	vs	IN
cord-005478-5iu38pr6	3064	7	absence	absence	NN
cord-005478-5iu38pr6	3064	8	of	of	IN
cord-005478-5iu38pr6	3064	9	del	del	NNP
cord-005478-5iu38pr6	3064	10	(	(	-LRB-
cord-005478-5iu38pr6	3064	11	17	17	CD
cord-005478-5iu38pr6	3064	12	)	)	-RRB-
cord-005478-5iu38pr6	3065	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3065	2	:	:	:
cord-005478-5iu38pr6	3066	1	In	in	IN
cord-005478-5iu38pr6	3066	2	NDMM	NDMM	NNP
cord-005478-5iu38pr6	3066	3	patients	patient	NNS
cord-005478-5iu38pr6	3066	4	with	with	IN
cord-005478-5iu38pr6	3066	5	at	at	RB
cord-005478-5iu38pr6	3066	6	least	least	RBS
cord-005478-5iu38pr6	3066	7	one	one	CD
cord-005478-5iu38pr6	3066	8	highrisk	highrisk	NN
cord-005478-5iu38pr6	3066	9	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3066	10	abnormality	abnormality	NN
cord-005478-5iu38pr6	3066	11	undergoing	undergo	VBG
cord-005478-5iu38pr6	3066	12	upfront	upfront	JJ
cord-005478-5iu38pr6	3066	13	transplantation	transplantation	NN
cord-005478-5iu38pr6	3066	14	,	,	,
cord-005478-5iu38pr6	3066	15	outcome	outcome	NN
cord-005478-5iu38pr6	3066	16	was	be	VBD
cord-005478-5iu38pr6	3066	17	similar	similar	JJ
cord-005478-5iu38pr6	3066	18	between	between	IN
cord-005478-5iu38pr6	3066	19	del(17	del(17	NNP
cord-005478-5iu38pr6	3066	20	)	)	-RRB-
cord-005478-5iu38pr6	3066	21	and	and	CC
cord-005478-5iu38pr6	3066	22	t(4;14	t(4;14	NNP
cord-005478-5iu38pr6	3066	23	)	)	-RRB-
cord-005478-5iu38pr6	3066	24	while	while	IN
cord-005478-5iu38pr6	3066	25	the	the	DT
cord-005478-5iu38pr6	3066	26	presence	presence	NN
cord-005478-5iu38pr6	3066	27	of	of	IN
cord-005478-5iu38pr6	3066	28	two	two	CD
cord-005478-5iu38pr6	3066	29	or	or	CC
cord-005478-5iu38pr6	3066	30	more	more	JJR
cord-005478-5iu38pr6	3066	31	high	high	JJ
cord-005478-5iu38pr6	3066	32	-	-	HYPH
cord-005478-5iu38pr6	3066	33	risk	risk	NN
cord-005478-5iu38pr6	3066	34	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3066	35	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	3066	36	showed	show	VBD
cord-005478-5iu38pr6	3066	37	significantly	significantly	RB
cord-005478-5iu38pr6	3066	38	worse	bad	JJR
cord-005478-5iu38pr6	3066	39	OS	os	NN
cord-005478-5iu38pr6	3066	40	compared	compare	VBN
cord-005478-5iu38pr6	3066	41	with	with	IN
cord-005478-5iu38pr6	3066	42	only	only	RB
cord-005478-5iu38pr6	3066	43	one	one	CD
cord-005478-5iu38pr6	3066	44	high	high	JJ
cord-005478-5iu38pr6	3066	45	-	-	HYPH
cord-005478-5iu38pr6	3066	46	risk	risk	NN
cord-005478-5iu38pr6	3066	47	abnormality	abnormality	NN
cord-005478-5iu38pr6	3066	48	.	.	.
cord-005478-5iu38pr6	3067	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3067	2	:	:	:
cord-005478-5iu38pr6	3067	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3067	4	to	to	TO
cord-005478-5iu38pr6	3067	5	declare	declare	VB
cord-005478-5iu38pr6	3067	6	.	.	.
cord-005478-5iu38pr6	3068	1	The	the	DT
cord-005478-5iu38pr6	3068	2	role	role	NN
cord-005478-5iu38pr6	3068	3	of	of	IN
cord-005478-5iu38pr6	3068	4	renal	renal	JJ
cord-005478-5iu38pr6	3068	5	impairment	impairment	NN
cord-005478-5iu38pr6	3068	6	at	at	IN
cord-005478-5iu38pr6	3068	7	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3068	8	in	in	IN
cord-005478-5iu38pr6	3068	9	multiple	multiple	JJ
cord-005478-5iu38pr6	3068	10	myeloma	myeloma	NN
cord-005478-5iu38pr6	3068	11	undergoing	undergo	VBG
cord-005478-5iu38pr6	3068	12	autologous	autologous	JJ
cord-005478-5iu38pr6	3068	13	transplantation	transplantation	NN
cord-005478-5iu38pr6	3068	14	.	.	.
cord-005478-5iu38pr6	3069	1	A	a	DT
cord-005478-5iu38pr6	3069	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3069	3	analysis	analysis	NN
cord-005478-5iu38pr6	3069	4	of	of	IN
cord-005478-5iu38pr6	3069	5	the	the	DT
cord-005478-5iu38pr6	3069	6	CMWP	CMWP	NNP
cord-005478-5iu38pr6	3069	7	Background	Background	NNP
cord-005478-5iu38pr6	3069	8	:	:	:
cord-005478-5iu38pr6	3070	1	Renal	renal	JJ
cord-005478-5iu38pr6	3070	2	impairment	impairment	NN
cord-005478-5iu38pr6	3070	3	(	(	-LRB-
cord-005478-5iu38pr6	3070	4	RI	RI	NNP
cord-005478-5iu38pr6	3070	5	)	)	-RRB-
cord-005478-5iu38pr6	3070	6	is	be	VBZ
cord-005478-5iu38pr6	3070	7	frequent	frequent	JJ
cord-005478-5iu38pr6	3070	8	in	in	IN
cord-005478-5iu38pr6	3070	9	newly	newly	RB
cord-005478-5iu38pr6	3070	10	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	3070	11	myeloma	myeloma	NN
cord-005478-5iu38pr6	3070	12	patients	patient	NNS
cord-005478-5iu38pr6	3070	13	and	and	CC
cord-005478-5iu38pr6	3070	14	is	be	VBZ
cord-005478-5iu38pr6	3070	15	considered	consider	VBN
cord-005478-5iu38pr6	3070	16	to	to	TO
cord-005478-5iu38pr6	3070	17	be	be	VB
cord-005478-5iu38pr6	3070	18	a	a	DT
cord-005478-5iu38pr6	3070	19	risk	risk	NN
cord-005478-5iu38pr6	3070	20	factor	factor	NN
cord-005478-5iu38pr6	3070	21	for	for	IN
cord-005478-5iu38pr6	3070	22	worse	bad	JJR
cord-005478-5iu38pr6	3070	23	overall	overall	JJ
cord-005478-5iu38pr6	3070	24	survival	survival	NN
cord-005478-5iu38pr6	3070	25	.	.	.
cord-005478-5iu38pr6	3071	1	With	with	IN
cord-005478-5iu38pr6	3071	2	active	active	JJ
cord-005478-5iu38pr6	3071	3	myeloma	myeloma	NN
cord-005478-5iu38pr6	3071	4	therapy	therapy	NN
cord-005478-5iu38pr6	3071	5	renal	renal	JJ
cord-005478-5iu38pr6	3071	6	function	function	NN
cord-005478-5iu38pr6	3071	7	often	often	RB
cord-005478-5iu38pr6	3071	8	improves	improve	VBZ
cord-005478-5iu38pr6	3071	9	or	or	CC
cord-005478-5iu38pr6	3071	10	even	even	RB
cord-005478-5iu38pr6	3071	11	normalises	normalise	VBZ
cord-005478-5iu38pr6	3071	12	.	.	.
cord-005478-5iu38pr6	3072	1	However	however	RB
cord-005478-5iu38pr6	3072	2	,	,	,
cord-005478-5iu38pr6	3072	3	it	-PRON-	PRP
cord-005478-5iu38pr6	3072	4	is	be	VBZ
cord-005478-5iu38pr6	3072	5	unclear	unclear	JJ
cord-005478-5iu38pr6	3072	6	whether	whether	IN
cord-005478-5iu38pr6	3072	7	renal	renal	JJ
cord-005478-5iu38pr6	3072	8	impairment	impairment	NN
cord-005478-5iu38pr6	3072	9	at	at	IN
cord-005478-5iu38pr6	3072	10	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3072	11	is	be	VBZ
cord-005478-5iu38pr6	3072	12	a	a	DT
cord-005478-5iu38pr6	3072	13	persisting	persist	VBG
cord-005478-5iu38pr6	3072	14	biological	biological	JJ
cord-005478-5iu38pr6	3072	15	risk	risk	NN
cord-005478-5iu38pr6	3072	16	factor	factor	NN
cord-005478-5iu38pr6	3072	17	or	or	CC
cord-005478-5iu38pr6	3072	18	rather	rather	RB
cord-005478-5iu38pr6	3072	19	a	a	DT
cord-005478-5iu38pr6	3072	20	potentially	potentially	RB
cord-005478-5iu38pr6	3072	21	reversible	reversible	JJ
cord-005478-5iu38pr6	3072	22	organ	organ	NN
cord-005478-5iu38pr6	3072	23	complication	complication	NN
cord-005478-5iu38pr6	3072	24	.	.	.
cord-005478-5iu38pr6	3073	1	Methods	method	NNS
cord-005478-5iu38pr6	3073	2	:	:	:
cord-005478-5iu38pr6	3073	3	From	from	IN
cord-005478-5iu38pr6	3073	4	the	the	DT
cord-005478-5iu38pr6	3073	5	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3073	6	CALM	calm	JJ
cord-005478-5iu38pr6	3073	7	study	study	NN
cord-005478-5iu38pr6	3073	8	database	database	NN
cord-005478-5iu38pr6	3073	9	all	all	DT
cord-005478-5iu38pr6	3073	10	myeloma	myeloma	NN
cord-005478-5iu38pr6	3073	11	patients	patient	NNS
cord-005478-5iu38pr6	3073	12	having	have	VBG
cord-005478-5iu38pr6	3073	13	received	receive	VBN
cord-005478-5iu38pr6	3073	14	a	a	DT
cord-005478-5iu38pr6	3073	15	first	first	JJ
cord-005478-5iu38pr6	3073	16	autologous	autologous	JJ
cord-005478-5iu38pr6	3073	17	transplant	transplant	NN
cord-005478-5iu38pr6	3073	18	between	between	IN
cord-005478-5iu38pr6	3073	19	2008	2008	CD
cord-005478-5iu38pr6	3073	20	and	and	CC
cord-005478-5iu38pr6	3073	21	2012	2012	CD
cord-005478-5iu38pr6	3073	22	with	with	IN
cord-005478-5iu38pr6	3073	23	information	information	NN
cord-005478-5iu38pr6	3073	24	on	on	IN
cord-005478-5iu38pr6	3073	25	renal	renal	JJ
cord-005478-5iu38pr6	3073	26	function	function	NN
cord-005478-5iu38pr6	3073	27	both	both	CC
cord-005478-5iu38pr6	3073	28	at	at	IN
cord-005478-5iu38pr6	3073	29	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3073	30	and	and	CC
cord-005478-5iu38pr6	3073	31	at	at	IN
cord-005478-5iu38pr6	3073	32	transplant	transplant	NN
cord-005478-5iu38pr6	3073	33	were	be	VBD
cord-005478-5iu38pr6	3073	34	extracted	extract	VBN
cord-005478-5iu38pr6	3073	35	.	.	.
cord-005478-5iu38pr6	3074	1	Renal	renal	JJ
cord-005478-5iu38pr6	3074	2	function	function	NN
cord-005478-5iu38pr6	3074	3	was	be	VBD
cord-005478-5iu38pr6	3074	4	classified	classify	VBN
cord-005478-5iu38pr6	3074	5	according	accord	VBG
cord-005478-5iu38pr6	3074	6	to	to	IN
cord-005478-5iu38pr6	3074	7	the	the	DT
cord-005478-5iu38pr6	3074	8	calculated	calculated	JJ
cord-005478-5iu38pr6	3074	9	glomerular	glomerular	JJ
cord-005478-5iu38pr6	3074	10	filtration	filtration	NN
cord-005478-5iu38pr6	3074	11	rate	rate	NN
cord-005478-5iu38pr6	3074	12	(	(	-LRB-
cord-005478-5iu38pr6	3074	13	GFR	GFR	NNP
cord-005478-5iu38pr6	3074	14	)	)	-RRB-
cord-005478-5iu38pr6	3074	15	rate	rate	NN
cord-005478-5iu38pr6	3074	16	as	as	IN
cord-005478-5iu38pr6	3074	17	normal	normal	JJ
cord-005478-5iu38pr6	3074	18	(	(	-LRB-
cord-005478-5iu38pr6	3074	19	"	"	``
cord-005478-5iu38pr6	3074	20	normal	normal	JJ
cord-005478-5iu38pr6	3074	21	"	"	''
cord-005478-5iu38pr6	3074	22	,	,	,
cord-005478-5iu38pr6	3074	23	GFR	GFR	NNP
cord-005478-5iu38pr6	3074	24	>	>	XX
cord-005478-5iu38pr6	3075	1	50	50	CD
cord-005478-5iu38pr6	3075	2	ml	ml	NNS
cord-005478-5iu38pr6	3075	3	/	/	SYM
cord-005478-5iu38pr6	3075	4	min	min	NNP
cord-005478-5iu38pr6	3075	5	)	)	-RRB-
cord-005478-5iu38pr6	3075	6	,	,	,
cord-005478-5iu38pr6	3075	7	moderately	moderately	RB
cord-005478-5iu38pr6	3075	8	impaired	impaired	JJ
cord-005478-5iu38pr6	3075	9	(	(	-LRB-
cord-005478-5iu38pr6	3075	10	"	"	``
cord-005478-5iu38pr6	3075	11	moderate	moderate	JJ
cord-005478-5iu38pr6	3075	12	"	"	''
cord-005478-5iu38pr6	3075	13	,	,	,
cord-005478-5iu38pr6	3075	14	GFR	GFR	NNP
cord-005478-5iu38pr6	3075	15	30	30	CD
cord-005478-5iu38pr6	3075	16	-	-	SYM
cord-005478-5iu38pr6	3075	17	50	50	CD
cord-005478-5iu38pr6	3075	18	ml	ml	NN
cord-005478-5iu38pr6	3075	19	/	/	SYM
cord-005478-5iu38pr6	3075	20	min	min	NN
cord-005478-5iu38pr6	3075	21	)	)	-RRB-
cord-005478-5iu38pr6	3075	22	or	or	CC
cord-005478-5iu38pr6	3075	23	severely	severely	RB
cord-005478-5iu38pr6	3075	24	impaired	impaired	JJ
cord-005478-5iu38pr6	3075	25	(	(	-LRB-
cord-005478-5iu38pr6	3075	26	"	"	``
cord-005478-5iu38pr6	3075	27	severe	severe	JJ
cord-005478-5iu38pr6	3075	28	"	"	''
cord-005478-5iu38pr6	3075	29	,	,	,
cord-005478-5iu38pr6	3075	30	GFR	GFR	NNP
cord-005478-5iu38pr6	3075	31	<	<	XX
cord-005478-5iu38pr6	3075	32	30	30	CD
cord-005478-5iu38pr6	3075	33	ml	ml	NN
cord-005478-5iu38pr6	3075	34	/	/	SYM
cord-005478-5iu38pr6	3075	35	min	min	NN
cord-005478-5iu38pr6	3075	36	)	)	-RRB-
cord-005478-5iu38pr6	3075	37	.	.	.
cord-005478-5iu38pr6	3076	1	Categorial	categorial	JJ
cord-005478-5iu38pr6	3076	2	variables	variable	NNS
cord-005478-5iu38pr6	3076	3	were	be	VBD
cord-005478-5iu38pr6	3076	4	tested	test	VBN
cord-005478-5iu38pr6	3076	5	by	by	IN
cord-005478-5iu38pr6	3076	6	Chi	Chi	NNP
cord-005478-5iu38pr6	3076	7	-	-	HYPH
cord-005478-5iu38pr6	3076	8	Square	Square	NNP
cord-005478-5iu38pr6	3076	9	test	test	NN
cord-005478-5iu38pr6	3076	10	.	.	.
cord-005478-5iu38pr6	3077	1	OS	OS	NNP
cord-005478-5iu38pr6	3077	2	was	be	VBD
cord-005478-5iu38pr6	3077	3	determined	determine	VBN
cord-005478-5iu38pr6	3077	4	from	from	IN
cord-005478-5iu38pr6	3077	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	3077	6	and	and	CC
cord-005478-5iu38pr6	3077	7	calculated	calculate	VBN
cord-005478-5iu38pr6	3077	8	by	by	IN
cord-005478-5iu38pr6	3077	9	Kaplan	Kaplan	NNP
cord-005478-5iu38pr6	3077	10	Meier	Meier	NNP
cord-005478-5iu38pr6	3077	11	with	with	IN
cord-005478-5iu38pr6	3077	12	logrank	logrank	NN
cord-005478-5iu38pr6	3077	13	testing	testing	NN
cord-005478-5iu38pr6	3077	14	.	.	.
cord-005478-5iu38pr6	3078	1	Results	result	NNS
cord-005478-5iu38pr6	3078	2	:	:	:
cord-005478-5iu38pr6	3079	1	1905	1905	CD
cord-005478-5iu38pr6	3079	2	patients	patient	NNS
cord-005478-5iu38pr6	3079	3	fulfilled	fulfil	VBD
cord-005478-5iu38pr6	3079	4	the	the	DT
cord-005478-5iu38pr6	3079	5	selection	selection	NN
cord-005478-5iu38pr6	3079	6	criteria	criterion	NNS
cord-005478-5iu38pr6	3079	7	and	and	CC
cord-005478-5iu38pr6	3079	8	were	be	VBD
cord-005478-5iu38pr6	3079	9	included	include	VBN
cord-005478-5iu38pr6	3079	10	.	.	.
cord-005478-5iu38pr6	3080	1	At	at	IN
cord-005478-5iu38pr6	3080	2	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3080	3	,	,	,
cord-005478-5iu38pr6	3080	4	1447	1447	CD
cord-005478-5iu38pr6	3080	5	patients	patient	NNS
cord-005478-5iu38pr6	3080	6	had	have	VBD
cord-005478-5iu38pr6	3080	7	normal	normal	JJ
cord-005478-5iu38pr6	3080	8	,	,	,
cord-005478-5iu38pr6	3080	9	184	184	CD
cord-005478-5iu38pr6	3080	10	moderate	moderate	JJ
cord-005478-5iu38pr6	3080	11	and	and	CC
cord-005478-5iu38pr6	3080	12	274	274	CD
cord-005478-5iu38pr6	3080	13	severe	severe	JJ
cord-005478-5iu38pr6	3080	14	RI	ri	NN
cord-005478-5iu38pr6	3080	15	.	.	.
cord-005478-5iu38pr6	3081	1	Median	median	JJ
cord-005478-5iu38pr6	3081	2	age	age	NN
cord-005478-5iu38pr6	3081	3	at	at	IN
cord-005478-5iu38pr6	3081	4	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3081	5	was	be	VBD
cord-005478-5iu38pr6	3081	6	58	58	CD
cord-005478-5iu38pr6	3081	7	,	,	,
cord-005478-5iu38pr6	3081	8	60	60	CD
cord-005478-5iu38pr6	3081	9	and	and	CC
cord-005478-5iu38pr6	3081	10	59	59	CD
cord-005478-5iu38pr6	3081	11	years	year	NNS
cord-005478-5iu38pr6	3081	12	in	in	IN
cord-005478-5iu38pr6	3081	13	the	the	DT
cord-005478-5iu38pr6	3081	14	RI	RI	NNP
cord-005478-5iu38pr6	3081	15	subgroups	subgroup	NNS
cord-005478-5iu38pr6	3081	16	.	.	.
cord-005478-5iu38pr6	3082	1	Genetic	genetic	JJ
cord-005478-5iu38pr6	3082	2	information	information	NN
cord-005478-5iu38pr6	3082	3	was	be	VBD
cord-005478-5iu38pr6	3082	4	available	available	JJ
cord-005478-5iu38pr6	3082	5	in	in	IN
cord-005478-5iu38pr6	3082	6	only	only	RB
cord-005478-5iu38pr6	3082	7	a	a	DT
cord-005478-5iu38pr6	3082	8	subgroup	subgroup	NN
cord-005478-5iu38pr6	3082	9	of	of	IN
cord-005478-5iu38pr6	3082	10	patients	patient	NNS
cord-005478-5iu38pr6	3082	11	.	.	.
cord-005478-5iu38pr6	3083	1	t(4;14	t(4;14	NNP
cord-005478-5iu38pr6	3083	2	)	)	-RRB-
cord-005478-5iu38pr6	3083	3	was	be	VBD
cord-005478-5iu38pr6	3083	4	present	present	JJ
cord-005478-5iu38pr6	3083	5	in	in	IN
cord-005478-5iu38pr6	3083	6	14	14	CD
cord-005478-5iu38pr6	3083	7	%	%	NN
cord-005478-5iu38pr6	3083	8	,	,	,
cord-005478-5iu38pr6	3083	9	22	22	CD
cord-005478-5iu38pr6	3083	10	%	%	NN
cord-005478-5iu38pr6	3083	11	and	and	CC
cord-005478-5iu38pr6	3083	12	13	13	CD
cord-005478-5iu38pr6	3083	13	%	%	NN
cord-005478-5iu38pr6	3083	14	respectively	respectively	RB
cord-005478-5iu38pr6	3083	15	and	and	CC
cord-005478-5iu38pr6	3083	16	del17	del17	NNP
cord-005478-5iu38pr6	3083	17	was	be	VBD
cord-005478-5iu38pr6	3083	18	found	find	VBN
cord-005478-5iu38pr6	3083	19	in	in	IN
cord-005478-5iu38pr6	3083	20	7	7	CD
cord-005478-5iu38pr6	3083	21	%	%	NN
cord-005478-5iu38pr6	3083	22	,	,	,
cord-005478-5iu38pr6	3083	23	8	8	CD
cord-005478-5iu38pr6	3083	24	%	%	NN
cord-005478-5iu38pr6	3083	25	and	and	CC
cord-005478-5iu38pr6	3083	26	4	4	CD
cord-005478-5iu38pr6	3083	27	%	%	NN
cord-005478-5iu38pr6	3083	28	.	.	.
cord-005478-5iu38pr6	3084	1	Bortezomib	Bortezomib	NNP
cord-005478-5iu38pr6	3084	2	-	-	HYPH
cord-005478-5iu38pr6	3084	3	based	base	VBN
cord-005478-5iu38pr6	3084	4	induction	induction	NN
cord-005478-5iu38pr6	3084	5	therapy	therapy	NN
cord-005478-5iu38pr6	3084	6	was	be	VBD
cord-005478-5iu38pr6	3084	7	given	give	VBN
cord-005478-5iu38pr6	3084	8	in	in	IN
cord-005478-5iu38pr6	3084	9	53	53	CD
cord-005478-5iu38pr6	3084	10	%	%	NN
cord-005478-5iu38pr6	3084	11	,	,	,
cord-005478-5iu38pr6	3084	12	58	58	CD
cord-005478-5iu38pr6	3084	13	%	%	NN
cord-005478-5iu38pr6	3084	14	and	and	CC
cord-005478-5iu38pr6	3084	15	64	64	CD
cord-005478-5iu38pr6	3084	16	%	%	NN
cord-005478-5iu38pr6	3084	17	of	of	IN
cord-005478-5iu38pr6	3084	18	cases	case	NNS
cord-005478-5iu38pr6	3084	19	(	(	-LRB-
cord-005478-5iu38pr6	3084	20	p=0.018	p=0.018	NNP
cord-005478-5iu38pr6	3084	21	)	)	-RRB-
cord-005478-5iu38pr6	3084	22	.	.	.
cord-005478-5iu38pr6	3085	1	OS	OS	NNP
cord-005478-5iu38pr6	3085	2	differed	differ	VBD
cord-005478-5iu38pr6	3085	3	significantly	significantly	RB
cord-005478-5iu38pr6	3085	4	between	between	IN
cord-005478-5iu38pr6	3085	5	the	the	DT
cord-005478-5iu38pr6	3085	6	RI	RI	NNP
cord-005478-5iu38pr6	3085	7	groups	group	NNS
cord-005478-5iu38pr6	3085	8	with	with	IN
cord-005478-5iu38pr6	3085	9	a	a	DT
cord-005478-5iu38pr6	3085	10	median	median	NN
cord-005478-5iu38pr6	3085	11	of	of	IN
cord-005478-5iu38pr6	3085	12	84	84	CD
cord-005478-5iu38pr6	3085	13	,	,	,
cord-005478-5iu38pr6	3085	14	72	72	CD
cord-005478-5iu38pr6	3085	15	and	and	CC
cord-005478-5iu38pr6	3085	16	62	62	CD
cord-005478-5iu38pr6	3085	17	months	month	NNS
cord-005478-5iu38pr6	3085	18	,	,	,
cord-005478-5iu38pr6	3085	19	respectively	respectively	RB
cord-005478-5iu38pr6	3085	20	(	(	-LRB-
cord-005478-5iu38pr6	3085	21	p	p	NN
cord-005478-5iu38pr6	3085	22	<	<	XX
cord-005478-5iu38pr6	3085	23	0.001	0.001	CD
cord-005478-5iu38pr6	3085	24	,	,	,
cord-005478-5iu38pr6	3085	25	Fig	Fig	NNP
cord-005478-5iu38pr6	3085	26	1	1	CD
cord-005478-5iu38pr6	3085	27	)	)	-RRB-
cord-005478-5iu38pr6	3085	28	.	.	.
cord-005478-5iu38pr6	3086	1	In	in	IN
cord-005478-5iu38pr6	3086	2	contrast	contrast	JJ
cord-005478-5iu38pr6	3086	3	renal	renal	JJ
cord-005478-5iu38pr6	3086	4	function	function	NN
cord-005478-5iu38pr6	3086	5	at	at	IN
cord-005478-5iu38pr6	3086	6	transplant	transplant	NN
cord-005478-5iu38pr6	3086	7	had	have	VBD
cord-005478-5iu38pr6	3086	8	no	no	DT
cord-005478-5iu38pr6	3086	9	impact	impact	NN
cord-005478-5iu38pr6	3086	10	on	on	IN
cord-005478-5iu38pr6	3086	11	OS	OS	NNP
cord-005478-5iu38pr6	3086	12	with	with	IN
cord-005478-5iu38pr6	3086	13	a	a	DT
cord-005478-5iu38pr6	3086	14	median	median	NN
cord-005478-5iu38pr6	3086	15	of	of	IN
cord-005478-5iu38pr6	3086	16	78	78	CD
cord-005478-5iu38pr6	3086	17	months	month	NNS
cord-005478-5iu38pr6	3086	18	(	(	-LRB-
cord-005478-5iu38pr6	3086	19	no	no	DT
cord-005478-5iu38pr6	3086	20	RI	RI	NNP
cord-005478-5iu38pr6	3086	21	at	at	IN
cord-005478-5iu38pr6	3086	22	transplant	transplant	NN
cord-005478-5iu38pr6	3086	23	)	)	-RRB-
cord-005478-5iu38pr6	3086	24	,	,	,
cord-005478-5iu38pr6	3086	25	79	79	CD
cord-005478-5iu38pr6	3086	26	months	month	NNS
cord-005478-5iu38pr6	3086	27	(	(	-LRB-
cord-005478-5iu38pr6	3086	28	moderate	moderate	JJ
cord-005478-5iu38pr6	3086	29	RI	RI	NNP
cord-005478-5iu38pr6	3086	30	at	at	IN
cord-005478-5iu38pr6	3086	31	transplant	transplant	NN
cord-005478-5iu38pr6	3086	32	)	)	-RRB-
cord-005478-5iu38pr6	3086	33	and	and	CC
cord-005478-5iu38pr6	3086	34	not	not	RB
cord-005478-5iu38pr6	3086	35	reached	reach	VBN
cord-005478-5iu38pr6	3086	36	(	(	-LRB-
cord-005478-5iu38pr6	3086	37	severe	severe	JJ
cord-005478-5iu38pr6	3086	38	RI	ri	NN
cord-005478-5iu38pr6	3086	39	at	at	IN
cord-005478-5iu38pr6	3086	40	transplant	transplant	NN
cord-005478-5iu38pr6	3086	41	)	)	-RRB-
cord-005478-5iu38pr6	3086	42	.	.	.
cord-005478-5iu38pr6	3087	1	Most	Most	JJS
cord-005478-5iu38pr6	3087	2	of	of	IN
cord-005478-5iu38pr6	3087	3	the	the	DT
cord-005478-5iu38pr6	3087	4	274	274	CD
cord-005478-5iu38pr6	3087	5	patients	patient	NNS
cord-005478-5iu38pr6	3087	6	with	with	IN
cord-005478-5iu38pr6	3087	7	severe	severe	JJ
cord-005478-5iu38pr6	3087	8	RI	ri	NN
cord-005478-5iu38pr6	3087	9	at	at	IN
cord-005478-5iu38pr6	3087	10	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3087	11	had	have	VBD
cord-005478-5iu38pr6	3087	12	improved	improve	VBN
cord-005478-5iu38pr6	3087	13	their	-PRON-	PRP$
cord-005478-5iu38pr6	3087	14	renal	renal	JJ
cord-005478-5iu38pr6	3087	15	function	function	NN
cord-005478-5iu38pr6	3087	16	by	by	IN
cord-005478-5iu38pr6	3087	17	the	the	DT
cord-005478-5iu38pr6	3087	18	time	time	NN
cord-005478-5iu38pr6	3087	19	of	of	IN
cord-005478-5iu38pr6	3087	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	3087	21	.	.	.
cord-005478-5iu38pr6	3088	1	However	however	RB
cord-005478-5iu38pr6	3088	2	,	,	,
cord-005478-5iu38pr6	3088	3	this	this	DT
cord-005478-5iu38pr6	3088	4	did	do	VBD
cord-005478-5iu38pr6	3088	5	not	not	RB
cord-005478-5iu38pr6	3088	6	positively	positively	RB
cord-005478-5iu38pr6	3088	7	impact	impact	VB
cord-005478-5iu38pr6	3088	8	on	on	IN
cord-005478-5iu38pr6	3088	9	OS	OS	NNP
cord-005478-5iu38pr6	3089	1	:	:	:
cord-005478-5iu38pr6	3089	2	Patients	patient	NNS
cord-005478-5iu38pr6	3089	3	with	with	IN
cord-005478-5iu38pr6	3089	4	no	no	DT
cord-005478-5iu38pr6	3089	5	RI	RI	NNP
cord-005478-5iu38pr6	3089	6	at	at	IN
cord-005478-5iu38pr6	3089	7	transplant	transplant	NN
cord-005478-5iu38pr6	3089	8	had	have	VBD
cord-005478-5iu38pr6	3089	9	a	a	DT
cord-005478-5iu38pr6	3089	10	median	median	JJ
cord-005478-5iu38pr6	3089	11	OS	os	NN
cord-005478-5iu38pr6	3089	12	of	of	IN
cord-005478-5iu38pr6	3089	13	37	37	CD
cord-005478-5iu38pr6	3089	14	months	month	NNS
cord-005478-5iu38pr6	3089	15	(	(	-LRB-
cord-005478-5iu38pr6	3089	16	n=132	n=132	UH
cord-005478-5iu38pr6	3089	17	)	)	-RRB-
cord-005478-5iu38pr6	3089	18	,	,	,
cord-005478-5iu38pr6	3089	19	while	while	IN
cord-005478-5iu38pr6	3089	20	it	-PRON-	PRP
cord-005478-5iu38pr6	3089	21	was	be	VBD
cord-005478-5iu38pr6	3089	22	65	65	CD
cord-005478-5iu38pr6	3089	23	months	month	NNS
cord-005478-5iu38pr6	3089	24	for	for	IN
cord-005478-5iu38pr6	3089	25	moderate	moderate	JJ
cord-005478-5iu38pr6	3089	26	RI	RI	NNP
cord-005478-5iu38pr6	3089	27	(	(	-LRB-
cord-005478-5iu38pr6	3089	28	n=71	n=71	NN
cord-005478-5iu38pr6	3089	29	)	)	-RRB-
cord-005478-5iu38pr6	3089	30	and	and	CC
cord-005478-5iu38pr6	3089	31	not	not	RB
cord-005478-5iu38pr6	3089	32	reached	reach	VBN
cord-005478-5iu38pr6	3089	33	in	in	IN
cord-005478-5iu38pr6	3089	34	patients	patient	NNS
cord-005478-5iu38pr6	3089	35	transplanted	transplant	VBN
cord-005478-5iu38pr6	3089	36	with	with	IN
cord-005478-5iu38pr6	3089	37	persisting	persist	VBG
cord-005478-5iu38pr6	3089	38	severe	severe	JJ
cord-005478-5iu38pr6	3089	39	RI	ri	NN
cord-005478-5iu38pr6	3089	40	(	(	-LRB-
cord-005478-5iu38pr6	3089	41	n=71,p	n=71,p	VBN
cord-005478-5iu38pr6	3089	42	<	<	XX
cord-005478-5iu38pr6	3089	43	0.001	0.001	CD
cord-005478-5iu38pr6	3089	44	)	)	-RRB-
cord-005478-5iu38pr6	3089	45	.	.	.
cord-005478-5iu38pr6	3090	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3090	2	:	:	:
cord-005478-5iu38pr6	3091	1	From	from	IN
cord-005478-5iu38pr6	3091	2	this	this	DT
cord-005478-5iu38pr6	3091	3	large	large	JJ
cord-005478-5iu38pr6	3091	4	analysis	analysis	NN
cord-005478-5iu38pr6	3091	5	including	include	VBG
cord-005478-5iu38pr6	3091	6	almost	almost	RB
cord-005478-5iu38pr6	3091	7	2000	2000	CD
cord-005478-5iu38pr6	3091	8	myeloma	myeloma	NN
cord-005478-5iu38pr6	3091	9	patients	patient	NNS
cord-005478-5iu38pr6	3091	10	renal	renal	JJ
cord-005478-5iu38pr6	3091	11	impairment	impairment	NN
cord-005478-5iu38pr6	3091	12	at	at	IN
cord-005478-5iu38pr6	3091	13	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3091	14	has	have	VBZ
cord-005478-5iu38pr6	3091	15	been	be	VBN
cord-005478-5iu38pr6	3091	16	found	find	VBN
cord-005478-5iu38pr6	3091	17	to	to	TO
cord-005478-5iu38pr6	3091	18	be	be	VB
cord-005478-5iu38pr6	3091	19	a	a	DT
cord-005478-5iu38pr6	3091	20	risk	risk	NN
cord-005478-5iu38pr6	3091	21	factor	factor	NN
cord-005478-5iu38pr6	3091	22	for	for	IN
cord-005478-5iu38pr6	3091	23	OS	OS	NNP
cord-005478-5iu38pr6	3091	24	,	,	,
cord-005478-5iu38pr6	3091	25	while	while	IN
cord-005478-5iu38pr6	3091	26	renal	renal	JJ
cord-005478-5iu38pr6	3091	27	function	function	NN
cord-005478-5iu38pr6	3091	28	at	at	IN
cord-005478-5iu38pr6	3091	29	transplant	transplant	NN
cord-005478-5iu38pr6	3091	30	did	do	VBD
cord-005478-5iu38pr6	3091	31	not	not	RB
cord-005478-5iu38pr6	3091	32	impact	impact	VB
cord-005478-5iu38pr6	3091	33	on	on	IN
cord-005478-5iu38pr6	3091	34	post	post	JJ
cord-005478-5iu38pr6	3091	35	transplant	transplant	NN
cord-005478-5iu38pr6	3091	36	survival	survival	NN
cord-005478-5iu38pr6	3091	37	.	.	.
cord-005478-5iu38pr6	3092	1	These	these	DT
cord-005478-5iu38pr6	3092	2	findings	finding	NNS
cord-005478-5iu38pr6	3092	3	support	support	VBP
cord-005478-5iu38pr6	3092	4	the	the	DT
cord-005478-5iu38pr6	3092	5	safety	safety	NN
cord-005478-5iu38pr6	3092	6	and	and	CC
cord-005478-5iu38pr6	3092	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	3092	8	of	of	IN
cord-005478-5iu38pr6	3092	9	autologous	autologous	JJ
cord-005478-5iu38pr6	3092	10	transplantation	transplantation	NN
cord-005478-5iu38pr6	3092	11	in	in	IN
cord-005478-5iu38pr6	3092	12	patients	patient	NNS
cord-005478-5iu38pr6	3092	13	with	with	IN
cord-005478-5iu38pr6	3092	14	severe	severe	JJ
cord-005478-5iu38pr6	3092	15	RI	ri	NN
cord-005478-5iu38pr6	3092	16	at	at	IN
cord-005478-5iu38pr6	3092	17	transplant	transplant	NN
cord-005478-5iu38pr6	3092	18	.	.	.
cord-005478-5iu38pr6	3093	1	On	on	IN
cord-005478-5iu38pr6	3093	2	the	the	DT
cord-005478-5iu38pr6	3093	3	other	other	JJ
cord-005478-5iu38pr6	3093	4	hand	hand	NN
cord-005478-5iu38pr6	3093	5	improving	improve	VBG
cord-005478-5iu38pr6	3093	6	renal	renal	JJ
cord-005478-5iu38pr6	3093	7	function	function	NN
cord-005478-5iu38pr6	3093	8	between	between	IN
cord-005478-5iu38pr6	3093	9	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3093	10	and	and	CC
cord-005478-5iu38pr6	3093	11	transplant	transplant	NN
cord-005478-5iu38pr6	3093	12	does	do	VBZ
cord-005478-5iu38pr6	3093	13	not	not	RB
cord-005478-5iu38pr6	3093	14	seem	seem	VB
cord-005478-5iu38pr6	3093	15	to	to	TO
cord-005478-5iu38pr6	3093	16	improve	improve	VB
cord-005478-5iu38pr6	3093	17	prognosis	prognosis	NN
cord-005478-5iu38pr6	3093	18	..	..	.
cord-005478-5iu38pr6	3094	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	3094	2	analysis	analysis	NN
cord-005478-5iu38pr6	3094	3	supports	support	VBZ
cord-005478-5iu38pr6	3094	4	the	the	DT
cord-005478-5iu38pr6	3094	5	notion	notion	NN
cord-005478-5iu38pr6	3094	6	that	that	IN
cord-005478-5iu38pr6	3094	7	RI	RI	NNP
cord-005478-5iu38pr6	3094	8	at	at	IN
cord-005478-5iu38pr6	3094	9	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3094	10	appears	appear	VBZ
cord-005478-5iu38pr6	3094	11	to	to	TO
cord-005478-5iu38pr6	3094	12	be	be	VB
cord-005478-5iu38pr6	3094	13	a	a	DT
cord-005478-5iu38pr6	3094	14	surrogate	surrogate	JJ
cord-005478-5iu38pr6	3094	15	parameter	parameter	NN
cord-005478-5iu38pr6	3094	16	for	for	IN
cord-005478-5iu38pr6	3094	17	a	a	DT
cord-005478-5iu38pr6	3094	18	more	more	RBR
cord-005478-5iu38pr6	3094	19	aggressive	aggressive	JJ
cord-005478-5iu38pr6	3094	20	disease	disease	NN
cord-005478-5iu38pr6	3094	21	course	course	NN
cord-005478-5iu38pr6	3094	22	.	.	.
cord-005478-5iu38pr6	3095	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3095	2	:	:	:
cord-005478-5iu38pr6	3095	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3095	4	to	to	TO
cord-005478-5iu38pr6	3095	5	declare	declare	VB
cord-005478-5iu38pr6	3095	6	Fig.1	Fig.1	NNP
cord-005478-5iu38pr6	3095	7	Oerall	Oerall	NNP
cord-005478-5iu38pr6	3095	8	survival	survival	NN
cord-005478-5iu38pr6	3095	9	according	accord	VBG
cord-005478-5iu38pr6	3095	10	to	to	IN
cord-005478-5iu38pr6	3095	11	RI	RI	NNP
cord-005478-5iu38pr6	3095	12	at	at	IN
cord-005478-5iu38pr6	3095	13	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3095	14	]	]	-RRB-
cord-005478-5iu38pr6	3095	15	Analysis	analysis	NN
cord-005478-5iu38pr6	3095	16	of	of	IN
cord-005478-5iu38pr6	3095	17	outcomes	outcome	NNS
cord-005478-5iu38pr6	3095	18	in	in	IN
cord-005478-5iu38pr6	3095	19	patients	patient	NNS
cord-005478-5iu38pr6	3095	20	with	with	IN
cord-005478-5iu38pr6	3095	21	myeloma	myeloma	NN
cord-005478-5iu38pr6	3095	22	who	who	WP
cord-005478-5iu38pr6	3095	23	had	have	VBD
cord-005478-5iu38pr6	3095	24	a	a	DT
cord-005478-5iu38pr6	3095	25	second	second	JJ
cord-005478-5iu38pr6	3095	26	allohct	allohct	NN
cord-005478-5iu38pr6	3095	27	EITHER	either	CC
cord-005478-5iu38pr6	3095	28	for	for	IN
cord-005478-5iu38pr6	3095	29	disease	disease	NN
cord-005478-5iu38pr6	3095	30	relapse	relapse	NN
cord-005478-5iu38pr6	3095	31	or	or	CC
cord-005478-5iu38pr6	3095	32	graft	graft	NN
cord-005478-5iu38pr6	3095	33	failure	failure	NN
cord-005478-5iu38pr6	3095	34	:	:	:
cord-005478-5iu38pr6	3096	1	AN	an	DT
cord-005478-5iu38pr6	3096	2	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3097	1	CMWP	CMWP	NNP
cord-005478-5iu38pr6	3097	2	study	study	NN
cord-005478-5iu38pr6	3097	3	Background	Background	NNP
cord-005478-5iu38pr6	3097	4	:	:	:
cord-005478-5iu38pr6	3098	1	The	the	DT
cord-005478-5iu38pr6	3098	2	options	option	NNS
cord-005478-5iu38pr6	3098	3	for	for	IN
cord-005478-5iu38pr6	3098	4	patients	patient	NNS
cord-005478-5iu38pr6	3098	5	with	with	IN
cord-005478-5iu38pr6	3098	6	myeloma	myeloma	NN
cord-005478-5iu38pr6	3098	7	(	(	-LRB-
cord-005478-5iu38pr6	3098	8	MM	MM	NNP
cord-005478-5iu38pr6	3098	9	)	)	-RRB-
cord-005478-5iu38pr6	3098	10	who	who	WP
cord-005478-5iu38pr6	3098	11	relapse	relapse	VBP
cord-005478-5iu38pr6	3098	12	or	or	CC
cord-005478-5iu38pr6	3098	13	develop	develop	VB
cord-005478-5iu38pr6	3098	14	graft	graft	NN
cord-005478-5iu38pr6	3098	15	failure	failure	NN
cord-005478-5iu38pr6	3098	16	after	after	IN
cord-005478-5iu38pr6	3098	17	an	an	DT
cord-005478-5iu38pr6	3098	18	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	3098	19	are	be	VBP
cord-005478-5iu38pr6	3098	20	limited	limit	VBN
cord-005478-5iu38pr6	3098	21	.	.	.
cord-005478-5iu38pr6	3099	1	A	a	DT
cord-005478-5iu38pr6	3099	2	second	second	JJ
cord-005478-5iu38pr6	3099	3	alloHCT	allohct	NN
cord-005478-5iu38pr6	3099	4	is	be	VBZ
cord-005478-5iu38pr6	3099	5	occasionally	occasionally	RB
cord-005478-5iu38pr6	3099	6	feasible	feasible	JJ
cord-005478-5iu38pr6	3099	7	though	though	RB
cord-005478-5iu38pr6	3099	8	is	be	VBZ
cord-005478-5iu38pr6	3099	9	high	high	JJ
cord-005478-5iu38pr6	3099	10	-	-	HYPH
cord-005478-5iu38pr6	3099	11	risk	risk	NN
cord-005478-5iu38pr6	3099	12	.	.	.
cord-005478-5iu38pr6	3100	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3100	2	performed	perform	VBD
cord-005478-5iu38pr6	3100	3	a	a	DT
cord-005478-5iu38pr6	3100	4	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3100	5	analysis	analysis	NN
cord-005478-5iu38pr6	3100	6	to	to	TO
cord-005478-5iu38pr6	3100	7	assess	assess	VB
cord-005478-5iu38pr6	3100	8	outcomes	outcome	NNS
cord-005478-5iu38pr6	3100	9	in	in	IN
cord-005478-5iu38pr6	3100	10	this	this	DT
cord-005478-5iu38pr6	3100	11	cohort	cohort	NN
cord-005478-5iu38pr6	3100	12	.	.	.
cord-005478-5iu38pr6	3101	1	Methods	method	NNS
cord-005478-5iu38pr6	3101	2	:	:	:
cord-005478-5iu38pr6	3101	3	Data	datum	NNS
cord-005478-5iu38pr6	3101	4	on	on	IN
cord-005478-5iu38pr6	3101	5	patients	patient	NNS
cord-005478-5iu38pr6	3101	6	with	with	IN
cord-005478-5iu38pr6	3101	7	MM	MM	NNP
cord-005478-5iu38pr6	3101	8	who	who	WP
cord-005478-5iu38pr6	3101	9	underwent	undergo	VBD
cord-005478-5iu38pr6	3101	10	a	a	DT
cord-005478-5iu38pr6	3101	11	second	second	JJ
cord-005478-5iu38pr6	3101	12	alloHCT	allohct	NN
cord-005478-5iu38pr6	3101	13	at	at	IN
cord-005478-5iu38pr6	3101	14	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3101	15	centres	centre	NNS
cord-005478-5iu38pr6	3101	16	between	between	IN
cord-005478-5iu38pr6	3101	17	1994	1994	CD
cord-005478-5iu38pr6	3101	18	and	and	CC
cord-005478-5iu38pr6	3101	19	2017	2017	CD
cord-005478-5iu38pr6	3101	20	were	be	VBD
cord-005478-5iu38pr6	3101	21	obtained	obtain	VBN
cord-005478-5iu38pr6	3101	22	from	from	IN
cord-005478-5iu38pr6	3101	23	the	the	DT
cord-005478-5iu38pr6	3101	24	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3101	25	registry	registry	NN
cord-005478-5iu38pr6	3101	26	.	.	.
cord-005478-5iu38pr6	3102	1	Results	result	NNS
cord-005478-5iu38pr6	3102	2	:	:	:
cord-005478-5iu38pr6	3103	1	A	a	DT
cord-005478-5iu38pr6	3103	2	total	total	NN
cord-005478-5iu38pr6	3103	3	of	of	IN
cord-005478-5iu38pr6	3103	4	273	273	CD
cord-005478-5iu38pr6	3103	5	patients	patient	NNS
cord-005478-5iu38pr6	3103	6	(	(	-LRB-
cord-005478-5iu38pr6	3103	7	165	165	CD
cord-005478-5iu38pr6	3103	8	M,108	M,108	NNP
cord-005478-5iu38pr6	3103	9	F	F	NNP
cord-005478-5iu38pr6	3103	10	)	)	-RRB-
cord-005478-5iu38pr6	3103	11	with	with	IN
cord-005478-5iu38pr6	3103	12	MM	MM	NNP
cord-005478-5iu38pr6	3103	13	(	(	-LRB-
cord-005478-5iu38pr6	3103	14	51	51	CD
cord-005478-5iu38pr6	3103	15	%	%	NN
cord-005478-5iu38pr6	3103	16	IgG	igg	NN
cord-005478-5iu38pr6	3103	17	,	,	,
cord-005478-5iu38pr6	3103	18	22	22	CD
cord-005478-5iu38pr6	3103	19	%	%	NN
cord-005478-5iu38pr6	3103	20	IgA	IgA	NNP
cord-005478-5iu38pr6	3103	21	,	,	,
cord-005478-5iu38pr6	3103	22	23	23	CD
cord-005478-5iu38pr6	3103	23	%	%	NN
cord-005478-5iu38pr6	3103	24	LC	LC	NNP
cord-005478-5iu38pr6	3103	25	)	)	-RRB-
cord-005478-5iu38pr6	3103	26	underwent	undergo	VBD
cord-005478-5iu38pr6	3103	27	a	a	DT
cord-005478-5iu38pr6	3103	28	second	second	JJ
cord-005478-5iu38pr6	3103	29	alloSCT	allosct	NN
cord-005478-5iu38pr6	3103	30	.	.	.
cord-005478-5iu38pr6	3104	1	The	the	DT
cord-005478-5iu38pr6	3104	2	median	median	NN
cord-005478-5iu38pr6	3104	3	(	(	-LRB-
cord-005478-5iu38pr6	3104	4	range	range	NN
cord-005478-5iu38pr6	3104	5	)	)	-RRB-
cord-005478-5iu38pr6	3104	6	age	age	NN
cord-005478-5iu38pr6	3104	7	at	at	IN
cord-005478-5iu38pr6	3104	8	the	the	DT
cord-005478-5iu38pr6	3104	9	first	first	JJ
cord-005478-5iu38pr6	3104	10	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3104	11	was	be	VBD
cord-005478-5iu38pr6	3104	12	48.5	48.5	CD
cord-005478-5iu38pr6	3104	13	(	(	-LRB-
cord-005478-5iu38pr6	3104	14	20.1	20.1	CD
cord-005478-5iu38pr6	3104	15	-	-	HYPH
cord-005478-5iu38pr6	3104	16	67.9	67.9	CD
cord-005478-5iu38pr6	3104	17	)	)	-RRB-
cord-005478-5iu38pr6	3104	18	years	year	NNS
cord-005478-5iu38pr6	3104	19	and	and	CC
cord-005478-5iu38pr6	3104	20	78.1	78.1	CD
cord-005478-5iu38pr6	3104	21	%	%	NN
cord-005478-5iu38pr6	3104	22	were	be	VBD
cord-005478-5iu38pr6	3104	23	>	>	XX
cord-005478-5iu38pr6	3104	24	/=PR	/=PR	.
cord-005478-5iu38pr6	3104	25	.	.	.
cord-005478-5iu38pr6	3105	1	When	when	WRB
cord-005478-5iu38pr6	3105	2	comparing	compare	VBG
cord-005478-5iu38pr6	3105	3	the	the	DT
cord-005478-5iu38pr6	3105	4	indications	indication	NNS
cord-005478-5iu38pr6	3105	5	for	for	IN
cord-005478-5iu38pr6	3105	6	the	the	DT
cord-005478-5iu38pr6	3106	1	2	2	CD
cord-005478-5iu38pr6	3106	2	nd	nd	NNP
cord-005478-5iu38pr6	3106	3	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3106	4	-relapsed	-relapsed	JJ
cord-005478-5iu38pr6	3106	5	MM	MM	NNP
cord-005478-5iu38pr6	3106	6	(	(	-LRB-
cord-005478-5iu38pr6	3106	7	74	74	CD
cord-005478-5iu38pr6	3106	8	%	%	NN
cord-005478-5iu38pr6	3106	9	)	)	-RRB-
cord-005478-5iu38pr6	3106	10	or	or	CC
cord-005478-5iu38pr6	3106	11	graft	graft	NN
cord-005478-5iu38pr6	3106	12	failure	failure	NN
cord-005478-5iu38pr6	3106	13	(	(	-LRB-
cord-005478-5iu38pr6	3106	14	26	26	CD
cord-005478-5iu38pr6	3106	15	%	%	NN
cord-005478-5iu38pr6	3106	16	)	)	-RRB-
cord-005478-5iu38pr6	3107	1	-patients	-patient	NNS
cord-005478-5iu38pr6	3107	2	with	with	IN
cord-005478-5iu38pr6	3107	3	graft	graft	NN
cord-005478-5iu38pr6	3107	4	failure	failure	NN
cord-005478-5iu38pr6	3107	5	were	be	VBD
cord-005478-5iu38pr6	3107	6	significantly	significantly	RB
cord-005478-5iu38pr6	3107	7	more	more	RBR
cord-005478-5iu38pr6	3107	8	likely	likely	JJ
cord-005478-5iu38pr6	3107	9	to	to	TO
cord-005478-5iu38pr6	3107	10	have	have	VB
cord-005478-5iu38pr6	3107	11	received	receive	VBN
cord-005478-5iu38pr6	3107	12	a	a	DT
cord-005478-5iu38pr6	3107	13	mismatched	mismatched	JJ
cord-005478-5iu38pr6	3107	14	(	(	-LRB-
cord-005478-5iu38pr6	3107	15	related	relate	VBN
cord-005478-5iu38pr6	3107	16	/	/	SYM
cord-005478-5iu38pr6	3107	17	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3107	18	)	)	-RRB-
cord-005478-5iu38pr6	3107	19	or	or	CC
cord-005478-5iu38pr6	3107	20	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3107	21	donor	donor	NN
cord-005478-5iu38pr6	3107	22	for	for	IN
cord-005478-5iu38pr6	3107	23	the	the	DT
cord-005478-5iu38pr6	3107	24	1	1	CD
cord-005478-5iu38pr6	3107	25	st	st	NNP
cord-005478-5iu38pr6	3107	26	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	3107	27	(	(	-LRB-
cord-005478-5iu38pr6	3107	28	58	58	CD
cord-005478-5iu38pr6	3107	29	%	%	NN
cord-005478-5iu38pr6	3107	30	vs.	vs.	CC
cord-005478-5iu38pr6	3107	31	31	31	CD
cord-005478-5iu38pr6	3107	32	%	%	NN
cord-005478-5iu38pr6	3107	33	)	)	-RRB-
cord-005478-5iu38pr6	3107	34	(	(	-LRB-
cord-005478-5iu38pr6	3107	35	p=0.001	p=0.001	NNP
cord-005478-5iu38pr6	3107	36	)	)	-RRB-
cord-005478-5iu38pr6	3107	37	,	,	,
cord-005478-5iu38pr6	3107	38	were	be	VBD
cord-005478-5iu38pr6	3107	39	more	more	RBR
cord-005478-5iu38pr6	3107	40	commonly	commonly	RB
cord-005478-5iu38pr6	3107	41	female	female	JJ
cord-005478-5iu38pr6	3107	42	(	(	-LRB-
cord-005478-5iu38pr6	3107	43	57	57	CD
cord-005478-5iu38pr6	3107	44	%	%	NN
cord-005478-5iu38pr6	3107	45	vs.	vs.	IN
cord-005478-5iu38pr6	3107	46	38	38	CD
cord-005478-5iu38pr6	3107	47	%	%	NN
cord-005478-5iu38pr6	3107	48	)	)	-RRB-
cord-005478-5iu38pr6	3107	49	(	(	-LRB-
cord-005478-5iu38pr6	3107	50	p=0.018	p=0.018	NNP
cord-005478-5iu38pr6	3107	51	)	)	-RRB-
cord-005478-5iu38pr6	3107	52	and	and	CC
cord-005478-5iu38pr6	3107	53	were	be	VBD
cord-005478-5iu38pr6	3107	54	more	more	RBR
cord-005478-5iu38pr6	3107	55	likely	likely	JJ
cord-005478-5iu38pr6	3107	56	to	to	TO
cord-005478-5iu38pr6	3107	57	have	have	VB
cord-005478-5iu38pr6	3107	58	had	have	VBN
cord-005478-5iu38pr6	3107	59	a	a	DT
cord-005478-5iu38pr6	3107	60	RIC	RIC	NNP
cord-005478-5iu38pr6	3107	61	as	as	IN
cord-005478-5iu38pr6	3107	62	opposed	oppose	VBN
cord-005478-5iu38pr6	3107	63	to	to	IN
cord-005478-5iu38pr6	3107	64	a	a	DT
cord-005478-5iu38pr6	3107	65	MAC	MAC	NNP
cord-005478-5iu38pr6	3107	66	alloSCT	allosct	NN
cord-005478-5iu38pr6	3107	67	(	(	-LRB-
cord-005478-5iu38pr6	3107	68	79	79	CD
cord-005478-5iu38pr6	3107	69	%	%	NN
cord-005478-5iu38pr6	3107	70	vs.	vs.	IN
cord-005478-5iu38pr6	3107	71	59	59	CD
cord-005478-5iu38pr6	3107	72	%	%	NN
cord-005478-5iu38pr6	3107	73	)	)	-RRB-
cord-005478-5iu38pr6	3108	1	(	(	-LRB-
cord-005478-5iu38pr6	3108	2	p=0.015	p=0.015	NNP
cord-005478-5iu38pr6	3108	3	)	)	-RRB-
cord-005478-5iu38pr6	3108	4	.	.	.
cord-005478-5iu38pr6	3109	1	The	the	DT
cord-005478-5iu38pr6	3109	2	median	median	NN
cord-005478-5iu38pr6	3109	3	(	(	-LRB-
cord-005478-5iu38pr6	3109	4	range	range	NN
cord-005478-5iu38pr6	3109	5	)	)	-RRB-
cord-005478-5iu38pr6	3109	6	interval	interval	NN
cord-005478-5iu38pr6	3109	7	between	between	IN
cord-005478-5iu38pr6	3109	8	the	the	DT
cord-005478-5iu38pr6	3109	9	1	1	CD
cord-005478-5iu38pr6	3109	10	st	st	NNP
cord-005478-5iu38pr6	3109	11	and	and	CC
cord-005478-5iu38pr6	3109	12	2	2	CD
cord-005478-5iu38pr6	3109	13	nd	nd	NNP
cord-005478-5iu38pr6	3110	1	alloHCTs	allohcts	DT
cord-005478-5iu38pr6	3110	2	was	be	VBD
cord-005478-5iu38pr6	3110	3	3.5	3.5	CD
cord-005478-5iu38pr6	3110	4	(	(	-LRB-
cord-005478-5iu38pr6	3110	5	7.7	7.7	CD
cord-005478-5iu38pr6	3110	6	-	-	HYPH
cord-005478-5iu38pr6	3110	7	66.6	66.6	CD
cord-005478-5iu38pr6	3110	8	)	)	-RRB-
cord-005478-5iu38pr6	3110	9	months	month	NNS
cord-005478-5iu38pr6	3110	10	in	in	IN
cord-005478-5iu38pr6	3110	11	cases	case	NNS
cord-005478-5iu38pr6	3110	12	of	of	IN
cord-005478-5iu38pr6	3110	13	graft	graft	NN
cord-005478-5iu38pr6	3110	14	failure	failure	NN
cord-005478-5iu38pr6	3110	15	and	and	CC
cord-005478-5iu38pr6	3110	16	40.5	40.5	CD
cord-005478-5iu38pr6	3110	17	(	(	-LRB-
cord-005478-5iu38pr6	3110	18	68.6	68.6	CD
cord-005478-5iu38pr6	3110	19	-	-	HYPH
cord-005478-5iu38pr6	3110	20	170.4	170.4	CD
cord-005478-5iu38pr6	3110	21	)	)	-RRB-
cord-005478-5iu38pr6	3110	22	months	month	NNS
cord-005478-5iu38pr6	3110	23	for	for	IN
cord-005478-5iu38pr6	3110	24	those	those	DT
cord-005478-5iu38pr6	3110	25	who	who	WP
cord-005478-5iu38pr6	3110	26	had	have	VBD
cord-005478-5iu38pr6	3110	27	relapsed	relapse	VBN
cord-005478-5iu38pr6	3110	28	.	.	.
cord-005478-5iu38pr6	3111	1	At	at	IN
cord-005478-5iu38pr6	3111	2	a	a	DT
cord-005478-5iu38pr6	3111	3	median	median	NN
cord-005478-5iu38pr6	3111	4	(	(	-LRB-
cord-005478-5iu38pr6	3111	5	95	95	CD
cord-005478-5iu38pr6	3111	6	%	%	NN
cord-005478-5iu38pr6	3111	7	CI	CI	NNP
cord-005478-5iu38pr6	3111	8	)	)	-RRB-
cord-005478-5iu38pr6	3111	9	follow	follow	NN
cord-005478-5iu38pr6	3111	10	-	-	HYPH
cord-005478-5iu38pr6	3111	11	up	up	NN
cord-005478-5iu38pr6	3111	12	of	of	IN
cord-005478-5iu38pr6	3111	13	107.2	107.2	CD
cord-005478-5iu38pr6	3111	14	(	(	-LRB-
cord-005478-5iu38pr6	3111	15	84.9	84.9	CD
cord-005478-5iu38pr6	3111	16	-141.7	-141.7	CD
cord-005478-5iu38pr6	3111	17	)	)	-RRB-
cord-005478-5iu38pr6	3111	18	months	month	NNS
cord-005478-5iu38pr6	3111	19	following	follow	VBG
cord-005478-5iu38pr6	3111	20	the	the	DT
cord-005478-5iu38pr6	3111	21	second	second	JJ
cord-005478-5iu38pr6	3111	22	alloHCT	allohct	NN
cord-005478-5iu38pr6	3111	23	,	,	,
cord-005478-5iu38pr6	3111	24	Overall	Overall	NNP
cord-005478-5iu38pr6	3111	25	Survival	Survival	NNP
cord-005478-5iu38pr6	3111	26	(	(	-LRB-
cord-005478-5iu38pr6	3111	27	OS	OS	NNP
cord-005478-5iu38pr6	3111	28	)	)	-RRB-
cord-005478-5iu38pr6	3111	29	was	be	VBD
cord-005478-5iu38pr6	3111	30	41	41	CD
cord-005478-5iu38pr6	3111	31	%	%	NN
cord-005478-5iu38pr6	3111	32	(	(	-LRB-
cord-005478-5iu38pr6	3111	33	35	35	CD
cord-005478-5iu38pr6	3111	34	-	-	SYM
cord-005478-5iu38pr6	3111	35	47	47	CD
cord-005478-5iu38pr6	3111	36	%	%	NN
cord-005478-5iu38pr6	3111	37	)	)	-RRB-
cord-005478-5iu38pr6	3111	38	at	at	IN
cord-005478-5iu38pr6	3111	39	two	two	CD
cord-005478-5iu38pr6	3111	40	years	year	NNS
cord-005478-5iu38pr6	3111	41	and	and	CC
cord-005478-5iu38pr6	3111	42	26	26	CD
cord-005478-5iu38pr6	3111	43	%	%	NN
cord-005478-5iu38pr6	3111	44	(	(	-LRB-
cord-005478-5iu38pr6	3111	45	20	20	CD
cord-005478-5iu38pr6	3111	46	-	-	SYM
cord-005478-5iu38pr6	3111	47	32	32	CD
cord-005478-5iu38pr6	3111	48	%	%	NN
cord-005478-5iu38pr6	3111	49	)	)	-RRB-
cord-005478-5iu38pr6	3111	50	at	at	IN
cord-005478-5iu38pr6	3111	51	five	five	CD
cord-005478-5iu38pr6	3111	52	years	year	NNS
cord-005478-5iu38pr6	3111	53	.	.	.
cord-005478-5iu38pr6	3112	1	There	there	EX
cord-005478-5iu38pr6	3112	2	was	be	VBD
cord-005478-5iu38pr6	3112	3	no	no	DT
cord-005478-5iu38pr6	3112	4	difference	difference	NN
cord-005478-5iu38pr6	3112	5	in	in	IN
cord-005478-5iu38pr6	3112	6	OS	OS	NNP
cord-005478-5iu38pr6	3112	7	at	at	IN
cord-005478-5iu38pr6	3112	8	five	five	CD
cord-005478-5iu38pr6	3112	9	years	year	NNS
cord-005478-5iu38pr6	3112	10	based	base	VBN
cord-005478-5iu38pr6	3112	11	on	on	IN
cord-005478-5iu38pr6	3112	12	the	the	DT
cord-005478-5iu38pr6	3112	13	indication	indication	NN
cord-005478-5iu38pr6	3112	14	for	for	IN
cord-005478-5iu38pr6	3112	15	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3112	16	:	:	:
cord-005478-5iu38pr6	3112	17	25	25	CD
cord-005478-5iu38pr6	3112	18	%	%	NN
cord-005478-5iu38pr6	3112	19	(	(	-LRB-
cord-005478-5iu38pr6	3112	20	17	17	CD
cord-005478-5iu38pr6	3112	21	-	-	SYM
cord-005478-5iu38pr6	3112	22	32	32	CD
cord-005478-5iu38pr6	3112	23	%	%	NN
cord-005478-5iu38pr6	3112	24	)	)	-RRB-
cord-005478-5iu38pr6	3112	25	for	for	IN
cord-005478-5iu38pr6	3112	26	relapse	relapse	NN
cord-005478-5iu38pr6	3112	27	and	and	CC
cord-005478-5iu38pr6	3112	28	32	32	CD
cord-005478-5iu38pr6	3112	29	%	%	NN
cord-005478-5iu38pr6	3112	30	(	(	-LRB-
cord-005478-5iu38pr6	3112	31	19	19	CD
cord-005478-5iu38pr6	3112	32	-	-	SYM
cord-005478-5iu38pr6	3112	33	45	45	CD
cord-005478-5iu38pr6	3112	34	%	%	NN
cord-005478-5iu38pr6	3112	35	)	)	-RRB-
cord-005478-5iu38pr6	3112	36	for	for	IN
cord-005478-5iu38pr6	3112	37	graft	graft	NN
cord-005478-5iu38pr6	3112	38	failure	failure	NN
cord-005478-5iu38pr6	3112	39	(	(	-LRB-
cord-005478-5iu38pr6	3112	40	p=0.595	p=0.595	NN
cord-005478-5iu38pr6	3112	41	)	)	-RRB-
cord-005478-5iu38pr6	3112	42	(	(	-LRB-
cord-005478-5iu38pr6	3112	43	Figure	figure	NN
cord-005478-5iu38pr6	3112	44	1	1	CD
cord-005478-5iu38pr6	3112	45	)	)	-RRB-
cord-005478-5iu38pr6	3112	46	.	.	.
cord-005478-5iu38pr6	3113	1	Neutrophil	Neutrophil	NNP
cord-005478-5iu38pr6	3113	2	engraftment	engraftment	NN
cord-005478-5iu38pr6	3113	3	following	follow	VBG
cord-005478-5iu38pr6	3113	4	the	the	DT
cord-005478-5iu38pr6	3113	5	2	2	CD
cord-005478-5iu38pr6	3113	6	nd	nd	NNP
cord-005478-5iu38pr6	3113	7	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3113	8	was	be	VBD
cord-005478-5iu38pr6	3113	9	achieved	achieve	VBN
cord-005478-5iu38pr6	3113	10	by	by	IN
cord-005478-5iu38pr6	3113	11	Day	Day	NNP
cord-005478-5iu38pr6	3113	12	+28	+28	NNS
cord-005478-5iu38pr6	3113	13	in	in	IN
cord-005478-5iu38pr6	3113	14	94	94	CD
cord-005478-5iu38pr6	3113	15	%	%	NN
cord-005478-5iu38pr6	3113	16	(	(	-LRB-
cord-005478-5iu38pr6	3113	17	90	90	CD
cord-005478-5iu38pr6	3113	18	-	-	SYM
cord-005478-5iu38pr6	3113	19	98	98	CD
cord-005478-5iu38pr6	3113	20	%	%	NN
cord-005478-5iu38pr6	3113	21	)	)	-RRB-
cord-005478-5iu38pr6	3113	22	and	and	CC
cord-005478-5iu38pr6	3113	23	80	80	CD
cord-005478-5iu38pr6	3113	24	%	%	NN
cord-005478-5iu38pr6	3113	25	(	(	-LRB-
cord-005478-5iu38pr6	3113	26	69	69	CD
cord-005478-5iu38pr6	3113	27	-	-	SYM
cord-005478-5iu38pr6	3113	28	92	92	CD
cord-005478-5iu38pr6	3113	29	%	%	NN
cord-005478-5iu38pr6	3113	30	)	)	-RRB-
cord-005478-5iu38pr6	3113	31	of	of	IN
cord-005478-5iu38pr6	3113	32	the	the	DT
cord-005478-5iu38pr6	3113	33	relapse	relapse	NN
cord-005478-5iu38pr6	3113	34	and	and	CC
cord-005478-5iu38pr6	3113	35	graft	graft	NN
cord-005478-5iu38pr6	3113	36	failure	failure	NN
cord-005478-5iu38pr6	3113	37	patients	patient	NNS
cord-005478-5iu38pr6	3113	38	,	,	,
cord-005478-5iu38pr6	3113	39	respectively	respectively	RB
cord-005478-5iu38pr6	3113	40	.	.	.
cord-005478-5iu38pr6	3114	1	The	the	DT
cord-005478-5iu38pr6	3114	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3114	3	incidence	incidence	NN
cord-005478-5iu38pr6	3114	4	of	of	IN
cord-005478-5iu38pr6	3114	5	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3114	6	(	(	-LRB-
cord-005478-5iu38pr6	3114	7	II	II	NNP
cord-005478-5iu38pr6	3114	8	-	-	HYPH
cord-005478-5iu38pr6	3114	9	IV	IV	NNP
cord-005478-5iu38pr6	3114	10	)	)	-RRB-
cord-005478-5iu38pr6	3114	11	and	and	CC
cord-005478-5iu38pr6	3114	12	cGVHD	cGVHD	NNP
cord-005478-5iu38pr6	3114	13	(	(	-LRB-
cord-005478-5iu38pr6	3114	14	at	at	IN
cord-005478-5iu38pr6	3114	15	five	five	CD
cord-005478-5iu38pr6	3114	16	years	year	NNS
cord-005478-5iu38pr6	3114	17	)	)	-RRB-
cord-005478-5iu38pr6	3115	1	following	follow	VBG
cord-005478-5iu38pr6	3115	2	the	the	DT
cord-005478-5iu38pr6	3115	3	2	2	CD
cord-005478-5iu38pr6	3115	4	nd	nd	NNP
cord-005478-5iu38pr6	3115	5	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3115	6	was	be	VBD
cord-005478-5iu38pr6	3115	7	27	27	CD
cord-005478-5iu38pr6	3115	8	%	%	NN
cord-005478-5iu38pr6	3115	9	(	(	-LRB-
cord-005478-5iu38pr6	3115	10	21	21	CD
cord-005478-5iu38pr6	3115	11	-	-	SYM
cord-005478-5iu38pr6	3115	12	33	33	CD
cord-005478-5iu38pr6	3115	13	%	%	NN
cord-005478-5iu38pr6	3115	14	)	)	-RRB-
cord-005478-5iu38pr6	3115	15	and	and	CC
cord-005478-5iu38pr6	3115	16	39	39	CD
cord-005478-5iu38pr6	3115	17	%	%	NN
cord-005478-5iu38pr6	3115	18	(	(	-LRB-
cord-005478-5iu38pr6	3115	19	32	32	CD
cord-005478-5iu38pr6	3115	20	-	-	SYM
cord-005478-5iu38pr6	3115	21	47	47	CD
cord-005478-5iu38pr6	3115	22	%	%	NN
cord-005478-5iu38pr6	3115	23	)	)	-RRB-
cord-005478-5iu38pr6	3115	24	,	,	,
cord-005478-5iu38pr6	3115	25	respectively	respectively	RB
cord-005478-5iu38pr6	3115	26	.	.	.
cord-005478-5iu38pr6	3116	1	Relapse	relapse	NN
cord-005478-5iu38pr6	3116	2	-	-	HYPH
cord-005478-5iu38pr6	3116	3	Free	Free	NNP
cord-005478-5iu38pr6	3116	4	Survival	Survival	NNP
cord-005478-5iu38pr6	3116	5	was	be	VBD
cord-005478-5iu38pr6	3116	6	12	12	CD
cord-005478-5iu38pr6	3116	7	%	%	NN
cord-005478-5iu38pr6	3116	8	(	(	-LRB-
cord-005478-5iu38pr6	3116	9	7	7	CD
cord-005478-5iu38pr6	3116	10	-	-	SYM
cord-005478-5iu38pr6	3116	11	17	17	CD
cord-005478-5iu38pr6	3116	12	%	%	NN
cord-005478-5iu38pr6	3116	13	)	)	-RRB-
cord-005478-5iu38pr6	3116	14	at	at	IN
cord-005478-5iu38pr6	3116	15	5	5	CD
cord-005478-5iu38pr6	3116	16	years	year	NNS
cord-005478-5iu38pr6	3116	17	,	,	,
cord-005478-5iu38pr6	3116	18	7	7	CD
cord-005478-5iu38pr6	3116	19	%	%	NN
cord-005478-5iu38pr6	3116	20	(	(	-LRB-
cord-005478-5iu38pr6	3116	21	2	2	CD
cord-005478-5iu38pr6	3116	22	-	-	SYM
cord-005478-5iu38pr6	3116	23	13	13	CD
cord-005478-5iu38pr6	3116	24	%	%	NN
cord-005478-5iu38pr6	3116	25	)	)	-RRB-
cord-005478-5iu38pr6	3116	26	in	in	IN
cord-005478-5iu38pr6	3116	27	those	those	DT
cord-005478-5iu38pr6	3116	28	transplanted	transplant	VBN
cord-005478-5iu38pr6	3116	29	for	for	IN
cord-005478-5iu38pr6	3116	30	disease	disease	NN
cord-005478-5iu38pr6	3116	31	relapse	relapse	NN
cord-005478-5iu38pr6	3116	32	and	and	CC
cord-005478-5iu38pr6	3116	33	22	22	CD
cord-005478-5iu38pr6	3116	34	%	%	NN
cord-005478-5iu38pr6	3116	35	(	(	-LRB-
cord-005478-5iu38pr6	3116	36	10	10	CD
cord-005478-5iu38pr6	3116	37	-	-	SYM
cord-005478-5iu38pr6	3116	38	35	35	CD
cord-005478-5iu38pr6	3116	39	%	%	NN
cord-005478-5iu38pr6	3116	40	)	)	-RRB-
cord-005478-5iu38pr6	3116	41	in	in	IN
cord-005478-5iu38pr6	3116	42	those	those	DT
cord-005478-5iu38pr6	3116	43	transplanted	transplant	VBN
cord-005478-5iu38pr6	3116	44	for	for	IN
cord-005478-5iu38pr6	3116	45	graft	graft	NN
cord-005478-5iu38pr6	3116	46	failure	failure	NN
cord-005478-5iu38pr6	3116	47	(	(	-LRB-
cord-005478-5iu38pr6	3116	48	p=0.061	p=0.061	NNP
cord-005478-5iu38pr6	3116	49	)	)	-RRB-
cord-005478-5iu38pr6	3116	50	.	.	.
cord-005478-5iu38pr6	3117	1	The	the	DT
cord-005478-5iu38pr6	3117	2	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3117	3	Incidence	incidence	NN
cord-005478-5iu38pr6	3117	4	of	of	IN
cord-005478-5iu38pr6	3117	5	Relapse	Relapse	NNP
cord-005478-5iu38pr6	3117	6	and	and	CC
cord-005478-5iu38pr6	3117	7	NRM	NRM	NNP
cord-005478-5iu38pr6	3117	8	at	at	IN
cord-005478-5iu38pr6	3117	9	five	five	CD
cord-005478-5iu38pr6	3117	10	years	year	NNS
cord-005478-5iu38pr6	3117	11	was	be	VBD
cord-005478-5iu38pr6	3117	12	64	64	CD
cord-005478-5iu38pr6	3117	13	%	%	NN
cord-005478-5iu38pr6	3117	14	(	(	-LRB-
cord-005478-5iu38pr6	3117	15	57	57	CD
cord-005478-5iu38pr6	3117	16	-	-	SYM
cord-005478-5iu38pr6	3117	17	71	71	CD
cord-005478-5iu38pr6	3117	18	%	%	NN
cord-005478-5iu38pr6	3117	19	)	)	-RRB-
cord-005478-5iu38pr6	3117	20	and	and	CC
cord-005478-5iu38pr6	3117	21	24	24	CD
cord-005478-5iu38pr6	3117	22	%	%	NN
cord-005478-5iu38pr6	3117	23	(	(	-LRB-
cord-005478-5iu38pr6	3117	24	18	18	CD
cord-005478-5iu38pr6	3117	25	-	-	SYM
cord-005478-5iu38pr6	3117	26	30	30	CD
cord-005478-5iu38pr6	3117	27	%	%	NN
cord-005478-5iu38pr6	3117	28	)	)	-RRB-
cord-005478-5iu38pr6	3117	29	,	,	,
cord-005478-5iu38pr6	3117	30	respectively	respectively	RB
cord-005478-5iu38pr6	3117	31	.	.	.
cord-005478-5iu38pr6	3118	1	The	the	DT
cord-005478-5iu38pr6	3118	2	five	five	CD
cord-005478-5iu38pr6	3118	3	-	-	HYPH
cord-005478-5iu38pr6	3118	4	year	year	NN
cord-005478-5iu38pr6	3118	5	OS	os	NN
cord-005478-5iu38pr6	3118	6	following	follow	VBG
cord-005478-5iu38pr6	3118	7	the	the	DT
cord-005478-5iu38pr6	3118	8	second	second	JJ
cord-005478-5iu38pr6	3119	1	alloSCT	alloSCT	NNP
cord-005478-5iu38pr6	3119	2	was	be	VBD
cord-005478-5iu38pr6	3119	3	14	14	CD
cord-005478-5iu38pr6	3119	4	%	%	NN
cord-005478-5iu38pr6	3119	5	(	(	-LRB-
cord-005478-5iu38pr6	3119	6	1	1	CD
cord-005478-5iu38pr6	3119	7	-	-	SYM
cord-005478-5iu38pr6	3119	8	28	28	CD
cord-005478-5iu38pr6	3119	9	%	%	NN
cord-005478-5iu38pr6	3119	10	)	)	-RRB-
cord-005478-5iu38pr6	3119	11	for	for	IN
cord-005478-5iu38pr6	3119	12	those	those	DT
cord-005478-5iu38pr6	3119	13	relapsing	relapse	VBG
cord-005478-5iu38pr6	3119	14	between	between	IN
cord-005478-5iu38pr6	3119	15	12	12	CD
cord-005478-5iu38pr6	3119	16	and	and	CC
cord-005478-5iu38pr6	3119	17	24	24	CD
cord-005478-5iu38pr6	3119	18	months	month	NNS
cord-005478-5iu38pr6	3119	19	after	after	IN
cord-005478-5iu38pr6	3119	20	the	the	DT
cord-005478-5iu38pr6	3119	21	first	first	JJ
cord-005478-5iu38pr6	3119	22	alloHCT	allohct	NN
cord-005478-5iu38pr6	3119	23	and	and	CC
cord-005478-5iu38pr6	3119	24	31	31	CD
cord-005478-5iu38pr6	3119	25	%	%	NN
cord-005478-5iu38pr6	3119	26	(	(	-LRB-
cord-005478-5iu38pr6	3119	27	21	21	CD
cord-005478-5iu38pr6	3119	28	-	-	SYM
cord-005478-5iu38pr6	3119	29	40	40	CD
cord-005478-5iu38pr6	3119	30	%	%	NN
cord-005478-5iu38pr6	3119	31	)	)	-RRB-
cord-005478-5iu38pr6	3119	32	for	for	IN
cord-005478-5iu38pr6	3119	33	those	those	DT
cord-005478-5iu38pr6	3119	34	relapsing	relapse	VBG
cord-005478-5iu38pr6	3119	35	later	later	RBR
cord-005478-5iu38pr6	3119	36	than	than	IN
cord-005478-5iu38pr6	3119	37	24	24	CD
cord-005478-5iu38pr6	3119	38	months	month	NNS
cord-005478-5iu38pr6	3119	39	(	(	-LRB-
cord-005478-5iu38pr6	3119	40	p=0.07).On	p=0.07).on	JJ
cord-005478-5iu38pr6	3119	41	univariate	univariate	JJ
cord-005478-5iu38pr6	3119	42	analysis	analysis	NN
cord-005478-5iu38pr6	3119	43	,	,	,
cord-005478-5iu38pr6	3119	44	OS	OS	NNP
cord-005478-5iu38pr6	3119	45	at	at	IN
cord-005478-5iu38pr6	3119	46	five	five	CD
cord-005478-5iu38pr6	3119	47	years	year	NNS
cord-005478-5iu38pr6	3119	48	was	be	VBD
cord-005478-5iu38pr6	3119	49	superior	superior	JJ
cord-005478-5iu38pr6	3119	50	in	in	IN
cord-005478-5iu38pr6	3119	51	patients	patient	NNS
cord-005478-5iu38pr6	3119	52	who	who	WP
cord-005478-5iu38pr6	3119	53	had	have	VBD
cord-005478-5iu38pr6	3119	54	had	have	VBN
cord-005478-5iu38pr6	3119	55	HLA	HLA	NNP
cord-005478-5iu38pr6	3119	56	identical	identical	JJ
cord-005478-5iu38pr6	3119	57	sibling	sibling	NN
cord-005478-5iu38pr6	3119	58	donors	donor	NNS
cord-005478-5iu38pr6	3119	59	as	as	IN
cord-005478-5iu38pr6	3119	60	opposed	oppose	VBN
cord-005478-5iu38pr6	3119	61	to	to	IN
cord-005478-5iu38pr6	3119	62	other	other	JJ
cord-005478-5iu38pr6	3119	63	donor	donor	NN
cord-005478-5iu38pr6	3119	64	sources	source	NNS
cord-005478-5iu38pr6	3119	65	:	:	:
cord-005478-5iu38pr6	3119	66	32	32	CD
cord-005478-5iu38pr6	3119	67	%	%	NN
cord-005478-5iu38pr6	3119	68	(	(	-LRB-
cord-005478-5iu38pr6	3119	69	24	24	CD
cord-005478-5iu38pr6	3119	70	-	-	SYM
cord-005478-5iu38pr6	3119	71	40	40	CD
cord-005478-5iu38pr6	3119	72	%	%	NN
cord-005478-5iu38pr6	3119	73	)	)	-RRB-
cord-005478-5iu38pr6	3119	74	vs.	vs.	CC
cord-005478-5iu38pr6	3119	75	17	17	CD
cord-005478-5iu38pr6	3119	76	%	%	NN
cord-005478-5iu38pr6	3119	77	(	(	-LRB-
cord-005478-5iu38pr6	3119	78	9	9	CD
cord-005478-5iu38pr6	3119	79	-	-	SYM
cord-005478-5iu38pr6	3119	80	25	25	CD
cord-005478-5iu38pr6	3119	81	%	%	NN
cord-005478-5iu38pr6	3119	82	)	)	-RRB-
cord-005478-5iu38pr6	3119	83	(	(	-LRB-
cord-005478-5iu38pr6	3119	84	p	p	NN
cord-005478-5iu38pr6	3119	85	<	<	XX
cord-005478-5iu38pr6	3119	86	0.001	0.001	CD
cord-005478-5iu38pr6	3119	87	)	)	-RRB-
cord-005478-5iu38pr6	3119	88	.	.	.
cord-005478-5iu38pr6	3120	1	On	on	IN
cord-005478-5iu38pr6	3120	2	multi	multi	JJ
cord-005478-5iu38pr6	3120	3	-	-	JJ
cord-005478-5iu38pr6	3120	4	variate	variate	JJ
cord-005478-5iu38pr6	3120	5	analysis	analysis	NN
cord-005478-5iu38pr6	3120	6	,	,	,
cord-005478-5iu38pr6	3120	7	donor	donor	NN
cord-005478-5iu38pr6	3120	8	source	source	NN
cord-005478-5iu38pr6	3120	9	(	(	-LRB-
cord-005478-5iu38pr6	3120	10	HLA	HLA	NNP
cord-005478-5iu38pr6	3120	11	identical	identical	JJ
cord-005478-5iu38pr6	3120	12	sibling	sibling	NN
cord-005478-5iu38pr6	3120	13	vs.	vs.	FW
cord-005478-5iu38pr6	3120	14	other	other	JJ
cord-005478-5iu38pr6	3120	15	)	)	-RRB-
cord-005478-5iu38pr6	3120	16	remained	remain	VBD
cord-005478-5iu38pr6	3120	17	a	a	DT
cord-005478-5iu38pr6	3120	18	predictive	predictive	JJ
cord-005478-5iu38pr6	3120	19	factor	factor	NN
cord-005478-5iu38pr6	3120	20	for	for	IN
cord-005478-5iu38pr6	3120	21	OS	OS	NNP
cord-005478-5iu38pr6	3120	22	(	(	-LRB-
cord-005478-5iu38pr6	3120	23	p=0.014	p=0.014	NNS
cord-005478-5iu38pr6	3120	24	)	)	-RRB-
cord-005478-5iu38pr6	3120	25	.	.	.
cord-005478-5iu38pr6	3121	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3121	2	:	:	:
cord-005478-5iu38pr6	3122	1	In	in	IN
cord-005478-5iu38pr6	3122	2	this	this	DT
cord-005478-5iu38pr6	3122	3	high	high	JJ
cord-005478-5iu38pr6	3122	4	-	-	HYPH
cord-005478-5iu38pr6	3122	5	risk	risk	NN
cord-005478-5iu38pr6	3122	6	MM	MM	NNP
cord-005478-5iu38pr6	3122	7	cohort	cohort	NN
cord-005478-5iu38pr6	3122	8	,	,	,
cord-005478-5iu38pr6	3122	9	one	one	CD
cord-005478-5iu38pr6	3122	10	quarter	quarter	NN
cord-005478-5iu38pr6	3122	11	of	of	IN
cord-005478-5iu38pr6	3122	12	patients	patient	NNS
cord-005478-5iu38pr6	3122	13	remained	remain	VBD
cord-005478-5iu38pr6	3122	14	alive	alive	JJ
cord-005478-5iu38pr6	3122	15	five	five	CD
cord-005478-5iu38pr6	3122	16	years	year	NNS
cord-005478-5iu38pr6	3122	17	after	after	IN
cord-005478-5iu38pr6	3122	18	the	the	DT
cord-005478-5iu38pr6	3122	19	2	2	CD
cord-005478-5iu38pr6	3122	20	nd	nd	NNP
cord-005478-5iu38pr6	3122	21	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3122	22	with	with	IN
cord-005478-5iu38pr6	3122	23	similar	similar	JJ
cord-005478-5iu38pr6	3122	24	outcomes	outcome	NNS
cord-005478-5iu38pr6	3122	25	seen	see	VBN
cord-005478-5iu38pr6	3122	26	following	follow	VBG
cord-005478-5iu38pr6	3122	27	disease	disease	NN
cord-005478-5iu38pr6	3122	28	relapse	relapse	NN
cord-005478-5iu38pr6	3122	29	and	and	CC
cord-005478-5iu38pr6	3122	30	graft	graft	NN
cord-005478-5iu38pr6	3122	31	failure	failure	NN
cord-005478-5iu38pr6	3122	32	.	.	.
cord-005478-5iu38pr6	3123	1	However	however	RB
cord-005478-5iu38pr6	3123	2	,	,	,
cord-005478-5iu38pr6	3123	3	the	the	DT
cord-005478-5iu38pr6	3123	4	relapse	relapse	NN
cord-005478-5iu38pr6	3123	5	-	-	HYPH
cord-005478-5iu38pr6	3123	6	free	free	JJ
cord-005478-5iu38pr6	3123	7	survival	survival	NN
cord-005478-5iu38pr6	3123	8	rate	rate	NN
cord-005478-5iu38pr6	3123	9	was	be	VBD
cord-005478-5iu38pr6	3123	10	low	low	JJ
cord-005478-5iu38pr6	3123	11	in	in	IN
cord-005478-5iu38pr6	3123	12	those	those	DT
cord-005478-5iu38pr6	3123	13	transplanted	transplant	VBN
cord-005478-5iu38pr6	3123	14	for	for	IN
cord-005478-5iu38pr6	3123	15	relapsed	relapse	VBN
cord-005478-5iu38pr6	3123	16	MM	MM	NNP
cord-005478-5iu38pr6	3123	17	.	.	.
cord-005478-5iu38pr6	3124	1	Later	later	RB
cord-005478-5iu38pr6	3124	2	relapses	relapse	NNS
cord-005478-5iu38pr6	3124	3	after	after	IN
cord-005478-5iu38pr6	3124	4	the	the	DT
cord-005478-5iu38pr6	3124	5	first	first	JJ
cord-005478-5iu38pr6	3124	6	alloHCT	alloHCT	NNP
cord-005478-5iu38pr6	3124	7	appear	appear	VBP
cord-005478-5iu38pr6	3124	8	to	to	TO
cord-005478-5iu38pr6	3124	9	fare	fare	VB
cord-005478-5iu38pr6	3124	10	better	well	RBR
cord-005478-5iu38pr6	3124	11	and	and	CC
cord-005478-5iu38pr6	3124	12	the	the	DT
cord-005478-5iu38pr6	3124	13	best	good	JJS
cord-005478-5iu38pr6	3124	14	outcomes	outcome	NNS
cord-005478-5iu38pr6	3124	15	are	be	VBP
cord-005478-5iu38pr6	3124	16	seen	see	VBN
cord-005478-5iu38pr6	3124	17	using	use	VBG
cord-005478-5iu38pr6	3124	18	matched	match	VBN
cord-005478-5iu38pr6	3124	19	sibling	sibling	NN
cord-005478-5iu38pr6	3124	20	donors	donor	NNS
cord-005478-5iu38pr6	3124	21	.	.	.
cord-005478-5iu38pr6	3125	1	A	a	DT
cord-005478-5iu38pr6	3125	2	2	2	CD
cord-005478-5iu38pr6	3125	3	nd	nd	NNP
cord-005478-5iu38pr6	3125	4	alloHCT	allohct	XX
cord-005478-5iu38pr6	3125	5	therefore	therefore	RB
cord-005478-5iu38pr6	3125	6	remains	remain	VBZ
cord-005478-5iu38pr6	3125	7	an	an	DT
cord-005478-5iu38pr6	3125	8	option	option	NN
cord-005478-5iu38pr6	3125	9	to	to	TO
cord-005478-5iu38pr6	3125	10	be	be	VB
cord-005478-5iu38pr6	3125	11	considered	consider	VBN
cord-005478-5iu38pr6	3125	12	for	for	IN
cord-005478-5iu38pr6	3125	13	selected	select	VBN
cord-005478-5iu38pr6	3125	14	MM	MM	NNP
cord-005478-5iu38pr6	3125	15	patients	patient	NNS
cord-005478-5iu38pr6	3125	16	.	.	.
cord-005478-5iu38pr6	3126	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3126	2	:	:	:
cord-005478-5iu38pr6	3126	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3126	4	to	to	TO
cord-005478-5iu38pr6	3126	5	declare	declare	VB
cord-005478-5iu38pr6	3126	6	Minimal	minimal	JJ
cord-005478-5iu38pr6	3126	7	residual	residual	JJ
cord-005478-5iu38pr6	3126	8	disease	disease	NN
cord-005478-5iu38pr6	3126	9	(	(	-LRB-
cord-005478-5iu38pr6	3126	10	MRD	MRD	NNP
cord-005478-5iu38pr6	3126	11	)	)	-RRB-
cord-005478-5iu38pr6	3126	12	ratio	ratio	NN
cord-005478-5iu38pr6	3126	13	before	before	IN
cord-005478-5iu38pr6	3126	14	and	and	CC
cord-005478-5iu38pr6	3126	15	after	after	IN
cord-005478-5iu38pr6	3126	16	autologous	autologous	JJ
cord-005478-5iu38pr6	3126	17	stem	stem	NN
cord-005478-5iu38pr6	3126	18	cells	cell	NNS
cord-005478-5iu38pr6	3126	19	transplantation	transplantation	NN
cord-005478-5iu38pr6	3126	20	(	(	-LRB-
cord-005478-5iu38pr6	3126	21	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3126	22	)	)	-RRB-
cord-005478-5iu38pr6	3126	23	in	in	IN
cord-005478-5iu38pr6	3126	24	multiple	multiple	JJ
cord-005478-5iu38pr6	3126	25	myeloma	myeloma	NN
cord-005478-5iu38pr6	3126	26	(	(	-LRB-
cord-005478-5iu38pr6	3126	27	MM	MM	NNP
cord-005478-5iu38pr6	3126	28	)	)	-RRB-
cord-005478-5iu38pr6	3127	1	Riccardo	Riccardo	NNP
cord-005478-5iu38pr6	3127	2	Boncompagni	Boncompagni	NNP
cord-005478-5iu38pr6	3127	3	1	1	CD
cord-005478-5iu38pr6	3127	4	,	,	,
cord-005478-5iu38pr6	3127	5	Michela	Michela	NNP
cord-005478-5iu38pr6	3127	6	Staderini	Staderini	NNP
cord-005478-5iu38pr6	3127	7	1	1	CD
cord-005478-5iu38pr6	3127	8	,	,	,
cord-005478-5iu38pr6	3127	9	Chiara	Chiara	NNP
cord-005478-5iu38pr6	3127	10	Nozzoli	Nozzoli	NNP
cord-005478-5iu38pr6	3127	11	1	1	CD
cord-005478-5iu38pr6	3127	12	,	,	,
cord-005478-5iu38pr6	3127	13	Elisabetta	Elisabetta	NNP
cord-005478-5iu38pr6	3127	14	Antonioli	Antonioli	NNP
cord-005478-5iu38pr6	3127	15	1	1	CD
cord-005478-5iu38pr6	3127	16	,	,	,
cord-005478-5iu38pr6	3127	17	Barbara	Barbara	NNP
cord-005478-5iu38pr6	3127	18	Accogli	Accogli	NNP
cord-005478-5iu38pr6	3127	19	1	1	CD
cord-005478-5iu38pr6	3127	20	,	,	,
cord-005478-5iu38pr6	3127	21	Riccardo	Riccardo	NNP
cord-005478-5iu38pr6	3127	22	Saccardi	Saccardi	NNP
cord-005478-5iu38pr6	3127	23	1	1	CD
cord-005478-5iu38pr6	3127	24	1	1	CD
cord-005478-5iu38pr6	3127	25	Careggi	Careggi	NNP
cord-005478-5iu38pr6	3127	26	University	University	NNP
cord-005478-5iu38pr6	3127	27	Hospital	Hospital	NNP
cord-005478-5iu38pr6	3127	28	,	,	,
cord-005478-5iu38pr6	3127	29	Florence	Florence	NNP
cord-005478-5iu38pr6	3127	30	,	,	,
cord-005478-5iu38pr6	3127	31	Italy	Italy	NNP
cord-005478-5iu38pr6	3127	32	,	,	,
cord-005478-5iu38pr6	3127	33	Background	background	NN
cord-005478-5iu38pr6	3127	34	:	:	:
cord-005478-5iu38pr6	3128	1	In	in	IN
cord-005478-5iu38pr6	3128	2	the	the	DT
cord-005478-5iu38pr6	3128	3	last	last	JJ
cord-005478-5iu38pr6	3128	4	ten	ten	CD
cord-005478-5iu38pr6	3128	5	years	year	NNS
cord-005478-5iu38pr6	3128	6	,	,	,
cord-005478-5iu38pr6	3128	7	Multiparametric	Multiparametric	NNP
cord-005478-5iu38pr6	3128	8	Flow	Flow	NNP
cord-005478-5iu38pr6	3128	9	Cytometry	Cytometry	NNP
cord-005478-5iu38pr6	3128	10	(	(	-LRB-
cord-005478-5iu38pr6	3128	11	MFC	MFC	NNP
cord-005478-5iu38pr6	3128	12	)	)	-RRB-
cord-005478-5iu38pr6	3128	13	has	have	VBZ
cord-005478-5iu38pr6	3128	14	been	be	VBN
cord-005478-5iu38pr6	3128	15	standardized	standardize	VBN
cord-005478-5iu38pr6	3128	16	and	and	CC
cord-005478-5iu38pr6	3128	17	routinely	routinely	RB
cord-005478-5iu38pr6	3128	18	applied	apply	VBN
cord-005478-5iu38pr6	3128	19	for	for	IN
cord-005478-5iu38pr6	3128	20	the	the	DT
cord-005478-5iu38pr6	3128	21	detection	detection	NN
cord-005478-5iu38pr6	3128	22	of	of	IN
cord-005478-5iu38pr6	3128	23	MRD	MRD	NNP
cord-005478-5iu38pr6	3128	24	as	as	IN
cord-005478-5iu38pr6	3128	25	a	a	DT
cord-005478-5iu38pr6	3128	26	prognostic	prognostic	JJ
cord-005478-5iu38pr6	3128	27	factor	factor	NN
cord-005478-5iu38pr6	3128	28	in	in	IN
cord-005478-5iu38pr6	3128	29	MM	MM	NNP
cord-005478-5iu38pr6	3128	30	patients	patient	NNS
cord-005478-5iu38pr6	3128	31	across	across	IN
cord-005478-5iu38pr6	3128	32	different	different	JJ
cord-005478-5iu38pr6	3128	33	lines	line	NNS
cord-005478-5iu38pr6	3128	34	of	of	IN
cord-005478-5iu38pr6	3128	35	therapy	therapy	NN
cord-005478-5iu38pr6	3128	36	.	.	.
cord-005478-5iu38pr6	3129	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3129	2	assessed	assess	VBD
cord-005478-5iu38pr6	3129	3	the	the	DT
cord-005478-5iu38pr6	3129	4	MRD	MRD	NNP
cord-005478-5iu38pr6	3129	5	carried	carry	VBD
cord-005478-5iu38pr6	3129	6	out	out	RP
cord-005478-5iu38pr6	3129	7	before	before	RB
cord-005478-5iu38pr6	3129	8	and	and	CC
cord-005478-5iu38pr6	3129	9	after	after	IN
cord-005478-5iu38pr6	3129	10	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3129	11	in	in	IN
cord-005478-5iu38pr6	3129	12	a	a	DT
cord-005478-5iu38pr6	3129	13	series	series	NN
cord-005478-5iu38pr6	3129	14	of	of	IN
cord-005478-5iu38pr6	3129	15	consecutive	consecutive	JJ
cord-005478-5iu38pr6	3129	16	MM	MM	NNP
cord-005478-5iu38pr6	3129	17	patients	patient	NNS
cord-005478-5iu38pr6	3129	18	in	in	IN
cord-005478-5iu38pr6	3129	19	order	order	NN
cord-005478-5iu38pr6	3129	20	to	to	TO
cord-005478-5iu38pr6	3129	21	investigate	investigate	VB
cord-005478-5iu38pr6	3129	22	whether	whether	IN
cord-005478-5iu38pr6	3129	23	the	the	DT
cord-005478-5iu38pr6	3129	24	ratio	ratio	NN
cord-005478-5iu38pr6	3129	25	of	of	IN
cord-005478-5iu38pr6	3129	26	the	the	DT
cord-005478-5iu38pr6	3129	27	two	two	CD
cord-005478-5iu38pr6	3129	28	determinations	determination	NNS
cord-005478-5iu38pr6	3129	29	might	may	MD
cord-005478-5iu38pr6	3129	30	increase	increase	VB
cord-005478-5iu38pr6	3129	31	the	the	DT
cord-005478-5iu38pr6	3129	32	prognostic	prognostic	JJ
cord-005478-5iu38pr6	3129	33	potential	potential	NN
cord-005478-5iu38pr6	3129	34	.	.	.
cord-005478-5iu38pr6	3130	1	Methods	method	NNS
cord-005478-5iu38pr6	3130	2	:	:	:
cord-005478-5iu38pr6	3131	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3131	2	collected	collect	VBD
cord-005478-5iu38pr6	3131	3	bone	bone	NN
cord-005478-5iu38pr6	3131	4	marrow	marrow	NN
cord-005478-5iu38pr6	3131	5	samples	sample	NNS
cord-005478-5iu38pr6	3131	6	for	for	IN
cord-005478-5iu38pr6	3131	7	MRD	MRD	NNP
cord-005478-5iu38pr6	3131	8	assessment	assessment	NN
cord-005478-5iu38pr6	3131	9	at	at	IN
cord-005478-5iu38pr6	3131	10	the	the	DT
cord-005478-5iu38pr6	3131	11	end	end	NN
cord-005478-5iu38pr6	3131	12	of	of	IN
cord-005478-5iu38pr6	3131	13	induction	induction	NN
cord-005478-5iu38pr6	3131	14	therapy	therapy	NN
cord-005478-5iu38pr6	3131	15	and	and	CC
cord-005478-5iu38pr6	3131	16	3	3	CD
cord-005478-5iu38pr6	3131	17	months	month	NNS
cord-005478-5iu38pr6	3131	18	after	after	IN
cord-005478-5iu38pr6	3131	19	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3131	20	from	from	IN
cord-005478-5iu38pr6	3131	21	61	61	CD
cord-005478-5iu38pr6	3131	22	MM	MM	NNP
cord-005478-5iu38pr6	3131	23	patients	patient	NNS
cord-005478-5iu38pr6	3131	24	treated	treat	VBN
cord-005478-5iu38pr6	3131	25	between	between	IN
cord-005478-5iu38pr6	3131	26	2013	2013	CD
cord-005478-5iu38pr6	3131	27	and	and	CC
cord-005478-5iu38pr6	3131	28	2017	2017	CD
cord-005478-5iu38pr6	3131	29	achieving	achieve	VBG
cord-005478-5iu38pr6	3131	30	at	at	IN
cord-005478-5iu38pr6	3131	31	least	least	JJS
cord-005478-5iu38pr6	3131	32	a	a	DT
cord-005478-5iu38pr6	3131	33	Very	very	RB
cord-005478-5iu38pr6	3131	34	Good	good	JJ
cord-005478-5iu38pr6	3131	35	Partial	partial	JJ
cord-005478-5iu38pr6	3131	36	Remission	remission	NN
cord-005478-5iu38pr6	3131	37	(	(	-LRB-
cord-005478-5iu38pr6	3131	38	VGPR	VGPR	NNP
cord-005478-5iu38pr6	3131	39	)	)	-RRB-
cord-005478-5iu38pr6	3131	40	with	with	IN
cord-005478-5iu38pr6	3131	41	a	a	DT
cord-005478-5iu38pr6	3131	42	bortezomib	bortezomib	NN
cord-005478-5iu38pr6	3131	43	-	-	HYPH
cord-005478-5iu38pr6	3131	44	based	base	VBN
cord-005478-5iu38pr6	3131	45	induction	induction	NN
cord-005478-5iu38pr6	3131	46	therapy	therapy	NN
cord-005478-5iu38pr6	3131	47	,	,	,
cord-005478-5iu38pr6	3131	48	according	accord	VBG
cord-005478-5iu38pr6	3131	49	to	to	IN
cord-005478-5iu38pr6	3131	50	the	the	DT
cord-005478-5iu38pr6	3131	51	most	most	RBS
cord-005478-5iu38pr6	3131	52	recent	recent	JJ
cord-005478-5iu38pr6	3131	53	International	International	NNP
cord-005478-5iu38pr6	3131	54	Myeloma	Myeloma	NNP
cord-005478-5iu38pr6	3131	55	Working	Working	NNP
cord-005478-5iu38pr6	3131	56	Group	Group	NNP
cord-005478-5iu38pr6	3131	57	(	(	-LRB-
cord-005478-5iu38pr6	3131	58	IMWG	IMWG	NNP
cord-005478-5iu38pr6	3131	59	)	)	-RRB-
cord-005478-5iu38pr6	3131	60	criteria	criterion	NNS
cord-005478-5iu38pr6	3131	61	(	(	-LRB-
cord-005478-5iu38pr6	3131	62	Kumar	Kumar	NNP
cord-005478-5iu38pr6	3131	63	S	S	NNP
cord-005478-5iu38pr6	3131	64	et	et	NNP
cord-005478-5iu38pr6	3131	65	al	al	NNP
cord-005478-5iu38pr6	3131	66	,	,	,
cord-005478-5iu38pr6	3131	67	Lancet	Lancet	NNP
cord-005478-5iu38pr6	3131	68	Oncol	Oncol	NNP
cord-005478-5iu38pr6	3131	69	2016	2016	CD
cord-005478-5iu38pr6	3131	70	)	)	-RRB-
cord-005478-5iu38pr6	3131	71	.	.	.
cord-005478-5iu38pr6	3132	1	MFC	mfc	NN
cord-005478-5iu38pr6	3132	2	-	-	HYPH
cord-005478-5iu38pr6	3132	3	determined	determine	VBN
cord-005478-5iu38pr6	3132	4	MRD	MRD	NNP
cord-005478-5iu38pr6	3132	5	was	be	VBD
cord-005478-5iu38pr6	3132	6	evaluated	evaluate	VBN
cord-005478-5iu38pr6	3132	7	according	accord	VBG
cord-005478-5iu38pr6	3132	8	to	to	IN
cord-005478-5iu38pr6	3132	9	EuroFlow	EuroFlow	NNP
cord-005478-5iu38pr6	3132	10	recommendations	recommendation	NNS
cord-005478-5iu38pr6	3132	11	(	(	-LRB-
cord-005478-5iu38pr6	3132	12	Kalina	Kalina	NNP
cord-005478-5iu38pr6	3132	13	T	T	NNP
cord-005478-5iu38pr6	3132	14	et	et	NNP
cord-005478-5iu38pr6	3132	15	al	al	NNP
cord-005478-5iu38pr6	3132	16	,	,	,
cord-005478-5iu38pr6	3132	17	Leukemia	Leukemia	NNP
cord-005478-5iu38pr6	3132	18	2012	2012	CD
cord-005478-5iu38pr6	3132	19	)	)	-RRB-
cord-005478-5iu38pr6	3132	20	.	.	.
cord-005478-5iu38pr6	3133	1	All	all	DT
cord-005478-5iu38pr6	3133	2	patients	patient	NNS
cord-005478-5iu38pr6	3133	3	were	be	VBD
cord-005478-5iu38pr6	3133	4	examined	examine	VBN
cord-005478-5iu38pr6	3133	5	with	with	IN
cord-005478-5iu38pr6	3133	6	18fluorodeoxyglucose	18fluorodeoxyglucose	CD
cord-005478-5iu38pr6	3133	7	positron	positron	NN
cord-005478-5iu38pr6	3133	8	emission	emission	NN
cord-005478-5iu38pr6	3133	9	tomography	tomography	NN
cord-005478-5iu38pr6	3133	10	/	/	SYM
cord-005478-5iu38pr6	3133	11	computed	compute	VBN
cord-005478-5iu38pr6	3133	12	tomography	tomography	NN
cord-005478-5iu38pr6	3133	13	(	(	-LRB-
cord-005478-5iu38pr6	3133	14	FDG	FDG	NNP
cord-005478-5iu38pr6	3133	15	-	-	HYPH
cord-005478-5iu38pr6	3133	16	PET	PET	NNP
cord-005478-5iu38pr6	3133	17	/	/	SYM
cord-005478-5iu38pr6	3133	18	CT	CT	NNP
cord-005478-5iu38pr6	3133	19	)	)	-RRB-
cord-005478-5iu38pr6	3133	20	scan	scan	VBP
cord-005478-5iu38pr6	3133	21	before	before	IN
cord-005478-5iu38pr6	3133	22	and	and	CC
cord-005478-5iu38pr6	3133	23	after	after	IN
cord-005478-5iu38pr6	3133	24	the	the	DT
cord-005478-5iu38pr6	3133	25	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3133	26	.	.	.
cord-005478-5iu38pr6	3134	1	Results	result	NNS
cord-005478-5iu38pr6	3134	2	:	:	:
cord-005478-5iu38pr6	3135	1	Post	post	JJ
cord-005478-5iu38pr6	3135	2	-	-	JJ
cord-005478-5iu38pr6	3135	3	induction	induction	JJ
cord-005478-5iu38pr6	3135	4	therapy	therapy	NN
cord-005478-5iu38pr6	3135	5	MRD	MRD	NNP
cord-005478-5iu38pr6	3135	6	was	be	VBD
cord-005478-5iu38pr6	3135	7	found	find	VBN
cord-005478-5iu38pr6	3135	8	predictive	predictive	JJ
cord-005478-5iu38pr6	3135	9	of	of	IN
cord-005478-5iu38pr6	3135	10	post	post	JJ
cord-005478-5iu38pr6	3135	11	-	-	JJ
cord-005478-5iu38pr6	3135	12	ASCT	asct	JJ
cord-005478-5iu38pr6	3135	13	MRD	MRD	NNP
cord-005478-5iu38pr6	3135	14	status	status	NN
cord-005478-5iu38pr6	3135	15	.	.	.
cord-005478-5iu38pr6	3136	1	Indeed	indeed	RB
cord-005478-5iu38pr6	3136	2	,	,	,
cord-005478-5iu38pr6	3136	3	patients	patient	NNS
cord-005478-5iu38pr6	3136	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	3136	5	in	in	IN
cord-005478-5iu38pr6	3136	6	a	a	DT
cord-005478-5iu38pr6	3136	7	MRD	MRD	NNP
cord-005478-5iu38pr6	3136	8	positive	positive	JJ
cord-005478-5iu38pr6	3136	9	status	status	NN
cord-005478-5iu38pr6	3136	10	had	have	VBD
cord-005478-5iu38pr6	3136	11	a	a	DT
cord-005478-5iu38pr6	3136	12	significantly	significantly	RB
cord-005478-5iu38pr6	3136	13	increased	increase	VBN
cord-005478-5iu38pr6	3136	14	risk	risk	NN
cord-005478-5iu38pr6	3136	15	to	to	TO
cord-005478-5iu38pr6	3136	16	maintain	maintain	VB
cord-005478-5iu38pr6	3136	17	a	a	DT
cord-005478-5iu38pr6	3136	18	MRD	MRD	NNP
cord-005478-5iu38pr6	3136	19	positivity	positivity	NN
cord-005478-5iu38pr6	3136	20	status	status	NN
cord-005478-5iu38pr6	3136	21	after	after	IN
cord-005478-5iu38pr6	3136	22	transplantation	transplantation	NN
cord-005478-5iu38pr6	3136	23	(	(	-LRB-
cord-005478-5iu38pr6	3136	24	Odds	Odds	NNPS
cord-005478-5iu38pr6	3136	25	Ratio	Ratio	NNP
cord-005478-5iu38pr6	3136	26	-OR	-or	NN
cord-005478-5iu38pr6	3136	27	-15,053	-15,053	NN
cord-005478-5iu38pr6	3136	28	,	,	,
cord-005478-5iu38pr6	3136	29	p	p	NN
cord-005478-5iu38pr6	3136	30	=	=	SYM
cord-005478-5iu38pr6	3136	31	0,002	0,002	CD
cord-005478-5iu38pr6	3136	32	)	)	-RRB-
cord-005478-5iu38pr6	3136	33	.	.	.
cord-005478-5iu38pr6	3137	1	Detection	detection	NN
cord-005478-5iu38pr6	3137	2	of	of	IN
cord-005478-5iu38pr6	3137	3	post	post	JJ
cord-005478-5iu38pr6	3137	4	-	-	JJ
cord-005478-5iu38pr6	3137	5	ASCT	asct	JJ
cord-005478-5iu38pr6	3137	6	MRD	MRD	NNP
cord-005478-5iu38pr6	3137	7	had	have	VBD
cord-005478-5iu38pr6	3137	8	a	a	DT
cord-005478-5iu38pr6	3137	9	negative	negative	JJ
cord-005478-5iu38pr6	3137	10	impact	impact	NN
cord-005478-5iu38pr6	3137	11	on	on	IN
cord-005478-5iu38pr6	3137	12	median	median	JJ
cord-005478-5iu38pr6	3137	13	PFS	PFS	NNP
cord-005478-5iu38pr6	3137	14	(	(	-LRB-
cord-005478-5iu38pr6	3137	15	28	28	CD
cord-005478-5iu38pr6	3137	16	months	month	NNS
cord-005478-5iu38pr6	3137	17	vs	vs	IN
cord-005478-5iu38pr6	3137	18	not	not	RB
cord-005478-5iu38pr6	3137	19	reached	reach	VBN
cord-005478-5iu38pr6	3137	20	respectively	respectively	RB
cord-005478-5iu38pr6	3137	21	,	,	,
cord-005478-5iu38pr6	3137	22	p	p	NN
cord-005478-5iu38pr6	3137	23	=	=	SYM
cord-005478-5iu38pr6	3137	24	0,001	0,001	CD
cord-005478-5iu38pr6	3137	25	)	)	-RRB-
cord-005478-5iu38pr6	3137	26	.	.	.
cord-005478-5iu38pr6	3138	1	In	in	IN
cord-005478-5iu38pr6	3138	2	Cox	Cox	NNP
cord-005478-5iu38pr6	3138	3	-	-	HYPH
cord-005478-5iu38pr6	3138	4	Regression	Regression	NNP
cord-005478-5iu38pr6	3138	5	analysis	analysis	NN
cord-005478-5iu38pr6	3138	6	,	,	,
cord-005478-5iu38pr6	3138	7	a	a	DT
cord-005478-5iu38pr6	3138	8	complete	complete	JJ
cord-005478-5iu38pr6	3138	9	remission	remission	NN
cord-005478-5iu38pr6	3138	10	status	status	NN
cord-005478-5iu38pr6	3138	11	(	(	-LRB-
cord-005478-5iu38pr6	3138	12	CR	cr	NN
cord-005478-5iu38pr6	3138	13	)	)	-RRB-
cord-005478-5iu38pr6	3138	14	with	with	IN
cord-005478-5iu38pr6	3138	15	an	an	DT
cord-005478-5iu38pr6	3138	16	undetectable	undetectable	JJ
cord-005478-5iu38pr6	3138	17	MRD	MRD	NNP
cord-005478-5iu38pr6	3138	18	after	after	IN
cord-005478-5iu38pr6	3138	19	the	the	DT
cord-005478-5iu38pr6	3138	20	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3138	21	resulted	result	VBD
cord-005478-5iu38pr6	3138	22	to	to	TO
cord-005478-5iu38pr6	3138	23	be	be	VB
cord-005478-5iu38pr6	3138	24	the	the	DT
cord-005478-5iu38pr6	3138	25	major	major	JJ
cord-005478-5iu38pr6	3138	26	protective	protective	JJ
cord-005478-5iu38pr6	3138	27	factor	factor	NN
cord-005478-5iu38pr6	3138	28	from	from	IN
cord-005478-5iu38pr6	3138	29	relapse	relapse	NN
cord-005478-5iu38pr6	3139	1	(	(	-LRB-
cord-005478-5iu38pr6	3139	2	Hazard	Hazard	NNP
cord-005478-5iu38pr6	3139	3	Ratio	Ratio	NNP
cord-005478-5iu38pr6	3139	4	-HR	-HR	NNP
cord-005478-5iu38pr6	3139	5	-0,012	-0,012	NNP
cord-005478-5iu38pr6	3139	6	,	,	,
cord-005478-5iu38pr6	3139	7	p	p	NN
cord-005478-5iu38pr6	3139	8	=	=	SYM
cord-005478-5iu38pr6	3139	9	0,005	0,005	CD
cord-005478-5iu38pr6	3139	10	)	)	-RRB-
cord-005478-5iu38pr6	3139	11	,	,	,
cord-005478-5iu38pr6	3139	12	while	while	IN
cord-005478-5iu38pr6	3139	13	patients	patient	NNS
cord-005478-5iu38pr6	3139	14	with	with	IN
cord-005478-5iu38pr6	3139	15	a	a	DT
cord-005478-5iu38pr6	3139	16	detectable	detectable	JJ
cord-005478-5iu38pr6	3139	17	MRD	MRD	NNP
cord-005478-5iu38pr6	3139	18	before	before	RB
cord-005478-5iu38pr6	3139	19	and	and	CC
cord-005478-5iu38pr6	3139	20	after	after	IN
cord-005478-5iu38pr6	3139	21	the	the	DT
cord-005478-5iu38pr6	3139	22	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3139	23	had	have	VBD
cord-005478-5iu38pr6	3139	24	the	the	DT
cord-005478-5iu38pr6	3139	25	worse	bad	JJR
cord-005478-5iu38pr6	3139	26	PFS	PFS	NNP
cord-005478-5iu38pr6	3139	27	(	(	-LRB-
cord-005478-5iu38pr6	3139	28	22	22	CD
cord-005478-5iu38pr6	3139	29	months	month	NNS
cord-005478-5iu38pr6	3139	30	,	,	,
cord-005478-5iu38pr6	3139	31	HR	HR	NNP
cord-005478-5iu38pr6	3139	32	2,958	2,958	CD
cord-005478-5iu38pr6	3139	33	;	;	:
cord-005478-5iu38pr6	3139	34	p	p	NN
cord-005478-5iu38pr6	3139	35	=	=	SYM
cord-005478-5iu38pr6	3139	36	0,029	0,029	CD
cord-005478-5iu38pr6	3139	37	)	)	-RRB-
cord-005478-5iu38pr6	3139	38	.	.	.
cord-005478-5iu38pr6	3140	1	Risk	risk	NN
cord-005478-5iu38pr6	3140	2	analysis	analysis	NN
cord-005478-5iu38pr6	3140	3	showed	show	VBD
cord-005478-5iu38pr6	3140	4	3	3	CD
cord-005478-5iu38pr6	3140	5	different	different	JJ
cord-005478-5iu38pr6	3140	6	PFS	PFS	NNP
cord-005478-5iu38pr6	3140	7	risk	risk	NN
cord-005478-5iu38pr6	3140	8	groups	group	NNS
cord-005478-5iu38pr6	3140	9	:	:	:
cord-005478-5iu38pr6	3140	10	"	"	``
cord-005478-5iu38pr6	3140	11	high	high	JJ
cord-005478-5iu38pr6	3140	12	"	"	''
cord-005478-5iu38pr6	3140	13	for	for	IN
cord-005478-5iu38pr6	3140	14	the	the	DT
cord-005478-5iu38pr6	3140	15	patients	patient	NNS
cord-005478-5iu38pr6	3140	16	with	with	IN
cord-005478-5iu38pr6	3140	17	MRD	MRD	NNP
cord-005478-5iu38pr6	3140	18	detectable	detectable	JJ
cord-005478-5iu38pr6	3140	19	before	before	IN
cord-005478-5iu38pr6	3140	20	and	and	CC
cord-005478-5iu38pr6	3140	21	after	after	IN
cord-005478-5iu38pr6	3140	22	the	the	DT
cord-005478-5iu38pr6	3140	23	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3140	24	,	,	,
cord-005478-5iu38pr6	3140	25	"	"	``
cord-005478-5iu38pr6	3140	26	intermediate	intermediate	JJ
cord-005478-5iu38pr6	3140	27	"	"	''
cord-005478-5iu38pr6	3140	28	for	for	IN
cord-005478-5iu38pr6	3140	29	patients	patient	NNS
cord-005478-5iu38pr6	3140	30	with	with	IN
cord-005478-5iu38pr6	3140	31	MRD	MRD	NNP
cord-005478-5iu38pr6	3140	32	positivity	positivity	NN
cord-005478-5iu38pr6	3140	33	before	before	IN
cord-005478-5iu38pr6	3140	34	the	the	DT
cord-005478-5iu38pr6	3140	35	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3140	36	who	who	WP
cord-005478-5iu38pr6	3140	37	achieve	achieve	VBP
cord-005478-5iu38pr6	3140	38	a	a	DT
cord-005478-5iu38pr6	3140	39	negativity	negativity	NN
cord-005478-5iu38pr6	3140	40	after	after	RB
cord-005478-5iu38pr6	3140	41	,	,	,
cord-005478-5iu38pr6	3140	42	and	and	CC
cord-005478-5iu38pr6	3140	43	"	"	``
cord-005478-5iu38pr6	3140	44	low	low	JJ
cord-005478-5iu38pr6	3140	45	"	"	''
cord-005478-5iu38pr6	3140	46	in	in	IN
cord-005478-5iu38pr6	3140	47	the	the	DT
cord-005478-5iu38pr6	3140	48	case	case	NN
cord-005478-5iu38pr6	3140	49	of	of	IN
cord-005478-5iu38pr6	3140	50	MRD	MRD	NNP
cord-005478-5iu38pr6	3140	51	undetectable	undetectable	JJ
cord-005478-5iu38pr6	3140	52	before	before	RB
cord-005478-5iu38pr6	3140	53	and	and	CC
cord-005478-5iu38pr6	3140	54	after	after	RB
cord-005478-5iu38pr6	3140	55	.	.	.
cord-005478-5iu38pr6	3141	1	In	in	IN
cord-005478-5iu38pr6	3141	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	3141	3	study	study	NN
cord-005478-5iu38pr6	3141	4	,	,	,
cord-005478-5iu38pr6	3141	5	response	response	NN
cord-005478-5iu38pr6	3141	6	evaluated	evaluate	VBN
cord-005478-5iu38pr6	3141	7	by	by	IN
cord-005478-5iu38pr6	3141	8	FDG	FDG	NNP
cord-005478-5iu38pr6	3141	9	-	-	HYPH
cord-005478-5iu38pr6	3141	10	PET	PET	NNP
cord-005478-5iu38pr6	3141	11	/	/	SYM
cord-005478-5iu38pr6	3141	12	CT	CT	NNP
cord-005478-5iu38pr6	3141	13	showed	show	VBD
cord-005478-5iu38pr6	3141	14	no	no	DT
cord-005478-5iu38pr6	3141	15	correlation	correlation	NN
cord-005478-5iu38pr6	3141	16	with	with	IN
cord-005478-5iu38pr6	3141	17	PFS	PFS	NNP
cord-005478-5iu38pr6	3141	18	.	.	.
cord-005478-5iu38pr6	3142	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3142	2	:	:	:
cord-005478-5iu38pr6	3143	1	Multiparametric	multiparametric	JJ
cord-005478-5iu38pr6	3143	2	flow	flow	NN
cord-005478-5iu38pr6	3143	3	cytometry	cytometry	NN
cord-005478-5iu38pr6	3143	4	is	be	VBZ
cord-005478-5iu38pr6	3143	5	a	a	DT
cord-005478-5iu38pr6	3143	6	relatively	relatively	RB
cord-005478-5iu38pr6	3143	7	recent	recent	JJ
cord-005478-5iu38pr6	3143	8	method	method	NN
cord-005478-5iu38pr6	3143	9	to	to	TO
cord-005478-5iu38pr6	3143	10	assay	assay	VB
cord-005478-5iu38pr6	3143	11	MM	MM	NNP
cord-005478-5iu38pr6	3143	12	MRD	MRD	NNP
cord-005478-5iu38pr6	3143	13	,	,	,
cord-005478-5iu38pr6	3143	14	and	and	CC
cord-005478-5iu38pr6	3143	15	its	-PRON-	PRP$
cord-005478-5iu38pr6	3143	16	role	role	NN
cord-005478-5iu38pr6	3143	17	in	in	IN
cord-005478-5iu38pr6	3143	18	MM	MM	NNP
cord-005478-5iu38pr6	3143	19	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	3143	20	path	path	NN
cord-005478-5iu38pr6	3143	21	is	be	VBZ
cord-005478-5iu38pr6	3143	22	still	still	RB
cord-005478-5iu38pr6	3143	23	under	under	IN
cord-005478-5iu38pr6	3143	24	investigation	investigation	NN
cord-005478-5iu38pr6	3143	25	.	.	.
cord-005478-5iu38pr6	3144	1	According	accord	VBG
cord-005478-5iu38pr6	3144	2	to	to	IN
cord-005478-5iu38pr6	3144	3	our	-PRON-	PRP$
cord-005478-5iu38pr6	3144	4	data	datum	NNS
cord-005478-5iu38pr6	3144	5	,	,	,
cord-005478-5iu38pr6	3144	6	a	a	DT
cord-005478-5iu38pr6	3144	7	detectable	detectable	JJ
cord-005478-5iu38pr6	3144	8	MRD	MRD	NNP
cord-005478-5iu38pr6	3144	9	after	after	IN
cord-005478-5iu38pr6	3144	10	the	the	DT
cord-005478-5iu38pr6	3144	11	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3144	12	is	be	VBZ
cord-005478-5iu38pr6	3144	13	a	a	DT
cord-005478-5iu38pr6	3144	14	major	major	JJ
cord-005478-5iu38pr6	3144	15	relapse	relapse	NN
cord-005478-5iu38pr6	3144	16	risk	risk	NN
cord-005478-5iu38pr6	3144	17	.	.	.
cord-005478-5iu38pr6	3145	1	Interestingly	interestingly	RB
cord-005478-5iu38pr6	3145	2	we	-PRON-	PRP
cord-005478-5iu38pr6	3145	3	found	find	VBD
cord-005478-5iu38pr6	3145	4	that	that	IN
cord-005478-5iu38pr6	3145	5	it	-PRON-	PRP
cord-005478-5iu38pr6	3145	6	can	can	MD
cord-005478-5iu38pr6	3145	7	be	be	VB
cord-005478-5iu38pr6	3145	8	early	early	RB
cord-005478-5iu38pr6	3145	9	predicted	predict	VBN
cord-005478-5iu38pr6	3145	10	by	by	IN
cord-005478-5iu38pr6	3145	11	the	the	DT
cord-005478-5iu38pr6	3145	12	post	post	JJ
cord-005478-5iu38pr6	3145	13	-	-	JJ
cord-005478-5iu38pr6	3145	14	induction	induction	JJ
cord-005478-5iu38pr6	3145	15	MRD	MRD	NNP
cord-005478-5iu38pr6	3145	16	status	status	NN
cord-005478-5iu38pr6	3145	17	and	and	CC
cord-005478-5iu38pr6	3145	18	its	-PRON-	PRP$
cord-005478-5iu38pr6	3145	19	negativization	negativization	NN
cord-005478-5iu38pr6	3145	20	after	after	IN
cord-005478-5iu38pr6	3145	21	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3145	22	has	have	VBZ
cord-005478-5iu38pr6	3145	23	a	a	DT
cord-005478-5iu38pr6	3145	24	modest	modest	JJ
cord-005478-5iu38pr6	3145	25	impact	impact	NN
cord-005478-5iu38pr6	3145	26	on	on	IN
cord-005478-5iu38pr6	3145	27	this	this	DT
cord-005478-5iu38pr6	3145	28	.	.	.
cord-005478-5iu38pr6	3146	1	Therefore	therefore	RB
cord-005478-5iu38pr6	3146	2	,	,	,
cord-005478-5iu38pr6	3146	3	we	-PRON-	PRP
cord-005478-5iu38pr6	3146	4	support	support	VBP
cord-005478-5iu38pr6	3146	5	the	the	DT
cord-005478-5iu38pr6	3146	6	concept	concept	NN
cord-005478-5iu38pr6	3146	7	of	of	IN
cord-005478-5iu38pr6	3146	8	treatment	treatment	NN
cord-005478-5iu38pr6	3146	9	escalation	escalation	NN
cord-005478-5iu38pr6	3146	10	when	when	WRB
cord-005478-5iu38pr6	3146	11	a	a	DT
cord-005478-5iu38pr6	3146	12	CR	cr	NN
cord-005478-5iu38pr6	3146	13	is	be	VBZ
cord-005478-5iu38pr6	3146	14	not	not	RB
cord-005478-5iu38pr6	3146	15	reached	reach	VBN
cord-005478-5iu38pr6	3146	16	after	after	IN
cord-005478-5iu38pr6	3146	17	the	the	DT
cord-005478-5iu38pr6	3146	18	induction	induction	NN
cord-005478-5iu38pr6	3146	19	treatment	treatment	NN
cord-005478-5iu38pr6	3146	20	,	,	,
cord-005478-5iu38pr6	3146	21	in	in	IN
cord-005478-5iu38pr6	3146	22	order	order	NN
cord-005478-5iu38pr6	3146	23	to	to	TO
cord-005478-5iu38pr6	3146	24	undergo	undergo	VB
cord-005478-5iu38pr6	3146	25	to	to	IN
cord-005478-5iu38pr6	3146	26	the	the	DT
cord-005478-5iu38pr6	3146	27	ASCT	ASCT	NNP
cord-005478-5iu38pr6	3146	28	in	in	IN
cord-005478-5iu38pr6	3146	29	the	the	DT
cord-005478-5iu38pr6	3146	30	best	good	JJS
cord-005478-5iu38pr6	3146	31	possible	possible	JJ
cord-005478-5iu38pr6	3146	32	response	response	NN
cord-005478-5iu38pr6	3146	33	.	.	.
cord-005478-5iu38pr6	3147	1	However	however	RB
cord-005478-5iu38pr6	3147	2	,	,	,
cord-005478-5iu38pr6	3147	3	double	double	JJ
cord-005478-5iu38pr6	3147	4	MRD	MRD	NNP
cord-005478-5iu38pr6	3147	5	determination	determination	NN
cord-005478-5iu38pr6	3147	6	before	before	IN
cord-005478-5iu38pr6	3147	7	and	and	CC
cord-005478-5iu38pr6	3147	8	after	after	IN
cord-005478-5iu38pr6	3147	9	VTD	VTD	NNP
cord-005478-5iu38pr6	3147	10	,	,	,
cord-005478-5iu38pr6	3147	11	with	with	IN
cord-005478-5iu38pr6	3147	12	≥60	≥60	JJ
cord-005478-5iu38pr6	3147	13	%	%	NN
cord-005478-5iu38pr6	3147	14	of	of	IN
cord-005478-5iu38pr6	3147	15	patients	patient	NNS
cord-005478-5iu38pr6	3147	16	achieving	achieve	VBG
cord-005478-5iu38pr6	3147	17	a	a	DT
cord-005478-5iu38pr6	3147	18	best	good	JJS
cord-005478-5iu38pr6	3147	19	response	response	NN
cord-005478-5iu38pr6	3147	20	of	of	IN
cord-005478-5iu38pr6	3147	21	≥VGPR	≥vgpr	NN
cord-005478-5iu38pr6	3147	22	.	.	.
cord-005478-5iu38pr6	3148	1	The	the	DT
cord-005478-5iu38pr6	3148	2	ORR	ORR	NNP
cord-005478-5iu38pr6	3148	3	in	in	IN
cord-005478-5iu38pr6	3148	4	patients	patient	NNS
cord-005478-5iu38pr6	3148	5	receiving	receive	VBG
cord-005478-5iu38pr6	3148	6	'	'	``
cord-005478-5iu38pr6	3148	7	other	other	JJ
cord-005478-5iu38pr6	3148	8	'	'	POS
cord-005478-5iu38pr6	3148	9	induction	induction	NN
cord-005478-5iu38pr6	3148	10	therapies	therapy	NNS
cord-005478-5iu38pr6	3148	11	was	be	VBD
cord-005478-5iu38pr6	3148	12	71	71	CD
cord-005478-5iu38pr6	3148	13	%	%	NN
cord-005478-5iu38pr6	3148	14	and	and	CC
cord-005478-5iu38pr6	3148	15	the	the	DT
cord-005478-5iu38pr6	3148	16	≥VGPR	≥vgpr	NN
cord-005478-5iu38pr6	3148	17	rate	rate	NN
cord-005478-5iu38pr6	3148	18	was	be	VBD
cord-005478-5iu38pr6	3148	19	29	29	CD
cord-005478-5iu38pr6	3148	20	%	%	NN
cord-005478-5iu38pr6	3148	21	.	.	.
cord-005478-5iu38pr6	3149	1	Finally	finally	RB
cord-005478-5iu38pr6	3149	2	,	,	,
cord-005478-5iu38pr6	3149	3	following	follow	VBG
cord-005478-5iu38pr6	3149	4	auto	auto	NN
cord-005478-5iu38pr6	3149	5	-	-	HYPH
cord-005478-5iu38pr6	3149	6	SCT	SCT	NNP
cord-005478-5iu38pr6	3149	7	,	,	,
cord-005478-5iu38pr6	3149	8	the	the	DT
cord-005478-5iu38pr6	3149	9	ORRs	orr	NNS
cord-005478-5iu38pr6	3149	10	for	for	IN
cord-005478-5iu38pr6	3149	11	patients	patient	NNS
cord-005478-5iu38pr6	3149	12	receiving	receive	VBG
cord-005478-5iu38pr6	3149	13	VTD	VTD	NNP
cord-005478-5iu38pr6	3149	14	induction	induction	NN
cord-005478-5iu38pr6	3149	15	were	be	VBD
cord-005478-5iu38pr6	3149	16	around	around	RB
cord-005478-5iu38pr6	3149	17	80	80	CD
cord-005478-5iu38pr6	3149	18	%	%	NN
cord-005478-5iu38pr6	3149	19	,	,	,
cord-005478-5iu38pr6	3149	20	60	60	CD
cord-005478-5iu38pr6	3149	21	%	%	NN
cord-005478-5iu38pr6	3149	22	,	,	,
cord-005478-5iu38pr6	3149	23	and	and	CC
cord-005478-5iu38pr6	3149	24	33	33	CD
cord-005478-5iu38pr6	3149	25	%	%	NN
cord-005478-5iu38pr6	3149	26	in	in	IN
cord-005478-5iu38pr6	3149	27	lines	line	NNS
cord-005478-5iu38pr6	3149	28	2	2	CD
cord-005478-5iu38pr6	3149	29	-	-	SYM
cord-005478-5iu38pr6	3149	30	3	3	CD
cord-005478-5iu38pr6	3149	31	,	,	,
cord-005478-5iu38pr6	3149	32	4	4	CD
cord-005478-5iu38pr6	3149	33	,	,	,
cord-005478-5iu38pr6	3149	34	and	and	CC
cord-005478-5iu38pr6	3149	35	5	5	CD
cord-005478-5iu38pr6	3149	36	+	+	NNS
cord-005478-5iu38pr6	3149	37	,	,	,
cord-005478-5iu38pr6	3149	38	respectively	respectively	RB
cord-005478-5iu38pr6	3149	39	.	.	.
cord-005478-5iu38pr6	3150	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3150	2	:	:	:
cord-005478-5iu38pr6	3151	1	This	this	DT
cord-005478-5iu38pr6	3151	2	analysis	analysis	NN
cord-005478-5iu38pr6	3151	3	provides	provide	VBZ
cord-005478-5iu38pr6	3151	4	prospective	prospective	JJ
cord-005478-5iu38pr6	3151	5	,	,	,
cord-005478-5iu38pr6	3151	6	realworld	realworld	JJ
cord-005478-5iu38pr6	3151	7	data	datum	NNS
cord-005478-5iu38pr6	3151	8	on	on	IN
cord-005478-5iu38pr6	3151	9	therapy	therapy	NN
cord-005478-5iu38pr6	3151	10	of	of	IN
cord-005478-5iu38pr6	3151	11	patients	patient	NNS
cord-005478-5iu38pr6	3151	12	with	with	IN
cord-005478-5iu38pr6	3151	13	MM	MM	NNP
cord-005478-5iu38pr6	3151	14	receiving	receive	VBG
cord-005478-5iu38pr6	3151	15	auto	auto	NN
cord-005478-5iu38pr6	3151	16	-	-	HYPH
cord-005478-5iu38pr6	3151	17	SCT	SCT	NNP
cord-005478-5iu38pr6	3151	18	.	.	.
cord-005478-5iu38pr6	3152	1	VTD	VTD	NNP
cord-005478-5iu38pr6	3152	2	is	be	VBZ
cord-005478-5iu38pr6	3152	3	the	the	DT
cord-005478-5iu38pr6	3152	4	most	most	RBS
cord-005478-5iu38pr6	3152	5	widely	widely	RB
cord-005478-5iu38pr6	3152	6	used	use	VBN
cord-005478-5iu38pr6	3152	7	induction	induction	NN
cord-005478-5iu38pr6	3152	8	regimen	regimen	NN
cord-005478-5iu38pr6	3152	9	prior	prior	RB
cord-005478-5iu38pr6	3152	10	to	to	IN
cord-005478-5iu38pr6	3152	11	auto	auto	NN
cord-005478-5iu38pr6	3152	12	-	-	HYPH
cord-005478-5iu38pr6	3152	13	SCT	SCT	NNP
cord-005478-5iu38pr6	3152	14	.	.	.
cord-005478-5iu38pr6	3153	1	Moreover	moreover	RB
cord-005478-5iu38pr6	3153	2	,	,	,
cord-005478-5iu38pr6	3153	3	the	the	DT
cord-005478-5iu38pr6	3153	4	response	response	NN
cord-005478-5iu38pr6	3153	5	rates	rate	NNS
cord-005478-5iu38pr6	3153	6	are	be	VBP
cord-005478-5iu38pr6	3153	7	in	in	IN
cord-005478-5iu38pr6	3153	8	line	line	NN
cord-005478-5iu38pr6	3153	9	with	with	IN
cord-005478-5iu38pr6	3153	10	reported	report	VBN
cord-005478-5iu38pr6	3153	11	rates	rate	NNS
cord-005478-5iu38pr6	3153	12	in	in	IN
cord-005478-5iu38pr6	3153	13	phase	phase	NN
cord-005478-5iu38pr6	3153	14	III	iii	CD
cord-005478-5iu38pr6	3153	15	clinical	clinical	JJ
cord-005478-5iu38pr6	3153	16	trials	trial	NNS
cord-005478-5iu38pr6	3153	17	.	.	.
cord-005478-5iu38pr6	3154	1	While	while	IN
cord-005478-5iu38pr6	3154	2	other	other	JJ
cord-005478-5iu38pr6	3154	3	induction	induction	NN
cord-005478-5iu38pr6	3154	4	regimens	regimen	NNS
cord-005478-5iu38pr6	3154	5	are	be	VBP
cord-005478-5iu38pr6	3154	6	being	be	VBG
cord-005478-5iu38pr6	3154	7	developed	develop	VBN
cord-005478-5iu38pr6	3154	8	,	,	,
cord-005478-5iu38pr6	3154	9	VTD	VTD	NNP
cord-005478-5iu38pr6	3154	10	is	be	VBZ
cord-005478-5iu38pr6	3154	11	likely	likely	JJ
cord-005478-5iu38pr6	3154	12	to	to	TO
cord-005478-5iu38pr6	3154	13	remain	remain	VB
cord-005478-5iu38pr6	3154	14	a	a	DT
cord-005478-5iu38pr6	3154	15	standard	standard	NN
cord-005478-5iu38pr6	3154	16	of	of	IN
cord-005478-5iu38pr6	3154	17	care	care	NN
cord-005478-5iu38pr6	3154	18	,	,	,
cord-005478-5iu38pr6	3154	19	because	because	IN
cord-005478-5iu38pr6	3154	20	access	access	NN
cord-005478-5iu38pr6	3154	21	to	to	IN
cord-005478-5iu38pr6	3154	22	novel	novel	JJ
cord-005478-5iu38pr6	3154	23	agents	agent	NNS
cord-005478-5iu38pr6	3154	24	will	will	MD
cord-005478-5iu38pr6	3154	25	continue	continue	VB
cord-005478-5iu38pr6	3154	26	to	to	TO
cord-005478-5iu38pr6	3154	27	vary	vary	VB
cord-005478-5iu38pr6	3154	28	greatly	greatly	RB
cord-005478-5iu38pr6	3154	29	from	from	IN
cord-005478-5iu38pr6	3154	30	country	country	NN
cord-005478-5iu38pr6	3154	31	to	to	IN
cord-005478-5iu38pr6	3154	32	country	country	NN
cord-005478-5iu38pr6	3154	33	due	due	JJ
cord-005478-5iu38pr6	3154	34	to	to	IN
cord-005478-5iu38pr6	3154	35	factors	factor	NNS
cord-005478-5iu38pr6	3154	36	such	such	JJ
cord-005478-5iu38pr6	3154	37	as	as	IN
cord-005478-5iu38pr6	3154	38	affordability	affordability	NN
cord-005478-5iu38pr6	3154	39	,	,	,
cord-005478-5iu38pr6	3154	40	local	local	JJ
cord-005478-5iu38pr6	3154	41	guidelines	guideline	NNS
cord-005478-5iu38pr6	3154	42	/	/	SYM
cord-005478-5iu38pr6	3154	43	restrictions	restriction	NNS
cord-005478-5iu38pr6	3154	44	,	,	,
cord-005478-5iu38pr6	3154	45	and	and	CC
cord-005478-5iu38pr6	3154	46	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3154	47	decisions	decision	NNS
cord-005478-5iu38pr6	3154	48	.	.	.
cord-005478-5iu38pr6	3155	1	Background	background	NN
cord-005478-5iu38pr6	3155	2	:	:	:
cord-005478-5iu38pr6	3156	1	CAR	car	NN
cord-005478-5iu38pr6	3156	2	-	-	HYPH
cord-005478-5iu38pr6	3156	3	T	t	NN
cord-005478-5iu38pr6	3156	4	cell	cell	NN
cord-005478-5iu38pr6	3156	5	therapy	therapy	NN
cord-005478-5iu38pr6	3156	6	against	against	IN
cord-005478-5iu38pr6	3156	7	the	the	DT
cord-005478-5iu38pr6	3156	8	CD19	CD19	NNP
cord-005478-5iu38pr6	3156	9	antigen	antigen	NN
cord-005478-5iu38pr6	3156	10	is	be	VBZ
cord-005478-5iu38pr6	3156	11	a	a	DT
cord-005478-5iu38pr6	3156	12	breakthrough	breakthrough	NN
cord-005478-5iu38pr6	3156	13	treatment	treatment	NN
cord-005478-5iu38pr6	3156	14	for	for	IN
cord-005478-5iu38pr6	3156	15	patients	patient	NNS
cord-005478-5iu38pr6	3156	16	with	with	IN
cord-005478-5iu38pr6	3156	17	relapsed/	relapsed/	NN
cord-005478-5iu38pr6	3156	18	refractory	refractory	NN
cord-005478-5iu38pr6	3156	19	(	(	-LRB-
cord-005478-5iu38pr6	3156	20	R	r	NN
cord-005478-5iu38pr6	3156	21	/	/	SYM
cord-005478-5iu38pr6	3156	22	R	r	NN
cord-005478-5iu38pr6	3156	23	)	)	-RRB-
cord-005478-5iu38pr6	3156	24	B	b	NN
cord-005478-5iu38pr6	3156	25	-	-	HYPH
cord-005478-5iu38pr6	3156	26	cell	cell	NN
cord-005478-5iu38pr6	3156	27	non	non	JJ
cord-005478-5iu38pr6	3156	28	-	-	JJ
cord-005478-5iu38pr6	3156	29	Hodgkin	hodgkin	JJ
cord-005478-5iu38pr6	3156	30	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3156	31	(	(	-LRB-
cord-005478-5iu38pr6	3156	32	NHL	NHL	NNP
cord-005478-5iu38pr6	3156	33	)	)	-RRB-
cord-005478-5iu38pr6	3156	34	.	.	.
cord-005478-5iu38pr6	3157	1	Despite	despite	IN
cord-005478-5iu38pr6	3157	2	impressive	impressive	JJ
cord-005478-5iu38pr6	3157	3	outcomes	outcome	NNS
cord-005478-5iu38pr6	3157	4	,	,	,
cord-005478-5iu38pr6	3157	5	non	non	JJ
cord-005478-5iu38pr6	3157	6	-	-	JJ
cord-005478-5iu38pr6	3157	7	response	response	NN
cord-005478-5iu38pr6	3157	8	and	and	CC
cord-005478-5iu38pr6	3157	9	relapse	relapse	VB
cord-005478-5iu38pr6	3157	10	with	with	IN
cord-005478-5iu38pr6	3157	11	CD19	CD19	NNP
cord-005478-5iu38pr6	3157	12	negative	negative	JJ
cord-005478-5iu38pr6	3157	13	disease	disease	NN
cord-005478-5iu38pr6	3157	14	remain	remain	VBP
cord-005478-5iu38pr6	3157	15	challenges	challenge	NNS
cord-005478-5iu38pr6	3157	16	.	.	.
cord-005478-5iu38pr6	3158	1	Through	through	IN
cord-005478-5iu38pr6	3158	2	dual	dual	JJ
cord-005478-5iu38pr6	3158	3	B	b	NN
cord-005478-5iu38pr6	3158	4	-	-	HYPH
cord-005478-5iu38pr6	3158	5	cell	cell	NN
cord-005478-5iu38pr6	3158	6	antigen	antigen	NN
cord-005478-5iu38pr6	3158	7	targeting	target	VBG
cord-005478-5iu38pr6	3158	8	of	of	IN
cord-005478-5iu38pr6	3158	9	CD20	CD20	NNP
cord-005478-5iu38pr6	3158	10	and	and	CC
cord-005478-5iu38pr6	3158	11	CD19	CD19	NNP
cord-005478-5iu38pr6	3158	12	,	,	,
cord-005478-5iu38pr6	3158	13	with	with	IN
cord-005478-5iu38pr6	3158	14	a	a	DT
cord-005478-5iu38pr6	3158	15	first	first	JJ
cord-005478-5iu38pr6	3158	16	-	-	HYPH
cord-005478-5iu38pr6	3158	17	in	in	IN
cord-005478-5iu38pr6	3158	18	-	-	HYPH
cord-005478-5iu38pr6	3158	19	human	human	JJ
cord-005478-5iu38pr6	3158	20	bispecific	bispecific	NN
cord-005478-5iu38pr6	3158	21	lentiviral	lentiviral	NNP
cord-005478-5iu38pr6	3158	22	CAR	CAR	NNP
cord-005478-5iu38pr6	3158	23	-	-	HYPH
cord-005478-5iu38pr6	3158	24	T	t	NN
cord-005478-5iu38pr6	3158	25	cell	cell	NN
cord-005478-5iu38pr6	3158	26	(	(	-LRB-
cord-005478-5iu38pr6	3158	27	LV20.19CAR	LV20.19CAR	NNP
cord-005478-5iu38pr6	3158	28	)	)	-RRB-
cord-005478-5iu38pr6	3158	29	,	,	,
cord-005478-5iu38pr6	3158	30	we	-PRON-	PRP
cord-005478-5iu38pr6	3158	31	attempt	attempt	VBP
cord-005478-5iu38pr6	3158	32	to	to	TO
cord-005478-5iu38pr6	3158	33	improve	improve	VB
cord-005478-5iu38pr6	3158	34	response	response	NN
cord-005478-5iu38pr6	3158	35	rates	rate	NNS
cord-005478-5iu38pr6	3158	36	while	while	IN
cord-005478-5iu38pr6	3158	37	limiting	limit	VBG
cord-005478-5iu38pr6	3158	38	relapses	relapse	NNS
cord-005478-5iu38pr6	3158	39	due	due	IN
cord-005478-5iu38pr6	3158	40	to	to	IN
cord-005478-5iu38pr6	3158	41	CD19	CD19	NNP
cord-005478-5iu38pr6	3158	42	antigen	antigen	NN
cord-005478-5iu38pr6	3158	43	loss	loss	NN
cord-005478-5iu38pr6	3158	44	.	.	.
cord-005478-5iu38pr6	3159	1	Production	production	NN
cord-005478-5iu38pr6	3159	2	was	be	VBD
cord-005478-5iu38pr6	3159	3	optimized	optimize	VBN
cord-005478-5iu38pr6	3159	4	with	with	IN
cord-005478-5iu38pr6	3159	5	point	point	NN
cord-005478-5iu38pr6	3159	6	of	of	IN
cord-005478-5iu38pr6	3159	7	care	care	NN
cord-005478-5iu38pr6	3159	8	automated	automate	VBN
cord-005478-5iu38pr6	3159	9	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	3159	10	using	use	VBG
cord-005478-5iu38pr6	3159	11	the	the	DT
cord-005478-5iu38pr6	3159	12	CliniMACS	CliniMACS	NNP
cord-005478-5iu38pr6	3159	13	Prodigy	Prodigy	NNP
cord-005478-5iu38pr6	3159	14	,	,	,
cord-005478-5iu38pr6	3159	15	a	a	DT
cord-005478-5iu38pr6	3159	16	compact	compact	JJ
cord-005478-5iu38pr6	3159	17	GMP	GMP	NNP
cord-005478-5iu38pr6	3159	18	compliant	compliant	JJ
cord-005478-5iu38pr6	3159	19	tabletop	tabletop	NN
cord-005478-5iu38pr6	3159	20	device	device	NN
cord-005478-5iu38pr6	3159	21	in	in	IN
cord-005478-5iu38pr6	3159	22	an	an	DT
cord-005478-5iu38pr6	3159	23	ISO7	ISO7	NNP
cord-005478-5iu38pr6	3159	24	clean	clean	JJ
cord-005478-5iu38pr6	3159	25	room	room	NN
cord-005478-5iu38pr6	3159	26	.	.	.
cord-005478-5iu38pr6	3160	1	Methods	method	NNS
cord-005478-5iu38pr6	3160	2	:	:	:
cord-005478-5iu38pr6	3160	3	Patients	patient	NNS
cord-005478-5iu38pr6	3160	4	were	be	VBD
cord-005478-5iu38pr6	3160	5	treated	treat	VBN
cord-005478-5iu38pr6	3160	6	on	on	IN
cord-005478-5iu38pr6	3160	7	our	-PRON-	PRP$
cord-005478-5iu38pr6	3160	8	Phase	phase	NN
cord-005478-5iu38pr6	3160	9	1	1	CD
cord-005478-5iu38pr6	3160	10	dose	dose	NN
cord-005478-5iu38pr6	3160	11	escalation	escalation	NN
cord-005478-5iu38pr6	3160	12	+	+	CC
cord-005478-5iu38pr6	3160	13	expansion	expansion	NN
cord-005478-5iu38pr6	3160	14	trial	trial	NN
cord-005478-5iu38pr6	3160	15	(	(	-LRB-
cord-005478-5iu38pr6	3160	16	NCT03019055	NCT03019055	NNP
cord-005478-5iu38pr6	3160	17	)	)	-RRB-
cord-005478-5iu38pr6	3160	18	to	to	TO
cord-005478-5iu38pr6	3160	19	demonstrate	demonstrate	VB
cord-005478-5iu38pr6	3160	20	feasibility	feasibility	NN
cord-005478-5iu38pr6	3160	21	of	of	IN
cord-005478-5iu38pr6	3160	22	point	point	NN
cord-005478-5iu38pr6	3160	23	of	of	IN
cord-005478-5iu38pr6	3160	24	care	care	NN
cord-005478-5iu38pr6	3160	25	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	3160	26	and	and	CC
cord-005478-5iu38pr6	3160	27	safety	safety	NN
cord-005478-5iu38pr6	3160	28	of	of	IN
cord-005478-5iu38pr6	3160	29	a	a	DT
cord-005478-5iu38pr6	3160	30	bispecific	bispecific	NN
cord-005478-5iu38pr6	3160	31	41BB	41bb	CD
cord-005478-5iu38pr6	3160	32	/	/	SYM
cord-005478-5iu38pr6	3160	33	CD3z	CD3z	NNP
cord-005478-5iu38pr6	3160	34	LV20.19CAR	LV20.19CAR	NNP
cord-005478-5iu38pr6	3160	35	T	T	NNP
cord-005478-5iu38pr6	3160	36	cell	cell	NN
cord-005478-5iu38pr6	3160	37	for	for	IN
cord-005478-5iu38pr6	3160	38	adults	adult	NNS
cord-005478-5iu38pr6	3160	39	with	with	IN
cord-005478-5iu38pr6	3160	40	R	r	NN
cord-005478-5iu38pr6	3160	41	/	/	SYM
cord-005478-5iu38pr6	3160	42	R	r	NN
cord-005478-5iu38pr6	3160	43	B	b	NN
cord-005478-5iu38pr6	3160	44	-	-	HYPH
cord-005478-5iu38pr6	3160	45	cell	cell	NN
cord-005478-5iu38pr6	3160	46	NHL	NHL	NNP
cord-005478-5iu38pr6	3160	47	.	.	.
cord-005478-5iu38pr6	3161	1	Safety	safety	NN
cord-005478-5iu38pr6	3161	2	was	be	VBD
cord-005478-5iu38pr6	3161	3	assessed	assess	VBN
cord-005478-5iu38pr6	3161	4	by	by	IN
cord-005478-5iu38pr6	3161	5	incidence	incidence	NN
cord-005478-5iu38pr6	3161	6	of	of	IN
cord-005478-5iu38pr6	3161	7	dose	dose	NN
cord-005478-5iu38pr6	3161	8	limiting	limit	VBG
cord-005478-5iu38pr6	3161	9	toxicities	toxicity	NNS
cord-005478-5iu38pr6	3161	10	(	(	-LRB-
cord-005478-5iu38pr6	3161	11	DLTs	dlt	NNS
cord-005478-5iu38pr6	3161	12	)	)	-RRB-
cord-005478-5iu38pr6	3161	13	within	within	IN
cord-005478-5iu38pr6	3161	14	28	28	CD
cord-005478-5iu38pr6	3161	15	days	day	NNS
cord-005478-5iu38pr6	3161	16	postinfusion	postinfusion	NN
cord-005478-5iu38pr6	3161	17	.	.	.
cord-005478-5iu38pr6	3162	1	Dose	dose	NN
cord-005478-5iu38pr6	3162	2	was	be	VBD
cord-005478-5iu38pr6	3162	3	escalated	escalate	VBN
cord-005478-5iu38pr6	3162	4	in	in	IN
cord-005478-5iu38pr6	3162	5	incremental	incremental	JJ
cord-005478-5iu38pr6	3162	6	3	3	CD
cord-005478-5iu38pr6	3162	7	+	+	SYM
cord-005478-5iu38pr6	3162	8	3	3	CD
cord-005478-5iu38pr6	3162	9	fashion	fashion	NN
cord-005478-5iu38pr6	3162	10	with	with	IN
cord-005478-5iu38pr6	3162	11	a	a	DT
cord-005478-5iu38pr6	3162	12	starting	starting	NN
cord-005478-5iu38pr6	3162	13	dose	dose	NN
cord-005478-5iu38pr6	3162	14	of	of	IN
cord-005478-5iu38pr6	3162	15	2.5	2.5	CD
cord-005478-5iu38pr6	3162	16	x	x	SYM
cord-005478-5iu38pr6	3162	17	10	10	CD
cord-005478-5iu38pr6	3162	18	5	5	CD
cord-005478-5iu38pr6	3162	19	cells	cell	NNS
cord-005478-5iu38pr6	3162	20	/	/	SYM
cord-005478-5iu38pr6	3162	21	kg	kg	NNS
cord-005478-5iu38pr6	3162	22	and	and	CC
cord-005478-5iu38pr6	3162	23	a	a	DT
cord-005478-5iu38pr6	3162	24	target	target	NN
cord-005478-5iu38pr6	3162	25	cell	cell	NN
cord-005478-5iu38pr6	3162	26	dose	dose	NN
cord-005478-5iu38pr6	3162	27	of	of	IN
cord-005478-5iu38pr6	3162	28	2.5	2.5	CD
cord-005478-5iu38pr6	3162	29	x	x	SYM
cord-005478-5iu38pr6	3162	30	10	10	CD
cord-005478-5iu38pr6	3162	31	6	6	CD
cord-005478-5iu38pr6	3162	32	cells	cell	NNS
cord-005478-5iu38pr6	3162	33	/	/	SYM
cord-005478-5iu38pr6	3162	34	kg	kg	NNS
cord-005478-5iu38pr6	3162	35	.	.	.
cord-005478-5iu38pr6	3163	1	Lymphodepletion	Lymphodepletion	NNP
cord-005478-5iu38pr6	3163	2	was	be	VBD
cord-005478-5iu38pr6	3163	3	with	with	IN
cord-005478-5iu38pr6	3163	4	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	3163	5	30	30	CD
cord-005478-5iu38pr6	3163	6	mg	mg	NNP
cord-005478-5iu38pr6	3163	7	/	/	SYM
cord-005478-5iu38pr6	3163	8	m	m	NNP
cord-005478-5iu38pr6	3163	9	2	2	CD
cord-005478-5iu38pr6	3163	10	x	x	SYM
cord-005478-5iu38pr6	3163	11	3	3	CD
cord-005478-5iu38pr6	3163	12	days	day	NNS
cord-005478-5iu38pr6	3163	13	and	and	CC
cord-005478-5iu38pr6	3163	14	cyclophosphamide	cyclophosphamide	VBD
cord-005478-5iu38pr6	3163	15	500	500	CD
cord-005478-5iu38pr6	3163	16	mg	mg	NNP
cord-005478-5iu38pr6	3163	17	/	/	SYM
cord-005478-5iu38pr6	3163	18	m	m	NNP
cord-005478-5iu38pr6	3163	19	2	2	CD
cord-005478-5iu38pr6	3163	20	x	x	SYM
cord-005478-5iu38pr6	3163	21	1	1	CD
cord-005478-5iu38pr6	3163	22	day	day	NN
cord-005478-5iu38pr6	3163	23	.	.	.
cord-005478-5iu38pr6	3164	1	Patients	patient	NNS
cord-005478-5iu38pr6	3164	2	received	receive	VBD
cord-005478-5iu38pr6	3164	3	either	either	CC
cord-005478-5iu38pr6	3164	4	fresh	fresh	JJ
cord-005478-5iu38pr6	3164	5	uncryopreserved	uncryopreserved	JJ
cord-005478-5iu38pr6	3164	6	CAR	car	NN
cord-005478-5iu38pr6	3164	7	-	-	HYPH
cord-005478-5iu38pr6	3164	8	T	t	NN
cord-005478-5iu38pr6	3164	9	cell	cell	NN
cord-005478-5iu38pr6	3164	10	infusions	infusion	NNS
cord-005478-5iu38pr6	3164	11	(	(	-LRB-
cord-005478-5iu38pr6	3164	12	N=	N=	NNP
cord-005478-5iu38pr6	3164	13	7	7	CD
cord-005478-5iu38pr6	3164	14	)	)	-RRB-
cord-005478-5iu38pr6	3164	15	or	or	CC
cord-005478-5iu38pr6	3164	16	cells	cell	NNS
cord-005478-5iu38pr6	3164	17	thawed	thaw	VBN
cord-005478-5iu38pr6	3164	18	(	(	-LRB-
cord-005478-5iu38pr6	3164	19	N=	N=	NNP
cord-005478-5iu38pr6	3164	20	3	3	CD
cord-005478-5iu38pr6	3164	21	)	)	-RRB-
cord-005478-5iu38pr6	3164	22	after	after	IN
cord-005478-5iu38pr6	3164	23	cryopreservation	cryopreservation	NN
cord-005478-5iu38pr6	3164	24	.	.	.
cord-005478-5iu38pr6	3165	1	Results	result	NNS
cord-005478-5iu38pr6	3165	2	:	:	:
cord-005478-5iu38pr6	3165	3	10	10	CD
cord-005478-5iu38pr6	3165	4	patients	patient	NNS
cord-005478-5iu38pr6	3165	5	have	have	VBP
cord-005478-5iu38pr6	3165	6	completed	complete	VBN
cord-005478-5iu38pr6	3165	7	treatment	treatment	NN
cord-005478-5iu38pr6	3165	8	:	:	:
cord-005478-5iu38pr6	3165	9	9	9	CD
cord-005478-5iu38pr6	3165	10	patients	patient	NNS
cord-005478-5iu38pr6	3165	11	in	in	IN
cord-005478-5iu38pr6	3165	12	dose	dose	JJ
cord-005478-5iu38pr6	3165	13	escalation	escalation	NN
cord-005478-5iu38pr6	3165	14	and	and	CC
cord-005478-5iu38pr6	3165	15	1	1	CD
cord-005478-5iu38pr6	3165	16	patient	patient	NN
cord-005478-5iu38pr6	3165	17	in	in	IN
cord-005478-5iu38pr6	3165	18	dose	dose	JJ
cord-005478-5iu38pr6	3165	19	expansion	expansion	NN
cord-005478-5iu38pr6	3165	20	.	.	.
cord-005478-5iu38pr6	3166	1	Median	median	JJ
cord-005478-5iu38pr6	3166	2	age	age	NN
cord-005478-5iu38pr6	3166	3	was	be	VBD
cord-005478-5iu38pr6	3166	4	55	55	CD
cord-005478-5iu38pr6	3166	5	years	year	NNS
cord-005478-5iu38pr6	3166	6	(	(	-LRB-
cord-005478-5iu38pr6	3166	7	46	46	CD
cord-005478-5iu38pr6	3166	8	-	-	SYM
cord-005478-5iu38pr6	3166	9	67	67	CD
cord-005478-5iu38pr6	3166	10	)	)	-RRB-
cord-005478-5iu38pr6	3166	11	and	and	CC
cord-005478-5iu38pr6	3166	12	histology	histology	NN
cord-005478-5iu38pr6	3166	13	included	include	VBN
cord-005478-5iu38pr6	3166	14	DLBCL	dlbcl	RB
cord-005478-5iu38pr6	3166	15	in	in	IN
cord-005478-5iu38pr6	3166	16	4	4	CD
cord-005478-5iu38pr6	3166	17	patients	patient	NNS
cord-005478-5iu38pr6	3166	18	,	,	,
cord-005478-5iu38pr6	3166	19	MCL	MCL	NNP
cord-005478-5iu38pr6	3166	20	in	in	IN
cord-005478-5iu38pr6	3166	21	4	4	CD
cord-005478-5iu38pr6	3166	22	patients	patient	NNS
cord-005478-5iu38pr6	3166	23	,	,	,
cord-005478-5iu38pr6	3166	24	and	and	CC
cord-005478-5iu38pr6	3166	25	CLL	CLL	NNP
cord-005478-5iu38pr6	3166	26	in	in	IN
cord-005478-5iu38pr6	3166	27	2	2	CD
cord-005478-5iu38pr6	3166	28	patients	patient	NNS
cord-005478-5iu38pr6	3166	29	.	.	.
cord-005478-5iu38pr6	3167	1	In	in	IN
cord-005478-5iu38pr6	3167	2	dose	dose	JJ
cord-005478-5iu38pr6	3167	3	escalation	escalation	NN
cord-005478-5iu38pr6	3167	4	,	,	,
cord-005478-5iu38pr6	3167	5	3	3	CD
cord-005478-5iu38pr6	3167	6	patients	patient	NNS
cord-005478-5iu38pr6	3167	7	were	be	VBD
cord-005478-5iu38pr6	3167	8	treated	treat	VBN
cord-005478-5iu38pr6	3167	9	at	at	IN
cord-005478-5iu38pr6	3167	10	2.5	2.5	CD
cord-005478-5iu38pr6	3167	11	x	x	SYM
cord-005478-5iu38pr6	3167	12	10	10	CD
cord-005478-5iu38pr6	3167	13	5	5	CD
cord-005478-5iu38pr6	3167	14	cells	cell	NNS
cord-005478-5iu38pr6	3167	15	/	/	SYM
cord-005478-5iu38pr6	3167	16	kg	kg	NNS
cord-005478-5iu38pr6	3167	17	,	,	,
cord-005478-5iu38pr6	3167	18	3	3	CD
cord-005478-5iu38pr6	3167	19	patients	patient	NNS
cord-005478-5iu38pr6	3167	20	at	at	IN
cord-005478-5iu38pr6	3167	21	7.5	7.5	CD
cord-005478-5iu38pr6	3167	22	x	x	SYM
cord-005478-5iu38pr6	3167	23	10	10	CD
cord-005478-5iu38pr6	3167	24	5	5	CD
cord-005478-5iu38pr6	3167	25	cells	cell	NNS
cord-005478-5iu38pr6	3167	26	/	/	SYM
cord-005478-5iu38pr6	3167	27	kg	kg	NNS
cord-005478-5iu38pr6	3167	28	,	,	,
cord-005478-5iu38pr6	3167	29	and	and	CC
cord-005478-5iu38pr6	3167	30	3	3	CD
cord-005478-5iu38pr6	3167	31	patients	patient	NNS
cord-005478-5iu38pr6	3167	32	at	at	IN
cord-005478-5iu38pr6	3167	33	2.5	2.5	CD
cord-005478-5iu38pr6	3167	34	x	x	SYM
cord-005478-5iu38pr6	3167	35	10	10	CD
cord-005478-5iu38pr6	3167	36	6	6	CD
cord-005478-5iu38pr6	3167	37	cells	cell	NNS
cord-005478-5iu38pr6	3167	38	/	/	SYM
cord-005478-5iu38pr6	3167	39	kg	kg	NNS
cord-005478-5iu38pr6	3167	40	with	with	IN
cord-005478-5iu38pr6	3167	41	no	no	DT
cord-005478-5iu38pr6	3167	42	DLTs	dlt	NNS
cord-005478-5iu38pr6	3167	43	to	to	TO
cord-005478-5iu38pr6	3167	44	report	report	VB
cord-005478-5iu38pr6	3167	45	.	.	.
cord-005478-5iu38pr6	3168	1	No	no	DT
cord-005478-5iu38pr6	3168	2	patient	patient	NN
cord-005478-5iu38pr6	3168	3	experienced	experience	VBD
cord-005478-5iu38pr6	3168	4	grade	grade	NN
cord-005478-5iu38pr6	3168	5	3	3	CD
cord-005478-5iu38pr6	3168	6	-	-	SYM
cord-005478-5iu38pr6	3168	7	4	4	CD
cord-005478-5iu38pr6	3168	8	cytokine	cytokine	NN
cord-005478-5iu38pr6	3168	9	release	release	NN
cord-005478-5iu38pr6	3168	10	syndrome	syndrome	NN
cord-005478-5iu38pr6	3168	11	(	(	-LRB-
cord-005478-5iu38pr6	3168	12	CRS	CRS	NNP
cord-005478-5iu38pr6	3168	13	)	)	-RRB-
cord-005478-5iu38pr6	3168	14	or	or	CC
cord-005478-5iu38pr6	3168	15	grade	grade	NN
cord-005478-5iu38pr6	3168	16	3	3	CD
cord-005478-5iu38pr6	3168	17	-	-	SYM
cord-005478-5iu38pr6	3168	18	4	4	CD
cord-005478-5iu38pr6	3168	19	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	3168	20	(	(	-LRB-
cord-005478-5iu38pr6	3168	21	NTX	NTX	NNP
cord-005478-5iu38pr6	3168	22	)	)	-RRB-
cord-005478-5iu38pr6	3168	23	allowing	allow	VBG
cord-005478-5iu38pr6	3168	24	start	start	NN
cord-005478-5iu38pr6	3168	25	of	of	IN
cord-005478-5iu38pr6	3168	26	a	a	DT
cord-005478-5iu38pr6	3168	27	dose	dose	JJ
cord-005478-5iu38pr6	3168	28	expansion	expansion	NN
cord-005478-5iu38pr6	3168	29	cohort	cohort	NN
cord-005478-5iu38pr6	3168	30	at	at	IN
cord-005478-5iu38pr6	3168	31	the	the	DT
cord-005478-5iu38pr6	3168	32	2.5	2.5	CD
cord-005478-5iu38pr6	3168	33	x	x	SYM
cord-005478-5iu38pr6	3168	34	10	10	CD
cord-005478-5iu38pr6	3168	35	6	6	CD
cord-005478-5iu38pr6	3168	36	cells	cell	NNS
cord-005478-5iu38pr6	3168	37	/	/	SYM
cord-005478-5iu38pr6	3168	38	kg	kg	NN
cord-005478-5iu38pr6	3168	39	level	level	NN
cord-005478-5iu38pr6	3168	40	.	.	.
cord-005478-5iu38pr6	3169	1	In	in	IN
cord-005478-5iu38pr6	3169	2	total	total	JJ
cord-005478-5iu38pr6	3169	3	,	,	,
cord-005478-5iu38pr6	3169	4	6	6	CD
cord-005478-5iu38pr6	3169	5	patients	patient	NNS
cord-005478-5iu38pr6	3169	6	had	have	VBD
cord-005478-5iu38pr6	3169	7	Grade	Grade	NNP
cord-005478-5iu38pr6	3169	8	1	1	CD
cord-005478-5iu38pr6	3169	9	-	-	SYM
cord-005478-5iu38pr6	3169	10	2	2	CD
cord-005478-5iu38pr6	3169	11	CRS	CRS	NNP
cord-005478-5iu38pr6	3169	12	and	and	CC
cord-005478-5iu38pr6	3169	13	3	3	CD
cord-005478-5iu38pr6	3169	14	patients	patient	NNS
cord-005478-5iu38pr6	3169	15	had	have	VBD
cord-005478-5iu38pr6	3169	16	Grade	Grade	NNP
cord-005478-5iu38pr6	3169	17	1	1	CD
cord-005478-5iu38pr6	3169	18	-	-	SYM
cord-005478-5iu38pr6	3169	19	2	2	CD
cord-005478-5iu38pr6	3169	20	NTX	NTX	NNP
cord-005478-5iu38pr6	3169	21	.	.	.
cord-005478-5iu38pr6	3170	1	Mean	mean	JJ
cord-005478-5iu38pr6	3170	2	time	time	NN
cord-005478-5iu38pr6	3170	3	to	to	IN
cord-005478-5iu38pr6	3170	4	CRS	CRS	NNP
cord-005478-5iu38pr6	3170	5	was	be	VBD
cord-005478-5iu38pr6	3170	6	Day	Day	NNP
cord-005478-5iu38pr6	3170	7	+9	+9	HYPH
cord-005478-5iu38pr6	3170	8	post	post	NN
cord-005478-5iu38pr6	3170	9	-	-	JJ
cord-005478-5iu38pr6	3170	10	infusion	infusion	NN
cord-005478-5iu38pr6	3170	11	and	and	CC
cord-005478-5iu38pr6	3171	1	no	no	DT
cord-005478-5iu38pr6	3171	2	patient	patient	NN
cord-005478-5iu38pr6	3171	3	required	require	VBD
cord-005478-5iu38pr6	3171	4	ICU	ICU	NNP
cord-005478-5iu38pr6	3171	5	level	level	NN
cord-005478-5iu38pr6	3171	6	care	care	NN
cord-005478-5iu38pr6	3171	7	.	.	.
cord-005478-5iu38pr6	3172	1	4	4	CD
cord-005478-5iu38pr6	3172	2	patients	patient	NNS
cord-005478-5iu38pr6	3172	3	required	require	VBD
cord-005478-5iu38pr6	3172	4	1	1	CD
cord-005478-5iu38pr6	3172	5	-	-	SYM
cord-005478-5iu38pr6	3172	6	2	2	CD
cord-005478-5iu38pr6	3172	7	doses	dose	NNS
cord-005478-5iu38pr6	3172	8	of	of	IN
cord-005478-5iu38pr6	3172	9	tocilizumab	tocilizumab	NNP
cord-005478-5iu38pr6	3172	10	.	.	.
cord-005478-5iu38pr6	3173	1	The	the	DT
cord-005478-5iu38pr6	3173	2	day	day	NN
cord-005478-5iu38pr6	3173	3	28	28	CD
cord-005478-5iu38pr6	3173	4	overall	overall	JJ
cord-005478-5iu38pr6	3173	5	response	response	NN
cord-005478-5iu38pr6	3173	6	rate	rate	NN
cord-005478-5iu38pr6	3173	7	for	for	IN
cord-005478-5iu38pr6	3173	8	all	all	DT
cord-005478-5iu38pr6	3173	9	patients	patient	NNS
cord-005478-5iu38pr6	3173	10	was	be	VBD
cord-005478-5iu38pr6	3173	11	80	80	CD
cord-005478-5iu38pr6	3173	12	%	%	NN
cord-005478-5iu38pr6	3173	13	with	with	IN
cord-005478-5iu38pr6	3173	14	5/10	5/10	CD
cord-005478-5iu38pr6	3173	15	achieving	achieve	VBG
cord-005478-5iu38pr6	3173	16	a	a	DT
cord-005478-5iu38pr6	3173	17	complete	complete	JJ
cord-005478-5iu38pr6	3173	18	response	response	NN
cord-005478-5iu38pr6	3173	19	(	(	-LRB-
cord-005478-5iu38pr6	3173	20	CR	CR	NNP
cord-005478-5iu38pr6	3173	21	)	)	-RRB-
cord-005478-5iu38pr6	3173	22	and	and	CC
cord-005478-5iu38pr6	3173	23	3/10	3/10	CD
cord-005478-5iu38pr6	3173	24	achieving	achieve	VBG
cord-005478-5iu38pr6	3173	25	a	a	DT
cord-005478-5iu38pr6	3173	26	partial	partial	JJ
cord-005478-5iu38pr6	3173	27	response	response	NN
cord-005478-5iu38pr6	3173	28	(	(	-LRB-
cord-005478-5iu38pr6	3173	29	PR	PR	NNP
cord-005478-5iu38pr6	3173	30	)	)	-RRB-
cord-005478-5iu38pr6	3173	31	.	.	.
cord-005478-5iu38pr6	3174	1	All	all	DT
cord-005478-5iu38pr6	3174	2	patients	patient	NNS
cord-005478-5iu38pr6	3174	3	in	in	IN
cord-005478-5iu38pr6	3174	4	CR	CR	NNP
cord-005478-5iu38pr6	3174	5	remain	remain	VBP
cord-005478-5iu38pr6	3174	6	in	in	IN
cord-005478-5iu38pr6	3174	7	remission	remission	NN
cord-005478-5iu38pr6	3174	8	,	,	,
cord-005478-5iu38pr6	3174	9	the	the	DT
cord-005478-5iu38pr6	3174	10	longest	long	JJS
cord-005478-5iu38pr6	3174	11	15	15	CD
cord-005478-5iu38pr6	3174	12	months	month	NNS
cord-005478-5iu38pr6	3174	13	from	from	IN
cord-005478-5iu38pr6	3174	14	treatment	treatment	NN
cord-005478-5iu38pr6	3174	15	.	.	.
cord-005478-5iu38pr6	3175	1	CAR	car	NN
cord-005478-5iu38pr6	3175	2	-	-	HYPH
cord-005478-5iu38pr6	3175	3	T	t	NN
cord-005478-5iu38pr6	3175	4	persistence	persistence	NN
cord-005478-5iu38pr6	3175	5	is	be	VBZ
cord-005478-5iu38pr6	3175	6	demonstrated	demonstrate	VBN
cord-005478-5iu38pr6	3175	7	in	in	IN
cord-005478-5iu38pr6	3175	8	Figure	Figure	NNP
cord-005478-5iu38pr6	3175	9	1	1	CD
cord-005478-5iu38pr6	3175	10	.	.	.
cord-005478-5iu38pr6	3176	1	Two	two	CD
cord-005478-5iu38pr6	3176	2	patients	patient	NNS
cord-005478-5iu38pr6	3176	3	had	have	VBD
cord-005478-5iu38pr6	3176	4	progressive	progressive	JJ
cord-005478-5iu38pr6	3176	5	disease	disease	NN
cord-005478-5iu38pr6	3176	6	(	(	-LRB-
cord-005478-5iu38pr6	3176	7	PD	PD	NNP
cord-005478-5iu38pr6	3176	8	)	)	-RRB-
cord-005478-5iu38pr6	3176	9	at	at	IN
cord-005478-5iu38pr6	3176	10	Day	day	NN
cord-005478-5iu38pr6	3176	11	28	28	CD
cord-005478-5iu38pr6	3176	12	and	and	CC
cord-005478-5iu38pr6	3176	13	2	2	CD
cord-005478-5iu38pr6	3176	14	patients	patient	NNS
cord-005478-5iu38pr6	3176	15	with	with	IN
cord-005478-5iu38pr6	3176	16	PR	PR	NNP
cord-005478-5iu38pr6	3176	17	,	,	,
cord-005478-5iu38pr6	3176	18	eventually	eventually	RB
cord-005478-5iu38pr6	3176	19	progressed	progress	VBD
cord-005478-5iu38pr6	3176	20	.	.	.
cord-005478-5iu38pr6	3177	1	All	all	DT
cord-005478-5iu38pr6	3177	2	progressing	progress	VBG
cord-005478-5iu38pr6	3177	3	patients	patient	NNS
cord-005478-5iu38pr6	3177	4	underwent	undergo	VBD
cord-005478-5iu38pr6	3177	5	repeat	repeat	NN
cord-005478-5iu38pr6	3177	6	biopsy	biopsy	NN
cord-005478-5iu38pr6	3177	7	,	,	,
cord-005478-5iu38pr6	3177	8	and	and	CC
cord-005478-5iu38pr6	3177	9	all	all	DT
cord-005478-5iu38pr6	3177	10	retained	retain	VBN
cord-005478-5iu38pr6	3177	11	either	either	CC
cord-005478-5iu38pr6	3177	12	CD19	CD19	NNP
cord-005478-5iu38pr6	3177	13	or	or	CC
cord-005478-5iu38pr6	3177	14	CD20	CD20	NNP
cord-005478-5iu38pr6	3177	15	positivity	positivity	NN
cord-005478-5iu38pr6	3177	16	.	.	.
cord-005478-5iu38pr6	3178	1	Target	target	VB
cord-005478-5iu38pr6	3178	2	dose	dose	NN
cord-005478-5iu38pr6	3178	3	LV20.19	LV20.19	NNP
cord-005478-5iu38pr6	3178	4	CAR	CAR	NNP
cord-005478-5iu38pr6	3178	5	T	t	NN
cord-005478-5iu38pr6	3178	6	cells	cell	NNS
cord-005478-5iu38pr6	3178	7	were	be	VBD
cord-005478-5iu38pr6	3178	8	produced	produce	VBN
cord-005478-5iu38pr6	3178	9	in	in	IN
cord-005478-5iu38pr6	3178	10	all	all	DT
cord-005478-5iu38pr6	3178	11	patients	patient	NNS
cord-005478-5iu38pr6	3178	12	indicating	indicate	VBG
cord-005478-5iu38pr6	3178	13	100	100	CD
cord-005478-5iu38pr6	3178	14	%	%	NN
cord-005478-5iu38pr6	3178	15	feasibility	feasibility	NN
cord-005478-5iu38pr6	3178	16	of	of	IN
cord-005478-5iu38pr6	3178	17	our	-PRON-	PRP$
cord-005478-5iu38pr6	3178	18	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	3178	19	process	process	NN
cord-005478-5iu38pr6	3178	20	.	.	.
cord-005478-5iu38pr6	3179	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3179	2	:	:	:
cord-005478-5iu38pr6	3180	1	Phase	phase	NN
cord-005478-5iu38pr6	3180	2	1	1	CD
cord-005478-5iu38pr6	3180	3	results	result	NNS
cord-005478-5iu38pr6	3180	4	from	from	IN
cord-005478-5iu38pr6	3180	5	the	the	DT
cord-005478-5iu38pr6	3180	6	first	first	JJ
cord-005478-5iu38pr6	3180	7	-	-	HYPH
cord-005478-5iu38pr6	3180	8	in	in	IN
cord-005478-5iu38pr6	3180	9	-	-	HYPH
cord-005478-5iu38pr6	3180	10	human	human	JJ
cord-005478-5iu38pr6	3180	11	bispecific	bispecific	NN
cord-005478-5iu38pr6	3180	12	LV20.19	LV20.19	NNP
cord-005478-5iu38pr6	3180	13	CAR	CAR	NNP
cord-005478-5iu38pr6	3180	14	T	T	NNP
cord-005478-5iu38pr6	3180	15	clinical	clinical	JJ
cord-005478-5iu38pr6	3180	16	trial	trial	NN
cord-005478-5iu38pr6	3180	17	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	3180	18	that	that	IN
cord-005478-5iu38pr6	3180	19	near	near	JJ
cord-005478-5iu38pr6	3180	20	patient	patient	JJ
cord-005478-5iu38pr6	3180	21	manufacturing	manufacturing	NN
cord-005478-5iu38pr6	3180	22	and	and	CC
cord-005478-5iu38pr6	3180	23	infusion	infusion	NN
cord-005478-5iu38pr6	3180	24	of	of	IN
cord-005478-5iu38pr6	3180	25	2.5	2.5	CD
cord-005478-5iu38pr6	3180	26	x	x	SYM
cord-005478-5iu38pr6	3180	27	10	10	CD
cord-005478-5iu38pr6	3180	28	6	6	CD
cord-005478-5iu38pr6	3180	29	cells/	cells/	CD
cord-005478-5iu38pr6	3180	30	kg	kg	NNS
cord-005478-5iu38pr6	3180	31	is	be	VBZ
cord-005478-5iu38pr6	3180	32	safe	safe	JJ
cord-005478-5iu38pr6	3180	33	for	for	IN
cord-005478-5iu38pr6	3180	34	further	further	JJ
cord-005478-5iu38pr6	3180	35	investigation	investigation	NN
cord-005478-5iu38pr6	3180	36	with	with	IN
cord-005478-5iu38pr6	3180	37	no	no	DT
cord-005478-5iu38pr6	3180	38	DLTs	dlt	NNS
cord-005478-5iu38pr6	3180	39	among	among	IN
cord-005478-5iu38pr6	3180	40	treated	treat	VBN
cord-005478-5iu38pr6	3180	41	patients	patient	NNS
cord-005478-5iu38pr6	3180	42	.	.	.
cord-005478-5iu38pr6	3181	1	Point	point	NN
cord-005478-5iu38pr6	3181	2	of	of	IN
cord-005478-5iu38pr6	3181	3	care	care	NN
cord-005478-5iu38pr6	3181	4	production	production	NN
cord-005478-5iu38pr6	3181	5	logistics	logistic	NNS
cord-005478-5iu38pr6	3181	6	aided	aid	VBD
cord-005478-5iu38pr6	3181	7	the	the	DT
cord-005478-5iu38pr6	3181	8	administration	administration	NN
cord-005478-5iu38pr6	3181	9	of	of	IN
cord-005478-5iu38pr6	3181	10	fresh	fresh	JJ
cord-005478-5iu38pr6	3181	11	CAR	CAR	NNP
cord-005478-5iu38pr6	3181	12	-	-	HYPH
cord-005478-5iu38pr6	3181	13	T	t	NN
cord-005478-5iu38pr6	3181	14	cells	cell	NNS
cord-005478-5iu38pr6	3181	15	in	in	IN
cord-005478-5iu38pr6	3181	16	the	the	DT
cord-005478-5iu38pr6	3181	17	majority	majority	NN
cord-005478-5iu38pr6	3181	18	.	.	.
cord-005478-5iu38pr6	3182	1	With	with	IN
cord-005478-5iu38pr6	3182	2	limited	limited	JJ
cord-005478-5iu38pr6	3182	3	toxicity	toxicity	NN
cord-005478-5iu38pr6	3182	4	and	and	CC
cord-005478-5iu38pr6	3182	5	60	60	CD
cord-005478-5iu38pr6	3182	6	%	%	NN
cord-005478-5iu38pr6	3182	7	sustained	sustained	JJ
cord-005478-5iu38pr6	3182	8	response	response	NN
cord-005478-5iu38pr6	3182	9	in	in	IN
cord-005478-5iu38pr6	3182	10	this	this	DT
cord-005478-5iu38pr6	3182	11	relapsed	relapse	VBN
cord-005478-5iu38pr6	3182	12	refractory	refractory	JJ
cord-005478-5iu38pr6	3182	13	population	population	NN
cord-005478-5iu38pr6	3182	14	,	,	,
cord-005478-5iu38pr6	3182	15	this	this	DT
cord-005478-5iu38pr6	3182	16	approach	approach	NN
cord-005478-5iu38pr6	3182	17	to	to	IN
cord-005478-5iu38pr6	3182	18	CAR	car	NN
cord-005478-5iu38pr6	3182	19	-	-	HYPH
cord-005478-5iu38pr6	3182	20	T	t	NN
cord-005478-5iu38pr6	3182	21	production	production	NN
cord-005478-5iu38pr6	3182	22	and	and	CC
cord-005478-5iu38pr6	3182	23	dual	dual	JJ
cord-005478-5iu38pr6	3182	24	B	b	NN
cord-005478-5iu38pr6	3182	25	-	-	HYPH
cord-005478-5iu38pr6	3182	26	cell	cell	NN
cord-005478-5iu38pr6	3182	27	targeting	target	VBG
cord-005478-5iu38pr6	3182	28	merits	merit	NNS
cord-005478-5iu38pr6	3182	29	further	further	JJ
cord-005478-5iu38pr6	3182	30	investigation	investigation	NN
cord-005478-5iu38pr6	3182	31	.	.	.
cord-005478-5iu38pr6	3183	1	O159	o159	CD
cord-005478-5iu38pr6	3183	2	CAR	CAR	NNP
cord-005478-5iu38pr6	3183	3	-	-	HYPH
cord-005478-5iu38pr6	3183	4	T	t	NN
cord-005478-5iu38pr6	3183	5	cell	cell	NN
cord-005478-5iu38pr6	3183	6	therapy	therapy	NN
cord-005478-5iu38pr6	3183	7	bridging	bridge	VBG
cord-005478-5iu38pr6	3183	8	to	to	IN
cord-005478-5iu38pr6	3183	9	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	3183	10	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3183	11	cell	cell	NN
cord-005478-5iu38pr6	3183	12	transplantation	transplantation	NN
cord-005478-5iu38pr6	3183	13	for	for	IN
cord-005478-5iu38pr6	3183	14	patients	patient	NNS
cord-005478-5iu38pr6	3183	15	with	with	IN
cord-005478-5iu38pr6	3183	16	refractory	refractory	JJ
cord-005478-5iu38pr6	3183	17	and	and	CC
cord-005478-5iu38pr6	3183	18	relapsed	relapsed	JJ
cord-005478-5iu38pr6	3183	19	acute	acute	JJ
cord-005478-5iu38pr6	3183	20	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	3183	21	leukemia	leukemia	NN
cord-005478-5iu38pr6	3183	22	Jia	Jia	NNP
cord-005478-5iu38pr6	3183	23	Chen	Chen	NNP
cord-005478-5iu38pr6	3183	24	1,2	1,2	CD
cord-005478-5iu38pr6	3183	25	,	,	,
cord-005478-5iu38pr6	3183	26	Yi	Yi	NNP
cord-005478-5iu38pr6	3183	27	Fan	Fan	NNP
cord-005478-5iu38pr6	3183	28	1,2	1,2	CD
cord-005478-5iu38pr6	3183	29	,	,	,
cord-005478-5iu38pr6	3183	30	Yang	Yang	NNP
cord-005478-5iu38pr6	3183	31	Xu	Xu	NNP
cord-005478-5iu38pr6	3183	32	1,2	1,2	CD
cord-005478-5iu38pr6	3183	33	,	,	,
cord-005478-5iu38pr6	3183	34	Suning	Suning	NNP
cord-005478-5iu38pr6	3183	35	Chen	Chen	NNP
cord-005478-5iu38pr6	3183	36	1,2	1,2	CD
cord-005478-5iu38pr6	3183	37	,	,	,
cord-005478-5iu38pr6	3183	38	Huiying	Huiying	NNP
cord-005478-5iu38pr6	3183	39	Qiu	Qiu	NNP
cord-005478-5iu38pr6	3183	40	1,2	1,2	CD
cord-005478-5iu38pr6	3183	41	,	,	,
cord-005478-5iu38pr6	3183	42	Xiaowen	Xiaowen	NNP
cord-005478-5iu38pr6	3183	43	Tang	Tang	NNP
cord-005478-5iu38pr6	3183	44	1,2	1,2	CD
cord-005478-5iu38pr6	3183	45	,	,	,
cord-005478-5iu38pr6	3183	46	Yue	Yue	NNP
cord-005478-5iu38pr6	3183	47	Han	Han	NNP
cord-005478-5iu38pr6	3183	48	1,2	1,2	CD
cord-005478-5iu38pr6	3183	49	,	,	,
cord-005478-5iu38pr6	3183	50	Chengcheng	Chengcheng	NNP
cord-005478-5iu38pr6	3183	51	Fu	Fu	NNP
cord-005478-5iu38pr6	3183	52	1,2	1,2	CD
cord-005478-5iu38pr6	3183	53	,	,	,
cord-005478-5iu38pr6	3183	54	Depei	Depei	NNP
cord-005478-5iu38pr6	3183	55	Wu	Wu	NNP
cord-005478-5iu38pr6	3183	56	1	1	CD
cord-005478-5iu38pr6	3183	57	,	,	,
cord-005478-5iu38pr6	3183	58	2	2	CD
cord-005478-5iu38pr6	3183	59	Background	background	NN
cord-005478-5iu38pr6	3183	60	:	:	:
cord-005478-5iu38pr6	3184	1	Refractory	refractory	JJ
cord-005478-5iu38pr6	3184	2	and	and	CC
cord-005478-5iu38pr6	3184	3	relapsed	relapse	VBD
cord-005478-5iu38pr6	3185	1	(	(	-LRB-
cord-005478-5iu38pr6	3185	2	R	r	NN
cord-005478-5iu38pr6	3185	3	/	/	SYM
cord-005478-5iu38pr6	3185	4	R	r	NN
cord-005478-5iu38pr6	3185	5	)	)	-RRB-
cord-005478-5iu38pr6	3185	6	acute	acute	JJ
cord-005478-5iu38pr6	3185	7	lymphoblastic	lymphoblastic	JJ
cord-005478-5iu38pr6	3185	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	3185	9	(	(	-LRB-
cord-005478-5iu38pr6	3185	10	ALL	all	DT
cord-005478-5iu38pr6	3185	11	)	)	-RRB-
cord-005478-5iu38pr6	3185	12	always	always	RB
cord-005478-5iu38pr6	3185	13	leads	lead	VBZ
cord-005478-5iu38pr6	3185	14	to	to	IN
cord-005478-5iu38pr6	3185	15	a	a	DT
cord-005478-5iu38pr6	3185	16	dismal	dismal	JJ
cord-005478-5iu38pr6	3185	17	outcome	outcome	NN
cord-005478-5iu38pr6	3185	18	.	.	.
cord-005478-5iu38pr6	3186	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	3186	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3186	3	cell	cell	NN
cord-005478-5iu38pr6	3186	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	3186	5	(	(	-LRB-
cord-005478-5iu38pr6	3186	6	HCT	HCT	NNP
cord-005478-5iu38pr6	3186	7	)	)	-RRB-
cord-005478-5iu38pr6	3186	8	is	be	VBZ
cord-005478-5iu38pr6	3186	9	the	the	DT
cord-005478-5iu38pr6	3186	10	only	only	JJ
cord-005478-5iu38pr6	3186	11	potentially	potentially	RB
cord-005478-5iu38pr6	3186	12	curative	curative	JJ
cord-005478-5iu38pr6	3186	13	modality	modality	NN
cord-005478-5iu38pr6	3186	14	for	for	IN
cord-005478-5iu38pr6	3186	15	R	r	NN
cord-005478-5iu38pr6	3186	16	/	/	SYM
cord-005478-5iu38pr6	3186	17	R	r	NN
cord-005478-5iu38pr6	3186	18	ALL	all	DT
cord-005478-5iu38pr6	3186	19	,	,	,
cord-005478-5iu38pr6	3186	20	but	but	CC
cord-005478-5iu38pr6	3186	21	the	the	DT
cord-005478-5iu38pr6	3186	22	long	long	JJ
cord-005478-5iu38pr6	3186	23	-	-	HYPH
cord-005478-5iu38pr6	3186	24	term	term	NN
cord-005478-5iu38pr6	3186	25	survival	survival	NN
cord-005478-5iu38pr6	3186	26	post	post	NN
cord-005478-5iu38pr6	3186	27	-	-	NN
cord-005478-5iu38pr6	3186	28	HCT	HCT	NNP
cord-005478-5iu38pr6	3186	29	remains	remain	VBZ
cord-005478-5iu38pr6	3186	30	unsatisfying	unsatisfying	JJ
cord-005478-5iu38pr6	3186	31	.	.	.
cord-005478-5iu38pr6	3187	1	CAR	car	NN
cord-005478-5iu38pr6	3187	2	-	-	HYPH
cord-005478-5iu38pr6	3187	3	T	t	NN
cord-005478-5iu38pr6	3187	4	cell	cell	NN
cord-005478-5iu38pr6	3187	5	therapy	therapy	NN
cord-005478-5iu38pr6	3187	6	targeting	target	VBG
cord-005478-5iu38pr6	3187	7	to	to	IN
cord-005478-5iu38pr6	3187	8	CD19	CD19	NNP
cord-005478-5iu38pr6	3187	9	produces	produce	VBZ
cord-005478-5iu38pr6	3187	10	promising	promising	JJ
cord-005478-5iu38pr6	3187	11	response	response	NN
cord-005478-5iu38pr6	3187	12	for	for	IN
cord-005478-5iu38pr6	3187	13	R	r	NN
cord-005478-5iu38pr6	3187	14	/	/	SYM
cord-005478-5iu38pr6	3187	15	R	r	NN
cord-005478-5iu38pr6	3187	16	ALL	all	DT
cord-005478-5iu38pr6	3187	17	patients	patient	NNS
cord-005478-5iu38pr6	3187	18	,	,	,
cord-005478-5iu38pr6	3187	19	but	but	CC
cord-005478-5iu38pr6	3187	20	the	the	DT
cord-005478-5iu38pr6	3187	21	recurrence	recurrence	NN
cord-005478-5iu38pr6	3187	22	is	be	VBZ
cord-005478-5iu38pr6	3187	23	the	the	DT
cord-005478-5iu38pr6	3187	24	major	major	JJ
cord-005478-5iu38pr6	3187	25	concern	concern	NN
cord-005478-5iu38pr6	3187	26	.	.	.
cord-005478-5iu38pr6	3188	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3188	2	investigated	investigate	VBD
cord-005478-5iu38pr6	3188	3	the	the	DT
cord-005478-5iu38pr6	3188	4	effectiveness	effectiveness	NN
cord-005478-5iu38pr6	3188	5	of	of	IN
cord-005478-5iu38pr6	3188	6	a	a	DT
cord-005478-5iu38pr6	3188	7	tandem	tandem	NN
cord-005478-5iu38pr6	3188	8	protocol	protocol	NN
cord-005478-5iu38pr6	3188	9	using	use	VBG
cord-005478-5iu38pr6	3188	10	CAR	car	NN
cord-005478-5iu38pr6	3188	11	-	-	HYPH
cord-005478-5iu38pr6	3188	12	T	t	NN
cord-005478-5iu38pr6	3188	13	cell	cell	NN
cord-005478-5iu38pr6	3188	14	therapy	therapy	NN
cord-005478-5iu38pr6	3188	15	followed	follow	VBN
cord-005478-5iu38pr6	3188	16	by	by	IN
cord-005478-5iu38pr6	3188	17	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3188	18	HCT	hct	NN
cord-005478-5iu38pr6	3188	19	.	.	.
cord-005478-5iu38pr6	3189	1	Methods	method	NNS
cord-005478-5iu38pr6	3189	2	:	:	:
cord-005478-5iu38pr6	3189	3	We	-PRON-	PRP
cord-005478-5iu38pr6	3189	4	conducted	conduct	VBD
cord-005478-5iu38pr6	3189	5	a	a	DT
cord-005478-5iu38pr6	3189	6	prospective	prospective	JJ
cord-005478-5iu38pr6	3189	7	study	study	NN
cord-005478-5iu38pr6	3189	8	to	to	TO
cord-005478-5iu38pr6	3189	9	enroll	enroll	VB
cord-005478-5iu38pr6	3189	10	the	the	DT
cord-005478-5iu38pr6	3189	11	patients	patient	NNS
cord-005478-5iu38pr6	3189	12	with	with	IN
cord-005478-5iu38pr6	3189	13	R	r	NN
cord-005478-5iu38pr6	3189	14	/	/	SYM
cord-005478-5iu38pr6	3189	15	R	r	NN
cord-005478-5iu38pr6	3189	16	ALL	all	DT
cord-005478-5iu38pr6	3189	17	.	.	.
cord-005478-5iu38pr6	3190	1	Major	major	JJ
cord-005478-5iu38pr6	3190	2	inclusion	inclusion	NN
cord-005478-5iu38pr6	3190	3	and	and	CC
cord-005478-5iu38pr6	3190	4	exclusion	exclusion	NN
cord-005478-5iu38pr6	3190	5	criteria	criterion	NNS
cord-005478-5iu38pr6	3190	6	are	be	VBP
cord-005478-5iu38pr6	3190	7	:	:	:
cord-005478-5iu38pr6	3190	8	1	1	LS
cord-005478-5iu38pr6	3190	9	)	)	-RRB-
cord-005478-5iu38pr6	3190	10	definitely	definitely	RB
cord-005478-5iu38pr6	3190	11	diagnosed	diagnose	VBN
cord-005478-5iu38pr6	3190	12	as	as	IN
cord-005478-5iu38pr6	3190	13	ALL	all	DT
cord-005478-5iu38pr6	3190	14	;	;	:
cord-005478-5iu38pr6	3190	15	2	2	LS
cord-005478-5iu38pr6	3190	16	)	)	-RRB-
cord-005478-5iu38pr6	3190	17	primary	primary	JJ
cord-005478-5iu38pr6	3190	18	refractory	refractory	NN
cord-005478-5iu38pr6	3190	19	(	(	-LRB-
cord-005478-5iu38pr6	3190	20	failed	fail	VBN
cord-005478-5iu38pr6	3190	21	to	to	TO
cord-005478-5iu38pr6	3190	22	achieve	achieve	VB
cord-005478-5iu38pr6	3190	23	CR	CR	NNP
cord-005478-5iu38pr6	3190	24	after	after	IN
cord-005478-5iu38pr6	3190	25	induction	induction	NN
cord-005478-5iu38pr6	3190	26	)	)	-RRB-
cord-005478-5iu38pr6	3190	27	patients	patient	NNS
cord-005478-5iu38pr6	3190	28	or	or	CC
cord-005478-5iu38pr6	3190	29	relapsed	relapse	VBD
cord-005478-5iu38pr6	3190	30	patients	patient	NNS
cord-005478-5iu38pr6	3190	31	with	with	IN
cord-005478-5iu38pr6	3190	32	no	no	DT
cord-005478-5iu38pr6	3190	33	response	response	NN
cord-005478-5iu38pr6	3190	34	for	for	IN
cord-005478-5iu38pr6	3190	35	salvage	salvage	NN
cord-005478-5iu38pr6	3190	36	therapy	therapy	NN
cord-005478-5iu38pr6	3190	37	;	;	:
cord-005478-5iu38pr6	3190	38	3	3	LS
cord-005478-5iu38pr6	3190	39	)	)	-RRB-
cord-005478-5iu38pr6	3190	40	with	with	IN
cord-005478-5iu38pr6	3190	41	an	an	DT
cord-005478-5iu38pr6	3190	42	available	available	JJ
cord-005478-5iu38pr6	3190	43	donor	donor	NN
cord-005478-5iu38pr6	3190	44	for	for	IN
cord-005478-5iu38pr6	3190	45	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3190	46	HCT	hct	NN
cord-005478-5iu38pr6	3190	47	;	;	:
cord-005478-5iu38pr6	3190	48	4	4	LS
cord-005478-5iu38pr6	3190	49	)	)	-RRB-
cord-005478-5iu38pr6	3190	50	without	without	IN
cord-005478-5iu38pr6	3190	51	severe	severe	JJ
cord-005478-5iu38pr6	3190	52	organ	organ	NN
cord-005478-5iu38pr6	3190	53	dysfunction	dysfunction	NN
cord-005478-5iu38pr6	3190	54	or	or	CC
cord-005478-5iu38pr6	3190	55	uncontrolled	uncontrolled	JJ
cord-005478-5iu38pr6	3190	56	infection	infection	NN
cord-005478-5iu38pr6	3190	57	.	.	.
cord-005478-5iu38pr6	3191	1	Patients	patient	NNS
cord-005478-5iu38pr6	3191	2	enrolled	enrol	VBD
cord-005478-5iu38pr6	3191	3	received	receive	VBN
cord-005478-5iu38pr6	3191	4	CAR	car	NN
cord-005478-5iu38pr6	3191	5	-	-	HYPH
cord-005478-5iu38pr6	3191	6	T	t	NN
cord-005478-5iu38pr6	3191	7	cell	cell	NN
cord-005478-5iu38pr6	3191	8	therapy	therapy	NN
cord-005478-5iu38pr6	3191	9	targeting	target	VBG
cord-005478-5iu38pr6	3191	10	to	to	IN
cord-005478-5iu38pr6	3191	11	CD19	CD19	NNP
cord-005478-5iu38pr6	3191	12	with	with	IN
cord-005478-5iu38pr6	3191	13	a	a	DT
cord-005478-5iu38pr6	3191	14	total	total	JJ
cord-005478-5iu38pr6	3191	15	dose	dose	NN
cord-005478-5iu38pr6	3191	16	of	of	IN
cord-005478-5iu38pr6	3191	17	5~10×10	5~10×10	CD
cord-005478-5iu38pr6	3191	18	6	6	CD
cord-005478-5iu38pr6	3191	19	/kg	/kg	CD
cord-005478-5iu38pr6	3191	20	of	of	IN
cord-005478-5iu38pr6	3191	21	recipient	recipient	NN
cord-005478-5iu38pr6	3191	22	weight	weight	NN
cord-005478-5iu38pr6	3191	23	,	,	,
cord-005478-5iu38pr6	3191	24	and	and	CC
cord-005478-5iu38pr6	3191	25	the	the	DT
cord-005478-5iu38pr6	3191	26	preparative	preparative	JJ
cord-005478-5iu38pr6	3191	27	regimen	regimen	NN
cord-005478-5iu38pr6	3191	28	before	before	IN
cord-005478-5iu38pr6	3191	29	CAR	CAR	NNP
cord-005478-5iu38pr6	3191	30	-	-	HYPH
cord-005478-5iu38pr6	3191	31	T	t	NN
cord-005478-5iu38pr6	3191	32	cell	cell	NN
cord-005478-5iu38pr6	3191	33	infusion	infusion	NN
cord-005478-5iu38pr6	3191	34	consisted	consist	VBD
cord-005478-5iu38pr6	3191	35	of	of	IN
cord-005478-5iu38pr6	3191	36	fludarabin	fludarabin	NN
cord-005478-5iu38pr6	3191	37	and	and	CC
cord-005478-5iu38pr6	3191	38	cyclophosphamide	cyclophosphamide	RB
cord-005478-5iu38pr6	3191	39	.	.	.
cord-005478-5iu38pr6	3192	1	After	after	IN
cord-005478-5iu38pr6	3192	2	the	the	DT
cord-005478-5iu38pr6	3192	3	evaluation	evaluation	NN
cord-005478-5iu38pr6	3192	4	at	at	IN
cord-005478-5iu38pr6	3192	5	30	30	CD
cord-005478-5iu38pr6	3192	6	days	day	NNS
cord-005478-5iu38pr6	3192	7	post	post	NN
cord-005478-5iu38pr6	3192	8	CAR	CAR	NNP
cord-005478-5iu38pr6	3192	9	-	-	HYPH
cord-005478-5iu38pr6	3192	10	T	t	NN
cord-005478-5iu38pr6	3192	11	cell	cell	NN
cord-005478-5iu38pr6	3192	12	infusion	infusion	NN
cord-005478-5iu38pr6	3192	13	,	,	,
cord-005478-5iu38pr6	3192	14	patients	patient	NNS
cord-005478-5iu38pr6	3192	15	started	start	VBD
cord-005478-5iu38pr6	3192	16	the	the	DT
cord-005478-5iu38pr6	3192	17	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3192	18	HCT	hct	NN
cord-005478-5iu38pr6	3192	19	procedure	procedure	NN
cord-005478-5iu38pr6	3192	20	using	use	VBG
cord-005478-5iu38pr6	3192	21	a	a	DT
cord-005478-5iu38pr6	3192	22	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	3192	23	conditioning	conditioning	NN
cord-005478-5iu38pr6	3192	24	(	(	-LRB-
cord-005478-5iu38pr6	3192	25	modified	modify	VBN
cord-005478-5iu38pr6	3192	26	Bu	Bu	NNP
cord-005478-5iu38pr6	3192	27	/	/	SYM
cord-005478-5iu38pr6	3192	28	Cy	Cy	NNP
cord-005478-5iu38pr6	3192	29	)	)	-RRB-
cord-005478-5iu38pr6	3192	30	.	.	.
cord-005478-5iu38pr6	3193	1	The	the	DT
cord-005478-5iu38pr6	3193	2	control	control	NN
cord-005478-5iu38pr6	3193	3	group	group	NN
cord-005478-5iu38pr6	3193	4	consisted	consist	VBD
cord-005478-5iu38pr6	3193	5	of	of	IN
cord-005478-5iu38pr6	3193	6	patients	patient	NNS
cord-005478-5iu38pr6	3193	7	with	with	IN
cord-005478-5iu38pr6	3193	8	R	r	NN
cord-005478-5iu38pr6	3193	9	/	/	SYM
cord-005478-5iu38pr6	3193	10	R	r	NN
cord-005478-5iu38pr6	3193	11	ALL	all	DT
cord-005478-5iu38pr6	3193	12	and	and	CC
cord-005478-5iu38pr6	3193	13	underwent	undergo	VBD
cord-005478-5iu38pr6	3193	14	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3193	15	HCT	hct	NN
cord-005478-5iu38pr6	3193	16	without	without	IN
cord-005478-5iu38pr6	3193	17	CAR	car	NN
cord-005478-5iu38pr6	3193	18	-	-	HYPH
cord-005478-5iu38pr6	3193	19	T	t	NN
cord-005478-5iu38pr6	3193	20	therapy	therapy	NN
cord-005478-5iu38pr6	3193	21	in	in	IN
cord-005478-5iu38pr6	3193	22	the	the	DT
cord-005478-5iu38pr6	3193	23	same	same	JJ
cord-005478-5iu38pr6	3193	24	time	time	NN
cord-005478-5iu38pr6	3193	25	frame	frame	NN
cord-005478-5iu38pr6	3193	26	.	.	.
cord-005478-5iu38pr6	3194	1	Results	result	NNS
cord-005478-5iu38pr6	3194	2	:	:	:
cord-005478-5iu38pr6	3195	1	Totally	totally	RB
cord-005478-5iu38pr6	3195	2	24	24	CD
cord-005478-5iu38pr6	3195	3	patients	patient	NNS
cord-005478-5iu38pr6	3195	4	were	be	VBD
cord-005478-5iu38pr6	3195	5	enrolled	enrol	VBN
cord-005478-5iu38pr6	3195	6	in	in	IN
cord-005478-5iu38pr6	3195	7	this	this	DT
cord-005478-5iu38pr6	3195	8	study	study	NN
cord-005478-5iu38pr6	3195	9	from	from	IN
cord-005478-5iu38pr6	3195	10	December	December	NNP
cord-005478-5iu38pr6	3195	11	,	,	,
cord-005478-5iu38pr6	3195	12	2016	2016	CD
cord-005478-5iu38pr6	3195	13	through	through	IN
cord-005478-5iu38pr6	3195	14	April	April	NNP
cord-005478-5iu38pr6	3195	15	,	,	,
cord-005478-5iu38pr6	3195	16	2018	2018	CD
cord-005478-5iu38pr6	3195	17	,	,	,
cord-005478-5iu38pr6	3195	18	including	include	VBG
cord-005478-5iu38pr6	3195	19	17	17	CD
cord-005478-5iu38pr6	3195	20	primary	primary	JJ
cord-005478-5iu38pr6	3195	21	refractory	refractory	JJ
cord-005478-5iu38pr6	3195	22	patients	patient	NNS
cord-005478-5iu38pr6	3195	23	and	and	CC
cord-005478-5iu38pr6	3195	24	7	7	CD
cord-005478-5iu38pr6	3195	25	relapsed	relapse	VBD
cord-005478-5iu38pr6	3195	26	patients	patient	NNS
cord-005478-5iu38pr6	3195	27	(	(	-LRB-
cord-005478-5iu38pr6	3195	28	details	detail	NNS
cord-005478-5iu38pr6	3195	29	in	in	IN
cord-005478-5iu38pr6	3195	30	Table	Table	NNP
cord-005478-5iu38pr6	3195	31	1	1	CD
cord-005478-5iu38pr6	3195	32	)	)	-RRB-
cord-005478-5iu38pr6	3195	33	.	.	.
cord-005478-5iu38pr6	3196	1	Twenty	twenty	CD
cord-005478-5iu38pr6	3196	2	patients	patient	NNS
cord-005478-5iu38pr6	3196	3	(	(	-LRB-
cord-005478-5iu38pr6	3196	4	83.3	83.3	CD
cord-005478-5iu38pr6	3196	5	%	%	NN
cord-005478-5iu38pr6	3196	6	)	)	-RRB-
cord-005478-5iu38pr6	3196	7	achieved	achieve	VBD
cord-005478-5iu38pr6	3196	8	CR	cr	NN
cord-005478-5iu38pr6	3196	9	after	after	IN
cord-005478-5iu38pr6	3196	10	CAR	car	NN
cord-005478-5iu38pr6	3196	11	-	-	HYPH
cord-005478-5iu38pr6	3196	12	T	t	NN
cord-005478-5iu38pr6	3196	13	cell	cell	NN
cord-005478-5iu38pr6	3196	14	therapy	therapy	NN
cord-005478-5iu38pr6	3196	15	,	,	,
cord-005478-5iu38pr6	3196	16	and	and	CC
cord-005478-5iu38pr6	3196	17	6	6	CD
cord-005478-5iu38pr6	3196	18	patients	patient	NNS
cord-005478-5iu38pr6	3196	19	(	(	-LRB-
cord-005478-5iu38pr6	3196	20	25	25	CD
cord-005478-5iu38pr6	3196	21	%	%	NN
cord-005478-5iu38pr6	3196	22	)	)	-RRB-
cord-005478-5iu38pr6	3196	23	developed	develop	VBN
cord-005478-5iu38pr6	3196	24	Grade	grade	NN
cord-005478-5iu38pr6	3196	25	2	2	CD
cord-005478-5iu38pr6	3196	26	or	or	CC
cord-005478-5iu38pr6	3196	27	higher	high	JJR
cord-005478-5iu38pr6	3196	28	CRS	CRS	NNP
cord-005478-5iu38pr6	3196	29	.	.	.
cord-005478-5iu38pr6	3197	1	No	no	DT
cord-005478-5iu38pr6	3197	2	irreversible	irreversible	JJ
cord-005478-5iu38pr6	3197	3	toxicities	toxicity	NNS
cord-005478-5iu38pr6	3197	4	emerged	emerge	VBD
cord-005478-5iu38pr6	3197	5	and	and	CC
cord-005478-5iu38pr6	3197	6	all	all	PDT
cord-005478-5iu38pr6	3197	7	the	the	DT
cord-005478-5iu38pr6	3197	8	patients	patient	NNS
cord-005478-5iu38pr6	3197	9	moved	move	VBD
cord-005478-5iu38pr6	3197	10	to	to	IN
cord-005478-5iu38pr6	3197	11	the	the	DT
cord-005478-5iu38pr6	3197	12	HCT	HCT	NNP
cord-005478-5iu38pr6	3197	13	procedure	procedure	NN
cord-005478-5iu38pr6	3197	14	.	.	.
cord-005478-5iu38pr6	3198	1	When	when	WRB
cord-005478-5iu38pr6	3198	2	comparing	compare	VBG
cord-005478-5iu38pr6	3198	3	with	with	IN
cord-005478-5iu38pr6	3198	4	the	the	DT
cord-005478-5iu38pr6	3198	5	control	control	NN
cord-005478-5iu38pr6	3198	6	group	group	NN
cord-005478-5iu38pr6	3198	7	(	(	-LRB-
cord-005478-5iu38pr6	3198	8	Figure	Figure	NNP
cord-005478-5iu38pr6	3198	9	1	1	CD
cord-005478-5iu38pr6	3198	10	)	)	-RRB-
cord-005478-5iu38pr6	3198	11	,	,	,
cord-005478-5iu38pr6	3198	12	the	the	DT
cord-005478-5iu38pr6	3198	13	1-year	1-year	CD
cord-005478-5iu38pr6	3198	14	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3198	15	incidence	incidence	NN
cord-005478-5iu38pr6	3198	16	of	of	IN
cord-005478-5iu38pr6	3198	17	relapse	relapse	NN
cord-005478-5iu38pr6	3198	18	was	be	VBD
cord-005478-5iu38pr6	3198	19	14.8	14.8	CD
cord-005478-5iu38pr6	3198	20	±	±	CD
cord-005478-5iu38pr6	3198	21	8.0	8.0	CD
cord-005478-5iu38pr6	3198	22	%	%	NN
cord-005478-5iu38pr6	3198	23	for	for	IN
cord-005478-5iu38pr6	3198	24	the	the	DT
cord-005478-5iu38pr6	3198	25	trial	trial	NN
cord-005478-5iu38pr6	3198	26	group	group	NN
cord-005478-5iu38pr6	3198	27	versus	versus	IN
cord-005478-5iu38pr6	3198	28	46.4	46.4	CD
cord-005478-5iu38pr6	3198	29	±	±	CD
cord-005478-5iu38pr6	3198	30	12.4	12.4	CD
cord-005478-5iu38pr6	3198	31	%	%	NN
cord-005478-5iu38pr6	3198	32	for	for	IN
cord-005478-5iu38pr6	3198	33	the	the	DT
cord-005478-5iu38pr6	3198	34	control	control	NN
cord-005478-5iu38pr6	3198	35	group	group	NN
cord-005478-5iu38pr6	3198	36	(	(	-LRB-
cord-005478-5iu38pr6	3198	37	P	p	NN
cord-005478-5iu38pr6	3198	38	=	=	SYM
cord-005478-5iu38pr6	3198	39	0.090	0.090	CD
cord-005478-5iu38pr6	3198	40	)	)	-RRB-
cord-005478-5iu38pr6	3198	41	,	,	,
cord-005478-5iu38pr6	3198	42	and	and	CC
cord-005478-5iu38pr6	3198	43	1-year	1-year	CD
cord-005478-5iu38pr6	3198	44	overall	overall	JJ
cord-005478-5iu38pr6	3198	45	survival	survival	NN
cord-005478-5iu38pr6	3198	46	was	be	VBD
cord-005478-5iu38pr6	3198	47	71.4	71.4	CD
cord-005478-5iu38pr6	3198	48	±	±	CD
cord-005478-5iu38pr6	3198	49	17.1	17.1	CD
cord-005478-5iu38pr6	3198	50	%	%	NN
cord-005478-5iu38pr6	3198	51	versus	versus	IN
cord-005478-5iu38pr6	3198	52	54.0	54.0	CD
cord-005478-5iu38pr6	3198	53	±	±	CD
cord-005478-5iu38pr6	3198	54	11.4	11.4	CD
cord-005478-5iu38pr6	3198	55	%	%	NN
cord-005478-5iu38pr6	3198	56	(	(	-LRB-
cord-005478-5iu38pr6	3198	57	P	p	NN
cord-005478-5iu38pr6	3198	58	=	=	SYM
cord-005478-5iu38pr6	3198	59	0.067	0.067	CD
cord-005478-5iu38pr6	3198	60	)	)	-RRB-
cord-005478-5iu38pr6	3198	61	.	.	.
cord-005478-5iu38pr6	3199	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3199	2	:	:	:
cord-005478-5iu38pr6	3200	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3200	2	concluded	conclude	VBD
cord-005478-5iu38pr6	3200	3	that	that	IN
cord-005478-5iu38pr6	3200	4	CAR	car	NN
cord-005478-5iu38pr6	3200	5	-	-	HYPH
cord-005478-5iu38pr6	3200	6	T	t	NN
cord-005478-5iu38pr6	3200	7	cell	cell	NN
cord-005478-5iu38pr6	3200	8	therapy	therapy	NN
cord-005478-5iu38pr6	3200	9	bridging	bridge	VBG
cord-005478-5iu38pr6	3200	10	to	to	IN
cord-005478-5iu38pr6	3200	11	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3200	12	HCT	hct	NN
cord-005478-5iu38pr6	3200	13	is	be	VBZ
cord-005478-5iu38pr6	3200	14	a	a	DT
cord-005478-5iu38pr6	3200	15	promising	promising	JJ
cord-005478-5iu38pr6	3200	16	approach	approach	NN
cord-005478-5iu38pr6	3200	17	for	for	IN
cord-005478-5iu38pr6	3200	18	R	r	NN
cord-005478-5iu38pr6	3200	19	/	/	SYM
cord-005478-5iu38pr6	3200	20	R	r	NN
cord-005478-5iu38pr6	3200	21	ALL	all	DT
cord-005478-5iu38pr6	3200	22	patients	patient	NNS
cord-005478-5iu38pr6	3200	23	,	,	,
cord-005478-5iu38pr6	3200	24	which	which	WDT
cord-005478-5iu38pr6	3200	25	leads	lead	VBZ
cord-005478-5iu38pr6	3200	26	to	to	IN
cord-005478-5iu38pr6	3200	27	both	both	CC
cord-005478-5iu38pr6	3200	28	high	high	JJ
cord-005478-5iu38pr6	3200	29	response	response	NN
cord-005478-5iu38pr6	3200	30	and	and	CC
cord-005478-5iu38pr6	3200	31	low	low	JJ
cord-005478-5iu38pr6	3200	32	risk	risk	NN
cord-005478-5iu38pr6	3200	33	of	of	IN
cord-005478-5iu38pr6	3200	34	relapse	relapse	NN
cord-005478-5iu38pr6	3200	35	.	.	.
cord-005478-5iu38pr6	3201	1	Besides	besides	RB
cord-005478-5iu38pr6	3201	2	,	,	,
cord-005478-5iu38pr6	3201	3	CAR	car	NN
cord-005478-5iu38pr6	3201	4	-	-	HYPH
cord-005478-5iu38pr6	3201	5	T	t	NN
cord-005478-5iu38pr6	3201	6	cell	cell	NN
cord-005478-5iu38pr6	3201	7	therapy	therapy	NN
cord-005478-5iu38pr6	3201	8	is	be	VBZ
cord-005478-5iu38pr6	3201	9	a	a	DT
cord-005478-5iu38pr6	3201	10	safe	safe	JJ
cord-005478-5iu38pr6	3201	11	modality	modality	NN
cord-005478-5iu38pr6	3201	12	as	as	IN
cord-005478-5iu38pr6	3201	13	salvage	salvage	NN
cord-005478-5iu38pr6	3201	14	treatment	treatment	NN
cord-005478-5iu38pr6	3201	15	for	for	IN
cord-005478-5iu38pr6	3201	16	R	r	NN
cord-005478-5iu38pr6	3201	17	/	/	SYM
cord-005478-5iu38pr6	3201	18	R	r	NN
cord-005478-5iu38pr6	3201	19	ALL	all	DT
cord-005478-5iu38pr6	3201	20	patients	patient	NNS
cord-005478-5iu38pr6	3201	21	,	,	,
cord-005478-5iu38pr6	3201	22	which	which	WDT
cord-005478-5iu38pr6	3201	23	had	have	VBD
cord-005478-5iu38pr6	3201	24	little	little	JJ
cord-005478-5iu38pr6	3201	25	negative	negative	JJ
cord-005478-5iu38pr6	3201	26	impact	impact	NN
cord-005478-5iu38pr6	3201	27	for	for	IN
cord-005478-5iu38pr6	3201	28	following	follow	VBG
cord-005478-5iu38pr6	3201	29	HCT	HCT	NNP
cord-005478-5iu38pr6	3201	30	.	.	.
cord-005478-5iu38pr6	3202	1	Methods	method	NNS
cord-005478-5iu38pr6	3202	2	:	:	:
cord-005478-5iu38pr6	3202	3	To	to	TO
cord-005478-5iu38pr6	3202	4	test	test	VB
cord-005478-5iu38pr6	3202	5	the	the	DT
cord-005478-5iu38pr6	3202	6	hypothesis	hypothesis	NN
cord-005478-5iu38pr6	3202	7	that	that	IN
cord-005478-5iu38pr6	3202	8	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3202	9	HCT	HCT	NNP
cord-005478-5iu38pr6	3202	10	would	would	MD
cord-005478-5iu38pr6	3202	11	be	be	VB
cord-005478-5iu38pr6	3202	12	a	a	DT
cord-005478-5iu38pr6	3202	13	valid	valid	JJ
cord-005478-5iu38pr6	3202	14	option	option	NN
cord-005478-5iu38pr6	3202	15	for	for	IN
cord-005478-5iu38pr6	3202	16	high	high	JJ
cord-005478-5iu38pr6	3202	17	-	-	HYPH
cord-005478-5iu38pr6	3202	18	risk	risk	NN
cord-005478-5iu38pr6	3202	19	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3202	20	AML	AML	NNP
cord-005478-5iu38pr6	3202	21	patients	patient	NNS
cord-005478-5iu38pr6	3202	22	lacking	lack	VBG
cord-005478-5iu38pr6	3202	23	a	a	DT
cord-005478-5iu38pr6	3202	24	matched	match	VBN
cord-005478-5iu38pr6	3202	25	donor	donor	NN
cord-005478-5iu38pr6	3202	26	,	,	,
cord-005478-5iu38pr6	3202	27	we	-PRON-	PRP
cord-005478-5iu38pr6	3202	28	designed	design	VBD
cord-005478-5iu38pr6	3202	29	a	a	DT
cord-005478-5iu38pr6	3202	30	diseasespecific	diseasespecific	NN
cord-005478-5iu38pr6	3202	31	,	,	,
cord-005478-5iu38pr6	3202	32	multi	multi	JJ
cord-005478-5iu38pr6	3202	33	-	-	JJ
cord-005478-5iu38pr6	3202	34	centre	centre	JJ
cord-005478-5iu38pr6	3202	35	study	study	NN
cord-005478-5iu38pr6	3202	36	.	.	.
cord-005478-5iu38pr6	3203	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3203	2	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	3203	3	analyzed	analyze	VBD
cord-005478-5iu38pr6	3203	4	179	179	CD
cord-005478-5iu38pr6	3203	5	consecutive	consecutive	JJ
cord-005478-5iu38pr6	3203	6	patients	patient	NNS
cord-005478-5iu38pr6	3203	7	under	under	IN
cord-005478-5iu38pr6	3203	8	18	18	CD
cord-005478-5iu38pr6	3203	9	years	year	NNS
cord-005478-5iu38pr6	3203	10	with	with	IN
cord-005478-5iu38pr6	3203	11	high	high	JJ
cord-005478-5iu38pr6	3203	12	-	-	HYPH
cord-005478-5iu38pr6	3203	13	risk	risk	NN
cord-005478-5iu38pr6	3203	14	AML	AML	NNP
cord-005478-5iu38pr6	3203	15	underwent	undergo	VBD
cord-005478-5iu38pr6	3203	16	matched	matched	JJ
cord-005478-5iu38pr6	3203	17	sibling	sibling	NN
cord-005478-5iu38pr6	3203	18	donor	donor	NN
cord-005478-5iu38pr6	3203	19	(	(	-LRB-
cord-005478-5iu38pr6	3203	20	MSD	MSD	NNP
cord-005478-5iu38pr6	3203	21	)	)	-RRB-
cord-005478-5iu38pr6	3203	22	(	(	-LRB-
cord-005478-5iu38pr6	3203	23	n=23	n=23	NNP
cord-005478-5iu38pr6	3203	24	)	)	-RRB-
cord-005478-5iu38pr6	3203	25	or	or	CC
cord-005478-5iu38pr6	3203	26	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3203	27	donor	donor	NN
cord-005478-5iu38pr6	3203	28	(	(	-LRB-
cord-005478-5iu38pr6	3203	29	HID	HID	NNP
cord-005478-5iu38pr6	3203	30	)	)	-RRB-
cord-005478-5iu38pr6	3203	31	HCT	HCT	NNP
cord-005478-5iu38pr6	3203	32	(	(	-LRB-
cord-005478-5iu38pr6	3203	33	n=156	n=156	NNP
cord-005478-5iu38pr6	3203	34	)	)	-RRB-
cord-005478-5iu38pr6	3203	35	between	between	IN
cord-005478-5iu38pr6	3203	36	July	July	NNP
cord-005478-5iu38pr6	3203	37	,	,	,
cord-005478-5iu38pr6	3203	38	2013	2013	CD
cord-005478-5iu38pr6	3203	39	and	and	CC
cord-005478-5iu38pr6	3203	40	Dec	Dec	NNP
cord-005478-5iu38pr6	3203	41	,	,	,
cord-005478-5iu38pr6	3203	42	2017	2017	CD
cord-005478-5iu38pr6	3203	43	.	.	.
cord-005478-5iu38pr6	3204	1	A	a	DT
cord-005478-5iu38pr6	3204	2	1:3	1:3	CD
cord-005478-5iu38pr6	3204	3	ratio	ratio	NN
cord-005478-5iu38pr6	3204	4	matched	match	VBN
cord-005478-5iu38pr6	3204	5	pair	pair	NN
cord-005478-5iu38pr6	3204	6	analysis	analysis	NN
cord-005478-5iu38pr6	3204	7	was	be	VBD
cord-005478-5iu38pr6	3204	8	implemented	implement	VBN
cord-005478-5iu38pr6	3204	9	with	with	IN
cord-005478-5iu38pr6	3204	10	the	the	DT
cord-005478-5iu38pr6	3204	11	following	following	JJ
cord-005478-5iu38pr6	3204	12	matching	matching	NN
cord-005478-5iu38pr6	3204	13	factors	factor	NNS
cord-005478-5iu38pr6	3204	14	:	:	:
cord-005478-5iu38pr6	3204	15	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3204	16	risk	risk	NN
cord-005478-5iu38pr6	3204	17	,	,	,
cord-005478-5iu38pr6	3204	18	disease	disease	NN
cord-005478-5iu38pr6	3204	19	status	status	NN
cord-005478-5iu38pr6	3204	20	(	(	-LRB-
cord-005478-5iu38pr6	3204	21	CR1	CR1	NNP
cord-005478-5iu38pr6	3204	22	/	/	SYM
cord-005478-5iu38pr6	3204	23	CR2/>CR2	CR2/>CR2	NNP
cord-005478-5iu38pr6	3204	24	)	)	-RRB-
cord-005478-5iu38pr6	3204	25	,	,	,
cord-005478-5iu38pr6	3204	26	age	age	NN
cord-005478-5iu38pr6	3204	27	and	and	CC
cord-005478-5iu38pr6	3204	28	sex	sex	NN
cord-005478-5iu38pr6	3204	29	of	of	IN
cord-005478-5iu38pr6	3204	30	patients	patient	NNS
cord-005478-5iu38pr6	3204	31	,	,	,
cord-005478-5iu38pr6	3204	32	sex	sex	NN
cord-005478-5iu38pr6	3204	33	of	of	IN
cord-005478-5iu38pr6	3204	34	donor	donor	NN
cord-005478-5iu38pr6	3204	35	,	,	,
cord-005478-5iu38pr6	3204	36	and	and	CC
cord-005478-5iu38pr6	3204	37	graft	graft	NN
cord-005478-5iu38pr6	3204	38	type	type	NN
cord-005478-5iu38pr6	3204	39	.	.	.
cord-005478-5iu38pr6	3205	1	Results	result	NNS
cord-005478-5iu38pr6	3205	2	:	:	:
cord-005478-5iu38pr6	3206	1	All	all	DT
cord-005478-5iu38pr6	3206	2	patients	patient	NNS
cord-005478-5iu38pr6	3206	3	achieved	achieve	VBD
cord-005478-5iu38pr6	3206	4	myeloid	myeloid	JJ
cord-005478-5iu38pr6	3206	5	recovery	recovery	NN
cord-005478-5iu38pr6	3206	6	with	with	IN
cord-005478-5iu38pr6	3206	7	a	a	DT
cord-005478-5iu38pr6	3206	8	median	median	JJ
cord-005478-5iu38pr6	3206	9	time	time	NN
cord-005478-5iu38pr6	3206	10	of	of	IN
cord-005478-5iu38pr6	3206	11	15d	15d	NNS
cord-005478-5iu38pr6	3206	12	and	and	CC
cord-005478-5iu38pr6	3206	13	13d	13d	CD
cord-005478-5iu38pr6	3206	14	for	for	IN
cord-005478-5iu38pr6	3206	15	MSD	MSD	NNP
cord-005478-5iu38pr6	3206	16	cohort	cohort	NN
cord-005478-5iu38pr6	3206	17	and	and	CC
cord-005478-5iu38pr6	3206	18	HID	HID	NNP
cord-005478-5iu38pr6	3206	19	group	group	NN
cord-005478-5iu38pr6	3206	20	(	(	-LRB-
cord-005478-5iu38pr6	3206	21	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	3206	22	)	)	-RRB-
cord-005478-5iu38pr6	3206	23	.	.	.
cord-005478-5iu38pr6	3207	1	The	the	DT
cord-005478-5iu38pr6	3207	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3207	3	incidence	incidence	NN
cord-005478-5iu38pr6	3207	4	of	of	IN
cord-005478-5iu38pr6	3207	5	grade	grade	NN
cord-005478-5iu38pr6	3207	6	II	II	NNP
cord-005478-5iu38pr6	3207	7	-	-	HYPH
cord-005478-5iu38pr6	3207	8	IV	IV	NNP
cord-005478-5iu38pr6	3207	9	acute	acute	JJ
cord-005478-5iu38pr6	3207	10	graft	graft	NN
cord-005478-5iu38pr6	3207	11	-	-	HYPH
cord-005478-5iu38pr6	3207	12	versus	versus	IN
cord-005478-5iu38pr6	3207	13	-	-	HYPH
cord-005478-5iu38pr6	3207	14	host	host	NN
cord-005478-5iu38pr6	3207	15	-	-	HYPH
cord-005478-5iu38pr6	3207	16	disease	disease	NN
cord-005478-5iu38pr6	3207	17	(	(	-LRB-
cord-005478-5iu38pr6	3207	18	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3207	19	)	)	-RRB-
cord-005478-5iu38pr6	3207	20	in	in	IN
cord-005478-5iu38pr6	3207	21	MSD	MSD	NNP
cord-005478-5iu38pr6	3207	22	cohort	cohort	NN
cord-005478-5iu38pr6	3207	23	(	(	-LRB-
cord-005478-5iu38pr6	3207	24	13	13	CD
cord-005478-5iu38pr6	3207	25	%	%	NN
cord-005478-5iu38pr6	3207	26	)	)	-RRB-
cord-005478-5iu38pr6	3207	27	was	be	VBD
cord-005478-5iu38pr6	3207	28	significantly	significantly	RB
cord-005478-5iu38pr6	3207	29	lower	low	JJR
cord-005478-5iu38pr6	3207	30	than	than	IN
cord-005478-5iu38pr6	3207	31	in	in	IN
cord-005478-5iu38pr6	3207	32	HID	HID	NNP
cord-005478-5iu38pr6	3207	33	group	group	NN
cord-005478-5iu38pr6	3207	34	(	(	-LRB-
cord-005478-5iu38pr6	3207	35	35	35	CD
cord-005478-5iu38pr6	3207	36	%	%	NN
cord-005478-5iu38pr6	3207	37	,	,	,
cord-005478-5iu38pr6	3207	38	P=0.048	P=0.048	NNP
cord-005478-5iu38pr6	3207	39	)	)	-RRB-
cord-005478-5iu38pr6	3207	40	;	;	:
cord-005478-5iu38pr6	3207	41	the	the	DT
cord-005478-5iu38pr6	3207	42	incidence	incidence	NN
cord-005478-5iu38pr6	3207	43	of	of	IN
cord-005478-5iu38pr6	3207	44	chronic	chronic	JJ
cord-005478-5iu38pr6	3207	45	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3207	46	was	be	VBD
cord-005478-5iu38pr6	3207	47	comparable	comparable	JJ
cord-005478-5iu38pr6	3207	48	between	between	IN
cord-005478-5iu38pr6	3207	49	the	the	DT
cord-005478-5iu38pr6	3207	50	two	two	CD
cord-005478-5iu38pr6	3207	51	groups	group	NNS
cord-005478-5iu38pr6	3207	52	.	.	.
cord-005478-5iu38pr6	3208	1	The	the	DT
cord-005478-5iu38pr6	3208	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3208	3	incidence	incidence	NN
cord-005478-5iu38pr6	3208	4	of	of	IN
cord-005478-5iu38pr6	3208	5	relapse	relapse	NN
cord-005478-5iu38pr6	3208	6	in	in	IN
cord-005478-5iu38pr6	3208	7	MSD	MSD	NNP
cord-005478-5iu38pr6	3208	8	cohort	cohort	NN
cord-005478-5iu38pr6	3208	9	(	(	-LRB-
cord-005478-5iu38pr6	3208	10	39	39	CD
cord-005478-5iu38pr6	3208	11	%	%	NN
cord-005478-5iu38pr6	3208	12	)	)	-RRB-
cord-005478-5iu38pr6	3208	13	was	be	VBD
cord-005478-5iu38pr6	3208	14	significantly	significantly	RB
cord-005478-5iu38pr6	3208	15	higher	high	JJR
cord-005478-5iu38pr6	3208	16	than	than	IN
cord-005478-5iu38pr6	3208	17	in	in	IN
cord-005478-5iu38pr6	3208	18	HID	HID	NNP
cord-005478-5iu38pr6	3208	19	group	group	NN
cord-005478-5iu38pr6	3208	20	(	(	-LRB-
cord-005478-5iu38pr6	3208	21	16	16	CD
cord-005478-5iu38pr6	3208	22	%	%	NN
cord-005478-5iu38pr6	3208	23	,	,	,
cord-005478-5iu38pr6	3208	24	P=0.037	P=0.037	NNP
cord-005478-5iu38pr6	3208	25	)	)	-RRB-
cord-005478-5iu38pr6	3208	26	;	;	:
cord-005478-5iu38pr6	3208	27	the	the	DT
cord-005478-5iu38pr6	3208	28	incidence	incidence	NN
cord-005478-5iu38pr6	3208	29	of	of	IN
cord-005478-5iu38pr6	3208	30	NRM	NRM	NNP
cord-005478-5iu38pr6	3208	31	was	be	VBD
cord-005478-5iu38pr6	3208	32	0	0	CD
cord-005478-5iu38pr6	3208	33	and	and	CC
cord-005478-5iu38pr6	3208	34	10	10	CD
cord-005478-5iu38pr6	3208	35	%	%	NN
cord-005478-5iu38pr6	3208	36	(	(	-LRB-
cord-005478-5iu38pr6	3208	37	p=0.12	p=0.12	NN
cord-005478-5iu38pr6	3208	38	)	)	-RRB-
cord-005478-5iu38pr6	3208	39	,	,	,
cord-005478-5iu38pr6	3208	40	respectively	respectively	RB
cord-005478-5iu38pr6	3208	41	.	.	.
cord-005478-5iu38pr6	3209	1	The	the	DT
cord-005478-5iu38pr6	3209	2	3-year	3-year	CD
cord-005478-5iu38pr6	3209	3	overall	overall	JJ
cord-005478-5iu38pr6	3209	4	survival	survival	NN
cord-005478-5iu38pr6	3209	5	(	(	-LRB-
cord-005478-5iu38pr6	3209	6	65	65	CD
cord-005478-5iu38pr6	3209	7	%	%	NN
cord-005478-5iu38pr6	3209	8	versus	versus	IN
cord-005478-5iu38pr6	3209	9	75	75	CD
cord-005478-5iu38pr6	3209	10	%	%	NN
cord-005478-5iu38pr6	3209	11	,	,	,
cord-005478-5iu38pr6	3209	12	P=0.68	p=0.68	NN
cord-005478-5iu38pr6	3209	13	)	)	-RRB-
cord-005478-5iu38pr6	3209	14	and	and	CC
cord-005478-5iu38pr6	3209	15	leukemia	leukemia	NN
cord-005478-5iu38pr6	3209	16	free	free	JJ
cord-005478-5iu38pr6	3209	17	survival	survival	NN
cord-005478-5iu38pr6	3209	18	(	(	-LRB-
cord-005478-5iu38pr6	3209	19	61	61	CD
cord-005478-5iu38pr6	3209	20	%	%	NN
cord-005478-5iu38pr6	3209	21	versus73	versus73	NN
cord-005478-5iu38pr6	3209	22	%	%	NN
cord-005478-5iu38pr6	3209	23	,	,	,
cord-005478-5iu38pr6	3209	24	P=0.29	p=0.29	CD
cord-005478-5iu38pr6	3209	25	)	)	-RRB-
cord-005478-5iu38pr6	3209	26	were	be	VBD
cord-005478-5iu38pr6	3209	27	comparable	comparable	JJ
cord-005478-5iu38pr6	3209	28	in	in	IN
cord-005478-5iu38pr6	3209	29	MSD	MSD	NNP
cord-005478-5iu38pr6	3209	30	-	-	HYPH
cord-005478-5iu38pr6	3209	31	HCT	HCT	NNP
cord-005478-5iu38pr6	3209	32	compared	compare	VBN
cord-005478-5iu38pr6	3209	33	with	with	IN
cord-005478-5iu38pr6	3209	34	HID	HID	NNP
cord-005478-5iu38pr6	3209	35	-	-	HYPH
cord-005478-5iu38pr6	3209	36	HCT	HCT	NNP
cord-005478-5iu38pr6	3209	37	.	.	.
cord-005478-5iu38pr6	3210	1	In	in	IN
cord-005478-5iu38pr6	3210	2	a	a	DT
cord-005478-5iu38pr6	3210	3	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3210	4	analysis	analysis	NN
cord-005478-5iu38pr6	3210	5	,	,	,
cord-005478-5iu38pr6	3210	6	HID	HID	NNP
cord-005478-5iu38pr6	3210	7	-	-	HYPH
cord-005478-5iu38pr6	3210	8	HCT	HCT	NNP
cord-005478-5iu38pr6	3210	9	remained	remain	VBD
cord-005478-5iu38pr6	3210	10	a	a	DT
cord-005478-5iu38pr6	3210	11	significant	significant	JJ
cord-005478-5iu38pr6	3210	12	factor	factor	NN
cord-005478-5iu38pr6	3210	13	for	for	IN
cord-005478-5iu38pr6	3210	14	reduced	reduce	VBN
cord-005478-5iu38pr6	3210	15	relapse	relapse	NN
cord-005478-5iu38pr6	3210	16	rate	rate	NN
cord-005478-5iu38pr6	3210	17	(	(	-LRB-
cord-005478-5iu38pr6	3210	18	HR	hr	NN
cord-005478-5iu38pr6	3210	19	0.259(0.092	0.259(0.092	CD
cord-005478-5iu38pr6	3210	20	-	-	HYPH
cord-005478-5iu38pr6	3210	21	0.731	0.731	CD
cord-005478-5iu38pr6	3210	22	)	)	-RRB-
cord-005478-5iu38pr6	3210	23	,	,	,
cord-005478-5iu38pr6	3210	24	P=	P=	NNP
cord-005478-5iu38pr6	3210	25	0.011	0.011	CD
cord-005478-5iu38pr6	3210	26	)	)	-RRB-
cord-005478-5iu38pr6	3210	27	in	in	IN
cord-005478-5iu38pr6	3210	28	comparison	comparison	NN
cord-005478-5iu38pr6	3210	29	with	with	IN
cord-005478-5iu38pr6	3210	30	MSD	MSD	NNP
cord-005478-5iu38pr6	3210	31	-	-	HYPH
cord-005478-5iu38pr6	3210	32	HCT	HCT	NNP
cord-005478-5iu38pr6	3210	33	.	.	.
cord-005478-5iu38pr6	3211	1	In	in	IN
cord-005478-5iu38pr6	3211	2	subgroup	subgroup	NN
cord-005478-5iu38pr6	3211	3	analysis	analysis	NN
cord-005478-5iu38pr6	3211	4	for	for	IN
cord-005478-5iu38pr6	3211	5	patients	patient	NNS
cord-005478-5iu38pr6	3211	6	with	with	IN
cord-005478-5iu38pr6	3211	7	known	know	VBN
cord-005478-5iu38pr6	3211	8	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	3211	9	and	and	CC
cord-005478-5iu38pr6	3211	10	transplanted	transplant	VBN
cord-005478-5iu38pr6	3211	11	in	in	IN
cord-005478-5iu38pr6	3211	12	the	the	DT
cord-005478-5iu38pr6	3211	13	first	first	JJ
cord-005478-5iu38pr6	3211	14	complete	complete	JJ
cord-005478-5iu38pr6	3211	15	remission	remission	NN
cord-005478-5iu38pr6	3211	16	(	(	-LRB-
cord-005478-5iu38pr6	3211	17	n=58	n=58	NN
cord-005478-5iu38pr6	3211	18	)	)	-RRB-
cord-005478-5iu38pr6	3211	19	,	,	,
cord-005478-5iu38pr6	3211	20	the	the	DT
cord-005478-5iu38pr6	3211	21	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3211	22	incidence	incidence	NN
cord-005478-5iu38pr6	3211	23	of	of	IN
cord-005478-5iu38pr6	3211	24	relapse	relapse	NN
cord-005478-5iu38pr6	3211	25	in	in	IN
cord-005478-5iu38pr6	3211	26	MSD	MSD	NNP
cord-005478-5iu38pr6	3211	27	cohort	cohort	NN
cord-005478-5iu38pr6	3211	28	(	(	-LRB-
cord-005478-5iu38pr6	3211	29	50	50	CD
cord-005478-5iu38pr6	3211	30	%	%	NN
cord-005478-5iu38pr6	3211	31	,	,	,
cord-005478-5iu38pr6	3211	32	n=14	n=14	NNP
cord-005478-5iu38pr6	3211	33	)	)	-RRB-
cord-005478-5iu38pr6	3211	34	was	be	VBD
cord-005478-5iu38pr6	3211	35	significantly	significantly	RB
cord-005478-5iu38pr6	3211	36	higher	high	JJR
cord-005478-5iu38pr6	3211	37	than	than	IN
cord-005478-5iu38pr6	3211	38	in	in	IN
cord-005478-5iu38pr6	3211	39	HID	HID	NNP
cord-005478-5iu38pr6	3211	40	group	group	NN
cord-005478-5iu38pr6	3211	41	(	(	-LRB-
cord-005478-5iu38pr6	3211	42	9	9	CD
cord-005478-5iu38pr6	3211	43	%	%	NN
cord-005478-5iu38pr6	3211	44	,	,	,
cord-005478-5iu38pr6	3211	45	n=44	n=44	NNP
cord-005478-5iu38pr6	3211	46	,	,	,
cord-005478-5iu38pr6	3211	47	P=0.001	P=0.001	NNP
cord-005478-5iu38pr6	3211	48	)	)	-RRB-
cord-005478-5iu38pr6	3211	49	;	;	:
cord-005478-5iu38pr6	3211	50	and	and	CC
cord-005478-5iu38pr6	3211	51	leukemia	leukemia	NN
cord-005478-5iu38pr6	3211	52	free	free	JJ
cord-005478-5iu38pr6	3211	53	survival	survival	NN
cord-005478-5iu38pr6	3211	54	(	(	-LRB-
cord-005478-5iu38pr6	3211	55	50	50	CD
cord-005478-5iu38pr6	3211	56	%	%	NN
cord-005478-5iu38pr6	3211	57	versus	versus	IN
cord-005478-5iu38pr6	3211	58	81	81	CD
cord-005478-5iu38pr6	3211	59	%	%	NN
cord-005478-5iu38pr6	3211	60	,	,	,
cord-005478-5iu38pr6	3211	61	P=0.021	P=0.021	NNP
cord-005478-5iu38pr6	3211	62	)	)	-RRB-
cord-005478-5iu38pr6	3211	63	were	be	VBD
cord-005478-5iu38pr6	3211	64	significantly	significantly	RB
cord-005478-5iu38pr6	3211	65	lower	low	JJR
cord-005478-5iu38pr6	3211	66	in	in	IN
cord-005478-5iu38pr6	3211	67	MSD	MSD	NNP
cord-005478-5iu38pr6	3211	68	-	-	HYPH
cord-005478-5iu38pr6	3211	69	HCT	HCT	NNP
cord-005478-5iu38pr6	3211	70	compared	compare	VBN
cord-005478-5iu38pr6	3211	71	with	with	IN
cord-005478-5iu38pr6	3211	72	HID	HID	NNP
cord-005478-5iu38pr6	3211	73	-	-	HYPH
cord-005478-5iu38pr6	3211	74	HCT	HCT	NNP
cord-005478-5iu38pr6	3211	75	.	.	.
cord-005478-5iu38pr6	3212	1	In	in	IN
cord-005478-5iu38pr6	3212	2	a	a	DT
cord-005478-5iu38pr6	3212	3	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3212	4	analysis	analysis	NN
cord-005478-5iu38pr6	3212	5	among	among	IN
cord-005478-5iu38pr6	3212	6	these	these	DT
cord-005478-5iu38pr6	3212	7	subgroup	subgroup	NN
cord-005478-5iu38pr6	3212	8	of	of	IN
cord-005478-5iu38pr6	3212	9	patients	patient	NNS
cord-005478-5iu38pr6	3212	10	,	,	,
cord-005478-5iu38pr6	3212	11	HID	HID	NNP
cord-005478-5iu38pr6	3212	12	-	-	HYPH
cord-005478-5iu38pr6	3212	13	HCT	HCT	NNP
cord-005478-5iu38pr6	3212	14	remained	remain	VBD
cord-005478-5iu38pr6	3212	15	a	a	DT
cord-005478-5iu38pr6	3212	16	significant	significant	JJ
cord-005478-5iu38pr6	3212	17	factor	factor	NN
cord-005478-5iu38pr6	3212	18	for	for	IN
cord-005478-5iu38pr6	3212	19	increased	increased	JJ
cord-005478-5iu38pr6	3212	20	LFS	lfs	NN
cord-005478-5iu38pr6	3212	21	(	(	-LRB-
cord-005478-5iu38pr6	3212	22	HR	HR	NNP
cord-005478-5iu38pr6	3212	23	0.304(0.102	0.304(0.102	CD
cord-005478-5iu38pr6	3212	24	-	-	HYPH
cord-005478-5iu38pr6	3212	25	0.905	0.905	CD
cord-005478-5iu38pr6	3212	26	)	)	-RRB-
cord-005478-5iu38pr6	3212	27	,	,	,
cord-005478-5iu38pr6	3212	28	P=	P=	NNP
cord-005478-5iu38pr6	3212	29	0.032	0.032	CD
cord-005478-5iu38pr6	3212	30	)	)	-RRB-
cord-005478-5iu38pr6	3213	1	in	in	IN
cord-005478-5iu38pr6	3213	2	comparison	comparison	NN
cord-005478-5iu38pr6	3213	3	with	with	IN
cord-005478-5iu38pr6	3213	4	MSD	MSD	NNP
cord-005478-5iu38pr6	3213	5	-	-	HYPH
cord-005478-5iu38pr6	3213	6	HCT	HCT	NNP
cord-005478-5iu38pr6	3213	7	.	.	.
cord-005478-5iu38pr6	3214	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3214	2	:	:	:
cord-005478-5iu38pr6	3215	1	In	in	IN
cord-005478-5iu38pr6	3215	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	3215	3	,	,	,
cord-005478-5iu38pr6	3215	4	unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	3215	5	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3215	6	-	-	HYPH
cord-005478-5iu38pr6	3215	7	HCT	HCT	NNP
cord-005478-5iu38pr6	3215	8	achieves	achieve	VBZ
cord-005478-5iu38pr6	3215	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	3215	10	comparable	comparable	JJ
cord-005478-5iu38pr6	3215	11	to	to	IN
cord-005478-5iu38pr6	3215	12	those	those	DT
cord-005478-5iu38pr6	3215	13	of	of	IN
cord-005478-5iu38pr6	3215	14	ISD	ISD	NNP
cord-005478-5iu38pr6	3215	15	-	-	HYPH
cord-005478-5iu38pr6	3215	16	HCT	HCT	NNP
cord-005478-5iu38pr6	3215	17	for	for	IN
cord-005478-5iu38pr6	3215	18	high	high	JJ
cord-005478-5iu38pr6	3215	19	-	-	HYPH
cord-005478-5iu38pr6	3215	20	risk	risk	NN
cord-005478-5iu38pr6	3215	21	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3215	22	AML	AML	NNP
cord-005478-5iu38pr6	3215	23	patients	patient	NNS
cord-005478-5iu38pr6	3215	24	and	and	CC
cord-005478-5iu38pr6	3215	25	even	even	RB
cord-005478-5iu38pr6	3215	26	exerts	exert	VBZ
cord-005478-5iu38pr6	3215	27	greater	great	JJR
cord-005478-5iu38pr6	3215	28	GVL	GVL	NNP
cord-005478-5iu38pr6	3215	29	effect	effect	NN
cord-005478-5iu38pr6	3215	30	in	in	IN
cord-005478-5iu38pr6	3215	31	some	some	DT
cord-005478-5iu38pr6	3215	32	circumstances	circumstance	NNS
cord-005478-5iu38pr6	3215	33	.	.	.
cord-005478-5iu38pr6	3216	1	Such	such	JJ
cord-005478-5iu38pr6	3216	2	transplantation	transplantation	NN
cord-005478-5iu38pr6	3216	3	was	be	VBD
cord-005478-5iu38pr6	3216	4	proved	prove	VBN
cord-005478-5iu38pr6	3216	5	to	to	TO
cord-005478-5iu38pr6	3216	6	be	be	VB
cord-005478-5iu38pr6	3216	7	a	a	DT
cord-005478-5iu38pr6	3216	8	valid	valid	JJ
cord-005478-5iu38pr6	3216	9	alternative	alternative	JJ
cord-005478-5iu38pr6	3216	10	treatment	treatment	NN
cord-005478-5iu38pr6	3216	11	for	for	IN
cord-005478-5iu38pr6	3216	12	high	high	JJ
cord-005478-5iu38pr6	3216	13	-	-	HYPH
cord-005478-5iu38pr6	3216	14	risk	risk	NN
cord-005478-5iu38pr6	3216	15	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3216	16	AML	AML	NNP
cord-005478-5iu38pr6	3216	17	patients	patient	NNS
cord-005478-5iu38pr6	3216	18	lacking	lack	VBG
cord-005478-5iu38pr6	3216	19	a	a	DT
cord-005478-5iu38pr6	3216	20	matched	match	VBN
cord-005478-5iu38pr6	3216	21	donor	donor	NN
cord-005478-5iu38pr6	3216	22	.	.	.
cord-005478-5iu38pr6	3217	1	Larger	large	JJR
cord-005478-5iu38pr6	3217	2	prospective	prospective	JJ
cord-005478-5iu38pr6	3217	3	studies	study	NNS
cord-005478-5iu38pr6	3217	4	are	be	VBP
cord-005478-5iu38pr6	3217	5	needed	need	VBN
cord-005478-5iu38pr6	3217	6	to	to	TO
cord-005478-5iu38pr6	3217	7	confirm	confirm	VB
cord-005478-5iu38pr6	3217	8	these	these	DT
cord-005478-5iu38pr6	3217	9	findings	finding	NNS
cord-005478-5iu38pr6	3217	10	.	.	.
cord-005478-5iu38pr6	3218	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3218	2	:	:	:
cord-005478-5iu38pr6	3218	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3218	4	to	to	TO
cord-005478-5iu38pr6	3218	5	declare	declare	VB
cord-005478-5iu38pr6	3218	6	.	.	.
cord-005478-5iu38pr6	3219	1	Background	background	NN
cord-005478-5iu38pr6	3219	2	:	:	:
cord-005478-5iu38pr6	3220	1	Allogeneic	allogeneic	IN
cord-005478-5iu38pr6	3220	2	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3220	3	stem	stem	NN
cord-005478-5iu38pr6	3220	4	cell	cell	NN
cord-005478-5iu38pr6	3220	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	3220	6	(	(	-LRB-
cord-005478-5iu38pr6	3220	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3220	8	)	)	-RRB-
cord-005478-5iu38pr6	3220	9	is	be	VBZ
cord-005478-5iu38pr6	3220	10	the	the	DT
cord-005478-5iu38pr6	3220	11	only	only	JJ
cord-005478-5iu38pr6	3220	12	curative	curative	JJ
cord-005478-5iu38pr6	3220	13	option	option	NN
cord-005478-5iu38pr6	3220	14	for	for	IN
cord-005478-5iu38pr6	3220	15	patients	patient	NNS
cord-005478-5iu38pr6	3220	16	with	with	IN
cord-005478-5iu38pr6	3220	17	beta	beta	NN
cord-005478-5iu38pr6	3220	18	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3220	19	major	major	NN
cord-005478-5iu38pr6	3220	20	.	.	.
cord-005478-5iu38pr6	3221	1	Although	although	IN
cord-005478-5iu38pr6	3221	2	limited	limited	JJ
cord-005478-5iu38pr6	3221	3	study	study	NN
cord-005478-5iu38pr6	3221	4	in	in	IN
cord-005478-5iu38pr6	3221	5	the	the	DT
cord-005478-5iu38pr6	3221	6	literature	literature	NN
cord-005478-5iu38pr6	3221	7	has	have	VBZ
cord-005478-5iu38pr6	3221	8	evaluated	evaluate	VBN
cord-005478-5iu38pr6	3221	9	the	the	DT
cord-005478-5iu38pr6	3221	10	impact	impact	NN
cord-005478-5iu38pr6	3221	11	of	of	IN
cord-005478-5iu38pr6	3221	12	age	age	NN
cord-005478-5iu38pr6	3221	13	on	on	IN
cord-005478-5iu38pr6	3221	14	success	success	NN
cord-005478-5iu38pr6	3221	15	of	of	IN
cord-005478-5iu38pr6	3221	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	3221	17	,	,	,
cord-005478-5iu38pr6	3221	18	more	more	JJR
cord-005478-5iu38pr6	3221	19	data	datum	NNS
cord-005478-5iu38pr6	3221	20	are	be	VBP
cord-005478-5iu38pr6	3221	21	needed	need	VBN
cord-005478-5iu38pr6	3221	22	.	.	.
cord-005478-5iu38pr6	3222	1	In	in	IN
cord-005478-5iu38pr6	3222	2	this	this	DT
cord-005478-5iu38pr6	3222	3	study	study	NN
cord-005478-5iu38pr6	3222	4	,	,	,
cord-005478-5iu38pr6	3222	5	we	-PRON-	PRP
cord-005478-5iu38pr6	3222	6	aimed	aim	VBD
cord-005478-5iu38pr6	3222	7	to	to	TO
cord-005478-5iu38pr6	3222	8	evaluate	evaluate	VB
cord-005478-5iu38pr6	3222	9	the	the	DT
cord-005478-5iu38pr6	3222	10	effect	effect	NN
cord-005478-5iu38pr6	3222	11	of	of	IN
cord-005478-5iu38pr6	3222	12	age	age	NN
cord-005478-5iu38pr6	3222	13	of	of	IN
cord-005478-5iu38pr6	3222	14	the	the	DT
cord-005478-5iu38pr6	3222	15	patients	patient	NNS
cord-005478-5iu38pr6	3222	16	on	on	IN
cord-005478-5iu38pr6	3222	17	transplant	transplant	NN
cord-005478-5iu38pr6	3222	18	outcome	outcome	NN
cord-005478-5iu38pr6	3222	19	in	in	IN
cord-005478-5iu38pr6	3222	20	cases	case	NNS
cord-005478-5iu38pr6	3222	21	who	who	WP
cord-005478-5iu38pr6	3222	22	underwent	undergo	VBD
cord-005478-5iu38pr6	3222	23	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3222	24	with	with	IN
cord-005478-5iu38pr6	3222	25	the	the	DT
cord-005478-5iu38pr6	3222	26	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3222	27	of	of	IN
cord-005478-5iu38pr6	3222	28	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3222	29	major	major	NN
cord-005478-5iu38pr6	3222	30	.	.	.
cord-005478-5iu38pr6	3223	1	Methods	method	NNS
cord-005478-5iu38pr6	3223	2	:	:	:
cord-005478-5iu38pr6	3224	1	All	all	DT
cord-005478-5iu38pr6	3224	2	cases	case	NNS
cord-005478-5iu38pr6	3224	3	who	who	WP
cord-005478-5iu38pr6	3224	4	underwent	undergo	VBD
cord-005478-5iu38pr6	3224	5	stem	stem	NN
cord-005478-5iu38pr6	3224	6	cell	cell	NN
cord-005478-5iu38pr6	3224	7	transplantation	transplantation	NN
cord-005478-5iu38pr6	3224	8	with	with	IN
cord-005478-5iu38pr6	3224	9	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3224	10	major	major	NN
cord-005478-5iu38pr6	3224	11	were	be	VBD
cord-005478-5iu38pr6	3224	12	included	include	VBN
cord-005478-5iu38pr6	3224	13	.	.	.
cord-005478-5iu38pr6	3225	1	All	all	DT
cord-005478-5iu38pr6	3225	2	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3225	3	major	major	JJ
cord-005478-5iu38pr6	3225	4	patients	patient	NNS
cord-005478-5iu38pr6	3225	5	with	with	IN
cord-005478-5iu38pr6	3225	6	a	a	DT
cord-005478-5iu38pr6	3225	7	median	median	JJ
cord-005478-5iu38pr6	3225	8	age	age	NN
cord-005478-5iu38pr6	3225	9	of	of	IN
cord-005478-5iu38pr6	3225	10	7	7	CD
cord-005478-5iu38pr6	3225	11	years	year	NNS
cord-005478-5iu38pr6	3225	12	(	(	-LRB-
cord-005478-5iu38pr6	3225	13	range	range	VBP
cord-005478-5iu38pr6	3225	14	7	7	CD
cord-005478-5iu38pr6	3225	15	month,17.7	month,17.7	NNS
cord-005478-5iu38pr6	3225	16	years	year	NNS
cord-005478-5iu38pr6	3225	17	)	)	-RRB-
cord-005478-5iu38pr6	3225	18	underwent	undergo	VBD
cord-005478-5iu38pr6	3225	19	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3225	20	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3225	21	using	use	VBG
cord-005478-5iu38pr6	3225	22	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	3225	23	conditioning	conditioning	NN
cord-005478-5iu38pr6	3225	24	regimen	regimen	NN
cord-005478-5iu38pr6	3225	25	.	.	.
cord-005478-5iu38pr6	3226	1	Cyclosporine	Cyclosporine	NNP
cord-005478-5iu38pr6	3226	2	and	and	CC
cord-005478-5iu38pr6	3226	3	methotrexate	methotrexate	NNP
cord-005478-5iu38pr6	3226	4	were	be	VBD
cord-005478-5iu38pr6	3226	5	used	use	VBN
cord-005478-5iu38pr6	3226	6	as	as	IN
cord-005478-5iu38pr6	3226	7	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3226	8	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3226	9	.	.	.
cord-005478-5iu38pr6	3227	1	In	in	IN
cord-005478-5iu38pr6	3227	2	total	total	NN
cord-005478-5iu38pr6	3227	3	,	,	,
cord-005478-5iu38pr6	3227	4	169	169	CD
cord-005478-5iu38pr6	3227	5	patients	patient	NNS
cord-005478-5iu38pr6	3227	6	underwent	undergo	VBD
cord-005478-5iu38pr6	3227	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3227	8	at	at	IN
cord-005478-5iu38pr6	3227	9	age	age	NN
cord-005478-5iu38pr6	3227	10	younger	young	JJR
cord-005478-5iu38pr6	3227	11	than	than	IN
cord-005478-5iu38pr6	3227	12	7	7	CD
cord-005478-5iu38pr6	3227	13	and	and	CC
cord-005478-5iu38pr6	3227	14	159	159	CD
cord-005478-5iu38pr6	3227	15	patients	patient	NNS
cord-005478-5iu38pr6	3227	16	underwent	undergo	VBD
cord-005478-5iu38pr6	3227	17	at	at	IN
cord-005478-5iu38pr6	3227	18	age	age	NN
cord-005478-5iu38pr6	3227	19	older	old	JJR
cord-005478-5iu38pr6	3227	20	than	than	IN
cord-005478-5iu38pr6	3227	21	7	7	CD
cord-005478-5iu38pr6	3227	22	years	year	NNS
cord-005478-5iu38pr6	3227	23	and	and	CC
cord-005478-5iu38pr6	3227	24	all	all	DT
cord-005478-5iu38pr6	3227	25	patients	patient	NNS
cord-005478-5iu38pr6	3227	26	were	be	VBD
cord-005478-5iu38pr6	3227	27	assigned	assign	VBN
cord-005478-5iu38pr6	3227	28	to	to	IN
cord-005478-5iu38pr6	3227	29	two	two	CD
cord-005478-5iu38pr6	3227	30	different	different	JJ
cord-005478-5iu38pr6	3227	31	groups	group	NNS
cord-005478-5iu38pr6	3227	32	according	accord	VBG
cord-005478-5iu38pr6	3227	33	to	to	IN
cord-005478-5iu38pr6	3227	34	transplantation	transplantation	NN
cord-005478-5iu38pr6	3227	35	age	age	NN
cord-005478-5iu38pr6	3227	36	.	.	.
cord-005478-5iu38pr6	3228	1	The	the	DT
cord-005478-5iu38pr6	3228	2	distribution	distribution	NN
cord-005478-5iu38pr6	3228	3	of	of	IN
cord-005478-5iu38pr6	3228	4	donor	donor	NN
cord-005478-5iu38pr6	3228	5	type	type	NN
cord-005478-5iu38pr6	3228	6	and	and	CC
cord-005478-5iu38pr6	3228	7	stem	stem	NN
cord-005478-5iu38pr6	3228	8	cell	cell	NN
cord-005478-5iu38pr6	3228	9	sources	source	NNS
cord-005478-5iu38pr6	3228	10	by	by	IN
cord-005478-5iu38pr6	3228	11	age	age	NN
cord-005478-5iu38pr6	3228	12	groups	group	NNS
cord-005478-5iu38pr6	3228	13	is	be	VBZ
cord-005478-5iu38pr6	3228	14	shown	show	VBN
cord-005478-5iu38pr6	3228	15	in	in	IN
cord-005478-5iu38pr6	3228	16	Table	Table	NNP
cord-005478-5iu38pr6	3228	17	1	1	CD
cord-005478-5iu38pr6	3228	18	.	.	.
cord-005478-5iu38pr6	3229	1	No	no	DT
cord-005478-5iu38pr6	3229	2	statistical	statistical	JJ
cord-005478-5iu38pr6	3229	3	difference	difference	NN
cord-005478-5iu38pr6	3229	4	was	be	VBD
cord-005478-5iu38pr6	3229	5	found	find	VBN
cord-005478-5iu38pr6	3229	6	between	between	IN
cord-005478-5iu38pr6	3229	7	the	the	DT
cord-005478-5iu38pr6	3229	8	two	two	CD
cord-005478-5iu38pr6	3229	9	age	age	NN
cord-005478-5iu38pr6	3229	10	groups	group	NNS
cord-005478-5iu38pr6	3229	11	in	in	IN
cord-005478-5iu38pr6	3229	12	terms	term	NNS
cord-005478-5iu38pr6	3229	13	of	of	IN
cord-005478-5iu38pr6	3229	14	donor	donor	NN
cord-005478-5iu38pr6	3229	15	type	type	NN
cord-005478-5iu38pr6	3229	16	and	and	CC
cord-005478-5iu38pr6	3229	17	stem	stem	NN
cord-005478-5iu38pr6	3229	18	cell	cell	NN
cord-005478-5iu38pr6	3229	19	source	source	NN
cord-005478-5iu38pr6	3229	20	.	.	.
cord-005478-5iu38pr6	3230	1	Patients	patient	NNS
cord-005478-5iu38pr6	3230	2	in	in	IN
cord-005478-5iu38pr6	3230	3	two	two	CD
cord-005478-5iu38pr6	3230	4	different	different	JJ
cord-005478-5iu38pr6	3230	5	age	age	NN
cord-005478-5iu38pr6	3230	6	groups	group	NNS
cord-005478-5iu38pr6	3230	7	were	be	VBD
cord-005478-5iu38pr6	3230	8	compared	compare	VBN
cord-005478-5iu38pr6	3230	9	with	with	IN
cord-005478-5iu38pr6	3230	10	cox	cox	NNP
cord-005478-5iu38pr6	3230	11	regression	regression	NN
cord-005478-5iu38pr6	3230	12	analysis	analysis	NN
cord-005478-5iu38pr6	3230	13	in	in	IN
cord-005478-5iu38pr6	3230	14	terms	term	NNS
cord-005478-5iu38pr6	3230	15	of	of	IN
cord-005478-5iu38pr6	3230	16	overall	overall	JJ
cord-005478-5iu38pr6	3230	17	survival	survival	NN
cord-005478-5iu38pr6	3230	18	,	,	,
cord-005478-5iu38pr6	3230	19	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3230	20	free	free	JJ
cord-005478-5iu38pr6	3230	21	survival	survival	NN
cord-005478-5iu38pr6	3230	22	and	and	CC
cord-005478-5iu38pr6	3230	23	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3230	24	-	-	HYPH
cord-005478-5iu38pr6	3230	25	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3230	26	free	free	JJ
cord-005478-5iu38pr6	3230	27	survival	survival	NN
cord-005478-5iu38pr6	3230	28	.	.	.
cord-005478-5iu38pr6	3231	1	Results	result	NNS
cord-005478-5iu38pr6	3231	2	:	:	:
cord-005478-5iu38pr6	3232	1	A	a	DT
cord-005478-5iu38pr6	3232	2	total	total	NN
cord-005478-5iu38pr6	3232	3	of	of	IN
cord-005478-5iu38pr6	3232	4	299	299	CD
cord-005478-5iu38pr6	3232	5	patients	patient	NNS
cord-005478-5iu38pr6	3232	6	;	;	:
cord-005478-5iu38pr6	3232	7	162	162	CD
cord-005478-5iu38pr6	3232	8	patients	patient	NNS
cord-005478-5iu38pr6	3232	9	under	under	IN
cord-005478-5iu38pr6	3232	10	7	7	CD
cord-005478-5iu38pr6	3232	11	years	year	NNS
cord-005478-5iu38pr6	3232	12	of	of	IN
cord-005478-5iu38pr6	3232	13	age	age	NN
cord-005478-5iu38pr6	3232	14	,	,	,
cord-005478-5iu38pr6	3232	15	137	137	CD
cord-005478-5iu38pr6	3232	16	patients	patient	NNS
cord-005478-5iu38pr6	3232	17	aged	age	VBN
cord-005478-5iu38pr6	3232	18	7	7	CD
cord-005478-5iu38pr6	3232	19	and	and	CC
cord-005478-5iu38pr6	3232	20	over	over	RB
cord-005478-5iu38pr6	3232	21	,	,	,
cord-005478-5iu38pr6	3232	22	were	be	VBD
cord-005478-5iu38pr6	3232	23	engrafted	engraft	VBN
cord-005478-5iu38pr6	3232	24	and	and	CC
cord-005478-5iu38pr6	3232	25	remained	remain	VBD
cord-005478-5iu38pr6	3232	26	transfusion	transfusion	NN
cord-005478-5iu38pr6	3232	27	independent	independent	JJ
cord-005478-5iu38pr6	3232	28	with	with	IN
cord-005478-5iu38pr6	3232	29	full	full	JJ
cord-005478-5iu38pr6	3232	30	or	or	CC
cord-005478-5iu38pr6	3232	31	mixed	mixed	JJ
cord-005478-5iu38pr6	3232	32	chimerism	chimerism	NN
cord-005478-5iu38pr6	3232	33	.	.	.
cord-005478-5iu38pr6	3233	1	Four	four	CD
cord-005478-5iu38pr6	3233	2	patients	patient	NNS
cord-005478-5iu38pr6	3233	3	,	,	,
cord-005478-5iu38pr6	3233	4	two	two	CD
cord-005478-5iu38pr6	3233	5	from	from	IN
cord-005478-5iu38pr6	3233	6	each	each	DT
cord-005478-5iu38pr6	3233	7	age	age	NN
cord-005478-5iu38pr6	3233	8	group	group	NN
cord-005478-5iu38pr6	3233	9	,	,	,
cord-005478-5iu38pr6	3233	10	did	do	VBD
cord-005478-5iu38pr6	3233	11	not	not	RB
cord-005478-5iu38pr6	3233	12	engrafted	engraft	VBN
cord-005478-5iu38pr6	3233	13	and	and	CC
cord-005478-5iu38pr6	3233	14	had	have	VBD
cord-005478-5iu38pr6	3233	15	primary	primary	JJ
cord-005478-5iu38pr6	3233	16	rejection	rejection	NN
cord-005478-5iu38pr6	3233	17	.	.	.
cord-005478-5iu38pr6	3234	1	Four	four	CD
cord-005478-5iu38pr6	3234	2	patients	patient	NNS
cord-005478-5iu38pr6	3234	3	under	under	IN
cord-005478-5iu38pr6	3234	4	seven	seven	CD
cord-005478-5iu38pr6	3234	5	years	year	NNS
cord-005478-5iu38pr6	3234	6	of	of	IN
cord-005478-5iu38pr6	3234	7	age	age	NN
cord-005478-5iu38pr6	3234	8	developed	develop	VBD
cord-005478-5iu38pr6	3234	9	secondary	secondary	JJ
cord-005478-5iu38pr6	3234	10	rejection	rejection	NN
cord-005478-5iu38pr6	3234	11	,	,	,
cord-005478-5iu38pr6	3234	12	whereas	whereas	IN
cord-005478-5iu38pr6	3234	13	in	in	IN
cord-005478-5iu38pr6	3234	14	the	the	DT
cord-005478-5iu38pr6	3234	15	group	group	NN
cord-005478-5iu38pr6	3234	16	of	of	IN
cord-005478-5iu38pr6	3234	17	patients	patient	NNS
cord-005478-5iu38pr6	3234	18	older	old	JJR
cord-005478-5iu38pr6	3234	19	than	than	IN
cord-005478-5iu38pr6	3234	20	7	7	CD
cord-005478-5iu38pr6	3234	21	years	year	NNS
cord-005478-5iu38pr6	3234	22	of	of	IN
cord-005478-5iu38pr6	3234	23	age	age	NN
cord-005478-5iu38pr6	3234	24	,	,	,
cord-005478-5iu38pr6	3234	25	17	17	CD
cord-005478-5iu38pr6	3234	26	patients	patient	NNS
cord-005478-5iu38pr6	3234	27	experienced	experience	VBD
cord-005478-5iu38pr6	3234	28	secondary	secondary	JJ
cord-005478-5iu38pr6	3234	29	rejection	rejection	NN
cord-005478-5iu38pr6	3234	30	(	(	-LRB-
cord-005478-5iu38pr6	3234	31	p	p	NN
cord-005478-5iu38pr6	3234	32	<	<	XX
cord-005478-5iu38pr6	3234	33	0.05	0.05	CD
cord-005478-5iu38pr6	3234	34	)	)	-RRB-
cord-005478-5iu38pr6	3234	35	.	.	.
cord-005478-5iu38pr6	3235	1	A	a	DT
cord-005478-5iu38pr6	3235	2	total	total	NN
cord-005478-5iu38pr6	3235	3	of	of	IN
cord-005478-5iu38pr6	3235	4	42	42	CD
cord-005478-5iu38pr6	3235	5	patients	patient	NNS
cord-005478-5iu38pr6	3235	6	developed	develop	VBD
cord-005478-5iu38pr6	3235	7	acute	acute	JJ
cord-005478-5iu38pr6	3235	8	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3235	9	(	(	-LRB-
cord-005478-5iu38pr6	3235	10	12.8	12.8	CD
cord-005478-5iu38pr6	3235	11	%	%	NN
cord-005478-5iu38pr6	3235	12	)	)	-RRB-
cord-005478-5iu38pr6	3235	13	and	and	CC
cord-005478-5iu38pr6	3235	14	their	-PRON-	PRP$
cord-005478-5iu38pr6	3235	15	rates	rate	NNS
cord-005478-5iu38pr6	3235	16	were	be	VBD
cord-005478-5iu38pr6	3235	17	similar	similar	JJ
cord-005478-5iu38pr6	3235	18	in	in	IN
cord-005478-5iu38pr6	3235	19	both	both	DT
cord-005478-5iu38pr6	3235	20	age	age	NN
cord-005478-5iu38pr6	3235	21	groups	group	NNS
cord-005478-5iu38pr6	3235	22	(	(	-LRB-
cord-005478-5iu38pr6	3235	23	10.6	10.6	CD
cord-005478-5iu38pr6	3235	24	%	%	NN
cord-005478-5iu38pr6	3235	25	vs	vs	IN
cord-005478-5iu38pr6	3235	26	15	15	CD
cord-005478-5iu38pr6	3235	27	%	%	NN
cord-005478-5iu38pr6	3235	28	)	)	-RRB-
cord-005478-5iu38pr6	3235	29	.	.	.
cord-005478-5iu38pr6	3236	1	Chronic	chronic	JJ
cord-005478-5iu38pr6	3236	2	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3236	3	development	development	NN
cord-005478-5iu38pr6	3236	4	rates	rate	NNS
cord-005478-5iu38pr6	3236	5	in	in	IN
cord-005478-5iu38pr6	3236	6	two	two	CD
cord-005478-5iu38pr6	3236	7	group	group	NN
cord-005478-5iu38pr6	3236	8	was	be	VBD
cord-005478-5iu38pr6	3236	9	also	also	RB
cord-005478-5iu38pr6	3236	10	similar	similar	JJ
cord-005478-5iu38pr6	3236	11	(	(	-LRB-
cord-005478-5iu38pr6	3236	12	9	9	CD
cord-005478-5iu38pr6	3236	13	%	%	NN
cord-005478-5iu38pr6	3236	14	vs	vs	IN
cord-005478-5iu38pr6	3236	15	7	7	CD
cord-005478-5iu38pr6	3236	16	%	%	NN
cord-005478-5iu38pr6	3236	17	)	)	-RRB-
cord-005478-5iu38pr6	3236	18	.	.	.
cord-005478-5iu38pr6	3237	1	The	the	DT
cord-005478-5iu38pr6	3237	2	median	median	JJ
cord-005478-5iu38pr6	3237	3	follow	follow	NN
cord-005478-5iu38pr6	3237	4	-	-	HYPH
cord-005478-5iu38pr6	3237	5	up	up	RP
cord-005478-5iu38pr6	3237	6	time	time	NN
cord-005478-5iu38pr6	3237	7	was	be	VBD
cord-005478-5iu38pr6	3237	8	34	34	CD
cord-005478-5iu38pr6	3237	9	months	month	NNS
cord-005478-5iu38pr6	3237	10	(	(	-LRB-
cord-005478-5iu38pr6	3237	11	range	range	VBP
cord-005478-5iu38pr6	3237	12	0.5	0.5	CD
cord-005478-5iu38pr6	3237	13	-	-	HYPH
cord-005478-5iu38pr6	3237	14	93	93	CD
cord-005478-5iu38pr6	3237	15	months	month	NNS
cord-005478-5iu38pr6	3237	16	)	)	-RRB-
cord-005478-5iu38pr6	3237	17	.	.	.
cord-005478-5iu38pr6	3238	1	The	the	DT
cord-005478-5iu38pr6	3238	2	3	3	CD
cord-005478-5iu38pr6	3238	3	-year	-year	JJ
cord-005478-5iu38pr6	3238	4	overall	overall	JJ
cord-005478-5iu38pr6	3238	5	survival	survival	NN
cord-005478-5iu38pr6	3238	6	rates	rate	NNS
cord-005478-5iu38pr6	3238	7	(	(	-LRB-
cord-005478-5iu38pr6	3238	8	OS	OS	NNP
cord-005478-5iu38pr6	3238	9	)	)	-RRB-
cord-005478-5iu38pr6	3238	10	,	,	,
cord-005478-5iu38pr6	3238	11	thalasemia	thalasemia	NN
cord-005478-5iu38pr6	3238	12	-	-	HYPH
cord-005478-5iu38pr6	3238	13	free	free	JJ
cord-005478-5iu38pr6	3238	14	survival	survival	NN
cord-005478-5iu38pr6	3238	15	rates	rate	NNS
cord-005478-5iu38pr6	3238	16	(	(	-LRB-
cord-005478-5iu38pr6	3238	17	TFS	TFS	NNP
cord-005478-5iu38pr6	3238	18	)	)	-RRB-
cord-005478-5iu38pr6	3238	19	,	,	,
cord-005478-5iu38pr6	3238	20	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3238	21	-	-	HYPH
cord-005478-5iu38pr6	3238	22	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3238	23	free	free	JJ
cord-005478-5iu38pr6	3238	24	survival	survival	NN
cord-005478-5iu38pr6	3238	25	rates	rate	NNS
cord-005478-5iu38pr6	3238	26	(	(	-LRB-
cord-005478-5iu38pr6	3238	27	DFS	DFS	NNP
cord-005478-5iu38pr6	3238	28	)	)	-RRB-
cord-005478-5iu38pr6	3238	29	were	be	VBD
cord-005478-5iu38pr6	3238	30	shown	show	VBN
cord-005478-5iu38pr6	3238	31	in	in	IN
cord-005478-5iu38pr6	3238	32	the	the	DT
cord-005478-5iu38pr6	3238	33	table	table	NN
cord-005478-5iu38pr6	3238	34	2	2	CD
cord-005478-5iu38pr6	3238	35	.	.	.
cord-005478-5iu38pr6	3239	1	Both	both	DT
cord-005478-5iu38pr6	3239	2	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3239	3	-	-	HYPH
cord-005478-5iu38pr6	3239	4	free	free	JJ
cord-005478-5iu38pr6	3239	5	survival	survival	NN
cord-005478-5iu38pr6	3239	6	and	and	CC
cord-005478-5iu38pr6	3239	7	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3239	8	-	-	HYPH
cord-005478-5iu38pr6	3239	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3239	10	free	free	JJ
cord-005478-5iu38pr6	3239	11	survival	survival	NN
cord-005478-5iu38pr6	3239	12	were	be	VBD
cord-005478-5iu38pr6	3239	13	higher	high	JJR
cord-005478-5iu38pr6	3239	14	in	in	IN
cord-005478-5iu38pr6	3239	15	patients	patient	NNS
cord-005478-5iu38pr6	3239	16	who	who	WP
cord-005478-5iu38pr6	3239	17	underwent	undergo	VBD
cord-005478-5iu38pr6	3239	18	transplantation	transplantation	NN
cord-005478-5iu38pr6	3239	19	under	under	IN
cord-005478-5iu38pr6	3239	20	seven	seven	CD
cord-005478-5iu38pr6	3239	21	years	year	NNS
cord-005478-5iu38pr6	3239	22	of	of	IN
cord-005478-5iu38pr6	3239	23	age	age	NN
cord-005478-5iu38pr6	3239	24	.	.	.
cord-005478-5iu38pr6	3240	1	There	there	EX
cord-005478-5iu38pr6	3240	2	was	be	VBD
cord-005478-5iu38pr6	3240	3	no	no	DT
cord-005478-5iu38pr6	3240	4	difference	difference	NN
cord-005478-5iu38pr6	3240	5	in	in	IN
cord-005478-5iu38pr6	3240	6	overall	overall	JJ
cord-005478-5iu38pr6	3240	7	survival	survival	NN
cord-005478-5iu38pr6	3240	8	.	.	.
cord-005478-5iu38pr6	3241	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3241	2	:	:	:
cord-005478-5iu38pr6	3242	1	The	the	DT
cord-005478-5iu38pr6	3242	2	results	result	NNS
cord-005478-5iu38pr6	3242	3	of	of	IN
cord-005478-5iu38pr6	3242	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	3242	5	study	study	NN
cord-005478-5iu38pr6	3242	6	show	show	VBP
cord-005478-5iu38pr6	3242	7	that	that	IN
cord-005478-5iu38pr6	3242	8	the	the	DT
cord-005478-5iu38pr6	3242	9	rates	rate	NNS
cord-005478-5iu38pr6	3242	10	of	of	IN
cord-005478-5iu38pr6	3242	11	rejection	rejection	NN
cord-005478-5iu38pr6	3242	12	are	be	VBP
cord-005478-5iu38pr6	3242	13	high	high	JJ
cord-005478-5iu38pr6	3242	14	,	,	,
cord-005478-5iu38pr6	3242	15	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3242	16	free	free	JJ
cord-005478-5iu38pr6	3242	17	and	and	CC
cord-005478-5iu38pr6	3242	18	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3242	19	/	/	,
cord-005478-5iu38pr6	3242	20	gvhd	gvhd	NNP
cord-005478-5iu38pr6	3243	1	free	free	JJ
cord-005478-5iu38pr6	3243	2	survival	survival	NN
cord-005478-5iu38pr6	3243	3	are	be	VBP
cord-005478-5iu38pr6	3243	4	low	low	JJ
cord-005478-5iu38pr6	3243	5	in	in	IN
cord-005478-5iu38pr6	3243	6	patients	patient	NNS
cord-005478-5iu38pr6	3243	7	who	who	WP
cord-005478-5iu38pr6	3243	8	underwent	undergo	VBD
cord-005478-5iu38pr6	3243	9	stem	stem	NN
cord-005478-5iu38pr6	3243	10	cell	cell	NN
cord-005478-5iu38pr6	3243	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	3243	12	over	over	IN
cord-005478-5iu38pr6	3243	13	seven	seven	CD
cord-005478-5iu38pr6	3243	14	years	year	NNS
cord-005478-5iu38pr6	3243	15	of	of	IN
cord-005478-5iu38pr6	3243	16	age	age	NN
cord-005478-5iu38pr6	3243	17	.	.	.
cord-005478-5iu38pr6	3244	1	In	in	IN
cord-005478-5iu38pr6	3244	2	the	the	DT
cord-005478-5iu38pr6	3244	3	light	light	NN
cord-005478-5iu38pr6	3244	4	of	of	IN
cord-005478-5iu38pr6	3244	5	successful	successful	JJ
cord-005478-5iu38pr6	3244	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	3244	7	results	result	NNS
cord-005478-5iu38pr6	3244	8	from	from	IN
cord-005478-5iu38pr6	3244	9	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3244	10	donors	donor	NNS
cord-005478-5iu38pr6	3244	11	,	,	,
cord-005478-5iu38pr6	3244	12	the	the	DT
cord-005478-5iu38pr6	3244	13	delay	delay	NN
cord-005478-5iu38pr6	3244	14	in	in	IN
cord-005478-5iu38pr6	3244	15	age	age	NN
cord-005478-5iu38pr6	3244	16	of	of	IN
cord-005478-5iu38pr6	3244	17	transplantation	transplantation	NN
cord-005478-5iu38pr6	3244	18	in	in	IN
cord-005478-5iu38pr6	3244	19	thalassemia	thalassemia	NN
cord-005478-5iu38pr6	3244	20	patients	patient	NNS
cord-005478-5iu38pr6	3244	21	should	should	MD
cord-005478-5iu38pr6	3244	22	also	also	RB
cord-005478-5iu38pr6	3244	23	be	be	VB
cord-005478-5iu38pr6	3244	24	avoided	avoid	VBN
cord-005478-5iu38pr6	3244	25	.	.	.
cord-005478-5iu38pr6	3245	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3245	2	:	:	:
cord-005478-5iu38pr6	3245	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3245	4	to	to	TO
cord-005478-5iu38pr6	3245	5	declare	declare	VB
cord-005478-5iu38pr6	3245	6	O167	O167	NNP
cord-005478-5iu38pr6	3245	7	HLA	HLA	NNP
cord-005478-5iu38pr6	3245	8	-	-	HYPH
cord-005478-5iu38pr6	3245	9	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3245	10	Transplantation	transplantation	NN
cord-005478-5iu38pr6	3245	11	with	with	IN
cord-005478-5iu38pr6	3245	12	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3245	13	and	and	CC
cord-005478-5iu38pr6	3245	14	conventional	conventional	JJ
cord-005478-5iu38pr6	3245	15	T	t	NN
cord-005478-5iu38pr6	3245	16	-	-	HYPH
cord-005478-5iu38pr6	3245	17	cell	cell	NN
cord-005478-5iu38pr6	3245	18	adoptive	adoptive	JJ
cord-005478-5iu38pr6	3245	19	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3245	20	in	in	IN
cord-005478-5iu38pr6	3245	21	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3245	22	patients	patient	NNS
cord-005478-5iu38pr6	3245	23	with	with	IN
cord-005478-5iu38pr6	3245	24	high	high	JJ
cord-005478-5iu38pr6	3245	25	-	-	HYPH
cord-005478-5iu38pr6	3245	26	risk	risk	NN
cord-005478-5iu38pr6	3245	27	acute	acute	JJ
cord-005478-5iu38pr6	3245	28	leukemia	leukemia	NN
cord-005478-5iu38pr6	3245	29	Background	background	NN
cord-005478-5iu38pr6	3245	30	:	:	:
cord-005478-5iu38pr6	3246	1	Post	post	JJ
cord-005478-5iu38pr6	3246	2	-	-	JJ
cord-005478-5iu38pr6	3246	3	transplant	transplant	JJ
cord-005478-5iu38pr6	3246	4	relapse	relapse	NN
cord-005478-5iu38pr6	3246	5	is	be	VBZ
cord-005478-5iu38pr6	3246	6	still	still	RB
cord-005478-5iu38pr6	3246	7	a	a	DT
cord-005478-5iu38pr6	3246	8	major	major	JJ
cord-005478-5iu38pr6	3246	9	cause	cause	NN
cord-005478-5iu38pr6	3246	10	of	of	IN
cord-005478-5iu38pr6	3246	11	treatment	treatment	NN
cord-005478-5iu38pr6	3246	12	failure	failure	NN
cord-005478-5iu38pr6	3246	13	in	in	IN
cord-005478-5iu38pr6	3246	14	high	high	JJ
cord-005478-5iu38pr6	3246	15	-	-	HYPH
cord-005478-5iu38pr6	3246	16	risk	risk	NN
cord-005478-5iu38pr6	3246	17	acute	acute	JJ
cord-005478-5iu38pr6	3246	18	leukemia	leukemia	NN
cord-005478-5iu38pr6	3246	19	(	(	-LRB-
cord-005478-5iu38pr6	3246	20	AL	AL	NNP
cord-005478-5iu38pr6	3246	21	)	)	-RRB-
cord-005478-5iu38pr6	3246	22	patients	patient	NNS
cord-005478-5iu38pr6	3246	23	.	.	.
cord-005478-5iu38pr6	3247	1	In	in	IN
cord-005478-5iu38pr6	3247	2	order	order	NN
cord-005478-5iu38pr6	3247	3	to	to	TO
cord-005478-5iu38pr6	3247	4	separate	separate	VB
cord-005478-5iu38pr6	3247	5	the	the	DT
cord-005478-5iu38pr6	3247	6	GvL	gvl	NN
cord-005478-5iu38pr6	3247	7	effect	effect	NN
cord-005478-5iu38pr6	3247	8	from	from	IN
cord-005478-5iu38pr6	3247	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3247	10	,	,	,
cord-005478-5iu38pr6	3247	11	we	-PRON-	PRP
cord-005478-5iu38pr6	3247	12	investigated	investigate	VBD
cord-005478-5iu38pr6	3247	13	the	the	DT
cord-005478-5iu38pr6	3247	14	role	role	NN
cord-005478-5iu38pr6	3247	15	of	of	IN
cord-005478-5iu38pr6	3247	16	a	a	DT
cord-005478-5iu38pr6	3247	17	thymic	thymic	JJ
cord-005478-5iu38pr6	3247	18	-	-	HYPH
cord-005478-5iu38pr6	3247	19	derived	derived	JJ
cord-005478-5iu38pr6	3247	20	CD4	CD4	NNP
cord-005478-5iu38pr6	3247	21	+	+	CC
cord-005478-5iu38pr6	3247	22	CD25	CD25	NNP
cord-005478-5iu38pr6	3247	23	+	+	CC
cord-005478-5iu38pr6	3247	24	FoxP3	FoxP3	NNP
cord-005478-5iu38pr6	3247	25	+	+	CC
cord-005478-5iu38pr6	3247	26	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3247	27	T	t	NN
cord-005478-5iu38pr6	3247	28	cells	cell	NNS
cord-005478-5iu38pr6	3247	29	(	(	-LRB-
cord-005478-5iu38pr6	3247	30	Tregs	Tregs	NNP
cord-005478-5iu38pr6	3247	31	)	)	-RRB-
cord-005478-5iu38pr6	3247	32	.	.	.
cord-005478-5iu38pr6	3248	1	The	the	DT
cord-005478-5iu38pr6	3248	2	Perugia	Perugia	NNP
cord-005478-5iu38pr6	3248	3	center	center	NN
cord-005478-5iu38pr6	3248	4	reported	report	VBD
cord-005478-5iu38pr6	3248	5	results	result	NNS
cord-005478-5iu38pr6	3248	6	from	from	IN
cord-005478-5iu38pr6	3248	7	69	69	CD
cord-005478-5iu38pr6	3248	8	adult	adult	NN
cord-005478-5iu38pr6	3248	9	high	high	JJ
cord-005478-5iu38pr6	3248	10	-	-	HYPH
cord-005478-5iu38pr6	3248	11	risk	risk	NN
cord-005478-5iu38pr6	3248	12	AL	AL	NNP
cord-005478-5iu38pr6	3248	13	patients	patient	NNS
cord-005478-5iu38pr6	3248	14	who	who	WP
cord-005478-5iu38pr6	3248	15	received	receive	VBD
cord-005478-5iu38pr6	3248	16	an	an	DT
cord-005478-5iu38pr6	3248	17	HLA	HLA	NNP
cord-005478-5iu38pr6	3248	18	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3248	19	T	t	NN
cord-005478-5iu38pr6	3248	20	-	-	HYPH
cord-005478-5iu38pr6	3248	21	cell	cell	NN
cord-005478-5iu38pr6	3248	22	-	-	HYPH
cord-005478-5iu38pr6	3248	23	depleted	deplete	VBN
cord-005478-5iu38pr6	3248	24	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3248	25	transplant	transplant	NN
cord-005478-5iu38pr6	3248	26	and	and	CC
cord-005478-5iu38pr6	3248	27	adoptive	adoptive	JJ
cord-005478-5iu38pr6	3248	28	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3248	29	with	with	IN
cord-005478-5iu38pr6	3248	30	donor	donor	NN
cord-005478-5iu38pr6	3248	31	Tregs	Tregs	NNP
cord-005478-5iu38pr6	3248	32	and	and	CC
cord-005478-5iu38pr6	3248	33	conventional	conventional	JJ
cord-005478-5iu38pr6	3248	34	T	t	NN
cord-005478-5iu38pr6	3248	35	cells	cell	NNS
cord-005478-5iu38pr6	3248	36	(	(	-LRB-
cord-005478-5iu38pr6	3248	37	Tcons	Tcons	NNP
cord-005478-5iu38pr6	3248	38	)	)	-RRB-
cord-005478-5iu38pr6	3248	39	(	(	-LRB-
cord-005478-5iu38pr6	3248	40	and	and	CC
cord-005478-5iu38pr6	3248	41	no	no	DT
cord-005478-5iu38pr6	3248	42	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	3248	43	pharmacologic	pharmacologic	JJ
cord-005478-5iu38pr6	3248	44	immunosuppressive	immunosuppressive	JJ
cord-005478-5iu38pr6	3248	45	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3248	46	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3248	47	)	)	-RRB-
cord-005478-5iu38pr6	3249	1	(	(	-LRB-
cord-005478-5iu38pr6	3249	2	Di	Di	NNP
cord-005478-5iu38pr6	3249	3	Ianni	Ianni	NNP
cord-005478-5iu38pr6	3249	4	et	et	NNP
cord-005478-5iu38pr6	3249	5	al	al	NNP
cord-005478-5iu38pr6	3249	6	.	.	NNP
cord-005478-5iu38pr6	3249	7	,	,	,
cord-005478-5iu38pr6	3250	1	Blood	blood	NN
cord-005478-5iu38pr6	3250	2	2011	2011	CD
cord-005478-5iu38pr6	3250	3	,	,	,
cord-005478-5iu38pr6	3250	4	Martelli	Martelli	NNP
cord-005478-5iu38pr6	3250	5	et	et	NNP
cord-005478-5iu38pr6	3250	6	al	al	NNP
cord-005478-5iu38pr6	3250	7	.	.	.
cord-005478-5iu38pr6	3251	1	Blood	blood	NN
cord-005478-5iu38pr6	3251	2	2014	2014	CD
cord-005478-5iu38pr6	3251	3	.	.	.
cord-005478-5iu38pr6	3252	1	Adoptive	adoptive	JJ
cord-005478-5iu38pr6	3252	2	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3252	3	with	with	IN
cord-005478-5iu38pr6	3252	4	Tregs	Tregs	NNP
cord-005478-5iu38pr6	3252	5	and	and	CC
cord-005478-5iu38pr6	3252	6	Tcons	Tcons	NNP
cord-005478-5iu38pr6	3252	7	prevented	prevent	VBD
cord-005478-5iu38pr6	3252	8	post	post	JJ
cord-005478-5iu38pr6	3252	9	-	-	JJ
cord-005478-5iu38pr6	3252	10	transplant	transplant	JJ
cord-005478-5iu38pr6	3252	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	3252	12	relapse	relapse	NN
cord-005478-5iu38pr6	3252	13	and	and	CC
cord-005478-5iu38pr6	3252	14	largely	largely	RB
cord-005478-5iu38pr6	3252	15	protected	protect	VBN
cord-005478-5iu38pr6	3252	16	patients	patient	NNS
cord-005478-5iu38pr6	3252	17	from	from	IN
cord-005478-5iu38pr6	3252	18	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3252	19	.	.	.
cord-005478-5iu38pr6	3253	1	In	in	IN
cord-005478-5iu38pr6	3253	2	this	this	DT
cord-005478-5iu38pr6	3253	3	report	report	NN
cord-005478-5iu38pr6	3253	4	we	-PRON-	PRP
cord-005478-5iu38pr6	3253	5	present	present	VBP
cord-005478-5iu38pr6	3253	6	a	a	DT
cord-005478-5iu38pr6	3253	7	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3253	8	cohort	cohort	NN
cord-005478-5iu38pr6	3253	9	of	of	IN
cord-005478-5iu38pr6	3253	10	high	high	JJ
cord-005478-5iu38pr6	3253	11	risk	risk	NN
cord-005478-5iu38pr6	3253	12	leukemia	leukemia	NN
cord-005478-5iu38pr6	3253	13	patients	patient	NNS
cord-005478-5iu38pr6	3253	14	who	who	WP
cord-005478-5iu38pr6	3253	15	received	receive	VBD
cord-005478-5iu38pr6	3253	16	a	a	DT
cord-005478-5iu38pr6	3253	17	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3253	18	Treg	Treg	NNP
cord-005478-5iu38pr6	3253	19	/	/	SYM
cord-005478-5iu38pr6	3253	20	Tcon	Tcon	NNP
cord-005478-5iu38pr6	3253	21	-	-	HYPH
cord-005478-5iu38pr6	3253	22	based	base	VBN
cord-005478-5iu38pr6	3253	23	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3253	24	transplant	transplant	NN
cord-005478-5iu38pr6	3253	25	.	.	.
cord-005478-5iu38pr6	3254	1	Methods	method	NNS
cord-005478-5iu38pr6	3254	2	:	:	:
cord-005478-5iu38pr6	3255	1	Twelve	twelve	CD
cord-005478-5iu38pr6	3255	2	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3255	3	patients	patient	NNS
cord-005478-5iu38pr6	3255	4	,	,	,
cord-005478-5iu38pr6	3255	5	median	median	JJ
cord-005478-5iu38pr6	3255	6	age	age	NN
cord-005478-5iu38pr6	3255	7	of	of	IN
cord-005478-5iu38pr6	3255	8	nine	nine	CD
cord-005478-5iu38pr6	3255	9	years	year	NNS
cord-005478-5iu38pr6	3255	10	(	(	-LRB-
cord-005478-5iu38pr6	3255	11	range	range	NN
cord-005478-5iu38pr6	3255	12	,	,	,
cord-005478-5iu38pr6	3255	13	5	5	CD
cord-005478-5iu38pr6	3255	14	-	-	SYM
cord-005478-5iu38pr6	3255	15	19	19	CD
cord-005478-5iu38pr6	3255	16	)	)	-RRB-
cord-005478-5iu38pr6	3255	17	with	with	IN
cord-005478-5iu38pr6	3255	18	high	high	JJ
cord-005478-5iu38pr6	3255	19	-	-	HYPH
cord-005478-5iu38pr6	3255	20	risk	risk	NN
cord-005478-5iu38pr6	3255	21	acute	acute	JJ
cord-005478-5iu38pr6	3255	22	leukemia	leukemia	NN
cord-005478-5iu38pr6	3255	23	underwent	undergo	VBD
cord-005478-5iu38pr6	3255	24	HLA	HLA	NNP
cord-005478-5iu38pr6	3255	25	-	-	HYPH
cord-005478-5iu38pr6	3255	26	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3255	27	stem	stem	NN
cord-005478-5iu38pr6	3255	28	cell	cell	NN
cord-005478-5iu38pr6	3255	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	3255	30	with	with	IN
cord-005478-5iu38pr6	3255	31	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3255	32	and	and	CC
cord-005478-5iu38pr6	3255	33	conventional	conventional	JJ
cord-005478-5iu38pr6	3255	34	T	t	NN
cord-005478-5iu38pr6	3255	35	-	-	HYPH
cord-005478-5iu38pr6	3255	36	cell	cell	NN
cord-005478-5iu38pr6	3255	37	adoptive	adoptive	JJ
cord-005478-5iu38pr6	3255	38	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3255	39	between	between	IN
cord-005478-5iu38pr6	3255	40	September	September	NNP
cord-005478-5iu38pr6	3255	41	2016	2016	CD
cord-005478-5iu38pr6	3255	42	and	and	CC
cord-005478-5iu38pr6	3255	43	December	December	NNP
cord-005478-5iu38pr6	3255	44	2017	2017	CD
cord-005478-5iu38pr6	3255	45	.	.	.
cord-005478-5iu38pr6	3256	1	Eleven	eleven	CD
cord-005478-5iu38pr6	3256	2	had	have	VBD
cord-005478-5iu38pr6	3256	3	ALL	all	DT
cord-005478-5iu38pr6	3256	4	(	(	-LRB-
cord-005478-5iu38pr6	3256	5	three	three	CD
cord-005478-5iu38pr6	3256	6	Ph+	Ph+	NNS
cord-005478-5iu38pr6	3256	7	)	)	-RRB-
cord-005478-5iu38pr6	3256	8	,	,	,
cord-005478-5iu38pr6	3256	9	one	one	CD
cord-005478-5iu38pr6	3256	10	secondary	secondary	JJ
cord-005478-5iu38pr6	3256	11	AML	AML	NNP
cord-005478-5iu38pr6	3256	12	.	.	.
cord-005478-5iu38pr6	3257	1	Seven	seven	CD
cord-005478-5iu38pr6	3257	2	patients	patient	NNS
cord-005478-5iu38pr6	3257	3	were	be	VBD
cord-005478-5iu38pr6	3257	4	transplanted	transplant	VBN
cord-005478-5iu38pr6	3257	5	in	in	IN
cord-005478-5iu38pr6	3257	6	CR1	CR1	NNP
cord-005478-5iu38pr6	3257	7	(	(	-LRB-
cord-005478-5iu38pr6	3257	8	3	3	CD
cord-005478-5iu38pr6	3257	9	Ph+	Ph+	NNP
cord-005478-5iu38pr6	3257	10	ALL	all	DT
cord-005478-5iu38pr6	3257	11	,	,	,
cord-005478-5iu38pr6	3257	12	1	1	CD
cord-005478-5iu38pr6	3257	13	ALL	all	DT
cord-005478-5iu38pr6	3257	14	in	in	IN
cord-005478-5iu38pr6	3257	15	CR	cr	NN
cord-005478-5iu38pr6	3257	16	after	after	IN
cord-005478-5iu38pr6	3257	17	second	second	JJ
cord-005478-5iu38pr6	3257	18	-	-	HYPH
cord-005478-5iu38pr6	3257	19	line	line	NN
cord-005478-5iu38pr6	3257	20	induction	induction	NN
cord-005478-5iu38pr6	3257	21	,	,	,
cord-005478-5iu38pr6	3257	22	1	1	CD
cord-005478-5iu38pr6	3257	23	ALL	all	DT
cord-005478-5iu38pr6	3257	24	with	with	IN
cord-005478-5iu38pr6	3257	25	extramedullary	extramedullary	JJ
cord-005478-5iu38pr6	3257	26	leukemia	leukemia	NN
cord-005478-5iu38pr6	3257	27	,	,	,
cord-005478-5iu38pr6	3257	28	1	1	CD
cord-005478-5iu38pr6	3257	29	ALL	all	DT
cord-005478-5iu38pr6	3257	30	with	with	IN
cord-005478-5iu38pr6	3257	31	t(19;11	t(19;11	NNP
cord-005478-5iu38pr6	3257	32	)	)	-RRB-
cord-005478-5iu38pr6	3257	33	,	,	,
cord-005478-5iu38pr6	3257	34	1	1	CD
cord-005478-5iu38pr6	3257	35	secondary	secondary	JJ
cord-005478-5iu38pr6	3257	36	AML	AML	NNP
cord-005478-5iu38pr6	3257	37	after	after	IN
cord-005478-5iu38pr6	3257	38	medulloblastoma	medulloblastoma	NNP
cord-005478-5iu38pr6	3257	39	)	)	-RRB-
cord-005478-5iu38pr6	3257	40	,	,	,
cord-005478-5iu38pr6	3257	41	two	two	CD
cord-005478-5iu38pr6	3257	42	patients	patient	NNS
cord-005478-5iu38pr6	3257	43	in	in	IN
cord-005478-5iu38pr6	3257	44	CR2	CR2	NNP
cord-005478-5iu38pr6	3257	45	,	,	,
cord-005478-5iu38pr6	3257	46	three	three	CD
cord-005478-5iu38pr6	3257	47	in	in	IN
cord-005478-5iu38pr6	3257	48	CR3	CR3	NNP
cord-005478-5iu38pr6	3257	49	.	.	.
cord-005478-5iu38pr6	3258	1	Median	median	JJ
cord-005478-5iu38pr6	3258	2	time	time	NN
cord-005478-5iu38pr6	3258	3	from	from	IN
cord-005478-5iu38pr6	3258	4	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3258	5	to	to	IN
cord-005478-5iu38pr6	3258	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	3258	7	was	be	VBD
cord-005478-5iu38pr6	3258	8	18.5	18.5	CD
cord-005478-5iu38pr6	3258	9	months	month	NNS
cord-005478-5iu38pr6	3258	10	(	(	-LRB-
cord-005478-5iu38pr6	3258	11	range	range	NN
cord-005478-5iu38pr6	3258	12	,	,	,
cord-005478-5iu38pr6	3258	13	5	5	CD
cord-005478-5iu38pr6	3258	14	-	-	SYM
cord-005478-5iu38pr6	3258	15	48	48	CD
cord-005478-5iu38pr6	3258	16	)	)	-RRB-
cord-005478-5iu38pr6	3258	17	,	,	,
cord-005478-5iu38pr6	3258	18	median	median	JJ
cord-005478-5iu38pr6	3258	19	time	time	NN
cord-005478-5iu38pr6	3258	20	from	from	IN
cord-005478-5iu38pr6	3258	21	relapse	relapse	NN
cord-005478-5iu38pr6	3258	22	to	to	IN
cord-005478-5iu38pr6	3258	23	especially	especially	RB
cord-005478-5iu38pr6	3258	24	for	for	IN
cord-005478-5iu38pr6	3258	25	AML	AML	NNP
cord-005478-5iu38pr6	3258	26	pts	pts	NNP
cord-005478-5iu38pr6	3258	27	.	.	.
cord-005478-5iu38pr6	3259	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	3259	2	analysis	analysis	NN
cord-005478-5iu38pr6	3259	3	suggests	suggest	VBZ
cord-005478-5iu38pr6	3259	4	that	that	IN
cord-005478-5iu38pr6	3259	5	early	early	JJ
cord-005478-5iu38pr6	3259	6	αβ	αβ	NN
cord-005478-5iu38pr6	3259	7	T	t	NN
cord-005478-5iu38pr6	3259	8	cell	cell	NN
cord-005478-5iu38pr6	3259	9	recovery	recovery	NN
cord-005478-5iu38pr6	3259	10	is	be	VBZ
cord-005478-5iu38pr6	3259	11	associated	associate	VBN
cord-005478-5iu38pr6	3259	12	with	with	IN
cord-005478-5iu38pr6	3259	13	a	a	DT
cord-005478-5iu38pr6	3259	14	relatively	relatively	RB
cord-005478-5iu38pr6	3259	15	low	low	JJ
cord-005478-5iu38pr6	3259	16	nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	3259	17	mortality	mortality	NN
cord-005478-5iu38pr6	3259	18	and	and	CC
cord-005478-5iu38pr6	3259	19	relapse	relapse	NN
cord-005478-5iu38pr6	3259	20	rate	rate	NN
cord-005478-5iu38pr6	3259	21	.	.	.
cord-005478-5iu38pr6	3260	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3260	2	:	:	:
cord-005478-5iu38pr6	3260	3	Nothing	nothing	NN
cord-005478-5iu38pr6	3260	4	to	to	TO
cord-005478-5iu38pr6	3260	5	declare	declare	VB
cord-005478-5iu38pr6	3260	6	Background	background	NN
cord-005478-5iu38pr6	3260	7	:	:	:
cord-005478-5iu38pr6	3260	8	Enhancing	enhance	VBG
cord-005478-5iu38pr6	3260	9	stem	stem	NN
cord-005478-5iu38pr6	3260	10	cell	cell	NN
cord-005478-5iu38pr6	3260	11	performance	performance	NN
cord-005478-5iu38pr6	3260	12	can	can	MD
cord-005478-5iu38pr6	3260	13	improve	improve	VB
cord-005478-5iu38pr6	3260	14	the	the	DT
cord-005478-5iu38pr6	3260	15	results	result	NNS
cord-005478-5iu38pr6	3260	16	of	of	IN
cord-005478-5iu38pr6	3260	17	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3260	18	stem	stem	NN
cord-005478-5iu38pr6	3260	19	cell	cell	NN
cord-005478-5iu38pr6	3260	20	transplant	transplant	NN
cord-005478-5iu38pr6	3260	21	(	(	-LRB-
cord-005478-5iu38pr6	3260	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3260	23	)	)	-RRB-
cord-005478-5iu38pr6	3260	24	for	for	IN
cord-005478-5iu38pr6	3260	25	diseases	disease	NNS
cord-005478-5iu38pr6	3260	26	in	in	IN
cord-005478-5iu38pr6	3260	27	which	which	WDT
cord-005478-5iu38pr6	3260	28	engraftment	engraftment	NN
cord-005478-5iu38pr6	3260	29	is	be	VBZ
cord-005478-5iu38pr6	3260	30	unpredictable	unpredictable	JJ
cord-005478-5iu38pr6	3260	31	,	,	,
cord-005478-5iu38pr6	3260	32	and	and	CC
cord-005478-5iu38pr6	3260	33	in	in	IN
cord-005478-5iu38pr6	3260	34	patients	patient	NNS
cord-005478-5iu38pr6	3260	35	receiving	receive	VBG
cord-005478-5iu38pr6	3260	36	pre	pre	JJ
cord-005478-5iu38pr6	3260	37	-	-	JJ
cord-005478-5iu38pr6	3260	38	HSCT	hsct	JJ
cord-005478-5iu38pr6	3260	39	conditioning	conditioning	NN
cord-005478-5iu38pr6	3260	40	regimens	regimen	NNS
cord-005478-5iu38pr6	3260	41	of	of	IN
cord-005478-5iu38pr6	3260	42	progressively	progressively	RB
cord-005478-5iu38pr6	3260	43	decreasing	decrease	VBG
cord-005478-5iu38pr6	3260	44	intensity	intensity	NN
cord-005478-5iu38pr6	3260	45	.	.	.
cord-005478-5iu38pr6	3261	1	In	in	IN
cord-005478-5iu38pr6	3261	2	a	a	DT
cord-005478-5iu38pr6	3261	3	series	series	NN
cord-005478-5iu38pr6	3261	4	of	of	IN
cord-005478-5iu38pr6	3261	5	preclinical	preclinical	JJ
cord-005478-5iu38pr6	3261	6	studies	study	NNS
cord-005478-5iu38pr6	3261	7	,	,	,
cord-005478-5iu38pr6	3261	8	we	-PRON-	PRP
cord-005478-5iu38pr6	3261	9	explored	explore	VBD
cord-005478-5iu38pr6	3261	10	the	the	DT
cord-005478-5iu38pr6	3261	11	use	use	NN
cord-005478-5iu38pr6	3261	12	of	of	IN
cord-005478-5iu38pr6	3261	13	Tat	Tat	NNP
cord-005478-5iu38pr6	3261	14	-	-	HYPH
cord-005478-5iu38pr6	3261	15	Myc	Myc	NNP
cord-005478-5iu38pr6	3261	16	,	,	,
cord-005478-5iu38pr6	3261	17	a	a	DT
cord-005478-5iu38pr6	3261	18	chimeric	chimeric	JJ
cord-005478-5iu38pr6	3261	19	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3261	20	protein	protein	NN
cord-005478-5iu38pr6	3261	21	,	,	,
cord-005478-5iu38pr6	3261	22	to	to	TO
cord-005478-5iu38pr6	3261	23	improve	improve	VB
cord-005478-5iu38pr6	3261	24	the	the	DT
cord-005478-5iu38pr6	3261	25	performance	performance	NN
cord-005478-5iu38pr6	3261	26	of	of	IN
cord-005478-5iu38pr6	3261	27	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3261	28	stem	stem	NN
cord-005478-5iu38pr6	3261	29	cell	cell	NN
cord-005478-5iu38pr6	3261	30	grafts	graft	NNS
cord-005478-5iu38pr6	3261	31	.	.	.
cord-005478-5iu38pr6	3262	1	Methods	method	NNS
cord-005478-5iu38pr6	3262	2	:	:	:
cord-005478-5iu38pr6	3263	1	Tat	Tat	NNP
cord-005478-5iu38pr6	3263	2	-	-	HYPH
cord-005478-5iu38pr6	3263	3	Myc	Myc	NNP
cord-005478-5iu38pr6	3263	4	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3263	5	protein	protein	NN
cord-005478-5iu38pr6	3263	6	encompasses	encompass	VBZ
cord-005478-5iu38pr6	3263	7	9	9	CD
cord-005478-5iu38pr6	3263	8	amino	amino	NN
cord-005478-5iu38pr6	3263	9	acids	acid	NNS
cord-005478-5iu38pr6	3263	10	from	from	IN
cord-005478-5iu38pr6	3263	11	the	the	DT
cord-005478-5iu38pr6	3263	12	N	n	CD
cord-005478-5iu38pr6	3263	13	-	-	HYPH
cord-005478-5iu38pr6	3263	14	terminal	terminal	JJ
cord-005478-5iu38pr6	3263	15	nuclear	nuclear	JJ
cord-005478-5iu38pr6	3263	16	localization	localization	NN
cord-005478-5iu38pr6	3263	17	domain	domain	NN
cord-005478-5iu38pr6	3263	18	of	of	IN
cord-005478-5iu38pr6	3263	19	HIV	HIV	NNP
cord-005478-5iu38pr6	3263	20	-	-	HYPH
cord-005478-5iu38pr6	3263	21	Tat	Tat	NNP
cord-005478-5iu38pr6	3263	22	,	,	,
cord-005478-5iu38pr6	3263	23	coupled	couple	VBN
cord-005478-5iu38pr6	3263	24	to	to	IN
cord-005478-5iu38pr6	3263	25	the	the	DT
cord-005478-5iu38pr6	3263	26	entire	entire	JJ
cord-005478-5iu38pr6	3263	27	coding	code	VBG
cord-005478-5iu38pr6	3263	28	sequence	sequence	NN
cord-005478-5iu38pr6	3263	29	of	of	IN
cord-005478-5iu38pr6	3263	30	c	c	NN
cord-005478-5iu38pr6	3263	31	-	-	:
cord-005478-5iu38pr6	3263	32	Myc	Myc	NNP
cord-005478-5iu38pr6	3263	33	,	,	,
cord-005478-5iu38pr6	3263	34	with	with	IN
cord-005478-5iu38pr6	3263	35	an	an	DT
cord-005478-5iu38pr6	3263	36	appended	append	VBN
cord-005478-5iu38pr6	3263	37	histidine	histidine	NN
cord-005478-5iu38pr6	3263	38	tag	tag	NN
cord-005478-5iu38pr6	3263	39	to	to	TO
cord-005478-5iu38pr6	3263	40	aid	aid	VB
cord-005478-5iu38pr6	3263	41	in	in	IN
cord-005478-5iu38pr6	3263	42	protein	protein	NN
cord-005478-5iu38pr6	3263	43	purification	purification	NN
cord-005478-5iu38pr6	3263	44	.	.	.
cord-005478-5iu38pr6	3264	1	The	the	DT
cord-005478-5iu38pr6	3264	2	construct	construct	NN
cord-005478-5iu38pr6	3264	3	was	be	VBD
cord-005478-5iu38pr6	3264	4	expressed	express	VBN
cord-005478-5iu38pr6	3264	5	in	in	IN
cord-005478-5iu38pr6	3264	6	bacteria	bacteria	NNS
cord-005478-5iu38pr6	3264	7	and	and	CC
cord-005478-5iu38pr6	3264	8	purified	purify	VBN
cord-005478-5iu38pr6	3264	9	to	to	IN
cord-005478-5iu38pr6	3264	10	pharmacological	pharmacological	JJ
cord-005478-5iu38pr6	3264	11	grade	grade	NN
cord-005478-5iu38pr6	3264	12	purity	purity	NN
cord-005478-5iu38pr6	3264	13	under	under	IN
cord-005478-5iu38pr6	3264	14	GLP	GLP	NNP
cord-005478-5iu38pr6	3264	15	conditions	condition	NNS
cord-005478-5iu38pr6	3264	16	.	.	.
cord-005478-5iu38pr6	3265	1	Results	result	NNS
cord-005478-5iu38pr6	3265	2	:	:	:
cord-005478-5iu38pr6	3266	1	Brief	brief	JJ
cord-005478-5iu38pr6	3266	2	(	(	-LRB-
cord-005478-5iu38pr6	3266	3	1	1	CD
cord-005478-5iu38pr6	3266	4	hour	hour	NN
cord-005478-5iu38pr6	3266	5	)	)	-RRB-
cord-005478-5iu38pr6	3266	6	culture	culture	NN
cord-005478-5iu38pr6	3266	7	of	of	IN
cord-005478-5iu38pr6	3266	8	fibroblasts	fibroblast	NNS
cord-005478-5iu38pr6	3266	9	or	or	CC
cord-005478-5iu38pr6	3266	10	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3266	11	cells	cell	NNS
cord-005478-5iu38pr6	3266	12	in	in	IN
cord-005478-5iu38pr6	3266	13	medium	medium	NN
cord-005478-5iu38pr6	3266	14	containing	contain	VBG
cord-005478-5iu38pr6	3266	15	10	10	CD
cord-005478-5iu38pr6	3266	16	microgram/	microgram/	NN
cord-005478-5iu38pr6	3266	17	ml	ml	NNP
cord-005478-5iu38pr6	3266	18	Tat	Tat	NNP
cord-005478-5iu38pr6	3266	19	-	-	HYPH
cord-005478-5iu38pr6	3266	20	Myc	Myc	NNP
cord-005478-5iu38pr6	3266	21	results	result	NNS
cord-005478-5iu38pr6	3266	22	in	in	IN
cord-005478-5iu38pr6	3266	23	rapid	rapid	JJ
cord-005478-5iu38pr6	3266	24	nuclear	nuclear	JJ
cord-005478-5iu38pr6	3266	25	localization	localization	NN
cord-005478-5iu38pr6	3266	26	of	of	IN
cord-005478-5iu38pr6	3266	27	the	the	DT
cord-005478-5iu38pr6	3266	28	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3266	29	protein	protein	NN
cord-005478-5iu38pr6	3267	1	,	,	,
cord-005478-5iu38pr6	3267	2	whence	whence	IN
cord-005478-5iu38pr6	3267	3	it	-PRON-	PRP
cord-005478-5iu38pr6	3267	4	disappears	disappear	VBZ
cord-005478-5iu38pr6	3267	5	within	within	IN
cord-005478-5iu38pr6	3267	6	48	48	CD
cord-005478-5iu38pr6	3267	7	hours	hour	NNS
cord-005478-5iu38pr6	3267	8	as	as	IN
cord-005478-5iu38pr6	3267	9	measured	measure	VBN
cord-005478-5iu38pr6	3267	10	by	by	IN
cord-005478-5iu38pr6	3267	11	Western	western	JJ
cord-005478-5iu38pr6	3267	12	blot	blot	NN
cord-005478-5iu38pr6	3267	13	.	.	.
cord-005478-5iu38pr6	3268	1	Flow	flow	VB
cord-005478-5iu38pr6	3268	2	cytometric	cytometric	NN
cord-005478-5iu38pr6	3268	3	assays	assay	NNS
cord-005478-5iu38pr6	3268	4	have	have	VBP
cord-005478-5iu38pr6	3268	5	been	be	VBN
cord-005478-5iu38pr6	3268	6	validated	validate	VBN
cord-005478-5iu38pr6	3268	7	to	to	TO
cord-005478-5iu38pr6	3268	8	measure	measure	VB
cord-005478-5iu38pr6	3268	9	the	the	DT
cord-005478-5iu38pr6	3268	10	uptake	uptake	NN
cord-005478-5iu38pr6	3268	11	of	of	IN
cord-005478-5iu38pr6	3268	12	Tat	Tat	NNP
cord-005478-5iu38pr6	3268	13	-	-	HYPH
cord-005478-5iu38pr6	3268	14	Myc	Myc	NNP
cord-005478-5iu38pr6	3268	15	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3268	16	protein	protein	NN
cord-005478-5iu38pr6	3268	17	into	into	IN
cord-005478-5iu38pr6	3268	18	nucleated	nucleated	JJ
cord-005478-5iu38pr6	3268	19	marrow	marrow	NN
cord-005478-5iu38pr6	3268	20	cells	cell	NNS
cord-005478-5iu38pr6	3268	21	.	.	.
cord-005478-5iu38pr6	3269	1	Marrow	marrow	NN
cord-005478-5iu38pr6	3269	2	homing	homing	NN
cord-005478-5iu38pr6	3269	3	of	of	IN
cord-005478-5iu38pr6	3269	4	Tat	Tat	NNP
cord-005478-5iu38pr6	3269	5	-	-	HYPH
cord-005478-5iu38pr6	3269	6	Myc	Myc	NNP
cord-005478-5iu38pr6	3269	7	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3269	8	protein	protein	NN
cord-005478-5iu38pr6	3269	9	-	-	HYPH
cord-005478-5iu38pr6	3269	10	treated	treat	VBN
cord-005478-5iu38pr6	3269	11	murine	murine	JJ
cord-005478-5iu38pr6	3269	12	marrow	marrow	NN
cord-005478-5iu38pr6	3269	13	increased	increase	VBD
cord-005478-5iu38pr6	3269	14	5-fold	5-fold	CD
cord-005478-5iu38pr6	3269	15	as	as	IN
cord-005478-5iu38pr6	3269	16	compared	compare	VBN
cord-005478-5iu38pr6	3269	17	to	to	IN
cord-005478-5iu38pr6	3269	18	that	that	DT
cord-005478-5iu38pr6	3269	19	of	of	IN
cord-005478-5iu38pr6	3269	20	control	control	NN
cord-005478-5iu38pr6	3269	21	cells	cell	NNS
cord-005478-5iu38pr6	3269	22	.	.	.
cord-005478-5iu38pr6	3270	1	Incubation	incubation	NN
cord-005478-5iu38pr6	3270	2	of	of	IN
cord-005478-5iu38pr6	3270	3	activated	activate	VBN
cord-005478-5iu38pr6	3270	4	murine	murine	JJ
cord-005478-5iu38pr6	3270	5	T	T	NNP
cord-005478-5iu38pr6	3270	6	cells	cell	NNS
cord-005478-5iu38pr6	3270	7	with	with	IN
cord-005478-5iu38pr6	3270	8	Tat	Tat	NNP
cord-005478-5iu38pr6	3270	9	-	-	HYPH
cord-005478-5iu38pr6	3270	10	Myc	Myc	NNP
cord-005478-5iu38pr6	3270	11	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3270	12	protein	protein	NN
cord-005478-5iu38pr6	3270	13	conferred	confer	VBD
cord-005478-5iu38pr6	3270	14	resistance	resistance	NN
cord-005478-5iu38pr6	3270	15	to	to	IN
cord-005478-5iu38pr6	3270	16	Granzyme	Granzyme	NNP
cord-005478-5iu38pr6	3270	17	B	B	NNP
cord-005478-5iu38pr6	3270	18	cytotoxicity	cytotoxicity	NN
cord-005478-5iu38pr6	3270	19	,	,	,
cord-005478-5iu38pr6	3270	20	but	but	CC
cord-005478-5iu38pr6	3270	21	did	do	VBD
cord-005478-5iu38pr6	3270	22	not	not	RB
cord-005478-5iu38pr6	3270	23	protect	protect	VB
cord-005478-5iu38pr6	3270	24	cells	cell	NNS
cord-005478-5iu38pr6	3270	25	from	from	IN
cord-005478-5iu38pr6	3270	26	effects	effect	NNS
cord-005478-5iu38pr6	3270	27	of	of	IN
cord-005478-5iu38pr6	3270	28	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	3270	29	.	.	.
cord-005478-5iu38pr6	3271	1	Tat	Tat	NNP
cord-005478-5iu38pr6	3271	2	-	-	HYPH
cord-005478-5iu38pr6	3271	3	Myc	Myc	NNP
cord-005478-5iu38pr6	3271	4	recombinant	recombinant	NN
cord-005478-5iu38pr6	3272	1	protein	protein	NN
cord-005478-5iu38pr6	3272	2	-	-	HYPH
cord-005478-5iu38pr6	3272	3	treated	treat	VBN
cord-005478-5iu38pr6	3272	4	marrow	marrow	NN
cord-005478-5iu38pr6	3272	5	could	could	MD
cord-005478-5iu38pr6	3272	6	be	be	VB
cord-005478-5iu38pr6	3272	7	serially	serially	RB
cord-005478-5iu38pr6	3272	8	transplanted	transplant	VBN
cord-005478-5iu38pr6	3272	9	in	in	IN
cord-005478-5iu38pr6	3272	10	mice	mouse	NNS
cord-005478-5iu38pr6	3272	11	for	for	IN
cord-005478-5iu38pr6	3272	12	three	three	CD
cord-005478-5iu38pr6	3272	13	generations	generation	NNS
cord-005478-5iu38pr6	3272	14	.	.	.
cord-005478-5iu38pr6	3273	1	Murine	murine	JJ
cord-005478-5iu38pr6	3273	2	bone	bone	NN
cord-005478-5iu38pr6	3273	3	marrow	marrow	NN
cord-005478-5iu38pr6	3273	4	harvested	harvest	VBN
cord-005478-5iu38pr6	3273	5	from	from	IN
cord-005478-5iu38pr6	3273	6	5fluorouracil	5fluorouracil	CD
cord-005478-5iu38pr6	3273	7	treated	treat	VBN
cord-005478-5iu38pr6	3273	8	mice	mouse	NNS
cord-005478-5iu38pr6	3273	9	and	and	CC
cord-005478-5iu38pr6	3273	10	briefly	briefly	NN
cord-005478-5iu38pr6	3273	11	incubated	incubate	VBN
cord-005478-5iu38pr6	3273	12	with	with	IN
cord-005478-5iu38pr6	3273	13	Tat	Tat	NNP
cord-005478-5iu38pr6	3273	14	-	-	HYPH
cord-005478-5iu38pr6	3273	15	Myc	Myc	NNP
cord-005478-5iu38pr6	3273	16	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3273	17	protein	protein	NN
cord-005478-5iu38pr6	3273	18	outcompeted	outcompete	VBD
cord-005478-5iu38pr6	3273	19	control	control	NN
cord-005478-5iu38pr6	3273	20	marrow	marrow	NN
cord-005478-5iu38pr6	3273	21	when	when	WRB
cord-005478-5iu38pr6	3273	22	transplanted	transplant	VBN
cord-005478-5iu38pr6	3273	23	in	in	IN
cord-005478-5iu38pr6	3273	24	sub	sub	NN
cord-005478-5iu38pr6	3273	25	-	-	JJ
cord-005478-5iu38pr6	3273	26	lethally	lethally	RB
cord-005478-5iu38pr6	3273	27	irradiated	irradiate	VBN
cord-005478-5iu38pr6	3273	28	immunedeficient	immunedeficient	JJ
cord-005478-5iu38pr6	3273	29	mice	mouse	NNS
cord-005478-5iu38pr6	3273	30	even	even	RB
cord-005478-5iu38pr6	3273	31	at	at	IN
cord-005478-5iu38pr6	3273	32	ratios	ratio	NNS
cord-005478-5iu38pr6	3273	33	of	of	IN
cord-005478-5iu38pr6	3273	34	1:9	1:9	CD
cord-005478-5iu38pr6	3273	35	treated	treat	VBN
cord-005478-5iu38pr6	3273	36	:	:	:
cord-005478-5iu38pr6	3273	37	control	control	NN
cord-005478-5iu38pr6	3273	38	cells	cell	NNS
cord-005478-5iu38pr6	3273	39	.	.	.
cord-005478-5iu38pr6	3274	1	T	T	NNP
cord-005478-5iu38pr6	3274	2	-	-	HYPH
cord-005478-5iu38pr6	3274	3	and	and	CC
cord-005478-5iu38pr6	3274	4	B	b	NN
cord-005478-5iu38pr6	3274	5	-	-	HYPH
cord-005478-5iu38pr6	3274	6	cell	cell	NN
cord-005478-5iu38pr6	3274	7	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3274	8	following	follow	VBG
cord-005478-5iu38pr6	3274	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	3274	10	in	in	IN
cord-005478-5iu38pr6	3274	11	immune	immune	JJ
cord-005478-5iu38pr6	3274	12	deficient	deficient	JJ
cord-005478-5iu38pr6	3274	13	mice	mouse	NNS
cord-005478-5iu38pr6	3274	14	was	be	VBD
cord-005478-5iu38pr6	3274	15	superior	superior	JJ
cord-005478-5iu38pr6	3274	16	following	follow	VBG
cord-005478-5iu38pr6	3274	17	Tat	Tat	NNP
cord-005478-5iu38pr6	3274	18	-	-	HYPH
cord-005478-5iu38pr6	3274	19	Myc	Myc	NNP
cord-005478-5iu38pr6	3274	20	vs	vs	IN
cord-005478-5iu38pr6	3274	21	control	control	NN
cord-005478-5iu38pr6	3274	22	incubation	incubation	NN
cord-005478-5iu38pr6	3274	23	of	of	IN
cord-005478-5iu38pr6	3274	24	murine	murine	JJ
cord-005478-5iu38pr6	3274	25	marrow	marrow	NN
cord-005478-5iu38pr6	3274	26	.	.	.
cord-005478-5iu38pr6	3275	1	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	3275	2	of	of	IN
cord-005478-5iu38pr6	3275	3	human	human	JJ
cord-005478-5iu38pr6	3275	4	umbilical	umbilical	JJ
cord-005478-5iu38pr6	3275	5	cord	cord	NN
cord-005478-5iu38pr6	3275	6	blood	blood	NN
cord-005478-5iu38pr6	3275	7	(	(	-LRB-
cord-005478-5iu38pr6	3275	8	UCB	UCB	NNP
cord-005478-5iu38pr6	3275	9	)	)	-RRB-
cord-005478-5iu38pr6	3275	10	cells	cell	NNS
cord-005478-5iu38pr6	3275	11	in	in	IN
cord-005478-5iu38pr6	3275	12	sub	sub	NN
cord-005478-5iu38pr6	3275	13	-	-	JJ
cord-005478-5iu38pr6	3275	14	lethally	lethally	RB
cord-005478-5iu38pr6	3275	15	irradiated	irradiate	VBN
cord-005478-5iu38pr6	3275	16	immune	immune	JJ
cord-005478-5iu38pr6	3275	17	deficient	deficient	JJ
cord-005478-5iu38pr6	3275	18	mice	mouse	NNS
cord-005478-5iu38pr6	3275	19	was	be	VBD
cord-005478-5iu38pr6	3275	20	markedly	markedly	RB
cord-005478-5iu38pr6	3275	21	improved	improve	VBN
cord-005478-5iu38pr6	3275	22	following	follow	VBG
cord-005478-5iu38pr6	3275	23	Tat	Tat	NNP
cord-005478-5iu38pr6	3275	24	-	-	HYPH
cord-005478-5iu38pr6	3275	25	Myc	Myc	NNP
cord-005478-5iu38pr6	3275	26	incubation	incubation	NN
cord-005478-5iu38pr6	3275	27	as	as	IN
cord-005478-5iu38pr6	3275	28	compared	compare	VBN
cord-005478-5iu38pr6	3275	29	to	to	IN
cord-005478-5iu38pr6	3275	30	that	that	DT
cord-005478-5iu38pr6	3275	31	of	of	IN
cord-005478-5iu38pr6	3275	32	control	control	NN
cord-005478-5iu38pr6	3275	33	UCB	UCB	NNP
cord-005478-5iu38pr6	3275	34	cells	cell	NNS
cord-005478-5iu38pr6	3275	35	.	.	.
cord-005478-5iu38pr6	3276	1	The	the	DT
cord-005478-5iu38pr6	3276	2	transforming	transform	VBG
cord-005478-5iu38pr6	3276	3	potential	potential	JJ
cord-005478-5iu38pr6	3276	4	Tat	Tat	NNP
cord-005478-5iu38pr6	3276	5	-	-	HYPH
cord-005478-5iu38pr6	3276	6	Myc	Myc	NNP
cord-005478-5iu38pr6	3276	7	protein	protein	NN
cord-005478-5iu38pr6	3276	8	was	be	VBD
cord-005478-5iu38pr6	3276	9	extensively	extensively	RB
cord-005478-5iu38pr6	3276	10	explored	explore	VBN
cord-005478-5iu38pr6	3276	11	.	.	.
cord-005478-5iu38pr6	3277	1	Tat	Tat	NNP
cord-005478-5iu38pr6	3277	2	-	-	HYPH
cord-005478-5iu38pr6	3277	3	Myc	Myc	NNP
cord-005478-5iu38pr6	3277	4	culture	culture	NN
cord-005478-5iu38pr6	3277	5	hematopoietic	hematopoietic	NN
cord-005478-5iu38pr6	3277	6	cells	cell	NNS
cord-005478-5iu38pr6	3277	7	did	do	VBD
cord-005478-5iu38pr6	3277	8	not	not	RB
cord-005478-5iu38pr6	3277	9	display	display	VB
cord-005478-5iu38pr6	3277	10	aneuploidy	aneuploidy	NN
cord-005478-5iu38pr6	3277	11	in	in	IN
cord-005478-5iu38pr6	3277	12	cytogenetic	cytogenetic	JJ
cord-005478-5iu38pr6	3277	13	or	or	CC
cord-005478-5iu38pr6	3277	14	spectral	spectral	JJ
cord-005478-5iu38pr6	3277	15	karyotypic	karyotypic	JJ
cord-005478-5iu38pr6	3277	16	analyses	analysis	NNS
cord-005478-5iu38pr6	3277	17	.	.	.
cord-005478-5iu38pr6	3278	1	Intramuscular	intramuscular	JJ
cord-005478-5iu38pr6	3278	2	injection	injection	NN
cord-005478-5iu38pr6	3278	3	of	of	IN
cord-005478-5iu38pr6	3278	4	10	10	CD
cord-005478-5iu38pr6	3278	5	micrograms	microgram	NNS
cord-005478-5iu38pr6	3278	6	of	of	IN
cord-005478-5iu38pr6	3278	7	Tat	Tat	NNP
cord-005478-5iu38pr6	3278	8	-	-	HYPH
cord-005478-5iu38pr6	3278	9	Myc	Myc	NNP
cord-005478-5iu38pr6	3278	10	protein	protein	NN
cord-005478-5iu38pr6	3278	11	in	in	IN
cord-005478-5iu38pr6	3278	12	p53	p53	NN
cord-005478-5iu38pr6	3278	13	+	+	CC
cord-005478-5iu38pr6	3278	14	/mice	/mice	NN
cord-005478-5iu38pr6	3278	15	for	for	IN
cord-005478-5iu38pr6	3278	16	12	12	CD
cord-005478-5iu38pr6	3278	17	consecutive	consecutive	JJ
cord-005478-5iu38pr6	3278	18	weeks	week	NNS
cord-005478-5iu38pr6	3278	19	did	do	VBD
cord-005478-5iu38pr6	3278	20	not	not	RB
cord-005478-5iu38pr6	3278	21	result	result	VB
cord-005478-5iu38pr6	3278	22	in	in	IN
cord-005478-5iu38pr6	3278	23	tumor	tumor	NN
cord-005478-5iu38pr6	3278	24	formation	formation	NN
cord-005478-5iu38pr6	3278	25	.	.	.
cord-005478-5iu38pr6	3279	1	To	to	TO
cord-005478-5iu38pr6	3279	2	exaggerate	exaggerate	VB
cord-005478-5iu38pr6	3279	3	potentially	potentially	RB
cord-005478-5iu38pr6	3279	4	transformative	transformative	JJ
cord-005478-5iu38pr6	3279	5	effects	effect	NNS
cord-005478-5iu38pr6	3279	6	of	of	IN
cord-005478-5iu38pr6	3279	7	Tat	Tat	NNP
cord-005478-5iu38pr6	3279	8	-	-	HYPH
cord-005478-5iu38pr6	3279	9	Myc	Myc	NNP
cord-005478-5iu38pr6	3279	10	protein	protein	NN
cord-005478-5iu38pr6	3279	11	,	,	,
cord-005478-5iu38pr6	3279	12	murine	murine	JJ
cord-005478-5iu38pr6	3279	13	marrow	marrow	NN
cord-005478-5iu38pr6	3279	14	was	be	VBD
cord-005478-5iu38pr6	3279	15	co	co	JJ
cord-005478-5iu38pr6	3279	16	-	-	VBN
cord-005478-5iu38pr6	3279	17	incubated	incubate	VBN
cord-005478-5iu38pr6	3279	18	with	with	IN
cord-005478-5iu38pr6	3279	19	both	both	CC
cord-005478-5iu38pr6	3279	20	Tat	Tat	NNP
cord-005478-5iu38pr6	3279	21	-	-	HYPH
cord-005478-5iu38pr6	3279	22	Myc	Myc	NNP
cord-005478-5iu38pr6	3279	23	and	and	CC
cord-005478-5iu38pr6	3279	24	Tat	Tat	NNP
cord-005478-5iu38pr6	3279	25	-	-	HYPH
cord-005478-5iu38pr6	3279	26	Bcl2	Bcl2	NNP
cord-005478-5iu38pr6	3279	27	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3279	28	proteins	protein	NNS
cord-005478-5iu38pr6	3279	29	prior	prior	RB
cord-005478-5iu38pr6	3279	30	to	to	IN
cord-005478-5iu38pr6	3279	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	3279	32	into	into	IN
cord-005478-5iu38pr6	3279	33	irradiated	irradiate	VBN
cord-005478-5iu38pr6	3279	34	immune	immune	JJ
cord-005478-5iu38pr6	3279	35	deficient	deficient	JJ
cord-005478-5iu38pr6	3279	36	mice	mouse	NNS
cord-005478-5iu38pr6	3279	37	.	.	.
cord-005478-5iu38pr6	3280	1	Mice	mouse	NNS
cord-005478-5iu38pr6	3280	2	were	be	VBD
cord-005478-5iu38pr6	3280	3	followed	follow	VBN
cord-005478-5iu38pr6	3280	4	for	for	IN
cord-005478-5iu38pr6	3280	5	24	24	CD
cord-005478-5iu38pr6	3280	6	weeks	week	NNS
cord-005478-5iu38pr6	3280	7	and	and	CC
cord-005478-5iu38pr6	3280	8	none	none	NN
cord-005478-5iu38pr6	3280	9	developed	develop	VBD
cord-005478-5iu38pr6	3280	10	malignancies	malignancy	NNS
cord-005478-5iu38pr6	3280	11	.	.	.
cord-005478-5iu38pr6	3281	1	Serially	serially	RB
cord-005478-5iu38pr6	3281	2	transplanted	transplant	VBN
cord-005478-5iu38pr6	3281	3	marrow	marrow	NN
cord-005478-5iu38pr6	3281	4	incubated	incubate	VBN
cord-005478-5iu38pr6	3281	5	with	with	IN
cord-005478-5iu38pr6	3281	6	both	both	CC
cord-005478-5iu38pr6	3281	7	Tat	Tat	NNP
cord-005478-5iu38pr6	3281	8	-	-	HYPH
cord-005478-5iu38pr6	3281	9	Myc	Myc	NNP
cord-005478-5iu38pr6	3281	10	and	and	CC
cord-005478-5iu38pr6	3281	11	Bcl-2	Bcl-2	NNP
cord-005478-5iu38pr6	3281	12	proteins	protein	NNS
cord-005478-5iu38pr6	3281	13	did	do	VBD
cord-005478-5iu38pr6	3281	14	not	not	RB
cord-005478-5iu38pr6	3281	15	result	result	VB
cord-005478-5iu38pr6	3281	16	in	in	IN
cord-005478-5iu38pr6	3281	17	malignancies	malignancy	NNS
cord-005478-5iu38pr6	3281	18	in	in	IN
cord-005478-5iu38pr6	3281	19	recipient	recipient	NN
cord-005478-5iu38pr6	3281	20	mice	mouse	NNS
cord-005478-5iu38pr6	3281	21	.	.	.
cord-005478-5iu38pr6	3282	1	Of	of	IN
cord-005478-5iu38pr6	3282	2	>	>	XX
cord-005478-5iu38pr6	3282	3	500	500	CD
cord-005478-5iu38pr6	3282	4	mice	mouse	NNS
cord-005478-5iu38pr6	3282	5	that	that	WDT
cord-005478-5iu38pr6	3282	6	have	have	VBP
cord-005478-5iu38pr6	3282	7	been	be	VBN
cord-005478-5iu38pr6	3282	8	exposed	expose	VBN
cord-005478-5iu38pr6	3282	9	to	to	IN
cord-005478-5iu38pr6	3282	10	Tat	Tat	NNP
cord-005478-5iu38pr6	3282	11	-	-	HYPH
cord-005478-5iu38pr6	3282	12	Myc	Myc	NNP
cord-005478-5iu38pr6	3282	13	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3282	14	protein	protein	NN
cord-005478-5iu38pr6	3282	15	in	in	IN
cord-005478-5iu38pr6	3282	16	our	-PRON-	PRP$
cord-005478-5iu38pr6	3282	17	experiments	experiment	NNS
cord-005478-5iu38pr6	3282	18	,	,	,
cord-005478-5iu38pr6	3282	19	none	none	NN
cord-005478-5iu38pr6	3282	20	has	have	VBZ
cord-005478-5iu38pr6	3282	21	developed	develop	VBN
cord-005478-5iu38pr6	3282	22	a	a	DT
cord-005478-5iu38pr6	3282	23	tumor	tumor	NN
cord-005478-5iu38pr6	3282	24	.	.	.
cord-005478-5iu38pr6	3283	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3283	2	:	:	:
cord-005478-5iu38pr6	3284	1	In	in	IN
cord-005478-5iu38pr6	3284	2	preclinical	preclinical	JJ
cord-005478-5iu38pr6	3284	3	studies	study	NNS
cord-005478-5iu38pr6	3284	4	,	,	,
cord-005478-5iu38pr6	3284	5	brief	brief	JJ
cord-005478-5iu38pr6	3284	6	incubation	incubation	NN
cord-005478-5iu38pr6	3284	7	with	with	IN
cord-005478-5iu38pr6	3284	8	Tat	Tat	NNP
cord-005478-5iu38pr6	3284	9	-	-	HYPH
cord-005478-5iu38pr6	3284	10	Myc	Myc	NNP
cord-005478-5iu38pr6	3284	11	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3284	12	protein	protein	NN
cord-005478-5iu38pr6	3284	13	enhances	enhance	VBZ
cord-005478-5iu38pr6	3284	14	homing	homing	NN
cord-005478-5iu38pr6	3284	15	,	,	,
cord-005478-5iu38pr6	3284	16	engraftment	engraftment	NN
cord-005478-5iu38pr6	3284	17	and	and	CC
cord-005478-5iu38pr6	3284	18	immune	immune	JJ
cord-005478-5iu38pr6	3284	19	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3284	20	of	of	IN
cord-005478-5iu38pr6	3284	21	murine	murine	JJ
cord-005478-5iu38pr6	3284	22	and	and	CC
cord-005478-5iu38pr6	3284	23	human	human	JJ
cord-005478-5iu38pr6	3284	24	cells	cell	NNS
cord-005478-5iu38pr6	3284	25	in	in	IN
cord-005478-5iu38pr6	3284	26	recipient	recipient	NN
cord-005478-5iu38pr6	3284	27	mice	mouse	NNS
cord-005478-5iu38pr6	3284	28	following	follow	VBG
cord-005478-5iu38pr6	3284	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	3284	30	.	.	.
cord-005478-5iu38pr6	3285	1	Brief	brief	JJ
cord-005478-5iu38pr6	3285	2	exposure	exposure	NN
cord-005478-5iu38pr6	3285	3	to	to	IN
cord-005478-5iu38pr6	3285	4	the	the	DT
cord-005478-5iu38pr6	3285	5	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3285	6	protein	protein	NN
cord-005478-5iu38pr6	3285	7	(	(	-LRB-
cord-005478-5iu38pr6	3285	8	as	as	IN
cord-005478-5iu38pr6	3285	9	opposed	oppose	VBN
cord-005478-5iu38pr6	3285	10	to	to	IN
cord-005478-5iu38pr6	3285	11	transduction	transduction	NN
cord-005478-5iu38pr6	3285	12	of	of	IN
cord-005478-5iu38pr6	3285	13	the	the	DT
cord-005478-5iu38pr6	3285	14	MYC	MYC	NNP
cord-005478-5iu38pr6	3285	15	gene	gene	NN
cord-005478-5iu38pr6	3285	16	)	)	-RRB-
cord-005478-5iu38pr6	3285	17	does	do	VBZ
cord-005478-5iu38pr6	3285	18	not	not	RB
cord-005478-5iu38pr6	3285	19	cause	cause	VB
cord-005478-5iu38pr6	3285	20	malignant	malignant	JJ
cord-005478-5iu38pr6	3285	21	transformation	transformation	NN
cord-005478-5iu38pr6	3285	22	of	of	IN
cord-005478-5iu38pr6	3285	23	cells	cell	NNS
cord-005478-5iu38pr6	3285	24	.	.	.
cord-005478-5iu38pr6	3286	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3286	2	are	be	VBP
cord-005478-5iu38pr6	3286	3	currently	currently	RB
cord-005478-5iu38pr6	3286	4	developing	develop	VBG
cord-005478-5iu38pr6	3286	5	clinical	clinical	JJ
cord-005478-5iu38pr6	3286	6	trials	trial	NNS
cord-005478-5iu38pr6	3286	7	using	use	VBG
cord-005478-5iu38pr6	3286	8	Tat	Tat	NNP
cord-005478-5iu38pr6	3286	9	-	-	HYPH
cord-005478-5iu38pr6	3286	10	Myc	Myc	NNP
cord-005478-5iu38pr6	3286	11	protein	protein	NN
cord-005478-5iu38pr6	3286	12	to	to	TO
cord-005478-5iu38pr6	3286	13	enhance	enhance	VB
cord-005478-5iu38pr6	3286	14	engraftment	engraftment	NN
cord-005478-5iu38pr6	3286	15	following	follow	VBG
cord-005478-5iu38pr6	3286	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3286	17	.	.	.
cord-005478-5iu38pr6	3287	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3287	2	:	:	:
cord-005478-5iu38pr6	3288	1	Greg	Greg	NNP
cord-005478-5iu38pr6	3288	2	Bird	Bird	NNP
cord-005478-5iu38pr6	3288	3	,	,	,
cord-005478-5iu38pr6	3288	4	Brian	Brian	NNP
cord-005478-5iu38pr6	3288	5	Turner	Turner	NNP
cord-005478-5iu38pr6	3288	6	,	,	,
cord-005478-5iu38pr6	3288	7	Thomas	Thomas	NNP
cord-005478-5iu38pr6	3288	8	Payne	Payne	NNP
cord-005478-5iu38pr6	3288	9	,	,	,
cord-005478-5iu38pr6	3288	10	Yosef	Yosef	NNP
cord-005478-5iu38pr6	3288	11	Refaeli	Refaeli	NNP
cord-005478-5iu38pr6	3288	12	are	be	VBP
cord-005478-5iu38pr6	3288	13	employees	employee	NNS
cord-005478-5iu38pr6	3288	14	and	and	CC
cord-005478-5iu38pr6	3288	15	or	or	CC
cord-005478-5iu38pr6	3288	16	shareholders	shareholder	NNS
cord-005478-5iu38pr6	3288	17	in	in	IN
cord-005478-5iu38pr6	3288	18	Taiga	Taiga	NNP
cord-005478-5iu38pr6	3288	19	Biotechnologies	Biotechnologies	NNPS
cord-005478-5iu38pr6	3288	20	.	.	.
cord-005478-5iu38pr6	3289	1	Jerry	Jerry	NNP
cord-005478-5iu38pr6	3289	2	Stein	Stein	NNP
cord-005478-5iu38pr6	3289	3	has	have	VBZ
cord-005478-5iu38pr6	3289	4	received	receive	VBN
cord-005478-5iu38pr6	3289	5	laboratory	laboratory	NN
cord-005478-5iu38pr6	3289	6	support	support	NN
cord-005478-5iu38pr6	3289	7	from	from	IN
cord-005478-5iu38pr6	3289	8	Taiga	Taiga	NNP
cord-005478-5iu38pr6	3289	9	Biotechnologies	Biotechnologies	NNPS
cord-005478-5iu38pr6	3289	10	Graft	Graft	NNP
cord-005478-5iu38pr6	3289	11	γδ	γδ	NNP
cord-005478-5iu38pr6	3289	12	T	t	NN
cord-005478-5iu38pr6	3289	13	-	-	HYPH
cord-005478-5iu38pr6	3289	14	cell	cell	NN
cord-005478-5iu38pr6	3289	15	receptor	receptor	NN
cord-005478-5iu38pr6	3289	16	sequencing	sequencing	NN
cord-005478-5iu38pr6	3289	17	identifies	identify	VBZ
cord-005478-5iu38pr6	3289	18	public	public	JJ
cord-005478-5iu38pr6	3289	19	clonotypes	clonotype	NNS
cord-005478-5iu38pr6	3289	20	associated	associate	VBN
cord-005478-5iu38pr6	3289	21	to	to	IN
cord-005478-5iu38pr6	3289	22	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3289	23	efficacy	efficacy	NN
cord-005478-5iu38pr6	3289	24	in	in	IN
cord-005478-5iu38pr6	3289	25	AML	AML	NNP
cord-005478-5iu38pr6	3289	26	patients	patient	NNS
cord-005478-5iu38pr6	3289	27	and	and	CC
cord-005478-5iu38pr6	3289	28	unravels	unravel	VBZ
cord-005478-5iu38pr6	3289	29	CMV	CMV	NNP
cord-005478-5iu38pr6	3289	30	impact	impact	NN
cord-005478-5iu38pr6	3289	31	on	on	IN
cord-005478-5iu38pr6	3289	32	repertoire	repertoire	NN
cord-005478-5iu38pr6	3289	33	distribution	distribution	NN
cord-005478-5iu38pr6	3289	34	Lucas	Lucas	NNP
cord-005478-5iu38pr6	3289	35	CM	CM	NNP
cord-005478-5iu38pr6	3289	36	Arruda	Arruda	NNP
cord-005478-5iu38pr6	3289	37	1	1	CD
cord-005478-5iu38pr6	3289	38	,	,	,
cord-005478-5iu38pr6	3289	39	Ahmed	Ahmed	NNP
cord-005478-5iu38pr6	3289	40	Gaballa	Gaballa	NNP
cord-005478-5iu38pr6	3289	41	1	1	CD
cord-005478-5iu38pr6	3289	42	,	,	,
cord-005478-5iu38pr6	3289	43	Michael	Michael	NNP
cord-005478-5iu38pr6	3289	44	Uhlin	Uhlin	NNP
cord-005478-5iu38pr6	3289	45	1,2,3	1,2,3	CD
cord-005478-5iu38pr6	3289	46	relapse	relapse	NN
cord-005478-5iu38pr6	3289	47	patient	patient	JJ
cord-005478-5iu38pr6	3289	48	group	group	NN
cord-005478-5iu38pr6	3289	49	had	have	VBD
cord-005478-5iu38pr6	3289	50	an	an	DT
cord-005478-5iu38pr6	3289	51	increased	increase	VBN
cord-005478-5iu38pr6	3289	52	proportion	proportion	NN
cord-005478-5iu38pr6	3289	53	of	of	IN
cord-005478-5iu38pr6	3289	54	long	long	JJ
cord-005478-5iu38pr6	3289	55	CDR3	CDR3	NNP
cord-005478-5iu38pr6	3289	56	sequences	sequence	NNS
cord-005478-5iu38pr6	3289	57	(	(	-LRB-
cord-005478-5iu38pr6	3289	58	54	54	CD
cord-005478-5iu38pr6	3289	59	-	-	SYM
cord-005478-5iu38pr6	3289	60	57	57	CD
cord-005478-5iu38pr6	3289	61	nucleotides	nucleotide	NNS
cord-005478-5iu38pr6	3289	62	)	)	-RRB-
cord-005478-5iu38pr6	3289	63	compared	compare	VBN
cord-005478-5iu38pr6	3289	64	to	to	IN
cord-005478-5iu38pr6	3289	65	relapse	relapse	NN
cord-005478-5iu38pr6	3289	66	patients	patient	NNS
cord-005478-5iu38pr6	3289	67	[	[	-LRB-
cord-005478-5iu38pr6	3289	68	0.41%vs0.27	0.41%vs0.27	CD
cord-005478-5iu38pr6	3289	69	%	%	NN
cord-005478-5iu38pr6	3289	70	(	(	-LRB-
cord-005478-5iu38pr6	3289	71	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3289	72	)	)	-RRB-
cord-005478-5iu38pr6	3289	73	and	and	CC
cord-005478-5iu38pr6	3289	74	0.11%vs0.04	0.11%vs0.04	CD
cord-005478-5iu38pr6	3289	75	%	%	NN
cord-005478-5iu38pr6	3289	76	(	(	-LRB-
cord-005478-5iu38pr6	3289	77	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3289	78	)	)	-RRB-
cord-005478-5iu38pr6	3289	79	]	]	-RRB-
cord-005478-5iu38pr6	3289	80	.	.	.
cord-005478-5iu38pr6	3290	1	Grafts	graft	NNS
cord-005478-5iu38pr6	3290	2	from	from	IN
cord-005478-5iu38pr6	3290	3	CMV	CMV	NNP
cord-005478-5iu38pr6	3290	4	-	-	HYPH
cord-005478-5iu38pr6	3290	5	positive	positive	JJ
cord-005478-5iu38pr6	3290	6	donors	donor	NNS
cord-005478-5iu38pr6	3290	7	presented	present	VBD
cord-005478-5iu38pr6	3290	8	significantly	significantly	RB
cord-005478-5iu38pr6	3290	9	reduced	reduce	VBN
cord-005478-5iu38pr6	3290	10	diversity	diversity	NN
cord-005478-5iu38pr6	3290	11	(	(	-LRB-
cord-005478-5iu38pr6	3290	12	inverse	inverse	JJ
cord-005478-5iu38pr6	3290	13	Simpson	Simpson	NNP
cord-005478-5iu38pr6	3290	14	's	's	POS
cord-005478-5iu38pr6	3290	15	DI	di	NN
cord-005478-5iu38pr6	3290	16	:	:	:
cord-005478-5iu38pr6	3290	17	30.70vs81.21	30.70vs81.21	CD
cord-005478-5iu38pr6	3290	18	,	,	,
cord-005478-5iu38pr6	3290	19	P=0.02	p=0.02	CD
cord-005478-5iu38pr6	3290	20	)	)	-RRB-
cord-005478-5iu38pr6	3290	21	,	,	,
cord-005478-5iu38pr6	3290	22	decreased	decrease	VBD
cord-005478-5iu38pr6	3290	23	proportion	proportion	NN
cord-005478-5iu38pr6	3290	24	of	of	IN
cord-005478-5iu38pr6	3290	25	CDR3	CDR3	NNP
cord-005478-5iu38pr6	3290	26	sequences	sequence	NNS
cord-005478-5iu38pr6	3290	27	having	have	VBG
cord-005478-5iu38pr6	3290	28	24	24	CD
cord-005478-5iu38pr6	3290	29	,	,	,
cord-005478-5iu38pr6	3290	30	27	27	CD
cord-005478-5iu38pr6	3290	31	,	,	,
cord-005478-5iu38pr6	3290	32	42	42	CD
cord-005478-5iu38pr6	3290	33	and	and	CC
cord-005478-5iu38pr6	3290	34	51	51	CD
cord-005478-5iu38pr6	3290	35	nucleotides	nucleotide	NNS
cord-005478-5iu38pr6	3290	36	[	[	-LRB-
cord-005478-5iu38pr6	3290	37	0.27%vs0.61	0.27%vs0.61	CD
cord-005478-5iu38pr6	3290	38	%	%	NN
cord-005478-5iu38pr6	3290	39	(	(	-LRB-
cord-005478-5iu38pr6	3290	40	P=0.01	P=0.01	NNP
cord-005478-5iu38pr6	3290	41	)	)	-RRB-
cord-005478-5iu38pr6	3290	42	,	,	,
cord-005478-5iu38pr6	3290	43	0.57%vs1.12	0.57%vs1.12	CD
cord-005478-5iu38pr6	3290	44	%	%	NN
cord-005478-5iu38pr6	3290	45	(	(	-LRB-
cord-005478-5iu38pr6	3290	46	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3290	47	)	)	-RRB-
cord-005478-5iu38pr6	3290	48	,	,	,
cord-005478-5iu38pr6	3290	49	5.11%vs7.54	5.11%vs7.54	CD
cord-005478-5iu38pr6	3290	50	%	%	NN
cord-005478-5iu38pr6	3290	51	(	(	-LRB-
cord-005478-5iu38pr6	3290	52	P=0.007	p=0.007	NN
cord-005478-5iu38pr6	3290	53	)	)	-RRB-
cord-005478-5iu38pr6	3290	54	and	and	CC
cord-005478-5iu38pr6	3290	55	0.61%vs2.1	0.61%vs2.1	CD
cord-005478-5iu38pr6	3290	56	%	%	NN
cord-005478-5iu38pr6	3290	57	(	(	-LRB-
cord-005478-5iu38pr6	3290	58	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3290	59	)	)	-RRB-
cord-005478-5iu38pr6	3290	60	]	]	-RRB-
cord-005478-5iu38pr6	3290	61	,	,	,
cord-005478-5iu38pr6	3290	62	and	and	CC
cord-005478-5iu38pr6	3290	63	an	an	DT
cord-005478-5iu38pr6	3290	64	increase	increase	NN
cord-005478-5iu38pr6	3290	65	of	of	IN
cord-005478-5iu38pr6	3290	66	sequences	sequence	NNS
cord-005478-5iu38pr6	3290	67	with	with	IN
cord-005478-5iu38pr6	3290	68	30	30	CD
cord-005478-5iu38pr6	3290	69	-	-	SYM
cord-005478-5iu38pr6	3290	70	39	39	CD
cord-005478-5iu38pr6	3290	71	nucleotides	nucleotide	NNS
cord-005478-5iu38pr6	3290	72	(	(	-LRB-
cord-005478-5iu38pr6	3290	73	5.32%vs4.13	5.32%vs4.13	CD
cord-005478-5iu38pr6	3290	74	%	%	NN
cord-005478-5iu38pr6	3290	75	,	,	,
cord-005478-5iu38pr6	3290	76	P=0.03	P=0.03	NNP
cord-005478-5iu38pr6	3290	77	)	)	-RRB-
cord-005478-5iu38pr6	3290	78	.	.	.
cord-005478-5iu38pr6	3291	1	Hyperexpanded	Hyperexpanded	NNP
cord-005478-5iu38pr6	3291	2	clones	clone	NNS
cord-005478-5iu38pr6	3291	3	took	take	VBD
cord-005478-5iu38pr6	3291	4	up	up	RP
cord-005478-5iu38pr6	3291	5	2.5	2.5	CD
cord-005478-5iu38pr6	3291	6	times	time	NNS
cord-005478-5iu38pr6	3291	7	more	more	JJR
cord-005478-5iu38pr6	3291	8	space	space	NN
cord-005478-5iu38pr6	3291	9	in	in	IN
cord-005478-5iu38pr6	3291	10	the	the	DT
cord-005478-5iu38pr6	3291	11	CMV	CMV	NNP
cord-005478-5iu38pr6	3291	12	positive	positive	JJ
cord-005478-5iu38pr6	3291	13	grafts	graft	NNS
cord-005478-5iu38pr6	3291	14	(	(	-LRB-
cord-005478-5iu38pr6	3291	15	49.33	49.33	CD
cord-005478-5iu38pr6	3291	16	%	%	NN
cord-005478-5iu38pr6	3291	17	vs19.38	vs19.38	NN
cord-005478-5iu38pr6	3291	18	%	%	NN
cord-005478-5iu38pr6	3291	19	,	,	,
cord-005478-5iu38pr6	3291	20	P=0.007	P=0.007	NNP
cord-005478-5iu38pr6	3291	21	)	)	-RRB-
cord-005478-5iu38pr6	3291	22	,	,	,
cord-005478-5iu38pr6	3291	23	who	who	WP
cord-005478-5iu38pr6	3291	24	presented	present	VBD
cord-005478-5iu38pr6	3291	25	a	a	DT
cord-005478-5iu38pr6	3291	26	skewed	skewed	JJ
cord-005478-5iu38pr6	3291	27	non	non	JJ
cord-005478-5iu38pr6	3291	28	-	-	JJ
cord-005478-5iu38pr6	3291	29	Gaussian	gaussian	JJ
cord-005478-5iu38pr6	3291	30	distribution	distribution	NN
cord-005478-5iu38pr6	3291	31	.	.	.
cord-005478-5iu38pr6	3292	1	For	for	IN
cord-005478-5iu38pr6	3292	2	all	all	DT
cord-005478-5iu38pr6	3292	3	samples	sample	NNS
cord-005478-5iu38pr6	3292	4	,	,	,
cord-005478-5iu38pr6	3292	5	the	the	DT
cord-005478-5iu38pr6	3292	6	segments	segment	NNS
cord-005478-5iu38pr6	3292	7	TRGV9	TRGV9	VBD
cord-005478-5iu38pr6	3292	8	and	and	CC
cord-005478-5iu38pr6	3292	9	TRGJP	TRGJP	NNP
cord-005478-5iu38pr6	3292	10	were	be	VBD
cord-005478-5iu38pr6	3292	11	the	the	DT
cord-005478-5iu38pr6	3292	12	most	most	RBS
cord-005478-5iu38pr6	3292	13	frequent	frequent	JJ
cord-005478-5iu38pr6	3292	14	.	.	.
cord-005478-5iu38pr6	3293	1	Nonrelapsing	Nonrelapsing	NNP
cord-005478-5iu38pr6	3293	2	group	group	NN
cord-005478-5iu38pr6	3293	3	received	receive	VBD
cord-005478-5iu38pr6	3293	4	grafts	graft	NNS
cord-005478-5iu38pr6	3293	5	with	with	IN
cord-005478-5iu38pr6	3293	6	lower	low	JJR
cord-005478-5iu38pr6	3293	7	usage	usage	NN
cord-005478-5iu38pr6	3293	8	of	of	IN
cord-005478-5iu38pr6	3293	9	TRGV4	trgv4	NN
cord-005478-5iu38pr6	3293	10	,	,	,
cord-005478-5iu38pr6	3293	11	TRGV5	TRGV5	NNP
cord-005478-5iu38pr6	3293	12	and	and	CC
cord-005478-5iu38pr6	3293	13	TRGJP2	trgjp2	NN
cord-005478-5iu38pr6	3293	14	segments	segment	NNS
cord-005478-5iu38pr6	3293	15	and	and	CC
cord-005478-5iu38pr6	3293	16	higher	high	JJR
cord-005478-5iu38pr6	3293	17	usage	usage	NN
cord-005478-5iu38pr6	3293	18	of	of	IN
cord-005478-5iu38pr6	3293	19	TRGJP1	trgjp1	NN
cord-005478-5iu38pr6	3293	20	compared	compare	VBN
cord-005478-5iu38pr6	3293	21	to	to	IN
cord-005478-5iu38pr6	3293	22	relapse	relapse	NN
cord-005478-5iu38pr6	3293	23	patients	patient	NNS
cord-005478-5iu38pr6	3293	24	[	[	-LRB-
cord-005478-5iu38pr6	3293	25	4.13%vs7.46	4.13%vs7.46	CD
cord-005478-5iu38pr6	3293	26	%	%	NN
cord-005478-5iu38pr6	3293	27	(	(	-LRB-
cord-005478-5iu38pr6	3293	28	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3293	29	)	)	-RRB-
cord-005478-5iu38pr6	3293	30	,	,	,
cord-005478-5iu38pr6	3293	31	1.12%vs4.77	1.12%vs4.77	CD
cord-005478-5iu38pr6	3293	32	%	%	NN
cord-005478-5iu38pr6	3293	33	(	(	-LRB-
cord-005478-5iu38pr6	3293	34	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3293	35	)	)	-RRB-
cord-005478-5iu38pr6	3293	36	,	,	,
cord-005478-5iu38pr6	3293	37	3.02%vs5.52	3.02%vs5.52	CD
cord-005478-5iu38pr6	3293	38	%	%	NN
cord-005478-5iu38pr6	3293	39	(	(	-LRB-
cord-005478-5iu38pr6	3293	40	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3293	41	)	)	-RRB-
cord-005478-5iu38pr6	3293	42	and	and	CC
cord-005478-5iu38pr6	3293	43	6.62%vs3.23	6.62%vs3.23	CD
cord-005478-5iu38pr6	3293	44	%	%	NN
cord-005478-5iu38pr6	3293	45	(	(	-LRB-
cord-005478-5iu38pr6	3293	46	P=0	P=0	NNP
cord-005478-5iu38pr6	3293	47	.	.	.
cord-005478-5iu38pr6	3293	48	02	02	CD
cord-005478-5iu38pr6	3293	49	)	)	-RRB-
cord-005478-5iu38pr6	3293	50	]	]	-RRB-
cord-005478-5iu38pr6	3293	51	.	.	.
cord-005478-5iu38pr6	3294	1	CMV	CMV	NNP
cord-005478-5iu38pr6	3294	2	-	-	HYPH
cord-005478-5iu38pr6	3294	3	positive	positive	JJ
cord-005478-5iu38pr6	3294	4	donor	donor	NN
cord-005478-5iu38pr6	3294	5	grafts	graft	NNS
cord-005478-5iu38pr6	3294	6	presented	present	VBD
cord-005478-5iu38pr6	3294	7	a	a	DT
cord-005478-5iu38pr6	3294	8	lower	low	JJR
cord-005478-5iu38pr6	3294	9	TRGV2	trgv2	NN
cord-005478-5iu38pr6	3294	10	and	and	CC
cord-005478-5iu38pr6	3294	11	TRGJP	TRGJP	NNP
cord-005478-5iu38pr6	3294	12	expression	expression	NN
cord-005478-5iu38pr6	3294	13	(	(	-LRB-
cord-005478-5iu38pr6	3294	14	6.29%vs8.99	6.29%vs8.99	CD
cord-005478-5iu38pr6	3294	15	%	%	NN
cord-005478-5iu38pr6	3294	16	,	,	,
cord-005478-5iu38pr6	3294	17	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3294	18	,	,	,
cord-005478-5iu38pr6	3294	19	and	and	CC
cord-005478-5iu38pr6	3294	20	30.99	30.99	CD
cord-005478-5iu38pr6	3294	21	%	%	NN
cord-005478-5iu38pr6	3294	22	vs60.63	vs60.63	NN
cord-005478-5iu38pr6	3294	23	%	%	NN
cord-005478-5iu38pr6	3294	24	,	,	,
cord-005478-5iu38pr6	3294	25	P=0.01	P=0.01	NNP
cord-005478-5iu38pr6	3294	26	)	)	-RRB-
cord-005478-5iu38pr6	3294	27	as	as	RB
cord-005478-5iu38pr6	3294	28	well	well	RB
cord-005478-5iu38pr6	3294	29	as	as	IN
cord-005478-5iu38pr6	3294	30	a	a	DT
cord-005478-5iu38pr6	3294	31	higher	high	JJR
cord-005478-5iu38pr6	3294	32	TRGJP1	trgjp1	NN
cord-005478-5iu38pr6	3294	33	gene	gene	NN
cord-005478-5iu38pr6	3294	34	usage	usage	NN
cord-005478-5iu38pr6	3294	35	(	(	-LRB-
cord-005478-5iu38pr6	3294	36	11.04%vs3.90	11.04%vs3.90	CD
cord-005478-5iu38pr6	3294	37	%	%	NN
cord-005478-5iu38pr6	3294	38	,	,	,
cord-005478-5iu38pr6	3294	39	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3294	40	)	)	-RRB-
cord-005478-5iu38pr6	3294	41	.	.	.
cord-005478-5iu38pr6	3295	1	The	the	DT
cord-005478-5iu38pr6	3295	2	V9-JP	v9-jp	NN
cord-005478-5iu38pr6	3295	3	combination	combination	NN
cord-005478-5iu38pr6	3295	4	was	be	VBD
cord-005478-5iu38pr6	3295	5	the	the	DT
cord-005478-5iu38pr6	3295	6	most	most	RBS
cord-005478-5iu38pr6	3295	7	frequent	frequent	JJ
cord-005478-5iu38pr6	3295	8	pairing	pairing	NN
cord-005478-5iu38pr6	3295	9	in	in	IN
cord-005478-5iu38pr6	3295	10	all	all	DT
cord-005478-5iu38pr6	3295	11	samples	sample	NNS
cord-005478-5iu38pr6	3295	12	.	.	.
cord-005478-5iu38pr6	3296	1	Non	non	JJ
cord-005478-5iu38pr6	3296	2	-	-	JJ
cord-005478-5iu38pr6	3296	3	relapse	relapse	JJ
cord-005478-5iu38pr6	3296	4	patients	patient	NNS
cord-005478-5iu38pr6	3296	5	received	receive	VBD
cord-005478-5iu38pr6	3296	6	grafts	graft	NNS
cord-005478-5iu38pr6	3296	7	with	with	IN
cord-005478-5iu38pr6	3296	8	lower	low	JJR
cord-005478-5iu38pr6	3296	9	usage	usage	NN
cord-005478-5iu38pr6	3296	10	of	of	IN
cord-005478-5iu38pr6	3296	11	the	the	DT
cord-005478-5iu38pr6	3296	12	pairing	pair	VBG
cord-005478-5iu38pr6	3296	13	V4-J2	V4-J2	NNP
cord-005478-5iu38pr6	3296	14	,	,	,
cord-005478-5iu38pr6	3296	15	V5-J2	V5-J2	NNP
cord-005478-5iu38pr6	3296	16	,	,	,
cord-005478-5iu38pr6	3296	17	V8-JP2	V8-JP2	NNP
cord-005478-5iu38pr6	3296	18	[	[	-LRB-
cord-005478-5iu38pr6	3296	19	3.12%vs6.57	3.12%vs6.57	CD
cord-005478-5iu38pr6	3296	20	%	%	NN
cord-005478-5iu38pr6	3296	21	(	(	-LRB-
cord-005478-5iu38pr6	3296	22	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3296	23	)	)	-RRB-
cord-005478-5iu38pr6	3296	24	,	,	.
cord-005478-5iu38pr6	3297	1	1.06	1.06	CD
cord-005478-5iu38pr6	3297	2	%	%	NN
cord-005478-5iu38pr6	3297	3	vs4.38	vs4.38	NN
cord-005478-5iu38pr6	3297	4	%	%	NN
cord-005478-5iu38pr6	3297	5	(	(	-LRB-
cord-005478-5iu38pr6	3297	6	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3297	7	)	)	-RRB-
cord-005478-5iu38pr6	3297	8	and	and	CC
cord-005478-5iu38pr6	3297	9	1.33%vs1.91	1.33%vs1.91	CD
cord-005478-5iu38pr6	3297	10	%	%	NN
cord-005478-5iu38pr6	3297	11	(	(	-LRB-
cord-005478-5iu38pr6	3297	12	P=0.03	p=0.03	NN
cord-005478-5iu38pr6	3297	13	)	)	-RRB-
cord-005478-5iu38pr6	3297	14	]	]	-RRB-
cord-005478-5iu38pr6	3297	15	and	and	CC
cord-005478-5iu38pr6	3297	16	higher	high	JJR
cord-005478-5iu38pr6	3297	17	usage	usage	NN
cord-005478-5iu38pr6	3297	18	of	of	IN
cord-005478-5iu38pr6	3297	19	V2-JP1	V2-JP1	NNP
cord-005478-5iu38pr6	3297	20	pairing	pair	VBG
cord-005478-5iu38pr6	3297	21	(	(	-LRB-
cord-005478-5iu38pr6	3297	22	1.28%vs0.36	1.28%vs0.36	CD
cord-005478-5iu38pr6	3297	23	%	%	NN
cord-005478-5iu38pr6	3297	24	,	,	,
cord-005478-5iu38pr6	3297	25	P=0.03	p=0.03	NN
cord-005478-5iu38pr6	3297	26	)	)	-RRB-
cord-005478-5iu38pr6	3298	1	than	than	IN
cord-005478-5iu38pr6	3298	2	relapse	relapse	NN
cord-005478-5iu38pr6	3298	3	patients	patient	NNS
cord-005478-5iu38pr6	3298	4	.	.	.
cord-005478-5iu38pr6	3299	1	The	the	DT
cord-005478-5iu38pr6	3299	2	TCR	TCR	NNP
cord-005478-5iu38pr6	3299	3	usage	usage	NN
cord-005478-5iu38pr6	3299	4	of	of	IN
cord-005478-5iu38pr6	3299	5	the	the	DT
cord-005478-5iu38pr6	3299	6	sequence	sequence	NN
cord-005478-5iu38pr6	3299	7	pairs	pair	VBZ
cord-005478-5iu38pr6	3299	8	V2-J2	V2-J2	NNP
cord-005478-5iu38pr6	3299	9	,	,	,
cord-005478-5iu38pr6	3300	1	V2-JP2	v2-jp2	NN
cord-005478-5iu38pr6	3300	2	,	,	,
cord-005478-5iu38pr6	3300	3	V4-JP2	V4-JP2	NNP
cord-005478-5iu38pr6	3300	4	,	,	,
cord-005478-5iu38pr6	3300	5	V9-JP	v9-jp	NN
cord-005478-5iu38pr6	3300	6	,	,	,
cord-005478-5iu38pr6	3300	7	and	and	CC
cord-005478-5iu38pr6	3300	8	V9-JP2	V9-JP2	NNP
cord-005478-5iu38pr6	3300	9	was	be	VBD
cord-005478-5iu38pr6	3300	10	lower	low	JJR
cord-005478-5iu38pr6	3300	11	in	in	IN
cord-005478-5iu38pr6	3300	12	CMV	CMV	NNP
cord-005478-5iu38pr6	3300	13	-	-	HYPH
cord-005478-5iu38pr6	3300	14	positive	positive	JJ
cord-005478-5iu38pr6	3300	15	grafts	graft	NNS
cord-005478-5iu38pr6	3300	16	[	[	-LRB-
cord-005478-5iu38pr6	3300	17	4.62%vs6.94	4.62%vs6.94	CD
cord-005478-5iu38pr6	3300	18	%	%	NN
cord-005478-5iu38pr6	3300	19	(	(	-LRB-
cord-005478-5iu38pr6	3300	20	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3300	21	)	)	-RRB-
cord-005478-5iu38pr6	3300	22	,	,	,
cord-005478-5iu38pr6	3300	23	0.59%vs1.33	0.59%vs1.33	CD
cord-005478-5iu38pr6	3300	24	%	%	NN
cord-005478-5iu38pr6	3300	25	(	(	-LRB-
cord-005478-5iu38pr6	3300	26	P=0.04	P=0.04	NNP
cord-005478-5iu38pr6	3300	27	)	)	-RRB-
cord-005478-5iu38pr6	3300	28	,	,	,
cord-005478-5iu38pr6	3300	29	0.31%vs0.09	0.31%vs0.09	CD
cord-005478-5iu38pr6	3300	30	%	%	NN
cord-005478-5iu38pr6	3300	31	(	(	-LRB-
cord-005478-5iu38pr6	3300	32	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3300	33	)	)	-RRB-
cord-005478-5iu38pr6	3300	34	,	,	,
cord-005478-5iu38pr6	3300	35	30.75%vs60.30	30.75%vs60.30	CD
cord-005478-5iu38pr6	3300	36	%	%	NN
cord-005478-5iu38pr6	3300	37	(	(	-LRB-
cord-005478-5iu38pr6	3300	38	P=0.02	P=0.02	NNP
cord-005478-5iu38pr6	3300	39	)	)	-RRB-
cord-005478-5iu38pr6	3300	40	and	and	CC
cord-005478-5iu38pr6	3300	41	0.07%vs0.29	0.07%vs0.29	CD
cord-005478-5iu38pr6	3300	42	%	%	NN
cord-005478-5iu38pr6	3300	43	(	(	-LRB-
cord-005478-5iu38pr6	3300	44	P=0.01	P=0.01	NNP
cord-005478-5iu38pr6	3300	45	)	)	-RRB-
cord-005478-5iu38pr6	3300	46	]	]	-RRB-
cord-005478-5iu38pr6	3300	47	.	.	.
cord-005478-5iu38pr6	3301	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3301	2	identified	identify	VBD
cord-005478-5iu38pr6	3301	3	12	12	CD
cord-005478-5iu38pr6	3301	4	public	public	JJ
cord-005478-5iu38pr6	3301	5	clones	clone	NNS
cord-005478-5iu38pr6	3301	6	shared	share	VBN
cord-005478-5iu38pr6	3301	7	exclusively	exclusively	RB
cord-005478-5iu38pr6	3301	8	between	between	IN
cord-005478-5iu38pr6	3301	9	the	the	DT
cord-005478-5iu38pr6	3301	10	grafts	graft	NNS
cord-005478-5iu38pr6	3301	11	received	receive	VBN
cord-005478-5iu38pr6	3301	12	by	by	IN
cord-005478-5iu38pr6	3301	13	non	non	JJ
cord-005478-5iu38pr6	3301	14	-	-	JJ
cord-005478-5iu38pr6	3301	15	relapsing	relapsing	JJ
cord-005478-5iu38pr6	3301	16	patients	patient	NNS
cord-005478-5iu38pr6	3301	17	in	in	IN
cord-005478-5iu38pr6	3301	18	addition	addition	NN
cord-005478-5iu38pr6	3301	19	to	to	IN
cord-005478-5iu38pr6	3301	20	four	four	CD
cord-005478-5iu38pr6	3301	21	private	private	JJ
cord-005478-5iu38pr6	3301	22	over	over	RB
cord-005478-5iu38pr6	3301	23	-	-	HYPH
cord-005478-5iu38pr6	3301	24	represented	represent	VBN
cord-005478-5iu38pr6	3301	25	sequences	sequence	NNS
cord-005478-5iu38pr6	3301	26	exclusively	exclusively	RB
cord-005478-5iu38pr6	3301	27	present	present	JJ
cord-005478-5iu38pr6	3301	28	in	in	IN
cord-005478-5iu38pr6	3301	29	grafts	graft	NNS
cord-005478-5iu38pr6	3301	30	given	give	VBN
cord-005478-5iu38pr6	3301	31	to	to	IN
cord-005478-5iu38pr6	3301	32	nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	3301	33	patients	patient	NNS
cord-005478-5iu38pr6	3301	34	,	,	,
cord-005478-5iu38pr6	3301	35	taking	take	VBG
cord-005478-5iu38pr6	3301	36	from	from	IN
cord-005478-5iu38pr6	3301	37	2.00	2.00	CD
cord-005478-5iu38pr6	3301	38	%	%	NN
cord-005478-5iu38pr6	3301	39	to	to	IN
cord-005478-5iu38pr6	3301	40	6.23	6.23	CD
cord-005478-5iu38pr6	3301	41	%	%	NN
cord-005478-5iu38pr6	3301	42	of	of	IN
cord-005478-5iu38pr6	3301	43	the	the	DT
cord-005478-5iu38pr6	3301	44	TRG	TRG	NNP
cord-005478-5iu38pr6	3301	45	repertoire	repertoire	NN
cord-005478-5iu38pr6	3301	46	and	and	CC
cord-005478-5iu38pr6	3301	47	longer	long	JJR
cord-005478-5iu38pr6	3301	48	than	than	IN
cord-005478-5iu38pr6	3301	49	45	45	CD
cord-005478-5iu38pr6	3301	50	nucleotides	nucleotide	NNS
cord-005478-5iu38pr6	3301	51	.	.	.
cord-005478-5iu38pr6	3302	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3302	2	also	also	RB
cord-005478-5iu38pr6	3302	3	identified	identify	VBD
cord-005478-5iu38pr6	3302	4	five	five	CD
cord-005478-5iu38pr6	3302	5	private	private	JJ
cord-005478-5iu38pr6	3302	6	over	over	RB
cord-005478-5iu38pr6	3302	7	-	-	HYPH
cord-005478-5iu38pr6	3302	8	represented	represent	VBN
cord-005478-5iu38pr6	3302	9	and	and	CC
cord-005478-5iu38pr6	3302	10	one	one	CD
cord-005478-5iu38pr6	3302	11	public	public	JJ
cord-005478-5iu38pr6	3302	12	CDR3	CDR3	NNP
cord-005478-5iu38pr6	3302	13	sequence	sequence	NN
cord-005478-5iu38pr6	3302	14	associated	associate	VBN
cord-005478-5iu38pr6	3302	15	to	to	IN
cord-005478-5iu38pr6	3302	16	CMV	CMV	NNP
cord-005478-5iu38pr6	3302	17	infection	infection	NN
cord-005478-5iu38pr6	3302	18	.	.	.
cord-005478-5iu38pr6	3303	1	Additionally	additionally	RB
cord-005478-5iu38pr6	3303	2	,	,	,
cord-005478-5iu38pr6	3303	3	CMV	CMV	NNP
cord-005478-5iu38pr6	3303	4	-	-	HYPH
cord-005478-5iu38pr6	3303	5	positive	positive	JJ
cord-005478-5iu38pr6	3303	6	grafts	graft	NNS
cord-005478-5iu38pr6	3303	7	presented	present	VBD
cord-005478-5iu38pr6	3303	8	the	the	DT
cord-005478-5iu38pr6	3303	9	highest	high	JJS
cord-005478-5iu38pr6	3303	10	percentage	percentage	NN
cord-005478-5iu38pr6	3303	11	or	or	CC
cord-005478-5iu38pr6	3303	12	repertoire	repertoire	NN
cord-005478-5iu38pr6	3303	13	taken	take	VBN
cord-005478-5iu38pr6	3303	14	by	by	IN
cord-005478-5iu38pr6	3303	15	private	private	JJ
cord-005478-5iu38pr6	3303	16	over	over	RB
cord-005478-5iu38pr6	3303	17	-	-	HYPH
cord-005478-5iu38pr6	3303	18	represented	represent	VBN
cord-005478-5iu38pr6	3303	19	clones	clone	NNS
cord-005478-5iu38pr6	3303	20	,	,	,
cord-005478-5iu38pr6	3303	21	ranging	range	VBG
cord-005478-5iu38pr6	3303	22	from	from	IN
cord-005478-5iu38pr6	3303	23	13.72	13.72	CD
cord-005478-5iu38pr6	3303	24	%	%	NN
cord-005478-5iu38pr6	3303	25	to	to	IN
cord-005478-5iu38pr6	3303	26	41.61	41.61	CD
cord-005478-5iu38pr6	3303	27	%	%	NN
cord-005478-5iu38pr6	3303	28	.	.	.
cord-005478-5iu38pr6	3304	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3304	2	:	:	:
cord-005478-5iu38pr6	3305	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	3305	2	findings	finding	NNS
cord-005478-5iu38pr6	3305	3	show	show	VBP
cord-005478-5iu38pr6	3305	4	that	that	IN
cord-005478-5iu38pr6	3305	5	the	the	DT
cord-005478-5iu38pr6	3305	6	TRG	TRG	NNP
cord-005478-5iu38pr6	3305	7	composition	composition	NN
cord-005478-5iu38pr6	3305	8	is	be	VBZ
cord-005478-5iu38pr6	3305	9	not	not	RB
cord-005478-5iu38pr6	3305	10	associated	associate	VBN
cord-005478-5iu38pr6	3305	11	to	to	IN
cord-005478-5iu38pr6	3305	12	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3305	13	incidence	incidence	NN
cord-005478-5iu38pr6	3305	14	,	,	,
cord-005478-5iu38pr6	3305	15	CMV	CMV	NNP
cord-005478-5iu38pr6	3305	16	infection	infection	NN
cord-005478-5iu38pr6	3305	17	reshapes	reshape	VBZ
cord-005478-5iu38pr6	3305	18	the	the	DT
cord-005478-5iu38pr6	3305	19	TRG	TRG	NNP
cord-005478-5iu38pr6	3305	20	repertoire	repertoire	NN
cord-005478-5iu38pr6	3305	21	and	and	CC
cord-005478-5iu38pr6	3305	22	several	several	JJ
cord-005478-5iu38pr6	3305	23	public	public	JJ
cord-005478-5iu38pr6	3305	24	sequences	sequence	NNS
cord-005478-5iu38pr6	3305	25	are	be	VBP
cord-005478-5iu38pr6	3305	26	associated	associate	VBN
cord-005478-5iu38pr6	3305	27	to	to	IN
cord-005478-5iu38pr6	3305	28	clinical	clinical	JJ
cord-005478-5iu38pr6	3305	29	remission	remission	NN
cord-005478-5iu38pr6	3305	30	.	.	.
cord-005478-5iu38pr6	3306	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3306	2	:	:	:
cord-005478-5iu38pr6	3307	1	The	the	DT
cord-005478-5iu38pr6	3307	2	authors	author	NNS
cord-005478-5iu38pr6	3307	3	have	have	VBP
cord-005478-5iu38pr6	3307	4	nothing	nothing	NN
cord-005478-5iu38pr6	3307	5	to	to	TO
cord-005478-5iu38pr6	3307	6	disclose	disclose	VB
cord-005478-5iu38pr6	3307	7	.	.	.
cord-005478-5iu38pr6	3308	1	Background	background	NN
cord-005478-5iu38pr6	3308	2	:	:	:
cord-005478-5iu38pr6	3309	1	Pediatric	pediatric	JJ
cord-005478-5iu38pr6	3309	2	patients	patient	NNS
cord-005478-5iu38pr6	3309	3	with	with	IN
cord-005478-5iu38pr6	3309	4	high	high	JJ
cord-005478-5iu38pr6	3309	5	-	-	HYPH
cord-005478-5iu38pr6	3309	6	risk	risk	NN
cord-005478-5iu38pr6	3309	7	alveolar	alveolar	NN
cord-005478-5iu38pr6	3309	8	rhabdomyosarcoma	rhabdomyosarcoma	NNS
cord-005478-5iu38pr6	3309	9	(	(	-LRB-
cord-005478-5iu38pr6	3309	10	aRMS	arm	NNS
cord-005478-5iu38pr6	3309	11	)	)	-RRB-
cord-005478-5iu38pr6	3309	12	above	above	IN
cord-005478-5iu38pr6	3309	13	the	the	DT
cord-005478-5iu38pr6	3309	14	age	age	NN
cord-005478-5iu38pr6	3309	15	of	of	IN
cord-005478-5iu38pr6	3309	16	10	10	CD
cord-005478-5iu38pr6	3309	17	years	year	NNS
cord-005478-5iu38pr6	3309	18	can	can	MD
cord-005478-5iu38pr6	3309	19	not	not	RB
cord-005478-5iu38pr6	3309	20	be	be	VB
cord-005478-5iu38pr6	3309	21	cured	cure	VBN
cord-005478-5iu38pr6	3309	22	by	by	IN
cord-005478-5iu38pr6	3309	23	conventional	conventional	JJ
cord-005478-5iu38pr6	3309	24	therapies	therapy	NNS
cord-005478-5iu38pr6	3309	25	.	.	.
cord-005478-5iu38pr6	3310	1	Immune	immune	JJ
cord-005478-5iu38pr6	3310	2	cells	cell	NNS
cord-005478-5iu38pr6	3310	3	targeting	target	VBG
cord-005478-5iu38pr6	3310	4	ErbB2	ErbB2	NNP
cord-005478-5iu38pr6	3310	5	with	with	IN
cord-005478-5iu38pr6	3310	6	a	a	DT
cord-005478-5iu38pr6	3310	7	chimeric	chimeric	JJ
cord-005478-5iu38pr6	3310	8	antigen	antigen	NN
cord-005478-5iu38pr6	3310	9	receptor	receptor	NN
cord-005478-5iu38pr6	3310	10	(	(	-LRB-
cord-005478-5iu38pr6	3310	11	CAR	car	NN
cord-005478-5iu38pr6	3310	12	)	)	-RRB-
cord-005478-5iu38pr6	3310	13	were	be	VBD
cord-005478-5iu38pr6	3310	14	recently	recently	RB
cord-005478-5iu38pr6	3310	15	considered	consider	VBN
cord-005478-5iu38pr6	3310	16	for	for	IN
cord-005478-5iu38pr6	3310	17	these	these	DT
cord-005478-5iu38pr6	3310	18	patients	patient	NNS
cord-005478-5iu38pr6	3310	19	.	.	.
cord-005478-5iu38pr6	3311	1	Cytokineinduced	Cytokineinduced	NNP
cord-005478-5iu38pr6	3311	2	killer	killer	NN
cord-005478-5iu38pr6	3311	3	(	(	-LRB-
cord-005478-5iu38pr6	3311	4	CIK	CIK	NNP
cord-005478-5iu38pr6	3311	5	)	)	-RRB-
cord-005478-5iu38pr6	3311	6	cells	cell	NNS
cord-005478-5iu38pr6	3311	7	already	already	RB
cord-005478-5iu38pr6	3311	8	capable	capable	JJ
cord-005478-5iu38pr6	3311	9	of	of	IN
cord-005478-5iu38pr6	3311	10	natural	natural	JJ
cord-005478-5iu38pr6	3311	11	killer	killer	NN
cord-005478-5iu38pr6	3311	12	(	(	-LRB-
cord-005478-5iu38pr6	3311	13	NK)-like	nk)-like	IN
cord-005478-5iu38pr6	3311	14	anti	anti	JJ
cord-005478-5iu38pr6	3311	15	-	-	JJ
cord-005478-5iu38pr6	3311	16	tumor	tumor	JJ
cord-005478-5iu38pr6	3311	17	capacity	capacity	NN
cord-005478-5iu38pr6	3311	18	additionally	additionally	RB
cord-005478-5iu38pr6	3311	19	redirected	redirect	VBD
cord-005478-5iu38pr6	3311	20	with	with	IN
cord-005478-5iu38pr6	3311	21	an	an	DT
cord-005478-5iu38pr6	3311	22	ErbB2	ErbB2	NNP
cord-005478-5iu38pr6	3311	23	CAR	car	NN
cord-005478-5iu38pr6	3311	24	may	may	MD
cord-005478-5iu38pr6	3311	25	provide	provide	VB
cord-005478-5iu38pr6	3311	26	overall	overall	JJ
cord-005478-5iu38pr6	3311	27	disease	disease	NN
cord-005478-5iu38pr6	3311	28	control	control	NN
cord-005478-5iu38pr6	3311	29	in	in	IN
cord-005478-5iu38pr6	3311	30	these	these	DT
cord-005478-5iu38pr6	3311	31	high	high	JJ
cord-005478-5iu38pr6	3311	32	-	-	HYPH
cord-005478-5iu38pr6	3311	33	risk	risk	NN
cord-005478-5iu38pr6	3311	34	tumors	tumor	NNS
cord-005478-5iu38pr6	3311	35	.	.	.
cord-005478-5iu38pr6	3312	1	Methods	method	NNS
cord-005478-5iu38pr6	3312	2	:	:	:
cord-005478-5iu38pr6	3313	1	ErbB2-CAR	ErbB2-CAR	NNP
cord-005478-5iu38pr6	3313	2	modified	modify	VBN
cord-005478-5iu38pr6	3313	3	CIK	CIK	NNP
cord-005478-5iu38pr6	3313	4	cells	cell	NNS
cord-005478-5iu38pr6	3313	5	were	be	VBD
cord-005478-5iu38pr6	3313	6	generated	generate	VBN
cord-005478-5iu38pr6	3313	7	from	from	IN
cord-005478-5iu38pr6	3313	8	conventional	conventional	JJ
cord-005478-5iu38pr6	3313	9	CIK	CIK	NNP
cord-005478-5iu38pr6	3313	10	cells	cell	NNS
cord-005478-5iu38pr6	3313	11	(	(	-LRB-
cord-005478-5iu38pr6	3313	12	WT	WT	NNP
cord-005478-5iu38pr6	3313	13	-	-	HYPH
cord-005478-5iu38pr6	3313	14	CIK	CIK	NNP
cord-005478-5iu38pr6	3313	15	)	)	-RRB-
cord-005478-5iu38pr6	3313	16	by	by	IN
cord-005478-5iu38pr6	3313	17	lentiviral	lentiviral	JJ
cord-005478-5iu38pr6	3313	18	gene	gene	NN
cord-005478-5iu38pr6	3313	19	transduction	transduction	NN
cord-005478-5iu38pr6	3313	20	on	on	IN
cord-005478-5iu38pr6	3313	21	day	day	NN
cord-005478-5iu38pr6	3313	22	4	4	CD
cord-005478-5iu38pr6	3313	23	of	of	IN
cord-005478-5iu38pr6	3313	24	culture	culture	NN
cord-005478-5iu38pr6	3313	25	.	.	.
cord-005478-5iu38pr6	3314	1	The	the	DT
cord-005478-5iu38pr6	3314	2	codon	codon	NN
cord-005478-5iu38pr6	3314	3	-	-	HYPH
cord-005478-5iu38pr6	3314	4	optimized	optimize	VBN
cord-005478-5iu38pr6	3314	5	CAR	car	NN
cord-005478-5iu38pr6	3314	6	sequence	sequence	NN
cord-005478-5iu38pr6	3314	7	consists	consist	VBZ
cord-005478-5iu38pr6	3314	8	of	of	IN
cord-005478-5iu38pr6	3314	9	an	an	DT
cord-005478-5iu38pr6	3314	10	IgG	igg	NN
cord-005478-5iu38pr6	3314	11	heavy	heavy	JJ
cord-005478-5iu38pr6	3314	12	-	-	HYPH
cord-005478-5iu38pr6	3314	13	chain	chain	NN
cord-005478-5iu38pr6	3314	14	signal	signal	NN
cord-005478-5iu38pr6	3314	15	peptide	peptide	NN
cord-005478-5iu38pr6	3314	16	,	,	,
cord-005478-5iu38pr6	3314	17	an	an	DT
cord-005478-5iu38pr6	3314	18	ErbB2-specific	erbb2-specific	NN
cord-005478-5iu38pr6	3314	19	antibody	antibody	NN
cord-005478-5iu38pr6	3314	20	fragment	fragment	NN
cord-005478-5iu38pr6	3314	21	scFv	scFv	NNP
cord-005478-5iu38pr6	3314	22	(	(	-LRB-
cord-005478-5iu38pr6	3314	23	FRP5	FRP5	NNP
cord-005478-5iu38pr6	3314	24	)	)	-RRB-
cord-005478-5iu38pr6	3314	25	and	and	CC
cord-005478-5iu38pr6	3314	26	a	a	DT
cord-005478-5iu38pr6	3314	27	modified	modify	VBN
cord-005478-5iu38pr6	3314	28	CD8α	CD8α	NNP
cord-005478-5iu38pr6	3314	29	hinge	hinge	NN
cord-005478-5iu38pr6	3314	30	region	region	NN
cord-005478-5iu38pr6	3314	31	,	,	,
cord-005478-5iu38pr6	3314	32	as	as	RB
cord-005478-5iu38pr6	3314	33	well	well	RB
cord-005478-5iu38pr6	3314	34	as	as	IN
cord-005478-5iu38pr6	3314	35	CD28	CD28	NNP
cord-005478-5iu38pr6	3314	36	transmembrane	transmembrane	NN
cord-005478-5iu38pr6	3314	37	and	and	CC
cord-005478-5iu38pr6	3314	38	intracellular	intracellular	JJ
cord-005478-5iu38pr6	3314	39	domains	domain	NNS
cord-005478-5iu38pr6	3314	40	and	and	CC
cord-005478-5iu38pr6	3314	41	a	a	DT
cord-005478-5iu38pr6	3314	42	CD3ζ	CD3ζ	NNP
cord-005478-5iu38pr6	3314	43	intracellular	intracellular	JJ
cord-005478-5iu38pr6	3314	44	domain	domain	NN
cord-005478-5iu38pr6	3314	45	.	.	.
cord-005478-5iu38pr6	3315	1	1x10	1x10	CD
cord-005478-5iu38pr6	3315	2	5	5	CD
cord-005478-5iu38pr6	3315	3	luciferase	luciferase	NN
cord-005478-5iu38pr6	3315	4	gene	gene	NN
cord-005478-5iu38pr6	3315	5	-	-	HYPH
cord-005478-5iu38pr6	3315	6	transduced	transduce	VBN
cord-005478-5iu38pr6	3315	7	RH30	RH30	NNP
cord-005478-5iu38pr6	3315	8	(	(	-LRB-
cord-005478-5iu38pr6	3315	9	aRMS	arm	NNS
cord-005478-5iu38pr6	3315	10	)	)	-RRB-
cord-005478-5iu38pr6	3315	11	cells	cell	NNS
cord-005478-5iu38pr6	3315	12	were	be	VBD
cord-005478-5iu38pr6	3315	13	engrafted	engraft	VBN
cord-005478-5iu38pr6	3315	14	in	in	IN
cord-005478-5iu38pr6	3315	15	immunodeficient	immunodeficient	JJ
cord-005478-5iu38pr6	3315	16	NOD	NOD	NNP
cord-005478-5iu38pr6	3315	17	/	/	SYM
cord-005478-5iu38pr6	3315	18	SCID	SCID	NNP
cord-005478-5iu38pr6	3315	19	/	/	SYM
cord-005478-5iu38pr6	3315	20	γc	γc	NNP
cord-005478-5iu38pr6	3315	21	-(NSG	-(nsg	NN
cord-005478-5iu38pr6	3315	22	)	)	-RRB-
cord-005478-5iu38pr6	3315	23	mice	mouse	NNS
cord-005478-5iu38pr6	3315	24	.	.	.
cord-005478-5iu38pr6	3316	1	Mice	mouse	NNS
cord-005478-5iu38pr6	3316	2	were	be	VBD
cord-005478-5iu38pr6	3316	3	randomly	randomly	RB
cord-005478-5iu38pr6	3316	4	selected	select	VBN
cord-005478-5iu38pr6	3316	5	into	into	IN
cord-005478-5iu38pr6	3316	6	5	5	CD
cord-005478-5iu38pr6	3316	7	different	different	JJ
cord-005478-5iu38pr6	3316	8	treatment	treatment	NN
cord-005478-5iu38pr6	3316	9	groups	group	NNS
cord-005478-5iu38pr6	3316	10	(	(	-LRB-
cord-005478-5iu38pr6	3316	11	DBPS	DBPS	NNP
cord-005478-5iu38pr6	3316	12	on	on	IN
cord-005478-5iu38pr6	3316	13	day	day	NN
cord-005478-5iu38pr6	3316	14	+1	+1	NNS
cord-005478-5iu38pr6	3316	15	,	,	,
cord-005478-5iu38pr6	3316	16	2.5x10	2.5x10	CD
cord-005478-5iu38pr6	3316	17	6	6	CD
cord-005478-5iu38pr6	3316	18	WT	WT	NNP
cord-005478-5iu38pr6	3316	19	-	-	HYPH
cord-005478-5iu38pr6	3316	20	CIK	CIK	NNP
cord-005478-5iu38pr6	3316	21	or	or	CC
cord-005478-5iu38pr6	3316	22	ErbB2	ErbB2	NNP
cord-005478-5iu38pr6	3316	23	CAR	CAR	NNP
cord-005478-5iu38pr6	3316	24	-	-	HYPH
cord-005478-5iu38pr6	3316	25	CIK	CIK	NNP
cord-005478-5iu38pr6	3316	26	cells	cell	NNS
cord-005478-5iu38pr6	3316	27	on	on	IN
cord-005478-5iu38pr6	3316	28	days	day	NNS
cord-005478-5iu38pr6	3316	29	+1	+1	NFP
cord-005478-5iu38pr6	3316	30	and	and	CC
cord-005478-5iu38pr6	3316	31	+36	+36	NNP
cord-005478-5iu38pr6	3316	32	,	,	,
cord-005478-5iu38pr6	3316	33	2.5x10	2.5x10	CD
cord-005478-5iu38pr6	3316	34	6	6	CD
cord-005478-5iu38pr6	3316	35	WT	WT	NNP
cord-005478-5iu38pr6	3316	36	-	-	HYPH
cord-005478-5iu38pr6	3316	37	CIK	CIK	NNP
cord-005478-5iu38pr6	3316	38	or	or	CC
cord-005478-5iu38pr6	3316	39	ErbB2	ErbB2	NNP
cord-005478-5iu38pr6	3316	40	CAR	CAR	NNP
cord-005478-5iu38pr6	3316	41	-	-	HYPH
cord-005478-5iu38pr6	3316	42	CIK	CIK	NNP
cord-005478-5iu38pr6	3316	43	cells	cell	NNS
cord-005478-5iu38pr6	3316	44	on	on	IN
cord-005478-5iu38pr6	3316	45	days	day	NNS
cord-005478-5iu38pr6	3316	46	+22	+22	NNS
cord-005478-5iu38pr6	3316	47	and	and	CC
cord-005478-5iu38pr6	3316	48	+57	+57	NN
cord-005478-5iu38pr6	3316	49	)	)	-RRB-
cord-005478-5iu38pr6	3316	50	.	.	.
cord-005478-5iu38pr6	3317	1	Mice	mouse	NNS
cord-005478-5iu38pr6	3317	2	were	be	VBD
cord-005478-5iu38pr6	3317	3	monitored	monitor	VBN
cord-005478-5iu38pr6	3317	4	by	by	IN
cord-005478-5iu38pr6	3317	5	bioluminescence	bioluminescence	NN
cord-005478-5iu38pr6	3317	6	imaging	imaging	NN
cord-005478-5iu38pr6	3317	7	(	(	-LRB-
cord-005478-5iu38pr6	3317	8	BLI	BLI	NNP
cord-005478-5iu38pr6	3317	9	)	)	-RRB-
cord-005478-5iu38pr6	3317	10	until	until	IN
cord-005478-5iu38pr6	3317	11	day	day	NN
cord-005478-5iu38pr6	3317	12	+100	+100	NNS
cord-005478-5iu38pr6	3317	13	.	.	.
cord-005478-5iu38pr6	3318	1	Tumor	tumor	NN
cord-005478-5iu38pr6	3318	2	engraftment	engraftment	NN
cord-005478-5iu38pr6	3318	3	and	and	CC
cord-005478-5iu38pr6	3318	4	immune	immune	JJ
cord-005478-5iu38pr6	3318	5	cell	cell	NN
cord-005478-5iu38pr6	3318	6	homing	homing	NN
cord-005478-5iu38pr6	3318	7	at	at	IN
cord-005478-5iu38pr6	3318	8	tumor	tumor	NN
cord-005478-5iu38pr6	3318	9	sites	site	NNS
cord-005478-5iu38pr6	3318	10	were	be	VBD
cord-005478-5iu38pr6	3318	11	analyzed	analyze	VBN
cord-005478-5iu38pr6	3318	12	by	by	IN
cord-005478-5iu38pr6	3318	13	FACS	FACS	NNP
cord-005478-5iu38pr6	3318	14	,	,	,
cord-005478-5iu38pr6	3318	15	chimerism	chimerism	NN
cord-005478-5iu38pr6	3318	16	and	and	CC
cord-005478-5iu38pr6	3318	17	immunohistochemistry	immunohistochemistry	NN
cord-005478-5iu38pr6	3318	18	analyses	analysis	NNS
cord-005478-5iu38pr6	3318	19	.	.	.
cord-005478-5iu38pr6	3319	1	Results	result	NNS
cord-005478-5iu38pr6	3319	2	:	:	:
cord-005478-5iu38pr6	3320	1	Human	human	JJ
cord-005478-5iu38pr6	3320	2	RMS	RMS	NNP
cord-005478-5iu38pr6	3320	3	xenografts	xenograft	NNS
cord-005478-5iu38pr6	3320	4	were	be	VBD
cord-005478-5iu38pr6	3320	5	established	establish	VBN
cord-005478-5iu38pr6	3320	6	in	in	IN
cord-005478-5iu38pr6	3320	7	all	all	DT
cord-005478-5iu38pr6	3320	8	mice	mouse	NNS
cord-005478-5iu38pr6	3320	9	treated	treat	VBN
cord-005478-5iu38pr6	3320	10	with	with	IN
cord-005478-5iu38pr6	3320	11	DBPS	DBPS	NNP
cord-005478-5iu38pr6	3320	12	only	only	RB
cord-005478-5iu38pr6	3320	13	.	.	.
cord-005478-5iu38pr6	3321	1	Control	control	NN
cord-005478-5iu38pr6	3321	2	-	-	HYPH
cord-005478-5iu38pr6	3321	3	mice	mouse	NNS
cord-005478-5iu38pr6	3321	4	showed	show	VBD
cord-005478-5iu38pr6	3321	5	a	a	DT
cord-005478-5iu38pr6	3321	6	median	median	JJ
cord-005478-5iu38pr6	3321	7	survival	survival	NN
cord-005478-5iu38pr6	3321	8	of	of	IN
cord-005478-5iu38pr6	3321	9	62	62	CD
cord-005478-5iu38pr6	3321	10	days	day	NNS
cord-005478-5iu38pr6	3321	11	.	.	.
cord-005478-5iu38pr6	3322	1	Human	Human	NNP
cord-005478-5iu38pr6	3322	2	RMS	RMS	NNP
cord-005478-5iu38pr6	3322	3	was	be	VBD
cord-005478-5iu38pr6	3322	4	identified	identify	VBN
cord-005478-5iu38pr6	3322	5	in	in	IN
cord-005478-5iu38pr6	3322	6	all	all	DT
cord-005478-5iu38pr6	3322	7	analyzed	analyze	VBN
cord-005478-5iu38pr6	3322	8	organs	organ	NNS
cord-005478-5iu38pr6	3322	9	,	,	,
cord-005478-5iu38pr6	3322	10	with	with	IN
cord-005478-5iu38pr6	3322	11	the	the	DT
cord-005478-5iu38pr6	3322	12	highest	high	JJS
cord-005478-5iu38pr6	3322	13	tumor	tumor	NN
cord-005478-5iu38pr6	3322	14	burden	burden	NN
cord-005478-5iu38pr6	3322	15	seen	see	VBN
cord-005478-5iu38pr6	3322	16	in	in	IN
cord-005478-5iu38pr6	3322	17	livers	liver	NNS
cord-005478-5iu38pr6	3322	18	of	of	IN
cord-005478-5iu38pr6	3322	19	DBPS	DBPS	NNP
cord-005478-5iu38pr6	3322	20	-	-	HYPH
cord-005478-5iu38pr6	3322	21	treated	treat	VBN
cord-005478-5iu38pr6	3322	22	mice	mouse	NNS
cord-005478-5iu38pr6	3322	23	.	.	.
cord-005478-5iu38pr6	3323	1	Mice	mouse	NNS
cord-005478-5iu38pr6	3323	2	injected	inject	VBD
cord-005478-5iu38pr6	3323	3	with	with	IN
cord-005478-5iu38pr6	3323	4	WT	WT	NNP
cord-005478-5iu38pr6	3323	5	or	or	CC
cord-005478-5iu38pr6	3323	6	ErbB2-CAR	ErbB2-CAR	NNP
cord-005478-5iu38pr6	3323	7	CIK	CIK	NNP
cord-005478-5iu38pr6	3323	8	cells	cell	NNS
cord-005478-5iu38pr6	3323	9	on	on	IN
cord-005478-5iu38pr6	3323	10	days	day	NNS
cord-005478-5iu38pr6	3323	11	+1	+1	NFP
cord-005478-5iu38pr6	3323	12	and	and	CC
cord-005478-5iu38pr6	3323	13	+36	+36	NNP
cord-005478-5iu38pr6	3323	14	showed	show	VBD
cord-005478-5iu38pr6	3323	15	a	a	DT
cord-005478-5iu38pr6	3323	16	significant	significant	JJ
cord-005478-5iu38pr6	3323	17	improved	improve	VBN
cord-005478-5iu38pr6	3323	18	(	(	-LRB-
cord-005478-5iu38pr6	3323	19	p	p	NN
cord-005478-5iu38pr6	3323	20	<	<	XX
cord-005478-5iu38pr6	3323	21	0.014	0.014	CD
cord-005478-5iu38pr6	3323	22	and	and	CC
cord-005478-5iu38pr6	3323	23	p	p	NN
cord-005478-5iu38pr6	3323	24	<	<	XX
cord-005478-5iu38pr6	3323	25	0.01	0.01	CD
cord-005478-5iu38pr6	3323	26	)	)	-RRB-
cord-005478-5iu38pr6	3323	27	disease	disease	NN
cord-005478-5iu38pr6	3323	28	-	-	HYPH
cord-005478-5iu38pr6	3323	29	free	free	JJ
cord-005478-5iu38pr6	3323	30	survival	survival	NN
cord-005478-5iu38pr6	3323	31	,	,	,
cord-005478-5iu38pr6	3323	32	respectively	respectively	RB
cord-005478-5iu38pr6	3323	33	.	.	.
cord-005478-5iu38pr6	3324	1	Furthermore	furthermore	RB
cord-005478-5iu38pr6	3324	2	,	,	,
cord-005478-5iu38pr6	3324	3	no	no	DT
cord-005478-5iu38pr6	3324	4	signs	sign	NNS
cord-005478-5iu38pr6	3324	5	of	of	IN
cord-005478-5iu38pr6	3324	6	tumor	tumor	NN
cord-005478-5iu38pr6	3324	7	engraftment	engraftment	NN
cord-005478-5iu38pr6	3324	8	were	be	VBD
cord-005478-5iu38pr6	3324	9	shown	show	VBN
cord-005478-5iu38pr6	3324	10	by	by	IN
cord-005478-5iu38pr6	3324	11	BLI	BLI	NNP
cord-005478-5iu38pr6	3324	12	in	in	IN
cord-005478-5iu38pr6	3324	13	ErbB2	ErbB2	NNP
cord-005478-5iu38pr6	3324	14	CAR	CAR	NNP
cord-005478-5iu38pr6	3324	15	-	-	HYPH
cord-005478-5iu38pr6	3324	16	CIK	CIK	NNP
cord-005478-5iu38pr6	3324	17	cell	cell	NN
cord-005478-5iu38pr6	3324	18	treated	treat	VBD
cord-005478-5iu38pr6	3324	19	mice	mouse	NNS
cord-005478-5iu38pr6	3324	20	while	while	IN
cord-005478-5iu38pr6	3324	21	some	some	DT
cord-005478-5iu38pr6	3324	22	of	of	IN
cord-005478-5iu38pr6	3324	23	the	the	DT
cord-005478-5iu38pr6	3324	24	mice	mouse	NNS
cord-005478-5iu38pr6	3324	25	treated	treat	VBN
cord-005478-5iu38pr6	3324	26	with	with	IN
cord-005478-5iu38pr6	3324	27	WT	WT	NNP
cord-005478-5iu38pr6	3324	28	-	-	HYPH
cord-005478-5iu38pr6	3324	29	CIK	CIK	NNP
cord-005478-5iu38pr6	3324	30	cells	cell	NNS
cord-005478-5iu38pr6	3324	31	developed	develop	VBD
cord-005478-5iu38pr6	3324	32	positive	positive	JJ
cord-005478-5iu38pr6	3324	33	tumor	tumor	NN
cord-005478-5iu38pr6	3324	34	signals	signal	NNS
cord-005478-5iu38pr6	3324	35	between	between	IN
cord-005478-5iu38pr6	3324	36	weeks	week	NNS
cord-005478-5iu38pr6	3324	37	7	7	CD
cord-005478-5iu38pr6	3324	38	and	and	CC
cord-005478-5iu38pr6	3324	39	10	10	CD
cord-005478-5iu38pr6	3324	40	.	.	.
cord-005478-5iu38pr6	3325	1	In	in	IN
cord-005478-5iu38pr6	3325	2	4	4	CD
cord-005478-5iu38pr6	3325	3	out	out	IN
cord-005478-5iu38pr6	3325	4	of	of	IN
cord-005478-5iu38pr6	3325	5	6	6	CD
cord-005478-5iu38pr6	3325	6	(	(	-LRB-
cord-005478-5iu38pr6	3325	7	64	64	CD
cord-005478-5iu38pr6	3325	8	%	%	NN
cord-005478-5iu38pr6	3325	9	)	)	-RRB-
cord-005478-5iu38pr6	3325	10	WT	WT	NNP
cord-005478-5iu38pr6	3325	11	-	-	:
cord-005478-5iu38pr6	3325	12	and	and	CC
cord-005478-5iu38pr6	3325	13	in	in	IN
cord-005478-5iu38pr6	3325	14	all	all	DT
cord-005478-5iu38pr6	3325	15	(	(	-LRB-
cord-005478-5iu38pr6	3325	16	8	8	CD
cord-005478-5iu38pr6	3325	17	of	of	IN
cord-005478-5iu38pr6	3325	18	8	8	CD
cord-005478-5iu38pr6	3325	19	,	,	,
cord-005478-5iu38pr6	3325	20	100	100	CD
cord-005478-5iu38pr6	3325	21	%	%	NN
cord-005478-5iu38pr6	3325	22	)	)	-RRB-
cord-005478-5iu38pr6	3325	23	CAR	CAR	NNP
cord-005478-5iu38pr6	3325	24	-	-	HYPH
cord-005478-5iu38pr6	3325	25	CIK	CIK	NNP
cord-005478-5iu38pr6	3325	26	cells	cell	NNS
cord-005478-5iu38pr6	3325	27	treated	treat	VBD
cord-005478-5iu38pr6	3325	28	mice	mouse	NNS
cord-005478-5iu38pr6	3325	29	no	no	DT
cord-005478-5iu38pr6	3325	30	residual	residual	JJ
cord-005478-5iu38pr6	3325	31	tumor	tumor	NN
cord-005478-5iu38pr6	3325	32	cells	cell	NNS
cord-005478-5iu38pr6	3325	33	were	be	VBD
cord-005478-5iu38pr6	3325	34	identified	identify	VBN
cord-005478-5iu38pr6	3325	35	by	by	IN
cord-005478-5iu38pr6	3325	36	PCR	PCR	NNP
cord-005478-5iu38pr6	3325	37	-	-	HYPH
cord-005478-5iu38pr6	3325	38	based	base	VBN
cord-005478-5iu38pr6	3325	39	analysis	analysis	NN
cord-005478-5iu38pr6	3325	40	.	.	.
cord-005478-5iu38pr6	3326	1	In	in	IN
cord-005478-5iu38pr6	3326	2	contrast	contrast	NN
cord-005478-5iu38pr6	3326	3	,	,	,
cord-005478-5iu38pr6	3326	4	tumor	tumor	NN
cord-005478-5iu38pr6	3326	5	cells	cell	NNS
cord-005478-5iu38pr6	3326	6	were	be	VBD
cord-005478-5iu38pr6	3326	7	detectable	detectable	JJ
cord-005478-5iu38pr6	3326	8	in	in	IN
cord-005478-5iu38pr6	3326	9	all	all	DT
cord-005478-5iu38pr6	3326	10	mice	mouse	NNS
cord-005478-5iu38pr6	3326	11	with	with	IN
cord-005478-5iu38pr6	3326	12	delayed	delay	VBN
cord-005478-5iu38pr6	3326	13	anti	anti	JJ
cord-005478-5iu38pr6	3326	14	-	-	JJ
cord-005478-5iu38pr6	3326	15	tumor	tumor	JJ
cord-005478-5iu38pr6	3326	16	treatment	treatment	NN
cord-005478-5iu38pr6	3326	17	applied	apply	VBN
cord-005478-5iu38pr6	3326	18	on	on	IN
cord-005478-5iu38pr6	3326	19	day	day	NN
cord-005478-5iu38pr6	3326	20	+22	+22	NNS
cord-005478-5iu38pr6	3326	21	and	and	CC
cord-005478-5iu38pr6	3326	22	+57	+57	NN
cord-005478-5iu38pr6	3326	23	.	.	.
cord-005478-5iu38pr6	3327	1	However	however	RB
cord-005478-5iu38pr6	3327	2	,	,	,
cord-005478-5iu38pr6	3327	3	tumor	tumor	NN
cord-005478-5iu38pr6	3327	4	growth	growth	NN
cord-005478-5iu38pr6	3327	5	was	be	VBD
cord-005478-5iu38pr6	3327	6	lower	low	JJR
cord-005478-5iu38pr6	3327	7	in	in	IN
cord-005478-5iu38pr6	3327	8	these	these	DT
cord-005478-5iu38pr6	3327	9	groups	group	NNS
cord-005478-5iu38pr6	3327	10	.	.	.
cord-005478-5iu38pr6	3328	1	Correspondingly	correspondingly	RB
cord-005478-5iu38pr6	3328	2	,	,	,
cord-005478-5iu38pr6	3328	3	BLI	BLI	NNP
cord-005478-5iu38pr6	3328	4	showed	show	VBD
cord-005478-5iu38pr6	3328	5	delayed	delay	VBN
cord-005478-5iu38pr6	3328	6	tumor	tumor	NN
cord-005478-5iu38pr6	3328	7	engraftment	engraftment	NN
cord-005478-5iu38pr6	3328	8	in	in	IN
cord-005478-5iu38pr6	3328	9	mice	mouse	NNS
cord-005478-5iu38pr6	3328	10	with	with	IN
cord-005478-5iu38pr6	3328	11	WT	WT	NNP
cord-005478-5iu38pr6	3328	12	-	-	:
cord-005478-5iu38pr6	3328	13	and	and	CC
cord-005478-5iu38pr6	3328	14	even	even	RB
cord-005478-5iu38pr6	3328	15	more	more	RBR
cord-005478-5iu38pr6	3328	16	with	with	IN
cord-005478-5iu38pr6	3328	17	CAR	CAR	NNP
cord-005478-5iu38pr6	3328	18	-	-	HYPH
cord-005478-5iu38pr6	3328	19	CIK	CIK	NNP
cord-005478-5iu38pr6	3328	20	cell	cell	NN
cord-005478-5iu38pr6	3328	21	treatment	treatment	NN
cord-005478-5iu38pr6	3328	22	given	give	VBN
cord-005478-5iu38pr6	3328	23	on	on	IN
cord-005478-5iu38pr6	3328	24	day	day	NN
cord-005478-5iu38pr6	3328	25	22	22	CD
cord-005478-5iu38pr6	3328	26	.	.	.
cord-005478-5iu38pr6	3329	1	Treatment	treatment	NN
cord-005478-5iu38pr6	3329	2	on	on	IN
cord-005478-5iu38pr6	3329	3	day	day	NN
cord-005478-5iu38pr6	3329	4	22	22	CD
cord-005478-5iu38pr6	3329	5	resulted	result	VBD
cord-005478-5iu38pr6	3329	6	in	in	IN
cord-005478-5iu38pr6	3329	7	a	a	DT
cord-005478-5iu38pr6	3329	8	significantly	significantly	RB
cord-005478-5iu38pr6	3329	9	improved	improve	VBN
cord-005478-5iu38pr6	3329	10	survival	survival	NN
cord-005478-5iu38pr6	3329	11	of	of	IN
cord-005478-5iu38pr6	3329	12	ErbB2-CAR	ErbB2-CAR	NNP
cord-005478-5iu38pr6	3329	13	CIK	CIK	NNP
cord-005478-5iu38pr6	3329	14	cell	cell	NN
cord-005478-5iu38pr6	3329	15	treated	treat	VBD
cord-005478-5iu38pr6	3329	16	mice	mouse	NNS
cord-005478-5iu38pr6	3329	17	(	(	-LRB-
cord-005478-5iu38pr6	3329	18	p	p	NN
cord-005478-5iu38pr6	3329	19	<	<	XX
cord-005478-5iu38pr6	3329	20	0.01	0.01	CD
cord-005478-5iu38pr6	3329	21	)	)	-RRB-
cord-005478-5iu38pr6	3329	22	,	,	,
cord-005478-5iu38pr6	3329	23	while	while	IN
cord-005478-5iu38pr6	3329	24	survival	survival	NN
cord-005478-5iu38pr6	3329	25	was	be	VBD
cord-005478-5iu38pr6	3329	26	not	not	RB
cord-005478-5iu38pr6	3329	27	improved	improve	VBN
cord-005478-5iu38pr6	3329	28	after	after	IN
cord-005478-5iu38pr6	3329	29	WT	WT	NNP
cord-005478-5iu38pr6	3329	30	-	-	HYPH
cord-005478-5iu38pr6	3329	31	CIK	CIK	NNP
cord-005478-5iu38pr6	3329	32	cell	cell	NN
cord-005478-5iu38pr6	3329	33	infusion	infusion	NN
cord-005478-5iu38pr6	3329	34	(	(	-LRB-
cord-005478-5iu38pr6	3329	35	p	p	NN
cord-005478-5iu38pr6	3329	36	>	>	XX
cord-005478-5iu38pr6	3329	37	0.07	0.07	CD
cord-005478-5iu38pr6	3329	38	)	)	-RRB-
cord-005478-5iu38pr6	3329	39	.	.	.
cord-005478-5iu38pr6	3330	1	Within	within	IN
cord-005478-5iu38pr6	3330	2	all	all	DT
cord-005478-5iu38pr6	3330	3	treatment	treatment	NN
cord-005478-5iu38pr6	3330	4	groups	group	NNS
cord-005478-5iu38pr6	3330	5	,	,	,
cord-005478-5iu38pr6	3330	6	immune	immune	JJ
cord-005478-5iu38pr6	3330	7	cells	cell	NNS
cord-005478-5iu38pr6	3330	8	were	be	VBD
cord-005478-5iu38pr6	3330	9	detected	detect	VBN
cord-005478-5iu38pr6	3330	10	by	by	IN
cord-005478-5iu38pr6	3330	11	chimerism	chimerism	NN
cord-005478-5iu38pr6	3330	12	and	and	CC
cord-005478-5iu38pr6	3330	13	FACS	FACS	NNP
cord-005478-5iu38pr6	3330	14	analyses	analysis	NNS
cord-005478-5iu38pr6	3330	15	.	.	.
cord-005478-5iu38pr6	3331	1	FACS	FACS	NNP
cord-005478-5iu38pr6	3331	2	analyses	analysis	NNS
cord-005478-5iu38pr6	3331	3	showed	show	VBD
cord-005478-5iu38pr6	3331	4	a	a	DT
cord-005478-5iu38pr6	3331	5	significant	significant	JJ
cord-005478-5iu38pr6	3331	6	increase	increase	NN
cord-005478-5iu38pr6	3331	7	of	of	IN
cord-005478-5iu38pr6	3331	8	NK	NK	NNP
cord-005478-5iu38pr6	3331	9	-	-	HYPH
cord-005478-5iu38pr6	3331	10	like	like	NNP
cord-005478-5iu38pr6	3331	11	T	t	NN
cord-005478-5iu38pr6	3331	12	cells	cell	NNS
cord-005478-5iu38pr6	3331	13	(	(	-LRB-
cord-005478-5iu38pr6	3331	14	p	p	NN
cord-005478-5iu38pr6	3331	15	<	<	XX
cord-005478-5iu38pr6	3331	16	0.01	0.01	CD
cord-005478-5iu38pr6	3331	17	and	and	CC
cord-005478-5iu38pr6	3331	18	<	<	XX
cord-005478-5iu38pr6	3331	19	0.05	0.05	CD
cord-005478-5iu38pr6	3331	20	,	,	,
cord-005478-5iu38pr6	3331	21	WTand	WTand	NNP
cord-005478-5iu38pr6	3331	22	ErbB2-CAR	ErbB2-CAR	NNP
cord-005478-5iu38pr6	3331	23	CIK	CIK	NNP
cord-005478-5iu38pr6	3331	24	cells	cell	NNS
cord-005478-5iu38pr6	3331	25	)	)	-RRB-
cord-005478-5iu38pr6	3331	26	.	.	.
cord-005478-5iu38pr6	3332	1	Additionally	additionally	RB
cord-005478-5iu38pr6	3332	2	,	,	,
cord-005478-5iu38pr6	3332	3	a	a	DT
cord-005478-5iu38pr6	3332	4	higher	high	JJR
cord-005478-5iu38pr6	3332	5	,	,	,
cord-005478-5iu38pr6	3332	6	but	but	CC
cord-005478-5iu38pr6	3332	7	not	not	RB
cord-005478-5iu38pr6	3332	8	significant	significant	JJ
cord-005478-5iu38pr6	3332	9	,	,	,
cord-005478-5iu38pr6	3332	10	amount	amount	NN
cord-005478-5iu38pr6	3332	11	of	of	IN
cord-005478-5iu38pr6	3332	12	effector	effector	JJ
cord-005478-5iu38pr6	3332	13	memory	memory	NN
cord-005478-5iu38pr6	3332	14	and	and	CC
cord-005478-5iu38pr6	3332	15	stem	stem	NN
cord-005478-5iu38pr6	3332	16	cell	cell	NN
cord-005478-5iu38pr6	3332	17	memory	memory	NN
cord-005478-5iu38pr6	3332	18	T	t	NN
cord-005478-5iu38pr6	3332	19	cells	cell	NNS
cord-005478-5iu38pr6	3332	20	were	be	VBD
cord-005478-5iu38pr6	3332	21	detected	detect	VBN
cord-005478-5iu38pr6	3332	22	.	.	.
cord-005478-5iu38pr6	3333	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3333	2	:	:	:
cord-005478-5iu38pr6	3334	1	These	these	DT
cord-005478-5iu38pr6	3334	2	pre	pre	JJ
cord-005478-5iu38pr6	3334	3	-	-	JJ
cord-005478-5iu38pr6	3334	4	clinical	clinical	JJ
cord-005478-5iu38pr6	3334	5	in	in	IN
cord-005478-5iu38pr6	3334	6	vivo	vivo	NN
cord-005478-5iu38pr6	3334	7	results	result	NNS
cord-005478-5iu38pr6	3334	8	indicate	indicate	VBP
cord-005478-5iu38pr6	3334	9	that	that	IN
cord-005478-5iu38pr6	3334	10	ErbB2-CAR	ErbB2-CAR	NNP
cord-005478-5iu38pr6	3334	11	redirection	redirection	NN
cord-005478-5iu38pr6	3334	12	of	of	IN
cord-005478-5iu38pr6	3334	13	CIK	CIK	NNP
cord-005478-5iu38pr6	3334	14	cells	cell	NNS
cord-005478-5iu38pr6	3334	15	improves	improve	VBZ
cord-005478-5iu38pr6	3334	16	both	both	CC
cord-005478-5iu38pr6	3334	17	homing	homing	NN
cord-005478-5iu38pr6	3334	18	and	and	CC
cord-005478-5iu38pr6	3334	19	NK	nk	NN
cord-005478-5iu38pr6	3334	20	-	-	HYPH
cord-005478-5iu38pr6	3334	21	like	like	JJ
cord-005478-5iu38pr6	3334	22	cytotoxicity	cytotoxicity	NN
cord-005478-5iu38pr6	3334	23	of	of	IN
cord-005478-5iu38pr6	3334	24	CIK	CIK	NNP
cord-005478-5iu38pr6	3334	25	cells	cell	NNS
cord-005478-5iu38pr6	3334	26	in	in	IN
cord-005478-5iu38pr6	3334	27	the	the	DT
cord-005478-5iu38pr6	3334	28	presence	presence	NN
cord-005478-5iu38pr6	3334	29	of	of	IN
cord-005478-5iu38pr6	3334	30	ErbB2-positive	erbb2-positive	PRP
cord-005478-5iu38pr6	3334	31	tumors	tumor	NNS
cord-005478-5iu38pr6	3334	32	,	,	,
cord-005478-5iu38pr6	3334	33	implying	imply	VBG
cord-005478-5iu38pr6	3334	34	that	that	IN
cord-005478-5iu38pr6	3334	35	this	this	DT
cord-005478-5iu38pr6	3334	36	therapy	therapy	NN
cord-005478-5iu38pr6	3334	37	may	may	MD
cord-005478-5iu38pr6	3334	38	represent	represent	VB
cord-005478-5iu38pr6	3334	39	a	a	DT
cord-005478-5iu38pr6	3334	40	step	step	NN
cord-005478-5iu38pr6	3334	41	forward	forward	RB
cord-005478-5iu38pr6	3334	42	in	in	IN
cord-005478-5iu38pr6	3334	43	the	the	DT
cord-005478-5iu38pr6	3334	44	treatment	treatment	NN
cord-005478-5iu38pr6	3334	45	of	of	IN
cord-005478-5iu38pr6	3334	46	patients	patient	NNS
cord-005478-5iu38pr6	3334	47	with	with	IN
cord-005478-5iu38pr6	3334	48	resistant	resistant	JJ
cord-005478-5iu38pr6	3334	49	,	,	,
cord-005478-5iu38pr6	3334	50	relapsed	relapsed	JJ
cord-005478-5iu38pr6	3334	51	and	and	CC
cord-005478-5iu38pr6	3334	52	advanced	advanced	JJ
cord-005478-5iu38pr6	3334	53	RMS	RMS	NNP
cord-005478-5iu38pr6	3334	54	.	.	.
cord-005478-5iu38pr6	3335	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3335	2	:	:	:
cord-005478-5iu38pr6	3336	1	Michael	Michael	NNP
cord-005478-5iu38pr6	3336	2	Merker	Merker	NNP
cord-005478-5iu38pr6	3336	3	,	,	,
cord-005478-5iu38pr6	3336	4	Juliane	Juliane	NNP
cord-005478-5iu38pr6	3336	5	Wagner	Wagner	NNP
cord-005478-5iu38pr6	3336	6	,	,	,
cord-005478-5iu38pr6	3336	7	Vida	Vida	NNP
cord-005478-5iu38pr6	3336	8	Meyer	Meyer	NNP
cord-005478-5iu38pr6	3336	9	,	,	,
cord-005478-5iu38pr6	3336	10	Thomas	Thomas	NNP
cord-005478-5iu38pr6	3336	11	Klingebiel	Klingebiel	NNP
cord-005478-5iu38pr6	3336	12	,	,	,
cord-005478-5iu38pr6	3336	13	Winfried	Winfried	NNP
cord-005478-5iu38pr6	3336	14	S.	S.	NNP
cord-005478-5iu38pr6	3336	15	Wels	Wels	NNPS
cord-005478-5iu38pr6	3336	16	and	and	CC
cord-005478-5iu38pr6	3336	17	Eva	Eva	NNP
cord-005478-5iu38pr6	3336	18	Rettinger	Rettinger	NNP
cord-005478-5iu38pr6	3336	19	have	have	VBP
cord-005478-5iu38pr6	3336	20	nothing	nothing	NN
cord-005478-5iu38pr6	3336	21	to	to	TO
cord-005478-5iu38pr6	3336	22	declare	declare	VB
cord-005478-5iu38pr6	3336	23	.	.	.
cord-005478-5iu38pr6	3337	1	Peter	Peter	NNP
cord-005478-5iu38pr6	3337	2	Bader	Bader	NNP
cord-005478-5iu38pr6	3337	3	declares	declare	VBZ
cord-005478-5iu38pr6	3337	4	the	the	DT
cord-005478-5iu38pr6	3337	5	following	follow	VBG
cord-005478-5iu38pr6	3337	6	potential	potential	JJ
cord-005478-5iu38pr6	3337	7	conflicts	conflict	NNS
cord-005478-5iu38pr6	3337	8	of	of	IN
cord-005478-5iu38pr6	3337	9	interest	interest	NN
cord-005478-5iu38pr6	3337	10	:	:	:
cord-005478-5iu38pr6	3337	11	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3337	12	(	(	-LRB-
cord-005478-5iu38pr6	3337	13	consultancy	consultancy	NN
cord-005478-5iu38pr6	3337	14	:	:	:
cord-005478-5iu38pr6	3337	15	included	include	VBN
cord-005478-5iu38pr6	3337	16	expert	expert	JJ
cord-005478-5iu38pr6	3337	17	testimony	testimony	NN
cord-005478-5iu38pr6	3337	18	,	,	,
cord-005478-5iu38pr6	3337	19	speaker	speaker	NNP
cord-005478-5iu38pr6	3337	20	bureau	bureau	NNP
cord-005478-5iu38pr6	3337	21	,	,	,
cord-005478-5iu38pr6	3337	22	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3337	23	)	)	-RRB-
cord-005478-5iu38pr6	3337	24	,	,	,
cord-005478-5iu38pr6	3337	25	Medac	Medac	NNP
cord-005478-5iu38pr6	3337	26	(	(	-LRB-
cord-005478-5iu38pr6	3337	27	Research	Research	NNP
cord-005478-5iu38pr6	3337	28	Funding	Funding	NNP
cord-005478-5iu38pr6	3337	29	,	,	,
cord-005478-5iu38pr6	3337	30	Patents	Patents	NNPS
cord-005478-5iu38pr6	3337	31	and	and	CC
cord-005478-5iu38pr6	3337	32	Royalties	Royalties	NNPS
cord-005478-5iu38pr6	3337	33	)	)	-RRB-
cord-005478-5iu38pr6	3337	34	,	,	,
cord-005478-5iu38pr6	3337	35	Riemser	Riemser	NNP
cord-005478-5iu38pr6	3337	36	(	(	-LRB-
cord-005478-5iu38pr6	3337	37	Research	Research	NNP
cord-005478-5iu38pr6	3337	38	Funding	Funding	NNP
cord-005478-5iu38pr6	3337	39	)	)	-RRB-
cord-005478-5iu38pr6	3337	40	,	,	,
cord-005478-5iu38pr6	3337	41	Neovii	Neovii	NNP
cord-005478-5iu38pr6	3337	42	(	(	-LRB-
cord-005478-5iu38pr6	3337	43	Research	Research	NNP
cord-005478-5iu38pr6	3337	44	Funding	Funding	NNP
cord-005478-5iu38pr6	3337	45	)	)	-RRB-
cord-005478-5iu38pr6	3337	46	,	,	,
cord-005478-5iu38pr6	3337	47	Amgen	Amgen	NNP
cord-005478-5iu38pr6	3337	48	(	(	-LRB-
cord-005478-5iu38pr6	3337	49	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3337	50	)	)	-RRB-
cord-005478-5iu38pr6	3337	51	.	.	.
cord-005478-5iu38pr6	3338	1	Genesis	Genesis	NNP
cord-005478-5iu38pr6	3338	2	-a	-a	HYPH
cord-005478-5iu38pr6	3338	3	phase	phase	NN
cord-005478-5iu38pr6	3338	4	III	iii	CD
cord-005478-5iu38pr6	3338	5	randomized	randomized	JJ
cord-005478-5iu38pr6	3338	6	double	double	JJ
cord-005478-5iu38pr6	3338	7	-	-	HYPH
cord-005478-5iu38pr6	3338	8	blind	blind	JJ
cord-005478-5iu38pr6	3338	9	,	,	,
cord-005478-5iu38pr6	3338	10	placebocontrolled	placebocontrolled	JJ
cord-005478-5iu38pr6	3338	11	trial	trial	NN
cord-005478-5iu38pr6	3338	12	,	,	,
cord-005478-5iu38pr6	3338	13	evaluating	evaluate	VBG
cord-005478-5iu38pr6	3338	14	safety	safety	NN
cord-005478-5iu38pr6	3338	15	and	and	CC
cord-005478-5iu38pr6	3338	16	efficacy	efficacy	NN
cord-005478-5iu38pr6	3338	17	of	of	IN
cord-005478-5iu38pr6	3338	18	BL-8040	bl-8040	NN
cord-005478-5iu38pr6	3338	19	and	and	CC
cord-005478-5iu38pr6	3338	20	G	G	NNP
cord-005478-5iu38pr6	3338	21	-	-	HYPH
cord-005478-5iu38pr6	3338	22	CSF	CSF	NNP
cord-005478-5iu38pr6	3338	23	in	in	IN
cord-005478-5iu38pr6	3338	24	mobilization	mobilization	NN
cord-005478-5iu38pr6	3338	25	of	of	IN
cord-005478-5iu38pr6	3338	26	HCS	HCS	NNP
cord-005478-5iu38pr6	3338	27	'S	'S	NNP
cord-005478-5iu38pr6	3338	28	for	for	IN
cord-005478-5iu38pr6	3338	29	autologous	autologous	JJ
cord-005478-5iu38pr6	3338	30	transplantation	transplantation	NN
cord-005478-5iu38pr6	3338	31	-	-	HYPH
cord-005478-5iu38pr6	3338	32	multiple	multiple	JJ
cord-005478-5iu38pr6	3338	33	myeloma	myeloma	NN
cord-005478-5iu38pr6	3339	1	Hemda	Hemda	NNP
cord-005478-5iu38pr6	3339	2	Chen	Chen	NNP
cord-005478-5iu38pr6	3339	3	1	1	CD
cord-005478-5iu38pr6	3340	1	,	,	,
cord-005478-5iu38pr6	3340	2	Zachary	Zachary	NNP
cord-005478-5iu38pr6	3340	3	D.	D.	NNP
cord-005478-5iu38pr6	3340	4	Crees	Crees	NNP
cord-005478-5iu38pr6	3340	5	2	2	CD
cord-005478-5iu38pr6	3340	6	,	,	,
cord-005478-5iu38pr6	3340	7	Keith	Keith	NNP
cord-005478-5iu38pr6	3340	8	Stockerl	Stockerl	NNP
cord-005478-5iu38pr6	3340	9	-	-	HYPH
cord-005478-5iu38pr6	3340	10	Goldstein	Goldstein	NNP
cord-005478-5iu38pr6	3340	11	K	K	NNP
cord-005478-5iu38pr6	3340	12	2	2	CD
cord-005478-5iu38pr6	3340	13	,	,	,
cord-005478-5iu38pr6	3340	14	Abi	Abi	NNP
cord-005478-5iu38pr6	3340	15	Vainstein	Vainstein	NNP
cord-005478-5iu38pr6	3340	16	1	1	CD
cord-005478-5iu38pr6	3340	17	,	,	,
cord-005478-5iu38pr6	3340	18	Ella	Ella	NNP
cord-005478-5iu38pr6	3340	19	Sorani	Sorani	NNP
cord-005478-5iu38pr6	3340	20	1	1	CD
cord-005478-5iu38pr6	3340	21	,	,	,
cord-005478-5iu38pr6	3340	22	Osnat	Osnat	NNP
cord-005478-5iu38pr6	3340	23	Bohana	Bohana	NNP
cord-005478-5iu38pr6	3340	24	-	-	HYPH
cord-005478-5iu38pr6	3340	25	Kashtan	Kashtan	NNP
cord-005478-5iu38pr6	3340	26	1	1	CD
cord-005478-5iu38pr6	3340	27	,	,	,
cord-005478-5iu38pr6	3340	28	John	John	NNP
cord-005478-5iu38pr6	3340	29	F	F	NNP
cord-005478-5iu38pr6	3340	30	Dipersio	Dipersio	NNP
cord-005478-5iu38pr6	3340	31	2	2	CD
cord-005478-5iu38pr6	3340	32	1	1	CD
cord-005478-5iu38pr6	3340	33	BiolineRx	BiolineRx	NNP
cord-005478-5iu38pr6	3340	34	,	,	,
cord-005478-5iu38pr6	3340	35	Tel	Tel	NNP
cord-005478-5iu38pr6	3340	36	Aviv	Aviv	NNP
cord-005478-5iu38pr6	3340	37	,	,	,
cord-005478-5iu38pr6	3340	38	Israel	Israel	NNP
cord-005478-5iu38pr6	3340	39	,	,	,
cord-005478-5iu38pr6	3340	40	2	2	CD
cord-005478-5iu38pr6	3340	41	Washington	Washington	NNP
cord-005478-5iu38pr6	3340	42	University	University	NNP
cord-005478-5iu38pr6	3340	43	in	in	IN
cord-005478-5iu38pr6	3340	44	St.	St.	NNP
cord-005478-5iu38pr6	3340	45	Louis	Louis	NNP
cord-005478-5iu38pr6	3340	46	,	,	,
cord-005478-5iu38pr6	3340	47	St.	St.	NNP
cord-005478-5iu38pr6	3340	48	Louis	Louis	NNP
cord-005478-5iu38pr6	3340	49	,	,	,
cord-005478-5iu38pr6	3340	50	WA	WA	NNP
cord-005478-5iu38pr6	3340	51	,	,	,
cord-005478-5iu38pr6	3341	1	United	United	NNP
cord-005478-5iu38pr6	3341	2	States	States	NNP
cord-005478-5iu38pr6	3341	3	Background	Background	NNP
cord-005478-5iu38pr6	3341	4	:	:	:
cord-005478-5iu38pr6	3341	5	CXCR4	CXCR4	NNP
cord-005478-5iu38pr6	3341	6	mediates	mediate	VBZ
cord-005478-5iu38pr6	3341	7	retention	retention	NN
cord-005478-5iu38pr6	3341	8	of	of	IN
cord-005478-5iu38pr6	3341	9	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3341	10	stem	stem	NN
cord-005478-5iu38pr6	3341	11	cells	cell	NNS
cord-005478-5iu38pr6	3341	12	(	(	-LRB-
cord-005478-5iu38pr6	3341	13	HSCs	HSCs	NNP
cord-005478-5iu38pr6	3341	14	)	)	-RRB-
cord-005478-5iu38pr6	3341	15	in	in	IN
cord-005478-5iu38pr6	3341	16	the	the	DT
cord-005478-5iu38pr6	3341	17	bone	bone	NN
cord-005478-5iu38pr6	3341	18	marrow	marrow	NN
cord-005478-5iu38pr6	3341	19	(	(	-LRB-
cord-005478-5iu38pr6	3341	20	BM	BM	NNP
cord-005478-5iu38pr6	3341	21	)	)	-RRB-
cord-005478-5iu38pr6	3341	22	niche	niche	NN
cord-005478-5iu38pr6	3341	23	.	.	.
cord-005478-5iu38pr6	3342	1	BL-8040	BL-8040	NNP
cord-005478-5iu38pr6	3342	2	,	,	,
cord-005478-5iu38pr6	3342	3	a	a	DT
cord-005478-5iu38pr6	3342	4	novel	novel	NN
cord-005478-5iu38pr6	3342	5	,	,	,
cord-005478-5iu38pr6	3342	6	high	high	JJ
cord-005478-5iu38pr6	3342	7	affinity	affinity	NN
cord-005478-5iu38pr6	3342	8	CXCR4	cxcr4	NN
cord-005478-5iu38pr6	3342	9	antagonist	antagonist	NN
cord-005478-5iu38pr6	3342	10	is	be	VBZ
cord-005478-5iu38pr6	3342	11	a	a	DT
cord-005478-5iu38pr6	3342	12	potent	potent	JJ
cord-005478-5iu38pr6	3342	13	mobilizer	mobilizer	NN
cord-005478-5iu38pr6	3342	14	of	of	IN
cord-005478-5iu38pr6	3342	15	HSCs	HSCs	NNP
cord-005478-5iu38pr6	3342	16	to	to	IN
cord-005478-5iu38pr6	3342	17	the	the	DT
cord-005478-5iu38pr6	3342	18	peripheral	peripheral	JJ
cord-005478-5iu38pr6	3342	19	blood	blood	NN
cord-005478-5iu38pr6	3342	20	with	with	IN
cord-005478-5iu38pr6	3342	21	numerous	numerous	JJ
cord-005478-5iu38pr6	3342	22	potential	potential	JJ
cord-005478-5iu38pr6	3342	23	clinical	clinical	JJ
cord-005478-5iu38pr6	3342	24	applications	application	NNS
cord-005478-5iu38pr6	3342	25	,	,	,
cord-005478-5iu38pr6	3342	26	including	include	VBG
cord-005478-5iu38pr6	3342	27	mobilization	mobilization	NN
cord-005478-5iu38pr6	3342	28	of	of	IN
cord-005478-5iu38pr6	3342	29	CD34	CD34	NNP
cord-005478-5iu38pr6	3342	30	+	+	CC
cord-005478-5iu38pr6	3342	31	cells	cell	NNS
cord-005478-5iu38pr6	3342	32	for	for	IN
cord-005478-5iu38pr6	3342	33	autologous	autologous	JJ
cord-005478-5iu38pr6	3342	34	HSC	HSC	NNP
cord-005478-5iu38pr6	3342	35	transplantation	transplantation	NN
cord-005478-5iu38pr6	3342	36	(	(	-LRB-
cord-005478-5iu38pr6	3342	37	auto	auto	NN
cord-005478-5iu38pr6	3342	38	-	-	HYPH
cord-005478-5iu38pr6	3342	39	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3342	40	)	)	-RRB-
cord-005478-5iu38pr6	3342	41	in	in	IN
cord-005478-5iu38pr6	3342	42	Multiple	Multiple	NNP
cord-005478-5iu38pr6	3342	43	Myeloma	Myeloma	NNP
cord-005478-5iu38pr6	3342	44	(	(	-LRB-
cord-005478-5iu38pr6	3342	45	MM	MM	NNP
cord-005478-5iu38pr6	3342	46	)	)	-RRB-
cord-005478-5iu38pr6	3342	47	.	.	.
cord-005478-5iu38pr6	3343	1	This	this	DT
cord-005478-5iu38pr6	3343	2	study	study	NN
cord-005478-5iu38pr6	3343	3	aims	aim	VBZ
cord-005478-5iu38pr6	3343	4	to	to	TO
cord-005478-5iu38pr6	3343	5	evaluate	evaluate	VB
cord-005478-5iu38pr6	3343	6	the	the	DT
cord-005478-5iu38pr6	3343	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	3343	8	of	of	IN
cord-005478-5iu38pr6	3343	9	single	single	JJ
cord-005478-5iu38pr6	3343	10	dose	dose	NN
cord-005478-5iu38pr6	3343	11	BL-8040	BL-8040	NNP
cord-005478-5iu38pr6	3343	12	plus	plus	CC
cord-005478-5iu38pr6	3343	13	G	G	NNP
cord-005478-5iu38pr6	3343	14	-	-	HYPH
cord-005478-5iu38pr6	3343	15	CSF	CSF	NNP
cord-005478-5iu38pr6	3343	16	in	in	IN
cord-005478-5iu38pr6	3343	17	mobilization	mobilization	NN
cord-005478-5iu38pr6	3343	18	of	of	IN
cord-005478-5iu38pr6	3343	19	≥6.0x10	≥6.0x10	CD
cord-005478-5iu38pr6	3343	20	6	6	CD
cord-005478-5iu38pr6	3344	1	CD34	CD34	NNP
cord-005478-5iu38pr6	3344	2	+	+	CC
cord-005478-5iu38pr6	3344	3	cells	cell	NNS
cord-005478-5iu38pr6	3344	4	/	/	SYM
cord-005478-5iu38pr6	3344	5	kg	kg	NNS
cord-005478-5iu38pr6	3344	6	in	in	IN
cord-005478-5iu38pr6	3344	7	up	up	IN
cord-005478-5iu38pr6	3344	8	to	to	TO
cord-005478-5iu38pr6	3344	9	2	2	CD
cord-005478-5iu38pr6	3344	10	apheresis	apheresis	NN
cord-005478-5iu38pr6	3344	11	sessions	session	NNS
cord-005478-5iu38pr6	3344	12	for	for	IN
cord-005478-5iu38pr6	3344	13	auto	auto	NN
cord-005478-5iu38pr6	3344	14	-	-	HYPH
cord-005478-5iu38pr6	3344	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3344	16	in	in	IN
cord-005478-5iu38pr6	3344	17	MM	MM	NNP
cord-005478-5iu38pr6	3344	18	.	.	.
cord-005478-5iu38pr6	3345	1	Methods	method	NNS
cord-005478-5iu38pr6	3345	2	:	:	:
cord-005478-5iu38pr6	3346	1	A	a	DT
cord-005478-5iu38pr6	3346	2	Phase	Phase	NNP
cord-005478-5iu38pr6	3346	3	III	iii	CD
cord-005478-5iu38pr6	3346	4	study	study	NN
cord-005478-5iu38pr6	3346	5	composed	compose	VBN
cord-005478-5iu38pr6	3346	6	of	of	IN
cord-005478-5iu38pr6	3346	7	an	an	DT
cord-005478-5iu38pr6	3346	8	open	open	JJ
cord-005478-5iu38pr6	3346	9	-	-	HYPH
cord-005478-5iu38pr6	3346	10	label	label	NN
cord-005478-5iu38pr6	3346	11	,	,	,
cord-005478-5iu38pr6	3346	12	single	single	JJ
cord-005478-5iu38pr6	3346	13	-	-	HYPH
cord-005478-5iu38pr6	3346	14	arm	arm	NN
cord-005478-5iu38pr6	3346	15	lead	lead	NN
cord-005478-5iu38pr6	3346	16	-	-	HYPH
cord-005478-5iu38pr6	3346	17	in	in	IN
cord-005478-5iu38pr6	3346	18	Part1	Part1	NNS
cord-005478-5iu38pr6	3346	19	followed	follow	VBN
cord-005478-5iu38pr6	3346	20	by	by	IN
cord-005478-5iu38pr6	3346	21	a	a	DT
cord-005478-5iu38pr6	3346	22	randomized	randomized	JJ
cord-005478-5iu38pr6	3346	23	,	,	,
cord-005478-5iu38pr6	3346	24	doubleblinded	doubleblinded	JJ
cord-005478-5iu38pr6	3346	25	,	,	,
cord-005478-5iu38pr6	3346	26	placebo	placebo	NN
cord-005478-5iu38pr6	3346	27	-	-	HYPH
cord-005478-5iu38pr6	3346	28	controlled	control	VBN
cord-005478-5iu38pr6	3346	29	Part2	part2	NN
cord-005478-5iu38pr6	3346	30	.	.	.
cord-005478-5iu38pr6	3347	1	Eligible	eligible	JJ
cord-005478-5iu38pr6	3347	2	MM	MM	NNP
cord-005478-5iu38pr6	3347	3	patients	patient	NNS
cord-005478-5iu38pr6	3347	4	age	age	NN
cord-005478-5iu38pr6	3347	5	18	18	CD
cord-005478-5iu38pr6	3347	6	-	-	SYM
cord-005478-5iu38pr6	3347	7	78	78	CD
cord-005478-5iu38pr6	3347	8	will	will	MD
cord-005478-5iu38pr6	3347	9	receive	receive	VB
cord-005478-5iu38pr6	3347	10	G	G	NNP
cord-005478-5iu38pr6	3347	11	-	-	HYPH
cord-005478-5iu38pr6	3347	12	CSF	CSF	NNP
cord-005478-5iu38pr6	3347	13	(	(	-LRB-
cord-005478-5iu38pr6	3347	14	10	10	CD
cord-005478-5iu38pr6	3347	15	μg	μg	NN
cord-005478-5iu38pr6	3347	16	/	/	SYM
cord-005478-5iu38pr6	3347	17	kg	kg	NNP
cord-005478-5iu38pr6	3347	18	;	;	:
cord-005478-5iu38pr6	3347	19	SC	SC	NNP
cord-005478-5iu38pr6	3347	20	)	)	-RRB-
cord-005478-5iu38pr6	3347	21	daily	daily	RB
cord-005478-5iu38pr6	3347	22	for	for	IN
cord-005478-5iu38pr6	3347	23	up	up	IN
cord-005478-5iu38pr6	3347	24	to	to	TO
cord-005478-5iu38pr6	3347	25	8	8	CD
cord-005478-5iu38pr6	3347	26	days	day	NNS
cord-005478-5iu38pr6	3347	27	and	and	CC
cord-005478-5iu38pr6	3347	28	one	one	CD
cord-005478-5iu38pr6	3347	29	dose	dose	NN
cord-005478-5iu38pr6	3347	30	of	of	IN
cord-005478-5iu38pr6	3347	31	BL-8040	bl-8040	NN
cord-005478-5iu38pr6	3347	32	(	(	-LRB-
cord-005478-5iu38pr6	3347	33	1.25	1.25	CD
cord-005478-5iu38pr6	3347	34	mg	mg	NNP
cord-005478-5iu38pr6	3347	35	/	/	SYM
cord-005478-5iu38pr6	3347	36	kg	kg	NNP
cord-005478-5iu38pr6	3347	37	;	;	:
cord-005478-5iu38pr6	3347	38	SC	SC	NNP
cord-005478-5iu38pr6	3347	39	)	)	-RRB-
cord-005478-5iu38pr6	3347	40	or	or	CC
cord-005478-5iu38pr6	3347	41	placebo	placebo	NN
cord-005478-5iu38pr6	3347	42	on	on	IN
cord-005478-5iu38pr6	3347	43	day	day	NN
cord-005478-5iu38pr6	3347	44	4	4	CD
cord-005478-5iu38pr6	3347	45	followed	follow	VBD
cord-005478-5iu38pr6	3347	46	by	by	IN
cord-005478-5iu38pr6	3347	47	up	up	IN
cord-005478-5iu38pr6	3347	48	to	to	TO
cord-005478-5iu38pr6	3347	49	2	2	CD
cord-005478-5iu38pr6	3347	50	apheresis	apheresis	NN
cord-005478-5iu38pr6	3347	51	sessions	session	NNS
cord-005478-5iu38pr6	3347	52	;	;	:
cord-005478-5iu38pr6	3347	53	and	and	CC
cord-005478-5iu38pr6	3347	54	if	if	IN
cord-005478-5iu38pr6	3347	55	needed	need	VBN
cord-005478-5iu38pr6	3347	56	a	a	DT
cord-005478-5iu38pr6	3347	57	second	second	JJ
cord-005478-5iu38pr6	3347	58	dose	dose	NN
cord-005478-5iu38pr6	3347	59	of	of	IN
cord-005478-5iu38pr6	3347	60	BL-8040	bl-8040	NN
cord-005478-5iu38pr6	3347	61	or	or	CC
cord-005478-5iu38pr6	3347	62	placebo	placebo	NN
cord-005478-5iu38pr6	3347	63	on	on	IN
cord-005478-5iu38pr6	3347	64	day	day	NN
cord-005478-5iu38pr6	3347	65	6	6	CD
cord-005478-5iu38pr6	3347	66	followed	follow	VBD
cord-005478-5iu38pr6	3347	67	by	by	IN
cord-005478-5iu38pr6	3347	68	up	up	IN
cord-005478-5iu38pr6	3347	69	to	to	TO
cord-005478-5iu38pr6	3347	70	2	2	CD
cord-005478-5iu38pr6	3347	71	apheresis	apheresis	NN
cord-005478-5iu38pr6	3347	72	sessions	session	NNS
cord-005478-5iu38pr6	3347	73	.	.	.
cord-005478-5iu38pr6	3348	1	progressive	progressive	JJ
cord-005478-5iu38pr6	3348	2	disease	disease	NN
cord-005478-5iu38pr6	3348	3	at	at	IN
cord-005478-5iu38pr6	3348	4	time	time	NN
cord-005478-5iu38pr6	3348	5	of	of	IN
cord-005478-5iu38pr6	3348	6	LDC	LDC	NNP
cord-005478-5iu38pr6	3348	7	did	do	VBD
cord-005478-5iu38pr6	3348	8	not	not	RB
cord-005478-5iu38pr6	3348	9	respond	respond	VB
cord-005478-5iu38pr6	3348	10	although	although	IN
cord-005478-5iu38pr6	3348	11	CAR	car	NN
cord-005478-5iu38pr6	3348	12	-	-	HYPH
cord-005478-5iu38pr6	3348	13	T	t	NN
cord-005478-5iu38pr6	3348	14	cells	cell	NNS
cord-005478-5iu38pr6	3348	15	could	could	MD
cord-005478-5iu38pr6	3348	16	be	be	VB
cord-005478-5iu38pr6	3348	17	seen	see	VBN
cord-005478-5iu38pr6	3348	18	morphologically	morphologically	RB
cord-005478-5iu38pr6	3348	19	under	under	IN
cord-005478-5iu38pr6	3348	20	the	the	DT
cord-005478-5iu38pr6	3348	21	microscope	microscope	NN
cord-005478-5iu38pr6	3348	22	.	.	.
cord-005478-5iu38pr6	3349	1	This	this	DT
cord-005478-5iu38pr6	3349	2	might	may	MD
cord-005478-5iu38pr6	3349	3	be	be	VB
cord-005478-5iu38pr6	3349	4	explained	explain	VBN
cord-005478-5iu38pr6	3349	5	by	by	IN
cord-005478-5iu38pr6	3349	6	multidrug	multidrug	NN
cord-005478-5iu38pr6	3349	7	related	relate	VBN
cord-005478-5iu38pr6	3349	8	phenomenon	phenomenon	NN
cord-005478-5iu38pr6	3349	9	protecting	protect	VBG
cord-005478-5iu38pr6	3349	10	refractory	refractory	JJ
cord-005478-5iu38pr6	3349	11	leukemia	leukemia	NN
cord-005478-5iu38pr6	3349	12	from	from	IN
cord-005478-5iu38pr6	3349	13	CAR	car	NN
cord-005478-5iu38pr6	3349	14	-	-	HYPH
cord-005478-5iu38pr6	3349	15	T	t	NN
cord-005478-5iu38pr6	3349	16	cell	cell	NN
cord-005478-5iu38pr6	3349	17	attack	attack	NN
cord-005478-5iu38pr6	3349	18	.	.	.
cord-005478-5iu38pr6	3350	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3350	2	:	:	:
cord-005478-5iu38pr6	3351	1	Commercial	commercial	JJ
cord-005478-5iu38pr6	3351	2	available	available	JJ
cord-005478-5iu38pr6	3351	3	CAR	car	NN
cord-005478-5iu38pr6	3351	4	-	-	HYPH
cord-005478-5iu38pr6	3351	5	T	t	NN
cord-005478-5iu38pr6	3351	6	cell	cell	NN
cord-005478-5iu38pr6	3351	7	product	product	NN
cord-005478-5iu38pr6	3352	1	Tisagenlecleucel	Tisagenlecleucel	NNP
cord-005478-5iu38pr6	3353	1	(	(	-LRB-
cord-005478-5iu38pr6	3353	2	Kymriah	Kymriah	NNP
cord-005478-5iu38pr6	3353	3	®	®	.
cord-005478-5iu38pr6	3353	4	)	)	-RRB-
cord-005478-5iu38pr6	3353	5	showed	show	VBD
cord-005478-5iu38pr6	3353	6	high	high	JJ
cord-005478-5iu38pr6	3353	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	3353	8	in	in	IN
cord-005478-5iu38pr6	3353	9	r	r	NN
cord-005478-5iu38pr6	3353	10	/	/	SYM
cord-005478-5iu38pr6	3353	11	r	r	NN
cord-005478-5iu38pr6	3353	12	-	-	:
cord-005478-5iu38pr6	3353	13	ALL	all	DT
cord-005478-5iu38pr6	3353	14	patients	patient	NNS
cord-005478-5iu38pr6	3353	15	to	to	TO
cord-005478-5iu38pr6	3353	16	re	re	VB
cord-005478-5iu38pr6	3353	17	-	-	VB
cord-005478-5iu38pr6	3353	18	induce	induce	VB
cord-005478-5iu38pr6	3353	19	CR	CR	NNP
cord-005478-5iu38pr6	3353	20	.	.	.
cord-005478-5iu38pr6	3354	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	3354	2	Trial	Trial	NNP
cord-005478-5iu38pr6	3354	3	Registry	Registry	NNP
cord-005478-5iu38pr6	3354	4	:	:	:
cord-005478-5iu38pr6	3355	1	Commercial	commercial	JJ
cord-005478-5iu38pr6	3355	2	available	available	JJ
cord-005478-5iu38pr6	3355	3	CAR	car	NN
cord-005478-5iu38pr6	3355	4	-	-	HYPH
cord-005478-5iu38pr6	3355	5	T	t	NN
cord-005478-5iu38pr6	3355	6	cell	cell	NN
cord-005478-5iu38pr6	3355	7	product	product	NN
cord-005478-5iu38pr6	3356	1	Tisagenlecleucel	Tisagenlecleucel	NNP
cord-005478-5iu38pr6	3357	1	(	(	-LRB-
cord-005478-5iu38pr6	3357	2	Kymriah	Kymriah	NNP
cord-005478-5iu38pr6	3357	3	®	®	.
cord-005478-5iu38pr6	3357	4	)	)	-RRB-
cord-005478-5iu38pr6	3357	5	showed	show	VBD
cord-005478-5iu38pr6	3357	6	high	high	JJ
cord-005478-5iu38pr6	3357	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	3357	8	in	in	IN
cord-005478-5iu38pr6	3357	9	r	r	NN
cord-005478-5iu38pr6	3357	10	/	/	SYM
cord-005478-5iu38pr6	3357	11	r	r	NN
cord-005478-5iu38pr6	3357	12	-	-	:
cord-005478-5iu38pr6	3357	13	ALL	all	DT
cord-005478-5iu38pr6	3357	14	patients	patient	NNS
cord-005478-5iu38pr6	3357	15	to	to	TO
cord-005478-5iu38pr6	3357	16	re	re	VB
cord-005478-5iu38pr6	3357	17	-	-	VB
cord-005478-5iu38pr6	3357	18	induce	induce	VB
cord-005478-5iu38pr6	3357	19	CR	CR	NNP
cord-005478-5iu38pr6	3357	20	.	.	.
cord-005478-5iu38pr6	3358	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3358	2	:	:	:
cord-005478-5iu38pr6	3358	3	PB	PB	NNP
cord-005478-5iu38pr6	3358	4	:	:	:
cord-005478-5iu38pr6	3358	5	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3358	6	(	(	-LRB-
cord-005478-5iu38pr6	3358	7	consultancy	consultancy	NN
cord-005478-5iu38pr6	3358	8	:	:	:
cord-005478-5iu38pr6	3358	9	included	include	VBN
cord-005478-5iu38pr6	3358	10	expert	expert	JJ
cord-005478-5iu38pr6	3358	11	testimony	testimony	NN
cord-005478-5iu38pr6	3358	12	,	,	,
cord-005478-5iu38pr6	3358	13	speaker	speaker	NNP
cord-005478-5iu38pr6	3358	14	bureau	bureau	NNP
cord-005478-5iu38pr6	3358	15	,	,	,
cord-005478-5iu38pr6	3358	16	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3358	17	)	)	-RRB-
cord-005478-5iu38pr6	3358	18	;	;	:
cord-005478-5iu38pr6	3358	19	Medac	Medac	NNP
cord-005478-5iu38pr6	3358	20	(	(	-LRB-
cord-005478-5iu38pr6	3358	21	Research	Research	NNP
cord-005478-5iu38pr6	3358	22	Funding	Funding	NNP
cord-005478-5iu38pr6	3358	23	,	,	,
cord-005478-5iu38pr6	3358	24	Patents	Patents	NNPS
cord-005478-5iu38pr6	3358	25	and	and	CC
cord-005478-5iu38pr6	3358	26	Royalties	Royalties	NNPS
cord-005478-5iu38pr6	3358	27	)	)	-RRB-
cord-005478-5iu38pr6	3358	28	;	;	:
cord-005478-5iu38pr6	3358	29	Riemser	Riemser	NNP
cord-005478-5iu38pr6	3358	30	(	(	-LRB-
cord-005478-5iu38pr6	3358	31	Research	Research	NNP
cord-005478-5iu38pr6	3358	32	Funding	Funding	NNP
cord-005478-5iu38pr6	3358	33	)	)	-RRB-
cord-005478-5iu38pr6	3358	34	;	;	:
cord-005478-5iu38pr6	3358	35	Neovii	Neovii	NNP
cord-005478-5iu38pr6	3358	36	(	(	-LRB-
cord-005478-5iu38pr6	3358	37	Research	Research	NNP
cord-005478-5iu38pr6	3358	38	Funding	Funding	NNP
cord-005478-5iu38pr6	3358	39	)	)	-RRB-
cord-005478-5iu38pr6	3358	40	;	;	:
cord-005478-5iu38pr6	3358	41	Amgen	Amgen	NNP
cord-005478-5iu38pr6	3358	42	(	(	-LRB-
cord-005478-5iu38pr6	3358	43	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3358	44	)	)	-RRB-
cord-005478-5iu38pr6	3358	45	.	.	.
cord-005478-5iu38pr6	3359	1	AJ	AJ	NNP
cord-005478-5iu38pr6	3359	2	:	:	:
cord-005478-5iu38pr6	3360	1	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3360	2	and	and	CC
cord-005478-5iu38pr6	3360	3	Bluebird	Bluebird	NNP
cord-005478-5iu38pr6	3360	4	:	:	:
cord-005478-5iu38pr6	3360	5	(	(	-LRB-
cord-005478-5iu38pr6	3360	6	Consultancy	consultancy	NN
cord-005478-5iu38pr6	3360	7	)	)	-RRB-
cord-005478-5iu38pr6	3360	8	.	.	.
cord-005478-5iu38pr6	3361	1	All	all	DT
cord-005478-5iu38pr6	3361	2	other	other	JJ
cord-005478-5iu38pr6	3361	3	author	author	NN
cord-005478-5iu38pr6	3361	4	declare	declare	VBP
cord-005478-5iu38pr6	3361	5	no	no	DT
cord-005478-5iu38pr6	3361	6	COI	COI	NNP
cord-005478-5iu38pr6	3361	7	.	.	.
cord-005478-5iu38pr6	3362	1	The	the	DT
cord-005478-5iu38pr6	3362	2	main	main	JJ
cord-005478-5iu38pr6	3362	3	causes	cause	NNS
cord-005478-5iu38pr6	3362	4	of	of	IN
cord-005478-5iu38pr6	3362	5	death	death	NN
cord-005478-5iu38pr6	3362	6	were	be	VBD
cord-005478-5iu38pr6	3362	7	SCT	SCT	NNP
cord-005478-5iu38pr6	3362	8	-	-	HYPH
cord-005478-5iu38pr6	3362	9	related	relate	VBN
cord-005478-5iu38pr6	3362	10	in	in	IN
cord-005478-5iu38pr6	3362	11	53	53	CD
cord-005478-5iu38pr6	3362	12	%	%	NN
cord-005478-5iu38pr6	3362	13	and	and	CC
cord-005478-5iu38pr6	3362	14	disease	disease	NN
cord-005478-5iu38pr6	3362	15	in	in	IN
cord-005478-5iu38pr6	3362	16	35	35	CD
cord-005478-5iu38pr6	3362	17	%	%	NN
cord-005478-5iu38pr6	3362	18	.	.	.
cord-005478-5iu38pr6	3363	1	36-months	36-months	CD
cord-005478-5iu38pr6	3363	2	PFS	PFS	NNP
cord-005478-5iu38pr6	3363	3	,	,	,
cord-005478-5iu38pr6	3363	4	OS	OS	NNP
cord-005478-5iu38pr6	3363	5	,	,	,
cord-005478-5iu38pr6	3363	6	IR	IR	NNP
cord-005478-5iu38pr6	3363	7	and	and	CC
cord-005478-5iu38pr6	3363	8	NRM	NRM	NNP
cord-005478-5iu38pr6	3363	9	were	be	VBD
cord-005478-5iu38pr6	3363	10	53	53	CD
cord-005478-5iu38pr6	3363	11	%	%	NN
cord-005478-5iu38pr6	3363	12	(	(	-LRB-
cord-005478-5iu38pr6	3363	13	44	44	CD
cord-005478-5iu38pr6	3363	14	-	-	SYM
cord-005478-5iu38pr6	3363	15	63	63	CD
cord-005478-5iu38pr6	3363	16	)	)	-RRB-
cord-005478-5iu38pr6	3363	17	,	,	,
cord-005478-5iu38pr6	3363	18	72	72	CD
cord-005478-5iu38pr6	3363	19	%	%	NN
cord-005478-5iu38pr6	3363	20	(	(	-LRB-
cord-005478-5iu38pr6	3363	21	64	64	CD
cord-005478-5iu38pr6	3363	22	-	-	SYM
cord-005478-5iu38pr6	3363	23	80	80	CD
cord-005478-5iu38pr6	3363	24	)	)	-RRB-
cord-005478-5iu38pr6	3363	25	,	,	,
cord-005478-5iu38pr6	3363	26	34	34	CD
cord-005478-5iu38pr6	3363	27	%	%	NN
cord-005478-5iu38pr6	3363	28	(	(	-LRB-
cord-005478-5iu38pr6	3363	29	25	25	CD
cord-005478-5iu38pr6	3363	30	-	-	SYM
cord-005478-5iu38pr6	3363	31	43	43	CD
cord-005478-5iu38pr6	3363	32	)	)	-RRB-
cord-005478-5iu38pr6	3363	33	and	and	CC
cord-005478-5iu38pr6	3363	34	13	13	CD
cord-005478-5iu38pr6	3363	35	%	%	NN
cord-005478-5iu38pr6	3363	36	(	(	-LRB-
cord-005478-5iu38pr6	3363	37	8	8	CD
cord-005478-5iu38pr6	3363	38	-	-	SYM
cord-005478-5iu38pr6	3363	39	20	20	CD
cord-005478-5iu38pr6	3363	40	)	)	-RRB-
cord-005478-5iu38pr6	3363	41	,	,	,
cord-005478-5iu38pr6	3363	42	respectively	respectively	RB
cord-005478-5iu38pr6	3363	43	.	.	.
cord-005478-5iu38pr6	3364	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3364	2	incidence	incidence	NN
cord-005478-5iu38pr6	3364	3	of	of	IN
cord-005478-5iu38pr6	3364	4	grade	grade	NN
cord-005478-5iu38pr6	3364	5	3	3	CD
cord-005478-5iu38pr6	3364	6	-	-	SYM
cord-005478-5iu38pr6	3364	7	4	4	CD
cord-005478-5iu38pr6	3364	8	acute	acute	JJ
cord-005478-5iu38pr6	3364	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3364	10	at	at	IN
cord-005478-5iu38pr6	3364	11	100	100	CD
cord-005478-5iu38pr6	3364	12	days	day	NNS
cord-005478-5iu38pr6	3364	13	after	after	IN
cord-005478-5iu38pr6	3364	14	RIC	RIC	NNP
cord-005478-5iu38pr6	3364	15	-	-	HYPH
cord-005478-5iu38pr6	3364	16	SCT	SCT	NNP
cord-005478-5iu38pr6	3364	17	was	be	VBD
cord-005478-5iu38pr6	3364	18	10	10	CD
cord-005478-5iu38pr6	3364	19	%	%	NN
cord-005478-5iu38pr6	3364	20	(	(	-LRB-
cord-005478-5iu38pr6	3364	21	5	5	CD
cord-005478-5iu38pr6	3364	22	-	-	SYM
cord-005478-5iu38pr6	3364	23	16	16	CD
cord-005478-5iu38pr6	3364	24	)	)	-RRB-
cord-005478-5iu38pr6	3364	25	and	and	CC
cord-005478-5iu38pr6	3364	26	chronic	chronic	JJ
cord-005478-5iu38pr6	3364	27	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3364	28	at	at	IN
cord-005478-5iu38pr6	3364	29	36	36	CD
cord-005478-5iu38pr6	3364	30	months	month	NNS
cord-005478-5iu38pr6	3365	1	48	48	CD
cord-005478-5iu38pr6	3365	2	%	%	NN
cord-005478-5iu38pr6	3366	1	PFS	PFS	NNP
cord-005478-5iu38pr6	3366	2	and	and	CC
cord-005478-5iu38pr6	3366	3	IR	IR	NNP
cord-005478-5iu38pr6	3366	4	were	be	VBD
cord-005478-5iu38pr6	3366	5	influenced	influence	VBN
cord-005478-5iu38pr6	3366	6	by	by	IN
cord-005478-5iu38pr6	3366	7	patient	patient	JJ
cord-005478-5iu38pr6	3366	8	sex	sex	NN
cord-005478-5iu38pr6	3366	9	(	(	-LRB-
cord-005478-5iu38pr6	3366	10	p=0.025	p=0.025	NNP
cord-005478-5iu38pr6	3366	11	and	and	CC
cord-005478-5iu38pr6	3366	12	0.04	0.04	CD
cord-005478-5iu38pr6	3366	13	)	)	-RRB-
cord-005478-5iu38pr6	3366	14	and	and	CC
cord-005478-5iu38pr6	3366	15	disease	disease	NN
cord-005478-5iu38pr6	3366	16	status	status	NN
cord-005478-5iu38pr6	3366	17	at	at	IN
cord-005478-5iu38pr6	3366	18	allo	allo	NN
cord-005478-5iu38pr6	3366	19	-	-	HYPH
cord-005478-5iu38pr6	3366	20	SCT	SCT	NNP
cord-005478-5iu38pr6	3366	21	039	039	CD
cord-005478-5iu38pr6	3366	22	)	)	-RRB-
cord-005478-5iu38pr6	3366	23	and	and	CC
cord-005478-5iu38pr6	3366	24	stem	stem	VB
cord-005478-5iu38pr6	3366	25	cell	cell	NN
cord-005478-5iu38pr6	3366	26	source	source	NN
cord-005478-5iu38pr6	3366	27	(	(	-LRB-
cord-005478-5iu38pr6	3366	28	p=0.04	p=0.04	NN
cord-005478-5iu38pr6	3366	29	)	)	-RRB-
cord-005478-5iu38pr6	3366	30	;	;	:
cord-005478-5iu38pr6	3366	31	acute	acute	JJ
cord-005478-5iu38pr6	3366	32	grade	grade	NN
cord-005478-5iu38pr6	3366	33	3	3	CD
cord-005478-5iu38pr6	3366	34	-	-	SYM
cord-005478-5iu38pr6	3366	35	4	4	CD
cord-005478-5iu38pr6	3366	36	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3366	37	by	by	IN
cord-005478-5iu38pr6	3366	38	donor	donor	NN
cord-005478-5iu38pr6	3366	39	type	type	NN
cord-005478-5iu38pr6	3366	40	(	(	-LRB-
cord-005478-5iu38pr6	3366	41	p=0.037	p=0.037	NNP
cord-005478-5iu38pr6	3366	42	)	)	-RRB-
cord-005478-5iu38pr6	3366	43	and	and	CC
cord-005478-5iu38pr6	3366	44	chronic	chronic	JJ
cord-005478-5iu38pr6	3366	45	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3366	46	by	by	IN
cord-005478-5iu38pr6	3366	47	allo	allo	NN
cord-005478-5iu38pr6	3366	48	-	-	HYPH
cord-005478-5iu38pr6	3366	49	SCT	sct	NN
cord-005478-5iu38pr6	3366	50	conditioning	conditioning	NN
cord-005478-5iu38pr6	3366	51	(	(	-LRB-
cord-005478-5iu38pr6	3366	52	p=0.016	p=0.016	JJS
cord-005478-5iu38pr6	3366	53	)	)	-RRB-
cord-005478-5iu38pr6	3366	54	and	and	CC
cord-005478-5iu38pr6	3366	55	donor	donor	NN
cord-005478-5iu38pr6	3366	56	sex	sex	NN
cord-005478-5iu38pr6	3366	57	(	(	-LRB-
cord-005478-5iu38pr6	3366	58	p=0.01	p=0.01	NNP
cord-005478-5iu38pr6	3366	59	)	)	-RRB-
cord-005478-5iu38pr6	3366	60	.	.	.
cord-005478-5iu38pr6	3367	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3367	2	:	:	:
cord-005478-5iu38pr6	3368	1	This	this	DT
cord-005478-5iu38pr6	3368	2	is	be	VBZ
cord-005478-5iu38pr6	3368	3	the	the	DT
cord-005478-5iu38pr6	3368	4	largest	large	JJS
cord-005478-5iu38pr6	3368	5	series	series	NN
cord-005478-5iu38pr6	3368	6	analysing	analyse	VBG
cord-005478-5iu38pr6	3368	7	the	the	DT
cord-005478-5iu38pr6	3368	8	efficacy	efficacy	NN
cord-005478-5iu38pr6	3368	9	and	and	CC
cord-005478-5iu38pr6	3368	10	safety	safety	NN
cord-005478-5iu38pr6	3368	11	of	of	IN
cord-005478-5iu38pr6	3368	12	a	a	DT
cord-005478-5iu38pr6	3368	13	tandem	tandem	JJ
cord-005478-5iu38pr6	3368	14	auto	auto	NN
cord-005478-5iu38pr6	3368	15	-	-	HYPH
cord-005478-5iu38pr6	3368	16	RIC	RIC	NNP
cord-005478-5iu38pr6	3368	17	-	-	HYPH
cord-005478-5iu38pr6	3368	18	SCT	SCT	NNP
cord-005478-5iu38pr6	3368	19	approach	approach	NN
cord-005478-5iu38pr6	3368	20	in	in	IN
cord-005478-5iu38pr6	3368	21	R	r	NN
cord-005478-5iu38pr6	3368	22	/	/	SYM
cord-005478-5iu38pr6	3368	23	R	r	NN
cord-005478-5iu38pr6	3368	24	HL	hl	NN
cord-005478-5iu38pr6	3368	25	.	.	.
cord-005478-5iu38pr6	3369	1	The	the	DT
cord-005478-5iu38pr6	3369	2	low	low	JJ
cord-005478-5iu38pr6	3369	3	NRM	NRM	NNP
cord-005478-5iu38pr6	3369	4	and	and	CC
cord-005478-5iu38pr6	3369	5	IR	IR	NNP
cord-005478-5iu38pr6	3369	6	with	with	IN
cord-005478-5iu38pr6	3369	7	promising	promising	JJ
cord-005478-5iu38pr6	3369	8	PFS	PFS	NNP
cord-005478-5iu38pr6	3369	9	and	and	CC
cord-005478-5iu38pr6	3369	10	OS	OS	NNP
cord-005478-5iu38pr6	3369	11	suggest	suggest	VBP
cord-005478-5iu38pr6	3369	12	that	that	IN
cord-005478-5iu38pr6	3369	13	this	this	DT
cord-005478-5iu38pr6	3369	14	might	may	MD
cord-005478-5iu38pr6	3369	15	be	be	VB
cord-005478-5iu38pr6	3369	16	an	an	DT
cord-005478-5iu38pr6	3369	17	effective	effective	JJ
cord-005478-5iu38pr6	3369	18	Post	post	JJ
cord-005478-5iu38pr6	3369	19	-	-	JJ
cord-005478-5iu38pr6	3369	20	transplant	transplant	NN
cord-005478-5iu38pr6	3369	21	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	3369	22	-	-	HYPH
cord-005478-5iu38pr6	3369	23	based	base	VBN
cord-005478-5iu38pr6	3369	24	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3369	25	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3369	26	compared	compare	VBN
cord-005478-5iu38pr6	3369	27	to	to	IN
cord-005478-5iu38pr6	3369	28	standard	standard	JJ
cord-005478-5iu38pr6	3369	29	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3369	30	in	in	IN
cord-005478-5iu38pr6	3369	31	patients	patient	NNS
cord-005478-5iu38pr6	3369	32	with	with	IN
cord-005478-5iu38pr6	3369	33	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3369	34	receiving	receive	VBG
cord-005478-5iu38pr6	3369	35	HLA	HLA	NNP
cord-005478-5iu38pr6	3369	36	identical	identical	JJ
cord-005478-5iu38pr6	3369	37	transplantation	transplantation	NN
cord-005478-5iu38pr6	3369	38	:	:	:
cord-005478-5iu38pr6	3369	39	A	a	DT
cord-005478-5iu38pr6	3369	40	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3369	41	study	study	NN
cord-005478-5iu38pr6	3369	42	from	from	IN
cord-005478-5iu38pr6	3369	43	the	the	DT
cord-005478-5iu38pr6	3369	44	LWP	LWP	NNP
cord-005478-5iu38pr6	3369	45	of	of	IN
cord-005478-5iu38pr6	3369	46	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3370	1	Luca	Luca	NNP
cord-005478-5iu38pr6	3370	2	Castagna	Castagna	NNP
cord-005478-5iu38pr6	3370	3	18	18	CD
cord-005478-5iu38pr6	3370	4	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3371	1	Lymphoma	Lymphoma	NNP
cord-005478-5iu38pr6	3371	2	Worky	Worky	NNP
cord-005478-5iu38pr6	3371	3	Party	Party	NNP
cord-005478-5iu38pr6	3371	4	Clinical	Clinical	NNP
cord-005478-5iu38pr6	3371	5	Trial	Trial	NNP
cord-005478-5iu38pr6	3371	6	Registry	Registry	NNP
cord-005478-5iu38pr6	3371	7	:	:	:
cord-005478-5iu38pr6	3372	1	NCT02445248	NCT02445248	NNP
cord-005478-5iu38pr6	3373	1	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3373	2	:	:	:
cord-005478-5iu38pr6	3373	3	Richard	Richard	NNP
cord-005478-5iu38pr6	3373	4	T.	T.	NNP
cord-005478-5iu38pr6	3373	5	Maziarz	Maziarz	NNP
cord-005478-5iu38pr6	3373	6	:	:	:
cord-005478-5iu38pr6	3373	7	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3373	8	,	,	,
cord-005478-5iu38pr6	3373	9	Membership	Membership	NNP
cord-005478-5iu38pr6	3373	10	of	of	IN
cord-005478-5iu38pr6	3373	11	Advisory	Advisory	NNP
cord-005478-5iu38pr6	3373	12	Committee	Committee	NNP
cord-005478-5iu38pr6	3373	13	and	and	CC
cord-005478-5iu38pr6	3373	14	Research	Research	NNP
cord-005478-5iu38pr6	3373	15	Funding	Funding	NNP
cord-005478-5iu38pr6	3373	16	Employment	Employment	NNP
cord-005478-5iu38pr6	3373	17	:	:	:
cord-005478-5iu38pr6	3373	18	Oregon	Oregon	NNP
cord-005478-5iu38pr6	3373	19	Health	Health	NNP
cord-005478-5iu38pr6	3373	20	&	&	CC
cord-005478-5iu38pr6	3373	21	Science	Science	NNP
cord-005478-5iu38pr6	3373	22	University	University	NNP
cord-005478-5iu38pr6	3373	23	(	(	-LRB-
cord-005478-5iu38pr6	3373	24	OHSU	OHSU	NNP
cord-005478-5iu38pr6	3373	25	)	)	-RRB-
cord-005478-5iu38pr6	3373	26	;	;	:
cord-005478-5iu38pr6	3374	1	The	the	DT
cord-005478-5iu38pr6	3374	2	potential	potential	JJ
cord-005478-5iu38pr6	3374	3	conflict	conflict	NN
cord-005478-5iu38pr6	3374	4	of	of	IN
cord-005478-5iu38pr6	3374	5	interest	interest	NN
cord-005478-5iu38pr6	3374	6	re	re	NN
cord-005478-5iu38pr6	3374	7	:	:	:
cord-005478-5iu38pr6	3374	8	consultant	consultant	NN
cord-005478-5iu38pr6	3374	9	services	service	NNS
cord-005478-5iu38pr6	3374	10	to	to	IN
cord-005478-5iu38pr6	3374	11	and	and	CC
cord-005478-5iu38pr6	3374	12	payment	payment	NN
cord-005478-5iu38pr6	3374	13	from	from	IN
cord-005478-5iu38pr6	3374	14	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3374	15	has	have	VBZ
cord-005478-5iu38pr6	3374	16	been	be	VBN
cord-005478-5iu38pr6	3374	17	reviewed	review	VBN
cord-005478-5iu38pr6	3374	18	and	and	CC
cord-005478-5iu38pr6	3374	19	managed	manage	VBN
cord-005478-5iu38pr6	3374	20	by	by	IN
cord-005478-5iu38pr6	3374	21	Dava	Dava	NNP
cord-005478-5iu38pr6	3374	22	Oncology	Oncology	NNP
cord-005478-5iu38pr6	3374	23	;	;	:
cord-005478-5iu38pr6	3374	24	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3374	25	and	and	CC
cord-005478-5iu38pr6	3374	26	Research	Research	NNP
cord-005478-5iu38pr6	3374	27	Funding	Funding	NNP
cord-005478-5iu38pr6	3374	28	:	:	:
cord-005478-5iu38pr6	3374	29	Genentech	Genentech	NNP
cord-005478-5iu38pr6	3374	30	;	;	:
cord-005478-5iu38pr6	3374	31	Membership	membership	NN
cord-005478-5iu38pr6	3374	32	on	on	IN
cord-005478-5iu38pr6	3374	33	an	an	DT
cord-005478-5iu38pr6	3374	34	entity	entity	NN
cord-005478-5iu38pr6	3374	35	's	's	POS
cord-005478-5iu38pr6	3374	36	Board	Board	NNP
cord-005478-5iu38pr6	3374	37	of	of	IN
cord-005478-5iu38pr6	3374	38	Directors	Directors	NNPS
cord-005478-5iu38pr6	3374	39	or	or	CC
cord-005478-5iu38pr6	3374	40	advisory	advisory	JJ
cord-005478-5iu38pr6	3374	41	committees	committee	NNS
cord-005478-5iu38pr6	3374	42	Membership	Membership	NNP
cord-005478-5iu38pr6	3374	43	on	on	IN
cord-005478-5iu38pr6	3374	44	an	an	DT
cord-005478-5iu38pr6	3374	45	entity	entity	NN
cord-005478-5iu38pr6	3374	46	's	's	POS
cord-005478-5iu38pr6	3374	47	Board	Board	NNP
cord-005478-5iu38pr6	3374	48	of	of	IN
cord-005478-5iu38pr6	3374	49	Directors	Directors	NNPS
cord-005478-5iu38pr6	3374	50	or	or	CC
cord-005478-5iu38pr6	3374	51	advisory	advisory	JJ
cord-005478-5iu38pr6	3374	52	committees	committee	NNS
cord-005478-5iu38pr6	3374	53	and	and	CC
cord-005478-5iu38pr6	3374	54	Research	Research	NNP
cord-005478-5iu38pr6	3374	55	Funding	Funding	NNP
cord-005478-5iu38pr6	3374	56	:	:	:
cord-005478-5iu38pr6	3375	1	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3375	2	Honoraria	Honoraria	NNP
cord-005478-5iu38pr6	3375	3	and	and	CC
cord-005478-5iu38pr6	3375	4	Membership	Membership	NNP
cord-005478-5iu38pr6	3375	5	on	on	IN
cord-005478-5iu38pr6	3375	6	an	an	DT
cord-005478-5iu38pr6	3375	7	entity	entity	NN
cord-005478-5iu38pr6	3375	8	's	's	POS
cord-005478-5iu38pr6	3375	9	Board	Board	NNP
cord-005478-5iu38pr6	3375	10	of	of	IN
cord-005478-5iu38pr6	3375	11	Directors	Directors	NNPS
cord-005478-5iu38pr6	3375	12	or	or	CC
cord-005478-5iu38pr6	3375	13	advisory	advisory	JJ
cord-005478-5iu38pr6	3375	14	committees	committee	NNS
cord-005478-5iu38pr6	3375	15	:	:	:
cord-005478-5iu38pr6	3376	1	Nordic	Nordic	NNP
cord-005478-5iu38pr6	3376	2	Nanovector	Nanovector	NNP
cord-005478-5iu38pr6	3376	3	.	.	.
cord-005478-5iu38pr6	3377	1	Vadim	Vadim	NNP
cord-005478-5iu38pr6	3377	2	V.	V.	NNP
cord-005478-5iu38pr6	3377	3	Romanoff	Romanoff	NNP
cord-005478-5iu38pr6	3377	4	:	:	:
cord-005478-5iu38pr6	3378	1	Employment	employment	NN
cord-005478-5iu38pr6	3378	2	:	:	:
cord-005478-5iu38pr6	3378	3	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3378	4	Employment	Employment	NNP
cord-005478-5iu38pr6	3378	5	:	:	:
cord-005478-5iu38pr6	3378	6	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3378	7	.	.	.
cord-005478-5iu38pr6	3379	1	James	James	NNP
cord-005478-5iu38pr6	3379	2	Signorovitch	Signorovitch	NNP
cord-005478-5iu38pr6	3379	3	:	:	:
cord-005478-5iu38pr6	3379	4	Employment	employment	NN
cord-005478-5iu38pr6	3379	5	:	:	:
cord-005478-5iu38pr6	3379	6	Analysis	Analysis	NNP
cord-005478-5iu38pr6	3379	7	Group	Group	NNP
cord-005478-5iu38pr6	3379	8	,	,	,
cord-005478-5iu38pr6	3379	9	which	which	WDT
cord-005478-5iu38pr6	3379	10	received	receive	VBD
cord-005478-5iu38pr6	3379	11	research	research	NN
cord-005478-5iu38pr6	3379	12	funding	funding	NN
cord-005478-5iu38pr6	3379	13	from	from	IN
cord-005478-5iu38pr6	3379	14	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3379	15	.	.	.
cord-005478-5iu38pr6	3380	1	Solveig	Solveig	NNP
cord-005478-5iu38pr6	3380	2	G.	G.	NNP
cord-005478-5iu38pr6	3380	3	Erickson	Erickson	NNP
cord-005478-5iu38pr6	3380	4	:	:	:
cord-005478-5iu38pr6	3380	5	Employment	employment	NN
cord-005478-5iu38pr6	3380	6	:	:	:
cord-005478-5iu38pr6	3380	7	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3380	8	.	.	.
cord-005478-5iu38pr6	3381	1	David	David	NNP
cord-005478-5iu38pr6	3381	2	G.	G.	NNP
cord-005478-5iu38pr6	3381	3	Maloney	Maloney	NNP
cord-005478-5iu38pr6	3381	4	:	:	:
cord-005478-5iu38pr6	3382	1	Research	research	NN
cord-005478-5iu38pr6	3382	2	Funding	funding	NN
cord-005478-5iu38pr6	3382	3	Other	other	JJ
cord-005478-5iu38pr6	3383	1	:	:	:
cord-005478-5iu38pr6	3383	2	Scientific	Scientific	NNP
cord-005478-5iu38pr6	3383	3	Advisor	Advisor	NNP
cord-005478-5iu38pr6	3383	4	:	:	:
cord-005478-5iu38pr6	3383	5	Kite	Kite	NNP
cord-005478-5iu38pr6	3383	6	Pharma	Pharma	NNP
cord-005478-5iu38pr6	3383	7	,	,	,
cord-005478-5iu38pr6	3384	1	Novartis	Novartis	NNP
cord-005478-5iu38pr6	3384	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	3384	3	:	:	:
cord-005478-5iu38pr6	3384	4	Nothing	nothing	NN
cord-005478-5iu38pr6	3384	5	to	to	TO
cord-005478-5iu38pr6	3384	6	declare	declare	VB
cord-005478-5iu38pr6	3384	7	O155	o155	CD
cord-005478-5iu38pr6	3384	8	Multiple	multiple	JJ
cord-005478-5iu38pr6	3384	9	myeloma	myeloma	NN
cord-005478-5iu38pr6	3384	10	treatment	treatment	NN
cord-005478-5iu38pr6	3384	11	in	in	IN
cord-005478-5iu38pr6	3384	12	real	real	JJ
cord-005478-5iu38pr6	3384	13	-	-	HYPH
cord-005478-5iu38pr6	3384	14	world	world	NN
cord-005478-5iu38pr6	3384	15	clinical	clinical	JJ
cord-005478-5iu38pr6	3384	16	practice	practice	NN
cord-005478-5iu38pr6	3384	17	:	:	:
cord-005478-5iu38pr6	3385	1	A	a	DT
cord-005478-5iu38pr6	3385	2	focus	focus	NN
cord-005478-5iu38pr6	3385	3	on	on	IN
cord-005478-5iu38pr6	3385	4	induction	induction	NN
cord-005478-5iu38pr6	3385	5	regimens	regimen	NNS
cord-005478-5iu38pr6	3385	6	prior	prior	RB
cord-005478-5iu38pr6	3385	7	to	to	IN
cord-005478-5iu38pr6	3385	8	autologous	autologous	JJ
cord-005478-5iu38pr6	3385	9	stem	stem	NN
cord-005478-5iu38pr6	3385	10	cell	cell	NN
cord-005478-5iu38pr6	3385	11	transplantation	transplantation	NN
cord-005478-5iu38pr6	3385	12	from	from	IN
cord-005478-5iu38pr6	3385	13	the	the	DT
cord-005478-5iu38pr6	3385	14	prospective	prospective	JJ
cord-005478-5iu38pr6	3385	15	,	,	,
cord-005478-5iu38pr6	3385	16	multinational	multinational	JJ
cord-005478-5iu38pr6	3385	17	,	,	,
cord-005478-5iu38pr6	3385	18	non	non	JJ
cord-005478-5iu38pr6	3385	19	-	-	JJ
cord-005478-5iu38pr6	3385	20	interventional	interventional	JJ
cord-005478-5iu38pr6	3385	21	emmos	emmos	NNP
cord-005478-5iu38pr6	3385	22	study	study	NN
cord-005478-5iu38pr6	3385	23	CIC	CIC	NNP
cord-005478-5iu38pr6	3385	24	,	,	,
cord-005478-5iu38pr6	3385	25	IBMCC	IBMCC	NNP
cord-005478-5iu38pr6	3385	26	(	(	-LRB-
cord-005478-5iu38pr6	3385	27	USAL	USAL	NNP
cord-005478-5iu38pr6	3385	28	-	-	HYPH
cord-005478-5iu38pr6	3385	29	CSIC	CSIC	NNP
cord-005478-5iu38pr6	3385	30	)	)	-RRB-
cord-005478-5iu38pr6	3386	1	13	13	CD
cord-005478-5iu38pr6	3386	2	State	State	NNP
cord-005478-5iu38pr6	3386	3	Budget	Budget	NNP
cord-005478-5iu38pr6	3386	4	Healthcare	Healthcare	NNP
cord-005478-5iu38pr6	3386	5	Institution	Institution	NNP
cord-005478-5iu38pr6	3386	6	of	of	IN
cord-005478-5iu38pr6	3386	7	Moscow	Moscow	NNP
cord-005478-5iu38pr6	3386	8	.	.	.
cord-005478-5iu38pr6	3387	1	City	City	NNP
cord-005478-5iu38pr6	3387	2	Outpatient	Outpatient	NNP
cord-005478-5iu38pr6	3387	3	Clinic	Clinic	NNP
cord-005478-5iu38pr6	3387	4	68	68	CD
cord-005478-5iu38pr6	3387	5	of	of	IN
cord-005478-5iu38pr6	3387	6	Healthcare	Healthcare	NNP
cord-005478-5iu38pr6	3387	7	Use	Use	NNP
cord-005478-5iu38pr6	3387	8	of	of	IN
cord-005478-5iu38pr6	3387	9	unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	3387	10	HLA	HLA	NNP
cord-005478-5iu38pr6	3387	11	-	-	HYPH
cord-005478-5iu38pr6	3387	12	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3387	13	donor	donor	NN
cord-005478-5iu38pr6	3387	14	transplants	transplant	NNS
cord-005478-5iu38pr6	3387	15	(	(	-LRB-
cord-005478-5iu38pr6	3387	16	haplo	haplo	NNP
cord-005478-5iu38pr6	3387	17	-	-	HYPH
cord-005478-5iu38pr6	3387	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3387	19	)	)	-RRB-
cord-005478-5iu38pr6	3387	20	is	be	VBZ
cord-005478-5iu38pr6	3387	21	constantly	constantly	RB
cord-005478-5iu38pr6	3387	22	increasing	increase	VBG
cord-005478-5iu38pr6	3387	23	in	in	IN
cord-005478-5iu38pr6	3387	24	the	the	DT
cord-005478-5iu38pr6	3387	25	last	last	JJ
cord-005478-5iu38pr6	3387	26	years	year	NNS
cord-005478-5iu38pr6	3387	27	.	.	.
cord-005478-5iu38pr6	3388	1	Few	few	JJ
cord-005478-5iu38pr6	3388	2	cases	case	NNS
cord-005478-5iu38pr6	3388	3	of	of	IN
cord-005478-5iu38pr6	3388	4	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3388	5	-	-	HYPH
cord-005478-5iu38pr6	3388	6	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3388	7	using	use	VBG
cord-005478-5iu38pr6	3388	8	posttransplant	posttransplant	NN
cord-005478-5iu38pr6	3388	9	-	-	,
cord-005478-5iu38pr6	3388	10	cyclophosphamide	cyclophosphamide	JJ
cord-005478-5iu38pr6	3388	11	(	(	-LRB-
cord-005478-5iu38pr6	3388	12	PT	PT	NNP
cord-005478-5iu38pr6	3388	13	-	-	HYPH
cord-005478-5iu38pr6	3388	14	Cy	Cy	NNP
cord-005478-5iu38pr6	3388	15	)	)	-RRB-
cord-005478-5iu38pr6	3388	16	for	for	IN
cord-005478-5iu38pr6	3388	17	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3388	18	patients	patient	NNS
cord-005478-5iu38pr6	3388	19	were	be	VBD
cord-005478-5iu38pr6	3388	20	reported	report	VBN
cord-005478-5iu38pr6	3388	21	by	by	IN
cord-005478-5iu38pr6	3388	22	single	single	JJ
cord-005478-5iu38pr6	3388	23	center	center	NN
cord-005478-5iu38pr6	3388	24	and	and	CC
cord-005478-5iu38pr6	3388	25	registry	registry	NN
cord-005478-5iu38pr6	3388	26	studies	study	NNS
cord-005478-5iu38pr6	3388	27	,	,	,
cord-005478-5iu38pr6	3388	28	with	with	IN
cord-005478-5iu38pr6	3388	29	an	an	DT
cord-005478-5iu38pr6	3388	30	incidence	incidence	NN
cord-005478-5iu38pr6	3388	31	of	of	IN
cord-005478-5iu38pr6	3388	32	grade	grade	NN
cord-005478-5iu38pr6	3388	33	II	II	NNP
cord-005478-5iu38pr6	3388	34	-	-	HYPH
cord-005478-5iu38pr6	3388	35	IV	IV	NNP
cord-005478-5iu38pr6	3388	36	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	3388	37	ranging	range	VBG
cord-005478-5iu38pr6	3388	38	from	from	IN
cord-005478-5iu38pr6	3388	39	30	30	CD
cord-005478-5iu38pr6	3388	40	%	%	NN
cord-005478-5iu38pr6	3388	41	to	to	IN
cord-005478-5iu38pr6	3388	42	40	40	CD
cord-005478-5iu38pr6	3388	43	%	%	NN
cord-005478-5iu38pr6	3388	44	and	and	CC
cord-005478-5iu38pr6	3388	45	cGVHD	cgvhd	NN
cord-005478-5iu38pr6	3388	46	approaching	approach	VBG
cord-005478-5iu38pr6	3388	47	up	up	IN
cord-005478-5iu38pr6	3388	48	to	to	TO
cord-005478-5iu38pr6	3388	49	40	40	CD
cord-005478-5iu38pr6	3388	50	%	%	NN
cord-005478-5iu38pr6	3388	51	,	,	,
cord-005478-5iu38pr6	3388	52	although	although	IN
cord-005478-5iu38pr6	3388	53	with	with	IN
cord-005478-5iu38pr6	3388	54	low	low	JJ
cord-005478-5iu38pr6	3388	55	incidence	incidence	NN
cord-005478-5iu38pr6	3388	56	of	of	IN
cord-005478-5iu38pr6	3388	57	extensive	extensive	JJ
cord-005478-5iu38pr6	3388	58	disease	disease	NN
cord-005478-5iu38pr6	3388	59	.	.	.
cord-005478-5iu38pr6	3389	1	Methods	method	NNS
cord-005478-5iu38pr6	3389	2	:	:	:
cord-005478-5iu38pr6	3389	3	We	-PRON-	PRP
cord-005478-5iu38pr6	3389	4	investigated	investigate	VBD
cord-005478-5iu38pr6	3389	5	the	the	DT
cord-005478-5iu38pr6	3389	6	outcomes	outcome	NNS
cord-005478-5iu38pr6	3389	7	of	of	IN
cord-005478-5iu38pr6	3389	8	children	child	NNS
cord-005478-5iu38pr6	3389	9	(	(	-LRB-
cord-005478-5iu38pr6	3389	10	<	<	XX
cord-005478-5iu38pr6	3389	11	=	=	SYM
cord-005478-5iu38pr6	3389	12	18y	18y	CD
cord-005478-5iu38pr6	3389	13	)	)	-RRB-
cord-005478-5iu38pr6	3390	1	undergoing	undergo	VBG
cord-005478-5iu38pr6	3390	2	haplo	haplo	NNP
cord-005478-5iu38pr6	3390	3	-	-	HYPH
cord-005478-5iu38pr6	3390	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3390	5	using	use	VBG
cord-005478-5iu38pr6	3390	6	PT	PT	NNP
cord-005478-5iu38pr6	3390	7	-	-	HYPH
cord-005478-5iu38pr6	3390	8	CY	CY	NNP
cord-005478-5iu38pr6	3390	9	as	as	IN
cord-005478-5iu38pr6	3390	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3390	11	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3390	12	Disease	Disease	NNP
cord-005478-5iu38pr6	3390	13	status	status	NN
cord-005478-5iu38pr6	3390	14	at	at	IN
cord-005478-5iu38pr6	3390	15	haplo	haplo	NNP
cord-005478-5iu38pr6	3390	16	-	-	HYPH
cord-005478-5iu38pr6	3390	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3390	18	was	be	VBD
cord-005478-5iu38pr6	3390	19	CR1	CR1	NNP
cord-005478-5iu38pr6	3390	20	for	for	IN
cord-005478-5iu38pr6	3390	21	31	31	CD
cord-005478-5iu38pr6	3390	22	%	%	NN
cord-005478-5iu38pr6	3390	23	,	,	,
cord-005478-5iu38pr6	3390	24	CR2	CR2	NNP
cord-005478-5iu38pr6	3390	25	43	43	CD
cord-005478-5iu38pr6	3390	26	%	%	NN
cord-005478-5iu38pr6	3390	27	and	and	CC
cord-005478-5iu38pr6	3390	28	advanced	advanced	JJ
cord-005478-5iu38pr6	3390	29	for	for	IN
cord-005478-5iu38pr6	3390	30	26	26	CD
cord-005478-5iu38pr6	3390	31	%	%	NN
cord-005478-5iu38pr6	3390	32	.	.	.
cord-005478-5iu38pr6	3391	1	Poor	poor	JJ
cord-005478-5iu38pr6	3391	2	-	-	HYPH
cord-005478-5iu38pr6	3391	3	risk	risk	NN
cord-005478-5iu38pr6	3391	4	cytogenetics	cytogenetic	NNS
cord-005478-5iu38pr6	3391	5	was	be	VBD
cord-005478-5iu38pr6	3391	6	reported	report	VBN
cord-005478-5iu38pr6	3391	7	in	in	IN
cord-005478-5iu38pr6	3391	8	36	36	CD
cord-005478-5iu38pr6	3391	9	%	%	NN
cord-005478-5iu38pr6	3391	10	of	of	IN
cord-005478-5iu38pr6	3391	11	AML	AML	NNP
cord-005478-5iu38pr6	3391	12	,	,	,
cord-005478-5iu38pr6	3391	13	and	and	CC
cord-005478-5iu38pr6	3391	14	11	11	CD
cord-005478-5iu38pr6	3391	15	%	%	NN
cord-005478-5iu38pr6	3391	16	had	have	VBD
cord-005478-5iu38pr6	3391	17	Ph+	Ph+	VBN
cord-005478-5iu38pr6	3392	1	ALL	all	DT
cord-005478-5iu38pr6	3393	1	All	all	DT
cord-005478-5iu38pr6	3393	2	patients	patient	NNS
cord-005478-5iu38pr6	3393	3	received	receive	VBD
cord-005478-5iu38pr6	3393	4	PT	PT	NNP
cord-005478-5iu38pr6	3393	5	-	-	HYPH
cord-005478-5iu38pr6	3393	6	Cy	Cy	NNP
cord-005478-5iu38pr6	3393	7	,	,	,
cord-005478-5iu38pr6	3393	8	in	in	IN
cord-005478-5iu38pr6	3393	9	association	association	NN
cord-005478-5iu38pr6	3393	10	with	with	IN
cord-005478-5iu38pr6	3393	11	Tacrolimus	Tacrolimus	NNP
cord-005478-5iu38pr6	3393	12	/	/	SYM
cord-005478-5iu38pr6	3393	13	MMF	MMF	NNP
cord-005478-5iu38pr6	3393	14	in	in	IN
cord-005478-5iu38pr6	3393	15	33	33	CD
cord-005478-5iu38pr6	3393	16	%	%	NN
cord-005478-5iu38pr6	3393	17	or	or	CC
cord-005478-5iu38pr6	3393	18	CSA	CSA	NNP
cord-005478-5iu38pr6	3393	19	/	/	SYM
cord-005478-5iu38pr6	3393	20	MMF	MMF	NNP
cord-005478-5iu38pr6	3393	21	in	in	IN
cord-005478-5iu38pr6	3393	22	28	28	CD
cord-005478-5iu38pr6	3393	23	%	%	NN
cord-005478-5iu38pr6	3393	24	or	or	CC
cord-005478-5iu38pr6	3393	25	Engraftment	Engraftment	NNP
cord-005478-5iu38pr6	3393	26	rate	rate	NN
cord-005478-5iu38pr6	3393	27	was	be	VBD
cord-005478-5iu38pr6	3393	28	89	89	CD
cord-005478-5iu38pr6	3393	29	%	%	NN
cord-005478-5iu38pr6	3393	30	with	with	IN
cord-005478-5iu38pr6	3393	31	22	22	CD
cord-005478-5iu38pr6	3393	32	patients	patient	NNS
cord-005478-5iu38pr6	3393	33	experiencing	experience	VBG
cord-005478-5iu38pr6	3393	34	graft	graft	NN
cord-005478-5iu38pr6	3393	35	failure	failure	NN
cord-005478-5iu38pr6	3393	36	.	.	.
cord-005478-5iu38pr6	3394	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3394	2	incidence	incidence	NN
cord-005478-5iu38pr6	3394	3	(	(	-LRB-
cord-005478-5iu38pr6	3394	4	CI	CI	NNP
cord-005478-5iu38pr6	3394	5	)	)	-RRB-
cord-005478-5iu38pr6	3394	6	of	of	IN
cord-005478-5iu38pr6	3394	7	day-100	day-100	NNP
cord-005478-5iu38pr6	3394	8	acute	acute	JJ
cord-005478-5iu38pr6	3394	9	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3394	10	grade	grade	NN
cord-005478-5iu38pr6	3394	11	II	II	NNP
cord-005478-5iu38pr6	3394	12	-	-	HYPH
cord-005478-5iu38pr6	3394	13	IV	IV	NNP
cord-005478-5iu38pr6	3394	14	and	and	CC
cord-005478-5iu38pr6	3394	15	grade	grade	NN
cord-005478-5iu38pr6	3394	16	III	III	NNP
cord-005478-5iu38pr6	3394	17	-	-	HYPH
cord-005478-5iu38pr6	3394	18	IV	IV	NNP
cord-005478-5iu38pr6	3394	19	were	be	VBD
cord-005478-5iu38pr6	3394	20	33	33	CD
cord-005478-5iu38pr6	3394	21	%	%	NN
cord-005478-5iu38pr6	3394	22	and	and	CC
cord-005478-5iu38pr6	3394	23	14	14	CD
cord-005478-5iu38pr6	3394	24	%	%	NN
cord-005478-5iu38pr6	3394	25	respectively	respectively	RB
cord-005478-5iu38pr6	3394	26	,	,	,
cord-005478-5iu38pr6	3394	27	and	and	CC
cord-005478-5iu38pr6	3394	28	CI	CI	NNP
cord-005478-5iu38pr6	3394	29	of	of	IN
cord-005478-5iu38pr6	3394	30	2-y	2-y	CD
cord-005478-5iu38pr6	3394	31	chronic	chronic	JJ
cord-005478-5iu38pr6	3394	32	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3394	33	was	be	VBD
cord-005478-5iu38pr6	3394	34	20	20	CD
cord-005478-5iu38pr6	3394	35	%	%	NN
cord-005478-5iu38pr6	3394	36	(	(	-LRB-
cord-005478-5iu38pr6	3394	37	9	9	CD
cord-005478-5iu38pr6	3394	38	%	%	NN
cord-005478-5iu38pr6	3394	39	extensive	extensive	JJ
cord-005478-5iu38pr6	3394	40	disease	disease	NN
cord-005478-5iu38pr6	3394	41	)	)	-RRB-
cord-005478-5iu38pr6	3394	42	.	.	.
cord-005478-5iu38pr6	3395	1	2-y	2-y	CD
cord-005478-5iu38pr6	3395	2	CI	CI	NNP
cord-005478-5iu38pr6	3395	3	of	of	IN
cord-005478-5iu38pr6	3395	4	NRM	NRM	NNP
cord-005478-5iu38pr6	3395	5	was	be	VBD
cord-005478-5iu38pr6	3395	6	19	19	CD
cord-005478-5iu38pr6	3395	7	%	%	NN
cord-005478-5iu38pr6	3395	8	and	and	CC
cord-005478-5iu38pr6	3395	9	relapse	relapse	NN
cord-005478-5iu38pr6	3395	10	41	41	CD
cord-005478-5iu38pr6	3395	11	%	%	NN
cord-005478-5iu38pr6	3395	12	.	.	.
cord-005478-5iu38pr6	3396	1	Disease	disease	NN
cord-005478-5iu38pr6	3396	2	recurrence	recurrence	NN
cord-005478-5iu38pr6	3396	3	and	and	CC
cord-005478-5iu38pr6	3396	4	infections	infection	NNS
cord-005478-5iu38pr6	3396	5	were	be	VBD
cord-005478-5iu38pr6	3396	6	the	the	DT
cord-005478-5iu38pr6	3396	7	most	most	RBS
cord-005478-5iu38pr6	3396	8	common	common	JJ
cord-005478-5iu38pr6	3396	9	causes	cause	NNS
cord-005478-5iu38pr6	3396	10	of	of	IN
cord-005478-5iu38pr6	3396	11	death	death	NN
cord-005478-5iu38pr6	3396	12	.	.	.
cord-005478-5iu38pr6	3397	1	2y	2y	NNP
cord-005478-5iu38pr6	3397	2	-	-	HYPH
cord-005478-5iu38pr6	3397	3	OS	OS	NNP
cord-005478-5iu38pr6	3397	4	and	and	CC
cord-005478-5iu38pr6	3397	5	LFS	LFS	NNP
cord-005478-5iu38pr6	3397	6	were	be	VBD
cord-005478-5iu38pr6	3397	7	49	49	CD
cord-005478-5iu38pr6	3397	8	%	%	NN
cord-005478-5iu38pr6	3397	9	and	and	CC
cord-005478-5iu38pr6	3397	10	40	40	CD
cord-005478-5iu38pr6	3397	11	%	%	NN
cord-005478-5iu38pr6	3397	12	.	.	.
cord-005478-5iu38pr6	3398	1	2y	2y	NNP
cord-005478-5iu38pr6	3398	2	-	-	HYPH
cord-005478-5iu38pr6	3398	3	OS	OS	NNP
cord-005478-5iu38pr6	3398	4	was	be	VBD
cord-005478-5iu38pr6	3398	5	53	53	CD
cord-005478-5iu38pr6	3398	6	%	%	NN
cord-005478-5iu38pr6	3398	7	and	and	CC
cord-005478-5iu38pr6	3398	8	47	47	CD
cord-005478-5iu38pr6	3398	9	%	%	NN
cord-005478-5iu38pr6	3398	10	(	(	-LRB-
cord-005478-5iu38pr6	3398	11	p=0.91	p=0.91	NNP
cord-005478-5iu38pr6	3398	12	)	)	-RRB-
cord-005478-5iu38pr6	3398	13	for	for	IN
cord-005478-5iu38pr6	3398	14	AML	AML	NNP
cord-005478-5iu38pr6	3398	15	and	and	CC
cord-005478-5iu38pr6	3398	16	ALL	all	DT
cord-005478-5iu38pr6	3398	17	;	;	:
cord-005478-5iu38pr6	3398	18	it	-PRON-	PRP
cord-005478-5iu38pr6	3398	19	was	be	VBD
cord-005478-5iu38pr6	3398	20	80	80	CD
cord-005478-5iu38pr6	3398	21	%	%	NN
cord-005478-5iu38pr6	3398	22	,	,	,
cord-005478-5iu38pr6	3398	23	47	47	CD
cord-005478-5iu38pr6	3398	24	%	%	NN
cord-005478-5iu38pr6	3398	25	and	and	CC
cord-005478-5iu38pr6	3398	26	22	22	CD
cord-005478-5iu38pr6	3398	27	%	%	NN
cord-005478-5iu38pr6	3398	28	(	(	-LRB-
cord-005478-5iu38pr6	3398	29	p	p	NN
cord-005478-5iu38pr6	3398	30	<	<	XX
cord-005478-5iu38pr6	3398	31	0.001	0.001	CD
cord-005478-5iu38pr6	3398	32	)	)	-RRB-
cord-005478-5iu38pr6	3398	33	for	for	IN
cord-005478-5iu38pr6	3398	34	patients	patient	NNS
cord-005478-5iu38pr6	3398	35	transplanted	transplant	VBN
cord-005478-5iu38pr6	3398	36	in	in	IN
cord-005478-5iu38pr6	3398	37	CR1	CR1	NNP
cord-005478-5iu38pr6	3398	38	,	,	,
cord-005478-5iu38pr6	3398	39	CR2	CR2	NNP
cord-005478-5iu38pr6	3398	40	and	and	CC
cord-005478-5iu38pr6	3398	41	advanced	advanced	JJ
cord-005478-5iu38pr6	3398	42	disease	disease	NN
cord-005478-5iu38pr6	3398	43	.	.	.
cord-005478-5iu38pr6	3399	1	For	for	IN
cord-005478-5iu38pr6	3399	2	2y	2y	CD
cord-005478-5iu38pr6	3399	3	-	-	HYPH
cord-005478-5iu38pr6	3399	4	LFS	LFS	NNP
cord-005478-5iu38pr6	3399	5	,	,	,
cord-005478-5iu38pr6	3399	6	no	no	DT
cord-005478-5iu38pr6	3399	7	significant	significant	JJ
cord-005478-5iu38pr6	3399	8	difference	difference	NN
cord-005478-5iu38pr6	3399	9	was	be	VBD
cord-005478-5iu38pr6	3399	10	found	find	VBN
cord-005478-5iu38pr6	3399	11	according	accord	VBG
cord-005478-5iu38pr6	3399	12	to	to	IN
cord-005478-5iu38pr6	3399	13	the	the	DT
cord-005478-5iu38pr6	3399	14	type	type	NN
cord-005478-5iu38pr6	3399	15	of	of	IN
cord-005478-5iu38pr6	3399	16	conditioning	conditioning	NN
cord-005478-5iu38pr6	3399	17	regimen	regimen	NN
cord-005478-5iu38pr6	3399	18	(	(	-LRB-
cord-005478-5iu38pr6	3399	19	39	39	CD
cord-005478-5iu38pr6	3399	20	%	%	NN
cord-005478-5iu38pr6	3399	21	MACchemotherapy	macchemotherapy	NN
cord-005478-5iu38pr6	3399	22	-	-	HYPH
cord-005478-5iu38pr6	3399	23	based	base	VBN
cord-005478-5iu38pr6	3399	24	,	,	,
cord-005478-5iu38pr6	3399	25	43	43	CD
cord-005478-5iu38pr6	3399	26	%	%	NN
cord-005478-5iu38pr6	3399	27	MAC	MAC	NNP
cord-005478-5iu38pr6	3399	28	-	-	HYPH
cord-005478-5iu38pr6	3399	29	TBI	TBI	NNP
cord-005478-5iu38pr6	3399	30	based	base	VBN
cord-005478-5iu38pr6	3399	31	and	and	CC
cord-005478-5iu38pr6	3399	32	38	38	CD
cord-005478-5iu38pr6	3399	33	%	%	NN
cord-005478-5iu38pr6	3399	34	for	for	IN
cord-005478-5iu38pr6	3399	35	RIC	RIC	NNP
cord-005478-5iu38pr6	3399	36	,	,	,
cord-005478-5iu38pr6	3399	37	p=0.97	p=0.97	NNP
cord-005478-5iu38pr6	3399	38	)	)	-RRB-
cord-005478-5iu38pr6	3399	39	.	.	.
cord-005478-5iu38pr6	3400	1	The	the	DT
cord-005478-5iu38pr6	3400	2	use	use	NN
cord-005478-5iu38pr6	3400	3	of	of	IN
cord-005478-5iu38pr6	3400	4	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3400	5	was	be	VBD
cord-005478-5iu38pr6	3400	6	associated	associate	VBN
cord-005478-5iu38pr6	3400	7	with	with	IN
cord-005478-5iu38pr6	3400	8	higher	high	JJR
cord-005478-5iu38pr6	3400	9	CI	CI	NNP
cord-005478-5iu38pr6	3400	10	of	of	IN
cord-005478-5iu38pr6	3400	11	grade	grade	NN
cord-005478-5iu38pr6	3400	12	OS	OS	NNP
cord-005478-5iu38pr6	3400	13	:	:	:
cord-005478-5iu38pr6	3400	14	CR2	CR2	NNP
cord-005478-5iu38pr6	3400	15	vs	vs	IN
cord-005478-5iu38pr6	3400	16	CR1	CR1	NNP
cord-005478-5iu38pr6	3400	17	Conclusions	Conclusions	NNPS
cord-005478-5iu38pr6	3400	18	:	:	:
cord-005478-5iu38pr6	3400	19	PT	PT	NNP
cord-005478-5iu38pr6	3400	20	-	-	HYPH
cord-005478-5iu38pr6	3400	21	Cy	Cy	NNP
cord-005478-5iu38pr6	3400	22	is	be	VBZ
cord-005478-5iu38pr6	3400	23	effective	effective	JJ
cord-005478-5iu38pr6	3400	24	in	in	IN
cord-005478-5iu38pr6	3400	25	preventing	prevent	VBG
cord-005478-5iu38pr6	3400	26	severe	severe	JJ
cord-005478-5iu38pr6	3400	27	GVHD	gvhd	NN
cord-005478-5iu38pr6	3400	28	in	in	IN
cord-005478-5iu38pr6	3400	29	children	child	NNS
cord-005478-5iu38pr6	3400	30	with	with	IN
cord-005478-5iu38pr6	3400	31	leukemia	leukemia	NN
cord-005478-5iu38pr6	3400	32	receiving	receive	VBG
cord-005478-5iu38pr6	3400	33	an	an	DT
cord-005478-5iu38pr6	3400	34	unmanipulated	unmanipulated	JJ
cord-005478-5iu38pr6	3400	35	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3400	36	-	-	HYPH
cord-005478-5iu38pr6	3400	37	donor	donor	NN
cord-005478-5iu38pr6	3400	38	transplant	transplant	NN
cord-005478-5iu38pr6	3400	39	.	.	.
cord-005478-5iu38pr6	3401	1	Disease	disease	NN
cord-005478-5iu38pr6	3401	2	status	status	NN
cord-005478-5iu38pr6	3401	3	remain	remain	VBP
cord-005478-5iu38pr6	3401	4	the	the	DT
cord-005478-5iu38pr6	3401	5	most	most	RBS
cord-005478-5iu38pr6	3401	6	important	important	JJ
cord-005478-5iu38pr6	3401	7	factor	factor	NN
cord-005478-5iu38pr6	3401	8	for	for	IN
cord-005478-5iu38pr6	3401	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	3401	10	.	.	.
cord-005478-5iu38pr6	3402	1	The	the	DT
cord-005478-5iu38pr6	3402	2	use	use	NN
cord-005478-5iu38pr6	3402	3	of	of	IN
cord-005478-5iu38pr6	3402	4	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3402	5	as	as	IN
cord-005478-5iu38pr6	3402	6	stem	stem	NN
cord-005478-5iu38pr6	3402	7	cell	cell	NN
cord-005478-5iu38pr6	3402	8	source	source	NN
cord-005478-5iu38pr6	3402	9	increases	increase	VBZ
cord-005478-5iu38pr6	3402	10	the	the	DT
cord-005478-5iu38pr6	3402	11	risk	risk	NN
cord-005478-5iu38pr6	3402	12	of	of	IN
cord-005478-5iu38pr6	3402	13	grade	grade	NN
cord-005478-5iu38pr6	3402	14	II	II	NNP
cord-005478-5iu38pr6	3402	15	-	-	HYPH
cord-005478-5iu38pr6	3402	16	IV	IV	NNP
cord-005478-5iu38pr6	3402	17	aGVHD	aGVHD	NNP
cord-005478-5iu38pr6	3402	18	.	.	.
cord-005478-5iu38pr6	3403	1	The	the	DT
cord-005478-5iu38pr6	3403	2	effect	effect	NN
cord-005478-5iu38pr6	3403	3	of	of	IN
cord-005478-5iu38pr6	3403	4	long	long	JJ
cord-005478-5iu38pr6	3403	5	-	-	HYPH
cord-005478-5iu38pr6	3403	6	term	term	NN
cord-005478-5iu38pr6	3403	7	complications	complication	NNS
cord-005478-5iu38pr6	3403	8	,	,	,
cord-005478-5iu38pr6	3403	9	and	and	CC
cord-005478-5iu38pr6	3403	10	morbidity	morbidity	NN
cord-005478-5iu38pr6	3403	11	related	relate	VBN
cord-005478-5iu38pr6	3403	12	to	to	IN
cord-005478-5iu38pr6	3403	13	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3403	14	Results	result	NNS
cord-005478-5iu38pr6	3403	15	:	:	:
cord-005478-5iu38pr6	3403	16	All	all	DT
cord-005478-5iu38pr6	3403	17	patients	patient	NNS
cord-005478-5iu38pr6	3403	18	achieved	achieve	VBD
cord-005478-5iu38pr6	3403	19	primary	primary	JJ
cord-005478-5iu38pr6	3403	20	,	,	,
cord-005478-5iu38pr6	3403	21	sustained	sustained	JJ
cord-005478-5iu38pr6	3403	22	fulldonor	fulldonor	NN
cord-005478-5iu38pr6	3403	23	engraftment	engraftment	NN
cord-005478-5iu38pr6	3403	24	(	(	-LRB-
cord-005478-5iu38pr6	3403	25	median	median	JJ
cord-005478-5iu38pr6	3403	26	neutrophils	neutrophil	NNS
cord-005478-5iu38pr6	3403	27	engraftment	engraftment	NN
cord-005478-5iu38pr6	3403	28	14	14	CD
cord-005478-5iu38pr6	3403	29	days	day	NNS
cord-005478-5iu38pr6	3403	30	,	,	,
cord-005478-5iu38pr6	3403	31	range	range	VBP
cord-005478-5iu38pr6	3403	32	9	9	CD
cord-005478-5iu38pr6	3403	33	-	-	SYM
cord-005478-5iu38pr6	3403	34	19	19	CD
cord-005478-5iu38pr6	3403	35	;	;	:
cord-005478-5iu38pr6	3403	36	median	median	JJ
cord-005478-5iu38pr6	3403	37	platelets	platelet	NNS
cord-005478-5iu38pr6	3403	38	15	15	CD
cord-005478-5iu38pr6	3403	39	days	day	NNS
cord-005478-5iu38pr6	3403	40	,	,	,
cord-005478-5iu38pr6	3403	41	9	9	CD
cord-005478-5iu38pr6	3403	42	-	-	SYM
cord-005478-5iu38pr6	3403	43	19	19	CD
cord-005478-5iu38pr6	3403	44	)	)	-RRB-
cord-005478-5iu38pr6	3403	45	.	.	.
cord-005478-5iu38pr6	3404	1	Five	five	CD
cord-005478-5iu38pr6	3404	2	patients	patient	NNS
cord-005478-5iu38pr6	3404	3	(	(	-LRB-
cord-005478-5iu38pr6	3404	4	42	42	CD
cord-005478-5iu38pr6	3404	5	%	%	NN
cord-005478-5iu38pr6	3404	6	)	)	-RRB-
cord-005478-5iu38pr6	3404	7	developed	develop	VBD
cord-005478-5iu38pr6	3404	8	≥	≥	CD
cord-005478-5iu38pr6	3404	9	grade	grade	NN
cord-005478-5iu38pr6	3404	10	2	2	CD
cord-005478-5iu38pr6	3404	11	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3404	12	(	(	-LRB-
cord-005478-5iu38pr6	3404	13	2/5	2/5	CD
cord-005478-5iu38pr6	3404	14	had	have	VBD
cord-005478-5iu38pr6	3404	15	concomitant	concomitant	JJ
cord-005478-5iu38pr6	3404	16	HCV	HCV	NNP
cord-005478-5iu38pr6	3404	17	hepatitis	hepatitis	NN
cord-005478-5iu38pr6	3404	18	and	and	CC
cord-005478-5iu38pr6	3404	19	developed	develop	VBD
cord-005478-5iu38pr6	3404	20	liver	liver	NN
cord-005478-5iu38pr6	3404	21	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3404	22	)	)	-RRB-
cord-005478-5iu38pr6	3404	23	,	,	,
cord-005478-5iu38pr6	3404	24	none	none	NN
cord-005478-5iu38pr6	3404	25	developed	develop	VBD
cord-005478-5iu38pr6	3404	26	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3404	27	.	.	.
cord-005478-5iu38pr6	3405	1	The	the	DT
cord-005478-5iu38pr6	3405	2	immune	immune	JJ
cord-005478-5iu38pr6	3405	3	recovery	recovery	NN
cord-005478-5iu38pr6	3405	4	was	be	VBD
cord-005478-5iu38pr6	3405	5	good	good	JJ
cord-005478-5iu38pr6	3405	6	in	in	IN
cord-005478-5iu38pr6	3405	7	all	all	DT
cord-005478-5iu38pr6	3405	8	patients	patient	NNS
cord-005478-5iu38pr6	3405	9	despite	despite	IN
cord-005478-5iu38pr6	3405	10	immune	immune	JJ
cord-005478-5iu38pr6	3405	11	suppressive	suppressive	JJ
cord-005478-5iu38pr6	3405	12	therapy	therapy	NN
cord-005478-5iu38pr6	3405	13	in	in	IN
cord-005478-5iu38pr6	3405	14	patients	patient	NNS
cord-005478-5iu38pr6	3405	15	with	with	IN
cord-005478-5iu38pr6	3405	16	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3405	17	Causes	cause	NNS
cord-005478-5iu38pr6	3405	18	of	of	IN
cord-005478-5iu38pr6	3405	19	NRM	NRM	NNP
cord-005478-5iu38pr6	3405	20	were	be	VBD
cord-005478-5iu38pr6	3405	21	:	:	:
cord-005478-5iu38pr6	3405	22	1	1	CD
cord-005478-5iu38pr6	3405	23	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3405	24	,	,	,
cord-005478-5iu38pr6	3405	25	1	1	CD
cord-005478-5iu38pr6	3405	26	invasive	invasive	JJ
cord-005478-5iu38pr6	3405	27	aspergillosis	aspergillosis	NN
cord-005478-5iu38pr6	3405	28	,	,	,
cord-005478-5iu38pr6	3405	29	1	1	CD
cord-005478-5iu38pr6	3405	30	thrombotic	thrombotic	JJ
cord-005478-5iu38pr6	3405	31	microangiopathy	microangiopathy	NN
cord-005478-5iu38pr6	3405	32	.	.	.
cord-005478-5iu38pr6	3406	1	Nine	nine	CD
cord-005478-5iu38pr6	3406	2	of	of	IN
cord-005478-5iu38pr6	3406	3	the	the	DT
cord-005478-5iu38pr6	3406	4	12	12	CD
cord-005478-5iu38pr6	3406	5	patients	patient	NNS
cord-005478-5iu38pr6	3406	6	are	be	VBP
cord-005478-5iu38pr6	3406	7	alive	alive	JJ
cord-005478-5iu38pr6	3406	8	at	at	IN
cord-005478-5iu38pr6	3406	9	a	a	DT
cord-005478-5iu38pr6	3406	10	median	median	JJ
cord-005478-5iu38pr6	3406	11	follow	follow	NN
cord-005478-5iu38pr6	3406	12	-	-	HYPH
cord-005478-5iu38pr6	3406	13	up	up	NN
cord-005478-5iu38pr6	3406	14	of	of	IN
cord-005478-5iu38pr6	3406	15	19	19	CD
cord-005478-5iu38pr6	3406	16	months	month	NNS
cord-005478-5iu38pr6	3406	17	(	(	-LRB-
cord-005478-5iu38pr6	3406	18	2	2	CD
cord-005478-5iu38pr6	3406	19	-	-	SYM
cord-005478-5iu38pr6	3406	20	22	22	CD
cord-005478-5iu38pr6	3406	21	months	month	NNS
cord-005478-5iu38pr6	3406	22	)	)	-RRB-
cord-005478-5iu38pr6	3406	23	,	,	,
cord-005478-5iu38pr6	3406	24	cGvHD/	cGvHD/	NNP
cord-005478-5iu38pr6	3406	25	leukemia	leukemia	NN
cord-005478-5iu38pr6	3406	26	-	-	HYPH
cord-005478-5iu38pr6	3406	27	free	free	JJ
cord-005478-5iu38pr6	3406	28	survival	survival	NN
cord-005478-5iu38pr6	3406	29	is	be	VBZ
cord-005478-5iu38pr6	3406	30	75	75	CD
cord-005478-5iu38pr6	3406	31	%	%	NN
cord-005478-5iu38pr6	3406	32	.	.	.
cord-005478-5iu38pr6	3407	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3407	2	:	:	:
cord-005478-5iu38pr6	3408	1	These	these	DT
cord-005478-5iu38pr6	3408	2	preliminary	preliminary	JJ
cord-005478-5iu38pr6	3408	3	data	datum	NNS
cord-005478-5iu38pr6	3408	4	in	in	IN
cord-005478-5iu38pr6	3408	5	12	12	CD
cord-005478-5iu38pr6	3408	6	very	very	RB
cord-005478-5iu38pr6	3408	7	high	high	JJ
cord-005478-5iu38pr6	3408	8	risk	risk	NN
cord-005478-5iu38pr6	3408	9	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3408	10	patients	patient	NNS
cord-005478-5iu38pr6	3408	11	showed	show	VBD
cord-005478-5iu38pr6	3408	12	that	that	IN
cord-005478-5iu38pr6	3408	13	HLA	HLA	NNP
cord-005478-5iu38pr6	3408	14	-	-	HYPH
cord-005478-5iu38pr6	3408	15	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3408	16	transplantation	transplantation	NN
cord-005478-5iu38pr6	3408	17	with	with	IN
cord-005478-5iu38pr6	3408	18	regulatory	regulatory	JJ
cord-005478-5iu38pr6	3408	19	and	and	CC
cord-005478-5iu38pr6	3408	20	conventional	conventional	JJ
cord-005478-5iu38pr6	3408	21	T	t	NN
cord-005478-5iu38pr6	3408	22	-	-	HYPH
cord-005478-5iu38pr6	3408	23	cell	cell	NN
cord-005478-5iu38pr6	3408	24	adoptive	adoptive	NN
cord-005478-5iu38pr6	3408	25	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3408	26	Russian	Russian	NNP
cord-005478-5iu38pr6	3408	27	Federation	Federation	NNP
cord-005478-5iu38pr6	3408	28	Background	Background	NNP
cord-005478-5iu38pr6	3408	29	:	:	:
cord-005478-5iu38pr6	3408	30	Relapse	Relapse	NNP
cord-005478-5iu38pr6	3408	31	,	,	,
cord-005478-5iu38pr6	3408	32	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3408	33	and	and	CC
cord-005478-5iu38pr6	3408	34	associated	associate	VBN
cord-005478-5iu38pr6	3408	35	non	non	JJ
cord-005478-5iu38pr6	3408	36	-	-	JJ
cord-005478-5iu38pr6	3408	37	relapse	relapse	JJ
cord-005478-5iu38pr6	3408	38	mortality	mortality	NN
cord-005478-5iu38pr6	3408	39	are	be	VBP
cord-005478-5iu38pr6	3408	40	the	the	DT
cord-005478-5iu38pr6	3408	41	main	main	JJ
cord-005478-5iu38pr6	3408	42	obstacles	obstacle	NNS
cord-005478-5iu38pr6	3408	43	to	to	IN
cord-005478-5iu38pr6	3408	44	successful	successful	JJ
cord-005478-5iu38pr6	3408	45	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3408	46	in	in	IN
cord-005478-5iu38pr6	3408	47	children	child	NNS
cord-005478-5iu38pr6	3408	48	with	with	IN
cord-005478-5iu38pr6	3408	49	leukemia	leukemia	NN
cord-005478-5iu38pr6	3408	50	.	.	.
cord-005478-5iu38pr6	3409	1	αβ	αβ	NNP
cord-005478-5iu38pr6	3409	2	T	t	NN
cord-005478-5iu38pr6	3409	3	cell	cell	NN
cord-005478-5iu38pr6	3409	4	depletion	depletion	NN
cord-005478-5iu38pr6	3409	5	was	be	VBD
cord-005478-5iu38pr6	3409	6	developed	develop	VBN
cord-005478-5iu38pr6	3409	7	to	to	TO
cord-005478-5iu38pr6	3409	8	prevent	prevent	VB
cord-005478-5iu38pr6	3409	9	GvHD	gvhd	NN
cord-005478-5iu38pr6	3409	10	and	and	CC
cord-005478-5iu38pr6	3409	11	improve	improve	VB
cord-005478-5iu38pr6	3409	12	immune	immune	JJ
cord-005478-5iu38pr6	3409	13	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3409	14	in	in	IN
cord-005478-5iu38pr6	3409	15	recipients	recipient	NNS
cord-005478-5iu38pr6	3409	16	of	of	IN
cord-005478-5iu38pr6	3409	17	mismatched	mismatched	JJ
cord-005478-5iu38pr6	3409	18	grafts	graft	NNS
cord-005478-5iu38pr6	3410	1	Either	either	CC
cord-005478-5iu38pr6	3410	2	melphalan	melphalan	NNP
cord-005478-5iu38pr6	3410	3	(	(	-LRB-
cord-005478-5iu38pr6	3410	4	n=41	n=41	RB
cord-005478-5iu38pr6	3410	5	)	)	-RRB-
cord-005478-5iu38pr6	3410	6	or	or	CC
cord-005478-5iu38pr6	3410	7	thiophosphamide	thiophosphamide	NNP
cord-005478-5iu38pr6	3410	8	(	(	-LRB-
cord-005478-5iu38pr6	3410	9	n=31	n=31	NNP
cord-005478-5iu38pr6	3410	10	)	)	-RRB-
cord-005478-5iu38pr6	3410	11	or	or	CC
cord-005478-5iu38pr6	3410	12	etoposide	etoposide	JJ
cord-005478-5iu38pr6	3410	13	(	(	-LRB-
cord-005478-5iu38pr6	3410	14	n=16	n=16	NNP
cord-005478-5iu38pr6	3410	15	)	)	-RRB-
cord-005478-5iu38pr6	3410	16	were	be	VBD
cord-005478-5iu38pr6	3410	17	added	add	VBN
cord-005478-5iu38pr6	3410	18	,	,	,
cord-005478-5iu38pr6	3410	19	fludarabine	fludarabine	NN
cord-005478-5iu38pr6	3410	20	was	be	VBD
cord-005478-5iu38pr6	3410	21	used	use	VBN
cord-005478-5iu38pr6	3410	22	in	in	IN
cord-005478-5iu38pr6	3410	23	all	all	DT
cord-005478-5iu38pr6	3410	24	pts	pt	NNS
cord-005478-5iu38pr6	3410	25	.	.	.
cord-005478-5iu38pr6	3411	1	Two	two	CD
cord-005478-5iu38pr6	3411	2	types	type	NNS
cord-005478-5iu38pr6	3411	3	of	of	IN
cord-005478-5iu38pr6	3411	4	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3411	5	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3411	6	were	be	VBD
cord-005478-5iu38pr6	3411	7	used	use	VBN
cord-005478-5iu38pr6	3411	8	:	:	:
cord-005478-5iu38pr6	3411	9	Type	type	NN
cord-005478-5iu38pr6	3411	10	1	1	CD
cord-005478-5iu38pr6	3411	11	(	(	-LRB-
cord-005478-5iu38pr6	3411	12	n=18	n=18	NN
cord-005478-5iu38pr6	3411	13	)	)	-RRB-
cord-005478-5iu38pr6	3411	14	:	:	:
cord-005478-5iu38pr6	3411	15	hATG	hatg	ADD
cord-005478-5iu38pr6	3412	1	50	50	CD
cord-005478-5iu38pr6	3413	1	mg	mg	NNP
cord-005478-5iu38pr6	3413	2	/	/	SYM
cord-005478-5iu38pr6	3413	3	kg	kg	NNP
cord-005478-5iu38pr6	3413	4	and	and	CC
cord-005478-5iu38pr6	3413	5	post	post	JJ
cord-005478-5iu38pr6	3413	6	-	-	JJ
cord-005478-5iu38pr6	3413	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3413	8	tacro	tacro	NNP
cord-005478-5iu38pr6	3413	9	/	/	SYM
cord-005478-5iu38pr6	3413	10	mtx	mtx	NN
cord-005478-5iu38pr6	3413	11	,	,	,
cord-005478-5iu38pr6	3413	12	type	type	NN
cord-005478-5iu38pr6	3413	13	2	2	CD
cord-005478-5iu38pr6	3413	14	(	(	-LRB-
cord-005478-5iu38pr6	3413	15	n=71	n=71	NN
cord-005478-5iu38pr6	3413	16	)	)	-RRB-
cord-005478-5iu38pr6	3414	1	:	:	:
cord-005478-5iu38pr6	3414	2	thymoglobulin(rATG	thymoglobulin(rATG	NNP
cord-005478-5iu38pr6	3414	3	)	)	-RRB-
cord-005478-5iu38pr6	3414	4	5mg	5mg	NN
cord-005478-5iu38pr6	3414	5	/	/	SYM
cord-005478-5iu38pr6	3414	6	kg	kg	NN
cord-005478-5iu38pr6	3415	1	The	the	DT
cord-005478-5iu38pr6	3415	2	median	median	JJ
cord-005478-5iu38pr6	3415	3	dose	dose	NN
cord-005478-5iu38pr6	3415	4	of	of	IN
cord-005478-5iu38pr6	3415	5	CD34	CD34	NNP
cord-005478-5iu38pr6	3416	1	+	+	CC
cord-005478-5iu38pr6	3416	2	cells	cell	NNS
cord-005478-5iu38pr6	3416	3	was	be	VBD
cord-005478-5iu38pr6	3416	4	8	8	CD
cord-005478-5iu38pr6	3416	5	x10	x10	CD
cord-005478-5iu38pr6	3416	6	6	6	CD
cord-005478-5iu38pr6	3417	1	/kg	/kg	NFP
cord-005478-5iu38pr6	3417	2	,	,	,
cord-005478-5iu38pr6	3417	3	aβ	aβ	NNP
cord-005478-5iu38pr6	3417	4	T	t	NN
cord-005478-5iu38pr6	3417	5	cells	cell	NNS
cord-005478-5iu38pr6	3417	6	-16	-16	''
cord-005478-5iu38pr6	3418	1	x10	x10	NN
cord-005478-5iu38pr6	3418	2	3	3	CD
cord-005478-5iu38pr6	3419	1	/kg	/kg	NFP
cord-005478-5iu38pr6	3419	2	.	.	.
cord-005478-5iu38pr6	3420	1	Results	result	NNS
cord-005478-5iu38pr6	3420	2	:	:	:
cord-005478-5iu38pr6	3421	1	Five	five	CD
cord-005478-5iu38pr6	3421	2	patients	patient	NNS
cord-005478-5iu38pr6	3421	3	(	(	-LRB-
cord-005478-5iu38pr6	3421	4	5,6	5,6	CD
cord-005478-5iu38pr6	3421	5	%	%	NN
cord-005478-5iu38pr6	3421	6	)	)	-RRB-
cord-005478-5iu38pr6	3421	7	died	die	VBD
cord-005478-5iu38pr6	3421	8	before	before	IN
cord-005478-5iu38pr6	3421	9	engraftment	engraftment	NN
cord-005478-5iu38pr6	3421	10	due	due	IN
cord-005478-5iu38pr6	3421	11	to	to	IN
cord-005478-5iu38pr6	3421	12	septic	septic	JJ
cord-005478-5iu38pr6	3421	13	event	event	NN
cord-005478-5iu38pr6	3421	14	.	.	.
cord-005478-5iu38pr6	3422	1	Primary	primary	JJ
cord-005478-5iu38pr6	3422	2	engraftment	engraftment	NN
cord-005478-5iu38pr6	3422	3	was	be	VBD
cord-005478-5iu38pr6	3422	4	achieved	achieve	VBN
cord-005478-5iu38pr6	3422	5	in	in	IN
cord-005478-5iu38pr6	3422	6	all	all	DT
cord-005478-5iu38pr6	3422	7	evaluable	evaluable	JJ
cord-005478-5iu38pr6	3422	8	pts	pt	NNS
cord-005478-5iu38pr6	3422	9	(	(	-LRB-
cord-005478-5iu38pr6	3422	10	100	100	CD
cord-005478-5iu38pr6	3422	11	%	%	NN
cord-005478-5iu38pr6	3422	12	)	)	-RRB-
cord-005478-5iu38pr6	3422	13	with	with	IN
cord-005478-5iu38pr6	3422	14	full	full	JJ
cord-005478-5iu38pr6	3422	15	donor	donor	NN
cord-005478-5iu38pr6	3422	16	chimerism	chimerism	NN
cord-005478-5iu38pr6	3422	17	.	.	.
cord-005478-5iu38pr6	3423	1	Among	among	IN
cord-005478-5iu38pr6	3423	2	the	the	DT
cord-005478-5iu38pr6	3423	3	whole	whole	JJ
cord-005478-5iu38pr6	3423	4	cohort	cohort	NN
cord-005478-5iu38pr6	3423	5	the	the	DT
cord-005478-5iu38pr6	3423	6	CI	CI	NNP
cord-005478-5iu38pr6	3423	7	of	of	IN
cord-005478-5iu38pr6	3423	8	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3423	9	grades	grade	NNS
cord-005478-5iu38pr6	3423	10	II	II	NNP
cord-005478-5iu38pr6	3423	11	-IV	-iv	NN
cord-005478-5iu38pr6	3423	12	and	and	CC
cord-005478-5iu38pr6	3423	13	III	III	NNP
cord-005478-5iu38pr6	3423	14	-IV	-IV	NNP
cord-005478-5iu38pr6	3423	15	was	be	VBD
cord-005478-5iu38pr6	3423	16	26	26	CD
cord-005478-5iu38pr6	3423	17	-	-	SYM
cord-005478-5iu38pr6	3423	18	74	74	CD
cord-005478-5iu38pr6	3423	19	)	)	-RRB-
cord-005478-5iu38pr6	3423	20	,	,	,
cord-005478-5iu38pr6	3423	21	p=0,002	p=0,002	NNP
cord-005478-5iu38pr6	3423	22	.	.	.
cord-005478-5iu38pr6	3424	1	rATG	rATG	NNP
cord-005478-5iu38pr6	3424	2	was	be	VBD
cord-005478-5iu38pr6	3424	3	also	also	RB
cord-005478-5iu38pr6	3424	4	effective	effective	JJ
cord-005478-5iu38pr6	3424	5	in	in	IN
cord-005478-5iu38pr6	3424	6	prevention	prevention	NN
cord-005478-5iu38pr6	3424	7	of	of	IN
cord-005478-5iu38pr6	3424	8	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3424	9	:	:	:
cord-005478-5iu38pr6	3424	10	CI	CI	NNP
cord-005478-5iu38pr6	3424	11	at	at	IN
cord-005478-5iu38pr6	3424	12	2	2	CD
cord-005478-5iu38pr6	3424	13	year	year	NN
cord-005478-5iu38pr6	3424	14	after	after	IN
cord-005478-5iu38pr6	3424	15	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3424	16	was	be	VBD
cord-005478-5iu38pr6	3424	17	15	15	CD
cord-005478-5iu38pr6	3424	18	%	%	NN
cord-005478-5iu38pr6	3424	19	vs	vs	IN
cord-005478-5iu38pr6	3424	20	33	33	CD
cord-005478-5iu38pr6	3424	21	%	%	NN
cord-005478-5iu38pr6	3424	22	,	,	,
cord-005478-5iu38pr6	3424	23	p=0,08	p=0,08	XX
cord-005478-5iu38pr6	3424	24	.	.	.
cord-005478-5iu38pr6	3424	25	3-year	3-year	CD
cord-005478-5iu38pr6	3424	26	pTRM	ptrm	NN
cord-005478-5iu38pr6	3424	27	was	be	VBD
cord-005478-5iu38pr6	3424	28	In	in	IN
cord-005478-5iu38pr6	3424	29	the	the	DT
cord-005478-5iu38pr6	3424	30	group	group	NN
cord-005478-5iu38pr6	3424	31	with	with	IN
cord-005478-5iu38pr6	3424	32	available	available	JJ
cord-005478-5iu38pr6	3424	33	immune	immune	JJ
cord-005478-5iu38pr6	3424	34	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3424	35	data	datum	NNS
cord-005478-5iu38pr6	3424	36	(	(	-LRB-
cord-005478-5iu38pr6	3425	1	n=68	n=68	NNP
cord-005478-5iu38pr6	3425	2	)	)	-RRB-
cord-005478-5iu38pr6	3425	3	αβ	αβ	VBZ
cord-005478-5iu38pr6	3425	4	T	t	NN
cord-005478-5iu38pr6	3425	5	cell	cell	NN
cord-005478-5iu38pr6	3425	6	recovery	recovery	NN
cord-005478-5iu38pr6	3425	7	at	at	IN
cord-005478-5iu38pr6	3425	8	day	day	NN
cord-005478-5iu38pr6	3425	9	+30	+30	CD
cord-005478-5iu38pr6	3425	10	was	be	VBD
cord-005478-5iu38pr6	3425	11	associated	associate	VBN
cord-005478-5iu38pr6	3425	12	with	with	IN
cord-005478-5iu38pr6	3425	13	a	a	DT
cord-005478-5iu38pr6	3425	14	trend	trend	NN
cord-005478-5iu38pr6	3425	15	to	to	IN
cord-005478-5iu38pr6	3425	16	decreased	decrease	VBN
cord-005478-5iu38pr6	3425	17	incidence	incidence	NN
cord-005478-5iu38pr6	3425	18	of	of	IN
cord-005478-5iu38pr6	3425	19	relapse	relapse	NN
cord-005478-5iu38pr6	3425	20	,	,	,
cord-005478-5iu38pr6	3425	21	CI	CI	NNP
cord-005478-5iu38pr6	3425	22	of	of	IN
cord-005478-5iu38pr6	3425	23	relapse	relapse	NN
cord-005478-5iu38pr6	3425	24	was	be	VBD
cord-005478-5iu38pr6	3425	25	29	29	CD
cord-005478-5iu38pr6	3425	26	%	%	NN
cord-005478-5iu38pr6	3425	27	(	(	-LRB-
cord-005478-5iu38pr6	3425	28	95	95	CD
cord-005478-5iu38pr6	3425	29	%	%	NN
cord-005478-5iu38pr6	3425	30	CI:15	CI:15	NNP
cord-005478-5iu38pr6	3425	31	-54	-54	NNP
cord-005478-5iu38pr6	3425	32	)	)	-RRB-
cord-005478-5iu38pr6	3425	33	in	in	IN
cord-005478-5iu38pr6	3425	34	those	those	DT
cord-005478-5iu38pr6	3425	35	with	with	IN
cord-005478-5iu38pr6	3425	36	αβ	αβ	XX
cord-005478-5iu38pr6	3425	37	-	-	HYPH
cord-005478-5iu38pr6	3425	38	T	t	NN
cord-005478-5iu38pr6	3425	39	cell	cell	NN
cord-005478-5iu38pr6	3425	40	count	count	NN
cord-005478-5iu38pr6	3425	41	<	<	XX
cord-005478-5iu38pr6	3425	42	median	median	NN
cord-005478-5iu38pr6	3425	43	vs	vs	IN
cord-005478-5iu38pr6	3425	44	15	15	CD
cord-005478-5iu38pr6	3425	45	%	%	NN
cord-005478-5iu38pr6	3425	46	(	(	-LRB-
cord-005478-5iu38pr6	3425	47	95	95	CD
cord-005478-5iu38pr6	3425	48	%	%	NN
cord-005478-5iu38pr6	3425	49	CI	ci	NN
cord-005478-5iu38pr6	3425	50	:	:	:
cord-005478-5iu38pr6	3425	51	6	6	CD
cord-005478-5iu38pr6	3425	52	-	-	SYM
cord-005478-5iu38pr6	3425	53	38	38	CD
cord-005478-5iu38pr6	3425	54	)	)	-RRB-
cord-005478-5iu38pr6	3425	55	in	in	IN
cord-005478-5iu38pr6	3425	56	those	those	DT
cord-005478-5iu38pr6	3425	57	with	with	IN
cord-005478-5iu38pr6	3425	58	αβ	αβ	XX
cord-005478-5iu38pr6	3425	59	-	-	HYPH
cord-005478-5iu38pr6	3425	60	cell	cell	NN
cord-005478-5iu38pr6	3425	61	count	count	NN
cord-005478-5iu38pr6	3425	62	>	>	XX
cord-005478-5iu38pr6	3425	63	median	median	JJ
cord-005478-5iu38pr6	3425	64	Italian	italian	JJ
cord-005478-5iu38pr6	3425	65	Bone	Bone	NNP
cord-005478-5iu38pr6	3425	66	Marrow	Marrow	NNP
cord-005478-5iu38pr6	3425	67	Donor	Donor	NNP
cord-005478-5iu38pr6	3425	68	Registry	Registry	NNP
cord-005478-5iu38pr6	3425	69	Hematopoietic	Hematopoietic	NNP
cord-005478-5iu38pr6	3425	70	stem	stem	NN
cord-005478-5iu38pr6	3425	71	cell	cell	NN
cord-005478-5iu38pr6	3425	72	transplantation	transplantation	NN
cord-005478-5iu38pr6	3425	73	(	(	-LRB-
cord-005478-5iu38pr6	3425	74	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3425	75	)	)	-RRB-
cord-005478-5iu38pr6	3425	76	from	from	IN
cord-005478-5iu38pr6	3425	77	HLA	HLA	NNP
cord-005478-5iu38pr6	3425	78	-	-	HYPH
cord-005478-5iu38pr6	3425	79	A	A	NNP
cord-005478-5iu38pr6	3425	80	,	,	,
cord-005478-5iu38pr6	3425	81	-B	-b	ADD
cord-005478-5iu38pr6	3425	82	,	,	,
cord-005478-5iu38pr6	3425	83	-C	-C	NNS
cord-005478-5iu38pr6	3425	84	and	and	CC
cord-005478-5iu38pr6	3425	85	-DRB1-matched	-drb1-matched	JJ
cord-005478-5iu38pr6	3425	86	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3425	87	donors	donor	NNS
cord-005478-5iu38pr6	3425	88	(	(	-LRB-
cord-005478-5iu38pr6	3425	89	8/8	8/8	CD
cord-005478-5iu38pr6	3425	90	UD	UD	NNP
cord-005478-5iu38pr6	3425	91	)	)	-RRB-
cord-005478-5iu38pr6	3425	92	is	be	VBZ
cord-005478-5iu38pr6	3425	93	performed	perform	VBN
cord-005478-5iu38pr6	3425	94	across	across	IN
cord-005478-5iu38pr6	3425	95	HLA	HLA	NNP
cord-005478-5iu38pr6	3425	96	-	-	HYPH
cord-005478-5iu38pr6	3425	97	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3425	98	barrier	barrier	NN
cord-005478-5iu38pr6	3425	99	in	in	IN
cord-005478-5iu38pr6	3425	100	more	more	JJR
cord-005478-5iu38pr6	3425	101	than	than	IN
cord-005478-5iu38pr6	3425	102	85	85	CD
cord-005478-5iu38pr6	3425	103	%	%	NN
cord-005478-5iu38pr6	3425	104	of	of	IN
cord-005478-5iu38pr6	3425	105	cases	case	NNS
cord-005478-5iu38pr6	3425	106	.	.	.
cord-005478-5iu38pr6	3426	1	Clinically	clinically	RB
cord-005478-5iu38pr6	3426	2	tolerable	tolerable	JJ
cord-005478-5iu38pr6	3426	3	(	(	-LRB-
cord-005478-5iu38pr6	3426	4	permissive	permissive	JJ
cord-005478-5iu38pr6	3426	5	)	)	-RRB-
cord-005478-5iu38pr6	3426	6	mismatches	mismatch	NNS
cord-005478-5iu38pr6	3426	7	(	(	-LRB-
cord-005478-5iu38pr6	3426	8	mm	mm	NNP
cord-005478-5iu38pr6	3426	9	)	)	-RRB-
cord-005478-5iu38pr6	3426	10	at	at	IN
cord-005478-5iu38pr6	3426	11	HLA	HLA	NNP
cord-005478-5iu38pr6	3426	12	-	-	HYPH
cord-005478-5iu38pr6	3426	13	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3426	14	locus	locus	NN
cord-005478-5iu38pr6	3426	15	have	have	VBP
cord-005478-5iu38pr6	3426	16	been	be	VBN
cord-005478-5iu38pr6	3426	17	classified	classify	VBN
cord-005478-5iu38pr6	3426	18	by	by	IN
cord-005478-5iu38pr6	3426	19	different	different	JJ
cord-005478-5iu38pr6	3426	20	immunogenetic	immunogenetic	JJ
cord-005478-5iu38pr6	3426	21	models	model	NNS
cord-005478-5iu38pr6	3426	22	.	.	.
cord-005478-5iu38pr6	3427	1	Here	here	RB
cord-005478-5iu38pr6	3427	2	we	-PRON-	PRP
cord-005478-5iu38pr6	3427	3	compare	compare	VBP
cord-005478-5iu38pr6	3427	4	the	the	DT
cord-005478-5iu38pr6	3427	5	prognostic	prognostic	JJ
cord-005478-5iu38pr6	3427	6	value	value	NN
cord-005478-5iu38pr6	3427	7	of	of	IN
cord-005478-5iu38pr6	3427	8	these	these	DT
cord-005478-5iu38pr6	3427	9	models	model	NNS
cord-005478-5iu38pr6	3427	10	II	II	NNP
cord-005478-5iu38pr6	3427	11	)	)	-RRB-
cord-005478-5iu38pr6	3427	12	a	a	DT
cord-005478-5iu38pr6	3427	13	similar	similar	JJ
cord-005478-5iu38pr6	3427	14	model	model	NN
cord-005478-5iu38pr6	3427	15	subdividing	subdivide	VBG
cord-005478-5iu38pr6	3427	16	alleles	allele	NNS
cord-005478-5iu38pr6	3427	17	in	in	IN
cord-005478-5iu38pr6	3427	18	4	4	CD
cord-005478-5iu38pr6	3427	19	TCE	TCE	NNP
cord-005478-5iu38pr6	3427	20	groups	group	NNS
cord-005478-5iu38pr6	3427	21	(	(	-LRB-
cord-005478-5iu38pr6	3427	22	TCE4	TCE4	NNP
cord-005478-5iu38pr6	3427	23	,	,	,
cord-005478-5iu38pr6	3427	24	Crocchiolo	Crocchiolo	NNP
cord-005478-5iu38pr6	3427	25	III	III	NNP
cord-005478-5iu38pr6	3427	26	)	)	-RRB-
cord-005478-5iu38pr6	3427	27	differences	difference	NNS
cord-005478-5iu38pr6	3427	28	in	in	IN
cord-005478-5iu38pr6	3427	29	"	"	``
cord-005478-5iu38pr6	3427	30	delta	delta	JJ
cord-005478-5iu38pr6	3427	31	functional	functional	JJ
cord-005478-5iu38pr6	3427	32	distance	distance	NN
cord-005478-5iu38pr6	3427	33	"	"	''
cord-005478-5iu38pr6	3427	34	scores	score	NNS
cord-005478-5iu38pr6	3427	35	of	of	IN
cord-005478-5iu38pr6	3427	36	12	12	CD
cord-005478-5iu38pr6	3427	37	polymorphic	polymorphic	JJ
cord-005478-5iu38pr6	3427	38	aminoacids	aminoacid	NNS
cord-005478-5iu38pr6	3427	39	in	in	IN
cord-005478-5iu38pr6	3427	40	HLA	HLA	NNP
cord-005478-5iu38pr6	3427	41	-	-	HYPH
cord-005478-5iu38pr6	3427	42	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3427	43	peptide	peptide	NN
cord-005478-5iu38pr6	3427	44	-	-	HYPH
cord-005478-5iu38pr6	3427	45	binding	bind	VBG
cord-005478-5iu38pr6	3427	46	groove	groove	NN
cord-005478-5iu38pr6	3428	1	(	(	-LRB-
cord-005478-5iu38pr6	3428	2	Crivello	Crivello	NNP
cord-005478-5iu38pr6	3428	3	While	while	IN
cord-005478-5iu38pr6	3428	4	the	the	DT
cord-005478-5iu38pr6	3428	5	first	first	JJ
cord-005478-5iu38pr6	3428	6	three	three	CD
cord-005478-5iu38pr6	3428	7	models	model	NNS
cord-005478-5iu38pr6	3428	8	were	be	VBD
cord-005478-5iu38pr6	3428	9	applicable	applicable	JJ
cord-005478-5iu38pr6	3428	10	to	to	IN
cord-005478-5iu38pr6	3428	11	all	all	DT
cord-005478-5iu38pr6	3428	12	382	382	CD
cord-005478-5iu38pr6	3428	13	HLA	HLA	NNP
cord-005478-5iu38pr6	3428	14	-	-	HYPH
cord-005478-5iu38pr6	3428	15	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3428	16	mm	mm	CD
cord-005478-5iu38pr6	3428	17	patients	patient	NNS
cord-005478-5iu38pr6	3428	18	,	,	,
cord-005478-5iu38pr6	3428	19	the	the	DT
cord-005478-5iu38pr6	3428	20	latter	latter	JJ
cord-005478-5iu38pr6	3428	21	was	be	VBD
cord-005478-5iu38pr6	3428	22	restricted	restrict	VBN
cord-005478-5iu38pr6	3428	23	to	to	IN
cord-005478-5iu38pr6	3428	24	229	229	CD
cord-005478-5iu38pr6	3428	25	of	of	IN
cord-005478-5iu38pr6	3428	26	them	-PRON-	PRP
cord-005478-5iu38pr6	3428	27	.	.	.
cord-005478-5iu38pr6	3429	1	The	the	DT
cord-005478-5iu38pr6	3429	2	TCE4	TCE4	NNP
cord-005478-5iu38pr6	3429	3	model	model	NN
cord-005478-5iu38pr6	3429	4	appeared	appear	VBD
cord-005478-5iu38pr6	3429	5	the	the	DT
cord-005478-5iu38pr6	3429	6	most	most	RBS
cord-005478-5iu38pr6	3429	7	restrictive	restrictive	JJ
cord-005478-5iu38pr6	3429	8	one	one	NN
cord-005478-5iu38pr6	3429	9	,	,	,
cord-005478-5iu38pr6	3429	10	with	with	IN
cord-005478-5iu38pr6	3429	11	only	only	RB
cord-005478-5iu38pr6	3429	12	36	36	CD
cord-005478-5iu38pr6	3429	13	%	%	NN
cord-005478-5iu38pr6	3429	14	of	of	IN
cord-005478-5iu38pr6	3429	15	mm	mm	NNP
cord-005478-5iu38pr6	3429	16	considered	consider	VBN
cord-005478-5iu38pr6	3429	17	to	to	TO
cord-005478-5iu38pr6	3429	18	be	be	VB
cord-005478-5iu38pr6	3429	19	permissive	permissive	JJ
cord-005478-5iu38pr6	3429	20	.	.	.
cord-005478-5iu38pr6	3430	1	Median	median	JJ
cord-005478-5iu38pr6	3430	2	follow	follow	NN
cord-005478-5iu38pr6	3430	3	-	-	HYPH
cord-005478-5iu38pr6	3430	4	up	up	NN
cord-005478-5iu38pr6	3430	5	was	be	VBD
cord-005478-5iu38pr6	3430	6	3.2	3.2	CD
cord-005478-5iu38pr6	3430	7	y.	y.	NN
cord-005478-5iu38pr6	3430	8	Results	result	NNS
cord-005478-5iu38pr6	3430	9	:	:	:
cord-005478-5iu38pr6	3430	10	HLA	HLA	NNP
cord-005478-5iu38pr6	3430	11	-	-	HYPH
cord-005478-5iu38pr6	3430	12	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3430	13	permissive	permissive	NN
cord-005478-5iu38pr6	3431	1	(	(	-LRB-
cord-005478-5iu38pr6	3431	2	P	p	NN
cord-005478-5iu38pr6	3431	3	)	)	-RRB-
cord-005478-5iu38pr6	3431	4	mm	mm	NN
cord-005478-5iu38pr6	3431	5	pairs	pair	NNS
cord-005478-5iu38pr6	3431	6	defined	define	VBN
cord-005478-5iu38pr6	3431	7	by	by	IN
cord-005478-5iu38pr6	3431	8	TCE4	TCE4	NNP
cord-005478-5iu38pr6	3431	9	model	model	NN
cord-005478-5iu38pr6	3431	10	(	(	-LRB-
cord-005478-5iu38pr6	3431	11	N=135	N=135	NNS
cord-005478-5iu38pr6	3431	12	)	)	-RRB-
cord-005478-5iu38pr6	3431	13	had	have	VBD
cord-005478-5iu38pr6	3431	14	superior	superior	JJ
cord-005478-5iu38pr6	3431	15	3-y	3-y	CD
cord-005478-5iu38pr6	3431	16	overall	overall	JJ
cord-005478-5iu38pr6	3431	17	survival	survival	NN
cord-005478-5iu38pr6	3431	18	(	(	-LRB-
cord-005478-5iu38pr6	3431	19	OS	OS	NNP
cord-005478-5iu38pr6	3431	20	)	)	-RRB-
cord-005478-5iu38pr6	3431	21	and	and	CC
cord-005478-5iu38pr6	3431	22	GvHD	gvhd	NN
cord-005478-5iu38pr6	3431	23	-	-	HYPH
cord-005478-5iu38pr6	3431	24	free	free	JJ
cord-005478-5iu38pr6	3431	25	&	&	CC
cord-005478-5iu38pr6	3431	26	Relapse	Relapse	NNP
cord-005478-5iu38pr6	3431	27	-	-	HYPH
cord-005478-5iu38pr6	3431	28	Free	Free	NNP
cord-005478-5iu38pr6	3431	29	Survival	Survival	NNP
cord-005478-5iu38pr6	3431	30	(	(	-LRB-
cord-005478-5iu38pr6	3431	31	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3431	32	)	)	-RRB-
cord-005478-5iu38pr6	3432	1	compared	compare	VBN
cord-005478-5iu38pr6	3432	2	to	to	IN
cord-005478-5iu38pr6	3432	3	non	non	JJ
cord-005478-5iu38pr6	3432	4	-	-	JJ
cord-005478-5iu38pr6	3432	5	permissive	permissive	JJ
cord-005478-5iu38pr6	3432	6	(	(	-LRB-
cord-005478-5iu38pr6	3432	7	NP	NP	NNP
cord-005478-5iu38pr6	3432	8	)	)	-RRB-
cord-005478-5iu38pr6	3432	9	mm	mm	NNP
cord-005478-5iu38pr6	3432	10	(	(	-LRB-
cord-005478-5iu38pr6	3432	11	N=247	n=247	NN
cord-005478-5iu38pr6	3432	12	)	)	-RRB-
cord-005478-5iu38pr6	3432	13	(	(	-LRB-
cord-005478-5iu38pr6	3432	14	60±8	60±8	CD
cord-005478-5iu38pr6	3432	15	%	%	NN
cord-005478-5iu38pr6	3432	16	vs	vs	IN
cord-005478-5iu38pr6	3432	17	49±7	49±7	CD
cord-005478-5iu38pr6	3432	18	%	%	NN
cord-005478-5iu38pr6	3432	19	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3432	20	(	(	-LRB-
cord-005478-5iu38pr6	3432	21	HR	HR	NNP
cord-005478-5iu38pr6	3432	22	1.6	1.6	CD
cord-005478-5iu38pr6	3432	23	,	,	,
cord-005478-5iu38pr6	3432	24	p	p	NN
cord-005478-5iu38pr6	3432	25	.03	.03	CD
cord-005478-5iu38pr6	3432	26	)	)	-RRB-
cord-005478-5iu38pr6	3432	27	and	and	CC
cord-005478-5iu38pr6	3432	28	extensive	extensive	JJ
cord-005478-5iu38pr6	3432	29	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3432	30	(	(	-LRB-
cord-005478-5iu38pr6	3432	31	HR	HR	NNP
cord-005478-5iu38pr6	3432	32	3.6	3.6	CD
cord-005478-5iu38pr6	3432	33	,	,	,
cord-005478-5iu38pr6	3433	1	p	p	LS
cord-005478-5iu38pr6	3433	2	<	<	XX
cord-005478-5iu38pr6	3433	3	.01	.01	NFP
cord-005478-5iu38pr6	3433	4	)	)	-RRB-
cord-005478-5iu38pr6	3433	5	.	.	.
cord-005478-5iu38pr6	3434	1	The	the	DT
cord-005478-5iu38pr6	3434	2	predicted	predict	VBN
cord-005478-5iu38pr6	3434	3	HLA	HLA	NNP
cord-005478-5iu38pr6	3434	4	-	-	HYPH
cord-005478-5iu38pr6	3434	5	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3434	6	mismatched	mismatched	JJ
cord-005478-5iu38pr6	3434	7	allele	allele	NN
cord-005478-5iu38pr6	3434	8	expression	expression	NN
cord-005478-5iu38pr6	3434	9	in	in	IN
cord-005478-5iu38pr6	3434	10	the	the	DT
cord-005478-5iu38pr6	3434	11	recipient	recipient	NN
cord-005478-5iu38pr6	3434	12	was	be	VBD
cord-005478-5iu38pr6	3434	13	associated	associate	VBN
cord-005478-5iu38pr6	3434	14	with	with	IN
cord-005478-5iu38pr6	3434	15	100-d	100-d	CD
cord-005478-5iu38pr6	3434	16	CI	CI	NNP
cord-005478-5iu38pr6	3434	17	of	of	IN
cord-005478-5iu38pr6	3434	18	grade≥2	grade≥2	NNP
cord-005478-5iu38pr6	3434	19	aGvHD	aGvHD	NNP
cord-005478-5iu38pr6	3434	20	:	:	:
cord-005478-5iu38pr6	3434	21	32±10	32±10	NN
cord-005478-5iu38pr6	3434	22	%	%	NN
cord-005478-5iu38pr6	3434	23	in	in	IN
cord-005478-5iu38pr6	3434	24	high	high	JJ
cord-005478-5iu38pr6	3434	25	expression	expression	NN
cord-005478-5iu38pr6	3434	26	(	(	-LRB-
cord-005478-5iu38pr6	3434	27	N=76	N=76	NNP
cord-005478-5iu38pr6	3434	28	)	)	-RRB-
cord-005478-5iu38pr6	3434	29	versus	versus	IN
cord-005478-5iu38pr6	3434	30	16±6	16±6	CD
cord-005478-5iu38pr6	3434	31	%	%	NN
cord-005478-5iu38pr6	3434	32	in	in	IN
cord-005478-5iu38pr6	3434	33	low	low	JJ
cord-005478-5iu38pr6	3434	34	expression	expression	NN
cord-005478-5iu38pr6	3434	35	(	(	-LRB-
cord-005478-5iu38pr6	3434	36	N=153	N=153	NNP
cord-005478-5iu38pr6	3434	37	)	)	-RRB-
cord-005478-5iu38pr6	3434	38	,	,	.
cord-005478-5iu38pr6	3435	1	p	p	LS
cord-005478-5iu38pr6	3435	2	<	<	XX
cord-005478-5iu38pr6	3435	3	.01	.01	NFP
cord-005478-5iu38pr6	3435	4	.	.	.
cord-005478-5iu38pr6	3436	1	This	this	DT
cord-005478-5iu38pr6	3436	2	was	be	VBD
cord-005478-5iu38pr6	3436	3	confirmed	confirm	VBN
cord-005478-5iu38pr6	3436	4	in	in	IN
cord-005478-5iu38pr6	3436	5	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3436	6	analysis	analysis	NN
cord-005478-5iu38pr6	3436	7	for	for	IN
cord-005478-5iu38pr6	3436	8	grade≥2	grade≥2	NNP
cord-005478-5iu38pr6	3436	9	aGvHD	aGvHD	.
cord-005478-5iu38pr6	3436	10	(	(	-LRB-
cord-005478-5iu38pr6	3436	11	HR	HR	NNP
cord-005478-5iu38pr6	3436	12	2.2	2.2	CD
cord-005478-5iu38pr6	3436	13	,	,	,
cord-005478-5iu38pr6	3436	14	p	p	NN
cord-005478-5iu38pr6	3436	15	<	<	XX
cord-005478-5iu38pr6	3436	16	.01	.01	NFP
cord-005478-5iu38pr6	3436	17	)	)	-RRB-
cord-005478-5iu38pr6	3436	18	,	,	,
cord-005478-5iu38pr6	3436	19	however	however	RB
cord-005478-5iu38pr6	3436	20	,	,	,
cord-005478-5iu38pr6	3436	21	without	without	IN
cord-005478-5iu38pr6	3436	22	higher	high	JJR
cord-005478-5iu38pr6	3436	23	hazards	hazard	NNS
cord-005478-5iu38pr6	3436	24	for	for	IN
cord-005478-5iu38pr6	3436	25	TRM	TRM	NNP
cord-005478-5iu38pr6	3436	26	and	and	CC
cord-005478-5iu38pr6	3436	27	overall	overall	JJ
cord-005478-5iu38pr6	3436	28	mortality	mortality	NN
cord-005478-5iu38pr6	3436	29	.	.	.
cord-005478-5iu38pr6	3437	1	The	the	DT
cord-005478-5iu38pr6	3437	2	overlap	overlap	NN
cord-005478-5iu38pr6	3437	3	among	among	IN
cord-005478-5iu38pr6	3437	4	the	the	DT
cord-005478-5iu38pr6	3437	5	four	four	CD
cord-005478-5iu38pr6	3437	6	models	model	NNS
cord-005478-5iu38pr6	3437	7	and	and	CC
cord-005478-5iu38pr6	3437	8	their	-PRON-	PRP$
cord-005478-5iu38pr6	3437	9	adjusted	adjust	VBN
cord-005478-5iu38pr6	3437	10	HR	hr	NN
cord-005478-5iu38pr6	3437	11	for	for	IN
cord-005478-5iu38pr6	3437	12	OS	OS	NNP
cord-005478-5iu38pr6	3437	13	is	be	VBZ
cord-005478-5iu38pr6	3437	14	shown	show	VBN
cord-005478-5iu38pr6	3437	15	in	in	IN
cord-005478-5iu38pr6	3437	16	Figure	figure	NN
cord-005478-5iu38pr6	3437	17	1	1	CD
cord-005478-5iu38pr6	3437	18	.	.	.
cord-005478-5iu38pr6	3438	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3438	2	:	:	:
cord-005478-5iu38pr6	3439	1	functional	functional	JJ
cord-005478-5iu38pr6	3439	2	HLA	HLA	NNP
cord-005478-5iu38pr6	3439	3	-	-	HYPH
cord-005478-5iu38pr6	3439	4	DPB1	DPB1	NNP
cord-005478-5iu38pr6	3439	5	matching	matching	NN
cord-005478-5iu38pr6	3439	6	is	be	VBZ
cord-005478-5iu38pr6	3439	7	of	of	IN
cord-005478-5iu38pr6	3439	8	prognostic	prognostic	JJ
cord-005478-5iu38pr6	3439	9	value	value	NN
cord-005478-5iu38pr6	3439	10	in	in	IN
cord-005478-5iu38pr6	3439	11	8/8	8/8	CD
cord-005478-5iu38pr6	3439	12	UD	UD	NNP
cord-005478-5iu38pr6	3439	13	-	-	HYPH
cord-005478-5iu38pr6	3439	14	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3439	15	outcomes	outcome	NNS
cord-005478-5iu38pr6	3439	16	.	.	.
cord-005478-5iu38pr6	3440	1	In	in	IN
cord-005478-5iu38pr6	3440	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	3440	3	cohort	cohort	NN
cord-005478-5iu38pr6	3440	4	,	,	,
cord-005478-5iu38pr6	3440	5	TCE4	TCE4	NNP
cord-005478-5iu38pr6	3440	6	appears	appear	VBZ
cord-005478-5iu38pr6	3440	7	superior	superior	JJ
cord-005478-5iu38pr6	3440	8	to	to	IN
cord-005478-5iu38pr6	3440	9	other	other	JJ
cord-005478-5iu38pr6	3440	10	models	model	NNS
cord-005478-5iu38pr6	3440	11	in	in	IN
cord-005478-5iu38pr6	3440	12	predicting	predict	VBG
cord-005478-5iu38pr6	3440	13	survival	survival	NN
cord-005478-5iu38pr6	3440	14	and	and	CC
cord-005478-5iu38pr6	3440	15	stratifying	stratify	VBG
cord-005478-5iu38pr6	3440	16	risks	risk	NNS
cord-005478-5iu38pr6	3440	17	of	of	IN
cord-005478-5iu38pr6	3440	18	TRM	TRM	NNP
cord-005478-5iu38pr6	3440	19	and	and	CC
cord-005478-5iu38pr6	3440	20	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3440	21	However	however	RB
cord-005478-5iu38pr6	3440	22	,	,	,
cord-005478-5iu38pr6	3440	23	it	-PRON-	PRP
cord-005478-5iu38pr6	3440	24	remains	remain	VBZ
cord-005478-5iu38pr6	3440	25	unclear	unclear	JJ
cord-005478-5iu38pr6	3440	26	how	how	WRB
cord-005478-5iu38pr6	3440	27	outcomes	outcome	NNS
cord-005478-5iu38pr6	3440	28	of	of	IN
cord-005478-5iu38pr6	3440	29	patients	patient	NNS
cord-005478-5iu38pr6	3440	30	with	with	IN
cord-005478-5iu38pr6	3440	31	ALL	all	DT
cord-005478-5iu38pr6	3440	32	treated	treat	VBN
cord-005478-5iu38pr6	3440	33	with	with	IN
cord-005478-5iu38pr6	3440	34	a	a	DT
cord-005478-5iu38pr6	3440	35	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3440	36	donor	donor	NN
cord-005478-5iu38pr6	3440	37	(	(	-LRB-
cord-005478-5iu38pr6	3440	38	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	3440	39	)	)	-RRB-
cord-005478-5iu38pr6	3440	40	compare	compare	VB
cord-005478-5iu38pr6	3440	41	with	with	IN
cord-005478-5iu38pr6	3440	42	HLA	HLA	NNP
cord-005478-5iu38pr6	3440	43	matched	match	VBN
cord-005478-5iu38pr6	3440	44	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3440	45	donor	donor	NN
cord-005478-5iu38pr6	3440	46	(	(	-LRB-
cord-005478-5iu38pr6	3440	47	MUD	mud	NN
cord-005478-5iu38pr6	3440	48	)	)	-RRB-
cord-005478-5iu38pr6	3440	49	transplants	transplant	NNS
cord-005478-5iu38pr6	3440	50	.	.	.
cord-005478-5iu38pr6	3441	1	Methods	method	NNS
cord-005478-5iu38pr6	3441	2	:	:	:
cord-005478-5iu38pr6	3442	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3442	2	,	,	,
cord-005478-5iu38pr6	3442	3	therefore	therefore	RB
cord-005478-5iu38pr6	3442	4	retrospectively	retrospectively	RB
cord-005478-5iu38pr6	3442	5	compared	compare	VBN
cord-005478-5iu38pr6	3442	6	outcomes	outcome	NNS
cord-005478-5iu38pr6	3442	7	of	of	IN
cord-005478-5iu38pr6	3442	8	506	506	CD
cord-005478-5iu38pr6	3442	9	patients	patient	NNS
cord-005478-5iu38pr6	3442	10	with	with	IN
cord-005478-5iu38pr6	3442	11	ALL	all	DT
cord-005478-5iu38pr6	3442	12	who	who	WP
cord-005478-5iu38pr6	3442	13	underwent	undergo	VBD
cord-005478-5iu38pr6	3442	14	haploHCT	haplohct	FW
cord-005478-5iu38pr6	3442	15	with	with	IN
cord-005478-5iu38pr6	3442	16	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3442	17	,	,	,
cord-005478-5iu38pr6	3442	18	reported	report	VBN
cord-005478-5iu38pr6	3442	19	from	from	IN
cord-005478-5iu38pr6	3442	20	the	the	DT
cord-005478-5iu38pr6	3442	21	participating	participate	VBG
cord-005478-5iu38pr6	3442	22	centers	center	NNS
cord-005478-5iu38pr6	3442	23	(	(	-LRB-
cord-005478-5iu38pr6	3442	24	HIT	HIT	NNP
cord-005478-5iu38pr6	3442	25	-	-	HYPH
cord-005478-5iu38pr6	3442	26	RC	RC	NNP
cord-005478-5iu38pr6	3442	27	and	and	CC
cord-005478-5iu38pr6	3442	28	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3442	29	)	)	-RRB-
cord-005478-5iu38pr6	3442	30	from	from	IN
cord-005478-5iu38pr6	3442	31	01/2005	01/2005	CD
cord-005478-5iu38pr6	3442	32	to	to	IN
cord-005478-5iu38pr6	3442	33	6/2018	6/2018	CD
cord-005478-5iu38pr6	3442	34	,	,	,
cord-005478-5iu38pr6	3442	35	with	with	IN
cord-005478-5iu38pr6	3442	36	a	a	DT
cord-005478-5iu38pr6	3442	37	matched	match	VBN
cord-005478-5iu38pr6	3442	38	cohort	cohort	NN
cord-005478-5iu38pr6	3442	39	of	of	IN
cord-005478-5iu38pr6	3442	40	1012	1012	CD
cord-005478-5iu38pr6	3442	41	patients	patient	NNS
cord-005478-5iu38pr6	3442	42	(	(	-LRB-
cord-005478-5iu38pr6	3442	43	1:2	1:2	CD
cord-005478-5iu38pr6	3442	44	)	)	-RRB-
cord-005478-5iu38pr6	3442	45	who	who	WP
cord-005478-5iu38pr6	3442	46	underwent	undergo	VBD
cord-005478-5iu38pr6	3442	47	MUD	MUD	NNP
cord-005478-5iu38pr6	3442	48	-	-	HYPH
cord-005478-5iu38pr6	3442	49	HCT	HCT	NNP
cord-005478-5iu38pr6	3442	50	and	and	CC
cord-005478-5iu38pr6	3442	51	were	be	VBD
cord-005478-5iu38pr6	3442	52	reported	report	VBN
cord-005478-5iu38pr6	3442	53	to	to	IN
cord-005478-5iu38pr6	3442	54	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3442	55	.	.	.
cord-005478-5iu38pr6	3443	1	Patients	patient	NNS
cord-005478-5iu38pr6	3443	2	were	be	VBD
cord-005478-5iu38pr6	3443	3	matched	match	VBN
cord-005478-5iu38pr6	3443	4	for	for	IN
cord-005478-5iu38pr6	3443	5	sex	sex	NN
cord-005478-5iu38pr6	3443	6	,	,	,
cord-005478-5iu38pr6	3443	7	age	age	NN
cord-005478-5iu38pr6	3443	8	at	at	IN
cord-005478-5iu38pr6	3443	9	transplant	transplant	NN
cord-005478-5iu38pr6	3443	10	(	(	-LRB-
cord-005478-5iu38pr6	3443	11	≤40	≤40	NN
cord-005478-5iu38pr6	3443	12	or	or	CC
cord-005478-5iu38pr6	3443	13	>	>	XX
cord-005478-5iu38pr6	3443	14	40	40	CD
cord-005478-5iu38pr6	3443	15	)	)	-RRB-
cord-005478-5iu38pr6	3443	16	,	,	,
cord-005478-5iu38pr6	3443	17	disease	disease	NN
cord-005478-5iu38pr6	3443	18	type	type	NN
cord-005478-5iu38pr6	3443	19	(	(	-LRB-
cord-005478-5iu38pr6	3443	20	B	b	NN
cord-005478-5iu38pr6	3443	21	-	-	:
cord-005478-5iu38pr6	3443	22	ALL	ALL	NNP
cord-005478-5iu38pr6	3443	23	Vs	Vs	NNP
cord-005478-5iu38pr6	3443	24	.	.	.
cord-005478-5iu38pr6	3444	1	T	T	NNP
cord-005478-5iu38pr6	3444	2	-	-	HYPH
cord-005478-5iu38pr6	3444	3	ALL	ALL	NNP
cord-005478-5iu38pr6	3444	4	)	)	-RRB-
cord-005478-5iu38pr6	3444	5	,	,	,
cord-005478-5iu38pr6	3444	6	disease	disease	NN
cord-005478-5iu38pr6	3444	7	stage	stage	NN
cord-005478-5iu38pr6	3444	8	(	(	-LRB-
cord-005478-5iu38pr6	3444	9	CR1	CR1	NNP
cord-005478-5iu38pr6	3444	10	Vs	Vs	NNP
cord-005478-5iu38pr6	3444	11	.	.	.
cord-005478-5iu38pr6	3445	1	CR2	CR2	NNP
cord-005478-5iu38pr6	3445	2	Vs	Vs	NNP
cord-005478-5iu38pr6	3445	3	.	.	.
cord-005478-5iu38pr6	3446	1	other	other	JJ
cord-005478-5iu38pr6	3446	2	)	)	-RRB-
cord-005478-5iu38pr6	3446	3	,	,	,
cord-005478-5iu38pr6	3446	4	disease	disease	NN
cord-005478-5iu38pr6	3446	5	risk	risk	NN
cord-005478-5iu38pr6	3446	6	(	(	-LRB-
cord-005478-5iu38pr6	3446	7	high	high	JJ
cord-005478-5iu38pr6	3446	8	Vs	Vs	NNP
cord-005478-5iu38pr6	3446	9	.	.	.
cord-005478-5iu38pr6	3447	1	others	other	NNS
cord-005478-5iu38pr6	3447	2	)	)	-RRB-
cord-005478-5iu38pr6	3447	3	,	,	,
cord-005478-5iu38pr6	3447	4	Philadelphia	Philadelphia	NNP
cord-005478-5iu38pr6	3447	5	chromosome	chromosome	NN
cord-005478-5iu38pr6	3447	6	status	status	NN
cord-005478-5iu38pr6	3447	7	(	(	-LRB-
cord-005478-5iu38pr6	3447	8	positive	positive	JJ
cord-005478-5iu38pr6	3447	9	Vs	Vs	NNP
cord-005478-5iu38pr6	3447	10	negative	negative	JJ
cord-005478-5iu38pr6	3447	11	)	)	-RRB-
cord-005478-5iu38pr6	3447	12	,	,	,
cord-005478-5iu38pr6	3447	13	and	and	CC
cord-005478-5iu38pr6	3447	14	conditioning	conditioning	NN
cord-005478-5iu38pr6	3447	15	regimen	regimen	NN
cord-005478-5iu38pr6	3447	16	(	(	-LRB-
cord-005478-5iu38pr6	3447	17	MAC	MAC	NNP
cord-005478-5iu38pr6	3447	18	Vs	Vs	NNP
cord-005478-5iu38pr6	3447	19	.	.	.
cord-005478-5iu38pr6	3448	1	RIC	RIC	NNP
cord-005478-5iu38pr6	3448	2	/	/	SYM
cord-005478-5iu38pr6	3448	3	NMA	NMA	NNP
cord-005478-5iu38pr6	3448	4	)	)	-RRB-
cord-005478-5iu38pr6	3449	1	In	in	IN
cord-005478-5iu38pr6	3449	2	multivariable	multivariable	JJ
cord-005478-5iu38pr6	3449	3	analysis	analysis	NN
cord-005478-5iu38pr6	3449	4	,	,	,
cord-005478-5iu38pr6	3449	5	OS	OS	NNP
cord-005478-5iu38pr6	3449	6	,	,	,
cord-005478-5iu38pr6	3449	7	PFS	PFS	NNP
cord-005478-5iu38pr6	3449	8	,	,	,
cord-005478-5iu38pr6	3449	9	NRM	NRM	NNP
cord-005478-5iu38pr6	3449	10	,	,	,
cord-005478-5iu38pr6	3449	11	and	and	CC
cord-005478-5iu38pr6	3449	12	relapse	relapse	NN
cord-005478-5iu38pr6	3449	13	rate	rate	NN
cord-005478-5iu38pr6	3449	14	were	be	VBD
cord-005478-5iu38pr6	3449	15	not	not	RB
cord-005478-5iu38pr6	3449	16	statistically	statistically	RB
cord-005478-5iu38pr6	3449	17	different	different	JJ
cord-005478-5iu38pr6	3449	18	between	between	IN
cord-005478-5iu38pr6	3449	19	patients	patient	NNS
cord-005478-5iu38pr6	3449	20	receiving	receive	VBG
cord-005478-5iu38pr6	3449	21	HCT	hct	NN
cord-005478-5iu38pr6	3449	22	from	from	IN
cord-005478-5iu38pr6	3449	23	HAPLO	HAPLO	NNP
cord-005478-5iu38pr6	3449	24	or	or	CC
cord-005478-5iu38pr6	3449	25	MUD	mud	NN
cord-005478-5iu38pr6	3449	26	,	,	,
cord-005478-5iu38pr6	3449	27	regardless	regardless	RB
cord-005478-5iu38pr6	3449	28	of	of	IN
cord-005478-5iu38pr6	3449	29	the	the	DT
cord-005478-5iu38pr6	3449	30	intensity	intensity	NN
cord-005478-5iu38pr6	3449	31	of	of	IN
cord-005478-5iu38pr6	3449	32	the	the	DT
cord-005478-5iu38pr6	3449	33	conditioning	conditioning	NN
cord-005478-5iu38pr6	3449	34	regimen	regimen	NN
cord-005478-5iu38pr6	3449	35	;	;	.
cord-005478-5iu38pr6	3450	1	(	(	-LRB-
cord-005478-5iu38pr6	3450	2	Table	table	NN
cord-005478-5iu38pr6	3450	3	1	1	CD
cord-005478-5iu38pr6	3450	4	)	)	-RRB-
cord-005478-5iu38pr6	3450	5	.	.	.
cord-005478-5iu38pr6	3451	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3451	2	:	:	:
cord-005478-5iu38pr6	3452	1	In	in	IN
cord-005478-5iu38pr6	3452	2	conclusion	conclusion	NN
cord-005478-5iu38pr6	3452	3	,	,	,
cord-005478-5iu38pr6	3452	4	in	in	IN
cord-005478-5iu38pr6	3452	5	this	this	DT
cord-005478-5iu38pr6	3452	6	large	large	JJ
cord-005478-5iu38pr6	3452	7	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3452	8	analysis	analysis	NN
cord-005478-5iu38pr6	3452	9	,	,	,
cord-005478-5iu38pr6	3452	10	outcomes	outcome	NNS
cord-005478-5iu38pr6	3452	11	of	of	IN
cord-005478-5iu38pr6	3452	12	patients	patient	NNS
cord-005478-5iu38pr6	3452	13	with	with	IN
cord-005478-5iu38pr6	3452	14	ALL	all	DT
cord-005478-5iu38pr6	3452	15	undergoing	undergo	VBG
cord-005478-5iu38pr6	3452	16	transplant	transplant	NN
cord-005478-5iu38pr6	3452	17	from	from	IN
cord-005478-5iu38pr6	3452	18	a	a	DT
cord-005478-5iu38pr6	3452	19	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3452	20	donor	donor	NN
cord-005478-5iu38pr6	3452	21	with	with	IN
cord-005478-5iu38pr6	3452	22	post	post	JJ
cord-005478-5iu38pr6	3452	23	Median	median	JJ
cord-005478-5iu38pr6	3452	24	follow	follow	NN
cord-005478-5iu38pr6	3452	25	-	-	HYPH
cord-005478-5iu38pr6	3452	26	up	up	NN
cord-005478-5iu38pr6	3452	27	was	be	VBD
cord-005478-5iu38pr6	3452	28	14,6	14,6	CD
cord-005478-5iu38pr6	3452	29	months	month	NNS
cord-005478-5iu38pr6	3452	30	and	and	CC
cord-005478-5iu38pr6	3452	31	was	be	VBD
cord-005478-5iu38pr6	3452	32	similar	similar	JJ
cord-005478-5iu38pr6	3452	33	in	in	IN
cord-005478-5iu38pr6	3452	34	both	both	DT
cord-005478-5iu38pr6	3452	35	cohorts	cohort	NNS
cord-005478-5iu38pr6	3452	36	(	(	-LRB-
cord-005478-5iu38pr6	3452	37	p=0.78	p=0.78	NNP
cord-005478-5iu38pr6	3452	38	)	)	-RRB-
cord-005478-5iu38pr6	3452	39	.	.	.
cord-005478-5iu38pr6	3453	1	2-year	2-year	CD
cord-005478-5iu38pr6	3453	2	overall	overall	JJ
cord-005478-5iu38pr6	3453	3	survival	survival	NN
cord-005478-5iu38pr6	3453	4	(	(	-LRB-
cord-005478-5iu38pr6	3453	5	OS	OS	NNP
cord-005478-5iu38pr6	3453	6	)	)	-RRB-
cord-005478-5iu38pr6	3453	7	was	be	VBD
cord-005478-5iu38pr6	3453	8	41.5	41.5	CD
cord-005478-5iu38pr6	3453	9	%	%	NN
cord-005478-5iu38pr6	3453	10	for	for	IN
cord-005478-5iu38pr6	3453	11	the	the	DT
cord-005478-5iu38pr6	3453	12	all	all	DT
cord-005478-5iu38pr6	3453	13	patients	patient	NNS
cord-005478-5iu38pr6	3453	14	and	and	CC
cord-005478-5iu38pr6	3453	15	did	do	VBD
cord-005478-5iu38pr6	3453	16	not	not	RB
cord-005478-5iu38pr6	3453	17	differ	differ	VB
cord-005478-5iu38pr6	3453	18	between	between	IN
cord-005478-5iu38pr6	3453	19	transplants	transplant	NNS
cord-005478-5iu38pr6	3453	20	from	from	IN
cord-005478-5iu38pr6	3453	21	a	a	DT
cord-005478-5iu38pr6	3453	22	IRD	IRD	NNP
cord-005478-5iu38pr6	3453	23	or	or	CC
cord-005478-5iu38pr6	3453	24	a	a	DT
cord-005478-5iu38pr6	3453	25	CRD	crd	NN
cord-005478-5iu38pr6	3453	26	(	(	-LRB-
cord-005478-5iu38pr6	3453	27	36	36	CD
cord-005478-5iu38pr6	3453	28	%	%	NN
cord-005478-5iu38pr6	3453	29	vs	vs	IN
cord-005478-5iu38pr6	3453	30	47	47	CD
cord-005478-5iu38pr6	3453	31	%	%	NN
cord-005478-5iu38pr6	3453	32	,	,	,
cord-005478-5iu38pr6	3453	33	p=0.33	p=0.33	NNP
cord-005478-5iu38pr6	3453	34	;	;	:
cord-005478-5iu38pr6	3453	35	Table	table	NN
cord-005478-5iu38pr6	3453	36	I	i	CD
cord-005478-5iu38pr6	3453	37	)	)	-RRB-
cord-005478-5iu38pr6	3453	38	.	.	.
cord-005478-5iu38pr6	3454	1	2-year	2-year	JJ
cord-005478-5iu38pr6	3454	2	progression	progression	NN
cord-005478-5iu38pr6	3454	3	-	-	HYPH
cord-005478-5iu38pr6	3454	4	free	free	JJ
cord-005478-5iu38pr6	3454	5	survival	survival	NN
cord-005478-5iu38pr6	3454	6	(	(	-LRB-
cord-005478-5iu38pr6	3454	7	PFS	PFS	NNP
cord-005478-5iu38pr6	3454	8	)	)	-RRB-
cord-005478-5iu38pr6	3454	9	and	and	CC
cord-005478-5iu38pr6	3454	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3454	11	/	/	SYM
cord-005478-5iu38pr6	3454	12	relapse	relapse	NN
cord-005478-5iu38pr6	3454	13	-	-	HYPH
cord-005478-5iu38pr6	3454	14	free	free	JJ
cord-005478-5iu38pr6	3454	15	survival	survival	NN
cord-005478-5iu38pr6	3454	16	(	(	-LRB-
cord-005478-5iu38pr6	3454	17	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3454	18	)	)	-RRB-
cord-005478-5iu38pr6	3454	19	was	be	VBD
cord-005478-5iu38pr6	3454	20	39	39	CD
cord-005478-5iu38pr6	3454	21	%	%	NN
cord-005478-5iu38pr6	3454	22	and	and	CC
cord-005478-5iu38pr6	3454	23	37	37	CD
cord-005478-5iu38pr6	3454	24	%	%	NN
cord-005478-5iu38pr6	3454	25	,	,	,
cord-005478-5iu38pr6	3454	26	respectively	respectively	RB
cord-005478-5iu38pr6	3454	27	.	.	.
cord-005478-5iu38pr6	3455	1	1-year	1-year	CD
cord-005478-5iu38pr6	3455	2	non	non	JJ
cord-005478-5iu38pr6	3455	3	-	-	JJ
cord-005478-5iu38pr6	3455	4	relapse	relapse	JJ
cord-005478-5iu38pr6	3455	5	mortality	mortality	NN
cord-005478-5iu38pr6	3455	6	(	(	-LRB-
cord-005478-5iu38pr6	3455	7	NRM	NRM	NNP
cord-005478-5iu38pr6	3455	8	)	)	-RRB-
cord-005478-5iu38pr6	3455	9	was	be	VBD
cord-005478-5iu38pr6	3455	10	22	22	CD
cord-005478-5iu38pr6	3455	11	%	%	NN
cord-005478-5iu38pr6	3455	12	and	and	CC
cord-005478-5iu38pr6	3455	13	was	be	VBD
cord-005478-5iu38pr6	3455	14	similar	similar	JJ
cord-005478-5iu38pr6	3455	15	between	between	IN
cord-005478-5iu38pr6	3455	16	IRD	IRD	NNP
cord-005478-5iu38pr6	3455	17	and	and	CC
cord-005478-5iu38pr6	3455	18	CRD	CRD	NNP
cord-005478-5iu38pr6	3455	19	(	(	-LRB-
cord-005478-5iu38pr6	3455	20	p=0.62	p=0.62	NNP
cord-005478-5iu38pr6	3455	21	,	,	,
cord-005478-5iu38pr6	3455	22	Table	Table	NNP
cord-005478-5iu38pr6	3455	23	I	i	CD
cord-005478-5iu38pr6	3455	24	)	)	-RRB-
cord-005478-5iu38pr6	3455	25	.	.	.
cord-005478-5iu38pr6	3456	1	6-months	6-months	CD
cord-005478-5iu38pr6	3456	2	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3456	3	incidence	incidence	NN
cord-005478-5iu38pr6	3456	4	of	of	IN
cord-005478-5iu38pr6	3456	5	grade	grade	NN
cord-005478-5iu38pr6	3456	6	2	2	CD
cord-005478-5iu38pr6	3456	7	-	-	SYM
cord-005478-5iu38pr6	3456	8	4	4	CD
cord-005478-5iu38pr6	3456	9	acute	acute	JJ
cord-005478-5iu38pr6	3456	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3456	11	,	,	,
cord-005478-5iu38pr6	3456	12	grade	grade	NN
cord-005478-5iu38pr6	3456	13	3	3	CD
cord-005478-5iu38pr6	3456	14	-	-	SYM
cord-005478-5iu38pr6	3456	15	4	4	CD
cord-005478-5iu38pr6	3456	16	acute	acute	JJ
cord-005478-5iu38pr6	3456	17	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3456	18	and	and	CC
cord-005478-5iu38pr6	3456	19	1-year	1-year	CD
cord-005478-5iu38pr6	3456	20	moderate	moderate	JJ
cord-005478-5iu38pr6	3456	21	-	-	HYPH
cord-005478-5iu38pr6	3456	22	severe	severe	JJ
cord-005478-5iu38pr6	3456	23	chronic	chronic	JJ
cord-005478-5iu38pr6	3456	24	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3456	25	was	be	VBD
cord-005478-5iu38pr6	3456	26	23	23	CD
cord-005478-5iu38pr6	3456	27	%	%	NN
cord-005478-5iu38pr6	3456	28	,	,	,
cord-005478-5iu38pr6	3456	29	8	8	CD
cord-005478-5iu38pr6	3456	30	%	%	NN
cord-005478-5iu38pr6	3456	31	and	and	CC
cord-005478-5iu38pr6	3456	32	19	19	CD
cord-005478-5iu38pr6	3456	33	%	%	NN
cord-005478-5iu38pr6	3456	34	,	,	,
cord-005478-5iu38pr6	3456	35	respectively	respectively	RB
cord-005478-5iu38pr6	3456	36	.	.	.
cord-005478-5iu38pr6	3457	1	Again	again	RB
cord-005478-5iu38pr6	3457	2	,	,	,
cord-005478-5iu38pr6	3457	3	there	there	EX
cord-005478-5iu38pr6	3457	4	was	be	VBD
cord-005478-5iu38pr6	3457	5	no	no	DT
cord-005478-5iu38pr6	3457	6	difference	difference	NN
cord-005478-5iu38pr6	3457	7	between	between	IN
cord-005478-5iu38pr6	3457	8	CRD	crd	NN
cord-005478-5iu38pr6	3457	9	and	and	CC
cord-005478-5iu38pr6	3457	10	IRD	IRD	NNP
cord-005478-5iu38pr6	3457	11	transplants	transplant	NNS
cord-005478-5iu38pr6	3457	12	in	in	IN
cord-005478-5iu38pr6	3457	13	terms	term	NNS
cord-005478-5iu38pr6	3457	14	of	of	IN
cord-005478-5iu38pr6	3457	15	grade	grade	NN
cord-005478-5iu38pr6	3457	16	2	2	CD
cord-005478-5iu38pr6	3457	17	-	-	SYM
cord-005478-5iu38pr6	3457	18	4	4	CD
cord-005478-5iu38pr6	3457	19	acute	acute	JJ
cord-005478-5iu38pr6	3457	20	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3457	21	and	and	CC
cord-005478-5iu38pr6	3457	22	moderate	moderate	JJ
cord-005478-5iu38pr6	3457	23	-	-	HYPH
cord-005478-5iu38pr6	3457	24	severe	severe	JJ
cord-005478-5iu38pr6	3457	25	chronic	chronic	JJ
cord-005478-5iu38pr6	3457	26	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3458	1	(	(	-LRB-
cord-005478-5iu38pr6	3458	2	Table	table	NN
cord-005478-5iu38pr6	3458	3	I	i	CD
cord-005478-5iu38pr6	3458	4	)	)	-RRB-
cord-005478-5iu38pr6	3458	5	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3458	6	:	:	:
cord-005478-5iu38pr6	3459	1	Our	-PRON-	PRP$
cord-005478-5iu38pr6	3459	2	results	result	NNS
cord-005478-5iu38pr6	3459	3	confirm	confirm	VBP
cord-005478-5iu38pr6	3459	4	previous	previous	JJ
cord-005478-5iu38pr6	3459	5	findings	finding	NNS
cord-005478-5iu38pr6	3459	6	that	that	IN
cord-005478-5iu38pr6	3459	7	a	a	DT
cord-005478-5iu38pr6	3459	8	CRD	CRD	NNP
cord-005478-5iu38pr6	3459	9	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3459	10	transplant	transplant	NN
cord-005478-5iu38pr6	3459	11	is	be	VBZ
cord-005478-5iu38pr6	3459	12	a	a	DT
cord-005478-5iu38pr6	3459	13	viable	viable	JJ
cord-005478-5iu38pr6	3459	14	option	option	NN
cord-005478-5iu38pr6	3459	15	for	for	IN
cord-005478-5iu38pr6	3459	16	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3459	17	-	-	HYPH
cord-005478-5iu38pr6	3459	18	SCT	SCT	NNP
cord-005478-5iu38pr6	3459	19	when	when	WRB
cord-005478-5iu38pr6	3459	20	a	a	DT
cord-005478-5iu38pr6	3459	21	first	first	JJ
cord-005478-5iu38pr6	3459	22	-	-	HYPH
cord-005478-5iu38pr6	3459	23	degree	degree	NN
cord-005478-5iu38pr6	3459	24	donor	donor	NN
cord-005478-5iu38pr6	3459	25	is	be	VBZ
cord-005478-5iu38pr6	3459	26	available	available	JJ
cord-005478-5iu38pr6	3459	27	.	.	.
cord-005478-5iu38pr6	3460	1	Main	main	JJ
cord-005478-5iu38pr6	3460	2	long	long	JJ
cord-005478-5iu38pr6	3460	3	-	-	HYPH
cord-005478-5iu38pr6	3460	4	term	term	NN
cord-005478-5iu38pr6	3460	5	outcome	outcome	NN
cord-005478-5iu38pr6	3460	6	are	be	VBP
cord-005478-5iu38pr6	3460	7	not	not	RB
cord-005478-5iu38pr6	3460	8	different	different	JJ
cord-005478-5iu38pr6	3460	9	in	in	IN
cord-005478-5iu38pr6	3460	10	this	this	DT
cord-005478-5iu38pr6	3460	11	matched	match	VBN
cord-005478-5iu38pr6	3460	12	pair	pair	NN
cord-005478-5iu38pr6	3460	13	analysis	analysis	NN
cord-005478-5iu38pr6	3460	14	.	.	.
cord-005478-5iu38pr6	3461	1	Extending	extend	VBG
cord-005478-5iu38pr6	3461	2	our	-PRON-	PRP$
cord-005478-5iu38pr6	3461	3	analysis	analysis	NN
cord-005478-5iu38pr6	3461	4	to	to	IN
cord-005478-5iu38pr6	3461	5	a	a	DT
cord-005478-5iu38pr6	3461	6	larger	large	JJR
cord-005478-5iu38pr6	3461	7	cohort	cohort	NN
cord-005478-5iu38pr6	3461	8	of	of	IN
cord-005478-5iu38pr6	3461	9	patients	patient	NNS
cord-005478-5iu38pr6	3461	10	receiving	receive	VBG
cord-005478-5iu38pr6	3461	11	a	a	DT
cord-005478-5iu38pr6	3461	12	CRD	crd	NN
cord-005478-5iu38pr6	3461	13	is	be	VBZ
cord-005478-5iu38pr6	3461	14	warranted	warrant	VBN
cord-005478-5iu38pr6	3461	15	to	to	TO
cord-005478-5iu38pr6	3461	16	confirm	confirm	VB
cord-005478-5iu38pr6	3461	17	our	-PRON-	PRP$
cord-005478-5iu38pr6	3461	18	preliminary	preliminary	JJ
cord-005478-5iu38pr6	3461	19	results	result	NNS
cord-005478-5iu38pr6	3461	20	.	.	.
cord-005478-5iu38pr6	3462	1	References	reference	NNS
cord-005478-5iu38pr6	3462	2	:	:	:
cord-005478-5iu38pr6	3462	3	1	1	CD
cord-005478-5iu38pr6	3462	4	Disclosure	disclosure	NN
cord-005478-5iu38pr6	3462	5	:	:	:
cord-005478-5iu38pr6	3463	1	The	the	DT
cord-005478-5iu38pr6	3463	2	authors	author	NNS
cord-005478-5iu38pr6	3463	3	have	have	VBP
cord-005478-5iu38pr6	3463	4	no	no	DT
cord-005478-5iu38pr6	3463	5	conflict	conflict	NN
cord-005478-5iu38pr6	3463	6	of	of	IN
cord-005478-5iu38pr6	3463	7	interest	interest	NN
cord-005478-5iu38pr6	3463	8	to	to	TO
cord-005478-5iu38pr6	3463	9	disclose	disclose	VB
cord-005478-5iu38pr6	3463	10	Stem	Stem	NNP
cord-005478-5iu38pr6	3463	11	cell	cell	NN
cord-005478-5iu38pr6	3463	12	mobilization	mobilization	NN
cord-005478-5iu38pr6	3463	13	,	,	,
cord-005478-5iu38pr6	3463	14	collection	collection	NN
cord-005478-5iu38pr6	3463	15	and	and	CC
cord-005478-5iu38pr6	3463	16	engineering	engineering	NN
cord-005478-5iu38pr6	3463	17	O173	o173	XX
cord-005478-5iu38pr6	3463	18	a	a	DT
cord-005478-5iu38pr6	3463	19	recombinant	recombinant	JJ
cord-005478-5iu38pr6	3463	20	chimeric	chimeric	JJ
cord-005478-5iu38pr6	3463	21	protein	protein	NN
cord-005478-5iu38pr6	3463	22	,	,	,
cord-005478-5iu38pr6	3463	23	safely	safely	RB
cord-005478-5iu38pr6	3463	24	enhances	enhance	VBZ
cord-005478-5iu38pr6	3463	25	graft	graft	NN
cord-005478-5iu38pr6	3463	26	performance	performance	NN
cord-005478-5iu38pr6	3463	27	following	follow	VBG
cord-005478-5iu38pr6	3463	28	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3463	29	stem	stem	NN
cord-005478-5iu38pr6	3463	30	cell	cell	NN
cord-005478-5iu38pr6	3463	31	transplantation	transplantation	NN
cord-005478-5iu38pr6	3463	32	Median	median	JJ
cord-005478-5iu38pr6	3463	33	follow	follow	NN
cord-005478-5iu38pr6	3463	34	-	-	HYPH
cord-005478-5iu38pr6	3463	35	up	up	NN
cord-005478-5iu38pr6	3463	36	time	time	NN
cord-005478-5iu38pr6	3463	37	for	for	IN
cord-005478-5iu38pr6	3463	38	survivors	survivor	NNS
cord-005478-5iu38pr6	3463	39	was	be	VBD
cord-005478-5iu38pr6	3463	40	27	27	CD
cord-005478-5iu38pr6	3463	41	months	month	NNS
cord-005478-5iu38pr6	3463	42	.	.	.
cord-005478-5iu38pr6	3464	1	Results	result	NNS
cord-005478-5iu38pr6	3464	2	:	:	:
cord-005478-5iu38pr6	3465	1	Overall	overall	JJ
cord-005478-5iu38pr6	3465	2	survival	survival	NN
cord-005478-5iu38pr6	3465	3	(	(	-LRB-
cord-005478-5iu38pr6	3465	4	OS	OS	NNP
cord-005478-5iu38pr6	3465	5	)	)	-RRB-
cord-005478-5iu38pr6	3465	6	and	and	CC
cord-005478-5iu38pr6	3465	7	relapse	relapse	NN
cord-005478-5iu38pr6	3465	8	-	-	HYPH
cord-005478-5iu38pr6	3465	9	free	free	JJ
cord-005478-5iu38pr6	3465	10	survival	survival	NN
cord-005478-5iu38pr6	3465	11	(	(	-LRB-
cord-005478-5iu38pr6	3465	12	RFS	RFS	NNP
cord-005478-5iu38pr6	3465	13	)	)	-RRB-
cord-005478-5iu38pr6	3465	14	rates	rate	NNS
cord-005478-5iu38pr6	3465	15	at	at	IN
cord-005478-5iu38pr6	3465	16	2	2	CD
cord-005478-5iu38pr6	3465	17	years	year	NNS
cord-005478-5iu38pr6	3465	18	after	after	IN
cord-005478-5iu38pr6	3465	19	transplantation	transplantation	NN
cord-005478-5iu38pr6	3465	20	were	be	VBD
cord-005478-5iu38pr6	3465	21	49	49	CD
cord-005478-5iu38pr6	3465	22	%	%	NN
cord-005478-5iu38pr6	3465	23	37	37	CD
cord-005478-5iu38pr6	3465	24	%	%	NN
cord-005478-5iu38pr6	3465	25	,	,	,
cord-005478-5iu38pr6	3465	26	respectively	respectively	RB
cord-005478-5iu38pr6	3465	27	.	.	.
cord-005478-5iu38pr6	3466	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3466	2	incidences	incidence	NNS
cord-005478-5iu38pr6	3466	3	of	of	IN
cord-005478-5iu38pr6	3466	4	non	non	JJ
cord-005478-5iu38pr6	3466	5	-	-	JJ
cord-005478-5iu38pr6	3466	6	relapse	relapse	JJ
cord-005478-5iu38pr6	3466	7	mortality	mortality	NN
cord-005478-5iu38pr6	3466	8	(	(	-LRB-
cord-005478-5iu38pr6	3466	9	NRM	NRM	NNP
cord-005478-5iu38pr6	3466	10	)	)	-RRB-
cord-005478-5iu38pr6	3466	11	and	and	CC
cord-005478-5iu38pr6	3466	12	relapse	relapse	VB
cord-005478-5iu38pr6	3466	13	at	at	IN
cord-005478-5iu38pr6	3466	14	2	2	CD
cord-005478-5iu38pr6	3466	15	years	year	NNS
cord-005478-5iu38pr6	3466	16	were	be	VBD
cord-005478-5iu38pr6	3466	17	21	21	CD
cord-005478-5iu38pr6	3466	18	%	%	NN
cord-005478-5iu38pr6	3466	19	and	and	CC
cord-005478-5iu38pr6	3466	20	43	43	CD
cord-005478-5iu38pr6	3466	21	%	%	NN
cord-005478-5iu38pr6	3466	22	,	,	,
cord-005478-5iu38pr6	3466	23	respectively	respectively	RB
cord-005478-5iu38pr6	3466	24	.	.	.
cord-005478-5iu38pr6	3467	1	In	in	IN
cord-005478-5iu38pr6	3467	2	multivariable	multivariable	JJ
cord-005478-5iu38pr6	3467	3	analysis	analysis	NN
cord-005478-5iu38pr6	3467	4	,	,	,
cord-005478-5iu38pr6	3467	5	performance	performance	NN
cord-005478-5iu38pr6	3467	6	status	status	NN
cord-005478-5iu38pr6	3467	7	(	(	-LRB-
cord-005478-5iu38pr6	3467	8	PS	PS	NNP
cord-005478-5iu38pr6	3467	9	)	)	-RRB-
cord-005478-5iu38pr6	3467	10	over	over	IN
cord-005478-5iu38pr6	3467	11	1	1	CD
cord-005478-5iu38pr6	3467	12	(	(	-LRB-
cord-005478-5iu38pr6	3467	13	PS>1	ps>1	NN
cord-005478-5iu38pr6	3467	14	vs	vs	IN
cord-005478-5iu38pr6	3467	15	PS	PS	NNP
cord-005478-5iu38pr6	3467	16	<	<	XX
cord-005478-5iu38pr6	3467	17	=	=	SYM
cord-005478-5iu38pr6	3467	18	1	1	CD
cord-005478-5iu38pr6	3467	19	,	,	,
cord-005478-5iu38pr6	3467	20	HR	HR	NNP
cord-005478-5iu38pr6	3467	21	2.49	2.49	CD
cord-005478-5iu38pr6	3467	22	,	,	,
cord-005478-5iu38pr6	3467	23	P=0.005	P=0.005	NNP
cord-005478-5iu38pr6	3467	24	)	)	-RRB-
cord-005478-5iu38pr6	3467	25	and	and	CC
cord-005478-5iu38pr6	3467	26	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3467	27	progression	progression	NN
cord-005478-5iu38pr6	3467	28	at	at	IN
cord-005478-5iu38pr6	3467	29	transplantation	transplantation	NN
cord-005478-5iu38pr6	3468	1	(	(	-LRB-
cord-005478-5iu38pr6	3468	2	CR	CR	NNP
cord-005478-5iu38pr6	3468	3	/	/	SYM
cord-005478-5iu38pr6	3468	4	CR	CR	NNP
cord-005478-5iu38pr6	3468	5	-	-	HYPH
cord-005478-5iu38pr6	3468	6	u	u	NNP
cord-005478-5iu38pr6	3468	7	/	/	SYM
cord-005478-5iu38pr6	3468	8	PR	PR	NNP
cord-005478-5iu38pr6	3468	9	vs	vs	IN
cord-005478-5iu38pr6	3468	10	others	other	NNS
cord-005478-5iu38pr6	3468	11	,	,	,
cord-005478-5iu38pr6	3468	12	HR	HR	NNP
cord-005478-5iu38pr6	3468	13	1.95	1.95	CD
cord-005478-5iu38pr6	3468	14	,	,	,
cord-005478-5iu38pr6	3468	15	P=0.043	P=0.043	NNP
cord-005478-5iu38pr6	3468	16	)	)	-RRB-
cord-005478-5iu38pr6	3468	17	showed	show	VBD
cord-005478-5iu38pr6	3468	18	significant	significant	JJ
cord-005478-5iu38pr6	3468	19	negative	negative	JJ
cord-005478-5iu38pr6	3468	20	impacts	impact	NNS
cord-005478-5iu38pr6	3468	21	on	on	IN
cord-005478-5iu38pr6	3468	22	OS	OS	NNP
cord-005478-5iu38pr6	3468	23	.	.	.
cord-005478-5iu38pr6	3469	1	CBT	CBT	NNP
cord-005478-5iu38pr6	3469	2	was	be	VBD
cord-005478-5iu38pr6	3469	3	strongly	strongly	RB
cord-005478-5iu38pr6	3469	4	associated	associate	VBN
cord-005478-5iu38pr6	3469	5	with	with	IN
cord-005478-5iu38pr6	3469	6	better	well	JJR
cord-005478-5iu38pr6	3469	7	OS	os	NN
cord-005478-5iu38pr6	3469	8	compared	compare	VBN
cord-005478-5iu38pr6	3469	9	to	to	IN
cord-005478-5iu38pr6	3469	10	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3469	11	BMT	BMT	NNP
cord-005478-5iu38pr6	3469	12	/	/	SYM
cord-005478-5iu38pr6	3469	13	PBSCT	PBSCT	NNP
cord-005478-5iu38pr6	3469	14	(	(	-LRB-
cord-005478-5iu38pr6	3469	15	HR	HR	NNP
cord-005478-5iu38pr6	3469	16	0.34	0.34	CD
cord-005478-5iu38pr6	3469	17	,	,	,
cord-005478-5iu38pr6	3469	18	P=0.003	P=0.003	NNP
cord-005478-5iu38pr6	3469	19	)	)	-RRB-
cord-005478-5iu38pr6	3469	20	and	and	CC
cord-005478-5iu38pr6	3469	21	comparable	comparable	JJ
cord-005478-5iu38pr6	3469	22	to	to	IN
cord-005478-5iu38pr6	3469	23	related	relate	VBN
cord-005478-5iu38pr6	3469	24	BMT	BMT	NNP
cord-005478-5iu38pr6	3469	25	/	/	SYM
cord-005478-5iu38pr6	3469	26	PBSCT	PBSCT	NNP
cord-005478-5iu38pr6	3469	27	.	.	.
cord-005478-5iu38pr6	3470	1	Lymphoma	Lymphoma	NNP
cord-005478-5iu38pr6	3470	2	control	control	NN
cord-005478-5iu38pr6	3470	3	status	status	NN
cord-005478-5iu38pr6	3470	4	at	at	IN
cord-005478-5iu38pr6	3470	5	transplantation	transplantation	NN
cord-005478-5iu38pr6	3470	6	was	be	VBD
cord-005478-5iu38pr6	3470	7	significantly	significantly	RB
cord-005478-5iu38pr6	3470	8	associated	associate	VBN
cord-005478-5iu38pr6	3470	9	with	with	IN
cord-005478-5iu38pr6	3470	10	relapse	relapse	NN
cord-005478-5iu38pr6	3470	11	(	(	-LRB-
cord-005478-5iu38pr6	3470	12	relapse	relapse	NN
cord-005478-5iu38pr6	3470	13	/	/	SYM
cord-005478-5iu38pr6	3470	14	induction	induction	NN
cord-005478-5iu38pr6	3470	15	failure	failure	NN
cord-005478-5iu38pr6	3470	16	vs	vs	IN
cord-005478-5iu38pr6	3470	17	CR	CR	NNP
cord-005478-5iu38pr6	3470	18	/	/	SYM
cord-005478-5iu38pr6	3470	19	CR	CR	NNP
cord-005478-5iu38pr6	3470	20	-	-	HYPH
cord-005478-5iu38pr6	3470	21	u	u	NNP
cord-005478-5iu38pr6	3470	22	/	/	SYM
cord-005478-5iu38pr6	3470	23	PR	PR	NNP
cord-005478-5iu38pr6	3470	24	,	,	,
cord-005478-5iu38pr6	3470	25	HR	HR	NNP
cord-005478-5iu38pr6	3470	26	2.61	2.61	CD
cord-005478-5iu38pr6	3470	27	,	,	,
cord-005478-5iu38pr6	3470	28	P=0.017	P=0.017	NNS
cord-005478-5iu38pr6	3470	29	)	)	-RRB-
cord-005478-5iu38pr6	3470	30	.	.	.
cord-005478-5iu38pr6	3471	1	Poor	poor	JJ
cord-005478-5iu38pr6	3471	2	PS	PS	NNP
cord-005478-5iu38pr6	3471	3	over	over	IN
cord-005478-5iu38pr6	3471	4	1	1	CD
cord-005478-5iu38pr6	3471	5	at	at	IN
cord-005478-5iu38pr6	3471	6	transplantation	transplantation	NN
cord-005478-5iu38pr6	3472	1	(	(	-LRB-
cord-005478-5iu38pr6	3472	2	PS>1	ps>1	NN
cord-005478-5iu38pr6	3472	3	vs	vs	IN
cord-005478-5iu38pr6	3472	4	PS	PS	NNP
cord-005478-5iu38pr6	3472	5	<	<	XX
cord-005478-5iu38pr6	3472	6	=	=	SYM
cord-005478-5iu38pr6	3472	7	1	1	CD
cord-005478-5iu38pr6	3472	8	,	,	,
cord-005478-5iu38pr6	3472	9	HR	HR	NNP
cord-005478-5iu38pr6	3472	10	3.35	3.35	CD
cord-005478-5iu38pr6	3472	11	,	,	,
cord-005478-5iu38pr6	3472	12	P=0.023	P=0.023	NNP
cord-005478-5iu38pr6	3472	13	)	)	-RRB-
cord-005478-5iu38pr6	3472	14	and	and	CC
cord-005478-5iu38pr6	3472	15	reduced	reduce	VBN
cord-005478-5iu38pr6	3472	16	-	-	HYPH
cord-005478-5iu38pr6	3472	17	intensity	intensity	NN
cord-005478-5iu38pr6	3472	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	3472	19	(	(	-LRB-
cord-005478-5iu38pr6	3472	20	RIC	RIC	NNP
cord-005478-5iu38pr6	3472	21	)	)	-RRB-
cord-005478-5iu38pr6	3472	22	regimen	regimen	NN
cord-005478-5iu38pr6	3472	23	(	(	-LRB-
cord-005478-5iu38pr6	3472	24	RIC	RIC	NNP
cord-005478-5iu38pr6	3472	25	vs	vs	IN
cord-005478-5iu38pr6	3472	26	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	3472	27	,	,	,
cord-005478-5iu38pr6	3472	28	HR	HR	NNP
cord-005478-5iu38pr6	3472	29	3.54	3.54	CD
cord-005478-5iu38pr6	3472	30	,	,	,
cord-005478-5iu38pr6	3472	31	P=0.025	P=0.025	NNP
cord-005478-5iu38pr6	3472	32	)	)	-RRB-
cord-005478-5iu38pr6	3472	33	were	be	VBD
cord-005478-5iu38pr6	3472	34	associated	associate	VBN
cord-005478-5iu38pr6	3472	35	with	with	IN
cord-005478-5iu38pr6	3472	36	higher	high	JJR
cord-005478-5iu38pr6	3472	37	risk	risk	NN
cord-005478-5iu38pr6	3472	38	of	of	IN
cord-005478-5iu38pr6	3472	39	NRM	NRM	NNP
cord-005478-5iu38pr6	3472	40	.	.	.
cord-005478-5iu38pr6	3473	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3473	2	:	:	:
cord-005478-5iu38pr6	3474	1	Allo	Allo	NNP
cord-005478-5iu38pr6	3474	2	-	-	HYPH
cord-005478-5iu38pr6	3474	3	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3474	4	could	could	MD
cord-005478-5iu38pr6	3474	5	improve	improve	VB
cord-005478-5iu38pr6	3474	6	overall	overall	JJ
cord-005478-5iu38pr6	3474	7	survival	survival	NN
cord-005478-5iu38pr6	3474	8	of	of	IN
cord-005478-5iu38pr6	3474	9	patient	patient	NN
cord-005478-5iu38pr6	3474	10	with	with	IN
cord-005478-5iu38pr6	3474	11	mature	mature	JJ
cord-005478-5iu38pr6	3474	12	T	T	NNP
cord-005478-5iu38pr6	3474	13	-	-	HYPH
cord-005478-5iu38pr6	3474	14	or	or	CC
cord-005478-5iu38pr6	3474	15	NK	nk	NN
cord-005478-5iu38pr6	3474	16	-	-	HYPH
cord-005478-5iu38pr6	3474	17	cell	cell	NN
cord-005478-5iu38pr6	3474	18	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3474	19	,	,	,
cord-005478-5iu38pr6	3474	20	if	if	IN
cord-005478-5iu38pr6	3474	21	performed	perform	VBN
cord-005478-5iu38pr6	3474	22	at	at	IN
cord-005478-5iu38pr6	3474	23	appropriate	appropriate	JJ
cord-005478-5iu38pr6	3474	24	timing	timing	NN
cord-005478-5iu38pr6	3474	25	with	with	IN
cord-005478-5iu38pr6	3474	26	good	good	JJ
cord-005478-5iu38pr6	3474	27	disease	disease	NN
cord-005478-5iu38pr6	3474	28	control	control	NN
cord-005478-5iu38pr6	3474	29	of	of	IN
cord-005478-5iu38pr6	3474	30	partial	partial	JJ
cord-005478-5iu38pr6	3474	31	remission	remission	NN
cord-005478-5iu38pr6	3474	32	(	(	-LRB-
cord-005478-5iu38pr6	3474	33	PR	PR	NNP
cord-005478-5iu38pr6	3474	34	)	)	-RRB-
cord-005478-5iu38pr6	3474	35	or	or	CC
cord-005478-5iu38pr6	3474	36	better	well	JJR
cord-005478-5iu38pr6	3474	37	.	.	.
cord-005478-5iu38pr6	3475	1	Cord	cord	NN
cord-005478-5iu38pr6	3475	2	blood	blood	NN
cord-005478-5iu38pr6	3475	3	unit	unit	NN
cord-005478-5iu38pr6	3475	4	could	could	MD
cord-005478-5iu38pr6	3475	5	be	be	VB
cord-005478-5iu38pr6	3475	6	a	a	DT
cord-005478-5iu38pr6	3475	7	favorable	favorable	JJ
cord-005478-5iu38pr6	3475	8	alternative	alternative	JJ
cord-005478-5iu38pr6	3475	9	donor	donor	NN
cord-005478-5iu38pr6	3475	10	source	source	NN
cord-005478-5iu38pr6	3475	11	when	when	WRB
cord-005478-5iu38pr6	3475	12	related	related	JJ
cord-005478-5iu38pr6	3475	13	donors	donor	NNS
cord-005478-5iu38pr6	3475	14	are	be	VBP
cord-005478-5iu38pr6	3475	15	not	not	RB
cord-005478-5iu38pr6	3475	16	available	available	JJ
cord-005478-5iu38pr6	3475	17	.	.	.
cord-005478-5iu38pr6	3476	1	On	on	IN
cord-005478-5iu38pr6	3476	2	the	the	DT
cord-005478-5iu38pr6	3476	3	other	other	JJ
cord-005478-5iu38pr6	3476	4	hands	hand	NNS
cord-005478-5iu38pr6	3476	5	,	,	,
cord-005478-5iu38pr6	3476	6	RIC	RIC	NNP
cord-005478-5iu38pr6	3476	7	regimen	regimen	NN
cord-005478-5iu38pr6	3476	8	did	do	VBD
cord-005478-5iu38pr6	3476	9	not	not	RB
cord-005478-5iu38pr6	3476	10	decrease	decrease	VB
cord-005478-5iu38pr6	3476	11	the	the	DT
cord-005478-5iu38pr6	3476	12	risk	risk	NN
cord-005478-5iu38pr6	3476	13	of	of	IN
cord-005478-5iu38pr6	3476	14	NRM	NRM	NNP
cord-005478-5iu38pr6	3476	15	in	in	IN
cord-005478-5iu38pr6	3476	16	allo	allo	NNP
cord-005478-5iu38pr6	3476	17	-	-	HYPH
cord-005478-5iu38pr6	3476	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3476	19	for	for	IN
cord-005478-5iu38pr6	3476	20	mature	mature	JJ
cord-005478-5iu38pr6	3476	21	T	T	NNP
cord-005478-5iu38pr6	3476	22	-	-	HYPH
cord-005478-5iu38pr6	3476	23	and	and	CC
cord-005478-5iu38pr6	3476	24	NK	nk	NN
cord-005478-5iu38pr6	3476	25	-	-	HYPH
cord-005478-5iu38pr6	3476	26	cell	cell	NN
cord-005478-5iu38pr6	3476	27	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3476	28	patients	patient	NNS
cord-005478-5iu38pr6	3476	29	in	in	IN
cord-005478-5iu38pr6	3476	30	our	-PRON-	PRP$
cord-005478-5iu38pr6	3476	31	setting	setting	NN
cord-005478-5iu38pr6	3476	32	.	.	.
cord-005478-5iu38pr6	3477	1	Out	out	IN
cord-005478-5iu38pr6	3477	2	study	study	NN
cord-005478-5iu38pr6	3477	3	also	also	RB
cord-005478-5iu38pr6	3477	4	suggested	suggest	VBD
cord-005478-5iu38pr6	3477	5	that	that	IN
cord-005478-5iu38pr6	3477	6	major	major	JJ
cord-005478-5iu38pr6	3477	7	problem	problem	NN
cord-005478-5iu38pr6	3477	8	of	of	IN
cord-005478-5iu38pr6	3477	9	allo	allo	NN
cord-005478-5iu38pr6	3477	10	-	-	HYPH
cord-005478-5iu38pr6	3477	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3477	12	is	be	VBZ
cord-005478-5iu38pr6	3477	13	still	still	RB
cord-005478-5iu38pr6	3477	14	a	a	DT
cord-005478-5iu38pr6	3477	15	high	high	JJ
cord-005478-5iu38pr6	3477	16	frequency	frequency	NN
cord-005478-5iu38pr6	3477	17	of	of	IN
cord-005478-5iu38pr6	3477	18	relapse	relapse	NN
cord-005478-5iu38pr6	3477	19	after	after	IN
cord-005478-5iu38pr6	3477	20	transplantation	transplantation	NN
cord-005478-5iu38pr6	3477	21	.	.	.
cord-005478-5iu38pr6	3478	1	Better	well	JJR
cord-005478-5iu38pr6	3478	2	disease	disease	NN
cord-005478-5iu38pr6	3478	3	control	control	NN
cord-005478-5iu38pr6	3478	4	is	be	VBZ
cord-005478-5iu38pr6	3478	5	mandatory	mandatory	JJ
cord-005478-5iu38pr6	3478	6	to	to	TO
cord-005478-5iu38pr6	3478	7	improve	improve	VB
cord-005478-5iu38pr6	3478	8	the	the	DT
cord-005478-5iu38pr6	3478	9	outcomes	outcome	NNS
cord-005478-5iu38pr6	3478	10	of	of	IN
cord-005478-5iu38pr6	3478	11	allo	allo	NN
cord-005478-5iu38pr6	3478	12	-	-	HYPH
cord-005478-5iu38pr6	3478	13	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3478	14	for	for	IN
cord-005478-5iu38pr6	3478	15	mature	mature	JJ
cord-005478-5iu38pr6	3478	16	T	T	NNP
cord-005478-5iu38pr6	3478	17	-	-	HYPH
cord-005478-5iu38pr6	3478	18	or	or	CC
cord-005478-5iu38pr6	3478	19	NK	NK	NNP
cord-005478-5iu38pr6	3478	20	Fabio	Fabio	NNP
cord-005478-5iu38pr6	3478	21	Ciceri	Ciceri	NNP
cord-005478-5iu38pr6	3478	22	1	1	CD
cord-005478-5iu38pr6	3478	23	,	,	,
cord-005478-5iu38pr6	3478	24	Luca	Luca	NNP
cord-005478-5iu38pr6	3478	25	Vago	Vago	NNP
cord-005478-5iu38pr6	3478	26	1	1	CD
cord-005478-5iu38pr6	3478	27	,	,	,
cord-005478-5iu38pr6	3478	28	Katharina	Katharina	NNP
cord-005478-5iu38pr6	3478	29	Fleischhauer	Fleischhauer	NNP
cord-005478-5iu38pr6	3478	30	5	5	CD
cord-005478-5iu38pr6	3478	31	Unite´de	unite´de	CD
cord-005478-5iu38pr6	3479	1	Recherche	Recherche	NNP
cord-005478-5iu38pr6	3479	2	Mixte	Mixte	NNP
cord-005478-5iu38pr6	3479	3	en	en	IN
cord-005478-5iu38pr6	3479	4	Sante´(UMR_S	sante´(umr_	NNS
cord-005478-5iu38pr6	3479	5	)	)	-RRB-
cord-005478-5iu38pr6	3479	6	938	938	CD
cord-005478-5iu38pr6	3479	7	,	,	,
cord-005478-5iu38pr6	3479	8	INSERM	INSERM	NNP
cord-005478-5iu38pr6	3479	9	Netherlands	Netherlands	NNP
cord-005478-5iu38pr6	3479	10	,	,	,
cord-005478-5iu38pr6	3479	11	11	11	CD
cord-005478-5iu38pr6	3479	12	Institute	Institute	NNP
cord-005478-5iu38pr6	3479	13	of	of	IN
cord-005478-5iu38pr6	3479	14	Hematology	Hematology	NNP
cord-005478-5iu38pr6	3479	15	and	and	CC
cord-005478-5iu38pr6	3479	16	Blood	Blood	NNP
cord-005478-5iu38pr6	3479	17	Transfusion	Transfusion	NNP
cord-005478-5iu38pr6	3479	18	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3479	19	is	be	VBZ
cord-005478-5iu38pr6	3479	20	largely	largely	RB
cord-005478-5iu38pr6	3479	21	adopted	adopt	VBN
cord-005478-5iu38pr6	3479	22	as	as	IN
cord-005478-5iu38pr6	3479	23	GvHDprophylaxis	GvHDprophylaxis	NNP
cord-005478-5iu38pr6	3479	24	backbone	backbone	NN
cord-005478-5iu38pr6	3479	25	in	in	IN
cord-005478-5iu38pr6	3479	26	haploidentical	haploidentical	JJ
cord-005478-5iu38pr6	3479	27	transplantation	transplantation	NN
cord-005478-5iu38pr6	3479	28	.	.	.
cord-005478-5iu38pr6	3480	1	The	the	DT
cord-005478-5iu38pr6	3480	2	encouraging	encouraging	JJ
cord-005478-5iu38pr6	3480	3	results	result	NNS
cord-005478-5iu38pr6	3480	4	prompted	prompt	VBD
cord-005478-5iu38pr6	3480	5	investigations	investigation	NNS
cord-005478-5iu38pr6	3480	6	to	to	TO
cord-005478-5iu38pr6	3480	7	assess	assess	VB
cord-005478-5iu38pr6	3480	8	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3480	9	also	also	RB
cord-005478-5iu38pr6	3480	10	in	in	IN
cord-005478-5iu38pr6	3480	11	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3480	12	donor	donor	NN
cord-005478-5iu38pr6	3480	13	(	(	-LRB-
cord-005478-5iu38pr6	3480	14	UD	UD	NNP
cord-005478-5iu38pr6	3480	15	)	)	-RRB-
cord-005478-5iu38pr6	3480	16	setting	setting	NN
cord-005478-5iu38pr6	3480	17	.	.	.
cord-005478-5iu38pr6	3481	1	High	high	JJ
cord-005478-5iu38pr6	3481	2	-	-	HYPH
cord-005478-5iu38pr6	3481	3	resolution	resolution	NN
cord-005478-5iu38pr6	3481	4	HLA	hla	NN
cord-005478-5iu38pr6	3481	5	-	-	HYPH
cord-005478-5iu38pr6	3481	6	matching	matching	NN
cord-005478-5iu38pr6	3481	7	contributes	contribute	VBZ
cord-005478-5iu38pr6	3481	8	to	to	IN
cord-005478-5iu38pr6	3481	9	UD	UD	NNP
cord-005478-5iu38pr6	3481	10	-	-	HYPH
cord-005478-5iu38pr6	3481	11	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3481	12	success	success	NN
cord-005478-5iu38pr6	3481	13	;	;	:
cord-005478-5iu38pr6	3481	14	however	however	RB
cord-005478-5iu38pr6	3481	15	,	,	,
cord-005478-5iu38pr6	3481	16	due	due	IN
cord-005478-5iu38pr6	3481	17	to	to	IN
cord-005478-5iu38pr6	3481	18	the	the	DT
cord-005478-5iu38pr6	3481	19	selective	selective	JJ
cord-005478-5iu38pr6	3481	20	in	in	IN
cord-005478-5iu38pr6	3481	21	-	-	HYPH
cord-005478-5iu38pr6	3481	22	vivo	vivo	NN
cord-005478-5iu38pr6	3481	23	deletion	deletion	NN
cord-005478-5iu38pr6	3481	24	of	of	IN
cord-005478-5iu38pr6	3481	25	alloreactive	alloreactive	NNP
cord-005478-5iu38pr6	3481	26	T	T	NNP
cord-005478-5iu38pr6	3481	27	-	-	HYPH
cord-005478-5iu38pr6	3481	28	cells	cell	NNS
cord-005478-5iu38pr6	3481	29	,	,	,
cord-005478-5iu38pr6	3481	30	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3481	31	could	could	MD
cord-005478-5iu38pr6	3481	32	modulate	modulate	VB
cord-005478-5iu38pr6	3481	33	HLA	HLA	NNP
cord-005478-5iu38pr6	3481	34	-	-	HYPH
cord-005478-5iu38pr6	3481	35	matching	match	VBG
cord-005478-5iu38pr6	3481	36	impact	impact	NN
cord-005478-5iu38pr6	3481	37	on	on	IN
cord-005478-5iu38pr6	3481	38	UD	UD	NNP
cord-005478-5iu38pr6	3481	39	-	-	HYPH
cord-005478-5iu38pr6	3481	40	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3481	41	.	.	.
cord-005478-5iu38pr6	3482	1	Methods	method	NNS
cord-005478-5iu38pr6	3482	2	:	:	:
cord-005478-5iu38pr6	3483	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3483	2	compared	compare	VBD
cord-005478-5iu38pr6	3483	3	the	the	DT
cord-005478-5iu38pr6	3483	4	outcomes	outcome	NNS
cord-005478-5iu38pr6	3483	5	of	of	IN
cord-005478-5iu38pr6	3483	6	acute	acute	JJ
cord-005478-5iu38pr6	3483	7	leukemia	leukemia	NN
cord-005478-5iu38pr6	3483	8	patients	patient	NNS
cord-005478-5iu38pr6	3483	9	receiving	receive	VBG
cord-005478-5iu38pr6	3483	10	10/10	10/10	CD
cord-005478-5iu38pr6	3483	11	(	(	-LRB-
cord-005478-5iu38pr6	3483	12	n=431	n=431	CD
cord-005478-5iu38pr6	3483	13	)	)	-RRB-
cord-005478-5iu38pr6	3483	14	and	and	CC
cord-005478-5iu38pr6	3483	15	9/10	9/10	CD
cord-005478-5iu38pr6	3483	16	(	(	-LRB-
cord-005478-5iu38pr6	3483	17	n=234	n=234	NNP
cord-005478-5iu38pr6	3483	18	)	)	-RRB-
cord-005478-5iu38pr6	3484	1	HLAallele	HLAallele	NNP
cord-005478-5iu38pr6	3484	2	matched	match	VBD
cord-005478-5iu38pr6	3484	3	UD	UD	NNP
cord-005478-5iu38pr6	3484	4	-	-	HYPH
cord-005478-5iu38pr6	3484	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3484	6	with	with	IN
cord-005478-5iu38pr6	3484	7	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3484	8	GvHD	gvhd	NN
cord-005478-5iu38pr6	3484	9	-	-	HYPH
cord-005478-5iu38pr6	3484	10	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3484	11	Table	table	NN
cord-005478-5iu38pr6	3484	12	1	1	CD
cord-005478-5iu38pr6	3484	13	illustrates	illustrate	VBZ
cord-005478-5iu38pr6	3484	14	patients	patient	NNS
cord-005478-5iu38pr6	3484	15	'	'	POS
cord-005478-5iu38pr6	3484	16	characteristics	characteristic	NNS
cord-005478-5iu38pr6	3484	17	.	.	.
cord-005478-5iu38pr6	3485	1	The	the	DT
cord-005478-5iu38pr6	3485	2	power	power	NN
cord-005478-5iu38pr6	3485	3	to	to	TO
cord-005478-5iu38pr6	3485	4	detect	detect	VB
cord-005478-5iu38pr6	3485	5	a	a	DT
cord-005478-5iu38pr6	3485	6	2-years	2-years	CD
cord-005478-5iu38pr6	3485	7	10	10	CD
cord-005478-5iu38pr6	3485	8	%	%	NN
cord-005478-5iu38pr6	3485	9	difference	difference	NN
cord-005478-5iu38pr6	3485	10	GRFS	grfs	NN
cord-005478-5iu38pr6	3485	11	between	between	IN
cord-005478-5iu38pr6	3485	12	the	the	DT
cord-005478-5iu38pr6	3485	13	2	2	CD
cord-005478-5iu38pr6	3485	14	groups	group	NNS
cord-005478-5iu38pr6	3485	15	was	be	VBD
cord-005478-5iu38pr6	3485	16	83	83	CD
cord-005478-5iu38pr6	3485	17	%	%	NN
cord-005478-5iu38pr6	3485	18	(	(	-LRB-
cord-005478-5iu38pr6	3485	19	alpha	alpha	NN
cord-005478-5iu38pr6	3485	20	2-sided=5	2-sided=5	CD
cord-005478-5iu38pr6	3485	21	%	%	NN
cord-005478-5iu38pr6	3485	22	)	)	-RRB-
cord-005478-5iu38pr6	3485	23	.	.	.
cord-005478-5iu38pr6	3486	1	Results	result	NNS
cord-005478-5iu38pr6	3486	2	:	:	:
cord-005478-5iu38pr6	3487	1	Outcome	outcome	NN
cord-005478-5iu38pr6	3487	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	3487	3	at	at	IN
cord-005478-5iu38pr6	3487	4	2	2	CD
cord-005478-5iu38pr6	3487	5	years	year	NNS
cord-005478-5iu38pr6	3487	6	were	be	VBD
cord-005478-5iu38pr6	3487	7	not	not	RB
cord-005478-5iu38pr6	3487	8	different	different	JJ
cord-005478-5iu38pr6	3487	9	between	between	IN
cord-005478-5iu38pr6	3487	10	±7	±7	NNS
cord-005478-5iu38pr6	3487	11	%	%	NN
cord-005478-5iu38pr6	3487	12	,	,	,
cord-005478-5iu38pr6	3487	13	p=0.5	p=0.5	NNP
cord-005478-5iu38pr6	3487	14	;	;	:
cord-005478-5iu38pr6	3487	15	LFS	LFS	NNP
cord-005478-5iu38pr6	3487	16	:	:	:
cord-005478-5iu38pr6	3487	17	56±5	56±5	CD
cord-005478-5iu38pr6	3487	18	%	%	NN
cord-005478-5iu38pr6	3487	19	and	and	CC
cord-005478-5iu38pr6	3487	20	55±7	55±7	CD
cord-005478-5iu38pr6	3487	21	%	%	NN
cord-005478-5iu38pr6	3487	22	,	,	,
cord-005478-5iu38pr6	3487	23	p=0.7	p=0.7	NNP
cord-005478-5iu38pr6	3487	24	;	;	:
cord-005478-5iu38pr6	3487	25	OS	OS	NNP
cord-005478-5iu38pr6	3487	26	:	:	:
cord-005478-5iu38pr6	3487	27	63±5	63±5	CD
cord-005478-5iu38pr6	3487	28	%	%	NN
cord-005478-5iu38pr6	3487	29	and	and	CC
cord-005478-5iu38pr6	3487	30	60±8	60±8	CD
cord-005478-5iu38pr6	3487	31	%	%	NN
cord-005478-5iu38pr6	3487	32	,	,	,
cord-005478-5iu38pr6	3487	33	p=0.9	p=0.9	NNP
cord-005478-5iu38pr6	3487	34	,	,	,
cord-005478-5iu38pr6	3487	35	respectively	respectively	RB
cord-005478-5iu38pr6	3487	36	)	)	-RRB-
cord-005478-5iu38pr6	3487	37	.	.	.
cord-005478-5iu38pr6	3488	1	The	the	DT
cord-005478-5iu38pr6	3488	2	100-day	100-day	JJ
cord-005478-5iu38pr6	3488	3	CI	ci	NN
cord-005478-5iu38pr6	3488	4	of	of	IN
cord-005478-5iu38pr6	3488	5	grade≥2	grade≥2	NNP
cord-005478-5iu38pr6	3488	6	and	and	CC
cord-005478-5iu38pr6	3488	7	grade≥3	grade≥3	NNP
cord-005478-5iu38pr6	3488	8	aGvHD	aGvHD	NNP
cord-005478-5iu38pr6	3488	9	were	be	VBD
cord-005478-5iu38pr6	3488	10	comparable	comparable	JJ
cord-005478-5iu38pr6	3488	11	for	for	IN
cord-005478-5iu38pr6	3488	12	10/10	10/10	CD
cord-005478-5iu38pr6	3488	13	and	and	CC
cord-005478-5iu38pr6	3488	14	9/10	9/10	CD
cord-005478-5iu38pr6	3488	15	UD	UD	NNP
cord-005478-5iu38pr6	3488	16	(	(	-LRB-
cord-005478-5iu38pr6	3488	17	31±5	31±5	CD
cord-005478-5iu38pr6	3488	18	%	%	NN
cord-005478-5iu38pr6	3488	19	and	and	CC
cord-005478-5iu38pr6	3488	20	28±6	28±6	CD
cord-005478-5iu38pr6	3488	21	%	%	NN
cord-005478-5iu38pr6	3488	22	,	,	,
cord-005478-5iu38pr6	3488	23	p=0.4	p=0.4	NNP
cord-005478-5iu38pr6	3488	24	and	and	CC
cord-005478-5iu38pr6	3488	25	10±3	10±3	CD
cord-005478-5iu38pr6	3488	26	%	%	NN
cord-005478-5iu38pr6	3488	27	and	and	CC
cord-005478-5iu38pr6	3488	28	9	9	CD
cord-005478-5iu38pr6	3489	1	Likewise	likewise	RB
cord-005478-5iu38pr6	3489	2	,	,	,
cord-005478-5iu38pr6	3489	3	the	the	DT
cord-005478-5iu38pr6	3489	4	2-y	2-y	CD
cord-005478-5iu38pr6	3489	5	CI	CI	NNP
cord-005478-5iu38pr6	3489	6	of	of	IN
cord-005478-5iu38pr6	3489	7	cGvHD	cGvHD	NNP
cord-005478-5iu38pr6	3489	8	and	and	CC
cord-005478-5iu38pr6	3489	9	extensive	extensive	JJ
cord-005478-5iu38pr6	3489	10	cGvHD	cgvhd	NN
cord-005478-5iu38pr6	3489	11	were	be	VBD
cord-005478-5iu38pr6	3489	12	similar	similar	JJ
cord-005478-5iu38pr6	3489	13	between	between	IN
cord-005478-5iu38pr6	3489	14	10	10	CD
cord-005478-5iu38pr6	3490	1	The	the	DT
cord-005478-5iu38pr6	3490	2	2-y	2-y	CD
cord-005478-5iu38pr6	3490	3	CI	CI	NNP
cord-005478-5iu38pr6	3490	4	of	of	IN
cord-005478-5iu38pr6	3490	5	TRM	TRM	NNP
cord-005478-5iu38pr6	3490	6	was	be	VBD
cord-005478-5iu38pr6	3490	7	19±4	19±4	CD
cord-005478-5iu38pr6	3490	8	%	%	NN
cord-005478-5iu38pr6	3490	9	after	after	IN
cord-005478-5iu38pr6	3490	10	10/10	10/10	CD
cord-005478-5iu38pr6	3490	11	and	and	CC
cord-005478-5iu38pr6	3490	12	17±5	17±5	CD
cord-005478-5iu38pr6	3490	13	%	%	NN
cord-005478-5iu38pr6	3490	14	after	after	IN
cord-005478-5iu38pr6	3490	15	9/10	9/10	CD
cord-005478-5iu38pr6	3490	16	UD	UD	NNP
cord-005478-5iu38pr6	3490	17	-	-	HYPH
cord-005478-5iu38pr6	3490	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3490	19	(	(	-LRB-
cord-005478-5iu38pr6	3490	20	p=0.4	p=0.4	NNP
cord-005478-5iu38pr6	3490	21	)	)	-RRB-
cord-005478-5iu38pr6	3490	22	.	.	.
cord-005478-5iu38pr6	3491	1	Relapse	relapse	NN
cord-005478-5iu38pr6	3491	2	incidence	incidence	NN
cord-005478-5iu38pr6	3491	3	at	at	IN
cord-005478-5iu38pr6	3491	4	2-y	2-y	CD
cord-005478-5iu38pr6	3491	5	was	be	VBD
cord-005478-5iu38pr6	3491	6	25±5	25±5	CD
cord-005478-5iu38pr6	3491	7	%	%	NN
cord-005478-5iu38pr6	3491	8	for	for	IN
cord-005478-5iu38pr6	3491	9	10/10	10/10	CD
cord-005478-5iu38pr6	3491	10	and	and	CC
cord-005478-5iu38pr6	3491	11	No	no	DT
cord-005478-5iu38pr6	3491	12	interaction	interaction	NN
cord-005478-5iu38pr6	3491	13	was	be	VBD
cord-005478-5iu38pr6	3491	14	found	find	VBN
cord-005478-5iu38pr6	3491	15	between	between	IN
cord-005478-5iu38pr6	3491	16	donor	donor	NN
cord-005478-5iu38pr6	3491	17	type	type	NN
cord-005478-5iu38pr6	3491	18	and	and	CC
cord-005478-5iu38pr6	3491	19	additional	additional	JJ
cord-005478-5iu38pr6	3491	20	ATG	ATG	NNP
cord-005478-5iu38pr6	3491	21	use	use	NN
cord-005478-5iu38pr6	3491	22	.	.	.
cord-005478-5iu38pr6	3492	1	Variables	variable	NNS
cord-005478-5iu38pr6	3492	2	associated	associate	VBN
cord-005478-5iu38pr6	3492	3	with	with	IN
cord-005478-5iu38pr6	3492	4	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3492	5	were	be	VBD
cord-005478-5iu38pr6	3492	6	active	active	JJ
cord-005478-5iu38pr6	3492	7	disease	disease	NN
cord-005478-5iu38pr6	3492	8	(	(	-LRB-
cord-005478-5iu38pr6	3492	9	HR	HR	NNP
cord-005478-5iu38pr6	3492	10	2.1	2.1	CD
cord-005478-5iu38pr6	3492	11	compared	compare	VBN
cord-005478-5iu38pr6	3492	12	to	to	IN
cord-005478-5iu38pr6	3492	13	1	1	CD
cord-005478-5iu38pr6	3492	14	st	st	NNP
cord-005478-5iu38pr6	3492	15	CR	CR	NNP
cord-005478-5iu38pr6	3492	16	,	,	,
cord-005478-5iu38pr6	3492	17	p	p	NN
cord-005478-5iu38pr6	3492	18	<	<	XX
cord-005478-5iu38pr6	3492	19	10	10	CD
cord-005478-5iu38pr6	3492	20	-5	-5	NNP
cord-005478-5iu38pr6	3492	21	)	)	-RRB-
cord-005478-5iu38pr6	3492	22	and	and	CC
cord-005478-5iu38pr6	3492	23	Karnofsky	Karnofsky	NNP
cord-005478-5iu38pr6	3492	24	PS≥90	PS≥90	NNP
cord-005478-5iu38pr6	3492	25	%	%	NN
cord-005478-5iu38pr6	3492	26	(	(	-LRB-
cord-005478-5iu38pr6	3492	27	HR	HR	NNP
cord-005478-5iu38pr6	3492	28	0.6	0.6	CD
cord-005478-5iu38pr6	3492	29	,	,	,
cord-005478-5iu38pr6	3492	30	p	p	NN
cord-005478-5iu38pr6	3492	31	<	<	XX
cord-005478-5iu38pr6	3492	32	10	10	CD
cord-005478-5iu38pr6	3492	33	-5	-5	CD
cord-005478-5iu38pr6	3492	34	)	)	-RRB-
cord-005478-5iu38pr6	3492	35	.	.	.
cord-005478-5iu38pr6	3493	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3493	2	:	:	:
cord-005478-5iu38pr6	3494	1	In	in	IN
cord-005478-5iu38pr6	3494	2	the	the	DT
cord-005478-5iu38pr6	3494	3	present	present	JJ
cord-005478-5iu38pr6	3494	4	series	series	NN
cord-005478-5iu38pr6	3494	5	of	of	IN
cord-005478-5iu38pr6	3494	6	acute	acute	JJ
cord-005478-5iu38pr6	3494	7	leukemia	leukemia	NN
cord-005478-5iu38pr6	3494	8	patients	patient	NNS
cord-005478-5iu38pr6	3494	9	transplanted	transplant	VBN
cord-005478-5iu38pr6	3494	10	with	with	IN
cord-005478-5iu38pr6	3494	11	PTCy	PTCy	NNS
cord-005478-5iu38pr6	3494	12	,	,	,
cord-005478-5iu38pr6	3494	13	we	-PRON-	PRP
cord-005478-5iu38pr6	3494	14	report	report	VBP
cord-005478-5iu38pr6	3494	15	comparable	comparable	JJ
cord-005478-5iu38pr6	3494	16	survival	survival	NN
cord-005478-5iu38pr6	3494	17	with	with	IN
cord-005478-5iu38pr6	3494	18	9/10	9/10	CD
cord-005478-5iu38pr6	3494	19	and	and	CC
cord-005478-5iu38pr6	3494	20	10/10	10/10	CD
cord-005478-5iu38pr6	3494	21	HLA	HLA	NNP
cord-005478-5iu38pr6	3494	22	-	-	HYPH
cord-005478-5iu38pr6	3494	23	matched	match	VBN
cord-005478-5iu38pr6	3494	24	UD	UD	NNP
cord-005478-5iu38pr6	3494	25	-	-	HYPH
cord-005478-5iu38pr6	3494	26	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3494	27	,	,	,
cord-005478-5iu38pr6	3494	28	across	across	IN
cord-005478-5iu38pr6	3494	29	all	all	DT
cord-005478-5iu38pr6	3494	30	disease	disease	NN
cord-005478-5iu38pr6	3494	31	stages	stage	NNS
cord-005478-5iu38pr6	3494	32	,	,	,
cord-005478-5iu38pr6	3494	33	suggesting	suggest	VBG
cord-005478-5iu38pr6	3494	34	that	that	IN
cord-005478-5iu38pr6	3494	35	this	this	DT
cord-005478-5iu38pr6	3494	36	platform	platform	NN
cord-005478-5iu38pr6	3494	37	could	could	MD
cord-005478-5iu38pr6	3494	38	alleviate	alleviate	VB
cord-005478-5iu38pr6	3494	39	the	the	DT
cord-005478-5iu38pr6	3494	40	detrimental	detrimental	JJ
cord-005478-5iu38pr6	3494	41	effect	effect	NN
cord-005478-5iu38pr6	3494	42	of	of	IN
cord-005478-5iu38pr6	3494	43	single	single	JJ
cord-005478-5iu38pr6	3494	44	HLA	HLA	NNP
cord-005478-5iu38pr6	3494	45	-	-	HYPH
cord-005478-5iu38pr6	3494	46	allele	allele	NN
cord-005478-5iu38pr6	3494	47	mismatching	mismatching	NN
cord-005478-5iu38pr6	3494	48	.	.	.
cord-005478-5iu38pr6	3495	1	These	these	DT
cord-005478-5iu38pr6	3495	2	results	result	NNS
cord-005478-5iu38pr6	3495	3	warrant	warrant	VBP
cord-005478-5iu38pr6	3495	4	prospective	prospective	JJ
cord-005478-5iu38pr6	3495	5	comparative	comparative	JJ
cord-005478-5iu38pr6	3495	6	trials	trial	NNS
cord-005478-5iu38pr6	3495	7	of	of	IN
cord-005478-5iu38pr6	3495	8	PTCy	PTCy	NNPS
cord-005478-5iu38pr6	3495	9	versus	versus	IN
cord-005478-5iu38pr6	3495	10	standard	standard	JJ
cord-005478-5iu38pr6	3495	11	use	use	NN
cord-005478-5iu38pr6	3495	12	of	of	IN
cord-005478-5iu38pr6	3495	13	ATG	ATG	NNP
cord-005478-5iu38pr6	3495	14	-	-	HYPH
cord-005478-5iu38pr6	3495	15	based	base	VBN
cord-005478-5iu38pr6	3495	16	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3495	17	Disease	Disease	NNP
cord-005478-5iu38pr6	3495	18	status	status	NN
cord-005478-5iu38pr6	3495	19	:	:	:
cord-005478-5iu38pr6	3495	20	CR1	CR1	NNP
cord-005478-5iu38pr6	3495	21	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	3495	22	:	:	:
cord-005478-5iu38pr6	3495	23	Nothing	nothing	NN
cord-005478-5iu38pr6	3495	24	to	to	TO
cord-005478-5iu38pr6	3495	25	declare	declare	VB
cord-005478-5iu38pr6	3495	26	O178	o178	JJ
cord-005478-5iu38pr6	3495	27	Myeloablative	Myeloablative	NNP
cord-005478-5iu38pr6	3495	28	conditioning	conditioning	NN
cord-005478-5iu38pr6	3495	29	for	for	IN
cord-005478-5iu38pr6	3495	30	first	first	JJ
cord-005478-5iu38pr6	3495	31	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3495	32	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3495	33	in	in	IN
cord-005478-5iu38pr6	3495	34	pediatric	pediatric	JJ
cord-005478-5iu38pr6	3495	35	all	all	DT
cord-005478-5iu38pr6	3495	36	:	:	:
cord-005478-5iu38pr6	3495	37	FTBI	ftbi	NN
cord-005478-5iu38pr6	3495	38	or	or	CC
cord-005478-5iu38pr6	3495	39	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	3495	40	?	?	.
cord-005478-5iu38pr6	3496	1	-An	-An	NNP
cord-005478-5iu38pr6	3497	1	update	update	NN
cord-005478-5iu38pr6	3497	2	of	of	IN
cord-005478-5iu38pr6	3497	3	the	the	DT
cord-005478-5iu38pr6	3497	4	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3497	5	multicenter	multicenter	JJ
cord-005478-5iu38pr6	3497	6	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3497	7	-	-	HYPH
cord-005478-5iu38pr6	3497	8	PDWP	PDWP	NNP
cord-005478-5iu38pr6	3497	9	study	study	NN
cord-005478-5iu38pr6	3497	10	Rose	Rose	NNP
cord-005478-5iu38pr6	3497	11	-	-	HYPH
cord-005478-5iu38pr6	3497	12	Marie	Marie	NNP
cord-005478-5iu38pr6	3497	13	Hamladji	Hamladji	NNP
cord-005478-5iu38pr6	3497	14	14	14	CD
cord-005478-5iu38pr6	3497	15	,	,	,
cord-005478-5iu38pr6	3497	16	Cristina	Cristina	NNP
cord-005478-5iu38pr6	3497	17	Diaz	Diaz	NNP
cord-005478-5iu38pr6	3497	18	de	de	NNP
cord-005478-5iu38pr6	3497	19	Heredia	Heredia	NNP
cord-005478-5iu38pr6	3497	20	15	15	CD
cord-005478-5iu38pr6	3497	21	,	,	,
cord-005478-5iu38pr6	3497	22	Elena	Elena	NNP
cord-005478-5iu38pr6	3497	23	Skorobogatova	Skorobogatova	NNP
cord-005478-5iu38pr6	3497	24	16	16	CD
cord-005478-5iu38pr6	3497	25	Czech	Czech	NNP
cord-005478-5iu38pr6	3497	26	Republic	Republic	NNP
cord-005478-5iu38pr6	3497	27	,	,	,
cord-005478-5iu38pr6	3497	28	4	4	CD
cord-005478-5iu38pr6	3497	29	Hôpital	Hôpital	NNP
cord-005478-5iu38pr6	3497	30	Robert	Robert	NNP
cord-005478-5iu38pr6	3497	31	Debré	Debré	NNP
cord-005478-5iu38pr6	3497	32	and	and	CC
cord-005478-5iu38pr6	3497	33	Paris	Paris	NNP
cord-005478-5iu38pr6	3497	34	-	-	HYPH
cord-005478-5iu38pr6	3497	35	Diderot	Diderot	NNP
cord-005478-5iu38pr6	3497	36	University	University	NNP
cord-005478-5iu38pr6	3497	37	Methods	Methods	NNPS
cord-005478-5iu38pr6	3498	1	:	:	:
cord-005478-5iu38pr6	3498	2	This	this	DT
cord-005478-5iu38pr6	3498	3	update	update	NN
cord-005478-5iu38pr6	3498	4	was	be	VBD
cord-005478-5iu38pr6	3498	5	done	do	VBN
cord-005478-5iu38pr6	3498	6	to	to	TO
cord-005478-5iu38pr6	3498	7	extend	extend	VB
cord-005478-5iu38pr6	3498	8	the	the	DT
cord-005478-5iu38pr6	3498	9	time	time	NN
cord-005478-5iu38pr6	3498	10	of	of	IN
cord-005478-5iu38pr6	3498	11	follow	follow	NN
cord-005478-5iu38pr6	3498	12	-	-	HYPH
cord-005478-5iu38pr6	3498	13	up	up	NN
cord-005478-5iu38pr6	3498	14	(	(	-LRB-
cord-005478-5iu38pr6	3498	15	FU	FU	NNP
cord-005478-5iu38pr6	3498	16	,	,	,
cord-005478-5iu38pr6	3498	17	date	date	NN
cord-005478-5iu38pr6	3498	18	of	of	IN
cord-005478-5iu38pr6	3498	19	analysis	analysis	NN
cord-005478-5iu38pr6	3498	20	:	:	:
cord-005478-5iu38pr6	3498	21	01	01	CD
cord-005478-5iu38pr6	3498	22	/	/	SYM
cord-005478-5iu38pr6	3498	23	OCT/2018	OCT/2018	NNP
cord-005478-5iu38pr6	3498	24	)	)	-RRB-
cord-005478-5iu38pr6	3498	25	.	.	.
cord-005478-5iu38pr6	3499	1	To	to	TO
cord-005478-5iu38pr6	3499	2	compare	compare	VB
cord-005478-5iu38pr6	3499	3	outcomes	outcome	NNS
cord-005478-5iu38pr6	3499	4	of	of	IN
cord-005478-5iu38pr6	3499	5	fTBI	ftbi	NN
cord-005478-5iu38pr6	3499	6	vs	vs	IN
cord-005478-5iu38pr6	3499	7	CHT	CHT	NNP
cord-005478-5iu38pr6	3499	8	-	-	HYPH
cord-005478-5iu38pr6	3499	9	conditioning	conditioning	NN
cord-005478-5iu38pr6	3499	10	,	,	,
cord-005478-5iu38pr6	3499	11	we	-PRON-	PRP
cord-005478-5iu38pr6	3499	12	performed	perform	VBD
cord-005478-5iu38pr6	3499	13	a	a	DT
cord-005478-5iu38pr6	3499	14	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3499	15	EBMT	EBMT	NNP
cord-005478-5iu38pr6	3499	16	-	-	HYPH
cord-005478-5iu38pr6	3499	17	registry	registry	NN
cord-005478-5iu38pr6	3499	18	study	study	NN
cord-005478-5iu38pr6	3499	19	.	.	.
cord-005478-5iu38pr6	3500	1	Children	child	NNS
cord-005478-5iu38pr6	3500	2	aged	aged	JJ
cord-005478-5iu38pr6	3500	3	2	2	CD
cord-005478-5iu38pr6	3500	4	-	-	SYM
cord-005478-5iu38pr6	3500	5	18	18	CD
cord-005478-5iu38pr6	3500	6	years	year	NNS
cord-005478-5iu38pr6	3500	7	(	(	-LRB-
cord-005478-5iu38pr6	3500	8	y	y	NN
cord-005478-5iu38pr6	3500	9	)	)	-RRB-
cord-005478-5iu38pr6	3500	10	after	after	IN
cord-005478-5iu38pr6	3500	11	MAC	MAC	NNP
cord-005478-5iu38pr6	3500	12	for	for	IN
cord-005478-5iu38pr6	3500	13	first	first	JJ
cord-005478-5iu38pr6	3500	14	allo	allo	NN
cord-005478-5iu38pr6	3500	15	-	-	HYPH
cord-005478-5iu38pr6	3500	16	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3500	17	of	of	IN
cord-005478-5iu38pr6	3500	18	BM/	BM/	-LRB-
cord-005478-5iu38pr6	3501	1	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3501	2	from	from	IN
cord-005478-5iu38pr6	3501	3	MSD	MSD	NNP
cord-005478-5iu38pr6	3501	4	/	/	SYM
cord-005478-5iu38pr6	3501	5	UD	UD	NNP
cord-005478-5iu38pr6	3501	6	in	in	IN
cord-005478-5iu38pr6	3501	7	CR1	CR1	NNP
cord-005478-5iu38pr6	3501	8	/	/	SYM
cord-005478-5iu38pr6	3501	9	CR2	CR2	NNP
cord-005478-5iu38pr6	3501	10	between	between	IN
cord-005478-5iu38pr6	3501	11	2000	2000	CD
cord-005478-5iu38pr6	3501	12	-	-	SYM
cord-005478-5iu38pr6	3501	13	2012	2012	CD
cord-005478-5iu38pr6	3501	14	were	be	VBD
cord-005478-5iu38pr6	3501	15	included	include	VBN
cord-005478-5iu38pr6	3501	16	.	.	.
cord-005478-5iu38pr6	3502	1	Propensity	propensity	NN
cord-005478-5iu38pr6	3502	2	-	-	HYPH
cord-005478-5iu38pr6	3502	3	score	score	NN
cord-005478-5iu38pr6	3502	4	-	-	HYPH
cord-005478-5iu38pr6	3502	5	weighting	weighting	NN
cord-005478-5iu38pr6	3502	6	was	be	VBD
cord-005478-5iu38pr6	3502	7	used	use	VBN
cord-005478-5iu38pr6	3502	8	to	to	TO
cord-005478-5iu38pr6	3502	9	control	control	VB
cord-005478-5iu38pr6	3502	10	pretreatment	pretreatment	NN
cord-005478-5iu38pr6	3502	11	imbalances	imbalance	NNS
cord-005478-5iu38pr6	3502	12	of	of	IN
cord-005478-5iu38pr6	3502	13	observed	observed	JJ
cord-005478-5iu38pr6	3502	14	variables	variable	NNS
cord-005478-5iu38pr6	3502	15	.	.	.
cord-005478-5iu38pr6	3503	1	This	this	DT
cord-005478-5iu38pr6	3503	2	statistical	statistical	JJ
cord-005478-5iu38pr6	3503	3	method	method	NN
cord-005478-5iu38pr6	3503	4	ensured	ensure	VBD
cord-005478-5iu38pr6	3503	5	that	that	IN
cord-005478-5iu38pr6	3503	6	analyzed	analyze	VBN
cord-005478-5iu38pr6	3503	7	groups	group	NNS
cord-005478-5iu38pr6	3503	8	differed	differ	VBD
cord-005478-5iu38pr6	3503	9	only	only	RB
cord-005478-5iu38pr6	3503	10	in	in	IN
cord-005478-5iu38pr6	3503	11	the	the	DT
cord-005478-5iu38pr6	3503	12	parameter	parameter	NN
cord-005478-5iu38pr6	3503	13	under	under	IN
cord-005478-5iu38pr6	3503	14	investigation	investigation	NN
cord-005478-5iu38pr6	3503	15	(	(	-LRB-
cord-005478-5iu38pr6	3503	16	here	here	RB
cord-005478-5iu38pr6	3503	17	:	:	:
cord-005478-5iu38pr6	3503	18	conditioning	conditioning	NN
cord-005478-5iu38pr6	3503	19	)	)	-RRB-
cord-005478-5iu38pr6	3504	1	Busulfan	Busulfan	NNP
cord-005478-5iu38pr6	3504	2	/	/	SYM
cord-005478-5iu38pr6	3504	3	Cyclophosphamide/	Cyclophosphamide/	NNP
cord-005478-5iu38pr6	3504	4	Etoposide	Etoposide	NNP
cord-005478-5iu38pr6	3504	5	(	(	-LRB-
cord-005478-5iu38pr6	3504	6	Bu	Bu	NNP
cord-005478-5iu38pr6	3504	7	/	/	SYM
cord-005478-5iu38pr6	3504	8	Cy	Cy	NNP
cord-005478-5iu38pr6	3504	9	/	/	SYM
cord-005478-5iu38pr6	3504	10	Eto	Eto	NNP
cord-005478-5iu38pr6	3504	11	)	)	-RRB-
cord-005478-5iu38pr6	3504	12	was	be	VBD
cord-005478-5iu38pr6	3504	13	the	the	DT
cord-005478-5iu38pr6	3504	14	most	most	RBS
cord-005478-5iu38pr6	3504	15	frequently	frequently	RB
cord-005478-5iu38pr6	3504	16	applied	apply	VBN
cord-005478-5iu38pr6	3504	17	CHT	CHT	NNP
cord-005478-5iu38pr6	3504	18	-	-	HYPH
cord-005478-5iu38pr6	3504	19	regimen	regimen	NN
cord-005478-5iu38pr6	3504	20	in	in	IN
cord-005478-5iu38pr6	3504	21	CR1	CR1	NNP
cord-005478-5iu38pr6	3504	22	(	(	-LRB-
cord-005478-5iu38pr6	3504	23	66	66	CD
cord-005478-5iu38pr6	3504	24	(	(	-LRB-
cord-005478-5iu38pr6	3504	25	31	31	CD
cord-005478-5iu38pr6	3504	26	%	%	NN
cord-005478-5iu38pr6	3504	27	)	)	-RRB-
cord-005478-5iu38pr6	3504	28	)	)	-RRB-
cord-005478-5iu38pr6	3504	29	and	and	CC
cord-005478-5iu38pr6	3504	30	Bu	Bu	NNP
cord-005478-5iu38pr6	3504	31	/	/	SYM
cord-005478-5iu38pr6	3504	32	Cy	Cy	NNP
cord-005478-5iu38pr6	3504	33	in	in	IN
cord-005478-5iu38pr6	3504	34	CR2	CR2	NNP
cord-005478-5iu38pr6	3504	35	(	(	-LRB-
cord-005478-5iu38pr6	3504	36	68	68	CD
cord-005478-5iu38pr6	3504	37	(	(	-LRB-
cord-005478-5iu38pr6	3504	38	32	32	CD
cord-005478-5iu38pr6	3504	39	%	%	NN
cord-005478-5iu38pr6	3504	40	)	)	-RRB-
cord-005478-5iu38pr6	3504	41	)	)	-RRB-
cord-005478-5iu38pr6	3504	42	.	.	.
cord-005478-5iu38pr6	3505	1	The	the	DT
cord-005478-5iu38pr6	3505	2	remaining	remain	VBG
cord-005478-5iu38pr6	3505	3	conditionings	conditioning	NNS
cord-005478-5iu38pr6	3505	4	Bu/	Bu/	NNP
cord-005478-5iu38pr6	3506	1	Cy	Cy	NNP
cord-005478-5iu38pr6	3506	2	(	(	-LRB-
cord-005478-5iu38pr6	3506	3	68	68	CD
cord-005478-5iu38pr6	3506	4	)	)	-RRB-
cord-005478-5iu38pr6	3506	5	or	or	CC
cord-005478-5iu38pr6	3506	6	other	other	JJ
cord-005478-5iu38pr6	3506	7	-	-	HYPH
cord-005478-5iu38pr6	3506	8	chemo	chemo	NN
cord-005478-5iu38pr6	3506	9	(	(	-LRB-
cord-005478-5iu38pr6	3506	10	143	143	CD
cord-005478-5iu38pr6	3506	11	)	)	-RRB-
cord-005478-5iu38pr6	3506	12	with	with	IN
cord-005478-5iu38pr6	3506	13	median	median	JJ
cord-005478-5iu38pr6	3506	14	-	-	HYPH
cord-005478-5iu38pr6	3506	15	FU	fu	NN
cord-005478-5iu38pr6	3506	16	of	of	IN
cord-005478-5iu38pr6	3506	17	6.2	6.2	CD
cord-005478-5iu38pr6	3506	18	,	,	,
cord-005478-5iu38pr6	3506	19	5.2	5.2	CD
cord-005478-5iu38pr6	3506	20	and	and	CC
cord-005478-5iu38pr6	3506	21	5.8	5.8	CD
cord-005478-5iu38pr6	3506	22	y.	y.	NN
cord-005478-5iu38pr6	3507	1	In	in	IN
cord-005478-5iu38pr6	3507	2	weighted	weighted	JJ
cord-005478-5iu38pr6	3507	3	univariate	univariate	JJ
cord-005478-5iu38pr6	3507	4	analysis	analysis	NN
cord-005478-5iu38pr6	3507	5	,	,	,
cord-005478-5iu38pr6	3507	6	5-y	5-y	CD
cord-005478-5iu38pr6	3507	7	-	-	HYPH
cord-005478-5iu38pr6	3507	8	OS	OS	NNP
cord-005478-5iu38pr6	3507	9	was	be	VBD
cord-005478-5iu38pr6	3507	10	31.1	31.1	CD
cord-005478-5iu38pr6	3507	11	%	%	NN
cord-005478-5iu38pr6	3507	12	after	after	IN
cord-005478-5iu38pr6	3507	13	other	other	JJ
cord-005478-5iu38pr6	3507	14	-	-	HYPH
cord-005478-5iu38pr6	3507	15	chemo	chemo	NN
cord-005478-5iu38pr6	3507	16	,	,	,
cord-005478-5iu38pr6	3507	17	43.5	43.5	CD
cord-005478-5iu38pr6	3507	18	%	%	NN
cord-005478-5iu38pr6	3507	19	after	after	IN
cord-005478-5iu38pr6	3507	20	Bu	Bu	NNP
cord-005478-5iu38pr6	3507	21	/	/	SYM
cord-005478-5iu38pr6	3507	22	Cy	Cy	NNP
cord-005478-5iu38pr6	3507	23	and	and	CC
cord-005478-5iu38pr6	3507	24	58.8	58.8	CD
cord-005478-5iu38pr6	3507	25	%	%	NN
cord-005478-5iu38pr6	3507	26	after	after	IN
cord-005478-5iu38pr6	3507	27	fTBI	ftbi	NN
cord-005478-5iu38pr6	3507	28	.	.	.
cord-005478-5iu38pr6	3508	1	In	in	IN
cord-005478-5iu38pr6	3508	2	weighted	weighted	JJ
cord-005478-5iu38pr6	3508	3	Cox	Cox	NNP
cord-005478-5iu38pr6	3508	4	-	-	HYPH
cord-005478-5iu38pr6	3508	5	model	model	NN
cord-005478-5iu38pr6	3508	6	,	,	,
cord-005478-5iu38pr6	3508	7	pts	pts	NNP
cord-005478-5iu38pr6	3508	8	having	have	VBG
cord-005478-5iu38pr6	3508	9	received	receive	VBN
cord-005478-5iu38pr6	3508	10	other	other	JJ
cord-005478-5iu38pr6	3508	11	-	-	HYPH
cord-005478-5iu38pr6	3508	12	chemo	chemo	NN
cord-005478-5iu38pr6	3508	13	had	have	VBD
cord-005478-5iu38pr6	3508	14	a	a	DT
cord-005478-5iu38pr6	3508	15	higher	high	JJR
cord-005478-5iu38pr6	3508	16	risk	risk	NN
cord-005478-5iu38pr6	3508	17	to	to	TO
cord-005478-5iu38pr6	3508	18	experience	experience	VB
cord-005478-5iu38pr6	3508	19	an	an	DT
cord-005478-5iu38pr6	3508	20	event	event	NN
cord-005478-5iu38pr6	3508	21	compared	compare	VBN
cord-005478-5iu38pr6	3508	22	to	to	IN
cord-005478-5iu38pr6	3508	23	fTBI	fTBI	NNP
cord-005478-5iu38pr6	3508	24	(	(	-LRB-
cord-005478-5iu38pr6	3508	25	HR=2.00	HR=2.00	NNP
cord-005478-5iu38pr6	3508	26	,	,	,
cord-005478-5iu38pr6	3508	27	P=	P=	NNP
cord-005478-5iu38pr6	3508	28	<	<	XX
cord-005478-5iu38pr6	3508	29	.0001	.0001	NNP
cord-005478-5iu38pr6	3508	30	)	)	-RRB-
cord-005478-5iu38pr6	3508	31	.	.	.
cord-005478-5iu38pr6	3509	1	5-y	5-y	CD
cord-005478-5iu38pr6	3509	2	-	-	HYPH
cord-005478-5iu38pr6	3509	3	LFS	LFS	NNP
cord-005478-5iu38pr6	3509	4	was	be	VBD
cord-005478-5iu38pr6	3509	5	25	25	CD
cord-005478-5iu38pr6	3509	6	Coxmodel	Coxmodel	NNP
cord-005478-5iu38pr6	3509	7	,	,	,
cord-005478-5iu38pr6	3509	8	pts	pt	NNS
cord-005478-5iu38pr6	3509	9	having	have	VBG
cord-005478-5iu38pr6	3509	10	received	receive	VBN
cord-005478-5iu38pr6	3509	11	Bu	Bu	NNP
cord-005478-5iu38pr6	3509	12	/	/	SYM
cord-005478-5iu38pr6	3509	13	Cy	Cy	NNP
cord-005478-5iu38pr6	3509	14	and	and	CC
cord-005478-5iu38pr6	3509	15	other	other	JJ
cord-005478-5iu38pr6	3509	16	-	-	HYPH
cord-005478-5iu38pr6	3509	17	chemo	chemo	NN
cord-005478-5iu38pr6	3509	18	had	have	VBD
cord-005478-5iu38pr6	3509	19	a	a	DT
cord-005478-5iu38pr6	3509	20	higher	high	JJR
cord-005478-5iu38pr6	3509	21	risk	risk	NN
cord-005478-5iu38pr6	3509	22	to	to	TO
cord-005478-5iu38pr6	3509	23	experience	experience	VB
cord-005478-5iu38pr6	3509	24	an	an	DT
cord-005478-5iu38pr6	3509	25	event	event	NN
cord-005478-5iu38pr6	3509	26	compared	compare	VBN
cord-005478-5iu38pr6	3509	27	to	to	IN
cord-005478-5iu38pr6	3510	1	fTBI	fTBI	NNP
cord-005478-5iu38pr6	3510	2	(	(	-LRB-
cord-005478-5iu38pr6	3510	3	HR=2.06	hr=2.06	UH
cord-005478-5iu38pr6	3510	4	,	,	,
cord-005478-5iu38pr6	3510	5	P=.006	P=.006	NNS
cord-005478-5iu38pr6	3510	6	;	;	:
cord-005478-5iu38pr6	3510	7	HR=2.13	HR=2.13	NNP
cord-005478-5iu38pr6	3510	8	,	,	,
cord-005478-5iu38pr6	3510	9	P	p	NN
cord-005478-5iu38pr6	3510	10	<	<	XX
cord-005478-5iu38pr6	3510	11	.0001	.0001	XX
cord-005478-5iu38pr6	3510	12	)	)	-RRB-
cord-005478-5iu38pr6	3510	13	.	.	.
cord-005478-5iu38pr6	3511	1	5-y	5-y	CD
cord-005478-5iu38pr6	3511	2	-	-	HYPH
cord-005478-5iu38pr6	3511	3	NRM	NRM	NNP
cord-005478-5iu38pr6	3511	4	(	(	-LRB-
cord-005478-5iu38pr6	3511	5	range	range	NN
cord-005478-5iu38pr6	3511	6	:	:	:
cord-005478-5iu38pr6	3511	7	18.3	18.3	CD
cord-005478-5iu38pr6	3511	8	%	%	NN
cord-005478-5iu38pr6	3511	9	(	(	-LRB-
cord-005478-5iu38pr6	3511	10	BuCy	BuCy	NNP
cord-005478-5iu38pr6	3511	11	)	)	-RRB-
cord-005478-5iu38pr6	3511	12	to	to	IN
cord-005478-5iu38pr6	3511	13	21.1	21.1	CD
cord-005478-5iu38pr6	3511	14	%	%	NN
cord-005478-5iu38pr6	3511	15	(	(	-LRB-
cord-005478-5iu38pr6	3511	16	other	other	JJ
cord-005478-5iu38pr6	3511	17	-	-	HYPH
cord-005478-5iu38pr6	3511	18	chemo	chemo	NN
cord-005478-5iu38pr6	3511	19	)	)	-RRB-
cord-005478-5iu38pr6	3511	20	)	)	-RRB-
cord-005478-5iu38pr6	3511	21	did	do	VBD
cord-005478-5iu38pr6	3511	22	not	not	RB
cord-005478-5iu38pr6	3511	23	show	show	VB
cord-005478-5iu38pr6	3511	24	significant	significant	JJ
cord-005478-5iu38pr6	3511	25	differences	difference	NNS
cord-005478-5iu38pr6	3511	26	in	in	IN
cord-005478-5iu38pr6	3511	27	weighted	weighted	JJ
cord-005478-5iu38pr6	3511	28	Cox	Cox	NNP
cord-005478-5iu38pr6	3511	29	-	-	HYPH
cord-005478-5iu38pr6	3511	30	model	model	NN
cord-005478-5iu38pr6	3511	31	.	.	.
cord-005478-5iu38pr6	3512	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3512	2	:	:	:
cord-005478-5iu38pr6	3513	1	This	this	DT
cord-005478-5iu38pr6	3513	2	recent	recent	JJ
cord-005478-5iu38pr6	3513	3	study	study	NN
cord-005478-5iu38pr6	3513	4	-	-	HYPH
cord-005478-5iu38pr6	3513	5	update	update	NN
cord-005478-5iu38pr6	3513	6	ensured	ensure	VBD
cord-005478-5iu38pr6	3513	7	a	a	DT
cord-005478-5iu38pr6	3513	8	substantial	substantial	JJ
cord-005478-5iu38pr6	3513	9	FU	fu	NN
cord-005478-5iu38pr6	3513	10	.	.	.
cord-005478-5iu38pr6	3514	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3514	2	confirmed	confirm	VBD
cord-005478-5iu38pr6	3514	3	the	the	DT
cord-005478-5iu38pr6	3514	4	clear	clear	JJ
cord-005478-5iu38pr6	3514	5	superiority	superiority	NN
cord-005478-5iu38pr6	3514	6	of	of	IN
cord-005478-5iu38pr6	3514	7	fTBIconditioning	ftbiconditione	VBG
cord-005478-5iu38pr6	3514	8	compared	compare	VBN
cord-005478-5iu38pr6	3514	9	to	to	IN
cord-005478-5iu38pr6	3514	10	CHT	CHT	NNP
cord-005478-5iu38pr6	3514	11	with	with	IN
cord-005478-5iu38pr6	3514	12	regard	regard	NN
cord-005478-5iu38pr6	3514	13	of	of	IN
cord-005478-5iu38pr6	3514	14	LFS	LFS	NNP
cord-005478-5iu38pr6	3514	15	and	and	CC
cord-005478-5iu38pr6	3514	16	RI	RI	NNP
cord-005478-5iu38pr6	3514	17	for	for	IN
cord-005478-5iu38pr6	3515	1	ALL	all	DT
cord-005478-5iu38pr6	3515	2	-	-	HYPH
cord-005478-5iu38pr6	3515	3	pts	pts	NN
cord-005478-5iu38pr6	3515	4	undergoing	undergo	VBG
cord-005478-5iu38pr6	3515	5	allo	allo	NN
cord-005478-5iu38pr6	3515	6	-	-	HYPH
cord-005478-5iu38pr6	3515	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3515	8	in	in	IN
cord-005478-5iu38pr6	3515	9	CR2	CR2	NNP
cord-005478-5iu38pr6	3515	10	.	.	.
cord-005478-5iu38pr6	3516	1	For	for	IN
cord-005478-5iu38pr6	3516	2	pts	pt	NNS
cord-005478-5iu38pr6	3516	3	in	in	IN
cord-005478-5iu38pr6	3516	4	CR1	CR1	NNP
cord-005478-5iu38pr6	3516	5	we	-PRON-	PRP
cord-005478-5iu38pr6	3516	6	could	could	MD
cord-005478-5iu38pr6	3516	7	not	not	RB
cord-005478-5iu38pr6	3516	8	find	find	VB
cord-005478-5iu38pr6	3516	9	significant	significant	JJ
cord-005478-5iu38pr6	3516	10	differences	difference	NNS
cord-005478-5iu38pr6	3516	11	between	between	IN
cord-005478-5iu38pr6	3516	12	fTBI	ftbi	NN
cord-005478-5iu38pr6	3516	13	and	and	CC
cord-005478-5iu38pr6	3516	14	CHT	CHT	NNP
cord-005478-5iu38pr6	3516	15	-	-	HYPH
cord-005478-5iu38pr6	3516	16	conditioning	conditioning	NN
cord-005478-5iu38pr6	3516	17	.	.	.
cord-005478-5iu38pr6	3517	1	These	these	DT
cord-005478-5iu38pr6	3517	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3517	3	findings	finding	NNS
cord-005478-5iu38pr6	3517	4	are	be	VBP
cord-005478-5iu38pr6	3517	5	currently	currently	RB
cord-005478-5iu38pr6	3517	6	re	re	VBN
cord-005478-5iu38pr6	3517	7	with	with	IN
cord-005478-5iu38pr6	3517	8	Data	Data	NNP
cord-005478-5iu38pr6	3517	9	Monitoring	Monitoring	NNP
cord-005478-5iu38pr6	3517	10	Committee	Committee	NNP
cord-005478-5iu38pr6	3517	11	(	(	-LRB-
cord-005478-5iu38pr6	3517	12	DMC	DMC	NNP
cord-005478-5iu38pr6	3517	13	)	)	-RRB-
cord-005478-5iu38pr6	3517	14	review	review	NN
cord-005478-5iu38pr6	3517	15	after	after	IN
cord-005478-5iu38pr6	3517	16	each	each	DT
cord-005478-5iu38pr6	3517	17	cohort	cohort	NN
cord-005478-5iu38pr6	3517	18	.	.	.
cord-005478-5iu38pr6	3518	1	Part2	Part2	NNP
cord-005478-5iu38pr6	3518	2	will	will	MD
cord-005478-5iu38pr6	3518	3	include	include	VB
cord-005478-5iu38pr6	3518	4	177	177	CD
cord-005478-5iu38pr6	3518	5	patients	patient	NNS
cord-005478-5iu38pr6	3518	6	randomized	randomized	JJ
cord-005478-5iu38pr6	3518	7	2:1	2:1	CD
cord-005478-5iu38pr6	3518	8	.	.	.
cord-005478-5iu38pr6	3519	1	Results	result	NNS
cord-005478-5iu38pr6	3519	2	:	:	:
cord-005478-5iu38pr6	3520	1	Part1	Part1	NNS
cord-005478-5iu38pr6	3520	2	enrolled	enrol	VBD
cord-005478-5iu38pr6	3520	3	11	11	CD
cord-005478-5iu38pr6	3520	4	patients	patient	NNS
cord-005478-5iu38pr6	3520	5	,	,	,
cord-005478-5iu38pr6	3520	6	median	median	JJ
cord-005478-5iu38pr6	3520	7	age	age	NN
cord-005478-5iu38pr6	3521	1	Following	follow	VBG
cord-005478-5iu38pr6	3521	2	these	these	DT
cord-005478-5iu38pr6	3521	3	promising	promising	JJ
cord-005478-5iu38pr6	3521	4	results	result	NNS
cord-005478-5iu38pr6	3521	5	,	,	,
cord-005478-5iu38pr6	3521	6	DMC	DMC	NNP
cord-005478-5iu38pr6	3521	7	recommended	recommend	VBD
cord-005478-5iu38pr6	3521	8	early	early	JJ
cord-005478-5iu38pr6	3521	9	continuation	continuation	NN
cord-005478-5iu38pr6	3521	10	to	to	IN
cord-005478-5iu38pr6	3521	11	Part2	Part2	NNP
cord-005478-5iu38pr6	3521	12	of	of	IN
cord-005478-5iu38pr6	3521	13	the	the	DT
cord-005478-5iu38pr6	3521	14	Phase	Phase	NNP
cord-005478-5iu38pr6	3521	15	III	III	NNP
cord-005478-5iu38pr6	3521	16	trial	trial	NN
cord-005478-5iu38pr6	3521	17	.	.	.
cord-005478-5iu38pr6	3522	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3522	2	:	:	:
cord-005478-5iu38pr6	3523	1	The	the	DT
cord-005478-5iu38pr6	3523	2	GENESIS	GENESIS	NNP
cord-005478-5iu38pr6	3523	3	lead	lead	NN
cord-005478-5iu38pr6	3523	4	-	-	HYPH
cord-005478-5iu38pr6	3523	5	in	in	RP
cord-005478-5iu38pr6	3523	6	results	result	NNS
cord-005478-5iu38pr6	3523	7	demonstrate	demonstrate	VBP
cord-005478-5iu38pr6	3523	8	BL-8040	bl-8040	NN
cord-005478-5iu38pr6	3523	9	is	be	VBZ
cord-005478-5iu38pr6	3523	10	a	a	DT
cord-005478-5iu38pr6	3523	11	potent	potent	JJ
cord-005478-5iu38pr6	3523	12	mobilizer	mobilizer	NN
cord-005478-5iu38pr6	3523	13	of	of	IN
cord-005478-5iu38pr6	3523	14	HSCs	HSCs	NNP
cord-005478-5iu38pr6	3523	15	,	,	,
cord-005478-5iu38pr6	3523	16	with	with	IN
cord-005478-5iu38pr6	3523	17	potential	potential	NN
cord-005478-5iu38pr6	3523	18	to	to	TO
cord-005478-5iu38pr6	3523	19	improve	improve	VB
cord-005478-5iu38pr6	3523	20	mobilization	mobilization	NN
cord-005478-5iu38pr6	3523	21	rates	rate	NNS
cord-005478-5iu38pr6	3523	22	while	while	IN
cord-005478-5iu38pr6	3523	23	minimizing	minimize	VBG
cord-005478-5iu38pr6	3523	24	mobilizationrelated	mobilizationrelated	JJ
cord-005478-5iu38pr6	3523	25	healthcare	healthcare	NN
cord-005478-5iu38pr6	3523	26	costs	cost	NNS
cord-005478-5iu38pr6	3523	27	.	.	.
cord-005478-5iu38pr6	3524	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	3524	2	Trial	Trial	NNP
cord-005478-5iu38pr6	3524	3	Registry	Registry	NNP
cord-005478-5iu38pr6	3524	4	:	:	:
cord-005478-5iu38pr6	3525	1	NCT03246529	NCT03246529	NNP
cord-005478-5iu38pr6	3525	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	3525	3	:	:	:
cord-005478-5iu38pr6	3526	1	Hemda	Hemda	NNP
cord-005478-5iu38pr6	3526	2	Chen	Chen	NNP
cord-005478-5iu38pr6	3526	3	-Medical	-Medical	NNP
cord-005478-5iu38pr6	3526	4	Director	Director	NNP
cord-005478-5iu38pr6	3526	5	,	,	,
cord-005478-5iu38pr6	3526	6	BiolineRx	BiolineRx	NNP
cord-005478-5iu38pr6	3526	7	Abi	Abi	NNP
cord-005478-5iu38pr6	3526	8	Vainstin	Vainstin	NNP
cord-005478-5iu38pr6	3526	9	-VP	-VP	:
cord-005478-5iu38pr6	3526	10	of	of	IN
cord-005478-5iu38pr6	3526	11	medical	medical	JJ
cord-005478-5iu38pr6	3526	12	affairs	affair	NNS
cord-005478-5iu38pr6	3526	13	,	,	.
cord-005478-5iu38pr6	3527	1	BiolineRx	BiolineRx	NNP
cord-005478-5iu38pr6	3527	2	Ella	Ella	NNP
cord-005478-5iu38pr6	3527	3	Sorani	Sorani	NNP
cord-005478-5iu38pr6	3527	4	-	-	HYPH
cord-005478-5iu38pr6	3527	5	VP	VP	NNP
cord-005478-5iu38pr6	3527	6	of	of	IN
cord-005478-5iu38pr6	3527	7	R&D	R&D	NNP
cord-005478-5iu38pr6	3527	8	,	,	,
cord-005478-5iu38pr6	3528	1	BiolineRx	BiolineRx	NNP
cord-005478-5iu38pr6	3528	2	Osnat	Osnat	NNP
cord-005478-5iu38pr6	3528	3	Bohana	Bohana	NNP
cord-005478-5iu38pr6	3528	4	-	-	HYPH
cord-005478-5iu38pr6	3528	5	Kashtan	Kashtan	NNP
cord-005478-5iu38pr6	3528	6	-	-	HYPH
cord-005478-5iu38pr6	3528	7	project	project	NN
cord-005478-5iu38pr6	3528	8	manager	manager	NN
cord-005478-5iu38pr6	3528	9	Markus	Markus	NNP
cord-005478-5iu38pr6	3528	10	Y.	Y.	NNP
cord-005478-5iu38pr6	3528	11	Mapara	Mapara	NNP
cord-005478-5iu38pr6	3528	12	1	1	CD
cord-005478-5iu38pr6	3528	13	,	,	,
cord-005478-5iu38pr6	3528	14	John	John	NNP
cord-005478-5iu38pr6	3528	15	F.	F.	NNP
cord-005478-5iu38pr6	3528	16	Tisdale	Tisdale	NNP
cord-005478-5iu38pr6	3528	17	2	2	CD
cord-005478-5iu38pr6	3528	18	,	,	,
cord-005478-5iu38pr6	3528	19	Julie	Julie	NNP
cord-005478-5iu38pr6	3528	20	Kanter	Kanter	NNP
cord-005478-5iu38pr6	3528	21	3	3	CD
cord-005478-5iu38pr6	3528	22	,	,	,
cord-005478-5iu38pr6	3528	23	Janet	Janet	NNP
cord-005478-5iu38pr6	3528	24	L.	L.	NNP
cord-005478-5iu38pr6	3528	25	Kwiatkowski	Kwiatkowski	NNP
cord-005478-5iu38pr6	3528	26	4,5	4,5	CD
cord-005478-5iu38pr6	3528	27	,	,	,
cord-005478-5iu38pr6	3528	28	Lakshmanan	Lakshmanan	NNP
cord-005478-5iu38pr6	3528	29	Krishnamurti	Krishnamurti	NNP
cord-005478-5iu38pr6	3528	30	6	6	CD
cord-005478-5iu38pr6	3528	31	,	,	,
cord-005478-5iu38pr6	3528	32	Manfred	Manfred	NNP
cord-005478-5iu38pr6	3528	33	Schmidt	Schmidt	NNP
cord-005478-5iu38pr6	3528	34	7	7	CD
cord-005478-5iu38pr6	3528	35	,	,	,
cord-005478-5iu38pr6	3528	36	Alexandra	Alexandra	NNP
cord-005478-5iu38pr6	3528	37	L.	L.	NNP
cord-005478-5iu38pr6	3528	38	Miller	Miller	NNP
cord-005478-5iu38pr6	3528	39	8	8	CD
cord-005478-5iu38pr6	3528	40	,	,	,
cord-005478-5iu38pr6	3528	41	Francis	Francis	NNP
cord-005478-5iu38pr6	3528	42	J.	J.	NNP
cord-005478-5iu38pr6	3528	43	Pierciey	Pierciey	NNP
cord-005478-5iu38pr6	3528	44	Jr.	Jr.	NNP
cord-005478-5iu38pr6	3528	45	8	8	CD
cord-005478-5iu38pr6	3528	46	 	 	_SP
cord-005478-5iu38pr6	3529	1	Background	background	NN
cord-005478-5iu38pr6	3529	2	:	:	:
cord-005478-5iu38pr6	3530	1	pHLH	pHLH	NNP
cord-005478-5iu38pr6	3530	2	is	be	VBZ
cord-005478-5iu38pr6	3530	3	a	a	DT
cord-005478-5iu38pr6	3530	4	rare	rare	JJ
cord-005478-5iu38pr6	3530	5	,	,	,
cord-005478-5iu38pr6	3530	6	genetic	genetic	JJ
cord-005478-5iu38pr6	3530	7	,	,	,
cord-005478-5iu38pr6	3530	8	hyper	hyper	JJ
cord-005478-5iu38pr6	3530	9	-	-	JJ
cord-005478-5iu38pr6	3530	10	inflammatory	inflammatory	JJ
cord-005478-5iu38pr6	3530	11	syndrome	syndrome	NN
cord-005478-5iu38pr6	3530	12	driven	drive	VBN
cord-005478-5iu38pr6	3530	13	by	by	IN
cord-005478-5iu38pr6	3530	14	high	high	JJ
cord-005478-5iu38pr6	3530	15	production	production	NN
cord-005478-5iu38pr6	3530	16	of	of	IN
cord-005478-5iu38pr6	3530	17	interferon	interferon	NN
cord-005478-5iu38pr6	3530	18	(	(	-LRB-
cord-005478-5iu38pr6	3530	19	IFN)-γ	ifn)-γ	NN
cord-005478-5iu38pr6	3530	20	.	.	.
cord-005478-5iu38pr6	3531	1	Emapalumab	Emapalumab	NNP
cord-005478-5iu38pr6	3531	2	(	(	-LRB-
cord-005478-5iu38pr6	3531	3	NI-0501	NI-0501	NNP
cord-005478-5iu38pr6	3531	4	)	)	-RRB-
cord-005478-5iu38pr6	3531	5	is	be	VBZ
cord-005478-5iu38pr6	3531	6	a	a	DT
cord-005478-5iu38pr6	3531	7	monoclonal	monoclonal	JJ
cord-005478-5iu38pr6	3531	8	antibody	antibody	NN
cord-005478-5iu38pr6	3531	9	that	that	WDT
cord-005478-5iu38pr6	3531	10	neutralizes	neutralize	VBZ
cord-005478-5iu38pr6	3531	11	IFN	IFN	NNP
cord-005478-5iu38pr6	3531	12	-	-	HYPH
cord-005478-5iu38pr6	3531	13	γ	γ	NNP
cord-005478-5iu38pr6	3531	14	and	and	CC
cord-005478-5iu38pr6	3531	15	is	be	VBZ
cord-005478-5iu38pr6	3531	16	developed	develop	VBN
cord-005478-5iu38pr6	3531	17	as	as	IN
cord-005478-5iu38pr6	3531	18	a	a	DT
cord-005478-5iu38pr6	3531	19	treatment	treatment	NN
cord-005478-5iu38pr6	3531	20	for	for	IN
cord-005478-5iu38pr6	3531	21	HLH.Methods	hlh.method	NNS
cord-005478-5iu38pr6	3531	22	:	:	:
cord-005478-5iu38pr6	3532	1	This	this	DT
cord-005478-5iu38pr6	3532	2	open	open	JJ
cord-005478-5iu38pr6	3532	3	-	-	HYPH
cord-005478-5iu38pr6	3532	4	label	label	NN
cord-005478-5iu38pr6	3532	5	phase	phase	NN
cord-005478-5iu38pr6	3532	6	2/3	2/3	CD
cord-005478-5iu38pr6	3532	7	study	study	NN
cord-005478-5iu38pr6	3532	8	(	(	-LRB-
cord-005478-5iu38pr6	3532	9	NCT01818492	NCT01818492	NNP
cord-005478-5iu38pr6	3532	10	,	,	,
cord-005478-5iu38pr6	3532	11	data	datum	NNS
cord-005478-5iu38pr6	3532	12	cut	cut	VBN
cord-005478-5iu38pr6	3532	13	-	-	HYPH
cord-005478-5iu38pr6	3532	14	off	off	NN
cord-005478-5iu38pr6	3532	15	is	be	VBZ
cord-005478-5iu38pr6	3532	16	July	July	NNP
cord-005478-5iu38pr6	3532	17	20	20	CD
cord-005478-5iu38pr6	3532	18	2017	2017	CD
cord-005478-5iu38pr6	3532	19	)	)	-RRB-
cord-005478-5iu38pr6	3532	20	includes	include	VBZ
cord-005478-5iu38pr6	3532	21	34	34	CD
cord-005478-5iu38pr6	3532	22	patients	patient	NNS
cord-005478-5iu38pr6	3532	23	≤18	≤18	NNP
cord-005478-5iu38pr6	3532	24	years	year	NNS
cord-005478-5iu38pr6	3532	25	old	old	JJ
cord-005478-5iu38pr6	3532	26	with	with	IN
cord-005478-5iu38pr6	3532	27	pHLH	pHLH	VBG
cord-005478-5iu38pr6	3532	28	based	base	VBN
cord-005478-5iu38pr6	3532	29	on	on	IN
cord-005478-5iu38pr6	3532	30	genetic	genetic	JJ
cord-005478-5iu38pr6	3532	31	confirmation	confirmation	NN
cord-005478-5iu38pr6	3532	32	,	,	,
cord-005478-5iu38pr6	3532	33	family	family	NN
cord-005478-5iu38pr6	3532	34	history	history	NN
cord-005478-5iu38pr6	3532	35	,	,	,
cord-005478-5iu38pr6	3532	36	or	or	CC
cord-005478-5iu38pr6	3532	37	presence	presence	NN
cord-005478-5iu38pr6	3532	38	of	of	IN
cord-005478-5iu38pr6	3532	39	≥5/8	≥5/8	NNP
cord-005478-5iu38pr6	3532	40	HLH-2004	HLH-2004	NNP
cord-005478-5iu38pr6	3532	41	diagnostic	diagnostic	JJ
cord-005478-5iu38pr6	3532	42	criteria	criterion	NNS
cord-005478-5iu38pr6	3532	43	.	.	.
cord-005478-5iu38pr6	3533	1	Patients	patient	NNS
cord-005478-5iu38pr6	3533	2	were	be	VBD
cord-005478-5iu38pr6	3533	3	treatment	treatment	NN
cord-005478-5iu38pr6	3533	4	-	-	HYPH
cord-005478-5iu38pr6	3533	5	naïve	naïve	JJ
cord-005478-5iu38pr6	3533	6	(	(	-LRB-
cord-005478-5iu38pr6	3533	7	7	7	CD
cord-005478-5iu38pr6	3533	8	)	)	-RRB-
cord-005478-5iu38pr6	3533	9	or	or	CC
cord-005478-5iu38pr6	3533	10	had	have	VBD
cord-005478-5iu38pr6	3533	11	failed	fail	VBN
cord-005478-5iu38pr6	3533	12	previous	previous	JJ
cord-005478-5iu38pr6	3533	13	conventional	conventional	JJ
cord-005478-5iu38pr6	3533	14	HLH	HLH	NNP
cord-005478-5iu38pr6	3533	15	therapies	therapy	NNS
cord-005478-5iu38pr6	3533	16	(	(	-LRB-
cord-005478-5iu38pr6	3533	17	27	27	CD
cord-005478-5iu38pr6	3533	18	)	)	-RRB-
cord-005478-5iu38pr6	3533	19	.	.	.
cord-005478-5iu38pr6	3534	1	Emapalumab	Emapalumab	NNP
cord-005478-5iu38pr6	3534	2	(	(	-LRB-
cord-005478-5iu38pr6	3534	3	1	1	CD
cord-005478-5iu38pr6	3534	4	mg	mg	NNP
cord-005478-5iu38pr6	3534	5	/	/	SYM
cord-005478-5iu38pr6	3534	6	kg	kg	CC
cord-005478-5iu38pr6	3534	7	intravenously	intravenously	RB
cord-005478-5iu38pr6	3534	8	every	every	DT
cord-005478-5iu38pr6	3534	9	3	3	CD
cord-005478-5iu38pr6	3534	10	-	-	SYM
cord-005478-5iu38pr6	3534	11	4	4	CD
cord-005478-5iu38pr6	3534	12	days	day	NNS
cord-005478-5iu38pr6	3534	13	,	,	,
cord-005478-5iu38pr6	3534	14	increased	increase	VBD
cord-005478-5iu38pr6	3534	15	up	up	IN
cord-005478-5iu38pr6	3534	16	to	to	TO
cord-005478-5iu38pr6	3534	17	10	10	CD
cord-005478-5iu38pr6	3534	18	mg	mg	NN
cord-005478-5iu38pr6	3534	19	/	/	SYM
cord-005478-5iu38pr6	3534	20	kg	kg	NNS
cord-005478-5iu38pr6	3534	21	based	base	VBN
cord-005478-5iu38pr6	3534	22	on	on	IN
cord-005478-5iu38pr6	3534	23	clinical	clinical	JJ
cord-005478-5iu38pr6	3534	24	and	and	CC
cord-005478-5iu38pr6	3534	25	laboratory	laboratory	NN
cord-005478-5iu38pr6	3534	26	response	response	NN
cord-005478-5iu38pr6	3534	27	parameters	parameter	NNS
cord-005478-5iu38pr6	3534	28	)	)	-RRB-
cord-005478-5iu38pr6	3534	29	was	be	VBD
cord-005478-5iu38pr6	3534	30	administered	administer	VBN
cord-005478-5iu38pr6	3534	31	with	with	IN
cord-005478-5iu38pr6	3534	32	dexamethasone	dexamethasone	NN
cord-005478-5iu38pr6	3534	33	(	(	-LRB-
cord-005478-5iu38pr6	3534	34	5	5	CD
cord-005478-5iu38pr6	3534	35	-	-	SYM
cord-005478-5iu38pr6	3534	36	10	10	CD
cord-005478-5iu38pr6	3534	37	mg	mg	NNP
cord-005478-5iu38pr6	3534	38	/	/	SYM
cord-005478-5iu38pr6	3534	39	m	m	NN
cord-005478-5iu38pr6	3534	40	2	2	CD
cord-005478-5iu38pr6	3534	41	/day	/day	.
cord-005478-5iu38pr6	3534	42	with	with	IN
cord-005478-5iu38pr6	3534	43	tapering	taper	VBG
cord-005478-5iu38pr6	3534	44	permitted	permit	VBN
cord-005478-5iu38pr6	3534	45	)	)	-RRB-
cord-005478-5iu38pr6	3534	46	.	.	.
cord-005478-5iu38pr6	3535	1	Treatment	treatment	NN
cord-005478-5iu38pr6	3535	2	duration	duration	NN
cord-005478-5iu38pr6	3535	3	was	be	VBD
cord-005478-5iu38pr6	3535	4	8	8	CD
cord-005478-5iu38pr6	3535	5	weeks	week	NNS
cord-005478-5iu38pr6	3535	6	with	with	IN
cord-005478-5iu38pr6	3535	7	possible	possible	JJ
cord-005478-5iu38pr6	3535	8	shortening	shortening	NN
cord-005478-5iu38pr6	3535	9	to	to	IN
cord-005478-5iu38pr6	3535	10	a	a	DT
cord-005478-5iu38pr6	3535	11	minimum	minimum	NN
cord-005478-5iu38pr6	3535	12	of	of	IN
cord-005478-5iu38pr6	3535	13	4	4	CD
cord-005478-5iu38pr6	3535	14	weeks	week	NNS
cord-005478-5iu38pr6	3535	15	or	or	CC
cord-005478-5iu38pr6	3535	16	extension	extension	VB
cord-005478-5iu38pr6	3535	17	up	up	RP
cord-005478-5iu38pr6	3535	18	to	to	IN
cord-005478-5iu38pr6	3535	19	allogeneic	allogeneic	VB
cord-005478-5iu38pr6	3535	20	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3535	21	stem	stem	NN
cord-005478-5iu38pr6	3535	22	cell	cell	NN
cord-005478-5iu38pr6	3535	23	transplantation	transplantation	NN
cord-005478-5iu38pr6	3535	24	(	(	-LRB-
cord-005478-5iu38pr6	3535	25	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3535	26	)	)	-RRB-
cord-005478-5iu38pr6	3535	27	.	.	.
cord-005478-5iu38pr6	3536	1	The	the	DT
cord-005478-5iu38pr6	3536	2	primary	primary	JJ
cord-005478-5iu38pr6	3536	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	3536	4	,	,	,
cord-005478-5iu38pr6	3536	5	Overall	overall	JJ
cord-005478-5iu38pr6	3536	6	Response	response	NN
cord-005478-5iu38pr6	3536	7	Rate	rate	NN
cord-005478-5iu38pr6	3536	8	(	(	-LRB-
cord-005478-5iu38pr6	3536	9	ORR	ORR	NNP
cord-005478-5iu38pr6	3536	10	)	)	-RRB-
cord-005478-5iu38pr6	3536	11	,	,	,
cord-005478-5iu38pr6	3536	12	was	be	VBD
cord-005478-5iu38pr6	3536	13	objectively	objectively	RB
cord-005478-5iu38pr6	3536	14	assessed	assess	VBN
cord-005478-5iu38pr6	3536	15	based	base	VBN
cord-005478-5iu38pr6	3536	16	on	on	IN
cord-005478-5iu38pr6	3536	17	normalization	normalization	NN
cord-005478-5iu38pr6	3536	18	or	or	CC
cord-005478-5iu38pr6	3536	19	≥50	≥50	DT
cord-005478-5iu38pr6	3536	20	%	%	NN
cord-005478-5iu38pr6	3536	21	improvement	improvement	NN
cord-005478-5iu38pr6	3536	22	in	in	IN
cord-005478-5iu38pr6	3536	23	pre	pre	JJ
cord-005478-5iu38pr6	3536	24	-	-	JJ
cord-005478-5iu38pr6	3536	25	defined	define	VBN
cord-005478-5iu38pr6	3536	26	criteria	criterion	NNS
cord-005478-5iu38pr6	3536	27	:	:	:
cord-005478-5iu38pr6	3536	28	fever	fever	NN
cord-005478-5iu38pr6	3536	29	,	,	,
cord-005478-5iu38pr6	3536	30	splenomegaly	splenomegaly	NN
cord-005478-5iu38pr6	3536	31	,	,	,
cord-005478-5iu38pr6	3536	32	cytopenias	cytopenias	NNP
cord-005478-5iu38pr6	3536	33	,	,	,
cord-005478-5iu38pr6	3536	34	hyperferritinemia	hyperferritinemia	NNP
cord-005478-5iu38pr6	3536	35	,	,	,
cord-005478-5iu38pr6	3536	36	fibrinogen	fibrinogen	NN
cord-005478-5iu38pr6	3536	37	and/or	and/or	CC
cord-005478-5iu38pr6	3536	38	D	D	NNP
cord-005478-5iu38pr6	3536	39	-	-	HYPH
cord-005478-5iu38pr6	3536	40	Dimer	Dimer	NNP
cord-005478-5iu38pr6	3536	41	levels	level	NNS
cord-005478-5iu38pr6	3536	42	,	,	,
cord-005478-5iu38pr6	3536	43	central	central	JJ
cord-005478-5iu38pr6	3536	44	nervous	nervous	JJ
cord-005478-5iu38pr6	3536	45	system	system	NN
cord-005478-5iu38pr6	3536	46	(	(	-LRB-
cord-005478-5iu38pr6	3536	47	CNS	CNS	NNP
cord-005478-5iu38pr6	3536	48	)	)	-RRB-
cord-005478-5iu38pr6	3536	49	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	3536	50	,	,	,
cord-005478-5iu38pr6	3536	51	with	with	IN
cord-005478-5iu38pr6	3536	52	no	no	DT
cord-005478-5iu38pr6	3536	53	sustained	sustain	VBN
cord-005478-5iu38pr6	3536	54	worsening	worsening	NN
cord-005478-5iu38pr6	3536	55	of	of	IN
cord-005478-5iu38pr6	3536	56	sCD25	scd25	JJ
cord-005478-5iu38pr6	3536	57	levels	level	NNS
cord-005478-5iu38pr6	3536	58	.	.	.
cord-005478-5iu38pr6	3537	1	An	an	DT
cord-005478-5iu38pr6	3537	2	exact	exact	JJ
cord-005478-5iu38pr6	3537	3	binomial	binomial	JJ
cord-005478-5iu38pr6	3537	4	test	test	NN
cord-005478-5iu38pr6	3537	5	at	at	IN
cord-005478-5iu38pr6	3537	6	one	one	CD
cord-005478-5iu38pr6	3537	7	-	-	HYPH
cord-005478-5iu38pr6	3537	8	sided	side	VBN
cord-005478-5iu38pr6	3537	9	0.025	0.025	CD
cord-005478-5iu38pr6	3537	10	significance	significance	NN
cord-005478-5iu38pr6	3537	11	level	level	NN
cord-005478-5iu38pr6	3537	12	was	be	VBD
cord-005478-5iu38pr6	3537	13	used	use	VBN
cord-005478-5iu38pr6	3537	14	to	to	TO
cord-005478-5iu38pr6	3537	15	evaluate	evaluate	VB
cord-005478-5iu38pr6	3537	16	the	the	DT
cord-005478-5iu38pr6	3537	17	null	null	JJ
cord-005478-5iu38pr6	3537	18	hypothesis	hypothesis	NN
cord-005478-5iu38pr6	3537	19	that	that	WDT
cord-005478-5iu38pr6	3537	20	ORR	ORR	NNP
cord-005478-5iu38pr6	3537	21	be	be	VB
cord-005478-5iu38pr6	3537	22	at	at	RB
cord-005478-5iu38pr6	3537	23	most	most	RBS
cord-005478-5iu38pr6	3537	24	40	40	CD
cord-005478-5iu38pr6	3537	25	%	%	NN
cord-005478-5iu38pr6	3537	26	.	.	.
cord-005478-5iu38pr6	3538	1	Following	follow	VBG
cord-005478-5iu38pr6	3538	2	completion	completion	NN
cord-005478-5iu38pr6	3538	3	of	of	IN
cord-005478-5iu38pr6	3538	4	the	the	DT
cord-005478-5iu38pr6	3538	5	study	study	NN
cord-005478-5iu38pr6	3538	6	,	,	,
cord-005478-5iu38pr6	3538	7	patients	patient	NNS
cord-005478-5iu38pr6	3538	8	entered	enter	VBD
cord-005478-5iu38pr6	3538	9	an	an	DT
cord-005478-5iu38pr6	3538	10	extension	extension	NN
cord-005478-5iu38pr6	3538	11	phase	phase	NN
cord-005478-5iu38pr6	3538	12	(	(	-LRB-
cord-005478-5iu38pr6	3538	13	NCT02069899).Results	nct02069899).results	NN
cord-005478-5iu38pr6	3538	14	:	:	:
cord-005478-5iu38pr6	3538	15	Patients	patient	NNS
cord-005478-5iu38pr6	3538	16	(	(	-LRB-
cord-005478-5iu38pr6	3538	17	median	median	JJ
cord-005478-5iu38pr6	3538	18	age	age	NN
cord-005478-5iu38pr6	3538	19	1.0	1.0	CD
cord-005478-5iu38pr6	3538	20	yr	yr	NN
cord-005478-5iu38pr6	3538	21	,	,	,
cord-005478-5iu38pr6	3538	22	range	range	VBP
cord-005478-5iu38pr6	3538	23	0.1	0.1	CD
cord-005478-5iu38pr6	3538	24	-	-	SYM
cord-005478-5iu38pr6	3538	25	13	13	CD
cord-005478-5iu38pr6	3538	26	yr	yr	NN
cord-005478-5iu38pr6	3538	27	)	)	-RRB-
cord-005478-5iu38pr6	3538	28	entered	enter	VBD
cord-005478-5iu38pr6	3538	29	the	the	DT
cord-005478-5iu38pr6	3538	30	study	study	NN
cord-005478-5iu38pr6	3538	31	with	with	IN
cord-005478-5iu38pr6	3538	32	broad	broad	JJ
cord-005478-5iu38pr6	3538	33	spectrum	spectrum	NN
cord-005478-5iu38pr6	3538	34	of	of	IN
cord-005478-5iu38pr6	3538	35	pHLH	phlh	JJ
cord-005478-5iu38pr6	3538	36	clinical	clinical	JJ
cord-005478-5iu38pr6	3538	37	abnormalities	abnormality	NNS
cord-005478-5iu38pr6	3538	38	,	,	,
cord-005478-5iu38pr6	3538	39	>	>	XX
cord-005478-5iu38pr6	3538	40	30	30	CD
cord-005478-5iu38pr6	3538	41	%	%	NN
cord-005478-5iu38pr6	3538	42	with	with	IN
cord-005478-5iu38pr6	3538	43	CNS	CNS	NNP
cord-005478-5iu38pr6	3538	44	involvement	involvement	NN
cord-005478-5iu38pr6	3538	45	.	.	.
cord-005478-5iu38pr6	3539	1	Mutations	mutation	NNS
cord-005478-5iu38pr6	3539	2	in	in	IN
cord-005478-5iu38pr6	3539	3	pHLH	phlh	JJ
cord-005478-5iu38pr6	3539	4	-	-	JJ
cord-005478-5iu38pr6	3539	5	associated	associate	VBN
cord-005478-5iu38pr6	3539	6	genes	gene	NNS
cord-005478-5iu38pr6	3539	7	were	be	VBD
cord-005478-5iu38pr6	3539	8	present	present	JJ
cord-005478-5iu38pr6	3539	9	in	in	IN
cord-005478-5iu38pr6	3539	10	79	79	CD
cord-005478-5iu38pr6	3539	11	%	%	NN
cord-005478-5iu38pr6	3539	12	of	of	IN
cord-005478-5iu38pr6	3539	13	patients	patient	NNS
cord-005478-5iu38pr6	3539	14	.	.	.
cord-005478-5iu38pr6	3540	1	ORR	ORR	NNP
cord-005478-5iu38pr6	3540	2	was	be	VBD
cord-005478-5iu38pr6	3540	3	significantly	significantly	RB
cord-005478-5iu38pr6	3540	4	higher	high	JJR
cord-005478-5iu38pr6	3540	5	than	than	IN
cord-005478-5iu38pr6	3540	6	the	the	DT
cord-005478-5iu38pr6	3540	7	pre	pre	JJ
cord-005478-5iu38pr6	3540	8	-	-	JJ
cord-005478-5iu38pr6	3540	9	specified	specified	JJ
cord-005478-5iu38pr6	3540	10	null	null	NN
cord-005478-5iu38pr6	3540	11	hypothesis	hypothesis	NN
cord-005478-5iu38pr6	3540	12	,	,	,
cord-005478-5iu38pr6	3540	13	thus	thus	RB
cord-005478-5iu38pr6	3540	14	meeting	meet	VBG
cord-005478-5iu38pr6	3540	15	the	the	DT
cord-005478-5iu38pr6	3540	16	primary	primary	JJ
cord-005478-5iu38pr6	3540	17	efficacy	efficacy	NN
cord-005478-5iu38pr6	3540	18	endpoint	endpoint	NN
cord-005478-5iu38pr6	3540	19	(	(	-LRB-
cord-005478-5iu38pr6	3540	20	Table	table	NN
cord-005478-5iu38pr6	3540	21	)	)	-RRB-
cord-005478-5iu38pr6	3540	22	.	.	.
cord-005478-5iu38pr6	3541	1	Response	response	NN
cord-005478-5iu38pr6	3541	2	rates	rate	NNS
cord-005478-5iu38pr6	3541	3	based	base	VBN
cord-005478-5iu38pr6	3541	4	on	on	IN
cord-005478-5iu38pr6	3541	5	Investigator	Investigator	NNP
cord-005478-5iu38pr6	3541	6	's	's	POS
cord-005478-5iu38pr6	3541	7	clinical	clinical	JJ
cord-005478-5iu38pr6	3541	8	judgement	judgement	NN
cord-005478-5iu38pr6	3541	9	were	be	VBD
cord-005478-5iu38pr6	3541	10	70.6	70.6	CD
cord-005478-5iu38pr6	3541	11	%	%	NN
cord-005478-5iu38pr6	3541	12	and	and	CC
cord-005478-5iu38pr6	3541	13	70.4	70.4	CD
cord-005478-5iu38pr6	3541	14	%	%	NN
cord-005478-5iu38pr6	3541	15	in	in	IN
cord-005478-5iu38pr6	3541	16	the	the	DT
cord-005478-5iu38pr6	3541	17	two	two	CD
cord-005478-5iu38pr6	3541	18	groups	group	NNS
cord-005478-5iu38pr6	3541	19	.	.	.
cord-005478-5iu38pr6	3542	1	Emapalumab	Emapalumab	NNP
cord-005478-5iu38pr6	3542	2	was	be	VBD
cord-005478-5iu38pr6	3542	3	safe	safe	JJ
cord-005478-5iu38pr6	3542	4	and	and	CC
cord-005478-5iu38pr6	3542	5	well	well	RB
cord-005478-5iu38pr6	3542	6	tolerated	tolerate	VBN
cord-005478-5iu38pr6	3542	7	.	.	.
cord-005478-5iu38pr6	3543	1	Mild	mild	JJ
cord-005478-5iu38pr6	3543	2	to	to	IN
cord-005478-5iu38pr6	3543	3	moderate	moderate	JJ
cord-005478-5iu38pr6	3543	4	infusion	infusion	NN
cord-005478-5iu38pr6	3543	5	-	-	HYPH
cord-005478-5iu38pr6	3543	6	related	relate	VBN
cord-005478-5iu38pr6	3543	7	reactions	reaction	NNS
cord-005478-5iu38pr6	3543	8	occurred	occur	VBD
cord-005478-5iu38pr6	3543	9	in	in	IN
cord-005478-5iu38pr6	3543	10	27	27	CD
cord-005478-5iu38pr6	3543	11	%	%	NN
cord-005478-5iu38pr6	3543	12	of	of	IN
cord-005478-5iu38pr6	3543	13	patients	patient	NNS
cord-005478-5iu38pr6	3543	14	.	.	.
cord-005478-5iu38pr6	3544	1	Infection	infection	NN
cord-005478-5iu38pr6	3544	2	caused	cause	VBN
cord-005478-5iu38pr6	3544	3	by	by	IN
cord-005478-5iu38pr6	3544	4	pathogens	pathogen	NNS
cord-005478-5iu38pr6	3544	5	potentially	potentially	RB
cord-005478-5iu38pr6	3544	6	favored	favor	VBN
cord-005478-5iu38pr6	3544	7	by	by	IN
cord-005478-5iu38pr6	3544	8	IFN	IFN	NNP
cord-005478-5iu38pr6	3544	9	-	-	HYPH
cord-005478-5iu38pr6	3544	10	γ	γ	NN
cord-005478-5iu38pr6	3544	11	neutralization	neutralization	NN
cord-005478-5iu38pr6	3544	12	occurred	occur	VBD
cord-005478-5iu38pr6	3544	13	in	in	IN
cord-005478-5iu38pr6	3544	14	1	1	CD
cord-005478-5iu38pr6	3544	15	patient	patient	NN
cord-005478-5iu38pr6	3544	16	(	(	-LRB-
cord-005478-5iu38pr6	3544	17	disseminated	disseminate	VBN
cord-005478-5iu38pr6	3544	18	histoplasmosis	histoplasmosis	NN
cord-005478-5iu38pr6	3544	19	,	,	,
cord-005478-5iu38pr6	3544	20	resolved	resolve	VBN
cord-005478-5iu38pr6	3544	21	with	with	IN
cord-005478-5iu38pr6	3544	22	treatment	treatment	NN
cord-005478-5iu38pr6	3544	23	)	)	-RRB-
cord-005478-5iu38pr6	3544	24	.	.	.
cord-005478-5iu38pr6	3545	1	No	no	DT
cord-005478-5iu38pr6	3545	2	off	off	IN
cord-005478-5iu38pr6	3545	3	-	-	HYPH
cord-005478-5iu38pr6	3545	4	target	target	NN
cord-005478-5iu38pr6	3545	5	effects	effect	NNS
cord-005478-5iu38pr6	3545	6	were	be	VBD
cord-005478-5iu38pr6	3545	7	observed	observe	VBN
cord-005478-5iu38pr6	3545	8	.	.	.
cord-005478-5iu38pr6	3546	1	Most	Most	JJS
cord-005478-5iu38pr6	3546	2	patients	patient	NNS
cord-005478-5iu38pr6	3546	3	proceeded	proceed	VBD
cord-005478-5iu38pr6	3546	4	to	to	IN
cord-005478-5iu38pr6	3546	5	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3546	6	(	(	-LRB-
cord-005478-5iu38pr6	3546	7	50	50	CD
cord-005478-5iu38pr6	3546	8	%	%	NN
cord-005478-5iu38pr6	3546	9	of	of	IN
cord-005478-5iu38pr6	3546	10	patients	patient	NNS
cord-005478-5iu38pr6	3546	11	received	receive	VBD
cord-005478-5iu38pr6	3546	12	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	3546	13	conditioning	conditioning	NN
cord-005478-5iu38pr6	3546	14	and	and	CC
cord-005478-5iu38pr6	3546	15	50	50	CD
cord-005478-5iu38pr6	3546	16	%	%	NN
cord-005478-5iu38pr6	3546	17	reduced	reduce	VBN
cord-005478-5iu38pr6	3546	18	intensity	intensity	NN
cord-005478-5iu38pr6	3546	19	conditioning	conditioning	NN
cord-005478-5iu38pr6	3546	20	)	)	-RRB-
cord-005478-5iu38pr6	3546	21	with	with	IN
cord-005478-5iu38pr6	3546	22	favorable	favorable	JJ
cord-005478-5iu38pr6	3546	23	outcome	outcome	NN
cord-005478-5iu38pr6	3546	24	(	(	-LRB-
cord-005478-5iu38pr6	3546	25	engraftment	engraftment	NN
cord-005478-5iu38pr6	3546	26	in	in	IN
cord-005478-5iu38pr6	3546	27	86	86	CD
cord-005478-5iu38pr6	3546	28	%	%	NN
cord-005478-5iu38pr6	3546	29	and	and	CC
cord-005478-5iu38pr6	3546	30	89	89	CD
cord-005478-5iu38pr6	3546	31	%	%	NN
cord-005478-5iu38pr6	3546	32	of	of	IN
cord-005478-5iu38pr6	3546	33	patients	patient	NNS
cord-005478-5iu38pr6	3546	34	,	,	,
cord-005478-5iu38pr6	3546	35	respectively	respectively	RB
cord-005478-5iu38pr6	3546	36	)	)	-RRB-
cord-005478-5iu38pr6	3546	37	and	and	CC
cord-005478-5iu38pr6	3546	38	90	90	CD
cord-005478-5iu38pr6	3546	39	%	%	NN
cord-005478-5iu38pr6	3546	40	of	of	IN
cord-005478-5iu38pr6	3546	41	patients	patient	NNS
cord-005478-5iu38pr6	3546	42	receiving	receive	VBG
cord-005478-5iu38pr6	3546	43	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3546	44	were	be	VBD
cord-005478-5iu38pr6	3546	45	alive	alive	JJ
cord-005478-5iu38pr6	3546	46	at	at	IN
cord-005478-5iu38pr6	3546	47	1	1	CD
cord-005478-5iu38pr6	3546	48	year	year	NN
cord-005478-5iu38pr6	3546	49	post	post	NN
cord-005478-5iu38pr6	3546	50	transplant	transplant	NN
cord-005478-5iu38pr6	3546	51	.	.	.
cord-005478-5iu38pr6	3547	1	Background	background	NN
cord-005478-5iu38pr6	3547	2	:	:	:
cord-005478-5iu38pr6	3548	1	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	3548	2	is	be	VBZ
cord-005478-5iu38pr6	3548	3	a	a	DT
cord-005478-5iu38pr6	3548	4	first	first	JJ
cord-005478-5iu38pr6	3548	5	-	-	HYPH
cord-005478-5iu38pr6	3548	6	in	in	IN
cord-005478-5iu38pr6	3548	7	-	-	HYPH
cord-005478-5iu38pr6	3548	8	class	class	NN
cord-005478-5iu38pr6	3548	9	,	,	,
cord-005478-5iu38pr6	3548	10	DNA	dna	NN
cord-005478-5iu38pr6	3548	11	-	-	HYPH
cord-005478-5iu38pr6	3548	12	based	base	VBN
cord-005478-5iu38pr6	3548	13	vaccine	vaccine	NN
cord-005478-5iu38pr6	3548	14	designed	design	VBN
cord-005478-5iu38pr6	3548	15	for	for	IN
cord-005478-5iu38pr6	3548	16	the	the	DT
cord-005478-5iu38pr6	3548	17	prevention	prevention	NN
cord-005478-5iu38pr6	3548	18	of	of	IN
cord-005478-5iu38pr6	3548	19	cytomegalovirus	cytomegalovirus	NNP
cord-005478-5iu38pr6	3548	20	(	(	-LRB-
cord-005478-5iu38pr6	3548	21	CMV	CMV	NNP
cord-005478-5iu38pr6	3548	22	)	)	-RRB-
cord-005478-5iu38pr6	3548	23	infection	infection	NN
cord-005478-5iu38pr6	3548	24	;	;	:
cord-005478-5iu38pr6	3548	25	it	-PRON-	PRP
cord-005478-5iu38pr6	3548	26	contains	contain	VBZ
cord-005478-5iu38pr6	3548	27	two	two	CD
cord-005478-5iu38pr6	3548	28	plasmids	plasmid	NNS
cord-005478-5iu38pr6	3548	29	encoding	encode	VBG
cord-005478-5iu38pr6	3548	30	glycoprotein	glycoprotein	NN
cord-005478-5iu38pr6	3548	31	B	B	NNP
cord-005478-5iu38pr6	3548	32	(	(	-LRB-
cord-005478-5iu38pr6	3548	33	gB	gB	NNP
cord-005478-5iu38pr6	3548	34	)	)	-RRB-
cord-005478-5iu38pr6	3548	35	and	and	CC
cord-005478-5iu38pr6	3548	36	phosphoprotein	phosphoprotein	NN
cord-005478-5iu38pr6	3548	37	65	65	CD
cord-005478-5iu38pr6	3548	38	(	(	-LRB-
cord-005478-5iu38pr6	3548	39	pp65	pp65	NNP
cord-005478-5iu38pr6	3548	40	)	)	-RRB-
cord-005478-5iu38pr6	3548	41	.	.	.
cord-005478-5iu38pr6	3549	1	This	this	DT
cord-005478-5iu38pr6	3549	2	study	study	NN
cord-005478-5iu38pr6	3549	3	aimed	aim	VBD
cord-005478-5iu38pr6	3549	4	to	to	TO
cord-005478-5iu38pr6	3549	5	investigate	investigate	VB
cord-005478-5iu38pr6	3549	6	the	the	DT
cord-005478-5iu38pr6	3549	7	efficacy	efficacy	NN
cord-005478-5iu38pr6	3549	8	,	,	,
cord-005478-5iu38pr6	3549	9	safety	safety	NN
cord-005478-5iu38pr6	3549	10	and	and	CC
cord-005478-5iu38pr6	3549	11	immunogenicity	immunogenicity	NN
cord-005478-5iu38pr6	3549	12	of	of	IN
cord-005478-5iu38pr6	3549	13	ASP0113	ASP0113	NNS
cord-005478-5iu38pr6	3549	14	compared	compare	VBN
cord-005478-5iu38pr6	3549	15	with	with	IN
cord-005478-5iu38pr6	3549	16	placebo	placebo	NN
cord-005478-5iu38pr6	3549	17	in	in	IN
cord-005478-5iu38pr6	3549	18	allogeneic	allogeneic	JJ
cord-005478-5iu38pr6	3549	19	haematopoietic	haematopoietic	JJ
cord-005478-5iu38pr6	3549	20	cell	cell	NN
cord-005478-5iu38pr6	3549	21	transplant	transplant	NN
cord-005478-5iu38pr6	3549	22	(	(	-LRB-
cord-005478-5iu38pr6	3549	23	allo	allo	NN
cord-005478-5iu38pr6	3549	24	-	-	HYPH
cord-005478-5iu38pr6	3549	25	HCT	HCT	NNP
cord-005478-5iu38pr6	3549	26	)	)	-RRB-
cord-005478-5iu38pr6	3549	27	recipients	recipient	NNS
cord-005478-5iu38pr6	3549	28	.	.	.
cord-005478-5iu38pr6	3550	1	Methods	method	NNS
cord-005478-5iu38pr6	3550	2	:	:	:
cord-005478-5iu38pr6	3550	3	This	this	DT
cord-005478-5iu38pr6	3550	4	was	be	VBD
cord-005478-5iu38pr6	3550	5	a	a	DT
cord-005478-5iu38pr6	3550	6	randomised	randomised	JJ
cord-005478-5iu38pr6	3550	7	,	,	,
cord-005478-5iu38pr6	3550	8	double	double	JJ
cord-005478-5iu38pr6	3550	9	-	-	HYPH
cord-005478-5iu38pr6	3550	10	blind	blind	JJ
cord-005478-5iu38pr6	3550	11	,	,	,
cord-005478-5iu38pr6	3550	12	placebocontrolled	placebocontrolled	JJ
cord-005478-5iu38pr6	3550	13	phase	phase	NN
cord-005478-5iu38pr6	3550	14	3	3	CD
cord-005478-5iu38pr6	3550	15	study	study	NN
cord-005478-5iu38pr6	3550	16	.	.	.
cord-005478-5iu38pr6	3551	1	CMV	CMV	NNP
cord-005478-5iu38pr6	3551	2	-	-	HYPH
cord-005478-5iu38pr6	3551	3	seropositive	seropositive	JJ
cord-005478-5iu38pr6	3551	4	allo	allo	NN
cord-005478-5iu38pr6	3551	5	-	-	HYPH
cord-005478-5iu38pr6	3551	6	HCT	hct	NN
cord-005478-5iu38pr6	3551	7	recipients	recipient	NNS
cord-005478-5iu38pr6	3551	8	received	receive	VBD
cord-005478-5iu38pr6	3551	9	five	five	CD
cord-005478-5iu38pr6	3551	10	intramuscular	intramuscular	JJ
cord-005478-5iu38pr6	3551	11	1	1	CD
cord-005478-5iu38pr6	3551	12	ml	ml	NNS
cord-005478-5iu38pr6	3551	13	doses	dose	NNS
cord-005478-5iu38pr6	3551	14	of	of	IN
cord-005478-5iu38pr6	3551	15	5	5	CD
cord-005478-5iu38pr6	3551	16	mg/	mg/	NN
cord-005478-5iu38pr6	3551	17	ml	ml	NN
cord-005478-5iu38pr6	3551	18	ASP0113	ASP0113	NNP
cord-005478-5iu38pr6	3551	19	or	or	CC
cord-005478-5iu38pr6	3551	20	placebo	placebo	NN
cord-005478-5iu38pr6	3551	21	(	(	-LRB-
cord-005478-5iu38pr6	3551	22	phosphate	phosphate	NN
cord-005478-5iu38pr6	3551	23	buffered	buffer	VBN
cord-005478-5iu38pr6	3551	24	saline	saline	NN
cord-005478-5iu38pr6	3551	25	)	)	-RRB-
cord-005478-5iu38pr6	3551	26	in	in	IN
cord-005478-5iu38pr6	3551	27	a	a	DT
cord-005478-5iu38pr6	3551	28	1:1	1:1	CD
cord-005478-5iu38pr6	3551	29	ratio	ratio	NN
cord-005478-5iu38pr6	3551	30	on	on	IN
cord-005478-5iu38pr6	3551	31	Days	day	NNS
cord-005478-5iu38pr6	3551	32	−14	−14	NNP
cord-005478-5iu38pr6	3551	33	to	to	IN
cord-005478-5iu38pr6	3551	34	−3	−3	NNP
cord-005478-5iu38pr6	3551	35	,	,	,
cord-005478-5iu38pr6	3551	36	14	14	CD
cord-005478-5iu38pr6	3551	37	to	to	TO
cord-005478-5iu38pr6	3551	38	40	40	CD
cord-005478-5iu38pr6	3551	39	,	,	,
cord-005478-5iu38pr6	3551	40	60±5	60±5	CD
cord-005478-5iu38pr6	3551	41	,	,	,
cord-005478-5iu38pr6	3551	42	90±10	90±10	CD
cord-005478-5iu38pr6	3551	43	and	and	CC
cord-005478-5iu38pr6	3551	44	180	180	CD
cord-005478-5iu38pr6	3551	45	±10	±10	NNP
cord-005478-5iu38pr6	3551	46	,	,	,
cord-005478-5iu38pr6	3551	47	relative	relative	JJ
cord-005478-5iu38pr6	3551	48	to	to	IN
cord-005478-5iu38pr6	3551	49	the	the	DT
cord-005478-5iu38pr6	3551	50	day	day	NN
cord-005478-5iu38pr6	3551	51	of	of	IN
cord-005478-5iu38pr6	3551	52	transplant	transplant	NN
cord-005478-5iu38pr6	3551	53	(	(	-LRB-
cord-005478-5iu38pr6	3551	54	Day	day	NN
cord-005478-5iu38pr6	3551	55	0	0	CD
cord-005478-5iu38pr6	3551	56	)	)	-RRB-
cord-005478-5iu38pr6	3551	57	.	.	.
cord-005478-5iu38pr6	3552	1	Plasma	plasma	NN
cord-005478-5iu38pr6	3552	2	CMV	CMV	NNP
cord-005478-5iu38pr6	3552	3	viral	viral	JJ
cord-005478-5iu38pr6	3552	4	load	load	NN
cord-005478-5iu38pr6	3552	5	was	be	VBD
cord-005478-5iu38pr6	3552	6	determined	determine	VBN
cord-005478-5iu38pr6	3552	7	through	through	IN
cord-005478-5iu38pr6	3552	8	1	1	CD
cord-005478-5iu38pr6	3552	9	year	year	NN
cord-005478-5iu38pr6	3552	10	and	and	CC
cord-005478-5iu38pr6	3552	11	analysed	analyse	VBD
cord-005478-5iu38pr6	3552	12	at	at	IN
cord-005478-5iu38pr6	3552	13	the	the	DT
cord-005478-5iu38pr6	3552	14	central	central	JJ
cord-005478-5iu38pr6	3552	15	laboratory	laboratory	NN
cord-005478-5iu38pr6	3552	16	.	.	.
cord-005478-5iu38pr6	3553	1	Treatment	treatment	NN
cord-005478-5iu38pr6	3553	2	-	-	HYPH
cord-005478-5iu38pr6	3553	3	emergent	emergent	JJ
cord-005478-5iu38pr6	3553	4	adverse	adverse	JJ
cord-005478-5iu38pr6	3553	5	events	event	NNS
cord-005478-5iu38pr6	3553	6	(	(	-LRB-
cord-005478-5iu38pr6	3553	7	TEAEs	teae	NNS
cord-005478-5iu38pr6	3553	8	)	)	-RRB-
cord-005478-5iu38pr6	3553	9	were	be	VBD
cord-005478-5iu38pr6	3553	10	recorded	record	VBN
cord-005478-5iu38pr6	3553	11	through	through	IN
cord-005478-5iu38pr6	3553	12	30	30	CD
cord-005478-5iu38pr6	3553	13	days	day	NNS
cord-005478-5iu38pr6	3553	14	after	after	IN
cord-005478-5iu38pr6	3553	15	the	the	DT
cord-005478-5iu38pr6	3553	16	last	last	JJ
cord-005478-5iu38pr6	3553	17	randomized	randomized	JJ
cord-005478-5iu38pr6	3553	18	treatment	treatment	NN
cord-005478-5iu38pr6	3553	19	injection	injection	NN
cord-005478-5iu38pr6	3553	20	.	.	.
cord-005478-5iu38pr6	3554	1	Immunogenicity	Immunogenicity	NNP
cord-005478-5iu38pr6	3554	2	was	be	VBD
cord-005478-5iu38pr6	3554	3	measured	measure	VBN
cord-005478-5iu38pr6	3554	4	by	by	IN
cord-005478-5iu38pr6	3554	5	T	t	NN
cord-005478-5iu38pr6	3554	6	-	-	HYPH
cord-005478-5iu38pr6	3554	7	cell	cell	NN
cord-005478-5iu38pr6	3554	8	responses	response	NNS
cord-005478-5iu38pr6	3554	9	to	to	IN
cord-005478-5iu38pr6	3554	10	pp65	pp65	NN
cord-005478-5iu38pr6	3554	11	and	and	CC
cord-005478-5iu38pr6	3554	12	gB	gb	NN
cord-005478-5iu38pr6	3554	13	-	-	JJ
cord-005478-5iu38pr6	3554	14	specific	specific	JJ
cord-005478-5iu38pr6	3554	15	antibody	antibody	NN
cord-005478-5iu38pr6	3554	16	levels	level	NNS
cord-005478-5iu38pr6	3554	17	through	through	IN
cord-005478-5iu38pr6	3554	18	1	1	CD
cord-005478-5iu38pr6	3554	19	year	year	NN
cord-005478-5iu38pr6	3554	20	after	after	IN
cord-005478-5iu38pr6	3554	21	the	the	DT
cord-005478-5iu38pr6	3554	22	first	first	JJ
cord-005478-5iu38pr6	3554	23	randomized	randomized	JJ
cord-005478-5iu38pr6	3554	24	treatment	treatment	NN
cord-005478-5iu38pr6	3554	25	injection	injection	NN
cord-005478-5iu38pr6	3554	26	.	.	.
cord-005478-5iu38pr6	3555	1	The	the	DT
cord-005478-5iu38pr6	3555	2	primary	primary	JJ
cord-005478-5iu38pr6	3555	3	endpoint	endpoint	NN
cord-005478-5iu38pr6	3555	4	was	be	VBD
cord-005478-5iu38pr6	3555	5	the	the	DT
cord-005478-5iu38pr6	3555	6	proportion	proportion	NN
cord-005478-5iu38pr6	3555	7	of	of	IN
cord-005478-5iu38pr6	3555	8	patients	patient	NNS
cord-005478-5iu38pr6	3555	9	with	with	IN
cord-005478-5iu38pr6	3555	10	a	a	DT
cord-005478-5iu38pr6	3555	11	composite	composite	NN
cord-005478-5iu38pr6	3555	12	of	of	IN
cord-005478-5iu38pr6	3555	13	all	all	DT
cord-005478-5iu38pr6	3555	14	-	-	HYPH
cord-005478-5iu38pr6	3555	15	cause	cause	NN
cord-005478-5iu38pr6	3555	16	mortality	mortality	NN
cord-005478-5iu38pr6	3555	17	and	and	CC
cord-005478-5iu38pr6	3555	18	adjudicated	adjudicate	VBD
cord-005478-5iu38pr6	3555	19	CMV	CMV	NNP
cord-005478-5iu38pr6	3555	20	end	end	NN
cord-005478-5iu38pr6	3555	21	-	-	HYPH
cord-005478-5iu38pr6	3555	22	organ	organ	NN
cord-005478-5iu38pr6	3555	23	disease	disease	NN
cord-005478-5iu38pr6	3555	24	(	(	-LRB-
cord-005478-5iu38pr6	3555	25	EOD	EOD	NNP
cord-005478-5iu38pr6	3555	26	)	)	-RRB-
cord-005478-5iu38pr6	3555	27	through	through	IN
cord-005478-5iu38pr6	3555	28	1	1	CD
cord-005478-5iu38pr6	3555	29	year	year	NN
cord-005478-5iu38pr6	3555	30	post	post	NN
cord-005478-5iu38pr6	3555	31	transplant	transplant	NN
cord-005478-5iu38pr6	3555	32	.	.	.
cord-005478-5iu38pr6	3556	1	Secondary	secondary	JJ
cord-005478-5iu38pr6	3556	2	endpoints	endpoint	NNS
cord-005478-5iu38pr6	3556	3	were	be	VBD
cord-005478-5iu38pr6	3556	4	CMV	CMV	NNP
cord-005478-5iu38pr6	3556	5	viraemia	viraemia	NN
cord-005478-5iu38pr6	3556	6	rate	rate	NN
cord-005478-5iu38pr6	3556	7	,	,	,
cord-005478-5iu38pr6	3556	8	adjudicated	adjudicate	VBD
cord-005478-5iu38pr6	3556	9	CMV	CMV	NNP
cord-005478-5iu38pr6	3556	10	-	-	HYPH
cord-005478-5iu38pr6	3556	11	specific	specific	JJ
cord-005478-5iu38pr6	3556	12	antiviral	antiviral	JJ
cord-005478-5iu38pr6	3556	13	therapy	therapy	NN
cord-005478-5iu38pr6	3556	14	(	(	-LRB-
cord-005478-5iu38pr6	3556	15	AVT	AVT	NNP
cord-005478-5iu38pr6	3556	16	)	)	-RRB-
cord-005478-5iu38pr6	3556	17	rate	rate	NN
cord-005478-5iu38pr6	3556	18	,	,	,
cord-005478-5iu38pr6	3556	19	a	a	DT
cord-005478-5iu38pr6	3556	20	composite	composite	NN
cord-005478-5iu38pr6	3556	21	of	of	IN
cord-005478-5iu38pr6	3556	22	protocol	protocol	NN
cord-005478-5iu38pr6	3556	23	-	-	HYPH
cord-005478-5iu38pr6	3556	24	defined	define	VBN
cord-005478-5iu38pr6	3556	25	CMV	CMV	NNP
cord-005478-5iu38pr6	3556	26	viraemia	viraemia	NN
cord-005478-5iu38pr6	3556	27	and	and	CC
cord-005478-5iu38pr6	3556	28	adjudicated	adjudicate	VBD
cord-005478-5iu38pr6	3556	29	CMV	CMV	NNP
cord-005478-5iu38pr6	3556	30	-	-	HYPH
cord-005478-5iu38pr6	3556	31	specific	specific	JJ
cord-005478-5iu38pr6	3556	32	AVT	AVT	NNP
cord-005478-5iu38pr6	3556	33	use	use	NN
cord-005478-5iu38pr6	3556	34	,	,	,
cord-005478-5iu38pr6	3556	35	first	first	JJ
cord-005478-5iu38pr6	3556	36	occurrence	occurrence	NN
cord-005478-5iu38pr6	3556	37	of	of	IN
cord-005478-5iu38pr6	3556	38	Background	Background	NNP
cord-005478-5iu38pr6	3556	39	:	:	:
cord-005478-5iu38pr6	3556	40	Haploidentical	Haploidentical	NNP
cord-005478-5iu38pr6	3556	41	stem	stem	NN
cord-005478-5iu38pr6	3556	42	cell	cell	NN
cord-005478-5iu38pr6	3556	43	transplantation	transplantation	NN
cord-005478-5iu38pr6	3556	44	(	(	-LRB-
cord-005478-5iu38pr6	3556	45	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3556	46	-	-	HYPH
cord-005478-5iu38pr6	3556	47	SCT	SCT	NNP
cord-005478-5iu38pr6	3556	48	)	)	-RRB-
cord-005478-5iu38pr6	3556	49	with	with	IN
cord-005478-5iu38pr6	3556	50	post	post	JJ
cord-005478-5iu38pr6	3556	51	-	-	JJ
cord-005478-5iu38pr6	3556	52	transplant	transplant	NN
cord-005478-5iu38pr6	3556	53	cyclophosphamide	cyclophosphamide	NN
cord-005478-5iu38pr6	3556	54	(	(	-LRB-
cord-005478-5iu38pr6	3556	55	PT	PT	NNP
cord-005478-5iu38pr6	3556	56	-	-	HYPH
cord-005478-5iu38pr6	3556	57	Cy	Cy	NNP
cord-005478-5iu38pr6	3556	58	)	)	-RRB-
cord-005478-5iu38pr6	3556	59	represents	represent	VBZ
cord-005478-5iu38pr6	3556	60	a	a	DT
cord-005478-5iu38pr6	3556	61	potential	potential	JJ
cord-005478-5iu38pr6	3556	62	curative	curative	JJ
cord-005478-5iu38pr6	3556	63	strategy	strategy	NN
cord-005478-5iu38pr6	3556	64	for	for	IN
cord-005478-5iu38pr6	3556	65	patients	patient	NNS
cord-005478-5iu38pr6	3556	66	with	with	IN
cord-005478-5iu38pr6	3556	67	Hodgkin	Hodgkin	NNP
cord-005478-5iu38pr6	3556	68	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3556	69	(	(	-LRB-
cord-005478-5iu38pr6	3556	70	HL	HL	NNP
cord-005478-5iu38pr6	3556	71	)	)	-RRB-
cord-005478-5iu38pr6	3556	72	when	when	WRB
cord-005478-5iu38pr6	3556	73	a	a	DT
cord-005478-5iu38pr6	3556	74	matched	match	VBN
cord-005478-5iu38pr6	3556	75	related	related	JJ
cord-005478-5iu38pr6	3556	76	or	or	CC
cord-005478-5iu38pr6	3556	77	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3556	78	donor	donor	NN
cord-005478-5iu38pr6	3556	79	is	be	VBZ
cord-005478-5iu38pr6	3556	80	not	not	RB
cord-005478-5iu38pr6	3556	81	available	available	JJ
cord-005478-5iu38pr6	3556	82	1	1	CD
cord-005478-5iu38pr6	3556	83	.	.	.
cord-005478-5iu38pr6	3557	1	While	while	IN
cord-005478-5iu38pr6	3557	2	bone	bone	NN
cord-005478-5iu38pr6	3557	3	marrow	marrow	NN
cord-005478-5iu38pr6	3557	4	(	(	-LRB-
cord-005478-5iu38pr6	3557	5	BM	BM	NNP
cord-005478-5iu38pr6	3557	6	)	)	-RRB-
cord-005478-5iu38pr6	3557	7	was	be	VBD
cord-005478-5iu38pr6	3557	8	originally	originally	RB
cord-005478-5iu38pr6	3557	9	the	the	DT
cord-005478-5iu38pr6	3557	10	preferred	prefer	VBN
cord-005478-5iu38pr6	3557	11	stem	stem	NN
cord-005478-5iu38pr6	3557	12	cell	cell	NN
cord-005478-5iu38pr6	3557	13	source	source	NN
cord-005478-5iu38pr6	3557	14	,	,	,
cord-005478-5iu38pr6	3557	15	more	more	RBR
cord-005478-5iu38pr6	3557	16	recently	recently	RB
cord-005478-5iu38pr6	3557	17	peripheral	peripheral	JJ
cord-005478-5iu38pr6	3557	18	blood	blood	NN
cord-005478-5iu38pr6	3557	19	stem	stem	NN
cord-005478-5iu38pr6	3557	20	cell	cell	NN
cord-005478-5iu38pr6	3557	21	(	(	-LRB-
cord-005478-5iu38pr6	3557	22	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3557	23	)	)	-RRB-
cord-005478-5iu38pr6	3557	24	is	be	VBZ
cord-005478-5iu38pr6	3557	25	more	more	RBR
cord-005478-5iu38pr6	3557	26	often	often	RB
cord-005478-5iu38pr6	3557	27	used	use	VBN
cord-005478-5iu38pr6	3557	28	.	.	.
cord-005478-5iu38pr6	3558	1	Some	some	DT
cord-005478-5iu38pr6	3558	2	retrospective	retrospective	JJ
cord-005478-5iu38pr6	3558	3	studies	study	NNS
cord-005478-5iu38pr6	3558	4	suggest	suggest	VBP
cord-005478-5iu38pr6	3558	5	that	that	IN
cord-005478-5iu38pr6	3558	6	the	the	DT
cord-005478-5iu38pr6	3558	7	risk	risk	NN
cord-005478-5iu38pr6	3558	8	to	to	TO
cord-005478-5iu38pr6	3558	9	develop	develop	VB
cord-005478-5iu38pr6	3558	10	acute	acute	JJ
cord-005478-5iu38pr6	3558	11	and	and	CC
cord-005478-5iu38pr6	3558	12	chronic	chronic	JJ
cord-005478-5iu38pr6	3558	13	graft	graft	NN
cord-005478-5iu38pr6	3558	14	-	-	HYPH
cord-005478-5iu38pr6	3558	15	versus	versus	IN
cord-005478-5iu38pr6	3558	16	-	-	HYPH
cord-005478-5iu38pr6	3558	17	host	host	NN
cord-005478-5iu38pr6	3558	18	-	-	HYPH
cord-005478-5iu38pr6	3558	19	disease	disease	NN
cord-005478-5iu38pr6	3558	20	(	(	-LRB-
cord-005478-5iu38pr6	3558	21	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3558	22	)	)	-RRB-
cord-005478-5iu38pr6	3558	23	is	be	VBZ
cord-005478-5iu38pr6	3558	24	higher	high	JJR
cord-005478-5iu38pr6	3558	25	with	with	IN
cord-005478-5iu38pr6	3558	26	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3558	27	than	than	IN
cord-005478-5iu38pr6	3558	28	BM	BM	NNP
cord-005478-5iu38pr6	3558	29	,	,	,
cord-005478-5iu38pr6	3558	30	while	while	IN
cord-005478-5iu38pr6	3558	31	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3558	32	may	may	MD
cord-005478-5iu38pr6	3558	33	reduce	reduce	VB
cord-005478-5iu38pr6	3558	34	the	the	DT
cord-005478-5iu38pr6	3558	35	risk	risk	NN
cord-005478-5iu38pr6	3558	36	of	of	IN
cord-005478-5iu38pr6	3558	37	relapse	relapse	NN
cord-005478-5iu38pr6	3558	38	2	2	CD
cord-005478-5iu38pr6	3558	39	.	.	.
cord-005478-5iu38pr6	3559	1	Here	here	RB
cord-005478-5iu38pr6	3559	2	we	-PRON-	PRP
cord-005478-5iu38pr6	3559	3	analyzed	analyze	VBD
cord-005478-5iu38pr6	3559	4	the	the	DT
cord-005478-5iu38pr6	3559	5	effect	effect	NN
cord-005478-5iu38pr6	3559	6	of	of	IN
cord-005478-5iu38pr6	3559	7	stem	stem	NN
cord-005478-5iu38pr6	3559	8	cell	cell	NN
cord-005478-5iu38pr6	3559	9	source	source	NN
cord-005478-5iu38pr6	3559	10	in	in	IN
cord-005478-5iu38pr6	3559	11	91	91	CD
cord-005478-5iu38pr6	3559	12	HL	HL	NNP
cord-005478-5iu38pr6	3559	13	patients	patient	NNS
cord-005478-5iu38pr6	3559	14	receiving	receive	VBG
cord-005478-5iu38pr6	3559	15	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3559	16	-	-	HYPH
cord-005478-5iu38pr6	3559	17	SCT	SCT	NNP
cord-005478-5iu38pr6	3559	18	with	with	IN
cord-005478-5iu38pr6	3559	19	PT	PT	NNP
cord-005478-5iu38pr6	3559	20	-	-	HYPH
cord-005478-5iu38pr6	3559	21	Cy	Cy	NNP
cord-005478-5iu38pr6	3559	22	,	,	,
cord-005478-5iu38pr6	3559	23	with	with	IN
cord-005478-5iu38pr6	3559	24	the	the	DT
cord-005478-5iu38pr6	3559	25	aim	aim	NN
cord-005478-5iu38pr6	3559	26	to	to	TO
cord-005478-5iu38pr6	3559	27	evaluate	evaluate	VB
cord-005478-5iu38pr6	3559	28	if	if	IN
cord-005478-5iu38pr6	3559	29	the	the	DT
cord-005478-5iu38pr6	3559	30	final	final	JJ
cord-005478-5iu38pr6	3559	31	outcome	outcome	NN
cord-005478-5iu38pr6	3559	32	is	be	VBZ
cord-005478-5iu38pr6	3559	33	modified	modify	VBN
cord-005478-5iu38pr6	3559	34	by	by	IN
cord-005478-5iu38pr6	3559	35	the	the	DT
cord-005478-5iu38pr6	3559	36	use	use	NN
cord-005478-5iu38pr6	3559	37	of	of	IN
cord-005478-5iu38pr6	3559	38	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3559	39	or	or	CC
cord-005478-5iu38pr6	3560	1	BM.Methods	bm.methods	RB
cord-005478-5iu38pr6	3560	2	:	:	:
cord-005478-5iu38pr6	3560	3	From	from	IN
cord-005478-5iu38pr6	3560	4	April	April	NNP
cord-005478-5iu38pr6	3560	5	2009	2009	CD
cord-005478-5iu38pr6	3560	6	to	to	IN
cord-005478-5iu38pr6	3560	7	January	January	NNP
cord-005478-5iu38pr6	3560	8	2017	2017	CD
cord-005478-5iu38pr6	3560	9	,	,	,
cord-005478-5iu38pr6	3560	10	91	91	CD
cord-005478-5iu38pr6	3560	11	consecutive	consecutive	JJ
cord-005478-5iu38pr6	3560	12	patients	patient	NNS
cord-005478-5iu38pr6	3560	13	with	with	IN
cord-005478-5iu38pr6	3560	14	poor	poor	JJ
cord-005478-5iu38pr6	3560	15	prognosis	prognosis	NN
cord-005478-5iu38pr6	3560	16	HL	HL	NNP
cord-005478-5iu38pr6	3560	17	received	receive	VBD
cord-005478-5iu38pr6	3560	18	a	a	DT
cord-005478-5iu38pr6	3560	19	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3560	20	-	-	HYPH
cord-005478-5iu38pr6	3560	21	SCT	SCT	NNP
cord-005478-5iu38pr6	3560	22	with	with	IN
cord-005478-5iu38pr6	3560	23	PT	PT	NNP
cord-005478-5iu38pr6	3560	24	-	-	HYPH
cord-005478-5iu38pr6	3560	25	Cy	Cy	NNP
cord-005478-5iu38pr6	3560	26	either	either	CC
cord-005478-5iu38pr6	3560	27	from	from	IN
cord-005478-5iu38pr6	3560	28	a	a	DT
cord-005478-5iu38pr6	3560	29	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3560	30	(	(	-LRB-
cord-005478-5iu38pr6	3560	31	n=38	n=38	NNP
cord-005478-5iu38pr6	3560	32	)	)	-RRB-
cord-005478-5iu38pr6	3560	33	or	or	CC
cord-005478-5iu38pr6	3560	34	BM	BM	NNP
cord-005478-5iu38pr6	3560	35	(	(	-LRB-
cord-005478-5iu38pr6	3560	36	n=53	n=53	NNP
cord-005478-5iu38pr6	3560	37	)	)	-RRB-
cord-005478-5iu38pr6	3560	38	.	.	.
cord-005478-5iu38pr6	3561	1	The	the	DT
cord-005478-5iu38pr6	3561	2	two	two	CD
cord-005478-5iu38pr6	3561	3	cohorts	cohort	NNS
cord-005478-5iu38pr6	3561	4	were	be	VBD
cord-005478-5iu38pr6	3561	5	similar	similar	JJ
cord-005478-5iu38pr6	3561	6	for	for	IN
cord-005478-5iu38pr6	3561	7	most	most	JJS
cord-005478-5iu38pr6	3561	8	characteristics	characteristic	NNS
cord-005478-5iu38pr6	3561	9	,	,	,
cord-005478-5iu38pr6	3561	10	but	but	CC
cord-005478-5iu38pr6	3561	11	the	the	DT
cord-005478-5iu38pr6	3561	12	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3561	13	group	group	NN
cord-005478-5iu38pr6	3561	14	had	have	VBD
cord-005478-5iu38pr6	3561	15	more	more	JJR
cord-005478-5iu38pr6	3561	16	patients	patient	NNS
cord-005478-5iu38pr6	3561	17	with	with	IN
cord-005478-5iu38pr6	3561	18	an	an	DT
cord-005478-5iu38pr6	3561	19	unfavorable	unfavorable	JJ
cord-005478-5iu38pr6	3561	20	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3561	21	stem	stem	NN
cord-005478-5iu38pr6	3561	22	cell	cell	NN
cord-005478-5iu38pr6	3561	23	transplant	transplant	NN
cord-005478-5iu38pr6	3561	24	comorbidity	comorbidity	NN
cord-005478-5iu38pr6	3561	25	index	index	NN
cord-005478-5iu38pr6	3561	26	(	(	-LRB-
cord-005478-5iu38pr6	3561	27	HCT	HCT	NNP
cord-005478-5iu38pr6	3561	28	-	-	HYPH
cord-005478-5iu38pr6	3561	29	CI	ci	NN
cord-005478-5iu38pr6	3561	30	)	)	-RRB-
cord-005478-5iu38pr6	3561	31	score	score	NN
cord-005478-5iu38pr6	3561	32	≥3	≥3	NNP
cord-005478-5iu38pr6	3561	33	(	(	-LRB-
cord-005478-5iu38pr6	3561	34	p=0.002	p=0.002	NNP
cord-005478-5iu38pr6	3561	35	)	)	-RRB-
cord-005478-5iu38pr6	3561	36	and	and	CC
cord-005478-5iu38pr6	3561	37	had	have	VBD
cord-005478-5iu38pr6	3561	38	received	receive	VBN
cord-005478-5iu38pr6	3561	39	a	a	DT
cord-005478-5iu38pr6	3561	40	non	non	JJ
cord-005478-5iu38pr6	3561	41	myeloablative	myeloablative	JJ
cord-005478-5iu38pr6	3561	42	conditioning	conditioning	NN
cord-005478-5iu38pr6	3561	43	(	(	-LRB-
cord-005478-5iu38pr6	3561	44	NMAC	NMAC	NNP
cord-005478-5iu38pr6	3561	45	;	;	:
cord-005478-5iu38pr6	3561	46	p=0.001).Results	p=0.001).results	NN
cord-005478-5iu38pr6	3561	47	:	:	:
cord-005478-5iu38pr6	3561	48	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3561	49	incidence	incidence	NN
cord-005478-5iu38pr6	3561	50	of	of	IN
cord-005478-5iu38pr6	3561	51	neutrophil>500	neutrophil>500	CD
cord-005478-5iu38pr6	3561	52	/	/	SYM
cord-005478-5iu38pr6	3561	53	ul	ul	NN
cord-005478-5iu38pr6	3561	54	at	at	IN
cord-005478-5iu38pr6	3561	55	day	day	NN
cord-005478-5iu38pr6	3561	56	+30	+30	CD
cord-005478-5iu38pr6	3561	57	and	and	CC
cord-005478-5iu38pr6	3561	58	of	of	IN
cord-005478-5iu38pr6	3561	59	platelet	platelet	NN
cord-005478-5iu38pr6	3561	60	>	>	XX
cord-005478-5iu38pr6	3562	1	20000	20000	CD
cord-005478-5iu38pr6	3562	2	/	/	SYM
cord-005478-5iu38pr6	3562	3	ul	ul	NN
cord-005478-5iu38pr6	3562	4	at	at	IN
cord-005478-5iu38pr6	3562	5	day	day	NN
cord-005478-5iu38pr6	3562	6	+60	+60	CD
cord-005478-5iu38pr6	3562	7	were	be	VBD
cord-005478-5iu38pr6	3562	8	96	96	CD
cord-005478-5iu38pr6	3562	9	%	%	NN
cord-005478-5iu38pr6	3562	10	(	(	-LRB-
cord-005478-5iu38pr6	3562	11	95	95	CD
cord-005478-5iu38pr6	3562	12	%	%	NN
cord-005478-5iu38pr6	3562	13	CI	ci	NN
cord-005478-5iu38pr6	3562	14	:	:	:
cord-005478-5iu38pr6	3562	15	89	89	CD
cord-005478-5iu38pr6	3562	16	-	-	SYM
cord-005478-5iu38pr6	3562	17	98	98	CD
cord-005478-5iu38pr6	3562	18	)	)	-RRB-
cord-005478-5iu38pr6	3562	19	and	and	CC
cord-005478-5iu38pr6	3562	20	96	96	CD
cord-005478-5iu38pr6	3562	21	%	%	NN
cord-005478-5iu38pr6	3562	22	(	(	-LRB-
cord-005478-5iu38pr6	3562	23	95	95	CD
cord-005478-5iu38pr6	3562	24	%	%	NN
cord-005478-5iu38pr6	3562	25	CI	ci	NN
cord-005478-5iu38pr6	3562	26	:	:	:
cord-005478-5iu38pr6	3562	27	88	88	CD
cord-005478-5iu38pr6	3562	28	-	-	SYM
cord-005478-5iu38pr6	3562	29	99	99	CD
cord-005478-5iu38pr6	3562	30	)	)	-RRB-
cord-005478-5iu38pr6	3562	31	,	,	,
cord-005478-5iu38pr6	3562	32	respectively	respectively	RB
cord-005478-5iu38pr6	3562	33	,	,	,
cord-005478-5iu38pr6	3562	34	with	with	IN
cord-005478-5iu38pr6	3562	35	no	no	DT
cord-005478-5iu38pr6	3562	36	significant	significant	JJ
cord-005478-5iu38pr6	3562	37	differences	difference	NNS
cord-005478-5iu38pr6	3562	38	between	between	IN
cord-005478-5iu38pr6	3562	39	the	the	DT
cord-005478-5iu38pr6	3562	40	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3562	41	and	and	CC
cord-005478-5iu38pr6	3562	42	BM	BM	NNP
cord-005478-5iu38pr6	3562	43	cohorts	cohort	NNS
cord-005478-5iu38pr6	3562	44	.	.	.
cord-005478-5iu38pr6	3563	1	With	with	IN
cord-005478-5iu38pr6	3563	2	a	a	DT
cord-005478-5iu38pr6	3563	3	median	median	JJ
cord-005478-5iu38pr6	3563	4	follow	follow	NN
cord-005478-5iu38pr6	3563	5	-	-	HYPH
cord-005478-5iu38pr6	3563	6	up	up	NN
cord-005478-5iu38pr6	3563	7	of	of	IN
cord-005478-5iu38pr6	3563	8	22.8	22.8	CD
cord-005478-5iu38pr6	3563	9	months	month	NNS
cord-005478-5iu38pr6	3563	10	,	,	,
cord-005478-5iu38pr6	3563	11	there	there	EX
cord-005478-5iu38pr6	3563	12	was	be	VBD
cord-005478-5iu38pr6	3563	13	no	no	DT
cord-005478-5iu38pr6	3563	14	difference	difference	NN
cord-005478-5iu38pr6	3563	15	between	between	IN
cord-005478-5iu38pr6	3563	16	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3563	17	and	and	CC
cord-005478-5iu38pr6	3563	18	BM	BM	NNP
cord-005478-5iu38pr6	3563	19	graft	graft	NN
cord-005478-5iu38pr6	3563	20	in	in	IN
cord-005478-5iu38pr6	3563	21	terms	term	NNS
cord-005478-5iu38pr6	3563	22	of	of	IN
cord-005478-5iu38pr6	3563	23	cumulative	cumulative	JJ
cord-005478-5iu38pr6	3563	24	incidence	incidence	NN
cord-005478-5iu38pr6	3563	25	of	of	IN
cord-005478-5iu38pr6	3563	26	grade	grade	NN
cord-005478-5iu38pr6	3563	27	2	2	CD
cord-005478-5iu38pr6	3563	28	-	-	SYM
cord-005478-5iu38pr6	3563	29	4	4	CD
cord-005478-5iu38pr6	3563	30	acute	acute	JJ
cord-005478-5iu38pr6	3563	31	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3563	32	(	(	-LRB-
cord-005478-5iu38pr6	3563	33	29	29	CD
cord-005478-5iu38pr6	3563	34	%	%	NN
cord-005478-5iu38pr6	3563	35	vs	vs	IN
cord-005478-5iu38pr6	3563	36	21	21	CD
cord-005478-5iu38pr6	3563	37	%	%	NN
cord-005478-5iu38pr6	3563	38	,	,	,
cord-005478-5iu38pr6	3563	39	p=0.3	p=0.3	NNP
cord-005478-5iu38pr6	3563	40	)	)	-RRB-
cord-005478-5iu38pr6	3563	41	,	,	,
cord-005478-5iu38pr6	3563	42	grade	grade	NN
cord-005478-5iu38pr6	3563	43	3	3	CD
cord-005478-5iu38pr6	3563	44	-	-	SYM
cord-005478-5iu38pr6	3563	45	4	4	CD
cord-005478-5iu38pr6	3563	46	acute	acute	JJ
cord-005478-5iu38pr6	3563	47	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3563	48	(	(	-LRB-
cord-005478-5iu38pr6	3563	49	3	3	CD
cord-005478-5iu38pr6	3563	50	%	%	NN
cord-005478-5iu38pr6	3563	51	vs	vs	IN
cord-005478-5iu38pr6	3563	52	4	4	CD
cord-005478-5iu38pr6	3563	53	%	%	NN
cord-005478-5iu38pr6	3563	54	,	,	,
cord-005478-5iu38pr6	3563	55	p=0.7	p=0.7	NNP
cord-005478-5iu38pr6	3563	56	)	)	-RRB-
cord-005478-5iu38pr6	3563	57	and	and	CC
cord-005478-5iu38pr6	3563	58	moderate	moderate	JJ
cord-005478-5iu38pr6	3563	59	-	-	HYPH
cord-005478-5iu38pr6	3563	60	severe	severe	JJ
cord-005478-5iu38pr6	3563	61	chronic	chronic	JJ
cord-005478-5iu38pr6	3563	62	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3564	1	(	(	-LRB-
cord-005478-5iu38pr6	3564	2	9	9	CD
cord-005478-5iu38pr6	3564	3	%	%	NN
cord-005478-5iu38pr6	3564	4	vs	vs	IN
cord-005478-5iu38pr6	3564	5	7	7	CD
cord-005478-5iu38pr6	3564	6	%	%	NN
cord-005478-5iu38pr6	3564	7	,	,	,
cord-005478-5iu38pr6	3564	8	p=0.7	p=0.7	NNP
cord-005478-5iu38pr6	3564	9	)	)	-RRB-
cord-005478-5iu38pr6	3564	10	.	.	.
cord-005478-5iu38pr6	3565	1	This	this	DT
cord-005478-5iu38pr6	3565	2	was	be	VBD
cord-005478-5iu38pr6	3565	3	also	also	RB
cord-005478-5iu38pr6	3565	4	confirmed	confirm	VBN
cord-005478-5iu38pr6	3565	5	by	by	IN
cord-005478-5iu38pr6	3565	6	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3565	7	analysis	analysis	NN
cord-005478-5iu38pr6	3565	8	.	.	.
cord-005478-5iu38pr6	3566	1	In	in	IN
cord-005478-5iu38pr6	3566	2	the	the	DT
cord-005478-5iu38pr6	3566	3	whole	whole	JJ
cord-005478-5iu38pr6	3566	4	population	population	NN
cord-005478-5iu38pr6	3566	5	,	,	,
cord-005478-5iu38pr6	3566	6	the	the	DT
cord-005478-5iu38pr6	3566	7	2-year	2-year	JJ
cord-005478-5iu38pr6	3566	8	overall	overall	JJ
cord-005478-5iu38pr6	3566	9	survival	survival	NN
cord-005478-5iu38pr6	3566	10	(	(	-LRB-
cord-005478-5iu38pr6	3566	11	OS	OS	NNP
cord-005478-5iu38pr6	3566	12	)	)	-RRB-
cord-005478-5iu38pr6	3566	13	,	,	,
cord-005478-5iu38pr6	3566	14	2-year	2-year	JJ
cord-005478-5iu38pr6	3566	15	progression	progression	NN
cord-005478-5iu38pr6	3566	16	-	-	HYPH
cord-005478-5iu38pr6	3566	17	free	free	JJ
cord-005478-5iu38pr6	3566	18	survival	survival	NN
cord-005478-5iu38pr6	3566	19	(	(	-LRB-
cord-005478-5iu38pr6	3566	20	PFS	PFS	NNP
cord-005478-5iu38pr6	3566	21	)	)	-RRB-
cord-005478-5iu38pr6	3566	22	and	and	CC
cord-005478-5iu38pr6	3566	23	1-year	1-year	CD
cord-005478-5iu38pr6	3566	24	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3566	25	/	/	SYM
cord-005478-5iu38pr6	3566	26	relapse	relapse	VB
cord-005478-5iu38pr6	3566	27	free	free	JJ
cord-005478-5iu38pr6	3566	28	survival	survival	NN
cord-005478-5iu38pr6	3566	29	(	(	-LRB-
cord-005478-5iu38pr6	3566	30	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3566	31	)	)	-RRB-
cord-005478-5iu38pr6	3566	32	rates	rate	NNS
cord-005478-5iu38pr6	3566	33	were	be	VBD
cord-005478-5iu38pr6	3566	34	67	67	CD
cord-005478-5iu38pr6	3566	35	%	%	NN
cord-005478-5iu38pr6	3566	36	,	,	,
cord-005478-5iu38pr6	3566	37	58	58	CD
cord-005478-5iu38pr6	3566	38	%	%	NN
cord-005478-5iu38pr6	3566	39	and	and	CC
cord-005478-5iu38pr6	3566	40	58	58	CD
cord-005478-5iu38pr6	3566	41	%	%	NN
cord-005478-5iu38pr6	3566	42	,	,	,
cord-005478-5iu38pr6	3566	43	respectively	respectively	RB
cord-005478-5iu38pr6	3566	44	.	.	.
cord-005478-5iu38pr6	3567	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3567	2	observed	observe	VBD
cord-005478-5iu38pr6	3567	3	a	a	DT
cord-005478-5iu38pr6	3567	4	trend	trend	NN
cord-005478-5iu38pr6	3567	5	for	for	IN
cord-005478-5iu38pr6	3567	6	improved	improve	VBN
cord-005478-5iu38pr6	3567	7	OS	OS	NNP
cord-005478-5iu38pr6	3567	8	(	(	-LRB-
cord-005478-5iu38pr6	3567	9	74	74	CD
cord-005478-5iu38pr6	3567	10	%	%	NN
cord-005478-5iu38pr6	3567	11	vs	vs	IN
cord-005478-5iu38pr6	3567	12	62	62	CD
cord-005478-5iu38pr6	3567	13	%	%	NN
cord-005478-5iu38pr6	3567	14	,	,	,
cord-005478-5iu38pr6	3567	15	p=	p=	JJ
cord-005478-5iu38pr6	3567	16	0.07	0.07	CD
cord-005478-5iu38pr6	3567	17	)	)	-RRB-
cord-005478-5iu38pr6	3567	18	and	and	CC
cord-005478-5iu38pr6	3567	19	PFS	PFS	NNP
cord-005478-5iu38pr6	3567	20	(	(	-LRB-
cord-005478-5iu38pr6	3567	21	62	62	CD
cord-005478-5iu38pr6	3567	22	%	%	NN
cord-005478-5iu38pr6	3567	23	vs	vs	IN
cord-005478-5iu38pr6	3567	24	56	56	CD
cord-005478-5iu38pr6	3567	25	%	%	NN
cord-005478-5iu38pr6	3567	26	,	,	,
cord-005478-5iu38pr6	3567	27	p=	p=	NNP
cord-005478-5iu38pr6	3567	28	0.1	0.1	CD
cord-005478-5iu38pr6	3567	29	)	)	-RRB-
cord-005478-5iu38pr6	3567	30	for	for	IN
cord-005478-5iu38pr6	3567	31	recipients	recipient	NNS
cord-005478-5iu38pr6	3567	32	of	of	IN
cord-005478-5iu38pr6	3567	33	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3567	34	relative	relative	JJ
cord-005478-5iu38pr6	3567	35	to	to	IN
cord-005478-5iu38pr6	3567	36	BM	BM	NNP
cord-005478-5iu38pr6	3567	37	cells	cell	NNS
cord-005478-5iu38pr6	3567	38	,	,	,
cord-005478-5iu38pr6	3567	39	but	but	CC
cord-005478-5iu38pr6	3567	40	pre	pre	JJ
cord-005478-5iu38pr6	3567	41	-	-	JJ
cord-005478-5iu38pr6	3567	42	transplant	transplant	JJ
cord-005478-5iu38pr6	3567	43	disease	disease	NN
cord-005478-5iu38pr6	3567	44	status	status	NN
cord-005478-5iu38pr6	3567	45	was	be	VBD
cord-005478-5iu38pr6	3567	46	the	the	DT
cord-005478-5iu38pr6	3567	47	only	only	JJ
cord-005478-5iu38pr6	3567	48	significant	significant	JJ
cord-005478-5iu38pr6	3567	49	variable	variable	NN
cord-005478-5iu38pr6	3567	50	by	by	IN
cord-005478-5iu38pr6	3567	51	univariate	univariate	JJ
cord-005478-5iu38pr6	3567	52	analysis	analysis	NN
cord-005478-5iu38pr6	3567	53	(	(	-LRB-
cord-005478-5iu38pr6	3567	54	Table	table	NN
cord-005478-5iu38pr6	3567	55	I	i	CD
cord-005478-5iu38pr6	3567	56	)	)	-RRB-
cord-005478-5iu38pr6	3567	57	.	.	.
cord-005478-5iu38pr6	3568	1	By	by	IN
cord-005478-5iu38pr6	3568	2	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3568	3	analysis	analysis	NN
cord-005478-5iu38pr6	3568	4	,	,	,
cord-005478-5iu38pr6	3568	5	pre	pre	JJ
cord-005478-5iu38pr6	3568	6	-	-	JJ
cord-005478-5iu38pr6	3568	7	transplant	transplant	JJ
cord-005478-5iu38pr6	3568	8	active	active	JJ
cord-005478-5iu38pr6	3568	9	disease	disease	NN
cord-005478-5iu38pr6	3568	10	status	status	NN
cord-005478-5iu38pr6	3568	11	,	,	,
cord-005478-5iu38pr6	3568	12	transplant	transplant	NN
cord-005478-5iu38pr6	3568	13	from	from	IN
cord-005478-5iu38pr6	3568	14	a	a	DT
cord-005478-5iu38pr6	3568	15	BM	BM	NNP
cord-005478-5iu38pr6	3568	16	and	and	CC
cord-005478-5iu38pr6	3568	17	HCT	HCT	NNP
cord-005478-5iu38pr6	3568	18	-	-	HYPH
cord-005478-5iu38pr6	3568	19	CI	ci	NN
cord-005478-5iu38pr6	3569	1	≥	≥	NN
cord-005478-5iu38pr6	3569	2	3	3	CD
cord-005478-5iu38pr6	3569	3	remained	remain	VBD
cord-005478-5iu38pr6	3569	4	the	the	DT
cord-005478-5iu38pr6	3569	5	only	only	JJ
cord-005478-5iu38pr6	3569	6	independent	independent	JJ
cord-005478-5iu38pr6	3569	7	predictors	predictor	NNS
cord-005478-5iu38pr6	3569	8	of	of	IN
cord-005478-5iu38pr6	3569	9	adverse	adverse	JJ
cord-005478-5iu38pr6	3569	10	outcome	outcome	NN
cord-005478-5iu38pr6	3569	11	in	in	IN
cord-005478-5iu38pr6	3569	12	terms	term	NNS
cord-005478-5iu38pr6	3569	13	of	of	IN
cord-005478-5iu38pr6	3569	14	OS	OS	NNP
cord-005478-5iu38pr6	3569	15	;	;	:
cord-005478-5iu38pr6	3569	16	PFS	PFS	NNP
cord-005478-5iu38pr6	3569	17	and	and	CC
cord-005478-5iu38pr6	3569	18	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3569	19	(	(	-LRB-
cord-005478-5iu38pr6	3569	20	Table	table	NN
cord-005478-5iu38pr6	3569	21	I	i	CD
cord-005478-5iu38pr6	3569	22	)	)	-RRB-
cord-005478-5iu38pr6	3569	23	.	.	.
cord-005478-5iu38pr6	3570	1	Nonrelapse	nonrelapse	JJ
cord-005478-5iu38pr6	3570	2	mortality	mortality	NN
cord-005478-5iu38pr6	3570	3	was	be	VBD
cord-005478-5iu38pr6	3570	4	not	not	RB
cord-005478-5iu38pr6	3570	5	affected	affect	VBN
cord-005478-5iu38pr6	3570	6	by	by	IN
cord-005478-5iu38pr6	3570	7	graft	graft	NN
cord-005478-5iu38pr6	3570	8	source	source	NN
cord-005478-5iu38pr6	3570	9	both	both	CC
cord-005478-5iu38pr6	3570	10	by	by	IN
cord-005478-5iu38pr6	3570	11	univariate	univariate	JJ
cord-005478-5iu38pr6	3570	12	and	and	CC
cord-005478-5iu38pr6	3570	13	multivariate	multivariate	JJ
cord-005478-5iu38pr6	3570	14	analysis	analysis	NN
cord-005478-5iu38pr6	3570	15	,	,	,
cord-005478-5iu38pr6	3570	16	while	while	IN
cord-005478-5iu38pr6	3570	17	pre	pre	JJ
cord-005478-5iu38pr6	3570	18	-	-	JJ
cord-005478-5iu38pr6	3570	19	transplant	transplant	JJ
cord-005478-5iu38pr6	3570	20	disease	disease	NN
cord-005478-5iu38pr6	3570	21	status	status	NN
cord-005478-5iu38pr6	3570	22	was	be	VBD
cord-005478-5iu38pr6	3570	23	the	the	DT
cord-005478-5iu38pr6	3570	24	only	only	JJ
cord-005478-5iu38pr6	3570	25	variable	variable	NN
cord-005478-5iu38pr6	3570	26	affecting	affect	VBG
cord-005478-5iu38pr6	3570	27	the	the	DT
cord-005478-5iu38pr6	3570	28	chance	chance	NN
cord-005478-5iu38pr6	3570	29	of	of	IN
cord-005478-5iu38pr6	3570	30	disease	disease	NN
cord-005478-5iu38pr6	3570	31	relapse	relapse	NN
cord-005478-5iu38pr6	3570	32	.	.	.
cord-005478-5iu38pr6	3571	1	Conclusions	conclusion	NNS
cord-005478-5iu38pr6	3571	2	:	:	:
cord-005478-5iu38pr6	3572	1	Overall	overall	RB
cord-005478-5iu38pr6	3572	2	these	these	DT
cord-005478-5iu38pr6	3572	3	data	datum	NNS
cord-005478-5iu38pr6	3572	4	suggest	suggest	VBP
cord-005478-5iu38pr6	3572	5	that	that	IN
cord-005478-5iu38pr6	3572	6	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3572	7	is	be	VBZ
cord-005478-5iu38pr6	3572	8	associated	associate	VBN
cord-005478-5iu38pr6	3572	9	with	with	IN
cord-005478-5iu38pr6	3572	10	better	well	JJR
cord-005478-5iu38pr6	3572	11	outcome	outcome	NN
cord-005478-5iu38pr6	3572	12	,	,	,
cord-005478-5iu38pr6	3572	13	in	in	IN
cord-005478-5iu38pr6	3572	14	terms	term	NNS
cord-005478-5iu38pr6	3572	15	of	of	IN
cord-005478-5iu38pr6	3572	16	OS	OS	NNP
cord-005478-5iu38pr6	3572	17	,	,	,
cord-005478-5iu38pr6	3572	18	PFS	PFS	NNP
cord-005478-5iu38pr6	3572	19	and	and	CC
cord-005478-5iu38pr6	3572	20	GRFS	GRFS	NNP
cord-005478-5iu38pr6	3572	21	,	,	,
cord-005478-5iu38pr6	3572	22	relative	relative	JJ
cord-005478-5iu38pr6	3572	23	to	to	IN
cord-005478-5iu38pr6	3572	24	BM	BM	NNP
cord-005478-5iu38pr6	3572	25	cells	cell	NNS
cord-005478-5iu38pr6	3572	26	as	as	IN
cord-005478-5iu38pr6	3572	27	graft	graft	NN
cord-005478-5iu38pr6	3572	28	source	source	NN
cord-005478-5iu38pr6	3572	29	for	for	IN
cord-005478-5iu38pr6	3572	30	patients	patient	NNS
cord-005478-5iu38pr6	3572	31	undergoing	undergo	VBG
cord-005478-5iu38pr6	3572	32	Haplo	Haplo	NNP
cord-005478-5iu38pr6	3572	33	-	-	HYPH
cord-005478-5iu38pr6	3572	34	SCT	SCT	NNP
cord-005478-5iu38pr6	3572	35	with	with	IN
cord-005478-5iu38pr6	3572	36	PT	PT	NNP
cord-005478-5iu38pr6	3572	37	-	-	HYPH
cord-005478-5iu38pr6	3572	38	Cy	Cy	NNP
cord-005478-5iu38pr6	3572	39	.	.	.
cord-005478-5iu38pr6	3573	1	In	in	IN
cord-005478-5iu38pr6	3573	2	addition	addition	NN
cord-005478-5iu38pr6	3573	3	,	,	,
cord-005478-5iu38pr6	3573	4	the	the	DT
cord-005478-5iu38pr6	3573	5	risk	risk	NN
cord-005478-5iu38pr6	3573	6	of	of	IN
cord-005478-5iu38pr6	3573	7	acute	acute	JJ
cord-005478-5iu38pr6	3573	8	and	and	CC
cord-005478-5iu38pr6	3573	9	chronic	chronic	JJ
cord-005478-5iu38pr6	3573	10	GVHD	GVHD	NNP
cord-005478-5iu38pr6	3573	11	is	be	VBZ
cord-005478-5iu38pr6	3573	12	not	not	RB
cord-005478-5iu38pr6	3573	13	increased	increase	VBN
cord-005478-5iu38pr6	3573	14	after	after	IN
cord-005478-5iu38pr6	3573	15	PBSC	PBSC	NNP
cord-005478-5iu38pr6	3573	16	relative	relative	JJ
cord-005478-5iu38pr6	3573	17	to	to	IN
cord-005478-5iu38pr6	3573	18	BM	BM	NNP
cord-005478-5iu38pr6	3573	19	graft	graft	NN
cord-005478-5iu38pr6	3573	20	.	.	.
cord-005478-5iu38pr6	3574	1	References	References	NNPS
cord-005478-5iu38pr6	3574	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	3574	3	:	:	:
cord-005478-5iu38pr6	3575	1	The	the	DT
cord-005478-5iu38pr6	3575	2	authors	author	NNS
cord-005478-5iu38pr6	3575	3	have	have	VBP
cord-005478-5iu38pr6	3575	4	no	no	DT
cord-005478-5iu38pr6	3575	5	conflict	conflict	NN
cord-005478-5iu38pr6	3575	6	of	of	IN
cord-005478-5iu38pr6	3575	7	interests	interest	NNS
cord-005478-5iu38pr6	3575	8	to	to	TO
cord-005478-5iu38pr6	3575	9	disclose	disclose	VB
cord-005478-5iu38pr6	3575	10	O139	o139	PRP$
cord-005478-5iu38pr6	3575	11	Consensus	Consensus	NNP
cord-005478-5iu38pr6	3575	12	CRS	CRS	NNP
cord-005478-5iu38pr6	3575	13	and	and	CC
cord-005478-5iu38pr6	3575	14	neurotoxicity	neurotoxicity	NN
cord-005478-5iu38pr6	3575	15	regrading	regrading	NN
cord-005478-5iu38pr6	3575	16	of	of	IN
cord-005478-5iu38pr6	3575	17	"	"	``
cord-005478-5iu38pr6	3575	18	Juliet	Juliet	NNP
cord-005478-5iu38pr6	3575	19	"	"	''
cord-005478-5iu38pr6	3575	20	:	:	:
cord-005478-5iu38pr6	3575	21	Phase	Phase	NNP
cord-005478-5iu38pr6	3575	22	II	ii	CD
cord-005478-5iu38pr6	3575	23	prospective	prospective	JJ
cord-005478-5iu38pr6	3575	24	study	study	NN
cord-005478-5iu38pr6	3575	25	of	of	IN
cord-005478-5iu38pr6	3575	26	tisagenlecleucel	tisagenlecleucel	JJ
cord-005478-5iu38pr6	3575	27	therapy	therapy	NN
cord-005478-5iu38pr6	3575	28	in	in	IN
cord-005478-5iu38pr6	3575	29	patients	patient	NNS
cord-005478-5iu38pr6	3575	30	with	with	IN
cord-005478-5iu38pr6	3575	31	relapsed/	relapsed/	NN
cord-005478-5iu38pr6	3575	32	refractory	refractory	JJ
cord-005478-5iu38pr6	3575	33	large	large	JJ
cord-005478-5iu38pr6	3575	34	B	b	NN
cord-005478-5iu38pr6	3575	35	cell	cell	NN
cord-005478-5iu38pr6	3575	36	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3575	37	Background	background	NN
cord-005478-5iu38pr6	3575	38	:	:	:
cord-005478-5iu38pr6	3575	39	T	t	NN
cord-005478-5iu38pr6	3575	40	-	-	HYPH
cord-005478-5iu38pr6	3575	41	cell	cell	NN
cord-005478-5iu38pr6	3575	42	depletion	depletion	NN
cord-005478-5iu38pr6	3575	43	using	use	VBG
cord-005478-5iu38pr6	3575	44	ex	ex	FW
cord-005478-5iu38pr6	3575	45	vivo	vivo	NN
cord-005478-5iu38pr6	3575	46	CD34	CD34	NNP
cord-005478-5iu38pr6	3575	47	+	+	CC
cord-005478-5iu38pr6	3575	48	cell	cell	NN
cord-005478-5iu38pr6	3575	49	selection	selection	NN
cord-005478-5iu38pr6	3575	50	reduces	reduce	VBZ
cord-005478-5iu38pr6	3575	51	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3575	52	risk	risk	NN
cord-005478-5iu38pr6	3575	53	after	after	IN
cord-005478-5iu38pr6	3575	54	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3575	55	HCT	hct	NN
cord-005478-5iu38pr6	3575	56	,	,	,
cord-005478-5iu38pr6	3575	57	but	but	CC
cord-005478-5iu38pr6	3575	58	delayed	delay	VBN
cord-005478-5iu38pr6	3575	59	immune	immune	JJ
cord-005478-5iu38pr6	3575	60	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3575	61	,	,	,
cord-005478-5iu38pr6	3575	62	particularly	particularly	RB
cord-005478-5iu38pr6	3575	63	T	t	NN
cord-005478-5iu38pr6	3575	64	-	-	HYPH
cord-005478-5iu38pr6	3575	65	cell	cell	NN
cord-005478-5iu38pr6	3575	66	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3575	67	,	,	,
cord-005478-5iu38pr6	3575	68	has	have	VBZ
cord-005478-5iu38pr6	3575	69	limited	limit	VBN
cord-005478-5iu38pr6	3575	70	improvement	improvement	NN
cord-005478-5iu38pr6	3575	71	in	in	IN
cord-005478-5iu38pr6	3575	72	survival	survival	NN
cord-005478-5iu38pr6	3575	73	.	.	.
cord-005478-5iu38pr6	3576	1	Sex	sex	NN
cord-005478-5iu38pr6	3576	2	steroids	steroid	NNS
cord-005478-5iu38pr6	3576	3	negatively	negatively	RB
cord-005478-5iu38pr6	3576	4	impact	impact	VBP
cord-005478-5iu38pr6	3576	5	lymphopoiesis	lymphopoiesis	NN
cord-005478-5iu38pr6	3576	6	,	,	,
cord-005478-5iu38pr6	3576	7	likely	likely	JJ
cord-005478-5iu38pr6	3576	8	by	by	IN
cord-005478-5iu38pr6	3576	9	thymic	thymic	JJ
cord-005478-5iu38pr6	3576	10	atrophy	atrophy	NN
cord-005478-5iu38pr6	3576	11	,	,	,
cord-005478-5iu38pr6	3576	12	and	and	CC
cord-005478-5iu38pr6	3577	1	our	-PRON-	PRP$
cord-005478-5iu38pr6	3577	2	preclinical	preclinical	JJ
cord-005478-5iu38pr6	3577	3	models	model	NNS
cord-005478-5iu38pr6	3577	4	have	have	VBP
cord-005478-5iu38pr6	3577	5	shown	show	VBN
cord-005478-5iu38pr6	3577	6	that	that	IN
cord-005478-5iu38pr6	3577	7	androgen	androgen	NN
cord-005478-5iu38pr6	3577	8	blockade	blockade	NN
cord-005478-5iu38pr6	3577	9	with	with	IN
cord-005478-5iu38pr6	3577	10	the	the	DT
cord-005478-5iu38pr6	3577	11	GnRH	GnRH	NNP
cord-005478-5iu38pr6	3577	12	agonist	agonist	NN
cord-005478-5iu38pr6	3577	13	leuprolide	leuprolide	NNP
cord-005478-5iu38pr6	3577	14	enhances	enhance	VBZ
cord-005478-5iu38pr6	3577	15	thymopoiesis	thymopoiesis	NNP
cord-005478-5iu38pr6	3577	16	(	(	-LRB-
cord-005478-5iu38pr6	3577	17	Goldberg	Goldberg	NNP
cord-005478-5iu38pr6	3577	18	,	,	,
cord-005478-5iu38pr6	3577	19	JI	JI	NNP
cord-005478-5iu38pr6	3577	20	2009	2009	CD
cord-005478-5iu38pr6	3577	21	;	;	:
cord-005478-5iu38pr6	3577	22	Velardi	Velardi	NNP
cord-005478-5iu38pr6	3577	23	,	,	,
cord-005478-5iu38pr6	3577	24	JEM	JEM	NNP
cord-005478-5iu38pr6	3577	25	2014	2014	CD
cord-005478-5iu38pr6	3577	26	)	)	-RRB-
cord-005478-5iu38pr6	3577	27	.	.	.
cord-005478-5iu38pr6	3578	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3578	2	hypothesized	hypothesize	VBD
cord-005478-5iu38pr6	3578	3	that	that	IN
cord-005478-5iu38pr6	3578	4	peri	peri	NN
cord-005478-5iu38pr6	3578	5	-	-	HYPH
cord-005478-5iu38pr6	3578	6	HCT	HCT	NNP
cord-005478-5iu38pr6	3578	7	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	3578	8	could	could	MD
cord-005478-5iu38pr6	3578	9	improve	improve	VB
cord-005478-5iu38pr6	3578	10	immune	immune	JJ
cord-005478-5iu38pr6	3578	11	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3578	12	among	among	IN
cord-005478-5iu38pr6	3578	13	recipients	recipient	NNS
cord-005478-5iu38pr6	3578	14	of	of	IN
cord-005478-5iu38pr6	3578	15	CD34selected	cd34selecte	VBN
cord-005478-5iu38pr6	3578	16	HCT.Methods	hct.method	NNS
cord-005478-5iu38pr6	3578	17	:	:	:
cord-005478-5iu38pr6	3579	1	This	this	DT
cord-005478-5iu38pr6	3579	2	was	be	VBD
cord-005478-5iu38pr6	3579	3	a	a	DT
cord-005478-5iu38pr6	3579	4	phase	phase	NN
cord-005478-5iu38pr6	3579	5	II	ii	CD
cord-005478-5iu38pr6	3579	6	clinical	clinical	JJ
cord-005478-5iu38pr6	3579	7	trial	trial	NN
cord-005478-5iu38pr6	3579	8	of	of	IN
cord-005478-5iu38pr6	3579	9	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	3579	10	in	in	IN
cord-005478-5iu38pr6	3579	11	CD34-selected	CD34-selected	NNP
cord-005478-5iu38pr6	3579	12	myeloablative	myeloablative	NNP
cord-005478-5iu38pr6	3579	13	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3579	14	PBSCT	PBSCT	NNP
cord-005478-5iu38pr6	3579	15	for	for	IN
cord-005478-5iu38pr6	3579	16	hematologic	hematologic	JJ
cord-005478-5iu38pr6	3579	17	malignancies	malignancy	NNS
cord-005478-5iu38pr6	3579	18	in	in	IN
cord-005478-5iu38pr6	3579	19	patients	patient	NNS
cord-005478-5iu38pr6	3579	20	aged	age	VBN
cord-005478-5iu38pr6	3579	21	18	18	CD
cord-005478-5iu38pr6	3579	22	-	-	SYM
cord-005478-5iu38pr6	3579	23	60	60	CD
cord-005478-5iu38pr6	3579	24	(	(	-LRB-
cord-005478-5iu38pr6	3579	25	NCT01746849	NCT01746849	NNP
cord-005478-5iu38pr6	3579	26	)	)	-RRB-
cord-005478-5iu38pr6	3579	27	.	.	.
cord-005478-5iu38pr6	3580	1	All	all	DT
cord-005478-5iu38pr6	3580	2	participants	participant	NNS
cord-005478-5iu38pr6	3580	3	received	receive	VBD
cord-005478-5iu38pr6	3580	4	conditioning	conditioning	NN
cord-005478-5iu38pr6	3580	5	with	with	IN
cord-005478-5iu38pr6	3580	6	TBI	TBI	NNP
cord-005478-5iu38pr6	3580	7	1375cGy	1375cGy	NNP
cord-005478-5iu38pr6	3580	8	,	,	,
cord-005478-5iu38pr6	3580	9	thiotepa	thiotepa	NNP
cord-005478-5iu38pr6	3580	10	10mg	10mg	NNP
cord-005478-5iu38pr6	3580	11	/	/	SYM
cord-005478-5iu38pr6	3580	12	kg	kg	NNP
cord-005478-5iu38pr6	3580	13	,	,	,
cord-005478-5iu38pr6	3580	14	and	and	CC
cord-005478-5iu38pr6	3580	15	cyclophosphamide	cyclophosphamide	RB
cord-005478-5iu38pr6	3580	16	120mg	120mg	NNP
cord-005478-5iu38pr6	3580	17	/	/	SYM
cord-005478-5iu38pr6	3580	18	kg	kg	NN
cord-005478-5iu38pr6	3580	19	;	;	:
cord-005478-5iu38pr6	3580	20	antirejection	antirejection	NN
cord-005478-5iu38pr6	3580	21	prophylaxis	prophylaxis	NN
cord-005478-5iu38pr6	3580	22	with	with	IN
cord-005478-5iu38pr6	3580	23	rabbit	rabbit	NN
cord-005478-5iu38pr6	3580	24	ATG	ATG	NNP
cord-005478-5iu38pr6	3580	25	5	5	CD
cord-005478-5iu38pr6	3580	26	-	-	SYM
cord-005478-5iu38pr6	3580	27	7.5mg	7.5mg	CD
cord-005478-5iu38pr6	3580	28	/	/	SYM
cord-005478-5iu38pr6	3580	29	kg	kg	NN
cord-005478-5iu38pr6	3580	30	;	;	:
cord-005478-5iu38pr6	3580	31	and	and	CC
cord-005478-5iu38pr6	3580	32	palifermin	palifermin	NN
cord-005478-5iu38pr6	3580	33	60	60	CD
cord-005478-5iu38pr6	3580	34	mg	mg	NNP
cord-005478-5iu38pr6	3581	1	/kg	/kg	NFP
cord-005478-5iu38pr6	3581	2	/	/	SYM
cord-005478-5iu38pr6	3581	3	d	d	XX
cord-005478-5iu38pr6	3581	4	on	on	IN
cord-005478-5iu38pr6	3581	5	days	day	NNS
cord-005478-5iu38pr6	3581	6	-13	-13	VBG
cord-005478-5iu38pr6	3581	7	to	to	IN
cord-005478-5iu38pr6	3581	8	-11	-11	NN
cord-005478-5iu38pr6	3581	9	and	and	CC
cord-005478-5iu38pr6	3581	10	0	0	CD
cord-005478-5iu38pr6	3581	11	to	to	IN
cord-005478-5iu38pr6	3581	12	+2	+2	CD
cord-005478-5iu38pr6	3581	13	.	.	.
cord-005478-5iu38pr6	3582	1	Patients	patient	NNS
cord-005478-5iu38pr6	3582	2	received	receive	VBD
cord-005478-5iu38pr6	3582	3	a	a	DT
cord-005478-5iu38pr6	3582	4	3-month	3-month	CD
cord-005478-5iu38pr6	3582	5	depot	depot	NN
cord-005478-5iu38pr6	3582	6	of	of	IN
cord-005478-5iu38pr6	3582	7	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	3582	8	11.25	11.25	CD
cord-005478-5iu38pr6	3582	9	mg	mg	NNP
cord-005478-5iu38pr6	3582	10	2	2	CD
cord-005478-5iu38pr6	3582	11	-	-	SYM
cord-005478-5iu38pr6	3582	12	6	6	CD
cord-005478-5iu38pr6	3582	13	weeks	week	NNS
cord-005478-5iu38pr6	3582	14	before	before	IN
cord-005478-5iu38pr6	3582	15	conditioning	conditioning	NN
cord-005478-5iu38pr6	3582	16	and	and	CC
cord-005478-5iu38pr6	3582	17	a	a	DT
cord-005478-5iu38pr6	3582	18	second	second	JJ
cord-005478-5iu38pr6	3582	19	depot	depot	NN
cord-005478-5iu38pr6	3582	20	3	3	CD
cord-005478-5iu38pr6	3582	21	months	month	NNS
cord-005478-5iu38pr6	3582	22	later	later	RB
cord-005478-5iu38pr6	3582	23	.	.	.
cord-005478-5iu38pr6	3583	1	Primary	primary	JJ
cord-005478-5iu38pr6	3583	2	endpoint	endpoint	NN
cord-005478-5iu38pr6	3583	3	was	be	VBD
cord-005478-5iu38pr6	3583	4	an	an	DT
cord-005478-5iu38pr6	3583	5	absolute	absolute	JJ
cord-005478-5iu38pr6	3583	6	CD4	CD4	NNP
cord-005478-5iu38pr6	3583	7	+	+	CC
cord-005478-5iu38pr6	3583	8	count	count	NN
cord-005478-5iu38pr6	3583	9	>	>	XX
cord-005478-5iu38pr6	3583	10	=	=	SYM
cord-005478-5iu38pr6	3583	11	200	200	CD
cord-005478-5iu38pr6	3583	12	by	by	IN
cord-005478-5iu38pr6	3583	13	6	6	CD
cord-005478-5iu38pr6	3583	14	months	month	NNS
cord-005478-5iu38pr6	3583	15	post	post	NN
cord-005478-5iu38pr6	3583	16	-	-	NN
cord-005478-5iu38pr6	3583	17	HCT	hct	NN
cord-005478-5iu38pr6	3583	18	.	.	.
cord-005478-5iu38pr6	3584	1	Patients	patient	NNS
cord-005478-5iu38pr6	3584	2	who	who	WP
cord-005478-5iu38pr6	3584	3	died	die	VBD
cord-005478-5iu38pr6	3584	4	,	,	,
cord-005478-5iu38pr6	3584	5	relapsed	relapse	VBN
cord-005478-5iu38pr6	3584	6	,	,	,
cord-005478-5iu38pr6	3584	7	or	or	CC
cord-005478-5iu38pr6	3584	8	otherwise	otherwise	RB
cord-005478-5iu38pr6	3584	9	did	do	VBD
cord-005478-5iu38pr6	3584	10	not	not	RB
cord-005478-5iu38pr6	3584	11	have	have	VB
cord-005478-5iu38pr6	3584	12	flow	flow	NN
cord-005478-5iu38pr6	3584	13	data	datum	NNS
cord-005478-5iu38pr6	3584	14	available	available	JJ
cord-005478-5iu38pr6	3584	15	at	at	IN
cord-005478-5iu38pr6	3584	16	day	day	NN
cord-005478-5iu38pr6	3585	1	+180	+180	NNP
cord-005478-5iu38pr6	3585	2	were	be	VBD
cord-005478-5iu38pr6	3585	3	excluded	exclude	VBN
cord-005478-5iu38pr6	3585	4	from	from	IN
cord-005478-5iu38pr6	3585	5	primary	primary	JJ
cord-005478-5iu38pr6	3585	6	endpoint	endpoint	NN
cord-005478-5iu38pr6	3585	7	analysis	analysis	NN
cord-005478-5iu38pr6	3585	8	but	but	CC
cord-005478-5iu38pr6	3585	9	included	include	VBN
cord-005478-5iu38pr6	3585	10	in	in	IN
cord-005478-5iu38pr6	3585	11	outcome	outcome	NN
cord-005478-5iu38pr6	3585	12	analyses	analysis	NNS
cord-005478-5iu38pr6	3585	13	.	.	.
cord-005478-5iu38pr6	3586	1	We	-PRON-	PRP
cord-005478-5iu38pr6	3586	2	excluded	exclude	VBD
cord-005478-5iu38pr6	3586	3	flow	flow	NN
cord-005478-5iu38pr6	3586	4	data	datum	NNS
cord-005478-5iu38pr6	3586	5	after	after	IN
cord-005478-5iu38pr6	3586	6	secondary	secondary	JJ
cord-005478-5iu38pr6	3586	7	cell	cell	NN
cord-005478-5iu38pr6	3586	8	infusions	infusion	NNS
cord-005478-5iu38pr6	3586	9	(	(	-LRB-
cord-005478-5iu38pr6	3586	10	DLI	DLI	NNP
cord-005478-5iu38pr6	3586	11	,	,	,
cord-005478-5iu38pr6	3586	12	CTLs	CTLs	NNP
cord-005478-5iu38pr6	3586	13	,	,	,
cord-005478-5iu38pr6	3586	14	second	second	JJ
cord-005478-5iu38pr6	3586	15	HCT	hct	NN
cord-005478-5iu38pr6	3586	16	,	,	,
cord-005478-5iu38pr6	3586	17	CD34	CD34	NNP
cord-005478-5iu38pr6	3586	18	+	+	CC
cord-005478-5iu38pr6	3586	19	cell	cell	NN
cord-005478-5iu38pr6	3586	20	boost	boost	NN
cord-005478-5iu38pr6	3586	21	)	)	-RRB-
cord-005478-5iu38pr6	3586	22	but	but	CC
cord-005478-5iu38pr6	3586	23	followed	follow	VBD
cord-005478-5iu38pr6	3586	24	recipients	recipient	NNS
cord-005478-5iu38pr6	3586	25	of	of	IN
cord-005478-5iu38pr6	3586	26	these	these	DT
cord-005478-5iu38pr6	3586	27	interventions	intervention	NNS
cord-005478-5iu38pr6	3586	28	for	for	IN
cord-005478-5iu38pr6	3586	29	survival	survival	NN
cord-005478-5iu38pr6	3586	30	analysis	analysis	NN
cord-005478-5iu38pr6	3586	31	.	.	.
cord-005478-5iu38pr6	3587	1	Descriptive	descriptive	JJ
cord-005478-5iu38pr6	3587	2	statistics	statistic	NNS
cord-005478-5iu38pr6	3587	3	summarized	summarize	VBD
cord-005478-5iu38pr6	3587	4	absolute	absolute	JJ
cord-005478-5iu38pr6	3587	5	levels	level	NNS
cord-005478-5iu38pr6	3587	6	of	of	IN
cord-005478-5iu38pr6	3587	7	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	3587	8	subset	subset	NN
cord-005478-5iu38pr6	3587	9	counts	count	NNS
cord-005478-5iu38pr6	3587	10	at	at	IN
cord-005478-5iu38pr6	3587	11	select	select	JJ
cord-005478-5iu38pr6	3587	12	time	time	NN
cord-005478-5iu38pr6	3587	13	intervals	interval	NNS
cord-005478-5iu38pr6	3587	14	.	.	.
cord-005478-5iu38pr6	3588	1	A	a	DT
cord-005478-5iu38pr6	3588	2	Kruskal	Kruskal	NNP
cord-005478-5iu38pr6	3588	3	-	-	HYPH
cord-005478-5iu38pr6	3588	4	Wallis	Wallis	NNP
cord-005478-5iu38pr6	3588	5	rank	rank	NN
cord-005478-5iu38pr6	3588	6	sum	sum	NN
cord-005478-5iu38pr6	3588	7	test	test	NN
cord-005478-5iu38pr6	3588	8	compared	compare	VBN
cord-005478-5iu38pr6	3588	9	counts	count	NNS
cord-005478-5iu38pr6	3588	10	among	among	IN
cord-005478-5iu38pr6	3588	11	patients	patient	NNS
cord-005478-5iu38pr6	3588	12	who	who	WP
cord-005478-5iu38pr6	3588	13	received	receive	VBD
cord-005478-5iu38pr6	3588	14	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	3588	15	/	/	SYM
cord-005478-5iu38pr6	3588	16	palifermin	palifermin	NN
cord-005478-5iu38pr6	3588	17	,	,	,
cord-005478-5iu38pr6	3588	18	historical	historical	JJ
cord-005478-5iu38pr6	3588	19	controls	control	NNS
cord-005478-5iu38pr6	3588	20	who	who	WP
cord-005478-5iu38pr6	3588	21	received	receive	VBD
cord-005478-5iu38pr6	3588	22	palifermin	palifermin	NNP
cord-005478-5iu38pr6	3588	23	alone	alone	RB
cord-005478-5iu38pr6	3588	24	,	,	,
cord-005478-5iu38pr6	3588	25	and	and	CC
cord-005478-5iu38pr6	3588	26	historical	historical	JJ
cord-005478-5iu38pr6	3588	27	controls	control	NNS
cord-005478-5iu38pr6	3588	28	who	who	WP
cord-005478-5iu38pr6	3588	29	received	receive	VBD
cord-005478-5iu38pr6	3588	30	neither	neither	RB
cord-005478-5iu38pr6	3588	31	.	.	.
cord-005478-5iu38pr6	3589	1	Kaplan	Kaplan	NNP
cord-005478-5iu38pr6	3589	2	-	-	HYPH
cord-005478-5iu38pr6	3589	3	Meier	Meier	NNP
cord-005478-5iu38pr6	3589	4	functions	function	NNS
cord-005478-5iu38pr6	3589	5	estimated	estimate	VBN
cord-005478-5iu38pr6	3589	6	OS/	os/	CC
cord-005478-5iu38pr6	3589	7	RFS	RFS	NNP
cord-005478-5iu38pr6	3589	8	.	.	.
cord-005478-5iu38pr6	3590	1	Cumulative	cumulative	JJ
cord-005478-5iu38pr6	3590	2	incidence	incidence	NN
cord-005478-5iu38pr6	3590	3	functions	function	NNS
cord-005478-5iu38pr6	3590	4	estimated	estimate	VBN
cord-005478-5iu38pr6	3590	5	GvHD/	gvhd/	NN
cord-005478-5iu38pr6	3591	1	NRM.Results	NRM.Results	NNP
cord-005478-5iu38pr6	3591	2	:	:	:
cord-005478-5iu38pr6	3592	1	Thirty	thirty	CD
cord-005478-5iu38pr6	3592	2	-	-	HYPH
cord-005478-5iu38pr6	3592	3	two	two	CD
cord-005478-5iu38pr6	3592	4	patients	patient	NNS
cord-005478-5iu38pr6	3592	5	received	receive	VBD
cord-005478-5iu38pr6	3592	6	at	at	IN
cord-005478-5iu38pr6	3592	7	least	least	RBS
cord-005478-5iu38pr6	3592	8	one	one	CD
cord-005478-5iu38pr6	3592	9	dose	dose	NN
cord-005478-5iu38pr6	3592	10	of	of	IN
cord-005478-5iu38pr6	3592	11	leuprolide	leuprolide	NN
cord-005478-5iu38pr6	3592	12	.	.	.
cord-005478-5iu38pr6	3593	1	Median	median	JJ
cord-005478-5iu38pr6	3593	2	age	age	NN
cord-005478-5iu38pr6	3593	3	was	be	VBD
cord-005478-5iu38pr6	3593	4	39	39	CD
cord-005478-5iu38pr6	3593	5	years	year	NNS
cord-005478-5iu38pr6	3594	1	(	(	-LRB-
cord-005478-5iu38pr6	3594	2	range	range	NNP
cord-005478-5iu38pr6	3594	3	21	21	CD
cord-005478-5iu38pr6	3594	4	-	-	SYM
cord-005478-5iu38pr6	3594	5	57	57	CD
cord-005478-5iu38pr6	3594	6	)	)	-RRB-
cord-005478-5iu38pr6	3594	7	.	.	.
cord-005478-5iu38pr6	3595	1	Twenty	twenty	CD
cord-005478-5iu38pr6	3595	2	-	-	HYPH
cord-005478-5iu38pr6	3595	3	six(82	six(82	NN
cord-005478-5iu38pr6	3595	4	%	%	NN
cord-005478-5iu38pr6	3595	5	)	)	-RRB-
cord-005478-5iu38pr6	3595	6	had	have	VBD
cord-005478-5iu38pr6	3595	7	acute	acute	JJ
cord-005478-5iu38pr6	3595	8	leukemia	leukemia	NN
cord-005478-5iu38pr6	3595	9	,	,	,
cord-005478-5iu38pr6	3595	10	3(9	3(9	NNP
cord-005478-5iu38pr6	3595	11	%	%	NN
cord-005478-5iu38pr6	3595	12	)	)	-RRB-
cord-005478-5iu38pr6	3596	1	MDS	MDS	NNP
cord-005478-5iu38pr6	3596	2	/	/	SYM
cord-005478-5iu38pr6	3596	3	MPN	MPN	NNP
cord-005478-5iu38pr6	3596	4	,	,	,
cord-005478-5iu38pr6	3596	5	and	and	CC
cord-005478-5iu38pr6	3596	6	3(9	3(9	CD
cord-005478-5iu38pr6	3596	7	%	%	NN
cord-005478-5iu38pr6	3596	8	)	)	-RRB-
cord-005478-5iu38pr6	3597	1	CML	CML	NNP
cord-005478-5iu38pr6	3597	2	.	.	.
cord-005478-5iu38pr6	3598	1	All	all	DT
cord-005478-5iu38pr6	3598	2	but	but	IN
cord-005478-5iu38pr6	3598	3	one	one	PRP
cord-005478-5iu38pr6	3598	4	had	have	VBD
cord-005478-5iu38pr6	3598	5	an	an	DT
cord-005478-5iu38pr6	3598	6	8/8-matched	8/8-matched	CD
cord-005478-5iu38pr6	3598	7	donor	donor	NN
cord-005478-5iu38pr6	3598	8	.	.	.
cord-005478-5iu38pr6	3599	1	At	at	IN
cord-005478-5iu38pr6	3599	2	median	median	JJ
cord-005478-5iu38pr6	3599	3	follow	follow	NN
cord-005478-5iu38pr6	3599	4	-	-	HYPH
cord-005478-5iu38pr6	3599	5	up	up	NN
cord-005478-5iu38pr6	3599	6	of	of	IN
cord-005478-5iu38pr6	3599	7	24	24	CD
cord-005478-5iu38pr6	3599	8	months	month	NNS
cord-005478-5iu38pr6	3599	9	among	among	IN
cord-005478-5iu38pr6	3599	10	survivors	survivor	NNS
cord-005478-5iu38pr6	3599	11	(	(	-LRB-
cord-005478-5iu38pr6	3599	12	range	range	VBP
cord-005478-5iu38pr6	3599	13	7	7	CD
cord-005478-5iu38pr6	3599	14	-	-	SYM
cord-005478-5iu38pr6	3599	15	61	61	CD
cord-005478-5iu38pr6	3599	16	)	)	-RRB-
cord-005478-5iu38pr6	3599	17	,	,	,
cord-005478-5iu38pr6	3599	18	estimated	estimate	VBN
cord-005478-5iu38pr6	3599	19	2Y	2y	NN
cord-005478-5iu38pr6	3599	20	OS	OS	NNP
cord-005478-5iu38pr6	3599	21	was	be	VBD
cord-005478-5iu38pr6	3599	22	74%(95%CI	74%(95%ci	CD
cord-005478-5iu38pr6	3599	23	60	60	CD
cord-005478-5iu38pr6	3599	24	-	-	SYM
cord-005478-5iu38pr6	3599	25	91	91	CD
cord-005478-5iu38pr6	3599	26	%	%	NN
cord-005478-5iu38pr6	3599	27	)	)	-RRB-
cord-005478-5iu38pr6	3599	28	and	and	CC
cord-005478-5iu38pr6	3599	29	RFS	RFS	NNP
cord-005478-5iu38pr6	3599	30	62%(95%CI	62%(95%ci	CD
cord-005478-5iu38pr6	3599	31	46	46	CD
cord-005478-5iu38pr6	3599	32	-	-	SYM
cord-005478-5iu38pr6	3599	33	83	83	CD
cord-005478-5iu38pr6	3599	34	%	%	NN
cord-005478-5iu38pr6	3599	35	)	)	-RRB-
cord-005478-5iu38pr6	3599	36	.	.	.
cord-005478-5iu38pr6	3600	1	CI	CI	NNP
cord-005478-5iu38pr6	3600	2	of	of	IN
cord-005478-5iu38pr6	3600	3	TRM	TRM	NNP
cord-005478-5iu38pr6	3600	4	at	at	IN
cord-005478-5iu38pr6	3600	5	2Y	2Y	NNP
cord-005478-5iu38pr6	3600	6	was	be	VBD
cord-005478-5iu38pr6	3600	7	10%(95%CI	10%(95%ci	CD
cord-005478-5iu38pr6	3600	8	2	2	CD
cord-005478-5iu38pr6	3600	9	-	-	SYM
cord-005478-5iu38pr6	3600	10	24	24	CD
cord-005478-5iu38pr6	3600	11	%	%	NN
cord-005478-5iu38pr6	3600	12	)	)	-RRB-
cord-005478-5iu38pr6	3600	13	.	.	.
cord-005478-5iu38pr6	3601	1	CI	CI	NNP
cord-005478-5iu38pr6	3601	2	of	of	IN
cord-005478-5iu38pr6	3601	3	grade	grade	NN
cord-005478-5iu38pr6	3601	4	III	III	NNP
cord-005478-5iu38pr6	3601	5	-	-	HYPH
cord-005478-5iu38pr6	3601	6	IV	IV	NNP
cord-005478-5iu38pr6	3601	7	acute	acute	JJ
cord-005478-5iu38pr6	3601	8	GvHD	GvHD	NNP
cord-005478-5iu38pr6	3601	9	was	be	VBD
cord-005478-5iu38pr6	3601	10	3%(95%CI	3%(95%ci	CD
cord-005478-5iu38pr6	3601	11	0.2	0.2	CD
cord-005478-5iu38pr6	3601	12	-	-	SYM
cord-005478-5iu38pr6	3601	13	14	14	CD
cord-005478-5iu38pr6	3601	14	%	%	NN
cord-005478-5iu38pr6	3601	15	)	)	-RRB-
cord-005478-5iu38pr6	3601	16	.	.	.
cord-005478-5iu38pr6	3602	1	Of	of	IN
cord-005478-5iu38pr6	3602	2	27	27	CD
cord-005478-5iu38pr6	3602	3	patients	patient	NNS
cord-005478-5iu38pr6	3602	4	with	with	IN
cord-005478-5iu38pr6	3602	5	evaluable	evaluable	JJ
cord-005478-5iu38pr6	3602	6	flow	flow	NN
cord-005478-5iu38pr6	3602	7	data	datum	NNS
cord-005478-5iu38pr6	3602	8	,	,	,
cord-005478-5iu38pr6	3602	9	30	30	CD
cord-005478-5iu38pr6	3602	10	%	%	NN
cord-005478-5iu38pr6	3602	11	achieved	achieve	VBD
cord-005478-5iu38pr6	3602	12	a	a	DT
cord-005478-5iu38pr6	3602	13	CD4	CD4	NNP
cord-005478-5iu38pr6	3602	14	+	+	CC
cord-005478-5iu38pr6	3602	15	count	count	NN
cord-005478-5iu38pr6	3602	16	>	>	XX
cord-005478-5iu38pr6	3603	1	=	=	SYM
cord-005478-5iu38pr6	3603	2	200	200	CD
cord-005478-5iu38pr6	3603	3	by	by	IN
cord-005478-5iu38pr6	3603	4	180+/-30	180+/-30	CD
cord-005478-5iu38pr6	3603	5	days	day	NNS
cord-005478-5iu38pr6	3603	6	,	,	,
cord-005478-5iu38pr6	3603	7	not	not	RB
cord-005478-5iu38pr6	3603	8	significantly	significantly	RB
cord-005478-5iu38pr6	3603	9	different	different	JJ
cord-005478-5iu38pr6	3603	10	from	from	IN
cord-005478-5iu38pr6	3603	11	historical	historical	JJ
cord-005478-5iu38pr6	3603	12	controls	control	NNS
cord-005478-5iu38pr6	3603	13	.	.	.
cord-005478-5iu38pr6	3604	1	Median	median	JJ
cord-005478-5iu38pr6	3604	2	lymphocyte	lymphocyte	NN
cord-005478-5iu38pr6	3604	3	counts	count	VBZ
cord-005478-5iu38pr6	3604	4	at	at	IN
cord-005478-5iu38pr6	3604	5	180+/-30	180+/-30	CD
cord-005478-5iu38pr6	3604	6	days	day	NNS
cord-005478-5iu38pr6	3604	7	did	do	VBD
cord-005478-5iu38pr6	3604	8	not	not	RB
cord-005478-5iu38pr6	3604	9	differ	differ	VB
cord-005478-5iu38pr6	3604	10	significantly	significantly	RB
cord-005478-5iu38pr6	3604	11	among	among	IN
cord-005478-5iu38pr6	3604	12	groups	group	NNS
cord-005478-5iu38pr6	3604	13	(	(	-LRB-
cord-005478-5iu38pr6	3604	14	Table	table	NN
cord-005478-5iu38pr6	3604	15	;	;	:
cord-005478-5iu38pr6	3604	16	Figure	figure	NN
cord-005478-5iu38pr6	3604	17	)	)	-RRB-
cord-005478-5iu38pr6	3605	1	.Conclusions	.conclusion	NNS
cord-005478-5iu38pr6	3605	2	:	:	:
cord-005478-5iu38pr6	3606	1	This	this	DT
cord-005478-5iu38pr6	3606	2	phase	phase	NN
cord-005478-5iu38pr6	3606	3	II	ii	CD
cord-005478-5iu38pr6	3606	4	study	study	NN
cord-005478-5iu38pr6	3606	5	did	do	VBD
cord-005478-5iu38pr6	3606	6	not	not	RB
cord-005478-5iu38pr6	3606	7	demonstrate	demonstrate	VB
cord-005478-5iu38pr6	3606	8	significant	significant	JJ
cord-005478-5iu38pr6	3606	9	quantitative	quantitative	JJ
cord-005478-5iu38pr6	3606	10	improvement	improvement	NN
cord-005478-5iu38pr6	3606	11	in	in	IN
cord-005478-5iu38pr6	3606	12	immune	immune	JJ
cord-005478-5iu38pr6	3606	13	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3606	14	after	after	IN
cord-005478-5iu38pr6	3606	15	leuprolide	leuprolide	NNP
cord-005478-5iu38pr6	3606	16	with	with	IN
cord-005478-5iu38pr6	3606	17	palifermin	palifermin	NNP
cord-005478-5iu38pr6	3606	18	in	in	IN
cord-005478-5iu38pr6	3606	19	recipients	recipient	NNS
cord-005478-5iu38pr6	3606	20	of	of	IN
cord-005478-5iu38pr6	3606	21	TBIbased	TBIbased	NNP
cord-005478-5iu38pr6	3606	22	CD34-selected	CD34-selected	NNP
cord-005478-5iu38pr6	3606	23	HCT	HCT	NNP
cord-005478-5iu38pr6	3606	24	.	.	.
cord-005478-5iu38pr6	3607	1	TCR	TCR	NNP
cord-005478-5iu38pr6	3607	2	sequencing	sequence	VBG
cord-005478-5iu38pr6	3607	3	to	to	TO
cord-005478-5iu38pr6	3607	4	identify	identify	VB
cord-005478-5iu38pr6	3607	5	possible	possible	JJ
cord-005478-5iu38pr6	3607	6	improvement	improvement	NN
cord-005478-5iu38pr6	3607	7	in	in	IN
cord-005478-5iu38pr6	3607	8	T	t	NN
cord-005478-5iu38pr6	3607	9	-	-	HYPH
cord-005478-5iu38pr6	3607	10	cell	cell	NN
cord-005478-5iu38pr6	3607	11	diversity	diversity	NN
cord-005478-5iu38pr6	3607	12	in	in	IN
cord-005478-5iu38pr6	3607	13	this	this	DT
cord-005478-5iu38pr6	3607	14	cohort	cohort	NN
cord-005478-5iu38pr6	3607	15	is	be	VBZ
cord-005478-5iu38pr6	3607	16	forthcoming	forthcoming	JJ
cord-005478-5iu38pr6	3607	17	.	.	.
cord-005478-5iu38pr6	3608	1	One	one	CD
cord-005478-5iu38pr6	3608	2	potential	potential	JJ
cord-005478-5iu38pr6	3608	3	explanation	explanation	NN
cord-005478-5iu38pr6	3608	4	for	for	IN
cord-005478-5iu38pr6	3608	5	these	these	DT
cord-005478-5iu38pr6	3608	6	results	result	NNS
cord-005478-5iu38pr6	3608	7	lies	lie	VBZ
cord-005478-5iu38pr6	3608	8	in	in	IN
cord-005478-5iu38pr6	3608	9	the	the	DT
cord-005478-5iu38pr6	3608	10	initial	initial	JJ
cord-005478-5iu38pr6	3608	11	surge	surge	NN
cord-005478-5iu38pr6	3608	12	in	in	IN
cord-005478-5iu38pr6	3608	13	sex	sex	NN
cord-005478-5iu38pr6	3608	14	steroid	steroid	NN
cord-005478-5iu38pr6	3608	15	levels	level	NNS
cord-005478-5iu38pr6	3608	16	immediately	immediately	RB
cord-005478-5iu38pr6	3608	17	after	after	IN
cord-005478-5iu38pr6	3608	18	Background	background	NN
cord-005478-5iu38pr6	3608	19	:	:	:
cord-005478-5iu38pr6	3608	20	The	the	DT
cord-005478-5iu38pr6	3608	21	prospective	prospective	JJ
cord-005478-5iu38pr6	3608	22	,	,	,
cord-005478-5iu38pr6	3608	23	multinational	multinational	JJ
cord-005478-5iu38pr6	3608	24	,	,	,
cord-005478-5iu38pr6	3608	25	noninterventional	noninterventional	NNP
cord-005478-5iu38pr6	3608	26	EMMOS	EMMOS	NNP
cord-005478-5iu38pr6	3608	27	study	study	NN
cord-005478-5iu38pr6	3608	28	aimed	aim	VBN
cord-005478-5iu38pr6	3608	29	to	to	IN
cord-005478-5iu38pr6	3608	30	document	document	NN
cord-005478-5iu38pr6	3608	31	,	,	,
cord-005478-5iu38pr6	3608	32	and	and	CC
cord-005478-5iu38pr6	3608	33	describe	describe	VB
cord-005478-5iu38pr6	3608	34	real	real	JJ
cord-005478-5iu38pr6	3608	35	-	-	HYPH
cord-005478-5iu38pr6	3608	36	world	world	NN
cord-005478-5iu38pr6	3608	37	treatment	treatment	NN
cord-005478-5iu38pr6	3608	38	regimens	regimen	NNS
cord-005478-5iu38pr6	3608	39	and	and	CC
cord-005478-5iu38pr6	3608	40	disease	disease	NN
cord-005478-5iu38pr6	3608	41	progression	progression	NN
cord-005478-5iu38pr6	3608	42	in	in	IN
cord-005478-5iu38pr6	3608	43	patients	patient	NNS
cord-005478-5iu38pr6	3608	44	with	with	IN
cord-005478-5iu38pr6	3608	45	MM	MM	NNP
cord-005478-5iu38pr6	3608	46	at	at	IN
cord-005478-5iu38pr6	3608	47	different	different	JJ
cord-005478-5iu38pr6	3608	48	stages	stage	NNS
cord-005478-5iu38pr6	3608	49	of	of	IN
cord-005478-5iu38pr6	3608	50	the	the	DT
cord-005478-5iu38pr6	3608	51	disease	disease	NN
cord-005478-5iu38pr6	3608	52	.	.	.
cord-005478-5iu38pr6	3609	1	Methods	method	NNS
cord-005478-5iu38pr6	3609	2	:	:	:
cord-005478-5iu38pr6	3610	1	Adult	adult	NN
cord-005478-5iu38pr6	3610	2	patients	patient	NNS
cord-005478-5iu38pr6	3610	3	initiating	initiate	VBG
cord-005478-5iu38pr6	3610	4	any	any	DT
cord-005478-5iu38pr6	3610	5	new	new	JJ
cord-005478-5iu38pr6	3610	6	MM	MM	NNP
cord-005478-5iu38pr6	3610	7	therapy	therapy	NN
cord-005478-5iu38pr6	3610	8	between	between	IN
cord-005478-5iu38pr6	3610	9	2010	2010	CD
cord-005478-5iu38pr6	3610	10	and	and	CC
cord-005478-5iu38pr6	3610	11	2012	2012	CD
cord-005478-5iu38pr6	3610	12	were	be	VBD
cord-005478-5iu38pr6	3610	13	eligible	eligible	JJ
cord-005478-5iu38pr6	3610	14	.	.	.
cord-005478-5iu38pr6	3611	1	A	a	DT
cord-005478-5iu38pr6	3611	2	multi	multi	JJ
cord-005478-5iu38pr6	3611	3	-	-	JJ
cord-005478-5iu38pr6	3611	4	staged	staged	JJ
cord-005478-5iu38pr6	3611	5	patient	patient	NN
cord-005478-5iu38pr6	3611	6	/	/	SYM
cord-005478-5iu38pr6	3611	7	site	site	NN
cord-005478-5iu38pr6	3611	8	recruitment	recruitment	NN
cord-005478-5iu38pr6	3611	9	model	model	NN
cord-005478-5iu38pr6	3611	10	was	be	VBD
cord-005478-5iu38pr6	3611	11	applied	apply	VBN
cord-005478-5iu38pr6	3611	12	to	to	TO
cord-005478-5iu38pr6	3611	13	minimize	minimize	VB
cord-005478-5iu38pr6	3611	14	selection	selection	NN
cord-005478-5iu38pr6	3611	15	bias	bias	NN
cord-005478-5iu38pr6	3611	16	,	,	,
cord-005478-5iu38pr6	3611	17	and	and	CC
cord-005478-5iu38pr6	3611	18	enrolment	enrolment	NN
cord-005478-5iu38pr6	3611	19	was	be	VBD
cord-005478-5iu38pr6	3611	20	stratified	stratify	VBN
cord-005478-5iu38pr6	3611	21	by	by	IN
cord-005478-5iu38pr6	3611	22	country	country	NN
cord-005478-5iu38pr6	3611	23	,	,	,
cord-005478-5iu38pr6	3611	24	region	region	NN
cord-005478-5iu38pr6	3611	25	,	,	,
cord-005478-5iu38pr6	3611	26	and	and	CC
cord-005478-5iu38pr6	3611	27	practice	practice	NN
cord-005478-5iu38pr6	3611	28	type	type	NN
cord-005478-5iu38pr6	3611	29	.	.	.
cord-005478-5iu38pr6	3612	1	Patients	patient	NNS
cord-005478-5iu38pr6	3612	2	'	'	POS
cord-005478-5iu38pr6	3612	3	medical	medical	JJ
cord-005478-5iu38pr6	3612	4	/	/	SYM
cord-005478-5iu38pr6	3612	5	disease	disease	NN
cord-005478-5iu38pr6	3612	6	features	feature	NNS
cord-005478-5iu38pr6	3612	7	,	,	,
cord-005478-5iu38pr6	3612	8	treatment	treatment	NN
cord-005478-5iu38pr6	3612	9	history	history	NN
cord-005478-5iu38pr6	3612	10	and	and	CC
cord-005478-5iu38pr6	3612	11	remission	remission	NN
cord-005478-5iu38pr6	3612	12	status	status	NN
cord-005478-5iu38pr6	3612	13	were	be	VBD
cord-005478-5iu38pr6	3612	14	recorded	record	VBN
cord-005478-5iu38pr6	3612	15	at	at	IN
cord-005478-5iu38pr6	3612	16	baseline	baseline	NN
cord-005478-5iu38pr6	3612	17	,	,	,
cord-005478-5iu38pr6	3612	18	and	and	CC
cord-005478-5iu38pr6	3612	19	prospective	prospective	JJ
cord-005478-5iu38pr6	3612	20	data	datum	NNS
cord-005478-5iu38pr6	3612	21	on	on	IN
cord-005478-5iu38pr6	3612	22	treatment	treatment	NN
cord-005478-5iu38pr6	3612	23	,	,	,
cord-005478-5iu38pr6	3612	24	efficacy	efficacy	NN
cord-005478-5iu38pr6	3612	25	and	and	CC
cord-005478-5iu38pr6	3612	26	safety	safety	NN
cord-005478-5iu38pr6	3612	27	were	be	VBD
cord-005478-5iu38pr6	3612	28	collected	collect	VBN
cord-005478-5iu38pr6	3612	29	electronically	electronically	RB
cord-005478-5iu38pr6	3612	30	every	every	DT
cord-005478-5iu38pr6	3612	31	3	3	CD
cord-005478-5iu38pr6	3612	32	months	month	NNS
cord-005478-5iu38pr6	3612	33	until	until	IN
cord-005478-5iu38pr6	3612	34	2	2	CD
cord-005478-5iu38pr6	3612	35	years	year	NNS
cord-005478-5iu38pr6	3612	36	after	after	IN
cord-005478-5iu38pr6	3612	37	last	last	JJ
cord-005478-5iu38pr6	3612	38	enrolment	enrolment	NN
cord-005478-5iu38pr6	3612	39	.	.	.
cord-005478-5iu38pr6	3613	1	Responses	response	NNS
cord-005478-5iu38pr6	3613	2	were	be	VBD
cord-005478-5iu38pr6	3613	3	investigatorassessed	investigatorassesse	VBN
cord-005478-5iu38pr6	3613	4	.	.	.
cord-005478-5iu38pr6	3614	1	Overall	overall	JJ
cord-005478-5iu38pr6	3614	2	findings	finding	NNS
cord-005478-5iu38pr6	3614	3	from	from	IN
cord-005478-5iu38pr6	3614	4	EMMOS	EMMOS	NNP
cord-005478-5iu38pr6	3614	5	were	be	VBD
cord-005478-5iu38pr6	3614	6	previously	previously	RB
cord-005478-5iu38pr6	3614	7	reported	report	VBN
cord-005478-5iu38pr6	3614	8	.	.	.
cord-005478-5iu38pr6	3615	1	Here	here	RB
cord-005478-5iu38pr6	3615	2	,	,	,
cord-005478-5iu38pr6	3615	3	we	-PRON-	PRP
cord-005478-5iu38pr6	3615	4	are	be	VBP
cord-005478-5iu38pr6	3615	5	presenting	present	VBG
cord-005478-5iu38pr6	3615	6	additional	additional	JJ
cord-005478-5iu38pr6	3615	7	analyses	analysis	NNS
cord-005478-5iu38pr6	3615	8	focusing	focus	VBG
cord-005478-5iu38pr6	3615	9	on	on	IN
cord-005478-5iu38pr6	3615	10	the	the	DT
cord-005478-5iu38pr6	3615	11	induction	induction	NN
cord-005478-5iu38pr6	3615	12	regimens	regimen	NNS
cord-005478-5iu38pr6	3615	13	used	use	VBN
cord-005478-5iu38pr6	3615	14	in	in	IN
cord-005478-5iu38pr6	3615	15	the	the	DT
cord-005478-5iu38pr6	3615	16	subgroup	subgroup	NN
cord-005478-5iu38pr6	3615	17	of	of	IN
cord-005478-5iu38pr6	3615	18	patients	patient	NNS
cord-005478-5iu38pr6	3615	19	who	who	WP
cord-005478-5iu38pr6	3615	20	proceeded	proceed	VBD
cord-005478-5iu38pr6	3615	21	to	to	IN
cord-005478-5iu38pr6	3615	22	auto	auto	NN
cord-005478-5iu38pr6	3615	23	-	-	HYPH
cord-005478-5iu38pr6	3615	24	SCT	SCT	NNP
cord-005478-5iu38pr6	3615	25	frontline	frontline	NN
cord-005478-5iu38pr6	3615	26	.	.	.
cord-005478-5iu38pr6	3616	1	Results	result	NNS
cord-005478-5iu38pr6	3616	2	:	:	:
cord-005478-5iu38pr6	3617	1	A	a	DT
cord-005478-5iu38pr6	3617	2	total	total	NN
cord-005478-5iu38pr6	3617	3	of	of	IN
cord-005478-5iu38pr6	3617	4	2358	2358	CD
cord-005478-5iu38pr6	3617	5	patients	patient	NNS
cord-005478-5iu38pr6	3617	6	(	(	-LRB-
cord-005478-5iu38pr6	3617	7	775	775	CD
cord-005478-5iu38pr6	3617	8	with	with	IN
cord-005478-5iu38pr6	3617	9	stem	stem	NN
cord-005478-5iu38pr6	3617	10	-	-	HYPH
cord-005478-5iu38pr6	3617	11	cell	cell	NN
cord-005478-5iu38pr6	3617	12	transplant	transplant	NN
cord-005478-5iu38pr6	3617	13	[	[	-LRB-
cord-005478-5iu38pr6	3617	14	SCT	SCT	NNP
cord-005478-5iu38pr6	3617	15	]	]	-RRB-
cord-005478-5iu38pr6	3617	16	and	and	CC
cord-005478-5iu38pr6	3617	17	1583	1583	CD
cord-005478-5iu38pr6	3617	18	without	without	IN
cord-005478-5iu38pr6	3617	19	)	)	-RRB-
cord-005478-5iu38pr6	3617	20	were	be	VBD
cord-005478-5iu38pr6	3617	21	enrolled	enrol	VBN
cord-005478-5iu38pr6	3617	22	.	.	.
cord-005478-5iu38pr6	3618	1	Patient	Patient	NNP
cord-005478-5iu38pr6	3618	2	demographics	demographic	NNS
cord-005478-5iu38pr6	3618	3	/	/	SYM
cord-005478-5iu38pr6	3618	4	baseline	baseline	JJ
cord-005478-5iu38pr6	3618	5	characteristics	characteristic	NNS
cord-005478-5iu38pr6	3618	6	were	be	VBD
cord-005478-5iu38pr6	3618	7	as	as	IN
cord-005478-5iu38pr6	3618	8	expected	expect	VBN
cord-005478-5iu38pr6	3618	9	.	.	.
cord-005478-5iu38pr6	3619	1	Of	of	IN
cord-005478-5iu38pr6	3619	2	380	380	CD
cord-005478-5iu38pr6	3619	3	recipients	recipient	NNS
cord-005478-5iu38pr6	3619	4	of	of	IN
cord-005478-5iu38pr6	3619	5	SCT	SCT	NNP
cord-005478-5iu38pr6	3619	6	after	after	IN
cord-005478-5iu38pr6	3619	7	enrolment	enrolment	NN
cord-005478-5iu38pr6	3619	8	,	,	,
cord-005478-5iu38pr6	3619	9	299	299	CD
cord-005478-5iu38pr6	3619	10	(	(	-LRB-
cord-005478-5iu38pr6	3619	11	79	79	CD
cord-005478-5iu38pr6	3619	12	%	%	NN
cord-005478-5iu38pr6	3619	13	)	)	-RRB-
cord-005478-5iu38pr6	3619	14	underwent	undergo	VBD
cord-005478-5iu38pr6	3619	15	auto	auto	NN
cord-005478-5iu38pr6	3619	16	-	-	HYPH
cord-005478-5iu38pr6	3619	17	SCT	SCT	NNP
cord-005478-5iu38pr6	3619	18	frontline	frontline	NN
cord-005478-5iu38pr6	3619	19	.	.	.
cord-005478-5iu38pr6	3620	1	90	90	CD
cord-005478-5iu38pr6	3620	2	%	%	NN
cord-005478-5iu38pr6	3620	3	of	of	IN
cord-005478-5iu38pr6	3620	4	the	the	DT
cord-005478-5iu38pr6	3620	5	auto	auto	NN
cord-005478-5iu38pr6	3620	6	-	-	HYPH
cord-005478-5iu38pr6	3620	7	SCT	SCT	NNP
cord-005478-5iu38pr6	3620	8	patients	patient	NNS
cord-005478-5iu38pr6	3620	9	were	be	VBD
cord-005478-5iu38pr6	3620	10	aged	aged	JJ
cord-005478-5iu38pr6	3620	11	≤65	≤65	NNP
cord-005478-5iu38pr6	3620	12	years	year	NNS
cord-005478-5iu38pr6	3620	13	.	.	.
cord-005478-5iu38pr6	3621	1	Among	among	IN
cord-005478-5iu38pr6	3621	2	these	these	DT
cord-005478-5iu38pr6	3621	3	299	299	CD
cord-005478-5iu38pr6	3621	4	frontline	frontline	JJ
cord-005478-5iu38pr6	3621	5	auto	auto	NN
cord-005478-5iu38pr6	3621	6	-	-	HYPH
cord-005478-5iu38pr6	3621	7	SCT	SCT	NNP
cord-005478-5iu38pr6	3621	8	patients	patient	NNS
cord-005478-5iu38pr6	3621	9	,	,	,
cord-005478-5iu38pr6	3621	10	the	the	DT
cord-005478-5iu38pr6	3621	11	majority	majority	NN
cord-005478-5iu38pr6	3621	12	had	have	VBD
cord-005478-5iu38pr6	3621	13	a	a	DT
cord-005478-5iu38pr6	3621	14	single	single	JJ
cord-005478-5iu38pr6	3621	15	transplant	transplant	NN
cord-005478-5iu38pr6	3621	16	(	(	-LRB-
cord-005478-5iu38pr6	3621	17	87	87	CD
cord-005478-5iu38pr6	3621	18	%	%	NN
cord-005478-5iu38pr6	3621	19	)	)	-RRB-
cord-005478-5iu38pr6	3621	20	.	.	.
cord-005478-5iu38pr6	3622	1	The	the	DT
cord-005478-5iu38pr6	3622	2	most	most	RBS
cord-005478-5iu38pr6	3622	3	frequent	frequent	JJ
cord-005478-5iu38pr6	3622	4	induction	induction	NN
cord-005478-5iu38pr6	3622	5	regimen	regimen	NN
cord-005478-5iu38pr6	3622	6	was	be	VBD
cord-005478-5iu38pr6	3622	7	bortezomibthalidomide	bortezomibthalidomide	NN
cord-005478-5iu38pr6	3622	8	-	-	HYPH
cord-005478-5iu38pr6	3622	9	dexamethasone	dexamethasone	VBN
cord-005478-5iu38pr6	3622	10	(	(	-LRB-
cord-005478-5iu38pr6	3622	11	VTD	VTD	NNP
cord-005478-5iu38pr6	3622	12	;	;	:
cord-005478-5iu38pr6	3622	13	n=95	n=95	RB
cord-005478-5iu38pr6	3622	14	;	;	:
cord-005478-5iu38pr6	3622	15	32	32	CD
cord-005478-5iu38pr6	3622	16	%	%	NN
cord-005478-5iu38pr6	3622	17	)	)	-RRB-
cord-005478-5iu38pr6	3622	18	,	,	,
cord-005478-5iu38pr6	3622	19	bortezomib	bortezomib	NNP
cord-005478-5iu38pr6	3622	20	-	-	HYPH
cord-005478-5iu38pr6	3622	21	dexamethasone	dexamethasone	VBN
cord-005478-5iu38pr6	3622	22	(	(	-LRB-
cord-005478-5iu38pr6	3622	23	VD	VD	NNP
cord-005478-5iu38pr6	3622	24	;	;	:
cord-005478-5iu38pr6	3622	25	n=56	n=56	NN
cord-005478-5iu38pr6	3622	26	;	;	:
cord-005478-5iu38pr6	3622	27	19	19	CD
cord-005478-5iu38pr6	3622	28	%	%	NN
cord-005478-5iu38pr6	3622	29	)	)	-RRB-
cord-005478-5iu38pr6	3622	30	,	,	,
cord-005478-5iu38pr6	3622	31	bortezomib	bortezomib	NN
cord-005478-5iu38pr6	3622	32	-	-	HYPH
cord-005478-5iu38pr6	3622	33	cyclophosphamide	cyclophosphamide	RB
cord-005478-5iu38pr6	3622	34	-	-	HYPH
cord-005478-5iu38pr6	3622	35	dexamethasone	dexamethasone	VBN
cord-005478-5iu38pr6	3622	36	(	(	-LRB-
cord-005478-5iu38pr6	3622	37	VCD	vcd	NN
cord-005478-5iu38pr6	3622	38	;	;	:
cord-005478-5iu38pr6	3622	39	n=49	n=49	NN
cord-005478-5iu38pr6	3622	40	;	;	:
cord-005478-5iu38pr6	3622	41	16	16	CD
cord-005478-5iu38pr6	3622	42	%	%	NN
cord-005478-5iu38pr6	3622	43	)	)	-RRB-
cord-005478-5iu38pr6	3622	44	,	,	,
cord-005478-5iu38pr6	3622	45	doxorubicin	doxorubicin	NN
cord-005478-5iu38pr6	3622	46	-	-	HYPH
cord-005478-5iu38pr6	3622	47	bortezomib	bortezomib	NN
cord-005478-5iu38pr6	3622	48	-	-	HYPH
cord-005478-5iu38pr6	3622	49	dexamethasone	dexamethasone	JJ
cord-005478-5iu38pr6	3622	50	(	(	-LRB-
cord-005478-5iu38pr6	3622	51	PAD	pad	NN
cord-005478-5iu38pr6	3622	52	;	;	:
cord-005478-5iu38pr6	3622	53	n=26	n=26	RB
cord-005478-5iu38pr6	3622	54	;	;	:
cord-005478-5iu38pr6	3622	55	9	9	CD
cord-005478-5iu38pr6	3622	56	%	%	NN
cord-005478-5iu38pr6	3622	57	)	)	-RRB-
cord-005478-5iu38pr6	3622	58	,	,	,
cord-005478-5iu38pr6	3622	59	and	and	CC
cord-005478-5iu38pr6	3622	60	cyclophosphamidedexamethasone	cyclophosphamidedexamethasone	NN
cord-005478-5iu38pr6	3622	61	-	-	HYPH
cord-005478-5iu38pr6	3622	62	thalidomide	thalidomide	NN
cord-005478-5iu38pr6	3622	63	(	(	-LRB-
cord-005478-5iu38pr6	3622	64	CTD	CTD	NNP
cord-005478-5iu38pr6	3622	65	;	;	:
cord-005478-5iu38pr6	3622	66	n=26	n=26	RB
cord-005478-5iu38pr6	3622	67	;	;	:
cord-005478-5iu38pr6	3622	68	9	9	CD
cord-005478-5iu38pr6	3622	69	%	%	NN
cord-005478-5iu38pr6	3622	70	)	)	-RRB-
cord-005478-5iu38pr6	3622	71	.	.	.
cord-005478-5iu38pr6	3623	1	Only	only	RB
cord-005478-5iu38pr6	3623	2	1	1	CD
cord-005478-5iu38pr6	3623	3	%	%	NN
cord-005478-5iu38pr6	3623	4	of	of	IN
cord-005478-5iu38pr6	3623	5	patients	patient	NNS
cord-005478-5iu38pr6	3623	6	received	receive	VBD
cord-005478-5iu38pr6	3623	7	a	a	DT
cord-005478-5iu38pr6	3623	8	bortezomib	bortezomib	NN
cord-005478-5iu38pr6	3623	9	-	-	HYPH
cord-005478-5iu38pr6	3623	10	lenalidomidedexamethasone	lenalidomidedexamethasone	JJ
cord-005478-5iu38pr6	3623	11	(	(	-LRB-
cord-005478-5iu38pr6	3623	12	VRD	VRD	NNP
cord-005478-5iu38pr6	3623	13	)	)	-RRB-
cord-005478-5iu38pr6	3623	14	induction	induction	NN
cord-005478-5iu38pr6	3623	15	regimen	regimen	NN
cord-005478-5iu38pr6	3623	16	,	,	,
cord-005478-5iu38pr6	3623	17	while	while	IN
cord-005478-5iu38pr6	3623	18	lenalidomide	lenalidomide	NN
cord-005478-5iu38pr6	3623	19	was	be	VBD
cord-005478-5iu38pr6	3623	20	shown	show	VBN
cord-005478-5iu38pr6	3623	21	to	to	TO
cord-005478-5iu38pr6	3623	22	be	be	VB
cord-005478-5iu38pr6	3623	23	the	the	DT
cord-005478-5iu38pr6	3623	24	most	most	RBS
cord-005478-5iu38pr6	3623	25	frequently	frequently	RB
cord-005478-5iu38pr6	3623	26	used	use	VBN
cord-005478-5iu38pr6	3623	27	agent	agent	NN
cord-005478-5iu38pr6	3623	28	in	in	IN
cord-005478-5iu38pr6	3623	29	lines	line	NNS
cord-005478-5iu38pr6	3623	30	2	2	CD
cord-005478-5iu38pr6	3623	31	and	and	CC
cord-005478-5iu38pr6	3623	32	3	3	CD
cord-005478-5iu38pr6	3623	33	at	at	IN
cord-005478-5iu38pr6	3623	34	time	time	NN
cord-005478-5iu38pr6	3623	35	of	of	IN
cord-005478-5iu38pr6	3623	36	relapse	relapse	NN
cord-005478-5iu38pr6	3623	37	.	.	.
cord-005478-5iu38pr6	3624	1	In	in	IN
cord-005478-5iu38pr6	3624	2	the	the	DT
cord-005478-5iu38pr6	3624	3	VTD	VTD	NNP
cord-005478-5iu38pr6	3624	4	subgroup	subgroup	NN
cord-005478-5iu38pr6	3624	5	,	,	,
cord-005478-5iu38pr6	3624	6	most	most	JJS
cord-005478-5iu38pr6	3624	7	patients	patient	NNS
cord-005478-5iu38pr6	3624	8	received	receive	VBD
cord-005478-5iu38pr6	3624	9	100	100	CD
cord-005478-5iu38pr6	3624	10	mg	mg	NNP
cord-005478-5iu38pr6	3624	11	thalidomide	thalidomide	NN
cord-005478-5iu38pr6	3624	12	dose	dose	NN
cord-005478-5iu38pr6	3624	13	during	during	IN
cord-005478-5iu38pr6	3624	14	induction	induction	NN
cord-005478-5iu38pr6	3624	15	.	.	.
cord-005478-5iu38pr6	3625	1	The	the	DT
cord-005478-5iu38pr6	3625	2	majority	majority	NN
cord-005478-5iu38pr6	3625	3	of	of	IN
cord-005478-5iu38pr6	3625	4	administration	administration	NN
cord-005478-5iu38pr6	3625	5	schedule	schedule	NN
cord-005478-5iu38pr6	3625	6	was	be	VBD
cord-005478-5iu38pr6	3625	7	based	base	VBN
cord-005478-5iu38pr6	3625	8	on	on	IN
cord-005478-5iu38pr6	3625	9	21	21	CD
cord-005478-5iu38pr6	3625	10	days	day	NNS
cord-005478-5iu38pr6	3625	11	cycles	cycle	NNS
cord-005478-5iu38pr6	3625	12	,	,	,
cord-005478-5iu38pr6	3625	13	while	while	IN
cord-005478-5iu38pr6	3625	14	a	a	DT
cord-005478-5iu38pr6	3625	15	few	few	JJ
cord-005478-5iu38pr6	3625	16	other	other	JJ
cord-005478-5iu38pr6	3625	17	schedules	schedule	NNS
cord-005478-5iu38pr6	3625	18	were	be	VBD
cord-005478-5iu38pr6	3625	19	seen	see	VBN
cord-005478-5iu38pr6	3625	20	corresponding	correspond	VBG
cord-005478-5iu38pr6	3625	21	to	to	IN
cord-005478-5iu38pr6	3625	22	35	35	CD
cord-005478-5iu38pr6	3625	23	days	day	NNS
cord-005478-5iu38pr6	3625	24	cycles	cycle	NNS
cord-005478-5iu38pr6	3625	25	or	or	CC
cord-005478-5iu38pr6	3625	26	to	to	TO
cord-005478-5iu38pr6	3625	27	delay	delay	VB
cord-005478-5iu38pr6	3625	28	due	due	IN
cord-005478-5iu38pr6	3625	29	to	to	IN
cord-005478-5iu38pr6	3625	30	adverse	adverse	JJ
cord-005478-5iu38pr6	3625	31	events	event	NNS
cord-005478-5iu38pr6	3625	32	or	or	CC
cord-005478-5iu38pr6	3625	33	other	other	JJ
cord-005478-5iu38pr6	3625	34	specific	specific	JJ
cord-005478-5iu38pr6	3625	35	reasons	reason	NNS
cord-005478-5iu38pr6	3625	36	.	.	.
cord-005478-5iu38pr6	3626	1	The	the	DT
cord-005478-5iu38pr6	3626	2	most	most	RBS
cord-005478-5iu38pr6	3626	3	prevalent	prevalent	JJ
cord-005478-5iu38pr6	3626	4	number	number	NN
cord-005478-5iu38pr6	3626	5	of	of	IN
cord-005478-5iu38pr6	3626	6	VTD	VTD	NNP
cord-005478-5iu38pr6	3626	7	cycles	cycle	NNS
cord-005478-5iu38pr6	3626	8	was	be	VBD
cord-005478-5iu38pr6	3626	9	3	3	CD
cord-005478-5iu38pr6	3626	10	and	and	CC
cord-005478-5iu38pr6	3626	11	4	4	CD
cord-005478-5iu38pr6	3626	12	(	(	-LRB-
cord-005478-5iu38pr6	3626	13	42	42	CD
cord-005478-5iu38pr6	3626	14	%	%	NN
cord-005478-5iu38pr6	3626	15	and	and	CC
cord-005478-5iu38pr6	3626	16	38	38	CD
cord-005478-5iu38pr6	3626	17	%	%	NN
cord-005478-5iu38pr6	3626	18	,	,	,
cord-005478-5iu38pr6	3626	19	respectively	respectively	RB
cord-005478-5iu38pr6	3626	20	)	)	-RRB-
cord-005478-5iu38pr6	3626	21	.	.	.
cord-005478-5iu38pr6	3627	1	Lower	low	JJR
cord-005478-5iu38pr6	3627	2	or	or	CC
cord-005478-5iu38pr6	3627	3	higher	high	JJR
cord-005478-5iu38pr6	3627	4	number	number	NN
cord-005478-5iu38pr6	3627	5	of	of	IN
cord-005478-5iu38pr6	3627	6	cycles	cycle	NNS
cord-005478-5iu38pr6	3627	7	was	be	VBD
cord-005478-5iu38pr6	3627	8	only	only	RB
cord-005478-5iu38pr6	3627	9	marginal	marginal	JJ
cord-005478-5iu38pr6	3627	10	(	(	-LRB-
cord-005478-5iu38pr6	3627	11	6	6	CD
cord-005478-5iu38pr6	3627	12	%	%	NN
cord-005478-5iu38pr6	3627	13	and	and	CC
cord-005478-5iu38pr6	3627	14	14	14	CD
cord-005478-5iu38pr6	3627	15	%	%	NN
cord-005478-5iu38pr6	3627	16	,	,	,
cord-005478-5iu38pr6	3627	17	respectively	respectively	RB
cord-005478-5iu38pr6	3627	18	)	)	-RRB-
cord-005478-5iu38pr6	3627	19	.	.	.
cord-005478-5iu38pr6	3628	1	Out	out	IN
cord-005478-5iu38pr6	3628	2	of	of	IN
cord-005478-5iu38pr6	3628	3	the	the	DT
cord-005478-5iu38pr6	3628	4	95	95	CD
cord-005478-5iu38pr6	3628	5	patients	patient	NNS
cord-005478-5iu38pr6	3628	6	with	with	IN
cord-005478-5iu38pr6	3628	7	VTD	VTD	NNP
cord-005478-5iu38pr6	3628	8	induction	induction	NN
cord-005478-5iu38pr6	3628	9	,	,	,
cord-005478-5iu38pr6	3628	10	39	39	CD
cord-005478-5iu38pr6	3628	11	%	%	NN
cord-005478-5iu38pr6	3628	12	achieved	achieve	VBD
cord-005478-5iu38pr6	3628	13	CR	CR	NNP
cord-005478-5iu38pr6	3628	14	as	as	IN
cord-005478-5iu38pr6	3628	15	best	good	JJS
cord-005478-5iu38pr6	3628	16	response	response	NN
cord-005478-5iu38pr6	3628	17	,	,	,
cord-005478-5iu38pr6	3628	18	28	28	CD
cord-005478-5iu38pr6	3628	19	%	%	NN
cord-005478-5iu38pr6	3628	20	nCR	ncr	IN
cord-005478-5iu38pr6	3628	21	or	or	CC
cord-005478-5iu38pr6	3628	22	VGPR	VGPR	NNP
cord-005478-5iu38pr6	3628	23	and	and	CC
cord-005478-5iu38pr6	3628	24	16	16	CD
cord-005478-5iu38pr6	3628	25	%	%	NN
cord-005478-5iu38pr6	3628	26	PR	pr	NN
cord-005478-5iu38pr6	3628	27	.	.	.
cord-005478-5iu38pr6	3629	1	After	after	IN
cord-005478-5iu38pr6	3629	2	auto	auto	NN
cord-005478-5iu38pr6	3629	3	-	-	HYPH
cord-005478-5iu38pr6	3629	4	SCT	SCT	NNP
cord-005478-5iu38pr6	3629	5	,	,	,
cord-005478-5iu38pr6	3629	6	the	the	DT
cord-005478-5iu38pr6	3629	7	best	good	JJS
cord-005478-5iu38pr6	3629	8	overall	overall	JJ
cord-005478-5iu38pr6	3629	9	response	response	NN
cord-005478-5iu38pr6	3629	10	rates	rate	NNS
cord-005478-5iu38pr6	3629	11	(	(	-LRB-
cord-005478-5iu38pr6	3629	12	ORR	ORR	NNP
cord-005478-5iu38pr6	3629	13	)	)	-RRB-
cord-005478-5iu38pr6	3629	14	at	at	IN
cord-005478-5iu38pr6	3629	15	any	any	DT
cord-005478-5iu38pr6	3629	16	time	time	NN
cord-005478-5iu38pr6	3629	17	during	during	IN
cord-005478-5iu38pr6	3629	18	frontline	frontline	JJ
cord-005478-5iu38pr6	3629	19	therapy	therapy	NN
cord-005478-5iu38pr6	3629	20	were	be	VBD
cord-005478-5iu38pr6	3629	21	>	>	XX
cord-005478-5iu38pr6	3629	22	85	85	CD
cord-005478-5iu38pr6	3629	23	%	%	NN
cord-005478-5iu38pr6	3629	24	for	for	IN
cord-005478-5iu38pr6	3629	25	those	those	DT
cord-005478-5iu38pr6	3629	26	patients	patient	NNS
cord-005478-5iu38pr6	3629	27	whose	whose	WP$
cord-005478-5iu38pr6	3629	28	treatment	treatment	NN
cord-005478-5iu38pr6	3629	29	included	include	VBD
cord-005478-5iu38pr6	3629	30	24	24	CD
cord-005478-5iu38pr6	3629	31	University	University	NNP
cord-005478-5iu38pr6	3629	32	Medicine	Medicine	NNP
cord-005478-5iu38pr6	3629	33	Greifswald	Greifswald	NNP
cord-005478-5iu38pr6	3629	34	,	,	,
cord-005478-5iu38pr6	3629	35	Greifswald	Greifswald	NNP
cord-005478-5iu38pr6	3629	36	,	,	,
cord-005478-5iu38pr6	3630	1	Germany	Germany	NNP
cord-005478-5iu38pr6	3630	2	Background	Background	NNP
cord-005478-5iu38pr6	3631	1	:	:	:
cord-005478-5iu38pr6	3631	2	We	-PRON-	PRP
cord-005478-5iu38pr6	3631	3	explored	explore	VBD
cord-005478-5iu38pr6	3631	4	the	the	DT
cord-005478-5iu38pr6	3631	5	effect	effect	NN
cord-005478-5iu38pr6	3631	6	of	of	IN
cord-005478-5iu38pr6	3631	7	dinutuximab	dinutuximab	NNP
cord-005478-5iu38pr6	3631	8	beta	beta	NN
cord-005478-5iu38pr6	3631	9	(	(	-LRB-
cord-005478-5iu38pr6	3631	10	ch14.18	ch14.18	FW
cord-005478-5iu38pr6	3631	11	/	/	SYM
cord-005478-5iu38pr6	3631	12	CHO	CHO	NNP
cord-005478-5iu38pr6	3631	13	)	)	-RRB-
cord-005478-5iu38pr6	3631	14	on	on	IN
cord-005478-5iu38pr6	3631	15	outcome	outcome	NN
cord-005478-5iu38pr6	3631	16	within	within	IN
cord-005478-5iu38pr6	3631	17	the	the	DT
cord-005478-5iu38pr6	3631	18	HR	HR	NNP
cord-005478-5iu38pr6	3631	19	-	-	HYPH
cord-005478-5iu38pr6	3631	20	NBL1	NBL1	NNP
cord-005478-5iu38pr6	3631	21	/	/	SYM
cord-005478-5iu38pr6	3631	22	SIOPEN	SIOPEN	NNP
cord-005478-5iu38pr6	3631	23	trial	trial	NN
cord-005478-5iu38pr6	3631	24	population	population	NN
cord-005478-5iu38pr6	3631	25	by	by	IN
cord-005478-5iu38pr6	3631	26	comparing	compare	VBG
cord-005478-5iu38pr6	3631	27	an	an	DT
cord-005478-5iu38pr6	3631	28	era	era	NN
cord-005478-5iu38pr6	3631	29	prior	prior	JJ
cord-005478-5iu38pr6	3631	30	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3631	31	availability	availability	NN
cord-005478-5iu38pr6	3631	32	.	.	.
cord-005478-5iu38pr6	3632	1	Methods	method	NNS
cord-005478-5iu38pr6	3632	2	:	:	:
cord-005478-5iu38pr6	3632	3	The	the	DT
cord-005478-5iu38pr6	3632	4	analysis	analysis	NN
cord-005478-5iu38pr6	3632	5	cohort	cohort	NN
cord-005478-5iu38pr6	3632	6	consists	consist	VBZ
cord-005478-5iu38pr6	3632	7	of	of	IN
cord-005478-5iu38pr6	3632	8	the	the	DT
cord-005478-5iu38pr6	3632	9	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3632	10	population	population	NN
cord-005478-5iu38pr6	3632	11	(	(	-LRB-
cord-005478-5iu38pr6	3632	12	IP	IP	NNP
cord-005478-5iu38pr6	3632	13	)	)	-RRB-
cord-005478-5iu38pr6	3632	14	(	(	-LRB-
cord-005478-5iu38pr6	3632	15	2009	2009	CD
cord-005478-5iu38pr6	3632	16	-	-	SYM
cord-005478-5iu38pr6	3632	17	2013	2013	CD
cord-005478-5iu38pr6	3632	18	)	)	-RRB-
cord-005478-5iu38pr6	3632	19	and	and	CC
cord-005478-5iu38pr6	3632	20	a	a	DT
cord-005478-5iu38pr6	3632	21	matched	match	VBN
cord-005478-5iu38pr6	3632	22	control	control	NN
cord-005478-5iu38pr6	3632	23	population	population	NN
cord-005478-5iu38pr6	3632	24	(	(	-LRB-
cord-005478-5iu38pr6	3632	25	CP	CP	NNP
cord-005478-5iu38pr6	3632	26	)	)	-RRB-
cord-005478-5iu38pr6	3632	27	(	(	-LRB-
cord-005478-5iu38pr6	3632	28	2002	2002	CD
cord-005478-5iu38pr6	3632	29	)	)	-RRB-
cord-005478-5iu38pr6	3632	30	(	(	-LRB-
cord-005478-5iu38pr6	3632	31	2003	2003	CD
cord-005478-5iu38pr6	3632	32	)	)	-RRB-
cord-005478-5iu38pr6	3632	33	(	(	-LRB-
cord-005478-5iu38pr6	3632	34	2004	2004	CD
cord-005478-5iu38pr6	3632	35	)	)	-RRB-
cord-005478-5iu38pr6	3632	36	(	(	-LRB-
cord-005478-5iu38pr6	3632	37	2005	2005	CD
cord-005478-5iu38pr6	3632	38	)	)	-RRB-
cord-005478-5iu38pr6	3632	39	(	(	-LRB-
cord-005478-5iu38pr6	3632	40	2006	2006	CD
cord-005478-5iu38pr6	3632	41	)	)	-RRB-
cord-005478-5iu38pr6	3632	42	(	(	-LRB-
cord-005478-5iu38pr6	3632	43	2007	2007	CD
cord-005478-5iu38pr6	3632	44	)	)	-RRB-
cord-005478-5iu38pr6	3632	45	(	(	-LRB-
cord-005478-5iu38pr6	3632	46	2008	2008	CD
cord-005478-5iu38pr6	3632	47	)	)	-RRB-
cord-005478-5iu38pr6	3632	48	(	(	-LRB-
cord-005478-5iu38pr6	3632	49	2009	2009	CD
cord-005478-5iu38pr6	3632	50	)	)	-RRB-
cord-005478-5iu38pr6	3632	51	.	.	.
cord-005478-5iu38pr6	3633	1	All	all	DT
cord-005478-5iu38pr6	3633	2	patients	patient	NNS
cord-005478-5iu38pr6	3633	3	had	have	VBD
cord-005478-5iu38pr6	3633	4	rapid	rapid	JJ
cord-005478-5iu38pr6	3633	5	COJEC	COJEC	NNP
cord-005478-5iu38pr6	3633	6	induction	induction	NN
cord-005478-5iu38pr6	3633	7	,	,	,
cord-005478-5iu38pr6	3633	8	up	up	IN
cord-005478-5iu38pr6	3633	9	to	to	TO
cord-005478-5iu38pr6	3633	10	two	two	CD
cord-005478-5iu38pr6	3633	11	TVD	TVD	NNP
cord-005478-5iu38pr6	3633	12	courses	course	NNS
cord-005478-5iu38pr6	3633	13	and	and	CC
cord-005478-5iu38pr6	3633	14	high	high	JJ
cord-005478-5iu38pr6	3633	15	-	-	HYPH
cord-005478-5iu38pr6	3633	16	dose	dose	NN
cord-005478-5iu38pr6	3633	17	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	3633	18	(	(	-LRB-
cord-005478-5iu38pr6	3633	19	BuMel	BuMel	NNP
cord-005478-5iu38pr6	3633	20	or	or	CC
cord-005478-5iu38pr6	3633	21	CEM	CEM	NNP
cord-005478-5iu38pr6	3633	22	)	)	-RRB-
cord-005478-5iu38pr6	3633	23	followed	follow	VBN
cord-005478-5iu38pr6	3633	24	by	by	IN
cord-005478-5iu38pr6	3633	25	autologous	autologous	JJ
cord-005478-5iu38pr6	3633	26	stem	stem	NN
cord-005478-5iu38pr6	3633	27	cell	cell	NN
cord-005478-5iu38pr6	3633	28	reinfusion	reinfusion	NN
cord-005478-5iu38pr6	3633	29	(	(	-LRB-
cord-005478-5iu38pr6	3633	30	HDC	HDC	NNP
cord-005478-5iu38pr6	3633	31	/	/	SYM
cord-005478-5iu38pr6	3633	32	ASCR	ASCR	NNP
cord-005478-5iu38pr6	3633	33	)	)	-RRB-
cord-005478-5iu38pr6	3633	34	within	within	IN
cord-005478-5iu38pr6	3633	35	9	9	CD
cord-005478-5iu38pr6	3633	36	months	month	NNS
cord-005478-5iu38pr6	3633	37	since	since	IN
cord-005478-5iu38pr6	3633	38	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3633	39	;	;	,
cord-005478-5iu38pr6	3633	40	local	local	JJ
cord-005478-5iu38pr6	3633	41	control	control	NN
cord-005478-5iu38pr6	3633	42	included	include	VBD
cord-005478-5iu38pr6	3633	43	surgery	surgery	NN
cord-005478-5iu38pr6	3633	44	and	and	CC
cord-005478-5iu38pr6	3633	45	local	local	JJ
cord-005478-5iu38pr6	3633	46	radiotherapy	radiotherapy	NN
cord-005478-5iu38pr6	3633	47	(	(	-LRB-
cord-005478-5iu38pr6	3633	48	21Gy	21gy	CD
cord-005478-5iu38pr6	3633	49	)	)	-RRB-
cord-005478-5iu38pr6	3633	50	followed	follow	VBN
cord-005478-5iu38pr6	3633	51	by	by	IN
cord-005478-5iu38pr6	3633	52	maintenance	maintenance	NN
cord-005478-5iu38pr6	3633	53	with	with	IN
cord-005478-5iu38pr6	3633	54	six	six	CD
cord-005478-5iu38pr6	3633	55	cycles	cycle	NNS
cord-005478-5iu38pr6	3633	56	of	of	IN
cord-005478-5iu38pr6	3633	57	isotretinoin	isotretinoin	NNP
cord-005478-5iu38pr6	3633	58	.	.	.
cord-005478-5iu38pr6	3634	1	IP	ip	NN
cord-005478-5iu38pr6	3634	2	patients	patient	NNS
cord-005478-5iu38pr6	3634	3	had	have	VBD
cord-005478-5iu38pr6	3634	4	additional	additional	JJ
cord-005478-5iu38pr6	3634	5	five	five	CD
cord-005478-5iu38pr6	3634	6	cycles	cycle	NNS
cord-005478-5iu38pr6	3634	7	of	of	IN
cord-005478-5iu38pr6	3634	8	dinutuximab	dinutuximab	NNP
cord-005478-5iu38pr6	3634	9	beta	beta	JJ
cord-005478-5iu38pr6	3634	10	short	short	JJ
cord-005478-5iu38pr6	3634	11	-	-	HYPH
cord-005478-5iu38pr6	3634	12	term	term	NN
cord-005478-5iu38pr6	3634	13	infusions	infusion	NNS
cord-005478-5iu38pr6	3634	14	with	with	IN
cord-005478-5iu38pr6	3634	15	or	or	CC
cord-005478-5iu38pr6	3634	16	without	without	IN
cord-005478-5iu38pr6	3634	17	subcutaneous	subcutaneous	JJ
cord-005478-5iu38pr6	3634	18	interleukin-2	interleukin-2	IN
cord-005478-5iu38pr6	3634	19	.	.	.
cord-005478-5iu38pr6	3635	1	CP	cp	NN
cord-005478-5iu38pr6	3635	2	patients	patient	NNS
cord-005478-5iu38pr6	3635	3	had	have	VBD
cord-005478-5iu38pr6	3635	4	to	to	TO
cord-005478-5iu38pr6	3635	5	be	be	VB
cord-005478-5iu38pr6	3635	6	part	part	NN
cord-005478-5iu38pr6	3635	7	of	of	IN
cord-005478-5iu38pr6	3635	8	the	the	DT
cord-005478-5iu38pr6	3635	9	HDC	hdc	NN
cord-005478-5iu38pr6	3635	10	randomization	randomization	NN
cord-005478-5iu38pr6	3635	11	.	.	.
cord-005478-5iu38pr6	3636	1	The	the	DT
cord-005478-5iu38pr6	3636	2	median	median	JJ
cord-005478-5iu38pr6	3636	3	time	time	NN
cord-005478-5iu38pr6	3636	4	between	between	IN
cord-005478-5iu38pr6	3636	5	ASCR	ASCR	NNP
cord-005478-5iu38pr6	3636	6	and	and	CC
cord-005478-5iu38pr6	3636	7	initiation	initiation	NN
cord-005478-5iu38pr6	3636	8	of	of	IN
cord-005478-5iu38pr6	3636	9	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3636	10	was	be	VBD
cord-005478-5iu38pr6	3636	11	109	109	CD
cord-005478-5iu38pr6	3636	12	days	day	NNS
cord-005478-5iu38pr6	3636	13	in	in	IN
cord-005478-5iu38pr6	3636	14	the	the	DT
cord-005478-5iu38pr6	3636	15	IP	ip	NN
cord-005478-5iu38pr6	3636	16	.	.	.
cord-005478-5iu38pr6	3637	1	Only	only	RB
cord-005478-5iu38pr6	3637	2	patients	patient	NNS
cord-005478-5iu38pr6	3637	3	without	without	IN
cord-005478-5iu38pr6	3637	4	progressive	progressive	JJ
cord-005478-5iu38pr6	3637	5	disease	disease	NN
cord-005478-5iu38pr6	3637	6	at	at	IN
cord-005478-5iu38pr6	3637	7	this	this	DT
cord-005478-5iu38pr6	3637	8	landmark	landmark	JJ
cord-005478-5iu38pr6	3637	9	time	time	NN
cord-005478-5iu38pr6	3637	10	point	point	NN
cord-005478-5iu38pr6	3637	11	were	be	VBD
cord-005478-5iu38pr6	3637	12	included	include	VBN
cord-005478-5iu38pr6	3637	13	in	in	IN
cord-005478-5iu38pr6	3637	14	the	the	DT
cord-005478-5iu38pr6	3637	15	CP	cp	NN
cord-005478-5iu38pr6	3637	16	.	.	.
cord-005478-5iu38pr6	3638	1	Median	median	JJ
cord-005478-5iu38pr6	3638	2	follow	follow	NN
cord-005478-5iu38pr6	3638	3	-	-	HYPH
cord-005478-5iu38pr6	3638	4	up	up	NN
cord-005478-5iu38pr6	3638	5	was	be	VBD
cord-005478-5iu38pr6	3638	6	5.8	5.8	CD
cord-005478-5iu38pr6	3638	7	years	year	NNS
cord-005478-5iu38pr6	3638	8	(	(	-LRB-
cord-005478-5iu38pr6	3638	9	IQR	iqr	NN
cord-005478-5iu38pr6	3638	10	:	:	:
cord-005478-5iu38pr6	3638	11	4.2	4.2	CD
cord-005478-5iu38pr6	3638	12	to	to	TO
cord-005478-5iu38pr6	3638	13	8.2	8.2	CD
cord-005478-5iu38pr6	3638	14	years	year	NNS
cord-005478-5iu38pr6	3638	15	)	)	-RRB-
cord-005478-5iu38pr6	3638	16	for	for	IN
cord-005478-5iu38pr6	3638	17	844	844	CD
cord-005478-5iu38pr6	3638	18	eligible	eligible	JJ
cord-005478-5iu38pr6	3638	19	patients	patient	NNS
cord-005478-5iu38pr6	3638	20	.	.	.
cord-005478-5iu38pr6	3639	1	Results	result	NNS
cord-005478-5iu38pr6	3639	2	:	:	:
cord-005478-5iu38pr6	3640	1	The	the	DT
cord-005478-5iu38pr6	3640	2	5y	5y	CD
cord-005478-5iu38pr6	3640	3	-	-	HYPH
cord-005478-5iu38pr6	3640	4	EFS	efs	NN
cord-005478-5iu38pr6	3640	5	of	of	IN
cord-005478-5iu38pr6	3640	6	the	the	DT
cord-005478-5iu38pr6	3640	7	IP	ip	NN
cord-005478-5iu38pr6	3640	8	(	(	-LRB-
cord-005478-5iu38pr6	3640	9	378	378	CD
cord-005478-5iu38pr6	3640	10	patients	patient	NNS
cord-005478-5iu38pr6	3640	11	)	)	-RRB-
cord-005478-5iu38pr6	3640	12	was	be	VBD
cord-005478-5iu38pr6	3640	13	57	57	CD
cord-005478-5iu38pr6	3640	14	%	%	NN
cord-005478-5iu38pr6	3640	15	±3	±3	NNP
cord-005478-5iu38pr6	3640	16	%	%	NN
cord-005478-5iu38pr6	3640	17	compared	compare	VBN
cord-005478-5iu38pr6	3640	18	to	to	IN
cord-005478-5iu38pr6	3640	19	42%±2	42%±2	CD
cord-005478-5iu38pr6	3640	20	%	%	NN
cord-005478-5iu38pr6	3640	21	for	for	IN
cord-005478-5iu38pr6	3640	22	the	the	DT
cord-005478-5iu38pr6	3640	23	CP	cp	NN
cord-005478-5iu38pr6	3640	24	(	(	-LRB-
cord-005478-5iu38pr6	3640	25	466	466	CD
cord-005478-5iu38pr6	3640	26	patients	patient	NNS
cord-005478-5iu38pr6	3640	27	;	;	:
cord-005478-5iu38pr6	3640	28	p	p	NN
cord-005478-5iu38pr6	3640	29	<	<	XX
cord-005478-5iu38pr6	3640	30	0.001	0.001	CD
cord-005478-5iu38pr6	3640	31	)	)	-RRB-
cord-005478-5iu38pr6	3640	32	.	.	.
cord-005478-5iu38pr6	3641	1	Both	both	DT
cord-005478-5iu38pr6	3641	2	populations	population	NNS
cord-005478-5iu38pr6	3641	3	were	be	VBD
cord-005478-5iu38pr6	3641	4	balanced	balance	VBN
cord-005478-5iu38pr6	3641	5	for	for	IN
cord-005478-5iu38pr6	3641	6	sex	sex	NN
cord-005478-5iu38pr6	3641	7	,	,	,
cord-005478-5iu38pr6	3641	8	age	age	NN
cord-005478-5iu38pr6	3641	9	,	,	,
cord-005478-5iu38pr6	3641	10	stage	stage	NN
cord-005478-5iu38pr6	3641	11	4	4	CD
cord-005478-5iu38pr6	3641	12	,	,	,
cord-005478-5iu38pr6	3641	13	MYCN	MYCN	NNP
cord-005478-5iu38pr6	3641	14	amplification	amplification	NN
cord-005478-5iu38pr6	3641	15	and	and	CC
cord-005478-5iu38pr6	3641	16	response	response	NN
cord-005478-5iu38pr6	3642	1	prior	prior	JJ
cord-005478-5iu38pr6	3642	2	HDC	HDC	NNP
cord-005478-5iu38pr6	3642	3	.	.	.
cord-005478-5iu38pr6	3643	1	Multivariate	multivariate	JJ
cord-005478-5iu38pr6	3643	2	analysis	analysis	NN
cord-005478-5iu38pr6	3643	3	showed	show	VBD
cord-005478-5iu38pr6	3643	4	an	an	DT
cord-005478-5iu38pr6	3643	5	independent	independent	JJ
cord-005478-5iu38pr6	3643	6	higher	high	JJR
cord-005478-5iu38pr6	3643	7	risk	risk	NN
cord-005478-5iu38pr6	3643	8	for	for	IN
cord-005478-5iu38pr6	3643	9	the	the	DT
cord-005478-5iu38pr6	3643	10	CP	cp	NN
cord-005478-5iu38pr6	3643	11	(	(	-LRB-
cord-005478-5iu38pr6	3643	12	p=0.0002	p=0.0002	UH
cord-005478-5iu38pr6	3643	13	,	,	,
cord-005478-5iu38pr6	3643	14	HR	HR	NNP
cord-005478-5iu38pr6	3643	15	1.573	1.573	CD
cord-005478-5iu38pr6	3643	16	)	)	-RRB-
cord-005478-5iu38pr6	3643	17	,	,	,
cord-005478-5iu38pr6	3643	18	for	for	IN
cord-005478-5iu38pr6	3643	19	CEM	CEM	NNP
cord-005478-5iu38pr6	3643	20	(	(	-LRB-
cord-005478-5iu38pr6	3643	21	p=0.0029	p=0.0029	NNS
cord-005478-5iu38pr6	3643	22	;	;	:
cord-005478-5iu38pr6	3643	23	HR	HR	NNP
cord-005478-5iu38pr6	3643	24	1.431	1.431	CD
cord-005478-5iu38pr6	3643	25	)	)	-RRB-
cord-005478-5iu38pr6	3643	26	,	,	,
cord-005478-5iu38pr6	3643	27	a	a	DT
cord-005478-5iu38pr6	3643	28	response	response	NN
cord-005478-5iu38pr6	3643	29	<	<	XX
cord-005478-5iu38pr6	3643	30	CR	CR	NNP
cord-005478-5iu38pr6	3643	31	prior	prior	RB
cord-005478-5iu38pr6	3643	32	to	to	IN
cord-005478-5iu38pr6	3643	33	maintenance	maintenance	NN
cord-005478-5iu38pr6	3643	34	therapy	therapy	NN
cord-005478-5iu38pr6	3643	35	(	(	-LRB-
cord-005478-5iu38pr6	3643	36	p=0.0043	p=0.0043	NNS
cord-005478-5iu38pr6	3643	37	,	,	,
cord-005478-5iu38pr6	3643	38	HR	HR	NNP
cord-005478-5iu38pr6	3643	39	1.494	1.494	CD
cord-005478-5iu38pr6	3643	40	)	)	-RRB-
cord-005478-5iu38pr6	3644	1	and	and	CC
cord-005478-5iu38pr6	3644	2	for	for	IN
cord-005478-5iu38pr6	3644	3	>	>	XX
cord-005478-5iu38pr6	3644	4	1	1	CD
cord-005478-5iu38pr6	3644	5	metastatic	metastatic	JJ
cord-005478-5iu38pr6	3644	6	compartment	compartment	NN
cord-005478-5iu38pr6	3644	7	at	at	IN
cord-005478-5iu38pr6	3644	8	diagnosis	diagnosis	NN
cord-005478-5iu38pr6	3644	9	(	(	-LRB-
cord-005478-5iu38pr6	3644	10	p	p	NN
cord-005478-5iu38pr6	3644	11	<	<	XX
cord-005478-5iu38pr6	3644	12	0.001	0.001	CD
cord-005478-5iu38pr6	3644	13	,	,	,
cord-005478-5iu38pr6	3644	14	HR	HR	NNP
cord-005478-5iu38pr6	3644	15	2.665	2.665	CD
cord-005478-5iu38pr6	3644	16	)	)	-RRB-
cord-005478-5iu38pr6	3644	17	.	.	.
cord-005478-5iu38pr6	3645	1	After	after	IN
cord-005478-5iu38pr6	3645	2	adjustment	adjustment	NN
cord-005478-5iu38pr6	3645	3	for	for	IN
cord-005478-5iu38pr6	3645	4	risk	risk	NN
cord-005478-5iu38pr6	3645	5	factors	factor	NNS
cord-005478-5iu38pr6	3645	6	,	,	,
cord-005478-5iu38pr6	3645	7	the	the	DT
cord-005478-5iu38pr6	3645	8	benefit	benefit	NN
cord-005478-5iu38pr6	3645	9	of	of	IN
cord-005478-5iu38pr6	3645	10	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3645	11	was	be	VBD
cord-005478-5iu38pr6	3645	12	confirmed	confirm	VBN
cord-005478-5iu38pr6	3645	13	in	in	IN
cord-005478-5iu38pr6	3645	14	BuMel-(p=0.0066	BuMel-(p=0.0066	NNP
cord-005478-5iu38pr6	3645	15	;	;	:
cord-005478-5iu38pr6	3645	16	HR	HR	NNP
cord-005478-5iu38pr6	3645	17	1.439	1.439	CD
cord-005478-5iu38pr6	3645	18	)	)	-RRB-
cord-005478-5iu38pr6	3645	19	and	and	CC
cord-005478-5iu38pr6	3645	20	in	in	IN
cord-005478-5iu38pr6	3645	21	CEM	CEM	NNP
cord-005478-5iu38pr6	3645	22	-	-	HYPH
cord-005478-5iu38pr6	3645	23	treated	treat	VBN
cord-005478-5iu38pr6	3645	24	patients	patient	NNS
cord-005478-5iu38pr6	3645	25	(	(	-LRB-
cord-005478-5iu38pr6	3645	26	p=0.0107	p=0.0107	NNP
cord-005478-5iu38pr6	3645	27	;	;	:
cord-005478-5iu38pr6	3645	28	HR	HR	NNP
cord-005478-5iu38pr6	3645	29	2.334).Conclusions	2.334).conclusions	CD
cord-005478-5iu38pr6	3645	30	:	:	:
cord-005478-5iu38pr6	3646	1	Results	result	NNS
cord-005478-5iu38pr6	3646	2	suggest	suggest	VBP
cord-005478-5iu38pr6	3646	3	a	a	DT
cord-005478-5iu38pr6	3646	4	patient	patient	JJ
cord-005478-5iu38pr6	3646	5	benefit	benefit	NN
cord-005478-5iu38pr6	3646	6	from	from	IN
cord-005478-5iu38pr6	3646	7	dinutuximab	dinutuximab	NNP
cord-005478-5iu38pr6	3646	8	beta	beta	NNP
cord-005478-5iu38pr6	3646	9	based	base	VBN
cord-005478-5iu38pr6	3646	10	immunotherapy	immunotherapy	NN
cord-005478-5iu38pr6	3646	11	with	with	IN
cord-005478-5iu38pr6	3646	12	or	or	CC
cord-005478-5iu38pr6	3646	13	without	without	IN
cord-005478-5iu38pr6	3646	14	IL2	IL2	NNP
cord-005478-5iu38pr6	3646	15	within	within	IN
cord-005478-5iu38pr6	3646	16	the	the	DT
cord-005478-5iu38pr6	3646	17	HR	HR	NNP
cord-005478-5iu38pr6	3646	18	-	-	HYPH
cord-005478-5iu38pr6	3646	19	NBL1	NBL1	NNP
cord-005478-5iu38pr6	3646	20	trial	trial	NN
cord-005478-5iu38pr6	3646	21	.	.	.
cord-005478-5iu38pr6	3647	1	Clinical	clinical	JJ
cord-005478-5iu38pr6	3647	2	Trial	Trial	NNP
cord-005478-5iu38pr6	3647	3	Registry	Registry	NNP
cord-005478-5iu38pr6	3647	4	:	:	:
cord-005478-5iu38pr6	3647	5	The	the	DT
cord-005478-5iu38pr6	3647	6	trial	trial	NN
cord-005478-5iu38pr6	3647	7	was	be	VBD
cord-005478-5iu38pr6	3647	8	registered	register	VBN
cord-005478-5iu38pr6	3647	9	with	with	IN
cord-005478-5iu38pr6	3647	10	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-005478-5iu38pr6	3647	11	(	(	-LRB-
cord-005478-5iu38pr6	3647	12	number	number	NN
cord-005478-5iu38pr6	3647	13	NCT01704716	NCT01704716	NNP
cord-005478-5iu38pr6	3647	14	)	)	-RRB-
cord-005478-5iu38pr6	3647	15	and	and	CC
cord-005478-5iu38pr6	3647	16	EudraCT	EudraCT	NNP
cord-005478-5iu38pr6	3647	17	(	(	-LRB-
cord-005478-5iu38pr6	3647	18	number	number	NN
cord-005478-5iu38pr6	3647	19	2006	2006	CD
cord-005478-5iu38pr6	3647	20	-	-	HYPH
cord-005478-5iu38pr6	3647	21	001489	001489	CD
cord-005478-5iu38pr6	3647	22	-	-	SYM
cord-005478-5iu38pr6	3647	23	17	17	CD
cord-005478-5iu38pr6	3647	24	)	)	-RRB-
cord-005478-5iu38pr6	3647	25	.	.	.
cord-005478-5iu38pr6	3648	1	https://www.siopen-r-net.org	https://www.siopen-r-net.org	NNP
cord-005478-5iu38pr6	3648	2	Disclosure	Disclosure	NNP
cord-005478-5iu38pr6	3648	3	:	:	:
cord-005478-5iu38pr6	3649	1	The	the	DT
cord-005478-5iu38pr6	3649	2	academic	academic	JJ
cord-005478-5iu38pr6	3649	3	data	datum	NNS
cord-005478-5iu38pr6	3649	4	supported	support	VBD
cord-005478-5iu38pr6	3649	5	APEIRON	APEIRON	NNP
cord-005478-5iu38pr6	3649	6	to	to	TO
cord-005478-5iu38pr6	3649	7	obtain	obtain	VB
cord-005478-5iu38pr6	3649	8	the	the	DT
cord-005478-5iu38pr6	3649	9	dinutuximab	dinutuximab	NN
cord-005478-5iu38pr6	3649	10	beta	beta	NN
cord-005478-5iu38pr6	3649	11	product	product	NN
cord-005478-5iu38pr6	3649	12	licensure	licensure	NN
cord-005478-5iu38pr6	3649	13	in	in	IN
cord-005478-5iu38pr6	3649	14	May	May	NNP
cord-005478-5iu38pr6	3649	15	2017	2017	CD
cord-005478-5iu38pr6	3649	16	in	in	IN
cord-005478-5iu38pr6	3649	17	the	the	DT
cord-005478-5iu38pr6	3649	18	European	European	NNP
cord-005478-5iu38pr6	3649	19	Union	Union	NNP
cord-005478-5iu38pr6	3649	20	(	(	-LRB-
cord-005478-5iu38pr6	3649	21	EMA	EMA	NNP
cord-005478-5iu38pr6	3649	22	)	)	-RRB-
cord-005478-5iu38pr6	3649	23	.	.	.
cord-005478-5iu38pr6	3650	1	SIOPEN	SIOPEN	NNP
cord-005478-5iu38pr6	3650	2	and	and	CC
cord-005478-5iu38pr6	3650	3	CCRI	CCRI	NNP
cord-005478-5iu38pr6	3650	4	had	have	VBD
cord-005478-5iu38pr6	3650	5	an	an	DT
cord-005478-5iu38pr6	3650	6	agreement	agreement	NN
cord-005478-5iu38pr6	3650	7	in	in	IN
cord-005478-5iu38pr6	3650	8	place	place	NN
cord-005478-5iu38pr6	3650	9	with	with	IN
cord-005478-5iu38pr6	3650	10	APEIRON	APEIRON	NNP
cord-005478-5iu38pr6	3650	11	regarding	regard	VBG
cord-005478-5iu38pr6	3650	12	the	the	DT
cord-005478-5iu38pr6	3650	13	provision	provision	NN
cord-005478-5iu38pr6	3650	14	of	of	IN
cord-005478-5iu38pr6	3650	15	academic	academic	JJ
cord-005478-5iu38pr6	3650	16	data	datum	NNS
cord-005478-5iu38pr6	3650	17	.	.	.
cord-005478-5iu38pr6	3651	1	Ruth	Ruth	NNP
cord-005478-5iu38pr6	3651	2	Ladenstein	Ladenstein	NNP
cord-005478-5iu38pr6	3651	3	and	and	CC
cord-005478-5iu38pr6	3651	4	Holger	Holger	NNP
cord-005478-5iu38pr6	3651	5	Lode	Lode	NNP
cord-005478-5iu38pr6	3651	6	acted	act	VBD
cord-005478-5iu38pr6	3651	7	as	as	IN
cord-005478-5iu38pr6	3651	8	consultants	consultant	NNS
cord-005478-5iu38pr6	3651	9	for	for	IN
cord-005478-5iu38pr6	3651	10	APEIRON	APEIRON	NNP
cord-005478-5iu38pr6	3651	11	on	on	IN
cord-005478-5iu38pr6	3651	12	behalf	behalf	NN
cord-005478-5iu38pr6	3651	13	of	of	IN
cord-005478-5iu38pr6	3651	14	SIOPEN	SIOPEN	NNP
cord-005478-5iu38pr6	3651	15	for	for	IN
cord-005478-5iu38pr6	3651	16	the	the	DT
cord-005478-5iu38pr6	3651	17	ch14.18	ch14.18	NNS
cord-005478-5iu38pr6	3651	18	/	/	SYM
cord-005478-5iu38pr6	3651	19	CHO	CHO	NNP
cord-005478-5iu38pr6	3651	20	development	development	NN
cord-005478-5iu38pr6	3651	21	.	.	.
cord-005478-5iu38pr6	3652	1	The	the	DT
cord-005478-5iu38pr6	3652	2	other	other	JJ
cord-005478-5iu38pr6	3652	3	authors	author	NNS
cord-005478-5iu38pr6	3652	4	declared	declare	VBD
cord-005478-5iu38pr6	3652	5	no	no	DT
cord-005478-5iu38pr6	3652	6	conflicts	conflict	NNS
cord-005478-5iu38pr6	3652	7	of	of	IN
cord-005478-5iu38pr6	3652	8	interest	interest	NN
cord-005478-5iu38pr6	3652	9	.	.	.
cord-005478-5iu38pr6	3653	1	19	19	CD
cord-005478-5iu38pr6	3653	2	out	out	IN
cord-005478-5iu38pr6	3653	3	of	of	IN
cord-005478-5iu38pr6	3653	4	24	24	CD
cord-005478-5iu38pr6	3653	5	(	(	-LRB-
cord-005478-5iu38pr6	3653	6	79	79	CD
cord-005478-5iu38pr6	3653	7	%	%	NN
cord-005478-5iu38pr6	3653	8	)	)	-RRB-
cord-005478-5iu38pr6	3653	9	received	receive	VBD
cord-005478-5iu38pr6	3653	10	serotherapy	serotherapy	NN
cord-005478-5iu38pr6	3653	11	with	with	IN
cord-005478-5iu38pr6	3653	12	Alemtuzumab	Alemtuzumab	NNP
cord-005478-5iu38pr6	3653	13	(	(	-LRB-
cord-005478-5iu38pr6	3653	14	n=12	n=12	NNP
cord-005478-5iu38pr6	3653	15	)	)	-RRB-
cord-005478-5iu38pr6	3653	16	or	or	CC
cord-005478-5iu38pr6	3653	17	ATG	ATG	NNP
cord-005478-5iu38pr6	3653	18	(	(	-LRB-
cord-005478-5iu38pr6	3653	19	n=6	n=6	NNP
cord-005478-5iu38pr6	3653	20	)	)	-RRB-
cord-005478-5iu38pr6	3653	21	before	before	IN
cord-005478-5iu38pr6	3653	22	viral	viral	JJ
cord-005478-5iu38pr6	3653	23	reactivation	reactivation	NN
cord-005478-5iu38pr6	3653	24	.	.	.
cord-005478-5iu38pr6	3654	1	Where	where	WRB
cord-005478-5iu38pr6	3654	2	possible	possible	JJ
cord-005478-5iu38pr6	3654	3	immunosuppression	immunosuppression	NN
cord-005478-5iu38pr6	3654	4	was	be	VBD
cord-005478-5iu38pr6	3654	5	withdrawn	withdraw	VBN
cord-005478-5iu38pr6	3654	6	in	in	IN
cord-005478-5iu38pr6	3654	7	combination	combination	NN
cord-005478-5iu38pr6	3654	8	to	to	IN
cord-005478-5iu38pr6	3654	9	BCV	BCV	NNP
cord-005478-5iu38pr6	3654	10	therapy	therapy	NN
cord-005478-5iu38pr6	3654	11	.	.	.
cord-005478-5iu38pr6	3655	1	Viral	viral	JJ
cord-005478-5iu38pr6	3655	2	load	load	NN
cord-005478-5iu38pr6	3655	3	was	be	VBD
cord-005478-5iu38pr6	3655	4	detected	detect	VBN
cord-005478-5iu38pr6	3655	5	in	in	IN
cord-005478-5iu38pr6	3655	6	blood	blood	NN
cord-005478-5iu38pr6	3655	7	by	by	IN
cord-005478-5iu38pr6	3655	8	PCR	PCR	NNP
cord-005478-5iu38pr6	3655	9	as	as	IN
cord-005478-5iu38pr6	3655	10	copies	copy	NNS
cord-005478-5iu38pr6	3655	11	/	/	SYM
cord-005478-5iu38pr6	3655	12	ml	ml	NN
cord-005478-5iu38pr6	3655	13	.	.	.
cord-005478-5iu38pr6	3656	1	Data	datum	NNS
cord-005478-5iu38pr6	3656	2	on	on	IN
cord-005478-5iu38pr6	3656	3	response	response	NN
cord-005478-5iu38pr6	3656	4	to	to	IN
cord-005478-5iu38pr6	3656	5	BCV	BCV	NNP
cord-005478-5iu38pr6	3656	6	was	be	VBD
cord-005478-5iu38pr6	3656	7	divided	divide	VBN
cord-005478-5iu38pr6	3656	8	into	into	IN
cord-005478-5iu38pr6	3656	9	complete	complete	JJ
cord-005478-5iu38pr6	3656	10	response	response	NN
cord-005478-5iu38pr6	3656	11	(	(	-LRB-
cord-005478-5iu38pr6	3656	12	CR	cr	NN
cord-005478-5iu38pr6	3656	13	)	)	-RRB-
cord-005478-5iu38pr6	3656	14	with	with	IN
cord-005478-5iu38pr6	3656	15	undetectable	undetectable	JJ
cord-005478-5iu38pr6	3656	16	virus	virus	NN
cord-005478-5iu38pr6	3656	17	in	in	IN
cord-005478-5iu38pr6	3656	18	blood	blood	NN
cord-005478-5iu38pr6	3656	19	and	and	CC
cord-005478-5iu38pr6	3656	20	resolution	resolution	NN
cord-005478-5iu38pr6	3656	21	of	of	IN
cord-005478-5iu38pr6	3656	22	symptoms	symptom	NNS
cord-005478-5iu38pr6	3656	23	,	,	,
cord-005478-5iu38pr6	3656	24	partial	partial	JJ
cord-005478-5iu38pr6	3656	25	response	response	NN
cord-005478-5iu38pr6	3656	26	(	(	-LRB-
cord-005478-5iu38pr6	3656	27	PR	PR	NNP
cord-005478-5iu38pr6	3656	28	)	)	-RRB-
cord-005478-5iu38pr6	3656	29	with	with	IN
cord-005478-5iu38pr6	3656	30	at	at	RB
cord-005478-5iu38pr6	3656	31	least	least	JJS
cord-005478-5iu38pr6	3656	32	1	1	CD
cord-005478-5iu38pr6	3656	33	log	log	NN
cord-005478-5iu38pr6	3656	34	drop	drop	NN
cord-005478-5iu38pr6	3656	35	in	in	IN
cord-005478-5iu38pr6	3656	36	viral	viral	JJ
cord-005478-5iu38pr6	3656	37	load	load	NN
cord-005478-5iu38pr6	3656	38	after	after	IN
cord-005478-5iu38pr6	3656	39	BCV	BCV	NNP
cord-005478-5iu38pr6	3656	40	,	,	,
cord-005478-5iu38pr6	3656	41	no	no	DT
cord-005478-5iu38pr6	3656	42	response	response	NN
cord-005478-5iu38pr6	3656	43	(	(	-LRB-
cord-005478-5iu38pr6	3656	44	NR	NR	NNP
cord-005478-5iu38pr6	3656	45	)	)	-RRB-
cord-005478-5iu38pr6	3656	46	with	with	IN
cord-005478-5iu38pr6	3656	47	no	no	DT
cord-005478-5iu38pr6	3656	48	change	change	NN
cord-005478-5iu38pr6	3656	49	in	in	IN
cord-005478-5iu38pr6	3656	50	the	the	DT
cord-005478-5iu38pr6	3656	51	viral	viral	JJ
cord-005478-5iu38pr6	3656	52	load	load	NN
cord-005478-5iu38pr6	3656	53	and	and	CC
cord-005478-5iu38pr6	3656	54	stationary	stationary	JJ
cord-005478-5iu38pr6	3656	55	disease	disease	NN
cord-005478-5iu38pr6	3656	56	and	and	CC
cord-005478-5iu38pr6	3656	57	progressive	progressive	JJ
cord-005478-5iu38pr6	3656	58	disease	disease	NN
cord-005478-5iu38pr6	3656	59	(	(	-LRB-
cord-005478-5iu38pr6	3656	60	PD	PD	NNP
cord-005478-5iu38pr6	3656	61	)	)	-RRB-
cord-005478-5iu38pr6	3656	62	with	with	IN
cord-005478-5iu38pr6	3656	63	evidence	evidence	NN
cord-005478-5iu38pr6	3656	64	of	of	IN
cord-005478-5iu38pr6	3656	65	at	at	IN
cord-005478-5iu38pr6	3656	66	least	least	JJS
cord-005478-5iu38pr6	3656	67	a	a	DT
cord-005478-5iu38pr6	3656	68	log	log	NN
cord-005478-5iu38pr6	3656	69	rise	rise	NN
cord-005478-5iu38pr6	3656	70	in	in	IN
cord-005478-5iu38pr6	3656	71	viral	viral	JJ
cord-005478-5iu38pr6	3656	72	load	load	NN
cord-005478-5iu38pr6	3656	73	by	by	IN
cord-005478-5iu38pr6	3656	74	PCR	PCR	NNP
cord-005478-5iu38pr6	3656	75	or	or	CC
cord-005478-5iu38pr6	3656	76	organ	organ	NN
cord-005478-5iu38pr6	3656	77	disease	disease	NN
cord-005478-5iu38pr6	3656	78	progression	progression	NN
cord-005478-5iu38pr6	3656	79	.	.	.
cord-005478-5iu38pr6	3657	1	Results	result	NNS
cord-005478-5iu38pr6	3657	2	:	:	:
cord-005478-5iu38pr6	3658	1	The	the	DT
cord-005478-5iu38pr6	3658	2	median	median	JJ
cord-005478-5iu38pr6	3658	3	viral	viral	JJ
cord-005478-5iu38pr6	3658	4	load	load	NN
cord-005478-5iu38pr6	3658	5	at	at	IN
cord-005478-5iu38pr6	3658	6	the	the	DT
cord-005478-5iu38pr6	3658	7	start	start	NN
cord-005478-5iu38pr6	3658	8	of	of	IN
cord-005478-5iu38pr6	3658	9	BCV	BCV	NNP
cord-005478-5iu38pr6	3658	10	was	be	VBD
cord-005478-5iu38pr6	3658	11	5.4	5.4	CD
cord-005478-5iu38pr6	3658	12	million	million	CD
cord-005478-5iu38pr6	3658	13	copies	copy	NNS
cord-005478-5iu38pr6	3658	14	/	/	SYM
cord-005478-5iu38pr6	3658	15	ml	ml	NN
cord-005478-5iu38pr6	3658	16	(	(	-LRB-
cord-005478-5iu38pr6	3658	17	range	range	NN
cord-005478-5iu38pr6	3658	18	:	:	:
cord-005478-5iu38pr6	3658	19	4142	4142	CD
cord-005478-5iu38pr6	3658	20	-	-	SYM
cord-005478-5iu38pr6	3658	21	85	85	CD
cord-005478-5iu38pr6	3658	22	million	million	CD
cord-005478-5iu38pr6	3658	23	copies	copy	NNS
cord-005478-5iu38pr6	3658	24	/	/	SYM
cord-005478-5iu38pr6	3658	25	ml	ml	NN
cord-005478-5iu38pr6	3658	26	)	)	-RRB-
cord-005478-5iu38pr6	3658	27	.	.	.
cord-005478-5iu38pr6	3659	1	BCV	BCV	NNP
cord-005478-5iu38pr6	3659	2	was	be	VBD
cord-005478-5iu38pr6	3659	3	used	use	VBN
cord-005478-5iu38pr6	3659	4	as	as	IN
cord-005478-5iu38pr6	3659	5	a	a	DT
cord-005478-5iu38pr6	3659	6	first	first	JJ
cord-005478-5iu38pr6	3659	7	line	line	NN
cord-005478-5iu38pr6	3659	8	treatment	treatment	NN
cord-005478-5iu38pr6	3659	9	in	in	IN
cord-005478-5iu38pr6	3659	10	8	8	CD
cord-005478-5iu38pr6	3659	11	cases	case	NNS
cord-005478-5iu38pr6	3659	12	and	and	CC
cord-005478-5iu38pr6	3659	13	as	as	IN
cord-005478-5iu38pr6	3659	14	second	second	JJ
cord-005478-5iu38pr6	3659	15	line	line	NN
cord-005478-5iu38pr6	3659	16	in	in	IN
cord-005478-5iu38pr6	3659	17	16	16	CD
cord-005478-5iu38pr6	3659	18	cases	case	NNS
cord-005478-5iu38pr6	3659	19	after	after	IN
cord-005478-5iu38pr6	3659	20	failure	failure	NN
cord-005478-5iu38pr6	3659	21	of	of	IN
cord-005478-5iu38pr6	3659	22	first	first	JJ
cord-005478-5iu38pr6	3659	23	line	line	NN
cord-005478-5iu38pr6	3659	24	therapy	therapy	NN
cord-005478-5iu38pr6	3659	25	(	(	-LRB-
cord-005478-5iu38pr6	3659	26	n=8	n=8	NN
cord-005478-5iu38pr6	3659	27	)	)	-RRB-
cord-005478-5iu38pr6	3659	28	,	,	,
cord-005478-5iu38pr6	3659	29	toxicity	toxicity	NN
cord-005478-5iu38pr6	3659	30	(	(	-LRB-
cord-005478-5iu38pr6	3659	31	n=5	n=5	NNP
cord-005478-5iu38pr6	3659	32	)	)	-RRB-
cord-005478-5iu38pr6	3659	33	or	or	CC
cord-005478-5iu38pr6	3659	34	both(n=3).13/24	both(n=3).13/24	NNP
cord-005478-5iu38pr6	3659	35	(	(	-LRB-
cord-005478-5iu38pr6	3659	36	54	54	CD
cord-005478-5iu38pr6	3659	37	%	%	NN
cord-005478-5iu38pr6	3659	38	)	)	-RRB-
cord-005478-5iu38pr6	3659	39	patients	patient	NNS
cord-005478-5iu38pr6	3659	40	had	have	VBD
cord-005478-5iu38pr6	3659	41	evidence	evidence	NN
cord-005478-5iu38pr6	3659	42	of	of	IN
cord-005478-5iu38pr6	3659	43	viral	viral	JJ
cord-005478-5iu38pr6	3659	44	induced	induce	VBN
cord-005478-5iu38pr6	3659	45	organ	organ	NN
cord-005478-5iu38pr6	3659	46	disease	disease	NN
cord-005478-5iu38pr6	3659	47	at	at	IN
cord-005478-5iu38pr6	3659	48	time	time	NN
cord-005478-5iu38pr6	3659	49	of	of	IN
cord-005478-5iu38pr6	3659	50	BCV	BCV	NNP
cord-005478-5iu38pr6	3659	51	administration	administration	NN
cord-005478-5iu38pr6	3659	52	;	;	:
cord-005478-5iu38pr6	3659	53	11	11	CD
cord-005478-5iu38pr6	3659	54	AdV	adv	NN
cord-005478-5iu38pr6	3659	55	disease	disease	NN
cord-005478-5iu38pr6	3659	56	(	(	-LRB-
cord-005478-5iu38pr6	3659	57	encephalitis	encephalitis	RB
cord-005478-5iu38pr6	3659	58	,	,	,
cord-005478-5iu38pr6	3659	59	pneumonitis	pneumonitis	NN
cord-005478-5iu38pr6	3659	60	,	,	,
cord-005478-5iu38pr6	3659	61	hepatitis	hepatitis	NN
cord-005478-5iu38pr6	3659	62	and	and	CC
cord-005478-5iu38pr6	3659	63	colitis	colitis	NNP
cord-005478-5iu38pr6	3659	64	)	)	-RRB-
cord-005478-5iu38pr6	3659	65	,	,	,
cord-005478-5iu38pr6	3659	66	1	1	CD
cord-005478-5iu38pr6	3659	67	Ganciclovir	Ganciclovir	NNP
cord-005478-5iu38pr6	3659	68	resistant	resistant	JJ
cord-005478-5iu38pr6	3659	69	CMV	CMV	NNP
cord-005478-5iu38pr6	3659	70	retinitis	retinitis	NN
cord-005478-5iu38pr6	3659	71	and	and	CC
cord-005478-5iu38pr6	3659	72	1	1	CD
cord-005478-5iu38pr6	3659	73	BK	BK	NNP
cord-005478-5iu38pr6	3659	74	haemorrhagic	haemorrhagic	JJ
cord-005478-5iu38pr6	3659	75	cystitis	cystitis	NN
cord-005478-5iu38pr6	3659	76	.	.	.
cord-005478-5iu38pr6	3659	77	19/24	19/24	CD
cord-005478-5iu38pr6	3659	78	(	(	-LRB-
cord-005478-5iu38pr6	3659	79	79	79	CD
cord-005478-5iu38pr6	3659	80	%	%	NN
cord-005478-5iu38pr6	3659	81	)	)	-RRB-
cord-005478-5iu38pr6	3659	82	patients	patient	NNS
cord-005478-5iu38pr6	3659	83	achieved	achieve	VBN
cord-005478-5iu38pr6	3659	84	either	either	CC
cord-005478-5iu38pr6	3659	85	a	a	DT
cord-005478-5iu38pr6	3659	86	CR	cr	NN
cord-005478-5iu38pr6	3659	87	(	(	-LRB-
cord-005478-5iu38pr6	3659	88	n=15	n=15	NNP
cord-005478-5iu38pr6	3659	89	)	)	-RRB-
cord-005478-5iu38pr6	3659	90	or	or	CC
cord-005478-5iu38pr6	3659	91	PR	PR	NNP
cord-005478-5iu38pr6	3659	92	(	(	-LRB-
cord-005478-5iu38pr6	3659	93	n=4	n=4	JJ
cord-005478-5iu38pr6	3659	94	)	)	-RRB-
cord-005478-5iu38pr6	3659	95	and	and	CC
cord-005478-5iu38pr6	3659	96	8/13(61	8/13(61	CD
cord-005478-5iu38pr6	3659	97	%	%	NN
cord-005478-5iu38pr6	3659	98	)	)	-RRB-
cord-005478-5iu38pr6	3659	99	patients	patient	NNS
cord-005478-5iu38pr6	3659	100	with	with	IN
cord-005478-5iu38pr6	3659	101	organ	organ	NN
cord-005478-5iu38pr6	3659	102	disease	disease	NN
cord-005478-5iu38pr6	3659	103	achieved	achieve	VBD
cord-005478-5iu38pr6	3659	104	a	a	DT
cord-005478-5iu38pr6	3659	105	CR.Two	CR.Two	NNP
cord-005478-5iu38pr6	3659	106	patients	patient	NNS
cord-005478-5iu38pr6	3659	107	with	with	IN
cord-005478-5iu38pr6	3659	108	AdV	adv	NN
cord-005478-5iu38pr6	3659	109	disease	disease	NN
cord-005478-5iu38pr6	3659	110	and	and	CC
cord-005478-5iu38pr6	3659	111	PR	PR	NNP
cord-005478-5iu38pr6	3659	112	received	receive	VBD
cord-005478-5iu38pr6	3659	113	donor	donor	NN
cord-005478-5iu38pr6	3659	114	derived	derive	VBD
cord-005478-5iu38pr6	3659	115	cytotoxic	cytotoxic	JJ
cord-005478-5iu38pr6	3659	116	T	t	NN
cord-005478-5iu38pr6	3659	117	lymphocytes	lymphocyte	NNS
cord-005478-5iu38pr6	3659	118	to	to	TO
cord-005478-5iu38pr6	3659	119	achieve	achieve	VB
cord-005478-5iu38pr6	3659	120	CR	CR	NNP
cord-005478-5iu38pr6	3659	121	.	.	.
cord-005478-5iu38pr6	3660	1	At	at	IN
cord-005478-5iu38pr6	3660	2	a	a	DT
cord-005478-5iu38pr6	3660	3	median	median	JJ
cord-005478-5iu38pr6	3660	4	follow	follow	NN
cord-005478-5iu38pr6	3660	5	-	-	HYPH
cord-005478-5iu38pr6	3660	6	up	up	NN
cord-005478-5iu38pr6	3660	7	of	of	IN
cord-005478-5iu38pr6	3660	8	20	20	CD
cord-005478-5iu38pr6	3660	9	months	month	NNS
cord-005478-5iu38pr6	3660	10	(	(	-LRB-
cord-005478-5iu38pr6	3660	11	range	range	NN
cord-005478-5iu38pr6	3660	12	:	:	:
cord-005478-5iu38pr6	3660	13	7	7	CD
cord-005478-5iu38pr6	3660	14	-	-	SYM
cord-005478-5iu38pr6	3660	15	53.8	53.8	CD
cord-005478-5iu38pr6	3660	16	)	)	-RRB-
cord-005478-5iu38pr6	3660	17	,	,	,
cord-005478-5iu38pr6	3660	18	patients	patient	NNS
cord-005478-5iu38pr6	3660	19	who	who	WP
cord-005478-5iu38pr6	3660	20	were	be	VBD
cord-005478-5iu38pr6	3660	21	in	in	IN
cord-005478-5iu38pr6	3660	22	CR	CR	NNP
cord-005478-5iu38pr6	3660	23	or	or	CC
cord-005478-5iu38pr6	3660	24	PR	PR	NNP
cord-005478-5iu38pr6	3660	25	did	do	VBD
cord-005478-5iu38pr6	3660	26	not	not	RB
cord-005478-5iu38pr6	3660	27	show	show	VB
cord-005478-5iu38pr6	3660	28	any	any	DT
cord-005478-5iu38pr6	3660	29	evidence	evidence	NN
cord-005478-5iu38pr6	3660	30	of	of	IN
cord-005478-5iu38pr6	3660	31	viral	viral	JJ
cord-005478-5iu38pr6	3660	32	reactivation	reactivation	NN
cord-005478-5iu38pr6	3660	33	after	after	IN
cord-005478-5iu38pr6	3660	34	BCV	BCV	NNP
cord-005478-5iu38pr6	3660	35	discontinuation	discontinuation	NN
cord-005478-5iu38pr6	3660	36	despite	despite	IN
cord-005478-5iu38pr6	3660	37	no	no	DT
cord-005478-5iu38pr6	3660	38	evidence	evidence	NN
cord-005478-5iu38pr6	3660	39	of	of	IN
cord-005478-5iu38pr6	3660	40	immune	immune	JJ
cord-005478-5iu38pr6	3660	41	reconstitution	reconstitution	NN
cord-005478-5iu38pr6	3660	42	(	(	-LRB-
cord-005478-5iu38pr6	3660	43	IR	IR	NNP
cord-005478-5iu38pr6	3660	44	)	)	-RRB-
cord-005478-5iu38pr6	3660	45	.	.	.
cord-005478-5iu38pr6	3661	1	Four	four	CD
cord-005478-5iu38pr6	3661	2	patients	patient	NNS
cord-005478-5iu38pr6	3661	3	had	have	VBD
cord-005478-5iu38pr6	3661	4	evidence	evidence	NN
cord-005478-5iu38pr6	3661	5	of	of	IN
cord-005478-5iu38pr6	3661	6	disease	disease	NN
cord-005478-5iu38pr6	3661	7	progression	progression	NN
cord-005478-5iu38pr6	3661	8	with	with	IN
cord-005478-5iu38pr6	3661	9	significant	significant	JJ
cord-005478-5iu38pr6	3661	10	rise	rise	NN
cord-005478-5iu38pr6	3661	11	in	in	IN
cord-005478-5iu38pr6	3661	12	viral	viral	JJ
cord-005478-5iu38pr6	3661	13	load	load	NN
cord-005478-5iu38pr6	3661	14	while	while	IN
cord-005478-5iu38pr6	3661	15	on	on	IN
cord-005478-5iu38pr6	3661	16	BCV	BCV	NNP
cord-005478-5iu38pr6	3661	17	therapy	therapy	NN
cord-005478-5iu38pr6	3661	18	and	and	CC
cord-005478-5iu38pr6	3661	19	all	all	DT
cord-005478-5iu38pr6	3661	20	4	4	CD
cord-005478-5iu38pr6	3661	21	died	die	VBD
cord-005478-5iu38pr6	3661	22	.	.	.
cord-005478-5iu38pr6	3662	1	The	the	DT
cord-005478-5iu38pr6	3662	2	patient	patient	NN
cord-005478-5iu38pr6	3662	3	with	with	IN
cord-005478-5iu38pr6	3662	4	Ganciclovir	Ganciclovir	NNP
cord-005478-5iu38pr6	3662	5	resistant	resistant	JJ
cord-005478-5iu38pr6	3662	6	CMV	CMV	NNP
cord-005478-5iu38pr6	3662	7	attained	attain	VBD
cord-005478-5iu38pr6	3662	8	CR	CR	NNP
cord-005478-5iu38pr6	3662	9	of	of	IN
cord-005478-5iu38pr6	3662	10	CMV	CMV	NNP
cord-005478-5iu38pr6	3662	11	retinitis	retinitis	NN
cord-005478-5iu38pr6	3662	12	.	.	.
cord-005478-5iu38pr6	3663	1	Among	among	IN
cord-005478-5iu38pr6	3663	2	22	22	CD
cord-005478-5iu38pr6	3663	3	patients	patient	NNS
cord-005478-5iu38pr6	3663	4	with	with	IN
cord-005478-5iu38pr6	3663	5	AdV	adv	NN
cord-005478-5iu38pr6	3663	6	viraemia	viraemia	NNP
cord-005478-5iu38pr6	3663	7	±	±	NNP
cord-005478-5iu38pr6	3663	8	disease	disease	NN
cord-005478-5iu38pr6	3663	9	;	;	:
cord-005478-5iu38pr6	3663	10	18	18	CD
cord-005478-5iu38pr6	3663	11	(	(	-LRB-
cord-005478-5iu38pr6	3663	12	81	81	CD
cord-005478-5iu38pr6	3663	13	%	%	NN
cord-005478-5iu38pr6	3663	14	)	)	-RRB-
cord-005478-5iu38pr6	3663	15	achieved	achieve	VBN
cord-005478-5iu38pr6	3663	16	either	either	CC
cord-005478-5iu38pr6	3663	17	CR	CR	NNP
cord-005478-5iu38pr6	3663	18	(	(	-LRB-
cord-005478-5iu38pr6	3663	19	n=14	n=14	NNP
cord-005478-5iu38pr6	3663	20	)	)	-RRB-
cord-005478-5iu38pr6	3663	21	or	or	CC
cord-005478-5iu38pr6	3663	22	PR	PR	NNP
cord-005478-5iu38pr6	3663	23	(	(	-LRB-
cord-005478-5iu38pr6	3663	24	n=4	n=4	NNS
cord-005478-5iu38pr6	3663	25	)	)	-RRB-
cord-005478-5iu38pr6	3663	26	.	.	.
cord-005478-5iu38pr6	3664	1	Nine	nine	CD
cord-005478-5iu38pr6	3664	2	cases	case	NNS
cord-005478-5iu38pr6	3664	3	had	have	VBD
cord-005478-5iu38pr6	3664	4	concomitant	concomitant	JJ
cord-005478-5iu38pr6	3664	5	BK±	BK±	NNS
cord-005478-5iu38pr6	3664	6	cystitis	cystitis	NN
cord-005478-5iu38pr6	3664	7	at	at	IN
cord-005478-5iu38pr6	3664	8	the	the	DT
cord-005478-5iu38pr6	3664	9	time	time	NN
cord-005478-5iu38pr6	3664	10	of	of	IN
cord-005478-5iu38pr6	3664	11	BCV	BCV	NNP
cord-005478-5iu38pr6	3664	12	therapy	therapy	NN
cord-005478-5iu38pr6	3664	13	and	and	CC
cord-005478-5iu38pr6	3664	14	all	all	DT
cord-005478-5iu38pr6	3664	15	had	have	VBD
cord-005478-5iu38pr6	3664	16	NR	NR	NNP
cord-005478-5iu38pr6	3664	17	.	.	.
cord-005478-5iu38pr6	3665	1	Toxicity	toxicity	NN
cord-005478-5iu38pr6	3665	2	was	be	VBD
cord-005478-5iu38pr6	3665	3	observed	observe	VBN
cord-005478-5iu38pr6	3665	4	in	in	IN
cord-005478-5iu38pr6	3665	5	4/24	4/24	CD
cord-005478-5iu38pr6	3665	6	cases	case	NNS
cord-005478-5iu38pr6	3665	7	;	;	,
cord-005478-5iu38pr6	3665	8	renal	renal	JJ
cord-005478-5iu38pr6	3665	9	impairment	impairment	NN
cord-005478-5iu38pr6	3665	10	(	(	-LRB-
cord-005478-5iu38pr6	3665	11	n=1	n=1	CD
cord-005478-5iu38pr6	3665	12	)	)	-RRB-
cord-005478-5iu38pr6	3665	13	,	,	,
cord-005478-5iu38pr6	3665	14	transaminitis	transaminitis	NNP
cord-005478-5iu38pr6	3665	15	(	(	-LRB-
cord-005478-5iu38pr6	3665	16	n=1	n=1	NN
cord-005478-5iu38pr6	3665	17	)	)	-RRB-
cord-005478-5iu38pr6	3665	18	and	and	CC
cord-005478-5iu38pr6	3665	19	diarrhoea	diarrhoea	NN
cord-005478-5iu38pr6	3665	20	(	(	-LRB-
cord-005478-5iu38pr6	3665	21	n=2	n=2	NNS
cord-005478-5iu38pr6	3665	22	)	)	-RRB-
cord-005478-5iu38pr6	3665	23	.	.	.
cord-005478-5iu38pr6	3666	1	Median	median	JJ
cord-005478-5iu38pr6	3666	2	CD3	CD3	NNP
cord-005478-5iu38pr6	3666	3	,	,	,
cord-005478-5iu38pr6	3666	4	CD4	CD4	NNP
cord-005478-5iu38pr6	3666	5	and	and	CC
cord-005478-5iu38pr6	3666	6	CD8	CD8	NNP
cord-005478-5iu38pr6	3666	7	were	be	VBD
cord-005478-5iu38pr6	3666	8	persistently	persistently	RB
cord-005478-5iu38pr6	3666	9	low	low	JJ
cord-005478-5iu38pr6	3666	10	both	both	DT
cord-005478-5iu38pr6	3666	11	pre	pre	JJ
cord-005478-5iu38pr6	3666	12	-	-	JJ
cord-005478-5iu38pr6	3666	13	BCV	BCV	NNP
cord-005478-5iu38pr6	3666	14	and	and	CC
cord-005478-5iu38pr6	3666	15	at	at	IN
cord-005478-5iu38pr6	3666	16	the	the	DT
cord-005478-5iu38pr6	3666	17	end	end	NN
cord-005478-5iu38pr6	3666	18	of	of	IN
cord-005478-5iu38pr6	3666	19	treatment	treatment	NN
cord-005478-5iu38pr6	3666	20	;	;	:
cord-005478-5iu38pr6	3666	21	100	100	CD
cord-005478-5iu38pr6	3666	22	cells	cell	NNS
cord-005478-5iu38pr6	3666	23	/	/	SYM
cord-005478-5iu38pr6	3666	24	ul	ul	NN
cord-005478-5iu38pr6	3666	25	vs	vs	IN
cord-005478-5iu38pr6	3666	26	290	290	CD
cord-005478-5iu38pr6	3666	27	cells	cell	NNS
cord-005478-5iu38pr6	3666	28	/	/	SYM
cord-005478-5iu38pr6	3666	29	ul	ul	NN
cord-005478-5iu38pr6	3666	30	,	,	,
cord-005478-5iu38pr6	3666	31	40	40	CD
cord-005478-5iu38pr6	3666	32	cells	cell	NNS
cord-005478-5iu38pr6	3666	33	/	/	SYM
cord-005478-5iu38pr6	3666	34	ul	ul	NN
cord-005478-5iu38pr6	3666	35	vs	vs	IN
cord-005478-5iu38pr6	3666	36	70	70	CD
cord-005478-5iu38pr6	3666	37	cells	cell	NNS
cord-005478-5iu38pr6	3666	38	/	/	SYM
cord-005478-5iu38pr6	3666	39	ul	ul	NN
cord-005478-5iu38pr6	3666	40	and	and	CC
cord-005478-5iu38pr6	3666	41	20	20	CD
cord-005478-5iu38pr6	3666	42	cells	cell	NNS
cord-005478-5iu38pr6	3666	43	/	/	SYM
cord-005478-5iu38pr6	3666	44	ul	ul	NN
cord-005478-5iu38pr6	3666	45	vs	vs	IN
cord-005478-5iu38pr6	3666	46	120	120	CD
cord-005478-5iu38pr6	3666	47	cells	cell	NNS
cord-005478-5iu38pr6	3667	1	/ul	/ul	:
cord-005478-5iu38pr6	3667	2	;	;	:
cord-005478-5iu38pr6	3667	3	p=0.2	p=0.2	NNP
cord-005478-5iu38pr6	3667	4	,	,	,
cord-005478-5iu38pr6	3667	5	p=0.34	p=0.34	NNP
cord-005478-5iu38pr6	3667	6	,	,	,
cord-005478-5iu38pr6	3667	7	p=0	p=0	NNP
cord-005478-5iu38pr6	3667	8	.5	.5	.
cord-005478-5iu38pr6	3668	1	respectively	respectively	RB
cord-005478-5iu38pr6	3668	2	(	(	-LRB-
cord-005478-5iu38pr6	3668	3	Figure	figure	NN
cord-005478-5iu38pr6	3668	4	1	1	CD
cord-005478-5iu38pr6	3668	5	)	)	-RRB-
cord-005478-5iu38pr6	3668	6	.	.	.
cord-005478-5iu38pr6	3669	1	At	at	IN
cord-005478-5iu38pr6	3669	2	last	last	JJ
cord-005478-5iu38pr6	3669	3	follow	follow	NN
cord-005478-5iu38pr6	3669	4	-	-	HYPH
cord-005478-5iu38pr6	3669	5	up	up	NN
cord-005478-5iu38pr6	3669	6	,	,	,
cord-005478-5iu38pr6	3669	7	15/24	15/24	CD
cord-005478-5iu38pr6	3669	8	(	(	-LRB-
cord-005478-5iu38pr6	3669	9	63	63	CD
cord-005478-5iu38pr6	3669	10	%	%	NN
cord-005478-5iu38pr6	3669	11	)	)	-RRB-
cord-005478-5iu38pr6	3669	12	were	be	VBD
cord-005478-5iu38pr6	3669	13	alive	alive	JJ
cord-005478-5iu38pr6	3669	14	.	.	.
cord-005478-5iu38pr6	3670	1	Of	of	IN
cord-005478-5iu38pr6	3670	2	these	these	DT
cord-005478-5iu38pr6	3670	3	,	,	,
cord-005478-5iu38pr6	3670	4	viral	viral	JJ
cord-005478-5iu38pr6	3670	5	infection	infection	NN
cord-005478-5iu38pr6	3670	6	related	relate	VBN
cord-005478-5iu38pr6	3670	7	mortality	mortality	NN
cord-005478-5iu38pr6	3670	8	was	be	VBD
cord-005478-5iu38pr6	3670	9	4/24	4/24	CD
cord-005478-5iu38pr6	3670	10	(	(	-LRB-
cord-005478-5iu38pr6	3670	11	17%).Conclusions	17%).conclusion	NNS
cord-005478-5iu38pr6	3670	12	:	:	:
cord-005478-5iu38pr6	3670	13	BCV	BCV	NNP
cord-005478-5iu38pr6	3670	14	is	be	VBZ
cord-005478-5iu38pr6	3670	15	an	an	DT
cord-005478-5iu38pr6	3670	16	effective	effective	JJ
cord-005478-5iu38pr6	3670	17	and	and	CC
cord-005478-5iu38pr6	3670	18	well	well	RB
cord-005478-5iu38pr6	3670	19	tolerated	tolerate	VBN
cord-005478-5iu38pr6	3670	20	treatment	treatment	NN
cord-005478-5iu38pr6	3670	21	in	in	IN
cord-005478-5iu38pr6	3670	22	immune	immune	JJ
cord-005478-5iu38pr6	3670	23	compromised	compromise	VBN
cord-005478-5iu38pr6	3670	24	patients	patient	NNS
cord-005478-5iu38pr6	3670	25	with	with	IN
cord-005478-5iu38pr6	3670	26	AdV	adv	NN
cord-005478-5iu38pr6	3670	27	infection	infection	NN
cord-005478-5iu38pr6	3670	28	with	with	IN
cord-005478-5iu38pr6	3670	29	a	a	DT
cord-005478-5iu38pr6	3670	30	response	response	NN
cord-005478-5iu38pr6	3670	31	rate	rate	NN
cord-005478-5iu38pr6	3670	32	of	of	IN
cord-005478-5iu38pr6	3670	33	80%.[[O163	80%.[[o163	CD
cord-005478-5iu38pr6	3670	34	Image	image	NN
cord-005478-5iu38pr6	3670	35	]	]	-RRB-
cord-005478-5iu38pr6	3670	36	1	1	CD
cord-005478-5iu38pr6	3670	37	.	.	.
cord-005478-5iu38pr6	3671	1	Background	background	NN
cord-005478-5iu38pr6	3671	2	:	:	:
cord-005478-5iu38pr6	3672	1	Although	although	IN
cord-005478-5iu38pr6	3672	2	the	the	DT
cord-005478-5iu38pr6	3672	3	impact	impact	NN
cord-005478-5iu38pr6	3672	4	of	of	IN
cord-005478-5iu38pr6	3672	5	donor	donor	NN
cord-005478-5iu38pr6	3672	6	graft	graft	NN
cord-005478-5iu38pr6	3672	7	composition	composition	NN
cord-005478-5iu38pr6	3672	8	on	on	IN
cord-005478-5iu38pr6	3672	9	clinical	clinical	JJ
cord-005478-5iu38pr6	3672	10	outcome	outcome	NN
cord-005478-5iu38pr6	3672	11	after	after	IN
cord-005478-5iu38pr6	3672	12	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3672	13	stem	stem	NN
cord-005478-5iu38pr6	3672	14	cell	cell	NN
cord-005478-5iu38pr6	3672	15	transplantation	transplantation	NN
cord-005478-5iu38pr6	3672	16	(	(	-LRB-
cord-005478-5iu38pr6	3672	17	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3672	18	)	)	-RRB-
cord-005478-5iu38pr6	3672	19	has	have	VBZ
cord-005478-5iu38pr6	3672	20	been	be	VBN
cord-005478-5iu38pr6	3672	21	studied	study	VBN
cord-005478-5iu38pr6	3672	22	,	,	,
cord-005478-5iu38pr6	3672	23	little	little	JJ
cord-005478-5iu38pr6	3672	24	is	be	VBZ
cord-005478-5iu38pr6	3672	25	known	know	VBN
cord-005478-5iu38pr6	3672	26	about	about	IN
cord-005478-5iu38pr6	3672	27	the	the	DT
cord-005478-5iu38pr6	3672	28	role	role	NN
cord-005478-5iu38pr6	3672	29	of	of	IN
cord-005478-5iu38pr6	3672	30	intra	intra	JJ
cord-005478-5iu38pr6	3672	31	-	-	JJ
cord-005478-5iu38pr6	3672	32	graft	graft	NN
cord-005478-5iu38pr6	3672	33	γδ	γδ	IN
cord-005478-5iu38pr6	3672	34	T	t	NN
cord-005478-5iu38pr6	3672	35	-	-	HYPH
cord-005478-5iu38pr6	3672	36	cell	cell	NN
cord-005478-5iu38pr6	3672	37	receptor	receptor	NN
cord-005478-5iu38pr6	3672	38	(	(	-LRB-
cord-005478-5iu38pr6	3672	39	TCR	TCR	NNP
cord-005478-5iu38pr6	3672	40	)	)	-RRB-
cord-005478-5iu38pr6	3672	41	repertoire	repertoire	NN
cord-005478-5iu38pr6	3672	42	on	on	IN
cord-005478-5iu38pr6	3672	43	clinical	clinical	JJ
cord-005478-5iu38pr6	3672	44	outcome	outcome	NN
cord-005478-5iu38pr6	3672	45	following	follow	VBG
cord-005478-5iu38pr6	3672	46	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3672	47	.	.	.
cord-005478-5iu38pr6	3673	1	Using	use	VBG
cord-005478-5iu38pr6	3673	2	high	high	JJ
cord-005478-5iu38pr6	3673	3	-	-	HYPH
cord-005478-5iu38pr6	3673	4	throughput	throughput	NN
cord-005478-5iu38pr6	3673	5	sequencing	sequencing	NN
cord-005478-5iu38pr6	3673	6	we	-PRON-	PRP
cord-005478-5iu38pr6	3673	7	sought	seek	VBD
cord-005478-5iu38pr6	3673	8	to	to	TO
cord-005478-5iu38pr6	3673	9	analyze	analyze	VB
cord-005478-5iu38pr6	3673	10	the	the	DT
cord-005478-5iu38pr6	3673	11	TCR	TCR	NNP
cord-005478-5iu38pr6	3673	12	γ	γ	NN
cord-005478-5iu38pr6	3673	13	-	-	HYPH
cord-005478-5iu38pr6	3673	14	chain	chain	NN
cord-005478-5iu38pr6	3673	15	(	(	-LRB-
cord-005478-5iu38pr6	3673	16	TRG	TRG	NNP
cord-005478-5iu38pr6	3673	17	)	)	-RRB-
cord-005478-5iu38pr6	3673	18	repertoire	repertoire	NN
cord-005478-5iu38pr6	3673	19	of	of	IN
cord-005478-5iu38pr6	3673	20	γδ	γδ	NNP
cord-005478-5iu38pr6	3673	21	T	T	NNP
cord-005478-5iu38pr6	3673	22	-	-	HYPH
cord-005478-5iu38pr6	3673	23	cells	cell	NNS
cord-005478-5iu38pr6	3673	24	within	within	IN
cord-005478-5iu38pr6	3673	25	donor	donor	NN
cord-005478-5iu38pr6	3673	26	stem	stem	NN
cord-005478-5iu38pr6	3673	27	cell	cell	NN
cord-005478-5iu38pr6	3673	28	grafts	graft	NNS
cord-005478-5iu38pr6	3673	29	and	and	CC
cord-005478-5iu38pr6	3673	30	address	address	VB
cord-005478-5iu38pr6	3673	31	its	-PRON-	PRP$
cord-005478-5iu38pr6	3673	32	potential	potential	JJ
cord-005478-5iu38pr6	3673	33	impact	impact	NN
cord-005478-5iu38pr6	3673	34	on	on	IN
cord-005478-5iu38pr6	3673	35	clinical	clinical	JJ
cord-005478-5iu38pr6	3673	36	response	response	NN
cord-005478-5iu38pr6	3673	37	in	in	IN
cord-005478-5iu38pr6	3673	38	the	the	DT
cord-005478-5iu38pr6	3673	39	corresponding	correspond	VBG
cord-005478-5iu38pr6	3673	40	patients	patient	NNS
cord-005478-5iu38pr6	3673	41	.	.	.
cord-005478-5iu38pr6	3674	1	Methods	method	NNS
cord-005478-5iu38pr6	3674	2	:	:	:
cord-005478-5iu38pr6	3674	3	We	-PRON-	PRP
cord-005478-5iu38pr6	3674	4	analyzed	analyze	VBD
cord-005478-5iu38pr6	3674	5	twenty	twenty	CD
cord-005478-5iu38pr6	3674	6	peripheral	peripheral	JJ
cord-005478-5iu38pr6	3674	7	blood	blood	NN
cord-005478-5iu38pr6	3674	8	stem	stem	NN
cord-005478-5iu38pr6	3674	9	cell	cell	NN
cord-005478-5iu38pr6	3674	10	grafts	graft	NNS
cord-005478-5iu38pr6	3674	11	from	from	IN
cord-005478-5iu38pr6	3674	12	matched	match	VBN
cord-005478-5iu38pr6	3674	13	unrelated	unrelated	JJ
cord-005478-5iu38pr6	3674	14	donors	donor	NNS
cord-005478-5iu38pr6	3674	15	and	and	CC
cord-005478-5iu38pr6	3674	16	classified	classify	VBD
cord-005478-5iu38pr6	3674	17	as	as	IN
cord-005478-5iu38pr6	3674	18	CMV	CMV	NNP
cord-005478-5iu38pr6	3674	19	-	-	HYPH
cord-005478-5iu38pr6	3674	20	positive	positive	JJ
cord-005478-5iu38pr6	3674	21	/	/	SYM
cord-005478-5iu38pr6	3674	22	negative	negative	JJ
cord-005478-5iu38pr6	3674	23	.	.	.
cord-005478-5iu38pr6	3675	1	The	the	DT
cord-005478-5iu38pr6	3675	2	respective	respective	JJ
cord-005478-5iu38pr6	3675	3	acute	acute	JJ
cord-005478-5iu38pr6	3675	4	myeloid	myeloid	NN
cord-005478-5iu38pr6	3675	5	leukemia	leukemia	NN
cord-005478-5iu38pr6	3675	6	recipients	recipient	NNS
cord-005478-5iu38pr6	3675	7	were	be	VBD
cord-005478-5iu38pr6	3675	8	followed	follow	VBN
cord-005478-5iu38pr6	3675	9	for	for	IN
cord-005478-5iu38pr6	3675	10	disease	disease	NN
cord-005478-5iu38pr6	3675	11	relapse	relapse	NN
cord-005478-5iu38pr6	3675	12	and	and	CC
cord-005478-5iu38pr6	3675	13	acute	acute	JJ
cord-005478-5iu38pr6	3675	14	graft	graft	NN
cord-005478-5iu38pr6	3675	15	-	-	HYPH
cord-005478-5iu38pr6	3675	16	vs	vs	IN
cord-005478-5iu38pr6	3675	17	-	-	HYPH
cord-005478-5iu38pr6	3675	18	host	host	NN
cord-005478-5iu38pr6	3675	19	disease	disease	NN
cord-005478-5iu38pr6	3675	20	(	(	-LRB-
cord-005478-5iu38pr6	3675	21	aGvHD	agvhd	NN
cord-005478-5iu38pr6	3675	22	)	)	-RRB-
cord-005478-5iu38pr6	3676	1	development	development	NNP
cord-005478-5iu38pr6	3676	2	post	post	NNP
cord-005478-5iu38pr6	3676	3	-	-	JJ
cord-005478-5iu38pr6	3676	4	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3676	5	.	.	.
cord-005478-5iu38pr6	3677	1	γδ	γδ	CC
cord-005478-5iu38pr6	3677	2	T	T	NNP
cord-005478-5iu38pr6	3677	3	-	-	HYPH
cord-005478-5iu38pr6	3677	4	cells	cell	NNS
cord-005478-5iu38pr6	3677	5	were	be	VBD
cord-005478-5iu38pr6	3677	6	isolated	isolate	VBN
cord-005478-5iu38pr6	3677	7	using	use	VBG
cord-005478-5iu38pr6	3677	8	magnetic	magnetic	JJ
cord-005478-5iu38pr6	3677	9	beads	bead	NNS
cord-005478-5iu38pr6	3677	10	and	and	CC
cord-005478-5iu38pr6	3677	11	the	the	DT
cord-005478-5iu38pr6	3677	12	gDNA	gdna	NN
cord-005478-5iu38pr6	3678	1	extracted	extract	VBN
cord-005478-5iu38pr6	3678	2	for	for	IN
cord-005478-5iu38pr6	3678	3	next	next	JJ
cord-005478-5iu38pr6	3678	4	-	-	HYPH
cord-005478-5iu38pr6	3678	5	generation	generation	NN
cord-005478-5iu38pr6	3678	6	sequencing	sequencing	NN
cord-005478-5iu38pr6	3678	7	(	(	-LRB-
cord-005478-5iu38pr6	3678	8	ImmunoSEQ	ImmunoSEQ	NNP
cord-005478-5iu38pr6	3678	9	,	,	,
cord-005478-5iu38pr6	3678	10	Adaptive	Adaptive	NNP
cord-005478-5iu38pr6	3678	11	Biotechnologies	Biotechnologies	NNPS
cord-005478-5iu38pr6	3678	12	)	)	-RRB-
cord-005478-5iu38pr6	3678	13	.	.	.
cord-005478-5iu38pr6	3679	1	TRG	TRG	NNP
cord-005478-5iu38pr6	3679	2	characteristics	characteristic	NNS
cord-005478-5iu38pr6	3679	3	were	be	VBD
cord-005478-5iu38pr6	3679	4	assessed	assess	VBN
cord-005478-5iu38pr6	3679	5	using	use	VBG
cord-005478-5iu38pr6	3679	6	VDJTools	vdjtool	NNS
cord-005478-5iu38pr6	3679	7	,	,	,
cord-005478-5iu38pr6	3679	8	VDJviz	VDJviz	NNP
cord-005478-5iu38pr6	3679	9	,	,	,
cord-005478-5iu38pr6	3679	10	tcR	tcR	NNP
cord-005478-5iu38pr6	3679	11	and	and	CC
cord-005478-5iu38pr6	3679	12	ImmunoSEQ	immunoseq	NN
cord-005478-5iu38pr6	3680	1	Analyzer	Analyzer	NNP
cord-005478-5iu38pr6	3680	2	platforms	platform	NNS
cord-005478-5iu38pr6	3680	3	.	.	.
cord-005478-5iu38pr6	3681	1	Results	result	NNS
cord-005478-5iu38pr6	3681	2	:	:	:
cord-005478-5iu38pr6	3682	1	Deep	deep	JJ
cord-005478-5iu38pr6	3682	2	sequencing	sequencing	NN
cord-005478-5iu38pr6	3682	3	showed	show	VBD
cord-005478-5iu38pr6	3682	4	similar	similar	JJ
cord-005478-5iu38pr6	3682	5	median	median	JJ
cord-005478-5iu38pr6	3682	6	total/	total/	POS
cord-005478-5iu38pr6	3682	7	unique	unique	JJ
cord-005478-5iu38pr6	3682	8	reads	read	NNS
cord-005478-5iu38pr6	3682	9	in	in	IN
cord-005478-5iu38pr6	3682	10	all	all	DT
cord-005478-5iu38pr6	3682	11	grafts	graft	NNS
cord-005478-5iu38pr6	3682	12	as	as	RB
cord-005478-5iu38pr6	3682	13	well	well	RB
cord-005478-5iu38pr6	3682	14	as	as	IN
cord-005478-5iu38pr6	3682	15	similarly	similarly	RB
cord-005478-5iu38pr6	3682	16	low	low	JJ
cord-005478-5iu38pr6	3682	17	unique	unique	JJ
cord-005478-5iu38pr6	3682	18	CDR3	CDR3	NNP
cord-005478-5iu38pr6	3682	19	TRG	TRG	NNP
cord-005478-5iu38pr6	3682	20	ratios	ratio	NNS
cord-005478-5iu38pr6	3682	21	.	.	.
cord-005478-5iu38pr6	3683	1	Grafts	graft	NNS
cord-005478-5iu38pr6	3683	2	presented	present	VBD
cord-005478-5iu38pr6	3683	3	multiple	multiple	JJ
cord-005478-5iu38pr6	3683	4	clonal	clonal	JJ
cord-005478-5iu38pr6	3683	5	overrepresentations	overrepresentation	NNS
cord-005478-5iu38pr6	3683	6	,	,	,
cord-005478-5iu38pr6	3683	7	with	with	IN
cord-005478-5iu38pr6	3683	8	no	no	DT
cord-005478-5iu38pr6	3683	9	differences	difference	NNS
cord-005478-5iu38pr6	3683	10	on	on	IN
cord-005478-5iu38pr6	3683	11	TCR	TCR	NNP
cord-005478-5iu38pr6	3683	12	richness	richness	NN
cord-005478-5iu38pr6	3683	13	between	between	IN
cord-005478-5iu38pr6	3683	14	patient	patient	JJ
cord-005478-5iu38pr6	3683	15	groups	group	NNS
cord-005478-5iu38pr6	3683	16	.	.	.
cord-005478-5iu38pr6	3684	1	Grafts	graft	NNS
cord-005478-5iu38pr6	3684	2	received	receive	VBN
cord-005478-5iu38pr6	3684	3	by	by	IN
cord-005478-5iu38pr6	3684	4	the	the	DT
cord-005478-5iu38pr6	3684	5	non	non	JJ
cord-005478-5iu38pr6	3684	6	-	-	JJ
cord-005478-5iu38pr6	3684	7	Background	background	NN
cord-005478-5iu38pr6	3684	8	:	:	:
cord-005478-5iu38pr6	3685	1	Prognosis	prognosis	NN
cord-005478-5iu38pr6	3685	2	of	of	IN
cord-005478-5iu38pr6	3685	3	mature	mature	JJ
cord-005478-5iu38pr6	3685	4	T	T	NNP
cord-005478-5iu38pr6	3685	5	-	-	HYPH
cord-005478-5iu38pr6	3685	6	and	and	CC
cord-005478-5iu38pr6	3685	7	NK	nk	NN
cord-005478-5iu38pr6	3685	8	-	-	HYPH
cord-005478-5iu38pr6	3685	9	cell	cell	NN
cord-005478-5iu38pr6	3685	10	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3685	11	remains	remain	VBZ
cord-005478-5iu38pr6	3685	12	poor	poor	JJ
cord-005478-5iu38pr6	3685	13	despite	despite	IN
cord-005478-5iu38pr6	3685	14	development	development	NN
cord-005478-5iu38pr6	3685	15	of	of	IN
cord-005478-5iu38pr6	3685	16	novel	novel	JJ
cord-005478-5iu38pr6	3685	17	therapeutic	therapeutic	JJ
cord-005478-5iu38pr6	3685	18	agents	agent	NNS
cord-005478-5iu38pr6	3685	19	.	.	.
cord-005478-5iu38pr6	3686	1	Accordingly	accordingly	RB
cord-005478-5iu38pr6	3686	2	,	,	,
cord-005478-5iu38pr6	3686	3	these	these	DT
cord-005478-5iu38pr6	3686	4	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3686	5	are	be	VBP
cord-005478-5iu38pr6	3686	6	still	still	RB
cord-005478-5iu38pr6	3686	7	good	good	JJ
cord-005478-5iu38pr6	3686	8	candidates	candidate	NNS
cord-005478-5iu38pr6	3686	9	of	of	IN
cord-005478-5iu38pr6	3686	10	allogenic	allogenic	JJ
cord-005478-5iu38pr6	3686	11	hematopoietic	hematopoietic	JJ
cord-005478-5iu38pr6	3686	12	stem	stem	NN
cord-005478-5iu38pr6	3686	13	cell	cell	NN
cord-005478-5iu38pr6	3686	14	transplantation	transplantation	NN
cord-005478-5iu38pr6	3686	15	(	(	-LRB-
cord-005478-5iu38pr6	3686	16	allo	allo	NN
cord-005478-5iu38pr6	3686	17	-	-	HYPH
cord-005478-5iu38pr6	3686	18	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3686	19	)	)	-RRB-
cord-005478-5iu38pr6	3686	20	to	to	TO
cord-005478-5iu38pr6	3686	21	achieve	achieve	VB
cord-005478-5iu38pr6	3686	22	long	long	RB
cord-005478-5iu38pr6	3686	23	-	-	HYPH
cord-005478-5iu38pr6	3686	24	lasting	last	VBG
cord-005478-5iu38pr6	3686	25	remission	remission	NN
cord-005478-5iu38pr6	3686	26	of	of	IN
cord-005478-5iu38pr6	3686	27	the	the	DT
cord-005478-5iu38pr6	3686	28	diseases	disease	NNS
cord-005478-5iu38pr6	3686	29	.	.	.
cord-005478-5iu38pr6	3687	1	However	however	RB
cord-005478-5iu38pr6	3687	2	,	,	,
cord-005478-5iu38pr6	3687	3	the	the	DT
cord-005478-5iu38pr6	3687	4	analysis	analysis	NN
cord-005478-5iu38pr6	3687	5	of	of	IN
cord-005478-5iu38pr6	3687	6	transplantations	transplantation	NNS
cord-005478-5iu38pr6	3687	7	for	for	IN
cord-005478-5iu38pr6	3687	8	these	these	DT
cord-005478-5iu38pr6	3687	9	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3687	10	is	be	VBZ
cord-005478-5iu38pr6	3687	11	scarce	scarce	JJ
cord-005478-5iu38pr6	3687	12	,	,	,
cord-005478-5iu38pr6	3687	13	mainly	mainly	RB
cord-005478-5iu38pr6	3687	14	due	due	IN
cord-005478-5iu38pr6	3687	15	to	to	IN
cord-005478-5iu38pr6	3687	16	the	the	DT
cord-005478-5iu38pr6	3687	17	rarity	rarity	NN
cord-005478-5iu38pr6	3687	18	of	of	IN
cord-005478-5iu38pr6	3687	19	these	these	DT
cord-005478-5iu38pr6	3687	20	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3687	21	.	.	.
cord-005478-5iu38pr6	3688	1	Hence	hence	RB
cord-005478-5iu38pr6	3688	2	,	,	,
cord-005478-5iu38pr6	3688	3	we	-PRON-	PRP
cord-005478-5iu38pr6	3688	4	analysed	analyse	VBD
cord-005478-5iu38pr6	3688	5	the	the	DT
cord-005478-5iu38pr6	3688	6	data	datum	NNS
cord-005478-5iu38pr6	3688	7	of	of	IN
cord-005478-5iu38pr6	3688	8	these	these	DT
cord-005478-5iu38pr6	3688	9	transplantations	transplantation	NNS
cord-005478-5iu38pr6	3688	10	operated	operate	VBN
cord-005478-5iu38pr6	3688	11	in	in	IN
cord-005478-5iu38pr6	3688	12	15	15	CD
cord-005478-5iu38pr6	3688	13	different	different	JJ
cord-005478-5iu38pr6	3688	14	Japanese	japanese	JJ
cord-005478-5iu38pr6	3688	15	institutions	institution	NNS
cord-005478-5iu38pr6	3688	16	as	as	IN
cord-005478-5iu38pr6	3688	17	a	a	DT
cord-005478-5iu38pr6	3688	18	multi	multi	JJ
cord-005478-5iu38pr6	3688	19	-	-	JJ
cord-005478-5iu38pr6	3688	20	institutional	institutional	JJ
cord-005478-5iu38pr6	3688	21	joint	joint	JJ
cord-005478-5iu38pr6	3688	22	research	research	NN
cord-005478-5iu38pr6	3688	23	and	and	CC
cord-005478-5iu38pr6	3688	24	examined	examine	VBN
cord-005478-5iu38pr6	3688	25	factors	factor	NNS
cord-005478-5iu38pr6	3688	26	that	that	WDT
cord-005478-5iu38pr6	3688	27	affected	affect	VBD
cord-005478-5iu38pr6	3688	28	the	the	DT
cord-005478-5iu38pr6	3688	29	outcomes	outcome	NNS
cord-005478-5iu38pr6	3688	30	in	in	IN
cord-005478-5iu38pr6	3688	31	aims	aim	NNS
cord-005478-5iu38pr6	3688	32	of	of	IN
cord-005478-5iu38pr6	3688	33	figuring	figure	VBG
cord-005478-5iu38pr6	3688	34	out	out	RP
cord-005478-5iu38pr6	3688	35	better	well	JJR
cord-005478-5iu38pr6	3688	36	transplant	transplant	NN
cord-005478-5iu38pr6	3688	37	strategies	strategy	NNS
cord-005478-5iu38pr6	3688	38	against	against	IN
cord-005478-5iu38pr6	3688	39	these	these	DT
cord-005478-5iu38pr6	3688	40	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3688	41	.	.	.
cord-005478-5iu38pr6	3689	1	Methods	method	NNS
cord-005478-5iu38pr6	3689	2	:	:	:
cord-005478-5iu38pr6	3690	1	A	a	DT
cord-005478-5iu38pr6	3690	2	total	total	NN
cord-005478-5iu38pr6	3690	3	of	of	IN
cord-005478-5iu38pr6	3690	4	116	116	CD
cord-005478-5iu38pr6	3690	5	patients	patient	NNS
cord-005478-5iu38pr6	3690	6	who	who	WP
cord-005478-5iu38pr6	3690	7	received	receive	VBD
cord-005478-5iu38pr6	3690	8	allo	allo	NN
cord-005478-5iu38pr6	3690	9	-	-	HYPH
cord-005478-5iu38pr6	3690	10	HSCTs	hsct	NNS
cord-005478-5iu38pr6	3690	11	for	for	IN
cord-005478-5iu38pr6	3690	12	mature	mature	JJ
cord-005478-5iu38pr6	3690	13	T	T	NNP
cord-005478-5iu38pr6	3690	14	-	-	HYPH
cord-005478-5iu38pr6	3690	15	and	and	CC
cord-005478-5iu38pr6	3690	16	NK	nk	NN
cord-005478-5iu38pr6	3690	17	-	-	HYPH
cord-005478-5iu38pr6	3690	18	cell	cell	NN
cord-005478-5iu38pr6	3690	19	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3690	20	(	(	-LRB-
cord-005478-5iu38pr6	3690	21	PTCL	PTCL	NNP
cord-005478-5iu38pr6	3690	22	-	-	HYPH
cord-005478-5iu38pr6	3690	23	NOS	NOS	NNP
cord-005478-5iu38pr6	3690	24	,	,	,
cord-005478-5iu38pr6	3690	25	n=38	n=38	JJ
cord-005478-5iu38pr6	3690	26	;	;	:
cord-005478-5iu38pr6	3690	27	NK	NK	NNP
cord-005478-5iu38pr6	3690	28	/	/	SYM
cord-005478-5iu38pr6	3690	29	T	T	NNP
cord-005478-5iu38pr6	3690	30	cell	cell	NN
cord-005478-5iu38pr6	3690	31	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3690	32	nasal	nasal	NN
cord-005478-5iu38pr6	3690	33	type	type	NN
cord-005478-5iu38pr6	3690	34	,	,	,
cord-005478-5iu38pr6	3690	35	n=22	n=22	NN
cord-005478-5iu38pr6	3690	36	;	;	:
cord-005478-5iu38pr6	3690	37	AITL	AITL	NNP
cord-005478-5iu38pr6	3690	38	,	,	,
cord-005478-5iu38pr6	3690	39	n=20	n=20	NN
cord-005478-5iu38pr6	3690	40	;	;	:
cord-005478-5iu38pr6	3690	41	ALCL	ALCL	NNP
cord-005478-5iu38pr6	3690	42	,	,	,
cord-005478-5iu38pr6	3690	43	n=12	n=12	VBN
cord-005478-5iu38pr6	3690	44	;	;	:
cord-005478-5iu38pr6	3690	45	EATL	EATL	NNP
cord-005478-5iu38pr6	3690	46	,	,	,
cord-005478-5iu38pr6	3690	47	n=8	n=8	NN
cord-005478-5iu38pr6	3690	48	;	;	.
cord-005478-5iu38pr6	3690	49	Other	other	JJ
cord-005478-5iu38pr6	3690	50	lymphomas	lymphoma	NNS
cord-005478-5iu38pr6	3690	51	,	,	,
cord-005478-5iu38pr6	3690	52	n=16	n=16	NNP
cord-005478-5iu38pr6	3690	53	)	)	-RRB-
cord-005478-5iu38pr6	3690	54	from	from	IN
cord-005478-5iu38pr6	3690	55	1998	1998	CD
cord-005478-5iu38pr6	3690	56	to	to	IN
cord-005478-5iu38pr6	3690	57	2016	2016	CD
cord-005478-5iu38pr6	3690	58	in	in	IN
cord-005478-5iu38pr6	3690	59	15	15	CD
cord-005478-5iu38pr6	3690	60	institutions	institution	NNS
cord-005478-5iu38pr6	3690	61	were	be	VBD
cord-005478-5iu38pr6	3690	62	examined	examine	VBN
cord-005478-5iu38pr6	3690	63	.	.	.
cord-005478-5iu38pr6	3691	1	Median	median	JJ
cord-005478-5iu38pr6	3691	2	age	age	NN
cord-005478-5iu38pr6	3691	3	at	at	IN
cord-005478-5iu38pr6	3691	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	3691	5	was	be	VBD
cord-005478-5iu38pr6	3691	6	50	50	CD
cord-005478-5iu38pr6	3692	1	(	(	-LRB-
cord-005478-5iu38pr6	3692	2	range	range	NN
cord-005478-5iu38pr6	3692	3	,	,	,
cord-005478-5iu38pr6	3692	4	18	18	CD
cord-005478-5iu38pr6	3692	5	-	-	SYM
cord-005478-5iu38pr6	3692	6	69	69	CD
cord-005478-5iu38pr6	3692	7	)	)	-RRB-
cord-005478-5iu38pr6	3692	8	.	.	.
cord-005478-5iu38pr6	3693	1	Forty	forty	CD
cord-005478-5iu38pr6	3693	2	patients	patient	NNS
cord-005478-5iu38pr6	3693	3	received	receive	VBD
cord-005478-5iu38pr6	3693	4	transplantation	transplantation	NN
cord-005478-5iu38pr6	3693	5	from	from	IN
cord-005478-5iu38pr6	3693	6	related	relate	VBN
cord-005478-5iu38pr6	3693	7	bone	bone	NN
cord-005478-5iu38pr6	3693	8	marrow	marrow	NN
cord-005478-5iu38pr6	3693	9	transplantation	transplantation	NN
cord-005478-5iu38pr6	3693	10	(	(	-LRB-
cord-005478-5iu38pr6	3693	11	BMT	BMT	NNP
cord-005478-5iu38pr6	3693	12	)	)	-RRB-
cord-005478-5iu38pr6	3693	13	/	/	NFP
cord-005478-5iu38pr6	3694	1	peripheral	peripheral	JJ
cord-005478-5iu38pr6	3694	2	blood	blood	NN
cord-005478-5iu38pr6	3694	3	stem	stem	NN
cord-005478-5iu38pr6	3694	4	cell	cell	NN
cord-005478-5iu38pr6	3694	5	Background	background	NN
cord-005478-5iu38pr6	3694	6	:	:	:
cord-005478-5iu38pr6	3694	7	Children	child	NNS
cord-005478-5iu38pr6	3694	8	,	,	,
cord-005478-5iu38pr6	3694	9	adolescents	adolescent	NNS
cord-005478-5iu38pr6	3694	10	and	and	CC
cord-005478-5iu38pr6	3694	11	young	young	JJ
cord-005478-5iu38pr6	3694	12	adult	adult	NN
cord-005478-5iu38pr6	3694	13	patients	patient	NNS
cord-005478-5iu38pr6	3694	14	with	with	IN
cord-005478-5iu38pr6	3694	15	ALL	all	DT
cord-005478-5iu38pr6	3694	16	with	with	IN
cord-005478-5iu38pr6	3694	17	second	second	JJ
cord-005478-5iu38pr6	3694	18	relapse	relapse	NN
cord-005478-5iu38pr6	3694	19	,	,	,
cord-005478-5iu38pr6	3694	20	relapse	relapse	NN
cord-005478-5iu38pr6	3694	21	after	after	IN
cord-005478-5iu38pr6	3694	22	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3694	23	SCT	SCT	NNP
cord-005478-5iu38pr6	3694	24	or	or	CC
cord-005478-5iu38pr6	3694	25	patients	patient	NNS
cord-005478-5iu38pr6	3694	26	with	with	IN
cord-005478-5iu38pr6	3694	27	primary	primary	JJ
cord-005478-5iu38pr6	3694	28	refractory	refractory	JJ
cord-005478-5iu38pr6	3694	29	disease	disease	NN
cord-005478-5iu38pr6	3694	30	have	have	VB
cord-005478-5iu38pr6	3694	31	a	a	DT
cord-005478-5iu38pr6	3694	32	poor	poor	JJ
cord-005478-5iu38pr6	3694	33	prognosis	prognosis	NN
cord-005478-5iu38pr6	3694	34	with	with	IN
cord-005478-5iu38pr6	3694	35	conventional	conventional	JJ
cord-005478-5iu38pr6	3694	36	treatment	treatment	NN
cord-005478-5iu38pr6	3694	37	concepts	concept	NNS
cord-005478-5iu38pr6	3694	38	.	.	.
cord-005478-5iu38pr6	3695	1	In	in	IN
cord-005478-5iu38pr6	3695	2	this	this	DT
cord-005478-5iu38pr6	3695	3	patient	patient	NN
cord-005478-5iu38pr6	3695	4	group	group	NN
cord-005478-5iu38pr6	3695	5	several	several	JJ
cord-005478-5iu38pr6	3695	6	studies	study	NNS
cord-005478-5iu38pr6	3695	7	using	use	VBG
cord-005478-5iu38pr6	3695	8	second	second	JJ
cord-005478-5iu38pr6	3695	9	generation	generation	NN
cord-005478-5iu38pr6	3695	10	CD19	CD19	NNP
cord-005478-5iu38pr6	3695	11	chimeric	chimeric	JJ
cord-005478-5iu38pr6	3695	12	antigen	antigen	NN
cord-005478-5iu38pr6	3695	13	receptor	receptor	NN
cord-005478-5iu38pr6	3695	14	T	T	NNP
cord-005478-5iu38pr6	3695	15	-	-	HYPH
cord-005478-5iu38pr6	3695	16	cells	cell	NNS
cord-005478-5iu38pr6	3695	17	(	(	-LRB-
cord-005478-5iu38pr6	3695	18	CAR	car	NN
cord-005478-5iu38pr6	3695	19	-	-	HYPH
cord-005478-5iu38pr6	3695	20	T	t	NN
cord-005478-5iu38pr6	3695	21	cells	cell	NNS
cord-005478-5iu38pr6	3695	22	)	)	-RRB-
cord-005478-5iu38pr6	3695	23	demonstrated	demonstrate	VBD
cord-005478-5iu38pr6	3695	24	high	high	JJ
cord-005478-5iu38pr6	3695	25	efficacy	efficacy	NN
cord-005478-5iu38pr6	3695	26	with	with	IN
cord-005478-5iu38pr6	3695	27	two	two	CD
cord-005478-5iu38pr6	3695	28	year	year	NN
cord-005478-5iu38pr6	3695	29	survival	survival	NN
cord-005478-5iu38pr6	3695	30	rates	rate	NNS
cord-005478-5iu38pr6	3695	31	of	of	IN
cord-005478-5iu38pr6	3695	32	up	up	IN
cord-005478-5iu38pr6	3695	33	to	to	TO
cord-005478-5iu38pr6	3695	34	65	65	CD
cord-005478-5iu38pr6	3695	35	%	%	NN
cord-005478-5iu38pr6	3695	36	.	.	.
cord-005478-5iu38pr6	3696	1	Recently	recently	RB
cord-005478-5iu38pr6	3696	2	,	,	,
cord-005478-5iu38pr6	3696	3	two	two	CD
cord-005478-5iu38pr6	3696	4	different	different	JJ
cord-005478-5iu38pr6	3696	5	CAR	car	NN
cord-005478-5iu38pr6	3696	6	-	-	HYPH
cord-005478-5iu38pr6	3696	7	T	t	NN
cord-005478-5iu38pr6	3696	8	cell	cell	NN
cord-005478-5iu38pr6	3696	9	products	product	NNS
cord-005478-5iu38pr6	3696	10	were	be	VBD
cord-005478-5iu38pr6	3696	11	approved	approve	VBN
cord-005478-5iu38pr6	3696	12	by	by	IN
cord-005478-5iu38pr6	3696	13	the	the	DT
cord-005478-5iu38pr6	3696	14	FDA	FDA	NNP
cord-005478-5iu38pr6	3696	15	and	and	CC
cord-005478-5iu38pr6	3696	16	in	in	IN
cord-005478-5iu38pr6	3696	17	2018	2018	CD
cord-005478-5iu38pr6	3696	18	also	also	RB
cord-005478-5iu38pr6	3696	19	by	by	IN
cord-005478-5iu38pr6	3696	20	the	the	DT
cord-005478-5iu38pr6	3696	21	EMA	EMA	NNP
cord-005478-5iu38pr6	3696	22	in	in	IN
cord-005478-5iu38pr6	3696	23	Europe	Europe	NNP
cord-005478-5iu38pr6	3696	24	:	:	:
cord-005478-5iu38pr6	3697	1	Tisagenlecleucel	Tisagenlecleucel	NNP
cord-005478-5iu38pr6	3697	2	(	(	-LRB-
cord-005478-5iu38pr6	3697	3	Kymriah	Kymriah	NNP
cord-005478-5iu38pr6	3697	4	®	®	VBP
cord-005478-5iu38pr6	3697	5	)	)	-RRB-
cord-005478-5iu38pr6	3697	6	for	for	IN
cord-005478-5iu38pr6	3697	7	the	the	DT
cord-005478-5iu38pr6	3697	8	treatment	treatment	NN
cord-005478-5iu38pr6	3697	9	of	of	IN
cord-005478-5iu38pr6	3697	10	patients	patient	NNS
cord-005478-5iu38pr6	3697	11	with	with	IN
cord-005478-5iu38pr6	3697	12	B	b	NN
cord-005478-5iu38pr6	3697	13	-	-	HYPH
cord-005478-5iu38pr6	3697	14	precursor	precursor	NN
cord-005478-5iu38pr6	3697	15	ALL	all	DT
cord-005478-5iu38pr6	3697	16	who	who	WP
cord-005478-5iu38pr6	3697	17	are	be	VBP
cord-005478-5iu38pr6	3697	18	i	i	NN
cord-005478-5iu38pr6	3697	19	)	)	-RRB-
cord-005478-5iu38pr6	3697	20	refractory	refractory	NN
cord-005478-5iu38pr6	3697	21	,	,	,
cord-005478-5iu38pr6	3697	22	ii	ii	LS
cord-005478-5iu38pr6	3697	23	)	)	-RRB-
cord-005478-5iu38pr6	3697	24	in	in	IN
cord-005478-5iu38pr6	3697	25	second	second	JJ
cord-005478-5iu38pr6	3697	26	relapse	relapse	NN
cord-005478-5iu38pr6	3697	27	or	or	CC
cord-005478-5iu38pr6	3697	28	iii	iii	NN
cord-005478-5iu38pr6	3697	29	)	)	-RRB-
cord-005478-5iu38pr6	3697	30	who	who	WP
cord-005478-5iu38pr6	3697	31	relapsed	relapse	VBD
cord-005478-5iu38pr6	3697	32	after	after	IN
cord-005478-5iu38pr6	3697	33	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3697	34	SCT	SCT	NNP
cord-005478-5iu38pr6	3697	35	(	(	-LRB-
cord-005478-5iu38pr6	3697	36	relapsed	relapse	VBN
cord-005478-5iu38pr6	3697	37	/	/	SYM
cord-005478-5iu38pr6	3697	38	refractory	refractory	JJ
cord-005478-5iu38pr6	3697	39	ALL	all	DT
cord-005478-5iu38pr6	3697	40	;	;	:
cord-005478-5iu38pr6	3697	41	r	r	NN
cord-005478-5iu38pr6	3697	42	/	/	SYM
cord-005478-5iu38pr6	3697	43	r	r	NN
cord-005478-5iu38pr6	3697	44	ALL	all	DT
cord-005478-5iu38pr6	3697	45	)	)	-RRB-
cord-005478-5iu38pr6	3697	46	as	as	RB
cord-005478-5iu38pr6	3697	47	well	well	RB
cord-005478-5iu38pr6	3697	48	as	as	IN
cord-005478-5iu38pr6	3697	49	for	for	IN
cord-005478-5iu38pr6	3697	50	diffuse	diffuse	VB
cord-005478-5iu38pr6	3697	51	large	large	JJ
cord-005478-5iu38pr6	3697	52	cell	cell	NN
cord-005478-5iu38pr6	3697	53	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3697	54	(	(	-LRB-
cord-005478-5iu38pr6	3697	55	DLBCL	DLBCL	NNP
cord-005478-5iu38pr6	3697	56	)	)	-RRB-
cord-005478-5iu38pr6	3697	57	and	and	CC
cord-005478-5iu38pr6	3697	58	Axicabtagen	Axicabtagen	NNP
cord-005478-5iu38pr6	3697	59	Ciloleucel	Ciloleucel	NNP
cord-005478-5iu38pr6	3697	60	(	(	-LRB-
cord-005478-5iu38pr6	3697	61	Yescarta	Yescarta	NNP
cord-005478-5iu38pr6	3697	62	®	®	POS
cord-005478-5iu38pr6	3697	63	)	)	-RRB-
cord-005478-5iu38pr6	3697	64	for	for	IN
cord-005478-5iu38pr6	3697	65	the	the	DT
cord-005478-5iu38pr6	3697	66	treatment	treatment	NN
cord-005478-5iu38pr6	3697	67	of	of	IN
cord-005478-5iu38pr6	3697	68	B	b	NN
cord-005478-5iu38pr6	3697	69	-	-	HYPH
cord-005478-5iu38pr6	3697	70	cell	cell	NN
cord-005478-5iu38pr6	3697	71	lymphoma	lymphoma	NN
cord-005478-5iu38pr6	3697	72	.	.	.
cord-005478-5iu38pr6	3698	1	Here	here	RB
cord-005478-5iu38pr6	3698	2	we	-PRON-	PRP
cord-005478-5iu38pr6	3698	3	report	report	VBP
cord-005478-5iu38pr6	3698	4	our	-PRON-	PRP$
cord-005478-5iu38pr6	3698	5	first	first	JJ
cord-005478-5iu38pr6	3698	6	results	result	NNS
cord-005478-5iu38pr6	3698	7	using	use	VBG
cord-005478-5iu38pr6	3698	8	commercially	commercially	RB
cord-005478-5iu38pr6	3698	9	available	available	JJ
cord-005478-5iu38pr6	3698	10	CAR	car	NN
cord-005478-5iu38pr6	3698	11	-	-	HYPH
cord-005478-5iu38pr6	3698	12	T	t	NN
cord-005478-5iu38pr6	3698	13	-	-	HYPH
cord-005478-5iu38pr6	3698	14	cell	cell	NN
cord-005478-5iu38pr6	3698	15	product	product	NN
cord-005478-5iu38pr6	3699	1	Tisagenlecleucel	Tisagenlecleucel	NNP
cord-005478-5iu38pr6	3700	1	(	(	-LRB-
cord-005478-5iu38pr6	3700	2	Kymriah	Kymriah	NNP
cord-005478-5iu38pr6	3700	3	®	®	VBP
cord-005478-5iu38pr6	3700	4	)	)	-RRB-
cord-005478-5iu38pr6	3700	5	in	in	IN
cord-005478-5iu38pr6	3700	6	patients	patient	NNS
cord-005478-5iu38pr6	3700	7	with	with	IN
cord-005478-5iu38pr6	3700	8	ALL	all	DT
cord-005478-5iu38pr6	3700	9	which	which	WDT
cord-005478-5iu38pr6	3700	10	were	be	VBD
cord-005478-5iu38pr6	3700	11	treated	treat	VBN
cord-005478-5iu38pr6	3700	12	by	by	IN
cord-005478-5iu38pr6	3700	13	the	the	DT
cord-005478-5iu38pr6	3700	14	University	University	NNP
cord-005478-5iu38pr6	3700	15	Hospital	Hospital	NNP
cord-005478-5iu38pr6	3700	16	for	for	IN
cord-005478-5iu38pr6	3700	17	Children	Children	NNP
cord-005478-5iu38pr6	3700	18	and	and	CC
cord-005478-5iu38pr6	3700	19	Adolescents	Adolescents	NNPS
cord-005478-5iu38pr6	3700	20	Frankfurt	Frankfurt	NNP
cord-005478-5iu38pr6	3700	21	am	be	VBP
cord-005478-5iu38pr6	3700	22	Main	Main	NNP
cord-005478-5iu38pr6	3700	23	(	(	-LRB-
cord-005478-5iu38pr6	3700	24	n=9	n=9	NN
cord-005478-5iu38pr6	3700	25	)	)	-RRB-
cord-005478-5iu38pr6	3700	26	,	,	,
cord-005478-5iu38pr6	3700	27	the	the	DT
cord-005478-5iu38pr6	3700	28	Department	Department	NNP
cord-005478-5iu38pr6	3700	29	of	of	IN
cord-005478-5iu38pr6	3700	30	Medicine	Medicine	NNP
cord-005478-5iu38pr6	3700	31	III	III	NNP
cord-005478-5iu38pr6	3700	32	,	,	,
cord-005478-5iu38pr6	3700	33	University	University	NNP
cord-005478-5iu38pr6	3700	34	Hospital	Hospital	NNP
cord-005478-5iu38pr6	3700	35	LMU	LMU	NNP
cord-005478-5iu38pr6	3700	36	Munich	Munich	NNP
cord-005478-5iu38pr6	3700	37	(	(	-LRB-
cord-005478-5iu38pr6	3700	38	n=1	n=1	CD
cord-005478-5iu38pr6	3700	39	)	)	-RRB-
cord-005478-5iu38pr6	3700	40	,	,	,
cord-005478-5iu38pr6	3700	41	and	and	CC
cord-005478-5iu38pr6	3700	42	the	the	DT
cord-005478-5iu38pr6	3700	43	von	von	NNP
cord-005478-5iu38pr6	3700	44	Hauner	Hauner	NNP
cord-005478-5iu38pr6	3700	45	Kinderspital	Kinderspital	NNP
cord-005478-5iu38pr6	3700	46	,	,	,
cord-005478-5iu38pr6	3700	47	LMU	LMU	NNP
cord-005478-5iu38pr6	3700	48	Munich	Munich	NNP
cord-005478-5iu38pr6	3700	49	,	,	,
cord-005478-5iu38pr6	3700	50	Germany	Germany	NNP
cord-005478-5iu38pr6	3700	51	(	(	-LRB-
cord-005478-5iu38pr6	3700	52	n=1).Methods	n=1).method	NNS
cord-005478-5iu38pr6	3700	53	:	:	:
cord-005478-5iu38pr6	3701	1	Between	between	IN
cord-005478-5iu38pr6	3701	2	October	October	NNP
cord-005478-5iu38pr6	3701	3	and	and	CC
cord-005478-5iu38pr6	3701	4	December	December	NNP
cord-005478-5iu38pr6	3701	5	2018	2018	CD
cord-005478-5iu38pr6	3701	6	eleven	eleven	CD
cord-005478-5iu38pr6	3701	7	patients	patient	NNS
cord-005478-5iu38pr6	3701	8	received	receive	VBD
cord-005478-5iu38pr6	3701	9	apheresis	apheresis	NN
cord-005478-5iu38pr6	3701	10	for	for	IN
cord-005478-5iu38pr6	3701	11	CAR	car	NN
cord-005478-5iu38pr6	3701	12	-	-	HYPH
cord-005478-5iu38pr6	3701	13	T	t	NN
cord-005478-5iu38pr6	3701	14	cell	cell	NN
cord-005478-5iu38pr6	3701	15	generation	generation	NN
cord-005478-5iu38pr6	3701	16	.	.	.
cord-005478-5iu38pr6	3702	1	Nine	nine	CD
cord-005478-5iu38pr6	3702	2	patients	patient	NNS
cord-005478-5iu38pr6	3702	3	suffered	suffer	VBD
cord-005478-5iu38pr6	3702	4	from	from	IN
cord-005478-5iu38pr6	3702	5	r	r	NNP
cord-005478-5iu38pr6	3702	6	/	/	SYM
cord-005478-5iu38pr6	3702	7	r	r	NN
cord-005478-5iu38pr6	3702	8	c	c	NN
cord-005478-5iu38pr6	3702	9	-	-	:
cord-005478-5iu38pr6	3702	10	ALL	all	DT
cord-005478-5iu38pr6	3702	11	,	,	,
cord-005478-5iu38pr6	3702	12	and	and	CC
cord-005478-5iu38pr6	3702	13	two	two	CD
cord-005478-5iu38pr6	3702	14	from	from	IN
cord-005478-5iu38pr6	3702	15	r	r	NN
cord-005478-5iu38pr6	3702	16	/	/	SYM
cord-005478-5iu38pr6	3702	17	r	r	NN
cord-005478-5iu38pr6	3702	18	Bprecursor	Bprecursor	NNP
cord-005478-5iu38pr6	3702	19	ALL	all	DT
cord-005478-5iu38pr6	3702	20	.	.	.
cord-005478-5iu38pr6	3703	1	Eight	eight	CD
cord-005478-5iu38pr6	3703	2	patients	patient	NNS
cord-005478-5iu38pr6	3703	3	had	have	VBD
cord-005478-5iu38pr6	3703	4	relapsed	relapse	VBN
cord-005478-5iu38pr6	3703	5	after	after	IN
cord-005478-5iu38pr6	3703	6	allogeneic	allogeneic	NN
cord-005478-5iu38pr6	3703	7	HSCT	HSCT	NNP
cord-005478-5iu38pr6	3703	8	,	,	,
cord-005478-5iu38pr6	3703	9	one	one	CD
cord-005478-5iu38pr6	3703	10	patient	patient	NN
cord-005478-5iu38pr6	3703	11	each	each	DT
cord-005478-5iu38pr6	3703	12	suffered	suffer	VBD
cord-005478-5iu38pr6	3703	13	from	from	IN
cord-005478-5iu38pr6	3703	14	first	first	JJ
cord-005478-5iu38pr6	3703	15	r	r	NN
cord-005478-5iu38pr6	3703	16	/	/	SYM
cord-005478-5iu38pr6	3703	17	relapse	relapse	NN
cord-005478-5iu38pr6	3703	18	,	,	,
cord-005478-5iu38pr6	3703	19	second	second	RB
cord-005478-5iu38pr6	3703	20	r	r	NN
cord-005478-5iu38pr6	3703	21	/	/	SYM
cord-005478-5iu38pr6	3703	22	relapse	relapse	NN
cord-005478-5iu38pr6	3703	23	or	or	CC
cord-005478-5iu38pr6	3703	24	from	from	IN
cord-005478-5iu38pr6	3703	25	primary	primary	JJ
cord-005478-5iu38pr6	3703	26	r	r	NN
cord-005478-5iu38pr6	3703	27	/	/	,
cord-005478-5iu38pr6	3703	28	ALL	all	DT
cord-005478-5iu38pr6	3703	29	.	.	.
cord-005478-5iu38pr6	3704	1	In	in	IN
cord-005478-5iu38pr6	3704	2	9/11	9/11	CD
cord-005478-5iu38pr6	3704	3	(	(	-LRB-
cord-005478-5iu38pr6	3704	4	82	82	CD
cord-005478-5iu38pr6	3704	5	%	%	NN
cord-005478-5iu38pr6	3704	6	)	)	-RRB-
cord-005478-5iu38pr6	3704	7	patients	patient	NNS
cord-005478-5iu38pr6	3704	8	CAR	car	NN
cord-005478-5iu38pr6	3704	9	-	-	HYPH
cord-005478-5iu38pr6	3704	10	T	t	NN
cord-005478-5iu38pr6	3704	11	cell	cell	NN
cord-005478-5iu38pr6	3704	12	production	production	NN
cord-005478-5iu38pr6	3704	13	was	be	VBD
cord-005478-5iu38pr6	3704	14	successful	successful	JJ
cord-005478-5iu38pr6	3704	15	after	after	IN
cord-005478-5iu38pr6	3704	16	one	one	CD
cord-005478-5iu38pr6	3704	17	and	and	CC
cord-005478-5iu38pr6	3704	18	in	in	IN
cord-005478-5iu38pr6	3704	19	2	2	CD
cord-005478-5iu38pr6	3704	20	patients	patient	NNS
cord-005478-5iu38pr6	3704	21	(	(	-LRB-
cord-005478-5iu38pr6	3704	22	18	18	CD
cord-005478-5iu38pr6	3704	23	%	%	NN
cord-005478-5iu38pr6	3704	24	)	)	-RRB-
cord-005478-5iu38pr6	3704	25	after	after	IN
cord-005478-5iu38pr6	3704	26	a	a	DT
cord-005478-5iu38pr6	3704	27	second	second	JJ
cord-005478-5iu38pr6	3704	28	apheresis	apheresis	NN
cord-005478-5iu38pr6	3704	29	.	.	.
cord-005478-5iu38pr6	3705	1	Median	median	JJ
cord-005478-5iu38pr6	3705	2	patients	patient	NNS
cord-005478-5iu38pr6	3705	3	'	'	POS
cord-005478-5iu38pr6	3705	4	age	age	NN
cord-005478-5iu38pr6	3705	5	was	be	VBD
cord-005478-5iu38pr6	3705	6	16.7	16.7	CD
cord-005478-5iu38pr6	3705	7	years	year	NNS
cord-005478-5iu38pr6	3705	8	(	(	-LRB-
cord-005478-5iu38pr6	3705	9	1.1	1.1	CD
cord-005478-5iu38pr6	3705	10	-	-	SYM
cord-005478-5iu38pr6	3705	11	25.4	25.4	CD
cord-005478-5iu38pr6	3705	12	)	)	-RRB-
cord-005478-5iu38pr6	3705	13	.	.	.
cord-005478-5iu38pr6	3706	1	Between	between	IN
cord-005478-5iu38pr6	3706	2	apheresis	apheresis	NN
cord-005478-5iu38pr6	3706	3	and	and	CC
cord-005478-5iu38pr6	3706	4	start	start	NN
cord-005478-5iu38pr6	3706	5	of	of	IN
cord-005478-5iu38pr6	3706	6	lymphodepleting	lymphodeplete	VBG
cord-005478-5iu38pr6	3706	7	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	3706	8	(	(	-LRB-
cord-005478-5iu38pr6	3706	9	LDC	LDC	NNP
cord-005478-5iu38pr6	3706	10	)	)	-RRB-
cord-005478-5iu38pr6	3706	11	,	,	,
cord-005478-5iu38pr6	3706	12	10/11	10/11	CD
cord-005478-5iu38pr6	3706	13	patients	patient	NNS
cord-005478-5iu38pr6	3706	14	received	receive	VBD
cord-005478-5iu38pr6	3706	15	low	low	JJ
cord-005478-5iu38pr6	3706	16	dose	dose	NN
cord-005478-5iu38pr6	3706	17	chemotherapy	chemotherapy	NN
cord-005478-5iu38pr6	3706	18	according	accord	VBG
cord-005478-5iu38pr6	3706	19	to	to	IN
cord-005478-5iu38pr6	3706	20	the	the	DT
cord-005478-5iu38pr6	3706	21	FRAPOSTALL	FRAPOSTALL	NNP
cord-005478-5iu38pr6	3706	22	protocol	protocol	NN
cord-005478-5iu38pr6	3706	23	(	(	-LRB-
cord-005478-5iu38pr6	3706	24	Willasch	Willasch	NNP
cord-005478-5iu38pr6	3706	25	et	et	NNP
cord-005478-5iu38pr6	3706	26	al	al	NNP
cord-005478-5iu38pr6	3706	27	.	.	.
cord-005478-5iu38pr6	3706	28	2016	2016	CD
cord-005478-5iu38pr6	3706	29	)	)	-RRB-
cord-005478-5iu38pr6	3706	30	and	and	CC
cord-005478-5iu38pr6	3706	31	one	one	CD
cord-005478-5iu38pr6	3706	32	patient	patient	NN
cord-005478-5iu38pr6	3706	33	was	be	VBD
cord-005478-5iu38pr6	3706	34	treated	treat	VBN
cord-005478-5iu38pr6	3706	35	with	with	IN
cord-005478-5iu38pr6	3706	36	inotuzumab	inotuzumab	NNS
cord-005478-5iu38pr6	3706	37	.	.	.
cord-005478-5iu38pr6	3707	1	Production	production	NN
cord-005478-5iu38pr6	3707	2	slots	slot	NNS
cord-005478-5iu38pr6	3707	3	were	be	VBD
cord-005478-5iu38pr6	3707	4	immediately	immediately	RB
cord-005478-5iu38pr6	3707	5	available	available	JJ
cord-005478-5iu38pr6	3707	6	,	,	,
cord-005478-5iu38pr6	3707	7	resulting	result	VBG
cord-005478-5iu38pr6	3707	8	in	in	IN
cord-005478-5iu38pr6	3707	9	turn	turn	NN
cord-005478-5iu38pr6	3707	10	-	-	HYPH
cord-005478-5iu38pr6	3707	11	around	around	IN
cord-005478-5iu38pr6	3707	12	-	-	HYPH
cord-005478-5iu38pr6	3707	13	time	time	NN
cord-005478-5iu38pr6	3707	14	from	from	IN
cord-005478-5iu38pr6	3707	15	apheresis	apheresis	NN
cord-005478-5iu38pr6	3707	16	to	to	IN
cord-005478-5iu38pr6	3707	17	product	product	NN
cord-005478-5iu38pr6	3707	18	delivery	delivery	NN
cord-005478-5iu38pr6	3707	19	of	of	IN
cord-005478-5iu38pr6	3707	20	3	3	CD
cord-005478-5iu38pr6	3707	21	-	-	SYM
cord-005478-5iu38pr6	3707	22	4	4	CD
cord-005478-5iu38pr6	3707	23	weeks	week	NNS
cord-005478-5iu38pr6	3707	24	.	.	.
cord-005478-5iu38pr6	3708	1	Disease	disease	NN
cord-005478-5iu38pr6	3708	2	status	status	NN
cord-005478-5iu38pr6	3708	3	at	at	IN
cord-005478-5iu38pr6	3708	4	start	start	NN
cord-005478-5iu38pr6	3708	5	of	of	IN
cord-005478-5iu38pr6	3708	6	LDC	LDC	NNP
cord-005478-5iu38pr6	3708	7	was	be	VBD
cord-005478-5iu38pr6	3708	8	CR	CR	NNP
cord-005478-5iu38pr6	3708	9	w/o	without	IN
cord-005478-5iu38pr6	3708	10	MRD	MRD	NNP
cord-005478-5iu38pr6	3708	11	(	(	-LRB-
cord-005478-5iu38pr6	3708	12	n=4	n=4	NNP
cord-005478-5iu38pr6	3708	13	)	)	-RRB-
cord-005478-5iu38pr6	3708	14	,	,	,
cord-005478-5iu38pr6	3708	15	CR	CR	NNP
cord-005478-5iu38pr6	3708	16	MRD	MRD	NNP
cord-005478-5iu38pr6	3708	17	pos	pos	NN
cord-005478-5iu38pr6	3708	18	.	.	.
cord-005478-5iu38pr6	3709	1	(	(	-LRB-
cord-005478-5iu38pr6	3709	2	n=2	n=2	NNS
cord-005478-5iu38pr6	3709	3	)	)	-RRB-
cord-005478-5iu38pr6	3709	4	,	,	,
cord-005478-5iu38pr6	3709	5	CRi	CRi	NNS
cord-005478-5iu38pr6	3709	6	(	(	-LRB-
cord-005478-5iu38pr6	3709	7	n=1	n=1	NNS
cord-005478-5iu38pr6	3709	8	)	)	-RRB-
cord-005478-5iu38pr6	3709	9	,	,	,
cord-005478-5iu38pr6	3709	10	persistence	persistence	NN
cord-005478-5iu38pr6	3709	11	of	of	IN
cord-005478-5iu38pr6	3709	12	blasts	blast	NNS
cord-005478-5iu38pr6	3709	13	(	(	-LRB-
cord-005478-5iu38pr6	3709	14	n=2	n=2	NNS
cord-005478-5iu38pr6	3709	15	)	)	-RRB-
cord-005478-5iu38pr6	3709	16	,	,	,
cord-005478-5iu38pr6	3709	17	and	and	CC
cord-005478-5iu38pr6	3709	18	disease	disease	NN
cord-005478-5iu38pr6	3709	19	progression	progression	NN
cord-005478-5iu38pr6	3709	20	(	(	-LRB-
cord-005478-5iu38pr6	3709	21	80	80	CD
cord-005478-5iu38pr6	3709	22	-	-	SYM
cord-005478-5iu38pr6	3709	23	100	100	CD
cord-005478-5iu38pr6	3709	24	%	%	NN
cord-005478-5iu38pr6	3709	25	blasts	blast	NNS
cord-005478-5iu38pr6	3709	26	,	,	,
cord-005478-5iu38pr6	3709	27	n=2	n=2	NNS
cord-005478-5iu38pr6	3709	28	)	)	-RRB-
cord-005478-5iu38pr6	3709	29	.	.	.
cord-005478-5iu38pr6	3710	1	LDC	LDC	NNP
cord-005478-5iu38pr6	3710	2	consisting	consist	VBG
cord-005478-5iu38pr6	3710	3	of	of	IN
cord-005478-5iu38pr6	3710	4	FLU	FLU	NNP
cord-005478-5iu38pr6	3710	5	-	-	HYPH
cord-005478-5iu38pr6	3710	6	CYC	CYC	NNP
cord-005478-5iu38pr6	3710	7	was	be	VBD
cord-005478-5iu38pr6	3710	8	given	give	VBN
cord-005478-5iu38pr6	3710	9	to	to	IN
cord-005478-5iu38pr6	3710	10	9/10	9/10	CD
cord-005478-5iu38pr6	3710	11	patients	patient	NNS
cord-005478-5iu38pr6	3710	12	,	,	,
cord-005478-5iu38pr6	3710	13	one	one	CD
cord-005478-5iu38pr6	3710	14	patient	patient	NN
cord-005478-5iu38pr6	3710	15	did	do	VBD
cord-005478-5iu38pr6	3710	16	not	not	RB
cord-005478-5iu38pr6	3710	17	receive	receive	VB
cord-005478-5iu38pr6	3710	18	LDC.Results	ldc.result	NNS
cord-005478-5iu38pr6	3710	19	:	:	:
cord-005478-5iu38pr6	3710	20	CAR	car	NN
cord-005478-5iu38pr6	3710	21	-	-	HYPH
cord-005478-5iu38pr6	3710	22	T	t	NN
cord-005478-5iu38pr6	3710	23	cells	cell	NNS
cord-005478-5iu38pr6	3710	24	could	could	MD
cord-005478-5iu38pr6	3710	25	be	be	VB
cord-005478-5iu38pr6	3710	26	transfused	transfuse	VBN
cord-005478-5iu38pr6	3710	27	to	to	IN
cord-005478-5iu38pr6	3710	28	10/11	10/11	CD
cord-005478-5iu38pr6	3710	29	patients	patient	NNS
cord-005478-5iu38pr6	3710	30	at	at	IN
cord-005478-5iu38pr6	3710	31	a	a	DT
cord-005478-5iu38pr6	3710	32	median	median	JJ
cord-005478-5iu38pr6	3710	33	dose	dose	NN
cord-005478-5iu38pr6	3710	34	of	of	IN
cord-005478-5iu38pr6	3710	35	1.5	1.5	CD
cord-005478-5iu38pr6	3710	36	Mio	Mio	NNP
cord-005478-5iu38pr6	3710	37	/	/	SYM
cord-005478-5iu38pr6	3710	38	kgBW	kgBW	NNP
cord-005478-5iu38pr6	3710	39	(	(	-LRB-
cord-005478-5iu38pr6	3710	40	0.145	0.145	CD
cord-005478-5iu38pr6	3710	41	Mio	Mio	NNP
cord-005478-5iu38pr6	3710	42	8.5	8.5	CD
cord-005478-5iu38pr6	3710	43	)	)	-RRB-
cord-005478-5iu38pr6	3710	44	.	.	.
cord-005478-5iu38pr6	3711	1	In	in	IN
cord-005478-5iu38pr6	3711	2	one	one	CD
cord-005478-5iu38pr6	3711	3	patient	patient	NN
cord-005478-5iu38pr6	3711	4	,	,	,
cord-005478-5iu38pr6	3711	5	in	in	IN
cord-005478-5iu38pr6	3711	6	whom	whom	WP
cord-005478-5iu38pr6	3711	7	a	a	DT
cord-005478-5iu38pr6	3711	8	second	second	JJ
cord-005478-5iu38pr6	3711	9	viral	viral	JJ
cord-005478-5iu38pr6	3711	10	transduction	transduction	NN
cord-005478-5iu38pr6	3711	11	procedure	procedure	NN
cord-005478-5iu38pr6	3711	12	was	be	VBD
cord-005478-5iu38pr6	3711	13	necessary	necessary	JJ
cord-005478-5iu38pr6	3711	14	;	;	:
cord-005478-5iu38pr6	3711	15	neither	neither	CC
cord-005478-5iu38pr6	3711	16	LDC	LDC	NNP
cord-005478-5iu38pr6	3711	17	nor	nor	CC
cord-005478-5iu38pr6	3711	18	CAR	CAR	NNP
cord-005478-5iu38pr6	3711	19	-	-	HYPH
cord-005478-5iu38pr6	3711	20	T	t	NN
cord-005478-5iu38pr6	3711	21	cell	cell	NN
cord-005478-5iu38pr6	3711	22	transfusion	transfusion	NN
cord-005478-5iu38pr6	3711	23	could	could	MD
cord-005478-5iu38pr6	3711	24	be	be	VB
cord-005478-5iu38pr6	3711	25	given	give	VBN
cord-005478-5iu38pr6	3711	26	because	because	IN
cord-005478-5iu38pr6	3711	27	of	of	IN
cord-005478-5iu38pr6	3711	28	diseases	disease	NNS
cord-005478-5iu38pr6	3711	29	progression	progression	NN
cord-005478-5iu38pr6	3711	30	and	and	CC
cord-005478-5iu38pr6	3711	31	deterioration	deterioration	NN
cord-005478-5iu38pr6	3711	32	of	of	IN
cord-005478-5iu38pr6	3711	33	the	the	DT
cord-005478-5iu38pr6	3711	34	patient	patient	NN
cord-005478-5iu38pr6	3711	35	's	's	POS
cord-005478-5iu38pr6	3711	36	general	general	JJ
cord-005478-5iu38pr6	3711	37	condition	condition	NN
cord-005478-5iu38pr6	3711	38	.	.	.
cord-005478-5iu38pr6	3712	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	3712	2	release	release	NN
cord-005478-5iu38pr6	3712	3	syndrome	syndrome	NN
cord-005478-5iu38pr6	3712	4	(	(	-LRB-
cord-005478-5iu38pr6	3712	5	CRS	CRS	NNP
cord-005478-5iu38pr6	3712	6	)	)	-RRB-
cord-005478-5iu38pr6	3712	7	grade	grade	NN
cord-005478-5iu38pr6	3713	1	I	-PRON-	PRP
cord-005478-5iu38pr6	3713	2	was	be	VBD
cord-005478-5iu38pr6	3713	3	observed	observe	VBN
cord-005478-5iu38pr6	3713	4	in	in	IN
cord-005478-5iu38pr6	3713	5	one	one	CD
cord-005478-5iu38pr6	3713	6	patient	patient	NN
cord-005478-5iu38pr6	3713	7	;	;	:
cord-005478-5iu38pr6	3713	8	8/10	8/10	CD
cord-005478-5iu38pr6	3713	9	patients	patient	NNS
cord-005478-5iu38pr6	3713	10	did	do	VBD
cord-005478-5iu38pr6	3713	11	not	not	RB
cord-005478-5iu38pr6	3713	12	develop	develop	VB
cord-005478-5iu38pr6	3713	13	CRS	CRS	NNP
cord-005478-5iu38pr6	3713	14	.	.	.
cord-005478-5iu38pr6	3714	1	Cytokine	cytokine	NN
cord-005478-5iu38pr6	3714	2	related	related	JJ
cord-005478-5iu38pr6	3714	3	encephalopathy	encephalopathy	NN
cord-005478-5iu38pr6	3714	4	syndrome	syndrome	NN
cord-005478-5iu38pr6	3714	5	(	(	-LRB-
cord-005478-5iu38pr6	3714	6	CRES	CRES	NNP
cord-005478-5iu38pr6	3714	7	)	)	-RRB-
cord-005478-5iu38pr6	3715	1	grade	grade	NN
cord-005478-5iu38pr6	3715	2	II	II	NNP
cord-005478-5iu38pr6	3715	3	was	be	VBD
cord-005478-5iu38pr6	3715	4	observed	observe	VBN
cord-005478-5iu38pr6	3715	5	in	in	IN
cord-005478-5iu38pr6	3715	6	1/10	1/10	CD
cord-005478-5iu38pr6	3715	7	patients	patient	NNS
cord-005478-5iu38pr6	3715	8	.	.	.
cord-005478-5iu38pr6	3716	1	At	at	IN
cord-005478-5iu38pr6	3716	2	day	day	NN
cord-005478-5iu38pr6	3716	3	+28	+28	CD
cord-005478-5iu38pr6	3716	4	8/10	8/10	CD
cord-005478-5iu38pr6	3716	5	patients	patient	NNS
cord-005478-5iu38pr6	3716	6	(	(	-LRB-
cord-005478-5iu38pr6	3716	7	80	80	CD
cord-005478-5iu38pr6	3716	8	%	%	NN
cord-005478-5iu38pr6	3716	9	)	)	-RRB-
cord-005478-5iu38pr6	3716	10	achieved	achieve	VBD
cord-005478-5iu38pr6	3716	11	MRD	MRD	NNP
cord-005478-5iu38pr6	3716	12	negative	negative	JJ
cord-005478-5iu38pr6	3716	13	CR	cr	NN
cord-005478-5iu38pr6	3716	14	.	.	.
cord-005478-5iu38pr6	3717	1	The	the	DT
cord-005478-5iu38pr6	3717	2	two	two	CD
cord-005478-5iu38pr6	3717	3	patients	patient	NNS
cord-005478-5iu38pr6	3717	4	with	with	IN